<SEC-DOCUMENT>0001140361-25-009257.txt : 20250318
<SEC-HEADER>0001140361-25-009257.hdr.sgml : 20250318
<ACCEPTANCE-DATETIME>20250318161208
ACCESSION NUMBER:		0001140361-25-009257
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		98
CONFORMED PERIOD OF REPORT:	20241231
FILED AS OF DATE:		20250318
DATE AS OF CHANGE:		20250318

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ADMA BIOLOGICS, INC.
		CENTRAL INDEX KEY:			0001368514
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				562590442
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36728
		FILM NUMBER:		25748408

	BUSINESS ADDRESS:	
		STREET 1:		C/O ADMA BIOLOGICS, INC.
		STREET 2:		465 STATE ROUTE 17
		CITY:			RAMSEY
		STATE:			NJ
		ZIP:			07446
		BUSINESS PHONE:		(201) 478-5552

	MAIL ADDRESS:	
		STREET 1:		C/O ADMA BIOLOGICS, INC.
		STREET 2:		465 STATE ROUTE 17
		CITY:			RAMSEY
		STATE:			NJ
		ZIP:			07446

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	R&R ACQUISITION VI, INC
		DATE OF NAME CHANGE:	20060707
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>ef20038923_10k.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:srt="http://fasb.org/srt/2024" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:country="http://xbrl.sec.gov/country/2024" xmlns:currency="http://xbrl.sec.gov/currency/2024" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:naics="http://xbrl.sec.gov/naics/2024" xmlns:sic="http://xbrl.sec.gov/sic/2024" xmlns:stpr="http://xbrl.sec.gov/stpr/2024" xmlns:exch="http://xbrl.sec.gov/exch/2024" xmlns:cef="http://xbrl.sec.gov/cef/2024" xmlns:ecd="http://xbrl.sec.gov/ecd/2024" xmlns:cyd="http://xbrl.sec.gov/cyd/2024" xmlns:adma="http://admabiologics.com/20241231" xmlns="http://www.w3.org/1999/xhtml">
  <head>
    <title></title>
    <!-- Licensed to: Summit Financial
         Document created using Broadridge PROfile 25.2.1.5287
         Copyright 1995 - 2025 Broadridge -->
    <meta http-equiv="Content-Type" content="text/html"/>
</head>

<body style="background-color: #ffffff; color: #000000;">
<div id="DSPFiXBRLHidden" style="display: none;"><ix:header><ix:hidden><ix:nonNumeric name="dei:AmendmentFlag" id="Fact_f913f05aeb804866b4528912837538bd" contextRef="c20240101to20241231" format="ixt:fixed-false">false</ix:nonNumeric><ix:nonNumeric name="dei:CurrentFiscalYearEndDate" id="Fact_c4538a1742b046abbb2573809a77a124" contextRef="c20240101to20241231" format="ixt:date-month-day">12-31</ix:nonNumeric><ix:nonNumeric name="dei:DocumentFiscalYearFocus" id="Fact_ddf2b11c0b2b4bdcbf61876eb49a0317" contextRef="c20240101to20241231">2024</ix:nonNumeric><ix:nonNumeric name="dei:DocumentFiscalPeriodFocus" id="Fact_50033b203c194a99b7b57117ffdf281b" contextRef="c20240101to20241231">FY</ix:nonNumeric><ix:nonNumeric name="dei:EntityCentralIndexKey" id="Fact_f6d4536bbc1b495fb7cd5dae2f035e52" contextRef="c20240101to20241231">0001368514</ix:nonNumeric><ix:nonNumeric name="ecd:TrdArrDuration" id="Fact_7095587f31264a6b95943ba8d0a4f402" contextRef="c20241001to20241231_IndividualAxis_AdamGrossmanMember">P391D</ix:nonNumeric><ix:nonNumeric name="adma:NumberOfBusinessDays" id="Fact_712874e87fcc4abab5ec40411ed75dc9" contextRef="c20231218to20231218_CreditFacilityAxis_TermLoanMember_VariableRateAxis_SecuredOvernightFinancingRateSofrMember">P2D</ix:nonNumeric><ix:nonNumeric name="adma:NumberOfBusinessDays" id="Fact_00f7b4da42784c0b85e89298c6447e23" contextRef="c20231218to20231218_CreditFacilityAxis_RevolvingCreditFacilityMember_VariableRateAxis_SecuredOvernightFinancingRateSofrMember">P2D</ix:nonNumeric><ix:nonNumeric name="adma:NumberOfBusinessDaysForPriorWrittenNoticeToPrepayOutstandingPrincipal" id="Fact_2496c3fd576a452da07200cbae1170f2" contextRef="c20240101to20241231_CounterpartyNameAxis_AresCreditAgreementMember_DebtInstrumentAxis_AresCreditFacilityMember">P3D</ix:nonNumeric><ix:nonNumeric name="adma:NumberOfBusinessDaysForPriorWrittenNoticeToPrepayOutstandingPrincipal" id="Fact_d55916c1abbd41dd8edc1e45abe3c678" contextRef="c20240101to20241231_CounterpartyNameAxis_AresCreditAgreementMember_DebtInstrumentAxis_AresCreditFacilityMember">P3D</ix:nonNumeric><ix:nonNumeric name="adma:ITTechnologySystemsInaccessiblePeriod" id="Fact_4754ce8ea55d44e195b5e28a95f3e9f0" contextRef="c20230619to20230619_RangeAxis_MaximumMember">P7D</ix:nonNumeric><ix:nonNumeric name="dei:AuditorFirmId" id="Fact_89c3f38fba7e479a9bb9abf5fd1f116f" contextRef="c20240101to20241231">185</ix:nonNumeric><ix:nonNumeric name="dei:AuditorFirmId" id="Fact_8de9ba90e6904aadaccdf07a6e27430f" contextRef="c20240101to20241231_CounterpartyNameAxis_CohnReznickLLPMember">596</ix:nonNumeric><ix:nonNumeric name="adma:AgreementWithTermExpirationDate" id="Fact_596502cac0e64068963eb61419709634" contextRef="c20240101to20241231_TypeOfArrangementAxis_ARGrifolsAgreementMember">2039-09-30</ix:nonNumeric><ix:nonNumeric name="adma:AgreementWithTermExpirationDate" id="Fact_08cb0657423a4fc9a23ab84cedf6874f" contextRef="c20240101to20241231_TypeOfArrangementAxis_KEDPlasmaAgreementMember">2031-07-31</ix:nonNumeric><ix:nonNumeric name="us-gaap:OperatingLossCarryforwardsExpirationDate" id="Fact_3caad71a9a1b440ba964fc32940d472a" contextRef="c20240101to20241231_RangeAxis_MinimumMember">2029-12-31</ix:nonNumeric><ix:nonNumeric name="us-gaap:OperatingLossCarryforwardsExpirationDate" id="Fact_8b85b23ae8fb4a49b2e8cb82e0d4603d" contextRef="c20240101to20241231_RangeAxis_MaximumMember">2043-12-31</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:href="adma-20241231.xsd" xlink:type="simple"/></ix:references><ix:resources><xbrli:context id="c20240101to20241231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20240630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20250310"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2025-03-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20240101to20241231_CounterpartyNameAxis_CohnReznickLLPMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adma:CohnReznickLLPMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20241231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20231231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20230101to20231231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20220101to20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20211231_StatementEquityComponentsAxis_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20211231_StatementEquityComponentsAxis_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20211231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20240101to20241231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20220101to20221231_StatementEquityComponentsAxis_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20220101to20221231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20230101to20231231_StatementEquityComponentsAxis_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20220101to20221231_StatementEquityComponentsAxis_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20230101to20231231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20240101to20241231_StatementEquityComponentsAxis_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20240101to20241231_StatementEquityComponentsAxis_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20230101to20231231_StatementEquityComponentsAxis_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20221231_StatementEquityComponentsAxis_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20231231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20221231_StatementEquityComponentsAxis_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20231231_StatementEquityComponentsAxis_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20221231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20241231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20241231_StatementEquityComponentsAxis_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20231231_StatementEquityComponentsAxis_CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20241231_StatementEquityComponentsAxis_RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20241001to20241231_IndividualAxis_AdamGrossmanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">adma:AdamGrossmanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-10-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20241001to20241231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-10-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20241231_TradingArrAxis_AdamGrossmanTradingPlanStockOptionsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:TradingArrAxis">adma:AdamGrossmanTradingPlanStockOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20241231_TradingArrAxis_AdamGrossmanTradingPlanCommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:TradingArrAxis">adma:AdamGrossmanTradingPlanCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20240101to20241231_ChangeInAccountingEstimateByTypeAxis_AccrualForUSMedicaidRebatesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ChangeInAccountingEstimateByTypeAxis">adma:AccrualForUSMedicaidRebatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20241231_ChangeInAccountingEstimateByTypeAxis_AccrualForUSMedicaidRebatesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ChangeInAccountingEstimateByTypeAxis">adma:AccrualForUSMedicaidRebatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20241231_RangeAxis_MinimumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20241231_PropertyPlantAndEquipmentByTypeAxis_BuildingMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20241231_RangeAxis_MaximumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20240101to20241231_TypeOfArrangementAxis_BiotestLicenseAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adma:BiotestLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20210101to20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20240101to20241231_AwardTypeAxis_RestrictedStockUnitsRSUMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20240101to20241231_AwardTypeAxis_EmployeeStockOptionMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20210901to20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-09-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20240101to20241231_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_RestrictedStockUnitsRSUMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20240101to20241231_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_EmployeeStockOptionMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20240101to20241231_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_WarrantMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20220101to20221231_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_EmployeeStockOptionMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20230101to20231231_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_WarrantMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20230101to20231231_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_EmployeeStockOptionMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20220101to20221231_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_RestrictedStockUnitsRSUMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20220101to20221231_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_WarrantMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20230101to20231231_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_RestrictedStockUnitsRSUMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20241231_PropertyPlantAndEquipmentByTypeAxis_AssetUnderConstructionMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:AssetUnderConstructionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20231231_PropertyPlantAndEquipmentByTypeAxis_OfficeEquipmentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20231231_PropertyPlantAndEquipmentByTypeAxis_LeaseholdImprovementsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20231231_PropertyPlantAndEquipmentByTypeAxis_ManufacturingFacilityMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ManufacturingFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20231231_PropertyPlantAndEquipmentByTypeAxis_FurnitureAndFixturesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20241231_PropertyPlantAndEquipmentByTypeAxis_LandMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20241231_PropertyPlantAndEquipmentByTypeAxis_FurnitureAndFixturesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20241231_PropertyPlantAndEquipmentByTypeAxis_BuildingAndBuildingImprovementsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20241231_PropertyPlantAndEquipmentByTypeAxis_OfficeEquipmentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20231231_PropertyPlantAndEquipmentByTypeAxis_AssetUnderConstructionMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:AssetUnderConstructionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20231231_PropertyPlantAndEquipmentByTypeAxis_LandMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20241231_PropertyPlantAndEquipmentByTypeAxis_ManufacturingFacilityMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ManufacturingFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20231231_PropertyPlantAndEquipmentByTypeAxis_BuildingAndBuildingImprovementsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20241231_PropertyPlantAndEquipmentByTypeAxis_LeaseholdImprovementsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20241231_FiniteLivedIntangibleAssetsByMajorClassAxis_RightToIntermediatesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">adma:RightToIntermediatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20241231_FiniteLivedIntangibleAssetsByMajorClassAxis_TrademarkAndOtherIntangibleRightsRelatedToNabiHBMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">adma:TrademarkAndOtherIntangibleRightsRelatedToNabiHBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20231231_FiniteLivedIntangibleAssetsByMajorClassAxis_RightToIntermediatesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">adma:RightToIntermediatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20231231_FiniteLivedIntangibleAssetsByMajorClassAxis_ComputerSoftwareIntangibleAssetMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20231231_FiniteLivedIntangibleAssetsByMajorClassAxis_TrademarkAndOtherIntangibleRightsRelatedToNabiHBMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">adma:TrademarkAndOtherIntangibleRightsRelatedToNabiHBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20241231_FiniteLivedIntangibleAssetsByMajorClassAxis_ComputerSoftwareIntangibleAssetMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20220323_CounterpartyNameAxis_HayfinCreditAgreementMember_DebtInstrumentAxis_HayfinDelayedDrawLoanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adma:HayfinCreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">adma:HayfinDelayedDrawLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20220323_CounterpartyNameAxis_HayfinCreditAgreementMember_DebtInstrumentAxis_HayfinCreditFacilityMember_RangeAxis_MaximumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">adma:HayfinCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adma:HayfinCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20220323_CounterpartyNameAxis_HayfinCreditAgreementMember_DebtInstrumentAxis_HayfinClosingDateLoanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">adma:HayfinClosingDateLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adma:HayfinCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20241231_CreditFacilityAxis_RevolvingCreditFacilityMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20231231_CreditFacilityAxis_TermLoanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">adma:TermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20231218"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-12-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20231231_CreditFacilityAxis_RevolvingCreditFacilityMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20241231_CreditFacilityAxis_TermLoanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">adma:TermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20231218_DebtInstrumentAxis_HayfinCreditFacilityMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">adma:HayfinCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20231218_CounterpartyNameAxis_AresCreditAgreementMember_DebtInstrumentAxis_AresCreditFacilityMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">adma:AresCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adma:AresCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20221231_CounterpartyNameAxis_HayfinSecondAmendmentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adma:HayfinSecondAmendmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20231231_CounterpartyNameAxis_HayfinSecondAmendmentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adma:HayfinSecondAmendmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20231218_CounterpartyNameAxis_HayfinCreditAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adma:HayfinCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20241219_CreditFacilityAxis_TermLoanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">adma:TermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-19</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20240101to20241231_CounterpartyNameAxis_HayfinSecondAmendmentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adma:HayfinSecondAmendmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20240101to20241231_CounterpartyNameAxis_HayfinCreditAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adma:HayfinCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20240101to20241231_CounterpartyNameAxis_HayfinCreditAgreementMember_DebtInstrumentAxis_HayfinCreditFacilityMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adma:HayfinCreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">adma:HayfinCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20240101to20241231_CounterpartyNameAxis_AresCreditAgreementMember_DebtInstrumentAxis_AresCreditFacilityMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">adma:AresCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adma:AresCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20230101to20231231_DebtInstrumentAxis_HayfinCreditFacilityMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">adma:HayfinCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20220323to20220323_CounterpartyNameAxis_HayfinCreditAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adma:HayfinCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-03-23</xbrli:startDate><xbrli:endDate>2022-03-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20241219to20241219_CreditFacilityAxis_TermLoanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">adma:TermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-12-19</xbrli:startDate><xbrli:endDate>2024-12-19</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20240814to20240814_CreditFacilityAxis_RevolvingCreditFacilityMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-08-14</xbrli:startDate><xbrli:endDate>2024-08-14</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20241231_CounterpartyNameAxis_AresCreditAgreementMember_DebtInstrumentAxis_AresCreditFacilityMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adma:AresCreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">adma:AresCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20240814_CounterpartyNameAxis_AresCreditAgreementMember_DebtInstrumentAxis_AresCreditFacilityMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adma:AresCreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">adma:AresCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-08-14</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20231218to20231218_CreditFacilityAxis_TermLoanMember_VariableRateAxis_SecuredOvernightFinancingRateSofrMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">adma:TermLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:SecuredOvernightFinancingRateSofrMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-12-18</xbrli:startDate><xbrli:endDate>2023-12-18</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20240101to20241231_CounterpartyNameAxis_HayfinCreditAgreementMember_VariableRateAxis_SecuredOvernightFinancingRateSofrMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:SecuredOvernightFinancingRateSofrMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adma:HayfinCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20231218to20231218_CreditFacilityAxis_RevolvingCreditFacilityMember_VariableRateAxis_SecuredOvernightFinancingRateSofrMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:SecuredOvernightFinancingRateSofrMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-12-18</xbrli:startDate><xbrli:endDate>2023-12-18</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20230430to20230430_CounterpartyNameAxis_HayfinSecondAmendmentMember_VariableRateAxis_SecuredOvernightFinancingRateSofrMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:SecuredOvernightFinancingRateSofrMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adma:HayfinSecondAmendmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-30</xbrli:startDate><xbrli:endDate>2023-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20230501to20230501_CounterpartyNameAxis_HayfinSecondAmendmentMember_VariableRateAxis_SecuredOvernightFinancingRateSofrMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:SecuredOvernightFinancingRateSofrMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adma:HayfinSecondAmendmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-05-01</xbrli:startDate><xbrli:endDate>2023-05-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20241231_CreditFacilityAxis_RevolvingCreditFacilityMember_VariableRateAxis_SecuredOvernightFinancingRateSofrMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:SecuredOvernightFinancingRateSofrMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20231231_CreditFacilityAxis_TermLoanMember_VariableRateAxis_SecuredOvernightFinancingRateSofrMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">adma:TermLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:SecuredOvernightFinancingRateSofrMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20241231_CreditFacilityAxis_TermLoanMember_VariableRateAxis_SecuredOvernightFinancingRateSofrMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:SecuredOvernightFinancingRateSofrMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">adma:TermLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20231231_CreditFacilityAxis_RevolvingCreditFacilityMember_VariableRateAxis_SecuredOvernightFinancingRateSofrMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:SecuredOvernightFinancingRateSofrMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20231218to20231218_CounterpartyNameAxis_AresCreditAgreementMember_DebtInstrumentAxis_AresCreditFacilityMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adma:AresCreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">adma:AresCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-12-18</xbrli:startDate><xbrli:endDate>2023-12-18</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20231218to20231218_CounterpartyNameAxis_AresCreditAgreementMember_RangeAxis_MinimumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adma:AresCreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-12-18</xbrli:startDate><xbrli:endDate>2023-12-18</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20231218to20231218_CounterpartyNameAxis_AresCreditAgreementMember_DebtInstrumentRedemptionPeriodAxis_PrepaidOnOrPriorToThirdAnniversaryMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">adma:PrepaidOnOrPriorToThirdAnniversaryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adma:AresCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-12-18</xbrli:startDate><xbrli:endDate>2023-12-18</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20231218to20231218_CounterpartyNameAxis_HayfinCreditAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adma:HayfinCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-12-18</xbrli:startDate><xbrli:endDate>2023-12-18</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20231218to20231218_CounterpartyNameAxis_AresCreditAgreementMember_DebtInstrumentRedemptionPeriodAxis_PrepaidAfterTheFirstAnniversaryMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adma:AresCreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">adma:PrepaidAfterTheFirstAnniversaryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-12-18</xbrli:startDate><xbrli:endDate>2023-12-18</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20231218to20231218_CounterpartyNameAxis_AresCreditAgreementMember_DebtInstrumentRedemptionPeriodAxis_PrepaidOnOrPriorToSecondAnniversaryMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">adma:PrepaidOnOrPriorToSecondAnniversaryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adma:AresCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-12-18</xbrli:startDate><xbrli:endDate>2023-12-18</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20231218to20231218_CounterpartyNameAxis_AresCreditAgreementMember_DebtInstrumentRedemptionPeriodAxis_PrepaidOnOrPriorToFirstAnniversaryMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">adma:PrepaidOnOrPriorToFirstAnniversaryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adma:AresCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-12-18</xbrli:startDate><xbrli:endDate>2023-12-18</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20231231_CounterpartyNameAxis_AresCreditAgreementMember_DebtInstrumentAxis_AresCreditFacilityMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adma:AresCreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">adma:AresCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20220323_CounterpartyNameAxis_HayfinCreditAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adma:HayfinCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20221231_CounterpartyNameAxis_HayfinCreditAgreementMember_DebtInstrumentAxis_HayfinClosingDateLoanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">adma:HayfinClosingDateLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adma:HayfinCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20221231_CounterpartyNameAxis_HayfinCreditAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adma:HayfinCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20231218_CounterpartyNameAxis_AresCreditAgreementMember_DebtInstrumentAxis_AresClosingDateLoanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adma:AresCreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">adma:AresClosingDateLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20241231_CounterpartyNameAxis_AresCreditAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adma:AresCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20240101to20241231_CounterpartyNameAxis_AresCreditAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adma:AresCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20220323to20220323_DebtInstrumentAxis_HayfinClosingDateLoanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">adma:HayfinClosingDateLoanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-03-23</xbrli:startDate><xbrli:endDate>2022-03-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20220323to20220323_CounterpartyNameAxis_HayfinCreditAgreementMember_DebtInstrumentAxis_HayfinClosingDateLoanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">adma:HayfinClosingDateLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adma:HayfinCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-03-23</xbrli:startDate><xbrli:endDate>2022-03-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20220323to20220323_CounterpartyNameAxis_HayfinCreditAgreementMember_VariableRateAxis_BaseRateMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adma:HayfinCreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-03-23</xbrli:startDate><xbrli:endDate>2022-03-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20230101to20231231_CounterpartyNameAxis_HayfinCreditAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adma:HayfinCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20220323_CounterpartyNameAxis_HayfinCreditAgreementMember_RangeAxis_MinimumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adma:HayfinCreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20220401to20220630_CounterpartyNameAxis_HayfinCreditAgreementMember_RangeAxis_MinimumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adma:HayfinCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20230701to20230930_CounterpartyNameAxis_HayfinCreditAgreementMember_RangeAxis_MaximumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adma:HayfinCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20230501_CounterpartyNameAxis_HayfinSecondAmendmentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adma:HayfinSecondAmendmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-05-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20221209to20221209_StatementEquityComponentsAxis_CommonStockMember_SubsidiarySaleOfStockAxis_OverAllotmentOptionMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-12-09</xbrli:startDate><xbrli:endDate>2022-12-09</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20230616to20230616_ClassOfWarrantOrRightAxis_HayfinWarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">adma:HayfinWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-06-16</xbrli:startDate><xbrli:endDate>2023-06-16</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20230616_ClassOfWarrantOrRightAxis_HayfinWarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">adma:HayfinWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20241231_ClassOfWarrantOrRightAxis_WarrantMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20220323_ClassOfWarrantOrRightAxis_HayfinWarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">adma:HayfinWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20240101to20241231_ClassOfWarrantOrRightAxis_HayfinWarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">adma:HayfinWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20220323to20220323_ClassOfWarrantOrRightAxis_HayfinWarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">adma:HayfinWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-03-23</xbrli:startDate><xbrli:endDate>2022-03-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20230501to20230501_CounterpartyNameAxis_HayfinSecondAmendmentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adma:HayfinSecondAmendmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-05-01</xbrli:startDate><xbrli:endDate>2023-05-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20211231_ClassOfWarrantOrRightAxis_WarrantMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20220101to20221231_ClassOfWarrantOrRightAxis_WarrantMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20230101to20231231_ClassOfWarrantOrRightAxis_WarrantMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20240101to20241231_ClassOfWarrantOrRightAxis_WarrantMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20221231_ClassOfWarrantOrRightAxis_WarrantMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20231231_ClassOfWarrantOrRightAxis_WarrantMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20220621_PlanNameAxis_Two022CompensationPlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">adma:Two022CompensationPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20230101to20231231_AwardTypeAxis_EmployeeStockOptionMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20220101to20221231_AwardTypeAxis_EmployeeStockOptionMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20231231_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_EquityIncentivePlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">adma:EquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20241231_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_EquityIncentivePlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">adma:EquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20240101to20241231_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_EquityIncentivePlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">adma:EquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20230101to20231231_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_EquityIncentivePlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">adma:EquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20231231_AwardTypeAxis_EmployeeStockOptionMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20230101to20231231_AwardTypeAxis_EmployeeStockOptionMember_RangeAxis_MinimumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20220101to20221231_AwardTypeAxis_EmployeeStockOptionMember_RangeAxis_MinimumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20230101to20231231_AwardTypeAxis_EmployeeStockOptionMember_RangeAxis_MaximumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20240101to20241231_AwardTypeAxis_EmployeeStockOptionMember_RangeAxis_MaximumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20220101to20221231_AwardTypeAxis_EmployeeStockOptionMember_RangeAxis_MaximumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20240101to20241231_AwardTypeAxis_EmployeeStockOptionMember_RangeAxis_MinimumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20211231_AwardTypeAxis_EmployeeStockOptionMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20221231_AwardTypeAxis_EmployeeStockOptionMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20241231_AwardTypeAxis_EmployeeStockOptionMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20240101to20241231_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ExercisePriceRange3Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">adma:ExercisePriceRange3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20240101to20241231_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ExercisePriceRange4Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">adma:ExercisePriceRange4Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20240101to20241231_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ExercisePriceRange5Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">adma:ExercisePriceRange5Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20240101to20241231_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ExercisePriceRange6Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">adma:ExercisePriceRange6Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20240101to20241231_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ExercisePriceRange1Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">adma:ExercisePriceRange1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20240101to20241231_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ExercisePriceRange2Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">adma:ExercisePriceRange2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20241231_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ExercisePriceRange1Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">adma:ExercisePriceRange1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20241231_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ExercisePriceRange5Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">adma:ExercisePriceRange5Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20241231_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ExercisePriceRange4Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">adma:ExercisePriceRange4Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20241231_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ExercisePriceRange3Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">adma:ExercisePriceRange3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20241231_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ExercisePriceRange6Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">adma:ExercisePriceRange6Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20241231_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ExercisePriceRange2Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">adma:ExercisePriceRange2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20241231_AwardTypeAxis_RestrictedStockUnitsRSUMember_PlanNameAxis_EquityIncentivePlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">adma:EquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20240101to20241231_AwardTypeAxis_RestrictedStockUnitsRSUMember_PlanNameAxis_EquityIncentivePlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">adma:EquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20230101to20231231_AwardTypeAxis_RestrictedStockUnitsRSUMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20220101to20221231_AwardTypeAxis_RestrictedStockUnitsRSUMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20240101to20241231_AwardTypeAxis_RestrictedStockUnitsRSUMember_TitleOfIndividualAxis_DirectorMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20240101to20241231_AwardTypeAxis_RestrictedStockUnitsRSUMember_TitleOfIndividualAxis_EmployeesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">adma:EmployeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20241231_AwardTypeAxis_RestrictedStockUnitsRSUMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20221231_AwardTypeAxis_RestrictedStockUnitsRSUMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20231231_AwardTypeAxis_RestrictedStockUnitsRSUMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20240101to20241231_TitleOfIndividualAxis_DirectorMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20240101to20241231_TitleOfIndividualAxis_EmployeesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">adma:EmployeesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20211231_AwardTypeAxis_RestrictedStockUnitsRSUMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20240101to20241231_IncomeStatementLocationAxis_ResearchAndDevelopmentExpenseMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20230101to20231231_IncomeStatementLocationAxis_ResearchAndDevelopmentExpenseMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20240101to20241231_IncomeStatementLocationAxis_OperatingExpenseMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20230101to20231231_IncomeStatementLocationAxis_OperatingExpenseMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20230101to20231231_IncomeStatementLocationAxis_CostOfSalesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20220101to20221231_IncomeStatementLocationAxis_OperatingExpenseMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20220101to20221231_IncomeStatementLocationAxis_CostOfSalesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20220101to20221231_IncomeStatementLocationAxis_SellingGeneralAndAdministrativeExpensesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20240101to20241231_IncomeStatementLocationAxis_SellingGeneralAndAdministrativeExpensesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20230101to20231231_IncomeStatementLocationAxis_SellingGeneralAndAdministrativeExpensesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20220101to20221231_IncomeStatementLocationAxis_ResearchAndDevelopmentExpenseMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20240101to20241231_IncomeStatementLocationAxis_CostOfSalesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20220101to20221231_CounterpartyNameAxis_ArethLLCMember_RelatedPartyTransactionsByRelatedPartyAxis_RelatedPartyMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adma:ArethLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20230101to20231231_CounterpartyNameAxis_ArethLLCMember_RelatedPartyTransactionsByRelatedPartyAxis_RelatedPartyMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adma:ArethLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20160101to20160131_CounterpartyNameAxis_ArethLLCMember_RelatedPartyTransactionsByRelatedPartyAxis_RelatedPartyMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adma:ArethLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-01-01</xbrli:startDate><xbrli:endDate>2016-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20240101to20241231_CounterpartyNameAxis_ArethLLCMember_RelatedPartyTransactionsByRelatedPartyAxis_RelatedPartyMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adma:ArethLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20240101to20241231_CounterpartyNameAxis_GenesisBPSMember_RelatedPartyTransactionsByRelatedPartyAxis_RelatedPartyMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adma:GenesisBPSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20220101to20221231_CounterpartyNameAxis_GenesisBPSMember_RelatedPartyTransactionsByRelatedPartyAxis_RelatedPartyMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adma:GenesisBPSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20230101to20231231_CounterpartyNameAxis_GenesisBPSMember_RelatedPartyTransactionsByRelatedPartyAxis_RelatedPartyMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adma:GenesisBPSMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20241119to20241119_AwardTypeAxis_RestrictedStockUnitsRSUMember_CounterpartyNameAxis_BryantFongMember_RelatedPartyTransactionsByRelatedPartyAxis_RelatedPartyMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adma:BryantFongMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-11-19</xbrli:startDate><xbrli:endDate>2024-11-19</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20240101to20241231_RangeAxis_MaximumMember_RelatedPartyTransactionsByRelatedPartyAxis_RelatedPartyMember_TitleOfIndividualAxis_ExecutiveVicePresidentAndChiefFinancialOfficerMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">adma:ExecutiveVicePresidentAndChiefFinancialOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20240101to20241231_RangeAxis_MinimumMember_RelatedPartyTransactionsByRelatedPartyAxis_RelatedPartyMember_TitleOfIndividualAxis_ExecutiveVicePresidentAndChiefFinancialOfficerMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">adma:ExecutiveVicePresidentAndChiefFinancialOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20240101to20241231_CounterpartyNameAxis_BryantFongMember_RangeAxis_MaximumMember_RelatedPartyTransactionsByRelatedPartyAxis_RelatedPartyMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adma:BryantFongMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20240101to20241231_CounterpartyNameAxis_BryantFongMember_RangeAxis_MinimumMember_RelatedPartyTransactionsByRelatedPartyAxis_RelatedPartyMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adma:BryantFongMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20240101to20241231_RelatedPartyTransactionsByRelatedPartyAxis_RelatedPartyMember_TitleOfIndividualAxis_ExecutiveVicePresidentAndChiefFinancialOfficerMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">adma:ExecutiveVicePresidentAndChiefFinancialOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20240101to20241231_CounterpartyNameAxis_BryantFongMember_RelatedPartyTransactionsByRelatedPartyAxis_RelatedPartyMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adma:BryantFongMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20230815to20230815_RelatedPartyTransactionsByRelatedPartyAxis_RelatedPartyMember_TitleOfIndividualAxis_ExecutiveOfficerMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ExecutiveOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-08-15</xbrli:startDate><xbrli:endDate>2023-08-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20220101to20221231_LineOfCreditFacilityAxis_PerceptiveCreditHoldingsIILPMember_RelatedPartyTransactionsByRelatedPartyAxis_RelatedPartyMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">adma:PerceptiveCreditHoldingsIILPMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20221209to20221209_OwnershipAxis_DirectOwnershipMember_RelatedPartyTransactionsByRelatedPartyAxis_RelatedPartyMember_TitleOfIndividualAxis_PresidentAndChiefExecutiveOfficerMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">adma:PresidentAndChiefExecutiveOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:OwnershipAxis">adma:DirectOwnershipMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-12-09</xbrli:startDate><xbrli:endDate>2022-12-09</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20221209to20221209_OwnershipAxis_IndirectOwnershipMember_RelatedPartyTransactionsByRelatedPartyAxis_RelatedPartyMember_TitleOfIndividualAxis_PresidentAndChiefExecutiveOfficerMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">adma:IndirectOwnershipMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">adma:PresidentAndChiefExecutiveOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-12-09</xbrli:startDate><xbrli:endDate>2022-12-09</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20221209to20221209_RelatedPartyTransactionsByRelatedPartyAxis_RelatedPartyMember_TitleOfIndividualAxis_ExecutiveVicePresidentAndChiefFinancialOfficerMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">adma:ExecutiveVicePresidentAndChiefFinancialOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-12-09</xbrli:startDate><xbrli:endDate>2022-12-09</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20221209_RelatedPartyTransactionsByRelatedPartyAxis_RelatedPartyMember_TitleOfIndividualAxis_ExecutiveVicePresidentAndChiefFinancialOfficerMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">adma:ExecutiveVicePresidentAndChiefFinancialOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-09</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20230619to20230619_RangeAxis_MaximumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-06-19</xbrli:startDate><xbrli:endDate>2023-06-19</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20230619to20230619"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-06-19</xbrli:startDate><xbrli:endDate>2023-06-19</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20230401to20230630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-04-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20250101to20250318_SubsequentEventTypeAxis_SubsequentEventMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-18</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20240101to20241231_RangeAxis_MaximumMember_TypeOfArrangementAxis_PlasmaPurchaseAgreementOneMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adma:PlasmaPurchaseAgreementOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20241001to20241001_TypeOfArrangementAxis_ARGrifolsAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adma:ARGrifolsAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-10-01</xbrli:startDate><xbrli:endDate>2024-10-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20240101to20241231_TypeOfArrangementAxis_KEDPlasmaAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adma:KEDPlasmaAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20240101to20241231_TypeOfArrangementAxis_ARGrifolsAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adma:ARGrifolsAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20240806to20240806_RangeAxis_MinimumMember_TypeOfArrangementAxis_KEDPlasmaAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adma:KEDPlasmaAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-08-06</xbrli:startDate><xbrli:endDate>2024-08-06</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20241001to20241001_RangeAxis_MinimumMember_TypeOfArrangementAxis_ARGrifolsAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adma:ARGrifolsAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-10-01</xbrli:startDate><xbrli:endDate>2024-10-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20220101to20221231_ProductOrServiceAxis_ASCENIVMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">adma:ASCENIVMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20190401to20190401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-04-01</xbrli:startDate><xbrli:endDate>2019-04-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20230101to20231231_ProductOrServiceAxis_BIVIGAMMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">adma:BIVIGAMMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20240101to20241231_ProductOrServiceAxis_BIVIGAMMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">adma:BIVIGAMMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20220101to20221231_ProductOrServiceAxis_BIVIGAMMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">adma:BIVIGAMMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20230101to20231231_ProductOrServiceAxis_ASCENIVMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">adma:ASCENIVMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20240101to20241231_ProductOrServiceAxis_ASCENIVMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">adma:ASCENIVMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20241231_IncomeTaxAuthorityAxis_InternalRevenueServiceIRSMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20241231_IncomeTaxAuthorityAxis_InternalRevenueServiceIRSMember_TaxPeriodAxis_TaxYear2031Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">adma:TaxYear2031Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20241231_IncomeTaxAuthorityAxis_InternalRevenueServiceIRSMember_TaxPeriodAxis_TaxYear2035Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">adma:TaxYear2035Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20241231_IncomeTaxAuthorityAxis_StateAndLocalJurisdictionMember_TaxPeriodAxis_TaxYear2028Through2043Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">adma:TaxYear2028Through2043Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20241231_IncomeTaxAuthorityAxis_InternalRevenueServiceIRSMember_TaxPeriodAxis_TaxYear2036Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">adma:TaxYear2036Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20241231_IncomeTaxAuthorityAxis_InternalRevenueServiceIRSMember_TaxPeriodAxis_TaxYear2034Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">adma:TaxYear2034Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20241231_IncomeTaxAuthorityAxis_InternalRevenueServiceIRSMember_TaxPeriodAxis_TaxYear2032Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">adma:TaxYear2032Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20241231_IncomeTaxAuthorityAxis_InternalRevenueServiceIRSMember_TaxPeriodAxis_TaxYear2037Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">adma:TaxYear2037Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20241231_IncomeTaxAuthorityAxis_InternalRevenueServiceIRSMember_TaxPeriodAxis_TaxYearAfter2037Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">adma:TaxYearAfter2037Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20241231_IncomeTaxAuthorityAxis_InternalRevenueServiceIRSMember_TaxPeriodAxis_TaxYear2033Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">adma:TaxYear2033Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20241231_IncomeTaxAuthorityAxis_InternalRevenueServiceIRSMember_TaxPeriodAxis_TaxYear2028Through2043Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">adma:TaxYear2028Through2043Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20241231_IncomeTaxAuthorityAxis_StateAndLocalJurisdictionMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20240101to20241231_RangeAxis_MinimumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20240101to20241231_RangeAxis_MaximumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20231231_IncomeTaxAuthorityAxis_InternalRevenueServiceIRSMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20231231_IncomeTaxAuthorityAxis_StateAndLocalJurisdictionMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20240101to20241231_ConsolidationItemsAxis_OperatingSegmentsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20230101to20231231_ConsolidationItemsAxis_MaterialReconcilingItemsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20220101to20221231_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_ADMABioManufacturingSegmentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">adma:ADMABioManufacturingSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20230101to20231231_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_ADMABioManufacturingSegmentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">adma:ADMABioManufacturingSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20240101to20241231_ConsolidationItemsAxis_MaterialReconcilingItemsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20240101to20241231_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_ADMABioManufacturingSegmentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">adma:ADMABioManufacturingSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20230101to20231231_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PlasmaCollectionCentersSegmentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">adma:PlasmaCollectionCentersSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20220101to20221231_ConsolidationItemsAxis_MaterialReconcilingItemsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20240101to20241231_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PlasmaCollectionCentersSegmentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">adma:PlasmaCollectionCentersSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20220101to20221231_ConsolidationItemsAxis_OperatingSegmentsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20220101to20221231_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PlasmaCollectionCentersSegmentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">adma:PlasmaCollectionCentersSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20230101to20231231_ConsolidationItemsAxis_OperatingSegmentsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20240101to20241231_ConsolidationItemsAxis_CorporateNonSegmentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20220101to20221231_ConsolidationItemsAxis_CorporateNonSegmentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20230101to20231231_ConsolidationItemsAxis_CorporateNonSegmentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20241231_ConsolidationItemsAxis_OperatingSegmentsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20241231_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_ADMABioManufacturingSegmentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">adma:ADMABioManufacturingSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20221231_ConsolidationItemsAxis_CorporateNonSegmentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20231231_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PlasmaCollectionCentersSegmentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">adma:PlasmaCollectionCentersSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20231231_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_ADMABioManufacturingSegmentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">adma:ADMABioManufacturingSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20241231_ConsolidationItemsAxis_CorporateNonSegmentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20241231_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PlasmaCollectionCentersSegmentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">adma:PlasmaCollectionCentersSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20231231_ConsolidationItemsAxis_CorporateNonSegmentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20221231_ConsolidationItemsAxis_OperatingSegmentsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20221231_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PlasmaCollectionCentersSegmentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">adma:PlasmaCollectionCentersSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20231231_ConsolidationItemsAxis_OperatingSegmentsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20221231_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_ADMABioManufacturingSegmentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">adma:ADMABioManufacturingSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20230101to20231231_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_ADMABioManufacturingSegmentMember_StatementGeographicalAxis_NonUsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">adma:ADMABioManufacturingSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20240101to20241231_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PlasmaCollectionCentersSegmentMember_StatementGeographicalAxis_US"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">adma:PlasmaCollectionCentersSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20230101to20231231_ConsolidationItemsAxis_OperatingSegmentsMember_StatementGeographicalAxis_US"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20230101to20231231_ConsolidationItemsAxis_OperatingSegmentsMember_StatementGeographicalAxis_NonUsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20220101to20221231_ConsolidationItemsAxis_OperatingSegmentsMember_StatementGeographicalAxis_US"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20230101to20231231_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_ADMABioManufacturingSegmentMember_StatementGeographicalAxis_US"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">adma:ADMABioManufacturingSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20240101to20241231_ConsolidationItemsAxis_MaterialReconcilingItemsMember_StatementGeographicalAxis_US"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20230101to20231231_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PlasmaCollectionCentersSegmentMember_StatementGeographicalAxis_NonUsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">adma:PlasmaCollectionCentersSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20220101to20221231_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_ADMABioManufacturingSegmentMember_StatementGeographicalAxis_NonUsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">adma:ADMABioManufacturingSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20240101to20241231_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PlasmaCollectionCentersSegmentMember_StatementGeographicalAxis_NonUsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">adma:PlasmaCollectionCentersSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20240101to20241231_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_ADMABioManufacturingSegmentMember_StatementGeographicalAxis_NonUsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">adma:ADMABioManufacturingSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20220101to20221231_ConsolidationItemsAxis_OperatingSegmentsMember_StatementGeographicalAxis_NonUsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20240101to20241231_ConsolidationItemsAxis_MaterialReconcilingItemsMember_StatementGeographicalAxis_NonUsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20240101to20241231_ConsolidationItemsAxis_OperatingSegmentsMember_StatementGeographicalAxis_US"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20230101to20231231_ConsolidationItemsAxis_MaterialReconcilingItemsMember_StatementGeographicalAxis_US"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20240101to20241231_StatementGeographicalAxis_NonUsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20220101to20221231_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_ADMABioManufacturingSegmentMember_StatementGeographicalAxis_US"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">adma:ADMABioManufacturingSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20220101to20221231_StatementGeographicalAxis_US"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20230101to20231231_ConsolidationItemsAxis_MaterialReconcilingItemsMember_StatementGeographicalAxis_NonUsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20240101to20241231_StatementGeographicalAxis_US"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20220101to20221231_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PlasmaCollectionCentersSegmentMember_StatementGeographicalAxis_US"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">adma:PlasmaCollectionCentersSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20230101to20231231_StatementGeographicalAxis_US"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20240101to20241231_ConsolidationItemsAxis_OperatingSegmentsMember_StatementGeographicalAxis_NonUsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20240101to20241231_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_ADMABioManufacturingSegmentMember_StatementGeographicalAxis_US"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">adma:ADMABioManufacturingSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20230101to20231231_StatementGeographicalAxis_NonUsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20220101to20221231_StatementGeographicalAxis_NonUsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20220101to20221231_ConsolidationItemsAxis_MaterialReconcilingItemsMember_StatementGeographicalAxis_US"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20220101to20221231_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PlasmaCollectionCentersSegmentMember_StatementGeographicalAxis_NonUsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">adma:PlasmaCollectionCentersSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20230101to20231231_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PlasmaCollectionCentersSegmentMember_StatementGeographicalAxis_US"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">adma:PlasmaCollectionCentersSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20220101to20221231_ConsolidationItemsAxis_MaterialReconcilingItemsMember_StatementGeographicalAxis_NonUsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20230101to20231231_ConcentrationRiskByBenchmarkAxis_AccountsReceivableMember_ConcentrationRiskByTypeAxis_CustomerConcentrationRiskMember_MajorCustomersAxis_FiveCustomersMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">adma:FiveCustomersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20220101to20221231_ConcentrationRiskByBenchmarkAxis_RevenueFromContractWithCustomerProductAndServiceBenchmarkMember_ConcentrationRiskByTypeAxis_CustomerConcentrationRiskMember_MajorCustomersAxis_TwoCustomersMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">adma:TwoCustomersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerProductAndServiceBenchmarkMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20240101to20241231_ConcentrationRiskByBenchmarkAxis_RevenueFromContractWithCustomerProductAndServiceBenchmarkMember_ConcentrationRiskByTypeAxis_CustomerConcentrationRiskMember_StatementBusinessSegmentsAxis_PlasmaCollectionCentersSegmentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerProductAndServiceBenchmarkMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">adma:PlasmaCollectionCentersSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20230101to20231231_ConcentrationRiskByBenchmarkAxis_RevenueFromContractWithCustomerProductAndServiceBenchmarkMember_ConcentrationRiskByTypeAxis_CustomerConcentrationRiskMember_MajorCustomersAxis_TwoCustomersMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerProductAndServiceBenchmarkMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">adma:TwoCustomersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20240101to20241231_ConcentrationRiskByBenchmarkAxis_RevenueFromContractWithCustomerProductAndServiceBenchmarkMember_ConcentrationRiskByTypeAxis_CustomerConcentrationRiskMember_MajorCustomersAxis_TwoCustomersMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerProductAndServiceBenchmarkMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">adma:TwoCustomersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20240101to20241231_ConcentrationRiskByBenchmarkAxis_AccountsReceivableMember_ConcentrationRiskByTypeAxis_CustomerConcentrationRiskMember_MajorCustomersAxis_ThreeCustomersMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">adma:ThreeCustomersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20211231_ValuationAllowancesAndReservesTypeAxis_SECSchedule1209ReserveAccruedRebatesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">adma:SECSchedule1209ReserveAccruedRebatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20231231_ValuationAllowancesAndReservesTypeAxis_ValuationAllowanceOfDeferredTaxAssetsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20231231_ValuationAllowancesAndReservesTypeAxis_SECSchedule1209ReserveAccruedRebatesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">adma:SECSchedule1209ReserveAccruedRebatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20221231_ValuationAllowancesAndReservesTypeAxis_InventoryValuationReserveMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:InventoryValuationReserveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20211231_ValuationAllowancesAndReservesTypeAxis_InventoryValuationReserveMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:InventoryValuationReserveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20221231_ValuationAllowancesAndReservesTypeAxis_SECSchedule1209ReserveAccruedRebatesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">adma:SECSchedule1209ReserveAccruedRebatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20221231_ValuationAllowancesAndReservesTypeAxis_ValuationAllowanceOfDeferredTaxAssetsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20231231_ValuationAllowancesAndReservesTypeAxis_InventoryValuationReserveMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:InventoryValuationReserveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20211231_ValuationAllowancesAndReservesTypeAxis_ValuationAllowanceOfDeferredTaxAssetsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20230101to20231231_ValuationAllowancesAndReservesTypeAxis_InventoryValuationReserveMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:InventoryValuationReserveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20240101to20241231_ValuationAllowancesAndReservesTypeAxis_ValuationAllowanceOfDeferredTaxAssetsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20240101to20241231_ValuationAllowancesAndReservesTypeAxis_SECSchedule1209ReserveAccruedRebatesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">adma:SECSchedule1209ReserveAccruedRebatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20230101to20231231_ValuationAllowancesAndReservesTypeAxis_SECSchedule1209ReserveAccruedRebatesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">adma:SECSchedule1209ReserveAccruedRebatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20240101to20241231_ValuationAllowancesAndReservesTypeAxis_InventoryValuationReserveMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:InventoryValuationReserveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20220101to20221231_ValuationAllowancesAndReservesTypeAxis_ValuationAllowanceOfDeferredTaxAssetsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20230101to20231231_ValuationAllowancesAndReservesTypeAxis_ValuationAllowanceOfDeferredTaxAssetsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20220101to20221231_ValuationAllowancesAndReservesTypeAxis_SECSchedule1209ReserveAccruedRebatesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">adma:SECSchedule1209ReserveAccruedRebatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20220101to20221231_ValuationAllowancesAndReservesTypeAxis_InventoryValuationReserveMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:InventoryValuationReserveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c20241231_ValuationAllowancesAndReservesTypeAxis_ValuationAllowanceOfDeferredTaxAssetsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20241231_ValuationAllowancesAndReservesTypeAxis_InventoryValuationReserveMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:InventoryValuationReserveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c20241231_ValuationAllowancesAndReservesTypeAxis_SECSchedule1209ReserveAccruedRebatesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001368514</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">adma:SECSchedule1209ReserveAccruedRebatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="U001"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:unit id="U002"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="U003"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="U004"><xbrli:measure>adma:Facility</xbrli:measure></xbrli:unit><xbrli:unit id="U005"><xbrli:measure>adma:Product</xbrli:measure></xbrli:unit><xbrli:unit id="U006"><xbrli:measure>adma:Officer</xbrli:measure></xbrli:unit><xbrli:unit id="U007"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="U008"><xbrli:measure>adma:Director</xbrli:measure></xbrli:unit><xbrli:unit id="U009"><xbrli:measure>adma:Employee</xbrli:measure></xbrli:unit><xbrli:unit id="U010"><xbrli:measure>adma:Batch</xbrli:measure></xbrli:unit><xbrli:unit id="U011"><xbrli:measure>adma:Term</xbrli:measure></xbrli:unit><xbrli:unit id="U012"><xbrli:measure>utr:l</xbrli:measure></xbrli:unit><xbrli:unit id="U013"><xbrli:measure>adma:Lease</xbrli:measure></xbrli:unit><xbrli:unit id="U014"><xbrli:measure>adma:Segment</xbrli:measure></xbrli:unit><xbrli:unit id="U015"><xbrli:measure>adma:Customer</xbrli:measure></xbrli:unit><ix:relationship order="1.0" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Fact_38cc8c1ba39345bb9c266112d2a58244" toRefs="Foot_09400bbe9814473cacf6009d441a9bbc" linkRole="http://www.xbrl.org/2003/role/link"/><ix:relationship order="1.0" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Fact_d50c136af3e64211860c504c901e8c64" toRefs="Foot_09400bbe9814473cacf6009d441a9bbc" linkRole="http://www.xbrl.org/2003/role/link"/><ix:relationship order="1.0" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Fact_1ebee0d4064242ba89bb9e7237a76696" toRefs="Foot_09400bbe9814473cacf6009d441a9bbc" linkRole="http://www.xbrl.org/2003/role/link"/><ix:relationship order="1.0" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Fact_cde715de13354b49a38d7dda07a2e372" toRefs="Foot_09400bbe9814473cacf6009d441a9bbc" linkRole="http://www.xbrl.org/2003/role/link"/><ix:relationship order="1.0" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Fact_4dc192bb6874460db027219d6a8cbdc1" toRefs="Foot_09400bbe9814473cacf6009d441a9bbc" linkRole="http://www.xbrl.org/2003/role/link"/><ix:relationship order="1.0" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Fact_59d303f1d98c47bf8afbfb622cfe76d6" toRefs="Foot_09400bbe9814473cacf6009d441a9bbc" linkRole="http://www.xbrl.org/2003/role/link"/><ix:relationship order="1.0" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Fact_92e4d85a8785438787156b3774d98556" toRefs="Foot_0c35b5dd3cb44596b792fca041b80d28" linkRole="http://www.xbrl.org/2003/role/link"/><ix:relationship order="1.0" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Fact_c0dc9246cefd4ef981112d0b8e335383" toRefs="Foot_0c35b5dd3cb44596b792fca041b80d28" linkRole="http://www.xbrl.org/2003/role/link"/><ix:relationship order="1.0" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="Fact_098496fadea04070a12725b9411291d8" toRefs="Foot_8c1cfdc8358b499c8ef892be7b50f8db" linkRole="http://www.xbrl.org/2003/role/link"/></ix:resources></ix:header></div>
<div style="line-height: initial;">

  <div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: rgb(0, 0, 0);">
    <div>
      <div style="text-align: left; font: 10pt 'Times New Roman';">
        <div id="XBRLDIV" style="display: none; text-align: left; font: 10pt 'Times New Roman';">0001368514false--12-31falseFY202000100000000000593183552390000563035110000060000000013685142020-01-012020-12-310001368514adma:JefferiesLLCMemberadma:SaleAgreementMemberus-gaap:SubsequentEventMember2021-02-012021-02-030001368514adma:JefferiesLLCMemberadma:SaleAgreementMemberus-gaap:SubsequentEventMember2021-01-012021-03-160001368514adma:InventoryPurchasesMemberadma:GrifolsMember2019-01-012019-12-310001368514adma:InventoryPurchasesMemberadma:GrifolsMember2020-01-012020-12-310001368514adma:RevenueMemberadma:ThreeCustomersMember2020-01-012020-12-310001368514adma:RevenueMemberadma:ThreeCustomersMember2019-01-012019-12-310001368514adma:ThreeCustomersMemberus-gaap:AccountsReceivableMember2020-01-012020-12-310001368514adma:TwoCustomersMemberus-gaap:AccountsReceivableMember2019-01-012019-12-310001368514adma:ConsolidatedMember2019-12-310001368514adma:ConsolidatedMember2020-12-310001368514adma:ConsolidatedMember2019-01-012019-12-310001368514adma:ConsolidatedMember2020-01-012020-12-310001368514us-gaap:CorporateMember2019-12-310001368514us-gaap:CorporateMember2020-12-310001368514us-gaap:CorporateMember2019-01-012019-12-310001368514us-gaap:CorporateMember2020-01-012020-12-310001368514adma:PlasmaCollectionCenterMember2019-12-310001368514adma:PlasmaCollectionCenterMember2020-12-310001368514adma:PlasmaCollectionCenterMember2019-01-012019-12-310001368514adma:PlasmaCollectionCenterMember2020-01-012020-12-310001368514adma:AdmaBiomanufacturingMember2019-12-310001368514adma:AdmaBiomanufacturingMember2020-12-310001368514adma:AdmaBiomanufacturingMember2019-01-012019-12-310001368514adma:AdmaBiomanufacturingMember2020-01-012020-12-310001368514adma:StateMember2020-12-310001368514adma:FederalMember2020-12-310001368514adma:ArethLLCMember2017-09-092017-10-010001368514adma:MedicalEquipmentAndServicesMember2020-01-012020-12-310001368514adma:ArethLLCMember2020-01-012020-12-310001368514adma:ArethLLCMember2019-01-012019-12-310001368514us-gaap:RestrictedStockUnitsRSUMember2020-12-310001368514adma:EquityIncentivePlanMember2020-12-310001368514adma:EquityIncentivePlanMember2019-01-012019-12-310001368514adma:EquityIncentivePlanMember2020-01-012020-12-310001368514adma:SaleAgreementMember2020-11-050001368514adma:SaleAgreementMember2020-01-012020-12-310001368514adma:SaleAgreementMember2020-08-0500013685142020-02-012020-02-2100013685142019-05-012019-05-2100013685142020-02-012020-02-1100013685142020-02-2100013685142019-05-2100013685142020-02-1100013685142019-08-230001368514adma:PerceptiveTrancheIvWarrantMember2020-12-310001368514adma:PerceptiveTrancheIIIWarrantMemberadma:MayThreeTwoThousandNinteenMember2020-01-012020-12-310001368514adma:PerceptiveTrancheIIIWarrantMemberadma:MayThreeTwoThousandNinteenMember2020-12-310001368514adma:JanuaryOneTwoThousandTwentyOneMember2020-12-310001368514us-gaap:CostOfGoodsTotalMember2020-01-012020-12-310001368514us-gaap:CostOfGoodsTotalMember2019-01-012019-12-310001368514adma:PlasmaCentersMember2020-01-012020-12-310001368514adma:PlasmaCentersMember2019-01-012019-12-310001368514us-gaap:GeneralAndAdministrativeExpenseMember2020-01-012020-12-310001368514us-gaap:GeneralAndAdministrativeExpenseMember2019-01-012019-12-310001368514us-gaap:ResearchAndDevelopmentExpenseMember2020-01-012020-12-310001368514us-gaap:ResearchAndDevelopmentExpenseMember2019-01-012019-12-310001368514adma:WeightedAverageGrantDateFairValueMember2020-12-310001368514adma:WeightedAverageGrantDateFairValueMember2020-01-012020-12-310001368514adma:Range4Member2020-01-012020-12-310001368514adma:Range4Member2020-12-310001368514adma:Range3Member2020-01-012020-12-310001368514adma:Range3Member2020-12-310001368514adma:Range2Member2020-01-012020-12-310001368514adma:Range2Member2020-12-310001368514adma:Range1Member2020-01-012020-12-310001368514adma:Range1Member2020-12-310001368514adma:RangeTotalMember2020-01-012020-12-310001368514adma:RangeTotalMember2020-12-310001368514adma:WeightedAverageExercisePriceMember2020-12-310001368514adma:WeightedAverageExercisePriceMember2020-01-012020-12-310001368514adma:WeightedAverageExercisePriceMember2019-01-012019-12-310001368514adma:WeightedAverageExercisePriceMember2019-12-310001368514adma:WeightedAverageExercisePriceMember2018-12-310001368514adma:SharesMember2019-12-310001368514adma:SharesMember2020-12-310001368514adma:SharesMember2019-01-012019-12-310001368514adma:SharesMember2020-01-012020-12-310001368514srt:MaximumMember2020-01-012020-12-310001368514srt:MinimumMember2020-01-012020-12-310001368514srt:MaximumMember2019-01-012019-12-310001368514srt:MinimumMember2019-01-012019-12-310001368514adma:MarathonHealthcareFinanceFundLPMember2019-05-030001368514adma:SecondPerceptiveAmendmentMember2020-12-310001368514adma:SecondPerceptiveAmendmentMember2020-01-012020-12-310001368514adma:MarathonHealthcareFinanceFundLPMember2019-01-012019-12-310001368514adma:MarathonHealthcareFinanceFundLPMember2019-04-112019-05-030001368514adma:BPCMember2020-01-012020-12-310001368514adma:PerceptiveTrancheIIILoanMember2020-03-012020-03-200001368514adma:PerceptiveTrancheIILoanMember2019-04-112019-05-030001368514adma:PerceptiveTrancheILoanMember2020-01-012020-12-310001368514adma:PerceptiveCreditAgreementMember2019-02-012019-02-110001368514adma:PerceptiveTrancheIvLoanMember2020-01-012020-12-310001368514adma:PerceptiveTrancheIvLoanMember2020-11-202020-12-080001368514adma:PerceptiveTrancheIIIWarrantMember2019-05-020001368514adma:PerceptiveCreditAgreementMember2020-12-310001368514adma:PerceptiveTrancheIIIWarrantMember2019-04-112019-05-020001368514adma:PerceptiveTrancheIvWarrantMember2020-01-012020-12-310001368514adma:PerceptiveCreditAgreementMember2020-01-012020-12-310001368514adma:BPCMember2020-12-3100013685142020-11-202020-12-080001368514adma:FirstPerceptiveAmendmentMember2019-04-112019-05-0300013685142020-12-080001368514us-gaap:CustomerContractsMember2020-12-310001368514adma:RightToIntermediatesMember2020-12-310001368514adma:TrademarksAndOtherIntangibleRightsMember2020-12-310001368514us-gaap:CustomerContractsMember2019-12-310001368514adma:RightToIntermediatesMember2019-12-310001368514adma:TrademarksAndOtherIntangibleRightsMember2019-12-310001368514us-gaap:AssetUnderConstructionMember2019-12-310001368514us-gaap:AssetUnderConstructionMember2020-12-310001368514us-gaap:BuildingMember2020-12-310001368514adma:LandsMember2020-12-310001368514us-gaap:LeaseholdImprovementsMember2020-12-310001368514us-gaap:FurnitureAndFixturesMember2020-12-310001368514us-gaap:OfficeEquipmentMember2020-12-310001368514adma:ManufacturingAndLaboratoryEquipmentMember2020-12-310001368514us-gaap:BuildingMember2019-12-310001368514adma:LandsMember2019-12-310001368514us-gaap:LeaseholdImprovementsMember2019-12-310001368514us-gaap:FurnitureAndFixturesMember2019-12-310001368514us-gaap:OfficeEquipmentMember2019-12-310001368514adma:ManufacturingAndLaboratoryEquipmentMember2019-12-310001368514adma:JanuaryOneTwoZeroOneNineMemberadma:TwoFacilitiesMember2020-01-012020-12-310001368514adma:JanuaryOneTwoZeroOneNineMemberadma:TwoFacilitiesMember2020-12-310001368514adma:LandAndBuildingsMembersrt:MinimumMember2020-01-012020-12-310001368514adma:LandAndBuildingsMembersrt:MaximumMember2020-01-012020-12-310001368514adma:BuildingsMember2020-01-012020-12-310001368514adma:BiotestLicenseAgreementMember2020-01-012020-12-310001368514adma:JanuaryOneTwoThousandNineteenMember2020-12-310001368514adma:ReserveAccountMember2019-12-310001368514adma:WarrantsMember2019-01-012019-12-310001368514adma:WarrantsMember2020-01-012020-12-310001368514us-gaap:RestrictedStockUnitsRSUMember2020-01-012020-12-310001368514adma:StockOptionsMember2019-01-012019-12-310001368514adma:StockOptionsMember2020-01-012020-12-310001368514adma:JefferiesLLCMemberadma:SaleAgreementMember2020-01-012020-12-310001368514adma:JefferiesLLCMemberadma:SaleAgreementMember2021-02-030001368514adma:JefferiesLLCMemberadma:SaleAgreementMember2020-08-050001368514us-gaap:RetainedEarningsMember2020-12-310001368514us-gaap:AdditionalPaidInCapitalMember2020-12-310001368514us-gaap:CommonStockMember2020-12-310001368514us-gaap:RetainedEarningsMember2020-01-012020-12-310001368514us-gaap:AdditionalPaidInCapitalMember2020-01-012020-12-310001368514us-gaap:RetainedEarningsMember2019-12-310001368514us-gaap:AdditionalPaidInCapitalMember2019-12-310001368514us-gaap:CommonStockMember2019-12-310001368514us-gaap:RetainedEarningsMember2019-01-012019-12-310001368514us-gaap:AdditionalPaidInCapitalMember2019-01-012019-12-310001368514us-gaap:CommonStockMember2019-01-012019-12-3100013685142018-12-310001368514us-gaap:RetainedEarningsMember2018-12-310001368514us-gaap:AdditionalPaidInCapitalMember2018-12-310001368514us-gaap:CommonStockMember2018-12-3100013685142019-01-012019-12-3100013685142019-12-3100013685142020-12-3100013685142021-03-1600013685142020-06-300001368514us-gaap:CommonStockMember2020-01-012020-12-310001368514us-gaap:PreferredStockMember2020-01-012020-12-31iso4217:USDxbrli:sharesiso4217:USDxbrli:sharesxbrli:pure</div>

        <table style="font-size:1px;width:100%">


  <tr>

    <td style="BORDER-BOTTOM: 5px solid;"><br/>
              </td>

  </tr>

  <tr>

    <td style="BORDER-BOTTOM: 2px solid;"><br/>
              </td>

  </tr>


</table>
        <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px;">&#160;</p>
        <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: center;"><strong>UNITED STATES&#160;</strong></p>
        <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: center;"><strong>SECURITIES AND EXCHANGE COMMISSION</strong></p>
        <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: center;"><strong>Washington, D.C. 20549</strong></p>
        <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;">&#160;<br/>
        </p>
        <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: center;"><strong><span style="font-size:18pt">FORM <ix:nonNumeric name="dei:DocumentType" id="Fact_4f28663ed1034d3bbe4d7a16732807a5" contextRef="c20240101to20241231">10-K</ix:nonNumeric></span></strong></p>
        <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: center;">&#160; </p>
        <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: left;">(Mark One)</p>
        <div>
          <table cellspacing="0" cellpadding="0" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt; border-spacing: 0;" class="DSPFListTable">


  <tr style="vertical-align: top;">

    <td style="vertical-align: top; width: 27pt;">
                  <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><span style="font-size: 10pt; font-family: 'Times New Roman';"><ix:nonNumeric name="dei:DocumentAnnualReport" id="Fact_8cb682f76d8349aea88d002e9257fcb4" contextRef="c20240101to20241231" format="ixt-sec:boolballotbox">&#9746;</ix:nonNumeric><br/>
                    </span></div>
                </td>

    <td style="align: left; vertical-align: top; width: auto;">
                  <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</div>
                </td>

  </tr>


</table>
        </div>

        <div>For the fiscal year ended <span style="font-weight: normal;"><ix:nonNumeric name="dei:DocumentPeriodEndDate" id="Fact_30a135f0fe584c1caff9f8be11aaec0d" contextRef="c20240101to20241231" format="ixt:date-monthname-day-year-en">December 31, 2024</ix:nonNumeric></span> </div>

        <div><br/>
        </div>

        <div>
          <div>
            <table cellspacing="0" cellpadding="0" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt; border-spacing: 0;" class="DSPFListTable">


  <tr style="vertical-align: top;">

    <td style="vertical-align: top; width: 27pt;">
                    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><span style="font-size: 10pt; font-family: 'Times New Roman';"><ix:nonNumeric name="dei:DocumentTransitionReport" id="Fact_4cc330f2682f418797872935f3700c11" contextRef="c20240101to20241231" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric><br/>
                      </span></div>
                  </td>

    <td style="align: left; vertical-align: top; width: auto;">
                    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</div>
                  </td>

  </tr>


</table>
          </div>

        </div>
<div>
        For the transition period from&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; to
        </div>
<p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: center;"> <br/>
        </p>
        <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: center;">Commission File Number: <span style="font-weight: normal;"><ix:nonNumeric name="dei:EntityFileNumber" id="Fact_8969207dfb554932922cfd2f711c1f42" contextRef="c20240101to20241231">001-36728</ix:nonNumeric></span></p>
      </div>

      <div style="text-align: left; font: 10pt 'Times New Roman';">
<div> &#160;
        </div>
<div style="text-align: center;"><span style="font-size: 18pt;"><strong style="font-size: 24pt;"><ix:nonNumeric name="dei:EntityRegistrantName" id="Fact_5b0256a1d461411f8d2572ab7acef8b9" contextRef="c20240101to20241231">ADMA BIOLOGICS, INC.</ix:nonNumeric></strong></span> </div>

        <div style="text-align: center;"> (Exact Name of Registrant as Specified in Its Charter) </div>

        <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: center;">&#160;</p>
        <table cellpadding="0" style="border-spacing:0;font-size:10pt;text-align:justify;margin-left:auto;margin-right:auto;width:85%">


  <tr style="height:15px">

    <td style="border-bottom: 2px solid rgb(0, 0, 0); width: 45%; vertical-align: top;">
                <p style="MARGIN: 0px 0px 0px 0in; text-align:center;"><span style="font-weight: bold;">&#160;<ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" id="Fact_f086bbebe3c74f73a547adcf4adda6cc" contextRef="c20240101to20241231" format="ixt-sec:stateprovnameen">Delaware</ix:nonNumeric></span><br/>
                  <strong></strong></p>
              </td>

    <td style="width: 10%; padding-bottom: 2px;">
                <p style="margin:0px">&#160;</p>
              </td>

    <td style="border-bottom: 2px solid rgb(0, 0, 0); width: 45%; vertical-align: top;">
                <p style="MARGIN: 0px 0px 0px 0in; text-align:center;"><span style="font-weight: bold;"><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" id="Fact_716d33906e774f45a14878e24f0dba51" contextRef="c20240101to20241231">56-2590442</ix:nonNumeric></span><br/>
                </p>
              </td>

  </tr>

  <tr style="height:15px">

    <td style="vertical-align:top;">
                <p style="MARGIN: 0px 0px 0px 0in; text-align:center;">(State or Other Jurisdiction of Incorporation or Organization)</p>
              </td>

    <td>
                <p style="margin:0px">&#160;</p>
              </td>

    <td style="vertical-align:top;">
                <p style="MARGIN: 0px 0px 0px 0in; text-align:center;">(I.R.S. Employer Identification No.)</p>
              </td>

  </tr>


</table>
        <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;">&#160;</p>
        <table cellpadding="0" style="border-spacing:0;font-size:10pt;text-align:justify;margin-left:auto;margin-right:auto;width:85%">


  <tr style="height:15px">

    <td style="border-bottom: 2px solid rgb(0, 0, 0); width: 45%; vertical-align: top;">
                <p style="MARGIN: 0px 0px 0px 0in; text-align:center;"><strong><ix:nonNumeric name="dei:EntityAddressAddressLine1" id="Fact_b0ecb973cb57414fbf911e8aa59772b7" contextRef="c20240101to20241231">465 State Route 17</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressCityOrTown" id="Fact_6947d7319bb849f681a362f4c16adf8d" contextRef="c20240101to20241231">Ramsey</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressStateOrProvince" id="Fact_38a9760044ea4a23a7f08fb0956380ca" contextRef="c20240101to20241231" format="ixt-sec:stateprovnameen">New Jersey</ix:nonNumeric></strong></p>
              </td>

    <td style="width: 10%; padding-bottom: 2px;">
                <p style="margin:0px">&#160;</p>
              </td>

    <td style="border-bottom: 2px solid rgb(0, 0, 0); width: 45%; vertical-align: top;">
                <p style="MARGIN: 0px 0px 0px 0in; text-align:center;"><span style="font-weight: bold;"><ix:nonNumeric name="dei:EntityAddressPostalZipCode" id="Fact_92a43b4ca38a4d7989aefddffd358bfa" contextRef="c20240101to20241231">07446</ix:nonNumeric></span> <br/>
                </p>
              </td>

  </tr>

  <tr style="height:15px">

    <td style="vertical-align:top;">
                <p style="MARGIN: 0px 0px 0px 0in; text-align:center;">(Address of Principal Executive Offices)</p>
              </td>

    <td>
                <p style="margin:0px">&#160;</p>
              </td>

    <td style="vertical-align:top;">
                <p style="MARGIN: 0px 0px 0px 0in; text-align:center;">(Zip Code)</p>
              </td>

  </tr>


</table>
        <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: center;">&#160;</p>
        <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: center;">&#160;Registrant&#8217;s telephone number, including area code: <strong>(<ix:nonNumeric name="dei:CityAreaCode" id="Fact_102e3e0d8f4c4a95aab192e254b49a60" contextRef="c20240101to20241231">201</ix:nonNumeric>) <ix:nonNumeric name="dei:LocalPhoneNumber" id="Fact_d2f9c96d063c43adac848a93380dda4d" contextRef="c20240101to20241231">478-5552</ix:nonNumeric></strong><strong>&#160;</strong> </p>
        <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: center;">&#160;Securities registered pursuant to Section 12(b) of the Act:</p>
        <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: center;">&#160;</p>
        <table cellpadding="0" style="border-spacing:0;font-size:10pt;width:100%">


  <tr style="height:15px">

    <td style="width: 33.33%; vertical-align: bottom;">
                <p style="MARGIN: 0px 0px 0px 0in; text-align:center;">&#160;<span style="text-decoration: underline;">Title of each class</span></p>
              </td>

    <td style="width: 33.33%; vertical-align: bottom;">
                <p style="MARGIN: 0px 0px 0px 0in; text-align:center;">&#160;Trading Symbol</p>
              </td>

    <td style="width: 33.33%; vertical-align: top;">
                <p style="margin: 0px 0px 0px 0in; text-align: center;"><span style="text-decoration: underline;">Name of each exchange on which registered</span></p>
              </td>

  </tr>

  <tr style="height:15px">

    <td>
                <p style="MARGIN: 0px 0px 0px 0in; text-align:center;"><strong><ix:nonNumeric name="dei:Security12bTitle" id="Fact_67d6bfd0b57b438eb1cdb914f38187f9" contextRef="c20240101to20241231">Common stock, par value $0.0001 per share</ix:nonNumeric><br/>
                  </strong></p>
              </td>

    <td>
                <p style="MARGIN: 0px 0px 0px 0in; text-align:center;"><ix:nonNumeric name="dei:TradingSymbol" id="Fact_0748a300a2ae4ac5ab139bc47fa848df" contextRef="c20240101to20241231">ADMA</ix:nonNumeric><br/>
                </p>
              </td>

    <td style="vertical-align:top;">
                <p style="MARGIN: 0px 0px 0px 0in; text-align:center;"><strong><ix:nonNumeric name="dei:SecurityExchangeName" id="Fact_d35b82726b1b4376b5219ecd86615019" contextRef="c20240101to20241231" format="ixt-sec:exchnameen">Nasdaq</ix:nonNumeric> Global Market<br/>
                  </strong></p>
              </td>

  </tr>


</table>
        <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: center;">&#160;</p>
        <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: center;">Securities registered pursuant to Section 12(g) of the Act: <strong>None</strong></p>
        <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: center;"><strong>&#160;</strong></p>
        <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: left;">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. <ix:nonNumeric name="dei:EntityWellKnownSeasonedIssuer" id="Fact_15e81501d13d4799a8e9a5c53bec405c" contextRef="c20240101to20241231">Yes</ix:nonNumeric> &#9746; No &#9744;</p>
        <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: left;">&#160;</p>
        <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: left;">Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Act. Yes &#9744;&#160;&#160; <ix:nonNumeric name="dei:EntityVoluntaryFilers" id="Fact_9c76db4427294482b3c00882d5761216" contextRef="c20240101to20241231">No</ix:nonNumeric> &#9746;</p>
        <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: left;">&#160;</p>
        <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: left;">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange
          Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. <ix:nonNumeric name="dei:EntityCurrentReportingStatus" id="Fact_4cec08d5f45043edb2c54208a242f7d7" contextRef="c20240101to20241231">Yes</ix:nonNumeric> &#9746; No &#9744;</p>
        <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: left;">&#160;</p>
        <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: left;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule
          405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). <ix:nonNumeric name="dei:EntityInteractiveDataCurrent" id="Fact_859719d50f5b420a94b8ad9aa9b155e6" contextRef="c20240101to20241231">Yes</ix:nonNumeric> &#9746; No &#9744;</p>
        <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: left;">&#160;</p>
        <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: left;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting
          company or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act. (Check one): &#9746;&#160;<ix:nonNumeric name="dei:EntityFilerCategory" id="Fact_23f05c13253747748ce8dc1cc9fb0a2b" contextRef="c20240101to20241231">Large Accelerated Filer</ix:nonNumeric> &#9744; Accelerated Filer &#9744; Non-accelerated Filer <ix:nonNumeric name="dei:EntitySmallBusiness" id="Fact_11eead77ad3d4a6590b094844258ac94" contextRef="c20240101to20241231" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric> Smaller Reporting Company <ix:nonNumeric name="dei:EntityEmergingGrowthCompany" id="Fact_b306d48ec53e44b18bd0469a184db8b2" contextRef="c20240101to20241231" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric> Emerging Growth Company</p>
        <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: left;"> <br/>
        </p>
        <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: left;"></p>
        <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: left;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with
          any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act &#9744;</p>
        <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: left;">&#160;</p>
        <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: left;">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its
          internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.&#160; Yes <ix:nonNumeric name="dei:IcfrAuditorAttestationFlag" id="Fact_e3c1e3aa83b146c68befe24d32fc154a" contextRef="c20240101to20241231" format="ixt-sec:boolballotbox">&#9746;</ix:nonNumeric>&#160;&#160; No &#9744;</p>
        <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: left;">&#160;</p>
        <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: left;">If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant
          included in the filing reflect the correction of an error to previously issued financial statements.&#160; <ix:nonNumeric name="dei:DocumentFinStmtErrorCorrectionFlag" id="Fact_bc0c88570262449a8fee521ad36ae235" contextRef="c20240101to20241231" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric> </p>
        <div style="font-family: 'Times New Roman';"><br/>
        </div>

        <div style="font-family: 'Times New Roman';">
          <div style="font-size: 10pt; text-align: left;">Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant&#8217;s executive
            officers during the relevant recovery period pursuant to &#167; 240.10D-1(b).&#160; <span style="font-size: 10pt;">&#9744;</span></div>

        </div>

        <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: left;"> <br/>
        </p>
        <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: left;">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes <ix:nonNumeric name="dei:EntityShellCompany" id="Fact_0bf64eade1f74315aac6fe1a683970d1" contextRef="c20240101to20241231" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric> No &#9746;</p>
        <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: left;"> <br/>
        </p>
        <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: left;">The aggregate market value of the registrant&#8217;s common stock held by non-affiliates was $<ix:nonFraction name="dei:EntityPublicFloat" id="Fact_02f9013899604461b9d0df3a5a42edad" contextRef="c20240630" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">2,535,856,298</ix:nonFraction> as of June 30, 2024 (the last business day of the registrant&#8217;s most recently completed second fiscal quarter), based on a total of 226,820,778 shares of common stock held by
          non-affiliates and a closing price of $11.18 as reported on the Nasdaq Global Market on June 28, 2024.&#160;</p>
        <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: left;">&#160;</p>
        <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: left;">As of March 10, 2025, there were <ix:nonFraction name="dei:EntityCommonStockSharesOutstanding" id="Fact_c7817761f6034283b88206091f43baf2" contextRef="c20250310" unitRef="U002" decimals="INF" scale="0" format="ixt:num-dot-decimal">237,615,100</ix:nonFraction>
          shares of the issuer&#8217;s common stock outstanding.</p>
        <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: center;">&#160;</p>
        <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: center;"><strong>DOCUMENTS INCORPORATED BY REFERENCE</strong></p>
        <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: left;">&#160;</p>
        <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: left;">Portions of the ADMA Biologics, Inc. definitive proxy statement to be filed pursuant to Regulation 14A within 120 days after the end of the
          fiscal year are incorporated by reference into Part III of this Annual Report on Form 10-K and certain documents are incorporated by reference into Part IV.</p>
        <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;">&#160;</p>
        <table style="font-size:1px;width:100%">


  <tr>

    <td style="BORDER-BOTTOM: 2px solid;"/>

  </tr>

  <tr>

    <td style="BORDER-BOTTOM: 5px solid;"/>

  </tr>


</table>
        <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
          <div class="BRPFPageBreak" style="page-break-after: always;">
            <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"/></div>

        </div>

        <!--PROfilePageNumberReset%LCR%1%%%--> </div>

    </div>

  </div>


  <div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
    <div>
      <hr style="background-color: #000000; border-bottom: medium none; border-left: medium none; border-right: medium none; border-top: medium none; color: #000000;"/>
      <div>
        <hr style="background-color: #000000; border-bottom: medium none; border-left: medium none; border-right: medium none; border-top: medium none; color: #000000;"/>
        <div>
          <div>
            <hr style="background-color: #000000; border-bottom: medium none; border-left: medium none; border-right: medium none; border-top: medium none; color: #000000;"/>
            <div>
              <div style="text-align: center; font-weight: bold;">
                <div><a id="ADMABIOLOGICSINC."><!--Anchor--></a> ADMA BIOLOGICS, INC.</div>

              </div>

              <div style="text-align: center; font-weight: bold;"> <br/>
              </div>

              <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 7%; vertical-align: top;">
                      <div>PART I</div>
                    </td>

    <td style="width: 83%; vertical-align: top;">&#160;</td>

    <td style="width: 10.21%; vertical-align: bottom;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 7%; vertical-align: top;">&#160;</td>

    <td style="width: 83%; vertical-align: top;">&#160;</td>

    <td style="width: 10.21%; vertical-align: bottom;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 7%; vertical-align: top; background-color: rgb(204, 238, 255);">
                      <div>Item 1.</div>
                    </td>

    <td style="width: 83%; vertical-align: top; background-color: rgb(204, 238, 255);">
                      <div><a href="#Business">Business</a></div>
                    </td>

    <td style="width: 10.21%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
                      <div style="text-align: right;">4</div>
                    </td>

  </tr>

  <tr>

    <td style="width: 7%; vertical-align: top;">&#160;</td>

    <td style="width: 83%; vertical-align: top;">&#160;</td>

    <td style="width: 10.21%; vertical-align: bottom;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 7%; vertical-align: top; background-color: rgb(204, 238, 255);">
                      <div>Item 1A.</div>
                    </td>

    <td style="width: 83%; vertical-align: top; background-color: rgb(204, 238, 255);">
                      <div><a href="#RiskFactors">Risk Factors</a></div>
                    </td>

    <td style="width: 10.21%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
                      <div style="text-align: right;">33</div>
                    </td>

  </tr>

  <tr>

    <td style="width: 7%; vertical-align: top;">&#160;</td>

    <td style="width: 83%; vertical-align: top;">&#160;</td>

    <td style="width: 10.21%; vertical-align: bottom;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 7%; vertical-align: top; background-color: rgb(204, 238, 255);">
                      <div>Item 1B.</div>
                    </td>

    <td style="width: 83%; vertical-align: top; background-color: rgb(204, 238, 255);">
                      <div><a href="#UnresolvedStaffComments">Unresolved Staff Comments</a></div>
                    </td>

    <td style="width: 10.21%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
                      <div style="text-align: right;">63</div>
                    </td>

  </tr>

  <tr>

    <td style="width: 7%; vertical-align: top;">&#160;</td>

    <td style="width: 83%; vertical-align: top;">&#160;</td>

    <td style="width: 10.21%; vertical-align: bottom;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 7%; vertical-align: top; background-color: rgb(204, 238, 255);">
                      <div>Item 1C.</div>
                    </td>

    <td style="width: 83%; vertical-align: top; background-color: rgb(204, 238, 255);">
                      <div><a href="#Cybersecurity">Cybersecurity</a></div>
                    </td>

    <td style="width: 10.21%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
                      <div style="text-align: right;">63</div>
                    </td>

  </tr>

  <tr>

    <td style="width: 7%; vertical-align: top;">&#160;</td>

    <td style="width: 83%; vertical-align: top;">&#160;</td>

    <td style="width: 10.21%; vertical-align: bottom;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 7%; vertical-align: top; background-color: rgb(204, 238, 255);">
                      <div>Item 2.</div>
                    </td>

    <td style="width: 83%; vertical-align: top; background-color: rgb(204, 238, 255);">
                      <div><a href="#Properties">Properties</a></div>
                    </td>

    <td style="width: 10.21%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
                      <div style="text-align: right;">65</div>
                    </td>

  </tr>

  <tr>

    <td style="width: 7%; vertical-align: top;">&#160;</td>

    <td style="width: 83%; vertical-align: top;">&#160;</td>

    <td style="width: 10.21%; vertical-align: bottom;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 7%; vertical-align: top; background-color: rgb(204, 238, 255);">
                      <div>Item 3.</div>
                    </td>

    <td style="width: 83%; vertical-align: top; background-color: rgb(204, 238, 255);">
                      <div><a href="#LegalProceedings">Legal Proceedings</a></div>
                    </td>

    <td style="width: 10.21%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
                      <div style="text-align: right;">65</div>
                    </td>

  </tr>

  <tr>

    <td style="width: 7%; vertical-align: top;">&#160;</td>

    <td style="width: 83%; vertical-align: top;">&#160;</td>

    <td style="width: 10.21%; vertical-align: bottom;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 7%; vertical-align: top; background-color: rgb(204, 238, 255);">
                      <div>Item 4.</div>
                    </td>

    <td style="width: 83%; vertical-align: top; background-color: rgb(204, 238, 255);">
                      <div><a href="#MineSafetyDisclosures">Mine Safety Disclosures</a></div>
                    </td>

    <td style="width: 10.21%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
                      <div style="text-align: right;">65</div>
                    </td>

  </tr>

  <tr>

    <td style="width: 7%; vertical-align: top;">&#160;</td>

    <td style="width: 83%; vertical-align: top;">&#160;</td>

    <td style="width: 10.21%; vertical-align: bottom;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 7%; vertical-align: top; background-color: rgb(204, 238, 255);">
                      <div>PART II</div>
                    </td>

    <td style="width: 83%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 10.21%; vertical-align: bottom; background-color: rgb(204, 238, 255);">&#160;</td>

  </tr>

  <tr>

    <td style="width: 7%; vertical-align: top;">&#160;</td>

    <td style="width: 83%; vertical-align: top;">&#160;</td>

    <td style="width: 10.21%; vertical-align: bottom;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 7%; vertical-align: top; background-color: rgb(204, 238, 255);">
                      <div>Item 5.</div>
                    </td>

    <td style="width: 83%; vertical-align: top; background-color: rgb(204, 238, 255);">
                      <div><a href="#MarketforRegistrantsCommo">Market For Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</a></div>
                    </td>

    <td style="width: 10.21%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
                      <div style="text-align: right;">66</div>
                    </td>

  </tr>

  <tr>

    <td style="width: 7%; vertical-align: top;">&#160;</td>

    <td style="width: 83%; vertical-align: top;">&#160;</td>

    <td style="width: 10.21%; vertical-align: bottom;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 7%; vertical-align: top; background-color: rgb(204, 238, 255);">
                      <div>Item 6.</div>
                    </td>

    <td style="width: 83%; vertical-align: top; background-color: rgb(204, 238, 255);">
                      <div><a href="#Reserved">Reserved</a></div>
                    </td>

    <td style="width: 10.21%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
                      <div style="text-align: right;">67</div>
                    </td>

  </tr>

  <tr>

    <td style="width: 7%; vertical-align: top;">&#160;</td>

    <td style="width: 83%; vertical-align: top;">&#160;</td>

    <td style="width: 10.21%; vertical-align: bottom; text-align: right;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 7%; vertical-align: top; background-color: rgb(204, 238, 255);">
                      <div>Item 7.</div>
                    </td>

    <td style="width: 83%; vertical-align: top; background-color: rgb(204, 238, 255);">
                      <div><a href="#ManagementsDiscussionandA">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></div>
                    </td>

    <td style="width: 10.21%; vertical-align: bottom; background-color: rgb(204, 238, 255); text-align: right;">68</td>

  </tr>

  <tr>

    <td style="width: 7%; vertical-align: top;">&#160;</td>

    <td style="width: 83%; vertical-align: top;">&#160;</td>

    <td style="width: 10.21%; vertical-align: bottom; text-align: right;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 7%; vertical-align: top; background-color: rgb(204, 238, 255);">
                      <div>Item 7A.</div>
                    </td>

    <td style="width: 83%; vertical-align: top; background-color: rgb(204, 238, 255);">
                      <div><a href="#QuantitativeandQualitativ">Quantitative and Qualitative Disclosures About Market Risk</a></div>
                    </td>

    <td style="width: 10.21%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
                      <div style="text-align: right;">83</div>
                    </td>

  </tr>

  <tr>

    <td style="width: 7%; vertical-align: top;">&#160;</td>

    <td style="width: 83%; vertical-align: top;">&#160;</td>

    <td style="width: 10.21%; vertical-align: bottom; text-align: right;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 7%; vertical-align: top; background-color: rgb(204, 238, 255);">
                      <div>Item 8.</div>
                    </td>

    <td style="width: 83%; vertical-align: top; background-color: rgb(204, 238, 255);">
                      <div><a href="#FinancialStatementsandSup">Financial Statements and Supplementary Data</a></div>
                    </td>

    <td style="width: 10.21%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
                      <div style="text-align: right;">83</div>
                    </td>

  </tr>

  <tr>

    <td style="width: 7%; vertical-align: top;">&#160;</td>

    <td style="width: 83%; vertical-align: top;">&#160;</td>

    <td style="width: 10.21%; vertical-align: bottom; text-align: right;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 7%; vertical-align: top; background-color: rgb(204, 238, 255);">
                      <div>Item 9.</div>
                    </td>

    <td style="width: 83%; vertical-align: top; background-color: rgb(204, 238, 255);">
                      <div><a href="#ChangesinandDisagreements">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</a></div>
                    </td>

    <td style="width: 10.21%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
                      <div style="text-align: right;">83</div>
                    </td>

  </tr>

  <tr>

    <td style="width: 7%; vertical-align: top;">&#160;</td>

    <td style="width: 83%; vertical-align: top;">&#160;</td>

    <td style="width: 10.21%; vertical-align: bottom; text-align: right;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 7%; vertical-align: top; background-color: rgb(204, 238, 255);">
                      <div>Item 9A.</div>
                    </td>

    <td style="width: 83%; vertical-align: top; background-color: rgb(204, 238, 255);">
                      <div><a href="#ControlsandProcedures">Controls and Procedures</a></div>
                    </td>

    <td style="width: 10.21%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
                      <div style="text-align: right;">83</div>
                    </td>

  </tr>

  <tr>

    <td style="width: 7%; vertical-align: top;">&#160;</td>

    <td style="width: 83%; vertical-align: top;">&#160;</td>

    <td style="width: 10.21%; vertical-align: bottom; text-align: right;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 7%; vertical-align: top; background-color: rgb(204, 238, 255);">
                      <div>Item 9B.</div>
                    </td>

    <td style="width: 83%; vertical-align: top; background-color: rgb(204, 238, 255);">
                      <div><a href="#OtherInformation">Other Information</a></div>
                    </td>

    <td style="width: 10.21%; vertical-align: bottom; background-color: rgb(204, 238, 255); text-align: right;">84</td>

  </tr>

  <tr>

    <td style="width: 7%; vertical-align: top;">&#160;</td>

    <td style="width: 83%; vertical-align: top;">&#160;</td>

    <td style="width: 10.21%; vertical-align: bottom; text-align: right;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 7%; vertical-align: top; background-color: rgb(204, 238, 255);">
                      <div>Item 9C.</div>
                    </td>

    <td style="width: 83%; vertical-align: top; background-color: rgb(204, 238, 255);">
                      <div><a href="#DisclosureRegardingForeig">Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</a></div>
                    </td>

    <td style="width: 10.21%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
                      <div style="text-align: right;">84</div>
                    </td>

  </tr>

  <tr>

    <td style="width: 7%; vertical-align: top;">&#160;</td>

    <td style="width: 83%; vertical-align: top;">&#160;</td>

    <td style="width: 10.21%; vertical-align: bottom; text-align: right;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 7%; vertical-align: top; background-color: rgb(204, 238, 255);">
                      <div>PART III</div>
                    </td>

    <td style="width: 83%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 10.21%; vertical-align: bottom; background-color: rgb(204, 238, 255); text-align: right;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 7%; vertical-align: top;">&#160;</td>

    <td style="width: 83%; vertical-align: top;">&#160;</td>

    <td style="width: 10.21%; vertical-align: bottom; text-align: right;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 7%; vertical-align: top; background-color: rgb(204, 238, 255);">
                      <div>Item 10.</div>
                    </td>

    <td style="width: 83%; vertical-align: top; background-color: rgb(204, 238, 255);">
                      <div><a href="#DirectorsExecutiveOfficer">Directors, Executive Officers and Corporate Governance</a></div>
                    </td>

    <td style="width: 10.21%; vertical-align: bottom; background-color: rgb(204, 238, 255); text-align: right;">85</td>

  </tr>

  <tr>

    <td style="width: 7%; vertical-align: top;">&#160;</td>

    <td style="width: 83%; vertical-align: top;">&#160;</td>

    <td style="width: 10.21%; vertical-align: bottom; text-align: right;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 7%; vertical-align: top; background-color: rgb(204, 238, 255);">
                      <div>Item 11.</div>
                    </td>

    <td style="width: 83%; vertical-align: top; background-color: rgb(204, 238, 255);">
                      <div><a href="#ExecutiveCompensation">Executive Compensation</a></div>
                    </td>

    <td style="width: 10.21%; vertical-align: bottom; background-color: rgb(204, 238, 255); text-align: right;">85</td>

  </tr>

  <tr>

    <td style="width: 7%; vertical-align: top;">&#160;</td>

    <td style="width: 83%; vertical-align: top;">&#160;</td>

    <td style="width: 10.21%; vertical-align: bottom; text-align: right;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 7%; vertical-align: top; background-color: rgb(204, 238, 255);">
                      <div>Item 12.</div>
                    </td>

    <td style="width: 83%; vertical-align: top; background-color: rgb(204, 238, 255);">
                      <div><a href="#SecurityOwnershipofCertai">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</a></div>
                    </td>

    <td style="width: 10.21%; vertical-align: bottom; background-color: rgb(204, 238, 255); text-align: right;">85</td>

  </tr>

  <tr>

    <td style="width: 7%; vertical-align: top;">&#160;</td>

    <td style="width: 83%; vertical-align: top;">&#160;</td>

    <td style="width: 10.21%; vertical-align: bottom; text-align: right;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 7%; vertical-align: top; background-color: rgb(204, 238, 255);">
                      <div>Item 13.</div>
                    </td>

    <td style="width: 83%; vertical-align: top; background-color: rgb(204, 238, 255);">
                      <div><a href="#CertainRelationshipsandRe">Certain Relationships and Related Transactions, and Director Independence</a></div>
                    </td>

    <td style="width: 10.21%; vertical-align: bottom; background-color: rgb(204, 238, 255); text-align: right;">86</td>

  </tr>

  <tr>

    <td style="width: 7%; vertical-align: top;">&#160;</td>

    <td style="width: 83%; vertical-align: top;">&#160;</td>

    <td style="width: 10.21%; vertical-align: bottom; text-align: right;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 7%; vertical-align: top; background-color: rgb(204, 238, 255);">
                      <div>Item 14.</div>
                    </td>

    <td style="width: 83%; vertical-align: top; background-color: rgb(204, 238, 255);">
                      <div><a href="#PrincipalAccountingFeesan">Principal Accounting Fees and Services</a></div>
                    </td>

    <td style="width: 10.21%; vertical-align: bottom; background-color: rgb(204, 238, 255); text-align: right;">86</td>

  </tr>

  <tr>

    <td style="width: 7%; vertical-align: top;">&#160;</td>

    <td style="width: 83%; vertical-align: top;">&#160;</td>

    <td style="width: 10.21%; vertical-align: bottom; text-align: right;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 7%; vertical-align: top; background-color: rgb(204, 238, 255);">
                      <div>PART IV</div>
                    </td>

    <td style="width: 83%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 10.21%; vertical-align: bottom; background-color: rgb(204, 238, 255); text-align: right;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 7%; vertical-align: top;">&#160;</td>

    <td style="width: 83%; vertical-align: top;">&#160;</td>

    <td style="width: 10.21%; vertical-align: bottom; text-align: right;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 7%; vertical-align: top; background-color: rgb(204, 238, 255);">
                      <div>Item 15.</div>
                    </td>

    <td style="width: 83%; vertical-align: top; background-color: rgb(204, 238, 255);">
                      <div><a href="#ExhibitsFinancialStatemen">Exhibits, Financial Statement Schedules</a></div>
                    </td>

    <td style="width: 10.21%; vertical-align: bottom; background-color: rgb(204, 238, 255); text-align: right;">87</td>

  </tr>

  <tr>

    <td style="width: 7%; vertical-align: top;">&#160;</td>

    <td style="width: 83%; vertical-align: top;">&#160;</td>

    <td style="width: 10.21%; vertical-align: bottom; text-align: right;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 7%; vertical-align: top; background-color: rgb(204, 238, 255);">
                      <div>Item 16.</div>
                    </td>

    <td style="width: 83%; vertical-align: top; background-color: rgb(204, 238, 255);">
                      <div><a href="#Form10-KSummary">Form 10-K Summary</a></div>
                    </td>

    <td style="width: 10.21%; vertical-align: bottom; background-color: rgb(204, 238, 255); text-align: right;">90</td>

  </tr>


</table>
              <div style="text-align: center;"><br/>
              </div>

              <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
                <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">i</span></div>

                <div class="BRPFPageBreak" style="page-break-after: always;">
                  <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"/></div>

                <div style="width: 100%;" class="BRPFPageHeader">
                  <div>
                    <div style="text-align: left; font-weight: bold; text-indent: -9pt; margin-left: 9pt;"><a href="#ADMABIOLOGICSINC."> <span style="font-style: italic; font-weight: normal; font-size: 8pt;">Table of Contents</span></a><br/>
                    </div>

                  </div>

                </div>

              </div>

              <!--PROfilePageNumberReset%Num%1%%%-->
              <div style="text-align: center; font-weight: bold;">Special Note Regarding Forward-Looking Statements</div>

              <div style="text-align: center;"><span style="font-weight: bold;">&#160;</span><br/>
              </div>

              <div style="text-indent: 36pt;">Some of the information in this Annual Report on Form 10-K contains &#8220;forward-looking statements&#8221; within the meaning of Section 27A of the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;) and Section
                21E of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), and such forward-looking statements involve risks and uncertainties. These forward-looking statements include, but are not limited to, statements about our plans,
                objectives, representations and contentions that are not historical facts and typically are identified by use of terms such as &#8220;may,&#8221; &#8220;should,&#8221; &#8220;could,&#8221; &#8220;would,&#8221; &#8220;expect,&#8221; &#8220;plan,&#8221; &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;predict,&#8221; &#8220;potential,&#8221;
                &#8220;project,&#8221; &#8220;continue,&#8221; or the negative thereof, or other variations or comparable terminology, although some forward-looking statements are expressed differently. The forward-looking statements included herein represent management&#8217;s current
                judgment and expectations, but our actual results, events and performance could differ materially from those in the forward-looking statements. These statements include statements about:</div>

              <div style="text-indent: 36pt;"> <br/>
              </div>

              <div>
                <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0); border-spacing: 0;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;">&#160;</td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="vertical-align: top;">
                        <div style="text-indent: -36pt; margin-left: 36pt;">our ability to further commercialize ASCENIV and BIVIGAM;</div>
                      </td>

  </tr>


</table>
                <div style="text-indent: -36pt; margin-left: 36pt;"> <br/>
                </div>

                <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0); border-spacing: 0;">


  <tr>

    <td style="width: 18pt;"><br/>
                      </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="vertical-align: top;">
                        <div>our plans to develop, manufacture, market, launch and expand our commercial infrastructure and commercialize our current and future products and the success of such efforts;</div>
                      </td>

  </tr>


</table>
                <div style="text-indent: -36pt; margin-left: 36pt;">&#160;</div>

                <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0); border-spacing: 0;">


  <tr>

    <td style="width: 18pt;"><br/>
                      </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="vertical-align: top;">
                        <div>the safety, efficacy and expected timing of and our ability to obtain and maintain regulatory approvals for our current products and product candidates, and the labeling or nature of any such approvals;</div>
                      </td>

  </tr>


</table>
                <div style="text-indent: -36pt; margin-left: 36pt;">&#160;</div>

                <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0); border-spacing: 0;">


  <tr>

    <td style="width: 18pt;"><br/>
                      </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="vertical-align: top;">
                        <div>the achievement of or expected timing, progress and results of clinical development, clinical trials and potential regulatory approvals for our product candidates;</div>
                      </td>

  </tr>


</table>
                <div style="text-indent: -36pt; margin-left: 36pt;">&#160;</div>

                <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0); border-spacing: 0;">


  <tr>

    <td style="width: 18pt;"><br/>
                      </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="vertical-align: top;">
                        <div>our dependence upon our third-party customers, suppliers and vendors and their compliance with applicable regulatory requirements;</div>
                      </td>

  </tr>


</table>
                <div><br/>
                </div>

                <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0); border-spacing: 0;">


  <tr>

    <td style="width: 18pt;"><br/>
                      </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="vertical-align: top;">
                        <div>our belief that we have addressed the delays experienced with final drug product current Good Manufacturing Practices (&#8220;cGMP&#8221;) release testing by our third-party vendors by adding additional release testing laboratories to our
                          U.S. Food and Drug Administration (the &#8220;FDA&#8221;)-approved consortium listed in our drug approval documents;</div>
                      </td>

  </tr>


</table>
                <div style="text-indent: -36pt; margin-left: 36pt;">&#160;</div>

                <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0); border-spacing: 0;">


  <tr>

    <td style="width: 18pt;"><br/>
                      </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="vertical-align: top;">
                        <div>our ability to obtain adequate quantities of FDA-approved plasma with proper specifications;</div>
                      </td>

  </tr>


</table>
                <div style="text-indent: -36pt; margin-left: 36pt;">&#160;</div>

                <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0); border-spacing: 0;">


  <tr>

    <td style="width: 18pt;"><br/>
                      </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="vertical-align: top;">
                        <div>our plans to increase our supplies of source plasma (including source plasma containing certain levels of antibodies to Respiratory Syncytial Virus), our ability to obtain and maintain regulatory compliance and reliance on
                          third-party supply agreements as well as any extensions to such agreements;</div>
                      </td>

  </tr>


</table>
                <div style="text-indent: -36pt; margin-left: 36pt;">&#160;&#160;</div>

                <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0); border-spacing: 0;">


  <tr>

    <td style="width: 18pt;"><br/>
                      </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="vertical-align: top;">
                        <div>the potential indications for our products and product candidates;</div>
                      </td>

  </tr>


</table>
                <div style="text-indent: -36pt; margin-left: 36pt;">&#160;</div>

                <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0); border-spacing: 0;">


  <tr>

    <td style="width: 18pt;"><br/>
                      </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="vertical-align: top;">
                        <div>potential investigational new product applications;</div>
                      </td>

  </tr>


</table>
                <div style="text-indent: -36pt; margin-left: 36pt;">&#160;</div>

                <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0); border-spacing: 0;">


  <tr>

    <td style="width: 18pt;"><br/>
                      </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="vertical-align: top;">
                        <div>the acceptability of any of our products, including ASCENIV, BIVIGAM and Nabi-HB, for any purpose, including FDA-approved indications, by physicians, patients or payers;</div>
                      </td>

  </tr>


</table>
                <div><br/>
                </div>

                <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0); border-spacing: 0;">


  <tr>

    <td style="width: 18pt;"><br/>
                      </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="vertical-align: top;">
                        <div>our plans to evaluate the clinical and regulatory paths to grow the ASCENIV franchise through expanded FDA-approved uses;</div>
                      </td>

  </tr>


</table>
                <div><br/>
                </div>

                <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0); border-spacing: 0;">


  <tr>

    <td style="width: 18pt;"><br/>
                      </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="vertical-align: top;">
                        <div>Federal, state and local regulatory and business review processes and timing by such governmental and regulatory agencies of our business and regulatory submissions;</div>
                      </td>

  </tr>


</table>
                <div><br/>
                </div>

                <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0); border-spacing: 0;">


  <tr>

    <td style="width: 18pt;"><br/>
                      </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="vertical-align: top;">
                        <div>concurrence by the FDA with our conclusions concerning our products and product candidates;</div>
                      </td>

  </tr>


</table>
                <div style="text-indent: -36pt; margin-left: 36pt;">&#160;</div>

                <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
                  <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">1</span></div>

                  <div style="page-break-after: always;" class="BRPFPageBreak">
                    <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: rgb(0, 0, 0); background-color: rgb(0, 0, 0);"/></div>

                  <div style="width: 100%;" class="BRPFPageHeader">
                    <div>
                      <div style="text-align: left; font-weight: bold; text-indent: -9pt; margin-left: 9pt;"><a href="#ADMABIOLOGICSINC."> <span style="font-style: italic; font-weight: normal; font-size: 8pt;">Table of Contents</span></a><br/>
                      </div>

                    </div>

                  </div>

                </div>

                <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0); border-spacing: 0;">


  <tr>

    <td style="width: 18pt;"><br/>
                      </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="vertical-align: top;">
                        <div>the comparability of results of our hyperimmune and immune globulin (&#8220;IG&#8221;) products to other comparably run hyperimmune and immune globulin clinical trials;</div>
                      </td>

  </tr>


</table>
                <div style="text-indent: -36pt; margin-left: 36pt;">&#160;</div>

                <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0); border-spacing: 0;">


  <tr>

    <td style="width: 18pt;"><br/>
                      </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="vertical-align: top;">
                        <div>the potential for ASCENIV and BIVIGAM to provide meaningful clinical improvement for patients living with Primary Humoral Immunodeficiency (&#8220;PI&#8221;), also known as Primary Immunodeficiency Disease (&#8220;PIDD&#8221;) or Inborn Errors of
                          Immunity, or other immune deficiencies or any other condition for which the products may be prescribed or evaluated;</div>
                      </td>

  </tr>


</table>
                <div style="text-indent: -36pt; margin-left: 36pt;">&#160;</div>

                <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0); border-spacing: 0;">


  <tr>

    <td style="width: 18pt;"><br/>
                      </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="vertical-align: top;">
                        <div>our ability to market and promote Nabi-HB in a highly competitive environment with increasing competition from other antiviral therapies and to generate meaningful revenues from this product;</div>
                      </td>

  </tr>


</table>
                <div><br/>
                </div>

                <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0); border-spacing: 0;">


  <tr>

    <td style="width: 18pt;"><br/>
                      </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="vertical-align: top;">
                        <div>our intellectual property position and the defense thereof, including our expectations regarding the scope of patent protection with respect to ASCENIV, SG-001 or other future pipeline product candidates;</div>
                      </td>

  </tr>


</table>
                <div><br/>
                </div>

                <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0); border-spacing: 0;">


  <tr>

    <td style="width: 18pt;"><br/>
                      </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="vertical-align: top;">
                        <div>our ability to develop, manufacture, receive regulatory approval and commercialize our potential pipeline of any new hyperimmune globulins, including SG-001;</div>
                      </td>

  </tr>


</table>
                <div style="text-indent: -36pt; margin-left: 36pt;">&#160;&#160;&#160;</div>

                <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0); border-spacing: 0;">


  <tr>

    <td style="width: 18pt;"><br/>
                      </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="vertical-align: top;">
                        <div>our manufacturing capabilities, third-party contractor capabilities and vertical integration strategy;</div>
                      </td>

  </tr>


</table>
                <div style="text-indent: -36pt; margin-left: 36pt;">&#160;</div>

                <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0); border-spacing: 0;">


  <tr>

    <td style="width: 18pt;"><br/>
                      </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="vertical-align: top;">
                        <div>our plans related to the expansion and efficiencies of our manufacturing capacity, yield improvements, supply-chain robustness, in-house fill-finish capabilities, distribution and other collaborative agreements and the success
                          of such endeavors;</div>
                      </td>

  </tr>


</table>
                <div style="text-indent: -36pt; margin-left: 36pt;">&#160;</div>

                <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0); border-spacing: 0;">


  <tr>

    <td style="width: 18pt;"><br/>
                      </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="vertical-align: top;">
                        <div>our estimates regarding revenues, net income, Adjusted EBITDA, expenses, capital requirements, ASCENIV&#8217;s growth, ability to maintain profitability and positive cash flows and the potential need for and availability of
                          additional financing;</div>
                      </td>

  </tr>


</table>
                <div><br/>
                </div>

                <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0); border-spacing: 0;">


  <tr>

    <td style="width: 18pt;"><br/>
                      </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="vertical-align: top;">
                        <div>our ability to realize our deferred tax assets or the need for a valuation allowance, or the effects of changes in tax laws on our deferred tax assets;</div>
                      </td>

  </tr>


</table>
                <div><br/>
                </div>

                <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0); border-spacing: 0;">


  <tr>

    <td style="width: 18pt;"><br/>
                      </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="vertical-align: top;">
                        <div>our estimates of future taxable income and the timing of a potential full or partial release of the valuation allowance against our net deferred tax assets, which could have a material impact on our financial condition or
                          financial results;</div>
                      </td>

  </tr>


</table>
                <div><br/>
                </div>

                <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0); border-spacing: 0;">


  <tr>

    <td style="width: 18pt;"><br/>
                      </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="vertical-align: top;">
                        <div>our estimates of future effective tax rates and corresponding tax obligations, which could have a material impact on our financial condition or financial results;</div>
                      </td>

  </tr>


</table>
                <div style="text-indent: -36pt; margin-left: 36pt;">&#160;</div>

                <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0); border-spacing: 0;">


  <tr>

    <td style="width: 18pt;"><br/>
                      </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="vertical-align: top;">
                        <div>possible or likely reimbursement levels for our currently marketed products;</div>
                      </td>

  </tr>


</table>
                <div style="text-indent: -36pt; margin-left: 36pt;">&#160;</div>

                <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0); border-spacing: 0;">


  <tr>

    <td style="width: 18pt;"><br/>
                      </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="vertical-align: top;">
                        <div>estimates regarding market size, projected growth and sales of our existing products as well as our expectations of market acceptance of ASCENIV and BIVIGAM;</div>
                      </td>

  </tr>


</table>
                <div><br/>
                </div>

                <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0); border-spacing: 0;">


  <tr>

    <td style="width: 18pt;"><br/>
                      </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="vertical-align: top;">
                        <div>pandemics, or a resurgence of a pandemic, may adversely affect our business, financial condition, liquidity or results of operations; and</div>
                      </td>

  </tr>


</table>
                <div><br/>
                </div>

                <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0); border-spacing: 0;">


  <tr>

    <td style="width: 18pt;"><br/>
                      </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="vertical-align: top;">
                        <div>future domestic and global economic conditions including, but not limited to, supply chain constraints, inflationary pressures or performance or geopolitical conditions, including the continuing conflicts in Europe and in the
                          Middle East and surrounding areas and international trade and U.S. tariff policies and any anticipated effects of such policies on the pricing and availability of imported raw materials used in the production of our products.</div>
                      </td>

  </tr>


</table>
                <div> <br/>
                </div>

                <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
                  <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">2</span></div>

                  <div style="page-break-after: always;" class="BRPFPageBreak">
                    <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: rgb(0, 0, 0); background-color: rgb(0, 0, 0);"/></div>

                  <div style="width: 100%;" class="BRPFPageHeader">
                    <div>
                      <div style="text-align: left; font-weight: bold; text-indent: -9pt; margin-left: 9pt;"><a href="#ADMABIOLOGICSINC."> <span style="font-style: italic; font-weight: normal; font-size: 8pt;">Table of Contents</span></a><br/>
                      </div>

                    </div>

                  </div>

                </div>

                <div style="text-indent: 36pt;"> In addition to the foregoing, you should also consider carefully the statements under the section entitled &#8220;Risk Factors&#8221; and other sections of this Annual Report on Form 10-K, which address additional
                  factors that could cause our actual results to differ from those set forth in the forward-looking statements.&#160; We undertake no obligation to release publicly any updates or revisions to any forward-looking statements contained herein to
                  reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law. </div>

                <div><br/>
                </div>

                <div style="text-indent: 36pt;">This Annual Report on Form 10-K includes our trademarks, trade names and service marks, such as &#8220;ASCENIV<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">TM</sup>&#8221;, &#8220;BIVIGAM&#174;&#8221; and
                  &#8220;Nabi-HB&#174;&#8221;, which are protected under applicable intellectual property laws and are the property of ADMA Biologics, Inc., or its subsidiaries. Solely for convenience, trademarks, trade names and service marks referred to in this Annual
                  Report may appear without the &#174; or &#8482; symbols, but the absence of such references are not intended to indicate, in any way, that we will not assert, to the fullest extent under applicable law, our rights or the right of the applicable
                  licensor to these trademarks, trade names and service marks. We do not intend our use or display of other parties&#8217; trademarks, trade names or service marks to imply, and such use or display should not be construed to imply, a relationship
                  with or endorsement or sponsorship of us by these other parties.</div>

                <div style="text-indent: 36pt;"> <br/>
                </div>

                <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
                  <div style="text-align: center; text-indent: -9pt; margin-left: 9pt;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">3</span></div>

                  <div class="BRPFPageBreak" style="page-break-after: always;">
                    <hr style="margin: 4px 0px; width: 100%; border-width: 0px; height: 2px; color: rgb(0, 0, 0); background-color: rgb(0, 0, 0); clear: both;"/></div>

                  <div style="width: 100%;" class="BRPFPageHeader">
                    <div>
                      <div style="text-align: left; font-weight: bold; text-indent: -9pt; margin-left: 9pt;"><a href="#ADMABIOLOGICSINC."> <span style="font-style: italic; font-weight: normal; font-size: 8pt;">Table of Contents</span></a><br/>
                      </div>

                    </div>

                  </div>

                </div>

                <div style="text-align: center; font-weight: bold;">PART I</div>

                <div style="text-align: center;"><span style="font-weight: bold;">&#160;</span><br/>
                </div>

                <div>
                  <a id="Business"><!--Anchor--></a>
<table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-spacing: 0;" class="DSPFListTable">


  <tr style="vertical-align: top;">

    <td style="text-align: right; vertical-align: top; width: 45pt;">
                          <div style="text-align: left; font-weight: bold;">Item&#160; 1.</div>
                        </td>

    <td style="text-align: left; vertical-align: top; width: auto;">
                          <div style="font-weight: bold;">Business</div>
                        </td>

  </tr>


</table>
                </div>

                <div>&#160;<br/>
                </div>

                <div><span style="font-style: italic;">Unless the context otherwise requires, references in this Business section to &#8220;ADMA,&#8221; &#8220;ADMA Biologics,&#8221; the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;us&#8221; and &#8220;our&#8221; refer to ADMA Biologics, Inc., a Delaware corporation, as well as
                  its wholly-owned subsidiaries, ADMA BioManufacturing, LLC, a Delaware limited liability company (&#8220;ADMA BioManufacturing&#8221;), ADMA BioCenters Georgia Inc., a Delaware corporation (&#8220;ADMA BioCenters&#8221;) and ADMA Plasma Biologics, Inc., a
                  Delaware corporation (&#8220;ADMA Plasma Biologics&#8221;). </span></div>

                <div style="font-weight: bold;"><span style="font-style: italic;">&#160;</span></div>

                <div>
                  <div style="font-weight: bold; text-indent: -9pt; margin-left: 9pt;">Overview</div>

                </div>

                <div><br/></div>

                <div style="text-indent: 36pt;">We are an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty biologics for the treatment of immunodeficient patients at risk for infection and
                  others at risk for certain infectious diseases. Our targeted patient populations include immune-compromised individuals who suffer from an underlying immune deficiency disorder or who may be immune-suppressed for medical reasons.</div>

                <div><br/>
                </div>

                <div style="text-indent: 36pt;">Through our ADMA BioManufacturing business segment, we currently have three products with U.S. Food and Drug Administration (the &#8220;FDA&#8221;) approval, all of which are currently marketed and commercially
                  available: (i) ASCENIV (Immune Globulin Intravenous, Human &#8211; slra 10% Liquid), an Intravenous Immune Globulin (&#8220;IVIG&#8221;) product indicated for the treatment of Primary Humoral Immunodeficiency (&#8220;PI&#8221;), also known as Primary Immunodeficiency
                  Disease (&#8220;PIDD&#8221;) or Inborn Errors of Immunity, in adults and adolescents, for which we received FDA approval on April 1, 2019 and commenced first commercial sales in October 2019; (ii) BIVIGAM , an IVIG product indicated for the treatment
                  of PI, and for which we received FDA approval on May 9, 2019 and commenced commercial sales in August 2019; and (iii) Nabi-HB (Hepatitis B Immune Globulin, Human), which is indicated for the treatment of acute exposure to blood containing
                  HBsAg and other listed exposures to Hepatitis B. We seek to develop a pipeline of plasma-derived therapeutics, including a product based on our most recently approved patent application under U.S. Patent Nos. 10,259,865 and 11,084,870
                  related to methods of treatment and prevention of <span style="font-style: italic;">S. pneumonia</span> infection for an immunoglobulin manufactured to contain standardized antibodies to numerous serotypes of <span style="font-style: italic;">S. pneumoniae</span>. We have successfully completed production of a pilot-scale batch and are conducting animal studies for our<span style="font-style: italic;"> S. pneumoniae</span> hyperimmune globulin program, SG-001. Our
                  products and product candidates are intended to be used by physician specialists focused on caring for immune-compromised patients with or at risk for certain infectious diseases.</div>

                <div><br/>
                </div>

                <div style="text-indent: 36pt;">We manufacture these products at our FDA-licensed, plasma fractionation and purification facility located in Boca Raton, Florida with a peak annual processing capability of up to 600,000 liters (the &#8220;Boca
                  Facility&#8221;). Based on current production yields, our completed and ongoing supply chain enhancements and capacity expansion initiatives, we believe this facility has the potential to produce sufficient quantities of our immune globulin
                  (&#8220;IG&#8221;) products representing projected annual revenues greater than $490 million in 2025 and $605 million in 2026. These revenue targets translate to potential fiscal year 2025 and 2026 Adjusted Net Income exceeding $175 million and $235
                  million, respectively, and Adjusted EBITDA exceeding $225 million and $305 million, respectively. The foregoing financial targets do not account for the potential FDA approval of our innovative yield enhancement production process
                  described below.</div>

                <div><br/>
                </div>

                <div style="text-indent: 36pt;">In December 2024, we successfully submitted a Prior Approval Supplement (the &#8220;PAS&#8221;) for potential approval of our innovative yield enhancement production process. Following FDA review of the submission, we
                  anticipate receiving FDA approval by mid-2025, with potential revenue and earnings accretion expected in the second half of the year. This innovative process has demonstrated an ability to increase production yields by approximately 20%
                  from the same starting plasma volume, potentially driving significant increases to financial targets, if approved.</div>

                <div><br/>
                </div>

                <div style="text-indent: 36pt;">Through our ADMA BioCenters subsidiary, we currently operate ten source plasma collection facilities in the U.S., all of which hold FDA licenses. This business unit, which we refer to as our Plasma Collection
                  Centers business segment, provides us with the blood plasma required for the manufacture of our products, and also allows us to sell certain quantities of source and hyperimmune plasma to third-party customers for further manufacturing.
                  In addition, three of our FDA-approved plasma collection centers also have approvals from the Korean Ministry of Food and Drug Safety (&#8220;MFDS&#8221;), as well as FDA approval to operate a Hepatitis B immunization program. A typical plasma
                  collection center, such as those operated by ADMA BioCenters, can collect approximately 30,000 to 50,000 liters of source plasma annually, which may be sold for different prices depending upon the type of plasma, quantity of purchase and
                  market conditions at the time of sale. Plasma collected from ADMA BioCenters&#8217; facilities that is not used to manufacture our products is sold to third-party customers in the U.S. and in other locations outside the U.S. where we are
                  approved under supply agreements or in the open &#8220;spot&#8221; market.</div>

                <div><br/>
                </div>

                <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
                  <div style="text-align: center; text-indent: -9pt; margin-left: 9pt;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">4</span></div>

                  <div style="page-break-after: always;" class="BRPFPageBreak">
                    <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: rgb(0, 0, 0); background-color: rgb(0, 0, 0);"/></div>

                  <div style="width: 100%;" class="BRPFPageHeader">
                    <div>
                      <div style="text-align: left; font-weight: bold; text-indent: -9pt; margin-left: 9pt;"><a href="#ADMABIOLOGICSINC."> <span style="font-style: italic; font-weight: normal; font-size: 8pt;">Table of Contents</span></a><br/>
                      </div>

                    </div>

                  </div>

                </div>

                <div style="text-indent: 36pt;">From time to time we may provide contract manufacturing services for certain third-party clients. We also provide laboratory contracting services to certain customers and may provide contract filling,
                  labeling and packing services utilizing our FDA-approved in-house fill-finish capabilities.</div>

                <div><br/>
                </div>

                <div style="text-indent: 36pt;">For the year ended December 31, 2024 we achieved net income of $197.7 million, the first time in our history that we achieved net income on a GAAP basis, and generated positive cash flow from operations of
                  $118.7 million. Our improved operating results are primarily the result of the substantial revenue growth and continued physician, patient and payer acceptance of ASCENIV.</div>

                <div><br/>
                </div>

                <div style="font-weight: bold; text-indent: -18pt; margin-left: 18pt;">Our Products</div>

                <div style="text-indent: 36pt;"> <br/>
                </div>

                <div style="font-style: italic; font-weight: bold; text-indent: -9pt; margin-left: 9pt;">ASCENIV</div>

                <div style="text-indent: 36pt;">ASCENIV is a plasma-derived IVIG that contains naturally occurring polyclonal antibodies, which are proteins that are used by the body&#8217;s immune system to neutralize microbes, such as bacteria and viruses, and
                  prevent against infection and disease. We manufacture ASCENIV under HHS License No. 2019 using a process known as fractionation. The Centers for Medicare and Medicaid Services (&#8220;CMS&#8221;) has issued a permanent, product-specific-J-code for
                  ASCENIV.&#160; Under the Healthcare Common Procedure Coding System (&#8220;HCPCS&#8221;), the J-code (J1554) became effective April 1, 2021. As part of our proprietary manufacturing process for ASCENIV, we leverage our unique, patented plasma donor
                  screening methodology and tailored plasma pooling design, which blends normal source plasma and plasma from donors tested to have high levels of neutralizing antibody titers to respiratory syncytial virus (&#8220;RSV&#8221;) using our proprietary
                  microneutralization testing assay. We are able to identify the high titer or &#8220;hyperimmune&#8221; plasma that meets our internal and required specifications for ASCENIV with our patented testing methods and assay. This type of high titer plasma
                  is typically found in less than 10% of the total donor collection samples we test.</div>

                <div><br/>
                </div>

                <div style="text-indent: 36pt;">ASCENIV is approved for the treatment of PIDD or PI, a class of inherited genetic disorders that causes a deficient or absent immune system in adults and adolescents (12 to 17 years of age). Our pivotal Phase
                  3 clinical trial in 59 PIDD patients met the primary endpoint of no Serious Bacterial Infections (&#8220;SBI&#8221;) reported during 12 months of treatment. Secondary efficacy endpoints further demonstrated the benefits of ASCENIV in the low
                  incidence of infection, therapeutic antibiotic use, days missed from work/school/daycare and unscheduled medical visits and hospitalizations. We believe this clinical data together with the FDA approval for the treatment of patients
                  diagnosed with PIDD better positions ADMA to potentially further evaluate ASCENIV in immune-compromised patients infected with or at-risk for RSV infection or potentially other respiratory viral pathogens at an appropriate time. Due to
                  the COVID-19 pandemic, our plans were delayed.&#160; In the future, we may elect to work with the FDA and the immunology and infectious disease community to potentially design an appropriate clinical trial to evaluate the use of ASCENIV in
                  this patient population. Commercial sales of ASCENIV commenced in October of 2019 and in 2023, we commenced manufacturing ASCENIV at the 4,400 Liter production scale. This expansion has improved the product&#8217;s margin profile and increased
                  plant production capacity as fewer batches are needed to support our revenue goals. ASCENIV&#8217;s prescriber and patient base continued to expand during 2024, which drove record utilization and pull-through for this product. These elevated
                  demand trends have sustained into 2025, and ADMA currently expects that this product&#8217;s rapid growth will continue throughout 2025 and beyond.</div>

                <div><br/>
                </div>

                <div style="text-indent: 36pt;">We anticipate filing our supplemental Biologics License Application (&#8220;sBLA&#8221;) in mid-2025, with potential FDA approval in the first half of 2026, for the expansion of ASCENIV&#8217;s label to include the pediatric
                  setting for patients who are two years and older.</div>

                <div><br/>
                </div>

                <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
                  <div style="text-align: center; text-indent: -9pt; margin-left: 9pt;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">5</span></div>

                  <div style="page-break-after: always;" class="BRPFPageBreak">
                    <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: rgb(0, 0, 0); background-color: rgb(0, 0, 0);"/></div>

                  <div style="width: 100%;" class="BRPFPageHeader">
                    <div>
                      <div style="text-align: left; font-weight: bold; text-indent: -9pt; margin-left: 9pt;"><a href="#ADMABIOLOGICSINC."> <span style="font-style: italic; font-weight: normal; font-size: 8pt;">Table of Contents</span></a><br/>
                      </div>

                    </div>

                  </div>

                </div>

                <div style="font-style: italic; font-weight: bold; text-indent: -9pt; margin-left: 9pt;">BIVIGAM</div>

                <div style="text-indent: 36pt;">BIVIGAM is a plasma-derived IVIG that contains a broad range of antibodies similar to those found in normal human plasma. These antibodies are directed against bacteria and viruses and help to protect PI
                  patients against serious infections. BIVIGAM is a purified, sterile, ready-to-use preparation of concentrated human Immunoglobulin G antibodies indicated for the treatment of PI, a group of genetic disorders. This includes, but is not
                  limited to, the humoral immune defect in common variable immunodeficiency, X-linked agammaglobulinemia, congenital agammaglobulinemia, Wiskott-Aldrich syndrome and severe combined immunodeficiency. These PIs are a group of genetic
                  disorders.&#160;Based on recent estimates, these disorders are no longer considered to be very rare, with as many as one in every 1,200 people in the United States having some form of PI.</div>

                <div><br/>
                </div>

                <div style="text-indent: 36pt;">On May 9, 2019, the FDA approved the PAS for the use of our IVIG manufacturing process (known as fractionation), thereby enabling us to re-launch and commercialize this product in the U.S. We resumed
                  production of BIVIGAM during the fourth quarter of 2017 and commercial production is ongoing, using our FDA-approved IVIG manufacturing process under U.S. Department of Health and Human Services (&#8220;HHS&#8221;) License No. 2019. The commercial
                  re-launch and first commercial sales for this product commenced in August of 2019.</div>

                <div><br/>
                </div>

                <div style="text-indent: 36pt;">On April 28, 2021, we announced that the FDA granted approval for our expanded plasma pool production scale process, allowing for a 4,400-liter plasma pool for the manufacture of our BIVIGAM IVIG product.
                  This increased IVIG plasma pool scale, which allows us to produce BIVIGAM at an expanded capacity utilizing the same equipment, release testing assays and labor force, has had a favorable impact on our gross margins, manufacturing
                  efficiencies and operating results.</div>

                <div><br/>
                </div>

                <div style="text-indent: 36pt;">On December 12, 2023, we announced that the FDA approved the expansion of BIVIGAM&#8217;s label in the U.S. to now include the pediatric setting for those two years of age and older.</div>

                <div><br/>
                </div>

                <div style="font-style: italic; font-weight: bold; text-indent: -9pt; margin-left: 9pt;">Nabi-HB</div>

                <div style="text-indent: 36pt;">Nabi-HB is a hyperimmune globulin that is rich in antibodies to the Hepatitis B virus. Nabi-HB is a purified human polyclonal antibody product collected from plasma donors who have been previously vaccinated
                  with a Hepatitis B vaccine. Nabi-HB is indicated for the treatment of acute exposure to blood containing HbsAg, prenatal exposure of infants born to HbsAg-positive mothers, sexual exposure to HbsAg-positive persons and household exposure
                  to persons with acute Hepatitis B virus infection in specific, listed settings. Hepatitis B is a potentially life-threatening liver infection caused by the Hepatitis B virus, which is a major global health problem. The Hepatitis B virus
                  can cause chronic infection and places people at high risk of death from cirrhosis and liver cancer. Nabi-HB has a well-documented record of long-term safety and effectiveness since its initial market introduction. The FDA approved
                  Nabi-HB on March 24, 1999.&#160; Production of Nabi-HB at the Boca Facility has continued under our leadership since the third quarter of 2017. In early 2018, we received authorization from the FDA for the release of our first commercial batch
                  of Nabi-HB for commercial distribution in the U.S. and we continue to manufacture Nabi-HB under HHS License No. 2019.</div>

                <div><br/>
                </div>

                <div style="font-weight: bold; text-indent: -9pt; margin-left: 9pt;">Evaluation of ASCENIV in PIDD Patients</div>

                <div> <br/>
                </div>

                <div style="text-indent: 36pt;">PIDD or PI, also known as Inborn Errors of Immunity, is a genetic disorder that causes a deficient or absent immune system, is caused by hereditary or genetic defects, and can affect anyone regardless of age
                  or gender. PIDD patients are more vulnerable to infections and more likely to suffer complications from these infections. IVIG is a plasma-derived product that is used to prevent serious infections in patients with PIDD. It is comprised
                  of polyclonal antibodies, which are proteins produced by B-cells that are used by the body&#8217;s immune system to neutralize foreign objects such as bacteria and viruses. It is estimated that there are about 250,000 diagnosed PIDD patients in
                  the U.S., approximately half of whom are treated with IVIG regularly. As reported by <span style="font-style: italic;">The Plasma Proteins Market In The United States</span>, the U.S. sales of immune and hyperimmune globulin products for
                  all its uses were reported to be approximately $12 billion in 2023 and are expected to exceed $20 billion by 2030.</div>

                <div style="text-indent: 36pt;"> <br/>
                </div>

                <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
                  <div style="text-align: center; text-indent: -9pt; margin-left: 9pt;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">6</span></div>

                  <div style="page-break-after: always;" class="BRPFPageBreak">
                    <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: rgb(0, 0, 0); background-color: rgb(0, 0, 0);"/></div>

                  <div style="width: 100%;" class="BRPFPageHeader">
                    <div>
                      <div style="text-align: left; font-weight: bold; text-indent: -9pt; margin-left: 9pt;"><a href="#ADMABIOLOGICSINC."> <span style="font-style: italic; font-weight: normal; font-size: 8pt;">Table of Contents</span></a><br/>
                      </div>

                    </div>

                  </div>

                </div>

                <div style="text-indent: 36pt;">ASCENIV, formerly known as RI-002, contains polyclonal antibodies against various infectious agents, such as streptococcus pneumoniae, H. influenza type B, CMV, measles and tetanus, including standardized
                  antibodies against RSV. RSV is a common respiratory virus that often presents during the winter months. Nearly all children will have been infected with RSV by three years of age; however, the immune systems of most healthy children
                  prevent significant morbidity and mortality. Conversely, in patients who are immune-compromised, such as those with PIDD or who have undergone a hematopoietic stem cell or solid organ transplant and may be on immunosuppressive drugs or
                  chemotherapy, RSV infection can be associated with significant morbidity and mortality. Immune-compromised patients historically have a 5% to 15% rate of RSV infection, and, if left untreated, lower respiratory tract RSV infections in
                  immune-compromised patients can result in a mortality rate of up to 40% of infected patients. In hematopoietic stem cell transplant (&#8220;HSCT&#8221;) patients, a subset of the immune-compromised patient population with approximately 25,000
                  transplants being performed annually in the U.S., it is estimated that about 25% of patients treated with the current standard of care (aerosolized Ribavirin) will progress to Lower Respiratory Tract Infection (&#8220;LRTI&#8221;) while 41% of
                  patients untreated with the current standard of care will progress to LRTI.</div>

                <div><br/>
                </div>

                <div style="text-indent: 36pt;">The RI-002 pivotal Phase III clinical trial was conducted as a single arm study in which patients were treated approximately once per month for a period of 12 months plus 90 days for follow up. Fifty-nine
                  patients were enrolled in nine treatment centers in the U.S. The pivotal Phase III primary endpoint followed published FDA industry guidance, which provides for a reduction in the incidence of SBI to less than one per year in each subject
                  receiving IVIG. The secondary outcome was safety and included other pharmacokinetic (&#8220;PK&#8221;) data collection points including antibody titers for certain agents, including RSV antibody levels at various time points after infusion.</div>

                <div> <br/>
                </div>

                <div style="text-indent: 36pt;">RI-002 demonstrated positive results in the Phase III study in patients with PIDD, meeting its primary endpoint of no SBIs reported. RI-002 was administered in a total of 793 infusions with zero serious
                  adverse events to 59 patients in nine treatment centers throughout the U.S. These results, included in our Biologics License Application (&#8220;BLA&#8221;), exceed the requirement specified by FDA guidance of &#8804; 1 serious infection per patient-year.</div>

                <div> <br/>
                </div>

                <div style="text-indent: 36pt;">On February 22, 2015, at the 2015 American Academy of Allergy, Asthma &amp; Immunology Annual Meeting, scientific investigators reported on the secondary outcomes that included: a total of 93 days, or 1.66
                  days per patient per year lost from work or school due to infection; one hospitalization due to an infection of only five days duration in the entire study and Immune Globulin (&#8220;IgG&#8221;) trough levels above those required by the FDA for IVIG
                  products. Additionally, there was a marked increase in all of the measured specific anti-pathogen antibodies in PK subjects (n=31). The mean of maximum fold increases in specific antibody levels after infusion of RI-002 ranged from 1.9
                  fold (S. pneumonia type 19A) to 5.3 fold (RSV), which were statistically significant fold increases from the pathogen&#8217;s specific measured baselines. The safety profile of ASCENIV is comparable to that of other immunoglobulins.</div>

                <div style="text-indent: 36pt;"> <br/>
                </div>

                <div style="font-weight: bold; text-indent: -9pt; margin-left: 9pt;">Evaluation of ASCENIV in RSV-Infected Patients</div>

                <div> <br/>
                </div>

                <div style="text-indent: 36pt;">RSV is a common virus that ordinarily leads to mild, cold-like symptoms in healthy adults and children. In high-risk groups, such as the PIDD population and other immune-compromised populations, RSV can lead
                  to a more serious infection and may even cause death. The polyclonal antibodies that are present in ASCENIV are expected to prevent infections in immune-compromised patients.</div>

                <div><br/>
                </div>

                <div style="text-indent: 36pt;">In October 2019, we announced the successful treatment of ASCENIV in two children suffering with RSV through our compassionate use program.&#160; The two immunocompromised children admitted to the Mayo Clinic each
                  were diagnosed with T-cell lymphoblastic lymphoma. Both patients were undergoing delayed intensification chemotherapy and each were diagnosed with RSV Lower Respiratory Tract Infection (&#8220;LRTI&#8221;). Both children were treated with ASCENIV
                  under an emergency FDA Investigational New Drug (&#8220;IND&#8221;) protocol.</div>

                <div> <br/>
                </div>

                <div style="text-indent: 36pt;">We previously conducted a randomized, double-blind, placebo-controlled Phase II clinical trial to evaluate RI-001, RI-002&#8217;s predecessor product candidate, in immune-compromised, RSV-infected patients. This
                  trial was conducted with 21 patients in the U.S., Canada, Australia, and New Zealand. The Phase II dose-ranging trial demonstrated a statistically significant improvement in the change from baseline RSV titers to day 18 in the high dose
                  and low dose treatment groups when compared with placebo (p=0.0043 and p=0.0268, respectively). The mean fold increase for high dose was 9.24 (95% CI 4.07, 21.02) and the observed mean fold increase for low dose was 4.85 (95% CI 2.22,
                  10.59). The mean fold change for placebo treated patients was 1.42 (95% CI 0.64, 3.17). In addition, more patients in the high dose (85.7%) and low dose (42.9%) groups experienced greater than a four-fold increase from baseline to day 18
                  in RSV titer levels compared to placebo (0%). There were no serious drug-related adverse events reported during the trial.</div>

                <div> <br/>
                </div>

                <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
                  <div style="text-align: center; text-indent: -9pt; margin-left: 9pt;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">7</span></div>

                  <div style="page-break-after: always;" class="BRPFPageBreak">
                    <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: rgb(0, 0, 0); background-color: rgb(0, 0, 0);"/></div>

                  <div style="width: 100%;" class="BRPFPageHeader">
                    <div>
                      <div style="text-align: left; font-weight: bold; text-indent: -9pt; margin-left: 9pt;"><a href="#ADMABIOLOGICSINC."> <span style="font-style: italic; font-weight: normal; font-size: 8pt;">Table of Contents</span></a><br/>
                      </div>

                    </div>

                  </div>

                </div>

                <div style="text-indent: 36pt;">From April 2009 through February 2011, RI-001 was also administered to 15 compassionate use patients where physicians requested access to the product for treating their patients with documented lower
                  respiratory tract RSV infections due to the fact that these patients had failed conventional therapeutic interventions. Serum samples were obtained from 13 patients. Samples showed that patients demonstrated a four-fold or greater rise in
                  RSV antibody titers from baseline. Serum samples were not obtained from two patients that received Palivizumab. All 11 surviving patients received RI-001 within an average of 4.4 days after the onset of the diagnosis of RSV. The drug was
                  well-tolerated in all 15 patients and there were no reports of serious adverse events attributable to RI-001.</div>

                <div><br/>
                </div>

                <div style="font-weight: bold; text-indent: -9pt; margin-left: 9pt;">Plasma Collection Operations</div>

                <div> <br/>
                </div>

                <div style="text-indent: 36pt;">ADMA BioCenters operates a total of ten U.S.-based plasma collection facilities, all of which hold FDA licenses and are actively collecting source and high-titer RSV plasma. Currently, three facilities have
                  also received approvals from MFDS as well as FDA approval to implement a Hepatitis B immunization program. Source plasma that is collected from our FDA-licensed facilities provides us with the blood plasma for the manufacture of our
                  products. A typical plasma collection center, such as those operated by ADMA BioCenters, can collect approximately 30,000 to 50,000 liters of source plasma annually, which may be sold for different prices depending upon the type of
                  plasma, quantity of purchase, and market conditions at the time of sale. Plasma collected from ADMA BioCenters&#8217; facilities that is not used to manufacture our products or product candidates are sold to third-party customers in the U.S.
                  and other international locations where we are approved under supply agreements or in the open &#8220;spot&#8221; market.</div>

                <div><br/>
                </div>

                <div style="font-weight: bold; text-indent: -9pt; margin-left: 9pt;">Our Strategy</div>

                <div> <br/>
                </div>

                <div style="text-indent: 36pt;">Our goal is to be a leader in manufacturing, marketing and developing specialty biologics that are intended to extend and enhance the lives of individuals who are naturally or medically immune-compromised.
                  The key elements of our strategy for achieving this goal are as follows:</div>

                <div> <br/>
                </div>

                <div>
                  <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0); border-spacing: 0;">


  <tr>

    <td style="width: 18pt;">&#160;</td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
                          <div><span style="font-weight: bold;">Continue to expand the commercial production of our IG products and notably drive a revenue mix shift favoring sales of ASCENIV for the treatment of patients with PI</span>. We continue to
                            enhance our recruiting initiatives and expand our existing specialty commercial sales force and commercial-facing organization to market ASCENIV and BIVIGAM to appropriate sites of care, including home healthcare infusion
                            facilities, hospitals, physician offices/clinics and other specialty treatment and infusion center organizations. We also anticipate staffing our Company with additional personnel for patient support, medical affairs, quality
                            assurance, quality control, inventory management, regulatory affairs, manufacturing, scientific affairs and third-party reimbursement. We currently use and may continue to partner with a network of national distributors to
                            fulfill orders for ASCENIV and BIVIGAM.</div>
                        </td>

  </tr>


</table>
                  <div><br/>
                  </div>

                  <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0); border-spacing: 0;">


  <tr>

    <td style="width: 18pt;"><br/>
                        </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
                          <div><span style="font-weight: bold;">Expand ASCENIV&#8217;s FDA-approved uses</span>. Having received approval by the FDA for ASCENIV as a treatment for PIDD, we may elect to evaluate the clinical and regulatory paths to grow the
                            ASCENIV franchise through expanded FDA-approved uses. We plan to leverage our previously conducted randomized, double-blind, placebo-controlled Phase II clinical trial evaluating RI-001, ASCENIV&#8217;s predecessor product candidate,
                            as well as the drug&#8217;s real-world impact on patient outcomes, to drive further penetration into ASCENIV&#8217;s targeted market principally comprised of patients suffering from complex and comorbid primary immunodeficiencies.</div>
                        </td>

  </tr>


</table>
                  <div style="text-indent: -36pt; margin-left: 36pt;">&#160;</div>

                  <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0); border-spacing: 0;">


  <tr>

    <td style="width: 18pt;"><br/>
                        </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
                          <div><span style="font-weight: bold;">Improve the Boca Facility&#8217;s and ADMA BioCenters&#8217; operating efficiencies, yields and gross margins. </span>During 2025, we plan to advance our biologic production yield enhancement initiative
                            to capture additional IG production yields from our manufacturing process with the same quantities of starting raw material. These initiatives are subject to further evaluation and requisite regulatory review. In December 2024,
                            we successfully submitted a PAS for potential approval of our innovative yield enhancement production process. Following FDA review of the submission, we anticipate receiving FDA approval by mid-2025, with potential revenue and
                            earnings accretion expected in the second half of the year. This innovative process has demonstrated an ability to increase production yields by approximately 20% from the same starting plasma volume, potentially driving
                            significant increases to financial targets, if approved. During 2021, we received FDA approvals for our 4,400L expanded IVIG production scale, as well as our in-house fill-finish and related operations production line using our
                            aseptic filling machine. In 2023, we commenced manufacturing ASCENIV at the 4,400 Liter production scale, and for the full year ended December 31, 2024, substantially all of our production batches sold were produced at the
                            expanded 4,400 Liter scale. This expansion has improved the product&#8217;s margin profile and increased plant production capacity as fewer batches are needed to support revenue goals.</div>
                        </td>

  </tr>


</table>
                  <div>&#160;</div>

                  <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
                    <div style="text-align: center; text-indent: -9pt; margin-left: 9pt;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">8</span></div>

                    <div style="page-break-after: always;" class="BRPFPageBreak">
                      <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: rgb(0, 0, 0); background-color: rgb(0, 0, 0);"/></div>

                    <div style="width: 100%;" class="BRPFPageHeader">
                      <div>
                        <div style="text-align: left; font-weight: bold; text-indent: -9pt; margin-left: 9pt;"><a href="#ADMABIOLOGICSINC."> <span style="font-style: italic; font-weight: normal; font-size: 8pt;">Table of Contents</span></a><br/>
                        </div>

                      </div>

                    </div>

                  </div>

                  <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0); border-spacing: 0;">


  <tr>

    <td style="width: 18pt;"><br/>
                        </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
                          <div><span style="font-weight: bold;">Broadly Implement Innovative AI Program, ADMAlytics, to improve efficiencies across our supply chain and production operations.</span> In February 2024, we announced the successful initial use
                            of our Artificial Intelligence (AI) program, named ADMAlytics. ADMAlytics combines AI and machine learning to improve and predict outcomes for production and operational processes. In early 2024, we successfully produced our
                            first batch of ASCENIV utilizing our innovative ADMAlytics software to prospectively automate and realize efficiency improvements to plasma pooling during commercial manufacturing. In the third quarter of 2024, we successfully
                            expanded implementation of ADMAlytics to our commercial division. When fully implemented, ADMAlytics is expected to further optimize our commercial growth strategy. The benefits of ADMAlytics include increased production
                            efficiency, enhanced visibility into the 7&#8211;12-month manufacturing process, optimized commercial planning, streamlined plasma pooling, and reduced variability and personnel hours. These efficiencies are expected to further
                            benefit our rapid earnings growth outlook.</div>
                        </td>

  </tr>


</table>
                  <div><br/>
                  </div>

                  <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0); border-spacing: 0;">


  <tr>

    <td style="width: 18pt;"><br/>
                        </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
                          <div><span style="font-weight: bold;">Label expansion. </span>Upon regulatory approval, the ongoing post-marketing clinical study of ASCENIV, which has successfully completed enrollment, may provide a label expansion opportunity
                            to include pediatric-aged PI patients as well as additional publications supporting product safety. We anticipate filing our sBLA in mid-2025, with potential FDA approval in the first half of 2026, for the expansion of ASCENIV&#8217;s
                            label in the U.S. to include the pediatric setting for patients who are two years and older.</div>
                        </td>

  </tr>


</table>
                  <div><br/>
                  </div>

                  <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0); border-spacing: 0;">


  <tr>

    <td style="width: 18pt;"><br/>
                        </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
                          <div><span style="font-weight: bold;">Expand and develop our pipeline with additional specialty plasma and/or hyperimmune immunoglobulin products</span>. Our core competency is in the development, manufacturing, testing and
                            commercialization of plasma-derived therapeutics. We believe there are a number of under-addressed medical conditions for which plasma-derived therapeutics may be beneficial. Utilizing our intellectual property patents, which
                            include our proprietary testing assay and other standardization methods and technologies, we have identified potential new product candidates that we may advance into preclinical activities. As part of expanding our product
                            pipeline, we are developing an S. pneumonia hyperimmune globulin, and in 2024 we successfully produced a pilot-scale batch of this pipeline program, named SG-001. We are currently conducting animal studies for SG-001. S.
                            pneumonia is the predominant cause of community-acquired pneumonia in the U.S., ranking as the ninth leading cause of overall mortality. We believe the strategic importance and unmet need are evident in both the prophylactic and
                            therapeutic settings where documented anti-infective resistance is on the rise. Approximately one million U.S. adults contract pneumococcal pneumonia annually, resulting in 400,000 hospitalizations and a 5-7% mortality rate, of
                            which approximately 7,000 deaths annually are attributable to anti-infective resistance. Despite vaccine availabilities, vaccine-naive and immune-compromised patient populations remain at risk and could potentially benefit from
                            the immediately available neutralizing antibodies conferred with a hyperimmune globulin in both the in-patient and out-patient treatment settings.&#160; We estimate that an S. pneumonia hyperimmune globulin, if approved, has the
                            potential to generate peak annual revenue of $300-500 million.</div>
                        </td>

  </tr>


</table>
                </div>

                <div> <br/>
                </div>

                <div style="font-weight: bold; text-indent: -9pt; margin-left: 9pt;">Primary Immunodeficiency Disease</div>

                <div> <br/>
                </div>

                <div style="text-indent: 36pt;">PIDD is a class of hereditary disorders characterized by defects in the immune system, due to either a lack of necessary antibodies or a failure of these antibodies to function properly. According to the
                  World Health Organization, there are over 150 different presentations of PIDD. As patients suffering from PIDD lack a properly functioning immune system, they typically receive monthly, outpatient infusions of IVIG therapy. Without this
                  exogenous antibody immune support, these patients would be susceptible to a wide variety of infectious diseases. PIDD has an estimated prevalence of 1:1,200 in the U.S., or approximately 250,000 people. As reported by <span style="font-style: italic;">The Plasma Proteins Market In The United States 2023 </span>and <span style="font-style: italic;">Marketing Research Bureau Inc., October 2023</span>, the U.S. market for IG in 2023 was approximately $12
                  billion and is expected to exceed $20 billion by 2030.</div>

                <div><br/>
                </div>

                <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
                  <div style="text-align: center; text-indent: -9pt; margin-left: 9pt;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">9</span></div>

                  <div style="page-break-after: always;" class="BRPFPageBreak">
                    <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: rgb(0, 0, 0); background-color: rgb(0, 0, 0);"/></div>

                  <div style="width: 100%;" class="BRPFPageHeader">
                    <div>
                      <div style="text-align: left; font-weight: bold; text-indent: -9pt; margin-left: 9pt;"><a href="#ADMABIOLOGICSINC."> <span style="font-style: italic; font-weight: normal; font-size: 8pt;">Table of Contents</span></a><br/>
                      </div>

                    </div>

                  </div>

                </div>

                <div style="text-indent: 36pt;">As most patients with PIDD present with infections, the differential diagnosis and initial investigations for an underlying immune defect are typically guided by the clinical presentation. In subjects with
                  PIDD, individual infections are not necessarily more severe than those that occur in a normal host. Rather, the clinical features suggestive of an immune defect may be the recurring and/or chronic nature of infections with common
                  pathogens that may result in end organ damage, such as bronchiectasis. In addition, subjects with PIDD will often respond poorly to standard antimicrobial therapy or they may have repeated infections with the same pathogen. The virulence
                  of the infecting organism should also be considered, and a subject&#8217;s immune competence should be questioned when invasive infections are caused by low virulence or opportunistic pathogens. For example, infection with the opportunistic
                  pathogens Pneumocystis jiroveci (previously Pneumocystis carinii) or atypical mycobacteria should prompt an investigation for underlying immunodeficiency. Typical clinical presentations for subjects with PIDD are:</div>

                <div> <br/>
                </div>

                <div>
                  <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0); border-spacing: 0;">


  <tr>

    <td style="width: 18pt;">&#160;</td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
                          <div>antibody deficiency and recurrent bacterial infections;</div>
                        </td>

  </tr>


</table>
                  <div style="text-indent: -36pt; margin-left: 36pt;">&#160;</div>

                  <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0); border-spacing: 0;">


  <tr>

    <td style="width: 18pt;"><br/>
                        </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
                          <div>T-lymphocyte deficiency and opportunistic infections;</div>
                        </td>

  </tr>


</table>
                  <div style="text-indent: -36pt; margin-left: 36pt;">&#160;</div>

                  <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0); border-spacing: 0;">


  <tr>

    <td style="width: 18pt;"><br/>
                        </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
                          <div>other lymphocyte defects causing opportunistic infections;</div>
                        </td>

  </tr>


</table>
                  <div style="text-indent: -36pt; margin-left: 36pt;">&#160;</div>

                  <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0); border-spacing: 0;">


  <tr>

    <td style="width: 18pt;"><br/>
                        </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
                          <div>neutrophil defects causing immunodeficiency; and</div>
                        </td>

  </tr>


</table>
                  <div style="text-indent: -36pt; margin-left: 36pt;">&#160;</div>

                  <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0); border-spacing: 0;">


  <tr>

    <td style="width: 18pt;"><br/>
                        </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
                          <div>complement deficiencies.</div>
                        </td>

  </tr>


</table>
                  <div><br/>
                  </div>

                </div>

                <div style="text-indent: 36pt;">PIDD can present at any age from birth to adulthood, posing a considerable challenge for the practicing physician to know when and how to evaluate a subject for a possible immune defect. Subjects with marked
                  antibody deficiencies are generally dependent on IVIG therapy for survival. Benefits of adequate IVIG therapy in subjects not able to produce antibodies normally include a reduction in the severity and frequency of infections, prevention
                  of chronic lung disease and prevention of enteroviral meningoencephalitis. Several immune globulin products have already been approved by the FDA.</div>

                <div> <br/>
                </div>

                <div style="font-weight: bold; text-indent: -9pt; margin-left: 9pt;">Plasma &#8211; Background, Composition and Manufacturing</div>

                <div><br/>
                </div>
<div>
                Human blood contains a number of components including:
                </div>
<div> <br/>
                </div>

                <div>
                  <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0); border-spacing: 0;">


  <tr>

    <td style="width: 18pt;">&#160;</td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
                          <div>Red blood cells &#8211; Used to carry oxygen from the lungs to the body;</div>
                        </td>

  </tr>


</table>
                  <div style="text-indent: -36pt; margin-left: 36pt;">&#160;</div>

                  <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0); border-spacing: 0;">


  <tr>

    <td style="width: 18pt;"><br/>
                        </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
                          <div>White blood cells &#8211; Used by the immune system to fight infection;</div>
                        </td>

  </tr>


</table>
                  <div style="text-indent: -36pt; margin-left: 36pt;">&#160;</div>

                  <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0); border-spacing: 0;">


  <tr>

    <td style="width: 18pt;"><br/>
                        </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
                          <div>Platelets &#8211; Used for blood clotting; and</div>
                        </td>

  </tr>


</table>
                  <div style="text-indent: -36pt; margin-left: 36pt;">&#160;</div>

                  <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0); border-spacing: 0;">


  <tr>

    <td style="width: 18pt;"><br/>
                        </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
                          <div>Plasma &#8211; Used to carry the aforementioned components throughout the body and provide support in clotting and immunity.</div>
                        </td>

  </tr>


</table>
                </div>

                <div> <br/>
                </div>

                <div style="text-indent: 36pt;">Plasma is the most abundant blood component, representing approximately 55% of total blood volume. Plasma, which is 90% water, is rich in proteins used by the human body for blood clotting and fighting
                  infection. These proteins account for approximately 7% of plasma&#8217;s volume. As plasma contains these valuable proteins, plasma collection and the manufacturing of human plasma-derived therapeutics provide therapeutic benefits for ill
                  patients.</div>

                <div> <br/>
                </div>

                <div style="text-indent: 36pt;">In order to produce plasma-derived therapeutics that can be administered to ill patients, raw material plasma must be collected from human donors and then manufactured into specialized products. Plasma is
                  collected from healthy donors at FDA-licensed plasma donation centers. To ensure safety of the collected plasma, all plasma donations are tested using FDA-approved methods of Nucleic Acid Testing for various infectious diseases, such as
                  HIV or HCV.</div>

                <div> <br/>
                </div>

                <div style="text-indent: 36pt;">Plasma is collected using a process known as &#8220;plasmapheresis.&#8221; During plasmapheresis, a donor&#8217;s blood is drawn into a specialized medical device that separates the plasma component through centrifugation, and
                  then returns the other blood components back into the donor&#8217;s bloodstream. Plasmapheresis is performed utilizing an FDA-authorized, automated device with a sterile, self-contained collection kit. The plasma that is collected is known as
                  &#8220;normal source plasma.&#8221; There are over 1,000 plasma donation centers in the U.S. As noted in a variety of plasma industry trade reports and related conferences, approximately 55.4 million liters of source plasma were collected in the U.S.
                  in 2023. In the U.S., a donor may donate plasma a maximum of two times during any seven-day period, with at least two days in between donations. Plasma donation centers in the U.S. typically pay donors $50 to $100 per donation and some
                  donors with rare or high antibody levels can be paid more.</div>

                <div style="text-indent: 36pt;"> <br/>
                </div>

                <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
                  <div style="text-align: center; text-indent: -9pt; margin-left: 9pt;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">10</span></div>

                  <div style="page-break-after: always;" class="BRPFPageBreak">
                    <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: rgb(0, 0, 0); background-color: rgb(0, 0, 0);"/></div>

                  <div style="width: 100%;" class="BRPFPageHeader">
                    <div>
                      <div style="text-align: left; font-weight: bold; text-indent: -9pt; margin-left: 9pt;"><a href="#ADMABIOLOGICSINC."> <span style="font-style: italic; font-weight: normal; font-size: 8pt;">Table of Contents</span></a><br/>
                      </div>

                    </div>

                  </div>

                </div>

                <div style="text-indent: 36pt;">In order to isolate the desired therapeutic elements in normal source plasma, it must initially go through the fractionation process. The process of fractionation was invented in the 1940&#8217;s by E.J. Cohn and
                  is referred to as the Cohn method or cold ethanol fractionation. First, the source plasma undergoes a process called pooling, in which the individual plasma donations are combined into a pooling tank. Second, the Cohn fractionation
                  method, which is a combination of time, temperature, pH, alcohol concentration and centrifugation, is used to separate the desired plasma protein components, or &#8220;fractions.&#8221; After fractionation, the separated proteins are then
                  re-suspended and are treated with a solvent detergent treatment process for viral inactivation. Next, other forms of filtration, such as nanofiltration, are performed as an additional viral removal and viral reduction step. Finally, with
                  the various components separated and purified, the bulk product is formulated and filled into final, finished vials. During these various steps of manufacturing, each lot is reviewed and tested for potency and purity prior to being
                  approved for release. The biologics manufacturing process is time consuming and complex.&#160; The time for collection, manufacturing and release of a batch of IG is estimated at 7 to 12 months, which is not unique to just ADMA as other
                  fractionators report similar production timelines.</div>

                <div> <br/>
                </div>

                <div style="text-indent: 36pt;">The proteins in human plasma fall into four categories: albumin (60% of protein volume), immune globulins (15% of protein volume), coagulation factors (1% of protein volume), and other proteins (24% of
                  protein volume) such as alpha-1 proteinase inhibitor, C1 esterase inhibitor, fibrin sealants and fibrinogen. Many of the other proteins in plasma have yet to be developed into commercial therapies. In the U.S., not only are the plasma
                  collection centers subject to FDA licensure, but each plasma protein product that is derived and fractionated from plasma must undergo an approval process with FDA&#8217;s Center for Biologics Evaluation and Research (&#8220;CBER&#8221;).</div>

                <div> <br/>
                </div>

                <div style="font-weight: bold; text-indent: -9pt; margin-left: 9pt;">Immune Globulins</div>

                <div> <br/>
                </div>

                <div style="text-indent: 36pt;">In June 2008, the FDA published the FDA Guidance for Industry outlining the regulatory pathway for the approval of IVIG for the treatment of PIDD <span style="font-style: italic;">(Guidance for Industry:
                    Safety, Efficacy, and Pharmacokinetic Studies to Support Marketing of Immune Globulin Intravenous (Human) as Replacement Therapy for Primary Humoral Immunodeficiency)</span>.</div>

                <div> <br/>
                </div>

                <div style="text-indent: 36pt;">Immune globulins can be administered in three ways: intramuscularly, intravenously or subcutaneously. IVIG principally contains antibodies and, as such, provides passive immunization for individuals who are
                  immune-deficient or who have been exposed to various infectious agents. IVIG is used therapeutically in a variety of immunological diseases/deficiencies, such as PIDD, idiopathic thrombocytopenic purpura, Guillain-Barr&#233; syndrome, Kawasaki
                  disease, bone marrow transplant, and chronic inflammatory demyelinating polyneuropathy. We are aware that other companies are also evaluating IVIG in a clinical trial for the treatment of Alzheimer&#8217;s disease. Additionally, IVIG is also
                  used as therapy in a variety of other diseases that do not involve primary or secondary immune deficiencies, such as multiple sclerosis, skin disease, and asthma. These latter uses are referred to as &#8220;off-label&#8221; or evidence-based uses
                  because the FDA has not approved their use in these indications and promotion of such uses is not permitted by FDA unless a BLA or BLA supplement with additional data is approved. Among the various IVIG products, there are only 14 labeled
                  indications approved by the FDA. However, medical literature identifies at least 150 evidence-based uses for IVIG, of which approximately 60 are currently included on lists of reimbursable uses by Medicare and other healthcare plans. This
                  provides opportunities for new product development and submissions to potentially expand the label for our existing products.</div>

                <div> <br/>
                </div>

                <div style="text-indent: 36pt;">There are two types of immune globulins; standard and hyperimmune. The difference between standard immune globulins and hyperimmune globulins is that the latter are manufactured using plasma obtained from
                  donors who have elevated amounts (high-titers) of specific antibodies. These high-titer products can be used to treat and prevent diseases that present those specific antigens that are reactive with the high-titer antibodies. Hyperimmune
                  products currently available include Hepatitis B, tetanus, rabies, CMV and RhoD immune globulins.</div>

                <div> <br/>
                </div>

                <div style="text-indent: 36pt;">As reported by <span style="font-style: italic;">The Plasma Proteins Market In The United States 2023&#160;</span>and <span style="font-style: italic;">Marketing Research Bureau Inc., October 2023</span>, the
                  U.S. sales of immune and hyperimmune globulin products for all its uses were reported to be approximately $12 billion in 2023 and are expected to exceed $20 billion in 2030. IVIG products are used to treat primary immune deficiencies,
                  certain autoimmune diseases, and other illnesses for immune-compromised patients and certain neuropathy indications. New research and data, secondary immune deficiencies, additional labeled indications, an aging population and emerging
                  countries with new markets are all adding to the worldwide demand and growth of IVIG utilization.</div>

                <div style="text-indent: 36pt;"> <br/>
                </div>

                <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
                  <div style="text-align: center; text-indent: -9pt; margin-left: 9pt;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">11</span></div>

                  <div style="page-break-after: always;" class="BRPFPageBreak">
                    <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: rgb(0, 0, 0); background-color: rgb(0, 0, 0);"/></div>

                  <div style="width: 100%;" class="BRPFPageHeader">
                    <div>
                      <div style="text-align: left; font-weight: bold; text-indent: -9pt; margin-left: 9pt;"><a href="#ADMABIOLOGICSINC."> <span style="font-style: italic; font-weight: normal; font-size: 8pt;">Table of Contents</span></a><br/>
                      </div>

                    </div>

                  </div>

                </div>

                <div style="font-weight: bold; text-indent: -9pt; margin-left: 9pt;">Manufacturing and Supply of Our Products</div>

                <div> <br/>
                </div>

                <div style="text-indent: 36pt;">In order to produce plasma-derived therapeutics that can be administered to patients, raw material plasma is collected from healthy donors at plasma collection facilities licensed by the FDA. When stored
                  under proper conditions, this plasma may have a shelf-life of up to ten years. Source plasma is collected at any one of over 1,000 FDA-licensed donation centers located throughout the U.S., using a process known as automated
                  plasmapheresis. This sterile, self-contained, automated process separates red blood cells and other cellular components in the blood, which are then returned to the donor. Source plasma obtained by plasmapheresis is tested and must be
                  negative for certain diseases, such as antibodies to human immunodeficiency virus types 1 and 2 (HIV-1/2), HbsAg and HCV, using FDA-approved serological test procedures.</div>

                <div> <br/>
                </div>

                <div style="text-indent: 36pt;">After receipt of the source plasma, the frozen plasma is thawed and pooled and goes through the fractionation process. During cold ethanol fractionation, classes of proteins are precipitated and removed by
                  centrifugation or filtration. The fractionation process includes the following steps; precipitation and absorption, depth filtration, centrifugation and chromatography. Because of the human origin of the raw material and the thousands of
                  donations required in the fractionation process, a significant risk associated with plasma products is the transmission of blood-borne infectious pathogens. These purification processes have the potential to reduce the viral load. The
                  manufacturing process also utilizes a multistep viral removal/inactivation system, which further increases the safety of the products. The following manufacturing processes have been validated for their capability to eliminate or
                  inactivate viruses: precipitation during cold ethanol fractionation, solvent/detergent treatment and nanofiltration. We incorporate these processes into the manufacturing process, which ensures that our products comply with the
                  requirements of the FDA and are safe and efficacious.</div>

                <div><br/>
                </div>

                <div style="text-indent: 36pt;">Once our drug-substance is produced in the Boca Facility, the product is further processed by certain third- party fill-finish providers or through our own in-house fill-finish process, which was approved by
                  the FDA in the second half of 2021. Labeling and packaging operations must further comply with regulatory requirements and products must be labeled in accordance with their regulatory approval and Drug Supply Chain Security Act (&#8220;DSCSA&#8221;)
                  serialization requirements.&#160; The end-to-end production cycle can take approximately seven to 12 months for a batch of FDA released drug product. Since 2020, we have successfully implemented several manufacturing and supply chain
                  enhancements, including the purchase and installation of a new aseptic filling machine and the manufacturing of ASCENIV and BIVIGAM at an increased scale.&#160; These initiatives are designed to reduce operating costs, improve margins and
                  provide for faster production cycle turnaround time, ultimately providing increased control and independence from third-party vendors and contractors.</div>

                <div><br/>
                </div>

                <div style="text-indent: 36pt;">ADMA BioCenters has a total of ten source plasma collection facilities in its network, all of which are FDA-licensed, and should allow the Company to be essentially self-sufficient for its raw material normal
                  source plasma supply to produce its commercial IG product portfolio. Three of our ADMA BioCenters plasma collection facilities also have approvals from the South Korean MFDS and licensure from the FDA for the collection and sale of
                  Hepatitis B hyperimmune plasma obtained from immunized donors. At the present time, we do not plan to build additional plasma collection facilities beyond the existing ten, but we continue to have third-party supply contracts in place to
                  augment our vertically integrated plasma collections.</div>

                <div style="text-indent: 36pt;"> <br/>
                </div>

                <div style="text-indent: 36pt;">Pursuant to the terms of a Plasma Purchase Agreement dated as of November 17, 2011 (the &#8220;2011 Plasma Purchase Agreement&#8221;), we agreed to purchase from our former contract manufacturer an annual minimum volume
                  of source plasma containing antibodies to RSV to be used in the manufacture of ASCENIV. We must purchase a to-be-determined and agreed upon annual minimum volume from the counterparty, and under the original 2011 Plasma Purchase Agreement
                  we were permitted to also collect high-titer plasma from up to five wholly-owned ADMA plasma collection facilities. During 2015, we amended the 2011 Plasma Purchase Agreement to (i) allow us to collect our raw material high-titer plasma
                  from any number of wholly-owned ADMA plasma collection facilities and (ii) allow us to purchase our raw material high-titer plasma from other third-party collection organizations, in each case, provided that the annual minimum volumes
                  from our former contract manufacturer were met, thus allowing us to expand our reach for raw material supply as we execute our commercialization plans for ASCENIV. On December 10, 2018, our former contract manufacturer assigned its rights
                  and obligations under the 2011 Plasma Purchase Agreement to Grifols Worldwide Operations Limited (&#8220;Grifols&#8221;) as its successor-in-interest, effective January 1, 2019. Effective October 1, 2024, we entered into an Amended and Restated
                  Plasma Purchase Agreement with Grifols (the &#8220;A&amp;R Grifols Agreement&#8221;) with a term expiring in September 2039, after which it may be renewed for two additional multi-year periods if agreed to by the parties. Pursuant to the A&amp;R
                  Grifols Agreement, Grifols supplies, on a non-exclusive basis, to ADMA BioManufacturing a minimum of 35,000 liters of RSV plasma annually to be used in the manufacture of ASCENIV, with an escalating price per liter depending on the volume
                  supplied in a given 12-month period, with a minimum annual price increase every 12 months.&#160; Additionally, Grifols will be entitled to receive a fixed bonus payment in the event that a specified liter amount of high-titer plasma is
                  supplied to us in any 12-month period during the term of the A&amp;R Grifols Agreement.</div>

                <div><br/>
                </div>

                <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
                  <div style="text-align: center; text-indent: -9pt; margin-left: 9pt;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">12</span></div>

                  <div style="page-break-after: always;" class="BRPFPageBreak">
                    <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: rgb(0, 0, 0); background-color: rgb(0, 0, 0);"/></div>

                  <div style="width: 100%;" class="BRPFPageHeader">
                    <div>
                      <div style="text-align: left; font-weight: bold; text-indent: -9pt; margin-left: 9pt;"><a href="#ADMABIOLOGICSINC."> <span style="font-style: italic; font-weight: normal; font-size: 8pt;">Table of Contents</span></a><br/>
                      </div>

                    </div>

                  </div>

                </div>

                <div style="text-indent: 36pt;">Effective August 6, 2024, we entered into a Plasma Purchase Agreement with KEDPlasma LLC (&#8220;KEDPlasma&#8221;) with a term expiring in July 2031, after which it may be renewed for an additional multi-year period if
                  agreed to by the parties (the &#8220;KEDPlasma Agreement&#8221;).&#160; Pursuant to the KEDPlasma Agreement, KEDPlasma supplies, on a non-exclusive basis, to ADMA BioManufacturing a minimum of 35,000 liters of RSV plasma annually commencing with the
                  12-month period ending July 31, 2026, with an escalating price per liter depending on the volume supplied in a given 12-month period. The price per liter of high titer plasma supplied pursuant to the KEDPlasma Agreement is also scheduled
                  to increase on an annual basis. Additionally, KEDPlasma will be entitled to receive a fixed bonus payment in the event that a specified liter amount of RSV plasma is supplied to us in any 12-month period during the term of the KEDPlasma
                  Agreement.</div>

                <div><br/>
                </div>

                <div style="text-indent: 36pt;">The A&amp;R Grifols Agreement, the KEDPlasma Agreement, our other plasma agreements with third parties and ADMA&#8217;s collection centers should allow us to source high titer plasma from approximately 250
                  collection centers in the U.S.</div>

                <div> <br/>
                </div>

                <div style="text-indent: 36pt;">On June 6, 2017, we entered into a Plasma Supply Agreement with our former contract manufacturer, pursuant to which the counterparty supplies, on an exclusive basis subject to certain exceptions, to ADMA
                  BioManufacturing an annual minimum volume of hyperimmune plasma that contain antibodies to the Hepatitis B virus for the manufacture of Nabi-HB. The Plasma Supply Agreement has a ten-year term. On July 19, 2018, the Plasma Supply
                  Agreement was amended to provide, among other things, that in the event the counterparty elects not to supply in excess of ADMA BioManufacturing&#8217;s specified amount of Hepatitis B plasma and ADMA BioManufacturing is unable to secure
                  Hepatitis B plasma from a third party at a price which is within a low double digit percentage of the price which ADMA BioManufacturing pays to the counterparty, then the counterparty shall reimburse ADMA BioManufacturing for the
                  difference in price ADMA BioManufacturing incurs. On December 10, 2018, our former contract manufacturer assigned its rights and obligations under the Plasma Supply Agreement to Grifols, effective January 1, 2019.</div>

                <div><br/>
                </div>

                <div style="font-weight: bold; text-indent: -9pt; margin-left: 9pt;">Sales and Commercialization of Our Products</div>

                <div> <br/>
                </div>

                <div style="text-indent: 36pt;">Currently, ASCENIV, BIVIGAM and Nabi-HB are sold primarily through independent distributors, drug wholesalers acting as sales agents, specialty pharmacies servicing both acute and ambulatory infusion centers
                  and the home health infusion setting and other alternate site providers. In the U.S., independent distributors or third-party drug wholesalers ship our products through their distribution centers. These centers are generally stocked with
                  adequate inventories to facilitate prompt customer service. Sales and distribution methods include frequent contact by sales and customer service representatives, automated communications via various electronic purchasing systems,
                  circulation of catalogs and merchandising bulletins, direct-mail campaigns, trade publication presence and advertising.</div>

                <div> <br/>
                </div>

                <div style="text-indent: 36pt;">We market and sell our products through our specialty sales force, distribution relationships and other customary industry methods. We focus our efforts specifically on the easily identifiable treatment
                  centers which specialize in the care and management of immune compromised individuals. We estimate that there are approximately 500 leading specialty programs in the U.S. which have significant patient populations for PIDD, suitable for
                  treatment with ASCENIV. Our management and Board of Directors (&#8220;Board&#8221;) have substantial prior direct marketing, sales and distribution experience with plasma-derived drugs, specialty immune globulins and other biological products. As is
                  customary in the plasma products industry, we may also use a network of national distribution organizations that have specialty divisions that focus on plasma products to fulfill orders for ASCENIV.</div>

                <div><br/>
                </div>

                <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
                  <div style="text-align: center; text-indent: -9pt; margin-left: 9pt;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">13</span></div>

                  <div style="page-break-after: always;" class="BRPFPageBreak">
                    <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: rgb(0, 0, 0); background-color: rgb(0, 0, 0);"/></div>

                  <div style="width: 100%;" class="BRPFPageHeader">
                    <div>
                      <div style="text-align: left; font-weight: bold; text-indent: -9pt; margin-left: 9pt;"><a href="#ADMABIOLOGICSINC."> <span style="font-style: italic; font-weight: normal; font-size: 8pt;">Table of Contents</span></a><br/>
                      </div>

                    </div>

                  </div>

                </div>

                <div style="text-indent: 36pt;">Efforts to generate increased market awareness for Nabi-HB include attending and presenting scientific information at medical conferences, as well as sponsoring medical education symposiums. We have also
                  hired a specialty sales force consisting of account managers, medical science liaisons and other customary scientific, medical and detail representatives to market BIVIGAM and ASCENIV to hospitals, physician offices/clinics, and other
                  specialty treatment organizations as applicable. In addition, we have expanded staffing efforts with additional personnel for patient support, medical affairs, quality assurance, regulatory affairs, scientific affairs, third-party
                  reimbursement, inventory and logistics, human resources and financial and operational management. We may also use a network of national and regional distributors to assist with order fulfillment for BIVIGAM and ASCENIV for use by
                  healthcare professionals and hospitals.</div>

                <div> <br/>
                </div>

                <div style="text-indent: 36pt;">Pursuant to our Manufacturing, Supply and License Agreement effective as of December 31, 2012, we granted to Biotest AG (&#8220;Biotest&#8221;) an exclusive license to market and sell ASCENIV in Europe and in selected
                  countries in North Africa and the Middle East (the &#8220;Territory&#8221;), to have access to our testing services for testing of Biotest&#8217;s plasma samples using our proprietary RSV assay, and to reference (but not access) our proprietary information
                  for the purpose of Biotest seeking regulatory approval for ASCENIV in the Territory. As consideration for the license, Biotest provided us with certain in-kind services and also compensated us with cash payments upon the completion of
                  certain milestones. Biotest is also obligated to pay us an adjustable royalty based on a percentage of revenues from the sale of ASCENIV in the Territory for 20 years from the date of first commercial sale.</div>

                <div><br/>
                </div>

                <div style="font-weight: bold; text-indent: -9pt; margin-left: 9pt;">Major Customers</div>

                <div><br/>
                </div>

                <div style="text-indent: 36pt;">For the year ended December 31, 2024, two customers, BioCARE, Inc. (&#8220;BioCare&#8221;) and Priority Healthcare Distribution, Inc. (&#8220;Curascript&#8221;), represented an aggregate of 72% of our consolidated revenues.</div>

                <div><br/>
                </div>

                <div style="font-weight: bold; text-indent: -9pt; margin-left: 9pt;">Competition</div>

                <div> <br/>
                </div>

                <div style="text-indent: 36pt;">The plasma products industry is highly competitive. We face, and will continue to face, intense competition from both U.S.-based and foreign producers of plasma products, some of which have lower cost
                  structures, greater access to capital, greater resources for research and development, and more sophisticated marketing capabilities.</div>

                <div><br/>
                </div>

                <div style="text-indent: 36pt;">&#160;These competitors may include but are not limited to: CSL Behring, Grifols, Takeda, Octapharma and BPL/Kedrion. There are four producers of plasma-derived products in the U.S. consisting of: CSL Behring,
                  Grifols, Takeda and ADMA Biologics. In addition to competition from other large worldwide plasma product providers, we face competition in local areas from smaller entities. In Europe, where the industry is highly regulated and healthcare
                  systems vary from country to country, local companies may have greater knowledge of local healthcare systems, more established infrastructures and existing regulatory approvals or a better understanding of the local regulatory process,
                  allowing them to market their products more quickly. Moreover, plasma therapy generally faces competition from non-plasma products and other courses of treatments. For example, recombinant Factor VIII products compete with plasma-derived
                  products in the treatment of Hemophilia A.</div>

                <div><br/>
                </div>

                <div style="text-indent: 36pt;">New technologies are being developed by biotech and pharmaceutical companies which may impact physician prescription and patient usage of IVIG.&#160; One such therapy approved by the FDA in 2021 is an anti-FcRn
                  inhibitor (neonatal Fc receptor, IgG receptor) which is a protein in humans responsible for maintaining IgG levels.&#160; This FDA approved anti-FcRn is for the treatment of generalized Myasthenia Gravis that may impact a subset of overall
                  general IVIG usage.&#160; Other such FcRn potential targeted indications in development that may disrupt general IVIG usage may include but are not limited to: Chronic Inflammatory Demyelinating Polyradiculoneuropathy (&#8220;CIDP&#8221;), a rare type of
                  autoimmune disorder, Immune Thrombocytopenic Purpura (&#8220;ITP&#8221;), a blood disorder characterized by a decrease in the number of platelets in the blood and Pemphigus Vulgaris (&#8220;PV&#8221;), a rare type of autoimmune disorder.</div>

                <div><br/>
                </div>

                <div style="font-weight: bold; text-indent: -9pt; margin-left: 9pt;">Intellectual Property</div>

                <div> <br/>
                </div>

                <div style="text-indent: 36pt;">We rely on a combination of patents, patent applications, copyrights and trademarks, as well as contracts, such as confidentiality, material data transfer, nondisclosure, non-competition, license and
                  invention assignment agreements, to protect our intellectual property rights. We also rely upon trade secret laws to protect unpatented know-how and advancing technological innovation.</div>

                <div><br/>
                </div>

                <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
                  <div style="text-align: center; text-indent: -9pt; margin-left: 9pt;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">14</span></div>

                  <div style="page-break-after: always;" class="BRPFPageBreak">
                    <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: rgb(0, 0, 0); background-color: rgb(0, 0, 0);"/></div>

                  <div style="width: 100%;" class="BRPFPageHeader">
                    <div>
                      <div style="text-align: left; font-weight: bold; text-indent: -9pt; margin-left: 9pt;"><a href="#ADMABIOLOGICSINC."> <span style="font-style: italic; font-weight: normal; font-size: 8pt;">Table of Contents</span></a><br/>
                      </div>

                    </div>

                  </div>

                </div>

                <div style="text-indent: 36pt;">We have intellectual property (patents, know-how, etc.) related to our immunotherapeutic compositions, manufacturing processes, immunotherapeutic treatment, and related methods and formulations.</div>

                <div><br/>
                </div>

                <div style="text-indent: 36pt;">Patents related to our immune globulin product ASCENIV include U.S. Patent No. 9,107,906, which covers compositions comprising pooled plasma, as well as immunoglobulin prepared therefrom, that contains a
                  standardized, elevated titer of RSV neutralizing antibodies and elevated levels of antibodies specific for one or more other respiratory pathogens, as well as methods of making and using the compositions. U.S. Patent Nos. 9,714,283,
                  9,815,886, 9,969,793, 10,683,343, 11,339,206 and 11,780,906, encompassing immunotherapeutic compositions and immunotherapeutic methods proprietary to us, also relate to ASCENIV.&#160; Additional U.S. and numerous foreign patents and patent
                  applications also pertain to this technology.</div>

                <div><br/>
                </div>

                <div style="text-indent: 36pt;">We also hold intellectual property, including patents and patent applications, related to immunotherapeutic compositions and immunotherapeutic methods for the treatment and prevention of <span style="font-style: italic;">S. pneumonia</span> infection. U.S. Patent Nos. 10,259,865, 11,084,870 and 11,897,943, each with a term through 2037, pertain to various aspects of this technology. Additional U.S. and numerous foreign patent
                  applications also relate to this technology.</div>

                <div><br/>
                </div>

                <div style="text-indent: 36pt;">We continue to prepare, file, and prosecute patent applications to provide broad and strong protection of our proprietary rights, including applications focused on existing and future products.</div>

                <div><br/>
                </div>

                <div style="text-indent: 36pt;">We seek to enhance and ensure our competitive position through a variety of means, including our unique and proprietary plasma donor selection criteria, our proprietary formulation methodologies and
                  proprietary reagents, controls, testing standards, standard operating procedures and methods used in our anti-RSV microneutralization assay. While we intend to defend against threats to our intellectual property, litigation can be costly
                  and there can be no assurance that our patents will be enforced or that our trade secret policies and practices or other agreements will adequately protect our intellectual property. We seek to preserve the integrity and confidentiality
                  of our data and trade secrets by maintaining physical security of our premises and physical and electronic security of our information technology systems. These processes, systems, and/or security measures may be breached, and we may not
                  have adequate remedies as a result of any such breaches. Third parties may also own or could obtain patents that may require us to negotiate licenses to conduct our business, and there can be no assurance that the required licenses would
                  be available on reasonable terms or at all.</div>

                <div> <br/>
                </div>

                <div style="text-indent: 36pt;">In addition, our trade secrets may otherwise become known or be independently discovered by competitors. We also seek to protect our proprietary technology and processes, in part, by confidentiality
                  agreements with our employees, consultants, scientific advisors and contractors. Although we rely, in part, on confidentiality, nondisclosure, non-competition and invention assignment agreements with employees, consultants and other
                  parties with access to our proprietary information to protect our trade secrets, proprietary technology, processes and other proprietary rights, there can be no assurance that these agreements or any other security measures related to
                  such trade secrets, proprietary technology, processes and proprietary rights will be adequate, will not be breached, that we will have adequate remedies for any breach, that others will not independently develop substantially equivalent
                  proprietary information or that third parties will not otherwise gain access to our trade secrets or proprietary knowledge. To the extent that our consultants, contractors or collaborators use intellectual property owned by others in
                  their work for us, disputes may arise as to the rights in related or resulting know-how and inventions.</div>

                <div><br/>
                </div>

                <div style="text-indent: 36pt;">We continue to invest in growing brand awareness globally. Our brand marketing is designed to increase awareness of the ADMA Biologics trade name and our product offerings by building on our industry
                  reputation and strength of relationships. We hold multiple trademarks, including but not limited to ADMA, ADMA Biologics (including logo), ASCENIV, BIVIGAM, CIVACIR, Nabi-HB, Designed to Deliver, Partner in Protection and Advantage Ig. We
                  will continue to allocate and expend resources to maintain and build market and consumer awareness and will defend our brand to the fullest extent possible.</div>

                <div> <br/>
                </div>

                <div style="font-weight: bold; text-indent: -9pt; margin-left: 9pt;">Government Regulation and Product Approval</div>

                <div> <br/>
                </div>

                <div style="text-indent: 36pt;">The FDA and comparable regulatory agencies in state and local jurisdictions and in foreign countries impose substantial requirements upon, among other things, the testing (preclinical and clinical), quality
                  control, research and development, approval and post-approval monitoring and reporting, manufacturing, labeling, storage, recordkeeping, advertising, promotion, import, export, marketing, sales and distribution of our products and product
                  candidates. If we do not comply with applicable requirements, we may be subject to civil penalties, suspension or withdrawal of regulatory approvals, product recalls, seizure of products, fines, refusal by the government to approve our
                  marketing applications and supplemental applications or to allow us to manufacture or market our products, and criminal prosecution, and we may be debarred or excluded from participation in government healthcare programs. These
                  requirements are continually evolving.&#160; We and our manufacturers may also be subject to regulations under other federal, state and local laws.</div>

                <div> <br/>
                </div>

                <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
                  <div style="text-align: center; text-indent: -9pt; margin-left: 9pt;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">15</span></div>

                  <div style="page-break-after: always;" class="BRPFPageBreak">
                    <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: rgb(0, 0, 0); background-color: rgb(0, 0, 0);"/></div>

                  <div style="width: 100%;" class="BRPFPageHeader">
                    <div>
                      <div style="text-align: left; font-weight: bold; text-indent: -9pt; margin-left: 9pt;"><a href="#ADMABIOLOGICSINC."> <span style="font-style: italic; font-weight: normal; font-size: 8pt;">Table of Contents</span></a><br/>
                      </div>

                    </div>

                  </div>

                </div>

                <div style="font-style: italic; font-weight: bold; text-indent: -9pt; margin-left: 9pt;">U.S. Government Regulation</div>

                <div style="text-indent: 36pt;">Our current and anticipated future product candidates are considered &#8220;biologics&#8221; under the FDA regulatory framework. Most pharmaceuticals or &#8220;conventional drugs&#8221; consist of pure chemical substances and their
                  structures are known. Most biologics, however, are complex mixtures that are not easily identified or characterized. Biological products differ from conventional drugs in that they tend to be heat-sensitive and susceptible to microbial
                  contamination. This requires sterile processes to be applied from initial manufacturing steps. In the U.S., the FDA regulates biologic products under the Federal Food, Drug and Cosmetic Act (the &#8220;FDCA&#8221;), the Public Health Service (&#8220;PHS&#8221;)
                  Act and related federal regulations under Title 21 of the Code of Federal Regulations (&#8220;CFR&#8221;). The FDA also issues nonbinding guidance documents on a continuous basis, which provide the agency&#8217;s interpretation of its laws and regulations,
                  as well as the FDA&#8217;s approach to scientific issues and questions. Biologics are also regulated under other federal, state, and local statutes and regulations by other regulatory authorities. The process required by the FDA before our
                  product candidates may be marketed in the U.S. generally involves the following (although the FDA is given wide discretion to impose different or more stringent requirements on a case-by-case basis):</div>

                <div> <br/>
                </div>

                <div>
                  <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0); border-spacing: 0;">


  <tr>

    <td style="width: 18pt;">&#160;</td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
                          <div>completion of extensive preclinical laboratory tests, preclinical, nonclinical and formulation studies performed in accordance with the FDA&#8217;s Good Laboratory Practice (&#8220;GLP&#8221;) regulations and other applicable laws and
                            regulations;</div>
                        </td>

  </tr>


</table>
                  <div style="text-indent: -36pt; margin-left: 36pt;">&#160;</div>

                  <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0); border-spacing: 0;">


  <tr>

    <td style="width: 18pt;"><br/>
                        </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
                          <div>submission to the FDA of an IND application which must become effective before clinical trials may begin;</div>
                        </td>

  </tr>


</table>
                  <div><br/>
                  </div>

                  <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0); border-spacing: 0;">


  <tr>

    <td style="width: 18pt;"><br/>
                        </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
                          <div>obtaining approval by an Institutional Review Board (&#8220;IRB&#8221;) at each clinical site before a clinical trial may be initiated at that site;</div>
                        </td>

  </tr>


</table>
                  <div style="text-indent: -36pt; margin-left: 36pt;">&#160;</div>

                  <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0); border-spacing: 0;">


  <tr>

    <td style="width: 18pt;"><br/>
                        </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
                          <div>performance of adequate and well-controlled clinical trials meeting FDA requirements, commonly referred to as Good Clinical Practices (&#8220;GCP&#8221;), and other additional requirements for the protection of human research subjects
                            and to establish the safety and efficacy of the product candidate for each proposed indication;</div>
                        </td>

  </tr>


</table>
                  <div style="text-indent: -36pt; margin-left: 36pt;">&#160;</div>

                  <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0); border-spacing: 0;">


  <tr>

    <td style="width: 18pt;"><br/>
                        </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
                          <div>manufacturing (through an FDA-approved facility) of product in accordance with the FDA&#8217;s current Good Manufacturing Practices (&#8220;cGMP&#8221;) to be used in the clinical trials and providing manufacturing information needed in
                            regulatory filings;</div>
                        </td>

  </tr>


</table>
                  <div style="text-indent: -36pt; margin-left: 36pt;">&#160;</div>

                  <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0); border-spacing: 0;">


  <tr>

    <td style="width: 18pt;"><br/>
                        </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
                          <div>submission of a BLA to the FDA for marketing approval that includes substantial evidence of safety, purity and potency from results of clinical trials; the results of preclinical testing; detailed information about the
                            Chemistry, Manufacturing, and Controls (&#8220;CMC&#8221;) and proposed labeling and packaging for the product candidate;</div>
                        </td>

  </tr>


</table>
                  <div style="text-indent: -36pt; margin-left: 36pt;">&#160;</div>

                  <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0); border-spacing: 0;">


  <tr>

    <td style="width: 18pt;"><br/>
                        </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
                          <div>satisfactory completion of an FDA pre-approval inspection of the manufacturing facilities at which the product candidate is produced, and potentially other involved facilities as well, to assess compliance with cGMP
                            regulations and other applicable regulations;</div>
                        </td>

  </tr>


</table>
                  <div><br/>
                  </div>

                  <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0); border-spacing: 0;">


  <tr>

    <td style="width: 18pt;"><br/>
                        </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
                          <div>satisfactory completion of potential FDA inspections of the preclinical study and clinical trial sites that generate the data in support of the BLA; and</div>
                        </td>

  </tr>


</table>
                  <div style="text-indent: -36pt; margin-left: 36pt;">&#160;</div>

                  <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0); border-spacing: 0;">


  <tr>

    <td style="width: 18pt;"><br/>
                        </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
                          <div>FDA review and approval of a BLA prior to any commercial marketing, sale or shipment of the product, including agreement on post-marketing commitments, and compliance with any post approval commitments, such as Risk
                            Evaluation and Mitigation Strategies (&#8220;REMS&#8221;) and post approval studies required by the FDA.</div>
                        </td>

  </tr>


</table>
                  <div><br/>
                  </div>

                  <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
                    <div style="text-align: center; text-indent: -9pt; margin-left: 9pt;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">16</span></div>

                    <div style="page-break-after: always;" class="BRPFPageBreak">
                      <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: rgb(0, 0, 0); background-color: rgb(0, 0, 0);"/></div>

                    <div style="width: 100%;" class="BRPFPageHeader">
                      <div>
                        <div style="text-align: left; font-weight: bold; text-indent: -9pt; margin-left: 9pt;"><a href="#ADMABIOLOGICSINC."> <span style="font-style: italic; font-weight: normal; font-size: 8pt;">Table of Contents</span></a><br/>
                        </div>

                      </div>

                    </div>

                  </div>

                </div>

                <div style="text-indent: 36pt;">The testing, review and approval process requires substantial time, effort and financial resources, and we cannot be certain that any approvals for our product candidates will be granted on a timely basis, if
                  at all. We may encounter difficulties or unanticipated costs in our efforts to secure necessary governmental approvals, which could delay or preclude us from marketing our product candidates. In addition, the FDA may limit the indications
                  for use or place other conditions on any approvals that could restrict the commercial application of our products. FDA may also conduct inspections, including remote regulatory assessments, of our facilities or the facilities of our
                  contractors, both during product development and following approval.&#160; Any findings from those inspections could materially impact our business.</div>

                <div> <br/>
                </div>

                <div style="font-style: italic; font-weight: bold; text-indent: -9pt; margin-left: 9pt;">Pre-Clinical Studies</div>

                <div style="text-indent: 36pt;">Prior to commencing the first clinical trial at a United States investigational site, we must submit manufacturing and analytical data, pre-clinical or nonclinical data from studies conducted in accordance
                  with GLP and clinical trial plans, among other information, to the FDA as part of an IND application. Subject to certain exceptions, an IND becomes effective 30 days after receipt by the FDA, unless the FDA, within the 30-day time period,
                  issues a clinical hold to delay a proposed clinical investigation due to concerns or questions about the product or the conduct of the clinical trial, including concerns that human research subjects will be exposed to unreasonable health
                  risks. In such a case, the IND sponsor and the FDA must resolve any outstanding concerns before the clinical trial can begin. Clinical holds also may be imposed by the FDA at any time before or during trials due to safety concerns or
                  non-compliance.</div>

                <div><br/>
                </div>

                <div style="text-indent: 36pt;">Our submission of an IND, or those of our collaboration partners, may not result in the FDA allowing us to commence a clinical trial. A separate submission to an existing IND must also be made for each
                  successive clinical trial conducted during product development. The FDA must also approve certain changes to an existing IND, such as certain manufacturing changes. Further, an independent IRB duly constituted to meet FDA requirements for
                  each medical center proposing to conduct the clinical trial must review and approve the plan for any clinical trial before it commences at that center and it must monitor the safety of the study and study subjects until completed. Special
                  clinical trial ethical considerations also must be taken into account if a study involves children. The FDA, the IRB or the sponsor may suspend a clinical trial at any time on various grounds, including a finding that the subjects or
                  patients are being exposed to an unacceptable health risk. Clinical testing also must satisfy extensive GCP requirements and regulations for informed consent and must be conducted with product meeting cGMPs. Additionally, some clinical
                  trials are overseen by an independent group of qualified experts organized by the clinical trial sponsor, known as a data safety monitoring board or committee, which reviews data and makes recommendations to the sponsor regarding the
                  trial.</div>

                <div> <br/>
                </div>

                <div style="font-style: italic; font-weight: bold; text-indent: -9pt; margin-left: 9pt;">Clinical Trials</div>

                <div style="text-indent: 36pt;">For purposes of BLA submission and approval, clinical trials are typically conducted in the following three sequential phases, which may overlap (although additional or different trials may be required by the
                  FDA as well):</div>

                <div> <br/>
                </div>

                <div>
                  <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0); border-spacing: 0;">


  <tr>

    <td style="width: 18pt;">&#160;</td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
                          <div>Phase I clinical trials are initially conducted in a limited population to test the product candidate for safety, dose tolerance, absorption, metabolism, distribution and excretion in healthy humans or, on occasion, in
                            patients, such as cancer patients.</div>
                        </td>

  </tr>


</table>
                  <div style="text-indent: -36pt; margin-left: 36pt;">&#160;</div>

                  <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0); border-spacing: 0;">


  <tr>

    <td style="width: 18pt;"><br/>
                        </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
                          <div>Phase II clinical trials are generally conducted in a larger but limited patient population to identify possible adverse effects and safety risks, to determine the efficacy of the product candidate for specific targeted
                            indications and to determine tolerance and optimal dosage. Multiple Phase II clinical trials may be conducted by the sponsor to obtain information prior to beginning larger and more expensive Phase III clinical trials.</div>
                        </td>

  </tr>


</table>
                  <div style="text-indent: -36pt; margin-left: 36pt;">&#160;</div>

                  <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0); border-spacing: 0;">


  <tr>

    <td style="width: 18pt;"><br/>
                        </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
                          <div>Phase III trials are conducted to establish the overall risk/benefit profile of the product. Certain Phase III clinical trials are referred to as pivotal trials. Phase III clinical trials aim to provide substantial evidence
                            of reproducibility of clinical efficacy and safety results for approval and to further test for safety in an expanded and diverse patient population at multiple, geographically dispersed clinical trial sites.</div>
                        </td>

  </tr>


</table>
                </div>

                <div> <br/>
                </div>

                <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
                  <div style="text-align: center; text-indent: -9pt; margin-left: 9pt;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">17</span></div>

                  <div style="page-break-after: always;" class="BRPFPageBreak">
                    <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: rgb(0, 0, 0); background-color: rgb(0, 0, 0);"/></div>

                  <div style="width: 100%;" class="BRPFPageHeader">
                    <div>
                      <div style="text-align: left; font-weight: bold; text-indent: -9pt; margin-left: 9pt;"><a href="#ADMABIOLOGICSINC."> <span style="font-style: italic; font-weight: normal; font-size: 8pt;">Table of Contents</span></a><br/>
                      </div>

                    </div>

                  </div>

                </div>

                <div style="text-indent: 36pt;">In addition, under the Pediatric Research Equity Act of 2003, a BLA or supplement for a new active ingredient, new indication, new dosage form, new dosing regimen, or new route of administration must contain
                  data that is adequate to assess the safety and effectiveness of the drug for the claimed indications in all relevant pediatric subpopulations, and to support dosing and administration for each pediatric subpopulation for which the product
                  is safe and effective, unless the applicant has obtained a waiver or deferral. In 2012, the Food and Drug Administration Safety and Innovation Act amended the FDCA to require that a sponsor who is planning to submit such an application
                  submit an initial Pediatric Study Plan (&#8220;iPSP&#8221;) within 60 days of an end-of-Phase II meeting or as may be agreed between the sponsor and the FDA. The FDA may, on its own initiative or at the request of the applicant, grant deferrals for
                  submission of data or full or partial waivers. The FDA and the sponsor must reach agreement on the iPSP. Congress also passed legislation that will require that sponsors submit to the FDA a diversity action plan for Phase III or other
                  pivotal studies, unless such requirement is waived by the FDA.</div>

                <div> <br/>
                </div>

                <div style="text-indent: 36pt;">In some cases, the FDA may condition continued approval of a BLA on the sponsor&#8217;s agreement to conduct additional clinical trials, or other commitments. Such post-approval studies are typically referred to as
                  Phase IV studies, which are used to gain additional experience from the treatment of patients in the intended therapeutic indication, particularly for long-term safety follow-up.</div>

                <div><br/>
                </div>

                <div style="text-indent: 36pt;">During all phases of clinical development, regulatory agencies require extensive monitoring and auditing of all clinical activities, clinical data and clinical trial investigators. Annual progress reports
                  detailing the results of the clinical trials must be submitted to the FDA. Written IND safety reports must be promptly submitted to the FDA and the investigators for: serious and unexpected adverse events; any findings from other studies,
                  tests in laboratory animals or in vitro testing and other sources that suggest a significant risk for human subjects; or any clinically important increase in the rate of a serious suspected adverse reaction over that listed in the
                  protocol or investigator brochure. The sponsor must submit an IND safety report within 15 calendar days after the sponsor determines that the information qualifies for reporting. The sponsor also must notify the FDA of any unexpected
                  fatal or life-threatening suspected adverse reaction within seven calendar days after the sponsor&#8217;s initial receipt of the information. Phase I, Phase II and Phase III clinical trials might not be completed successfully within any
                  specified period, if at all. The FDA or the sponsor may suspend a clinical trial at any time on various grounds, including a finding that the research subjects or patients are being exposed to an unacceptable health risk. Similarly, an
                  IRB can suspend or terminate approval of a clinical trial at its institution if the clinical trial is not being conducted in accordance with the IRB&#8217;s requirements or if the biological product has been associated with unexpected serious
                  harm to patients.&#160;&#160; Information about clinical trials, including results, must be submitted within specific timeframes for listing on the ClinicalTrials.gov website.</div>

                <div><br/>
                </div>

                <div style="text-indent: 36pt;">In limited circumstances, the FDA also permits the administration of investigational biological products to patients under its expanded access program. Under this program, provided certain qualifying criteria
                  are met, patients who are not able to participate in a clinical trial may be eligible for accessing investigational products, including through individual compassionate or emergency use in concert with their requesting physician. Sponsors
                  or distributors of investigational products for the diagnosis, monitoring, or treatment of one or more serious diseases or conditions must also have a publicly available policy on evaluating and responding to requests for expanded access.</div>

                <div><br/>
                </div>

                <div style="text-indent: 36pt;">Concurrent with clinical trials, companies usually complete additional preclinical studies, animal studies, develop additional information about the physical characteristics of the biological product
                  candidate and finalize a process for manufacturing the product in commercial quantities in accordance with cGMP requirements. To help reduce the risk of the introduction of adventitious agents with use of biological products, the PHS Act
                  emphasizes the importance of manufacturing controls for products whose attributes cannot be precisely defined. The manufacturing process must be capable of consistently producing quality batches of the product candidate and, among other
                  things, the sponsor must develop methods for testing the identity, strength, quality, potency and purity of the final biological product. Additionally, appropriate packaging must be selected and tested, and stability studies must be
                  conducted to demonstrate that the biological product candidate does not undergo unacceptable deterioration over its shelf life.</div>

                <div><br/>
                </div>

                <div style="text-indent: 36pt;">The manufacture of Investigational biologics for the conduct of human clinical trials is subject to cGMP requirements. Investigational biologics and active ingredients and therapeutic substances imported into
                  the United States are also subject to regulation by the FDA. Further, the export of investigational products outside the United States is subject to regulatory requirements of the receiving country as well as U.S. export requirements
                  under the FDCA.</div>

                <div><br/>
                </div>

                <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
                  <div style="text-align: center; text-indent: -18pt; margin-left: 18pt;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">18</span></div>

                  <div style="page-break-after: always;" class="BRPFPageBreak">
                    <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: rgb(0, 0, 0); background-color: rgb(0, 0, 0);"/></div>

                  <div style="width: 100%;" class="BRPFPageHeader">
                    <div>
                      <div style="text-align: left; font-weight: bold; text-indent: -9pt; margin-left: 9pt;"><a href="#ADMABIOLOGICSINC."> <span style="font-style: italic; font-weight: normal; font-size: 8pt;">Table of Contents</span></a><br/>
                      </div>

                    </div>

                  </div>

                </div>

                <div style="font-style: italic; font-weight: bold; text-indent: -9pt; margin-left: 9pt;">Biologics License Applications</div>

                <div style="text-indent: 36pt;">The results of product candidate development, preclinical and nonclinical testing and clinical trials, together with, among other things, detailed information on the manufacture and composition of the product
                  and proposed labeling, and the payment of a user fee, are submitted to the FDA as part of a BLA. Under the Prescription Drug User Fee Act (&#8220;PDUFA&#8221;), the fees payable to the FDA for reviewing an original BLA, as well as annual program fees
                  for approved products can be substantial, subject to certain limited deferrals, waivers and reductions that may be available. The FDA has agreed to specified performance goals in the review of BLAs under the PDUFA.</div>

                <div><br/>
                </div>

                <div style="text-indent: 36pt;">Following submission, the FDA has 60 days to review all BLAs to determine if they are substantially complete before it accepts them for filing. The FDA may refuse to file a BLA that it deems incomplete or not
                  reviewable at the time of submission, in which case the BLA will have to be updated and resubmitted. The FDA may also request additional information to be submitted in a very short time frame before accepting a BLA for filing.</div>

                <div><br/>
                </div>

                <div style="text-indent: 36pt;">If the FDA accepts the application for filing, the FDA reviews the BLA to determine, among other things, whether the proposed product is safe, pure, and potent for its intended use, and whether the product is
                  being manufactured in compliance with cGMP. During its review of a BLA, the FDA may refer the application for novel product candidates or products that present difficult questions to an advisory committee of experts for their review,
                  evaluation and recommendation as to whether the application should be approved, which information is taken into consideration along with the FDA&#8217;s own review findings. The FDA&#8217;s PDUFA review goal is to review 90% of priority BLAs within
                  six months of filing and 90% of standard applications within ten months of filing, but the FDA can and frequently does extend this review timeline to consider certain later-submitted information or information intended to clarify or
                  supplement an initial submission. The FDA may not complete its review or approve a BLA within these established goal review times.</div>

                <div><br/>
                </div>

                <div style="text-indent: 36pt;">Before approving a marketing application, the FDA typically will inspect the facility or facilities where the product is manufactured, referred to as a Pre-Approval Inspection, as well as one or more clinical
                  trial sites. The FDA will not approve a product candidate unless cGMP compliance is satisfactory.</div>

                <div><br/>
                </div>

                <div style="text-indent: 36pt;">After the FDA conducts its in-depth review of the application and after the inspection of the manufacturing facilities and clinical trial sites, the FDA issues either an approval letter or a Complete Response
                  Letter (&#8220;CRL&#8221;). A CRL generally outlines the deficiencies in the submission and may also require additional clinical or other data, including one or more additional pivotal Phase III clinical trials. Even if such requested data are
                  submitted, the FDA may ultimately decide that the BLA does not satisfy the criteria for approval and issue a denial of the BLA. Data from clinical trials are not always conclusive and the FDA may interpret data differently than we do. If
                  the FDA&#8217;s evaluations of the BLA, the clinical and manufacturing procedures and facilities are favorable, the FDA may issue an approval letter. If the evaluations are not favorable the FDA will issue a CRL, which may contain the
                  conditions that must be met in order to secure final approval of the BLA. If a CRL is issued, a company has up to 12 months to resubmit or withdraw the BLA, unless the FDA allows for an extension as requested by a sponsor. If a CRL is
                  issued, resubmissions for original applications and supplements of different types are subject to varying agency review procedures and review timing goals. For example, upon the resubmission of an original BLA application or efficacy
                  supplement, CBER will classify the resubmission as either Class 1 (triggering a two-month review goal for the FDA) or Class 2 (triggering a six-month review goal for the FDA) depending on the circumstances. CBER also includes specific
                  goals for review of manufacturing and labeling supplements, though in practice, FDA reviews may take longer than the stated goals.</div>

                <div><br/>
                </div>

                <div style="text-indent: 36pt;">If and when the items identified in a CRL have been resolved to the FDA&#8217;s satisfaction, the FDA will issue an approval letter, authorizing commercial marketing of the product for certain indications. The FDA
                  may withdraw product approval if ongoing regulatory requirements are not met or if safety problems occur after the product reaches the market. In addition, the FDA may require testing, including Phase IV post-approval clinical trials, and
                  surveillance programs to monitor the effect of approved products that have been commercialized, and the FDA has the power to prevent or limit further marketing of a product based on the results of these post-marketing programs.</div>

                <div><br/>
                </div>

                <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
                  <div style="text-align: center; text-indent: -9pt; margin-left: 9pt;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">19</span></div>

                  <div style="page-break-after: always;" class="BRPFPageBreak">
                    <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: rgb(0, 0, 0); background-color: rgb(0, 0, 0);"/></div>

                  <div style="width: 100%;" class="BRPFPageHeader">
                    <div>
                      <div style="text-align: left; font-weight: bold; text-indent: -9pt; margin-left: 9pt;"><a href="#ADMABIOLOGICSINC."> <span style="font-style: italic; font-weight: normal; font-size: 8pt;">Table of Contents</span></a><br/>
                      </div>

                    </div>

                  </div>

                </div>

                <div style="text-indent: 36pt;">&#160;Even if the FDA approves a product, it may limit the approved indications or populations for use of the product, require that contraindications, warnings, or precautions be included in the product labeling,
                  including a boxed warning, require testing and surveillance programs to monitor the product after commercialization, or impose other conditions, including distribution restrictions or other risk management mechanisms under a REMS.<span style="font-size: 12pt;">&#160;</span>If the FDA concludes a REMS is needed, the sponsor of the BLA must submit a proposed REMS; the FDA will not approve the BLA without a REMS, if required. A REMS could include medication guides, physician
                  communication plans or elements to assure safe use, such as restricted distribution methods, patient registries and other risk minimization tools. Any of these limitations on approval or marketing can materially affect the potential
                  market and profitability of the product.<span style="font-size: 12pt;">&#160;</span>The FDA may also not approve label statements that are necessary for successful commercialization and marketing. Products may be marketed only for the
                  FDA-approved indications and in accordance with the FDA-approved label. The FDA does not allow drugs to be promoted for &#8220;off-label&#8221; uses &#8211; that is, uses that are not described in the product&#8217;s approved labeling and that differ from those
                  that were approved by the FDA. Furthermore, the FDA generally limits approved uses to those studied in clinical trials. If there are any modifications to the product, including changes in indications, other labeling changes, or
                  manufacturing processes or facilities, we may be required to submit for and obtain FDA approval of a new BLA or BLA supplement, which may require us to develop additional data or conduct additional preclinical studies and clinical trials,
                  and/or require additional manufacturing data.</div>

                <div> <br/>
                </div>

                <div style="text-indent: 36pt;">Satisfaction of the FDA regulations and approval requirements or similar requirements of foreign regulatory agencies typically takes many years, and the actual time required may vary substantially based upon
                  the type, complexity and novelty of the product or disease. Typically, if a product candidate is intended to treat a chronic disease, as was the case with ASCENIV, safety and efficacy data must be gathered over an extended period of time.
                  Government regulation may delay or prevent marketing of product candidates for a considerable period of time and impose costly procedures upon our activities. The FDA or any other regulatory agency may not grant approvals for any changes
                  on a timely basis, or at all. Even if a product candidate receives regulatory approval, the approval may be significantly limited to specific disease states, patient populations and dosages. Further, even after regulatory approval is
                  obtained, later discovery of previously unknown problems with a product may result in restrictions on the product or even complete withdrawal of the product from the market. Delays in obtaining, or failures to obtain, regulatory approvals
                  for any of our product candidates would harm our business. In addition, we cannot predict what adverse governmental regulations may arise from future U.S. or foreign governmental action.</div>

                <div><br/>
                </div>

                <div style="font-style: italic; font-weight: bold; text-indent: -9pt; margin-left: 9pt;">Post-Approval Regulatory Requirements</div>

                <div style="text-indent: 36pt;">After regulatory approval is obtained, biological drug products are subject to extensive and continuing regulation by the FDA, which may impose a number of post-approval requirements as a condition of
                  approval of an application. For example, as a condition of approval of a BLA, the FDA may require post-marketing testing and surveillance to monitor the product&#8217;s safety or efficacy. In addition, holders of an approved BLA are required to
                  keep extensive records (including certain electronic records and signature requirements), submit annual reports, report certain adverse reactions and production problems to the FDA, provide updated safety and efficacy information and
                  comply with requirements concerning advertising and promotional labeling for their products. After approval, most changes to the approved product, such as adding new indications or other labeling claims, are subject to prior FDA review
                  and approval. There also are annual user fee requirements for any marketed products, as well as new application fees for supplemental applications with clinical data. The FDA may withdraw a product approval if compliance with regulatory
                  requirements is not maintained or if problems occur after the product reaches the market. Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, problems with
                  manufacturing processes or failure to comply with regulatory requirements, may result in restrictions on the product or even complete withdrawal of the product from the market. Failure to comply with the statutory and regulatory
                  requirements can subject a manufacturer to possible legal or regulatory action, such as refusal to approve pending applications, license suspension or revocation, withdrawal of approval of a BLA, imposition of a clinical hold or
                  termination of clinical trials, warning letters, untitled letters, suspension of manufacturing, sales or use, product seizures or recalls, import restrictions, injunctive action or possible fines and other penalties. We cannot be certain
                  that we or our present or future third-party manufacturers or suppliers will be able to comply with the cGMP regulations and other ongoing FDA regulatory requirements.</div>

                <div style="text-indent: 36pt;"> <br/>
                </div>

                <div style="text-indent: 36pt;">Manufacturers must continue to comply with cGMP requirements, which are extensive and require considerable time, resources and ongoing investment to ensure compliance. In addition, changes to the
                  manufacturing process generally require prior FDA approval before being implemented. Other types of changes to the approved product, such as adding new indications and additional labeling claims, are also subject to further FDA review and
                  approval. Certain manufacturing deviations and unexpected manufacturing events must be investigated, corrected, and reported to the FDA.</div>

                <div> <br/>
                </div>

                <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
                  <div style="text-align: center; text-indent: -9pt; margin-left: 9pt;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">20</span></div>

                  <div style="page-break-after: always;" class="BRPFPageBreak">
                    <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: rgb(0, 0, 0); background-color: rgb(0, 0, 0);"/></div>

                  <div style="width: 100%;" class="BRPFPageHeader">
                    <div>
                      <div style="text-align: left; font-weight: bold; text-indent: -9pt; margin-left: 9pt;"><a href="#ADMABIOLOGICSINC."> <span style="font-style: italic; font-weight: normal; font-size: 8pt;">Table of Contents</span></a><br/>
                      </div>

                    </div>

                  </div>

                </div>

                <div style="text-indent: 36pt;">Manufacturers and certain other entities involved in the manufacturing and distribution of approved products are required to register their establishments with the FDA and certain state agencies, list the
                  manufactured products to the FDA, and are subject to periodic unannounced inspections or remote regulatory assessments by the FDA and certain state agencies for compliance with cGMP and other laws. The cGMP requirements apply to all
                  stages of the manufacturing process, including the production, processing, sterilization, packaging, labeling, storage and shipment of the product. Manufacturers must establish validated systems to ensure that products meet specifications
                  and regulatory standards and test each product batch or lot prior to its release. The information that must be submitted to FDA regarding manufactured products was expanded through the Coronavirus Aid, Relief, and Economic Security
                  (&#8220;CARES&#8221;) Act to include the volume of drugs produced during the prior year. For biologics products subject to lot release, for each product lot the applicant must submit materials related to that lot to the FDA prior to that lot being
                  released for distribution.</div>

                <div style="text-indent: 36pt;"> <br/>
                </div>

                <div style="text-indent: 36pt;">Changes to the manufacturing process are strictly regulated and often require prior FDA approval before implementation. FDA regulations also require investigation and correction of any deviations from cGMP
                  and impose reporting and documentation requirements upon the sponsor and any third-party manufacturers that the sponsor may decide to use. Accordingly, manufacturers must continue to expend time, money, and effort towards production and
                  quality control to maintain cGMP compliance.</div>

                <div> <br/>
                </div>

                <div style="text-indent: 36pt;">The commercial distribution of prescription drugs (including biological drug products) is subject to the DSCSA, which regulates the distribution of the products at the federal level and sets certain standards
                  for federal or state registration and compliance of entities in the supply chain (manufacturers and repackagers, wholesale distributors, third-party logistics providers, and dispensers). The DSCSA preempts previously enacted state
                  pedigree laws and the pedigree requirements of the Prescription Drug Marketing Act &#8220;PDMA&#8221;). Trading partners within the drug supply chain must now ensure certain product tracing requirements are met and are required to exchange certain
                  transaction-related information in an electronic, and, as of November 2023, an interoperable form. Further, the DSCSA limits the distribution of prescription pharmaceutical products and imposes requirements to ensure overall
                  accountability and security in the drug supply chain, including requirements related to the detection and investigation of suspect and illegitimate products. The distribution of product samples continues to be regulated under the PDMA. </div>

                <div><br/>
                </div>

                <div style="text-indent: 36pt;">FDA post-approval requirements are continually evolving. For example, in March 2020, the U.S. Congress passed the CARES Act, which includes various provisions regarding FDA drug shortage and manufacturing
                  volume reporting requirements, as well as provisions regarding supply chain security, such as risk management plan requirements, and the promotion of supply chain redundancy and domestic manufacturing. As part of the CARES Act
                  implementation, the FDA issued a guidance on the reporting of the volume of drugs produced, which reporting will require additional administrative efforts by drug manufacturers. Executive orders have also been issued to encourage domestic
                  manufacturing.</div>

                <div><br/>
                </div>

                <div style="font-style: italic; font-weight: bold; text-indent: -9pt; margin-left: 9pt;">Advertising and Promotion</div>

                <div style="text-indent: 36pt;">The FDA closely regulates the post-approval marketing and promotion of products, including standards and regulations for direct-to-consumer advertising, off-label promotion, industry-sponsored scientific and
                  educational activities and promotional activities involving the Internet. A product cannot be promoted before it is approved. After approval, product promotion can include only those claims related to safety and effectiveness that are
                  consistent with the labeling approved by the FDA. Healthcare providers are permitted to prescribe drugs for &#8220;off-label&#8221; uses&#8211;- that is, uses not approved by the FDA and not described in the product&#8217;s labeling because the FDA does not
                  regulate the practice of medicine. However, FDA regulations impose restrictions on manufacturers&#8217; communications regarding off-label uses. Broadly speaking, a manufacturer may not promote a drug for off-label use, but under certain
                  conditions may engage in non-promotional, balanced, scientific communication regarding off-label use. Failure to comply with applicable FDA requirements and restrictions in this area may subject a company to adverse publicity and
                  enforcement action by the FDA, the Department of Justice, or the Office of Inspector General of the Department of Health and Human Services, as well as state authorities. This could subject a company to a range of penalties that could
                  have a significant commercial impact, including civil penalties, criminal fines and agreements that materially restrict the manner in which a company promotes or distributes a drug.</div>

                <div><br/>
                </div>

                <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
                  <div style="text-align: center; text-indent: -9pt; margin-left: 9pt;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">21</span></div>

                  <div style="page-break-after: always;" class="BRPFPageBreak">
                    <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: rgb(0, 0, 0); background-color: rgb(0, 0, 0);"/></div>

                  <div style="width: 100%;" class="BRPFPageHeader">
                    <div>
                      <div style="text-align: left; font-weight: bold; text-indent: -9pt; margin-left: 9pt;"><a href="#ADMABIOLOGICSINC."> <span style="font-style: italic; font-weight: normal; font-size: 8pt;">Table of Contents</span></a><br/>
                      </div>

                    </div>

                  </div>

                </div>

                <div style="text-indent: 36pt;">Companies are required to supply sufficient information that balances the risks of a product in its marketing and promotional materials. In 2023, the FDA implemented several measures in the advertising and
                  promotional areas. These included the issuance of a final rule and a guidance on the disclosure of risks and effectiveness in direct-to-consumer advertising, as well as a guidance on the dissemination of off-label scientific data about
                  approved products. From time to time, legislation is drafted, introduced and passed in Congress that could significantly change the statutory provisions governing the approval, manufacturing and marketing of products regulated by the FDA.
                  In addition to new legislation, FDA and other agency regulations, guidance, and policies are often revised or reinterpreted in ways that may significantly affect our business. It is impossible to predict whether further legislative or FDA
                  regulation or other regulatory policy changes will be enacted or implemented and what the impact of such changes, if any, may be. It is possible that certain prior regulatory requirements may be postponed or frozen.</div>

                <div><br/>
                </div>

                <div style="font-style: italic; font-weight: bold; text-indent: -9pt; margin-left: 9pt;">Regulation of ADMA BioCenters</div>

                <div style="text-indent: 36pt;">With some limited exceptions, all blood and blood product collection and manufacturing centers which engage in interstate commerce must be licensed by and registered with the FDA. In order to achieve
                  licensure, the organization must submit a BLA and obtain BLA approval prior to distribution of any product. The approval of the BLA requires passage of an FDA inspection. ADMA BioCenters has completed these requirements and holds an FDA
                  license for all ten of its plasma collection facilities for source plasma. In order to maintain an FDA license, under FDA guidance each such facility operated by ADMA BioCenters will be inspected within the first year of operations and
                  then at least every two years and must meet certain regulatory requirements. ADMA BioCenters is also required to submit annual reports to the FDA, as well as reports of fatalities related to blood and blood component collection or
                  transfusion.&#160; Establishments must also comply with the FDA&#8217;s regulatory standards which include a variety of requirements related to, among other areas, cGMPs, deviation investigation and reporting, donor screening and product testing, as
                  well as product labeling.&#160; Facilities must further ensure that all tests and equipment that are used are appropriate for their intended use, which may include FDA clearance and/or approval of the applicable test or equipment.</div>

                <div> <br/>
                </div>

                <div style="text-indent: 36pt;">Blood plasma collection and manufacturing centers are also subject to the Clinical Laboratory Improvement Amendments (&#8220;CLIA&#8221;), state licensure and compliance with industry standards such as the International
                  Quality Plasma Program. Compliance with state and industry standards is verified by means of routine inspection. State requirements may differ significantly from federal requirements, which may complicate compliance efforts. We believe
                  that our existing ADMA BioCenters facilities are currently in compliance with state and industry standards. Delays in obtaining, or failures to maintain, regulatory approvals for any facilities operated by ADMA BioCenters would harm our
                  business. In addition, we cannot predict what adverse federal and state regulations and industry standards may arise in the future.</div>

                <div><br/>
                </div>

                <div style="font-style: italic; font-weight: bold; text-indent: -9pt; margin-left: 9pt;">Foreign Regulation</div>

                <div style="text-indent: 36pt;">In addition to regulations in the U.S., if we choose to pursue clinical development and commercialization in the European Union, we will be subject to a variety of foreign regulations governing clinical
                  trials and commercial sales and distribution of any future product. Whether or not we obtain FDA approval for a product, we must obtain approval by the comparable regulatory authorities of foreign countries before we can commence clinical
                  trials or marketing of the product in those countries. The approval process varies from country to country, and the time may be longer or shorter than that required for FDA approval. The requirements governing the conduct of clinical
                  trials, product licensing, pricing and reimbursement vary greatly from country to country.</div>

                <div> <br/>
                </div>

                <div style="text-indent: 36pt;">Under European Union regulatory systems, marketing authorizations may be submitted either under a centralized, decentralized or national or mutual recognition procedure. The centralized procedure provides for
                  the grant of a single marketing authorization that is valid for all European Union member states. The decentralized procedure provides for approval by one or more &#8220;concerned&#8221; member states based on an assessment of an application
                  performed by one member state, known as the &#8220;reference&#8221; member state. Under the decentralized approval procedure, an applicant submits an application, or dossier, and related materials to the reference member state and concerned member
                  states. The reference member state prepares a draft assessment report and drafts of the related materials within 120 days after receipt of a valid application. Within 90 days of receiving the reference member state&#8217;s assessment report,
                  each concerned member state must decide whether to approve the assessment report and related materials. If a member state does not recognize the marketing authorization, the disputed points are eventually referred to the European
                  Commission, whose decision is binding on all member states. In addition to the centralized procedure and the decentralized procedure, it may also be possible to obtain a marketing authorization for one single member state through a
                  national procedure.&#160;The mutual recognition procedure provides for mutual recognition of national approval decisions. Under this procedure, the holder of a national marketing authorization may submit an application to the remaining member
                  states. Within 90 days of receiving the applications and assessment report, each member state must decide whether to recognize approval, refuse it or request additional information.</div>

                <div> <br/>
                </div>

                <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
                  <div style="text-align: center; text-indent: -9pt; margin-left: 9pt;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">22</span></div>

                  <div style="page-break-after: always;" class="BRPFPageBreak">
                    <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: rgb(0, 0, 0); background-color: rgb(0, 0, 0);"/></div>

                  <div style="width: 100%;" class="BRPFPageHeader">
                    <div>
                      <div style="text-align: left; font-weight: bold; text-indent: -9pt; margin-left: 9pt;"><a href="#ADMABIOLOGICSINC."> <span style="font-style: italic; font-weight: normal; font-size: 8pt;">Table of Contents</span></a><br/>
                      </div>

                    </div>

                  </div>

                </div>

                <div style="font-style: italic; font-weight: bold; text-indent: -9pt; margin-left: 9pt;">Pharmaceutical Pricing and Reimbursement of Our Products</div>

                <div style="text-indent: 36pt;">In the United States, our activities are potentially subject to additional regulation by various federal, state and local authorities in addition to the FDA, including CMS, other divisions of HHS (e.g., the
                  Office of Inspector General), the U.S. Department of Justice (&#8220;DOJ&#8221;) and individual U.S. Attorney offices within the DOJ, and state and local governments. If a drug product is reimbursed by Medicare or Medicaid, pricing and rebate
                  programs must comply with, as applicable, the Medicare Prescription Drug, Improvement, and Modernization Act of 2003 as well as the Medicaid rebate requirements of the Omnibus Budget Reconciliation Act of 1990 (the &#8220;OBRA&#8221;), the Veterans
                  Health Care Act of 1992, Deficit Reduction Act of 2005, Patient Protection and Affordable Care Act (the &#8220;ACA&#8221;), and the Inflation Reduction Act of 2022, each as amended. Among other things, the OBRA requires drug manufacturers to
                  calculate and report complex pricing metrics used to determine rebates paid on prescription drugs to state Medicaid programs. Under the Veterans Health Care Act (the &#8220;VHCA&#8221;), drug companies are required to offer &#8220;covered drugs&#8221; (including
                  all drugs approved under an NDA) at no more than a statutory ceiling price, calculated based on a manufacturer&#8217;s required price calculations, to four federal agencies, including the U.S. Department of Veterans Affairs (&#8220;VA&#8221;), Indian
                  Health Service, and Department of Defense (&#8220;DoD&#8221;), and the Public Health Service (&#8220;PHS&#8221;). Also, under the VHCA, manufacturers are required to offer drugs for sale at no more than a separate statutory ceiling price calculated by the
                  manufacturer to Public Health Service designated entities in order to participate in other federal funding programs including Medicaid. Legislation subsequent to the VHCA has required that certain discounted prices under the VHCA also be
                  offered for specified DoD purchases for its TRICARE program via a rebate system. Participation under the VHCA requires submission of pricing data and calculation of discounts and rebates pursuant to complex statutory formulas, as well as
                  the entry into government procurement contracts governed by the Federal Acquisition Regulation.</div>

                <div><br/>
                </div>

                <div style="text-indent: 36pt;">Because of the breadth of these laws and the narrowness of available statutory and regulatory exemptions, it is possible that some of our business activities could be subject to challenge under one or more of
                  such laws. If our operations are found to be in violation of any of the federal and state laws described above or any other governmental regulations that apply to us, we may be subject to penalties, including criminal and significant
                  civil monetary penalties, damages, fines, imprisonment, exclusion from participation in government healthcare programs, injunctions, recall or seizure of products, total or partial suspension of production, denial or withdrawal of
                  pre-marketing product approvals, private &#8220;qui tam&#8221; actions brought by individual whistleblowers in the name of the government, suspension or debarment prohibiting us from participating in federal procurement and non-procurement
                  transactions, including government contracts, and the curtailment or restructuring of our operations, any of which could adversely affect our ability to operate our business and our results of operations.</div>

                <div><br/>
                </div>

                <div style="text-indent: 36pt;">In order to distribute products commercially, we must comply with state laws that require the registration of manufacturers and wholesale distributors of pharmaceutical products in a state, including, in some
                  states, manufacturers and distributors who ship products into the state even if such manufacturers or distributors have no place of business within the state. Several states have enacted legislation requiring pharmaceutical companies to,
                  among other things, establish marketing compliance programs, file periodic reports with the state, make periodic public disclosures on sales, marketing, pricing, clinical trials and other activities, and/or register their sales
                  representatives, as well as to prohibit pharmacies and other healthcare entities from providing specified physician prescribing data to pharmaceutical companies for use in sales and marketing, and to prohibit other specified sales and
                  marketing practices. Additionally, some states have enacted laws that cap increases in prices charged for drugs in that state. All of our activities are potentially subject to federal and state consumer protection and unfair competition
                  laws.</div>

                <div><br/>
                </div>

                <div style="text-indent: 36pt;">All sales in the U.S. of BIVIGAM, ASCENIV and Nabi-HB depend in part upon the availability of reimbursement from third-party payers. Third-party payers include government health programs, managed care
                  providers, private health insurers and other organizations. Our products are reimbursed or purchased under several government programs, including Medicaid, Medicare Parts B and D, the 340B Drug Pricing Program/Public Health Service
                  program, and pursuant to an existing contract with the Department of Veterans Affairs. Medicaid is a joint state and federal government health plan that provides covered outpatient prescription drugs for low-income and disabled
                  individuals. Under Medicaid, drug manufacturers pay rebates to the states based on utilization data provided by the states. CMS has issued a permanent, product-specific-J-code for ASCENIV.&#160; Under the HCPCS, the J-code (J1554) became
                  effective April 1, 2021.</div>

                <div><br/>
                </div>

                <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
                  <div style="text-align: center; text-indent: -9pt; margin-left: 9pt;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">23</span></div>

                  <div style="page-break-after: always;" class="BRPFPageBreak">
                    <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: rgb(0, 0, 0); background-color: rgb(0, 0, 0);"/></div>

                  <div style="width: 100%;" class="BRPFPageHeader">
                    <div>
                      <div style="text-align: left; font-weight: bold; text-indent: -9pt; margin-left: 9pt;"><a href="#ADMABIOLOGICSINC."> <span style="font-style: italic; font-weight: normal; font-size: 8pt;">Table of Contents</span></a><br/>
                      </div>

                    </div>

                  </div>

                </div>

                <div style="text-indent: 36pt;">Significant uncertainties exist as to the coverage and reimbursement status of our current products as well as any products for which we may obtain regulatory approval. In the U.S., sales of BIVIGAM, ASCENIV
                  and Nabi-HB, as well as any products for which we may receive regulatory approval for commercial sale will depend in part on the availability of coverage and reimbursement from third-party payers. Third-party payers include government
                  authorities, managed care providers, private health insurers and other organizations. No uniform policy of coverage and reimbursement for drug products exists. Accordingly, decisions regarding the extent of coverage and amount of
                  reimbursement to be provided for any of our products will be made on a payor-by-payor basis. As a result, the coverage determination process is often a time-consuming and costly process that will require us to provide scientific and
                  clinical support for the use of our products to each payor separately, with no assurance that coverage and adequate reimbursement will be obtained. The process for determining whether a payer will provide coverage for a drug product may
                  be separate from the process for setting the reimbursement rate that the payer will pay for the drug product. Third-party payers may limit coverage to specific drug products on an approved list, or formulary, which might not include all
                  of the FDA-approved drugs for a particular indication. Third-party payers also may choose not to cover our products or implement measures such as prior authorizations and step-throughs to secure coverage and reimbursement. Moreover, a
                  payer&#8217;s decision to provide coverage for a drug product does not imply that an adequate reimbursement rate will be approved. Adequate third-party reimbursement may not be available to enable us to maintain price levels sufficient to
                  realize an appropriate return on our investment in product development.</div>

                <div> <br/>
                </div>

                <div style="text-indent: 36pt;">Third-party payers are increasingly challenging the price and examining the medical necessity and cost-effectiveness of medical products and services, in addition to their safety and efficacy. In order to
                  obtain coverage and reimbursement for our current products and any product that might be approved for sale, we may need to conduct expensive pharmacoeconomic studies in order to demonstrate the medical necessity and cost-effectiveness of
                  any products, in addition to the costs required to obtain regulatory approvals. Our current products may not be considered medically necessary or cost-effective. If third-party payers do not consider a product to be cost-effective
                  compared to other available therapies, they may not cover the product after approval as a benefit under their plans or, if they do, the level of payment may not be sufficient to allow a company to sell its products at a profit.</div>

                <div> <br/>
                </div>

                <div style="text-indent: 36pt;">The U.S. government and state legislatures have shown significant interest in implementing cost containment programs to limit the growth of government-paid healthcare costs, including price controls,
                  limitations on coverage, increased rebates, restrictions on reimbursement and requirements for substitution of generic products for branded prescription drugs. For example, the ACA and the companion Healthcare and Education Reconciliation
                  Act (which together are referred to as the &#8220;Healthcare Reform Law&#8221;) contains provisions that may reduce the profitability of drug products, including, for example, increased rebates for drugs reimbursed by Medicaid programs, extension of
                  Medicaid rebates to Medicaid managed care plans, mandatory discounts for certain Medicare Part D beneficiaries and annual fees based on pharmaceutical companies&#8217; share of sales to federal healthcare programs. Similarly, the Inflation
                  Reduction Act of 2022 requires manufacturers of selected drugs to negotiate discounted prices with the Secretary of the Department of Health and Human Services. Failure to reach an agreement can subject manufacturers to an excise tax or
                  withdraw of all drug products from coverage under Medicare and Medicaid.&#160;We have addressed additional reforms related to government pricing programs that could be relevant to our products below. These and any additional healthcare reform
                  measures could further constrain our business or limit the amounts that federal and state governments will pay for healthcare products and services, which could result in additional pricing pressures. Adoption of government controls and
                  measures and tightening of restrictive policies in jurisdictions with existing controls and measures, could limit payments for pharmaceuticals.</div>

                <div> <br/>
                </div>

                <div>
                  <div style="text-align: justify; text-indent: 36pt;">The marketability of our current products and any products for which we receive regulatory approval for commercial sale may suffer if the government and third-party payers fail to
                    provide adequate coverage and reimbursement. In addition, the emphasis on cost containment measures in the U.S. has increased and we expect will continue to increase the pressure on pharmaceutical pricing. Adoption of price controls and
                    cost-containment measures, along with adoption of more restrictive policies in jurisdictions with existing controls and measures, could further limit a company&#8217;s revenue generated from the sale of any approved product(s). Coverage
                    policies and third-party reimbursement rates may change at any time. Even if favorable coverage and reimbursement status is attained for one or more products, less favorable coverage policies and reimbursement rates may be implemented
                    in the future. Any reduction in reimbursement from Medicare and/or other government programs may result in a similar reduction in payments from private payors. The implementation of cost containment measures or other healthcare reforms
                    may prevent the generation of revenue, attainment of profitability, or commercialization of products. In addition, it is possible that there will be further legislation or regulation that could harm our business, financial condition,
                    and results of operations.</div>

                </div>

                <div><br/>
                </div>

                <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
                  <div style="text-align: center; text-indent: -9pt; margin-left: 9pt;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">24</span></div>

                  <div style="page-break-after: always;" class="BRPFPageBreak">
                    <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: rgb(0, 0, 0); background-color: rgb(0, 0, 0);"/></div>

                  <div style="width: 100%;" class="BRPFPageHeader">
                    <div>
                      <div style="text-align: left; font-weight: bold; text-indent: -9pt; margin-left: 9pt;"><a href="#ADMABIOLOGICSINC."> <span style="font-style: italic; font-weight: normal; font-size: 8pt;">Table of Contents</span></a><br/>
                      </div>

                    </div>

                  </div>

                </div>

                <div style="text-align: justify; font-style: italic; font-weight: bold; text-indent: -9pt; margin-left: 9pt;">Government Price Reporting</div>

                <div style="text-indent: 36pt;">Manufacturers participate in, and have certain price reporting obligations under, the Medicaid Drug Rebate Program, state Medicaid supplemental rebate program(s), and other governmental pricing programs.
                  Effective for calendar quarters beginning January 1, 2022, manufacturers are required to report the average sales price for certain drugs under the Medicare program regardless of whether the manufacturer participates in the Medicaid Drug
                  Rebate Program.&#160; Previously, this reporting obligation extended only to manufacturers participating in the Medicaid Drug Rebate Program. Under this Program, manufacturers are required to pay a rebate to each state Medicaid program for
                  covered outpatient drugs that are dispensed to Medicaid beneficiaries and paid for by a state Medicaid program as a condition of having federal funds being made available for their drugs under Medicaid and Part B of the Medicare program.</div>

                <div><br/>
                </div>

                <div style="text-indent: 36pt;">Medicaid rebates are based on pricing data reported by manufacturers on a monthly and quarterly basis to the CMS, the federal agency that administers the Medicaid and Medicare programs. This data includes the
                  average manufacturer price and, in the case of innovator products, the best price for each drug, which, in general, represents the lowest price available from the manufacturer to any entity in the U.S. in any pricing structure, calculated
                  to include all sales and associated rebates, discounts, and other price concessions. The amount of the rebate is adjusted upward if the average manufacturer price increases more than inflation (measured by reference to the Consumer Price
                  Index&#8211;- Urban). Previously, the rebate was capped at 100% of the average manufacturer price, but, effective January 1, 2024, this cap on the rebate was removed, and our rebate liability could increase accordingly.</div>

                <div><br/>
                </div>

                <div style="text-indent: 36pt;">If a manufacturer becomes aware that its reporting for a prior quarter was incorrect or has changed as a result of recalculating the pricing data, the manufacturer is obligated to resubmit the corrected data
                  for up to three years after it was originally due, which revisions could affect rebate liability for prior quarters. The ACA made significant changes to the Medicaid Drug Rebate Program, and CMS issued a final regulation, which became
                  effective on April 1, 2016, to implement the changes to the Medicaid Drug Rebate Program under the ACA. On December 21, 2020, CMS issued a final rule that modified the Medicaid Drug Rebate Program regulations to permit reporting multiple
                  best price figures with regard to value&#8209;based purchasing arrangements (beginning in 2022); provided definitions for &#8220;line extension&#8221;, &#8220;new formulation,&#8221; and related terms with the practical effect of expanding the scope of drugs
                  considered to be line extensions (beginning in 2022); and revised best price and average manufacturer price exclusions of manufacturer-sponsored patient benefit programs, particularly regarding potential inapplicability of such exclusions
                  in the context of pharmacy benefit manager &#8220;accumulator&#8221; programs (beginning in 2023).</div>

                <div><br/>
                </div>

                <div style="text-indent: 36pt;">Medicare is a federal program that is administered by the federal government that covers individuals age 65 and over or that are disabled as well as those with certain health conditions. Medicare Part B
                  generally covers drugs that must be administered by physicians or other health care practitioners, among others. Medicare Part B generally pays for such drugs under a payment methodology based on the average sales price of the drugs.
                  Manufacturers are required to report average sales price information to CMS on a quarterly basis. The manufacturer-submitted information is used by CMS to calculate Medicare payment rates.</div>

                <div style="text-indent: 36pt;"> <br/>
                </div>

                <div style="text-indent: 36pt;">Congress could enact additional changes that affect our overall rebate liability and the information manufacturers report to the government as part of price reporting calculations. For example, Congress is
                  considering a Medicare Part B inflation rebate, under which manufacturers would owe additional rebates if the average sales price of a drug were to increase faster than the pace of inflation.</div>

                <div><br/>
                </div>

                <div style="text-indent: 36pt;">Civil monetary penalties can be applied if a manufacturer is (1) found to have knowingly submitted any false pricing or other information to the government, (2) found to have made a misrepresentation in the
                  reporting of average sales price, or (3) fails to submit the required data on a timely basis. Such conduct also could be grounds for CMS to terminate a Medicaid Drug Rebate Program agreement, in which case federal payments may not be
                  available under Medicaid or Medicare Part B for the manufacturer&#8217;s covered outpatient drugs.</div>

                <div><br/>
                </div>

                <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
                  <div style="text-align: center; text-indent: -9pt; margin-left: 9pt;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">25</span></div>

                  <div style="page-break-after: always;" class="BRPFPageBreak">
                    <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: rgb(0, 0, 0); background-color: rgb(0, 0, 0);"/></div>

                  <div style="width: 100%;" class="BRPFPageHeader">
                    <div>
                      <div style="text-align: left; font-weight: bold; text-indent: -9pt; margin-left: 9pt;"><a href="#ADMABIOLOGICSINC."> <span style="font-style: italic; font-weight: normal; font-size: 8pt;">Table of Contents</span></a><br/>
                      </div>

                    </div>

                  </div>

                </div>

                <div style="text-indent: 36pt;">Federal law requires that any company that participates in the Medicaid Drug Rebate Program also participate in the Public Health Service&#8217;s 340B drug pricing program (the &#8220;340B program&#8221;) in order for federal
                  funds to be available for the manufacturer&#8217;s drugs under Medicaid and Medicare Part B. The 340B program, which is administered by the Health Resources and Services Administration (&#8220;HRSA&#8221;), requires participating manufacturers to agree to
                  charge statutorily defined covered entities no more than the 340B &#8220;ceiling price&#8221; for the manufacturer&#8217;s covered outpatient drugs. Covered entities include hospitals that serve a disproportionate share of financially needy patients,
                  community health clinics, and other entities that receive certain types of grants under the Public Health Service Act. The ACA expanded the list of covered entities to include certain free-standing cancer hospitals, critical access
                  hospitals, rural referral centers, and sole community hospitals, but exempts &#8220;orphan drugs&#8221; from the ceiling price requirements for these covered entities. The 340B ceiling price is calculated using a statutory formula, which is based on
                  the average manufacturer price and Medicaid rebate amount for the covered outpatient drug as calculated under the Medicaid Drug Rebate Program. In general, products subject to Medicaid price reporting and rebate liability are also subject
                  to the 340B ceiling price calculation and discount requirement.</div>

                <div><br/>
                </div>

                <div style="text-indent: 36pt;">The final regulation issued by HRSA regarding the calculation of the 340B ceiling price and the imposition of civil monetary penalties on manufacturers that knowingly and intentionally overcharge covered
                  entities has affected manufacturer obligations and potential liability under the 340B program. Any charge by HRSA that a manufacturer has violated the requirements of the regulation could result in civil monetary penalties. Moreover,
                  under a final regulation effective January 13, 2021, HRSA established a new Administrative Dispute Resolution &#8220;ADR&#8221;) process for claims by covered entities that a manufacturer has engaged in overcharging, and by manufacturers that a
                  covered entity violated the prohibitions against diversion or duplicate discounts. Such claims are to be resolved through an ADR panel of government officials rendering a decision that can be appealed to a federal court. An ADR proceeding
                  could subject a manufacturer to onerous procedural requirements and could result in additional liability. HRSA also implemented a price reporting system under which manufacturers are required to report 340B ceiling prices on a quarterly
                  basis to HRSA, which then publishes those prices to 340B covered entities. In addition, legislation could be passed, that would further expand the 340B program to additional covered entities, or participating manufacturers could be
                  required to agree to provide 340B discounted pricing on drugs used in an inpatient setting.</div>

                <div><br/>
                </div>

                <div style="text-indent: 36pt;">In order to be eligible to have their products paid for with federal funds under the Medicaid and Medicare Part B programs and purchased by certain federal agencies, including the VA, DoD, Coast Guard, and
                  PHS and grantees, manufacturers must participate in the VA Federal Supply Schedule (&#8220;FSS&#8221;) pricing program. Prices for innovator drugs purchased by the VA, DoD, Coast Guard, and PHS are subject to a cap (known as the &#8220;Federal Ceiling
                  Price&#8221;) equal to 76% of the annual Non-Federal Average Manufacturer price (&#8220;non-FAMP&#8221;) minus, if applicable, an additional discount. The additional discount applies if non-FAMP increases more than inflation (measured by reference to the
                  Consumer Price Index &#8211; Urban (&#8220;CPIU&#8221;)). In addition, in the second and subsequent year, the price also is capped at the prior year FSS contract plus CPIU. Manufacturers must also participate in the Tricare Retail Pharmacy Program, under
                  which they pay quarterly rebates to DoD for prescriptions of innovator drugs dispensed to Tricare beneficiaries through Tricare Retail network pharmacies. The governing statute provides for civil monetary penalties for failure to provide
                  information timely or for knowing submission of false information to the government.</div>

                <div><br/>
                </div>

                <div style="text-indent: 36pt;">Medicare Part D generally provides coverage to enrolled Medicare patients for self-administered drugs (<span style="font-style: italic;">i.e.</span>, drugs that are not administered by a physician). Medicare
                  Part D is administered by private prescription drug plans approved by the U.S. government and subject to detailed program rules and government oversight. Each drug plan establishes its own Medicare Part D formulary for prescription drug
                  coverage and pricing, which the drug plan may modify from time to time. The prescription drug plans negotiate pricing with manufacturers and pharmacies and may condition formulary placement on the availability of manufacturer rebates. In
                  addition, manufacturers are required to provide to CMS a 70% discount on brand name prescription drugs utilized by Medicare Part D beneficiaries when those beneficiaries are in the coverage gap phase of the Part D benefit design. If a
                  manufacturer fails to provide these discounts, civil monetary penalties can be applied in the amount of 125% of the discount that was due. Congress could enact legislation that sunsets this discount program and replaces it with a new
                  manufacturer discount program. Congress further could enact a Medicare Part D inflation rebate, under which manufacturers would owe additional rebates if the average manufacturer price of a drug were to increase faster than the pace of
                  inflation.</div>

                <div><br/>
                </div>

                <div style="text-indent: 36pt;">Congress also could enact a drug price negotiation program under which the prices for certain high Medicare spend single source drugs would be capped by reference to the non-FAMP price. This or any other
                  legislative change could impact the market conditions for our products. We expect further continued scrutiny on government price reporting from Congress, federal agencies, and other bodies.</div>

                <div><br/>
                </div>

                <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
                  <div style="text-align: center; text-indent: -9pt; margin-left: 9pt;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">26</span></div>

                  <div style="page-break-after: always;" class="BRPFPageBreak">
                    <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: rgb(0, 0, 0); background-color: rgb(0, 0, 0);"/></div>

                  <div style="width: 100%;" class="BRPFPageHeader">
                    <div>
                      <div style="text-align: left; font-weight: bold; text-indent: -9pt; margin-left: 9pt;"><a href="#ADMABIOLOGICSINC."> <span style="font-style: italic; font-weight: normal; font-size: 8pt;">Table of Contents</span></a><br/>
                      </div>

                    </div>

                  </div>

                </div>

                <div style="text-indent: 36pt;">Group health plans, health insurance issuers, health maintenance organizations, other healthcare payors, and pharmacy benefit managers in the United States are adopting more aggressive utilization management
                  techniques and are increasingly requiring significant discounts and rebates from manufacturers as a condition to including products on formulary with favorable coverage and cost-sharing. These payors may not cover or adequately reimburse
                  for use of our products or may do so at levels that disadvantage them relative to competitive products. Outside the United States, within the EU, our products are paid for by a variety of payors, with governments being the primary source
                  of payment. Government health authorities in the EU determine or influence reimbursement of products and set prices or otherwise regulate pricing. Negotiating prices with governmental authorities can delay commercialization of our
                  products. Governments may use a variety of cost-containment measures to control the cost of products, including price cuts, mandatory rebates, value-based pricing and reference pricing (<span style="font-style: italic;">i.e.</span>,
                  referencing prices in other countries or prices of competitive products and using those reference prices to set a price). Budgetary pressures in many EU countries are continuing to cause governments to consider or implement various
                  cost-containment measures, such as price freezes, increased price cuts and rebates and expanded generic substitution and patient cost-sharing. Recently, several states also have enacted or are considering legislation intended to make drug
                  prices more transparent and deter significant price increases that impose reporting requirements on biopharmaceutical companies. These laws may affect our future sales, marketing, and other promotional activities by imposing
                  administrative and compliance burdens.&#160; Such laws also typically impose significant civil monetary penalties for each instance of reporting noncompliance that can quickly aggregate into millions of dollars.</div>

                <div><br/>
                </div>

                <div style="text-align: justify; font-style: italic; font-weight: bold; text-indent: -9pt; margin-left: 9pt;">U.S. Healthcare Reform</div>

                <div style="text-indent: 36pt;">The containment of healthcare costs has become a priority of Federal and state governments, and the prices of drugs have been a focus in this effort. Changes in government legislation or regulation and
                  changes in private third-party payors&#8217; policies toward reimbursement for our products, if successfully developed and approved, may reduce reimbursement of our products&#8217; costs to physicians, pharmacies, patients and distributors. The U.S.
                  government, state legislatures and foreign governments have shown significant interest in implementing cost-containment programs, including price controls, payment of rebates, restrictions on reimbursement and requirements for
                  substitution of generic products. Adoption of price controls and cost-containment measures, and adoption of more restrictive policies in jurisdictions with existing controls and measures, could limit our net revenue and results for
                  products, if any, we commercialize in the future.</div>

                <div><br/>
                </div>

                <div style="text-indent: 36pt;">The pricing and reimbursement environment for our products may change in the future and become more challenging due to state and federal healthcare reform measures. The American Recovery and Reinvestment Act
                  of 2009 (&#8220;ARRA&#8221;), for example, allocated new federal funding to compare the effectiveness of different treatments for the same condition. The plan for the research was published in 2012 by the Department of Health and Human Services, the
                  Agency for Healthcare Research and Quality and the National Institutes for Health, and periodic reports on the status of the research and related expenditures are made to Congress. Although ARRA does not mandate the use of the results of
                  comparative effectiveness studies for reimbursement purposes, it is not clear what effect, if any, the research will have on the sales of any products for which we receive marketing approval or on the reimbursement policies of public and
                  private payors. It is possible that comparative effectiveness research demonstrating benefits in a competitor&#8217;s product could adversely affect the sales of any product for which we receive marketing approval. For example, if third-party
                  payors find our products not to be cost-effective compared to other available therapies, they may not cover our products after approval as a benefit under their plans or, if they do, the level of payment may not be sufficient to allow us
                  to sell our products on a profitable basis.</div>

                <div><br/>
                </div>

                <div style="text-indent: 36pt;">The ACA is a sweeping measure intended to expand healthcare coverage within the U.S., primarily through the imposition of health insurance mandates on employers and individuals, the provision of subsidies to
                  eligible individuals enrolled in plans offered on the health insurance exchanges, and the expansion of the Medicaid program. This law has substantially changed the way healthcare is financed by both governmental and private insurers and
                  has significantly impacted the pharmaceutical industry. Changes that may affect our business include those governing enrollment in Federal healthcare programs, reimbursement changes, benefits for patients within a coverage gap in the
                  Medicare Part D prescription drug program (commonly known as the &#8220;donut hole&#8221;), rules regarding prescription drug benefits under the health insurance exchanges, changes to the Medicaid Drug Rebate Program, expansion of the Public Health
                  Service Act&#8217;s 340B drug pricing program, or 340B program, and fraud and abuse enforcement. These changes have impacted previously existing government healthcare programs and have resulted in the development of new programs, including
                  Medicare payment for performance initiatives and improvements to the Medicare physician quality reporting system and feedback program.</div>

                <div><br/>
                </div>

                <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
                  <div style="text-align: center; text-indent: -9pt; margin-left: 9pt;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">27</span></div>

                  <div style="page-break-after: always;" class="BRPFPageBreak">
                    <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: rgb(0, 0, 0); background-color: rgb(0, 0, 0);"/></div>

                  <div style="width: 100%;" class="BRPFPageHeader">
                    <div>
                      <div style="text-align: left; font-weight: bold; text-indent: -9pt; margin-left: 9pt;"><a href="#ADMABIOLOGICSINC."> <span style="font-style: italic; font-weight: normal; font-size: 8pt;">Table of Contents</span></a><br/>
                      </div>

                    </div>

                  </div>

                </div>

                <div style="text-indent: 36pt;">One of the goals of ACA was to expand coverage for the uninsured while at the same time containing overall healthcare costs. With regard to pharmaceutical products, among other things, the ACA increased
                  minimum rebates a manufacturer must pay under the Medicaid Drug Rebate Program and extended manufacturers&#8217; Medicaid rebate liability to drugs dispensed to individuals who are enrolled in Medicaid managed care organizations. The ACA also
                  requires manufacturers of drugs, devices, biologics, and medical supplies for which payment is available under Medicare, Medicaid or the Children&#8217;s Health Insurance Program (with certain exceptions) to report annually to CMS information
                  related to certain direct or indirect payments and other transfers of value to U.S.-licensed physicians, physician assistants, nurse practitioners, clinical nurse specialists, certified nurse anesthetists and certified nurse-midwives and
                  to U.S. teaching hospitals, as well as ownership and investment interests held in the company by physicians and their immediate family members. Failure to submit required information may result in civil monetary penalties of $1,000 to
                  $10,000 for each payment or ownership interest that is not timely, accurately, or completely reported (annual maximum of $150,000), and $10,000 to $100,000 for each knowing failure to report (annual maximum of $1 million) (for an
                  aggregate annual maximum of $1,150,000).</div>

                <div><br/>
                </div>

                <div style="text-indent: 36pt;">Some states have elected not to expand their Medicaid programs by raising the income limit to 133% of the federal poverty level, as is permitted under the ACA. For each state that does not choose to expand
                  its Medicaid program, there may be fewer insured patients overall, which could impact sales of our products that are approved and that we successfully commercialize, and our business and financial condition. Where Medicaid patients
                  receive insurance coverage under any of the new options made available through the ACA, the possibility exists that manufacturers may be required to pay Medicaid rebates on drugs used under these circumstances, a decision that could
                  impact manufacturer revenues.</div>

                <div><br/>
                </div>

                <div style="text-indent: 36pt;">Certain provisions of the ACA have been subject to judicial challenges as well as efforts to modify them or to alter their interpretation or implementation. For example, Congress eliminated, starting January
                  1, 2019, the tax penalty for not complying with the ACA&#8217;s individual mandate to carry health insurance. Further, the Bipartisan Budget Act of 2018, among other things, amended the Medicare statute to reduce the coverage gap in most
                  Medicare drugs plans, commonly known as the &#8220;donut hole,&#8221; by raising the required manufacturer point-of-sale discount from 50% to 70% off the negotiated price effective as of January 1, 2019. Additional legislative changes, regulatory
                  changes, and judicial challenges related to the ACA remain possible, but the nature and extent of such potential changes or challenges are uncertain at this time. It is unclear how the ACA and its implementation, as well as efforts to
                  modify or invalidate the ACA, or portions thereof, or its implementation, will affect our business, financial condition and results of operations. It is possible that the ACA, as currently enacted or as it may be amended in the future,
                  and other healthcare reform measures that may be adopted in the future could have a material adverse effect on our industry generally and on our ability to maintain or increase sales of our products or product candidates for which we
                  receive regulatory approval or to successfully commercialize our products and product candidates.</div>

                <div><br/>
                </div>

                <div style="text-indent: 36pt;">Other legislative changes related to reimbursement have been adopted in the U.S. since the ACA was enacted. For example, on August 2, 2011, the Budget Control Act of 2011, among other things, created the
                  Joint Select Committee on Deficit Reduction to recommend to Congress proposals for spending reductions. The Joint Select Committee did not achieve a targeted deficit reduction, which triggered the legislation&#8217;s automatic reductions. In
                  concert with subsequent legislation, this has resulted in aggregate reductions to Medicare payments to providers of, on average, 2% per fiscal year through 2031 (with the exception of a temporary suspension from May 1, 2020 through March
                  31, 2022, due to the COVID-19 pandemic). The law provides for 1% Medicare sequestration in the second quarter of 2022 and allows the full 2% sequestration thereafter until 2031. As long as these cuts remain in effect, they could adversely
                  impact payment for any products we may commercialize in the future. We expect that additional federal healthcare reform measures will be adopted in the future, any of which could limit the amounts that federal and state governments will
                  pay for healthcare products and services, and in turn could significantly reduce the projected value of certain development projects and reduce our profitability.</div>

                <div><br/>
                </div>

                <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
                  <div style="text-align: center; text-indent: -9pt; margin-left: 9pt;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">28</span></div>

                  <div style="page-break-after: always;" class="BRPFPageBreak">
                    <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: rgb(0, 0, 0); background-color: rgb(0, 0, 0);"/></div>

                  <div style="width: 100%;" class="BRPFPageHeader">
                    <div>
                      <div style="text-align: left; font-weight: bold; text-indent: -9pt; margin-left: 9pt;"><a href="#ADMABIOLOGICSINC."> <span style="font-style: italic; font-weight: normal; font-size: 8pt;">Table of Contents</span></a><br/>
                      </div>

                    </div>

                  </div>

                </div>

                <div style="text-indent: 36pt;">Additional legislative changes, regulatory changes, or guidance could be adopted, which may impact the marketing approvals and reimbursement for our product candidates. For example, there has been increasing
                  legislative, regulatory, and enforcement interest in the United States with respect to drug pricing practices. There have been several Congressional inquiries and proposed and enacted federal and state legislation and regulatory
                  initiatives designed to, among other things, bring more transparency to product pricing, evaluate the relationship between pricing and manufacturer patient assistance and support programs, potentially permit government negotiation of
                  Medicare pricing with manufacturers relative to certain international prices paid, and reform government healthcare program reimbursement methodologies for drug products. If healthcare policies or reforms intended to curb healthcare costs
                  are adopted or if we experience negative publicity with respect to pricing of our products or the pricing of pharmaceutical drugs generally, the prices that we charge for any approved products may be limited, our commercial opportunity
                  may be limited and/or our revenues from sales of our products may be negatively impacted.</div>

                <div><br/>
                </div>

                <div style="text-indent: 36pt;">It is possible that the ACA, as currently enacted or may be amended in the future, as well as other healthcare reform measures that may be adopted in the future, may result in additional reductions in
                  Medicare and other healthcare funding, more rigorous coverage criteria and new payment methodologies and in additional downward pressure on coverage and payment and the price that we receive for any approved product. Any reduction in
                  reimbursement from Medicare or other government programs may result in a similar reduction in payments from private payors. The implementation of cost containment measures or other healthcare reforms may prevent us from being able to
                  generate revenue, attain profitability or commercialize our products. We cannot be sure whether additional legislative changes will be enacted in the U.S. or outside the U.S., or whether regulatory changes, guidance or interpretations
                  will be changed, or what the impact of such changes on the marketing approvals of our product candidates, if any, may be.</div>

                <div><br/>
                </div>

                <div style="text-align: justify; font-style: italic; font-weight: bold; text-indent: -9pt; margin-left: 9pt;">Anti-Fraud and Abuse Laws</div>

                <div style="text-indent: 36pt;">We are also subject to numerous fraud and abuse laws and regulations globally.&#160; In the U.S., there are a variety of Federal and state laws restricting certain marketing practices in the pharmaceutical
                  industry pertaining to healthcare fraud and abuse, including anti-kickback laws and false claims laws. Our sales, marketing, patient support and medical activities may be subject to scrutiny under these laws. The U.S. Federal healthcare
                  program Anti-Kickback Statute prohibits, among other things, knowingly and willfully offering, paying, soliciting or receiving anything of value (&#8220;remuneration&#8221;) to induce (or in return for) the referral of business, including the
                  purchase, recommendation or prescription of a particular drug reimbursable under Medicare, Medicaid or other federally financed healthcare programs. The statute has been interpreted to apply to arrangements between pharmaceutical
                  companies on one hand and patients, prescribers, purchasers and formulary managers on the other. The Beneficiary Inducement Civil Monetary Penalties Law imposes similar restrictions on interactions between pharmaceutical manufacturers and
                  federal healthcare program beneficiaries. Although there are a number of statutory exemptions and regulatory safe harbors protecting certain common manufacturer business arrangements and activities from prosecution and administrative
                  sanction, the exceptions and safe harbors are drawn narrowly and are subject to regulatory revision or changes in interpretation by the DOJ, and the Office of Inspector General of the U.S. Department of Health and Human Services (&#8220;OIG&#8221;).
                  Recent regulations eliminate the discount safe harbor protection for manufacturer rebates paid directly, or indirectly through a Pharmacy Benefit Manager (&#8220;PBM&#8221;) to Medicare Part D or Medicare Advantage plans. Recent legislation and a
                  final rule promulgated on December 29, 2023 delayed implementation of this portion of the 2020 final rule until January 1, 2032. Practices or arrangements that involve remuneration may be subject to scrutiny if they do not qualify for an
                  exception or safe harbor. Failure to meet all the requirements of a particular applicable statutory exception or regulatory safe harbor does not make the conduct per se illegal under the Anti-Kickback Statute.&#160; Instead, the legality of
                  the arrangement will be evaluated on a case-by-case basis based on a cumulative review of all its facts and circumstances.</div>

                <div><br/>
                </div>

                <div style="text-indent: 36pt;">Several courts have interpreted the statute&#8217;s intent requirement to mean that if any one purpose of an arrangement involving remuneration is to induce or reward referrals of federal healthcare program
                  business, including purchases of products paid by federal healthcare programs, the statute has been violated. Violations of the federal Anti-Kickback Statute may be established without providing specific intent to violate the statute, and
                  may be punishable by civil, criminal, and administrative fines and penalties, damages, imprisonment, and/or exclusion from participation in federal healthcare programs.</div>

                <div><br/>
                </div>

                <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
                  <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">29</span></div>

                  <div style="page-break-after: always;" class="BRPFPageBreak">
                    <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: rgb(0, 0, 0); background-color: rgb(0, 0, 0);"/></div>

                  <div style="width: 100%;" class="BRPFPageHeader">
                    <div>
                      <div style="text-align: left; font-weight: bold; text-indent: -9pt; margin-left: 9pt;"><a href="#ADMABIOLOGICSINC."> <span style="font-style: italic; font-weight: normal; font-size: 8pt;">Table of Contents</span></a><br/>
                      </div>

                    </div>

                  </div>

                </div>

                <div style="text-indent: 36pt;">The Federal civil False Claims Act (&#8220;FCA&#8221;) prohibits, among other things, any person from knowingly presenting, or causing to be presented, a false or fraudulent claim for payment of federal funds, or
                  knowingly making, or causing to be made, a false statement to get a false claim paid, or knowingly and improperly avoiding, decreasing or concealing an obligation to pay money to the federal government. A claim includes &#8220;any request or
                  demand&#8221; for money or property presented to the U.S. government. The FCA has been used to assert liability on the basis of improper referrals, improperly reported government pricing metrics such as Best Price or Average Manufacturer Price,
                  improper use of Medicare provider or supplier numbers when detailing a provider of services, improper promotion of off-label uses not expressly approved by the FDA in a product&#8217;s label, and allegations as to misrepresentations with
                  respect to products, contractual requirements, and services rendered.&#160; In addition, private payers have been filing follow-on lawsuits alleging fraudulent misrepresentation, although establishing liability and damages in these cases is
                  more difficult than under the FCA. Intent to deceive or actual knowledge of falsity is not required to establish liability under the FCA. Rather, a claim may be false for deliberate ignorance of the truth or falsity of the information
                  provided or for acts in reckless disregard of the truth or falsity of that information. A claim resulting from a violation of the federal Anti-Kickback Statute constitutes a per se false or fraudulent claim. The False Claims Act also
                  permits a private individual acting as a &#8220;whistleblower&#8221; to bring actions on behalf of themselves and the federal government alleging violations of the statute and to share in any monetary recovery. Violations of the False Claims Act may
                  result in significant financial penalties (including mandatory penalties on a per claim or statement basis), treble damages and exclusion from participation in federal health care programs. For these reasons, since 2004, False Claims Act
                  lawsuits against pharmaceutical companies have increased significantly in volume and breadth, leading to several substantial civil and criminal settlements, as much as $3.0 billion, regarding certain sales practices and promoting off
                  label uses.</div>

                <div><br/>
                </div>

                <div style="text-indent: 36pt;">The government may further prosecute conduct constituting a false claim under the criminal False Claims Act.&#160; The criminal False Claims Act prohibits the making or presenting of a claim to the government
                  knowing such claim to be false, fictitious, or fraudulent and, unlike the FCA, requires proof of intent to submit a false claim.</div>

                <div><br/>
                </div>

                <div style="text-indent: 36pt;">Pharmaceutical companies are subject to other federal false claim and statements laws, some of which extend to non-government health benefit programs. For example, the healthcare fraud provisions under the
                  Health Insurance Portability and Accountability Act of 1996 and its implementing regulations, or HIPAA, impose criminal liability for, among other things, knowingly and willfully executing, or attempting to execute, a scheme to defraud
                  any health care benefit program, including private third party payors, or falsifying or covering up a material fact or making any materially false or fraudulent statement in connection with the delivery of or payment for health care
                  benefits, items or services. Violations of HIPAA fraud provisions may result in criminal, civil and administrative fines, penalties and damages, including exclusion from participation in federal healthcare programs.</div>

                <div><br/>
                </div>

                <div style="text-indent: 36pt;">The majority of states have adopted analogous laws and regulations, including state anti-kickback and false claims laws, that may apply to our business practices, including but not limited to, research,
                  distribution, sales and marketing arrangements and claims involving healthcare items or services reimbursed by any third-party payer, including private insurers. Other states have adopted laws and regulations that, among other things,
                  require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines with respect to interactions with healthcare professionals and the relevant compliance program guidance promulgated by the U.S.
                  Federal government that otherwise restrict payments that may be made to healthcare professionals and other potential referral sources, and that require drug manufacturers to file reports related to pricing and marketing information, which
                  requires tracking price increases and gifts and other remuneration and items of value provided to healthcare professionals and entities. In addition, some jurisdictions have laws requiring pharmaceutical sales representatives to be
                  registered or licensed, and still others impose limits on co-pay assistance that pharmaceutical companies can offer to patients.</div>

                <div><br/>
                </div>

                <div style="text-indent: 36pt;">The Federal Physician Payment Sunshine Act requires tracking of certain payments and transfers of value to U.S.-licensed physicians, physician assistants, nurse practitioners, clinical nurse specialists,
                  certified nurse anesthetists and certified nurse-midwives and to U.S. teaching hospitals, and ownership interests held by physicians and their families, and reporting to the federal government and public disclosure by the federal
                  government of this data.</div>

                <div style="text-indent: 36pt;"> <br/>
                </div>

                <div>
                  <div style="text-align: justify; font-style: italic; font-weight: bold; text-indent: -9pt; margin-left: 9pt;">Data Protection and Privacy</div>

                  <div style="text-indent: 36pt;">Throughout the clinical trial process, we may obtain the private health information of our trial subjects. There are a number of state, federal and international laws protecting the privacy and security of
                    health information and personal data. The Healthcare Information Portability and Accountability Act of 1996 (&#8220;HIPAA&#8221;) imposes privacy, security, breach reporting obligations, and mandatory contractual terms on covered entity health care
                    providers, health plans, and health care clearinghouses, as well as their &#8220;business associates&#8221; &#8211; certain persons or covered entities that create, receive, maintain, or transmit protected health information in connection with providing
                    a specified service or performing a function on behalf of a covered entity. We could potentially be subject to civil and criminal penalties if we, our affiliates, or our agents use or disclose protected health information maintained by
                    a HIPAA-covered entity in a manner that is not authorized or permitted by HIPAA.</div>

                  <div>&#160;</div>

                  <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
                    <div style="text-align: center; text-indent: -9pt; margin-left: 9pt;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">30</span></div>

                    <div style="page-break-after: always;" class="BRPFPageBreak">
                      <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: rgb(0, 0, 0); background-color: rgb(0, 0, 0);"/></div>

                    <div style="width: 100%;" class="BRPFPageHeader">
                      <div>
                        <div style="text-align: left; font-weight: bold; text-indent: -9pt; margin-left: 9pt;"><a href="#ADMABIOLOGICSINC."> <span style="font-style: italic; font-weight: normal; font-size: 8pt;">Table of Contents</span></a><br/>
                        </div>

                      </div>

                    </div>

                  </div>

                  <div style="text-indent: 36pt;">Even when HIPAA does not apply, according to the Federal Trade Commission (&#8220;FTC&#8221;) failing to take appropriate steps to keep consumers&#8217; personal information secure, or failing to provide a level of security
                    commensurate to promises made to individuals about the security of their personal information (such as in a privacy notice) may constitute unfair or deceptive acts or practices in violation of Section 5(a) of the Federal Trade
                    Commission Act (&#8220;FTC Act&#8221;). The FTC expects a company&#8217;s data security measures to be reasonable and appropriate in light of the sensitivity and volume of consumer information it holds, the size and complexity of its business, and the
                    cost of available tools to improve security and reduce vulnerabilities. Individually identifiable health information is considered sensitive data that merits stronger safeguards. The FTC&#8217;s guidance for appropriately securing consumers&#8217;
                    personal information is similar to, but less prescriptive than, what is required by the HIPAA Security Rule. Enforcement by the FTC under the FTC Act can result in civil penalties or enforcement actions.</div>

                  <div>&#160;</div>

                  <div style="text-indent: 36pt;">All states have laws requiring notification of affected individuals and state regulators (breach notification laws) in the event of a breach of personal information. Some state laws impose significant data
                    security requirements, such as encryption, to ensure ongoing protection of personal information. Additionally, in California, the California Consumer Privacy Act (&#8220;CCPA&#8221;) establishes certain requirements for data use and sharing
                    transparency and creates new data privacy rights for California residents. The CCPA and its implementing regulations have already been amended multiple times since their enactment. In November 2020, California voters approved the
                    California Privacy Rights Act (&#8220;CPRA&#8221;) ballot initiative, which introduced significant amendments to the CCPA and established and funded a dedicated California privacy regulator, the California Privacy Protection Agency (&#8220;CPPA&#8221;).&#160; The
                    amendments introduced by the CPRA became effective on January 1, 2023. Failure to comply with the CCPA may result in, among other things, significant civil penalties and injunctive relief, or statutory or actual damages. In addition,
                    California residents have the right to bring a private right of action in connection with certain types of security incidents. These claims may result in significant liability and damages. Virginia, Colorado, Connecticut and Utah have
                    also enacted privacy laws that became effective in 2023 and are similar in many respects to the CCPA.</div>

                  <div>&#160;</div>

                  <div style="text-indent: 36pt;">Activities outside of the U.S. implicate local and national data protection standards, impose additional compliance requirements and generate additional risks of enforcement for non-compliance. For example,
                    the European Union&#8217;s General Data Protection Regulation (&#8220;GDPR&#8221;), which imposes fines of up to EUR 20 million or 4% of the annual global revenue of a noncompliant company, whichever is greater, and other data protection, privacy and
                    similar national, state/provincial and local laws may also restrict the access, use and disclosure of patient health information abroad. We may be required to expend significant capital and other resources to ensure ongoing compliance
                    with applicable privacy and data security laws, to protect against security breaches and hackers, or to alleviate problems caused by such breaches. Compliance with these laws is difficult, constantly evolving, time consuming, and
                    requires a flexible privacy framework and substantial resources. Compliance efforts will likely be an increasing and substantial cost in the future.</div>

                  <div><br/>
                  </div>

                  <div style="font-weight: bold; text-indent: -9pt; margin-left: 9pt;">Environmental, Social and Governance (&#8220;ESG&#8221;)</div>

                  <div><br/>
                  </div>

                  <div style="text-indent: 36pt;">Our Code of Ethics and Business Conduct states that employees should strive to conserve resources and reduce water consumption and emissions through recycling and other energy conservation measures.
                    Employees are responsible for promptly reporting any known or suspected violations of environmental laws or any events that may result in a discharge or emissions of hazardous materials. We manufacture, market and develop specialty
                    biologics for the prevention and treatment of infectious diseases in the immune compromised and other patients at risk for infection, and, as such, we consider our environmental impact to be low. These activities do not include either
                    industrial production or distribution, and therefore do not use raw materials that would result in significant releases into the environment or greenhouse gas emissions from our manufacturing emissions.&#160; Further, our activities do not
                    produce any particular noise nuisance for staff or neighboring tenants or residents as well as wildlife surrounding our facilities and offices. Annual electricity and water consumption are monitored and factored into our sustainable
                    resource practices.</div>

                  <div><br/>
                  </div>

                  <div style="font-style: italic; font-weight: bold; text-indent: -9pt; margin-left: 9pt;">Waste Management Policy</div>

                  <div style="text-indent: 36pt;">The objective of our waste management policy is to identify and mitigate risks and hazards with the aim of achieving zero incidents, zero injuries, and zero spills or environmental harm. We are dedicated to
                    the safe handling and management of all non-hazardous and hazardous materials, and all employees are responsible for appropriate waste management.</div>

                  <div><br/>
                  </div>

                  <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
                    <div style="text-align: center; text-indent: -9pt; margin-left: 9pt;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">31</span></div>

                    <div style="page-break-after: always;" class="BRPFPageBreak">
                      <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: rgb(0, 0, 0); background-color: rgb(0, 0, 0);"/></div>

                    <div style="width: 100%;" class="BRPFPageHeader">
                      <div>
                        <div style="text-align: left; font-weight: bold; text-indent: -9pt; margin-left: 9pt;"><a href="#ADMABIOLOGICSINC."> <span style="font-style: italic; font-weight: normal; font-size: 8pt;">Table of Contents</span></a><br/>
                        </div>

                      </div>

                    </div>

                  </div>

                  <div style="text-indent: 36pt;">We are dedicated to high environmental standards and expect all employees to be familiar with and comply with the contents of this policy. We are committed to providing a safe and healthy work environment.
                    We comply with all applicable laws, regulations, and requirements associated with our environmental obligations and impact. We strive for the continual improvement of all environmental impacts associated with our operations. We are
                    committed to the prevention of pollution in all aspects of our business activities, as well as a sustainable approach to the development and provision of our products and services.</div>

                  <div><br/>
                  </div>

                  <div style="font-style: italic; font-weight: bold; text-indent: -9pt; margin-left: 9pt;">Social</div>

                  <div style="text-indent: 36pt;">We actively sponsor and participate in industry-related charitable events on a local and national level and encourage our employees to actively participate and volunteer their time and participation.&#160; We
                    actively support and fund initiatives designed to improve the communities in which we operate and where our employees and stakeholders reside.</div>

                  <div><br/>
                  </div>

                  <div style="font-style: italic; font-weight: bold; text-indent: -9pt; margin-left: 9pt;">Employee Development</div>

                  <div style="text-indent: 36pt;">The ongoing development of our employees continues to be a catalyst for our growth and success as a company. Many of our employees have obtained advanced degrees in their professions. We support our
                    employees&#8217; further development with individualized development plans, mentoring, coaching, department-level training, and conference attendance. Pursuant to our educational assistance policy, we also provide employees interested in
                    furthering their formal education with tuition reimbursement for pre-approved coursework. We often require employees to complete a training effectiveness evaluation for instructor-led trainings at ADMA, and we use the results of these
                    evaluations to improve future in-house trainings.</div>

                  <div><br/>
                  </div>

                  <div style="font-style: italic; font-weight: bold; text-indent: -9pt; margin-left: 9pt;">Health and Safety</div>

                  <div style="text-indent: 36pt;">We remain focused on promoting the total wellness of our employees, including resources, programs and services to support their physical, mental and financial well-being. For example, we host an internal
                    health and wellness portal where employees can learn more about, among other things, mental health and stress management, weight management and financial wellness. The portal includes, among other things, mindfulness and meditation
                    podcasts, flyers and newsletters dedicated to promoting mental health and gym discounts. We have recently bolstered our health insurance to cover the reimbursement of weight management therapies which were previously excluded by our
                    insurance carrier. We have established safety policies and protocols, and we regularly update our employees with respect to any changes. We also encourage those who may be ill to stay home. To further protect our on-site employees, we
                    have provided personal protective equipment and cleaning supplies. We have also provided general information updates and support for our employees to ensure that they have resources and information to protect their health and that of
                    those around them, including their families and co-workers. Furthermore, we offer, at no cost, an Employee Assistance Program (&#8220;EAP&#8221;) to help employees and their dependents confidentially manage personal problems that they feel may
                    adversely affect job performance or personal well-being. The EAP offers personal counseling services for a wide range of concerns, including alcohol abuse, drug abuse, parenting support, marital/family relationships, interpersonal
                    problems on the job, stress, depression, and referrals for financial and/or legal challenges.</div>

                  <div><br/>
                  </div>

                  <div style="font-style: italic; font-weight: bold; text-indent: -9pt; margin-left: 9pt;">Employee Communications and Engagement</div>

                  <div style="text-indent: 36pt;">We employ a variety of tools to facilitate open and direct communication including open forums with executives (such as regular town hall meetings and management meetings), employee surveys and an open-door
                    policy. We endeavor to further refine our employee programs through our employee engagement survey.&#160; We actively monitor employee engagement to foster a supportive and high-performing workplace. In 2023, our engagement survey achieved a
                    92% participation rate, exceeding 91% in 2020, despite a 14% workforce increase - well above industry benchmarks. Results showed a 3% rise in overall engagement and an 11% improvement in leadership communication compared to the 2020
                    survey. Survey results are shared across the organization to provide greater transparency into employee responses and to reinforce how employee feedback directly informs leadership decisions. By consistently tracking and acting on
                    engagement data, we strengthen our commitment to a collaborative, communicative, and employee-focused culture.</div>

                  <div><br/>
                  </div>

                  <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
                    <div style="text-align: center; text-indent: -9pt; margin-left: 9pt;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">32</span></div>

                    <div style="page-break-after: always;" class="BRPFPageBreak">
                      <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: rgb(0, 0, 0); background-color: rgb(0, 0, 0);"/></div>

                    <div style="width: 100%;" class="BRPFPageHeader">
                      <div>
                        <div style="text-align: left; font-weight: bold; text-indent: -9pt; margin-left: 9pt;"><a href="#ADMABIOLOGICSINC."> <span style="font-style: italic; font-weight: normal; font-size: 8pt;">Table of Contents</span></a><br/>
                        </div>

                      </div>

                    </div>

                  </div>

                  <div style="font-style: italic; font-weight: bold; text-indent: -9pt; margin-left: 9pt;">Governance</div>

                  <div style="text-indent: 36pt;">We pursue fair employment practices in every aspect of our business. We strive to ensure and are extremely proud that our Board and our employee base is diverse and consists of individuals of varying
                    gender, origin, sexual orientation and backgrounds with various and relevant career experience, relevant technical skills, education, industry knowledge and experience and possess local or community ties.</div>

                  <div>&#160;</div>

                  <div style="font-weight: bold; text-indent: -9pt; margin-left: 9pt;">Employees</div>

                  <div>&#160;</div>

                  <div style="text-indent: 36pt;">As of December 31, 2024, we had a total of 685 employees, eight of whom are part-time. Over the course of the next year, we anticipate hiring additional full-time employees devoted to compliance,
                    production, quality assurance, quality control, plasma collection and processing, sales and marketing, medical and scientific affairs and administration, as well as hiring additional staff for our plasma collection centers as
                    appropriate. We use Clinical Research Organizations (&#8220;CROs&#8221;), third parties and consultants to perform our post-marketing commitment clinical studies and other process and/or analytical development projects to augment our in-house
                    capabilities and staff.</div>

                  <div style="text-indent: 36pt;">&#160;</div>

                  <div style="font-weight: bold; text-indent: -9pt; margin-left: 9pt;">Corporate Information</div>

                  <div>&#160;</div>

                  <div style="text-align: justify; text-indent: 36pt;">ADMA Biologics, Inc. was founded on June 24, 2004 as a New Jersey corporation and re-incorporated in Delaware on July 16, 2007. We operate through our wholly-owned subsidiaries ADMA
                    BioManufacturing, ADMA BioCenters and ADMA Plasma Biologics. ADMA BioManufacturing was formed in January 2017 to facilitate the acquisition of certain assets held by the Company&#8217;s then-third-party contract manufacturer. ADMA BioCenters
                    is the Company&#8217;s source plasma collection business which operates in the U.S. Each of ADMA&#8217;s ten operational plasma collection centers have a license with the FDA and may obtain additional certifications from other regulatory agencies.</div>

                  <div style="text-align: justify;">&#160;</div>

                  <div style="text-indent: 36pt;">We maintain our headquarters at 465 State Route 17, Ramsey, NJ 07446. Our telephone number is (201) 478-5552. Our Florida campus is located at 5800 Park of Commerce Boulevard, Northwest, Boca Raton, FL
                    33487. The Florida telephone number is (561) 989-5800. We maintain a website at www.admabiologics.com; however, the information on, or that can be accessed through, our website is not part of this Annual Report on Form 10-K. This Annual
                    Report and all of our filings under the Exchange Act, including copies of Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, and any amendments to those reports, are available free of charge
                    through our website on the date we file those materials with, or furnish them to, the U.S. Securities and Exchange Commission (the &#8220;SEC&#8221;). Such filings are also available to the public on the SEC&#8217;s website at www.sec.gov.</div>

                  <div><br/>
                  </div>

                  <div>
                    <a id="RiskFactors"><!--Anchor--></a>
<table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-spacing: 0;" class="DSPFListTable">


  <tr style="vertical-align: top;">

    <td style="text-align: right; vertical-align: top; width: 45pt;">
                            <div style="text-align: left; font-weight: bold;">Item 1A.</div>
                          </td>

    <td style="text-align: left; vertical-align: top; width: auto;">
                            <div style="font-weight: bold;">Risk Factors</div>
                          </td>

  </tr>


</table>
                  </div>

                  <div style="font-weight: bold;">&#160;</div>

                  <div style="font-weight: bold; text-indent: -9pt; margin-left: 9pt;">Summary of Risk Factors</div>

                  <div><br/>
                  </div>

                  <div style="font-style: italic; text-indent: 0pt;">Below is a summary of the principal factors that make an investment in our common stock speculative or risky. This summary does not address all of the risks that we face. Additional
                    discussion of the risks summarized in this risk factor summary, and other risks that we face, can be found below under the heading &#8220;Risk Factors&#8221; and should be carefully considered, together with other information in this Form 10-K and
                    our other filings with the SEC, before making an investment decision regarding our common stock.</div>

                  <div>&#160;</div>

                  <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0); border-spacing: 0;">


  <tr>

    <td style="width: 18pt;"><br/>
                        </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
                          <div>Although we achieved net income on a GAAP basis for the year ended December 31, 2024 for the first time, we may not be able to maintain profitability and continue to generate positive cashflows in the future.</div>
                        </td>

  </tr>


</table>
                  <div>&#160;</div>

                  <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0); border-spacing: 0;">


  <tr>

    <td style="width: 18pt;"><br/>
                        </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
                          <div>We contract with third parties for the filling, packaging, testing and labeling of the drug substance we manufacture, and we also obtain source plasma from certain third parties. This reliance on third parties carries the
                            risk that the services and raw materials upon which we rely may not be performed in a timely manner, in sufficient quantities or according to our specifications, which could delay the availability of our finished drug product
                            and could adversely affect our commercialization efforts and our revenues.</div>
                        </td>

  </tr>


</table>
                  <div>&#160;</div>

                  <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0); border-spacing: 0;">


  <tr>

    <td style="width: 18pt;"><br/>
                        </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
                          <div>The estimates of market opportunity and forecasts of market and revenue growth included in our filings may prove to be inaccurate, and even if the markets in which we compete achieve the forecasted growth, our business could
                            fail to grow at similar rates, if at all.</div>
                        </td>

  </tr>


</table>
                  <div>&#160;</div>

                  <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
                    <div style="text-align: center; text-indent: -9pt; margin-left: 9pt;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">33</span></div>

                    <div style="page-break-after: always;" class="BRPFPageBreak">
                      <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: rgb(0, 0, 0); background-color: rgb(0, 0, 0);"/></div>

                    <div style="width: 100%;" class="BRPFPageHeader">
                      <div>
                        <div style="text-align: left; font-weight: bold; text-indent: -9pt; margin-left: 9pt;"><a href="#ADMABIOLOGICSINC."> <span style="font-style: italic; font-weight: normal; font-size: 8pt;">Table of Contents</span></a><br/>
                        </div>

                      </div>

                    </div>

                  </div>

                  <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0); border-spacing: 0;">


  <tr>

    <td style="width: 18pt;"><br/>
                        </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
                          <div>Both of our business segments and our facilities, as well as our suppliers and contractors, are subject to periodic inspections by the FDA and other regulatory authorities, which, depending on the outcome of such inspections,
                            could result in certain regulatory actions, including the issuance of observations, notices, citations, warning letters or other enforcement actions.</div>
                        </td>

  </tr>


</table>
                  <div>&#160;</div>

                  <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0); border-spacing: 0;">


  <tr>

    <td style="width: 18pt;"><br/>
                        </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
                          <div>Business interruptions could adversely affect our business.</div>
                        </td>

  </tr>


</table>
                  <div>&#160;</div>

                  <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0); border-spacing: 0;">


  <tr>

    <td style="width: 18pt;"><br/>
                        </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
                          <div>Although we have received approval from the FDA to market ASCENIV as a treatment for PIDD, our ability to market or seek approval for ASCENIV for alternative indications could be limited unless additional clinical trials are
                            conducted successfully and the FDA approves a Biologics License Application (&#8220;BLA&#8221;) or other required submission for review.</div>
                        </td>

  </tr>


</table>
                  <div>&#160;</div>

                  <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0); border-spacing: 0;">


  <tr>

    <td style="width: 18pt;"><br/>
                        </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
                          <div>With the approval of ASCENIV, there can be no assurance that we will be successful in further developing and expanding commercial operations, collecting and procuring an adequate supply of high-titer antibody RSV plasma or
                            balancing our research and development activities with our commercialization activities.</div>
                        </td>

  </tr>


</table>
                  <div>&#160;</div>

                  <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0); border-spacing: 0;">


  <tr>

    <td style="width: 18pt;"><br/>
                        </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
                          <div>We depend on third-party researchers, developers and vendors to develop, manufacture, supply materials for or test our products and product candidates, as well as for other pre-and post-approval services, and such parties&#8217;
                            performance is, to some extent, outside of our control.</div>
                        </td>

  </tr>


</table>
                  <div>&#160;</div>

                  <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0); border-spacing: 0;">


  <tr>

    <td style="width: 18pt;"><br/>
                        </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
                          <div>We may be unable to successfully expand our manufacturing processes to fulfill demand for our products or increase our production capabilities through the addition of new equipment, including if we do not obtain requisite
                            approval from the FDA.</div>
                        </td>

  </tr>


</table>
                  <div>&#160;</div>

                  <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0); border-spacing: 0;">


  <tr>

    <td style="width: 18pt;"><br/>
                        </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
                          <div>Our products, and any additional products for which we may obtain marketing approval in the future, could be subject to post-marketing restrictions or withdrawal from the market and we could be subject to substantial
                            penalties if we fail to comply with regulatory requirements or if we experience unanticipated problems with our products following approval.</div>
                        </td>

  </tr>


</table>
                  <div>&#160;</div>

                  <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0); border-spacing: 0;">


  <tr>

    <td style="width: 18pt;"><br/>
                        </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
                          <div>Historically, a few customers have accounted for a significant amount of our total revenue and accounts receivable and the loss of any of these customers could have a material adverse effect on our business, results of
                            operations and financial condition.</div>
                        </td>

  </tr>


</table>
                  <div>&#160;</div>

                  <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0); border-spacing: 0;">


  <tr>

    <td style="width: 18pt;"><br/>
                        </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
                          <div>Issues with product quality and compliance could have a material adverse effect upon our business, subject us to regulatory actions and cause a loss of customer confidence in us or our products.</div>
                        </td>

  </tr>


</table>
                  <div>&#160;</div>

                  <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0); border-spacing: 0;">


  <tr>

    <td style="width: 18pt;"><br/>
                        </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
                          <div>If physicians, payers and patients do not accept and use our current products or our future product candidates, our ability to generate revenue from these products will be materially impaired.</div>
                        </td>

  </tr>


</table>
                  <div>&#160;</div>

                  <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0); border-spacing: 0;">


  <tr>

    <td style="width: 18pt;"><br/>
                        </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
                          <div>Our accruals for U.S. Medicaid rebates and other liabilities related to the sale of our immunoglobulin products are estimates based on historical experience and other assumptions. These estimates are subject to change based
                            on actual results and other factors. Any such change could have a material effect on our business, financial position and operating results.</div>
                        </td>

  </tr>


</table>
                  <div>&#160;</div>

                  <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0); border-spacing: 0;">


  <tr>

    <td style="width: 18pt;"><br/>
                        </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
                          <div>Our long-term success may depend on our ability to supplement our existing product portfolio through new product development or the in-license or acquisition of other new products, product candidates and label expansion of
                            existing products, and if our business development efforts are not successful, our ability to maintain profitability may be adversely impacted.</div>
                        </td>

  </tr>


</table>
                  <div>&#160;</div>

                  <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0); border-spacing: 0;">


  <tr>

    <td style="width: 18pt;"><br/>
                        </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
                          <div>Our ADMA BioCenters operations collect information from donors in the United States that subjects us to consumer and health privacy laws, which could create enforcement and litigation exposure if we fail to meet their
                            requirements.</div>
                        </td>

  </tr>


</table>
                  <div>&#160;</div>

                  <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0); border-spacing: 0;">


  <tr>

    <td style="width: 18pt;"><br/>
                        </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
                          <div>Our senior secured credit facility with Ares Capital Corporation and certain of its affiliates (&#8220;Ares&#8221;) is subject to acceleration in specified circumstances, which may result in Ares taking possession and disposing of any
                            collateral.</div>
                        </td>

  </tr>


</table>
                  <div>&#160;</div>

                  <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0); border-spacing: 0;">


  <tr>

    <td style="width: 18pt;"><br/>
                        </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
                          <div>If we are unable to protect our patents, trade secrets or other proprietary rights, if our patents are challenged or if our provisional patent applications do not get approved, our competitiveness and business prospects may
                            be materially damaged.</div>
                        </td>

  </tr>


</table>
                  <div>&#160;</div>

                  <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0); border-spacing: 0;">


  <tr>

    <td style="width: 18pt;"><br/>
                        </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
                          <div>Cyberattacks and other security breaches could compromise our proprietary and confidential information or otherwise penetrate our network, which could harm our business and reputation.</div>
                        </td>

  </tr>


</table>
                  <div>&#160;</div>

                  <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
                    <div style="text-align: center; text-indent: -9pt; margin-left: 9pt;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">34</span></div>

                    <div style="page-break-after: always;" class="BRPFPageBreak">
                      <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: rgb(0, 0, 0); background-color: rgb(0, 0, 0);"/></div>

                    <div style="width: 100%;" class="BRPFPageHeader">
                      <div>
                        <div style="text-align: left; font-weight: bold; text-indent: -9pt; margin-left: 9pt;"><a href="#ADMABIOLOGICSINC."> <span style="font-style: italic; font-weight: normal; font-size: 8pt;">Table of Contents</span></a><br/>
                        </div>

                      </div>

                    </div>

                  </div>

                  <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0); border-spacing: 0;">


  <tr>

    <td style="width: 18pt;"><br/>
                        </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
                          <div>Our ability to continue to produce safe and effective products depends on the safety of our plasma supply, testing by third parties and the timing of receiving the testing results, and the manufacturing processes we have in
                            place to counter transmittable diseases.</div>
                        </td>

  </tr>


</table>
                  <div>&#160;</div>

                  <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0); border-spacing: 0;">


  <tr>

    <td style="width: 18pt;"><br/>
                        </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
                          <div>We could become supply-constrained and our financial performance would suffer if we cannot obtain adequate quantities of FDA-approved source and high-titer plasma with proper specifications or other necessary raw materials.</div>
                        </td>

  </tr>


</table>
                  <div>&#160;</div>

                  <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0); border-spacing: 0;">


  <tr>

    <td style="width: 18pt;"><br/>
                        </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
                          <div>Our ability to use our net operating loss carryforwards (&#8220;NOLs&#8221;) may be limited.</div>
                        </td>

  </tr>


</table>
                  <div>&#160;</div>

                  <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0); border-spacing: 0;">


  <tr>

    <td style="width: 18pt;"><br/>
                        </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
                          <div>Fluctuations in our tax obligations and effective tax rate and realization of our net deferred tax assets may result in volatility of our operating results and materially impact our financial condition or financial results.</div>
                        </td>

  </tr>


</table>
                  <div>&#160;</div>

                  <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0); border-spacing: 0;">


  <tr>

    <td style="width: 18pt;"><br/>
                        </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
                          <div>The market price of our common stock may be volatile and may fluctuate in a way that is disproportionate to our operating performance.</div>
                        </td>

  </tr>


</table>
                  <div><br/>
                  </div>

                  <div style="font-weight: bold; text-indent: -9pt; margin-left: 9pt;">Risk Factors</div>

                  <div style="font-weight: bold;"> <br/>
                  </div>

                  <div style="font-style: italic; text-indent: 0pt;">Described below are various risks and uncertainties that may affect our business. These risks and uncertainties are not the only ones we face. You should recognize that other significant
                    risks and uncertainties may arise in the future, which we cannot foresee at this time. Also, the risks that we now foresee might affect us to a greater or different degree than expected. Certain risks and uncertainties, including ones
                    that we currently deem immaterial or that are similar to those faced by other companies in our industry or business in general, may also affect our business. If any of the risks described below actually occur, our business, financial
                    condition or results of operations could be materially and adversely affected. You should carefully consider the following risk factors and the section entitled &#8220;Special Note Regarding Forward-Looking Statements&#8221; before you decide to
                    invest in our securities.</div>

                  <div><br/>
                  </div>

                  <div style="font-weight: bold; text-indent: -9pt; margin-left: 9pt;">Risks Relating to our Business</div>

                  <div style="font-style: italic; font-weight: bold; text-indent: 9pt;">&#160;</div>

                  <div style="font-weight: bold; text-indent: 0pt; font-style: italic;">Although we achieved net income on a GAAP basis for the year ended December 31, 2024 for the first time, we may not be able to maintain profitability&#160; andcontinue to
                    generate positive cash flows in the future.</div>

                  <div>&#160;</div>

                  <div style="text-indent: 36pt;">We have a history of losses through December 31, 2023, and we may not be able to maintain profitability. Although we achieved net income of $197.7 million for the year ended December 31, 2024, for the years
                    ended December 31, 2023 and 2022, we incurred net losses of $28.2 million and $65.9 million, respectively. From our inception in 2004 through December 31, 2024, we have incurred an accumulated deficit of $308.6 million. We may not be
                    able to maintain profitability in 2025 or beyond, and if we are unable to continue to consistently achieve positive cash flows we may need to finance our operations through additional equity or debt financings or corporate collaboration
                    and licensing agreements. If, in the future, our operating or financial results for a particular period do not meet our guidance, analyst estimates or the expectations of investors, or if we reduce our guidance for future periods, our
                    stock price may decline. Any sustained or increased profitability or financial performance may contribute to increased scrutiny from the investment community and applicable federal, state and foreign regulatory authorities and
                    government bodies. We also expect to continue to incur significant operating and capital expenditures and anticipate that as our business continues to grow our operating expenses will increase accordingly as we:</div>

                  <div>&#160;&#160;</div>

                  <div>
                    <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0); border-spacing: 0;">


  <tr>

    <td style="width: 18pt;">&#160;</td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
                            <div>expand commercialization and marketing efforts;</div>
                          </td>

  </tr>


</table>
                    <div><br/>
                    </div>

                    <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0); border-spacing: 0;">


  <tr>

    <td style="width: 18pt;"><br/>
                          </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
                            <div>expand our research and development programs;</div>
                          </td>

  </tr>


</table>
                    <div style="text-indent: -36pt; margin-left: 36pt;">&#160;</div>

                    <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0); border-spacing: 0;">


  <tr>

    <td style="width: 18pt;"><br/>
                          </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
                            <div>implement additional internal systems, controls and infrastructure;</div>
                          </td>

  </tr>


</table>
                    <div style="text-indent: -36pt; margin-left: 36pt;">&#160;</div>

                    <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0); border-spacing: 0;">


  <tr>

    <td style="width: 18pt;"><br/>
                          </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
                            <div>hire additional personnel; and</div>
                          </td>

  </tr>


</table>
                    <div><br/>
                    </div>

                    <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0); border-spacing: 0;">


  <tr>

    <td style="width: 18pt;"><br/>
                          </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
                            <div>expand production capacity at the Boca Facility.</div>
                          </td>

  </tr>


</table>
                  </div>

                  <div> <br/>
                  </div>

                  <div style="text-indent: 36pt;">As a result, we will need to continue to generate significant revenues in order to maintain profitability. We may not be able to generate these revenues or maintain profitability in the future.</div>

                  <div><br/>
                  </div>

                  <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
                    <div style="text-align: center; text-indent: -9pt; margin-left: 9pt;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">35</span></div>

                    <div style="page-break-after: always;" class="BRPFPageBreak">
                      <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: rgb(0, 0, 0); background-color: rgb(0, 0, 0);"/></div>

                    <div style="width: 100%;" class="BRPFPageHeader">
                      <div>
                        <div style="text-align: left; font-weight: bold; text-indent: -9pt; margin-left: 9pt;"><a href="#ADMABIOLOGICSINC."> <span style="font-style: italic; font-weight: normal; font-size: 8pt;">Table of Contents</span></a><br/>
                        </div>

                      </div>

                    </div>

                  </div>

                  <div>
                    <div style="font-style: italic; font-weight: bold; text-indent: -9pt; margin-left: 9pt;">Pandemics, or a resurgence of a pandemic, may adversely affect our business, financial condition, liquidity or results of operations.</div>

                    <div>&#160;</div>

                  </div>

                  <div>
                    <div style="text-indent: 36pt;">The COVID-19 pandemic negatively impacted certain aspects of our business and operations. The resurgence of the COVID-19 pandemic, or a future pandemic or health epidemic, could adversely affect our
                      business, financial condition, liquidity or results of operations. These adverse effects include, but are not limited to, the potential adverse effects on the global economy, our manufacturing processes, including our supply chain,
                      our submissions or applications to the FDA and our employees. The ultimate impact will depend on the severity and duration of the pandemic and actions taken by governmental authorities and other third parties in response, each of
                      which is unforeseeable and difficult to predict.</div>

                  </div>

                  <div><br/>
                  </div>

                  <div style="font-style: italic; font-weight: bold; text-indent: 0pt;">We contract with third parties for a portion of the filling, packaging, testing and labeling of the drug substance we manufacture, and also obtain plasma from certain
                    third parties. This reliance on third parties carries the risk that the services and raw materials upon which we rely may not be performed in a timely manner, in sufficient quantities or according to our specifications, which could
                    delay the availability of our finished drug product and could adversely affect our commercialization efforts and our revenues.</div>

                  <div><br/>
                  </div>

                  <div style="text-indent: 36pt;">Third parties may not perform as agreed or in accordance with FDA requirements. Any significant problem that our third-party providers experience could delay or interrupt our supply of finished drug product
                    until the service provider cures the problem or until we locate, negotiate for, validate and receive FDA approval for an alternative provider (when necessary), if one is available. Failure to obtain the needed services, raw materials
                    and products meeting the necessary quality standards or at all could have a material and adverse effect on our products, business, financial condition and results from operations.</div>

                  <div><br/>
                  </div>

                  <div style="text-indent: 36pt;">Although we are utilizing our FDA-approved fill/finish suite that we built at the Boca Facility for a portion of our finished drug product and although we receive our raw material plasma from our ADMA
                    BioCenters plasma collection facilities, we also intend to continue to utilize third parties to supplement our fill/finish process for final drug product and to supply raw material source and high-titer RSV plasma. Any failure by us,
                    our contract fill/finishers, or other third parties involved in the process for producing our products or product candidates to comply with the applicable manufacturing and regulatory requirements, including quality requirements, could
                    place us and them at risk of regulatory enforcement actions, recalls and other adverse consequences, could adversely impact our products, and could adversely impact patients receiving our products, which may negatively impact our
                    business and our ability to produce and supply products to meet commercial and clinical needs.</div>

                  <div><br/>
                  </div>

                  <div style="text-indent: 36pt;">Our anticipated reliance on a limited number of third-party contractors exposes us to the following risks:</div>

                  <div><br/>
                  </div>

                  <div>
                    <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0); border-spacing: 0;">


  <tr>

    <td style="width: 36pt; vertical-align: top; text-align: center;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
                            <div>we may be unable to identify contractors on acceptable terms or at all because the number of potential service providers is limited and the FDA must inspect and qualify any contract manufacturers for current cGMP compliance
                              as part of our marketing application;</div>
                          </td>

  </tr>


</table>
                    <div> <br/>
                    </div>

                    <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0); border-spacing: 0;">


  <tr>

    <td style="width: 36pt; vertical-align: top; text-align: center;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
                            <div>a new fill/finisher would have to be educated in, or develop substantially equivalent processes for, the production of our products and product candidates;</div>
                          </td>

  </tr>


</table>
                    <div> <br/>
                    </div>

                    <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0); border-spacing: 0;">


  <tr>

    <td style="width: 36pt; vertical-align: top; text-align: center;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
                            <div>a pandemic, or the resurgence of a pandemic such as the COVID-19 pandemic, or a cyberattack or data breach, could adversely affect our contractors&#8217; operations, supply chain or workforce;</div>
                          </td>

  </tr>


</table>
                    <div> <br/>
                    </div>

                    <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0); border-spacing: 0;">


  <tr>

    <td style="width: 36pt; vertical-align: top; text-align: center;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
                            <div>our contracted fill/finishers&#8217; resources and level of expertise with plasma-derived biologics may be limited, therefore they may require a significant amount of support from us in order to implement and maintain the
                              infrastructure and processes required to deliver our finished drug product;</div>
                          </td>

  </tr>


</table>
                    <div> <br/>
                    </div>

                    <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0); border-spacing: 0;">


  <tr>

    <td style="width: 36pt; vertical-align: top; text-align: center;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
                            <div>our third-party contractors might be unable to timely provide finished drug product or raw material plasma in sufficient quantity or in accordance with our specifications to meet our commercial needs;</div>
                          </td>

  </tr>


</table>
                    <div> <br/>
                    </div>

                    <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0); border-spacing: 0;">


  <tr>

    <td style="width: 36pt; vertical-align: top; text-align: center;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
                            <div>contractors may not be able to execute our inspection procedures and required tests appropriately;</div>
                          </td>

  </tr>


</table>
                    <div> <br/>
                    </div>

                    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
                      <div style="text-align: center; text-indent: -9pt; margin-left: 9pt;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">36</span></div>

                      <div style="page-break-after: always;" class="BRPFPageBreak">
                        <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: rgb(0, 0, 0); background-color: rgb(0, 0, 0);"/></div>

                      <div style="width: 100%;" class="BRPFPageHeader">
                        <div>
                          <div style="text-align: left; font-weight: bold; text-indent: -9pt; margin-left: 9pt;"><a href="#ADMABIOLOGICSINC."> <span style="font-style: italic; font-weight: normal; font-size: 8pt;">Table of Contents</span></a><br/>
                          </div>

                        </div>

                      </div>

                    </div>

                    <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0); border-spacing: 0;">


  <tr>

    <td style="width: 36pt; vertical-align: top; text-align: center;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
                            <div>contractors are subject to ongoing periodic unannounced inspection by the FDA and corresponding state agencies to ensure strict compliance with cGMP and other government regulations, and we do not have control over
                              third-party providers&#8217; compliance with these regulations;</div>
                          </td>

  </tr>


</table>
                    <div> <br/>
                    </div>

                    <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0); border-spacing: 0;">


  <tr>

    <td style="width: 36pt; vertical-align: top; text-align: center;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
                            <div>contractors may fail to comply with applicable regulatory requirements, placing them and us at risk of regulatory enforcement actions, recalls and other adverse consequences, and which place our patients at risk, which may
                              negatively impact our business and their ability to supply products to meet our development, clinical and commercial needs;</div>
                          </td>

  </tr>


</table>
                    <div> <br/>
                    </div>

                    <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0); border-spacing: 0;">


  <tr>

    <td style="width: 36pt; vertical-align: top; text-align: center;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
                            <div>our third parties could breach or terminate their agreements with us; and</div>
                          </td>

  </tr>


</table>
                    <div> <br/>
                    </div>

                    <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0); border-spacing: 0;">


  <tr>

    <td style="width: 36pt; vertical-align: top; text-align: center;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
                            <div>our contract fill/finishers may have unacceptable or inconsistent drug product quality success rates and yields, and we have no direct control over our contract fill/finishers&#8217; ability to maintain adequate quality control,
                              quality assurance and qualified personnel.</div>
                          </td>

  </tr>


</table>
                  </div>

                  <div><br/>
                  </div>

                  <div style="text-indent: 0pt;">Each of these risks could delay or prevent production, the completion of our finished drug product and the release of finished drug product by us or the FDA, which could result in higher costs or adversely
                    impact our revenues. These risks could also result in the delay in obtaining clinical supplies, which would delay our development programs. In addition, our contract fill/finishers and our other third-party vendors may source their
                    materials and supplies globally and are therefore subject to supply disruptions in the event of fire, weather related events such as hurricanes, wind and rain, international conflicts, strikes, embargoes, trade and sanction requirements
                    and limits, other acts of God or force majeure events or global health occurrences and emergencies.</div>

                  <div><br/>
                  </div>

                  <div style="font-style: italic; font-weight: bold; text-indent: 0pt;">The estimates of market opportunity and forecasts of market and revenue growth included in our filings may prove to be inaccurate, and even if the markets in which we
                    compete achieve the forecasted growth, our business could fail to grow at similar rates, if at all.</div>

                  <div><br/>
                  </div>

                  <div style="text-indent: 36pt;">Market opportunity estimates and growth forecasts are subject to significant uncertainty and are based on assumptions and estimates that may not prove to be accurate. In particular, the size and growth of
                    the overall U.S. IVIG and source plasma markets and the potential market opportunity for an<span style="font-style: italic;"> S. pneumoniae</span> hyperimmune globulin are subject to significant variables that can be difficult to
                    measure, estimate or quantify. Additionally, we anticipate receiving FDA approval by mid-2025 for the PAS for our innovative yield enhancement production process, which has demonstrated an ability to increase production yields by
                    approximately 20% from the same starting plasma volume, potentially driving significant increases to financial targets beginning in the second half of 2025, if approved. Although our financial targets for 2025 and 2026 described in Part
                    1, Item 1. Business- Overview do not account for the potential FDA approval of our innovative yield enhancement production process, in the event that the FDA does not approve the PAS, or in the event that such approval occurs after
                    mid-2025, our growth rate may be materially impacted.</div>

                  <div><br/>
                  </div>

                  <div style="text-indent: 36pt;">Our business depends on, among other things, successful commercialization of our existing products, market acceptance of such products and ensuring that our products are safe and effective. Further, there
                    can be no assurance that we will be able to generate the revenue that we believe our products and plasma collection facilities are capable of generating. As a result, we may not be able to accurately forecast or predict revenue. For
                    these reasons, the estimates and forecasts in our filings relating to revenue generation and growth may prove to be inaccurate. Even if the markets in which we compete meet our size estimates and forecasted growth, our business could
                    fail to grow at similar rates, if at all.</div>

                  <div><br/>
                  </div>

                  <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
                    <div style="text-align: center; text-indent: -9pt; margin-left: 9pt;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">37</span></div>

                    <div style="page-break-after: always;" class="BRPFPageBreak">
                      <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: rgb(0, 0, 0); background-color: rgb(0, 0, 0);"/></div>

                    <div style="width: 100%;" class="BRPFPageHeader">
                      <div>
                        <div style="text-align: left; font-weight: bold; text-indent: -9pt; margin-left: 9pt;"><a href="#ADMABIOLOGICSINC."> <span style="font-style: italic; font-weight: normal; font-size: 8pt;">Table of Contents</span></a><br/>
                        </div>

                      </div>

                    </div>

                  </div>

                  <div style="font-style: italic; font-weight: bold; text-indent: -9pt; margin-left: 9pt;">Geopolitical and economic conditions, war, terrorism or other military actions may have a material adverse effect on our business.</div>

                  <div><br/>
                  </div>

                  <div style="text-indent: 36pt;">Geopolitical conflicts, war or other military action or international acts of terrorism may cause significant disruption to commerce throughout the world. To the extent that such disruptions result in
                    disruptions to our supply chain, delays or cancellations of customer orders, a general decrease in consumer spending, our inability to effectively market and distribute our products and/or our inability to access the capital markets,
                    our business and results of operations could be materially and adversely affected. For example, in response to the ongoing conflict between Russia and Ukraine, the United States has imposed and may further impose, and other countries
                    may additionally impose, broad sanctions or other restrictive actions against governmental and other entities in Russia. Additionally, further escalation of geopolitical tensions, such as ongoing conflicts in the Middle East and the
                    surrounding areas could have a broader impact that extends into other markets where we do business. Additionally, rapid changes in U.S. trade policy, such as the imposition of additional tariffs and trade barriers, as well as potential
                    retaliatory measures taken by other governments, could increase the price of and/or affect the availability of imported raw materials used in the production of our products. We are unable to predict whether geopolitical or economic
                    conditions, acts of international terrorism or the involvement in a war or other military actions will result in any long-term commercial disruptions or if such involvement or responses will have any long-term material adverse effect on
                    our business, results of operations, or financial condition.</div>

                  <div><br/>
                  </div>

                  <div style="font-style: italic; font-weight: bold; text-indent: 0pt;">Both of our business segments and our facilities, as well as our suppliers and contractors, are subject to periodic inspections by the FDA and other regulatory
                    authorities, which, depending on the outcome of such inspections, could result in certain regulatory actions, including the issuance of observations, notices, citations, warning letters or other enforcement actions.</div>

                  <div><br/>
                  </div>

                  <div style="text-indent: 36pt;">We and our suppliers and contractors may be unable to comply with our specifications, cGMP requirements and with other FDA, state, and foreign regulatory requirements for commercial and clinical supply. The
                    FDA and other regulatory authorities are authorized to perform inspections and remote regulatory assessments of our and our suppliers&#8217; facilities, including the Boca Facility. The FDA and other regulatory authorities also may inspect
                    and approve our and our third-parties&#8217; facilities before they may be used for commercial production. If we or our suppliers are not able to comply with the applicable regulatory requirements, we or they may be subject to regulatory
                    enforcement actions, which can materially impact our business. For instance, at the end of such an inspection, the FDA could issue a Form 483 Notice of Inspectional Observations, which could cause the FDA to not approve the use of the
                    facility and cause us to modify certain activities identified during the inspection. Following such inspections, the FDA may issue an untitled letter as an initial correspondence that cites violations that do not meet the threshold of
                    regulatory significance of a warning letter. FDA guidelines also provide for the issuance of warning letters for violations of &#8220;regulatory significance&#8221; for which the failure to adequately and promptly achieve correction may be expected
                    to result in an enforcement action. FDA also may issue warning letters and untitled letters in connection with events or circumstances unrelated to an FDA inspection. Depending on the seriousness of any findings, we or our suppliers may
                    be subject to additional significant enforcement actions which could have a material impact on our business.</div>

                  <div><br/>
                  </div>

                  <div style="text-indent: 36pt;">In the event of any enforcement actions, we and our third-party contractors would need to implement remedial actions which may be time-intensive or costly. We may not be able to timely resolve concerns
                    raised by the applicable regulator as a result of an inspection or without expending significant resources. We are unable to control the timing of inspections, communications and actions, and will be required to respond to the regulator
                    and make certain submissions within certain timeframes. We also do not know whether or not the regulator will change its requirements, guidance or expectations. If the regulator determines that we have not remediated the issues
                    identified in a warning letter or any other inspection issues and deficiencies, any failure of ours to address or provide requested documentation of corrections for these issues could disrupt our business operations and the timing of
                    our commercialization efforts and could have a material adverse effect on our financial condition and operating results.</div>

                  <div><br/>
                  </div>

                  <div style="font-style: italic; font-weight: bold; text-indent: 0pt;">If we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could have a material
                    adverse effect on the success of our business.</div>

                  <div><br/>
                  </div>

                  <div style="text-indent: 36pt;">We are subject to numerous environmental, health and safety laws and regulations, including those governing laboratory procedures and the handling, use, storage, treatment and disposal of hazardous
                    materials and wastes. Our commercial manufacturing and any research and development activities involve the use of biological and hazardous materials and produce hazardous waste products. We generally contract with third parties for the
                    disposal of these materials. We cannot eliminate the risk of contamination or injury from these materials, which could cause an interruption to our commercialization efforts, research and development efforts and business operations,
                    environmental damage resulting in costly clean-up and liabilities under applicable laws and regulations governing the use, storage, handling and disposal of these materials and specified waste products. Although we believe that the
                    safety procedures utilized internally and by our third-party manufacturers and service providers for handling and disposing of these materials generally comply with the standards prescribed by these laws and regulations, we cannot
                    guarantee that this is the case or eliminate the risk of accidental contamination or injury from these materials. In such an event, we may be held liable for any resulting damages and such liability could exceed our resources and state
                    or federal or other applicable authorities may curtail our use of certain materials and/or interrupt our business operations. Furthermore, environmental laws and regulations are complex, change frequently and have tended to become more
                    stringent. We cannot predict the impact of such changes and cannot be certain of our future compliance. In addition, we may incur substantial costs in order to comply with current or future environmental, health and safety laws and
                    regulations. These current or future laws and regulations may impair our commercial manufacturing, research and development, or production efforts. Failure to comply with these laws and regulations also may result in substantial fines,
                    penalties, or other sanctions.</div>

                  <div><br/>
                  </div>

                  <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
                    <div style="text-align: center; text-indent: -9pt; margin-left: 9pt;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">38</span></div>

                    <div style="page-break-after: always;" class="BRPFPageBreak">
                      <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: rgb(0, 0, 0); background-color: rgb(0, 0, 0);"/></div>

                    <div style="width: 100%;" class="BRPFPageHeader">
                      <div>
                        <div style="text-align: left; font-weight: bold; text-indent: -9pt; margin-left: 9pt;"><a href="#ADMABIOLOGICSINC."> <span style="font-style: italic; font-weight: normal; font-size: 8pt;">Table of Contents</span></a><br/>
                        </div>

                      </div>

                    </div>

                  </div>

                  <div style="text-indent: -9pt; margin-left: 9pt;"><span style="font-weight: bold; font-style: italic;">Business interruptions could adversely affect our business</span><span style="font-weight: bold;">.</span>&#160;</div>

                  <div>&#160;</div>

                  <div style="text-indent: 36pt;">Our operations, including our headquarters located in Ramsey, NJ, the Boca Facility and our plasma collection facilities, are vulnerable to interruption by fire, weather related events such as hurricanes,
                    wind and rain, other acts of God or force majeure events, electric power loss, telecommunications failure, equipment failure and breakdown, cyberattacks on our operations and information technology systems as well as the systems of our
                    customers, suppliers and related entities, human error, employee issues, global health occurrences such as a pandemic, global and economic uncertainty, war, terrorism, geopolitical conditions and emergencies, product liability claims
                    and events beyond our control. While we maintain several insurance policies with reputable carriers that provide partial coverage for a variety of these risks, including replacing or rebuilding a part of our facilities, these policies
                    are subject to the insurance carriers&#8217; final determination of compensation to us and we may not have adequate coverage if we need to rebuild or replace our inventory, infrastructure, business income or our entire facility.&#160; In addition,
                    our disaster recovery plans for our facilities may not be adequate and we do not have an alternative manufacturing facility or contractual arrangements with other manufacturers in the event of a casualty to or destruction of any of our
                    facilities. If we are required to rebuild or relocate any of our facilities, a substantial investment in improvements and equipment would be necessary. We carry only a limited amount of business interruption insurance, which may not
                    sufficiently compensate us for losses that may occur. As a result, any significant business interruption could adversely affect our business and results of operations.&#160;</div>

                  <div><br/>
                  </div>

                  <div style="margin: 0px; font-style: italic; font-weight: bold; text-indent: 0pt;">If we are unsuccessful in obtaining regulatory approval for any of our product candidates or if any of our product candidates do not provide positive
                    results, we may be required to delay or abandon development of such product, which would have a material adverse impact on our business.</div>

                  <div>&#160;</div>

                  <div style="text-indent: 36pt;">Product candidates require extensive clinical data analysis and regulatory review and may require additional testing. Clinical trials and data analysis can be very expensive, time-consuming and difficult to
                    design and implement. The conduct of preclinical studies and clinical trials is subject to numerous risks and results of the studies and trials are highly uncertain.<span style="font-weight: bold; font-style: italic;">&#160;</span>Human
                    clinical trials are very expensive and difficult to design and implement, in part because they are subject to rigorous regulatory requirements. The clinical trial process is also time-consuming. Furthermore, delays or setbacks can occur
                    at any stage of the process, and we could encounter problems that cause us to abandon our product development programs and related IND applications or BLAs, or to repeat clinical trials. The commencement and completion of clinical
                    trials or ultimate product approval for any current or future development product candidate may be delayed by several factors, including:</div>

                  <div>&#160;</div>

                  <div>
                    <div>
                      <div>
                        <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-spacing: 0;">


  <tr style="vertical-align: top;">

    <td style="width: 18pt;">&#160;</td>

    <td style="text-align: right; vertical-align: top; width: 18pt;">
                                <div style="text-align: left; text-indent: -9pt; margin-left: 9pt;">&#8226;</div>
                              </td>

    <td style="text-align: left; vertical-align: top; width: auto;">
                                <div style="text-align: left; text-indent: -9pt; margin-left: 9pt;">unforeseen safety issues;</div>
                              </td>

  </tr>


</table>
                      </div>

                    </div>

                    <div style="text-indent: -36pt; margin-left: 36pt;">&#160;</div>

                    <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0); border-spacing: 0;">


  <tr>

    <td style="width: 18pt;"><br/>
                          </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
                            <div>determination of dosing issues;</div>
                          </td>

  </tr>


</table>
                    <div style="text-indent: -36pt; margin-left: 36pt;">&#160;&#160;</div>

                    <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0); border-spacing: 0;">


  <tr>

    <td style="width: 18pt;"><br/>
                          </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
                            <div>lack of safety or effectiveness, or other adverse study results during clinical trials;</div>
                          </td>

  </tr>


</table>
                    <div style="text-indent: -36pt; margin-left: 36pt;">&#160;</div>

                    <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0); border-spacing: 0;">


  <tr>

    <td style="width: 18pt;"><br/>
                          </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
                            <div>slower than expected rates of patient recruitment or noncompliance with clinical trial requirements;</div>
                          </td>

  </tr>


</table>
                    <div style="text-indent: -36pt; margin-left: 36pt;">&#160;</div>

                    <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0); border-spacing: 0;">


  <tr>

    <td style="width: 18pt;"><br/>
                          </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
                            <div>inability to monitor patients adequately during or after treatment; and</div>
                          </td>

  </tr>


</table>
                    <div style="text-indent: -36pt; margin-left: 36pt;">&#160;</div>

                    <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0); border-spacing: 0;">


  <tr>

    <td style="width: 18pt;"><br/>
                          </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
                            <div>inability or unwillingness of medical investigators to follow our clinical protocols.</div>
                          </td>

  </tr>


</table>
                  </div>

                  <div><br/>
                  </div>

                  <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
                    <div style="text-align: center; text-indent: -9pt; margin-left: 9pt;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">39</span></div>

                    <div style="page-break-after: always;" class="BRPFPageBreak">
                      <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: rgb(0, 0, 0); background-color: rgb(0, 0, 0);"/></div>

                    <div style="width: 100%;" class="BRPFPageHeader">
                      <div>
                        <div style="text-align: left; font-weight: bold; text-indent: -9pt; margin-left: 9pt;"><a href="#ADMABIOLOGICSINC."> <span style="font-style: italic; font-weight: normal; font-size: 8pt;">Table of Contents</span></a><br/>
                        </div>

                      </div>

                    </div>

                  </div>

                  <div style="text-indent: 36pt;">We cannot be certain as to what type and how many clinical trials the FDA, or equivalent foreign regulatory agencies, will require us to conduct before we may successfully gain approval to market any of our
                    product candidates that still require FDA approval. Prior to approving a new drug or biologic, the FDA generally requires that the effectiveness of the product candidate (which is not typically fully investigated until Phase III) be
                    demonstrated in two adequate and well-controlled clinical trials. However, if the FDA or an equivalent foreign regulatory authority determines that our Phase III clinical trial results do not demonstrate a statistically significant,
                    clinically meaningful benefit with an acceptable safety profile, or if a relevant regulator requires us to conduct additional Phase III clinical trials in order to gain approval, we will incur significant additional development costs
                    and commercialization of these products would be prevented or delayed and our business could be adversely affected.</div>

                  <div><br/>
                  </div>

                  <div style="text-indent: 36pt;">In addition, the FDA or an IRB may not permit us to commence a clinical trial, may require amendments to our clinical trial protocols, or may suspend our clinical trials at any time if it appears that we
                    are exposing participants to unacceptable health risks or if the FDA or IRB finds deficiencies in our IND submissions or the conduct of these trials. Regulatory authorities may also not accept data from clinical trials if the trials are
                    not conducted in accordance with the applicable regulatory requirements. Failure to comply with the applicable regulatory requirements may also result in enforcement actions. Therefore, we cannot provide any assurance or predict with
                    certainty the schedule for future clinical trials. In the event we do not ultimately receive regulatory approval for our product candidates, we may be required to terminate development of such product candidates. If we fail to obtain
                    regulatory approval to market and sell our product candidates, or if approval is delayed, we will be unable to generate revenue from the sale of these products, our potential for generating positive cash flow will be diminished and the
                    capital necessary to fund our operations will increase.</div>

                  <div>&#160;</div>

                  <div style="font-style: italic; font-weight: bold; text-indent: 0pt;">If the results of our clinical trials do not support our product candidate claims, completing the development of such product candidate may be significantly delayed or
                    we may be forced to abandon development of such product candidate altogether.</div>

                  <div>&#160;</div>

                  <div style="text-indent: 36pt;">We cannot be certain that the clinical trial results of our product candidates will support our product candidates&#8217; claims. Success in preclinical testing and early clinical trials does not ensure that
                    later clinical trials will be successful, and we cannot be sure that the results of later clinical trials will replicate the results of prior clinical trials and preclinical testing.</div>

                  <div><br/>
                  </div>

                  <div style="text-indent: 36pt;">The clinical trial process may fail to demonstrate that our product candidates are safe for humans and effective for indicated uses. This failure would cause us to abandon a product candidate and may delay
                    the development of other product candidates. Any delay in, or termination of, our clinical trials will delay our ability to commercialize our product candidates and generate product revenues.</div>

                  <div><br/>
                  </div>

                  <div style="text-indent: 36pt;">Other issues that may impact our clinical trials and that could delay or prevent our ability to receive marketing approval or commercialize our product candidates, include:</div>

                  <div><br/>
                  </div>

                  <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0); border-spacing: 0;">


  <tr>

    <td style="width: 18pt;"><br/>
                        </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
                          <div>Delays in reaching, or failure to reach, agreement on acceptable clinical trial contracts or clinical trial protocols with prospective trial sites and our contract research organizations (&#8220;CROs&#8221;);</div>
                        </td>

  </tr>


</table>
                  <div><br/>
                  </div>

                  <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0); border-spacing: 0;">


  <tr>

    <td style="width: 18pt;"><br/>
                        </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
                          <div>Regulators requiring us to perform additional or unanticipated clinical trials to obtain approval or becoming subject to additional post-marketing testing, surveillance, or Risk Evaluation and Mitigation Strategies
                            requirements to maintain regulatory approval;</div>
                        </td>

  </tr>


</table>
                  <div><br/>
                  </div>

                  <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0); border-spacing: 0;">


  <tr>

    <td style="width: 18pt;"><br/>
                        </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
                          <div>Failure by our third-party contractors to comply with regulatory requirements or the clinical trial protocol, or meet their contractual obligations to us in a timely manner, or at all, or our being required to engage in
                            additional clinical trial site monitoring;</div>
                        </td>

  </tr>


</table>
                  <div><br/>
                  </div>

                  <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0); border-spacing: 0;">


  <tr>

    <td style="width: 18pt;"><br/>
                        </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
                          <div>The cost of clinical trials of our product candidates being greater than we anticipate;</div>
                        </td>

  </tr>


</table>
                  <div><br/>
                  </div>

                  <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0); border-spacing: 0;">


  <tr>

    <td style="width: 18pt;"><br/>
                        </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
                          <div>Insufficient supply or inadequate quality of our product candidates or other materials necessary to conduct clinical trials;</div>
                        </td>

  </tr>


</table>
                  <div><br/>
                  </div>

                  <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0); border-spacing: 0;">


  <tr>

    <td style="width: 18pt;"><br/>
                        </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
                          <div>Inability to achieve sufficient study enrollment, subjects dropping out or withdrawing from our studies, delays in adding new investigators or clinical trial sites or a withdrawal of clinical trial sites;</div>
                        </td>

  </tr>


</table>
                  <div><br/>
                  </div>

                  <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0); border-spacing: 0;">


  <tr>

    <td style="width: 18pt;"><br/>
                        </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
                          <div>Flaws in our clinical trial design that are not discoverable until the clinical trial has progressed;</div>
                        </td>

  </tr>


</table>
                  <div><br/>
                  </div>

                  <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
                    <div style="text-align: center; text-indent: -9pt; margin-left: 9pt;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">40</span></div>

                    <div style="page-break-after: always;" class="BRPFPageBreak">
                      <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: rgb(0, 0, 0); background-color: rgb(0, 0, 0);"/></div>

                    <div style="width: 100%;" class="BRPFPageHeader">
                      <div>
                        <div style="text-align: left; font-weight: bold; text-indent: -9pt; margin-left: 9pt;"><a href="#ADMABIOLOGICSINC."> <span style="font-style: italic; font-weight: normal; font-size: 8pt;">Table of Contents</span></a><br/>
                        </div>

                      </div>

                    </div>

                  </div>

                  <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0); border-spacing: 0;">


  <tr>

    <td style="width: 18pt;"><br/>
                        </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
                          <div>Disagreement by the FDA or comparable foreign regulatory authorities with our intended indications or study design, including endpoints, or our interpretation of data from preclinical studies and clinical trials, finding that
                            a product candidate&#8217;s benefits do not outweigh its safety risks or requiring that we conduct additional development or study work;</div>
                        </td>

  </tr>


</table>
                  <div><br/>
                  </div>

                  <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0); border-spacing: 0;">


  <tr>

    <td style="width: 18pt;"><br/>
                        </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
                          <div>The need to make changes to our product candidates that require additional testing or that cause our product candidates to perform differently than expected;</div>
                        </td>

  </tr>


</table>
                  <div><br/>
                  </div>

                  <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0); border-spacing: 0;">


  <tr>

    <td style="width: 18pt;"><br/>
                        </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
                          <div>Global trade policies that may impact our ability to obtain raw materials and/or finished product for commercialization;</div>
                        </td>

  </tr>


</table>
                  <div><br/>
                  </div>

                  <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0); border-spacing: 0;">


  <tr>

    <td style="width: 18pt;"><br/>
                        </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
                          <div>FDA or comparable regulatory authorities taking longer than we anticipate to make decisions on our products or product candidates; and</div>
                        </td>

  </tr>


</table>
                  <div><br/>
                  </div>

                  <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0); border-spacing: 0;">


  <tr>

    <td style="width: 18pt;"><br/>
                        </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
                          <div>Potential inability to demonstrate that a product or product candidate provides an advantage over current standards of care or current or future competitive therapies in development.</div>
                        </td>

  </tr>


</table>
                  <div><br/>
                  </div>

                  <div style="text-indent: 36pt;">In addition, our clinical trials involve a relatively small patient population. Because of the small sample size, the results of these clinical trials may not be indicative of future results. In addition,
                    certain portions of our clinical trials and product testing for our product candidates may be performed outside of the United States, and therefore, may not be performed in accordance with standards normally required by the FDA and
                    other regulatory agencies.</div>

                  <div>&#160;</div>

                  <div style="font-style: italic; font-weight: bold; text-indent: 0pt;">If we do not obtain and maintain the necessary U.S. or international regulatory approvals to commercialize a product candidate, we will not be able to sell that product
                    candidate, which would make it difficult for us to recover the costs of researching and developing such product candidate.</div>

                  <div>&#160;</div>

                  <div style="text-indent: 36pt;">If we are not able to generate revenue from our products and product candidates, our sources of revenue may continue to be from a product mix consisting only of plasma collection and sales revenues,
                    revenues generated from sales of our FDA-approved commercial products and revenues generated from new contract manufacturing arrangements with third parties. We cannot assure you that we will receive the approvals necessary to
                    commercialize any product candidate we may acquire or develop in the future or that we will be able to maintain our current approvals. In order to obtain FDA approval of any product candidate requiring FDA approval, our clinical
                    development must demonstrate that the product candidate is safe for humans and effective for its intended use, and we must successfully complete an FDA BLA review. Obtaining FDA approval of a product candidate generally requires
                    significant research and testing, referred to as preclinical studies, as well as human tests, referred to as clinical trials. Satisfaction of the FDA&#8217;s regulatory requirements typically takes many years, depends upon the type,
                    complexity and novelty of the product candidate and requires substantial resources for research, development and testing. We cannot predict whether our research and clinical approaches will result in products that the FDA considers safe
                    for humans and effective for indicated uses. The FDA has substantial discretion in the product approval process and may require us to conduct additional preclinical and clinical testing or to perform post-marketing studies or may
                    require additional CMC or other data and information, and the development and provision of this data and information may be time-consuming and expensive. The approval process may also be delayed by changes in government regulation,
                    future legislation or administrative action or changes in FDA policy that occur prior to or during our regulatory review. Delays in obtaining regulatory approvals may:</div>

                  <div>&#160;</div>

                  <div>
                    <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0); border-spacing: 0;">


  <tr>

    <td style="width: 18pt;">&#160;</td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
                            <div>delay commercialization of, and our ability to derive revenues from, our product candidates;</div>
                          </td>

  </tr>


</table>
                    <div style="text-indent: -36pt; margin-left: 36pt;">&#160;</div>

                    <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0); border-spacing: 0;">


  <tr>

    <td style="width: 18pt;"><br/>
                          </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
                            <div>impose costly procedures on us; and</div>
                          </td>

  </tr>


</table>
                    <div style="text-indent: -36pt; margin-left: 36pt;">&#160;</div>

                    <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0); border-spacing: 0;">


  <tr>

    <td style="width: 18pt;"><br/>
                          </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
                            <div>diminish any competitive advantages that we may otherwise enjoy.</div>
                          </td>

  </tr>


</table>
                  </div>

                  <div><br/>
                  </div>

                  <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
                    <div style="text-align: center; text-indent: -9pt; margin-left: 9pt;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">41</span></div>

                    <div style="page-break-after: always;" class="BRPFPageBreak">
                      <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: rgb(0, 0, 0); background-color: rgb(0, 0, 0);"/></div>

                    <div style="width: 100%;" class="BRPFPageHeader">
                      <div>
                        <div style="text-align: left; font-weight: bold; text-indent: -9pt; margin-left: 9pt;"><a href="#ADMABIOLOGICSINC."> <span style="font-style: italic; font-weight: normal; font-size: 8pt;">Table of Contents</span></a><br/>
                        </div>

                      </div>

                    </div>

                  </div>

                  <div style="text-indent: 36pt;">Even if we comply with all FDA requests, the FDA may ultimately reject our product candidate&#8217;s BLA. In addition, the FDA could determine that we must test additional subjects and/or require that we conduct
                    further studies with more subjects.&#160;We may never obtain regulatory approval for any future potential product candidate or label expansion activity. Failure to obtain FDA approval for any of our product candidates will severely undermine
                    our business by leaving us without the ability to generate additional accretive revenues. There is no guarantee that we will ever be able to develop or acquire other product candidates. In foreign jurisdictions, we must receive approval
                    from the appropriate regulatory authorities before we can commercialize any products or product candidates outside the U.S. Foreign regulatory approval processes generally include all of the risks and uncertainties associated with the
                    FDA review, inspection and approval procedures described above. We cannot assure you that we will receive the approvals necessary to commercialize any product candidate for sale outside the United States.</div>

                  <div>&#160;</div>

                  <div style="font-style: italic; font-weight: bold; text-indent: 0pt;">Although we have received approval from the&#160;FDA to market ASCENIV as a treatment for PIDD, our ability to market or seek approval for ASCENIV for alternative
                    indications could be limited, unless additional clinical trials are conducted successfully and the FDA approves a BLA or other required submission for review.</div>

                  <div>&#160;</div>

                  <div style="text-indent: 36pt;">The FDA and other governmental authorities strictly regulate and monitor marketing, labeling and the advertising and promotion of prescription drugs. These regulations include standards and restrictions for
                    direct-to-consumer advertising, industry-sponsored scientific and educational activities, promotional activities involving the Internet and off-label promotion. The FDA does not allow drugs to be promoted for &#8220;off-label&#8221; uses&#8201;-&#8201;that is,
                    uses that are not described in the product&#8217;s labeling and that differ from those that were approved by the FDA. The FDA limits approved uses to those studied by a company in its clinical trials. In addition to the FDA approval required
                    for new formulations, any new indication for an approved product also requires FDA approval. Although we have received approval from the FDA to market ASCENIV as a treatment for PIDD, we cannot be sure whether we will be able to obtain
                    FDA approval for any desired future indications for ASCENIV.</div>

                  <div>&#160;</div>

                  <div style="text-indent: 36pt;">While physicians in the United States may choose, and are generally permitted, to prescribe drugs for uses that are not described in the product&#8217;s labeling, and for uses that differ from those tested in
                    clinical studies and approved by the regulatory authorities, our ability to promote our products is narrowly limited to those indications that are specifically approved by the FDA. &#8220;Off-label&#8221; uses are common across medical specialties
                    and may constitute an appropriate treatment for some patients in varied circumstances. Regulatory authorities in the United States generally do not regulate the behavior of physicians in their choice of treatments. Regulatory
                    authorities do, however, restrict communications by pharmaceutical companies on the subject of off-label use. If the FDA determines that our promotional activities fail to comply with the FDA&#8217;s regulations or guidelines, we may be
                    subject to warnings from, or enforcement action by, these authorities. In addition, our failure to follow FDA rules and guidelines related to promotion and advertising may cause the FDA to issue warning letters or untitled letters,
                    bring an enforcement action against us, suspend or withdraw an approved product from the market, require a recall, require payment of civil fines or could result in disgorgement of money, operating restrictions, injunctions or criminal
                    prosecution, among other consequences, any of which could harm our reputation and our business.</div>

                  <div><br/>
                  </div>

                  <div style="font-style: italic; font-weight: bold; text-indent: 0pt;">With the approval of ASCENIV, there can be no assurance that we will be successful in further developing and expanding commercial operations, collecting and procuring
                    an adequate supply of high-titer antibody RSV plasma or balancing our research and development activities with our commercialization activities.</div>

                  <div><br/>
                  </div>

                  <div style="text-indent: 36pt;">Since receiving FDA approval for ASCENIV, we have been commercializing this product while also continuing our research and development activities. There can be no assurance that we will be able to
                    successfully manage the balance of our research and development operations with our commercialization activities. Potential investors and stockholders should be aware of the problems, delays, expenses and difficulties frequently
                    encountered by companies balancing development of product candidates, which can include problems such as unanticipated issues related to clinical trials and receipt of approvals from the FDA and foreign regulatory bodies, with
                    commercialization efforts, which can include problems related to managing manufacturing and supply, including supply chain constraints, reimbursement, marketing challenges, development of a comprehensive compliance program, and other
                    related and additional costs. For example, the raw material plasma we collect and procure to manufacture ASCENIV using our patented proprietary microneutralization assay is comprised of plasma collected from donors which contains
                    high-titer antibodies to RSV.&#160;This high-titer plasma which meets our internal specifications for the manufacture of ASCENIV that we are able to identify with our patented testing assay amounts to less than 10% of the total donor
                    collection samples we test. As a result, we may experience an insufficient supply of this plasma.</div>

                  <div><br/>
                  </div>

                  <div style="text-indent: 36pt;">Our product candidates will require significant additional research and clinical trials, and we will need to overcome significant regulatory burdens prior to commercialization in the United States and other
                    countries. In addition, we may be required to spend significant funds on building out our commercial operations. There can be no assurance that after the expenditure of substantial funds and efforts, we will successfully develop and
                    commercialize any of our product candidates, generate any significant revenues or ever achieve and maintain a substantial level of sales of our products.</div>

                  <div>&#160;</div>

                  <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
                    <div style="text-align: center; text-indent: -9pt; margin-left: 9pt;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">42</span></div>

                    <div style="page-break-after: always;" class="BRPFPageBreak">
                      <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: rgb(0, 0, 0); background-color: rgb(0, 0, 0);"/></div>

                    <div style="width: 100%;" class="BRPFPageHeader">
                      <div>
                        <div style="text-align: left; font-weight: bold; text-indent: -9pt; margin-left: 9pt;"><a href="#ADMABIOLOGICSINC."> <span style="font-style: italic; font-weight: normal; font-size: 8pt;">Table of Contents</span></a><br/>
                        </div>

                      </div>

                    </div>

                  </div>

                  <div style="font-style: italic; font-weight: bold; text-indent: 0pt;">We depend on third-party researchers, developers and vendors to develop, manufacture, supply materials for or test our products and product candidates, as well as for
                    other pre and post-approval services, and such parties&#8217; performance is, to some extent, outside of our control.</div>

                  <div>&#160;</div>

                  <div style="text-indent: 36pt;">We depend on independent investigators and collaborators, such as universities and medical institutions, contract laboratories, CROs, contract manufacturers, contract fill/finishers, third-party plasma
                    centers and consultants to conduct our preclinical activities, clinical trials, CMC testing and other activities under agreements with us. We also depend on third-party suppliers for materials used in our operations. These collaborators
                    are not our employees and we cannot control the amount or timing of resources that they devote to our programs. These third parties may not assign as great a priority to our programs or pursue them as diligently as we would if we were
                    undertaking such programs ourselves. Additionally, certain of our third-party suppliers may be single-sourced or may not be able to supply sufficient materials for our operations, and it may be time-consuming, expensive or otherwise not
                    feasible to locate an alternative supplier. If outside collaborators fail to devote sufficient time and resources to our products and/or development programs, or if their performance is substandard or does not comply with the applicable
                    regulatory standards, our trials may be repeated, extended, delayed, or terminated, the approval of our FDA application(s), if any, and our introduction of new products, if any, will be delayed, and we may not be able to maintain
                    existing approvals or meet our regulatory requirements or we may not be able to produce forecasted amounts of product. We or they may also be subject to regulatory enforcement actions, may need to take corrective actions, including
                    initiating recalls, and we may not be able to meet commercial demand. These collaborators may also have relationships with other commercial entities, some of whom may compete with us. If our collaborators assist our competitors at our
                    expense, our competitive position would be harmed. Additionally, any change in the regulatory compliance status of any of our vendors may impede our ability to receive and maintain approval for our product candidates.</div>

                  <div><br/>
                  </div>

                  <div style="font-style: italic; font-weight: bold; text-indent: 0pt;">We may be unable to successfully expand our manufacturing processes to fulfill demand for our products or increase our production capabilities through the addition of
                    new equipment, including if we do not obtain requisite approval from the FDA. </div>

                  <div><br/>
                  </div>

                  <div style="text-indent: 36pt;">We currently anticipate expanding the manufacturing capacity and product output capability of our Boca Facility. Following the expansion of any of our manufacturing processes or the addition of new
                    equipment, such as our fill-finish machine, we will need to validate the expanded facility and equipment, make the necessary submissions to FDA, obtain any FDA-required approvals and have it inspected by the FDA. Given the significant
                    delays that may result during the validation process, we may experience a supply shortage of our products or our production capabilities may be limited until completion of and validation of our facility expansion and new manufacturing
                    equipment.</div>

                  <div><br/>
                  </div>

                  <div style="font-style: italic; font-weight: bold; text-align: justify; text-indent: 0pt;">Our products, and any additional products for which we may obtain marketing approval in the future, could be subject to post-marketing restrictions
                    or withdrawal from the market and we could be subject to substantial penalties if we fail to comply with regulatory requirements or if we experience unanticipated problems with our products following approval.</div>

                  <div><br/>
                  </div>

                  <div style="text-indent: 36pt;">Our products, and any additional products for which we may obtain marketing approval in the future, could be subject to post-marketing restrictions, new FDA guidance, or other regulatory actions, such as
                    withdrawal from the market. Such products, as well as the manufacturing processes, post-marketing studies and measures, labeling and advertising and promotional activities for such products, among other things, are subject to ongoing
                    regulatory compliance requirements, and oversight, review, and inspection by the FDA and other regulatory authorities. These requirements include submissions of safety and other post-marketing information and reports, registration and
                    listing requirements, adherence with labeling and promotional requirements and restrictions, requirements related to manufacturing, quality control, quality assurance and corresponding maintenance of records and documents, requirements
                    regarding safeguarding the drug supply chain as well as the distribution of samples to physicians and recordkeeping. For example, the FDA&#8217;s approval of our application supplement to allow for the commercial relaunch of BIVIGAM, as well
                    as the FDA&#8217;s approval of our BLA for ASCENIV, required us to conduct specified post-marketing studies, including pediatric and safety studies. If, during the post-marketing period (after marketing approval) previously unknown adverse
                    events emerge, there is the discovery that the product is less effective than previously thought, or other potential concerns regarding our products or their manufacturing processes emerge, or we are observed in any way to fail to
                    comply with the numerous regulatory requirements to which we are subject, those circumstances may yield various results, including:</div>

                  <div style="text-indent: 36pt;"> <br/>
                  </div>

                  <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
                    <div style="text-align: center; text-indent: -9pt; margin-left: 9pt;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">43</span></div>

                    <div style="page-break-after: always;" class="BRPFPageBreak">
                      <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: rgb(0, 0, 0); background-color: rgb(0, 0, 0);"/></div>

                    <div style="width: 100%;" class="BRPFPageHeader">
                      <div>
                        <div style="text-align: left; font-weight: bold; text-indent: -9pt; margin-left: 9pt;"><a href="#ADMABIOLOGICSINC."> <span style="font-style: italic; font-weight: normal; font-size: 8pt;">Table of Contents</span></a><br/>
                        </div>

                      </div>

                    </div>

                  </div>

                  <div>
                    <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0); border-spacing: 0;">


  <tr>

    <td style="width: 36pt;">
                            <div>&#160;</div>
                          </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
                            <div>restrictions on such products or manufacturing processes;</div>
                          </td>

  </tr>


</table>
                    <div style="text-indent: -36pt; margin-left: 36pt;">&#160;</div>

                    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0); border-spacing: 0;" class="DSPFListTable">


  <tr>

    <td style="width: 36pt;"><br/>
                          </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">restrictions on the labeling or marketing of a product;</td>

  </tr>


</table>
                    <div style="text-indent: -36pt; margin-left: 36pt;"> <br/>
                    </div>

                    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0); border-spacing: 0;" class="DSPFListTable">


  <tr>

    <td style="width: 36pt;"><br/>
                          </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
                            <div>restrictions on product distribution or use;</div>
                          </td>

  </tr>


</table>
                    <div style="text-indent: -36pt; margin-left: 36pt;"> <br/>
                    </div>

                    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0); border-spacing: 0;" class="DSPFListTable">


  <tr>

    <td style="width: 36pt;"><br/>
                          </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
                            <div>clinical holds or termination of clinical trials;</div>
                          </td>

  </tr>


</table>
                    <div style="text-indent: -36pt; margin-left: 36pt;"> <br/>
                    </div>

                    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0); border-spacing: 0;" class="DSPFListTable">


  <tr>

    <td style="width: 36pt;"><br/>
                          </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
                            <div style="text-align: justify; text-indent: -36pt; margin-left: 36pt;">requirements to conduct further post-marketing studies or clinical trials, implement risk mitigation strategies, or to issue corrective information;</div>
                          </td>

  </tr>


</table>
                    <div style="text-indent: -36pt; margin-left: 36pt;"> <br/>
                    </div>

                    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0); border-spacing: 0;" class="DSPFListTable">


  <tr>

    <td style="width: 36pt;"><br/>
                          </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
                            <div style="text-indent: -36pt; margin-left: 36pt;">warning letters or untitled letters;</div>
                          </td>

  </tr>


</table>
                    <div style="text-indent: -36pt; margin-left: 36pt;"> <br/>
                    </div>

                    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0); border-spacing: 0;" class="DSPFListTable">


  <tr>

    <td style="width: 36pt;"><br/>
                          </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
                            <div style="text-indent: -36pt; margin-left: 36pt;">withdrawal of the products from the market;</div>
                          </td>

  </tr>


</table>
                    <div style="text-indent: -36pt; margin-left: 36pt;"> <br/>
                    </div>

                    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0); border-spacing: 0;" class="DSPFListTable">


  <tr>

    <td style="width: 36pt;"><br/>
                          </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
                            <div>refusal to approve pending applications or supplements to approved applications that we submit;</div>
                          </td>

  </tr>


</table>
                    <div style="text-indent: -36pt; margin-left: 36pt;"> <br/>
                    </div>

                    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0); border-spacing: 0;" class="DSPFListTable">


  <tr>

    <td style="width: 36pt;"><br/>
                          </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
                            <div style="text-indent: -36pt; margin-left: 36pt;">recall of products;</div>
                          </td>

  </tr>


</table>
                    <div style="text-indent: -36pt; margin-left: 36pt;"> <br/>
                    </div>

                    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0); border-spacing: 0;" class="DSPFListTable">


  <tr>

    <td style="width: 36pt;"><br/>
                          </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
                            <div>restrictions on coverage by third-party payers;</div>
                          </td>

  </tr>


</table>
                    <div style="text-indent: -36pt; margin-left: 36pt;"> <br/>
                    </div>

                    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0); border-spacing: 0;" class="DSPFListTable">


  <tr>

    <td style="width: 36pt;"><br/>
                          </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
                            <div>fines, restitution or disgorgement of profits or revenues;</div>
                          </td>

  </tr>


</table>
                    <div style="text-indent: -36pt; margin-left: 36pt;"> <br/>
                    </div>

                    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0); border-spacing: 0;" class="DSPFListTable">


  <tr>

    <td style="width: 36pt;"><br/>
                          </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
                            <div>suspension or withdrawal of marketing approvals;</div>
                          </td>

  </tr>


</table>
                    <div style="text-indent: -36pt; margin-left: 36pt;"> <br/>
                    </div>

                    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0); border-spacing: 0;" class="DSPFListTable">


  <tr>

    <td style="width: 36pt;"><br/>
                          </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
                            <div style="text-indent: -36pt; margin-left: 36pt;">refusal to permit the import or export of products;</div>
                          </td>

  </tr>


</table>
                    <div style="text-indent: -36pt; margin-left: 36pt;"> <br/>
                    </div>

                    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0); border-spacing: 0;" class="DSPFListTable">


  <tr>

    <td style="width: 36pt;"><br/>
                          </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
                            <div>FDA debarment, suspension and debarment from government programs, refusal of orders under existing government contracts, exclusion from participation in federal healthcare programs, consent decrees, deferred or
                              non-prosecution agreements or corporate integrity agreements;</div>
                          </td>

  </tr>


</table>
                    <div style="text-indent: -36pt; margin-left: 36pt;"> <br/>
                    </div>

                    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0); border-spacing: 0;" class="DSPFListTable">


  <tr>

    <td style="width: 36pt;"><br/>
                          </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
                            <div>product seizure or detention; or</div>
                          </td>

  </tr>


</table>
                    <div style="text-indent: -36pt; margin-left: 36pt;"> <br/>
                    </div>

                    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0); border-spacing: 0;" class="DSPFListTable">


  <tr>

    <td style="width: 36pt;"><br/>
                          </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
                            <div style="text-indent: -36pt; margin-left: 36pt;">injunctions or the imposition of civil penalties or criminal fines.</div>
                          </td>

  </tr>


</table>
                    <div style="text-indent: -36pt; margin-left: 36pt;"><br/>
                    </div>

                    <div style="font-style: italic; font-weight: bold; text-indent: 0pt;">Historically, a few customers have accounted for a significant amount of our total revenue and accounts receivable and the loss of any of these customers could have a
                      material adverse effect on our business, results of operations and financial condition.</div>

                    <div>&#160;</div>

                    <div style="text-indent: 36pt;">For the years ended December 31, 2024 and 2023, two customers, BioCARE, Inc. (&#8220;BioCare&#8221;) and Priority Healthcare Distribution, Inc. d/b/a CuraScript SD Specialty Distribution (&#8220;Curascript&#8221;), represented
                      an aggregate of approximately 72% of our consolidated revenues.</div>

                    <div><br/>
                    </div>

                    <div style="text-indent: 36pt;">As of December 31, 2024, three customers, BioCare, Healix Infusion Therapy, LLC (&#8220;Healix&#8221;) and Cencora, Inc. (f/k/a AmerisourceBergen Corporation), represented an aggregate of approximately 91% of our
                      consolidated accounts receivable. As of December 31, 2023, five customers, BioCare, Healix, Curascript, Cencora, Inc. and Reliance Life Sciences Pvt. Limited (&#8220;Reliance&#8221;), represented an aggregate of approximately 98% of our
                      consolidated accounts receivable.</div>

                    <div>&#160;</div>

                    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
                      <div style="text-align: center; text-indent: -9pt; margin-left: 9pt;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">44</span></div>

                      <div style="page-break-after: always;" class="BRPFPageBreak">
                        <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: rgb(0, 0, 0); background-color: rgb(0, 0, 0);"/></div>

                      <div style="width: 100%;" class="BRPFPageHeader">
                        <div>
                          <div style="text-align: left; font-weight: bold; text-indent: -9pt; margin-left: 9pt;"><a href="#ADMABIOLOGICSINC."> <span style="font-style: italic; font-weight: normal; font-size: 8pt;">Table of Contents</span></a><br/>
                          </div>

                        </div>

                      </div>

                    </div>

                    <div style="text-indent: 36pt;">The loss of any key customers or a material change in the revenue generated by any of these customers, other than Reliance, could have a material adverse effect on our business, results of operations and
                      financial condition. Moreover, we anticipate deriving increased revenue from some of these customers over the next few years. Factors that could influence our relationships with our customers include, among other things:</div>

                    <div>&#160;</div>

                    <div>
                      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0); border-spacing: 0;">


  <tr>

    <td style="width: 36pt;">&#160;</td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
                              <div>our ability to sell our products at competitive prices;</div>
                            </td>

  </tr>


</table>
                      <div style="text-indent: -36pt; margin-left: 36pt;">&#160;</div>

                      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0); border-spacing: 0;">


  <tr>

    <td style="width: 36pt;"><br/>
                            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
                              <div>our ability to maintain features and quality standards for our products sufficient to meet the expectations of our customers;</div>
                            </td>

  </tr>


</table>
                      <div style="text-indent: -36pt; margin-left: 36pt;">&#160;</div>

                      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0); border-spacing: 0;">


  <tr>

    <td style="width: 36pt;"><br/>
                            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
                              <div>our ability to produce and deliver a sufficient quantity of our products in a timely manner to meet our customers&#8217; requirements;</div>
                            </td>

  </tr>


</table>
                      <div><br/>
                      </div>

                      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0); border-spacing: 0;">


  <tr>

    <td style="width: 36pt;"><br/>
                            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
                              <div>the impact of a pandemic, or the resurgence of a pandemic, and government responses thereto on our customers and their businesses, operations and financial condition;</div>
                            </td>

  </tr>


</table>
                      <div><br/>
                      </div>

                      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0); border-spacing: 0;">


  <tr>

    <td style="width: 36pt;"><br/>
                            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
                              <div>the impact of a cyberattack or data breach on our customers or related entities; and</div>
                            </td>

  </tr>


</table>
                      <div><br/>
                      </div>

                      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0); border-spacing: 0;">


  <tr>

    <td style="width: 36pt;"><br/>
                            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
                              <div>widespread economic conditions or geopolitical conditions, including the exacerbated conflicts in Europe, the Middle East and the surrounding areas.</div>
                            </td>

  </tr>


</table>
                    </div>

                    <div><br/>
                    </div>

                    <div style="text-indent: 0pt;">Additionally, an adverse change in the financial condition of any of our key customers could negatively affect revenue derived from such customer, which in turn could have a material adverse effect on our
                      business and results of operations.</div>

                    <div>&#160;</div>

                    <div style="font-style: italic; font-weight: bold; text-indent: 0pt;">Issues with product quality and compliance could have a material adverse effect upon our business, subject us to regulatory actions and cause a loss of customer
                      confidence in us or our products.</div>

                    <div>&#160;</div>

                    <div style="text-indent: 36pt;">Our success depends upon the quality of our products. Quality management plays an essential role in meeting customer requirements, preventing defects, improving our products and services and assuring the
                      safety and efficacy of our products. Our future success depends on our ability to maintain and continuously improve our quality management program. A quality or safety issue may result in failure to obtain product approval, adverse
                      inspection reports, warning letters, product recalls or seizures, monetary sanctions, injunctions to halt manufacture and distribution of products, civil or criminal sanctions, costly litigation, patient injury, refusal of a
                      government to grant approvals and licenses, restrictions on operations or withdrawal of existing approvals and licenses. An inability to address a quality or safety issue by us or by a third-party vendor in an effective and timely
                      manner may also cause negative publicity or a loss of customer confidence in us or our current or future products, which may result in the loss of sales and difficulty in successfully commercializing our current products and launching
                      new products.</div>

                    <div><br/>
                    </div>

                    <div style="text-indent: 36pt;">In addition, as a manufacturer of biological products, we are subject to the risks inherent in biological production, which could include normal course losses and failures inherent in the manufacturing
                      process. As our biologics production levels increase, there may be normal course inventory losses or write-downs as we ensure product quality and compliance with cGMP, FDA and state and local regulations, or due to testing results not
                      meeting specifications. As a result, our operating results are subject to potentially significant variability from one reporting period to the next should such losses or write-downs occur in any given period. Additionally, because our
                      products and product candidates are plasma-based products, not only are we subject to the FDA&#8217;s drug and biologic cGMP requirements, but we are also subject to special requirements for the collection, testing, handling, storage, and
                      use of blood products.&#160; This adds an extra level of compliance and complexity to our operations, which we may not be able to successfully meet.&#160; Failure to meet any regulatory quality standards could have an adverse impact on our
                      business.</div>

                    <div>&#160;</div>

                    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
                      <div style="text-align: center; text-indent: -9pt; margin-left: 9pt;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">45</span></div>

                      <div class="BRPFPageBreak" style="page-break-after: always;">
                        <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: rgb(0, 0, 0); background-color: rgb(0, 0, 0);"/></div>

                      <div style="width: 100%;" class="BRPFPageHeader">
                        <div>
                          <div style="text-align: left; font-weight: bold; text-indent: -9pt; margin-left: 9pt;"><a href="#ADMABIOLOGICSINC."> <span style="font-style: italic; font-weight: normal; font-size: 8pt;">Table of Contents</span></a><br/>
                          </div>

                        </div>

                      </div>

                    </div>

                    <div style="font-style: italic; font-weight: bold; text-indent: 0pt;">If physicians, payers and patients do not accept and use our current products or our future product candidates, our ability to generate revenue from these products
                      will be materially impaired.</div>

                    <div>&#160;</div>

                    <div style="text-indent: 36pt;">Even if the FDA approves a product made by us, physicians, payers and patients may not accept and use it. Acceptance and use of our products depends on a number of factors including, but not limited to:</div>

                    <div>&#160;</div>

                    <div>
                      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0); border-spacing: 0;">


  <tr>

    <td style="width: 18pt;"><br/>
                            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
                              <div>perceptions by members of the healthcare community, including physicians, about the safety and effectiveness of our products;</div>
                            </td>

  </tr>


</table>
                      <div style="text-indent: -36pt; margin-left: 36pt;">&#160;</div>

                      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0); border-spacing: 0;">


  <tr>

    <td style="width: 18pt;"><br/>
                            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
                              <div>cost-effectiveness of our products relative to competing products;</div>
                            </td>

  </tr>


</table>
                      <div style="text-indent: -36pt; margin-left: 36pt;">&#160;</div>

                      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0); border-spacing: 0;">


  <tr>

    <td style="width: 18pt;"><br/>
                            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
                              <div>availability of reimbursement for our products from government or other healthcare payers; and</div>
                            </td>

  </tr>


</table>
                      <div style="text-indent: -36pt; margin-left: 36pt;">&#160;</div>

                      <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0); border-spacing: 0;">


  <tr>

    <td style="width: 18pt;"><br/>
                            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
                              <div>the effectiveness of marketing and distribution efforts by us and our licensees and distributors, if any.</div>
                            </td>

  </tr>


</table>
                    </div>

                    <div><br/>
                    </div>

                    <div style="text-indent: 0pt;">The failure of our current or future products to find market acceptance would harm our business and could require us to seek additional financing or make such financing difficult to obtain on favorable
                      terms, if at all.</div>

                    <div>&#160;</div>

                    <div style="font-style: italic; font-weight: bold; text-indent: 0pt;">Our accruals for U.S. Medicaid rebates and other liabilities related to the sale of our immunoglobulin products are estimates based on historical experience and other
                      assumptions.&#160; These estimates are subject to change based on actual results and other factors. Any such change could have a material effect on our business, financial position, and operating results.</div>

                    <div><br/>
                    </div>

                    <div style="text-indent: 36pt;">Our gross product revenues are subject to a variety of deductions which are estimated and recorded in the same period that the revenues are recognized. These deductions primarily consist of rebates,
                      distribution fees, chargebacks and sales allowances. These deductions represent estimates of the related obligations, some of which are contractual in nature and do not require extensive judgment to be exercised by management, while
                      other estimates require complex or subjective matters of knowledge and judgment when estimating the impact of these revenue deductions on net revenues for a reporting period. Significant estimates include, among other things, accruals
                      for U.S. Medicaid rebates related to the sale of our immunoglobulin products. We accrue these rebates at the time of sale based on our estimates of the sales mix of our products and the portion of the products we sell that will be
                      prescribed to Medicaid beneficiaries. These estimates are based on historical experience and certain other assumptions, and while we believe that such estimates are reasonable, they are subject to change based on future experience,
                      Medicaid utilization trends and other factors.&#160; If any of our ratios, factors, assessments, experiences or judgments are not indicative or accurate estimates of our future experience, our results could be materially affected.
                      Estimates that are most at risk for material adjustment include those associated with U.S. Medicaid rebates because of the extensive time delay between the recording of the accrual and its ultimate settlement, an interval that can
                      generally take up to several years or more. These estimates may change from time to time based on changes in utilization, payer and channel mixes or the ultimate settlement or resolution of payor claims. For example, during 2024 we
                      engaged a third-party specialist to assist in the evaluation of our accrual for U.S. Medicaid rebates related to the sale of our immunoglobulin products. As a result of this evaluation, we recognized a reduction in this accrual and a
                      corresponding increase to net revenues of $12.6 million for the year ended December 31, 2024. We considered several qualitative factors when evaluating our rebate accrual, such as the absence of a statutory limitation on the rebate
                      amounts drug manufacturers pay to state Medicaid programs and general uncertainty that pharmaceutical manufacturers have historically seen with government payors often submitting lagged claims many periods after the initial dispensing
                      of a product to an end patient. There was additional new information that arose during June 2024 that suggested our liabilities for certain payor claims were successfully resolved, which resulted in the $12.6 million adjustment to the
                      accrual for U.S. Medicaid rebates in June 2024.</div>

                    <div><br/>
                    </div>

                    <div style="text-indent: 36pt;">In addition, the Patient Protection and Affordable Care Act (&#8220;ACA&#8221;) included a significant expansion of state Medicaid programs. As more individuals become eligible for coverage under these programs,
                      Medicaid utilization of our products could increase, resulting in a corresponding increase in our rebate payments. Such rebate payments may exceed what we have accrued for during the applicable period.&#160; Increases in Medicaid rebate
                      payments could decrease our net revenues from product sales, which in turn could adversely affect our business, financial position, and operating results.</div>

                    <div><br/>
                    </div>

                    <div style="font-style: italic; font-weight: bold; text-indent: 0pt;">Our long-term success may depend on our ability to supplement our existing product portfolio through new product development or the in-license or acquisition of other
                      new products, product candidates and label expansion of existing products, and if our business development efforts are not successful, our ability to maintain profitability may be adversely impacted.</div>

                    <div>&#160;</div>

                    <div style="text-indent: 36pt;">Our current product development portfolio consists primarily of label expansion activities for ASCENIV, as well as expanding our IP estate with patents issued for <span style="font-style: italic;">S.
                        pneumoniae</span> hyperimmune IG. We have initiated small-scale preclinical activities to potentially expand our current portfolio through new product development efforts. If we are not successful in developing or acquiring
                      additional products and product candidates, we will have to depend on our ability to continue to generate revenues from ASCENIV, BIVIGAM, Nabi-HB, contract manufacturing and plasma attributable to the operations of ADMA BioCenters to
                      support our operations.</div>

                    <div>&#160;</div>

                    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
                      <div style="text-align: center; text-indent: -9pt; margin-left: 9pt;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">46</span></div>

                      <div class="BRPFPageBreak" style="page-break-after: always;">
                        <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: rgb(0, 0, 0); background-color: rgb(0, 0, 0);"/></div>

                      <div style="width: 100%;" class="BRPFPageHeader">
                        <div>
                          <div style="text-align: left; font-weight: bold; text-indent: -9pt; margin-left: 9pt;"><a href="#ADMABIOLOGICSINC."> <span style="font-style: italic; font-weight: normal; font-size: 8pt;">Table of Contents</span></a><br/>
                          </div>

                        </div>

                      </div>

                    </div>

                    <div style="font-style: italic; font-weight: bold; text-indent: 0pt;">Our ADMA BioCenters operations collect information from donors in the United States that subjects us to consumer and health privacy laws, which could create
                      enforcement and litigation exposure if we fail to meet their requirements.</div>

                    <div><br/>
                    </div>

                    <div style="text-indent: 36pt;">Consumer privacy is highly protected by federal and state law. The Health Insurance Portability and Accountability Act of 1996 (&#8220;HIPAA&#8221;), as amended by the Health Information Technology for Economic and
                      Clinical Health Act of 2009 (&#8220;HITECH&#8221;), and their respective implementing regulations, impose requirements with respect to safeguarding the privacy, security and transmission of protected health information (&#8220;PHI&#8221;) held by covered
                      entities and business associates. HIPAA &#8220;covered entities&#8221; include health plans/insurers, healthcare providers engaging in HIPAA standard electronic transactions and healthcare clearinghouses. A &#8220;business associate&#8221; provides services
                      to covered entities (directly or as subcontractors to other business associates) involving arranging, creating, receiving, maintaining, or transmitting PHI on a covered entity&#8217;s behalf.&#160; In order to legally provide access to PHI to
                      service providers, covered entities and business associates must enter into a &#8220;business associate agreement&#8221; with the service provider that receives PHI on behalf of the entity.</div>

                    <div><br/>
                    </div>

                    <div style="text-indent: 36pt;">While we are not a covered entity or business associate subject to HIPAA, personal information that we obtain pursuant to a clinical trial may be subject to U.S. Federal Trade Commission (the &#8220;FTC&#8221;)
                      privacy regulation. Failing to take appropriate steps to keep consumers&#8217; personal information secure may constitute an unfair act or practice violating Section 5(a) of the Federal Trade Commission Act, 15 U.S.C &#167; 45(a). The FTC
                      expects a company&#8217;s data security measures to be reasonable and appropriate in light of the sensitivity and volume of consumer information it holds, the size and complexity of its business, and the cost of available tools to improve
                      security and reduce vulnerabilities. Medical data is considered sensitive data that merits stronger safeguards. The FTC&#8217;s guidance for appropriately securing consumers&#8217; personal information is similar to, but less prescriptive than,
                      what is required by the HIPAA Security Rule. In addition, states impose a variety of laws protecting consumer information, with certain sensitive information such as HIV/Sexually Transmitted Disease status subject to heightened
                      standards.&#160; In addition, federal and state privacy, data security, and breach notification laws, rules and regulations, and other laws apply to the collection, use and security of personal information, including social security
                      numbers, driver&#8217;s license numbers, government identifiers, credit card and financial account numbers. For example, the CCPA was amended by the CPRA, effective January 1, 2023. The CCPA, among other things, imposes data privacy
                      obligations for covered companies and provides new privacy rights to California residents, including the right to opt out of certain disclosures of their information. The CCPA also creates a private right of action with statutory
                      damages for certain data breaches, thereby potentially increasing risks associated with a data breach. We could be subject to enforcement action and litigation exposure if we fail to adhere to these data privacy and security laws.
                      Virginia, Colorado, Connecticut and Utah have also enacted privacy laws that became effective in 2023 and are similar in many respects to the CCPA. Several other states have also enacted privacy laws similar to the CCPA that will
                      become effective in the coming years, adding to potential privacy compliance obligations.</div>

                    <div>&#160;</div>

                    <div style="margin: 0px; font-style: italic; font-weight: bold; text-indent: 0pt;">The Ares Credit Facility is subject to acceleration in specified circumstances, which may result in Ares taking possession and disposing of any
                      collateral.</div>

                    <div>&#160;</div>

                    <div style="text-indent: 36pt;">On December 18, 2023 (the &#8220;Ares Closing Date&#8221;), we entered into a credit agreement with Ares (the &#8220;Ares Credit Agreement&#8221;) (see &#8220;Liquidity and Capital Resources&#8221;). The Ares Credit Agreement provided for a
                      total of $135 million in senior secured credit facilities (the &#8220;Ares Credit Facility&#8221;) consisting of (i) a term loan in the aggregate principal amount of $62.5 million and (ii) a revolving credit facility in the aggregate principal
                      amount of $72.5 million (collectively, the &#8220;Ares Loans&#8221;), both of which were fully drawn on the Ares Closing Date. The Ares Credit Facility has a maturity date of December 20, 2027 (the &#8220;Ares Maturity Date&#8221;). On August 14, 2024, we
                      repaid $30.0 million against the revolving credit facility and on December 19, 2024 we repaid $30.0 million against the term loan. As of December 31, 2024, we had $42.5 million and $32.5 million of borrowings outstanding under the
                      revolving credit facility and the term loan, respectively. The Ares Loans are secured by substantially all of our assets, including our intellectual property. Events of default include, among others, non-payment of principal, interest
                      or fees, violation of covenants, inaccuracy of representations and warranties, bankruptcy and insolvency events, material judgments, cross-defaults to material contracts and events constituting a change of control. If there is an
                      event of default, we would incur an increase in the rate of interest on the Ares Loans of 2% per annum. The occurrence of an event of default could result in, among other things, the termination of commitments under the Ares Credit
                      Facility, the declaration that all outstanding loans are immediately due and payable in whole or in part, and Ares taking immediate possession of, and selling, any collateral securing the Ares Loans.</div>

                    <div>&#160;</div>

                    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
                      <div style="text-align: center; text-indent: -9pt; margin-left: 9pt;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">47</span></div>

                      <div class="BRPFPageBreak" style="page-break-after: always;">
                        <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: rgb(0, 0, 0); background-color: rgb(0, 0, 0);"/></div>

                      <div style="width: 100%;" class="BRPFPageHeader">
                        <div>
                          <div style="text-align: left; font-weight: bold; text-indent: -9pt; margin-left: 9pt;"><a href="#ADMABIOLOGICSINC."> <span style="font-style: italic; font-weight: normal; font-size: 8pt;">Table of Contents</span></a><br/>
                          </div>

                        </div>

                      </div>

                    </div>

                    <div style="font-style: italic; font-weight: bold; text-indent: -9pt; margin-left: 9pt;">Developments by competitors may render our products or technologies obsolete or non-competitive.</div>

                    <div>&#160;</div>

                    <div style="text-indent: 36pt;">The biotechnology and pharmaceutical industries are intensely competitive and subject to rapid and significant technological change. Our current products and any future product we may develop will have to
                      compete with other marketed therapies. In addition, other companies may pursue the development of pharmaceuticals that target the same diseases and conditions that we are targeting. We face competition from pharmaceutical and
                      biotechnology companies in the United States and abroad. In addition, companies pursuing different but related fields represent substantial competition. Many of these organizations competing with us have substantially greater
                      financial resources, larger research and development staffs and facilities, longer product development history in obtaining regulatory approvals and greater manufacturing and marketing capabilities than we do. These organizations also
                      compete with us to attract qualified personnel and parties for acquisitions, joint ventures or other collaborations.</div>

                    <div>&#160;</div>

                    <div style="margin: 0px; font-style: italic; font-weight: bold; text-indent: 0pt;">If we are unable to protect our patents, trade secrets or other proprietary rights, if our patents are challenged or if our provisional patent
                      applications do not get approved, our competitiveness and business prospects may be materially damaged.</div>

                    <div>&#160;</div>

                    <div style="text-indent: 36pt;">As we move forward in clinical development, we continue to discover novel technologies related to our products and we may draft patent applications directed to these technologies.&#160;We rely on a combination
                      of patent rights, trade secrets, intellectual property assignment agreements and nondisclosure and non-competition agreements to protect our proprietary intellectual property, and we will continue to do so. There can be no assurance
                      that our patents, trade secret policies and practices or other agreements will adequately protect our intellectual property. Our issued patents may be challenged, found to be over-broad or otherwise invalidated in subsequent
                      proceedings before courts, the U.S. Patent and Trademark Office or foreign patent offices. Even if enforceable, we cannot provide any assurances that they will provide significant protection from competition. The processes, systems,
                      and/or security measures we use to preserve the integrity and confidentiality of our data and trade secrets may be breached, and we may not have adequate remedies as a result of any such breaches. In addition, our trade secrets may
                      otherwise become known or be independently discovered by competitors. There can be no assurance that the confidentiality, invention assignment, nondisclosure and non-competition agreements with employees, consultants and other parties
                      with access to our proprietary information to protect our trade secrets, proprietary technology, processes and other proprietary rights, or any other security measures relating to such trade secrets, proprietary technology, processes
                      and proprietary rights, will be adequate, will not be breached, that we will have adequate remedies for any breach, that others will not independently develop substantially equivalent proprietary information or that third parties will
                      not otherwise gain access to our trade secrets or proprietary knowledge. To the extent that our consultants, contractors or collaborators use intellectual property owned by others in their work for us, disputes may arise as to the
                      rights in related or resulting know-how and inventions.</div>

                    <div style="font-style: italic; font-weight: bold; text-indent: -9pt; margin-left: 9pt;"> <br/>
                    </div>

                    <div style="font-style: italic; font-weight: bold; text-indent: -9pt; margin-left: 9pt;">We could lose market exclusivity of a product earlier than expected.</div>

                    <div>&#160;</div>

                    <div style="text-indent: 36pt;">In the pharmaceutical and biotechnology industries, the majority of an innovative product&#8217;s commercial value is realized during its market exclusivity period. In the United States and in some other
                      countries, when market exclusivity expires and generic or biosimilar versions are approved and marketed or when biosimilars are introduced (even if only for a competing product), there are usually very substantial and rapid declines
                      in a product&#8217;s revenues.</div>

                    <div>&#160;</div>

                    <div style="text-indent: 36pt;">Market exclusivity for our products is based upon patent rights and certain regulatory forms of exclusivity. The scope of our patent rights may vary from country to country and may also be dependent on
                      the availability of meaningful legal remedies in a country. The failure to obtain patent and other intellectual property rights, limitations on the use or loss of such rights could be material to us. In some countries, basic patent
                      protections for our products may not exist because certain countries did not historically offer the right to obtain specific types of patents and/or we (or our licensors) did not file in those markets. In addition, the patent
                      environment can be unpredictable and the validity and enforceability of patents cannot be predicted with certainty. Absent relevant patent protection for a product, once the data exclusivity period expires, generic versions can be
                      approved and marketed.</div>

                    <div>&#160;</div>

                    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
                      <div style="text-align: center; text-indent: -9pt; margin-left: 9pt;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">48</span></div>

                      <div class="BRPFPageBreak" style="page-break-after: always;">
                        <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: rgb(0, 0, 0); background-color: rgb(0, 0, 0);"/></div>

                      <div style="width: 100%;" class="BRPFPageHeader">
                        <div>
                          <div style="text-align: left; font-weight: bold; text-indent: -9pt; margin-left: 9pt;"><a href="#ADMABIOLOGICSINC."> <span style="font-style: italic; font-weight: normal; font-size: 8pt;">Table of Contents</span></a><br/>
                          </div>

                        </div>

                      </div>

                    </div>

                    <div style="text-indent: 36pt;">Patent rights covering our products may become subject to patent litigation. In some cases, manufacturers may seek regulatory approval by submitting their own clinical trial data to obtain marketing
                      approval or choose to launch a generic product &#8220;at risk&#8221; before the expiration of our patent rights/or before the final resolution of related patent litigation. Enforcement of claims in patent litigation can be very costly,
                      time-consuming and&#160;no assurance can be given that we will prevail.&#160;In addition, any such litigation may divert our management's attention from our core business and reduce the resources available for our clinical development,
                      manufacturing and marketing activities, and consequently have a material and adverse effect on our business and prospects, regardless of the outcome.There is no assurance that ASCENIV, or any other of our products for which we are
                      issued a patent, will enjoy market exclusivity for the full time period of the respective patent. </div>

                    <div>&#160;</div>

                    <div style="margin: 0px; font-style: italic; font-weight: bold; text-indent: 0pt;">Third parties could obtain patents that may require us to negotiate licenses to conduct our business, and there can be no assurance that the required
                      licenses would be available on reasonable terms or at all.</div>

                    <div>&#160;</div>

                    <div style="text-indent: 36pt;">We may not be able to operate our business without infringing third-party patents. Numerous U.S. and foreign patents and pending patent applications owned by third parties exist in fields that relate to
                      the development and commercialization of IG. In addition, many companies have employed intellectual property litigation as a way to gain a competitive advantage. It is possible that infringement claims may occur as the number of
                      products and competitors in our market increases. In addition, to the extent that we gain greater visibility and market exposure as a public company, we face a greater risk of being the subject of intellectual property infringement
                      claims. We cannot be certain that the conduct of our business does not and will not infringe intellectual property or other proprietary rights of others in the United States and in foreign jurisdictions. If our products, methods,
                      processes and other technologies are found to infringe third-party patent rights, we could be prohibited from manufacturing and commercializing the infringing technology, process or product unless we obtain a license under the
                      applicable third-party patent and pay royalties or are able to design around such patent. We may be unable to obtain a license on terms acceptable to us, or at all, and we may not be able to redesign our products or processes to avoid
                      infringement. Even if we are able to redesign our products or processes to avoid an infringement claim, our efforts to design around the patent could require significant time, effort and expense and ultimately may lead to an inferior
                      or more costly product and/or process. Any claim of infringement by a third party, even those without merit, could cause us to incur substantial costs defending against the claim and could distract our management from our business.
                      Furthermore, if any such claim is successful, a court could order us to pay substantial damages, including compensatory damages for any infringement, plus prejudgment interest and could, in certain circumstances, treble the
                      compensatory damages and award attorney fees. These damages could be substantial and could harm our reputation, business, financial condition and operating results. A court also could enter orders that temporarily, preliminarily or
                      permanently prohibit us, our licensees, if any, or our customers from making, using, selling, offering to sell or importing one or more of our products or practicing our proprietary technologies or processes, or could enter an order
                      mandating that we undertake certain remedial activities. Any of these events could seriously harm our business, operating results and financial condition.</div>

                    <div><br/></div>

                    <div style="font-style: italic; font-weight: bold; text-indent: -9pt; margin-left: 9pt;">If we are unable to successfully manage our growth, our business may be harmed.</div>

                    <div>&#160;</div>

                    <div style="text-indent: 36pt;">Our success will depend on the expansion of our commercial and manufacturing activities, supply of raw material plasma and overall operations and the effective management of our growth, which will place a
                      significant strain on our management and on our administrative, operational and financial resources. To manage this growth, we must expand our operational, financial and management systems and hire and train additional qualified
                      personnel. If we are unable to manage our growth effectively, our business could be harmed.</div>

                    <div>&#160;</div>

                    <div style="font-style: italic; font-weight: bold; text-indent: -9pt; margin-left: 9pt;">The loss of one or more key members of our management team could adversely affect our business.</div>

                    <div>&#160;</div>

                    <div style="text-indent: 36pt;">Our performance is substantially dependent on the continued service and performance of our management team, who have extensive experience and specialized expertise in our business. In particular, the loss
                      of Adam S. Grossman, our President and Chief Executive Officer, could adversely affect our business and operating results. We do not have &#8220;key person&#8221; life insurance policies for any members of our management team. We have employment
                      agreements with each of our executive officers; however, the existence of an employment agreement does not guarantee retention of members of our management team and we may not be able to retain those individuals for the duration of or
                      beyond the end of their respective terms. The loss of services of key personnel, or the inability to attract and retain additional qualified personnel, could result in delays in development or approval of our product candidates and
                      diversion of management resources.</div>

                    <div><br/>
                    </div>

                    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
                      <div style="text-align: center; text-indent: -9pt; margin-left: 9pt;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">49</span></div>

                      <div class="BRPFPageBreak" style="page-break-after: always;">
                        <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: rgb(0, 0, 0); background-color: rgb(0, 0, 0);"/></div>

                      <div style="width: 100%;" class="BRPFPageHeader">
                        <div>
                          <div style="text-align: left; font-weight: bold; text-indent: -9pt; margin-left: 9pt;"><a href="#ADMABIOLOGICSINC."> <span style="font-style: italic; font-weight: normal; font-size: 8pt;">Table of Contents</span></a><br/>
                          </div>

                        </div>

                      </div>

                    </div>

                    <div style="font-style: italic; font-weight: bold; text-indent: 0pt;">Cyberattacks and other security breaches could compromise our proprietary and confidential information or otherwise penetrate our network, which could harm our
                      business and reputation.</div>

                    <div><br/>
                    </div>

                    <div style="text-indent: 36pt;">In the ordinary course of our business, we generate, collect and store proprietary information, including intellectual property and business information. The secure storage, maintenance, and transmission
                      of and access to this information is important to our operations and reputation. Computer hackers may attempt to penetrate our computer systems and, if successful, misappropriate our proprietary and confidential information including
                      e-mails and other electronic communications. Cybersecurity vulnerabilities can also arise from human error, fraud or malice on the part of our employees, other insiders or third parties, or from technology or product enhancements or
                      the migration of information and data to new technology platforms, systems or applications. Hackers may impersonate our vendors, suppliers or other third parties with whom we do business, which may result in financial harm to our
                      business. Further, while many of our employees and certain suppliers with whom we do business operate in a remote working environment, the risk of cybersecurity attacks and data breaches, particularly through phishing attempts, may be
                      increased as we and third parties with whom we interact leverage our IT infrastructure in unanticipated ways. In addition, an employee, contractor, or other third party with whom we do business may attempt to obtain such information
                      and may purposefully or inadvertently cause a breach involving such information. While we have certain safeguards in place to reduce the risk of and detect cyberattacks, including a Company-wide cybersecurity policy, our information
                      technology networks and infrastructure may be vulnerable to unpermitted access by hackers or other breaches, such as the IT disruption described elsewhere in this report, or employee error or malfeasance. Any such compromise of our
                      data security and access to, or public disclosure or loss of, confidential business or proprietary information could disrupt our operations, damage our reputation, provide our competitors with valuable information and subject us to
                      additional costs which could adversely affect our business.</div>

                    <div><br/>
                    </div>

                    <div style="margin: 0px; font-style: italic; font-weight: bold; text-indent: 0pt;">If we are unable to hire and retain a substantial number of qualified personnel, our ability to sustain and grow our business may be harmed.</div>

                    <div>&#160;</div>

                    <div style="text-indent: 36pt;">Our success depends in part on our ability to attract, motivate, and retain a sufficient number of qualified employees across various areas of our operations, such as research and development,
                      manufacturing operations and sales, who understand and appreciate our strategy and culture and are able to contribute to our mission. We will need to hire additional qualified personnel with expertise in commercialization, sales,
                      marketing, medical affairs, reimbursement, government regulation, formulation, quality control, manufacturing, finance, general and operational management and plasma collections. In particular, over the next 12-24 months, we expect to
                      hire several new employees devoted to our plasma collection centers, commercialization, sales, marketing, medical and scientific affairs, regulatory affairs, quality control, information technology, finance and general and operational
                      management. Qualified individuals of the requisite caliber and number needed to fill these positions may be in short supply in some areas. We compete for qualified individuals with numerous biopharmaceutical companies, universities
                      and other research institutions. Competition for such individuals is intense, and we cannot assure you that our search for such personnel will be successful. If we are unable to hire and retain personnel capable of consistently
                      performing at a high level, our business and operations could be materially adversely affected. Additionally, any material increases in existing employee turnover rates or increases in labor costs could have a material adverse effect
                      on our business, financial condition or operating results.</div>

                    <div><br/>
                    </div>

                    <div><span style="font-weight: bold; font-style: italic;">We currently collect human blood plasma at our ADMA BioCenters facilities, and if we cannot maintain FDA licensure for these facilities or obtain FDA licensure for additional
                      facilities that we may construct or acquire rights to, we may be adversely affected and may not be able to sell or use this human blood plasma for future commercial purposes.</span></div>

                    <div>
                      <div>&#160;</div>

                      <div style="text-indent: 36pt;">We intend to maintain FDA licensure of our current and future ADMA BioCenters collection facilities for the collection of human blood plasma and we may seek other governmental and regulatory approvals
                        for these facilities. Collection facilities are subject to FDA and potentially other governmental and regulatory inspections and extensive regulation, including compliance with current cGMP and blood standards and FDA licensure and
                        other governmental approvals, as applicable. Failure to comply with applicable governmental regulations or to receive applicable approvals for our current or future facilities may result in enforcement actions, such as adverse
                        inspection reports, warning or untitled letters, product recalls or seizures, monetary sanctions, injunctions to halt manufacture and distribution of products, civil or criminal sanctions, costly litigation, refusal of regulatory
                        authority approvals and licenses, restrictions on operations or withdrawal of existing approvals and licenses, any of which may significantly delay or suspend our operations for these locations, potentially having a material adverse
                        effect on our ability to manufacture our products or offer for sale plasma collected at the affected sites. Failure to comply with applicable governmental regulations may also impact the ultimate quality and compliance of our
                        finished biologic products, which may have a material adverse effect on our business.</div>

                      <div>&#160;</div>

                      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
                        <div style="text-align: center; text-indent: -9pt; margin-left: 9pt;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">50</span></div>

                        <div class="BRPFPageBreak" style="page-break-after: always;">
                          <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: rgb(0, 0, 0); background-color: rgb(0, 0, 0);"/></div>

                        <div style="width: 100%;" class="BRPFPageHeader">
                          <div>
                            <div style="text-align: left; font-weight: bold; text-indent: -9pt; margin-left: 9pt;"><a href="#ADMABIOLOGICSINC."> <span style="font-style: italic; font-weight: normal; font-size: 8pt;">Table of Contents</span></a><br/>
                            </div>

                          </div>

                        </div>

                      </div>

                      <div style="margin: 0px; font-style: italic; font-weight: bold; text-indent: 0pt;">We manufacture our current marketed products, pipeline products, and products for third parties in our manufacturing and testing facilities, and if we
                        or our vendors cannot maintain appropriate FDA status for these facilities, we may be adversely affected, and may not be able to sell, manufacture or commercialize these products.</div>

                      <div>&#160;</div>

                      <div style="text-indent: 36pt;">There are no assurances we will be able to maintain compliance with all FDA or other regulations. There is also no guarantee that we will be able to fulfill our contractual requirements to our
                        customers. Moreover, to the extent that we use third-party vendors to fulfill our regulatory or contractual requirements, these third-party vendors may perform activities for themselves or other clients and we may not be privy to
                        all regulatory findings or issues discovered by the FDA or other regulatory agencies. Such findings, which are out of our control, may adversely affect our ability to continue to work with these vendors, or our ability to release
                        commercial drug product or perform necessary testing or other actions for us or our clients, which may be required in order to remain FDA compliant or to commercialize our products. If we are not able to maintain manufacturing
                        compliance at our facilities or our vendors&#8217; facilities for our products and product candidates, we may not be able to successfully develop and commercialize our products and product candidates and we may face potential contractual
                        or regulatory actions, which would have an adverse impact on our business.</div>

                      <div>&#160;</div>

                      <div style="margin: 0px; font-style: italic; font-weight: bold; text-indent: 0pt;">We may incur substantial liabilities and may be required to limit commercialization of our products in response to product liability lawsuits.</div>

                      <div>&#160;</div>

                      <div style="text-indent: 36pt;">The testing and marketing of medical products entail an inherent risk of product liability. If we cannot successfully defend ourselves against product liability claims, we may incur substantial
                        liabilities or be required to limit commercialization of our products. Product liability claims may also result in recalls and/or regulatory enforcement actions. Even successful defense, however, could impair our results of
                        operations. Our inability to obtain and maintain sufficient product liability insurance at an acceptable cost to protect against potential product liability claims could prevent or inhibit the commercialization of pharmaceutical
                        products we develop, either alone or with collaborators.</div>

                      <div><br/></div>

                      <div style="font-style: italic; font-weight: bold; text-indent: 0pt;">Many of our business practices are subject to scrutiny by federal and state regulatory authorities, as well as to lawsuits brought by private citizens under federal
                        and state laws. Failure to comply with applicable law or an adverse decision in lawsuits may result in adverse consequences to us.</div>

                      <div>&#160;</div>

                      <div style="text-indent: 36pt;">The laws governing our conduct in the United States are enforceable on the federal, state and local levels by criminal, civil and administrative sanctions. Violations of laws such as the FDCA, the
                        Social Security Act (including the Anti-Kickback Statute), the Public Health Service Act, the civil and criminal federal False Claims Act, the civil monetary penalty statute, requirements regarding the reporting and repayment of
                        overpayments, other fraud and abuse laws and any regulations promulgated under the authority of the preceding, may result in significant criminal and/or civil sanctions, including jail sentences, fines or exclusion from
                        participation in or debarment from federal and state healthcare or government procurement programs, pursuant to enforcement actions by DOJ, Medicare, Medicaid, OIG and other regulatory authorities. Similarly, the violation of
                        applicable laws, rules and regulations of states, including the State of Florida, with respect to the manufacture and marketing of our products and product candidates may result in significant criminal and/or civil sanctions,
                        including jail sentences, fines or exclusion from participation in applicable state healthcare programs.&#160;There can be no assurance that our activities will not come under the scrutiny of federal and/or state regulators and other
                        government authorities or that our practices will not be found to violate applicable laws, rules and regulations or prompt lawsuits by private citizen &#8220;relators&#8221; under federal or state false claims laws.</div>

                      <div>&#160;</div>

                      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
                        <div style="text-align: center; text-indent: -9pt; margin-left: 9pt;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">51</span></div>

                        <div class="BRPFPageBreak" style="page-break-after: always;">
                          <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: rgb(0, 0, 0); background-color: rgb(0, 0, 0);"/></div>

                        <div style="width: 100%;" class="BRPFPageHeader">
                          <div>
                            <div style="text-align: left; font-weight: bold; text-indent: -9pt; margin-left: 9pt;"><a href="#ADMABIOLOGICSINC."> <span style="font-style: italic; font-weight: normal; font-size: 8pt;">Table of Contents</span></a><br/>
                            </div>

                          </div>

                        </div>

                      </div>

                      <div style="text-indent: 36pt;">For example, under the Anti-Kickback Statute and similar state laws and regulations, the offer or payment of anything of value to induce or reward patient referrals, or in return for purchasing,
                        leasing, ordering or arranging for or recommending the purchase, lease, or ordering of any item or service reimbursable in whole or in part by a federal healthcare program is prohibited.&#160;&#160;This places constraints on the marketing and
                        promotion of products and on common business arrangements, such as discounted terms and volume incentives for customers in a position to recommend or choose products for patients, such as physicians and hospitals, and these
                        practices can result in substantial legal penalties, including, among others, exclusion from participation in the Medicare and Medicaid programs. Arrangements with referral sources such as purchasers, group purchasing organizations,
                        healthcare organizations, physicians and pharmacists must be structured with care to comply with applicable requirements. Legislators and regulators may seek to further restrict the scope of financial relationships that are
                        considered appropriate. For example, HHS recently promulgated a regulation that is effective in two phases.&#160; First, the regulation excludes from the definition of &#8220;remuneration&#8221; limited categories of (a) PBM rebates or other
                        reductions in price to a plan sponsor under Medicare Part D or a Medicaid Managed Care Organization plan reflected in point-of-sale reductions in price and (b) PBM service fees paid by a manufacturer to a PBM.&#160; Second, effective
                        January 1, 2023, the regulation expressly provides that rebates to plan sponsors under Medicare Part D either directly to the plan sponsor under Medicare Part D, or indirectly through a pharmacy benefit manager, will not be
                        protected under the Anti-Kickback Statute discounts safe harbor. Recent legislation and a final rule promulgated on December 29, 2023 delayed implementation of this portion of the rule until January 1, 2032.</div>

                      <div><br/>
                      </div>

                      <div style="text-indent: 36pt;">Also, certain business practices, such as payments of consulting fees to healthcare professionals, sponsorship of educational or research grants, charitable donations, interactions with healthcare
                        professionals who prescribe products for uses not&#160;approved by the FDA and financial support for continuing medical education programs, must be conducted within narrowly prescribed and controlled limits to avoid any possibility of
                        wrongfully influencing healthcare professionals to prescribe or purchase particular products or as a reward for past prescribing. Under the Healthcare Reform Law, payments and transfers of value by pharmaceutical manufacturers of
                        drugs, devices, biologics and medical supplies for which payment is available under Medicare, Medicaid or the Children&#8217;s Health Insurance Program (with certain exceptions) to or at the request of covered recipients, such as, but
                        limited to, U.S.-licensed physicians, physician assistants, nurse practitioners, clinical nurse specialists and certified registered nurse anesthetists and U.S. teaching hospitals, must be tracked and reported to CMS, and are
                        publicly disclosed. Such &#8220;applicable manufacturers&#8221; are also required to report certain ownership interests held by physicians and their immediate family members. A number of states have similar laws in place. Additional and
                        stricter prohibitions could be implemented by federal and state authorities. Where such practices have been found to be improper incentives to use such products, government investigations and sanctions against manufacturers have
                        resulted in substantial fines, penalties and damages. Many manufacturers have been required to enter into consent decrees or orders that prescribe allowable corporate conduct and/or Corporate Integrity Agreements that impose ongoing
                        compliance requirements on a manufacturer.</div>

                      <div>&#160;</div>

                      <div style="text-indent: 36pt;">Failure to satisfy requirements under the FDCA can also result in penalties, as well as requirements to enter into consent decrees or orders that prescribe allowable corporate conduct. In addition,
                        while regulatory authorities generally do not regulate physicians&#8217; discretion in their choice of treatments for their patients, they do restrict communications by manufacturers on unapproved uses of approved products or on the
                        potential safety and efficacy of unapproved products in development. Companies in the United States, Canada and the European Union cannot promote approved products for other indications that are not specifically approved by the
                        competent regulatory authorities such as the FDA in the United States, nor can companies promote unapproved products. In limited circumstances, companies may disseminate to physicians information regarding unapproved uses of
                        approved products or results of studies involving investigational products. If such activities fail to comply with applicable regulations and guidelines of the various regulatory authorities, we may be subject to warnings from, or
                        enforcement action by, these authorities. Furthermore, if such activities are prohibited, it may harm demand for our products. Promotion of unapproved drugs or devices or unapproved indications for a drug or device is a violation of
                        the FDCA and subjects us to civil and criminal sanctions. Furthermore, sanctions under the federal False Claims Act have been brought against companies accused of promoting off-label uses of drugs, because such promotion induces
                        unapproved use and subsequent claims for reimbursement under Medicare and other federal programs. Similar actions for off-label promotion have been initiated by several states for Medicaid fraud. The Healthcare Reform Law
                        significantly strengthened provisions of the federal False Claims Act, the federal Anti-Kickback Statute that applies to government healthcare programs, and other healthcare fraud provisions, leading to the possibility of greatly
                        increased lawsuits by whistleblowers for perceived violations. Violations or allegations of violations of the foregoing restrictions could materially and adversely affect our business.</div>

                      <div>&#160;</div>

                      <div style="text-indent: 36pt;">We are required to report detailed pricing information, net of included discounts, rebates and other concessions, to CMS for the purpose of calculating national reimbursement levels, certain federal
                        prices and certain federal and state rebate obligations. Inaccurate or incomplete reporting of pricing information could result in criminal and/or civil liability under the federal False Claims Act, the federal Anti-Kickback Statute
                        and various other laws, rules and regulations.</div>

                      <div>&#160;</div>

                      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
                        <div style="text-align: center; text-indent: -9pt; margin-left: 9pt;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">52</span></div>

                        <div class="BRPFPageBreak" style="page-break-after: always;">
                          <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: rgb(0, 0, 0); background-color: rgb(0, 0, 0);"/></div>

                        <div style="width: 100%;" class="BRPFPageHeader">
                          <div>
                            <div style="text-align: left; font-weight: bold; text-indent: -9pt; margin-left: 9pt;"><a href="#ADMABIOLOGICSINC."> <span style="font-style: italic; font-weight: normal; font-size: 8pt;">Table of Contents</span></a><br/>
                            </div>

                          </div>

                        </div>

                      </div>

                      <div style="text-indent: 36pt;">We have established systems for collecting and reporting this data accurately to CMS and have instituted a compliance program to assure that the information collected is complete in all respects. If we
                        report pricing information that is not accurate to the federal government, we could be subject to fines and other sanctions that could adversely affect our business. If we choose to pursue clinical development and commercialization
                        in the European Union or otherwise market and sell our products outside of the United States, we must obtain and maintain regulatory approvals and comply with regulatory requirements in such jurisdictions. The approval procedures
                        vary among countries in complexity and timing. We may not obtain approvals from regulatory authorities outside the United States on a timely basis, if at all, which would preclude us from commercializing products in those markets.</div>

                      <div>&#160;</div>

                      <div style="text-indent: 36pt;">In addition, some countries, particularly the countries of the European Union, regulate the pricing of prescription pharmaceuticals. In these countries, pricing discussions with governmental authorities
                        can take considerable time after the receipt of marketing approval for a product. To obtain reimbursement or pricing approval in some countries, we may be required to conduct a clinical trial that compares the cost-effectiveness of
                        our product candidate to other available therapies. Such trials may be time-consuming and expensive and may not show an advantage in efficacy for our products. If reimbursement of our products is unavailable or limited in scope or
                        amount, or if pricing is set at unsatisfactory levels, in either the U.S. or the European Union, we could be adversely affected.</div>

                      <div>&#160;</div>

                      <div style="text-indent: 36pt;">Also, under the U.S. Foreign Corrupt Practices Act, the United States has increasingly focused on regulating the conduct by U.S. businesses occurring outside of the United States, generally prohibiting
                        remuneration to foreign officials for the purpose of obtaining or retaining business. To enhance compliance with applicable healthcare laws, and mitigate potential liability in the event of noncompliance, regulatory authorities such
                        as the HHS Office of Inspector General (the &#8220;OIG&#8221;) have recommended the adoption and implementation of a comprehensive healthcare compliance program that generally contains the elements of an effective compliance and ethics program
                        described in Section 8B2.1 of the U.S. Sentencing Commission Guidelines Manual. Most U.S.-based pharmaceutical companies have such programs. We will need to adopt healthcare compliance and ethics programs that would incorporate the
                        OIG&#8217;s recommendations and voluntary industry guidelines and train our employees. Such a program may be expensive and may not provide assurance that we will avoid compliance issues.</div>

                      <div><br/>
                      </div>

                      <div style="text-indent: 36pt;">We are also required to comply with the applicable laws, rules, regulations and permit requirements of the various states and localities in which our business operates, including the State of Florida
                        where our manufacturing facility is located.&#160; These regulations and permit requirements are not always in concert with applicable federal laws, rules and regulations regulating our business.&#160; Although compliant with applicable
                        federal requirements, we may be required to comply with additional state and local laws, rules, regulations and permits.&#160; Failure to appropriately comply with such state and local requirements could result in temporary or long-term
                        cessation of our manufacturing&#160;operations, as well as fines and other sanctions.&#160; Any such&#160;penalties may have a material adverse effect on our business and results of operations.</div>

                      <div><br/></div>

                      <div style="font-style: italic; font-weight: bold; text-indent: 0pt;">We are subject to extensive and rigorous governmental regulation, including the requirement of FDA and other federal, state and local business regulatory&#160;approvals
                        before our products and product candidates may be lawfully marketed, and our ability to obtain regulatory approval of our products and product candidates from the FDA in a timely manner, access the public markets and obtain
                        necessary capital in order to properly capitalize and continue our operations may be hindered by inadequate funding for the FDA, the SEC and other state and local government agencies.</div>

                      <div><br/>
                      </div>

                      <div style="text-indent: 36pt;">Both before and after the approval of our products, our products, operations, facilities, suppliers and CROs are subject to extensive regulation by federal, state and local governmental authorities in
                        the United States and other countries, with regulations differing from country to country. In the United States, the FDA regulates, among other things, the pre-clinical and nonclinical testing, clinical trials, manufacturing,
                        safety, efficacy, potency, labeling, storage, record keeping, quality systems, advertising, promotion, sale and distribution of therapeutic products. Failure to comply with applicable requirements could result in, among other
                        things, one or more of the following actions: notices of violation, untitled letters, warning letters, CRLs, fines and other monetary penalties, unanticipated expenditures, delays in approval or refusal to approve a product or
                        product candidate, product recall or seizure, interruption of manufacturing or clinical trials, operating restrictions, injunctions and criminal prosecution. Our products and product candidates cannot be lawfully marketed in the
                        United States without FDA and other federal, state and local business regulatory approvals. Any failure to receive the marketing approvals necessary to commercialize our products or product candidates could harm our business.</div>

                      <div><br/>
                      </div>

                      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
                        <div style="text-align: center; text-indent: -9pt; margin-left: 9pt;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">53</span></div>

                        <div class="BRPFPageBreak" style="page-break-after: always;">
                          <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: rgb(0, 0, 0); background-color: rgb(0, 0, 0);"/></div>

                        <div style="width: 100%;" class="BRPFPageHeader">
                          <div>
                            <div style="text-align: left; font-weight: bold; text-indent: -9pt; margin-left: 9pt;"><a href="#ADMABIOLOGICSINC."> <span style="font-style: italic; font-weight: normal; font-size: 8pt;">Table of Contents</span></a><br/>
                            </div>

                          </div>

                        </div>

                      </div>

                      <div style="text-indent: 36pt;">Additionally, the ability of the FDA and other federal, state and local business regulatory agencies to review and approve products and product candidates can be affected by a variety of factors,
                        including government budget and funding levels, ability to hire and retain key personnel and to accept the payment of user fees, as well as statutory, regulatory, and policy changes. Average review times at the FDA and other
                        federal, state and local business regulatory agencies have fluctuated in recent years as a result. In addition, government funding of the SEC and other government agencies on which our operations may rely, including those that fund
                        research and development activities, is subject to the political process, which is inherently fluid and unpredictable. Disruptions at the FDA and other agencies may also slow the time necessary for products and product candidate
                        submissions to be reviewed and/or approved by necessary government agencies, which would adversely affect our business. For example, over the last few years, including in December 2018 and January 2019, the U.S. government has shut
                        down several times and certain regulatory agencies, such as the FDA and the SEC, have had to furlough critical employees and stop critical activities. Separately, in response to the COVID-19 pandemic, the FDA postponed most
                        inspections at domestic and foreign manufacturing facilities from March 2020 until July 2021. If a prolonged government shutdown or regulatory agency disruption reoccurs, it could significantly impact the ability of the FDA to
                        timely review and process our regulatory submissions and other reporting requirements which could have a material adverse effect on our business. Further, future government shutdowns could impact our ability to access the public
                        markets and obtain capital that may be necessary in order to properly capitalize and continue our operations.</div>

                      <div><br/>
                      </div>

                      <div style="font-style: italic; font-weight: bold; text-indent: 0pt;">The manufacturing processes for plasma-based biologics are complex and involve biological intermediates that are susceptible to contamination and impurities.</div>

                      <div>&#160;</div>

                      <div style="text-indent: 36pt;">Plasma is a raw material that is susceptible to damage and contamination and may contain human pathogens, any of which would render the plasma unsuitable as raw material for further manufacturing. For
                        instance, improper storage of plasma, by us or third-party suppliers, may require us to destroy some of our raw material. If unsuitable plasma is not identified and discarded prior to the release of the plasma to the manufacturing
                        process, it may be necessary to discard intermediate or finished product made from that plasma or to recall any finished product released to the market, resulting in a charge to cost of product revenue. The manufacture of our plasma
                        products is an extremely complex process of fractionation, purification, testing, filling and finishing. Our products can become non-releasable or otherwise fail to meet our stringent specifications or regulatory agencies&#8217;
                        specifications through a failure in one or more of these process steps. We may detect instances in which an unreleased product was produced without adherence to our manufacturing procedures or plasma used in our production process
                        was not collected or stored in a compliant manner consistent with cGMP or other regulations. Such an event of noncompliance would likely result in our determination that the implicated products should not be released or maybe
                        replaced or withdrawn from the market and therefore should be destroyed. Once manufactured, our plasma-derived products must be handled carefully and kept at appropriate temperatures. Our failure, or the failure of third parties
                        that supply, test, ship or distribute our products or product components to properly care for our products, may require that those products be destroyed. Even if handled properly, biologics may form or contain particulates or have
                        other issues or problems after storage which may require products to be destroyed or recalled. While we expect to write off certain amounts of raw materials and work-in-process inventory in the ordinary course of business due to the
                        complex nature of plasma, our processes and our products, unanticipated events may lead to write-offs and other costs materially in excess of our expectations and the reserves we have established for these purposes. Such write-offs
                        or losses and other costs could cause material fluctuations in our results of operations. Product or component quality issues may also result in regulatory enforcement actions, liability, corrective actions and recalls, among other
                        actions, as described elsewhere in this Annual Report on Form 10-K.</div>

                      <div>&#160;</div>

                      <div>
                        <div style="text-indent: 36pt;">Furthermore, contamination of our products could cause investors, consumers, or other third parties with whom we conduct business to lose confidence in the reliability of our manufacturing procedures,
                          which could adversely affect our revenues. In addition, faulty or contaminated products that are unknowingly distributed could result in patient harm, threaten the reputation of our products and expose us to product liability
                          damages and claims from companies for whom we do contract manufacturing.</div>

                        <div style="text-indent: 36pt;"> <br/>
                        </div>

                      </div>

                      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
                        <div style="text-align: center; text-indent: -9pt; margin-left: 9pt;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">54</span></div>

                        <div style="page-break-after: always;" class="BRPFPageBreak">
                          <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: rgb(0, 0, 0); background-color: rgb(0, 0, 0);"/></div>

                        <div style="width: 100%;" class="BRPFPageHeader">
                          <div>
                            <div style="text-align: left; font-weight: bold; text-indent: -9pt; margin-left: 9pt;"><a href="#ADMABIOLOGICSINC."> <span style="font-style: italic; font-weight: normal; font-size: 8pt;">Table of Contents</span></a><br/>
                            </div>

                          </div>

                        </div>

                      </div>

                      <div style="font-style: italic; font-weight: bold; text-indent: 0pt;">Our ability to continue to produce safe and effective products depends on the safety of our plasma supply, testing by third parties and the timing of receiving the
                        testing results, and manufacturing processes we have in place to counter transmittable diseases.</div>

                      <div>&#160;</div>

                      <div style="text-indent: 36pt;">Despite overlapping safeguards, including the screening of donors and other steps to remove or inactivate viruses and other infectious disease-causing agents, the risk of transmissible disease through
                        blood plasma products cannot be entirely eliminated. For example, since plasma-derived therapeutics involves the use and purification of human plasma, there has been concern raised about the risk of transmitting HIV, prions, West
                        Nile virus, H1N1 virus or &#8220;swine flu&#8221; and other blood-borne pathogens through plasma-derived products. There are also concerns about the future transmission of H5N1 virus, or &#8220;bird flu.&#8221; In the 1980s, thousands of hemophiliacs
                        worldwide were infected with HIV through the use of contaminated Factor VIII. Other producers of Factor VIII, though not us, were defendants in numerous lawsuits resulting from these infections. New infectious diseases emerge in the
                        human population from time to time. If a new infectious disease has a period during which time the causative agent is present in the bloodstream but symptoms are not present, it is possible that plasma donations could be
                        contaminated by that infectious agent. Typically, early in an outbreak of a new disease, tests for the causative agent do not exist. During this early phase, we must rely on screening of donors for behavioral risk factors or
                        physical symptoms to reduce the risk of plasma contamination. Screening methods are generally less sensitive and specific than a direct test as a means of identifying potentially contaminated plasma units. During the early phase of
                        an outbreak of a new infectious disease, our ability to manufacture safe products would depend on the manufacturing process&#8217; capacity to inactivate or remove the infectious agent. To the extent our manufacturing processes are
                        inadequate to inactivate or remove an infectious agent, our ability to manufacture and distribute our products would be impaired. If a new infectious disease were to emerge in the human population or if there were a reemergence of
                        an infectious disease, the regulatory and public health authorities could impose precautions to limit the transmission of the disease that would impair our ability to procure plasma, manufacture our products or both. Such
                        precautionary measures could be taken before there is conclusive medical or scientific evidence that a disease poses a risk for plasma-derived products. In recent years, new testing and viral inactivation methods have been developed
                        that more effectively detect and inactivate infectious viruses in collected plasma. There can be no assurance, however, that such new testing and inactivation methods will adequately screen for, and inactivate, infectious agents in
                        the plasma used in the production of our products.</div>

                      <div>&#160;</div>

                      <div style="font-style: italic; font-weight: bold; text-indent: 0pt;">We could become supply-constrained and our financial performance would suffer if we cannot obtain adequate quantities of FDA-approved source and high-titer plasma
                        with proper specifications or other necessary raw materials.</div>

                      <div>&#160;</div>

                      <div style="text-indent: 36pt;">In order for plasma to be used in the manufacturing of our products, the individual centers at which the plasma is collected must generally be licensed by the FDA and approved by the regulatory
                        authorities of any country in which we may wish to commercialize our products. When we open a new plasma center, and on an ongoing basis after licensure, it must be inspected by the FDA for compliance with cGMP and other regulatory
                        requirements. Therefore, even if we are able to construct new plasma collection centers to complement our current plasma collection facilities, an unsatisfactory inspection could prevent a new center from being licensed or risk the
                        suspension or revocation of an existing license, among other enforcement actions. Additionally, although we achieved normal source plasma supply self-sufficiency with the approval of our tenth plasma collection center in November
                        2023, we remain reliant on the purchase of RSV plasma from third parties and the collection of RSV and normal source plasma from our FDA-licensed plasma collection centers to manufacture our products. We can give no assurances that
                        appropriate plasma will be available to us through our own plasma collection facilities or on commercially reasonable terms, or at all, to manufacture our products, or that third parties will be able to supply plasma to us in
                        accordance with plasma purchase agreements. Further, the COVID-19 pandemic resulted in significant constraints in raw material supply across various different industries, including the supply of plasma. It is possible that in the
                        future, pandemics and government responses thereto will have an adverse effect on our ability to source plasma from donors in quantity and quality sufficient for our manufacturing processes. In order to maintain a plasma center&#8217;s
                        license, its operations must continue to conform to cGMP and other regulatory requirements. In the event that we determine that plasma was not collected in compliance with cGMP and other applicable regulatory requirements, we may be
                        unable to use and may ultimately destroy plasma collected from that center, which would be recorded as a charge to cost of product revenue. Additionally, if non-compliance in the plasma collection process is identified after the
                        impacted plasma has been pooled with compliant plasma from other sources, entire plasma pools, in-process intermediate materials and final products could be impacted. Consequently, we could experience significant inventory
                        impairment provisions and write-offs which could adversely affect our business and financial results. We plan to increase our supplies of plasma for use in the manufacturing processes through increased purchases of plasma from
                        third-party suppliers as well as collections from our existing ADMA BioCenters plasma collection facilities. This strategy is dependent upon our ability to maintain a cGMP compliant environment at our plasma collection facilities
                        and to expand production and attract donors to our facilities. There is no assurance that the FDA will inspect and license any of our current or future unlicensed plasma collection facilities in a timely manner consistent with our
                        production plans. If we misjudge the readiness of a center for an FDA inspection, we may lose credibility with the FDA and cause the FDA to more closely examine all of our operations. Such additional scrutiny could materially hamper
                        our operations and our ability to increase plasma collections. Our ability to expand production and increase our plasma collection facilities to more efficient production levels may be affected by changes in the economic environment
                        and population in selected regions where ADMA BioCenters operates its current or future plasma facilities, by the entry of competitive plasma centers into regions where ADMA BioCenters operates such centers, by misjudging the
                        demographic potential of individual regions where ADMA BioCenters expects to expand production and attract new donors, by unexpected facility related challenges, or by unexpected management challenges at selected plasma facilities
                        held by us from time to time.</div>

                      <div><br/>
                      </div>

                      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
                        <div style="text-align: center; text-indent: -9pt; margin-left: 9pt;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">55</span></div>

                        <div class="BRPFPageBreak" style="page-break-after: always;">
                          <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: rgb(0, 0, 0); background-color: rgb(0, 0, 0);"/></div>

                        <div style="width: 100%;" class="BRPFPageHeader">
                          <div>
                            <div style="text-align: left; font-weight: bold; text-indent: -9pt; margin-left: 9pt;"><a href="#ADMABIOLOGICSINC."> <span style="font-style: italic; font-weight: normal; font-size: 8pt;">Table of Contents</span></a><br/>
                            </div>

                          </div>

                        </div>

                      </div>

                      <div style="font-style: italic; font-weight: bold; text-indent: 0pt;">Our ability to commercialize our products, alone or with collaborators, will depend in part upon the extent to which reimbursement will be available from
                        governmental agencies, health administration authorities, private health maintenance organizations and health insurers and other healthcare payers, and also depends upon the approval, timing and representations by the FDA or other
                        governmental authorities for our product candidates.</div>

                      <div>&#160;</div>

                      <div style="text-indent: 36pt;">Our ability to generate product revenues will be diminished if our products sell for inadequate prices or patients are unable to obtain adequate levels of insurance coverage. Significant uncertainty
                        exists as to the reimbursement status of newly approved healthcare products, as well as to the timing, language, specifications and other details pertaining to the approval of such products. Healthcare payers, including Medicare,
                        are challenging the prices charged for medical products and services. Government and other healthcare payers increasingly attempt to contain healthcare costs by limiting both coverage and the level of reimbursement for products.
                        Even if one of our product candidates is approved by the FDA, insurance coverage may not be available, and reimbursement levels may be inadequate, to cover such product. If government and other healthcare payers do not provide
                        adequate coverage and reimbursement levels for one of our products, once approved, market acceptance of such product could be reduced. Prices in many countries, including many in Europe, are subject to local regulation and certain
                        pharmaceutical products, such as plasma-derived products, are subject to price controls in several of the world&#8217;s principal markets, including many countries within the European Union. In the United States, where pricing levels for
                        our products are substantially established by third-party payers, including Medicare, if payers reduce the amount of reimbursement for a product, it may cause groups or individuals dispensing the product to discontinue
                        administration of the product, to administer lower doses, to substitute lower cost products or to seek additional price-related concessions. These actions could have a negative effect on our financial results, particularly in cases
                        where our products command a premium price in the marketplace, or where changes in reimbursement induce a shift in the site of treatment. The existence of direct and indirect price controls and pressures over our products could
                        materially adversely affect our financial prospects and performance.</div>

                      <div style="text-indent: 36pt;"> <br/>
                      </div>

                      <div style="text-indent: 36pt;">
                        <div>
                          <div>
                            <div style="margin: 0px; font-style: italic; font-weight: bold; text-indent: 0pt;"><span style="font-style: italic; font-weight: bold;">The </span>biosimilar pathway established as part of healthcare reform may make it easier
                              for competitors to market biosimilar products.</div>

                          </div>

                        </div>

                        <div>&#160;</div>

                        <div style="text-indent: 36pt;">The ACA and the companion Healthcare and Education Reconciliation Act (which together are referred to as the &#8220;Healthcare Reform Law&#8221;) introduced an abbreviated licensure pathway for biological
                          products that are demonstrated to be biosimilar to an FDA-licensed biological product.&#160; A biological product may be demonstrated to be &#8220;biosimilar&#8221; if data shows that, among other things, the product is &#8220;highly similar&#8221; to an
                          already-approved biological product, known as a reference product, and has no clinically meaningful differences in terms of safety and effectiveness from the reference product. The law provides that a biosimilar application may be
                          submitted as soon as four years after the reference product is first licensed, and that the FDA may not make approval of an application effective until 12 years after the reference product was first licensed.&#160; Since the enactment
                          of the law, the FDA has issued several guidance documents to assist sponsors of biosimilar products in preparing their approval applications.&#160;Moreover, in an effort to increase competition in the biologic product marketplace,
                          Congress, the executive branch, and the FDA have taken certain legislative and regulatory steps. For example, in 2020 the FDA finalized a guidance to facilitate biologic product importation. The 2020 Further Consolidated
                          Appropriations Act included provisions requiring that sponsors of approved biologic products provide samples of the approved products to persons developing biosimilar products within specified timeframes, in sufficient quantities,
                          and on commercially reasonable market-based terms. The FDA approved the first biosimilar product in 2015 and has since approved a number of biosimilars.&#160; As a result of the biosimilar pathway in the United States, we expect in the
                          future to face greater competition from biosimilar products, including a possible increase in patent challenges.</div>

                        <div><br/>
                        </div>

                      </div>

                      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
                        <div style="text-align: center; text-indent: -9pt; margin-left: 9pt;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">56</span></div>

                        <div style="page-break-after: always;" class="BRPFPageBreak">
                          <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: rgb(0, 0, 0); background-color: rgb(0, 0, 0);"/></div>

                        <div style="width: 100%;" class="BRPFPageHeader">
                          <div>
                            <div style="text-align: left; font-weight: bold; text-indent: -9pt; margin-left: 9pt;"><a href="#ADMABIOLOGICSINC."> <span style="font-style: italic; font-weight: normal; font-size: 8pt;">Table of Contents</span></a><br/>
                            </div>

                          </div>

                        </div>

                      </div>

                      <div style="margin: 0px; font-style: italic; font-weight: bold; text-indent: 0pt;">The implementation of the Healthcare Reform Law in the United States may adversely affect our business.</div>

                      <div>&#160;</div>

                      <div style="text-indent: 36pt;">Through the March 2010 adoption of the Healthcare Reform Law in the United States, substantial changes are being made to the current system for paying for healthcare in the United States, including
                        programs to extend medical benefits to millions of individuals who currently lack insurance coverage. This reform establishes significant cost-saving measures with respect to several government healthcare programs, including
                        Medicaid and Medicare Parts B and D, that may cover the cost of our future products, and these efforts could have a material adverse impact on our future financial prospects and performance. For example, in order for a
                        manufacturer&#8217;s products to be reimbursed by federal funding under Medicaid, the manufacturer must enter into a Medicaid rebate agreement with the Secretary of HHS and pay certain rebates to the states based on utilization data
                        provided by each state to the manufacturer and to CMS and pricing data provided by the manufacturer to the federal government. The states share these savings with the federal government, and sometimes implement their own additional
                        supplemental rebate programs. Under the Medicaid drug rebate program, the rebate amount for most branded drug products was previously equal to a minimum of 15.1% of the Average Manufacturer Price (&#8220;AMP&#8221;) or the AMP less Best Price,
                        whichever is greater, plus the inflation penalty if applicable. Effective January 1, 2010, the Healthcare Reform Law generally increased the size of the Medicaid rebates paid by manufacturers for single source and innovator multiple
                        source (brand name) drug products from a minimum of 15.1% to a minimum of 23.1% of AMP, subject to certain exceptions, plus the inflation penalty if applicable. For non-innovator multiple source (generic) products, the rebate
                        percentage was increased from a minimum of 11.0% to a minimum of 13.0% of AMP, and the Bipartisan Budget Act of 2015 established a new inflation penalty for these drugs.&#160;&#160;In 2010, the Healthcare Reform Law also newly extended the
                        Medicaid drug rebate obligation to prescription drugs covered by Medicaid managed care organizations. These increases in required rebates may adversely affect our future financial prospects and performance. In order for a
                        pharmaceutical product to receive federal reimbursement under the Medicare Part B and Medicaid programs or to be sold directly to U.S. government agencies, the manufacturer must extend discounts to entities eligible to participate
                        in the 340B drug pricing program.&#160;&#160;The required 340B discount on a given product is calculated based on the AMP and Medicaid rebate amounts reported by the manufacturer.&#160;&#160;As the 340B drug pricing is determined based on AMP and
                        Medicaid rebate data, the revisions to the Medicaid rebate formula and AMP definition described above could cause the required 340B discount to increase, and recent regulations have established a civil monetary penalty for failure
                        to refund these overcharges.</div>

                      <div>&#160;</div>

                      <div style="text-indent: 36pt;">Effective in 2011, the Healthcare Reform Law imposed an annual, nondeductible fee on any entity that manufactures or imports certain branded prescription drugs and biologic agents, apportioned among
                        these entities according to their market share in certain government healthcare programs. These fees may adversely affect our future financial prospects and performance.&#160;</div>

                      <div>&#160;</div>

                      <div style="text-indent: 36pt;">The Healthcare Reform Law also created new rebate obligations for our products under Medicare Part D, a partial, voluntary prescription drug benefit created by the U.S. federal government primarily for
                        persons 65 years old and over. The Part D drug program is administered through private insurers that contract with CMS. Beginning in 2011, the Healthcare Reform Law generally requires that in order for a drug manufacturer&#8217;s products
                        to be reimbursed under Medicare Part D, the manufacturer must enter into a Medicare Coverage Gap Discount Program agreement with the Secretary of HHS, and reimburse each Medicare Part D plan sponsor an amount now equal to 70%
                        savings for the manufacturer&#8217;s brand name drugs and biologics which the Part D plan sponsor has provided to its Medicare Part D beneficiaries who are in the &#8220;donut hole&#8221; (or a gap in Medicare Part D coverage for beneficiaries who
                        have expended certain amounts for drugs). The Part D plan sponsor is responsible for calculating and providing the discount directly to its beneficiaries and for reporting these amounts paid to CMS&#8217;s contractor, which notifies drug
                        manufacturers of the rebate amounts it must pay to each Part D plan sponsor. The rebate requirement could adversely affect our future financial performance, particularly if contracts with Part D plans cannot be favorably
                        renegotiated or the Part D plan sponsors fail to accurately calculate payments due in a manner that overstates our rebate obligation. Regarding access to our products, the Healthcare Reform Law established and provided significant
                        funding for a Patient-Centered Outcomes Research Institute to coordinate and fund Comparative Effectiveness Research (&#8220;CER&#8221;). While the stated intent of CER is to develop information to guide providers to the most efficacious
                        therapies, outcomes of CER could influence the reimbursement or coverage for therapies that are determined to be less cost-effective than others. Should any of our products be determined to be less cost effective than alternative
                        therapies, the levels of reimbursement for these products, or the willingness to reimburse at all, could be impacted, which could materially impact our future financial prospects and results. </div>

                      <div> <br/>
                      </div>

                      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
                        <div style="text-align: center; text-indent: -9pt; margin-left: 9pt;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">57</span></div>

                        <div style="page-break-after: always;" class="BRPFPageBreak">
                          <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: rgb(0, 0, 0); background-color: rgb(0, 0, 0);"/></div>

                        <div style="width: 100%;" class="BRPFPageHeader">
                          <div>
                            <div style="text-align: left; font-weight: bold; text-indent: -9pt; margin-left: 9pt;"><a href="#ADMABIOLOGICSINC."> <span style="font-style: italic; font-weight: normal; font-size: 8pt;">Table of Contents</span></a><br/>
                            </div>

                          </div>

                        </div>

                      </div>

                      <div style="text-indent: 36pt;">There have been repeated legal challenges and attempts by Congress to repeal or change the Healthcare Reform Law and the possibility of future challenges or legislative changes contribute to the
                        uncertainty of the ongoing implementation and impact of the law and also underscores the potential for additional reform going forward. We cannot assure that the law, as currently enacted or as amended in the future, will not
                        adversely affect our business and financial results and we cannot predict how future federal or state legislative or administrative changes relating to healthcare reform will affect our business.&#160; Certain provisions of enacted or
                        proposed legislative changes may negatively impact coverage and reimbursement of, or rebates paid by manufacturers for, healthcare items and services. We will continue to evaluate the effect that the Healthcare Reform Law and any
                        potential changes may have on our business.&#160;</div>

                      <div>&#160;</div>

                      <div style="font-style: italic; font-weight: bold; text-indent: 0pt;">Corporate responsibility, specifically related to Environmental, Social and Governance (&#8220;ESG&#8221;) matters, may impose additional costs and expose us to new risks.</div>

                      <div>&#160;</div>

                      <div style="text-indent: 36pt;">Public ESG and sustainability reporting is becoming more broadly expected by investors, stockholders and other third parties. Certain organizations that provide corporate governance and other corporate
                        risk information to investors and stockholders have developed, and others may in the future develop, scores and ratings to evaluate companies and investment funds based upon ESG or &#8220;sustainability&#8221; metrics. Many investment funds
                        focus on positive ESG business practices and sustainability scores when making investments and may consider a company&#8217;s ESG or sustainability scores as a reputational or other factor in making an investment decision. In addition,
                        investors, particularly institutional investors, use these scores to benchmark companies against their peers and if a company is perceived as lagging, these investors may engage with such company to improve ESG disclosure or
                        performance and may also make voting decisions, or take other actions, to hold these companies and their boards of directors accountable.&#160;Board&#160;diversity&#160;is an ESG topic that is, in particular, receiving heightened attention by
                        investors, stockholders, lawmakers and listing exchanges. Certain states have passed laws requiring companies to meet certain gender and ethnic diversity requirements on their boards of directors. We may face reputational damage in
                        the event our corporate responsibility initiatives or objectives, including with respect to&#160;board&#160;diversity, do not meet the standards set by our investors, stockholders, lawmakers, listing exchanges or other constituencies, or if
                        we are unable to achieve an acceptable ESG or sustainability rating from third-party rating&#160;services. A low ESG or sustainability rating by a third-party rating service could also result in the exclusion of our common stock from
                        consideration by certain investors who may elect to invest with our competition instead. Ongoing focus on corporate responsibility matters by investors and other parties as described above may impose additional costs or expose us to
                        new risks.</div>

                      <div><br/>
                      </div>

                      <div>
                        <div style="font-weight: bold; text-indent: -9pt; margin-left: 9pt;">Risks Relating to our Finances, Capital Requirements and Other Financial Matters</div>

                        <div><br/>
                        </div>

                        <div style="font-style: italic; font-weight: bold; text-indent: 0pt;">We may not have cash available to us in amounts sufficient to enable us to make interest or principal payments on our indebtedness when due.</div>

                        <div><br/>
                        </div>

                        <div style="text-indent: 36pt;">The Ares Credit Facility provided for total senior secured loans in an aggregate principal amount of $135.0 million, of which $75.0 million is currently outstanding. Borrowings under the Ares Credit
                          Facility currently bear interest at a weighted-average rate of approximately 9.4% per annum, which reflects the three-month term SOFR rate; provided, however, that upon, and during the continuance of, an event of default, the
                          interest rate will automatically increase by an additional 200 basis points. We are currently required to make quarterly payments of interest during the remaining term of the Ares Credit Facility of approximately $1.8 million,
                          with all principal and unpaid interest due at maturity. In addition, our monthly interest rate obligation is subject to rising interest rates. The Ares Credit Facility has a maturity date of December 20, 2027, subject to
                          acceleration pursuant to the Ares Credit Agreement, including upon an event of default. All of our obligations under the Ares Credit Facility are secured by a first-priority lien and security interest in substantially all of our
                          and our subsidiaries&#8217; tangible and intangible assets, including intellectual property, and all of the equity interests in our subsidiaries.</div>

                        <div><br/>
                        </div>

                        <div style="text-indent: 36pt;">Our current and projected cash, cash equivalents and accounts receivable may not be sufficient to repay all of our current outstanding debt obligations as they mature. If we are unable to maintain
                          sufficient positive cash flow to repay our outstanding debt obligations as they mature, we would need to obtain additional financing in the amounts necessary to repay our outstanding debt obligations when due. If we are unable to
                          repay our outstanding debt obligations when they mature, our creditors would be able to accelerate all of the amounts due and, in the case of the Ares Credit Facility, seek to enforce their security interests, which could lead to
                          our creditors taking immediate possession of and selling substantially all of our assets with no return provided to our stockholders.</div>

                        <div style="text-indent: 36pt;"> <br/>
                        </div>

                      </div>

                      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
                        <div style="text-align: center; text-indent: -9pt; margin-left: 9pt;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">58</span></div>

                        <div style="page-break-after: always;" class="BRPFPageBreak">
                          <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: rgb(0, 0, 0); background-color: rgb(0, 0, 0);"/></div>

                        <div style="width: 100%;" class="BRPFPageHeader">
                          <div>
                            <div style="text-align: left; font-weight: bold; text-indent: -9pt; margin-left: 9pt;"><a href="#ADMABIOLOGICSINC."> <span style="font-style: italic; font-weight: normal; font-size: 8pt;">Table of Contents</span></a><br/>
                            </div>

                          </div>

                        </div>

                      </div>

                      <div style="font-style: italic; font-weight: bold; text-indent: 0pt;">Raising additional funds by issuing securities or through licensing or lending arrangements may cause dilution to our existing stockholders, restrict our operations
                        or require us to relinquish proprietary rights.</div>

                      <div>&#160;</div>

                      <div style="text-indent: 36pt;">To the extent that we raise additional capital by issuing equity securities, the share ownership of existing stockholders will be diluted. Any future debt financing may involve covenants that, among
                        other restrictions, limit our ability to incur liens or additional debt, pay dividends, redeem or repurchase our common stock, make certain investments or engage in certain merger, consolidation or asset sale transactions. In
                        addition, if we raise additional funds through licensing arrangements or the disposition of any of our assets, it may be necessary to relinquish potentially valuable rights to our product candidates or grant licenses on terms that
                        are not favorable to us.</div>

                      <div>&#160;</div>

                      <div style="margin: 0px; font-style: italic; font-weight: bold; text-indent: 0pt;">Our cash and cash equivalents could be adversely affected if the financial institutions in which we hold our cash and cash equivalents fail.</div>

                      <div>&#160;</div>

                      <div style="text-indent: 36pt;">We regularly maintain cash balances at third-party financial institutions in excess of the Federal Deposit Insurance Corporation insurance limit. While we monitor the cash balances in our operating
                        accounts on a daily basis and adjust the balances as appropriate, these balances could be impacted, and there could be a material adverse effect on our business, if one or more of the financial institutions with which we deposit
                        cash fails or is subject to other adverse conditions in the financial or credit markets. To date, we have experienced no loss or lack of access to our invested cash or cash equivalents; however, we can provide no assurance that
                        access to our invested cash and cash equivalents will not be impacted by adverse conditions in the financial and credit markets.</div>

                      <div>&#160;</div>

                      <div style="margin: 0px; font-style: italic; font-weight: bold; text-indent: 0pt;">If we fail to maintain proper and effective internal control over financial reporting in the future, our ability to produce accurate and timely
                        financial statements could be impaired, which could result in investors losing confidence in the accuracy and completeness of our financial statements, harm our operating results and negatively affect the market price of our common
                        stock.</div>

                      <div>&#160;</div>

                      <div style="text-indent: 36pt;">Pursuant to Section 404 of the Sarbanes-Oxley Act of 2002 and related rules (the &#8220;Sarbanes-Oxley Act&#8221;), we are required to maintain internal control over financial reporting and our management is
                        required to report on the effectiveness of our internal control over financial reporting, including any material weaknesses in such internal controls. The rules governing the standards that must be met for management to assess our
                        internal control over financial reporting are complex and require significant documentation, testing and possible remediation. To comply with the requirements of being a reporting company under the Exchange Act, we have been
                        required to upgrade, and will need to implement further upgrades, to our financial, information and operating systems, implement additional financial and management controls, reporting systems and procedures and hire additional
                        accounting and finance staff.</div>

                      <div><br/>
                      </div>

                      <div style="text-indent: 36pt;">Because we became a large accelerated filer effective December 31, 2023, the Sarbanes-Oxley Act requires our independent registered public accounting firm to attest to the effectiveness of our internal
                        control over financial reporting. Our transition to large accelerated filer status and becoming subject to additional requirements of the Sarbanes-Oxley Act has been and will continue to be time-consuming, and there is a risk of
                        noncompliance. Further, the costs associated with the compliance with and implementation of procedures under these and future laws and related rules could have a material impact on our results of operations.</div>

                      <div><br/>
                      </div>

                      <div>
                        <div style="text-indent: 36pt;">Consequently, we have incurred increased costs related to our compliance with Section 404 of the Sarbanes-Oxley Act and will continue to do so. Our Audit Committee has retained the services of BDO, a
                          Sarbanes-Oxley advisor, to assist with our internal control over financial reporting and information technology related to the Sarbanes-Oxley Act. Moreover, if we have a material weakness in our internal control over financial
                          reporting, we may not detect errors on a timely basis and our financial statements may be materially misstated. If we identify material weaknesses in our internal control over financial reporting, if we are unable to comply with
                          the requirements of Section 404 of the Sarbanes-Oxley Act in a timely manner, if we are unable to assert that our internal control over financial reporting is effective or if our independent registered public accounting firm is
                          unable to express an opinion as to the effectiveness of our internal control over financial reporting, investors may lose confidence in the accuracy and completeness of our financial reports, and the market price of our common
                          stock could be negatively affected. In addition, we could become subject to investigations by any stock exchange on which our securities are listed, the SEC or other regulatory authorities, which could require additional financial
                          and management resources, which could have an adverse impact on our business.</div>

                        <div style="text-indent: 36pt;"> <br/>
                        </div>

                      </div>

                      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
                        <div style="text-align: center; text-indent: -9pt; margin-left: 9pt;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">59</span></div>

                        <div style="page-break-after: always;" class="BRPFPageBreak">
                          <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: rgb(0, 0, 0); background-color: rgb(0, 0, 0);"/></div>

                        <div style="width: 100%;" class="BRPFPageHeader">
                          <div>
                            <div style="text-align: left; font-weight: bold; text-indent: -9pt; margin-left: 9pt;"><a href="#ADMABIOLOGICSINC."> <span style="font-style: italic; font-weight: normal; font-size: 8pt;">Table of Contents</span></a><br/>
                            </div>

                          </div>

                        </div>

                      </div>

                      <div style="margin: 0px; font-style: italic; font-weight: bold; text-indent: 0pt;">Our ability to use our net operating loss carryforwards (&#8220;NOLs&#8221;) may be limited.</div>

                      <div>&#160;</div>

                      <div style="text-indent: 36pt;">We have incurred substantial losses during our history. As of December 31, 2024, we had federal and state NOLs of $265.6 million and $203.4 million, respectively. Federal and state NOLs of approximately
                        $33.4 million and $62.0 million, respectively, will begin to expire at various dates beginning in 2028, if not limited by triggering events prior to such time. Under the provisions of the Internal Revenue Code of 1986, as amended
                        (the &#8220;Code&#8221;), changes in our ownership, in certain circumstances, will limit the amount of federal NOLs that can be utilized annually in the future to offset taxable income. In particular, Section 382 of the Code ("Section 382")
                        imposes limitations on a company&#8217;s ability to use NOLs upon certain changes in such ownership. If we are limited in our ability to use our NOLs in future years in which we have taxable income, we will pay more taxes than if we were
                        able to fully utilize our NOLs. The acquisition transaction that we completed on June 6, 2017 resulted in a change in ownership of ADMA under Section 382 and, as a result, we were required to write off $57.6 million of federal NOLs.
                        On October 25, 2021, we completed a public offering of our common stock whereby we issued 57,500,000 shares of our common stock resulting in another change of ownership for ADMA under section 382 of the Code, resulting in an
                        additional write-off of $3.0 million of federal NOLs, $28.1 million of state NOLs and $1.0 million of research and development credits. Although we did not experience any ownership changes for the years ended December 31, 2024 and
                        2023, we may experience ownership changes in the future as a result of subsequent changes in our stock ownership that we cannot predict or control that could result in further limitations being placed on our ability to utilize our
                        federal NOLs.</div>

                      <div><br/>
                      </div>

                      <div style="margin: 0px; font-style: italic; font-weight: bold; text-indent: 0pt;">Fluctuations in our tax obligations and effective tax rate and realization of our net deferred tax assets may result in volatility of our operating
                        results and materially impact our financial condition or financial results.</div>

                      <div><br/>
                      </div>

                      <div style="text-indent: 36pt;">We are subject to taxes by the U.S. federal, state, and local tax authorities. We record income tax expense based on our estimates of future payments, which may include the recording of, or adjustments
                        to, liabilities for uncertain tax positions, and changes in the valuation allowance related to our net deferred tax assets. In addition, at any one time multiple tax years may be subject to audit by various tax authorities. The
                        results of these audits and negotiations with taxing authorities may affect the ultimate settlement of these issues and impact our results of operations. We expect that during fiscal year 2025 and beyond there could be ongoing
                        variability in our effective tax rate as events occur and exposures are evaluated. The volatility of our future effective tax rate could be materially impacted by a number of factors, including:</div>

                      <div>
                        <div>&#160;</div>

                        <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0); border-spacing: 0;">


  <tr>

    <td style="width: 18pt;">&#160;</td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="vertical-align: top;">
                                <div>changes in the valuation of our deferred tax assets and liabilities;</div>
                              </td>

  </tr>


</table>
                        <div>&#160;</div>

                        <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0); border-spacing: 0;">


  <tr>

    <td style="width: 18pt;">&#160;</td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
                                <div>expected timing and amount of the release of any valuation allowance on our deferred tax assets; or</div>
                              </td>

  </tr>


</table>
                        <div>&#160;</div>

                        <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: rgb(0, 0, 0); border-spacing: 0;">


  <tr>

    <td style="width: 18pt;">&#160;</td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
                                <div>changes in U.S. federal, state and local tax rates, tax laws, regulations, or interpretations thereof.</div>
                              </td>

  </tr>


</table>
                      </div>

                      <div> <br/>
                      </div>

                      <div style="text-indent: 36pt;">In addition, our effective tax rate in a given financial statement period may be materially impacted by a variety of factors including, but not limited to, changes in the mix and level of earnings,
                        deductible expenses and availability of NOLs in the different states in which we operate, fluctuations in the valuation allowance on our deferred tax assets, or by changes to existing accounting rules or regulations. Further, tax
                        legislation may be enacted or amended, as applicable, in the future which could materially impact our current or future tax structure and effective tax rates. We may be subject to audits of our income, sales, and other transaction
                        taxes by U.S. federal, state, and local taxing authorities. Outcomes from these audits could have a material effect on our financial condition or financial results.</div>

                      <div><br/></div>

                    </div>

                  </div>

                </div>

              </div>

            </div>

          </div>

        </div>

      </div>

      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div style="text-align: center; text-indent: -9pt; margin-left: 9pt;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">60</span></div>

        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"/></div>

        <div style="width: 100%;" class="BRPFPageHeader">
          <div>
            <div style="text-align: left; font-weight: bold; text-indent: -9pt; margin-left: 9pt;"><a href="#ADMABIOLOGICSINC."> <span style="font-style: italic; font-weight: normal; font-size: 8pt;">Table of Contents</span></a><br/>
            </div>

          </div>

        </div>

      </div>

      <div style="font-weight: bold;">Risks Associated with our Common Stock</div>

      <div>&#160;</div>

      <div style="font-style: italic; font-weight: bold;">The market price of our common stock may be volatile and may fluctuate in a way that is disproportionate to our operating performance.</div>

      <div> <br/>
      </div>

      <div style="text-indent: 36pt;">Our stock price may experience substantial volatility as a result of a number of factors, including:</div>

      <div> <br/>
      </div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
              <div>sales or potential sales of substantial amounts of our common stock;</div>
            </td>

  </tr>


</table>
      <div> <br/>
      </div>

      <div>
        <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-spacing: 0;">


  <tr style="vertical-align: top;">

    <td style="width: 18pt;">&#160;</td>

    <td style="text-align: right; vertical-align: top; width: 18pt;">
                <div style="text-align: left;">&#8226;</div>
              </td>

    <td style="text-align: left; vertical-align: top; width: auto;">
                <div>delay or failure in initiating or completing preclinical or clinical trials or unsatisfactory results of these trials;</div>
              </td>

  </tr>


</table>
      </div>

      <div> <br/>
      </div>

      <div>
        <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-spacing: 0;">


  <tr style="vertical-align: top;">

    <td style="width: 18pt;">&#160;</td>

    <td style="text-align: right; vertical-align: top; width: 18pt;">
                <div style="text-align: left;">&#8226;</div>
              </td>

    <td style="text-align: left; vertical-align: top; width: auto;">
                <div>delay in a decision by federal, state or local business regulatory authority;</div>
              </td>

  </tr>


</table>
      </div>

      <div><br/>
      </div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
              <div>the timing of acceptance, third-party reimbursement and sales of BIVIGAM and ASCENIV;</div>
            </td>

  </tr>


</table>
      <div><br/>
      </div>

      <div>
        <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-spacing: 0;">


  <tr style="vertical-align: top;">

    <td style="width: 18pt;">&#160;</td>

    <td style="text-align: right; vertical-align: top; width: 18pt;">
                <div style="text-align: left;">&#8226;</div>
              </td>

    <td style="text-align: left; vertical-align: top; width: auto;">
                <div>announcements about us or about our competitors, including clinical trial results, regulatory approvals or new product introductions;</div>
              </td>

  </tr>


</table>
      </div>

      <div> <br/>
      </div>

      <div>
        <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-spacing: 0;">


  <tr style="vertical-align: top;">

    <td style="width: 18pt;">&#160;</td>

    <td style="text-align: right; vertical-align: top; width: 18pt;">
                <div style="text-align: left;">&#8226;</div>
              </td>

    <td style="text-align: left; vertical-align: top; width: auto;">
                <div>developments concerning our licensors or third-party vendors;</div>
              </td>

  </tr>


</table>
      </div>

      <div> <br/>
      </div>

      <div>
        <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-spacing: 0;">


  <tr style="vertical-align: top;">

    <td style="width: 18pt;">&#160;</td>

    <td style="text-align: right; vertical-align: top; width: 18pt;">
                <div style="text-align: left;">&#8226;</div>
              </td>

    <td style="text-align: left; vertical-align: top; width: auto;">
                <div>litigation and other developments relating to our patents or other proprietary rights or those of our competitors;</div>
              </td>

  </tr>


</table>
      </div>

      <div> <br/>
      </div>

      <div>
        <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-spacing: 0;">


  <tr style="vertical-align: top;">

    <td style="width: 18pt;">&#160;</td>

    <td style="text-align: right; vertical-align: top; width: 18pt;">
                <div style="text-align: left;">&#8226;</div>
              </td>

    <td style="text-align: left; vertical-align: top; width: auto;">
                <div>conditions in the pharmaceutical or biotechnology industries;</div>
              </td>

  </tr>


</table>
      </div>

      <div> <br/>
      </div>

      <div>
        <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-spacing: 0;">


  <tr style="vertical-align: top;">

    <td style="width: 18pt;">&#160;</td>

    <td style="text-align: right; vertical-align: top; width: 18pt;">
                <div style="text-align: left;">&#8226;</div>
              </td>

    <td style="text-align: left; vertical-align: top; width: auto;">
                <div>governmental regulation and legislation;</div>
              </td>

  </tr>


</table>
      </div>

      <div><br/>
      </div>

      <div>
        <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-spacing: 0;">


  <tr style="vertical-align: top;">

    <td style="width: 18pt;">&#160;</td>

    <td style="text-align: right; vertical-align: top; width: 18pt;">
                <div style="text-align: left;">&#8226;</div>
              </td>

    <td style="text-align: left; vertical-align: top; width: auto;">
                <div>overall market volatility;</div>
              </td>

  </tr>


</table>
      </div>

      <div><br/>
      </div>

      <div>
        <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-spacing: 0;">


  <tr style="vertical-align: top;">

    <td style="width: 18pt;">&#160;</td>

    <td style="text-align: right; vertical-align: top; width: 18pt;">
                <div style="text-align: left;">&#8226;</div>
              </td>

    <td style="text-align: left; vertical-align: top; width: auto;">
                <div>global and economic uncertainty;</div>
              </td>

  </tr>


</table>
      </div>

      <div> <br/>
      </div>

      <div>
        <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-spacing: 0;">


  <tr style="vertical-align: top;">

    <td style="width: 18pt;">&#160;</td>

    <td style="text-align: right; vertical-align: top; width: 18pt;">
                <div style="text-align: left;">&#8226;</div>
              </td>

    <td style="text-align: left; vertical-align: top; width: auto;">
                <div>variations in our anticipated or actual operating results; and</div>
              </td>

  </tr>


</table>
      </div>

      <div> <br/>
      </div>

      <div>
        <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-spacing: 0;">


  <tr style="vertical-align: top;">

    <td style="width: 18pt;">&#160;</td>

    <td style="text-align: right; vertical-align: top; width: 18pt;">
                <div style="text-align: left;">&#8226;</div>
              </td>

    <td style="text-align: left; vertical-align: top; width: auto;">
                <div>change in securities analysts&#8217; estimates of our performance, or our failure to meet analysts&#8217; expectations.</div>
              </td>

  </tr>


</table>
      </div>

      <div> <br/>
      </div>

      <div>Many of these factors are beyond our control. The stock markets in general, and the market for pharmaceutical and biotechnology companies in particular, have historically experienced extreme price and volume fluctuations. These fluctuations
        often have been unrelated or disproportionate to the operating performance of these companies. These broad market and industry factors could reduce the market price of our common stock, regardless of our actual operating performance.</div>

      <div> <br/>
      </div>

      <div style="font-style: italic; font-weight: bold;">Sales of a substantial number of shares of our common stock, or the perception that such sales may occur, may adversely affect the market price of our common stock.</div>

      <div> <br/>
      </div>

      <div style="text-indent: 36pt;">As of March 10, 2025, most of our 237,615,100 outstanding shares of common stock, as well as a substantial number of shares of our common stock underlying outstanding warrants, were available for sale in the public
        market, subject to certain restrictions with respect to sales of our common stock by our affiliates, either pursuant to Rule 144 under the Securities Act, or under effective registration statements. Sales of a substantial number of shares of our
        common stock, or the perception that such sales may occur, could cause the market price of our common stock to decline or adversely affect demand for our common stock.</div>

      <div><br/>
      </div>

      <div style="font-style: italic; font-weight: bold;">Our affiliates control a substantial amount of our shares of common stock. Provisions in our Second Amended and Restated Certificate of Incorporation, as amended (the &#8220;Certificate of
        Incorporation&#8221;), our Amended and Restated Bylaws (the &#8220;Bylaws&#8221;) and Delaware law might discourage, delay or prevent a change in control of our Company or changes in our management and, therefore, depress the trading price of our common stock.</div>

      <div> <br/>
      </div>

      <div style="text-indent: 36pt;">As of December 31, 2024, BlackRock Inc., The Vanguard Group, Inc., State Street Corporation, Invesco Ltd. and our directors and executive officers and their affiliates owned approximately 37% of the outstanding shares
        of our common stock. Provisions of our Certificate of Incorporation, our Bylaws and Delaware law may have the effect of deterring unsolicited takeovers or delaying or preventing a change in control of our Company or changes in our management,
        including transactions in which our stockholders might otherwise receive a premium for their shares over then current market prices. In addition, these provisions may limit the ability of stockholders to approve transactions that they may deem to
        be in their best interests. These provisions include:</div>

      <div> <br/>
      </div>

      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">61</span></div>

        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"/></div>

        <div style="width: 100%;" class="BRPFPageHeader">
          <div>
            <div style="text-align: left; font-weight: bold; text-indent: -9pt; margin-left: 9pt;"><a href="#ADMABIOLOGICSINC."> <span style="font-style: italic; font-weight: normal; font-size: 8pt;">Table of Contents</span></a><br/>
            </div>

          </div>

        </div>

      </div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
              <div>the inability of stockholders to call special meetings;</div>
            </td>

  </tr>


</table>
      <div><br/>
      </div>

      <div>
        <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-spacing: 0;">


  <tr style="vertical-align: top;">

    <td style="width: 18pt;">&#160;</td>

    <td style="text-align: right; vertical-align: top; width: 18pt;">
                <div style="text-align: left;">&#8226;</div>
              </td>

    <td style="text-align: left; vertical-align: top; width: auto;">
                <div>classification of our Board and limitation on filling of vacancies could make it more difficult for a third party to acquire, or discourage a third party from seeking to acquire, control of our Company; and</div>
              </td>

  </tr>


</table>
      </div>

      <div> <br/>
      </div>

      <div>
        <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-spacing: 0;">


  <tr style="vertical-align: top;">

    <td style="width: 18pt;">&#160;</td>

    <td style="text-align: right; vertical-align: top; width: 18pt;">
                <div style="text-align: left;">&#8226;</div>
              </td>

    <td style="text-align: left; vertical-align: top; width: auto;">
                <div>authorization of the issuance of &#8220;blank check&#8221; preferred stock, with such designation rights and preferences as may be determined from time to time by the Board, without any need for action by stockholders.</div>
              </td>

  </tr>


</table>
      </div>

      <div> <br/>
      </div>

      <div style="text-indent: 36pt;">In addition, Section 203 of the Delaware General Corporation Law prohibits a publicly-held Delaware corporation from engaging in a business combination with an interested stockholder, generally a person which together
        with its affiliates owns, or within the last three years, has owned 15% of our voting stock, for a period of three years after the date of the transaction in which the person became an interested stockholder, unless the business combination is
        approved in a prescribed manner.&#160; The existence of the foregoing provisions and anti-takeover measures could limit the price that investors might be willing to pay in the future for shares of our common stock. They could also deter potential
        acquirers of our Company, thereby reducing the likelihood that you could receive a premium for your common stock in an acquisition. In addition, as a result of the concentration of ownership of our shares of common stock, our stockholders may, from
        time to time, observe instances where there may be less liquidity in the public markets for our securities.</div>

      <div><br/>
      </div>

      <div style="font-style: italic; font-weight: bold;">We have never paid and do not intend to pay cash dividends in the foreseeable future. As a result, capital appreciation, if any, will be your sole source of gain.</div>

      <div> <br/>
      </div>

      <div style="text-indent: 36pt;">We have never paid cash dividends on any of our capital stock, and we currently intend to retain future earnings, if any, to fund the development and growth of our business. In addition, the terms of existing and
        future debt agreements may preclude us from paying dividends. For example, the Ares Credit Agreement prohibits us from paying dividends. As a result, capital appreciation, if any, of our common stock will be your sole source of gain for the
        foreseeable future.</div>

      <div> <br/>
      </div>

      <div style="font-style: italic; font-weight: bold;">If we fail to adhere to the strict listing requirements of the Nasdaq Global Market (&#8220;Nasdaq&#8221;), we may be subject to delisting. As a result, our stock price may decline and our common stock may be
        delisted.&#160; If our stock were no longer listed on Nasdaq, the liquidity of our securities likely would be impaired.</div>

      <div> <br/>
      </div>

      <div style="text-indent: 36pt;">Our Common Stock currently trades on the Nasdaq Global Market under the symbol &#8220;ADMA.&#8221; If we fail to adhere to Nasdaq&#8217;s strict listing criteria, including with respect to stock price, market capitalization and
        stockholders&#8217; equity, our stock may be delisted. This could potentially impair the liquidity of our securities not only in the number of shares that could be bought and sold at a given price, which may be depressed by the relative illiquidity, but
        also through delays in the timing of transactions and the potential reduction in media coverage. As a result, an investor might find it more difficult to dispose of our common stock. We believe that current and prospective investors would view an
        investment in our common stock more favorably if it continues to be listed on Nasdaq. Any failure at any time to meet the Nasdaq continued listing requirements could have an adverse impact on the value and trading activity of our common stock.
        Although we currently satisfy the listing criteria for Nasdaq, if our stock price declines dramatically, we could be at risk of failing to meet the Nasdaq continued listing criteria.</div>

      <div><br/>
      </div>

      <div style="text-align: justify; font-style: italic; font-weight: bold;">Our Board may, without stockholder approval, issue and fix the terms of shares of preferred stock and issue additional shares of common stock adversely affecting the rights of
        holders of our common stock.</div>

      <div style="text-align: justify;"> <br/>
      </div>

      <div style="text-indent: 36pt;">Our Certificate of Incorporation authorizes the issuance of up to 10,000,000 shares of &#8220;blank check&#8221; preferred stock, with such designation rights and preferences as may be determined from time to time by the Board.
        Currently, our Certificate of Incorporation authorizes the issuance of up to 300,000,000 shares of common stock. As of December 31, 2024, there were 36,093,118 shares remaining available for issuance, after giving effect to 11,854,060 shares of our
        common stock that were subject to outstanding stock options, RSUs and warrants as of December 31, 2024 that may be issued by us without stockholder approval, as well as an additional 15,432,277 shares reserved for the future issuance of awards
        under our equity compensation plans.</div>

      <div><br/>
      </div>

      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">62</span></div>

        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"/></div>

        <div style="width: 100%;" class="BRPFPageHeader">
          <div>
            <div style="text-align: left; font-weight: bold; text-indent: -9pt; margin-left: 9pt;"><a href="#ADMABIOLOGICSINC."> <span style="font-style: italic; font-weight: normal; font-size: 8pt;">Table of Contents</span></a><br/>
            </div>

          </div>

        </div>

      </div>

      <a id="UnresolvedStaffComments"><!--Anchor--></a>
<table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;" class="DSPFListTable">


  <tr>

    <td style="width: 45pt; vertical-align: top; font-weight: bold;">Item 1B.</td>

    <td style="width: auto; vertical-align: top;">
              <div style="font-weight: bold;">Unresolved Staff Comments</div>
            </td>

  </tr>


</table>
      <div><span style="font-weight: bold;"> </span><br/>
      </div>

      <div style="text-indent: 36pt;">Not Applicable.</div>

      <div><br/></div>

    </div>

  </div>


  <div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: rgb(0, 0, 0);">
    <div>
      <div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
        <div>
          <a id="Cybersecurity"><!--Anchor--></a>
<table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;" class="DSPFListTable">


  <tr>

    <td style="width: 45pt; vertical-align: top; font-weight: bold;">Item 1C.</td>

    <td style="width: auto; vertical-align: top;">
                  <div style="font-weight: bold;">Cybersecurity</div>
                </td>

  </tr>


</table>
          <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
          </div>


          <ix:nonNumeric name="cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" id="Text_95aac64285b64b8395916ca032524c20" contextRef="c20240101to20241231" escape="true" continuedAt="Text_6803630a9e3948b3b7f6b4a5386c7ea31">
<div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"><span style="text-decoration: underline;">Risk Management and Strategy</span></div>
</ix:nonNumeric>
          <ix:continuation id="Text_6803630a9e3948b3b7f6b4a5386c7ea31" continuedAt="Text_6803630a9e3948b3b7f6b4a5386c7ea32">
<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">We recognize the importance of managing the material risks of cybersecurity threats, and we have implemented processes for identifying and assessing cybersecurity
            risks and incidents. <ix:nonNumeric name="cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock" id="Text_cc2a0e3e85fd40fdb8df7d12166848ce" contextRef="c20240101to20241231" escape="true"><span style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000;"><ix:nonNumeric name="cyd:CybersecurityRiskManagementProcessesIntegratedFlag" id="Fact_9961142de24947e7b88fedccb2e08cf9" contextRef="c20240101to20241231" format="ixt:fixed-true">We have also integrated these processes into our overall risk management system, including senior management&#8217;s periodic reviews of cybersecurity risks or threats.</ix:nonNumeric> Senior management oversees and works closely with our IT department to continuously review and evaluate cybersecurity risks in alignment with
            our business goals and needs.</span></ix:nonNumeric></div>
</ix:continuation>

          <ix:continuation id="Text_6803630a9e3948b3b7f6b4a5386c7ea32" continuedAt="Text_6803630a9e3948b3b7f6b4a5386c7ea33">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
          </div>
</ix:continuation>
          <ix:continuation id="Text_6803630a9e3948b3b7f6b4a5386c7ea33" continuedAt="Text_6803630a9e3948b3b7f6b4a5386c7ea34">
<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonNumeric name="cyd:CybersecurityRiskManagementThirdPartyEngagedFlag" id="Fact_25fb28637942491e93d356e606175fb2" contextRef="c20240101to20241231" format="ixt:fixed-true">With respect to cybersecurity risks and threats, we utilize various third-party consultants and advisors to assist us with regular reviews, internal audits and best practices, including threat prevention and detection, security reviews and enhancements, penetration testing and full scope IT audits.</ix:nonNumeric>
            <ix:nonNumeric name="cyd:CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" id="Fact_ce2dc3476554478281ceaef6e632f10e" contextRef="c20240101to20241231" format="ixt:fixed-true">ADMA also has strict processes in place for the review of third-party service providers engaged, including thorough security assessments before engagement and annual monitoring of their IT environments and controls.</ix:nonNumeric></div>
</ix:continuation>
          <ix:continuation id="Text_6803630a9e3948b3b7f6b4a5386c7ea34" continuedAt="Text_6803630a9e3948b3b7f6b4a5386c7ea35">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
          </div>
</ix:continuation>

          <ix:nonNumeric name="cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" id="Text_d544260485b84bc6903515637a3f275c" contextRef="c20240101to20241231" escape="true"><ix:continuation id="Text_6803630a9e3948b3b7f6b4a5386c7ea35">
<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">During the year ended December 31, 2023, as initially disclosed in our Quarterly Report on Form 10-Q for the period ending June 30, 2023 and updated elsewhere in our
            subsequent filings with the SEC, <ix:nonNumeric name="cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" id="Fact_869c0f8300564044ae323bb0b0dc1772" contextRef="c20240101to20241231" format="ixt:fixed-true">we experienced an IT systems disruption, which did result in a non-recurring charge to our results of operations.</ix:nonNumeric>
            There was no original financial systems data loss or any evidence of data exfiltrated due to this disruption. Normal course operations quickly resumed across the Company&#8217;s business units.</div>
</ix:continuation></ix:nonNumeric>

          <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
          </div>

          <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
            <div class="BRPFPageNumberArea" style="text-align: center;"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">63</span></div>

            <div style="page-break-after: always;" class="BRPFPageBreak">
              <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"/></div>

            <div class="BRPFPageHeader" style="width: 100%;">
              <div>
                <div style="text-align: left; font-weight: bold; text-indent: -9pt; margin-left: 9pt;"><a href="#ADMABIOLOGICSINC."> <span style="font-style: italic; font-weight: normal; font-size: 8pt;">Table of Contents</span></a><br/>
                </div>

              </div>

            </div>

          </div>

          <!--PROfilePageNumberReset%Num%64%%%-->
          <ix:nonNumeric name="cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock" id="Text_b1dba2831457485093db4c91c86dacb2" contextRef="c20240101to20241231" escape="true" continuedAt="Text_2db44822021a4a2788089ff26b67f3c31">
<div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"><span style="text-decoration: underline;">Governance</span></div>
</ix:nonNumeric>
          <ix:continuation id="Text_2db44822021a4a2788089ff26b67f3c31" continuedAt="Text_2db44822021a4a2788089ff26b67f3c32">
<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">Our President and Chief Executive Officer and Chief Operating Officer are primarily responsible for timely updating the Board and Audit Committee about any material
            cybersecurity incidents or threats or any cybersecurity related issues worthy of their attention.</div>
</ix:continuation>
          <ix:continuation id="Text_2db44822021a4a2788089ff26b67f3c32" continuedAt="Text_2db44822021a4a2788089ff26b67f3c33">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
          </div>
</ix:continuation>

          <ix:continuation id="Text_2db44822021a4a2788089ff26b67f3c33" continuedAt="Text_2db44822021a4a2788089ff26b67f3c34">
<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonNumeric name="cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" id="Text_5290ed66ee024fc5ad78e2f0af1dfc81" contextRef="c20240101to20241231" escape="true"><span style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000;">Our Board has designated the Audit Committee as the primary committee responsible for reviewing and managing cybersecurity risks and threats at ADMA.</span></ix:nonNumeric> <ix:nonNumeric name="cyd:CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" id="Text_0cc1f53ac16f4c398c22a1a6b27982cf" contextRef="c20240101to20241231" escape="true"><span style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000;">The Audit Committee is comprised of Board members with diverse experience in healthcare, finance and information
            technology, enabling them to effectively oversee cybersecurity risks and threats.</span></ix:nonNumeric> <ix:nonNumeric name="cyd:CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" id="Text_1ac1af67993e4c2d9c8e84028a293c35" contextRef="c20240101to20241231" escape="true"><span style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000;">Our management team, with
            assistance from third-party consultants or advisors as appropriate, provides quarterly updates regarding cybersecurity risks and threats to the Audit Committee and ad hoc updates or communications are provided to the entire Board as needed.</span></ix:nonNumeric></div>
</ix:continuation>

          <ix:continuation id="Text_2db44822021a4a2788089ff26b67f3c34" continuedAt="Text_2db44822021a4a2788089ff26b67f3c35">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
          </div>
</ix:continuation>

          <ix:continuation id="Text_2db44822021a4a2788089ff26b67f3c35"><ix:nonNumeric name="cyd:CybersecurityRiskRoleOfManagementTextBlock" id="Text_04c39f02ab2140e4abb758ce149b52fe" contextRef="c20240101to20241231" escape="true"><ix:nonNumeric name="cyd:CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" id="Text_1fcba4777d9044c59dfcce55b8dbd907" contextRef="c20240101to20241231" escape="true">
<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonNumeric name="cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" id="Text_9367888ccfce414485c2bc5a51d8ca4f" contextRef="c20240101to20241231" escape="true"><span style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000;"><ix:nonNumeric name="cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" id="Fact_f5d242371e3e4a1c8970022c7ff829e1" contextRef="c20240101to20241231" format="ixt:fixed-true">The Data Integrity and IT Operations team are primarily responsible for the timely identification, review, severity assessment and management of cybersecurity incidents.</ix:nonNumeric></span></ix:nonNumeric> In the event of a cybersecurity incident, the IT Department leadership follows the procedures outlined in our Cybersecurity Incident Response Policy and works closely with
            management to form a Security Incident Response Team comprised of members from the appropriate functional teams. <ix:nonNumeric name="cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" id="Fact_37f218e86cb14d2891be4c746016e1bd" contextRef="c20240101to20241231" format="ixt:fixed-true">In accordance with this policy, senior management will also communicate the occurrence of any significant cybersecurity incidents to our Board, Audit Committee and auditors on a timely basis and will keep them informed of the remediation plans and progress.</ix:nonNumeric></div>
</ix:nonNumeric></ix:nonNumeric></ix:continuation>

          <div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
          </div>

          <a id="Item2."><!--Anchor--></a> </div>

      </div>

    </div>

  </div>


  <div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: rgb(0, 0, 0);">
    <div>
      <hr style="background-color: #000000; border-bottom: medium none; border-left: medium none; border-right: medium none; border-top: medium none; color: #000000;"/>
      <div>
        <hr style="background-color: #000000; border-bottom: medium none; border-left: medium none; border-right: medium none; border-top: medium none; color: #000000;"/> </div>

      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageNumberArea" style="text-align: center;"><span style="font-family: 'Times New Roman'; font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">64</span></div>

        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"/></div>

      </div>

      <a id="Properties"><!--Anchor--></a>
<table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;" class="DSPFListTable">


  <tr>

    <td style="width: 45pt; vertical-align: top; font-weight: bold;">Item 2.</td>

    <td style="width: auto; vertical-align: top;">
              <div style="font-weight: bold;">Properties</div>
            </td>

  </tr>


</table>
      <div><span style="font-weight: bold;"> </span><br/>
      </div>

      <div style="text-indent: 36pt;">The table below describes our principal facilities as of December 31, 2024:</div>

      <div>&#160;</div>

      <div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 21.15%; vertical-align: bottom;">
                <div style="color: #000000; font-weight: bold;">Location</div>
              </td>

    <td style="width: 42.99%; vertical-align: bottom;">
                <div style="color: #000000; font-weight: bold;">Principal Business Activity</div>
              </td>

    <td style="width: 14.71%; vertical-align: bottom;">
                <div style="color: rgb(0, 0, 0); font-weight: bold; text-align: center;">Approximate</div>
                <div style="color: rgb(0, 0, 0); font-weight: bold; text-align: center;">Square Feet</div>
              </td>

    <td style="width: 21.15%; vertical-align: bottom;">
                <div style="text-align: center; color: #000000; font-weight: bold;">Owned or expiration</div>
                <div style="text-align: center; color: #000000; font-weight: bold;">date of lease</div>
              </td>

  </tr>

  <tr>

    <td style="width: 21.15%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
                <div style="color: #000000;">Ramsey, NJ</div>
              </td>

    <td style="width: 42.99%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
                <div style="color: #000000;">Corporate Headquarters</div>
              </td>

    <td style="width: 14.71%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
                <div style="color: rgb(0, 0, 0); text-align: center;">4,200</div>
              </td>

    <td style="width: 21.15%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
                <div style="text-align: center; color: #000000;">December 31, 2026 *</div>
              </td>

  </tr>

  <tr>

    <td style="width: 21.15%; vertical-align: bottom;">
                <div style="color: #000000;">Boca Raton, FL</div>
              </td>

    <td style="width: 42.99%; vertical-align: bottom;">
                <div style="color: #000000;">Manufacturing and Administration</div>
              </td>

    <td style="width: 14.71%; vertical-align: bottom;">
                <div style="color: rgb(0, 0, 0); text-align: center;">84,462</div>
              </td>

    <td style="width: 21.15%; vertical-align: bottom;">
                <div style="text-align: center; color: #000000;">Owned</div>
              </td>

  </tr>

  <tr>

    <td style="width: 21.15%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
                <div style="color: #000000;">Boca Raton, FL</div>
              </td>

    <td style="width: 42.99%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
                <div style="color: #000000;">Laboratory and Administration</div>
              </td>

    <td style="width: 14.71%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
                <div style="color: rgb(0, 0, 0); text-align: center;">44,495</div>
              </td>

    <td style="width: 21.15%; vertical-align: bottom; background-color: rgb(204, 238, 255);">
                <div style="text-align: center; color: #000000;">Owned</div>
              </td>

  </tr>


</table>
      </div>

      <div>&#160;</div>

      <div style="text-indent: 36pt;">* Pursuant to a shared services agreement, as amended, with Areth, LLC ("Areth") for office, warehouse space and related services pursuant to which the Company pays Areth monthly lease payments of $10,000. Areth is a
        company controlled by Dr. Jerrold B. Grossman, our Vice Chairman of the Board of Directors, and Adam S. Grossman, our President and Chief Executive Officer.</div>

      <div><br/>
      </div>

      <div style="text-indent: 36pt;">We also have ten plasma collection centers in leased facilities mainly in the southeastern part of the U.S., which require lease payments through the respective lease terms that expire at various dates through 2033
        (see Note 12 to the consolidated financial statements appearing elsewhere in this report).</div>

      <div><br/>
      </div>

      <div style="text-indent: 36pt;">We believe that our leased and owned properties are adequate to meet our current and future needs.</div>

      <div><br/>
      </div>

      <a id="LegalProceedings"><!--Anchor--></a>
<table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;" class="DSPFListTable">


  <tr>

    <td style="width: 45pt; vertical-align: top; font-weight: bold;">Item 3.</td>

    <td style="width: auto; vertical-align: top;">
              <div style="font-weight: bold;">Legal Proceedings</div>
            </td>

  </tr>


</table>
      <div><span style="font-weight: bold;"> </span><br/>
      </div>

      <div style="text-indent: 36pt;">We are and may become subject to certain legal proceedings and claims arising in connection with the normal course of our business. Neither the Company nor any of its subsidiaries are a party to any material pending
        legal proceedings, other than ordinary routine litigation incidental to our business.</div>

      <div><br/>
      </div>

      <a id="MineSafetyDisclosures"><!--Anchor--></a>
<table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;" class="DSPFListTable">


  <tr>

    <td style="width: 45pt; vertical-align: top; font-weight: bold;">Item 4.</td>

    <td style="width: auto; vertical-align: top;">
              <div style="font-weight: bold;">Mine Safety Disclosures</div>
            </td>

  </tr>


</table>
      <div><br/>
      </div>

      <div>Not applicable.</div>

      <div> <br/>
      </div>

      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageNumberArea" style="text-align: center;"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">65</span></div>

        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"/></div>

        <div class="BRPFPageHeader" style="width: 100%;">
          <div>
            <div style="text-align: left; font-weight: bold; text-indent: -9pt; margin-left: 9pt;"><a href="#ADMABIOLOGICSINC."> <span style="font-style: italic; font-weight: normal; font-size: 8pt;">Table of Contents</span></a><br/>
            </div>

          </div>

        </div>

      </div>

      <div style="text-align: center; font-weight: bold;">PART II</div>

      <div>&#160;</div>

      <a id="MarketforRegistrantsCommo"><!--Anchor--></a>
<table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;" class="DSPFListTable">


  <tr>

    <td style="width: 45pt; vertical-align: top; font-weight: bold;">Item 5.</td>

    <td style="vertical-align: top; width: auto;">
              <div style="font-weight: bold;">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</div>
            </td>

  </tr>


</table>
      <div> <br/>
      </div>

      <div style="font-weight: bold;">Market Information</div>

      <div> <br/>
      </div>

      <div style="text-indent: 36pt;">Our Common Stock had been listed on the Nasdaq Capital Market (&#8220;Nasdaq&#8221;) under the symbol &#8220;ADMA&#8221; since November 10, 2014. Since October 22, 2019, our Common Stock has been listed on the Nasdaq Global Market.</div>

      <div style="text-indent: 36pt;"> <br/>
      </div>

      <div style="font-weight: bold;">Holders</div>

      <div> <br/>
      </div>

      <div style="text-indent: 36pt;">As of December 31, 2024, there were five record holders of our Common Stock, based upon information received from our transfer agent. However, this number does not include beneficial owners whose shares were held of
        record by nominees or broker dealers. As of February 1, 2025, we estimate that there are more than 30,000 beneficial owners of our Common Stock.</div>

      <div style="text-indent: 36pt;"> <br/>
      </div>

      <div style="font-weight: bold;">Dividend Policy</div>

      <div><span style="font-weight: bold;"> </span><br/>
      </div>

      <div style="text-indent: 36pt;">We have never paid any cash dividends on our capital stock.&#160; We anticipate that we will retain earnings, if any, to support operations and to finance the growth and development of our business.&#160; In addition, the terms
        of our Credit Agreement with Ares preclude us from paying cash dividends without their consent.&#160; Therefore, we do not expect to pay any cash dividends for the foreseeable future.</div>

      <div style="text-indent: 36pt;"> <br/>
      </div>

      <div style="font-weight: bold;">Stock Performance Graph</div>

      <div>&#160;</div>

      <div style="text-indent: 36pt;">The following graph assumes a $100 investment on December 31, 2019 in each of the Company&#8217;s Common Stock, the XBI Biotech Index of biotechnology companies and the Russell 2000 Index.</div>

      <div><br/></div>

      <div style="text-align: center;">
        <div><img src="image00002.jpg" alt="graphic"/></div>

        <div><br/>
        </div>

        <div>
          <div style="text-align: left;">
            <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%; border-spacing: 0;" class="cfttable">


  <tr>

    <td valign="bottom">
                    <div>&#160;</div>
                  </td>

    <td valign="bottom" style="font-weight: bold; text-align: center; vertical-align: bottom;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: bold; text-align: center;" colspan="2"><span style="text-decoration: underline;"> 2019<br/>
                    </span></td>

    <td valign="bottom" style="font-weight: bold; text-align: left; vertical-align: bottom; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: bold; text-align: center; vertical-align: bottom;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: bold; text-align: center;" colspan="2"><span style="text-decoration: underline;">2020<br/>
                    </span></td>

    <td valign="bottom" style="font-weight: bold; text-align: left; vertical-align: bottom; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: bold; text-align: center; vertical-align: bottom;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: bold; text-align: center;" colspan="2"><span style="text-decoration: underline;">2021<br/>
                    </span></td>

    <td valign="bottom" style="font-weight: bold; text-align: left; vertical-align: bottom; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: bold; text-align: center; vertical-align: bottom;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: bold; text-align: center;" colspan="2"><span style="text-decoration: underline;">2022<br/>
                    </span></td>

    <td valign="bottom" style="font-weight: bold; text-align: left; vertical-align: bottom; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: bold; text-align: center; vertical-align: bottom;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: bold; text-align: center;" colspan="2"><span style="text-decoration: underline;">2023<br/>
                    </span></td>

    <td valign="bottom" style="font-weight: bold; text-align: left; vertical-align: bottom; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: bold; text-align: center; vertical-align: bottom;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-weight: bold; text-align: center;" colspan="2"><span style="text-decoration: underline;">2024<br/>
                    </span></td>

    <td valign="bottom" style="font-weight: bold; text-align: left; vertical-align: bottom; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="width: 28%; background-color: #CCEEFF;">ADMA<br/>
                  </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">$</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">100.00</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">$</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">48.75</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">$</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">35.25</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">$</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">97.00</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">$</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">113.00</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">428.75<br/>
                  </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="width: 28%;">XBI<br/>
                  </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">$</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">100.00</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">$</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">148.02</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">$</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">117.72</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">$</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">87.27</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">$</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">93.88</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">94.69<br/>
                  </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="width: 28%; background-color: #CCEEFF;">Russell 2000<br/>
                  </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">$</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">100.00</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">$</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">118.34</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">$</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">134.27</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">$</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">105.25</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">$</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">121.15</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">133.37<br/>
                  </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>


</table>
          </div>

          <div><br/>
          </div>

        </div>

      </div>

      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageNumberArea" style="text-align: center;"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">66</span></div>

        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"/></div>

        <div class="BRPFPageHeader" style="width: 100%;">
          <div>
            <div style="text-align: left; font-weight: bold; text-indent: -9pt; margin-left: 9pt;"><a href="#ADMABIOLOGICSINC."> <span style="font-style: italic; font-weight: normal; font-size: 8pt;">Table of Contents</span></a><br/>
            </div>

          </div>

        </div>

      </div>

      <div style="font-weight: bold;">Sale of Unregistered Securities</div>

      <div> <br/>
      </div>

      <div style="text-indent: 36pt;">During the year ended December 31, 2024, we had no sales of unregistered securities that have not been previously disclosed in a Current Report on Form 8-K or Quarterly Report on Form 10-Q.</div>

      <div style="text-indent: 36pt;"> <br/>
      </div>

      <div style="font-weight: bold;">Purchases of Equity Securities by the Issuer and Affiliated Purchasers</div>

      <div> <br/>
      </div>

      <div style="text-indent: 36pt;">We did not repurchase any of our securities during the three months ended December 31, 2024.</div>

      <div><br/>
      </div>

      <a id="Reserved"><!--Anchor--></a>
<table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;" class="DSPFListTable">


  <tr>

    <td style="width: 45pt; vertical-align: top; font-weight: bold;">Item 6.</td>

    <td style="width: auto; vertical-align: top;">
              <div style="font-weight: bold;">Reserved</div>
            </td>

  </tr>


</table>
      <div> <br/>
      </div>

      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageNumberArea" style="text-align: center;"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">67</span></div>

        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"/></div>

        <div class="BRPFPageHeader" style="width: 100%;">
          <div>
            <div style="text-align: left; font-weight: bold; text-indent: -9pt; margin-left: 9pt;"><a href="#ADMABIOLOGICSINC."> <span style="font-style: italic; font-weight: normal; font-size: 8pt;">Table of Contents</span></a><br/>
            </div>

          </div>

        </div>

      </div>

      <a id="ManagementsDiscussionandA"><!--Anchor--></a>
<table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;" class="DSPFListTable">


  <tr>

    <td style="width: 45pt; vertical-align: top; font-weight: bold;">Item 7.</td>

    <td style="width: auto; vertical-align: top;">
              <div style="font-weight: bold;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</div>
            </td>

  </tr>


</table>
      <div> <br/>
      </div>

      <div style="font-style: italic;">The following discussion of our financial condition and results of operations should be read in conjunction with the consolidated financial statements and notes thereto included elsewhere in this Annual Report on Form
        10-K. The various sections of this discussion contain a number of forward-looking statements, all of which are based on our current expectations and could be materially affected by the uncertainties and risk factors described throughout this Annual
        Report.&#160; See &#8220;Special Note Regarding Forward-Looking Statements.&#8221;&#160; Our actual results may differ materially.</div>

      <div> <br/>
      </div>

      <div style="text-align: center; font-weight: bold;"><span style="text-decoration: underline;">OVERVIEW</span></div>

      <div>&#160;</div>

      <div style="font-weight: bold;">Our Business</div>

      <div><br/>
      </div>

      <div style="text-indent: 36pt;">ADMA Biologics, Inc. (the &#8220;Company,&#8221; &#8220;ADMA,&#8221; &#8220;we,&#8221; &#8220;us&#8221; or &#8220;our&#8221;) is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty biologics for the treatment of
        immunodeficient patients at risk for infection and others at risk for certain infectious diseases. Our targeted patient populations include immune-compromised individuals who suffer from an underlying immune deficiency disorder or who may be
        immune-suppressed for medical reasons.</div>

      <div><br/>
      </div>

      <div style="text-indent: 36pt;">Through our ADMA BioManufacturing business segment, we currently have three products with U.S. Food and Drug Administration (the &#8220;FDA&#8221;) approval, all of which are currently marketed and commercially available: (i)
        ASCENIV (Immune Globulin Intravenous, Human &#8211; slra 10% Liquid), an Intravenous Immune Globulin (&#8220;IVIG&#8221;)&#160; product indicated for the treatment of Primary Humoral Immunodeficiency (&#8220;PI&#8221;), also known as Primary Immunodeficiency Disease (&#8220;PIDD&#8221;) or
        Inborn Errors of immunity in adults and adolescents, for which we received FDA approval on April 1, 2019 and commenced first commercial sales in October 2019; (ii) BIVIGAM (Immune Globulin Intravenous, Human), an IVIG product indicated for the
        treatment of PI, and for which we received FDA approval on May 9, 2019 and commenced commercial sales in August 2019;&#160; and (iii) Nabi-HB (Hepatitis B Immune Globulin, Human), which is indicated for the treatment of acute exposure to blood
        containing HBsAg and other listed exposures to Hepatitis B. We seek to develop a pipeline of plasma-derived therapeutics, including a product based on our most recently approved patent application under U.S. Patent Nos. 10,259,865 and 11,084,870
        related to methods of treatment and prevention of <span style="font-style: italic;">S. pneumonia</span> infection for an immunoglobulin manufactured to contain standardized antibodies to numerous serotypes of <span style="font-style: italic;">S.
          pneumoniae</span>. We have successfully completed production of a pilot-scale batch and are conducting animal studies for our<span style="font-style: italic;"> S. pneumoniae</span> hyperimmune globulin program, SG-001. Our products and product
        candidates are intended to be used by physician specialists focused on caring for immune-compromised patients with or at risk for certain infectious diseases.</div>

      <div><br/>
      </div>

      <div style="text-indent: 36pt;">We manufacture these products at our FDA-licensed, plasma fractionation and purification facility located in Boca Raton, Florida with a peak annual processing capability of up to 600,000 liters (the &#8220;Boca Facility&#8221;).
        Based on current production yields, our completed and ongoing supply chain enhancements and capacity expansion initiatives, we believe this facility has the potential to produce sufficient quantities of our immune globulin (&#8220;IG&#8221;) products
        representing projected annual revenues greater than $490 million in 2025 and $605 million in 2026. These revenue targets translate to potential fiscal year 2025 and 2026 Adjusted Net Income exceeding $175 million and $235 million, respectively, and
        Adjusted EBITDA exceeding $225 million and $305 million, respectively.&#160;The foregoing financial targets do not account for the potential FDA approval of our innovative yield enhancement production process described below.</div>

      <div><br/>
      </div>

      <div style="text-indent: 36pt;">In December 2024, we successfully submitted a <span style="color: #000000;">Prior Approval Supplement (the &#8220;PAS&#8221;)</span> for potential approval of our innovative yield enhancement production process. Following FDA
        review of the submission, we anticipate receiving FDA approval by mid-2025, with potential revenue and earnings accretion expected in the second half of the year. This innovative process has demonstrated an ability to increase production yields by
        approximately 20% from the same starting plasma volume, potentially driving significant increases to financial targets, if approved.</div>

      <div><br/>
      </div>

      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageNumberArea" style="text-align: center;"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">68</span></div>

        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"/></div>

        <div class="BRPFPageHeader" style="width: 100%;">
          <div>
            <div style="text-align: left; font-weight: bold; text-indent: -9pt; margin-left: 9pt;"><a href="#ADMABIOLOGICSINC."> <span style="font-style: italic; font-weight: normal; font-size: 8pt;">Table of Contents</span></a><br/>
            </div>

          </div>

        </div>

      </div>

      <div style="text-indent: 36pt;">Through our ADMA BioCenters subsidiary, we currently operate ten source plasma collection facilities in the U.S., all of which hold FDA licenses. This business unit, which we refer to as our Plasma Collection Centers
        business segment, provides us with the blood plasma required for the manufacture of our products, and also allows us to sell certain quantities of source and hyperimmune plasma to third-party customers for further manufacturing. In addition, three
        of our FDA-approved plasma collection centers also have approvals from the Korean Ministry of Food and Drug Safety (&#8220;MFDS&#8221;), as well as FDA approval to operate a Hepatitis B immunization program. A typical plasma collection center, such as those
        operated by ADMA BioCenters, can collect approximately 30,000 to 50,000 liters of source plasma annually, which may be sold for different prices depending upon the type of plasma, quantity of purchase and market conditions at the time of sale.
        Plasma collected from ADMA BioCenters&#8217; facilities that is not used to manufacture our products is sold to third-party customers in the U.S. and in other locations outside the U.S. where we are approved under supply agreements or in the open &#8220;spot&#8221;
        market.</div>

      <div><br/>
      </div>

      <div style="text-indent: 36pt;">From time to time we may provide contract manufacturing services for certain third-party clients. We also provide laboratory contracting services to certain customers and may provide contract filling, labeling and
        packing services utilizing our FDA-approved in-house fill-finish capabilities.</div>

      <div><br/>
      </div>

      <div style="text-indent: 36pt;">For the year ended December 31, 2024 we achieved net income of $197.7 million, the first time in our history that we achieved net income on a GAAP basis, and generated positive cash flow from operations of $118.7
        million. Our improved operating results are primarily the result of the substantial revenue growth and continued physician, patient and payer acceptance of ASCENIV.</div>

      <div><br/>
      </div>

      <div style="font-weight: bold;">Our Products</div>

      <div><br/>
      </div>

      <div style="color: #000000; font-style: italic; font-weight: bold;">ASCENIV</div>

      <div style="text-indent: 36pt;">ASCENIV is a plasma-derived IVIG that contains naturally occurring polyclonal antibodies, which are proteins that are used by the body&#8217;s immune system to neutralize microbes, such as bacteria and viruses, and prevent
        against infection and disease. We manufacture ASCENIV under HHS License No. 2019 using a process known as fractionation. The Centers for Medicare and Medicaid Services (&#8220;CMS&#8221;) has issued a permanent, product-specific-J-code for ASCENIV.&#160; Under the
        Healthcare Common Procedure Coding System (&#8220;HCPCS&#8221;), the J-code (J1554) became effective April 1, 2021. As part of our proprietary manufacturing process for ASCENIV, we leverage our unique, patented plasma donor screening methodology and tailored
        plasma pooling design, which blends normal source plasma and plasma from donors tested to have high levels of neutralizing antibody titers to Respiratory Syncytial Virus (&#8220;RSV&#8221;) using our proprietary microneutralization testing assay. With our
        patented testing methods and assay, we are able to identify the high-titer or &#8220;hyperimmune&#8221; plasma that meets our internal and required specifications for ASCENIV. This type of high-titer plasma is typically found in less than 10% of the total
        donor collection samples we test.</div>

      <div><br/>
      </div>

      <div style="text-indent: 36pt;"><span style="color: #000000;">ASCENIV is approved for the treatment of PIDD or PI, a class of inherited genetic disorders that causes a deficient or absent immune system in adults and adolescents (12 to 17 years of
          age). Our pivotal Phase 3 clinical trial in 59 PIDD patients met the primary endpoint of no Serious Bacterial Infections (&#8220;SBI&#8221;) reported during 12 months of treatment. Secondary efficacy endpoints further demonstrated the benefits of ASCENIV in
          the low incidence of infection, therapeutic antibiotic use, days missed from work, school and daycare and unscheduled medical visits and hospitalizations. We believe this clinical data together with the FDA approval for the treatment of PIDD
          better positions ADMA to potentially further evaluate ASCENIV in immune-compromised patients infected with or at-risk for RSV infection or potentially other respiratory viral pathogens at an appropriate time. Due to the COVID-19 pandemic, our
          plans have been delayed.&#160; In the future however, we may elect to work with the FDA and the immunology and infectious disease community to design an appropriate clinical trial to evaluate the use of ASCENIV in this patient population. Following
          FDA approval in April 2019, commercial sales of ASCENIV commenced in October of 2019 and in</span> 2023 we commenced manufacturing ASCENIV at the 4,400 Liter production scale. This expansion has improved the product&#8217;s margin profile and increased
        plant production capacity as fewer batches are needed to support our revenue goals<span style="color: #000000;">. </span>ASCENIV&#8217;s prescriber and patient base continued to expand during 2024, which drove record utilization and pull-through for
        this product. These elevated demand trends have sustained into 2025, and ADMA currently expects that this product&#8217;s rapid growth will continue throughout 2025 and beyond.</div>

      <div><br/>
      </div>

      <div style="text-indent: 36pt;">We anticipate filing our supplemental Biologics License Application (&#8220;sBLA&#8221;) in mid-2025, with potential FDA approval in the first half of 2026 for the expansion of ASCENIV&#8217;s label to include the pediatric setting for
        patients who are two years and older.</div>

      <div><br/>
      </div>

      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageNumberArea" style="text-align: center;"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">69</span></div>

        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"/></div>

        <div class="BRPFPageHeader" style="width: 100%;">
          <div>
            <div style="text-align: left; font-weight: bold; text-indent: -9pt; margin-left: 9pt;"><a href="#ADMABIOLOGICSINC."> <span style="font-style: italic; font-weight: normal; font-size: 8pt;">Table of Contents</span></a><br/>
            </div>

          </div>

        </div>

      </div>

      <div style="font-style: italic; font-weight: bold;">BIVIGAM</div>

      <div style="text-indent: 36pt;">BIVIGAM is a plasma-derived IVIG that contains a broad range of antibodies similar to those found in normal human plasma. These antibodies are directed against bacteria and viruses and help to protect PI patients
        against serious infections. BIVIGAM is a purified, sterile, ready-to-use preparation of concentrated human Immunoglobulin G antibodies indicated for the treatment of PI, a group of genetic disorders. This includes, but is not limited to, the
        humoral immune defect in common variable immunodeficiency, X-linked agammaglobulinemia, congenital agammaglobulinemia, Wiskott-Aldrich syndrome and severe combined immunodeficiency. These PIs are a group of genetic disorders. Based on recent
        estimates, these disorders are no longer considered to be very rare, with as many as one in every 1,200 people in the United States having some form of PI.</div>

      <div><br/>
      </div>

      <div style="text-indent: 36pt;">On May 9, 2019, the FDA approved the Prior Approval Supplement (the &#8220;PAS&#8221;) for the use of our IVIG manufacturing process, thereby enabling us to re-launch and commercialize this product in the U.S. We resumed
        production of BIVIGAM during the fourth quarter of 2017 and commercial production is ongoing, using our FDA-approved IVIG manufacturing process under U.S. Department of Health and Human Services (&#8220;HHS&#8221;) License No. 2019. The commercial re-launch
        and first commercial sales for this product commenced in August of 2019.</div>

      <div><br/>
      </div>

      <div style="text-indent: 36pt;">On April 28, 2021, we announced that the FDA granted approval for our expanded plasma pool production scale process, allowing for a 4,400-liter plasma pool for the manufacture of our BIVIGAM IVIG product. This
        increased IVIG plasma pool scale, which allows us to produce BIVIGAM at an expanded capacity utilizing the same equipment, release testing assays and labor force, has had a favorable impact on our gross margins, manufacturing efficiencies and
        operating results.</div>

      <div><br/>
      </div>

      <div style="text-indent: 36pt;">On December 12, 2023, we announced that the FDA approved the expansion of BIVIGAM&#8217;s label in the U.S. to now include the pediatric setting for those two years of age and older.</div>

      <div><br/>
      </div>

      <div style="font-style: italic; font-weight: bold;">Nabi-HB</div>

      <div style="text-indent: 36pt;">Nabi-HB is a hyperimmune globulin that is rich in antibodies to the Hepatitis B virus. Nabi-HB is a purified human polyclonal antibody product collected from plasma donors who have been previously vaccinated with a
        Hepatitis B vaccine. Nabi-HB is indicated for the treatment of acute exposure to blood containing HBsAg, prenatal exposure of infants born to HBsAg-positive mothers, sexual exposure to HBsAg-positive persons and household exposure to persons with
        acute Hepatitis B virus infection in specific, listed settings. Hepatitis B is a potentially life-threatening liver infection caused by the Hepatitis B virus, which is a major global health problem. The Hepatitis B virus can cause chronic infection
        and places people at high risk of death from cirrhosis and liver cancer. Nabi-HB has a well-documented record of long-term safety and effectiveness since its initial market introduction. The FDA approved Nabi-HB on March 24, 1999.&#160; Production of
        Nabi-HB at the Boca Facility has continued under our leadership since the third quarter of 2017. In early 2018, we received authorization from the FDA for the release of our first commercial batch of Nabi-HB for commercial distribution in the U.S.
        and we continue to manufacture Nabi-HB under HHS License No. 2019.</div>

      <div><br/>
      </div>

      <div style="text-align: center; font-weight: bold;"><span style="text-decoration: underline;">RESULTS OF OPERATIONS</span></div>

      <div><br/>
      </div>

      <div style="font-weight: bold;">Critical Accounting Policies and Estimates</div>

      <div><br/>
      </div>

      <div style="text-indent: 36pt;">This Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations is based on our consolidated financial statements, which have been prepared in accordance with accounting principles generally
        accepted in the United States of America (&#8220;U.S. GAAP&#8221;). The preparation of these condensed consolidated financial statements requires us to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and
        expenses. On an ongoing basis, we evaluate these estimates and assumptions, including those described below. We base our estimates on our historical experience and on various other assumptions that we believe to be reasonable under the
        circumstances. These estimates and assumptions form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results and experiences may differ materially from these
        estimates.</div>

      <div><br/>
      </div>

      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageNumberArea" style="text-align: center;"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">70</span></div>

        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"/></div>

        <div class="BRPFPageHeader" style="width: 100%;">
          <div>
            <div style="text-align: left; font-weight: bold; text-indent: -9pt; margin-left: 9pt;"><a href="#ADMABIOLOGICSINC."> <span style="font-style: italic; font-weight: normal; font-size: 8pt;">Table of Contents</span></a><br/>
            </div>

          </div>

        </div>

      </div>

      <div style="text-indent: 36pt;">Some of the estimates and assumptions we have to make under U.S. GAAP require very difficult, subjective and/or complex judgments about matters that are inherently uncertain and, as a result, we have identified those
        as critical accounting estimates, which are considered critical to an understanding of our historical financial condition and results of operations and are reasonably likely to have a material impact on our future results of operations and
        financial condition. Critical accounting estimates include rebates and potentially certain other deductions from gross revenues, assumptions used in the fair value of awards granted under our equity incentive plans and estimates related to the
        valuation allowance for our deferred tax assets. For a description of our significant accounting policies, see Note 2 to the Consolidated Financial Statements.</div>

      <div><br/>
      </div>

      <div style="font-style: italic; font-weight: bold;">Revenue Deductions for Rebates and Chargebacks</div>

      <div style="text-indent: 36pt;">Our gross product revenues are subject to a variety of deductions which are estimated and recorded in the same period that the revenues are recognized. These deductions primarily consist of rebates, distribution fees,
        chargebacks and sales allowances. These deductions represent estimates of the related obligations, some of which are contractual in nature and do not require extensive judgment to be exercised by management, while other estimates require complex or
        subjective matters of knowledge and judgment when estimating the impact of these revenue deductions on net revenues for a reporting period.</div>

      <div><br/>
      </div>

      <div style="text-indent: 36pt;">Prior to 2024, adjustments to these estimates to reflect actual results or updated expectations have not been material to our overall business. While we have some historical sales and rebate experience from our two
        primary immunoglobulin products, ASCENIV and BIVIGAM, since their FDA approvals in 2019, our historical experience is not extensive. If any of our ratios, factors, assessments, experiences or judgments are not indicative or accurate estimates of
        our future experience, our results could be materially affected. Estimates that are most at risk for material adjustment are those associated with U.S. Medicaid rebates because of the extensive time delay between the recording of the accrual and
        its ultimate settlement, an interval that can generally take up to several years or more. These estimates may change from time to time based on changes in utilization, payer and channel mixes. During 2024, we engaged a third-party specialist to
        assist in the evaluation of our accrual for U.S. Medicaid rebates related to the sale of our immunoglobulin products. As a result of this evaluation, we recognized a reduction in this accrual and a corresponding increase to net revenues of $12.6
        million during the year ended December 31, 2024 (see Note 2 to the Consolidated Financial Statements). We considered several qualitative factors when evaluating our rebate accrual, such as the absence of a statutory limitation on the rebate amounts
        drug manufacturers pay to state Medicaid programs and general uncertainty that pharmaceutical manufacturers have historically seen with government payors often submitting lagged claims many periods after the initial dispensing of a product to an
        end patient. There was additional new information that arose during June 2024 that suggested our liabilities for certain payor claims were successfully resolved, which resulted in the $12.6 million adjustment to the accrual for U.S. Medicaid
        rebates in June 2024. Additional changes in estimate assumptions surrounding U.S. Medicaid and other rebate obligations could materially impact our revenues and our results of operations in the future.</div>

      <div><br/>
      </div>

      <div style="font-style: italic; font-weight: bold;">Stock-Based Compensation</div>

      <div style="text-indent: 36pt;">All equity-based payments, including grants of stock options and restricted stock units (&#8220;RSUs&#8221;), are recognized at their estimated fair value at the date of grant, and compensation expense is recognized on a
        straight-line basis over the grantee&#8217;s requisite vesting period. For the purpose of valuing stock options granted to our employees, directors and executive officers, we use the Black-Scholes option pricing model. We also use the Black-Scholes model
        when determining additional compensation cost resulting from the modification to previously issued option grants. The Black-Scholes option pricing model was developed for use in estimating the fair value of publicly traded options, which have no
        vesting restrictions and are fully transferable. The Company&#8217;s employee stock options have characteristics significantly different from those of traded options, and changes in the underlying Black-Scholes assumptions can materially affect the fair
        value estimate. To determine the risk-free interest rate, we utilize the U.S. Treasury yield curve in effect at the time of the grant with a term consistent with the term of our awards. The expected term of the options granted is in accordance with
        U.S. Securities and Exchange Commission (&#8220;SEC&#8221;) Staff Accounting Bulletins 107 and 110 and is based on the average between vesting terms and contractual terms. The expected dividend yield reflects our current and expected future policy for
        dividends on our common stock. The expected stock price volatility for our stock options was calculated by examining the historical volatility of our common stock since our common stock became publicly traded. We will continue to analyze the
        expected stock price volatility and expected term assumptions and will adjust our Black-Scholes option pricing assumptions as appropriate. Any changes in the foregoing Black-Scholes assumptions, or our election to utilize an alternative method for
        valuing stock options granted to employees, directors and executive officers, could potentially impact our stock-based compensation expense and our results of operations.</div>

      <div><br/>
      </div>

      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageNumberArea" style="text-align: center;"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">71</span></div>

        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"/></div>

        <div class="BRPFPageHeader" style="width: 100%;">
          <div>
            <div style="text-align: left; font-weight: bold; text-indent: -9pt; margin-left: 9pt;"><a href="#ADMABIOLOGICSINC."> <span style="font-style: italic; font-weight: normal; font-size: 8pt;">Table of Contents</span></a><br/>
            </div>

          </div>

        </div>

      </div>

      <div style="font-style: italic; font-weight: bold;">Deferred Tax Assets</div>

      <div style="text-indent: 36pt;">Prior to December 31, 2024, we maintained a full valuation allowance against all of our net deferred tax assets, and as a result we have historically not recorded an income tax benefit in the accompanying consolidated
        financial statements despite continued losses through December 31, 2023. This valuation allowance reflected our assessment of whether it is more likely than not that we would generate sufficient taxable income in the future to be able to utilize
        our deferred tax assets. In determining whether a valuation allowance is warranted, we evaluate factors such as prior earnings history, expected future earnings, carryback and carryforward periods and tax strategies. We consider all positive and
        negative evidence to estimate if sufficient future taxable income will be generated to realize our deferred tax assets, and we considered cumulative losses in recent years to be a significant type of negative evidence. As of December 31, 2024, we
        determined that it is more-likely-than-not that our federal and state deferred tax assets will be realized. As a result, we recorded a release of the valuation allowance associated with these deferred tax assets, which was due in part to achieving
        three years of cumulative taxable income and projected taxable income that is more than sufficient to realize our federal and state deferred tax assets, and we recorded a deferred income tax benefit in the amount of $84.3 million for the year ended
        December 31, 2024 (see Note 11 to the consolidated financial statements).</div>

      <div><br/>
      </div>

      <div style="text-align: justify; font-weight: bold;">Year Ended December 31, 2024 Compared to Year Ended December 31, 2023</div>

      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">The following table presents a summary of the changes in our results of operations for the year ended December 31, 2024 compared to the year ended December 31, 2023:</div>

      <div><br/>
      </div>

      <table cellspacing="0" cellpadding="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%; border-spacing: 0;">


  <tr>

    <td valign="bottom" rowspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;"><br/>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="10" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;">
              <div style="text-align: center; color: #000000; font-weight: bold;">Year Ended December 31,</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" rowspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">
              <div style="text-align: center; text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-size: 8pt; font-style: italic;">(in thousands)</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;">
              <div style="text-align: center; color: #000000; font-weight: bold;">2024</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;">
              <div style="text-align: center; color: #000000; font-weight: bold;">2023</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;">
              <div style="text-align: center; color: #000000; font-weight: bold;">Increase</div>
              <div style="text-align: center; color: #000000; font-weight: bold;">(Decrease)</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #CCEEFF; white-space: nowrap;">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: #000000;">Revenues</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
              <div style="color: #000000;">$</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
              <div style="color: #000000;">426,454</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
              <div style="color: #000000;">$</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
              <div style="color: #000000;">258,215</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
              <div style="color: #000000;">$</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
              <div style="color: #000000;">168,239</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; padding-bottom: 2px;">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: #000000;">Cost of product revenue</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;">
              <div style="color: #000000;">206,901</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;">
              <div style="color: #000000;">169,273</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;">
              <div style="color: #000000;">37,628</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #CCEEFF; white-space: nowrap;">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: #000000;">Gross profit</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
              <div style="color: #000000;">219,553</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
              <div style="color: #000000;">88,942</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
              <div style="color: #000000;">130,611</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; white-space: nowrap;">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: #000000;">Research and development expenses</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
              <div style="color: #000000;">1,813</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
              <div style="color: #000000;">3,300</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
              <div style="color: #000000;">(1,487</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">
              <div style="color: #000000;">)</div>
            </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #CCEEFF; white-space: nowrap;">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: #000000;">Plasma center operating expenses</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
              <div style="color: #000000;">4,245</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
              <div style="color: #000000;">4,266</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
              <div style="color: #000000;">(21</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
              <div style="color: #000000;">)</div>
            </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; white-space: nowrap;">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: #000000;">Amortization of intangibles</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
              <div style="color: #000000;">388</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
              <div style="color: #000000;">724</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
              <div style="color: #000000;">(336</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">
              <div style="color: #000000;">)</div>
            </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: #000000;">Selling, general and administrative expenses</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">
              <div style="color: #000000;">74,124</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">
              <div style="color: #000000;">59,020</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">
              <div style="color: #000000;">15,104</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; white-space: nowrap;">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: #000000;">Income from operations</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
              <div style="color: #000000;">138,983</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
              <div style="color: #000000;">21,632</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
              <div style="color: #000000;">117,351</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #CCEEFF; white-space: nowrap;">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: #000000;">Interest expense</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
              <div style="color: #000000;">(13,930</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
              <div style="color: #000000;">)</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
              <div style="color: #000000;">(25,027</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
              <div style="color: #000000;">)</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
              <div style="color: #000000;">11,097</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; white-space: nowrap;">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: #000000;">Loss on extinguishment of debt</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
              <div style="color: #000000;">(1,243</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">
              <div style="color: #000000;">)</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
              <div style="color: #000000;">(26,174</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">
              <div style="color: #000000;">)</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
              <div style="color: #000000;">24,931</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: #000000;">Other income, net</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">
              <div style="color: #000000;">1,904</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">
              <div style="color: #000000;">1,330</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">
              <div style="color: #000000;">574</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; white-space: nowrap;">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: #000000;">Income (loss) from before taxes</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
              <div style="color: #000000;">125,714</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
              <div style="color: #000000;">(28,239</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">
              <div style="color: #000000;">)</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
              <div style="color: #000000;">153,953</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #CCEEFF; white-space: nowrap;">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: #000000;">Income tax benefit</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
              <div style="color: #000000;">(71,959</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
              <div style="color: #000000;">)</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
              <div style="color: #000000;">-</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
              <div style="color: #000000;">(71,959</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
              <div style="color: #000000;">)</div>
            </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: #000000;">Net income (loss)</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;">
              <div style="color: #000000;">$</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;">
              <div style="color: #000000;">197,673</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;">
              <div style="color: #000000;">$</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;">
              <div style="color: #000000;">(28,239</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">
              <div style="color: #000000;">)</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;">
              <div style="color: #000000;">$</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;">
              <div style="color: #000000;">225,912</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: #000000;">Adjusted EBITDA *</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;">
              <div style="color: #000000;">$</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;">
              <div style="color: #000000;">164,612</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;">
              <div style="color: #000000;">$</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;">
              <div style="color: #000000;">40,251</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;">
              <div style="color: #000000;">$</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;">
              <div style="color: #000000;">124,361</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: #000000;">Adjusted net income*</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;">
              <div style="color: #000000;">$</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;">
              <div style="color: #000000;">119,218</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;">
              <div style="color: #000000;">$</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;">
              <div style="color: #000000;">705</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;">
              <div style="color: #000000;">$</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;">
              <div style="color: #000000;">118,513</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>


</table>
      <div><br/>
      </div>

      <div style="text-indent: -36pt; margin-left: 36pt; color: rgb(0, 0, 0);">* - See Non-GAAP Financial Measures appearing at the end of this discussion</div>

      <div><br/>
      </div>

      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageNumberArea" style="text-align: center;"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">72</span></div>

        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"/></div>

        <div class="BRPFPageHeader" style="width: 100%;">
          <div>
            <div style="text-align: left; font-weight: bold; text-indent: -9pt; margin-left: 9pt;"><a href="#ADMABIOLOGICSINC."> <span style="font-style: italic; font-weight: normal; font-size: 8pt;">Table of Contents</span></a><br/>
            </div>

          </div>

        </div>

      </div>

      <div style="font-style: italic; font-weight: bold;">Revenues</div>

      <div style="text-indent: 36pt;">We recorded total revenues of $426.5 million for the year ended December 31, 2024, as compared to $258.2 million for the year ended December 31, 2023, an increase of $168.2 million, or 65%. Excluding the $12.6 million
        adjustment we recorded in the second quarter of 2024 to decrease our accrual for estimated U.S. Medicaid rebates (which had the effect of increasing net revenues by $12.6 million), revenue increased by approximately $155.6 million, or 60%. This
        increase is primarily related to increased sales of ASCENIV, as we continue to experience increased physician, payer and patient acceptance and utilization of this product, as well as sales increases for some of our other IG products. The revenue
        increase also includes an increase in sales of normal source plasma (&#8220;NSP&#8221;) and hyperimmune Hepatitis B plasma by our Plasma Collection Centers business segment in the amount of $2.2 million.</div>

      <div style="text-indent: 36pt;"> <br/>
      </div>

      <div style="font-style: italic; font-weight: bold;">Cost of Product Revenue and Gross Profit</div>

      <div style="text-indent: 36pt;">Cost of product revenue was $206.9 million for the year ended December 31, 2024, as compared to $169.3 million for the year ended December 31, 2023. This increase is primarily attributable to volume-driven increases in
        product revenue costs related to our increased sales of IG products and plasma of $39.5 million and $3.1 million, respectively, partially offset by a reduction in other manufacturing costs, mainly unabsorbed manufacturing expenses, of $5.1 million.</div>

      <div><br/>
      </div>

      <div style="text-indent: 36pt;">For the year ended December 31, 2024, we had gross profit of $219.6 million, as compared to $88.9 million for the prior year, which represents a gross margin for fiscal 2024 of 51.5%, as compared to 34.4% for fiscal
        2023. Excluding the $12.6 million adjustment we recorded in the second quarter of 2024 to reduce our accrual for estimated U.S. Medicaid rebates, our gross profit for the year ended December 31, 2024 was approximately $207.0 million, representing a
        gross margin of approximately 50.0%. The improvement in gross margin is mainly driven by a significantly more favorable mix of higher margin IG sales in 2024 as compared to 2023, along with the reduction in other manufacturing costs. We expect to
        see further shifts in our revenue mix toward higher margin IVIG products in fiscal 2025.</div>

      <div><br/>
      </div>

      <div style="font-style: italic; font-weight: bold;">Research and Development Expenses</div>

      <div style="text-indent: 36pt;">Research and development (&#8220;R&amp;D&#8221;) expenses totaled $1.8 million for the year ended December 31, 2024, as compared to $3.3 million for the year ended December 31, 2023. The decrease is primarily due to the absence of
        expenditures in 2024 related to the BIVIGAM post-marketing commitments, for which we incurred $1.7 million of expenses in 2023, partially offset by an increase in expenses associated with our ASCENIV pediatric study in the amount of $0.3 million.</div>

      <div><br/>
      </div>

      <div style="font-style: italic; font-weight: bold;">Plasma Center Operating Expenses</div>

      <div style="text-indent: 36pt;">Plasma center operating expenses, which primarily consists of compensation, benefits and travel for plasma center management and administrative staff, along with certain initial opening, marketing and start-up costs,
        were essentially unchanged at $4.2 million for the year ended December 31, 2024 as compared to approximately $4.3 million for the year ended December 31, 2023.</div>

      <div><br/>
      </div>

      <div style="font-style: italic; font-weight: bold;">Amortization of Intangibles</div>

      <div style="text-indent: 36pt;">Amortization expense mainly pertains to the amortization of intangible assets acquired in a 2017 acquisition transaction and was $0.4 million and $0.7 million for the years ended December 31, 2024 and 2023,
        respectively. The intangible assets acquired in 2017 became fully amortized in June of 2024.</div>

      <div><br/>
      </div>

      <div style="font-style: italic; font-weight: bold;">Selling, General and Administrative Expenses</div>

      <div style="text-indent: 36pt;">Selling, general and administrative (&#8220;SG&amp;A&#8221;) expenses were $74.1 million for the year ended December 31, 2024, an increase of $15.1 million from the year ended December 31, 2023, and reflects an increase in
        stock-based compensation expense of $6.4 million in 2024, largely due to the higher valuation of grants awarded in 2024 and to additional compensation expense recognized for the modification of certain outstanding equity awards. The increase in
        SG&amp;A also reflects increases in employee-related costs, including salaries and wages, benefits, relocation and recruiting, in the aggregate amount of $4.8 million, software maintenance expense of $1.2 million, consulting and professional fees
        of $0.9 million, audit and tax fees of $0.6 million, insurance expense of $0.6 million and temporary labor expense of $0.7 million. SG&amp;A expenses as a percentage of net revenues decreased from 22.9% in fiscal 2023 to 17.4% in fiscal 2024.</div>

      <div><br/>
      </div>

      <div style="font-style: italic; font-weight: bold;">Income from Operations</div>

      <div style="text-indent: 36pt;">Our operating income was $139.0 million for the year ended December 31, 2024, as compared to $21.6 million for the year ended December 31, 2023. The $117.4 million increase in operating income was mainly due to the
        improved gross profit, driven by both the year-over-year revenue growth and the shift in revenue mix toward significantly higher margin IVIG products, partially offset by $13.3 million of higher total operating expenses. The higher gross profit
        also reflects the foregoing adjustment to our accrual for estimated U.S. Medicaid rebates which increased our revenues for the year ended December 31, 2024 by $12.6 million.</div>

      <div><br/>
      </div>

      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageNumberArea" style="text-align: center;"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">73</span></div>

        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"/></div>

        <div class="BRPFPageHeader" style="width: 100%;">
          <div>
            <div style="text-align: left; font-weight: bold; text-indent: -9pt; margin-left: 9pt;"><a href="#ADMABIOLOGICSINC."> <span style="font-style: italic; font-weight: normal; font-size: 8pt;">Table of Contents</span></a><br/>
            </div>

          </div>

        </div>

      </div>

      <div style="font-style: italic; font-weight: bold;">Interest Expense</div>

      <div style="text-indent: 36pt;">Interest expense for the year ended December 31, 2024 was $13.9 million, as compared to $25.0 million for the year ended December 31, 2023. Prior to the refinancing of our senior debt on December 18, 2023 (see
        &#8220;Liquidity and Capital Resources&#8221;), our outstanding debt principal balance throughout 2023 ranged between $155.1 million and $158.6 million. The refinancing transaction reduced our debt principal to $135.0 million as of December 31, 2023, and we
        made additional principal payments on this indebtedness of $30.0 million on each of August 14, 2024 and December 19, 2024, reducing our debt principal balance to $75.0 million as of December 31, 2024. In addition, the stated interest rate on our
        debt during 2024 was approximately 10.1%, as compared to approximately 13.9% during 2023. We also incurred lower expense related to the amortization of debt discount in 2024 in the amount of $1.6 million. We expect our interest expense to continue
        to decline in 2025 due to the reduced debt principal balance and potential further repayments on our outstanding debt.</div>

      <div><br/>
      </div>

      <div style="font-style: italic; font-weight: bold;">Loss on Extinguishment of Debt</div>

      <div style="text-indent: 36pt;">As a result of the prepayment we made on our senior debt on December 19, 2024, we incurred a prepayment penalty in the amount of $0.45 million and recorded a partial write-down of unamortized debt discount of
        approximately $0.8 million, for a loss on this partial extinguishment of debt in the amount of $1.2 million. In connection with the foregoing refinancing of our senior debt in December of 2023, we incurred a loss on extinguishment of debt in the
        amount of $26.2 million, which is comprised of a prepayment penalty paid to our previous lender in the amount of $11.1 million, and the write-off of unamortized discount related to the retired indebtedness in the approximate amount of $15.1 million
        (see Note 7 to the Consolidated Financial Statements).</div>

      <div><br/>
      </div>

      <div style="font-style: italic; font-weight: bold;">Other Income, Net</div>

      <div style="text-indent: 36pt;">Other income, net, for the year ended December 31, 2024 was $1.9 million, as compared to $1.3 million for the year ended December 31, 2023. The increase is mainly due to an increase in interest income of $0.5 million
        in 2024 resulting from higher average cash balances in 2024.</div>

      <div><br/>
      </div>

      <div style="font-style: italic; font-weight: bold;">Income Tax Benefit</div>

      <div style="text-indent: 36pt;">We recorded a total income tax benefit of $72.0 million for the year ended December 31, 2024, with no comparable amount for the year ended December 31, 2023. The provision for income taxes for fiscal 2024 includes a
        deferred tax benefit of $84.3 million related to the release of the valuation allowance against our net deferred tax assets, partially offset by current income tax expense of $12.3 million, which reflects federal and state income tax liabilities
        that are not fully sheltered by NOLs due to limitations from prior ownership changes and other limitations on net operating loss carryforwards under the Internal Revenue Code of 1986, as amended (see &#8220;Risk Factors - Our ability to use our net
        operating loss carryforwards (&#8220;NOLs&#8221;) may be limited.&#8221; appearing elsewhere in this report and Note 11 to the Consolidated Financial Statements). We expect that we will record income tax expense in 2025 and beyond as we expect to continue to
        generate additional taxable income for the foreseeable future.</div>

      <div><br/>
      </div>

      <div style="font-style: italic; font-weight: bold;">Net Income/Loss</div>

      <div style="text-indent: 36pt;">Our net income was $197.7 million for the year ended December 31, 2024, as compared to a net loss of $28.2 million for the year ended December 31, 2023, an improvement of $225.9 million. The increase was primarily due
        to the increase in operating income of $117.4 million, lower interest expense of $11.1 million discussed above, a reduced loss on the extinguishment of debt as compared to fiscal 2023 and the income tax benefit of $72.0 million. The foregoing
        change in estimate in our accrual for Medicaid rebates favorably impacted our net after-tax income for the year ended December 31, 2024 by approximately $11.4 million.</div>

      <div><br/>
      </div>

      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageNumberArea" style="text-align: center;"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">74</span></div>

        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"/></div>

        <div class="BRPFPageHeader" style="width: 100%;">
          <div>
            <div style="text-align: left; font-weight: bold; text-indent: -9pt; margin-left: 9pt;"><a href="#ADMABIOLOGICSINC."> <span style="font-style: italic; font-weight: normal; font-size: 8pt;">Table of Contents</span></a><br/>
            </div>

          </div>

        </div>

      </div>

      <div style="text-align: justify; font-weight: bold;">Year Ended December 31, 2023 Compared to Year Ended December 31, 2022</div>

      <div>&#160;</div>

      <div style="text-align: justify; text-indent: 36pt;">The following table presents a summary of the changes in our results of operations for the year ended December 31, 2023, compared to the year ended December 31, 2022:</div>

      <div><br/>
      </div>

      <table cellspacing="0" cellpadding="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%; border-spacing: 0;">


  <tr>

    <td valign="bottom" rowspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;"><br/>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="10" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;">
              <div style="text-align: center; color: #000000; font-weight: bold;">Year Ended December 31,</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" rowspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">
              <div style="text-align: center; text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-size: 10pt; font-style: italic;">(in thousands)</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;">
              <div style="text-align: center; color: #000000; font-weight: bold;">2023</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;">
              <div style="text-align: center; color: #000000; font-weight: bold;">2022</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px;">
              <div style="text-align: center; color: #000000; font-weight: bold;">Increase</div>
              <div style="text-align: center; color: #000000; font-weight: bold;">(Decrease)</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #CCEEFF; white-space: nowrap;">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: #000000;">Revenues</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
              <div style="color: #000000;">$</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
              <div style="color: #000000;">258,215</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
              <div style="color: #000000;">$</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
              <div style="color: #000000;">154,080</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
              <div style="color: #000000;">$</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
              <div style="color: #000000;">104,135</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; padding-bottom: 2px;">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: #000000;">Cost of product revenue</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;">
              <div style="color: #000000;">169,273</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;">
              <div style="color: #000000;">118,815</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;">
              <div style="color: #000000;">50,458</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #CCEEFF; white-space: nowrap;">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: #000000;">Gross profit</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
              <div style="color: #000000;">88,942</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
              <div style="color: #000000;">35,265</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
              <div style="color: #000000;">53,677</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; white-space: nowrap;">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: #000000;">Research and development expenses</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
              <div style="color: #000000;">3,300</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
              <div style="color: #000000;">3,614</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
              <div style="color: #000000;">(314</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">
              <div style="color: #000000;">)</div>
            </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #CCEEFF; white-space: nowrap;">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: #000000;">Plasma center operating expenses</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
              <div style="color: #000000;">4,266</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
              <div style="color: #000000;">17,843</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
              <div style="color: #000000;">(13,577</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
              <div style="color: #000000;">)</div>
            </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; white-space: nowrap;">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: #000000;">Amortization of intangibles</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
              <div style="color: #000000;">724</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
              <div style="color: #000000;">715</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
              <div style="color: #000000;">9</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: #000000;">Selling, general and administrative expenses</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">
              <div style="color: #000000;">59,020</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">
              <div style="color: #000000;">52,458</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">
              <div style="color: #000000;">6,562</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; white-space: nowrap;">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: #000000;">Income (loss) from operations</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
              <div style="color: #000000;">21,632</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
              <div style="color: #000000;">(39,365</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">
              <div style="color: #000000;">)</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
              <div style="color: #000000;">60,997</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #CCEEFF; white-space: nowrap;">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: #000000;">Interest expense</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
              <div style="color: #000000;">(25,027</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
              <div style="color: #000000;">)</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
              <div style="color: #000000;">(19,279</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
              <div style="color: #000000;">)</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
              <div style="color: #000000;">(5,748</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
              <div style="color: #000000;">)</div>
            </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; white-space: nowrap;">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: #000000;">Loss on extinguishment of debt</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
              <div style="color: #000000;">(26,174</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">
              <div style="color: #000000;">)</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
              <div style="color: #000000;">(6,670</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">
              <div style="color: #000000;">)</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
              <div style="color: #000000;">(19,504</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">
              <div style="color: #000000;">)</div>
            </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: #000000;">Other income (expense), net</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">
              <div style="color: #000000;">1,330</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">
              <div style="color: #000000;">(590</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">
              <div style="color: #000000;">)</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">
              <div style="color: #000000;">1,920</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; padding-bottom: 4px; white-space: nowrap;">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: #000000;">Net loss</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;">
              <div style="color: #000000;">$</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;">
              <div style="color: #000000;">(28,239</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">
              <div style="color: #000000;">)</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;">
              <div style="color: #000000;">$</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;">
              <div style="color: #000000;">(65,904</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">
              <div style="color: #000000;">)</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;">
              <div style="color: #000000;">$</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;">
              <div style="color: #000000;">37,665</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; padding-bottom: 4px; white-space: nowrap;">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: #000000;">Adjusted EBITDA *</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;">
              <div style="color: #000000;">$</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;">
              <div style="color: #000000;">40,251</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;">
              <div style="color: #000000;">$</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;">
              <div style="color: #000000;">(27,627</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">
              <div style="color: #000000;">)</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;">
              <div style="color: #000000;">$</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;">
              <div style="color: #000000;">67,878</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: #000000;">Adjusted net income (loss) *</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;">
              <div style="color: #000000;">$</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;">
              <div style="color: #000000;">705</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;">
              <div style="color: #000000;">$</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;">
              <div style="color: #000000;">(59,234</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">
              <div style="color: #000000;">)</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;">
              <div style="color: #000000;">$</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;">
              <div style="color: #000000;">59,939</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>


</table>
      <div><br/>
      </div>

      <div style="color: rgb(0, 0, 0);">* - See Non-GAAP Financial Measures appearing at the end of this discussion</div>

      <div><br/>
      </div>

      <div style="font-style: italic; font-weight: bold;">Revenues</div>

      <div style="text-indent: 36pt;">We recorded total revenues of $258.2 million for the year ended December 31, 2023, as compared to $154.1 million for the year ended December 31, 2022, an increase of $104.1 million, or approximately 68%. The increase
        is primarily related to increased sales of our immunoglobulin products, mainly ASCENIV and BIVIGAM, generated by our Boca Facility manufacturing operations in 2023 of $105.8 million, as we continue to experience increased physician, payer and
        patient acceptance and utilization of ASCENIV and expand our customer base for BIVIGAM, partially offset by a decrease in sales of plasma in our Plasma Collection Centers business segment of $1.5 million. During 2023, we began utilizing a
        substantial majority of the plasma collected at our plasma collection facilities for our IVIG production, with significantly less emphasis on plasma sales to third-party customers.</div>

      <div><br/>
      </div>

      <div style="font-style: italic; font-weight: bold;">Cost of Product Revenue and Gross Profit</div>

      <div style="text-indent: 36pt;">Cost of product revenue was $169.3 million for the year ended December 31, 2023, as compared to $118.8 million for the year ended December 31, 2022. This increase is primarily attributable to volume-driven increases in
        product revenue costs related to the increased sales of our immunoglobulin products of $54.9 million. Cost of product revenue was also impacted by the inventory losses of $2.1 million related to the June 2023 IT disruption, partially offset by a
        decrease in other manufacturing expenses of approximately $6.2 million in 2023, mainly due to a shorter planned shutdown of the Boca Facility in 2023 as compared to 2022.</div>

      <div><br/>
      </div>

      <div style="text-indent: 36pt;">For the year ended December 31, 2023, we had gross profit of $88.9 million, as compared to $35.3 million for the same period of a year ago. This gross profit increase of $53.7 million was primarily due to the revenue
        increases and the supply chain and manufacturing enhancements at the Boca Facility which include producing at the increased 4,400 liter scale, along with the reduction in other manufacturing costs discussed above as we elected to extend our
        otherwise-routine plant shutdown in the first quarter of 2022 in order to complete certain projects. We also experienced a more favorable sales mix in 2023 toward our higher margin products and benefitted from price increases for ASCENIV and
        BIVIGAM that were implemented late in 2022. As a result, we achieved a gross margin of 34.4% for the year ended December 31, 2023 as compared to 22.9% for the year ended December 31, 2022.</div>

      <div><br/>
      </div>

      <div style="font-style: italic; font-weight: bold;">Research and Development Expenses</div>

      <div style="text-indent: 36pt;">R&amp;D expenses totaled $3.3 million for the year ended December 31, 2023, as compared to $3.6 million for the year ended December 31, 2022. The decrease is primarily due to lower expenditures attributable to a
        third-party service provider in connection with an R&amp;D project that was completed in early 2023.</div>

      <div><br/>
      </div>

      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageNumberArea" style="text-align: center;"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">75</span></div>

        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"/></div>

        <div class="BRPFPageHeader" style="width: 100%;">
          <div>
            <div style="text-align: left; font-weight: bold; text-indent: -9pt; margin-left: 9pt;"><a href="#ADMABIOLOGICSINC."> <span style="font-style: italic; font-weight: normal; font-size: 8pt;">Table of Contents</span></a><br/>
            </div>

          </div>

        </div>

      </div>

      <div style="font-style: italic; font-weight: bold;">Plasma Center Operating Expenses</div>

      <div style="text-indent: 36pt;">Plasma Center Operating Expenses decreased from $17.8 million in the year ended December 31, 2022 to $4.3 million in the year ended December 31, 2023. As a result of our now having ten plasma centers in operation, we
        were able to more than double the number of liters of plasma collected, with a corresponding reduction in the cost per liter, in 2023 as compared to 2022, coupled with the changes in the market price of normal source plasma and its impact on the
        net realizable value of our plasma inventory, the amount of plasma center costs we capitalized into inventory increased by approximately $43.2 million in 2023. This amount was largely offset by increases in donor fees of $12.8 million,
        compensation, benefits and temporary labor of $3.9 million, softgoods and supplies of $5.0 million, donor testing expenses of $4.8 million, depreciation of $0.8 million, software maintenance expense of $0.9 million, janitorial, security and
        utilities expense of $0.5 million, travel expenses of $0.1 million, advertising expense of $0.2 million, repairs and maintenance expense of $0.2 million and rent of $0.2 million.&#160; In addition, our plasma center collections and operating costs were
        unfavorably impacted by approximately $0.7 million due to the temporary closing of our plasma collection centers attributable to an IT disruption occurring in June 2023, of which all systems have since been fully restored.</div>

      <div><br/>
      </div>

      <div style="font-style: italic; font-weight: bold;">Amortization of Intangibles</div>

      <div style="text-indent: 36pt;">Amortization expense mainly pertains to the amortization of intangible assets acquired in a 2017 acquisition transaction and was $0.7 million for the years ended December 31, 2023 and 2022.</div>

      <div><br/>
      </div>

      <div style="font-style: italic; font-weight: bold;">Selling, General and Administrative Expenses</div>

      <div style="text-indent: 36pt;">Selling, general and administrative (&#8220;SG&amp;A&#8221;) expenses were $59.0 million for the year ended December 31, 2023, an increase of $6.6 million from the year ended December 31, 2022. The increase reflects higher
        expenses for employee-related costs including salaries, benefits, stock-based compensation, travel, relocation and recruiting of $2.4 million, data services and market intelligence fees in support of the continued ASCENIV and BIVIGAM
        commercialization efforts in the amount of $1.8 million, marketing and advertising expenses of $1.0 million, insurance expense of $0.6 million, software maintenance expense of $0.6 million and state and local taxes of $0.2 million.</div>

      <div><br/>
      </div>

      <div style="font-style: italic; font-weight: bold;">Income/Loss from Operations</div>

      <div style="text-indent: 36pt;">For the year ended December 31, 2023, we had operating income of $21.6 million, as compared to an operating loss of $39.4 million for the year ended December 31, 2022. The $61.0 million improvement in operating results
        was mainly due to the improved gross profit of $53.7 million, largely driven by the year-over-year revenue growth and shift in revenue mix toward higher margin IVIG products, and the lower total operating expenses of $7.3 million.</div>

      <div><br/>
      </div>

      <div style="font-style: italic; font-weight: bold;">Interest Expense</div>

      <div style="text-indent: 36pt;">Interest expense for the year ended December 31, 2023 was $25.0 million, as compared to $19.3 million for the year ended December 31, 2022. The increase is mainly due to approximately $51.8 million of additional debt
        principal resulting from the refinancing of our senior credit facility on March 23, 2022, additional debt principal resulting from interest payments made &#8220;in kind&#8221; in the form of additional indebtedness of approximately $6.8 million, as well as an
        increase in the stated interest rate on our senior debt from 10.75% in 2022 to as high as 14.4% at certain points in fiscal 2023 as a result of increases in the Secured Overnight Financing Rate (&#8220;SOFR&#8221;). We expect our interest expense to decrease
        in 2024 as a result of the refinancing transaction we completed in December of 2023 (see &#8220;Liquidity and Capital Resources&#8221;), which resulted in a lower debt principal balance and a reduction in the interest rate.</div>

      <div><br/>
      </div>

      <div style="font-style: italic; font-weight: bold;">Loss on Extinguishment of Debt</div>

      <div style="text-indent: 36pt;">In connection with the foregoing refinancing of our senior debt in December of 2023, we incurred a loss on extinguishment of debt in the amount of $26.2 million, which is comprised of a prepayment penalty paid to our
        previous lender in the amount of $11.1 million, and the write-off of unamortized discount related to the retired indebtedness in the approximate amount of $15.1 million (see &#8220;Liquidity and Capital Resources&#8221;).</div>

      <div><br/>
      </div>

      <div style="text-indent: 36pt;">In connection with the refinancing of our senior credit facility on March 23, 2022, we incurred a loss on the extinguishment of debt in the amount of $6.7 million as a result of the redemption premium we paid to retire
        our previously existing credit facility in the amount of $2.0 million, and the write-off of unamortized debt discount of $4.7 million related to that facility (see Note 7 to the Consolidated Financial Statements).</div>

      <div><br/>
      </div>

      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageNumberArea" style="text-align: center;"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">76</span></div>

        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"/></div>

        <div class="BRPFPageHeader" style="width: 100%;">
          <div>
            <div style="text-align: left; font-weight: bold; text-indent: -9pt; margin-left: 9pt;"><a href="#ADMABIOLOGICSINC."> <span style="font-style: italic; font-weight: normal; font-size: 8pt;">Table of Contents</span></a><br/>
            </div>

          </div>

        </div>

      </div>

      <div style="font-style: italic; font-weight: bold;">Other Income (Expense), Net</div>

      <div style="text-indent: 36pt;">Other income, net, for the year ended December 31, 2023 was $1.3 million, as compared to other expense, net, of $0.6 million for the year ended December 31, 2022. The increase is mainly due to an increase in interest
        income of approximately $1.6 million in 2023 due to higher interest earned on our cash balances in 2023.</div>

      <div><br/>
      </div>

      <div style="font-style: italic; font-weight: bold;">Net Loss</div>

      <div style="text-indent: 36pt;">Our net loss was $28.2 million for the year ended December 31, 2023, as compared to $65.9 million for the year ended December 31, 2022. The $37.7 million decrease in net loss was mainly due to the improvement in
        operating income/loss of $61.0 million and the $1.9 million increase in other income/expense, partially offset by a higher loss on extinguishment of debt of $19.5 million and higher interest expense of $5.7 million.</div>

      <div><br/>
      </div>

      <div style="font-style: italic; font-weight: bold;">Non-GAAP Financial Measures</div>

      <div>&#160;</div>

      <div style="font-style: italic; font-weight: bold;">Earnings Before Interest, Taxes, Depreciation and Amortization (&#8220;EBITDA&#8221;), Adjusted EBITDA and Adjusted Net Income (Loss)</div>

      <div style="text-indent: 36pt;">EBITDA, Adjusted EBITDA and Adjusted net income (loss) are important non-GAAP financial measures used by our management and Board of Directors to assess our operating performance. We use EBITDA, Adjusted EBITDA and
        Adjusted net income (loss) as key performance measures because we believe that they facilitate operating performance comparisons from period to period that exclude, in the case of Adjusted net income (loss), items that are expected to be
        non-recurring, and in the case of EBITDA and Adjusted EBITDA, potential differences driven by the impact of variations of non-cash items such as depreciation and amortization, as well as, in the case of Adjusted EBITDA, stock-based compensation or
        certain one-time and non-recurring items. In addition, we believe that EBITDA, Adjusted EBITDA and Adjusted net loss and similar measures are widely used by investors, securities analysts, ratings agencies and other parties in evaluating companies
        in our industry as a measure of financial performance and debt-service capabilities. See below for a reconciliation of our EBITDA, Adjusted EBITDA and Adjusted net income (loss) to net loss, the most directly comparable financial measure calculated
        and presented in accordance with U.S. GAAP.</div>

      <div><br/>
      </div>

      <div style="text-indent: 36pt;">Because EBITDA, Adjusted EBITDA and Adjusted net income (loss) are measures not deemed to be in accordance with U.S. GAAP and are susceptible to varying calculations, our EBITDA, Adjusted EBITDA and Adjusted net income
        (loss) may not be comparable to similarly titled measures of other companies, including companies in our industry, because other companies may calculate EBITDA, Adjusted EBITDA and Adjusted net income (loss) in a different manner than we calculate
        these measurements. <span style="color: #000000;">Although the Company uses Adjusted EBITDA as one of several financial measures to assess its operating performance, its use is limited as it excludes certain significant operating expenses. EBITDA,
          Adjusted EBITDA and Adjusted net income (loss) are not intended to represent cash flows for the periods presented, nor have they been presented as an alternative to operating income/loss, net income/loss or as an indicator of operating
          performance and should not be considered in isolation or as a substitute for measures of performance prepared in accordance with U.S. GAAP. The following table presents the reconciliation of net loss to EBITDA and Adjusted EBITDA for the years
          ended December 31, 2024, 2023 and 2022:</span></div>

      <div style="text-indent: 36pt;"><span style="color: #000000;"> <br/>
        </span></div>

      <table cellspacing="0" cellpadding="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%; border-spacing: 0;">


  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="10" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;">
              <div style="text-align: center; font-weight: bold;">Year Ended December 31,</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;">
              <div style="text-align: center; font-weight: bold;"> 2024</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;">
              <div style="text-align: center; font-weight: bold;">2023</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;">
              <div style="text-align: center; font-weight: bold;">2022</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="10" style="vertical-align: bottom; white-space: nowrap;">
              <div style="text-align: center; font-size: 10pt; font-style: italic;">(In thousands)</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #CCEEFF; white-space: nowrap;">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;">Net income (loss)</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
              <div>$</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
              <div>197,673</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
              <div>$</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
              <div>(28,239</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
              <div>)</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
              <div>$</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
              <div>(65,904</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
              <div>)</div>
            </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; white-space: nowrap;">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: #000000;">Depreciation</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
              <div style="color: #000000;">7,657</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
              <div style="color: #000000;">7,608</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
              <div style="color: #000000;">6,398</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #CCEEFF; white-space: nowrap;">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: #000000;">Amortization</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
              <div style="color: #000000;">388</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
              <div style="color: #000000;">724</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
              <div style="color: #000000;">715</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; white-space: nowrap;">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: #000000;">Income tax benefit</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
              <div style="color: #000000;">(71,959</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">
              <div style="color: #000000;">)</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
              <div style="color: #000000;">-</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
              <div style="color: #000000;">-</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: #000000;">Interest expense</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">
              <div style="color: #000000;">13,930</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">
              <div style="color: #000000;">25,027</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">
              <div style="color: #000000;">19,279</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; white-space: nowrap;">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: #000000; font-weight: bold;">EBITDA</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
              <div style="color: #000000;">147,689</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
              <div style="color: #000000;">5,120</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
              <div style="color: #000000;">(39,512</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">
              <div style="color: #000000;">)</div>
            </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #CCEEFF; white-space: nowrap;">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: #000000;">Stock-based compensation</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
              <div style="color: #000000;">13,616</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
              <div style="color: #000000;">6,187</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
              <div style="color: #000000;">5,215</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; white-space: nowrap;">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: #000000;">Loss on extinguishment of debt</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
              <div style="color: #000000;">1,243</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
              <div style="color: #000000;">26,174</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
              <div style="color: #000000;">6,670</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #CCEEFF; white-space: nowrap;">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: #000000;">Yield enhancement</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
              <div style="color: #000000;">2,064</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
              <div style="color: #000000;">-</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
              <div style="color: #000000;">-</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; padding-bottom: 2px; white-space: nowrap;">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: #000000;">IT systems disruption</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">
              <div style="color: #000000;">-</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">
              <div style="color: #000000;">2,770</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">
              <div style="color: #000000;">-</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: #000000; font-weight: bold;">Adjusted EBITDA</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;">
              <div style="color: #000000;">$</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;">
              <div style="color: #000000;">164,612</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;">
              <div style="color: #000000;">$</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;">
              <div style="color: #000000;">40,251</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;">
              <div style="color: #000000;">$</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;">
              <div style="color: #000000;">(27,627</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">
              <div style="color: #000000;">)</div>
            </td>

  </tr>


</table>
      <div><br/>
      </div>

      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageNumberArea" style="text-align: center;"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">77</span></div>

        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"/></div>

        <div class="BRPFPageHeader" style="width: 100%;">
          <div>
            <div style="text-align: left; font-weight: bold; text-indent: -9pt; margin-left: 9pt;"><a href="#ADMABIOLOGICSINC."> <span style="font-style: italic; font-weight: normal; font-size: 8pt;">Table of Contents</span></a><br/>
            </div>

          </div>

        </div>

      </div>

      <div style="text-indent: 36pt;">Adjusted EBITDA improved by $122.3 million for the year ended December 31, 2024 as compared to the year ended December 31, 2023, mainly due to the substantial increase in operating income in 2024 of $117.4 million.
        Adjusted EBITDA increased by $67.9 million for the year ended December 31, 2023 as compared to the same period of a year ago. The improvement is driven primarily by an increase in operating income in 2023 of $61.0 million.</div>

      <div><br/>
      </div>

      <div style="text-indent: 36pt; color: #000000;">The following table presents the reconciliation of Net income (loss) to Adjusted net income (loss) for the years ended December 31, 2024, 2023 and 2022:</div>

      <div><br/>
      </div>

      <table cellspacing="0" cellpadding="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%; border-spacing: 0;">


  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="10" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;">
              <div style="text-align: center; color: #000000; font-weight: bold;">Years Ended December 31,</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">
              <div style="text-align: center; text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-size: 10pt; font-style: italic;">(in thousands)</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;">
              <div style="text-align: center; font-weight: bold;">2024</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;">
              <div style="text-align: center; font-weight: bold;">2023</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;">
              <div style="text-align: center; font-weight: bold;">2022</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #CCEEFF; white-space: nowrap;">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt; font-weight: bold;">Net income (loss)</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
              <div>$</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
              <div>197,673</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
              <div>$</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
              <div>(28,239</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
              <div>)</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
              <div>$</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
              <div>(65,904</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
              <div>)</div>
            </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; white-space: nowrap;">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: #000000;">Loss on extinguishment of debt</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
              <div style="color: #000000;">1,243</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
              <div style="color: #000000;">26,174</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
              <div style="color: #000000;">6,670</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #CCEEFF; white-space: nowrap;">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: #000000;">Deferred tax benefit</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
              <div style="color: #000000;">(84,280</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
              <div style="color: #000000;">)</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
              <div style="color: #000000;">-</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
              <div style="color: #000000;">-</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; white-space: nowrap;">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: #000000;">Yield enhancement</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
              <div style="color: #000000;">2,064</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
              <div style="color: #000000;">-</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
              <div style="color: #000000;">-</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #CCEEFF; white-space: nowrap;">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: #000000;">Stock-based compenstion modifications</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
              <div style="color: #000000;">2,518</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
              <div style="color: #000000;">-</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
              <div style="color: #000000;">-</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; padding-bottom: 2px; white-space: nowrap;">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: #000000;">IT systems disruption</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">
              <div style="color: #000000;">-</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">
              <div style="color: #000000;">2,770</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">
              <div style="color: #000000;">-</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt; color: #000000; font-weight: bold;">Adjusted net income (loss)</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;">
              <div style="color: #000000;">$</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;">
              <div style="color: #000000;">119,218</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;">
              <div style="color: #000000;">$</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;">
              <div style="color: #000000;">705</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;">
              <div style="color: #000000;">$</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;">
              <div style="color: #000000;">(59,234</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">
              <div style="color: #000000;">)</div>
            </td>

  </tr>


</table>
      <div><br/>
      </div>

      <div style="text-align: center; font-weight: bold;"><span style="text-decoration: underline;">LIQUIDITY AND CAPITAL RESOURCES</span></div>

      <div> <br/>
      </div>

      <div style="text-indent: 36pt;">At December 31, 2024, we had working capital of $275.9 million, primarily consisting of $170.2 million of inventory, cash and cash equivalents of $103.1 million and $50.0 million of accounts receivable, partially
        offset by current liabilities of $55.5 million, as compared to working capital at December 31, 2023 of $207.2 million, primarily consisting of $172.9 million of inventory, cash and cash equivalents of $51.4 million and accounts receivable of $27.4
        million, partially offset by current liabilities of $49.8 million. Although we have incurred an accumulated deficit of $308.6 million since inception, we had positive cash flow from operations for the years ended December 31, 2024 and 2023 of
        $118.7 million and $8.8 million for the years ended December 31, 2024 and 2023, respectively. Prior to fiscal 2024, we funded our operations over the previous few years primarily from the sale of our equity securities and debt financings. Our
        material cash requirements are primarily comprised of:</div>

      <div>&#160;</div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
              <div>The collection and procurement of raw material source plasma, which includes plasma donor fees and plasma center supplies, and other raw materials necessary to maintain and scale up our manufacturing operations;</div>
            </td>

  </tr>


</table>
      <div>&#160;</div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
              <div>Employee compensation and benefits;</div>
            </td>

  </tr>


</table>
      <div>&#160;</div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
              <div>Capital expenditures for equipment upgrades and capacity expansion at the Boca Facility and to maintain our plasma collection facilities;</div>
            </td>

  </tr>


</table>
      <div>&#160;</div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
              <div>Interest on our debt;</div>
            </td>

  </tr>


</table>
      <div>&#160;</div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
              <div>Marketing programs, medical education and continued commercialization efforts;</div>
            </td>

  </tr>


</table>
      <div>&#160;</div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
              <div>Boca Facility maintenance, improvements, repairs and supplies;</div>
            </td>

  </tr>


</table>
      <div>&#160;</div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
              <div>Conducting required post-marketing clinical trials for ASCENIV; and</div>
            </td>

  </tr>


</table>
      <div>&#160;</div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000; border-spacing: 0;" class="DSPFListTable">


  <tr>

    <td style="width: 18pt;"><br/>
            </td>

    <td style="width: 18pt; vertical-align: top;">&#8226;</td>

    <td style="width: auto; vertical-align: top;">
              <div>Continuous improvements and updates to our IT infrastructure, laboratory equipment and assays, and facilities and engineering equipment.</div>
            </td>

  </tr>


</table>
      <div><br/>
      </div>

      <div>As we continue to onboard new staff and expand production at the Boca Facility, we may also decide to use cash on hand, in whole or in part, to purchase additional real estate to add redundancies, expand operations and prepare for future growth
        opportunities. In addition, our end-to-end production cycle time from procurement of raw materials to commercial release of finished product can take between seven and 12 months or potentially longer, requiring substantial inventories of raw
        material plasma and other manufacturing and laboratory testing materials and single use disposables.</div>

      <div><br/>
      </div>

      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageNumberArea" style="text-align: center;"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">78</span></div>

        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"/></div>

        <div class="BRPFPageHeader" style="width: 100%;">
          <div>
            <div style="text-align: left; font-weight: bold; text-indent: -9pt; margin-left: 9pt;"><a href="#ADMABIOLOGICSINC."> <span style="font-style: italic; font-weight: normal; font-size: 8pt;">Table of Contents</span></a><br/>
            </div>

          </div>

        </div>

      </div>

      <div style="text-indent: 36pt;">For the year ended December 31, 2024, we had pre-tax income and GAAP net income of $125.7 million and $197.7 million, respectively. We currently anticipate, based upon our projected revenue and expenditures, that our
        current cash, cash equivalents and accounts receivable, along with our projected future operating cash flow, will be sufficient to fund our operations, as currently conducted, through the end of the first quarter of fiscal 2026. However, our
        current outlook with respect to cash flows and profitability may change based upon several factors, including the continued success of our commercial efforts with respect to the sale of our products and the continued acceptability of our immune
        globulin products by physicians, patients or payers, and whether or not the assumptions underlying our projected revenues and expenses are correct. If we are unable to maintain positive cash flow throughout fiscal 2025, we may choose to raise
        additional capital. If we are unable to generate sufficient revenue to maintain positive cash flow throughout fiscal 2025 and elect to raise additional capital, we may decide to do so through public or private equity offerings or debt financings,
        or we may enter into a corporate collaboration or licensing arrangement.&#160; The sale of additional equity securities or debt financings, if convertible, could result in dilution to our stockholders and, in such event, the value and potential future
        market price of our common stock may decline.</div>

      <div><br/>
      </div>

      <div style="text-indent: 36pt;">ADMA continues to evaluate a variety of strategic alternatives, and the exploration of value-creating opportunities remains a top corporate priority.</div>

      <div><br/>
      </div>

      <div>
        <div style="text-indent: 36pt; color: #000000;">On December 18, 2023 (the &#8220;Ares Closing Date&#8221;), we and all of our subsidiaries entered into a senior secured credit facility (the &#8220;Ares Credit Agreement&#8221;) with Ares Capital Corporation and certain
          credit funds affiliated with Ares Capital Corporation (collectively, &#8220;Ares&#8221;). The Ares Credit Agreement provided for a total of $135.0 million in senior secured credit facilities (the &#8220;Ares Credit Facility&#8221;) consisting of (i) a term loan in the
          aggregate principal amount of $62.5 million and (ii) a revolving credit facility in the aggregate principal amount of $72.5 million (collectively, the &#8220;Ares Loans&#8221;), both of which were fully drawn on the Ares Closing Date. The Ares Credit
          Facility has a maturity date of December 20, 2027 (the &#8220;Ares Maturity Date&#8221;). On the Ares Closing Date, we used the proceeds from the Ares Loans, along with a portion of our existing cash on hand, to terminate and pay in full all of the
          outstanding obligations under our previous senior credit facility (the &#8220;Hayfin Credit Facility&#8221;) with Hayfin Services LLP (&#8220;Hayfin&#8221;) including the outstanding principal in the amount of $158.6 million, a prepayment penalty in the amount $11.1
          million, an exit fee of $1.6 million, all accrued and unpaid interest outstanding on the Hayfin Credit Facility as of the Ares Closing date, as well as certain fees and expenses related thereto. In connection with the payoff and termination of
          the Hayfin Credit Facility, we also wrote off $15.0 million of unamortized debt discount related to the Hayfin Credit Facility. As a result of this transaction, we recorded a loss on the extinguishment of the Hayfin Credit Facility in the amount
          of $26.2 million in the year ended December 31, 2023, which is mainly comprised of the write-off of unamortized debt discount and the prepayment penalty.</div>

      </div>

      <div>
        <div><br/>
        </div>

      </div>

      <div>
        <div style="text-indent: 36pt; color: #000000;">On August 14, 2024, we repaid $30.0 million against the revolving credit facility and the outstanding balance on the revolving credit facility as of December 31, 2024 was $42.5 million. On December
          19, 2024 we repaid $30.0 million against the term loan and the outstanding balance on the term loan as of December 31, 2024 was $32.5 million. In connection with the repayment against the term loan, we recognized a loss on extinguishment of debt
          in the approximate amount of $1.2 million, which is comprised of a prepayment penalty in the amount of $0.45 million and a partial write-off of unamortized discount attributable to the term loan in the amount of $0.8 million.</div>

        <div><br/>
        </div>

        <div style="text-indent: 36pt; color: #000000;">Borrowings under the term loan bear interest at the adjusted Term SOFR for a three&#8209;month tenor in effect on the day that is two business days prior to the first day of the applicable calendar quarter
          plus 6.50% (the &#8220;Initial SOFR Term Loan Applicable Margin&#8221;). Borrowings under the revolving facility bear interest at the adjusted Term SOFR for a three&#8209;month tenor in effect on the day that is two business days prior to the first day of the
          applicable calendar quarter<span style="font-style: italic;">&#160;</span>plus<span style="font-style: italic;">&#160;</span>3.75% (the &#8220;SOFR Revolving Facility Applicable Margin&#8221;). On the Ares Closing Date, the interest rate on the term loan was
          approximately 11.9% and the interest rate on the revolving facility was approximately 9.1%, representing a weighted-average interest rate of approximately 10.4%. As of December 31, 2024, the interest rate on the term loan was approximately 10.9%
          and the interest rate on the revolving facility was approximately 8.3%, representing a weighted-average interest rate of approximately 9.4%.</div>

      </div>

      <div>
        <div><br/>
        </div>

      </div>

      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageNumberArea" style="text-align: center;"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">79</span></div>

        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"/></div>

        <div class="BRPFPageHeader" style="width: 100%;">
          <div>
            <div style="text-align: left; font-weight: bold; text-indent: -9pt; margin-left: 9pt;"><a href="#ADMABIOLOGICSINC."> <span style="font-style: italic; font-weight: normal; font-size: 8pt;">Table of Contents</span></a><br/>
            </div>

          </div>

        </div>

      </div>

      <div>
        <div style="text-indent: 36pt; color: #000000;">On the Ares Maturity Date, we are required to pay Ares the entire outstanding principal amount underlying the Ares Loans and any accrued and unpaid interest thereon. Prior to the Ares Maturity Date,
          there are no scheduled principal payments on the Ares Credit Facility, and we are required to make quarterly interest payments during the term of Ares Credit Facility of approximately $1.8 million. We may prepay the outstanding principal under
          the revolving facility, together with any accrued but unpaid interest on the prepaid principal amount, at any time and from time to time upon three business days&#8217; prior written notice with no prepayment premium. However, in the event that we pay
          down an aggregate amount under the revolving facility that is greater than 50% of revolving facility commitment of $72.5 million, we will still be required to pay interest on 50% of this amount, or $36.3 million, through the term of Ares Credit
          Facility. We may prepay the outstanding principal on the term loan, together with any accrued but unpaid interest on the prepaid principal amount, at any time and from time to time upon three business days&#8217; prior written notice, subject to the
          payment to Ares of a prepayment premium equal to (i) the present value as of such date of all remaining required interest payments on the principal amount being repaid plus 1.5% of the prepaid principal amount, if prepaid on or prior to the first
          anniversary of the Ares Closing Date, (ii) 1.5% of the prepaid principal amount, if prepaid after the first anniversary of the Ares Closing Date and on or prior to the second anniversary of the Ares Closing Date, or (iii) 1.0% of the prepaid
          principal amount, if prepaid on or prior to the third anniversary of the Ares Closing Date.</div>

        <div><br/>
        </div>

        <div style="text-indent: 36pt; color: #000000;">In connection with the closing of the Ares Credit Facility, we incurred fees and expenses related to the transaction of approximately $2.7 million, including a $1.7 million original issue discount
          payable to Ares, all of which was deducted from the Ares loan proceeds. In addition, we are also required to pay Ares an exit fee of $1.7 million upon the earlier of any prepayment date or the Ares Maturity Date, and this obligation has been
          accrued as a separate liability in our consolidated balance sheet as of December 31, 2024 and 2023 in the amount of $1.3 million and $1.7 million, respectively. As a result, we recognized an aggregate debt discount of $4.4 million as of the Ares
          Closing Date, and the weighted-average effective interest rate on the Ares Loans as of December 31, 2024 and 2023 was 10.81% and 11.39%, respectively. In connection with the prepayment of the term loan on December 19, 2024, we also paid a pro
          rata portion of the exit fee in the amount of $0.4 million.</div>

      </div>

      <div>
        <div><br/>
        </div>

      </div>

      <div>
        <div style="text-indent: 36pt; color: #000000;">All of our obligations under the Ares Credit Agreement are secured by a first-priority lien and security interest in substantially all of our tangible and intangible assets, including intellectual
          property and all of the equity interests in our subsidiaries. The Ares Credit Agreement contains certain representations and warranties, affirmative covenants, negative covenants and conditions that are customarily required for similar
          financings. The negative covenants include certain financial covenants, including maximum total leverage ratios and a $15.0 million liquidity covenant, and also restrict or limit our ability and the ability of our subsidiaries to, among other
          things and subject to certain exceptions contained in the Ares Credit Agreement, incur new indebtedness; create liens on assets; engage in certain fundamental corporate changes, such as mergers or acquisitions, or changes to our or our
          subsidiaries&#8217; business activities; make certain Investments or Restricted Payments (each as defined in the Ares Credit Agreement); engage in certain affiliate transactions; or enter into, amend or terminate any other agreements that have the
          impact of restricting our ability to make loan repayments under the Ares Credit Agreement. As of December 31, 2024, we were in compliance with all of the covenants contained in the Ares Credit Agreement.</div>

        <div>&#160;</div>

      </div>

      <div style="text-indent: 36pt;">Events of default on the Ares Loans include, among others, non-payment of principal, interest or fees, violation of covenants, inaccuracy of representations and warranties, bankruptcy and insolvency events, material
        judgments, cross-defaults to material contracts and events constituting a change of control. If there is an event of default, we will incur an increase in the rate of interest on the Ares Loans of 2% per annum.</div>

      <div><br/>
      </div>

      <div style="text-indent: 36pt;">On March 23, 2022 (the &#8220;Hayfin Closing Date&#8221;), we and all of our subsidiaries entered into the Hayfin Credit Agreement with Hayfin. The Hayfin Credit Agreement, as amended, provided for a senior secured term loan
        facility in a principal amount of up to $175.0 million, composed of (i) a term loan made on the Hayfin Closing Date in the principal amount of $150.0 million (the &#8220;Hayfin Closing Date Loan&#8221;), and (ii) a delayed draw term loan in the principal
        amount of $25.0 million (the &#8220;Hayfin Delayed Draw Loan&#8221; and, together with the Hayfin Closing Date Loan, the &#8220;Hayfin Loans&#8221;). The Hayfin Delayed Draw Loan was not drawn prior to our termination of the Hayfin Credit Agreement. The Hayfin Credit
        Facility had a maturity date of March 23, 2027 (the &#8220;Hayfin Maturity Date&#8221;), subject to acceleration pursuant to the Hayfin Credit Agreement, including upon an Event of Default (as defined in the Hayfin Credit Agreement).</div>

      <div><br/>
      </div>

      <div style="text-indent: 36pt;">On the Hayfin Closing Date, we used $100.0 million of the Hayfin Closing Date Loan to terminate and pay in full all of the outstanding obligations under our previous senior credit facility with Perceptive (see Note 7
        to the Consolidated Financial Statements). We also used $2.0 million of the Hayfin Closing Date Loan proceeds to pay a redemption premium to Perceptive and used approximately $1.0 million of the Hayfin Closing Date Loan proceeds to pay certain fees
        and expenses incurred in connection with this transaction. In addition, a $1.8 million upfront fee payable to Hayfin was paid &#8220;in kind&#8221; and was added to the outstanding principal balance in accordance with the terms of the Hayfin Credit Agreement.</div>

      <div><br/>
      </div>

      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageNumberArea" style="text-align: center;"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">80</span></div>

        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"/></div>

        <div class="BRPFPageHeader" style="width: 100%;">
          <div>
            <div style="text-align: left; font-weight: bold; text-indent: -9pt; margin-left: 9pt;"><a href="#ADMABIOLOGICSINC."> <span style="font-style: italic; font-weight: normal; font-size: 8pt;">Table of Contents</span></a><br/>
            </div>

          </div>

        </div>

      </div>

      <div style="text-indent: 36pt;">Borrowings under the Hayfin Credit Agreement bore interest at the adjusted Term SOFR for either a one-month or three-month tenor, as elected by us, and subject to a floor of 1.25%, plus an applicable margin of 9.5%
        (the &#8220;Applicable Margin&#8221;); provided, however, that upon, and during the continuance of, an Event of Default, the Applicable Margin would increase by an additional 3% per annum. On May 1, 2023 the Hayfin Credit Agreement was amended to reduce the
        Applicable Margin from 9.5% to 8.5%. On the last day of each calendar month prior to the Ares Closing Date we paid accrued interest to Hayfin. On the Hayfin Closing Date, December 31, 2022 and the Ares Closing Date, the stated interest rate on the
        Hayfin Loans was 10.75%, approximately 13.7% and approximately 13.9%, respectively. We were also permitted to pay &#8220;in kind&#8221; a portion of the interest on the Hayfin Loans for each monthly interest period in an amount equal to 2.5% per annum, which
        was added to the principal amount of the outstanding debt under the Hayfin Credit Facility. From the Hayfin Closing Date through December 31, 2022, $3.0 million of interest was paid in kind and added to the balance of the outstanding Hayfin Loans.
        For the year ended December 31, 2023, $3.8 million of interest was paid in kind and added to the balance of the outstanding Hayfin Loans.</div>

      <div><br/>
      </div>

      <div style="text-indent: 36pt;">On the Ares Closing Date, we paid Hayfin the entire outstanding principal amount underlying the Hayfin Loans and any accrued and unpaid interest thereon, as well as an exit fee of 1.0% of the outstanding principal
        amount being paid. In accordance with the terms of the Hayfin Credit Agreement, we also paid Hayfin the early prepayment fee in the amount equal 7.0% of the prepaid principal amount, or $11.1 million.</div>

      <div><br/>
      </div>

      <div style="text-indent: 36pt;">All of our obligations under the Hayfin Credit Agreement were secured by a first-priority lien and security interest in substantially all of our tangible and intangible assets, including intellectual property and all
        of the equity interests in our subsidiaries. The Hayfin Credit Agreement contained certain representations and warranties, affirmative covenants, negative covenants and conditions that are customarily required for similar financings. The negative
        covenants restricted or limited our ability and the ability of our subsidiaries to, among other things and subject to certain exceptions contained in the Hayfin Credit Agreement, incur new indebtedness; create liens on assets; engage in certain
        fundamental corporate changes, such as mergers or acquisitions, or changes to our or our subsidiaries&#8217; business activities; make certain Investments or Restricted Payments (each as defined in the Hayfin Credit Agreement); change our fiscal year;
        pay dividends; repay other certain indebtedness; engage in certain affiliate transactions; or enter into, amend or terminate any other agreements that have the impact of restricting our ability to make loan repayments under the Hayfin Credit
        Agreement. In addition, we were required (i) at all times prior to the Hayfin Maturity Date to maintain a minimum cash balance of $6.0 million; and (ii) as of the last day of each fiscal quarter, report IVIG product and related revenues for the
        trailing 12-month period that exceed the amounts set forth in the Hayfin Credit Agreement, which ranged from $75.0 million for the fiscal quarter ending June 30, 2022 to $110.0 million for the fiscal quarter ending September 30, 2023. As of the
        Ares Closing Date and December 31, 2022, we were in compliance with all of the financial covenants contained in the Hayfin Credit Agreement.</div>

      <div><br/>
      </div>

      <div style="text-indent: 36pt;">On December 9, 2022, we completed an underwritten public offering whereby we issued 24,125,873 shares of our common stock. Net proceeds after underwriting discounts and expenses associated with the offering were
        approximately $64.6 million and were used to accelerate commercialization and production activities, complete plasma center buildouts and obtain FDA approvals, to conclude post&#8209;FDA marketing approval research and development projects, and for
        working capital, capital expenditures and general corporate purposes.</div>

      <div><br/>
      </div>

      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageNumberArea" style="text-align: center;"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">81</span></div>

        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"/></div>

        <div class="BRPFPageHeader" style="width: 100%;">
          <div>
            <div style="text-align: left; font-weight: bold; text-indent: -9pt; margin-left: 9pt;"><a href="#ADMABIOLOGICSINC."> <span style="font-style: italic; font-weight: normal; font-size: 8pt;">Table of Contents</span></a><br/>
            </div>

          </div>

        </div>

      </div>

      <div style="font-weight: bold;">Cash Flows</div>

      <div>&#160;</div>

      <div style="text-indent: 36pt;">The following table sets forth a summary of our cash flows for the periods indicated:&#160;</div>

      <table cellspacing="0" cellpadding="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%; border-spacing: 0;">


  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="10" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;">
              <div style="text-align: center; font-weight: bold;">Year Ended December 31,</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">
              <div style="text-align: center; text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-size: 10pt; font-style: italic;">(in thousands)</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;">
              <div style="text-align: center; font-weight: bold;">2024</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;">
              <div style="text-align: center; font-weight: bold;">2023</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;">
              <div style="text-align: center; font-weight: bold;">2022</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #CCEEFF; white-space: nowrap;">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Net cash provided by (used in) operating activities</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
              <div>$</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
              <div>118,672</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
              <div>$</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
              <div>8,800</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
              <div>$</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
              <div>(59,508</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
              <div>)</div>
            </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; white-space: nowrap;">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Net cash used in investing activities</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
              <div>(8,575</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">
              <div>)</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
              <div>(4,981</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">
              <div>)</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
              <div>(13,911</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">
              <div>)</div>
            </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Net cash (used in) provided by financing activities</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">
              <div>(58,302</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">
              <div>)</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">
              <div>(38,989</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">
              <div>)</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">
              <div>108,852</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; white-space: nowrap;">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Net change in cash and cash equivalents</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
              <div>51,795</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
              <div>(35,170</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">
              <div>)</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
              <div>35,433</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; padding-bottom: 2px; white-space: nowrap;">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Cash and cash equivalents - beginning of year</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">
              <div>51,352</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">
              <div>86,522</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">
              <div>51,089</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Cash and cash equivalents - end of year</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;">
              <div>$</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;">
              <div>103,147</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;">
              <div>$</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;">
              <div>51,352</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;">
              <div>$</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;">
              <div>86,522</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>


</table>
      <div><br/>
      </div>

      <div style="font-style: italic; font-weight: bold;">Net Cash Provided by (Used in) Operating Activities</div>

      <div style="font-style: italic; font-weight: bold;"> <br/>
      </div>

      <div style="text-indent: 36pt;">Cash provided by operations for the year ended December 31, 2024 was $118.7 million, as compared to $8.8 million for the year ended December 31, 2023. The increase is mainly due to substantially higher net income. The
        improvement in cash flow from operations in 2023 as compared to the year ended December 31, 2022 was mainly due to the improvement in our operating results, driven by higher revenues and gross margins, and a lower increase in inventories. The
        following table illustrates the primary components of our cash flows from operations:</div>

      <div><br/>
      </div>

      <table cellspacing="0" cellpadding="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000; width: 100%; border-spacing: 0;">


  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="10" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;">
              <div style="text-align: center; font-weight: bold;">Year Ended December 31,</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">
              <div style="text-align: center; text-indent: -7.2pt; margin-left: 7.2pt; color: rgb(0, 0, 0); font-size: 10pt; font-style: italic;">(in thousands)</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;">
              <div style="text-align: center; font-weight: bold;">2024</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;">
              <div style="text-align: center; font-weight: bold;">2023</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;">
              <div style="text-align: center; font-weight: bold;">2022</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #CCEEFF; white-space: nowrap;">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Net income (loss)</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
              <div>$</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
              <div>197,673</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
              <div>$</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
              <div>(28,239</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
              <div>)</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
              <div>$</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
              <div>(65,904</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
              <div>)</div>
            </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; white-space: nowrap;">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Non-cash expenses, gains and losses</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
              <div>(60,462</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">
              <div>)</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
              <div>47,162</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
              <div>24,682</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #CCEEFF; white-space: nowrap;">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Changes in accounts receivable</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
              <div>(22,578</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
              <div>)</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
              <div>(11,916</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
              <div>)</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
              <div>13,072</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; white-space: nowrap;">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Changes in inventories</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
              <div>2,671</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
              <div>(9,626</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">
              <div>)</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
              <div>(38,556</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; white-space: nowrap;">
              <div>)</div>
            </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; background-color: #CCEEFF; white-space: nowrap;">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Changes in accounts payable and accrued expenses</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
              <div>5,192</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
              <div>11,369</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
              <div>8,334</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; padding-bottom: 2px; white-space: nowrap;">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Other</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">
              <div>(3,824</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">
              <div>)</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">
              <div>50</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">
              <div>(1,136</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">
              <div>)</div>
            </td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 64%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">
              <div style="text-indent: -7.2pt; margin-left: 7.2pt;">Cash provided by (used in) operations</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;">
              <div>$</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;">
              <div>118,672</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;">
              <div>$</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;">
              <div>8,800</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;">
              <div>$</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;">
              <div>(59,508</div>
            </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">
              <div>)</div>
            </td>

  </tr>


</table>
      <div><br/>
      </div>

      <div style="font-style: italic; font-weight: bold;">Net Cash Used in Investing Activities</div>

      <div style="text-indent: 36pt;">Cash used in investing activities for the year ended December 31, 2024 was $8.6 million and is mainly comprised of equipment purchases and other capital expenditures at the Boca Facility. Cash used in investing
        activities for the year ended December 31, 2023 was $5.0 million, which was primarily comprised of capital expenditures of $3.0 million for equipment purchases and facilities upgrades at the Boca Facility, and $1.8 million to complete the buildout
        of our plasma collection facilities. Net cash used in investing activities for the year ended December 31, 2022 was $13.9 million, which consisted of $8.7 million for the construction and buildout of several new plasma collection facilities and
        $5.2 million for equipment purchases and upgrades to the Boca Facility. While we do not have any firm commitments for material capital expenditures in 2025, we expect our total capital expenditures will be between $12.0 million and $18.0 million
        for fiscal 2025.</div>

      <div><br/>
      </div>

      <div style="font-style: italic; font-weight: bold;">Net Cash (Used in) Provided by Financing Activities</div>

      <div style="text-indent: 36pt;">Net cash used in financing activities for the year ended December 31, 2024 was $58.3 million and was primarily composed of an aggregate of $60.0 million of debt principal payments during the year. Net cash used in
        financing activities for the year ended December 31, 2023 was $39.0 million, as we reduced our outstanding debt principal by $23.6 million with the refinancing of our senior debt on December 18, 2023 and paid approximately $12.7 million to exit the
        Hayfin Credit Facility. Net cash provided by financing activities for the year ended December 31, 2022 was $108.9 million, as we received approximately $47.0 in net proceeds from the refinancing of our senior credit facility in March of 2022 and
        $64.6 million in net proceeds from the December 9, 2022 public offering of our common stock.</div>

      <div><br/>
      </div>

      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageNumberArea" style="text-align: center;"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">82</span></div>

        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"/></div>

        <div class="BRPFPageHeader" style="width: 100%;">
          <div>
            <div style="text-align: left; font-weight: bold; text-indent: -9pt; margin-left: 9pt;"><a href="#ADMABIOLOGICSINC."> <span style="font-style: italic; font-weight: normal; font-size: 8pt;">Table of Contents</span></a><br/>
            </div>

          </div>

        </div>

      </div>

      <div style="font-weight: bold;">Effect of Inflation</div>

      <div>&#160;</div>

      <div style="text-indent: 36pt;">Inflation impacted a number of facets of our business during the years ended December 31, 2024, 2023 and 2022 at each of our business segments. Disruptions in the global economy have impeded global supply chains,
        resulted in longer lead times and delays in procuring certain raw materials, and resulted in inflationary cost increases in certain raw materials, labor and transportation. We also experienced price increases for, among other items, consumable
        supplies, services for repairs and maintenance of our facilities, utilities, shipping and freight charges, fuel surcharges and labor costs, among other expenses. Based upon the macroeconomic environment, publicly available information and reports
        from the U.S. government, we expect this trend to subside somewhat in 2025, however we cannot predict the extent to which future domestic and global economic conditions including, but not limited to, supply chain constraints or geopolitical
        conditions, including the continuing conflicts in Europe and in the Middle East and surrounding areas, could have a significant impact on our future results of operations. In addition, some of our third-party inventory purchase agreements provide
        for scheduled price increases that are tied to various consumer price indices, which have resulted in higher than historical percentage price increases and could result in higher source plasma and other raw material and supplies costs in 2025 and
        beyond. Also, in a higher inflationary environment, we may not be able to raise the prices of our products to keep up with the rate of inflation.</div>

      <div><br/>
      </div>

      <div>
        <a id="QuantitativeandQualitativ"><!--Anchor--></a>
<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-spacing: 0;">


  <tr style="vertical-align: top;">

    <td style="text-align: right; vertical-align: top; width: 45pt;">
                <div style="text-align: left;"><span style="font-weight: bold;">Item 7A.</span> <br/>
                </div>
              </td>

    <td style="text-align: left; vertical-align: top; width: auto;">
                <div><span style="font-weight: bold;">Quantitative and Qualitative Disclosures About Market Risk</span></div>
              </td>

  </tr>


</table>
      </div>

      <div> <br/>
      </div>

      <div style="text-indent: 36pt;">We are exposed to market risk as the result of changes in interest rates. Our senior credit facility with Ares requires quarterly payments of interest based on the adjusted Term SOFR plus the Applicable Margin. We
        currently do not utilize any derivative financial instruments, such as interest rate swaps or caps, to mitigate this risk. As of December 31, 2024, we had $75.0 million outstanding under our senior credit facility that is subject to a variable
        interest rate. As a result, the effect of a hypothetical, instantaneous and unfavorable change of 100 basis points in the interest rate would have an approximate $0.8 million annualized negative impact on our earnings and cash flows.</div>

      <div style="text-indent: 36pt;"><br/>
      </div>

      <div>
        <a id="FinancialStatementsandSup"><!--Anchor--></a>
<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-spacing: 0;">


  <tr style="vertical-align: top;">

    <td style="text-align: right; vertical-align: top; width: 45pt;">
                <div style="text-align: left;"><span style="font-weight: bold;">Item 8.</span></div>
              </td>

    <td style="text-align: left; vertical-align: top; width: auto;">
                <div><span style="font-weight: bold;">Financial Statements and Supplementary Data</span></div>
              </td>

  </tr>


</table>
      </div>

      <div> <br/>
      </div>

      <div style="text-indent: 36pt;">Our financial statements required to be filed pursuant to this Item 8 appear in a separate section of this Annual Report on Form 10-K, beginning on page F-1.</div>

      <div><br/>
      </div>

      <div>
        <a id="ChangesinandDisagreements"><!--Anchor--></a>
<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-spacing: 0;">


  <tr style="vertical-align: top;">

    <td style="text-align: right; vertical-align: top; width: 45pt;">
                <div style="text-align: left;"><span style="font-weight: bold;">Item 9.</span></div>
              </td>

    <td style="text-align: left; vertical-align: top; width: auto;">
                <div><span style="font-weight: bold;">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</span></div>
              </td>

  </tr>


</table>
      </div>

      <div> <br/>
      </div>

      <div style="text-indent: 36pt;">None.</div>

      <div><br/>
      </div>

      <div>
        <a id="ControlsandProcedures"><!--Anchor--></a>
<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-spacing: 0;">


  <tr style="vertical-align: top;">

    <td style="text-align: right; vertical-align: top; width: 45pt;">
                <div style="text-align: left;"><span style="font-weight: bold;">Item 9A.</span></div>
              </td>

    <td style="text-align: left; vertical-align: top; width: auto;">
                <div><span style="font-weight: bold;">Controls and Procedures</span></div>
              </td>

  </tr>


</table>
      </div>

      <div>&#160;</div>

      <div style="font-weight: bold;">Disclosure Controls and Procedures</div>

      <div><span style="font-weight: bold;"> </span><br/>
      </div>

      <div style="text-indent: 36pt;">Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures as of December 31, 2024. The term &#8220;disclosure
        controls and procedures,&#8221; as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act, means controls and other procedures of a company that are designed to ensure that information required to be disclosed by a company in the reports that it
        files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC&#8217;s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed
        to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the company&#8217;s management, including its principal executive and principal financial
        officers, as appropriate to allow timely decisions regarding required disclosure. Management recognizes that any set of controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their
        objectives and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Based on the evaluation of our disclosure controls and procedures as of December 31, 2024, our Chief
        Executive Officer and Chief Financial Officer concluded that, as of such date, our disclosure controls and procedures were effective at the reasonable assurance level.</div>

      <div><br/>
      </div>

      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageNumberArea" style="text-align: center;"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">83</span></div>

        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"/></div>

        <div class="BRPFPageHeader" style="width: 100%;">
          <div>
            <div style="text-align: left; font-weight: bold; text-indent: -9pt; margin-left: 9pt;"><a href="#ADMABIOLOGICSINC."> <span style="font-style: italic; font-weight: normal; font-size: 8pt;">Table of Contents</span></a><br/>
            </div>

          </div>

        </div>

      </div>

      <div style="font-weight: bold;">Management&#8217;s Annual Report on Internal Control Over Financial Reporting</div>

      <div><br/>
      </div>

      <div style="text-indent: 36pt;">Management&#8217;s annual report on internal control over financial reporting (as defined in Rule 13a- 15(f) under the Exchange Act) is included with the financial statements reflected in Item 8 of this Annual Report on Form
        10-K and is incorporated herein by reference.</div>

      <div><br/>
      </div>

      <div style="font-weight: bold;">Report of Independent Registered Public Accounting Firms</div>

      <div><br/>
      </div>

      <div style="text-indent: 36pt;">The effectiveness of our internal control over financial reporting as of December 31, 2024 has been audited by KPMG. KPMG is an independent registered public accounting firm, as stated in their reports which appear in
        Item 8 of this Annual Report on Form 10-K.</div>

      <div><br/>
      </div>

      <div style="font-weight: bold;">Changes in Internal Control Over Financial Reporting</div>

      <div><span style="font-weight: bold;"> </span><br/>
      </div>

      <div style="text-indent: 36pt;">There has been no change in our internal control over financial reporting during the quarter ending December 31, 2024 that has materially affected, or is reasonably likely to materially affect, our internal control
        over financial reporting.</div>

      <div style="text-indent: 36pt;"> <br/>
      </div>

      <div>
        <a id="OtherInformation"><!--Anchor--></a>
<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-spacing: 0;">


  <tr style="vertical-align: top;">

    <td style="text-align: right; vertical-align: top; width: 45pt;">
                <div style="text-align: left;"><span style="font-weight: bold;">Item 9B.</span></div>
              </td>

    <td style="text-align: left; vertical-align: top; width: auto;">
                <div><span style="font-weight: bold;">Other Information</span></div>
              </td>

  </tr>


</table>
      </div>

      <div><span style="font-weight: bold;"> </span><br/>
      </div>

      <div style="text-indent: 36pt;">Our directors and executive officers may from time to time enter into plans or other arrangements for the purchase or sale of our common stock that are intended to satisfy the affirmative defense conditions of Rule
        10b5-1(c) or may constitute a non-Rule 10b5-1 trading arrangement under the Exchange Act.</div>

      <div><br/>
      </div>


      <ix:nonNumeric name="ecd:MtrlTermsOfTrdArrTextBlock" id="Text_7c487e6e04094111a51f1e383ea32939" contextRef="c20241001to20241231_IndividualAxis_AdamGrossmanMember" escape="true">
<div style="display:none;"><br/></div>
<div style="text-indent: 36pt;">During the quarter ended December 31, 2024, none of our directors or executive officers <ix:nonNumeric name="ecd:NonRule10b51ArrAdoptedFlag" id="Fact_9cf971c178de474986334675d24b8e8f" contextRef="c20241001to20241231" format="ixt:fixed-false">adopted</ix:nonNumeric> or <ix:nonNumeric name="ecd:NonRule10b51ArrTrmntdFlag" id="Fact_354e25ef00234919a134028df3ab65d7" contextRef="c20241001to20241231" format="ixt:fixed-false"><ix:nonNumeric name="ecd:Rule10b51ArrTrmntdFlag" id="Fact_2e40f150ef574124963441af7ff18ed7" contextRef="c20241001to20241231_IndividualAxis_AdamGrossmanMember" format="ixt:fixed-false">terminated</ix:nonNumeric></ix:nonNumeric> any such contract, instruction or written plans except for <ix:nonNumeric name="ecd:TrdArrIndName" id="Fact_001e940f94f0432585fbebbbde0b0fc0" contextRef="c20241001to20241231_IndividualAxis_AdamGrossmanMember">Adam Grossman</ix:nonNumeric>, our <ix:nonNumeric name="ecd:TrdArrIndTitle" id="Fact_fdff22a2ae1540bdaab34cf5163d0ec2" contextRef="c20241001to20241231_IndividualAxis_AdamGrossmanMember">President and CEO</ix:nonNumeric>, who entered into a Rule <ix:nonNumeric name="ecd:Rule10b51ArrAdoptedFlag" id="Fact_54d28122aa704b3fa1fb55066d80fb7e" contextRef="c20241001to20241231_IndividualAxis_AdamGrossmanMember" format="ixt:fixed-true">105b-1</ix:nonNumeric> trading plan with Fidelity Brokerage Services LLC on <ix:nonNumeric name="ecd:TrdArrAdoptionDate" id="Fact_39fae28a74db4de9b19171e8e0d46df8" contextRef="c20241001to20241231_IndividualAxis_AdamGrossmanMember">December 5, 2024</ix:nonNumeric> (the &#8220;Grossman Plan&#8221;).&#160;The Grossman Plan provides that Mr. Grossman may sell up to an aggregate of (i) <ix:nonFraction name="ecd:TrdArrSecuritiesAggAvailAmt" id="Fact_c0cfdcd889d94ca38955bbf9b7b1784a" contextRef="c20241231_TradingArrAxis_AdamGrossmanTradingPlanCommonStockMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">60,000</ix:nonFraction>
        shares of our common stock and (ii) <ix:nonFraction name="ecd:TrdArrSecuritiesAggAvailAmt" id="Fact_5eb3986a564642a68aa910150d247927" contextRef="c20241231_TradingArrAxis_AdamGrossmanTradingPlanStockOptionsMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">150,000</ix:nonFraction> shares of our common stock to be received upon the exercise of vested options granted to Mr.
        Grossman. The Grossman Plan is scheduled to terminate on <ix:nonNumeric name="ecd:TrdArrExpirationDate" id="Fact_30c212d1f9fc41e4b04406b54f0df7da" contextRef="c20241001to20241231_IndividualAxis_AdamGrossmanMember">December 31, 2025</ix:nonNumeric>, subject to earlier <span style="-sec-ix-hidden:Fact_7095587f31264a6b95943ba8d0a4f402">termination</span> upon the sale of all shares subject to the plan, upon termination by Mr. Grossman or the broker, or as otherwise provided in the plan.</div>
</ix:nonNumeric>

      <div><br/>
      </div>

      <div>
        <a id="DisclosureRegardingForeig"><!--Anchor--></a>
<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-spacing: 0;">


  <tr style="vertical-align: top;">

    <td style="text-align: right; vertical-align: top; width: 45pt;">
                <div style="text-align: left;"><span style="font-weight: bold;">Item 9C.</span><br/>
                </div>
              </td>

    <td style="text-align: left; vertical-align: top; width: auto;">
                <div><span style="font-weight: bold;">Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</span></div>
              </td>

  </tr>


</table>
      </div>

      <div><span style="font-weight: bold;"> </span><br/>
      </div>

      <div style="text-indent: 36pt;">None.</div>

      <div><br/>
      </div>

      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageNumberArea" style="text-align: center;"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">84</span></div>

        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"/></div>

        <div class="BRPFPageHeader" style="width: 100%;">
          <div>
            <div style="text-align: left; font-weight: bold; text-indent: -9pt; margin-left: 9pt;"><a href="#ADMABIOLOGICSINC."> <span style="font-style: italic; font-weight: normal; font-size: 8pt;">Table of Contents</span></a><br/>
            </div>

          </div>

        </div>

      </div>

      <div style="text-align: center; font-weight: bold;">PART III</div>

      <div style="text-align: center;"><span style="font-weight: bold;"> </span><br/>
      </div>

      <div>
        <a id="DirectorsExecutiveOfficer"><!--Anchor--></a>
<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-spacing: 0;">


  <tr style="vertical-align: top;">

    <td style="text-align: right; vertical-align: top; width: 45pt;">
                <div style="text-align: left;"><span style="font-weight: bold;">Item <span style="font-weight: bold;">10.</span> </span></div>
              </td>

    <td style="text-align: left; vertical-align: top; width: auto;">
                <div><span style="font-weight: bold;">Directors, Executive Officers and Corporate Governance</span></div>
              </td>

  </tr>


</table>
      </div>

      <div><span style="font-weight: bold;"> </span><br/>
      </div>

      <div style="text-indent: 36pt;">Information required to be disclosed by this Item with respect to our executive officers is incorporated into this Annual Report on Form 10-K by reference from the section entitled &#8220;Executive Officers and Director and
        Officer Compensation: Executive Officers&#8221; contained in our definitive proxy statement for our 2025 annual meeting of stockholders, which we intend to file within 120 days of the end of our fiscal year ended December 31, 2024.</div>

      <div style="text-indent: 36pt;"> <br/>
      </div>

      <div style="text-align: justify; text-indent: 36pt;">Information required to be disclosed by this Item about our Board of Directors (the &#8220;Board&#8221;) is incorporated into this Annual Report on Form 10-K by reference from the section entitled &#8220;Proposal
        No. 1: Election of Directors&#8221; contained in our definitive proxy statement for our 2025 annual meeting of stockholders, which we intend to file within 120 days of the end of our fiscal year ended December 31, 2024.</div>

      <div style="text-align: justify; text-indent: 36pt;"> <br/>
      </div>

      <div style="text-align: justify; text-indent: 36pt;">To the extent necessary, information required to be disclosed by this Item about the Section 16(a) compliance of our directors and executive officers is incorporated into this Annual Report on Form
        10-K, as applicable, by reference from the section entitled &#8220;Delinquent Section 16(a) Reports&#8221; contained in our definitive proxy statement for our 2025 annual meeting of stockholders, which we intend to file within 120 days of the end of our fiscal
        year ended December 31, 2024.</div>

      <div style="text-align: justify; text-indent: 36pt;"> <br/>
      </div>

      <div style="text-indent: 36pt;">Information required to be disclosed by this Item about our Board, the Audit Committee of our Board, our audit committee financial expert, our Code of Ethics and Business Conduct, and other corporate governance matters
        is incorporated into this Annual Report on Form 10-K by reference from the section entitled &#8220;Corporate Governance&#8221; contained in our definitive proxy statement for our 2025 annual meeting of stockholders, which we intend to file within 120 days of
        the end of our fiscal year ended December 31, 2024.</div>

      <div style="text-indent: 36pt;"> <br/>
      </div>

      <div style="text-indent: 36pt;">The text of our Code of Ethics and Business Conduct, which applies to our directors and employees (including our principal executive officer, principal financial officer, principal accounting officer or controller and
        persons performing similar functions), is posted in the &#8220;Corporate Governance&#8221; section of the Investors section of our website, www.admabiologics.com. A copy of the Code of Ethics and Business Conduct can be obtained free of charge on our website.
        We intend to disclose on our website any amendments to, or waivers from, our Code of Ethics and Business Conduct that are required to be disclosed pursuant to the rules of the SEC and The Nasdaq Stock Market.</div>

      <div style="text-indent: 36pt;"> <br/>
      </div>

      <div style="text-align: justify; text-indent: 36pt;">The information presented on our website is not a part of this Annual Report on Form 10-K and the reference to our website is intended to be an inactive textual reference only.</div>

      <div><br/>
      </div>

      <div style="text-align: justify; text-indent: 36pt;">Our Insider Trading Policy governs transactions in our securities by our directors, officers and employees and is designed to promote compliance with applicable insider trading laws, rules and
        regulations. A copy of our Insider Trading Policy is filed with this Annual Report on Form 10-K as Exhibit 19.</div>

      <div style="text-align: justify; text-indent: 36pt;"> <br/>
      </div>

      <div>
        <a id="ExecutiveCompensation"><!--Anchor--></a>
<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-spacing: 0;">


  <tr style="vertical-align: top;">

    <td style="text-align: right; vertical-align: top; width: 45pt;">
                <div style="text-align: left;"><span style="font-weight: bold;">Item 11.</span></div>
              </td>

    <td style="text-align: left; vertical-align: top; width: auto;">
                <div><span style="font-weight: bold;">Executive Compensation</span></div>
              </td>

  </tr>


</table>
      </div>

      <div><span style="font-weight: bold;"> </span><br/>
      </div>

      <div style="text-indent: 36pt;">Information required to be disclosed by this Item is incorporated into this Annual Report on Form 10-K by reference from the section entitled &#8220;Executive Officers and Director and Officer Compensation&#8221; contained in our
        definitive proxy statement for our 2025 annual meeting of stockholders, which we intend to file within 120 days of the end of our fiscal year ended December 31, 2024.</div>

      <div style="text-indent: 36pt;"> <br/>
      </div>

      <div>
        <a id="SecurityOwnershipofCertai"><!--Anchor--></a>
<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-spacing: 0;">


  <tr style="vertical-align: top;">

    <td style="text-align: right; vertical-align: top; width: 45pt;">
                <div style="text-align: left;"><span style="font-weight: bold;">Item 12.</span></div>
              </td>

    <td style="text-align: left; vertical-align: top; width: auto;">
                <div><span style="font-weight: bold;">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</span></div>
              </td>

  </tr>


</table>
      </div>

      <div><span style="font-weight: bold;"> </span><br/>
      </div>

      <div style="text-indent: 36pt;">Information required to be disclosed by this Item is incorporated into this Annual Report on Form 10-K by reference from the sections entitled &#8220;Security Ownership of Certain Beneficial Owners and Management and Related
        Stockholder Matters&#8221; contained in our definitive proxy statement for our 2025 annual meeting of stockholders, which we intend to file within 120 days of the end of our fiscal year ended December 31, 2024.</div>

      <div style="text-indent: 36pt;"> <br/>
      </div>

      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageNumberArea" style="text-align: center;"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">85</span></div>

        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"/></div>

        <div class="BRPFPageHeader" style="width: 100%;">
          <div>
            <div style="text-align: left; font-weight: bold; text-indent: -9pt; margin-left: 9pt;"><a href="#ADMABIOLOGICSINC."> <span style="font-style: italic; font-weight: normal; font-size: 8pt;">Table of Contents</span></a><br/>
            </div>

          </div>

        </div>

      </div>

      <div>
        <a id="CertainRelationshipsandRe"><!--Anchor--></a>
<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-spacing: 0;">


  <tr style="vertical-align: top;">

    <td style="text-align: right; vertical-align: top; width: 45pt;">
                <div style="text-align: left;"><span style="font-weight: bold;">Item 13.</span></div>
              </td>

    <td style="text-align: left; vertical-align: top; width: auto;">
                <div><span style="font-weight: bold;">Certain Relationships and Related Transactions, and Director Independence</span></div>
              </td>

  </tr>


</table>
      </div>

      <div><span style="font-weight: bold;"> </span><br/>
      </div>

      <div style="text-indent: 36pt;">The information required to be disclosed by this Item is incorporated in this Annual Report on Form 10-K by reference from the section entitled &#8220;Certain Relationships and Related Transactions, and Director
        Independence&#8221; contained in our definitive proxy statement for our 2025 annual meeting of stockholders, which we intend to file within 120 days of the end of our fiscal year ended December 31, 2024.</div>

      <div style="text-indent: 36pt;"> <br/>
      </div>

      <div>
        <a id="PrincipalAccountingFeesan"><!--Anchor--></a>
<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-spacing: 0;">


  <tr style="vertical-align: top;">

    <td style="text-align: right; vertical-align: top; width: 45pt;">
                <div style="text-align: left;"><span style="font-weight: bold;">Item 14.</span></div>
              </td>

    <td style="text-align: left; vertical-align: top; width: auto;">
                <div><span style="font-weight: bold;">Principal Accounting Fees and Services</span></div>
              </td>

  </tr>


</table>
      </div>

      <div><span style="font-weight: bold;"> </span><br/>
      </div>

      <div style="text-indent: 36pt;">The information required to be disclosed by this Item is incorporated into this Annual Report on Form 10-K by reference from the section entitled &#8220;Audit and Other Fees&#8221; contained in our definitive proxy statement for
        our 2025 annual meeting of stockholders, which we intend to file within 120 days of the end of our fiscal year ended December 31, 2024.</div>

      <div><br/>
      </div>

      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageNumberArea" style="text-align: center;"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">86</span></div>

        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"/></div>

        <div class="BRPFPageHeader" style="width: 100%;">
          <div>
            <div style="text-align: left; font-weight: bold; text-indent: -9pt; margin-left: 9pt;"><a href="#ADMABIOLOGICSINC."> <span style="font-style: italic; font-weight: normal; font-size: 8pt;">Table of Contents</span></a><br/>
            </div>

          </div>

        </div>

      </div>

      <div style="text-align: center; font-weight: bold;">PART IV</div>

      <div style="text-align: center;"><span style="font-weight: bold;"> </span><br/>
      </div>

      <div>
        <a id="ExhibitsFinancialStatemen"><!--Anchor--></a>
<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-spacing: 0;">


  <tr style="vertical-align: top;">

    <td style="text-align: right; vertical-align: top; width: 45pt;">
                <div style="text-align: left;"><span style="font-weight: bold;">Item 15.</span></div>
              </td>

    <td style="text-align: left; vertical-align: top; width: auto;">
                <div><span style="font-weight: bold;">Exhibits, Financial Statement Schedules</span></div>
              </td>

  </tr>


</table>
      </div>

      <div><span style="font-weight: bold;"> </span><br/>
      </div>

      <div style="font-weight: bold;">Financial Statement Schedules</div>

      <div><span style="font-weight: bold;"> </span><br/>
      </div>

      <div>(a) The following documents are filed as part of this Annual Report on Form 10-K:</div>

      <div> <br/>
      </div>

      <div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-spacing: 0;" class="DSPFListTable">


  <tr style="vertical-align: top;">

    <td style="width: 36pt;">&#160;</td>

    <td style="text-align: right; vertical-align: top; width: 18pt;">
                <div style="text-align: left;">(1)</div>
              </td>

    <td style="text-align: left; vertical-align: top; width: auto;">
                <div>Consolidated Financial Statements.</div>
              </td>

  </tr>


</table>
      </div>

      <div style="text-indent: 36pt;"> <br/>
      </div>

      <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 92%; vertical-align: top;">&#160;</td>

    <td style="width: 8%; vertical-align: top; border-bottom: #000000 2px solid;">
              <div style="text-align: center;">Page</div>
            </td>

  </tr>

  <tr>

    <td style="width: 92%; vertical-align: top; background-color: #CCEEFF;">
              <div>Management&#8217;s Annual Report on Internal Control Over Financial Reporting</div>
            </td>

    <td style="width: 8%; vertical-align: top; background-color: #CCEEFF;">
              <div style="text-align: center;">F-2</div>
            </td>

  </tr>

  <tr>

    <td style="width: 92%; vertical-align: top;">
              <div>Reports of Independent Registered Public Accounting Firm (PCAOB ID 185)</div>
            </td>

    <td style="width: 8%; vertical-align: top;">
              <div style="text-align: center;">F-3</div>
            </td>

  </tr>

  <tr>

    <td style="width: 92%; vertical-align: top; background-color: #CCEEFF;">
              <div>Report of Independent Registered Public Accounting Firm (PCAOB ID 596)</div>
            </td>

    <td style="width: 8%; vertical-align: top; background-color: #CCEEFF;">
              <div style="text-align: center;">F-7</div>
            </td>

  </tr>

  <tr>

    <td style="width: 92%; vertical-align: top;">
              <div>Consolidated Balance Sheets as of December 31, 2024 and 2023</div>
            </td>

    <td style="width: 8%; vertical-align: top;">
              <div style="text-align: center;">F-8</div>
            </td>

  </tr>

  <tr>

    <td style="width: 92%; vertical-align: top; background-color: #CCEEFF;">
              <div>Consolidated Statements of Operations for the years ended December 31, 2024, 2023 and 2022</div>
            </td>

    <td style="width: 8%; vertical-align: top; background-color: #CCEEFF;">
              <div style="text-align: center;">F-9</div>
            </td>

  </tr>

  <tr>

    <td style="width: 92%; vertical-align: top;">
              <div>Consolidated Statements of Changes in Stockholders&#8217; Equity for the years ended December 31, 2024, 2023 and 2022</div>
            </td>

    <td style="width: 8%; vertical-align: bottom;">
              <div style="text-align: center;">F-10</div>
            </td>

  </tr>

  <tr>

    <td style="width: 92%; vertical-align: top; background-color: #CCEEFF;">
              <div>Consolidated Statements of Cash Flows for the years ended December 31, 2024, 2023 and 2022</div>
            </td>

    <td style="width: 8%; vertical-align: top; background-color: #CCEEFF;">
              <div style="text-align: center;">F-11</div>
            </td>

  </tr>

  <tr>

    <td style="width: 92%; vertical-align: top;">
              <div>Notes to Consolidated Financial Statements</div>
            </td>

    <td style="width: 8%; vertical-align: top;">
              <div style="text-align: center;">F-12</div>
            </td>

  </tr>


</table>
      <div><br/>
      </div>

      <div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-spacing: 0;" class="DSPFListTable">


  <tr style="vertical-align: top;">

    <td style="width: 36pt;">&#160;</td>

    <td style="text-align: right; vertical-align: top; width: 18pt;">
                <div style="text-align: left;">(2)</div>
              </td>

    <td style="text-align: left; vertical-align: top; width: auto;">
                <div>Financial Statement Schedules.</div>
              </td>

  </tr>


</table>
      </div>

      <div style="text-indent: 54pt;">Required information is included in the footnotes to the financial statements.</div>

      <div> <br/>
      </div>

      <div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-spacing: 0;" class="DSPFListTable">


  <tr style="vertical-align: top;">

    <td style="width: 36pt;">&#160;</td>

    <td style="text-align: right; vertical-align: top; width: 18pt;">
                <div style="text-align: left;">(3)</div>
              </td>

    <td style="text-align: left; vertical-align: top; width: auto;">
                <div>Index to Exhibits.</div>
              </td>

  </tr>


</table>
      </div>

      <div><br/>
      </div>

      <div style="text-align: center; font-weight: bold;">INDEX TO EXHIBITS</div>

      <div><br/>
      </div>

      <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 10%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="font-weight: bold;">Exhibit</div>
              <div style="font-weight: bold;">No.</div>
            </td>

    <td style="width: 5%; vertical-align: top;">&#160;</td>

    <td style="width: 85%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="font-weight: bold;">Description</div>
            </td>

  </tr>

  <tr>

    <td style="width: 10%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);">
              <div><a href="https://www.sec.gov/Archives/edgar/data/1368514/000119380519000774/e618626_ex3-1.htm">3.1</a></div>
            </td>

    <td style="width: 5%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 85%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);">
              <div>Second Amended and Restated Certificate of Incorporation of the Company (incorporated herein by reference to Exhibit 3.1 to the Company&#8217;s Current Report on Form 8-K, filed with the SEC on August 23, 2019).</div>
            </td>

  </tr>

  <tr>

    <td style="width: 10%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
              <div><a href="https://www.sec.gov/Archives/edgar/data/1368514/000119380521000749/e620651_ex3-1.htm">3.1.1</a></div>
            </td>

    <td style="width: 5%; vertical-align: top;">&#160;</td>

    <td style="width: 85%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
              <div>Certificate of Amendment of the Second Amended and Restated Certificate of Incorporation of ADMA Biologics, Inc., dated as of May 27, 2021 (incorporated herein by reference to Exhibit 3.1 to the Company&#8217;s Current Report on Form 8-K filed
                on May 28, 2021).</div>
            </td>

  </tr>

  <tr>

    <td style="width: 10%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);">
              <div><a href="https://www.sec.gov/Archives/edgar/data/1368514/000114036124031778/ef20031848_ex3-1.htm">3.2</a></div>
            </td>

    <td style="width: 5%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 85%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);">
              <div>Second Amended and Restated Bylaws (incorporated herein by reference to Exhibit 3.1 to the Company&#8217;s Current Report on Form 8-K, filed with the SEC on June 28, 2024).</div>
            </td>

  </tr>

  <tr>

    <td style="width: 10%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
              <div><a href="https://www.sec.gov/Archives/edgar/data/1368514/000114036121042611/brhc10032042_ex3-1.htm">3.3</a></div>
            </td>

    <td style="width: 5%; vertical-align: top;">&#160;</td>

    <td style="width: 85%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
              <div>Amended and Restated Certificate of Designation of Series A Junior Participating Preferred Stock of ADMA Biologics, Inc. (incorporated herein by reference to Exhibit 3.1 to the Company&#8217;s Current Report on Form 8-K filed with the SEC on
                December 21, 2021).</div>
            </td>

  </tr>

  <tr>

    <td style="width: 10%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);">
              <div><a href="https://www.sec.gov/Archives/edgar/data/1368514/000119380512000555/e609522_ex4-1.htm">4.1</a></div>
            </td>

    <td style="width: 5%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 85%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);">
              <div>Specimen Common Stock Certificate (incorporated herein by reference to Exhibit 4.1 to Amendment No. 1 to the Company&#8217;s Current Report on Form 8-K/A, filed with the SEC on March 29, 2012).</div>
            </td>

  </tr>


</table>
      <div><br/>
      </div>

      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageNumberArea" style="text-align: center;"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">87</span></div>

        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"/></div>

        <div class="BRPFPageHeader" style="width: 100%;">
          <div>
            <div style="text-align: left; font-weight: bold; text-indent: -9pt; margin-left: 9pt;"><a href="#ADMABIOLOGICSINC."> <span style="font-style: italic; font-weight: normal; font-size: 8pt;">Table of Contents</span></a><br/>
            </div>

          </div>

        </div>

      </div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 10%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);">
              <div><a href="https://www.sec.gov/Archives/edgar/data/1368514/000114036122011030/brhc10035480_ex4-13.htm">4.2</a></div>
            </td>

    <td style="width: 5%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 85%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);">
              <div>Form of Warrant to Purchase Common Stock, in the form issued by the Company to various entities affiliated with Hayfin Services LLP, dated as of March 23, 2022 (incorporated herein by reference to Exhibit 4.13 to the Company&#8217;s Annual
                Report on Form 10-K, filed with the SEC on March 24, 2022).</div>
            </td>

  </tr>

  <tr>

    <td style="width: 10%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
              <div><a href="https://www.sec.gov/Archives/edgar/data/1368514/000114036123022312/brhc20052223_ex4-1.htm">4.3</a></div>
            </td>

    <td style="width: 5%; vertical-align: top;">&#160;</td>

    <td style="width: 85%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
              <div>Form of Warrant to Purchase Common Stock, in the form issued by the Company to various entities affiliated with Hayfin Services LLP, dated as of May 1, 2023 (incorporated herein by reference to Exhibit 4.1 to the Company&#8217;s Current Report
                on Form 8-K, filed with the SEC on May 2, 2023).</div>
            </td>

  </tr>

  <tr>

    <td style="width: 10%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);">
              <div><a href="https://www.sec.gov/Archives/edgar/data/1368514/000114036122011030/brhc10035480_ex4-11.htm">4.4</a></div>
            </td>

    <td style="width: 5%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 85%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);">
              <div>Description of Securities Registered under Section 12 of the Securities Exchange Act of 1934 (incorporated herein by reference to Exhibit 4.11 to the Company&#8217;s Annual Report on Form 10-K, filed with the SEC on March 24, 2022).</div>
            </td>

  </tr>

  <tr>

    <td style="width: 10%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
              <div><a href="https://www.sec.gov/Archives/edgar/data/1368514/000119380517001506/e616485_ex10-1.htm">10.1&#8224;</a></div>
            </td>

    <td style="width: 5%; vertical-align: top;">&#160;</td>

    <td style="width: 85%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
              <div>Amended and Restated ADMA Biologics, Inc. 2014 Omnibus Incentive Compensation Plan (incorporated herein by reference to Exhibit 10.1 to the Company&#8217;s Registration Statement on Form S-8, filed with the SEC on August 18, 2017).</div>
            </td>

  </tr>

  <tr>

    <td style="width: 10%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);">
              <div><a href="https://www.sec.gov/Archives/edgar/data/1368514/000114036122023666/brhc10038967_ex10-1.htm">10.2&#8224;</a></div>
            </td>

    <td style="width: 5%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 85%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);">
              <div>ADMA Biologics, Inc. 2022 Equity Compensation Plan (incorporated herein by reference to Exhibit 10.1 to the Registrant&#8217;s Current Report on Form 8-K filed with the SEC on June 21, 2022).</div>
            </td>

  </tr>

  <tr>

    <td style="width: 10%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
              <div><a href="https://www.sec.gov/Archives/edgar/data/1368514/000119380519000098/e618169_ex10-1.htm">10.3&#8224;</a></div>
            </td>

    <td style="width: 5%; vertical-align: top;">&#160;</td>

    <td style="width: 85%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
              <div>Amended and Restated Employment Agreement, dated January 29, 2019, by and between ADMA Biologics, Inc. and Adam Grossman (incorporated herein by reference to Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K, filed with the SEC on
                January 29, 2019).</div>
            </td>

  </tr>

  <tr>

    <td style="width: 10%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);">
              <div><a href="https://www.sec.gov/Archives/edgar/data/1368514/000114036121033302/brhc10029407_ex10-2.htm">10.3.1&#8224;</a></div>
            </td>

    <td style="width: 5%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 85%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);">
              <div>Amendment to Employment Agreement, dated as of September 29, 2021, by and between ADMA Biologics, Inc. and Adam Grossman (incorporated herein by reference to Exhibit 10.2 to the Company&#8217;s Current Report on Form 8-K, filed with the SEC on
                October 1, 2021).</div>
            </td>

  </tr>

  <tr>

    <td style="width: 10%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
              <div><a href="https://www.sec.gov/Archives/edgar/data/1368514/000114036124017331/ef20025617_ex10-1.htm">10.4&#8224;</a></div>
            </td>

    <td style="width: 5%; vertical-align: top;">&#160;</td>

    <td style="width: 85%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
              <div>Employment Agreement, dated April 1, 2024, by and between ADMA Biologics, Inc. and Kaitlin Kestenberg (incorporated herein by reference to Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K, filed with the SEC on April 2, 2024).</div>
            </td>

  </tr>

  <tr>

    <td style="width: 10%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);">
              <div><a href="https://www.sec.gov/Archives/edgar/data/1368514/000114036124034440/ef20033085_ex10-1.htm">10.5&#8224;</a></div>
            </td>

    <td style="width: 5%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 85%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);">
              <div>Employment Agreement, dated as of July 24, 2024, by and between ADMA Biologics, Inc. and Brad Tade (incorporated herein by reference to Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K, filed with the SEC on July 26, 2024).</div>
            </td>

  </tr>

  <tr>

    <td style="width: 10%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
              <div><a href="https://www.sec.gov/Archives/edgar/data/1368514/000114036124010100/ef20022642_ex10-1.htm">10.6&#8224;</a></div>
            </td>

    <td style="width: 5%; vertical-align: top;">&#160;</td>

    <td style="width: 85%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
              <div>Consulting Services Agreement, effective as of April 1, 2024, by and between ADMA Biologics, Inc. and Brian Lenz (incorporated herein by reference to Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K, filed with the SEC on
                February 28, 2024).</div>
            </td>

  </tr>

  <tr>

    <td style="width: 10%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);">
              <div><a href="ef20038923_ex10-7.htm">10.7++*</a></div>
            </td>

    <td style="width: 5%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 85%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);">
              <div>Amended and Restated Plasma Purchase Agreement, effective as of October 1, 2024, by and between Grifols Worldwide Operations Limited and ADMA BioManufacturing, LLC.</div>
            </td>

  </tr>

  <tr>

    <td style="width: 10%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
              <div><a href="ef20038923_ex10-8.htm">10.8++*</a></div>
            </td>

    <td style="width: 5%; vertical-align: top;">&#160;</td>

    <td style="width: 85%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
              <div>Plasma Purchase Agreement, effective as of August 6, 2024, by and between KEDPlasma LLC and ADMA BioManufacturing, LLC.</div>
            </td>

  </tr>

  <tr>

    <td style="width: 10%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);">
              <div><a href="https://www.sec.gov/Archives/edgar/data/1368514/000119380517001446/e616455_ex10-5.htm">10.9+</a></div>
            </td>

    <td style="width: 5%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 85%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);">
              <div>Plasma Supply Agreement, dated as of June 6, 2017, by and between ADMA BioManufacturing, LLC and Biotest Pharmaceuticals Corporation (incorporated herein by reference to Exhibit 10.5 to the Company&#8217;s Quarterly Report on Form 10-Q, filed
                with the SEC on August 11, 2017).</div>
            </td>

  </tr>


</table>
      <div><br/>
      </div>

      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageNumberArea" style="text-align: center;"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">88</span></div>

        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"/></div>

        <div class="BRPFPageHeader" style="width: 100%;">
          <div>
            <div style="text-align: left; font-weight: bold; text-indent: -9pt; margin-left: 9pt;"><a href="#ADMABIOLOGICSINC."> <span style="font-style: italic; font-weight: normal; font-size: 8pt;">Table of Contents</span></a><br/>
            </div>

          </div>

        </div>

      </div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 10%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);">
              <div><a href="https://www.sec.gov/Archives/edgar/data/1368514/000119380518001059/e618214_ex10-2.htm">10.9.1+</a></div>
            </td>

    <td style="width: 5%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 85%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);">
              <div>Amendment #1 to the Plasma Supply Agreement, dated as of July 19, 2018, by and between Biotest Pharmaceuticals Corporation and ADMA BioManufacturing, LLC (incorporated herein by reference to Exhibit 10.2 to the Company&#8217;s Quarterly Report
                on Form 10-Q, filed with the SEC on August 10, 2018).</div>
            </td>

  </tr>

  <tr>

    <td style="width: 10%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
              <div><a href="https://www.sec.gov/Archives/edgar/data/1368514/000119380516003725/e615266_ex10-18.htm">10.10</a></div>
            </td>

    <td style="width: 5%; vertical-align: top;">&#160;</td>

    <td style="width: 85%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
              <div>Amended and Restated Agreement for Services, effective as of January 1, 2016, as amended, by and between ADMA BioManufacturing, LLC and Areth LLC (incorporated herein by reference to Exhibit 10.18 to the Company&#8217;s Quarterly Report on
                Form 10-Q, filed with the SEC on August 12, 2016).</div>
            </td>

  </tr>

  <tr>

    <td style="width: 10%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);">
              <div><a href="https://www.sec.gov/Archives/edgar/data/1368514/000119380520000348/e619435_ex10-27.htm">10.10.1</a></div>
            </td>

    <td style="width: 5%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 85%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);">
              <div>Amendment 3 to the Amended and Restated Agreement for Services, effective as of November 7, 2019, by and between ADMA BioManufacturing, LLC and Areth LLC (incorporated herein by reference to the Exhibit 10.27 to the Company&#8217;s Annual
                Report on Form 10-K filed March 13, 2020).</div>
            </td>

  </tr>

  <tr>

    <td style="width: 10%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
              <div><a href="https://www.sec.gov/Archives/edgar/data/1368514/000114036122040738/brhc10043861_ex10-1.htm">10.10.2</a></div>
            </td>

    <td style="width: 5%; vertical-align: top;">&#160;</td>

    <td style="width: 85%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
              <div>Amendment 4 to the Amended and Restated Agreement For Services Between ADMA BioManufacturing, LLC and Areth LLC (incorporated herein by reference to Exhibit 10.1 to the Company&#8217;s Quarterly Report on Form 10-Q filed on November 9, 2022).</div>
            </td>

  </tr>

  <tr>

    <td style="width: 10%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);">
              <div><a href="ef20038923_ex10-11.htm">10.11*</a></div>
            </td>

    <td style="width: 5%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 85%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);">
              <div>Form of Indemnification Agreement.</div>
            </td>

  </tr>

  <tr>

    <td style="width: 10%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
              <div><a href="https://www.sec.gov/Archives/edgar/data/1368514/000119380513000287/e610467_ex10-21.htm">10.12+</a></div>
            </td>

    <td style="width: 5%; vertical-align: top;">&#160;</td>

    <td style="width: 85%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
              <div>License Agreement, effective as of December 31, 2012, by and between ADMA Biologics, Inc. and Biotest AG (incorporated herein by reference to Exhibit 10.21 to the Company&#8217;s Registration Statement on Form S-1, filed with the SEC on
                February 11, 2013).</div>
            </td>

  </tr>

  <tr>

    <td style="width: 10%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);">
              <div><a href="https://www.sec.gov/Archives/edgar/data/1368514/000119380517001446/e616455_ex10-8.htm">10.12.1</a></div>
            </td>

    <td style="width: 5%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 85%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);">
              <div>First Amendment to License Agreement, dated as of June 6, 2017, by and between the Company and Biotest AG (incorporated herein by reference to Exhibit 10.8 to the Company&#8217;s Quarterly Report on Form 10-Q, filed with the SEC on August 11,
                2017).</div>
            </td>

  </tr>

  <tr>

    <td style="width: 10%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
              <div><a href="https://www.sec.gov/Archives/edgar/data/1368514/000114036123058160/ef20016811_ex10-1.htm">10.13</a></div>
            </td>

    <td style="width: 5%; vertical-align: top;">&#160;</td>

    <td style="width: 85%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
              <div>Credit Agreement, dated as of December 18, 2023, by and among the Company, as Administrative Borrower, ADMA BioManufacturing, LLC, ADMA Plasma Biologics, Inc. and ADMA BioCenters Georgia Inc., each as Borrowers, certain subsidiaries of
                the Company, as Guarantors, from time to time party thereto, the Lenders from time to time party thereto, Ares Capital Corporation, as Administrative Agent and as Collateral Agent, and ACF FINCO I LP, as Revolving Agent (incorporated herein
                by reference to Exhibit 10.1 to the Registrant&#8217;s Current Report on Form 8-K filed with the Commission on December 18, 2023).</div>
            </td>

  </tr>

  <tr>

    <td style="width: 10%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);">
              <div><a href="https://www.sec.gov/Archives/edgar/data/1368514/000114036123058160/ef20016811_ex10-2.htm">10.14</a></div>
            </td>

    <td style="width: 5%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 85%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);">
              <div>Security Agreement, dated as of December 18, 2023, by and among the Company, ADMA BioManufacturing, LLC, ADMA Plasma Biologics, Inc. and ADMA BioCenters Georgia, Inc., as Grantors, and Ares Capital Corporation, as Collateral Agent
                (incorporated herein by reference to Exhibit 10.2 to the Registrant&#8217;s Current Report on Form 8-K filed with the Commission on December 18, 2023).</div>
            </td>

  </tr>

  <tr>

    <td style="width: 10%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
              <div><a href="https://www.sec.gov/Archives/edgar/data/1368514/000114036124043222/ef20037071_ex16-1.htm">16.1</a></div>
            </td>

    <td style="width: 5%; vertical-align: top;">&#160;</td>

    <td style="width: 85%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
              <div>Letter, dated October 9, 2024, from CohnReznick LLP addressed to the Commission (incorporated herein by reference to Exhibit 16.1 to the Registrant&#8217;s Current Report on Form 8-K filed with the Commission on October 9, 2024).</div>
            </td>

  </tr>

  <tr>

    <td style="width: 10%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);">
              <div><a href="ef20038923_ex19-1.htm">19.1*</a></div>
            </td>

    <td style="width: 5%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 85%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);">
              <div>The Company&#8217;s Insider Trading Policy, effective September 2024.</div>
            </td>

  </tr>

  <tr>

    <td style="width: 10%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
              <div><a href="ef20038923_ex21-1.htm">21.1*</a></div>
            </td>

    <td style="width: 5%; vertical-align: top;">&#160;</td>

    <td style="width: 85%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
              <div>Subsidiaries of the Company.</div>
            </td>

  </tr>

  <tr>

    <td style="width: 10%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);">
              <div><a href="ef20038923_ex23-1.htm">23.1*</a></div>
            </td>

    <td style="width: 5%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 85%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);">
              <div>Consent of KPMG LLP.</div>
            </td>

  </tr>

  <tr>

    <td style="width: 10%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
              <div><a href="ef20038923_ex23-2.htm">23.2*</a></div>
            </td>

    <td style="width: 5%; vertical-align: top;">&#160;</td>

    <td style="width: 85%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">Consent of CohnReznick LLP. </td>

  </tr>


</table>
      <div><br/>
      </div>

      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div class="BRPFPageNumberArea" style="text-align: center;"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">89</span></div>

        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"/></div>

        <div class="BRPFPageHeader" style="width: 100%;">
          <div>
            <div style="text-align: left; font-weight: bold; text-indent: -9pt; margin-left: 9pt;"><a href="#ADMABIOLOGICSINC."> <span style="font-style: italic; font-weight: normal; font-size: 8pt;">Table of Contents</span></a><br/>
            </div>

          </div>

        </div>

      </div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 10%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);">
              <div><a href="ef20038923_ex31-1.htm">31.1*</a></div>
            </td>

    <td style="width: 5%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 85%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);">
              <div>Certification of Principal Executive Officer pursuant to Rules 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</div>
            </td>

  </tr>

  <tr>

    <td style="width: 10%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
              <div><a href="ef20038923_ex31-2.htm">31.2*</a></div>
            </td>

    <td style="width: 5%; vertical-align: top;">&#160;</td>

    <td style="width: 85%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
              <div>Certification of Principal Financial Officer pursuant to Rules 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</div>
            </td>

  </tr>

  <tr>

    <td style="width: 10%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);">
              <div><a href="ef20038923_ex32-1.htm">32.1**</a></div>
            </td>

    <td style="width: 5%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 85%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);">
              <div>Certification of Principal Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</div>
            </td>

  </tr>

  <tr>

    <td style="width: 10%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
              <div>&#160;</div>
              <div><a href="ef20038923_ex32-2.htm">32.2**</a></div>
            </td>

    <td style="width: 5%; vertical-align: top;">&#160;</td>

    <td style="width: 85%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
              <div>Certification of Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</div>
            </td>

  </tr>

  <tr>

    <td style="width: 10%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);">
              <div><a href="https://www.sec.gov/Archives/edgar/data/1368514/000114036124010147/ef20015264_ex97.htm">97</a></div>
            </td>

    <td style="width: 5%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 85%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);">
              <div>ADMA Biologics, Inc. Compensation Recoupment Policy (incorporated herein by reference to Ex. 97 to the Company&#8217;s Annual Report on Form 10-K filed with the Commission on February 28, 2024).</div>
            </td>

  </tr>

  <tr>

    <td style="width: 10%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
              <div>101*</div>
            </td>

    <td style="width: 5%; vertical-align: top; padding-bottom: 2px;">&#160;</td>

    <td style="width: 85%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
              <div>The following materials from ADMA Biologics, Inc. Form 10-K for the year ended December 31, 2024, formatted in Extensible Business Reporting Language (XBRL): (i) Consolidated Balance Sheets at December 31, 2024 and December 31, 2023,
                (ii) Consolidated Statements of Operations for the years ended December 31, 2024, 2023 and 2022, (iii) Consolidated Statements of Changes in Stockholders&#8217; Equity for the years ended December 31, 2024, 2023 and 2022, (iv) Consolidated
                Statements of Cash Flows for the years ended December 31, 2024, 2023 and 2022; and (v) Notes to Consolidated Financial Statements.</div>
            </td>

  </tr>

  <tr>

    <td style="width: 10%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);">
              <div>104</div>
            </td>

    <td style="width: 5%; vertical-align: top; background-color: rgb(204, 238, 255);">&#160;</td>

    <td style="width: 85%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255);">
              <div>Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).</div>
            </td>

  </tr>


</table>
      <div> <br/>
      </div>

      <div>+ Confidential treatment has been granted with respect as to certain portions of this exhibit.&#160; Such portions have been redacted and submitted separately to the SEC.</div>

      <div><br/>
      </div>

      <div>++ Portions of this exhibit and the schedules thereto have been omitted pursuant to Item 601(b)(10)(iv) of Regulation S-K.</div>

      <div><br/>
      </div>

      <div>* Filed herewith.</div>

      <div> <br/>
      </div>

      <div>** Furnished herewith.</div>

      <div> <br/>
      </div>

      <div>&#8224; Management compensatory plan, contract or arrangement.</div>

      <div><br/>
      </div>

      <div>
        <a id="Form10-KSummary"><!--Anchor--></a>
<table cellspacing="0" cellpadding="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-spacing: 0;">


  <tr style="vertical-align: top;">

    <td style="text-align: right; vertical-align: top; width: 45pt;">
                <div style="text-align: left;"><span style="font-weight: bold;">Item <span style="font-weight: bold;">16.</span> </span></div>
              </td>

    <td style="text-align: left; vertical-align: top;">
                <div><span style="font-weight: bold;">Form 10-K Summary</span></div>
              </td>

  </tr>


</table>
      </div>

      <div><br/>
      </div>

      <div>None.</div>

      <div><br/></div>

      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div class="BRPFPageNumberArea" style="text-align: center;"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">90</span></div>

        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"/></div>

        <div class="BRPFPageHeader" style="width: 100%;">
          <div>
            <div style="text-align: left; font-weight: bold; text-indent: -9pt; margin-left: 9pt;"><a href="#ADMABIOLOGICSINC."> <span style="font-style: italic; font-weight: normal; font-size: 8pt;">Table of Contents</span></a><br/>
            </div>

          </div>

        </div>

      </div>

      <div style="text-align: center; font-weight: bold;">SIGNATURES</div>

      <div style="text-align: center;"> <br/>
      </div>

      <div style="text-indent: 36pt;">Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</div>

      <div> <br/>
      </div>

      <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 49.65%; vertical-align: top;">&#160;</td>

    <td colspan="2" style="vertical-align: middle;">
              <div style="font-weight: bold;">ADMA Biologics, Inc.</div>
            </td>

  </tr>

  <tr>

    <td style="width: 49.65%; vertical-align: top;">&#160;</td>

    <td colspan="2" style="vertical-align: middle;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 49.65%; vertical-align: top; padding-bottom: 2px;">
              <div>Date: March 18, 2025</div>
            </td>

    <td style="width: 5%; vertical-align: middle; padding-bottom: 2px;">
              <div>By:</div>
            </td>

    <td style="width: 44.65%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
              <div>/s/ Adam S. Grossman</div>
            </td>

  </tr>

  <tr>

    <td style="width: 49.65%; vertical-align: top;">&#160;</td>

    <td style="width: 5%; vertical-align: middle;">
              <div>Name:</div>
              <div>Title:</div>
            </td>

    <td style="width: 44.65%; vertical-align: top;">
              <div>Adam S. Grossman</div>
              <div>President and Chief Executive Officer</div>
            </td>

  </tr>


</table>
      <div> <br/>
      </div>

      <div style="text-indent: 36pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated:</div>

      <div style="text-indent: 36pt;"> <br/>
      </div>

      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000; border-spacing: 0;">


  <tr>

    <td style="width: 34%; vertical-align: top; border-bottom: #000000 2px solid;">
              <div style="font-weight: bold;">Signature</div>
            </td>

    <td style="width: 2%; vertical-align: top;">&#160;</td>

    <td style="width: 31%; vertical-align: top; border-bottom: #000000 2px solid;">
              <div style="font-weight: bold;">Title</div>
            </td>

    <td style="width: 2%; vertical-align: top;">&#160;</td>

    <td style="width: 31%; vertical-align: top; border-bottom: #000000 2px solid;">
              <div style="font-weight: bold;">Date</div>
            </td>

  </tr>

  <tr>

    <td style="width: 34%; vertical-align: top;">&#160;</td>

    <td style="width: 2%; vertical-align: top;">&#160;</td>

    <td style="width: 31%; vertical-align: top;">&#160;</td>

    <td style="width: 2%; vertical-align: top;">&#160;</td>

    <td style="width: 31%; vertical-align: top;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 34%; vertical-align: top; border-bottom: #000000 2px solid;">
              <div>/s/ Adam S. Grossman</div>
            </td>

    <td style="width: 2%; vertical-align: top;">&#160;</td>

    <td style="width: 31%; vertical-align: top;">&#160;</td>

    <td style="width: 2%; vertical-align: top;">&#160;</td>

    <td style="width: 31%; vertical-align: top;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 34%; vertical-align: top;">
              <div>Adam S. Grossman</div>
            </td>

    <td style="width: 2%; vertical-align: top;">&#160;</td>

    <td style="width: 31%; vertical-align: top;">
              <div>President and Chief Executive Officer (Principal Executive Officer) and Director</div>
            </td>

    <td style="width: 2%; vertical-align: top;">&#160;</td>

    <td style="width: 31%; vertical-align: top;">
              <div style="text-align: center;">March 18, 2025</div>
            </td>

  </tr>

  <tr>

    <td style="width: 34%; vertical-align: top;">&#160;</td>

    <td style="width: 2%; vertical-align: top;">&#160;</td>

    <td style="width: 31%; vertical-align: top;">&#160;</td>

    <td style="width: 2%; vertical-align: top;">&#160;</td>

    <td style="width: 31%; vertical-align: top;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 34%; vertical-align: top; border-bottom: #000000 2px solid;">
              <div>/s/ Brad Tade</div>
            </td>

    <td style="width: 2%; vertical-align: top;">&#160;</td>

    <td style="width: 31%; vertical-align: top;">&#160;</td>

    <td style="width: 2%; vertical-align: top;">&#160;</td>

    <td style="width: 31%; vertical-align: top;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 34%; vertical-align: top;">
              <div>Brad Tade</div>
            </td>

    <td style="width: 2%; vertical-align: top;">&#160;</td>

    <td style="width: 31%; vertical-align: top;">
              <div>Chief Financial Officer (Principal Financial Officer and Principal Accounting Officer)</div>
            </td>

    <td style="width: 2%; vertical-align: top;">&#160;</td>

    <td style="width: 31%; vertical-align: top;">
              <div style="text-align: center;">March 18, 2025</div>
            </td>

  </tr>

  <tr>

    <td style="width: 34%; vertical-align: top;">&#160;</td>

    <td style="width: 2%; vertical-align: top;">&#160;</td>

    <td style="width: 31%; vertical-align: top;">&#160;</td>

    <td style="width: 2%; vertical-align: top;">&#160;</td>

    <td style="width: 31%; vertical-align: top;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 34%; vertical-align: top; border-bottom: #000000 2px solid;">
              <div>/s/ Steven A. Elms</div>
            </td>

    <td style="width: 2%; vertical-align: top;">&#160;</td>

    <td style="width: 31%; vertical-align: top;">&#160;</td>

    <td style="width: 2%; vertical-align: top;">&#160;</td>

    <td style="width: 31%; vertical-align: top;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 34%; vertical-align: top;">
              <div>Steven A. Elms</div>
            </td>

    <td style="width: 2%; vertical-align: top;">&#160;</td>

    <td style="width: 31%; vertical-align: top;">
              <div>Chairman of the Board of Directors</div>
            </td>

    <td style="width: 2%; vertical-align: top;">&#160;</td>

    <td style="width: 31%; vertical-align: top;">
              <div style="text-align: center;">March 18, 2025</div>
            </td>

  </tr>

  <tr>

    <td style="width: 34%; vertical-align: top;">&#160;</td>

    <td style="width: 2%; vertical-align: top;">&#160;</td>

    <td style="width: 31%; vertical-align: top;">&#160;</td>

    <td style="width: 2%; vertical-align: top;">&#160;</td>

    <td style="width: 31%; vertical-align: top;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 34%; vertical-align: top; border-bottom: #000000 2px solid;">
              <div>/s/ Dr. Jerrold B. Grossman</div>
            </td>

    <td style="width: 2%; vertical-align: top;">&#160;</td>

    <td style="width: 31%; vertical-align: top;">&#160;</td>

    <td style="width: 2%; vertical-align: top;">&#160;</td>

    <td style="width: 31%; vertical-align: top;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 34%; vertical-align: top;">
              <div>Dr. Jerrold B. Grossman</div>
            </td>

    <td style="width: 2%; vertical-align: top;">&#160;</td>

    <td style="width: 31%; vertical-align: top;">
              <div>Vice Chairman of the Board of Directors</div>
            </td>

    <td style="width: 2%; vertical-align: top;">&#160;</td>

    <td style="width: 31%; vertical-align: top;">
              <div style="text-align: center;">March 18, 2025</div>
            </td>

  </tr>

  <tr>

    <td style="width: 34%; vertical-align: top;">&#160;</td>

    <td style="width: 2%; vertical-align: top;">&#160;</td>

    <td style="width: 31%; vertical-align: top;">&#160;</td>

    <td style="width: 2%; vertical-align: top;">&#160;</td>

    <td style="width: 31%; vertical-align: top;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 34%; vertical-align: top; border-bottom: #000000 2px solid;">
              <div>/s/ Alison Finger</div>
            </td>

    <td style="width: 2%; vertical-align: top;">&#160;</td>

    <td style="width: 31%; vertical-align: top;">&#160;</td>

    <td style="width: 2%; vertical-align: top;">&#160;</td>

    <td style="width: 31%; vertical-align: top;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 34%; vertical-align: top;">
              <div>Alison Finger</div>
            </td>

    <td style="width: 2%; vertical-align: top;">&#160;</td>

    <td style="width: 31%; vertical-align: top;">
              <div>Director</div>
            </td>

    <td style="width: 2%; vertical-align: top;">&#160;</td>

    <td style="width: 31%; vertical-align: top;">
              <div style="text-align: center;">March 18, 2025</div>
            </td>

  </tr>

  <tr>

    <td style="width: 34%; vertical-align: top;">&#160;</td>

    <td style="width: 2%; vertical-align: top;">&#160;</td>

    <td style="width: 31%; vertical-align: top;">&#160;</td>

    <td style="width: 2%; vertical-align: top;">&#160;</td>

    <td style="width: 31%; vertical-align: top;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 34%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
              <div>/s/ Lawrence P. Guiheen</div>
            </td>

    <td style="width: 2%; vertical-align: top; padding-bottom: 2px;">&#160;</td>

    <td style="width: 31%; vertical-align: top; padding-bottom: 2px;">&#160;</td>

    <td style="width: 2%; vertical-align: top; padding-bottom: 2px;">&#160;</td>

    <td style="width: 31%; vertical-align: top; padding-bottom: 2px;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 34%; vertical-align: top;">
              <div>Lawrence P. Guiheen</div>
            </td>

    <td style="width: 2%; vertical-align: top;">&#160;</td>

    <td style="width: 31%; vertical-align: top;">
              <div>Director</div>
            </td>

    <td style="width: 2%; vertical-align: top;">&#160;</td>

    <td style="width: 31%; vertical-align: top;">
              <div style="text-align: center;">March 18, 2025</div>
            </td>

  </tr>

  <tr>

    <td style="width: 34%; vertical-align: top;">&#160;</td>

    <td style="width: 2%; vertical-align: top;">&#160;</td>

    <td style="width: 31%; vertical-align: top;">&#160;</td>

    <td style="width: 2%; vertical-align: top;">&#160;</td>

    <td style="width: 31%; vertical-align: top;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 34%; vertical-align: top; border-bottom: #000000 2px solid;">
              <div>/s/ Young T. Kwon</div>
            </td>

    <td style="width: 2%; vertical-align: top;">&#160;</td>

    <td style="width: 31%; vertical-align: top;">&#160;</td>

    <td style="width: 2%; vertical-align: top;">&#160;</td>

    <td style="width: 31%; vertical-align: top;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 34%; vertical-align: top;">
              <div>Young T. Kwon</div>
            </td>

    <td style="width: 2%; vertical-align: top;">&#160;</td>

    <td style="width: 31%; vertical-align: top;">
              <div>Director</div>
            </td>

    <td style="width: 2%; vertical-align: top;">&#160;</td>

    <td style="width: 31%; vertical-align: top;">
              <div style="text-align: center;">March 18, 2025</div>
            </td>

  </tr>

  <tr>

    <td style="width: 34%; vertical-align: top;">&#160;</td>

    <td style="width: 2%; vertical-align: top;">&#160;</td>

    <td style="width: 31%; vertical-align: top;">&#160;</td>

    <td style="width: 2%; vertical-align: top;">&#160;</td>

    <td style="width: 31%; vertical-align: top;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 34%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
              <div>/s/ Eduardo Rene Salas</div>
            </td>

    <td style="width: 2%; vertical-align: top; padding-bottom: 2px;">&#160;</td>

    <td style="width: 31%; vertical-align: top; padding-bottom: 2px;">&#160;</td>

    <td style="width: 2%; vertical-align: top; padding-bottom: 2px;">&#160;</td>

    <td style="width: 31%; vertical-align: top; padding-bottom: 2px;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 34%; vertical-align: top;">
              <div>Eduardo Rene Salas</div>
            </td>

    <td style="width: 2%; vertical-align: top;">&#160;</td>

    <td style="width: 31%; vertical-align: top;">
              <div>Director</div>
            </td>

    <td style="width: 2%; vertical-align: top;">&#160;</td>

    <td style="width: 31%; vertical-align: top;">
              <div style="text-align: center;">March 18, 2025</div>
            </td>

  </tr>


</table>
      <div><br/>
      </div>

    </div>

    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageNumberArea" style="text-align: center;"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">91</span></div>

      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"/></div>

      <div class="BRPFPageHeader" style="width: 100%;">
        <div>
          <div style="text-align: left; font-weight: bold; text-indent: -9pt; margin-left: 9pt;"><a href="#ADMABIOLOGICSINC."> <span style="font-style: italic; font-weight: normal; font-size: 8pt;">Table of Contents</span></a><br/>
          </div>

        </div>

      </div>

    </div>

    <!--PROfilePageNumberReset%Num%1%F-%%--> </div>


  <div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: rgb(0, 0, 0);">
    <div>
      <div style="text-align: left; font: 10pt 'Times New Roman';">
        <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: center;"><strong>ADMA BIOLOGICS, INC. AND SUBSIDIARIES</strong></p>
        <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: center;">&#160;</p>
        <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: center;"><strong>CONSOLIDATED FINANCIAL STATEMENTS</strong></p>
        <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;">&#160;</p>
        <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: center;"><strong><span style="display: inline" class="atag"><!--Anchor-->TABLE OF CONTENTS</span></strong></p>
        <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;"><br/>
        </p>
        <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: rgb(0, 0, 0); border-spacing: 0;">


  <tr>

    <td style="width: 92%; vertical-align: top;">
                <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">&#160;</div>
              </td>

    <td style="width: 8%; vertical-align: top; border-bottom: #000000 2px solid;">
                <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;">Page</div>
              </td>

  </tr>

  <tr>

    <td style="width: 92%; vertical-align: top; background-color: #CCEEFF;">
                <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"><a href="#ManagementsAnnualReporton">Management&#8217;s Annual Report on Internal Control Over Financial Reporting</a></div>
              </td>

    <td style="width: 8%; vertical-align: top; background-color: #CCEEFF;">
                <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;">F-2</div>
              </td>

  </tr>

  <tr>

    <td style="width: 92%; vertical-align: top;" rowspan="1">
                <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"><a href="#RegisteredPublicAccountin">Reports of Independent Registered Public Accounting Firm (PCAOB ID <span style="-sec-ix-hidden:Fact_89c3f38fba7e479a9bb9abf5fd1f116f">185</span>)</a></div>
              </td>

    <td style="width: 8%; vertical-align: top; text-align: center;" rowspan="1">F-3</td>

  </tr>

  <tr>

    <td style="width: 92%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"><a href="#ReportofIndependent">Report of Independent Registered Public Accounting Firm (PCAOB ID <span style="-sec-ix-hidden:Fact_8de9ba90e6904aadaccdf07a6e27430f">596</span>)</a></div>
              </td>

    <td style="width: 8%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;">F-7</div>
              </td>

  </tr>

  <tr>

    <td style="width: 92%; vertical-align: top;">
                <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"><a href="#CONSOLIDATEDBALANCESHEETS">Consolidated Balance Sheets as of December 31, 2024 and 2023</a></div>
              </td>

    <td style="width: 8%; vertical-align: top;">
                <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;">F-8</div>
              </td>

  </tr>

  <tr>

    <td style="width: 92%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"><a href="#STATEMENTSOFOPERATIONS">Consolidated Statements of Operations for the years ended December 31, 2024, 2023 and 2022</a></div>
              </td>

    <td style="width: 8%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;">F-9</div>
              </td>

  </tr>

  <tr>

    <td style="width: 92%; vertical-align: top;">
                <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"><a href="#STOCKHOLDERSEQUITY">Consolidated Statements of Changes in Stockholders&#8217; Equity for the years ended December 31, 2024, 2023 and 2022</a></div>
              </td>

    <td style="width: 8%; vertical-align: bottom;">
                <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;">F-10</div>
              </td>

  </tr>

  <tr>

    <td style="width: 92%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"><a href="#CASHFLOWS">Consolidated Statements of Cash Flows for the years ended December 31, 2024, 2023 and 2022</a></div>
              </td>

    <td style="width: 8%; vertical-align: top; background-color: rgb(204, 238, 255);">
                <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;">F-11</div>
              </td>

  </tr>

  <tr>

    <td style="width: 92%; vertical-align: top;">
                <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"><a href="#NOTES">Notes to Consolidated Financial Statements</a></div>
              </td>

    <td style="width: 8%; vertical-align: top;">
                <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;">F-12</div>
              </td>

  </tr>


</table>
        <div> <br/>
        </div>

        <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;"> </p>
        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div class="BRPFPageNumberArea" style="text-align: center;"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">F-1</span></div>

          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"/></div>

          <div class="BRPFPageHeader" style="width: 100%;">
            <div>
              <div style="text-align: left; font-weight: bold; text-indent: -9pt; margin-left: 9pt;"><a href="#ADMABIOLOGICSINC."> <span style="font-style: italic; font-weight: normal; font-size: 8pt;">Table of Contents</span></a><br/>
              </div>

            </div>

          </div>

        </div>

      </div>

    </div>

  </div>


  <div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;"> <div><span style="font-size: 10pt;"> </span></div>

    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; text-indent: 0px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-align: center; font-weight: bold;"><a id="ManagementsAnnualReporton"><!--Anchor--></a><span style="text-decoration: underline;">Management&#8217;s Annual Report on
        Internal Control Over Financial Reporting</span></div>

    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial;"><br/>
    </div>

    <div style="background-color: #FFFFFF; letter-spacing: normal; white-space: normal; word-spacing: 0px; color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-weight: normal; text-align: justify; text-indent: 36pt; text-transform: none;">The Management of ADMA Biologics, Inc. (the &#8220;Company&#8221;) is responsible for establishing and maintaining adequate internal control over financial reporting for the Company. Internal control over financial reporting is defined in
      Rule 13a-15(f) or 15d-15(f) promulgated under the Securities Exchange Act of 1934, as amended, as a process designed by, or under the supervision of, the Company&#8217;s principal executive and principal financial officers and effected by the Company&#8217;s
      Board of Directors, management and other personnel, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with accounting principles generally
      accepted in the United States of America (&#8220;U.S. GAAP&#8221;) and includes those policies and procedures that: (i) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the
      assets of the Company; (ii) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with U.S. GAAP, and that receipts and expenditures of our Company are being made only in
      accordance with authorizations of management and Directors of the Company; and (iii) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of our Company&#8217;s assets that could have a
      material effect on the financial statements.</div>

    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial;"><br/>
    </div>

    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: justify; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-indent: 36pt;">Internal control over financial reporting is designed to provide reasonable assurance
      regarding the reliability of financial reporting and the preparation of financial statements prepared for external purposes in accordance with U.S. GAAP. Because of its inherent limitations, internal control over financial reporting may not prevent
      or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or
      procedures may deteriorate.</div>

    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial;"><br/>
    </div>

    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: justify; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-indent: 36pt;">Management, with the participation of the Company&#8217;s Chief Executive Officer and Chief
      Financial Officer, assessed the effectiveness of its internal control over financial reporting as of December 31, 2024. In making this assessment, management used the criteria set forth in the Internal Control-Integrated Framework (2013) issued by
      the Committee of Sponsoring Organizations of the Treadway Commission. Based on its assessment, management concluded that the Company&#8217;s internal control over financial reporting was effective as of December 31, 2024 based on those criteria.</div>

    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial;"><br/>
    </div>

    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: justify; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-indent: 36pt;">Our independent registered public accounting firm, which has audited the consolidated
      financial statements included in this Annual Report on Form 10-K, has also issued an audit report on the effectiveness of our internal control over financial reporting as of December 31, 2024. Their report appears on page F-3 of this Annual Report on
      Form 10-K.</div>

    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial;"><br/>
    </div>

    <table cellspacing="0" cellpadding="0" border="0" style="background-color: #FFFFFF; border-collapse: collapse; letter-spacing: normal; width: 100%; word-spacing: 0px; color: #000000; font-family: 'Times New Roman'; font-size: 10pt; text-align: left; text-transform: none; border-spacing: 0;">


  <tr>

    <td style="width: 60%; vertical-align: top; font-size: 10pt;">
            <div><span style="text-decoration: underline;">/s/ Adam S. Grossman</span></div>
          </td>

    <td style="width: 40%; vertical-align: top; font-size: 10pt;">
            <div><span style="text-decoration: underline;">/s/ Brad Tade</span></div>
          </td>

  </tr>

  <tr>

    <td style="width: 60%; vertical-align: top; font-size: 10pt;">
            <div>Adam S. Grossman</div>
          </td>

    <td style="width: 40%; vertical-align: top; font-size: 10pt;">
            <div>Brad Tade</div>
          </td>

  </tr>

  <tr>

    <td style="width: 60%; vertical-align: top; font-size: 10pt;">
            <div>President and Chief Executive Officer</div>
          </td>

    <td style="width: 40%; vertical-align: top; font-size: 10pt;">
            <div>Chief Financial Officer</div>
          </td>

  </tr>

  <tr>

    <td style="width: 60%; vertical-align: top; font-size: 10pt;">&#160;</td>

    <td style="width: 40%; vertical-align: top; font-size: 10pt;">&#160;</td>

  </tr>

  <tr>

    <td style="width: 60%; vertical-align: top; font-size: 10pt;">
            <div>March 18, 2025</div>
          </td>

    <td style="width: 40%; vertical-align: top; font-size: 10pt;">
            <div>March 18, 2025</div>
          </td>

  </tr>


</table>
    <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial;">&#160;</div>

    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">F-2</span></div>

      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"/></div>

      <div style="width: 100%;" class="BRPFPageHeader">
        <div>
          <div style="text-align: left; font-weight: bold; text-indent: -9pt; margin-left: 9pt;"><a href="#ADMABIOLOGICSINC."> <span style="font-style: italic; font-weight: normal; font-size: 8pt;">Table of Contents</span></a><br/>
          </div>

        </div>

      </div>

    </div>

    <div><span style="font-size: 10pt;"> </span></div>
 </div>


  <div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: rgb(0, 0, 0);"> <div><span style="font-family: 'Times New Roman'; font-size: 10pt;"> <span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-variant: normal; text-transform: none;"> </span> </span></div>
<!--PROfilePageNumberReset%Num%4%F-%%-->
    <div>
      <div style="text-align: left; font: 10pt 'Times New Roman';">
        <!--Anchor-->
        <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;"><!--Anchor--><!--Anchor-->
          <div style="margin: 0px; font-family: 'Times New Roman'; font-size: 10pt; text-align: left;"> <div><span style="font-size: 10pt; font-family: 'Times New Roman'; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-variant: normal; text-transform: none;"><!--Anchor--><br/></span></div>

            <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-align: left; font-weight: bold;"> <span style="font-family: 'Times New Roman'; font-size: 10pt;"><img src="image00001.jpg" alt="graphic"/></span></div>

            <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; text-indent: 0px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-align: center; font-weight: bold;">Report of
              <!--Anchor-->Independent Registered Public Accounting Firm<a id="RegisteredPublicAccountin"><!--Anchor--></a></div>

            <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial;"><span style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
              </span> </div>

            <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial;">To the Stockholders and Board of Directors</div>

            <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial;">ADMA Biologics, Inc.:</div>

            <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial;"><span style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
              </span> </div>

            <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; text-align: left; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-indent: -72pt; margin-left: 72pt; font-style: normal; font-weight: bold;">Opinion on Internal Control Over Financial Reporting</div>

            <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial;"><span style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
              </span> </div>

            <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial;">We have audited ADMA Biologics, Inc. and subsidiaries&#8217; (the Company) internal
              control over financial reporting as of December 31, 2024, based on&#160;<a id="z_0"></a>criteria established in&#160;Internal Control &#8211; Integrated Framework (2013)&#160;issued by the Committee of Sponsoring Organizations of the Treadway Commission. In our
              opinion, the Company maintained, in all material respects, effective internal control over financial reporting as of December 31, 2024, based on criteria established in&#160;Internal Control &#8211; Integrated Framework (2013)&#160;issued by the Committee of
              Sponsoring Organizations of the Treadway Commission.</div>

            <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial;"><span style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
              </span> </div>

            <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial;">We also have audited, in accordance with the standards of the Public Company
              Accounting Oversight Board (United States) (PCAOB), the consolidated&#160;<a id="z_2"></a>balance sheet of the Company as of December 31, 2024, the related consolidated statements of operations, changes in stockholders&#8217; equity, and cash flows
              for&#160;<a id="z_3"></a>the year ended December 31, 2024, and the related notes and financial statement schedule II - valuation and qualifying accounts(collectively, the consolidated financial statements), and our report dated&#160;<a id="z_4"></a>March











              18, 2025&#160;<a id="z_5"></a>expressed an unqualified opinion on those consolidated financial statements.</div>

            <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial;"><span style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
              </span> </div>

            <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; text-align: left; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-indent: -72pt; margin-left: 72pt; font-style: normal; font-weight: bold;">Basis for Opinion</div>

            <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial;"><span style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
              </span> </div>

            <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial;">The Company&#8217;s management is responsible for maintaining effective internal
              control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting, included in the accompanying&#160;<a id="z_6"></a>Management&#8217;s Annual Report on Internal Control Over Financial Reporting.
              Our responsibility is to express an opinion on the Company&#8217;s internal control over financial reporting based on our audit. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the
              Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</div>

            <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial;"><span style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
              </span> </div>

            <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial;">We conducted our audit in accordance with the standards of the PCAOB. Those
              standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects. Our audit of internal control over financial
              reporting included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the
              assessed risk. Our audit also included performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.</div>

            <div><br/></div>

            <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
              <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">F-3</span></div>

              <div class="BRPFPageBreak" style="page-break-after: always;">
                <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"/></div>

              <div style="width: 100%;" class="BRPFPageHeader">
                <div>
                  <div style="text-align: left; font-weight: bold; text-indent: -9pt; margin-left: 9pt;"><a href="#ADMABIOLOGICSINC."> <span style="font-style: italic; font-weight: normal; font-size: 8pt;">Table of Contents</span></a><br/>
                  </div>

                </div>

              </div>

            </div>

            <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial;">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; text-align: left; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-indent: -72pt; margin-left: 72pt; font-style: normal; font-weight: bold;">Definition and Limitations of Internal Control Over
                Financial Reporting</div>

              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial;"><span style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
                </span> </div>

              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial;">A company&#8217;s internal control over financial reporting is a process designed
                to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company&#8217;s internal control
                over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2)
                provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being
                made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company&#8217;s assets
                that could have a material effect on the financial statements.</div>

              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial;"> <br/>
              </div>

            </div>

            <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial;">Because of its inherent limitations, internal control over financial
              reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of
              compliance with the policies or procedures may deteriorate.</div>

            <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial;"><span style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
              </span> </div>

            <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-indent: 0px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-align: center;">/s/ KPMG LLP</div>

            <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; text-align: center;"><span style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
              </span> </div>

            <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial;">Stamford, Connecticut</div>

            <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial;">March 18, 2025</div>

            <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial;">&#160;</div>

            <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
              <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">F-4</span></div>

              <div class="BRPFPageBreak" style="page-break-after: always;">
                <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"/></div>

              <div style="width: 100%;" class="BRPFPageHeader">
                <div>
                  <div style="text-align: left; font-weight: bold; text-indent: -9pt; margin-left: 9pt;"><a href="#ADMABIOLOGICSINC."> <span style="font-style: italic; font-weight: normal; font-size: 8pt;">Table of Contents</span></a><br/>
                  </div>

                </div>

              </div>

            </div>

            <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial;"><img src="image00001.jpg" alt="graphic"/></div>

            <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial;"><span style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
              </span> </div>

            <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; text-indent: 0px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-align: center; font-weight: bold;">Report of Independent
              <!--Anchor-->Registered Public Accounting Firm</div>

            <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial;">&#160;</div>

            <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial;">To the Stockholders and Board of Directors</div>

            <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial;">ADMA Biologics, Inc.:</div>

            <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial;"><span style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
              </span> </div>

            <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; orphans: 2; text-align: left; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; text-indent: -72pt; margin-left: 72pt; font-weight: bold;"><span style="font-style: normal; font-family: 'Times New Roman'; font-size: 10pt;">Opinion on the&#160;Consolidated Financial Statements</span></div>

            <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial;"><span style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
              </span> </div>

            <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial;">We have audited the accompanying consolidated balance sheet of ADMA
              Biologics, Inc. and subsidiaries (the Company) as of December 31, 2024, the related consolidated statements of operations, changes in stockholders&#8217; equity, and cash flows for&#160;<a id="z_1"></a>the period ended December 31, 2024, and the
              related notes and financial statement schedule II - valuation and qualified accounts (collectively, the consolidated financial statements). In our opinion, the consolidated financial statements present fairly, in all material respects, the
              financial position of the Company as of December 31, 2024, and the results of its operations and its cash flows for the period ended December 31, 2024, in conformity with U.S. generally accepted accounting principles.</div>

            <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial;"><span style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
              </span> </div>

            <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial;">We also have audited, in accordance with the standards of the Public Company
              Accounting Oversight Board (United States) (PCAOB), the Company&#8217;s internal control over financial reporting as of December 31, 2024, based on criteria established in&#160;Internal Control &#8211; Integrated Framework (2013)&#160;issued by the Committee of
              Sponsoring Organizations of the Treadway Commission, and our report dated March 18, 2025 expressed an unqualified opinion on the effectiveness of the Company&#8217;s internal control over financial reporting.</div>

            <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial;"><span style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
              </span> </div>

            <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; text-align: left; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-indent: -72pt; margin-left: 72pt; font-style: normal; font-weight: bold;">Basis for Opinion</div>

            <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial;"><span style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
              </span> </div>

            <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial;">These consolidated financial statements are the responsibility of the
              Company&#8217;s management. Our responsibility is to express an opinion on these consolidated financial statements based on our audit. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the
              Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</div>

            <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial;"><span style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
              </span> </div>

            <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial;">We conducted our audit in accordance with the standards of the PCAOB. Those
              standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud. Our audit included performing procedures
              to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence
              regarding the amounts and disclosures in the consolidated financial statements. Our audit also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of
              the consolidated financial statements. We believe that our audit provides a reasonable basis for our opinion.</div>

            <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial;"><span style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
              </span> </div>

            <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
              <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">F-5</span></div>

              <div class="BRPFPageBreak" style="page-break-after: always;">
                <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"/></div>

              <div style="width: 100%;" class="BRPFPageHeader">
                <div>
                  <div style="text-align: left; font-weight: bold; text-indent: -9pt; margin-left: 9pt;"><a href="#ADMABIOLOGICSINC."> <span style="font-style: italic; font-weight: normal; font-size: 8pt;">Table of Contents</span></a><br/>
                  </div>

                </div>

              </div>

            </div>

            <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial;">
              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; text-align: left; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-indent: -72pt; margin-left: 72pt; font-style: normal; font-weight: bold;">Critical Audit Matter</div>

              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial;"><span style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
                </span> </div>

              <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial;">The critical audit matter communicated below is a matter arising from the
                current period audit of the consolidated financial statements that was communicated or required to be communicated to the audit committee and that: (1) relates to accounts or disclosures that are material to the consolidated financial
                statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of a critical audit matter does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we
                are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the accounts or disclosures to which it relates.</div>

              <div><br/></div>

            </div>

            <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial;">Valuation of the U.S. Medicaid rebate accrual for immunoglobulin products</div>

            <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial;"><span style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
              </span> </div>

            <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial;">As disclosed in Note 2 to the consolidated financial statements, the Company
              recognizes immunoglobulin product revenue net of estimated rebates. The amount of these rebate are based on contractual agreements and historical experience. These estimated rebates include U.S. Medicaid rebates, which, the Company accrues
              for in the same period the product is sold, however, third-party reporting and payments of the rebate amount occur on a time lag. As of December 31, 2024, the Company had recorded $4.2 million of accrued rebates included in accrued expenses
              and other liabilities on the balance sheet, of which a portion related to Medicaid rebates.</div>

            <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial;"><span style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
              </span> </div>

            <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial;">We identified the estimate of rebate accruals for U.S. Medicaid claims as a
              critical audit matter. The evaluation of historical claims experience, current sales volumes and the claims processing time lag associated with U.S. Medicaid reporting rebate amounts involved subjective auditor judgement. The key assumptions
              made included the historical percentage of U.S. Medicaid rebates paid to gross sales and assumption that the historical patterns will be indicative of future patterns.</div>

            <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial;"><span style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
              </span> </div>

            <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial;">The following are the primary procedures we performed to address this
              critical audit matter. We evaluated the design and tested the operating effectiveness of certain internal controls related to the Company&#8217;s process to estimate the U.S. Medicaid rebate accrual, including historical claims experience, current
              sales volumes and the claims time lag. We evaluated the U.S. Medicaid rebate accrual by (1) obtaining an understanding of the estimation methodology, (2) recalculating management&#8217;s estimate of the accrual by utilizing current gross sales and
              the historical revenue and rebates paid data and(3) testing the appropriateness of the assumptions of using a certain number of months of historical data and that historical results are indicative of future expectations by reviewing the
              Company&#8217;s historical trends.</div>

            <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial;"><span style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
              </span> </div>

            <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-indent: 0px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-align: center;">/s/ <ix:nonNumeric name="dei:AuditorName" id="Fact_d5266f29c405489bbc9397454341ea01" contextRef="c20240101to20241231">KPMG LLP</ix:nonNumeric></div>

            <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; text-align: center;"><span style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
              </span> </div>

            <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial;">We have served as the Company&#8217;s auditor since 2024.</div>

            <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial;"><span style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
              </span> </div>

            <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial;"><ix:nonNumeric name="dei:AuditorLocation" id="Fact_d8617e76d72e452191cac73d2844ecd8" contextRef="c20240101to20241231">Stamford, Connecticut</ix:nonNumeric><br/>
            </div>

            <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial;">March 18, 2025</div>

            <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-indent: 0px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-align: center;">&#160;</div>

            <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
              <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">F-6</span></div>

              <div class="BRPFPageBreak" style="page-break-after: always;">
                <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"/></div>

              <div style="width: 100%;" class="BRPFPageHeader">
                <div>
                  <div style="text-align: left; font-weight: bold; text-indent: -9pt; margin-left: 9pt;"><a href="#ADMABIOLOGICSINC."> <span style="font-style: italic; font-weight: normal; font-size: 8pt;">Table of Contents</span></a><br/>
                  </div>

                </div>

              </div>

            </div>

            <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; text-indent: 0px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-align: center; font-style: italic; font-weight: bold;"><a id="ReportofIndependent"><!--Anchor--></a>Report of Independent Registered
              Public Accounting Firm</div>

            <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial;"><span style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
              </span> </div>

            <div><br/></div>

            <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">Board of Directors and Stockholders</div>

            <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">ADMA Biologics, Inc.</div>

            <div><br/>
            </div>

            <div style="text-align: justify; color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic;">Opinion on the Consolidated Financial Statements</div>

            <div><br/>
            </div>

            <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">We have audited the accompanying consolidated balance sheet of ADMA Biologics, Inc. and subsidiaries (the &#8220;Company&#8221;) as of December 31, 2023, and the related
              consolidated statements of operations, changes in stockholders&#8217; equity, and cash flows for each of the years in the two-year period ended December 31, 2023 and the related notes <a id="z_Hlk159406757"></a>and financial statement schedule
              II &#8211; valuation and qualifying accounts (collectively referred to as the &#8220;consolidated financial statements&#8221;).</div>

            <div><br/>
            </div>

            <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the financial position of the Company as of
              December 31, 2023, and the results of its operations and its cash flows for each of the years in the two-year period ended December 31, 2023, in conformity with accounting principles generally accepted in the United States of America.</div>

            <div><br/>
            </div>

            <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic;">Basis for Opinion</div>

            <div><br/>
            </div>

            <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">These consolidated financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s
              consolidated financial statements. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (&#8220;PCAOB&#8221;) and are required to be independent with respect to the Company in accordance with the
              U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</div>

            <div><br/>
            </div>

            <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance
              about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud.</div>

            <div><br/>
            </div>

            <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">Our audit of the consolidated financial statements included performing procedures to assess the risks of material misstatement of the consolidated financial
              statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements.
              Our audit also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements.</div>

            <div style="margin: 0px; font-family: 'Times New Roman'; font-size: 10pt; text-align: justify;"> <span style="font-size: 10pt; font-family: 'Times New Roman'; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-variant: normal; text-transform: none;"><br/>
              </span> </div>

            <div style="margin: 0px; font-family: 'Times New Roman'; font-size: 10pt; text-align: justify;">
<div><span style="font-size: 10pt; font-family: 'Times New Roman'; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-variant: normal; text-transform: none;">/s/ <ix:nonNumeric name="dei:AuditorName" id="Fact_dd1485d3a71c4bebb5607ae7503fd7ae" contextRef="c20240101to20241231_CounterpartyNameAxis_CohnReznickLLPMember">CohnReznick LLP</ix:nonNumeric></span></div>

              <div><span style="font-size: 10pt; font-family: 'Times New Roman'; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-variant: normal; text-transform: none;"><br/>
                </span> </div>

              <div>
                <div style="text-align: justify;">
<div>We served as the Company&#8217;s auditor from 2008 through November 7, 2024. <span style="font-size: 10pt; font-family: 'Times New Roman'; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-variant: normal; text-transform: none;"> </span></div>

                  <div><br/>
                  </div>

                  <div style="text-align: justify;">
<div><ix:nonNumeric name="dei:AuditorLocation" id="Fact_70fb6afd89164593a8eadb274a02335e" contextRef="c20240101to20241231_CounterpartyNameAxis_CohnReznickLLPMember">Parsippany, New Jersey</ix:nonNumeric></div>

                    <div><span style="font-size: 10pt; font-family: 'Times New Roman'; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-variant: normal; text-transform: none;"><br/>
                      </span> </div>

                    <div>
                      <div style="text-align: justify; font-size: 10pt; font-family: 'Times New Roman'; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-variant: normal; text-transform: none;">February 28, 2024, except
                        for Note 11 and Note 13 as to which the date is March 18, 2025</div>

                    </div>

                  </div>

                </div>

              </div>

            </div>

          </div>

        </div>

        <div>
<div><span style="font-size: 10pt; font-family: 'Times New Roman'; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-variant: normal; text-transform: none;"><br/>
          </span></div>

          <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
            <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">F-7</span></div>

            <div class="BRPFPageBreak" style="page-break-after: always;">
              <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"/></div>

            <div style="width: 100%;" class="BRPFPageHeader">
              <div>
                <div style="text-align: left; font-weight: bold; text-indent: -9pt; margin-left: 9pt;"><a href="#ADMABIOLOGICSINC."> <span style="font-style: italic; font-weight: normal; font-size: 8pt;">Table of Contents</span></a><br/>
                </div>

              </div>

            </div>

          </div>

        </div>

      </div>

      <div><span style="font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-variant: normal; text-transform: none;"> </span></div>
 </div>

    <div><span style="font-family: 'Times New Roman'; font-size: 10pt;"> <span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-variant: normal; text-transform: none;"> </span> </span></div>
 </div>


  <div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: rgb(0, 0, 0);">
    <div>
      <div style="text-align: left; font: 10pt 'Times New Roman';">
        <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: center;"><strong><span style="display: inline" class="atag">ADMA BIOLOGICS, INC. AND SUBSIDIARIES</span></strong></p>
        <a id="CONSOLIDATEDBALANCESHEETS"><!--Anchor--></a><a id="BALANCESHEETS"><!--Anchor--></a><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: center;"><strong>CONSOLIDATED
            <!--Anchor-->
            <!--Anchor-->BALANCE SHEETS</strong></p>
        <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: center;"><strong>Years Ended December 31, 2024 and 2023</strong></p>
        <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;">&#160;</p>
        <table cellspacing="0" cellpadding="0" border="0" class="cfttable" style="text-align: left; font: 10pt 'Times New Roman'; width: 100%; border-spacing: 0;">


  <tr style="height: 15px;">

    <td valign="bottom" rowspan="1">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: center; vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" rowspan="1" style="vertical-align: bottom; text-align: center; white-space: nowrap;">
                <p style="margin: 0px 0px 0px 0in; text-align: center;"><strong>December 31,</strong></p>
              </td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: center; vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" rowspan="1" style="vertical-align: bottom; text-align: center; white-space: nowrap;">
                <p style="margin: 0px 0px 0px 0in; text-align: center;"><strong>December 31,</strong></p>
              </td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="padding-bottom: 2px;"><br/>
              </td>

    <td valign="bottom" colspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: #000000 solid 2px;"><strong>2024</strong></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: #000000 solid 2px; white-space: nowrap;"><strong>2023</strong></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" rowspan="1" style="vertical-align: top;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td valign="bottom" style="text-align: center; white-space: nowrap;" colspan="6" rowspan="1"> <span style="font-style: italic;"> (In thousands, except share data)</span><br/>
              </td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="vertical-align: top;">
                <p style="margin: 0px 0px 0px 0in;"><strong>ASSETS</strong></p>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom;">&#160;</td>

    <td valign="bottom" colspan="2"><br/>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom;">&#160;</td>

    <td valign="bottom" colspan="2">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="vertical-align: top;">
                <p style="margin: 0px;">Current assets:</p>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom;">&#160;</td>

    <td valign="bottom" colspan="2">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom;">&#160;</td>

    <td valign="bottom" colspan="2">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="vertical-align: top; width: 76%; background-color: #CCEEFF;">
                <p style="margin: 0px 0px 0px 15px;">Cash and cash equivalents</p>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">$</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" id="Fact_0dd990aea60f4236a8737a5fde657bc1" contextRef="c20241231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">103,147</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">$</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" id="Fact_068a3019356e497a8e44066729a663b5" contextRef="c20231231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">51,352</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="vertical-align: top; width: 76%;">
                <p style="margin: 0px 0px 0px 15px;">Accounts receivable, net</p>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;"><ix:nonFraction name="us-gaap:AccountsReceivableNetCurrent" id="Fact_ed3bbc4e659848908fac8137ddf4e073" contextRef="c20241231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">49,999</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;"><ix:nonFraction name="us-gaap:AccountsReceivableNetCurrent" id="Fact_e14390b1f9a147e9a59f82163f669e41" contextRef="c20231231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">27,421</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="vertical-align: top; width: 76%; background-color: #CCEEFF;">
                <p style="margin: 0px 0px 0px 15px;">Inventories</p>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><ix:nonFraction name="us-gaap:InventoryNet" id="Fact_d4018025e54944918461856069cda7f4" contextRef="c20241231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">170,235</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><ix:nonFraction name="us-gaap:InventoryNet" id="Fact_54e39784c23f40f0ac31321a8f8221f1" contextRef="c20231231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">172,906</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="vertical-align: top; width: 76%; padding-bottom: 2px;">
                <p style="margin: 0px 0px 0px 15px;">Prepaid expenses and other current assets</p>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" id="Fact_1f822fe2eea4497d985026e22d2b6b04" contextRef="c20241231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">8,029</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" id="Fact_fcbcd37d63004138a4339866a7da1965" contextRef="c20231231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">5,334</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="vertical-align: top; width: 76%; background-color: #CCEEFF;">
                <p style="margin: 0px 0px 0px 30px;">Total current assets</p>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><ix:nonFraction name="us-gaap:AssetsCurrent" id="Fact_a1833916b8754fb88f08e82ba4952f88" contextRef="c20241231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">331,410</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><ix:nonFraction name="us-gaap:AssetsCurrent" id="Fact_98688a7ecdbc4d4683fd5124e37b1074" contextRef="c20231231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">257,013</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="vertical-align: top; width: 76%;">
                <p style="margin: 0px;">Property and equipment, net</p>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" id="Fact_bcffa5a7b2e44feb964946ff4a5529d4" contextRef="c20241231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">54,707</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" id="Fact_5ba34ddabe454913917ca75232b3c7fa" contextRef="c20231231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">53,835</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="vertical-align: top; width: 76%; background-color: #CCEEFF;">
                <p style="margin: 0px;">Intangible assets, net</p>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><ix:nonFraction name="us-gaap:IntangibleAssetsNetExcludingGoodwill" id="Fact_4d15e111e7154fa19f80999f64f5f69e" contextRef="c20241231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">460</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><ix:nonFraction name="us-gaap:IntangibleAssetsNetExcludingGoodwill" id="Fact_1de4b6195ac841aeb817cdab57df468d" contextRef="c20231231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">499</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="vertical-align: top; width: 76%;">
                <p style="margin: 0px;">Goodwill</p>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;"><ix:nonFraction name="us-gaap:Goodwill" id="Fact_d8e2154aea9f444785261aa1bf34c8b8" contextRef="c20241231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,530</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;"><ix:nonFraction name="us-gaap:Goodwill" id="Fact_dc37b03726934a94b159a4bd3e3fa106" contextRef="c20231231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,530</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" rowspan="1" style="vertical-align: top; width: 76%; background-color: #CCEEFF;">Deferred tax assets, net<br/>
              </td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><ix:nonFraction name="us-gaap:DeferredIncomeTaxAssetsNet" id="Fact_18b8139a094748229a149678c55b7152" contextRef="c20241231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">84,280</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><ix:nonFraction name="us-gaap:DeferredIncomeTaxAssetsNet" id="Fact_cd79bfc17d00436486ffb6a6b63ec138" contextRef="c20231231" unitRef="U001" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="vertical-align: top; width: 76%;">
                <p style="margin: 0px;">Right-of-use assets</p>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" id="Fact_5f174980e6d54933b37976ebf5bc4ac6" contextRef="c20241231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">8,634</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" id="Fact_6017bca0542441fda9ebb31d6be4186c" contextRef="c20231231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">9,635</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="vertical-align: top; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;">
                <p style="margin: 0px;">Deposits and other assets</p>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><ix:nonFraction name="adma:DepositsAndOtherNoncurrentAssets" id="Fact_05ec2b3a0f784810a62bb76c61fdc257" contextRef="c20241231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">5,657</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><ix:nonFraction name="adma:DepositsAndOtherNoncurrentAssets" id="Fact_79232a7388144eb19fe14d4fb1b176ac" contextRef="c20231231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,670</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="vertical-align: top; width: 76%; padding-bottom: 3px;">
                <p style="margin: 0px;"><strong>TOTAL ASSETS</strong></p>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 3px;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 3px; border-bottom: double 3px;">$</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 3px; border-bottom: double 3px;"><ix:nonFraction name="us-gaap:Assets" id="Fact_9f34eeb3c3fd4808ad1d89e6dc020563" contextRef="c20241231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">488,678</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 3px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 3px;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 3px; border-bottom: double 3px;">$</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 3px; border-bottom: double 3px;"><ix:nonFraction name="us-gaap:Assets" id="Fact_15b46b1d6b754de3ac40966266963a74" contextRef="c20231231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">329,182</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 3px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="width: 76%; background-color: #CCEEFF;">
                <p style="margin: 0px;">&#160;</p>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="vertical-align: top; width: 76%;">
                <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">LIABILITIES AND <span style="font-size: 10pt; font-family: 'Times New Roman';">STOCKHOLDERS&#8217;</span> EQUITY</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="vertical-align: top; width: 76%; background-color: #CCEEFF;">
                <p style="margin: 0px;">Current liabilities:</p>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="vertical-align: top; width: 76%;">
                <p style="margin: 0px 0px 0px 15px;">Accounts payable</p>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;">$</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" id="Fact_b6749577bd374ee6828a6ce0284b9734" contextRef="c20241231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">20,219</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;">$</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" id="Fact_253d0afba69b428d879bc422e16e1cee" contextRef="c20231231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">15,660</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="vertical-align: top; width: 76%; background-color: #CCEEFF;">
                <p style="margin: 0px 0px 0px 15px;">Accrued expenses and other current liabilities</p>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><ix:nonFraction name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" id="Fact_9eee52eb8f514db1882ba4325e82a4c2" contextRef="c20241231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">33,962</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><ix:nonFraction name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" id="Fact_eeca5f2b173d4a41af769710ac5e1762" contextRef="c20231231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">32,919</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="vertical-align: top; width: 76%;">
                <p style="margin: 0px 0px 0px 15px;">Current portion of deferred revenue</p>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;"><ix:nonFraction name="us-gaap:ContractWithCustomerLiabilityCurrent" id="Fact_3e7166e1004e4ee28cafcad11e3fb4fc" contextRef="c20241231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">143</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;"><ix:nonFraction name="us-gaap:ContractWithCustomerLiabilityCurrent" id="Fact_9f53c187f29a443f96b2c372553b64dc" contextRef="c20231231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">182</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="vertical-align: top; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;">
                <p style="margin: 0px 0px 0px 15px;">Current portion of lease obligations</p>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" id="Fact_859602c0a67b47cdbf15b601feebdd9f" contextRef="c20241231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,218</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" id="Fact_38ad720aa9484e84870dff234708b77e" contextRef="c20231231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,045</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="vertical-align: top; width: 76%;">
                <p style="margin: 0px 0px 0px 30px;">Total current liabilities</p>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" id="Fact_d5817405c5ff4055950f615064f15169" contextRef="c20241231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">55,542</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" id="Fact_fb5c3c9a3d834498839dc5ac5c961add" contextRef="c20231231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">49,806</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="vertical-align: top; width: 76%; background-color: #CCEEFF;">
                <p style="margin: 0px;">Senior notes payable, net of discount</p>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><ix:nonFraction name="us-gaap:SeniorLongTermNotes" id="Fact_33a7acbbc8a643b4ab65e9ad4971676b" contextRef="c20241231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">72,337</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><ix:nonFraction name="us-gaap:SeniorLongTermNotes" id="Fact_4519bad714214f4ea45e1ad1bbaffd80" contextRef="c20231231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">130,594</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="vertical-align: top; width: 76%;">
                <p style="margin: 0px;">Deferred revenue, net of current portion</p>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;"><ix:nonFraction name="us-gaap:DeferredRevenueNoncurrent" id="Fact_f4b76fb1b2df4de9bfe6df06e2b9b826" contextRef="c20241231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,547</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;"><ix:nonFraction name="us-gaap:DeferredRevenueNoncurrent" id="Fact_85bac8ddf19e41899f7b4392d55f72ed" contextRef="c20231231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,690</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" rowspan="1" style="vertical-align: top; width: 76%; background-color: #CCEEFF;">End of term fee<br/>
              </td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><ix:nonFraction name="adma:LongTermLiabilityEndOfTermFeePayable" id="Fact_b3e4fb112805457fa441d3ae69243ffd" contextRef="c20241231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,313</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><ix:nonFraction name="adma:LongTermLiabilityEndOfTermFeePayable" id="Fact_4c7e9504c47e4029bbe79e17c76c634c" contextRef="c20231231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,688</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="vertical-align: top; width: 76%;">
                <p style="margin: 0px;">Lease obligations, net of current portion</p>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" id="Fact_2641be08e11545a88275bee9a021a576" contextRef="c20241231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">8,561</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" id="Fact_97e5eb0a8dfa443a9271d4f1ec2b223f" contextRef="c20231231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">9,779</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="vertical-align: top; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;">
                <p style="margin: 0px;">Other non-current liabilities</p>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><ix:nonFraction name="us-gaap:OtherLiabilitiesNoncurrent" id="Fact_4fe31e7bdbc64e86bb6b5f510b142626" contextRef="c20241231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">360</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><ix:nonFraction name="us-gaap:OtherLiabilitiesNoncurrent" id="Fact_906a8f82f95445378f0936525b4b1282" contextRef="c20231231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">419</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="vertical-align: top; width: 76%; padding-bottom: 2px;">
                <p style="margin: 0px;"><strong>TOTAL LIABILITIES</strong></p>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;"><ix:nonFraction name="us-gaap:Liabilities" id="Fact_34509b57d150448e9df0ad3c18ae54dd" contextRef="c20241231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">139,660</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;"><ix:nonFraction name="us-gaap:Liabilities" id="Fact_2aaafe323504468b928c2d3f6df0eb4b" contextRef="c20231231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">193,976</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="width: 76%; background-color: #CCEEFF;">
                <p style="margin: 0px;">&#160;</p>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="vertical-align: top; width: 76%;">
                <p style="margin: 0px;"><strong>COMMITMENTS AND CONTINGENCIES</strong></p>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;"><ix:nonFraction name="us-gaap:CommitmentsAndContingencies" id="Fact_2175e880d30e4057b795f147338c612e" contextRef="c20241231" unitRef="U001" xsi:nil="true" format="ixt:fixed-empty"></ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;"><ix:nonFraction name="us-gaap:CommitmentsAndContingencies" id="Fact_d6745333bacc42ff9b396000cd446ce1" contextRef="c20231231" unitRef="U001" xsi:nil="true" format="ixt:fixed-empty"></ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="width: 76%; background-color: #CCEEFF;">
                <p style="margin: 0px;">&#160;</p>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="vertical-align: top; width: 76%;">
                <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><span style="font-size: 10pt; font-family: 'Times New Roman';">STOCKHOLDERS&#8217;</span> EQUITY</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="vertical-align: top; width: 76%; background-color: #CCEEFF;">
                <p style="margin: 0px 0px 0px 9pt; text-indent: -9pt;">Preferred Stock, $<span style="text-indent: 0pt;"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" id="Fact_a99858e5d5ee4c36a79e79e2430c7ea2" contextRef="c20241231" unitRef="U003" decimals="4" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" id="Fact_6eb2d4dfa57e43f0ad65b1c524e4385a" contextRef="c20231231" unitRef="U003" decimals="4" scale="0" format="ixt:num-dot-decimal">0.0001</ix:nonFraction></ix:nonFraction></span> par value, <span style="text-indent: 0pt;"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" id="Fact_51222fc46b6b4a36ad9ad11cac554740" contextRef="c20231231" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" id="Fact_03ae8cce83534553925a2c1ee6288837" contextRef="c20241231" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">10,000,000</ix:nonFraction></ix:nonFraction></span> shares authorized, <span style="text-indent: 0pt;"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" id="Fact_fc95638b28284512977c274e49771ac7" contextRef="c20241231" unitRef="U002" decimals="INF" scale="0" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" id="Fact_fa58feaf160e47de9e51b5aeec819008" contextRef="c20231231" unitRef="U002" decimals="INF" scale="0" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" id="Fact_dedfc06f266044e3bf7e595c2c65d33c" contextRef="c20231231" unitRef="U002" decimals="INF" scale="0" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" id="Fact_03e2971dd5814c33a0b8b7618cbf616b" contextRef="c20241231" unitRef="U002" decimals="INF" scale="0" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span>
                  shares issued and outstanding<br/>
                </p>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><ix:nonFraction name="us-gaap:PreferredStockValue" id="Fact_f0df411966894d0c932cd9203c41d28e" contextRef="c20241231" unitRef="U001" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><ix:nonFraction name="us-gaap:PreferredStockValue" id="Fact_a94025c3bbbd462191439d0777cfa65f" contextRef="c20231231" unitRef="U001" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="vertical-align: top; width: 76%;">
                <p style="margin: 0px 0px 0px 9pt; text-indent: -9pt;">Common Stock - voting, $<span style="text-indent: 0pt;"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" id="Fact_9f26d6e4ec8841089effb3ef1e1d2be2" contextRef="c20241231" unitRef="U003" decimals="4" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" id="Fact_17bda77f14504f87a118f150b7c981e5" contextRef="c20231231" unitRef="U003" decimals="4" scale="0" format="ixt:num-dot-decimal">0.0001</ix:nonFraction></ix:nonFraction></span> par value, <span style="text-indent: 0pt;"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" id="Fact_ba922c30134e420d88739a7810a4a1a9" contextRef="c20241231" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" id="Fact_5375042f6e5f46fb95707eb658af72a7" contextRef="c20231231" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">300,000,000</ix:nonFraction></ix:nonFraction></span> shares authorized, <span style="text-indent: 0pt;"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" id="Fact_d97461d96dca4e56b9b6589d8fa32c1c" contextRef="c20241231" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" id="Fact_940057368b6744ac8542981b26c5540d" contextRef="c20241231" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">236,620,545</ix:nonFraction></ix:nonFraction></span>
                  and <span style="text-indent: 0pt;"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" id="Fact_e55f5cf8a8c64c459e1856cf16f19e9f" contextRef="c20231231" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" id="Fact_982c0a47c98c43f3b275cf3064166bab" contextRef="c20231231" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">226,063,032</ix:nonFraction></ix:nonFraction></span> shares issued and outstanding at December 31, 2024 and December 31, 2023<br/>
                </p>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;"><ix:nonFraction name="us-gaap:CommonStockValue" id="Fact_64215ef58a8b492b91a0eb6e4c1d4c3b" contextRef="c20241231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">24</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;"><ix:nonFraction name="us-gaap:CommonStockValue" id="Fact_ed4f929379334e0a85d77ce2d314d378" contextRef="c20231231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">23</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="vertical-align: top; width: 76%; background-color: #CCEEFF;">
                <p style="margin: 0px;">Additional paid-in capital</p>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" id="Fact_8d893cc91c1c446c8ff7903a7f6fe4fe" contextRef="c20241231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">657,577</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" id="Fact_6ace361aed7144a4b137c0045fa688db" contextRef="c20231231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">641,439</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="vertical-align: top; width: 76%; padding-bottom: 2px;">
                <p style="margin: 0px;">Accumulated deficit</p>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" id="Fact_4bec83f2a7de421b96d640747ef82ba6" contextRef="c20241231" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">308,583</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">)</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" id="Fact_10067ad05ec54addae1ffb23d3107806" contextRef="c20231231" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">506,256</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">)</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="vertical-align: top; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;">
                <p style="margin: 0px;"><strong>TOTAL STOCKHOLDERS&#8217; EQUITY </strong></p>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_0c2c1d0885f44a7c8bca301e053bfe2a" contextRef="c20241231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">349,018</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_182da382183d40baaf1ed7081cf8ce56" contextRef="c20231231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">135,206</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="vertical-align: top; width: 76%; padding-bottom: 4px;">
                <p style="margin: 0px;"><strong>TOTAL LIABILITIES AND STOCKHOLDERS&#8217; EQUITY </strong></p>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;">$</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" id="Fact_e9215b422f1e4c36b09e986822c8d22e" contextRef="c20241231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">488,678</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;">$</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" id="Fact_db9c5e54cd5246859d41c64e635be1da" contextRef="c20231231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">329,182</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">&#160;</td>

  </tr>


</table>
        <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;">&#160;&#160; &#160;</p>
        <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: center;">The accompanying notes are an integral part of these consolidated financial statements.</p>
        <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;">&#160; </p>
        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">F-8</span></div>

          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"/></div>

          <div style="width: 100%;" class="BRPFPageHeader">
            <div>
              <div style="text-align: left; font-weight: bold; text-indent: -9pt; margin-left: 9pt;"><a href="#ADMABIOLOGICSINC."> <span style="font-style: italic; font-weight: normal; font-size: 8pt;">Table of Contents</span></a><br/>
              </div>

            </div>

          </div>

        </div>

      </div>

    </div>

  </div>


  <div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: rgb(0, 0, 0);">
    <div>
      <div style="text-align: left; font: 10pt 'Times New Roman';">
        <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: center;"><span style="display: inline" class="atag">&#160;<strong>ADMA BIOLOGICS, INC. AND SUBSIDIARIES</strong></span></p>
        <a id="CONSOLIDATEDSTATEMENTSOFO"><!--Anchor--></a><a id="STATEMENTSOFOPERATIONS"><!--Anchor--></a><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: center;"><strong>CONSOLIDATED STATEMENTS OF
            <!--Anchor-->
            <!--Anchor-->OPERATIONS</strong></p>
        <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: center;"><strong><br/>
          </strong></p>
        <table cellspacing="0" cellpadding="0" border="0" class="cfttable" style="text-align: left; font: 10pt 'Times New Roman'; width: 100%; border-spacing: 0;">


  <tr style="height: 15px;">

    <td valign="bottom" style="padding-bottom: 2px;">
                <p style="margin: 0px;">&#160;</p>
              </td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="10" rowspan="1" style="vertical-align: bottom; text-align: center; border-bottom: #000000 solid 2px;">
                <p style="margin: 0px 0px 0px 0in; text-align: center;"><strong>Years ended December 31,</strong></p>
              </td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="padding-bottom: 2px;">
                <p style="margin: 0px;">&#160;</p>
              </td>

    <td valign="bottom" colspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: #000000 solid 2px;">
                <p style="margin: 0px 0px 0px 0in; text-align: center;"><strong> 2024<br/>
                  </strong></p>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: #000000 solid 2px;">
                <p style="margin: 0px 0px 0px 0in; text-align: center;"><strong>2023<br/>
                  </strong></p>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="2" style="text-align: center; vertical-align: bottom; border-bottom: #000000 solid 2px;"><span style="font-weight: bold;">2022<br/>
                </span></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom">
                <p style="margin: 0px;">&#160;</p>
              </td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: center; vertical-align: bottom;">&#160;</td>

    <td valign="bottom" colspan="10" rowspan="1" style="text-align: center;"><span style="font-style: italic;">(In thousands, except share and per share data)</span><br/>
              </td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" rowspan="1">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom;">&#160;</td>

    <td valign="bottom" colspan="2" rowspan="1">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom;">&#160;</td>

    <td valign="bottom" colspan="2" rowspan="1">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom;">&#160;</td>

    <td valign="bottom" colspan="2" rowspan="1" style="text-align: left; vertical-align: bottom;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="vertical-align: top; width: 64%; background-color: #CCEEFF;">
                <p style="margin: 0px 0px 0px 0in;"><strong>REVENUES</strong></p>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">$</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_8441c2eee5f64cbcbfd4af516b16fb44" contextRef="c20240101to20241231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">426,454</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">$</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_6e83eaf3da7c4ac6865bfdd903d49a09" contextRef="c20230101to20231231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">258,215</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">$</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_e213a96045854ef486dd409e855a3104" contextRef="c20220101to20221231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">154,080</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" rowspan="1" style="vertical-align: top; width: 64%; padding-bottom: 2px;">
                <p style="margin: 0px;"><strong></strong>Cost of product revenue</p>
              </td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;"><ix:nonFraction name="us-gaap:CostOfRevenue" id="Fact_34d9efb510f04dd1946432195dc53356" contextRef="c20240101to20241231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">206,901</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;"><ix:nonFraction name="us-gaap:CostOfRevenue" id="Fact_1f54b51c41c240c0be0151d2d198b81e" contextRef="c20230101to20231231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">169,273</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;"><ix:nonFraction name="us-gaap:CostOfRevenue" id="Fact_fe2ed189ca244f7781e59579e680cc07" contextRef="c20220101to20221231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">118,815</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" rowspan="1" style="vertical-align: top; font-weight: bold; width: 64%; padding-bottom: 2px; background-color: #CCEEFF;">
                <p style="margin: 0px 0px 0px 30px;"><strong></strong>Gross profit<br/>
                </p>
              </td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><ix:nonFraction name="us-gaap:GrossProfit" id="Fact_6cf0ed75e4d042a4a957dcf7ea541e1e" contextRef="c20240101to20241231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">219,553</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><ix:nonFraction name="us-gaap:GrossProfit" id="Fact_fa0ff4ed65ab4bfea5b4477d1fbc5176" contextRef="c20230101to20231231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">88,942</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;"><ix:nonFraction name="us-gaap:GrossProfit" id="Fact_b069b41efaec4b078677c97514472525" contextRef="c20220101to20221231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">35,265</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="width: 64%;">
                <p style="margin: 0px;">&#160;</p>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="vertical-align: top; width: 64%; background-color: #CCEEFF;">
                <p style="margin: 0px;"><strong>OPERATING EXPENSES:</strong></p>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="vertical-align: top; width: 64%;">
                <p style="margin: 0px 0px 0px 15px;">Research and development</p>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" id="Fact_06cc04d2a9fa40d782af19fe7390a996" contextRef="c20240101to20241231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,813</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" id="Fact_741aeae524c644c9923937f9c16926af" contextRef="c20230101to20231231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,300</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" id="Fact_7921ec6d8f9048d9bc5e314b8c3c06b3" contextRef="c20220101to20221231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,614</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="vertical-align: top; width: 64%; background-color: #CCEEFF;">
                <p style="margin: 0px 0px 0px 15px;">Plasma center operating expenses</p>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><ix:nonFraction name="us-gaap:OtherCostAndExpenseOperating" id="Fact_c3122830ecd64d218180cf982da922eb" contextRef="c20240101to20241231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,245</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><ix:nonFraction name="us-gaap:OtherCostAndExpenseOperating" id="Fact_77ceeb9a17af44e3976dc1be23915d42" contextRef="c20230101to20231231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,266</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;"><ix:nonFraction name="us-gaap:OtherCostAndExpenseOperating" id="Fact_bc33aa5f2821419b8f69581e4f98dab4" contextRef="c20220101to20221231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">17,843</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="vertical-align: top; width: 64%;">
                <p style="margin: 0px 0px 0px 15px;">Amortization of intangible assets</p>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;"><ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" id="Fact_41facc4c11384f3883bf2d6004558468" contextRef="c20240101to20241231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">388</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;"><ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" id="Fact_5e2c4933b6e34cffb64991bb6b2979ad" contextRef="c20230101to20231231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">724</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;"><ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" id="Fact_9b82deccea1d490e96077064752f5bf5" contextRef="c20220101to20221231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">715</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="vertical-align: top; width: 64%; padding-bottom: 2px; background-color: #CCEEFF;">
                <p style="margin: 0px 0px 0px 15px;">Selling, general and administrative</p>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><ix:nonFraction name="us-gaap:SellingGeneralAndAdministrativeExpense" id="Fact_457ce99c4eb049c2876a1e008f1c2fb6" contextRef="c20240101to20241231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">74,124</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><ix:nonFraction name="us-gaap:SellingGeneralAndAdministrativeExpense" id="Fact_e5426dd3e6ab46f3a287e173570eef14" contextRef="c20230101to20231231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">59,020</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;"><ix:nonFraction name="us-gaap:SellingGeneralAndAdministrativeExpense" id="Fact_453d8acbed3040509da7136a0fb06ce7" contextRef="c20220101to20221231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">52,458</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="margin: 0px 0px 0px 15px; vertical-align: top; width: 64%; padding-bottom: 2px;">
                <p style="margin: 0px 0px 0px 30px;"><strong>Total operating expenses</strong></p>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;"><ix:nonFraction name="us-gaap:OperatingExpenses" id="Fact_4c46c3dd004645fca629d306c3567250" contextRef="c20240101to20241231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">80,570</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;"><ix:nonFraction name="us-gaap:OperatingExpenses" id="Fact_ae4f4d0f71b04814bed832cb69649875" contextRef="c20230101to20231231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">67,310</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;"><ix:nonFraction name="us-gaap:OperatingExpenses" id="Fact_ec84f46ddd5a4da9aa8fa278ad90b2fe" contextRef="c20220101to20221231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">74,630</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="width: 64%; background-color: #CCEEFF;">
                <p style="margin: 0px;">&#160;</p>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="vertical-align: top; width: 64%; padding-bottom: 2px;">
                <p style="margin: 0px;"><strong>INCOME (LOSS) FROM OPERATIONS</strong></p>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;"><ix:nonFraction name="us-gaap:OperatingIncomeLoss" id="Fact_8589ad04f794443e96e06027238b649a" contextRef="c20240101to20241231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">138,983</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;"><ix:nonFraction name="us-gaap:OperatingIncomeLoss" id="Fact_c0a0fe25d07645a7883a605441fc0b1c" contextRef="c20230101to20231231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">21,632</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" id="Fact_8d571bbcb2f04ec284c4c7ef8e2bc523" contextRef="c20220101to20221231" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">39,365</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">)</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="width: 64%; background-color: #CCEEFF;">
                <p style="margin: 0px;">&#160;</p>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="vertical-align: top; width: 64%;">
                <p style="margin: 0px;"><strong>OTHER INCOME (EXPENSE):</strong></p>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="vertical-align: top; width: 64%; background-color: #CCEEFF;">
                <p style="margin: 0px 0px 0px 15px;">Interest income</p>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><ix:nonFraction name="us-gaap:InvestmentIncomeInterest" id="Fact_36e811b341fb49feb9f43a08bc51f88b" contextRef="c20240101to20241231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,097</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><ix:nonFraction name="us-gaap:InvestmentIncomeInterest" id="Fact_927da705790f4a4b9dfad8f1f1f73228" contextRef="c20230101to20231231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,617</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;"><ix:nonFraction name="us-gaap:InvestmentIncomeInterest" id="Fact_28e95287cc9b443c8e7ec36406ae7447" contextRef="c20220101to20221231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">45</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="vertical-align: top; width: 64%;">
                <p style="margin: 0px 0px 0px 15px;">Interest expense</p>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">(<ix:nonFraction name="us-gaap:InterestExpenseNonoperating" id="Fact_a398c69a4f1a4c07ba7ec3e9d22e3cc9" contextRef="c20240101to20241231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">13,930</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">)</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">(<ix:nonFraction name="us-gaap:InterestExpenseNonoperating" id="Fact_f907a7db3e7b4d9c91a135a73c71b97d" contextRef="c20230101to20231231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">25,027</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">)</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">(<ix:nonFraction name="us-gaap:InterestExpenseNonoperating" id="Fact_d0ad4ad1c75e440086744e1923f25f5a" contextRef="c20220101to20221231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">19,279</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">)</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="vertical-align: top; width: 64%; background-color: #CCEEFF;">
                <p style="margin: 0px 0px 0px 15px;">Loss on extinguishment of debt</p>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">(<ix:nonFraction name="us-gaap:GainsLossesOnExtinguishmentOfDebt" id="Fact_ac4422d0fc2842f0833f95f0cffe4b93" contextRef="c20240101to20241231" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">1,243</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">)</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">(<ix:nonFraction name="us-gaap:GainsLossesOnExtinguishmentOfDebt" id="Fact_0e96bb9b5eb745559d4267f65f722122" contextRef="c20230101to20231231" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">26,174</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">)</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">(<ix:nonFraction name="us-gaap:GainsLossesOnExtinguishmentOfDebt" id="Fact_4b2c2e0cd8a04c48851b7531598e396a" contextRef="c20220101to20221231" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">6,670</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">)</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="vertical-align: top; width: 64%; padding-bottom: 2px;">
                <p style="margin: 0px 0px 0px 15px;">Other expense</p>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;">(<ix:nonFraction name="us-gaap:OtherNonoperatingIncomeExpense" id="Fact_0de861c1959c45d29d400b3da306dd04" contextRef="c20240101to20241231" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">193</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">)</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;">(<ix:nonFraction name="us-gaap:OtherNonoperatingIncomeExpense" id="Fact_cf51f4ea7c93457d91bc853e3dee8837" contextRef="c20230101to20231231" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">287</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">)</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;">(<ix:nonFraction name="us-gaap:OtherNonoperatingIncomeExpense" id="Fact_3d86f0fd2287471d9ae96ca4d4eb554a" contextRef="c20220101to20221231" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">635</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">)</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="margin: 0px 0px 0px 30px; vertical-align: top; width: 64%; padding-bottom: 2px; background-color: #CCEEFF;">
                <p style="margin: 0px 0px 0px 30px;"><strong>Other expense, net</strong></p>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">(<ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" id="Fact_00f538777a414d988f030d64f37bc696" contextRef="c20240101to20241231" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">13,269</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">)</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">(<ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" id="Fact_f308679fd57f41d1aae4c81742478c5d" contextRef="c20230101to20231231" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">49,871</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">)</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">(<ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" id="Fact_bd2c53addbeb473c8c4d658d7d848a33" contextRef="c20220101to20221231" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">26,539</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">)</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="width: 64%;">
                <p style="margin: 0px;">&#160;</p>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" rowspan="1" style="width: 64%; background-color: #CCEEFF;"><span style="font-weight: bold;">INCOME (LOSS) BEFORE INCOME TAXES</span><br/>
              </td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" id="Fact_621c6258109a4361a7aa22f58f9f126c" contextRef="c20240101to20241231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">125,714</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" id="Fact_26137543ed1547499e9d14c76e8fc817" contextRef="c20230101to20231231" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">28,239</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">)</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" id="Fact_9f7d4eb2f0034edbb03977ce06922b80" contextRef="c20220101to20221231" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">65,904</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">)</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" rowspan="1" style="width: 64%;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" rowspan="1" style="width: 64%; background-color: #CCEEFF;">
                <div style="margin: 0px 0px 0px 15px;">Income tax benefit<br/>
                </div>
              </td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">(<ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" id="Fact_039c3e26d0bf4410b4a4bbec6c7329cb" contextRef="c20240101to20241231" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">71,959</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">)</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" id="Fact_6c116cf8cee6489d938399abf0b3a281" contextRef="c20230101to20231231" unitRef="U001" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" id="Fact_00963fac0e24459493048b3971b7dbf0" contextRef="c20220101to20221231" unitRef="U001" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" rowspan="1" style="width: 64%; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="vertical-align: top; width: 64%; padding-bottom: 4px; background-color: #CCEEFF;">
                <p style="margin: 0px;"><strong>NET INCOME (LOSS)</strong></p>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;">$</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"><ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_46f886d7f28f43dfabe25ef0087b7596" contextRef="c20240101to20241231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">197,673</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;">$</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_37d64baf4c76490a95b688902bdbd4f2" contextRef="c20230101to20231231" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">28,239</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">)</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;">$</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_ad49603301a04cd78537f6fe115e1b19" contextRef="c20220101to20221231" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">65,904</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">)</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="width: 64%;">
                <p style="margin: 0px;">&#160;</p>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="vertical-align: top; width: 64%; padding-bottom: 4px; background-color: #CCEEFF;"><strong>BASIC EARNINGS (LOSS) PER COMMON SHARE</strong><br/>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;">$</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"><ix:nonFraction name="us-gaap:EarningsPerShareBasic" id="Fact_589c4b0450ce4d42bb8aa77a1a0b613c" contextRef="c20240101to20241231" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">0.85</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;">$</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" id="Fact_03f09bc663074a54beff258a46e9c6ce" contextRef="c20230101to20231231" unitRef="U003" decimals="2" sign="-" scale="0" format="ixt:num-dot-decimal">0.13</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">)</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;">$</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" id="Fact_911bb3cc40284474804bf1e9454a8be3" contextRef="c20220101to20221231" unitRef="U003" decimals="2" sign="-" scale="0" format="ixt:num-dot-decimal">0.33</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">)</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" rowspan="1" style="vertical-align: top; width: 64%; padding-bottom: 4px;"><span style="font-weight: bold;">DILUTED EARNINGS (LOSS) PER COMMON SHARE</span><br/>
              </td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;">$</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;"><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" id="Fact_a9281e2d94054363914f30e200817d56" contextRef="c20240101to20241231" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">0.81</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;">$</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;">(<ix:nonFraction name="us-gaap:EarningsPerShareDiluted" id="Fact_c7b8dba182c84ea1b8b4be8c293cec49" contextRef="c20230101to20231231" unitRef="U003" decimals="2" sign="-" scale="0" format="ixt:num-dot-decimal">0.13</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">)</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;">$</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;">(<ix:nonFraction name="us-gaap:EarningsPerShareDiluted" id="Fact_e4d86b5a1f97425b9f881ba143e0ba0a" contextRef="c20220101to20221231" unitRef="U003" decimals="2" sign="-" scale="0" format="ixt:num-dot-decimal">0.33</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">)</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="width: 64%; background-color: #CCEEFF;">
                <p style="margin: 0px;">&#160;</p>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="vertical-align: top; width: 64%;">
                <p style="margin: 0px;"><strong>WEIGHTED AVERAGE COMMON SHARES OUTSTANDING:</strong></p>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="vertical-align: top; width: 64%; padding-bottom: 4px; background-color: #CCEEFF;">
                <p style="margin: 0px 0px 0px 15px;"><strong>Basic<br/>
                  </strong></p>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" id="Fact_41c77f3f09ef4b6396de0107f9c16470" contextRef="c20240101to20241231" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">233,084,236</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" id="Fact_833e6c4bdcb04c1990329ee5970d2d72" contextRef="c20230101to20231231" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">223,977,315</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" id="Fact_b902d11a63b64f55b82a987db59aaedf" contextRef="c20220101to20221231" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">197,874,895</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" rowspan="1" style="vertical-align: top; width: 64%; padding-bottom: 4px;">
                <div style="margin: 0px 0px 0px 15px;"><strong>Diluted</strong></div>
              </td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" id="Fact_f34133a90d214c0b81c019ae9be144be" contextRef="c20240101to20241231" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">243,342,466</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" id="Fact_9dd045022277405b986093936727e926" contextRef="c20230101to20231231" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">223,977,315</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" id="Fact_f9ab553e1ea248189a99b8455a132e6d" contextRef="c20220101to20221231" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">197,874,895</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">&#160;</td>

  </tr>


</table>
        <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;">&#160;&#160; &#160;</p>
        <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: center;">The accompanying notes are an integral part of these consolidated financial statements.</p>
        <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;">&#160;&#160; </p>
        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div class="BRPFPageNumberArea" style="text-align: center;"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">F-9</span></div>

          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"/></div>

          <div class="BRPFPageHeader" style="width: 100%;">
            <div>
              <div style="text-align: left; font-weight: bold; text-indent: -9pt; margin-left: 9pt;"><a href="#ADMABIOLOGICSINC."> <span style="font-style: italic; font-weight: normal; font-size: 8pt;">Table of Contents</span></a><br/>
              </div>

            </div>

          </div>

        </div>

      </div>

    </div>

  </div>


  <div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: rgb(0, 0, 0);">
    <div>
      <div style="text-align: left; font: 10pt 'Times New Roman';">
        <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: center;"><strong><span style="display: inline" class="atag">ADMA BIOLOGICS, INC. AND SUBSIDIARIES</span></strong></p>
        <a id="STOCKHOLDERSEQUITY"><!--Anchor--></a><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: center;"><strong>CONSOLIDATED STATEMENTS OF CHANGES IN
            <!--Anchor--><!--Anchor-->STOCKHOLDERS&#8217;
            <!--Anchor-->EQUITY</strong></p>
        <div style="text-align: center;"> <span style="font-style: italic;">(In thousands, except share data)</span> </div>

        <div style="text-align: center;"><span style="font-style: italic;"> <br/>
          </span></div>

        <table cellspacing="0" cellpadding="0" border="0" style="text-align: left; font: 10pt 'Times New Roman'; width: 100%; border-spacing: 0;" class="cfttable">


  <tr style="height: 15px;">

    <td valign="bottom">
                <p style="margin: 0px;">&#160;</p>
              </td>

    <td valign="bottom" style="text-align: center; vertical-align: bottom;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: center;" colspan="6">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: center; vertical-align: bottom;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: center;" colspan="2">
                <p style="margin: 0px 0px 0px 0in; text-align: center;"><strong> Additional </strong></p>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom;" colspan="1">&#160;</td>

    <td valign="bottom" colspan="2">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: center; vertical-align: bottom;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: center;" colspan="2">
                <p style="margin: 0px 0px 0px 0in; text-align: center;"><strong>Total</strong></p>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="padding-bottom: 2px;">
                <p style="margin: 0px;">&#160;</p>
              </td>

    <td valign="bottom" style="text-align: center; vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: center; border-bottom: #000000 solid 2px;" colspan="6">
                <p style="margin: 0px 0px 0px 0in; text-align: center;"><strong> Common Stock </strong></p>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: center; vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: center;" colspan="2">
                <p style="margin: 0px 0px 0px 0in; text-align: center;"><strong> Paid-in </strong></p>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: center; vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: center;" colspan="2">
                <p style="margin: 0px 0px 0px 0in; text-align: center;"><strong> Accumulated </strong></p>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: center; vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: center;" colspan="2">
                <p style="margin: 0px 0px 0px 0in; text-align: center;"><strong>Stockholders&#8217;</strong></p>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="padding-bottom: 2px;">
                <p style="margin: 0px;">&#160;</p>
              </td>

    <td valign="bottom" style="text-align: center; vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: center; border-bottom: #000000 solid 2px;" colspan="2">
                <p style="margin: 0px 0px 0px 0in; text-align: center;"><strong> Shares </strong></p>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: center; vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: center; border-bottom: #000000 solid 2px;" colspan="2">
                <p style="margin: 0px 0px 0px 0in; text-align: center;"><strong> Amount </strong></p>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: center; vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: center; border-bottom: #000000 solid 2px;" colspan="2">
                <p style="margin: 0px 0px 0px 0in; text-align: center;"><strong> Capital </strong></p>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: center; vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: center; border-bottom: #000000 solid 2px;" colspan="2">
                <p style="margin: 0px 0px 0px 0in; text-align: center;"><strong> Deficit </strong></p>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: center; vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: center; border-bottom: #000000 solid 2px;" colspan="2">
                <p style="margin: 0px 0px 0px 0in; text-align: center;"><strong>Equity</strong></p>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="vertical-align: top; width: 40%; background-color: #CCEEFF;">
                <p style="margin-top: 0px; margin-bottom: 0px; text-indent: -9pt; margin-left: 9pt; font-weight: bold;">Balance at <span style="text-indent: 0pt;">December 31, 2021</span></p>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1"><ix:nonFraction name="us-gaap:SharesOutstanding" id="Fact_341e56e1ad9c4bb5bc287c7a1fbb9041" contextRef="c20211231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">195,813,817</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">$</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1"><ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_0b87f6d277f44a809bbc6ff0c82ac41a" contextRef="c20211231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">20</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">$</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1"><ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_bcd3dd368df24122b910cd51dff9b82d" contextRef="c20211231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">553,266</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">$</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">(<ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_38a7538d45c4498c92b85f92cc482785" contextRef="c20211231_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">412,113</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">)</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">$</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1"><ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_9572fcefa5424a728479ff110b319766" contextRef="c20211231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">141,173</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="vertical-align: top; width: 40%;">
                <p style="margin-top: 0px; margin-bottom: 0px; text-indent: -9pt; margin-left: 9pt;">Stock-based compensation</p>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">-</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" id="Fact_51128c74f1124146b9b253a9e4a112ef" contextRef="c20220101to20221231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" id="Fact_d1a3dce8a6a0401886cc9030813dcedd" contextRef="c20220101to20221231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">5,215</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" id="Fact_8bf40810b65f42beb8a28bca611d9656" contextRef="c20220101to20221231_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U001" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" id="Fact_ea896c2d947f483881fcca0f6dcef402" contextRef="c20220101to20221231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">5,215</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="vertical-align: top; width: 40%; background-color: #CCEEFF;">
                <p style="margin-top: 0px; margin-bottom: 0px; text-indent: -9pt; margin-left: 9pt;">Issuance of common stock, net of offering expenses</p>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" id="Fact_bd76ec52997d47ebbb445969fbe326fa" contextRef="c20220101to20221231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">24,125,873</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" id="Fact_797e264061b54ca399bf4349e3c48fa9" contextRef="c20220101to20221231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">2</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" id="Fact_01d9e2c66eba4812bd4a3f040f060968" contextRef="c20220101to20221231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">64,642</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" id="Fact_14846006528c4338bf80307323765d02" contextRef="c20220101to20221231_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U001" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" id="Fact_66c5b9a9f96341ee82e6afcfa66f4994" contextRef="c20220101to20221231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">64,644</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="vertical-align: top; width: 40%;" rowspan="1">
                <div style="margin-left: 9pt; text-indent: -9pt;">Vesting of Restricted Stock Units, net of shares withheld for taxes<br/>
                </div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" rowspan="1" colspan="1"><ix:nonFraction name="adma:VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesShares" id="Fact_b75f0705b7164b4587242ec5317ab5f3" contextRef="c20220101to20221231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">1,808,561</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" rowspan="1" colspan="1"><ix:nonFraction name="adma:VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAmount" id="Fact_782da4e3d95f484a98e4031873058176" contextRef="c20220101to20221231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" rowspan="1" colspan="1">(<ix:nonFraction name="adma:VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAmount" id="Fact_b9e97117738849268ae8ba06a4f4f1cc" contextRef="c20220101to20221231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,899</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">)</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" rowspan="1" colspan="1"><ix:nonFraction name="adma:VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAmount" id="Fact_a6334213280148f68d8097109bca7820" contextRef="c20220101to20221231_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U001" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" rowspan="1" colspan="1">(<ix:nonFraction name="adma:VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAmount" id="Fact_7880d8599dbc4dadb676a8dce224dfdf" contextRef="c20220101to20221231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,899</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">)</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="vertical-align: top; width: 40%; background-color: #CCEEFF;" rowspan="1">Warrants issued in connection with note payable<br/>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" rowspan="1" colspan="1">-</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" id="Fact_54b5a2202cab4462a684bbfabdfcf524" contextRef="c20220101to20221231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" id="Fact_2c266dd20506485389bd82a7c8b402f9" contextRef="c20220101to20221231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">9,570</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" id="Fact_095a1a1efbc4472f8c5ae5322c9c2312" contextRef="c20220101to20221231_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U001" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" id="Fact_a8e5ba06d2ff454c96cb0e805134a0ee" contextRef="c20220101to20221231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">9,570</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="vertical-align: top; width: 40%;" rowspan="1">Exercise of stock options<br/>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" id="Fact_4aa22eecd2ad462c8899a4cde067d32f" contextRef="c20220101to20221231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">68,679</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" id="Fact_42c7751c362b40ca98fe44c98cc78d33" contextRef="c20220101to20221231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" id="Fact_061622ca6bac41cea109222c7f59254d" contextRef="c20220101to20221231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">175</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" id="Fact_0159da5e860f437390524420e977b2d3" contextRef="c20220101to20221231_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U001" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" id="Fact_dad4ac27fbb04ac29ab371551ac9ea52" contextRef="c20220101to20221231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">175</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="vertical-align: top; width: 40%; padding-bottom: 2px; background-color: #CCEEFF;">
                <p style="margin-top: 0px; margin-bottom: 0px; text-indent: -9pt; margin-left: 9pt;">Net loss</p>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" colspan="1">-</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" colspan="1"><ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_ed34d4f8c4f1451ca9b0eee91ce741a7" contextRef="c20220101to20221231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" colspan="1"><ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_bbce859aa3a148db8cb9b15d152bf50e" contextRef="c20220101to20221231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U001" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" colspan="1">(<ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_2ca81145c7cf418b852e848c066aad7a" contextRef="c20220101to20221231_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">65,904</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">)</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" colspan="1">(<ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_561d383061c749b996b3efb9e510e4f6" contextRef="c20220101to20221231" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">65,904</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">)</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="vertical-align: top; width: 40%;">
                <p style="margin-top: 0px; margin-bottom: 0px; text-indent: -9pt; margin-left: 9pt; font-weight: bold;">Balance at <span style="text-indent: 0pt;">December 31, 2022</span></p>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1"><ix:nonFraction name="us-gaap:SharesOutstanding" id="Fact_ec0660d449bb4fd29a321bcb535b1b59" contextRef="c20221231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">221,816,930</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1"><ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_92db333566674749b5337fd2ff197fed" contextRef="c20221231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">22</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1"><ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_6519cd2b2a4f4aee8de97e8d79e88cd2" contextRef="c20221231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">629,969</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">(<ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_3a763d31fde7403caef02501eb321a28" contextRef="c20221231_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">478,017</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">)</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1"><ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_864f2c932dd54fb0b486cc4ea8361125" contextRef="c20221231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">151,974</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="vertical-align: top; width: 40%; background-color: #CCEEFF;">
                <p style="margin-top: 0px; margin-bottom: 0px; text-indent: -9pt; margin-left: 9pt;">Stock-based compensation</p>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">-</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" id="Fact_e4d26de2092c4352af5ca5fbee71cf32" contextRef="c20230101to20231231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" id="Fact_c47351a2a2a84f19a71664238a2821ac" contextRef="c20230101to20231231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">6,187</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" id="Fact_de7893fcafa44c3aa8e0e11df4153aaa" contextRef="c20230101to20231231_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U001" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" id="Fact_98d9b22c1ebe422eafb5241be203c81a" contextRef="c20230101to20231231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">6,187</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="vertical-align: top; width: 40%;" rowspan="1">
                <div style="text-indent: -9pt; margin-left: 9pt;">Vesting of Restricted Stock Units, net of shares withheld for taxes<br/>
                </div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" rowspan="1" colspan="1"><ix:nonFraction name="adma:VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesShares" id="Fact_64cd0442c54e4b9283b6330d6869d260" contextRef="c20230101to20231231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">833,722</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" rowspan="1" colspan="1"><ix:nonFraction name="adma:VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAmount" id="Fact_adca6f7468234f1ca00a795d3adfe434" contextRef="c20230101to20231231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" rowspan="1" colspan="1">(<ix:nonFraction name="adma:VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAmount" id="Fact_1887487de75745c08c154c38c6705721" contextRef="c20230101to20231231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,415</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">)</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" rowspan="1" colspan="1"><ix:nonFraction name="adma:VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAmount" id="Fact_9966989d5dc44ce7a6d96d519ddd7d14" contextRef="c20230101to20231231_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U001" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" rowspan="1" colspan="1">(<ix:nonFraction name="adma:VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAmount" id="Fact_ecf0462edcf74bc5a93289fd782b3284" contextRef="c20230101to20231231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,415</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">)</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="vertical-align: top; width: 40%; background-color: #CCEEFF;" rowspan="1">
                <div style="margin-left: 9pt; text-indent: -9pt;">Warrants issued in connection with notes payable<br/>
                </div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" rowspan="1" colspan="1">-</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" id="Fact_f925ae0589064a0b8ab00ce2b494ac8d" contextRef="c20230101to20231231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" id="Fact_27735ccc3ad44011a90c14eb6ef95c5b" contextRef="c20230101to20231231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">5,595</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" id="Fact_f7395889fcc041de99ff96c09f259f33" contextRef="c20230101to20231231_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U001" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" id="Fact_1bfddcd0201c4fc0a3f3d635a9873b9e" contextRef="c20230101to20231231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">5,595</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="vertical-align: top; width: 40%;">
                <p style="margin-top: 0px; margin-bottom: 0px; text-indent: -9pt; margin-left: 9pt;">Exercise of stock options<br/>
                </p>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" id="Fact_d17414a6cdf1424994b4c1b8233093ac" contextRef="c20230101to20231231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">1,444,533</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" id="Fact_fb2a84df4c604074898e0f75e4c88563" contextRef="c20230101to20231231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">1</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" id="Fact_4e692b54297c496e9a2b63744ccb2637" contextRef="c20230101to20231231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,103</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" id="Fact_a8f7612556de40798a70f02742e27b48" contextRef="c20230101to20231231_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U001" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" id="Fact_28fcb77983524cde8f70183d12cd61a7" contextRef="c20230101to20231231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,104</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="vertical-align: top; width: 40%; background-color: #CCEEFF;" rowspan="1">Cashless exercise of warrants<br/>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" rowspan="1" colspan="1"><ix:nonFraction name="adma:StockIssuedDuringPeriodSharesCashlessExerciseOfWarrants" id="Fact_0459c87db28a445f8d2cbb38f9cffa3f" contextRef="c20230101to20231231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">1,967,847</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" rowspan="1" colspan="1"><ix:nonFraction name="adma:StockIssuedDuringPeriodValueCashlessExerciseOfWarrants" id="Fact_aefc6574de174857af69e809db06d8af" contextRef="c20230101to20231231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" rowspan="1" colspan="1"><ix:nonFraction name="adma:StockIssuedDuringPeriodValueCashlessExerciseOfWarrants" id="Fact_5f55198aa5d24661b9b129dba4611ce5" contextRef="c20230101to20231231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U001" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" rowspan="1" colspan="1"><ix:nonFraction name="adma:StockIssuedDuringPeriodValueCashlessExerciseOfWarrants" id="Fact_b5348b2e54b3489689f99511d9783141" contextRef="c20230101to20231231_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U001" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" rowspan="1" colspan="1"><ix:nonFraction name="adma:StockIssuedDuringPeriodValueCashlessExerciseOfWarrants" id="Fact_01c84a664db443328e25e1ffd801cea0" contextRef="c20230101to20231231" unitRef="U001" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="vertical-align: top; width: 40%; padding-bottom: 2px;">
                <p style="margin-top: 0px; margin-bottom: 0px; text-indent: -9pt; margin-left: 9pt;">Net loss</p>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" colspan="1">-</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" colspan="1"><ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_6f1bf817e5f949d5909106dfde579061" contextRef="c20230101to20231231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" colspan="1"><ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_cbbceeef04404058955f32041dcc12a3" contextRef="c20230101to20231231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U001" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" colspan="1">(<ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_6208c2b9df744597bf9a2a7ec00ceb9f" contextRef="c20230101to20231231_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">28,239</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">)</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" colspan="1">(<ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_13cf9f64ba99421db4f4b6c46aa1465d" contextRef="c20230101to20231231" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">28,239</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">)<br/>
              </td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="vertical-align: top; width: 40%; background-color: #CCEEFF;">
                <p style="margin-top: 0px; margin-bottom: 0px; text-indent: -18pt; margin-left: 18pt; font-weight: bold;">Balance at <span style="text-indent: 0pt;">December 31, 2023</span></p>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1"><ix:nonFraction name="us-gaap:SharesOutstanding" id="Fact_c50cbb1c86b044a1a984cc8af0e8ad9e" contextRef="c20231231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">226,063,032</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1"><ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_be652c6f05174ee381a179c2ca94e472" contextRef="c20231231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">23</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1"><ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_8612862bf7214c3d8aafc64adf6f499a" contextRef="c20231231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">641,439</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">(<ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_b962a1851cbf442a9881d54916a37832" contextRef="c20231231_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">506,256</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">)</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1"><ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_dbe1fd332b1b4d84b05cc863a2442f11" contextRef="c20231231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">135,206</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="vertical-align: top; width: 40%;" rowspan="1">
                <div style="margin-left: 9pt; text-indent: -9pt;">Stock-based compensation<br/>
                </div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" rowspan="1" colspan="1">-</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" id="Fact_abffced7c2a44828b6859688847abca6" contextRef="c20240101to20241231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" id="Fact_d9b7e4b9a9c145468de1b12d92859415" contextRef="c20240101to20241231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">13,616</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" id="Fact_a3023bf8c83446b4bd2e5532b64899f7" contextRef="c20240101to20241231_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U001" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" id="Fact_3134a85fb61e4610bf14af92f2e09dd1" contextRef="c20240101to20241231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">13,616</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="vertical-align: top; width: 40%; background-color: #CCEEFF;" rowspan="1">
                <div style="margin-left: 9pt; text-indent: -9pt;">Vesting of Restricted Stock Units, net of shares withheld for taxes<br/>
                </div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" rowspan="1" colspan="1"><ix:nonFraction name="adma:VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesShares" id="Fact_c6e047b2ce1c445680e2c36e652724cf" contextRef="c20240101to20241231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">1,344,555</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" rowspan="1" colspan="1"><ix:nonFraction name="adma:VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAmount" id="Fact_88252ace49064803ad5cebbfad6c87da" contextRef="c20240101to20241231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" rowspan="1" colspan="1">(<ix:nonFraction name="adma:VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAmount" id="Fact_59e5094aac854376933b175bde228318" contextRef="c20240101to20241231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,971</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">)</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" rowspan="1" colspan="1"><ix:nonFraction name="adma:VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAmount" id="Fact_cbd605074d0b4665be7b44583616b9b2" contextRef="c20240101to20241231_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U001" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" rowspan="1" colspan="1">(<ix:nonFraction name="adma:VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAmount" id="Fact_7af6ddf84a9f44cd82ed37f112e52bfd" contextRef="c20240101to20241231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,971</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">)</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="vertical-align: top; width: 40%;" rowspan="1">Exercise of stock options<br/>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" id="Fact_4bfb828c541f4ddd9fc1bb5ec55b32e0" contextRef="c20240101to20241231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">1,988,066</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" id="Fact_15f632ff75c040c1b988ea2f1affbaec" contextRef="c20240101to20241231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" id="Fact_8997f7944ec5488384e08cffb5873cd9" contextRef="c20240101to20241231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">7,494</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" id="Fact_b5a2a622241d4ec9b151031cfd75506a" contextRef="c20240101to20241231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">7,494</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="vertical-align: top; width: 40%; background-color: #CCEEFF;" rowspan="1">Cashless exercise of warrants<br/>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" rowspan="1" colspan="1"><ix:nonFraction name="adma:StockIssuedDuringPeriodSharesCashlessExerciseOfWarrants" id="Fact_eaaefe130c804edba8db604e7f353995" contextRef="c20240101to20241231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">7,224,892</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" rowspan="1" colspan="1"><ix:nonFraction name="adma:StockIssuedDuringPeriodValueCashlessExerciseOfWarrants" id="Fact_63eff24008de4c1faaba83a1b07d56f9" contextRef="c20240101to20241231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">1</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" rowspan="1" colspan="1">(<ix:nonFraction name="adma:StockIssuedDuringPeriodValueCashlessExerciseOfWarrants" id="Fact_97177ce4d3f94af69d193b2512db9b2e" contextRef="c20240101to20241231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">1</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">)</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" rowspan="1" colspan="1"><ix:nonFraction name="adma:StockIssuedDuringPeriodValueCashlessExerciseOfWarrants" id="Fact_244fa1eb3f68481a960f093c5485f28f" contextRef="c20240101to20241231_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U001" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" rowspan="1" colspan="1"><ix:nonFraction name="adma:StockIssuedDuringPeriodValueCashlessExerciseOfWarrants" id="Fact_a28cfe11b9114f2ea1eeebc38256c355" contextRef="c20240101to20241231" unitRef="U001" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="vertical-align: top; width: 40%; padding-bottom: 2px;" rowspan="1">Net income<br/>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" rowspan="1" colspan="1">-</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_e2108b9c1a764cbca2eb7f6da506193a" contextRef="c20240101to20241231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_a08ee1f791b14cb6a0f06d0b3d2bf248" contextRef="c20240101to20241231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U001" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_571869f9b4864a46b21adea2d67fe833" contextRef="c20240101to20241231_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">197,673</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_4c79d811eebf453e8501cb13f7e8d445" contextRef="c20240101to20241231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">197,673</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="vertical-align: top; width: 40%; padding-bottom: 4px; background-color: #CCEEFF;" rowspan="1"><span style="font-weight: bold;">Balance at December 31, 2024 </span></td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:SharesOutstanding" id="Fact_cb279aec97b74557941910e742aefeee" contextRef="c20241231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">236,620,545</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" rowspan="1" colspan="1">$</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_50a83989754d4837864af02b9c61786e" contextRef="c20241231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">24</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" rowspan="1" colspan="1">$</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_16416af1ae4a4f58b21626dac535b978" contextRef="c20241231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">657,577</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" rowspan="1" colspan="1">$</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" rowspan="1" colspan="1">(<ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_30ef5ca48da941638393a202eec8ab10" contextRef="c20241231_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">308,583</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">)</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" rowspan="1" colspan="1">$</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:StockholdersEquity" id="Fact_db999768439f48b28be28cb5f7ab92b8" contextRef="c20241231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">349,018</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>


</table>
        <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px;">&#160; &#160;</p>
        <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: center;">The accompanying notes are an integral part of these consolidated financial statements.</p>
        <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;">&#160;&#160; &#160;</p>
        <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
          <div class="BRPFPageNumberArea" style="text-align: center;"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">F-10</span></div>

          <div class="BRPFPageBreak" style="page-break-after: always;">
            <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"/></div>

          <div class="BRPFPageHeader" style="width: 100%;">
            <div>
              <div style="text-align: left; font-weight: bold; text-indent: -9pt; margin-left: 9pt;"><a href="#ADMABIOLOGICSINC."> <span style="font-style: italic; font-weight: normal; font-size: 8pt;">Table of Contents</span></a><br/>
              </div>

            </div>

          </div>

        </div>

      </div>

    </div>

  </div>


  <div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: rgb(0, 0, 0);">
    <div>
      <div style="text-align: left; font: 10pt 'Times New Roman';">
        <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: center;"><strong><span style="display: inline" class="atag">ADMA BIOLOGICS, INC. AND SUBSIDIARIES</span></strong></p>
        <a id="CASHFLOWS"><!--Anchor--></a><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: center;"><strong>CONSOLIDATED STATEMENTS OF
            <!--Anchor-->
            <!--Anchor--><!--Anchor-->CASH FLOWS</strong></p>
        <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: center;"><strong><br/>
          </strong></p>
        <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;">&#160;</p>
        <table cellspacing="0" cellpadding="0" border="0" class="cfttable" style="text-align: left; font: 10pt 'Times New Roman'; width: 100%; border-spacing: 0;">


  <tr style="height: 15px;">

    <td valign="bottom" style="padding-bottom: 2px;">
                <p style="margin: 0px;">&#160;</p>
              </td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="10" rowspan="1" style="vertical-align: bottom; text-align: center; border-bottom: #000000 solid 2px;">
                <p style="margin: 0px 0px 0px 0in; text-align: center;"><strong>Year Ended December 31,</strong></p>
              </td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="padding-bottom: 2px;">
                <p style="margin: 0px;">&#160;</p>
              </td>

    <td valign="bottom" colspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: #000000 solid 2px;">
                <p style="margin: 0px 0px 0px 0in; text-align: center;"><strong> 2024<br/>
                  </strong></p>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: #000000 solid 2px;">
                <p style="margin: 0px 0px 0px 0in; text-align: center;"><strong>2023<br/>
                  </strong></p>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: center; font-weight: bold; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" style="text-align: center; vertical-align: bottom; font-weight: bold; border-bottom: #000000 solid 2px;"> 2022</td>

    <td valign="bottom" colspan="1" style="font-weight: bold; text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" rowspan="1">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: center; vertical-align: bottom;">&#160;</td>

    <td valign="bottom" colspan="10" rowspan="1" style="vertical-align: bottom; text-align: center;"><span style="font-style: italic;">(In thousands)</span><br/>
              </td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="vertical-align: top;">
                <p style="margin: 0px 0px 0px 0in;"><strong>CASH FLOWS FROM OPERATING ACTIVITIES:</strong></p>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom;">&#160;</td>

    <td valign="bottom" colspan="2">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom;">&#160;</td>

    <td valign="bottom" colspan="2">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" style="text-align: left; vertical-align: bottom;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="vertical-align: top; width: 64%; background-color: #CCEEFF;">
                <p style="margin: 0px 0px 0px 15px;">Net income (loss)</p>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">$</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_1e982170e59245dabe35456dd64ff7ce" contextRef="c20240101to20241231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">197,673</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">$</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_4dab74ee418a4a99b02f040f0b4d712e" contextRef="c20230101to20231231" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">28,239</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">)</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">$</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">(<ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_bafd7c280cdc4f0b96f97caca73aa117" contextRef="c20220101to20221231" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">65,904</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">)</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="vertical-align: top; width: 64%;">
                <p style="margin: 0px 0px 0px 15px;">Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:<br/>
                </p>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="vertical-align: top; width: 64%; background-color: #CCEEFF;">
                <p style="margin: 0px 0px 0px 30px;">Depreciation and amortization</p>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><ix:nonFraction name="us-gaap:DepreciationAndAmortization" id="Fact_48aab7d322c34d20bd96d9802f13248a" contextRef="c20240101to20241231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">8,045</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><ix:nonFraction name="us-gaap:DepreciationAndAmortization" id="Fact_8851c9b949a146e99698c22918149f46" contextRef="c20230101to20231231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">8,332</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;"><ix:nonFraction name="us-gaap:DepreciationAndAmortization" id="Fact_50e0f60ba1ad40eb895452ff243c0758" contextRef="c20220101to20221231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">7,113</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="vertical-align: top; width: 64%;">
                <p style="margin: 0px 0px 0px 30px;">Loss on disposal of fixed assets</p>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;"><ix:nonFraction name="us-gaap:GainLossOnDispositionOfAssets" id="Fact_4da852e24d484dd8b874fa68ad27ac1d" contextRef="c20240101to20241231" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">106</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;"><ix:nonFraction name="us-gaap:GainLossOnDispositionOfAssets" id="Fact_3b26b89eb1734833b964cc41375c61c4" contextRef="c20230101to20231231" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">182</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;"><ix:nonFraction name="us-gaap:GainLossOnDispositionOfAssets" id="Fact_600eff9fadbc4dea95954adc4a352213" contextRef="c20220101to20221231" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">427</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" rowspan="1" style="margin: 0px; text-align: justify; width: 64%; background-color: #CCEEFF;">
                <div style="margin-left: 9pt;">
                  <div style="margin: 0px 0px 0px 12pt;">Deferred income tax benefit<br/>
                  </div>
                </div>
              </td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInDeferredIncomeTaxes" id="Fact_e886223760354677a5fca3760075efc6" contextRef="c20240101to20241231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">84,280</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">)</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInDeferredIncomeTaxes" id="Fact_ee5358e49e7a43a99457f613041986c0" contextRef="c20230101to20231231" unitRef="U001" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInDeferredIncomeTaxes" id="Fact_737fec08a55f499fbb30ee76e358db29" contextRef="c20220101to20221231" unitRef="U001" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" rowspan="1" style="margin: 0px; text-align: justify; width: 64%;">
                <div style="margin: 0px 0px 0px 30px;">Interest paid in kind</div>
              </td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;"><ix:nonFraction name="us-gaap:PaidInKindInterest" id="Fact_1bafda83913741b9894c3d320dd56d4f" contextRef="c20240101to20241231" unitRef="U001" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction><br/>
              </td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;"><ix:nonFraction name="us-gaap:PaidInKindInterest" id="Fact_30f420b58d4d4e3a840f7f745fede7e1" contextRef="c20230101to20231231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,836</ix:nonFraction><br/>
              </td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;"><ix:nonFraction name="us-gaap:PaidInKindInterest" id="Fact_c20a5f49341e48588f54dd2dbc6a8f00" contextRef="c20220101to20221231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,998</ix:nonFraction><br/>
              </td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="vertical-align: top; width: 64%; background-color: #CCEEFF;">
                <p style="margin: 0px 0px 0px 21pt;">Stock-based compensation</p>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><ix:nonFraction name="us-gaap:ShareBasedCompensation" id="Fact_c1456b495c884804b49bfe8092e9c0f8" contextRef="c20240101to20241231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">13,616</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><ix:nonFraction name="us-gaap:ShareBasedCompensation" id="Fact_8320ddaff4cf4bbc8c1cf55b1e3eba5c" contextRef="c20230101to20231231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">6,187</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;"><ix:nonFraction name="us-gaap:ShareBasedCompensation" id="Fact_1548d1e168814e1fb7a8eaf1d624f4b5" contextRef="c20220101to20221231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">5,215</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="vertical-align: top; width: 64%;">
                <p style="margin: 0px 0px 0px 21pt;">Amortization of debt discount</p>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;"><ix:nonFraction name="us-gaap:AmortizationOfDebtDiscountPremium" id="Fact_83896ecd612a482a9e5e4ece331de76d" contextRef="c20240101to20241231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">951</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;"><ix:nonFraction name="us-gaap:AmortizationOfDebtDiscountPremium" id="Fact_c86fc82f0d40469dad9a2888cb3eb759" contextRef="c20230101to20231231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,594</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;"><ix:nonFraction name="us-gaap:AmortizationOfDebtDiscountPremium" id="Fact_854de1c510b94cfbb44f58085045db49" contextRef="c20220101to20221231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,402</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="vertical-align: top; width: 64%; background-color: #CCEEFF;">
                <p style="margin: 0px 0px 0px 21pt;">Loss on extinguishment of debt</p>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><ix:nonFraction name="us-gaap:GainsLossesOnExtinguishmentOfDebt" id="Fact_f67927914b48491e9aa063e57868178d" contextRef="c20240101to20241231" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">1,243</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><ix:nonFraction name="us-gaap:GainsLossesOnExtinguishmentOfDebt" id="Fact_c20be1fc061d44e694222827e3493f06" contextRef="c20230101to20231231" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">26,174</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;"><ix:nonFraction name="us-gaap:GainsLossesOnExtinguishmentOfDebt" id="Fact_bd928a1efb824f32b8c0867848ad8da8" contextRef="c20220101to20221231" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">6,670</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="vertical-align: top; width: 64%;">
                <p style="margin: 0px 0px 0px 21pt;">Amortization of license revenue</p>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">(<ix:nonFraction name="adma:AmortizationOfLicenseRevenue" id="Fact_f0fe00b8757c46c08e0fa6083b117573" contextRef="c20240101to20241231" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">143</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">)</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">(<ix:nonFraction name="adma:AmortizationOfLicenseRevenue" id="Fact_60199c8cb254441d8d336796b3903ea3" contextRef="c20230101to20231231" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">143</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">)</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">(<ix:nonFraction name="adma:AmortizationOfLicenseRevenue" id="Fact_93ce053fc4064893af499841ee1b39f2" contextRef="c20220101to20221231" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">143</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">)</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="vertical-align: top; width: 64%; background-color: #CCEEFF;">
                <p style="margin: 0px 0px 0px 15px;">Changes in operating assets and liabilities:</p>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="vertical-align: top; width: 64%;">
                <p style="margin: 0px 0px 0px 30px;">Accounts receivable</p>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsReceivable" id="Fact_04fb81e0e6274dce908dd36d3114ad12" contextRef="c20240101to20241231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">22,578</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">)</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsReceivable" id="Fact_e4a0e1f108844c3087eb8e26bdfd94c0" contextRef="c20230101to20231231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">11,916</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">)</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsReceivable" id="Fact_46c1ecae59c24d218296e1b9c4ec1fea" contextRef="c20220101to20221231" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">13,072</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="vertical-align: top; width: 64%; background-color: #CCEEFF;">
                <p style="margin: 0px 0px 0px 30px;">Inventories</p>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInInventories" id="Fact_e7cf5e4641bc45af870c12fb278516d7" contextRef="c20240101to20241231" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">2,671</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInInventories" id="Fact_e53bbe123b194eb3aa18f5606807377d" contextRef="c20230101to20231231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">9,626</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">)</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInInventories" id="Fact_696c3813ea984938b7b4812165ebe8d4" contextRef="c20220101to20221231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">38,556</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">)</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="vertical-align: top; width: 64%;">
                <p style="margin: 0px 0px 0px 30px;">Prepaid expenses and other current assets</p>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" id="Fact_c662b0469907430e959c7b4b0f21c88d" contextRef="c20240101to20241231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,695</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">)</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" id="Fact_9eb1a95a32cb4140af0dc16f1b9b612a" contextRef="c20230101to20231231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">239</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">)</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" id="Fact_82af8b5ff070491e8257c0d549710be4" contextRef="c20220101to20221231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">756</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">)</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="vertical-align: top; width: 64%; background-color: #CCEEFF;">
                <p style="margin: 0px 0px 0px 30px;">Deposits and other assets</p>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><ix:nonFraction name="adma:IncreaseDecreaseInDepositsAndOtherAssets" id="Fact_d8a8adabe5094e459f17ea01449c70d7" contextRef="c20240101to20241231" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">15</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><ix:nonFraction name="adma:IncreaseDecreaseInDepositsAndOtherAssets" id="Fact_02b855e13667495cb128769a18a834d7" contextRef="c20230101to20231231" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">1,080</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;"><ix:nonFraction name="adma:IncreaseDecreaseInDepositsAndOtherAssets" id="Fact_e3cd7802bf4a48d997158eae7d4f067c" contextRef="c20220101to20221231" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">122</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="vertical-align: top; width: 64%;">
                <p style="margin: 0px 0px 0px 30px;">Accounts payable</p>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayable" id="Fact_d8ebd70a203845e896e21b7e332bb9e2" contextRef="c20240101to20241231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,150</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayable" id="Fact_1f545f8f2cdd4b38a7f3305d867169a8" contextRef="c20230101to20231231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,839</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayable" id="Fact_f0046a7804044f4c8e3021a6e6df4e0a" contextRef="c20220101to20221231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">800</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="vertical-align: top; width: 64%; background-color: #CCEEFF;">
                <p style="margin: 0px 0px 0px 30px;">Accrued expenses</p>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccruedLiabilities" id="Fact_69847d4661a848fd88d5eb5878b1ca90" contextRef="c20240101to20241231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,042</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccruedLiabilities" id="Fact_9a569cc34bc04c90971ff3e84ee5c7a9" contextRef="c20230101to20231231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">7,530</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccruedLiabilities" id="Fact_354be84296884a869e515478e678e9fa" contextRef="c20220101to20221231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">7,534</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="vertical-align: top; width: 64%; padding-bottom: 2px;">
                <p style="margin: 0px 0px 0px 30px;">Other current and non-current liabilities</p>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" id="Fact_4f3b1e89ec5f400da9ca494def09052c" contextRef="c20240101to20241231" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">1,144</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">)</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" id="Fact_eb2949933541432c8b63e21187b3409e" contextRef="c20230101to20231231" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">791</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">)</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" id="Fact_6c55065b50174b10bcd0c55be8a37bab" contextRef="c20220101to20221231" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">502</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">)</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="vertical-align: top; width: 64%; padding-bottom: 2px; background-color: #CCEEFF;">
                <p style="margin: 0px 0px 0px 30px;">Net cash provided by (used in) operating activities</p>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" id="Fact_6cad2392826444ce85e31b8c8896fcf9" contextRef="c20240101to20241231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">118,672</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" id="Fact_f704cb8ae12947a08d164df6022c107c" contextRef="c20230101to20231231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">8,800</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" id="Fact_cb962bcbf8094179b698e74d7aa764bc" contextRef="c20220101to20221231" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">59,508</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">)</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="width: 64%;">
                <p style="margin: 0px;">&#160;</p>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="vertical-align: top; width: 64%; background-color: #CCEEFF;">
                <p style="margin: 0px 0px 0px 0in;"><strong>CASH FLOWS FROM INVESTING ACTIVITIES:</strong></p>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="vertical-align: top; width: 64%;">
                <p style="margin-top: 0px; margin-bottom: 0px; margin-left: 18pt;">Purchase of property and equipment</p>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">(<ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" id="Fact_6abf001b5532488299b7d3ccebce13be" contextRef="c20240101to20241231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">8,226</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">)</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">(<ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" id="Fact_fe6b1d83c3fa43b7a821dbd468d22f0e" contextRef="c20230101to20231231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,771</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">)</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">(<ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" id="Fact_2a7b8b67379340728b1100d95c7d06c6" contextRef="c20220101to20221231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">13,911</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">)</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" rowspan="1" style="vertical-align: top; width: 64%; padding-bottom: 2px; background-color: #CCEEFF;">
                <div>
                  <div>
                    <div style="margin-left: 18pt;">Acquisition of intangible assets<br/>
                    </div>
                  </div>
                </div>
              </td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">(<ix:nonFraction name="us-gaap:PaymentsToAcquireIntangibleAssets" id="Fact_bf2276a47e8c4ebeafeb890ddf6a963d" contextRef="c20240101to20241231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">349</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">)</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">(<ix:nonFraction name="us-gaap:PaymentsToAcquireIntangibleAssets" id="Fact_bdacd63424c4493884a956c4ef2b89b0" contextRef="c20230101to20231231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">210</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">)</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;"><ix:nonFraction name="us-gaap:PaymentsToAcquireIntangibleAssets" id="Fact_bdfef01d52534d5ba716e3ea3f56a6f1" contextRef="c20220101to20221231" unitRef="U001" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="vertical-align: top; width: 64%; padding-bottom: 2px;">
                <p style="margin-top: 0px; margin-bottom: 0px; margin-left: 18pt;">Net cash used in investing activities</p>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" id="Fact_ac7f86b39caa44bd959cd8dc70acd72c" contextRef="c20240101to20241231" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">8,575</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">)</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" id="Fact_f7a51116283f49caa2038cda74415fec" contextRef="c20230101to20231231" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">4,981</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">)</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" id="Fact_56a0b20d5170410ca782b52082995c99" contextRef="c20220101to20221231" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">13,911</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">)</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="width: 64%; background-color: #CCEEFF;">
                <p style="margin: 0px;">&#160;</p>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="vertical-align: top; width: 64%;">
                <p style="margin: 0px 0px 0px 0in;"><strong>CASH FLOWS FROM FINANCING ACTIVITIES:</strong></p>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="vertical-align: top; width: 64%; background-color: #CCEEFF;">
                <p style="margin-top: 0px; margin-bottom: 0px; margin-left: 18pt;">Principal payments on notes payable</p>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">(<ix:nonFraction name="us-gaap:RepaymentsOfNotesPayable" id="Fact_364b022883ef46828e0534c35447a69a" contextRef="c20240101to20241231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">60,000</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">)</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">(<ix:nonFraction name="us-gaap:RepaymentsOfNotesPayable" id="Fact_a6840b4dab694e7f8a989fee88640a50" contextRef="c20230101to20231231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">158,584</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">)</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">(<ix:nonFraction name="us-gaap:RepaymentsOfNotesPayable" id="Fact_61376d9fb5ce4451ae5d209729c2356c" contextRef="c20220101to20221231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">100,000</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">)</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="vertical-align: top; width: 64%;">
                <p style="margin-top: 0px; margin-bottom: 0px; margin-left: 18pt;">Proceeds from issuance of common stock, net of offering expenses</p>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" id="Fact_38eb9b07eeae4ab784fb39b386c4703b" contextRef="c20240101to20241231" unitRef="U001" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" id="Fact_414099d5f3b24dc4b410d81cb4822ec5" contextRef="c20230101to20231231" unitRef="U001" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" id="Fact_a554f1b0e0444d42867329005248bd55" contextRef="c20220101to20221231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">64,645</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="vertical-align: top; width: 64%; background-color: #CCEEFF;">
                <p style="margin-top: 0px; margin-bottom: 0px; margin-left: 18pt;">Prepayment penalties on repayment of debt<br/>
                </p>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">(<ix:nonFraction name="adma:PaymentOfDebtRefinancingFees" id="Fact_aca301fa4fcb45208de42cbb0ae0a543" contextRef="c20240101to20241231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">450</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">)</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">(<ix:nonFraction name="adma:PaymentOfDebtRefinancingFees" id="Fact_1282ee9fa6af4ac395c9211a7175e2e1" contextRef="c20230101to20231231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">11,140</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">)</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">(<ix:nonFraction name="adma:PaymentOfDebtRefinancingFees" id="Fact_bcd173c6f8d84d399c842a73abae4750" contextRef="c20220101to20221231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,000</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">)</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="vertical-align: top; width: 64%;">
                <p style="margin-top: 0px; margin-bottom: 0px; margin-left: 18pt;">Proceeds from issuance of note payable</p>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;"><ix:nonFraction name="us-gaap:ProceedsFromNotesPayable" id="Fact_b6b11e3e07894e3989a64c5cc40ae9d7" contextRef="c20240101to20241231" unitRef="U001" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;"><ix:nonFraction name="us-gaap:ProceedsFromNotesPayable" id="Fact_40d3694266624e35b2913a8847481059" contextRef="c20230101to20231231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">135,000</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;"><ix:nonFraction name="us-gaap:ProceedsFromNotesPayable" id="Fact_ca04129c096b491b940347184e402de3" contextRef="c20220101to20221231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">151,750</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" rowspan="1" style="vertical-align: top; width: 64%; background-color: #CCEEFF;">
                <p style="margin-top: 0px; margin-bottom: 0px; margin-left: 18pt;">Taxes paid on vested Restricted Stock Units</p>
              </td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">(<ix:nonFraction name="adma:TaxesPaidOnVestedRestrictedStockUnits" id="Fact_565d503174ed4445900bf7a975e5f5a2" contextRef="c20240101to20241231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,971</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">)</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">(<ix:nonFraction name="adma:TaxesPaidOnVestedRestrictedStockUnits" id="Fact_1d8ee1ce932645c0a013907689f8004a" contextRef="c20230101to20231231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,415</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">)</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">(<ix:nonFraction name="adma:TaxesPaidOnVestedRestrictedStockUnits" id="Fact_dc8de57eff954f658914b4e23311901d" contextRef="c20220101to20221231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,899</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">)</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="vertical-align: top; width: 64%;">
                <p style="margin-top: 0px; margin-bottom: 0px; margin-left: 18pt;">Payments on finance lease obligations</p>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;"><ix:nonFraction name="us-gaap:FinanceLeasePrincipalPayments" id="Fact_dba53f2ea537473d81f35a0ee9aba9fc" contextRef="c20240101to20241231" unitRef="U001" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">(<ix:nonFraction name="us-gaap:FinanceLeasePrincipalPayments" id="Fact_a99d6ae8351546fa99b5969ac5b329e9" contextRef="c20230101to20231231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">17</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">)</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">(<ix:nonFraction name="us-gaap:FinanceLeasePrincipalPayments" id="Fact_190f85e762d84d4c97af77713957c3f7" contextRef="c20220101to20221231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">36</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">)</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" rowspan="1" style="vertical-align: top; width: 64%; background-color: #CCEEFF;">
                <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; margin-left: 18pt;">Net proceeds from the exercise of stock options</div>
              </td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><ix:nonFraction name="us-gaap:ProceedsFromStockOptionsExercised" id="Fact_462eb58d67364e309b90fd056393c990" contextRef="c20240101to20241231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">7,494</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><ix:nonFraction name="us-gaap:ProceedsFromStockOptionsExercised" id="Fact_6492be3a19d54a1dbf35dcd4257411a8" contextRef="c20230101to20231231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,104</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;"><ix:nonFraction name="us-gaap:ProceedsFromStockOptionsExercised" id="Fact_abe2c49bf26e466ab11110cd5dcf86c4" contextRef="c20220101to20221231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">175</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" rowspan="1" style="vertical-align: top; width: 64%;">
                <div>
                  <div>
                    <div style="margin-left: 18pt;">Payment of end of term fee<br/>
                    </div>
                  </div>
                </div>
              </td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">(<ix:nonFraction name="adma:PaymentOfEndOfTermFee" id="Fact_785546c6344542f591f943f775446721" contextRef="c20240101to20241231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">375</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">)</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">(<ix:nonFraction name="adma:PaymentOfEndOfTermFee" id="Fact_fc5cdbc5a4884427a562ddec49f06c27" contextRef="c20230101to20231231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,586</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">)</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;"><ix:nonFraction name="adma:PaymentOfEndOfTermFee" id="Fact_9be6f73500624ae8876a00999ef056dd" contextRef="c20220101to20221231" unitRef="U001" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" rowspan="1" style="vertical-align: top; width: 64%; padding-bottom: 2px; background-color: #CCEEFF;">
                <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; margin-left: 18pt;">Payment of deferred financing fees</div>
              </td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><ix:nonFraction name="us-gaap:PaymentsOfFinancingCosts" id="Fact_335b0edd2478421b9cf63abb40edeb9b" contextRef="c20240101to20241231" unitRef="U001" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">(<ix:nonFraction name="us-gaap:PaymentsOfFinancingCosts" id="Fact_34a9c1887fce4c609c0f7e130f1d98b9" contextRef="c20230101to20231231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,351</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">)</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">(<ix:nonFraction name="us-gaap:PaymentsOfFinancingCosts" id="Fact_be16c95103b64f70961b109417f39f0e" contextRef="c20220101to20221231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,783</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">)</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="vertical-align: top; width: 64%; padding-bottom: 2px;">
                <p style="margin-top: 0px; margin-bottom: 0px; margin-left: 18pt;">Net cash (used in) provided by financing activities</p>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" id="Fact_a00311f2fc384f59863011980c10251a" contextRef="c20240101to20241231" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">58,302</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">)</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" id="Fact_f04b16306a204fdb8a3e075dbe55d84b" contextRef="c20230101to20231231" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">38,989</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">)</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" id="Fact_8aa9bb01d3ee4f0eb0ce34a4957493c0" contextRef="c20220101to20221231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">108,852</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="width: 64%; background-color: #CCEEFF;">
                <p style="margin: 0px;">&#160;</p>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="vertical-align: top; width: 64%;">
                <div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Net increase (decrease) in cash and cash equivalents</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" id="Fact_b6eedd3f6bd740c1a4105460c0141845" contextRef="c20240101to20241231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">51,795</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">(<ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" id="Fact_9aaf34310e8540c58f1ca4e78ef8b892" contextRef="c20230101to20231231" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">35,170</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">)</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" id="Fact_d1bed04c4196465e9feec2e77c31c347" contextRef="c20220101to20221231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">35,433</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="vertical-align: top; width: 64%; padding-bottom: 2px; background-color: #CCEEFF;">
                <p style="margin: 0px 0px 0px 0in;"><strong>Cash and cash equivalents - beginning of year</strong></p>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" id="Fact_87e8086a42f74fe497fe93492567be5d" contextRef="c20231231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">51,352</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" id="Fact_18a04f61a60541a3bc4dcaf1d930dd30" contextRef="c20221231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">86,522</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" id="Fact_33f22b16561c4f16a6f004b2f03238ea" contextRef="c20211231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">51,089</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="vertical-align: top; width: 64%; padding-bottom: 4px;">
                <p style="margin: 0px 0px 0px 0in;"><strong>Cash and cash equivalents - end of year</strong></p>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;">$</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" id="Fact_a1dac8c7935a4c5fac7a44c0abb65547" contextRef="c20241231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">103,147</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;">$</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" id="Fact_5ea6f406df8845689101d89ae70ecaea" contextRef="c20231231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">51,352</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;">$</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" id="Fact_9e603a16150443abbb8de73eed3f81bd" contextRef="c20221231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">86,522</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">&#160;</td>

  </tr>


</table>
        <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;">&#160; &#160;</p>
        <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: center;">The accompanying notes are an integral part of these consolidated financial statements. </p>
        <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: left;">&#160; </p>
        <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
          <div class="BRPFPageNumberArea" style="text-align: center;"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">F-11</span></div>

          <div class="BRPFPageBreak" style="page-break-after: always;">
            <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"/></div>

          <div class="BRPFPageHeader" style="width: 100%;">
            <div>
              <div style="text-align: left; font-weight: bold; text-indent: -9pt; margin-left: 9pt;"><a href="#ADMABIOLOGICSINC."> <span style="font-style: italic; font-weight: normal; font-size: 8pt;">Table of Contents</span></a><br/>
              </div>

            </div>

          </div>

        </div>

        <!--PROfilePageNumberReset%Num%8%F-%%--> </div>

    </div>

  </div>


  <div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: rgb(0, 0, 0);">
    <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">ADMA BIOLOGICS, INC. AND SUBSIDIARIES</div>

    <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><!--Anchor--><!--Anchor--><!--Anchor--><a id="NOTES"><!--Anchor--></a>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</div>

    <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
    </div>

    <div>
      <div style="text-align: left; font: 10pt 'Times New Roman';">
        <ix:nonNumeric name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" id="Text_bc8b2ab4f01b481a8021ac1c87a4e540" contextRef="c20240101to20241231" escape="true" continuedAt="Text_f3082b0503eb4de699e8be9db08b50551">
<div>
          <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt; border-spacing: 0;">


  <tr style="vertical-align: top;">

    <td style="vertical-align: top; width: 27pt;">
                  <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: left;"><strong>1.</strong></p>
                </td>

    <td style="align: left; vertical-align: top; width: auto;">
                  <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: left;"><strong><span style="text-decoration: underline;">ORGANIZATION AND BUSINESS</span></strong></p>
                </td>

  </tr>


</table>
        </div>
</ix:nonNumeric>
        <ix:continuation id="Text_f3082b0503eb4de699e8be9db08b50551" continuedAt="Text_f3082b0503eb4de699e8be9db08b50552">
<div><br/></div>
</ix:continuation>
        <ix:continuation id="Text_f3082b0503eb4de699e8be9db08b50552" continuedAt="Text_f3082b0503eb4de699e8be9db08b50553"><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-indent: 45px; text-align: left;">ADMA Biologics, Inc. (&#8220;ADMA&#8221; or the &#8220;Company&#8221;) is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing
          and developing specialty biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The Company&#8217;s targeted patient populations include immune-compromised individuals who
          suffer from an underlying immune deficiency disorder or who may be immune-suppressed for medical reasons.</p></ix:continuation>
        <ix:continuation id="Text_f3082b0503eb4de699e8be9db08b50553" continuedAt="Text_f3082b0503eb4de699e8be9db08b50554"><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-indent: 45px; text-align: left;"><br/>
        </p></ix:continuation>
        <ix:continuation id="Text_f3082b0503eb4de699e8be9db08b50554" continuedAt="Text_f3082b0503eb4de699e8be9db08b50555"><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-indent: 45px; text-align: left;">ADMA operates through its wholly-owned subsidiaries ADMA BioManufacturing, LLC (&#8220;ADMA BioManufacturing&#8221;) and ADMA BioCenters Georgia Inc.
          (&#8220;ADMA BioCenters&#8221;). ADMA BioManufacturing was formed in January 2017 to facilitate the acquisition of certain assets held by the Company&#8217;s former third-party contract manufacturer, which included the U.S. Food and Drug Administration
          (&#8220;FDA&#8221;)-licensed BIVIGAM and Nabi-HB immunoglobulin products, and an FDA-licensed plasma fractionation manufacturing facility located in Boca Raton, FL (the &#8220;Boca Facility&#8221;). ADMA BioCenters is the Company&#8217;s source plasma collection business with
          <ix:nonFraction name="adma:NumberOfFDALicensedPlasmaCollectionFacilities" id="Fact_47d59e153b5b4569b8bbc893e294a40f" contextRef="c20240101to20241231" unitRef="U004" decimals="INF" scale="0" format="ixt-sec:numwordsen">ten</ix:nonFraction> plasma collection facilities located throughout the U.S., all of which hold an approved license with the FDA.</p></ix:continuation>
        <ix:continuation id="Text_f3082b0503eb4de699e8be9db08b50555" continuedAt="Text_f3082b0503eb4de699e8be9db08b50556"><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-indent: 45px; text-align: left;"><br/>
        </p></ix:continuation>
        <ix:continuation id="Text_f3082b0503eb4de699e8be9db08b50556"><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-indent: 45px; text-align: left;">The Company has <ix:nonFraction name="adma:NumberOfFDAApprovedProduct" id="Fact_92b435a310ae4071b48979b882fbf4b0" contextRef="c20240101to20241231" unitRef="U005" decimals="INF" scale="0" format="ixt-sec:numwordsen">three</ix:nonFraction>
          FDA-approved products, all of which are currently marketed and commercially available: (i) <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: left; text-indent: 45px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">ASCENIV (Immune Globulin Intravenous, Human &#8211; slra 10% Liquid), an intravenous immune globulin (&#8220;IVIG&#8221;) product indicated for the treatment of Primary Humoral Immunodeficiency (&#8220;PI&#8221;), also known as Primary
            Immunodeficiency Disease (&#8220;PIDD&#8221;) or Inborn Errors of Immunity, for which the Company received FDA approval on April 1, 2019 and commenced first commercial sales in October 2019; (ii) BIVIGAM (Immune Globulin Intravenous, Human), an IVIG
            product indicated for the treatment of PI, and for which the Company received FDA approval on May 9, 2019 and commenced commercial sales in August 2019;&#160; and (iii) Nabi-HB (Hepatitis B Immune Globulin, Human), which is indicated for the
            treatment of acute exposure to blood containing Hepatitis B surface antigen (&#8220;HBsAg&#8221;) and other listed exposures to Hepatitis B. In addition to its commercially available immunoglobulin products, the Company generates revenues from the sale of
            intermediate by-products that result from the immunoglobulin production process and from time to time provides contract manufacturing and laboratory services for certain clients. The Company seeks to develop a pipeline of plasma-derived
            therapeutics, and its products and product candidates are intended to be used by physician specialists focused on caring for immune-compromised patients with or at risk for certain infectious diseases</span>.</p></ix:continuation>

        <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;">&#160;</p>
      </div>

    </div>

  </div>


  <div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: rgb(0, 0, 0);"> <div><span style="font-family: 'Times New Roman'; font-size: 10pt;"> </span></div>

    <div>
      <div style="text-align: left; font: 10pt 'Times New Roman';">
        <ix:nonNumeric name="us-gaap:SignificantAccountingPoliciesTextBlock" id="Text_f55c9b9ba1a3493492e762fba0f4466c" contextRef="c20240101to20241231" escape="true" continuedAt="Text_63aa8b379f274e8cb46d81d1852d31941">
<div>
          <table cellspacing="0" cellpadding="0" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt; border-spacing: 0;" class="DSPFListTable">


  <tr style="vertical-align: top;">

    <td style="vertical-align: top; width: 27pt;">
                  <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;"><strong>2.</strong></p>
                </td>

    <td style="align: left; vertical-align: top; width: auto;">
                  <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;"><strong><span style="text-decoration: underline;">SIGNIFICANT ACCOUNTING POLICIES</span></strong></p>
                </td>

  </tr>


</table>
        </div>
</ix:nonNumeric>
        <ix:continuation id="Text_63aa8b379f274e8cb46d81d1852d31941" continuedAt="Text_63aa8b379f274e8cb46d81d1852d31942"><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;"><span style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
          </span> </p></ix:continuation>

        <ix:nonNumeric name="us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" id="Text_3754daa7e856458586d1a364d9ab905f" contextRef="c20240101to20241231" escape="true" continuedAt="Text_abb4c4fbc6164e06a223c066a1d9e7ae1"><ix:continuation id="Text_63aa8b379f274e8cb46d81d1852d31942" continuedAt="Text_63aa8b379f274e8cb46d81d1852d31943"><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;"><span style="text-decoration:underline">Principles of consolidation and basis of presentation</span></p></ix:continuation></ix:nonNumeric>
        <ix:continuation id="Text_abb4c4fbc6164e06a223c066a1d9e7ae1" continuedAt="Text_abb4c4fbc6164e06a223c066a1d9e7ae2"><ix:continuation id="Text_63aa8b379f274e8cb46d81d1852d31943" continuedAt="Text_63aa8b379f274e8cb46d81d1852d31944"><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;">&#160;</p></ix:continuation></ix:continuation>
        <ix:continuation id="Text_abb4c4fbc6164e06a223c066a1d9e7ae2" continuedAt="Text_abb4c4fbc6164e06a223c066a1d9e7ae3"><ix:continuation id="Text_63aa8b379f274e8cb46d81d1852d31944" continuedAt="Text_63aa8b379f274e8cb46d81d1852d31945"><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-indent: 45px; text-align: left;">The accompanying consolidated financial statements include the accounts of ADMA and its wholly-owned subsidiaries and have been prepared
          in conformity with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;) and in accordance with Article 3 of Regulation S-X of the Securities and Exchange Commission (the &#8220;SEC&#8221;). All intercompany balances have
          been eliminated in consolidation. Any reference in these notes to applicable guidance is meant to refer to U.S. GAAP as found in the Accounting Standards Codification (&#8220;ASC&#8221;) and Accounting Standards Updates (&#8220;ASU&#8221;) of the Financial Accounting
          Standards Board (the &#8220;FASB&#8221;). </p></ix:continuation></ix:continuation>
        <ix:continuation id="Text_abb4c4fbc6164e06a223c066a1d9e7ae3" continuedAt="Text_abb4c4fbc6164e06a223c066a1d9e7ae4"><ix:continuation id="Text_63aa8b379f274e8cb46d81d1852d31945" continuedAt="Text_63aa8b379f274e8cb46d81d1852d31946"><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-indent: 45px; text-align: left;"> <span style="font-size: 10pt; font-family: 'Times New Roman';"><br/>
          </span></p></ix:continuation></ix:continuation>
        <ix:continuation id="Text_abb4c4fbc6164e06a223c066a1d9e7ae4"><ix:continuation id="Text_63aa8b379f274e8cb46d81d1852d31946" continuedAt="Text_63aa8b379f274e8cb46d81d1852d31947"><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-indent: 45px; text-align: left;">During the years ended December 31, 2024, 2023 and 2022, <span style="font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">comprehensive income (loss) was equal to the net income (loss) amounts presented for the respective periods in the accompanying consolidated statements of operations.&#160;</span><span style="font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial;">In addition, certain prior year balances have been reclassified to conform to the current presentation. Specifically, the disaggregation of some of the Company&#8217;s accrued expenses and other current liabilities
            (see Note 6) and deferred tax assets and liabilities, as well as the rate reconciliation for U.S. federal income taxes (see Note 11), as of December 31, 2023 have been adjusted to conform to the presentation as of December 31, 2024</span>.</p></ix:continuation></ix:continuation>

        <ix:continuation id="Text_63aa8b379f274e8cb46d81d1852d31947" continuedAt="Text_63aa8b379f274e8cb46d81d1852d31948"><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-indent: 45px; text-align: left;"> </p></ix:continuation>
        <ix:continuation id="Text_63aa8b379f274e8cb46d81d1852d31948" continuedAt="Text_63aa8b379f274e8cb46d81d1852d31949"><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;"><span style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
          </span> </p></ix:continuation>
        <ix:continuation id="Text_63aa8b379f274e8cb46d81d1852d31949" continuedAt="Text_63aa8b379f274e8cb46d81d1852d319410"><ix:nonNumeric name="us-gaap:UseOfEstimates" id="Text_39934c12f03e4ae29b1b729042ad214d" contextRef="c20240101to20241231" escape="true" continuedAt="Text_1033bc4a9574480aa5d4d34155c256591">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt;"><span style="text-decoration: underline;"></span></span></div>
</ix:nonNumeric></ix:continuation></div>

      <div style="text-align: left; font: 10pt 'Times New Roman';">
        <ix:continuation id="Text_63aa8b379f274e8cb46d81d1852d319410" continuedAt="Text_63aa8b379f274e8cb46d81d1852d319411"><ix:continuation id="Text_1033bc4a9574480aa5d4d34155c256591" continuedAt="Text_1033bc4a9574480aa5d4d34155c256592"><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 9pt; text-indent: -9pt; text-align: left;"><span style="text-decoration: underline;">Use of estimates</span></p></ix:continuation></ix:continuation>
        <ix:continuation id="Text_63aa8b379f274e8cb46d81d1852d319411" continuedAt="Text_63aa8b379f274e8cb46d81d1852d319412"><ix:continuation id="Text_1033bc4a9574480aa5d4d34155c256592" continuedAt="Text_1033bc4a9574480aa5d4d34155c256593"><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 9pt; text-indent: -9pt; text-align: left;"> <span style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
          </span> </p></ix:continuation></ix:continuation>
        <ix:continuation id="Text_63aa8b379f274e8cb46d81d1852d319412" continuedAt="Text_63aa8b379f274e8cb46d81d1852d319413"><ix:continuation id="Text_1033bc4a9574480aa5d4d34155c256593" continuedAt="Text_1033bc4a9574480aa5d4d34155c256594"><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-indent: 45px; text-align: left;">The preparation of financial statements requires management to make estimates and assumptions that affect the reported amounts of assets
          and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.
          Significant estimates include rebates and chargebacks deducted from gross revenues, assumptions used in the fair value of awards granted under the Company&#8217;s equity incentive plans and the valuation allowance for the Company&#8217;s deferred tax assets.</p></ix:continuation></ix:continuation>
        <ix:continuation id="Text_63aa8b379f274e8cb46d81d1852d319413" continuedAt="Text_63aa8b379f274e8cb46d81d1852d319414"><ix:continuation id="Text_1033bc4a9574480aa5d4d34155c256594" continuedAt="Text_1033bc4a9574480aa5d4d34155c256595"><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-indent: 45px; text-align: left;"><span style="font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"> <br/>
          </span></p></ix:continuation></ix:continuation>
        <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
          <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">F-12</span></div>

          <div class="BRPFPageBreak" style="page-break-after: always;">
            <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"/></div>

          <div style="width: 100%;" class="BRPFPageHeader">
            <div>
              <div style="text-align: left; font-weight: bold; text-indent: -9pt; margin-left: 9pt;"><a href="#ADMABIOLOGICSINC."> <span style="font-style: italic; font-weight: normal; font-size: 8pt;">Table of Contents</span></a><br/>
              </div>

              <div style="text-align: left; font-weight: bold; text-indent: -9pt; margin-left: 9pt;"><a href="#ADMABIOLOGICSINC."><span style="font-style: italic; font-weight: normal; font-size: 8pt;"> <br/>
                  </span></a></div>

              <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">ADMA BIOLOGICS, INC. AND SUBSIDIARIES</div>

              <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</div>

            </div>

          </div>

        </div>

        <ix:continuation id="Text_63aa8b379f274e8cb46d81d1852d319414" continuedAt="Text_63aa8b379f274e8cb46d81d1852d319415"><ix:continuation id="Text_1033bc4a9574480aa5d4d34155c256595"><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-indent: 45px; text-align: left; font-weight: normal; font-style: normal; font-variant: normal; text-transform: none;"><span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; text-align: left; text-indent: 48px; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">The
            Company engaged a third-party specialist to assist in the evaluation of the Company&#8217;s accrual for U.S. Medicaid rebates related to the sale of the Company&#8217;s immunoglobulin products. As a result of this evaluation, the Company recognized a
            reduction in this accrual and a corresponding increase to net revenues of $<ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_ce16ab952e4044458b0765a4689d3a37" contextRef="c20240101to20241231_ChangeInAccountingEstimateByTypeAxis_AccrualForUSMedicaidRebatesMember" unitRef="U001" decimals="-5" scale="6" format="ixt:num-dot-decimal">12.6</ix:nonFraction> million for the year ended December 31, 2024. The
            Company considered several qualitative factors when evaluating its rebate accrual, such as the absence of a statutory limitation on the rebate amounts drug manufacturers pay to state Medicaid programs and general uncertainty that pharmaceutical
            manufacturers have historically seen with government payors often submitting lagged claims many periods after the initial dispensing of a product to an end patient. There was additional new information that arose during June 2024 that suggested
            the Company&#8217;s liabilities for certain payor claims were successfully resolved, which resulted in the $<ix:nonFraction name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" id="Fact_c72074835f594a39b8d474724f6931d9" contextRef="c20241231_ChangeInAccountingEstimateByTypeAxis_AccrualForUSMedicaidRebatesMember" unitRef="U001" decimals="-5" scale="6" format="ixt:num-dot-decimal">12.6</ix:nonFraction> million adjustment to the
            accrual for U.S. Medicaid rebates in June 2024.</span></p></ix:continuation></ix:continuation>

        <ix:continuation id="Text_63aa8b379f274e8cb46d81d1852d319415" continuedAt="Text_63aa8b379f274e8cb46d81d1852d319416"><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;">&#160;</p></ix:continuation>

        <ix:nonNumeric name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="Text_d17c6fece48a455da94ca52ef400c45d" contextRef="c20240101to20241231" escape="true" continuedAt="Text_164dc39dda12402fba2bbc6458ff1dab1"><ix:continuation id="Text_63aa8b379f274e8cb46d81d1852d319416" continuedAt="Text_63aa8b379f274e8cb46d81d1852d319417"><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;"><span style="text-decoration:underline">Cash and cash equivalents</span></p></ix:continuation></ix:nonNumeric>
        <ix:continuation id="Text_164dc39dda12402fba2bbc6458ff1dab1" continuedAt="Text_164dc39dda12402fba2bbc6458ff1dab2"><ix:continuation id="Text_63aa8b379f274e8cb46d81d1852d319417" continuedAt="Text_63aa8b379f274e8cb46d81d1852d319418"><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;">&#160;</p></ix:continuation></ix:continuation>
        <ix:continuation id="Text_164dc39dda12402fba2bbc6458ff1dab2" continuedAt="Text_164dc39dda12402fba2bbc6458ff1dab3"><ix:continuation id="Text_63aa8b379f274e8cb46d81d1852d319418" continuedAt="Text_63aa8b379f274e8cb46d81d1852d319419"><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-indent: 45px; text-align: left;">The Company considers all highly liquid instruments purchased with a maturity of three months or less to be cash equivalents. </p></ix:continuation></ix:continuation>
        <ix:continuation id="Text_164dc39dda12402fba2bbc6458ff1dab3" continuedAt="Text_164dc39dda12402fba2bbc6458ff1dab4"><ix:continuation id="Text_63aa8b379f274e8cb46d81d1852d319419" continuedAt="Text_63aa8b379f274e8cb46d81d1852d319420">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
        </span></div>
</ix:continuation></ix:continuation>
        <ix:continuation id="Text_164dc39dda12402fba2bbc6458ff1dab4"><ix:continuation id="Text_63aa8b379f274e8cb46d81d1852d319420" continuedAt="Text_63aa8b379f274e8cb46d81d1852d319421"><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-indent: 45px; text-align: left;">The Company regularly maintains cash and cash equivalents at third-party financial institutions in excess of the Federal Deposit Insurance
          Corporation insurance limit. Although the Company monitors the daily cash balances in its operating accounts and adjusts the balances as appropriate, these balances could be impacted, and there could be a material adverse effect on the Company&#8217;s
          business, if one or more of the financial institutions with which the Company has deposits fails or is subject to other adverse conditions in the financial or credit markets. To date, the Company has not experienced a loss or lack of access to
          its deposited cash or cash equivalents; however, the Company cannot provide assurance that access to its cash and cash equivalents will not be impacted by adverse conditions in the financial and credit markets in the future.</p></ix:continuation></ix:continuation>

        <ix:continuation id="Text_63aa8b379f274e8cb46d81d1852d319421" continuedAt="Text_63aa8b379f274e8cb46d81d1852d319422"><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;"><span style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
          </span> </p></ix:continuation>

        <ix:nonNumeric name="us-gaap:ReceivablesPolicyTextBlock" id="Text_e6c40437b8c84bd5882b6bfd34f4f709" contextRef="c20240101to20241231" escape="true" continuedAt="Text_39fb30de4d564240ad265743281221f51"><ix:continuation id="Text_63aa8b379f274e8cb46d81d1852d319422" continuedAt="Text_63aa8b379f274e8cb46d81d1852d319423"><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;"><span style="text-decoration:underline">Accounts receivable</span></p></ix:continuation></ix:nonNumeric>
        <ix:continuation id="Text_39fb30de4d564240ad265743281221f51" continuedAt="Text_39fb30de4d564240ad265743281221f52"><ix:continuation id="Text_63aa8b379f274e8cb46d81d1852d319423" continuedAt="Text_63aa8b379f274e8cb46d81d1852d319424"><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;">&#160;</p></ix:continuation></ix:continuation>
        <ix:continuation id="Text_39fb30de4d564240ad265743281221f52"><ix:continuation id="Text_63aa8b379f274e8cb46d81d1852d319424" continuedAt="Text_63aa8b379f274e8cb46d81d1852d319425"><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-indent: 45px; text-align: left;"><span style="font-family: 'Times New Roman'; font-size: 10pt;">Accounts receivable is reported at realizable value, net of allowances for
            contractual credits and doubtful accounts in the amount of $<ix:nonFraction name="adma:AccountsReceivableAllowanceForContractualCreditsAndDoubtfulAccounts" id="Fact_fc8700678ba34ca2a530323c463be289" contextRef="c20241231" unitRef="U001" decimals="-5" scale="6" format="ixt:num-dot-decimal">0.2</ix:nonFraction> million and $<ix:nonFraction name="adma:AccountsReceivableAllowanceForContractualCreditsAndDoubtfulAccounts" id="Fact_cb99e23b4dbb428ea10b8aa366f8a86c" contextRef="c20231231" unitRef="U001" decimals="-5" scale="6" format="ixt:num-dot-decimal">0.1</ix:nonFraction> million at December 31, 2024 and 2023, respectively, which are recognized in the period the related revenue is recorded. The Company extends credit to its customers
            based upon an evaluation of each customer&#8217;s financial condition and credit history. Evaluations of the financial condition and associated credit risk of customers are performed on an ongoing basis.<br/>
          </span> </p></ix:continuation></ix:continuation>

        <ix:continuation id="Text_63aa8b379f274e8cb46d81d1852d319425" continuedAt="Text_63aa8b379f274e8cb46d81d1852d319426"><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;"><span style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
          </span> </p></ix:continuation>

        <ix:nonNumeric name="us-gaap:InventoryPolicyTextBlock" id="Text_f6f5e5fc1c6d4b319280cb596c3a4d2a" contextRef="c20240101to20241231" escape="true" continuedAt="Text_ce187c954cc641b58dbd386ef29df81e1"><ix:continuation id="Text_63aa8b379f274e8cb46d81d1852d319426" continuedAt="Text_63aa8b379f274e8cb46d81d1852d319427"><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;"><span style="text-decoration:underline">Inventories</span></p></ix:continuation></ix:nonNumeric>
        <ix:continuation id="Text_ce187c954cc641b58dbd386ef29df81e1" continuedAt="Text_ce187c954cc641b58dbd386ef29df81e2"><ix:continuation id="Text_63aa8b379f274e8cb46d81d1852d319427" continuedAt="Text_63aa8b379f274e8cb46d81d1852d319428"><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;">&#160;</p></ix:continuation></ix:continuation>
        <ix:continuation id="Text_ce187c954cc641b58dbd386ef29df81e2" continuedAt="Text_ce187c954cc641b58dbd386ef29df81e3"><ix:continuation id="Text_63aa8b379f274e8cb46d81d1852d319428" continuedAt="Text_63aa8b379f274e8cb46d81d1852d319429"><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-indent: 45px; text-align: left;">Raw materials inventory consists of <span style="font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"><span style="font-weight: normal; font-style: normal; font-variant: normal; text-transform: none;">normal source plasma (&#8220;NSP&#8221;) and Respiratory Syncytial Virus (&#8220;RSV&#8221;) high titer plasma collected at the Company&#8217;s plasma collection
              facilities or purchased from third parties, along with</span> </span>various materials purchased from suppliers, used in the production of the Company&#8217;s products. Work-in-process and finished goods inventories (see Note 3) reflect the cost
          of raw materials as well as costs for direct and indirect labor, primarily salaries, wages and benefits for applicable employees, as well as an allocation of overhead costs related to the Boca Facility including utilities, property taxes, general
          repairs and maintenance, consumable supplies and depreciation. The allocation of Boca Facility overhead to inventory is generally based upon the estimated square footage of the Boca Facility that is used in the production of the Company&#8217;s
          products relative to the total square footage of the facility. </p></ix:continuation></ix:continuation>
        <ix:continuation id="Text_ce187c954cc641b58dbd386ef29df81e3" continuedAt="Text_ce187c954cc641b58dbd386ef29df81e4"><ix:continuation id="Text_63aa8b379f274e8cb46d81d1852d319429" continuedAt="Text_63aa8b379f274e8cb46d81d1852d319430"><p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-bottom: 0px; text-align: left;"> </p></ix:continuation></ix:continuation>
        <ix:continuation id="Text_ce187c954cc641b58dbd386ef29df81e4" continuedAt="Text_ce187c954cc641b58dbd386ef29df81e5"><ix:continuation id="Text_63aa8b379f274e8cb46d81d1852d319430" continuedAt="Text_63aa8b379f274e8cb46d81d1852d319431">
<div><br/></div>
</ix:continuation></ix:continuation>
        <ix:continuation id="Text_ce187c954cc641b58dbd386ef29df81e5"><ix:continuation id="Text_63aa8b379f274e8cb46d81d1852d319431" continuedAt="Text_63aa8b379f274e8cb46d81d1852d319432">
<div style="display:none;"><br/></div>
<div style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-indent: 45px; text-align: left;">Inventories, including plasma intended for resale and plasma intended for internal use in the Company&#8217;s manufacturing, commercialization
          or research and development activities, are carried at the lower of cost or net realizable value determined by the first-in, first-out method. For both the Company&#8217;s immune globulin products and plasma intended for resale and internal use, net
          realizable value is generally determined based upon the consideration the Company expects to receive when the inventory is sold, less costs to deliver the inventory to the recipient. The estimates for net realizable value of inventory are based
          on contractual terms or upon historical experience and certain other assumptions, and the Company believes that such assumptions are reasonable. Inventory is periodically reviewed to ensure that its carrying value does not exceed its net
          realizable value, and adjustments are recorded to write down such inventory, with a corresponding charge to cost of product revenue, when the carrying value or historical cost exceeds its estimated net realizable value. In addition, costs
          associated with the production of engineering lots that would not qualify as immediately available for commercial sale are charged to cost of product revenue and not capitalized into inventory.</div>
</ix:continuation></ix:continuation>

        <ix:continuation id="Text_63aa8b379f274e8cb46d81d1852d319432" continuedAt="Text_63aa8b379f274e8cb46d81d1852d319433"><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;"><span style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
          </span> </p></ix:continuation>
        <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
          <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">F-13</span></div>

          <div class="BRPFPageBreak" style="page-break-after: always;">
            <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"/></div>

          <div style="width: 100%;" class="BRPFPageHeader">
            <div>
              <div style="text-align: left; font-weight: bold; text-indent: -9pt; margin-left: 9pt;"><a href="#ADMABIOLOGICSINC."> <span style="font-style: italic; font-weight: normal; font-size: 8pt;">Table of Contents</span></a><br/>
              </div>

              <div style="text-align: left; font-weight: bold; text-indent: -9pt; margin-left: 9pt;"><a href="#ADMABIOLOGICSINC."><span style="font-style: italic; font-weight: normal; font-size: 8pt;"> <br/>
                  </span></a></div>

              <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">ADMA BIOLOGICS, INC. AND SUBSIDIARIES</div>

              <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</div>

            </div>

          </div>

        </div>


        <ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="Text_7868c3d564fa4c1e8147b54693ecfd11" contextRef="c20240101to20241231" escape="true" continuedAt="Text_0901f2a0b2874f2f8a2428a94da1c42e1"><ix:continuation id="Text_63aa8b379f274e8cb46d81d1852d319433" continuedAt="Text_63aa8b379f274e8cb46d81d1852d319434"><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;"><span style="text-decoration: underline; font-family: 'Times New Roman'; font-size: 10pt;">Property and equipment</span> </p></ix:continuation></ix:nonNumeric>
        <ix:continuation id="Text_0901f2a0b2874f2f8a2428a94da1c42e1" continuedAt="Text_0901f2a0b2874f2f8a2428a94da1c42e2"><ix:continuation id="Text_63aa8b379f274e8cb46d81d1852d319434" continuedAt="Text_63aa8b379f274e8cb46d81d1852d319435"><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;">&#160;</p></ix:continuation></ix:continuation>
        <ix:continuation id="Text_63aa8b379f274e8cb46d81d1852d319435" continuedAt="Text_63aa8b379f274e8cb46d81d1852d319436"><ix:continuation id="Text_0901f2a0b2874f2f8a2428a94da1c42e2"><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-indent: 45px; text-align: left;"><span style="font-family: 'Times New Roman'; font-size: 10pt;">Assets comprising property and equipment (see Note 4) are stated at cost
            less accumulated depreciation. Depreciation is calculated using the straight-line method over the asset&#8217;s estimated useful life. Land is not depreciated. The buildings have been assigned a useful life of <ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="Fact_8ea857edb33a42c7808a6a9b42eb12d0" contextRef="c20241231_PropertyPlantAndEquipmentByTypeAxis_BuildingMember" format="ixt-sec:durwordsen">30 years</ix:nonNumeric>. Property and equipment other than land and buildings have useful lives ranging from <ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="Fact_ecf4032f3e104ec89d255a3f03600b14" contextRef="c20241231_RangeAxis_MinimumMember" format="ixt-sec:duryear">3</ix:nonNumeric> to <ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="Fact_3b4b126ba1c941e78cd8f7354b299dd2" contextRef="c20241231_RangeAxis_MaximumMember" format="ixt-sec:durwordsen">15 years</ix:nonNumeric>. Leasehold improvements are amortized over the
            lesser of the lease term or their estimated useful lives.</span> </p></ix:continuation></ix:continuation>
        <ix:continuation id="Text_63aa8b379f274e8cb46d81d1852d319436" continuedAt="Text_63aa8b379f274e8cb46d81d1852d319437"><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;"><span style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
          </span> </p></ix:continuation>

        <ix:nonNumeric name="us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy" id="Text_00e559e88d2845e689436e9102998e31" contextRef="c20240101to20241231" escape="true" continuedAt="Text_b1217b092a8442dc859e25b14664ea711"><ix:continuation id="Text_63aa8b379f274e8cb46d81d1852d319437" continuedAt="Text_63aa8b379f274e8cb46d81d1852d319438"><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;"><span style="text-decoration:underline">Goodwill</span></p></ix:continuation></ix:nonNumeric>
        <ix:continuation id="Text_b1217b092a8442dc859e25b14664ea711" continuedAt="Text_b1217b092a8442dc859e25b14664ea712"><ix:continuation id="Text_63aa8b379f274e8cb46d81d1852d319438" continuedAt="Text_63aa8b379f274e8cb46d81d1852d319439"><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;">&#160;</p></ix:continuation></ix:continuation>
        <ix:continuation id="Text_b1217b092a8442dc859e25b14664ea712" continuedAt="Text_b1217b092a8442dc859e25b14664ea713"><ix:continuation id="Text_63aa8b379f274e8cb46d81d1852d319439" continuedAt="Text_63aa8b379f274e8cb46d81d1852d319440"><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-indent: 45px; text-align: left;">Goodwill represents the excess of purchase price over the fair value of net assets acquired by the Company. Goodwill at December 31, 2024
          and 2023 was $<ix:nonFraction name="us-gaap:Goodwill" id="Fact_f68aadafa9464ae0967f6c1fa756b42b" contextRef="c20241231" unitRef="U001" decimals="-5" scale="6" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:Goodwill" id="Fact_7a4d9aa6c5874c1f965f3ecca6ebbd27" contextRef="c20231231" unitRef="U001" decimals="-5" scale="6" format="ixt:num-dot-decimal">3.5</ix:nonFraction></ix:nonFraction> million, all of which is attributable to the Company&#8217;s ADMA BioManufacturing business segment. There were <ix:nonFraction name="us-gaap:GoodwillImpairmentLoss" id="Fact_f78a05ec586e4bb8a30fe31383a7e47c" contextRef="c20220101to20221231" unitRef="U001" decimals="-3" scale="3" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:GoodwillImpairmentLoss" id="Fact_b232bc9588ea49e5aecaa5c99300b09d" contextRef="c20240101to20241231" unitRef="U001" decimals="-3" scale="3" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:GoodwillImpairmentLoss" id="Fact_0467a3bcb4104afe8db57a7682d7e259" contextRef="c20230101to20231231" unitRef="U001" decimals="-3" scale="3" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></ix:nonFraction> changes to the carrying amount of goodwill during the years ended December 31, 2024, 2023 and 2022.</p></ix:continuation></ix:continuation>
        <ix:continuation id="Text_b1217b092a8442dc859e25b14664ea713" continuedAt="Text_b1217b092a8442dc859e25b14664ea714"><ix:continuation id="Text_63aa8b379f274e8cb46d81d1852d319440" continuedAt="Text_63aa8b379f274e8cb46d81d1852d319441">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt;"> &#160; </span></div>
</ix:continuation></ix:continuation>
        <ix:continuation id="Text_b1217b092a8442dc859e25b14664ea714"><ix:continuation id="Text_63aa8b379f274e8cb46d81d1852d319441" continuedAt="Text_63aa8b379f274e8cb46d81d1852d319442"><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-indent: 45px; text-align: left;">Goodwill is not amortized but is assessed for impairment on an annual basis or more frequently if impairment indicators exist. The Company
          has the option to perform a qualitative assessment of goodwill to determine whether it is more likely than not that the fair value of its reporting unit is less than its carrying amount, including goodwill and other intangible assets. If the
          Company concludes that this is the case, then it must perform a goodwill impairment test by comparing the fair value of the reporting unit to its carrying value. An impairment charge is recorded to the extent the reporting unit&#8217;s carrying value
          exceeds its fair value, not to exceed the total amount of goodwill allocated to that reporting unit. The Company performs its annual goodwill impairment assessment as of October 1 of each year. The Company&#8217;s annual goodwill impairment assessments
          as of October 1, 2024, 2023 and 2022 did not result in any impairment charges related to goodwill for the years ended December 31, 2024, 2023 and 2022.</p></ix:continuation></ix:continuation>

        <ix:continuation id="Text_63aa8b379f274e8cb46d81d1852d319442" continuedAt="Text_63aa8b379f274e8cb46d81d1852d319443"><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;"><span style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
          </span> </p></ix:continuation>

        <ix:nonNumeric name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" id="Text_f38a8775e287430db5d7d3cd5a2a6792" contextRef="c20240101to20241231" escape="true" continuedAt="Text_1cc5d81d20324852a0757fed81056f931"><ix:continuation id="Text_63aa8b379f274e8cb46d81d1852d319443" continuedAt="Text_63aa8b379f274e8cb46d81d1852d319444"><p style="margin: 0px; font-family: 'Times New Roman'; font-size: 10pt; text-align: left;"><span style="text-decoration:underline">Impairment of long-lived assets</span></p></ix:continuation></ix:nonNumeric>
        <ix:continuation id="Text_1cc5d81d20324852a0757fed81056f931" continuedAt="Text_1cc5d81d20324852a0757fed81056f932"><ix:continuation id="Text_63aa8b379f274e8cb46d81d1852d319444" continuedAt="Text_63aa8b379f274e8cb46d81d1852d319445"><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;">&#160;</p></ix:continuation></ix:continuation>
        <ix:continuation id="Text_1cc5d81d20324852a0757fed81056f932"><ix:continuation id="Text_63aa8b379f274e8cb46d81d1852d319445" continuedAt="Text_63aa8b379f274e8cb46d81d1852d319446"><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-indent: 45px; text-align: left;">The Company assesses the recoverability of its long-lived assets, which include property and equipment and finite-lived intangible assets,
          whenever significant events or changes in circumstances indicate impairment may have occurred. If indicators of impairment exist, projected future undiscounted cash flows associated with the asset are compared to its carrying amount to determine
          whether the asset&#8217;s carrying value is recoverable. Any resulting impairment is recorded as a reduction in the carrying value of the related asset in excess of fair value and a charge to operating results. For the years ended December 31, 2024,
          2023 and 2022, the Company determined that there was <ix:nonFraction name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" id="Fact_88e73a6bfdd84f1ab8d9c5baa2c2f5c3" contextRef="c20230101to20231231" unitRef="U001" decimals="-3" scale="3" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" id="Fact_7d47420384544482b425d24fa574a9c5" contextRef="c20240101to20241231" unitRef="U001" decimals="-3" scale="3" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" id="Fact_09a296926b2349139ab9c06dd4e21826" contextRef="c20220101to20221231" unitRef="U001" decimals="-3" scale="3" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></ix:nonFraction> impairment of its long-lived assets. </p></ix:continuation></ix:continuation>

        <ix:continuation id="Text_63aa8b379f274e8cb46d81d1852d319446" continuedAt="Text_63aa8b379f274e8cb46d81d1852d319447"><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;"><span style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
          </span> </p></ix:continuation>

        <ix:nonNumeric name="us-gaap:RevenueRecognitionPolicyTextBlock" id="Text_1b42af333ebe4902a12f992e07550b40" contextRef="c20240101to20241231" escape="true" continuedAt="Text_da14936cb71e4752ad247aef2983fe701"><ix:continuation id="Text_63aa8b379f274e8cb46d81d1852d319447" continuedAt="Text_63aa8b379f274e8cb46d81d1852d319448"><p style="margin: 0px; font-family: 'Times New Roman'; font-size: 10pt; text-align: left;"><span style="text-decoration:underline">Revenue recognition</span></p></ix:continuation></ix:nonNumeric>
        <ix:continuation id="Text_da14936cb71e4752ad247aef2983fe701" continuedAt="Text_da14936cb71e4752ad247aef2983fe702"><ix:continuation id="Text_63aa8b379f274e8cb46d81d1852d319448" continuedAt="Text_63aa8b379f274e8cb46d81d1852d319449"><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;">&#160;</p></ix:continuation></ix:continuation>
        <ix:continuation id="Text_da14936cb71e4752ad247aef2983fe702" continuedAt="Text_da14936cb71e4752ad247aef2983fe703"><ix:continuation id="Text_63aa8b379f274e8cb46d81d1852d319449" continuedAt="Text_63aa8b379f274e8cb46d81d1852d319450"><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-indent: 45px; text-align: left;">Revenues for the years ended December 31, 2024, 2023 and 2022 are comprised of (i) revenues from the sale of the Company&#8217;s immunoglobulin
          products, ASCENIV, BIVIGAM and Nabi-HB, (ii) product revenues from the sale of human plasma collected by the Company&#8217;s Plasma Collection Centers business segment, (iii) contract manufacturing and laboratory services revenue, (iv) revenues from
          the sale of intermediate by-products and (v) license and other revenues primarily attributable to the out-licensing of ASCENIV to Biotest AG (&#8220;Biotest&#8221;) in 2012 to market and sell this product in Europe and selected countries in North Africa and
          the Middle East. Biotest has provided the Company with certain services and financial payments in accordance with the related Biotest license agreement and is obligated to pay the Company certain amounts in the future if certain milestones are
          achieved. Deferred revenue is amortized into income over the term of the Biotest license, representing a period of approximately <ix:nonNumeric name="adma:DeferredRevenueRemainingAmortizationPeriod" id="Fact_96ebe731caac45deadba18287277afb1" contextRef="c20240101to20241231_TypeOfArrangementAxis_BiotestLicenseAgreementMember" format="ixt-sec:durwordsen">22 years</ix:nonNumeric>.
        </p></ix:continuation></ix:continuation>
      </div>

      <ix:continuation id="Text_da14936cb71e4752ad247aef2983fe703" continuedAt="Text_da14936cb71e4752ad247aef2983fe704"><ix:continuation id="Text_63aa8b379f274e8cb46d81d1852d319450" continuedAt="Text_63aa8b379f274e8cb46d81d1852d319451">
<div><br/></div>
</ix:continuation></ix:continuation>
      <div style="line-height: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-align: left;">
        <ix:continuation id="Text_da14936cb71e4752ad247aef2983fe704" continuedAt="Text_da14936cb71e4752ad247aef2983fe705"><ix:continuation id="Text_63aa8b379f274e8cb46d81d1852d319451" continuedAt="Text_63aa8b379f274e8cb46d81d1852d319452">
<div style="display:none;"><br/></div>
<div style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-indent: 45px; text-align: left;">Product revenue is recognized when the customer is deemed to have control over the product and the performance obligation is satisfied.
          Control is determined based on when the product is shipped or delivered and title passes to the customer. Revenue is recorded in an amount that reflects the consideration the Company expects to receive in exchange. Revenue from the sale of the
          Company&#8217;s immunoglobulin products is recognized when the product reaches the customer&#8217;s destination, and is recorded net of estimated rebates, <span style="font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">wholesaler distribution and related
            fees, customer incentives, including prompt pay discounts, wholesaler chargebacks, group purchasing organization fees and reimbursements for patient assistance. These estimates are based on contractual arrangements, historical experience and
            certain other assumptions, and while the Company believes that such estimates are reasonable, they are subject to change based on future developments and other factors.</span></div>
</ix:continuation></ix:continuation>
        <ix:continuation id="Text_da14936cb71e4752ad247aef2983fe705" continuedAt="Text_da14936cb71e4752ad247aef2983fe706"><ix:continuation id="Text_63aa8b379f274e8cb46d81d1852d319452" continuedAt="Text_63aa8b379f274e8cb46d81d1852d319453">
<div style="display:none;"><br/></div>
<div style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-indent: 45px; text-align: left;"><span style="font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"> <br/>
          </span></div>
</ix:continuation></ix:continuation>
        <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
          <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">F-14</span></div>

          <div class="BRPFPageBreak" style="page-break-after: always;">
            <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"/></div>

          <div style="width: 100%;" class="BRPFPageHeader">
            <div>
              <div style="text-align: left; font-weight: bold; text-indent: -9pt; margin-left: 9pt;"><a href="#ADMABIOLOGICSINC."> <span style="font-style: italic; font-weight: normal; font-size: 8pt;">Table of Contents</span></a><br/>
              </div>

              <div style="text-align: left; font-weight: bold; text-indent: -9pt; margin-left: 9pt;"><a href="#ADMABIOLOGICSINC."><span style="font-style: italic; font-weight: normal; font-size: 8pt;"> <br/>
                  </span></a></div>

              <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">ADMA BIOLOGICS, INC. AND SUBSIDIARIES</div>

              <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</div>

            </div>

          </div>

        </div>

        <ix:continuation id="Text_da14936cb71e4752ad247aef2983fe706" continuedAt="Text_da14936cb71e4752ad247aef2983fe707"><ix:continuation id="Text_63aa8b379f274e8cb46d81d1852d319453" continuedAt="Text_63aa8b379f274e8cb46d81d1852d319454">
<div style="display:none;"><br/></div>
<div style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-indent: 45px; text-align: left;"><span style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">For revenues
            associated with contract manufacturing and the sale of intermediates, control transfers to the customer and the performance obligation is satisfied when the customer takes possession of the product from the Boca Facility</span><span style="font-family: 'Times New Roman'; font-size: 10pt;">.</span></div>
</ix:continuation></ix:continuation>
        <ix:continuation id="Text_da14936cb71e4752ad247aef2983fe707" continuedAt="Text_da14936cb71e4752ad247aef2983fe708"><ix:continuation id="Text_63aa8b379f274e8cb46d81d1852d319454" continuedAt="Text_63aa8b379f274e8cb46d81d1852d319455"><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-indent: 45px; text-align: left;">&#160;</p></ix:continuation></ix:continuation>
        <ix:continuation id="Text_da14936cb71e4752ad247aef2983fe708" continuedAt="Text_da14936cb71e4752ad247aef2983fe709"><ix:continuation id="Text_63aa8b379f274e8cb46d81d1852d319455" continuedAt="Text_63aa8b379f274e8cb46d81d1852d319456"><p style="margin: 0px; font-family: 'Times New Roman'; font-size: 10pt; text-align: left; text-indent: 45px;">Product revenues from the sale of human plasma collected at the Company&#8217;s plasma collection centers are recognized at the time control of
          the product has been transferred to the customer<span style="font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"> and the performance obligation is satisfied, which generally occurs at the time of shipment from
            one of the Company&#8217;s plasma collection facilities or from a third-party warehouse that is utilized by the Company. Product revenues are recognized at the time of delivery if the Company retains control of the product during shipment</span>.</p></ix:continuation></ix:continuation>
        <ix:continuation id="Text_da14936cb71e4752ad247aef2983fe709" continuedAt="Text_da14936cb71e4752ad247aef2983fe7010"><ix:continuation id="Text_63aa8b379f274e8cb46d81d1852d319456" continuedAt="Text_63aa8b379f274e8cb46d81d1852d319457"><p style="margin: 0px; font-family: 'Times New Roman'; font-size: 10pt; text-align: left; text-indent: 45px;"> <br/>
        </p></ix:continuation></ix:continuation>
        <ix:continuation id="Text_da14936cb71e4752ad247aef2983fe7010"><ix:continuation id="Text_63aa8b379f274e8cb46d81d1852d319457" continuedAt="Text_63aa8b379f274e8cb46d81d1852d319458"><p style="margin: 0px; font-family: 'Times New Roman'; font-size: 10pt; text-align: left; text-indent: 45px;"><span style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">For all of the Company&#8217;s product revenues, payment from the customer is typically due within <ix:nonNumeric name="adma:CustomerPaymentTerms" id="Fact_aaaf8b6498e84a1dafce6025d305a87c" contextRef="c20240101to20241231" format="ixt-sec:durwordsen">90 days</ix:nonNumeric> of sale.</span><span style="font-size: 10pt; font-family: 'Times New Roman';"> </span></p></ix:continuation></ix:continuation>
        <ix:continuation id="Text_63aa8b379f274e8cb46d81d1852d319458" continuedAt="Text_63aa8b379f274e8cb46d81d1852d319459">
<div><span style="font-size: 10pt; font-family: 'Times New Roman';">  </span></div>
</ix:continuation>
        <ix:continuation id="Text_63aa8b379f274e8cb46d81d1852d319459" continuedAt="Text_63aa8b379f274e8cb46d81d1852d319460"><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;">&#160;</p></ix:continuation>

        <ix:nonNumeric name="us-gaap:CostOfSalesPolicyTextBlock" id="Text_f12240e613db430ba73d76321a1921ee" contextRef="c20240101to20241231" escape="true" continuedAt="Text_869206ecd5274f17a5df04707f4d02fc1"><ix:continuation id="Text_63aa8b379f274e8cb46d81d1852d319460" continuedAt="Text_63aa8b379f274e8cb46d81d1852d319461"><p style="margin: 0px; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-align: left; text-indent: 0px; text-transform: none;"><span style="text-decoration: underline;">Cost of product revenue</span></p></ix:continuation></ix:nonNumeric>
        <ix:continuation id="Text_869206ecd5274f17a5df04707f4d02fc1" continuedAt="Text_869206ecd5274f17a5df04707f4d02fc2"><ix:continuation id="Text_63aa8b379f274e8cb46d81d1852d319461" continuedAt="Text_63aa8b379f274e8cb46d81d1852d319462"><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;">&#160;</p></ix:continuation></ix:continuation>
        <ix:continuation id="Text_63aa8b379f274e8cb46d81d1852d319462" continuedAt="Text_63aa8b379f274e8cb46d81d1852d319463"><ix:continuation id="Text_869206ecd5274f17a5df04707f4d02fc2"><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-indent: 45px; text-align: left;"><span style="font-family: 'Times New Roman'; font-size: 10pt;">Cost of product revenue includes costs associated with the manufacture of
            the Company&#8217;s FDA approved products and intermediates and for the collection of human source plasma, as well as expenses related to conformance batch production, process development and scientific and technical operations when these operations
            are attributable to marketed products. When the activities of these operations are attributable to new products in development, the expenses are classified as research and development expenses.</span> </p></ix:continuation></ix:continuation>
        <ix:continuation id="Text_63aa8b379f274e8cb46d81d1852d319463" continuedAt="Text_63aa8b379f274e8cb46d81d1852d319464"><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;"><span style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
          </span> </p></ix:continuation>

        <ix:nonNumeric name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="Text_6284068be49f44f0b5ccb6e0e2e860ac" contextRef="c20240101to20241231" escape="true" continuedAt="Text_23364b23a0d4487f9b04b7099015a7ba1"><ix:continuation id="Text_63aa8b379f274e8cb46d81d1852d319464" continuedAt="Text_63aa8b379f274e8cb46d81d1852d319465"><p style="margin: 0px; font-family: 'Times New Roman'; font-size: 10pt; text-align: left; text-indent: 0px;"><span style="text-decoration:underline">Research and development expenses</span></p></ix:continuation></ix:nonNumeric>
        <ix:continuation id="Text_23364b23a0d4487f9b04b7099015a7ba1" continuedAt="Text_23364b23a0d4487f9b04b7099015a7ba2"><ix:continuation id="Text_63aa8b379f274e8cb46d81d1852d319465" continuedAt="Text_63aa8b379f274e8cb46d81d1852d319466"><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;">&#160;</p></ix:continuation></ix:continuation>
        <ix:continuation id="Text_63aa8b379f274e8cb46d81d1852d319466" continuedAt="Text_63aa8b379f274e8cb46d81d1852d319467"><ix:continuation id="Text_23364b23a0d4487f9b04b7099015a7ba2"><p style="margin: 0px; font-family: 'Times New Roman'; font-size: 10pt; text-align: left; text-indent: 45px;"><span style="font-family: 'Times New Roman'; font-size: 10pt;">Research and development expenses consist of clinical research organization
            costs, costs related to clinical trials, post-marketing commitment studies for BIVIGAM and ASCENIV and salaries, benefits and stock-based compensation for employees directly related to research and development activities. All research and
            development costs are expensed as incurred.</span> </p></ix:continuation></ix:continuation>
        <ix:continuation id="Text_63aa8b379f274e8cb46d81d1852d319467" continuedAt="Text_63aa8b379f274e8cb46d81d1852d319468"><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;"><span style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
          </span> </p></ix:continuation>
        <ix:continuation id="Text_63aa8b379f274e8cb46d81d1852d319468" continuedAt="Text_63aa8b379f274e8cb46d81d1852d319469"><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;"> </p></ix:continuation>

        <ix:nonNumeric name="adma:OtherOperatingExpensesPolicyTextBlock" id="Text_6c66c0d7d7a647c58e69ddba41f70301" contextRef="c20240101to20241231" escape="true" continuedAt="Text_857bbb594651443c9e23ef89934599431"><ix:continuation id="Text_63aa8b379f274e8cb46d81d1852d319469" continuedAt="Text_63aa8b379f274e8cb46d81d1852d319470">
<div style="display:none;"><br/></div>
<div style="margin: 0px; font-family: 'Times New Roman'; font-size: 10pt; text-align: left; text-indent: 0px;"><span style="text-decoration: underline;">Plasma center operating expenses</span></div>
</ix:continuation></ix:nonNumeric>
        <ix:continuation id="Text_857bbb594651443c9e23ef89934599431" continuedAt="Text_857bbb594651443c9e23ef89934599432"><ix:continuation id="Text_63aa8b379f274e8cb46d81d1852d319470" continuedAt="Text_63aa8b379f274e8cb46d81d1852d319471">
<div style="display:none;"><br/></div>
<div style="margin: 0px; font-family: 'Times New Roman'; font-size: 10pt; text-align: left; text-indent: 0px;"><span style="text-decoration: underline;"> <br/>
          </span></div>
</ix:continuation></ix:continuation>
        <ix:continuation id="Text_857bbb594651443c9e23ef89934599432"><ix:continuation id="Text_63aa8b379f274e8cb46d81d1852d319471" continuedAt="Text_63aa8b379f274e8cb46d81d1852d319472">
<div style="display:none;"><br/></div>
<div style="margin: 0px; font-family: 'Times New Roman'; font-size: 10pt; text-align: left; text-indent: 45px;">Plasma center operating expenses consist of certain general and administrative plasma center costs, initial opening, marketing and
          start-up costs, rent expense, maintenance, utilities and compensation and benefits for administrative staff.</div>
</ix:continuation></ix:continuation>

        <ix:continuation id="Text_63aa8b379f274e8cb46d81d1852d319472" continuedAt="Text_63aa8b379f274e8cb46d81d1852d319473"><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;"> <span style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
          </span> </p></ix:continuation>

        <ix:nonNumeric name="us-gaap:AdvertisingCostsPolicyTextBlock" id="Text_1420b2c05dce42c5afef742834375b0d" contextRef="c20240101to20241231" escape="true" continuedAt="Text_3e515ebe5076421885549abf47eb99bf1"><ix:continuation id="Text_63aa8b379f274e8cb46d81d1852d319473" continuedAt="Text_63aa8b379f274e8cb46d81d1852d319474"><p style="margin: 0px; font-family: 'Times New Roman'; font-size: 10pt; text-align: left; text-indent: 0px;"><span style="text-decoration:underline">Advertising and marketing expenses</span></p></ix:continuation></ix:nonNumeric>
        <ix:continuation id="Text_3e515ebe5076421885549abf47eb99bf1" continuedAt="Text_3e515ebe5076421885549abf47eb99bf2"><ix:continuation id="Text_63aa8b379f274e8cb46d81d1852d319474" continuedAt="Text_63aa8b379f274e8cb46d81d1852d319475"><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;">&#160;</p></ix:continuation></ix:continuation>
        <ix:continuation id="Text_3e515ebe5076421885549abf47eb99bf2"><ix:continuation id="Text_63aa8b379f274e8cb46d81d1852d319475" continuedAt="Text_63aa8b379f274e8cb46d81d1852d319476"><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-indent: 45px; text-align: left;">Advertising and marketing expense includes cost for promotional materials and trade show expenses for the marketing of the Company&#8217;s
          products and expenses incurred for attracting donors to the Company&#8217;s plasma collection centers. All advertising and marketing expenses are expensed as incurred.&#160; Advertising and marketing expenses were $<ix:nonFraction name="us-gaap:MarketingAndAdvertisingExpense" id="Fact_e84ec44532b0411f9b5907bdb1aed7c1" contextRef="c20240101to20241231" unitRef="U001" decimals="-5" scale="6" format="ixt:num-dot-decimal">2.7</ix:nonFraction> million, $<ix:nonFraction name="us-gaap:MarketingAndAdvertisingExpense" id="Fact_3650d7390aed4368937ce9c7a285c709" contextRef="c20230101to20231231" unitRef="U001" decimals="-5" scale="6" format="ixt:num-dot-decimal">3.3</ix:nonFraction> million and $<ix:nonFraction name="us-gaap:MarketingAndAdvertisingExpense" id="Fact_ca981ef63a1e4b15a11a893c5471f6b8" contextRef="c20210101to20211231" unitRef="U001" decimals="-5" scale="6" format="ixt:num-dot-decimal">2.2</ix:nonFraction> million for the years ended December 31, 2024, 2023 and 2022, respectively.</p></ix:continuation></ix:continuation>

        <ix:continuation id="Text_63aa8b379f274e8cb46d81d1852d319476" continuedAt="Text_63aa8b379f274e8cb46d81d1852d319477"><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;"><span style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
          </span> </p></ix:continuation>

        <ix:nonNumeric name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="Text_c06d7acd7a154c838cab1d55352a88f6" contextRef="c20240101to20241231" escape="true" continuedAt="Text_def51f0fbd224d3b9c35a21817877d831"><ix:continuation id="Text_63aa8b379f274e8cb46d81d1852d319477" continuedAt="Text_63aa8b379f274e8cb46d81d1852d319478"><p style="margin: 0px; font-family: 'Times New Roman'; font-size: 10pt; text-align: left; text-indent: 0px;"><span style="text-decoration:underline">Stock-based compensation</span></p></ix:continuation></ix:nonNumeric>
        <ix:continuation id="Text_def51f0fbd224d3b9c35a21817877d831" continuedAt="Text_def51f0fbd224d3b9c35a21817877d832"><ix:continuation id="Text_63aa8b379f274e8cb46d81d1852d319478" continuedAt="Text_63aa8b379f274e8cb46d81d1852d319479"><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;">&#160;</p></ix:continuation></ix:continuation>
        <ix:continuation id="Text_def51f0fbd224d3b9c35a21817877d832"><ix:continuation id="Text_63aa8b379f274e8cb46d81d1852d319479" continuedAt="Text_63aa8b379f274e8cb46d81d1852d319480"><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-indent: 45px; text-align: left;">The Company follows recognized accounting guidance which requires all equity-based payments, including grants of stock options and
          restricted stock unit awards (&#8220;RSUs&#8221;), to be recognized in the statement of operations as compensation expense based on their fair values at the date of grant. Compensation expense related to awards to employees and directors with service-based
          vesting conditions is recognized on a straight-line basis over the associated vesting period of the award based on the grant date fair value of the award. Stock options granted to employees under the Company&#8217;s equity incentive plans generally
          have a <ix:nonNumeric name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Fact_1422437a30924586ab3d39ca21e5a446" contextRef="c20240101to20241231_AwardTypeAxis_EmployeeStockOptionMember" format="ixt-sec:durwordsen">four-year</ix:nonNumeric> vesting period and a term of <ix:nonNumeric name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" id="Fact_7ffa535a9eb447dba3631f86108655e7" contextRef="c20240101to20241231_AwardTypeAxis_EmployeeStockOptionMember" format="ixt-sec:durwordsen">10 years</ix:nonNumeric>. RSUs granted to employees also have a <ix:nonNumeric name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Fact_17997dbb1c9f4b47bc4962c0135d341f" contextRef="c20240101to20241231_AwardTypeAxis_RestrictedStockUnitsRSUMember" format="ixt-sec:durwordsen">four-year</ix:nonNumeric> vesting period. For milestone-based equity
          awards, <span style="font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">which were awarded to <ix:nonFraction name="adma:NumberOfExecutiveOfficers" id="Fact_8672cd6c32e5438fbff9e8b1c63dc29a" contextRef="c20210901to20210930" unitRef="U006" decimals="INF" scale="0" format="ixt-sec:numwordsen">two</ix:nonFraction>
            of the Company&#8217;s executive officers in September of 2021 and vested during fiscal 2022,</span> the Company would periodically assess the probability of vesting for each milestone-based award and adjust compensation expense based on its
          probability assessment. Pursuant to ASU No. 2016-09, <span style="font-style: italic;">Improvements to Employee Share-Based Payment Accounting (Topic 718)</span>, the Company has elected not to establish a forfeiture rate, as stock-based
          compensation expense related to forfeitures of unvested equity awards is fully reversed at the time of forfeiture.</p></ix:continuation></ix:continuation>

        <ix:continuation id="Text_63aa8b379f274e8cb46d81d1852d319480" continuedAt="Text_63aa8b379f274e8cb46d81d1852d319481"><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;">&#160;</p></ix:continuation>
        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">F-15</span></div>

          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"/></div>

          <div style="width: 100%;" class="BRPFPageHeader">
            <div>
              <div style="text-align: left; font-weight: bold; text-indent: -9pt; margin-left: 9pt;"><a href="#ADMABIOLOGICSINC."> <span style="font-style: italic; font-weight: normal; font-size: 8pt;">Table of Contents</span></a><br/>
              </div>

              <div style="text-align: left; font-weight: bold; text-indent: -9pt; margin-left: 9pt;"><a href="#ADMABIOLOGICSINC."><span style="font-style: italic; font-weight: normal; font-size: 8pt;"> <br/>
                  </span></a></div>

              <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">ADMA BIOLOGICS, INC. AND SUBSIDIARIES</div>

              <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</div>

            </div>

          </div>

        </div>


        <ix:nonNumeric name="us-gaap:IncomeTaxPolicyTextBlock" id="Text_eb96bceb2c0944d8bde71a50bde19653" contextRef="c20240101to20241231" escape="true" continuedAt="Text_e3b26eb035ae4478afef30d69da3aa571"><ix:continuation id="Text_63aa8b379f274e8cb46d81d1852d319481" continuedAt="Text_63aa8b379f274e8cb46d81d1852d319482"><p style="margin: 0px; font-family: 'Times New Roman'; font-size: 10pt; text-align: left; text-indent: 0px;"><span style="text-decoration:underline">Income taxes</span></p></ix:continuation></ix:nonNumeric>
        <ix:continuation id="Text_e3b26eb035ae4478afef30d69da3aa571" continuedAt="Text_e3b26eb035ae4478afef30d69da3aa572"><ix:continuation id="Text_63aa8b379f274e8cb46d81d1852d319482" continuedAt="Text_63aa8b379f274e8cb46d81d1852d319483"><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;">&#160;</p></ix:continuation></ix:continuation>
        <ix:continuation id="Text_e3b26eb035ae4478afef30d69da3aa572"><ix:continuation id="Text_63aa8b379f274e8cb46d81d1852d319483" continuedAt="Text_63aa8b379f274e8cb46d81d1852d319484"><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-indent: 45px; text-align: left;">The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of events that have been included in
          the consolidated financial statements or its tax returns. Under this method, deferred tax assets and liabilities are recognized for the temporary differences between the tax bases of assets and liabilities and their respective financial reporting
          amounts at enacted tax rates in effect for the years in which the temporary differences are expected to reverse. The Company records a valuation allowance on its deferred tax assets if it is more likely than not that the Company will not generate
          sufficient taxable income to utilize its deferred tax assets (see Note 11). The Company is subject to income tax examinations by major taxing authorities for all tax years since 2020 and for previous periods as it relates to the Company&#8217;s net
          operating loss carryforwards.</p></ix:continuation></ix:continuation>

        <ix:continuation id="Text_63aa8b379f274e8cb46d81d1852d319484" continuedAt="Text_63aa8b379f274e8cb46d81d1852d319485"><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-indent: 45px; text-align: left;"> </p></ix:continuation>
        <ix:continuation id="Text_63aa8b379f274e8cb46d81d1852d319485" continuedAt="Text_63aa8b379f274e8cb46d81d1852d319486">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
        </span></div>
</ix:continuation> </div>

      <div style="line-height: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-align: left;">
        <ix:nonNumeric name="us-gaap:EarningsPerSharePolicyTextBlock" id="Text_7014fa885d7644e980bf5bc564f13e37" contextRef="c20240101to20241231" escape="true" continuedAt="Text_dd55db7f99f94a5dbeba5d33096492561"><ix:continuation id="Text_63aa8b379f274e8cb46d81d1852d319486" continuedAt="Text_63aa8b379f274e8cb46d81d1852d319487"><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 9pt; text-align: left; text-indent: -9pt;"><span style="font-family: 'Times New Roman'; font-size: 10pt;"><span style="text-decoration: underline;">Earnings (Loss) Per Share</span></span> </p></ix:continuation></ix:nonNumeric>
        <ix:continuation id="Text_dd55db7f99f94a5dbeba5d33096492561" continuedAt="Text_dd55db7f99f94a5dbeba5d33096492562"><ix:continuation id="Text_63aa8b379f274e8cb46d81d1852d319487" continuedAt="Text_63aa8b379f274e8cb46d81d1852d319488"><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 9pt; text-align: left; text-indent: -9pt;"><span style="text-decoration: underline;"> <br/>
          </span></p></ix:continuation></ix:continuation>
        <ix:continuation id="Text_dd55db7f99f94a5dbeba5d33096492562" continuedAt="Text_dd55db7f99f94a5dbeba5d33096492563"><ix:continuation id="Text_63aa8b379f274e8cb46d81d1852d319488" continuedAt="Text_63aa8b379f274e8cb46d81d1852d319489"><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-indent: 45px; text-align: left;">Basic earnings (loss) per share is computed by dividing net income or loss attributable to common stockholders by the weighted average
          number of shares of common stock outstanding during the period. Diluted loss per share is calculated by dividing net income or loss attributable to common stockholders as adjusted for the effect of dilutive securities, if any, by the weighted
          average number of shares of common stock and dilutive common stock outstanding during the period. Potentially dilutive common stock includes the shares of common stock issuable upon the exercise of outstanding stock options and warrants (using
          the treasury stock method) <span style="font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">and upon the vesting of restricted stock units (&#8220;RSUs&#8221;). Potentially dilutive common stock in the diluted net
            earnings (loss) per share computation is excluded to the extent that it would be anti-dilutive. <ix:nonNumeric name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="Text_ea5ca822722a40b78455d5aa0974104b" contextRef="c20240101to20241231" escape="true" continuedAt="Text_fe94626b6aba46cd88e39e4a60b6f9e41"><span style="font-style: normal; font-weight: 400; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; color: rgb(0, 0, 0);">For the year ended December 31, 2024, basic and diluted earnings per share are calculated as follows:</span></ix:nonNumeric></span></p></ix:continuation></ix:continuation>
        <ix:continuation id="Text_dd55db7f99f94a5dbeba5d33096492563" continuedAt="Text_dd55db7f99f94a5dbeba5d33096492564"><ix:continuation id="Text_63aa8b379f274e8cb46d81d1852d319489" continuedAt="Text_63aa8b379f274e8cb46d81d1852d319490"><ix:continuation id="Text_fe94626b6aba46cd88e39e4a60b6f9e41" continuedAt="Text_fe94626b6aba46cd88e39e4a60b6f9e42">
<div style="display:none;"><br/></div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial;"><span style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
          </span> </div>
</ix:continuation></ix:continuation></ix:continuation>
        <ix:continuation id="Text_dd55db7f99f94a5dbeba5d33096492564" continuedAt="Text_dd55db7f99f94a5dbeba5d33096492565"><ix:continuation id="Text_63aa8b379f274e8cb46d81d1852d319490" continuedAt="Text_63aa8b379f274e8cb46d81d1852d319491"><ix:continuation id="Text_fe94626b6aba46cd88e39e4a60b6f9e42">
<table cellspacing="0" cellpadding="0" border="0" class="cfttable" style="letter-spacing: normal; width: 100%; word-spacing: 0px; font-family: 'Times New Roman'; font-size: 10pt; text-align: left; text-transform: none; border-spacing: 0;">


  <tr>

    <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-align: center; text-transform: none;"><br/>
              </td>

    <td valign="bottom" colspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;">
                <div style="text-align: center; font-weight: bold;">Year Ended</div>
              </td>

    <td valign="bottom" colspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; white-space: nowrap; padding: 0px 0px 0px; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; border-bottom: #000000 solid 2px; white-space: nowrap;">
                <div style="text-align: center; font-weight: bold;">December 31, 2024</div>
              </td>

    <td valign="bottom" colspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; width: 88%; background-color: #CCEEFF;">
                <div>Net income available to common stockholders ($000&#8217;s) (numerator)</div>
              </td>

    <td valign="bottom" colspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">
                <div>$</div>
              </td>

    <td valign="bottom" colspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:NetIncomeLoss" id="Fact_ab6144541a99494eb74f182153f91816" contextRef="c20240101to20241231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">197,673</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; width: 88%; padding-bottom: 2px;">
                <div>Weighted-average number of common shares (denominator)</div>
              </td>

    <td valign="bottom" colspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" id="Fact_e3981f93a83e49b7883b51d5427fbecf" contextRef="c20240101to20241231" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">233,084,236</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; white-space: nowrap; padding: 0px 0px 4px; color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; width: 88%; padding-bottom: 4px; background-color: #CCEEFF;">
                <div>Basic earnings per common shares</div>
              </td>

    <td valign="bottom" colspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;">
                <div>$</div>
              </td>

    <td valign="bottom" colspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:EarningsPerShareBasic" id="Fact_7ca0804959f74ea3bef1b028d6646e8c" contextRef="c20240101to20241231" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">0.85</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; font-style: normal; font-variant: normal; text-transform: none; width: 88%;"><br/>
              </td>

    <td valign="bottom" colspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; width: 88%; background-color: #CCEEFF;">
                <div>Weighted-average number of common shares</div>
              </td>

    <td valign="bottom" colspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" id="Fact_2adf932e22644489996608076f9f4d0e" contextRef="c20240101to20241231" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">233,084,236</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; width: 88%;">
                <div>Potential shares of common stock arising from outstanding stock options</div>
              </td>

    <td valign="bottom" colspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" id="Fact_7279edcb069a47a6bd2bf5c2085932f7" contextRef="c20240101to20241231_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_EmployeeStockOptionMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">4,150,584</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; width: 88%; background-color: #CCEEFF;">
                <div>Potential shares of common stock arising from outstanding warrants</div>
              </td>

    <td valign="bottom" colspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" id="Fact_eac4d6d114ef4972a1d227e100ce4fa6" contextRef="c20240101to20241231_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_WarrantMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">3,085,640</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; width: 88%; padding-bottom: 2px;">
                <div>Potential shares of common stock arising from unvested RSUs</div>
              </td>

    <td valign="bottom" colspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" id="Fact_e09215834b024bd89c254c06c6a21298" contextRef="c20240101to20241231_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_RestrictedStockUnitsRSUMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">3,022,006</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; width: 88%; padding-bottom: 2px; background-color: #CCEEFF;">
                <div>Total shares - diluted (denominator)</div>
              </td>

    <td valign="bottom" colspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" id="Fact_0ff92aa3bca14d28baebb5d4663dace3" contextRef="c20240101to20241231" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">243,342,466</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; width: 88%; padding-bottom: 4px;">
                <div>Diluted earnings per common share</div>
              </td>

    <td valign="bottom" colspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;">
                <div>$</div>
              </td>

    <td valign="bottom" colspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;">
                <div><ix:nonFraction name="us-gaap:EarningsPerShareDiluted" id="Fact_488932243faa48869143e8b4ecacb1bf" contextRef="c20240101to20241231" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">0.81</ix:nonFraction></div>
              </td>

    <td valign="bottom" colspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">&#160;</td>

  </tr>


</table>
</ix:continuation></ix:continuation></ix:continuation>

        <ix:continuation id="Text_dd55db7f99f94a5dbeba5d33096492565" continuedAt="Text_dd55db7f99f94a5dbeba5d33096492566"><ix:continuation id="Text_63aa8b379f274e8cb46d81d1852d319491" continuedAt="Text_63aa8b379f274e8cb46d81d1852d319492"><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-indent: 45px; text-align: left;"> <span style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
          </span> </p></ix:continuation></ix:continuation>
        <ix:continuation id="Text_dd55db7f99f94a5dbeba5d33096492566" continuedAt="Text_dd55db7f99f94a5dbeba5d33096492567"><ix:continuation id="Text_63aa8b379f274e8cb46d81d1852d319492" continuedAt="Text_63aa8b379f274e8cb46d81d1852d319493"><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-indent: 45px; text-align: left;"><span style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">For the year ended December 31, 2024, there were <ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" id="Fact_1e962461f4c94dfcaeee073eb17f2fbf" contextRef="c20240101to20241231" unitRef="U002" decimals="INF" scale="0" format="ixt-sec:numwordsen">no</ix:nonFraction> shares with an anti-dilutive effect that needed to be excluded
            from the earnings per share computation. For the years ended December 31, 2023 and 2022, <ix:nonFraction name="adma:DilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmountShares" id="Fact_ee09b96234c24a0489145b0eff1808fe" contextRef="c20230101to20231231" unitRef="U002" decimals="INF" scale="0" format="ixt-sec:numwordsen"><ix:nonFraction name="adma:DilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmountShares" id="Fact_aeb789a87da04e898c6aad3ab76c4211" contextRef="c20220101to20221231" unitRef="U002" decimals="INF" scale="0" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction> potentially dilutive securities are
            included in the computation of diluted loss per share in the accompanying consolidated financial statements as the Company reported a net loss for these periods.</span><span style="font-family: 'Times New Roman'; font-size: 10pt;"> <ix:nonNumeric name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="Text_9fc1c73cd75141cca1b7d186ce684320" contextRef="c20240101to20241231" escape="true" continuedAt="Text_a6a103ad5e094164b98b760371a5bc001"><span style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; color: rgb(0, 0, 0);">For
            the years ended December 31, 2023 and 2022, the following securities were excluded from the calculation of diluted loss per common share because of their anti-dilutive effects:</span></ix:nonNumeric></span></p></ix:continuation></ix:continuation>
        <ix:continuation id="Text_dd55db7f99f94a5dbeba5d33096492567" continuedAt="Text_dd55db7f99f94a5dbeba5d33096492568"><ix:continuation id="Text_63aa8b379f274e8cb46d81d1852d319493" continuedAt="Text_63aa8b379f274e8cb46d81d1852d319494"><ix:continuation id="Text_a6a103ad5e094164b98b760371a5bc001" continuedAt="Text_a6a103ad5e094164b98b760371a5bc002"><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px;"><span style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;&#160; <br/>
          </span> </p></ix:continuation></ix:continuation></ix:continuation>
        <ix:continuation id="Text_dd55db7f99f94a5dbeba5d33096492568"><ix:continuation id="Text_63aa8b379f274e8cb46d81d1852d319494" continuedAt="Text_63aa8b379f274e8cb46d81d1852d319495"><ix:continuation id="Text_a6a103ad5e094164b98b760371a5bc002">
<table cellspacing="0" cellpadding="0" border="0" class="cfttable" style="text-align: left; font: 10pt 'Times New Roman'; width: 100%; border-spacing: 0;">


  <tr style="height: 15px;">

    <td valign="bottom" style="font-family: 'Times New Roman'; font-size: 10pt; padding-bottom: 2px;">
                <p style="margin: 0px;">&#160;</p>
              </td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="6" rowspan="1" style="vertical-align: bottom; text-align: center; font-family: 'Times New Roman'; font-size: 10pt; border-bottom: #000000 solid 2px;">
                <p style="margin: 0px 0px 0px 0in; text-align: center;"><strong>For the Years Ended December 31,</strong></p>
              </td>

    <td valign="bottom" colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="font-family: 'Times New Roman'; font-size: 10pt; padding-bottom: 2px;">
                <p style="margin: 0px;">&#160;</p>
              </td>

    <td valign="bottom" colspan="1" style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; text-align: center; font-family: 'Times New Roman'; font-size: 10pt; border-bottom: #000000 solid 2px;">
                <p style="margin: 0px 0px 0px 0in; text-align: center;"><strong>2023<br/>
                  </strong></p>
              </td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: center; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" style="text-align: center; vertical-align: bottom; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; border-bottom: #000000 solid 2px; white-space: nowrap;">2022</td>

    <td valign="bottom" colspan="1" style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt; width: 76%; background-color: #CCEEFF;">
                <p style="margin: 0px 0px 0px 0in;">Stock Options</p>
              </td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" id="Fact_0b4d2d542e8448b8b3836681f39a5c6f" contextRef="c20230101to20231231_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_EmployeeStockOptionMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">5,906,184</ix:nonFraction><br/>
              </td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" id="Fact_ee69a4e376f04a50810d658a46e464cf" contextRef="c20220101to20221231_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_EmployeeStockOptionMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">8,256,211</ix:nonFraction><br/>
              </td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt; width: 76%;">
                <p style="margin: 0px 0px 0px 0in;">Restricted Stock Units</p>
              </td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%;"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" id="Fact_8ac68441ad9443b8b061f3564dc2064c" contextRef="c20230101to20231231_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_RestrictedStockUnitsRSUMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">4,657,297</ix:nonFraction><br/>
              </td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" id="Fact_42f665449a814fada762a880fbbb8194" contextRef="c20220101to20221231_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_RestrictedStockUnitsRSUMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">2,866,987</ix:nonFraction><br/>
              </td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;">
                <p style="margin: 0px 0px 0px 0in;">Warrants</p>
              </td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" id="Fact_b618ba4a26b847ce9ee743483a5e8e17" contextRef="c20230101to20231231_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_WarrantMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">12,502,906</ix:nonFraction><br/>
              </td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" id="Fact_2517a71120ba4e369e616d228507b9ba" contextRef="c20220101to20221231_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_WarrantMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">13,525,148</ix:nonFraction><br/>
              </td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="font-family: 'Times New Roman'; font-size: 10pt; width: 76%; padding-bottom: 4px;">
                <p style="margin-top: 0px; margin-bottom: 0px; margin-left: 9pt;">Total<br/>
                </p>
              </td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" id="Fact_933058c0dd6049fcbe600389e9e96e54" contextRef="c20230101to20231231" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">23,066,387</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" id="Fact_f02539349b6a4ae0991e197b3c48b48b" contextRef="c20220101to20221231" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">24,648,346</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">&#160;</td>

  </tr>


</table>
</ix:continuation></ix:continuation></ix:continuation>
        <ix:continuation id="Text_63aa8b379f274e8cb46d81d1852d319495" continuedAt="Text_63aa8b379f274e8cb46d81d1852d319496">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt;"> </span></div>
</ix:continuation>
        <ix:continuation id="Text_63aa8b379f274e8cb46d81d1852d319496" continuedAt="Text_63aa8b379f274e8cb46d81d1852d319497"><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;">&#160; </p></ix:continuation>
        <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
          <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">F-16</span></div>

          <div class="BRPFPageBreak" style="page-break-after: always;">
            <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"/></div>

          <div style="width: 100%;" class="BRPFPageHeader">
            <div>
              <div style="text-align: left; font-weight: bold; text-indent: -9pt; margin-left: 9pt;"><a href="#ADMABIOLOGICSINC."> <span style="font-style: italic; font-weight: normal; font-size: 8pt;">Table of Contents</span></a><br/>
              </div>

              <div style="text-align: left; font-weight: bold; text-indent: -9pt; margin-left: 9pt;"><a href="#ADMABIOLOGICSINC."><span style="font-style: italic; font-weight: normal; font-size: 8pt;"> <br/>
                  </span></a></div>

              <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">ADMA BIOLOGICS, INC. AND SUBSIDIARIES</div>

              <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</div>

            </div>

          </div>

        </div>


        <ix:nonNumeric name="us-gaap:FairValueOfFinancialInstrumentsPolicy" id="Text_7cead0bd46204dea8748b918efdbd677" contextRef="c20240101to20241231" escape="true" continuedAt="Text_8ad336a501184dcfb51bf13b9ddeca051"><ix:continuation id="Text_63aa8b379f274e8cb46d81d1852d319497" continuedAt="Text_63aa8b379f274e8cb46d81d1852d319498"><p style="margin: 0px; line-height: normal; font-family: 'Times New Roman'; font-size: 10pt; text-align: left; text-indent: 0px;"><span style="text-decoration:underline">Fair value of financial instruments</span></p></ix:continuation></ix:nonNumeric>
        <ix:continuation id="Text_8ad336a501184dcfb51bf13b9ddeca051" continuedAt="Text_8ad336a501184dcfb51bf13b9ddeca052"><ix:continuation id="Text_63aa8b379f274e8cb46d81d1852d319498" continuedAt="Text_63aa8b379f274e8cb46d81d1852d319499"><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;">&#160;</p></ix:continuation></ix:continuation>
        <ix:continuation id="Text_63aa8b379f274e8cb46d81d1852d319499" continuedAt="Text_63aa8b379f274e8cb46d81d1852d3194100"><ix:continuation id="Text_8ad336a501184dcfb51bf13b9ddeca052"><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-indent: 45px; text-align: left;"><span style="font-family: 'Times New Roman'; font-size: 10pt;">The carrying amounts of certain of the Company&#8217;s financial instruments,
            including cash and cash equivalents, accounts receivable and accounts payable are shown at cost, which approximates fair value due to the short-term nature of these instruments. The debt outstanding under the Company&#8217;s senior notes payable (see
            Note 7) also approximates fair value, based on a Level 3 classification under the fair value hierarchy, due to the variable interest rate on this debt.</span> </p></ix:continuation></ix:continuation>
        <ix:continuation id="Text_63aa8b379f274e8cb46d81d1852d3194100" continuedAt="Text_63aa8b379f274e8cb46d81d1852d3194101"><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;">&#160;</p></ix:continuation>

        <ix:nonNumeric name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="Text_94063da814ab4996a6453d69ff1d5772" contextRef="c20240101to20241231" escape="true" continuedAt="Text_8ed0c7ac3d8142e1a1707cfe13495b241"><ix:continuation id="Text_63aa8b379f274e8cb46d81d1852d3194101" continuedAt="Text_63aa8b379f274e8cb46d81d1852d3194102"><p style="margin: 0px; font-family: 'Times New Roman'; font-size: 10pt; text-align: left; text-indent: 0px;"><span style="text-decoration:underline">Recent Accounting Pronouncements</span></p></ix:continuation></ix:nonNumeric>
        <ix:continuation id="Text_8ed0c7ac3d8142e1a1707cfe13495b241" continuedAt="Text_8ed0c7ac3d8142e1a1707cfe13495b242"><ix:continuation id="Text_63aa8b379f274e8cb46d81d1852d3194102" continuedAt="Text_63aa8b379f274e8cb46d81d1852d3194103"><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;">&#160;</p></ix:continuation></ix:continuation>
        <div style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-indent: 45px; text-align: left; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">
          <ix:continuation id="Text_8ed0c7ac3d8142e1a1707cfe13495b242" continuedAt="Text_8ed0c7ac3d8142e1a1707cfe13495b243"><ix:continuation id="Text_63aa8b379f274e8cb46d81d1852d3194103" continuedAt="Text_63aa8b379f274e8cb46d81d1852d3194104">
<div style="display:none;"><br/></div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-transform: none; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; text-indent: 36pt;">In November of 2024 the FASB issued ASU No. 2024-03,&#160;<span style="font-style: italic;">Income Statement - Reporting Comprehensive Income &#8211;
              Expense Disaggregation Disclosures (Subtopic 220-40).&#160;</span>The amendments in this Update require disclosure, in the notes to the financial statements, of specified information about certain costs and expenses, including but not limited to,
            purchases of inventory, employee compensation and selling expense. This Update becomes effective for fiscal years beginning after December 15, 2026. The Company has yet to determine the impact this Update may have on the Company&#8217;s consolidated
            financial statements.</div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_8ed0c7ac3d8142e1a1707cfe13495b243" continuedAt="Text_8ed0c7ac3d8142e1a1707cfe13495b244"><ix:continuation id="Text_63aa8b379f274e8cb46d81d1852d3194104" continuedAt="Text_63aa8b379f274e8cb46d81d1852d3194105">
<div style="display:none;"><br/></div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial;"><br/>
          </div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_8ed0c7ac3d8142e1a1707cfe13495b244" continuedAt="Text_8ed0c7ac3d8142e1a1707cfe13495b245"><ix:continuation id="Text_63aa8b379f274e8cb46d81d1852d3194105" continuedAt="Text_63aa8b379f274e8cb46d81d1852d3194106">
<div style="display:none;"><br/></div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-transform: none; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; text-indent: 36pt;">In December of 2023 the FASB issued ASU 2023-09,&#160;<span style="font-style: italic;">Income Taxes (Topic 740):</span>&#160;<span style="font-style: italic;">Improvements to Income Tax Disclosures.&#160;</span>This Update requires disaggregated information about a reporting entity&#8217;s effective tax rate reconciliation as well as information on income taxes paid and becomes
            effective for public business entities for fiscal years beginning after December 15, 2024. The Company is currently evaluating the impact that this Update may have on the Company&#8217;s consolidated financial statements.</div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_8ed0c7ac3d8142e1a1707cfe13495b245" continuedAt="Text_8ed0c7ac3d8142e1a1707cfe13495b246"><ix:continuation id="Text_63aa8b379f274e8cb46d81d1852d3194106" continuedAt="Text_63aa8b379f274e8cb46d81d1852d3194107">
<div style="display:none;"><br/></div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial;"><br/>
          </div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_8ed0c7ac3d8142e1a1707cfe13495b246" continuedAt="Text_8ed0c7ac3d8142e1a1707cfe13495b247"><ix:continuation id="Text_63aa8b379f274e8cb46d81d1852d3194107" continuedAt="Text_63aa8b379f274e8cb46d81d1852d3194108">
<div style="display:none;"><br/></div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-transform: none; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; text-indent: 36pt;">In November of 2023 the FASB issued ASU No. 2023-07,&#160;<span style="font-style: italic;">Segment Reporting (Topic 280): Improvements to
              Reportable Segment Disclosures.&#160;</span>The amendments in this Update are intended to provide financial statement users with more disaggregated expense information about a public entity&#8217;s reportable segments, however the Update does not change
            the definition of a business segment or the method for determining reportable segments. This update became effective for fiscal years beginning after December 15, 2023 (see Note 13). Adoption of this Update did not have a material impact on the
            Company&#8217;s consolidated financial statements.</div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_8ed0c7ac3d8142e1a1707cfe13495b247" continuedAt="Text_8ed0c7ac3d8142e1a1707cfe13495b248"><ix:continuation id="Text_63aa8b379f274e8cb46d81d1852d3194108" continuedAt="Text_63aa8b379f274e8cb46d81d1852d3194109">
<div style="display:none;"><br/></div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial;"><br/>
          </div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_8ed0c7ac3d8142e1a1707cfe13495b248"><ix:continuation id="Text_63aa8b379f274e8cb46d81d1852d3194109">
<div style="display:none;"><br/></div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-transform: none; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; text-indent: 36pt;">There were no new accounting pronouncements adopted during the years ended December 31, 2023 and 2022 that had a significant impact on the
            Company&#8217;s consolidated financial statements.</div>
</ix:continuation></ix:continuation>
        </div>

        <div><span style="font-family: 'Times New Roman'; font-size: 10pt;"> </span></div>
 </div>

      <div style="text-align: left; font: 10pt 'Times New Roman';">&#160; </div>

    </div>

    <div><span style="font-family: 'Times New Roman'; font-size: 10pt;"> </span></div>
 </div>


  <div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: rgb(0, 0, 0);">
    <div>
      <div style="text-align: left; font: 10pt 'Times New Roman';">
        <ix:nonNumeric name="us-gaap:InventoryDisclosureTextBlock" id="Text_5842db1e643b42c7a22429b6a5cc1610" contextRef="c20240101to20241231" escape="true" continuedAt="Text_c56b924cdbae467f84a99efb16acf5771">
<div>
          <table cellspacing="0" cellpadding="0" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt; border-spacing: 0;" class="DSPFListTable">


  <tr style="vertical-align: top;">

    <td style="vertical-align: top; width: 27pt;">
                  <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;"><strong>3.</strong></p>
                </td>

    <td style="align: left; vertical-align: top; width: auto;">
                  <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;"><strong><span style="text-decoration: underline;">INVENTORIES</span></strong></p>
                </td>

  </tr>


</table>
        </div>
</ix:nonNumeric>
        <ix:continuation id="Text_c56b924cdbae467f84a99efb16acf5771" continuedAt="Text_c56b924cdbae467f84a99efb16acf5772"><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;">&#160;</p></ix:continuation>

        <ix:continuation id="Text_c56b924cdbae467f84a99efb16acf5772" continuedAt="Text_c56b924cdbae467f84a99efb16acf5773"><ix:nonNumeric name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" id="Text_3f978a7e17f74bb0a907c88e26b773cf" contextRef="c20240101to20241231" escape="true" continuedAt="Text_29ee7a3075ee4083beb4ea67bd4c7ced1"><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-indent: 45px; text-align: left;">The following table provides the components of inventories:</p></ix:nonNumeric></ix:continuation>
        <ix:continuation id="Text_c56b924cdbae467f84a99efb16acf5773" continuedAt="Text_c56b924cdbae467f84a99efb16acf5774"><ix:continuation id="Text_29ee7a3075ee4083beb4ea67bd4c7ced1" continuedAt="Text_29ee7a3075ee4083beb4ea67bd4c7ced2"><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px;"><br/>
        </p></ix:continuation></ix:continuation>
        <ix:continuation id="Text_c56b924cdbae467f84a99efb16acf5774" continuedAt="Text_c56b924cdbae467f84a99efb16acf5775"><ix:continuation id="Text_29ee7a3075ee4083beb4ea67bd4c7ced2">
<table cellspacing="0" cellpadding="0" border="0" class="cfttable" style="text-align: left; font: 10pt 'Times New Roman'; width: 100%; border-spacing: 0;">


  <tr style="height: 15px;">

    <td valign="bottom" style="padding-bottom: 2px;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px;">&#160;</p>
              </td>

    <td valign="bottom" colspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: #000000 solid 2px; white-space: nowrap;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: center;"><strong>December 31,<br/>
                    2024</strong></p>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: #000000 solid 2px; white-space: nowrap;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: center;"><strong>December 31,<br/>
                    2023</strong></p>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" rowspan="1" style="vertical-align: top;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: center; vertical-align: bottom;">&#160;</td>

    <td valign="bottom" colspan="6" rowspan="1" style="text-align: center; vertical-align: bottom;"><span style="font-style: italic;">(In thousands)</span><br/>
              </td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="vertical-align: top; width: 76%; background-color: #CCEEFF;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in;">Raw materials</p>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">$</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><ix:nonFraction name="us-gaap:InventoryRawMaterials" id="Fact_ababcb9226644f059ecf7d71ff87c676" contextRef="c20241231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">60,473</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">$</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><ix:nonFraction name="us-gaap:InventoryRawMaterials" id="Fact_543dd9811e0e42488ccf781175bd36f2" contextRef="c20231231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">52,999</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="vertical-align: top; width: 76%;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in;">Work-in-process</p>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;"><ix:nonFraction name="us-gaap:InventoryWorkInProcess" id="Fact_8052c96b93654a95a0958ce1da260183" contextRef="c20241231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">61,641</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;"><ix:nonFraction name="us-gaap:InventoryWorkInProcess" id="Fact_4bbe08fd2a414c528cbcefaf028e85f0" contextRef="c20231231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">49,621</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="vertical-align: top; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in;">Finished goods</p>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><ix:nonFraction name="us-gaap:InventoryFinishedGoods" id="Fact_622be231ac2c4c5485b50eed52d8bc88" contextRef="c20241231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">48,121</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;"><ix:nonFraction name="us-gaap:InventoryFinishedGoods" id="Fact_6b17adaeee1a4be8a38d19f1d8f02f4c" contextRef="c20231231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">70,286</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="vertical-align: top; width: 76%; padding-bottom: 4px;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in;">Total inventories</p>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);">$</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);"><ix:nonFraction name="us-gaap:InventoryNet" id="Fact_2ea7132a86e2498ca6049223a75a86c1" contextRef="c20241231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">170,235</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);">$</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);"><ix:nonFraction name="us-gaap:InventoryNet" id="Fact_bcc0b372000140a2a21b4e3523ae87c1" contextRef="c20231231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">172,906</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">&#160;</td>

  </tr>


</table>
</ix:continuation></ix:continuation>

        <ix:continuation id="Text_c56b924cdbae467f84a99efb16acf5775" continuedAt="Text_c56b924cdbae467f84a99efb16acf5776"><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-indent: 45px; text-align: left;"> <br/>
        </p></ix:continuation>
        <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
          <div class="BRPFPageNumberArea" style="text-align: center;"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">F-17</span></div>

          <div class="BRPFPageBreak" style="page-break-after: always;">
            <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"/></div>

          <div class="BRPFPageHeader" style="width: 100%;">
            <div>
              <div style="text-align: left; font-weight: bold; text-indent: -9pt; margin-left: 9pt;"><a href="#ADMABIOLOGICSINC."> <span style="font-style: italic; font-weight: normal; font-size: 8pt;">Table of Contents</span></a><br/>
              </div>

              <div style="text-align: left; font-weight: bold; text-indent: -9pt; margin-left: 9pt;"><a href="#ADMABIOLOGICSINC."><span style="font-style: italic; font-weight: normal; font-size: 8pt;"> <br/>
                  </span></a></div>

              <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">ADMA BIOLOGICS, INC. AND SUBSIDIARIES</div>

              <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</div>

            </div>

          </div>

        </div>

        <ix:continuation id="Text_c56b924cdbae467f84a99efb16acf5776" continuedAt="Text_c56b924cdbae467f84a99efb16acf5777"><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-indent: 45px; text-align: left;">Raw materials includes plasma and other materials expected to be used in the production of ASCENIV, BIVIGAM and Nabi-HB. These materials
          will be consumed in the production of products expected to be available for sale or otherwise have alternative uses that provide a probable future benefit.<br/>
        </p></ix:continuation>
        <ix:continuation id="Text_c56b924cdbae467f84a99efb16acf5777" continuedAt="Text_c56b924cdbae467f84a99efb16acf5778">
<div><br/></div>
</ix:continuation>
        <ix:continuation id="Text_c56b924cdbae467f84a99efb16acf5778" continuedAt="Text_c56b924cdbae467f84a99efb16acf5779"><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-indent: 45px; text-align: left;">Work-in-process inventory primarily consists <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">of the Company&#8217;s IVIG products that are manufactured to the bulk drug substance and unlabeled filled vials stage of
            production</span>.</p></ix:continuation>
        <ix:continuation id="Text_c56b924cdbae467f84a99efb16acf5779" continuedAt="Text_c56b924cdbae467f84a99efb16acf57710"><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-indent: 45px; text-align: left;"> <br/>
        </p></ix:continuation>
        <ix:continuation id="Text_c56b924cdbae467f84a99efb16acf57710"><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-indent: 45px; text-align: left;"> Finished goods inventory is comprised <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">of the Company&#8217;s immunoglobulin products that have reached the filled, labeled and serialized vial stage of production and related
            intermediates that are available for commercial sale, as well as plasma collected at the Company&#8217;s plasma collection centers which is expected to be sold to third-party customers</span>. </p></ix:continuation>
         </div>

      <div><br/></div>

    </div>

  </div>


  <div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: rgb(0, 0, 0);">
    <div>
      <div style="text-align: left; font: 10pt 'Times New Roman';">
        <ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="Text_25e7f8717b9f42dca455b5e4b0aeeb1d" contextRef="c20240101to20241231" escape="true" continuedAt="Text_9442bb8cc8324bb68860d8bd6b38b5871">
<div>
          <table cellspacing="0" cellpadding="0" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt; border-spacing: 0;" class="DSPFListTable">


  <tr style="vertical-align: top;">

    <td style="vertical-align: top; width: 27pt;">
                  <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;"><strong>4.</strong></p>
                </td>

    <td style="align: left; vertical-align: top; width: auto;">
                  <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;"><strong><span style="text-decoration: underline;">PROPERTY AND EQUIPMENT</span></strong></p>
                </td>

  </tr>


</table>
        </div>
</ix:nonNumeric>
        <ix:continuation id="Text_9442bb8cc8324bb68860d8bd6b38b5871" continuedAt="Text_9442bb8cc8324bb68860d8bd6b38b5872"><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;">&#160;</p></ix:continuation>

        <ix:continuation id="Text_9442bb8cc8324bb68860d8bd6b38b5872" continuedAt="Text_9442bb8cc8324bb68860d8bd6b38b5873"><ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="Text_e933337894f14c85baba60c14f8fd2a7" contextRef="c20240101to20241231" escape="true" continuedAt="Text_c5a2ae1171264f798d87bb30d7b53e1a1"><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-indent: 45px; text-align: left;">Property and equipment at December 31, 2024 and 2023 is summarized as follows:</p></ix:nonNumeric></ix:continuation>
        <ix:continuation id="Text_9442bb8cc8324bb68860d8bd6b38b5873" continuedAt="Text_9442bb8cc8324bb68860d8bd6b38b5874"><ix:continuation id="Text_c5a2ae1171264f798d87bb30d7b53e1a1" continuedAt="Text_c5a2ae1171264f798d87bb30d7b53e1a2"><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;">&#160; </p></ix:continuation></ix:continuation>
        <ix:continuation id="Text_9442bb8cc8324bb68860d8bd6b38b5874" continuedAt="Text_9442bb8cc8324bb68860d8bd6b38b5875"><ix:continuation id="Text_c5a2ae1171264f798d87bb30d7b53e1a2">
<table cellspacing="0" cellpadding="0" border="0" style="text-align: left; font: 10pt 'Times New Roman'; width: 100%; border-spacing: 0;" class="cfttable">


  <tr style="height: 15px;">

    <td valign="bottom" style="padding-bottom: 2px;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px;">&#160;</p>
              </td>

    <td valign="bottom" style="text-align: center; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: center; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="2">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: center;"><strong>December 31, 2024</strong></p>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: center; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: center; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="2">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: center;"><strong>December 31, 2023</strong></p>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="vertical-align: top;" rowspan="1">&#160;</td>

    <td valign="bottom" style="text-align: center; vertical-align: bottom;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: center; vertical-align: bottom;" rowspan="1" colspan="6"><span style="font-style: italic;">(In thousands)</span><br/>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="vertical-align: top; width: 76%; background-color: #CCEEFF;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px;">Manufacturing and laboratory equipment</p>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">$</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" id="Fact_aa6dbf497b564214ab43ccfdd9535918" contextRef="c20241231_PropertyPlantAndEquipmentByTypeAxis_ManufacturingFacilityMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">21,305</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">$</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" id="Fact_a47e53229d6240d5a048fd8a8b22bd85" contextRef="c20231231_PropertyPlantAndEquipmentByTypeAxis_ManufacturingFacilityMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">21,093</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="vertical-align: top; width: 76%;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px;">Office equipment and computer software</p>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" id="Fact_36abaf9bb11c484fb52773346d8edfab" contextRef="c20241231_PropertyPlantAndEquipmentByTypeAxis_OfficeEquipmentMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">5,772</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" id="Fact_107912be80b64011bc60694ad8f94e49" contextRef="c20231231_PropertyPlantAndEquipmentByTypeAxis_OfficeEquipmentMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">6,062</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="vertical-align: top; width: 76%; background-color: #CCEEFF;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px;">Furniture and fixtures</p>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" id="Fact_30119b6ed38d47b4b3d5135f83c7c329" contextRef="c20241231_PropertyPlantAndEquipmentByTypeAxis_FurnitureAndFixturesMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">5,840</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" id="Fact_46fc38e5353247edb47a8907215e4a41" contextRef="c20231231_PropertyPlantAndEquipmentByTypeAxis_FurnitureAndFixturesMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">5,776</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="vertical-align: top; width: 76%;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px;">Construction in process</p>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" id="Fact_e0c83890b374412c917a59159bf875c0" contextRef="c20241231_PropertyPlantAndEquipmentByTypeAxis_AssetUnderConstructionMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">8,149</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" id="Fact_06f4f3f9723d4b398fa9034db5633c02" contextRef="c20231231_PropertyPlantAndEquipmentByTypeAxis_AssetUnderConstructionMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,273</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="vertical-align: top; width: 76%; background-color: #CCEEFF;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px;">Leasehold improvements</p>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" id="Fact_aff492e75f9c4986896e96393e223a76" contextRef="c20241231_PropertyPlantAndEquipmentByTypeAxis_LeaseholdImprovementsMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">21,066</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" id="Fact_88d3b55ecd4a421f8fdf400edb659c74" contextRef="c20231231_PropertyPlantAndEquipmentByTypeAxis_LeaseholdImprovementsMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">20,811</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="vertical-align: top; width: 76%;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px;">Land</p>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" id="Fact_0a3e74b485584eb7bea25b949a606c37" contextRef="c20241231_PropertyPlantAndEquipmentByTypeAxis_LandMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,339</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" id="Fact_8a1351672878495386c5ec3a2e402a9b" contextRef="c20231231_PropertyPlantAndEquipmentByTypeAxis_LandMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,339</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="vertical-align: top; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px;">Buildings and building improvements</p>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" colspan="1"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" id="Fact_532b19e3f53344a68069f09928210551" contextRef="c20241231_PropertyPlantAndEquipmentByTypeAxis_BuildingAndBuildingImprovementsMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">21,788</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" colspan="1"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" id="Fact_b891b7bfc6e84dd5bc7e8b579d68148e" contextRef="c20231231_PropertyPlantAndEquipmentByTypeAxis_BuildingAndBuildingImprovementsMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">20,218</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="width: 76%;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px;">&#160;</p>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" id="Fact_1e4d15e6d32b4c629ca8cf77df291d81" contextRef="c20241231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">88,259</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" id="Fact_847117890a41452381585968751b34ac" contextRef="c20231231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">80,572</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="vertical-align: top; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px;">Less: Accumulated depreciation </p>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" colspan="1">(<ix:nonFraction name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" id="Fact_43899c0decaf4f3db7ab64a9565a6017" contextRef="c20241231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">33,552</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">)</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" colspan="1">(<ix:nonFraction name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" id="Fact_cfde5134cc644d89a297b6cf39c4c8a4" contextRef="c20231231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">26,737</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">)</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="vertical-align: top; width: 76%; padding-bottom: 4px;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px;">Total property and equipment, net</p>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);" colspan="1">$</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);" colspan="1"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" id="Fact_0693a2b468234da6b2d3a5e7e53b7e1b" contextRef="c20241231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">54,707</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);" colspan="1">$</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);" colspan="1"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" id="Fact_3c3a5252c63d4f0abd2c9f376cbd828b" contextRef="c20231231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">53,835</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>


</table>
</ix:continuation></ix:continuation>

        <ix:continuation id="Text_9442bb8cc8324bb68860d8bd6b38b5875" continuedAt="Text_9442bb8cc8324bb68860d8bd6b38b5876"><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;">&#160; &#160;</p></ix:continuation>
        <ix:continuation id="Text_9442bb8cc8324bb68860d8bd6b38b5876"><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-indent: 45px; text-align: left;">The Company recorded depreciation expense on property and equipment of $<ix:nonFraction name="us-gaap:DepreciationDepletionAndAmortization" id="Fact_42ffff15e85c41209d48374b23672321" contextRef="c20240101to20241231" unitRef="U001" decimals="-5" scale="6" format="ixt:num-dot-decimal">7.7</ix:nonFraction> million, $<ix:nonFraction name="us-gaap:DepreciationDepletionAndAmortization" id="Fact_88c379b7469e4058920e1a1fd9fc30c5" contextRef="c20230101to20231231" unitRef="U001" decimals="-5" scale="6" format="ixt:num-dot-decimal">7.6</ix:nonFraction> million and $<ix:nonFraction name="us-gaap:DepreciationDepletionAndAmortization" id="Fact_11a2db5a715d43049e08ed29fe7b0770" contextRef="c20220101to20221231" unitRef="U001" decimals="-5" scale="6" format="ixt:num-dot-decimal">6.4</ix:nonFraction> million for the years ended December 31, 2024, 2023 and 2022, respectively.</p></ix:continuation>

        <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;">&#160;</p>
      </div>

    </div>

  </div>


  <div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: rgb(0, 0, 0);">
    <div>
      <div style="text-align: left; font: 10pt 'Times New Roman';">
        <ix:nonNumeric name="us-gaap:IntangibleAssetsDisclosureTextBlock" id="Text_9d38a8bafc864fcd8a731e561133b603" contextRef="c20240101to20241231" escape="true" continuedAt="Text_80ec0633b4a54b06a7942a107bddfeec1">
<div>
          <table cellspacing="0" cellpadding="0" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt; border-spacing: 0;" class="DSPFListTable">


  <tr style="vertical-align: top;">

    <td style="vertical-align: top; width: 27pt;">
                  <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;"><strong>5.</strong></p>
                </td>

    <td style="align: left; vertical-align: top; width: auto;">
                  <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;"><strong><span style="text-decoration: underline;">INTANGIBLE ASSETS</span></strong></p>
                </td>

  </tr>


</table>
        </div>
</ix:nonNumeric>
        <ix:continuation id="Text_80ec0633b4a54b06a7942a107bddfeec1" continuedAt="Text_80ec0633b4a54b06a7942a107bddfeec2"><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;">&#160;</p></ix:continuation>

        <ix:continuation id="Text_80ec0633b4a54b06a7942a107bddfeec2" continuedAt="Text_80ec0633b4a54b06a7942a107bddfeec3"><ix:nonNumeric name="us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" id="Text_c02597785ecc4e12b70404aeb5f94939" contextRef="c20240101to20241231" escape="true" continuedAt="Text_c2a5be85305f42599b34ebbc46a053571"><p style="margin: 0px 0px; font-family: 'Times New Roman'; font-size: 10pt; text-align: left; text-indent: 45px;">Intangible assets at December 31, 2024 and 2023 consist of the following:</p></ix:nonNumeric></ix:continuation>
        <ix:continuation id="Text_80ec0633b4a54b06a7942a107bddfeec3" continuedAt="Text_80ec0633b4a54b06a7942a107bddfeec4"><ix:continuation id="Text_c2a5be85305f42599b34ebbc46a053571" continuedAt="Text_c2a5be85305f42599b34ebbc46a053572"><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;">&#160; </p></ix:continuation></ix:continuation>
        <ix:continuation id="Text_80ec0633b4a54b06a7942a107bddfeec4" continuedAt="Text_80ec0633b4a54b06a7942a107bddfeec5"><ix:continuation id="Text_c2a5be85305f42599b34ebbc46a053572">
<table cellspacing="0" cellpadding="0" border="0" style="text-align: left; font: 10pt 'Times New Roman'; width: 100%; border-spacing: 0;" class="cfttable">


  <tr style="height: 15px;">

    <td valign="bottom" style="padding-bottom: 2px;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px;">&#160;</p>
              </td>

    <td valign="bottom" style="text-align: center; vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: center; border-bottom: #000000 solid 2px;" colspan="10">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: center;"><span style="font-weight: bold;">December 31, 2024</span><br/>
                </p>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: center; vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: center; border-bottom: #000000 solid 2px;" colspan="10">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: center;"><span style="font-weight: bold;">December 31, 2023</span><br/>
                </p>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" rowspan="1">&#160;</td>

    <td valign="bottom" style="text-align: center; vertical-align: bottom;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: center;" rowspan="1" colspan="22"><span style="font-style: italic;">(In thousands) </span> <br/>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="padding-bottom: 2px;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px;">&#160;</p>
              </td>

    <td valign="bottom" style="text-align: center; vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: center; border-bottom: #000000 solid 2px;" colspan="2">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: center;"><strong> Cost</strong></p>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: center; vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: center; border-bottom: #000000 solid 2px;" colspan="2">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in;"><strong>Accumulated</strong></p>
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in;"><strong>Amortization</strong></p>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: center; vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: center; border-bottom: #000000 solid 2px;" colspan="2">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: center;"><strong>Net</strong></p>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: center; vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: center; border-bottom: #000000 solid 2px;" colspan="2">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: center;"><strong>Cost</strong></p>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: center; vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: center; border-bottom: #000000 solid 2px;" colspan="2">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in;"><strong>Accumulated</strong></p>
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in;"><strong>Amortization</strong></p>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: center; vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: center; border-bottom: #000000 solid 2px;" colspan="2">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: center;"><strong>Net</strong></p>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="vertical-align: top; width: 28%; background-color: #CCEEFF;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-bottom: 0px; text-indent: -9pt; margin-left: 9pt;">Trademark and other intangible rights related to Nabi-HB</p>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">$</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" id="Fact_534fc1de43f44be1b24f66ca7b877327" contextRef="c20241231_FiniteLivedIntangibleAssetsByMajorClassAxis_TrademarkAndOtherIntangibleRightsRelatedToNabiHBMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,100</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">$</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" id="Fact_0479e2bce8f64fb9aa7bed020a2af6cf" contextRef="c20241231_FiniteLivedIntangibleAssetsByMajorClassAxis_TrademarkAndOtherIntangibleRightsRelatedToNabiHBMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,100</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">$</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" id="Fact_2aa9cfad7a4d441d8993094838ebf649" contextRef="c20241231_FiniteLivedIntangibleAssetsByMajorClassAxis_TrademarkAndOtherIntangibleRightsRelatedToNabiHBMember" unitRef="U001" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">$</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" id="Fact_d76168a506fc45de82f46cca41c13a7c" contextRef="c20231231_FiniteLivedIntangibleAssetsByMajorClassAxis_TrademarkAndOtherIntangibleRightsRelatedToNabiHBMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,100</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">$</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" id="Fact_5e6d01896e914b8c830d79cbfd996aa7" contextRef="c20231231_FiniteLivedIntangibleAssetsByMajorClassAxis_TrademarkAndOtherIntangibleRightsRelatedToNabiHBMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,856</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">$</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" id="Fact_c1b3dee22278445ea13416936b914cdd" contextRef="c20231231_FiniteLivedIntangibleAssetsByMajorClassAxis_TrademarkAndOtherIntangibleRightsRelatedToNabiHBMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">244</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="vertical-align: top; font-size: 10pt; width: 28%;" rowspan="1"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: -9.6px; text-transform: none; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">Internally developed software</span></td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" id="Fact_3352f25612b944b1b8ca2fbf5f8b0328" contextRef="c20241231_FiniteLivedIntangibleAssetsByMajorClassAxis_ComputerSoftwareIntangibleAssetMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">559</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" id="Fact_8126edd30a4b4d8a9f9ec2fde01e56f3" contextRef="c20241231_FiniteLivedIntangibleAssetsByMajorClassAxis_ComputerSoftwareIntangibleAssetMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">99</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" id="Fact_97298e60f3694fe1966380e12b466030" contextRef="c20241231_FiniteLivedIntangibleAssetsByMajorClassAxis_ComputerSoftwareIntangibleAssetMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">460</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" id="Fact_504f6fdde49a4bcf8ccd23455230bdc4" contextRef="c20231231_FiniteLivedIntangibleAssetsByMajorClassAxis_ComputerSoftwareIntangibleAssetMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">210</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" id="Fact_426c54bda1124e7fb774b857e2e4b4b1" contextRef="c20231231_FiniteLivedIntangibleAssetsByMajorClassAxis_ComputerSoftwareIntangibleAssetMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">9</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" id="Fact_7da85b5734694e39ac4610e300189cb0" contextRef="c20231231_FiniteLivedIntangibleAssetsByMajorClassAxis_ComputerSoftwareIntangibleAssetMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">201</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="vertical-align: top; width: 28%; padding-bottom: 2px; background-color: #CCEEFF;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-bottom: 0px; text-indent: -9pt; margin-left: 9pt;">Rights to intermediates</p>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" colspan="1"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" id="Fact_cd2db5e1b50944469cf7cbc23fb182eb" contextRef="c20241231_FiniteLivedIntangibleAssetsByMajorClassAxis_RightToIntermediatesMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">907</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" colspan="1"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" id="Fact_7b1605ed35054eecb92e7189ce58d666" contextRef="c20241231_FiniteLivedIntangibleAssetsByMajorClassAxis_RightToIntermediatesMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">907</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" colspan="1"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" id="Fact_e6feb7f4495f43109e3e87c432870678" contextRef="c20241231_FiniteLivedIntangibleAssetsByMajorClassAxis_RightToIntermediatesMember" unitRef="U001" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" colspan="1"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" id="Fact_00d2ccdaffc248169b383103970c463f" contextRef="c20231231_FiniteLivedIntangibleAssetsByMajorClassAxis_RightToIntermediatesMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">907</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" colspan="1"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" id="Fact_ee0f724f67b849ff87345b9e0fa4de89" contextRef="c20231231_FiniteLivedIntangibleAssetsByMajorClassAxis_RightToIntermediatesMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">853</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" colspan="1"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" id="Fact_3e48ffb1becf4744ae890916360e9775" contextRef="c20231231_FiniteLivedIntangibleAssetsByMajorClassAxis_RightToIntermediatesMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">54</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="width: 28%; padding-bottom: 4px;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px;">&#160;</p>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);" colspan="1">$</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);" colspan="1"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" id="Fact_9559a344ab084f93ba7db85035e579bb" contextRef="c20241231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">5,566</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);" colspan="1">$</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);" colspan="1"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" id="Fact_ec50e08f01524352a984c94040cc44e6" contextRef="c20241231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">5,106</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);" colspan="1">$</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);" colspan="1"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" id="Fact_382a62bd170e4c8d891beed28dc413b2" contextRef="c20241231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">460</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);" colspan="1">$</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);" colspan="1"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" id="Fact_8ec4bd2649f044c9ac74dea20865c49e" contextRef="c20231231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">5,217</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);" colspan="1">$</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);" colspan="1"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" id="Fact_ac0bae978421496dbb21c5bc12e92aaf" contextRef="c20231231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,718</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);" colspan="1">$</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);" colspan="1"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsNet" id="Fact_8390571e75fa4c5d9b4184613d373abf" contextRef="c20231231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">499</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>


</table>
</ix:continuation></ix:continuation>

        <ix:continuation id="Text_80ec0633b4a54b06a7942a107bddfeec5" continuedAt="Text_80ec0633b4a54b06a7942a107bddfeec6"><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;">&#160; &#160;</p></ix:continuation>
        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div class="BRPFPageNumberArea" style="text-align: center;"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">F-18</span></div>

          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"/></div>

          <div class="BRPFPageHeader" style="width: 100%;">
            <div>
              <div style="text-align: left; font-weight: bold; text-indent: -9pt; margin-left: 9pt;"><a href="#ADMABIOLOGICSINC."> <span style="font-style: italic; font-weight: normal; font-size: 8pt;">Table of Contents</span></a><br/>
              </div>

              <div style="text-align: left; font-weight: bold; text-indent: -9pt; margin-left: 9pt;"><a href="#ADMABIOLOGICSINC."><span style="font-style: italic; font-weight: normal; font-size: 8pt;"> <br/>
                  </span></a></div>

              <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">ADMA BIOLOGICS, INC. AND SUBSIDIARIES</div>

              <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</div>

            </div>

          </div>

        </div>

        <ix:continuation id="Text_80ec0633b4a54b06a7942a107bddfeec6" continuedAt="Text_80ec0633b4a54b06a7942a107bddfeec7"><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-indent: 45px; text-align: left;"> </p></ix:continuation>
        <ix:continuation id="Text_80ec0633b4a54b06a7942a107bddfeec7" continuedAt="Text_80ec0633b4a54b06a7942a107bddfeec8">
<div style="display:none;"><br/></div>
<div style="margin: 0px 0px 0px; font-family: 'Times New Roman'; font-size: 10pt; text-align: left; text-indent: 27pt;">Under the previous contract manufacturing agreement between ADMA and Biotest, intermediate by-products derived from the
          manufacture of ASCENIV were property of Biotest.&#160; As a result of the acquisition of certain assets from Biotest on June 6, 2017, ADMA obtained the right to these intermediate products as well as the intangible rights to Nabi-HB, which were
          amortized over a period of <ix:nonNumeric name="us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" id="Fact_fcd67a71fa3440f586a12eece43d3035" contextRef="c20241231_FiniteLivedIntangibleAssetsByMajorClassAxis_TrademarkAndOtherIntangibleRightsRelatedToNabiHBMember" format="ixt-sec:durwordsen">seven years</ix:nonNumeric>. As of December 31, 2024, the Company&#8217;s intangible assets are comprised of several internally
          developed data intelligence and analytics programs at a cost of approximately $<ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsGross" id="Fact_2ac313a3adda4c118f1f868eb7f4d822" contextRef="c20241231_FiniteLivedIntangibleAssetsByMajorClassAxis_ComputerSoftwareIntangibleAssetMember" unitRef="U001" decimals="-5" scale="6" format="ixt:num-dot-decimal">0.6</ix:nonFraction> million which is being amortized over a period of <ix:nonNumeric name="us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" id="Fact_a264a5e595b54ce4a17382d1a2f801a4" contextRef="c20241231_FiniteLivedIntangibleAssetsByMajorClassAxis_ComputerSoftwareIntangibleAssetMember" format="ixt-sec:durwordsen">four years</ix:nonNumeric>.</div>
</ix:continuation>
        <ix:continuation id="Text_80ec0633b4a54b06a7942a107bddfeec8" continuedAt="Text_80ec0633b4a54b06a7942a107bddfeec9">
<div style="display:none;"><br/></div>
<div style="margin: 0px 0px 0px; font-family: 'Times New Roman'; font-size: 10pt; text-align: left; text-indent: 27pt;"> <br/>
        </div>
</ix:continuation>

        <ix:continuation id="Text_80ec0633b4a54b06a7942a107bddfeec9" continuedAt="Text_80ec0633b4a54b06a7942a107bddfeec10"><ix:nonNumeric name="us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" id="Text_9bcc8822d32f4c3e9de7c27000ab8495" contextRef="c20240101to20241231" escape="true" continuedAt="Text_9c5d819fcbea488a8971b44e93f8f9ed1"><p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-bottom: 0px; text-align: left; text-indent: 27pt;">Amortization expense related to the Company&#8217;s intangible assets for the years ended December 31, 2024, 2023 and
          2022 was $<ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" id="Fact_267044ebfc6b4560a757a9bc2b642e5d" contextRef="c20240101to20241231" unitRef="U001" decimals="-5" scale="6" format="ixt:num-dot-decimal">0.4</ix:nonFraction> million, $<ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" id="Fact_c273c5446532412c817cb4d801c9e96f" contextRef="c20230101to20231231" unitRef="U001" decimals="-5" scale="6" format="ixt:num-dot-decimal">0.7</ix:nonFraction>
          million and $<ix:nonFraction name="us-gaap:AmortizationOfIntangibleAssets" id="Fact_1e8b7036359b462cabe0dc4ce4ea8771" contextRef="c20220101to20221231" unitRef="U001" decimals="-5" scale="6" format="ixt:num-dot-decimal">0.7</ix:nonFraction> million, respectively. Estimated aggregate future aggregate amortization expense is expected to be as follows (in
          thousands):</p></ix:nonNumeric></ix:continuation>
        <ix:continuation id="Text_80ec0633b4a54b06a7942a107bddfeec10" continuedAt="Text_80ec0633b4a54b06a7942a107bddfeec11"><ix:continuation id="Text_9c5d819fcbea488a8971b44e93f8f9ed1" continuedAt="Text_9c5d819fcbea488a8971b44e93f8f9ed2"><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;">&#160;</p></ix:continuation></ix:continuation>
        <ix:continuation id="Text_80ec0633b4a54b06a7942a107bddfeec11"><ix:continuation id="Text_9c5d819fcbea488a8971b44e93f8f9ed2">
<table cellspacing="0" cellpadding="0" border="0" class="cfttable" style="text-align: left; font: 10pt 'Times New Roman'; width: 100%; border-spacing: 0;">


  <tr style="height: 15px;">

    <td valign="bottom" style="vertical-align: top; width: 88%; background-color: #CCEEFF;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in;">2025<br/>
                </p>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">$<br/>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths" id="Fact_72efdd44d1364ed6b8e52365d2022111" contextRef="c20241231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">140</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="vertical-align: top; width: 88%;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in;">2026<br/>
                </p>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;">$ <br/>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo" id="Fact_e92dc7cb12f84c13bdd57149c2b28638" contextRef="c20241231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">140</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" rowspan="1" style="vertical-align: top; width: 88%; background-color: #CCEEFF;">
                <div>2027<br/>
                </div>
              </td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">$ <br/>
              </td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree" id="Fact_a7d614e9ded14bbe84c05fa4f8c4d342" contextRef="c20241231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">130</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" rowspan="1" style="vertical-align: top; width: 88%;">2028<br/>
              </td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;">$ <br/>
              </td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;"><ix:nonFraction name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour" id="Fact_72beb712b8134178a3debcd79a032fe4" contextRef="c20241231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">50</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>


</table>
</ix:continuation></ix:continuation>
          </div>

      <div><br/></div>

    </div>

  </div>


  <div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: rgb(0, 0, 0);">
    <div>
      <div style="text-align: left; font: 10pt 'Times New Roman';">
        <ix:nonNumeric name="us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" id="Text_ca422ff2de49406a93a9174f6351500f" contextRef="c20240101to20241231" escape="true" continuedAt="Text_ab18889cd70642b786c42e6957d7063c1">
<div>
          <table cellspacing="0" cellpadding="0" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt; border-spacing: 0;" class="DSPFListTable">


  <tr style="vertical-align: top;">

    <td style="vertical-align: top; width: 27pt;">
                  <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;"><strong>6.</strong></p>
                </td>

    <td style="align: left; vertical-align: top; width: auto;">
                  <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;"><strong><span style="text-decoration: underline;">ACCRUED EXPENSES AND OTHER LIABILITIES</span></strong></p>
                </td>

  </tr>


</table>
        </div>
</ix:nonNumeric>
        <ix:continuation id="Text_ab18889cd70642b786c42e6957d7063c1" continuedAt="Text_ab18889cd70642b786c42e6957d7063c2"><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;">&#160;</p></ix:continuation>

        <ix:continuation id="Text_ab18889cd70642b786c42e6957d7063c2" continuedAt="Text_ab18889cd70642b786c42e6957d7063c3"><ix:nonNumeric name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="Text_efc75356c82444eabb05c5bcc9aad4db" contextRef="c20240101to20241231" escape="true" continuedAt="Text_20d85b6d0b09458e9b1e4cbb20a647d31"><p style="margin: 0px 0px; font-family: 'Times New Roman'; font-size: 10pt; text-align: left; text-indent: 45px;">Accrued expenses and other current liabilities at December 31, 2024 and 2023 are as follows:</p></ix:nonNumeric></ix:continuation>
        <ix:continuation id="Text_ab18889cd70642b786c42e6957d7063c3" continuedAt="Text_ab18889cd70642b786c42e6957d7063c4"><ix:continuation id="Text_20d85b6d0b09458e9b1e4cbb20a647d31" continuedAt="Text_20d85b6d0b09458e9b1e4cbb20a647d32"><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;">&#160;</p></ix:continuation></ix:continuation>
        <ix:continuation id="Text_ab18889cd70642b786c42e6957d7063c4"><ix:continuation id="Text_20d85b6d0b09458e9b1e4cbb20a647d32">
<table cellspacing="0" cellpadding="0" border="0" style="text-align: left; font: 10pt 'Times New Roman'; width: 100%; border-spacing: 0;" class="cfttable">


  <tr style="height: 15px;">

    <td valign="bottom" style="padding-bottom: 2px; white-space: nowrap;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px;">&#160;</p>
              </td>

    <td valign="bottom" style="text-align: center; vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: center; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="2">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: center;"><strong>December 31, 2024
                  </strong></p>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: center; vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: center; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="2"><strong>December 31, 2023</strong></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" rowspan="1" style="white-space: nowrap;">&#160;</td>

    <td valign="bottom" style="text-align: center; vertical-align: bottom;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: center;" rowspan="1" colspan="6"><span style="font-style: italic;">(In thousands)</span> <br/>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="vertical-align: top; width: 76%; background-color: #CCEEFF;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-bottom: 0px; text-indent: -9pt; margin-left: 9pt;">Accrued rebates</p>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">$ <br/>
              </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1"><ix:nonFraction name="adma:AccruedRebatesCurrent" id="Fact_2520dc9659e6456382d3b2598fd5800a" contextRef="c20241231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,155</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">$</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1"><ix:nonFraction name="adma:AccruedRebatesCurrent" id="Fact_d244dfd97ccb4da299238074a38a8d0f" contextRef="c20231231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">16,608</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="vertical-align: top; width: 76%;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-bottom: 0px; text-indent: -9pt; margin-left: 9pt;">Accrued distribution fees</p>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1"><ix:nonFraction name="us-gaap:AccruedProfessionalFeesCurrent" id="Fact_d055a4f1abb6441dbf84dd4adc217854" contextRef="c20241231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">11,565</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1"><ix:nonFraction name="us-gaap:AccruedProfessionalFeesCurrent" id="Fact_4b9deac527db4a9893c6436d01cabb70" contextRef="c20231231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">5,954</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="vertical-align: top; width: 76%; background-color: #CCEEFF;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-bottom: 0px; text-indent: -9pt; margin-left: 9pt;">Accrued incentives</p>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1"><ix:nonFraction name="us-gaap:AccruedBonusesCurrent" id="Fact_8b76dd60c6974e739dad88d11ec39233" contextRef="c20241231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">5,892</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1"><ix:nonFraction name="us-gaap:AccruedBonusesCurrent" id="Fact_5d5b91778c7b41fb8ad8368becc5c251" contextRef="c20231231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,961</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="vertical-align: top; width: 76%;" rowspan="1">Accrued interest<br/>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:InterestPayableCurrent" id="Fact_b161695ff8834e8eadcb90e9876dd36c" contextRef="c20241231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,857</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:InterestPayableCurrent" id="Fact_eb6746edff8f42179244467604520382" contextRef="c20231231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">546</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="vertical-align: top; width: 76%; background-color: #CCEEFF;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-bottom: 0px; text-indent: -9pt; margin-left: 9pt;">Accrued testing</p>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1"><ix:nonFraction name="adma:AccruedTestingCurrent" id="Fact_c67935c3b02846f18b7b5b199a6f3844" contextRef="c20241231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">827</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1"><ix:nonFraction name="adma:AccruedTestingCurrent" id="Fact_ad81e063c08843449d4a1637d9d6f84a" contextRef="c20231231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">282</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="vertical-align: top; width: 76%;">
                <div style="color: rgb(0, 0, 0); text-indent: -9pt; margin-left: 9pt;">Accrued payroll and other compensation</div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1"><ix:nonFraction name="us-gaap:AccruedSalariesCurrent" id="Fact_c9bc5533fa18499a9d544a44b787d360" contextRef="c20241231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,332</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1"><ix:nonFraction name="us-gaap:AccruedSalariesCurrent" id="Fact_c435e74add454f2993fb472cef56c0c8" contextRef="c20231231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,203</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="vertical-align: top; width: 76%; background-color: #CCEEFF;" rowspan="1">Income taxes payable<br/>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:TaxesPayableCurrent" id="Fact_5d65b6e6a59747bba0b8cfb2c7fcc6fa" contextRef="c20241231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,481</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:TaxesPayableCurrent" id="Fact_6a4ecf3a44a342d6af3c65bc691fce6b" contextRef="c20231231" unitRef="U001" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="vertical-align: top; width: 76%; padding-bottom: 2px;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-bottom: 0px; text-indent: -9pt; margin-left: 9pt;">Other</p>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" colspan="1"><ix:nonFraction name="us-gaap:OtherAccruedLiabilitiesCurrent" id="Fact_15d72dec1c21407abc16c779291c02c4" contextRef="c20241231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,853</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" colspan="1"><ix:nonFraction name="us-gaap:OtherAccruedLiabilitiesCurrent" id="Fact_ed0341fc4057473f90de6fb1c1ca38b8" contextRef="c20231231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,365</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="vertical-align: top; width: 76%; background-color: rgb(204, 238, 255); padding-bottom: 4px;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-bottom: 0px; text-indent: -9pt; margin-left: 18pt;">Total accrued expenses and other current liabilities</p>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 4px double rgb(0, 0, 0);" colspan="1">$ <br/>
              </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 4px double rgb(0, 0, 0);" colspan="1"><ix:nonFraction name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" id="Fact_d91dcf9a3ce644a29b87e130926d727f" contextRef="c20241231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">33,962</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 4px double rgb(0, 0, 0);" colspan="1">$</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 4px double rgb(0, 0, 0);" colspan="1"><ix:nonFraction name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" id="Fact_15ac5c61a7e74ec28f279f8c090ecb5e" contextRef="c20231231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">32,919</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>


</table>
</ix:continuation></ix:continuation>


        <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;">&#160; &#160;</p>
      </div>

    </div>

  </div>


  <div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: rgb(0, 0, 0);">
    <div>
      <div style="text-align: left; font: 10pt 'Times New Roman';">
        <ix:nonNumeric name="us-gaap:LongTermDebtTextBlock" id="Text_a51f5e7cb0d14433ac93262403a99623" contextRef="c20240101to20241231" escape="true" continuedAt="Text_d63af97cb57443219f8e78cbdd4b93361">
<div>
          <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt; border-spacing: 0;">


  <tr style="vertical-align: top;">

    <td style="vertical-align: top; width: 27pt;">
                  <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;"><strong>7.</strong></p>
                </td>

    <td style="vertical-align: top; width: auto;">
                  <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;"><strong><span style="text-decoration: underline;">NOTES PAYABLE<br/>
                      </span></strong></p>
                </td>

  </tr>


</table>
        </div>
</ix:nonNumeric>
        <ix:continuation id="Text_d63af97cb57443219f8e78cbdd4b93361" continuedAt="Text_d63af97cb57443219f8e78cbdd4b93362"><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;">&#160;</p></ix:continuation>
        <ix:continuation id="Text_d63af97cb57443219f8e78cbdd4b93362" continuedAt="Text_d63af97cb57443219f8e78cbdd4b93363"><p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-bottom: 0px; text-align: left;"><span style="text-decoration: underline;">Senior Notes Payable</span></p></ix:continuation>
        <ix:continuation id="Text_d63af97cb57443219f8e78cbdd4b93363" continuedAt="Text_d63af97cb57443219f8e78cbdd4b93364"><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;">&#160;</p></ix:continuation>

        <ix:continuation id="Text_d63af97cb57443219f8e78cbdd4b93364" continuedAt="Text_d63af97cb57443219f8e78cbdd4b93365"><ix:nonNumeric name="us-gaap:ScheduleOfDebtTableTextBlock" id="Text_fbdb6915daed4323a06f872dafe9a2af" contextRef="c20240101to20241231" escape="true" continuedAt="Text_bbdf55560de846a09dcfa25ede1492711"><p style="margin-top: 0px; margin-bottom: 0px; font-family: 'Times New Roman'; font-size: 10pt; text-align: left; text-indent: 27pt;">A summary of outstanding senior notes payable is as follows:</p></ix:nonNumeric></ix:continuation>
        <ix:continuation id="Text_d63af97cb57443219f8e78cbdd4b93365" continuedAt="Text_d63af97cb57443219f8e78cbdd4b93366"><ix:continuation id="Text_bbdf55560de846a09dcfa25ede1492711" continuedAt="Text_bbdf55560de846a09dcfa25ede1492712"><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px;">&#160;&#160; <br/>
        </p></ix:continuation></ix:continuation>
        <ix:continuation id="Text_d63af97cb57443219f8e78cbdd4b93366" continuedAt="Text_d63af97cb57443219f8e78cbdd4b93367"><ix:continuation id="Text_bbdf55560de846a09dcfa25ede1492712">
<table cellspacing="0" cellpadding="0" border="0" style="text-align: left; font: 10pt 'Times New Roman'; width: 100%; border-spacing: 0;" class="cfttable">


  <tr style="height: 15px;">

    <td valign="bottom" style="padding-bottom: 2px; white-space: nowrap;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px;">&#160;</p>
              </td>

    <td valign="bottom" style="text-align: center; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: center; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" colspan="2">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: center;"><strong>December 31, 2024</strong></p>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: center; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: center; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" colspan="2">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: center;"><strong>December 31, 2023</strong></p>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" rowspan="1" style="vertical-align: top; width: 76%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" rowspan="1" style="text-align: center; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="6"><span style="font-style: italic;">(In thousands)</span><br/>
              </td>

    <td valign="bottom" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="vertical-align: top; width: 76%; background-color: rgb(204, 238, 255);">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 9pt; text-indent: -9pt;">Term loan<br/>
                </p>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">$</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1"><ix:nonFraction name="adma:SeniorNotesPayableBeforeDebtDiscount" id="Fact_9d0dd84a5e764974b5fe205672e8523b" contextRef="c20241231_CreditFacilityAxis_TermLoanMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">32,500</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">$</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1"><ix:nonFraction name="adma:SeniorNotesPayableBeforeDebtDiscount" id="Fact_b8cb21b7157e4f31849c0a5ee02bcd4d" contextRef="c20231231_CreditFacilityAxis_TermLoanMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">62,500</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="vertical-align: top; width: 76%;" rowspan="1">
                <div style="margin-left: 9pt; text-indent: -9pt;">Revolving credit facility<br/>
                </div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1" rowspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1" rowspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1" rowspan="1"><ix:nonFraction name="adma:SeniorNotesPayableBeforeDebtDiscount" id="Fact_63d32cc0856f40e8bd166cc04cd4e84a" contextRef="c20241231_CreditFacilityAxis_RevolvingCreditFacilityMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">42,500</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1" rowspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1" rowspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1" rowspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1" rowspan="1"><ix:nonFraction name="adma:SeniorNotesPayableBeforeDebtDiscount" id="Fact_4c4499632d58430abc9e9a32d333dc64" contextRef="c20231231_CreditFacilityAxis_RevolvingCreditFacilityMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">72,500</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1" rowspan="1">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="vertical-align: top; width: 76%; background-color: rgb(204, 238, 255);">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in;">Less:<br/>
                </p>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="vertical-align: top; width: 76%; padding-bottom: 2px;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 15px;">Debt discount</p>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1">(<ix:nonFraction name="us-gaap:DebtInstrumentUnamortizedDiscount" id="Fact_11c432f666f34c7694c8af6fb0fe4743" contextRef="c20241231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,663</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">)</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" colspan="1">(<ix:nonFraction name="us-gaap:DebtInstrumentUnamortizedDiscount" id="Fact_d9ef24ea668f46f1b2643b9b3a6dcba4" contextRef="c20231231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,406</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">)</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="vertical-align: top; width: 76%; background-color: rgb(204, 238, 255); padding-bottom: 4px;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in;">Senior notes payable</p>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 4px double rgb(0, 0, 0);" colspan="1">$</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 4px double rgb(0, 0, 0);" colspan="1"><ix:nonFraction name="us-gaap:SeniorLongTermNotes" id="Fact_f035b68443964af39d20af8975fedfa6" contextRef="c20241231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">72,337</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 4px double rgb(0, 0, 0);" colspan="1">$</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 4px double rgb(0, 0, 0);" colspan="1"><ix:nonFraction name="us-gaap:SeniorLongTermNotes" id="Fact_f79c082a7ec94b49995d7ba0c531a119" contextRef="c20231231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">130,594</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>


</table>
</ix:continuation></ix:continuation>

        <ix:continuation id="Text_d63af97cb57443219f8e78cbdd4b93367" continuedAt="Text_d63af97cb57443219f8e78cbdd4b93368"><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px;">&#160;&#160; &#160;</p></ix:continuation>
        <div style="font-family: 'Times New Roman';">
          <ix:continuation id="Text_d63af97cb57443219f8e78cbdd4b93368" continuedAt="Text_d63af97cb57443219f8e78cbdd4b93369">
<div style="display:none;"><br/></div>
<div style="text-align: left; font-size: 10pt; text-indent: 27pt; font-weight: normal; font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none;">On December 18, 2023 (the &#8220;Ares Closing Date&#8221;), the Company
            and all of its subsidiaries entered into a new senior secured credit facility (the &#8220;Ares Credit Agreement&#8221;) with Ares Capital Corporation and certain credit funds affiliated with Ares Capital Corporation (collectively, &#8220;Ares&#8221;). The Ares Credit
            Agreement provided for a total of $<ix:nonFraction name="adma:SeniorNotesPayableBeforeDebtDiscount" id="Fact_3583fceccc6e4d038ec945011c367736" contextRef="c20231218" unitRef="U001" decimals="-5" scale="6" format="ixt:num-dot-decimal">135.0</ix:nonFraction> million in senior secured credit facilities (the &#8220;Ares Credit Facility&#8221;) consisting of (i) a
            term loan in the aggregate principal amount of $<ix:nonFraction name="adma:SeniorNotesPayableBeforeDebtDiscount" id="Fact_0b91c70b806e4c8cb3ec5aef33328c28" contextRef="c20231231_CreditFacilityAxis_TermLoanMember" unitRef="U001" decimals="-5" scale="6" format="ixt:num-dot-decimal">62.5</ix:nonFraction> million and (ii) a revolving credit facility in the aggregate principal amount
            of $<ix:nonFraction name="adma:SeniorNotesPayableBeforeDebtDiscount" id="Fact_f7896de8cb124b048313cb85323eee36" contextRef="c20231231_CreditFacilityAxis_RevolvingCreditFacilityMember" unitRef="U001" decimals="-5" scale="6" format="ixt:num-dot-decimal">72.5</ix:nonFraction> million (collectively, the &#8220;Ares Loans&#8221;), both of which were fully drawn on the Ares Closing Date. The Ares Credit Facility
            has a maturity date of <ix:nonNumeric name="us-gaap:DebtInstrumentMaturityDate" id="Fact_26c04a165e944612ba27afe84f85f788" contextRef="c20240101to20241231_CounterpartyNameAxis_AresCreditAgreementMember_DebtInstrumentAxis_AresCreditFacilityMember" format="ixt:date-monthname-day-year-en">December 20, 2027</ix:nonNumeric> (the &#8220;Ares Maturity Date&#8221;). On the Ares Closing Date, the Company used the proceeds from
            the Ares Loans, along with a portion of its existing cash on hand, to terminate and pay in full all of the outstanding obligations under the Company&#8217;s previous senior credit facility (the &#8220;Hayfin Credit Facility&#8221;) with Hayfin Services LLP
            (&#8220;Hayfin&#8221;) including the outstanding principal in the amount of $<ix:nonFraction name="us-gaap:DebtInstrumentCarryingAmount" id="Fact_f48ff84a07b3435eb448923bffd4c1ab" contextRef="c20231218_DebtInstrumentAxis_HayfinCreditFacilityMember" unitRef="U001" decimals="-5" scale="6" format="ixt:num-dot-decimal">158.6</ix:nonFraction> million, a prepayment penalty in the amount $<ix:nonFraction name="adma:LongTermDebtPrepaymentPenalty" id="Fact_8fc951edb9eb490699ce77510f9327a0" contextRef="c20231218_DebtInstrumentAxis_HayfinCreditFacilityMember" unitRef="U001" decimals="-5" scale="6" format="ixt:num-dot-decimal">11.1</ix:nonFraction> million, an exit fee of $<ix:nonFraction name="adma:DebtInstrumentExitFee" id="Fact_49793c36e5ad43fb8a6996ac887e02e1" contextRef="c20231218_DebtInstrumentAxis_HayfinCreditFacilityMember" unitRef="U001" decimals="-5" scale="6" format="ixt:num-dot-decimal">1.6</ix:nonFraction>
            million, all accrued and unpaid interest outstanding on the Hayfin Credit Facility as of the Ares Closing date, as well as certain fees and expenses related thereto. In connection with the payoff and termination of the Hayfin Credit Facility,
            the Company also wrote off $<ix:nonFraction name="us-gaap:DebtInstrumentUnamortizedDiscount" id="Fact_7ca2cddd21aa43a4abbc0351a2e62ab4" contextRef="c20231218_DebtInstrumentAxis_HayfinCreditFacilityMember" unitRef="U001" decimals="-5" scale="6" format="ixt:num-dot-decimal">15.0</ix:nonFraction> million of unamortized debt discount related to the Hayfin Credit Facility. As a result of this
            transaction, the Company recorded a loss on the extinguishment of the Hayfin Credit Facility for the year ended December 31, 2023 in the amount of $<ix:nonFraction name="us-gaap:GainsLossesOnExtinguishmentOfDebt" id="Fact_c4bebc1029794b76830602db0eef68b2" contextRef="c20230101to20231231_DebtInstrumentAxis_HayfinCreditFacilityMember" unitRef="U001" decimals="-5" scale="6" sign="-" format="ixt:num-dot-decimal">26.2</ix:nonFraction>
            million, which is mainly comprised of the write-off of unamortized debt discount and the prepayment penalty.</div>
</ix:continuation>
          <ix:continuation id="Text_d63af97cb57443219f8e78cbdd4b93369" continuedAt="Text_d63af97cb57443219f8e78cbdd4b933610">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt;"> </span></div>
</ix:continuation>
          <ix:continuation id="Text_d63af97cb57443219f8e78cbdd4b933610" continuedAt="Text_d63af97cb57443219f8e78cbdd4b933611">
<div style="display:none;"><br/></div>
<div style="text-align: left; font-size: 10pt; text-indent: 27pt; font-weight: normal; font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none;"><span style="font-family: 'Times New Roman'; font-size: 10pt;">
              <br/>
            </span> </div>
</ix:continuation>
          <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
            <div class="BRPFPageNumberArea" style="text-align: center;"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">F-19</span></div>

            <div style="page-break-after: always;" class="BRPFPageBreak">
              <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"/></div>

            <div class="BRPFPageHeader" style="width: 100%;">
              <div>
                <div style="text-align: left; font-weight: bold; text-indent: -9pt; margin-left: 9pt;"><a href="#ADMABIOLOGICSINC."> <span style="font-style: italic; font-weight: normal; font-size: 8pt;">Table of Contents</span></a><br/>
                </div>

                <div style="text-align: left; font-weight: bold; text-indent: -9pt; margin-left: 9pt;"><a href="#ADMABIOLOGICSINC."><span style="font-style: italic; font-weight: normal; font-size: 8pt;"> <br/>
                    </span></a></div>

                <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">ADMA BIOLOGICS, INC. AND SUBSIDIARIES</div>

                <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</div>

              </div>

            </div>

          </div>

          <ix:continuation id="Text_d63af97cb57443219f8e78cbdd4b933611" continuedAt="Text_d63af97cb57443219f8e78cbdd4b933612">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt;"> </span></div>
</ix:continuation>
          <div style="text-align: left; font-size: 10pt; font-weight: normal; font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none;">
            <ix:continuation id="Text_d63af97cb57443219f8e78cbdd4b933612" continuedAt="Text_d63af97cb57443219f8e78cbdd4b933613">
<div style="display:none;"><br/></div>
<div style="text-indent: 27pt;"><span style="font-family: 'Times New Roman'; font-size: 10pt;">On August 14, 2024, the Company repaid $<ix:nonFraction name="us-gaap:RepaymentsOfLongTermLinesOfCredit" id="Fact_fda7d7b72c604a92ab4aca800dec6845" contextRef="c20240814to20240814_CreditFacilityAxis_RevolvingCreditFacilityMember" unitRef="U001" decimals="-5" scale="6" format="ixt:num-dot-decimal">30.0</ix:nonFraction>
                million against the revolving credit facility and the outstanding balance on the revolving credit facility as of December 31, 2024 was $<ix:nonFraction name="adma:SeniorNotesPayableBeforeDebtDiscount" id="Fact_d2f0f38a7f3b46f8a6ab45b5d9dc1850" contextRef="c20241231_CreditFacilityAxis_RevolvingCreditFacilityMember" unitRef="U001" decimals="-5" scale="6" format="ixt:num-dot-decimal">42.5</ix:nonFraction>
                million, with an additional $<ix:nonFraction name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" id="Fact_00aede4314d244e1bcf593a859ce6283" contextRef="c20240814_CounterpartyNameAxis_AresCreditAgreementMember_DebtInstrumentAxis_AresCreditFacilityMember" unitRef="U001" decimals="-5" scale="6" format="ixt:num-dot-decimal">30.0</ix:nonFraction> million of availability through the Ares Maturity Date. The Company is required to pay an
                unused commitment fee of <ix:nonFraction name="us-gaap:LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" id="Fact_c3ead516860a40e5a3f33c3e964ad3b6" contextRef="c20240101to20241231_CounterpartyNameAxis_AresCreditAgreementMember_DebtInstrumentAxis_AresCreditFacilityMember" unitRef="U007" decimals="3" scale="-2" format="ixt:num-dot-decimal">0.5</ix:nonFraction>% per annum for this availability. </span> </div>
</ix:continuation>
            <ix:continuation id="Text_d63af97cb57443219f8e78cbdd4b933613" continuedAt="Text_d63af97cb57443219f8e78cbdd4b933614">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
              </span></div>
</ix:continuation>
            <ix:continuation id="Text_d63af97cb57443219f8e78cbdd4b933614" continuedAt="Text_d63af97cb57443219f8e78cbdd4b933615">
<div style="display:none;"><br/></div>
<div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; text-indent: 27pt;">On December 19, 2024 the Company repaid $<ix:nonFraction name="us-gaap:RepaymentsOfLongTermLinesOfCredit" id="Fact_5801c883bada4f828ad6fd4a4613d5f4" contextRef="c20241219to20241219_CreditFacilityAxis_TermLoanMember" unitRef="U001" decimals="-5" scale="6" format="ixt:num-dot-decimal">30.0</ix:nonFraction>
              million against the term loan and the outstanding balance on the term loan as of December 31, 2024 was $<ix:nonFraction name="adma:SeniorNotesPayableBeforeDebtDiscount" id="Fact_1f375045f1904f00b8ed3e6d406fd503" contextRef="c20241231_CreditFacilityAxis_TermLoanMember" unitRef="U001" decimals="-5" scale="6" format="ixt:num-dot-decimal">32.5</ix:nonFraction> million. In connection
              with the repayment against the term loan, the Company recognized a loss on extinguishment of debt in the approximate amount of $<ix:nonFraction name="us-gaap:GainsLossesOnExtinguishmentOfDebt" id="Fact_4ca13ed17e9741f8af710bc2762bd1ca" contextRef="c20241219to20241219_CreditFacilityAxis_TermLoanMember" unitRef="U001" decimals="-5" scale="6" sign="-" format="ixt:num-dot-decimal">1.2</ix:nonFraction>
              million, which is comprised of a prepayment penalty in the amount of $<ix:nonFraction name="adma:LongTermDebtPrepaymentPenalty" id="Fact_adf245de51424d55beba4935aa79c663" contextRef="c20241219_CreditFacilityAxis_TermLoanMember" unitRef="U001" decimals="-5" scale="6" format="ixt:num-dot-decimal">0.5</ix:nonFraction> million and a partial write-off of unamortized discount
              attributable to the term loan in the amount of $<ix:nonFraction name="us-gaap:DebtInstrumentUnamortizedDiscount" id="Fact_0e08ac39b5f94e73ab15da0a144ea2f7" contextRef="c20241219_CreditFacilityAxis_TermLoanMember" unitRef="U001" decimals="-5" scale="6" format="ixt:num-dot-decimal">0.8</ix:nonFraction> million.</div>
</ix:continuation>
          </div>

          <ix:continuation id="Text_d63af97cb57443219f8e78cbdd4b933615" continuedAt="Text_d63af97cb57443219f8e78cbdd4b933616">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt;"> <span style="font-weight: normal; font-style: normal; font-variant: normal; text-transform: none;"> </span></span></div>
</ix:continuation></div>

        <ix:continuation id="Text_d63af97cb57443219f8e78cbdd4b933616" continuedAt="Text_d63af97cb57443219f8e78cbdd4b933617">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt;"> <span style="font-weight: normal; font-style: normal; font-variant: normal; text-transform: none;"> </span> </span></div>
</ix:continuation>
        <div style="font-family: 'Times New Roman';">
          <ix:continuation id="Text_d63af97cb57443219f8e78cbdd4b933617" continuedAt="Text_d63af97cb57443219f8e78cbdd4b933618">
<div><span style="font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
            </span> </div>
</ix:continuation>
        </div>

        <ix:continuation id="Text_d63af97cb57443219f8e78cbdd4b933618" continuedAt="Text_d63af97cb57443219f8e78cbdd4b933619">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt;"> <span style="font-weight: normal; font-style: normal; font-variant: normal; text-transform: none;"> </span> </span></div>
</ix:continuation>
        <div style="font-family: 'Times New Roman';">
          <ix:continuation id="Text_d63af97cb57443219f8e78cbdd4b933619" continuedAt="Text_d63af97cb57443219f8e78cbdd4b933620">
<div style="display:none;"><br/></div>
<div style="text-align: left; font-size: 10pt; text-indent: 27pt; font-weight: normal; font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none;">Borrowings under the term loan bear interest at the adjusted
            Term SOFR for a <ix:nonNumeric name="adma:DebtInstrumentTermOfVariableRate" id="Fact_dc7f109102454a9fb2db750fc47ae480" contextRef="c20231218to20231218_CreditFacilityAxis_TermLoanMember_VariableRateAxis_SecuredOvernightFinancingRateSofrMember" format="ixt-sec:durwordsen">three-month</ix:nonNumeric> tenor in effect on the day that is <span style="-sec-ix-hidden:Fact_712874e87fcc4abab5ec40411ed75dc9">two</span> business days prior to the first day of the applicable calendar quarter plus <ix:nonFraction name="adma:DebtInstrumentApplicableMargin" id="Fact_2f31cf9427214a4487f1c1c6fccf09c1" contextRef="c20231218to20231218_CreditFacilityAxis_TermLoanMember_VariableRateAxis_SecuredOvernightFinancingRateSofrMember" unitRef="U007" decimals="4" scale="-2" format="ixt:num-dot-decimal">6.50</ix:nonFraction>%.
            Borrowings under the revolving facility initially bear interest at the adjusted Term SOFR for a <ix:nonNumeric name="adma:DebtInstrumentTermOfVariableRate" id="Fact_103c36c429204ae1a37b07043655c4a5" contextRef="c20231218to20231218_CreditFacilityAxis_RevolvingCreditFacilityMember_VariableRateAxis_SecuredOvernightFinancingRateSofrMember" format="ixt-sec:durwordsen">three-month</ix:nonNumeric> tenor in effect on the
            day that is <span style="-sec-ix-hidden:Fact_00f7b4da42784c0b85e89298c6447e23">two</span> business days prior to the first day of the applicable calendar quarter&#160;plus <ix:nonFraction name="adma:DebtInstrumentApplicableMargin" id="Fact_8b2a8740400c4a898c0486e4860563ce" contextRef="c20231218to20231218_CreditFacilityAxis_RevolvingCreditFacilityMember_VariableRateAxis_SecuredOvernightFinancingRateSofrMember" unitRef="U007" decimals="4" scale="-2" format="ixt:num-dot-decimal">3.75</ix:nonFraction>%. As of December 31, 2024 and December 31, 2023, the interest rate on the term loan was approximately <ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" id="Fact_5a46654e774145a78236d7ce8dc85e6d" contextRef="c20241231_CreditFacilityAxis_TermLoanMember_VariableRateAxis_SecuredOvernightFinancingRateSofrMember" unitRef="U007" decimals="4" scale="-2" format="ixt:num-dot-decimal">10.85</ix:nonFraction>% and <ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" id="Fact_e4add2ccb9804900baafbbad8777177c" contextRef="c20231231_CreditFacilityAxis_TermLoanMember_VariableRateAxis_SecuredOvernightFinancingRateSofrMember" unitRef="U007" decimals="4" scale="-2" format="ixt:num-dot-decimal">11.88</ix:nonFraction>%, respectively, and the interest rate on
            the revolving facility was&#160;approximately <ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" id="Fact_7df64436c4e041808959db59c8dfd2dc" contextRef="c20241231_CreditFacilityAxis_RevolvingCreditFacilityMember_VariableRateAxis_SecuredOvernightFinancingRateSofrMember" unitRef="U007" decimals="4" scale="-2" format="ixt:num-dot-decimal">8.34</ix:nonFraction>% and <ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" id="Fact_e2ae150492704308a177844771dac32d" contextRef="c20231231_CreditFacilityAxis_RevolvingCreditFacilityMember_VariableRateAxis_SecuredOvernightFinancingRateSofrMember" unitRef="U007" decimals="4" scale="-2" format="ixt:num-dot-decimal">9.13</ix:nonFraction>%, respectively.</div>
</ix:continuation>
        </div>

        <ix:continuation id="Text_d63af97cb57443219f8e78cbdd4b933620" continuedAt="Text_d63af97cb57443219f8e78cbdd4b933621">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt;"> <span style="font-weight: normal; font-style: normal; font-variant: normal; text-transform: none;"> </span> </span></div>
</ix:continuation>
        <div style="font-family: 'Times New Roman';"><ix:continuation id="Text_d63af97cb57443219f8e78cbdd4b933621" continuedAt="Text_d63af97cb57443219f8e78cbdd4b933622">
<div><span style="font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
          <ix:continuation id="Text_d63af97cb57443219f8e78cbdd4b933622" continuedAt="Text_d63af97cb57443219f8e78cbdd4b933623">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
            </span> </div>
</ix:continuation>
        </div>

        <ix:continuation id="Text_d63af97cb57443219f8e78cbdd4b933623" continuedAt="Text_d63af97cb57443219f8e78cbdd4b933624">
<div style="display:none;"><br/></div>
<div style="text-indent: 27pt;"><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">On the
            Ares Maturity Date, the Company is required to pay Ares the entire outstanding principal amount underlying the Ares Loans and any accrued and unpaid interest thereon. Prior to the Ares Maturity Date, there are <ix:nonFraction name="us-gaap:DebtInstrumentPeriodicPaymentPrincipal" id="Fact_0f2b9740fdc94489b7a256b5c85b3a29" contextRef="c20231218to20231218_CounterpartyNameAxis_AresCreditAgreementMember_DebtInstrumentAxis_AresCreditFacilityMember" unitRef="U001" decimals="-6" scale="6" format="ixt-sec:numwordsen">no</ix:nonFraction> scheduled principal payments on the Ares Credit Facilities. After giving effect to the principal payments made during the year ended December 31,
            2024, the Company is required to make <ix:nonNumeric name="us-gaap:DebtInstrumentFrequencyOfPeriodicPayment" id="Fact_6540f7076d374059bcdbe4dba734ad60" contextRef="c20240101to20241231_CounterpartyNameAxis_AresCreditAgreementMember_DebtInstrumentAxis_AresCreditFacilityMember">quarterly</ix:nonNumeric> interest payments to Ares of approximately $<ix:nonFraction name="us-gaap:DebtInstrumentPeriodicPaymentInterest" id="Fact_9fad5f10948643da9e410e7c0d40e0f1" contextRef="c20231218to20231218_CounterpartyNameAxis_AresCreditAgreementMember_DebtInstrumentAxis_AresCreditFacilityMember" unitRef="U001" decimals="-5" scale="6" format="ixt:num-dot-decimal">1.8</ix:nonFraction> million. The Company may prepay the outstanding principal under the revolving facility, together with any accrued but unpaid interest on the prepaid principal amount,
            at any time and from time to time upon <span style="-sec-ix-hidden:Fact_d55916c1abbd41dd8edc1e45abe3c678">three</span> business days&#8217; prior written notice with <ix:nonFraction name="adma:PrepaymentsOfDebtPremium" id="Fact_3e8b8d3660e74d2785474da40f1b1904" contextRef="c20231218to20231218_CounterpartyNameAxis_AresCreditAgreementMember_DebtInstrumentAxis_AresCreditFacilityMember" unitRef="U001" decimals="-6" scale="6" format="ixt-sec:numwordsen">no</ix:nonFraction> prepayment premium. However, in the event the Company pays down an aggregate amount under the Revolving Facility that is greater than <ix:nonFraction name="us-gaap:LineOfCreditFacilityCommitmentFeePercentage" id="Fact_d72e81843abe4a1ea2a868c8ad570750" contextRef="c20231218to20231218_CounterpartyNameAxis_AresCreditAgreementMember_RangeAxis_MinimumMember" unitRef="U007" decimals="2" scale="-2" format="ixt:num-dot-decimal">50</ix:nonFraction>% of the $<ix:nonFraction name="adma:SeniorNotesPayableBeforeDebtDiscount" id="Fact_d1d479cc86bb4479bfeebce95d67da85" contextRef="c20231231_CreditFacilityAxis_RevolvingCreditFacilityMember" unitRef="U001" decimals="-5" scale="6" format="ixt:num-dot-decimal">72.5</ix:nonFraction> million commitment
            amount, the Company will still be required to pay interest on <ix:nonFraction name="us-gaap:LineOfCreditFacilityCommitmentFeePercentage" id="Fact_052923961b9847f08664191d0d968634" contextRef="c20231218to20231218_CounterpartyNameAxis_AresCreditAgreementMember_RangeAxis_MinimumMember" unitRef="U007" decimals="2" scale="-2" format="ixt:num-dot-decimal">50</ix:nonFraction>% of this amount, or $<ix:nonFraction name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" id="Fact_dfbd8a9a76fd42729523a3c54bd1016d" contextRef="c20241231_CounterpartyNameAxis_AresCreditAgreementMember_DebtInstrumentAxis_AresCreditFacilityMember" unitRef="U001" decimals="-5" scale="6" format="ixt:num-dot-decimal">36.3</ix:nonFraction> million, through the term of Ares Credit Facility. The Company may prepay the outstanding principal on the term loan, together with any accrued but unpaid interest on
            the prepaid principal amount, at any time and from time to time upon <span style="-sec-ix-hidden:Fact_2496c3fd576a452da07200cbae1170f2">three</span> business days&#8217; prior written notice, subject to the
            payment to Ares of a prepayment premium equal to (i) the present value as of such date of all remaining required interest payments on the principal amount being repaid plus <ix:nonFraction name="us-gaap:DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" id="Fact_1363e9d8a1184cc48176a08c6444093e" contextRef="c20231218to20231218_CounterpartyNameAxis_AresCreditAgreementMember_DebtInstrumentRedemptionPeriodAxis_PrepaidOnOrPriorToFirstAnniversaryMember" unitRef="U007" decimals="3" scale="-2" format="ixt:num-dot-decimal">1.5</ix:nonFraction>% of the prepaid principal amount, if prepaid on or prior to the first anniversary of the Ares Closing Date, (ii) <ix:nonFraction name="us-gaap:DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" id="Fact_e6d8befa4dc342d2882a272f25c55e60" contextRef="c20231218to20231218_CounterpartyNameAxis_AresCreditAgreementMember_DebtInstrumentRedemptionPeriodAxis_PrepaidOnOrPriorToSecondAnniversaryMember" unitRef="U007" decimals="3" scale="-2" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" id="Fact_92268f303f2e4571b11b9248d01d34a9" contextRef="c20231218to20231218_CounterpartyNameAxis_AresCreditAgreementMember_DebtInstrumentRedemptionPeriodAxis_PrepaidAfterTheFirstAnniversaryMember" unitRef="U007" decimals="3" scale="-2" format="ixt:num-dot-decimal">1.5</ix:nonFraction></ix:nonFraction>% of the prepaid principal amount, if prepaid after the first anniversary of the Ares Closing Date and on or prior to the second anniversary of the Ares Closing Date, or (iii) <ix:nonFraction name="us-gaap:DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" id="Fact_bdd1ddc0c8444081ad46e6a328777d00" contextRef="c20231218to20231218_CounterpartyNameAxis_AresCreditAgreementMember_DebtInstrumentRedemptionPeriodAxis_PrepaidOnOrPriorToThirdAnniversaryMember" unitRef="U007" decimals="3" scale="-2" format="ixt:num-dot-decimal">1.0</ix:nonFraction>% of the prepaid principal amount, if prepaid on or prior to the third anniversary of the Ares Closing Date. </span></div>
</ix:continuation>
        <div style="text-indent: 27pt;">
          <ix:continuation id="Text_d63af97cb57443219f8e78cbdd4b933624" continuedAt="Text_d63af97cb57443219f8e78cbdd4b933625">
<div style="font-family: 'Times New Roman';"><span style="font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"><br/>
            </span> </div>
</ix:continuation>
          <ix:continuation id="Text_d63af97cb57443219f8e78cbdd4b933625" continuedAt="Text_d63af97cb57443219f8e78cbdd4b933626">
<div style="display:none;"><br/></div>
<div style="text-indent: 27pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">In connection with
            the closing of the Ares Credit Facility, the Company incurred fees and expenses related to the transaction of $<ix:nonFraction name="us-gaap:DebtInstrumentFeeAmount" id="Fact_e3249724132e469e91939698cfbd967a" contextRef="c20241231_CounterpartyNameAxis_AresCreditAgreementMember_DebtInstrumentAxis_AresCreditFacilityMember" unitRef="U001" decimals="-5" scale="6" format="ixt:num-dot-decimal">2.8</ix:nonFraction> million, including
            a $<ix:nonFraction name="adma:OriginalDiscountPayableCreditFacility" id="Fact_aac4a50024a342d4ae24a6d49704d940" contextRef="c20241231_CounterpartyNameAxis_AresCreditAgreementMember_DebtInstrumentAxis_AresCreditFacilityMember" unitRef="U001" decimals="-5" scale="6" format="ixt:num-dot-decimal">1.7</ix:nonFraction> million original discount payable to Ares, all of which was deducted from the Ares loan proceeds. In addition, the Company is
            also required to pay Ares an exit fee of $<ix:nonFraction name="adma:DebtInstrumentExitFee" id="Fact_f5a4e57daa63465a8edb571a237bf00b" contextRef="c20241231_CounterpartyNameAxis_AresCreditAgreementMember_DebtInstrumentAxis_AresCreditFacilityMember" unitRef="U001" decimals="-5" scale="6" format="ixt:num-dot-decimal">1.7</ix:nonFraction> million upon the earlier of any prepayment date or the Ares Maturity Date, and this
            obligation was accrued as a separate liability in the Company&#8217;s consolidated balance sheet as of December 31, 2023. As a result, the Company recognized an aggregate debt discount of $<ix:nonFraction name="us-gaap:DebtInstrumentUnamortizedDiscount" id="Fact_865c21a3cadd49d3827911bef7aa0a15" contextRef="c20231218_CounterpartyNameAxis_AresCreditAgreementMember_DebtInstrumentAxis_AresCreditFacilityMember" unitRef="U001" decimals="-5" scale="6" format="ixt:num-dot-decimal">4.4</ix:nonFraction> million as of the Ares Closing Date, and the weighted-average effective interest rate on the Ares Loans was <ix:nonFraction name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" id="Fact_b133aee534bb4f5ca8b62b09f35fec56" contextRef="c20241231_CounterpartyNameAxis_AresCreditAgreementMember_DebtInstrumentAxis_AresCreditFacilityMember" unitRef="U007" decimals="4" scale="-2" format="ixt:num-dot-decimal">10.81</ix:nonFraction>% and <ix:nonFraction name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" id="Fact_cd344bc22dd140a8873ed3b379ab569b" contextRef="c20231231_CounterpartyNameAxis_AresCreditAgreementMember_DebtInstrumentAxis_AresCreditFacilityMember" unitRef="U007" decimals="4" scale="-2" format="ixt:num-dot-decimal">11.39</ix:nonFraction>% as of December 31, 2024 and 2023, respectively. This
            debt discount was recorded as a reduction to the face amount of the debt and is being amortized as interest expense over the term of the debt using the interest method. In connection with the prepayment of the term loan on December 19, 2024,
            the Company also paid a pro rata portion of the exit fee in the amount of $<ix:nonFraction name="adma:DebtInstrumentExitFee" id="Fact_63614b1ef06b4939a6562136e705a8f1" contextRef="c20241219_CreditFacilityAxis_TermLoanMember" unitRef="U001" decimals="-5" scale="6" format="ixt:num-dot-decimal">0.4</ix:nonFraction> million, and the balance of the exit fee liability as
            of December 31, 2024 is $<ix:nonFraction name="adma:ExitFeeLiability" id="Fact_35c221b208094909874db44e9374ea4f" contextRef="c20241231_CreditFacilityAxis_TermLoanMember" unitRef="U001" decimals="-5" scale="6" format="ixt:num-dot-decimal">1.3</ix:nonFraction> million. </div>
</ix:continuation>
        </div>

        <ix:continuation id="Text_d63af97cb57443219f8e78cbdd4b933626" continuedAt="Text_d63af97cb57443219f8e78cbdd4b933627">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt;"> </span></div>
</ix:continuation>
        <ix:continuation id="Text_d63af97cb57443219f8e78cbdd4b933627" continuedAt="Text_d63af97cb57443219f8e78cbdd4b933628">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
          </span> </div>
</ix:continuation>
        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div class="BRPFPageNumberArea" style="text-align: center;"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">F-20</span></div>

          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"/></div>

          <div class="BRPFPageHeader" style="width: 100%;">
            <div>
              <div style="text-align: left; font-weight: bold; text-indent: -9pt; margin-left: 9pt;"><a href="#ADMABIOLOGICSINC."> <span style="font-style: italic; font-weight: normal; font-size: 8pt;">Table of Contents</span></a><br/>
              </div>

              <div style="text-align: left; font-weight: bold; text-indent: -9pt; margin-left: 9pt;"><a href="#ADMABIOLOGICSINC."><span style="font-style: italic; font-weight: normal; font-size: 8pt;"> <br/>
                  </span></a></div>

              <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">ADMA BIOLOGICS, INC. AND SUBSIDIARIES</div>

              <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</div>

            </div>

          </div>

        </div>

        <ix:continuation id="Text_d63af97cb57443219f8e78cbdd4b933628" continuedAt="Text_d63af97cb57443219f8e78cbdd4b933629">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt;"> </span></div>
</ix:continuation>
        <div>
          <div>
            <ix:continuation id="Text_d63af97cb57443219f8e78cbdd4b933629" continuedAt="Text_d63af97cb57443219f8e78cbdd4b933630">
<div style="display:none;"><br/></div>
<div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; text-indent: 27pt;">All of the Company&#8217;s obligations under the Ares Credit Agreement are secured by a first-priority lien and security interest in substantially all
              of the Company&#8217;s tangible and intangible assets, including intellectual property and all of the equity interests in the Company&#8217;s subsidiaries. The Ares Credit Agreement contains certain representations and warranties, affirmative covenants,
              negative covenants and conditions that are customarily required for similar debt financings. The negative covenants include certain financial covenants, including maximum total leverage ratios and a $<ix:nonFraction name="adma:MinimumLiquidityCovenantsCreditFacilities" id="Fact_7ee82f8111644a29b1d1d11e144affe6" contextRef="c20241231_CounterpartyNameAxis_AresCreditAgreementMember" unitRef="U001" decimals="-5" scale="6" format="ixt:num-dot-decimal">15.0</ix:nonFraction> million minimum liquidity covenant, and also restrict or limit the Company&#8217;s ability and the ability of the Company&#8217;s subsidiaries to, among other things and subject
              to certain exceptions contained in the Ares Credit Agreement, incur new indebtedness; create liens on assets; engage in certain fundamental corporate changes, such as mergers or acquisitions, or changes to the Company&#8217;s or the Company&#8217;s
              subsidiaries&#8217; business activities; make certain Investments or Restricted Payments (each as defined in the Ares Credit Agreement); engage in certain affiliate transactions; or enter into, amend or terminate any other agreements that have the
              impact of restricting the Company&#8217;s ability to make loan repayments under the Ares Credit Agreement. As of December 31, 2024 the Company was in compliance with all of the covenants contained in the Ares Credit Agreement.</div>
</ix:continuation>
            <ix:continuation id="Text_d63af97cb57443219f8e78cbdd4b933630" continuedAt="Text_d63af97cb57443219f8e78cbdd4b933631">
<div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"> <span style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
              </span></div>
</ix:continuation>
          </div>

          <ix:continuation id="Text_d63af97cb57443219f8e78cbdd4b933631" continuedAt="Text_d63af97cb57443219f8e78cbdd4b933632">
<div style="display:none;"><br/></div>
<div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; text-indent: 27pt;">Events of Default on the Ares Loans include, among others, non-payment of principal, interest or fees, violation of covenants, inaccuracy of
            representations and warranties, bankruptcy and insolvency events, material judgments, cross-defaults to material contracts and events constituting a change of control. If there is an event of default, the Company will incur an increase in the
            rate of interest on the Ares Loans of <ix:nonFraction name="us-gaap:DebtInstrumentInterestRateIncreaseDecrease" id="Fact_4adb98e25a364fb7926896ec467627f2" contextRef="c20240101to20241231_CounterpartyNameAxis_AresCreditAgreementMember" unitRef="U007" decimals="2" scale="-2" format="ixt:num-dot-decimal">2</ix:nonFraction>% per annum.</div>
</ix:continuation>
          <ix:continuation id="Text_d63af97cb57443219f8e78cbdd4b933632" continuedAt="Text_d63af97cb57443219f8e78cbdd4b933633">
<div style="display:none;"><br/></div>
<div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; text-indent: 27pt;"> <span style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
            </span> </div>
</ix:continuation>
        </div>

        <ix:continuation id="Text_d63af97cb57443219f8e78cbdd4b933633" continuedAt="Text_d63af97cb57443219f8e78cbdd4b933634">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt;"> </span></div>
</ix:continuation>
        <ix:continuation id="Text_d63af97cb57443219f8e78cbdd4b933634" continuedAt="Text_d63af97cb57443219f8e78cbdd4b933635"><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px;"> </p></ix:continuation>
        <ix:continuation id="Text_d63af97cb57443219f8e78cbdd4b933635" continuedAt="Text_d63af97cb57443219f8e78cbdd4b933636">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt;"> </span></div>
</ix:continuation>
        <ix:continuation id="Text_d63af97cb57443219f8e78cbdd4b933636" continuedAt="Text_d63af97cb57443219f8e78cbdd4b933637"><p style="margin-top: 0px; margin-bottom: 0px; font-family: 'Times New Roman'; font-size: 10pt; text-align: left; text-indent: 27pt;"><span style="font-family: 'Times New Roman'; font-size: 10pt;">On <span style="color: rgb(0, 0, 0); background-color: rgb(255, 255, 255); font-weight: normal; font-style: normal; font-variant: normal; text-transform: none;">March 23,&#160;2022 (the &#8220;Hayfin Closing Date&#8221;), the Company and all of its subsidiaries entered into the Hayfin Credit
              Agreement with Hayfin. The Hayfin Credit Agreement provided for a senior secured term loan facility in a principal amount of up to</span> $<ix:nonFraction name="adma:SeniorNotesPayableBeforeDebtDiscount" id="Fact_b96df6933a5c416482db6cf5b2a67b5d" contextRef="c20220323_CounterpartyNameAxis_HayfinCreditAgreementMember_DebtInstrumentAxis_HayfinCreditFacilityMember_RangeAxis_MaximumMember" unitRef="U001" decimals="-5" scale="6" format="ixt:num-dot-decimal">175.0</ix:nonFraction>
            million, <span style="color: rgb(0, 0, 0); background-color: rgb(255, 255, 255); font-weight: normal; font-style: normal; font-variant: normal; text-transform: none;">composed of (i) a term loan made on the Hayfin Closing Date in the principal
              amount of</span> $<ix:nonFraction name="adma:SeniorNotesPayableBeforeDebtDiscount" id="Fact_acab3009ec7e4ba883c4f34a71105654" contextRef="c20220323_CounterpartyNameAxis_HayfinCreditAgreementMember_DebtInstrumentAxis_HayfinClosingDateLoanMember" unitRef="U001" decimals="-5" scale="6" format="ixt:num-dot-decimal">150.0</ix:nonFraction> million<span style="color: rgb(0, 0, 0); font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"> (<span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">the &#8220;Hayfin Closing Date
                Loan&#8221;), and (ii) a delayed draw term loan in the principal amount of </span></span>$<ix:nonFraction name="adma:SeniorNotesPayableBeforeDebtDiscount" id="Fact_358df53a73ad45c19cde9406cdbdfe15" contextRef="c20220323_CounterpartyNameAxis_HayfinCreditAgreementMember_DebtInstrumentAxis_HayfinDelayedDrawLoanMember" unitRef="U001" decimals="-5" scale="6" format="ixt:num-dot-decimal">25.0</ix:nonFraction> million (the &#8220;<span style="color: rgb(0, 0, 0); background-color: rgb(255, 255, 255); font-weight: normal; font-style: normal; font-variant: normal; text-transform: none;">Hayfin </span><span style="color: rgb(0, 0, 0); font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">Delayed Draw Loan</span>&#8221; <span style="color: rgb(0, 0, 0); font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">and, together with the Hayfin Closing Date Loan, the &#8220;Hayfin Loans</span></span>&#8221;). <span style="color: rgb(0, 0, 0); font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: left; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">The Hayfin Delayed Draw Loan was not drawn prior to the Ares Closing Date. The Hayfin Credit Facility had a maturity date of <ix:nonNumeric name="us-gaap:DebtInstrumentMaturityDate" id="Fact_116027784ff64e9bbaf2464454b2e310" contextRef="c20240101to20241231_CounterpartyNameAxis_HayfinCreditAgreementMember_DebtInstrumentAxis_HayfinCreditFacilityMember" format="ixt:date-monthname-day-year-en">March 23, 2027</ix:nonNumeric> (the &#8220;Hayfin Maturity Date&#8221;), subject to acceleration pursuant to the Hayfin Credit Agreement, including upon an Event of Default
              (as defined in the Hayfin Credit Agreement).</span></span><span style="font-size: 10pt;"> <br/>
          </span> </p></ix:continuation>
        <ix:continuation id="Text_d63af97cb57443219f8e78cbdd4b933637" continuedAt="Text_d63af97cb57443219f8e78cbdd4b933638">
<div><span style="font-size: 10pt;"> </span></div>
</ix:continuation></div>

      <ix:continuation id="Text_d63af97cb57443219f8e78cbdd4b933638" continuedAt="Text_d63af97cb57443219f8e78cbdd4b933639">
<div><span style="font-size: 10pt;"> <br/>
      </span></div>
</ix:continuation><!--PROfilePageNumberReset%Num%15%F-%%-->
      <ix:continuation id="Text_d63af97cb57443219f8e78cbdd4b933639" continuedAt="Text_d63af97cb57443219f8e78cbdd4b933640">
<div style="display:none;"><br/></div>
<div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; text-indent: 27pt;">On the
        Hayfin Closing Date, the Company used $<ix:nonFraction name="us-gaap:RepaymentsOfNotesPayable" id="Fact_f00128d2a70945e9b9d0093b589539c2" contextRef="c20220323to20220323_DebtInstrumentAxis_HayfinClosingDateLoanMember" unitRef="U001" decimals="-5" scale="6" format="ixt:num-dot-decimal">100.0</ix:nonFraction> million of the Hayfin Closing Date Loan to terminate and pay in full all of the outstanding
        obligations under the Company&#8217;s previously existing credit facility (the &#8220;Perceptive Credit Facility&#8221;) with Perceptive Credit Holdings II, LP (&#8220;Perceptive&#8221;). The Company also used $<ix:nonFraction name="us-gaap:DebtInstrumentUnamortizedPremium" id="Fact_f2d7dd0613ee48bdab6df240365e281d" contextRef="c20220323_CounterpartyNameAxis_HayfinCreditAgreementMember_DebtInstrumentAxis_HayfinClosingDateLoanMember" unitRef="U001" decimals="-5" scale="6" format="ixt:num-dot-decimal">2.0</ix:nonFraction> million of the Hayfin Closing Date Loan proceeds to pay a redemption premium to Perceptive and used approximately $<ix:nonFraction name="us-gaap:PaymentsOfDebtIssuanceCosts" id="Fact_e7421535dc834d64bac715353c3e9992" contextRef="c20220323to20220323_CounterpartyNameAxis_HayfinCreditAgreementMember_DebtInstrumentAxis_HayfinClosingDateLoanMember" unitRef="U001" decimals="-5" scale="6" format="ixt:num-dot-decimal">1.0</ix:nonFraction> million of the Hayfin Closing Date Loan proceeds to pay certain fees and expenses incurred in connection with this transaction. In addition, a $<ix:nonFraction name="adma:DebtInstrumentUpfrontFeePaidInKind" id="Fact_ac52a9f15a7f4a858b12a6952503dd22" contextRef="c20220323to20220323_CounterpartyNameAxis_HayfinCreditAgreementMember" unitRef="U001" decimals="-5" scale="6" format="ixt:num-dot-decimal">1.8</ix:nonFraction> million upfront fee payable to Hayfin was paid &#8220;in kind&#8221; and was added to the outstanding principal balance in accordance with the terms of the Hayfin Credit Agreement. In
        connection with the retirement of the Perceptive Credit Facility and all of the obligations thereunder, the Company recorded a loss on extinguishment of debt in the amount of $<ix:nonFraction name="us-gaap:GainsLossesOnExtinguishmentOfDebt" id="Fact_0a38348b0b1244d29e65a71d0012029e" contextRef="c20220323to20220323_CounterpartyNameAxis_HayfinCreditAgreementMember" unitRef="U001" decimals="-5" scale="6" sign="-" format="ixt:num-dot-decimal">6.7</ix:nonFraction> million, consisting of the write-off of unamortized discount related to the Perceptive indebtedness and the redemption premium paid to Perceptive.</div>
</ix:continuation>
      <ix:continuation id="Text_d63af97cb57443219f8e78cbdd4b933640" continuedAt="Text_d63af97cb57443219f8e78cbdd4b933641">
<div><span style="font-size: 10pt;"> </span></div>
</ix:continuation>
      <ix:continuation id="Text_d63af97cb57443219f8e78cbdd4b933641" continuedAt="Text_d63af97cb57443219f8e78cbdd4b933642">
<div style="display:none;"><br/></div>
<div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"> <span style="font-size: 10pt;"><br/>
        </span> </div>
</ix:continuation>
      <ix:continuation id="Text_d63af97cb57443219f8e78cbdd4b933642" continuedAt="Text_d63af97cb57443219f8e78cbdd4b933643">
<div><span style="font-size: 10pt;"> </span></div>
</ix:continuation>
      <ix:continuation id="Text_d63af97cb57443219f8e78cbdd4b933643" continuedAt="Text_d63af97cb57443219f8e78cbdd4b933644">
<div style="display:none;"><br/></div>
<div style="text-align: left; text-indent: 27pt;"><span style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0); background-color: rgb(255, 255, 255); font-weight: normal; font-style: normal; font-variant: normal; text-transform: none;"><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none;">Borrowings under the Hayfin Credit Agreement bore
            interest, at the Company&#8217;s election, at the adjusted Term SOFR for a <ix:nonNumeric name="adma:DebtInstrumentTermOfVariableRate" id="Fact_adc4caa915304208a671c809ea58f8cd" contextRef="c20240101to20241231_CounterpartyNameAxis_HayfinCreditAgreementMember_VariableRateAxis_SecuredOvernightFinancingRateSofrMember" format="ixt-sec:durwordsen">one-month</ix:nonNumeric> tenor, subject to a floor of <ix:nonFraction name="adma:DebtInstrumentFloorInterestRate" id="Fact_d26f491b872243fe8fd329d5f6ec10cf" contextRef="c20220323to20220323_CounterpartyNameAxis_HayfinCreditAgreementMember_VariableRateAxis_BaseRateMember" unitRef="U007" decimals="4" scale="-2" format="ixt:num-dot-decimal">1.25</ix:nonFraction>%, plus an applicable margin of <ix:nonFraction name="adma:DebtInstrumentApplicableMargin" id="Fact_da7a909ac9a7412eb7866ed01f97e59e" contextRef="c20220323to20220323_CounterpartyNameAxis_HayfinCreditAgreementMember" unitRef="U007" decimals="3" scale="-2" format="ixt:num-dot-decimal">9.5</ix:nonFraction>%
            (the &#8220;Applicable Margin&#8221;); provided, however, that upon, and during the continuance of, an Event of Default, the Applicable Margin would increase by an additional <ix:nonFraction name="us-gaap:DebtInstrumentInterestRateIncreaseDecrease" id="Fact_c28c13228f1647c081836bfd17481da5" contextRef="c20220323to20220323_CounterpartyNameAxis_HayfinCreditAgreementMember" unitRef="U007" decimals="2" scale="-2" format="ixt:num-dot-decimal">3</ix:nonFraction>% per annum. On May 1, 2023 the Hayfin Credit Agreement was amended to reduce the Applicable Margin from <ix:nonFraction name="adma:DebtInstrumentApplicableMargin" id="Fact_8ba15853057c427f8d6e51b7574da0fd" contextRef="c20230430to20230430_CounterpartyNameAxis_HayfinSecondAmendmentMember_VariableRateAxis_SecuredOvernightFinancingRateSofrMember" unitRef="U007" decimals="3" scale="-2" format="ixt:num-dot-decimal">9.5</ix:nonFraction>% to <ix:nonFraction name="adma:DebtInstrumentApplicableMargin" id="Fact_191541fdfa70411aadc0d591f7da5ca9" contextRef="c20230501to20230501_CounterpartyNameAxis_HayfinSecondAmendmentMember_VariableRateAxis_SecuredOvernightFinancingRateSofrMember" unitRef="U007" decimals="3" scale="-2" format="ixt:num-dot-decimal">8.5</ix:nonFraction>%. On the last day of each calendar month prior to the Ares
            Closing Date, the Company paid accrued interest to Hayfin. The rate of interest in effect as of the Hayfin Closing Date, December 31, 2022 and the Ares Closing Date was <ix:nonFraction name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" id="Fact_8d3a26a91c2a400eb4b28af7c4ce0091" contextRef="c20220323_CounterpartyNameAxis_HayfinCreditAgreementMember_DebtInstrumentAxis_HayfinClosingDateLoanMember" unitRef="U007" decimals="4" scale="-2" format="ixt:num-dot-decimal">10.75</ix:nonFraction>%, approximately <ix:nonFraction name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" id="Fact_d23ba2d8de1c4fbd9250a5d53a29d13f" contextRef="c20221231_CounterpartyNameAxis_HayfinCreditAgreementMember_DebtInstrumentAxis_HayfinClosingDateLoanMember" unitRef="U007" decimals="3" scale="-2" format="ixt:num-dot-decimal">13.7</ix:nonFraction>% and approximately <ix:nonFraction name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" id="Fact_7bceb21e1dc949b5b192e3ea33feffd7" contextRef="c20231218_CounterpartyNameAxis_AresCreditAgreementMember_DebtInstrumentAxis_AresClosingDateLoanMember" unitRef="U007" decimals="3" scale="-2" format="ixt:num-dot-decimal">13.9</ix:nonFraction>%, respectively. The Company was also permitted to pay &#8220;in kind&#8221; a portion of the interest on the Hayfin Loans for each monthly interest period
            in an amount equal to <ix:nonFraction name="adma:DebtInstrumentInterestAmountToBePayInKind" id="Fact_dd9eca0ac5044c76908132dbfa624504" contextRef="c20220323to20220323_CounterpartyNameAxis_HayfinCreditAgreementMember" unitRef="U007" decimals="3" scale="-2" format="ixt:num-dot-decimal">2.5</ix:nonFraction>% per annum, which was added to the principal amount of the outstanding debt under the Hayfin Credit
            Facility. From the Hayfin Closing Date through December 31, 2022, $<ix:nonFraction name="us-gaap:PaidInKindInterest" id="Fact_af1f2239cd1749cc85249e527ab61bef" contextRef="c20230101to20231231_CounterpartyNameAxis_HayfinCreditAgreementMember" unitRef="U001" decimals="-5" scale="6" format="ixt:num-dot-decimal">3.0</ix:nonFraction> million of interest was paid in kind and added to the balance
            of the outstanding Hayfin Loans. For the year ended December 31, 2023, $<ix:nonFraction name="us-gaap:PaidInKindInterest" id="Fact_672605cd67c641e999494dbdd77e7e5f" contextRef="c20240101to20241231_CounterpartyNameAxis_HayfinCreditAgreementMember" unitRef="U001" decimals="-5" scale="6" format="ixt:num-dot-decimal">3.8</ix:nonFraction> million of interest was paid in kind and added to the
            balance of the outstanding Hayfin Loans.</span></span> </div>
</ix:continuation>
      <ix:continuation id="Text_d63af97cb57443219f8e78cbdd4b933644" continuedAt="Text_d63af97cb57443219f8e78cbdd4b933645">
<div><span style="font-size: 10pt;"> </span></div>
</ix:continuation>
      <div style="text-align: left; font: 10pt 'Times New Roman';">
        <ix:continuation id="Text_d63af97cb57443219f8e78cbdd4b933645" continuedAt="Text_d63af97cb57443219f8e78cbdd4b933646"><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-indent: 45px; text-align: left;"> </p></ix:continuation>
        <ix:continuation id="Text_d63af97cb57443219f8e78cbdd4b933646" continuedAt="Text_d63af97cb57443219f8e78cbdd4b933647">
<div><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
        <ix:continuation id="Text_d63af97cb57443219f8e78cbdd4b933647" continuedAt="Text_d63af97cb57443219f8e78cbdd4b933648"><p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-bottom: 0px; text-align: left; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; text-indent: 27pt;">&#160; &#160;</p></ix:continuation>
        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div class="BRPFPageNumberArea" style="text-align: center;"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">F-21</span></div>

          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"/></div>

          <div class="BRPFPageHeader" style="width: 100%;">
            <div>
              <div style="text-align: left; font-weight: bold; text-indent: -9pt; margin-left: 9pt;"><a href="#ADMABIOLOGICSINC."> <span style="font-style: italic; font-weight: normal; font-size: 8pt;">Table of Contents</span></a><br/>
              </div>

              <div style="text-align: left; font-weight: bold; text-indent: -9pt; margin-left: 9pt;"><a href="#ADMABIOLOGICSINC."><span style="font-style: italic; font-weight: normal; font-size: 8pt;"> <br/>
                  </span></a></div>

              <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">ADMA BIOLOGICS, INC. AND SUBSIDIARIES</div>

              <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</div>

            </div>

          </div>

        </div>

        <ix:continuation id="Text_d63af97cb57443219f8e78cbdd4b933648" continuedAt="Text_d63af97cb57443219f8e78cbdd4b933649"><p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-bottom: 0px; text-align: left; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; text-indent: 27pt;"> <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: left; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">On the Ares Closing Date, the Company
            paid Hayfin the entire outstanding principal amount underlying the Hayfin Loans and all accrued and unpaid interest thereon, as well as the exit fee of <ix:nonFraction name="adma:PercentageOfExitFeeOfOutstandingPrincipalAmountBeingPaid" id="Fact_faf38bd428c24761bb1afdd19a98874d" contextRef="c20231218to20231218_CounterpartyNameAxis_HayfinCreditAgreementMember" unitRef="U007" decimals="3" scale="-2" format="ixt:num-dot-decimal">1.0</ix:nonFraction>% of the outstanding principal amount paid. This exit fee had been recorded separately as a non-current liability on the accompanying consolidated balance sheet as of December 31,
            2022. In accordance with the terms of the Hayfin Credit Agreement, the Company also paid Hayfin the early prepayment fee in the amount equal to <ix:nonFraction name="us-gaap:DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" id="Fact_b0d604280bc24c6c83a1af5f9f1cfc9a" contextRef="c20231218to20231218_CounterpartyNameAxis_HayfinCreditAgreementMember" unitRef="U007" decimals="3" scale="-2" format="ixt:num-dot-decimal">7.0</ix:nonFraction>%
            of the prepaid principal amount of $<ix:nonFraction name="us-gaap:DebtInstrumentCarryingAmount" id="Fact_362decde0240484b96dee65c5e6b6cfc" contextRef="c20231218_DebtInstrumentAxis_HayfinCreditFacilityMember" unitRef="U001" decimals="-5" scale="6" format="ixt:num-dot-decimal">158.6</ix:nonFraction> million, or $<ix:nonFraction name="adma:LongTermDebtPrepaymentPenalty" id="Fact_e7715346fb694f7788953a775330ef42" contextRef="c20231218_DebtInstrumentAxis_HayfinCreditFacilityMember" unitRef="U001" decimals="-5" scale="6" format="ixt:num-dot-decimal">11.1</ix:nonFraction> million.</span></p></ix:continuation>
        <ix:continuation id="Text_d63af97cb57443219f8e78cbdd4b933649" continuedAt="Text_d63af97cb57443219f8e78cbdd4b933650"><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-indent: 45px; text-align: left; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"> <span style="font-size: 10pt;"><br/>
          </span> </p></ix:continuation>
        <ix:continuation id="Text_d63af97cb57443219f8e78cbdd4b933650" continuedAt="Text_d63af97cb57443219f8e78cbdd4b933651">
<div><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
        <ix:continuation id="Text_d63af97cb57443219f8e78cbdd4b933651" continuedAt="Text_d63af97cb57443219f8e78cbdd4b933652"><p style="background-color: rgb(255, 255, 255); margin-top: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-align: left; text-transform: none; text-indent: 27pt;">All of the Company&#8217;s obligations under the Hayfin Credit Agreement were secured by a first-priority lien and security interest in substantially all of the Company&#8217;s tangible and intangible assets,
          including intellectual property, and all of the equity interests in the Company&#8217;s subsidiaries. The Hayfin Credit Agreement contained certain representations and warranties, affirmative covenants, negative covenants and conditions that are
          customarily required for similar debt financings. The negative covenants restricted or limited the ability of the Company and its subsidiaries to, among other things and subject to certain exceptions contained in the Hayfin Credit Agreement,
          incur new indebtedness; create liens on assets; engage in certain fundamental corporate changes, such as mergers or acquisitions, or changes to the Company&#8217;s or its subsidiaries&#8217; business activities; make certain Investments or Restricted
          Payments (each as defined in the Hayfin Credit Agreement); change its fiscal year; pay dividends; repay certain other indebtedness; engage in certain affiliate transactions; or enter into, amend or terminate any other agreements that have the
          impact of restricting the Company&#8217;s ability to make loan repayments under the Hayfin Credit Agreement. In addition, the Company was required (i) at all times prior to the Hayfin Maturity Date to maintain a minimum cash balance of $<ix:nonFraction name="us-gaap:Cash" id="Fact_c5228979a4ef451ab148becef8a3563c" contextRef="c20220323_CounterpartyNameAxis_HayfinCreditAgreementMember_RangeAxis_MinimumMember" unitRef="U001" decimals="-5" scale="6" format="ixt:num-dot-decimal">6.0</ix:nonFraction> million; and (ii) as of the last day of each fiscal quarter, report IVIG product and related revenues for the trailing 12-month period that exceed
          the amounts set forth in the <span style="font-family: 'Times New Roman'; color: rgb(0, 0, 0); background-color: rgb(255, 255, 255); font-weight: normal; font-style: normal; font-variant: normal; text-transform: none;"><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none;">Hayfin</span></span> Credit Agreement, which ranged from $<ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_74caae59e979443285ab4504193b6990" contextRef="c20220401to20220630_CounterpartyNameAxis_HayfinCreditAgreementMember_RangeAxis_MinimumMember" unitRef="U001" decimals="-5" scale="6" format="ixt:num-dot-decimal">75.0</ix:nonFraction> million for the fiscal quarter ended June 30, 2022 to $<ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_b158297267e7478eae492595eaecb9bf" contextRef="c20230701to20230930_CounterpartyNameAxis_HayfinCreditAgreementMember_RangeAxis_MaximumMember" unitRef="U001" decimals="-5" scale="6" format="ixt:num-dot-decimal">110.0</ix:nonFraction> million for the fiscal quarter ended September 30, 2023. As of the Ares Closing Date and December 31, 2022, the Company was in compliance with all of the covenants contained in the <span style="font-family: 'Times New Roman'; color: rgb(0, 0, 0); background-color: rgb(255, 255, 255); font-weight: normal; font-style: normal; font-variant: normal; text-transform: none;"><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none;">Hayfin</span></span> Credit Agreement. </p></ix:continuation>
        <ix:continuation id="Text_d63af97cb57443219f8e78cbdd4b933652" continuedAt="Text_d63af97cb57443219f8e78cbdd4b933653">
<div><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
        <ix:continuation id="Text_d63af97cb57443219f8e78cbdd4b933653" continuedAt="Text_d63af97cb57443219f8e78cbdd4b933654"><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-indent: 45px; text-align: left; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p></ix:continuation>
        <ix:continuation id="Text_d63af97cb57443219f8e78cbdd4b933654" continuedAt="Text_d63af97cb57443219f8e78cbdd4b933655">
<div><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
        <ix:continuation id="Text_d63af97cb57443219f8e78cbdd4b933655" continuedAt="Text_d63af97cb57443219f8e78cbdd4b933656">
<div style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; As consideration for the Hayfin
          Credit Agreement, on the Hayfin Closing Date the Company issued to various entities affiliated with Hayfin warrants to purchase an aggregate of <ix:nonFraction name="adma:SharesIssuedUponExerciseOfWarrants" id="Fact_3e59ab66e4524ddfb3a916ef7b0cf674" contextRef="c20220323to20220323_CounterpartyNameAxis_HayfinCreditAgreementMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">9,103,047</ix:nonFraction>
          shares of the Company&#8217;s common stock (the &#8220;Hayfin Warrants&#8221;). The Hayfin Warrants have an exercise price equal to $<ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" id="Fact_8e51d53f35174c67b42f3564e71035e6" contextRef="c20220323_CounterpartyNameAxis_HayfinCreditAgreementMember" unitRef="U003" decimals="4" scale="0" format="ixt:num-dot-decimal">1.6478</ix:nonFraction> per share,
          which is equal to the trailing <ix:nonNumeric name="adma:TrailingPeriodForVolumeWeightedAveragePrice" id="Fact_fbf1e05eb11c473eab42586e459bf193" contextRef="c20240101to20241231_CounterpartyNameAxis_HayfinCreditAgreementMember" format="ixt-sec:durday">30</ix:nonNumeric>-day Volume Weighted-average Price of the Company&#8217;s common stock on the business day immediately
          prior to the Hayfin Closing Date. The Hayfin Warrants were valued by the Company at approximately $<ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" id="Fact_78bf1724d03148fda424b209e117d85d" contextRef="c20220323to20220323_CounterpartyNameAxis_HayfinCreditAgreementMember" unitRef="U001" decimals="-5" scale="6" format="ixt:num-dot-decimal">9.6</ix:nonFraction> million as of the Hayfin Closing
          Date and have an expiration date of <ix:nonNumeric name="us-gaap:DebtInstrumentMaturityDate" id="Fact_7345e896d16c4ea38920d74a90723dd3" contextRef="c20240101to20241231_CounterpartyNameAxis_HayfinCreditAgreementMember" format="ixt:date-monthname-day-year-en">March 23, 2029</ix:nonNumeric> (see Note 8). As consideration for the foregoing amendment to the Hayfin Credit
          Agreement on May 1, 2023, the Company issued additional warrants to the lenders to purchase <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" id="Fact_7f29acaeae1948e89399ec7b402fc51e" contextRef="c20230501_CounterpartyNameAxis_HayfinSecondAmendmentMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">2,391,244</ix:nonFraction> shares of the Company&#8217;s common
          stock at an exercise price of $<ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" id="Fact_49feb7ce2e8343ffad540bf0278791e1" contextRef="c20230501_CounterpartyNameAxis_HayfinSecondAmendmentMember" unitRef="U003" decimals="4" scale="0" format="ixt:num-dot-decimal">3.2619</ix:nonFraction> per share (the &#8220;Hayfin Second Amendment Warrants&#8221;). The Hayfin Second Amendment Warrants were
          valued at approximately $<ix:nonFraction name="us-gaap:WarrantsAndRightsOutstanding" id="Fact_67d13b07df784755839b86b1e56703aa" contextRef="c20230501_CounterpartyNameAxis_HayfinSecondAmendmentMember" unitRef="U001" decimals="-5" scale="6" format="ixt:num-dot-decimal">5.6</ix:nonFraction> million and have an expiration date of <ix:nonNumeric name="us-gaap:DebtInstrumentMaturityDate" id="Fact_5e35bced93e34709b0b331a9666538c4" contextRef="c20240101to20241231_CounterpartyNameAxis_HayfinSecondAmendmentMember" format="ixt:date-monthname-day-year-en">May 1, 2030</ix:nonNumeric>.</div>
</ix:continuation>
        <ix:continuation id="Text_d63af97cb57443219f8e78cbdd4b933656" continuedAt="Text_d63af97cb57443219f8e78cbdd4b933657">
<div><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation> </div>

      <ix:continuation id="Text_d63af97cb57443219f8e78cbdd4b933657" continuedAt="Text_d63af97cb57443219f8e78cbdd4b933658">
<div><span style="font-size: 10pt;"> </span></div>
</ix:continuation>
      <div style="text-align: left; font: 10pt 'Times New Roman';"><ix:continuation id="Text_d63af97cb57443219f8e78cbdd4b933658" continuedAt="Text_d63af97cb57443219f8e78cbdd4b933659">
<div><br/></div>
</ix:continuation>
        <ix:continuation id="Text_d63af97cb57443219f8e78cbdd4b933659"><p style="margin-top: 0px; margin-bottom: 0px; font-family: 'Times New Roman'; font-size: 10pt; text-align: left; text-indent: 27pt;"><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">As a result of the upfront fee and exit fee paid or payable to Hayfin, the expenses incurred by the Company&#160; in connection with this transaction and
            the value of the Hayfin Warrants and Hayfin Second Amendment Warrants, the Company recognized a discount on the Hayfin Loans in the amount of $<ix:nonFraction name="us-gaap:DebtInstrumentUnamortizedDiscount" id="Fact_d6714d355e9d424db7009453b0c12abb" contextRef="c20221231_CounterpartyNameAxis_HayfinSecondAmendmentMember" unitRef="U001" decimals="-5" scale="6" format="ixt:num-dot-decimal">13.9</ix:nonFraction>
            million for the year ended December 31, 2022 and an additional debt discount in the year ended December 31, 2023 in the amount of $<ix:nonFraction name="us-gaap:DebtInstrumentUnamortizedDiscount" id="Fact_2253e1acc3834842917cbe85269250d0" contextRef="c20231231_CounterpartyNameAxis_HayfinSecondAmendmentMember" unitRef="U001" decimals="-5" scale="6" format="ixt:num-dot-decimal">5.7</ix:nonFraction>
            million. The Company records debt discount as a reduction to the face amount of the debt, and the debt discount is amortized as interest expense over the life of the debt using the interest method. As of the Ares Closing Date, $<ix:nonFraction name="us-gaap:DebtInstrumentUnamortizedDiscount" id="Fact_4a324304f65a43088371c17ce60de103" contextRef="c20231218_CounterpartyNameAxis_HayfinCreditAgreementMember" unitRef="U001" decimals="-5" scale="6" format="ixt:num-dot-decimal">15.0</ix:nonFraction> million of the aggregate debt discount associated with the Hayfin Credit Facility was unamortized, and this amount is reflected in the loss on
            extinguishment of debt for the year ended December 31, 2023. Based on the fair value of the Hayfin Warrants and the aggregate amount of fees and expenses associated with obtaining the Hayfin Credit Facility, the effective interest rate on the
            Hayfin Loans as of the Hayfin Closing Date and as of December 31, 2022 was approximately <ix:nonFraction name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" id="Fact_561bb3d249e74eceb4b44c3c404e3b83" contextRef="c20220323_CounterpartyNameAxis_HayfinCreditAgreementMember" unitRef="U007" decimals="3" scale="-2" format="ixt:num-dot-decimal">13.0</ix:nonFraction>% and <ix:nonFraction name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" id="Fact_3b720d463c12485a89707a26281f6b5b" contextRef="c20221231_CounterpartyNameAxis_HayfinCreditAgreementMember" unitRef="U007" decimals="3" scale="-2" format="ixt:num-dot-decimal">16.1</ix:nonFraction>%, respectively<span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: left; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">.</span> </span><span style="font-size: 10pt;"><br/>
          </span> </p></ix:continuation>
<div><span style="font-size: 10pt;"> </span>
        <span style="font-size: 10pt;"> </span></div>

        <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;">&#160;</p>
        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div class="BRPFPageNumberArea" style="text-align: center;"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">F-22</span></div>

          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"/></div>

          <div class="BRPFPageHeader" style="width: 100%;">
            <div>
              <div style="text-align: left; font-weight: bold; text-indent: -9pt; margin-left: 9pt;"><a href="#ADMABIOLOGICSINC."> <span style="font-style: italic; font-weight: normal; font-size: 8pt;">Table of Contents</span></a><br/>
              </div>

              <div style="text-align: left; font-weight: bold; text-indent: -9pt; margin-left: 9pt;"><a href="#ADMABIOLOGICSINC."><span style="font-style: italic; font-weight: normal; font-size: 8pt;"> <br/>
                  </span></a></div>

              <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">ADMA BIOLOGICS, INC. AND SUBSIDIARIES</div>

              <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</div>

            </div>

          </div>

        </div>

      </div>

    </div>

  </div>


  <div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: rgb(0, 0, 0);"> <div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>

    <div>
      <div style="text-align: left; font: 10pt 'Times New Roman';">
        <ix:nonNumeric name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="Text_d2a744264d9845e4b504a91fa7aad051" contextRef="c20240101to20241231" escape="true" continuedAt="Text_dc9d2d26f01543f296ae7c67bdf0853e1">
<div>
          <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt; border-spacing: 0;">


  <tr style="vertical-align: top;">

    <td style="vertical-align: top; width: 27pt;">
                  <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"><strong>8.</strong></p>
                </td>

    <td style="vertical-align: top; width: auto;">
                  <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"><span style="text-decoration: underline;"><strong>STOCKHOLDERS</strong></span><strong><span style="text-decoration: underline;">&#8217; EQUITY</span><br/>
                    </strong></p>
                </td>

  </tr>


</table>
        </div>
</ix:nonNumeric>
        <ix:continuation id="Text_dc9d2d26f01543f296ae7c67bdf0853e1" continuedAt="Text_dc9d2d26f01543f296ae7c67bdf0853e2"><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p></ix:continuation>
        <ix:continuation id="Text_dc9d2d26f01543f296ae7c67bdf0853e2" continuedAt="Text_dc9d2d26f01543f296ae7c67bdf0853e3"><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"><span style="text-decoration: underline;">Preferred Stock</span></p></ix:continuation>
        <ix:continuation id="Text_dc9d2d26f01543f296ae7c67bdf0853e3" continuedAt="Text_dc9d2d26f01543f296ae7c67bdf0853e4"><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p></ix:continuation>
        <ix:continuation id="Text_dc9d2d26f01543f296ae7c67bdf0853e4" continuedAt="Text_dc9d2d26f01543f296ae7c67bdf0853e5"><p style="margin: 0px; font-family: 'Times New Roman'; font-size: 10pt; text-align: left; text-indent: 36pt; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">The Company is currently authorized to issue up to <ix:nonFraction name="us-gaap:PreferredStockCapitalSharesReservedForFutureIssuance" id="Fact_171a85c03c514919aec6117d955cf139" contextRef="c20241231" unitRef="U002" decimals="-6" scale="6" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:PreferredStockCapitalSharesReservedForFutureIssuance" id="Fact_09ab236f400c4f87a98940893a91b3e7" contextRef="c20231231" unitRef="U002" decimals="-6" scale="6" format="ixt:num-dot-decimal">10</ix:nonFraction></ix:nonFraction> million shares of preferred stock, $<ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" id="Fact_d89a6f2ab4de4dac91479eae5e729385" contextRef="c20241231" unitRef="U003" decimals="4" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" id="Fact_67c6359c525d474d86b16dbea70c8977" contextRef="c20231231" unitRef="U003" decimals="4" scale="0" format="ixt:num-dot-decimal">0.0001</ix:nonFraction></ix:nonFraction>
          par value per share. There were <ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" id="Fact_ae0a3f4fdb294bd4a5332de2db680cb7" contextRef="c20231231" unitRef="U002" decimals="INF" scale="0" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" id="Fact_16e4119a40e9496a8185bf0d3697eb23" contextRef="c20241231" unitRef="U002" decimals="INF" scale="0" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction> shares of preferred stock outstanding at December 31, 2024 and 2023.</p></ix:continuation>
        <ix:continuation id="Text_dc9d2d26f01543f296ae7c67bdf0853e5" continuedAt="Text_dc9d2d26f01543f296ae7c67bdf0853e6"><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p></ix:continuation>
        <ix:continuation id="Text_dc9d2d26f01543f296ae7c67bdf0853e6" continuedAt="Text_dc9d2d26f01543f296ae7c67bdf0853e7"><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"><span style="text-decoration: underline;">Common Stock</span></p></ix:continuation>
        <ix:continuation id="Text_dc9d2d26f01543f296ae7c67bdf0853e7" continuedAt="Text_dc9d2d26f01543f296ae7c67bdf0853e8"><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p></ix:continuation>
        <ix:continuation id="Text_dc9d2d26f01543f296ae7c67bdf0853e8" continuedAt="Text_dc9d2d26f01543f296ae7c67bdf0853e9"><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-indent: 45px; text-align: left;"> </p></ix:continuation>
        <ix:continuation id="Text_dc9d2d26f01543f296ae7c67bdf0853e9" continuedAt="Text_dc9d2d26f01543f296ae7c67bdf0853e10">
<div style="display:none;"><br/></div>
<div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">As of
          December 31, 2024 and 2023, the Company was authorized to issue <ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" id="Fact_a902b445fd914c2c83161cb608827c47" contextRef="c20241231" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" id="Fact_194a715a494f4ec693662aac78d4340e" contextRef="c20231231" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">300,000,000</ix:nonFraction></ix:nonFraction> shares of its common stock, $<ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" id="Fact_865ee28bbbd94e03979bb50d751d4703" contextRef="c20231231" unitRef="U003" decimals="4" scale="0" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" id="Fact_110a81c970df4047a9f25ac93fee6271" contextRef="c20241231" unitRef="U003" decimals="4" scale="0" format="ixt:num-dot-decimal">0.0001</ix:nonFraction></ix:nonFraction> par value per share, and <ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" id="Fact_1047011eb9194116941456ebb8b4bc2c" contextRef="c20241231" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">236,620,545</ix:nonFraction>
          and <ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" id="Fact_6088a0a43dee428bbaff950524d94b2a" contextRef="c20231231" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">226,063,032</ix:nonFraction> shares of common stock were outstanding as of December 31, 2024 and 2023, respectively.&#160; After giving effect to shares
          reserved for the issuance of warrants and for awards issued under the Company&#8217;s equity incentive plans, <ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" id="Fact_075f00de28744193a7b7105ad8515899" contextRef="c20241231" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">36,093,118</ix:nonFraction> shares of common
          stock were available for issuance as of December 31, 2024.</div>
</ix:continuation>
        <ix:continuation id="Text_dc9d2d26f01543f296ae7c67bdf0853e10" continuedAt="Text_dc9d2d26f01543f296ae7c67bdf0853e11">
<div style="display:none;"><br/></div>
<div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"><span style="background-color: rgb(255, 255, 255); display: inline; float: none; letter-spacing: normal; white-space: normal; word-spacing: 0px; font-weight: 400; text-align: left;"> <br/>
          </span></div>
</ix:continuation>
        <ix:continuation id="Text_dc9d2d26f01543f296ae7c67bdf0853e11" continuedAt="Text_dc9d2d26f01543f296ae7c67bdf0853e12">
<div style="display:none;"><br/></div>
<div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"><span style="background-color: rgb(255, 255, 255); display: inline; float: none; letter-spacing: normal; white-space: normal; word-spacing: 0px; font-weight: 400; text-align: left;"><span style="background-color: rgb(255, 255, 255); font-weight: normal;"> During the years ended December 31, 2024, 2023 and 2022, outstanding stock options aggregating to <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" id="Fact_0bda77157e944a818d906f8285760c06" contextRef="c20240101to20241231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">1,988,066</ix:nonFraction>, <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" id="Fact_2405063e46d947bd9791e66cfa3d4c55" contextRef="c20230101to20231231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">1,444,533</ix:nonFraction> and <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" id="Fact_5428a67635eb4790aec89f603a7bf721" contextRef="c20220101to20221231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">68,679</ix:nonFraction> shares,
              respectively, of common stock were exercised, and the Company received net proceeds from the exercises of approximately $<ix:nonFraction name="us-gaap:ProceedsFromStockOptionsExercised" id="Fact_be293a9582bf4766af924ab70126f475" contextRef="c20240101to20241231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="-5" scale="6" format="ixt:num-dot-decimal">7.5</ix:nonFraction>
              million, $<ix:nonFraction name="us-gaap:ProceedsFromStockOptionsExercised" id="Fact_57d6461bd593485787eed86f3aef627d" contextRef="c20230101to20231231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="-5" scale="6" format="ixt:num-dot-decimal">1.1</ix:nonFraction> million and $<ix:nonFraction name="us-gaap:ProceedsFromStockOptionsExercised" id="Fact_ed6f2bc0b8354ca997aa898918ad5175" contextRef="c20220101to20221231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U001" decimals="-5" scale="6" format="ixt:num-dot-decimal">0.2</ix:nonFraction>
              million, respectively.</span><br/>
          </span></div>
</ix:continuation>
        <ix:continuation id="Text_dc9d2d26f01543f296ae7c67bdf0853e12" continuedAt="Text_dc9d2d26f01543f296ae7c67bdf0853e13">
<div style="display:none;"><br/></div>
<div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"><span style="background-color: rgb(255, 255, 255); display: inline; float: none; letter-spacing: normal; white-space: normal; word-spacing: 0px; font-weight: 400; text-align: left;"> <br/>
          </span></div>
</ix:continuation>
        <ix:continuation id="Text_dc9d2d26f01543f296ae7c67bdf0853e13" continuedAt="Text_dc9d2d26f01543f296ae7c67bdf0853e14">
<div style="display:none;"><br/></div>
<div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"><span style="background-color: rgb(255, 255, 255); display: inline; float: none; letter-spacing: normal; white-space: normal; word-spacing: 0px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-weight: 400; text-align: left; text-transform: none; font-variant: normal;">On December 9, 2022, the Company completed an underwritten public offering whereby the Company issued <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" id="Fact_0b4676f2466840b4bcb0cfb4bc793f89" contextRef="c20221209to20221209_StatementEquityComponentsAxis_CommonStockMember_SubsidiarySaleOfStockAxis_OverAllotmentOptionMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">24,125,873</ix:nonFraction> shares of its common stock. Net proceeds after underwriting discounts and expenses associated with the offering were approximately $<ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" id="Fact_25f5460f04cc4563add02bd4595f503a" contextRef="c20221209to20221209_StatementEquityComponentsAxis_CommonStockMember_SubsidiarySaleOfStockAxis_OverAllotmentOptionMember" unitRef="U001" decimals="-5" scale="6" format="ixt:num-dot-decimal">64.6</ix:nonFraction> million and were used to accelerate commercialization and production activities, complete plasma center buildouts and obtain FDA approvals, to conclude post&#8209;FDA
            marketing approval research and development projects, and for working capital, capital expenditures and general corporate purposes.</span><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
          </span> </div>
</ix:continuation>
      </div>
<ix:continuation id="Text_dc9d2d26f01543f296ae7c67bdf0853e14" continuedAt="Text_dc9d2d26f01543f296ae7c67bdf0853e15">
<div><span style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"> </span>
       <span style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"> </span> <span style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"> <span style="background-color: rgb(255, 255, 255); font-weight: normal;"> </span> </span></div>
</ix:continuation>
      <div style="line-height: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-align: left;">
        <div style="margin: 0px 0px 0px; font-family: 'Times New Roman'; font-size: 10pt; text-align: left;"><ix:continuation id="Text_dc9d2d26f01543f296ae7c67bdf0853e15" continuedAt="Text_dc9d2d26f01543f296ae7c67bdf0853e16">
<div><span style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">
          </span></div>
</ix:continuation>
          <div style="font-family: 'Times New Roman';"><ix:continuation id="Text_dc9d2d26f01543f296ae7c67bdf0853e16" continuedAt="Text_dc9d2d26f01543f296ae7c67bdf0853e17">
<div><br/></div>
</ix:continuation>
            <ix:continuation id="Text_dc9d2d26f01543f296ae7c67bdf0853e17" continuedAt="Text_dc9d2d26f01543f296ae7c67bdf0853e18">
<div><span style="text-decoration: underline;"><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Warrants</span></span><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
              </span> </div>
</ix:continuation>
            <div style="line-height: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-align: left;">
              <ix:continuation id="Text_dc9d2d26f01543f296ae7c67bdf0853e18" continuedAt="Text_dc9d2d26f01543f296ae7c67bdf0853e19"><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"> <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
                </span> </p></ix:continuation>
              <ix:continuation id="Text_dc9d2d26f01543f296ae7c67bdf0853e19" continuedAt="Text_dc9d2d26f01543f296ae7c67bdf0853e20">
<div><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
              <ix:continuation id="Text_dc9d2d26f01543f296ae7c67bdf0853e20" continuedAt="Text_dc9d2d26f01543f296ae7c67bdf0853e21">
<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-indent: 36pt;"><span style="font-weight: normal; letter-spacing: normal; text-align: left; text-indent: 48px; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"><span style="background-color: rgb(255, 255, 255); font-weight: normal;">
                    During the year ended December 31, 2024, several of the Company&#8217;s former noteholders exercised an aggregate of <ix:nonFraction name="adma:ClassOfWarrantOrRightExercised" id="Fact_8eb3bc376c334b598bc9f2026f26363f" contextRef="c20240101to20241231" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">11,308,702</ix:nonFraction>
                    warrants in cashless exercise transactions resulting in the Company issuing <ix:nonFraction name="us-gaap:CommonStockSharesIssued" id="Fact_9303b9bca5d24f3a94ca7dd954c91fdb" contextRef="c20241231_ClassOfWarrantOrRightAxis_WarrantMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">7,224,892</ix:nonFraction> shares of its common stock. Also
                    during the year ended December 31, 2024, warrants to purchase <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" id="Fact_e2bce4ba46ff48e08357a41e906a4be9" contextRef="c20241231" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">227,650</ix:nonFraction> shares of common stock that had been issued to former
                    noteholders of the Company expired in accordance with their terms.</span><br/>
                </span></div>
</ix:continuation>
              <ix:continuation id="Text_dc9d2d26f01543f296ae7c67bdf0853e21" continuedAt="Text_dc9d2d26f01543f296ae7c67bdf0853e22">
<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-indent: 36pt;"><span style="font-weight: normal; letter-spacing: normal; text-align: left; text-indent: 48px; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"> <br/>
                </span></div>
</ix:continuation>
              <ix:continuation id="Text_dc9d2d26f01543f296ae7c67bdf0853e22" continuedAt="Text_dc9d2d26f01543f296ae7c67bdf0853e23">
<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-indent: 36pt;"> <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">On June 16, 2023, various entities affiliated with Hayfin exercised <ix:nonFraction name="adma:ClassOfWarrantOrRightExercised" id="Fact_098cb36b4ad9424ea4bdc1f5ba46cb9b" contextRef="c20230616to20230616_ClassOfWarrantOrRightAxis_HayfinWarrantsMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">3,388,686</ix:nonFraction> Hayfin Warrants in a cashless exercise transaction resulting in the Company issuing <ix:nonFraction name="us-gaap:CommonStockSharesIssued" id="Fact_b56eaec63b384f64aa28f64da6ef1f54" contextRef="c20230616_ClassOfWarrantOrRightAxis_HayfinWarrantsMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">1,967,847</ix:nonFraction> shares of its common stock to such entities. On May 1, 2023 the Company issued the Hayfin Second Amendment Warrants (see Note 7), which were valued at $<ix:nonFraction name="us-gaap:WarrantsAndRightsOutstanding" id="Fact_13be2e8a097c45118092b3440b8ac8b8" contextRef="c20230501_CounterpartyNameAxis_HayfinSecondAmendmentMember" unitRef="U001" decimals="-5" scale="6" format="ixt:num-dot-decimal">5.6</ix:nonFraction> million using the Black-Scholes option-pricing model assuming an expected term of <ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Fact_aa575bc68b8946f0850a45d1a722d3d2" contextRef="c20240101to20241231_CounterpartyNameAxis_HayfinSecondAmendmentMember" format="ixt-sec:durwordsen">seven years</ix:nonNumeric>, a volatility of <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" id="Fact_bd57b751f72a4b85a4bd082b4683b243" contextRef="c20230501to20230501_CounterpartyNameAxis_HayfinSecondAmendmentMember" unitRef="U007" decimals="3" scale="-2" format="ixt:num-dot-decimal">67.8</ix:nonFraction>%, a dividend yield of <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" id="Fact_ad696fcaec7441209d8021d8aa97d0e1" contextRef="c20230501to20230501_CounterpartyNameAxis_HayfinSecondAmendmentMember" unitRef="U007" decimals="2" scale="-2" format="ixt:num-dot-decimal">0</ix:nonFraction>% and a risk-free rate of interest of <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" id="Fact_691e2ae9196542429767af3635a22867" contextRef="c20230501to20230501_CounterpartyNameAxis_HayfinSecondAmendmentMember" unitRef="U007" decimals="4" scale="-2" format="ixt:num-dot-decimal">3.62</ix:nonFraction>%.</span></div>
</ix:continuation>
              <ix:continuation id="Text_dc9d2d26f01543f296ae7c67bdf0853e23" continuedAt="Text_dc9d2d26f01543f296ae7c67bdf0853e24">
<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-indent: 36pt;"><span style="font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 48px; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"> <br/>
                </span></div>
</ix:continuation>
              <ix:continuation id="Text_dc9d2d26f01543f296ae7c67bdf0853e24" continuedAt="Text_dc9d2d26f01543f296ae7c67bdf0853e25">
<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-indent: 36pt;">On March 23, 2022, the Company issued the Hayfin Warrants, whereby affiliates of Hayfin may purchase an aggregate
                of <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" id="Fact_a1f6fc29cc504542bed65320b267009d" contextRef="c20220323_ClassOfWarrantOrRightAxis_HayfinWarrantsMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">9,103,047</ix:nonFraction> shares of common stock at an exercise price of $<ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" id="Fact_9b477fd1a2834049978ff805143134ec" contextRef="c20220323_ClassOfWarrantOrRightAxis_HayfinWarrantsMember" unitRef="U003" decimals="4" scale="0" format="ixt:num-dot-decimal">1.6478</ix:nonFraction> per share (see Note 7). The Hayfin Warrants were valued at $<ix:nonFraction name="us-gaap:WarrantsAndRightsOutstanding" id="Fact_e564d0ff72d240ad81e95a0e3b096dbd" contextRef="c20220323_ClassOfWarrantOrRightAxis_HayfinWarrantsMember" unitRef="U001" decimals="-5" scale="6" format="ixt:num-dot-decimal">9.6</ix:nonFraction>
                million, using the Black-Scholes option pricing model assuming an expected term of <ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Fact_504d540f2b164991b3ea743e1177a090" contextRef="c20240101to20241231_ClassOfWarrantOrRightAxis_HayfinWarrantsMember" format="ixt-sec:duryear">7</ix:nonNumeric> years, a volatility of <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" id="Fact_ed877cf8c50b48988d83888ba1ba9e9b" contextRef="c20220323to20220323_ClassOfWarrantOrRightAxis_HayfinWarrantsMember" unitRef="U007" decimals="3" scale="-2" format="ixt:num-dot-decimal">68.1</ix:nonFraction>%, a dividend yield of <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" id="Fact_81a8a7f6b4f64c1d9544a073f1b0c824" contextRef="c20220323to20220323_ClassOfWarrantOrRightAxis_HayfinWarrantsMember" unitRef="U007" decimals="2" scale="-2" format="ixt:num-dot-decimal">0</ix:nonFraction>%
                and a risk-free interest rate of <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" id="Fact_aee346211c9b4086a5b69fc884e50480" contextRef="c20220323to20220323_ClassOfWarrantOrRightAxis_HayfinWarrantsMember" unitRef="U007" decimals="4" scale="-2" format="ixt:num-dot-decimal">2.36</ix:nonFraction>%. During the year ended December 31, 2022, warrants to purchase <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" id="Fact_8c81f2422cc84138a800ca6c4e920c78" contextRef="c20221231" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">106,059</ix:nonFraction> shares of common stock that had been issued to former noteholders of the Company expired. </div>
</ix:continuation>
              <ix:continuation id="Text_dc9d2d26f01543f296ae7c67bdf0853e25" continuedAt="Text_dc9d2d26f01543f296ae7c67bdf0853e26">
<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-indent: 36pt;"> <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
                </span> </div>
</ix:continuation>
              <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
                <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">F-23</span></div>

                <div style="page-break-after: always;" class="BRPFPageBreak">
                  <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"/></div>

                <div style="width: 100%;" class="BRPFPageHeader">
                  <div>
                    <div style="text-align: left; font-weight: bold; text-indent: -9pt; margin-left: 9pt;"><a href="#ADMABIOLOGICSINC."> <span style="font-style: italic; font-weight: normal; font-size: 8pt;">Table of Contents</span></a><br/>
                    </div>

                    <div style="text-align: left; font-weight: bold; text-indent: -9pt; margin-left: 9pt;"><a href="#ADMABIOLOGICSINC."><span style="font-style: italic; font-weight: normal; font-size: 8pt;"> <br/>
                        </span></a></div>

                    <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">ADMA BIOLOGICS, INC. AND SUBSIDIARIES</div>

                    <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</div>

                  </div>

                </div>

              </div>

              <div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left;">
                <ix:continuation id="Text_dc9d2d26f01543f296ae7c67bdf0853e26" continuedAt="Text_dc9d2d26f01543f296ae7c67bdf0853e27">
<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-indent: 36pt;">At December 31, 2024 and 2023, the Company had outstanding warrants to purchase an aggregate of <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" id="Fact_39fac70ee80f40e28840be95d2da2a51" contextRef="c20241231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">966,554</ix:nonFraction> and <ix:nonFraction name="us-gaap:ClassOfWarrantOrRightOutstanding" id="Fact_06aec9d2b09445f8abcda19fbd633ca7" contextRef="c20231231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">12,502,906</ix:nonFraction> shares,
                  respectively, of common stock, with a weighted average exercise price of $<ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" id="Fact_7cd9bba577c7470da63cd79b7f9d68d5" contextRef="c20241231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">1.98</ix:nonFraction> and $<ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" id="Fact_b83571c4ddf1404092151802c9521417" contextRef="c20231231_StatementEquityComponentsAxis_CommonStockMember" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">2.32</ix:nonFraction> per share, respectively, and expiration dates ranging between March 2029 and May 2030. <span style="background-color: rgb(255, 255, 255); font-weight: normal;">
                    <span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; text-align: left; text-indent: 48px; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"><ix:nonNumeric name="us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" id="Text_818bae965ac04c37b65fbafa5c0999d9" contextRef="c20240101to20241231" escape="true" continuedAt="Text_32d05bb607884683a3b634c040cd374b1"><span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal;">The






























                      following table summarizes information about warrants outstanding as of December 31, 2024, 2023 and 2022:</span></ix:nonNumeric></span> </span></div>
</ix:continuation>
                <ix:continuation id="Text_dc9d2d26f01543f296ae7c67bdf0853e27" continuedAt="Text_dc9d2d26f01543f296ae7c67bdf0853e28"><ix:continuation id="Text_32d05bb607884683a3b634c040cd374b1" continuedAt="Text_32d05bb607884683a3b634c040cd374b2">
<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-indent: 36pt;"><span style="background-color: rgb(255, 255, 255); font-weight: normal;"><span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; text-align: left; text-indent: 48px; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"> <br/>
                    </span></span></div>
</ix:continuation></ix:continuation>
                <div style="background-color: #FFFFFF; letter-spacing: normal; white-space: normal; word-spacing: 0px; color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-weight: 400; text-align: left; text-transform: none;">
                  <ix:continuation id="Text_dc9d2d26f01543f296ae7c67bdf0853e28" continuedAt="Text_dc9d2d26f01543f296ae7c67bdf0853e29"><ix:continuation id="Text_32d05bb607884683a3b634c040cd374b2">
<table cellspacing="0" cellpadding="0" class="cfttable" style="font-family: 'Times New Roman'; letter-spacing: normal; text-transform: none; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%; border-spacing: 0;">


  <tr>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;"><br class="Apple-interchange-newline"/>
                          &#160;</td>

    <td valign="bottom" colspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: 2px solid rgb(0, 0, 0);"><span style="font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Shares </span><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
                          </span> </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
                          <div style="text-align: center; font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Weighted</div>
                          <div style="text-align: center; font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Average</div>
                          <div style="text-align: center; font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Exercise Price</div>
                        </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255); white-space: nowrap;">
                          <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Warrants outstanding at December 31, 2021</div>
                        </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;">
                          <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" id="Fact_ed1b27bcd04944b9ab9a0bdf8bfb3ccd" contextRef="c20211231_ClassOfWarrantOrRightAxis_WarrantMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">4,528,160</ix:nonFraction></div>
                        </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">
                          <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">$</div>
                        </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;">
                          <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" id="Fact_16ed96969de140ee96a4225010b61ea7" contextRef="c20211231_ClassOfWarrantOrRightAxis_WarrantMember" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">2.82</ix:nonFraction></div>
                        </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; white-space: nowrap;">
                          <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Expired</div>
                        </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                          <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">(<ix:nonFraction name="adma:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod" id="Fact_561954a945054ee78437b56b9b788f44" contextRef="c20220101to20221231_ClassOfWarrantOrRightAxis_WarrantMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">106,059</ix:nonFraction></div>
                        </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">
                          <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">)</div>
                        </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">
                          <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">$</div>
                        </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                          <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><ix:nonFraction name="adma:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriodWeightedAverageGrantDateFairValue" id="Fact_dfd3c0b4ea72421095fe1aa3f6372215" contextRef="c20220101to20221231_ClassOfWarrantOrRightAxis_WarrantMember" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">8.23</ix:nonFraction></div>
                        </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255); white-space: nowrap;">
                          <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Granted</div>
                        </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;">
                          <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" id="Fact_b27bb0ddfba744b4b9ae3411d596261b" contextRef="c20220101to20221231_ClassOfWarrantOrRightAxis_WarrantMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">9,103,047</ix:nonFraction></div>
                        </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">
                          <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">$</div>
                        </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;">
                          <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" id="Fact_8e4f57f19c9149ea90d24ddb11540e7a" contextRef="c20220101to20221231_ClassOfWarrantOrRightAxis_WarrantMember" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">1.65</ix:nonFraction></div>
                        </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px; white-space: nowrap;">
                          <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Exercised</div>
                        </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">
                          <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><ix:nonFraction name="adma:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod" id="Fact_ea9c02ff810f4dc2b54381686665adde" contextRef="c20220101to20221231_ClassOfWarrantOrRightAxis_WarrantMember" unitRef="U002" decimals="INF" scale="0" format="ixt:fixed-zero">-</ix:nonFraction></div>
                        </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">
                          <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">$</div>
                        </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; white-space: nowrap;">
                          <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><ix:nonFraction name="adma:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageGrantDateFairValue" id="Fact_a108b7a1b84d4b4e8ff022ee2ce34c2d" contextRef="c20220101to20221231_ClassOfWarrantOrRightAxis_WarrantMember" unitRef="U003" decimals="0" scale="0" format="ixt:fixed-zero">-</ix:nonFraction></div>
                        </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255); white-space: nowrap;">
                          <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Warrants outstanding at December 31, 2022</div>
                        </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;">
                          <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" id="Fact_9884369018914b9da80f20e1ef4aec62" contextRef="c20221231_ClassOfWarrantOrRightAxis_WarrantMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">13,525,148</ix:nonFraction></div>
                        </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">
                          <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">$</div>
                        </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;">
                          <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" id="Fact_066ca890123c4399b984a24cd0c7766e" contextRef="c20221231_ClassOfWarrantOrRightAxis_WarrantMember" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">1.99</ix:nonFraction></div>
                        </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; white-space: nowrap;">
                          <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Expired</div>
                        </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                          <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">(<ix:nonFraction name="adma:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod" id="Fact_31dfd4afd8ff49c387e91d15f9ab713d" contextRef="c20230101to20231231_ClassOfWarrantOrRightAxis_WarrantMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">24,800</ix:nonFraction></div>
                        </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">
                          <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">)</div>
                        </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">
                          <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">$</div>
                        </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;">
                          <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><ix:nonFraction name="adma:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriodWeightedAverageGrantDateFairValue" id="Fact_0ecb61044a6b43158c4f105388ca43f0" contextRef="c20230101to20231231_ClassOfWarrantOrRightAxis_WarrantMember" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">6.37</ix:nonFraction></div>
                        </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255); white-space: nowrap;">
                          <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Granted</div>
                        </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;">
                          <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" id="Fact_ebdaac7ff3734f76b8e8219fe6f6015b" contextRef="c20230101to20231231_ClassOfWarrantOrRightAxis_WarrantMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">2,391,244</ix:nonFraction></div>
                        </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">
                          <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">$</div>
                        </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;">
                          <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" id="Fact_0559b1871447401d9ba548f5267f64bd" contextRef="c20230101to20231231_ClassOfWarrantOrRightAxis_WarrantMember" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">3.26</ix:nonFraction></div>
                        </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; padding-bottom: 2px; white-space: nowrap;">
                          <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Exercised</div>
                        </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">
                          <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">(<ix:nonFraction name="adma:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod" id="Fact_d1a7338cade84766a53477f9746a993c" contextRef="c20230101to20231231_ClassOfWarrantOrRightAxis_WarrantMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">3,388,686</ix:nonFraction></div>
                        </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">
                          <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">)</div>
                        </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">
                          <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">$</div>
                        </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; white-space: nowrap;">
                          <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><ix:nonFraction name="adma:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageGrantDateFairValue" id="Fact_890dc5da46aa406a89a5ea3f22f9e5b4" contextRef="c20230101to20231231_ClassOfWarrantOrRightAxis_WarrantMember" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">1.65</ix:nonFraction></div>
                        </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255); white-space: nowrap;">
                          <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Warrants outstanding at December 31, 2023</div>
                        </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;">
                          <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" id="Fact_242a177106d34b09ab34d021433866e9" contextRef="c20231231_ClassOfWarrantOrRightAxis_WarrantMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">12,502,906</ix:nonFraction></div>
                        </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">
                          <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">$</div>
                        </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;">
                          <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" id="Fact_2d5c0aecbee841959540726981f479b1" contextRef="c20231231_ClassOfWarrantOrRightAxis_WarrantMember" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">2.32</ix:nonFraction></div>
                        </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" rowspan="1" style="vertical-align: bottom; width: 76%; white-space: nowrap;"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Expired<br/>
                          </span> </td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;">(<ix:nonFraction name="adma:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod" id="Fact_7c71f2ce5fdd48fa94f73f8ba96497a8" contextRef="c20240101to20241231_ClassOfWarrantOrRightAxis_WarrantMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">227,650</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;">)</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;">$</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;"><ix:nonFraction name="adma:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriodWeightedAverageGrantDateFairValue" id="Fact_06044553a4ff4fc6be8d71ab75908e98" contextRef="c20240101to20241231_ClassOfWarrantOrRightAxis_WarrantMember" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">4.21</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" rowspan="1" style="vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255); white-space: nowrap;"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Granted<br/>
                          </span> </td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" id="Fact_2fd19d92c6c04422bcc0f184de68ce13" contextRef="c20240101to20241231_ClassOfWarrantOrRightAxis_WarrantMember" unitRef="U002" decimals="INF" scale="0" format="ixt:fixed-zero">-</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;">$</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" id="Fact_a4604e36a54a4709bc7633972397d7b1" contextRef="c20240101to20241231_ClassOfWarrantOrRightAxis_WarrantMember" unitRef="U003" decimals="0" scale="0" format="ixt:fixed-zero">-</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" rowspan="1" style="vertical-align: bottom; width: 76%; padding-bottom: 2px; white-space: nowrap;"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Exercised<br/>
                          </span> </td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">(<ix:nonFraction name="adma:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod" id="Fact_c23b856b5b104f7f90825751360d7e65" contextRef="c20240101to20241231_ClassOfWarrantOrRightAxis_WarrantMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">11,308,702</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; padding-bottom: 2px; white-space: nowrap;">)</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; padding-bottom: 2px; white-space: nowrap;">$</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; padding-bottom: 2px; white-space: nowrap;"><ix:nonFraction name="adma:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageGrantDateFairValue" id="Fact_556401170f964072b47209360a4e8bc4" contextRef="c20240101to20241231_ClassOfWarrantOrRightAxis_WarrantMember" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">2.31</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" rowspan="1" style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Warrants outstanding at December 31, 2024<br/>
                          </span> </td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" id="Fact_1d153626d71d4bdebdf42697f0f63852" contextRef="c20241231_ClassOfWarrantOrRightAxis_WarrantMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">966,554</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;">$</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" id="Fact_79f8b0b4bb7c4ad9933115efec60de79" contextRef="c20241231_ClassOfWarrantOrRightAxis_WarrantMember" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">1.98</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

  </tr>


</table>
</ix:continuation></ix:continuation><ix:continuation id="Text_dc9d2d26f01543f296ae7c67bdf0853e29" continuedAt="Text_dc9d2d26f01543f296ae7c67bdf0853e30">
<div>
                   <span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; text-align: left; text-indent: 48px; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"> </span></span></div>
</ix:continuation></div>

                <ix:continuation id="Text_dc9d2d26f01543f296ae7c67bdf0853e30" continuedAt="Text_dc9d2d26f01543f296ae7c67bdf0853e31">
<div><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation>
                <ix:continuation id="Text_dc9d2d26f01543f296ae7c67bdf0853e31" continuedAt="Text_dc9d2d26f01543f296ae7c67bdf0853e32">
<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-indent: 36pt;"><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span><span style="font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
                  </span></div>
</ix:continuation><ix:continuation id="Text_dc9d2d26f01543f296ae7c67bdf0853e32" continuedAt="Text_dc9d2d26f01543f296ae7c67bdf0853e33">
<div><span style="text-decoration: underline;"><span style="font-family: 'Times New Roman'; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Equity Incentive Plans</span></span>

                <span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation> </div>

              <ix:continuation id="Text_dc9d2d26f01543f296ae7c67bdf0853e33" continuedAt="Text_dc9d2d26f01543f296ae7c67bdf0853e34"><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p></ix:continuation>
              <ix:continuation id="Text_dc9d2d26f01543f296ae7c67bdf0853e34" continuedAt="Text_dc9d2d26f01543f296ae7c67bdf0853e35"><p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-bottom: 0px; text-align: left; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; text-indent: 36pt;"><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> On June 21, 2022, the Company&#8217;s stockholders approved the ADMA Biologics, Inc. 2022 Compensation Plan (the &#8220;2022 Equity Plan&#8221;), which replaced the Company&#8217;s Amended and Restated 2014 Omnibus Incentive Compensation
                  Plan (the &#8220;2014 Plan&#8221;). Approval of the 2022 Equity Plan resulted in approximately <ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" id="Fact_2ab185c599b048c5a0eb608443126078" contextRef="c20220621_PlanNameAxis_Two022CompensationPlanMember" unitRef="U002" decimals="-6" scale="6" format="ixt:num-dot-decimal">18</ix:nonFraction> million additional shares of the
                  Company&#8217;s common stock being reserved for future awards. The 2022 Equity Plan provides for the Company&#8217;s Board of Directors (the &#8220;Board&#8221;) or a Committee of the Board (the &#8220;Committee&#8221;) to grant awards to grantees and to determine the
                  exercise price, vesting term, expiration date and all other terms and conditions of the awards, including acceleration of the vesting of an award at any time. Any options granted under the 2022 Equity Plan are intended to be Incentive
                  Stock Options (&#8220;ISOs&#8221;), unless specified by the Committee to be Non-Qualified Options (&#8220;NQOs&#8221;) as defined by the Internal Revenue Code. ISOs and NQOs may be granted to employees, consultants or Board members at an option price not less
                  than the fair market value of the common stock subject to the stock option agreement. Shares issued in connection with the exercise of stock options or the vesting of RSUs are newly issued shares.</span> </p></ix:continuation>
              <div style="text-indent: 36pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">
                <ix:continuation id="Text_dc9d2d26f01543f296ae7c67bdf0853e35" continuedAt="Text_dc9d2d26f01543f296ae7c67bdf0853e36">
<div style="display:none;"><br/></div>
<div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"> <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
                  </span> </div>
</ix:continuation>
                <ix:continuation id="Text_dc9d2d26f01543f296ae7c67bdf0853e36" continuedAt="Text_dc9d2d26f01543f296ae7c67bdf0853e37">
<div style="display:none;"><br/></div>
<div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">For the years ended December 31,
                  2024, 2023 and 2022, the Company granted options to purchase an aggregate of <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" id="Fact_13e7ef50d673430980e97cdf9b0d3617" contextRef="c20240101to20241231_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">1,531,635</ix:nonFraction>, <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" id="Fact_1d96e2c908ab4e6fb148c9e3acd23685" contextRef="c20230101to20231231_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">1,826,380</ix:nonFraction> and <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" id="Fact_c5806177a2d44d26be31cd683eb4d987" contextRef="c20220101to20221231_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">1,194,032</ix:nonFraction>
                  shares, respectively, of common stock to employees and directors under the 2022 Equity Plan and 2014 Plan. During the year ended December 31, 2024, options to purchase <ix:nonFraction name="adma:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedNumber" id="Fact_7f7f3b574cca4d5aa08927f0c2eab215" contextRef="c20240101to20241231_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">2,020,142</ix:nonFraction> shares of common stock were exercised, for which <ix:nonFraction name="adma:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSharesWithheldToCoverAggregateExercisePrices" id="Fact_6b6eab4d715748be81c2bc7597a7ea47" contextRef="c20241231_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_EquityIncentivePlanMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">32,076</ix:nonFraction>
                  shares were withheld to cover the aggregate exercise prices and payroll taxes, and the Company received aggregate net exercise proceeds of $<ix:nonFraction name="us-gaap:ProceedsFromStockOptionsExercised" id="Fact_897d3cedc58446ff8b89595961156362" contextRef="c20240101to20241231_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_EquityIncentivePlanMember" unitRef="U001" decimals="-5" scale="6" format="ixt:num-dot-decimal">7.5</ix:nonFraction>
                  million. During the year ended December 31, 2023, options to purchase <ix:nonFraction name="adma:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedNumber" id="Fact_a9f08eba66274efcb9027fef86718520" contextRef="c20230101to20231231_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">3,814,122</ix:nonFraction> shares of common stock were exercised, for
                  which <ix:nonFraction name="adma:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSharesWithheldToCoverAggregateExercisePrices" id="Fact_ea5bbe6a28f641f2a15aa2a4892f7521" contextRef="c20231231_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_EquityIncentivePlanMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">2,109,722</ix:nonFraction> shares were withheld to cover the aggregate exercise prices and <ix:nonFraction name="adma:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSharesWithheldForPayrollTaxes" id="Fact_34b278ebf2b14a50927246cd97c2b4fa" contextRef="c20231231_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">259,867</ix:nonFraction> shares were withheld to cover payroll taxes, and the Company received aggregate net exercise proceeds of $<ix:nonFraction name="us-gaap:ProceedsFromStockOptionsExercised" id="Fact_c132b181bb4143749726b5419fb60bbf" contextRef="c20230101to20231231_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_EquityIncentivePlanMember" unitRef="U001" decimals="-5" scale="6" format="ixt:num-dot-decimal">1.1</ix:nonFraction> million.</div>
</ix:continuation>
              </div>

              <ix:continuation id="Text_dc9d2d26f01543f296ae7c67bdf0853e37" continuedAt="Text_dc9d2d26f01543f296ae7c67bdf0853e38">
<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
                </span> </div>
</ix:continuation>
              <ix:continuation id="Text_dc9d2d26f01543f296ae7c67bdf0853e38" continuedAt="Text_dc9d2d26f01543f296ae7c67bdf0853e39">
<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">The fair value of
                stock options granted was determined on the date of grant using the Black-Scholes model. The Black-Scholes option pricing model was developed for use in estimating the fair value of publicly traded options, which have no vesting
                restrictions and are fully transferable. The Company&#8217;s employee stock options have characteristics significantly different from those of traded options, and changes in the underlying Black-Scholes assumptions can materially affect the fair
                value estimate. To determine the risk-free interest rate, the Company utilized the U.S. Treasury yield curve in effect at the time of the grant with a term consistent with the term of the awards granted by the Company. The expected term of
                all options granted is in accordance with Staff Accounting Bulletins 107 and 110, which is based on the average between vesting terms and contractual terms as the Company had a limited history of option exercises prior to the middle of
                fiscal 2023. The expected dividend yield reflects the Company&#8217;s current and expected future policy for dividends on the Company&#8217;s common stock. For the years ended December 31, 2024, 2023 and 2022, the expected stock price volatility for
                the Company&#8217;s stock options was calculated by examining the historical volatility of the Company&#8217;s common stock since the stock became publicly traded in the fourth quarter of 2013. </div>
</ix:continuation>
              <ix:continuation id="Text_dc9d2d26f01543f296ae7c67bdf0853e39" continuedAt="Text_dc9d2d26f01543f296ae7c67bdf0853e40">
<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
                </span> </div>
</ix:continuation>
              <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
                <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">F-24</span></div>

                <div style="page-break-after: always;" class="BRPFPageBreak">
                  <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"/></div>

                <div style="width: 100%;" class="BRPFPageHeader">
                  <div>
                    <div style="text-align: left; font-weight: bold; text-indent: -9pt; margin-left: 9pt;"><a href="#ADMABIOLOGICSINC."> <span style="font-style: italic; font-weight: normal; font-size: 8pt;">Table of Contents</span></a><br/>
                    </div>

                    <div style="text-align: left; font-weight: bold; text-indent: -9pt; margin-left: 9pt;"><a href="#ADMABIOLOGICSINC."><span style="font-style: italic; font-weight: normal; font-size: 8pt;"> <br/>
                        </span></a></div>

                    <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">ADMA BIOLOGICS, INC. AND SUBSIDIARIES</div>

                    <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</div>

                  </div>

                </div>

              </div>

            </div>

          </div>


          <ix:continuation id="Text_dc9d2d26f01543f296ae7c67bdf0853e40" continuedAt="Text_dc9d2d26f01543f296ae7c67bdf0853e41"><ix:nonNumeric name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="Text_6a64f989a1b84e6582cf1f436059143b" contextRef="c20240101to20241231" escape="true" continuedAt="Text_21ff98d529134ec4a92f5adeb72aa64f1">
<div style="display:none;"><br/></div>
<div style="text-indent: 36pt;"><span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">The grant date fair values of stock options
              awarded during the years ended December 31, 2024, 2023 and 2022 were determined using the Black-Scholes option pricing model with the following assumptions:</span> <span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> </div>
</ix:nonNumeric></ix:continuation>
        </div>

      </div>

      <div style="line-height: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-align: left;">
        <ix:continuation id="Text_dc9d2d26f01543f296ae7c67bdf0853e41" continuedAt="Text_dc9d2d26f01543f296ae7c67bdf0853e42"><ix:continuation id="Text_21ff98d529134ec4a92f5adeb72aa64f1" continuedAt="Text_21ff98d529134ec4a92f5adeb72aa64f2"><p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px;"><span style="font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><span style="font-weight: normal;">&#160; </span><br/>
          </span> </p></ix:continuation></ix:continuation>
        <ix:continuation id="Text_dc9d2d26f01543f296ae7c67bdf0853e42" continuedAt="Text_dc9d2d26f01543f296ae7c67bdf0853e43"><ix:continuation id="Text_21ff98d529134ec4a92f5adeb72aa64f2">
<table cellspacing="0" cellpadding="0" border="0" class="cfttable" style="text-align: left; font: 10pt 'Times New Roman'; margin-right: auto; width: 100%; border-spacing: 0;">


  <tr style="height: 15px;">

    <td valign="bottom" style="padding-bottom: 2px;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td valign="bottom" colspan="10" rowspan="1" style="vertical-align: bottom; text-align: center; border-bottom: #000000 solid 2px;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; text-align: center; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"><strong>Years Ended
                  </strong></p>
              </td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="padding-bottom: 2px;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td valign="bottom" colspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-bottom: 0px; text-align: center; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"><strong>December 31,</strong></p>
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-bottom: 0px; text-align: center; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"><strong>2024 </strong></p>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: center; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-bottom: 0px; text-align: center; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"><strong>December 31,</strong></p>
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-bottom: 0px; text-align: center; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"><strong>2023 </strong></p>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" style="text-align: left; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;">
                <div style="text-align: center;"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><strong>December 31,</strong> <br/>
                  </span> </div>
                <div style="text-align: center;"><span style="font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">202<strong>2</strong></span><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><strong><br/>
                    </strong></span></div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">Expected term</p>
              </td>

    <td valign="bottom" colspan="1" style="text-align: center; vertical-align: bottom; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; text-align: center; background-color: rgb(204, 238, 255);">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; text-align: right; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Fact_e790aaca6e244c03bba149a77cd0c528" contextRef="c20240101to20241231_AwardTypeAxis_EmployeeStockOptionMember_RangeAxis_MinimumMember" format="ixt-sec:duryear">5.5</ix:nonNumeric>-<ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Fact_3b7b248c1dc0433a984a7c770f5e317e" contextRef="c20240101to20241231_AwardTypeAxis_EmployeeStockOptionMember_RangeAxis_MaximumMember" format="ixt-sec:duryear">6.3</ix:nonNumeric> years</p>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: center; vertical-align: bottom; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; text-align: center; background-color: rgb(204, 238, 255);">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; text-align: right; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Fact_21cfc9cbc2bd45188e0fab59cd65dd5a" contextRef="c20230101to20231231_AwardTypeAxis_EmployeeStockOptionMember_RangeAxis_MinimumMember" format="ixt-sec:duryear">5.5</ix:nonNumeric>-<ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Fact_0a24ce0016904ea6873f31f930bcd524" contextRef="c20230101to20231231_AwardTypeAxis_EmployeeStockOptionMember_RangeAxis_MaximumMember" format="ixt-sec:duryear">6.3</ix:nonNumeric> years</p>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; text-align: right; background-color: rgb(204, 238, 255); white-space: nowrap;">
                <div style="text-align: right; font-family: 'Times New Roman'; font-size: 10pt; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Fact_30a391a8163541ce9d641d367cce5e71" contextRef="c20220101to20221231_AwardTypeAxis_EmployeeStockOptionMember_RangeAxis_MinimumMember" format="ixt-sec:duryear">5.5</ix:nonNumeric>-<ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Fact_d5c97fa495ff48c3a75a0a0922dd2650" contextRef="c20220101to20221231_AwardTypeAxis_EmployeeStockOptionMember_RangeAxis_MaximumMember" format="ixt-sec:duryear">6.3</ix:nonNumeric> years</div>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="vertical-align: bottom; width: 64%;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">Volatility</p>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" id="Fact_5485e1151c1b46509ff4cccf47313f58" contextRef="c20240101to20241231_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U007" decimals="2" scale="-2" format="ixt:num-dot-decimal">66</ix:nonFraction></p>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">%</p>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" id="Fact_07e759826ffb4b778e34187c34d82951" contextRef="c20230101to20231231_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U007" decimals="2" scale="-2" format="ixt:num-dot-decimal">68</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;">%</td>

    <td valign="bottom" colspan="1" style="text-align: right; font-weight: normal; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-weight: normal; text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-weight: normal; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" id="Fact_3f7431b5ba6644bda14b9c3c283f8435" contextRef="c20220101to20221231_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U007" decimals="2" scale="-2" format="ixt:num-dot-decimal">68</ix:nonFraction><br/>
                </span> </td>

    <td valign="bottom" colspan="1" style="font-weight: normal; text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;"><strong style="font-weight: normal;">%</strong></td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="vertical-align: top; width: 64%; background-color: rgb(204, 238, 255);">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">Dividend yield</p>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" id="Fact_f5c88f0e77434a09a2f9fff1b14d71ee" contextRef="c20240101to20241231_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U007" decimals="1" scale="0" format="ixt:num-dot-decimal">0.0</ix:nonFraction><br/>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" id="Fact_e41568a8f26c4215979c2d6a0949e7ae" contextRef="c20230101to20231231_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U007" decimals="1" scale="0" format="ixt:num-dot-decimal">0.0</ix:nonFraction><br/>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" id="Fact_78d870e3b46d401aa2a1501b02f14075" contextRef="c20220101to20221231_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U007" decimals="1" scale="0" format="ixt:num-dot-decimal">0.0</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="vertical-align: top; width: 64%;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">Risk-free interest rate</p>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" id="Fact_ba0ddcfea276406aa68ae0f0872f4336" contextRef="c20240101to20241231_AwardTypeAxis_EmployeeStockOptionMember_RangeAxis_MinimumMember" unitRef="U007" decimals="4" scale="-2" format="ixt:num-dot-decimal">4.16</ix:nonFraction>-<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" id="Fact_859d40684d5c4cd8a80becf3cbe125e4" contextRef="c20240101to20241231_AwardTypeAxis_EmployeeStockOptionMember_RangeAxis_MaximumMember" unitRef="U007" decimals="4" scale="-2" format="ixt:num-dot-decimal">4.39</ix:nonFraction></p>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">%</p>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" id="Fact_4a2526a1c1104da9817a823d84d20e85" contextRef="c20230101to20231231_AwardTypeAxis_EmployeeStockOptionMember_RangeAxis_MinimumMember" unitRef="U007" decimals="4" scale="-2" format="ixt:num-dot-decimal">4.20</ix:nonFraction>-<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" id="Fact_0a0e4933aee143f29371b24799f083e5" contextRef="c20230101to20231231_AwardTypeAxis_EmployeeStockOptionMember_RangeAxis_MaximumMember" unitRef="U007" decimals="4" scale="-2" format="ixt:num-dot-decimal">4.62</ix:nonFraction></p>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">%</p>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" id="Fact_8815224f797a4fd89f4f7248ce02b298" contextRef="c20220101to20221231_AwardTypeAxis_EmployeeStockOptionMember_RangeAxis_MinimumMember" unitRef="U007" decimals="4" scale="-2" format="ixt:num-dot-decimal">1.72</ix:nonFraction>-<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" id="Fact_810c825b81794177a81dee0572aad2bf" contextRef="c20220101to20221231_AwardTypeAxis_EmployeeStockOptionMember_RangeAxis_MaximumMember" unitRef="U007" decimals="4" scale="-2" format="ixt:num-dot-decimal">1.73</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;">%</td>

  </tr>


</table>
</ix:continuation></ix:continuation>
         </div>

      <ix:continuation id="Text_dc9d2d26f01543f296ae7c67bdf0853e43" continuedAt="Text_dc9d2d26f01543f296ae7c67bdf0853e44">
<div style="display:none;"><br/></div>
<div style="text-indent: 9pt;"> <span style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"><br/>
        </span></div>
</ix:continuation>
      <div style="line-height: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-align: left;"><ix:continuation id="Text_dc9d2d26f01543f296ae7c67bdf0853e44" continuedAt="Text_dc9d2d26f01543f296ae7c67bdf0853e45"><ix:nonNumeric name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="Text_28fce9198907494bbd8538ebc489c8b6" contextRef="c20240101to20241231" escape="true" continuedAt="Text_29f339d0d5e34d9e8efa205cc9c950991">
<div><span style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"> </span> </div>
</ix:nonNumeric></ix:continuation>
        <ix:continuation id="Text_dc9d2d26f01543f296ae7c67bdf0853e45" continuedAt="Text_dc9d2d26f01543f296ae7c67bdf0853e46"><ix:continuation id="Text_29f339d0d5e34d9e8efa205cc9c950991" continuedAt="Text_29f339d0d5e34d9e8efa205cc9c950992"><p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-bottom: 0px; text-align: left; text-indent: 36pt; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"><span style="font-size: 10pt;">The following table summarizes information about stock options outstanding as of December 31, <strong><span style="font-weight: normal;">2024,</span> </strong>2023 and 2022:</span> </p></ix:continuation></ix:continuation>
        <ix:continuation id="Text_dc9d2d26f01543f296ae7c67bdf0853e46" continuedAt="Text_dc9d2d26f01543f296ae7c67bdf0853e47"><ix:continuation id="Text_29f339d0d5e34d9e8efa205cc9c950992" continuedAt="Text_29f339d0d5e34d9e8efa205cc9c950993"><p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px;"><span style="font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;&#160;&#160; <br/>
          </span> </p></ix:continuation></ix:continuation>
        <ix:continuation id="Text_dc9d2d26f01543f296ae7c67bdf0853e47" continuedAt="Text_dc9d2d26f01543f296ae7c67bdf0853e48"><ix:continuation id="Text_29f339d0d5e34d9e8efa205cc9c950993">
<table cellspacing="0" cellpadding="0" border="0" class="cfttable" style="text-align: left; font: 10pt 'Times New Roman'; width: 100%; border-spacing: 0;">


  <tr style="height: 15px;">

    <td valign="bottom" style="padding-bottom: 2px;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td valign="bottom" colspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: #000000 solid 2px;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; text-align: center; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"><strong>Shares</strong></p>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: #000000 solid 2px;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; text-align: center; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"><strong>Weighted</strong></p>
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; text-align: center; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"><strong>Average</strong></p>
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; text-align: center; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"><strong>Exercise
                    Price</strong></p>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="vertical-align: top; width: 76%; background-color: #CCEEFF;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">Options outstanding, vested and
                  expected to vest at December 31, 2021</p>
              </td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" id="Fact_5ab09d8ab6cc49efa99e41f6f2aa6530" contextRef="c20211231_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">7,862,722</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">$</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" id="Fact_246a386c69da42c9a4d24de2285506d2" contextRef="c20211231_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">3.93</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="vertical-align: top; width: 76%;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">Forfeited</p>
              </td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">(<ix:nonFraction name="adma:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedNumber" id="Fact_f3ffd95473af4e91aa610dca3ecdfe8c" contextRef="c20220101to20221231_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">31,540</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;">)</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">$</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><ix:nonFraction name="adma:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedWeightedAverageExercisePrice" id="Fact_4f98ec69f2504af1a3e14f8b65ac83d9" contextRef="c20220101to20221231_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">2.37</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="vertical-align: top; width: 76%; background-color: #CCEEFF;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">Expired</p>
              </td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">(<ix:nonFraction name="adma:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredNumber" id="Fact_c50dbb2ba088431fa3de40d873385f09" contextRef="c20220101to20221231_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">700,324</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;">)</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">$</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><ix:nonFraction name="adma:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredWeightedAverageExercisePrice" id="Fact_616eb9f014e7404e9f8a0ae6c4bb3773" contextRef="c20220101to20221231_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">6.86</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="vertical-align: top; width: 76%;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">Granted</p>
              </td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><ix:nonFraction name="adma:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedNumber" id="Fact_af9c9831bfd449dcbd424882344d8dd2" contextRef="c20220101to20221231_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">1,194,032</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">$</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><ix:nonFraction name="adma:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedWeightedAverageExercisePrice" id="Fact_65bda1a44ab0452ba9d5c1b5835dfefb" contextRef="c20220101to20221231_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">1.67</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="vertical-align: top; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">Exercised</p>
              </td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">(<ix:nonFraction name="adma:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedNumber" id="Fact_45bf2eeb1b5241d5a538f3f377a87aa1" contextRef="c20220101to20221231_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">68,679</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;">)</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">$</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><ix:nonFraction name="adma:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedWeightedAverageExercisePrice" id="Fact_302459abfe324e32a33769a0046a5366" contextRef="c20220101to20221231_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">2.55</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="vertical-align: top; width: 76%;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">Options outstanding, vested and
                  expected to vest at December 31, 2022</p>
              </td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" id="Fact_147791beeb874021bbd4cdea0dae260b" contextRef="c20221231_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">8,256,211</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">$</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" id="Fact_c03b3b4361bc4032a25396e0b48ca6d7" contextRef="c20221231_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">3.37</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="vertical-align: top; width: 76%; background-color: #CCEEFF;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">Forfeited</p>
              </td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">(<ix:nonFraction name="adma:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedNumber" id="Fact_f7421a33aa934816880badd539c9b4b1" contextRef="c20230101to20231231_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">99,345</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;">)</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">$</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><ix:nonFraction name="adma:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedWeightedAverageExercisePrice" id="Fact_63149b7d709e49e0bd3ae66870f9686a" contextRef="c20230101to20231231_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">2.73</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="vertical-align: top; width: 76%;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">Expired</p>
              </td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">(<ix:nonFraction name="adma:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredNumber" id="Fact_4ef0ce8359ea4e528ea4862a645b6d4f" contextRef="c20230101to20231231_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">262,940</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;">)</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">$</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><ix:nonFraction name="adma:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredWeightedAverageExercisePrice" id="Fact_722e06668aee48758d1efd0be9b8872d" contextRef="c20230101to20231231_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">6.42</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="vertical-align: top; width: 76%; background-color: #CCEEFF;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">Granted</p>
              </td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><ix:nonFraction name="adma:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedNumber" id="Fact_5140e2c2a2ca4e66b5dc366debe07ea7" contextRef="c20230101to20231231_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">1,826,380</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">$</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><ix:nonFraction name="adma:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedWeightedAverageExercisePrice" id="Fact_2677dd96e80c428987c25446b44c8746" contextRef="c20230101to20231231_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">3.36</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="vertical-align: top; width: 76%; padding-bottom: 2px;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">Exercised</p>
              </td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">(<ix:nonFraction name="adma:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedNumber" id="Fact_517532f962ac45049fefd613a6037703" contextRef="c20230101to20231231_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">3,814,122</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;">)</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">$</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><ix:nonFraction name="adma:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedWeightedAverageExercisePrice" id="Fact_839b14bb59b9426a9be8617989cf5a25" contextRef="c20230101to20231231_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">3.15</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="vertical-align: top; width: 76%; background-color: #CCEEFF;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">Options outstanding, vested and
                  expected to vest at December 31, 2023</p>
              </td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" id="Fact_fbcf3be7b9a3475baac296d761b18cb9" contextRef="c20231231_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">5,906,184</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">$</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" id="Fact_87c5713fd74e4d7ead8ac7e5e021626e" contextRef="c20231231_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">3.38</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" rowspan="1" style="vertical-align: top; width: 76%;"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Forfeited<br/>
                </span> </td>

    <td valign="bottom" colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">(<ix:nonFraction name="adma:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedNumber" id="Fact_195ace18aedb44ee967d3a38759eb975" contextRef="c20240101to20241231_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">30,094</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;">)</td>

    <td valign="bottom" colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">$</td>

    <td valign="bottom" colspan="1" rowspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><ix:nonFraction name="adma:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedWeightedAverageExercisePrice" id="Fact_dcca7468c90b4bb39d3e9a0cbd0dd9e5" contextRef="c20240101to20241231_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">3.36</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" rowspan="1" style="vertical-align: top; width: 76%; background-color: #CCEEFF;"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Expired<br/>
                </span> </td>

    <td valign="bottom" colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">(<ix:nonFraction name="adma:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredNumber" id="Fact_ca8ea30eb65a4150a07879063a0ed0bf" contextRef="c20240101to20241231_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">246,067</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;">)</td>

    <td valign="bottom" colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">$</td>

    <td valign="bottom" colspan="1" rowspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><ix:nonFraction name="adma:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredWeightedAverageExercisePrice" id="Fact_a7972ee999f64c66acb7f5c9506cda31" contextRef="c20240101to20241231_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">7.01</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" rowspan="1" style="vertical-align: top; width: 76%;"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Granted<br/>
                </span> </td>

    <td valign="bottom" colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><ix:nonFraction name="adma:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedNumber" id="Fact_bc806c0acb674ba78191c22331944cb9" contextRef="c20240101to20241231_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">1,531,635</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">$</td>

    <td valign="bottom" colspan="1" rowspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><ix:nonFraction name="adma:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedWeightedAverageExercisePrice" id="Fact_417d489cb8a94cabbe85a83c0674c0b6" contextRef="c20240101to20241231_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">6.40</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" rowspan="1" style="vertical-align: top; width: 76%; background-color: rgb(204, 238, 255); padding-bottom: 2px;"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Exercised<br/>
                </span> </td>

    <td valign="bottom" colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; border-bottom: 2px solid rgb(0, 0, 0);">(<ix:nonFraction name="adma:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedNumber" id="Fact_178daded10794075a1a4aee0518a0c89" contextRef="c20240101to20241231_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">2,020,142</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; padding-bottom: 2px; white-space: nowrap;">)</td>

    <td valign="bottom" colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; padding-bottom: 2px;">$</td>

    <td valign="bottom" colspan="1" rowspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; padding-bottom: 2px;"><ix:nonFraction name="adma:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedWeightedAverageExercisePrice" id="Fact_ca4c1956c732439f9991d2a13f778bd9" contextRef="c20240101to20241231_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">3.90</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" rowspan="1" style="vertical-align: top; width: 76%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; padding-bottom: 4px;">Options
                outstanding, vested and expected to vest at December 31, 2024</td>

    <td valign="bottom" colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; padding-bottom: 4px;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; border-bottom: 4px double rgb(0, 0, 0);">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; border-bottom: 4px double rgb(0, 0, 0);"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" id="Fact_fcc5fd86f25a42b5885f1d2fd84f57d7" contextRef="c20241231_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">5,141,516</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; padding-bottom: 4px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; padding-bottom: 4px;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; padding-bottom: 4px;">$</td>

    <td valign="bottom" colspan="1" rowspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; padding-bottom: 4px;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" id="Fact_3b758798be9b458cb1e526f7befc264c" contextRef="c20241231_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">3.90</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; padding-bottom: 4px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="width: 76%; background-color: #CCEEFF;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="vertical-align: top; width: 76%; padding-bottom: 4px;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">Options exercisable</p>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; padding-bottom: 4px;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; border-bottom: 4px double rgb(0, 0, 0);">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; border-bottom: 4px double rgb(0, 0, 0);"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" id="Fact_e499de90070c466d92755049b55a67bf" contextRef="c20241231_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">2,657,932</ix:nonFraction><br/>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; padding-bottom: 4px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; padding-bottom: 4px;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; border-bottom: 4px double rgb(0, 0, 0);">$</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; border-bottom: 4px double rgb(0, 0, 0);"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" id="Fact_5edb42454e7a483bb2ea814e0e3fe5c5" contextRef="c20241231_AwardTypeAxis_EmployeeStockOptionMember" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">3.03</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; padding-bottom: 4px; white-space: nowrap;">&#160;</td>

  </tr>


</table>
</ix:continuation></ix:continuation>

        <ix:continuation id="Text_dc9d2d26f01543f296ae7c67bdf0853e48" continuedAt="Text_dc9d2d26f01543f296ae7c67bdf0853e49">
<div><span style="font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
          </span> </div>
</ix:continuation>
        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">F-25</span></div>

          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"/></div>

          <div style="width: 100%;" class="BRPFPageHeader">
            <div>
              <div style="text-align: left; font-weight: bold; text-indent: -9pt; margin-left: 9pt;"><a href="#ADMABIOLOGICSINC."> <span style="font-style: italic; font-weight: normal; font-size: 8pt;">Table of Contents</span></a><br/>
              </div>

              <div style="text-align: left; font-weight: bold; text-indent: -9pt; margin-left: 9pt;"><a href="#ADMABIOLOGICSINC."><span style="font-style: italic; font-weight: normal; font-size: 8pt;"> <br/>
                  </span></a></div>

              <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">ADMA BIOLOGICS, INC. AND SUBSIDIARIES</div>

              <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</div>

            </div>

          </div>

        </div>

        <ix:continuation id="Text_dc9d2d26f01543f296ae7c67bdf0853e49" continuedAt="Text_dc9d2d26f01543f296ae7c67bdf0853e50">
<div style="display:none;"><br/></div>
<div style="text-indent: 36pt;"> <span style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">As of December 31, 2024, the Company had $<ix:nonFraction name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" id="Fact_09ef5d86de4f4729b198075c8dc5a095" contextRef="c20241231_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_EquityIncentivePlanMember" unitRef="U001" decimals="-5" scale="6" format="ixt:num-dot-decimal">6.7</ix:nonFraction> million of unrecognized compensation expense related to stock options granted under the Company&#8217;s equity incentive plans, which is expected to
            be recognized over a weighted-average period of <ix:nonNumeric name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="Fact_ea04050dd259411491d8e70fc662eb0f" contextRef="c20240101to20241231_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_EquityIncentivePlanMember" format="ixt-sec:duryear">2.8</ix:nonNumeric> years. The weighted average remaining contractual term of stock options
            outstanding and expected to vest at December 31, 2024 is <ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" id="Fact_edd59e19dfcc469ba5172b73f4cffede" contextRef="c20240101to20241231_AwardTypeAxis_EmployeeStockOptionMember" format="ixt-sec:duryear"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="Fact_89aa0f60fd084162a3cbd779b343e48e" contextRef="c20240101to20241231_AwardTypeAxis_EmployeeStockOptionMember" format="ixt-sec:duryear">7.1</ix:nonNumeric></ix:nonNumeric> years. The weighted average remaining contractual term of stock
            options exercisable at December 31, 2024 is <ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" id="Fact_630571731edb4117bd922c3ed7da9e43" contextRef="c20240101to20241231_AwardTypeAxis_EmployeeStockOptionMember" format="ixt-sec:duryear">5.7</ix:nonNumeric> years. <ix:nonNumeric name="us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" id="Text_d83011daf06d4d7a93ed0e8beedb331a" contextRef="c20240101to20241231" escape="true" continuedAt="Text_4765321d4b044a86b5a3c61ded66565f1"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal;">The following table summarizes additional information regarding
            outstanding and exercisable options under the stock option plans at December 31, 2024: </span></ix:nonNumeric></span></div>
</ix:continuation>
        <ix:continuation id="Text_dc9d2d26f01543f296ae7c67bdf0853e50" continuedAt="Text_dc9d2d26f01543f296ae7c67bdf0853e51"><ix:continuation id="Text_4765321d4b044a86b5a3c61ded66565f1" continuedAt="Text_4765321d4b044a86b5a3c61ded66565f2"><p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px;"><span style="font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160; <br/>
          </span> </p></ix:continuation></ix:continuation>
        <ix:continuation id="Text_dc9d2d26f01543f296ae7c67bdf0853e51" continuedAt="Text_dc9d2d26f01543f296ae7c67bdf0853e52"><ix:continuation id="Text_4765321d4b044a86b5a3c61ded66565f2">
<table cellspacing="0" cellpadding="0" border="0" style="text-align: left; font: 10pt 'Times New Roman'; width: 100%; border-spacing: 0;">


  <tr style="height: 15px;">

    <td style="width: 28%; padding-bottom: 2px;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td colspan="1" style="white-space: nowrap; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td style="white-space: nowrap; width: 1%; padding-bottom: 2px;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td colspan="14" style="border-bottom: 2px solid rgb(0, 0, 0); vertical-align: bottom; text-align: center;" class="hdcell">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; text-align: center; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"><strong>Stock
                    Options Outstanding</strong></p>
              </td>

    <td style="white-space: nowrap; width: 1%; padding-bottom: 2px;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td style="white-space: nowrap; width: 1%; padding-bottom: 2px;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td colspan="14" style="border-bottom: 2px solid rgb(0, 0, 0); vertical-align: bottom; text-align: center;" class="hdcell">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; text-align: center; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"><strong>Stock
                    Options Exercisable</strong></p>
              </td>

    <td style="white-space: nowrap; width: 1%; padding-bottom: 2px;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

  </tr>

  <tr style="height: 15px;">

    <td style="vertical-align: bottom; width: 28%; padding-bottom: 2px; white-space: nowrap;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; text-align: center; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">Range of</p>
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; text-align: center; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">Exercise Prices</p>
              </td>

    <td colspan="1" style="white-space: nowrap; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td style="white-space: nowrap; width: 1%; padding-bottom: 2px;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td colspan="2" style="border-bottom: 2px solid rgb(0, 0, 0); vertical-align: bottom; text-align: center;" class="hdcell">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; text-align: center; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">Options Outstanding</p>
              </td>

    <td style="padding-bottom: 2px; white-space: nowrap; width: 1%;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td style="white-space: nowrap; width: 1%; padding-bottom: 2px;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td colspan="2" style="border-bottom: 2px solid rgb(0, 0, 0); vertical-align: bottom; text-align: center;" class="hdcell">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; text-align: center; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">Weighted</p>
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; text-align: center; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">Average</p>
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; text-align: center; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">Remaining</p>
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; text-align: center; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">Contractual</p>
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; text-align: center; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">Life (Years)</p>
              </td>

    <td style="padding-bottom: 2px; white-space: nowrap; width: 1%;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td style="white-space: nowrap; width: 1%; padding-bottom: 2px;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td colspan="2" style="border-bottom: 2px solid rgb(0, 0, 0); vertical-align: bottom; text-align: center;" class="hdcell">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; text-align: center; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">Weighted Average
                  Exercise Price</p>
              </td>

    <td style="padding-bottom: 2px; white-space: nowrap; width: 1%;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td style="white-space: nowrap; width: 1%; padding-bottom: 2px;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td colspan="2" style="border-bottom: 2px solid rgb(0, 0, 0); vertical-align: bottom; text-align: center;" class="hdcell">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; text-align: center; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">Aggregate Intrinsic
                  Value</p>
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; text-align: center;"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> ($000&#8217;s)<br/>
                  </span> </p>
              </td>

    <td style="padding-bottom: 2px; white-space: nowrap; width: 1%;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td style="white-space: nowrap; width: 1%; padding-bottom: 2px;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td colspan="2" style="border-bottom: 2px solid rgb(0, 0, 0); vertical-align: bottom; text-align: center;" class="hdcell">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; text-align: center; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">Options Outstanding</p>
              </td>

    <td style="padding-bottom: 2px; white-space: nowrap; width: 1%;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td style="white-space: nowrap; width: 1%; padding-bottom: 2px;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td colspan="2" style="border-bottom: 2px solid rgb(0, 0, 0); vertical-align: bottom; text-align: center;" class="hdcell">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; text-align: center; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">Weighted</p>
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; text-align: center; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">Average</p>
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; text-align: center; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">Remaining</p>
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; text-align: center; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">Contractual</p>
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; text-align: center; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">Life (Years)</p>
              </td>

    <td style="padding-bottom: 2px; white-space: nowrap; width: 1%;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td style="white-space: nowrap; width: 1%; padding-bottom: 2px;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td colspan="2" style="border-bottom: 2px solid rgb(0, 0, 0); vertical-align: bottom; text-align: center; white-space: nowrap;" class="hdcell">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; text-align: center; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">Weighted</p>
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; text-align: center; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"> Average</p>
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; text-align: center; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"> Exercise</p>
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; text-align: center; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"> Price</p>
              </td>

    <td style="padding-bottom: 2px; white-space: nowrap; width: 1%;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td style="white-space: nowrap; width: 1%; padding-bottom: 2px;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td colspan="2" style="border-bottom: 2px solid rgb(0, 0, 0); vertical-align: bottom; text-align: center; white-space: nowrap;" class="hdcell">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; text-align: center; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">Aggregate</p>
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; text-align: center; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"> Intrinsic</p>
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; text-align: center; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"> Value</p>
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; text-align: center; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"> ($000&#8217;s)</p>
              </td>

    <td style="padding-bottom: 2px; white-space: nowrap; width: 1%;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

  </tr>

  <tr style="height: 15px;">

    <td style="vertical-align: top; width: 28%; background-color: rgb(204, 238, 255);">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">$<ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" id="Fact_ec79f11027f640b7badda3e33c25f9b9" contextRef="c20240101to20241231_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ExercisePriceRange1Member" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">1.10</ix:nonFraction> - $<ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" id="Fact_a388507371f54bd687c8741c7b2ed968" contextRef="c20240101to20241231_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ExercisePriceRange1Member" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">1.67</ix:nonFraction></p>
              </td>

    <td colspan="1" style="width: 1%; white-space: nowrap; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td style="width: 1%; white-space: nowrap; background-color: rgb(204, 238, 255);">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td style="width: 1%; white-space: nowrap; background-color: rgb(204, 238, 255);">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td style="width: 6%; vertical-align: bottom; text-align: right; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" class="ffcell"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" id="Fact_fe59777583ed4b30ae110b2eaf28a76c" contextRef="c20241231_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ExercisePriceRange1Member" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">981,093</ix:nonFraction></td>

    <td style="width: 1%; white-space: nowrap; background-color: rgb(204, 238, 255);">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td style="width: 1%; white-space: nowrap; background-color: rgb(204, 238, 255);">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td style="width: 1%; white-space: nowrap; background-color: rgb(204, 238, 255);">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td style="width: 6%; vertical-align: bottom; text-align: right; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" class="ffcell"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="Fact_e65a34f9d06c4c6aaf42c8c8446e3214" contextRef="c20240101to20241231_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ExercisePriceRange1Member" format="ixt-sec:duryear">6.8</ix:nonNumeric></td>

    <td style="width: 1%; white-space: nowrap; background-color: rgb(204, 238, 255);">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td style="width: 1%; white-space: nowrap; background-color: rgb(204, 238, 255);">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td style="width: 1%; vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">$</td>

    <td style="width: 6%; vertical-align: bottom; text-align: right; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" class="ffcell"><ix:nonFraction name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" id="Fact_310a2eb567284558ad7acfcdd37ad17f" contextRef="c20241231_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ExercisePriceRange1Member" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">1.60</ix:nonFraction></td>

    <td style="width: 1%; white-space: nowrap; background-color: rgb(204, 238, 255);">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td style="width: 1%; white-space: nowrap; background-color: rgb(204, 238, 255);">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td style="width: 1%; vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">$</td>

    <td style="width: 6%; vertical-align: bottom; text-align: right; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" class="ffcell"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" id="Fact_d05ede6ff4d846d8bfa3f2886b34eaa9" contextRef="c20241231_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ExercisePriceRange1Member" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">15,252</ix:nonFraction></td>

    <td style="width: 1%; white-space: nowrap; background-color: rgb(204, 238, 255);">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td style="width: 1%; white-space: nowrap; background-color: rgb(204, 238, 255);">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td style="width: 1%; white-space: nowrap; background-color: rgb(204, 238, 255);">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td style="width: 6%; vertical-align: bottom; text-align: right; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" class="ffcell"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" id="Fact_56d3f5ac190d4868a97869c7c6df83bb" contextRef="c20241231_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ExercisePriceRange1Member" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">676,542</ix:nonFraction></td>

    <td style="width: 1%; white-space: nowrap; background-color: rgb(204, 238, 255);">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td style="width: 1%; white-space: nowrap; background-color: rgb(204, 238, 255);">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td style="width: 1%; white-space: nowrap; background-color: rgb(204, 238, 255);">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td style="width: 6%; vertical-align: bottom; text-align: right; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" class="ffcell"><ix:nonNumeric name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" id="Fact_91f8c19c97bc4f828fe9fc9ccd732a80" contextRef="c20240101to20241231_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ExercisePriceRange1Member" format="ixt-sec:duryear">6.6</ix:nonNumeric></td>

    <td style="width: 1%; white-space: nowrap; background-color: rgb(204, 238, 255);">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td style="width: 1%; white-space: nowrap; background-color: rgb(204, 238, 255);">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td style="width: 1%; vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">$</td>

    <td style="width: 6%; vertical-align: bottom; text-align: right; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" class="ffcell"><ix:nonFraction name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" id="Fact_13f80784f6444743b16188f3bc6488ec" contextRef="c20241231_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ExercisePriceRange1Member" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">1.58</ix:nonFraction></td>

    <td style="width: 1%; white-space: nowrap; background-color: rgb(204, 238, 255);">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td style="width: 1%; white-space: nowrap; background-color: rgb(204, 238, 255);">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td style="width: 1%; vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">$</td>

    <td style="width: 6%; vertical-align: bottom; text-align: right; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" class="ffcell"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" id="Fact_9d9a04b1979649d28e594e6cc58a2f4e" contextRef="c20241231_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ExercisePriceRange1Member" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">10,532</ix:nonFraction></td>

    <td style="width: 1%; white-space: nowrap; background-color: rgb(204, 238, 255);">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

  </tr>

  <tr style="height: 15px;">

    <td style="vertical-align: top; width: 28%;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">$<ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" id="Fact_b485bf61556346d0bada59859a86511b" contextRef="c20240101to20241231_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ExercisePriceRange2Member" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">1.73</ix:nonFraction> - $<ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" id="Fact_4d1a5cbed0e34e37b6ce01171b5b17c1" contextRef="c20240101to20241231_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ExercisePriceRange2Member" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">2.60</ix:nonFraction></p>
              </td>

    <td colspan="1" style="white-space: nowrap; width: 1%; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td style="white-space: nowrap; width: 1%;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td style="white-space: nowrap; width: 1%;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td style="vertical-align: bottom; text-align: right; width: 6%; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" class="ffcell"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" id="Fact_a33282afcc9546b798240f933235407b" contextRef="c20241231_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ExercisePriceRange2Member" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">629,655</ix:nonFraction></td>

    <td style="white-space: nowrap; width: 1%;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td style="white-space: nowrap; width: 1%;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td style="white-space: nowrap; width: 1%;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td style="vertical-align: bottom; text-align: right; width: 6%; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" class="ffcell"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="Fact_4ca8e063ad0b4fc09f9ebed79c6a98ee" contextRef="c20240101to20241231_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ExercisePriceRange2Member" format="ixt-sec:duryear">5.7</ix:nonNumeric></td>

    <td style="white-space: nowrap; width: 1%;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td style="white-space: nowrap; width: 1%;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td style="vertical-align: bottom; white-space: nowrap; width: 1%; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">$</td>

    <td style="vertical-align: bottom; text-align: right; width: 6%; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" class="ffcell"><ix:nonFraction name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" id="Fact_5cd1535c0f3a415e94297af1e1163d7b" contextRef="c20241231_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ExercisePriceRange2Member" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">2.32</ix:nonFraction></td>

    <td style="white-space: nowrap; width: 1%;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td style="white-space: nowrap; width: 1%;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td style="white-space: nowrap; width: 1%;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td style="vertical-align: bottom; text-align: right; width: 6%; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" class="ffcell"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" id="Fact_b74cf9f129284cbab9da29c05f5a4fb8" contextRef="c20241231_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ExercisePriceRange2Member" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">9,336</ix:nonFraction></td>

    <td style="white-space: nowrap; width: 1%;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td style="white-space: nowrap; width: 1%;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td style="white-space: nowrap; width: 1%;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td style="vertical-align: bottom; text-align: right; width: 6%; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" class="ffcell"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" id="Fact_122597664b004fa2ad92c3dff95608d6" contextRef="c20241231_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ExercisePriceRange2Member" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">585,771</ix:nonFraction></td>

    <td style="white-space: nowrap; width: 1%;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td style="white-space: nowrap; width: 1%;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td style="white-space: nowrap; width: 1%;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td style="vertical-align: bottom; text-align: right; width: 6%; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" class="ffcell"><ix:nonNumeric name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" id="Fact_7cdea4e6589f473f99a2563218cf5c3f" contextRef="c20240101to20241231_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ExercisePriceRange2Member" format="ixt-sec:duryear">5.6</ix:nonNumeric></td>

    <td style="white-space: nowrap; width: 1%;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td style="white-space: nowrap; width: 1%;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td style="vertical-align: bottom; white-space: nowrap; width: 1%; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">$</td>

    <td style="vertical-align: bottom; text-align: right; width: 6%; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" class="ffcell"><ix:nonFraction name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" id="Fact_8d49cf6fbae043b7b3f93444df81d633" contextRef="c20241231_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ExercisePriceRange2Member" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">2.33</ix:nonFraction></td>

    <td style="white-space: nowrap; width: 1%;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td style="white-space: nowrap; width: 1%;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td style="white-space: nowrap; width: 1%;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td style="vertical-align: bottom; text-align: right; width: 6%; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" class="ffcell"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" id="Fact_94b71120c88e4202aaf0e48b16b1017a" contextRef="c20241231_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ExercisePriceRange2Member" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">8,683</ix:nonFraction></td>

    <td style="white-space: nowrap; width: 1%;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

  </tr>

  <tr style="height: 15px;">

    <td style="vertical-align: top; width: 28%; background-color: rgb(204, 238, 255);">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">$<ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" id="Fact_e4732be16d68407bbe330ec78708c162" contextRef="c20240101to20241231_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ExercisePriceRange3Member" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">2.67</ix:nonFraction> - $<ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" id="Fact_adcb6a977b664928b507850ee4b402a8" contextRef="c20240101to20241231_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ExercisePriceRange3Member" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">4.01</ix:nonFraction></p>
              </td>

    <td colspan="1" style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255);">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255);">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td style="vertical-align: bottom; text-align: right; width: 6%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" class="ffcell"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" id="Fact_0f11c57203ba42489361d37b690b2baf" contextRef="c20241231_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ExercisePriceRange3Member" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">1,809,746</ix:nonFraction></td>

    <td style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255);">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255);">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255);">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td style="vertical-align: bottom; text-align: right; width: 6%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" class="ffcell"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="Fact_d30d56bddd534d9fabea41384342fdac" contextRef="c20240101to20241231_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ExercisePriceRange3Member" format="ixt-sec:duryear">6.6</ix:nonNumeric></td>

    <td style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255);">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255);">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td style="vertical-align: bottom; white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">$</td>

    <td style="vertical-align: bottom; text-align: right; width: 6%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" class="ffcell"><ix:nonFraction name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" id="Fact_0c36a27f40214b4e9c9843c2de0d9fc2" contextRef="c20241231_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ExercisePriceRange3Member" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">3.41</ix:nonFraction></td>

    <td style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255);">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255);">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255);">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td style="vertical-align: bottom; text-align: right; width: 6%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" class="ffcell"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" id="Fact_6563ef367ae44f99a6c643b58745206a" contextRef="c20241231_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ExercisePriceRange3Member" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">24,868</ix:nonFraction></td>

    <td style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255);">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255);">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255);">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td style="vertical-align: bottom; text-align: right; width: 6%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" class="ffcell"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" id="Fact_a6a731deba7b4498ab4eba353cc814a3" contextRef="c20241231_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ExercisePriceRange3Member" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">1,012,271</ix:nonFraction></td>

    <td style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255);">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255);">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255);">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td style="vertical-align: bottom; text-align: right; width: 6%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" class="ffcell"><ix:nonNumeric name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" id="Fact_aedcfa0de8844dc5b09af0b3a82ce3a8" contextRef="c20240101to20241231_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ExercisePriceRange3Member" format="ixt-sec:duryear">5.4</ix:nonNumeric></td>

    <td style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255);">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255);">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td style="vertical-align: bottom; white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">$</td>

    <td style="vertical-align: bottom; text-align: right; width: 6%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" class="ffcell"><ix:nonFraction name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" id="Fact_2f753a140a47472195dcf41b804d0f0e" contextRef="c20241231_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ExercisePriceRange3Member" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">3.46</ix:nonFraction></td>

    <td style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255);">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255);">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255);">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td style="vertical-align: bottom; text-align: right; width: 6%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" class="ffcell"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" id="Fact_1861fddadb714875b86f9878cac49dc8" contextRef="c20241231_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ExercisePriceRange3Member" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">13,863</ix:nonFraction></td>

    <td style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255);">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

  </tr>

  <tr style="height: 15px;">

    <td rowspan="1" style="vertical-align: top; width: 28%; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">$<ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" id="Fact_c42575e4d4b5453b9b3b8279b2f5b177" contextRef="c20240101to20241231_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ExercisePriceRange4Member" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">4.09</ix:nonFraction> - $<ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" id="Fact_115ac93605bb4d248d16e373b38c7f19" contextRef="c20240101to20241231_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ExercisePriceRange4Member" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">6.14</ix:nonFraction></td>

    <td rowspan="1" colspan="1" style="white-space: nowrap; width: 1%; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td rowspan="1" style="white-space: nowrap; width: 1%; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td rowspan="1" style="white-space: nowrap; width: 1%; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td rowspan="1" style="vertical-align: bottom; text-align: right; width: 6%; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" class="ffcell"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" id="Fact_2e7fdfc242204862a39d315d347008ca" contextRef="c20241231_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ExercisePriceRange4Member" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">1,264,083</ix:nonFraction></td>

    <td rowspan="1" style="white-space: nowrap; width: 1%; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td rowspan="1" style="white-space: nowrap; width: 1%; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td rowspan="1" style="white-space: nowrap; width: 1%; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td rowspan="1" style="vertical-align: bottom; text-align: right; width: 6%; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" class="ffcell"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="Fact_97a2155c14aa4fff9e675d99bc353e68" contextRef="c20240101to20241231_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ExercisePriceRange4Member" format="ixt-sec:duryear">8.1</ix:nonNumeric></td>

    <td rowspan="1" style="white-space: nowrap; width: 1%; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td rowspan="1" style="white-space: nowrap; width: 1%; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td rowspan="1" style="vertical-align: bottom; white-space: nowrap; width: 1%;"><span style="font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">$<br/>
                </span> </td>

    <td rowspan="1" style="vertical-align: bottom; text-align: right; width: 6%; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" class="ffcell"><ix:nonFraction name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" id="Fact_7653ff81b81e408ab4cb6f6ec1cb5a1a" contextRef="c20241231_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ExercisePriceRange4Member" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">5.35</ix:nonFraction></td>

    <td rowspan="1" style="white-space: nowrap; width: 1%; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td rowspan="1" style="white-space: nowrap; width: 1%; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td rowspan="1" style="white-space: nowrap; width: 1%; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td rowspan="1" style="vertical-align: bottom; text-align: right; width: 6%; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" class="ffcell"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" id="Fact_2297ecb28df340fab62c5e0c418d07d1" contextRef="c20241231_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ExercisePriceRange4Member" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">14,913</ix:nonFraction></td>

    <td rowspan="1" style="white-space: nowrap; width: 1%; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td rowspan="1" style="white-space: nowrap; width: 1%; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td rowspan="1" style="white-space: nowrap; width: 1%; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td rowspan="1" style="vertical-align: bottom; text-align: right; width: 6%; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" class="ffcell"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" id="Fact_3a429b0197224a1bb7bd93970bfd601b" contextRef="c20241231_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ExercisePriceRange4Member" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">361,848</ix:nonFraction></td>

    <td rowspan="1" style="white-space: nowrap; width: 1%; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td rowspan="1" style="white-space: nowrap; width: 1%; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td rowspan="1" style="white-space: nowrap; width: 1%; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td rowspan="1" style="vertical-align: bottom; text-align: right; width: 6%; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" class="ffcell"><ix:nonNumeric name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" id="Fact_005ff17387624f7b8d5ad087d95930b0" contextRef="c20240101to20241231_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ExercisePriceRange4Member" format="ixt-sec:duryear">5.4</ix:nonNumeric></td>

    <td rowspan="1" style="white-space: nowrap; width: 1%; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td rowspan="1" style="white-space: nowrap; width: 1%; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td rowspan="1" style="vertical-align: bottom; white-space: nowrap; width: 1%;"><span style="font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">$<br/>
                </span> </td>

    <td rowspan="1" style="vertical-align: bottom; text-align: right; width: 6%; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" class="ffcell"><ix:nonFraction name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" id="Fact_745fe88d1b3d4ad998849212b50114b1" contextRef="c20241231_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ExercisePriceRange4Member" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">5.23</ix:nonFraction></td>

    <td rowspan="1" style="white-space: nowrap; width: 1%; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td rowspan="1" style="white-space: nowrap; width: 1%; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td rowspan="1" style="white-space: nowrap; width: 1%; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td rowspan="1" style="vertical-align: bottom; text-align: right; width: 6%; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" class="ffcell"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" id="Fact_2669dcf87d8d4c20b44a1b8b0d7b8842" contextRef="c20241231_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ExercisePriceRange4Member" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,312</ix:nonFraction></td>

    <td rowspan="1" style="white-space: nowrap; width: 1%; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td rowspan="1" style="vertical-align: top; width: 28%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">$<ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" id="Fact_cd216e5d9a0e429e8598a65ded14b5a4" contextRef="c20240101to20241231_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ExercisePriceRange5Member" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">6.54</ix:nonFraction> - $<ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" id="Fact_25b15c1265884957b6d77a7e839da54f" contextRef="c20240101to20241231_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ExercisePriceRange5Member" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">9.81</ix:nonFraction></td>

    <td rowspan="1" colspan="1" style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td rowspan="1" style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td rowspan="1" style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td rowspan="1" style="vertical-align: bottom; text-align: right; width: 6%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" class="ffcell"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" id="Fact_8631d2abeb85439b981a27604189a28c" contextRef="c20241231_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ExercisePriceRange5Member" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">307,828</ix:nonFraction></td>

    <td rowspan="1" style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td rowspan="1" style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td rowspan="1" style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td rowspan="1" style="vertical-align: bottom; text-align: right; width: 6%; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; background-color: rgb(204, 238, 255);" class="ffcell"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="Fact_b026a0252d474ae2a8530af1d2edf0a3" contextRef="c20240101to20241231_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ExercisePriceRange5Member" format="ixt-sec:duryear">9.0</ix:nonNumeric></td>

    <td rowspan="1" style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td rowspan="1" style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td rowspan="1" style="vertical-align: bottom; white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255);"><span style="font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">$<br/>
                </span> </td>

    <td rowspan="1" style="vertical-align: bottom; text-align: right; width: 6%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" class="ffcell"><ix:nonFraction name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" id="Fact_dd9a7a7111e34f26ad1ccb12e513467c" contextRef="c20241231_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ExercisePriceRange5Member" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">6.60</ix:nonFraction></td>

    <td rowspan="1" style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td rowspan="1" style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td rowspan="1" style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td rowspan="1" style="vertical-align: bottom; text-align: right; width: 6%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" class="ffcell"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" id="Fact_822d53b84e9a4914bfa2aeacbf1e187a" contextRef="c20241231_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ExercisePriceRange5Member" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,248</ix:nonFraction></td>

    <td rowspan="1" style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td rowspan="1" style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td rowspan="1" style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td rowspan="1" style="vertical-align: bottom; text-align: right; width: 6%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" class="ffcell"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" id="Fact_3f2d798b6315436d8267625516a68a1c" contextRef="c20241231_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ExercisePriceRange5Member" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">7,500</ix:nonFraction></td>

    <td rowspan="1" style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td rowspan="1" style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td rowspan="1" style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td rowspan="1" style="vertical-align: bottom; text-align: right; width: 6%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" class="ffcell"><ix:nonNumeric name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" id="Fact_9567d37e365e46abbcf063d71a716e90" contextRef="c20240101to20241231_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ExercisePriceRange5Member" format="ixt-sec:duryear">0.6</ix:nonNumeric></td>

    <td rowspan="1" style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td rowspan="1" style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td rowspan="1" style="vertical-align: bottom; white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255);"><span style="font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">$<br/>
                </span> </td>

    <td rowspan="1" style="vertical-align: bottom; text-align: right; width: 6%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" class="ffcell"><ix:nonFraction name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" id="Fact_311155ba33e64b8faacf66469ab96306" contextRef="c20241231_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ExercisePriceRange5Member" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">8.98</ix:nonFraction></td>

    <td rowspan="1" style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td rowspan="1" style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td rowspan="1" style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td rowspan="1" style="vertical-align: bottom; text-align: right; width: 6%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" class="ffcell"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" id="Fact_27794cd5a6044d0d9af8db75d84c354c" contextRef="c20241231_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ExercisePriceRange5Member" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">61</ix:nonFraction></td>

    <td rowspan="1" style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td style="vertical-align: top; width: 28%; padding-bottom: 2px;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">$<ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" id="Fact_2d1b7155c22842b2b1fe675e4b1aa06d" contextRef="c20240101to20241231_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ExercisePriceRange6Member" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">10.80</ix:nonFraction> - $<ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" id="Fact_02ce9e15c4a7468faebeb3299307b861" contextRef="c20240101to20241231_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ExercisePriceRange6Member" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">17.49</ix:nonFraction></p>
              </td>

    <td colspan="1" style="white-space: nowrap; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td style="white-space: nowrap; width: 1%; padding-bottom: 2px;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td style="border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap; width: 1%;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td style="border-bottom: 2px solid rgb(0, 0, 0); vertical-align: bottom; text-align: right; width: 6%;" class="ffcell"><span style="font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" id="Fact_c18f33ffa9d145988ee78b0bae8c27b3" contextRef="c20241231_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ExercisePriceRange6Member" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">149,111</ix:nonFraction><br/>
                </span> </td>

    <td style="padding-bottom: 2px; white-space: nowrap; width: 1%;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td style="white-space: nowrap; width: 1%; padding-bottom: 2px;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td style="white-space: nowrap; width: 1%; padding-bottom: 2px;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td style="vertical-align: bottom; text-align: right; width: 6%; padding-bottom: 2px; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" class="ffcell"><span style="font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="Fact_f82c4e7ebee14b47b30a3c2dc2508fa4" contextRef="c20240101to20241231_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ExercisePriceRange6Member" format="ixt-sec:duryear">8.7</ix:nonNumeric><br/>
                </span> </td>

    <td style="white-space: nowrap; width: 1%; padding-bottom: 2px;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td style="white-space: nowrap; width: 1%; padding-bottom: 2px;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td style="vertical-align: bottom; white-space: nowrap; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">$</td>

    <td style="vertical-align: bottom; text-align: right; width: 6%; padding-bottom: 2px;" class="ffcell"><span style="font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" id="Fact_f3726c327eaf48f1aa1692dde27daf31" contextRef="c20241231_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ExercisePriceRange6Member" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">8.74</ix:nonFraction><br/>
                </span> </td>

    <td style="white-space: nowrap; width: 1%; padding-bottom: 2px;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td style="white-space: nowrap; width: 1%; padding-bottom: 2px;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td style="border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap; width: 1%;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td style="border-bottom: 2px solid rgb(0, 0, 0); vertical-align: bottom; text-align: right; width: 6%;" class="ffcell"><span style="font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" id="Fact_0829fcd5c153466992ff355e37fdbd2d" contextRef="c20241231_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ExercisePriceRange6Member" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">500</ix:nonFraction><br/>
                </span> </td>

    <td style="padding-bottom: 2px; white-space: nowrap; width: 1%;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td style="white-space: nowrap; width: 1%; padding-bottom: 2px;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td style="border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap; width: 1%;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td style="border-bottom: 2px solid rgb(0, 0, 0); vertical-align: bottom; text-align: right; width: 6%;" class="ffcell"><span style="font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" id="Fact_731bb7cd609c49189c7e2acb17107fd5" contextRef="c20241231_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ExercisePriceRange6Member" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">14,000</ix:nonFraction><br/>
                </span> </td>

    <td style="padding-bottom: 2px; white-space: nowrap; width: 1%;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td style="white-space: nowrap; width: 1%; padding-bottom: 2px;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td style="white-space: nowrap; width: 1%; padding-bottom: 2px;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td style="vertical-align: bottom; text-align: right; width: 6%; padding-bottom: 2px;" class="ffcell"><span style="font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><ix:nonNumeric name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" id="Fact_fb961bb906cb45908b75599a37693df9" contextRef="c20240101to20241231_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ExercisePriceRange6Member" format="ixt-sec:duryear">0.1</ix:nonNumeric><br/>
                </span> </td>

    <td style="white-space: nowrap; width: 1%; padding-bottom: 2px;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td style="white-space: nowrap; width: 1%; padding-bottom: 2px;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td style="vertical-align: bottom; white-space: nowrap; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">$</td>

    <td style="vertical-align: bottom; text-align: right; width: 6%; padding-bottom: 2px;" class="ffcell"><span style="font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" id="Fact_de9ae107284640b8839a1cc465b45b79" contextRef="c20241231_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ExercisePriceRange6Member" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">10.80</ix:nonFraction><br/>
                </span> </td>

    <td style="white-space: nowrap; width: 1%; padding-bottom: 2px;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td style="white-space: nowrap; width: 1%; padding-bottom: 2px;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td style="border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap; width: 1%;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td style="border-bottom: 2px solid rgb(0, 0, 0); vertical-align: bottom; text-align: right; width: 6%; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" class="ffcell"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" id="Fact_d58a8def70b64aa1a59416aba6d825dc" contextRef="c20241231_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ExercisePriceRange6Member" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">89</ix:nonFraction></td>

    <td style="padding-bottom: 2px; white-space: nowrap; width: 1%;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

  </tr>

  <tr style="height: 15px;">

    <td style="width: 28%; background-color: rgb(204, 238, 255); padding-bottom: 4px;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td colspan="1" style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; padding-bottom: 4px;">&#160;</td>

    <td style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 4px double rgb(0, 0, 0);">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td style="vertical-align: bottom; text-align: right; width: 6%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; border-bottom: 4px double rgb(0, 0, 0);" class="ffcell"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" id="Fact_8de4cd99452d47a2a212e0158ed8a778" contextRef="c20241231" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">5,141,516</ix:nonFraction></td>

    <td style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td style="vertical-align: bottom; text-align: right; width: 6%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; padding-bottom: 4px;" class="ffcell"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="Fact_2b529d363b7a40c5a6f6a4f3e1b501c2" contextRef="c20240101to20241231" format="ixt-sec:duryear">7.1</ix:nonNumeric></td>

    <td style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td style="vertical-align: bottom; white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; padding-bottom: 4px;">$</td>

    <td style="vertical-align: bottom; text-align: right; width: 6%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; padding-bottom: 4px;" class="ffcell"><ix:nonFraction name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" id="Fact_989106913a25416382da00b223d16762" contextRef="c20241231" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">3.90</ix:nonFraction></td>

    <td style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td style="vertical-align: bottom; white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; border-bottom: 4px double rgb(0, 0, 0);">$</td>

    <td style="vertical-align: bottom; text-align: right; width: 6%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; border-bottom: 4px double rgb(0, 0, 0);" class="ffcell"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" id="Fact_ef5c31c198b74c56a6ee5e8ad51ddfa8" contextRef="c20241231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">68,117</ix:nonFraction></td>

    <td style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 4px double rgb(0, 0, 0);">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td style="vertical-align: bottom; text-align: right; width: 6%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; border-bottom: 4px double rgb(0, 0, 0);" class="ffcell"><ix:nonFraction name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" id="Fact_2ef5df55495c4064a975fb562bc6a716" contextRef="c20241231" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">2,657,932</ix:nonFraction></td>

    <td style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td style="vertical-align: bottom; text-align: right; width: 6%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; padding-bottom: 4px;" class="ffcell"><ix:nonNumeric name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" id="Fact_d755b85bd693435680a8aab963658632" contextRef="c20240101to20241231" format="ixt-sec:duryear">5.7</ix:nonNumeric></td>

    <td style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td style="vertical-align: bottom; white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; padding-bottom: 4px;">$</td>

    <td style="vertical-align: bottom; text-align: right; width: 6%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; padding-bottom: 4px;" class="ffcell"><ix:nonFraction name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" id="Fact_03cde827eec44d319929b8e824b201ef" contextRef="c20241231" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">3.03</ix:nonFraction></td>

    <td style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td style="vertical-align: bottom; white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; border-bottom: 4px double rgb(0, 0, 0);">$</td>

    <td style="vertical-align: bottom; text-align: right; width: 6%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; border-bottom: 4px double rgb(0, 0, 0);" class="ffcell"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" id="Fact_04d76419ddc3481bbcda8ac463317cbc" contextRef="c20241231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">37,540</ix:nonFraction></td>

    <td style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

  </tr>


</table>
</ix:continuation></ix:continuation>

        <ix:continuation id="Text_dc9d2d26f01543f296ae7c67bdf0853e52" continuedAt="Text_dc9d2d26f01543f296ae7c67bdf0853e53"><p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; text-align: left; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;&#160; </p></ix:continuation>
        <ix:continuation id="Text_dc9d2d26f01543f296ae7c67bdf0853e53" continuedAt="Text_dc9d2d26f01543f296ae7c67bdf0853e54">
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><span style="background-color: rgb(255, 255, 255); font-weight: normal;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; During the
            years ended December 31, 2024, 2023 and 2022, the Company granted RSUs representing an aggregate of <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" id="Fact_6edf1cdf0b7e40d7b3d12ad60cda11be" contextRef="c20240101to20241231_AwardTypeAxis_RestrictedStockUnitsRSUMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">3,278,688</ix:nonFraction>, <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" id="Fact_fa157343ff924b03b215afa5ea24b08c" contextRef="c20230101to20231231_AwardTypeAxis_RestrictedStockUnitsRSUMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">3,389,760</ix:nonFraction> and <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" id="Fact_ef0c45768ed045669ffd945027c66507" contextRef="c20220101to20221231_AwardTypeAxis_RestrictedStockUnitsRSUMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">1,174,266</ix:nonFraction> shares,
            respectively, to certain employees and consultants of the Company and to members of the Board. The RSUs generally vest annually over a period of <ix:nonNumeric name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Fact_44bf68822544466fb46b507888bb89e6" contextRef="c20240101to20241231_AwardTypeAxis_RestrictedStockUnitsRSUMember_TitleOfIndividualAxis_EmployeesMember" format="ixt-sec:durwordsen">four years</ix:nonNumeric> for employees and semi-annually over a period of <ix:nonNumeric name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Fact_f1e89c147b154ad1a28f27d8022c94b0" contextRef="c20240101to20241231_AwardTypeAxis_RestrictedStockUnitsRSUMember_TitleOfIndividualAxis_DirectorMember" format="ixt-sec:durwordsen">one year</ix:nonNumeric> for directors. </span></div>
</ix:continuation>
        <ix:continuation id="Text_dc9d2d26f01543f296ae7c67bdf0853e54" continuedAt="Text_dc9d2d26f01543f296ae7c67bdf0853e55">
<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> <br/>
        </div>
</ix:continuation>
        <ix:continuation id="Text_dc9d2d26f01543f296ae7c67bdf0853e55" continuedAt="Text_dc9d2d26f01543f296ae7c67bdf0853e56">
<div style="display:none;"><br/></div>
<div style="text-indent: 36pt;"><span style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">During the years ended December 31, 2024, 2023 and 2022, <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" id="Fact_22dfbce76aaa4656ac5120fa75a416d8" contextRef="c20240101to20241231_AwardTypeAxis_RestrictedStockUnitsRSUMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">1,886,463</ix:nonFraction>,&#160;<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" id="Fact_a2c3899226324d7690ea37bba2836996" contextRef="c20230101to20231231_AwardTypeAxis_RestrictedStockUnitsRSUMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">1,199,445</ix:nonFraction> and <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" id="Fact_5b8f5d9a5e1c4a4a98bbf911c4d7c0df" contextRef="c20220101to20221231_AwardTypeAxis_RestrictedStockUnitsRSUMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">2,727,412</ix:nonFraction> shares, <span style="font-weight: normal; letter-spacing: normal; text-align: left; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">respectively, vested in connection with grants of RSUs. <span style="font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 48px; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">With respect to RSUs vested during the year ended December 31, 2024, <ix:nonFraction name="adma:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesWithheldForEmployeesTaxLiabilities" id="Fact_5ed75399d2da432697f35793caa440d3" contextRef="c20241231_AwardTypeAxis_RestrictedStockUnitsRSUMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">541,908</ix:nonFraction>
                shares valued at approximately $<ix:nonFraction name="adma:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesValueWithheldForEmployeesTaxLiabilities" id="Fact_ab054ff077f54df4a263ab30ad77e991" contextRef="c20241231_AwardTypeAxis_RestrictedStockUnitsRSUMember" unitRef="U001" decimals="-5" scale="6" format="ixt:num-dot-decimal">5.0</ix:nonFraction> million were withheld were withheld to cover employees&#8217; tax liabilities. </span>With respect
              to RSUs vested during the year ended December 31, 2023, <ix:nonFraction name="adma:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesWithheldForEmployeesTaxLiabilities" id="Fact_5d4fd31704e04ac581bebbccd4df6f22" contextRef="c20231231_AwardTypeAxis_RestrictedStockUnitsRSUMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">365,722</ix:nonFraction> shares valued at approximately $<ix:nonFraction name="adma:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesValueWithheldForEmployeesTaxLiabilities" id="Fact_0791c2b163ac475098c968b4402bb59f" contextRef="c20231231_AwardTypeAxis_RestrictedStockUnitsRSUMember" unitRef="U001" decimals="-5" scale="6" format="ixt:num-dot-decimal">1.3</ix:nonFraction> million were withheld by the Company to cover employees&#8217; tax liabilities</span><span style="background-color: rgb(255, 255, 255); font-weight: normal;">. <span style="font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">With respect to the RSUs vested during the year ended December 31, 2022</span>, <ix:nonFraction name="adma:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesWithheldForEmployeesTaxLiabilities" id="Fact_abc97bfc8eda4c3995a67fd8e6e317ff" contextRef="c20221231_AwardTypeAxis_RestrictedStockUnitsRSUMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">918,851</ix:nonFraction> shares valued at approximately $<ix:nonFraction name="adma:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesValueWithheldForEmployeesTaxLiabilities" id="Fact_e00a78ca6aa84987bf008c2fd9751a68" contextRef="c20221231_AwardTypeAxis_RestrictedStockUnitsRSUMember" unitRef="U001" decimals="-5" scale="6" format="ixt:num-dot-decimal">2.9</ix:nonFraction> million were
              withheld by the Company to cover employees&#8217; tax liabilities.<span style="letter-spacing: normal; text-align: left; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"> All of these shares have been retired by the Company or were otherwise no longer outstanding as of December 31, 2024</span></span>. <ix:nonNumeric name="us-gaap:ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock" id="Text_87a2312734e04197a39a66f812b397f5" contextRef="c20240101to20241231" escape="true" continuedAt="Text_1731b60b7eda4dbaa283a0190f0e01b21"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal;">A summary of the Company&#8217;s unvested RSU activity and related information is as follows: </span></ix:nonNumeric><br/>
          </span> </div>
</ix:continuation>
        <div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left;">
          <ix:continuation id="Text_dc9d2d26f01543f296ae7c67bdf0853e56" continuedAt="Text_dc9d2d26f01543f296ae7c67bdf0853e57"><ix:continuation id="Text_1731b60b7eda4dbaa283a0190f0e01b21" continuedAt="Text_1731b60b7eda4dbaa283a0190f0e01b22">
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left;"> <span style="font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
            </span> </div>
</ix:continuation></ix:continuation>
        </div>

        <ix:continuation id="Text_dc9d2d26f01543f296ae7c67bdf0853e57" continuedAt="Text_dc9d2d26f01543f296ae7c67bdf0853e58"><ix:continuation id="Text_1731b60b7eda4dbaa283a0190f0e01b22">
<table cellspacing="0" cellpadding="0" border="0" class="cfttable" style="text-align: left; font: 10pt 'Times New Roman'; width: 100%; border-spacing: 0;">


  <tr style="height: 15px;">

    <td valign="bottom" style="padding-bottom: 2px;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td valign="bottom" colspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: #000000 solid 2px; white-space: nowrap;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; text-align: center; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"><strong>Shares</strong></p>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: #000000 solid 2px; white-space: nowrap;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; text-align: center; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"><strong>Weighted</strong></p>
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; text-align: center; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"><strong>Average
                    Grant</strong></p>
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; text-align: center; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"><strong>Date Fair
                    Value</strong></p>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="vertical-align: top; width: 76%; background-color: #CCEEFF;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">Balance at December 31, 2021</p>
              </td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" id="Fact_d418c7d137214bf9835b7abaf11aaaf7" contextRef="c20211231_AwardTypeAxis_RestrictedStockUnitsRSUMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">4,485,133</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">$</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" id="Fact_d9f188430bdb4be0a3061d62b417d8c8" contextRef="c20211231_AwardTypeAxis_RestrictedStockUnitsRSUMember" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">1.34</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="vertical-align: top; width: 76%;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">Granted</p>
              </td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" id="Fact_fb432319d3c44a1b94a07a5ced0acd32" contextRef="c20220101to20221231_AwardTypeAxis_RestrictedStockUnitsRSUMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">1,174,266</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">$</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" id="Fact_e660f37e0d2a4d829ec64cdae64e362a" contextRef="c20220101to20221231_AwardTypeAxis_RestrictedStockUnitsRSUMember" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">1.74</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="vertical-align: top; width: 76%; background-color: #CCEEFF;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">Vested</p>
              </td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" id="Fact_10f07536474c4bab80031d0bbf3f01ad" contextRef="c20220101to20221231_AwardTypeAxis_RestrictedStockUnitsRSUMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">2,727,412</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;">)</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">$</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" id="Fact_bef97b13d8f94a0a86a1380df2ead166" contextRef="c20220101to20221231_AwardTypeAxis_RestrictedStockUnitsRSUMember" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">1.25</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="vertical-align: top; width: 76%; padding-bottom: 2px;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">Forfeited</p>
              </td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" id="Fact_16bfab3e91b14a64b0179aa9c385e7c8" contextRef="c20220101to20221231_AwardTypeAxis_RestrictedStockUnitsRSUMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">65,000</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;">)</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">$</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" id="Fact_61b6665583114b0dad7757cf92f1855e" contextRef="c20220101to20221231_AwardTypeAxis_RestrictedStockUnitsRSUMember" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">1.40</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" rowspan="1" style="vertical-align: top; font-family: 'Times New Roman'; width: 76%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Balance at December 31, 2022</td>

    <td valign="bottom" colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" id="Fact_7064c412a1934ed0859b37048262b7a4" contextRef="c20221231_AwardTypeAxis_RestrictedStockUnitsRSUMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">2,866,987</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">$</td>

    <td valign="bottom" colspan="1" rowspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" id="Fact_343984b1e4904f54b5f2e34dbb9b45bb" contextRef="c20221231_AwardTypeAxis_RestrictedStockUnitsRSUMember" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">1.59</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" rowspan="1" style="vertical-align: top; width: 76%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Granted<br/>
              </td>

    <td valign="bottom" colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" id="Fact_58ca734ad6e840758254282e3690263d" contextRef="c20230101to20231231_AwardTypeAxis_RestrictedStockUnitsRSUMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">3,389,760</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">$</td>

    <td valign="bottom" colspan="1" rowspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" id="Fact_55a7e60252d0468cb94b50ce4f4f80d4" contextRef="c20230101to20231231_AwardTypeAxis_RestrictedStockUnitsRSUMember" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">3.42</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" rowspan="1" style="vertical-align: top; width: 76%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Vested<br/>
              </td>

    <td valign="bottom" colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" id="Fact_c50920e413a14e08a274a7391f039150" contextRef="c20230101to20231231_AwardTypeAxis_RestrictedStockUnitsRSUMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">1,199,445</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;">)</td>

    <td valign="bottom" colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">$</td>

    <td valign="bottom" colspan="1" rowspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" id="Fact_550c78f825d946d78bf8c3a6cac719ef" contextRef="c20230101to20231231_AwardTypeAxis_RestrictedStockUnitsRSUMember" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">1.63</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" rowspan="1" style="vertical-align: top; width: 76%; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Forfeited<br/>
              </td>

    <td valign="bottom" colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" id="Fact_3209f84920574cc08ff1671e4fd08b67" contextRef="c20230101to20231231_AwardTypeAxis_RestrictedStockUnitsRSUMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">400,005</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;">)</td>

    <td valign="bottom" colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">$</td>

    <td valign="bottom" colspan="1" rowspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" id="Fact_b2943c3449b344a29ae8e01570c54d96" contextRef="c20230101to20231231_AwardTypeAxis_RestrictedStockUnitsRSUMember" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">2.71</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="vertical-align: top; width: 76%; background-color: #CCEEFF;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">Balance at December 31, 2023</p>
              </td>

    <td valign="bottom" colspan="1" style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" id="Fact_992969368a2d4e4b94dc2cc433e66ece" contextRef="c20231231_AwardTypeAxis_RestrictedStockUnitsRSUMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">4,657,297</ix:nonFraction><br/>
              </td>

    <td valign="bottom" colspan="1" style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">$</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" id="Fact_d97a46c259944d64932cdae632f4b0a5" contextRef="c20231231_AwardTypeAxis_RestrictedStockUnitsRSUMember" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">2.81</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" rowspan="1" style="vertical-align: top; width: 76%;"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Granted<br/>
                </span> </td>

    <td valign="bottom" colspan="1" rowspan="1" style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" id="Fact_6cfd4c95162f486f92a39a8f56cfb829" contextRef="c20240101to20241231_AwardTypeAxis_RestrictedStockUnitsRSUMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">3,278,688</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">$<br/>
                </span> </td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" id="Fact_d69ab82b6217460f9632435809b4f512" contextRef="c20240101to20241231_AwardTypeAxis_RestrictedStockUnitsRSUMember" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">7.44</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" rowspan="1" style="vertical-align: top; width: 76%; background-color: rgb(204, 238, 255);"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Vested<br/>
                </span> </td>

    <td valign="bottom" colspan="1" rowspan="1" style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" id="Fact_d0391685eb4948f2b9ead3797387bd0a" contextRef="c20240101to20241231_AwardTypeAxis_RestrictedStockUnitsRSUMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">1,886,463</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">)</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">$<br/>
                </span> </td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" id="Fact_adafcc68553749849c70d461aeea6ca5" contextRef="c20240101to20241231_AwardTypeAxis_RestrictedStockUnitsRSUMember" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">2.50</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" rowspan="1" style="vertical-align: top; width: 76%; padding-bottom: 2px;"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Forfeited<br/>
                </span> </td>

    <td valign="bottom" colspan="1" rowspan="1" style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" id="Fact_2f9fc91239f149c4ac6d69b44eaa4e89" contextRef="c20240101to20241231_AwardTypeAxis_RestrictedStockUnitsRSUMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">303,532</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">)</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px;"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">$<br/>
                </span> </td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" id="Fact_9d8ae6dedf884193ba65c887c6a1964c" contextRef="c20240101to20241231_AwardTypeAxis_RestrictedStockUnitsRSUMember" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">3.92</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" rowspan="1" style="vertical-align: top; width: 76%; padding-bottom: 4px; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Balance at December 31, 2024</td>

    <td valign="bottom" colspan="1" rowspan="1" style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" id="Fact_a44fa255c9b2460894668e578887b429" contextRef="c20241231_AwardTypeAxis_RestrictedStockUnitsRSUMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">5,745,990</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">$<br/>
                </span> </td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" id="Fact_4343c775daaa47eebc9bc2da75468576" contextRef="c20241231_AwardTypeAxis_RestrictedStockUnitsRSUMember" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">5.50</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

  </tr>


</table>
</ix:continuation></ix:continuation>

        <ix:continuation id="Text_dc9d2d26f01543f296ae7c67bdf0853e58" continuedAt="Text_dc9d2d26f01543f296ae7c67bdf0853e59">
<div> <span style="font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
          </span> </div>
</ix:continuation>
      </div>

      <ix:continuation id="Text_dc9d2d26f01543f296ae7c67bdf0853e59" continuedAt="Text_dc9d2d26f01543f296ae7c67bdf0853e60">
<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><span style="background-color: rgb(255, 255, 255); font-weight: normal;">As of
          December 31, 2024, the Company had $<ix:nonFraction name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" id="Fact_80536c021f4a4112b250696f261c44df" contextRef="c20241231_AwardTypeAxis_RestrictedStockUnitsRSUMember_PlanNameAxis_EquityIncentivePlanMember" unitRef="U001" decimals="-5" scale="6" format="ixt:num-dot-decimal">25.3</ix:nonFraction> million of unrecognized compensation expense related to unvested RSUs granted under the
          Company&#8217;s equity incentive plans, which is expected to be recognized over a weighted-average period of <ix:nonNumeric name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="Fact_96ef003358a04ef990e13b4759ab33c3" contextRef="c20240101to20241231_AwardTypeAxis_RestrictedStockUnitsRSUMember_PlanNameAxis_EquityIncentivePlanMember" format="ixt-sec:duryear">3.1</ix:nonNumeric> years.</span></div>
</ix:continuation>
      <ix:continuation id="Text_dc9d2d26f01543f296ae7c67bdf0853e60" continuedAt="Text_dc9d2d26f01543f296ae7c67bdf0853e61">
<div style="display:none;"><br/></div>
<div style="text-indent: 36pt;"><span style="font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
        </span> <span style="font-family: 'Times New Roman'; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> <span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> </div>
</ix:continuation>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">F-26</span></div>

        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"/></div>

        <div style="width: 100%;" class="BRPFPageHeader">
          <div>
            <div style="text-align: left; font-weight: bold; text-indent: -9pt; margin-left: 9pt;"><a href="#ADMABIOLOGICSINC."> <span style="font-style: italic; font-weight: normal; font-size: 8pt;">Table of Contents</span></a><br/>
            </div>

            <div style="text-align: left; font-weight: bold; text-indent: -9pt; margin-left: 9pt;"><a href="#ADMABIOLOGICSINC."><span style="font-style: italic; font-weight: normal; font-size: 8pt;"> <br/>
                </span></a></div>

            <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">ADMA BIOLOGICS, INC. AND SUBSIDIARIES</div>

            <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</div>

          </div>

        </div>

      </div>

      <div style="line-height: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-align: left;">
        <ix:continuation id="Text_dc9d2d26f01543f296ae7c67bdf0853e61" continuedAt="Text_dc9d2d26f01543f296ae7c67bdf0853e62"><p style="background-color: rgb(255, 255, 255); margin: 0px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-align: left; text-indent: 36pt; text-transform: none;"><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span><span style="font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><span style="background-color: rgb(255, 255, 255); font-weight: normal;">During the year ended
              December 31, 2024, <ix:nonFraction name="adma:NumberOfIndividualsThatReceivedModificationsToTheirOutstandingStockOptionAndRSUAwards" id="Fact_97fadf7cdbd54bcc9d088d34483d4aef" contextRef="c20240101to20241231_TitleOfIndividualAxis_EmployeesMember" unitRef="U009" decimals="INF" scale="0" format="ixt-sec:numwordsen">three</ix:nonFraction> of the Company&#8217;s employees and <ix:nonFraction name="adma:NumberOfIndividualsThatReceivedModificationsToTheirOutstandingStockOptionAndRSUAwards" id="Fact_a67250288c214449bc57606ca1fde918" contextRef="c20240101to20241231_TitleOfIndividualAxis_DirectorMember" unitRef="U008" decimals="INF" scale="0" format="ixt-sec:numwordsen">one</ix:nonFraction> of the Company&#8217;s non-employee directors received modifications to their outstanding stock option and RSU awards in connection with their departure from the Company or
              transition from an employee to a consulting role (see Note 9). The modifications allowed, among other things, the former employees to continue to participate in the Company&#8217;s equity incentive plans with respect to certain of their outstanding
              awards when they would otherwise not be eligible to do so. In connection with these modifications, the Company recognized an aggregate of $<ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" id="Fact_254f1178dbf74204a2a7722ae9d974d5" contextRef="c20240101to20241231_AwardTypeAxis_RestrictedStockUnitsRSUMember" unitRef="U001" decimals="-5" scale="6" format="ixt:num-dot-decimal">2.5</ix:nonFraction>
              million of additional compensation expense in the year ended December 31, 2024. <ix:nonNumeric name="us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" id="Text_bdb87adfaf7b4ef8b1ee6faafa1e7de4" contextRef="c20240101to20241231" escape="true" continuedAt="Text_18302545125b4e58a49c0cea1dfb67271"><span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal;">Total stock-based compensation expense for all awards granted under the Company&#8217;s equity incentive plans for the years ended December 31, 2024, 2023 and 2022
              was as follows (in thousands):</span></ix:nonNumeric></span><br/>
          </span> </p></ix:continuation><ix:continuation id="Text_dc9d2d26f01543f296ae7c67bdf0853e62" continuedAt="Text_dc9d2d26f01543f296ae7c67bdf0853e63"><ix:continuation id="Text_18302545125b4e58a49c0cea1dfb67271" continuedAt="Text_18302545125b4e58a49c0cea1dfb67272">
<div><span style="font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
        </span>
         <span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>
</ix:continuation></ix:continuation>
        <ix:continuation id="Text_dc9d2d26f01543f296ae7c67bdf0853e63"><ix:continuation id="Text_18302545125b4e58a49c0cea1dfb67272">
<table cellspacing="0" cellpadding="0" border="0" class="cfttable" style="text-align: left; font: 10pt 'Times New Roman'; margin-left: auto; margin-right: auto; width: 100%; border-spacing: 0;">


  <tr style="height: 15px;">

    <td valign="bottom" rowspan="1" style="text-align: center; font-style: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">&#160;</td>

    <td valign="bottom" rowspan="1" colspan="1" style="text-align: center; vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td valign="bottom" rowspan="1" colspan="10" style="vertical-align: bottom; text-align: center;"><span style="font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Year Ended December 31, </span><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
                </span> </td>

    <td valign="bottom" rowspan="1" colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" rowspan="1" style="padding-bottom: 2px; text-align: center; font-style: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;">&#160;(in thousands)</td>

    <td valign="bottom" rowspan="1" colspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td valign="bottom" rowspan="1" colspan="2" style="vertical-align: bottom; text-align: center; border-top: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: center; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"><strong> 2024<br/>
                  </strong></p>
              </td>

    <td valign="bottom" rowspan="1" colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; border-top: 2px solid rgb(0, 0, 0); white-space: nowrap;">&#160;</td>

    <td valign="bottom" rowspan="1" colspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; border-top: 2px solid rgb(0, 0, 0);">&#160;</td>

    <td valign="bottom" rowspan="1" colspan="2" style="vertical-align: bottom; text-align: center; border-top: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;<strong>2023</strong></td>

    <td valign="bottom" rowspan="1" colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; border-top: 2px solid rgb(0, 0, 0); white-space: nowrap;">&#160;</td>

    <td valign="bottom" rowspan="1" colspan="1" style="text-align: center; font-family: 'Times New Roman'; vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; border-top: 2px solid rgb(0, 0, 0); white-space: nowrap;">&#160;</td>

    <td valign="bottom" rowspan="1" colspan="2" style="text-align: center; vertical-align: bottom; font-family: 'Times New Roman'; border-top: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;<span style="font-weight: bold;">2022</span></td>

    <td valign="bottom" rowspan="1" colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="vertical-align: top; width: 64%; background-color: #CCEEFF;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">Research and development</p>
              </td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">$</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:ShareBasedCompensation" id="Fact_38bf5208486c478a84e61a0163ccd7af" contextRef="c20240101to20241231_IncomeStatementLocationAxis_ResearchAndDevelopmentExpenseMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">98</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">$</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:ShareBasedCompensation" id="Fact_7c67f1626cde4d06aacb99c32aeee1e0" contextRef="c20230101to20231231_IncomeStatementLocationAxis_ResearchAndDevelopmentExpenseMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">40</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;">$</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;"><ix:nonFraction name="us-gaap:ShareBasedCompensation" id="Fact_187ed1ca24454d0fa89a6af2ab62e545" contextRef="c20220101to20221231_IncomeStatementLocationAxis_ResearchAndDevelopmentExpenseMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">19</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="vertical-align: top; width: 64%;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">Plasma center operating expenses</p>
              </td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:ShareBasedCompensation" id="Fact_fc1bf715ff5444ff83433909d2f6830e" contextRef="c20240101to20241231_IncomeStatementLocationAxis_OperatingExpenseMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">184</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:ShareBasedCompensation" id="Fact_205751fd30894aaaaeb308085d6105a3" contextRef="c20230101to20231231_IncomeStatementLocationAxis_OperatingExpenseMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">146</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;"><ix:nonFraction name="us-gaap:ShareBasedCompensation" id="Fact_31fde3b26bf34d57a4082b5a8932cc98" contextRef="c20220101to20221231_IncomeStatementLocationAxis_OperatingExpenseMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">82</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="vertical-align: top; width: 64%; background-color: #CCEEFF;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">Selling, general and administrative</p>
              </td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:ShareBasedCompensation" id="Fact_7550905e2d084922bd5ad85cf45f7855" contextRef="c20240101to20241231_IncomeStatementLocationAxis_SellingGeneralAndAdministrativeExpensesMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">11,720</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:ShareBasedCompensation" id="Fact_fa6a387ff3bc4c43b2fbc3ecbc289d93" contextRef="c20230101to20231231_IncomeStatementLocationAxis_SellingGeneralAndAdministrativeExpensesMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">5,331</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;"><ix:nonFraction name="us-gaap:ShareBasedCompensation" id="Fact_caadf250883347929357ae29d2c303dc" contextRef="c20220101to20221231_IncomeStatementLocationAxis_SellingGeneralAndAdministrativeExpensesMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,717</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="vertical-align: top; width: 64%; padding-bottom: 2px;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">Cost of product revenue</p>
              </td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:ShareBasedCompensation" id="Fact_61c5340becc24518b8f7e68a160c64ab" contextRef="c20240101to20241231_IncomeStatementLocationAxis_CostOfSalesMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,614</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:ShareBasedCompensation" id="Fact_06958c9a33024464a6d752ea08918cf6" contextRef="c20230101to20231231_IncomeStatementLocationAxis_CostOfSalesMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">670</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;"><ix:nonFraction name="us-gaap:ShareBasedCompensation" id="Fact_b0ad4535327848e19a40b874f389bcf6" contextRef="c20220101to20221231_IncomeStatementLocationAxis_CostOfSalesMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">397</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="vertical-align: top; width: 64%; padding-bottom: 4px; background-color: rgb(204, 238, 255);">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-indent: 9.5pt; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">Total stock-based compensation expense</p>
              </td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">$</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:ShareBasedCompensation" id="Fact_e301cd14405c4cc4a7b318e08c53f87a" contextRef="c20240101to20241231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">13,616</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">$</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><ix:nonFraction name="us-gaap:ShareBasedCompensation" id="Fact_28b6a4bca5954e9ea03107e859a4e4db" contextRef="c20230101to20231231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">6,187</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;">$</td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;"><ix:nonFraction name="us-gaap:ShareBasedCompensation" id="Fact_682a6601217a42b283d8d26f78aee1d5" contextRef="c20220101to20221231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">5,215</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;">&#160;</td>

  </tr>


</table>
</ix:continuation></ix:continuation>
        <div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>

        <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
      </div>

    </div>

    <div><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>
 </div>


  <div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: rgb(0, 0, 0);">
    <div>
      <div style="text-align: left; font: 10pt 'Times New Roman';">
        <ix:nonNumeric name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" id="Text_674930182f70406e9c3674013f1474da" contextRef="c20240101to20241231" escape="true" continuedAt="Text_86f00647b651441888ef6cee6bb036f81">
<div>
          <table cellspacing="0" cellpadding="0" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt; border-spacing: 0;" class="DSPFListTable">


  <tr style="vertical-align: top;">

    <td style="vertical-align: top; width: 27pt;">
                  <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;"><strong>9.</strong></p>
                </td>

    <td style="align: left; vertical-align: top; width: auto;">
                  <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;"><span style="text-decoration: underline;"><span style="background-color: rgb(255, 255, 255); font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><strong>RELATED PARTY TRANSACTIONS</strong></span></span><strong><span style="text-decoration: underline;"><br/>
                      </span></strong></p>
                </td>

  </tr>


</table>
        </div>
</ix:nonNumeric>
        <ix:continuation id="Text_86f00647b651441888ef6cee6bb036f81" continuedAt="Text_86f00647b651441888ef6cee6bb036f82"><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;">&#160;</p></ix:continuation>
        <ix:continuation id="Text_86f00647b651441888ef6cee6bb036f82" continuedAt="Text_86f00647b651441888ef6cee6bb036f83"><p style="margin: 0px; font-family: 'Times New Roman'; font-size: 10pt; text-align: left; text-indent: 36pt;"><span style="font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none;">The Company leases an office building and equipment from Areth, LLC (&#8220;Areth&#8221;) pursuant to an agreement for services effective as of January 1, 2016, as amended from time
            to time<span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; text-align: left; text-indent: 48px; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">, and pays</span> monthly rent on this facility in the amount of $<ix:nonFraction name="us-gaap:OperatingCostsAndExpenses" id="Fact_a14a1e27b8eb4d7f87d82d0eb5bbb99f" contextRef="c20160101to20160131_CounterpartyNameAxis_ArethLLCMember_RelatedPartyTransactionsByRelatedPartyAxis_RelatedPartyMember" unitRef="U001" decimals="0" scale="0" format="ixt:num-dot-decimal">10,000</ix:nonFraction>. On <span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; text-align: left; text-indent: 48px; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">October 18, 2022</span>, the <span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; text-align: left; text-indent: 48px; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">Company</span> <span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; text-align: left; text-indent: 48px; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">amended the agreement to extend its term to <ix:nonNumeric name="us-gaap:LeaseExpirationDate1" id="Fact_c8b6d664cf77495d95799e8d28a38c8e" contextRef="c20240101to20241231_CounterpartyNameAxis_ArethLLCMember_RelatedPartyTransactionsByRelatedPartyAxis_RelatedPartyMember" format="ixt:date-monthname-day-year-en">December 31, 2026</ix:nonNumeric>, with automatic successive <ix:nonNumeric name="adma:RelatedPartyTransactionLeaseRenewalPeriod" id="Fact_424e89fd78a44e7392ce41eb8e4e095f" contextRef="c20240101to20241231_CounterpartyNameAxis_ArethLLCMember_RelatedPartyTransactionsByRelatedPartyAxis_RelatedPartyMember" format="ixt-sec:durwordsen">one-year</ix:nonNumeric>
              renewals thereafter. Either party may terminate the agreement by providing the other party with</span> <ix:nonNumeric name="adma:RelatedPartyTransactionLeaseTerminationPeriod" id="Fact_520d06d1ae1b4101959a606d379ecd01" contextRef="c20240101to20241231_CounterpartyNameAxis_ArethLLCMember_RelatedPartyTransactionsByRelatedPartyAxis_RelatedPartyMember" format="ixt-sec:durwordsen">one year</ix:nonNumeric><span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; text-align: left; text-indent: 48px; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">&#8217;s prior written notice</span>. Rent expense for the years ended December 31, 2024, 2023 and 2022 amounted to $<ix:nonFraction name="us-gaap:OperatingCostsAndExpenses" id="Fact_ffd63497f53445aa9b3498359fd6e0eb" contextRef="c20230101to20231231_CounterpartyNameAxis_ArethLLCMember_RelatedPartyTransactionsByRelatedPartyAxis_RelatedPartyMember" unitRef="U001" decimals="-5" scale="6" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:OperatingCostsAndExpenses" id="Fact_ba199790a8af46f09979ccc6cbec9e42" contextRef="c20220101to20221231_CounterpartyNameAxis_ArethLLCMember_RelatedPartyTransactionsByRelatedPartyAxis_RelatedPartyMember" unitRef="U001" decimals="-5" scale="6" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:OperatingCostsAndExpenses" id="Fact_628b0e508d514c7eb4c521a89f845f2d" contextRef="c20240101to20241231_CounterpartyNameAxis_ArethLLCMember_RelatedPartyTransactionsByRelatedPartyAxis_RelatedPartyMember" unitRef="U001" decimals="-5" scale="6" format="ixt:num-dot-decimal">0.1</ix:nonFraction></ix:nonFraction></ix:nonFraction>
            million. Areth is a company controlled by Dr. Jerrold B. Grossman, the Vice Chairman of the Board, and Adam S. Grossman, the Company&#8217;s President and Chief Executive Officer. The Company also reimburses Areth for office, warehousing and building
            related (common area) expenses, equipment and certain other operational expenses, which were not material to the consolidated financial statements for the years ended <span style="font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none;">December 31, 2024, 2023 and 2022</span>.</span> </p></ix:continuation>
        <ix:continuation id="Text_86f00647b651441888ef6cee6bb036f83" continuedAt="Text_86f00647b651441888ef6cee6bb036f84"><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-indent: 45px; text-align: left;">&#160;</p></ix:continuation>
        <ix:continuation id="Text_86f00647b651441888ef6cee6bb036f84" continuedAt="Text_86f00647b651441888ef6cee6bb036f85"><p style="margin: 0px; font-family: 'Times New Roman'; font-size: 10pt; text-align: left; text-indent: 36pt;">During the years ended December 31, 2024, 2023 and 2022, the Company purchased certain specialized equipment and repair services used for
          the collection and processing of source plasma from GenesisBPS and its affiliates (&#8220;Genesis&#8221;) in the amount of $<ix:nonFraction name="us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty" id="Fact_276ff91b5af5421ca068e8ee4e9aa5f8" contextRef="c20240101to20241231_CounterpartyNameAxis_GenesisBPSMember_RelatedPartyTransactionsByRelatedPartyAxis_RelatedPartyMember" unitRef="U001" decimals="-5" scale="6" format="ixt:num-dot-decimal">0.2</ix:nonFraction> million, $<ix:nonFraction name="us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty" id="Fact_d4da687522fc4aedaa8d53ef957322bc" contextRef="c20230101to20231231_CounterpartyNameAxis_GenesisBPSMember_RelatedPartyTransactionsByRelatedPartyAxis_RelatedPartyMember" unitRef="U001" decimals="-5" scale="6" format="ixt:num-dot-decimal">0.4</ix:nonFraction> million and $<ix:nonFraction name="us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty" id="Fact_a764d87779244aadadad1b00842f6cf3" contextRef="c20220101to20221231_CounterpartyNameAxis_GenesisBPSMember_RelatedPartyTransactionsByRelatedPartyAxis_RelatedPartyMember" unitRef="U001" decimals="-5" scale="6" format="ixt:num-dot-decimal">0.2</ix:nonFraction> million,
          respectively. Genesis is owned by Dr. Grossman and Adam Grossman.</p></ix:continuation>
        <ix:continuation id="Text_86f00647b651441888ef6cee6bb036f85" continuedAt="Text_86f00647b651441888ef6cee6bb036f86"><p style="margin: 0px; font-family: 'Times New Roman'; font-size: 10pt; text-align: left; text-indent: 36pt;"> <br/>
        </p></ix:continuation>
        <ix:continuation id="Text_86f00647b651441888ef6cee6bb036f86" continuedAt="Text_86f00647b651441888ef6cee6bb036f87"><p style="margin: 0px; font-family: 'Times New Roman'; font-size: 10pt; text-align: left; text-indent: 36pt;">On November 19, 2024, the Company entered into an agreement with Bryant Fong whereby the Company agreed, in conjunction with Mr. Fong&#8217;s
          resignation from the Board, to immediately vest all of Mr. Fong&#8217;s <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" id="Fact_13c2ef9759ee49aaaf3700ec4cd65f2a" contextRef="c20241119to20241119_AwardTypeAxis_RestrictedStockUnitsRSUMember_CounterpartyNameAxis_BryantFongMember_RelatedPartyTransactionsByRelatedPartyAxis_RelatedPartyMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">12,020</ix:nonFraction> unvested RSUs. The agreement also extended the
          post-termination exercise period for his vested stock options from <ix:nonNumeric name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Fact_03cdd40b2c744f69b18d41f2e56afaa4" contextRef="c20240101to20241231_CounterpartyNameAxis_BryantFongMember_RangeAxis_MinimumMember_RelatedPartyTransactionsByRelatedPartyAxis_RelatedPartyMember" format="ixt-sec:durwordsen">90 days</ix:nonNumeric> to <ix:nonNumeric name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Fact_07ddfe7e7af341eaa57c59b4d55003c2" contextRef="c20240101to20241231_CounterpartyNameAxis_BryantFongMember_RangeAxis_MaximumMember_RelatedPartyTransactionsByRelatedPartyAxis_RelatedPartyMember" format="ixt-sec:durwordsen">two years</ix:nonNumeric> (or earlier, if such options&#8217; <ix:nonNumeric name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" id="Fact_702c3f0d9d574d0ab0b291fbf19f1038" contextRef="c20240101to20241231_CounterpartyNameAxis_BryantFongMember_RelatedPartyTransactionsByRelatedPartyAxis_RelatedPartyMember" format="ixt-sec:durwordsen">10-year</ix:nonNumeric> expiration date occurs
          sooner than <ix:nonNumeric name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" id="Fact_0f64d308348b44dc9437e7a5d558700d" contextRef="c20240101to20241231_CounterpartyNameAxis_BryantFongMember_RelatedPartyTransactionsByRelatedPartyAxis_RelatedPartyMember" format="ixt:date-monthname-day-year-en">November 19, 2026</ix:nonNumeric>). All of Mr. Fong&#8217;s unvested stock options were forfeited in accordance with the terms of the 2022
          Equity Plan. In connection with this modification of Mr. Fong&#8217;s equity awards, the Company recorded additional compensation expense of $<ix:nonFraction name="us-gaap:ShareBasedCompensation" id="Fact_296c5595fd3c4f71ba9fabfb8a48c5a3" contextRef="c20240101to20241231_CounterpartyNameAxis_BryantFongMember_RelatedPartyTransactionsByRelatedPartyAxis_RelatedPartyMember" unitRef="U001" decimals="-5" scale="6" format="ixt:num-dot-decimal">0.3</ix:nonFraction>
          million (see Note 8) in the year ended December 31, 2024.</p></ix:continuation>
        <ix:continuation id="Text_86f00647b651441888ef6cee6bb036f87" continuedAt="Text_86f00647b651441888ef6cee6bb036f88"><p style="margin: 0px; font-family: 'Times New Roman'; font-size: 10pt; text-align: left; text-indent: 36pt;">&#160;</p></ix:continuation>
        <ix:continuation id="Text_86f00647b651441888ef6cee6bb036f88" continuedAt="Text_86f00647b651441888ef6cee6bb036f89"><p style="margin: 0px; font-family: 'Times New Roman'; font-size: 10pt; text-align: left; text-indent: 36pt;">On April 1, 2024, the Company entered into a consulting agreement with Brian Lenz, the Company&#8217;s former Executive Vice President, Chief
          Financial Officer and General Manager, ADMA BioCenters, whereby Mr. Lenz&#8217;s outstanding equity awards were modified in connection with his transition to a consulting role. Under the terms of the consulting agreement, Mr. Lenz remained eligible to
          participate in the Company&#8217;s equity compensation plans with respect to continued vesting of the subject awards as set forth in the agreement. In addition, the post-termination exercise period for Mr. Lenz&#8217;s vested stock options was extended from
          <ix:nonNumeric name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Fact_4bee219989df4b8cb7712d2508c85373" contextRef="c20240101to20241231_RangeAxis_MinimumMember_RelatedPartyTransactionsByRelatedPartyAxis_RelatedPartyMember_TitleOfIndividualAxis_ExecutiveVicePresidentAndChiefFinancialOfficerMember" format="ixt-sec:durwordsen">90 days</ix:nonNumeric> to <ix:nonNumeric name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Fact_9a89ccc086b2487f854230c9bc1db637" contextRef="c20240101to20241231_RangeAxis_MaximumMember_RelatedPartyTransactionsByRelatedPartyAxis_RelatedPartyMember_TitleOfIndividualAxis_ExecutiveVicePresidentAndChiefFinancialOfficerMember" format="ixt-sec:durwordsen">two years</ix:nonNumeric>
          from the date of the consulting agreement (or earlier, if such options&#8217; <ix:nonNumeric name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" id="Fact_2d5e8aef71404604aaf0616e7f839e02" contextRef="c20240101to20241231_RelatedPartyTransactionsByRelatedPartyAxis_RelatedPartyMember_TitleOfIndividualAxis_ExecutiveVicePresidentAndChiefFinancialOfficerMember" format="ixt-sec:durwordsen">10-year</ix:nonNumeric> expiration date occurs sooner than <ix:nonNumeric name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" id="Fact_7f76d2feb14e4bef841565139378575f" contextRef="c20240101to20241231_RelatedPartyTransactionsByRelatedPartyAxis_RelatedPartyMember_TitleOfIndividualAxis_ExecutiveVicePresidentAndChiefFinancialOfficerMember" format="ixt:date-monthname-day-year-en">March 31, 2026</ix:nonNumeric>). In connection with this modification, the Company recorded $<ix:nonFraction name="us-gaap:ShareBasedCompensation" id="Fact_5f273c74892c41e28f00bbc298c308df" contextRef="c20240101to20241231_RelatedPartyTransactionsByRelatedPartyAxis_RelatedPartyMember_TitleOfIndividualAxis_ExecutiveVicePresidentAndChiefFinancialOfficerMember" unitRef="U001" decimals="-5" scale="6" format="ixt:num-dot-decimal">1.6</ix:nonFraction> million of additional compensation expense for the year ended December 31, 2024.</p></ix:continuation>
        <ix:continuation id="Text_86f00647b651441888ef6cee6bb036f89" continuedAt="Text_86f00647b651441888ef6cee6bb036f810"><p style="margin: 0px; font-family: 'Times New Roman'; font-size: 10pt; text-align: left; text-indent: 36pt;"> </p></ix:continuation>
        <ix:continuation id="Text_86f00647b651441888ef6cee6bb036f810" continuedAt="Text_86f00647b651441888ef6cee6bb036f811"><p style="margin: 0px; font-family: 'Times New Roman'; font-size: 10pt; text-align: left; text-indent: 36pt;"> </p></ix:continuation>
        <ix:continuation id="Text_86f00647b651441888ef6cee6bb036f811" continuedAt="Text_86f00647b651441888ef6cee6bb036f812"><p style="margin: 0px; font-family: 'Times New Roman'; font-size: 10pt; text-align: left; text-indent: 36pt;"> <br/>
        </p></ix:continuation>
        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">F-27</span></div>

          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"/></div>

          <div style="width: 100%;" class="BRPFPageHeader">
            <div>
              <div style="text-align: left; font-weight: bold; text-indent: -9pt; margin-left: 9pt;"><a href="#ADMABIOLOGICSINC."> <span style="font-style: italic; font-weight: normal; font-size: 8pt;">Table of Contents</span></a><br/>
              </div>

              <div style="text-align: left; font-weight: bold; text-indent: -9pt; margin-left: 9pt;"><a href="#ADMABIOLOGICSINC."><span style="font-style: italic; font-weight: normal; font-size: 8pt;"> <br/>
                  </span></a></div>

              <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">ADMA BIOLOGICS, INC. AND SUBSIDIARIES</div>

              <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</div>

            </div>

          </div>

        </div>

        <ix:continuation id="Text_86f00647b651441888ef6cee6bb036f812" continuedAt="Text_86f00647b651441888ef6cee6bb036f813"><p style="margin: 0px; font-family: 'Times New Roman'; font-size: 10pt; text-align: left; text-indent: 36pt;"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">On August 15, 2023, <ix:nonFraction name="adma:NumberOfExecutiveOfficersThatExercisedOptions" id="Fact_cc34bb6fc29d44a8a5c997f8d3e4f6db" contextRef="c20230815to20230815_RelatedPartyTransactionsByRelatedPartyAxis_RelatedPartyMember_TitleOfIndividualAxis_ExecutiveOfficerMember" unitRef="U006" decimals="INF" scale="0" format="ixt-sec:numwordsen">two</ix:nonFraction> of the Company&#8217;s executive
            officers exercised options to purchase <ix:nonFraction name="adma:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedInCashlessTransactionForAward" id="Fact_20d53f5167a64aec81cab0bc8e617183" contextRef="c20230815to20230815_RelatedPartyTransactionsByRelatedPartyAxis_RelatedPartyMember_TitleOfIndividualAxis_ExecutiveOfficerMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">2,909,721</ix:nonFraction> shares of the Company&#8217;s common stock on a cashless basis, and <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" id="Fact_70ab7f3cf5b74e0dbdb47f82467a3614" contextRef="c20230815to20230815_RelatedPartyTransactionsByRelatedPartyAxis_RelatedPartyMember_TitleOfIndividualAxis_ExecutiveOfficerMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">688,657</ix:nonFraction> shares of common stock were issued to these executive officers, net of <ix:nonFraction name="us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation" id="Fact_e60522463dd04ab1a0734edc529cb8d2" contextRef="c20230815to20230815_RelatedPartyTransactionsByRelatedPartyAxis_RelatedPartyMember_TitleOfIndividualAxis_ExecutiveOfficerMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">257,867</ix:nonFraction> shares of common stock to cover a portion of their tax liabilities (see Note 8)</span><span style="font-size: 10pt;">.</span><br/>
        </p></ix:continuation>
        <ix:continuation id="Text_86f00647b651441888ef6cee6bb036f813" continuedAt="Text_86f00647b651441888ef6cee6bb036f814"><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-indent: 45px; text-align: left;"><br/>
        </p></ix:continuation>
        <ix:continuation id="Text_86f00647b651441888ef6cee6bb036f814" continuedAt="Text_86f00647b651441888ef6cee6bb036f815">
<div style="display:none;"><br/></div>
<div style="margin: 0px 0px 0px; font-family: 'Times New Roman'; font-size: 10pt; text-align: left; text-indent: 36pt;">See Note 7 for a discussion of the Company&#8217;s prior credit facility and related transactions with Perceptive, a holder of more
          than <ix:nonFraction name="adma:MinimumPercentageOfCommonStockHeldByLender" id="Fact_61ac4aba87504d9f93eec53583d84bee" contextRef="c20220101to20221231_LineOfCreditFacilityAxis_PerceptiveCreditHoldingsIILPMember_RelatedPartyTransactionsByRelatedPartyAxis_RelatedPartyMember" unitRef="U007" decimals="2" scale="-2" format="ixt:num-dot-decimal">5</ix:nonFraction>% of the Company&#8217;s common stock during the year ended December 31, 2022.</div>
</ix:continuation>
        <ix:continuation id="Text_86f00647b651441888ef6cee6bb036f815" continuedAt="Text_86f00647b651441888ef6cee6bb036f816">
<div style="display:none;"><br/></div>
<div style="margin: 0px 0px 0px; font-family: 'Times New Roman'; font-size: 10pt; text-align: left; text-indent: 36pt;"> <br/>
        </div>
</ix:continuation>
        <ix:continuation id="Text_86f00647b651441888ef6cee6bb036f816">
<div style="display:none;"><br/></div>
<div style="margin: 0px 0px 0px; font-family: 'Times New Roman'; font-size: 10pt; text-align: left; text-indent: 36pt;">In connection with the 2022 public offering of the Company&#8217;s common stock (see Note 8) on December 9, 2022: (i) Mr. Grossman
          purchased <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" id="Fact_ac80364d5ee54bbd88f29bb173ec8a2f" contextRef="c20221209to20221209_OwnershipAxis_DirectOwnershipMember_RelatedPartyTransactionsByRelatedPartyAxis_RelatedPartyMember_TitleOfIndividualAxis_PresidentAndChiefExecutiveOfficerMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">14,983</ix:nonFraction> shares of common stock directly and <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" id="Fact_5634fb52b0ef4f76ba5cafa5a8d6cf3e" contextRef="c20221209to20221209_OwnershipAxis_IndirectOwnershipMember_RelatedPartyTransactionsByRelatedPartyAxis_RelatedPartyMember_TitleOfIndividualAxis_PresidentAndChiefExecutiveOfficerMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">14,982</ix:nonFraction> shares of common stock indirectly through an entity he controls, and (ii) Mr. Lenz purchased <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" id="Fact_d85cd60f028a409dada1eed69a529e37" contextRef="c20221209to20221209_RelatedPartyTransactionsByRelatedPartyAxis_RelatedPartyMember_TitleOfIndividualAxis_ExecutiveVicePresidentAndChiefFinancialOfficerMember" unitRef="U002" decimals="0" scale="0" format="ixt:num-dot-decimal">6,993</ix:nonFraction>
          shares of common stock, all at the public offering price of $<ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" id="Fact_1a868ed132da4763b926db93443daea4" contextRef="c20221209_RelatedPartyTransactionsByRelatedPartyAxis_RelatedPartyMember_TitleOfIndividualAxis_ExecutiveVicePresidentAndChiefFinancialOfficerMember" unitRef="U003" decimals="2" scale="0" format="ixt:num-dot-decimal">2.86</ix:nonFraction> per share. </div>
</ix:continuation>
        <div><br/></div>

      </div>

    </div>

  </div>


  <div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: rgb(0, 0, 0);">
    <div>
      <div style="text-align: left; font: 10pt 'Times New Roman';">
        <ix:nonNumeric name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="Text_3764710572044ead9e6dfb83c5c95cdc" contextRef="c20240101to20241231" escape="true" continuedAt="Text_c5712140386548d5ac59a9c977c131c81">
<div>
          <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt; border-spacing: 0;">


  <tr style="vertical-align: top;">

    <td style="vertical-align: top; width: 27pt;">
                  <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;"><strong>10.</strong></p>
                </td>

    <td style="align: left; vertical-align: top; width: auto;">
                  <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;"><span style="text-decoration: underline;"><span style="background-color: rgb(255, 255, 255); font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><strong>COMMITMENTS AND CONTINGENCIES</strong></span></span><strong><span style="text-decoration: underline;"><br/>
                      </span></strong></p>
                </td>

  </tr>


</table>
        </div>
</ix:nonNumeric>
        <ix:continuation id="Text_c5712140386548d5ac59a9c977c131c81" continuedAt="Text_c5712140386548d5ac59a9c977c131c82"><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;">&#160;</p></ix:continuation>
        <ix:continuation id="Text_c5712140386548d5ac59a9c977c131c82" continuedAt="Text_c5712140386548d5ac59a9c977c131c83"><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;"><span style="text-decoration:underline">General Legal Matters</span></p></ix:continuation>
        <ix:continuation id="Text_c5712140386548d5ac59a9c977c131c83" continuedAt="Text_c5712140386548d5ac59a9c977c131c84"><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;">&#160;</p></ix:continuation>
        <ix:continuation id="Text_c5712140386548d5ac59a9c977c131c84" continuedAt="Text_c5712140386548d5ac59a9c977c131c85"><p style="margin: 0px; font-family: 'Times New Roman'; font-size: 10pt; text-align: left; text-indent: 36pt;">From time to time the Company is or may become subject to certain legal proceedings and claims arising in connection with the normal
          course of its business. Management does not expect that the outcome of any such claims or actions will have a material effect on the Company&#8217;s liquidity, results of operations or financial condition.</p></ix:continuation>
        <ix:continuation id="Text_c5712140386548d5ac59a9c977c131c85" continuedAt="Text_c5712140386548d5ac59a9c977c131c86"><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;">&#160;</p></ix:continuation>
        <ix:continuation id="Text_c5712140386548d5ac59a9c977c131c86" continuedAt="Text_c5712140386548d5ac59a9c977c131c87"><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;"><span style="text-decoration:underline">IT Systems Disruption</span></p></ix:continuation>
        <ix:continuation id="Text_c5712140386548d5ac59a9c977c131c87" continuedAt="Text_c5712140386548d5ac59a9c977c131c88"><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;">&#160;</p></ix:continuation>
        <ix:continuation id="Text_c5712140386548d5ac59a9c977c131c88" continuedAt="Text_c5712140386548d5ac59a9c977c131c89"><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-indent: 45px; text-align: left;"> </p></ix:continuation>
        <ix:continuation id="Text_c5712140386548d5ac59a9c977c131c89" continuedAt="Text_c5712140386548d5ac59a9c977c131c810">
<div style="display:none;"><br/></div>
<div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; text-indent: 36pt;">On June 19, 2023, the Company experienced an IT systems disruption, which rendered certain of the Company&#8217;s IT technology
          systems inaccessible for less than <span style="-sec-ix-hidden:Fact_4754ce8ea55d44e195b5e28a95f3e9f0">one</span> week. The Company&#8217;s investigation of the disruption has essentially been completed with the
          assistance of third-party consultants, and no definitive root cause was identified. At the time of the disruption, the Company was in production of <ix:nonFraction name="adma:NumberOfBatchesInProductionAtTheTimeOfDisruption" id="Fact_34fa1d4cc4494acd8e3e801bea3409bf" contextRef="c20230619to20230619" unitRef="U010" decimals="INF" scale="0" format="ixt-sec:numwordsen">two</ix:nonFraction>
          batches of BIVIGAM, and after a prolonged hold time, it was deemed to be a prudent GMP quality decision to discard these <ix:nonFraction name="adma:NumberOfBatchesInProductionAtTheTimeOfDisruption" id="Fact_bb82d26ddc944240a0480d393b8390fb" contextRef="c20230619to20230619" unitRef="U010" decimals="INF" scale="0" format="ixt-sec:numwordsen">two</ix:nonFraction>
          in-process production batches as these batches were no longer viable for further production or had any alternative use. As a result, the Company recorded a one-time, non-recurring charge of $<ix:nonFraction name="us-gaap:InventoryWriteDown" id="Fact_9a38b7f121254b83b7c6661f8a9442e1" contextRef="c20230401to20230630" unitRef="U001" decimals="-5" scale="6" format="ixt:num-dot-decimal">2.1</ix:nonFraction> million in the second quarter of 2023 for this inventory, which is reflected in Cost of product revenue in the accompanying consolidated statement of operations for the year ending
          December 31, 2023. In addition, the Company&#8217;s Plasma center operating expenses were adversely impacted by approximately $<ix:nonFraction name="us-gaap:OtherCostAndExpenseOperating" id="Fact_ab59fb8b1a494363bc1953dfc4ac4a62" contextRef="c20230401to20230630" unitRef="U001" decimals="-5" scale="6" format="ixt:num-dot-decimal">0.7</ix:nonFraction> million
          due to the temporary closing of the Company&#8217;s plasma collection centers while their IT systems were restored.</div>
</ix:continuation>
        <ix:continuation id="Text_c5712140386548d5ac59a9c977c131c810" continuedAt="Text_c5712140386548d5ac59a9c977c131c811">
<div style="display:none;"><br/></div>
<div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; text-indent: 36pt;"> <br/>
        </div>
</ix:continuation>
        <ix:continuation id="Text_c5712140386548d5ac59a9c977c131c811" continuedAt="Text_c5712140386548d5ac59a9c977c131c812">
<div style="display:none;"><br/></div>
<div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; text-indent: 36pt;"> The Company carries appropriate insurance for these types of instances. During each of the years ended December 31, 2024 and
          2023, the Company&#8217;s cybersecurity insurer paid the Company an aggregate of $<ix:nonFraction name="adma:RestorationCostsReceived" id="Fact_251584b58f804f2493bf01047265d992" contextRef="c20230101to20231231" unitRef="U001" decimals="-5" scale="6" format="ixt:num-dot-decimal"><ix:nonFraction name="adma:RestorationCostsReceived" id="Fact_12ff9470323c47de98fd7cd55e674388" contextRef="c20240101to20241231" unitRef="U001" decimals="-5" scale="6" format="ixt:num-dot-decimal">0.2</ix:nonFraction></ix:nonFraction> million for approved restoration-related costs.&#160;
          During the first quarter of 2025, the Company&#8217;s cybersecurity insurer paid the Company $<ix:nonFraction name="us-gaap:ProceedsFromInsuranceSettlementOperatingActivities" id="Fact_e8a4b46ab388413ab82c33c22d032ac5" contextRef="c20250101to20250318_SubsequentEventTypeAxis_SubsequentEventMember" unitRef="U001" decimals="-5" scale="6" format="ixt:num-dot-decimal">0.4</ix:nonFraction> million in business interruption loss
          coverage.</div>
</ix:continuation>
      </div>

      <div style="text-align: left; font: 10pt 'Times New Roman';"> <ix:continuation id="Text_c5712140386548d5ac59a9c977c131c812" continuedAt="Text_c5712140386548d5ac59a9c977c131c813">
<div><br/></div>
</ix:continuation>
        <ix:continuation id="Text_c5712140386548d5ac59a9c977c131c813" continuedAt="Text_c5712140386548d5ac59a9c977c131c814"><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left; font-style: normal;"><span style="text-decoration:underline">Vendor Commitments</span></p></ix:continuation>
        <ix:continuation id="Text_c5712140386548d5ac59a9c977c131c814" continuedAt="Text_c5712140386548d5ac59a9c977c131c815"><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;">&#160;</p></ix:continuation>
        <ix:continuation id="Text_c5712140386548d5ac59a9c977c131c815" continuedAt="Text_c5712140386548d5ac59a9c977c131c816"><p style="margin: 0px; font-family: 'Times New Roman'; font-size: 10pt; text-align: left; text-indent: 36pt;">Pursuant to the terms of a Plasma Purchase Agreement dated as of November 17, 2011 (the &#8220;2011 Plasma Purchase Agreement&#8221;), the Company
          agreed to purchase from its former contract manufacturer an annual minimum volume of source plasma containing antibodies to RSV to be used in the manufacture of ASCENIV. The Company must purchase a to-be-determined and agreed upon annual minimum
          volume from the counterparty, and under the original 2011 Plasma Purchase Agreement the Company was permitted to also collect high-titer plasma from up to <ix:nonFraction name="adma:NumberOfPlasmaCollectionFacilities" id="Fact_b99e96ac92f34dd9b64dfcc8cc4d8aed" contextRef="c20240101to20241231_RangeAxis_MaximumMember_TypeOfArrangementAxis_PlasmaPurchaseAgreementOneMember" unitRef="U004" decimals="INF" scale="0" format="ixt-sec:numwordsen">five</ix:nonFraction> wholly-owned ADMA plasma collection facilities. During 2015, the Company amended the 2011 Plasma Purchase Agreement to (i) allow the Company to collect its raw material high-titer
          plasma from any number of wholly-owned ADMA plasma collection facilities and (ii) allow the Company to purchase its raw material high-titer plasma from other third-party collection organizations, in each case, provided that the annual minimum
          volumes from the Company&#8217;s former contract manufacturer were met, thus allowing the Company to expand its reach for raw material supply as it executes its commercialization plans for ASCENIV. On December 10, 2018, the Company&#8217;s former contract
          manufacturer assigned its rights and obligations under the 2011 Plasma Purchase Agreement to Grifols Worldwide Operations Limited (&#8220;Grifols&#8221;) as its successor-in-interest, effective January 1, 2019. Effective October 1, 2024, the Company entered
          into an Amended and Restated Plasma Purchase Agreement with Grifols (the &#8220;A&amp;R Grifols Agreement&#8221;) with a term expiring in <span style="-sec-ix-hidden:Fact_596502cac0e64068963eb61419709634">September 2039</span>,
          after which it may be renewed for <ix:nonFraction name="adma:NumberOfRenewalTerms" id="Fact_718fb7633ede4a02be83f48f3b0fda6a" contextRef="c20241001to20241001_TypeOfArrangementAxis_ARGrifolsAgreementMember" unitRef="U011" decimals="INF" scale="0" format="ixt-sec:numwordsen">two</ix:nonFraction> additional multi-year periods if agreed to by the parties. Pursuant to the A&amp;R Grifols
          Agreement, Grifols supplies, on a non-exclusive basis, to ADMA BioManufacturing a minimum of <ix:nonFraction name="adma:QuantityOfRespiratorySyncytialVirusPlasmaUsed" id="Fact_442ef8ce2d5042579eb510f53c250d0a" contextRef="c20241001to20241001_RangeAxis_MinimumMember_TypeOfArrangementAxis_ARGrifolsAgreementMember" unitRef="U012" decimals="0" scale="0" format="ixt:num-dot-decimal">35,000</ix:nonFraction> liters of RSV plasma annually to
          be used in the manufacture of ASCENIV, with an escalating price per liter depending on the volume supplied in a given <ix:nonNumeric name="adma:RespiratorySyncytialVirusPlasmaVolumeSuppliedPeriod" id="Fact_8c0d6d6afb4c4b44889c290b95a36a1a" contextRef="c20240101to20241231_TypeOfArrangementAxis_ARGrifolsAgreementMember" format="ixt-sec:durwordsen">12-month</ix:nonNumeric> period,
          with a minimum annual price increase every <ix:nonNumeric name="adma:IncreaseInMinimumAnnualPriceTerm" id="Fact_71326e76750749089b06bd3784ce77e9" contextRef="c20240101to20241231_TypeOfArrangementAxis_ARGrifolsAgreementMember" format="ixt-sec:durwordsen">12 months</ix:nonNumeric>.&#160; Additionally, Grifols will be entitled to receive a fixed bonus payment in the
          event that a specified liter amount of high-titer plasma is supplied to the Company in any <ix:nonNumeric name="adma:RespiratorySyncytialVirusPlasmaVolumeSuppliedPeriod" id="Fact_4817b31887004ebb9152e60edb77d432" contextRef="c20240101to20241231_TypeOfArrangementAxis_ARGrifolsAgreementMember" format="ixt-sec:durwordsen">12-month</ix:nonNumeric> period during the term of the
          A&amp;R Grifols Agreement.</p></ix:continuation>
        <ix:continuation id="Text_c5712140386548d5ac59a9c977c131c816" continuedAt="Text_c5712140386548d5ac59a9c977c131c817"><p style="margin: 0px; font-family: 'Times New Roman'; font-size: 10pt; text-align: left; text-indent: 36pt;"> <br/>
        </p></ix:continuation>
        <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
          <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">F-28</span></div>

          <div class="BRPFPageBreak" style="page-break-after: always;">
            <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"/></div>

          <div style="width: 100%;" class="BRPFPageHeader">
            <div>
              <div style="text-align: left; font-weight: bold; text-indent: -9pt; margin-left: 9pt;"><a href="#ADMABIOLOGICSINC."> <span style="font-style: italic; font-weight: normal; font-size: 8pt;">Table of Contents</span></a><br/>
              </div>

              <div style="text-align: left; font-weight: bold; text-indent: -9pt; margin-left: 9pt;"><a href="#ADMABIOLOGICSINC."><span style="font-style: italic; font-weight: normal; font-size: 8pt;"> <br/>
                  </span></a></div>

              <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">ADMA BIOLOGICS, INC. AND SUBSIDIARIES</div>

              <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</div>

            </div>

          </div>

        </div>

        <ix:continuation id="Text_c5712140386548d5ac59a9c977c131c817" continuedAt="Text_c5712140386548d5ac59a9c977c131c818"><p style="margin: 0px; font-family: 'Times New Roman'; font-size: 10pt; text-align: left; text-indent: 36pt;">Effective August 6, 2024, the Company entered into a Plasma Purchase Agreement with KEDPlasma LLC (&#8220;KEDPlasma&#8221;) with a term expiring in <span style="-sec-ix-hidden:Fact_08cb0657423a4fc9a23ab84cedf6874f">July 2031</span>, after which it may be renewed for an additional <ix:nonNumeric name="adma:PlasmaPurchaseAgreementRenewalPeriod" id="Fact_d78ce8d2f8144bf5acdf5021981f2378" contextRef="c20240101to20241231_TypeOfArrangementAxis_KEDPlasmaAgreementMember" format="ixt-sec:durwordsen">five-year</ix:nonNumeric> period if agreed to by the parties (the &#8220;KEDPlasma Agreement&#8221;).&#160; Pursuant to the KEDPlasma Agreement, KEDPlasma supplies, on a non-exclusive basis, to ADMA BioManufacturing a minimum of <ix:nonFraction name="adma:QuantityOfRespiratorySyncytialVirusPlasmaUsed" id="Fact_42ccf61e34c2403a8778ac785ef88e5e" contextRef="c20240806to20240806_RangeAxis_MinimumMember_TypeOfArrangementAxis_KEDPlasmaAgreementMember" unitRef="U012" decimals="0" scale="0" format="ixt:num-dot-decimal">35,000</ix:nonFraction> liters of RSV plasma annually commencing with the <ix:nonNumeric name="adma:RespiratorySyncytialVirusPlasmaVolumeSuppliedPeriod" id="Fact_92daecc2b4b740a5b7a52a826f4a052c" contextRef="c20240101to20241231_TypeOfArrangementAxis_KEDPlasmaAgreementMember" format="ixt-sec:durwordsen">12-month</ix:nonNumeric>
          period ending July 31, 2026, with an escalating price per liter depending on the volume supplied in a given <ix:nonNumeric name="adma:RespiratorySyncytialVirusPlasmaVolumeSuppliedPeriod" id="Fact_84ec38ceca094e1bac9049a9cdb12350" contextRef="c20240101to20241231_TypeOfArrangementAxis_KEDPlasmaAgreementMember" format="ixt-sec:durwordsen">12-month</ix:nonNumeric> period. The price
          per liter of high-titer plasma supplied pursuant to the KEDPlasma Agreement is also scheduled to increase on an annual basis. Additionally, KEDPlasma will be entitled to receive a fixed bonus payment in the event that a specified liter amount of
          RSV plasma is supplied to the Company in any <ix:nonNumeric name="adma:RespiratorySyncytialVirusPlasmaVolumeSuppliedPeriod" id="Fact_4e45db2701b4442fafbe40dc1219b7a8" contextRef="c20240101to20241231_TypeOfArrangementAxis_KEDPlasmaAgreementMember" format="ixt-sec:durwordsen">12-month</ix:nonNumeric> period during the term of the KEDPlasma Agreement. </p></ix:continuation>
      </div>

      <ix:continuation id="Text_c5712140386548d5ac59a9c977c131c818" continuedAt="Text_c5712140386548d5ac59a9c977c131c819">
<div><br/></div>
</ix:continuation>
      <div style="text-align: left; font: 10pt 'Times New Roman';">
        <ix:continuation id="Text_c5712140386548d5ac59a9c977c131c819" continuedAt="Text_c5712140386548d5ac59a9c977c131c820"><p style="margin: 0px; font-family: 'Times New Roman'; font-size: 10pt; text-align: left; text-indent: 36pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">On June 6, 2017, the Company entered into a Plasma Supply Agreement with its former contract manufacturer, pursuant to which the counterparty supplies, on an exclusive basis subject to certain exceptions, to ADMA BioManufacturing an annual
          minimum volume of hyperimmune plasma that contain antibodies to the Hepatitis B virus for the manufacture of Nabi-HB. The Plasma Supply Agreement has a <ix:nonNumeric name="adma:PlasmaSupplyAgreementTerm" id="Fact_566e61ac8bae440e8eb3546ca1cf2796" contextRef="c20240101to20241231" format="ixt-sec:durwordsen">10-year</ix:nonNumeric>
          term. On July 19, 2018, <span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; text-align: left; text-indent: 48px; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">the Plasma Supply Agreement was amended to provide, among other things, that in the event the counterparty elects not to supply in excess of ADMA BioManufacturing&#8217;s
            specified amount of Hepatitis B plasma and ADMA BioManufacturing is unable to secure Hepatitis B plasma from a third party at a price that is within a low double- digit percentage of the price that ADMA BioManufacturing pays to the
            counterparty, then the counterparty shall reimburse ADMA BioManufacturing for the difference in price ADMA BioManufacturing incurs. On December 10, 2018, the Company&#8217;s former contract manufacturer assigned its rights and obligations under the
            Plasma Supply Agreement to Grifols, effective January 1, 201</span>9.</p></ix:continuation>
        <ix:continuation id="Text_c5712140386548d5ac59a9c977c131c820" continuedAt="Text_c5712140386548d5ac59a9c977c131c821">
<div><br/></div>
</ix:continuation>
        <ix:continuation id="Text_c5712140386548d5ac59a9c977c131c821" continuedAt="Text_c5712140386548d5ac59a9c977c131c822"><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left; font-style: normal;"><span style="text-decoration:underline">Post-Marketing Commitments</span></p></ix:continuation>
        <ix:continuation id="Text_c5712140386548d5ac59a9c977c131c822" continuedAt="Text_c5712140386548d5ac59a9c977c131c823"><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;">&#160;</p></ix:continuation>
        <ix:continuation id="Text_c5712140386548d5ac59a9c977c131c823" continuedAt="Text_c5712140386548d5ac59a9c977c131c824"><p style="margin: 0px; font-family: 'Times New Roman'; font-size: 10pt; text-align: left; text-indent: 36pt;"> In connection with the FDA approval of ASCENIV on April 1, 2019, the Company is required to perform a pediatric study to evaluate the
          safety and efficacy of ASCENIV in children and adolescents, for which patient enrollment has been successfully completed. For the years ended December 31, 2024, 2023 and 2022, the Company incurred expenses related to this study in the amount of $<ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" id="Fact_7f8c4dfa57a740cd8d3baf1e2d7623ed" contextRef="c20240101to20241231_ProductOrServiceAxis_ASCENIVMember" unitRef="U001" decimals="-5" scale="6" format="ixt:num-dot-decimal">1.2</ix:nonFraction> million, $<ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" id="Fact_334f15802b3f420e941d3e5127f05b17" contextRef="c20230101to20231231_ProductOrServiceAxis_ASCENIVMember" unitRef="U001" decimals="-5" scale="6" format="ixt:num-dot-decimal">1.0</ix:nonFraction> million and $<ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" id="Fact_e2915302d1ec485baf32dbbc3e82a5fd" contextRef="c20220101to20221231_ProductOrServiceAxis_ASCENIVMember" unitRef="U001" decimals="-5" scale="6" format="ixt:num-dot-decimal">0.5</ix:nonFraction> million, respectively. The Company expects to incur expenses of approximately $<ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" id="Fact_294ac1199fe84e5491e99603b6bab1c4" contextRef="c20190401to20190401" unitRef="U001" decimals="-5" scale="6" format="ixt:num-dot-decimal">1.0</ix:nonFraction> million to complete this study, which is required to be completed by June of 2026.</p></ix:continuation>
        <ix:continuation id="Text_c5712140386548d5ac59a9c977c131c824" continuedAt="Text_c5712140386548d5ac59a9c977c131c825"><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;"> <br/>
        </p></ix:continuation>
        <ix:continuation id="Text_c5712140386548d5ac59a9c977c131c825" continuedAt="Text_c5712140386548d5ac59a9c977c131c826"><p style="margin: 0px; font-family: 'Times New Roman'; font-size: 10pt; text-align: left; text-indent: 36pt;"> In connection with the FDA approval of the BLA for BIVIGAM on December 19, 2012, Biotest committed to perform two additional
          post-marketing studies, a pediatric study to evaluate the efficacy and safety of BIVIGAM in children and adolescents, and a post-authorization safety study to further assess the potential risk of hypotension and hepatic and renal impairment in
          BIVIGAM-treated patients with primary humoral immunodeficiency. These studies were required to be completed by June 30, 2023. Both studies have been completed and the study reports have been submitted to the FDA. ADMA had assumed the remaining
          obligations, and the costs of the studies were expensed as incurred as research and development expenses. The Company did <ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" id="Fact_61cb6030c7dd4741b4432499b4e0bb4a" contextRef="c20240101to20241231_ProductOrServiceAxis_BIVIGAMMember" unitRef="U001" decimals="-6" scale="6" format="ixt-sec:numwordsen">no</ix:nonFraction>t incur
          any expenses related to this commitment for the year ended December 31, 2024. For the years ended December 31, 2023 and 2022, the Company incurred expenses related to these studies of $<ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" id="Fact_98e893f87fc9410c8d2d78b02d6b4955" contextRef="c20230101to20231231_ProductOrServiceAxis_BIVIGAMMember" unitRef="U001" decimals="-5" scale="6" format="ixt:num-dot-decimal">1.7</ix:nonFraction> million and $<ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" id="Fact_626a03f4e9d641d388821e912a0c20b2" contextRef="c20220101to20221231_ProductOrServiceAxis_BIVIGAMMember" unitRef="U001" decimals="-5" scale="6" format="ixt:num-dot-decimal">2.2</ix:nonFraction> million, respectively.</p></ix:continuation>
        <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial;">
          <ix:continuation id="Text_c5712140386548d5ac59a9c977c131c826" continuedAt="Text_c5712140386548d5ac59a9c977c131c827">
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-size: 10pt;"><br/>
            </span> </div>
</ix:continuation>
        </div>

        <ix:continuation id="Text_c5712140386548d5ac59a9c977c131c827" continuedAt="Text_c5712140386548d5ac59a9c977c131c828">
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial;"><span style="text-decoration:underline">Other Commitments</span></div>
</ix:continuation>
        <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial;"> <ix:continuation id="Text_c5712140386548d5ac59a9c977c131c828" continuedAt="Text_c5712140386548d5ac59a9c977c131c829">
<div><span style="font-size: 10pt;"> </span></div>
</ix:continuation>
          <ix:continuation id="Text_c5712140386548d5ac59a9c977c131c829" continuedAt="Text_c5712140386548d5ac59a9c977c131c830">
<div style="display:none;"><br/></div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-indent: 36pt;"> <br/>
          </div>
</ix:continuation>
          <ix:continuation id="Text_c5712140386548d5ac59a9c977c131c830">
<div style="display:none;"><br/></div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-indent: 36pt;">In the normal course of business, the Company enters into contracts that contain a variety of indemnifications with its employees, licensors, suppliers and service
            providers. Further, the Company indemnifies its directors and officers who are, or were, serving at the Company&#8217;s request in such capacities. The Company&#8217;s maximum exposure under these arrangements is unknown as of December 31, 2024. The
            Company does not anticipate recognizing any significant losses relating to these arrangements.</div>
</ix:continuation>
           </div>

      </div>

    </div>

  </div>


  <div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: rgb(0, 0, 0);">
    <div>
      <div style="text-align: left; font: 10pt 'Times New Roman';">
        <div>
          <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
            <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">F-29</span></div>

            <div class="BRPFPageBreak" style="page-break-after: always;">
              <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: rgb(0, 0, 0); background-color: rgb(0, 0, 0);"/></div>

            <div style="width: 100%;" class="BRPFPageHeader">
              <div>
                <div style="text-align: left; font-weight: bold; text-indent: -9pt; margin-left: 9pt;"><a href="#ADMABIOLOGICSINC."> <span style="font-style: italic; font-weight: normal; font-size: 8pt;">Table of Contents</span></a><br/>
                </div>

                <div style="text-align: left; font-weight: bold; text-indent: -9pt; margin-left: 9pt;"><a href="#ADMABIOLOGICSINC."><span style="font-style: italic; font-weight: normal; font-size: 8pt;"> <br/>
                    </span></a></div>

                <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">ADMA BIOLOGICS, INC. AND SUBSIDIARIES</div>

                <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</div>

              </div>

            </div>

          </div>


          <ix:nonNumeric name="us-gaap:IncomeTaxDisclosureTextBlock" id="Text_858651dccc404c6b92b7cdef5e17400e" contextRef="c20240101to20241231" escape="true" continuedAt="Text_2c61ffa0f3be425dba9df6bdea8fd6641">
<table cellspacing="0" cellpadding="0" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt; border-spacing: 0;" class="DSPFListTable">


  <tr style="vertical-align: top;">

    <td style="vertical-align: top; width: 27pt;">
                  <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;"><strong>11.</strong></p>
                </td>

    <td style="vertical-align: top; width: auto;">
                  <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;"><span style="text-decoration: underline;"><span style="background-color: rgb(255, 255, 255); font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><strong>INCOME TAXES</strong></span></span><strong><span style="text-decoration: underline;"><br/>
                      </span></strong></p>
                </td>

  </tr>


</table>
</ix:nonNumeric>
        </div>

        <ix:continuation id="Text_2c61ffa0f3be425dba9df6bdea8fd6641" continuedAt="Text_2c61ffa0f3be425dba9df6bdea8fd6642"><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;">&#160;</p></ix:continuation>
        <ix:continuation id="Text_2c61ffa0f3be425dba9df6bdea8fd6642" continuedAt="Text_2c61ffa0f3be425dba9df6bdea8fd6643"><ix:nonNumeric name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" id="Text_53c101e371fa4c5f81f2da5a8248b8fc" contextRef="c20240101to20241231" escape="true" continuedAt="Text_07be0c57b5db40cebcd9266fdf5ad19d1"><p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-bottom: 0px; text-align: left;"> </p></ix:nonNumeric></ix:continuation>
        <ix:continuation id="Text_2c61ffa0f3be425dba9df6bdea8fd6643" continuedAt="Text_2c61ffa0f3be425dba9df6bdea8fd6644"><ix:continuation id="Text_07be0c57b5db40cebcd9266fdf5ad19d1" continuedAt="Text_07be0c57b5db40cebcd9266fdf5ad19d2"><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 36pt; text-align: left;">The components of the Company&#8217;s income tax expense (benefit) are as follows:<br/>
        </p></ix:continuation></ix:continuation>
        <ix:continuation id="Text_2c61ffa0f3be425dba9df6bdea8fd6644" continuedAt="Text_2c61ffa0f3be425dba9df6bdea8fd6645"><ix:continuation id="Text_07be0c57b5db40cebcd9266fdf5ad19d2" continuedAt="Text_07be0c57b5db40cebcd9266fdf5ad19d3"><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 36pt; text-align: left;"> <br/>
        </p></ix:continuation></ix:continuation>
        <ix:continuation id="Text_2c61ffa0f3be425dba9df6bdea8fd6645" continuedAt="Text_2c61ffa0f3be425dba9df6bdea8fd6646"><ix:continuation id="Text_07be0c57b5db40cebcd9266fdf5ad19d3" continuedAt="Text_07be0c57b5db40cebcd9266fdf5ad19d4"><p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-bottom: 0px; text-align: left;"> </p></ix:continuation></ix:continuation>
        <ix:continuation id="Text_2c61ffa0f3be425dba9df6bdea8fd6646" continuedAt="Text_2c61ffa0f3be425dba9df6bdea8fd6647"><ix:continuation id="Text_07be0c57b5db40cebcd9266fdf5ad19d4">
<table cellspacing="0" cellpadding="0" border="0" style="text-align: left; font: 10pt 'Times New Roman'; width: 100%; border-spacing: 0;" class="cfttable">


  <tr style="height: 15px;">

    <td valign="bottom" style="padding-bottom: 2px;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px;">&#160;</p>
              </td>

    <td valign="bottom" style="text-align: center; vertical-align: bottom; padding-bottom: 2px;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: center; border-bottom: #000000 solid 2px;" rowspan="1" colspan="10">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: center;"><strong>Year Ended December 31,</strong></p>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="padding-bottom: 2px;" rowspan="1">&#160;</td>

    <td valign="bottom" style="text-align: center; vertical-align: bottom; padding-bottom: 2px;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: center; border-bottom: #000000 solid 2px;" rowspan="1" colspan="10"><span style="font-style: italic;">(In thousands) </span> <br/>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="vertical-align: bottom; padding: 0px 0px 2px; padding-bottom: 2px;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px;">&#160;</p>
              </td>

    <td valign="bottom" style="text-align: center; vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: center; border-bottom: 2px solid rgb(0, 0, 0);" colspan="2"><span style="font-weight: bold;">2024</span><br/>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: center; vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: center; border-bottom: 2px solid rgb(0, 0, 0);" colspan="2"><span style="font-weight: bold;">2023</span><br/>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: center; vertical-align: bottom; padding-bottom: 2px;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: center; border-bottom: 2px solid rgb(0, 0, 0);" rowspan="1" colspan="2"><span style="font-weight: bold;">2022</span><br/>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="vertical-align: top;">Current:<br/>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right;" colspan="2">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right;" colspan="2">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right;" colspan="2"><br/>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="vertical-align: top; text-indent: 9pt; width: 64%; background-color: #CCEEFF;">Federal<br/>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">$</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1"><ix:nonFraction name="us-gaap:CurrentFederalTaxExpenseBenefit" id="Fact_29d1c2aa57594c62b5dd51d05cc6d897" contextRef="c20240101to20241231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">10,434</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">$</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1"><ix:nonFraction name="us-gaap:CurrentFederalTaxExpenseBenefit" id="Fact_5928d131ec5241afa45cfaa56db7e2e5" contextRef="c20230101to20231231" unitRef="U001" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">$</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1"><ix:nonFraction name="us-gaap:CurrentFederalTaxExpenseBenefit" id="Fact_68bc306153ca42c4a76ec5d529fcb1c9" contextRef="c20220101to20221231" unitRef="U001" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="vertical-align: top; text-indent: 9pt; width: 64%; padding-bottom: 2px;">State<br/>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" colspan="1"><ix:nonFraction name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" id="Fact_b51edb75ea114ee0a12da235a3ce6879" contextRef="c20240101to20241231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,887</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" colspan="1"><ix:nonFraction name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" id="Fact_8bf36c661081486f9a1499a74931edc3" contextRef="c20230101to20231231" unitRef="U001" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1"><ix:nonFraction name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" id="Fact_59aa6d78cd22479abbec4b784177dff3" contextRef="c20220101to20221231" unitRef="U001" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="vertical-align: top; text-indent: 18pt; width: 64%; background-color: #CCEEFF;">Total current<br/>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1"><ix:nonFraction name="us-gaap:CurrentIncomeTaxExpenseBenefit" id="Fact_ea8e69ac73c4476298bff92c3cb4c8c8" contextRef="c20240101to20241231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">12,321</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1"><ix:nonFraction name="us-gaap:CurrentIncomeTaxExpenseBenefit" id="Fact_3b91ae13223c4982b5663c8dbc5c0cb1" contextRef="c20230101to20231231" unitRef="U001" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1"><ix:nonFraction name="us-gaap:CurrentIncomeTaxExpenseBenefit" id="Fact_3828fe73efbb43d88a66873ae08beefb" contextRef="c20220101to20221231" unitRef="U001" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="vertical-align: top; width: 64%;" rowspan="1">Deferred:<br/>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" rowspan="1" colspan="1"><br/>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="vertical-align: top; text-indent: 9pt; width: 64%; background-color: #CCEEFF;" rowspan="1">Federal<br/>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" rowspan="1" colspan="1">(<ix:nonFraction name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" id="Fact_3434b7f5b7c64bc8a11ec4ef29fce9df" contextRef="c20240101to20241231" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">72,858</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">)</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" id="Fact_53a1fe926f974a30b74f493cc7d93095" contextRef="c20230101to20231231" unitRef="U001" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" id="Fact_dd19071a896e4d8e92f1435b43aa89b7" contextRef="c20220101to20221231" unitRef="U001" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="vertical-align: top; text-indent: 9pt; width: 64%; padding-bottom: 2px;">State<br/>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" colspan="1">(<ix:nonFraction name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" id="Fact_46d76394f880404dae9ef0e7e2bde0e8" contextRef="c20240101to20241231" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">11,422</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">)</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" colspan="1"><ix:nonFraction name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" id="Fact_da3e343c8cc94a7c9667a6359185f676" contextRef="c20230101to20231231" unitRef="U001" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1"><ix:nonFraction name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" id="Fact_b757f0a08e8944d79dbd55784dc178e7" contextRef="c20220101to20221231" unitRef="U001" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="vertical-align: top; text-indent: 18pt; width: 64%; padding-bottom: 2px; background-color: #CCEEFF;" rowspan="1">Total deferred<br/>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" rowspan="1" colspan="1">(<ix:nonFraction name="us-gaap:DeferredIncomeTaxExpenseBenefit" id="Fact_19364bf7dd4d4790b6560a1bf9d0359b" contextRef="c20240101to20241231" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">84,280</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">)</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:DeferredIncomeTaxExpenseBenefit" id="Fact_ea0bf190102e419a8ec4f7daa9a7ef1d" contextRef="c20230101to20231231" unitRef="U001" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:DeferredIncomeTaxExpenseBenefit" id="Fact_bde1a1c8ffe044548f5b60d7118b900f" contextRef="c20220101to20221231" unitRef="U001" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="vertical-align: top; width: 64%; padding-bottom: 4px;">Total benefit from income taxes<br/>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" colspan="1">$</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" colspan="1">(<ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" id="Fact_35b7a3e2569b4875b2267896557edfdd" contextRef="c20240101to20241231" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">71,959</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" colspan="1">)</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" colspan="1">$</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" colspan="1"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" id="Fact_89cb54cf420d47e08e3e27a48300b387" contextRef="c20230101to20231231" unitRef="U001" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" colspan="1">$</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" colspan="1"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" id="Fact_22dd55e791484be2a4425e264a6f028f" contextRef="c20220101to20221231" unitRef="U001" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>


</table>
</ix:continuation></ix:continuation>

        <ix:continuation id="Text_2c61ffa0f3be425dba9df6bdea8fd6647" continuedAt="Text_2c61ffa0f3be425dba9df6bdea8fd6648"><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;"> <br/>
        </p></ix:continuation>

        <ix:continuation id="Text_2c61ffa0f3be425dba9df6bdea8fd6648" continuedAt="Text_2c61ffa0f3be425dba9df6bdea8fd6649"><ix:nonNumeric name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="Text_f0d42a4f475c4fc68acb5e7fba470fa9" contextRef="c20240101to20241231" escape="true" continuedAt="Text_7d91e223c0214125a902845a462d40711"><p style="margin: 0px; font-family: 'Times New Roman'; font-size: 10pt; text-align: left; text-indent: 36pt;">A reconciliation of income taxes at the U.S. federal statutory rate to the benefit for income taxes is as follows:</p></ix:nonNumeric></ix:continuation>
        <ix:continuation id="Text_2c61ffa0f3be425dba9df6bdea8fd6649" continuedAt="Text_2c61ffa0f3be425dba9df6bdea8fd66410"><ix:continuation id="Text_7d91e223c0214125a902845a462d40711" continuedAt="Text_7d91e223c0214125a902845a462d40712"><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;">&#160;</p></ix:continuation></ix:continuation>
        <ix:continuation id="Text_2c61ffa0f3be425dba9df6bdea8fd66410" continuedAt="Text_2c61ffa0f3be425dba9df6bdea8fd66411"><ix:continuation id="Text_7d91e223c0214125a902845a462d40712">
<table cellspacing="0" cellpadding="0" border="0" style="text-align: left; font: 10pt 'Times New Roman'; width: 100%; border-spacing: 0;" class="cfttable">


  <tr style="height: 15px;">

    <td valign="bottom" style="padding-bottom: 2px;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px;">&#160;</p>
              </td>

    <td valign="bottom" style="text-align: center; vertical-align: bottom; padding-bottom: 2px;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: center; border-bottom: #000000 solid 2px;" rowspan="1" colspan="10">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: center;"><strong>Year Ended December 31,</strong></p>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="padding-bottom: 2px;" rowspan="1">&#160;</td>

    <td valign="bottom" style="text-align: center; vertical-align: bottom; padding-bottom: 2px;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: center; border-bottom: #000000 solid 2px;" rowspan="1" colspan="10"><span style="font-style: italic;">(In thousands) </span> <br/>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="padding-bottom: 2px;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px;">&#160;</p>
              </td>

    <td valign="bottom" style="text-align: center; vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: center; border-bottom: #000000 solid 2px;" colspan="2"><span style="font-weight: bold;">2024</span><br/>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: center; vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: center; border-bottom: #000000 solid 2px;" colspan="2"><span style="font-weight: bold;">2023</span><br/>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: center; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: center; vertical-align: bottom; border-bottom: #000000 solid 2px;" rowspan="1" colspan="2"><span style="font-weight: bold;">2022</span><br/>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="vertical-align: top; width: 64%; background-color: rgb(204, 238, 255);">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-bottom: 0px; text-indent: -9pt; margin-left: 9pt;">Tax provision (benefit) at U.S. federal statutory rate</p>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">$</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" id="Fact_e8916b8fa9624552a7d60c2c9d39ac77" contextRef="c20240101to20241231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">26,400</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">$</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">(<ix:nonFraction name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" id="Fact_ee69eadd0f52485d9dfc2ab6e9b87ded" contextRef="c20230101to20231231" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">5,930</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">)</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">$</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">(<ix:nonFraction name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" id="Fact_bd98861f7d754d6b9e52748e63924fab" contextRef="c20220101to20221231" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">13,840</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">)</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="vertical-align: top; width: 64%;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-bottom: 0px; text-indent: -9pt; margin-left: 9pt;">State taxes<span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">,</span> net of federal benefit<br/>
                </p>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">(<ix:nonFraction name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" id="Fact_e28e7806781f488ebab0219b57716114" contextRef="c20240101to20241231" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">9,931</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">)</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">(<ix:nonFraction name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" id="Fact_5988ddd8d6374bbdab8b5ffb199d27e7" contextRef="c20230101to20231231" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">763</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">)</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" colspan="1">(<ix:nonFraction name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" id="Fact_fc79db6ada3444fabfc8b6926eb1a829" contextRef="c20220101to20221231" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">1,773</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">)</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="vertical-align: top; width: 64%; background-color: rgb(204, 238, 255);" rowspan="1">
                <div style="text-indent: -9pt; margin-left: 9pt;">Non-deductible executive compensation<br/>
                </div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" rowspan="1" colspan="1">
                <div><ix:nonFraction name="us-gaap:IncomeTaxReconciliationNondeductibleExpense" id="Fact_6d317bd7bceb41bbbabdc31766e2d733" contextRef="c20240101to20241231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,340</ix:nonFraction></div>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationNondeductibleExpense" id="Fact_04cd55ab1a1640038827dbe4598526f7" contextRef="c20230101to20231231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">983</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationNondeductibleExpense" id="Fact_e1858b2cc8df461b874af9acc2c5fcd9" contextRef="c20220101to20221231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">862</ix:nonFraction><br/>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="vertical-align: top; width: 64%;" rowspan="1">
                <div style="text-indent: -9pt; margin-left: 9pt;">Excess tax benefits related to stock-based compensation<br/>
                </div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" rowspan="1" colspan="1">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" id="Fact_d9983c0f86464eb5b77e83f33771ab05" contextRef="c20240101to20241231" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">5,661</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">)</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" id="Fact_c9c647cd48f84c9d9957d9ac82c16ffb" contextRef="c20230101to20231231" unitRef="U001" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" id="Fact_bc76d864174144a8b7016255d3616b19" contextRef="c20220101to20221231" unitRef="U001" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction><br/>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="vertical-align: top; width: 64%; background-color: rgb(204, 238, 255);">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-bottom: 0px; text-indent: -9pt; margin-left: 9pt;">Change in valuation allowance</p>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">(<ix:nonFraction name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" id="Fact_e4292c6ddf8b42778a10e034d775e9f6" contextRef="c20240101to20241231" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">87,969</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">)</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" id="Fact_c46a0edea8484877a285da448a6f5759" contextRef="c20230101to20231231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,696</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" id="Fact_75182d53d6e64aed8c660677877ce2e9" contextRef="c20220101to20221231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">15,117</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="vertical-align: top; width: 64%; padding-bottom: 2px;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-bottom: 0px; text-indent: -9pt; margin-left: 9pt;">Other</p>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" colspan="1"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationOtherAdjustments" id="Fact_1d47aa877046431d83042c1fafa7aad4" contextRef="c20240101to20241231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">862</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" colspan="1"><ix:nonFraction name="us-gaap:IncomeTaxReconciliationOtherAdjustments" id="Fact_782d6daec74e43d1ad5834862de65851" contextRef="c20230101to20231231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,014</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">(<ix:nonFraction name="us-gaap:IncomeTaxReconciliationOtherAdjustments" id="Fact_59969f468ca540f1b516cfcffa1f1ca7" contextRef="c20220101to20221231" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">366</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">)</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="vertical-align: top; width: 64%; padding-bottom: 4px; background-color: rgb(204, 238, 255);">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-bottom: 0px; text-indent: -9pt; margin-left: 9pt;">Benefit for income taxes</p>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" colspan="1">$</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" colspan="1">(<ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" id="Fact_8e5e9ce76c684212b6c6b96face230bd" contextRef="c20240101to20241231" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">71,959</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">)</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" colspan="1">$</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" colspan="1"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" id="Fact_1afe101a8bd548d4975837d5ca60f7c0" contextRef="c20230101to20231231" unitRef="U001" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">$</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1"><ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" id="Fact_cbf50e56dc814195981d4fb89f097889" contextRef="c20220101to20221231" unitRef="U001" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>


</table>
</ix:continuation></ix:continuation>

        <ix:continuation id="Text_2c61ffa0f3be425dba9df6bdea8fd66411" continuedAt="Text_2c61ffa0f3be425dba9df6bdea8fd66412"><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;">&#160; &#160;</p></ix:continuation>
        <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
          <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">F-30</span></div>

          <div class="BRPFPageBreak" style="page-break-after: always;">
            <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"/></div>

          <div style="width: 100%;" class="BRPFPageHeader">
            <div>
              <div style="text-align: left; font-weight: bold; text-indent: -9pt; margin-left: 9pt;"><a href="#ADMABIOLOGICSINC."> <span style="font-style: italic; font-weight: normal; font-size: 8pt;">Table of Contents</span></a><br/>
              </div>

              <div style="text-align: left; font-weight: bold; text-indent: -9pt; margin-left: 9pt;"><a href="#ADMABIOLOGICSINC."><span style="font-style: italic; font-weight: normal; font-size: 8pt;"> <br/>
                  </span></a></div>

              <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">ADMA BIOLOGICS, INC. AND SUBSIDIARIES</div>

              <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</div>

            </div>

          </div>

        </div>


        <ix:continuation id="Text_2c61ffa0f3be425dba9df6bdea8fd66412" continuedAt="Text_2c61ffa0f3be425dba9df6bdea8fd66413"><ix:nonNumeric name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="Text_86e07ad8ed5344718e0d6fda9bf0c818" contextRef="c20240101to20241231" escape="true" continuedAt="Text_0456c0d866084e42be59e9e4d9bb04a31"><p style="margin: 0px; font-family: 'Times New Roman'; font-size: 10pt; text-align: left; text-indent: 36pt;">The significant components of the Company&#8217;s deferred tax assets are as follows:</p></ix:nonNumeric></ix:continuation>
        <ix:continuation id="Text_2c61ffa0f3be425dba9df6bdea8fd66413" continuedAt="Text_2c61ffa0f3be425dba9df6bdea8fd66414"><ix:continuation id="Text_0456c0d866084e42be59e9e4d9bb04a31" continuedAt="Text_0456c0d866084e42be59e9e4d9bb04a32"><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;">&#160;</p></ix:continuation></ix:continuation>
        <ix:continuation id="Text_2c61ffa0f3be425dba9df6bdea8fd66414" continuedAt="Text_2c61ffa0f3be425dba9df6bdea8fd66415"><ix:continuation id="Text_0456c0d866084e42be59e9e4d9bb04a32">
<table cellspacing="0" cellpadding="0" border="0" class="cfttable" style="text-align: left; font: 10pt 'Times New Roman'; width: 100%; border-spacing: 0;">


  <tr style="height: 15px;">

    <td valign="bottom" style="padding-bottom: 2px;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px;">&#160;</p>
              </td>

    <td valign="bottom" colspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="6" style="vertical-align: bottom; text-align: center; border-bottom: #000000 solid 2px;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: center;"><strong>Year Ended December 31,</strong></p>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="padding-bottom: 2px;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px;">&#160;</p>
              </td>

    <td valign="bottom" colspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: #000000 solid 2px;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: center;"><strong> 2024<br/>
                  </strong></p>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: #000000 solid 2px;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: center;"><strong>2023<br/>
                  </strong></p>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" rowspan="1">Deferred tax assets: <br/>
              </td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: center; vertical-align: bottom;">&#160;</td>

    <td valign="bottom" colspan="6" rowspan="1" style="vertical-align: bottom; text-align: center;"><span style="font-style: italic;">(in thousands)</span> <br/>
              </td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="vertical-align: top; width: 76%; background-color: #CCEEFF;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-indent: 9pt;">Federal and state net operating loss carryforwards</p>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">$</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic" id="Fact_d1b7e8b1dfa447db896d923996adb1c3" contextRef="c20241231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">65,615</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">$</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic" id="Fact_d5fdb4d673a04bb1bcc4ffe88b344ab2" contextRef="c20231231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">76,645</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="vertical-align: top; width: 76%;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-indent: 9pt;">Interest expense limitation carryforwards</p>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;"><ix:nonFraction name="us-gaap:DeferredTaxAssetInterestCarryforward" id="Fact_d3dcb1b0dc264f6c8e47cb70cf5ccf93" contextRef="c20241231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">13,604</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;"><ix:nonFraction name="us-gaap:DeferredTaxAssetInterestCarryforward" id="Fact_bb76cf7b993140cebd7977fffb6e6f6b" contextRef="c20231231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">21,165</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="vertical-align: top; width: 76%; background-color: #CCEEFF;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-indent: 9pt;">Inventory</p>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsInventory" id="Fact_610645c789094f8f8e3aad671e0b2334" contextRef="c20241231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,911</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsInventory" id="Fact_3ec53b78284b449b94877a3e26bba4b3" contextRef="c20231231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,937</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="vertical-align: top; width: 76%;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-indent: 9pt;">Stock-based compensation<br/>
                </p>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" id="Fact_32fa22ff77794a9ab004753a38403e7a" contextRef="c20241231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,523</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" id="Fact_bb6e624e729346c8a3a24349230cd169" contextRef="c20231231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,795</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" rowspan="1" style="vertical-align: top; text-indent: 9pt; width: 76%; background-color: #CCEEFF;">Lease obligations <br/>
              </td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><ix:nonFraction name="adma:DeferredTaxAssetsLeaseObligations" id="Fact_a66784a84be54e07b004ea2d0d93ebe5" contextRef="c20241231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,549</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><ix:nonFraction name="adma:DeferredTaxAssetsLeaseObligations" id="Fact_b16ad11b2dd94728ad03585587b7b9c2" contextRef="c20231231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,330</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="vertical-align: top; width: 76%; padding-bottom: 2px;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-indent: 9pt;">Accrued expenses and other</p>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" id="Fact_81f63bec5df94bc0a9e2cb15499959a5" contextRef="c20241231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">5,779</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" id="Fact_3d58947e399d464aa71cfa2348eaddd7" contextRef="c20231231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">5,831</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="vertical-align: top; width: 76%; background-color: #CCEEFF;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-bottom: 0px; text-indent: 9pt;">Total gross deferred tax assets</p>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsGross" id="Fact_9f80c16d582847deb77c37861c121edd" contextRef="c20241231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">93,981</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsGross" id="Fact_d1f578a118a34ec0a4182eaa34b11947" contextRef="c20231231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">110,703</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="vertical-align: top; width: 76%; padding-bottom: 2px;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in;">Less: valuation allowance for deferred tax assets</p>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsValuationAllowance" id="Fact_2682a714114d43179cbc8722291e2fc3" contextRef="c20241231" unitRef="U001" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;">(<ix:nonFraction name="us-gaap:DeferredTaxAssetsValuationAllowance" id="Fact_b67341e0bba8494dba75a59bf586dff4" contextRef="c20231231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">101,422</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">)</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" rowspan="1" style="vertical-align: top; text-indent: 18pt; width: 76%; background-color: #CCEEFF;">Total deferred tax assets, net of valuation allowance<br/>
              </td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsNet" id="Fact_65deac69914f4bf6a7b445d7fd7afd2b" contextRef="c20241231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">93,981</ix:nonFraction><br/>
              </td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsNet" id="Fact_77f9d4218a9c4c0cba82bc1208ade8bc" contextRef="c20231231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">9,281</ix:nonFraction><br/>
              </td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" rowspan="1" style="vertical-align: top; width: 76%;">Deferred tax liabilities:<br/>
              </td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" rowspan="1" style="vertical-align: top; text-indent: 9pt; width: 76%; background-color: #CCEEFF;">Depreciation of property and equipment <br/>
              </td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">(<ix:nonFraction name="adma:DeferredTaxLiabilitiesDepreciationOfPropertyAndEquipment" id="Fact_39cd3cfe97114b75846066bab11db026" contextRef="c20241231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">6,166</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">)</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;">(<ix:nonFraction name="adma:DeferredTaxLiabilitiesDepreciationOfPropertyAndEquipment" id="Fact_22580152a9344e52a504cdae64755bd3" contextRef="c20231231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">6,837</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">)</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" rowspan="1" style="vertical-align: top; text-indent: 9pt; width: 76%;">Right-of-use assets<br/>
              </td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">(<ix:nonFraction name="adma:DeferredTaxLiabilitiesRightOfUseAsset" id="Fact_080cb502bc1b4209bfe4075864f5bb02" contextRef="c20241231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,247</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">)</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">(<ix:nonFraction name="adma:DeferredTaxLiabilitiesRightOfUseAsset" id="Fact_dda8a4e0bcee43ffabbff198f2153868" contextRef="c20231231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,077</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">)</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" rowspan="1" style="vertical-align: top; text-indent: 9pt; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;">Other deferred tax liabilities <br/>
              </td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">(<ix:nonFraction name="us-gaap:DeferredTaxLiabilitiesOther" id="Fact_59394c2c73ea4a1da02a0f331bfedd35" contextRef="c20241231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,288</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">)</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">(<ix:nonFraction name="us-gaap:DeferredTaxLiabilitiesOther" id="Fact_4ad1622566f047a78f3b3bf9a41132f4" contextRef="c20231231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">367</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">)</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" rowspan="1" style="vertical-align: top; text-indent: 18pt; width: 76%; padding-bottom: 2px;">Total deferred tax liabilities <br/>
              </td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;">(<ix:nonFraction name="us-gaap:DeferredIncomeTaxLiabilities" id="Fact_c95031c4e99c4e4d933d005ecf5cee0d" contextRef="c20241231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">9,701</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">)</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;">&#160;</td>

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;">(<ix:nonFraction name="us-gaap:DeferredIncomeTaxLiabilities" id="Fact_fb256aa0b9e340cda3c41403b57d9841" contextRef="c20231231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">9,281</ix:nonFraction></td>

    <td valign="bottom" colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">)</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="vertical-align: top; width: 76%; padding-bottom: 4px; background-color: #CCEEFF;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in;">Net deferred tax assets</p>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;">$</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsLiabilitiesNet" id="Fact_be5b561db918419fa8920c1c9f97c7af" contextRef="c20241231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">84,280</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;">$</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;"><ix:nonFraction name="us-gaap:DeferredTaxAssetsLiabilitiesNet" id="Fact_bc34f141a3d94ae8a0001323fbbdb592" contextRef="c20231231" unitRef="U001" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>


</table>
</ix:continuation></ix:continuation>

        <ix:continuation id="Text_2c61ffa0f3be425dba9df6bdea8fd66415" continuedAt="Text_2c61ffa0f3be425dba9df6bdea8fd66416"><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;">&#160;</p></ix:continuation>
        <ix:continuation id="Text_2c61ffa0f3be425dba9df6bdea8fd66416" continuedAt="Text_2c61ffa0f3be425dba9df6bdea8fd66417"><p style="margin: 0px; font-family: 'Times New Roman'; font-size: 10pt; text-indent: 36pt;"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">As of December 31, 2024, the Company has federal and state (post-apportioned basis) net operating losses (&#8220;NOLs&#8221;) of $<ix:nonFraction name="us-gaap:OperatingLossCarryforwards" id="Fact_1b0cfd37782f4f28b9cdad0b14f6a48e" contextRef="c20241231_IncomeTaxAuthorityAxis_InternalRevenueServiceIRSMember" unitRef="U001" decimals="-5" scale="6" format="ixt:num-dot-decimal">265.6</ix:nonFraction> million and $<ix:nonFraction name="us-gaap:OperatingLossCarryforwards" id="Fact_5d177eb51b784a40b17cb28a3c9c7dfa" contextRef="c20241231_IncomeTaxAuthorityAxis_StateAndLocalJurisdictionMember" unitRef="U001" decimals="-5" scale="6" format="ixt:num-dot-decimal">204.0</ix:nonFraction> million, respectively. Approximately
            $<ix:nonFraction name="us-gaap:OperatingLossCarryforwards" id="Fact_5202c6981fcb4cf89134d7f9d7e57ff2" contextRef="c20241231_IncomeTaxAuthorityAxis_InternalRevenueServiceIRSMember_TaxPeriodAxis_TaxYear2028Through2043Member" unitRef="U001" decimals="-5" scale="6" format="ixt:num-dot-decimal">33.4</ix:nonFraction> million and $<ix:nonFraction name="us-gaap:OperatingLossCarryforwards" id="Fact_e70aaf9620ce420d95676de6f2640595" contextRef="c20241231_IncomeTaxAuthorityAxis_StateAndLocalJurisdictionMember_TaxPeriodAxis_TaxYear2028Through2043Member" unitRef="U001" decimals="-5" scale="6" format="ixt:num-dot-decimal">62.0</ix:nonFraction>
            million of the foregoing Federal and state NOLs, respectively, will expire at various dates from <span style="-sec-ix-hidden:Fact_3caad71a9a1b440ba964fc32940d472a">2029</span> through <span style="-sec-ix-hidden:Fact_8b85b23ae8fb4a49b2e8cb82e0d4603d">2043</span>, if not limited by triggering events prior to such time. </span>Under the provisions of the Internal Revenue Code, changes in ownership of the
          Company, in certain circumstances, would limit the amount of federal NOLs that can be utilized annually in the future to offset taxable income. In particular, Section 382 of the Internal Revenue Code (&#8220;Section 382&#8221;) imposes limitations on an
          entity&#8217;s ability to use NOLs upon certain changes in ownership. If the Company is limited in its ability to use its NOLs in future years in which it has taxable income, then the Company will pay more taxes than if it were otherwise able to fully
          utilize its NOLs. The Company may experience ownership changes in the future as a result of subsequent shifts in ownership of the Company&#8217;s capital stock that the Company cannot predict or control that could result in further limitations being
          placed on the Company&#8217;s ability to utilize its Federal NOLs. <ix:nonNumeric name="us-gaap:SummaryOfOperatingLossCarryforwardsTextBlock" id="Text_3fc9760ca72b430d9a98caf5f67b16bb" contextRef="c20240101to20241231" escape="true" continuedAt="Text_6b16a0938fd942ebabd8c8b6e7510bb31"><span style="font-family: 'Times New Roman'; font-size: 10pt; color: rgb(0, 0, 0);">The annual amount of Federal NOLs that expire each year is as follows (in thousands):<br/>
        </span></ix:nonNumeric></p></ix:continuation>
        <ix:continuation id="Text_2c61ffa0f3be425dba9df6bdea8fd66417" continuedAt="Text_2c61ffa0f3be425dba9df6bdea8fd66418"><ix:continuation id="Text_6b16a0938fd942ebabd8c8b6e7510bb31" continuedAt="Text_6b16a0938fd942ebabd8c8b6e7510bb32"><p style="margin: 0px; font-family: 'Times New Roman'; font-size: 10pt; text-indent: 36pt;"> <br/>
        </p></ix:continuation></ix:continuation>
        <ix:continuation id="Text_2c61ffa0f3be425dba9df6bdea8fd66418" continuedAt="Text_2c61ffa0f3be425dba9df6bdea8fd66419"><ix:continuation id="Text_6b16a0938fd942ebabd8c8b6e7510bb32" continuedAt="Text_6b16a0938fd942ebabd8c8b6e7510bb33"><p style="margin: 0px; font-family: 'Times New Roman'; font-size: 10pt; text-indent: 36pt;"> </p></ix:continuation></ix:continuation>
        <ix:continuation id="Text_2c61ffa0f3be425dba9df6bdea8fd66419" continuedAt="Text_2c61ffa0f3be425dba9df6bdea8fd66420"><ix:continuation id="Text_6b16a0938fd942ebabd8c8b6e7510bb33">
<table cellspacing="0" cellpadding="0" border="0" style="text-align: left; font: 10pt 'Times New Roman'; width: 100%; border-spacing: 0;" class="cfttable">


  <tr style="height: 15px;">

    <td colspan="1" rowspan="1" style="vertical-align: top; width: 12%; padding-top: 0px; padding-right: 0px; padding-left: 0px; text-align: center; border-bottom: 2px solid rgb(0, 0, 0);">Expiration Date</td>

    <td rowspan="1" style="vertical-align: top; width: 74%; padding: 0px 0px 2px;">&#160;<br/>
              </td>

    <td rowspan="1" style="vertical-align: bottom; white-space: nowrap; width: 1.18%; padding: 0px 0px 2px; text-align: right;" colspan="1">&#160;</td>

    <td rowspan="1" style="border-bottom: 2px solid; vertical-align: bottom; white-space: nowrap; text-align: center;" colspan="2">Remaining Available&#160; <br/>
              </td>

    <td rowspan="1" style="vertical-align: bottom; white-space: nowrap; width: 1.18%; padding: 0px 0px 2px; text-align: left;" colspan="1">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" rowspan="1" colspan="1" style="vertical-align: top; width: 12%; text-align: center; background-color: rgb(204, 238, 255);">2031</td>

    <td valign="bottom" rowspan="1" style="vertical-align: top; width: 74%; text-align: center; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1.18%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">$ <br/>
              </td>

    <td valign="bottom" rowspan="1" style="vertical-align: bottom; text-align: right; width: 11%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1"><ix:nonFraction name="us-gaap:OperatingLossCarryforwards" id="Fact_d4cbc36017504bcdaaf06fe72669073b" contextRef="c20241231_IncomeTaxAuthorityAxis_InternalRevenueServiceIRSMember_TaxPeriodAxis_TaxYear2031Member" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,409</ix:nonFraction></td>

    <td valign="bottom" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1.18%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" colspan="1" style="vertical-align: top; width: 12%; text-align: center;">2032 <br/>
              </td>

    <td valign="bottom" style="vertical-align: top; width: 74%; text-align: center;"><br/>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1.18%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;<br/>
              </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 11%; white-space: nowrap;" colspan="1"><ix:nonFraction name="us-gaap:OperatingLossCarryforwards" id="Fact_e4f06bf32b004e3f878fd2a0d85a35ea" contextRef="c20241231_IncomeTaxAuthorityAxis_InternalRevenueServiceIRSMember_TaxPeriodAxis_TaxYear2032Member" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">7,430</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1.18%; white-space: nowrap;" colspan="1"><br/>
              </td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" colspan="1" style="vertical-align: top; width: 12%; text-align: center; background-color: rgb(204, 238, 255);" rowspan="1">&#160;2033</td>

    <td valign="bottom" style="vertical-align: top; width: 74%; text-align: center; background-color: rgb(204, 238, 255);" rowspan="1"><br/>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1.18%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 11%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:OperatingLossCarryforwards" id="Fact_4fd1f29e0b6248b6859b256c7997e224" contextRef="c20241231_IncomeTaxAuthorityAxis_InternalRevenueServiceIRSMember_TaxPeriodAxis_TaxYear2033Member" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">11,295</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1.18%; background-color: rgb(204, 238, 255); white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" colspan="1" style="vertical-align: top; width: 12%; text-align: center;" rowspan="1">&#160;2034</td>

    <td valign="bottom" style="vertical-align: top; width: 74%; text-align: center;" rowspan="1"><br/>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1.18%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 11%; white-space: nowrap;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:OperatingLossCarryforwards" id="Fact_6d90c8df873d4acf95cade614cf1c29f" contextRef="c20241231_IncomeTaxAuthorityAxis_InternalRevenueServiceIRSMember_TaxPeriodAxis_TaxYear2034Member" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,025</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1.18%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" colspan="1" style="vertical-align: top; width: 12%; text-align: center; background-color: rgb(204, 238, 255);">&#160;2035</td>

    <td valign="bottom" style="vertical-align: top; width: 74%; text-align: center; background-color: rgb(204, 238, 255);"><br/>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1.18%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 11%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1"><ix:nonFraction name="us-gaap:OperatingLossCarryforwards" id="Fact_d5c9c0a238584e679b97e290e472dc15" contextRef="c20241231_IncomeTaxAuthorityAxis_InternalRevenueServiceIRSMember_TaxPeriodAxis_TaxYear2035Member" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,025</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1.18%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: top; width: 12%; text-align: center;">&#160;2036</td>

    <td valign="bottom" rowspan="1" style="vertical-align: top; width: 74%; text-align: center;"><br/>
              </td>

    <td valign="bottom" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1.18%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" rowspan="1" style="vertical-align: bottom; text-align: right; width: 11%; white-space: nowrap;" colspan="1"><ix:nonFraction name="us-gaap:OperatingLossCarryforwards" id="Fact_066a189d525a4b74bb1e541da704c342" contextRef="c20241231_IncomeTaxAuthorityAxis_InternalRevenueServiceIRSMember_TaxPeriodAxis_TaxYear2036Member" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,025</ix:nonFraction></td>

    <td valign="bottom" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1.18%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" colspan="1" rowspan="1" style="vertical-align: top; width: 12%; text-align: center; background-color: rgb(204, 238, 255);">&#160;2037</td>

    <td valign="bottom" rowspan="1" style="vertical-align: top; width: 74%; text-align: center; background-color: rgb(204, 238, 255);"><br/>
              </td>

    <td valign="bottom" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1.18%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" rowspan="1" style="vertical-align: bottom; text-align: right; width: 11%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1"><ix:nonFraction name="us-gaap:OperatingLossCarryforwards" id="Fact_9a8dbb2ea67c456fbac805cbb8e9529e" contextRef="c20241231_IncomeTaxAuthorityAxis_InternalRevenueServiceIRSMember_TaxPeriodAxis_TaxYear2037Member" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">9,157</ix:nonFraction></td>

    <td valign="bottom" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1.18%; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" colspan="1" style="vertical-align: top; width: 12%; padding-bottom: 2px; text-align: center;">&#160;Indefinite</td>

    <td valign="bottom" style="vertical-align: top; width: 74%; padding-bottom: 2px; text-align: center;"><br/>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1.18%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 11%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" colspan="1"><ix:nonFraction name="us-gaap:OperatingLossCarryforwards" id="Fact_4ec67351c26b4f4893655146eb2e38da" contextRef="c20241231_IncomeTaxAuthorityAxis_InternalRevenueServiceIRSMember_TaxPeriodAxis_TaxYearAfter2037Member" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">232,240</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1.18%; padding-bottom: 2px; white-space: nowrap;" colspan="1"><br/>
              </td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" colspan="1" style="vertical-align: top; width: 12%; text-align: center; padding-bottom: 4px; background-color: rgb(204, 238, 255);">&#160;Total</td>

    <td valign="bottom" style="vertical-align: top; width: 74%; text-align: center; padding-bottom: 4px; background-color: rgb(204, 238, 255);"><br/>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1.18%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">$</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 11%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1"><ix:nonFraction name="us-gaap:OperatingLossCarryforwards" id="Fact_6b6ce1f608824faf99ba605a9424b9fa" contextRef="c20241231_IncomeTaxAuthorityAxis_InternalRevenueServiceIRSMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">265,606</ix:nonFraction><br/>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1.18%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" colspan="1">&#160;</td>

  </tr>


</table>
</ix:continuation></ix:continuation>

        <ix:continuation id="Text_2c61ffa0f3be425dba9df6bdea8fd66420" continuedAt="Text_2c61ffa0f3be425dba9df6bdea8fd66421"><p style="margin: 0px; font-family: 'Times New Roman'; font-size: 10pt; text-indent: 36pt;"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"> <br/>
          </span></p></ix:continuation>
        <ix:continuation id="Text_2c61ffa0f3be425dba9df6bdea8fd66421" continuedAt="Text_2c61ffa0f3be425dba9df6bdea8fd66422"><p style="margin: 0px; font-family: 'Times New Roman'; font-size: 10pt; text-align: left; text-indent: 36pt;">A valuation allowance, if needed, reduces deferred tax assets to the amount expected to be realized. When determining the amount of net
          deferred tax assets that are more likely than not to be realized, the Company assesses all available positive and negative evidence. This evidence includes, but is not limited to, prior earnings history, expected future earnings, carry-back and
          carry-forward periods and the feasibility of ongoing tax strategies that could potentially enhance the likelihood of the realization of a deferred tax asset. The weight given to the positive and negative evidence is commensurate with the extent
          the evidence may be objectively verified.<br/>
        </p></ix:continuation>
      </div>

      <ix:continuation id="Text_2c61ffa0f3be425dba9df6bdea8fd66422" continuedAt="Text_2c61ffa0f3be425dba9df6bdea8fd66423">
<div><br/></div>
</ix:continuation>
      <div style="text-align: left; font: 10pt 'Times New Roman';">
        <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
          <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">F-31</span></div>

          <div class="BRPFPageBreak" style="page-break-after: always;">
            <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: rgb(0, 0, 0); background-color: rgb(0, 0, 0);"/></div>

          <div style="width: 100%;" class="BRPFPageHeader">
            <div>
              <div style="text-align: left; font-weight: bold; text-indent: -9pt; margin-left: 9pt;"><a href="#ADMABIOLOGICSINC."> <span style="font-style: italic; font-weight: normal; font-size: 8pt;">Table of Contents</span></a><br/>
              </div>

              <div style="text-align: left; font-weight: bold; text-indent: -9pt; margin-left: 9pt;"><a href="#ADMABIOLOGICSINC."><span style="font-style: italic; font-weight: normal; font-size: 8pt;"> <br/>
                  </span></a></div>

              <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">ADMA BIOLOGICS, INC. AND SUBSIDIARIES</div>

              <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</div>

            </div>

          </div>

        </div>

        <ix:continuation id="Text_2c61ffa0f3be425dba9df6bdea8fd66423" continuedAt="Text_2c61ffa0f3be425dba9df6bdea8fd66424"><p style="margin: 0px; font-family: 'Times New Roman'; font-size: 10pt; text-align: left; text-indent: 36pt;"> As of December 31, 2024, the Company believes it is more-likely-than-not that the Company&#8217;s federal and state deferred tax assets will be
          realized. The Company recorded a release of its valuation allowance associated with federal and state deferred tax assets which was due in part to achieving three years of cumulative taxable income and projected taxable income that is more than
          adequate to realize the Company&#8217;s federal and state deferred tax assets. As a result, the Company reversed the federal and state valuation allowance recorded as of December 31, 2023 of $<ix:nonFraction name="us-gaap:TaxCreditCarryforwardValuationAllowance" id="Fact_1fb63bc58cd54ef58e7b66ec459bd9a7" contextRef="c20231231_IncomeTaxAuthorityAxis_InternalRevenueServiceIRSMember" unitRef="U001" decimals="-5" scale="6" format="ixt:num-dot-decimal">88.0</ix:nonFraction> million and $<ix:nonFraction name="us-gaap:TaxCreditCarryforwardValuationAllowance" id="Fact_961e4ef145474248a631cd304f21b905" contextRef="c20231231_IncomeTaxAuthorityAxis_StateAndLocalJurisdictionMember" unitRef="U001" decimals="-5" scale="6" format="ixt:num-dot-decimal">13.4</ix:nonFraction> million, respectively, resulting in a
          tax benefit to the income tax provision for the year ended December 31, 2024.<br/>
        </p></ix:continuation>
        <ix:continuation id="Text_2c61ffa0f3be425dba9df6bdea8fd66424" continuedAt="Text_2c61ffa0f3be425dba9df6bdea8fd66425"><p style="margin: 0px; font-family: 'Times New Roman'; font-size: 10pt; text-align: left; text-indent: 36pt;"> <br/>
        </p></ix:continuation>
        <ix:continuation id="Text_2c61ffa0f3be425dba9df6bdea8fd66425" continuedAt="Text_2c61ffa0f3be425dba9df6bdea8fd66426"><p style="margin: 0px; font-family: 'Times New Roman'; font-size: 10pt; text-align: left; text-indent: 36pt;">In accordance with U.S. GAAP, the Company is required to determine whether a tax position of the Company is more likely than not to be
          sustained upon examination by the applicable taxing authority, including resolution of any related appeals or litigation processes, based on the technical merits of the position. The tax benefit to be recognized is measured as the largest amount
          of benefit that is greater than 50% likely of being realized upon ultimate settlement. Derecognition of a tax benefit previously recognized could result in the Company recording a tax liability that would reduce net assets. The amount of the
          liability for which an exposure exists is measured as the largest amount of benefit determined on a cumulative probability basis that the Company believes is more likely than not to be realized upon ultimate settlement of the position. Components
          of the liability are classified as either a current or a long-term liability in the accompanying consolidated balance sheets based on when the Company expects each of the items to be settled. The Company does <ix:nonFraction name="us-gaap:UnrecognizedTaxBenefits" id="Fact_896cc76177d248b887669a96bb040b25" contextRef="c20241231" unitRef="U001" decimals="0" scale="0" format="ixt-sec:numwordsen"><ix:nonFraction name="us-gaap:UnrecognizedTaxBenefits" id="Fact_60d89ff97b004428854735d821b6641f" contextRef="c20231231" unitRef="U001" decimals="0" scale="0" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction>t have any unrecognized tax benefits as of December 31, 2024 and 2023 and does not anticipate a significant change in unrecognized tax benefits
          during the next 12 months. </p></ix:continuation>
        <ix:continuation id="Text_2c61ffa0f3be425dba9df6bdea8fd66426" continuedAt="Text_2c61ffa0f3be425dba9df6bdea8fd66427"><p style="margin: 0px; font-family: 'Times New Roman'; font-size: 10pt; text-align: left; text-indent: 36pt;"><br/>
        </p></ix:continuation>
        <ix:continuation id="Text_2c61ffa0f3be425dba9df6bdea8fd66427"><p style="margin: 0px; font-family: 'Times New Roman'; font-size: 10pt; text-align: left; text-indent: 36pt;">The Company files income tax returns in the U.S. federal and various state jurisdictions. All net operating losses and tax credits
          generated to date are subject to adjustment for U.S. federal and state income tax purposes. The Company&#8217;s income tax returns are open to examination for tax years 2007 through 2023.</p></ix:continuation>

        <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;">&#160;</p>
      </div>

    </div>

  </div>


  <div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: rgb(0, 0, 0);">
    <div>
      <div style="text-align: left; font: 10pt 'Times New Roman';">
        <ix:nonNumeric name="us-gaap:LesseeOperatingLeasesTextBlock" id="Text_a5ffab10c60b4ce997716f9eb2c61ef8" contextRef="c20240101to20241231" escape="true" continuedAt="Text_74b8a491af3e43a79730fbef14ea24961">
<div>
          <table cellspacing="0" cellpadding="0" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt; border-spacing: 0;" class="DSPFListTable">


  <tr style="vertical-align: top;">

    <td style="vertical-align: top; width: 27pt;">
                  <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;"><strong>12.</strong></p>
                </td>

    <td style="align: left; vertical-align: top; width: auto;">
                  <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;"><span style="text-decoration: underline;"><span style="background-color: rgb(255, 255, 255); font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><strong>LEASE OBLIGATIONS</strong></span></span><strong><span style="text-decoration: underline;"><br/>
                      </span></strong></p>
                </td>

  </tr>


</table>
        </div>
</ix:nonNumeric>
        <ix:continuation id="Text_74b8a491af3e43a79730fbef14ea24961" continuedAt="Text_74b8a491af3e43a79730fbef14ea24962"><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;">&#160;</p></ix:continuation>
        <ix:continuation id="Text_74b8a491af3e43a79730fbef14ea24962" continuedAt="Text_74b8a491af3e43a79730fbef14ea24963"><p style="margin: 0px; font-family: 'Times New Roman'; font-size: 10pt; text-align: left; text-indent: 36pt;">The Company leases certain properties and equipment for its ADMA BioCenters and ADMA BioManufacturing subsidiaries, which leases provide
          the right to use the underlying assets and require lease payments through the respective lease terms which expire at various dates through 2033. The Company&#8217;s lease agreements do not contain any material residual value guarantees or material
          restrictive covenants. Upon adoption of ASU No. 2016-02, <span style="font-style: italic;">Leases (Topic 842)</span> effective January 1, 2019, the Company elected the package of practical expedients, which permits the Company to not reassess
          under the new standard its prior conclusions about lease identification, lease classification and initial direct costs. In addition, the Company elected the short-term lease recognition exemption for all leases that qualify, </p></ix:continuation>
        <ix:continuation id="Text_74b8a491af3e43a79730fbef14ea24963" continuedAt="Text_74b8a491af3e43a79730fbef14ea24964">
<div><span style="font-size: 10pt;"> </span></div>
</ix:continuation>
        <ix:continuation id="Text_74b8a491af3e43a79730fbef14ea24964" continuedAt="Text_74b8a491af3e43a79730fbef14ea24965"><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-indent: 45px; text-align: left;">&#160;</p></ix:continuation>
        <ix:continuation id="Text_74b8a491af3e43a79730fbef14ea24965" continuedAt="Text_74b8a491af3e43a79730fbef14ea24966">
<div><span style="font-size: 10pt;"> </span></div>
</ix:continuation>
        <ix:continuation id="Text_74b8a491af3e43a79730fbef14ea24966" continuedAt="Text_74b8a491af3e43a79730fbef14ea24967"><p style="margin: 0px; font-family: 'Times New Roman'; font-size: 10pt; text-align: left; text-indent: 36pt;"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">The Company determines if an arrangement is an operating lease or a financing lease at inception. Leases with an initial term of 12 months or less are not recorded on
            the balance sheet and lease expense for such leases are recognized on a straight-line basis over the lease term. All other leases are recorded on the balance sheet with assets representing the right to use the underlying asset for the lease
            term and lease liabilities representing the obligation to make lease payments arising from the lease. Right-of-use assets and lease liabilities are recognized at the lease commencement date based on the present value of lease payments over the
            lease term and include options to extend or terminate the lease when they are reasonably certain to be exercised. The present value of the lease payments is determined using the Company&#8217;s estimated incremental borrowing rate as of the lease
            commencement date. There were no new material leases entered into during the year ended December 31, 2024. For the lease liabilities recognized during the years ended December 31, 2023 and 2022, the Company used discount rates of <ix:nonFraction name="adma:OperatingLeaseIncrementalBorrowingRatePercent" id="Fact_171f99876b59493c97140ceb8bd9a164" contextRef="c20230101to20231231" unitRef="U007" decimals="2" scale="-2" format="ixt:num-dot-decimal">13</ix:nonFraction>% to <ix:nonFraction name="adma:OperatingLeaseIncrementalBorrowingRatePercent" id="Fact_5ae9c45c1e1f47cfab457cd89286fb84" contextRef="c20220101to20221231" unitRef="U007" decimals="2" scale="-2" format="ixt:num-dot-decimal">16</ix:nonFraction>%, representing a weighted
            average discount rate of <ix:nonFraction name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" id="Fact_803e0c0e5feb4196abcbdc62c7f4a3c2" contextRef="c20241231" unitRef="U007" decimals="4" scale="-2" format="ixt:num-dot-decimal">13.02</ix:nonFraction>%, to determine the present value of its lease obligations. The Company&#8217;s operating lease expense is
            recognized on a straight-line basis over the lease term and is reflected in Plasma center operating expenses and Selling, general and administrative expenses in the accompanying consolidated statements of operations. Aggregate lease expense for
            the Company&#8217;s operating leases for the years ended December 31, 2024, 2023 and 2022 was $<ix:nonFraction name="us-gaap:OperatingLeaseExpense" id="Fact_01a1b5dbff9d4b29b204f75f8ab251ff" contextRef="c20240101to20241231" unitRef="U001" decimals="-5" scale="6" format="ixt:num-dot-decimal">2.4</ix:nonFraction> million, $<ix:nonFraction name="us-gaap:OperatingLeaseExpense" id="Fact_86e368e678be4f14ac526ba2abcfa614" contextRef="c20230101to20231231" unitRef="U001" decimals="-5" scale="6" format="ixt:num-dot-decimal">2.4</ix:nonFraction> million and <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">$<ix:nonFraction name="us-gaap:OperatingLeaseExpense" id="Fact_0cf8aaf972d2408893aa86d05ac199d9" contextRef="c20220101to20221231" unitRef="U001" decimals="-5" scale="6" format="ixt:num-dot-decimal">2.1</ix:nonFraction> million</span>, respectively. Aggregate
            cash paid on these leases for the years ended December 31, 2024, 2023 and 2022 was $<ix:nonFraction name="us-gaap:OperatingLeasePayments" id="Fact_0751d0bb32474ce7ba29b84ac580e782" contextRef="c20240101to20241231" unitRef="U001" decimals="-5" scale="6" format="ixt:num-dot-decimal">2.4</ix:nonFraction> million, $<ix:nonFraction name="us-gaap:OperatingLeasePayments" id="Fact_fbddfcdd6e4b494382b18ace317dabbc" contextRef="c20230101to20231231" unitRef="U001" decimals="-5" scale="6" format="ixt:num-dot-decimal">2.4</ix:nonFraction> million and $<ix:nonFraction name="us-gaap:OperatingLeasePayments" id="Fact_f79d7e152edd480eb2f28f0277d2e806" contextRef="c20220101to20221231" unitRef="U001" decimals="-5" scale="6" format="ixt:num-dot-decimal">1.8</ix:nonFraction> million,
            respectively.</span> </p></ix:continuation>
        <ix:continuation id="Text_74b8a491af3e43a79730fbef14ea24967" continuedAt="Text_74b8a491af3e43a79730fbef14ea24968">
<div><span style="font-size: 10pt;"> </span></div>
</ix:continuation>
        <ix:continuation id="Text_74b8a491af3e43a79730fbef14ea24968" continuedAt="Text_74b8a491af3e43a79730fbef14ea24969"><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-indent: 45px; text-align: left;">&#160;</p></ix:continuation>
        <ix:continuation id="Text_74b8a491af3e43a79730fbef14ea24969" continuedAt="Text_74b8a491af3e43a79730fbef14ea249610">
<div><span style="font-size: 10pt;"> </span></div>
</ix:continuation>
        <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
          <div class="BRPFPageNumberArea" style="text-align: center;"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">F-32</span></div>

          <div class="BRPFPageBreak" style="page-break-after: always;">
            <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"/></div>

          <div class="BRPFPageHeader" style="width: 100%;">
            <div>
              <div style="text-align: left; font-weight: bold; text-indent: -9pt; margin-left: 9pt;"><a href="#ADMABIOLOGICSINC."> <span style="font-style: italic; font-weight: normal; font-size: 8pt;">Table of Contents</span></a><br/>
              </div>

              <div style="text-align: left; font-weight: bold; text-indent: -9pt; margin-left: 9pt;"><a href="#ADMABIOLOGICSINC."><span style="font-style: italic; font-weight: normal; font-size: 8pt;"> <br/>
                  </span></a></div>

              <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">ADMA BIOLOGICS, INC. AND SUBSIDIARIES</div>

              <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</div>

            </div>

          </div>

        </div>

        <ix:continuation id="Text_74b8a491af3e43a79730fbef14ea249610" continuedAt="Text_74b8a491af3e43a79730fbef14ea249611"><p style="margin: 0px; font-family: 'Times New Roman'; font-size: 10pt; text-align: left; text-indent: 36pt;"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 48px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; display: inline !important; float: none;"><span style="font-size: 10pt;"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 48px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; display: inline !important; float: none;">During the year ended December 31, 2023, the Company recognized <ix:nonFraction name="adma:NumberOfNewPropertyLeases" id="Fact_f24a0065c9044eac8e4db49d66b00442" contextRef="c20230101to20231231" unitRef="U013" decimals="INF" scale="0" format="ixt-sec:numwordsen">one</ix:nonFraction> additional right-of-use
                asset and corresponding lease liability in the amount of $<ix:nonFraction name="adma:LesseeOperatingLeaseLiabilitiesRelatedToPropertyLease" id="Fact_f6436e8c2c7c4bd3a5baf0e7eac523bd" contextRef="c20231231" unitRef="U001" decimals="-5" scale="6" format="ixt:num-dot-decimal"><ix:nonFraction name="adma:LesseeOperatingLeaseRightOfUseAssetRelatedToPropertyLease" id="Fact_53ea3f5f6e414201a54f34bb2d1ebe98" contextRef="c20231231" unitRef="U001" decimals="-5" scale="6" format="ixt:num-dot-decimal">0.1</ix:nonFraction></ix:nonFraction> million for office equipment leased for the Boca Facility.</span>
              During the year ended December 31, 2022, the Company recognized additional right-of-use assets and corresponding lease liabilities aggregating to approximately $<ix:nonFraction name="adma:LesseeOperatingLeaseLiabilitiesRelatedToPropertyLease" id="Fact_c6254518a8c046dd9a316774dc9e7d02" contextRef="c20221231" unitRef="U001" decimals="-5" scale="6" format="ixt:num-dot-decimal"><ix:nonFraction name="adma:LesseeOperatingLeaseRightOfUseAssetRelatedToPropertyLease" id="Fact_97609a061a9c4d0498919c1ffc7ce78d" contextRef="c20221231" unitRef="U001" decimals="-5" scale="6" format="ixt:num-dot-decimal">4.0</ix:nonFraction></ix:nonFraction> million in connection with <ix:nonFraction name="adma:NumberOfNewPropertyLeases" id="Fact_8fb7d32a3f6948bda95bd7e9d34788d7" contextRef="c20220101to20221231" unitRef="U013" decimals="INF" scale="0" format="ixt-sec:numwordsen">two</ix:nonFraction> new property leases where the Company
              has opened additional plasma collection facilities, a property lease for the storage of raw materials inventory and a property lease for the building that the Company utilizes as its corporate headquarters (see Note 9). The Company has
              aggregate lease liabilities of $<ix:nonFraction name="adma:OperatingAndFinancingLeaseLiability" id="Fact_34f79b1d29a540f2b600ebe08cde742e" contextRef="c20241231" unitRef="U001" decimals="-5" scale="6" format="ixt:num-dot-decimal">9.8</ix:nonFraction> million and $<ix:nonFraction name="adma:OperatingAndFinancingLeaseLiability" id="Fact_989217ae9380489ca2d3e23ec03d2242" contextRef="c20231231" unitRef="U001" decimals="-5" scale="6" format="ixt:num-dot-decimal">10.8</ix:nonFraction> million as of December 31, 2024 and 2023, respectively, which are comprised primarily of the leases for the Company&#8217;s plasma collection centers.&#160; </span><span style="font-size: 10pt;"><ix:nonNumeric name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="Text_7ae4405ee9bd4ed9bd90c116671a3584" contextRef="c20240101to20241231" escape="true" continuedAt="Text_4e0ff00d46584c9280411da219e2252b1"><span style="font-size: 10pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-weight: 400;">The Company&#8217;s operating leases
              have a weighted average remaining term of <ix:nonNumeric name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" id="Fact_092530dd0e5e4a8c9b34d21061c88fc4" contextRef="c20241231" format="ixt-sec:duryear">6.8</ix:nonNumeric></span></ix:nonNumeric><ix:continuation id="Text_4e0ff00d46584c9280411da219e2252b1" continuedAt="Text_4e0ff00d46584c9280411da219e2252b2"><span style="font-size: 10pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-weight: 400;"> years. Scheduled payments under the Company&#8217;s lease obligations</span></ix:continuation><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><ix:continuation id="Text_4e0ff00d46584c9280411da219e2252b2" continuedAt="Text_4e0ff00d46584c9280411da219e2252b3"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal;"> are as follows</span></ix:continuation></span></span></span><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><ix:continuation id="Text_4e0ff00d46584c9280411da219e2252b3" continuedAt="Text_4e0ff00d46584c9280411da219e2252b4"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal;"> (in thousands)</span></ix:continuation></span><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 48px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; display: inline !important; float: none;"><span style="font-size: 10pt;"><ix:continuation id="Text_4e0ff00d46584c9280411da219e2252b4" continuedAt="Text_4e0ff00d46584c9280411da219e2252b5"><span style="font-size: 10pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-weight: 400;">:</span></ix:continuation></span></span></p></ix:continuation>
        <ix:continuation id="Text_74b8a491af3e43a79730fbef14ea249611" continuedAt="Text_74b8a491af3e43a79730fbef14ea249612"><ix:continuation id="Text_4e0ff00d46584c9280411da219e2252b5" continuedAt="Text_4e0ff00d46584c9280411da219e2252b6"><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-indent: 45px; text-align: left;"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 48px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; display: inline !important; float: none;"><br/>
          </span> </p></ix:continuation></ix:continuation>
        <ix:continuation id="Text_74b8a491af3e43a79730fbef14ea249612"><ix:continuation id="Text_4e0ff00d46584c9280411da219e2252b6">
<table cellspacing="0" cellpadding="0" border="0" class="cfttable" style="text-align: left; font: 10pt 'Times New Roman'; width: 100%; border-spacing: 0;">


  <tr style="height: 15px;">

    <td valign="bottom" style="vertical-align: top; width: 88%; background-color: #CCEEFF; white-space: nowrap;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: left;">Year ended December 31, 2025</p>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;"><br/>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" id="Fact_d35fa105db0d4bd7860c9f15c9f68b56" contextRef="c20241231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,421</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="vertical-align: top; width: 88%;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: left;">2026<br/>
                </p>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" id="Fact_5aff44c50f3b41f68cbbed5cd9628d03" contextRef="c20241231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,157</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="vertical-align: top; width: 88%; background-color: #CCEEFF;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: left;">2027<br/>
                </p>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" id="Fact_f29ac4d9064742e6ad282ed46e2de203" contextRef="c20241231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,041</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="vertical-align: top; width: 88%;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: left;">2028<br/>
                </p>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" id="Fact_4be66520224d415bb0077bdfaddba8f6" contextRef="c20241231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,088</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="vertical-align: top; width: 88%; background-color: #CCEEFF;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: left;">2029<br/>
                </p>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" id="Fact_90efb09170bb4a6084cccc0f1a69881d" contextRef="c20241231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,109</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="vertical-align: top; width: 88%; padding-bottom: 2px;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: left;">Thereafter</p>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" id="Fact_05f0e282fdaa48ce862fdd38bde3af45" contextRef="c20241231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,041</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="vertical-align: top; width: 88%; background-color: #CCEEFF;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: left;">Total payments</p>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" id="Fact_e4e35878beed4b7bb2a7aa9367262861" contextRef="c20241231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">14,857</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="vertical-align: top; width: 88%;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: left;">Less: imputed interest</p>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;">(<ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" id="Fact_dc22273d99ed452db58df6b2220f9a01" contextRef="c20241231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">5,078</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;">)</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="vertical-align: top; width: 88%; padding-bottom: 2px; background-color: #CCEEFF;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: left;">Current portion</p>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;">(<ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" id="Fact_eb519305d0174bd0a15206bd2b5445f3" contextRef="c20241231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,218</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;">)</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="vertical-align: top; width: 88%; padding-bottom: 4px; white-space: nowrap;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: left;">Balance at December 31, 2024</p>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);">$</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" id="Fact_6b2a9f57bb994f7d953c6ccc4178381d" contextRef="c20241231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">8,561</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">&#160;</td>

  </tr>


</table>
</ix:continuation></ix:continuation>
          </div>

      <div><br/></div>

    </div>

  </div>


  <div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: rgb(0, 0, 0);">
    <div>
      <div style="text-align: left; font: 10pt 'Times New Roman';">
        <ix:nonNumeric name="us-gaap:SegmentReportingDisclosureTextBlock" id="Text_97850d1a001748a1a11dbb0349e265c1" contextRef="c20240101to20241231" escape="true" continuedAt="Text_0749860a5f6042ceb1695fcf4886baa91">
<div>
          <table cellspacing="0" cellpadding="0" class="DSPFListTable" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt; border-spacing: 0;">


  <tr style="vertical-align: top;">

    <td style="vertical-align: top; width: 27pt;">
                  <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;"><strong>13.</strong></p>
                </td>

    <td style="align: left; vertical-align: top; width: auto;">
                  <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;"><span style="text-decoration: underline;"><span style="background-color: rgb(255, 255, 255); font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><strong>SEGMENTS</strong></span></span><strong><span style="text-decoration: underline;"><br/>
                      </span></strong></p>
                </td>

  </tr>


</table>
        </div>
</ix:nonNumeric>
        <ix:continuation id="Text_0749860a5f6042ceb1695fcf4886baa91" continuedAt="Text_0749860a5f6042ceb1695fcf4886baa92"><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;">&#160;</p></ix:continuation>
        <ix:continuation id="Text_0749860a5f6042ceb1695fcf4886baa92" continuedAt="Text_0749860a5f6042ceb1695fcf4886baa93"><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-indent: 45px; text-align: left;">The Company is engaged in the manufacture, marketing and development of specialty plasma-derived biologics.&#160; The Company&#8217;s ADMA
          BioManufacturing operating segment reflects the Company&#8217;s immunoglobulin manufacturing, commercial and development operations in Boca Raton, FL.&#160; The Plasma Collection Centers operating segment consists of <ix:nonFraction name="adma:NumberOfPlasmaCollectionFacilitiesUnderDevelopment" id="Fact_97173a504bcb44bfbd5b6d92a9da0d35" contextRef="c20240101to20241231" unitRef="U004" decimals="INF" scale="0" format="ixt-sec:numwordsen">ten</ix:nonFraction> plasma collection facilities located throughout the United States, all of which are operational, collecting plasma and currently holding FDA
          licenses. The Company defines its operating segments as those business units whose operating results are regularly reviewed by the chief operating decision maker (&#8220;CODM&#8221;) to analyze performance and allocate resources. The Corporate information
          included in the reconciliations below generally consists of certain unallocated general and administrative overhead expenses and interest expense on the Company&#8217;s senior debt (see Note 7). The Company&#8217;s CODM is its President and Chief Executive
          Officer. For the Company&#8217;s two operating segments, the CODM uses income/loss before taxes as the measure of segment profit to determine the allocation of resources for each segment. Transactions between the <ix:nonFraction name="us-gaap:NumberOfOperatingSegments" id="Fact_135c393eaf254fd3998993ab8df11c59" contextRef="c20240101to20241231" unitRef="U014" decimals="INF" scale="0" format="ixt-sec:numwordsen">two</ix:nonFraction> operating segments consist solely of the transfer of raw material plasma inventory at cost from the Plasma Collection Centers segment to the ADMA
          BioManufacturing segment with no markup or intercompany profit. Income tax benefit/expense is recorded at the Corporate entity and is not allocated to the operating segments. <ix:nonNumeric name="us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock" id="Text_2e8a7ada35eb4cac85512185a7df2676" contextRef="c20240101to20241231" escape="true" continuedAt="Text_e517091741664c3c9ead9e199c0a71d91"><span style="font-family: 'Times New Roman'; font-size: 10pt; color: rgb(0, 0, 0);">Summarized financial information concerning reportable segments is
          shown in the following tables:</span></ix:nonNumeric></p></ix:continuation>
        <ix:continuation id="Text_0749860a5f6042ceb1695fcf4886baa93" continuedAt="Text_0749860a5f6042ceb1695fcf4886baa94"><ix:continuation id="Text_e517091741664c3c9ead9e199c0a71d91" continuedAt="Text_e517091741664c3c9ead9e199c0a71d92"><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;">&#160;&#160;&#160;</p></ix:continuation></ix:continuation>
        <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
          <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">F-33</span></div>

          <div class="BRPFPageBreak" style="page-break-after: always;">
            <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"/></div>

          <div style="width: 100%;" class="BRPFPageHeader">
            <div>
              <div style="text-align: left; font-weight: bold; text-indent: -9pt; margin-left: 9pt;"><a href="#ADMABIOLOGICSINC."> <span style="font-style: italic; font-weight: normal; font-size: 8pt;">Table of Contents</span></a><br/>
              </div>

              <div style="text-align: left; font-weight: bold; text-indent: -9pt; margin-left: 9pt;"><a href="#ADMABIOLOGICSINC."><span style="font-style: italic; font-weight: normal; font-size: 8pt;"> <br/>
                  </span></a></div>

              <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">ADMA BIOLOGICS, INC. AND SUBSIDIARIES</div>

              <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</div>

            </div>

          </div>

        </div>

        <ix:continuation id="Text_0749860a5f6042ceb1695fcf4886baa94" continuedAt="Text_0749860a5f6042ceb1695fcf4886baa95"><ix:continuation id="Text_e517091741664c3c9ead9e199c0a71d92" continuedAt="Text_e517091741664c3c9ead9e199c0a71d93">
<table cellspacing="0" cellpadding="0" border="0" style="text-align: left; font: 10pt 'Times New Roman'; width: 100%; border-spacing: 0;" class="cfttable">


  <tr style="height: 15px;">

    <td valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;" colspan="12">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: center;"><strong>Year Ended December 31, 2024</strong></p>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="padding-bottom: 2px;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: center;"><span style="font-style: italic;">(in thousands)</span><br/>
                </p>
              </td>

    <td valign="bottom" style="text-align: center; vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: center; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="2">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: center;"><strong>ADMA</strong></p>
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: center;"><strong> BioManufacturing</strong></p>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: center; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: center; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="2">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: center;"><strong>Plasma Collection<br/>
                  </strong></p>
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: center;"><span style="font-weight: bold;">Centers</span><strong><br/>
                  </strong></p>
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: center;"><strong> </strong></p>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: center; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: center; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="2">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: center;"><strong>Total</strong></p>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="vertical-align: top; width: 64%; background-color: #CCEEFF;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in;">Revenues</p>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">$</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_c3620621cb394dd783d0169bdd8075f3" contextRef="c20240101to20241231_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_ADMABioManufacturingSegmentMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">415,806</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">$</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_1c5297f4cca54f9198875c6ed4eb37f4" contextRef="c20240101to20241231_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PlasmaCollectionCentersSegmentMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">10,505</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">$</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_04caccce64b448afabe69fb9c3e2b051" contextRef="c20240101to20241231_ConsolidationItemsAxis_OperatingSegmentsMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">426,311</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="width: 64%;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px;">&#160;</p>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="vertical-align: top; width: 64%; background-color: #CCEEFF;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in;">Cost of product revenue</p>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1"><ix:nonFraction name="us-gaap:CostOfRevenue" id="Fact_46a01c3649164cccb33893e524db6c19" contextRef="c20240101to20241231_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_ADMABioManufacturingSegmentMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">195,605</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1"><ix:nonFraction name="us-gaap:CostOfRevenue" id="Fact_9ea8a72b8dae454b86551d456955de05" contextRef="c20240101to20241231_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PlasmaCollectionCentersSegmentMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">11,296</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1"><ix:nonFraction name="us-gaap:CostOfRevenue" id="Fact_aba665100e114e759df5a3aa422fed35" contextRef="c20240101to20241231_ConsolidationItemsAxis_OperatingSegmentsMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">206,901</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="width: 64%;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px;">&#160;</p>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="vertical-align: top; width: 64%; background-color: #CCEEFF;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in;">Research and development<br/>
                </p>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" id="Fact_91f2a2da3e464bc8a6f81fc70950f6a1" contextRef="c20240101to20241231_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_ADMABioManufacturingSegmentMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,813</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" id="Fact_17a8511b3d03464795695a397eacbd01" contextRef="c20240101to20241231_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PlasmaCollectionCentersSegmentMember" unitRef="U001" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" id="Fact_fa4fe93c958241f9a2bf622cdf60dd09" contextRef="c20240101to20241231_ConsolidationItemsAxis_OperatingSegmentsMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,813</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="width: 64%;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px;">&#160;</p>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="vertical-align: top; width: 64%; background-color: #CCEEFF;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in;">Plasma center operating expenses<br/>
                </p>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1"><ix:nonFraction name="us-gaap:OtherCostAndExpenseOperating" id="Fact_4b8ffbeb90fc4e64b8045ca1e5b234e8" contextRef="c20240101to20241231_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_ADMABioManufacturingSegmentMember" unitRef="U001" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1"><ix:nonFraction name="us-gaap:OtherCostAndExpenseOperating" id="Fact_274946dad1154e9ca85d7645df5548ad" contextRef="c20240101to20241231_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PlasmaCollectionCentersSegmentMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,245</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1"><ix:nonFraction name="us-gaap:OtherCostAndExpenseOperating" id="Fact_9f8f7f3ebb1f41a6a91d8f3f971bd785" contextRef="c20240101to20241231_ConsolidationItemsAxis_OperatingSegmentsMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,245</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="width: 64%;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px;">&#160;</p>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="vertical-align: top; width: 64%; background-color: #CCEEFF;" rowspan="1">Selling, marketing and distribution<br/>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:SellingAndMarketingExpense" id="Fact_d8672edcd57649fda7c976c73202895c" contextRef="c20240101to20241231_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_ADMABioManufacturingSegmentMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">18,683</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:SellingAndMarketingExpense" id="Fact_97d394a0a1534e2a8071cd50fdbb1cb5" contextRef="c20240101to20241231_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PlasmaCollectionCentersSegmentMember" unitRef="U001" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:SellingAndMarketingExpense" id="Fact_219f0327bbcb44e9a6d03e6b02455f2d" contextRef="c20240101to20241231_ConsolidationItemsAxis_OperatingSegmentsMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">18,683</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="vertical-align: top; width: 64%;" rowspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="vertical-align: top; width: 64%; background-color: #CCEEFF;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in;">Depreciation and amortization expense<br/>
                </p>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1"><ix:nonFraction name="us-gaap:DepreciationAndAmortization" id="Fact_255c50c739a54604ae8355a00c57e724" contextRef="c20240101to20241231_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_ADMABioManufacturingSegmentMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,827</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1"><ix:nonFraction name="us-gaap:DepreciationAndAmortization" id="Fact_a8e50c03a44645fc950f4723c806e69e" contextRef="c20240101to20241231_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PlasmaCollectionCentersSegmentMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,218</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1"><ix:nonFraction name="us-gaap:DepreciationAndAmortization" id="Fact_cbf7fadd7b1040938807b6e7ebb7e1de" contextRef="c20240101to20241231_ConsolidationItemsAxis_OperatingSegmentsMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">8,045</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="width: 64%;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px;">&#160;</p>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="width: 64%; background-color: #CCEEFF;" rowspan="1">General and administrative expense<br/>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" id="Fact_d1fb21ae472c4a2082c0bb5f7e63c255" contextRef="c20240101to20241231_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_ADMABioManufacturingSegmentMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">26,001</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" id="Fact_29ff77a6b9a640f48a705693a04bd957" contextRef="c20240101to20241231_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PlasmaCollectionCentersSegmentMember" unitRef="U001" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" id="Fact_24da8a783c1a4a2e8ec2fc20446100de" contextRef="c20240101to20241231_ConsolidationItemsAxis_OperatingSegmentsMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">26,001</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="width: 64%;" rowspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="width: 64%; background-color: #CCEEFF;" rowspan="1">Other expense, net<br/>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" rowspan="1" colspan="1">(<ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" id="Fact_c838cf5792744b5fb2d4a63960e5f5c9" contextRef="c20240101to20241231_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_ADMABioManufacturingSegmentMember" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">178</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">)</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" rowspan="1" colspan="1">(<ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" id="Fact_af1ec71281084fc1900f22cfd58e06f3" contextRef="c20240101to20241231_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PlasmaCollectionCentersSegmentMember" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">5</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">)</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" rowspan="1" colspan="1">(<ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" id="Fact_0028e46f41ad4e5789ec4602a9a1900b" contextRef="c20240101to20241231_ConsolidationItemsAxis_OperatingSegmentsMember" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">183</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">)</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="width: 64%;" rowspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="width: 64%; background-color: #CCEEFF;" rowspan="1">Income (loss) before taxes<br/>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" id="Fact_30bd72760b01449999945f4487e06fd8" contextRef="c20240101to20241231_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_ADMABioManufacturingSegmentMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">173,138</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" rowspan="1" colspan="1">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" id="Fact_2971ac15b5d24ac19c93c2c204e1073c" contextRef="c20240101to20241231_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PlasmaCollectionCentersSegmentMember" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">5,041</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">)</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" id="Fact_ec41b21b79fc49e2a024493f9f0653fd" contextRef="c20240101to20241231_ConsolidationItemsAxis_OperatingSegmentsMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">168,097</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="width: 64%;" rowspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="vertical-align: top; width: 64%; background-color: #CCEEFF;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in;">Expenditures for additions to long-lived assets<br/>
                </p>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1"><ix:nonFraction name="us-gaap:SegmentExpenditureAdditionToLongLivedAssets" id="Fact_8f81e80b244447bba3eee87b1ff6b2e4" contextRef="c20240101to20241231_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_ADMABioManufacturingSegmentMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">8,352</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1"><ix:nonFraction name="us-gaap:SegmentExpenditureAdditionToLongLivedAssets" id="Fact_b5cd1945a9fb430caf06c760a931ac0e" contextRef="c20240101to20241231_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PlasmaCollectionCentersSegmentMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">223</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1"><ix:nonFraction name="us-gaap:SegmentExpenditureAdditionToLongLivedAssets" id="Fact_c0fcb914e7314235864809fd1a6c684d" contextRef="c20240101to20241231_ConsolidationItemsAxis_OperatingSegmentsMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">8,575</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="vertical-align: top; width: 64%;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in;">Total assets</p>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1"><ix:nonFraction name="us-gaap:Assets" id="Fact_885de1c4cd434f11be03575ecc9a1557" contextRef="c20241231_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_ADMABioManufacturingSegmentMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">289,297</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1"><ix:nonFraction name="us-gaap:Assets" id="Fact_ea4cc76fe6ec40229cba601fcca5d8f1" contextRef="c20241231_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PlasmaCollectionCentersSegmentMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">30,477</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1"><ix:nonFraction name="us-gaap:Assets" id="Fact_09d85b6ddbee473083417eb7b6ebcff2" contextRef="c20241231_ConsolidationItemsAxis_OperatingSegmentsMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">319,774</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="vertical-align: top; width: 64%; background-color: #CCEEFF;" rowspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="vertical-align: top; width: 64%;" rowspan="1"><span style="font-style: italic;">Reconciliation of revenues:</span><br/>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="vertical-align: top; text-indent: 9pt; width: 64%; background-color: #CCEEFF;" rowspan="1">Segment revenue<br/>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">$</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_a491b394cdf94b0ebd9706435d82beab" contextRef="c20240101to20241231_ConsolidationItemsAxis_OperatingSegmentsMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">426,311</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="vertical-align: top; text-indent: 9pt; width: 64%; padding-bottom: 2px;" rowspan="1">License revenue (see Note 2 - Revenue Recognition)<br/>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_e165a811a4614d9b9c593462302fee6d" contextRef="c20240101to20241231_ConsolidationItemsAxis_MaterialReconcilingItemsMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">143</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="vertical-align: top; text-indent: 18pt; width: 64%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" rowspan="1">Consolidated revenues<br/>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 4px double rgb(0, 0, 0);" rowspan="1" colspan="1">$<br/>
              </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 4px double rgb(0, 0, 0);" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_9f8dc061e52140e88a54138e73088b0c" contextRef="c20240101to20241231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">426,454</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="vertical-align: top; width: 64%;" rowspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="vertical-align: top; width: 64%; background-color: rgb(204, 238, 255);" rowspan="1">
                <div style="margin-left: 9pt; text-indent: -9pt;"><span style="font-style: italic;">Reconciliation of selling, general and administrative expense:</span><br/>
                </div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="vertical-align: top; text-indent: 9pt; width: 64%;" rowspan="1">Segment selling, marketing and distribution expense<br/>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">$</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:SellingAndMarketingExpense" id="Fact_68ea26b2cb214432aa686a3b9549ab01" contextRef="c20240101to20241231_ConsolidationItemsAxis_OperatingSegmentsMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">18,683</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="vertical-align: top; text-indent: 9pt; width: 64%; background-color: #CCEEFF;" rowspan="1">Segment general and administrative expense<br/>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" id="Fact_b7e205b88bea435e97b9b05d6a34fb32" contextRef="c20240101to20241231_ConsolidationItemsAxis_OperatingSegmentsMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">26,001</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="vertical-align: top; text-indent: 9pt; width: 64%; padding-bottom: 2px;" rowspan="1">Corporate general and administrative expense (a)<br/>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" id="Fact_38cc8c1ba39345bb9c266112d2a58244" contextRef="c20240101to20241231_ConsolidationItemsAxis_CorporateNonSegmentMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">29,440</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="vertical-align: top; width: 64%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" rowspan="1">
                <div style="margin-left: 9pt">
                  <div style="margin-left: 9pt">
                    <div style="margin-left: 9pt; text-indent: -9pt;">Consolidated selling, general and administrative expense<br/>
                    </div>
                  </div>
                </div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 4px double rgb(0, 0, 0);" rowspan="1" colspan="1">$<br/>
              </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 4px double rgb(0, 0, 0);" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:SellingGeneralAndAdministrativeExpense" id="Fact_038983a770644c7c807353c1782297e7" contextRef="c20240101to20241231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">74,124</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="vertical-align: top; width: 64%;" rowspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="vertical-align: top; width: 64%; background-color: #CCEEFF;" rowspan="1"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: italic; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: nowrap; background-color: rgb(204, 238, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; display: inline !important; float: none;">Reconciliation of income (loss) before taxes:</span> </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="vertical-align: top; text-indent: 9pt; width: 64%;" rowspan="1">Segment income before taxes<br/>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">$</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" id="Fact_afa4436802544e3b8a92d8cc6c1fb874" contextRef="c20240101to20241231_ConsolidationItemsAxis_OperatingSegmentsMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">168,097</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="vertical-align: top; text-indent: 9pt; width: 64%; background-color: #CCEEFF;" rowspan="1">License revenue<br/>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" id="Fact_8f468320d8354b8b9dfe61bfa8bc87c0" contextRef="c20240101to20241231_ConsolidationItemsAxis_MaterialReconcilingItemsMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">143</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="vertical-align: top; width: 64%;" rowspan="1">
                <div style="margin-left: 9pt">
                  <div style="margin-left: 9pt; text-indent: -9pt;">Unallocated interest expense, primarily related to interest on senior debt (see Note 7)<br/>
                  </div>
                </div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" rowspan="1" colspan="1">(<ix:nonFraction name="us-gaap:InterestExpenseNonoperating" id="Fact_e69824c701094257952573ea2c6f96e4" contextRef="c20240101to20241231_ConsolidationItemsAxis_MaterialReconcilingItemsMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">13,930</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">)</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="vertical-align: top; text-indent: 9pt; width: 64%; background-color: #CCEEFF;" rowspan="1">Loss on extinguishment of debt (see Note 7)<br/>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" rowspan="1" colspan="1">(<ix:nonFraction name="us-gaap:GainsLossesOnExtinguishmentOfDebt" id="Fact_101b438a3a014300b9e4efd0fb8e66d4" contextRef="c20240101to20241231_ConsolidationItemsAxis_MaterialReconcilingItemsMember" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">1,243</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">)</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="vertical-align: top; text-indent: 9pt; width: 64%;" rowspan="1">Unallocated interest income<br/>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:InvestmentIncomeInterest" id="Fact_4fafbd5689374cf5928875e6d0ed8aae" contextRef="c20240101to20241231_ConsolidationItemsAxis_MaterialReconcilingItemsMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,087</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="vertical-align: top; text-indent: 9pt; width: 64%; background-color: rgb(204, 238, 255); padding-bottom: 2px;" rowspan="1">Corporate general and administrative expense (a)<br/>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); padding-bottom: 2px;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); padding-bottom: 2px;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0);" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0);" rowspan="1" colspan="1">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" id="Fact_cde715de13354b49a38d7dda07a2e372" contextRef="c20240101to20241231_ConsolidationItemsAxis_CorporateNonSegmentMember" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">29,440</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; white-space: nowrap;" rowspan="1" colspan="1">)</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="vertical-align: top; text-indent: 18pt; width: 64%; padding-bottom: 4px;" rowspan="1">Consolidated income before taxes<br/>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);" rowspan="1" colspan="1">$<br/>
              </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" id="Fact_a04cc9906c7348e7b0a2eeab156d323c" contextRef="c20240101to20241231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">125,714</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="vertical-align: top; width: 64%; background-color: #CCEEFF;" rowspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="vertical-align: top; width: 64%;" rowspan="1"><span style="font-style: italic;">Reconciliation of total assets:</span><br/>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="vertical-align: top; text-indent: 9pt; width: 64%; background-color: #CCEEFF;" rowspan="1">Total segment assets<br/>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">$</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:Assets" id="Fact_044f824334c94aa3b7f04a9485500d74" contextRef="c20241231_ConsolidationItemsAxis_OperatingSegmentsMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">319,774</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="vertical-align: top; text-indent: 9pt; width: 64%; padding-bottom: 2px;" rowspan="1">Corporate (b)<br/>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:Assets" id="Fact_098496fadea04070a12725b9411291d8" contextRef="c20241231_ConsolidationItemsAxis_CorporateNonSegmentMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">168,904</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="vertical-align: top; text-indent: 18pt; width: 64%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" rowspan="1">Consolidated total assets<br/>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 4px double rgb(0, 0, 0);" rowspan="1" colspan="1">$<br/>
              </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 4px double rgb(0, 0, 0);" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:Assets" id="Fact_f67ce43a57e34a4c854548e5234dc3fa" contextRef="c20241231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">488,678</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>


</table>
</ix:continuation></ix:continuation>
        <ix:continuation id="Text_0749860a5f6042ceb1695fcf4886baa95" continuedAt="Text_0749860a5f6042ceb1695fcf4886baa96"><ix:continuation id="Text_e517091741664c3c9ead9e199c0a71d93" continuedAt="Text_e517091741664c3c9ead9e199c0a71d94"><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;"><br/>
        </p></ix:continuation></ix:continuation>
        <ix:continuation id="Text_0749860a5f6042ceb1695fcf4886baa96" continuedAt="Text_0749860a5f6042ceb1695fcf4886baa97"><ix:continuation id="Text_e517091741664c3c9ead9e199c0a71d94" continuedAt="Text_e517091741664c3c9ead9e199c0a71d95">
<div>
          <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-spacing: 0;" class="DSPFListTable">


  <tr style="vertical-align: top;">

    <td style="text-align: right; vertical-align: top; width: 27pt;">
                  <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;">(a) - <br/>
                  </p>
                </td>

    <td style="text-align: left; vertical-align: top;">
                  <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: justify;"><ix:footnote id="Foot_09400bbe9814473cacf6009d441a9bbc" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US">Primarily includes compensation expense,
                    including stock-based compensation expense, for certain executive officers and consultants, insurance, legal and investor relations expenses and accounting and tax fees that are not allocated to the Company&#8217;s operating segments.</ix:footnote></p>
                </td>

  </tr>


</table>
        </div>
</ix:continuation></ix:continuation>
        <ix:continuation id="Text_0749860a5f6042ceb1695fcf4886baa97" continuedAt="Text_0749860a5f6042ceb1695fcf4886baa98"><ix:continuation id="Text_e517091741664c3c9ead9e199c0a71d95" continuedAt="Text_e517091741664c3c9ead9e199c0a71d96"><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;"><br/>
        </p></ix:continuation></ix:continuation>
        <ix:continuation id="Text_0749860a5f6042ceb1695fcf4886baa98" continuedAt="Text_0749860a5f6042ceb1695fcf4886baa99"><ix:continuation id="Text_e517091741664c3c9ead9e199c0a71d96" continuedAt="Text_e517091741664c3c9ead9e199c0a71d97">
<table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-spacing: 0;" class="DSPFListTable">


  <tr style="vertical-align: top;">

    <td style="text-align: right; vertical-align: top; width: 27pt;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;">(b) -<br/>
                </p>
              </td>

    <td style="text-align: left; vertical-align: top;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;"><ix:footnote id="Foot_8c1cfdc8358b499c8ef892be7b50f8db" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US">Primarily consists of cash and deferred tax
                  assets.</ix:footnote></p>
              </td>

  </tr>


</table>
</ix:continuation></ix:continuation>
        <ix:continuation id="Text_0749860a5f6042ceb1695fcf4886baa99" continuedAt="Text_0749860a5f6042ceb1695fcf4886baa910"><ix:continuation id="Text_e517091741664c3c9ead9e199c0a71d97" continuedAt="Text_e517091741664c3c9ead9e199c0a71d98"><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;"><br/>
        </p></ix:continuation></ix:continuation>
        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">F-34</span></div>

          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"/></div>

          <div style="width: 100%;" class="BRPFPageHeader">
            <div>
              <div style="text-align: left; font-weight: bold; text-indent: -9pt; margin-left: 9pt;"><a href="#ADMABIOLOGICSINC."> <span style="font-style: italic; font-weight: normal; font-size: 8pt;">Table of Contents</span></a><br/>
              </div>

              <div style="text-align: left; font-weight: bold; text-indent: -9pt; margin-left: 9pt;"><a href="#ADMABIOLOGICSINC."><span style="font-style: italic; font-weight: normal; font-size: 8pt;"> <br/>
                  </span></a></div>

              <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">ADMA BIOLOGICS, INC. AND SUBSIDIARIES</div>

              <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</div>

            </div>

          </div>

        </div>

        <ix:continuation id="Text_0749860a5f6042ceb1695fcf4886baa910" continuedAt="Text_0749860a5f6042ceb1695fcf4886baa911"><ix:continuation id="Text_e517091741664c3c9ead9e199c0a71d98" continuedAt="Text_e517091741664c3c9ead9e199c0a71d99"><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;"> </p></ix:continuation></ix:continuation>
        <ix:continuation id="Text_0749860a5f6042ceb1695fcf4886baa911" continuedAt="Text_0749860a5f6042ceb1695fcf4886baa912"><ix:continuation id="Text_e517091741664c3c9ead9e199c0a71d99" continuedAt="Text_e517091741664c3c9ead9e199c0a71d910">
<table cellspacing="0" cellpadding="0" border="0" style="text-align: left; font: 10pt 'Times New Roman'; width: 100%; border-spacing: 0;" class="cfttable">


  <tr style="height: 15px;">

    <td valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;" colspan="12">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: center;"><strong>Year Ended December 31, 2023</strong></p>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="padding-bottom: 2px;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: center;"><span style="font-style: italic;">(in thousands)</span><br/>
                </p>
              </td>

    <td valign="bottom" style="text-align: center; vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: center; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="2">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: center;"><strong>ADMA</strong></p>
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: center;"><strong> BioManufacturing</strong></p>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: center; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: center; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="2">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: center;"><strong>Plasma Collection<br/>
                  </strong></p>
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: center;"><span style="font-weight: bold;">Centers</span><strong><br/>
                  </strong></p>
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: center;"><strong> </strong></p>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: center; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: center; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="2">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: center;"><strong>Total</strong></p>
              </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="vertical-align: top; width: 64%; background-color: #CCEEFF;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in;">Revenues</p>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">$</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_5f541712d1cf4c89863c736ad162978b" contextRef="c20230101to20231231_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_ADMABioManufacturingSegmentMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">249,738</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">$</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_aaf13fd70cbf4ff5ae34417fb8f88b3a" contextRef="c20230101to20231231_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PlasmaCollectionCentersSegmentMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">8,334</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">$</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_92ccdd883bbe48b6b9a3440706a2ee26" contextRef="c20230101to20231231_ConsolidationItemsAxis_OperatingSegmentsMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">258,072</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="width: 64%;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px;">&#160;</p>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="vertical-align: top; width: 64%; background-color: #CCEEFF;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in;">Cost of product revenue</p>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1"><ix:nonFraction name="us-gaap:CostOfRevenue" id="Fact_28e73ffec29e416582b3e44ea730ad7a" contextRef="c20230101to20231231_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_ADMABioManufacturingSegmentMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">161,157</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1"><ix:nonFraction name="us-gaap:CostOfRevenue" id="Fact_7ac9fc2044b04078a6a6fbaa5c713db8" contextRef="c20230101to20231231_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PlasmaCollectionCentersSegmentMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">8,116</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1"><ix:nonFraction name="us-gaap:CostOfRevenue" id="Fact_2734e10fe9f748bdb5f7b5d9fd32941b" contextRef="c20230101to20231231_ConsolidationItemsAxis_OperatingSegmentsMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">169,273</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="width: 64%;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px;">&#160;</p>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="vertical-align: top; width: 64%; background-color: #CCEEFF;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in;">Research and development<br/>
                </p>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" id="Fact_189c95ebe5d145cdb38a4e62a73582af" contextRef="c20230101to20231231_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_ADMABioManufacturingSegmentMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,300</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" id="Fact_77c0dc3d55d4488cb078bf765b4e3e68" contextRef="c20230101to20231231_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PlasmaCollectionCentersSegmentMember" unitRef="U001" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" id="Fact_e44d2cd5bf9a4d3b9fbef95e80027983" contextRef="c20230101to20231231_ConsolidationItemsAxis_OperatingSegmentsMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,300</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="width: 64%;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px;">&#160;</p>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="vertical-align: top; width: 64%; background-color: #CCEEFF;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in;">Plasma center operating expenses<br/>
                </p>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1"><ix:nonFraction name="us-gaap:OtherCostAndExpenseOperating" id="Fact_dd0c1c57c89843fbba6af02393ae682c" contextRef="c20230101to20231231_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_ADMABioManufacturingSegmentMember" unitRef="U001" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1"><ix:nonFraction name="us-gaap:OtherCostAndExpenseOperating" id="Fact_13697e8831a045e684bff3f8845960d5" contextRef="c20230101to20231231_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PlasmaCollectionCentersSegmentMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,266</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1"><ix:nonFraction name="us-gaap:OtherCostAndExpenseOperating" id="Fact_d856676e6c4c4e0ebf4cc07c4643efbd" contextRef="c20230101to20231231_ConsolidationItemsAxis_OperatingSegmentsMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,266</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="width: 64%;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px;">&#160;</p>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="vertical-align: top; width: 64%; background-color: #CCEEFF;" rowspan="1">Selling, marketing and distribution<br/>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:SellingAndMarketingExpense" id="Fact_e18eea701fc14e459e13e5511d7c386d" contextRef="c20230101to20231231_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_ADMABioManufacturingSegmentMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">18,407</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:SellingAndMarketingExpense" id="Fact_50057d6e9d434cd79cd00d0e07f8d25e" contextRef="c20230101to20231231_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PlasmaCollectionCentersSegmentMember" unitRef="U001" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:SellingAndMarketingExpense" id="Fact_414d0c803f3c4d41a0a5d05f745a6164" contextRef="c20230101to20231231_ConsolidationItemsAxis_OperatingSegmentsMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">18,407</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="vertical-align: top; width: 64%;" rowspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="vertical-align: top; width: 64%; background-color: #CCEEFF;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in;">Depreciation and amortization expense<br/>
                </p>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1"><ix:nonFraction name="us-gaap:DepreciationAndAmortization" id="Fact_ec797854ac3741e49b482220b27b91d8" contextRef="c20230101to20231231_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_ADMABioManufacturingSegmentMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">5,156</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1"><ix:nonFraction name="us-gaap:DepreciationAndAmortization" id="Fact_7b56c78b504e464882968bf21d99ff26" contextRef="c20230101to20231231_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PlasmaCollectionCentersSegmentMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,176</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1"><ix:nonFraction name="us-gaap:DepreciationAndAmortization" id="Fact_fcb614236487426ab7bbd0f6b01be4c0" contextRef="c20230101to20231231_ConsolidationItemsAxis_OperatingSegmentsMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">8,332</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="width: 64%;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px;">&#160;</p>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="width: 64%; background-color: #CCEEFF;" rowspan="1">General and administrative expense<br/>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" id="Fact_628ac3cbb7b04f459f0770a288b62092" contextRef="c20230101to20231231_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_ADMABioManufacturingSegmentMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">18,625</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" id="Fact_6a6e77cfb1464389890aada2fa65327e" contextRef="c20230101to20231231_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PlasmaCollectionCentersSegmentMember" unitRef="U001" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" id="Fact_46462a3ba98e40fcb80bda530a705a98" contextRef="c20230101to20231231_ConsolidationItemsAxis_OperatingSegmentsMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">18,625</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="width: 64%;" rowspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="width: 64%; background-color: #CCEEFF;" rowspan="1">Income (loss) before taxes<br/>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" id="Fact_2ee8518b832549e3b94020aad6b063bb" contextRef="c20230101to20231231_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_ADMABioManufacturingSegmentMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">47,267</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" rowspan="1" colspan="1">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" id="Fact_63c03940be574ab0af7fdbb6631b9f2a" contextRef="c20230101to20231231_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PlasmaCollectionCentersSegmentMember" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">4,049</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">)</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" id="Fact_0a5dd9007b0340ac9181f5ca5c512a51" contextRef="c20230101to20231231_ConsolidationItemsAxis_OperatingSegmentsMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">43,218</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="width: 64%;" rowspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="vertical-align: top; width: 64%; background-color: #CCEEFF;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in;">Expenditures for additions to long-lived assets<br/>
                </p>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1"><ix:nonFraction name="us-gaap:SegmentExpenditureAdditionToLongLivedAssets" id="Fact_f8f78c1912d249afbe4bd053df7f5e9b" contextRef="c20230101to20231231_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_ADMABioManufacturingSegmentMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,952</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1"><ix:nonFraction name="us-gaap:SegmentExpenditureAdditionToLongLivedAssets" id="Fact_6c0a9b0ac0894aba9ec291c5cb901b96" contextRef="c20230101to20231231_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PlasmaCollectionCentersSegmentMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,819</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1"><ix:nonFraction name="us-gaap:SegmentExpenditureAdditionToLongLivedAssets" id="Fact_3416f57f15e042a4a1527af5f5735e02" contextRef="c20230101to20231231_ConsolidationItemsAxis_OperatingSegmentsMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,771</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="vertical-align: top; width: 64%;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in;">Total assets</p>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1"><ix:nonFraction name="us-gaap:Assets" id="Fact_8d8d22a697d6490484d2574192cba8ca" contextRef="c20231231_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_ADMABioManufacturingSegmentMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">246,719</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1"><ix:nonFraction name="us-gaap:Assets" id="Fact_d797fcb2c4b74ed780a746116aa4149d" contextRef="c20231231_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PlasmaCollectionCentersSegmentMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">34,733</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1"><ix:nonFraction name="us-gaap:Assets" id="Fact_d9a64c183218446ab0c8b63acd16f238" contextRef="c20231231_ConsolidationItemsAxis_OperatingSegmentsMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">281,452</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="vertical-align: top; width: 64%; background-color: #CCEEFF;" rowspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="vertical-align: top; width: 64%;" rowspan="1"><span style="font-style: italic;">Reconciliation of revenues:</span><br/>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="vertical-align: top; text-indent: 9pt; width: 64%; background-color: #CCEEFF;" rowspan="1">Segment revenue<br/>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">$ <br/>
              </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_fedd377204174df0bb3a7dfa410c9501" contextRef="c20230101to20231231_ConsolidationItemsAxis_OperatingSegmentsMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">258,072</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="vertical-align: top; text-indent: 9pt; width: 64%; padding-bottom: 2px;" rowspan="1">License revenue (see Note 2 - Revenue Recognition)<br/>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_cfefda0de2f345df82ce3633a814b744" contextRef="c20230101to20231231_ConsolidationItemsAxis_MaterialReconcilingItemsMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">143</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="vertical-align: top; text-indent: 18pt; width: 64%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" rowspan="1">Consolidated revenues<br/>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 4px double rgb(0, 0, 0);" rowspan="1" colspan="1">$</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 4px double rgb(0, 0, 0);" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_8c70def57fbc4414ac73f039de0476b4" contextRef="c20230101to20231231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">258,215</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="vertical-align: top; width: 64%;" rowspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="vertical-align: top; width: 64%; background-color: rgb(204, 238, 255);" rowspan="1">
                <div style="margin-left: 9pt; text-indent: -9pt;"><span style="font-style: italic;">Reconciliation of selling, general and administrative expense:</span><br/>
                </div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="vertical-align: top; text-indent: 9pt; width: 64%;" rowspan="1">Segment selling, marketing and distribution expense<br/>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">$</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:SellingAndMarketingExpense" id="Fact_10bbaf3f1cb644b2ad9612fe946783de" contextRef="c20230101to20231231_ConsolidationItemsAxis_OperatingSegmentsMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">18,407</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="vertical-align: top; text-indent: 9pt; width: 64%; background-color: #CCEEFF;" rowspan="1">Segment general and administrative expense<br/>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" id="Fact_6e7ecc7cc7454800a77f94265ae2fdd0" contextRef="c20230101to20231231_ConsolidationItemsAxis_OperatingSegmentsMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">18,625</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="vertical-align: top; text-indent: 9pt; width: 64%; padding-bottom: 2px;" rowspan="1">Corporate general and administrative expense (a)<br/>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" id="Fact_1ebee0d4064242ba89bb9e7237a76696" contextRef="c20230101to20231231_ConsolidationItemsAxis_CorporateNonSegmentMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">21,988</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="vertical-align: top; width: 64%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" rowspan="1">
                <div style="margin-left: 9pt">
                  <div style="margin-left: 9pt">
                    <div style="margin-left: 9pt; text-indent: -9pt;">Consolidated selling, general and administrative expense<br/>
                    </div>
                  </div>
                </div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 4px double rgb(0, 0, 0);" rowspan="1" colspan="1">$</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 4px double rgb(0, 0, 0);" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:SellingGeneralAndAdministrativeExpense" id="Fact_ca4d6839999745f2a3ce25d30036a3fe" contextRef="c20230101to20231231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">59,020</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="vertical-align: top; width: 64%;" rowspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="vertical-align: top; width: 64%; background-color: #CCEEFF;" rowspan="1"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: italic; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: nowrap; background-color: rgb(204, 238, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; display: inline !important; float: none;">Reconciliation of income (loss) before taxes:</span></td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="vertical-align: top; text-indent: 9pt; width: 64%;" rowspan="1">Segment income before taxes<br/>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">$</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" id="Fact_9e293c19334546728387bfc4030e02a6" contextRef="c20230101to20231231_ConsolidationItemsAxis_OperatingSegmentsMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">43,218</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="vertical-align: top; text-indent: 9pt; width: 64%; background-color: #CCEEFF;" rowspan="1">License revenue<br/>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" id="Fact_744bc2720acb40348cc4c2503eb8ac01" contextRef="c20230101to20231231_ConsolidationItemsAxis_MaterialReconcilingItemsMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">143</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="vertical-align: top; width: 64%;" rowspan="1">
                <div style="margin-left: 9pt">
                  <div style="margin-left: 9pt; text-indent: -9pt;">Unallocated interest expense, primaril related to interest on senior debt (see Note 7)<br/>
                  </div>
                </div>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" rowspan="1" colspan="1">(<ix:nonFraction name="us-gaap:InterestExpenseNonoperating" id="Fact_5a4703098c3b4110bea4a7b670315895" contextRef="c20230101to20231231_ConsolidationItemsAxis_MaterialReconcilingItemsMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">25,027</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">)</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="vertical-align: top; text-indent: 9pt; width: 64%; background-color: #CCEEFF;" rowspan="1">Loss on extinguishment of debt (see Note 7)<br/>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" rowspan="1" colspan="1">(<ix:nonFraction name="us-gaap:GainsLossesOnExtinguishmentOfDebt" id="Fact_1eca47fbd2fb4aa0b039c90fd3e6b4ff" contextRef="c20230101to20231231_ConsolidationItemsAxis_MaterialReconcilingItemsMember" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">26,174</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">)</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="vertical-align: top; text-indent: 9pt; width: 64%;" rowspan="1">Unallocated interest income<br/>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:InvestmentIncomeInterest" id="Fact_1f2b517d71d14f6f8848374d9de6d3fd" contextRef="c20230101to20231231_ConsolidationItemsAxis_MaterialReconcilingItemsMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,589</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="vertical-align: top; text-indent: 9pt; width: 64%; background-color: rgb(204, 238, 255); padding-bottom: 2px;" rowspan="1">Corporate general and administrative expense (a)<br/>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); padding-bottom: 2px;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); padding-bottom: 2px;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0);" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0);" rowspan="1" colspan="1">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" id="Fact_59d303f1d98c47bf8afbfb622cfe76d6" contextRef="c20230101to20231231_ConsolidationItemsAxis_CorporateNonSegmentMember" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">21,988</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; white-space: nowrap;" rowspan="1" colspan="1">)</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="vertical-align: top; text-indent: 18pt; width: 64%; padding-bottom: 4px;" rowspan="1">Consolidated income before taxes<br/>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);" rowspan="1" colspan="1">$</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);" rowspan="1" colspan="1">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" id="Fact_75bc1402d2b44c57af4f5a6040f47847" contextRef="c20230101to20231231" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">28,239</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" rowspan="1" colspan="1">)</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="vertical-align: top; width: 64%; background-color: #CCEEFF;" rowspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="vertical-align: top; width: 64%;" rowspan="1"><span style="font-style: italic;">Reconciliation of total assets:</span><br/>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="vertical-align: top; text-indent: 9pt; width: 64%; background-color: #CCEEFF;" rowspan="1">Total segment assets<br/>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">$ <br/>
              </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:Assets" id="Fact_ac41d72eaf96475dbf5d16581d82ad69" contextRef="c20231231_ConsolidationItemsAxis_OperatingSegmentsMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">281,452</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="vertical-align: top; text-indent: 9pt; width: 64%; padding-bottom: 2px;" rowspan="1">Corporate (b)<br/>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:Assets" id="Fact_c0dc9246cefd4ef981112d0b8e335383" contextRef="c20231231_ConsolidationItemsAxis_CorporateNonSegmentMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">47,730</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="vertical-align: top; text-indent: 18pt; width: 64%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" rowspan="1">Consolidated total assets<br/>
              </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 4px double rgb(0, 0, 0);" rowspan="1" colspan="1">$</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 4px double rgb(0, 0, 0);" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:Assets" id="Fact_e413a6e1252545f2ac7d715724e468ac" contextRef="c20231231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">329,182</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>


</table>
</ix:continuation></ix:continuation>
        <ix:continuation id="Text_0749860a5f6042ceb1695fcf4886baa912" continuedAt="Text_0749860a5f6042ceb1695fcf4886baa913"><ix:continuation id="Text_e517091741664c3c9ead9e199c0a71d910" continuedAt="Text_e517091741664c3c9ead9e199c0a71d911"><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;"> <br/>
        </p></ix:continuation></ix:continuation>
        <ix:continuation id="Text_0749860a5f6042ceb1695fcf4886baa913" continuedAt="Text_0749860a5f6042ceb1695fcf4886baa914"><ix:continuation id="Text_e517091741664c3c9ead9e199c0a71d911" continuedAt="Text_e517091741664c3c9ead9e199c0a71d912">
<table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-spacing: 0;" class="DSPFListTable">


  <tr style="vertical-align: top;">

    <td style="text-align: right; vertical-align: top; width: 27pt;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;">(a) - <br/>
                </p>
              </td>

    <td style="text-align: left; vertical-align: top;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: justify;">Primarily includes compensation expense, including stock-based compensation expense, for certain executive officers and consultants, insurance,
                  legal and investor relations expenses and accounting and tax fees that are not allocated to the Company&#8217;s operating segments.</p>
              </td>

  </tr>


</table>
</ix:continuation></ix:continuation>
        <ix:continuation id="Text_0749860a5f6042ceb1695fcf4886baa914" continuedAt="Text_0749860a5f6042ceb1695fcf4886baa915"><ix:continuation id="Text_e517091741664c3c9ead9e199c0a71d912" continuedAt="Text_e517091741664c3c9ead9e199c0a71d913"><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;"> </p></ix:continuation></ix:continuation>
        <ix:continuation id="Text_0749860a5f6042ceb1695fcf4886baa915" continuedAt="Text_0749860a5f6042ceb1695fcf4886baa916"><ix:continuation id="Text_e517091741664c3c9ead9e199c0a71d913" continuedAt="Text_e517091741664c3c9ead9e199c0a71d914"><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;"> </p></ix:continuation></ix:continuation>
        <ix:continuation id="Text_0749860a5f6042ceb1695fcf4886baa916" continuedAt="Text_0749860a5f6042ceb1695fcf4886baa917"><ix:continuation id="Text_e517091741664c3c9ead9e199c0a71d914" continuedAt="Text_e517091741664c3c9ead9e199c0a71d915"><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;"> <br/>
        </p></ix:continuation></ix:continuation>
        <ix:continuation id="Text_0749860a5f6042ceb1695fcf4886baa917" continuedAt="Text_0749860a5f6042ceb1695fcf4886baa918"><ix:continuation id="Text_e517091741664c3c9ead9e199c0a71d915" continuedAt="Text_e517091741664c3c9ead9e199c0a71d916">
<table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-spacing: 0;" class="DSPFListTable">


  <tr style="vertical-align: top;">

    <td style="text-align: right; vertical-align: top; width: 27pt;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;">(b) -<br/>
                </p>
              </td>

    <td style="text-align: left; vertical-align: top;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;"><ix:footnote id="Foot_0c35b5dd3cb44596b792fca041b80d28" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US">Primarily consists of cash.</ix:footnote></p>
              </td>

  </tr>


</table>
</ix:continuation></ix:continuation>
        <ix:continuation id="Text_0749860a5f6042ceb1695fcf4886baa918" continuedAt="Text_0749860a5f6042ceb1695fcf4886baa919"><ix:continuation id="Text_e517091741664c3c9ead9e199c0a71d916" continuedAt="Text_e517091741664c3c9ead9e199c0a71d917"><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;"> </p></ix:continuation></ix:continuation>
        <ix:continuation id="Text_0749860a5f6042ceb1695fcf4886baa919" continuedAt="Text_0749860a5f6042ceb1695fcf4886baa920"><ix:continuation id="Text_e517091741664c3c9ead9e199c0a71d917" continuedAt="Text_e517091741664c3c9ead9e199c0a71d918"><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;"> </p></ix:continuation></ix:continuation>
        <ix:continuation id="Text_0749860a5f6042ceb1695fcf4886baa920" continuedAt="Text_0749860a5f6042ceb1695fcf4886baa921"><ix:continuation id="Text_e517091741664c3c9ead9e199c0a71d918" continuedAt="Text_e517091741664c3c9ead9e199c0a71d919"><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;"> <br/>
        </p></ix:continuation></ix:continuation>
        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">F-35</span></div>

          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"/></div>

          <div style="width: 100%;" class="BRPFPageHeader">
            <div>
              <div style="text-align: left; font-weight: bold; text-indent: -9pt; margin-left: 9pt;"><a href="#ADMABIOLOGICSINC."> <span style="font-style: italic; font-weight: normal; font-size: 8pt;">Table of Contents</span></a><br/>
              </div>

              <div style="text-align: left; font-weight: bold; text-indent: -9pt; margin-left: 9pt;"><a href="#ADMABIOLOGICSINC."><span style="font-style: italic; font-weight: normal; font-size: 8pt;"> <br/>
                  </span></a></div>

              <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">ADMA BIOLOGICS, INC. AND SUBSIDIARIES</div>

              <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</div>

            </div>

          </div>

        </div>

        <div>
          <ix:continuation id="Text_0749860a5f6042ceb1695fcf4886baa921" continuedAt="Text_0749860a5f6042ceb1695fcf4886baa922"><ix:continuation id="Text_e517091741664c3c9ead9e199c0a71d919" continuedAt="Text_e517091741664c3c9ead9e199c0a71d920">
<table cellspacing="0" cellpadding="0" border="0" style="text-align: left; font: 10pt 'Times New Roman'; width: 100%; border-spacing: 0;" class="cfttable">


  <tr style="height: 15px;">

    <td valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;" colspan="12">
                  <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: center;"><strong>Year Ended December 31, 2022</strong></p>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="padding-bottom: 2px;">
                  <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: center;"><span style="font-style: italic;">(in thousands)</span><br/>
                  </p>
                </td>

    <td valign="bottom" style="text-align: center; vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: center; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="2">
                  <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: center;"><strong>ADMA</strong></p>
                  <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: center;"><strong> BioManufacturing</strong></p>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: center; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: center; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="2">
                  <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: center;"><strong>Plasma Collection<br/>
                    </strong></p>
                  <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: center;"><span style="font-weight: bold;">Centers</span><strong><br/>
                    </strong></p>
                  <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: center;"><strong> </strong></p>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: center; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: center; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="2">
                  <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: center;"><strong>Total</strong></p>
                </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="vertical-align: top; width: 64%; background-color: #CCEEFF;">
                  <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in;">Revenues</p>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">$</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_f96d1dbcd0134075955b04bbdca12cad" contextRef="c20220101to20221231_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_ADMABioManufacturingSegmentMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">144,070</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">$</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_d7a716999d1d4f6cb583eecb70b5d7ea" contextRef="c20220101to20221231_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PlasmaCollectionCentersSegmentMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">9,867</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">$</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_72336b532f954dcdb84d53ec77305175" contextRef="c20220101to20221231_ConsolidationItemsAxis_OperatingSegmentsMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">153,937</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="width: 64%;">
                  <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px;">&#160;</p>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="vertical-align: top; width: 64%; background-color: #CCEEFF;">
                  <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in;">Cost of product revenue</p>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1"><ix:nonFraction name="us-gaap:CostOfRevenue" id="Fact_cf086a75ef524bf69b11a8012be7fc83" contextRef="c20220101to20221231_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_ADMABioManufacturingSegmentMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">108,882</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1"><ix:nonFraction name="us-gaap:CostOfRevenue" id="Fact_d0fa356c45434ec4b8f546270f40701c" contextRef="c20220101to20221231_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PlasmaCollectionCentersSegmentMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">9,933</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1"><ix:nonFraction name="us-gaap:CostOfRevenue" id="Fact_68c77333a7a54c8b860716e338e12c43" contextRef="c20220101to20221231_ConsolidationItemsAxis_OperatingSegmentsMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">118,815</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="width: 64%;">
                  <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px;">&#160;</p>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="vertical-align: top; width: 64%; background-color: #CCEEFF;">
                  <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in;">Research and development<br/>
                  </p>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" id="Fact_c011512cbed54d61aa377153553876b3" contextRef="c20220101to20221231_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_ADMABioManufacturingSegmentMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,614</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" id="Fact_a4b752a71f5547b5bd41d034637b1cb3" contextRef="c20220101to20221231_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PlasmaCollectionCentersSegmentMember" unitRef="U001" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" id="Fact_fd7d859e097f4834b659fd8daf2625b7" contextRef="c20220101to20221231_ConsolidationItemsAxis_OperatingSegmentsMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,614</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="width: 64%;">
                  <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px;">&#160;</p>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="vertical-align: top; width: 64%; background-color: #CCEEFF;">
                  <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in;">Plasma center operating expenses<br/>
                  </p>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1"><ix:nonFraction name="us-gaap:OtherCostAndExpenseOperating" id="Fact_7dd536d22abc4f8eb78c45879b84b53c" contextRef="c20220101to20221231_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_ADMABioManufacturingSegmentMember" unitRef="U001" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1"><ix:nonFraction name="us-gaap:OtherCostAndExpenseOperating" id="Fact_fa0e60b8c05541ef9b745e43e5b8ba2e" contextRef="c20220101to20221231_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PlasmaCollectionCentersSegmentMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">17,843</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1"><ix:nonFraction name="us-gaap:OtherCostAndExpenseOperating" id="Fact_b662b88ed21645c3829c49430943f68a" contextRef="c20220101to20221231_ConsolidationItemsAxis_OperatingSegmentsMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">17,843</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="width: 64%;">
                  <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px;">&#160;</p>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="vertical-align: top; width: 64%; background-color: #CCEEFF;" rowspan="1">Selling, marketing and distribution<br/>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:SellingAndMarketingExpense" id="Fact_cf26603248ed47448a1c16cda7d5e26d" contextRef="c20220101to20221231_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_ADMABioManufacturingSegmentMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">13,667</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:SellingAndMarketingExpense" id="Fact_13596668ee4f4f79b0f7b653a3fa6088" contextRef="c20220101to20221231_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PlasmaCollectionCentersSegmentMember" unitRef="U001" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:SellingAndMarketingExpense" id="Fact_ff99c9c2c0114411a69ab0e70645a877" contextRef="c20220101to20221231_ConsolidationItemsAxis_OperatingSegmentsMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">13,667</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="vertical-align: top; width: 64%;" rowspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="vertical-align: top; width: 64%; background-color: #CCEEFF;">
                  <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in;">Depreciation and amortization expense<br/>
                  </p>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1"><ix:nonFraction name="us-gaap:DepreciationAndAmortization" id="Fact_67fe4ffe95b8427db77c1de051d0fb49" contextRef="c20220101to20221231_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_ADMABioManufacturingSegmentMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,709</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1"><ix:nonFraction name="us-gaap:DepreciationAndAmortization" id="Fact_0a1859b34bb0496f8220534dc30e2a69" contextRef="c20220101to20221231_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PlasmaCollectionCentersSegmentMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,404</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1"><ix:nonFraction name="us-gaap:DepreciationAndAmortization" id="Fact_d1e6f8e02a7f489298750456aeec56c6" contextRef="c20220101to20221231_ConsolidationItemsAxis_OperatingSegmentsMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">7,113</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="width: 64%;">
                  <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px;">&#160;</p>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="width: 64%; background-color: #CCEEFF;" rowspan="1">General and administrative expense<br/>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" id="Fact_336f0045a1c04933a1aca2e1e1d15a99" contextRef="c20220101to20221231_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_ADMABioManufacturingSegmentMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">16,312</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" id="Fact_9af1c560887c46c8a72763338b6274ed" contextRef="c20220101to20221231_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PlasmaCollectionCentersSegmentMember" unitRef="U001" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" id="Fact_b8c7013cb32244ce80a91810a7e84747" contextRef="c20220101to20221231_ConsolidationItemsAxis_OperatingSegmentsMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">16,312</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="width: 64%;" rowspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="width: 64%; background-color: #CCEEFF;" rowspan="1">Income (loss) before taxes<br/>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" id="Fact_eb4f5bf8650a40dda6d35a0f10d940e0" contextRef="c20220101to20221231_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_ADMABioManufacturingSegmentMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">374</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" rowspan="1" colspan="1">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" id="Fact_4b835b043227440b94ba4e14b5296fed" contextRef="c20220101to20221231_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PlasmaCollectionCentersSegmentMember" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">17,911</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">)</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" rowspan="1" colspan="1">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" id="Fact_91b3dc9ed1554bd88a7763bc97023bf8" contextRef="c20220101to20221231_ConsolidationItemsAxis_OperatingSegmentsMember" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">17,537</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">)</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="width: 64%;" rowspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="vertical-align: top; width: 64%; background-color: #CCEEFF;">
                  <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in;">Expenditures for additions to long-lived assets<br/>
                  </p>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1"><ix:nonFraction name="us-gaap:SegmentExpenditureAdditionToLongLivedAssets" id="Fact_3766fa168232400a9109a827f3b3407f" contextRef="c20220101to20221231_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_ADMABioManufacturingSegmentMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">5,247</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1"><ix:nonFraction name="us-gaap:SegmentExpenditureAdditionToLongLivedAssets" id="Fact_56da8687941e4a32a8e20b1f27c49ab9" contextRef="c20220101to20221231_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PlasmaCollectionCentersSegmentMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">8,664</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1"><ix:nonFraction name="us-gaap:SegmentExpenditureAdditionToLongLivedAssets" id="Fact_7f0afb0ea11a47008b50308f09c9e1a6" contextRef="c20220101to20221231_ConsolidationItemsAxis_OperatingSegmentsMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">13,911</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="vertical-align: top; width: 64%;">
                  <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in;">Total assets</p>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1"><ix:nonFraction name="us-gaap:Assets" id="Fact_ca255aabfbe54b9b98eb0bb30364b145" contextRef="c20221231_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_ADMABioManufacturingSegmentMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">238,159</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1"><ix:nonFraction name="us-gaap:Assets" id="Fact_1823cf8b14a84819a1a8a53c40bfe015" contextRef="c20221231_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PlasmaCollectionCentersSegmentMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">37,071</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1"><ix:nonFraction name="us-gaap:Assets" id="Fact_f6be072f53fb43638c4767d3ac86dfd6" contextRef="c20221231_ConsolidationItemsAxis_OperatingSegmentsMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">275,230</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="vertical-align: top; width: 64%; background-color: #CCEEFF;" rowspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="vertical-align: top; width: 64%;" rowspan="1"><span style="font-style: italic;">Reconciliation of revenues:</span><br/>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="vertical-align: top; text-indent: 9pt; width: 64%; background-color: #CCEEFF;" rowspan="1">Segment revenue<br/>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">$</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_6453bdfe288e4681b53882fed47d6c4e" contextRef="c20220101to20221231_ConsolidationItemsAxis_OperatingSegmentsMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">153,937</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="vertical-align: top; text-indent: 9pt; width: 64%; padding-bottom: 2px;" rowspan="1">License revenue (see Note 2 - Revenue Recognition)<br/>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_0e65fb9e11d3400791d0cefa87e371e4" contextRef="c20220101to20221231_ConsolidationItemsAxis_MaterialReconcilingItemsMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">143</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="vertical-align: top; text-indent: 18pt; width: 64%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" rowspan="1">Consolidated revenues<br/>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 4px double rgb(0, 0, 0);" rowspan="1" colspan="1">$</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 4px double rgb(0, 0, 0);" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_9ef9c00ce7724e4a96028448ccbf04ac" contextRef="c20220101to20221231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">154,080</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="vertical-align: top; width: 64%;" rowspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="vertical-align: top; width: 64%; background-color: rgb(204, 238, 255); font-style: italic;" rowspan="1">
                  <div style="margin-left: 9pt; text-indent: -9pt;">Reconciliation of selling, general and administrative expense:<br/>
                  </div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="vertical-align: top; text-indent: 9pt; width: 64%;" rowspan="1">Segment selling, marketing and distribution expense<br/>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">$</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:SellingAndMarketingExpense" id="Fact_4f3bb5e71b55455cbb14cc756fadfcab" contextRef="c20220101to20221231_ConsolidationItemsAxis_OperatingSegmentsMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">13,667</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="vertical-align: top; text-indent: 9pt; width: 64%; background-color: #CCEEFF;" rowspan="1">Segment general and administrative expense<br/>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" id="Fact_130fdb769184487eafd388e0df0668ad" contextRef="c20220101to20221231_ConsolidationItemsAxis_OperatingSegmentsMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">16,312</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="vertical-align: top; text-indent: 9pt; width: 64%; padding-bottom: 2px;" rowspan="1">Corporate general and administrative expense (a)<br/>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" id="Fact_d50c136af3e64211860c504c901e8c64" contextRef="c20220101to20221231_ConsolidationItemsAxis_CorporateNonSegmentMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">22,479</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="vertical-align: top; width: 64%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" rowspan="1">
                  <div style="margin-left: 27pt; text-indent: -9pt;">Consolidated selling, general and administrative expense<br/>
                  </div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 4px double rgb(0, 0, 0);" rowspan="1" colspan="1">$</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 4px double rgb(0, 0, 0);" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:SellingGeneralAndAdministrativeExpense" id="Fact_c2cf3e4b09b54d979b956374a9c5f0fd" contextRef="c20220101to20221231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">52,458</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="vertical-align: top; width: 64%;" rowspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="vertical-align: top; width: 64%; background-color: #CCEEFF;" rowspan="1"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: italic; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: nowrap; background-color: rgb(204, 238, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; display: inline !important; float: none;">Reconciliation of income (loss) before taxes:</span> </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="vertical-align: top; text-indent: 9pt; width: 64%;" rowspan="1">Segment income before taxes<br/>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">$</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" rowspan="1" colspan="1">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" id="Fact_7209d793b2994319b95fe9ef251f3e2d" contextRef="c20220101to20221231_ConsolidationItemsAxis_OperatingSegmentsMember" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">17,537</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">)</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="vertical-align: top; text-indent: 9pt; width: 64%; background-color: #CCEEFF;" rowspan="1">License revenue<br/>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" id="Fact_6bb98e9f0a4844c1b5baac97ac44ad13" contextRef="c20220101to20221231_ConsolidationItemsAxis_MaterialReconcilingItemsMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">143</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="vertical-align: top; width: 64%;" rowspan="1">
                  <div style="margin-left: 9pt">
                    <div style="margin-left: 9pt; text-indent: -9pt;">Unallocated interest expense, primaril related to interest on senior debt (see Note 7)<br/>
                    </div>
                  </div>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" rowspan="1" colspan="1">(<ix:nonFraction name="us-gaap:InterestExpenseNonoperating" id="Fact_09db89ae53b8440ab284f78e50c79e5b" contextRef="c20220101to20221231_ConsolidationItemsAxis_MaterialReconcilingItemsMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">19,276</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">)</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="vertical-align: top; text-indent: 9pt; width: 64%; background-color: #CCEEFF;" rowspan="1">Loss on extinguishment of debt (see Note 7)<br/>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" rowspan="1" colspan="1">(<ix:nonFraction name="us-gaap:GainsLossesOnExtinguishmentOfDebt" id="Fact_60450abc58df4411a8d9b2e7cf2fd1ca" contextRef="c20220101to20221231_ConsolidationItemsAxis_MaterialReconcilingItemsMember" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">6,670</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">)</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="vertical-align: top; text-indent: 9pt; width: 64%;" rowspan="1">Other expense<br/>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" rowspan="1" colspan="1">(<ix:nonFraction name="us-gaap:NonoperatingIncomeExpense" id="Fact_1702eb25c5774d3181942a7c1ee87126" contextRef="c20220101to20221231_ConsolidationItemsAxis_OperatingSegmentsMember" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">85</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">)</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="vertical-align: top; text-indent: 9pt; width: 64%; background-color: rgb(204, 238, 255); padding-bottom: 2px;" rowspan="1">Corporate general and administrative expense (a)<br/>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); padding-bottom: 2px;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); padding-bottom: 2px;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0);" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0);" rowspan="1" colspan="1">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" id="Fact_4dc192bb6874460db027219d6a8cbdc1" contextRef="c20220101to20221231_ConsolidationItemsAxis_CorporateNonSegmentMember" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">22,479</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; white-space: nowrap;" rowspan="1" colspan="1">)</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="vertical-align: top; text-indent: 18pt; width: 64%; padding-bottom: 4px;" rowspan="1">Consolidated income before taxes<br/>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);" rowspan="1" colspan="1">$</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);" rowspan="1" colspan="1">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" id="Fact_dc87a1ba197a49558c968cf461149ec5" contextRef="c20220101to20221231" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">65,904</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" rowspan="1" colspan="1">)</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="vertical-align: top; width: 64%; background-color: #CCEEFF;" rowspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="vertical-align: top; width: 64%;" rowspan="1"><span style="font-style: italic;">Reconciliation of total assets:</span><br/>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="vertical-align: top; text-indent: 9pt; width: 64%; background-color: #CCEEFF;" rowspan="1">Total segment assets<br/>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" rowspan="1" colspan="1">$</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:Assets" id="Fact_77ad8e25bc79486f937301c3ec7a7c1a" contextRef="c20221231_ConsolidationItemsAxis_OperatingSegmentsMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">275,230</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="vertical-align: top; text-indent: 9pt; width: 64%; padding-bottom: 2px;" rowspan="1">Corporate (b)<br/>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:Assets" id="Fact_92e4d85a8785438787156b3774d98556" contextRef="c20221231_ConsolidationItemsAxis_CorporateNonSegmentMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">73,231</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="vertical-align: top; text-indent: 18pt; width: 64%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" rowspan="1">Consolidated total assets<br/>
                </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 4px double rgb(0, 0, 0);" rowspan="1" colspan="1">$</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 4px double rgb(0, 0, 0);" rowspan="1" colspan="1"><ix:nonFraction name="us-gaap:Assets" id="Fact_22b4ad4fed9242b39e838a90f901879f" contextRef="c20221231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">348,461</ix:nonFraction></td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

  </tr>


</table>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_0749860a5f6042ceb1695fcf4886baa922" continuedAt="Text_0749860a5f6042ceb1695fcf4886baa923"><ix:continuation id="Text_e517091741664c3c9ead9e199c0a71d920" continuedAt="Text_e517091741664c3c9ead9e199c0a71d921">
<div><br/>
          </div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_0749860a5f6042ceb1695fcf4886baa923" continuedAt="Text_0749860a5f6042ceb1695fcf4886baa924"><ix:continuation id="Text_e517091741664c3c9ead9e199c0a71d921" continuedAt="Text_e517091741664c3c9ead9e199c0a71d922">
<div>
            <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-spacing: 0;" class="DSPFListTable">


  <tr style="vertical-align: top;">

    <td style="text-align: right; vertical-align: top; width: 27pt;">
                    <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;">(a) - <br/>
                    </p>
                  </td>

    <td style="text-align: left; vertical-align: top;">
                    <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: justify;">Primarily includes compensation expense, including stock-based compensation expense, for certain executive officers and consultants,
                      insurance, legal and investor relations expenses and accounting and tax fees that are not allocated to the Company&#8217;s operating segments.</p>
                  </td>

  </tr>


</table>
          </div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_0749860a5f6042ceb1695fcf4886baa924" continuedAt="Text_0749860a5f6042ceb1695fcf4886baa925"><ix:continuation id="Text_e517091741664c3c9ead9e199c0a71d922" continuedAt="Text_e517091741664c3c9ead9e199c0a71d923">
<div><br/>
          </div>
</ix:continuation></ix:continuation>
          <ix:continuation id="Text_0749860a5f6042ceb1695fcf4886baa925" continuedAt="Text_0749860a5f6042ceb1695fcf4886baa926"><ix:continuation id="Text_e517091741664c3c9ead9e199c0a71d923">
<div>
            <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-spacing: 0;" class="DSPFListTable">


  <tr style="vertical-align: top;">

    <td style="text-align: right; vertical-align: top; width: 27pt;">
                    <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;">(b) -<br/>
                    </p>
                  </td>

    <td style="text-align: left; vertical-align: top;">
                    <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;">Primarily consists of cash.</p>
                  </td>

  </tr>


</table>
             </div>
</ix:continuation></ix:continuation>
          <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
            <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">F-36</span></div>

            <div style="page-break-after: always;" class="BRPFPageBreak">
              <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"/></div>

            <div style="width: 100%;" class="BRPFPageHeader">
              <div>
                <div style="text-align: left; font-weight: bold; text-indent: -9pt; margin-left: 9pt;"><a href="#ADMABIOLOGICSINC."> <span style="font-style: italic; font-weight: normal; font-size: 8pt;">Table of Contents</span></a><br/>
                </div>

                <div style="text-align: left; font-weight: bold; text-indent: -9pt; margin-left: 9pt;"><a href="#ADMABIOLOGICSINC."><span style="font-style: italic; font-weight: normal; font-size: 8pt;"> <br/>
                    </span></a></div>

                <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">ADMA BIOLOGICS, INC. AND SUBSIDIARIES</div>

                <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</div>

              </div>

            </div>

          </div>

          <div style="text-indent: 18pt;">
            <ix:continuation id="Text_0749860a5f6042ceb1695fcf4886baa926" continuedAt="Text_0749860a5f6042ceb1695fcf4886baa927">
<div style="display:none;"><br/></div>
<div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
            </div>
</ix:continuation>

            <ix:continuation id="Text_0749860a5f6042ceb1695fcf4886baa927" continuedAt="Text_0749860a5f6042ceb1695fcf4886baa928"><ix:nonNumeric name="us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock" id="Text_ecd64bba03eb424597eb6fcf5ab856c7" contextRef="c20240101to20241231" escape="true" continuedAt="Text_0177192540874422bab99ea5c2a336531">
<div style="display:none;"><br/></div>
<div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">Net revenues according to geographic area, based on the location of where the product is shipped, are as follows:</div>
</ix:nonNumeric></ix:continuation>
            <ix:continuation id="Text_0749860a5f6042ceb1695fcf4886baa928" continuedAt="Text_0749860a5f6042ceb1695fcf4886baa929"><ix:continuation id="Text_0177192540874422bab99ea5c2a336531" continuedAt="Text_0177192540874422bab99ea5c2a336532">
<div><br/>
            </div>
</ix:continuation></ix:continuation>
            <ix:continuation id="Text_0749860a5f6042ceb1695fcf4886baa929" continuedAt="Text_0749860a5f6042ceb1695fcf4886baa930"><ix:continuation id="Text_0177192540874422bab99ea5c2a336532" continuedAt="Text_0177192540874422bab99ea5c2a336533">
<table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%; border-spacing: 0;" class="cfttable">


  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" colspan="18">
                    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Year Ended December 31, 2024</div>
                  </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="2">
                    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">ADMA </div>
                    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">BioManufacturing</div>
                  </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="2">
                    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Plasma Centers</div>
                  </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="2">
                    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Total Segment </div>
                    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Revenue</div>
                  </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="2">
                    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">License </div>
                    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Revenue</div>
                  </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="2">
                    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Consolidated </div>
                    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Revenue</div>
                  </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 40%; background-color: #CCEEFF; white-space: nowrap;">
                    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">United States</div>
                  </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
                  </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_1ee5c7750fee4a309a3c1072332325e7" contextRef="c20240101to20241231_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_ADMABioManufacturingSegmentMember_StatementGeographicalAxis_US" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">400,336</ix:nonFraction></div>
                  </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
                  </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_06bb92271c774c7db3be9bc65672b196" contextRef="c20240101to20241231_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PlasmaCollectionCentersSegmentMember_StatementGeographicalAxis_US" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">9,669</ix:nonFraction></div>
                  </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
                  </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_8634c730e39b423a82a243592aa311c7" contextRef="c20240101to20241231_ConsolidationItemsAxis_OperatingSegmentsMember_StatementGeographicalAxis_US" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">410,005</ix:nonFraction></div>
                  </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
                  </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_137825885e454d5ba7cbb255939c4a6c" contextRef="c20240101to20241231_ConsolidationItemsAxis_MaterialReconcilingItemsMember_StatementGeographicalAxis_US" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">143</ix:nonFraction></div>
                  </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
                  </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_de6a386d5581405dbce900eeece23f0e" contextRef="c20240101to20241231_StatementGeographicalAxis_US" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">410,148</ix:nonFraction></div>
                  </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 40%; padding-bottom: 2px; white-space: nowrap;">
                    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">International</div>
                  </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_1f2de7f70a154db58e6281f1ee32956a" contextRef="c20240101to20241231_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_ADMABioManufacturingSegmentMember_StatementGeographicalAxis_NonUsMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">15,470</ix:nonFraction></div>
                  </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_af6bb08259de4e8eb02751466f21ba52" contextRef="c20240101to20241231_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PlasmaCollectionCentersSegmentMember_StatementGeographicalAxis_NonUsMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">836</ix:nonFraction></div>
                  </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_e30b5a28a13c4e29ae7976594b5c1695" contextRef="c20240101to20241231_ConsolidationItemsAxis_OperatingSegmentsMember_StatementGeographicalAxis_NonUsMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">16,306</ix:nonFraction></div>
                  </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_caf25de36915484a81c7bc2be4247f83" contextRef="c20240101to20241231_ConsolidationItemsAxis_MaterialReconcilingItemsMember_StatementGeographicalAxis_NonUsMember" unitRef="U001" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></div>
                  </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_b48ef3b4f5a34ef58fc99c316f76eb0b" contextRef="c20240101to20241231_StatementGeographicalAxis_NonUsMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">16,306</ix:nonFraction></div>
                  </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 40%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">
                    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Total revenues</div>
                  </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
                  </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_96dce6ab5b7747ac92d3715d2282daa3" contextRef="c20240101to20241231_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_ADMABioManufacturingSegmentMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">415,806</ix:nonFraction></div>
                  </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
                  </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_b5cf992908704ac8959dc605894ecbf9" contextRef="c20240101to20241231_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PlasmaCollectionCentersSegmentMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">10,505</ix:nonFraction></div>
                  </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
                  </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_941188c6e74e4318bdc858ebdd9a1d4d" contextRef="c20240101to20241231_ConsolidationItemsAxis_OperatingSegmentsMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">426,311</ix:nonFraction></div>
                  </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
                  </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_354a9b038dfa4c6ead3b7c7217e41981" contextRef="c20240101to20241231_ConsolidationItemsAxis_MaterialReconcilingItemsMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">143</ix:nonFraction></div>
                  </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
                  </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_7dd1ac4efffb4f019e711dc76d0973b5" contextRef="c20240101to20241231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">426,454</ix:nonFraction></div>
                  </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>


</table>
</ix:continuation></ix:continuation>
            <ix:continuation id="Text_0749860a5f6042ceb1695fcf4886baa930" continuedAt="Text_0749860a5f6042ceb1695fcf4886baa931"><ix:continuation id="Text_0177192540874422bab99ea5c2a336533" continuedAt="Text_0177192540874422bab99ea5c2a336534">
<div><br/>
            </div>
</ix:continuation></ix:continuation>
            <ix:continuation id="Text_0749860a5f6042ceb1695fcf4886baa931" continuedAt="Text_0749860a5f6042ceb1695fcf4886baa932"><ix:continuation id="Text_0177192540874422bab99ea5c2a336534" continuedAt="Text_0177192540874422bab99ea5c2a336535">
<table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%; border-spacing: 0;" class="cfttable">


  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" colspan="18">
                    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Year Ended December 31, 2023</div>
                  </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="2">
                    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">ADMA </div>
                    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">BioManufacturing</div>
                  </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="2">
                    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Plasma Centers</div>
                  </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="2">
                    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Total Segment </div>
                    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Revenue</div>
                  </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="2">
                    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">License </div>
                    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Revenue</div>
                  </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="2">
                    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Consolidated </div>
                    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Revenue</div>
                  </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 40%; background-color: #CCEEFF; white-space: nowrap;">
                    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">United States</div>
                  </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
                  </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_ae2744628c9444c7ad5745b01ff041fe" contextRef="c20230101to20231231_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_ADMABioManufacturingSegmentMember_StatementGeographicalAxis_US" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">237,454</ix:nonFraction></div>
                  </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
                  </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_1c1a22a3d5ab47d6af3f68d64a1b56be" contextRef="c20230101to20231231_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PlasmaCollectionCentersSegmentMember_StatementGeographicalAxis_US" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">7,284</ix:nonFraction></div>
                  </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
                  </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_aa444822605d42568890bf98641dfbdb" contextRef="c20230101to20231231_ConsolidationItemsAxis_OperatingSegmentsMember_StatementGeographicalAxis_US" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">244,738</ix:nonFraction></div>
                  </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
                  </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_00ccb6c323d0491485f7dd1b9b8e5bd9" contextRef="c20230101to20231231_ConsolidationItemsAxis_MaterialReconcilingItemsMember_StatementGeographicalAxis_US" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">143</ix:nonFraction></div>
                  </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
                  </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_6f0a386b81944a6088da937db876f6e9" contextRef="c20230101to20231231_StatementGeographicalAxis_US" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">244,881</ix:nonFraction></div>
                  </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 40%; padding-bottom: 2px; white-space: nowrap;">
                    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">International</div>
                  </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_85370041d8ca4aa8966aeebf89c3c533" contextRef="c20230101to20231231_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_ADMABioManufacturingSegmentMember_StatementGeographicalAxis_NonUsMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">12,284</ix:nonFraction></div>
                  </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_32ca595dee9844c9b9f951139c2f22ee" contextRef="c20230101to20231231_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PlasmaCollectionCentersSegmentMember_StatementGeographicalAxis_NonUsMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,050</ix:nonFraction></div>
                  </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_a1bf8fdff1134f3f915c86dcca8483a3" contextRef="c20230101to20231231_ConsolidationItemsAxis_OperatingSegmentsMember_StatementGeographicalAxis_NonUsMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">13,334</ix:nonFraction></div>
                  </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_a69eba547a7541dda2a3f10deaf215b8" contextRef="c20230101to20231231_ConsolidationItemsAxis_MaterialReconcilingItemsMember_StatementGeographicalAxis_NonUsMember" unitRef="U001" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></div>
                  </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_0f19cc0475b849f3983cd60e444df5f7" contextRef="c20230101to20231231_StatementGeographicalAxis_NonUsMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">13,334</ix:nonFraction></div>
                  </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 40%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">
                    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Total revenues</div>
                  </td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
                  </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_11adb00d4888498f9d09e9bba9831a76" contextRef="c20230101to20231231_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_ADMABioManufacturingSegmentMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">249,738</ix:nonFraction></div>
                  </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
                  </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_8cb7c0779a6c4f0e8225323591e0bd84" contextRef="c20230101to20231231_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PlasmaCollectionCentersSegmentMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">8,334</ix:nonFraction></div>
                  </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
                  </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_4ca9d6ab04644187b6e5a6cb960f5113" contextRef="c20230101to20231231_ConsolidationItemsAxis_OperatingSegmentsMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">258,072</ix:nonFraction></div>
                  </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
                  </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_02b6f09cc3104aa5bb8c4be8574eb355" contextRef="c20230101to20231231_ConsolidationItemsAxis_MaterialReconcilingItemsMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">143</ix:nonFraction></div>
                  </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
                  </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_21fc46a934434d858e98c9e75612f21b" contextRef="c20230101to20231231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">258,215</ix:nonFraction></div>
                  </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>


</table>
</ix:continuation></ix:continuation>
            <ix:continuation id="Text_0749860a5f6042ceb1695fcf4886baa932" continuedAt="Text_0749860a5f6042ceb1695fcf4886baa933"><ix:continuation id="Text_0177192540874422bab99ea5c2a336535" continuedAt="Text_0177192540874422bab99ea5c2a336536">
<div><br/>
            </div>
</ix:continuation></ix:continuation>
            <ix:continuation id="Text_0749860a5f6042ceb1695fcf4886baa933"><ix:continuation id="Text_0177192540874422bab99ea5c2a336536">
<table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%; border-spacing: 0;" class="cfttable">


  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" colspan="18">
                    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Year Ended December 31, 2022</div>
                  </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="2">
                    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">ADMA </div>
                    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">BioManufacturing</div>
                  </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="2">
                    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Plasma Centers</div>
                  </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="2">
                    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Total Segment </div>
                    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Revenue</div>
                  </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="2">
                    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">License </div>
                    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Revenue</div>
                  </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="2">
                    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Consolidated </div>
                    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Revenue</div>
                  </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 40%; background-color: #CCEEFF; white-space: nowrap;">
                    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">United States</div>
                  </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
                  </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_843bdf3c4c584e3c97a2254308f05beb" contextRef="c20220101to20221231_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_ADMABioManufacturingSegmentMember_StatementGeographicalAxis_US" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">136,827</ix:nonFraction></div>
                  </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
                  </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_d3cb8c72d3b04decb7835a2b2678f866" contextRef="c20220101to20221231_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PlasmaCollectionCentersSegmentMember_StatementGeographicalAxis_US" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">9,457</ix:nonFraction></div>
                  </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
                  </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_d49112fdda4e436abb0a50413e287a4a" contextRef="c20220101to20221231_ConsolidationItemsAxis_OperatingSegmentsMember_StatementGeographicalAxis_US" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">146,284</ix:nonFraction></div>
                  </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
                  </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_b3616a6718854a9187fe4e5de5094ffb" contextRef="c20220101to20221231_ConsolidationItemsAxis_MaterialReconcilingItemsMember_StatementGeographicalAxis_US" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">143</ix:nonFraction></div>
                  </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
                  </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_fbc73f6ecc8640829af21068d586954d" contextRef="c20220101to20221231_StatementGeographicalAxis_US" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">146,427</ix:nonFraction></div>
                  </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 40%; padding-bottom: 2px; white-space: nowrap;">
                    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">International</div>
                  </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_01d08f2030114af3941788677713adf6" contextRef="c20220101to20221231_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_ADMABioManufacturingSegmentMember_StatementGeographicalAxis_NonUsMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">7,243</ix:nonFraction></div>
                  </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_a06d48a011284af4beaa946bcbb0bfce" contextRef="c20220101to20221231_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PlasmaCollectionCentersSegmentMember_StatementGeographicalAxis_NonUsMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">410</ix:nonFraction></div>
                  </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_58a4cd68080c4d11a67e35eae87f0d93" contextRef="c20220101to20221231_ConsolidationItemsAxis_OperatingSegmentsMember_StatementGeographicalAxis_NonUsMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">7,653</ix:nonFraction></div>
                  </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_c9175b1ed2424b308053acc0a0bf5e3b" contextRef="c20220101to20221231_ConsolidationItemsAxis_MaterialReconcilingItemsMember_StatementGeographicalAxis_NonUsMember" unitRef="U001" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></div>
                  </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="1">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_54b05a920a134f9596367c8237b4cf46" contextRef="c20220101to20221231_StatementGeographicalAxis_NonUsMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">7,653</ix:nonFraction></div>
                  </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; width: 40%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;">
                    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Total revenues</div>
                  </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
                  </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_906425153b154ba58d66b7683d51c743" contextRef="c20220101to20221231_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_ADMABioManufacturingSegmentMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">144,070</ix:nonFraction></div>
                  </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
                  </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_685fd1406a5c4d85855aac60e13b87b5" contextRef="c20220101to20221231_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PlasmaCollectionCentersSegmentMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">9,867</ix:nonFraction></div>
                  </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
                  </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_73ed5a0a23cc464db11e317f40a035c5" contextRef="c20220101to20221231_ConsolidationItemsAxis_OperatingSegmentsMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">153,937</ix:nonFraction></div>
                  </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
                  </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_34ccb488ca224416b690c3c5f9703f68" contextRef="c20220101to20221231_ConsolidationItemsAxis_MaterialReconcilingItemsMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">143</ix:nonFraction></div>
                  </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
                  </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact_b1d18e6546e34c7f931c61daa9f70bed" contextRef="c20220101to20221231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">154,080</ix:nonFraction></div>
                  </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>


</table>
</ix:continuation></ix:continuation>
              </div>

        </div>

        <div><br/></div>

      </div>

    </div>

  </div>


  <div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: rgb(0, 0, 0);">
    <div>
      <div style="text-align: justify; font: 10pt 'Times New Roman';">
        <ix:nonNumeric name="us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock" id="Text_3cd31721beed4c10b4a1000d193d1350" contextRef="c20240101to20241231" escape="true" continuedAt="Text_8dd140c30d8d4c51b8386f9c0e691aaf1">
<div>
          <table cellspacing="0" cellpadding="0" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt; border-spacing: 0;" class="DSPFListTable">


  <tr style="vertical-align: top;">

    <td style="vertical-align: top; width: 27pt;">
                  <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: justify;"><strong>14.</strong></p>
                </td>

    <td style="vertical-align: top; width: auto;">
                  <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: justify;"><span style="text-decoration: underline;"><span style="background-color: rgb(255, 255, 255); font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><strong>OTHER EMPLOYEE BENEFITS</strong></span></span><strong><span style="text-decoration: underline;"><br/>
                      </span></strong></p>
                </td>

  </tr>


</table>
        </div>
</ix:nonNumeric>
        <ix:continuation id="Text_8dd140c30d8d4c51b8386f9c0e691aaf1" continuedAt="Text_8dd140c30d8d4c51b8386f9c0e691aaf2"><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: justify;">&#160;</p></ix:continuation>
        <ix:continuation id="Text_8dd140c30d8d4c51b8386f9c0e691aaf2"><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-indent: 45px; text-align: justify;">The Company sponsors a 401(k) savings plan. Under the plan, employees may make contributions which are eligible for a Company
          discretionary percentage contribution as defined in the plan and determined by the Board. The Company recognized $<ix:nonFraction name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" id="Fact_908e4bf201b340c7bd552e08905a32f8" contextRef="c20240101to20241231" unitRef="U001" decimals="-5" scale="6" format="ixt:num-dot-decimal">1.5</ix:nonFraction> million, $<ix:nonFraction name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" id="Fact_0bce84e1f695468c91641ccddb33de83" contextRef="c20230101to20231231" unitRef="U001" decimals="-5" scale="6" format="ixt:num-dot-decimal">1.3</ix:nonFraction> million and $<ix:nonFraction name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" id="Fact_4cdc3d10cb3c462282162b7857f66dc9" contextRef="c20220101to20221231" unitRef="U001" decimals="-5" scale="6" format="ixt:num-dot-decimal">1.3</ix:nonFraction> million of related
          compensation expense for the years ended December 31, 2024, 2023 and 2022, respectively.</p></ix:continuation>

        <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: justify;">&#160;</p>
      </div>

    </div>

  </div>


  <div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: rgb(0, 0, 0);">
    <div>
      <div style="text-align: left; font: 10pt 'Times New Roman';">
        <ix:nonNumeric name="us-gaap:CashFlowSupplementalDisclosuresTextBlock" id="Text_a3169a60a8a94cd78a7b2bec3d6f21dd" contextRef="c20240101to20241231" escape="true" continuedAt="Text_81b0b26eaffb455fa038f761d448f3911">
<div>
          <table cellspacing="0" cellpadding="0" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt; border-spacing: 0;" class="DSPFListTable">


  <tr style="vertical-align: top;">

    <td style="vertical-align: top; width: 27pt;">
                  <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;"><strong>15.</strong></p>
                </td>

    <td style="align: left; vertical-align: top; width: auto;">
                  <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;"><span style="text-decoration: underline;"><span style="background-color: rgb(255, 255, 255); font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><strong>SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION</strong></span></span><strong><span style="text-decoration: underline;"><br/>
                      </span></strong></p>
                </td>

  </tr>


</table>
        </div>
</ix:nonNumeric>
        <ix:continuation id="Text_81b0b26eaffb455fa038f761d448f3911" continuedAt="Text_81b0b26eaffb455fa038f761d448f3912"><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;">&#160;</p></ix:continuation>

        <ix:continuation id="Text_81b0b26eaffb455fa038f761d448f3912" continuedAt="Text_81b0b26eaffb455fa038f761d448f3913"><ix:nonNumeric name="us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" id="Text_58f4837d87a74351b86e2556e60e2456" contextRef="c20240101to20241231" escape="true" continuedAt="Text_73df53918db14fb8b80510ed4f4f62321"><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-indent: 45px; text-align: justify;">Supplemental cash flow information for the years ended December 31, 2024, 2023 and 2022 is as follows:</p></ix:nonNumeric></ix:continuation>
        <ix:continuation id="Text_81b0b26eaffb455fa038f761d448f3913" continuedAt="Text_81b0b26eaffb455fa038f761d448f3914"><ix:continuation id="Text_73df53918db14fb8b80510ed4f4f62321" continuedAt="Text_73df53918db14fb8b80510ed4f4f62322"><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px;">&#160; <br/>
        </p></ix:continuation></ix:continuation>
        <ix:continuation id="Text_81b0b26eaffb455fa038f761d448f3914" continuedAt="Text_81b0b26eaffb455fa038f761d448f3915"><ix:continuation id="Text_73df53918db14fb8b80510ed4f4f62322">
<table cellspacing="0" cellpadding="0" border="0" class="cfttable" style="text-align: left; font: 10pt 'Times New Roman'; width: 100%; border-spacing: 0;">


  <tr style="height: 15px;">

    <td valign="bottom" style="padding-bottom: 2px;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px;">&#160;</p>
              </td>

    <td valign="bottom" colspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: #000000 solid 2px;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: center;"><strong>2024</strong></p>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: #000000 solid 2px;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: center;"><strong>2023</strong></p>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" style="text-align: center; vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;"><span style="font-weight: bold;">2022</span><br/>
              </td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" rowspan="1" style="vertical-align: top;">&#160;</td>

    <td valign="bottom" rowspan="1" colspan="1" style="vertical-align: bottom;">&#160;</td>

    <td valign="bottom" style="text-align: center;" rowspan="1" colspan="10"><span style="font-style: italic;">(In thousands)</span><br/>
              </td>

    <td valign="bottom" rowspan="1" colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="vertical-align: top;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in;"><strong>SUPPLEMENTAL CASH FLOW INFORMATION:</strong></p>
              </td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom;">&#160;</td>

    <td valign="bottom" colspan="2">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom;">&#160;</td>

    <td valign="bottom" colspan="2">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="2" style="text-align: left; vertical-align: bottom; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="vertical-align: top; width: 64%; padding-bottom: 4px; background-color: rgb(204, 238, 255);">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 15px;">Cash paid for interest</p>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 4px double rgb(0, 0, 0);">$</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 4px double rgb(0, 0, 0);"><ix:nonFraction name="us-gaap:InterestPaidNet" id="Fact_4a525ff0c80e43f58988c822ab60e287" contextRef="c20240101to20241231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">10,668</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 4px double rgb(0, 0, 0);">$</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 4px double rgb(0, 0, 0);"><ix:nonFraction name="us-gaap:InterestPaidNet" id="Fact_99fd1ea3714e4d46a51fa745d7bac75f" contextRef="c20230101to20231231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">18,051</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;">$</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;"><ix:nonFraction name="us-gaap:InterestPaidNet" id="Fact_dd2758a535864f2c91d27c178b6adf42" contextRef="c20220101to20221231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">13,880</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td rowspan="1" style="margin-top: 0px; margin-right: 0px; margin-bottom: 0px; vertical-align: top; width: 64%; padding: 0px 0px 4px; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">
                <div style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 15px;">Cash paid for income taxes<br/>
                </div>
              </td>

    <td valign="bottom" rowspan="1" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td>

    <td valign="bottom" rowspan="1" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);">$</td>

    <td valign="bottom" rowspan="1" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);"><ix:nonFraction name="us-gaap:IncomeTaxesPaid" id="Fact_2b8b19ea0d9345c3b8187482d30ad2ae" contextRef="c20240101to20241231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">9,392</ix:nonFraction></td>

    <td valign="bottom" rowspan="1" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" rowspan="1" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td>

    <td valign="bottom" rowspan="1" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);">$<br/>
              </td>

    <td valign="bottom" rowspan="1" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);"><ix:nonFraction name="us-gaap:IncomeTaxesPaid" id="Fact_58eb88de6ba54f75b6bc96f39fd71203" contextRef="c20230101to20231231" unitRef="U001" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></td>

    <td valign="bottom" rowspan="1" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" rowspan="1" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" rowspan="1" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;">$<br/>
              </td>

    <td valign="bottom" rowspan="1" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;"><ix:nonFraction name="us-gaap:IncomeTaxesPaid" id="Fact_90fb5cc803e84d158364024f61a2eff6" contextRef="c20220101to20221231" unitRef="U001" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></td>

    <td valign="bottom" rowspan="1" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="vertical-align: top; width: 64%; background-color: rgb(204, 238, 255);">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in;"><strong>Noncash Financing and Investing Activities:</strong></p>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="vertical-align: top; width: 64%; padding-bottom: 4px; white-space: nowrap;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 15px;">Equipment acquired reflected in accounts payable and accrued liabilities</p>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);">$</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);"><ix:nonFraction name="adma:EquipmentAcquiredReflectedInAccountsPayableAndAccruedLiabilities" id="Fact_76924ad22184411794ed62eb9e340806" contextRef="c20240101to20241231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">725</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);">$</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);"><ix:nonFraction name="adma:EquipmentAcquiredReflectedInAccountsPayableAndAccruedLiabilities" id="Fact_ffd9b6e8fc6a4782b7ee4985fdda9a5a" contextRef="c20230101to20231231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">86</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;">$</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;"><ix:nonFraction name="adma:EquipmentAcquiredReflectedInAccountsPayableAndAccruedLiabilities" id="Fact_9704a17cdfd844a087b67d7bbb9be391" contextRef="c20220101to20221231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,495</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="vertical-align: top; width: 64%; padding-bottom: 4px; background-color: rgb(204, 238, 255);">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 15px;">Right-to-use assets in exchange for lease obligations</p>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);">$</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);"><ix:nonFraction name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" id="Fact_9f857909992945ea8430ade00020ce34" contextRef="c20240101to20241231" unitRef="U001" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);">$</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);"><ix:nonFraction name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" id="Fact_89c1484f56134d769e2216939cf54236" contextRef="c20230101to20231231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">130</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;">$</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;"><ix:nonFraction name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" id="Fact_dedbeb1b146d4693b1634571e1703694" contextRef="c20220101to20221231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,048</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td valign="bottom" style="vertical-align: top; width: 64%; padding-bottom: 4px;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 15px;">Warrants issued in connection with notes payable</p>
              </td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);">$</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);"><ix:nonFraction name="adma:WarrantsIssuedInConnectionWithNotesPayable" id="Fact_e994d22c6f4a491483c9560861474db1" contextRef="c20240101to20241231" unitRef="U001" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);">$</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);"><ix:nonFraction name="adma:WarrantsIssuedInConnectionWithNotesPayable" id="Fact_33cd574a6b1343b394fae8971ab893e3" contextRef="c20230101to20231231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">5,595</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">&#160;</td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;">$</td>

    <td valign="bottom" colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;"><ix:nonFraction name="adma:WarrantsIssuedInConnectionWithNotesPayable" id="Fact_2161baabf73e4648a31d2e83f18ecbfa" contextRef="c20220101to20221231" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">9,570</ix:nonFraction></td>

    <td valign="bottom" colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;">&#160;</td>

  </tr>


</table>
</ix:continuation></ix:continuation>

        <ix:continuation id="Text_81b0b26eaffb455fa038f761d448f3915" continuedAt="Text_81b0b26eaffb455fa038f761d448f3916"><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;"> <br/>
        </p></ix:continuation>
        <ix:continuation id="Text_81b0b26eaffb455fa038f761d448f3916"><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: justify;">See Note 8 and the Consolidated Statement of Stockholders&#8217; Equity for cashless exercise activity related to the Company&#8217;s outstanding warrants.<br/>
        </p></ix:continuation>
      </div>

    </div>


    <div><br/>
    </div>

    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageNumberArea" style="text-align: center;"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">F-37</span></div>

      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"/></div>

      <div class="BRPFPageHeader" style="width: 100%;">
        <div>
          <div style="text-align: left; font-weight: bold; text-indent: -9pt; margin-left: 9pt;"><a href="#ADMABIOLOGICSINC."> <span style="font-style: italic; font-weight: normal; font-size: 8pt;">Table of Contents</span></a><br/>
          </div>

          <div style="text-align: left; font-weight: bold; text-indent: -9pt; margin-left: 9pt;"><a href="#ADMABIOLOGICSINC."><span style="font-style: italic; font-weight: normal; font-size: 8pt;"> <br/>
              </span></a></div>

          <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">ADMA BIOLOGICS, INC. AND SUBSIDIARIES</div>

          <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</div>

        </div>

      </div>

    </div>

  </div>


  <div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: rgb(0, 0, 0);">
    <div>
      <div style="text-align: justify; font: 10pt 'Times New Roman';">
        <ix:nonNumeric name="us-gaap:ConcentrationRiskDisclosureTextBlock" id="Text_3e54a7496f0a43cdb3963175ff4e5c11" contextRef="c20240101to20241231" escape="true" continuedAt="Text_c1ecff5f836a4f7cbab982441813e89a1">
<div>
          <table cellspacing="0" cellpadding="0" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt; border-spacing: 0;" class="DSPFListTable">


  <tr style="vertical-align: top;">

    <td style="vertical-align: top; width: 27pt;">
                  <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: justify;"><strong>16.</strong></p>
                </td>

    <td style="vertical-align: top; width: auto;">
                  <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: justify;"><span style="text-decoration: underline;"><span style="background-color: rgb(255, 255, 255); font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><strong>CONCENTRATIONS</strong></span></span><strong><span style="text-decoration: underline;"><br/>
                      </span></strong></p>
                </td>

  </tr>


</table>
        </div>
</ix:nonNumeric>
        <ix:continuation id="Text_c1ecff5f836a4f7cbab982441813e89a1" continuedAt="Text_c1ecff5f836a4f7cbab982441813e89a2"><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: justify;">&#160;</p></ix:continuation>
        <ix:continuation id="Text_c1ecff5f836a4f7cbab982441813e89a2" continuedAt="Text_c1ecff5f836a4f7cbab982441813e89a3"><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-indent: 45px; text-align: justify;">Financial instruments that potentially subject the Company to concentrations of credit risk consist of accounts receivable. At December
          31, 2024, <ix:nonFraction name="adma:NumberOfCustomers" id="Fact_2bebdde6141c4f9c818adec260eee322" contextRef="c20240101to20241231_ConcentrationRiskByBenchmarkAxis_AccountsReceivableMember_ConcentrationRiskByTypeAxis_CustomerConcentrationRiskMember_MajorCustomersAxis_ThreeCustomersMember" unitRef="U015" decimals="INF" scale="0" format="ixt-sec:numwordsen">three</ix:nonFraction> customers accounted for approximately <ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" id="Fact_18bf48e919824ece9bba44680810f61d" contextRef="c20240101to20241231_ConcentrationRiskByBenchmarkAxis_AccountsReceivableMember_ConcentrationRiskByTypeAxis_CustomerConcentrationRiskMember_MajorCustomersAxis_ThreeCustomersMember" unitRef="U007" decimals="2" scale="-2" format="ixt:num-dot-decimal">91</ix:nonFraction>% of the Company&#8217;s consolidated accounts receivable. At December 31, 2023, <ix:nonFraction name="adma:NumberOfCustomers" id="Fact_bd8cfb783db6405daf51983e9a3f754f" contextRef="c20230101to20231231_ConcentrationRiskByBenchmarkAxis_AccountsReceivableMember_ConcentrationRiskByTypeAxis_CustomerConcentrationRiskMember_MajorCustomersAxis_FiveCustomersMember" unitRef="U015" decimals="INF" scale="0" format="ixt-sec:numwordsen">five</ix:nonFraction>
          customers accounted for approximately <ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" id="Fact_c551604aa2e2480dbedacd3e37919985" contextRef="c20230101to20231231_ConcentrationRiskByBenchmarkAxis_AccountsReceivableMember_ConcentrationRiskByTypeAxis_CustomerConcentrationRiskMember_MajorCustomersAxis_FiveCustomersMember" unitRef="U007" decimals="2" scale="-2" format="ixt:num-dot-decimal">98</ix:nonFraction>% of the Company&#8217;s consolidated accounts receivable. </p></ix:continuation>
        <ix:continuation id="Text_c1ecff5f836a4f7cbab982441813e89a3" continuedAt="Text_c1ecff5f836a4f7cbab982441813e89a4"><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-indent: 45px; text-align: justify;">&#160;</p></ix:continuation>
        <ix:continuation id="Text_c1ecff5f836a4f7cbab982441813e89a4" continuedAt="Text_c1ecff5f836a4f7cbab982441813e89a5"><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-indent: 45px; text-align: justify;"><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">For the years ended December 31, 2024 and 2023, <ix:nonFraction name="adma:NumberOfCustomers" id="Fact_8cb86e38e581476e9a432907773422fe" contextRef="c20240101to20241231_ConcentrationRiskByBenchmarkAxis_RevenueFromContractWithCustomerProductAndServiceBenchmarkMember_ConcentrationRiskByTypeAxis_CustomerConcentrationRiskMember_MajorCustomersAxis_TwoCustomersMember" unitRef="U015" decimals="INF" scale="0" format="ixt-sec:numwordsen"><ix:nonFraction name="adma:NumberOfCustomers" id="Fact_232e6e8dd2dd434ba4029c5f343226dd" contextRef="c20230101to20231231_ConcentrationRiskByBenchmarkAxis_RevenueFromContractWithCustomerProductAndServiceBenchmarkMember_ConcentrationRiskByTypeAxis_CustomerConcentrationRiskMember_MajorCustomersAxis_TwoCustomersMember" unitRef="U015" decimals="INF" scale="0" format="ixt-sec:numwordsen">two</ix:nonFraction></ix:nonFraction>
            customers accounted for approximately <ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" id="Fact_8d29ce6d85e644fabd9eaec4c3c694ef" contextRef="c20240101to20241231_ConcentrationRiskByBenchmarkAxis_RevenueFromContractWithCustomerProductAndServiceBenchmarkMember_ConcentrationRiskByTypeAxis_CustomerConcentrationRiskMember_MajorCustomersAxis_TwoCustomersMember" unitRef="U007" decimals="2" scale="-2" format="ixt:num-dot-decimal"><ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" id="Fact_59d310872f5448c59a70c578a52fe947" contextRef="c20230101to20231231_ConcentrationRiskByBenchmarkAxis_RevenueFromContractWithCustomerProductAndServiceBenchmarkMember_ConcentrationRiskByTypeAxis_CustomerConcentrationRiskMember_MajorCustomersAxis_TwoCustomersMember" unitRef="U007" decimals="2" scale="-2" format="ixt:num-dot-decimal">72</ix:nonFraction></ix:nonFraction>% of the Company&#8217;s consolidated revenues. For the year ended December 31, 2022, <ix:nonFraction name="adma:NumberOfCustomers" id="Fact_cfd8dc0f35c24632ab9a11bd4107aa29" contextRef="c20220101to20221231_ConcentrationRiskByBenchmarkAxis_RevenueFromContractWithCustomerProductAndServiceBenchmarkMember_ConcentrationRiskByTypeAxis_CustomerConcentrationRiskMember_MajorCustomersAxis_TwoCustomersMember" unitRef="U015" decimals="INF" scale="0" format="ixt-sec:numwordsen">two</ix:nonFraction> customers accounted for approximately <ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" id="Fact_719e27d732a045c9aa60db1639cf2b9f" contextRef="c20220101to20221231_ConcentrationRiskByBenchmarkAxis_RevenueFromContractWithCustomerProductAndServiceBenchmarkMember_ConcentrationRiskByTypeAxis_CustomerConcentrationRiskMember_MajorCustomersAxis_TwoCustomersMember" unitRef="U007" decimals="2" scale="-2" format="ixt:num-dot-decimal">74</ix:nonFraction>%
            of the Company&#8217;s consolidated revenues. </span>Revenues for both of these customers are attributable to the ADMA BioManufacturing business segment. There were <ix:nonFraction name="adma:NumberOfCustomers" id="Fact_96a4f4ff21b94d958584bc5e2ce7453e" contextRef="c20240101to20241231_ConcentrationRiskByBenchmarkAxis_RevenueFromContractWithCustomerProductAndServiceBenchmarkMember_ConcentrationRiskByTypeAxis_CustomerConcentrationRiskMember_StatementBusinessSegmentsAxis_PlasmaCollectionCentersSegmentMember" unitRef="U015" decimals="INF" scale="0" format="ixt-sec:numwordsen">no</ix:nonFraction> customers attributable to the Plasma Collections Center whose revenues exceeded <ix:nonFraction name="us-gaap:ConcentrationRiskPercentage1" id="Fact_398054758f8041b4bb26694c56f4e455" contextRef="c20240101to20241231_ConcentrationRiskByBenchmarkAxis_RevenueFromContractWithCustomerProductAndServiceBenchmarkMember_ConcentrationRiskByTypeAxis_CustomerConcentrationRiskMember_StatementBusinessSegmentsAxis_PlasmaCollectionCentersSegmentMember" unitRef="U007" decimals="2" scale="-2" format="ixt:num-dot-decimal">10</ix:nonFraction>%
          of the Company&#8217;s consolidated revenues.</p></ix:continuation>
        <ix:continuation id="Text_c1ecff5f836a4f7cbab982441813e89a5" continuedAt="Text_c1ecff5f836a4f7cbab982441813e89a6"><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-indent: 45px;"> </p></ix:continuation>
        <ix:continuation id="Text_c1ecff5f836a4f7cbab982441813e89a6"><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-indent: 45px;"> </p></ix:continuation>
      </div>

    </div>


    <div><br/>
    </div>

    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="text-align: center;" class="BRPFPageNumberArea"><span style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">F-38</span></div>

      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"/></div>

      <div style="width: 100%;" class="BRPFPageHeader">
        <div>
          <div style="text-align: left; font-weight: bold; text-indent: -9pt; margin-left: 9pt;"><a href="#ADMABIOLOGICSINC."> <span style="font-style: italic; font-weight: normal; font-size: 8pt;">Table of Contents</span></a><br/>
          </div>

          <div style="text-align: left; font-weight: bold; text-indent: -9pt; margin-left: 9pt;"><a href="#ADMABIOLOGICSINC."><span style="font-style: italic; font-weight: normal; font-size: 8pt;"> <br/>
              </span></a></div>

          <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">ADMA BIOLOGICS, INC. AND SUBSIDIARIES</div>

          <div style="text-align: center; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</div>

        </div>

      </div>

    </div>

  </div>


  <div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: rgb(0, 0, 0);">
    <div>
      <ix:nonNumeric name="srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock" id="Text_81057c8f0096429483805d774e33e559" contextRef="c20240101to20241231" escape="true" continuedAt="Text_682ebe8de1f54aad977f8d6fdc3e766f1">
<div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Schedule II &#8211; Valuation and Qualifying Accounts</div>
</ix:nonNumeric>
      <ix:continuation id="Text_682ebe8de1f54aad977f8d6fdc3e766f1" continuedAt="Text_682ebe8de1f54aad977f8d6fdc3e766f2">
<div><span style="font-size: 10pt; font-family: 'Times New Roman';"> </span></div>
</ix:continuation>
      <ix:continuation id="Text_682ebe8de1f54aad977f8d6fdc3e766f2" continuedAt="Text_682ebe8de1f54aad977f8d6fdc3e766f3">
<div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold; text-align: center;">Years ended December 31, 2024, 2023 and 2022</div>
</ix:continuation>
      <ix:continuation id="Text_682ebe8de1f54aad977f8d6fdc3e766f3" continuedAt="Text_682ebe8de1f54aad977f8d6fdc3e766f4">
<div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold; text-align: center;"> <br/>
      </div>
</ix:continuation>
    </div>

    <ix:continuation id="Text_682ebe8de1f54aad977f8d6fdc3e766f4">
<table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%; border-spacing: 0;" class="cfttable">


  <tr>

    <td valign="bottom" style="vertical-align: top; font-family: 'Times New Roman'; padding-bottom: 2px;">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: top; font-family: 'Times New Roman';" colspan="2">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;" rowspan="1" colspan="6">
            <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Additions</div>
          </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" rowspan="1" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: top; font-family: 'Times New Roman';" colspan="2">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: top; font-family: 'Times New Roman';" colspan="2">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; padding-bottom: 2px;" colspan="1"><span style="font-style: italic;">(in thousands)</span><br/>
          </td>

    <td valign="bottom" style="text-align: center; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: center; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="2">
            <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Balance at</div>
            <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">beginning of year</div>
          </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="2">
            <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Charged to costs</div>
            <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">and expenses</div>
          </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: center; vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: center; border-bottom: #000000 solid 2px;" colspan="2">
            <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Other</div>
          </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: center; vertical-align: bottom; padding-bottom: 2px;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; text-align: center; border-bottom: #000000 solid 2px;" colspan="2">
            <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Deductions</div>
          </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px; white-space: nowrap;" colspan="2">
            <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Balance at</div>
            <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">end of year</div>
          </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; border-bottom: #000000 solid 2px;" colspan="1">
            <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Year ended December 31, 2024</div>
          </td>

    <td valign="bottom" style="font-family: 'Times New Roman'; vertical-align: bottom;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: top; font-family: 'Times New Roman';" colspan="2">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; vertical-align: bottom;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: top; font-family: 'Times New Roman';" colspan="2">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; vertical-align: bottom;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: top; font-family: 'Times New Roman';" colspan="2">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; vertical-align: bottom;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: top; font-family: 'Times New Roman';" colspan="2">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; vertical-align: bottom;" colspan="1">&#160;</td>

    <td valign="bottom" style="vertical-align: top; font-family: 'Times New Roman';" colspan="2">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 40%; background-color: #CCEEFF;" colspan="1">
            <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; text-indent: 18pt;">Accrued rebates</div>
          </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">
            <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
            <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:ValuationAllowancesAndReservesBalance" id="Fact_b8465323bef642fca9c1006f98160609" contextRef="c20231231_ValuationAllowancesAndReservesTypeAxis_SECSchedule1209ReserveAccruedRebatesMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">16,608</ix:nonFraction></div>
          </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">
            <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
            <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense" id="Fact_458da5c7cd9b4278adca0d060a6f5a85" contextRef="c20240101to20241231_ValuationAllowancesAndReservesTypeAxis_SECSchedule1209ReserveAccruedRebatesMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">8,514</ix:nonFraction></div>
          </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">
            <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
            <div style="font-family: 'Times New Roman'; font-size: 10pt;">(<ix:nonFraction name="us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts" id="Fact_27c3f5c861b04fd99820d33a92d40363" contextRef="c20240101to20241231_ValuationAllowancesAndReservesTypeAxis_SECSchedule1209ReserveAccruedRebatesMember" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">12,618</ix:nonFraction></div>
          </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
            <div style="font-family: 'Times New Roman'; font-size: 10pt;">)</div>
          </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">
            <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
            <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:ValuationAllowancesAndReservesDeductions" id="Fact_c5633a011f00404db4d85c9dfa4e4700" contextRef="c20240101to20241231_ValuationAllowancesAndReservesTypeAxis_SECSchedule1209ReserveAccruedRebatesMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">8,349</ix:nonFraction></div>
          </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">
            <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
            <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:ValuationAllowancesAndReservesBalance" id="Fact_33911fd248ad4024b62c90132f58b336" contextRef="c20241231_ValuationAllowancesAndReservesTypeAxis_SECSchedule1209ReserveAccruedRebatesMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,155</ix:nonFraction></div>
          </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 40%;" colspan="1">
            <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; text-indent: -18pt; margin-left: 36pt;">Inventory valuation allowance</div>
          </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">
            <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
            <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:ValuationAllowancesAndReservesBalance" id="Fact_deb2897448d347d8b6358f0936b81377" contextRef="c20231231_ValuationAllowancesAndReservesTypeAxis_InventoryValuationReserveMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,992</ix:nonFraction></div>
          </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">
            <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
            <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense" id="Fact_13c8f8cd3dcc42f5a47fabba70b869ea" contextRef="c20240101to20241231_ValuationAllowancesAndReservesTypeAxis_InventoryValuationReserveMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">9,338</ix:nonFraction></div>
          </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">
            <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
            <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts" id="Fact_80627bb5bd444a6aaf69277d68537d43" contextRef="c20240101to20241231_ValuationAllowancesAndReservesTypeAxis_InventoryValuationReserveMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">118</ix:nonFraction></div>
          </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">
            <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
            <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:ValuationAllowancesAndReservesDeductions" id="Fact_40367eaba92746a5ad4bc12229158c57" contextRef="c20240101to20241231_ValuationAllowancesAndReservesTypeAxis_InventoryValuationReserveMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">7,287</ix:nonFraction></div>
          </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">
            <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
            <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:ValuationAllowancesAndReservesBalance" id="Fact_e5928b6822514db79ea4160bb4a7321b" contextRef="c20241231_ValuationAllowancesAndReservesTypeAxis_InventoryValuationReserveMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">5,161</ix:nonFraction></div>
          </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 40%; background-color: #CCEEFF;" colspan="1">
            <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; text-indent: -9pt; margin-left: 27pt;">Deferred tax asset valuation allowance</div>
          </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">
            <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
            <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:ValuationAllowancesAndReservesBalance" id="Fact_43d4fb8f83294e60a9c5af98462ffa57" contextRef="c20231231_ValuationAllowancesAndReservesTypeAxis_ValuationAllowanceOfDeferredTaxAssetsMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">101,421</ix:nonFraction></div>
          </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">
            <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
            <div style="font-family: 'Times New Roman'; font-size: 10pt;">(<ix:nonFraction name="us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense" id="Fact_cb41b3bef5f2490b977cb3f651c35391" contextRef="c20240101to20241231_ValuationAllowancesAndReservesTypeAxis_ValuationAllowanceOfDeferredTaxAssetsMember" unitRef="U001" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal">84,280</ix:nonFraction></div>
          </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">
            <div style="font-family: 'Times New Roman'; font-size: 10pt;">)</div>
          </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">
            <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
            <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts" id="Fact_e90825d352614ca6adb7825b56918cf1" contextRef="c20240101to20241231_ValuationAllowancesAndReservesTypeAxis_ValuationAllowanceOfDeferredTaxAssetsMember" unitRef="U001" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></div>
          </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">
            <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
            <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:ValuationAllowancesAndReservesDeductions" id="Fact_19d783fea23546be81aec9b29433e1e3" contextRef="c20240101to20241231_ValuationAllowancesAndReservesTypeAxis_ValuationAllowanceOfDeferredTaxAssetsMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">17,141</ix:nonFraction></div>
          </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">
            <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
            <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:ValuationAllowancesAndReservesBalance" id="Fact_dcf1b85129bb4ea682dbf10eb58dbc7e" contextRef="c20241231_ValuationAllowancesAndReservesTypeAxis_ValuationAllowanceOfDeferredTaxAssetsMember" unitRef="U001" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></div>
          </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; font-family: 'Times New Roman'; width: 40%;">&#160;</td>

    <td valign="bottom" style="text-align: right; font-family: 'Times New Roman'; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; font-family: 'Times New Roman'; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; font-family: 'Times New Roman'; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; font-family: 'Times New Roman'; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; font-family: 'Times New Roman'; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; font-family: 'Times New Roman'; width: 40%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" style="text-align: right; font-family: 'Times New Roman'; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; font-family: 'Times New Roman'; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; font-family: 'Times New Roman'; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; font-family: 'Times New Roman'; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; font-family: 'Times New Roman'; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 40%; border-bottom: #000000 solid 2px;" colspan="1">
            <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Year ended December 31, 2023</div>
          </td>

    <td valign="bottom" style="text-align: right; font-family: 'Times New Roman'; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; font-family: 'Times New Roman'; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; font-family: 'Times New Roman'; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; font-family: 'Times New Roman'; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; font-family: 'Times New Roman'; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 40%; background-color: #CCEEFF;" colspan="1">
            <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; text-indent: 18pt;">Accrued rebates</div>
          </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">
            <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
            <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:ValuationAllowancesAndReservesBalance" id="Fact_28b9c9ec9d8d467b8b1f44a2acd6d529" contextRef="c20221231_ValuationAllowancesAndReservesTypeAxis_SECSchedule1209ReserveAccruedRebatesMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">11,437</ix:nonFraction></div>
          </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">
            <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
            <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense" id="Fact_9a0b15dd651548c4bf3d02bc308b4568" contextRef="c20230101to20231231_ValuationAllowancesAndReservesTypeAxis_SECSchedule1209ReserveAccruedRebatesMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">8,448</ix:nonFraction></div>
          </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; font-family: 'Times New Roman'; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">$ <br/>
          </td>

    <td valign="bottom" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1"><ix:nonFraction name="us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts" id="Fact_b49b659a80114f0985c8073be77b9c6f" contextRef="c20230101to20231231_ValuationAllowancesAndReservesTypeAxis_SECSchedule1209ReserveAccruedRebatesMember" unitRef="U001" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">
            <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
            <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:ValuationAllowancesAndReservesDeductions" id="Fact_8f995c689b3d440e886e982f4a1b7b07" contextRef="c20230101to20231231_ValuationAllowancesAndReservesTypeAxis_SECSchedule1209ReserveAccruedRebatesMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">3,277</ix:nonFraction></div>
          </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">
            <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
            <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:ValuationAllowancesAndReservesBalance" id="Fact_e799cc8e34fb476cb4b26f9f0a73bc8e" contextRef="c20231231_ValuationAllowancesAndReservesTypeAxis_SECSchedule1209ReserveAccruedRebatesMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">16,608</ix:nonFraction></div>
          </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 40%;" colspan="1">
            <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; text-indent: -9pt; margin-left: 27pt;">Inventory valuation allowance</div>
          </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">
            <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
            <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:ValuationAllowancesAndReservesBalance" id="Fact_da78ce4ed7014716bc52dfdbfffe7f3a" contextRef="c20221231_ValuationAllowancesAndReservesTypeAxis_InventoryValuationReserveMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">5,400</ix:nonFraction></div>
          </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">
            <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
            <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense" id="Fact_bafd6a6cc059474cbe01ccd3b9a93b21" contextRef="c20230101to20231231_ValuationAllowancesAndReservesTypeAxis_InventoryValuationReserveMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">6,963</ix:nonFraction></div>
          </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">
            <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
            <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts" id="Fact_bf50149b44d5499d89e6ea030334cefa" contextRef="c20230101to20231231_ValuationAllowancesAndReservesTypeAxis_InventoryValuationReserveMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">6</ix:nonFraction></div>
          </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">
            <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
            <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:ValuationAllowancesAndReservesDeductions" id="Fact_951eb64eb7ac44989846f36a31d95e31" contextRef="c20230101to20231231_ValuationAllowancesAndReservesTypeAxis_InventoryValuationReserveMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">9,377</ix:nonFraction></div>
          </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">
            <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
            <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:ValuationAllowancesAndReservesBalance" id="Fact_e78d2b99ae4245e6853819befc288631" contextRef="c20231231_ValuationAllowancesAndReservesTypeAxis_InventoryValuationReserveMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,992</ix:nonFraction></div>
          </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 40%; background-color: #CCEEFF;" colspan="1">
            <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; text-indent: -9pt; margin-left: 27pt;">Deferred tax asset valuation allowance</div>
          </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">
            <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
            <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:ValuationAllowancesAndReservesBalance" id="Fact_1360fff8a4ed4a5a86aff1d3b52be419" contextRef="c20221231_ValuationAllowancesAndReservesTypeAxis_ValuationAllowanceOfDeferredTaxAssetsMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">96,725</ix:nonFraction></div>
          </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">
            <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
            <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense" id="Fact_606536fe97f949f9bf68fa95a4d5fb13" contextRef="c20230101to20231231_ValuationAllowancesAndReservesTypeAxis_ValuationAllowanceOfDeferredTaxAssetsMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">4,696</ix:nonFraction></div>
          </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">
            <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
            <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts" id="Fact_b4ce525fdb4a46588c03ed125284cdc3" contextRef="c20230101to20231231_ValuationAllowancesAndReservesTypeAxis_ValuationAllowanceOfDeferredTaxAssetsMember" unitRef="U001" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></div>
          </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">
            <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
            <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:ValuationAllowancesAndReservesDeductions" id="Fact_09b5a83b5e0841b49f7f014822226a10" contextRef="c20230101to20231231_ValuationAllowancesAndReservesTypeAxis_ValuationAllowanceOfDeferredTaxAssetsMember" unitRef="U001" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></div>
          </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">
            <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
            <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:ValuationAllowancesAndReservesBalance" id="Fact_398321f563d54e79b563f1d3958b50ce" contextRef="c20231231_ValuationAllowancesAndReservesTypeAxis_ValuationAllowanceOfDeferredTaxAssetsMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">101,421</ix:nonFraction></div>
          </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; font-family: 'Times New Roman'; width: 40%;">&#160;</td>

    <td valign="bottom" style="text-align: right; font-family: 'Times New Roman'; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; font-family: 'Times New Roman'; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; font-family: 'Times New Roman'; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; font-family: 'Times New Roman'; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; font-family: 'Times New Roman'; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; font-family: 'Times New Roman'; width: 40%; background-color: #CCEEFF;">&#160;</td>

    <td valign="bottom" style="text-align: right; font-family: 'Times New Roman'; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; font-family: 'Times New Roman'; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; font-family: 'Times New Roman'; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; font-family: 'Times New Roman'; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; font-family: 'Times New Roman'; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 40%; border-bottom: #000000 solid 2px;" colspan="1">
            <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Year ended December 31, 2022</div>
          </td>

    <td valign="bottom" style="text-align: right; font-family: 'Times New Roman'; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; font-family: 'Times New Roman'; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; font-family: 'Times New Roman'; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; font-family: 'Times New Roman'; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; font-family: 'Times New Roman'; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%;" colspan="1">&#160;</td>

    <td valign="bottom" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 40%; background-color: #CCEEFF;" colspan="1">
            <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; text-indent: 18pt;">Accrued rebates</div>
          </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">
            <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
            <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:ValuationAllowancesAndReservesBalance" id="Fact_0574ebaae2a1470baad5fb62afc55bab" contextRef="c20211231_ValuationAllowancesAndReservesTypeAxis_SECSchedule1209ReserveAccruedRebatesMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">5,040</ix:nonFraction></div>
          </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">
            <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
            <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense" id="Fact_156001a09b3240b1a11ab88570d852cc" contextRef="c20220101to20221231_ValuationAllowancesAndReservesTypeAxis_SECSchedule1209ReserveAccruedRebatesMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">8,227</ix:nonFraction></div>
          </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1"><br/>
          </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">
            <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
            <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:ValuationAllowancesAndReservesDeductions" id="Fact_2d487d624d944151979a9543b1ac6cf8" contextRef="c20220101to20221231_ValuationAllowancesAndReservesTypeAxis_SECSchedule1209ReserveAccruedRebatesMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">1,830</ix:nonFraction></div>
          </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">
            <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
            <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:ValuationAllowancesAndReservesBalance" id="Fact_ecdc281211cf4b1886a4c04c68c66463" contextRef="c20221231_ValuationAllowancesAndReservesTypeAxis_SECSchedule1209ReserveAccruedRebatesMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">11,437</ix:nonFraction></div>
          </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 40%;" colspan="1">
            <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; text-indent: -9pt; margin-left: 27pt;">Inventory valuation allowance</div>
          </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">
            <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
            <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:ValuationAllowancesAndReservesBalance" id="Fact_564b32c73e1c4e6fb3d99b949da6fb30" contextRef="c20211231_ValuationAllowancesAndReservesTypeAxis_InventoryValuationReserveMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">8,577</ix:nonFraction></div>
          </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">
            <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
            <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense" id="Fact_3357706e24b6439089033a8130dedd30" contextRef="c20220101to20221231_ValuationAllowancesAndReservesTypeAxis_InventoryValuationReserveMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">2,744</ix:nonFraction></div>
          </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">
            <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
            <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts" id="Fact_421992e9b44847dca93972e978c470c3" contextRef="c20220101to20221231_ValuationAllowancesAndReservesTypeAxis_InventoryValuationReserveMember" unitRef="U001" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></div>
          </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">
            <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
            <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:ValuationAllowancesAndReservesDeductions" id="Fact_ce6709c240d94b389ce06721028b13a9" contextRef="c20220101to20221231_ValuationAllowancesAndReservesTypeAxis_InventoryValuationReserveMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">5,921</ix:nonFraction></div>
          </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%;" colspan="1">
            <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%;" colspan="1">
            <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:ValuationAllowancesAndReservesBalance" id="Fact_8dc8580be16d4f648459678945a685b3" contextRef="c20221231_ValuationAllowancesAndReservesTypeAxis_InventoryValuationReserveMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">5,400</ix:nonFraction></div>
          </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>

  <tr>

    <td valign="bottom" style="vertical-align: top; width: 40%; background-color: #CCEEFF;" colspan="1">
            <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; text-indent: -9pt; margin-left: 27pt;">Deferred tax asset valuation allowance</div>
          </td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">
            <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
            <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:ValuationAllowancesAndReservesBalance" id="Fact_c7269ac33fb84ae5864358d57b53c089" contextRef="c20211231_ValuationAllowancesAndReservesTypeAxis_ValuationAllowanceOfDeferredTaxAssetsMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">81,608</ix:nonFraction></div>
          </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">
            <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
            <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense" id="Fact_c11f6b26eee34fe6962656fafa714e5c" contextRef="c20220101to20221231_ValuationAllowancesAndReservesTypeAxis_ValuationAllowanceOfDeferredTaxAssetsMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">15,117</ix:nonFraction></div>
          </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">
            <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
            <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts" id="Fact_a20495d5757043098b7b09b7a04f172a" contextRef="c20220101to20221231_ValuationAllowancesAndReservesTypeAxis_ValuationAllowanceOfDeferredTaxAssetsMember" unitRef="U001" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></div>
          </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">
            <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
            <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:ValuationAllowancesAndReservesDeductions" id="Fact_fe21b88e1d6a4d32a0deebcb295c2eec" contextRef="c20220101to20221231_ValuationAllowancesAndReservesTypeAxis_ValuationAllowanceOfDeferredTaxAssetsMember" unitRef="U001" decimals="-3" scale="3" format="ixt:fixed-zero">-</ix:nonFraction></div>
          </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">&#160;</td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" colspan="1">
            <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
          </td>

    <td valign="bottom" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" colspan="1">
            <div style="font-family: 'Times New Roman'; font-size: 10pt;"><ix:nonFraction name="us-gaap:ValuationAllowancesAndReservesBalance" id="Fact_56a6fdaec0a54f1ba7927b575242ab73" contextRef="c20221231_ValuationAllowancesAndReservesTypeAxis_ValuationAllowanceOfDeferredTaxAssetsMember" unitRef="U001" decimals="-3" scale="3" format="ixt:num-dot-decimal">96,725</ix:nonFraction></div>
          </td>

    <td valign="bottom" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" colspan="1">&#160;</td>

  </tr>


</table>
</ix:continuation>

    <div> <br/>
    </div>

    <div>
      <div>
        <div style="text-align: center;"><span style="font-family: 'Times New Roman'; font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;">F-39</span></div>

      </div>

      <hr style="height: 2px; color: #000000; background-color: #000000; text-align: center; border: none; margin-left: auto; margin-right: auto;"/> </div>

  </div>


</div>
</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.7
<SEQUENCE>2
<FILENAME>ef20038923_ex10-7.htm
<DESCRIPTION>EXHIBIT 10.7
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Summit Financial
         Document created using Broadridge PROfile 25.2.1.5287
         Copyright 1995 - 2025 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
  <!--PROfilePageNumberReset%Num%1%- % -%-->
  <div style="text-align: center; font-family: 'Times New Roman'; font-size: 12pt; font-weight: bold;">
    <hr noshade="noshade" align="center" style="height: 4px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;">
    <div style="text-align: right; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"> Exhibit 10.7<br>
    </div>
    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"> <br>
    </div>
    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Information in this exhibit identified by [***] is confidential and has been excluded pursuant to Item 601(b)(10)(iv) of Regulation S-K because it is
      both (i) not material and (ii) would likely cause competitive harm to the registrant if publicly disclosed.</div>
    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"> <font style="font-size: 10pt;"><br>
      </font></div>
  </div>
  <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><u>AMENDED AND RESTATED PLASMA PURCHASE AGREEMENT</u></div>
  <div style="font-size: 10pt;">&#160;</div>
  <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">THIS AMENDED AND RESTATED PLASMA PURCHASE AGREEMENT</font><font style="font-size: 10pt;"> (&#8220;<font style="font-family: 'Times New Roman'; font-weight: bold;">Agreement</font>&#8221;) between Grifols Worldwide Operations Limited, a corporation having a place of business at Grange Castle Business Park, Grange Castle,
      Clondalkin, Dublin 22, Ireland (&#8220;<font style="font-family: 'Times New Roman'; font-weight: bold;">PLASMA SUPPLIER</font>&#8221;), and ADMA BioManufacturing, LLC, a Delaware limited liability company, having a place of business at 5800 Park of Commerce
      Boulevard, NW, Boca Raton, Florida 33487 (&#8220;<font style="font-family: 'Times New Roman'; font-weight: bold;">ADMA</font>&#8221;), shall be effective as of October 1, 2024 (the &#8220;<font style="font-family: 'Times New Roman'; font-weight: bold;">Effective Date</font>&#8221;).&#160;




      PLASMA SUPPLIER and ADMA are each sometimes referred to herein individually as a &#8220;<font style="font-family: 'Times New Roman'; font-weight: bold;">Party</font>&#8221; or collectively as the &#8220;<font style="font-family: 'Times New Roman'; font-weight: bold;">Parties</font>&#8221;.</font></div>
  <div style="font-size: 10pt;">&#160;</div>
  <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">RECITALS</div>
  <div style="font-size: 10pt;">&#160;</div>
  <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">WHEREAS</font><font style="font-size: 10pt;">, PLASMA SUPPLIER (as
      successor-in-interest to Biotest Pharmaceuticals Corporation) and ADMA are parties to that certain Purchase Agreement, effective as of November 17, 2011, as last amended on January 1, 2019, whereupon PLASMA SUPPLIER sold, and ADMA purchased, RSV
      Plasma (the &#8220;<font style="font-family: 'Times New Roman'; font-weight: bold;">Prior Agreement</font>&#8221;);</font></div>
  <div style="font-size: 10pt;">&#160;</div>
  <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">WHEREAS</font><font style="font-size: 10pt;">, the Parties now desire
      to amend and restate the Prior Agreement on the terms set forth herein; and</font></div>
  <div style="font-size: 10pt;">&#160;</div>
  <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">WHEREAS</font><font style="font-size: 10pt;">, PLASMA SUPPLIER desires
      to continue to sell, and ADMA desires to continue to purchase on a non-exclusive basis certain quantities of source plasma containing certain levels of antibodies to Respiratory Syncytial Virus (&#8220;<font style="font-family: 'Times New Roman'; font-weight: bold;">RSV</font>&#8221; or &#8220;<font style="font-family: 'Times New Roman'; font-weight: bold;">RSV Plasma</font>&#8221;) to be used by ADMA in the manufacturing and/or research and development of Human Immune Globulin(s) (&#8220;<font style="font-family: 'Times New Roman'; font-weight: bold;">Product</font>&#8221;), solely on the terms and conditions set forth in this Agreement.</font></div>
  <div style="font-size: 10pt;">&#160;</div>
  <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">PROVISIONS</div>
  <div style="font-size: 10pt;">&#160;</div>
  <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">NOW, THEREFORE</font><font style="font-size: 10pt;">, in consideration
      of the covenants and agreements contained herein, and other good and valuable consideration, the receipt and legal sufficiency of which are hereby acknowledged, and with the intent to be legally bound hereby, ADMA and PLASMA SUPPLIER agree as
      follows:</font></div>
  <div style="font-size: 10pt;">&#160;</div>
  <div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%;" id="zd3a6cf986a1144f0be65303231943660" class="DSPFListTable">

        <tr style="vertical-align: top;">
          <td style="text-align: right; vertical-align: top; width: 36pt;">
            <div style="text-align: left;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">A.</font></div>
          </td>
          <td style="text-align: left; vertical-align: top; width: auto;">
            <div><font style="font-size: 10pt;"><font style="font-family: 'Times New Roman';"><font style="font-family: 'Times New Roman'; font-weight: bold;"><u>PURCHASE AND SALE OF RSV PLASMA</u></font>.</font></font></div>
          </td>
        </tr>

    </table>
  </div>
  <div style="font-size: 10pt;">&#160;</div>
  <div style="text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">1.</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman';"><font style="font-family: 'Times New Roman'; font-weight: bold;"><u>TERM OF AGREEMENT</u></font>.&#160; Unless terminated earlier as provided herein, the initial term of this Agreement shall commence on the Effective Date and expire on September 30, 2034 (the &#8220;<font style="font-family: 'Times New Roman'; font-weight: bold;">Initial Term</font>&#8221;, and together with any renewals, the &#8220;<font style="font-family: 'Times New Roman'; font-weight: bold;">Term</font>&#8221;).&#160; After the Initial Term, this Agreement may be renewed for up to two (2)
        additional [***] ([***])-year periods (i.e., through [***] and [***], respectively) upon the mutual written consent of the Parties.&#160; Each Party agrees that it will endeavor, in good faith, to conclude any negotiations relating to such renewals no
        less than [***] ([***]) months ([***] calendar days) before the expiration of this Agreement or renewal term, as applicable.</font></font></div>
  <div style="font-size: 10pt;">&#160;</div>
  <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
    <div class="BRPFPageNumberArea" style="text-align: center;"><font style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">- 1 -</font></div>
    <div class="BRPFPageBreak" style="page-break-after: always;">
      <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
  </div>
  <div style="text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">2.</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman';"><font style="font-family: 'Times New Roman'; font-weight: bold;"><u>PRICE AND VOLUMES</u></font>.</font></font></div>
  <div style="font-size: 10pt;">&#160;</div>
  <div style="text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">a.</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman';">From and after the Effective Date, ADMA agrees to purchase, and
        PLASMA SUPPLIER agrees to sell, RSV Plasma, in quantities and prices as further described in this Agreement.</font></font></div>
  <div style="font-size: 10pt;">&#160;</div>
  <div style="text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">b.</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman';">Notwithstanding anything to the contrary contained herein, ADMA
        shall not be obligated to purchase any RSV Plasma in the event PLASMA SUPPLIER does not, or fails to, provide necessary plasma samples for testing and identifying donors.&#160; The Parties mutually agree and understand that identifying sufficient donors
        with naturally occurring RSV antibody levels vary. The Parties mutually agree that this naturally occurring variation may, due to no fault of PLASMA SUPPLIER or ADMA, affect total acceptable RSV Plasma volumes. This Agreement does not bind either
        Party to the other in an exclusive supply or purchase relationship; and for the avoidance of doubt, ADMA shall be free to purchase any quantity of plasma, including RSV Plasma, from other sources or obtain it from its own collection facilities.&#160;
        Notwithstanding the foregoing, PLASMA SUPPLIER covenants and agrees to use best efforts to provide ADMA with the volume of RSV Plasma set forth in subsection (d) below.</font></font></div>
  <div style="font-size: 10pt;">&#160;</div>
  <div style="text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">c.</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman';">Beginning on the Effective Date PLASMA SUPPLIER agrees to use
        best efforts to collect as much RSV Plasma as possible, and in no event shall sell less than 35,000L per each Contract Year (as defined below) commencing with the Effective Date. From the Effective Date through the end of the first Contract Year,
        pricing for RSV Plasma will start at $[***] per liter, subject to escalation depending on the volume of RSV Plasma provided to ADMA, as further described in the table below. The price per liter of RSV Plasma shall increase on the anniversary of
        each Contract Year at the lesser of (i) [***] percent ([***]%) and (ii) [***] (the &#8220;<font style="font-family: 'Times New Roman'; font-weight: bold;">Annual Increase</font>&#8221;).&#160; Within [***] ([***]) business days following ADMA&#8217;s purchase of RSV
        Plasma from PLASMA SUPPLIER in excess of the high end of a range set forth in the table below, PLASMA SUPPLIER shall send a written notice to ADMA (e-mail being sufficient) notifying ADMA of the new price per liter of RSV Plasma on a go-forward
        basis in a given Contract Year. Additionally, in the event that PLASMA SUPPLIER provides ADMA with [***]L of RSV Plasma in a given Contract Year, at the end of such Contract Year PLASMA SUPPLIER shall invoice ADMA in the amount of $[***] (the &#8220;<font style="font-family: 'Times New Roman'; font-weight: bold;">Bonus Amount</font>&#8221;). For purposes of clarity, the price per Liter at the end of a Contract Year shall automatically reset to the base amount (i.e., the amount adjacent to &#8220;First
        35,000L&#8221;) set forth in the table below at the beginning of the subsequent Contract Year, subject to Annual Increases.&#160;&#160; This price includes all required screening tests, and NAT for HIV, HBV, HCV, HAV and Parvo B-19.&#160; For purposes of this section
        A.2, &#8220;<font style="font-family: 'Times New Roman'; font-weight: bold;">Contract Year</font>&#8221; means the twelve (12)-month period beginning on the Effective Date and each subsequent twelve (12)-month period thereafter during the Term that commences
        on an anniversary of the Effective Date.</font></font></div>
  <div style="font-size: 10pt;">&#160;</div>
  <div style="text-indent: 72pt;"><font style="font-family: 'Times New Roman'; font-size: 10pt;">d.</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman';">The table below sets forth annual volume ranges of RSV Plasma
        and the corresponding price during the Term:</font></font></div>
  <div style="font-size: 10pt;">&#160;</div>
  <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
    <div class="BRPFPageNumberArea" style="text-align: center;"><font style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">- 2 -</font></div>
    <div class="BRPFPageBreak" style="page-break-after: always;">
      <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
  </div>
  <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="z71d85aa1d8674743b75e8646f4e1086b">

      <tr>
        <td colspan="1" style="width: 1%; vertical-align: top; border-left: 2px solid rgb(0, 0, 0); font-size: 10pt; border-top: 2px solid rgb(0, 0, 0);"><br>
        </td>
        <td style="width: 44%; vertical-align: top; border-right: 2px solid rgb(0, 0, 0); font-size: 10pt; border-top: 2px solid rgb(0, 0, 0);">
          <div style="text-align: justify; font-family: 'Times New Roman';">Annual Volume (L) (Subject to Section A.8 below)</div>
        </td>
        <td colspan="1" style="width: 1%; vertical-align: top; border-left: 2px solid rgb(0, 0, 0); font-size: 10pt; border-top: 2px solid rgb(0, 0, 0);"><br>
        </td>
        <td style="width: 54%; vertical-align: top; border-right: 2px solid rgb(0, 0, 0); font-size: 10pt; border-top: 2px solid rgb(0, 0, 0);">
          <div style="text-align: justify; font-family: 'Times New Roman';">Price (L) (Excluding Annual Increases)</div>
        </td>
      </tr>
      <tr>
        <td colspan="1" style="width: 1%; vertical-align: top; border-left: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); font-size: 10pt;" rowspan="1">&#160;</td>
        <td style="width: 44%; vertical-align: top; border-right: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); font-size: 10pt;" rowspan="1">&#160;</td>
        <td colspan="1" style="width: 1%; vertical-align: top; border-left: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); font-size: 10pt;" rowspan="1">&#160;</td>
        <td style="width: 54%; vertical-align: top; border-right: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); font-size: 10pt;" rowspan="1">&#160;</td>
      </tr>
      <tr>
        <td colspan="1" style="width: 1%; vertical-align: top; border-left: 2px solid rgb(0, 0, 0); font-size: 10pt;"><br>
        </td>
        <td style="width: 44%; vertical-align: top; border-right: 2px solid rgb(0, 0, 0); font-size: 10pt;">
          <div style="text-align: justify; font-family: 'Times New Roman';">First 35,000L</div>
        </td>
        <td colspan="1" style="width: 1%; vertical-align: top; border-left: 2px solid rgb(0, 0, 0); font-size: 10pt;"><br>
        </td>
        <td style="width: 54%; vertical-align: top; border-right: 2px solid rgb(0, 0, 0); font-size: 10pt;">
          <div style="text-align: justify; font-family: 'Times New Roman';">$[***]</div>
        </td>
      </tr>
      <tr>
        <td colspan="1" style="width: 1%; vertical-align: top; border-left: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); font-size: 10pt;" rowspan="1">&#160;</td>
        <td style="width: 44%; vertical-align: top; border-right: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); font-size: 10pt;" rowspan="1">&#160;</td>
        <td colspan="1" style="width: 1%; vertical-align: top; border-left: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); font-size: 10pt;" rowspan="1">&#160;</td>
        <td style="width: 54%; vertical-align: top; border-right: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); font-size: 10pt;" rowspan="1">&#160;</td>
      </tr>
      <tr>
        <td colspan="1" style="width: 1%; vertical-align: top; border-left: 2px solid rgb(0, 0, 0); font-size: 10pt;"><br>
        </td>
        <td style="width: 44%; vertical-align: top; border-right: 2px solid rgb(0, 0, 0); font-size: 10pt;">
          <div style="text-align: justify; font-family: 'Times New Roman';">[***]L &#8211; [***]L</div>
        </td>
        <td colspan="1" style="width: 1%; vertical-align: top; border-left: 2px solid rgb(0, 0, 0); font-size: 10pt;"><br>
        </td>
        <td style="width: 54%; vertical-align: top; border-right: 2px solid rgb(0, 0, 0); font-size: 10pt;">
          <div style="text-align: justify; font-family: 'Times New Roman';">$<font style="font-family: 'Times New Roman';">[***]</font></div>
        </td>
      </tr>
      <tr>
        <td colspan="1" style="width: 1%; vertical-align: top; border-left: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); font-size: 10pt;" rowspan="1">&#160;</td>
        <td style="width: 44%; vertical-align: top; border-right: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); font-size: 10pt;" rowspan="1">&#160;</td>
        <td colspan="1" style="width: 1%; vertical-align: top; border-left: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); font-size: 10pt;" rowspan="1">&#160;</td>
        <td style="width: 54%; vertical-align: top; border-right: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); font-size: 10pt;" rowspan="1">&#160;</td>
      </tr>
      <tr>
        <td colspan="1" style="width: 1%; vertical-align: top; border-left: 2px solid rgb(0, 0, 0); font-size: 10pt;"><br>
        </td>
        <td style="width: 44%; vertical-align: top; border-right: 2px solid rgb(0, 0, 0); font-size: 10pt;">
          <div style="text-align: justify; font-family: 'Times New Roman';">[***]L &#8211; [***]L</div>
        </td>
        <td colspan="1" style="width: 1%; vertical-align: top; border-left: 2px solid rgb(0, 0, 0); font-size: 10pt;"><br>
        </td>
        <td style="width: 54%; vertical-align: top; border-right: 2px solid rgb(0, 0, 0); font-size: 10pt;">
          <div style="text-align: justify; font-family: 'Times New Roman';">$[***]</div>
        </td>
      </tr>
      <tr>
        <td colspan="1" style="width: 1%; vertical-align: top; border-left: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); font-size: 10pt;" rowspan="1">&#160;</td>
        <td style="width: 44%; vertical-align: top; border-right: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); font-size: 10pt;" rowspan="1">&#160;</td>
        <td colspan="1" style="width: 1%; vertical-align: top; border-left: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); font-size: 10pt;" rowspan="1">&#160;</td>
        <td style="width: 54%; vertical-align: top; border-right: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); font-size: 10pt;" rowspan="1">&#160;</td>
      </tr>
      <tr>
        <td colspan="1" style="width: 1%; vertical-align: top; border-left: 2px solid rgb(0, 0, 0); font-size: 10pt;"><br>
        </td>
        <td style="width: 44%; vertical-align: top; border-right: 2px solid rgb(0, 0, 0); font-size: 10pt;">
          <div style="text-align: justify; font-family: 'Times New Roman';">[***]L &#8211; [***]L</div>
        </td>
        <td colspan="1" style="width: 1%; vertical-align: top; border-left: 2px solid rgb(0, 0, 0); font-size: 10pt;"><br>
        </td>
        <td style="width: 54%; vertical-align: top; border-right: 2px solid rgb(0, 0, 0); font-size: 10pt;">
          <div style="text-align: justify; font-family: 'Times New Roman';">$[***]</div>
        </td>
      </tr>
      <tr>
        <td colspan="1" style="width: 1%; vertical-align: top; border-left: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); font-size: 10pt;" rowspan="1">&#160;</td>
        <td style="width: 44%; vertical-align: top; border-right: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); font-size: 10pt;" rowspan="1">&#160;</td>
        <td colspan="1" style="width: 1%; vertical-align: top; border-left: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); font-size: 10pt;" rowspan="1">&#160;</td>
        <td style="width: 54%; vertical-align: top; border-right: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); font-size: 10pt;" rowspan="1">&#160;</td>
      </tr>
      <tr>
        <td colspan="1" style="width: 1%; vertical-align: top; border-left: 2px solid rgb(0, 0, 0); font-size: 10pt;"><br>
        </td>
        <td style="width: 44%; vertical-align: top; border-right: 2px solid rgb(0, 0, 0); font-size: 10pt;">
          <div style="text-align: justify; font-family: 'Times New Roman';">[***]L &#8211; [***]L</div>
        </td>
        <td colspan="1" style="width: 1%; vertical-align: top; border-left: 2px solid rgb(0, 0, 0); font-size: 10pt;"><br>
        </td>
        <td style="width: 54%; vertical-align: top; border-right: 2px solid rgb(0, 0, 0); font-size: 10pt;">
          <div style="text-align: justify; font-family: 'Times New Roman';">$[***]</div>
        </td>
      </tr>
      <tr>
        <td colspan="1" style="width: 1%; vertical-align: top; border-left: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); font-size: 10pt;" rowspan="1">&#160;</td>
        <td style="width: 44%; vertical-align: top; border-right: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); font-size: 10pt;" rowspan="1">&#160;</td>
        <td colspan="1" style="width: 1%; vertical-align: top; border-left: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); font-size: 10pt;" rowspan="1">&#160;</td>
        <td style="width: 54%; vertical-align: top; border-right: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); font-size: 10pt;" rowspan="1">&#160;</td>
      </tr>
      <tr>
        <td colspan="1" style="width: 1%; vertical-align: top; border-left: 2px solid rgb(0, 0, 0); font-size: 10pt;"><br>
        </td>
        <td style="width: 44%; vertical-align: top; border-right: 2px solid rgb(0, 0, 0); font-size: 10pt;">
          <div style="text-align: justify; font-family: 'Times New Roman';">[***]L +</div>
        </td>
        <td colspan="1" style="width: 1%; vertical-align: top; border-left: 2px solid rgb(0, 0, 0); font-size: 10pt;"><br>
        </td>
        <td style="width: 54%; vertical-align: top; border-right: 2px solid rgb(0, 0, 0); font-size: 10pt;">
          <div style="text-align: justify; font-family: 'Times New Roman';">$[***] (plus the Bonus Amount described above)</div>
        </td>
      </tr>
      <tr>
        <td colspan="1" style="width: 1%; vertical-align: top; border-left: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); font-size: 10pt;" rowspan="1">&#160;</td>
        <td style="width: 44%; vertical-align: top; border-right: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); font-size: 10pt;" rowspan="1">&#160;</td>
        <td colspan="1" style="width: 1%; vertical-align: top; border-left: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); font-size: 10pt;" rowspan="1">&#160;</td>
        <td style="width: 54%; vertical-align: top; border-right: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); font-size: 10pt;" rowspan="1">&#160;</td>
      </tr>

  </table>
  <div style="font-size: 10pt;"><br>
  </div>
  <div style="text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">e.</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman';">PLASMA SUPPLIER agrees to provide commercially reasonable
        efforts to make necessary U.S. Food and Drug Administration (FDA) submissions, as needed (and amendments thereto, as applicable), to ensure continuous FDA approval of the Centers (as such term is defined below), at PLASMA SUPPLIER&#8217;s sole cost and
        expense.</font></font></div>
  <div style="font-size: 10pt;">&#160;</div>
  <div style="text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">f.</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman';">In the event of any change to existing law, guidance or
        industry standard applicable to the plasma to be supplied pursuant to this Agreement or any one or more new government regulations, tests, quality procedure or change in the specifications requested by ADMA (any of the foregoing being a &#8220;<font style="font-family: 'Times New Roman'; font-weight: bold;">Required Change</font>&#8221;) is recommended but is not contemplated in this Agreement and results in a material increase to PLASMA SUPPLIER&#8217;s actual costs to procure, store, provide and
        supply the RSV Plasma, both Parties shall re-negotiate the change in the purchase price in good faith within [***] ([***]) days of the Required Change and the Parties&#8217; obligations hereunder shall be suspended until such time as the Parties agree on
        a purchase price and, if not, this Agreement shall automatically terminate at the end of such [***] ([***])-day period without any penalties or further obligations by either Party, except for those specifically stated as surviving termination
        pursuant to Section D(4) below.</font></font></div>
  <div style="font-size: 10pt;">&#160;</div>
  <div style="text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">g.</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman';">In the event that demand for ADMA&#8217;s ASCENIV&#8482; (immune globulin
        intravenous, human &#8211; slra 10% liquid) materially changes from the demand on the Effective Date, both Parties shall re-negotiate the annual volume requirements and price set forth in this <font style="font-family: 'Times New Roman';"><u>Section A.2</u></font>
        in good faith within [***] ([***]) days of ADMA&#8217;s written notice to PLASMA SUPPLIER of such material change in demand. ADMA shall continue to purchase RSV Plasma from PLASMA SUPPLIER on the existing terms set forth herein until such time as the
        Parties agree on updated volumes of RSV Plasma to be provided hereunder and, if an agreement is not reached, this Agreement shall automatically terminate at the end of such [***] ([***])-day period without any penalties or further obligations by
        either Party, except for those specifically stated as surviving termination pursuant to Section D(4) below.</font></font></div>
  <div style="font-size: 10pt;">&#160;</div>
  <div style="text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">3.</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman';"><font style="font-family: 'Times New Roman'; font-weight: bold;"><u>PAYMENT TERMS</u></font>. ADMA shall deliver payment in full to PLASMA SUPPLIER for all RSV Plasma shipped to ADMA within [***] ([***]) days from ADMA&#8217;s receipt of the corresponding invoice. PLASMA SUPPLIER shall issue
        invoices promptly after ADMA or its carrier takes possession of the RSV Plasma from the Designated Location (as defined below) or, in the event PLASMA SUPPLIER earns the Bonus Amount, such invoice shall be issued promptly following the end of the
        applicable Contract Year. All payments due hereunder from ADMA to PLASMA SUPPLIER shall be sent to PLASMA SUPPLIER at the times set forth herein delivered in the form of wire transfer or check to such accounts as PLASMA SUPPLIER may designate to
        ADMA.</font></font></div>
  <div style="font-size: 10pt;">&#160;</div>
  <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
    <div class="BRPFPageNumberArea" style="text-align: center;"><font style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">- 3 -</font></div>
    <div class="BRPFPageBreak" style="page-break-after: always;">
      <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
  </div>
  <div style="text-align: left; margin-left: 72pt; font-family: 'Times New Roman'; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>Invoices to ADMA, and inquiries and correspondence regarding payment, shall be directed
        to</u></font><font style="font-size: 10pt;">:<font style="font-family: 'Times New Roman';"><br>
      </font>ADMA Biologics<font style="font-family: 'Times New Roman';"><br>
      </font>Attn: Accounts Payable<font style="font-family: 'Times New Roman';"><br>
      </font>5800 Park of Commerce Blvd., NW</font></div>
  <div style="text-align: left; margin-left: 72pt; font-family: 'Times New Roman'; font-size: 10pt;">Boca Raton, FL 33487</div>
  <div style="text-align: left; margin-left: 72pt; font-family: 'Times New Roman'; font-size: 10pt;">[***]</div>
  <div style="font-size: 10pt;"><br>
  </div>
  <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">Wire transfer instructions and a check mailing address will be provided to ADMA by PLASMA SUPPLIER under separate written notice, e-mail being
    sufficient.&#160; Modifications of bank account information, including wiring instructions, and any payment address shall be confirmed pursuant to written notice (email being sufficient) and verbally confirmed by the Parties.</div>
  <div style="font-size: 10pt;">&#160;</div>
  <div style="text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">4.</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman';"><font style="font-family: 'Times New Roman'; font-weight: bold;"><u>INSPECTION AND ACCEPTANCE</u></font>.</font></font></div>
  <div style="font-size: 10pt;">&#160;</div>
  <div style="text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">a.</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman';">PLASMA SUPPLIER shall make RSV Plasma available for pickup at
        PLASMA SUPPLIER&#8217;s approved GPLCE [***] and GPLCW [***] (the &#8220;<font style="font-family: 'Times New Roman'; font-weight: bold;">Designated Location</font>&#8221;), as set forth in a delivery schedule to be mutually agreed to by the Parties from time to
        time as hereinafter provided herein, unless otherwise mutually agreed between the Parties. Title and risk of loss shall pass upon transfer of the RSV Plasma to ADMA at [***].&#160; ADMA shall inspect each shipment of RSV Plasma for conformity with the
        specifications as set forth in <font style="font-family: 'Times New Roman';"><u>Exhibit A</u></font> (&#8220;<font style="font-family: 'Times New Roman'; font-weight: bold;">ADMA Specifications</font>&#8221;) within [***] ([***]) days following delivery of
        RSV Plasma to ADMA&#8217;s Boca Raton, Florida campus.&#160; ADMA shall promptly notify PLASMA SUPPLIER in writing of its determination of any non-conformity of the RSV Plasma with ADMA Specifications within such aforementioned [***] ([***])-day period (&#8220;<font style="font-family: 'Times New Roman'; font-weight: bold;">Non-Conformity Notice</font>&#8221;).</font></font></div>
  <div style="font-size: 10pt;">&#160;</div>
  <div style="text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">b.</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman';">If a Non-Conformity Notice is received by PLASMA SUPPLIER
        within the time period specified in <font style="font-family: 'Times New Roman';"><u>Section A.4(a)</u></font> above, the Parties shall meet within [***] ([***]) business days following PLASMA SUPPLIER&#8217;s receipt of the Non-Conformity Notice to
        determine whether such RSV Plasma meets the ADMA Specifications.&#160; If it is determined by both Parties that the RSV Plasma does not meet the ADMA Specifications, PLASMA SUPPLIER shall replace any non-conforming RSV Plasma, as promptly as possible,
        taking into account the time required to produce such quantities of RSV Plasma.&#160; In the event the Parties fail to agree whether or not any given shipment of RSV Plasma conforms with the ADMA Specifications, then the matter will be promptly referred
        to an independent expert agreed upon in good faith by both Parties, whose decision shall be binding on the Parties.&#160; The cost of referral to the expert will be borne by the Party determined to have been in error as to conformity, or lack thereof,
        with the ADMA Specifications.&#160; ADMA shall not be required to pay for any non-conforming RSV Plasma.</font></font></div>
  <div style="font-size: 10pt;">&#160;</div>
  <div style="text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">c.</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman';">For each shipment of RSV Plasma delivered, PLASMA SUPPLIER
        shall provide to ADMA all documents required in ADMA Specifications.</font></font></div>
  <div style="font-size: 10pt;">&#160;</div>
  <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
    <div class="BRPFPageNumberArea" style="text-align: center;"><font style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">- 4 -</font></div>
    <div class="BRPFPageBreak" style="page-break-after: always;">
      <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
  </div>
  <div style="text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">5.</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman';"><font style="font-family: 'Times New Roman'; font-weight: bold;"><u>SHIPMENT TERMS</u></font>. PLASMA SUPPLIER shall pay for all shipments to the Designated Location in accordance with the delivery schedule agreed to by the Parties. ADMA will take ownership and bear all risk of loss upon
        pick up by ADMA or ADMA&#8217;s designated carrier from [***]. ADMA shall use commercially reasonable efforts to arrange to have the RSV Plasma picked up at least [***] ([***]) times a year in approximately equally spaced intervals. ADMA shall, at its
        own expense, be responsible for freight charges, insurance, handling and forwarding agent&#8217;s fees, taxes, storage and all other charges applicable to the RSV Plasma from that Designated Location.</font></font></div>
  <div style="font-size: 10pt;">&#160;</div>
  <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold; margin-left: 72pt;"><u>QUALITY OF RSV PLASMA.</u></div>
  <div style="font-size: 10pt;">&#160;</div>
  <div style="text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">6.</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman';">PLASMA SUPPLIER shall provide ADMA, at no
        cost to ADMA, plasma samples in amounts and at times mutually agreed upon by ADMA and PLASMA SUPPLIER to enable ADMA to test and identify plasma donors suitable for producing RSV Plasma for ADMA in accordance with the ADMA Specifications (&#8220;<font style="font-family: 'Times New Roman'; font-weight: bold;">Source Plasma Specifications</font>&#8221;), attached hereto as <font style="font-family: 'Times New Roman';"><u>Exhibit A</u></font> and incorporated herein by reference.&#160; ADMA shall bear the
        cost of freight for such samples to their designation location. For the avoidance of doubt, ADMA will bear all costs associated with the testing of the samples.&#160; Based on said testing, ADMA shall identify plasma donors whom ADMA has tested as
        suitable for producing RSV Plasma in accordance with <a name="OLE_LINK5"></a><a name="OLE_LINK6"></a>ADMA Specifications (&#8220;<font style="font-family: 'Times New Roman'; font-weight: bold;">Acceptable Donors</font>&#8221;).&#160; PLASMA SUPPLIER shall produce
        RSV Plasma for ADMA based on the number of Acceptable Donors identified by ADMA.&#160; ADMA&#8217;s acceptance of the donor shall not constitute ADMA&#8217;s acceptance of RSV Plasma.&#160; PLASMA SUPPLIER will use commercially reasonable efforts in-line with industry
        standard incentive programs and donor retention programs to provide plasma from as many of the Acceptable Donors identified by ADMA as possible.&#160; In particular, PLASMA SUPPLIER covenants and agrees, unless otherwise permitted by ADMA in writing
        (e-mail being acceptable), to provide samples for RSV donor testing from: (i) [***] Centers from the Effective Date through [***]; (ii) [***] Centers from [***] through [***]; (iii) [***] Centers from [***] through [***]; (iv) [***] Centers from
        [***] through [***]; and (v) [***] Centers from [***] through the remainder of the Term.</font></font></div>
  <div style="font-size: 10pt;">&#160;</div>
  <div style="text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">7.</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman';">Once ADMA has identified a donor as an
        Acceptable Donor and notified PLASMA SUPPLIER in writing of such designation (e-mail being sufficient), ADMA agrees to purchase all RSV Plasma collected from the Acceptable Donor until it notifies PLASMA SUPPLIER in writing (e-mail being
        sufficient) that the donor is no longer an Acceptable Donor. ADMA is obligated to purchase all RSV Plasma, on a monthly basis, from Acceptable Donors that PLASMA SUPPLIER has collected and delivered in conformity with the ADMA Specifications.&#160; ADMA
        may, <a name="OLE_LINK1"></a>upon [***] ([***]) business days&#8217; prior written notice (e-mail being sufficient), terminate Acceptable Donor status for any donor at any time at its sole discretion. ADMA will not be obligated to purchase RSV Plasma
        from donors who are not Acceptable Donors or have been dropped as Acceptable Donors following ADMA&#8217;s [***] ([***]) business days&#8217; written drop notification.&#160; ADMA will be obligated to purchase any RSV Plasma collected through the drop notification
        period.&#160; Business days are defined as Monday through Friday 9am to 5pm Eastern Standard Time, with weekends and holidays (applicable to each Center) specifically excluded.</font></font></div>
  <div style="font-size: 10pt;">&#160;</div>
  <div style="text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">8.</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman';">PLASMA SUPPLIER shall have no obligation to
        provide RSV Plasma to ADMA in the event the failure to provide RSV Plasma is due to a Force Majeure Event described in <font style="font-family: 'Times New Roman';"><u>Article F</u></font> or the unavailability of Acceptable Donors.&#160; Additionally,
        ADMA shall have no obligation to purchase RSV Plasma from PLASMA SUPPLIER in the event of a Force Majeure Event affecting ADMA.</font></font></div>
  <div style="font-size: 10pt;">&#160;</div>
  <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
    <div class="BRPFPageNumberArea" style="text-align: center;"><font style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">- 5 -</font></div>
    <div class="BRPFPageBreak" style="page-break-after: always;">
      <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
  </div>
  <div style="text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">9.</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman';">Following donor acceptance and receipt of
        such RSV Plasma units into ADMA&#8217;s inventory in accordance with <font style="font-family: 'Times New Roman';"><u>Section A.4</u></font> (Inspection and Acceptance), ADMA shall bear the expense of unusable RSV Plasma due to a recall, or the
        destruction of any RSV Plasma due to post-donation &#8220;look back&#8221; issues in accordance with FDA regulations and guidance.</font></font></div>
  <div style="font-size: 10pt;">&#160;</div>
  <div style="text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">10.</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman';"><font style="font-family: 'Times New Roman';">PLASMA SUPPLIER shall supply to ADMA, for the Term, RSV Plasma to be derived from automated plasmapheresis procedures conducted at plasma centers approved by ADMA and specified in <u>Exhibit B</u> (the &#8220;</font><font style="font-family: 'Times New Roman'; font-weight: bold;">Centers</font><font style="font-family: 'Times New Roman';">&#8221;).</font>&#160;<font style="font-family: 'Times New Roman';"><u>Exhibit B</u> shall be updated from time to time to reflect additional Centers approved
          by ADMA to be built or otherwise collecting RSV Plasma by PLASMA SUPPLIER or its affiliates/subsidiaries which PLASMA SUPPLIER will utilize to supply RSV Plasma pursuant to the terms of this Agreement.</font></font></font></div>
  <div style="font-size: 10pt;">&#160;</div>
  <div style="text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">11.</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman';">ADMA Biologics, Inc. and PLASMA SUPPLIER
        shall execute a mutually agreeable Amended and Restated Source Plasma Specifications and Quality Agreement within [***] ([***]) days of the Effective Date, which shall be attached as <font style="font-family: 'Times New Roman'; font-weight: bold;"><u>Exhibit




            A</u></font> hereto (the &#8220;<font style="font-family: 'Times New Roman'; font-weight: bold;">A&amp;R</font>&#160;<font style="font-family: 'Times New Roman'; font-weight: bold;">Quality Agreement</font>&#8221;). Until such time that the A&amp;R Quality
        Agreement is fully executed, that certain Source Plasma Specification and Quality Agreement, effective as of November 17, 2011, by and between ADMA Biologics, Inc. and PLASMA SUPPLIER (as successor-in-interest to Biotest Pharmaceuticals
        Corporation), shall remain in effect.&#160; In the event of a conflict between any of the provisions of this Agreement and the Quality Agreement or A&amp;R Quality Agreement, as applicable, with respect to quality-related activities, including
        compliance with applicable laws, the provisions of the Quality Agreement or A&amp;R Quality Agreement, as applicable, shall prevail.&#160; In the event of a conflict between any of the provisions of this Agreement and the Quality Agreement or A&amp;R
        Quality Agreement, as applicable, with respect to any commercial matters, including allocation of risk, liability, and financial responsibility, the provisions of this Agreement shall prevail.</font></font></div>
  <div style="font-size: 10pt;">&#160;</div>
  <div style="text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">12.</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';">ADMA shall have the right to conduct
        inspections of PLASMA SUPPLIER&#8217;s Centers and facilities pertaining to the RSV Plasma at times mutually agreeable to the Parties.&#160; Such inspections shall be limited to matters directly related to this Agreement and shall be conducted in conformance
        with generally accepted industry practices. ADMA will provide PLASMA SUPPLIER with not less than [***] ([***]) days&#8217; notice prior to any of its inspections, unless mutually agreed otherwise by the Parties. Upon receipt of ADMA&#8217;s inspection report,
        PLASMA SUPPLIER shall have [***] ([***]) days to send a written response to ADMA, outlining the corrective actions that PLASMA SUPPLIER will take at its expense, to correct the inspection deficiencies.&#160; Further, PLASMA SUPPLIER agrees to provide
        ADMA with copies of all written reports (including FDA 483s) and correspondence between PLASMA SUPPLIER and any governmental agency regarding any such inspection or review of records within [***] ([***]) days of (i) receipt of any such report or
        correspondence from the governmental agency or (ii) the issuance or delivery of any response or correspondence by PLASMA SUPPLIER; provided, however, that in the event the report or correspondence relates to a material problem that could effect the
        continuous supply, or quality of the Plasma, then PLASMA SUPPLIER agrees to use all reasonable efforts to notify ADMA within [***] ([***]) days of receipt of such report or correspondence and to promptly provide ADMA with a copy of such report or
        correspondence.</font></font></div>
  <div style="font-size: 10pt;">&#160;</div>
  <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
    <div class="BRPFPageNumberArea" style="text-align: center;"><font style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">- 6 -</font></div>
    <div class="BRPFPageBreak" style="page-break-after: always;">
      <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
  </div>
  <div style="text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">13.</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';">PLASMA SUPPLIER, in compliance with 21 CFR
        &#167;640.69(f), agrees to hold all RSV Plasma units for a minimum of [***] ([***]) calendar days from the collection date prior to delivery of the RSV Plasma to the Designated Location. ADMA further agrees that if ADMA is informed by PLASMA SUPPLIER
        (through the established lookback process) that a donor has been subsequently deferred pursuant to 21 CFR &#167;610.41 or subsequently determined to be ineligible under 21 CFR &#167;630.10 due to risk factors closely associated with exposure to, or clinical
        evidence of, infection due to a relevant transfusion-transmitted infection, all donations on hold from that donor will not be used in the further manufacturing of injectable products.</font></font></div>
  <div style="font-size: 10pt;">&#160;</div>
  <div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%;" id="za8878df924d1432cad0d937a7708fc35" class="DSPFListTable">

        <tr style="vertical-align: top;">
          <td style="text-align: right; vertical-align: top; width: 36pt;">
            <div style="text-align: left;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">B.</font></div>
          </td>
          <td style="text-align: left; vertical-align: top; width: auto;">
            <div><font style="font-size: 10pt;"><font style="font-family: 'Times New Roman';"><font style="font-family: 'Times New Roman'; font-weight: bold;"><u>REPRESENTATIONS AND WARRANTIES</u></font>.</font></font></div>
          </td>
        </tr>

    </table>
  </div>
  <div style="font-size: 10pt;">&#160;</div>
  <div style="text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">1.</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman';">Each Party hereto hereby represents and
        warrants to the other as follows: (i) such Party hereto has all requisite power and authority to enter into this Agreement and to consummate the transactions contemplated hereby, (ii) such Party is validly organized and existing and in good
        standing under the laws of the jurisdiction of its incorporation or organization, (iii) such Party is duly qualified to do business and is in good standing as a foreign entity in each jurisdiction where the nature of its business requires such
        qualification, (iv) the execution and delivery of this Agreement and the consummation by such Party of the transactions contemplated hereby have been duly authorized by all necessary action on the part of such Party, and (v) this Agreement has been
        duly and validly executed and delivered by such Party and constitutes the valid and binding obligation of such Party, enforceable against such Party in accordance with its terms.</font></font></div>
  <div style="font-size: 10pt;">&#160;</div>
  <div style="text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">2.</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman';">PLASMA SUPPLIER represents and warrants that
        it will only release RSV Plasma to ADMA or its loading dock under this Agreement from the Designated Location that have the requisite FDA approval at the time of such release, and that it shall thereafter maintain such approval during the Term of
        this Agreement.&#160; All information provided by PLASMA SUPPLIER to ADMA with respect to the RSV Plasma is complete and accurate in all material respects.</font></font></div>
  <div style="font-size: 10pt;">&#160;</div>
  <div style="text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">3.</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman';">PLASMA SUPPLIER represents and warrants to
        ADMA that RSV Plasma will be collected, produced, packaged, labeled, handled, stored and shipped in accordance with ADMA Specifications, the Quality Agreement or A&amp;R Quality Agreement, as applicable, and PLASMA SUPPLIER approved standard
        operating procedures.&#160; PLASMA SUPPLIER represents, warrants and agrees that any and all RSV Plasma shall be collected, produced and packaged, labeled, handled, stored and shipped in accordance with all applicable local, state and federal laws,
        regulations, and requirements.&#160; ADMA shall have all rights and remedies available to it under this Agreement and shall not be obligated to buy or pay for any RSV Plasma which does not, in all respects, comply with the ADMA Specifications and
        applicable law, rules and regulations and as otherwise required by this Agreement, provided ADMA must submit notification of rejection within [***] ([***]) days of receipt of such RSV Plasma.&#160; PLASMA SUPPLIER represents and warrants that its
        collection and supply of RSV Plasma under this Agreement will not breach or misappropriate the intellectual property rights of any third party.</font></font></div>
  <div style="font-size: 10pt;">&#160;</div>
  <div style="text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">4.</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman';">EXCEPT AS OTHERWISE SET FORTH HEREIN, PLASMA
        SUPPLIER MAKES NO REPRESENTATIONS NOR EXTENDS ANY WARRANTIES OR CONDITIONS OF ANY KIND, EITHER EXPRESS OR IMPLIED, WITH RESPECT TO RSV PLASMA, INCLUDING, BUT NOT LIMITED TO, WARRANTIES OF MERCHANTABILITY.</font></font></div>
  <div style="font-size: 10pt;">&#160;</div>
  <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
    <div class="BRPFPageNumberArea" style="text-align: center;"><font style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">- 7 -</font></div>
    <div class="BRPFPageBreak" style="page-break-after: always;">
      <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
  </div>
  <div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%;" id="z04b8438ed2c3464b91170fc9d45f4a7f" class="DSPFListTable">

        <tr style="vertical-align: top;">
          <td style="text-align: right; vertical-align: top; width: 36pt;">
            <div style="text-align: left;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">C.</font></div>
          </td>
          <td style="text-align: left; vertical-align: top; width: auto;">
            <div><font style="font-size: 10pt;"><font style="font-family: 'Times New Roman';"><font style="font-family: 'Times New Roman'; font-weight: bold;"><u>MISCELLANEOUS</u></font>.</font></font></div>
          </td>
        </tr>

    </table>
  </div>
  <div style="font-size: 10pt;">&#160;</div>
  <div style="text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">1.</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman';"><font style="font-family: 'Times New Roman'; font-weight: bold;"><u>CONFIDENTIALITY</u></font>.</font></font></div>
  <div style="font-size: 10pt;">&#160;</div>
  <div style="text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">a.</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman';">Each Party agrees to maintain the confidentiality of the
        contents of this Agreement, the dealings between the Parties under this Agreement and any other confidential, non-public or proprietary information disclosed by the other Party during the Term, whether or not such information is labeled or
        otherwise identified as &#8220;confidential,&#8221; including that obtained through documents (whether written or electronic), observations, inspections or audits, and discussions (collectively, &#8220;<font style="font-family: 'Times New Roman'; font-weight: bold;">Confidential




          Information</font>&#8221;) with the same degree of care as they use to protect their own proprietary, confidential or trade secret information.&#160; A receiving Party shall not disclose to any third party, excluding such Party&#8217;s affiliates, agents,
        attorneys, consultants, advisors, and other representatives with a need-to-know such information and that is under an obligation of confidentiality therewith, any Confidential Information received from the disclosing Party hereunder without that
        disclosing Party&#8217;s prior written consent and shall use it only for the purpose of this Agreement.&#160; Said obligation of secrecy shall not apply to any information which (a) was in the public domain at the time of its disclosure or thereafter becomes
        part of the public domain by publication or otherwise subsequent to the time of disclosure under this Agreement through no fault of the receiving Party; (b) was known to the receiving Party or in its possession prior to or at the time of disclosure
        as shown by written records; (c) is independently developed by the receiving Party without use of the other Party&#8217;s Confidential Information as shown by written documentation; (d) is disclosed with the written approval of the disclosing Party; or
        (e) is rightfully furnished to the receiving Party by a third party having the authority to disclose such Confidential Information without restrictions.</font></font></div>
  <div style="font-size: 10pt;">&#160;</div>
  <div style="text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">b.</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman';">If a Party is required to disclose the other Party&#8217;s
        Confidential Information by law or regulation or in response to a valid order of a court or other governmental body, or for registration of a product by competent authorities, such disclosure is permissible under this Section C.1, but only to the
        extent required under such law, regulation, order or registration, and only if the receiving Party, to the extent legally permissible, first notifies the disclosing Party of the required disclosure and permits the disclosing Party, at its expense,
        to seek an appropriate legal remedy to maintain the confidentiality of the Confidential Information to the maximum extent possible.&#160; All Confidential Information is provided &#8220;AS IS&#8221; and without any warranty, express, implied or otherwise regarding
        its accuracy or performance.</font></font></div>
  <div style="font-size: 10pt;">&#160;</div>
  <div style="text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">c.</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman';">The above obligations shall survive the termination of this
        Agreement and shall continue with respect to donor information and trade secrets without limit of time and in respect of other Confidential Information for a period of [***] ([***]) years.</font></font></div>
  <div style="font-size: 10pt;">&#160;</div>
  <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">d.</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';">PLASMA SUPPLIER recognizes that in the
        course of performing under this Agreement, PLASMA SUPPLIER may receive from ADMA or others information that may be considered &#8220;material, nonpublic information&#8221; concerning a public company that is subject to the reporting requirements of the
        Securities and Exchange Act of 1934, as amended. PLASMA SUPPLIER represents, warrants and covenants to NOT: (a) purchase or sell, directly or indirectly, any securities of ADMA or any company while in possession of relevant material, nonpublic
        information relating to ADMA or such company; or (b) communicate any material, nonpublic information to any other person in which it is reasonably foreseeable that such person is likely to (i) purchase or sell securities of ADMA or any such company
        with respect to which such information relates, or (ii) otherwise directly or indirectly benefit from such information. Without limiting any of the confidentiality obligations and restrictions on insider trading included in this Agreement or in any
        other confidentiality agreement between the Parties, PLASMA SUPPLIER shall not discuss any information concerning ADMA obtained by PLASMA SUPPLIER in the course of performing this Agreement with any financial, securities or industry analyst or with
        the media without the prior written consent of ADMA.</font></font></div>
  <div style="font-size: 10pt;">&#160;</div>
  <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
    <div class="BRPFPageNumberArea" style="text-align: center;"><font style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">- 8 -</font></div>
    <div class="BRPFPageBreak" style="page-break-after: always;">
      <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
  </div>
  <div style="text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">2.</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman';"><font style="font-family: 'Times New Roman'; font-weight: bold;"><u>RELATIONSHIP OF THE PARTIES</u></font>.&#160; The relationship between ADMA and PLASMA SUPPLIER during the Term of this Agreement is solely that of independent contractors.&#160; Neither Party is, in any way, the legal
        representative, agent, joint venture or partner of the other Party for any purpose whatsoever and neither Party has any control or authority whatsoever to bind the other Party or any other person with respect to the other Party or incur any
        obligations on the other Party&#8217;s behalf.</font></font></div>
  <div style="font-size: 10pt;">&#160;</div>
  <div style="text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">3.</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman';"><a name="z_Hlk31005808"></a><font style="font-family: 'Times New Roman'; font-weight: bold;"><u>INDEMNIFICATION</u></font>.&#160; PLASMA SUPPLIER and ADMA hereby agree to indemnify, defend and hold harmless each other and their respective affiliates, subsidiaries, members, managers,
        lenders, agents, employees, officers and directors, from and against any and all third-party claims, losses, liabilities, damages, reasonable attorneys&#8217; fees, costs and expenses (hereinafter &#8220;<font style="font-family: 'Times New Roman'; font-weight: bold;">Claims</font>&#8221;) which may be sustained by and/or claimed against a Party by virtue of (i) their negligent acts, negligent omissions or the negligent handling or furnishing of materials or performance of services rendered by
        the other Party, (ii) failure by the other Party to materially comply with its obligations under this Agreement, (iii) the willful misconduct by the other Party or its directors, officers, employees or agents, or (iv) the other Party&#8217;s material
        breach of any representation, warranty or term contained in this Agreement.&#160; The indemnifying Party&#8217;s liability shall be reduced to the extent any such Claims arise as a result of the indemnified Party&#8217;s own misconduct, breach or negligence.&#160; To
        the extent RSV Plasma is being used to manufacture Products to be used in research or for commercial purposes, ADMA specifically shall indemnify, defend and hold harmless PLASMA SUPPLIER, its affiliates, subsidiaries, directors, officers, agents
        and employees, from any and all Claims arising from the use of Product or any procedure required by the research protocol or related to the commercial sale of such Product, provided that the RSV Plasma is not the direct or contributing cause of
        such liability, loss or damage. The Party from whom indemnity is sought under this <font style="font-family: 'Times New Roman';"><u>Section C.3</u></font> shall be entitled at its option to defend or control the defense and/or settlement of any
        such Claims; provided that the indemnifying Party shall not settle any such Claim without the prior written consent of the indemnified Party (which consent shall not be unreasonably withheld or delayed).&#160; Each Party shall notify the other Party in
        writing of any Claim or potential Claim as soon as it becomes aware that such Claim or potential Claim has arisen and shall provide to the other Party, all reasonable assistance in respect thereof; provided that the failure of the indemnified Party
        to provide timely notice shall only relieve the indemnifying Party of liability to the extent the indemnifying Party can demonstrate that it actually was prejudiced by any delayed notification. The indemnified Party shall have the right to be
        represented by legal counsel of its choice, at its sole cost and expense.</font></font></div>
  <div style="font-size: 10pt;">&#160;</div>
  <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
    <div class="BRPFPageNumberArea" style="text-align: center;"><font style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">- 9 -</font></div>
    <div style="page-break-after: always;" class="BRPFPageBreak">
      <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
  </div>
  <div style="text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">4.</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman';"><font style="font-family: 'Times New Roman'; font-weight: bold;"><u>LIMITATION OF LIABILITY</u></font>.&#160; EXCEPT FOR ANY BREACH OF CONFIDENTIALITY UNDER <font style="font-family: 'Times New Roman';"><u>SECTION C.1</u></font>, IN NO EVENT WILL EITHER PARTY HAVE ANY LIABILITY FOR ANY LOSS OF
        INCOME, PROFIT, INTEREST OR SAVINGS BY THE OTHER PARTY OR FOR ANY INDIRECT, INCIDENTAL, CONSEQUENTIAL, PUNITIVE OR SPECIAL DAMAGES SUFFERED BY THE OTHER PARTY, ARISING FROM OR RELATED TO THIS AGREEMENT, INCLUDING WITHOUT LIMITATION, THE SALE OR USE
        OF ANY RSV PLASMA, REGARDLESS OF THE FORM OF ACTION, AND WHETHER IN CONTRACT, INDEMNITY, WARRANTY OR TORT, INCLUDING WITHOUT LIMITATION, STRICT LIABILITY AND NEGLIGENCE OR ANY OTHER LEGAL OR EQUITABLE GROUNDS, EVEN IF SUCH PARTY HAS BEEN ADVISED OF
        THE POSSIBILITY OF SUCH LOSSES OR DAMAGES. THIS LIMITATION WILL NOT APPLY TO ANY LIABILITY FOR DAMAGES THAT MAY RESULT FROM THE GROSS NEGLIGENCE OR WILLFUL MISCONDUCT OF A PARTY.</font></font></div>
  <div style="font-size: 10pt;">&#160;</div>
  <div style="text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">5.</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman';"><font style="font-family: 'Times New Roman'; font-weight: bold;"><u>INSURANCE</u></font>.&#160; ADMA and PLASMA SUPPLIER shall each be required to maintain general and product liability insurance in an amount of at least [***] Dollars ($[***]) during the Term and to promptly furnish certificates
        evidencing the insurance required by this Section upon the other Party&#8217;s written request.&#160; The Parties shall provide [***] ([***]) days&#8217; advance written notice in the event the insurance required by this <font style="font-family: 'Times New Roman';"><u>Section C.5</u></font> is materially modified, cancelled or otherwise terminated for any reason.&#160; The Parties intend that any and all damages, losses, liabilities, penalties, judgments, settlements, payments, costs and expenses,
        whether or not resulting from third-party claims, including the costs and expenses of any such claims subject to indemnification or reimbursement pursuant to <font style="font-family: 'Times New Roman';"><u>Section C.3</u></font> (&#8220;<font style="font-family: 'Times New Roman'; font-weight: bold;">Loss</font>&#8221;) will be net of insurance proceeds that actually reduce the amount of the Loss. Accordingly, the amount which any Party (an &#8220;<font style="font-family: 'Times New Roman'; font-weight: bold;">Indemnifying Party</font>&#8221;) is required to pay to any Person entitled to indemnification hereunder (an &#8220;<font style="font-family: 'Times New Roman'; font-weight: bold;">Indemnitee</font>&#8221;) will be reduced by any insurance
        proceeds theretofore actually recovered by or on behalf of the Indemnitee in respect of the related Loss. If an Indemnitee receives a payment (an &#8220;<font style="font-family: 'Times New Roman'; font-weight: bold;">Indemnity Payment</font>&#8221;) required
        by this Agreement from an Indemnifying Party in respect of any Loss and subsequently receives insurance proceeds, then the Indemnitee will pay to the Indemnifying Party an amount equal to the excess of the Indemnity Payment received over the amount
        of the Indemnity Payment that would have been due if the insurance proceeds had been received, realized or recovered before the Indemnity Payment was made.</font></font></div>
  <div style="font-size: 10pt;">&#160;</div>
  <div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%;" id="zd4472c15278b4135b513e26928f106f7" class="DSPFListTable">

        <tr style="vertical-align: top;">
          <td style="text-align: right; vertical-align: top; width: 36pt;">
            <div style="text-align: left;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">D.</font></div>
          </td>
          <td style="text-align: left; vertical-align: top; width: auto;">
            <div><font style="font-size: 10pt;"><font style="font-family: 'Times New Roman';"><font style="font-family: 'Times New Roman'; font-weight: bold;"><u>TERMINATION</u></font>.</font></font></div>
          </td>
        </tr>

    </table>
  </div>
  <div style="font-size: 10pt;">&#160;</div>
  <div style="text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">1.</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman';">In addition to any other remedy it may have,
        either Party shall have the right to terminate this Agreement if the other Party fails to remedy and make good any default in the performance of any material condition or obligation under this Agreement within a cure period of [***] ([***]) days of
        written notice thereof.</font></font></div>
  <div style="font-size: 10pt;">&#160;</div>
  <div style="text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">2.</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman';">Additionally, ADMA shall have the right to
        terminate this Agreement on [***] ([***]) days&#8217; written notice in the event that the FDA withdraws its approval of ASCENIV&#8482; during the Term, or in the event that ASCENIV&#8482; is otherwise unable to be commercially sold.</font></font></div>
  <div style="font-size: 10pt;">&#160;</div>
  <div style="text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">3.</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman';">Upon giving the appropriate written notice,
        either Party may terminate this Agreement upon the occurrence of a proceeding under any bankruptcy, reorganization, arrangement of debts, insolvency or receivership law is filed by or against the other Party, and is not dismissed or stayed within
        [***] ([***]) days, or a receiver or trustee is appointed for all or a substantial portion of the assets of the other Party, or if the other Party makes an assignment for the benefit of its creditors or becomes insolvent.</font></font></div>
  <div style="font-size: 10pt;">&#160;</div>
  <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
    <div class="BRPFPageNumberArea" style="text-align: center;"><font style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">- 10 -</font></div>
    <div class="BRPFPageBreak" style="page-break-after: always;">
      <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
  </div>
  <div style="text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">4.</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman';">Upon termination of this Agreement, ADMA
        must pay for any RSV Plasma already delivered to ADMA and for any RSV Plasma collected and scheduled for delivery under the terms of this Agreement, provided, in each case that such RSV Plasma conforms to the ADMA Specifications.</font></font></div>
  <div style="font-size: 10pt;">&#160;</div>
  <div style="text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">5.</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman';">Notwithstanding anything to the contrary set
        forth herein, the Parties&#8217; obligations under this Agreement in <font style="font-family: 'Times New Roman';"><u>Sections A</u></font>, <font style="font-family: 'Times New Roman';"><u>C</u></font>, <font style="font-family: 'Times New Roman';"><u>D</u></font>,
        <font style="font-family: 'Times New Roman';"><u>F</u></font>, <font style="font-family: 'Times New Roman';"><u>G</u></font>, <font style="font-family: 'Times New Roman';"><u>I</u></font>, <font style="font-family: 'Times New Roman';"><u>J</u></font>,
        <font style="font-family: 'Times New Roman';"><u>K</u></font> and <font style="font-family: 'Times New Roman';"><u>L</u></font> shall survive the termination of this Agreement to the extent necessary to give effect to their reasonable intentions.</font></font></div>
  <div style="font-size: 10pt;">&#160;</div>
  <div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%;" id="zd867d9c6b52348559f23784239b11cca" class="DSPFListTable">

        <tr style="vertical-align: top;">
          <td style="text-align: right; vertical-align: top; width: 36pt;">
            <div style="text-align: left;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">E.</font></div>
          </td>
          <td style="text-align: left; vertical-align: top; width: auto;">
            <div><font style="font-size: 10pt;"><font style="font-family: 'Times New Roman';"><font style="font-family: 'Times New Roman'; font-weight: bold;"><u>FORCE MAJEURE</u></font>.</font></font></div>
          </td>
        </tr>

    </table>
  </div>
  <div style="font-size: 10pt;">&#160;</div>
  <div style="text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">1.</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman';">Neither Party shall be liable for any
        failure to perform its obligations under this Agreement caused by strikes, fires, explosions, acts of God, riots, civil or international war, future widespread outbreaks of illness or a pandemic acts of terrorism, an unexpected downturn in the
        acceptable donor population adversely affecting the industry as a whole, an inability to fully test samples of RSV Plasma or any other similar cause beyond the reasonable control of either Party (including any such events at a Center or third-party
        testing laboratory) which prevents the performance of a Party&#8217;s obligations under this Agreement or the Quality Agreement or A&amp;R Quality Agreement, as applicable (each, a &#8220;<font style="font-family: 'Times New Roman'; font-weight: bold;">Force
          Majeure Event</font>&#8221;).</font></font></div>
  <div style="font-size: 10pt;">&#160;</div>
  <div style="text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">2.</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman';">The affected Party shall immediately inform
        the other Party of a Force Majeure Event, including a full description of the nature of the Force Majeure Event, and its cause and possible consequences of such occurrences.&#160; Upon giving notice to the other Party, the Party affected by a Force
        Majeure Event shall be released without any liability on its part from the performance of its obligations under this Agreement, except for the obligation to pay any amounts due and owing hereunder, but only to the extent and only for the period
        that its performance of such obligations is prevented by the Force Majeure Event.&#160; The Party claiming Force Majeure shall promptly notify the other Party of the termination of such event.</font></font></div>
  <div style="font-size: 10pt;">&#160;</div>
  <div style="text-indent: 36pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">3.</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman';">Should the period of Force Majeure continue
        for more than [***] ([***]) days, then the Party not suffering the Force Majeure Event may terminate this Agreement immediately upon giving written notice to the other Party.</font></font></div>
  <div style="font-size: 10pt;">&#160;</div>
  <div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%;" id="z00147d80cc594759bad34862a6275e98" class="DSPFListTable">

        <tr style="vertical-align: top;">
          <td style="text-align: right; vertical-align: top; width: 36pt;">
            <div style="text-align: left;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">F.</font></div>
          </td>
          <td style="text-align: left; vertical-align: top; width: auto;">
            <div><font style="font-size: 10pt;"><font style="font-weight: bold; font-family: 'Times New Roman';"><u>DONOR INFORMATION</u></font></font></div>
          </td>
        </tr>

    </table>
  </div>
  <div style="font-size: 10pt;">&#160;</div>
  <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">PLASMA SUPPLIER agrees that all donor information supplied by ADMA and antibody test results supplied by ADMA are the property of ADMA and that PLASMA
    SUPPLIER has no right to share this information with any other party or use the information for its own commercial use, but may use the information to comply with regulatory requirements and for its own record keeping requirements. This information
    shall be considered ADMA&#8217;s Confidential Information.</div>
  <div style="font-size: 10pt;">&#160;</div>
  <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">PLASMA SUPPLIER agrees to provide ADMA, on a monthly basis during the Term, with certain aggregate and deidentified information about Acceptable Donors
    in PLASMA SUPPLIER&#8217;s RSV Plasma program [***], provided that it complies with the applicable data protection legislation and [***].</div>
  <div style="font-size: 10pt;">&#160;</div>
  <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
    <div class="BRPFPageNumberArea" style="text-align: center;"><font style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">- 11 -</font></div>
    <div class="BRPFPageBreak" style="page-break-after: always;">
      <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
  </div>
  <div>
    <div>
      <div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%;" id="z877779cadbc446a59f020cf68e9f1330" class="DSPFListTable">

            <tr style="vertical-align: top;">
              <td style="text-align: right; vertical-align: top; width: 36pt;">
                <div style="text-align: justify; font-family: 'Times New Roman'; font-weight: bold;"><font style="text-align: left; font-family: 'Times New Roman'; font-weight: bold;">G.</font></div>
              </td>
              <td style="text-align: left; vertical-align: top; width: auto;">
                <div style="text-align: justify; font-family: 'Times New Roman'; font-weight: bold;"><u>DISCLOSURES AND PUBLICITY</u></div>
              </td>
            </tr>

        </table>
      </div>
    </div>
  </div>
  <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;"> <br>
  </div>
  <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">Neither Party shall, without the approval of the other Party, make any press release or other public announcement concerning the transactions
    contemplated by this Agreement, except as and to the extent that any such Party shall be so obligated by law, in which case the other Party shall be advised and the Parties shall use their commercially reasonable efforts to cause a mutually agreeable
    release or announcement to be issued; provided, however, that the foregoing shall not preclude communications or disclosures necessary to implement the provisions of this Agreement or to comply with the accounting and disclosure obligations of the
    Securities and Exchange Commission (&#8220;<font style="font-family: 'Times New Roman'; font-weight: bold;">SEC</font>&#8221;) or the rules of any stock exchange.&#160; Notwithstanding any contrary term contained in the confidentiality provisions of this Agreement, to
    the extent that either Party determines that it or the other Party is required to publicly file or register this Agreement, a summary thereof, or a notification thereof, and/or descriptions related thereto, to comply with the requirements of an
    applicable stock exchange, SEC regulation, or any governmental authority, including the SEC, or to enable either Party to obtain debt or equity financing, such Party shall use its best efforts to provide the maximum amount of advance written notice of
    any such required disclosure to the other Party, to the extent practicable, with a minimum advance notice period of [***] ([***]) business days.&#160; Prior to making any such filing, registration or notification, the Parties shall consult with respect
    thereto regarding confidentiality.&#160; The Parties shall cooperate, each at its own expense, in such filing, registration or notification, including such confidential treatment request, if applicable, and shall execute all documents reasonably required in
    connection therewith.</div>
  <div style="font-size: 10pt;">&#160;</div>
  <div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%;" id="zae1501d1e2684c129b9a0eb5da9900f5" class="DSPFListTable">

        <tr style="vertical-align: top;">
          <td style="text-align: right; vertical-align: top; width: 36pt;">
            <div style="text-align: left;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">H.</font></div>
          </td>
          <td style="text-align: left; vertical-align: top; width: auto;">
            <div><font style="font-size: 10pt;"><font style="font-family: 'Times New Roman';"><font style="font-family: 'Times New Roman'; font-weight: bold;"><u>ASSIGNMENT</u></font>.</font></font></div>
          </td>
        </tr>

    </table>
  </div>
  <div style="font-size: 10pt;">&#160;</div>
  <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">Neither Party shall assign this Agreement or any of its rights or obligations hereunder without the express written consent of the other Party, except
    as hereinafter provided.&#160; Any such consent shall not be unreasonably delayed, conditioned, or withheld.&#160; With notice to the other Party, either Party without the other Party&#8217;s consent may assign this Agreement to (i) its affiliates, or (ii) a successor
    to all or substantially all of the assets or equity ownership relating to the business of that Party which is involved in the fulfillment of its obligations under this Agreement, and such successor or assignee (if such successor or assignee is not a
    Party hereto) shall expressly assume in writing the performance of all of the terms and conditions of this Agreement then to be performed by such successor or assignee as if it were named herein as a Party.</div>
  <div style="font-size: 10pt;">&#160;</div>
  <div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%;" id="z3ae310999b8341ca9474acd9fe621256" class="DSPFListTable">

        <tr style="vertical-align: top;">
          <td style="text-align: right; vertical-align: top; width: 36pt;">
            <div style="text-align: left;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">I.</font></div>
          </td>
          <td style="text-align: left; vertical-align: top; width: auto;">
            <div><font style="font-size: 10pt;"><font style="font-family: 'Times New Roman';"><font style="font-family: 'Times New Roman'; font-weight: bold;"><u>NOTICES</u></font>.&#160; Except as otherwise provided in this Agreement, all notices, demands,
                  requests, consents or approvals furnished by a Party under this Agreement must be in writing and delivered personally to the other Party or sent by overnight courier service, registered or certified mail, or electronic mail (&#8220;<font style="font-family: 'Times New Roman'; font-weight: bold;">e-mail</font>&#8221;), addressed to such Party as set forth below (or to such other (physical or e-mail) address(es) as such Party may hereafter specify for the purpose by notice to
                  the other Party in accordance herewith):</font></font></div>
          </td>
        </tr>

    </table>
  </div>
  <div style="font-size: 10pt;">&#160;</div>
  <div style="text-align: left; text-indent: -108pt; margin-left: 144pt; font-family: 'Times New Roman'; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>To PLASMA SUPPLIER</u></font><font style="font-size: 10pt;">:</font></div>
  <div style="text-align: left; text-indent: -108pt; margin-left: 144pt; font-family: 'Times New Roman'; font-size: 10pt;"><font style="font-family: 'Times New Roman';"><br>
    </font>[***]</div>
  <div style="text-align: left; margin-left: 144pt; font-family: 'Times New Roman'; font-size: 10pt;">[***]</div>
  <div style="text-align: left; margin-left: 144pt; font-family: 'Times New Roman'; font-size: 10pt;">Grifols Worldwide Operations Limited</div>
  <div style="text-align: left; margin-left: 144pt; font-family: 'Times New Roman'; font-size: 10pt;">Grange Castle Business Park, Grange Castle</div>
  <div style="text-align: left; margin-left: 144pt; font-family: 'Times New Roman'; font-size: 10pt;">Clondalkin, Dublin 22, Ireland</div>
  <div style="text-align: left; margin-left: 144pt; font-family: 'Times New Roman'; font-size: 10pt;">E-mail: [***]</div>
  <div style="font-size: 10pt;"><br>
  </div>
  <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z4fc4739533f14bbd9553b53b46e242e0">

      <tr>
        <td style="width: 36pt; font-size: 10pt;"><br>
        </td>
        <td style="width: 108pt; vertical-align: top;"><font style="font-size: 10pt; font-family: 'Times New Roman';"><u>To ADMA</u>:</font></td>
        <td style="width: auto; vertical-align: top; text-align: left; font-size: 10pt;">
          <div style="font-family: 'Times New Roman';">[***]</div>
        </td>
      </tr>

  </table>
  <div style="text-align: left; margin-left: 144pt; font-family: 'Times New Roman'; font-size: 10pt;">General Counsel<font style="font-family: 'Times New Roman';"><br>
    </font>ADMA Biologics<font style="font-family: 'Times New Roman';"><br>
    </font>5800 Park of Commerce Boulevard, NW</div>
  <div style="text-align: left; margin-left: 144pt; font-family: 'Times New Roman'; font-size: 10pt;">Boca Raton, FL 33487</div>
  <div style="text-align: left; margin-left: 144pt; font-family: 'Times New Roman'; font-size: 10pt;">E-mail: [***]</div>
  <div style="font-size: 10pt;"><br>
  </div>
  <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
    <div class="BRPFPageNumberArea" style="text-align: center;"><font style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">- 12 -</font></div>
    <div class="BRPFPageBreak" style="page-break-after: always;">
      <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
  </div>
  <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">All notices, requests, consents and other communications hereunder shall be deemed to have been properly given (a) if by hand, at the time of the
    delivery thereof to the receiving Party at the address of such Party set forth above, (b) if sent by overnight courier, on the next business day following the day such notice is delivered to the courier service, (c) if sent by registered or certified
    mail, on the fifth business day following the day such mailing is made, or (d) if sent via e-mail, upon written confirmation of receipt (whether from an automated confirmation of delivery or &#8220;read receipt&#8221; or otherwise).</div>
  <div style="font-size: 10pt;">&#160;</div>
  <div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%;" id="z15aff5570c8f495fa5312c4658ccb8c7" class="DSPFListTable">

        <tr style="vertical-align: top;">
          <td style="text-align: right; vertical-align: top; width: 36pt;">
            <div style="text-align: left;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">J.</font></div>
          </td>
          <td style="text-align: left; vertical-align: top; width: auto;">
            <div><font style="font-size: 10pt;"><font style="font-family: 'Times New Roman';"><font style="font-family: 'Times New Roman'; font-weight: bold;"><u>INTEGRATION; AMENDMENT; EFFECT OF AMENDMENT</u></font>.</font></font></div>
          </td>
        </tr>

    </table>
  </div>
  <div style="font-size: 10pt;">&#160;</div>
  <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">This Agreement, including all attachments, schedules or other agreements specifically incorporated by reference, constitute the entire agreement between
    the Parties with respect to the subject matter of this Agreement and supersede any and all other prior written or oral agreements, understandings, negotiations or discussions among the Parties with respect to the subject matter of this Agreement.&#160; This
    Agreement may not be modified or amended in any respect except by an instrument in writing signed by both Parties.</div>
  <div style="font-size: 10pt;">&#160;</div>
  <div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%;" id="z1e779851981f406ba77e51c724188006" class="DSPFListTable">

        <tr style="vertical-align: top;">
          <td style="text-align: right; vertical-align: top; width: 36pt;">
            <div style="text-align: left;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">K.</font></div>
          </td>
          <td style="text-align: left; vertical-align: top; width: auto;">
            <div><font style="font-size: 10pt;"><font style="font-family: 'Times New Roman';"><font style="font-family: 'Times New Roman'; font-weight: bold;"><u>CHOICE OF LAW</u></font>.</font></font></div>
          </td>
        </tr>

    </table>
  </div>
  <div style="font-size: 10pt;">&#160;</div>
  <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">This Agreement shall be governed by, and construed under laws of the State of [***], without regard to its conflict of laws principles and is subject to
    exclusive jurisdiction of the courts of State of [***].</div>
  <div style="font-size: 10pt;">&#160;</div>
  <div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%;" id="z303b1cfa0d4b4ec082d321bf9b9b7df7" class="DSPFListTable">

        <tr style="vertical-align: top;">
          <td style="text-align: right; vertical-align: top; width: 36pt;">
            <div style="text-align: left;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">L.</font></div>
          </td>
          <td style="text-align: left; vertical-align: top; width: auto;">
            <div><font style="font-size: 10pt;"><font style="font-family: 'Times New Roman';"><font style="font-family: 'Times New Roman'; font-weight: bold;"><u>NO WAIVER</u></font>.</font></font></div>
          </td>
        </tr>

    </table>
  </div>
  <div style="font-size: 10pt;">&#160;</div>
  <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">Any failure or delay on the part of any Party exercising any power or right hereunder shall not operate as a waiver thereof, nor shall any single or
    partial exercise of any such right or power preclude any other or further exercise thereof or the exercise of any other right or power hereunder or otherwise available in law or in equity.</div>
  <div style="font-size: 10pt;">&#160;</div>
  <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
    <div class="BRPFPageNumberArea" style="text-align: center;"><font style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">- 13 -</font></div>
    <div class="BRPFPageBreak" style="page-break-after: always;">
      <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
  </div>
  <div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%;" id="z601c672de56e4ac6a7f02dcbb29a1444" class="DSPFListTable">

        <tr style="vertical-align: top;">
          <td style="text-align: right; vertical-align: top; width: 36pt;">
            <div style="text-align: left;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">M.</font></div>
          </td>
          <td style="text-align: left; vertical-align: top; width: auto;">
            <div><font style="font-size: 10pt;"><font style="font-family: 'Times New Roman';"><font style="font-family: 'Times New Roman'; font-weight: bold;"><u>NO SUBCONTRACTORS</u></font>.</font></font></div>
          </td>
        </tr>

    </table>
  </div>
  <div style="font-size: 10pt;">&#160;</div>
  <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">PLASMA SUPPLIER covenants and agrees to not use any vendors, suppliers, contractors or subcontractors, in each case without ADMA&#8217;s prior written
    consent, in order to perform its obligations hereunder.</div>
  <div style="font-size: 10pt;">&#160;</div>
  <div>
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%;" id="zd4988aa832944e7f8dcdebfa4c48b271" class="DSPFListTable">

        <tr style="vertical-align: top;">
          <td style="text-align: right; vertical-align: top; width: 36pt;">
            <div style="text-align: left;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">N.</font></div>
          </td>
          <td style="text-align: left; vertical-align: top; width: auto;">
            <div><font style="font-size: 10pt;"><font style="font-family: 'Times New Roman';"><font style="font-family: 'Times New Roman'; font-weight: bold;"><u>COUNTERPARTS</u></font>.</font></font></div>
          </td>
        </tr>

    </table>
  </div>
  <div style="font-size: 10pt;">&#160;</div>
  <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">This Agreement may be executed in any number of original counterparts or other electronic means, each of which when executed and delivered will be
    deemed to be an original and all of which taken together will constitute but one and the same instrument.&#160; One or more counterparts of this Agreement may be delivered by facsimile or other electronic means, with the intention that delivery by such
    means shall have the same effect as delivery of an original counterpart hereof.</div>
  <div style="font-size: 10pt;">&#160;</div>
  <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;">[Remainder of page intentionally left blank; signature page follows]</div>
  <div style="font-size: 10pt;">&#160;</div>
  <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
    <div class="BRPFPageNumberArea" style="text-align: center;"><font style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">- 14 -</font></div>
    <div style="page-break-after: always;" class="BRPFPageBreak">
      <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
  </div>
  <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 12pt;"><font style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: bold;">IN WITNESS WHEREOF</font><font style="font-size: 10pt;">, the Parties
      hereto have executed this Agreement by their duly authorized officers as of the Effective Date.</font></div>
  <div style="font-size: 10pt;">&#160;</div>
  <div style="font-size: 10pt;">&#160;</div>
  <div style="font-size: 10pt;">
    <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="zf8dccd98de424900b24233928bbfeacb">

        <tr>
          <td style="width: 52.7%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: left; font-family: 'Times New Roman'; font-weight: bold;">ADMA BIOMANUFACTURING, LLC</div>
          </td>
          <td style="width: 47.3%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: left; font-family: 'Times New Roman'; font-weight: bold;">GRIFOLS WORLDWIDE </div>
            <div style="text-align: left; font-family: 'Times New Roman'; font-weight: bold;">OPERATIONS LIMITED</div>
          </td>
        </tr>
        <tr>
          <td style="width: 52.7%; vertical-align: top; font-size: 10pt;" rowspan="1">&#160;</td>
          <td style="width: 47.3%; vertical-align: top; font-size: 10pt;" rowspan="1">&#160;</td>
        </tr>
        <tr>
          <td style="width: 52.7%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: left; font-family: 'Times New Roman';">By: <u><font style="font-family: 'Times New Roman';">/s/ Adam Grossman</font></u></div>
          </td>
          <td style="width: 47.3%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: left; font-family: 'Times New Roman';">By: <u><font style="font-family: 'Times New Roman';">/s/ Shane O&#8217;Brien</font></u></div>
          </td>
        </tr>
        <tr>
          <td style="width: 52.7%; vertical-align: top; font-size: 10pt;" rowspan="1">&#160;</td>
          <td style="width: 47.3%; vertical-align: top; font-size: 10pt;" rowspan="1">&#160;</td>
        </tr>
        <tr>
          <td style="width: 52.7%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: left; font-family: 'Times New Roman';">Name: Adam Grossman</div>
          </td>
          <td style="width: 47.3%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: left; font-family: 'Times New Roman';">Name: Shane O'Brien</div>
          </td>
        </tr>
        <tr>
          <td style="width: 52.7%; vertical-align: top; font-size: 10pt;" rowspan="1">&#160;</td>
          <td style="width: 47.3%; vertical-align: top; font-size: 10pt;" rowspan="1">&#160;</td>
        </tr>
        <tr>
          <td style="width: 52.7%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: left; font-family: 'Times New Roman';">Title: President and CEO</div>
          </td>
          <td style="width: 47.3%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: left; font-family: 'Times New Roman';">Title:&#160; Managing Director</div>
          </td>
        </tr>
        <tr>
          <td style="width: 52.7%; vertical-align: top; font-size: 10pt;" rowspan="1">&#160;</td>
          <td style="width: 47.3%; vertical-align: top; font-size: 10pt;" rowspan="1">&#160;</td>
        </tr>
        <tr>
          <td style="width: 52.7%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: left; font-family: 'Times New Roman';">Date: October 1, 2024</div>
          </td>
          <td style="width: 47.3%; vertical-align: top; font-size: 10pt;">
            <div style="text-align: left; font-family: 'Times New Roman';">Date: October 2, 2024</div>
          </td>
        </tr>

    </table>
  </div>
  <br>
  <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
    <div class="BRPFPageNumberArea" style="text-align: center;"><font style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">- 15 -</font></div>
    <div style="page-break-after: always;" class="BRPFPageBreak">
      <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
  </div>
  <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><u>EXHIBIT A</u></div>
  <div style="font-size: 10pt;">&#160;</div>
  <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Amended and Restated Source Plasma Specifications and Quality Agreement</div>
  <div style="font-size: 10pt;">&#160;</div>
  <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;">(To be attached within [***] days of the Effective Date)</div>
  <div style="font-size: 10pt;">&#160;</div>
  <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
    <div class="BRPFPageNumberArea" style="text-align: center;"><font style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">- 16 -</font></div>
    <div style="page-break-after: always;" class="BRPFPageBreak">
      <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
  </div>
  <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"><u>EXHIBIT B</u></div>
  <div style="font-size: 10pt;">&#160;</div>
  <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Plasma Supplier Plasma Centers</div>
  <div style="font-size: 10pt;">&#160;</div>
  <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;">[***]</div>
  <div style="font-size: 10pt;">&#160;</div>
  <div style="font-size: 10pt;"> <br>
  </div>
  <div style="font-size: 10pt; text-align: center;"><font style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">- 17 -</font> </div>
  <div style="font-size: 10pt; text-align: center;">
    <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"><font style="font-size: 8pt;"> </font></div>
  <div style="text-align: center; font-size: 10pt;"><a name="ga"></a><a name="nm"></a><a name="oh"></a><a name="pa"></a></div>
  <font style="font-family: 'Times New Roman'; font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;"> </font> <font style="font-family: 'Times New Roman'; font-size: 8pt; color: #000000; font-weight: normal; font-style: normal;"> </font>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.8
<SEQUENCE>3
<FILENAME>ef20038923_ex10-8.htm
<DESCRIPTION>EXHIBIT 10.8
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Summit Financial
         Document created using Broadridge PROfile 25.2.1.5287
         Copyright 1995 - 2025 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
  <!--PROfilePageNumberReset%Num%1%- % -%--> <font style="font-size: 10pt;"> </font>
  <div>
    <hr noshade="noshade" align="center" style="height: 4px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;">
    <div style="text-align: right;"> <font style="font-weight: bold; font-size: 10pt;">Exhibit 10.8</font><font style="font-size: 10pt;"><br>
      </font> </div>
    <div> <font style="font-size: 10pt;"><br>
      </font> </div>
  </div>
  <font style="font-size: 10pt;"> </font>
  <div>
    <div style="font-weight: bold; font-size: 10pt;">Information in this exhibit identified by [***] is confidential and has been excluded pursuant to Item 601(b)(10)(iv) of Regulation S-K because it is both (i) not material and (ii) would likely cause
      competitive harm to the registrant if publicly disclosed.</div>
    <div>
      <div style="text-align: center; font-weight: bold; font-size: 10pt;"><u> <br>
        </u></div>
      <div style="text-align: center; font-weight: bold; font-size: 10pt;"><u>PLASMA PURCHASE AGREEMENT</u></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; font-size: 12pt;"><font style="font-size: 10pt; font-weight: bold;">THIS PLASMA PURCHASE AGREEMENT</font><font style="font-size: 10pt;"> (&#8220;<font style="font-weight: bold;">Agreement</font>&#8221;) between
          KEDPlasma LLC, a Delaware limited liability company, having a place of business at Parker Plaza, 400 Kelby Street, 11<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">th</sup> Floor, Fort Lee, New Jersey 07024 (&#8220;<font style="font-weight: bold;">PLASMA SUPPLIER</font>&#8221;), and ADMA BioManufacturing, LLC, a Delaware limited liability company, having a place of business at 5800 Park of Commerce Boulevard, NW, Boca Raton, Florida 33487 (&#8220;<font style="font-weight: bold;">ADMA</font>&#8221;), shall be effective as of the last date of signature (the &#8220;<font style="font-weight: bold;">Effective Date</font>&#8221;).&#160; PLASMA SUPPLIER and ADMA are each sometimes referred to herein individually as a &#8220;<font style="font-weight: bold;">Party</font>&#8221; or collectively as the &#8220;<font style="font-weight: bold;">Parties</font>&#8221;.</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: center; font-weight: bold; font-size: 10pt;">RECITALS</div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; font-size: 12pt;"><font style="font-size: 10pt; font-weight: bold;">WHEREAS</font><font style="font-size: 10pt;">, PLASMA SUPPLIER desires to sell, and ADMA desires to purchase on a non-exclusive
          basis certain quantities of source plasma containing certain levels of antibodies to Respiratory Syncytial Virus (&#8220;<font style="font-weight: bold;">RSV</font>&#8221; or &#8220;<font style="font-weight: bold;">RSV Plasma</font>&#8221;) to be used by ADMA in the
          manufacturing and/or research and development of Human Immune Globulin(s) (&#8220;<font style="font-weight: bold;">Product</font>&#8221;), solely on the terms and conditions set forth in this Agreement.</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: center; font-weight: bold; font-size: 10pt;">PROVISIONS</div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; font-size: 12pt;"><font style="font-size: 10pt; font-weight: bold;">NOW, THEREFORE</font><font style="font-size: 10pt;">, in consideration of the covenants and agreements contained herein, and other
          good and valuable consideration, the receipt and legal sufficiency of which are hereby acknowledged, and with the intent to be legally bound hereby, ADMA and PLASMA SUPPLIER agree as follows:</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%;" id="zfd80f2c53d324b75b663db40794c96b5" class="DSPFListTable">

            <tr style="vertical-align: top;">
              <td style="text-align: right; vertical-align: top; width: 36pt;">
                <div style="text-align: left; font-size: 10pt;"><font style="font-weight: bold;">A.</font></div>
              </td>
              <td style="text-align: left; vertical-align: top; width: auto;">
                <div><font style="font-weight: bold; font-size: 10pt;"><u>PURCHASE AND SALE OF RSV PLASMA</u></font><font style="font-size: 10pt;">.</font></div>
              </td>
            </tr>

        </table>
      </div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-indent: 36pt;"><font style="font-weight: bold; font-size: 10pt;">1.</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-weight: bold;"><u>TERM OF AGREEMENT</u></font>.&#160; Unless terminated earlier as provided herein, the
          initial term of this Agreement shall commence on the Effective Date and expire on July 31, 2031 (the &#8220;<font style="font-weight: bold;">Initial Term</font>&#8221;, and together with any renewal, the &#8220;<font style="font-weight: bold;">Term</font>&#8221;).&#160;
          After the Initial Term, this Agreement may be renewed for one (1) additional [***] ([***])-year period (i.e., through [***]) upon the mutual written consent of the Parties.&#160; Each Party agrees that it will endeavor, in good faith, to conclude any
          negotiations relating to such renewal no less than [***] ([***]) months ([***] calendar days) before the expiration of this Agreement.</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-indent: 36pt;"><font style="font-weight: bold; font-size: 10pt;">2.</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-weight: bold;"><u>PRICE AND VOLUMES</u></font>.</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-indent: 72pt; font-size: 10pt;">a.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;From and after the Effective Date of this Agreement, ADMA agrees to purchase, and PLASMA SUPPLIER agrees to sell, RSV Plasma, in quantities and prices as further described in this
        Agreement.</div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-indent: 72pt; font-size: 10pt;">b.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Notwithstanding anything to the contrary contained herein, ADMA shall not be obligated to purchase any RSV Plasma in the event PLASMA SUPPLIER does not, or fails to, provide necessary
        plasma samples for testing and identifying donors.&#160; The Parties mutually agree and understand that identifying sufficient donors with naturally occurring RSV antibody levels vary. The Parties mutually agree that this naturally occurring variation
        may, due to no fault of PLASMA SUPPLIER or ADMA, affect total acceptable RSV Plasma volumes. This Agreement does not bind either Party to the other in an exclusive supply or purchase relationship; and for the avoidance of doubt, ADMA shall be free
        to purchase any quantity of plasma, including RSV Plasma, from other sources or obtain it from its own collection facilities.&#160; Notwithstanding the foregoing, PLASMA SUPPLIER covenants and agrees to use reasonable best efforts to provide ADMA with
        the volume of RSV Plasma set forth in subsection (d) below.</div>
      <div style="font-size: 10pt;">&#160;</div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-size: 8pt; color: rgb(0, 0, 0); font-weight: normal; font-style: normal; font-family: 'Times New Roman';">- 1 -</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <!--PROfilePageNumberReset%Num%2%- % -%-->
      <div style="text-indent: 72pt; font-size: 10pt;">c.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Beginning on the Effective Date of the Agreement, PLASMA SUPPLIER agrees to use reasonable best efforts to collect as much RSV Plasma as possible. In no event shall PLASMA SUPPLIER sell
        less than 35,000L per each Contract Year (as defined below) commencing with the Contract Year ending July 31, 2026. From the Effective Date through the end of the first Contract Year, pricing for RSV Plasma will start at $[***] per liter, subject
        to escalation depending on the volume of RSV Plasma provided to ADMA, as further described in the table below. The price per liter of RSV Plasma shall increase on the anniversary of each Contract Year at the lesser of (i) [***] percent ([***]%) or
        (ii) [***] (the &#8220;<font style="font-weight: bold;">Annual Increase</font>&#8221;). Within [***] ([***]) business days following ADMA&#8217;s purchase of RSV from PLASMA SUPPLIER in excess of the high end of the range set forth in the table below, PLASMA
        SUPPLIER shall send a written notice to ADMA (e-mail being sufficient) notifying ADMA of the new price per liter of RSV Plasma on a go-forward basis in a given Contract Year.&#160; Additionally, in the event that PLASMA SUPPLIER provides ADMA with
        [***]L of RSV Plasma in a given Contract Year, at the end of such Contract Year PLASMA SUPPLIER shall invoice ADMA in the amount of $[***] (the &#8220;<font style="font-weight: bold;">Bonus Amount</font>&#8221;). For purposes of clarity, the price per Liter at
        the end of a Contract Year shall automatically reset to the base amount (i.e., the amount adjacent to &#8220;First 35,000L&#8221;) set forth in the table below at the beginning of the subsequent Contract Year, subject to Annual Increases. This price includes
        all required screening tests, and NAT for HIV, HBV, HCV, HAV and Parvo B-19.&#160; For purposes of this section A.2(c), &#8220;<font style="font-weight: bold;">Contract Year</font>&#8221; means the twelve (12)-month period beginning on the Effective Date and each
        subsequent twelve (12)-month period thereafter during the Term that commences on an anniversary of the Effective Date.</div>
      <div style="font-size: 10pt;">&#160;</div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-size: 8pt; color: rgb(0, 0, 0); font-weight: normal; font-style: normal; font-family: 'Times New Roman';">- 2 -</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-indent: 72pt; font-size: 10pt;">d.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The table below sets forth annual volume ranges of RSV Plasma and the corresponding price during the Term:</div>
      <div style="font-size: 10pt;">&#160;</div>
      <table cellspacing="0" cellpadding="0" border="0" id="z74f16938fb1c4e66bf049795ee4ce7cb" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">

          <tr>
            <td style="width: 1%; vertical-align: top; border-left: 2px solid rgb(0, 0, 0); border-top: 2px solid rgb(0, 0, 0); font-size: 10pt;">&#160;</td>
            <td style="width: 49%; vertical-align: middle; border-right: 2px solid rgb(0, 0, 0); border-top: 2px solid rgb(0, 0, 0);">
              <div style="text-align: justify; font-size: 10pt;">Annual Volume (L) (Subject to Section A.9 below)</div>
            </td>
            <td style="width: 1%; vertical-align: top; border-left: 2px solid rgb(0, 0, 0); border-top: 2px solid rgb(0, 0, 0); font-size: 10pt;">&#160;</td>
            <td style="width: 49%; vertical-align: middle; border-right: 2px solid rgb(0, 0, 0); border-top: 2px solid rgb(0, 0, 0);">
              <div style="text-align: justify; font-size: 10pt;">Price (L) (Excluding Annual Increases)</div>
            </td>
          </tr>
          <tr>
            <td style="width: 1%; vertical-align: top; border-left: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); font-size: 10pt;" rowspan="1">&#160;</td>
            <td style="width: 49%; vertical-align: middle; border-right: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); font-size: 10pt;" rowspan="1">&#160;</td>
            <td style="width: 1%; vertical-align: top; border-left: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); font-size: 10pt;" rowspan="1">&#160;</td>
            <td style="width: 49%; vertical-align: middle; border-right: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); font-size: 10pt;" rowspan="1">&#160;</td>
          </tr>
          <tr>
            <td style="width: 1%; vertical-align: top; border-left: 2px solid rgb(0, 0, 0); font-size: 10pt;">&#160;</td>
            <td style="width: 49%; vertical-align: middle; border-right: 2px solid rgb(0, 0, 0);">
              <div style="font-size: 10pt;">First 35,000L</div>
            </td>
            <td style="width: 1%; vertical-align: top; border-left: 2px solid rgb(0, 0, 0); font-size: 10pt;">&#160;</td>
            <td style="width: 49%; vertical-align: middle; border-right: 2px solid rgb(0, 0, 0);">
              <div style="font-size: 10pt;">$[***]</div>
            </td>
          </tr>
          <tr>
            <td style="width: 1%; vertical-align: top; border-left: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); font-size: 10pt;" rowspan="1">&#160;</td>
            <td style="width: 49%; vertical-align: middle; border-right: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); font-size: 10pt;" rowspan="1">&#160;</td>
            <td style="width: 1%; vertical-align: top; border-left: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); font-size: 10pt;" rowspan="1">&#160;</td>
            <td style="width: 49%; vertical-align: middle; border-right: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); font-size: 10pt;" rowspan="1">&#160;</td>
          </tr>
          <tr>
            <td style="width: 1%; vertical-align: top; border-left: 2px solid rgb(0, 0, 0); font-size: 10pt;">&#160;</td>
            <td style="width: 49%; vertical-align: middle; border-right: 2px solid rgb(0, 0, 0);">
              <div style="font-size: 10pt;">[***]L &#8211; [***]L</div>
            </td>
            <td style="width: 1%; vertical-align: top; border-left: 2px solid rgb(0, 0, 0); font-size: 10pt;">&#160;</td>
            <td style="width: 49%; vertical-align: middle; border-right: 2px solid rgb(0, 0, 0);">
              <div style="font-size: 10pt;">$[***]</div>
            </td>
          </tr>
          <tr>
            <td style="width: 1%; vertical-align: top; border-left: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); font-size: 10pt;" rowspan="1">&#160;</td>
            <td style="width: 49%; vertical-align: middle; border-right: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); font-size: 10pt;" rowspan="1">&#160;</td>
            <td style="width: 1%; vertical-align: top; border-left: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); font-size: 10pt;" rowspan="1">&#160;</td>
            <td style="width: 49%; vertical-align: middle; border-right: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); font-size: 10pt;" rowspan="1">&#160;</td>
          </tr>
          <tr>
            <td style="width: 1%; vertical-align: top; border-left: 2px solid rgb(0, 0, 0); font-size: 10pt;">&#160;</td>
            <td style="width: 49%; vertical-align: middle; border-right: 2px solid rgb(0, 0, 0);">
              <div style="font-size: 10pt;">[***]L &#8211; [***]L</div>
            </td>
            <td style="width: 1%; vertical-align: top; border-left: 2px solid rgb(0, 0, 0); font-size: 10pt;">&#160;</td>
            <td style="width: 49%; vertical-align: middle; border-right: 2px solid rgb(0, 0, 0);">
              <div style="font-size: 10pt;">$[***]</div>
            </td>
          </tr>
          <tr>
            <td style="width: 1%; vertical-align: top; border-left: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); font-size: 10pt;" rowspan="1">&#160;</td>
            <td style="width: 49%; vertical-align: middle; border-right: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); font-size: 10pt;" rowspan="1">&#160;</td>
            <td style="width: 1%; vertical-align: top; border-left: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); font-size: 10pt;" rowspan="1">&#160;</td>
            <td style="width: 49%; vertical-align: middle; border-right: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); font-size: 10pt;" rowspan="1">&#160;</td>
          </tr>
          <tr>
            <td style="width: 1%; vertical-align: top; border-left: 2px solid rgb(0, 0, 0); font-size: 10pt;">&#160;</td>
            <td style="width: 49%; vertical-align: middle; border-right: 2px solid rgb(0, 0, 0);">
              <div style="font-size: 10pt;">[***]L &#8211; [***]L</div>
            </td>
            <td style="width: 1%; vertical-align: top; border-left: 2px solid rgb(0, 0, 0); font-size: 10pt;">&#160;</td>
            <td style="width: 49%; vertical-align: middle; border-right: 2px solid rgb(0, 0, 0);">
              <div style="font-size: 10pt;">$[***]<br>
                (plus the Bonus Amount described above)</div>
            </td>
          </tr>
          <tr>
            <td style="width: 1%; vertical-align: top; border-left: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); font-size: 10pt;" rowspan="1">&#160;</td>
            <td style="width: 49%; vertical-align: middle; border-right: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); font-size: 10pt;" rowspan="1">&#160;</td>
            <td style="width: 1%; vertical-align: top; border-left: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); font-size: 10pt;" rowspan="1">&#160;</td>
            <td style="width: 49%; vertical-align: middle; border-right: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); font-size: 10pt;" rowspan="1">&#160;</td>
          </tr>
          <tr>
            <td style="width: 1%; vertical-align: top; border-left: 2px solid rgb(0, 0, 0); font-size: 10pt;">&#160;</td>
            <td style="width: 49%; vertical-align: middle; border-right: 2px solid rgb(0, 0, 0);">
              <div style="font-size: 10pt;">[***]L+</div>
            </td>
            <td style="width: 1%; vertical-align: top; border-left: 2px solid rgb(0, 0, 0); font-size: 10pt;">&#160;</td>
            <td style="width: 49%; vertical-align: middle; border-right: 2px solid rgb(0, 0, 0);">
              <div style="font-size: 10pt;">$[***]</div>
            </td>
          </tr>
          <tr>
            <td style="width: 1%; vertical-align: top; border-left: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); font-size: 10pt;" rowspan="1">&#160;</td>
            <td style="width: 49%; vertical-align: middle; border-right: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); font-size: 10pt;" rowspan="1">&#160;</td>
            <td style="width: 1%; vertical-align: top; border-left: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); font-size: 10pt;" rowspan="1">&#160;</td>
            <td style="width: 49%; vertical-align: middle; border-right: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); font-size: 10pt;" rowspan="1">&#160;</td>
          </tr>

      </table>
      <div><font style="font-size: 10pt;"><br>
        </font> </div>
      <div style="text-indent: 72pt; font-size: 10pt;">e.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;PLASMA SUPPLIER agrees to make reasonable best efforts to make necessary U.S. Food and Drug Administration (FDA) submissions, as needed (and amendments thereto, as applicable), to ensure
        continuous FDA approval of the Centers, at PLASMA SUPPLIER&#8217;s sole cost and expense.</div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-indent: 72pt; font-size: 10pt;">f.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;In the event of any change to existing law, guidance or industry standard applicable to the plasma to be supplied pursuant to this Agreement or any one or more new government regulations,
        tests, quality procedure or change in the specifications requested by ADMA (any of the foregoing being a &#8220;<font style="font-weight: bold;">Required Change</font>&#8221;) is recommended but is not contemplated in this Agreement and results in a material
        increase to PLASMA SUPPLIER&#8217;s actual costs to procure, store, provide and supply the RSV Plasma, both Parties shall re-negotiate the change in the purchase price in good faith within [***] ([***]) days of the Required Change and the Parties&#8217;
        obligations hereunder shall be suspended until such time as the Parties agree on a purchase price and, if not, this Agreement shall automatically terminate at the end of such [***] ([***])-day period without any penalties or further obligations by
        either Party, except for those specifically stated as surviving termination pursuant to Section D(4) below.</div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-indent: 72pt; font-size: 10pt;">g.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;In the event that demand for ADMA&#8217;s ASCENIV&#8482; materially changes from the demand on the Effective Date, both Parties shall re-negotiate the annual volume requirements set forth in this <u>Section

          A.2</u> in good faith within [***] ([***]) days of ADMA&#8217;s written notice to PLASMA SUPPLIER of such material change in demand.&#160; Both Parties&#8217; obligations hereunder shall be suspended until such time as the Parties agree on updated volumes of RSV
        Plasma to be provided hereunder and, if not, this Agreement shall automatically terminate at the end of such [***] ([***])-day period without any penalties or further obligations by either Party, except for those specifically stated as surviving
        termination pursuant to Section D.5 below.</div>
      <div style="font-size: 10pt;">&#160;</div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-size: 8pt; color: rgb(0, 0, 0); font-weight: normal; font-style: normal; font-family: 'Times New Roman';">- 3 -</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-indent: 36pt;"><font style="font-weight: bold; font-size: 10pt;">3.</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-weight: bold;"><u>PAYMENT TERMS</u></font>. ADMA shall deliver payment in full to PLASMA SUPPLIER
          for all RSV Plasma shipped to ADMA within [***] ([***]) days from ADMA&#8217;s receipt of the corresponding invoice. PLASMA SUPPLIER shall issue invoices promptly after ADMA or its carrier takes possession of the RSV Plasma from the Designated Location
          (as defined below) or, in the event PLASMA SUPPLIER earns the Bonus Amount, such invoice shall be issued promptly following the end of the applicable Calendar Year. All payments due hereunder from ADMA to PLASMA SUPPLIER shall be sent to PLASMA
          SUPPLIER at the times set forth herein delivered in the form of wire transfer or check to such accounts as PLASMA SUPPLIER may designate to ADMA.</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="margin-left: 72pt; font-size: 10pt;"><u>Invoices to ADMA, and inquiries and correspondence regarding payment, shall be directed to</u>:<br>
        ADMA Biologics<br>
        Attn: [***]<br>
        5800 Park of Commerce Blvd., NW</div>
      <div style="margin-left: 72pt; font-size: 10pt;">Boca Raton, FL 33487</div>
      <div style="margin-left: 72pt; font-size: 10pt;">[***]</div>
      <div><font style="font-size: 10pt;"><br>
        </font> </div>
      <div style="text-align: justify; text-indent: 36pt; font-size: 10pt;">Wire transfer instructions and a check mailing address will be provided to ADMA by PLASMA SUPPLIER under separate written notice, e-mail being sufficient.&#160; Modifications of bank
        account information, including wiring instructions, and any payment address shall be confirmed pursuant to written notice (email being sufficient) and verbally confirmed by the Parties.</div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-indent: 36pt;"><font style="font-weight: bold; font-size: 10pt;">4.</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-weight: bold;"><u>INSPECTION AND ACCEPTANCE</u></font>.</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-indent: 72pt; font-size: 10pt;">a.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;PLASMA SUPPLIER shall make RSV Plasma available for pickup at PLASMA SUPPLIER&#8217;s approved plasma warehouse, [***], at [***] (the &#8220;<font style="font-weight: bold;">Designated Location</font>&#8221;),

        as set forth in a delivery schedule to be mutually agreed to by the Parties from time to time as hereinafter provided herein, unless otherwise mutually agreed between the Parties. Title and risk of loss shall pass upon transfer of the RSV Plasma to
        ADMA at [***]. ADMA shall inspect each shipment of RSV Plasma for conformity with the specifications as set forth in <u>Exhibit A</u> (&#8220;<font style="font-weight: bold;">ADMA Specifications</font>&#8221;) within [***] ([***]) days of receipt of the RSV
        Plasma.&#160; ADMA shall promptly notify PLASMA SUPPLIER in writing of its determination of any non-conformity of the RSV Plasma with ADMA Specifications within such aforementioned [***] ([***])-day period (&#8220;<font style="font-weight: bold;">Non-Conformity

          Notice</font>&#8221;).</div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-indent: 72pt; font-size: 10pt;">b.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;If a Non-Conformity Notice is received by PLASMA SUPPLIER within the time period specified in <u>Section A.4(a)</u> above, the Parties shall meet within [***] ([***]) business days
        following PLASMA SUPPLIER&#8217;s receipt of the Non-Conformity Notice to determine whether such RSV Plasma meets the ADMA Specifications.&#160; If it is determined by both Parties that the RSV Plasma does not meet the ADMA Specifications, PLASMA SUPPLIER
        shall replace any non-conforming RSV Plasma, as promptly as possible, taking into account the time required to produce such quantities of RSV Plasma.&#160; In the event the Parties fail to agree whether or not any given shipment of RSV Plasma conforms
        with the ADMA Specifications, then the matter will be promptly referred to an independent expert agreed upon in good faith by both Parties, whose decision shall be binding on the Parties.&#160; The cost of referral to the expert will be borne by the
        Party determined to have been in error as to conformity, or lack thereof, with the ADMA Specifications.&#160; ADMA shall not be required to pay for any non-conforming RSV Plasma.</div>
      <div style="font-size: 10pt;">&#160;</div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-size: 8pt; color: rgb(0, 0, 0); font-weight: normal; font-style: normal; font-family: 'Times New Roman';">- 4 -</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-indent: 72pt; font-size: 10pt;">c.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;For each shipment of RSV Plasma delivered, PLASMA SUPPLIER shall provide to ADMA all documents required in ADMA Specifications.</div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-indent: 36pt;"><font style="font-weight: bold; font-size: 10pt;">5.</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-weight: bold;"><u>SHIPMENT TERMS</u></font>. PLASMA SUPPLIER shall pay for all shipments to the
          Designated Location in accordance with the delivery schedule agreed to by the Parties. ADMA will take ownership and bear all risk of loss upon pick up by ADMA or ADMA&#8217;s designated carrier from [***]. ADMA shall use commercially reasonable efforts
          to arrange to have the RSV Plasma picked up at least [***] ([***]) times a year in approximately equally spaced intervals. ADMA shall, at its own expense, be responsible for freight charges, insurance, handling and forwarding agent&#8217;s fees, taxes,
          storage and all other charges applicable to the RSV Plasma from that Designated Location.</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-indent: 36pt;"><font style="font-weight: bold; font-size: 10pt;">6.</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-weight: bold;"><u>DELIVERY</u><u>.</u></font>&#160; All shipments shall be made Ex Works (Incoterms 2020)
          from the Designated Location. Except as set forth in Section A.5 above, ADMA shall pay for all RSV Plasma shipping costs and PLASMA SUPPLIER shall comply with the RSV Plasma shipping specifications as set forth in Exhibit A of this Agreement.</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: justify; font-weight: bold; font-size: 10pt; margin-left: 63pt;">&#160; <u>QUALITY OF RSV PLASMA.</u></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-indent: 36pt;"><font style="font-weight: bold; font-size: 10pt;">7.</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;PLASMA SUPPLIER shall provide ADMA, at no cost to ADMA, plasma samples in amounts and at times mutually agreed upon by
          ADMA and PLASMA SUPPLIER to enable ADMA to test and identify plasma donors suitable for producing RSV Plasma for ADMA in accordance with the ADMA Specifications (&#8220;<font style="font-weight: bold;">Source Plasma Specifications</font>&#8221;), attached
          hereto as <u>Exhibit A</u> and incorporated herein by reference.&#160; ADMA shall bear the cost of freight for such samples to their designation location. For the avoidance of doubt, ADMA will bear all costs associated with the testing of the
          samples.&#160; Based on said testing, ADMA shall identify plasma donors whom ADMA has tested as suitable for producing RSV Plasma in accordance with ADMA Specifications (&#8220;<font style="font-weight: bold;">Acceptable Donors</font>&#8221;).&#160; PLASMA SUPPLIER
          shall produce RSV Plasma for ADMA based on the number of Acceptable Donors identified by ADMA.&#160; ADMA&#8217;s acceptance of the donor shall not constitute ADMA&#8217;s acceptance of RSV Plasma.&#160; PLASMA SUPPLIER will use commercially reasonable efforts in-line
          with industry standard incentive programs and donor retention programs to provide plasma from as many of the Acceptable Donors identified by ADMA as possible.&#160; In particular, PLASMA SUPPLIER covenants and agrees, unless otherwise permitted by
          ADMA in writing (e-mail being acceptable), to provide samples of RSV Plasma from: (i) [***] Centers from the Effective Date through [***]; (ii) [***] Centers from [***] through [***]; (iii) [***] Centers from [***] through [***] and (iv) [***]
          Centers from [***] through the remainder of the Term.</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-indent: 36pt;"><font style="font-weight: bold; font-size: 10pt;">8.</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Once ADMA has identified a donor as an Acceptable Donor and notified PLASMA SUPPLIER in writing of such designation
          (e-mail being sufficient), ADMA agrees to purchase all RSV Plasma collected from the Acceptable Donor until it notifies PLASMA SUPPLIER in writing (e-mail being sufficient) that the donor is no longer an Acceptable Donor. ADMA is obligated to
          purchase all RSV Plasma, on a monthly basis, from Acceptable Donors that PLASMA SUPPLIER has collected and delivered in conformity with the ADMA Specifications.&#160; ADMA may, upon [***] ([***]) business days&#8217; prior written notice (e-mail being
          sufficient), terminate Acceptable Donor status for any donor at any time at its sole discretion. ADMA will not be obligated to purchase RSV Plasma from donors who are not Acceptable Donors or have been dropped as Acceptable Donors following
          ADMA&#8217;s [***] ([***]) business days&#8217; written drop notification.&#160; ADMA will be obligated to purchase any RSV Plasma collected through the drop notification period.&#160; Business days are defined as Monday through Friday 9 am to 5 pm Eastern Standard
          Time, with weekends and holidays (applicable to each Center) specifically excluded.</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-size: 8pt; color: rgb(0, 0, 0); font-weight: normal; font-style: normal; font-family: 'Times New Roman';">- 5 -</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-indent: 36pt;"><font style="font-weight: bold; font-size: 10pt;">9.</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;PLASMA SUPPLIER shall have no obligation to provide RSV Plasma to ADMA in the event the failure to provide RSV Plasma
          is due to a Force Majeure Event described in <u>Article F</u> or the unavailability of Acceptable Donors.&#160; Additionally, ADMA shall have no obligation to purchase RSV Plasma from PLASMA SUPPLIER in the event of a Force Majeure Event affecting
          ADMA.</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-indent: 36pt;"><font style="font-weight: bold; font-size: 10pt;">10.</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160; Following donor acceptance and receipt of such RSV Plasma units into ADMA&#8217;s inventory in accordance with <u>Section
            A.4</u> (Inspection and Acceptance), ADMA shall bear the expense of unusable RSV Plasma due to a recall, or the destruction of any RSV Plasma due to post-donation &#8220;look back&#8221; issues in accordance with FDA regulations and guidance.</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-indent: 36pt;"><font style="font-weight: bold; font-size: 10pt;">11.</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; PLASMA SUPPLIER shall supply to ADMA, for the Term, RSV Plasma to be derived from automated plasmapheresis procedures
          conducted at plasma centers approved by ADMA and specified in <u>Exhibit B</u> (the &#8220;<font style="font-weight: bold;">Centers</font>&#8221;).&#160;<u>Exhibit B</u> shall be updated from time to time to reflect additional Centers approved by ADMA to be
          built or otherwise collecting RSV Plasma by PLASMA SUPPLIER or its affiliates/subsidiaries which PLASMA SUPPLIER will utilize to supply RSV Plasma pursuant to the terms of this Agreement.</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-indent: 36pt;"><font style="font-weight: bold; font-size: 10pt;">12.</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160; ADMA and PLASMA SUPPLIER shall execute a mutually agreeable Source Plasma Specifications and Quality Agreement
          effective on the Effective Date, in substantially the form attached hereto as <font style="font-weight: bold;"><u>Exhibit A</u></font> (the &#8220;<font style="font-weight: bold;">Quality Agreement</font>&#8221;). In the event of a conflict between any of
          the provisions of this Agreement and the Quality Agreement with respect to quality-related activities, including compliance with applicable laws, the provisions of the Quality Agreement shall govern.&#160; In the event of a conflict between any of the
          provisions of this Agreement and the Quality Agreement with respect to any commercial matters, including allocation of risk, liability, and financial responsibility, the provisions of this Agreement shall govern.</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-indent: 36pt;"><font style="font-weight: bold; font-size: 10pt;">13.</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160; ADMA shall have the right to conduct inspections of PLASMA SUPPLIER&#8217;s Centers and facilities pertaining to the RSV
          Plasma at times mutually agreeable to the Parties.&#160; Such inspections shall be limited to matters directly related to this Agreement and shall be conducted in conformance with generally accepted industry practices.&#160; ADMA will provide PLASMA
          SUPPLIER with not less than [***] ([***]) days&#8217; notice prior to any of its inspections, unless mutually agreed otherwise by the Parties.&#160; Upon receipt of ADMA&#8217;s inspection report, PLASMA SUPPLIER shall have [***] ([***]) calendar days to send a
          written response to ADMA, outlining the corrective actions that PLASMA SUPPLIER will take at its expense, to correct the inspection deficiencies.</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-indent: 36pt;"><font style="font-weight: bold; font-size: 10pt;">14.</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160; PLASMA SUPPLIER, in compliance with 21 CFR &#167;640.69(f), agrees to hold all RSV Plasma units for a minimum of [***]
          ([***]) calendar days from the collection date prior to delivery of the RSV Plasma to the Designated Location.&#160; ADMA further agrees that if ADMA is informed by PLASMA SUPPLIER (through the established lookback process) that a donor has been
          subsequently deferred pursuant to 21 CFR &#167;610.41 or subsequently determined to be ineligible under 21 CFR &#167;630.10 due to risk factors closely associated with exposure to, or clinical evidence of, infection due to a relevant
          transfusion-transmitted infection, all donations on hold from that donor will not be used in the further manufacturing of injectable products.</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-size: 8pt; color: rgb(0, 0, 0); font-weight: normal; font-style: normal; font-family: 'Times New Roman';">- 6 -</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%;" id="z9030ece34a1149e1a84b0d2196e7804f" class="DSPFListTable">

            <tr style="vertical-align: top;">
              <td style="text-align: right; vertical-align: top; width: 36pt;">
                <div style="text-align: left; font-size: 10pt;"><font style="font-weight: bold;">B.</font></div>
              </td>
              <td style="text-align: left; vertical-align: top; width: auto;">
                <div><font style="font-weight: bold; font-size: 10pt;"><u>REPRESENTATIONS AND WARRANTIES</u></font><font style="font-size: 10pt;">.</font></div>
              </td>
            </tr>

        </table>
      </div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-indent: 36pt;"><font style="font-weight: bold; font-size: 10pt;">1.</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Each Party hereto hereby represents and warrants to the other as follows: (i) such Party hereto has all requisite
          power and authority to enter into this Agreement and to consummate the transactions contemplated hereby, (ii) such Party is validly organized and existing and in good standing under the laws of the jurisdiction of its incorporation or
          organization, (iii) such Party is duly qualified to do business and is in good standing as a foreign entity in each jurisdiction where the nature of its business requires such qualification, (iv) the execution and delivery of this Agreement and
          the consummation by such Party of the transactions contemplated hereby have been duly authorized by all necessary action on the part of such Party, and (v) this Agreement has been duly and validly executed and delivered by such Party and
          constitutes the valid and binding obligation of such Party, enforceable against such Party in accordance with its terms.</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-indent: 36pt;"><font style="font-weight: bold; font-size: 10pt;">2.</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;PLASMA SUPPLIER represents and warrants that it will only release RSV Plasma to ADMA or its loading dock under this
          Agreement from the Designated Location that have the requisite FDA approval at the time of such release, and that it shall thereafter maintain such approval during the Term of this Agreement.&#160; All information provided by PLASMA SUPPLIER to ADMA
          with respect to the RSV Plasma is complete and accurate in all material respects.</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-indent: 36pt;"><font style="font-weight: bold; font-size: 10pt;">3.</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;PLASMA SUPPLIER represents and warrants to ADMA that RSV Plasma will be collected, produced, packaged, labeled,
          handled, stored and shipped in accordance with ADMA Specifications, the Quality Agreement, and PLASMA SUPPLIER approved standard operating procedures.&#160; PLASMA SUPPLIER represents, warrants and agrees that any and all RSV Plasma shall be
          collected, produced and packaged, labeled, handled, stored and shipped in accordance with all applicable local, state and federal laws, regulations, and requirements.&#160; ADMA shall have all rights and remedies available to it under this Agreement
          and shall not be obligated to buy or pay for any RSV Plasma which does not, in all respects, comply with the ADMA Specifications and applicable law, rules and regulations and as otherwise required by this Agreement, provided ADMA must submit
          notification of rejection within [***] ([***]) calendar days of receipt of such RSV Plasma.&#160; PLASMA SUPPLIER represents and warrants that its collection and supply of RSV Plasma under this Agreement will not breach or misappropriate the
          intellectual property rights of any third party.</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-indent: 36pt;"><font style="font-weight: bold; font-size: 10pt;">4.</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;EXCEPT AS OTHERWISE SET FORTH HEREIN, PLASMA SUPPLIER MAKES NO REPRESENTATIONS NOR EXTENDS ANY WARRANTIES OR
          CONDITIONS OF ANY KIND, EITHER EXPRESS OR IMPLIED, WITH RESPECT TO RSV PLASMA, INCLUDING, BUT NOT LIMITED TO, WARRANTIES OF MERCHANTABILITY.</font></div>
      <br>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-size: 8pt; color: rgb(0, 0, 0); font-weight: normal; font-style: normal; font-family: 'Times New Roman';">- 7 -</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="font-size: 10pt;">
        <div>
          <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%;" class="DSPFListTable">

              <tr style="vertical-align: top;">
                <td style="text-align: right; vertical-align: top; width: 36pt;">
                  <div style="text-align: left; font-size: 10pt;"><font style="font-weight: bold;">C.</font></div>
                </td>
                <td style="text-align: left; vertical-align: top; width: auto;">
                  <div><font style="font-weight: bold; font-size: 10pt;"><u>MISCELLANEOUS</u></font><font style="font-size: 10pt;">.</font></div>
                </td>
              </tr>

          </table>
        </div>
        <div style="font-size: 10pt;">&#160;</div>
        <div style="text-indent: 36pt;"><font style="font-weight: bold; font-size: 10pt;">1.</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-weight: bold;"><u>CONFIDENTIALITY</u></font>.</font></div>
      </div>
      <div style="font-size: 10pt;"> <br>
      </div>
      <div style="text-indent: 72pt; font-size: 10pt;">a.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Each Party agrees to maintain the confidentiality of the contents of this Agreement, the dealings between the Parties under this Agreement and any other confidential, non-public or
        proprietary information disclosed by the other Party during the Term, whether or not such information is labeled or otherwise identified as &#8220;confidential,&#8221; including that obtained through documents (whether written or electronic), observations,
        inspections or audits, and discussions (collectively, &#8220;<font style="font-weight: bold;">Confidential Information</font>&#8221;) with the same degree of care as they use to protect their own proprietary, confidential or trade secret information.&#160; A
        receiving Party shall not disclose to any third party, excluding such Party&#8217;s affiliates, agents, attorneys, consultants, advisors, and other representatives with a need-to-know such information and that is under an obligation of confidentiality
        therewith, any Confidential Information received from the disclosing Party hereunder without that disclosing Party&#8217;s prior written consent and shall use it only for the purpose of this Agreement.&#160; Said obligation of secrecy shall not apply to any
        information which (a) was in the public domain at the time of its disclosure or thereafter becomes part of the public domain by publication or otherwise subsequent to the time of disclosure under this Agreement through no fault of the receiving
        Party; (b) was known to the receiving Party or in its possession prior to or at the time of disclosure as shown by written records; (c) is independently developed by the receiving Party without use of the other Party&#8217;s Confidential Information as
        shown by written documentation; (d) is disclosed with the written approval of the disclosing Party; or (e) is rightfully furnished to the receiving Party by a third party having the authority to disclose such Confidential Information without
        restrictions.</div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-indent: 72pt; font-size: 10pt;">b.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;If a Party is required to disclose the other Party&#8217;s Confidential Information by law or regulation or in response to a valid order of a court or other governmental body, or for registration
        of a product by competent authorities, such disclosure is permissible under this Section C.1, but only to the extent required under such law, regulation, order or registration, and only if the receiving Party, to the extent legally permissible,
        first notifies the disclosing Party of the required disclosure and permits the disclosing Party, at its expense, to seek an appropriate legal remedy to maintain the confidentiality of the Confidential Information to the maximum extent possible.&#160;
        All Confidential Information is provided &#8220;AS IS&#8221; and without any warranty, express, implied or otherwise regarding its accuracy or performance.</div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-indent: 72pt; font-size: 10pt;">c.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The above obligations shall survive the termination of this Agreement and shall continue with respect to donor information and trade secrets without limit of time and in respect of other
        Confidential Information for a period of [***] ([***]) years.</div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: justify; text-indent: 72pt; font-size: 10pt;">d.&#160;&#160;&#160;&#160;&#160;&#160; PLASMA SUPPPLIER recognizes that in the course of performing under this Agreement, PLASMA SUPPLIER may receive from ADMA or others information that may be considered
        &#8220;material, nonpublic information&#8221; concerning a public company that is subject to the reporting requirements of the Securities and Exchange Act of 1934, as amended. PLASMA SUPPLIER represents, warrants and covenants to NOT: (a) purchase or sell,
        directly or indirectly, any securities of ADMA or any company while in possession of relevant material, nonpublic information relating to ADMA or such company; or (b) communicate any material, nonpublic information to any other person in which it
        is reasonably foreseeable that such person is likely to (i) purchase or sell securities of ADMA or any such company with respect to which such information relates, or (ii) otherwise directly or indirectly benefit from such information. Without
        limiting any of the confidentiality obligations and restrictions on insider trading included in this Agreement or in that certain Mutual Confidential Disclosure Agreement, effective as of March 14, 2024, between PLASMA SUPPLIER and ADMA Biologics,
        Inc., ADMA&#8217;s parent company, PLASMA SUPPLIER shall not discuss any information concerning ADMA obtained by PLASMA SUPPLIER in the course of performing this Agreement with any financial, securities or industry analyst or with the media without the
        prior written consent of ADMA.</div>
      <div style="font-size: 10pt;">&#160;</div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-size: 8pt; color: rgb(0, 0, 0); font-weight: normal; font-style: normal; font-family: 'Times New Roman';">- 8 -</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-indent: 36pt;"><font style="font-weight: bold; font-size: 10pt;">2.</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-weight: bold;"><u>RELATIONSHIP OF THE PARTIES</u></font>.&#160; The relationship between ADMA and PLASMA
          SUPPLIER during the Term of this Agreement is solely that of independent contractors.&#160; Neither Party is, in any way, the legal representative, agent, joint venture or partner of the other Party for any purpose whatsoever and neither Party has any
          control or authority whatsoever to bind the other Party or any other person with respect to the other Party or incur any obligations on the other Party&#8217;s behalf.</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-indent: 36pt;"><font style="font-weight: bold; font-size: 10pt;">3.</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-weight: bold;"><u>INDEMNIFICATION</u></font>.&#160; PLASMA SUPPLIER and ADMA hereby agree to indemnify,
          defend and hold harmless each other and their respective affiliates, subsidiaries, members, managers, lenders, agents, employees, officers and directors, from and against any and all third-party claims, losses, liabilities, damages, reasonable
          attorneys&#8217; fees, costs and expenses (hereinafter &#8220;<font style="font-weight: bold;">Claims</font>&#8221;) which may be sustained by and/or claimed against a Party by virtue of (i) their negligent acts, negligent omissions or the negligent handling or
          furnishing of materials or performance of services rendered by the other Party, (ii) failure by the other Party to materially comply with its obligations under this Agreement, (iii) the willful misconduct by the other Party or its directors,
          officers, employees or agents, or (iv) the other Party&#8217;s material breach of any representation, warranty or term contained in this Agreement.&#160; The indemnifying party&#8217;s liability shall be reduced to the extent any such Claims arise as a result of
          the indemnified party&#8217;s own misconduct, breach or negligence.&#160; To the extent RSV Plasma is being used to manufacture Products to be used in research or for commercial purposes, ADMA specifically shall indemnify, defend and hold harmless PLASMA
          SUPPLIER, its affiliates, subsidiaries, directors, officers, agents and employees, from any and all Claims arising from the use of Product or any procedure required by the research protocol or related to the commercial sale of such Product,
          provided that the RSV Plasma is not the direct or contributing cause of such liability, loss or damage. The Party from whom indemnity is sought under this <u>Section C.3</u> shall be entitled at its option to defend or control the defense and/or
          settlement of any such Claims; provided that the indemnifying Party shall not settle any such Claim without the prior written consent of the indemnified Party (which consent shall not be unreasonably withheld or delayed).&#160; Each Party shall notify
          the other Party in writing of any Claim or potential Claim as soon as it becomes aware that such Claim or potential Claim has arisen and shall provide to the other Party, all reasonable assistance in respect thereof; provided that the failure of
          the indemnified Party to provide timely notice shall only relieve the indemnifying Party of liability to the extent the indemnifying Party can demonstrate that it actually was prejudiced by any delayed notification. The indemnified Party shall
          have the right to be represented by legal counsel of its choice, at its sole cost and expense.</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-indent: 36pt;"><font style="font-weight: bold; font-size: 10pt;">4.</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-weight: bold;"><u>LIMITATION OF LIABILITY</u></font>.&#160; EXCEPT FOR ANY BREACH OF CONFIDENTIALITY
          UNDER <u>SECTION C.1</u>, IN NO EVENT WILL EITHER PARTY HAVE ANY LIABILITY FOR ANY LOSS OF INCOME, PROFIT, INTEREST OR SAVINGS BY THE OTHER PARTY OR FOR ANY INDIRECT, INCIDENTAL, CONSEQUENTIAL, PUNITIVE OR SPECIAL DAMAGES SUFFERED BY THE OTHER
          PARTY, ARISING FROM OR RELATED TO THIS AGREEMENT, INCLUDING WITHOUT LIMITATION, THE SALE OR USE OF ANY RSV PLASMA, REGARDLESS OF THE FORM OF ACTION, AND WHETHER IN CONTRACT, INDEMNITY, WARRANTY OR TORT, INCLUDING WITHOUT LIMITATION, STRICT
          LIABILITY AND NEGLIGENCE OR ANY OTHER LEGAL OR EQUITABLE GROUNDS, EVEN IF SUCH PARTY HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH LOSSES OR DAMAGES. THIS LIMITATION WILL NOT APPLY TO ANY LIABILITY FOR DAMAGES THAT MAY RESULT FROM THE GROSS
          NEGLIGENCE OR WILLFUL MISCONDUCT OF A PARTY.</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-size: 8pt; color: rgb(0, 0, 0); font-weight: normal; font-style: normal; font-family: 'Times New Roman';">- 9 -</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-indent: 36pt;"><font style="font-weight: bold; font-size: 10pt;">5.</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-weight: bold;"><u>INSURANCE</u></font>.&#160; ADMA and PLASMA SUPPLIER shall each be required to maintain
          general and product liability insurance in an amount of at least [***] Dollars ($[***]) during the Term and to promptly furnish certificates evidencing the insurance required by this Section upon the other Party&#8217;s written request.&#160; The Parties
          shall provide [***] ([***]) days&#8217; advance written notice in the event the insurance required by this <u>Section C.5</u> is materially modified, cancelled or otherwise terminated for any reason.&#160; The Parties intend that any and all damages,
          losses, liabilities, penalties, judgments, settlements, payments, costs and expenses, whether or not resulting from third-party claims, including the costs and expenses of any such claims subject to indemnification or reimbursement pursuant to <u>Section

            C.3</u> (&#8220;<font style="font-weight: bold;">Loss</font>&#8221;) will be net of insurance proceeds that actually reduce the amount of the Loss. Accordingly, the amount which any Party (an &#8220;<font style="font-weight: bold;">Indemnifying Party</font>&#8221;) is
          required to pay to any Person entitled to indemnification hereunder (an &#8220;<font style="font-weight: bold;">Indemnitee</font>&#8221;) will be reduced by any insurance proceeds theretofore actually recovered by or on behalf of the Indemnitee in respect of
          the related Loss. If an Indemnitee receives a payment (an &#8220;<font style="font-weight: bold;">Indemnity Payment</font>&#8221;) required by this Agreement from an Indemnifying Party in respect of any Loss and subsequently receives insurance proceeds, then
          the Indemnitee will pay to the Indemnifying Party an amount equal to the excess of the Indemnity Payment received over the amount of the Indemnity Payment that would have been due if the insurance proceeds had been received, realized or recovered
          before the Indemnity Payment was made.</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%;" id="zad391aece2104f20b6420fe0fb64ab9d" class="DSPFListTable">

            <tr style="vertical-align: top;">
              <td style="text-align: right; vertical-align: top; width: 36pt;">
                <div style="text-align: left; font-size: 10pt;"><font style="font-weight: bold;">D.</font></div>
              </td>
              <td style="text-align: left; vertical-align: top; width: auto;">
                <div><font style="font-weight: bold; font-size: 10pt;"><u>TERMINATION</u></font><font style="font-size: 10pt;">.</font></div>
              </td>
            </tr>

        </table>
      </div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-indent: 36pt;"><font style="font-weight: bold; font-size: 10pt;">1.</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;In addition to any other remedy it may have, either Party shall have the right to terminate this Agreement if the
          other Party fails to remedy and make good any default in the performance of any material condition or obligation under this Agreement within a cure period of [***] ([***]) days of written notice thereof.</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-indent: 36pt;"><font style="font-weight: bold; font-size: 10pt;">2.</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Additionally, ADMA shall have the right to terminate this Agreement on [***] ([***]) days&#8217; written notice in the event
          that the FDA withdraws its approval of ASCENIV&#8482; during the Term, or in the event that ASCENIV&#8482; is otherwise unable to be commercially sold.</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-indent: 36pt;"><font style="font-weight: bold; font-size: 10pt;">3.</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Upon giving the appropriate written notice, either Party may terminate this Agreement upon the occurrence of a
          proceeding under any bankruptcy, reorganization, arrangement of debts, insolvency or receivership law is filed by or against the other Party, and is not dismissed or stayed within [***] ([***]) days, or a receiver or trustee is appointed for all
          or a substantial portion of the assets of the other Party, or if the other Party makes an assignment for the benefit of its creditors or becomes insolvent.</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-indent: 36pt;"><font style="font-weight: bold; font-size: 10pt;">4.</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Upon termination of this Agreement, ADMA must pay for any RSV Plasma already delivered to ADMA and for any RSV Plasma
          collected and scheduled for delivery under the terms of this Agreement, provided, in each case that such RSV Plasma conforms to the ADMA Specifications.</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-size: 8pt; color: rgb(0, 0, 0); font-weight: normal; font-style: normal; font-family: 'Times New Roman';">- 10 -</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-indent: 36pt;"><font style="font-weight: bold; font-size: 10pt;">5.</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Notwithstanding anything to the contrary set forth herein, the Parties&#8217; obligations under this Agreement in <u>Sections

            A</u>, <u>C</u>, <u>D</u>, <u>F</u>, <u>G</u>, <u>I</u>, <u>J</u>, <u>K</u> and <u>L</u> shall survive the termination of this Agreement to the extent necessary to give effect to their reasonable intentions.</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%;" id="zb003a7552a0b4d3cac5157361164c8aa" class="DSPFListTable">

            <tr style="vertical-align: top;">
              <td style="text-align: right; vertical-align: top; width: 36pt;">
                <div style="text-align: left; font-size: 10pt;"><font style="font-weight: bold;">E.</font></div>
              </td>
              <td style="text-align: left; vertical-align: top; width: auto;">
                <div><font style="font-weight: bold; font-size: 10pt;"><u>FORCE MAJEURE</u></font><font style="font-size: 10pt;">.</font></div>
              </td>
            </tr>

        </table>
      </div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-indent: 36pt;"><font style="font-weight: bold; font-size: 10pt;">1.</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Neither Party shall be liable for any failure to perform its obligations under this Agreement caused by strikes,
          fires, explosions, acts of God, riots, civil or international war, future widespread outbreaks of illness or a pandemic acts of terrorism, an unexpected downturn in the acceptable donor population adversely affecting the industry as a whole, a
          decrease of acceptable donor population affecting the PLASMA SUPPLIER&#8217;s RSV program, an inability to fully test samples of RSV Plasma or any other similar cause beyond the reasonable control of either Party (including any such events at a Center
          or third-party testing laboratory) which prevents the performance of a Party&#8217;s obligations under this Agreement or the Quality Agreement (each, a &#8220;<font style="font-weight: bold;">Force Majeure Event</font>&#8221;).</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-indent: 36pt;"><font style="font-weight: bold; font-size: 10pt;">2.</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The affected Party shall immediately inform the other Party of a Force Majeure Event, including a full description of
          the nature of the event of Force Majeure, and its cause and possible consequences of such occurrences.&#160; Upon giving notice to the other Party, the Party affected by an event of Force Majeure shall be released without any liability on its part
          from the performance of its obligations under this Agreement, except for the obligation to pay any amounts due and owing hereunder, but only to the extent and only for the period that its performance of such obligations is prevented by the event
          of Force Majeure.&#160; The Party claiming Force Majeure shall promptly notify the other Party of the termination of such event.</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-indent: 36pt;"><font style="font-weight: bold; font-size: 10pt;">3.</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Should the period of Force Majeure continue for more than [***] ([***]) days, then the Party not suffering the Force
          Majeure event may terminate this Agreement immediately upon giving written notice to the other Party.</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%;" id="za0adb1daa86548de9cf855107fdd1855" class="DSPFListTable">

            <tr style="vertical-align: top;">
              <td style="text-align: right; vertical-align: top; width: 36pt;">
                <div style="text-align: left; font-size: 10pt;"><font style="font-weight: bold;">F.</font></div>
              </td>
              <td style="text-align: left; vertical-align: top; width: auto;">
                <div style="font-size: 10pt;"><font style="font-weight: bold;"><u>DONOR INFORMATION</u></font></div>
              </td>
            </tr>

        </table>
      </div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; font-size: 10pt;">PLASMA SUPPLIER agrees that all donor information supplied by ADMA and antibody test results supplied by ADMA are the property of ADMA and that PLASMA SUPPLIER has no right to
        share this information with any other party or use the information for its own commercial use, but may use the information to comply with regulatory requirements and for its own record keeping requirements. This information shall be considered
        ADMA&#8217;s Confidential Information.</div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; font-size: 10pt;">PLASMA SUPPLIER agrees to provide ADMA, on a monthly basis during the Term, with certain deidentified information about Acceptable Donors in PLASMA SUPPLIER&#8217;s RSV Plasma program,
        [***]. For the avoidance of doubt, PLASMA SUPPLIER shall not provide a donor number or social security number for any such data provided hereunder.</div>
      <div style="font-size: 10pt;">&#160;</div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-size: 8pt; color: rgb(0, 0, 0); font-weight: normal; font-style: normal; font-family: 'Times New Roman';">- 11 -</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div>
        <table cellspacing="0" cellpadding="0" id="z86b28a0440ad4108be3299066ba809ae" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 36pt; vertical-align: top; text-align: right;">
                <div style="text-align: left; font-weight: bold; font-size: 10pt;">G.</div>
              </td>
              <td style="width: auto; vertical-align: top;">
                <div style="text-align: justify; font-weight: bold; font-size: 10pt;"><u>DISCLOSURES AND PUBLICITY</u></div>
              </td>
            </tr>

        </table>
      </div>
      <div> <font style="font-size: 10pt;"><br>
        </font> </div>
      <div style="text-align: justify; text-indent: 36pt; font-size: 10pt;">Neither Party shall, without the approval of the other Party, make any press release or other public announcement concerning the transactions contemplated by this Agreement, except
        as and to the extent that any such Party shall be so obligated by law, in which case the other Party shall be advised and the Parties shall use their commercially reasonable efforts to cause a mutually agreeable release or announcement to be
        issued; provided, however, that the foregoing shall not preclude communications or disclosures necessary to implement the provisions of this Agreement or to comply with the accounting and disclosure obligations of the Securities and Exchange
        Commission (&#8220;<font style="font-weight: bold;">SEC</font>&#8221;) or the rules of any stock exchange.&#160; Notwithstanding any contrary term contained in the confidentiality provisions of this Agreement, to the extent that either Party determines that it or
        the other Party is required to publicly file or register this Agreement, a summary thereof, or a notification thereof, and/or descriptions related thereto, to comply with the requirements of an applicable stock exchange, SEC regulation, or any
        governmental authority, including the SEC, or to enable either Party to obtain debt or equity financing, such Party shall use its best efforts to provide the maximum amount of advance written notice of any such required disclosure to the other
        Party, to the extent practicable, with a minimum advance notice period of [***] ([***]) business days.&#160; Prior to making any such filing, registration or notification, the Parties shall consult with respect thereto regarding confidentiality.&#160; The
        Parties shall cooperate, each at its own expense, in such filing, registration or notification, including such confidential treatment request, if applicable, and shall execute all documents reasonably required in connection therewith.</div>
      <div style="font-size: 10pt;">&#160;</div>
      <div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%;" id="zbdd9caa5912b46238a2eeebfdeb71b9a" class="DSPFListTable">

            <tr style="vertical-align: top;">
              <td style="text-align: right; vertical-align: top; width: 36pt;">
                <div style="text-align: left; font-size: 10pt;"><font style="font-weight: bold;">H.</font></div>
              </td>
              <td style="text-align: left; vertical-align: top; width: auto;">
                <div><font style="font-weight: bold; font-size: 10pt;"><u>ASSIGNMENT</u></font><font style="font-size: 10pt;">.</font></div>
              </td>
            </tr>

        </table>
      </div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; font-size: 10pt;">Neither Party shall assign this Agreement or any of its rights or obligations hereunder without the express written consent of the other Party, except as hereinafter provided.&#160; Any
        such consent shall not be unreasonably delayed, conditioned, or withheld.&#160; With notice to the other Party, either Party without the other Party&#8217;s consent may assign this Agreement to (i) its direct affiliate, or (ii) a successor to all or
        substantially all of the assets or equity ownership relating to the business of that Party which is involved in the fulfillment of its obligations under this Agreement, and such successor or assignee (if such successor or assignee is not a Party
        hereto) shall expressly assume in writing the performance of all of the terms and conditions of this Agreement then to be performed by such successor or assignee as if it were named herein as a Party.</div>
      <div style="font-size: 10pt;">&#160;</div>
      <div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%;" id="z58f36c7ebc5e4c81b08aae06058d9bc9" class="DSPFListTable">

            <tr style="vertical-align: top;">
              <td style="text-align: right; vertical-align: top; width: 36pt;">
                <div style="text-align: left; font-size: 10pt;"><font style="font-weight: bold;">I.</font></div>
              </td>
              <td style="text-align: left; vertical-align: top; width: auto;">
                <div><font style="font-weight: bold; font-size: 10pt;"><u>NOTICES</u></font><font style="font-size: 10pt;">.&#160; Except as otherwise provided in this Agreement, all notices, demands, requests, consents or approvals furnished by a Party under
                    this Agreement must be in writing and delivered personally to the other Party or sent by overnight courier service, registered or certified mail, or electronic mail (&#8220;<font style="font-weight: bold;">e-mail</font>&#8221;), addressed to such
                    Party as set forth below (or to such other (physical or e-mail) address(es) as such Party may hereafter specify for the purpose by notice to the other Party in accordance herewith):</font></div>
              </td>
            </tr>

        </table>
      </div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-indent: -108pt; margin-left: 144pt; font-size: 10pt;"><u>To PLASMA SUPPLIER</u>:</div>
      <div style="text-indent: -108pt; margin-left: 144pt;"><font style="font-size: 10pt;"><br>
        </font> <font style="font-size: 10pt;"><br>
          [***]</font></div>
      <div style="margin-left: 144pt; font-size: 10pt;">KEDPlasma LLC</div>
      <div style="margin-left: 144pt; font-size: 10pt;">Park Plaza</div>
      <div style="margin-left: 144pt; font-size: 10pt;">400 Kelby Street, 11<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">th</sup> Floor</div>
      <div style="margin-left: 144pt; font-size: 10pt;">Fort Lee, NJ 07024</div>
      <div style="margin-left: 144pt; font-size: 10pt;">E-mail: [***]</div>
      <div><font style="font-size: 10pt;"><br>
        </font> </div>
      <div style="margin-left: 144pt; font-size: 10pt;">With copies to:</div>
      <div><font style="font-size: 10pt;"><br>
        </font> </div>
      <div style="margin-left: 144pt; font-size: 10pt;">E-mail: [***]</div>
      <div style="text-indent: 36pt; margin-left: 135pt; font-size: 10pt;">&#160; [***]</div>
      <div><font style="font-size: 10pt;"><br>
        </font> </div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-size: 8pt; color: rgb(0, 0, 0); font-weight: normal; font-style: normal; font-family: 'Times New Roman';">- 12 -</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <table cellspacing="0" cellpadding="0" id="z7f6b2c959db04d248c4423d04f13c14d" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 36pt;"><font style="font-size: 10pt;"><br>
              </font> </td>
            <td style="width: 108pt; vertical-align: top; font-size: 10pt;"><u>To ADMA</u>:</td>
            <td style="width: auto; vertical-align: top;">
              <div style="font-size: 10pt;">[***]</div>
            </td>
          </tr>

      </table>
      <div style="margin-left: 144pt; font-size: 10pt;">General Counsel<br>
        ADMA Biologics<br>
        5800 Park of Commerce Boulevard, NW</div>
      <div style="margin-left: 144pt; font-size: 10pt;">Boca Raton, FL 33487</div>
      <div style="margin-left: 144pt; font-size: 10pt;">E-mail: [***]</div>
      <div><font style="font-size: 10pt;"><br>
        </font> </div>
      <div style="text-align: justify; text-indent: 36pt; font-size: 10pt;">All notices, requests, consents and other communications hereunder shall be deemed to have been properly given (a) if by hand, at the time of the delivery thereof to the receiving
        Party at the address of such Party set forth above, (b) if sent by overnight courier, on the next business day following the day such notice is delivered to the courier service, (c) if sent by registered or certified mail, on the fifth business day
        following the day such mailing is made, or (d) if sent via e-mail, upon written confirmation of receipt (whether from an automated confirmation of delivery or &#8220;read receipt&#8221; or otherwise).</div>
      <div style="font-size: 10pt;">&#160;</div>
      <div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%;" id="zc671240019354838a350a1b485b9630b" class="DSPFListTable">

            <tr style="vertical-align: top;">
              <td style="text-align: right; vertical-align: top; width: 36pt;">
                <div style="text-align: left; font-size: 10pt;"><font style="font-weight: bold;">J.</font></div>
              </td>
              <td style="text-align: left; vertical-align: top; width: auto;">
                <div><font style="font-weight: bold; font-size: 10pt;"><u>INTEGRATION; AMENDMENT; EFFECT OF AMENDMENT</u></font><font style="font-size: 10pt;">.</font></div>
              </td>
            </tr>

        </table>
      </div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; font-size: 10pt;">This Agreement, including all attachments, schedules or other agreements specifically incorporated by reference, constitute the entire agreement between the Parties with respect to
        the subject matter of this Agreement and supersede any and all other prior written or oral agreements, understandings, negotiations or discussions among the Parties with respect to the subject matter of this Agreement.&#160; This Agreement may not be
        modified or amended in any respect except by an instrument in writing signed by both Parties.</div>
      <div style="font-size: 10pt;">&#160;</div>
      <div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%;" id="z3d87749a9b114327bd2be11f0a88134f" class="DSPFListTable">

            <tr style="vertical-align: top;">
              <td style="text-align: right; vertical-align: top; width: 36pt;">
                <div style="text-align: left; font-size: 10pt;"><font style="font-weight: bold;">K.</font></div>
              </td>
              <td style="text-align: left; vertical-align: top; width: auto;">
                <div><font style="font-weight: bold; font-size: 10pt;"><u>CHOICE OF LAW</u></font><font style="font-size: 10pt;">.</font></div>
              </td>
            </tr>

        </table>
      </div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; font-size: 10pt;">This Agreement shall be governed by, and construed under laws of the State of [***], without regard to its conflict of laws principles and is subject to exclusive jurisdiction of
        the courts of State of [***].</div>
      <div style="font-size: 10pt;">&#160;</div>
      <div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%;" id="z6b15b7847bb84e178991e2a84699f3bd" class="DSPFListTable">

            <tr style="vertical-align: top;">
              <td style="text-align: right; vertical-align: top; width: 36pt;">
                <div style="text-align: left; font-size: 10pt;"><font style="font-weight: bold;">L.</font></div>
              </td>
              <td style="text-align: left; vertical-align: top; width: auto;">
                <div><font style="font-weight: bold; font-size: 10pt;"><u>NO WAIVER</u></font><font style="font-size: 10pt;">.</font></div>
              </td>
            </tr>

        </table>
      </div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; font-size: 10pt;">Any failure or delay on the part of any Party exercising any power or right hereunder shall not operate as a waiver thereof, nor shall any single or partial exercise of any such
        right or power preclude any other or further exercise thereof or the exercise of any other right or power hereunder or otherwise available in law or in equity.</div>
      <div style="font-size: 10pt;">&#160;</div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-size: 8pt; color: rgb(0, 0, 0); font-weight: normal; font-style: normal; font-family: 'Times New Roman';">- 13 -</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%;" id="zf2a7e1071a4845e0aaea7a89d5ce1c04" class="DSPFListTable">

            <tr style="vertical-align: top;">
              <td style="text-align: right; vertical-align: top; width: 36pt;">
                <div style="text-align: left; font-size: 10pt;"><font style="font-weight: bold;">M.</font></div>
              </td>
              <td style="text-align: left; vertical-align: top; width: auto;">
                <div><font style="font-weight: bold; font-size: 10pt;"><u>NO SUBCONTRACTORS</u></font><font style="font-size: 10pt;">.</font></div>
              </td>
            </tr>

        </table>
      </div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; font-size: 10pt;">PLASMA SUPPLIER covenants and agrees to not use any subcontractors without ADMA&#8217;s prior written consent, in order to perform its obligations hereunder.</div>
      <div style="font-size: 10pt;">&#160;</div>
      <div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%;" id="z695aac4255934d3193ce2262f7670dd9" class="DSPFListTable">

            <tr style="vertical-align: top;">
              <td style="text-align: right; vertical-align: top; width: 36pt;">
                <div style="text-align: left; font-size: 10pt;"><font style="font-weight: bold;">N.</font></div>
              </td>
              <td style="text-align: left; vertical-align: top; width: auto;">
                <div><font style="font-weight: bold; font-size: 10pt;"><u>COUNTERPARTS</u></font><font style="font-size: 10pt;">.</font></div>
              </td>
            </tr>

        </table>
      </div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; font-size: 10pt;">This Agreement may be executed in any number of original counterparts or by facsimile or other electronic means, each of which when executed and delivered will be deemed to be an
        original and all of which taken together will constitute but one and the same instrument.&#160; One or more counterparts of this Agreement may be delivered by facsimile or other electronic means, with the intention that delivery by such means shall have
        the same effect as delivery of an original counterpart hereof.</div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: center; font-size: 10pt;">[Remainder of page intentionally left blank; signature page follows]</div>
      <div style="font-size: 10pt;">&#160;</div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-size: 8pt; color: rgb(0, 0, 0); font-weight: normal; font-style: normal; font-family: 'Times New Roman';">- 14 -</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: justify; text-indent: 36pt; font-size: 12pt;"><font style="font-size: 10pt; font-weight: bold;">IN WITNESS WHEREOF</font><font style="font-size: 10pt;">, the Parties hereto have executed this Agreement by their duly authorized
          officers as of the Effective Date.</font></div>
      <div style="font-size: 10pt;">&#160;</div>
      <table cellspacing="0" cellpadding="0" border="0" id="z3590b68399564585a1e817df1ec74d5d" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">

          <tr>
            <td style="vertical-align: top;" colspan="2">
              <div style="font-weight: bold; font-size: 10pt;">ADMA BIOMANUFACTURING, LLC</div>
            </td>
            <td style="vertical-align: top;" colspan="2">
              <div style="font-weight: bold; font-size: 10pt;">KEDPLASMA LLC</div>
            </td>
          </tr>
          <tr>
            <td style="vertical-align: top; font-size: 10pt;" colspan="2" rowspan="1">&#160;</td>
            <td style="vertical-align: top; font-size: 10pt;" colspan="2" rowspan="1">&#160;</td>
          </tr>
          <tr>
            <td style="width: 3%; vertical-align: top;">
              <div style="font-size: 10pt;">By:</div>
            </td>
            <td style="width: 47%; vertical-align: top;">
              <div style="font-size: 10pt;"><u>/s/ Adam Grossman</u></div>
            </td>
            <td style="width: 3%; vertical-align: top;">
              <div style="font-size: 10pt;">&#160;By:</div>
            </td>
            <td style="width: 47%; vertical-align: top;">
              <div style="font-size: 10pt;"><u>/s/ Federico Latini</u></div>
            </td>
          </tr>
          <tr>
            <td style="width: 3%; vertical-align: top; font-size: 10pt;" rowspan="1">&#160;</td>
            <td style="width: 47%; vertical-align: top; font-size: 10pt;" rowspan="1">&#160;</td>
            <td style="width: 3%; vertical-align: top; font-size: 10pt;" rowspan="1">&#160;</td>
            <td style="width: 47%; vertical-align: top; font-size: 10pt;" rowspan="1">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align: top;" colspan="2">
              <div style="font-size: 10pt;">Name: Adam Grossman</div>
            </td>
            <td style="vertical-align: top;" colspan="2">
              <div style="font-size: 10pt;">Name: Federico Latini</div>
            </td>
          </tr>
          <tr>
            <td style="vertical-align: top; font-size: 10pt;" colspan="2" rowspan="1">&#160;</td>
            <td style="vertical-align: top; font-size: 10pt;" colspan="2" rowspan="1">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align: top;" colspan="2">
              <div style="font-size: 10pt;">Title: President and CEO</div>
            </td>
            <td style="vertical-align: top;" colspan="2">
              <div style="font-size: 10pt;">Title: CEO</div>
            </td>
          </tr>
          <tr>
            <td style="vertical-align: top; font-size: 10pt;" colspan="2" rowspan="1">&#160;</td>
            <td style="vertical-align: top; font-size: 10pt;" colspan="2" rowspan="1">&#160;</td>
          </tr>
          <tr>
            <td style="vertical-align: top;" colspan="2">
              <div style="font-size: 10pt;">Date: August 6, 2024</div>
            </td>
            <td style="vertical-align: top;" colspan="2">
              <div style="font-size: 10pt;">Date: August 6, 2024</div>
            </td>
          </tr>

      </table>
      <div> <font style="font-size: 10pt;"><br>
        </font> </div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-size: 8pt; color: rgb(0, 0, 0); font-weight: normal; font-style: normal; font-family: 'Times New Roman';">- 15 -</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: center; font-weight: bold; font-size: 10pt;"><u>EXHIBIT A</u></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: center; font-weight: bold; font-size: 10pt;">Source Plasma Specifications and Quality Agreement</div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: center; font-size: 10pt;">(See attached)</div>
      <div style="font-size: 10pt;">&#160;</div>
      <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
        <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-size: 8pt; color: rgb(0, 0, 0); font-weight: normal; font-style: normal; font-family: 'Times New Roman';">- 16 -</font></div>
        <div class="BRPFPageBreak" style="page-break-after: always;">
          <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
      </div>
      <div style="text-align: center; font-weight: bold; font-size: 10pt;"><u>EXHIBIT B</u></div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: center; font-weight: bold; font-size: 10pt;">Plasma Supplier Plasma Centers</div>
      <div style="font-size: 10pt;">&#160;</div>
      <div style="text-align: center; font-size: 10pt;">[***]</div>
      <div style="font-size: 10pt;">&#160;</div>
      <div><font style="font-size: 10pt;"><br>
        </font> </div>
    </div>
  </div>
  <font style="font-size: 10pt;"> </font>
  <div style="text-align: center; font-size: 10pt;" class="BRPFPageNumberArea"><font style="color: rgb(0, 0, 0); font-weight: normal; font-style: normal; font-family: 'Times New Roman'; font-size: 8pt;">- 17 -</font></div>
  <font style="font-size: 10pt;"> </font>
  <div style="text-align: center;" class="BRPFPageNumberArea">
    <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; margin-left: auto; margin-right: auto; border: none;"></div>
  <font style="font-size: 10pt;"> </font>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.11
<SEQUENCE>4
<FILENAME>ef20038923_ex10-11.htm
<DESCRIPTION>EXHIBIT 10.11
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Summit Financial
         Document created using Broadridge PROfile 25.2.1.5287
         Copyright 1995 - 2025 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">


  <font style="font-size: 10pt;"> </font>
  <div>
    <hr noshade="noshade" align="center" style="height: 4px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;">
    <div style="text-align: right;"><font style="font-weight: bold; font-size: 10pt;">Exhibit 10.11</font>
      <div style="text-align: left; font-size: 10pt;"><br>
      </div>
      <div style="text-align: left;">
        <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">INDEMNIFICATION AGREEMENT</div>
        <div style="font-size: 10pt;">&#160;</div>
        <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">THIS INDEMNIFICATION AGREEMENT (the &#8220;<font style="font-family: 'Times New Roman'; font-weight: bold;">Agreement</font>&#8221;) is made and entered into
          as of ___________ between ADMA Biologics, Inc., a Delaware corporation (the &#8220;<font style="font-family: 'Times New Roman'; font-weight: bold;">Company</font>&#8221;), and ___________ (&#8220;<font style="font-family: 'Times New Roman'; font-weight: bold;">Indemnitee</font>&#8221;).</div>
        <div style="font-size: 10pt;">&#160;</div>
        <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">WITNESSETH THAT:</div>
        <div style="font-size: 10pt;">&#160;</div>
        <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">WHEREAS, highly competent persons have become more reluctant to serve corporations as directors or in other capacities unless they are provided
          with adequate protection through insurance or adequate indemnification against inordinate risks of claims and actions against them arising out of their service to and activities on behalf of the corporation;</div>
        <div style="font-size: 10pt;">&#160;</div>
        <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">WHEREAS, the Board of Directors of the Company (the &#8220;<font style="font-family: 'Times New Roman'; font-weight: bold;">Board</font>&#8221;) has
          determined that, in order to attract and retain qualified individuals, the Company will attempt to maintain on an ongoing basis, at its sole expense, liability insurance to protect persons serving the Company and its subsidiaries from certain
          liabilities.&#160; Although the furnishing of such insurance has been a customary and widespread practice among United States-based corporations and other business enterprises, the Company believes that, given current market conditions and trends,
          such insurance may be available to it in the future only at higher premiums and with more exclusions.&#160; At the same time, directors, officers, and other persons in service to corporations or business enterprises are being increasingly subjected to
          expensive and time-consuming litigation relating to, among other things, matters that traditionally would have been brought only against the Company or business enterprise itself.&#160; The certificate of incorporation of the Company, as amended and
          restated (as it may be further amended from time to time, the &#8220;<font style="font-family: 'Times New Roman'; font-weight: bold;">Certificate of Incorporation</font>&#8221;), and the bylaws of the Company, as amended and restated (as it may be further
          amended from time to time, the &#8220;<font style="font-family: 'Times New Roman'; font-weight: bold;">Bylaws</font>&#8221;), requires indemnification of the directors, officers, employees or agents of the Company.&#160; Indemnitee may also be entitled to
          indemnification pursuant to the General Corporation Law of the State of Delaware (&#8220;<font style="font-family: 'Times New Roman'; font-weight: bold;">DGCL</font>&#8221;).&#160; The DGCL expressly provides that the indemnification provisions set forth therein
          are not exclusive, and thereby contemplates that contracts may be entered into between the Company and members of the board of directors, officers and other persons with respect to indemnification;</div>
        <div style="font-size: 10pt;">&#160;</div>
        <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">WHEREAS, the uncertainties relating to such insurance and to indemnification have increased the difficulty of attracting and retaining such
          persons;</div>
        <div style="font-size: 10pt;">&#160;</div>
        <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">WHEREAS, the Board has determined that the increased difficulty in attracting and retaining such persons is detrimental to the best interests of
          the Company&#8217;s stockholders and that the Company should act to assure such persons that there will be increased certainty of such protection in the future;</div>
        <div style="font-size: 10pt;">&#160;</div>
        <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">WHEREAS, it is reasonable, prudent and necessary for the Company contractually to obligate itself to indemnify, and to advance expenses on behalf
          of, such persons to the fullest extent permitted by applicable law so that they will serve or continue to serve the Company free from undue concern that they will not be so indemnified;</div>
        <div style="font-size: 10pt;">&#160;</div>
        <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">WHEREAS, this Agreement is a supplement to and in furtherance of the Certificate of Incorporation and Bylaws of the Company and any resolutions
          adopted pursuant thereto, and shall not be deemed a substitute therefor, nor to diminish or abrogate any rights of Indemnitee thereunder; and</div>
        <div style="font-size: 10pt;">&#160;</div>
        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
        </div>
        <!--PROfilePageNumberReset%Num%2%%%-->
        <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">WHEREAS, Indemnitee does not regard the protection available under the Company&#8217;s insurance, if any, as adequate in the present circumstances, and
          may not be willing to serve as an officer or director without adequate protection, and the Company desires Indemnitee to serve in such capacity.&#160; Indemnitee is willing to serve, continue to serve and to take on additional service for or on behalf
          of the Company on the condition that he be so indemnified.</div>
        <div style="font-size: 10pt;">&#160;</div>
        <div style="text-align: justify; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">NOW, THEREFORE, in consideration of Indemnitee&#8217;s agreement to serve as a director or officer (as the case may be) of the Company, the parties
          hereto agree as follows:</div>
        <div style="font-size: 10pt;">&#160;</div>
        <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">1.</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160; <font style="font-family: 'Times New Roman';"><font style="font-family: 'Times New Roman';"><u>Indemnity of Indemnitee</u></font>.&#160; The Company hereby agrees to hold harmless and indemnify Indemnitee to the fullest extent permitted by law, as such may be amended from time to time.&#160; In furtherance of the foregoing
              indemnification, and without limiting the generality thereof:</font></font></div>
        <div style="font-size: 10pt;">&#160;</div>
        <div style="text-align: justify; text-indent: 108pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(a)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman';"><font style="font-family: 'Times New Roman';"><u>Proceedings Other Than Proceedings by or in the Right of the Company</u></font>.&#160; Indemnitee shall be entitled to the rights of indemnification provided in this <font style="font-family: 'Times New Roman';"><u>Section 1(a)</u></font>
              if, by reason of his Corporate Status (as hereinafter defined), the Indemnitee is, or is threatened to be made, a party to or participant in any Proceeding (as hereinafter defined) other than a Proceeding by or in the right of the Company.&#160;
              Pursuant to this <font style="font-family: 'Times New Roman';"><u>Section 1(a)</u></font>, Indemnitee shall be indemnified against all Expenses (as hereinafter defined), judgments, penalties, fines and amounts paid in settlement actually and
              reasonably incurred by him, or on his behalf, in connection with such Proceeding or any claim, issue or matter therein, if the Indemnitee acted in good faith and in a manner the Indemnitee reasonably believed to be in or not opposed to the
              best interests of the Company, and with respect to any criminal Proceeding, had no reasonable cause to believe the Indemnitee&#8217;s conduct was unlawful.</font></font></div>
        <div style="font-size: 10pt;">&#160;</div>
        <div style="text-align: justify; text-indent: 108pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(b)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman';"><font style="font-family: 'Times New Roman';"><u>Proceedings by or in the Right of the Company</u></font>.&#160; Indemnitee shall be entitled to the rights of indemnification provided in this <font style="font-family: 'Times New Roman';"><u>Section 1(b)</u></font> if, by
              reason of his Corporate Status, the Indemnitee is, or is threatened to be made, a party to or participant in any Proceeding brought by or in the right of the Company.&#160; Pursuant to this <font style="font-family: 'Times New Roman';"><u>Section
                  1(b)</u></font>, Indemnitee shall be indemnified against all Expenses actually and reasonably incurred by the Indemnitee, or on the Indemnitee&#8217;s behalf, in connection with such Proceeding if the Indemnitee acted in good faith and in a
              manner the Indemnitee reasonably believed to be in or not opposed to the best interests of the Company; provided, however, if applicable law so provides, no indemnification against such Expenses shall be made in respect of any claim, issue or
              matter in such Proceeding as to which Indemnitee shall have been adjudged to be liable to the Company unless and to the extent that the Court of Chancery of the State of Delaware shall determine that such indemnification may be made.</font></font></div>
        <div style="font-size: 10pt;">&#160;</div>
        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div class="BRPFPageNumberArea" style="text-align: center;"><font style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">2</font></div>
          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
        </div>
        <div style="text-align: justify; text-indent: 108pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(c)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160;&#160; <font style="font-family: 'Times New Roman';"><font style="font-family: 'Times New Roman';"><u>Indemnification for Expenses of a Party Who is Wholly or Partly Successful</u></font>.&#160; Notwithstanding any other provision of this Agreement, to the extent that Indemnitee is, by reason of his Corporate Status, a party to
              and is successful, on the merits or otherwise, in any Proceeding, he shall be indemnified to the maximum extent permitted by law, as such may be amended from time to time, against all Expenses actually and reasonably incurred by him or on his
              behalf in connection therewith.&#160; If Indemnitee is not wholly successful in such Proceeding but is successful, on the merits or otherwise, as to one or more but less than all claims, issues or matters in such Proceeding, the Company shall
              indemnify Indemnitee against all Expenses actually and reasonably incurred by him or on his behalf in connection with each successfully resolved claim, issue or matter.&#160; For purposes of this Section and without limitation, the termination of
              any claim, issue or matter in such a Proceeding by dismissal, with or without prejudice, shall be deemed to be a successful result as to such claim, issue or matter.</font></font></div>
        <div style="font-size: 10pt;">&#160;</div>
        <div style="text-align: justify; text-indent: 108pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(d)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman';"><font style="font-family: 'Times New Roman';"><u>Indemnification of Related Parties</u></font>.&#160; If (i) Indemnitee is or was affiliated with one or more venture capital funds that has invested in the Company (an &#8220;<font style="font-family: 'Times New Roman'; font-weight: bold;">Appointing Stockholder</font>&#8221;), (ii) the Appointing Stockholder is, or is threatened to be made, a party to or a participant in any proceeding, and (iii) the Appointing Stockholder&#8217;s involvement in the proceeding is related to
              Indemnitee&#8217;s service to the Company as a director of the Company or any direct or indirect subsidiaries of the Company, then, to the extent resulting from any claim based on the Indemnitee&#8217;s service to the Company as a director of the Company
              or any direct or indirect subsidiaries of the Company, the Appointing Stockholder will be entitled to indemnification hereunder for Expenses to the same extent as Indemnitee.</font></font></div>
        <div style="font-size: 10pt;">&#160;</div>
        <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">2.</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman';"><font style="font-family: 'Times New Roman';"><u>Additional Indemnity</u></font>.&#160; In addition to, and without regard to any limitations on, the indemnification provided for in <font style="font-family: 'Times New Roman';"><u>Section 1</u></font> of this Agreement, the
              Company shall and hereby does indemnify and hold harmless Indemnitee against all Expenses, judgments, penalties, fines and amounts paid in settlement actually and reasonably incurred by him or on his behalf if, by reason of his Corporate
              Status, he is, or is threatened to be made, a party to or participant in any Proceeding (including a Proceeding by or in the right of the Company), including, without limitation, all liability arising out of the negligence or active or
              passive wrongdoing of Indemnitee.&#160; The only limitation that shall exist upon the Company&#8217;s obligations pursuant to this Agreement shall be that the Company shall not be obligated to make any payment to Indemnitee that is finally determined
              (under the procedures, and subject to the presumptions, set forth in <font style="font-family: 'Times New Roman';"><u>Sections 6</u></font> and <font style="font-family: 'Times New Roman';"><u>7</u></font> hereof) to be unlawful.</font></font></div>
        <div style="font-size: 10pt;">&#160;</div>
        <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">3.</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';"><font style="font-family: 'Times New Roman';"><u>Contribution</u></font>.</font></font></div>
        <div style="font-size: 10pt;">&#160;</div>
        <div style="text-align: justify; text-indent: 108pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(a)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman';">Whether or not the indemnification
              provided in <font style="font-family: 'Times New Roman';"><u>Sections 1</u></font> and <font style="font-family: 'Times New Roman';"><u>2</u></font> hereof is available, in respect of any threatened, pending or completed action, suit or
              proceeding in which the Company is jointly liable with Indemnitee (or would be if joined in such action, suit or proceeding), the Company shall pay, in the first instance, the entire amount of any judgment or settlement of such action, suit
              or proceeding without requiring Indemnitee to contribute to such payment and the Company hereby waives and relinquishes any right of contribution it may have against Indemnitee.&#160; The Company shall not enter into any settlement of any action,
              suit or proceeding in which the Company is jointly liable with Indemnitee (or would be if joined in such action, suit or proceeding) unless such settlement provides for a full and final release of all claims asserted against Indemnitee.</font></font></div>
        <div style="font-size: 10pt;">&#160;</div>
        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div class="BRPFPageNumberArea" style="text-align: center;"><font style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">3</font></div>
          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
        </div>
        <div style="text-align: justify; text-indent: 108pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(b)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman';">Without diminishing or impairing
              the obligations of the Company set forth in the preceding subparagraph, if, for any reason, Indemnitee shall elect or be required to pay all or any portion of any judgment or settlement in any threatened, pending or completed action, suit or
              proceeding in which the Company is jointly liable with Indemnitee (or would be if joined in such action, suit or proceeding), the Company shall contribute to the amount of Expenses, judgments, fines and amounts paid in settlement actually and
              reasonably incurred and paid or payable by Indemnitee in proportion to the relative benefits received by the Company and all officers, directors or employees of the Company, other than Indemnitee, who are jointly liable with Indemnitee (or
              would be if joined in such action, suit or proceeding), on the one hand, and Indemnitee, on the other hand, from the transaction from which such action, suit or proceeding arose; provided, however, that the proportion determined on the basis
              of relative benefit may, to the extent necessary to conform to law, be further adjusted by reference to the relative fault of the Company and all officers, directors or employees of the Company other than Indemnitee who are jointly liable
              with Indemnitee (or would be if joined in such action, suit or proceeding), on the one hand, and Indemnitee, on the other hand, in connection with the events that resulted in such expenses, judgments, fines or settlement amounts, as well as
              any other equitable considerations which the law may require to be considered.&#160; The relative fault of the Company and all officers, directors or employees of the Company, other than Indemnitee, who are jointly liable with Indemnitee (or would
              be if joined in such action, suit or proceeding), on the one hand, and Indemnitee, on the other hand, shall be determined by reference to, among other things, the degree to which their actions were motivated by intent to gain personal profit
              or advantage, the degree to which their liability is primary or secondary and the degree to which their conduct is active or passive.</font></font></div>
        <div style="font-size: 10pt;">&#160;</div>
        <div style="text-align: justify; text-indent: 108pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(c)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';">The Company hereby agrees to
              fully indemnify and hold Indemnitee harmless from any claims of contribution which may be brought by officers, directors or employees of the Company, other than Indemnitee, who may be jointly liable with Indemnitee.</font></font></div>
        <div style="font-size: 10pt;">&#160;</div>
        <div style="text-align: justify; text-indent: 108pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(d)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';">To the fullest extent permissible
              under applicable law, if the indemnification provided for in this Agreement is unavailable to Indemnitee for any reason whatsoever, the Company, in lieu of indemnifying Indemnitee, shall contribute to the amount incurred by Indemnitee,
              whether for judgments, fines, penalties, excise taxes, amounts paid or to be paid in settlement and/or for Expenses, in connection with any claim relating to an indemnifiable event under this Agreement, in such proportion as is deemed fair
              and reasonable in light of all of the circumstances of such Proceeding in order to reflect (i) the relative benefits received by the Company and Indemnitee as a result of the event(s) and/or transaction(s) giving cause to such Proceeding;
              and/or (ii) the relative fault of the Company (and its directors, officers, employees and agents) and Indemnitee in connection with such event(s) and/or transaction(s).</font></font></div>
        <div style="font-size: 10pt;">&#160;</div>
        <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">4.</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman';"><font style="font-family: 'Times New Roman';"><u>Indemnification for Expenses of a Witness</u></font>.&#160; Notwithstanding any other provision of this Agreement, to the extent that Indemnitee is, by reason of his Corporate Status, a witness, or is made (or asked to) respond to
              discovery requests, in any Proceeding to which Indemnitee is not a party, he shall be indemnified against all Expenses actually and reasonably incurred by him or on his behalf in connection therewith.</font></font></div>
        <div style="font-size: 10pt;">&#160;</div>
        <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">5.</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman';"><font style="font-family: 'Times New Roman';"><u>Advancement of Expenses</u></font>.&#160; Notwithstanding any other provision of this Agreement, the Company shall advance all Expenses incurred by or on behalf of Indemnitee in connection with any Proceeding by reason of
              Indemnitee&#8217;s Corporate Status within thirty (30) days after the receipt by the Company of a statement or statements from Indemnitee requesting such advance or advances from time to time, whether prior to or after final disposition of such
              Proceeding.&#160; Such statement or statements shall reasonably evidence the Expenses incurred by Indemnitee and shall include or be preceded or accompanied by an undertaking by or on behalf of Indemnitee to repay any Expenses advanced if it shall
              ultimately be determined that Indemnitee is not entitled to be indemnified against such Expenses.&#160; Any advances and undertakings to repay pursuant to this <font style="font-family: 'Times New Roman';"><u>Section 5</u></font> shall be
              unsecured and interest free.</font></font></div>
        <div style="font-size: 10pt;">&#160;</div>
        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div class="BRPFPageNumberArea" style="text-align: center;"><font style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">4</font></div>
          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
        </div>
        <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">6.</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman';"><font style="font-family: 'Times New Roman';"><u>Procedures and Presumptions for Determination of Entitlement to Indemnification</u></font>.&#160; It is the intent of this Agreement to secure for Indemnitee rights of indemnity that are as favorable as may be permitted under the
              DGCL and public policy of the State of Delaware.&#160; Accordingly, the parties agree that the following procedures and presumptions shall apply in the event of any question as to whether Indemnitee is entitled to indemnification under this
              Agreement:</font></font></div>
        <div style="font-size: 10pt;">&#160;</div>
        <div style="text-align: justify; text-indent: 108pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(a)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';">To obtain indemnification under
              this Agreement, Indemnitee shall submit to the Company a written request, including therein or therewith such documentation and information as is reasonably available to Indemnitee and is reasonably necessary to determine whether and to what
              extent Indemnitee is entitled to indemnification.&#160; The Secretary of the Company shall, promptly upon receipt of such a request for indemnification, advise the Board of Directors in writing that Indemnitee has requested indemnification.&#160;
              Notwithstanding the foregoing, any failure of Indemnitee to provide such a request to the Company, or to provide such a request in a timely fashion, shall not relieve the Company of any liability that it may have to Indemnitee unless, and to
              the extent that, such failure actually and materially prejudices the interests of the Company.</font></font></div>
        <div style="font-size: 10pt;">&#160;</div>
        <div style="text-align: justify; text-indent: 108pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(b)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';">Upon written request by Indemnitee
              for indemnification pursuant to the first sentence of <font style="font-family: 'Times New Roman';"><u>Section 6(a)</u></font> hereof, a determination, if required by applicable law, with respect to Indemnitee&#8217;s entitlement thereto shall be
              made in the specific case by one of the following four methods, which shall be at the election of the board:&#160; (1) by a majority vote of the disinterested directors, even though less than a quorum, (2) by a committee of disinterested directors
              designated by a majority vote of the disinterested directors, even though less than a quorum, (3) if there are no disinterested directors or if the disinterested directors so direct, by independent legal counsel in a written opinion to the
              Board of Directors, a copy of which shall be delivered to the Indemnitee, or (4) if so directed by the Board of Directors, by the stockholders of the Company.&#160; For purposes hereof, disinterested directors are those members of the board of
              directors of the Company who are not parties to the action, suit or proceeding in respect of which indemnification is sought by Indemnitee.</font></font></div>
        <div style="font-size: 10pt;">&#160;</div>
        <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
          <div class="BRPFPageNumberArea" style="text-align: center;"><font style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">5</font></div>
          <div class="BRPFPageBreak" style="page-break-after: always;">
            <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
        </div>
        <div style="text-align: justify; text-indent: 108pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(c)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';">If the determination of
              entitlement to indemnification is to be made by Independent Counsel pursuant to <font style="font-family: 'Times New Roman';"><u>Section 6(b)</u></font> hereof, the Independent Counsel shall be selected as provided in this <font style="font-family: 'Times New Roman';"><u>Section 6(c)</u></font>.&#160; The Independent Counsel shall be selected by the Board of Directors.&#160; Indemnitee may, within 10 days after such written notice of selection shall have been given, deliver
              to the Company, as the case may be, a written objection to such selection; provided, however, that such objection may be asserted only on the ground that the Independent Counsel so selected does not meet the requirements of &#8220;<font style="font-family: 'Times New Roman'; font-weight: bold;">Independent Counsel</font>&#8221; as defined in <font style="font-family: 'Times New Roman';"><u>Section 13</u></font> of this Agreement, and the objection shall set forth with
              particularity the factual basis of such assertion.&#160; Absent a proper and timely objection, the person so selected shall act as Independent Counsel.&#160; If a written objection is made and substantiated, the Independent Counsel selected may not
              serve as Independent Counsel unless and until such objection is withdrawn or a court has determined that such objection is without merit.&#160; If, within 20 days after submission by Indemnitee of a written request for indemnification pursuant to
              <font style="font-family: 'Times New Roman';"><u>Section 6(a)</u></font> hereof, no Independent Counsel shall have been selected and not objected to, either the Company or Indemnitee may petition the Court of Chancery of the State of Delaware
              or other court of competent jurisdiction for resolution of any objection which shall have been made by the Indemnitee to the Company&#8217;s selection of Independent Counsel and/or for the appointment as Independent Counsel of a person selected by
              the court or by such other person as the court shall designate, and the person with respect to whom all objections are so resolved or the person so appointed shall act as Independent Counsel under <font style="font-family: 'Times New Roman';"><u>Section 6(b)</u></font> hereof.&#160; The Company shall pay any and all reasonable fees and expenses of Independent Counsel incurred by such Independent Counsel in connection with acting pursuant to <font style="font-family: 'Times New Roman';"><u>Section 6(b)</u></font> hereof, and the Company shall pay all reasonable fees and expenses incident to the procedures of this <font style="font-family: 'Times New Roman';"><u>Section 6(c)</u></font>, regardless of the
              manner in which such Independent Counsel was selected or appointed.</font></font></div>
        <div style="font-size: 10pt;">&#160;</div>
        <div style="text-align: justify; text-indent: 108pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(d)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160; <font style="font-family: 'Times New Roman';">In making a determination with
              respect to entitlement to indemnification hereunder, the person or persons or entity making such determination shall presume that Indemnitee is entitled to indemnification under this Agreement.&#160; Anyone seeking to overcome this presumption
              shall have the burden of proof and the burden of persuasion by clear and convincing evidence.&#160; Neither the failure of the Company (including by its directors or independent legal counsel) to have made a determination prior to the commencement
              of any action pursuant to this Agreement that indemnification is proper in the circumstances because Indemnitee has met the applicable standard of conduct, nor an actual determination by the Company (including by its directors or independent
              legal counsel) that Indemnitee has not met such applicable standard of conduct, shall be a defense to the action or create a presumption that Indemnitee has not met the applicable standard of conduct.</font></font></div>
        <div style="font-size: 10pt;">&#160;</div>
        <div style="text-align: justify; text-indent: 108pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(e)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';">Indemnitee shall be deemed to
              have acted in good faith if Indemnitee&#8217;s action is based on the records or books of account of the Enterprise, including financial statements, or on information supplied to Indemnitee by the officers of the Enterprise (as hereinafter defined)
              in the course of their duties, or on the advice of legal counsel for the Enterprise or on information or records given or reports made to the Enterprise by an independent certified public accountant or by an appraiser or other expert selected
              with reasonable care by the Enterprise.&#160; In addition, the knowledge and/or actions, or failure to act, of any director, officer, agent or employee of the Enterprise shall not be imputed to Indemnitee for purposes of determining the right to
              indemnification under this Agreement.&#160; Whether or not the foregoing provisions of this <font style="font-family: 'Times New Roman';"><u>Section 6(e)</u></font> are satisfied, it shall in any event be presumed that Indemnitee has at all times
              acted in good faith and in a manner he reasonably believed to be in or not opposed to the best interests of the Company.&#160; Anyone seeking to overcome this presumption shall have the burden of proof and the burden of persuasion by clear and
              convincing evidence.</font></font></div>
        <div style="font-size: 10pt;">&#160;</div>
        <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
          <div class="BRPFPageNumberArea" style="text-align: center;"><font style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">6</font></div>
          <div class="BRPFPageBreak" style="page-break-after: always;">
            <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
        </div>
        <div style="text-align: justify; text-indent: 108pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(f)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman';">If the person, persons or entity
              empowered or selected under <font style="font-family: 'Times New Roman';"><u>Section 6</u></font> to determine whether Indemnitee is entitled to indemnification shall not have made a determination within sixty (60) days after receipt by the
              Company of the request therefor, the requisite determination of entitlement to indemnification shall be deemed to have been made and Indemnitee shall be entitled to such indemnification absent (i) a misstatement by Indemnitee of a material
              fact, or an omission of a material fact necessary to make Indemnitee&#8217;s statement not materially misleading, in connection with the request for indemnification, or (ii) a prohibition of such indemnification under applicable law; provided,
              however, that such 60-day period may be extended for a reasonable time, not to exceed an additional thirty (30) days, if the person, persons or entity making such determination with respect to entitlement to indemnification in good faith
              requires such additional time to obtain or evaluate documentation and/or information relating thereto; and provided, further, that the foregoing provisions of this <font style="font-family: 'Times New Roman';"><u>Section 6(g)</u></font>
              shall not apply if the determination of entitlement to indemnification is to be made by the stockholders pursuant to <font style="font-family: 'Times New Roman';"><u>Section 6(b)</u></font> of this Agreement and if (A) within fifteen (15)
              days after receipt by the Company of the request for such determination, the Board of Directors or the Disinterested Directors, if appropriate, resolve to submit such determination to the stockholders for their consideration at an annual
              meeting thereof to be held within seventy-five (75) days after such receipt and such determination is made thereat, or (B) a special meeting of stockholders is called within fifteen (15) days after such receipt for the purpose of making such
              determination, such meeting is held for such purpose within sixty (60) days after having been so called and such determination is made thereat.</font></font></div>
        <div style="font-size: 10pt;">&#160;</div>
        <div style="text-align: justify; text-indent: 108pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(g)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman';">Indemnitee shall cooperate with
              the person, persons or entity making such determination with respect to Indemnitee&#8217;s entitlement to indemnification, including providing to such person, persons or entity upon reasonable advance request any documentation or information which
              is not privileged or otherwise protected from disclosure and which is reasonably available to Indemnitee and reasonably necessary to such determination.&#160; Any Independent Counsel, member of the Board of Directors or stockholder of the Company
              shall act reasonably and in good faith in making a determination regarding the Indemnitee&#8217;s entitlement to indemnification under this Agreement.&#160; Any costs or expenses (including attorneys&#8217; fees and disbursements) incurred by Indemnitee in so
              cooperating with the person, persons or entity making such determination shall be borne by the Company (irrespective of the determination as to Indemnitee&#8217;s entitlement to indemnification) and the Company hereby indemnifies and agrees to hold
              Indemnitee harmless therefrom.</font></font></div>
        <div style="font-size: 10pt;">&#160;</div>
        <div style="text-align: justify; text-indent: 108pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(h)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman';">The Company acknowledges that a
              settlement or other disposition short of final judgment may be successful if it permits a party to avoid expense, delay, distraction, disruption and uncertainty.&#160; In the event that any action, claim or proceeding to which Indemnitee is a
              party is resolved in any manner other than by adverse judgment against Indemnitee (including, without limitation, settlement of such action, claim or proceeding with or without payment of money or other consideration) it shall be presumed
              that Indemnitee has been successful on the merits or otherwise in such action, suit or proceeding.&#160; Anyone seeking to overcome this presumption shall have the burden of proof and the burden of persuasion by clear and convincing evidence.</font></font></div>
        <div style="font-size: 10pt;">&#160;</div>
        <div style="text-align: justify; text-indent: 108pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(i)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman';">The termination of any Proceeding
              or of any claim, issue or matter therein, by judgment, order, settlement or conviction, or upon a plea of nolo contendere or its equivalent, shall not (except as otherwise expressly provided in this Agreement) of itself adversely affect the
              right of Indemnitee to indemnification or create a presumption that Indemnitee did not act in good faith and in a manner which he reasonably believed to be in or not opposed to the best interests of the Company or, with respect to any
              criminal Proceeding, that Indemnitee had reasonable cause to believe that his conduct was unlawful.</font></font></div>
        <div style="font-size: 10pt;">&#160;</div>
        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div class="BRPFPageNumberArea" style="text-align: center;"><font style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">7</font></div>
          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
        </div>
        <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">7.</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman';"><font style="font-family: 'Times New Roman';"><u>Remedies of Indemnitee</u></font>.</font></font></div>
        <div style="font-size: 10pt;">&#160;</div>
        <div style="text-align: justify; text-indent: 108pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(a)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman';">In the event that (i) a
              determination is made pursuant to <font style="font-family: 'Times New Roman';"><u>Section 6</u></font> of this Agreement that Indemnitee is not entitled to indemnification under this Agreement, (ii) advancement of Expenses is not timely
              made pursuant to <font style="font-family: 'Times New Roman';"><u>Section 5</u></font> of this Agreement, (iii) no determination of entitlement to indemnification is made pursuant to <font style="font-family: 'Times New Roman';"><u>Section
                  6(b)</u></font> of this Agreement within 90 days after receipt by the Company of the request for indemnification, (iv) payment of indemnification is not made pursuant to this Agreement within ten (10) days after receipt by the Company of
              a written request therefor or (v) payment of indemnification is not made within ten (10) days after a determination has been made that Indemnitee is entitled to indemnification or such determination is deemed to have been made pursuant to <font style="font-family: 'Times New Roman';"><u>Section 6</u></font> of this Agreement, Indemnitee shall be entitled to an adjudication in an appropriate court of the State of Delaware, or in any other court of competent jurisdiction, of
              Indemnitee&#8217;s entitlement to such indemnification.&#160; Indemnitee shall commence such proceeding seeking an adjudication within 180 days following the date on which Indemnitee first has the right to commence such proceeding pursuant to this <font style="font-family: 'Times New Roman';"><u>Section 7(a)</u></font>.&#160; The Company shall not oppose Indemnitee&#8217;s right to seek any such adjudication.</font></font></div>
        <div style="font-size: 10pt;">&#160;</div>
        <div style="text-align: justify; text-indent: 108pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(b)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman';">In the event that a determination
              shall have been made pursuant to <font style="font-family: 'Times New Roman';"><u>Section 6(b)</u></font> of this Agreement that Indemnitee is not entitled to indemnification, any judicial proceeding commenced pursuant to this <font style="font-family: 'Times New Roman';"><u>Section 7</u></font> shall be conducted in all respects as a de novo trial on the merits, and Indemnitee shall not be prejudiced by reason of the adverse determination under <font style="font-family: 'Times New Roman';"><u>Section 6(b)</u></font>.</font></font></div>
        <div style="font-size: 10pt;">&#160;</div>
        <div style="text-align: justify; text-indent: 108pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(c)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman';">If a determination shall have been
              made pursuant to <font style="font-family: 'Times New Roman';"><u>Section 6(b)</u></font> of this Agreement that Indemnitee is entitled to indemnification, the Company shall be bound by such determination in any judicial proceeding commenced
              pursuant to this <font style="font-family: 'Times New Roman';"><u>Section 7</u></font>, absent (i) a misstatement by Indemnitee of a material fact, or an omission of a material fact necessary to make Indemnitee&#8217;s misstatement not materially
              misleading in connection with the application for indemnification, or (ii) a prohibition of such indemnification under applicable law.</font></font></div>
        <div style="font-size: 10pt;">&#160;</div>
        <div style="text-align: justify; text-indent: 108pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(d)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman';">In the event that Indemnitee,
              pursuant to this <font style="font-family: 'Times New Roman';"><u>Section 7</u></font>, seeks a judicial adjudication of his rights under, or to recover damages for breach of, this Agreement, or to recover under any directors&#8217; and officers&#8217;
              liability insurance policies maintained by the Company, the Company shall pay on his behalf, in advance, any and all expenses (of the types described in the definition of Expenses in <font style="font-family: 'Times New Roman';"><u>Section
                  13</u></font> of this Agreement) actually and reasonably incurred by him in such judicial adjudication, regardless of whether Indemnitee ultimately is determined to be entitled to such indemnification, advancement of expenses or insurance
              recovery.</font></font></div>
        <div style="font-size: 10pt;">&#160;</div>
        <div style="text-align: justify; text-indent: 108pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(e)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';">The Company shall be precluded from
              asserting in any judicial proceeding commenced pursuant to this <font style="font-family: 'Times New Roman';"><u>Section 7</u></font> that the procedures and presumptions of this Agreement are not valid, binding and enforceable and shall
              stipulate in any such court that the Company is bound by all the provisions of this Agreement.&#160; The Company shall indemnify Indemnitee against any and all Expenses and, if requested by Indemnitee, shall (within ten (10) days after receipt by
              the Company of a written request therefore) advance, to the extent not prohibited by law, such expenses to Indemnitee, which are incurred by Indemnitee in connection with any action brought by Indemnitee for indemnification or advance of
              Expenses from the Company under this Agreement or under any directors&#8217; and officers&#8217; liability insurance policies maintained by the Company, regardless of whether Indemnitee ultimately is determined to be entitled to such indemnification,
              advancement of Expenses or insurance recovery, as the case may be.</font></font></div>
        <div style="font-size: 10pt;">&#160;</div>
        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div class="BRPFPageNumberArea" style="text-align: center;"><font style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">8</font></div>
          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
        </div>
        <div style="text-align: justify; text-indent: 108pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(f)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman';">Notwithstanding anything in this
              Agreement to the contrary, no determination as to entitlement to indemnification under this Agreement shall be required to be made prior to the final disposition of the Proceeding.</font></font></div>
        <div style="font-size: 10pt;">&#160;</div>
        <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">8.</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman';"><font style="font-family: 'Times New Roman';"><u>Non-Exclusivity; Survival of Rights; Insurance; Primacy of Indemnification; Subrogation</u></font>.</font></font></div>
        <div style="font-size: 10pt;">&#160;</div>
        <div style="text-align: justify; text-indent: 108pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(a)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman';">The rights of indemnification as
              provided by this Agreement shall not be deemed exclusive of any other rights to which Indemnitee may at any time be entitled under applicable law, the Certificate of Incorporation, the Bylaws, any agreement, a vote of stockholders, a
              resolution of directors or otherwise.&#160; No amendment, alteration or repeal of this Agreement or of any provision hereof shall limit or restrict any right of Indemnitee under this Agreement in respect of any action taken or omitted by such
              Indemnitee in his Corporate Status prior to such amendment, alteration or repeal.&#160; To the extent that a change in the DGCL, whether by statute or judicial decision, permits greater indemnification than would be afforded currently under the
              Bylaws and this Agreement, it is the intent of the parties hereto that Indemnitee shall enjoy by this Agreement the greater benefits so afforded by such change.&#160; No right or remedy herein conferred is intended to be exclusive of any other
              right or remedy, and every other right and remedy shall be cumulative and in addition to every other right and remedy given hereunder or now or hereafter existing at law or in equity or otherwise.&#160; The assertion or employment of any right or
              remedy hereunder, or otherwise, shall not prevent the concurrent assertion or employment of any other right or remedy.</font></font></div>
        <div style="font-size: 10pt;">&#160;</div>
        <div style="text-align: justify; text-indent: 108pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(b)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman';">To the extent that the Company
              maintains an insurance policy or policies providing liability insurance for directors, officers, employees, or agents or fiduciaries of the Company or of any other corporation, partnership, joint venture, trust, employee benefit plan or other
              enterprise that such person serves at the request of the Company, Indemnitee shall be covered by such policy or policies in accordance with its or their terms to the maximum extent of the coverage available for any director, officer,
              employee, agent or fiduciary under such policy or policies.&#160; If, at the time of the receipt of a notice of a claim pursuant to the terms hereof, the Company has director and officer liability insurance in effect, the Company shall give prompt
              notice of the commencement of such proceeding to the insurers in accordance with the procedures set forth in the respective policies.&#160; The Company shall thereafter take all necessary or desirable action to cause such insurers to pay, on
              behalf of the Indemnitee, all amounts payable as a result of such proceeding in accordance with the terms of such policies.</font></font></div>
        <div style="font-size: 10pt;">&#160;</div>
        <div style="text-align: justify; text-indent: 108pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(c)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman';">In the event of any payment under
              this Agreement, the Company shall be subrogated to the extent of such payment to all of the rights of recovery of Indemnitee, who shall execute all papers required and take all action necessary to secure such rights, including execution of
              such documents as are necessary to enable the Company to bring suit to enforce such rights.</font></font></div>
        <div style="font-size: 10pt;">&#160;</div>
        <div style="text-align: justify; text-indent: 108pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(d)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman';">The Company shall not be liable
              under this Agreement to make any payment of amounts otherwise indemnifiable hereunder if and to the extent that Indemnitee has otherwise actually received such payment under any insurance policy, contract, agreement or otherwise.</font></font></div>
        <div style="font-size: 10pt;">&#160;</div>
        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div class="BRPFPageNumberArea" style="text-align: center;"><font style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">9</font></div>
          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
        </div>
        <div style="text-align: justify; text-indent: 108pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(e)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman';">The Company&#8217;s obligation to
              indemnify or advance Expenses hereunder to Indemnitee who is or was serving at the request of the Company as a director, officer, employee or agent of any other corporation, partnership, joint venture, trust, employee benefit plan or other
              enterprise shall be reduced by any amount Indemnitee has actually received as indemnification or advancement of expenses from such other corporation, partnership, joint venture, trust, employee benefit plan or other enterprise.</font></font></div>
        <div style="font-size: 10pt;">&#160;</div>
        <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">9.</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman';"><font style="font-family: 'Times New Roman';"><u>Exception to Right of Indemnification</u></font>.&#160; Notwithstanding any provision in this Agreement, the Company shall not be obligated under this Agreement to make any indemnity in connection with any claim made against
              Indemnitee:</font></font></div>
        <div style="font-size: 10pt;">&#160;</div>
        <div style="text-align: justify; text-indent: 108pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(a)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman';">for which payment has actually
              been made to or on behalf of Indemnitee under any insurance policy or other indemnity provision, except with respect to any excess beyond the amount paid under any insurance policy or other indemnity provision; or</font></font></div>
        <div style="font-size: 10pt;">&#160;</div>
        <div style="text-align: justify; text-indent: 108pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(b)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman';">for an accounting of profits made
              from the purchase and sale (or sale and purchase) by Indemnitee of securities of the Company within the meaning of Section 16(b) of the Securities Exchange Act of 1934, as amended, or similar provisions of state statutory law or common law;
              or</font></font></div>
        <div style="font-size: 10pt;">&#160;</div>
        <div style="text-align: justify; text-indent: 108pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(c)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman';">in connection with any Proceeding
              (or any part of any Proceeding) initiated by Indemnitee, including any Proceeding (or any part of any Proceeding) initiated by Indemnitee against the Company or its directors, officers, employees or other indemnitees, unless (i) the Board of
              Directors of the Company authorized the Proceeding (or any part of any Proceeding) prior to its initiation or (ii) the Company provides the indemnification, in its sole discretion, pursuant to the powers vested in the Company under applicable
              law.</font></font></div>
        <div style="font-size: 10pt;">&#160;</div>
        <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">10.</font><font style="font-size: 10pt;"> &#160;&#160; &#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';"><font style="font-family: 'Times New Roman';"><u>Duration of Agreement</u></font>.&#160; All agreements and obligations of the Company contained herein shall continue during the period Indemnitee is an officer or director of the Company (or is or was serving at the request of
              the Company as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise) and shall continue thereafter so with respect to any Proceeding (or any proceeding commenced under <font style="font-family: 'Times New Roman';"><u>Section 7</u></font> hereof) by reason of his Corporate Status, whether or not he is acting or serving in any such capacity at the time any liability or expense is incurred for which
              indemnification can be provided under this Agreement.&#160; This Agreement shall be binding upon and inure to the benefit of and be enforceable by the parties hereto and their respective successors (including any direct or indirect successor by
              purchase, merger, consolidation or otherwise to all or substantially all of the business or assets of the Company), assigns, spouses, heirs, executors and personal and legal representatives.</font></font></div>
        <div style="font-size: 10pt;">&#160;</div>
        <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">11.</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';"><font style="font-family: 'Times New Roman';"><u>Security</u></font>.&#160; To the extent requested by Indemnitee and approved by the Board of Directors of the Company, the Company may at any time and from time to time provide security to Indemnitee for the Company&#8217;s
              obligations hereunder through an irrevocable bank line of credit, funded trust or other collateral.&#160; Any such security, once provided to Indemnitee, may not be revoked or released without the prior written consent of the Indemnitee.</font></font></div>
        <div style="font-size: 10pt;">&#160;</div>
        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div class="BRPFPageNumberArea" style="text-align: center;"><font style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">10</font></div>
          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
        </div>
        <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">12.</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman';"><font style="font-family: 'Times New Roman';"><u>Enforcement</u></font>.</font></font></div>
        <div style="font-size: 10pt;">&#160;</div>
        <div style="text-align: justify; text-indent: 108pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(a)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman';">The Company expressly confirms and
              agrees that it has entered into this Agreement and assumes the obligations imposed on it hereby in order to induce Indemnitee to serve as an officer or director of the Company, and the Company acknowledges that Indemnitee is relying upon this
              Agreement in serving as an officer or director of the Company.</font></font></div>
        <div style="font-size: 10pt;">&#160;</div>
        <div style="text-align: justify; text-indent: 108pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(b)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';">This Agreement constitutes the
              entire agreement between the parties hereto with respect to the subject matter hereof and supersedes all prior agreements and understandings, oral, written and implied, between the parties hereto with respect to the subject matter hereof.</font></font></div>
        <div style="font-size: 10pt;">&#160;</div>
        <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">13.</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-family: 'Times New Roman';"><font style="font-family: 'Times New Roman';"><u>Definitions</u></font>.&#160; For purposes of this Agreement:</font></font></div>
        <div style="font-size: 10pt;">&#160;</div>
        <div style="text-align: justify; text-indent: 108pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(a)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160; &#160; &#160; <font style="font-family: 'Times New Roman';">&#8220;<font style="font-family: 'Times New Roman'; font-weight: bold;">Corporate Status</font>&#8221; describes the status of a person who is or was a director (or a person entitled to designate a director), officer, employee, agent or fiduciary of the Company or of any other
              corporation, partnership, joint venture, trust, employee benefit plan or other enterprise that such person is or was serving at the express written request of the Company.</font></font></div>
        <div style="font-size: 10pt;">&#160;</div>
        <div style="text-align: justify; text-indent: 108pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(b)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160; &#160; &#160;&#160;&#160; <font style="font-family: 'Times New Roman';">&#8220;<font style="font-family: 'Times New Roman'; font-weight: bold;">Disinterested Director</font>&#8221; means a director of the Company who is not and was not a party to the Proceeding in respect of which indemnification is sought by Indemnitee.</font></font></div>
        <div style="font-size: 10pt;">&#160;</div>
        <div style="text-align: justify; text-indent: 108pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(c)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';">&#8220;<font style="font-family: 'Times New Roman'; font-weight: bold;">Enterprise</font>&#8221; means the Company and any other corporation, partnership, joint venture, trust, employee benefit plan or other enterprise that Indemnitee is or was serving at the express written request of
              the Company as a director, officer, employee, agent or fiduciary.</font></font></div>
        <div style="font-size: 10pt;">&#160;</div>
        <div style="text-align: justify; text-indent: 108pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(d)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';">&#8220;<font style="font-family: 'Times New Roman'; font-weight: bold;">Expenses</font>&#8221; shall include all reasonable attorneys&#8217; fees, retainers, court costs, transcript costs, fees of experts, witness fees, travel expenses, duplicating costs, printing and binding costs,
              telephone charges, postage, delivery service fees and all other disbursements or expenses of the types customarily incurred in connection with prosecuting, defending, preparing to prosecute or defend, investigating, participating, or being or
              preparing to be a witness in a Proceeding, or responding to, or objecting to, a request to provide discovery in any Proceeding.&#160; Expenses also shall include Expenses incurred in connection with any appeal resulting from any Proceeding and any
              federal, state, local or foreign taxes imposed on the Indemnitee as a result of the actual or deemed receipt of any payments under this Agreement, including without limitation the premium, security for, and other costs relating to any cost
              bond, supersede as bond, or other appeal bond or its equivalent.&#160; Expenses, however, shall not include amounts paid in settlement by Indemnitee or the amount of judgments or fines against Indemnitee.</font></font></div>
        <div style="font-size: 10pt;">&#160;</div>
        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div class="BRPFPageNumberArea" style="text-align: center;"><font style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">11</font></div>
          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
        </div>
        <div style="text-align: justify; text-indent: 108pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(e)</font><font style="font-size: 10pt;">&#160;&#160;&#160; &#160; &#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';">&#8220;<font style="font-family: 'Times New Roman'; font-weight: bold;">Independent Counsel</font>&#8221; means a law firm, or a member of a law firm, that is experienced in matters of corporation law and neither presently is, nor in the past five years has been, retained to
              represent:&#160; (i) the Company or Indemnitee in any matter material to either such party (other than with respect to matters concerning Indemnitee under this Agreement, or of other indemnitees under similar indemnification agreements), or (ii)
              any other party to the Proceeding giving rise to a claim for indemnification hereunder.&#160; Notwithstanding the foregoing, the term &#8220;Independent Counsel&#8221; shall not include any person who, under the applicable standards of professional conduct
              then prevailing, would have a conflict of interest in representing either the Company or Indemnitee in an action to determine Indemnitee&#8217;s rights under this Agreement.&#160; The Company agrees to pay the reasonable fees of the Independent Counsel
              referred to above and to fully indemnify such counsel against any and all Expenses, claims, liabilities and damages arising out of or relating to this Agreement or its engagement pursuant hereto.</font></font></div>
        <div style="font-size: 10pt;">&#160;</div>
        <div style="text-align: justify; text-indent: 108pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(f)</font><font style="font-size: 10pt;">&#160;&#160;&#160; &#160;&#160; &#160;&#160;&#160; <font style="font-family: 'Times New Roman';">&#8220;<font style="font-family: 'Times New Roman'; font-weight: bold;">Proceeding</font>&#8221; includes any threatened, pending or completed action, suit, arbitration, alternate dispute resolution mechanism, investigation, inquiry, administrative hearing or any other actual,
              threatened or completed proceeding, whether brought by or in the right of the Company or otherwise and whether civil, criminal, administrative or investigative, in which Indemnitee was, is or will be involved as a party or otherwise, by
              reason of the fact that Indemnitee is or was an officer or director of the Company (or designated a director), by reason of any action taken by him or of any inaction on his part while acting as an officer or director of the Company, or by
              reason of the fact that he is or was serving at the request of the Company as a director, officer, employee, agent or fiduciary of another corporation, partnership, joint venture, trust or other Enterprise; in each case whether or not he is
              acting or serving in any such capacity at the time any liability or expense is incurred for which indemnification can be provided under this Agreement; including one pending on or before the date of this Agreement, but excluding one initiated
              by an Indemnitee pursuant to <font style="font-family: 'Times New Roman';"><u>Section 7</u></font> of this Agreement to enforce his rights under this Agreement.</font></font></div>
        <div style="font-size: 10pt;">&#160;</div>
        <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">14.</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';"><font style="font-family: 'Times New Roman';"><u>Severability</u></font>.&#160; The invalidity or unenforceability of any provision hereof shall in no way affect the validity or enforceability of any other provision.&#160; Without limiting the generality of the foregoing, this Agreement
              is intended to confer upon Indemnitee indemnification rights to the fullest extent permitted by applicable laws.&#160; In the event any provision hereof conflicts with any applicable law, such provision shall be deemed modified, consistent with
              the aforementioned intent, to the extent necessary to resolve such conflict.</font></font></div>
        <div style="font-size: 10pt;">&#160;</div>
        <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">15.</font><font style="font-size: 10pt;">&#160;&#160;&#160; &#160;&#160; &#160; <font style="font-family: 'Times New Roman';"><font style="font-family: 'Times New Roman';"><u>Modification and Waiver</u></font>.&#160; No supplement, modification, termination or amendment of this Agreement shall be binding unless executed in writing by both of the parties hereto.&#160; No waiver of any of the provisions of
              this Agreement shall be deemed or shall constitute a waiver of any other provisions hereof (whether or not similar) nor shall such waiver constitute a continuing waiver.</font></font></div>
        <div style="font-size: 10pt;">&#160;</div>
        <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">16.</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';"><font style="font-family: 'Times New Roman';"><u>Notice By Indemnitee</u></font>.&#160; Indemnitee agrees promptly to notify the Company in writing upon being served with or otherwise receiving any summons, citation, subpoena, complaint, indictment, information or other
              document relating to any Proceeding or matter which may be subject to indemnification covered hereunder.&#160; The failure to so notify the Company shall not relieve the Company of any obligation which it may have to Indemnitee under this
              Agreement or otherwise unless and only to the extent that such failure or delay materially prejudices the Company.</font></font></div>
        <div style="font-size: 10pt;">&#160;</div>
        <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
          <div class="BRPFPageNumberArea" style="text-align: center;"><font style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">12</font></div>
          <div style="page-break-after: always;" class="BRPFPageBreak">
            <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
        </div>
        <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">17.</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160; &#160;&#160; &#160; <font style="font-family: 'Times New Roman';"><font style="font-family: 'Times New Roman';"><u>Notices</u></font>.&#160; All notices and other communications given or made pursuant to this Agreement shall be in writing and shall be deemed effectively given:&#160; (a) upon personal delivery to the party to be notified, (b) when
              sent by confirmed electronic mail or facsimile if sent during normal business hours of the recipient, and if not so confirmed, then on the next business day, (c) five (5) days after having been sent by registered or certified mail, return
              receipt requested, postage prepaid, or (d) one (1) day after deposit with a nationally recognized overnight courier, specifying next day delivery, with written verification of receipt.&#160; All communications shall be sent:</font></font></div>
        <div style="font-size: 10pt;">&#160;</div>
        <div style="text-align: justify; text-indent: 108pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(a)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160; <font style="font-family: 'Times New Roman';">To Indemnitee at the address set
              forth below Indemnitee signature hereto.</font></font></div>
        <div style="font-size: 10pt;">&#160;</div>
        <div style="text-align: justify; text-indent: 108pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">(b)</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160; <font style="font-family: 'Times New Roman';">To the Company at:</font></font></div>
        <div style="font-size: 10pt;">&#160;</div>
        <div style="text-align: left; margin-left: 144pt; font-family: 'Times New Roman'; font-size: 10pt;">&#160;ADMA Biologics, Inc.<font style="font-family: 'Times New Roman';"><br>
          </font>&#160;465 State Route 17</div>
        <div style="text-align: left; margin-left: 144pt; font-family: 'Times New Roman'; font-size: 10pt;">&#160;Ramsey, New Jersey 07446</div>
        <div style="text-align: left; margin-left: 144pt; font-family: 'Times New Roman'; font-size: 10pt;">&#160;Attention:&#160; President and Chief Executive Officer</div>
        <div style="font-size: 10pt;">&#160;</div>
        <div style="text-align: justify; font-family: 'Times New Roman'; font-size: 10pt;">or to such other address as may have been furnished to Indemnitee by the Company or to the Company by Indemnitee, as the case may be.</div>
        <div style="font-size: 10pt;">&#160;</div>
        <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">18.</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';"><font style="font-family: 'Times New Roman';"><u>Counterparts</u></font>.&#160; This Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same Agreement.&#160; This Agreement may also be
              executed and delivered by facsimile signature and in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument.</font></font></div>
        <div style="font-size: 10pt;">&#160;</div>
        <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">19.</font><font style="font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';"><font style="font-family: 'Times New Roman';"><u>Headings</u></font>.&#160; The headings of the paragraphs of this Agreement are inserted for convenience only and shall not be deemed to constitute part of this Agreement or to affect the construction thereof.</font></font></div>
        <div style="font-size: 10pt;">&#160;</div>
        <div style="text-align: justify; text-indent: 72pt;"><font style="font-size: 10pt; font-family: 'Times New Roman';">20.</font><font style="font-size: 10pt;">&#160; &#160; &#160;&#160;&#160;&#160; <font style="font-family: 'Times New Roman';"><font style="font-family: 'Times New Roman';"><u>Governing Law and Consent to Jurisdiction</u></font>.&#160; This Agreement and the legal relations among the parties shall be governed by, and construed and enforced in accordance with, the laws of the State of Delaware, without
              regard to its conflict of laws rules.&#160; The Company and Indemnitee hereby irrevocably and unconditionally (i) agree that any action or proceeding arising out of or in connection with this Agreement shall be brought only in the Chancery Court
              of the State of Delaware (the &#8220;<font style="font-family: 'Times New Roman'; font-weight: bold;">Delaware Court</font>&#8221;), and not in any other state or federal court in the United States of America or any court in any other country, (ii)
              consent to submit to the exclusive jurisdiction of the Delaware Court for purposes of any action or proceeding arising out of or in connection with this Agreement, (iii) waive any objection to the laying of venue of any such action or
              proceeding in the Delaware Court, and (iv) waive, and agree not to plead or to make, any claim that any such action or proceeding brought in the Delaware Court has been brought in an improper or inconvenient forum.</font></font></div>
        <div style="font-size: 10pt;">&#160;</div>
        <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; font-weight: bold;">SIGNATURE PAGE TO FOLLOW</div>
        <div style="font-size: 10pt;">&#160;</div>
        <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
          <div class="BRPFPageNumberArea" style="text-align: center;"><font style="font-family: 'Times New Roman'; font-size: 8pt; font-weight: normal; font-style: normal;">13</font></div>
          <div class="BRPFPageBreak" style="page-break-after: always;">
            <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
        </div>
        <div style="text-align: justify; text-indent: 72pt; font-family: 'Times New Roman'; font-size: 10pt;">IN WITNESS WHEREOF, the parties hereto have executed this Indemnification Agreement on and as of the day and year below written.</div>
        <div style="font-size: 10pt;">&#160;</div>
        <table cellspacing="0" cellpadding="0" border="0" id="zaa8f6ee1f29d4c37a7867847c3cffca1" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">

            <tr>
              <td style="width: 50%; vertical-align: top; font-size: 10pt;">&#160;</td>
              <td style="vertical-align: top; font-size: 10pt;" colspan="2">
                <div style="text-align: left; font-family: 'Times New Roman'; font-weight: bold;">ADMA BIOLOGICS, INC.</div>
              </td>
            </tr>
            <tr>
              <td style="width: 50%; vertical-align: top; font-size: 10pt;">&#160;</td>
              <td style="width: 5%; vertical-align: top; font-size: 10pt;">&#160;</td>
              <td style="width: 45%; vertical-align: top; font-size: 10pt;">&#160;</td>
            </tr>
            <tr>
              <td style="width: 50%; vertical-align: top; font-size: 10pt; padding-bottom: 2px;">&#160;</td>
              <td style="width: 5%; vertical-align: top; font-size: 10pt; padding-bottom: 2px;">
                <div style="text-align: left; font-family: 'Times New Roman';">By:</div>
              </td>
              <td style="width: 45%; vertical-align: top; font-size: 10pt; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
            </tr>
            <tr>
              <td style="width: 50%; vertical-align: top; font-size: 10pt;">&#160;</td>
              <td style="width: 5%; vertical-align: top; font-size: 10pt;">
                <div style="text-align: left; font-family: 'Times New Roman';">Name:</div>
              </td>
              <td style="width: 45%; vertical-align: top; font-size: 10pt;">&#160;</td>
            </tr>
            <tr>
              <td style="width: 50%; vertical-align: top; font-size: 10pt;">&#160;</td>
              <td style="width: 5%; vertical-align: top; font-size: 10pt;">
                <div style="text-align: left; font-family: 'Times New Roman';">Title:</div>
              </td>
              <td style="width: 45%; vertical-align: top; font-size: 10pt;">&#160;</td>
            </tr>
            <tr>
              <td style="width: 50%; vertical-align: top; font-size: 10pt; padding-bottom: 2px;">&#160;</td>
              <td style="width: 5%; vertical-align: top; font-size: 10pt; padding-bottom: 2px;">
                <div style="text-align: left; font-family: 'Times New Roman';">Date:</div>
              </td>
              <td style="width: 45%; vertical-align: top; font-size: 10pt; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
            </tr>
            <tr>
              <td style="width: 50%; vertical-align: top; font-size: 10pt;">&#160;</td>
              <td style="width: 5%; vertical-align: top; font-size: 10pt;">&#160;</td>
              <td style="width: 45%; vertical-align: top; font-size: 10pt;">&#160;</td>
            </tr>
            <tr>
              <td style="width: 50%; vertical-align: top; font-size: 10pt;">&#160;</td>
              <td style="vertical-align: top; font-size: 10pt;" colspan="2">
                <div style="text-align: left; font-family: 'Times New Roman'; font-weight: bold;">INDEMNITEE</div>
              </td>
            </tr>
            <tr>
              <td style="width: 50%; vertical-align: top; font-size: 10pt;">&#160;</td>
              <td style="width: 5%; vertical-align: top; font-size: 10pt;">&#160;</td>
              <td style="width: 45%; vertical-align: top; font-size: 10pt;">&#160;</td>
            </tr>
            <tr>
              <td style="width: 50%; vertical-align: top; font-size: 10pt; padding-bottom: 2px;" rowspan="1">&#160;</td>
              <td style="width: 5%; vertical-align: top; font-size: 10pt; border-bottom: 2px solid rgb(0, 0, 0);" rowspan="1">&#160;</td>
              <td style="width: 45%; vertical-align: top; font-size: 10pt; border-bottom: 2px solid rgb(0, 0, 0);" rowspan="1">&#160;</td>
            </tr>
            <tr>
              <td style="width: 50%; vertical-align: top; font-size: 10pt;">&#160;</td>
              <td style="width: 5%; vertical-align: top; font-size: 10pt;">
                <div style="text-align: left; font-family: 'Times New Roman';">Name:</div>
              </td>
              <td style="width: 45%; vertical-align: top; font-size: 10pt;">&#160;</td>
            </tr>
            <tr>
              <td style="width: 50%; vertical-align: top; font-size: 10pt; padding-bottom: 2px;">&#160;</td>
              <td style="width: 5%; vertical-align: top; font-size: 10pt; padding-bottom: 2px;">
                <div style="text-align: left; font-family: 'Times New Roman';">Date:</div>
              </td>
              <td style="width: 45%; vertical-align: top; font-size: 10pt; border-bottom: 2px solid rgb(0, 0, 0);">&#160;</td>
            </tr>
            <tr>
              <td style="width: 50%; vertical-align: top; font-size: 10pt;">&#160;</td>
              <td style="width: 5%; vertical-align: top; font-size: 10pt;">&#160;</td>
              <td style="width: 45%; vertical-align: top; font-size: 10pt;">&#160;</td>
            </tr>
            <tr>
              <td style="width: 50%; vertical-align: top; font-size: 10pt;">&#160;</td>
              <td style="width: 5%; vertical-align: top; font-size: 10pt;">
                <div style="text-align: left; font-family: 'Times New Roman';">Address:</div>
              </td>
              <td style="width: 45%; vertical-align: top; font-size: 10pt;">&#160;</td>
            </tr>
            <tr>
              <td style="width: 50%; vertical-align: top; font-size: 10pt;">&#160;</td>
              <td style="width: 5%; vertical-align: top; font-size: 10pt;">&#160;</td>
              <td style="width: 45%; vertical-align: top; font-size: 10pt;">&#160;</td>
            </tr>
            <tr>
              <td style="width: 50%; vertical-align: top; font-size: 10pt;">&#160;</td>
              <td style="vertical-align: top;" colspan="2">
                <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">c/o ADMA Biologics, Inc.</div>
              </td>
            </tr>
            <tr>
              <td style="width: 50%; vertical-align: top; font-size: 10pt;">&#160;</td>
              <td style="vertical-align: top;" colspan="2">
                <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">465 State Route 17</div>
              </td>
            </tr>
            <tr>
              <td style="width: 50%; vertical-align: top; font-size: 10pt;">&#160;</td>
              <td style="vertical-align: top;" colspan="2">
                <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Ramsey, New Jersey 07446</div>
              </td>
            </tr>

        </table>
        <div style="font-size: 10pt;"><br>
        </div>
        <div style="font-size: 10pt;"><br>
        </div>
        <div style="font-size: 10pt; text-align: center;"><font style="font-family: 'Times New Roman'; font-size: 8pt; color: rgb(0, 0, 0); font-weight: normal; font-style: normal;">14</font></div>
        <div style="font-size: 10pt;">
          <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"></div>
      </div>
    </div>
  </div>
  <font style="font-size: 10pt;"> </font>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-19.1
<SEQUENCE>5
<FILENAME>ef20038923_ex19-1.htm
<DESCRIPTION>EXHIBIT 19.1
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Summit Financial
         Document created using Broadridge PROfile 25.2.1.5287
         Copyright 1995 - 2025 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">

  <div>
    <hr noshade="noshade" align="center" style="height: 4px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;">
    <div style="text-align: right;"> <font style="font-weight: bold;">Exhibit 19.1</font><br>
    </div>
    <div> <br>
      <div style="text-align: justify;">Effective September 2024</div>
      <div>&#160;</div>
      <div>
        <div style="text-align: center; text-indent: 36pt; font-weight: bold;">INSIDER TRADING POLICY</div>
        <div>&#160;</div>
        <div style="text-align: justify;">ADMA has adopted the policies and procedures described herein in order to prevent insider trading. The Company prohibits trading based on Material Nonpublic Information regarding the Company or gained during the
          course of work for the Company.&#160; The policy covers all officers, directors, members of the scientific advisory board, employees, consultants, advisors and independent contractors of the Company (including all Company affiliates or subsidiaries)
          (collectively, &#8220;Covered Persons&#8221;), who may have access to Material Nonpublic Information.&#160;&#160; The Company has determined that &#8220;Access Persons&#8221; (as defined in this policy) are subject to the pre-clearance requirement described below because the
          Company believes those Access Persons have, or are likely to have, access to Material Nonpublic Information on a more frequent basis than other employees.&#160; The current list of Access Persons is maintained by the Insider Trading Compliance
          Officer, and such persons have been separately notified.&#160; This list of Access Persons is subject to change at the Insider Trading Compliance Officer&#8217;s discretion, and it will be updated periodically.&#160; Under special circumstances, certain persons
          not defined as an Access Person under this policy may come to have access to Material Nonpublic Information.&#160; During any period that a person is in possession of Material Nonpublic Information, that person will be deemed an Access Person and will
          be subject to the pre-clearance procedure described in this policy.</div>
        <div>&#160;</div>
        <div style="text-align: justify; font-weight: bold;">Applicability</div>
        <div>&#160;</div>
        <div style="text-align: justify;">This policy applies to all transactions in the Company&#8217;s securities, including common stock, options for stock, preferred stock, warrants, convertible debentures, and derivative securities relating to the Company&#8217;s
          stock (such as exchange-traded options), whether or not issued by the Company.&#160; This policy applies to all of the Company&#8217;s Covered Persons.&#160; This policy also applies to Family Members of Covered Persons.&#160; &#8220;Family Member&#8221; includes any spouse,
          partner, child, grandchild, parent, sibling, grandparent, family-in-law, step-family, guardian or caretaker, aunt, uncle, niece, nephew, cousin, any person living in the same household, and/or the spouse or partner of the foregoing individuals.
          For the avoidance of doubt, the definition of &#8220;Family Member&#8221; includes adoptive relationships.&#160; Covered Persons are responsible for compliance by their Family Members.</div>
        <div>&#160;</div>
        <div style="text-align: justify;">Violations of this policy can result in civil and criminal penalties, as well as discipline, or termination of employment or business relationship with the Company.</div>
        <div>&#160;</div>
        <div style="text-align: justify; font-weight: bold;">Material Nonpublic Information</div>
        <div>&#160;</div>
        <div style="text-align: justify;">Information is &#8220;Material Nonpublic Information&#8221; if: (1) there is a reasonable likelihood that the information would be considered important to an investor making an investment decision regarding the transaction of
          securities (&#8220;material information&#8221;), and (2) it has not been previously disclosed to the general public and is otherwise not available to the general public (&#8220;nonpublic information&#8221;).</div>
        <div>&#160;</div>
        <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
          <div class="BRPFPageBreak" style="page-break-after: always;">
            <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
        </div>
        <!--PROfilePageNumberReset%Num%2%%%-->
        <div style="text-align: justify;">The below categories of Company information (either positive or negative) are particularly sensitive and should be considered material information:</div>
        <div>&#160;</div>
        <table cellspacing="0" cellpadding="0" id="zd433df1c3a1b4907975e202f7196170c" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 36pt;"><br>
              </td>
              <td style="width: 18pt; vertical-align: top;">&#8226;</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>Financial results</div>
              </td>
            </tr>

        </table>
        <div>&#160;</div>
        <table cellspacing="0" cellpadding="0" id="ze233bdd4a0fc46b8b0f6016291d19bea" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 36pt;"><br>
              </td>
              <td style="width: 18pt; vertical-align: top;">&#8226;</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>Projections of future earnings or losses</div>
              </td>
            </tr>

        </table>
        <div>&#160;</div>
        <table cellspacing="0" cellpadding="0" id="z9b1a677be006479e8901377fe1e0c8a3" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 36pt;"><br>
              </td>
              <td style="width: 18pt; vertical-align: top;">&#8226;</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>News of a pending or proposed merger or acquisition</div>
              </td>
            </tr>

        </table>
        <div>&#160;</div>
        <table cellspacing="0" cellpadding="0" id="zecbb2a05c4a94bb5b9e59f6aa99ce73b" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 36pt;"><br>
              </td>
              <td style="width: 18pt; vertical-align: top;">&#8226;</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>News of the disposition of a subsidiary</div>
              </td>
            </tr>

        </table>
        <div>&#160;</div>
        <table cellspacing="0" cellpadding="0" id="z7ead755fb7344765a977652fb8eecc29" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 36pt;"><br>
              </td>
              <td style="width: 18pt; vertical-align: top;">&#8226;</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>Impending bankruptcy or financial liquidity problems</div>
              </td>
            </tr>

        </table>
        <div>&#160;</div>
        <table cellspacing="0" cellpadding="0" id="z905393f2cde84568b35ec6a476ddbc67" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 36pt;"><br>
              </td>
              <td style="width: 18pt; vertical-align: top;">&#8226;</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>Gain or loss of a substantial customer or supplier</div>
              </td>
            </tr>

        </table>
        <div>&#160;</div>
        <table cellspacing="0" cellpadding="0" id="z2e4dd097aa164540a4114ecd473c165a" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 36pt;"><br>
              </td>
              <td style="width: 18pt; vertical-align: top;">&#8226;</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>Procurement or loss of significant contracts</div>
              </td>
            </tr>

        </table>
        <div>&#160;</div>
        <table cellspacing="0" cellpadding="0" id="zb078321b98bc4cd2ba20d6535de860ac" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 36pt;"><br>
              </td>
              <td style="width: 18pt; vertical-align: top;">&#8226;</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>Status of significant projects/initiatives</div>
              </td>
            </tr>

        </table>
        <div>&#160;</div>
        <table cellspacing="0" cellpadding="0" id="z34baa40df9e44f9c9882678732fd6113" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 36pt;"><br>
              </td>
              <td style="width: 18pt; vertical-align: top;">&#8226;</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>Changes in dividend policy</div>
              </td>
            </tr>

        </table>
        <div>&#160;</div>
        <table cellspacing="0" cellpadding="0" id="za0b94aa4858448dc8d5570c2559c5249" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 36pt;"><br>
              </td>
              <td style="width: 18pt; vertical-align: top;">&#8226;</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>New product announcements of a significant nature</div>
              </td>
            </tr>

        </table>
        <div>&#160;</div>
        <table cellspacing="0" cellpadding="0" id="z28771cad2c2e4bcb9c26ab4575c812fd" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 36pt;"><br>
              </td>
              <td style="width: 18pt; vertical-align: top;">&#8226;</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>Results of any clinical trials</div>
              </td>
            </tr>

        </table>
        <div>&#160;</div>
        <table cellspacing="0" cellpadding="0" id="zf114f6262a674fbeafb89477b2e6d541" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 36pt;"><br>
              </td>
              <td style="width: 18pt; vertical-align: top;">&#8226;</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>Significant product defects or modifications</div>
              </td>
            </tr>

        </table>
        <div>&#160;</div>
        <table cellspacing="0" cellpadding="0" id="z80413438358840fc914594bb42d78e92" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 36pt;"><br>
              </td>
              <td style="width: 18pt; vertical-align: top;">&#8226;</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>Significant operations-related information</div>
              </td>
            </tr>

        </table>
        <div>&#160;</div>
        <table cellspacing="0" cellpadding="0" id="z54ce7a8de03641baa3aadbf776c719e9" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 36pt;"><br>
              </td>
              <td style="width: 18pt; vertical-align: top;">&#8226;</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>Significant pricing changes</div>
              </td>
            </tr>

        </table>
        <div>&#160;</div>
        <table cellspacing="0" cellpadding="0" id="z9bb186932aaa4b5e985a606fb2417167" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 36pt;"><br>
              </td>
              <td style="width: 18pt; vertical-align: top;">&#8226;</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>Stock splits</div>
              </td>
            </tr>

        </table>
        <div>&#160;</div>
        <table cellspacing="0" cellpadding="0" id="z60a98ba155244b19b60b8ebb56dea55d" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 36pt;"><br>
              </td>
              <td style="width: 18pt; vertical-align: top;">&#8226;</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>New equity or debt offerings</div>
              </td>
            </tr>

        </table>
        <div>&#160;</div>
        <table cellspacing="0" cellpadding="0" id="z85a8a2f5b34b487db94e1e112246ed20" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 36pt;"><br>
              </td>
              <td style="width: 18pt; vertical-align: top;">&#8226;</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>Potential for significant litigation exposure</div>
              </td>
            </tr>

        </table>
        <div>&#160;</div>
        <table cellspacing="0" cellpadding="0" id="z3bf35dbdb50d4ba88b673a1f230eaaa1" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 36pt;"><br>
              </td>
              <td style="width: 18pt; vertical-align: top;">&#8226;</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>Changes in senior management</div>
              </td>
            </tr>

        </table>
        <div>&#160;</div>
        <div style="text-align: justify; font-style: italic; font-weight: bold;">Applicability to Material Nonpublic Information Regarding Other Companies</div>
        <div>&#160;</div>
        <div style="text-align: justify;">This policy and the guidelines described herein also apply to Material Nonpublic Information relating to other companies, including the Company&#8217;s collaborative partners, customers, vendors, or suppliers
          (collectively, &#8220;business partners&#8221;), potential acquisition targets or acquirors, or competitors, when the Material Nonpublic Information is obtained in the course of employment or services performed for the Company, or otherwise obtained.&#160;
          Covered Persons must not engage in transactions of securities for the Company&#8217;s business partners or competitors while in possession of their Material Nonpublic Information.&#160; Moreover, Covered Persons must not engage in transactions of securities
          for any closely correlated or economically-linked business partners or competitors while in possession of Material Nonpublic Information about the Company (i.e., &#8220;shadow trading&#8221;).</div>
        <div>&#160;</div>
        <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
          <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-size: 8pt; color: rgb(0, 0, 0); font-weight: normal; font-style: normal; font-family: 'Times New Roman';">2</font></div>
          <div class="BRPFPageBreak" style="page-break-after: always;">
            <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
        </div>
        <div style="text-align: justify; font-weight: bold;">Designations for Covered Persons</div>
        <div>&#160;</div>
        <div style="text-align: justify;">The Company has determined that those persons identified on Exhibit 1 (&#8220;Section 16 Individuals&#8221;) are subject to the reporting and penalty provisions of Section 16 of the Securities Exchange Act of 1934, as amended
          (&#8220;Section 16&#8221;).&#160; The Company has determined that Section 16 Individuals are subject to the pre-clearance requirement described below because they are likely to have access to Material Nonpublic Information.</div>
        <div>&#160;</div>
        <div style="text-align: justify;">The Company has also determined that Access Persons who are not Section 16 Individuals are subject to the pre-clearance requirement described below because they are likely to have access to Material Nonpublic
          Information.&#160; The Insider Trading Compliance Officer may designate additional Access Persons, as necessary from time to time.&#160; During any period of time where someone not previously identified as an Access Person has access to Material Nonpublic
          Information, that person shall become an Access Person subject to additional provisions of this policy.</div>
        <div>&#160;</div>
        <div style="text-align: justify; font-weight: bold;">Considerations Related to Insider Trading</div>
        <div>&#160;</div>
        <div style="text-align: justify;">The Company prohibits the unauthorized disclosure of confidential information acquired while performing services for the Company and the misuse of Material Nonpublic Information in securities trading.&#160; Specific
          restrictions on securities trading are outlined below.</div>
        <div>&#160;</div>
        <div style="text-align: justify; margin-left: 36pt;">A.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-weight: bold;"><u>Prohibitions on Trading</u></font>.&#160; Covered Persons are prohibited from entering into any trade immediately after the Company has made a public
          announcement of material information, including earnings releases.&#160; Covered Persons must not engage in any transaction involving a purchase or sale of the Company&#8217;s securities from the date that they possess Material Nonpublic Information
          concerning the Company, until either (1) the passage of two full Trading Days following the public disclosure of that information, or (2) such time as that nonpublic information is no longer material.&#160; For example, if a public announcement is
          made on a Monday afternoon, Covered Persons may not make trades of Company securities until Thursday.&#160; &#8220;Trading Day&#8221; means a day on which national stock exchanges are open for trading, and a &#8220;full&#8221; Trading Day includes from market open to market
          close.</div>
        <div>&#160;</div>
        <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
          <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-size: 8pt; color: rgb(0, 0, 0); font-weight: normal; font-style: normal; font-family: 'Times New Roman';">3</font></div>
          <div class="BRPFPageBreak" style="page-break-after: always;">
            <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
        </div>
        <div style="text-align: justify; margin-left: 36pt;">B.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-weight: bold;"><u>Disclosure of Information to Others</u></font>. The Company is required to avoid the selective disclosure of Material Nonpublic Information.&#160; The
          Company has established procedures for releasing material information in a manner designed to achieve broad public dissemination of the information immediately upon its release.&#160; Covered Persons may not disclose material information to anyone
          outside the Company, including Family Members, relatives, friends, or acquaintances, other than in accordance with these procedures.&#160; Covered Persons may not disclose or discuss the Company&#8217;s confidential information or material information in
          any public forum, including internet blogs, posts, or other web forums, unless that Covered Person is authorized as a Company spokesperson in accordance with these procedures.</div>
        <div>&#160;</div>
        <div style="text-align: justify; margin-left: 36pt;">C.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-weight: bold;"><u>Confidentiality of Nonpublic Information</u></font>.&#160; The nondisclosure obligations under this policy are in addition to any confidentially
          obligations Covered Persons have to the Company.&#160; Nonpublic information relating to the Company is the property of the Company and the unauthorized disclosure of such information is strictly prohibited.</div>
        <div>&#160;</div>
        <div style="text-align: justify; margin-left: 36pt;">D.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-weight: bold;"><u>Appearance of Impropriety</u></font>.&#160; Covered Persons must also avoid transactions that may appear to be improper.</div>
        <div>&#160;</div>
        <div style="text-align: justify; margin-left: 36pt;">E.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-weight: bold;"><u>Twenty-Twenty Hindsight</u></font>.&#160; If securities transactions become subject to scrutiny, they will be viewed after-the-fact with the benefit of
          hindsight.&#160; As a result, before engaging in any transaction, Covered Persons should carefully consider how regulators and others might perceive their transactions after-the-fact.</div>
        <div>&#160;</div>
        <div style="text-align: justify; font-weight: bold;">Trading Restrictions</div>
        <div>&#160;</div>
        <div style="text-align: justify; margin-left: 36pt;">A.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-weight: bold;"><u>Prohibition on Trading During Blackout Periods</u></font>.&#160; The Company prohibits Covered Persons from buying or selling the Company&#8217;s securities
          during the quarterly blackout period unless they have established a pre-arranged trading plan that complies with Rule 10b5-1 (&#8220;Rule 10b5-1&#8221;) promulgated under the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;).&#160; Each blackout
          period begins on the 20th day of the last month of the fiscal quarter and continues until two full Trading Days have passed after the public release of quarterly results (or annual results in the case of the fourth quarter).</div>
        <div>&#160;</div>
        <div style="text-align: justify; margin-left: 36pt;">In addition, the Insider Trading Compliance Officer may designate additional blackout periods when Covered Persons may not purchase or sell Company securities.&#160; If the Insider Trading Compliance
          Officer declares a blackout period under this section of the policy, the Company will notify those Covered Persons to whom the blackout period applies when the blackout period begins and ends.&#160; The existence of an extended blackout period or
          event-specific blackout period is highly confidential and must not be disclosed by a Covered Person to any other person.</div>
        <div>&#160;</div>
        <div style="text-align: justify; margin-left: 36pt; font-size: 12pt;"><font style="font-size: 10pt; font-weight: bold; font-style: italic;">Trading on dates that are outside of blackout periods will not protect anyone with Material Nonpublic
            Information from liability.</font><font style="font-size: 10pt;">&#160; Although the Company may, from time to time, recommend that certain individuals stop trading in Company securities, each Covered Person is individually responsible at all times
            for compliance with the prohibitions against insider trading.&#160; Trading in the Company&#8217;s securities during periods that are outside of any blackout period should not be considered a &#8220;safe harbor&#8221; and all Covered Persons must use good judgment at
            all times.</font></div>
        <div>&#160;</div>
        <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
          <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-size: 8pt; color: rgb(0, 0, 0); font-weight: normal; font-style: normal; font-family: 'Times New Roman';">4</font></div>
          <div class="BRPFPageBreak" style="page-break-after: always;">
            <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
        </div>
        <div style="text-align: justify; margin-left: 36pt;">B.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-weight: bold;"><u>Pre-clearance of Trades</u></font>.&#160; Access Persons may not purchase, sell, or otherwise transact securities of the Company without obtaining prior
          clearance of the transaction via e-mail by the Insider Trading Compliance Officer.&#160; Access Persons are required to complete the Notice of Trading in Company Securities form to the Insider Trading Compliance Officer&#8217;s satisfaction, and may not
          trade absent such e-mail approval. The Insider Trading Compliance Officer will review the proposed transaction for compliance with regulatory requirements.&#160; The Insider Trading Compliance Officer may not trade Company securities without
          completing the Notice of Trading in Company Securities form and receiving approval from the President and Chief Executive Officer.</div>
        <div>&#160;</div>
        <div style="text-align: justify; margin-left: 36pt;">The Company may also find it necessary, from time to time, to require that certain Covered Persons who are not Access Persons comply with the pre-clearance process. At those times, those Covered
          Persons will be designated as Access Persons and notified when they begin being designated an Access Person as well as when they cease being designated as an Access Person.</div>
        <div>&#160;</div>
        <div style="text-align: justify; margin-left: 36pt;">C.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-weight: bold;"><u>Additional Requirements</u></font>.&#160; The Company has established the following additional policies for Covered Persons trading Company securities:</div>
        <div>&#160;</div>
        <table cellspacing="0" cellpadding="0" id="z2e6a842ad13c4abf87f3c785b23d4715" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 36pt;"><br>
              </td>
              <td style="width: 18pt; vertical-align: top;">&#8226;</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>Any Company stock purchased in the open market by a Covered Person must be held for a minimum of six months.&#160; Unless otherwise specified, this prohibition does not apply to the sale of: (a) stock acquired upon the exercise of stock
                  options, or (b) stock acquired under an employee stock purchase plan.</div>
              </td>
            </tr>

        </table>
        <div>&#160;</div>
        <table cellspacing="0" cellpadding="0" id="z7a86f15797fa4f22aa189c632b160b5d" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 36pt;"><br>
              </td>
              <td style="width: 18pt; vertical-align: top;">&#8226;</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>Covered Persons may not engage in short sales.&#160; &#8220;Short sales&#8221; of Company stock include borrowing Company stock, selling it, and then buying (or intending to buy) the stock again at a lower price to replace the borrowed shares within a
                  short period of time following the initial sale of the borrowed shares.</div>
              </td>
            </tr>

        </table>
        <div>&#160;</div>
        <table cellspacing="0" cellpadding="0" id="z02ad57bdf1b7492fbea0addad6217113" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 36pt;"><br>
              </td>
              <td style="width: 18pt; vertical-align: top;">&#8226;</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>Covered Persons may not purchase Company stock on margin.&#160; However, Covered Persons may establish loan accounts secured by Company stock.</div>
              </td>
            </tr>

        </table>
        <div>&#160;</div>
        <table cellspacing="0" cellpadding="0" id="z2f9550f41c184c3093c7617f9cc54a26" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 36pt;"><br>
              </td>
              <td style="width: 18pt; vertical-align: top;">&#8226;</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>Covered Persons may not buy or sell puts or calls for Company stock.&#160; &#8220;Puts&#8221; are options or rights to sell a specific stock at a specific price prior to a set date.&#160; &#8220;Calls&#8221; are options or rights to buy a specific stock at a specific
                  price prior to a set date.&#160; These transactions appear improper because they suggest that the Covered Person believes the price of Company stock will rise or fall.</div>
              </td>
            </tr>

        </table>
        <div>&#160;</div>
        <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
          <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-size: 8pt; color: rgb(0, 0, 0); font-weight: normal; font-style: normal; font-family: 'Times New Roman';">5</font></div>
          <div class="BRPFPageBreak" style="page-break-after: always;">
            <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
        </div>
        <div style="text-align: justify; margin-left: 36pt;">D.&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-weight: bold;"><u>Rule 10b5-1 Trading Programs</u></font>.&#160; Individuals may trade on Company securities in certain circumstances where it is clear that Material
          Nonpublic Information was not a factor in the decision to trade.&#160; Per Rule 10b5-1, an individual who buys or sells securities while aware of Material Nonpublic Information does not violate Rule 10b5 if buying or selling in conformity with a
          binding contract, instruction, or written plan that was put into place at a time when the individual was not aware of Material Nonpublic Information (also known as a &#8220;Rule 10b5-1 Trading Program&#8221;).&#160; This type of pre-arranged trading plan provides
          an opportunity to limit potential insider trading liability.</div>
        <div>&#160;</div>
        <div style="text-align: justify; margin-left: 36pt;">The Company permits only those Access Persons listed in Exhibit 1 and members of senior management determined by the Insider Trading Compliance Officer (collectively, &#8220;Eligible 10b5-1
          Participants&#8221;) to set up Rule 10b5-1 Trading Programs.&#160; However, these Rule 10b5-1 Trading Programs must be utilized carefully for the following reasons:</div>
        <div>&#160;</div>
        <table cellspacing="0" cellpadding="0" id="z0b1bccdf733d4eb1b30be596951da527" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 36pt;"><br>
              </td>
              <td style="width: 18pt; vertical-align: top;">&#8226;</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>In order to comply with Rule 10b5-1, binding contracts, instructions, and written plans must: (i) lock in the amount, price, and dates of future trades; (ii) provide a formula or algorithm for determining future trades; or (iii)
                  delegate discretion for determining amount, price and dates to a third party as provided under the rule.</div>
              </td>
            </tr>

        </table>
        <div>&#160;</div>
        <table cellspacing="0" cellpadding="0" id="z4cd26fa772954247892bad26f8593378" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 36pt;"><br>
              </td>
              <td style="width: 18pt; vertical-align: top;">&#8226;</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>It is risky to modify or terminate these arrangements.</div>
              </td>
            </tr>

        </table>
        <div>&#160;</div>
        <table cellspacing="0" cellpadding="0" id="zaa94ecb41a6d40f3ae5f2b68d0eb1c18" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 36pt;"><br>
              </td>
              <td style="width: 18pt; vertical-align: top;">&#8226;</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>Rule 10b5-1 does not eliminate other requirements and prohibitions under securities laws and transactions must also comply with, for example, reporting and short-swing profit rules under Section 16, limitations on insider selling
                  imposed by Rule 144 promulgated under the Securities Act of 1933, as amended (&#8220;Rule 144&#8221;), prohibitions on trading during administrative blackouts under pension plans, and any other requirements.</div>
              </td>
            </tr>

        </table>
        <div>&#160;</div>
        <table cellspacing="0" cellpadding="0" id="z0e4e03eb0c414ad890019598db97587b" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 36pt;"><br>
              </td>
              <td style="width: 18pt; vertical-align: top;">&#8226;</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>The liability avoidance provisions of Rule 10b5-1 are affirmative defenses in litigation, which means that the individual is required to prove that any trades were pursuant to a contract, instruction, or written plan compliant with
                  Rule 10b5-1.</div>
              </td>
            </tr>

        </table>
        <div>&#160;</div>
        <table cellspacing="0" cellpadding="0" id="z82216d75060e46eeabb757e897bc50c0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 36pt;"><br>
              </td>
              <td style="width: 18pt; vertical-align: top;">&#8226;</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>Compliance must be well-documented, keeping in mind the possibility of defending a legal action.</div>
              </td>
            </tr>

        </table>
        <div>&#160;</div>
        <div style="text-align: justify; margin-left: 36pt;">E.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-weight: bold;"><u>Establishing Rule 10b5-1 Trading Programs</u></font>.&#160; Eligible 10b5-1 Participants who wish to establish a Rule 10b5-1 Trading Program must ensure
          that:</div>
        <div>&#160;</div>
        <table cellspacing="0" cellpadding="0" id="zf0b1d0e860a642bfb3ef91ec45f8d70f" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 36pt;"><br>
              </td>
              <td style="width: 18pt; vertical-align: top;">&#8226;</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>the arrangement is a written contract;</div>
              </td>
            </tr>

        </table>
        <div>&#160;</div>
        <table cellspacing="0" cellpadding="0" id="z5b59accc5a3345ff9ef22d19b9cb8477" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 36pt;"><br>
              </td>
              <td style="width: 18pt; vertical-align: top;">&#8226;</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>the contract was reviewed and pre-approved by the Company&#8217;s Insider Trading Compliance Officer (or, if the Eligible 10b5-1 Participant is the Insider Trading Compliance Officer, the Board) prior to finalization;</div>
              </td>
            </tr>

        </table>
        <div>&#160;</div>
        <table cellspacing="0" cellpadding="0" id="z2ce30e88f0ef4daca537f049af538688" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 36pt;"><br>
              </td>
              <td style="width: 18pt; vertical-align: top;">&#8226;</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>the contract is entered into when the Eligible 10b5-1 Participant is not in possession of any Material Nonpublic Information and not subject to any blackout period;</div>
              </td>
            </tr>

        </table>
        <div>&#160;</div>
        <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
          <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-size: 8pt; color: rgb(0, 0, 0); font-weight: normal; font-style: normal; font-family: 'Times New Roman';">6</font></div>
          <div class="BRPFPageBreak" style="page-break-after: always;">
            <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
        </div>
        <table cellspacing="0" cellpadding="0" id="zf3b4060b0baf4a058ddeb5831ba357cc" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 36pt;"><br>
              </td>
              <td style="width: 18pt; vertical-align: top;">&#8226;</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>the Eligible 10b5-1 Participant does not cancel or make any changes to the contract while in possession of any Material Nonpublic Information or during any blackout period.&#160; All cancellations or amendments require advance, written
                  approval by the Company&#8217;s Insider Trading Compliance Officer (or, if the Eligible 10b5-1 Participant is the Insider Trading Compliance Officer, the Board); and</div>
              </td>
            </tr>

        </table>
        <div>&#160;</div>
        <table cellspacing="0" cellpadding="0" id="z014cbb0ae5874b4bb2d87aeb3fcfa93f" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 36pt;"><br>
              </td>
              <td style="width: 18pt; vertical-align: top;">&#8226;</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>the contract does one of the following:</div>
              </td>
            </tr>

        </table>
        <div>&#160;</div>
        <table cellspacing="0" cellpadding="0" id="z7ee8007524404a26b81fe0f9755262d3" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 54pt;"><br>
              </td>
              <td style="width: 18pt; vertical-align: top;">o</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>specifies the amount of securities to be purchased or sold (<font style="font-style: italic;">i.e.</font>, a set number of shares or a set dollar amount), including the price and date on which the securities are to be purchased or
                  sold;</div>
              </td>
            </tr>

        </table>
        <div>&#160;</div>
        <table cellspacing="0" cellpadding="0" id="za1d831c9b03c41e5b3c3b692c2b75464" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 54pt;"><br>
              </td>
              <td style="width: 18pt; vertical-align: top;">o</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>includes a written formula or algorithm for determining the amount of securities to be purchased or sold, and includes the price and date of their purchase or sale; or</div>
              </td>
            </tr>

        </table>
        <div>&#160;</div>
        <table cellspacing="0" cellpadding="0" id="z7c2001fc88d547f39e45e4e6a0b7888b" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 54pt;"><br>
              </td>
              <td style="width: 18pt; vertical-align: top;">o</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>delegates all power to a third party who does not have access to any Material Nonpublic Information, and who will determine how, when, or whether to effectuate purchases or sales.</div>
              </td>
            </tr>

        </table>
        <div>&#160;</div>
        <div style="text-align: justify; margin-left: 36pt;">Individuals considering such an arrangement should be aware that the Company may be required to publicly disclose the arrangement, and the details of any transactions made pursuant to this Rule
          10b5-1 Trading Program may be public.&#160; Additionally, the Company will establish a procedure with the entity handling the transactions to ensure the prompt filing of a Form 4 after each transaction and compliance with Rule 144 at the time of any
          sale.</div>
        <div>&#160;</div>
        <div style="text-align: justify; margin-left: 36pt;">Many sophisticated brokers, investment bankers, and advisors have developed protocols for Rule 10b5-1 trading plans.&#160; We strongly recommend that Eligible 10b5-1 Participants work with an
          experienced advisor on these matters.</div>
        <div>&#160;</div>
        <div style="text-align: justify; margin-left: 36pt; font-style: italic; font-weight: bold;">In order to ensure compliance with Rule 10b5-1 and applicable securities laws, Eligible 10b5-1 Participants are required to notify the Company&#8217;s Insider
          Trading Compliance Officer via e-mail of any planned adoption, termination or amendment of a 10b5-1 Trading Program, and also submit any 10b5-1 Trading Program subject to potential adoption, termination or amendment for the Company&#8217;s Insider
          Trading Compliance Officer&#8217;s review and approval, no later than five (5) Trading Days prior to the anticipated date of adoption, termination or amendment.</div>
        <div>&#160;</div>
        <div style="text-align: justify; margin-left: 36pt;">F.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-weight: bold;"><u>Trading Restrictions During Administrative Blackout Periods</u></font>.&#160; Access Persons are prohibited from trading in any Company securities
          during any period of three or more consecutive days during which at least 50% of the participants or beneficiaries in a Company individual account retirement plan are unable to purchase, sell, or otherwise acquire or transfer an interest in the
          equity of the Company held in such plan due to a temporary suspension by the Company or the plan fiduciary (&#8220;administrative blackout period&#8221;) unless the individual has established a pre-arranged trading plan that complies with Rule 10b5-1.&#160;
          Individual account plans include, without limitation, defined contribution plans such as broad-based tax-qualified 401(k) plans and profit-sharing plans, stock bonus plans, and similar plans.</div>
        <div>&#160;</div>
        <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
          <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-size: 8pt; color: rgb(0, 0, 0); font-weight: normal; font-style: normal; font-family: 'Times New Roman';">7</font></div>
          <div class="BRPFPageBreak" style="page-break-after: always;">
            <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
        </div>
        <div style="text-align: justify; margin-left: 36pt;">The Company&#8217;s Insider Trading Compliance Officer will advise Access Persons of any administrative blackout periods.</div>
        <div>&#160;</div>
        <div style="text-align: justify; margin-left: 36pt; font-style: italic; font-weight: bold;">Note that any profits gained from a prohibited transaction are recoverable by the Company without regard to the intent of the person who entered into the
          prohibited transaction.</div>
        <div>&#160;</div>
        <div style="text-align: justify; margin-left: 36pt;">G.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-weight: bold;"><u>Individual Responsibility</u></font>.&#160; Every Covered Person has an individual responsibility to comply with this policy.&#160; A Covered Person may,
          from time to time, have to forego a planned or proposed transaction in the Company&#8217;s securities.&#160; <font style="font-weight: bold; font-style: italic;"><u>There are no exceptions to this policy</u></font>.</div>
        <div>&#160;</div>
        <div style="text-align: justify; font-weight: bold;">Exercise of Stock Options</div>
        <div>&#160;</div>
        <div style="text-align: justify;">The following transactions are not covered by this policy: (1) the exercise of stock options for cash under the Company&#8217;s stock option plans, (2) the purchase of shares under any Company employee stock purchase
          plan (but not the sale of any such shares) and (3) the automatic exercise of expiring in-the-money stock options under the Company&#8217;s stock option plans pursuant to the Company&#8217;s brokerage platform.&#160; Individuals may perform these transactions at
          any time, unless the Company specifically instructs you otherwise.</div>
        <div>&#160;</div>
        <div style="text-align: justify; font-weight: bold;">Additional Information for Directors and Officers</div>
        <div>&#160;</div>
        <div style="text-align: justify;">Section 16 Individuals must also comply with the reporting obligations and limitations on short-swing transactions.&#160; Section 16 Individuals who purchase and sell the Company&#8217;s securities within a six-month period
          must disgorge all profits to the Company regardless of whether they had knowledge of Material Nonpublic Information.&#160; Under these provisions, the receipt of an option under the Company&#8217;s option plans, the exercise of an option under the Company&#8217;s
          option plans, and/or the receipt of stock under the Company&#8217;s employee stock purchase plan are not typically deemed a purchase under Section 16.&#160; However, the sale of any such stock is a sale under Section 16, such that the purchase and sale must
          be reported on Form&#160;4.&#160; In addition, Section 16 Individuals must not make a short sale of the Company&#8217;s stock.&#160; The Company will provide separate memoranda and other materials to Section 16 Individuals regarding compliance with Section 16.</div>
        <div>&#160;</div>
        <div style="text-align: justify; font-weight: bold;">Potential Criminal Liability, Civil Liability, and/or Disciplinary Action</div>
        <div>&#160;</div>
        <div style="text-align: justify;">Insider trading violations can lead to substantial discipline, liability, and reputational damage:</div>
        <div>&#160;</div>
        <div style="text-align: justify; margin-left: 36pt;">A.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-weight: bold;"><u>Liability for Insider Trading</u></font>.&#160; Covered Persons who violate these provisions may be subject to fines of up to $5,000,000, penalties of
          up to three times the profit gained or loss avoided, and up to 20 years imprisonment.</div>
        <div>&#160;</div>
        <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
          <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-size: 8pt; color: rgb(0, 0, 0); font-weight: normal; font-style: normal; font-family: 'Times New Roman';">8</font></div>
          <div class="BRPFPageBreak" style="page-break-after: always;">
            <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
        </div>
        <div style="text-align: justify; margin-left: 36pt;">B.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-weight: bold;"><u>Liability for Tipping</u></font>.&#160; Covered Persons may also be liable for improper transactions by any person to whom they have disclosed Material
          Nonpublic Information, made recommendations, or expressed opinions regarding trading in the Company&#8217;s securities.&#160; This applies to trading in the Company&#8217;s securities as well as the securities of any other company on the basis of Material
          Nonpublic Information.&#160; For example, if an employee learns that the Company is entering into a contract with another public company, then the employee is prohibited from trading in or advising others regarding trades in the securities of that
          other company based on Material Nonpublic Information.&#160; Regulatory authorities use sophisticated electronic surveillance techniques to uncover insider trading and have imposed large penalties even when the disclosing person did not personally
          profit from the trading.</div>
        <div>&#160;</div>
        <div style="text-align: justify; margin-left: 36pt;">C.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<font style="font-weight: bold;"><u>Disciplinary Action</u></font>.&#160; Covered Persons who violate this policy will also be subject to disciplinary action by the Company, including
          disqualification from participation in the Company&#8217;s equity incentive plans, up to and including termination of employment.</div>
        <div>&#160;</div>
        <div style="text-align: justify; margin-left: 36pt;">D.&#160;&#160;&#160;&#160;&#160;&#160;&#160; <font style="font-weight: bold;"><u>Reputational Damage</u></font>.&#160; Note that reputational damage may result even in the absence of criminal or civil penalties.&#160; An SEC investigation
          alone can tarnish or irreparably damage a career.</div>
        <div>&#160;</div>
        <div style="text-align: justify; font-weight: bold;">Certification and Questions</div>
        <div>&#160;</div>
        <div style="text-align: justify;">All Covered Persons will be required to certify in writing their understanding of and intent to comply with the Insider Trading Policy on the commencement of their relationship with the Company.&#160; In addition, all
          Covered Persons will be required to certify their compliance with the Insider Trading Policy on an annual basis.</div>
        <div>&#160;</div>
        <div style="text-align: justify;">Please direct all questions or concerns related to this policy to the Company&#8217;s Insider Trading Compliance Officer.</div>
        <div>&#160;</div>
        <div style="text-align: center; font-weight: bold;">INSIDER TRADING COMPLIANCE OFFICER</div>
        <div>&#160;</div>
        <div style="text-align: justify; font-weight: bold;">Appointment of Insider Trading Compliance Officer</div>
        <div>&#160;</div>
        <div style="text-align: justify;">The Company&#8217;s Compliance Officer shall also serve as the Company&#8217;s Insider Trading Compliance Officer.</div>
        <div>&#160;</div>
        <div style="text-align: justify; font-weight: bold;">Duties of Insider Trading Compliance Officer</div>
        <div>&#160;</div>
        <div style="text-align: justify;">The duties of the Insider Trading Compliance Officer include, but are not limited to:</div>
        <div>&#160;</div>
        <table cellspacing="0" cellpadding="0" id="zef5ae37fc13f42f596b6855d8e2dfe32" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 36pt;"><br>
              </td>
              <td style="width: 18pt; vertical-align: top;">&#8226;</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>Pre-clearance of all transactions involving the Company&#8217;s securities by all Access Persons, in order to determine compliance with the Insider Trading Policy, applicable law, Section 16, Rule 10b5-1, and Rule 144;</div>
              </td>
            </tr>

        </table>
        <div>&#160;</div>
        <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
          <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-size: 8pt; color: rgb(0, 0, 0); font-weight: normal; font-style: normal; font-family: 'Times New Roman';">9</font></div>
          <div class="BRPFPageBreak" style="page-break-after: always;">
            <hr noshade="noshade" style="margin: 4px 0px; width: 100%; border-width: 0; height: 2px; color: #000000; background-color: #000000; clear: both;"></div>
        </div>
        <table cellspacing="0" cellpadding="0" id="z41e252718a8f4ec4a0f2a64b4788d9ed" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 36pt;"><br>
              </td>
              <td style="width: 18pt; vertical-align: top;">&#8226;</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>Review of Rule 10b5-1 Trading Programs;</div>
              </td>
            </tr>

        </table>
        <div>&#160;</div>
        <table cellspacing="0" cellpadding="0" id="z55955efca59d421d9bf1d56fde4752bc" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 36pt;"><br>
              </td>
              <td style="width: 18pt; vertical-align: top;">&#8226;</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>Assist in the preparation of Section 16 reports (Forms 3, 4, and 5) for all Section 16 Individuals;</div>
              </td>
            </tr>

        </table>
        <div>&#160;</div>
        <table cellspacing="0" cellpadding="0" id="z2109221cb3074c91b527f38e3815ef43" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 36pt;"><br>
              </td>
              <td style="width: 18pt; vertical-align: top;">&#8226;</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>Provide reminders to all Section 16 Individuals regarding their obligations for Section 16 reports (Forms 3, 4, and 5);</div>
              </td>
            </tr>

        </table>
        <div>&#160;</div>
        <table cellspacing="0" cellpadding="0" id="za3e7647e79c34a2790ab2406bce4f3da" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 36pt;"><br>
              </td>
              <td style="width: 18pt; vertical-align: top;">&#8226;</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>Perform cross-checks of available materials related to trading activity by officers, directors, and others with access to Material Nonpublic Information.&#160; Materials to be reviewed include Form 144, Forms 3, 4, and 5, officer and
                  director questionnaires, and reports received from the Company&#8217;s stock administrator and transfer agent;</div>
              </td>
            </tr>

        </table>
        <div>&#160;</div>
        <table cellspacing="0" cellpadding="0" id="ze7e71dda9b31493f819b0bea89ea616c" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 36pt;"><br>
              </td>
              <td style="width: 18pt; vertical-align: top;">&#8226;</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>Distribution of the policy each year to those who have or may have access to Material Nonpublic Information;</div>
              </td>
            </tr>

        </table>
        <div>&#160;</div>
        <table cellspacing="0" cellpadding="0" id="zd31f4367ffd5431b9f64922e64b039e7" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 36pt;"><br>
              </td>
              <td style="width: 18pt; vertical-align: top;">&#8226;</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>Notification to Access Persons of each administrative blackout period under any retirement or pension plan, including individual account retirement or 401(k) plans; and</div>
              </td>
            </tr>

        </table>
        <div>&#160;</div>
        <table cellspacing="0" cellpadding="0" id="z65a1dba7d8ab4dfcb84172555104d0c3" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 36pt;"><br>
              </td>
              <td style="width: 18pt; vertical-align: top;">&#8226;</td>
              <td style="width: auto; vertical-align: top; text-align: justify;">
                <div>Provide any additional advice or assistance necessary to help Covered Persons comply with the Insider Trading Policy.</div>
              </td>
            </tr>

        </table>
        <div>&#160;</div>
        <div> <br>
        </div>
      </div>
    </div>
  </div>
  <div style="text-align: center;" class="BRPFPageNumberArea"><font style="font-size: 8pt; color: rgb(0, 0, 0); font-weight: normal; font-style: normal; font-family: 'Times New Roman';">10</font></div>
  <div style="text-align: center;" class="BRPFPageNumberArea">
    <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; margin-left: auto; margin-right: auto; border: none;"></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>6
<FILENAME>ef20038923_ex21-1.htm
<DESCRIPTION>EXHIBIT 21.1
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Summit Financial
         Document created using Broadridge PROfile 25.2.1.5287
         Copyright 1995 - 2025 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <hr align="center" noshade="noshade" style="height: 4px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;">
    <div>
      <div>
        <div style="text-align: right; font-weight: bold;">EXHIBIT 21.1</div>
        <div>&#160;</div>
      </div>
      <div>
        <div style="text-align: center; font-weight: bold;"><u>ADMA BioCenters Georgia Inc.</u></div>
        <div>&#160;</div>
      </div>
      <table cellspacing="0" cellpadding="0" id="zc7e2a1cda1ef47a0832016e5ac24b719" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">

          <tr>
            <td style="width: 50.06%; vertical-align: top; background-color: #CCEEFF;">
              <div>Jurisdiction of incorporation:</div>
            </td>
            <td style="width: 49.94%; vertical-align: top; background-color: #CCEEFF;">
              <div>Delaware</div>
            </td>
          </tr>
          <tr>
            <td style="width: 50.06%; vertical-align: top;">
              <div>Name under which business conducted:</div>
            </td>
            <td style="width: 49.94%; vertical-align: top;">
              <div>ADMA BioCenters Georgia Inc.</div>
            </td>
          </tr>

      </table>
      <div><br>
      </div>
      <div>
        <div style="text-align: center; font-weight: bold;"><u>ADMA Plasma Biologics, Inc.</u></div>
        <div>&#160;</div>
      </div>
      <table cellspacing="0" cellpadding="0" id="z64bf14d3b8dc40a0aab4ce2bc6990e28" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">

          <tr>
            <td style="width: 50.06%; vertical-align: top; background-color: #CCEEFF;">
              <div>Jurisdiction of incorporation:</div>
            </td>
            <td style="width: 49.94%; vertical-align: top; background-color: #CCEEFF;">
              <div>Delaware</div>
            </td>
          </tr>
          <tr>
            <td style="width: 50.06%; vertical-align: top;">
              <div>Name under which business conducted:</div>
            </td>
            <td style="width: 49.94%; vertical-align: top;">
              <div>ADMA Plasma Biologics, Inc.</div>
            </td>
          </tr>

      </table>
      <div><br>
      </div>
      <div>
        <div style="text-align: center; font-weight: bold;"><u>ADMA BioManufacturing, LLC</u></div>
        <div>&#160;</div>
      </div>
      <table cellspacing="0" cellpadding="0" border="0" id="z67a8653e9c8c4deb904e09e7a5af8c3a" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">

          <tr>
            <td style="width: 50.06%; vertical-align: top; background-color: #CCEEFF;">
              <div>Jurisdiction of incorporation:</div>
            </td>
            <td style="width: 49.94%; vertical-align: top; background-color: #CCEEFF;">
              <div>Delaware</div>
            </td>
          </tr>
          <tr>
            <td style="width: 50.06%; vertical-align: top;">
              <div>Name under which business conducted:</div>
            </td>
            <td style="width: 49.94%; vertical-align: top;">
              <div>ADMA BioManufacturing, LLC</div>
            </td>
          </tr>

      </table>
      <div><br>
      </div>
      <div>&#160;</div>
      <div>
        <hr align="center" noshade="noshade" style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"></div>
      <div><br>
      </div>
      <div><br>
      </div>
      <div><br>
      </div>
      <div><br>
      </div>
      <div><br>
      </div>
      <div><br>
      </div>
      <div><br>
      </div>
      <div><br>
      </div>
      <div><br>
      </div>
      <div><br>
      </div>
      <div><br>
      </div>
      <div><br>
      </div>
      <div><br>
      </div>
      <div><br>
      </div>
      <div><br>
      </div>
      <div><br>
      </div>
      <div><br>
      </div>
      <div><br>
      </div>
      <div><br>
      </div>
      <div><br>
      </div>
      <div><br>
      </div>
      <div><br>
      </div>
    </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>7
<FILENAME>ef20038923_ex23-1.htm
<DESCRIPTION>EXHIBIT 23.1
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Summit Financial
         Document created using Broadridge PROfile 25.2.1.5287
         Copyright 1995 - 2025 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <div>
      <hr noshade="noshade" align="center" style="height: 4px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;">
      <div>
        <div style="text-align: right; font-weight: bold;">Exhibit 23.1</div>
        <div><br>
        </div>
        <div style="text-align: center; font-weight: bold;"> <br>
        </div>
        <div style="text-align: left; font-weight: bold;"> <img src="image00003.jpg">
          <div>
            <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;" id="za0f4a4bad625452fa81cca7d248bb93a">

                <tr>
                  <td style="width: 20%;">
                    <div>&#160;</div>
                  </td>
                  <td style="width: 80%;">
                    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 8pt;">KPMG LLP</div>
                  </td>
                </tr>
                <tr>
                  <td style="width: 20%;">
                    <div>&#160;</div>
                  </td>
                  <td style="width: 80%;">
                    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">677 Washington Boulevard</div>
                  </td>
                </tr>
                <tr>
                  <td style="width: 20%;">
                    <div>&#160;</div>
                  </td>
                  <td style="width: 80%;">
                    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Stamford, CT 06901</div>
                  </td>
                </tr>

            </table>
          </div>
        </div>
        <div style="text-align: center; font-weight: bold;"> <br>
        </div>
        <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Consent of Independent Registered Public Accounting Firm</div>
        <div>&#160;</div>
        <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">We consent to the incorporation by reference in the registration statements (Nos. 333-266291, 333-263345, 333-254770, 333-237658, 333-229921, 333-224492, 333-220058,
          and 333-204590) on Form <a name="z_0"></a>S-8 of our reports dated <a name="z_1"></a>March 18, 2025, with respect to the consolidated financial statements of ADMA Biologics, Inc. and subsidiaries and the effectiveness of internal control over
          financial reporting.</div>
        <div>&#160;</div>
        <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt;">/s/ KPMG LLP</div>
        <div>&#160;</div>
        <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Stamford, Connecticut<a name="z_2"></a><font style="font-size: 10pt; font-family: 'Times New Roman';"><br>
          </font>March 18, 2025</div>
        <div>&#160;</div>
        <div>
          <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000; width: 100%;" id="z8d188e7e4a4048bf8a56bb8c007c1c82">

              <tr>
                <td style="width: 35%;">
                  <div style="font-size: 5pt;">&#160;</div>
                </td>
                <td style="width: 65%;">
                  <div style="text-align: left; font-family: 'Times New Roman'; font-size: 7pt;">KPMG LLP, a Delaware limited liability partnership and a member firm of</div>
                </td>
              </tr>
              <tr>
                <td style="width: 35%;">
                  <div style="font-size: 5pt;">&#160;</div>
                </td>
                <td style="width: 65%;">
                  <div style="text-align: left; font-family: 'Times New Roman'; font-size: 7pt;">the KPMG global organization of independent member firms affiliated with</div>
                </td>
              </tr>
              <tr>
                <td style="width: 35%;">
                  <div style="font-size: 5pt;">&#160;</div>
                </td>
                <td style="width: 65%;">
                  <div style="text-align: left; font-family: 'Times New Roman'; font-size: 7pt;">KPMG International Limited, a private English company limited by guarantee.</div>
                </td>
              </tr>

          </table>
        </div>
        <div>
          <hr noshade="noshade" align="center" style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"></div>
      </div>
    </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.2
<SEQUENCE>8
<FILENAME>ef20038923_ex23-2.htm
<DESCRIPTION>EXHIBIT 23.2
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Summit Financial
         Document created using Broadridge PROfile 25.2.1.5287
         Copyright 1995 - 2025 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <div>
      <hr align="center" noshade="noshade" style="height: 4px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;">
      <div>
        <div style="text-align: right; font-weight: bold;">Exhibit 23.2</div>
        <div><br>
        </div>
        <div style="text-align: center; font-weight: bold;">Consent of Independent Registered</div>
        <div style="text-align: center; font-weight: bold;">Public Accounting Firm</div>
        <div><br>
        </div>
        <div style="text-align: justify;">We consent to the incorporation by reference, in the registration statements on Form S-8 (File Nos. 333-266291, 333-263345, 333-254770, 333-237658, 333-229921, 333-224492, 333-220058 and 333-204590) of ADMA
          Biologics, Inc., of our report, dated February 28, 2024, except for Note 11 and Note 13 as to which the date is March 18, 2025, with respect to the consolidated balance sheet of ADMA Biologics, Inc. and subsidiaries as of December 31, 2023, and
          the related consolidated statements of operations, changes in stockholders&#8217; equity, and cash flows and financial statement schedule II &#8211; valuation and qualifying accounts for each of the years in the two-year period ended December 31, 2023,
          included in the Annual Report on Form 10-K of ADMA Biologics, Inc. and subsidiaries for the year ended December 31, 2024.</div>
        <div><br>
        </div>
        <table cellspacing="0" cellpadding="0" border="0" id="zc50930769c814f77bc24ade0ad875b55" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">

            <tr>
              <td style="width: 50%; vertical-align: top;">
                <div style="text-align: justify;">/s/ CohnReznick LLP</div>
              </td>
              <td style="width: 50%; vertical-align: top;" colspan="1">&#160;</td>
            </tr>
            <tr>
              <td style="width: 50%; vertical-align: top;">&#160;</td>
              <td style="width: 50%; vertical-align: top;" colspan="1">&#160;</td>
            </tr>
            <tr>
              <td style="width: 50%; vertical-align: top;">
                <div style="text-align: justify;">Parsippany, New Jersey</div>
              </td>
              <td style="width: 50%; vertical-align: top;" colspan="1">&#160;</td>
            </tr>
            <tr>
              <td style="width: 50%; vertical-align: top;">
                <div>March 18, 2025</div>
              </td>
              <td style="width: 50%; vertical-align: top;" colspan="1">&#160;</td>
            </tr>

        </table>
        <div>&#160;</div>
        <div> <br>
        </div>
        <hr align="center" noshade="noshade" style="height: 2px; width: 100%; color: #54301A; background-color: #54301A; text-align: center; margin-left: auto; margin-right: auto; border: none;"> </div>
    </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>9
<FILENAME>ef20038923_ex31-1.htm
<DESCRIPTION>EXHIBIT 31.1
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Summit Financial
         Document created using Broadridge PROfile 25.2.1.5287
         Copyright 1995 - 2025 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <div>
      <hr align="center" noshade="noshade" style="height: 4px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;">
      <div>
        <div style="text-align: right; font-weight: bold;">Exhibit 31.1</div>
        <div style="text-align: right;">&#160;</div>
        <div style="text-align: center;">CERTIFICATION OF THE PRINCIPAL EXECUTIVE OFFICER</div>
        <div style="text-align: center;">PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</div>
        <div style="text-align: center;">&#160;</div>
        <div style="text-align: justify;">I, Adam S. Grossman, certify that:</div>
        <div style="text-align: justify;">&#160;</div>
        <table cellspacing="0" cellpadding="0" id="z2f85a1c7a6604234a6f76cfc8326758f" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 9pt;"><br>
              </td>
              <td style="width: 18pt; vertical-align: top;">1.</td>
              <td style="width: auto; vertical-align: top;">
                <div>I have reviewed this Annual Report on Form 10-K of ADMA Biologics, Inc. for the year ended December 31, 2024;</div>
              </td>
            </tr>

        </table>
        <div style="text-indent: -36pt; margin-left: 36pt;">&#160;</div>
        <table cellspacing="0" cellpadding="0" id="z62b3957053234221ae9f5e2ae6c33957" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 9pt;"><br>
              </td>
              <td style="width: 18pt; vertical-align: top;">2.</td>
              <td style="width: auto; vertical-align: top;">
                <div>Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary To Whom It May Concern: make the statements made, in light of the circumstances under which such
                  statements were made, not misleading with respect to the period covered by this report;</div>
              </td>
            </tr>

        </table>
        <div style="text-indent: -36pt; margin-left: 36pt;">&#160;</div>
        <table cellspacing="0" cellpadding="0" id="ze3d99851af6540c99461e98e65cc216a" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 9pt;"><br>
              </td>
              <td style="width: 18pt; vertical-align: top;">3.</td>
              <td style="width: auto; vertical-align: top;">
                <div>Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of,
                  and for, the periods presented in this report;</div>
              </td>
            </tr>

        </table>
        <div style="text-indent: -36pt; margin-left: 36pt;">&#160;</div>
        <table cellspacing="0" cellpadding="0" id="zfab192a5364e444b9b8368bc7045827e" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 9pt;"><br>
              </td>
              <td style="width: 18pt; vertical-align: top;">4.</td>
              <td style="width: auto; vertical-align: top;">
                <div>The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial
                  reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</div>
              </td>
            </tr>

        </table>
        <div style="text-indent: -36pt; margin-left: 36pt;">&#160;</div>
        <div>
          <div>
            <table cellspacing="0" cellpadding="0" class="DSPFListTable" id="zb651d1dc1a4a49668536132aadcab6ab" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%;">

                <tr style="vertical-align: top;">
                  <td style="width: 27pt;">&#160;</td>
                  <td style="text-align: right; vertical-align: top; width: 18pt;">
                    <div style="text-align: left;">(a)</div>
                  </td>
                  <td style="text-align: left; vertical-align: top; width: auto;">
                    <div>Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated
                      subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</div>
                  </td>
                </tr>

            </table>
          </div>

        </div>
        <div style="text-indent: -36pt; margin-left: 36pt;">&#160;</div>
        <div>
          <div>
            <table cellspacing="0" cellpadding="0" class="DSPFListTable" id="zc658c5fbe8fd4f1cb54898fbcd2dae46" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%;">

                <tr style="vertical-align: top;">
                  <td style="width: 27pt;">&#160;</td>
                  <td style="text-align: right; vertical-align: top; width: 18pt;">
                    <div style="text-align: left;">(b)</div>
                  </td>
                  <td style="text-align: left; vertical-align: top; width: auto;">
                    <div>Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial
                      reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</div>
                  </td>
                </tr>

            </table>
          </div>

        </div>
        <div style="text-indent: -36pt; margin-left: 36pt;">&#160;</div>
        <div>
          <div>
            <table cellspacing="0" cellpadding="0" class="DSPFListTable" id="zcca4379fba4642e6b24c1780bb2713c9" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%;">

                <tr style="vertical-align: top;">
                  <td style="width: 27pt;">&#160;</td>
                  <td style="text-align: right; vertical-align: top; width: 18pt;">
                    <div style="text-align: left;">(c)</div>
                  </td>
                  <td style="text-align: left; vertical-align: top; width: auto;">
                    <div>Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered
                      by this report based on such evaluation; and</div>
                  </td>
                </tr>

            </table>
          </div>

        </div>
        <div>
          <div><br>
          </div>
          <div>
            <table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z4f340710c9854bde959a5110923237cd" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%;">

                <tr style="vertical-align: top;">
                  <td style="width: 27pt;">&#160;</td>
                  <td style="text-align: right; vertical-align: top; width: 18pt;">
                    <div style="text-align: left;">(d)</div>
                  </td>
                  <td style="text-align: left; vertical-align: top; width: auto;">
                    <div>Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual
                      report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</div>
                  </td>
                </tr>

            </table>
          </div>

        </div>
        <div style="text-indent: -36pt; margin-left: 36pt;">&#160;</div>
        <table cellspacing="0" cellpadding="0" id="zeeb41f565207480594e535c91553601e" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 9pt;"><br>
              </td>
              <td style="width: 18pt; vertical-align: top;">5.</td>
              <td style="width: auto; vertical-align: top;">
                <div>The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of
                  directors (or persons performing the equivalent functions):</div>
              </td>
            </tr>

        </table>
        <div style="text-indent: -36pt; margin-left: 36pt;">&#160;</div>
        <div>
          <div>
            <table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z6c385c6a0ee84158896c8832432a093f" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%;">

                <tr style="vertical-align: top;">
                  <td style="width: 27pt;">&#160;</td>
                  <td style="text-align: right; vertical-align: top; width: 18pt;">
                    <div style="text-align: left;">(a)</div>
                  </td>
                  <td style="text-align: left; vertical-align: top; width: auto;">
                    <div>All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and
                      report financial information; and</div>
                  </td>
                </tr>

            </table>
          </div>

        </div>
        <div style="text-indent: -36pt; margin-left: 36pt;">&#160;</div>
        <div>
          <div>
            <table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z441284a773a3410b9edf04bab016f821" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%;">

                <tr style="vertical-align: top;">
                  <td style="width: 27pt;">&#160;</td>
                  <td style="text-align: right; vertical-align: top; width: 18pt;">
                    <div style="text-align: left;">(b)</div>
                  </td>
                  <td style="text-align: left; vertical-align: top; width: auto;">
                    <div>Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</div>
                  </td>
                </tr>

            </table>
          </div>

        </div>
        <div>&#160;</div>
        <table cellspacing="0" cellpadding="0" border="0" id="za57c752fd53a42c89b267aae8caed7d8" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">

            <tr>
              <td style="width: 50%; vertical-align: top;">
                <div>March 18, 2025</div>
              </td>
              <td style="vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);" colspan="2">
                <div>/s/ Adam S. Grossman</div>
              </td>
            </tr>
            <tr>
              <td style="width: 50%; vertical-align: top;">
                <div>&#160;</div>
              </td>
              <td style="width: 5%; vertical-align: top;">
                <div>Name:</div>
              </td>
              <td style="width: 45%; vertical-align: top;">
                <div>Adam S. Grossman</div>
              </td>
            </tr>
            <tr>
              <td style="width: 50%; vertical-align: top;">
                <div>&#160;</div>
              </td>
              <td style="width: 5%; vertical-align: top;">
                <div>Title:</div>
              </td>
              <td style="width: 45%; vertical-align: top;">
                <div>President and Chief Executive Officer</div>
                <div>(Principal Executive Officer)</div>
              </td>
            </tr>

        </table>
        <div> <br>
        </div>
        <div> <br>
        </div>
        <div>
          <hr align="center" noshade="noshade" style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"> </div>
      </div>
    </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>10
<FILENAME>ef20038923_ex31-2.htm
<DESCRIPTION>EXHIBIT 31.2
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Summit Financial
         Document created using Broadridge PROfile 25.2.1.5287
         Copyright 1995 - 2025 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <div>
      <hr align="center" noshade="noshade" style="height: 4px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;">
      <div>
        <div style="text-align: right; font-weight: bold;">Exhibit 31.2</div>
        <div style="text-align: right;">&#160;</div>
        <div style="text-align: center;">CERTIFICATION OF THE PRINCIPAL FINANCIAL OFFICER</div>
        <div style="text-align: center;">PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</div>
        <div style="text-align: center;">&#160;</div>
        <div style="text-align: justify;">I, Brad Tade, certify that:</div>
        <div style="text-align: justify;">&#160;</div>
        <table cellspacing="0" cellpadding="0" id="z70ce776d0e8d4972b211798a498b42d3" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 9pt;"><br>
              </td>
              <td style="width: 18pt; vertical-align: top;">1.</td>
              <td style="width: auto; vertical-align: top;">
                <div>I have reviewed this Annual Report on Form 10-K of ADMA Biologics, Inc. for the year ended December 31, 2024;</div>
              </td>
            </tr>

        </table>
        <div style="text-indent: -36pt; margin-left: 36pt;">&#160;</div>
        <table cellspacing="0" cellpadding="0" id="z94bd6bcdbae8458c95a750a549ecb0b2" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 9pt;"><br>
              </td>
              <td style="width: 18pt; vertical-align: top;">2.</td>
              <td style="width: auto; vertical-align: top;">
                <div>Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made,
                  not misleading with respect to the period covered by this report;</div>
              </td>
            </tr>

        </table>
        <div style="text-indent: -36pt; margin-left: 36pt;">&#160;</div>
        <table cellspacing="0" cellpadding="0" id="z5885747eff164e30b61e83d04d894296" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 9pt;"><br>
              </td>
              <td style="width: 18pt; vertical-align: top;">3.</td>
              <td style="width: auto; vertical-align: top;">
                <div>Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of,
                  and for, the periods presented in this report;</div>
              </td>
            </tr>

        </table>
        <div style="text-indent: -36pt; margin-left: 36pt;">&#160;</div>
        <table cellspacing="0" cellpadding="0" id="z0f7c95930afc41a3af406118c94ffc20" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 9pt;"><br>
              </td>
              <td style="width: 18pt; vertical-align: top;">4.</td>
              <td style="width: auto; vertical-align: top;">
                <div>The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial
                  reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</div>
              </td>
            </tr>

        </table>
        <div style="text-indent: -36pt; margin-left: 36pt;">&#160;</div>
        <div>
          <div>
            <table cellspacing="0" cellpadding="0" class="DSPFListTable" id="ze98b1a330f1e4bfc87aa18048399f765" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%;">

                <tr style="vertical-align: top;">
                  <td style="width: 27pt;">&#160;</td>
                  <td style="text-align: right; vertical-align: top; width: 18pt;">
                    <div style="text-align: left;">(a)</div>
                  </td>
                  <td style="text-align: left; vertical-align: top; width: auto;">
                    <div>Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated
                      subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</div>
                  </td>
                </tr>

            </table>
          </div>

        </div>
        <div>&#160;</div>
        <div>
          <div>
            <table cellspacing="0" cellpadding="0" class="DSPFListTable" id="z2ee2df81543a4bdf8d525adf2aa35d4d" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%;">

                <tr style="vertical-align: top;">
                  <td style="width: 27pt;">&#160;</td>
                  <td style="text-align: right; vertical-align: top; width: 18pt;">
                    <div style="text-align: left;">(b)</div>
                  </td>
                  <td style="text-align: left; vertical-align: top; width: auto;">
                    <div>Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial
                      reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</div>
                  </td>
                </tr>

            </table>
          </div>
        </div>
        <div>
          <div><br>
          </div>
          <div>
            <table cellspacing="0" cellpadding="0" class="DSPFListTable" id="zd3785e092117461e84f2f784609ae683" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%;">

                <tr style="vertical-align: top;">
                  <td style="width: 27pt;">&#160;</td>
                  <td style="text-align: right; vertical-align: top; width: 18pt;">
                    <div style="text-align: left;">(c)</div>
                  </td>
                  <td style="text-align: left; vertical-align: top; width: auto;">
                    <div>Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered
                      by this report based on such evaluation; and</div>
                  </td>
                </tr>

            </table>
          </div>

        </div>
        <div>&#160;</div>
        <div>
          <div>
            <table cellspacing="0" cellpadding="0" class="DSPFListTable" id="zff266af8a3c749ba99b6b80e309eaca9" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%;">

                <tr style="vertical-align: top;">
                  <td style="width: 27pt;">&#160;</td>
                  <td style="text-align: right; vertical-align: top; width: 18pt;">
                    <div style="text-align: left;">(d)</div>
                  </td>
                  <td style="text-align: left; vertical-align: top; width: auto;">
                    <div>Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual
                      report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</div>
                  </td>
                </tr>

            </table>
          </div>

        </div>
        <div style="text-indent: -36pt; margin-left: 36pt;">&#160;</div>
        <table cellspacing="0" cellpadding="0" id="zb5a5396714de4d7ea0245d88922fa8f4" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

            <tr>
              <td style="width: 9pt;"><br>
              </td>
              <td style="width: 18pt; vertical-align: top;">5.</td>
              <td style="width: auto; vertical-align: top;">
                <div>The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of
                  directors (or persons performing the equivalent functions):</div>
              </td>
            </tr>

        </table>
        <div style="text-indent: -36pt; margin-left: 36pt;">&#160;</div>
        <div>
          <div>
            <table cellspacing="0" cellpadding="0" class="DSPFListTable" id="zcc805c42afcf4565b71e7ce7e8be8f7c" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%;">

                <tr style="vertical-align: top;">
                  <td style="width: 27pt;">&#160;</td>
                  <td style="text-align: right; vertical-align: top; width: 18pt;">
                    <div style="text-align: left;">(a)</div>
                  </td>
                  <td style="text-align: left; vertical-align: top; width: auto;">
                    <div>All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and
                      report financial information; and</div>
                  </td>
                </tr>

            </table>
          </div>

        </div>
        <div style="text-indent: -36pt; margin-left: 36pt;">&#160;</div>
        <div>
          <div>
            <table cellspacing="0" cellpadding="0" class="DSPFListTable" id="zdb3339289aa9435ea9d3e27377644a2f" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%;">

                <tr style="vertical-align: top;">
                  <td style="width: 27pt;">&#160;</td>
                  <td style="text-align: right; vertical-align: top; width: 18pt;">
                    <div style="text-align: left;">(b)</div>
                  </td>
                  <td style="text-align: left; vertical-align: top; width: auto;">
                    <div>Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</div>
                  </td>
                </tr>

            </table>
          </div>

        </div>
        <div style="text-indent: -36pt; margin-left: 36pt;">&#160;</div>
        <table cellspacing="0" cellpadding="0" border="0" id="z711b422cdaad41d9b3c1545af858e0bc" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">

            <tr>
              <td style="width: 50%; vertical-align: top;">
                <div>March 18, 2025</div>
              </td>
              <td style="vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);" colspan="2">
                <div>/s/ Brad Tade</div>
              </td>
            </tr>
            <tr>
              <td style="width: 50%; vertical-align: top;">
                <div>&#160;</div>
              </td>
              <td style="width: 5%; vertical-align: top;">
                <div>Name:</div>
              </td>
              <td style="width: 45%; vertical-align: top;">
                <div>Brad Tade</div>
              </td>
            </tr>
            <tr>
              <td style="width: 50%; vertical-align: top;">
                <div>&#160;</div>
              </td>
              <td style="width: 5%; vertical-align: top;">
                <div>Title:</div>
              </td>
              <td style="width: 45%; vertical-align: top;">
                <div>Chief Financial Officer</div>
                <div>(Principal Financial Officer)</div>
              </td>
            </tr>

        </table>
        <div>&#160;</div>
        <div> <br>
        </div>
        <div>
          <hr align="center" noshade="noshade" style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"> </div>
      </div>
    </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>11
<FILENAME>ef20038923_ex32-1.htm
<DESCRIPTION>EXHIBIT 32.1
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Summit Financial
         Document created using Broadridge PROfile 25.2.1.5287
         Copyright 1995 - 2025 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <hr align="center" noshade="noshade" style="height: 4px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;">
    <div>
      <div style="text-align: right; font-weight: bold;">Exhibit 32.1</div>
      <div style="text-align: right;">&#160;</div>
      <div style="text-align: center;">CERTIFICATION OF THE PRINCIPAL EXECUTIVE OFFICER</div>
      <div style="text-align: center;">PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</div>
      <div style="text-align: center;">&#160;</div>
      <div style="text-indent: 36pt;">In connection with the annual report of ADMA Biologics, Inc., a Delaware corporation (the &#8220;Company&#8221;),&#160; on Form 10-K for the year ended December 31, 2024, as filed with the Securities and Exchange Commission on the date
        hereof (the &#8220;Report&#8221;), I, Adam S. Grossman, President and Chief Executive Officer of the Company, hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge:</div>
      <div style="text-indent: 36pt;">&#160;</div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z82c10ea6748b4fbdb4569bd3939e0d20">

          <tr>
            <td style="width: 36pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top;">(1)</td>
            <td style="width: auto; vertical-align: top;">
              <div>The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and</div>
            </td>
          </tr>

      </table>
      <div style="text-indent: -36pt; margin-left: 36pt;">&#160;</div>
      <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z670962eb360c433c8901b1060dc89730">

          <tr>
            <td style="width: 36pt;"><br>
            </td>
            <td style="width: 36pt; vertical-align: top;">(2)</td>
            <td style="width: auto; vertical-align: top;">
              <div>The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</div>
            </td>
          </tr>

      </table>
      <div>&#160;</div>
      <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="z20a1b5af306a4963a3da75fc3b08a84a">

          <tr>
            <td style="width: 50%; vertical-align: top;">
              <div>March 18, 2025</div>
            </td>
            <td colspan="2" style="vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
              <div>/s/ Adam S. Grossman</div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;">
              <div>&#160;</div>
            </td>
            <td style="width: 5%; vertical-align: top;">
              <div>Name:</div>
            </td>
            <td style="width: 45%; vertical-align: top;">
              <div>Adam S. Grossman</div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;">
              <div>&#160;</div>
            </td>
            <td style="width: 5%; vertical-align: top;">
              <div>Title:</div>
            </td>
            <td style="width: 45%; vertical-align: top;">
              <div>President and Chief Executive Officer</div>
              <div>(Principal Executive Officer)</div>
            </td>
          </tr>

      </table>
      <div><br>
      </div>
      <div>&#160;</div>
      <hr align="center" noshade="noshade" style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;">
      <div><br>
      </div>
      <div>&#160;</div>
    </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>12
<FILENAME>ef20038923_ex32-2.htm
<DESCRIPTION>EXHIBIT 32.2
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Summit Financial
         Document created using Broadridge PROfile 25.2.1.5287
         Copyright 1995 - 2025 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <div>
      <hr align="center" noshade="noshade" style="height: 4px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;">
      <div>
        <div style="text-align: right; font-weight: bold;">Exhibit 32.2</div>
        <div style="text-align: right;">&#160;</div>
        <div style="text-align: center;">CERTIFICATION OF THE PRINCIPAL FINANCIAL OFFICER</div>
        <div style="text-align: center;">PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</div>
        <div style="text-align: center;">&#160;</div>
        <div style="text-indent: 36pt;">In connection with the annual report of ADMA Biologics, Inc., a Delaware corporation (the &#8220;Company&#8221;), on Form 10-K for the year ended December 31, 2024, as filed with the Securities and Exchange Commission on the
          date hereof (the &#8220;Report&#8221;), I, Brad Tade, Chief Financial Officer of the Company, hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge:</div>
        <div style="text-indent: 36pt;">&#160;</div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z6ad0a442d5c94be4ac804c64f47e7be6">

            <tr>
              <td style="width: 36pt;"><br>
              </td>
              <td style="width: 36pt; vertical-align: top;">(1)</td>
              <td style="width: auto; vertical-align: top;">
                <div>The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and</div>
              </td>
            </tr>

        </table>
        <div style="text-indent: -36pt; margin-left: 36pt;">&#160;</div>
        <table cellspacing="0" cellpadding="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; text-align: left; color: #000000;" class="DSPFListTable" id="z609b63dc224c44aeba7d532f016c08e3">

            <tr>
              <td style="width: 36pt;"><br>
              </td>
              <td style="width: 36pt; vertical-align: top;">(2)</td>
              <td style="width: auto; vertical-align: top;">
                <div>The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</div>
              </td>
            </tr>

        </table>
        <div>&#160;</div>
        <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;" id="z216dc3600db34fac95ffb6b3cd05e9c6">

            <tr>
              <td style="width: 50%; vertical-align: top;">
                <div>March 18, 2025</div>
              </td>
              <td colspan="2" style="vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
                <div>/s/ Brad Tade</div>
              </td>
            </tr>
            <tr>
              <td style="width: 50%; vertical-align: top;">
                <div>&#160;</div>
              </td>
              <td style="width: 5%; vertical-align: top;">
                <div>Name:</div>
              </td>
              <td style="width: 45%; vertical-align: top;">
                <div>Brad Tade</div>
              </td>
            </tr>
            <tr>
              <td style="width: 50%; vertical-align: top;">
                <div>&#160;</div>
              </td>
              <td style="width: 5%; vertical-align: top;">
                <div>Title:</div>
              </td>
              <td style="width: 45%; vertical-align: top;">
                <div>Chief Financial Officer</div>
                <div>(Principal Financial Officer)</div>
              </td>
            </tr>

        </table>
        <div><br>
        </div>
        <div>&#160;
          <hr align="center" noshade="noshade" style="height: 2px; color: #000000; background-color: #000000; text-align: center; margin-left: auto; margin-right: auto; border: none;"></div>
      </div>
    </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>13
<FILENAME>adma-20241231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--Generated by Broadridge PROfile 25.2.1.5287 Broadridge-->
<xs:schema targetNamespace="http://admabiologics.com/20241231" elementFormDefault="qualified" xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:adma="http://admabiologics.com/20241231" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:us-types="http://fasb.org/us-types/2024" xmlns:srt-types="http://fasb.org/srt-types/2024">
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xlink:type="simple" xlink:href="adma-20241231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="adma-20241231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="adma-20241231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="adma-20241231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:roleType roleURI="http://admabiologics.com/role/DocumentAndEntityInformation" id="DocumentAndEntityInformation">
        <link:definition>000100 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/ConsolidatedBalanceSheets" id="ConsolidatedBalanceSheets">
        <link:definition>010000 - Statement - CONSOLIDATED BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/ConsolidatedBalanceSheetsParenthetical" id="ConsolidatedBalanceSheetsParenthetical">
        <!--Parent Role: CONSOLIDATED BALANCE SHEETS-->
        <link:definition>010100 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/ConsolidatedStatementsOfOperations" id="ConsolidatedStatementsOfOperations">
        <link:definition>020000 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity" id="ConsolidatedStatementsOfChangesInStockholdersEquity">
        <link:definition>030000 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/ConsolidatedStatementsOfCashFlows" id="ConsolidatedStatementsOfCashFlows">
        <link:definition>040000 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/OrganizationAndBusiness" id="OrganizationAndBusiness">
        <link:definition>060100 - Disclosure - ORGANIZATION AND BUSINESS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/SignificantAccountingPolicies" id="SignificantAccountingPolicies">
        <link:definition>060200 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/Inventories" id="Inventories">
        <link:definition>060300 - Disclosure - INVENTORIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/PropertyAndEquipment" id="PropertyAndEquipment">
        <link:definition>060400 - Disclosure - PROPERTY AND EQUIPMENT</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/IntangibleAssets" id="IntangibleAssets">
        <link:definition>060500 - Disclosure - INTANGIBLE ASSETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/AccruedExpensesAndOtherLiabilities" id="AccruedExpensesAndOtherLiabilities">
        <link:definition>060600 - Disclosure - ACCRUED EXPENSES AND OTHER LIABILITIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/NotesPayable" id="NotesPayable">
        <link:definition>060700 - Disclosure - NOTES PAYABLE</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/StockholdersEquity" id="StockholdersEquity">
        <link:definition>060800 - Disclosure - STOCKHOLDERS' EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/RelatedPartyTransactions" id="RelatedPartyTransactions">
        <link:definition>060900 - Disclosure - RELATED PARTY TRANSACTIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/CommitmentsAndContingencies" id="CommitmentsAndContingencies">
        <link:definition>061000 - Disclosure - COMMITMENTS AND CONTINGENCIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/IncomeTaxes" id="IncomeTaxes">
        <link:definition>061100 - Disclosure - INCOME TAXES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/LeaseObligations" id="LeaseObligations">
        <link:definition>061200 - Disclosure - LEASE OBLIGATIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/Segments" id="Segments">
        <link:definition>061300 - Disclosure - SEGMENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/OtherEmployeeBenefits" id="OtherEmployeeBenefits">
        <link:definition>061400 - Disclosure - OTHER EMPLOYEE BENEFITS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/SupplementalDisclosureOfCashFlowInformation" id="SupplementalDisclosureOfCashFlowInformation">
        <link:definition>061500 - Disclosure - SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/Concentrations" id="Concentrations">
        <link:definition>061600 - Disclosure - CONCENTRATIONS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/ScheduleIiValuationAndQualifyingAccounts" id="ScheduleIiValuationAndQualifyingAccounts">
        <link:definition>061700 - Disclosure - SCHEDULE II - VALUATION AND QUALIFYING ACCOUNTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/CybersecurityRiskManagementAndStrategyDisclosure" id="CybersecurityRiskManagementAndStrategyDisclosure">
        <link:definition>061800 - Disclosure - CYBERSECURITY RISK MANAGEMENT AND STRATEGY DISCLOSURE</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/InsiderTradingArrangements" id="InsiderTradingArrangements">
        <link:definition>061900 - Disclosure - INSIDER TRADING ARRANGEMENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/SignificantAccountingPoliciesPolicies" id="SignificantAccountingPoliciesPolicies">
        <!--Parent Role: SIGNIFICANT ACCOUNTING POLICIES-->
        <link:definition>070200 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/SignificantAccountingPoliciesTables" id="SignificantAccountingPoliciesTables">
        <!--Parent Role: SIGNIFICANT ACCOUNTING POLICIES-->
        <link:definition>080200 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/InventoriesTables" id="InventoriesTables">
        <!--Parent Role: INVENTORIES-->
        <link:definition>080300 - Disclosure - INVENTORIES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/PropertyAndEquipmentTables" id="PropertyAndEquipmentTables">
        <!--Parent Role: PROPERTY AND EQUIPMENT-->
        <link:definition>080400 - Disclosure - PROPERTY AND EQUIPMENT (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/IntangibleAssetsTables" id="IntangibleAssetsTables">
        <!--Parent Role: INTANGIBLE ASSETS-->
        <link:definition>080500 - Disclosure - INTANGIBLE ASSETS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/AccruedExpensesAndOtherLiabilitiesTables" id="AccruedExpensesAndOtherLiabilitiesTables">
        <!--Parent Role: ACCRUED EXPENSES AND OTHER LIABILITIES-->
        <link:definition>080600 - Disclosure - ACCRUED EXPENSES AND OTHER LIABILITIES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/NotesPayableTables" id="NotesPayableTables">
        <!--Parent Role: NOTES PAYABLE-->
        <link:definition>080700 - Disclosure - NOTES PAYABLE (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/StockholdersEquityTables" id="StockholdersEquityTables">
        <!--Parent Role: STOCKHOLDERS' EQUITY-->
        <link:definition>080800 - Disclosure - STOCKHOLDERS EQUITY (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/IncomeTaxesTables" id="IncomeTaxesTables">
        <!--Parent Role: INCOME TAXES-->
        <link:definition>081100 - Disclosure - INCOME TAXES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/LeaseObligationsTables" id="LeaseObligationsTables">
        <!--Parent Role: LEASE OBLIGATIONS-->
        <link:definition>081200 - Disclosure - LEASE OBLIGATIONS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/SegmentsTables" id="SegmentsTables">
        <!--Parent Role: SEGMENTS-->
        <link:definition>081300 - Disclosure - SEGMENTS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/SupplementalDisclosureOfCashFlowInformationTables" id="SupplementalDisclosureOfCashFlowInformationTables">
        <!--Parent Role: SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION-->
        <link:definition>081500 - Disclosure - SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/OrganizationAndBusinessDetails" id="OrganizationAndBusinessDetails">
        <!--Parent Role: ORGANIZATION AND BUSINESS-->
        <link:definition>090100 - Disclosure - ORGANIZATION AND BUSINESS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/SignificantAccountingPoliciesUseOfEstimatesDetails" id="SignificantAccountingPoliciesUseOfEstimatesDetails">
        <!--Parent Role: SIGNIFICANT ACCOUNTING POLICIES-->
        <link:definition>090200 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES, Use of Estimates (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/SignificantAccountingPoliciesAccountsReceivableDetails" id="SignificantAccountingPoliciesAccountsReceivableDetails">
        <!--Parent Role: SIGNIFICANT ACCOUNTING POLICIES-->
        <link:definition>090202 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES, Accounts Receivable (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/SignificantAccountingPoliciesPropertyAndEquipmentDetails" id="SignificantAccountingPoliciesPropertyAndEquipmentDetails">
        <!--Parent Role: SIGNIFICANT ACCOUNTING POLICIES-->
        <link:definition>090204 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES, Property and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/SignificantAccountingPoliciesGoodwillDetails" id="SignificantAccountingPoliciesGoodwillDetails">
        <!--Parent Role: SIGNIFICANT ACCOUNTING POLICIES-->
        <link:definition>090206 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES, Goodwill (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/SignificantAccountingPoliciesImpairmentOfLonglivedAssetsDetails" id="SignificantAccountingPoliciesImpairmentOfLonglivedAssetsDetails">
        <!--Parent Role: SIGNIFICANT ACCOUNTING POLICIES-->
        <link:definition>090208 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES, Impairment of Long-lived Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/SignificantAccountingPoliciesRevenueRecognitionDetails" id="SignificantAccountingPoliciesRevenueRecognitionDetails">
        <!--Parent Role: SIGNIFICANT ACCOUNTING POLICIES-->
        <link:definition>090210 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES, Revenue Recognition (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/SignificantAccountingPoliciesRevenueRecognitionDetailsDefault" id="SignificantAccountingPoliciesRevenueRecognitionDetailsDefault">
        <link:definition>090210 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES, Revenue Recognition (Details)Default</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/SignificantAccountingPoliciesAdvertisingAndMarketingExpensesDetails" id="SignificantAccountingPoliciesAdvertisingAndMarketingExpensesDetails">
        <!--Parent Role: SIGNIFICANT ACCOUNTING POLICIES-->
        <link:definition>090212 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES, Advertising and Marketing Expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/SignificantAccountingPoliciesStockbasedCompensationDetails" id="SignificantAccountingPoliciesStockbasedCompensationDetails">
        <!--Parent Role: SIGNIFICANT ACCOUNTING POLICIES-->
        <link:definition>090214 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES, Stock-based Compensation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/SignificantAccountingPoliciesEarningsLossPerShareDetails" id="SignificantAccountingPoliciesEarningsLossPerShareDetails">
        <!--Parent Role: SIGNIFICANT ACCOUNTING POLICIES-->
        <link:definition>090216 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES, Earnings (Loss) Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/InventoriesDetails" id="InventoriesDetails">
        <!--Parent Role: INVENTORIES-->
        <link:definition>090300 - Disclosure - INVENTORIES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/PropertyAndEquipmentDetails" id="PropertyAndEquipmentDetails">
        <!--Parent Role: PROPERTY AND EQUIPMENT-->
        <link:definition>090400 - Disclosure - PROPERTY AND EQUIPMENT (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/IntangibleAssetsSummaryDetails" id="IntangibleAssetsSummaryDetails">
        <!--Parent Role: INTANGIBLE ASSETS-->
        <link:definition>090500 - Disclosure - INTANGIBLE ASSETS, Summary (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/IntangibleAssetsFutureAggregateAmortizationExpenseDetails" id="IntangibleAssetsFutureAggregateAmortizationExpenseDetails">
        <!--Parent Role: INTANGIBLE ASSETS-->
        <link:definition>090502 - Disclosure - INTANGIBLE ASSETS, Future Aggregate Amortization Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/AccruedExpensesAndOtherLiabilitiesDetails" id="AccruedExpensesAndOtherLiabilitiesDetails">
        <!--Parent Role: ACCRUED EXPENSES AND OTHER LIABILITIES-->
        <link:definition>090600 - Disclosure - ACCRUED EXPENSES AND OTHER LIABILITIES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/NotesPayableDetails" id="NotesPayableDetails">
        <!--Parent Role: NOTES PAYABLE-->
        <link:definition>090700 - Disclosure - NOTES PAYABLE (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/StockholdersEquityPreferredStockDetails" id="StockholdersEquityPreferredStockDetails">
        <!--Parent Role: STOCKHOLDERS' EQUITY-->
        <link:definition>090800 - Disclosure - STOCKHOLDERS' EQUITY, Preferred Stock (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/StockholdersEquityCommonStockDetails" id="StockholdersEquityCommonStockDetails">
        <!--Parent Role: STOCKHOLDERS' EQUITY-->
        <link:definition>090802 - Disclosure - STOCKHOLDERS' EQUITY, Common Stock (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/StockholdersEquityWarrantsDetails" id="StockholdersEquityWarrantsDetails">
        <!--Parent Role: STOCKHOLDERS' EQUITY-->
        <link:definition>090804 - Disclosure - STOCKHOLDERS' EQUITY, Warrants (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails" id="StockholdersEquityEquityIncentivePlansDetails">
        <!--Parent Role: STOCKHOLDERS' EQUITY-->
        <link:definition>090806 - Disclosure - STOCKHOLDERS' EQUITY, Equity Incentive Plans (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/RelatedPartyTransactionsDetails" id="RelatedPartyTransactionsDetails">
        <!--Parent Role: RELATED PARTY TRANSACTIONS-->
        <link:definition>090900 - Disclosure - RELATED PARTY TRANSACTIONS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/CommitmentsAndContingenciesDetails" id="CommitmentsAndContingenciesDetails">
        <!--Parent Role: COMMITMENTS AND CONTINGENCIES-->
        <link:definition>091000 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/IncomeTaxesIncomeTaxExpenseBenefitDetails" id="IncomeTaxesIncomeTaxExpenseBenefitDetails">
        <!--Parent Role: INCOME TAXES-->
        <link:definition>091100 - Disclosure - INCOME TAXES, Income Tax Expense (Benefit) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/IncomeTaxesReconciliationOfIncomeTaxesDetails" id="IncomeTaxesReconciliationOfIncomeTaxesDetails">
        <!--Parent Role: INCOME TAXES-->
        <link:definition>091102 - Disclosure - INCOME TAXES, Reconciliation of Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/IncomeTaxesDeferredTaxAssetsDetails" id="IncomeTaxesDeferredTaxAssetsDetails">
        <!--Parent Role: INCOME TAXES-->
        <link:definition>091104 - Disclosure - INCOME TAXES, Deferred Tax Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/IncomeTaxesNetOperatingLossCarryforwardsDetails" id="IncomeTaxesNetOperatingLossCarryforwardsDetails">
        <!--Parent Role: INCOME TAXES-->
        <link:definition>091106 - Disclosure - INCOME TAXES, Net Operating Loss Carryforwards (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/LeaseObligationsDetails" id="LeaseObligationsDetails">
        <!--Parent Role: LEASE OBLIGATIONS-->
        <link:definition>091200 - Disclosure - LEASE OBLIGATIONS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/LeaseObligationsDetailsCalc01" id="LeaseObligationsDetailsCalc01">
        <!--Parent Role: LEASE OBLIGATIONS (Details)-->
        <link:definition>091202 - Disclosure - LEASE OBLIGATIONS (Details) CALC 01</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/SegmentsSummarizedFinancialInformationBySegmentDetails" id="SegmentsSummarizedFinancialInformationBySegmentDetails">
        <!--Parent Role: SEGMENTS-->
        <link:definition>091300 - Disclosure - SEGMENTS, Summarized Financial Information by Segment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/SegmentsNetRevenuesAccordingToGeographicAreaDetails" id="SegmentsNetRevenuesAccordingToGeographicAreaDetails">
        <!--Parent Role: SEGMENTS-->
        <link:definition>091302 - Disclosure - SEGMENTS, Net Revenues According to Geographic Area (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/OtherEmployeeBenefitsDetails" id="OtherEmployeeBenefitsDetails">
        <!--Parent Role: OTHER EMPLOYEE BENEFITS-->
        <link:definition>091400 - Disclosure - OTHER EMPLOYEE BENEFITS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/SupplementalDisclosureOfCashFlowInformationDetails" id="SupplementalDisclosureOfCashFlowInformationDetails">
        <!--Parent Role: SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION-->
        <link:definition>091500 - Disclosure - SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/ConcentrationsDetails" id="ConcentrationsDetails">
        <!--Parent Role: CONCENTRATIONS-->
        <link:definition>091600 - Disclosure - CONCENTRATIONS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://admabiologics.com/role/ScheduleIiValuationAndQualifyingAccountsDetails" id="ScheduleIiValuationAndQualifyingAccountsDetails">
        <!--Parent Role: SCHEDULE II - VALUATION AND QUALIFYING ACCOUNTS-->
        <link:definition>091700 - Disclosure - SCHEDULE II - VALUATION AND QUALIFYING ACCOUNTS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:import namespace="http://fasb.org/us-gaap/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/dei/2024" schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/country/2024" schemaLocation="https://xbrl.sec.gov/country/2024/country-2024.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/currency/2024" schemaLocation="https://xbrl.sec.gov/currency/2024/currency-2024.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/exch/2024" schemaLocation="https://xbrl.sec.gov/exch/2024/exch-2024.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/naics/2024" schemaLocation="https://xbrl.sec.gov/naics/2024/naics-2024.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/sic/2024" schemaLocation="https://xbrl.sec.gov/sic/2024/sic-2024.xsd" />
  <xs:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <xs:import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/stpr/2024" schemaLocation="https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd" />
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xs:import namespace="http://www.xbrl.org/2004/ref" schemaLocation="http://www.xbrl.org/2004/ref-2004-08-10.xsd" />
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xs:import namespace="http://fasb.org/us-types/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd" />
  <xs:import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" />
  <xs:import namespace="http://fasb.org/srt/2024" schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd" />
  <xs:import namespace="http://fasb.org/srt-types/2024" schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd" />
  <xs:import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/ecd/2024" schemaLocation="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd" />
  <xs:import namespace="http://xbrl.sec.gov/cyd/2024" schemaLocation="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd" />
  <xs:element name="DeferredTaxLiabilitiesDepreciationOfPropertyAndEquipment" id="adma_DeferredTaxLiabilitiesDepreciationOfPropertyAndEquipment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" />
  <xs:element name="DeferredTaxLiabilitiesRightOfUseAsset" id="adma_DeferredTaxLiabilitiesRightOfUseAsset" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" />
  <xs:element name="DeferredTaxAssetsLeaseObligations" id="adma_DeferredTaxAssetsLeaseObligations" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" />
  <xs:element name="TaxYear2034Member" id="adma_TaxYear2034Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="TaxYear2032Member" id="adma_TaxYear2032Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="TaxYear2028Through2043Member" id="adma_TaxYear2028Through2043Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="TaxYear2036Member" id="adma_TaxYear2036Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="TaxYearAfter2037Member" id="adma_TaxYearAfter2037Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="TaxYear2033Member" id="adma_TaxYear2033Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="NetOperatingLossCarryforwardsAbstract" id="adma_NetOperatingLossCarryforwardsAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="TaxYear2035Member" id="adma_TaxYear2035Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="TaxYear2037Member" id="adma_TaxYear2037Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="TaxYear2031Member" id="adma_TaxYear2031Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="CohnReznickLLPMember" id="adma_CohnReznickLLPMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="VendorAndLicensorCommitmentsAbstract" id="adma_VendorAndLicensorCommitmentsAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="PlasmaSupplyAgreementTerm" id="adma_PlasmaSupplyAgreementTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="PlasmaPurchaseAgreementRenewalPeriod" id="adma_PlasmaPurchaseAgreementRenewalPeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="NumberOfBatchesInProductionAtTheTimeOfDisruption" id="adma_NumberOfBatchesInProductionAtTheTimeOfDisruption" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="AgreementWithTermExpirationDate" id="adma_AgreementWithTermExpirationDate" type="xbrli:dateItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="ITTechnologySystemsInaccessiblePeriod" id="adma_ITTechnologySystemsInaccessiblePeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="NumberOfPlasmaCollectionFacilities" id="adma_NumberOfPlasmaCollectionFacilities" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="IncreaseInMinimumAnnualPriceTerm" id="adma_IncreaseInMinimumAnnualPriceTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="NumberOfRenewalTerms" id="adma_NumberOfRenewalTerms" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="RestorationCostsReceived" id="adma_RestorationCostsReceived" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" />
  <xs:element name="ARGrifolsAgreementMember" id="adma_ARGrifolsAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="PlasmaPurchaseAgreementOneMember" id="adma_PlasmaPurchaseAgreementOneMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="BIVIGAMMember" id="adma_BIVIGAMMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="QuantityOfRespiratorySyncytialVirusPlasmaUsed" id="adma_QuantityOfRespiratorySyncytialVirusPlasmaUsed" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="ASCENIVMember" id="adma_ASCENIVMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="RespiratorySyncytialVirusPlasmaVolumeSuppliedPeriod" id="adma_RespiratorySyncytialVirusPlasmaVolumeSuppliedPeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="KEDPlasmaAgreementMember" id="adma_KEDPlasmaAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="PostMarketingCommitmentsAbstract" id="adma_PostMarketingCommitmentsAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="SECSchedule1209ReserveAccruedRebatesMember" id="adma_SECSchedule1209ReserveAccruedRebatesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="RightToIntermediatesMember" id="adma_RightToIntermediatesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="TrademarkAndOtherIntangibleRightsRelatedToNabiHBMember" id="adma_TrademarkAndOtherIntangibleRightsRelatedToNabiHBMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="NumberOfFDAApprovedProduct" id="adma_NumberOfFDAApprovedProduct" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="NumberOfFDALicensedPlasmaCollectionFacilities" id="adma_NumberOfFDALicensedPlasmaCollectionFacilities" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="PrepaidOnOrPriorToFirstAnniversaryMember" id="adma_PrepaidOnOrPriorToFirstAnniversaryMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="AresCreditAgreementMember" id="adma_AresCreditAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="HayfinSecondAmendmentMember" id="adma_HayfinSecondAmendmentMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="DebtInstrumentFloorInterestRate" id="adma_DebtInstrumentFloorInterestRate" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="NumberOfBusinessDaysForPriorWrittenNoticeToPrepayOutstandingPrincipal" id="adma_NumberOfBusinessDaysForPriorWrittenNoticeToPrepayOutstandingPrincipal" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="MinimumLiquidityCovenantsCreditFacilities" id="adma_MinimumLiquidityCovenantsCreditFacilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" />
  <xs:element name="PercentageOfExitFeeOfOutstandingPrincipalAmountBeingPaid" id="adma_PercentageOfExitFeeOfOutstandingPrincipalAmountBeingPaid" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="SharesIssuedUponExerciseOfWarrants" id="adma_SharesIssuedUponExerciseOfWarrants" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="PrepaymentsOfDebtPremium" id="adma_PrepaymentsOfDebtPremium" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" />
  <xs:element name="DebtInstrumentApplicableMargin" id="adma_DebtInstrumentApplicableMargin" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="DebtInstrumentUpfrontFeePaidInKind" id="adma_DebtInstrumentUpfrontFeePaidInKind" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" />
  <xs:element name="DebtInstrumentInterestAmountToBePayInKind" id="adma_DebtInstrumentInterestAmountToBePayInKind" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="OriginalDiscountPayableCreditFacility" id="adma_OriginalDiscountPayableCreditFacility" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" />
  <xs:element name="DebtInstrumentExitFee" id="adma_DebtInstrumentExitFee" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" />
  <xs:element name="DebtInstrumentTermOfVariableRate" id="adma_DebtInstrumentTermOfVariableRate" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="PrepaidAfterTheFirstAnniversaryMember" id="adma_PrepaidAfterTheFirstAnniversaryMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="PrepaidOnOrPriorToThirdAnniversaryMember" id="adma_PrepaidOnOrPriorToThirdAnniversaryMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="SeniorNotesPayableBeforeDebtDiscount" id="adma_SeniorNotesPayableBeforeDebtDiscount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" />
  <xs:element name="ExitFeeLiability" id="adma_ExitFeeLiability" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" />
  <xs:element name="HayfinCreditFacilityMember" id="adma_HayfinCreditFacilityMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="HayfinDelayedDrawLoanMember" id="adma_HayfinDelayedDrawLoanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="HayfinClosingDateLoanMember" id="adma_HayfinClosingDateLoanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="AresClosingDateLoanMember" id="adma_AresClosingDateLoanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="LongTermDebtPrepaymentPenalty" id="adma_LongTermDebtPrepaymentPenalty" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" />
  <xs:element name="PrepaidOnOrPriorToSecondAnniversaryMember" id="adma_PrepaidOnOrPriorToSecondAnniversaryMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="HayfinCreditAgreementMember" id="adma_HayfinCreditAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="TrailingPeriodForVolumeWeightedAveragePrice" id="adma_TrailingPeriodForVolumeWeightedAveragePrice" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="AresCreditFacilityMember" id="adma_AresCreditFacilityMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="NumberOfBusinessDays" id="adma_NumberOfBusinessDays" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="TermLoanMember" id="adma_TermLoanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="DilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmountShares" id="adma_DilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmountShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="TaxesPaidOnVestedRestrictedStockUnits" id="adma_TaxesPaidOnVestedRestrictedStockUnits" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" />
  <xs:element name="PaymentOfDebtRefinancingFees" id="adma_PaymentOfDebtRefinancingFees" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" />
  <xs:element name="PaymentOfEndOfTermFee" id="adma_PaymentOfEndOfTermFee" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" />
  <xs:element name="IncreaseDecreaseInDepositsAndOtherAssets" id="adma_IncreaseDecreaseInDepositsAndOtherAssets" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" />
  <xs:element name="AmortizationOfLicenseRevenue" id="adma_AmortizationOfLicenseRevenue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" />
  <xs:element name="OtherOperatingExpensesPolicyTextBlock" id="adma_OtherOperatingExpensesPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="EquipmentAcquiredReflectedInAccountsPayableAndAccruedLiabilities" id="adma_EquipmentAcquiredReflectedInAccountsPayableAndAccruedLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" />
  <xs:element name="WarrantsIssuedInConnectionWithNotesPayable" id="adma_WarrantsIssuedInConnectionWithNotesPayable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" />
  <xs:element name="UseOfEstimatesAbstract" id="adma_UseOfEstimatesAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="AccrualForUSMedicaidRebatesMember" id="adma_AccrualForUSMedicaidRebatesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="NumberOfExecutiveOfficers" id="adma_NumberOfExecutiveOfficers" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="PlasmaCollectionCentersSegmentMember" id="adma_PlasmaCollectionCentersSegmentMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="NumberOfCustomers" id="adma_NumberOfCustomers" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="ThreeCustomersMember" id="adma_ThreeCustomersMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="TwoCustomersMember" id="adma_TwoCustomersMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="FiveCustomersMember" id="adma_FiveCustomersMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesShares" id="adma_VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="StockIssuedDuringPeriodSharesCashlessExerciseOfWarrants" id="adma_StockIssuedDuringPeriodSharesCashlessExerciseOfWarrants" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAmount" id="adma_VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" />
  <xs:element name="StockIssuedDuringPeriodValueCashlessExerciseOfWarrants" id="adma_StockIssuedDuringPeriodValueCashlessExerciseOfWarrants" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" />
  <xs:element name="DepositsAndOtherNoncurrentAssets" id="adma_DepositsAndOtherNoncurrentAssets" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" />
  <xs:element name="LongTermLiabilityEndOfTermFeePayable" id="adma_LongTermLiabilityEndOfTermFeePayable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" />
  <xs:element name="OperatingAndFinancingLeaseLiability" id="adma_OperatingAndFinancingLeaseLiability" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" />
  <xs:element name="LesseeOperatingLeaseRightOfUseAssetRelatedToPropertyLease" id="adma_LesseeOperatingLeaseRightOfUseAssetRelatedToPropertyLease" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" />
  <xs:element name="LesseeOperatingLeaseLiabilitiesRelatedToPropertyLease" id="adma_LesseeOperatingLeaseLiabilitiesRelatedToPropertyLease" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" />
  <xs:element name="OperatingLeaseIncrementalBorrowingRatePercent" id="adma_OperatingLeaseIncrementalBorrowingRatePercent" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="NumberOfNewPropertyLeases" id="adma_NumberOfNewPropertyLeases" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="Two022CompensationPlanMember" id="adma_Two022CompensationPlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="ExercisePriceRange6Member" id="adma_ExercisePriceRange6Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="ExercisePriceRange5Member" id="adma_ExercisePriceRange5Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="ExercisePriceRange4Member" id="adma_ExercisePriceRange4Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="ExercisePriceRange3Member" id="adma_ExercisePriceRange3Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="EmployeesMember" id="adma_EmployeesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="ExercisePriceRange2Member" id="adma_ExercisePriceRange2Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="ExercisePriceRange1Member" id="adma_ExercisePriceRange1Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="RestrictedStockUnitsAbstract" id="adma_RestrictedStockUnitsAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="NumberOfIndividualsThatReceivedModificationsToTheirOutstandingStockOptionAndRSUAwards" id="adma_NumberOfIndividualsThatReceivedModificationsToTheirOutstandingStockOptionAndRSUAwards" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesWithheldForEmployeesTaxLiabilities" id="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesWithheldForEmployeesTaxLiabilities" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" />
  <xs:element name="StockOptionsAbstract" id="adma_StockOptionsAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="StockOptionsWeightedAverageExercisePriceAbstract" id="adma_StockOptionsWeightedAverageExercisePriceAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSharesWithheldToCoverAggregateExercisePrices" id="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSharesWithheldToCoverAggregateExercisePrices" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" />
  <xs:element name="StockOptionSharesAbstract" id="adma_StockOptionSharesAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedNumber" id="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedNumber" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedNumber" id="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedNumber" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredNumber" id="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredNumber" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedWeightedAverageExercisePrice" id="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedWeightedAverageExercisePrice" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedWeightedAverageExercisePrice" id="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedWeightedAverageExercisePrice" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredWeightedAverageExercisePrice" id="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredWeightedAverageExercisePrice" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedWeightedAverageExercisePrice" id="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedWeightedAverageExercisePrice" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedNumber" id="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedNumber" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="StockOptionOutstandingAndExcercisableAbstract" id="adma_StockOptionOutstandingAndExcercisableAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="EquityIncentivePlanMember" id="adma_EquityIncentivePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesValueWithheldForEmployeesTaxLiabilities" id="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesValueWithheldForEmployeesTaxLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" />
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSharesWithheldForPayrollTaxes" id="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSharesWithheldForPayrollTaxes" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" />
  <xs:element name="CustomerPaymentTerms" id="adma_CustomerPaymentTerms" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="DeferredRevenueRemainingAmortizationPeriod" id="adma_DeferredRevenueRemainingAmortizationPeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="BiotestLicenseAgreementMember" id="adma_BiotestLicenseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="AccountsReceivableAllowanceForContractualCreditsAndDoubtfulAccounts" id="adma_AccountsReceivableAllowanceForContractualCreditsAndDoubtfulAccounts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" />
  <xs:element name="HayfinWarrantsMember" id="adma_HayfinWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="WarrantsAbstract" id="adma_WarrantsAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="ClassOfWarrantOrRightExercised" id="adma_ClassOfWarrantOrRightExercised" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod" id="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageGrantDateFairValue" id="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageGrantDateFairValue" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod" id="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriodWeightedAverageGrantDateFairValue" id="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriodWeightedAverageGrantDateFairValue" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="AccruedTestingCurrent" id="adma_AccruedTestingCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" />
  <xs:element name="AccruedRebatesCurrent" id="adma_AccruedRebatesCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" />
  <xs:element name="DirectOwnershipMember" id="adma_DirectOwnershipMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="BryantFongMember" id="adma_BryantFongMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="GenesisBPSMember" id="adma_GenesisBPSMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="ArethLLCMember" id="adma_ArethLLCMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="PresidentAndChiefExecutiveOfficerMember" id="adma_PresidentAndChiefExecutiveOfficerMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="ExecutiveVicePresidentAndChiefFinancialOfficerMember" id="adma_ExecutiveVicePresidentAndChiefFinancialOfficerMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="RelatedPartyTransactionAbstract" id="adma_RelatedPartyTransactionAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="RelatedPartyTransactionLeaseRenewalPeriod" id="adma_RelatedPartyTransactionLeaseRenewalPeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="NumberOfExecutiveOfficersThatExercisedOptions" id="adma_NumberOfExecutiveOfficersThatExercisedOptions" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedInCashlessTransactionForAward" id="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedInCashlessTransactionForAward" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="RelatedPartyTransactionLeaseTerminationPeriod" id="adma_RelatedPartyTransactionLeaseTerminationPeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="MinimumPercentageOfCommonStockHeldByLender" id="adma_MinimumPercentageOfCommonStockHeldByLender" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="PerceptiveCreditHoldingsIILPMember" id="adma_PerceptiveCreditHoldingsIILPMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="IndirectOwnershipMember" id="adma_IndirectOwnershipMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="NumberOfPlasmaCollectionFacilitiesUnderDevelopment" id="adma_NumberOfPlasmaCollectionFacilitiesUnderDevelopment" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" abstract="false" xbrli:periodType="duration" />
  <xs:element name="ADMABioManufacturingSegmentMember" id="adma_ADMABioManufacturingSegmentMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="AdamGrossmanMember" id="adma_AdamGrossmanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="AdamGrossmanTradingPlanCommonStockMember" id="adma_AdamGrossmanTradingPlanCommonStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
  <xs:element name="AdamGrossmanTradingPlanStockOptionsMember" id="adma_AdamGrossmanTradingPlanStockOptionsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" abstract="true" xbrli:periodType="duration" />
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>14
<FILENAME>adma-20241231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--Generated by Broadridge PROfile 25.2.1.5287 Broadridge-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <link:arcroleRef arcroleURI="https://xbrl.org/2023/arcrole/summation-item" xlink:type="simple" xlink:href="https://www.xbrl.org/2023/calculation-1.1.xsd#summation-item" />
  <link:roleRef roleURI="http://admabiologics.com/role/LeaseObligationsDetailsCalc01" xlink:type="simple" xlink:href="adma-20241231.xsd#LeaseObligationsDetailsCalc01" />
  <link:roleRef roleURI="http://admabiologics.com/role/LeaseObligationsDetails" xlink:type="simple" xlink:href="adma-20241231.xsd#LeaseObligationsDetails" />
  <link:roleRef roleURI="http://admabiologics.com/role/IncomeTaxesDeferredTaxAssetsDetails" xlink:type="simple" xlink:href="adma-20241231.xsd#IncomeTaxesDeferredTaxAssetsDetails" />
  <link:roleRef roleURI="http://admabiologics.com/role/IncomeTaxesReconciliationOfIncomeTaxesDetails" xlink:type="simple" xlink:href="adma-20241231.xsd#IncomeTaxesReconciliationOfIncomeTaxesDetails" />
  <link:roleRef roleURI="http://admabiologics.com/role/IncomeTaxesIncomeTaxExpenseBenefitDetails" xlink:type="simple" xlink:href="adma-20241231.xsd#IncomeTaxesIncomeTaxExpenseBenefitDetails" />
  <link:roleRef roleURI="http://admabiologics.com/role/NotesPayableDetails" xlink:type="simple" xlink:href="adma-20241231.xsd#NotesPayableDetails" />
  <link:roleRef roleURI="http://admabiologics.com/role/AccruedExpensesAndOtherLiabilitiesDetails" xlink:type="simple" xlink:href="adma-20241231.xsd#AccruedExpensesAndOtherLiabilitiesDetails" />
  <link:roleRef roleURI="http://admabiologics.com/role/PropertyAndEquipmentDetails" xlink:type="simple" xlink:href="adma-20241231.xsd#PropertyAndEquipmentDetails" />
  <link:roleRef roleURI="http://admabiologics.com/role/InventoriesDetails" xlink:type="simple" xlink:href="adma-20241231.xsd#InventoriesDetails" />
  <link:roleRef roleURI="http://admabiologics.com/role/ConsolidatedStatementsOfCashFlows" xlink:type="simple" xlink:href="adma-20241231.xsd#ConsolidatedStatementsOfCashFlows" />
  <link:roleRef roleURI="http://admabiologics.com/role/ConsolidatedStatementsOfOperations" xlink:type="simple" xlink:href="adma-20241231.xsd#ConsolidatedStatementsOfOperations" />
  <link:roleRef roleURI="http://admabiologics.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="adma-20241231.xsd#ConsolidatedBalanceSheets" />
  <link:calculationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/ConsolidatedBalanceSheets">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="LiabilitiesAndStockholdersEquity" xlink:title="LiabilitiesAndStockholdersEquity" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="StockholdersEquity" xlink:title="StockholdersEquity" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="CommonStockValue" xlink:title="CommonStockValue" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="StockholdersEquity" xlink:to="CommonStockValue" xlink:title="calculation: StockholdersEquity to CommonStockValue" order="2.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="AdditionalPaidInCapital" xlink:title="AdditionalPaidInCapital" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="StockholdersEquity" xlink:to="AdditionalPaidInCapital" xlink:title="calculation: StockholdersEquity to AdditionalPaidInCapital" order="3.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="RetainedEarningsAccumulatedDeficit" xlink:title="RetainedEarningsAccumulatedDeficit" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="StockholdersEquity" xlink:to="RetainedEarningsAccumulatedDeficit" xlink:title="calculation: StockholdersEquity to RetainedEarningsAccumulatedDeficit" order="4.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue" xlink:label="PreferredStockValue" xlink:title="PreferredStockValue" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="StockholdersEquity" xlink:to="PreferredStockValue" xlink:title="calculation: StockholdersEquity to PreferredStockValue" order="1.0" weight="1.0" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="LiabilitiesAndStockholdersEquity" xlink:to="StockholdersEquity" xlink:title="calculation: LiabilitiesAndStockholdersEquity to StockholdersEquity" order="2.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="Liabilities" xlink:title="Liabilities" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_LongTermLiabilityEndOfTermFeePayable" xlink:label="LongTermLiabilityEndOfTermFeePayable" xlink:title="LongTermLiabilityEndOfTermFeePayable" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="Liabilities" xlink:to="LongTermLiabilityEndOfTermFeePayable" xlink:title="calculation: Liabilities to LongTermLiabilityEndOfTermFeePayable" order="4.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="LiabilitiesCurrent" xlink:title="LiabilitiesCurrent" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="AccruedLiabilitiesAndOtherLiabilities" xlink:title="AccruedLiabilitiesAndOtherLiabilities" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="LiabilitiesCurrent" xlink:to="AccruedLiabilitiesAndOtherLiabilities" xlink:title="calculation: LiabilitiesCurrent to AccruedLiabilitiesAndOtherLiabilities" order="3.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="ContractWithCustomerLiabilityCurrent" xlink:title="ContractWithCustomerLiabilityCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="LiabilitiesCurrent" xlink:to="ContractWithCustomerLiabilityCurrent" xlink:title="calculation: LiabilitiesCurrent to ContractWithCustomerLiabilityCurrent" order="2.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="OperatingLeaseLiabilityCurrent" xlink:title="OperatingLeaseLiabilityCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="LiabilitiesCurrent" xlink:to="OperatingLeaseLiabilityCurrent" xlink:title="calculation: LiabilitiesCurrent to OperatingLeaseLiabilityCurrent" order="1.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="AccountsPayableCurrent" xlink:title="AccountsPayableCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="LiabilitiesCurrent" xlink:to="AccountsPayableCurrent" xlink:title="calculation: LiabilitiesCurrent to AccountsPayableCurrent" order="4.0" weight="1.0" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="Liabilities" xlink:to="LiabilitiesCurrent" xlink:title="calculation: Liabilities to LiabilitiesCurrent" order="7.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeniorLongTermNotes" xlink:label="SeniorLongTermNotes" xlink:title="SeniorLongTermNotes" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="Liabilities" xlink:to="SeniorLongTermNotes" xlink:title="calculation: Liabilities to SeniorLongTermNotes" order="6.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="OtherLiabilitiesNoncurrent" xlink:title="OtherLiabilitiesNoncurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="Liabilities" xlink:to="OtherLiabilitiesNoncurrent" xlink:title="calculation: Liabilities to OtherLiabilitiesNoncurrent" order="1.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="OperatingLeaseLiabilityNoncurrent" xlink:title="OperatingLeaseLiabilityNoncurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="Liabilities" xlink:to="OperatingLeaseLiabilityNoncurrent" xlink:title="calculation: Liabilities to OperatingLeaseLiabilityNoncurrent" order="3.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="DeferredRevenueNoncurrent" xlink:title="DeferredRevenueNoncurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="Liabilities" xlink:to="DeferredRevenueNoncurrent" xlink:title="calculation: Liabilities to DeferredRevenueNoncurrent" order="5.0" weight="1.0" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="LiabilitiesAndStockholdersEquity" xlink:to="Liabilities" xlink:title="calculation: LiabilitiesAndStockholdersEquity to Liabilities" order="1.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="Assets" xlink:title="Assets" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="PropertyPlantAndEquipmentNet" xlink:title="PropertyPlantAndEquipmentNet" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="Assets" xlink:to="PropertyPlantAndEquipmentNet" xlink:title="calculation: Assets to PropertyPlantAndEquipmentNet" order="6.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_DepositsAndOtherNoncurrentAssets" xlink:label="DepositsAndOtherNoncurrentAssets" xlink:title="DepositsAndOtherNoncurrentAssets" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="Assets" xlink:to="DepositsAndOtherNoncurrentAssets" xlink:title="calculation: Assets to DepositsAndOtherNoncurrentAssets" order="1.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="AssetsCurrent" xlink:title="AssetsCurrent" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNet" xlink:label="InventoryNet" xlink:title="InventoryNet" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="AssetsCurrent" xlink:to="InventoryNet" xlink:title="calculation: AssetsCurrent to InventoryNet" order="2.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="CashAndCashEquivalentsAtCarryingValue" xlink:title="CashAndCashEquivalentsAtCarryingValue" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="AssetsCurrent" xlink:to="CashAndCashEquivalentsAtCarryingValue" xlink:title="calculation: AssetsCurrent to CashAndCashEquivalentsAtCarryingValue" order="4.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="AccountsReceivableNetCurrent" xlink:title="AccountsReceivableNetCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="AssetsCurrent" xlink:to="AccountsReceivableNetCurrent" xlink:title="calculation: AssetsCurrent to AccountsReceivableNetCurrent" order="3.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="PrepaidExpenseAndOtherAssetsCurrent" xlink:title="PrepaidExpenseAndOtherAssetsCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="AssetsCurrent" xlink:to="PrepaidExpenseAndOtherAssetsCurrent" xlink:title="calculation: AssetsCurrent to PrepaidExpenseAndOtherAssetsCurrent" order="1.0" weight="1.0" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="Assets" xlink:to="AssetsCurrent" xlink:title="calculation: Assets to AssetsCurrent" order="7.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="OperatingLeaseRightOfUseAsset" xlink:title="OperatingLeaseRightOfUseAsset" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="Assets" xlink:to="OperatingLeaseRightOfUseAsset" xlink:title="calculation: Assets to OperatingLeaseRightOfUseAsset" order="3.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Goodwill" xlink:label="Goodwill" xlink:title="Goodwill" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="Assets" xlink:to="Goodwill" xlink:title="calculation: Assets to Goodwill" order="4.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="IntangibleAssetsNetExcludingGoodwill" xlink:title="IntangibleAssetsNetExcludingGoodwill" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="Assets" xlink:to="IntangibleAssetsNetExcludingGoodwill" xlink:title="calculation: Assets to IntangibleAssetsNetExcludingGoodwill" order="5.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxAssetsNet" xlink:label="DeferredIncomeTaxAssetsNet" xlink:title="DeferredIncomeTaxAssetsNet" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="Assets" xlink:to="DeferredIncomeTaxAssetsNet" xlink:title="calculation: Assets to DeferredIncomeTaxAssetsNet" order="2.0" weight="1.0" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/ConsolidatedStatementsOfOperations">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="NetIncomeLoss" xlink:title="NetIncomeLoss" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:title="IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="OperatingIncomeLoss" xlink:title="OperatingIncomeLoss" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="OperatingExpenses" xlink:title="OperatingExpenses" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="AmortizationOfIntangibleAssets" xlink:title="AmortizationOfIntangibleAssets" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="OperatingExpenses" xlink:to="AmortizationOfIntangibleAssets" xlink:title="calculation: OperatingExpenses to AmortizationOfIntangibleAssets" order="2.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="ResearchAndDevelopmentExpense" xlink:title="ResearchAndDevelopmentExpense" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="OperatingExpenses" xlink:to="ResearchAndDevelopmentExpense" xlink:title="calculation: OperatingExpenses to ResearchAndDevelopmentExpense" order="4.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCostAndExpenseOperating" xlink:label="OtherCostAndExpenseOperating" xlink:title="OtherCostAndExpenseOperating" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="OperatingExpenses" xlink:to="OtherCostAndExpenseOperating" xlink:title="calculation: OperatingExpenses to OtherCostAndExpenseOperating" order="3.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="SellingGeneralAndAdministrativeExpense" xlink:title="SellingGeneralAndAdministrativeExpense" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="OperatingExpenses" xlink:to="SellingGeneralAndAdministrativeExpense" xlink:title="calculation: OperatingExpenses to SellingGeneralAndAdministrativeExpense" order="1.0" weight="1.0" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="OperatingIncomeLoss" xlink:to="OperatingExpenses" xlink:title="calculation: OperatingIncomeLoss to OperatingExpenses" order="1.0" weight="-1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GrossProfit" xlink:label="GrossProfit" xlink:title="GrossProfit" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfRevenue" xlink:label="CostOfRevenue" xlink:title="CostOfRevenue" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="GrossProfit" xlink:to="CostOfRevenue" xlink:title="calculation: GrossProfit to CostOfRevenue" order="1.0" weight="-1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="RevenueFromContractWithCustomerExcludingAssessedTax" xlink:title="RevenueFromContractWithCustomerExcludingAssessedTax" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="GrossProfit" xlink:to="RevenueFromContractWithCustomerExcludingAssessedTax" xlink:title="calculation: GrossProfit to RevenueFromContractWithCustomerExcludingAssessedTax" order="0.0" weight="1.0" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="OperatingIncomeLoss" xlink:to="GrossProfit" xlink:title="calculation: OperatingIncomeLoss to GrossProfit" order="3.0" weight="1.0" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="OperatingIncomeLoss" xlink:title="calculation: IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest to OperatingIncomeLoss" order="0.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="NonoperatingIncomeExpense" xlink:title="NonoperatingIncomeExpense" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="GainsLossesOnExtinguishmentOfDebt" xlink:title="GainsLossesOnExtinguishmentOfDebt" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="NonoperatingIncomeExpense" xlink:to="GainsLossesOnExtinguishmentOfDebt" xlink:title="calculation: NonoperatingIncomeExpense to GainsLossesOnExtinguishmentOfDebt" order="2.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="InvestmentIncomeInterest" xlink:title="InvestmentIncomeInterest" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="NonoperatingIncomeExpense" xlink:to="InvestmentIncomeInterest" xlink:title="calculation: NonoperatingIncomeExpense to InvestmentIncomeInterest" order="1.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="OtherNonoperatingIncomeExpense" xlink:title="OtherNonoperatingIncomeExpense" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="NonoperatingIncomeExpense" xlink:to="OtherNonoperatingIncomeExpense" xlink:title="calculation: NonoperatingIncomeExpense to OtherNonoperatingIncomeExpense" order="5.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseNonoperating" xlink:label="InterestExpenseNonoperating" xlink:title="InterestExpenseNonoperating" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="NonoperatingIncomeExpense" xlink:to="InterestExpenseNonoperating" xlink:title="calculation: NonoperatingIncomeExpense to InterestExpenseNonoperating" order="4.0" weight="-1.0" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="NonoperatingIncomeExpense" xlink:title="calculation: IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest to NonoperatingIncomeExpense" order="1.0" weight="1.0" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="NetIncomeLoss" xlink:to="IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:title="calculation: NetIncomeLoss to IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="0.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="IncomeTaxExpenseBenefit" xlink:title="IncomeTaxExpenseBenefit" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="NetIncomeLoss" xlink:to="IncomeTaxExpenseBenefit" xlink:title="calculation: NetIncomeLoss to IncomeTaxExpenseBenefit" order="1.0" weight="-1.0" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/ConsolidatedStatementsOfCashFlows">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:title="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="NetCashProvidedByUsedInFinancingActivities" xlink:title="NetCashProvidedByUsedInFinancingActivities" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfFinancingCosts" xlink:label="PaymentsOfFinancingCosts" xlink:title="PaymentsOfFinancingCosts" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInFinancingActivities" xlink:to="PaymentsOfFinancingCosts" xlink:title="calculation: NetCashProvidedByUsedInFinancingActivities to PaymentsOfFinancingCosts" order="4.0" weight="-1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="ProceedsFromIssuanceOfCommonStock" xlink:title="ProceedsFromIssuanceOfCommonStock" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInFinancingActivities" xlink:to="ProceedsFromIssuanceOfCommonStock" xlink:title="calculation: NetCashProvidedByUsedInFinancingActivities to ProceedsFromIssuanceOfCommonStock" order="2.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="ProceedsFromStockOptionsExercised" xlink:title="ProceedsFromStockOptionsExercised" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInFinancingActivities" xlink:to="ProceedsFromStockOptionsExercised" xlink:title="calculation: NetCashProvidedByUsedInFinancingActivities to ProceedsFromStockOptionsExercised" order="3.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="ProceedsFromNotesPayable" xlink:title="ProceedsFromNotesPayable" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInFinancingActivities" xlink:to="ProceedsFromNotesPayable" xlink:title="calculation: NetCashProvidedByUsedInFinancingActivities to ProceedsFromNotesPayable" order="7.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="RepaymentsOfNotesPayable" xlink:title="RepaymentsOfNotesPayable" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInFinancingActivities" xlink:to="RepaymentsOfNotesPayable" xlink:title="calculation: NetCashProvidedByUsedInFinancingActivities to RepaymentsOfNotesPayable" order="0.0" weight="-1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeasePrincipalPayments" xlink:label="FinanceLeasePrincipalPayments" xlink:title="FinanceLeasePrincipalPayments" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInFinancingActivities" xlink:to="FinanceLeasePrincipalPayments" xlink:title="calculation: NetCashProvidedByUsedInFinancingActivities to FinanceLeasePrincipalPayments" order="10.0" weight="-1.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_PaymentOfEndOfTermFee" xlink:label="PaymentOfEndOfTermFee" xlink:title="PaymentOfEndOfTermFee" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInFinancingActivities" xlink:to="PaymentOfEndOfTermFee" xlink:title="calculation: NetCashProvidedByUsedInFinancingActivities to PaymentOfEndOfTermFee" order="6.0" weight="-1.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_TaxesPaidOnVestedRestrictedStockUnits" xlink:label="TaxesPaidOnVestedRestrictedStockUnits" xlink:title="TaxesPaidOnVestedRestrictedStockUnits" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInFinancingActivities" xlink:to="TaxesPaidOnVestedRestrictedStockUnits" xlink:title="calculation: NetCashProvidedByUsedInFinancingActivities to TaxesPaidOnVestedRestrictedStockUnits" order="9.0" weight="-1.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_PaymentOfDebtRefinancingFees" xlink:label="PaymentOfDebtRefinancingFees" xlink:title="PaymentOfDebtRefinancingFees" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInFinancingActivities" xlink:to="PaymentOfDebtRefinancingFees" xlink:title="calculation: NetCashProvidedByUsedInFinancingActivities to PaymentOfDebtRefinancingFees" order="5.0" weight="-1.0" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="NetCashProvidedByUsedInFinancingActivities" xlink:title="calculation: CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect to NetCashProvidedByUsedInFinancingActivities" order="1.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="NetCashProvidedByUsedInInvestingActivities" xlink:title="NetCashProvidedByUsedInInvestingActivities" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="PaymentsToAcquireIntangibleAssets" xlink:title="PaymentsToAcquireIntangibleAssets" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInInvestingActivities" xlink:to="PaymentsToAcquireIntangibleAssets" xlink:title="calculation: NetCashProvidedByUsedInInvestingActivities to PaymentsToAcquireIntangibleAssets" order="3.0" weight="-1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="PaymentsToAcquirePropertyPlantAndEquipment" xlink:title="PaymentsToAcquirePropertyPlantAndEquipment" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInInvestingActivities" xlink:to="PaymentsToAcquirePropertyPlantAndEquipment" xlink:title="calculation: NetCashProvidedByUsedInInvestingActivities to PaymentsToAcquirePropertyPlantAndEquipment" order="2.0" weight="-1.0" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="NetCashProvidedByUsedInInvestingActivities" xlink:title="calculation: CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect to NetCashProvidedByUsedInInvestingActivities" order="2.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="NetCashProvidedByUsedInOperatingActivities" xlink:title="NetCashProvidedByUsedInOperatingActivities" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="ShareBasedCompensation" xlink:title="ShareBasedCompensation" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="ShareBasedCompensation" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivities to ShareBasedCompensation" order="4.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnDispositionOfAssets" xlink:label="GainLossOnDispositionOfAssets" xlink:title="GainLossOnDispositionOfAssets" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="GainLossOnDispositionOfAssets" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivities to GainLossOnDispositionOfAssets" order="2.0" weight="-1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="NetIncomeLoss" xlink:title="NetIncomeLoss" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="NetIncomeLoss" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivities to NetIncomeLoss" order="0.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="AmortizationOfDebtDiscountPremium" xlink:title="AmortizationOfDebtDiscountPremium" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="AmortizationOfDebtDiscountPremium" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivities to AmortizationOfDebtDiscountPremium" order="6.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="GainsLossesOnExtinguishmentOfDebt" xlink:title="GainsLossesOnExtinguishmentOfDebt" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="GainsLossesOnExtinguishmentOfDebt" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivities to GainsLossesOnExtinguishmentOfDebt" order="7.0" weight="-1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="IncreaseDecreaseInInventories" xlink:title="IncreaseDecreaseInInventories" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="IncreaseDecreaseInInventories" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivities to IncreaseDecreaseInInventories" order="10.0" weight="-1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationAndAmortization" xlink:label="DepreciationAndAmortization" xlink:title="DepreciationAndAmortization" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="DepreciationAndAmortization" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivities to DepreciationAndAmortization" order="1.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="IncreaseDecreaseInAccountsPayable" xlink:title="IncreaseDecreaseInAccountsPayable" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="IncreaseDecreaseInAccountsPayable" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivities to IncreaseDecreaseInAccountsPayable" order="13.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:title="IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivities to IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="11.0" weight="-1.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_IncreaseDecreaseInDepositsAndOtherAssets" xlink:label="IncreaseDecreaseInDepositsAndOtherAssets" xlink:title="IncreaseDecreaseInDepositsAndOtherAssets" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="IncreaseDecreaseInDepositsAndOtherAssets" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivities to IncreaseDecreaseInDepositsAndOtherAssets" order="12.0" weight="-1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="IncreaseDecreaseInAccruedLiabilities" xlink:title="IncreaseDecreaseInAccruedLiabilities" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="IncreaseDecreaseInAccruedLiabilities" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivities to IncreaseDecreaseInAccruedLiabilities" order="14.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaidInKindInterest" xlink:label="PaidInKindInterest" xlink:title="PaidInKindInterest" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="PaidInKindInterest" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivities to PaidInKindInterest" order="3.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="IncreaseDecreaseInAccountsReceivable" xlink:title="IncreaseDecreaseInAccountsReceivable" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="IncreaseDecreaseInAccountsReceivable" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivities to IncreaseDecreaseInAccountsReceivable" order="9.0" weight="-1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:label="IncreaseDecreaseInOtherOperatingLiabilities" xlink:title="IncreaseDecreaseInOtherOperatingLiabilities" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="IncreaseDecreaseInOtherOperatingLiabilities" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivities to IncreaseDecreaseInOtherOperatingLiabilities" order="15.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_AmortizationOfLicenseRevenue" xlink:label="AmortizationOfLicenseRevenue" xlink:title="AmortizationOfLicenseRevenue" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="AmortizationOfLicenseRevenue" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivities to AmortizationOfLicenseRevenue" order="8.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:label="IncreaseDecreaseInDeferredIncomeTaxes" xlink:title="IncreaseDecreaseInDeferredIncomeTaxes" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="IncreaseDecreaseInDeferredIncomeTaxes" xlink:title="calculation: NetCashProvidedByUsedInOperatingActivities to IncreaseDecreaseInDeferredIncomeTaxes" order="5.0" weight="-1.0" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="NetCashProvidedByUsedInOperatingActivities" xlink:title="calculation: CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect to NetCashProvidedByUsedInOperatingActivities" order="3.0" weight="1.0" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/InventoriesDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNet" xlink:label="InventoryNet" xlink:title="InventoryNet" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryFinishedGoods" xlink:label="InventoryFinishedGoods" xlink:title="InventoryFinishedGoods" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="InventoryNet" xlink:to="InventoryFinishedGoods" xlink:title="calculation: InventoryNet to InventoryFinishedGoods" order="3.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryWorkInProcess" xlink:label="InventoryWorkInProcess" xlink:title="InventoryWorkInProcess" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="InventoryNet" xlink:to="InventoryWorkInProcess" xlink:title="calculation: InventoryNet to InventoryWorkInProcess" order="2.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryRawMaterials" xlink:label="InventoryRawMaterials" xlink:title="InventoryRawMaterials" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="InventoryNet" xlink:to="InventoryRawMaterials" xlink:title="calculation: InventoryNet to InventoryRawMaterials" order="1.0" weight="1.0" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/PropertyAndEquipmentDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="PropertyPlantAndEquipmentNet" xlink:title="PropertyPlantAndEquipmentNet" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:title="AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="PropertyPlantAndEquipmentNet" xlink:to="AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:title="calculation: PropertyPlantAndEquipmentNet to AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="2.0" weight="-1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="PropertyPlantAndEquipmentGross" xlink:title="PropertyPlantAndEquipmentGross" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="PropertyPlantAndEquipmentNet" xlink:to="PropertyPlantAndEquipmentGross" xlink:title="calculation: PropertyPlantAndEquipmentNet to PropertyPlantAndEquipmentGross" order="1.0" weight="1.0" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/AccruedExpensesAndOtherLiabilitiesDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="AccruedLiabilitiesAndOtherLiabilities" xlink:title="AccruedLiabilitiesAndOtherLiabilities" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPayableCurrent" xlink:label="InterestPayableCurrent" xlink:title="InterestPayableCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="AccruedLiabilitiesAndOtherLiabilities" xlink:to="InterestPayableCurrent" xlink:title="calculation: AccruedLiabilitiesAndOtherLiabilities to InterestPayableCurrent" order="3.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxesPayableCurrent" xlink:label="TaxesPayableCurrent" xlink:title="TaxesPayableCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="AccruedLiabilitiesAndOtherLiabilities" xlink:to="TaxesPayableCurrent" xlink:title="calculation: AccruedLiabilitiesAndOtherLiabilities to TaxesPayableCurrent" order="6.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedSalariesCurrent" xlink:label="AccruedSalariesCurrent" xlink:title="AccruedSalariesCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="AccruedLiabilitiesAndOtherLiabilities" xlink:to="AccruedSalariesCurrent" xlink:title="calculation: AccruedLiabilitiesAndOtherLiabilities to AccruedSalariesCurrent" order="5.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_AccruedRebatesCurrent" xlink:label="AccruedRebatesCurrent" xlink:title="AccruedRebatesCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="AccruedLiabilitiesAndOtherLiabilities" xlink:to="AccruedRebatesCurrent" xlink:title="calculation: AccruedLiabilitiesAndOtherLiabilities to AccruedRebatesCurrent" order="0.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="OtherAccruedLiabilitiesCurrent" xlink:title="OtherAccruedLiabilitiesCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="AccruedLiabilitiesAndOtherLiabilities" xlink:to="OtherAccruedLiabilitiesCurrent" xlink:title="calculation: AccruedLiabilitiesAndOtherLiabilities to OtherAccruedLiabilitiesCurrent" order="7.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="AccruedProfessionalFeesCurrent" xlink:title="AccruedProfessionalFeesCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="AccruedLiabilitiesAndOtherLiabilities" xlink:to="AccruedProfessionalFeesCurrent" xlink:title="calculation: AccruedLiabilitiesAndOtherLiabilities to AccruedProfessionalFeesCurrent" order="1.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedBonusesCurrent" xlink:label="AccruedBonusesCurrent" xlink:title="AccruedBonusesCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="AccruedLiabilitiesAndOtherLiabilities" xlink:to="AccruedBonusesCurrent" xlink:title="calculation: AccruedLiabilitiesAndOtherLiabilities to AccruedBonusesCurrent" order="2.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_AccruedTestingCurrent" xlink:label="AccruedTestingCurrent" xlink:title="AccruedTestingCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="AccruedLiabilitiesAndOtherLiabilities" xlink:to="AccruedTestingCurrent" xlink:title="calculation: AccruedLiabilitiesAndOtherLiabilities to AccruedTestingCurrent" order="4.0" weight="1.0" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/NotesPayableDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeniorLongTermNotes" xlink:label="SeniorLongTermNotes" xlink:title="SeniorLongTermNotes" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_SeniorNotesPayableBeforeDebtDiscount" xlink:label="SeniorNotesPayableBeforeDebtDiscount" xlink:title="SeniorNotesPayableBeforeDebtDiscount" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="SeniorLongTermNotes" xlink:to="SeniorNotesPayableBeforeDebtDiscount" xlink:title="calculation: SeniorLongTermNotes to SeniorNotesPayableBeforeDebtDiscount" order="1.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="DebtInstrumentUnamortizedDiscount" xlink:title="DebtInstrumentUnamortizedDiscount" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="SeniorLongTermNotes" xlink:to="DebtInstrumentUnamortizedDiscount" xlink:title="calculation: SeniorLongTermNotes to DebtInstrumentUnamortizedDiscount" order="2.0" weight="-1.0" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/IncomeTaxesIncomeTaxExpenseBenefitDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="IncomeTaxExpenseBenefit" xlink:title="IncomeTaxExpenseBenefit" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="CurrentIncomeTaxExpenseBenefit" xlink:title="CurrentIncomeTaxExpenseBenefit" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="CurrentFederalTaxExpenseBenefit" xlink:title="CurrentFederalTaxExpenseBenefit" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="CurrentIncomeTaxExpenseBenefit" xlink:to="CurrentFederalTaxExpenseBenefit" xlink:title="calculation: CurrentIncomeTaxExpenseBenefit to CurrentFederalTaxExpenseBenefit" order="0.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="CurrentStateAndLocalTaxExpenseBenefit" xlink:title="CurrentStateAndLocalTaxExpenseBenefit" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="CurrentIncomeTaxExpenseBenefit" xlink:to="CurrentStateAndLocalTaxExpenseBenefit" xlink:title="calculation: CurrentIncomeTaxExpenseBenefit to CurrentStateAndLocalTaxExpenseBenefit" order="1.0" weight="1.0" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="IncomeTaxExpenseBenefit" xlink:to="CurrentIncomeTaxExpenseBenefit" xlink:title="calculation: IncomeTaxExpenseBenefit to CurrentIncomeTaxExpenseBenefit" order="0.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="DeferredIncomeTaxExpenseBenefit" xlink:title="DeferredIncomeTaxExpenseBenefit" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="DeferredFederalIncomeTaxExpenseBenefit" xlink:title="DeferredFederalIncomeTaxExpenseBenefit" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="DeferredIncomeTaxExpenseBenefit" xlink:to="DeferredFederalIncomeTaxExpenseBenefit" xlink:title="calculation: DeferredIncomeTaxExpenseBenefit to DeferredFederalIncomeTaxExpenseBenefit" order="0.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:title="DeferredStateAndLocalIncomeTaxExpenseBenefit" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="DeferredIncomeTaxExpenseBenefit" xlink:to="DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:title="calculation: DeferredIncomeTaxExpenseBenefit to DeferredStateAndLocalIncomeTaxExpenseBenefit" order="1.0" weight="1.0" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="IncomeTaxExpenseBenefit" xlink:to="DeferredIncomeTaxExpenseBenefit" xlink:title="calculation: IncomeTaxExpenseBenefit to DeferredIncomeTaxExpenseBenefit" order="1.0" weight="1.0" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/IncomeTaxesReconciliationOfIncomeTaxesDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="IncomeTaxExpenseBenefit" xlink:title="IncomeTaxExpenseBenefit" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:title="IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="IncomeTaxExpenseBenefit" xlink:to="IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:title="calculation: IncomeTaxExpenseBenefit to IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" order="0.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:title="IncomeTaxReconciliationStateAndLocalIncomeTaxes" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="IncomeTaxExpenseBenefit" xlink:to="IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:title="calculation: IncomeTaxExpenseBenefit to IncomeTaxReconciliationStateAndLocalIncomeTaxes" order="3.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" xlink:label="EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" xlink:title="EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="IncomeTaxExpenseBenefit" xlink:to="EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" xlink:title="calculation: IncomeTaxExpenseBenefit to EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" order="2.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:label="IncomeTaxReconciliationNondeductibleExpense" xlink:title="IncomeTaxReconciliationNondeductibleExpense" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="IncomeTaxExpenseBenefit" xlink:to="IncomeTaxReconciliationNondeductibleExpense" xlink:title="calculation: IncomeTaxExpenseBenefit to IncomeTaxReconciliationNondeductibleExpense" order="1.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:title="IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="IncomeTaxExpenseBenefit" xlink:to="IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:title="calculation: IncomeTaxExpenseBenefit to IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="4.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:label="IncomeTaxReconciliationOtherAdjustments" xlink:title="IncomeTaxReconciliationOtherAdjustments" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="IncomeTaxExpenseBenefit" xlink:to="IncomeTaxReconciliationOtherAdjustments" xlink:title="calculation: IncomeTaxExpenseBenefit to IncomeTaxReconciliationOtherAdjustments" order="8.0" weight="1.0" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/IncomeTaxesDeferredTaxAssetsDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="DeferredTaxAssetsLiabilitiesNet" xlink:title="DeferredTaxAssetsLiabilitiesNet" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="DeferredIncomeTaxLiabilities" xlink:title="DeferredIncomeTaxLiabilities" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesOther" xlink:label="DeferredTaxLiabilitiesOther" xlink:title="DeferredTaxLiabilitiesOther" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="DeferredIncomeTaxLiabilities" xlink:to="DeferredTaxLiabilitiesOther" xlink:title="calculation: DeferredIncomeTaxLiabilities to DeferredTaxLiabilitiesOther" order="2.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_DeferredTaxLiabilitiesRightOfUseAsset" xlink:label="DeferredTaxLiabilitiesRightOfUseAsset" xlink:title="DeferredTaxLiabilitiesRightOfUseAsset" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="DeferredIncomeTaxLiabilities" xlink:to="DeferredTaxLiabilitiesRightOfUseAsset" xlink:title="calculation: DeferredIncomeTaxLiabilities to DeferredTaxLiabilitiesRightOfUseAsset" order="1.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_DeferredTaxLiabilitiesDepreciationOfPropertyAndEquipment" xlink:label="DeferredTaxLiabilitiesDepreciationOfPropertyAndEquipment" xlink:title="DeferredTaxLiabilitiesDepreciationOfPropertyAndEquipment" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="DeferredIncomeTaxLiabilities" xlink:to="DeferredTaxLiabilitiesDepreciationOfPropertyAndEquipment" xlink:title="calculation: DeferredIncomeTaxLiabilities to DeferredTaxLiabilitiesDepreciationOfPropertyAndEquipment" order="0.0" weight="1.0" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="DeferredTaxAssetsLiabilitiesNet" xlink:to="DeferredIncomeTaxLiabilities" xlink:title="calculation: DeferredTaxAssetsLiabilitiesNet to DeferredIncomeTaxLiabilities" order="1.0" weight="-1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="DeferredTaxAssetsNet" xlink:title="DeferredTaxAssetsNet" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="DeferredTaxAssetsGross" xlink:title="DeferredTaxAssetsGross" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_DeferredTaxAssetsLeaseObligations" xlink:label="DeferredTaxAssetsLeaseObligations" xlink:title="DeferredTaxAssetsLeaseObligations" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="DeferredTaxAssetsGross" xlink:to="DeferredTaxAssetsLeaseObligations" xlink:title="calculation: DeferredTaxAssetsGross to DeferredTaxAssetsLeaseObligations" order="8.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:label="DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:title="DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="DeferredTaxAssetsGross" xlink:to="DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:title="calculation: DeferredTaxAssetsGross to DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" order="5.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:title="DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="DeferredTaxAssetsGross" xlink:to="DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:title="calculation: DeferredTaxAssetsGross to DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" order="7.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:label="DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:title="DeferredTaxAssetsOperatingLossCarryforwardsDomestic" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="DeferredTaxAssetsGross" xlink:to="DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:title="calculation: DeferredTaxAssetsGross to DeferredTaxAssetsOperatingLossCarryforwardsDomestic" order="0.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetInterestCarryforward" xlink:label="DeferredTaxAssetInterestCarryforward" xlink:title="DeferredTaxAssetInterestCarryforward" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="DeferredTaxAssetsGross" xlink:to="DeferredTaxAssetInterestCarryforward" xlink:title="calculation: DeferredTaxAssetsGross to DeferredTaxAssetInterestCarryforward" order="2.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsInventory" xlink:label="DeferredTaxAssetsInventory" xlink:title="DeferredTaxAssetsInventory" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="DeferredTaxAssetsGross" xlink:to="DeferredTaxAssetsInventory" xlink:title="calculation: DeferredTaxAssetsGross to DeferredTaxAssetsInventory" order="6.0" weight="1.0" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="DeferredTaxAssetsNet" xlink:to="DeferredTaxAssetsGross" xlink:title="calculation: DeferredTaxAssetsNet to DeferredTaxAssetsGross" order="0.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="DeferredTaxAssetsValuationAllowance" xlink:title="DeferredTaxAssetsValuationAllowance" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="DeferredTaxAssetsNet" xlink:to="DeferredTaxAssetsValuationAllowance" xlink:title="calculation: DeferredTaxAssetsNet to DeferredTaxAssetsValuationAllowance" order="1.0" weight="-1.0" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="DeferredTaxAssetsLiabilitiesNet" xlink:to="DeferredTaxAssetsNet" xlink:title="calculation: DeferredTaxAssetsLiabilitiesNet to DeferredTaxAssetsNet" order="0.0" weight="1.0" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/LeaseObligationsDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="LesseeOperatingLeaseLiabilityPaymentsDue" xlink:title="LesseeOperatingLeaseLiabilityPaymentsDue" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:title="LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:title="calculation: LesseeOperatingLeaseLiabilityPaymentsDue to LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="1.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:title="LesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:title="calculation: LesseeOperatingLeaseLiabilityPaymentsDue to LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="4.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:title="LesseeOperatingLeaseLiabilityPaymentsDueYearFive" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:title="calculation: LesseeOperatingLeaseLiabilityPaymentsDue to LesseeOperatingLeaseLiabilityPaymentsDueYearFive" order="6.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:title="LesseeOperatingLeaseLiabilityPaymentsDueYearFour" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:title="calculation: LesseeOperatingLeaseLiabilityPaymentsDue to LesseeOperatingLeaseLiabilityPaymentsDueYearFour" order="5.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:title="LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:title="calculation: LesseeOperatingLeaseLiabilityPaymentsDue to LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" order="7.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:title="LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:title="calculation: LesseeOperatingLeaseLiabilityPaymentsDue to LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="3.0" weight="1.0" />
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/LeaseObligationsDetailsCalc01">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="LesseeOperatingLeaseLiabilityPaymentsDue" xlink:title="LesseeOperatingLeaseLiabilityPaymentsDue" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:title="LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:title="calculation: LesseeOperatingLeaseLiabilityPaymentsDue to LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="1.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="OperatingLeaseLiabilityCurrent" xlink:title="OperatingLeaseLiabilityCurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="OperatingLeaseLiabilityCurrent" xlink:title="calculation: LesseeOperatingLeaseLiabilityPaymentsDue to OperatingLeaseLiabilityCurrent" order="2.0" weight="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="OperatingLeaseLiabilityNoncurrent" xlink:title="OperatingLeaseLiabilityNoncurrent" />
    <link:calculationArc xlink:type="arc" xlink:arcrole="https://xbrl.org/2023/arcrole/summation-item" xlink:from="LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="OperatingLeaseLiabilityNoncurrent" xlink:title="calculation: LesseeOperatingLeaseLiabilityPaymentsDue to OperatingLeaseLiabilityNoncurrent" order="3.0" weight="1.0" />
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>15
<FILENAME>adma-20241231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--Generated by Broadridge PROfile 25.2.1.5287 Broadridge-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:t1="http://xbrl.org/2005/xbrldt">
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="simple" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd#eedm" />
  <link:roleRef roleURI="http://admabiologics.com/role/ScheduleIiValuationAndQualifyingAccountsDetails" xlink:type="simple" xlink:href="adma-20241231.xsd#ScheduleIiValuationAndQualifyingAccountsDetails" />
  <link:roleRef roleURI="http://admabiologics.com/role/ConcentrationsDetails" xlink:type="simple" xlink:href="adma-20241231.xsd#ConcentrationsDetails" />
  <link:roleRef roleURI="http://admabiologics.com/role/SupplementalDisclosureOfCashFlowInformationDetails" xlink:type="simple" xlink:href="adma-20241231.xsd#SupplementalDisclosureOfCashFlowInformationDetails" />
  <link:roleRef roleURI="http://admabiologics.com/role/OtherEmployeeBenefitsDetails" xlink:type="simple" xlink:href="adma-20241231.xsd#OtherEmployeeBenefitsDetails" />
  <link:roleRef roleURI="http://admabiologics.com/role/SegmentsNetRevenuesAccordingToGeographicAreaDetails" xlink:type="simple" xlink:href="adma-20241231.xsd#SegmentsNetRevenuesAccordingToGeographicAreaDetails" />
  <link:roleRef roleURI="http://admabiologics.com/role/SegmentsSummarizedFinancialInformationBySegmentDetails" xlink:type="simple" xlink:href="adma-20241231.xsd#SegmentsSummarizedFinancialInformationBySegmentDetails" />
  <link:roleRef roleURI="http://admabiologics.com/role/LeaseObligationsDetailsCalc01" xlink:type="simple" xlink:href="adma-20241231.xsd#LeaseObligationsDetailsCalc01" />
  <link:roleRef roleURI="http://admabiologics.com/role/LeaseObligationsDetails" xlink:type="simple" xlink:href="adma-20241231.xsd#LeaseObligationsDetails" />
  <link:roleRef roleURI="http://admabiologics.com/role/IncomeTaxesNetOperatingLossCarryforwardsDetails" xlink:type="simple" xlink:href="adma-20241231.xsd#IncomeTaxesNetOperatingLossCarryforwardsDetails" />
  <link:roleRef roleURI="http://admabiologics.com/role/IncomeTaxesDeferredTaxAssetsDetails" xlink:type="simple" xlink:href="adma-20241231.xsd#IncomeTaxesDeferredTaxAssetsDetails" />
  <link:roleRef roleURI="http://admabiologics.com/role/IncomeTaxesReconciliationOfIncomeTaxesDetails" xlink:type="simple" xlink:href="adma-20241231.xsd#IncomeTaxesReconciliationOfIncomeTaxesDetails" />
  <link:roleRef roleURI="http://admabiologics.com/role/IncomeTaxesIncomeTaxExpenseBenefitDetails" xlink:type="simple" xlink:href="adma-20241231.xsd#IncomeTaxesIncomeTaxExpenseBenefitDetails" />
  <link:roleRef roleURI="http://admabiologics.com/role/CommitmentsAndContingenciesDetails" xlink:type="simple" xlink:href="adma-20241231.xsd#CommitmentsAndContingenciesDetails" />
  <link:roleRef roleURI="http://admabiologics.com/role/RelatedPartyTransactionsDetails" xlink:type="simple" xlink:href="adma-20241231.xsd#RelatedPartyTransactionsDetails" />
  <link:roleRef roleURI="http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails" xlink:type="simple" xlink:href="adma-20241231.xsd#StockholdersEquityEquityIncentivePlansDetails" />
  <link:roleRef roleURI="http://admabiologics.com/role/StockholdersEquityWarrantsDetails" xlink:type="simple" xlink:href="adma-20241231.xsd#StockholdersEquityWarrantsDetails" />
  <link:roleRef roleURI="http://admabiologics.com/role/StockholdersEquityCommonStockDetails" xlink:type="simple" xlink:href="adma-20241231.xsd#StockholdersEquityCommonStockDetails" />
  <link:roleRef roleURI="http://admabiologics.com/role/StockholdersEquityPreferredStockDetails" xlink:type="simple" xlink:href="adma-20241231.xsd#StockholdersEquityPreferredStockDetails" />
  <link:roleRef roleURI="http://admabiologics.com/role/NotesPayableDetails" xlink:type="simple" xlink:href="adma-20241231.xsd#NotesPayableDetails" />
  <link:roleRef roleURI="http://admabiologics.com/role/AccruedExpensesAndOtherLiabilitiesDetails" xlink:type="simple" xlink:href="adma-20241231.xsd#AccruedExpensesAndOtherLiabilitiesDetails" />
  <link:roleRef roleURI="http://admabiologics.com/role/IntangibleAssetsFutureAggregateAmortizationExpenseDetails" xlink:type="simple" xlink:href="adma-20241231.xsd#IntangibleAssetsFutureAggregateAmortizationExpenseDetails" />
  <link:roleRef roleURI="http://admabiologics.com/role/IntangibleAssetsSummaryDetails" xlink:type="simple" xlink:href="adma-20241231.xsd#IntangibleAssetsSummaryDetails" />
  <link:roleRef roleURI="http://admabiologics.com/role/PropertyAndEquipmentDetails" xlink:type="simple" xlink:href="adma-20241231.xsd#PropertyAndEquipmentDetails" />
  <link:roleRef roleURI="http://admabiologics.com/role/InventoriesDetails" xlink:type="simple" xlink:href="adma-20241231.xsd#InventoriesDetails" />
  <link:roleRef roleURI="http://admabiologics.com/role/SignificantAccountingPoliciesEarningsLossPerShareDetails" xlink:type="simple" xlink:href="adma-20241231.xsd#SignificantAccountingPoliciesEarningsLossPerShareDetails" />
  <link:roleRef roleURI="http://admabiologics.com/role/SignificantAccountingPoliciesStockbasedCompensationDetails" xlink:type="simple" xlink:href="adma-20241231.xsd#SignificantAccountingPoliciesStockbasedCompensationDetails" />
  <link:roleRef roleURI="http://admabiologics.com/role/SignificantAccountingPoliciesAdvertisingAndMarketingExpensesDetails" xlink:type="simple" xlink:href="adma-20241231.xsd#SignificantAccountingPoliciesAdvertisingAndMarketingExpensesDetails" />
  <link:roleRef roleURI="http://admabiologics.com/role/SignificantAccountingPoliciesRevenueRecognitionDetailsDefault" xlink:type="simple" xlink:href="adma-20241231.xsd#SignificantAccountingPoliciesRevenueRecognitionDetailsDefault" />
  <link:roleRef roleURI="http://admabiologics.com/role/SignificantAccountingPoliciesRevenueRecognitionDetails" xlink:type="simple" xlink:href="adma-20241231.xsd#SignificantAccountingPoliciesRevenueRecognitionDetails" />
  <link:roleRef roleURI="http://admabiologics.com/role/SignificantAccountingPoliciesImpairmentOfLonglivedAssetsDetails" xlink:type="simple" xlink:href="adma-20241231.xsd#SignificantAccountingPoliciesImpairmentOfLonglivedAssetsDetails" />
  <link:roleRef roleURI="http://admabiologics.com/role/SignificantAccountingPoliciesGoodwillDetails" xlink:type="simple" xlink:href="adma-20241231.xsd#SignificantAccountingPoliciesGoodwillDetails" />
  <link:roleRef roleURI="http://admabiologics.com/role/SignificantAccountingPoliciesPropertyAndEquipmentDetails" xlink:type="simple" xlink:href="adma-20241231.xsd#SignificantAccountingPoliciesPropertyAndEquipmentDetails" />
  <link:roleRef roleURI="http://admabiologics.com/role/SignificantAccountingPoliciesAccountsReceivableDetails" xlink:type="simple" xlink:href="adma-20241231.xsd#SignificantAccountingPoliciesAccountsReceivableDetails" />
  <link:roleRef roleURI="http://admabiologics.com/role/SignificantAccountingPoliciesUseOfEstimatesDetails" xlink:type="simple" xlink:href="adma-20241231.xsd#SignificantAccountingPoliciesUseOfEstimatesDetails" />
  <link:roleRef roleURI="http://admabiologics.com/role/OrganizationAndBusinessDetails" xlink:type="simple" xlink:href="adma-20241231.xsd#OrganizationAndBusinessDetails" />
  <link:roleRef roleURI="http://admabiologics.com/role/SupplementalDisclosureOfCashFlowInformationTables" xlink:type="simple" xlink:href="adma-20241231.xsd#SupplementalDisclosureOfCashFlowInformationTables" />
  <link:roleRef roleURI="http://admabiologics.com/role/SegmentsTables" xlink:type="simple" xlink:href="adma-20241231.xsd#SegmentsTables" />
  <link:roleRef roleURI="http://admabiologics.com/role/LeaseObligationsTables" xlink:type="simple" xlink:href="adma-20241231.xsd#LeaseObligationsTables" />
  <link:roleRef roleURI="http://admabiologics.com/role/IncomeTaxesTables" xlink:type="simple" xlink:href="adma-20241231.xsd#IncomeTaxesTables" />
  <link:roleRef roleURI="http://admabiologics.com/role/StockholdersEquityTables" xlink:type="simple" xlink:href="adma-20241231.xsd#StockholdersEquityTables" />
  <link:roleRef roleURI="http://admabiologics.com/role/NotesPayableTables" xlink:type="simple" xlink:href="adma-20241231.xsd#NotesPayableTables" />
  <link:roleRef roleURI="http://admabiologics.com/role/AccruedExpensesAndOtherLiabilitiesTables" xlink:type="simple" xlink:href="adma-20241231.xsd#AccruedExpensesAndOtherLiabilitiesTables" />
  <link:roleRef roleURI="http://admabiologics.com/role/IntangibleAssetsTables" xlink:type="simple" xlink:href="adma-20241231.xsd#IntangibleAssetsTables" />
  <link:roleRef roleURI="http://admabiologics.com/role/PropertyAndEquipmentTables" xlink:type="simple" xlink:href="adma-20241231.xsd#PropertyAndEquipmentTables" />
  <link:roleRef roleURI="http://admabiologics.com/role/InventoriesTables" xlink:type="simple" xlink:href="adma-20241231.xsd#InventoriesTables" />
  <link:roleRef roleURI="http://admabiologics.com/role/SignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="adma-20241231.xsd#SignificantAccountingPoliciesTables" />
  <link:roleRef roleURI="http://admabiologics.com/role/SignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="adma-20241231.xsd#SignificantAccountingPoliciesPolicies" />
  <link:roleRef roleURI="http://admabiologics.com/role/CybersecurityRiskManagementAndStrategyDisclosure" xlink:type="simple" xlink:href="adma-20241231.xsd#CybersecurityRiskManagementAndStrategyDisclosure" />
  <link:roleRef roleURI="http://admabiologics.com/role/ScheduleIiValuationAndQualifyingAccounts" xlink:type="simple" xlink:href="adma-20241231.xsd#ScheduleIiValuationAndQualifyingAccounts" />
  <link:roleRef roleURI="http://admabiologics.com/role/Concentrations" xlink:type="simple" xlink:href="adma-20241231.xsd#Concentrations" />
  <link:roleRef roleURI="http://admabiologics.com/role/SupplementalDisclosureOfCashFlowInformation" xlink:type="simple" xlink:href="adma-20241231.xsd#SupplementalDisclosureOfCashFlowInformation" />
  <link:roleRef roleURI="http://admabiologics.com/role/OtherEmployeeBenefits" xlink:type="simple" xlink:href="adma-20241231.xsd#OtherEmployeeBenefits" />
  <link:roleRef roleURI="http://admabiologics.com/role/Segments" xlink:type="simple" xlink:href="adma-20241231.xsd#Segments" />
  <link:roleRef roleURI="http://admabiologics.com/role/LeaseObligations" xlink:type="simple" xlink:href="adma-20241231.xsd#LeaseObligations" />
  <link:roleRef roleURI="http://admabiologics.com/role/IncomeTaxes" xlink:type="simple" xlink:href="adma-20241231.xsd#IncomeTaxes" />
  <link:roleRef roleURI="http://admabiologics.com/role/CommitmentsAndContingencies" xlink:type="simple" xlink:href="adma-20241231.xsd#CommitmentsAndContingencies" />
  <link:roleRef roleURI="http://admabiologics.com/role/RelatedPartyTransactions" xlink:type="simple" xlink:href="adma-20241231.xsd#RelatedPartyTransactions" />
  <link:roleRef roleURI="http://admabiologics.com/role/StockholdersEquity" xlink:type="simple" xlink:href="adma-20241231.xsd#StockholdersEquity" />
  <link:roleRef roleURI="http://admabiologics.com/role/NotesPayable" xlink:type="simple" xlink:href="adma-20241231.xsd#NotesPayable" />
  <link:roleRef roleURI="http://admabiologics.com/role/AccruedExpensesAndOtherLiabilities" xlink:type="simple" xlink:href="adma-20241231.xsd#AccruedExpensesAndOtherLiabilities" />
  <link:roleRef roleURI="http://admabiologics.com/role/IntangibleAssets" xlink:type="simple" xlink:href="adma-20241231.xsd#IntangibleAssets" />
  <link:roleRef roleURI="http://admabiologics.com/role/PropertyAndEquipment" xlink:type="simple" xlink:href="adma-20241231.xsd#PropertyAndEquipment" />
  <link:roleRef roleURI="http://admabiologics.com/role/Inventories" xlink:type="simple" xlink:href="adma-20241231.xsd#Inventories" />
  <link:roleRef roleURI="http://admabiologics.com/role/SignificantAccountingPolicies" xlink:type="simple" xlink:href="adma-20241231.xsd#SignificantAccountingPolicies" />
  <link:roleRef roleURI="http://admabiologics.com/role/OrganizationAndBusiness" xlink:type="simple" xlink:href="adma-20241231.xsd#OrganizationAndBusiness" />
  <link:roleRef roleURI="http://admabiologics.com/role/ConsolidatedStatementsOfCashFlows" xlink:type="simple" xlink:href="adma-20241231.xsd#ConsolidatedStatementsOfCashFlows" />
  <link:roleRef roleURI="http://admabiologics.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity" xlink:type="simple" xlink:href="adma-20241231.xsd#ConsolidatedStatementsOfChangesInStockholdersEquity" />
  <link:roleRef roleURI="http://admabiologics.com/role/ConsolidatedStatementsOfOperations" xlink:type="simple" xlink:href="adma-20241231.xsd#ConsolidatedStatementsOfOperations" />
  <link:roleRef roleURI="http://admabiologics.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="adma-20241231.xsd#ConsolidatedBalanceSheetsParenthetical" />
  <link:roleRef roleURI="http://admabiologics.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="adma-20241231.xsd#ConsolidatedBalanceSheets" />
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/TradingArrangementsOnly" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#TradingArrangmentsOnly" />
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/IndividualsOnly" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#IndividualsOnly" />
  <link:roleRef roleURI="http://admabiologics.com/role/DocumentAndEntityInformation" xlink:type="simple" xlink:href="adma-20241231.xsd#DocumentAndEntityInformation" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" />
  <link:definitionLink xlink:type="extended" xlink:role="http://admabiologics.com/role/DocumentAndEntityInformation">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentInformationLineItems" xlink:label="DocumentInformationLineItems" xlink:title="DocumentInformationLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="DocumentType" xlink:title="DocumentType" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DocumentInformationLineItems" xlink:to="DocumentType" xlink:title="definition: DocumentInformationLineItems to DocumentType" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="AmendmentFlag" xlink:title="AmendmentFlag" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DocumentInformationLineItems" xlink:to="AmendmentFlag" xlink:title="definition: DocumentInformationLineItems to AmendmentFlag" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport" xlink:label="DocumentAnnualReport" xlink:title="DocumentAnnualReport" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DocumentInformationLineItems" xlink:to="DocumentAnnualReport" xlink:title="definition: DocumentInformationLineItems to DocumentAnnualReport" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="DocumentPeriodEndDate" xlink:title="DocumentPeriodEndDate" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DocumentInformationLineItems" xlink:to="DocumentPeriodEndDate" xlink:title="definition: DocumentInformationLineItems to DocumentPeriodEndDate" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="CurrentFiscalYearEndDate" xlink:title="CurrentFiscalYearEndDate" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DocumentInformationLineItems" xlink:to="CurrentFiscalYearEndDate" xlink:title="definition: DocumentInformationLineItems to CurrentFiscalYearEndDate" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="DocumentFiscalYearFocus" xlink:title="DocumentFiscalYearFocus" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DocumentInformationLineItems" xlink:to="DocumentFiscalYearFocus" xlink:title="definition: DocumentInformationLineItems to DocumentFiscalYearFocus" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="DocumentFiscalPeriodFocus" xlink:title="DocumentFiscalPeriodFocus" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DocumentInformationLineItems" xlink:to="DocumentFiscalPeriodFocus" xlink:title="definition: DocumentInformationLineItems to DocumentFiscalPeriodFocus" order="7.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="DocumentTransitionReport" xlink:title="DocumentTransitionReport" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DocumentInformationLineItems" xlink:to="DocumentTransitionReport" xlink:title="definition: DocumentInformationLineItems to DocumentTransitionReport" order="8.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="EntityFileNumber" xlink:title="EntityFileNumber" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DocumentInformationLineItems" xlink:to="EntityFileNumber" xlink:title="definition: DocumentInformationLineItems to EntityFileNumber" order="9.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="EntityRegistrantName" xlink:title="EntityRegistrantName" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DocumentInformationLineItems" xlink:to="EntityRegistrantName" xlink:title="definition: DocumentInformationLineItems to EntityRegistrantName" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="EntityCentralIndexKey" xlink:title="EntityCentralIndexKey" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DocumentInformationLineItems" xlink:to="EntityCentralIndexKey" xlink:title="definition: DocumentInformationLineItems to EntityCentralIndexKey" order="11.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="EntityIncorporationStateCountryCode" xlink:title="EntityIncorporationStateCountryCode" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DocumentInformationLineItems" xlink:to="EntityIncorporationStateCountryCode" xlink:title="definition: DocumentInformationLineItems to EntityIncorporationStateCountryCode" order="12.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="EntityTaxIdentificationNumber" xlink:title="EntityTaxIdentificationNumber" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DocumentInformationLineItems" xlink:to="EntityTaxIdentificationNumber" xlink:title="definition: DocumentInformationLineItems to EntityTaxIdentificationNumber" order="13.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="EntityAddressAddressLine1" xlink:title="EntityAddressAddressLine1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DocumentInformationLineItems" xlink:to="EntityAddressAddressLine1" xlink:title="definition: DocumentInformationLineItems to EntityAddressAddressLine1" order="14.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="EntityAddressCityOrTown" xlink:title="EntityAddressCityOrTown" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DocumentInformationLineItems" xlink:to="EntityAddressCityOrTown" xlink:title="definition: DocumentInformationLineItems to EntityAddressCityOrTown" order="15.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="EntityAddressStateOrProvince" xlink:title="EntityAddressStateOrProvince" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DocumentInformationLineItems" xlink:to="EntityAddressStateOrProvince" xlink:title="definition: DocumentInformationLineItems to EntityAddressStateOrProvince" order="16.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="EntityAddressPostalZipCode" xlink:title="EntityAddressPostalZipCode" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DocumentInformationLineItems" xlink:to="EntityAddressPostalZipCode" xlink:title="definition: DocumentInformationLineItems to EntityAddressPostalZipCode" order="17.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="CityAreaCode" xlink:title="CityAreaCode" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DocumentInformationLineItems" xlink:to="CityAreaCode" xlink:title="definition: DocumentInformationLineItems to CityAreaCode" order="18.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="LocalPhoneNumber" xlink:title="LocalPhoneNumber" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DocumentInformationLineItems" xlink:to="LocalPhoneNumber" xlink:title="definition: DocumentInformationLineItems to LocalPhoneNumber" order="19.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="Security12bTitle" xlink:title="Security12bTitle" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DocumentInformationLineItems" xlink:to="Security12bTitle" xlink:title="definition: DocumentInformationLineItems to Security12bTitle" order="20.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="TradingSymbol" xlink:title="TradingSymbol" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DocumentInformationLineItems" xlink:to="TradingSymbol" xlink:title="definition: DocumentInformationLineItems to TradingSymbol" order="21.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="SecurityExchangeName" xlink:title="SecurityExchangeName" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DocumentInformationLineItems" xlink:to="SecurityExchangeName" xlink:title="definition: DocumentInformationLineItems to SecurityExchangeName" order="22.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="EntityWellKnownSeasonedIssuer" xlink:title="EntityWellKnownSeasonedIssuer" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DocumentInformationLineItems" xlink:to="EntityWellKnownSeasonedIssuer" xlink:title="definition: DocumentInformationLineItems to EntityWellKnownSeasonedIssuer" order="23.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers" xlink:label="EntityVoluntaryFilers" xlink:title="EntityVoluntaryFilers" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DocumentInformationLineItems" xlink:to="EntityVoluntaryFilers" xlink:title="definition: DocumentInformationLineItems to EntityVoluntaryFilers" order="24.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="EntityCurrentReportingStatus" xlink:title="EntityCurrentReportingStatus" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DocumentInformationLineItems" xlink:to="EntityCurrentReportingStatus" xlink:title="definition: DocumentInformationLineItems to EntityCurrentReportingStatus" order="25.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="EntityInteractiveDataCurrent" xlink:title="EntityInteractiveDataCurrent" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DocumentInformationLineItems" xlink:to="EntityInteractiveDataCurrent" xlink:title="definition: DocumentInformationLineItems to EntityInteractiveDataCurrent" order="26.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="EntityFilerCategory" xlink:title="EntityFilerCategory" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DocumentInformationLineItems" xlink:to="EntityFilerCategory" xlink:title="definition: DocumentInformationLineItems to EntityFilerCategory" order="27.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="EntitySmallBusiness" xlink:title="EntitySmallBusiness" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DocumentInformationLineItems" xlink:to="EntitySmallBusiness" xlink:title="definition: DocumentInformationLineItems to EntitySmallBusiness" order="28.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="EntityEmergingGrowthCompany" xlink:title="EntityEmergingGrowthCompany" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DocumentInformationLineItems" xlink:to="EntityEmergingGrowthCompany" xlink:title="definition: DocumentInformationLineItems to EntityEmergingGrowthCompany" order="29.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="IcfrAuditorAttestationFlag" xlink:title="IcfrAuditorAttestationFlag" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DocumentInformationLineItems" xlink:to="IcfrAuditorAttestationFlag" xlink:title="definition: DocumentInformationLineItems to IcfrAuditorAttestationFlag" order="30.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="DocumentFinStmtErrorCorrectionFlag" xlink:title="DocumentFinStmtErrorCorrectionFlag" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DocumentInformationLineItems" xlink:to="DocumentFinStmtErrorCorrectionFlag" xlink:title="definition: DocumentInformationLineItems to DocumentFinStmtErrorCorrectionFlag" order="31.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="EntityShellCompany" xlink:title="EntityShellCompany" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DocumentInformationLineItems" xlink:to="EntityShellCompany" xlink:title="definition: DocumentInformationLineItems to EntityShellCompany" order="32.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat" xlink:label="EntityPublicFloat" xlink:title="EntityPublicFloat" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DocumentInformationLineItems" xlink:to="EntityPublicFloat" xlink:title="definition: DocumentInformationLineItems to EntityPublicFloat" order="33.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="EntityCommonStockSharesOutstanding" xlink:title="EntityCommonStockSharesOutstanding" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DocumentInformationLineItems" xlink:to="EntityCommonStockSharesOutstanding" xlink:title="definition: DocumentInformationLineItems to EntityCommonStockSharesOutstanding" order="34.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorFirmId" xlink:label="AuditorFirmId" xlink:title="AuditorFirmId" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DocumentInformationLineItems" xlink:to="AuditorFirmId" xlink:title="definition: DocumentInformationLineItems to AuditorFirmId" order="35.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorName" xlink:label="AuditorName" xlink:title="AuditorName" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DocumentInformationLineItems" xlink:to="AuditorName" xlink:title="definition: DocumentInformationLineItems to AuditorName" order="36.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorLocation" xlink:label="AuditorLocation" xlink:title="AuditorLocation" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DocumentInformationLineItems" xlink:to="AuditorLocation" xlink:title="definition: DocumentInformationLineItems to AuditorLocation" order="37.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentInformationTable" xlink:label="DocumentInformationTable" xlink:title="DocumentInformationTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="DocumentInformationLineItems" xlink:to="DocumentInformationTable" xlink:title="definition: DocumentInformationLineItems to DocumentInformationTable" order="38.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis" xlink:label="CounterpartyNameAxis" xlink:title="CounterpartyNameAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="DocumentInformationTable" xlink:to="CounterpartyNameAxis" xlink:title="definition: DocumentInformationTable to CounterpartyNameAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="RepurchaseAgreementCounterpartyNameDomain" xlink:title="RepurchaseAgreementCounterpartyNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="CounterpartyNameAxis" xlink:to="RepurchaseAgreementCounterpartyNameDomain" xlink:title="definition: CounterpartyNameAxis to RepurchaseAgreementCounterpartyNameDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="RepurchaseAgreementCounterpartyNameDomain_2" xlink:title="RepurchaseAgreementCounterpartyNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="CounterpartyNameAxis" xlink:to="RepurchaseAgreementCounterpartyNameDomain_2" xlink:title="definition: CounterpartyNameAxis to RepurchaseAgreementCounterpartyNameDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_CohnReznickLLPMember" xlink:label="CohnReznickLLPMember" xlink:title="CohnReznickLLPMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RepurchaseAgreementCounterpartyNameDomain" xlink:to="CohnReznickLLPMember" xlink:title="definition: RepurchaseAgreementCounterpartyNameDomain to CohnReznickLLPMember" order="1.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/IndividualsOnly">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember" xlink:label="AllIndividualsMember" xlink:title="AllIndividualsMember" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_AdamGrossmanMember" xlink:label="AdamGrossmanMember" xlink:title="AdamGrossmanMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AllIndividualsMember" xlink:to="AdamGrossmanMember" xlink:title="definition: AllIndividualsMember to AdamGrossmanMember" order="1.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/TradingArrangementsOnly">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllTradingArrangementsMember" xlink:label="AllTradingArrangementsMember" xlink:title="AllTradingArrangementsMember" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_AdamGrossmanTradingPlanCommonStockMember" xlink:label="AdamGrossmanTradingPlanCommonStockMember" xlink:title="AdamGrossmanTradingPlanCommonStockMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AllTradingArrangementsMember" xlink:to="AdamGrossmanTradingPlanCommonStockMember" xlink:title="definition: AllTradingArrangementsMember to AdamGrossmanTradingPlanCommonStockMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_AdamGrossmanTradingPlanStockOptionsMember" xlink:label="AdamGrossmanTradingPlanStockOptionsMember" xlink:title="AdamGrossmanTradingPlanStockOptionsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AllTradingArrangementsMember" xlink:to="AdamGrossmanTradingPlanStockOptionsMember" xlink:title="definition: AllTradingArrangementsMember to AdamGrossmanTradingPlanStockOptionsMember" order="2.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://admabiologics.com/role/ConsolidatedBalanceSheets" />
  <link:definitionLink xlink:type="extended" xlink:role="http://admabiologics.com/role/ConsolidatedBalanceSheetsParenthetical" />
  <link:definitionLink xlink:type="extended" xlink:role="http://admabiologics.com/role/ConsolidatedStatementsOfOperations" />
  <link:definitionLink xlink:type="extended" xlink:role="http://admabiologics.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="StatementLineItems" xlink:title="StatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="IncreaseDecreaseInStockholdersEquityRollForward" xlink:title="IncreaseDecreaseInStockholdersEquityRollForward" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="IncreaseDecreaseInStockholdersEquityRollForward" xlink:title="definition: StatementLineItems to IncreaseDecreaseInStockholdersEquityRollForward" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="StockholdersEquity" xlink:title="StockholdersEquity" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="StockholdersEquity" xlink:title="definition: StatementLineItems to StockholdersEquity" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="SharesOutstanding" xlink:title="SharesOutstanding" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="SharesOutstanding" xlink:title="definition: StatementLineItems to SharesOutstanding" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:label="AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:title="AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:title="definition: StatementLineItems to AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="StockIssuedDuringPeriodValueNewIssues" xlink:title="StockIssuedDuringPeriodValueNewIssues" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="StockIssuedDuringPeriodValueNewIssues" xlink:title="definition: StatementLineItems to StockIssuedDuringPeriodValueNewIssues" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="StockIssuedDuringPeriodSharesNewIssues" xlink:title="StockIssuedDuringPeriodSharesNewIssues" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="StockIssuedDuringPeriodSharesNewIssues" xlink:title="definition: StatementLineItems to StockIssuedDuringPeriodSharesNewIssues" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAmount" xlink:label="VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAmount" xlink:title="VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAmount" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAmount" xlink:title="definition: StatementLineItems to VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAmount" order="7.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesShares" xlink:label="VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesShares" xlink:title="VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesShares" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesShares" xlink:title="definition: StatementLineItems to VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesShares" order="8.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:title="AdjustmentsToAdditionalPaidInCapitalWarrantIssued" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:title="definition: StatementLineItems to AdjustmentsToAdditionalPaidInCapitalWarrantIssued" order="9.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="StockIssuedDuringPeriodValueStockOptionsExercised" xlink:title="StockIssuedDuringPeriodValueStockOptionsExercised" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="StockIssuedDuringPeriodValueStockOptionsExercised" xlink:title="definition: StatementLineItems to StockIssuedDuringPeriodValueStockOptionsExercised" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:title="StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:title="definition: StatementLineItems to StockIssuedDuringPeriodSharesStockOptionsExercised" order="11.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_StockIssuedDuringPeriodValueCashlessExerciseOfWarrants" xlink:label="StockIssuedDuringPeriodValueCashlessExerciseOfWarrants" xlink:title="StockIssuedDuringPeriodValueCashlessExerciseOfWarrants" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="StockIssuedDuringPeriodValueCashlessExerciseOfWarrants" xlink:title="definition: StatementLineItems to StockIssuedDuringPeriodValueCashlessExerciseOfWarrants" order="12.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_StockIssuedDuringPeriodSharesCashlessExerciseOfWarrants" xlink:label="StockIssuedDuringPeriodSharesCashlessExerciseOfWarrants" xlink:title="StockIssuedDuringPeriodSharesCashlessExerciseOfWarrants" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="StockIssuedDuringPeriodSharesCashlessExerciseOfWarrants" xlink:title="definition: StatementLineItems to StockIssuedDuringPeriodSharesCashlessExerciseOfWarrants" order="13.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="NetIncomeLoss" xlink:title="NetIncomeLoss" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="StatementLineItems" xlink:to="NetIncomeLoss" xlink:title="definition: StatementLineItems to NetIncomeLoss" order="14.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="StatementTable" xlink:title="StatementTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="StatementLineItems" xlink:to="StatementTable" xlink:title="definition: StatementLineItems to StatementTable" order="15.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="StatementEquityComponentsAxis" xlink:title="StatementEquityComponentsAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="StatementTable" xlink:to="StatementEquityComponentsAxis" xlink:title="definition: StatementTable to StatementEquityComponentsAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="EquityComponentDomain" xlink:title="EquityComponentDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="StatementEquityComponentsAxis" xlink:to="EquityComponentDomain" xlink:title="definition: StatementEquityComponentsAxis to EquityComponentDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="EquityComponentDomain_2" xlink:title="EquityComponentDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="StatementEquityComponentsAxis" xlink:to="EquityComponentDomain_2" xlink:title="definition: StatementEquityComponentsAxis to EquityComponentDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="CommonStockMember" xlink:title="CommonStockMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EquityComponentDomain" xlink:to="CommonStockMember" xlink:title="definition: EquityComponentDomain to CommonStockMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="AdditionalPaidInCapitalMember" xlink:title="AdditionalPaidInCapitalMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EquityComponentDomain" xlink:to="AdditionalPaidInCapitalMember" xlink:title="definition: EquityComponentDomain to AdditionalPaidInCapitalMember" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="RetainedEarningsMember" xlink:title="RetainedEarningsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EquityComponentDomain" xlink:to="RetainedEarningsMember" xlink:title="definition: EquityComponentDomain to RetainedEarningsMember" order="3.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://admabiologics.com/role/ConsolidatedStatementsOfCashFlows" />
  <link:definitionLink xlink:type="extended" xlink:role="http://admabiologics.com/role/OrganizationAndBusiness" />
  <link:definitionLink xlink:type="extended" xlink:role="http://admabiologics.com/role/SignificantAccountingPolicies" />
  <link:definitionLink xlink:type="extended" xlink:role="http://admabiologics.com/role/Inventories" />
  <link:definitionLink xlink:type="extended" xlink:role="http://admabiologics.com/role/PropertyAndEquipment" />
  <link:definitionLink xlink:type="extended" xlink:role="http://admabiologics.com/role/IntangibleAssets" />
  <link:definitionLink xlink:type="extended" xlink:role="http://admabiologics.com/role/AccruedExpensesAndOtherLiabilities" />
  <link:definitionLink xlink:type="extended" xlink:role="http://admabiologics.com/role/NotesPayable" />
  <link:definitionLink xlink:type="extended" xlink:role="http://admabiologics.com/role/StockholdersEquity" />
  <link:definitionLink xlink:type="extended" xlink:role="http://admabiologics.com/role/RelatedPartyTransactions" />
  <link:definitionLink xlink:type="extended" xlink:role="http://admabiologics.com/role/CommitmentsAndContingencies" />
  <link:definitionLink xlink:type="extended" xlink:role="http://admabiologics.com/role/IncomeTaxes" />
  <link:definitionLink xlink:type="extended" xlink:role="http://admabiologics.com/role/LeaseObligations" />
  <link:definitionLink xlink:type="extended" xlink:role="http://admabiologics.com/role/Segments" />
  <link:definitionLink xlink:type="extended" xlink:role="http://admabiologics.com/role/OtherEmployeeBenefits" />
  <link:definitionLink xlink:type="extended" xlink:role="http://admabiologics.com/role/SupplementalDisclosureOfCashFlowInformation" />
  <link:definitionLink xlink:type="extended" xlink:role="http://admabiologics.com/role/Concentrations" />
  <link:definitionLink xlink:type="extended" xlink:role="http://admabiologics.com/role/ScheduleIiValuationAndQualifyingAccounts" />
  <link:definitionLink xlink:type="extended" xlink:role="http://admabiologics.com/role/CybersecurityRiskManagementAndStrategyDisclosure" />
  <link:definitionLink xlink:type="extended" xlink:role="http://admabiologics.com/role/SignificantAccountingPoliciesPolicies" />
  <link:definitionLink xlink:type="extended" xlink:role="http://admabiologics.com/role/SignificantAccountingPoliciesTables" />
  <link:definitionLink xlink:type="extended" xlink:role="http://admabiologics.com/role/InventoriesTables" />
  <link:definitionLink xlink:type="extended" xlink:role="http://admabiologics.com/role/PropertyAndEquipmentTables" />
  <link:definitionLink xlink:type="extended" xlink:role="http://admabiologics.com/role/IntangibleAssetsTables" />
  <link:definitionLink xlink:type="extended" xlink:role="http://admabiologics.com/role/AccruedExpensesAndOtherLiabilitiesTables" />
  <link:definitionLink xlink:type="extended" xlink:role="http://admabiologics.com/role/NotesPayableTables" />
  <link:definitionLink xlink:type="extended" xlink:role="http://admabiologics.com/role/StockholdersEquityTables" />
  <link:definitionLink xlink:type="extended" xlink:role="http://admabiologics.com/role/IncomeTaxesTables" />
  <link:definitionLink xlink:type="extended" xlink:role="http://admabiologics.com/role/LeaseObligationsTables" />
  <link:definitionLink xlink:type="extended" xlink:role="http://admabiologics.com/role/SegmentsTables" />
  <link:definitionLink xlink:type="extended" xlink:role="http://admabiologics.com/role/SupplementalDisclosureOfCashFlowInformationTables" />
  <link:definitionLink xlink:type="extended" xlink:role="http://admabiologics.com/role/OrganizationAndBusinessDetails" />
  <link:definitionLink xlink:type="extended" xlink:role="http://admabiologics.com/role/SignificantAccountingPoliciesUseOfEstimatesDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ChangeInAccountingEstimateLineItems" xlink:label="ChangeInAccountingEstimateLineItems" xlink:title="ChangeInAccountingEstimateLineItems" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_UseOfEstimatesAbstract" xlink:label="UseOfEstimatesAbstract" xlink:title="UseOfEstimatesAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ChangeInAccountingEstimateLineItems" xlink:to="UseOfEstimatesAbstract" xlink:title="definition: ChangeInAccountingEstimateLineItems to UseOfEstimatesAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="RevenueFromContractWithCustomerExcludingAssessedTax" xlink:title="RevenueFromContractWithCustomerExcludingAssessedTax" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ChangeInAccountingEstimateLineItems" xlink:to="RevenueFromContractWithCustomerExcludingAssessedTax" xlink:title="definition: ChangeInAccountingEstimateLineItems to RevenueFromContractWithCustomerExcludingAssessedTax" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="AccruedLiabilitiesAndOtherLiabilities" xlink:title="AccruedLiabilitiesAndOtherLiabilities" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ChangeInAccountingEstimateLineItems" xlink:to="AccruedLiabilitiesAndOtherLiabilities" xlink:title="definition: ChangeInAccountingEstimateLineItems to AccruedLiabilitiesAndOtherLiabilities" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfChangeInAccountingEstimateTable" xlink:label="ScheduleOfChangeInAccountingEstimateTable" xlink:title="ScheduleOfChangeInAccountingEstimateTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ChangeInAccountingEstimateLineItems" xlink:to="ScheduleOfChangeInAccountingEstimateTable" xlink:title="definition: ChangeInAccountingEstimateLineItems to ScheduleOfChangeInAccountingEstimateTable" order="4.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ChangeInAccountingEstimateByTypeAxis" xlink:label="ChangeInAccountingEstimateByTypeAxis" xlink:title="ChangeInAccountingEstimateByTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfChangeInAccountingEstimateTable" xlink:to="ChangeInAccountingEstimateByTypeAxis" xlink:title="definition: ScheduleOfChangeInAccountingEstimateTable to ChangeInAccountingEstimateByTypeAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ChangeInAccountingEstimateTypeDomain" xlink:label="ChangeInAccountingEstimateTypeDomain" xlink:title="ChangeInAccountingEstimateTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ChangeInAccountingEstimateByTypeAxis" xlink:to="ChangeInAccountingEstimateTypeDomain" xlink:title="definition: ChangeInAccountingEstimateByTypeAxis to ChangeInAccountingEstimateTypeDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ChangeInAccountingEstimateTypeDomain" xlink:label="ChangeInAccountingEstimateTypeDomain_2" xlink:title="ChangeInAccountingEstimateTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ChangeInAccountingEstimateByTypeAxis" xlink:to="ChangeInAccountingEstimateTypeDomain_2" xlink:title="definition: ChangeInAccountingEstimateByTypeAxis to ChangeInAccountingEstimateTypeDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_AccrualForUSMedicaidRebatesMember" xlink:label="AccrualForUSMedicaidRebatesMember" xlink:title="AccrualForUSMedicaidRebatesMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ChangeInAccountingEstimateTypeDomain" xlink:to="AccrualForUSMedicaidRebatesMember" xlink:title="definition: ChangeInAccountingEstimateTypeDomain to AccrualForUSMedicaidRebatesMember" order="1.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://admabiologics.com/role/SignificantAccountingPoliciesAccountsReceivableDetails" />
  <link:definitionLink xlink:type="extended" xlink:role="http://admabiologics.com/role/SignificantAccountingPoliciesPropertyAndEquipmentDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="PropertyPlantAndEquipmentLineItems" xlink:title="PropertyPlantAndEquipmentLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="PropertyPlantAndEquipmentAbstract" xlink:title="PropertyPlantAndEquipmentAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="PropertyPlantAndEquipmentLineItems" xlink:to="PropertyPlantAndEquipmentAbstract" xlink:title="definition: PropertyPlantAndEquipmentLineItems to PropertyPlantAndEquipmentAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="PropertyPlantAndEquipmentUsefulLife" xlink:title="PropertyPlantAndEquipmentUsefulLife" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="PropertyPlantAndEquipmentLineItems" xlink:to="PropertyPlantAndEquipmentUsefulLife" xlink:title="definition: PropertyPlantAndEquipmentLineItems to PropertyPlantAndEquipmentUsefulLife" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="ScheduleOfPropertyPlantAndEquipmentTable" xlink:title="ScheduleOfPropertyPlantAndEquipmentTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="PropertyPlantAndEquipmentLineItems" xlink:to="ScheduleOfPropertyPlantAndEquipmentTable" xlink:title="definition: PropertyPlantAndEquipmentLineItems to ScheduleOfPropertyPlantAndEquipmentTable" order="3.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="PropertyPlantAndEquipmentByTypeAxis" xlink:title="PropertyPlantAndEquipmentByTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="PropertyPlantAndEquipmentByTypeAxis" xlink:title="definition: ScheduleOfPropertyPlantAndEquipmentTable to PropertyPlantAndEquipmentByTypeAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="PropertyPlantAndEquipmentTypeDomain" xlink:title="PropertyPlantAndEquipmentTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="PropertyPlantAndEquipmentByTypeAxis" xlink:to="PropertyPlantAndEquipmentTypeDomain" xlink:title="definition: PropertyPlantAndEquipmentByTypeAxis to PropertyPlantAndEquipmentTypeDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="PropertyPlantAndEquipmentTypeDomain_2" xlink:title="PropertyPlantAndEquipmentTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="PropertyPlantAndEquipmentByTypeAxis" xlink:to="PropertyPlantAndEquipmentTypeDomain_2" xlink:title="definition: PropertyPlantAndEquipmentByTypeAxis to PropertyPlantAndEquipmentTypeDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BuildingMember" xlink:label="BuildingMember" xlink:title="BuildingMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="PropertyPlantAndEquipmentTypeDomain" xlink:to="BuildingMember" xlink:title="definition: PropertyPlantAndEquipmentTypeDomain to BuildingMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="RangeAxis" xlink:title="RangeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="RangeAxis" xlink:title="definition: ScheduleOfPropertyPlantAndEquipmentTable to RangeAxis" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="RangeMember" xlink:title="RangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="RangeAxis" xlink:to="RangeMember" xlink:title="definition: RangeAxis to RangeMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="RangeMember_2" xlink:title="RangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="RangeAxis" xlink:to="RangeMember_2" xlink:title="definition: RangeAxis to RangeMember_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="MinimumMember" xlink:title="MinimumMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RangeMember" xlink:to="MinimumMember" xlink:title="definition: RangeMember to MinimumMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="MaximumMember" xlink:title="MaximumMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RangeMember" xlink:to="MaximumMember" xlink:title="definition: RangeMember to MaximumMember" order="2.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://admabiologics.com/role/SignificantAccountingPoliciesGoodwillDetails" />
  <link:definitionLink xlink:type="extended" xlink:role="http://admabiologics.com/role/SignificantAccountingPoliciesImpairmentOfLonglivedAssetsDetails" />
  <link:definitionLink xlink:type="extended" xlink:role="http://admabiologics.com/role/SignificantAccountingPoliciesRevenueRecognitionDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:label="RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:title="RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="RevenueFromContractWithCustomerAbstract" xlink:title="RevenueFromContractWithCustomerAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:to="RevenueFromContractWithCustomerAbstract" xlink:title="definition: RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems to RevenueFromContractWithCustomerAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_DeferredRevenueRemainingAmortizationPeriod" xlink:label="DeferredRevenueRemainingAmortizationPeriod" xlink:title="DeferredRevenueRemainingAmortizationPeriod" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:to="DeferredRevenueRemainingAmortizationPeriod" xlink:title="definition: RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems to DeferredRevenueRemainingAmortizationPeriod" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_CustomerPaymentTerms" xlink:label="CustomerPaymentTerms" xlink:title="CustomerPaymentTerms" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:to="CustomerPaymentTerms" xlink:title="definition: RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems to CustomerPaymentTerms" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:label="RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:title="RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:to="RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:title="definition: RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems to RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" order="4.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="TypeOfArrangementAxis" xlink:title="TypeOfArrangementAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:to="TypeOfArrangementAxis" xlink:title="definition: RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable to TypeOfArrangementAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="ArrangementsAndNonarrangementTransactionsMember" xlink:title="ArrangementsAndNonarrangementTransactionsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="TypeOfArrangementAxis" xlink:to="ArrangementsAndNonarrangementTransactionsMember" xlink:title="definition: TypeOfArrangementAxis to ArrangementsAndNonarrangementTransactionsMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="ArrangementsAndNonarrangementTransactionsMember_2" xlink:title="ArrangementsAndNonarrangementTransactionsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="TypeOfArrangementAxis" xlink:to="ArrangementsAndNonarrangementTransactionsMember_2" xlink:title="definition: TypeOfArrangementAxis to ArrangementsAndNonarrangementTransactionsMember_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_BiotestLicenseAgreementMember" xlink:label="BiotestLicenseAgreementMember" xlink:title="BiotestLicenseAgreementMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ArrangementsAndNonarrangementTransactionsMember" xlink:to="BiotestLicenseAgreementMember" xlink:title="definition: ArrangementsAndNonarrangementTransactionsMember to BiotestLicenseAgreementMember" order="1.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://admabiologics.com/role/SignificantAccountingPoliciesRevenueRecognitionDetailsDefault">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:label="RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:title="RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="RevenueFromContractWithCustomerAbstract" xlink:title="RevenueFromContractWithCustomerAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:to="RevenueFromContractWithCustomerAbstract" xlink:title="definition: RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems to RevenueFromContractWithCustomerAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_DeferredRevenueRemainingAmortizationPeriod" xlink:label="DeferredRevenueRemainingAmortizationPeriod" xlink:title="DeferredRevenueRemainingAmortizationPeriod" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:to="DeferredRevenueRemainingAmortizationPeriod" xlink:title="definition: RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems to DeferredRevenueRemainingAmortizationPeriod" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_CustomerPaymentTerms" xlink:label="CustomerPaymentTerms" xlink:title="CustomerPaymentTerms" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:to="CustomerPaymentTerms" xlink:title="definition: RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems to CustomerPaymentTerms" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:label="RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:title="RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:to="RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:title="definition: RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems to RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" order="4.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="TypeOfArrangementAxis" xlink:title="TypeOfArrangementAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:to="TypeOfArrangementAxis" xlink:title="definition: RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable to TypeOfArrangementAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="ArrangementsAndNonarrangementTransactionsMember" xlink:title="ArrangementsAndNonarrangementTransactionsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="TypeOfArrangementAxis" xlink:to="ArrangementsAndNonarrangementTransactionsMember" xlink:title="definition: TypeOfArrangementAxis to ArrangementsAndNonarrangementTransactionsMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="ArrangementsAndNonarrangementTransactionsMember_2" xlink:title="ArrangementsAndNonarrangementTransactionsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="TypeOfArrangementAxis" xlink:to="ArrangementsAndNonarrangementTransactionsMember_2" xlink:title="definition: TypeOfArrangementAxis to ArrangementsAndNonarrangementTransactionsMember_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_BiotestLicenseAgreementMember" xlink:label="BiotestLicenseAgreementMember" xlink:title="BiotestLicenseAgreementMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ArrangementsAndNonarrangementTransactionsMember" xlink:to="BiotestLicenseAgreementMember" xlink:title="definition: ArrangementsAndNonarrangementTransactionsMember to BiotestLicenseAgreementMember" order="1.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://admabiologics.com/role/SignificantAccountingPoliciesAdvertisingAndMarketingExpensesDetails" />
  <link:definitionLink xlink:type="extended" xlink:role="http://admabiologics.com/role/SignificantAccountingPoliciesStockbasedCompensationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationAbstract" xlink:label="ShareBasedCompensationAbstract" xlink:title="ShareBasedCompensationAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationAbstract" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_NumberOfExecutiveOfficers" xlink:label="NumberOfExecutiveOfficers" xlink:title="NumberOfExecutiveOfficers" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="NumberOfExecutiveOfficers" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to NumberOfExecutiveOfficers" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="5.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="AwardTypeAxis" xlink:title="AwardTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="AwardTypeAxis" xlink:title="definition: ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to AwardTypeAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="AwardTypeAxis" xlink:to="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="definition: AwardTypeAxis to ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="AwardTypeAxis" xlink:to="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2" xlink:title="definition: AwardTypeAxis to ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="EmployeeStockOptionMember" xlink:title="EmployeeStockOptionMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="EmployeeStockOptionMember" xlink:title="definition: ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain to EmployeeStockOptionMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="RestrictedStockUnitsRSUMember" xlink:title="RestrictedStockUnitsRSUMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="RestrictedStockUnitsRSUMember" xlink:title="definition: ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain to RestrictedStockUnitsRSUMember" order="2.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://admabiologics.com/role/SignificantAccountingPoliciesEarningsLossPerShareDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:title="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="EarningsPerShareAbstract" xlink:title="EarningsPerShareAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="EarningsPerShareAbstract" xlink:title="definition: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems to EarningsPerShareAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract" xlink:label="EarningsPerShareDilutedOtherDisclosuresAbstract" xlink:title="EarningsPerShareDilutedOtherDisclosuresAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="EarningsPerShareDilutedOtherDisclosuresAbstract" xlink:title="definition: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems to EarningsPerShareDilutedOtherDisclosuresAbstract" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:title="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:title="definition: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems to AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_DilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmountShares" xlink:label="DilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmountShares" xlink:title="DilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmountShares" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="DilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmountShares" xlink:title="definition: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems to DilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmountShares" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="NetIncomeLoss" xlink:title="NetIncomeLoss" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="NetIncomeLoss" xlink:title="definition: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems to NetIncomeLoss" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="WeightedAverageNumberOfSharesOutstandingBasic" xlink:title="WeightedAverageNumberOfSharesOutstandingBasic" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="WeightedAverageNumberOfSharesOutstandingBasic" xlink:title="definition: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems to WeightedAverageNumberOfSharesOutstandingBasic" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic" xlink:label="EarningsPerShareBasic" xlink:title="EarningsPerShareBasic" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="EarningsPerShareBasic" xlink:title="definition: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems to EarningsPerShareBasic" order="7.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:label="WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:title="WeightedAverageNumberDilutedSharesOutstandingAdjustment" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:title="definition: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems to WeightedAverageNumberDilutedSharesOutstandingAdjustment" order="8.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="WeightedAverageNumberOfDilutedSharesOutstanding" xlink:title="WeightedAverageNumberOfDilutedSharesOutstanding" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="WeightedAverageNumberOfDilutedSharesOutstanding" xlink:title="definition: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems to WeightedAverageNumberOfDilutedSharesOutstanding" order="9.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="EarningsPerShareDiluted" xlink:title="EarningsPerShareDiluted" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="EarningsPerShareDiluted" xlink:title="definition: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems to EarningsPerShareDiluted" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:title="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:title="definition: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems to ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="11.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:title="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:title="definition: ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable to AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="AntidilutiveSecuritiesNameDomain" xlink:title="AntidilutiveSecuritiesNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="AntidilutiveSecuritiesNameDomain" xlink:title="definition: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis to AntidilutiveSecuritiesNameDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="AntidilutiveSecuritiesNameDomain_2" xlink:title="AntidilutiveSecuritiesNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="AntidilutiveSecuritiesNameDomain_2" xlink:title="definition: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis to AntidilutiveSecuritiesNameDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="EmployeeStockOptionMember" xlink:title="EmployeeStockOptionMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AntidilutiveSecuritiesNameDomain" xlink:to="EmployeeStockOptionMember" xlink:title="definition: AntidilutiveSecuritiesNameDomain to EmployeeStockOptionMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="WarrantMember" xlink:title="WarrantMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AntidilutiveSecuritiesNameDomain" xlink:to="WarrantMember" xlink:title="definition: AntidilutiveSecuritiesNameDomain to WarrantMember" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="RestrictedStockUnitsRSUMember" xlink:title="RestrictedStockUnitsRSUMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AntidilutiveSecuritiesNameDomain" xlink:to="RestrictedStockUnitsRSUMember" xlink:title="definition: AntidilutiveSecuritiesNameDomain to RestrictedStockUnitsRSUMember" order="3.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://admabiologics.com/role/InventoriesDetails" />
  <link:definitionLink xlink:type="extended" xlink:role="http://admabiologics.com/role/PropertyAndEquipmentDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="PropertyPlantAndEquipmentLineItems" xlink:title="PropertyPlantAndEquipmentLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:label="PropertyPlantAndEquipmentNetAbstract" xlink:title="PropertyPlantAndEquipmentNetAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="PropertyPlantAndEquipmentLineItems" xlink:to="PropertyPlantAndEquipmentNetAbstract" xlink:title="definition: PropertyPlantAndEquipmentLineItems to PropertyPlantAndEquipmentNetAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="DepreciationDepletionAndAmortization" xlink:title="DepreciationDepletionAndAmortization" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="PropertyPlantAndEquipmentLineItems" xlink:to="DepreciationDepletionAndAmortization" xlink:title="definition: PropertyPlantAndEquipmentLineItems to DepreciationDepletionAndAmortization" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="PropertyPlantAndEquipmentGross" xlink:title="PropertyPlantAndEquipmentGross" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="PropertyPlantAndEquipmentLineItems" xlink:to="PropertyPlantAndEquipmentGross" xlink:title="definition: PropertyPlantAndEquipmentLineItems to PropertyPlantAndEquipmentGross" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:title="AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="PropertyPlantAndEquipmentLineItems" xlink:to="AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:title="definition: PropertyPlantAndEquipmentLineItems to AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="PropertyPlantAndEquipmentNet" xlink:title="PropertyPlantAndEquipmentNet" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="PropertyPlantAndEquipmentLineItems" xlink:to="PropertyPlantAndEquipmentNet" xlink:title="definition: PropertyPlantAndEquipmentLineItems to PropertyPlantAndEquipmentNet" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="ScheduleOfPropertyPlantAndEquipmentTable" xlink:title="ScheduleOfPropertyPlantAndEquipmentTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="PropertyPlantAndEquipmentLineItems" xlink:to="ScheduleOfPropertyPlantAndEquipmentTable" xlink:title="definition: PropertyPlantAndEquipmentLineItems to ScheduleOfPropertyPlantAndEquipmentTable" order="6.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="PropertyPlantAndEquipmentByTypeAxis" xlink:title="PropertyPlantAndEquipmentByTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="PropertyPlantAndEquipmentByTypeAxis" xlink:title="definition: ScheduleOfPropertyPlantAndEquipmentTable to PropertyPlantAndEquipmentByTypeAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="PropertyPlantAndEquipmentTypeDomain" xlink:title="PropertyPlantAndEquipmentTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="PropertyPlantAndEquipmentByTypeAxis" xlink:to="PropertyPlantAndEquipmentTypeDomain" xlink:title="definition: PropertyPlantAndEquipmentByTypeAxis to PropertyPlantAndEquipmentTypeDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="PropertyPlantAndEquipmentTypeDomain_2" xlink:title="PropertyPlantAndEquipmentTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="PropertyPlantAndEquipmentByTypeAxis" xlink:to="PropertyPlantAndEquipmentTypeDomain_2" xlink:title="definition: PropertyPlantAndEquipmentByTypeAxis to PropertyPlantAndEquipmentTypeDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ManufacturingFacilityMember" xlink:label="ManufacturingFacilityMember" xlink:title="ManufacturingFacilityMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="PropertyPlantAndEquipmentTypeDomain" xlink:to="ManufacturingFacilityMember" xlink:title="definition: PropertyPlantAndEquipmentTypeDomain to ManufacturingFacilityMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OfficeEquipmentMember" xlink:label="OfficeEquipmentMember" xlink:title="OfficeEquipmentMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="PropertyPlantAndEquipmentTypeDomain" xlink:to="OfficeEquipmentMember" xlink:title="definition: PropertyPlantAndEquipmentTypeDomain to OfficeEquipmentMember" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="FurnitureAndFixturesMember" xlink:title="FurnitureAndFixturesMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="PropertyPlantAndEquipmentTypeDomain" xlink:to="FurnitureAndFixturesMember" xlink:title="definition: PropertyPlantAndEquipmentTypeDomain to FurnitureAndFixturesMember" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetUnderConstructionMember" xlink:label="AssetUnderConstructionMember" xlink:title="AssetUnderConstructionMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="PropertyPlantAndEquipmentTypeDomain" xlink:to="AssetUnderConstructionMember" xlink:title="definition: PropertyPlantAndEquipmentTypeDomain to AssetUnderConstructionMember" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="LeaseholdImprovementsMember" xlink:title="LeaseholdImprovementsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="PropertyPlantAndEquipmentTypeDomain" xlink:to="LeaseholdImprovementsMember" xlink:title="definition: PropertyPlantAndEquipmentTypeDomain to LeaseholdImprovementsMember" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LandMember" xlink:label="LandMember" xlink:title="LandMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="PropertyPlantAndEquipmentTypeDomain" xlink:to="LandMember" xlink:title="definition: PropertyPlantAndEquipmentTypeDomain to LandMember" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BuildingAndBuildingImprovementsMember" xlink:label="BuildingAndBuildingImprovementsMember" xlink:title="BuildingAndBuildingImprovementsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="PropertyPlantAndEquipmentTypeDomain" xlink:to="BuildingAndBuildingImprovementsMember" xlink:title="definition: PropertyPlantAndEquipmentTypeDomain to BuildingAndBuildingImprovementsMember" order="7.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://admabiologics.com/role/IntangibleAssetsSummaryDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="FiniteLivedIntangibleAssetsLineItems" xlink:title="FiniteLivedIntangibleAssetsLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:label="FiniteLivedIntangibleAssetsNetAbstract" xlink:title="FiniteLivedIntangibleAssetsNetAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FiniteLivedIntangibleAssetsLineItems" xlink:to="FiniteLivedIntangibleAssetsNetAbstract" xlink:title="definition: FiniteLivedIntangibleAssetsLineItems to FiniteLivedIntangibleAssetsNetAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:label="FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:title="FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FiniteLivedIntangibleAssetsLineItems" xlink:to="FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:title="definition: FiniteLivedIntangibleAssetsLineItems to FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="AmortizationOfIntangibleAssets" xlink:title="AmortizationOfIntangibleAssets" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FiniteLivedIntangibleAssetsLineItems" xlink:to="AmortizationOfIntangibleAssets" xlink:title="definition: FiniteLivedIntangibleAssetsLineItems to AmortizationOfIntangibleAssets" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="FiniteLivedIntangibleAssetsGross" xlink:title="FiniteLivedIntangibleAssetsGross" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FiniteLivedIntangibleAssetsLineItems" xlink:to="FiniteLivedIntangibleAssetsGross" xlink:title="definition: FiniteLivedIntangibleAssetsLineItems to FiniteLivedIntangibleAssetsGross" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:title="FiniteLivedIntangibleAssetsAccumulatedAmortization" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FiniteLivedIntangibleAssetsLineItems" xlink:to="FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:title="definition: FiniteLivedIntangibleAssetsLineItems to FiniteLivedIntangibleAssetsAccumulatedAmortization" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="FiniteLivedIntangibleAssetsNet" xlink:title="FiniteLivedIntangibleAssetsNet" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FiniteLivedIntangibleAssetsLineItems" xlink:to="FiniteLivedIntangibleAssetsNet" xlink:title="definition: FiniteLivedIntangibleAssetsLineItems to FiniteLivedIntangibleAssetsNet" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:title="ScheduleOfFiniteLivedIntangibleAssetsTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="FiniteLivedIntangibleAssetsLineItems" xlink:to="ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:title="definition: FiniteLivedIntangibleAssetsLineItems to ScheduleOfFiniteLivedIntangibleAssetsTable" order="7.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:title="FiniteLivedIntangibleAssetsByMajorClassAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:title="definition: ScheduleOfFiniteLivedIntangibleAssetsTable to FiniteLivedIntangibleAssetsByMajorClassAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:title="FiniteLivedIntangibleAssetsMajorClassNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:title="definition: FiniteLivedIntangibleAssetsByMajorClassAxis to FiniteLivedIntangibleAssetsMajorClassNameDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="FiniteLivedIntangibleAssetsMajorClassNameDomain_2" xlink:title="FiniteLivedIntangibleAssetsMajorClassNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="FiniteLivedIntangibleAssetsMajorClassNameDomain_2" xlink:title="definition: FiniteLivedIntangibleAssetsByMajorClassAxis to FiniteLivedIntangibleAssetsMajorClassNameDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_TrademarkAndOtherIntangibleRightsRelatedToNabiHBMember" xlink:label="TrademarkAndOtherIntangibleRightsRelatedToNabiHBMember" xlink:title="TrademarkAndOtherIntangibleRightsRelatedToNabiHBMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="TrademarkAndOtherIntangibleRightsRelatedToNabiHBMember" xlink:title="definition: FiniteLivedIntangibleAssetsMajorClassNameDomain to TrademarkAndOtherIntangibleRightsRelatedToNabiHBMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:label="ComputerSoftwareIntangibleAssetMember" xlink:title="ComputerSoftwareIntangibleAssetMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="ComputerSoftwareIntangibleAssetMember" xlink:title="definition: FiniteLivedIntangibleAssetsMajorClassNameDomain to ComputerSoftwareIntangibleAssetMember" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_RightToIntermediatesMember" xlink:label="RightToIntermediatesMember" xlink:title="RightToIntermediatesMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="RightToIntermediatesMember" xlink:title="definition: FiniteLivedIntangibleAssetsMajorClassNameDomain to RightToIntermediatesMember" order="3.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://admabiologics.com/role/IntangibleAssetsFutureAggregateAmortizationExpenseDetails" />
  <link:definitionLink xlink:type="extended" xlink:role="http://admabiologics.com/role/AccruedExpensesAndOtherLiabilitiesDetails" />
  <link:definitionLink xlink:type="extended" xlink:role="http://admabiologics.com/role/NotesPayableDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="DebtInstrumentLineItems" xlink:title="DebtInstrumentLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentsAbstract" xlink:label="DebtInstrumentsAbstract" xlink:title="DebtInstrumentsAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="DebtInstrumentsAbstract" xlink:title="definition: DebtInstrumentLineItems to DebtInstrumentsAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NotesPayableAbstract" xlink:label="NotesPayableAbstract" xlink:title="NotesPayableAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="NotesPayableAbstract" xlink:title="definition: DebtInstrumentLineItems to NotesPayableAbstract" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="DebtInstrumentMaturityDate" xlink:title="DebtInstrumentMaturityDate" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="DebtInstrumentMaturityDate" xlink:title="definition: DebtInstrumentLineItems to DebtInstrumentMaturityDate" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="DebtInstrumentCarryingAmount" xlink:title="DebtInstrumentCarryingAmount" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="DebtInstrumentCarryingAmount" xlink:title="definition: DebtInstrumentLineItems to DebtInstrumentCarryingAmount" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_LongTermDebtPrepaymentPenalty" xlink:label="LongTermDebtPrepaymentPenalty" xlink:title="LongTermDebtPrepaymentPenalty" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="LongTermDebtPrepaymentPenalty" xlink:title="definition: DebtInstrumentLineItems to LongTermDebtPrepaymentPenalty" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="GainsLossesOnExtinguishmentOfDebt" xlink:title="GainsLossesOnExtinguishmentOfDebt" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="GainsLossesOnExtinguishmentOfDebt" xlink:title="definition: DebtInstrumentLineItems to GainsLossesOnExtinguishmentOfDebt" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfLongTermLinesOfCredit" xlink:label="RepaymentsOfLongTermLinesOfCredit" xlink:title="RepaymentsOfLongTermLinesOfCredit" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="RepaymentsOfLongTermLinesOfCredit" xlink:title="definition: DebtInstrumentLineItems to RepaymentsOfLongTermLinesOfCredit" order="7.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="LineOfCreditFacilityMaximumBorrowingCapacity" xlink:title="LineOfCreditFacilityMaximumBorrowingCapacity" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="LineOfCreditFacilityMaximumBorrowingCapacity" xlink:title="definition: DebtInstrumentLineItems to LineOfCreditFacilityMaximumBorrowingCapacity" order="8.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" xlink:label="LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" xlink:title="LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" xlink:title="definition: DebtInstrumentLineItems to LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" order="9.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_DebtInstrumentTermOfVariableRate" xlink:label="DebtInstrumentTermOfVariableRate" xlink:title="DebtInstrumentTermOfVariableRate" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="DebtInstrumentTermOfVariableRate" xlink:title="definition: DebtInstrumentLineItems to DebtInstrumentTermOfVariableRate" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_NumberOfBusinessDays" xlink:label="NumberOfBusinessDays" xlink:title="NumberOfBusinessDays" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="NumberOfBusinessDays" xlink:title="definition: DebtInstrumentLineItems to NumberOfBusinessDays" order="11.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_DebtInstrumentApplicableMargin" xlink:label="DebtInstrumentApplicableMargin" xlink:title="DebtInstrumentApplicableMargin" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="DebtInstrumentApplicableMargin" xlink:title="definition: DebtInstrumentLineItems to DebtInstrumentApplicableMargin" order="12.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="DebtInstrumentInterestRateStatedPercentage" xlink:title="DebtInstrumentInterestRateStatedPercentage" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="DebtInstrumentInterestRateStatedPercentage" xlink:title="definition: DebtInstrumentLineItems to DebtInstrumentInterestRateStatedPercentage" order="13.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_ExitFeeLiability" xlink:label="ExitFeeLiability" xlink:title="ExitFeeLiability" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="ExitFeeLiability" xlink:title="definition: DebtInstrumentLineItems to ExitFeeLiability" order="14.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentPeriodicPaymentPrincipal" xlink:label="DebtInstrumentPeriodicPaymentPrincipal" xlink:title="DebtInstrumentPeriodicPaymentPrincipal" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="DebtInstrumentPeriodicPaymentPrincipal" xlink:title="definition: DebtInstrumentLineItems to DebtInstrumentPeriodicPaymentPrincipal" order="15.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFrequencyOfPeriodicPayment" xlink:label="DebtInstrumentFrequencyOfPeriodicPayment" xlink:title="DebtInstrumentFrequencyOfPeriodicPayment" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="DebtInstrumentFrequencyOfPeriodicPayment" xlink:title="definition: DebtInstrumentLineItems to DebtInstrumentFrequencyOfPeriodicPayment" order="16.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentPeriodicPaymentInterest" xlink:label="DebtInstrumentPeriodicPaymentInterest" xlink:title="DebtInstrumentPeriodicPaymentInterest" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="DebtInstrumentPeriodicPaymentInterest" xlink:title="definition: DebtInstrumentLineItems to DebtInstrumentPeriodicPaymentInterest" order="17.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_NumberOfBusinessDaysForPriorWrittenNoticeToPrepayOutstandingPrincipal" xlink:label="NumberOfBusinessDaysForPriorWrittenNoticeToPrepayOutstandingPrincipal" xlink:title="NumberOfBusinessDaysForPriorWrittenNoticeToPrepayOutstandingPrincipal" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="NumberOfBusinessDaysForPriorWrittenNoticeToPrepayOutstandingPrincipal" xlink:title="definition: DebtInstrumentLineItems to NumberOfBusinessDaysForPriorWrittenNoticeToPrepayOutstandingPrincipal" order="18.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_PrepaymentsOfDebtPremium" xlink:label="PrepaymentsOfDebtPremium" xlink:title="PrepaymentsOfDebtPremium" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="PrepaymentsOfDebtPremium" xlink:title="definition: DebtInstrumentLineItems to PrepaymentsOfDebtPremium" order="19.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:label="LineOfCreditFacilityCommitmentFeePercentage" xlink:title="LineOfCreditFacilityCommitmentFeePercentage" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="LineOfCreditFacilityCommitmentFeePercentage" xlink:title="definition: DebtInstrumentLineItems to LineOfCreditFacilityCommitmentFeePercentage" order="20.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" xlink:label="DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" xlink:title="DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" xlink:title="definition: DebtInstrumentLineItems to DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" order="21.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFeeAmount" xlink:label="DebtInstrumentFeeAmount" xlink:title="DebtInstrumentFeeAmount" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="DebtInstrumentFeeAmount" xlink:title="definition: DebtInstrumentLineItems to DebtInstrumentFeeAmount" order="22.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_OriginalDiscountPayableCreditFacility" xlink:label="OriginalDiscountPayableCreditFacility" xlink:title="OriginalDiscountPayableCreditFacility" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="OriginalDiscountPayableCreditFacility" xlink:title="definition: DebtInstrumentLineItems to OriginalDiscountPayableCreditFacility" order="23.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_DebtInstrumentExitFee" xlink:label="DebtInstrumentExitFee" xlink:title="DebtInstrumentExitFee" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="DebtInstrumentExitFee" xlink:title="definition: DebtInstrumentLineItems to DebtInstrumentExitFee" order="24.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="DebtInstrumentInterestRateEffectivePercentage" xlink:title="DebtInstrumentInterestRateEffectivePercentage" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="DebtInstrumentInterestRateEffectivePercentage" xlink:title="definition: DebtInstrumentLineItems to DebtInstrumentInterestRateEffectivePercentage" order="25.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_MinimumLiquidityCovenantsCreditFacilities" xlink:label="MinimumLiquidityCovenantsCreditFacilities" xlink:title="MinimumLiquidityCovenantsCreditFacilities" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="MinimumLiquidityCovenantsCreditFacilities" xlink:title="definition: DebtInstrumentLineItems to MinimumLiquidityCovenantsCreditFacilities" order="26.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateIncreaseDecrease" xlink:label="DebtInstrumentInterestRateIncreaseDecrease" xlink:title="DebtInstrumentInterestRateIncreaseDecrease" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="DebtInstrumentInterestRateIncreaseDecrease" xlink:title="definition: DebtInstrumentLineItems to DebtInstrumentInterestRateIncreaseDecrease" order="27.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="RepaymentsOfNotesPayable" xlink:title="RepaymentsOfNotesPayable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="RepaymentsOfNotesPayable" xlink:title="definition: DebtInstrumentLineItems to RepaymentsOfNotesPayable" order="28.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentUnamortizedPremium" xlink:label="DebtInstrumentUnamortizedPremium" xlink:title="DebtInstrumentUnamortizedPremium" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="DebtInstrumentUnamortizedPremium" xlink:title="definition: DebtInstrumentLineItems to DebtInstrumentUnamortizedPremium" order="29.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:label="PaymentsOfDebtIssuanceCosts" xlink:title="PaymentsOfDebtIssuanceCosts" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="PaymentsOfDebtIssuanceCosts" xlink:title="definition: DebtInstrumentLineItems to PaymentsOfDebtIssuanceCosts" order="30.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_DebtInstrumentUpfrontFeePaidInKind" xlink:label="DebtInstrumentUpfrontFeePaidInKind" xlink:title="DebtInstrumentUpfrontFeePaidInKind" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="DebtInstrumentUpfrontFeePaidInKind" xlink:title="definition: DebtInstrumentLineItems to DebtInstrumentUpfrontFeePaidInKind" order="31.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_DebtInstrumentFloorInterestRate" xlink:label="DebtInstrumentFloorInterestRate" xlink:title="DebtInstrumentFloorInterestRate" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="DebtInstrumentFloorInterestRate" xlink:title="definition: DebtInstrumentLineItems to DebtInstrumentFloorInterestRate" order="32.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_DebtInstrumentInterestAmountToBePayInKind" xlink:label="DebtInstrumentInterestAmountToBePayInKind" xlink:title="DebtInstrumentInterestAmountToBePayInKind" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="DebtInstrumentInterestAmountToBePayInKind" xlink:title="definition: DebtInstrumentLineItems to DebtInstrumentInterestAmountToBePayInKind" order="33.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaidInKindInterest" xlink:label="PaidInKindInterest" xlink:title="PaidInKindInterest" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="PaidInKindInterest" xlink:title="definition: DebtInstrumentLineItems to PaidInKindInterest" order="34.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_PercentageOfExitFeeOfOutstandingPrincipalAmountBeingPaid" xlink:label="PercentageOfExitFeeOfOutstandingPrincipalAmountBeingPaid" xlink:title="PercentageOfExitFeeOfOutstandingPrincipalAmountBeingPaid" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="PercentageOfExitFeeOfOutstandingPrincipalAmountBeingPaid" xlink:title="definition: DebtInstrumentLineItems to PercentageOfExitFeeOfOutstandingPrincipalAmountBeingPaid" order="35.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Cash" xlink:label="Cash" xlink:title="Cash" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="Cash" xlink:title="definition: DebtInstrumentLineItems to Cash" order="36.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="RevenueFromContractWithCustomerExcludingAssessedTax" xlink:title="RevenueFromContractWithCustomerExcludingAssessedTax" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="RevenueFromContractWithCustomerExcludingAssessedTax" xlink:title="definition: DebtInstrumentLineItems to RevenueFromContractWithCustomerExcludingAssessedTax" order="37.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_SharesIssuedUponExerciseOfWarrants" xlink:label="SharesIssuedUponExerciseOfWarrants" xlink:title="SharesIssuedUponExerciseOfWarrants" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="SharesIssuedUponExerciseOfWarrants" xlink:title="definition: DebtInstrumentLineItems to SharesIssuedUponExerciseOfWarrants" order="38.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:title="ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:title="definition: DebtInstrumentLineItems to ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="39.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:title="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:title="definition: DebtInstrumentLineItems to ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="40.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_TrailingPeriodForVolumeWeightedAveragePrice" xlink:label="TrailingPeriodForVolumeWeightedAveragePrice" xlink:title="TrailingPeriodForVolumeWeightedAveragePrice" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="TrailingPeriodForVolumeWeightedAveragePrice" xlink:title="definition: DebtInstrumentLineItems to TrailingPeriodForVolumeWeightedAveragePrice" order="41.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="FairValueAdjustmentOfWarrants" xlink:title="FairValueAdjustmentOfWarrants" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="FairValueAdjustmentOfWarrants" xlink:title="definition: DebtInstrumentLineItems to FairValueAdjustmentOfWarrants" order="42.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="WarrantsAndRightsOutstanding" xlink:title="WarrantsAndRightsOutstanding" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="WarrantsAndRightsOutstanding" xlink:title="definition: DebtInstrumentLineItems to WarrantsAndRightsOutstanding" order="43.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_SeniorNotesPayableBeforeDebtDiscount" xlink:label="SeniorNotesPayableBeforeDebtDiscount" xlink:title="SeniorNotesPayableBeforeDebtDiscount" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="SeniorNotesPayableBeforeDebtDiscount" xlink:title="definition: DebtInstrumentLineItems to SeniorNotesPayableBeforeDebtDiscount" order="44.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="DebtInstrumentUnamortizedDiscount" xlink:title="DebtInstrumentUnamortizedDiscount" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="DebtInstrumentUnamortizedDiscount" xlink:title="definition: DebtInstrumentLineItems to DebtInstrumentUnamortizedDiscount" order="45.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeniorLongTermNotes" xlink:label="SeniorLongTermNotes" xlink:title="SeniorLongTermNotes" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentLineItems" xlink:to="SeniorLongTermNotes" xlink:title="definition: DebtInstrumentLineItems to SeniorLongTermNotes" order="46.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTable" xlink:label="DebtInstrumentTable" xlink:title="DebtInstrumentTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="DebtInstrumentLineItems" xlink:to="DebtInstrumentTable" xlink:title="definition: DebtInstrumentLineItems to DebtInstrumentTable" order="47.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis" xlink:label="DebtInstrumentAxis" xlink:title="DebtInstrumentAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="DebtInstrumentTable" xlink:to="DebtInstrumentAxis" xlink:title="definition: DebtInstrumentTable to DebtInstrumentAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="DebtInstrumentNameDomain" xlink:title="DebtInstrumentNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="DebtInstrumentAxis" xlink:to="DebtInstrumentNameDomain" xlink:title="definition: DebtInstrumentAxis to DebtInstrumentNameDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="DebtInstrumentNameDomain_2" xlink:title="DebtInstrumentNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="DebtInstrumentAxis" xlink:to="DebtInstrumentNameDomain_2" xlink:title="definition: DebtInstrumentAxis to DebtInstrumentNameDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_AresCreditFacilityMember" xlink:label="AresCreditFacilityMember" xlink:title="AresCreditFacilityMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentNameDomain" xlink:to="AresCreditFacilityMember" xlink:title="definition: DebtInstrumentNameDomain to AresCreditFacilityMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_HayfinCreditFacilityMember" xlink:label="HayfinCreditFacilityMember" xlink:title="HayfinCreditFacilityMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentNameDomain" xlink:to="HayfinCreditFacilityMember" xlink:title="definition: DebtInstrumentNameDomain to HayfinCreditFacilityMember" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_HayfinClosingDateLoanMember" xlink:label="HayfinClosingDateLoanMember" xlink:title="HayfinClosingDateLoanMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="HayfinCreditFacilityMember" xlink:to="HayfinClosingDateLoanMember" xlink:title="definition: HayfinCreditFacilityMember to HayfinClosingDateLoanMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_HayfinDelayedDrawLoanMember" xlink:label="HayfinDelayedDrawLoanMember" xlink:title="HayfinDelayedDrawLoanMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="HayfinCreditFacilityMember" xlink:to="HayfinDelayedDrawLoanMember" xlink:title="definition: HayfinCreditFacilityMember to HayfinDelayedDrawLoanMember" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_AresClosingDateLoanMember" xlink:label="AresClosingDateLoanMember" xlink:title="AresClosingDateLoanMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="HayfinCreditFacilityMember" xlink:to="AresClosingDateLoanMember" xlink:title="definition: HayfinCreditFacilityMember to AresClosingDateLoanMember" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityAxis" xlink:label="CreditFacilityAxis" xlink:title="CreditFacilityAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="DebtInstrumentTable" xlink:to="CreditFacilityAxis" xlink:title="definition: DebtInstrumentTable to CreditFacilityAxis" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityDomain" xlink:label="CreditFacilityDomain" xlink:title="CreditFacilityDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="CreditFacilityAxis" xlink:to="CreditFacilityDomain" xlink:title="definition: CreditFacilityAxis to CreditFacilityDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityDomain" xlink:label="CreditFacilityDomain_2" xlink:title="CreditFacilityDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="CreditFacilityAxis" xlink:to="CreditFacilityDomain_2" xlink:title="definition: CreditFacilityAxis to CreditFacilityDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_TermLoanMember" xlink:label="TermLoanMember" xlink:title="TermLoanMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CreditFacilityDomain" xlink:to="TermLoanMember" xlink:title="definition: CreditFacilityDomain to TermLoanMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevolvingCreditFacilityMember" xlink:label="RevolvingCreditFacilityMember" xlink:title="RevolvingCreditFacilityMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="CreditFacilityDomain" xlink:to="RevolvingCreditFacilityMember" xlink:title="definition: CreditFacilityDomain to RevolvingCreditFacilityMember" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis" xlink:label="CounterpartyNameAxis" xlink:title="CounterpartyNameAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="DebtInstrumentTable" xlink:to="CounterpartyNameAxis" xlink:title="definition: DebtInstrumentTable to CounterpartyNameAxis" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="RepurchaseAgreementCounterpartyNameDomain" xlink:title="RepurchaseAgreementCounterpartyNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="CounterpartyNameAxis" xlink:to="RepurchaseAgreementCounterpartyNameDomain" xlink:title="definition: CounterpartyNameAxis to RepurchaseAgreementCounterpartyNameDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="RepurchaseAgreementCounterpartyNameDomain_2" xlink:title="RepurchaseAgreementCounterpartyNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="CounterpartyNameAxis" xlink:to="RepurchaseAgreementCounterpartyNameDomain_2" xlink:title="definition: CounterpartyNameAxis to RepurchaseAgreementCounterpartyNameDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_AresCreditAgreementMember" xlink:label="AresCreditAgreementMember" xlink:title="AresCreditAgreementMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RepurchaseAgreementCounterpartyNameDomain" xlink:to="AresCreditAgreementMember" xlink:title="definition: RepurchaseAgreementCounterpartyNameDomain to AresCreditAgreementMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_HayfinCreditAgreementMember" xlink:label="HayfinCreditAgreementMember" xlink:title="HayfinCreditAgreementMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RepurchaseAgreementCounterpartyNameDomain" xlink:to="HayfinCreditAgreementMember" xlink:title="definition: RepurchaseAgreementCounterpartyNameDomain to HayfinCreditAgreementMember" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_HayfinSecondAmendmentMember" xlink:label="HayfinSecondAmendmentMember" xlink:title="HayfinSecondAmendmentMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RepurchaseAgreementCounterpartyNameDomain" xlink:to="HayfinSecondAmendmentMember" xlink:title="definition: RepurchaseAgreementCounterpartyNameDomain to HayfinSecondAmendmentMember" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VariableRateAxis" xlink:label="VariableRateAxis" xlink:title="VariableRateAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="DebtInstrumentTable" xlink:to="VariableRateAxis" xlink:title="definition: DebtInstrumentTable to VariableRateAxis" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VariableRateDomain" xlink:label="VariableRateDomain" xlink:title="VariableRateDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="VariableRateAxis" xlink:to="VariableRateDomain" xlink:title="definition: VariableRateAxis to VariableRateDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VariableRateDomain" xlink:label="VariableRateDomain_2" xlink:title="VariableRateDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="VariableRateAxis" xlink:to="VariableRateDomain_2" xlink:title="definition: VariableRateAxis to VariableRateDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SecuredOvernightFinancingRateSofrMember" xlink:label="SecuredOvernightFinancingRateSofrMember" xlink:title="SecuredOvernightFinancingRateSofrMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="VariableRateDomain" xlink:to="SecuredOvernightFinancingRateSofrMember" xlink:title="definition: VariableRateDomain to SecuredOvernightFinancingRateSofrMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BaseRateMember" xlink:label="BaseRateMember" xlink:title="BaseRateMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="VariableRateDomain" xlink:to="BaseRateMember" xlink:title="definition: VariableRateDomain to BaseRateMember" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="RangeAxis" xlink:title="RangeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="DebtInstrumentTable" xlink:to="RangeAxis" xlink:title="definition: DebtInstrumentTable to RangeAxis" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="RangeMember" xlink:title="RangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="RangeAxis" xlink:to="RangeMember" xlink:title="definition: RangeAxis to RangeMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="RangeMember_2" xlink:title="RangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="RangeAxis" xlink:to="RangeMember_2" xlink:title="definition: RangeAxis to RangeMember_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="MinimumMember" xlink:title="MinimumMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RangeMember" xlink:to="MinimumMember" xlink:title="definition: RangeMember to MinimumMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="MaximumMember" xlink:title="MaximumMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RangeMember" xlink:to="MaximumMember" xlink:title="definition: RangeMember to MaximumMember" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:label="DebtInstrumentRedemptionPeriodAxis" xlink:title="DebtInstrumentRedemptionPeriodAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="DebtInstrumentTable" xlink:to="DebtInstrumentRedemptionPeriodAxis" xlink:title="definition: DebtInstrumentTable to DebtInstrumentRedemptionPeriodAxis" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:label="DebtInstrumentRedemptionPeriodDomain" xlink:title="DebtInstrumentRedemptionPeriodDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="DebtInstrumentRedemptionPeriodAxis" xlink:to="DebtInstrumentRedemptionPeriodDomain" xlink:title="definition: DebtInstrumentRedemptionPeriodAxis to DebtInstrumentRedemptionPeriodDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:label="DebtInstrumentRedemptionPeriodDomain_2" xlink:title="DebtInstrumentRedemptionPeriodDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="DebtInstrumentRedemptionPeriodAxis" xlink:to="DebtInstrumentRedemptionPeriodDomain_2" xlink:title="definition: DebtInstrumentRedemptionPeriodAxis to DebtInstrumentRedemptionPeriodDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_PrepaidOnOrPriorToFirstAnniversaryMember" xlink:label="PrepaidOnOrPriorToFirstAnniversaryMember" xlink:title="PrepaidOnOrPriorToFirstAnniversaryMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentRedemptionPeriodDomain" xlink:to="PrepaidOnOrPriorToFirstAnniversaryMember" xlink:title="definition: DebtInstrumentRedemptionPeriodDomain to PrepaidOnOrPriorToFirstAnniversaryMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_PrepaidAfterTheFirstAnniversaryMember" xlink:label="PrepaidAfterTheFirstAnniversaryMember" xlink:title="PrepaidAfterTheFirstAnniversaryMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentRedemptionPeriodDomain" xlink:to="PrepaidAfterTheFirstAnniversaryMember" xlink:title="definition: DebtInstrumentRedemptionPeriodDomain to PrepaidAfterTheFirstAnniversaryMember" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_PrepaidOnOrPriorToSecondAnniversaryMember" xlink:label="PrepaidOnOrPriorToSecondAnniversaryMember" xlink:title="PrepaidOnOrPriorToSecondAnniversaryMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentRedemptionPeriodDomain" xlink:to="PrepaidOnOrPriorToSecondAnniversaryMember" xlink:title="definition: DebtInstrumentRedemptionPeriodDomain to PrepaidOnOrPriorToSecondAnniversaryMember" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_PrepaidOnOrPriorToThirdAnniversaryMember" xlink:label="PrepaidOnOrPriorToThirdAnniversaryMember" xlink:title="PrepaidOnOrPriorToThirdAnniversaryMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="DebtInstrumentRedemptionPeriodDomain" xlink:to="PrepaidOnOrPriorToThirdAnniversaryMember" xlink:title="definition: DebtInstrumentRedemptionPeriodDomain to PrepaidOnOrPriorToThirdAnniversaryMember" order="4.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://admabiologics.com/role/StockholdersEquityPreferredStockDetails" />
  <link:definitionLink xlink:type="extended" xlink:role="http://admabiologics.com/role/StockholdersEquityCommonStockDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems" xlink:label="ClassOfStockLineItems" xlink:title="ClassOfStockLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:label="CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:title="CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfStockLineItems" xlink:to="CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:title="definition: ClassOfStockLineItems to CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="CommonStockSharesAuthorized" xlink:title="CommonStockSharesAuthorized" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfStockLineItems" xlink:to="CommonStockSharesAuthorized" xlink:title="definition: ClassOfStockLineItems to CommonStockSharesAuthorized" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="CommonStockParOrStatedValuePerShare" xlink:title="CommonStockParOrStatedValuePerShare" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfStockLineItems" xlink:to="CommonStockParOrStatedValuePerShare" xlink:title="definition: ClassOfStockLineItems to CommonStockParOrStatedValuePerShare" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="CommonStockSharesOutstanding" xlink:title="CommonStockSharesOutstanding" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfStockLineItems" xlink:to="CommonStockSharesOutstanding" xlink:title="definition: ClassOfStockLineItems to CommonStockSharesOutstanding" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="CommonStockCapitalSharesReservedForFutureIssuance" xlink:title="CommonStockCapitalSharesReservedForFutureIssuance" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfStockLineItems" xlink:to="CommonStockCapitalSharesReservedForFutureIssuance" xlink:title="definition: ClassOfStockLineItems to CommonStockCapitalSharesReservedForFutureIssuance" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:title="StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfStockLineItems" xlink:to="StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:title="definition: ClassOfStockLineItems to StockIssuedDuringPeriodSharesStockOptionsExercised" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="ProceedsFromStockOptionsExercised" xlink:title="ProceedsFromStockOptionsExercised" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfStockLineItems" xlink:to="ProceedsFromStockOptionsExercised" xlink:title="definition: ClassOfStockLineItems to ProceedsFromStockOptionsExercised" order="7.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="StockIssuedDuringPeriodSharesNewIssues" xlink:title="StockIssuedDuringPeriodSharesNewIssues" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfStockLineItems" xlink:to="StockIssuedDuringPeriodSharesNewIssues" xlink:title="definition: ClassOfStockLineItems to StockIssuedDuringPeriodSharesNewIssues" order="8.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="ProceedsFromIssuanceOfCommonStock" xlink:title="ProceedsFromIssuanceOfCommonStock" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfStockLineItems" xlink:to="ProceedsFromIssuanceOfCommonStock" xlink:title="definition: ClassOfStockLineItems to ProceedsFromIssuanceOfCommonStock" order="9.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="ScheduleOfStockByClassTable" xlink:title="ScheduleOfStockByClassTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ClassOfStockLineItems" xlink:to="ScheduleOfStockByClassTable" xlink:title="definition: ClassOfStockLineItems to ScheduleOfStockByClassTable" order="10.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="StatementEquityComponentsAxis" xlink:title="StatementEquityComponentsAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfStockByClassTable" xlink:to="StatementEquityComponentsAxis" xlink:title="definition: ScheduleOfStockByClassTable to StatementEquityComponentsAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="EquityComponentDomain" xlink:title="EquityComponentDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="StatementEquityComponentsAxis" xlink:to="EquityComponentDomain" xlink:title="definition: StatementEquityComponentsAxis to EquityComponentDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="EquityComponentDomain_2" xlink:title="EquityComponentDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="StatementEquityComponentsAxis" xlink:to="EquityComponentDomain_2" xlink:title="definition: StatementEquityComponentsAxis to EquityComponentDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="CommonStockMember" xlink:title="CommonStockMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EquityComponentDomain" xlink:to="CommonStockMember" xlink:title="definition: EquityComponentDomain to CommonStockMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="SubsidiarySaleOfStockAxis" xlink:title="SubsidiarySaleOfStockAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfStockByClassTable" xlink:to="SubsidiarySaleOfStockAxis" xlink:title="definition: ScheduleOfStockByClassTable to SubsidiarySaleOfStockAxis" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="SaleOfStockNameOfTransactionDomain" xlink:title="SaleOfStockNameOfTransactionDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="SubsidiarySaleOfStockAxis" xlink:to="SaleOfStockNameOfTransactionDomain" xlink:title="definition: SubsidiarySaleOfStockAxis to SaleOfStockNameOfTransactionDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="SaleOfStockNameOfTransactionDomain_2" xlink:title="SaleOfStockNameOfTransactionDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="SubsidiarySaleOfStockAxis" xlink:to="SaleOfStockNameOfTransactionDomain_2" xlink:title="definition: SubsidiarySaleOfStockAxis to SaleOfStockNameOfTransactionDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="OverAllotmentOptionMember" xlink:title="OverAllotmentOptionMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SaleOfStockNameOfTransactionDomain" xlink:to="OverAllotmentOptionMember" xlink:title="definition: SaleOfStockNameOfTransactionDomain to OverAllotmentOptionMember" order="1.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://admabiologics.com/role/StockholdersEquityWarrantsDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="ClassOfWarrantOrRightLineItems" xlink:title="ClassOfWarrantOrRightLineItems" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_WarrantsAbstract" xlink:label="WarrantsAbstract" xlink:title="WarrantsAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfWarrantOrRightLineItems" xlink:to="WarrantsAbstract" xlink:title="definition: ClassOfWarrantOrRightLineItems to WarrantsAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfWarrantOrRightLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:title="definition: ClassOfWarrantOrRightLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfWarrantOrRightLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:title="definition: ClassOfWarrantOrRightLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfWarrantOrRightLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:title="definition: ClassOfWarrantOrRightLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriodWeightedAverageGrantDateFairValue" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriodWeightedAverageGrantDateFairValue" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriodWeightedAverageGrantDateFairValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfWarrantOrRightLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriodWeightedAverageGrantDateFairValue" xlink:title="definition: ClassOfWarrantOrRightLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriodWeightedAverageGrantDateFairValue" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfWarrantOrRightLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:title="definition: ClassOfWarrantOrRightLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageGrantDateFairValue" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageGrantDateFairValue" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageGrantDateFairValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfWarrantOrRightLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageGrantDateFairValue" xlink:title="definition: ClassOfWarrantOrRightLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageGrantDateFairValue" order="7.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfWarrantOrRightLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:title="definition: ClassOfWarrantOrRightLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="8.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfWarrantOrRightLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod" xlink:title="definition: ClassOfWarrantOrRightLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod" order="9.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfWarrantOrRightLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:title="definition: ClassOfWarrantOrRightLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfWarrantOrRightLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod" xlink:title="definition: ClassOfWarrantOrRightLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod" order="11.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_ClassOfWarrantOrRightExercised" xlink:label="ClassOfWarrantOrRightExercised" xlink:title="ClassOfWarrantOrRightExercised" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfWarrantOrRightLineItems" xlink:to="ClassOfWarrantOrRightExercised" xlink:title="definition: ClassOfWarrantOrRightLineItems to ClassOfWarrantOrRightExercised" order="12.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="CommonStockSharesIssued" xlink:title="CommonStockSharesIssued" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfWarrantOrRightLineItems" xlink:to="CommonStockSharesIssued" xlink:title="definition: ClassOfWarrantOrRightLineItems to CommonStockSharesIssued" order="13.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:title="ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfWarrantOrRightLineItems" xlink:to="ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:title="definition: ClassOfWarrantOrRightLineItems to ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="14.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="WarrantsAndRightsOutstanding" xlink:title="WarrantsAndRightsOutstanding" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfWarrantOrRightLineItems" xlink:to="WarrantsAndRightsOutstanding" xlink:title="definition: ClassOfWarrantOrRightLineItems to WarrantsAndRightsOutstanding" order="15.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfWarrantOrRightLineItems" xlink:to="SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:title="definition: ClassOfWarrantOrRightLineItems to SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="16.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfWarrantOrRightLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:title="definition: ClassOfWarrantOrRightLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="17.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfWarrantOrRightLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:title="definition: ClassOfWarrantOrRightLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="18.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfWarrantOrRightLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:title="definition: ClassOfWarrantOrRightLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="19.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:title="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfWarrantOrRightLineItems" xlink:to="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:title="definition: ClassOfWarrantOrRightLineItems to ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="20.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="ClassOfWarrantOrRightOutstanding" xlink:title="ClassOfWarrantOrRightOutstanding" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfWarrantOrRightLineItems" xlink:to="ClassOfWarrantOrRightOutstanding" xlink:title="definition: ClassOfWarrantOrRightLineItems to ClassOfWarrantOrRightOutstanding" order="21.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="ClassOfWarrantOrRightTable" xlink:title="ClassOfWarrantOrRightTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ClassOfWarrantOrRightLineItems" xlink:to="ClassOfWarrantOrRightTable" xlink:title="definition: ClassOfWarrantOrRightLineItems to ClassOfWarrantOrRightTable" order="22.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="ClassOfWarrantOrRightAxis" xlink:title="ClassOfWarrantOrRightAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ClassOfWarrantOrRightTable" xlink:to="ClassOfWarrantOrRightAxis" xlink:title="definition: ClassOfWarrantOrRightTable to ClassOfWarrantOrRightAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="ClassOfWarrantOrRightDomain" xlink:title="ClassOfWarrantOrRightDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ClassOfWarrantOrRightAxis" xlink:to="ClassOfWarrantOrRightDomain" xlink:title="definition: ClassOfWarrantOrRightAxis to ClassOfWarrantOrRightDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="ClassOfWarrantOrRightDomain_2" xlink:title="ClassOfWarrantOrRightDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ClassOfWarrantOrRightAxis" xlink:to="ClassOfWarrantOrRightDomain_2" xlink:title="definition: ClassOfWarrantOrRightAxis to ClassOfWarrantOrRightDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_HayfinWarrantsMember" xlink:label="HayfinWarrantsMember" xlink:title="HayfinWarrantsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfWarrantOrRightDomain" xlink:to="HayfinWarrantsMember" xlink:title="definition: ClassOfWarrantOrRightDomain to HayfinWarrantsMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="WarrantMember" xlink:title="WarrantMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ClassOfWarrantOrRightDomain" xlink:to="WarrantMember" xlink:title="definition: ClassOfWarrantOrRightDomain to WarrantMember" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="StatementEquityComponentsAxis" xlink:title="StatementEquityComponentsAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ClassOfWarrantOrRightTable" xlink:to="StatementEquityComponentsAxis" xlink:title="definition: ClassOfWarrantOrRightTable to StatementEquityComponentsAxis" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="EquityComponentDomain" xlink:title="EquityComponentDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="StatementEquityComponentsAxis" xlink:to="EquityComponentDomain" xlink:title="definition: StatementEquityComponentsAxis to EquityComponentDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="EquityComponentDomain_2" xlink:title="EquityComponentDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="StatementEquityComponentsAxis" xlink:to="EquityComponentDomain_2" xlink:title="definition: StatementEquityComponentsAxis to EquityComponentDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="CommonStockMember" xlink:title="CommonStockMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="EquityComponentDomain" xlink:to="CommonStockMember" xlink:title="definition: EquityComponentDomain to CommonStockMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis" xlink:label="CounterpartyNameAxis" xlink:title="CounterpartyNameAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ClassOfWarrantOrRightTable" xlink:to="CounterpartyNameAxis" xlink:title="definition: ClassOfWarrantOrRightTable to CounterpartyNameAxis" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="RepurchaseAgreementCounterpartyNameDomain" xlink:title="RepurchaseAgreementCounterpartyNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="CounterpartyNameAxis" xlink:to="RepurchaseAgreementCounterpartyNameDomain" xlink:title="definition: CounterpartyNameAxis to RepurchaseAgreementCounterpartyNameDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="RepurchaseAgreementCounterpartyNameDomain_2" xlink:title="RepurchaseAgreementCounterpartyNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="CounterpartyNameAxis" xlink:to="RepurchaseAgreementCounterpartyNameDomain_2" xlink:title="definition: CounterpartyNameAxis to RepurchaseAgreementCounterpartyNameDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_HayfinSecondAmendmentMember" xlink:label="HayfinSecondAmendmentMember" xlink:title="HayfinSecondAmendmentMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RepurchaseAgreementCounterpartyNameDomain" xlink:to="HayfinSecondAmendmentMember" xlink:title="definition: RepurchaseAgreementCounterpartyNameDomain to HayfinSecondAmendmentMember" order="1.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_StockOptionsAbstract" xlink:label="StockOptionsAbstract" xlink:title="StockOptionsAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="StockOptionsAbstract" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to StockOptionsAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_StockOptionOutstandingAndExcercisableAbstract" xlink:label="StockOptionOutstandingAndExcercisableAbstract" xlink:title="StockOptionOutstandingAndExcercisableAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="StockOptionOutstandingAndExcercisableAbstract" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to StockOptionOutstandingAndExcercisableAbstract" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:title="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:title="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_RestrictedStockUnitsAbstract" xlink:label="RestrictedStockUnitsAbstract" xlink:title="RestrictedStockUnitsAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="RestrictedStockUnitsAbstract" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to RestrictedStockUnitsAbstract" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract" xlink:label="ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract" xlink:title="ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="ShareBasedCompensation" xlink:title="ShareBasedCompensation" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensation" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensation" order="7.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" order="8.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" order="9.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesWithheldForEmployeesTaxLiabilities" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesWithheldForEmployeesTaxLiabilities" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesWithheldForEmployeesTaxLiabilities" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesWithheldForEmployeesTaxLiabilities" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesWithheldForEmployeesTaxLiabilities" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesValueWithheldForEmployeesTaxLiabilities" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesValueWithheldForEmployeesTaxLiabilities" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesValueWithheldForEmployeesTaxLiabilities" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesValueWithheldForEmployeesTaxLiabilities" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesValueWithheldForEmployeesTaxLiabilities" order="11.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_NumberOfIndividualsThatReceivedModificationsToTheirOutstandingStockOptionAndRSUAwards" xlink:label="NumberOfIndividualsThatReceivedModificationsToTheirOutstandingStockOptionAndRSUAwards" xlink:title="NumberOfIndividualsThatReceivedModificationsToTheirOutstandingStockOptionAndRSUAwards" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="NumberOfIndividualsThatReceivedModificationsToTheirOutstandingStockOptionAndRSUAwards" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to NumberOfIndividualsThatReceivedModificationsToTheirOutstandingStockOptionAndRSUAwards" order="12.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="AllocatedShareBasedCompensationExpense" xlink:title="AllocatedShareBasedCompensationExpense" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="AllocatedShareBasedCompensationExpense" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to AllocatedShareBasedCompensationExpense" order="13.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" order="14.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" order="15.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" order="16.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="17.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" order="18.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" order="19.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="20.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="21.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" order="22.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" order="23.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:label="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:title="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" order="24.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:label="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:title="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" order="25.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:label="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:title="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" order="26.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="27.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:label="SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:title="SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" order="28.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="29.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:label="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:title="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" order="30.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:label="SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:title="SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" order="31.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:label="SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:title="SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" order="32.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" order="33.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="CommonStockCapitalSharesReservedForFutureIssuance" xlink:title="CommonStockCapitalSharesReservedForFutureIssuance" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="CommonStockCapitalSharesReservedForFutureIssuance" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to CommonStockCapitalSharesReservedForFutureIssuance" order="34.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="35.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSharesWithheldToCoverAggregateExercisePrices" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSharesWithheldToCoverAggregateExercisePrices" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSharesWithheldToCoverAggregateExercisePrices" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSharesWithheldToCoverAggregateExercisePrices" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSharesWithheldToCoverAggregateExercisePrices" order="36.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="ProceedsFromStockOptionsExercised" xlink:title="ProceedsFromStockOptionsExercised" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ProceedsFromStockOptionsExercised" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ProceedsFromStockOptionsExercised" order="37.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSharesWithheldForPayrollTaxes" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSharesWithheldForPayrollTaxes" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSharesWithheldForPayrollTaxes" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSharesWithheldForPayrollTaxes" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSharesWithheldForPayrollTaxes" order="38.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:title="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" order="39.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" order="40.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="41.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" order="42.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract" order="43.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_StockOptionSharesAbstract" xlink:label="StockOptionSharesAbstract" xlink:title="StockOptionSharesAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="StockOptionSharesAbstract" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to StockOptionSharesAbstract" order="44.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_StockOptionsWeightedAverageExercisePriceAbstract" xlink:label="StockOptionsWeightedAverageExercisePriceAbstract" xlink:title="StockOptionsWeightedAverageExercisePriceAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="StockOptionsWeightedAverageExercisePriceAbstract" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to StockOptionsWeightedAverageExercisePriceAbstract" order="45.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" order="46.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedWeightedAverageExercisePrice" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedWeightedAverageExercisePrice" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedWeightedAverageExercisePrice" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedWeightedAverageExercisePrice" order="47.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredWeightedAverageExercisePrice" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredWeightedAverageExercisePrice" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredWeightedAverageExercisePrice" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredWeightedAverageExercisePrice" order="48.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedWeightedAverageExercisePrice" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedWeightedAverageExercisePrice" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedWeightedAverageExercisePrice" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedWeightedAverageExercisePrice" order="49.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedWeightedAverageExercisePrice" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedWeightedAverageExercisePrice" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedWeightedAverageExercisePrice" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedWeightedAverageExercisePrice" order="50.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="51.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" order="52.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedNumber" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedNumber" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedNumber" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedNumber" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedNumber" order="53.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredNumber" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredNumber" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredNumber" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredNumber" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredNumber" order="54.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedNumber" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedNumber" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedNumber" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedNumber" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedNumber" order="55.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedNumber" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedNumber" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedNumber" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedNumber" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedNumber" order="56.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="57.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="58.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="59.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="60.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="61.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="definition: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="62.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="AwardTypeAxis" xlink:title="AwardTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="AwardTypeAxis" xlink:title="definition: ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to AwardTypeAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="AwardTypeAxis" xlink:to="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="definition: AwardTypeAxis to ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="AwardTypeAxis" xlink:to="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2" xlink:title="definition: AwardTypeAxis to ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="EmployeeStockOptionMember" xlink:title="EmployeeStockOptionMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="EmployeeStockOptionMember" xlink:title="definition: ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain to EmployeeStockOptionMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="RestrictedStockUnitsRSUMember" xlink:title="RestrictedStockUnitsRSUMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="RestrictedStockUnitsRSUMember" xlink:title="definition: ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain to RestrictedStockUnitsRSUMember" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="PlanNameAxis" xlink:title="PlanNameAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="PlanNameAxis" xlink:title="definition: ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to PlanNameAxis" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="PlanNameDomain" xlink:title="PlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="PlanNameAxis" xlink:to="PlanNameDomain" xlink:title="definition: PlanNameAxis to PlanNameDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="PlanNameDomain_2" xlink:title="PlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="PlanNameAxis" xlink:to="PlanNameDomain_2" xlink:title="definition: PlanNameAxis to PlanNameDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_Two022CompensationPlanMember" xlink:label="Two022CompensationPlanMember" xlink:title="Two022CompensationPlanMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="PlanNameDomain" xlink:to="Two022CompensationPlanMember" xlink:title="definition: PlanNameDomain to Two022CompensationPlanMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_EquityIncentivePlanMember" xlink:label="EquityIncentivePlanMember" xlink:title="EquityIncentivePlanMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="PlanNameDomain" xlink:to="EquityIncentivePlanMember" xlink:title="definition: PlanNameDomain to EquityIncentivePlanMember" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="TitleOfIndividualAxis" xlink:title="TitleOfIndividualAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="TitleOfIndividualAxis" xlink:title="definition: ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to TitleOfIndividualAxis" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="TitleOfIndividualWithRelationshipToEntityDomain" xlink:title="TitleOfIndividualWithRelationshipToEntityDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="TitleOfIndividualAxis" xlink:to="TitleOfIndividualWithRelationshipToEntityDomain" xlink:title="definition: TitleOfIndividualAxis to TitleOfIndividualWithRelationshipToEntityDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="TitleOfIndividualWithRelationshipToEntityDomain_2" xlink:title="TitleOfIndividualWithRelationshipToEntityDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="TitleOfIndividualAxis" xlink:to="TitleOfIndividualWithRelationshipToEntityDomain_2" xlink:title="definition: TitleOfIndividualAxis to TitleOfIndividualWithRelationshipToEntityDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_EmployeesMember" xlink:label="EmployeesMember" xlink:title="EmployeesMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="EmployeesMember" xlink:title="definition: TitleOfIndividualWithRelationshipToEntityDomain to EmployeesMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_DirectorMember" xlink:label="DirectorMember" xlink:title="DirectorMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="DirectorMember" xlink:title="definition: TitleOfIndividualWithRelationshipToEntityDomain to DirectorMember" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="RangeAxis" xlink:title="RangeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="RangeAxis" xlink:title="definition: ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to RangeAxis" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="RangeMember" xlink:title="RangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="RangeAxis" xlink:to="RangeMember" xlink:title="definition: RangeAxis to RangeMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="RangeMember_2" xlink:title="RangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="RangeAxis" xlink:to="RangeMember_2" xlink:title="definition: RangeAxis to RangeMember_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="MinimumMember" xlink:title="MinimumMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RangeMember" xlink:to="MinimumMember" xlink:title="definition: RangeMember to MinimumMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="MaximumMember" xlink:title="MaximumMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RangeMember" xlink:to="MaximumMember" xlink:title="definition: RangeMember to MaximumMember" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:title="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:title="definition: ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:title="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:title="definition: ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis to ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_2" xlink:title="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_2" xlink:title="definition: ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis to ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_ExercisePriceRange1Member" xlink:label="ExercisePriceRange1Member" xlink:title="ExercisePriceRange1Member" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="ExercisePriceRange1Member" xlink:title="definition: ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain to ExercisePriceRange1Member" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_ExercisePriceRange2Member" xlink:label="ExercisePriceRange2Member" xlink:title="ExercisePriceRange2Member" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="ExercisePriceRange2Member" xlink:title="definition: ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain to ExercisePriceRange2Member" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_ExercisePriceRange3Member" xlink:label="ExercisePriceRange3Member" xlink:title="ExercisePriceRange3Member" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="ExercisePriceRange3Member" xlink:title="definition: ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain to ExercisePriceRange3Member" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_ExercisePriceRange4Member" xlink:label="ExercisePriceRange4Member" xlink:title="ExercisePriceRange4Member" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="ExercisePriceRange4Member" xlink:title="definition: ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain to ExercisePriceRange4Member" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_ExercisePriceRange5Member" xlink:label="ExercisePriceRange5Member" xlink:title="ExercisePriceRange5Member" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="ExercisePriceRange5Member" xlink:title="definition: ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain to ExercisePriceRange5Member" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_ExercisePriceRange6Member" xlink:label="ExercisePriceRange6Member" xlink:title="ExercisePriceRange6Member" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="ExercisePriceRange6Member" xlink:title="definition: ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain to ExercisePriceRange6Member" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="IncomeStatementLocationAxis" xlink:title="IncomeStatementLocationAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="IncomeStatementLocationAxis" xlink:title="definition: ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to IncomeStatementLocationAxis" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="IncomeStatementLocationDomain" xlink:title="IncomeStatementLocationDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="IncomeStatementLocationAxis" xlink:to="IncomeStatementLocationDomain" xlink:title="definition: IncomeStatementLocationAxis to IncomeStatementLocationDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="IncomeStatementLocationDomain_2" xlink:title="IncomeStatementLocationDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="IncomeStatementLocationAxis" xlink:to="IncomeStatementLocationDomain_2" xlink:title="definition: IncomeStatementLocationAxis to IncomeStatementLocationDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="ResearchAndDevelopmentExpenseMember" xlink:title="ResearchAndDevelopmentExpenseMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="IncomeStatementLocationDomain" xlink:to="ResearchAndDevelopmentExpenseMember" xlink:title="definition: IncomeStatementLocationDomain to ResearchAndDevelopmentExpenseMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenseMember" xlink:label="OperatingExpenseMember" xlink:title="OperatingExpenseMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="IncomeStatementLocationDomain" xlink:to="OperatingExpenseMember" xlink:title="definition: IncomeStatementLocationDomain to OperatingExpenseMember" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="SellingGeneralAndAdministrativeExpensesMember" xlink:title="SellingGeneralAndAdministrativeExpensesMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="IncomeStatementLocationDomain" xlink:to="SellingGeneralAndAdministrativeExpensesMember" xlink:title="definition: IncomeStatementLocationDomain to SellingGeneralAndAdministrativeExpensesMember" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfSalesMember" xlink:label="CostOfSalesMember" xlink:title="CostOfSalesMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="IncomeStatementLocationDomain" xlink:to="CostOfSalesMember" xlink:title="definition: IncomeStatementLocationDomain to CostOfSalesMember" order="4.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://admabiologics.com/role/RelatedPartyTransactionsDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="RelatedPartyTransactionLineItems" xlink:title="RelatedPartyTransactionLineItems" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_RelatedPartyTransactionAbstract" xlink:label="RelatedPartyTransactionAbstract" xlink:title="RelatedPartyTransactionAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RelatedPartyTransactionLineItems" xlink:to="RelatedPartyTransactionAbstract" xlink:title="definition: RelatedPartyTransactionLineItems to RelatedPartyTransactionAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingCostsAndExpenses" xlink:label="OperatingCostsAndExpenses" xlink:title="OperatingCostsAndExpenses" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RelatedPartyTransactionLineItems" xlink:to="OperatingCostsAndExpenses" xlink:title="definition: RelatedPartyTransactionLineItems to OperatingCostsAndExpenses" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseExpirationDate1" xlink:label="LeaseExpirationDate1" xlink:title="LeaseExpirationDate1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RelatedPartyTransactionLineItems" xlink:to="LeaseExpirationDate1" xlink:title="definition: RelatedPartyTransactionLineItems to LeaseExpirationDate1" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_RelatedPartyTransactionLeaseRenewalPeriod" xlink:label="RelatedPartyTransactionLeaseRenewalPeriod" xlink:title="RelatedPartyTransactionLeaseRenewalPeriod" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RelatedPartyTransactionLineItems" xlink:to="RelatedPartyTransactionLeaseRenewalPeriod" xlink:title="definition: RelatedPartyTransactionLineItems to RelatedPartyTransactionLeaseRenewalPeriod" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_RelatedPartyTransactionLeaseTerminationPeriod" xlink:label="RelatedPartyTransactionLeaseTerminationPeriod" xlink:title="RelatedPartyTransactionLeaseTerminationPeriod" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RelatedPartyTransactionLineItems" xlink:to="RelatedPartyTransactionLeaseTerminationPeriod" xlink:title="definition: RelatedPartyTransactionLineItems to RelatedPartyTransactionLeaseTerminationPeriod" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty" xlink:label="RelatedPartyTransactionPurchasesFromRelatedParty" xlink:title="RelatedPartyTransactionPurchasesFromRelatedParty" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RelatedPartyTransactionLineItems" xlink:to="RelatedPartyTransactionPurchasesFromRelatedParty" xlink:title="definition: RelatedPartyTransactionLineItems to RelatedPartyTransactionPurchasesFromRelatedParty" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RelatedPartyTransactionLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:title="definition: RelatedPartyTransactionLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" order="7.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RelatedPartyTransactionLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:title="definition: RelatedPartyTransactionLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" order="8.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RelatedPartyTransactionLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:title="definition: RelatedPartyTransactionLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" order="9.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RelatedPartyTransactionLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" xlink:title="definition: RelatedPartyTransactionLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="ShareBasedCompensation" xlink:title="ShareBasedCompensation" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RelatedPartyTransactionLineItems" xlink:to="ShareBasedCompensation" xlink:title="definition: RelatedPartyTransactionLineItems to ShareBasedCompensation" order="11.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_NumberOfExecutiveOfficersThatExercisedOptions" xlink:label="NumberOfExecutiveOfficersThatExercisedOptions" xlink:title="NumberOfExecutiveOfficersThatExercisedOptions" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RelatedPartyTransactionLineItems" xlink:to="NumberOfExecutiveOfficersThatExercisedOptions" xlink:title="definition: RelatedPartyTransactionLineItems to NumberOfExecutiveOfficersThatExercisedOptions" order="12.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedInCashlessTransactionForAward" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedInCashlessTransactionForAward" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedInCashlessTransactionForAward" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RelatedPartyTransactionLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedInCashlessTransactionForAward" xlink:title="definition: RelatedPartyTransactionLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedInCashlessTransactionForAward" order="13.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:title="StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RelatedPartyTransactionLineItems" xlink:to="StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:title="definition: RelatedPartyTransactionLineItems to StockIssuedDuringPeriodSharesStockOptionsExercised" order="14.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:label="SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:title="SharesPaidForTaxWithholdingForShareBasedCompensation" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RelatedPartyTransactionLineItems" xlink:to="SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:title="definition: RelatedPartyTransactionLineItems to SharesPaidForTaxWithholdingForShareBasedCompensation" order="15.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_MinimumPercentageOfCommonStockHeldByLender" xlink:label="MinimumPercentageOfCommonStockHeldByLender" xlink:title="MinimumPercentageOfCommonStockHeldByLender" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RelatedPartyTransactionLineItems" xlink:to="MinimumPercentageOfCommonStockHeldByLender" xlink:title="definition: RelatedPartyTransactionLineItems to MinimumPercentageOfCommonStockHeldByLender" order="16.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="StockIssuedDuringPeriodSharesNewIssues" xlink:title="StockIssuedDuringPeriodSharesNewIssues" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RelatedPartyTransactionLineItems" xlink:to="StockIssuedDuringPeriodSharesNewIssues" xlink:title="definition: RelatedPartyTransactionLineItems to StockIssuedDuringPeriodSharesNewIssues" order="17.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="SharesIssuedPricePerShare" xlink:title="SharesIssuedPricePerShare" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RelatedPartyTransactionLineItems" xlink:to="SharesIssuedPricePerShare" xlink:title="definition: RelatedPartyTransactionLineItems to SharesIssuedPricePerShare" order="18.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:title="ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="RelatedPartyTransactionLineItems" xlink:to="ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:title="definition: RelatedPartyTransactionLineItems to ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" order="19.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="RelatedPartyTransactionsByRelatedPartyAxis" xlink:title="RelatedPartyTransactionsByRelatedPartyAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="RelatedPartyTransactionsByRelatedPartyAxis" xlink:title="definition: ScheduleOfRelatedPartyTransactionsByRelatedPartyTable to RelatedPartyTransactionsByRelatedPartyAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="RelatedPartyDomain" xlink:title="RelatedPartyDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="RelatedPartyDomain" xlink:title="definition: RelatedPartyTransactionsByRelatedPartyAxis to RelatedPartyDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="RelatedPartyDomain_2" xlink:title="RelatedPartyDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="RelatedPartyDomain_2" xlink:title="definition: RelatedPartyTransactionsByRelatedPartyAxis to RelatedPartyDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyMember" xlink:label="RelatedPartyMember" xlink:title="RelatedPartyMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RelatedPartyDomain" xlink:to="RelatedPartyMember" xlink:title="definition: RelatedPartyDomain to RelatedPartyMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis" xlink:label="CounterpartyNameAxis" xlink:title="CounterpartyNameAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="CounterpartyNameAxis" xlink:title="definition: ScheduleOfRelatedPartyTransactionsByRelatedPartyTable to CounterpartyNameAxis" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="RepurchaseAgreementCounterpartyNameDomain" xlink:title="RepurchaseAgreementCounterpartyNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="CounterpartyNameAxis" xlink:to="RepurchaseAgreementCounterpartyNameDomain" xlink:title="definition: CounterpartyNameAxis to RepurchaseAgreementCounterpartyNameDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="RepurchaseAgreementCounterpartyNameDomain_2" xlink:title="RepurchaseAgreementCounterpartyNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="CounterpartyNameAxis" xlink:to="RepurchaseAgreementCounterpartyNameDomain_2" xlink:title="definition: CounterpartyNameAxis to RepurchaseAgreementCounterpartyNameDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_ArethLLCMember" xlink:label="ArethLLCMember" xlink:title="ArethLLCMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RepurchaseAgreementCounterpartyNameDomain" xlink:to="ArethLLCMember" xlink:title="definition: RepurchaseAgreementCounterpartyNameDomain to ArethLLCMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_GenesisBPSMember" xlink:label="GenesisBPSMember" xlink:title="GenesisBPSMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RepurchaseAgreementCounterpartyNameDomain" xlink:to="GenesisBPSMember" xlink:title="definition: RepurchaseAgreementCounterpartyNameDomain to GenesisBPSMember" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_BryantFongMember" xlink:label="BryantFongMember" xlink:title="BryantFongMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RepurchaseAgreementCounterpartyNameDomain" xlink:to="BryantFongMember" xlink:title="definition: RepurchaseAgreementCounterpartyNameDomain to BryantFongMember" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="RangeAxis" xlink:title="RangeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="RangeAxis" xlink:title="definition: ScheduleOfRelatedPartyTransactionsByRelatedPartyTable to RangeAxis" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="RangeMember" xlink:title="RangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="RangeAxis" xlink:to="RangeMember" xlink:title="definition: RangeAxis to RangeMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="RangeMember_2" xlink:title="RangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="RangeAxis" xlink:to="RangeMember_2" xlink:title="definition: RangeAxis to RangeMember_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="MinimumMember" xlink:title="MinimumMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RangeMember" xlink:to="MinimumMember" xlink:title="definition: RangeMember to MinimumMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="MaximumMember" xlink:title="MaximumMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RangeMember" xlink:to="MaximumMember" xlink:title="definition: RangeMember to MaximumMember" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="AwardTypeAxis" xlink:title="AwardTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="AwardTypeAxis" xlink:title="definition: ScheduleOfRelatedPartyTransactionsByRelatedPartyTable to AwardTypeAxis" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="AwardTypeAxis" xlink:to="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="definition: AwardTypeAxis to ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="AwardTypeAxis" xlink:to="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2" xlink:title="definition: AwardTypeAxis to ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="RestrictedStockUnitsRSUMember" xlink:title="RestrictedStockUnitsRSUMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="RestrictedStockUnitsRSUMember" xlink:title="definition: ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain to RestrictedStockUnitsRSUMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityAxis" xlink:label="LineOfCreditFacilityAxis" xlink:title="LineOfCreditFacilityAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="LineOfCreditFacilityAxis" xlink:title="definition: ScheduleOfRelatedPartyTransactionsByRelatedPartyTable to LineOfCreditFacilityAxis" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="LineOfCreditFacilityLenderDomain" xlink:title="LineOfCreditFacilityLenderDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="LineOfCreditFacilityAxis" xlink:to="LineOfCreditFacilityLenderDomain" xlink:title="definition: LineOfCreditFacilityAxis to LineOfCreditFacilityLenderDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="LineOfCreditFacilityLenderDomain_2" xlink:title="LineOfCreditFacilityLenderDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="LineOfCreditFacilityAxis" xlink:to="LineOfCreditFacilityLenderDomain_2" xlink:title="definition: LineOfCreditFacilityAxis to LineOfCreditFacilityLenderDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_PerceptiveCreditHoldingsIILPMember" xlink:label="PerceptiveCreditHoldingsIILPMember" xlink:title="PerceptiveCreditHoldingsIILPMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LineOfCreditFacilityLenderDomain" xlink:to="PerceptiveCreditHoldingsIILPMember" xlink:title="definition: LineOfCreditFacilityLenderDomain to PerceptiveCreditHoldingsIILPMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="TitleOfIndividualAxis" xlink:title="TitleOfIndividualAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="TitleOfIndividualAxis" xlink:title="definition: ScheduleOfRelatedPartyTransactionsByRelatedPartyTable to TitleOfIndividualAxis" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="TitleOfIndividualWithRelationshipToEntityDomain" xlink:title="TitleOfIndividualWithRelationshipToEntityDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="TitleOfIndividualAxis" xlink:to="TitleOfIndividualWithRelationshipToEntityDomain" xlink:title="definition: TitleOfIndividualAxis to TitleOfIndividualWithRelationshipToEntityDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="TitleOfIndividualWithRelationshipToEntityDomain_2" xlink:title="TitleOfIndividualWithRelationshipToEntityDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="TitleOfIndividualAxis" xlink:to="TitleOfIndividualWithRelationshipToEntityDomain_2" xlink:title="definition: TitleOfIndividualAxis to TitleOfIndividualWithRelationshipToEntityDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ExecutiveOfficerMember" xlink:label="ExecutiveOfficerMember" xlink:title="ExecutiveOfficerMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="ExecutiveOfficerMember" xlink:title="definition: TitleOfIndividualWithRelationshipToEntityDomain to ExecutiveOfficerMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_PresidentAndChiefExecutiveOfficerMember" xlink:label="PresidentAndChiefExecutiveOfficerMember" xlink:title="PresidentAndChiefExecutiveOfficerMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="PresidentAndChiefExecutiveOfficerMember" xlink:title="definition: TitleOfIndividualWithRelationshipToEntityDomain to PresidentAndChiefExecutiveOfficerMember" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_ExecutiveVicePresidentAndChiefFinancialOfficerMember" xlink:label="ExecutiveVicePresidentAndChiefFinancialOfficerMember" xlink:title="ExecutiveVicePresidentAndChiefFinancialOfficerMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="ExecutiveVicePresidentAndChiefFinancialOfficerMember" xlink:title="definition: TitleOfIndividualWithRelationshipToEntityDomain to ExecutiveVicePresidentAndChiefFinancialOfficerMember" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OwnershipAxis" xlink:label="OwnershipAxis" xlink:title="OwnershipAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="OwnershipAxis" xlink:title="definition: ScheduleOfRelatedPartyTransactionsByRelatedPartyTable to OwnershipAxis" order="7.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OwnershipDomain" xlink:label="OwnershipDomain" xlink:title="OwnershipDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="OwnershipAxis" xlink:to="OwnershipDomain" xlink:title="definition: OwnershipAxis to OwnershipDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OwnershipDomain" xlink:label="OwnershipDomain_2" xlink:title="OwnershipDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="OwnershipAxis" xlink:to="OwnershipDomain_2" xlink:title="definition: OwnershipAxis to OwnershipDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_DirectOwnershipMember" xlink:label="DirectOwnershipMember" xlink:title="DirectOwnershipMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="OwnershipDomain" xlink:to="DirectOwnershipMember" xlink:title="definition: OwnershipDomain to DirectOwnershipMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_IndirectOwnershipMember" xlink:label="IndirectOwnershipMember" xlink:title="IndirectOwnershipMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="OwnershipDomain" xlink:to="IndirectOwnershipMember" xlink:title="definition: OwnershipDomain to IndirectOwnershipMember" order="2.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://admabiologics.com/role/CommitmentsAndContingenciesDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingenciesLineItems" xlink:label="LossContingenciesLineItems" xlink:title="LossContingenciesLineItems" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_VendorAndLicensorCommitmentsAbstract" xlink:label="VendorAndLicensorCommitmentsAbstract" xlink:title="VendorAndLicensorCommitmentsAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LossContingenciesLineItems" xlink:to="VendorAndLicensorCommitmentsAbstract" xlink:title="definition: LossContingenciesLineItems to VendorAndLicensorCommitmentsAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_PostMarketingCommitmentsAbstract" xlink:label="PostMarketingCommitmentsAbstract" xlink:title="PostMarketingCommitmentsAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LossContingenciesLineItems" xlink:to="PostMarketingCommitmentsAbstract" xlink:title="definition: LossContingenciesLineItems to PostMarketingCommitmentsAbstract" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="ResearchAndDevelopmentExpense" xlink:title="ResearchAndDevelopmentExpense" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LossContingenciesLineItems" xlink:to="ResearchAndDevelopmentExpense" xlink:title="definition: LossContingenciesLineItems to ResearchAndDevelopmentExpense" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_ITTechnologySystemsInaccessiblePeriod" xlink:label="ITTechnologySystemsInaccessiblePeriod" xlink:title="ITTechnologySystemsInaccessiblePeriod" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LossContingenciesLineItems" xlink:to="ITTechnologySystemsInaccessiblePeriod" xlink:title="definition: LossContingenciesLineItems to ITTechnologySystemsInaccessiblePeriod" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_NumberOfBatchesInProductionAtTheTimeOfDisruption" xlink:label="NumberOfBatchesInProductionAtTheTimeOfDisruption" xlink:title="NumberOfBatchesInProductionAtTheTimeOfDisruption" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LossContingenciesLineItems" xlink:to="NumberOfBatchesInProductionAtTheTimeOfDisruption" xlink:title="definition: LossContingenciesLineItems to NumberOfBatchesInProductionAtTheTimeOfDisruption" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryWriteDown" xlink:label="InventoryWriteDown" xlink:title="InventoryWriteDown" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LossContingenciesLineItems" xlink:to="InventoryWriteDown" xlink:title="definition: LossContingenciesLineItems to InventoryWriteDown" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCostAndExpenseOperating" xlink:label="OtherCostAndExpenseOperating" xlink:title="OtherCostAndExpenseOperating" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LossContingenciesLineItems" xlink:to="OtherCostAndExpenseOperating" xlink:title="definition: LossContingenciesLineItems to OtherCostAndExpenseOperating" order="7.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_RestorationCostsReceived" xlink:label="RestorationCostsReceived" xlink:title="RestorationCostsReceived" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LossContingenciesLineItems" xlink:to="RestorationCostsReceived" xlink:title="definition: LossContingenciesLineItems to RestorationCostsReceived" order="8.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromInsuranceSettlementOperatingActivities" xlink:label="ProceedsFromInsuranceSettlementOperatingActivities" xlink:title="ProceedsFromInsuranceSettlementOperatingActivities" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LossContingenciesLineItems" xlink:to="ProceedsFromInsuranceSettlementOperatingActivities" xlink:title="definition: LossContingenciesLineItems to ProceedsFromInsuranceSettlementOperatingActivities" order="9.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_NumberOfPlasmaCollectionFacilities" xlink:label="NumberOfPlasmaCollectionFacilities" xlink:title="NumberOfPlasmaCollectionFacilities" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LossContingenciesLineItems" xlink:to="NumberOfPlasmaCollectionFacilities" xlink:title="definition: LossContingenciesLineItems to NumberOfPlasmaCollectionFacilities" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_NumberOfRenewalTerms" xlink:label="NumberOfRenewalTerms" xlink:title="NumberOfRenewalTerms" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LossContingenciesLineItems" xlink:to="NumberOfRenewalTerms" xlink:title="definition: LossContingenciesLineItems to NumberOfRenewalTerms" order="11.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_PlasmaPurchaseAgreementRenewalPeriod" xlink:label="PlasmaPurchaseAgreementRenewalPeriod" xlink:title="PlasmaPurchaseAgreementRenewalPeriod" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LossContingenciesLineItems" xlink:to="PlasmaPurchaseAgreementRenewalPeriod" xlink:title="definition: LossContingenciesLineItems to PlasmaPurchaseAgreementRenewalPeriod" order="12.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_AgreementWithTermExpirationDate" xlink:label="AgreementWithTermExpirationDate" xlink:title="AgreementWithTermExpirationDate" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LossContingenciesLineItems" xlink:to="AgreementWithTermExpirationDate" xlink:title="definition: LossContingenciesLineItems to AgreementWithTermExpirationDate" order="13.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_QuantityOfRespiratorySyncytialVirusPlasmaUsed" xlink:label="QuantityOfRespiratorySyncytialVirusPlasmaUsed" xlink:title="QuantityOfRespiratorySyncytialVirusPlasmaUsed" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LossContingenciesLineItems" xlink:to="QuantityOfRespiratorySyncytialVirusPlasmaUsed" xlink:title="definition: LossContingenciesLineItems to QuantityOfRespiratorySyncytialVirusPlasmaUsed" order="14.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_RespiratorySyncytialVirusPlasmaVolumeSuppliedPeriod" xlink:label="RespiratorySyncytialVirusPlasmaVolumeSuppliedPeriod" xlink:title="RespiratorySyncytialVirusPlasmaVolumeSuppliedPeriod" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LossContingenciesLineItems" xlink:to="RespiratorySyncytialVirusPlasmaVolumeSuppliedPeriod" xlink:title="definition: LossContingenciesLineItems to RespiratorySyncytialVirusPlasmaVolumeSuppliedPeriod" order="15.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_IncreaseInMinimumAnnualPriceTerm" xlink:label="IncreaseInMinimumAnnualPriceTerm" xlink:title="IncreaseInMinimumAnnualPriceTerm" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LossContingenciesLineItems" xlink:to="IncreaseInMinimumAnnualPriceTerm" xlink:title="definition: LossContingenciesLineItems to IncreaseInMinimumAnnualPriceTerm" order="16.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_PlasmaSupplyAgreementTerm" xlink:label="PlasmaSupplyAgreementTerm" xlink:title="PlasmaSupplyAgreementTerm" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="LossContingenciesLineItems" xlink:to="PlasmaSupplyAgreementTerm" xlink:title="definition: LossContingenciesLineItems to PlasmaSupplyAgreementTerm" order="17.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingenciesTable" xlink:label="LossContingenciesTable" xlink:title="LossContingenciesTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="LossContingenciesLineItems" xlink:to="LossContingenciesTable" xlink:title="definition: LossContingenciesLineItems to LossContingenciesTable" order="18.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="TypeOfArrangementAxis" xlink:title="TypeOfArrangementAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="LossContingenciesTable" xlink:to="TypeOfArrangementAxis" xlink:title="definition: LossContingenciesTable to TypeOfArrangementAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="ArrangementsAndNonarrangementTransactionsMember" xlink:title="ArrangementsAndNonarrangementTransactionsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="TypeOfArrangementAxis" xlink:to="ArrangementsAndNonarrangementTransactionsMember" xlink:title="definition: TypeOfArrangementAxis to ArrangementsAndNonarrangementTransactionsMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="ArrangementsAndNonarrangementTransactionsMember_2" xlink:title="ArrangementsAndNonarrangementTransactionsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="TypeOfArrangementAxis" xlink:to="ArrangementsAndNonarrangementTransactionsMember_2" xlink:title="definition: TypeOfArrangementAxis to ArrangementsAndNonarrangementTransactionsMember_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_PlasmaPurchaseAgreementOneMember" xlink:label="PlasmaPurchaseAgreementOneMember" xlink:title="PlasmaPurchaseAgreementOneMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ArrangementsAndNonarrangementTransactionsMember" xlink:to="PlasmaPurchaseAgreementOneMember" xlink:title="definition: ArrangementsAndNonarrangementTransactionsMember to PlasmaPurchaseAgreementOneMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_ARGrifolsAgreementMember" xlink:label="ARGrifolsAgreementMember" xlink:title="ARGrifolsAgreementMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ArrangementsAndNonarrangementTransactionsMember" xlink:to="ARGrifolsAgreementMember" xlink:title="definition: ArrangementsAndNonarrangementTransactionsMember to ARGrifolsAgreementMember" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_KEDPlasmaAgreementMember" xlink:label="KEDPlasmaAgreementMember" xlink:title="KEDPlasmaAgreementMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ArrangementsAndNonarrangementTransactionsMember" xlink:to="KEDPlasmaAgreementMember" xlink:title="definition: ArrangementsAndNonarrangementTransactionsMember to KEDPlasmaAgreementMember" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="RangeAxis" xlink:title="RangeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="LossContingenciesTable" xlink:to="RangeAxis" xlink:title="definition: LossContingenciesTable to RangeAxis" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="RangeMember" xlink:title="RangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="RangeAxis" xlink:to="RangeMember" xlink:title="definition: RangeAxis to RangeMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="RangeMember_2" xlink:title="RangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="RangeAxis" xlink:to="RangeMember_2" xlink:title="definition: RangeAxis to RangeMember_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="MinimumMember" xlink:title="MinimumMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RangeMember" xlink:to="MinimumMember" xlink:title="definition: RangeMember to MinimumMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="MaximumMember" xlink:title="MaximumMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RangeMember" xlink:to="MaximumMember" xlink:title="definition: RangeMember to MaximumMember" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="SubsequentEventTypeAxis" xlink:title="SubsequentEventTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="LossContingenciesTable" xlink:to="SubsequentEventTypeAxis" xlink:title="definition: LossContingenciesTable to SubsequentEventTypeAxis" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="SubsequentEventTypeDomain" xlink:title="SubsequentEventTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="SubsequentEventTypeAxis" xlink:to="SubsequentEventTypeDomain" xlink:title="definition: SubsequentEventTypeAxis to SubsequentEventTypeDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="SubsequentEventTypeDomain_2" xlink:title="SubsequentEventTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="SubsequentEventTypeAxis" xlink:to="SubsequentEventTypeDomain_2" xlink:title="definition: SubsequentEventTypeAxis to SubsequentEventTypeDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="SubsequentEventMember" xlink:title="SubsequentEventMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SubsequentEventTypeDomain" xlink:to="SubsequentEventMember" xlink:title="definition: SubsequentEventTypeDomain to SubsequentEventMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis" xlink:label="ProductOrServiceAxis" xlink:title="ProductOrServiceAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="LossContingenciesTable" xlink:to="ProductOrServiceAxis" xlink:title="definition: LossContingenciesTable to ProductOrServiceAxis" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="ProductsAndServicesDomain" xlink:title="ProductsAndServicesDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ProductOrServiceAxis" xlink:to="ProductsAndServicesDomain" xlink:title="definition: ProductOrServiceAxis to ProductsAndServicesDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="ProductsAndServicesDomain_2" xlink:title="ProductsAndServicesDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ProductOrServiceAxis" xlink:to="ProductsAndServicesDomain_2" xlink:title="definition: ProductOrServiceAxis to ProductsAndServicesDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_ASCENIVMember" xlink:label="ASCENIVMember" xlink:title="ASCENIVMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ProductsAndServicesDomain" xlink:to="ASCENIVMember" xlink:title="definition: ProductsAndServicesDomain to ASCENIVMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_BIVIGAMMember" xlink:label="BIVIGAMMember" xlink:title="BIVIGAMMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ProductsAndServicesDomain" xlink:to="BIVIGAMMember" xlink:title="definition: ProductsAndServicesDomain to BIVIGAMMember" order="2.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://admabiologics.com/role/IncomeTaxesIncomeTaxExpenseBenefitDetails" />
  <link:definitionLink xlink:type="extended" xlink:role="http://admabiologics.com/role/IncomeTaxesReconciliationOfIncomeTaxesDetails" />
  <link:definitionLink xlink:type="extended" xlink:role="http://admabiologics.com/role/IncomeTaxesDeferredTaxAssetsDetails" />
  <link:definitionLink xlink:type="extended" xlink:role="http://admabiologics.com/role/IncomeTaxesNetOperatingLossCarryforwardsDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="OperatingLossCarryforwardsLineItems" xlink:title="OperatingLossCarryforwardsLineItems" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_NetOperatingLossCarryforwardsAbstract" xlink:label="NetOperatingLossCarryforwardsAbstract" xlink:title="NetOperatingLossCarryforwardsAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="OperatingLossCarryforwardsLineItems" xlink:to="NetOperatingLossCarryforwardsAbstract" xlink:title="definition: OperatingLossCarryforwardsLineItems to NetOperatingLossCarryforwardsAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="OperatingLossCarryforwards" xlink:title="OperatingLossCarryforwards" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="OperatingLossCarryforwardsLineItems" xlink:to="OperatingLossCarryforwards" xlink:title="definition: OperatingLossCarryforwardsLineItems to OperatingLossCarryforwards" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwardsExpirationDate" xlink:label="OperatingLossCarryforwardsExpirationDate" xlink:title="OperatingLossCarryforwardsExpirationDate" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="OperatingLossCarryforwardsLineItems" xlink:to="OperatingLossCarryforwardsExpirationDate" xlink:title="definition: OperatingLossCarryforwardsLineItems to OperatingLossCarryforwardsExpirationDate" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardValuationAllowance" xlink:label="TaxCreditCarryforwardValuationAllowance" xlink:title="TaxCreditCarryforwardValuationAllowance" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="OperatingLossCarryforwardsLineItems" xlink:to="TaxCreditCarryforwardValuationAllowance" xlink:title="definition: OperatingLossCarryforwardsLineItems to TaxCreditCarryforwardValuationAllowance" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="UnrecognizedTaxBenefits" xlink:title="UnrecognizedTaxBenefits" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="OperatingLossCarryforwardsLineItems" xlink:to="UnrecognizedTaxBenefits" xlink:title="definition: OperatingLossCarryforwardsLineItems to UnrecognizedTaxBenefits" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="OperatingLossCarryforwardsTable" xlink:title="OperatingLossCarryforwardsTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="OperatingLossCarryforwardsLineItems" xlink:to="OperatingLossCarryforwardsTable" xlink:title="definition: OperatingLossCarryforwardsLineItems to OperatingLossCarryforwardsTable" order="6.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="IncomeTaxAuthorityAxis" xlink:title="IncomeTaxAuthorityAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="OperatingLossCarryforwardsTable" xlink:to="IncomeTaxAuthorityAxis" xlink:title="definition: OperatingLossCarryforwardsTable to IncomeTaxAuthorityAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="IncomeTaxAuthorityDomain" xlink:title="IncomeTaxAuthorityDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="IncomeTaxAuthorityAxis" xlink:to="IncomeTaxAuthorityDomain" xlink:title="definition: IncomeTaxAuthorityAxis to IncomeTaxAuthorityDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="IncomeTaxAuthorityDomain_2" xlink:title="IncomeTaxAuthorityDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="IncomeTaxAuthorityAxis" xlink:to="IncomeTaxAuthorityDomain_2" xlink:title="definition: IncomeTaxAuthorityAxis to IncomeTaxAuthorityDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InternalRevenueServiceIRSMember" xlink:label="InternalRevenueServiceIRSMember" xlink:title="InternalRevenueServiceIRSMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="IncomeTaxAuthorityDomain" xlink:to="InternalRevenueServiceIRSMember" xlink:title="definition: IncomeTaxAuthorityDomain to InternalRevenueServiceIRSMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="StateAndLocalJurisdictionMember" xlink:title="StateAndLocalJurisdictionMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="IncomeTaxAuthorityDomain" xlink:to="StateAndLocalJurisdictionMember" xlink:title="definition: IncomeTaxAuthorityDomain to StateAndLocalJurisdictionMember" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="RangeAxis" xlink:title="RangeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="OperatingLossCarryforwardsTable" xlink:to="RangeAxis" xlink:title="definition: OperatingLossCarryforwardsTable to RangeAxis" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="RangeMember" xlink:title="RangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="RangeAxis" xlink:to="RangeMember" xlink:title="definition: RangeAxis to RangeMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="RangeMember_2" xlink:title="RangeMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="RangeAxis" xlink:to="RangeMember_2" xlink:title="definition: RangeAxis to RangeMember_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="MinimumMember" xlink:title="MinimumMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RangeMember" xlink:to="MinimumMember" xlink:title="definition: RangeMember to MinimumMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="MaximumMember" xlink:title="MaximumMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RangeMember" xlink:to="MaximumMember" xlink:title="definition: RangeMember to MaximumMember" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxPeriodAxis" xlink:label="TaxPeriodAxis" xlink:title="TaxPeriodAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="OperatingLossCarryforwardsTable" xlink:to="TaxPeriodAxis" xlink:title="definition: OperatingLossCarryforwardsTable to TaxPeriodAxis" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxPeriodDomain" xlink:label="TaxPeriodDomain" xlink:title="TaxPeriodDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="TaxPeriodAxis" xlink:to="TaxPeriodDomain" xlink:title="definition: TaxPeriodAxis to TaxPeriodDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxPeriodDomain" xlink:label="TaxPeriodDomain_2" xlink:title="TaxPeriodDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="TaxPeriodAxis" xlink:to="TaxPeriodDomain_2" xlink:title="definition: TaxPeriodAxis to TaxPeriodDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_TaxYear2028Through2043Member" xlink:label="TaxYear2028Through2043Member" xlink:title="TaxYear2028Through2043Member" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="TaxPeriodDomain" xlink:to="TaxYear2028Through2043Member" xlink:title="definition: TaxPeriodDomain to TaxYear2028Through2043Member" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_TaxYear2031Member" xlink:label="TaxYear2031Member" xlink:title="TaxYear2031Member" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="TaxPeriodDomain" xlink:to="TaxYear2031Member" xlink:title="definition: TaxPeriodDomain to TaxYear2031Member" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_TaxYear2032Member" xlink:label="TaxYear2032Member" xlink:title="TaxYear2032Member" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="TaxPeriodDomain" xlink:to="TaxYear2032Member" xlink:title="definition: TaxPeriodDomain to TaxYear2032Member" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_TaxYear2033Member" xlink:label="TaxYear2033Member" xlink:title="TaxYear2033Member" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="TaxPeriodDomain" xlink:to="TaxYear2033Member" xlink:title="definition: TaxPeriodDomain to TaxYear2033Member" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_TaxYear2034Member" xlink:label="TaxYear2034Member" xlink:title="TaxYear2034Member" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="TaxPeriodDomain" xlink:to="TaxYear2034Member" xlink:title="definition: TaxPeriodDomain to TaxYear2034Member" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_TaxYear2035Member" xlink:label="TaxYear2035Member" xlink:title="TaxYear2035Member" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="TaxPeriodDomain" xlink:to="TaxYear2035Member" xlink:title="definition: TaxPeriodDomain to TaxYear2035Member" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_TaxYear2036Member" xlink:label="TaxYear2036Member" xlink:title="TaxYear2036Member" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="TaxPeriodDomain" xlink:to="TaxYear2036Member" xlink:title="definition: TaxPeriodDomain to TaxYear2036Member" order="7.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_TaxYear2037Member" xlink:label="TaxYear2037Member" xlink:title="TaxYear2037Member" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="TaxPeriodDomain" xlink:to="TaxYear2037Member" xlink:title="definition: TaxPeriodDomain to TaxYear2037Member" order="8.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_TaxYearAfter2037Member" xlink:label="TaxYearAfter2037Member" xlink:title="TaxYearAfter2037Member" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="TaxPeriodDomain" xlink:to="TaxYearAfter2037Member" xlink:title="definition: TaxPeriodDomain to TaxYearAfter2037Member" order="9.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://admabiologics.com/role/LeaseObligationsDetails" />
  <link:definitionLink xlink:type="extended" xlink:role="http://admabiologics.com/role/LeaseObligationsDetailsCalc01" />
  <link:definitionLink xlink:type="extended" xlink:role="http://admabiologics.com/role/SegmentsSummarizedFinancialInformationBySegmentDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="SegmentReportingInformationLineItems" xlink:title="SegmentReportingInformationLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingInformationProfitLossAbstract" xlink:label="SegmentReportingInformationProfitLossAbstract" xlink:title="SegmentReportingInformationProfitLossAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SegmentReportingInformationLineItems" xlink:to="SegmentReportingInformationProfitLossAbstract" xlink:title="definition: SegmentReportingInformationLineItems to SegmentReportingInformationProfitLossAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract" xlink:label="ReconciliationFromSegmentTotalsToConsolidatedAbstract" xlink:title="ReconciliationFromSegmentTotalsToConsolidatedAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SegmentReportingInformationLineItems" xlink:to="ReconciliationFromSegmentTotalsToConsolidatedAbstract" xlink:title="definition: SegmentReportingInformationLineItems to ReconciliationFromSegmentTotalsToConsolidatedAbstract" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="SellingGeneralAndAdministrativeExpense" xlink:title="SellingGeneralAndAdministrativeExpense" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SegmentReportingInformationLineItems" xlink:to="SellingGeneralAndAdministrativeExpense" xlink:title="definition: SegmentReportingInformationLineItems to SellingGeneralAndAdministrativeExpense" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseNonoperating" xlink:label="InterestExpenseNonoperating" xlink:title="InterestExpenseNonoperating" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SegmentReportingInformationLineItems" xlink:to="InterestExpenseNonoperating" xlink:title="definition: SegmentReportingInformationLineItems to InterestExpenseNonoperating" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="GainsLossesOnExtinguishmentOfDebt" xlink:title="GainsLossesOnExtinguishmentOfDebt" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SegmentReportingInformationLineItems" xlink:to="GainsLossesOnExtinguishmentOfDebt" xlink:title="definition: SegmentReportingInformationLineItems to GainsLossesOnExtinguishmentOfDebt" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="InvestmentIncomeInterest" xlink:title="InvestmentIncomeInterest" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SegmentReportingInformationLineItems" xlink:to="InvestmentIncomeInterest" xlink:title="definition: SegmentReportingInformationLineItems to InvestmentIncomeInterest" order="6.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_NumberOfPlasmaCollectionFacilitiesUnderDevelopment" xlink:label="NumberOfPlasmaCollectionFacilitiesUnderDevelopment" xlink:title="NumberOfPlasmaCollectionFacilitiesUnderDevelopment" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SegmentReportingInformationLineItems" xlink:to="NumberOfPlasmaCollectionFacilitiesUnderDevelopment" xlink:title="definition: SegmentReportingInformationLineItems to NumberOfPlasmaCollectionFacilitiesUnderDevelopment" order="7.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="NumberOfOperatingSegments" xlink:title="NumberOfOperatingSegments" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SegmentReportingInformationLineItems" xlink:to="NumberOfOperatingSegments" xlink:title="definition: SegmentReportingInformationLineItems to NumberOfOperatingSegments" order="8.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="RevenueFromContractWithCustomerExcludingAssessedTax" xlink:title="RevenueFromContractWithCustomerExcludingAssessedTax" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SegmentReportingInformationLineItems" xlink:to="RevenueFromContractWithCustomerExcludingAssessedTax" xlink:title="definition: SegmentReportingInformationLineItems to RevenueFromContractWithCustomerExcludingAssessedTax" order="9.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfRevenue" xlink:label="CostOfRevenue" xlink:title="CostOfRevenue" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SegmentReportingInformationLineItems" xlink:to="CostOfRevenue" xlink:title="definition: SegmentReportingInformationLineItems to CostOfRevenue" order="10.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="ResearchAndDevelopmentExpense" xlink:title="ResearchAndDevelopmentExpense" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SegmentReportingInformationLineItems" xlink:to="ResearchAndDevelopmentExpense" xlink:title="definition: SegmentReportingInformationLineItems to ResearchAndDevelopmentExpense" order="11.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCostAndExpenseOperating" xlink:label="OtherCostAndExpenseOperating" xlink:title="OtherCostAndExpenseOperating" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SegmentReportingInformationLineItems" xlink:to="OtherCostAndExpenseOperating" xlink:title="definition: SegmentReportingInformationLineItems to OtherCostAndExpenseOperating" order="12.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingAndMarketingExpense" xlink:label="SellingAndMarketingExpense" xlink:title="SellingAndMarketingExpense" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SegmentReportingInformationLineItems" xlink:to="SellingAndMarketingExpense" xlink:title="definition: SegmentReportingInformationLineItems to SellingAndMarketingExpense" order="13.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationAndAmortization" xlink:label="DepreciationAndAmortization" xlink:title="DepreciationAndAmortization" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SegmentReportingInformationLineItems" xlink:to="DepreciationAndAmortization" xlink:title="definition: SegmentReportingInformationLineItems to DepreciationAndAmortization" order="14.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="GeneralAndAdministrativeExpense" xlink:title="GeneralAndAdministrativeExpense" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SegmentReportingInformationLineItems" xlink:to="GeneralAndAdministrativeExpense" xlink:title="definition: SegmentReportingInformationLineItems to GeneralAndAdministrativeExpense" order="15.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="NonoperatingIncomeExpense" xlink:title="NonoperatingIncomeExpense" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SegmentReportingInformationLineItems" xlink:to="NonoperatingIncomeExpense" xlink:title="definition: SegmentReportingInformationLineItems to NonoperatingIncomeExpense" order="16.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:title="IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SegmentReportingInformationLineItems" xlink:to="IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:title="definition: SegmentReportingInformationLineItems to IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="17.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentExpenditureAdditionToLongLivedAssets" xlink:label="SegmentExpenditureAdditionToLongLivedAssets" xlink:title="SegmentExpenditureAdditionToLongLivedAssets" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SegmentReportingInformationLineItems" xlink:to="SegmentExpenditureAdditionToLongLivedAssets" xlink:title="definition: SegmentReportingInformationLineItems to SegmentExpenditureAdditionToLongLivedAssets" order="18.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="Assets" xlink:title="Assets" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SegmentReportingInformationLineItems" xlink:to="Assets" xlink:title="definition: SegmentReportingInformationLineItems to Assets" order="19.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="ScheduleOfSegmentReportingInformationBySegmentTable" xlink:title="ScheduleOfSegmentReportingInformationBySegmentTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="SegmentReportingInformationLineItems" xlink:to="ScheduleOfSegmentReportingInformationBySegmentTable" xlink:title="definition: SegmentReportingInformationLineItems to ScheduleOfSegmentReportingInformationBySegmentTable" order="20.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidationItemsAxis" xlink:label="ConsolidationItemsAxis" xlink:title="ConsolidationItemsAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="ConsolidationItemsAxis" xlink:title="definition: ScheduleOfSegmentReportingInformationBySegmentTable to ConsolidationItemsAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidationItemsDomain" xlink:label="ConsolidationItemsDomain" xlink:title="ConsolidationItemsDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ConsolidationItemsAxis" xlink:to="ConsolidationItemsDomain" xlink:title="definition: ConsolidationItemsAxis to ConsolidationItemsDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidationItemsDomain" xlink:label="ConsolidationItemsDomain_2" xlink:title="ConsolidationItemsDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ConsolidationItemsAxis" xlink:to="ConsolidationItemsDomain_2" xlink:title="definition: ConsolidationItemsAxis to ConsolidationItemsDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingSegmentsMember" xlink:label="OperatingSegmentsMember" xlink:title="OperatingSegmentsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ConsolidationItemsDomain" xlink:to="OperatingSegmentsMember" xlink:title="definition: ConsolidationItemsDomain to OperatingSegmentsMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MaterialReconcilingItemsMember" xlink:label="MaterialReconcilingItemsMember" xlink:title="MaterialReconcilingItemsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ConsolidationItemsDomain" xlink:to="MaterialReconcilingItemsMember" xlink:title="definition: ConsolidationItemsDomain to MaterialReconcilingItemsMember" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CorporateNonSegmentMember" xlink:label="CorporateNonSegmentMember" xlink:title="CorporateNonSegmentMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ConsolidationItemsDomain" xlink:to="CorporateNonSegmentMember" xlink:title="definition: ConsolidationItemsDomain to CorporateNonSegmentMember" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="StatementBusinessSegmentsAxis" xlink:title="StatementBusinessSegmentsAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="StatementBusinessSegmentsAxis" xlink:title="definition: ScheduleOfSegmentReportingInformationBySegmentTable to StatementBusinessSegmentsAxis" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain" xlink:label="SegmentDomain" xlink:title="SegmentDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="StatementBusinessSegmentsAxis" xlink:to="SegmentDomain" xlink:title="definition: StatementBusinessSegmentsAxis to SegmentDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain" xlink:label="SegmentDomain_2" xlink:title="SegmentDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="StatementBusinessSegmentsAxis" xlink:to="SegmentDomain_2" xlink:title="definition: StatementBusinessSegmentsAxis to SegmentDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_ADMABioManufacturingSegmentMember" xlink:label="ADMABioManufacturingSegmentMember" xlink:title="ADMABioManufacturingSegmentMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SegmentDomain" xlink:to="ADMABioManufacturingSegmentMember" xlink:title="definition: SegmentDomain to ADMABioManufacturingSegmentMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_PlasmaCollectionCentersSegmentMember" xlink:label="PlasmaCollectionCentersSegmentMember" xlink:title="PlasmaCollectionCentersSegmentMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SegmentDomain" xlink:to="PlasmaCollectionCentersSegmentMember" xlink:title="definition: SegmentDomain to PlasmaCollectionCentersSegmentMember" order="2.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://admabiologics.com/role/SegmentsNetRevenuesAccordingToGeographicAreaDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:label="RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:title="RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentsGeographicalAreasAbstract" xlink:label="SegmentsGeographicalAreasAbstract" xlink:title="SegmentsGeographicalAreasAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:to="SegmentsGeographicalAreasAbstract" xlink:title="definition: RevenuesFromExternalCustomersAndLongLivedAssetsLineItems to SegmentsGeographicalAreasAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="RevenueFromContractWithCustomerExcludingAssessedTax" xlink:title="RevenueFromContractWithCustomerExcludingAssessedTax" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:to="RevenueFromContractWithCustomerExcludingAssessedTax" xlink:title="definition: RevenuesFromExternalCustomersAndLongLivedAssetsLineItems to RevenueFromContractWithCustomerExcludingAssessedTax" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:label="ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:title="ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:to="ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:title="definition: RevenuesFromExternalCustomersAndLongLivedAssetsLineItems to ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" order="3.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidationItemsAxis" xlink:label="ConsolidationItemsAxis" xlink:title="ConsolidationItemsAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:to="ConsolidationItemsAxis" xlink:title="definition: ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable to ConsolidationItemsAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidationItemsDomain" xlink:label="ConsolidationItemsDomain" xlink:title="ConsolidationItemsDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ConsolidationItemsAxis" xlink:to="ConsolidationItemsDomain" xlink:title="definition: ConsolidationItemsAxis to ConsolidationItemsDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidationItemsDomain" xlink:label="ConsolidationItemsDomain_2" xlink:title="ConsolidationItemsDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ConsolidationItemsAxis" xlink:to="ConsolidationItemsDomain_2" xlink:title="definition: ConsolidationItemsAxis to ConsolidationItemsDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingSegmentsMember" xlink:label="OperatingSegmentsMember" xlink:title="OperatingSegmentsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ConsolidationItemsDomain" xlink:to="OperatingSegmentsMember" xlink:title="definition: ConsolidationItemsDomain to OperatingSegmentsMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MaterialReconcilingItemsMember" xlink:label="MaterialReconcilingItemsMember" xlink:title="MaterialReconcilingItemsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ConsolidationItemsDomain" xlink:to="MaterialReconcilingItemsMember" xlink:title="definition: ConsolidationItemsDomain to MaterialReconcilingItemsMember" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="StatementBusinessSegmentsAxis" xlink:title="StatementBusinessSegmentsAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:to="StatementBusinessSegmentsAxis" xlink:title="definition: ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable to StatementBusinessSegmentsAxis" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain" xlink:label="SegmentDomain" xlink:title="SegmentDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="StatementBusinessSegmentsAxis" xlink:to="SegmentDomain" xlink:title="definition: StatementBusinessSegmentsAxis to SegmentDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain" xlink:label="SegmentDomain_2" xlink:title="SegmentDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="StatementBusinessSegmentsAxis" xlink:to="SegmentDomain_2" xlink:title="definition: StatementBusinessSegmentsAxis to SegmentDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_ADMABioManufacturingSegmentMember" xlink:label="ADMABioManufacturingSegmentMember" xlink:title="ADMABioManufacturingSegmentMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SegmentDomain" xlink:to="ADMABioManufacturingSegmentMember" xlink:title="definition: SegmentDomain to ADMABioManufacturingSegmentMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_PlasmaCollectionCentersSegmentMember" xlink:label="PlasmaCollectionCentersSegmentMember" xlink:title="PlasmaCollectionCentersSegmentMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SegmentDomain" xlink:to="PlasmaCollectionCentersSegmentMember" xlink:title="definition: SegmentDomain to PlasmaCollectionCentersSegmentMember" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis" xlink:label="StatementGeographicalAxis" xlink:title="StatementGeographicalAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:to="StatementGeographicalAxis" xlink:title="definition: ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable to StatementGeographicalAxis" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain" xlink:label="SegmentGeographicalDomain" xlink:title="SegmentGeographicalDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="StatementGeographicalAxis" xlink:to="SegmentGeographicalDomain" xlink:title="definition: StatementGeographicalAxis to SegmentGeographicalDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain" xlink:label="SegmentGeographicalDomain_2" xlink:title="SegmentGeographicalDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="StatementGeographicalAxis" xlink:to="SegmentGeographicalDomain_2" xlink:title="definition: StatementGeographicalAxis to SegmentGeographicalDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_US" xlink:label="US" xlink:title="US" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SegmentGeographicalDomain" xlink:to="US" xlink:title="definition: SegmentGeographicalDomain to US" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonUsMember" xlink:label="NonUsMember" xlink:title="NonUsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SegmentGeographicalDomain" xlink:to="NonUsMember" xlink:title="definition: SegmentGeographicalDomain to NonUsMember" order="2.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://admabiologics.com/role/OtherEmployeeBenefitsDetails" />
  <link:definitionLink xlink:type="extended" xlink:role="http://admabiologics.com/role/SupplementalDisclosureOfCashFlowInformationDetails" />
  <link:definitionLink xlink:type="extended" xlink:role="http://admabiologics.com/role/ConcentrationsDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskLineItems" xlink:label="ConcentrationRiskLineItems" xlink:title="ConcentrationRiskLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RisksAndUncertaintiesAbstract" xlink:label="RisksAndUncertaintiesAbstract" xlink:title="RisksAndUncertaintiesAbstract" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ConcentrationRiskLineItems" xlink:to="RisksAndUncertaintiesAbstract" xlink:title="definition: ConcentrationRiskLineItems to RisksAndUncertaintiesAbstract" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_NumberOfCustomers" xlink:label="NumberOfCustomers" xlink:title="NumberOfCustomers" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ConcentrationRiskLineItems" xlink:to="NumberOfCustomers" xlink:title="definition: ConcentrationRiskLineItems to NumberOfCustomers" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="ConcentrationRiskPercentage1" xlink:title="ConcentrationRiskPercentage1" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ConcentrationRiskLineItems" xlink:to="ConcentrationRiskPercentage1" xlink:title="definition: ConcentrationRiskLineItems to ConcentrationRiskPercentage1" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskTable" xlink:label="ConcentrationRiskTable" xlink:title="ConcentrationRiskTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ConcentrationRiskLineItems" xlink:to="ConcentrationRiskTable" xlink:title="definition: ConcentrationRiskLineItems to ConcentrationRiskTable" order="4.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="ConcentrationRiskByBenchmarkAxis" xlink:title="ConcentrationRiskByBenchmarkAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ConcentrationRiskTable" xlink:to="ConcentrationRiskByBenchmarkAxis" xlink:title="definition: ConcentrationRiskTable to ConcentrationRiskByBenchmarkAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="ConcentrationRiskBenchmarkDomain" xlink:title="ConcentrationRiskBenchmarkDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ConcentrationRiskByBenchmarkAxis" xlink:to="ConcentrationRiskBenchmarkDomain" xlink:title="definition: ConcentrationRiskByBenchmarkAxis to ConcentrationRiskBenchmarkDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="ConcentrationRiskBenchmarkDomain_2" xlink:title="ConcentrationRiskBenchmarkDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ConcentrationRiskByBenchmarkAxis" xlink:to="ConcentrationRiskBenchmarkDomain_2" xlink:title="definition: ConcentrationRiskByBenchmarkAxis to ConcentrationRiskBenchmarkDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableMember" xlink:label="AccountsReceivableMember" xlink:title="AccountsReceivableMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ConcentrationRiskBenchmarkDomain" xlink:to="AccountsReceivableMember" xlink:title="definition: ConcentrationRiskBenchmarkDomain to AccountsReceivableMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerProductAndServiceBenchmarkMember" xlink:label="RevenueFromContractWithCustomerProductAndServiceBenchmarkMember" xlink:title="RevenueFromContractWithCustomerProductAndServiceBenchmarkMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ConcentrationRiskBenchmarkDomain" xlink:to="RevenueFromContractWithCustomerProductAndServiceBenchmarkMember" xlink:title="definition: ConcentrationRiskBenchmarkDomain to RevenueFromContractWithCustomerProductAndServiceBenchmarkMember" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="ConcentrationRiskByTypeAxis" xlink:title="ConcentrationRiskByTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ConcentrationRiskTable" xlink:to="ConcentrationRiskByTypeAxis" xlink:title="definition: ConcentrationRiskTable to ConcentrationRiskByTypeAxis" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="ConcentrationRiskTypeDomain" xlink:title="ConcentrationRiskTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ConcentrationRiskByTypeAxis" xlink:to="ConcentrationRiskTypeDomain" xlink:title="definition: ConcentrationRiskByTypeAxis to ConcentrationRiskTypeDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="ConcentrationRiskTypeDomain_2" xlink:title="ConcentrationRiskTypeDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ConcentrationRiskByTypeAxis" xlink:to="ConcentrationRiskTypeDomain_2" xlink:title="definition: ConcentrationRiskByTypeAxis to ConcentrationRiskTypeDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="CustomerConcentrationRiskMember" xlink:title="CustomerConcentrationRiskMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ConcentrationRiskTypeDomain" xlink:to="CustomerConcentrationRiskMember" xlink:title="definition: ConcentrationRiskTypeDomain to CustomerConcentrationRiskMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MajorCustomersAxis" xlink:label="MajorCustomersAxis" xlink:title="MajorCustomersAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ConcentrationRiskTable" xlink:to="MajorCustomersAxis" xlink:title="definition: ConcentrationRiskTable to MajorCustomersAxis" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_NameOfMajorCustomerDomain" xlink:label="NameOfMajorCustomerDomain" xlink:title="NameOfMajorCustomerDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="MajorCustomersAxis" xlink:to="NameOfMajorCustomerDomain" xlink:title="definition: MajorCustomersAxis to NameOfMajorCustomerDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_NameOfMajorCustomerDomain" xlink:label="NameOfMajorCustomerDomain_2" xlink:title="NameOfMajorCustomerDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="MajorCustomersAxis" xlink:to="NameOfMajorCustomerDomain_2" xlink:title="definition: MajorCustomersAxis to NameOfMajorCustomerDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_ThreeCustomersMember" xlink:label="ThreeCustomersMember" xlink:title="ThreeCustomersMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="NameOfMajorCustomerDomain" xlink:to="ThreeCustomersMember" xlink:title="definition: NameOfMajorCustomerDomain to ThreeCustomersMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_FiveCustomersMember" xlink:label="FiveCustomersMember" xlink:title="FiveCustomersMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="NameOfMajorCustomerDomain" xlink:to="FiveCustomersMember" xlink:title="definition: NameOfMajorCustomerDomain to FiveCustomersMember" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_TwoCustomersMember" xlink:label="TwoCustomersMember" xlink:title="TwoCustomersMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="NameOfMajorCustomerDomain" xlink:to="TwoCustomersMember" xlink:title="definition: NameOfMajorCustomerDomain to TwoCustomersMember" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="StatementBusinessSegmentsAxis" xlink:title="StatementBusinessSegmentsAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ConcentrationRiskTable" xlink:to="StatementBusinessSegmentsAxis" xlink:title="definition: ConcentrationRiskTable to StatementBusinessSegmentsAxis" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain" xlink:label="SegmentDomain" xlink:title="SegmentDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="StatementBusinessSegmentsAxis" xlink:to="SegmentDomain" xlink:title="definition: StatementBusinessSegmentsAxis to SegmentDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain" xlink:label="SegmentDomain_2" xlink:title="SegmentDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="StatementBusinessSegmentsAxis" xlink:to="SegmentDomain_2" xlink:title="definition: StatementBusinessSegmentsAxis to SegmentDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_PlasmaCollectionCentersSegmentMember" xlink:label="PlasmaCollectionCentersSegmentMember" xlink:title="PlasmaCollectionCentersSegmentMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="SegmentDomain" xlink:to="PlasmaCollectionCentersSegmentMember" xlink:title="definition: SegmentDomain to PlasmaCollectionCentersSegmentMember" order="1.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://admabiologics.com/role/ScheduleIiValuationAndQualifyingAccountsDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:label="ValuationAndQualifyingAccountsDisclosureLineItems" xlink:title="ValuationAndQualifyingAccountsDisclosureLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:label="MovementInValuationAllowancesAndReservesRollForward" xlink:title="MovementInValuationAllowancesAndReservesRollForward" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ValuationAndQualifyingAccountsDisclosureLineItems" xlink:to="MovementInValuationAllowancesAndReservesRollForward" xlink:title="definition: ValuationAndQualifyingAccountsDisclosureLineItems to MovementInValuationAllowancesAndReservesRollForward" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowancesAndReservesBalance" xlink:label="ValuationAllowancesAndReservesBalance" xlink:title="ValuationAllowancesAndReservesBalance" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ValuationAndQualifyingAccountsDisclosureLineItems" xlink:to="ValuationAllowancesAndReservesBalance" xlink:title="definition: ValuationAndQualifyingAccountsDisclosureLineItems to ValuationAllowancesAndReservesBalance" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense" xlink:label="ValuationAllowancesAndReservesChargedToCostAndExpense" xlink:title="ValuationAllowancesAndReservesChargedToCostAndExpense" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ValuationAndQualifyingAccountsDisclosureLineItems" xlink:to="ValuationAllowancesAndReservesChargedToCostAndExpense" xlink:title="definition: ValuationAndQualifyingAccountsDisclosureLineItems to ValuationAllowancesAndReservesChargedToCostAndExpense" order="3.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts" xlink:label="ValuationAllowancesAndReservesChargedToOtherAccounts" xlink:title="ValuationAllowancesAndReservesChargedToOtherAccounts" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ValuationAndQualifyingAccountsDisclosureLineItems" xlink:to="ValuationAllowancesAndReservesChargedToOtherAccounts" xlink:title="definition: ValuationAndQualifyingAccountsDisclosureLineItems to ValuationAllowancesAndReservesChargedToOtherAccounts" order="4.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowancesAndReservesDeductions" xlink:label="ValuationAllowancesAndReservesDeductions" xlink:title="ValuationAllowancesAndReservesDeductions" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ValuationAndQualifyingAccountsDisclosureLineItems" xlink:to="ValuationAllowancesAndReservesDeductions" xlink:title="definition: ValuationAndQualifyingAccountsDisclosureLineItems to ValuationAllowancesAndReservesDeductions" order="5.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:label="ValuationAndQualifyingAccountsDisclosureTable" xlink:title="ValuationAndQualifyingAccountsDisclosureTable" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="ValuationAndQualifyingAccountsDisclosureLineItems" xlink:to="ValuationAndQualifyingAccountsDisclosureTable" xlink:title="definition: ValuationAndQualifyingAccountsDisclosureLineItems to ValuationAndQualifyingAccountsDisclosureTable" order="6.0" t1:closed="true" t1:contextElement="segment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:label="ValuationAllowancesAndReservesTypeAxis" xlink:title="ValuationAllowancesAndReservesTypeAxis" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="ValuationAndQualifyingAccountsDisclosureTable" xlink:to="ValuationAllowancesAndReservesTypeAxis" xlink:title="definition: ValuationAndQualifyingAccountsDisclosureTable to ValuationAllowancesAndReservesTypeAxis" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowancesAndReservesDomain" xlink:label="ValuationAllowancesAndReservesDomain" xlink:title="ValuationAllowancesAndReservesDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="ValuationAllowancesAndReservesTypeAxis" xlink:to="ValuationAllowancesAndReservesDomain" xlink:title="definition: ValuationAllowancesAndReservesTypeAxis to ValuationAllowancesAndReservesDomain" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowancesAndReservesDomain" xlink:label="ValuationAllowancesAndReservesDomain_2" xlink:title="ValuationAllowancesAndReservesDomain" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="ValuationAllowancesAndReservesTypeAxis" xlink:to="ValuationAllowancesAndReservesDomain_2" xlink:title="definition: ValuationAllowancesAndReservesTypeAxis to ValuationAllowancesAndReservesDomain_2" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_SECSchedule1209ReserveAccruedRebatesMember" xlink:label="SECSchedule1209ReserveAccruedRebatesMember" xlink:title="SECSchedule1209ReserveAccruedRebatesMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ValuationAllowancesAndReservesDomain" xlink:to="SECSchedule1209ReserveAccruedRebatesMember" xlink:title="definition: ValuationAllowancesAndReservesDomain to SECSchedule1209ReserveAccruedRebatesMember" order="1.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryValuationReserveMember" xlink:label="InventoryValuationReserveMember" xlink:title="InventoryValuationReserveMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ValuationAllowancesAndReservesDomain" xlink:to="InventoryValuationReserveMember" xlink:title="definition: ValuationAllowancesAndReservesDomain to InventoryValuationReserveMember" order="2.0" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember" xlink:label="ValuationAllowanceOfDeferredTaxAssetsMember" xlink:title="ValuationAllowanceOfDeferredTaxAssetsMember" />
    <link:definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="ValuationAllowancesAndReservesDomain" xlink:to="ValuationAllowanceOfDeferredTaxAssetsMember" xlink:title="definition: ValuationAllowancesAndReservesDomain to ValuationAllowanceOfDeferredTaxAssetsMember" order="3.0" />
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>16
<FILENAME>adma-20241231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--Generated by Broadridge PROfile 25.2.1.5287 Broadridge-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" />
  <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis" xlink:label="IndividualAxis" xlink:title="IndividualAxis" />
    <link:label xlink:type="resource" xlink:label="ecd_IndividualAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ecd_IndividualAxis" xml:lang="en-US" id="ecd_IndividualAxis">Individual [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IndividualAxis" xlink:to="ecd_IndividualAxis" xlink:title="label: IndividualAxis to ecd_IndividualAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember" xlink:label="AllIndividualsMember" xlink:title="AllIndividualsMember" />
    <link:label xlink:type="resource" xlink:label="ecd_AllIndividualsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ecd_AllIndividualsMember" xml:lang="en-US" id="ecd_AllIndividualsMember">All Individuals [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AllIndividualsMember" xlink:to="ecd_AllIndividualsMember" xlink:title="label: AllIndividualsMember to ecd_AllIndividualsMember" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTradingArrLineItems" xlink:label="InsiderTradingArrLineItems" xlink:title="InsiderTradingArrLineItems" />
    <link:label xlink:type="resource" xlink:label="ecd_InsiderTradingArrLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ecd_InsiderTradingArrLineItems" xml:lang="en-US" id="ecd_InsiderTradingArrLineItems">Insider Trading Arrangements [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InsiderTradingArrLineItems" xlink:to="ecd_InsiderTradingArrLineItems" xlink:title="label: InsiderTradingArrLineItems to ecd_InsiderTradingArrLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TradingArrAxis" xlink:label="TradingArrAxis" xlink:title="TradingArrAxis" />
    <link:label xlink:type="resource" xlink:label="ecd_TradingArrAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ecd_TradingArrAxis" xml:lang="en-US" id="ecd_TradingArrAxis">Trading Arrangement [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TradingArrAxis" xlink:to="ecd_TradingArrAxis" xlink:title="label: TradingArrAxis to ecd_TradingArrAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllTradingArrangementsMember" xlink:label="AllTradingArrangementsMember" xlink:title="AllTradingArrangementsMember" />
    <link:label xlink:type="resource" xlink:label="ecd_AllTradingArrangementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ecd_AllTradingArrangementsMember" xml:lang="en-US" id="ecd_AllTradingArrangementsMember">All Trading Arrangements [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AllTradingArrangementsMember" xlink:to="ecd_AllTradingArrangementsMember" xlink:title="label: AllTradingArrangementsMember to ecd_AllTradingArrangementsMember" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrAdoptedFlag" xlink:label="Rule10b51ArrAdoptedFlag" xlink:title="Rule10b51ArrAdoptedFlag" />
    <link:label xlink:type="resource" xlink:label="ecd_Rule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ecd_Rule10b51ArrAdoptedFlag" xml:lang="en-US" id="ecd_Rule10b51ArrAdoptedFlag">Rule 10b5-1 Arrangement Adopted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Rule10b51ArrAdoptedFlag" xlink:to="ecd_Rule10b51ArrAdoptedFlag" xlink:title="label: Rule10b51ArrAdoptedFlag to ecd_Rule10b51ArrAdoptedFlag" />
    <link:label xlink:type="resource" xlink:label="ecd_Rule10b51ArrAdoptedFlag_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ecd_Rule10b51ArrAdoptedFlag_lbl1" xml:lang="en-US" id="ecd_Rule10b51ArrAdoptedFlag_lbl1">Rule 10b5-1 Arrangement Adopted [Flag]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Rule10b51ArrAdoptedFlag" xlink:to="ecd_Rule10b51ArrAdoptedFlag_lbl1" xlink:title="label: Rule10b51ArrAdoptedFlag to ecd_Rule10b51ArrAdoptedFlag_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrTrmntdFlag" xlink:label="Rule10b51ArrTrmntdFlag" xlink:title="Rule10b51ArrTrmntdFlag" />
    <link:label xlink:type="resource" xlink:label="ecd_Rule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ecd_Rule10b51ArrTrmntdFlag" xml:lang="en-US" id="ecd_Rule10b51ArrTrmntdFlag">Rule 10b5-1 Arrangement Terminated</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Rule10b51ArrTrmntdFlag" xlink:to="ecd_Rule10b51ArrTrmntdFlag" xlink:title="label: Rule10b51ArrTrmntdFlag to ecd_Rule10b51ArrTrmntdFlag" />
    <link:label xlink:type="resource" xlink:label="ecd_Rule10b51ArrTrmntdFlag_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ecd_Rule10b51ArrTrmntdFlag_lbl1" xml:lang="en-US" id="ecd_Rule10b51ArrTrmntdFlag_lbl1">Rule 10b5-1 Arrangement Terminated [Flag]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Rule10b51ArrTrmntdFlag" xlink:to="ecd_Rule10b51ArrTrmntdFlag_lbl1" xlink:title="label: Rule10b51ArrTrmntdFlag to ecd_Rule10b51ArrTrmntdFlag_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrAdoptedFlag" xlink:label="NonRule10b51ArrAdoptedFlag" xlink:title="NonRule10b51ArrAdoptedFlag" />
    <link:label xlink:type="resource" xlink:label="ecd_NonRule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ecd_NonRule10b51ArrAdoptedFlag" xml:lang="en-US" id="ecd_NonRule10b51ArrAdoptedFlag">Non-Rule 10b5-1 Arrangement Adopted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NonRule10b51ArrAdoptedFlag" xlink:to="ecd_NonRule10b51ArrAdoptedFlag" xlink:title="label: NonRule10b51ArrAdoptedFlag to ecd_NonRule10b51ArrAdoptedFlag" />
    <link:label xlink:type="resource" xlink:label="ecd_NonRule10b51ArrAdoptedFlag_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ecd_NonRule10b51ArrAdoptedFlag_lbl1" xml:lang="en-US" id="ecd_NonRule10b51ArrAdoptedFlag_lbl1">Non-Rule 10b5-1 Arrangement Adopted [Flag]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NonRule10b51ArrAdoptedFlag" xlink:to="ecd_NonRule10b51ArrAdoptedFlag_lbl1" xlink:title="label: NonRule10b51ArrAdoptedFlag to ecd_NonRule10b51ArrAdoptedFlag_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrTrmntdFlag" xlink:label="NonRule10b51ArrTrmntdFlag" xlink:title="NonRule10b51ArrTrmntdFlag" />
    <link:label xlink:type="resource" xlink:label="ecd_NonRule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ecd_NonRule10b51ArrTrmntdFlag" xml:lang="en-US" id="ecd_NonRule10b51ArrTrmntdFlag">Non-Rule 10b5-1 Arrangement Terminated</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NonRule10b51ArrTrmntdFlag" xlink:to="ecd_NonRule10b51ArrTrmntdFlag" xlink:title="label: NonRule10b51ArrTrmntdFlag to ecd_NonRule10b51ArrTrmntdFlag" />
    <link:label xlink:type="resource" xlink:label="ecd_NonRule10b51ArrTrmntdFlag_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ecd_NonRule10b51ArrTrmntdFlag_lbl1" xml:lang="en-US" id="ecd_NonRule10b51ArrTrmntdFlag_lbl1">Non-Rule 10b5-1 Arrangement Terminated [Flag]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NonRule10b51ArrTrmntdFlag" xlink:to="ecd_NonRule10b51ArrTrmntdFlag_lbl1" xlink:title="label: NonRule10b51ArrTrmntdFlag to ecd_NonRule10b51ArrTrmntdFlag_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MtrlTermsOfTrdArrTextBlock" xlink:label="MtrlTermsOfTrdArrTextBlock" xlink:title="MtrlTermsOfTrdArrTextBlock" />
    <link:label xlink:type="resource" xlink:label="ecd_MtrlTermsOfTrdArrTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ecd_MtrlTermsOfTrdArrTextBlock" xml:lang="en-US" id="ecd_MtrlTermsOfTrdArrTextBlock">Material Terms of Trading Arrangement</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MtrlTermsOfTrdArrTextBlock" xlink:to="ecd_MtrlTermsOfTrdArrTextBlock" xlink:title="label: MtrlTermsOfTrdArrTextBlock to ecd_MtrlTermsOfTrdArrTextBlock" />
    <link:label xlink:type="resource" xlink:label="ecd_MtrlTermsOfTrdArrTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ecd_MtrlTermsOfTrdArrTextBlock_lbl1" xml:lang="en-US" id="ecd_MtrlTermsOfTrdArrTextBlock_lbl1">Material Terms of Trading Arrangement [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MtrlTermsOfTrdArrTextBlock" xlink:to="ecd_MtrlTermsOfTrdArrTextBlock_lbl1" xlink:title="label: MtrlTermsOfTrdArrTextBlock to ecd_MtrlTermsOfTrdArrTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TradingArrByIndTable" xlink:label="TradingArrByIndTable" xlink:title="TradingArrByIndTable" />
    <link:label xlink:type="resource" xlink:label="ecd_TradingArrByIndTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ecd_TradingArrByIndTable" xml:lang="en-US" id="ecd_TradingArrByIndTable">Trading Arrangements, by Individual [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TradingArrByIndTable" xlink:to="ecd_TradingArrByIndTable" xlink:title="label: TradingArrByIndTable to ecd_TradingArrByIndTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrIndName" xlink:label="TrdArrIndName" xlink:title="TrdArrIndName" />
    <link:label xlink:type="resource" xlink:label="ecd_TrdArrIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ecd_TrdArrIndName" xml:lang="en-US" id="ecd_TrdArrIndName">Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TrdArrIndName" xlink:to="ecd_TrdArrIndName" xlink:title="label: TrdArrIndName to ecd_TrdArrIndName" />
    <link:label xlink:type="resource" xlink:label="ecd_TrdArrIndName_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ecd_TrdArrIndName_lbl1" xml:lang="en-US" id="ecd_TrdArrIndName_lbl1">Trading Arrangement, Individual Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TrdArrIndName" xlink:to="ecd_TrdArrIndName_lbl1" xlink:title="label: TrdArrIndName to ecd_TrdArrIndName_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrIndTitle" xlink:label="TrdArrIndTitle" xlink:title="TrdArrIndTitle" />
    <link:label xlink:type="resource" xlink:label="ecd_TrdArrIndTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ecd_TrdArrIndTitle" xml:lang="en-US" id="ecd_TrdArrIndTitle">Title</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TrdArrIndTitle" xlink:to="ecd_TrdArrIndTitle" xlink:title="label: TrdArrIndTitle to ecd_TrdArrIndTitle" />
    <link:label xlink:type="resource" xlink:label="ecd_TrdArrIndTitle_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ecd_TrdArrIndTitle_lbl1" xml:lang="en-US" id="ecd_TrdArrIndTitle_lbl1">Trading Arrangement, Individual Title</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TrdArrIndTitle" xlink:to="ecd_TrdArrIndTitle_lbl1" xlink:title="label: TrdArrIndTitle to ecd_TrdArrIndTitle_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrAdoptionDate" xlink:label="TrdArrAdoptionDate" xlink:title="TrdArrAdoptionDate" />
    <link:label xlink:type="resource" xlink:label="ecd_TrdArrAdoptionDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ecd_TrdArrAdoptionDate" xml:lang="en-US" id="ecd_TrdArrAdoptionDate">Adoption Date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TrdArrAdoptionDate" xlink:to="ecd_TrdArrAdoptionDate" xlink:title="label: TrdArrAdoptionDate to ecd_TrdArrAdoptionDate" />
    <link:label xlink:type="resource" xlink:label="ecd_TrdArrAdoptionDate_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ecd_TrdArrAdoptionDate_lbl1" xml:lang="en-US" id="ecd_TrdArrAdoptionDate_lbl1">Trading Arrangement Adoption Date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TrdArrAdoptionDate" xlink:to="ecd_TrdArrAdoptionDate_lbl1" xlink:title="label: TrdArrAdoptionDate to ecd_TrdArrAdoptionDate_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrExpirationDate" xlink:label="TrdArrExpirationDate" xlink:title="TrdArrExpirationDate" />
    <link:label xlink:type="resource" xlink:label="ecd_TrdArrExpirationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ecd_TrdArrExpirationDate" xml:lang="en-US" id="ecd_TrdArrExpirationDate">Expiration Date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TrdArrExpirationDate" xlink:to="ecd_TrdArrExpirationDate" xlink:title="label: TrdArrExpirationDate to ecd_TrdArrExpirationDate" />
    <link:label xlink:type="resource" xlink:label="ecd_TrdArrExpirationDate_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ecd_TrdArrExpirationDate_lbl1" xml:lang="en-US" id="ecd_TrdArrExpirationDate_lbl1">Trading Arrangement Expiration Date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TrdArrExpirationDate" xlink:to="ecd_TrdArrExpirationDate_lbl1" xlink:title="label: TrdArrExpirationDate to ecd_TrdArrExpirationDate_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrDuration" xlink:label="TrdArrDuration" xlink:title="TrdArrDuration" />
    <link:label xlink:type="resource" xlink:label="ecd_TrdArrDuration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ecd_TrdArrDuration" xml:lang="en-US" id="ecd_TrdArrDuration">Arrangement Duration</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TrdArrDuration" xlink:to="ecd_TrdArrDuration" xlink:title="label: TrdArrDuration to ecd_TrdArrDuration" />
    <link:label xlink:type="resource" xlink:label="ecd_TrdArrDuration_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ecd_TrdArrDuration_lbl1" xml:lang="en-US" id="ecd_TrdArrDuration_lbl1">Trading Arrangement Duration</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TrdArrDuration" xlink:to="ecd_TrdArrDuration_lbl1" xlink:title="label: TrdArrDuration to ecd_TrdArrDuration_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrSecuritiesAggAvailAmt" xlink:label="TrdArrSecuritiesAggAvailAmt" xlink:title="TrdArrSecuritiesAggAvailAmt" />
    <link:label xlink:type="resource" xlink:label="ecd_TrdArrSecuritiesAggAvailAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="ecd_TrdArrSecuritiesAggAvailAmt" xml:lang="en-US" id="ecd_TrdArrSecuritiesAggAvailAmt">Aggregate Available</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TrdArrSecuritiesAggAvailAmt" xlink:to="ecd_TrdArrSecuritiesAggAvailAmt" xlink:title="label: TrdArrSecuritiesAggAvailAmt to ecd_TrdArrSecuritiesAggAvailAmt" />
    <link:label xlink:type="resource" xlink:label="ecd_TrdArrSecuritiesAggAvailAmt_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="ecd_TrdArrSecuritiesAggAvailAmt_lbl1" xml:lang="en-US" id="ecd_TrdArrSecuritiesAggAvailAmt_lbl1">Trading Arrangement, Securities Aggregate Available Amount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TrdArrSecuritiesAggAvailAmt" xlink:to="ecd_TrdArrSecuritiesAggAvailAmt_lbl1" xlink:title="label: TrdArrSecuritiesAggAvailAmt to ecd_TrdArrSecuritiesAggAvailAmt_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:title="AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xml:lang="en-US" id="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">ACCRUED EXPENSES AND OTHER LIABILITIES</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:title="label: AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock to us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl1" xml:lang="en-US" id="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl1">Accounts Payable and Accrued Liabilities Disclosure [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl1" xlink:title="label: AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock to us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="AccountsReceivableNetCurrent" xlink:title="AccountsReceivableNetCurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AccountsReceivableNetCurrent" xml:lang="en-US" id="us-gaap_AccountsReceivableNetCurrent">Accounts receivable, net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent" xlink:title="label: AccountsReceivableNetCurrent to us-gaap_AccountsReceivableNetCurrent" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:title="FiniteLivedIntangibleAssetsAccumulatedAmortization" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xml:lang="en-US" id="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">Accumulated amortization</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:title="label: FiniteLivedIntangibleAssetsAccumulatedAmortization to us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:title="AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xml:lang="en-US" id="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">Less: accumulated depreciation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:title="label: AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment to us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl1" xml:lang="en-US" id="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl1">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl1" xlink:title="label: AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment to us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="AdditionalPaidInCapital" xlink:title="AdditionalPaidInCapital" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_AdditionalPaidInCapital" xml:lang="en-US" id="us-gaap_AdditionalPaidInCapital">Additional paid-in capital</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital" xlink:title="label: AdditionalPaidInCapital to us-gaap_AdditionalPaidInCapital" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapital_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AdditionalPaidInCapital_lbl1" xml:lang="en-US" id="us-gaap_AdditionalPaidInCapital_lbl1">Additional Paid in Capital</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl1" xlink:title="label: AdditionalPaidInCapital to us-gaap_AdditionalPaidInCapital_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdvertisingCostsPolicyTextBlock" xlink:label="AdvertisingCostsPolicyTextBlock" xlink:title="AdvertisingCostsPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AdvertisingCostsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AdvertisingCostsPolicyTextBlock" xml:lang="en-US" id="us-gaap_AdvertisingCostsPolicyTextBlock">Advertising and Marketing Expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AdvertisingCostsPolicyTextBlock" xlink:to="us-gaap_AdvertisingCostsPolicyTextBlock" xlink:title="label: AdvertisingCostsPolicyTextBlock to us-gaap_AdvertisingCostsPolicyTextBlock" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryValuationReserveMember" xlink:label="InventoryValuationReserveMember" xlink:title="InventoryValuationReserveMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_InventoryValuationReserveMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_InventoryValuationReserveMember" xml:lang="en-US" id="us-gaap_InventoryValuationReserveMember">Inventory Valuation Allowance [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InventoryValuationReserveMember" xlink:to="us-gaap_InventoryValuationReserveMember" xlink:title="label: InventoryValuationReserveMember to us-gaap_InventoryValuationReserveMember" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="AmortizationOfIntangibleAssets" xlink:title="AmortizationOfIntangibleAssets" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_AmortizationOfIntangibleAssets" xml:lang="en-US" id="us-gaap_AmortizationOfIntangibleAssets">Amortization of intangible assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AmortizationOfIntangibleAssets" xlink:to="us-gaap_AmortizationOfIntangibleAssets" xlink:title="label: AmortizationOfIntangibleAssets to us-gaap_AmortizationOfIntangibleAssets" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AmortizationOfIntangibleAssets1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AmortizationOfIntangibleAssets1" xml:lang="en-US" id="us-gaap_AmortizationOfIntangibleAssets1">Amortization of intangible assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AmortizationOfIntangibleAssets" xlink:to="us-gaap_AmortizationOfIntangibleAssets1" xlink:title="label: AmortizationOfIntangibleAssets to us-gaap_AmortizationOfIntangibleAssets1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetImpairmentChargesAbstract" xlink:label="AssetImpairmentChargesAbstract" xlink:title="AssetImpairmentChargesAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AssetImpairmentChargesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AssetImpairmentChargesAbstract" xml:lang="en-US" id="us-gaap_AssetImpairmentChargesAbstract">Impairment of Long-lived Assets [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AssetImpairmentChargesAbstract" xlink:to="us-gaap_AssetImpairmentChargesAbstract" xlink:title="label: AssetImpairmentChargesAbstract to us-gaap_AssetImpairmentChargesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetUnderConstructionMember" xlink:label="AssetUnderConstructionMember" xlink:title="AssetUnderConstructionMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AssetUnderConstructionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AssetUnderConstructionMember" xml:lang="en-US" id="us-gaap_AssetUnderConstructionMember">Construction in Process [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AssetUnderConstructionMember" xlink:to="us-gaap_AssetUnderConstructionMember" xlink:title="label: AssetUnderConstructionMember to us-gaap_AssetUnderConstructionMember" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="StatementOfFinancialPositionAbstract" xlink:title="StatementOfFinancialPositionAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StatementOfFinancialPositionAbstract" xml:lang="en-US" id="us-gaap_StatementOfFinancialPositionAbstract">CONSOLIDATED BALANCE SHEETS [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract" xlink:title="label: StatementOfFinancialPositionAbstract to us-gaap_StatementOfFinancialPositionAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic" xlink:label="EarningsPerShareBasic" xlink:title="EarningsPerShareBasic" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_EarningsPerShareBasic" xml:lang="en-US" id="us-gaap_EarningsPerShareBasic">BASIC EARNINGS (LOSS) PER COMMON SHARE (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic" xlink:title="label: EarningsPerShareBasic to us-gaap_EarningsPerShareBasic" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_EarningsPerShareBasic1" xml:lang="en-US" id="us-gaap_EarningsPerShareBasic1">Basic earnings per common shares (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic1" xlink:title="label: EarningsPerShareBasic to us-gaap_EarningsPerShareBasic1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_EarningsPerShareBasic_lbl2" xml:lang="en-US" id="us-gaap_EarningsPerShareBasic_lbl2">Earnings Per Share, Basic</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl2" xlink:title="label: EarningsPerShareBasic to us-gaap_EarningsPerShareBasic_lbl2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="AmortizationOfDebtDiscountPremium" xlink:title="AmortizationOfDebtDiscountPremium" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AmortizationOfDebtDiscountPremium" xml:lang="en-US" id="us-gaap_AmortizationOfDebtDiscountPremium">Amortization of debt discount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AmortizationOfDebtDiscountPremium" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium" xlink:title="label: AmortizationOfDebtDiscountPremium to us-gaap_AmortizationOfDebtDiscountPremium" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BuildingMember" xlink:label="BuildingMember" xlink:title="BuildingMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_BuildingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_BuildingMember" xml:lang="en-US" id="us-gaap_BuildingMember">Buildings [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BuildingMember" xlink:to="us-gaap_BuildingMember" xlink:title="label: BuildingMember to us-gaap_BuildingMember" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="CashAndCashEquivalentsAtCarryingValue" xlink:title="CashAndCashEquivalentsAtCarryingValue" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CashAndCashEquivalentsAtCarryingValue" xml:lang="en-US" id="us-gaap_CashAndCashEquivalentsAtCarryingValue">Cash and cash equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:title="label: CashAndCashEquivalentsAtCarryingValue to us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="CashAndCashEquivalentsPolicyTextBlock" xlink:title="CashAndCashEquivalentsPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xml:lang="en-US" id="us-gaap_CashAndCashEquivalentsPolicyTextBlock">Cash and Cash Equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:title="label: CashAndCashEquivalentsPolicyTextBlock to us-gaap_CashAndCashEquivalentsPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl1" xml:lang="en-US" id="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl1">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl1" xlink:title="label: CashAndCashEquivalentsPolicyTextBlock to us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPaidNet" xlink:label="InterestPaidNet" xlink:title="InterestPaidNet" />
    <link:label xlink:type="resource" xlink:label="us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_InterestPaidNet" xml:lang="en-US" id="us-gaap_InterestPaidNet">Cash paid for interest</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InterestPaidNet" xlink:to="us-gaap_InterestPaidNet" xlink:title="label: InterestPaidNet to us-gaap_InterestPaidNet" />
    <link:label xlink:type="resource" xlink:label="us-gaap_InterestPaidNet_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_InterestPaidNet_lbl1" xml:lang="en-US" id="us-gaap_InterestPaidNet_lbl1">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl1" xlink:title="label: InterestPaidNet to us-gaap_InterestPaidNet_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="IncreaseDecreaseInAccountsReceivable" xlink:title="IncreaseDecreaseInAccountsReceivable" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_IncreaseDecreaseInAccountsReceivable" xml:lang="en-US" id="us-gaap_IncreaseDecreaseInAccountsReceivable">Accounts receivable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:title="label: IncreaseDecreaseInAccountsReceivable to us-gaap_IncreaseDecreaseInAccountsReceivable" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl1" xml:lang="en-US" id="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl1">Increase (Decrease) in Accounts Receivable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl1" xlink:title="label: IncreaseDecreaseInAccountsReceivable to us-gaap_IncreaseDecreaseInAccountsReceivable_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ChangeInAccountingEstimateByTypeAxis" xlink:label="ChangeInAccountingEstimateByTypeAxis" xlink:title="ChangeInAccountingEstimateByTypeAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ChangeInAccountingEstimateByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ChangeInAccountingEstimateByTypeAxis" xml:lang="en-US" id="us-gaap_ChangeInAccountingEstimateByTypeAxis">Change in Accounting Estimate by Type [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ChangeInAccountingEstimateByTypeAxis" xlink:to="us-gaap_ChangeInAccountingEstimateByTypeAxis" xlink:title="label: ChangeInAccountingEstimateByTypeAxis to us-gaap_ChangeInAccountingEstimateByTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ChangeInAccountingEstimateTypeDomain" xlink:label="ChangeInAccountingEstimateTypeDomain" xlink:title="ChangeInAccountingEstimateTypeDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ChangeInAccountingEstimateTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ChangeInAccountingEstimateTypeDomain" xml:lang="en-US" id="us-gaap_ChangeInAccountingEstimateTypeDomain">Change in Accounting Estimate, Type [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ChangeInAccountingEstimateTypeDomain" xlink:to="us-gaap_ChangeInAccountingEstimateTypeDomain" xlink:title="label: ChangeInAccountingEstimateTypeDomain to us-gaap_ChangeInAccountingEstimateTypeDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ChangeInAccountingEstimateLineItems" xlink:label="ChangeInAccountingEstimateLineItems" xlink:title="ChangeInAccountingEstimateLineItems" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ChangeInAccountingEstimateLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ChangeInAccountingEstimateLineItems" xml:lang="en-US" id="us-gaap_ChangeInAccountingEstimateLineItems">Change in Accounting Estimate [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ChangeInAccountingEstimateLineItems" xlink:to="us-gaap_ChangeInAccountingEstimateLineItems" xlink:title="label: ChangeInAccountingEstimateLineItems to us-gaap_ChangeInAccountingEstimateLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfChangeInAccountingEstimateTable" xlink:label="ScheduleOfChangeInAccountingEstimateTable" xlink:title="ScheduleOfChangeInAccountingEstimateTable" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfChangeInAccountingEstimateTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ScheduleOfChangeInAccountingEstimateTable" xml:lang="en-US" id="us-gaap_ScheduleOfChangeInAccountingEstimateTable">Change in Accounting Estimate [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfChangeInAccountingEstimateTable" xlink:to="us-gaap_ScheduleOfChangeInAccountingEstimateTable" xlink:title="label: ScheduleOfChangeInAccountingEstimateTable to us-gaap_ScheduleOfChangeInAccountingEstimateTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="IncreaseDecreaseInInventories" xlink:title="IncreaseDecreaseInInventories" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_IncreaseDecreaseInInventories" xml:lang="en-US" id="us-gaap_IncreaseDecreaseInInventories">Inventories</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInInventories" xlink:to="us-gaap_IncreaseDecreaseInInventories" xlink:title="label: IncreaseDecreaseInInventories to us-gaap_IncreaseDecreaseInInventories" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInInventories_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncreaseDecreaseInInventories_lbl1" xml:lang="en-US" id="us-gaap_IncreaseDecreaseInInventories_lbl1">Increase (Decrease) in Inventories</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInInventories" xlink:to="us-gaap_IncreaseDecreaseInInventories_lbl1" xlink:title="label: IncreaseDecreaseInInventories to us-gaap_IncreaseDecreaseInInventories_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:title="IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xml:lang="en-US" id="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">Prepaid expenses and other current assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:title="label: IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets to us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl1" xml:lang="en-US" id="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl1">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl1" xlink:title="label: IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets to us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="IncreaseDecreaseInOperatingCapitalAbstract" xlink:title="IncreaseDecreaseInOperatingCapitalAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xml:lang="en-US" id="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">Changes in operating assets and liabilities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:title="label: IncreaseDecreaseInOperatingCapitalAbstract to us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="IncreaseDecreaseInAccountsPayable" xlink:title="IncreaseDecreaseInAccountsPayable" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_IncreaseDecreaseInAccountsPayable" xml:lang="en-US" id="us-gaap_IncreaseDecreaseInAccountsPayable">Accounts payable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:title="label: IncreaseDecreaseInAccountsPayable to us-gaap_IncreaseDecreaseInAccountsPayable" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncreaseDecreaseInAccountsPayable_lbl1" xml:lang="en-US" id="us-gaap_IncreaseDecreaseInAccountsPayable_lbl1">Increase (Decrease) in Accounts Payable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl1" xlink:title="label: IncreaseDecreaseInAccountsPayable to us-gaap_IncreaseDecreaseInAccountsPayable_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="IncreaseDecreaseInAccruedLiabilities" xlink:title="IncreaseDecreaseInAccruedLiabilities" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncreaseDecreaseInAccruedLiabilities" xml:lang="en-US" id="us-gaap_IncreaseDecreaseInAccruedLiabilities">Accrued expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:title="label: IncreaseDecreaseInAccruedLiabilities to us-gaap_IncreaseDecreaseInAccruedLiabilities" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="CommitmentsAndContingenciesDisclosureTextBlock" xlink:title="CommitmentsAndContingenciesDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xml:lang="en-US" id="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">COMMITMENTS AND CONTINGENCIES</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:title="label: CommitmentsAndContingenciesDisclosureTextBlock to us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl1" xml:lang="en-US" id="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl1">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl1" xlink:title="label: CommitmentsAndContingenciesDisclosureTextBlock to us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="CommonStockSharesAuthorized" xlink:title="CommonStockSharesAuthorized" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_CommonStockSharesAuthorized" xml:lang="en-US" id="us-gaap_CommonStockSharesAuthorized">Common stock, shares authorized (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized" xlink:title="label: CommonStockSharesAuthorized to us-gaap_CommonStockSharesAuthorized" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CommonStockSharesAuthorized1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CommonStockSharesAuthorized1" xml:lang="en-US" id="us-gaap_CommonStockSharesAuthorized1">Common stock, shares authorized (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized1" xlink:title="label: CommonStockSharesAuthorized to us-gaap_CommonStockSharesAuthorized1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="CommonStockSharesIssued" xlink:title="CommonStockSharesIssued" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CommonStockSharesIssued" xml:lang="en-US" id="us-gaap_CommonStockSharesIssued">Common stock, shares issued (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued" xlink:title="label: CommonStockSharesIssued to us-gaap_CommonStockSharesIssued" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="CommonStockSharesOutstanding" xlink:title="CommonStockSharesOutstanding" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_CommonStockSharesOutstanding" xml:lang="en-US" id="us-gaap_CommonStockSharesOutstanding">Common stock, shares outstanding (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding" xlink:title="label: CommonStockSharesOutstanding to us-gaap_CommonStockSharesOutstanding" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CommonStockSharesOutstanding1" xml:lang="en-US" id="us-gaap_CommonStockSharesOutstanding1">Common stock, shares outstanding (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding1" xlink:title="label: CommonStockSharesOutstanding to us-gaap_CommonStockSharesOutstanding1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="CommonStockValue" xlink:title="CommonStockValue" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CommonStockValue" xml:lang="en-US" id="us-gaap_CommonStockValue">Common Stock - voting, $0.0001 par value, 300,000,000 shares authorized, 236,620,545 and 226,063,032 shares issued and outstanding at December 31, 2024 and December 31, 2023</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockValue" xlink:to="us-gaap_CommonStockValue" xlink:title="label: CommonStockValue to us-gaap_CommonStockValue" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract" xlink:label="ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract" xlink:title="ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract" xml:lang="en-US" id="us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract">Stock-based compensation expense [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract" xlink:to="us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract" xlink:title="label: ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract to us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:title="CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xml:lang="en-US" id="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract">Current:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:title="label: CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract to us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:title="DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xml:lang="en-US" id="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract">Deferred:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:title="label: DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract to us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:label="ComputerSoftwareIntangibleAssetMember" xlink:title="ComputerSoftwareIntangibleAssetMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ComputerSoftwareIntangibleAssetMember" xml:lang="en-US" id="us-gaap_ComputerSoftwareIntangibleAssetMember">Internally Developed Software [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ComputerSoftwareIntangibleAssetMember" xlink:to="us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:title="label: ComputerSoftwareIntangibleAssetMember to us-gaap_ComputerSoftwareIntangibleAssetMember" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskDisclosureTextBlock" xlink:label="ConcentrationRiskDisclosureTextBlock" xlink:title="ConcentrationRiskDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ConcentrationRiskDisclosureTextBlock" xml:lang="en-US" id="us-gaap_ConcentrationRiskDisclosureTextBlock">CONCENTRATIONS</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConcentrationRiskDisclosureTextBlock" xlink:to="us-gaap_ConcentrationRiskDisclosureTextBlock" xlink:title="label: ConcentrationRiskDisclosureTextBlock to us-gaap_ConcentrationRiskDisclosureTextBlock" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="ConcentrationRiskByTypeAxis" xlink:title="ConcentrationRiskByTypeAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ConcentrationRiskByTypeAxis" xml:lang="en-US" id="us-gaap_ConcentrationRiskByTypeAxis">Concentration Risk Type [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskByTypeAxis" xlink:title="label: ConcentrationRiskByTypeAxis to us-gaap_ConcentrationRiskByTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskLineItems" xlink:label="ConcentrationRiskLineItems" xlink:title="ConcentrationRiskLineItems" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ConcentrationRiskLineItems" xml:lang="en-US" id="us-gaap_ConcentrationRiskLineItems">Concentration Risk [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConcentrationRiskLineItems" xlink:to="us-gaap_ConcentrationRiskLineItems" xlink:title="label: ConcentrationRiskLineItems to us-gaap_ConcentrationRiskLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskTable" xlink:label="ConcentrationRiskTable" xlink:title="ConcentrationRiskTable" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ConcentrationRiskTable" xml:lang="en-US" id="us-gaap_ConcentrationRiskTable">Concentration Risk [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConcentrationRiskTable" xlink:to="us-gaap_ConcentrationRiskTable" xlink:title="label: ConcentrationRiskTable to us-gaap_ConcentrationRiskTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="ConcentrationRiskTypeDomain" xlink:title="ConcentrationRiskTypeDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ConcentrationRiskTypeDomain" xml:lang="en-US" id="us-gaap_ConcentrationRiskTypeDomain">Concentration Risk Type [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConcentrationRiskTypeDomain" xlink:to="us-gaap_ConcentrationRiskTypeDomain" xlink:title="label: ConcentrationRiskTypeDomain to us-gaap_ConcentrationRiskTypeDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryWriteDown" xlink:label="InventoryWriteDown" xlink:title="InventoryWriteDown" />
    <link:label xlink:type="resource" xlink:label="us-gaap_InventoryWriteDown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_InventoryWriteDown" xml:lang="en-US" id="us-gaap_InventoryWriteDown">Non recurring charge of inventory</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InventoryWriteDown" xlink:to="us-gaap_InventoryWriteDown" xlink:title="label: InventoryWriteDown to us-gaap_InventoryWriteDown" />
    <link:label xlink:type="resource" xlink:label="us-gaap_InventoryWriteDown_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_InventoryWriteDown_lbl1" xml:lang="en-US" id="us-gaap_InventoryWriteDown_lbl1">Inventory Write-down</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InventoryWriteDown" xlink:to="us-gaap_InventoryWriteDown_lbl1" xlink:title="label: InventoryWriteDown to us-gaap_InventoryWriteDown_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfRevenue" xlink:label="CostOfRevenue" xlink:title="CostOfRevenue" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CostOfRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_CostOfRevenue" xml:lang="en-US" id="us-gaap_CostOfRevenue">Cost of product revenue</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CostOfRevenue" xlink:to="us-gaap_CostOfRevenue" xlink:title="label: CostOfRevenue to us-gaap_CostOfRevenue" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CostOfRevenue1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_CostOfRevenue1" xml:lang="en-US" id="us-gaap_CostOfRevenue1">Cost of product revenue</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CostOfRevenue" xlink:to="us-gaap_CostOfRevenue1" xlink:title="label: CostOfRevenue to us-gaap_CostOfRevenue1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CostOfRevenue_lbl2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CostOfRevenue_lbl2" xml:lang="en-US" id="us-gaap_CostOfRevenue_lbl2">Cost of Revenue</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CostOfRevenue" xlink:to="us-gaap_CostOfRevenue_lbl2" xlink:title="label: CostOfRevenue to us-gaap_CostOfRevenue_lbl2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfSalesPolicyTextBlock" xlink:label="CostOfSalesPolicyTextBlock" xlink:title="CostOfSalesPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CostOfSalesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CostOfSalesPolicyTextBlock" xml:lang="en-US" id="us-gaap_CostOfSalesPolicyTextBlock">Cost of Product Revenue</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CostOfSalesPolicyTextBlock" xlink:to="us-gaap_CostOfSalesPolicyTextBlock" xlink:title="label: CostOfSalesPolicyTextBlock to us-gaap_CostOfSalesPolicyTextBlock" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="CurrentFederalTaxExpenseBenefit" xlink:title="CurrentFederalTaxExpenseBenefit" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CurrentFederalTaxExpenseBenefit" xml:lang="en-US" id="us-gaap_CurrentFederalTaxExpenseBenefit">Federal</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CurrentFederalTaxExpenseBenefit" xlink:to="us-gaap_CurrentFederalTaxExpenseBenefit" xlink:title="label: CurrentFederalTaxExpenseBenefit to us-gaap_CurrentFederalTaxExpenseBenefit" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="CurrentIncomeTaxExpenseBenefit" xlink:title="CurrentIncomeTaxExpenseBenefit" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_CurrentIncomeTaxExpenseBenefit" xml:lang="en-US" id="us-gaap_CurrentIncomeTaxExpenseBenefit">Total current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:title="label: CurrentIncomeTaxExpenseBenefit to us-gaap_CurrentIncomeTaxExpenseBenefit" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl1" xml:lang="en-US" id="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl1">Current Income Tax Expense (Benefit)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl1" xlink:title="label: CurrentIncomeTaxExpenseBenefit to us-gaap_CurrentIncomeTaxExpenseBenefit_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="LiabilitiesCurrent" xlink:title="LiabilitiesCurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_LiabilitiesCurrent" xml:lang="en-US" id="us-gaap_LiabilitiesCurrent">Total current liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent" xlink:title="label: LiabilitiesCurrent to us-gaap_LiabilitiesCurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrent_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LiabilitiesCurrent_lbl1" xml:lang="en-US" id="us-gaap_LiabilitiesCurrent_lbl1">Liabilities, Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl1" xlink:title="label: LiabilitiesCurrent to us-gaap_LiabilitiesCurrent_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="LiabilitiesCurrentAbstract" xlink:title="LiabilitiesCurrentAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LiabilitiesCurrentAbstract" xml:lang="en-US" id="us-gaap_LiabilitiesCurrentAbstract">Current liabilities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" xlink:title="label: LiabilitiesCurrentAbstract to us-gaap_LiabilitiesCurrentAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="CurrentStateAndLocalTaxExpenseBenefit" xlink:title="CurrentStateAndLocalTaxExpenseBenefit" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xml:lang="en-US" id="us-gaap_CurrentStateAndLocalTaxExpenseBenefit">State</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CurrentStateAndLocalTaxExpenseBenefit" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:title="label: CurrentStateAndLocalTaxExpenseBenefit to us-gaap_CurrentStateAndLocalTaxExpenseBenefit" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="CustomerConcentrationRiskMember" xlink:title="CustomerConcentrationRiskMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CustomerConcentrationRiskMember" xml:lang="en-US" id="us-gaap_CustomerConcentrationRiskMember">Customer Concentration Risk [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CustomerConcentrationRiskMember" xlink:to="us-gaap_CustomerConcentrationRiskMember" xlink:title="label: CustomerConcentrationRiskMember to us-gaap_CustomerConcentrationRiskMember" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="DebtInstrumentCarryingAmount" xlink:title="DebtInstrumentCarryingAmount" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DebtInstrumentCarryingAmount" xml:lang="en-US" id="us-gaap_DebtInstrumentCarryingAmount">Outstanding principal amount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentCarryingAmount" xlink:to="us-gaap_DebtInstrumentCarryingAmount" xlink:title="label: DebtInstrumentCarryingAmount to us-gaap_DebtInstrumentCarryingAmount" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFeeAmount" xlink:label="DebtInstrumentFeeAmount" xlink:title="DebtInstrumentFeeAmount" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DebtInstrumentFeeAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_DebtInstrumentFeeAmount" xml:lang="en-US" id="us-gaap_DebtInstrumentFeeAmount">Incurred fees and expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentFeeAmount" xlink:to="us-gaap_DebtInstrumentFeeAmount" xlink:title="label: DebtInstrumentFeeAmount to us-gaap_DebtInstrumentFeeAmount" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DebtInstrumentFeeAmount_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DebtInstrumentFeeAmount_lbl1" xml:lang="en-US" id="us-gaap_DebtInstrumentFeeAmount_lbl1">Debt Instrument, Fee Amount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentFeeAmount" xlink:to="us-gaap_DebtInstrumentFeeAmount_lbl1" xlink:title="label: DebtInstrumentFeeAmount to us-gaap_DebtInstrumentFeeAmount_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFrequencyOfPeriodicPayment" xlink:label="DebtInstrumentFrequencyOfPeriodicPayment" xlink:title="DebtInstrumentFrequencyOfPeriodicPayment" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DebtInstrumentFrequencyOfPeriodicPayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DebtInstrumentFrequencyOfPeriodicPayment" xml:lang="en-US" id="us-gaap_DebtInstrumentFrequencyOfPeriodicPayment">Frequency of periodic payment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentFrequencyOfPeriodicPayment" xlink:to="us-gaap_DebtInstrumentFrequencyOfPeriodicPayment" xlink:title="label: DebtInstrumentFrequencyOfPeriodicPayment to us-gaap_DebtInstrumentFrequencyOfPeriodicPayment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="DebtInstrumentInterestRateEffectivePercentage" xlink:title="DebtInstrumentInterestRateEffectivePercentage" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DebtInstrumentInterestRateEffectivePercentage" xml:lang="en-US" id="us-gaap_DebtInstrumentInterestRateEffectivePercentage">Effective interest rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentInterestRateEffectivePercentage" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:title="label: DebtInstrumentInterestRateEffectivePercentage to us-gaap_DebtInstrumentInterestRateEffectivePercentage" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="DebtInstrumentInterestRateStatedPercentage" xlink:title="DebtInstrumentInterestRateStatedPercentage" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DebtInstrumentInterestRateStatedPercentage" xml:lang="en-US" id="us-gaap_DebtInstrumentInterestRateStatedPercentage">Interest rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentInterestRateStatedPercentage" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:title="label: DebtInstrumentInterestRateStatedPercentage to us-gaap_DebtInstrumentInterestRateStatedPercentage" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="DebtInstrumentMaturityDate" xlink:title="DebtInstrumentMaturityDate" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DebtInstrumentMaturityDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DebtInstrumentMaturityDate" xml:lang="en-US" id="us-gaap_DebtInstrumentMaturityDate">Maturity date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentMaturityDate" xlink:to="us-gaap_DebtInstrumentMaturityDate" xlink:title="label: DebtInstrumentMaturityDate to us-gaap_DebtInstrumentMaturityDate" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="DebtInstrumentNameDomain" xlink:title="DebtInstrumentNameDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DebtInstrumentNameDomain" xml:lang="en-US" id="us-gaap_DebtInstrumentNameDomain">Debt Instrument, Name [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentNameDomain" xlink:to="us-gaap_DebtInstrumentNameDomain" xlink:title="label: DebtInstrumentNameDomain to us-gaap_DebtInstrumentNameDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentPeriodicPaymentInterest" xlink:label="DebtInstrumentPeriodicPaymentInterest" xlink:title="DebtInstrumentPeriodicPaymentInterest" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DebtInstrumentPeriodicPaymentInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DebtInstrumentPeriodicPaymentInterest" xml:lang="en-US" id="us-gaap_DebtInstrumentPeriodicPaymentInterest">Interest payments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentPeriodicPaymentInterest" xlink:to="us-gaap_DebtInstrumentPeriodicPaymentInterest" xlink:title="label: DebtInstrumentPeriodicPaymentInterest to us-gaap_DebtInstrumentPeriodicPaymentInterest" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentPeriodicPaymentPrincipal" xlink:label="DebtInstrumentPeriodicPaymentPrincipal" xlink:title="DebtInstrumentPeriodicPaymentPrincipal" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DebtInstrumentPeriodicPaymentPrincipal" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DebtInstrumentPeriodicPaymentPrincipal" xml:lang="en-US" id="us-gaap_DebtInstrumentPeriodicPaymentPrincipal">Scheduled principal payments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentPeriodicPaymentPrincipal" xlink:to="us-gaap_DebtInstrumentPeriodicPaymentPrincipal" xlink:title="label: DebtInstrumentPeriodicPaymentPrincipal to us-gaap_DebtInstrumentPeriodicPaymentPrincipal" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="DebtInstrumentUnamortizedDiscount" xlink:title="DebtInstrumentUnamortizedDiscount" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_DebtInstrumentUnamortizedDiscount" xml:lang="en-US" id="us-gaap_DebtInstrumentUnamortizedDiscount">Less: Debt discount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentUnamortizedDiscount" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscount" xlink:title="label: DebtInstrumentUnamortizedDiscount to us-gaap_DebtInstrumentUnamortizedDiscount" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DebtInstrumentUnamortizedDiscount_lbl1" xml:lang="en-US" id="us-gaap_DebtInstrumentUnamortizedDiscount_lbl1">Debt Instrument, Unamortized Discount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentUnamortizedDiscount" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscount_lbl1" xlink:title="label: DebtInstrumentUnamortizedDiscount to us-gaap_DebtInstrumentUnamortizedDiscount_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentUnamortizedPremium" xlink:label="DebtInstrumentUnamortizedPremium" xlink:title="DebtInstrumentUnamortizedPremium" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DebtInstrumentUnamortizedPremium" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_DebtInstrumentUnamortizedPremium" xml:lang="en-US" id="us-gaap_DebtInstrumentUnamortizedPremium">Redemption premium</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentUnamortizedPremium" xlink:to="us-gaap_DebtInstrumentUnamortizedPremium" xlink:title="label: DebtInstrumentUnamortizedPremium to us-gaap_DebtInstrumentUnamortizedPremium" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DebtInstrumentUnamortizedPremium_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DebtInstrumentUnamortizedPremium_lbl1" xml:lang="en-US" id="us-gaap_DebtInstrumentUnamortizedPremium_lbl1">Debt Instrument, Unamortized Premium</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentUnamortizedPremium" xlink:to="us-gaap_DebtInstrumentUnamortizedPremium_lbl1" xlink:title="label: DebtInstrumentUnamortizedPremium to us-gaap_DebtInstrumentUnamortizedPremium_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentsAbstract" xlink:label="DebtInstrumentsAbstract" xlink:title="DebtInstrumentsAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DebtInstrumentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DebtInstrumentsAbstract" xml:lang="en-US" id="us-gaap_DebtInstrumentsAbstract">Debt Instruments [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentsAbstract" xlink:to="us-gaap_DebtInstrumentsAbstract" xlink:title="label: DebtInstrumentsAbstract to us-gaap_DebtInstrumentsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis" xlink:label="DebtInstrumentAxis" xlink:title="DebtInstrumentAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DebtInstrumentAxis" xml:lang="en-US" id="us-gaap_DebtInstrumentAxis">Debt Instrument [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentAxis" xlink:title="label: DebtInstrumentAxis to us-gaap_DebtInstrumentAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="DebtInstrumentLineItems" xlink:title="DebtInstrumentLineItems" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_DebtInstrumentLineItems" xml:lang="en-US" id="us-gaap_DebtInstrumentLineItems">Debt Instrument [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentLineItems" xlink:title="label: DebtInstrumentLineItems to us-gaap_DebtInstrumentLineItems" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DebtInstrumentLineItems_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DebtInstrumentLineItems_lbl1" xml:lang="en-US" id="us-gaap_DebtInstrumentLineItems_lbl1">Debt Instrument [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentLineItems_lbl1" xlink:title="label: DebtInstrumentLineItems to us-gaap_DebtInstrumentLineItems_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTable" xlink:label="DebtInstrumentTable" xlink:title="DebtInstrumentTable" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DebtInstrumentTable" xml:lang="en-US" id="us-gaap_DebtInstrumentTable">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentTable" xlink:title="label: DebtInstrumentTable to us-gaap_DebtInstrumentTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:label="PaymentsOfDebtIssuanceCosts" xlink:title="PaymentsOfDebtIssuanceCosts" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_PaymentsOfDebtIssuanceCosts" xml:lang="en-US" id="us-gaap_PaymentsOfDebtIssuanceCosts">Payment for certain fees and expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PaymentsOfDebtIssuanceCosts" xlink:to="us-gaap_PaymentsOfDebtIssuanceCosts" xlink:title="label: PaymentsOfDebtIssuanceCosts to us-gaap_PaymentsOfDebtIssuanceCosts" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PaymentsOfDebtIssuanceCosts_lbl1" xml:lang="en-US" id="us-gaap_PaymentsOfDebtIssuanceCosts_lbl1">Payments of Debt Issuance Costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PaymentsOfDebtIssuanceCosts" xlink:to="us-gaap_PaymentsOfDebtIssuanceCosts_lbl1" xlink:title="label: PaymentsOfDebtIssuanceCosts to us-gaap_PaymentsOfDebtIssuanceCosts_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="DeferredFederalIncomeTaxExpenseBenefit" xlink:title="DeferredFederalIncomeTaxExpenseBenefit" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xml:lang="en-US" id="us-gaap_DeferredFederalIncomeTaxExpenseBenefit">Federal</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredFederalIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:title="label: DeferredFederalIncomeTaxExpenseBenefit to us-gaap_DeferredFederalIncomeTaxExpenseBenefit" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl1" xml:lang="en-US" id="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl1">Deferred Federal Income Tax Expense (Benefit)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredFederalIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl1" xlink:title="label: DeferredFederalIncomeTaxExpenseBenefit to us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="DeferredIncomeTaxExpenseBenefit" xlink:title="DeferredIncomeTaxExpenseBenefit" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_DeferredIncomeTaxExpenseBenefit" xml:lang="en-US" id="us-gaap_DeferredIncomeTaxExpenseBenefit">Total deferred</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:title="label: DeferredIncomeTaxExpenseBenefit to us-gaap_DeferredIncomeTaxExpenseBenefit" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl1" xml:lang="en-US" id="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl1">Deferred Income Tax Expense (Benefit)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl1" xlink:title="label: DeferredIncomeTaxExpenseBenefit to us-gaap_DeferredIncomeTaxExpenseBenefit_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="DeferredIncomeTaxLiabilities" xlink:title="DeferredIncomeTaxLiabilities" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:title="us-gaap_DeferredIncomeTaxLiabilities" xml:lang="en-US" id="us-gaap_DeferredIncomeTaxLiabilities">Total deferred tax liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredIncomeTaxLiabilities" xlink:to="us-gaap_DeferredIncomeTaxLiabilities" xlink:title="label: DeferredIncomeTaxLiabilities to us-gaap_DeferredIncomeTaxLiabilities" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DeferredIncomeTaxLiabilities_lbl1" xml:lang="en-US" id="us-gaap_DeferredIncomeTaxLiabilities_lbl1">Deferred Tax Liabilities, Gross</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredIncomeTaxLiabilities" xlink:to="us-gaap_DeferredIncomeTaxLiabilities_lbl1" xlink:title="label: DeferredIncomeTaxLiabilities to us-gaap_DeferredIncomeTaxLiabilities_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:title="DeferredStateAndLocalIncomeTaxExpenseBenefit" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xml:lang="en-US" id="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit">State</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:title="label: DeferredStateAndLocalIncomeTaxExpenseBenefit to us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl1" xml:lang="en-US" id="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl1">Deferred State and Local Income Tax Expense (Benefit)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl1" xlink:title="label: DeferredStateAndLocalIncomeTaxExpenseBenefit to us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="DeferredTaxAssetsGross" xlink:title="DeferredTaxAssetsGross" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_DeferredTaxAssetsGross" xml:lang="en-US" id="us-gaap_DeferredTaxAssetsGross">Total gross deferred tax assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross" xlink:title="label: DeferredTaxAssetsGross to us-gaap_DeferredTaxAssetsGross" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DeferredTaxAssetsGross_lbl1" xml:lang="en-US" id="us-gaap_DeferredTaxAssetsGross_lbl1">Deferred Tax Assets, Gross</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl1" xlink:title="label: DeferredTaxAssetsGross to us-gaap_DeferredTaxAssetsGross_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsInventory" xlink:label="DeferredTaxAssetsInventory" xlink:title="DeferredTaxAssetsInventory" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsInventory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DeferredTaxAssetsInventory" xml:lang="en-US" id="us-gaap_DeferredTaxAssetsInventory">Inventory</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredTaxAssetsInventory" xlink:to="us-gaap_DeferredTaxAssetsInventory" xlink:title="label: DeferredTaxAssetsInventory to us-gaap_DeferredTaxAssetsInventory" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="DeferredTaxAssetsLiabilitiesNet" xlink:title="DeferredTaxAssetsLiabilitiesNet" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_DeferredTaxAssetsLiabilitiesNet" xml:lang="en-US" id="us-gaap_DeferredTaxAssetsLiabilitiesNet">Net deferred tax assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:title="label: DeferredTaxAssetsLiabilitiesNet to us-gaap_DeferredTaxAssetsLiabilitiesNet" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl1" xml:lang="en-US" id="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl1">Deferred Tax Assets, Net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl1" xlink:title="label: DeferredTaxAssetsLiabilitiesNet to us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="DeferredTaxAssetsNet" xlink:title="DeferredTaxAssetsNet" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_DeferredTaxAssetsNet" xml:lang="en-US" id="us-gaap_DeferredTaxAssetsNet">Total deferred tax assets, net of valuation allowance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet" xlink:title="label: DeferredTaxAssetsNet to us-gaap_DeferredTaxAssetsNet" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DeferredTaxAssetsNet_lbl1" xml:lang="en-US" id="us-gaap_DeferredTaxAssetsNet_lbl1">Deferred Tax Assets, Net of Valuation Allowance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl1" xlink:title="label: DeferredTaxAssetsNet to us-gaap_DeferredTaxAssetsNet_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:label="DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:title="DeferredTaxAssetsOperatingLossCarryforwardsDomestic" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xml:lang="en-US" id="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic">Federal and state net operating loss carryforwards</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:title="label: DeferredTaxAssetsOperatingLossCarryforwardsDomestic to us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:title="DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xml:lang="en-US" id="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">Stock-based compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:title="label: DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost to us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl1" xml:lang="en-US" id="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl1">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl1" xlink:title="label: DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost to us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:label="DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:title="DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xml:lang="en-US" id="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals">Accrued expenses and other</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:title="label: DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals to us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="DeferredTaxAssetsValuationAllowance" xlink:title="DeferredTaxAssetsValuationAllowance" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_DeferredTaxAssetsValuationAllowance" xml:lang="en-US" id="us-gaap_DeferredTaxAssetsValuationAllowance">Less: valuation allowance for deferred tax assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:title="label: DeferredTaxAssetsValuationAllowance to us-gaap_DeferredTaxAssetsValuationAllowance" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DeferredTaxAssetsValuationAllowance_lbl1" xml:lang="en-US" id="us-gaap_DeferredTaxAssetsValuationAllowance_lbl1">Deferred Tax Assets, Valuation Allowance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl1" xlink:title="label: DeferredTaxAssetsValuationAllowance to us-gaap_DeferredTaxAssetsValuationAllowance_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesOther" xlink:label="DeferredTaxLiabilitiesOther" xlink:title="DeferredTaxLiabilitiesOther" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesOther" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_DeferredTaxLiabilitiesOther" xml:lang="en-US" id="us-gaap_DeferredTaxLiabilitiesOther">Other deferred tax liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredTaxLiabilitiesOther" xlink:to="us-gaap_DeferredTaxLiabilitiesOther" xlink:title="label: DeferredTaxLiabilitiesOther to us-gaap_DeferredTaxLiabilitiesOther" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesOther_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DeferredTaxLiabilitiesOther_lbl1" xml:lang="en-US" id="us-gaap_DeferredTaxLiabilitiesOther_lbl1">Deferred Tax Liabilities, Other</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredTaxLiabilitiesOther" xlink:to="us-gaap_DeferredTaxLiabilitiesOther_lbl1" xlink:title="label: DeferredTaxLiabilitiesOther to us-gaap_DeferredTaxLiabilitiesOther_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="DeferredRevenueNoncurrent" xlink:title="DeferredRevenueNoncurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DeferredRevenueNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DeferredRevenueNoncurrent" xml:lang="en-US" id="us-gaap_DeferredRevenueNoncurrent">Deferred revenue, net of current portion</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredRevenueNoncurrent" xlink:to="us-gaap_DeferredRevenueNoncurrent" xlink:title="label: DeferredRevenueNoncurrent to us-gaap_DeferredRevenueNoncurrent" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationAndAmortization" xlink:label="DepreciationAndAmortization" xlink:title="DepreciationAndAmortization" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_DepreciationAndAmortization" xml:lang="en-US" id="us-gaap_DepreciationAndAmortization">Depreciation and amortization expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DepreciationAndAmortization" xlink:to="us-gaap_DepreciationAndAmortization" xlink:title="label: DepreciationAndAmortization to us-gaap_DepreciationAndAmortization" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DepreciationAndAmortization1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DepreciationAndAmortization1" xml:lang="en-US" id="us-gaap_DepreciationAndAmortization1">Depreciation and amortization</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DepreciationAndAmortization" xlink:to="us-gaap_DepreciationAndAmortization1" xlink:title="label: DepreciationAndAmortization to us-gaap_DepreciationAndAmortization1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="EarningsPerShareDiluted" xlink:title="EarningsPerShareDiluted" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_EarningsPerShareDiluted" xml:lang="en-US" id="us-gaap_EarningsPerShareDiluted">DILUTED EARNINGS (LOSS) PER COMMON SHARE (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted" xlink:title="label: EarningsPerShareDiluted to us-gaap_EarningsPerShareDiluted" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_EarningsPerShareDiluted1" xml:lang="en-US" id="us-gaap_EarningsPerShareDiluted1">Diluted earnings per common share (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted1" xlink:title="label: EarningsPerShareDiluted to us-gaap_EarningsPerShareDiluted1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_EarningsPerShareDiluted_lbl2" xml:lang="en-US" id="us-gaap_EarningsPerShareDiluted_lbl2">Earnings Per Share, Diluted</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl2" xlink:title="label: EarningsPerShareDiluted to us-gaap_EarningsPerShareDiluted_lbl2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="AllocatedShareBasedCompensationExpense" xlink:title="AllocatedShareBasedCompensationExpense" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AllocatedShareBasedCompensationExpense" xml:lang="en-US" id="us-gaap_AllocatedShareBasedCompensationExpense">Share based compensation expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" xlink:title="label: AllocatedShareBasedCompensationExpense to us-gaap_AllocatedShareBasedCompensationExpense" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="ShareBasedCompensation" xlink:title="ShareBasedCompensation" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_ShareBasedCompensation" xml:lang="en-US" id="us-gaap_ShareBasedCompensation">Stock-based compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation" xlink:title="label: ShareBasedCompensation to us-gaap_ShareBasedCompensation" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensation1" xml:lang="en-US" id="us-gaap_ShareBasedCompensation1">Stock-based compensation expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation1" xlink:title="label: ShareBasedCompensation to us-gaap_ShareBasedCompensation1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ShareBasedCompensation2" xml:lang="en-US" id="us-gaap_ShareBasedCompensation2">Compensation expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation2" xlink:title="label: ShareBasedCompensation to us-gaap_ShareBasedCompensation2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationAbstract" xlink:label="ShareBasedCompensationAbstract" xlink:title="ShareBasedCompensationAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationAbstract" xml:lang="en-US" id="us-gaap_ShareBasedCompensationAbstract">Stock-based Compensation [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationAbstract" xlink:to="us-gaap_ShareBasedCompensationAbstract" xlink:title="label: ShareBasedCompensationAbstract to us-gaap_ShareBasedCompensationAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="FairValueOfFinancialInstrumentsPolicy" xlink:title="FairValueOfFinancialInstrumentsPolicy" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_FairValueOfFinancialInstrumentsPolicy" xml:lang="en-US" id="us-gaap_FairValueOfFinancialInstrumentsPolicy">Fair Value of Financial Instruments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueOfFinancialInstrumentsPolicy" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:title="label: FairValueOfFinancialInstrumentsPolicy to us-gaap_FairValueOfFinancialInstrumentsPolicy" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl1" xml:lang="en-US" id="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl1">Fair Value of Financial Instruments, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueOfFinancialInstrumentsPolicy" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl1" xlink:title="label: FairValueOfFinancialInstrumentsPolicy to us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfFinancingCosts" xlink:label="PaymentsOfFinancingCosts" xlink:title="PaymentsOfFinancingCosts" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PaymentsOfFinancingCosts" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_PaymentsOfFinancingCosts" xml:lang="en-US" id="us-gaap_PaymentsOfFinancingCosts">Payment of deferred financing fees</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PaymentsOfFinancingCosts" xlink:to="us-gaap_PaymentsOfFinancingCosts" xlink:title="label: PaymentsOfFinancingCosts to us-gaap_PaymentsOfFinancingCosts" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PaymentsOfFinancingCosts_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PaymentsOfFinancingCosts_lbl1" xml:lang="en-US" id="us-gaap_PaymentsOfFinancingCosts_lbl1">Payments of Financing Costs</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PaymentsOfFinancingCosts" xlink:to="us-gaap_PaymentsOfFinancingCosts_lbl1" xlink:title="label: PaymentsOfFinancingCosts to us-gaap_PaymentsOfFinancingCosts_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:title="FiniteLivedIntangibleAssetsMajorClassNameDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xml:lang="en-US" id="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:title="label: FiniteLivedIntangibleAssetsMajorClassNameDomain to us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:title="FiniteLivedIntangibleAssetsByMajorClassAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xml:lang="en-US" id="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis">Finite Lived Intangible Assets By Major Class Axis</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:title="label: FiniteLivedIntangibleAssetsByMajorClassAxis to us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="FiniteLivedIntangibleAssetsLineItems" xlink:title="FiniteLivedIntangibleAssetsLineItems" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FiniteLivedIntangibleAssetsLineItems" xml:lang="en-US" id="us-gaap_FiniteLivedIntangibleAssetsLineItems">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FiniteLivedIntangibleAssetsLineItems" xlink:to="us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:title="label: FiniteLivedIntangibleAssetsLineItems to us-gaap_FiniteLivedIntangibleAssetsLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:label="FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:title="FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xml:lang="en-US" id="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract">Estimated Aggregate Amortization Expense [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:title="label: FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract to us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="FurnitureAndFixturesMember" xlink:title="FurnitureAndFixturesMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FurnitureAndFixturesMember" xml:lang="en-US" id="us-gaap_FurnitureAndFixturesMember">Furniture and Fixtures [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember" xlink:title="label: FurnitureAndFixturesMember to us-gaap_FurnitureAndFixturesMember" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnDispositionOfAssets" xlink:label="GainLossOnDispositionOfAssets" xlink:title="GainLossOnDispositionOfAssets" />
    <link:label xlink:type="resource" xlink:label="us-gaap_GainLossOnDispositionOfAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_GainLossOnDispositionOfAssets" xml:lang="en-US" id="us-gaap_GainLossOnDispositionOfAssets">Loss on disposal of fixed assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GainLossOnDispositionOfAssets" xlink:to="us-gaap_GainLossOnDispositionOfAssets" xlink:title="label: GainLossOnDispositionOfAssets to us-gaap_GainLossOnDispositionOfAssets" />
    <link:label xlink:type="resource" xlink:label="us-gaap_GainLossOnDispositionOfAssets_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_GainLossOnDispositionOfAssets_lbl1" xml:lang="en-US" id="us-gaap_GainLossOnDispositionOfAssets_lbl1">Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber Property</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GainLossOnDispositionOfAssets" xlink:to="us-gaap_GainLossOnDispositionOfAssets_lbl1" xlink:title="label: GainLossOnDispositionOfAssets to us-gaap_GainLossOnDispositionOfAssets_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="GainsLossesOnExtinguishmentOfDebt" xlink:title="GainsLossesOnExtinguishmentOfDebt" />
    <link:label xlink:type="resource" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_GainsLossesOnExtinguishmentOfDebt" xml:lang="en-US" id="us-gaap_GainsLossesOnExtinguishmentOfDebt">Loss on extinguishment of debt</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GainsLossesOnExtinguishmentOfDebt" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:title="label: GainsLossesOnExtinguishmentOfDebt to us-gaap_GainsLossesOnExtinguishmentOfDebt" />
    <link:label xlink:type="resource" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_GainsLossesOnExtinguishmentOfDebt1" xml:lang="en-US" id="us-gaap_GainsLossesOnExtinguishmentOfDebt1">Loss on extinguishment of debt</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GainsLossesOnExtinguishmentOfDebt" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt1" xlink:title="label: GainsLossesOnExtinguishmentOfDebt to us-gaap_GainsLossesOnExtinguishmentOfDebt1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt2" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_GainsLossesOnExtinguishmentOfDebt2" xml:lang="en-US" id="us-gaap_GainsLossesOnExtinguishmentOfDebt2">Loss on extinguishment of debt</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GainsLossesOnExtinguishmentOfDebt" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt2" xlink:title="label: GainsLossesOnExtinguishmentOfDebt to us-gaap_GainsLossesOnExtinguishmentOfDebt2" />
    <link:label xlink:type="resource" xlink:label="us-gaap_GainsLossesOnExtinguishmentOfDebt3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_GainsLossesOnExtinguishmentOfDebt3" xml:lang="en-US" id="us-gaap_GainsLossesOnExtinguishmentOfDebt3">Loss on extinguishment of debt (see Note 7)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GainsLossesOnExtinguishmentOfDebt" xlink:to="us-gaap_GainsLossesOnExtinguishmentOfDebt3" xlink:title="label: GainsLossesOnExtinguishmentOfDebt to us-gaap_GainsLossesOnExtinguishmentOfDebt3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="GeneralAndAdministrativeExpense" xlink:title="GeneralAndAdministrativeExpense" />
    <link:label xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_GeneralAndAdministrativeExpense" xml:lang="en-US" id="us-gaap_GeneralAndAdministrativeExpense">General and administrative expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense" xlink:title="label: GeneralAndAdministrativeExpense to us-gaap_GeneralAndAdministrativeExpense" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:label="GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:title="GoodwillAndIntangibleAssetsGoodwillPolicy" />
    <link:label xlink:type="resource" xlink:label="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xml:lang="en-US" id="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy">Goodwill</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:to="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:title="label: GoodwillAndIntangibleAssetsGoodwillPolicy to us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" />
    <link:label xlink:type="resource" xlink:label="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_lbl1" xml:lang="en-US" id="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_lbl1">Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:to="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_lbl1" xlink:title="label: GoodwillAndIntangibleAssetsGoodwillPolicy to us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GrossProfit" xlink:label="GrossProfit" xlink:title="GrossProfit" />
    <link:label xlink:type="resource" xlink:label="us-gaap_GrossProfit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_GrossProfit" xml:lang="en-US" id="us-gaap_GrossProfit">Gross profit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GrossProfit" xlink:to="us-gaap_GrossProfit" xlink:title="label: GrossProfit to us-gaap_GrossProfit" />
    <link:label xlink:type="resource" xlink:label="us-gaap_GrossProfit_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_GrossProfit_lbl1" xml:lang="en-US" id="us-gaap_GrossProfit_lbl1">Gross Profit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GrossProfit" xlink:to="us-gaap_GrossProfit_lbl1" xlink:title="label: GrossProfit to us-gaap_GrossProfit_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:label="ImpairmentOfLongLivedAssetsHeldForUse" xlink:title="ImpairmentOfLongLivedAssetsHeldForUse" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xml:lang="en-US" id="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse">Impairment of long-lived assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ImpairmentOfLongLivedAssetsHeldForUse" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:title="label: ImpairmentOfLongLivedAssetsHeldForUse to us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl1" xml:lang="en-US" id="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl1">Impairment, Long-Lived Asset, Held-for-Use</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ImpairmentOfLongLivedAssetsHeldForUse" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl1" xlink:title="label: ImpairmentOfLongLivedAssetsHeldForUse to us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="GoodwillImpairmentLoss" xlink:title="GoodwillImpairmentLoss" />
    <link:label xlink:type="resource" xlink:label="us-gaap_GoodwillImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_GoodwillImpairmentLoss" xml:lang="en-US" id="us-gaap_GoodwillImpairmentLoss">Impairment charges related to goodwill</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GoodwillImpairmentLoss" xlink:to="us-gaap_GoodwillImpairmentLoss" xlink:title="label: GoodwillImpairmentLoss to us-gaap_GoodwillImpairmentLoss" />
    <link:label xlink:type="resource" xlink:label="us-gaap_GoodwillImpairmentLoss_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_GoodwillImpairmentLoss_lbl1" xml:lang="en-US" id="us-gaap_GoodwillImpairmentLoss_lbl1">Goodwill, Impairment Loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GoodwillImpairmentLoss" xlink:to="us-gaap_GoodwillImpairmentLoss_lbl1" xlink:title="label: GoodwillImpairmentLoss to us-gaap_GoodwillImpairmentLoss_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract" xlink:label="IncomeStatementAbstract" xlink:title="IncomeStatementAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncomeStatementAbstract" xml:lang="en-US" id="us-gaap_IncomeStatementAbstract">CONSOLIDATED STATEMENTS OF OPERATIONS [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract" xlink:title="label: IncomeStatementAbstract to us-gaap_IncomeStatementAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="IncomeTaxDisclosureTextBlock" xlink:title="IncomeTaxDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncomeTaxDisclosureTextBlock" xml:lang="en-US" id="us-gaap_IncomeTaxDisclosureTextBlock">INCOME TAXES</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" xlink:title="label: IncomeTaxDisclosureTextBlock to us-gaap_IncomeTaxDisclosureTextBlock" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="IncomeTaxPolicyTextBlock" xlink:title="IncomeTaxPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_IncomeTaxPolicyTextBlock" xml:lang="en-US" id="us-gaap_IncomeTaxPolicyTextBlock">Income Taxes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" xlink:title="label: IncomeTaxPolicyTextBlock to us-gaap_IncomeTaxPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncomeTaxPolicyTextBlock_lbl1" xml:lang="en-US" id="us-gaap_IncomeTaxPolicyTextBlock_lbl1">Income Tax, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl1" xlink:title="label: IncomeTaxPolicyTextBlock to us-gaap_IncomeTaxPolicyTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:title="IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xml:lang="en-US" id="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate">Tax provision (benefit) at U.S. Federal statutory rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:title="label: IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate to us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:label="IncomeTaxReconciliationNondeductibleExpense" xlink:title="IncomeTaxReconciliationNondeductibleExpense" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncomeTaxReconciliationNondeductibleExpense" xml:lang="en-US" id="us-gaap_IncomeTaxReconciliationNondeductibleExpense">Non-deductible executive compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeTaxReconciliationNondeductibleExpense" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:title="label: IncomeTaxReconciliationNondeductibleExpense to us-gaap_IncomeTaxReconciliationNondeductibleExpense" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:label="IncomeTaxReconciliationOtherAdjustments" xlink:title="IncomeTaxReconciliationOtherAdjustments" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_IncomeTaxReconciliationOtherAdjustments" xml:lang="en-US" id="us-gaap_IncomeTaxReconciliationOtherAdjustments">Other</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeTaxReconciliationOtherAdjustments" xlink:to="us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:title="label: IncomeTaxReconciliationOtherAdjustments to us-gaap_IncomeTaxReconciliationOtherAdjustments" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncomeTaxReconciliationOtherAdjustments_lbl1" xml:lang="en-US" id="us-gaap_IncomeTaxReconciliationOtherAdjustments_lbl1">Effective Income Tax Rate Reconciliation, Other Adjustments, Amount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeTaxReconciliationOtherAdjustments" xlink:to="us-gaap_IncomeTaxReconciliationOtherAdjustments_lbl1" xlink:title="label: IncomeTaxReconciliationOtherAdjustments to us-gaap_IncomeTaxReconciliationOtherAdjustments_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:title="IncomeTaxReconciliationStateAndLocalIncomeTaxes" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xml:lang="en-US" id="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes">State taxes, net of federal benefit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:title="label: IncomeTaxReconciliationStateAndLocalIncomeTaxes to us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="IntangibleAssetsNetExcludingGoodwill" xlink:title="IntangibleAssetsNetExcludingGoodwill" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IntangibleAssetsNetExcludingGoodwill" xml:lang="en-US" id="us-gaap_IntangibleAssetsNetExcludingGoodwill">Intangible assets, net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IntangibleAssetsNetExcludingGoodwill" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:title="label: IntangibleAssetsNetExcludingGoodwill to us-gaap_IntangibleAssetsNetExcludingGoodwill" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="FiniteLivedIntangibleAssetsGross" xlink:title="FiniteLivedIntangibleAssetsGross" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FiniteLivedIntangibleAssetsGross" xml:lang="en-US" id="us-gaap_FiniteLivedIntangibleAssetsGross">Cost</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FiniteLivedIntangibleAssetsGross" xlink:to="us-gaap_FiniteLivedIntangibleAssetsGross" xlink:title="label: FiniteLivedIntangibleAssetsGross to us-gaap_FiniteLivedIntangibleAssetsGross" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="FiniteLivedIntangibleAssetsNet" xlink:title="FiniteLivedIntangibleAssetsNet" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FiniteLivedIntangibleAssetsNet" xml:lang="en-US" id="us-gaap_FiniteLivedIntangibleAssetsNet">Net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FiniteLivedIntangibleAssetsNet" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNet" xlink:title="label: FiniteLivedIntangibleAssetsNet to us-gaap_FiniteLivedIntangibleAssetsNet" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:label="FiniteLivedIntangibleAssetsNetAbstract" xlink:title="FiniteLivedIntangibleAssetsNetAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xml:lang="en-US" id="us-gaap_FiniteLivedIntangibleAssetsNetAbstract">Finite-Lived Intangible Assets, Net [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FiniteLivedIntangibleAssetsNetAbstract" xlink:to="us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:title="label: FiniteLivedIntangibleAssetsNetAbstract to us-gaap_FiniteLivedIntangibleAssetsNetAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Goodwill" xlink:label="Goodwill" xlink:title="Goodwill" />
    <link:label xlink:type="resource" xlink:label="us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_Goodwill" xml:lang="en-US" id="us-gaap_Goodwill">Goodwill</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Goodwill" xlink:to="us-gaap_Goodwill" xlink:title="label: Goodwill to us-gaap_Goodwill" />
    <link:label xlink:type="resource" xlink:label="us-gaap_Goodwill1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_Goodwill1" xml:lang="en-US" id="us-gaap_Goodwill1">Goodwill</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Goodwill" xlink:to="us-gaap_Goodwill1" xlink:title="label: Goodwill to us-gaap_Goodwill1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryFinishedGoods" xlink:label="InventoryFinishedGoods" xlink:title="InventoryFinishedGoods" />
    <link:label xlink:type="resource" xlink:label="us-gaap_InventoryFinishedGoods" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_InventoryFinishedGoods" xml:lang="en-US" id="us-gaap_InventoryFinishedGoods">Finished goods</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InventoryFinishedGoods" xlink:to="us-gaap_InventoryFinishedGoods" xlink:title="label: InventoryFinishedGoods to us-gaap_InventoryFinishedGoods" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNet" xlink:label="InventoryNet" xlink:title="InventoryNet" />
    <link:label xlink:type="resource" xlink:label="us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_InventoryNet" xml:lang="en-US" id="us-gaap_InventoryNet">Inventories</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InventoryNet" xlink:to="us-gaap_InventoryNet" xlink:title="label: InventoryNet to us-gaap_InventoryNet" />
    <link:label xlink:type="resource" xlink:label="us-gaap_InventoryNet1" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_InventoryNet1" xml:lang="en-US" id="us-gaap_InventoryNet1">Total inventories</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InventoryNet" xlink:to="us-gaap_InventoryNet1" xlink:title="label: InventoryNet to us-gaap_InventoryNet1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_InventoryNet_lbl2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_InventoryNet_lbl2" xml:lang="en-US" id="us-gaap_InventoryNet_lbl2">Inventory, Net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InventoryNet" xlink:to="us-gaap_InventoryNet_lbl2" xlink:title="label: InventoryNet to us-gaap_InventoryNet_lbl2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryRawMaterials" xlink:label="InventoryRawMaterials" xlink:title="InventoryRawMaterials" />
    <link:label xlink:type="resource" xlink:label="us-gaap_InventoryRawMaterials" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_InventoryRawMaterials" xml:lang="en-US" id="us-gaap_InventoryRawMaterials">Raw materials</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InventoryRawMaterials" xlink:to="us-gaap_InventoryRawMaterials" xlink:title="label: InventoryRawMaterials to us-gaap_InventoryRawMaterials" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryWorkInProcess" xlink:label="InventoryWorkInProcess" xlink:title="InventoryWorkInProcess" />
    <link:label xlink:type="resource" xlink:label="us-gaap_InventoryWorkInProcess" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_InventoryWorkInProcess" xml:lang="en-US" id="us-gaap_InventoryWorkInProcess">Work-in-process</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InventoryWorkInProcess" xlink:to="us-gaap_InventoryWorkInProcess" xlink:title="label: InventoryWorkInProcess to us-gaap_InventoryWorkInProcess" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="InventoryPolicyTextBlock" xlink:title="InventoryPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_InventoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_InventoryPolicyTextBlock" xml:lang="en-US" id="us-gaap_InventoryPolicyTextBlock">Inventories</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InventoryPolicyTextBlock" xlink:to="us-gaap_InventoryPolicyTextBlock" xlink:title="label: InventoryPolicyTextBlock to us-gaap_InventoryPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_InventoryPolicyTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_InventoryPolicyTextBlock_lbl1" xml:lang="en-US" id="us-gaap_InventoryPolicyTextBlock_lbl1">Inventory, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InventoryPolicyTextBlock" xlink:to="us-gaap_InventoryPolicyTextBlock_lbl1" xlink:title="label: InventoryPolicyTextBlock to us-gaap_InventoryPolicyTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LandMember" xlink:label="LandMember" xlink:title="LandMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LandMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LandMember" xml:lang="en-US" id="us-gaap_LandMember">Land [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LandMember" xlink:to="us-gaap_LandMember" xlink:title="label: LandMember to us-gaap_LandMember" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="LeaseholdImprovementsMember" xlink:title="LeaseholdImprovementsMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LeaseholdImprovementsMember" xml:lang="en-US" id="us-gaap_LeaseholdImprovementsMember">Leasehold Improvements [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember" xlink:title="label: LeaseholdImprovementsMember to us-gaap_LeaseholdImprovementsMember" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="Liabilities" xlink:title="Liabilities" />
    <link:label xlink:type="resource" xlink:label="us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_Liabilities" xml:lang="en-US" id="us-gaap_Liabilities">TOTAL LIABILITIES</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Liabilities" xlink:to="us-gaap_Liabilities" xlink:title="label: Liabilities to us-gaap_Liabilities" />
    <link:label xlink:type="resource" xlink:label="us-gaap_Liabilities_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_Liabilities_lbl1" xml:lang="en-US" id="us-gaap_Liabilities_lbl1">Liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Liabilities" xlink:to="us-gaap_Liabilities_lbl1" xlink:title="label: Liabilities to us-gaap_Liabilities_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="LiabilitiesAndStockholdersEquity" xlink:title="LiabilitiesAndStockholdersEquity" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_LiabilitiesAndStockholdersEquity" xml:lang="en-US" id="us-gaap_LiabilitiesAndStockholdersEquity">TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" xlink:title="label: LiabilitiesAndStockholdersEquity to us-gaap_LiabilitiesAndStockholdersEquity" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LiabilitiesAndStockholdersEquity_lbl1" xml:lang="en-US" id="us-gaap_LiabilitiesAndStockholdersEquity_lbl1">Liabilities and Equity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl1" xlink:title="label: LiabilitiesAndStockholdersEquity to us-gaap_LiabilitiesAndStockholdersEquity_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="LiabilitiesAndStockholdersEquityAbstract" xlink:title="LiabilitiesAndStockholdersEquityAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xml:lang="en-US" id="us-gaap_LiabilitiesAndStockholdersEquityAbstract">LIABILITIES AND STOCKHOLDERS' EQUITY</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:title="label: LiabilitiesAndStockholdersEquityAbstract to us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="LineOfCreditFacilityLenderDomain" xlink:title="LineOfCreditFacilityLenderDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LineOfCreditFacilityLenderDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LineOfCreditFacilityLenderDomain" xml:lang="en-US" id="us-gaap_LineOfCreditFacilityLenderDomain">Line of Credit Facility, Lender [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LineOfCreditFacilityLenderDomain" xlink:to="us-gaap_LineOfCreditFacilityLenderDomain" xlink:title="label: LineOfCreditFacilityLenderDomain to us-gaap_LineOfCreditFacilityLenderDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="LineOfCreditFacilityMaximumBorrowingCapacity" xlink:title="LineOfCreditFacilityMaximumBorrowingCapacity" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xml:lang="en-US" id="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">Aggregate principal amount revolving credit facility</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:title="label: LineOfCreditFacilityMaximumBorrowingCapacity to us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityAxis" xlink:label="LineOfCreditFacilityAxis" xlink:title="LineOfCreditFacilityAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LineOfCreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LineOfCreditFacilityAxis" xml:lang="en-US" id="us-gaap_LineOfCreditFacilityAxis">Lender Name [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LineOfCreditFacilityAxis" xlink:to="us-gaap_LineOfCreditFacilityAxis" xlink:title="label: LineOfCreditFacilityAxis to us-gaap_LineOfCreditFacilityAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingenciesLineItems" xlink:label="LossContingenciesLineItems" xlink:title="LossContingenciesLineItems" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LossContingenciesLineItems" xml:lang="en-US" id="us-gaap_LossContingenciesLineItems">Contingencies [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LossContingenciesLineItems" xlink:to="us-gaap_LossContingenciesLineItems" xlink:title="label: LossContingenciesLineItems to us-gaap_LossContingenciesLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingenciesTable" xlink:label="LossContingenciesTable" xlink:title="LossContingenciesTable" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LossContingenciesTable" xml:lang="en-US" id="us-gaap_LossContingenciesTable">Loss Contingencies [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LossContingenciesTable" xlink:to="us-gaap_LossContingenciesTable" xlink:title="label: LossContingenciesTable to us-gaap_LossContingenciesTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ManufacturingFacilityMember" xlink:label="ManufacturingFacilityMember" xlink:title="ManufacturingFacilityMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ManufacturingFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ManufacturingFacilityMember" xml:lang="en-US" id="us-gaap_ManufacturingFacilityMember">Manufacturing and Laboratory Equipment [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ManufacturingFacilityMember" xlink:to="us-gaap_ManufacturingFacilityMember" xlink:title="label: ManufacturingFacilityMember to us-gaap_ManufacturingFacilityMember" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="RelatedPartyTransactionsByRelatedPartyAxis" xlink:title="RelatedPartyTransactionsByRelatedPartyAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xml:lang="en-US" id="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis">Related and Nonrelated Parties [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:title="label: RelatedPartyTransactionsByRelatedPartyAxis to us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="NetCashProvidedByUsedInFinancingActivities" xlink:title="NetCashProvidedByUsedInFinancingActivities" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_NetCashProvidedByUsedInFinancingActivities" xml:lang="en-US" id="us-gaap_NetCashProvidedByUsedInFinancingActivities">Net cash (used in) provided by financing activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:title="label: NetCashProvidedByUsedInFinancingActivities to us-gaap_NetCashProvidedByUsedInFinancingActivities" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl1" xml:lang="en-US" id="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl1">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl1" xlink:title="label: NetCashProvidedByUsedInFinancingActivities to us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:title="NetCashProvidedByUsedInFinancingActivitiesAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xml:lang="en-US" id="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">CASH FLOWS FROM FINANCING ACTIVITIES:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:title="label: NetCashProvidedByUsedInFinancingActivitiesAbstract to us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="NetCashProvidedByUsedInInvestingActivities" xlink:title="NetCashProvidedByUsedInInvestingActivities" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_NetCashProvidedByUsedInInvestingActivities" xml:lang="en-US" id="us-gaap_NetCashProvidedByUsedInInvestingActivities">Net cash used in investing activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:title="label: NetCashProvidedByUsedInInvestingActivities to us-gaap_NetCashProvidedByUsedInInvestingActivities" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl1" xml:lang="en-US" id="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl1">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl1" xlink:title="label: NetCashProvidedByUsedInInvestingActivities to us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:title="NetCashProvidedByUsedInInvestingActivitiesAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xml:lang="en-US" id="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">CASH FLOWS FROM INVESTING ACTIVITIES:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:title="label: NetCashProvidedByUsedInInvestingActivitiesAbstract to us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="NetCashProvidedByUsedInOperatingActivities" xlink:title="NetCashProvidedByUsedInOperatingActivities" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_NetCashProvidedByUsedInOperatingActivities" xml:lang="en-US" id="us-gaap_NetCashProvidedByUsedInOperatingActivities">Net cash provided by (used in) operating activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:title="label: NetCashProvidedByUsedInOperatingActivities to us-gaap_NetCashProvidedByUsedInOperatingActivities" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl1" xml:lang="en-US" id="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl1">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl1" xlink:title="label: NetCashProvidedByUsedInOperatingActivities to us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:title="NetCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US" id="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">CASH FLOWS FROM OPERATING ACTIVITIES:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:title="label: NetCashProvidedByUsedInOperatingActivitiesAbstract to us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="NetIncomeLoss" xlink:title="NetIncomeLoss" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_NetIncomeLoss" xml:lang="en-US" id="us-gaap_NetIncomeLoss">Net income (loss)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss" xlink:title="label: NetIncomeLoss to us-gaap_NetIncomeLoss" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss1" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_NetIncomeLoss1" xml:lang="en-US" id="us-gaap_NetIncomeLoss1">NET INCOME (LOSS)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss1" xlink:title="label: NetIncomeLoss to us-gaap_NetIncomeLoss1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_NetIncomeLoss2" xml:lang="en-US" id="us-gaap_NetIncomeLoss2">Net income available to common stockholders (numerator)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss2" xlink:title="label: NetIncomeLoss to us-gaap_NetIncomeLoss2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="NonoperatingIncomeExpense" xlink:title="NonoperatingIncomeExpense" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_NonoperatingIncomeExpense" xml:lang="en-US" id="us-gaap_NonoperatingIncomeExpense">Other expense, net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense" xlink:title="label: NonoperatingIncomeExpense to us-gaap_NonoperatingIncomeExpense" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NonoperatingIncomeExpense1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_NonoperatingIncomeExpense1" xml:lang="en-US" id="us-gaap_NonoperatingIncomeExpense1">Other expense, net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense1" xlink:title="label: NonoperatingIncomeExpense to us-gaap_NonoperatingIncomeExpense1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="NonoperatingIncomeExpenseAbstract" xlink:title="NonoperatingIncomeExpenseAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_NonoperatingIncomeExpenseAbstract" xml:lang="en-US" id="us-gaap_NonoperatingIncomeExpenseAbstract">OTHER INCOME (EXPENSE):</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:title="label: NonoperatingIncomeExpenseAbstract to us-gaap_NonoperatingIncomeExpenseAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketingAndAdvertisingExpense" xlink:label="MarketingAndAdvertisingExpense" xlink:title="MarketingAndAdvertisingExpense" />
    <link:label xlink:type="resource" xlink:label="us-gaap_MarketingAndAdvertisingExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_MarketingAndAdvertisingExpense" xml:lang="en-US" id="us-gaap_MarketingAndAdvertisingExpense">Advertising and marketing expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MarketingAndAdvertisingExpense" xlink:to="us-gaap_MarketingAndAdvertisingExpense" xlink:title="label: MarketingAndAdvertisingExpense to us-gaap_MarketingAndAdvertisingExpense" />
    <link:label xlink:type="resource" xlink:label="us-gaap_MarketingAndAdvertisingExpense_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_MarketingAndAdvertisingExpense_lbl1" xml:lang="en-US" id="us-gaap_MarketingAndAdvertisingExpense_lbl1">Marketing and Advertising Expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MarketingAndAdvertisingExpense" xlink:to="us-gaap_MarketingAndAdvertisingExpense_lbl1" xlink:title="label: MarketingAndAdvertisingExpense to us-gaap_MarketingAndAdvertisingExpense_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketingAndAdvertisingExpenseAbstract" xlink:label="MarketingAndAdvertisingExpenseAbstract" xlink:title="MarketingAndAdvertisingExpenseAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_MarketingAndAdvertisingExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_MarketingAndAdvertisingExpenseAbstract" xml:lang="en-US" id="us-gaap_MarketingAndAdvertisingExpenseAbstract">Advertising and Marketing Expenses [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MarketingAndAdvertisingExpenseAbstract" xlink:to="us-gaap_MarketingAndAdvertisingExpenseAbstract" xlink:title="label: MarketingAndAdvertisingExpenseAbstract to us-gaap_MarketingAndAdvertisingExpenseAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NotesPayableAbstract" xlink:label="NotesPayableAbstract" xlink:title="NotesPayableAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NotesPayableAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_NotesPayableAbstract" xml:lang="en-US" id="us-gaap_NotesPayableAbstract">Senior Notes Payable [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NotesPayableAbstract" xlink:to="us-gaap_NotesPayableAbstract" xlink:title="label: NotesPayableAbstract to us-gaap_NotesPayableAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OfficeEquipmentMember" xlink:label="OfficeEquipmentMember" xlink:title="OfficeEquipmentMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OfficeEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OfficeEquipmentMember" xml:lang="en-US" id="us-gaap_OfficeEquipmentMember">Office Equipment and Computer Software [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OfficeEquipmentMember" xlink:to="us-gaap_OfficeEquipmentMember" xlink:title="label: OfficeEquipmentMember to us-gaap_OfficeEquipmentMember" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="OperatingLossCarryforwards" xlink:title="OperatingLossCarryforwards" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OperatingLossCarryforwards" xml:lang="en-US" id="us-gaap_OperatingLossCarryforwards">Net operating loss carryforwards</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards" xlink:title="label: OperatingLossCarryforwards to us-gaap_OperatingLossCarryforwards" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="OperatingIncomeLoss" xlink:title="OperatingIncomeLoss" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_OperatingIncomeLoss" xml:lang="en-US" id="us-gaap_OperatingIncomeLoss">INCOME (LOSS) FROM OPERATIONS</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss" xlink:title="label: OperatingIncomeLoss to us-gaap_OperatingIncomeLoss" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OperatingIncomeLoss_lbl1" xml:lang="en-US" id="us-gaap_OperatingIncomeLoss_lbl1">Operating Income (Loss)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl1" xlink:title="label: OperatingIncomeLoss to us-gaap_OperatingIncomeLoss_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:title="OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xml:lang="en-US" id="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">ORGANIZATION AND BUSINESS</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:title="label: OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock to us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="OtherNonoperatingIncomeExpense" xlink:title="OtherNonoperatingIncomeExpense" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OtherNonoperatingIncomeExpense" xml:lang="en-US" id="us-gaap_OtherNonoperatingIncomeExpense">Other expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" xlink:title="label: OtherNonoperatingIncomeExpense to us-gaap_OtherNonoperatingIncomeExpense" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:label="PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:title="PensionAndOtherPostretirementBenefitsDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xml:lang="en-US" id="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock">OTHER EMPLOYEE BENEFITS</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:title="label: PensionAndOtherPostretirementBenefitsDisclosureTextBlock to us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_lbl1" xml:lang="en-US" id="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_lbl1">Retirement Benefits [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_lbl1" xlink:title="label: PensionAndOtherPostretirementBenefitsDisclosureTextBlock to us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockCapitalSharesReservedForFutureIssuance" xlink:label="PreferredStockCapitalSharesReservedForFutureIssuance" xlink:title="PreferredStockCapitalSharesReservedForFutureIssuance" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PreferredStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_PreferredStockCapitalSharesReservedForFutureIssuance" xml:lang="en-US" id="us-gaap_PreferredStockCapitalSharesReservedForFutureIssuance">Preferred stock, shares authorized (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreferredStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_PreferredStockCapitalSharesReservedForFutureIssuance" xlink:title="label: PreferredStockCapitalSharesReservedForFutureIssuance to us-gaap_PreferredStockCapitalSharesReservedForFutureIssuance" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PreferredStockCapitalSharesReservedForFutureIssuance_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PreferredStockCapitalSharesReservedForFutureIssuance_lbl1" xml:lang="en-US" id="us-gaap_PreferredStockCapitalSharesReservedForFutureIssuance_lbl1">Preferred Stock, Capital Shares Reserved for Future Issuance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreferredStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_PreferredStockCapitalSharesReservedForFutureIssuance_lbl1" xlink:title="label: PreferredStockCapitalSharesReservedForFutureIssuance to us-gaap_PreferredStockCapitalSharesReservedForFutureIssuance_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="PreferredStockSharesAuthorized" xlink:title="PreferredStockSharesAuthorized" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PreferredStockSharesAuthorized" xml:lang="en-US" id="us-gaap_PreferredStockSharesAuthorized">Preferred stock, shares authorized (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized" xlink:title="label: PreferredStockSharesAuthorized to us-gaap_PreferredStockSharesAuthorized" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="PreferredStockSharesIssued" xlink:title="PreferredStockSharesIssued" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PreferredStockSharesIssued" xml:lang="en-US" id="us-gaap_PreferredStockSharesIssued">Preferred stock, shares issued (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued" xlink:title="label: PreferredStockSharesIssued to us-gaap_PreferredStockSharesIssued" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="PreferredStockSharesOutstanding" xlink:title="PreferredStockSharesOutstanding" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_PreferredStockSharesOutstanding" xml:lang="en-US" id="us-gaap_PreferredStockSharesOutstanding">Preferred stock, outstanding (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding" xlink:title="label: PreferredStockSharesOutstanding to us-gaap_PreferredStockSharesOutstanding" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PreferredStockSharesOutstanding1" xml:lang="en-US" id="us-gaap_PreferredStockSharesOutstanding1">Preferred stock, shares outstanding (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding1" xlink:title="label: PreferredStockSharesOutstanding to us-gaap_PreferredStockSharesOutstanding1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="PreferredStockParOrStatedValuePerShare" xlink:title="PreferredStockParOrStatedValuePerShare" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_PreferredStockParOrStatedValuePerShare" xml:lang="en-US" id="us-gaap_PreferredStockParOrStatedValuePerShare">Preferred stock, par value (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:title="label: PreferredStockParOrStatedValuePerShare to us-gaap_PreferredStockParOrStatedValuePerShare" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PreferredStockParOrStatedValuePerShare1" xml:lang="en-US" id="us-gaap_PreferredStockParOrStatedValuePerShare1">Preferred stock, par value (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare1" xlink:title="label: PreferredStockParOrStatedValuePerShare to us-gaap_PreferredStockParOrStatedValuePerShare1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="ProceedsFromIssuanceOfCommonStock" xlink:title="ProceedsFromIssuanceOfCommonStock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ProceedsFromIssuanceOfCommonStock" xml:lang="en-US" id="us-gaap_ProceedsFromIssuanceOfCommonStock">Proceeds from issuance of common stock, net of offering expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:title="label: ProceedsFromIssuanceOfCommonStock to us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ProceedsFromIssuanceOfCommonStock1" xml:lang="en-US" id="us-gaap_ProceedsFromIssuanceOfCommonStock1">Proceeds from issuance of common stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock1" xlink:title="label: ProceedsFromIssuanceOfCommonStock to us-gaap_ProceedsFromIssuanceOfCommonStock1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquityAbstract" xlink:label="ProceedsFromIssuanceOrSaleOfEquityAbstract" xlink:title="ProceedsFromIssuanceOrSaleOfEquityAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ProceedsFromIssuanceOrSaleOfEquityAbstract" xml:lang="en-US" id="us-gaap_ProceedsFromIssuanceOrSaleOfEquityAbstract">Organization and Business [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromIssuanceOrSaleOfEquityAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquityAbstract" xlink:title="label: ProceedsFromIssuanceOrSaleOfEquityAbstract to us-gaap_ProceedsFromIssuanceOrSaleOfEquityAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquityAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ProceedsFromIssuanceOrSaleOfEquityAbstract_lbl1" xml:lang="en-US" id="us-gaap_ProceedsFromIssuanceOrSaleOfEquityAbstract_lbl1">Proceeds from Issuance or Sale of Equity [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromIssuanceOrSaleOfEquityAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquityAbstract_lbl1" xlink:title="label: ProceedsFromIssuanceOrSaleOfEquityAbstract to us-gaap_ProceedsFromIssuanceOrSaleOfEquityAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="ProceedsFromNotesPayable" xlink:title="ProceedsFromNotesPayable" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ProceedsFromNotesPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ProceedsFromNotesPayable" xml:lang="en-US" id="us-gaap_ProceedsFromNotesPayable">Proceeds from issuance of note payable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromNotesPayable" xlink:to="us-gaap_ProceedsFromNotesPayable" xlink:title="label: ProceedsFromNotesPayable to us-gaap_ProceedsFromNotesPayable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="ProceedsFromStockOptionsExercised" xlink:title="ProceedsFromStockOptionsExercised" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ProceedsFromStockOptionsExercised" xml:lang="en-US" id="us-gaap_ProceedsFromStockOptionsExercised">Net proceeds from the exercise of stock options</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" xlink:title="label: ProceedsFromStockOptionsExercised to us-gaap_ProceedsFromStockOptionsExercised" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ProceedsFromStockOptionsExercised1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ProceedsFromStockOptionsExercised1" xml:lang="en-US" id="us-gaap_ProceedsFromStockOptionsExercised1">Aggregate exercise proceeds</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised1" xlink:title="label: ProceedsFromStockOptionsExercised to us-gaap_ProceedsFromStockOptionsExercised1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ProceedsFromStockOptionsExercised2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_ProceedsFromStockOptionsExercised2" xml:lang="en-US" id="us-gaap_ProceedsFromStockOptionsExercised2">Net proceeds from stock options exercised</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised2" xlink:title="label: ProceedsFromStockOptionsExercised to us-gaap_ProceedsFromStockOptionsExercised2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="PropertyPlantAndEquipmentGross" xlink:title="PropertyPlantAndEquipmentGross" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PropertyPlantAndEquipmentGross" xml:lang="en-US" id="us-gaap_PropertyPlantAndEquipmentGross">Property and equipment, gross</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" xlink:title="label: PropertyPlantAndEquipmentGross to us-gaap_PropertyPlantAndEquipmentGross" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="PropertyPlantAndEquipmentNet" xlink:title="PropertyPlantAndEquipmentNet" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_PropertyPlantAndEquipmentNet" xml:lang="en-US" id="us-gaap_PropertyPlantAndEquipmentNet">Total property and equipment, net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" xlink:title="label: PropertyPlantAndEquipmentNet to us-gaap_PropertyPlantAndEquipmentNet" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PropertyPlantAndEquipmentNet1" xml:lang="en-US" id="us-gaap_PropertyPlantAndEquipmentNet1">Property and equipment, net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet1" xlink:title="label: PropertyPlantAndEquipmentNet to us-gaap_PropertyPlantAndEquipmentNet1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="PropertyPlantAndEquipmentAbstract" xlink:title="PropertyPlantAndEquipmentAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PropertyPlantAndEquipmentAbstract" xml:lang="en-US" id="us-gaap_PropertyPlantAndEquipmentAbstract">PROPERTY AND EQUIPMENT [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:title="label: PropertyPlantAndEquipmentAbstract to us-gaap_PropertyPlantAndEquipmentAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_PropertyPlantAndEquipmentAbstract1" xml:lang="en-US" id="us-gaap_PropertyPlantAndEquipmentAbstract1">Property and Equipment [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract1" xlink:title="label: PropertyPlantAndEquipmentAbstract to us-gaap_PropertyPlantAndEquipmentAbstract1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="PropertyPlantAndEquipmentPolicyTextBlock" xlink:title="PropertyPlantAndEquipmentPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xml:lang="en-US" id="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">Property and Equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:title="label: PropertyPlantAndEquipmentPolicyTextBlock to us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl1" xml:lang="en-US" id="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl1">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl1" xlink:title="label: PropertyPlantAndEquipmentPolicyTextBlock to us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="PaymentsToAcquireIntangibleAssets" xlink:title="PaymentsToAcquireIntangibleAssets" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_PaymentsToAcquireIntangibleAssets" xml:lang="en-US" id="us-gaap_PaymentsToAcquireIntangibleAssets">Acquisition of intangible assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PaymentsToAcquireIntangibleAssets" xlink:to="us-gaap_PaymentsToAcquireIntangibleAssets" xlink:title="label: PaymentsToAcquireIntangibleAssets to us-gaap_PaymentsToAcquireIntangibleAssets" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireIntangibleAssets_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PaymentsToAcquireIntangibleAssets_lbl1" xml:lang="en-US" id="us-gaap_PaymentsToAcquireIntangibleAssets_lbl1">Payments to Acquire Intangible Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PaymentsToAcquireIntangibleAssets" xlink:to="us-gaap_PaymentsToAcquireIntangibleAssets_lbl1" xlink:title="label: PaymentsToAcquireIntangibleAssets to us-gaap_PaymentsToAcquireIntangibleAssets_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="PaymentsToAcquirePropertyPlantAndEquipment" xlink:title="PaymentsToAcquirePropertyPlantAndEquipment" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xml:lang="en-US" id="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">Purchase of property and equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:title="label: PaymentsToAcquirePropertyPlantAndEquipment to us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl1" xml:lang="en-US" id="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl1">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl1" xlink:title="label: PaymentsToAcquirePropertyPlantAndEquipment to us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReceivablesPolicyTextBlock" xlink:label="ReceivablesPolicyTextBlock" xlink:title="ReceivablesPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ReceivablesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ReceivablesPolicyTextBlock" xml:lang="en-US" id="us-gaap_ReceivablesPolicyTextBlock">Accounts Receivable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ReceivablesPolicyTextBlock" xlink:to="us-gaap_ReceivablesPolicyTextBlock" xlink:title="label: ReceivablesPolicyTextBlock to us-gaap_ReceivablesPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ReceivablesPolicyTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ReceivablesPolicyTextBlock_lbl1" xml:lang="en-US" id="us-gaap_ReceivablesPolicyTextBlock_lbl1">Receivable [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ReceivablesPolicyTextBlock" xlink:to="us-gaap_ReceivablesPolicyTextBlock_lbl1" xlink:title="label: ReceivablesPolicyTextBlock to us-gaap_ReceivablesPolicyTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="RelatedPartyDomain" xlink:title="RelatedPartyDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_RelatedPartyDomain" xml:lang="en-US" id="us-gaap_RelatedPartyDomain">Related and Nonrelated Parties [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyDomain" xlink:title="label: RelatedPartyDomain to us-gaap_RelatedPartyDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="RelatedPartyTransactionLineItems" xlink:title="RelatedPartyTransactionLineItems" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_RelatedPartyTransactionLineItems" xml:lang="en-US" id="us-gaap_RelatedPartyTransactionLineItems">Related Party Transaction [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionLineItems" xlink:title="label: RelatedPartyTransactionLineItems to us-gaap_RelatedPartyTransactionLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="RelatedPartyTransactionsDisclosureTextBlock" xlink:title="RelatedPartyTransactionsDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xml:lang="en-US" id="us-gaap_RelatedPartyTransactionsDisclosureTextBlock">RELATED PARTY TRANSACTIONS</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:title="label: RelatedPartyTransactionsDisclosureTextBlock to us-gaap_RelatedPartyTransactionsDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl1" xml:lang="en-US" id="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl1">Related Party Transactions Disclosure [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl1" xlink:title="label: RelatedPartyTransactionsDisclosureTextBlock to us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:title="ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xml:lang="en-US" id="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:title="label: ScheduleOfRelatedPartyTransactionsByRelatedPartyTable to us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfLongTermLinesOfCredit" xlink:label="RepaymentsOfLongTermLinesOfCredit" xlink:title="RepaymentsOfLongTermLinesOfCredit" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RepaymentsOfLongTermLinesOfCredit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_RepaymentsOfLongTermLinesOfCredit" xml:lang="en-US" id="us-gaap_RepaymentsOfLongTermLinesOfCredit">Repayment of revolving credit facility</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RepaymentsOfLongTermLinesOfCredit" xlink:to="us-gaap_RepaymentsOfLongTermLinesOfCredit" xlink:title="label: RepaymentsOfLongTermLinesOfCredit to us-gaap_RepaymentsOfLongTermLinesOfCredit" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RepaymentsOfLongTermLinesOfCredit_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_RepaymentsOfLongTermLinesOfCredit_lbl1" xml:lang="en-US" id="us-gaap_RepaymentsOfLongTermLinesOfCredit_lbl1">Repayments of Long-Term Lines of Credit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RepaymentsOfLongTermLinesOfCredit" xlink:to="us-gaap_RepaymentsOfLongTermLinesOfCredit_lbl1" xlink:title="label: RepaymentsOfLongTermLinesOfCredit to us-gaap_RepaymentsOfLongTermLinesOfCredit_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="RepaymentsOfNotesPayable" xlink:title="RepaymentsOfNotesPayable" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RepaymentsOfNotesPayable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_RepaymentsOfNotesPayable" xml:lang="en-US" id="us-gaap_RepaymentsOfNotesPayable">Principal payments on notes payable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RepaymentsOfNotesPayable" xlink:to="us-gaap_RepaymentsOfNotesPayable" xlink:title="label: RepaymentsOfNotesPayable to us-gaap_RepaymentsOfNotesPayable" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RepaymentsOfNotesPayable1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_RepaymentsOfNotesPayable1" xml:lang="en-US" id="us-gaap_RepaymentsOfNotesPayable1">Payment for outstanding obligations</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RepaymentsOfNotesPayable" xlink:to="us-gaap_RepaymentsOfNotesPayable1" xlink:title="label: RepaymentsOfNotesPayable to us-gaap_RepaymentsOfNotesPayable1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RepaymentsOfNotesPayable_lbl2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_RepaymentsOfNotesPayable_lbl2" xml:lang="en-US" id="us-gaap_RepaymentsOfNotesPayable_lbl2">Repayments of Notes Payable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RepaymentsOfNotesPayable" xlink:to="us-gaap_RepaymentsOfNotesPayable_lbl2" xlink:title="label: RepaymentsOfNotesPayable to us-gaap_RepaymentsOfNotesPayable_lbl2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="ResearchAndDevelopmentExpensePolicy" xlink:title="ResearchAndDevelopmentExpensePolicy" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ResearchAndDevelopmentExpensePolicy" xml:lang="en-US" id="us-gaap_ResearchAndDevelopmentExpensePolicy">Research and Development Expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:title="label: ResearchAndDevelopmentExpensePolicy to us-gaap_ResearchAndDevelopmentExpensePolicy" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="RetainedEarningsAccumulatedDeficit" xlink:title="RetainedEarningsAccumulatedDeficit" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_RetainedEarningsAccumulatedDeficit" xml:lang="en-US" id="us-gaap_RetainedEarningsAccumulatedDeficit">Accumulated deficit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:title="label: RetainedEarningsAccumulatedDeficit to us-gaap_RetainedEarningsAccumulatedDeficit" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_RetainedEarningsAccumulatedDeficit_lbl1" xml:lang="en-US" id="us-gaap_RetainedEarningsAccumulatedDeficit_lbl1">Retained Earnings (Accumulated Deficit)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl1" xlink:title="label: RetainedEarningsAccumulatedDeficit to us-gaap_RetainedEarningsAccumulatedDeficit_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="RevenueRecognitionPolicyTextBlock" xlink:title="RevenueRecognitionPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_RevenueRecognitionPolicyTextBlock" xml:lang="en-US" id="us-gaap_RevenueRecognitionPolicyTextBlock">Revenue Recognition</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RevenueRecognitionPolicyTextBlock" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:title="label: RevenueRecognitionPolicyTextBlock to us-gaap_RevenueRecognitionPolicyTextBlock" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="SaleOfStockNameOfTransactionDomain" xlink:title="SaleOfStockNameOfTransactionDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SaleOfStockNameOfTransactionDomain" xml:lang="en-US" id="us-gaap_SaleOfStockNameOfTransactionDomain">Sale of Stock [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:title="label: SaleOfStockNameOfTransactionDomain to us-gaap_SaleOfStockNameOfTransactionDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="InventoryDisclosureTextBlock" xlink:title="InventoryDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_InventoryDisclosureTextBlock" xml:lang="en-US" id="us-gaap_InventoryDisclosureTextBlock">INVENTORIES</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InventoryDisclosureTextBlock" xlink:to="us-gaap_InventoryDisclosureTextBlock" xlink:title="label: InventoryDisclosureTextBlock to us-gaap_InventoryDisclosureTextBlock" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="PropertyPlantAndEquipmentTextBlock" xlink:title="PropertyPlantAndEquipmentTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_PropertyPlantAndEquipmentTextBlock" xml:lang="en-US" id="us-gaap_PropertyPlantAndEquipmentTextBlock">Property and Equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:title="label: PropertyPlantAndEquipmentTextBlock to us-gaap_PropertyPlantAndEquipmentTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl1" xml:lang="en-US" id="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl1">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl1" xlink:title="label: PropertyPlantAndEquipmentTextBlock to us-gaap_PropertyPlantAndEquipmentTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="SegmentReportingDisclosureTextBlock" xlink:title="SegmentReportingDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SegmentReportingDisclosureTextBlock" xml:lang="en-US" id="us-gaap_SegmentReportingDisclosureTextBlock">SEGMENTS</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SegmentReportingDisclosureTextBlock" xlink:to="us-gaap_SegmentReportingDisclosureTextBlock" xlink:title="label: SegmentReportingDisclosureTextBlock to us-gaap_SegmentReportingDisclosureTextBlock" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:label="ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:title="ScheduleOfSegmentReportingInformationBySegmentTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xml:lang="en-US" id="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock">Summarized Financial Information Concerning Reportable Segments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:title="label: ScheduleOfSegmentReportingInformationBySegmentTextBlock to us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="SegmentReportingInformationLineItems" xlink:title="SegmentReportingInformationLineItems" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SegmentReportingInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SegmentReportingInformationLineItems" xml:lang="en-US" id="us-gaap_SegmentReportingInformationLineItems">Segment Reporting Information [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SegmentReportingInformationLineItems" xlink:to="us-gaap_SegmentReportingInformationLineItems" xlink:title="label: SegmentReportingInformationLineItems to us-gaap_SegmentReportingInformationLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="ScheduleOfSegmentReportingInformationBySegmentTable" xlink:title="ScheduleOfSegmentReportingInformationBySegmentTable" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xml:lang="en-US" id="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:title="label: ScheduleOfSegmentReportingInformationBySegmentTable to us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="SellingGeneralAndAdministrativeExpense" xlink:title="SellingGeneralAndAdministrativeExpense" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SellingGeneralAndAdministrativeExpense" xml:lang="en-US" id="us-gaap_SellingGeneralAndAdministrativeExpense">Selling, general and administrative</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SellingGeneralAndAdministrativeExpense" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:title="label: SellingGeneralAndAdministrativeExpense to us-gaap_SellingGeneralAndAdministrativeExpense" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_SellingGeneralAndAdministrativeExpense1" xml:lang="en-US" id="us-gaap_SellingGeneralAndAdministrativeExpense1">Consolidated selling, general and administrative expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SellingGeneralAndAdministrativeExpense" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense1" xlink:title="label: SellingGeneralAndAdministrativeExpense to us-gaap_SellingGeneralAndAdministrativeExpense1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingAndMarketingExpense" xlink:label="SellingAndMarketingExpense" xlink:title="SellingAndMarketingExpense" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SellingAndMarketingExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SellingAndMarketingExpense" xml:lang="en-US" id="us-gaap_SellingAndMarketingExpense">Selling, marketing and distribution</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SellingAndMarketingExpense" xlink:to="us-gaap_SellingAndMarketingExpense" xlink:title="label: SellingAndMarketingExpense to us-gaap_SellingAndMarketingExpense" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeniorLongTermNotes" xlink:label="SeniorLongTermNotes" xlink:title="SeniorLongTermNotes" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SeniorLongTermNotes" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_SeniorLongTermNotes" xml:lang="en-US" id="us-gaap_SeniorLongTermNotes">Senior notes payable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SeniorLongTermNotes" xlink:to="us-gaap_SeniorLongTermNotes" xlink:title="label: SeniorLongTermNotes to us-gaap_SeniorLongTermNotes" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SeniorLongTermNotes1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SeniorLongTermNotes1" xml:lang="en-US" id="us-gaap_SeniorLongTermNotes1">Senior notes payable, net of discount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SeniorLongTermNotes" xlink:to="us-gaap_SeniorLongTermNotes1" xlink:title="label: SeniorLongTermNotes to us-gaap_SeniorLongTermNotes1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">Forfeited (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl1">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">Granted (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod1">Granted (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">Granted (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl1">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">Ending balance (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber1" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber1">Beginning balance (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl2" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl2">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl2" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">Ending balance (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue1" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue1">Beginning balance (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl2" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl2">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl2" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">Vested (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod1">Vested (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl2" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl2">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl2" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">Vested (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:label="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:title="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xml:lang="en-US" id="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions">Options exercisable (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:title="label: ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions to us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_lbl1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_lbl1">Share-Based Payment Arrangement, Option, Exercise Price Range, Shares Exercisable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_lbl1" xlink:title="label: ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions to us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:title="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xml:lang="en-US" id="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain">Exercise Price Range [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:title="label: ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain to us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:title="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xml:lang="en-US" id="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">Exercise Price Range [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:title="label: ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis to us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:label="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:title="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xml:lang="en-US" id="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions">Outstanding at beginning of period (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:title="label: ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions to us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:label="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:title="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xml:lang="en-US" id="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit">Exercise price range, upper limit (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:title="label: ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit to us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">Options outstanding, aggregate intrinsic value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">Options exercisable (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl1">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">Options exercisable (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl1">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">Dividend yield</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate1">Dividend yield</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">Volatility</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate1">Volatility</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">Risk-free interest rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate1">Risk-free interest rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl2" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl2">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl2" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain">Award Type [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="label: ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain to us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems1">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:label="ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:title="ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xml:lang="en-US" id="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock">Summary of Outstanding and Exercisable Options by Price Range</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:title="label: ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock to us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xml:lang="en-US" id="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="label: ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable1" xml:lang="en-US" id="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable1">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable1" xlink:title="label: ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="SignificantAccountingPoliciesTextBlock" xlink:title="SignificantAccountingPoliciesTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SignificantAccountingPoliciesTextBlock" xml:lang="en-US" id="us-gaap_SignificantAccountingPoliciesTextBlock">SIGNIFICANT ACCOUNTING POLICIES</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:title="label: SignificantAccountingPoliciesTextBlock to us-gaap_SignificantAccountingPoliciesTextBlock" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="StateAndLocalJurisdictionMember" xlink:title="StateAndLocalJurisdictionMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StateAndLocalJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StateAndLocalJurisdictionMember" xml:lang="en-US" id="us-gaap_StateAndLocalJurisdictionMember">State [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StateAndLocalJurisdictionMember" xlink:to="us-gaap_StateAndLocalJurisdictionMember" xlink:title="label: StateAndLocalJurisdictionMember to us-gaap_StateAndLocalJurisdictionMember" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="StatementOfCashFlowsAbstract" xlink:title="StatementOfCashFlowsAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StatementOfCashFlowsAbstract" xml:lang="en-US" id="us-gaap_StatementOfCashFlowsAbstract">CONSOLIDATED STATEMENTS OF CASH FLOWS [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract" xlink:title="label: StatementOfCashFlowsAbstract to us-gaap_StatementOfCashFlowsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="StatementOfStockholdersEquityAbstract" xlink:title="StatementOfStockholdersEquityAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StatementOfStockholdersEquityAbstract" xml:lang="en-US" id="us-gaap_StatementOfStockholdersEquityAbstract">CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS EQUITY [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract" xlink:title="label: StatementOfStockholdersEquityAbstract to us-gaap_StatementOfStockholdersEquityAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:title="ShareBasedCompensationOptionAndIncentivePlansPolicy" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xml:lang="en-US" id="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">Stock-Based Compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:title="label: ShareBasedCompensationOptionAndIncentivePlansPolicy to us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="StockholdersEquityAbstract" xlink:title="StockholdersEquityAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_StockholdersEquityAbstract" xml:lang="en-US" id="us-gaap_StockholdersEquityAbstract">STOCKHOLDERS' EQUITY</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" xlink:title="label: StockholdersEquityAbstract to us-gaap_StockholdersEquityAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockholdersEquityAbstract1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_StockholdersEquityAbstract1" xml:lang="en-US" id="us-gaap_StockholdersEquityAbstract1">STOCKHOLDERS' EQUITY</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract1" xlink:title="label: StockholdersEquityAbstract to us-gaap_StockholdersEquityAbstract1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockholdersEquityAbstract_lbl2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StockholdersEquityAbstract_lbl2" xml:lang="en-US" id="us-gaap_StockholdersEquityAbstract_lbl2">Equity, Attributable to Parent [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl2" xlink:title="label: StockholdersEquityAbstract to us-gaap_StockholdersEquityAbstract_lbl2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="ClassOfWarrantOrRightOutstanding" xlink:title="ClassOfWarrantOrRightOutstanding" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ClassOfWarrantOrRightOutstanding" xml:lang="en-US" id="us-gaap_ClassOfWarrantOrRightOutstanding">Warrants outstanding (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:title="label: ClassOfWarrantOrRightOutstanding to us-gaap_ClassOfWarrantOrRightOutstanding" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ClassOfWarrantOrRightOutstanding_lbl1" xml:lang="en-US" id="us-gaap_ClassOfWarrantOrRightOutstanding_lbl1">Class of Warrant or Right, Outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_lbl1" xlink:title="label: ClassOfWarrantOrRightOutstanding to us-gaap_ClassOfWarrantOrRightOutstanding_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="StockholdersEquityNoteDisclosureTextBlock" xlink:title="StockholdersEquityNoteDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xml:lang="en-US" id="us-gaap_StockholdersEquityNoteDisclosureTextBlock">STOCKHOLDERS' EQUITY</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:title="label: StockholdersEquityNoteDisclosureTextBlock to us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:title="ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xml:lang="en-US" id="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">Warrant to purchase shares of common stock (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:title="label: ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights to us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="SubsequentEventTypeAxis" xlink:title="SubsequentEventTypeAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SubsequentEventTypeAxis" xml:lang="en-US" id="us-gaap_SubsequentEventTypeAxis">Subsequent Event Type [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis" xlink:title="label: SubsequentEventTypeAxis to us-gaap_SubsequentEventTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="SubsequentEventTypeDomain" xlink:title="SubsequentEventTypeDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SubsequentEventTypeDomain" xml:lang="en-US" id="us-gaap_SubsequentEventTypeDomain">Subsequent Event Type [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain" xlink:title="label: SubsequentEventTypeDomain to us-gaap_SubsequentEventTypeDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="SubsidiarySaleOfStockAxis" xlink:title="SubsidiarySaleOfStockAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SubsidiarySaleOfStockAxis" xml:lang="en-US" id="us-gaap_SubsidiarySaleOfStockAxis">Sale of Stock [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" xlink:title="label: SubsidiarySaleOfStockAxis to us-gaap_SubsidiarySaleOfStockAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="SupplementalCashFlowInformationAbstract" xlink:title="SupplementalCashFlowInformationAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SupplementalCashFlowInformationAbstract" xml:lang="en-US" id="us-gaap_SupplementalCashFlowInformationAbstract">SUPPLEMENTAL CASH FLOW INFORMATION [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract" xlink:title="label: SupplementalCashFlowInformationAbstract to us-gaap_SupplementalCashFlowInformationAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardValuationAllowance" xlink:label="TaxCreditCarryforwardValuationAllowance" xlink:title="TaxCreditCarryforwardValuationAllowance" />
    <link:label xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_TaxCreditCarryforwardValuationAllowance" xml:lang="en-US" id="us-gaap_TaxCreditCarryforwardValuationAllowance">Valuation allowance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TaxCreditCarryforwardValuationAllowance" xlink:to="us-gaap_TaxCreditCarryforwardValuationAllowance" xlink:title="label: TaxCreditCarryforwardValuationAllowance to us-gaap_TaxCreditCarryforwardValuationAllowance" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxesPaid" xlink:label="IncomeTaxesPaid" xlink:title="IncomeTaxesPaid" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncomeTaxesPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncomeTaxesPaid" xml:lang="en-US" id="us-gaap_IncomeTaxesPaid">Cash paid for income taxes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeTaxesPaid" xlink:to="us-gaap_IncomeTaxesPaid" xlink:title="label: IncomeTaxesPaid to us-gaap_IncomeTaxesPaid" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="AssetsCurrent" xlink:title="AssetsCurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_AssetsCurrent" xml:lang="en-US" id="us-gaap_AssetsCurrent">Total current assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AssetsCurrent" xlink:to="us-gaap_AssetsCurrent" xlink:title="label: AssetsCurrent to us-gaap_AssetsCurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AssetsCurrent_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AssetsCurrent_lbl1" xml:lang="en-US" id="us-gaap_AssetsCurrent_lbl1">Assets, Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl1" xlink:title="label: AssetsCurrent to us-gaap_AssetsCurrent_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="AssetsCurrentAbstract" xlink:title="AssetsCurrentAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AssetsCurrentAbstract" xml:lang="en-US" id="us-gaap_AssetsCurrentAbstract">Current assets:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" xlink:title="label: AssetsCurrentAbstract to us-gaap_AssetsCurrentAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="UnrecognizedTaxBenefits" xlink:title="UnrecognizedTaxBenefits" />
    <link:label xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_UnrecognizedTaxBenefits" xml:lang="en-US" id="us-gaap_UnrecognizedTaxBenefits">Unrecognized tax benefits</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="UnrecognizedTaxBenefits" xlink:to="us-gaap_UnrecognizedTaxBenefits" xlink:title="label: UnrecognizedTaxBenefits to us-gaap_UnrecognizedTaxBenefits" />
    <link:label xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_UnrecognizedTaxBenefits_lbl1" xml:lang="en-US" id="us-gaap_UnrecognizedTaxBenefits_lbl1">Unrecognized Tax Benefits</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="UnrecognizedTaxBenefits" xlink:to="us-gaap_UnrecognizedTaxBenefits_lbl1" xlink:title="label: UnrecognizedTaxBenefits to us-gaap_UnrecognizedTaxBenefits_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember" xlink:label="ValuationAllowanceOfDeferredTaxAssetsMember" xlink:title="ValuationAllowanceOfDeferredTaxAssetsMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember" xml:lang="en-US" id="us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember">Deferred Tax Asset Valuation Allowance [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ValuationAllowanceOfDeferredTaxAssetsMember" xlink:to="us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember" xlink:title="label: ValuationAllowanceOfDeferredTaxAssetsMember to us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowancesAndReservesBalance" xlink:label="ValuationAllowancesAndReservesBalance" xlink:title="ValuationAllowancesAndReservesBalance" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ValuationAllowancesAndReservesBalance" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:title="us-gaap_ValuationAllowancesAndReservesBalance" xml:lang="en-US" id="us-gaap_ValuationAllowancesAndReservesBalance">Balance at end of year</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ValuationAllowancesAndReservesBalance" xlink:to="us-gaap_ValuationAllowancesAndReservesBalance" xlink:title="label: ValuationAllowancesAndReservesBalance to us-gaap_ValuationAllowancesAndReservesBalance" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ValuationAllowancesAndReservesBalance1" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:title="us-gaap_ValuationAllowancesAndReservesBalance1" xml:lang="en-US" id="us-gaap_ValuationAllowancesAndReservesBalance1">Balance at beginning of year</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ValuationAllowancesAndReservesBalance" xlink:to="us-gaap_ValuationAllowancesAndReservesBalance1" xlink:title="label: ValuationAllowancesAndReservesBalance to us-gaap_ValuationAllowancesAndReservesBalance1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ValuationAllowancesAndReservesBalance_lbl2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ValuationAllowancesAndReservesBalance_lbl2" xml:lang="en-US" id="us-gaap_ValuationAllowancesAndReservesBalance_lbl2">SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ValuationAllowancesAndReservesBalance" xlink:to="us-gaap_ValuationAllowancesAndReservesBalance_lbl2" xlink:title="label: ValuationAllowancesAndReservesBalance to us-gaap_ValuationAllowancesAndReservesBalance_lbl2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense" xlink:label="ValuationAllowancesAndReservesChargedToCostAndExpense" xlink:title="ValuationAllowancesAndReservesChargedToCostAndExpense" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense" xml:lang="en-US" id="us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense">Charged to costs and expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ValuationAllowancesAndReservesChargedToCostAndExpense" xlink:to="us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense" xlink:title="label: ValuationAllowancesAndReservesChargedToCostAndExpense to us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts" xlink:label="ValuationAllowancesAndReservesChargedToOtherAccounts" xlink:title="ValuationAllowancesAndReservesChargedToOtherAccounts" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts" xml:lang="en-US" id="us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts">Other</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ValuationAllowancesAndReservesChargedToOtherAccounts" xlink:to="us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts" xlink:title="label: ValuationAllowancesAndReservesChargedToOtherAccounts to us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts_lbl1" xml:lang="en-US" id="us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts_lbl1">SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Other Account</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ValuationAllowancesAndReservesChargedToOtherAccounts" xlink:to="us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts_lbl1" xlink:title="label: ValuationAllowancesAndReservesChargedToOtherAccounts to us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowancesAndReservesDeductions" xlink:label="ValuationAllowancesAndReservesDeductions" xlink:title="ValuationAllowancesAndReservesDeductions" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ValuationAllowancesAndReservesDeductions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ValuationAllowancesAndReservesDeductions" xml:lang="en-US" id="us-gaap_ValuationAllowancesAndReservesDeductions">Deductions</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ValuationAllowancesAndReservesDeductions" xlink:to="us-gaap_ValuationAllowancesAndReservesDeductions" xlink:title="label: ValuationAllowancesAndReservesDeductions to us-gaap_ValuationAllowancesAndReservesDeductions" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowancesAndReservesDomain" xlink:label="ValuationAllowancesAndReservesDomain" xlink:title="ValuationAllowancesAndReservesDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ValuationAllowancesAndReservesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ValuationAllowancesAndReservesDomain" xml:lang="en-US" id="us-gaap_ValuationAllowancesAndReservesDomain">Valuation Allowances and Reserves [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ValuationAllowancesAndReservesDomain" xlink:to="us-gaap_ValuationAllowancesAndReservesDomain" xlink:title="label: ValuationAllowancesAndReservesDomain to us-gaap_ValuationAllowancesAndReservesDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:label="ValuationAllowancesAndReservesTypeAxis" xlink:title="ValuationAllowancesAndReservesTypeAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ValuationAllowancesAndReservesTypeAxis" xml:lang="en-US" id="us-gaap_ValuationAllowancesAndReservesTypeAxis">Valuation Allowances and Reserves Type [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ValuationAllowancesAndReservesTypeAxis" xlink:to="us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:title="label: ValuationAllowancesAndReservesTypeAxis to us-gaap_ValuationAllowancesAndReservesTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="WarrantMember" xlink:title="WarrantMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_WarrantMember" xml:lang="en-US" id="us-gaap_WarrantMember">Warrants [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WarrantMember" xlink:to="us-gaap_WarrantMember" xlink:title="label: WarrantMember to us-gaap_WarrantMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_WarrantMember1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_WarrantMember1" xml:lang="en-US" id="us-gaap_WarrantMember1">Warrant [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WarrantMember" xlink:to="us-gaap_WarrantMember1" xlink:title="label: WarrantMember to us-gaap_WarrantMember1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="WarrantsAndRightsOutstanding" xlink:title="WarrantsAndRightsOutstanding" />
    <link:label xlink:type="resource" xlink:label="us-gaap_WarrantsAndRightsOutstanding" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_WarrantsAndRightsOutstanding" xml:lang="en-US" id="us-gaap_WarrantsAndRightsOutstanding">Fair value of warrants</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WarrantsAndRightsOutstanding" xlink:to="us-gaap_WarrantsAndRightsOutstanding" xlink:title="label: WarrantsAndRightsOutstanding to us-gaap_WarrantsAndRightsOutstanding" />
    <link:label xlink:type="resource" xlink:label="us-gaap_WarrantsAndRightsOutstanding_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_WarrantsAndRightsOutstanding_lbl1" xml:lang="en-US" id="us-gaap_WarrantsAndRightsOutstanding_lbl1">Warrants and Rights Outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WarrantsAndRightsOutstanding" xlink:to="us-gaap_WarrantsAndRightsOutstanding_lbl1" xlink:title="label: WarrantsAndRightsOutstanding to us-gaap_WarrantsAndRightsOutstanding_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="WeightedAverageNumberOfDilutedSharesOutstanding" xlink:title="WeightedAverageNumberOfDilutedSharesOutstanding" />
    <link:label xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xml:lang="en-US" id="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">Diluted (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:title="label: WeightedAverageNumberOfDilutedSharesOutstanding to us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" />
    <link:label xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding1" xml:lang="en-US" id="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding1">Total shares - diluted (denominator) (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding1" xlink:title="label: WeightedAverageNumberOfDilutedSharesOutstanding to us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:label="WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:title="WeightedAverageNumberDilutedSharesOutstandingAdjustment" />
    <link:label xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xml:lang="en-US" id="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment">Potential shares of common stock arising from outstanding stock options, warrants and unvested RSUs (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:to="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:title="label: WeightedAverageNumberDilutedSharesOutstandingAdjustment to us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="WeightedAverageNumberOfSharesOutstandingBasic" xlink:title="WeightedAverageNumberOfSharesOutstandingBasic" />
    <link:label xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xml:lang="en-US" id="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">Basic (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:title="label: WeightedAverageNumberOfSharesOutstandingBasic to us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
    <link:label xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic1" xml:lang="en-US" id="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic1">Weighted-average number of common shares (denominator) (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic1" xlink:title="label: WeightedAverageNumberOfSharesOutstandingBasic to us-gaap_WeightedAverageNumberOfSharesOutstandingBasic1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="CommonStockMember" xlink:title="CommonStockMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CommonStockMember" xml:lang="en-US" id="us-gaap_CommonStockMember">Common Stock [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockMember" xlink:to="us-gaap_CommonStockMember" xlink:title="label: CommonStockMember to us-gaap_CommonStockMember" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="PropertyPlantAndEquipmentDisclosureTextBlock" xlink:title="PropertyPlantAndEquipmentDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xml:lang="en-US" id="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">PROPERTY AND EQUIPMENT</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:title="label: PropertyPlantAndEquipmentDisclosureTextBlock to us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="PropertyPlantAndEquipmentTypeDomain" xlink:title="PropertyPlantAndEquipmentTypeDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PropertyPlantAndEquipmentTypeDomain" xml:lang="en-US" id="us-gaap_PropertyPlantAndEquipmentTypeDomain">Long-Lived Tangible Asset [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:title="label: PropertyPlantAndEquipmentTypeDomain to us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_PropertyPlantAndEquipmentTypeDomain1" xml:lang="en-US" id="us-gaap_PropertyPlantAndEquipmentTypeDomain1">Long-Lived Tangible Asset [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain1" xlink:title="label: PropertyPlantAndEquipmentTypeDomain to us-gaap_PropertyPlantAndEquipmentTypeDomain1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BuildingAndBuildingImprovementsMember" xlink:label="BuildingAndBuildingImprovementsMember" xlink:title="BuildingAndBuildingImprovementsMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_BuildingAndBuildingImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_BuildingAndBuildingImprovementsMember" xml:lang="en-US" id="us-gaap_BuildingAndBuildingImprovementsMember">Buildings and Building Improvements [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BuildingAndBuildingImprovementsMember" xlink:to="us-gaap_BuildingAndBuildingImprovementsMember" xlink:title="label: BuildingAndBuildingImprovementsMember to us-gaap_BuildingAndBuildingImprovementsMember" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:label="PropertyPlantAndEquipmentNetAbstract" xlink:title="PropertyPlantAndEquipmentNetAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_PropertyPlantAndEquipmentNetAbstract" xml:lang="en-US" id="us-gaap_PropertyPlantAndEquipmentNetAbstract">Property, Plant and Equipment [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PropertyPlantAndEquipmentNetAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:title="label: PropertyPlantAndEquipmentNetAbstract to us-gaap_PropertyPlantAndEquipmentNetAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNetAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PropertyPlantAndEquipmentNetAbstract_lbl1" xml:lang="en-US" id="us-gaap_PropertyPlantAndEquipmentNetAbstract_lbl1">Property, Plant and Equipment, Net [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PropertyPlantAndEquipmentNetAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNetAbstract_lbl1" xlink:title="label: PropertyPlantAndEquipmentNetAbstract to us-gaap_PropertyPlantAndEquipmentNetAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="ResearchAndDevelopmentExpense" xlink:title="ResearchAndDevelopmentExpense" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ResearchAndDevelopmentExpense" xml:lang="en-US" id="us-gaap_ResearchAndDevelopmentExpense">Amount of expenses to complete studies</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense" xlink:title="label: ResearchAndDevelopmentExpense to us-gaap_ResearchAndDevelopmentExpense" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ResearchAndDevelopmentExpense1" xml:lang="en-US" id="us-gaap_ResearchAndDevelopmentExpense1">Research and development</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense1" xlink:title="label: ResearchAndDevelopmentExpense to us-gaap_ResearchAndDevelopmentExpense1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Cash" xlink:label="Cash" xlink:title="Cash" />
    <link:label xlink:type="resource" xlink:label="us-gaap_Cash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_Cash" xml:lang="en-US" id="us-gaap_Cash">Cash balance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Cash" xlink:to="us-gaap_Cash" xlink:title="label: Cash to us-gaap_Cash" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="Assets" xlink:title="Assets" />
    <link:label xlink:type="resource" xlink:label="us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_Assets" xml:lang="en-US" id="us-gaap_Assets">TOTAL ASSETS</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Assets" xlink:to="us-gaap_Assets" xlink:title="label: Assets to us-gaap_Assets" />
    <link:label xlink:type="resource" xlink:label="us-gaap_Assets1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_Assets1" xml:lang="en-US" id="us-gaap_Assets1">Total assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Assets" xlink:to="us-gaap_Assets1" xlink:title="label: Assets to us-gaap_Assets1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetAbstract" xlink:label="AccountsReceivableNetAbstract" xlink:title="AccountsReceivableNetAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AccountsReceivableNetAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AccountsReceivableNetAbstract" xml:lang="en-US" id="us-gaap_AccountsReceivableNetAbstract">Accounts Receivable [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccountsReceivableNetAbstract" xlink:to="us-gaap_AccountsReceivableNetAbstract" xlink:title="label: AccountsReceivableNetAbstract to us-gaap_AccountsReceivableNetAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:label="IntangibleAssetsDisclosureTextBlock" xlink:title="IntangibleAssetsDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IntangibleAssetsDisclosureTextBlock" xml:lang="en-US" id="us-gaap_IntangibleAssetsDisclosureTextBlock">INTANGIBLE ASSETS</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IntangibleAssetsDisclosureTextBlock" xlink:to="us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:title="label: IntangibleAssetsDisclosureTextBlock to us-gaap_IntangibleAssetsDisclosureTextBlock" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="InvestmentIncomeInterest" xlink:title="InvestmentIncomeInterest" />
    <link:label xlink:type="resource" xlink:label="us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_InvestmentIncomeInterest" xml:lang="en-US" id="us-gaap_InvestmentIncomeInterest">Interest income</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InvestmentIncomeInterest" xlink:to="us-gaap_InvestmentIncomeInterest" xlink:title="label: InvestmentIncomeInterest to us-gaap_InvestmentIncomeInterest" />
    <link:label xlink:type="resource" xlink:label="us-gaap_InvestmentIncomeInterest1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_InvestmentIncomeInterest1" xml:lang="en-US" id="us-gaap_InvestmentIncomeInterest1">Unallocated interest income</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InvestmentIncomeInterest" xlink:to="us-gaap_InvestmentIncomeInterest1" xlink:title="label: InvestmentIncomeInterest to us-gaap_InvestmentIncomeInterest1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="OtherLiabilitiesNoncurrent" xlink:title="OtherLiabilitiesNoncurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OtherLiabilitiesNoncurrent" xml:lang="en-US" id="us-gaap_OtherLiabilitiesNoncurrent">Other non-current liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherLiabilitiesNoncurrent" xlink:to="us-gaap_OtherLiabilitiesNoncurrent" xlink:title="label: OtherLiabilitiesNoncurrent to us-gaap_OtherLiabilitiesNoncurrent" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="ConcentrationRiskByBenchmarkAxis" xlink:title="ConcentrationRiskByBenchmarkAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ConcentrationRiskByBenchmarkAxis" xml:lang="en-US" id="us-gaap_ConcentrationRiskByBenchmarkAxis">Concentration Risk Benchmark [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:title="label: ConcentrationRiskByBenchmarkAxis to us-gaap_ConcentrationRiskByBenchmarkAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="ConcentrationRiskBenchmarkDomain" xlink:title="ConcentrationRiskBenchmarkDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ConcentrationRiskBenchmarkDomain" xml:lang="en-US" id="us-gaap_ConcentrationRiskBenchmarkDomain">Concentration Risk Benchmark [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:title="label: ConcentrationRiskBenchmarkDomain to us-gaap_ConcentrationRiskBenchmarkDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRisksTypesNoConcentrationPercentageAbstract" xlink:label="ConcentrationRisksTypesNoConcentrationPercentageAbstract" xlink:title="ConcentrationRisksTypesNoConcentrationPercentageAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ConcentrationRisksTypesNoConcentrationPercentageAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ConcentrationRisksTypesNoConcentrationPercentageAbstract" xml:lang="en-US" id="us-gaap_ConcentrationRisksTypesNoConcentrationPercentageAbstract">CONCENTRATIONS [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConcentrationRisksTypesNoConcentrationPercentageAbstract" xlink:to="us-gaap_ConcentrationRisksTypesNoConcentrationPercentageAbstract" xlink:title="label: ConcentrationRisksTypesNoConcentrationPercentageAbstract to us-gaap_ConcentrationRisksTypesNoConcentrationPercentageAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="IncomeTaxAuthorityDomain" xlink:title="IncomeTaxAuthorityDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncomeTaxAuthorityDomain" xml:lang="en-US" id="us-gaap_IncomeTaxAuthorityDomain">Income Tax Jurisdiction [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeTaxAuthorityDomain" xlink:to="us-gaap_IncomeTaxAuthorityDomain" xlink:title="label: IncomeTaxAuthorityDomain to us-gaap_IncomeTaxAuthorityDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromInsuranceSettlementOperatingActivities" xlink:label="ProceedsFromInsuranceSettlementOperatingActivities" xlink:title="ProceedsFromInsuranceSettlementOperatingActivities" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ProceedsFromInsuranceSettlementOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ProceedsFromInsuranceSettlementOperatingActivities" xml:lang="en-US" id="us-gaap_ProceedsFromInsuranceSettlementOperatingActivities">Proceeds on business interruption loss coverage</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProceedsFromInsuranceSettlementOperatingActivities" xlink:to="us-gaap_ProceedsFromInsuranceSettlementOperatingActivities" xlink:title="label: ProceedsFromInsuranceSettlementOperatingActivities to us-gaap_ProceedsFromInsuranceSettlementOperatingActivities" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingInformationProfitLossAbstract" xlink:label="SegmentReportingInformationProfitLossAbstract" xlink:title="SegmentReportingInformationProfitLossAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SegmentReportingInformationProfitLossAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SegmentReportingInformationProfitLossAbstract" xml:lang="en-US" id="us-gaap_SegmentReportingInformationProfitLossAbstract">Segment Reporting Information [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SegmentReportingInformationProfitLossAbstract" xlink:to="us-gaap_SegmentReportingInformationProfitLossAbstract" xlink:title="label: SegmentReportingInformationProfitLossAbstract to us-gaap_SegmentReportingInformationProfitLossAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="StatementTable" xlink:title="StatementTable" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StatementTable" xml:lang="en-US" id="us-gaap_StatementTable">Statement [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StatementTable" xlink:to="us-gaap_StatementTable" xlink:title="label: StatementTable to us-gaap_StatementTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="AntidilutiveSecuritiesNameDomain" xlink:title="AntidilutiveSecuritiesNameDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_AntidilutiveSecuritiesNameDomain" xml:lang="en-US" id="us-gaap_AntidilutiveSecuritiesNameDomain">Antidilutive Securities, Name [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:title="label: AntidilutiveSecuritiesNameDomain to us-gaap_AntidilutiveSecuritiesNameDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AntidilutiveSecuritiesNameDomain_lbl1" xml:lang="en-US" id="us-gaap_AntidilutiveSecuritiesNameDomain_lbl1">Antidilutive Securities, Name [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl1" xlink:title="label: AntidilutiveSecuritiesNameDomain to us-gaap_AntidilutiveSecuritiesNameDomain_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:label="MovementInValuationAllowancesAndReservesRollForward" xlink:title="MovementInValuationAllowancesAndReservesRollForward" />
    <link:label xlink:type="resource" xlink:label="us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_MovementInValuationAllowancesAndReservesRollForward" xml:lang="en-US" id="us-gaap_MovementInValuationAllowancesAndReservesRollForward">Valuation and Qualifying Accounts [Roll Forward]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MovementInValuationAllowancesAndReservesRollForward" xlink:to="us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:title="label: MovementInValuationAllowancesAndReservesRollForward to us-gaap_MovementInValuationAllowancesAndReservesRollForward" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract" xlink:label="AssetsAbstract" xlink:title="AssetsAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_AssetsAbstract" xml:lang="en-US" id="us-gaap_AssetsAbstract">ASSETS</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AssetsAbstract" xlink:to="us-gaap_AssetsAbstract" xlink:title="label: AssetsAbstract to us-gaap_AssetsAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AssetsAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AssetsAbstract_lbl1" xml:lang="en-US" id="us-gaap_AssetsAbstract_lbl1">Assets [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl1" xlink:title="label: AssetsAbstract to us-gaap_AssetsAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="StatementLineItems" xlink:title="StatementLineItems" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StatementLineItems" xml:lang="en-US" id="us-gaap_StatementLineItems">Statement [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StatementLineItems" xlink:to="us-gaap_StatementLineItems" xlink:title="label: StatementLineItems to us-gaap_StatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:title="ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xml:lang="en-US" id="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock">Warrants Outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:title="label: ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock to us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="ClassOfWarrantOrRightTable" xlink:title="ClassOfWarrantOrRightTable" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ClassOfWarrantOrRightTable" xml:lang="en-US" id="us-gaap_ClassOfWarrantOrRightTable">Class of Warrant or Right [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightTable" xlink:title="label: ClassOfWarrantOrRightTable to us-gaap_ClassOfWarrantOrRightTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="ClassOfWarrantOrRightAxis" xlink:title="ClassOfWarrantOrRightAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ClassOfWarrantOrRightAxis" xml:lang="en-US" id="us-gaap_ClassOfWarrantOrRightAxis">Class of Warrant or Right [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" xlink:title="label: ClassOfWarrantOrRightAxis to us-gaap_ClassOfWarrantOrRightAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="ClassOfWarrantOrRightDomain" xlink:title="ClassOfWarrantOrRightDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ClassOfWarrantOrRightDomain" xml:lang="en-US" id="us-gaap_ClassOfWarrantOrRightDomain">Class of Warrant or Right [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClassOfWarrantOrRightDomain" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" xlink:title="label: ClassOfWarrantOrRightDomain to us-gaap_ClassOfWarrantOrRightDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="OperatingLossCarryforwardsTable" xlink:title="OperatingLossCarryforwardsTable" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwardsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OperatingLossCarryforwardsTable" xml:lang="en-US" id="us-gaap_OperatingLossCarryforwardsTable">Operating Loss Carryforwards [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLossCarryforwardsTable" xlink:to="us-gaap_OperatingLossCarryforwardsTable" xlink:title="label: OperatingLossCarryforwardsTable to us-gaap_OperatingLossCarryforwardsTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="OperatingLossCarryforwardsLineItems" xlink:title="OperatingLossCarryforwardsLineItems" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OperatingLossCarryforwardsLineItems" xml:lang="en-US" id="us-gaap_OperatingLossCarryforwardsLineItems">Operating Loss Carryforwards [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwardsLineItems" xlink:title="label: OperatingLossCarryforwardsLineItems to us-gaap_OperatingLossCarryforwardsLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock" xlink:label="SummaryOfOperatingLossCarryforwardsTextBlock" xlink:title="SummaryOfOperatingLossCarryforwardsTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock" xml:lang="en-US" id="us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock">Expiration of Federal Net Operating Loss</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SummaryOfOperatingLossCarryforwardsTextBlock" xlink:to="us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock" xlink:title="label: SummaryOfOperatingLossCarryforwardsTextBlock to us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="EquityAbstract" xlink:title="EquityAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_EquityAbstract" xml:lang="en-US" id="us-gaap_EquityAbstract">STOCKHOLDERS' EQUITY [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EquityAbstract" xlink:to="us-gaap_EquityAbstract" xlink:title="label: EquityAbstract to us-gaap_EquityAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RisksAndUncertaintiesAbstract" xlink:label="RisksAndUncertaintiesAbstract" xlink:title="RisksAndUncertaintiesAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RisksAndUncertaintiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_RisksAndUncertaintiesAbstract" xml:lang="en-US" id="us-gaap_RisksAndUncertaintiesAbstract">Risks and Uncertainties [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RisksAndUncertaintiesAbstract" xlink:to="us-gaap_RisksAndUncertaintiesAbstract" xlink:title="label: RisksAndUncertaintiesAbstract to us-gaap_RisksAndUncertaintiesAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RisksAndUncertaintiesAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_RisksAndUncertaintiesAbstract_lbl1" xml:lang="en-US" id="us-gaap_RisksAndUncertaintiesAbstract_lbl1">Risks and Uncertainties [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RisksAndUncertaintiesAbstract" xlink:to="us-gaap_RisksAndUncertaintiesAbstract_lbl1" xlink:title="label: RisksAndUncertaintiesAbstract to us-gaap_RisksAndUncertaintiesAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="ClassOfWarrantOrRightLineItems" xlink:title="ClassOfWarrantOrRightLineItems" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ClassOfWarrantOrRightLineItems" xml:lang="en-US" id="us-gaap_ClassOfWarrantOrRightLineItems">Class of Warrant or Right [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightLineItems" xlink:title="label: ClassOfWarrantOrRightLineItems to us-gaap_ClassOfWarrantOrRightLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashFlowSupplementalDisclosuresTextBlock" xlink:label="CashFlowSupplementalDisclosuresTextBlock" xlink:title="CashFlowSupplementalDisclosuresTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CashFlowSupplementalDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CashFlowSupplementalDisclosuresTextBlock" xml:lang="en-US" id="us-gaap_CashFlowSupplementalDisclosuresTextBlock">SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashFlowSupplementalDisclosuresTextBlock" xlink:to="us-gaap_CashFlowSupplementalDisclosuresTextBlock" xlink:title="label: CashFlowSupplementalDisclosuresTextBlock to us-gaap_CashFlowSupplementalDisclosuresTextBlock" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InternalRevenueServiceIRSMember" xlink:label="InternalRevenueServiceIRSMember" xlink:title="InternalRevenueServiceIRSMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_InternalRevenueServiceIRSMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_InternalRevenueServiceIRSMember" xml:lang="en-US" id="us-gaap_InternalRevenueServiceIRSMember">Federal [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InternalRevenueServiceIRSMember" xlink:to="us-gaap_InternalRevenueServiceIRSMember" xlink:title="label: InternalRevenueServiceIRSMember to us-gaap_InternalRevenueServiceIRSMember" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="IncreaseDecreaseInStockholdersEquityRollForward" xlink:title="IncreaseDecreaseInStockholdersEquityRollForward" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xml:lang="en-US" id="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:title="label: IncreaseDecreaseInStockholdersEquityRollForward to us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:title="AdjustmentsToAdditionalPaidInCapitalWarrantIssued" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xml:lang="en-US" id="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued">Warrants issued in connection with notes payable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:title="label: AdjustmentsToAdditionalPaidInCapitalWarrantIssued to us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl1" xml:lang="en-US" id="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl1">Adjustments to Additional Paid in Capital, Warrant Issued</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl1" xlink:title="label: AdjustmentsToAdditionalPaidInCapitalWarrantIssued to us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:label="IncreaseDecreaseInDeferredIncomeTaxes" xlink:title="IncreaseDecreaseInDeferredIncomeTaxes" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xml:lang="en-US" id="us-gaap_IncreaseDecreaseInDeferredIncomeTaxes">Deferred income tax benefit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInDeferredIncomeTaxes" xlink:to="us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:title="label: IncreaseDecreaseInDeferredIncomeTaxes to us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_lbl1" xml:lang="en-US" id="us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_lbl1">Increase (Decrease) in Deferred Income Taxes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInDeferredIncomeTaxes" xlink:to="us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_lbl1" xlink:title="label: IncreaseDecreaseInDeferredIncomeTaxes to us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCostAndExpenseOperating" xlink:label="OtherCostAndExpenseOperating" xlink:title="OtherCostAndExpenseOperating" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OtherCostAndExpenseOperating" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_OtherCostAndExpenseOperating" xml:lang="en-US" id="us-gaap_OtherCostAndExpenseOperating">Impact of operating expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherCostAndExpenseOperating" xlink:to="us-gaap_OtherCostAndExpenseOperating" xlink:title="label: OtherCostAndExpenseOperating to us-gaap_OtherCostAndExpenseOperating" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OtherCostAndExpenseOperating1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OtherCostAndExpenseOperating1" xml:lang="en-US" id="us-gaap_OtherCostAndExpenseOperating1">Plasma center operating expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherCostAndExpenseOperating" xlink:to="us-gaap_OtherCostAndExpenseOperating1" xlink:title="label: OtherCostAndExpenseOperating to us-gaap_OtherCostAndExpenseOperating1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="OperatingExpenses" xlink:title="OperatingExpenses" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_OperatingExpenses" xml:lang="en-US" id="us-gaap_OperatingExpenses">Total operating expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingExpenses" xlink:to="us-gaap_OperatingExpenses" xlink:title="label: OperatingExpenses to us-gaap_OperatingExpenses" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingExpenses_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OperatingExpenses_lbl1" xml:lang="en-US" id="us-gaap_OperatingExpenses_lbl1">Operating Expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl1" xlink:title="label: OperatingExpenses to us-gaap_OperatingExpenses_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:title="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xml:lang="en-US" id="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">Potentially dilutive securities (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:title="label: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount to us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:title="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xml:lang="en-US" id="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">Antidilutive Securities [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:title="label: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis to us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:title="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xml:lang="en-US" id="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:title="label: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems to us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="EarningsPerShareAbstract" xlink:title="EarningsPerShareAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_EarningsPerShareAbstract" xml:lang="en-US" id="us-gaap_EarningsPerShareAbstract">Earnings (Loss) Per Share [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract" xlink:title="label: EarningsPerShareAbstract to us-gaap_EarningsPerShareAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:title="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xml:lang="en-US" id="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">Calculation of Diluted Loss Per Common Share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:title="label: ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock to us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl1" xml:lang="en-US" id="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl1">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl1" xlink:title="label: ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock to us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:title="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xml:lang="en-US" id="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable">Antidilutive Security, Excluded EPS Calculation [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:title="label: ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable to us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="EarningsPerSharePolicyTextBlock" xlink:title="EarningsPerSharePolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_EarningsPerSharePolicyTextBlock" xml:lang="en-US" id="us-gaap_EarningsPerSharePolicyTextBlock">Earnings (Loss) Per Share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" xlink:title="label: EarningsPerSharePolicyTextBlock to us-gaap_EarningsPerSharePolicyTextBlock" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract" xlink:label="EarningsPerShareDilutedOtherDisclosuresAbstract" xlink:title="EarningsPerShareDilutedOtherDisclosuresAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract" xml:lang="en-US" id="us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract">Loss Per Share [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EarningsPerShareDilutedOtherDisclosuresAbstract" xlink:to="us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract" xlink:title="label: EarningsPerShareDilutedOtherDisclosuresAbstract to us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:label="IncreaseDecreaseInOtherOperatingLiabilities" xlink:title="IncreaseDecreaseInOtherOperatingLiabilities" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xml:lang="en-US" id="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities">Other current and non-current liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInOtherOperatingLiabilities" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:title="label: IncreaseDecreaseInOtherOperatingLiabilities to us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="ScheduleOfPropertyPlantAndEquipmentTable" xlink:title="ScheduleOfPropertyPlantAndEquipmentTable" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xml:lang="en-US" id="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable">Property, Plant and Equipment [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:title="label: ScheduleOfPropertyPlantAndEquipmentTable to us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="CommonStockParOrStatedValuePerShare" xlink:title="CommonStockParOrStatedValuePerShare" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_CommonStockParOrStatedValuePerShare" xml:lang="en-US" id="us-gaap_CommonStockParOrStatedValuePerShare">Common stock, par value (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" xlink:title="label: CommonStockParOrStatedValuePerShare to us-gaap_CommonStockParOrStatedValuePerShare" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CommonStockParOrStatedValuePerShare1" xml:lang="en-US" id="us-gaap_CommonStockParOrStatedValuePerShare1">Common stock, par value (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare1" xlink:title="label: CommonStockParOrStatedValuePerShare to us-gaap_CommonStockParOrStatedValuePerShare1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="PropertyPlantAndEquipmentByTypeAxis" xlink:title="PropertyPlantAndEquipmentByTypeAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xml:lang="en-US" id="us-gaap_PropertyPlantAndEquipmentByTypeAxis">Long-Lived Tangible Asset [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:title="label: PropertyPlantAndEquipmentByTypeAxis to us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_PropertyPlantAndEquipmentByTypeAxis1" xml:lang="en-US" id="us-gaap_PropertyPlantAndEquipmentByTypeAxis1">Long-Lived Tangible Asset [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis1" xlink:title="label: PropertyPlantAndEquipmentByTypeAxis to us-gaap_PropertyPlantAndEquipmentByTypeAxis1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="PropertyPlantAndEquipmentLineItems" xlink:title="PropertyPlantAndEquipmentLineItems" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PropertyPlantAndEquipmentLineItems" xml:lang="en-US" id="us-gaap_PropertyPlantAndEquipmentLineItems">Property, Plant and Equipment [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:title="label: PropertyPlantAndEquipmentLineItems to us-gaap_PropertyPlantAndEquipmentLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="CommonStockCapitalSharesReservedForFutureIssuance" xlink:title="CommonStockCapitalSharesReservedForFutureIssuance" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xml:lang="en-US" id="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">Shares reserved for grant (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:title="label: CommonStockCapitalSharesReservedForFutureIssuance to us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance1" xml:lang="en-US" id="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance1">Common stock, available for issuance (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance1" xlink:title="label: CommonStockCapitalSharesReservedForFutureIssuance to us-gaap_CommonStockCapitalSharesReservedForFutureIssuance1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingCostsAndExpenses" xlink:label="OperatingCostsAndExpenses" xlink:title="OperatingCostsAndExpenses" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingCostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OperatingCostsAndExpenses" xml:lang="en-US" id="us-gaap_OperatingCostsAndExpenses">Rent expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingCostsAndExpenses" xlink:to="us-gaap_OperatingCostsAndExpenses" xlink:title="label: OperatingCostsAndExpenses to us-gaap_OperatingCostsAndExpenses" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="StockholdersEquity" xlink:title="StockholdersEquity" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:title="us-gaap_StockholdersEquity" xml:lang="en-US" id="us-gaap_StockholdersEquity">Balance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockholdersEquity" xlink:to="us-gaap_StockholdersEquity" xlink:title="label: StockholdersEquity to us-gaap_StockholdersEquity" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockholdersEquity1" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:title="us-gaap_StockholdersEquity1" xml:lang="en-US" id="us-gaap_StockholdersEquity1">Balance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockholdersEquity" xlink:to="us-gaap_StockholdersEquity1" xlink:title="label: StockholdersEquity to us-gaap_StockholdersEquity1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockholdersEquity2" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_StockholdersEquity2" xml:lang="en-US" id="us-gaap_StockholdersEquity2">TOTAL STOCKHOLDERS' EQUITY</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockholdersEquity" xlink:to="us-gaap_StockholdersEquity2" xlink:title="label: StockholdersEquity to us-gaap_StockholdersEquity2" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StockholdersEquity_lbl3" xml:lang="en-US" id="us-gaap_StockholdersEquity_lbl3">Equity, Attributable to Parent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl3" xlink:title="label: StockholdersEquity to us-gaap_StockholdersEquity_lbl3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:title="IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xml:lang="en-US" id="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance">Change in valuation allowance</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:title="label: IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance to us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:label="ComponentsOfDeferredTaxAssetsAbstract" xlink:title="ComponentsOfDeferredTaxAssetsAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xml:lang="en-US" id="us-gaap_ComponentsOfDeferredTaxAssetsAbstract">Deferred tax assets:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ComponentsOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:title="label: ComponentsOfDeferredTaxAssetsAbstract to us-gaap_ComponentsOfDeferredTaxAssetsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:label="ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:title="ComponentsOfDeferredTaxLiabilitiesAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xml:lang="en-US" id="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract">Deferred tax liabilities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:to="us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:title="label: ComponentsOfDeferredTaxLiabilitiesAbstract to us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="IncomeTaxExpenseBenefit" xlink:title="IncomeTaxExpenseBenefit" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncomeTaxExpenseBenefit" xml:lang="en-US" id="us-gaap_IncomeTaxExpenseBenefit">Income tax benefit</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit" xlink:title="label: IncomeTaxExpenseBenefit to us-gaap_IncomeTaxExpenseBenefit" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit1" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_IncomeTaxExpenseBenefit1" xml:lang="en-US" id="us-gaap_IncomeTaxExpenseBenefit1">Total benefit from income taxes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit1" xlink:title="label: IncomeTaxExpenseBenefit to us-gaap_IncomeTaxExpenseBenefit1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue" xlink:label="PreferredStockValue" xlink:title="PreferredStockValue" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PreferredStockValue" xml:lang="en-US" id="us-gaap_PreferredStockValue">Preferred Stock, $0.0001 par value, 10,000,000 shares authorized, no shares issued and outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreferredStockValue" xlink:to="us-gaap_PreferredStockValue" xlink:title="label: PreferredStockValue to us-gaap_PreferredStockValue" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:label="CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:title="CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xml:lang="en-US" id="us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract">Common Stock [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:title="label: CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract to us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:label="PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:title="PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xml:lang="en-US" id="us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract">Preferred Stock [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:title="label: PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract to us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableMember" xlink:label="AccountsReceivableMember" xlink:title="AccountsReceivableMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AccountsReceivableMember" xml:lang="en-US" id="us-gaap_AccountsReceivableMember">Accounts Receivable [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccountsReceivableMember" xlink:to="us-gaap_AccountsReceivableMember" xlink:title="label: AccountsReceivableMember to us-gaap_AccountsReceivableMember" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="StatementEquityComponentsAxis" xlink:title="StatementEquityComponentsAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StatementEquityComponentsAxis" xml:lang="en-US" id="us-gaap_StatementEquityComponentsAxis">Equity Components [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis" xlink:title="label: StatementEquityComponentsAxis to us-gaap_StatementEquityComponentsAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="AdditionalPaidInCapitalMember" xlink:title="AdditionalPaidInCapitalMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AdditionalPaidInCapitalMember" xml:lang="en-US" id="us-gaap_AdditionalPaidInCapitalMember">Additional Paid-in Capital [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember" xlink:title="label: AdditionalPaidInCapitalMember to us-gaap_AdditionalPaidInCapitalMember" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="RetainedEarningsMember" xlink:title="RetainedEarningsMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_RetainedEarningsMember" xml:lang="en-US" id="us-gaap_RetainedEarningsMember">Accumulated Deficit [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember" xlink:title="label: RetainedEarningsMember to us-gaap_RetainedEarningsMember" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="EquityComponentDomain" xlink:title="EquityComponentDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_EquityComponentDomain" xml:lang="en-US" id="us-gaap_EquityComponentDomain">Equity Component [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain" xlink:title="label: EquityComponentDomain to us-gaap_EquityComponentDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:label="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:title="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xml:lang="en-US" id="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit">Exercise price range, lower limit (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:title="label: ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit to us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="EmployeeStockOptionMember" xlink:title="EmployeeStockOptionMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_EmployeeStockOptionMember" xml:lang="en-US" id="us-gaap_EmployeeStockOptionMember">Stock Options [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember" xlink:title="label: EmployeeStockOptionMember to us-gaap_EmployeeStockOptionMember" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaidInKindInterest" xlink:label="PaidInKindInterest" xlink:title="PaidInKindInterest" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PaidInKindInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_PaidInKindInterest" xml:lang="en-US" id="us-gaap_PaidInKindInterest">Interest paid-in-kind</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PaidInKindInterest" xlink:to="us-gaap_PaidInKindInterest" xlink:title="label: PaidInKindInterest to us-gaap_PaidInKindInterest" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PaidInKindInterest1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PaidInKindInterest1" xml:lang="en-US" id="us-gaap_PaidInKindInterest1">Interest paid in kind</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PaidInKindInterest" xlink:to="us-gaap_PaidInKindInterest1" xlink:title="label: PaidInKindInterest to us-gaap_PaidInKindInterest1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtTextBlock" xlink:label="LongTermDebtTextBlock" xlink:title="LongTermDebtTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LongTermDebtTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LongTermDebtTextBlock" xml:lang="en-US" id="us-gaap_LongTermDebtTextBlock">NOTES PAYABLE</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LongTermDebtTextBlock" xlink:to="us-gaap_LongTermDebtTextBlock" xlink:title="label: LongTermDebtTextBlock to us-gaap_LongTermDebtTextBlock" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="StockIssuedDuringPeriodValueNewIssues" xlink:title="StockIssuedDuringPeriodValueNewIssues" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StockIssuedDuringPeriodValueNewIssues" xml:lang="en-US" id="us-gaap_StockIssuedDuringPeriodValueNewIssues">Issuance of common stock, net of offering expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:title="label: StockIssuedDuringPeriodValueNewIssues to us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="StockIssuedDuringPeriodValueStockOptionsExercised" xlink:title="StockIssuedDuringPeriodValueStockOptionsExercised" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xml:lang="en-US" id="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">Exercise of stock options</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:title="label: StockIssuedDuringPeriodValueStockOptionsExercised to us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="StockIssuedDuringPeriodSharesNewIssues" xlink:title="StockIssuedDuringPeriodSharesNewIssues" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xml:lang="en-US" id="us-gaap_StockIssuedDuringPeriodSharesNewIssues">Issuance of common stock, net of offering expenses (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:title="label: StockIssuedDuringPeriodSharesNewIssues to us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StockIssuedDuringPeriodSharesNewIssues1" xml:lang="en-US" id="us-gaap_StockIssuedDuringPeriodSharesNewIssues1">Common stock shares sold during the period (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues1" xlink:title="label: StockIssuedDuringPeriodSharesNewIssues to us-gaap_StockIssuedDuringPeriodSharesNewIssues1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:title="StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xml:lang="en-US" id="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">Exercise of stock options (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:title="label: StockIssuedDuringPeriodSharesStockOptionsExercised to us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised1" xml:lang="en-US" id="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised1">Stock options exercised (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised1" xlink:title="label: StockIssuedDuringPeriodSharesStockOptionsExercised to us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised2" xml:lang="en-US" id="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised2">Common stock shares issued (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised2" xlink:title="label: StockIssuedDuringPeriodSharesStockOptionsExercised to us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="StatementBusinessSegmentsAxis" xlink:title="StatementBusinessSegmentsAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_StatementBusinessSegmentsAxis" xml:lang="en-US" id="us-gaap_StatementBusinessSegmentsAxis">Segments [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StatementBusinessSegmentsAxis" xlink:to="us-gaap_StatementBusinessSegmentsAxis" xlink:title="label: StatementBusinessSegmentsAxis to us-gaap_StatementBusinessSegmentsAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostsAndExpensesAbstract" xlink:label="CostsAndExpensesAbstract" xlink:title="CostsAndExpensesAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CostsAndExpensesAbstract" xml:lang="en-US" id="us-gaap_CostsAndExpensesAbstract">OPERATING EXPENSES:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CostsAndExpensesAbstract" xlink:to="us-gaap_CostsAndExpensesAbstract" xlink:title="label: CostsAndExpensesAbstract to us-gaap_CostsAndExpensesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">Unvested RSU, Shares [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward1">Warrants Outstanding [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract">Stock Options, Vested and Expected to Vest [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">Options outstanding, vested and expected to vest, ending balance (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice1" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice1">Options outstanding, vested and expected to vest, beginning balance (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl2" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl2">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl2" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">Options outstanding, vested and expected to vest, beginning balance (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber1" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber1">Options outstanding, vested and expected to vest, ending balance (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl2" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl2">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl2" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract">Fair Value Assumptions and Methodology [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="WeightedAverageNumberOfSharesOutstandingAbstract" xlink:title="WeightedAverageNumberOfSharesOutstandingAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xml:lang="en-US" id="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">WEIGHTED AVERAGE COMMON SHARES OUTSTANDING:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:title="label: WeightedAverageNumberOfSharesOutstandingAbstract to us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="DepreciationDepletionAndAmortization" xlink:title="DepreciationDepletionAndAmortization" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_DepreciationDepletionAndAmortization" xml:lang="en-US" id="us-gaap_DepreciationDepletionAndAmortization">Depreciation expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DepreciationDepletionAndAmortization" xlink:to="us-gaap_DepreciationDepletionAndAmortization" xlink:title="label: DepreciationDepletionAndAmortization to us-gaap_DepreciationDepletionAndAmortization" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DepreciationDepletionAndAmortization_lbl1" xml:lang="en-US" id="us-gaap_DepreciationDepletionAndAmortization_lbl1">Depreciation, Depletion and Amortization</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DepreciationDepletionAndAmortization" xlink:to="us-gaap_DepreciationDepletionAndAmortization_lbl1" xlink:title="label: DepreciationDepletionAndAmortization to us-gaap_DepreciationDepletionAndAmortization_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems" xlink:label="ClassOfStockLineItems" xlink:title="ClassOfStockLineItems" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ClassOfStockLineItems" xml:lang="en-US" id="us-gaap_ClassOfStockLineItems">Class of Stock [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClassOfStockLineItems" xlink:to="us-gaap_ClassOfStockLineItems" xlink:title="label: ClassOfStockLineItems to us-gaap_ClassOfStockLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="ScheduleOfStockByClassTable" xlink:title="ScheduleOfStockByClassTable" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ScheduleOfStockByClassTable" xml:lang="en-US" id="us-gaap_ScheduleOfStockByClassTable">Schedule of Stock by Class [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfStockByClassTable" xlink:to="us-gaap_ScheduleOfStockByClassTable" xlink:title="label: ScheduleOfStockByClassTable to us-gaap_ScheduleOfStockByClassTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract" xlink:label="LeasesAbstract" xlink:title="LeasesAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LeasesAbstract" xml:lang="en-US" id="us-gaap_LeasesAbstract">LEASE OBLIGATIONS [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LeasesAbstract" xlink:to="us-gaap_LeasesAbstract" xlink:title="label: LeasesAbstract to us-gaap_LeasesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="CommitmentsAndContingencies" xlink:title="CommitmentsAndContingencies" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_CommitmentsAndContingencies" xml:lang="en-US" id="us-gaap_CommitmentsAndContingencies">COMMITMENTS AND CONTINGENCIES</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies" xlink:title="label: CommitmentsAndContingencies to us-gaap_CommitmentsAndContingencies" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingencies_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CommitmentsAndContingencies_lbl1" xml:lang="en-US" id="us-gaap_CommitmentsAndContingencies_lbl1">Commitments and Contingencies</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl1" xlink:title="label: CommitmentsAndContingencies to us-gaap_CommitmentsAndContingencies_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:title="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US" id="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:title="label: AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="AccountsPayableCurrent" xlink:title="AccountsPayableCurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AccountsPayableCurrent" xml:lang="en-US" id="us-gaap_AccountsPayableCurrent">Accounts payable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent" xlink:title="label: AccountsPayableCurrent to us-gaap_AccountsPayableCurrent" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedBonusesCurrent" xlink:label="AccruedBonusesCurrent" xlink:title="AccruedBonusesCurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AccruedBonusesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AccruedBonusesCurrent" xml:lang="en-US" id="us-gaap_AccruedBonusesCurrent">Accrued incentives</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccruedBonusesCurrent" xlink:to="us-gaap_AccruedBonusesCurrent" xlink:title="label: AccruedBonusesCurrent to us-gaap_AccruedBonusesCurrent" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="AccruedProfessionalFeesCurrent" xlink:title="AccruedProfessionalFeesCurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AccruedProfessionalFeesCurrent" xml:lang="en-US" id="us-gaap_AccruedProfessionalFeesCurrent">Accrued distribution fees</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccruedProfessionalFeesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" xlink:title="label: AccruedProfessionalFeesCurrent to us-gaap_AccruedProfessionalFeesCurrent" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedSalariesCurrent" xlink:label="AccruedSalariesCurrent" xlink:title="AccruedSalariesCurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AccruedSalariesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AccruedSalariesCurrent" xml:lang="en-US" id="us-gaap_AccruedSalariesCurrent">Accrued payroll and other compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccruedSalariesCurrent" xlink:to="us-gaap_AccruedSalariesCurrent" xlink:title="label: AccruedSalariesCurrent to us-gaap_AccruedSalariesCurrent" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPayableCurrent" xlink:label="InterestPayableCurrent" xlink:title="InterestPayableCurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_InterestPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_InterestPayableCurrent" xml:lang="en-US" id="us-gaap_InterestPayableCurrent">Accrued interest</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InterestPayableCurrent" xlink:to="us-gaap_InterestPayableCurrent" xlink:title="label: InterestPayableCurrent to us-gaap_InterestPayableCurrent" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="OtherAccruedLiabilitiesCurrent" xlink:title="OtherAccruedLiabilitiesCurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OtherAccruedLiabilitiesCurrent" xml:lang="en-US" id="us-gaap_OtherAccruedLiabilitiesCurrent">Other</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:title="label: OtherAccruedLiabilitiesCurrent to us-gaap_OtherAccruedLiabilitiesCurrent" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxesPayableCurrent" xlink:label="TaxesPayableCurrent" xlink:title="TaxesPayableCurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_TaxesPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_TaxesPayableCurrent" xml:lang="en-US" id="us-gaap_TaxesPayableCurrent">Income taxes payable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TaxesPayableCurrent" xlink:to="us-gaap_TaxesPayableCurrent" xlink:title="label: TaxesPayableCurrent to us-gaap_TaxesPayableCurrent" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:title="IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xml:lang="en-US" id="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">INCOME (LOSS) BEFORE INCOME TAXES</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:title="label: IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest to us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest1" xml:lang="en-US" id="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest1">Income (loss) before taxes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest1" xlink:title="label: IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest to us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="PrepaidExpenseAndOtherAssetsCurrent" xlink:title="PrepaidExpenseAndOtherAssetsCurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xml:lang="en-US" id="us-gaap_PrepaidExpenseAndOtherAssetsCurrent">Prepaid expenses and other current assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:title="label: PrepaidExpenseAndOtherAssetsCurrent to us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain" xlink:label="SegmentDomain" xlink:title="SegmentDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SegmentDomain" xml:lang="en-US" id="us-gaap_SegmentDomain">Segments [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SegmentDomain" xlink:to="us-gaap_SegmentDomain" xlink:title="label: SegmentDomain to us-gaap_SegmentDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MaterialReconcilingItemsMember" xlink:label="MaterialReconcilingItemsMember" xlink:title="MaterialReconcilingItemsMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_MaterialReconcilingItemsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_MaterialReconcilingItemsMember" xml:lang="en-US" id="us-gaap_MaterialReconcilingItemsMember">Reconciling Item [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MaterialReconcilingItemsMember" xlink:to="us-gaap_MaterialReconcilingItemsMember" xlink:title="label: MaterialReconcilingItemsMember to us-gaap_MaterialReconcilingItemsMember" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingSegmentsMember" xlink:label="OperatingSegmentsMember" xlink:title="OperatingSegmentsMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingSegmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OperatingSegmentsMember" xml:lang="en-US" id="us-gaap_OperatingSegmentsMember">Operating Segments [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingSegmentsMember" xlink:to="us-gaap_OperatingSegmentsMember" xlink:title="label: OperatingSegmentsMember to us-gaap_OperatingSegmentsMember" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentsGeographicalAreasAbstract" xlink:label="SegmentsGeographicalAreasAbstract" xlink:title="SegmentsGeographicalAreasAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SegmentsGeographicalAreasAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SegmentsGeographicalAreasAbstract" xml:lang="en-US" id="us-gaap_SegmentsGeographicalAreasAbstract">Revenues, Geographic Area [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SegmentsGeographicalAreasAbstract" xlink:to="us-gaap_SegmentsGeographicalAreasAbstract" xlink:title="label: SegmentsGeographicalAreasAbstract to us-gaap_SegmentsGeographicalAreasAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:label="ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:title="ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xml:lang="en-US" id="us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable">Schedule of Revenues from External Customers and Long-Lived Assets [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:to="us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:title="label: ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable to us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:label="RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:title="RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xml:lang="en-US" id="us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems">Revenues from External Customers and Long-Lived Assets [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:to="us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:title="label: RevenuesFromExternalCustomersAndLongLivedAssetsLineItems to us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract" xlink:label="ReconciliationFromSegmentTotalsToConsolidatedAbstract" xlink:title="ReconciliationFromSegmentTotalsToConsolidatedAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract" xml:lang="en-US" id="us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract">Segment Reconciliation [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ReconciliationFromSegmentTotalsToConsolidatedAbstract" xlink:to="us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract" xlink:title="label: ReconciliationFromSegmentTotalsToConsolidatedAbstract to us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="TypeOfArrangementAxis" xlink:title="TypeOfArrangementAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_TypeOfArrangementAxis" xml:lang="en-US" id="us-gaap_TypeOfArrangementAxis">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis" xlink:title="label: TypeOfArrangementAxis to us-gaap_TypeOfArrangementAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillImpairedAccumulatedImpairmentLossAbstract" xlink:label="GoodwillImpairedAccumulatedImpairmentLossAbstract" xlink:title="GoodwillImpairedAccumulatedImpairmentLossAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_GoodwillImpairedAccumulatedImpairmentLossAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_GoodwillImpairedAccumulatedImpairmentLossAbstract" xml:lang="en-US" id="us-gaap_GoodwillImpairedAccumulatedImpairmentLossAbstract">Goodwill [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GoodwillImpairedAccumulatedImpairmentLossAbstract" xlink:to="us-gaap_GoodwillImpairedAccumulatedImpairmentLossAbstract" xlink:title="label: GoodwillImpairedAccumulatedImpairmentLossAbstract to us-gaap_GoodwillImpairedAccumulatedImpairmentLossAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_GoodwillImpairedAccumulatedImpairmentLossAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_GoodwillImpairedAccumulatedImpairmentLossAbstract_lbl1" xml:lang="en-US" id="us-gaap_GoodwillImpairedAccumulatedImpairmentLossAbstract_lbl1">Goodwill, Impaired, Accumulated Impairment Loss [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GoodwillImpairedAccumulatedImpairmentLossAbstract" xlink:to="us-gaap_GoodwillImpairedAccumulatedImpairmentLossAbstract_lbl1" xlink:title="label: GoodwillImpairedAccumulatedImpairmentLossAbstract to us-gaap_GoodwillImpairedAccumulatedImpairmentLossAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:label="SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:title="SharesPaidForTaxWithholdingForShareBasedCompensation" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xml:lang="en-US" id="us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation">Shares withheld to cover portion of tax liabilities (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:to="us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:title="label: SharesPaidForTaxWithholdingForShareBasedCompensation to us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_lbl1" xml:lang="en-US" id="us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_lbl1">Share-Based Payment Arrangement, Shares Withheld for Tax Withholding Obligation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:to="us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_lbl1" xlink:title="label: SharesPaidForTaxWithholdingForShareBasedCompensation to us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:label="OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:title="OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xml:lang="en-US" id="us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock">Principles of Consolidation and Basis of Presentation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:to="us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:title="label: OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock to us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="PayablesAndAccrualsAbstract" xlink:title="PayablesAndAccrualsAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PayablesAndAccrualsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PayablesAndAccrualsAbstract" xml:lang="en-US" id="us-gaap_PayablesAndAccrualsAbstract">ACCRUED EXPENSES AND OTHER LIABILITIES [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PayablesAndAccrualsAbstract" xlink:to="us-gaap_PayablesAndAccrualsAbstract" xlink:title="label: PayablesAndAccrualsAbstract to us-gaap_PayablesAndAccrualsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:title="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xml:lang="en-US" id="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">ORGANIZATION AND BUSINESS [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:title="label: OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract to us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="SharesOutstanding" xlink:title="SharesOutstanding" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:title="us-gaap_SharesOutstanding" xml:lang="en-US" id="us-gaap_SharesOutstanding">Balance (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharesOutstanding" xlink:to="us-gaap_SharesOutstanding" xlink:title="label: SharesOutstanding to us-gaap_SharesOutstanding" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SharesOutstanding1" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:title="us-gaap_SharesOutstanding1" xml:lang="en-US" id="us-gaap_SharesOutstanding1">Balance (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharesOutstanding" xlink:to="us-gaap_SharesOutstanding1" xlink:title="label: SharesOutstanding to us-gaap_SharesOutstanding1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SharesOutstanding_lbl2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SharesOutstanding_lbl2" xml:lang="en-US" id="us-gaap_SharesOutstanding_lbl2">Shares, Outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl2" xlink:title="label: SharesOutstanding to us-gaap_SharesOutstanding_lbl2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:title="ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xml:lang="en-US" id="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">Deferred Tax Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:title="label: ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock to us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:title="ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xml:lang="en-US" id="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">Income Tax Expense (Benefit)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:title="label: ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock to us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl1" xml:lang="en-US" id="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl1">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl1" xlink:title="label: ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock to us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:title="ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xml:lang="en-US" id="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">Reconciliation of Income Taxes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:title="label: ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock to us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:title="ScheduleOfAccruedLiabilitiesTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xml:lang="en-US" id="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">Accrued Expenses and Other Current Liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:title="label: ScheduleOfAccruedLiabilitiesTableTextBlock to us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl1" xml:lang="en-US" id="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl1">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl1" xlink:title="label: ScheduleOfAccruedLiabilitiesTableTextBlock to us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="ScheduleOfInventoryCurrentTableTextBlock" xlink:title="ScheduleOfInventoryCurrentTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xml:lang="en-US" id="us-gaap_ScheduleOfInventoryCurrentTableTextBlock">Components of Inventory</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfInventoryCurrentTableTextBlock" xlink:to="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:title="label: ScheduleOfInventoryCurrentTableTextBlock to us-gaap_ScheduleOfInventoryCurrentTableTextBlock" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="CommitmentsAndContingenciesDisclosureAbstract" xlink:title="CommitmentsAndContingenciesDisclosureAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xml:lang="en-US" id="us-gaap_CommitmentsAndContingenciesDisclosureAbstract">COMMITMENTS AND CONTINGENCIES [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:title="label: CommitmentsAndContingenciesDisclosureAbstract to us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="IncomeTaxDisclosureAbstract" xlink:title="IncomeTaxDisclosureAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncomeTaxDisclosureAbstract" xml:lang="en-US" id="us-gaap_IncomeTaxDisclosureAbstract">INCOME TAXES [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract" xlink:title="label: IncomeTaxDisclosureAbstract to us-gaap_IncomeTaxDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:title="GoodwillAndIntangibleAssetsDisclosureAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xml:lang="en-US" id="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">INTANGIBLE ASSETS [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:title="label: GoodwillAndIntangibleAssetsDisclosureAbstract to us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:label="ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:title="ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xml:lang="en-US" id="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock">Supplemental Cash Flow Information</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:to="us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:title="label: ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock to us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="InventoryDisclosureAbstract" xlink:title="InventoryDisclosureAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_InventoryDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_InventoryDisclosureAbstract" xml:lang="en-US" id="us-gaap_InventoryDisclosureAbstract">INVENTORIES [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InventoryDisclosureAbstract" xlink:to="us-gaap_InventoryDisclosureAbstract" xlink:title="label: InventoryDisclosureAbstract to us-gaap_InventoryDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="DebtDisclosureAbstract" xlink:title="DebtDisclosureAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DebtDisclosureAbstract" xml:lang="en-US" id="us-gaap_DebtDisclosureAbstract">NOTES PAYABLE [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureAbstract" xlink:title="label: DebtDisclosureAbstract to us-gaap_DebtDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="CompensationAndRetirementDisclosureAbstract" xlink:title="CompensationAndRetirementDisclosureAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CompensationAndRetirementDisclosureAbstract" xml:lang="en-US" id="us-gaap_CompensationAndRetirementDisclosureAbstract">OTHER EMPLOYEE BENEFITS [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:title="label: CompensationAndRetirementDisclosureAbstract to us-gaap_CompensationAndRetirementDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:label="ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:title="ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xml:lang="en-US" id="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock">Schedule of Stock-Based Compensation Expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:to="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:title="label: ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock to us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:title="ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xml:lang="en-US" id="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">Schedule of Option Activity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:title="label: ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock to us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:title="ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xml:lang="en-US" id="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">Schedule of Assumptions</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:title="label: ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock to us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:label="AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:title="AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xml:lang="en-US" id="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition">Stock-based compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:title="label: AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition to us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_lbl1" xml:lang="en-US" id="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_lbl1">APIC, Share-Based Payment Arrangement, Option, Increase for Cost Recognition</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_lbl1" xlink:title="label: AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition to us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates" xlink:label="UseOfEstimates" xlink:title="UseOfEstimates" />
    <link:label xlink:type="resource" xlink:label="us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_UseOfEstimates" xml:lang="en-US" id="us-gaap_UseOfEstimates">Use of Estimates</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="UseOfEstimates" xlink:to="us-gaap_UseOfEstimates" xlink:title="label: UseOfEstimates to us-gaap_UseOfEstimates" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" xlink:label="LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" xlink:title="LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" xml:lang="en-US" id="us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage">Unused commitment fee</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" xlink:to="us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" xlink:title="label: LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage to us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage_lbl1" xml:lang="en-US" id="us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage_lbl1">Line of Credit Facility, Unused Capacity, Commitment Fee Percentage</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" xlink:to="us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage_lbl1" xlink:title="label: LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage to us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:label="LineOfCreditFacilityCommitmentFeePercentage" xlink:title="LineOfCreditFacilityCommitmentFeePercentage" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xml:lang="en-US" id="us-gaap_LineOfCreditFacilityCommitmentFeePercentage">Revolving facility percentage</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LineOfCreditFacilityCommitmentFeePercentage" xlink:to="us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:title="label: LineOfCreditFacilityCommitmentFeePercentage to us-gaap_LineOfCreditFacilityCommitmentFeePercentage" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDebtTableTextBlock" xlink:label="ScheduleOfDebtTableTextBlock" xlink:title="ScheduleOfDebtTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ScheduleOfDebtTableTextBlock" xml:lang="en-US" id="us-gaap_ScheduleOfDebtTableTextBlock">Summary of Outstanding Senior Notes Payable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfDebtTableTextBlock" xlink:to="us-gaap_ScheduleOfDebtTableTextBlock" xlink:title="label: ScheduleOfDebtTableTextBlock to us-gaap_ScheduleOfDebtTableTextBlock" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="RestrictedStockUnitsRSUMember" xlink:title="RestrictedStockUnitsRSUMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_RestrictedStockUnitsRSUMember" xml:lang="en-US" id="us-gaap_RestrictedStockUnitsRSUMember">Restricted Stock Units [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" xlink:title="label: RestrictedStockUnitsRSUMember to us-gaap_RestrictedStockUnitsRSUMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RestrictedStockUnitsRSUMember1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_RestrictedStockUnitsRSUMember1" xml:lang="en-US" id="us-gaap_RestrictedStockUnitsRSUMember1">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember1" xlink:title="label: RestrictedStockUnitsRSUMember to us-gaap_RestrictedStockUnitsRSUMember1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RestrictedStockUnitsRSUMember2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_RestrictedStockUnitsRSUMember2" xml:lang="en-US" id="us-gaap_RestrictedStockUnitsRSUMember2">RSUs [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember2" xlink:title="label: RestrictedStockUnitsRSUMember to us-gaap_RestrictedStockUnitsRSUMember2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:label="ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:title="ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xml:lang="en-US" id="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock">Intangible Asset Future Aggregate Amortization Expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:to="us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:title="label: ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock to us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="ResearchAndDevelopmentExpenseMember" xlink:title="ResearchAndDevelopmentExpenseMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ResearchAndDevelopmentExpenseMember" xml:lang="en-US" id="us-gaap_ResearchAndDevelopmentExpenseMember">Research and Development [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:title="label: ResearchAndDevelopmentExpenseMember to us-gaap_ResearchAndDevelopmentExpenseMember" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="AccountingPoliciesAbstract" xlink:title="AccountingPoliciesAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AccountingPoliciesAbstract" xml:lang="en-US" id="us-gaap_AccountingPoliciesAbstract">SIGNIFICANT ACCOUNTING POLICIES [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract" xlink:title="label: AccountingPoliciesAbstract to us-gaap_AccountingPoliciesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract" xlink:label="SegmentReportingAbstract" xlink:title="SegmentReportingAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SegmentReportingAbstract" xml:lang="en-US" id="us-gaap_SegmentReportingAbstract">SEGMENTS [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SegmentReportingAbstract" xlink:to="us-gaap_SegmentReportingAbstract" xlink:title="label: SegmentReportingAbstract to us-gaap_SegmentReportingAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="RelatedPartyTransactionsAbstract" xlink:title="RelatedPartyTransactionsAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_RelatedPartyTransactionsAbstract" xml:lang="en-US" id="us-gaap_RelatedPartyTransactionsAbstract">RELATED PARTY TRANSACTIONS [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract" xlink:title="label: RelatedPartyTransactionsAbstract to us-gaap_RelatedPartyTransactionsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowElementsAbstract" xlink:label="SupplementalCashFlowElementsAbstract" xlink:title="SupplementalCashFlowElementsAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SupplementalCashFlowElementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SupplementalCashFlowElementsAbstract" xml:lang="en-US" id="us-gaap_SupplementalCashFlowElementsAbstract">SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SupplementalCashFlowElementsAbstract" xlink:to="us-gaap_SupplementalCashFlowElementsAbstract" xlink:title="label: SupplementalCashFlowElementsAbstract to us-gaap_SupplementalCashFlowElementsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="ArrangementsAndNonarrangementTransactionsMember" xlink:title="ArrangementsAndNonarrangementTransactionsMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xml:lang="en-US" id="us-gaap_ArrangementsAndNonarrangementTransactionsMember">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:title="label: ArrangementsAndNonarrangementTransactionsMember to us-gaap_ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="IncomeTaxAuthorityAxis" xlink:title="IncomeTaxAuthorityAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncomeTaxAuthorityAxis" xml:lang="en-US" id="us-gaap_IncomeTaxAuthorityAxis">Income Tax Jurisdiction [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityAxis" xlink:title="label: IncomeTaxAuthorityAxis to us-gaap_IncomeTaxAuthorityAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">Number of stock options granted (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="NoncashInvestingAndFinancingItemsAbstract" xlink:title="NoncashInvestingAndFinancingItemsAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xml:lang="en-US" id="us-gaap_NoncashInvestingAndFinancingItemsAbstract">Noncash Financing and Investing Activities [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:title="label: NoncashInvestingAndFinancingItemsAbstract to us-gaap_NoncashInvestingAndFinancingItemsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:title="ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xml:lang="en-US" id="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">Calculation of Basic and Diluted Earnings Per Share</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:title="label: ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock to us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:label="SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:title="SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xml:lang="en-US" id="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1">Options exercisable, weighted average exercise price (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:title="label: SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1 to us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_lbl1" xml:lang="en-US" id="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_lbl1">Share-Based Payment Arrangement, Option, Exercise Price Range, Exercisable, Weighted Average Exercise Price</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_lbl1" xlink:title="label: SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1 to us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:label="SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:title="SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xml:lang="en-US" id="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1">Options outstanding, weighted average exercise price (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:title="label: SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1 to us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xml:lang="en-US" id="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">Options exercisable, aggregate intrinsic value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:title="label: SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 to us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:label="DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:title="DefinedContributionPlanEmployerDiscretionaryContributionAmount" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xml:lang="en-US" id="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount">Compensation expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:to="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:title="label: DefinedContributionPlanEmployerDiscretionaryContributionAmount to us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty" xlink:label="RelatedPartyTransactionPurchasesFromRelatedParty" xlink:title="RelatedPartyTransactionPurchasesFromRelatedParty" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty" xml:lang="en-US" id="us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty">Purchased materials amount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RelatedPartyTransactionPurchasesFromRelatedParty" xlink:to="us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty" xlink:title="label: RelatedPartyTransactionPurchasesFromRelatedParty to us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty_lbl1" xml:lang="en-US" id="us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty_lbl1">Related Party Transaction, Purchases from Related Party</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RelatedPartyTransactionPurchasesFromRelatedParty" xlink:to="us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty_lbl1" xlink:title="label: RelatedPartyTransactionPurchasesFromRelatedParty to us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:label="ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:title="ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" xml:lang="en-US" id="us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock">Schedule of Intangible Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:to="us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:title="label: ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock to us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock_lbl1" xml:lang="en-US" id="us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock_lbl1">Schedule of Indefinite-Lived Intangible Assets [Table Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:to="us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock_lbl1" xlink:title="label: ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock to us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:title="ScheduleOfFiniteLivedIntangibleAssetsTable" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xml:lang="en-US" id="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable">Intangible Asset, Finite-Lived [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:title="label: ScheduleOfFiniteLivedIntangibleAssetsTable to us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted">Number of restricted stock units granted (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">Unvested RSU, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward1">Warrants Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">Forfeited (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:title="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xml:lang="en-US" id="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">Unrecognized compensation expense, stock options</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:title="label: EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions to us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:title="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xml:lang="en-US" id="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions">Unrecognized compensation expense, non option</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:title="label: EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions to us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl1" xml:lang="en-US" id="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl1">Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl1" xlink:title="label: EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions to us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" xlink:label="ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" xlink:title="ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" xml:lang="en-US" id="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock">Impairment of Long-Lived Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" xlink:title="label: ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock to us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="PlanNameAxis" xlink:title="PlanNameAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PlanNameAxis" xml:lang="en-US" id="us-gaap_PlanNameAxis">Plan Name [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PlanNameAxis" xlink:to="us-gaap_PlanNameAxis" xlink:title="label: PlanNameAxis to us-gaap_PlanNameAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="PlanNameDomain" xlink:title="PlanNameDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PlanNameDomain" xml:lang="en-US" id="us-gaap_PlanNameDomain">Plan Name [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PlanNameDomain" xlink:to="us-gaap_PlanNameDomain" xlink:title="label: PlanNameDomain to us-gaap_PlanNameDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="AwardTypeAxis" xlink:title="AwardTypeAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AwardTypeAxis" xml:lang="en-US" id="us-gaap_AwardTypeAxis">Award Type [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis" xlink:title="label: AwardTypeAxis to us-gaap_AwardTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="SubsequentEventMember" xlink:title="SubsequentEventMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SubsequentEventMember" xml:lang="en-US" id="us-gaap_SubsequentEventMember">Subsequent Event [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember" xlink:title="label: SubsequentEventMember to us-gaap_SubsequentEventMember" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="IncomeStatementLocationAxis" xlink:title="IncomeStatementLocationAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncomeStatementLocationAxis" xml:lang="en-US" id="us-gaap_IncomeStatementLocationAxis">Statement of Income Location, Balance [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis" xlink:title="label: IncomeStatementLocationAxis to us-gaap_IncomeStatementLocationAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="IncomeStatementLocationDomain" xlink:title="IncomeStatementLocationDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_IncomeStatementLocationDomain" xml:lang="en-US" id="us-gaap_IncomeStatementLocationDomain">Statement of Income Location, Balance [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain" xlink:title="label: IncomeStatementLocationDomain to us-gaap_IncomeStatementLocationDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:title="NewAccountingPronouncementsPolicyPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xml:lang="en-US" id="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">Recent Accounting Pronouncements</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:title="label: NewAccountingPronouncementsPolicyPolicyTextBlock to us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:label="AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:title="AccruedLiabilitiesAndOtherLiabilitiesAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xml:lang="en-US" id="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract">Accrued Expenses and Other Current Liabilities [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:title="label: AccruedLiabilitiesAndOtherLiabilitiesAbstract to us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="AccruedLiabilitiesAndOtherLiabilities" xlink:title="AccruedLiabilitiesAndOtherLiabilities" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xml:lang="en-US" id="us-gaap_AccruedLiabilitiesAndOtherLiabilities">Accrual adjustments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccruedLiabilitiesAndOtherLiabilities" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:title="label: AccruedLiabilitiesAndOtherLiabilities to us-gaap_AccruedLiabilitiesAndOtherLiabilities" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_AccruedLiabilitiesAndOtherLiabilities1" xml:lang="en-US" id="us-gaap_AccruedLiabilitiesAndOtherLiabilities1">Accrued expenses and other current liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccruedLiabilitiesAndOtherLiabilities" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilities1" xlink:title="label: AccruedLiabilitiesAndOtherLiabilities to us-gaap_AccruedLiabilitiesAndOtherLiabilities1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities2" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_AccruedLiabilitiesAndOtherLiabilities2" xml:lang="en-US" id="us-gaap_AccruedLiabilitiesAndOtherLiabilities2">Total accrued expenses and other current liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccruedLiabilitiesAndOtherLiabilities" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilities2" xlink:title="label: AccruedLiabilitiesAndOtherLiabilities to us-gaap_AccruedLiabilitiesAndOtherLiabilities2" />
    <link:label xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities_lbl3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_AccruedLiabilitiesAndOtherLiabilities_lbl3" xml:lang="en-US" id="us-gaap_AccruedLiabilitiesAndOtherLiabilities_lbl3">Accrued Liabilities and Other Liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccruedLiabilitiesAndOtherLiabilities" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilities_lbl3" xlink:title="label: AccruedLiabilitiesAndOtherLiabilities to us-gaap_AccruedLiabilitiesAndOtherLiabilities_lbl3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevolvingCreditFacilityMember" xlink:label="RevolvingCreditFacilityMember" xlink:title="RevolvingCreditFacilityMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_RevolvingCreditFacilityMember" xml:lang="en-US" id="us-gaap_RevolvingCreditFacilityMember">Revolving Credit Facility [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RevolvingCreditFacilityMember" xlink:to="us-gaap_RevolvingCreditFacilityMember" xlink:title="label: RevolvingCreditFacilityMember to us-gaap_RevolvingCreditFacilityMember" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityAxis" xlink:label="CreditFacilityAxis" xlink:title="CreditFacilityAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CreditFacilityAxis" xml:lang="en-US" id="us-gaap_CreditFacilityAxis">Credit Facility [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CreditFacilityAxis" xlink:to="us-gaap_CreditFacilityAxis" xlink:title="label: CreditFacilityAxis to us-gaap_CreditFacilityAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityDomain" xlink:label="CreditFacilityDomain" xlink:title="CreditFacilityDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CreditFacilityDomain" xml:lang="en-US" id="us-gaap_CreditFacilityDomain">Credit Facility [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CreditFacilityDomain" xlink:to="us-gaap_CreditFacilityDomain" xlink:title="label: CreditFacilityDomain to us-gaap_CreditFacilityDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="PropertyPlantAndEquipmentUsefulLife" xlink:title="PropertyPlantAndEquipmentUsefulLife" />
    <link:label xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_PropertyPlantAndEquipmentUsefulLife" xml:lang="en-US" id="us-gaap_PropertyPlantAndEquipmentUsefulLife">Useful life</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:title="label: PropertyPlantAndEquipmentUsefulLife to us-gaap_PropertyPlantAndEquipmentUsefulLife" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths" xlink:label="FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths" xlink:title="FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths" xml:lang="en-US" id="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths">2025</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths" xlink:title="label: FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths to us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths_lbl1" xml:lang="en-US" id="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths_lbl1">Finite-Lived Intangible Assets, Amortization Expense, Next Rolling 12 Months</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths_lbl1" xlink:title="label: FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths to us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo" xlink:label="FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo" xlink:title="FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo" xml:lang="en-US" id="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo">2026</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo" xlink:title="label: FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo to us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree" xlink:label="FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree" xlink:title="FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree" xml:lang="en-US" id="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree">2027</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree" xlink:title="label: FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree to us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour" xlink:label="FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour" xlink:title="FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour" xml:lang="en-US" id="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour">2028</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour" xlink:title="label: FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour to us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour_lbl1" xml:lang="en-US" id="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour_lbl1">Finite-Lived Intangible Assets, Amortization Expense, Rolling Year Four</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour" xlink:to="us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour_lbl1" xlink:title="label: FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour to us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xml:lang="en-US" id="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">Weighted average remaining contractual life of stock options, outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:title="label: SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 to us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xml:lang="en-US" id="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">Weighted average remaining contractual life of stock options, exercisable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:title="label: SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 to us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl1" xml:lang="en-US" id="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl1">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl1" xlink:title="label: SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 to us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xml:lang="en-US" id="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">Weighted average remaining contractual life of stock options, expected to vest</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:title="label: SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 to us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xml:lang="en-US" id="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">Expected term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:title="label: SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 to us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm2" xml:lang="en-US" id="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm2">Expected term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm2" xlink:title="label: SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 to us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1">Equity incentive plans, term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1 to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod2" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod2">Exercise term for his vested stock options</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod2" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1 to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod2" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_lbl2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_lbl2" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_lbl2">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Requisite Service Period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_lbl2" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1 to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_lbl2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">Equity incentive plans, vesting period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod2" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod2">Restricted stock units vested over a period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod2" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod2" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod3" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod3" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod3">Exercise period for his vested stock options</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod3" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod3" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:title="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xml:lang="en-US" id="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">Unrecognized compensation expense recognition period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:title="label: EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 to us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:label="SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:title="SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xml:lang="en-US" id="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2">Weighted average remaining contractual life of stock options, exercisable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:title="label: SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2 to us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseExpirationDate1" xlink:label="LeaseExpirationDate1" xlink:title="LeaseExpirationDate1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LeaseExpirationDate1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_LeaseExpirationDate1" xml:lang="en-US" id="us-gaap_LeaseExpirationDate1">Lease extended maturity date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LeaseExpirationDate1" xlink:to="us-gaap_LeaseExpirationDate1" xlink:title="label: LeaseExpirationDate1 to us-gaap_LeaseExpirationDate1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LeaseExpirationDate1_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LeaseExpirationDate1_lbl1" xml:lang="en-US" id="us-gaap_LeaseExpirationDate1_lbl1">Lease Expiration Date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LeaseExpirationDate1" xlink:to="us-gaap_LeaseExpirationDate1_lbl1" xlink:title="label: LeaseExpirationDate1 to us-gaap_LeaseExpirationDate1_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" xml:lang="en-US" id="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate">Award expiration date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate to us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="NumberOfOperatingSegments" xlink:title="NumberOfOperatingSegments" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_NumberOfOperatingSegments" xml:lang="en-US" id="us-gaap_NumberOfOperatingSegments">Number of operating segments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfOperatingSegments" xlink:to="us-gaap_NumberOfOperatingSegments" xlink:title="label: NumberOfOperatingSegments to us-gaap_NumberOfOperatingSegments" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="SellingGeneralAndAdministrativeExpensesMember" xlink:title="SellingGeneralAndAdministrativeExpensesMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SellingGeneralAndAdministrativeExpensesMember" xml:lang="en-US" id="us-gaap_SellingGeneralAndAdministrativeExpensesMember">Selling, General and Administrative [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SellingGeneralAndAdministrativeExpensesMember" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:title="label: SellingGeneralAndAdministrativeExpensesMember to us-gaap_SellingGeneralAndAdministrativeExpensesMember" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="ConcentrationRiskPercentage1" xlink:title="ConcentrationRiskPercentage1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ConcentrationRiskPercentage1" xml:lang="en-US" id="us-gaap_ConcentrationRiskPercentage1">Concentration risk, percentage</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConcentrationRiskPercentage1" xlink:to="us-gaap_ConcentrationRiskPercentage1" xlink:title="label: ConcentrationRiskPercentage1 to us-gaap_ConcentrationRiskPercentage1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock" xlink:label="ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock" xlink:title="ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock" xml:lang="en-US" id="us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock">Schedule of Unvested RSU Activity</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock" xlink:to="us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock" xlink:title="label: ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock to us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfSalesMember" xlink:label="CostOfSalesMember" xlink:title="CostOfSalesMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CostOfSalesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CostOfSalesMember" xml:lang="en-US" id="us-gaap_CostOfSalesMember">Cost of Product Revenue [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CostOfSalesMember" xlink:to="us-gaap_CostOfSalesMember" xlink:title="label: CostOfSalesMember to us-gaap_CostOfSalesMember" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenseMember" xlink:label="OperatingExpenseMember" xlink:title="OperatingExpenseMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OperatingExpenseMember" xml:lang="en-US" id="us-gaap_OperatingExpenseMember">Plasma Center Operating Expenses [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingExpenseMember" xlink:to="us-gaap_OperatingExpenseMember" xlink:title="label: OperatingExpenseMember to us-gaap_OperatingExpenseMember" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwardsExpirationDate" xlink:label="OperatingLossCarryforwardsExpirationDate" xlink:title="OperatingLossCarryforwardsExpirationDate" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwardsExpirationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OperatingLossCarryforwardsExpirationDate" xml:lang="en-US" id="us-gaap_OperatingLossCarryforwardsExpirationDate">Net operating loss carryforwards, expiration</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLossCarryforwardsExpirationDate" xlink:to="us-gaap_OperatingLossCarryforwardsExpirationDate" xlink:title="label: OperatingLossCarryforwardsExpirationDate to us-gaap_OperatingLossCarryforwardsExpirationDate" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:label="RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:title="RevenueFromExternalCustomersByGeographicAreasTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xml:lang="en-US" id="us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock">Net Revenues According to Geographic Area</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:to="us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:title="label: RevenueFromExternalCustomersByGeographicAreasTableTextBlock to us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="SharesIssuedPricePerShare" xlink:title="SharesIssuedPricePerShare" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SharesIssuedPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SharesIssuedPricePerShare" xml:lang="en-US" id="us-gaap_SharesIssuedPricePerShare">Public offering price (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare" xlink:title="label: SharesIssuedPricePerShare to us-gaap_SharesIssuedPricePerShare" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:label="DebtInstrumentRedemptionPeriodAxis" xlink:title="DebtInstrumentRedemptionPeriodAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DebtInstrumentRedemptionPeriodAxis" xml:lang="en-US" id="us-gaap_DebtInstrumentRedemptionPeriodAxis">Debt Instrument, Redemption, Period [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentRedemptionPeriodAxis" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:title="label: DebtInstrumentRedemptionPeriodAxis to us-gaap_DebtInstrumentRedemptionPeriodAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:label="DebtInstrumentRedemptionPeriodDomain" xlink:title="DebtInstrumentRedemptionPeriodDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DebtInstrumentRedemptionPeriodDomain" xml:lang="en-US" id="us-gaap_DebtInstrumentRedemptionPeriodDomain">Debt Instrument, Redemption, Period [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentRedemptionPeriodDomain" xlink:to="us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:title="label: DebtInstrumentRedemptionPeriodDomain to us-gaap_DebtInstrumentRedemptionPeriodDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="FairValueAdjustmentOfWarrants" xlink:title="FairValueAdjustmentOfWarrants" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FairValueAdjustmentOfWarrants" xml:lang="en-US" id="us-gaap_FairValueAdjustmentOfWarrants">Fair value of warrants</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FairValueAdjustmentOfWarrants" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" xlink:title="label: FairValueAdjustmentOfWarrants to us-gaap_FairValueAdjustmentOfWarrants" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:label="FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:title="FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xml:lang="en-US" id="us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1">Amortization period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:to="us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:title="label: FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1 to us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_lbl1" xml:lang="en-US" id="us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_lbl1">Finite-Lived Intangible Assets, Remaining Amortization Period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:to="us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_lbl1" xlink:title="label: FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1 to us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateIncreaseDecrease" xlink:label="DebtInstrumentInterestRateIncreaseDecrease" xlink:title="DebtInstrumentInterestRateIncreaseDecrease" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DebtInstrumentInterestRateIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DebtInstrumentInterestRateIncreaseDecrease" xml:lang="en-US" id="us-gaap_DebtInstrumentInterestRateIncreaseDecrease">Increase applicable margin</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentInterestRateIncreaseDecrease" xlink:to="us-gaap_DebtInstrumentInterestRateIncreaseDecrease" xlink:title="label: DebtInstrumentInterestRateIncreaseDecrease to us-gaap_DebtInstrumentInterestRateIncreaseDecrease" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" xlink:label="DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" xlink:title="DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" xml:lang="en-US" id="us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed">Percentage of prepaid principal amount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" xlink:to="us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" xlink:title="label: DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed to us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VariableRateAxis" xlink:label="VariableRateAxis" xlink:title="VariableRateAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_VariableRateAxis" xml:lang="en-US" id="us-gaap_VariableRateAxis">Variable Rate [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="VariableRateAxis" xlink:to="us-gaap_VariableRateAxis" xlink:title="label: VariableRateAxis to us-gaap_VariableRateAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VariableRateDomain" xlink:label="VariableRateDomain" xlink:title="VariableRateDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_VariableRateDomain" xml:lang="en-US" id="us-gaap_VariableRateDomain">Variable Rate [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="VariableRateDomain" xlink:to="us-gaap_VariableRateDomain" xlink:title="label: VariableRateDomain to us-gaap_VariableRateDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BaseRateMember" xlink:label="BaseRateMember" xlink:title="BaseRateMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_BaseRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_BaseRateMember" xml:lang="en-US" id="us-gaap_BaseRateMember">Base Rate [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BaseRateMember" xlink:to="us-gaap_BaseRateMember" xlink:title="label: BaseRateMember to us-gaap_BaseRateMember" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CorporateNonSegmentMember" xlink:label="CorporateNonSegmentMember" xlink:title="CorporateNonSegmentMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CorporateNonSegmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CorporateNonSegmentMember" xml:lang="en-US" id="us-gaap_CorporateNonSegmentMember">Corporate [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CorporateNonSegmentMember" xlink:to="us-gaap_CorporateNonSegmentMember" xlink:title="label: CorporateNonSegmentMember to us-gaap_CorporateNonSegmentMember" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="OverAllotmentOptionMember" xlink:title="OverAllotmentOptionMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OverAllotmentOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OverAllotmentOptionMember" xml:lang="en-US" id="us-gaap_OverAllotmentOptionMember">Underwritten Public Offering [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OverAllotmentOptionMember" xlink:to="us-gaap_OverAllotmentOptionMember" xlink:title="label: OverAllotmentOptionMember to us-gaap_OverAllotmentOptionMember" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxPeriodAxis" xlink:label="TaxPeriodAxis" xlink:title="TaxPeriodAxis" />
    <link:label xlink:type="resource" xlink:label="us-gaap_TaxPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_TaxPeriodAxis" xml:lang="en-US" id="us-gaap_TaxPeriodAxis">Tax Period [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TaxPeriodAxis" xlink:to="us-gaap_TaxPeriodAxis" xlink:title="label: TaxPeriodAxis to us-gaap_TaxPeriodAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxPeriodDomain" xlink:label="TaxPeriodDomain" xlink:title="TaxPeriodDomain" />
    <link:label xlink:type="resource" xlink:label="us-gaap_TaxPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_TaxPeriodDomain" xml:lang="en-US" id="us-gaap_TaxPeriodDomain">Tax Period [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TaxPeriodDomain" xlink:to="us-gaap_TaxPeriodDomain" xlink:title="label: TaxPeriodDomain to us-gaap_TaxPeriodDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:title="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xml:lang="en-US" id="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">Warrant exercise price per share (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:title="label: ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 to us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights2" xml:lang="en-US" id="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights2">Warrant exercise price (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights2" xlink:title="label: ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 to us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxAssetsNet" xlink:label="DeferredIncomeTaxAssetsNet" xlink:title="DeferredIncomeTaxAssetsNet" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_DeferredIncomeTaxAssetsNet" xml:lang="en-US" id="us-gaap_DeferredIncomeTaxAssetsNet">Deferred tax assets, net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredIncomeTaxAssetsNet" xlink:to="us-gaap_DeferredIncomeTaxAssetsNet" xlink:title="label: DeferredIncomeTaxAssetsNet to us-gaap_DeferredIncomeTaxAssetsNet" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxAssetsNet_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DeferredIncomeTaxAssetsNet_lbl1" xml:lang="en-US" id="us-gaap_DeferredIncomeTaxAssetsNet_lbl1">Deferred Income Tax Assets, Net</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredIncomeTaxAssetsNet" xlink:to="us-gaap_DeferredIncomeTaxAssetsNet_lbl1" xlink:title="label: DeferredIncomeTaxAssetsNet to us-gaap_DeferredIncomeTaxAssetsNet_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonUsMember" xlink:label="NonUsMember" xlink:title="NonUsMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_NonUsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_NonUsMember" xml:lang="en-US" id="us-gaap_NonUsMember">International [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NonUsMember" xlink:to="us-gaap_NonUsMember" xlink:title="label: NonUsMember to us-gaap_NonUsMember" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="RevenueFromContractWithCustomerAbstract" xlink:title="RevenueFromContractWithCustomerAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_RevenueFromContractWithCustomerAbstract" xml:lang="en-US" id="us-gaap_RevenueFromContractWithCustomerAbstract">Revenue Recognition [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RevenueFromContractWithCustomerAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerAbstract" xlink:title="label: RevenueFromContractWithCustomerAbstract to us-gaap_RevenueFromContractWithCustomerAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:label="RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:title="RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xml:lang="en-US" id="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:to="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:title="label: RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable to us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:label="RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:title="RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xml:lang="en-US" id="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:to="us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:title="label: RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems to us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="ContractWithCustomerLiabilityCurrent" xlink:title="ContractWithCustomerLiabilityCurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_ContractWithCustomerLiabilityCurrent" xml:lang="en-US" id="us-gaap_ContractWithCustomerLiabilityCurrent">Current portion of deferred revenue</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ContractWithCustomerLiabilityCurrent" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent" xlink:title="label: ContractWithCustomerLiabilityCurrent to us-gaap_ContractWithCustomerLiabilityCurrent" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="OperatingLeaseRightOfUseAsset" xlink:title="OperatingLeaseRightOfUseAsset" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OperatingLeaseRightOfUseAsset" xml:lang="en-US" id="us-gaap_OperatingLeaseRightOfUseAsset">Right-of-use assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" xlink:title="label: OperatingLeaseRightOfUseAsset to us-gaap_OperatingLeaseRightOfUseAsset" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:label="OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:title="OperatingLeaseLiabilitiesPaymentsDueAbstract" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xml:lang="en-US" id="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract">Payments Under Lease Obligations [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:title="label: OperatingLeaseLiabilitiesPaymentsDueAbstract to us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="RevenueFromContractWithCustomerExcludingAssessedTax" xlink:title="RevenueFromContractWithCustomerExcludingAssessedTax" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xml:lang="en-US" id="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">REVENUES</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:title="label: RevenueFromContractWithCustomerExcludingAssessedTax to us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax1" xml:lang="en-US" id="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax1">Revenues</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax1" xlink:title="label: RevenueFromContractWithCustomerExcludingAssessedTax to us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:title="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xml:lang="en-US" id="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">Net increase (decrease) in cash and cash equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:title="label: CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect to us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl1" xml:lang="en-US" id="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl1">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl1" xlink:title="label: CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect to us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:title="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:title="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xml:lang="en-US" id="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">Cash and cash equivalents - beginning of year</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:title="label: CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents to us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents1" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:title="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents1" xml:lang="en-US" id="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents1">Cash and cash equivalents - end of year</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents1" xlink:title="label: CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents to us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl2" xml:lang="en-US" id="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl2">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl2" xlink:title="label: CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents to us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeasePayments" xlink:label="OperatingLeasePayments" xlink:title="OperatingLeasePayments" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_OperatingLeasePayments" xml:lang="en-US" id="us-gaap_OperatingLeasePayments">Cash payments for lease</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments" xlink:title="label: OperatingLeasePayments to us-gaap_OperatingLeasePayments" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingLeasePayments_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OperatingLeasePayments_lbl1" xml:lang="en-US" id="us-gaap_OperatingLeasePayments_lbl1">Operating Lease, Payments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_lbl1" xlink:title="label: OperatingLeasePayments to us-gaap_OperatingLeasePayments_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeasePrincipalPayments" xlink:label="FinanceLeasePrincipalPayments" xlink:title="FinanceLeasePrincipalPayments" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FinanceLeasePrincipalPayments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_FinanceLeasePrincipalPayments" xml:lang="en-US" id="us-gaap_FinanceLeasePrincipalPayments">Payments on finance lease obligations</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FinanceLeasePrincipalPayments" xlink:to="us-gaap_FinanceLeasePrincipalPayments" xlink:title="label: FinanceLeasePrincipalPayments to us-gaap_FinanceLeasePrincipalPayments" />
    <link:label xlink:type="resource" xlink:label="us-gaap_FinanceLeasePrincipalPayments_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_FinanceLeasePrincipalPayments_lbl1" xml:lang="en-US" id="us-gaap_FinanceLeasePrincipalPayments_lbl1">Finance Lease, Principal Payments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FinanceLeasePrincipalPayments" xlink:to="us-gaap_FinanceLeasePrincipalPayments_lbl1" xlink:title="label: FinanceLeasePrincipalPayments to us-gaap_FinanceLeasePrincipalPayments_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:title="RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xml:lang="en-US" id="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">Right-to-use assets in exchange for lease obligations</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:title="label: RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability to us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl1" xml:lang="en-US" id="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl1">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl1" xlink:title="label: RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability to us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="OperatingLeaseWeightedAverageDiscountRatePercent" xlink:title="OperatingLeaseWeightedAverageDiscountRatePercent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xml:lang="en-US" id="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">Weighted average discount rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:title="label: OperatingLeaseWeightedAverageDiscountRatePercent to us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl1" xml:lang="en-US" id="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl1">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl1" xlink:title="label: OperatingLeaseWeightedAverageDiscountRatePercent to us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="LesseeOperatingLeaseLiabilityPaymentsDue" xlink:title="LesseeOperatingLeaseLiabilityPaymentsDue" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:title="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xml:lang="en-US" id="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">Total payments</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:title="label: LesseeOperatingLeaseLiabilityPaymentsDue to us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl1" xml:lang="en-US" id="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl1">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl1" xlink:title="label: LesseeOperatingLeaseLiabilityPaymentsDue to us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:title="LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xml:lang="en-US" id="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">Thereafter</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:title="label: LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive to us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:title="LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xml:lang="en-US" id="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">Year ended December 31, 2025</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:title="label: LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths to us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl1" xml:lang="en-US" id="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl1">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl1" xlink:title="label: LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths to us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:title="LesseeOperatingLeaseLiabilityPaymentsDueYearFive" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xml:lang="en-US" id="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">2029</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:title="label: LesseeOperatingLeaseLiabilityPaymentsDueYearFive to us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:title="LesseeOperatingLeaseLiabilityPaymentsDueYearFour" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xml:lang="en-US" id="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">2028</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:title="label: LesseeOperatingLeaseLiabilityPaymentsDueYearFour to us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl1" xml:lang="en-US" id="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl1">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl1" xlink:title="label: LesseeOperatingLeaseLiabilityPaymentsDueYearFour to us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:title="LesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xml:lang="en-US" id="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">2027</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:title="label: LesseeOperatingLeaseLiabilityPaymentsDueYearThree to us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl1" xml:lang="en-US" id="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl1">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl1" xlink:title="label: LesseeOperatingLeaseLiabilityPaymentsDueYearThree to us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:title="LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xml:lang="en-US" id="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">2026</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:title="label: LesseeOperatingLeaseLiabilityPaymentsDueYearTwo to us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl1" xml:lang="en-US" id="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl1">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl1" xlink:title="label: LesseeOperatingLeaseLiabilityPaymentsDueYearTwo to us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:title="LesseeOperatingLeaseLiabilityMaturityTableTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xml:lang="en-US" id="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">Payments Under Lease Obligations</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:title="label: LesseeOperatingLeaseLiabilityMaturityTableTextBlock to us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseExpense" xlink:label="OperatingLeaseExpense" xlink:title="OperatingLeaseExpense" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:title="us-gaap_OperatingLeaseExpense" xml:lang="en-US" id="us-gaap_OperatingLeaseExpense">Aggregate lease expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLeaseExpense" xlink:to="us-gaap_OperatingLeaseExpense" xlink:title="label: OperatingLeaseExpense to us-gaap_OperatingLeaseExpense" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingLeaseExpense_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OperatingLeaseExpense_lbl1" xml:lang="en-US" id="us-gaap_OperatingLeaseExpense_lbl1">Operating Lease, Expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLeaseExpense" xlink:to="us-gaap_OperatingLeaseExpense_lbl1" xlink:title="label: OperatingLeaseExpense to us-gaap_OperatingLeaseExpense_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="OperatingLeaseLiabilityCurrent" xlink:title="OperatingLeaseLiabilityCurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OperatingLeaseLiabilityCurrent" xml:lang="en-US" id="us-gaap_OperatingLeaseLiabilityCurrent">Current portion of lease obligations</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" xlink:title="label: OperatingLeaseLiabilityCurrent to us-gaap_OperatingLeaseLiabilityCurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent1" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_OperatingLeaseLiabilityCurrent1" xml:lang="en-US" id="us-gaap_OperatingLeaseLiabilityCurrent1">Current portion</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent1" xlink:title="label: OperatingLeaseLiabilityCurrent to us-gaap_OperatingLeaseLiabilityCurrent1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:title="LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xml:lang="en-US" id="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">Less: imputed interest</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:title="label: LesseeOperatingLeaseLiabilityUndiscountedExcessAmount to us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl1" xml:lang="en-US" id="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl1">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl1" xlink:title="label: LesseeOperatingLeaseLiabilityUndiscountedExcessAmount to us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="OperatingLeaseLiabilityNoncurrent" xlink:title="OperatingLeaseLiabilityNoncurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_OperatingLeaseLiabilityNoncurrent" xml:lang="en-US" id="us-gaap_OperatingLeaseLiabilityNoncurrent">Balance at December 31, 2024</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:title="label: OperatingLeaseLiabilityNoncurrent to us-gaap_OperatingLeaseLiabilityNoncurrent" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OperatingLeaseLiabilityNoncurrent1" xml:lang="en-US" id="us-gaap_OperatingLeaseLiabilityNoncurrent1">Lease obligations, net of current portion</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent1" xlink:title="label: OperatingLeaseLiabilityNoncurrent to us-gaap_OperatingLeaseLiabilityNoncurrent1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="LesseeOperatingLeasesTextBlock" xlink:title="LesseeOperatingLeasesTextBlock" />
    <link:label xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_LesseeOperatingLeasesTextBlock" xml:lang="en-US" id="us-gaap_LesseeOperatingLeasesTextBlock">LEASE OBLIGATIONS</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeOperatingLeasesTextBlock" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock" xlink:title="label: LesseeOperatingLeasesTextBlock to us-gaap_LesseeOperatingLeasesTextBlock" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:title="OperatingLeaseWeightedAverageRemainingLeaseTerm1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xml:lang="en-US" id="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">Weighted average remaining term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:title="label: OperatingLeaseWeightedAverageRemainingLeaseTerm1 to us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" xlink:label="EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" xlink:title="EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" />
    <link:label xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" xml:lang="en-US" id="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount">Excess tax benefits related to stock-based compensation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" xlink:title="label: EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount to us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetInterestCarryforward" xlink:label="DeferredTaxAssetInterestCarryforward" xlink:title="DeferredTaxAssetInterestCarryforward" />
    <link:label xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetInterestCarryforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_DeferredTaxAssetInterestCarryforward" xml:lang="en-US" id="us-gaap_DeferredTaxAssetInterestCarryforward">Interest expense limitations carryforwards</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredTaxAssetInterestCarryforward" xlink:to="us-gaap_DeferredTaxAssetInterestCarryforward" xlink:title="label: DeferredTaxAssetInterestCarryforward to us-gaap_DeferredTaxAssetInterestCarryforward" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerProductAndServiceBenchmarkMember" xlink:label="RevenueFromContractWithCustomerProductAndServiceBenchmarkMember" xlink:title="RevenueFromContractWithCustomerProductAndServiceBenchmarkMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerProductAndServiceBenchmarkMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_RevenueFromContractWithCustomerProductAndServiceBenchmarkMember" xml:lang="en-US" id="us-gaap_RevenueFromContractWithCustomerProductAndServiceBenchmarkMember">Revenue [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RevenueFromContractWithCustomerProductAndServiceBenchmarkMember" xlink:to="us-gaap_RevenueFromContractWithCustomerProductAndServiceBenchmarkMember" xlink:title="label: RevenueFromContractWithCustomerProductAndServiceBenchmarkMember to us-gaap_RevenueFromContractWithCustomerProductAndServiceBenchmarkMember" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentExpenditureAdditionToLongLivedAssets" xlink:label="SegmentExpenditureAdditionToLongLivedAssets" xlink:title="SegmentExpenditureAdditionToLongLivedAssets" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SegmentExpenditureAdditionToLongLivedAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="us-gaap_SegmentExpenditureAdditionToLongLivedAssets" xml:lang="en-US" id="us-gaap_SegmentExpenditureAdditionToLongLivedAssets">Expenditures for additions to long-lived assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SegmentExpenditureAdditionToLongLivedAssets" xlink:to="us-gaap_SegmentExpenditureAdditionToLongLivedAssets" xlink:title="label: SegmentExpenditureAdditionToLongLivedAssets to us-gaap_SegmentExpenditureAdditionToLongLivedAssets" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SegmentExpenditureAdditionToLongLivedAssets_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SegmentExpenditureAdditionToLongLivedAssets_lbl1" xml:lang="en-US" id="us-gaap_SegmentExpenditureAdditionToLongLivedAssets_lbl1">Segment, Expenditure, Addition to Long-Lived Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SegmentExpenditureAdditionToLongLivedAssets" xlink:to="us-gaap_SegmentExpenditureAdditionToLongLivedAssets_lbl1" xlink:title="label: SegmentExpenditureAdditionToLongLivedAssets to us-gaap_SegmentExpenditureAdditionToLongLivedAssets_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyMember" xlink:label="RelatedPartyMember" xlink:title="RelatedPartyMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_RelatedPartyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_RelatedPartyMember" xml:lang="en-US" id="us-gaap_RelatedPartyMember">Related Party [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RelatedPartyMember" xlink:to="us-gaap_RelatedPartyMember" xlink:title="label: RelatedPartyMember to us-gaap_RelatedPartyMember" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SecuredOvernightFinancingRateSofrMember" xlink:label="SecuredOvernightFinancingRateSofrMember" xlink:title="SecuredOvernightFinancingRateSofrMember" />
    <link:label xlink:type="resource" xlink:label="us-gaap_SecuredOvernightFinancingRateSofrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_SecuredOvernightFinancingRateSofrMember" xml:lang="en-US" id="us-gaap_SecuredOvernightFinancingRateSofrMember">SOFR [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SecuredOvernightFinancingRateSofrMember" xlink:to="us-gaap_SecuredOvernightFinancingRateSofrMember" xlink:title="label: SecuredOvernightFinancingRateSofrMember to us-gaap_SecuredOvernightFinancingRateSofrMember" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseNonoperating" xlink:label="InterestExpenseNonoperating" xlink:title="InterestExpenseNonoperating" />
    <link:label xlink:type="resource" xlink:label="us-gaap_InterestExpenseNonoperating" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="us-gaap_InterestExpenseNonoperating" xml:lang="en-US" id="us-gaap_InterestExpenseNonoperating">Interest expense</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InterestExpenseNonoperating" xlink:to="us-gaap_InterestExpenseNonoperating" xlink:title="label: InterestExpenseNonoperating to us-gaap_InterestExpenseNonoperating" />
    <link:label xlink:type="resource" xlink:label="us-gaap_InterestExpenseNonoperating1" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:title="us-gaap_InterestExpenseNonoperating1" xml:lang="en-US" id="us-gaap_InterestExpenseNonoperating1">Unallocated interest expense, primarily related to interest on senior debt (see Note 7)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InterestExpenseNonoperating" xlink:to="us-gaap_InterestExpenseNonoperating1" xlink:title="label: InterestExpenseNonoperating to us-gaap_InterestExpenseNonoperating1" />
    <link:label xlink:type="resource" xlink:label="us-gaap_InterestExpenseNonoperating_lbl2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="us-gaap_InterestExpenseNonoperating_lbl2" xml:lang="en-US" id="us-gaap_InterestExpenseNonoperating_lbl2">Interest Expense, Nonoperating</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="InterestExpenseNonoperating" xlink:to="us-gaap_InterestExpenseNonoperating_lbl2" xlink:title="label: InterestExpenseNonoperating to us-gaap_InterestExpenseNonoperating_lbl2" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="TitleOfIndividualWithRelationshipToEntityDomain" xlink:title="TitleOfIndividualWithRelationshipToEntityDomain" />
    <link:label xlink:type="resource" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="srt_TitleOfIndividualWithRelationshipToEntityDomain" xml:lang="en-US" id="srt_TitleOfIndividualWithRelationshipToEntityDomain">Title and Position [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:title="label: TitleOfIndividualWithRelationshipToEntityDomain to srt_TitleOfIndividualWithRelationshipToEntityDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_NameOfMajorCustomerDomain" xlink:label="NameOfMajorCustomerDomain" xlink:title="NameOfMajorCustomerDomain" />
    <link:label xlink:type="resource" xlink:label="srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="srt_NameOfMajorCustomerDomain" xml:lang="en-US" id="srt_NameOfMajorCustomerDomain">Customer [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NameOfMajorCustomerDomain" xlink:to="srt_NameOfMajorCustomerDomain" xlink:title="label: NameOfMajorCustomerDomain to srt_NameOfMajorCustomerDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock" xlink:label="ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock" xlink:title="ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock" xml:lang="en-US" id="srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock">Schedule II - Valuation and Qualifying Accounts</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock" xlink:to="srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock" xlink:title="label: ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock to srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock" />
    <link:label xlink:type="resource" xlink:label="srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock_lbl1" xml:lang="en-US" id="srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock_lbl1">SEC Schedule, 12-09, Schedule of Valuation and Qualifying Accounts Disclosure [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock" xlink:to="srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock_lbl1" xlink:title="label: ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock to srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:label="ValuationAndQualifyingAccountsDisclosureLineItems" xlink:title="ValuationAndQualifyingAccountsDisclosureLineItems" />
    <link:label xlink:type="resource" xlink:label="srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="srt_ValuationAndQualifyingAccountsDisclosureLineItems" xml:lang="en-US" id="srt_ValuationAndQualifyingAccountsDisclosureLineItems">Valuation and Qualifying Accounts Disclosure [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ValuationAndQualifyingAccountsDisclosureLineItems" xlink:to="srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:title="label: ValuationAndQualifyingAccountsDisclosureLineItems to srt_ValuationAndQualifyingAccountsDisclosureLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:label="ValuationAndQualifyingAccountsDisclosureTable" xlink:title="ValuationAndQualifyingAccountsDisclosureTable" />
    <link:label xlink:type="resource" xlink:label="srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="srt_ValuationAndQualifyingAccountsDisclosureTable" xml:lang="en-US" id="srt_ValuationAndQualifyingAccountsDisclosureTable">Valuation and Qualifying Accounts Disclosure [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ValuationAndQualifyingAccountsDisclosureTable" xlink:to="srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:title="label: ValuationAndQualifyingAccountsDisclosureTable to srt_ValuationAndQualifyingAccountsDisclosureTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_DirectorMember" xlink:label="DirectorMember" xlink:title="DirectorMember" />
    <link:label xlink:type="resource" xlink:label="srt_DirectorMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="srt_DirectorMember" xml:lang="en-US" id="srt_DirectorMember">Directors [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DirectorMember" xlink:to="srt_DirectorMember" xlink:title="label: DirectorMember to srt_DirectorMember" />
    <link:label xlink:type="resource" xlink:label="srt_DirectorMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="srt_DirectorMember_lbl1" xml:lang="en-US" id="srt_DirectorMember_lbl1">Director [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DirectorMember" xlink:to="srt_DirectorMember_lbl1" xlink:title="label: DirectorMember to srt_DirectorMember_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ExecutiveOfficerMember" xlink:label="ExecutiveOfficerMember" xlink:title="ExecutiveOfficerMember" />
    <link:label xlink:type="resource" xlink:label="srt_ExecutiveOfficerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="srt_ExecutiveOfficerMember" xml:lang="en-US" id="srt_ExecutiveOfficerMember">Executive Officer [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ExecutiveOfficerMember" xlink:to="srt_ExecutiveOfficerMember" xlink:title="label: ExecutiveOfficerMember to srt_ExecutiveOfficerMember" />
    <link:label xlink:type="resource" xlink:label="srt_ExecutiveOfficerMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="srt_ExecutiveOfficerMember_lbl1" xml:lang="en-US" id="srt_ExecutiveOfficerMember_lbl1">Executive Officer [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ExecutiveOfficerMember" xlink:to="srt_ExecutiveOfficerMember_lbl1" xlink:title="label: ExecutiveOfficerMember to srt_ExecutiveOfficerMember_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain" xlink:label="SegmentGeographicalDomain" xlink:title="SegmentGeographicalDomain" />
    <link:label xlink:type="resource" xlink:label="srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="srt_SegmentGeographicalDomain" xml:lang="en-US" id="srt_SegmentGeographicalDomain">Geographical [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SegmentGeographicalDomain" xlink:to="srt_SegmentGeographicalDomain" xlink:title="label: SegmentGeographicalDomain to srt_SegmentGeographicalDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis" xlink:label="StatementGeographicalAxis" xlink:title="StatementGeographicalAxis" />
    <link:label xlink:type="resource" xlink:label="srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="srt_StatementGeographicalAxis" xml:lang="en-US" id="srt_StatementGeographicalAxis">Geographical [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StatementGeographicalAxis" xlink:to="srt_StatementGeographicalAxis" xlink:title="label: StatementGeographicalAxis to srt_StatementGeographicalAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MajorCustomersAxis" xlink:label="MajorCustomersAxis" xlink:title="MajorCustomersAxis" />
    <link:label xlink:type="resource" xlink:label="srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="srt_MajorCustomersAxis" xml:lang="en-US" id="srt_MajorCustomersAxis">Customer [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MajorCustomersAxis" xlink:to="srt_MajorCustomersAxis" xlink:title="label: MajorCustomersAxis to srt_MajorCustomersAxis" />
    <link:label xlink:type="resource" xlink:label="srt_MajorCustomersAxis_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="srt_MajorCustomersAxis_lbl1" xml:lang="en-US" id="srt_MajorCustomersAxis_lbl1">Customer [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MajorCustomersAxis" xlink:to="srt_MajorCustomersAxis_lbl1" xlink:title="label: MajorCustomersAxis to srt_MajorCustomersAxis_lbl1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ValuationAndQualifyingAccountsAbstract" xlink:label="ValuationAndQualifyingAccountsAbstract" xlink:title="ValuationAndQualifyingAccountsAbstract" />
    <link:label xlink:type="resource" xlink:label="srt_ValuationAndQualifyingAccountsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="srt_ValuationAndQualifyingAccountsAbstract" xml:lang="en-US" id="srt_ValuationAndQualifyingAccountsAbstract">Schedule II - Valuation and Qualifying Accounts [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ValuationAndQualifyingAccountsAbstract" xlink:to="srt_ValuationAndQualifyingAccountsAbstract" xlink:title="label: ValuationAndQualifyingAccountsAbstract to srt_ValuationAndQualifyingAccountsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="RangeAxis" xlink:title="RangeAxis" />
    <link:label xlink:type="resource" xlink:label="srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="srt_RangeAxis" xml:lang="en-US" id="srt_RangeAxis">Statistical Measurement [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RangeAxis" xlink:to="srt_RangeAxis" xlink:title="label: RangeAxis to srt_RangeAxis" />
    <link:label xlink:type="resource" xlink:label="srt_RangeAxis1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="srt_RangeAxis1" xml:lang="en-US" id="srt_RangeAxis1">Statistical Measurement [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RangeAxis" xlink:to="srt_RangeAxis1" xlink:title="label: RangeAxis to srt_RangeAxis1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="RangeMember" xlink:title="RangeMember" />
    <link:label xlink:type="resource" xlink:label="srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="srt_RangeMember" xml:lang="en-US" id="srt_RangeMember">Statistical Measurement [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RangeMember" xlink:to="srt_RangeMember" xlink:title="label: RangeMember to srt_RangeMember" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="MaximumMember" xlink:title="MaximumMember" />
    <link:label xlink:type="resource" xlink:label="srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="srt_MaximumMember" xml:lang="en-US" id="srt_MaximumMember">Maximum [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MaximumMember" xlink:to="srt_MaximumMember" xlink:title="label: MaximumMember to srt_MaximumMember" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="MinimumMember" xlink:title="MinimumMember" />
    <link:label xlink:type="resource" xlink:label="srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="srt_MinimumMember" xml:lang="en-US" id="srt_MinimumMember">Minimum [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MinimumMember" xlink:to="srt_MinimumMember" xlink:title="label: MinimumMember to srt_MinimumMember" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis" xlink:label="CounterpartyNameAxis" xlink:title="CounterpartyNameAxis" />
    <link:label xlink:type="resource" xlink:label="srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="srt_CounterpartyNameAxis" xml:lang="en-US" id="srt_CounterpartyNameAxis">Counterparty Name [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CounterpartyNameAxis" xlink:to="srt_CounterpartyNameAxis" xlink:title="label: CounterpartyNameAxis to srt_CounterpartyNameAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="RepurchaseAgreementCounterpartyNameDomain" xlink:title="RepurchaseAgreementCounterpartyNameDomain" />
    <link:label xlink:type="resource" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="srt_RepurchaseAgreementCounterpartyNameDomain" xml:lang="en-US" id="srt_RepurchaseAgreementCounterpartyNameDomain">Counterparty Name [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RepurchaseAgreementCounterpartyNameDomain" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:title="label: RepurchaseAgreementCounterpartyNameDomain to srt_RepurchaseAgreementCounterpartyNameDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="TitleOfIndividualAxis" xlink:title="TitleOfIndividualAxis" />
    <link:label xlink:type="resource" xlink:label="srt_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="srt_TitleOfIndividualAxis" xml:lang="en-US" id="srt_TitleOfIndividualAxis">Title and Position [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis" xlink:title="label: TitleOfIndividualAxis to srt_TitleOfIndividualAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidationItemsAxis" xlink:label="ConsolidationItemsAxis" xlink:title="ConsolidationItemsAxis" />
    <link:label xlink:type="resource" xlink:label="srt_ConsolidationItemsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="srt_ConsolidationItemsAxis" xml:lang="en-US" id="srt_ConsolidationItemsAxis">Consolidation Items [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConsolidationItemsAxis" xlink:to="srt_ConsolidationItemsAxis" xlink:title="label: ConsolidationItemsAxis to srt_ConsolidationItemsAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidationItemsDomain" xlink:label="ConsolidationItemsDomain" xlink:title="ConsolidationItemsDomain" />
    <link:label xlink:type="resource" xlink:label="srt_ConsolidationItemsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="srt_ConsolidationItemsDomain" xml:lang="en-US" id="srt_ConsolidationItemsDomain">Consolidation Items [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ConsolidationItemsDomain" xlink:to="srt_ConsolidationItemsDomain" xlink:title="label: ConsolidationItemsDomain to srt_ConsolidationItemsDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OwnershipAxis" xlink:label="OwnershipAxis" xlink:title="OwnershipAxis" />
    <link:label xlink:type="resource" xlink:label="srt_OwnershipAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="srt_OwnershipAxis" xml:lang="en-US" id="srt_OwnershipAxis">Ownership [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OwnershipAxis" xlink:to="srt_OwnershipAxis" xlink:title="label: OwnershipAxis to srt_OwnershipAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OwnershipDomain" xlink:label="OwnershipDomain" xlink:title="OwnershipDomain" />
    <link:label xlink:type="resource" xlink:label="srt_OwnershipDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="srt_OwnershipDomain" xml:lang="en-US" id="srt_OwnershipDomain">Ownership [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OwnershipDomain" xlink:to="srt_OwnershipDomain" xlink:title="label: OwnershipDomain to srt_OwnershipDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="ProductsAndServicesDomain" xlink:title="ProductsAndServicesDomain" />
    <link:label xlink:type="resource" xlink:label="srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="srt_ProductsAndServicesDomain" xml:lang="en-US" id="srt_ProductsAndServicesDomain">Product and Service [Domain]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProductsAndServicesDomain" xlink:to="srt_ProductsAndServicesDomain" xlink:title="label: ProductsAndServicesDomain to srt_ProductsAndServicesDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis" xlink:label="ProductOrServiceAxis" xlink:title="ProductOrServiceAxis" />
    <link:label xlink:type="resource" xlink:label="srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="srt_ProductOrServiceAxis" xml:lang="en-US" id="srt_ProductOrServiceAxis">Product and Service [Axis]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ProductOrServiceAxis" xlink:to="srt_ProductOrServiceAxis" xlink:title="label: ProductOrServiceAxis to srt_ProductOrServiceAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_US" xlink:label="US" xlink:title="US" />
    <link:label xlink:type="resource" xlink:label="country_US" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="country_US" xml:lang="en-US" id="country_US">United States [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="US" xlink:to="country_US" xlink:title="label: US to country_US" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:label="CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:title="CybersecurityRiskManagementStrategyAndGovernanceAbstract" />
    <link:label xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xml:lang="en-US" id="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract">Cybersecurity Risk Management, Strategy, and Governance [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:to="cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:title="label: CybersecurityRiskManagementStrategyAndGovernanceAbstract to cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:label="CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:title="CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" />
    <link:label xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xml:lang="en-US" id="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock">Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:title="label: CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock to cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedFlag" xlink:label="CybersecurityRiskManagementProcessesIntegratedFlag" xlink:title="CybersecurityRiskManagementProcessesIntegratedFlag" />
    <link:label xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="cyd_CybersecurityRiskManagementProcessesIntegratedFlag" xml:lang="en-US" id="cyd_CybersecurityRiskManagementProcessesIntegratedFlag">Cybersecurity Risk Management Processes Integrated [Flag]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CybersecurityRiskManagementProcessesIntegratedFlag" xlink:to="cyd_CybersecurityRiskManagementProcessesIntegratedFlag" xlink:title="label: CybersecurityRiskManagementProcessesIntegratedFlag to cyd_CybersecurityRiskManagementProcessesIntegratedFlag" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" xlink:label="CybersecurityRiskManagementProcessesIntegratedTextBlock" xlink:title="CybersecurityRiskManagementProcessesIntegratedTextBlock" />
    <link:label xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" xml:lang="en-US" id="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock">Cybersecurity Risk Management Processes Integrated [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CybersecurityRiskManagementProcessesIntegratedTextBlock" xlink:to="cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" xlink:title="label: CybersecurityRiskManagementProcessesIntegratedTextBlock to cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" xlink:label="CybersecurityRiskManagementThirdPartyEngagedFlag" xlink:title="CybersecurityRiskManagementThirdPartyEngagedFlag" />
    <link:label xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" xml:lang="en-US" id="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag">Cybersecurity Risk Management Third Party Engaged [Flag]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CybersecurityRiskManagementThirdPartyEngagedFlag" xlink:to="cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" xlink:title="label: CybersecurityRiskManagementThirdPartyEngagedFlag to cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" xlink:label="CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" xlink:title="CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" />
    <link:label xlink:type="resource" xlink:label="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" xml:lang="en-US" id="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag">Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" xlink:to="cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" xlink:title="label: CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag to cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" xlink:label="CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" xlink:title="CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" />
    <link:label xlink:type="resource" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" xml:lang="en-US" id="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" xlink:title="label: CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag to cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" xlink:label="CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" xlink:title="CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" />
    <link:label xlink:type="resource" xlink:label="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" xml:lang="en-US" id="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" xlink:to="cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" xlink:title="label: CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock to cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:label="CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:title="CybersecurityRiskBoardOfDirectorsOversightTextBlock" />
    <link:label xlink:type="resource" xlink:label="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xml:lang="en-US" id="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock">Cybersecurity Risk Board of Directors Oversight [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:title="label: CybersecurityRiskBoardOfDirectorsOversightTextBlock to cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:label="CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:title="CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" />
    <link:label xlink:type="resource" xlink:label="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xml:lang="en-US" id="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock">Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:to="cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:title="label: CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock to cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:label="CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:title="CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" />
    <link:label xlink:type="resource" xlink:label="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xml:lang="en-US" id="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock">Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:to="cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:title="label: CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock to cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskRoleOfManagementTextBlock" xlink:label="CybersecurityRiskRoleOfManagementTextBlock" xlink:title="CybersecurityRiskRoleOfManagementTextBlock" />
    <link:label xlink:type="resource" xlink:label="cyd_CybersecurityRiskRoleOfManagementTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="cyd_CybersecurityRiskRoleOfManagementTextBlock" xml:lang="en-US" id="cyd_CybersecurityRiskRoleOfManagementTextBlock">Cybersecurity Risk Role of Management [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CybersecurityRiskRoleOfManagementTextBlock" xlink:to="cyd_CybersecurityRiskRoleOfManagementTextBlock" xlink:title="label: CybersecurityRiskRoleOfManagementTextBlock to cyd_CybersecurityRiskRoleOfManagementTextBlock" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" xlink:label="CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" xlink:title="CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" />
    <link:label xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" xml:lang="en-US" id="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag">Cybersecurity Risk Management Positions or Committees Responsible [Flag]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" xlink:title="label: CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag to cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" xlink:label="CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" xlink:title="CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" />
    <link:label xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" xml:lang="en-US" id="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock">Cybersecurity Risk Management Positions or Committees Responsible [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" xlink:title="label: CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock to cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" xlink:label="CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" xlink:title="CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" />
    <link:label xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" xml:lang="en-US" id="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock">Cybersecurity Risk Management Expertise of Management Responsible [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" xlink:to="cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" xlink:title="label: CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock to cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" xlink:label="CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" xlink:title="CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" />
    <link:label xlink:type="resource" xlink:label="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" xml:lang="en-US" id="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock">Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" xlink:to="cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" xlink:title="label: CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock to cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" xlink:label="CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" xlink:title="CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" />
    <link:label xlink:type="resource" xlink:label="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" xml:lang="en-US" id="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag">Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" xlink:to="cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" xlink:title="label: CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag to cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="CoverAbstract" xlink:title="CoverAbstract" />
    <link:label xlink:type="resource" xlink:label="dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_CoverAbstract" xml:lang="en-US" id="dei_CoverAbstract">Cover [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CoverAbstract" xlink:to="dei_CoverAbstract" xlink:title="label: CoverAbstract to dei_CoverAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentInformationTable" xlink:label="DocumentInformationTable" xlink:title="DocumentInformationTable" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentInformationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentInformationTable" xml:lang="en-US" id="dei_DocumentInformationTable">Document Information [Table]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentInformationTable" xlink:to="dei_DocumentInformationTable" xlink:title="label: DocumentInformationTable to dei_DocumentInformationTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentInformationLineItems" xlink:label="DocumentInformationLineItems" xlink:title="DocumentInformationLineItems" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentInformationLineItems" xml:lang="en-US" id="dei_DocumentInformationLineItems">Document Information [Line Items]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentInformationLineItems" xlink:to="dei_DocumentInformationLineItems" xlink:title="label: DocumentInformationLineItems to dei_DocumentInformationLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="DocumentType" xlink:title="DocumentType" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentType" xml:lang="en-US" id="dei_DocumentType">Document Type</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentType" xlink:to="dei_DocumentType" xlink:title="label: DocumentType to dei_DocumentType" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport" xlink:label="DocumentAnnualReport" xlink:title="DocumentAnnualReport" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentAnnualReport" xml:lang="en-US" id="dei_DocumentAnnualReport">Document Annual Report</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport" xlink:title="label: DocumentAnnualReport to dei_DocumentAnnualReport" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="DocumentTransitionReport" xlink:title="DocumentTransitionReport" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentTransitionReport" xml:lang="en-US" id="dei_DocumentTransitionReport">Document Transition Report</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport" xlink:title="label: DocumentTransitionReport to dei_DocumentTransitionReport" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="DocumentFinStmtErrorCorrectionFlag" xlink:title="DocumentFinStmtErrorCorrectionFlag" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentFinStmtErrorCorrectionFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentFinStmtErrorCorrectionFlag" xml:lang="en-US" id="dei_DocumentFinStmtErrorCorrectionFlag">Document Financial Statement Error Correction [Flag]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentFinStmtErrorCorrectionFlag" xlink:to="dei_DocumentFinStmtErrorCorrectionFlag" xlink:title="label: DocumentFinStmtErrorCorrectionFlag to dei_DocumentFinStmtErrorCorrectionFlag" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="EntityInteractiveDataCurrent" xlink:title="EntityInteractiveDataCurrent" />
    <link:label xlink:type="resource" xlink:label="dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityInteractiveDataCurrent" xml:lang="en-US" id="dei_EntityInteractiveDataCurrent">Entity Interactive Data Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent" xlink:title="label: EntityInteractiveDataCurrent to dei_EntityInteractiveDataCurrent" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="AmendmentFlag" xlink:title="AmendmentFlag" />
    <link:label xlink:type="resource" xlink:label="dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_AmendmentFlag" xml:lang="en-US" id="dei_AmendmentFlag">Amendment Flag</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AmendmentFlag" xlink:to="dei_AmendmentFlag" xlink:title="label: AmendmentFlag to dei_AmendmentFlag" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="IcfrAuditorAttestationFlag" xlink:title="IcfrAuditorAttestationFlag" />
    <link:label xlink:type="resource" xlink:label="dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_IcfrAuditorAttestationFlag" xml:lang="en-US" id="dei_IcfrAuditorAttestationFlag">ICFR Auditor Attestation Flag</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag" xlink:title="label: IcfrAuditorAttestationFlag to dei_IcfrAuditorAttestationFlag" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="DocumentFiscalYearFocus" xlink:title="DocumentFiscalYearFocus" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentFiscalYearFocus" xml:lang="en-US" id="dei_DocumentFiscalYearFocus">Document Fiscal Year Focus</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus" xlink:title="label: DocumentFiscalYearFocus to dei_DocumentFiscalYearFocus" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="DocumentFiscalPeriodFocus" xlink:title="DocumentFiscalPeriodFocus" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentFiscalPeriodFocus" xml:lang="en-US" id="dei_DocumentFiscalPeriodFocus">Document Fiscal Period Focus</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus" xlink:title="label: DocumentFiscalPeriodFocus to dei_DocumentFiscalPeriodFocus" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="DocumentPeriodEndDate" xlink:title="DocumentPeriodEndDate" />
    <link:label xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_DocumentPeriodEndDate" xml:lang="en-US" id="dei_DocumentPeriodEndDate">Document Period End Date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate" xlink:title="label: DocumentPeriodEndDate to dei_DocumentPeriodEndDate" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="EntityRegistrantName" xlink:title="EntityRegistrantName" />
    <link:label xlink:type="resource" xlink:label="dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityRegistrantName" xml:lang="en-US" id="dei_EntityRegistrantName">Entity Registrant Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityRegistrantName" xlink:to="dei_EntityRegistrantName" xlink:title="label: EntityRegistrantName to dei_EntityRegistrantName" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="EntityCentralIndexKey" xlink:title="EntityCentralIndexKey" />
    <link:label xlink:type="resource" xlink:label="dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityCentralIndexKey" xml:lang="en-US" id="dei_EntityCentralIndexKey">Entity Central Index Key</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey" xlink:title="label: EntityCentralIndexKey to dei_EntityCentralIndexKey" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="EntityFileNumber" xlink:title="EntityFileNumber" />
    <link:label xlink:type="resource" xlink:label="dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityFileNumber" xml:lang="en-US" id="dei_EntityFileNumber">Entity File Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityFileNumber" xlink:to="dei_EntityFileNumber" xlink:title="label: EntityFileNumber to dei_EntityFileNumber" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="EntityTaxIdentificationNumber" xlink:title="EntityTaxIdentificationNumber" />
    <link:label xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityTaxIdentificationNumber" xml:lang="en-US" id="dei_EntityTaxIdentificationNumber">Entity Tax Identification Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber" xlink:title="label: EntityTaxIdentificationNumber to dei_EntityTaxIdentificationNumber" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="EntityIncorporationStateCountryCode" xlink:title="EntityIncorporationStateCountryCode" />
    <link:label xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityIncorporationStateCountryCode" xml:lang="en-US" id="dei_EntityIncorporationStateCountryCode">Entity Incorporation, State or Country Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode" xlink:title="label: EntityIncorporationStateCountryCode to dei_EntityIncorporationStateCountryCode" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="CurrentFiscalYearEndDate" xlink:title="CurrentFiscalYearEndDate" />
    <link:label xlink:type="resource" xlink:label="dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_CurrentFiscalYearEndDate" xml:lang="en-US" id="dei_CurrentFiscalYearEndDate">Current Fiscal Year End Date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate" xlink:title="label: CurrentFiscalYearEndDate to dei_CurrentFiscalYearEndDate" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="EntityWellKnownSeasonedIssuer" xlink:title="EntityWellKnownSeasonedIssuer" />
    <link:label xlink:type="resource" xlink:label="dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityWellKnownSeasonedIssuer" xml:lang="en-US" id="dei_EntityWellKnownSeasonedIssuer">Entity Well-known Seasoned Issuer</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer" xlink:title="label: EntityWellKnownSeasonedIssuer to dei_EntityWellKnownSeasonedIssuer" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers" xlink:label="EntityVoluntaryFilers" xlink:title="EntityVoluntaryFilers" />
    <link:label xlink:type="resource" xlink:label="dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityVoluntaryFilers" xml:lang="en-US" id="dei_EntityVoluntaryFilers">Entity Voluntary Filers</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers" xlink:title="label: EntityVoluntaryFilers to dei_EntityVoluntaryFilers" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="EntityCurrentReportingStatus" xlink:title="EntityCurrentReportingStatus" />
    <link:label xlink:type="resource" xlink:label="dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityCurrentReportingStatus" xml:lang="en-US" id="dei_EntityCurrentReportingStatus">Entity Current Reporting Status</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus" xlink:title="label: EntityCurrentReportingStatus to dei_EntityCurrentReportingStatus" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="EntityShellCompany" xlink:title="EntityShellCompany" />
    <link:label xlink:type="resource" xlink:label="dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityShellCompany" xml:lang="en-US" id="dei_EntityShellCompany">Entity Shell Company</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityShellCompany" xlink:to="dei_EntityShellCompany" xlink:title="label: EntityShellCompany to dei_EntityShellCompany" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="EntityFilerCategory" xlink:title="EntityFilerCategory" />
    <link:label xlink:type="resource" xlink:label="dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityFilerCategory" xml:lang="en-US" id="dei_EntityFilerCategory">Entity Filer Category</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityFilerCategory" xlink:to="dei_EntityFilerCategory" xlink:title="label: EntityFilerCategory to dei_EntityFilerCategory" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="EntitySmallBusiness" xlink:title="EntitySmallBusiness" />
    <link:label xlink:type="resource" xlink:label="dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntitySmallBusiness" xml:lang="en-US" id="dei_EntitySmallBusiness">Entity Small Business</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness" xlink:title="label: EntitySmallBusiness to dei_EntitySmallBusiness" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="EntityEmergingGrowthCompany" xlink:title="EntityEmergingGrowthCompany" />
    <link:label xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityEmergingGrowthCompany" xml:lang="en-US" id="dei_EntityEmergingGrowthCompany">Entity Emerging Growth Company</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany" xlink:title="label: EntityEmergingGrowthCompany to dei_EntityEmergingGrowthCompany" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat" xlink:label="EntityPublicFloat" xlink:title="EntityPublicFloat" />
    <link:label xlink:type="resource" xlink:label="dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityPublicFloat" xml:lang="en-US" id="dei_EntityPublicFloat">Entity Public Float</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityPublicFloat" xlink:to="dei_EntityPublicFloat" xlink:title="label: EntityPublicFloat to dei_EntityPublicFloat" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="EntityAddressAddressLine1" xlink:title="EntityAddressAddressLine1" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressAddressLine1" xml:lang="en-US" id="dei_EntityAddressAddressLine1">Entity Address, Address Line One</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1" xlink:title="label: EntityAddressAddressLine1 to dei_EntityAddressAddressLine1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="EntityAddressCityOrTown" xlink:title="EntityAddressCityOrTown" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressCityOrTown" xml:lang="en-US" id="dei_EntityAddressCityOrTown">Entity Address, City or Town</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown" xlink:title="label: EntityAddressCityOrTown to dei_EntityAddressCityOrTown" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="EntityAddressStateOrProvince" xlink:title="EntityAddressStateOrProvince" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressStateOrProvince" xml:lang="en-US" id="dei_EntityAddressStateOrProvince">Entity Address, State or Province</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince" xlink:title="label: EntityAddressStateOrProvince to dei_EntityAddressStateOrProvince" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="EntityAddressPostalZipCode" xlink:title="EntityAddressPostalZipCode" />
    <link:label xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityAddressPostalZipCode" xml:lang="en-US" id="dei_EntityAddressPostalZipCode">Entity Address, Postal Zip Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode" xlink:title="label: EntityAddressPostalZipCode to dei_EntityAddressPostalZipCode" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="CityAreaCode" xlink:title="CityAreaCode" />
    <link:label xlink:type="resource" xlink:label="dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_CityAreaCode" xml:lang="en-US" id="dei_CityAreaCode">City Area Code</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CityAreaCode" xlink:to="dei_CityAreaCode" xlink:title="label: CityAreaCode to dei_CityAreaCode" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="LocalPhoneNumber" xlink:title="LocalPhoneNumber" />
    <link:label xlink:type="resource" xlink:label="dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_LocalPhoneNumber" xml:lang="en-US" id="dei_LocalPhoneNumber">Local Phone Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber" xlink:title="label: LocalPhoneNumber to dei_LocalPhoneNumber" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="Security12bTitle" xlink:title="Security12bTitle" />
    <link:label xlink:type="resource" xlink:label="dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_Security12bTitle" xml:lang="en-US" id="dei_Security12bTitle">Title of 12(b) Security</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Security12bTitle" xlink:to="dei_Security12bTitle" xlink:title="label: Security12bTitle to dei_Security12bTitle" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="TradingSymbol" xlink:title="TradingSymbol" />
    <link:label xlink:type="resource" xlink:label="dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_TradingSymbol" xml:lang="en-US" id="dei_TradingSymbol">Trading Symbol</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TradingSymbol" xlink:to="dei_TradingSymbol" xlink:title="label: TradingSymbol to dei_TradingSymbol" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="SecurityExchangeName" xlink:title="SecurityExchangeName" />
    <link:label xlink:type="resource" xlink:label="dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_SecurityExchangeName" xml:lang="en-US" id="dei_SecurityExchangeName">Security Exchange Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SecurityExchangeName" xlink:to="dei_SecurityExchangeName" xlink:title="label: SecurityExchangeName to dei_SecurityExchangeName" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="EntityCommonStockSharesOutstanding" xlink:title="EntityCommonStockSharesOutstanding" />
    <link:label xlink:type="resource" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_EntityCommonStockSharesOutstanding" xml:lang="en-US" id="dei_EntityCommonStockSharesOutstanding">Entity Common Stock, Shares Outstanding</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding" xlink:title="label: EntityCommonStockSharesOutstanding to dei_EntityCommonStockSharesOutstanding" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorName" xlink:label="AuditorName" xlink:title="AuditorName" />
    <link:label xlink:type="resource" xlink:label="dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_AuditorName" xml:lang="en-US" id="dei_AuditorName">Auditor Name</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AuditorName" xlink:to="dei_AuditorName" xlink:title="label: AuditorName to dei_AuditorName" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorFirmId" xlink:label="AuditorFirmId" xlink:title="AuditorFirmId" />
    <link:label xlink:type="resource" xlink:label="dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_AuditorFirmId" xml:lang="en-US" id="dei_AuditorFirmId">Auditor Firm ID</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AuditorFirmId" xlink:to="dei_AuditorFirmId" xlink:title="label: AuditorFirmId to dei_AuditorFirmId" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorLocation" xlink:label="AuditorLocation" xlink:title="AuditorLocation" />
    <link:label xlink:type="resource" xlink:label="dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="dei_AuditorLocation" xml:lang="en-US" id="dei_AuditorLocation">Auditor Location</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AuditorLocation" xlink:to="dei_AuditorLocation" xlink:title="label: AuditorLocation to dei_AuditorLocation" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_DeferredTaxLiabilitiesDepreciationOfPropertyAndEquipment" xlink:label="DeferredTaxLiabilitiesDepreciationOfPropertyAndEquipment" xlink:title="DeferredTaxLiabilitiesDepreciationOfPropertyAndEquipment" />
    <link:label xlink:type="resource" xlink:label="adma_DeferredTaxLiabilitiesDepreciationOfPropertyAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_DeferredTaxLiabilitiesDepreciationOfPropertyAndEquipment_lbl" xml:lang="en-US" id="adma_DeferredTaxLiabilitiesDepreciationOfPropertyAndEquipment_lbl">Amount of deferred tax liability attributable to taxable temporary differences from depreciation of property and equipment.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredTaxLiabilitiesDepreciationOfPropertyAndEquipment" xlink:to="adma_DeferredTaxLiabilitiesDepreciationOfPropertyAndEquipment_lbl" xlink:title="label: DeferredTaxLiabilitiesDepreciationOfPropertyAndEquipment to adma_DeferredTaxLiabilitiesDepreciationOfPropertyAndEquipment_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_DeferredTaxLiabilitiesDepreciationOfPropertyAndEquipment_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_DeferredTaxLiabilitiesDepreciationOfPropertyAndEquipment_lbl1" xml:lang="en-US" id="adma_DeferredTaxLiabilitiesDepreciationOfPropertyAndEquipment_lbl1">Deferred Tax Liabilities, Depreciation of Property and Equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredTaxLiabilitiesDepreciationOfPropertyAndEquipment" xlink:to="adma_DeferredTaxLiabilitiesDepreciationOfPropertyAndEquipment_lbl1" xlink:title="label: DeferredTaxLiabilitiesDepreciationOfPropertyAndEquipment to adma_DeferredTaxLiabilitiesDepreciationOfPropertyAndEquipment_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_DeferredTaxLiabilitiesDepreciationOfPropertyAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="adma_DeferredTaxLiabilitiesDepreciationOfPropertyAndEquipment" xml:lang="en-US" id="adma_DeferredTaxLiabilitiesDepreciationOfPropertyAndEquipment">Depreciation of property and equipment</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredTaxLiabilitiesDepreciationOfPropertyAndEquipment" xlink:to="adma_DeferredTaxLiabilitiesDepreciationOfPropertyAndEquipment" xlink:title="label: DeferredTaxLiabilitiesDepreciationOfPropertyAndEquipment to adma_DeferredTaxLiabilitiesDepreciationOfPropertyAndEquipment" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_DeferredTaxLiabilitiesRightOfUseAsset" xlink:label="DeferredTaxLiabilitiesRightOfUseAsset" xlink:title="DeferredTaxLiabilitiesRightOfUseAsset" />
    <link:label xlink:type="resource" xlink:label="adma_DeferredTaxLiabilitiesRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_DeferredTaxLiabilitiesRightOfUseAsset_lbl" xml:lang="en-US" id="adma_DeferredTaxLiabilitiesRightOfUseAsset_lbl">Amount of deferred tax liability attributable to taxable temporary differences from right-of-use assets.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredTaxLiabilitiesRightOfUseAsset" xlink:to="adma_DeferredTaxLiabilitiesRightOfUseAsset_lbl" xlink:title="label: DeferredTaxLiabilitiesRightOfUseAsset to adma_DeferredTaxLiabilitiesRightOfUseAsset_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_DeferredTaxLiabilitiesRightOfUseAsset_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_DeferredTaxLiabilitiesRightOfUseAsset_lbl1" xml:lang="en-US" id="adma_DeferredTaxLiabilitiesRightOfUseAsset_lbl1">Deferred Tax Liabilities, Right Of Use Asset</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredTaxLiabilitiesRightOfUseAsset" xlink:to="adma_DeferredTaxLiabilitiesRightOfUseAsset_lbl1" xlink:title="label: DeferredTaxLiabilitiesRightOfUseAsset to adma_DeferredTaxLiabilitiesRightOfUseAsset_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_DeferredTaxLiabilitiesRightOfUseAsset" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="adma_DeferredTaxLiabilitiesRightOfUseAsset" xml:lang="en-US" id="adma_DeferredTaxLiabilitiesRightOfUseAsset">Right-of-use assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredTaxLiabilitiesRightOfUseAsset" xlink:to="adma_DeferredTaxLiabilitiesRightOfUseAsset" xlink:title="label: DeferredTaxLiabilitiesRightOfUseAsset to adma_DeferredTaxLiabilitiesRightOfUseAsset" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_DeferredTaxAssetsLeaseObligations" xlink:label="DeferredTaxAssetsLeaseObligations" xlink:title="DeferredTaxAssetsLeaseObligations" />
    <link:label xlink:type="resource" xlink:label="adma_DeferredTaxAssetsLeaseObligations_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_DeferredTaxAssetsLeaseObligations_lbl" xml:lang="en-US" id="adma_DeferredTaxAssetsLeaseObligations_lbl">Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from lease obligation.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredTaxAssetsLeaseObligations" xlink:to="adma_DeferredTaxAssetsLeaseObligations_lbl" xlink:title="label: DeferredTaxAssetsLeaseObligations to adma_DeferredTaxAssetsLeaseObligations_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_DeferredTaxAssetsLeaseObligations_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_DeferredTaxAssetsLeaseObligations_lbl1" xml:lang="en-US" id="adma_DeferredTaxAssetsLeaseObligations_lbl1">Deferred Tax Assets, Lease Obligations</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredTaxAssetsLeaseObligations" xlink:to="adma_DeferredTaxAssetsLeaseObligations_lbl1" xlink:title="label: DeferredTaxAssetsLeaseObligations to adma_DeferredTaxAssetsLeaseObligations_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_DeferredTaxAssetsLeaseObligations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_DeferredTaxAssetsLeaseObligations" xml:lang="en-US" id="adma_DeferredTaxAssetsLeaseObligations">Lease obligations</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredTaxAssetsLeaseObligations" xlink:to="adma_DeferredTaxAssetsLeaseObligations" xlink:title="label: DeferredTaxAssetsLeaseObligations to adma_DeferredTaxAssetsLeaseObligations" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_TaxYear2034Member" xlink:label="TaxYear2034Member" xlink:title="TaxYear2034Member" />
    <link:label xlink:type="resource" xlink:label="adma_TaxYear2034Member_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_TaxYear2034Member_lbl" xml:lang="en-US" id="adma_TaxYear2034Member_lbl">Identified as tax year 2034.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TaxYear2034Member" xlink:to="adma_TaxYear2034Member_lbl" xlink:title="label: TaxYear2034Member to adma_TaxYear2034Member_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_TaxYear2034Member_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_TaxYear2034Member_lbl1" xml:lang="en-US" id="adma_TaxYear2034Member_lbl1">Tax Year 2034 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TaxYear2034Member" xlink:to="adma_TaxYear2034Member_lbl1" xlink:title="label: TaxYear2034Member to adma_TaxYear2034Member_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_TaxYear2034Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_TaxYear2034Member" xml:lang="en-US" id="adma_TaxYear2034Member">2034 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TaxYear2034Member" xlink:to="adma_TaxYear2034Member" xlink:title="label: TaxYear2034Member to adma_TaxYear2034Member" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_TaxYear2032Member" xlink:label="TaxYear2032Member" xlink:title="TaxYear2032Member" />
    <link:label xlink:type="resource" xlink:label="adma_TaxYear2032Member_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_TaxYear2032Member_lbl" xml:lang="en-US" id="adma_TaxYear2032Member_lbl">Identified as tax year 2032.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TaxYear2032Member" xlink:to="adma_TaxYear2032Member_lbl" xlink:title="label: TaxYear2032Member to adma_TaxYear2032Member_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_TaxYear2032Member_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_TaxYear2032Member_lbl1" xml:lang="en-US" id="adma_TaxYear2032Member_lbl1">Tax Year 2032 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TaxYear2032Member" xlink:to="adma_TaxYear2032Member_lbl1" xlink:title="label: TaxYear2032Member to adma_TaxYear2032Member_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_TaxYear2032Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_TaxYear2032Member" xml:lang="en-US" id="adma_TaxYear2032Member">2032 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TaxYear2032Member" xlink:to="adma_TaxYear2032Member" xlink:title="label: TaxYear2032Member to adma_TaxYear2032Member" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_TaxYear2028Through2043Member" xlink:label="TaxYear2028Through2043Member" xlink:title="TaxYear2028Through2043Member" />
    <link:label xlink:type="resource" xlink:label="adma_TaxYear2028Through2043Member_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_TaxYear2028Through2043Member_lbl" xml:lang="en-US" id="adma_TaxYear2028Through2043Member_lbl">Identified as tax years 2028 through 2043.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TaxYear2028Through2043Member" xlink:to="adma_TaxYear2028Through2043Member_lbl" xlink:title="label: TaxYear2028Through2043Member to adma_TaxYear2028Through2043Member_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_TaxYear2028Through2043Member_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_TaxYear2028Through2043Member_lbl1" xml:lang="en-US" id="adma_TaxYear2028Through2043Member_lbl1">Tax Year 2028 through 2043 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TaxYear2028Through2043Member" xlink:to="adma_TaxYear2028Through2043Member_lbl1" xlink:title="label: TaxYear2028Through2043Member to adma_TaxYear2028Through2043Member_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_TaxYear2028Through2043Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_TaxYear2028Through2043Member" xml:lang="en-US" id="adma_TaxYear2028Through2043Member">2028 through 2043 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TaxYear2028Through2043Member" xlink:to="adma_TaxYear2028Through2043Member" xlink:title="label: TaxYear2028Through2043Member to adma_TaxYear2028Through2043Member" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_TaxYear2036Member" xlink:label="TaxYear2036Member" xlink:title="TaxYear2036Member" />
    <link:label xlink:type="resource" xlink:label="adma_TaxYear2036Member_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_TaxYear2036Member_lbl" xml:lang="en-US" id="adma_TaxYear2036Member_lbl">Identified as tax year 2036.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TaxYear2036Member" xlink:to="adma_TaxYear2036Member_lbl" xlink:title="label: TaxYear2036Member to adma_TaxYear2036Member_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_TaxYear2036Member_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_TaxYear2036Member_lbl1" xml:lang="en-US" id="adma_TaxYear2036Member_lbl1">Tax Year 2036 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TaxYear2036Member" xlink:to="adma_TaxYear2036Member_lbl1" xlink:title="label: TaxYear2036Member to adma_TaxYear2036Member_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_TaxYear2036Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_TaxYear2036Member" xml:lang="en-US" id="adma_TaxYear2036Member">2036 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TaxYear2036Member" xlink:to="adma_TaxYear2036Member" xlink:title="label: TaxYear2036Member to adma_TaxYear2036Member" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_TaxYearAfter2037Member" xlink:label="TaxYearAfter2037Member" xlink:title="TaxYearAfter2037Member" />
    <link:label xlink:type="resource" xlink:label="adma_TaxYearAfter2037Member_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_TaxYearAfter2037Member_lbl" xml:lang="en-US" id="adma_TaxYearAfter2037Member_lbl">Identified as tax year after 2037.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TaxYearAfter2037Member" xlink:to="adma_TaxYearAfter2037Member_lbl" xlink:title="label: TaxYearAfter2037Member to adma_TaxYearAfter2037Member_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_TaxYearAfter2037Member_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_TaxYearAfter2037Member_lbl1" xml:lang="en-US" id="adma_TaxYearAfter2037Member_lbl1">Tax Year After 2037 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TaxYearAfter2037Member" xlink:to="adma_TaxYearAfter2037Member_lbl1" xlink:title="label: TaxYearAfter2037Member to adma_TaxYearAfter2037Member_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_TaxYearAfter2037Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_TaxYearAfter2037Member" xml:lang="en-US" id="adma_TaxYearAfter2037Member">Indefinite [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TaxYearAfter2037Member" xlink:to="adma_TaxYearAfter2037Member" xlink:title="label: TaxYearAfter2037Member to adma_TaxYearAfter2037Member" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_TaxYear2033Member" xlink:label="TaxYear2033Member" xlink:title="TaxYear2033Member" />
    <link:label xlink:type="resource" xlink:label="adma_TaxYear2033Member_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_TaxYear2033Member_lbl" xml:lang="en-US" id="adma_TaxYear2033Member_lbl">Identified as tax year 2033.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TaxYear2033Member" xlink:to="adma_TaxYear2033Member_lbl" xlink:title="label: TaxYear2033Member to adma_TaxYear2033Member_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_TaxYear2033Member_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_TaxYear2033Member_lbl1" xml:lang="en-US" id="adma_TaxYear2033Member_lbl1">Tax Year 2033 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TaxYear2033Member" xlink:to="adma_TaxYear2033Member_lbl1" xlink:title="label: TaxYear2033Member to adma_TaxYear2033Member_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_TaxYear2033Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_TaxYear2033Member" xml:lang="en-US" id="adma_TaxYear2033Member">2033 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TaxYear2033Member" xlink:to="adma_TaxYear2033Member" xlink:title="label: TaxYear2033Member to adma_TaxYear2033Member" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_NetOperatingLossCarryforwardsAbstract" xlink:label="NetOperatingLossCarryforwardsAbstract" xlink:title="NetOperatingLossCarryforwardsAbstract" />
    <link:label xlink:type="resource" xlink:label="adma_NetOperatingLossCarryforwardsAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_NetOperatingLossCarryforwardsAbstract_lbl1" xml:lang="en-US" id="adma_NetOperatingLossCarryforwardsAbstract_lbl1">Net Operating Loss Carryforwards [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetOperatingLossCarryforwardsAbstract" xlink:to="adma_NetOperatingLossCarryforwardsAbstract_lbl1" xlink:title="label: NetOperatingLossCarryforwardsAbstract to adma_NetOperatingLossCarryforwardsAbstract_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_NetOperatingLossCarryforwardsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_NetOperatingLossCarryforwardsAbstract" xml:lang="en-US" id="adma_NetOperatingLossCarryforwardsAbstract">Net Operating Loss Carryforwards [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NetOperatingLossCarryforwardsAbstract" xlink:to="adma_NetOperatingLossCarryforwardsAbstract" xlink:title="label: NetOperatingLossCarryforwardsAbstract to adma_NetOperatingLossCarryforwardsAbstract" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_TaxYear2035Member" xlink:label="TaxYear2035Member" xlink:title="TaxYear2035Member" />
    <link:label xlink:type="resource" xlink:label="adma_TaxYear2035Member_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_TaxYear2035Member_lbl" xml:lang="en-US" id="adma_TaxYear2035Member_lbl">Identified as tax year 2035.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TaxYear2035Member" xlink:to="adma_TaxYear2035Member_lbl" xlink:title="label: TaxYear2035Member to adma_TaxYear2035Member_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_TaxYear2035Member_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_TaxYear2035Member_lbl1" xml:lang="en-US" id="adma_TaxYear2035Member_lbl1">Tax Year 2035 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TaxYear2035Member" xlink:to="adma_TaxYear2035Member_lbl1" xlink:title="label: TaxYear2035Member to adma_TaxYear2035Member_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_TaxYear2035Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_TaxYear2035Member" xml:lang="en-US" id="adma_TaxYear2035Member">2035 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TaxYear2035Member" xlink:to="adma_TaxYear2035Member" xlink:title="label: TaxYear2035Member to adma_TaxYear2035Member" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_TaxYear2037Member" xlink:label="TaxYear2037Member" xlink:title="TaxYear2037Member" />
    <link:label xlink:type="resource" xlink:label="adma_TaxYear2037Member_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_TaxYear2037Member_lbl" xml:lang="en-US" id="adma_TaxYear2037Member_lbl">Identified as tax year 2037.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TaxYear2037Member" xlink:to="adma_TaxYear2037Member_lbl" xlink:title="label: TaxYear2037Member to adma_TaxYear2037Member_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_TaxYear2037Member_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_TaxYear2037Member_lbl1" xml:lang="en-US" id="adma_TaxYear2037Member_lbl1">Tax Year 2037 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TaxYear2037Member" xlink:to="adma_TaxYear2037Member_lbl1" xlink:title="label: TaxYear2037Member to adma_TaxYear2037Member_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_TaxYear2037Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_TaxYear2037Member" xml:lang="en-US" id="adma_TaxYear2037Member">2037 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TaxYear2037Member" xlink:to="adma_TaxYear2037Member" xlink:title="label: TaxYear2037Member to adma_TaxYear2037Member" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_TaxYear2031Member" xlink:label="TaxYear2031Member" xlink:title="TaxYear2031Member" />
    <link:label xlink:type="resource" xlink:label="adma_TaxYear2031Member_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_TaxYear2031Member_lbl" xml:lang="en-US" id="adma_TaxYear2031Member_lbl">Identified as tax year 2031.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TaxYear2031Member" xlink:to="adma_TaxYear2031Member_lbl" xlink:title="label: TaxYear2031Member to adma_TaxYear2031Member_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_TaxYear2031Member_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_TaxYear2031Member_lbl1" xml:lang="en-US" id="adma_TaxYear2031Member_lbl1">Tax Year 2031 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TaxYear2031Member" xlink:to="adma_TaxYear2031Member_lbl1" xlink:title="label: TaxYear2031Member to adma_TaxYear2031Member_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_TaxYear2031Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_TaxYear2031Member" xml:lang="en-US" id="adma_TaxYear2031Member">2031 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TaxYear2031Member" xlink:to="adma_TaxYear2031Member" xlink:title="label: TaxYear2031Member to adma_TaxYear2031Member" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_CohnReznickLLPMember" xlink:label="CohnReznickLLPMember" xlink:title="CohnReznickLLPMember" />
    <link:label xlink:type="resource" xlink:label="adma_CohnReznickLLPMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_CohnReznickLLPMember_lbl" xml:lang="en-US" id="adma_CohnReznickLLPMember_lbl">Previous auditor.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CohnReznickLLPMember" xlink:to="adma_CohnReznickLLPMember_lbl" xlink:title="label: CohnReznickLLPMember to adma_CohnReznickLLPMember_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_CohnReznickLLPMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_CohnReznickLLPMember_lbl1" xml:lang="en-US" id="adma_CohnReznickLLPMember_lbl1">CohnReznick LLP [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CohnReznickLLPMember" xlink:to="adma_CohnReznickLLPMember_lbl1" xlink:title="label: CohnReznickLLPMember to adma_CohnReznickLLPMember_lbl1" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_VendorAndLicensorCommitmentsAbstract" xlink:label="VendorAndLicensorCommitmentsAbstract" xlink:title="VendorAndLicensorCommitmentsAbstract" />
    <link:label xlink:type="resource" xlink:label="adma_VendorAndLicensorCommitmentsAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_VendorAndLicensorCommitmentsAbstract_lbl1" xml:lang="en-US" id="adma_VendorAndLicensorCommitmentsAbstract_lbl1">Vendor and Licensor Commitments [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="VendorAndLicensorCommitmentsAbstract" xlink:to="adma_VendorAndLicensorCommitmentsAbstract_lbl1" xlink:title="label: VendorAndLicensorCommitmentsAbstract to adma_VendorAndLicensorCommitmentsAbstract_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_VendorAndLicensorCommitmentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_VendorAndLicensorCommitmentsAbstract" xml:lang="en-US" id="adma_VendorAndLicensorCommitmentsAbstract">Vendor and Licensor Commitments [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="VendorAndLicensorCommitmentsAbstract" xlink:to="adma_VendorAndLicensorCommitmentsAbstract" xlink:title="label: VendorAndLicensorCommitmentsAbstract to adma_VendorAndLicensorCommitmentsAbstract" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_PlasmaSupplyAgreementTerm" xlink:label="PlasmaSupplyAgreementTerm" xlink:title="PlasmaSupplyAgreementTerm" />
    <link:label xlink:type="resource" xlink:label="adma_PlasmaSupplyAgreementTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_PlasmaSupplyAgreementTerm_lbl" xml:lang="en-US" id="adma_PlasmaSupplyAgreementTerm_lbl">Plasma supply agreement term period, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PlasmaSupplyAgreementTerm" xlink:to="adma_PlasmaSupplyAgreementTerm_lbl" xlink:title="label: PlasmaSupplyAgreementTerm to adma_PlasmaSupplyAgreementTerm_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_PlasmaSupplyAgreementTerm_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_PlasmaSupplyAgreementTerm_lbl1" xml:lang="en-US" id="adma_PlasmaSupplyAgreementTerm_lbl1">Plasma supply agreement term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PlasmaSupplyAgreementTerm" xlink:to="adma_PlasmaSupplyAgreementTerm_lbl1" xlink:title="label: PlasmaSupplyAgreementTerm to adma_PlasmaSupplyAgreementTerm_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_PlasmaSupplyAgreementTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_PlasmaSupplyAgreementTerm" xml:lang="en-US" id="adma_PlasmaSupplyAgreementTerm">Plasma supply agreement term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PlasmaSupplyAgreementTerm" xlink:to="adma_PlasmaSupplyAgreementTerm" xlink:title="label: PlasmaSupplyAgreementTerm to adma_PlasmaSupplyAgreementTerm" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_PlasmaPurchaseAgreementRenewalPeriod" xlink:label="PlasmaPurchaseAgreementRenewalPeriod" xlink:title="PlasmaPurchaseAgreementRenewalPeriod" />
    <link:label xlink:type="resource" xlink:label="adma_PlasmaPurchaseAgreementRenewalPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_PlasmaPurchaseAgreementRenewalPeriod_lbl" xml:lang="en-US" id="adma_PlasmaPurchaseAgreementRenewalPeriod_lbl">Plasma purchase agreement renewal period, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PlasmaPurchaseAgreementRenewalPeriod" xlink:to="adma_PlasmaPurchaseAgreementRenewalPeriod_lbl" xlink:title="label: PlasmaPurchaseAgreementRenewalPeriod to adma_PlasmaPurchaseAgreementRenewalPeriod_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_PlasmaPurchaseAgreementRenewalPeriod_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_PlasmaPurchaseAgreementRenewalPeriod_lbl1" xml:lang="en-US" id="adma_PlasmaPurchaseAgreementRenewalPeriod_lbl1">Plasma Purchase Agreement Renewal Period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PlasmaPurchaseAgreementRenewalPeriod" xlink:to="adma_PlasmaPurchaseAgreementRenewalPeriod_lbl1" xlink:title="label: PlasmaPurchaseAgreementRenewalPeriod to adma_PlasmaPurchaseAgreementRenewalPeriod_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_PlasmaPurchaseAgreementRenewalPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_PlasmaPurchaseAgreementRenewalPeriod" xml:lang="en-US" id="adma_PlasmaPurchaseAgreementRenewalPeriod">Plasma purchase agreement renewal period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PlasmaPurchaseAgreementRenewalPeriod" xlink:to="adma_PlasmaPurchaseAgreementRenewalPeriod" xlink:title="label: PlasmaPurchaseAgreementRenewalPeriod to adma_PlasmaPurchaseAgreementRenewalPeriod" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_NumberOfBatchesInProductionAtTheTimeOfDisruption" xlink:label="NumberOfBatchesInProductionAtTheTimeOfDisruption" xlink:title="NumberOfBatchesInProductionAtTheTimeOfDisruption" />
    <link:label xlink:type="resource" xlink:label="adma_NumberOfBatchesInProductionAtTheTimeOfDisruption_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_NumberOfBatchesInProductionAtTheTimeOfDisruption_lbl" xml:lang="en-US" id="adma_NumberOfBatchesInProductionAtTheTimeOfDisruption_lbl">The number of batches that were in production at the time of disruption.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfBatchesInProductionAtTheTimeOfDisruption" xlink:to="adma_NumberOfBatchesInProductionAtTheTimeOfDisruption_lbl" xlink:title="label: NumberOfBatchesInProductionAtTheTimeOfDisruption to adma_NumberOfBatchesInProductionAtTheTimeOfDisruption_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_NumberOfBatchesInProductionAtTheTimeOfDisruption_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_NumberOfBatchesInProductionAtTheTimeOfDisruption_lbl1" xml:lang="en-US" id="adma_NumberOfBatchesInProductionAtTheTimeOfDisruption_lbl1">Number of Batches in Production at the Time of Disruption</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfBatchesInProductionAtTheTimeOfDisruption" xlink:to="adma_NumberOfBatchesInProductionAtTheTimeOfDisruption_lbl1" xlink:title="label: NumberOfBatchesInProductionAtTheTimeOfDisruption to adma_NumberOfBatchesInProductionAtTheTimeOfDisruption_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_NumberOfBatchesInProductionAtTheTimeOfDisruption" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_NumberOfBatchesInProductionAtTheTimeOfDisruption" xml:lang="en-US" id="adma_NumberOfBatchesInProductionAtTheTimeOfDisruption">Number of batches in production at the time of disruption</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfBatchesInProductionAtTheTimeOfDisruption" xlink:to="adma_NumberOfBatchesInProductionAtTheTimeOfDisruption" xlink:title="label: NumberOfBatchesInProductionAtTheTimeOfDisruption to adma_NumberOfBatchesInProductionAtTheTimeOfDisruption" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_AgreementWithTermExpirationDate" xlink:label="AgreementWithTermExpirationDate" xlink:title="AgreementWithTermExpirationDate" />
    <link:label xlink:type="resource" xlink:label="adma_AgreementWithTermExpirationDate_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_AgreementWithTermExpirationDate_lbl" xml:lang="en-US" id="adma_AgreementWithTermExpirationDate_lbl">Date the agreement with term expired, in YYYY-MM-DD format.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AgreementWithTermExpirationDate" xlink:to="adma_AgreementWithTermExpirationDate_lbl" xlink:title="label: AgreementWithTermExpirationDate to adma_AgreementWithTermExpirationDate_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_AgreementWithTermExpirationDate_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_AgreementWithTermExpirationDate_lbl1" xml:lang="en-US" id="adma_AgreementWithTermExpirationDate_lbl1">Agreement with Term Expiration Date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AgreementWithTermExpirationDate" xlink:to="adma_AgreementWithTermExpirationDate_lbl1" xlink:title="label: AgreementWithTermExpirationDate to adma_AgreementWithTermExpirationDate_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_AgreementWithTermExpirationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_AgreementWithTermExpirationDate" xml:lang="en-US" id="adma_AgreementWithTermExpirationDate">Agreement term expiring date</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AgreementWithTermExpirationDate" xlink:to="adma_AgreementWithTermExpirationDate" xlink:title="label: AgreementWithTermExpirationDate to adma_AgreementWithTermExpirationDate" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_ITTechnologySystemsInaccessiblePeriod" xlink:label="ITTechnologySystemsInaccessiblePeriod" xlink:title="ITTechnologySystemsInaccessiblePeriod" />
    <link:label xlink:type="resource" xlink:label="adma_ITTechnologySystemsInaccessiblePeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_ITTechnologySystemsInaccessiblePeriod_lbl" xml:lang="en-US" id="adma_ITTechnologySystemsInaccessiblePeriod_lbl">IT technology systems inaccessible period at the time disruption in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ITTechnologySystemsInaccessiblePeriod" xlink:to="adma_ITTechnologySystemsInaccessiblePeriod_lbl" xlink:title="label: ITTechnologySystemsInaccessiblePeriod to adma_ITTechnologySystemsInaccessiblePeriod_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_ITTechnologySystemsInaccessiblePeriod_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_ITTechnologySystemsInaccessiblePeriod_lbl1" xml:lang="en-US" id="adma_ITTechnologySystemsInaccessiblePeriod_lbl1">IT Technology Systems Inaccessible Period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ITTechnologySystemsInaccessiblePeriod" xlink:to="adma_ITTechnologySystemsInaccessiblePeriod_lbl1" xlink:title="label: ITTechnologySystemsInaccessiblePeriod to adma_ITTechnologySystemsInaccessiblePeriod_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_ITTechnologySystemsInaccessiblePeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_ITTechnologySystemsInaccessiblePeriod" xml:lang="en-US" id="adma_ITTechnologySystemsInaccessiblePeriod">IT technology systems inaccessible period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ITTechnologySystemsInaccessiblePeriod" xlink:to="adma_ITTechnologySystemsInaccessiblePeriod" xlink:title="label: ITTechnologySystemsInaccessiblePeriod to adma_ITTechnologySystemsInaccessiblePeriod" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_NumberOfPlasmaCollectionFacilities" xlink:label="NumberOfPlasmaCollectionFacilities" xlink:title="NumberOfPlasmaCollectionFacilities" />
    <link:label xlink:type="resource" xlink:label="adma_NumberOfPlasmaCollectionFacilities_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_NumberOfPlasmaCollectionFacilities_lbl" xml:lang="en-US" id="adma_NumberOfPlasmaCollectionFacilities_lbl">Number of wholly-owned plasma collection facilities of the entity.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfPlasmaCollectionFacilities" xlink:to="adma_NumberOfPlasmaCollectionFacilities_lbl" xlink:title="label: NumberOfPlasmaCollectionFacilities to adma_NumberOfPlasmaCollectionFacilities_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_NumberOfPlasmaCollectionFacilities_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_NumberOfPlasmaCollectionFacilities_lbl1" xml:lang="en-US" id="adma_NumberOfPlasmaCollectionFacilities_lbl1">Number of Plasma Collection Facilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfPlasmaCollectionFacilities" xlink:to="adma_NumberOfPlasmaCollectionFacilities_lbl1" xlink:title="label: NumberOfPlasmaCollectionFacilities to adma_NumberOfPlasmaCollectionFacilities_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_NumberOfPlasmaCollectionFacilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_NumberOfPlasmaCollectionFacilities" xml:lang="en-US" id="adma_NumberOfPlasmaCollectionFacilities">Number of plasma collection facilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfPlasmaCollectionFacilities" xlink:to="adma_NumberOfPlasmaCollectionFacilities" xlink:title="label: NumberOfPlasmaCollectionFacilities to adma_NumberOfPlasmaCollectionFacilities" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_IncreaseInMinimumAnnualPriceTerm" xlink:label="IncreaseInMinimumAnnualPriceTerm" xlink:title="IncreaseInMinimumAnnualPriceTerm" />
    <link:label xlink:type="resource" xlink:label="adma_IncreaseInMinimumAnnualPriceTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_IncreaseInMinimumAnnualPriceTerm_lbl" xml:lang="en-US" id="adma_IncreaseInMinimumAnnualPriceTerm_lbl">Increase in annual price term period on usage of RSV Plasma, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseInMinimumAnnualPriceTerm" xlink:to="adma_IncreaseInMinimumAnnualPriceTerm_lbl" xlink:title="label: IncreaseInMinimumAnnualPriceTerm to adma_IncreaseInMinimumAnnualPriceTerm_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_IncreaseInMinimumAnnualPriceTerm_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_IncreaseInMinimumAnnualPriceTerm_lbl1" xml:lang="en-US" id="adma_IncreaseInMinimumAnnualPriceTerm_lbl1">Increase in Minimum Annual Price, Term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseInMinimumAnnualPriceTerm" xlink:to="adma_IncreaseInMinimumAnnualPriceTerm_lbl1" xlink:title="label: IncreaseInMinimumAnnualPriceTerm to adma_IncreaseInMinimumAnnualPriceTerm_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_IncreaseInMinimumAnnualPriceTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_IncreaseInMinimumAnnualPriceTerm" xml:lang="en-US" id="adma_IncreaseInMinimumAnnualPriceTerm">Increase in minimum annual price, term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseInMinimumAnnualPriceTerm" xlink:to="adma_IncreaseInMinimumAnnualPriceTerm" xlink:title="label: IncreaseInMinimumAnnualPriceTerm to adma_IncreaseInMinimumAnnualPriceTerm" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_NumberOfRenewalTerms" xlink:label="NumberOfRenewalTerms" xlink:title="NumberOfRenewalTerms" />
    <link:label xlink:type="resource" xlink:label="adma_NumberOfRenewalTerms_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_NumberOfRenewalTerms_lbl" xml:lang="en-US" id="adma_NumberOfRenewalTerms_lbl">Number of renewal terms to extend purchase agreement, if agreed to by the parties.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfRenewalTerms" xlink:to="adma_NumberOfRenewalTerms_lbl" xlink:title="label: NumberOfRenewalTerms to adma_NumberOfRenewalTerms_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_NumberOfRenewalTerms_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_NumberOfRenewalTerms_lbl1" xml:lang="en-US" id="adma_NumberOfRenewalTerms_lbl1">Number of Renewal Terms</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfRenewalTerms" xlink:to="adma_NumberOfRenewalTerms_lbl1" xlink:title="label: NumberOfRenewalTerms to adma_NumberOfRenewalTerms_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_NumberOfRenewalTerms" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_NumberOfRenewalTerms" xml:lang="en-US" id="adma_NumberOfRenewalTerms">Number of renewal terms</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfRenewalTerms" xlink:to="adma_NumberOfRenewalTerms" xlink:title="label: NumberOfRenewalTerms to adma_NumberOfRenewalTerms" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_RestorationCostsReceived" xlink:label="RestorationCostsReceived" xlink:title="RestorationCostsReceived" />
    <link:label xlink:type="resource" xlink:label="adma_RestorationCostsReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_RestorationCostsReceived_lbl" xml:lang="en-US" id="adma_RestorationCostsReceived_lbl">Restoration cost received from cybersecurity insurance.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RestorationCostsReceived" xlink:to="adma_RestorationCostsReceived_lbl" xlink:title="label: RestorationCostsReceived to adma_RestorationCostsReceived_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_RestorationCostsReceived_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_RestorationCostsReceived_lbl1" xml:lang="en-US" id="adma_RestorationCostsReceived_lbl1">Restoration Costs Received</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RestorationCostsReceived" xlink:to="adma_RestorationCostsReceived_lbl1" xlink:title="label: RestorationCostsReceived to adma_RestorationCostsReceived_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_RestorationCostsReceived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_RestorationCostsReceived" xml:lang="en-US" id="adma_RestorationCostsReceived">Restoration costs received</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RestorationCostsReceived" xlink:to="adma_RestorationCostsReceived" xlink:title="label: RestorationCostsReceived to adma_RestorationCostsReceived" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_ARGrifolsAgreementMember" xlink:label="ARGrifolsAgreementMember" xlink:title="ARGrifolsAgreementMember" />
    <link:label xlink:type="resource" xlink:label="adma_ARGrifolsAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_ARGrifolsAgreementMember_lbl" xml:lang="en-US" id="adma_ARGrifolsAgreementMember_lbl">Restated Plasma Purchase Agreement with Grifols used in the manufacture of ASCENIV.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ARGrifolsAgreementMember" xlink:to="adma_ARGrifolsAgreementMember_lbl" xlink:title="label: ARGrifolsAgreementMember to adma_ARGrifolsAgreementMember_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_ARGrifolsAgreementMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_ARGrifolsAgreementMember_lbl1" xml:lang="en-US" id="adma_ARGrifolsAgreementMember_lbl1">A&amp;R Grifols Agreement [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ARGrifolsAgreementMember" xlink:to="adma_ARGrifolsAgreementMember_lbl1" xlink:title="label: ARGrifolsAgreementMember to adma_ARGrifolsAgreementMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_ARGrifolsAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_ARGrifolsAgreementMember" xml:lang="en-US" id="adma_ARGrifolsAgreementMember">A&amp;R Grifols Agreement [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ARGrifolsAgreementMember" xlink:to="adma_ARGrifolsAgreementMember" xlink:title="label: ARGrifolsAgreementMember to adma_ARGrifolsAgreementMember" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_PlasmaPurchaseAgreementOneMember" xlink:label="PlasmaPurchaseAgreementOneMember" xlink:title="PlasmaPurchaseAgreementOneMember" />
    <link:label xlink:type="resource" xlink:label="adma_PlasmaPurchaseAgreementOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_PlasmaPurchaseAgreementOneMember_lbl" xml:lang="en-US" id="adma_PlasmaPurchaseAgreementOneMember_lbl">Plasma purchase agreement to purchase plasma containing antibodies to RSV to be used in the manufacture of ASCENIV.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PlasmaPurchaseAgreementOneMember" xlink:to="adma_PlasmaPurchaseAgreementOneMember_lbl" xlink:title="label: PlasmaPurchaseAgreementOneMember to adma_PlasmaPurchaseAgreementOneMember_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_PlasmaPurchaseAgreementOneMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_PlasmaPurchaseAgreementOneMember_lbl1" xml:lang="en-US" id="adma_PlasmaPurchaseAgreementOneMember_lbl1">Plasma Purchase Agreement One [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PlasmaPurchaseAgreementOneMember" xlink:to="adma_PlasmaPurchaseAgreementOneMember_lbl1" xlink:title="label: PlasmaPurchaseAgreementOneMember to adma_PlasmaPurchaseAgreementOneMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_PlasmaPurchaseAgreementOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_PlasmaPurchaseAgreementOneMember" xml:lang="en-US" id="adma_PlasmaPurchaseAgreementOneMember">2011 Plasma Purchase Agreement [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PlasmaPurchaseAgreementOneMember" xlink:to="adma_PlasmaPurchaseAgreementOneMember" xlink:title="label: PlasmaPurchaseAgreementOneMember to adma_PlasmaPurchaseAgreementOneMember" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_BIVIGAMMember" xlink:label="BIVIGAMMember" xlink:title="BIVIGAMMember" />
    <link:label xlink:type="resource" xlink:label="adma_BIVIGAMMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_BIVIGAMMember_lbl" xml:lang="en-US" id="adma_BIVIGAMMember_lbl">BIVIGAM an Intravenous Immune Globulin ("IVIG") product indicated for the treatment of Primary Humoral Immunodeficiency ("PI"), also known as Primary Immunodeficiency Disease ("PIDD").</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BIVIGAMMember" xlink:to="adma_BIVIGAMMember_lbl" xlink:title="label: BIVIGAMMember to adma_BIVIGAMMember_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_BIVIGAMMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_BIVIGAMMember_lbl1" xml:lang="en-US" id="adma_BIVIGAMMember_lbl1">BIVIGAM [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BIVIGAMMember" xlink:to="adma_BIVIGAMMember_lbl1" xlink:title="label: BIVIGAMMember to adma_BIVIGAMMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_BIVIGAMMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_BIVIGAMMember" xml:lang="en-US" id="adma_BIVIGAMMember">BIVIGAM [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BIVIGAMMember" xlink:to="adma_BIVIGAMMember" xlink:title="label: BIVIGAMMember to adma_BIVIGAMMember" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_QuantityOfRespiratorySyncytialVirusPlasmaUsed" xlink:label="QuantityOfRespiratorySyncytialVirusPlasmaUsed" xlink:title="QuantityOfRespiratorySyncytialVirusPlasmaUsed" />
    <link:label xlink:type="resource" xlink:label="adma_QuantityOfRespiratorySyncytialVirusPlasmaUsed_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_QuantityOfRespiratorySyncytialVirusPlasmaUsed_lbl" xml:lang="en-US" id="adma_QuantityOfRespiratorySyncytialVirusPlasmaUsed_lbl">Respiratory Syncytial Virus (RSV) Converted human plasma used by company.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QuantityOfRespiratorySyncytialVirusPlasmaUsed" xlink:to="adma_QuantityOfRespiratorySyncytialVirusPlasmaUsed_lbl" xlink:title="label: QuantityOfRespiratorySyncytialVirusPlasmaUsed to adma_QuantityOfRespiratorySyncytialVirusPlasmaUsed_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_QuantityOfRespiratorySyncytialVirusPlasmaUsed_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_QuantityOfRespiratorySyncytialVirusPlasmaUsed_lbl1" xml:lang="en-US" id="adma_QuantityOfRespiratorySyncytialVirusPlasmaUsed_lbl1">Quantity of Respiratory Syncytial Virus Plasma Used</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QuantityOfRespiratorySyncytialVirusPlasmaUsed" xlink:to="adma_QuantityOfRespiratorySyncytialVirusPlasmaUsed_lbl1" xlink:title="label: QuantityOfRespiratorySyncytialVirusPlasmaUsed to adma_QuantityOfRespiratorySyncytialVirusPlasmaUsed_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_QuantityOfRespiratorySyncytialVirusPlasmaUsed" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_QuantityOfRespiratorySyncytialVirusPlasmaUsed" xml:lang="en-US" id="adma_QuantityOfRespiratorySyncytialVirusPlasmaUsed">Quantity of RSV plasma used</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="QuantityOfRespiratorySyncytialVirusPlasmaUsed" xlink:to="adma_QuantityOfRespiratorySyncytialVirusPlasmaUsed" xlink:title="label: QuantityOfRespiratorySyncytialVirusPlasmaUsed to adma_QuantityOfRespiratorySyncytialVirusPlasmaUsed" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_ASCENIVMember" xlink:label="ASCENIVMember" xlink:title="ASCENIVMember" />
    <link:label xlink:type="resource" xlink:label="adma_ASCENIVMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_ASCENIVMember_lbl" xml:lang="en-US" id="adma_ASCENIVMember_lbl">ASCENIV an Intravenous Immune Globulin ("IVIG") product indicated for the treatment of Primary Humoral Immunodeficiency ("PI"), also known as Primary Immunodeficiency Disease ("PIDD").</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ASCENIVMember" xlink:to="adma_ASCENIVMember_lbl" xlink:title="label: ASCENIVMember to adma_ASCENIVMember_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_ASCENIVMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_ASCENIVMember_lbl1" xml:lang="en-US" id="adma_ASCENIVMember_lbl1">ASCENIV [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ASCENIVMember" xlink:to="adma_ASCENIVMember_lbl1" xlink:title="label: ASCENIVMember to adma_ASCENIVMember_lbl1" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_RespiratorySyncytialVirusPlasmaVolumeSuppliedPeriod" xlink:label="RespiratorySyncytialVirusPlasmaVolumeSuppliedPeriod" xlink:title="RespiratorySyncytialVirusPlasmaVolumeSuppliedPeriod" />
    <link:label xlink:type="resource" xlink:label="adma_RespiratorySyncytialVirusPlasmaVolumeSuppliedPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_RespiratorySyncytialVirusPlasmaVolumeSuppliedPeriod_lbl" xml:lang="en-US" id="adma_RespiratorySyncytialVirusPlasmaVolumeSuppliedPeriod_lbl">Supplied period on usage of RSV plasma in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RespiratorySyncytialVirusPlasmaVolumeSuppliedPeriod" xlink:to="adma_RespiratorySyncytialVirusPlasmaVolumeSuppliedPeriod_lbl" xlink:title="label: RespiratorySyncytialVirusPlasmaVolumeSuppliedPeriod to adma_RespiratorySyncytialVirusPlasmaVolumeSuppliedPeriod_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_RespiratorySyncytialVirusPlasmaVolumeSuppliedPeriod_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_RespiratorySyncytialVirusPlasmaVolumeSuppliedPeriod_lbl1" xml:lang="en-US" id="adma_RespiratorySyncytialVirusPlasmaVolumeSuppliedPeriod_lbl1">Respiratory Syncytial Virus Plasma Volume Supplied Period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RespiratorySyncytialVirusPlasmaVolumeSuppliedPeriod" xlink:to="adma_RespiratorySyncytialVirusPlasmaVolumeSuppliedPeriod_lbl1" xlink:title="label: RespiratorySyncytialVirusPlasmaVolumeSuppliedPeriod to adma_RespiratorySyncytialVirusPlasmaVolumeSuppliedPeriod_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_RespiratorySyncytialVirusPlasmaVolumeSuppliedPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_RespiratorySyncytialVirusPlasmaVolumeSuppliedPeriod" xml:lang="en-US" id="adma_RespiratorySyncytialVirusPlasmaVolumeSuppliedPeriod">Volume supplied period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RespiratorySyncytialVirusPlasmaVolumeSuppliedPeriod" xlink:to="adma_RespiratorySyncytialVirusPlasmaVolumeSuppliedPeriod" xlink:title="label: RespiratorySyncytialVirusPlasmaVolumeSuppliedPeriod to adma_RespiratorySyncytialVirusPlasmaVolumeSuppliedPeriod" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_KEDPlasmaAgreementMember" xlink:label="KEDPlasmaAgreementMember" xlink:title="KEDPlasmaAgreementMember" />
    <link:label xlink:type="resource" xlink:label="adma_KEDPlasmaAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_KEDPlasmaAgreementMember_lbl" xml:lang="en-US" id="adma_KEDPlasmaAgreementMember_lbl">Plasma Purchase Agreement with KEDPlasma LLC for usage of RSV Plasma.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="KEDPlasmaAgreementMember" xlink:to="adma_KEDPlasmaAgreementMember_lbl" xlink:title="label: KEDPlasmaAgreementMember to adma_KEDPlasmaAgreementMember_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_KEDPlasmaAgreementMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_KEDPlasmaAgreementMember_lbl1" xml:lang="en-US" id="adma_KEDPlasmaAgreementMember_lbl1">KEDPlasma Agreement [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="KEDPlasmaAgreementMember" xlink:to="adma_KEDPlasmaAgreementMember_lbl1" xlink:title="label: KEDPlasmaAgreementMember to adma_KEDPlasmaAgreementMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_KEDPlasmaAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_KEDPlasmaAgreementMember" xml:lang="en-US" id="adma_KEDPlasmaAgreementMember">KEDPlasma Agreement [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="KEDPlasmaAgreementMember" xlink:to="adma_KEDPlasmaAgreementMember" xlink:title="label: KEDPlasmaAgreementMember to adma_KEDPlasmaAgreementMember" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_PostMarketingCommitmentsAbstract" xlink:label="PostMarketingCommitmentsAbstract" xlink:title="PostMarketingCommitmentsAbstract" />
    <link:label xlink:type="resource" xlink:label="adma_PostMarketingCommitmentsAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_PostMarketingCommitmentsAbstract_lbl1" xml:lang="en-US" id="adma_PostMarketingCommitmentsAbstract_lbl1">Post-Marketing Commitments [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PostMarketingCommitmentsAbstract" xlink:to="adma_PostMarketingCommitmentsAbstract_lbl1" xlink:title="label: PostMarketingCommitmentsAbstract to adma_PostMarketingCommitmentsAbstract_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_PostMarketingCommitmentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_PostMarketingCommitmentsAbstract" xml:lang="en-US" id="adma_PostMarketingCommitmentsAbstract">Post-Marketing Commitments [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PostMarketingCommitmentsAbstract" xlink:to="adma_PostMarketingCommitmentsAbstract" xlink:title="label: PostMarketingCommitmentsAbstract to adma_PostMarketingCommitmentsAbstract" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_SECSchedule1209ReserveAccruedRebatesMember" xlink:label="SECSchedule1209ReserveAccruedRebatesMember" xlink:title="SECSchedule1209ReserveAccruedRebatesMember" />
    <link:label xlink:type="resource" xlink:label="adma_SECSchedule1209ReserveAccruedRebatesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_SECSchedule1209ReserveAccruedRebatesMember_lbl" xml:lang="en-US" id="adma_SECSchedule1209ReserveAccruedRebatesMember_lbl">Reserve for accrued rebates for Medicaid or other third parties related to sale of product.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SECSchedule1209ReserveAccruedRebatesMember" xlink:to="adma_SECSchedule1209ReserveAccruedRebatesMember_lbl" xlink:title="label: SECSchedule1209ReserveAccruedRebatesMember to adma_SECSchedule1209ReserveAccruedRebatesMember_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_SECSchedule1209ReserveAccruedRebatesMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_SECSchedule1209ReserveAccruedRebatesMember_lbl1" xml:lang="en-US" id="adma_SECSchedule1209ReserveAccruedRebatesMember_lbl1">SEC Schedule, 12-09, Reserve, Accrued Rebates [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SECSchedule1209ReserveAccruedRebatesMember" xlink:to="adma_SECSchedule1209ReserveAccruedRebatesMember_lbl1" xlink:title="label: SECSchedule1209ReserveAccruedRebatesMember to adma_SECSchedule1209ReserveAccruedRebatesMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_SECSchedule1209ReserveAccruedRebatesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_SECSchedule1209ReserveAccruedRebatesMember" xml:lang="en-US" id="adma_SECSchedule1209ReserveAccruedRebatesMember">Accrued Rebates [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SECSchedule1209ReserveAccruedRebatesMember" xlink:to="adma_SECSchedule1209ReserveAccruedRebatesMember" xlink:title="label: SECSchedule1209ReserveAccruedRebatesMember to adma_SECSchedule1209ReserveAccruedRebatesMember" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_RightToIntermediatesMember" xlink:label="RightToIntermediatesMember" xlink:title="RightToIntermediatesMember" />
    <link:label xlink:type="resource" xlink:label="adma_RightToIntermediatesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_RightToIntermediatesMember_lbl" xml:lang="en-US" id="adma_RightToIntermediatesMember_lbl">Entity's established relationships with its customers through contracts.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RightToIntermediatesMember" xlink:to="adma_RightToIntermediatesMember_lbl" xlink:title="label: RightToIntermediatesMember to adma_RightToIntermediatesMember_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_RightToIntermediatesMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_RightToIntermediatesMember_lbl1" xml:lang="en-US" id="adma_RightToIntermediatesMember_lbl1">Right to Intermediates [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RightToIntermediatesMember" xlink:to="adma_RightToIntermediatesMember_lbl1" xlink:title="label: RightToIntermediatesMember to adma_RightToIntermediatesMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_RightToIntermediatesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_RightToIntermediatesMember" xml:lang="en-US" id="adma_RightToIntermediatesMember">Rights to Intermediates [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RightToIntermediatesMember" xlink:to="adma_RightToIntermediatesMember" xlink:title="label: RightToIntermediatesMember to adma_RightToIntermediatesMember" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_TrademarkAndOtherIntangibleRightsRelatedToNabiHBMember" xlink:label="TrademarkAndOtherIntangibleRightsRelatedToNabiHBMember" xlink:title="TrademarkAndOtherIntangibleRightsRelatedToNabiHBMember" />
    <link:label xlink:type="resource" xlink:label="adma_TrademarkAndOtherIntangibleRightsRelatedToNabiHBMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_TrademarkAndOtherIntangibleRightsRelatedToNabiHBMember_lbl" xml:lang="en-US" id="adma_TrademarkAndOtherIntangibleRightsRelatedToNabiHBMember_lbl">Entity's established relationships with its customers through contracts.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TrademarkAndOtherIntangibleRightsRelatedToNabiHBMember" xlink:to="adma_TrademarkAndOtherIntangibleRightsRelatedToNabiHBMember_lbl" xlink:title="label: TrademarkAndOtherIntangibleRightsRelatedToNabiHBMember to adma_TrademarkAndOtherIntangibleRightsRelatedToNabiHBMember_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_TrademarkAndOtherIntangibleRightsRelatedToNabiHBMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_TrademarkAndOtherIntangibleRightsRelatedToNabiHBMember_lbl1" xml:lang="en-US" id="adma_TrademarkAndOtherIntangibleRightsRelatedToNabiHBMember_lbl1">Trademark and Other Intangible Rights Related to Nabi-HB [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TrademarkAndOtherIntangibleRightsRelatedToNabiHBMember" xlink:to="adma_TrademarkAndOtherIntangibleRightsRelatedToNabiHBMember_lbl1" xlink:title="label: TrademarkAndOtherIntangibleRightsRelatedToNabiHBMember to adma_TrademarkAndOtherIntangibleRightsRelatedToNabiHBMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_TrademarkAndOtherIntangibleRightsRelatedToNabiHBMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_TrademarkAndOtherIntangibleRightsRelatedToNabiHBMember" xml:lang="en-US" id="adma_TrademarkAndOtherIntangibleRightsRelatedToNabiHBMember">Trademark and Other Intangible Rights Related to Nabi-HB [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TrademarkAndOtherIntangibleRightsRelatedToNabiHBMember" xlink:to="adma_TrademarkAndOtherIntangibleRightsRelatedToNabiHBMember" xlink:title="label: TrademarkAndOtherIntangibleRightsRelatedToNabiHBMember to adma_TrademarkAndOtherIntangibleRightsRelatedToNabiHBMember" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_NumberOfFDAApprovedProduct" xlink:label="NumberOfFDAApprovedProduct" xlink:title="NumberOfFDAApprovedProduct" />
    <link:label xlink:type="resource" xlink:label="adma_NumberOfFDAApprovedProduct_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_NumberOfFDAApprovedProduct_lbl" xml:lang="en-US" id="adma_NumberOfFDAApprovedProduct_lbl">Number of products approved by FDA.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfFDAApprovedProduct" xlink:to="adma_NumberOfFDAApprovedProduct_lbl" xlink:title="label: NumberOfFDAApprovedProduct to adma_NumberOfFDAApprovedProduct_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_NumberOfFDAApprovedProduct_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_NumberOfFDAApprovedProduct_lbl1" xml:lang="en-US" id="adma_NumberOfFDAApprovedProduct_lbl1">Number of FDA Approved Product</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfFDAApprovedProduct" xlink:to="adma_NumberOfFDAApprovedProduct_lbl1" xlink:title="label: NumberOfFDAApprovedProduct to adma_NumberOfFDAApprovedProduct_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_NumberOfFDAApprovedProduct" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_NumberOfFDAApprovedProduct" xml:lang="en-US" id="adma_NumberOfFDAApprovedProduct">Number of FDA approved product</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfFDAApprovedProduct" xlink:to="adma_NumberOfFDAApprovedProduct" xlink:title="label: NumberOfFDAApprovedProduct to adma_NumberOfFDAApprovedProduct" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_NumberOfFDALicensedPlasmaCollectionFacilities" xlink:label="NumberOfFDALicensedPlasmaCollectionFacilities" xlink:title="NumberOfFDALicensedPlasmaCollectionFacilities" />
    <link:label xlink:type="resource" xlink:label="adma_NumberOfFDALicensedPlasmaCollectionFacilities_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_NumberOfFDALicensedPlasmaCollectionFacilities_lbl" xml:lang="en-US" id="adma_NumberOfFDALicensedPlasmaCollectionFacilities_lbl">Number of plasma collection facilities having FDA license.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfFDALicensedPlasmaCollectionFacilities" xlink:to="adma_NumberOfFDALicensedPlasmaCollectionFacilities_lbl" xlink:title="label: NumberOfFDALicensedPlasmaCollectionFacilities to adma_NumberOfFDALicensedPlasmaCollectionFacilities_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_NumberOfFDALicensedPlasmaCollectionFacilities_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_NumberOfFDALicensedPlasmaCollectionFacilities_lbl1" xml:lang="en-US" id="adma_NumberOfFDALicensedPlasmaCollectionFacilities_lbl1">Number of FDA-Licensed Plasma Collection Facilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfFDALicensedPlasmaCollectionFacilities" xlink:to="adma_NumberOfFDALicensedPlasmaCollectionFacilities_lbl1" xlink:title="label: NumberOfFDALicensedPlasmaCollectionFacilities to adma_NumberOfFDALicensedPlasmaCollectionFacilities_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_NumberOfFDALicensedPlasmaCollectionFacilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_NumberOfFDALicensedPlasmaCollectionFacilities" xml:lang="en-US" id="adma_NumberOfFDALicensedPlasmaCollectionFacilities">Number of FDA-licensed plasma collection facilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfFDALicensedPlasmaCollectionFacilities" xlink:to="adma_NumberOfFDALicensedPlasmaCollectionFacilities" xlink:title="label: NumberOfFDALicensedPlasmaCollectionFacilities to adma_NumberOfFDALicensedPlasmaCollectionFacilities" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_PrepaidOnOrPriorToFirstAnniversaryMember" xlink:label="PrepaidOnOrPriorToFirstAnniversaryMember" xlink:title="PrepaidOnOrPriorToFirstAnniversaryMember" />
    <link:label xlink:type="resource" xlink:label="adma_PrepaidOnOrPriorToFirstAnniversaryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_PrepaidOnOrPriorToFirstAnniversaryMember_lbl" xml:lang="en-US" id="adma_PrepaidOnOrPriorToFirstAnniversaryMember_lbl">The first anniversary representing most current period of debt redemption features under terms of the debt agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PrepaidOnOrPriorToFirstAnniversaryMember" xlink:to="adma_PrepaidOnOrPriorToFirstAnniversaryMember_lbl" xlink:title="label: PrepaidOnOrPriorToFirstAnniversaryMember to adma_PrepaidOnOrPriorToFirstAnniversaryMember_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_PrepaidOnOrPriorToFirstAnniversaryMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_PrepaidOnOrPriorToFirstAnniversaryMember_lbl1" xml:lang="en-US" id="adma_PrepaidOnOrPriorToFirstAnniversaryMember_lbl1">Prepaid on or Prior to First Anniversary [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PrepaidOnOrPriorToFirstAnniversaryMember" xlink:to="adma_PrepaidOnOrPriorToFirstAnniversaryMember_lbl1" xlink:title="label: PrepaidOnOrPriorToFirstAnniversaryMember to adma_PrepaidOnOrPriorToFirstAnniversaryMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_PrepaidOnOrPriorToFirstAnniversaryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_PrepaidOnOrPriorToFirstAnniversaryMember" xml:lang="en-US" id="adma_PrepaidOnOrPriorToFirstAnniversaryMember">Prepaid on or Prior to First Anniversary [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PrepaidOnOrPriorToFirstAnniversaryMember" xlink:to="adma_PrepaidOnOrPriorToFirstAnniversaryMember" xlink:title="label: PrepaidOnOrPriorToFirstAnniversaryMember to adma_PrepaidOnOrPriorToFirstAnniversaryMember" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_AresCreditAgreementMember" xlink:label="AresCreditAgreementMember" xlink:title="AresCreditAgreementMember" />
    <link:label xlink:type="resource" xlink:label="adma_AresCreditAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_AresCreditAgreementMember_lbl" xml:lang="en-US" id="adma_AresCreditAgreementMember_lbl">Ares credit agreement is a legally-binding contract documenting the terms of a loan agreement; it is made between a person or party borrowing money and a lender.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AresCreditAgreementMember" xlink:to="adma_AresCreditAgreementMember_lbl" xlink:title="label: AresCreditAgreementMember to adma_AresCreditAgreementMember_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_AresCreditAgreementMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_AresCreditAgreementMember_lbl1" xml:lang="en-US" id="adma_AresCreditAgreementMember_lbl1">Ares Credit Agreement [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AresCreditAgreementMember" xlink:to="adma_AresCreditAgreementMember_lbl1" xlink:title="label: AresCreditAgreementMember to adma_AresCreditAgreementMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_AresCreditAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_AresCreditAgreementMember" xml:lang="en-US" id="adma_AresCreditAgreementMember">Ares Credit Agreement [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AresCreditAgreementMember" xlink:to="adma_AresCreditAgreementMember" xlink:title="label: AresCreditAgreementMember to adma_AresCreditAgreementMember" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_HayfinSecondAmendmentMember" xlink:label="HayfinSecondAmendmentMember" xlink:title="HayfinSecondAmendmentMember" />
    <link:label xlink:type="resource" xlink:label="adma_HayfinSecondAmendmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_HayfinSecondAmendmentMember_lbl" xml:lang="en-US" id="adma_HayfinSecondAmendmentMember_lbl">Entity entered into second amendment "Hayfin Second Amendment" in a debt arrangement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HayfinSecondAmendmentMember" xlink:to="adma_HayfinSecondAmendmentMember_lbl" xlink:title="label: HayfinSecondAmendmentMember to adma_HayfinSecondAmendmentMember_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_HayfinSecondAmendmentMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_HayfinSecondAmendmentMember_lbl1" xml:lang="en-US" id="adma_HayfinSecondAmendmentMember_lbl1">Hayfin Second Amendment [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HayfinSecondAmendmentMember" xlink:to="adma_HayfinSecondAmendmentMember_lbl1" xlink:title="label: HayfinSecondAmendmentMember to adma_HayfinSecondAmendmentMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_HayfinSecondAmendmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_HayfinSecondAmendmentMember" xml:lang="en-US" id="adma_HayfinSecondAmendmentMember">Hayfin Second Amendment [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HayfinSecondAmendmentMember" xlink:to="adma_HayfinSecondAmendmentMember" xlink:title="label: HayfinSecondAmendmentMember to adma_HayfinSecondAmendmentMember" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_DebtInstrumentFloorInterestRate" xlink:label="DebtInstrumentFloorInterestRate" xlink:title="DebtInstrumentFloorInterestRate" />
    <link:label xlink:type="resource" xlink:label="adma_DebtInstrumentFloorInterestRate_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_DebtInstrumentFloorInterestRate_lbl" xml:lang="en-US" id="adma_DebtInstrumentFloorInterestRate_lbl">The percentage floor rate on debt instrument.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentFloorInterestRate" xlink:to="adma_DebtInstrumentFloorInterestRate_lbl" xlink:title="label: DebtInstrumentFloorInterestRate to adma_DebtInstrumentFloorInterestRate_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_DebtInstrumentFloorInterestRate_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_DebtInstrumentFloorInterestRate_lbl1" xml:lang="en-US" id="adma_DebtInstrumentFloorInterestRate_lbl1">Debt Instrument, Floor Interest Rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentFloorInterestRate" xlink:to="adma_DebtInstrumentFloorInterestRate_lbl1" xlink:title="label: DebtInstrumentFloorInterestRate to adma_DebtInstrumentFloorInterestRate_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_DebtInstrumentFloorInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_DebtInstrumentFloorInterestRate" xml:lang="en-US" id="adma_DebtInstrumentFloorInterestRate">Percentage of floor interest rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentFloorInterestRate" xlink:to="adma_DebtInstrumentFloorInterestRate" xlink:title="label: DebtInstrumentFloorInterestRate to adma_DebtInstrumentFloorInterestRate" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_NumberOfBusinessDaysForPriorWrittenNoticeToPrepayOutstandingPrincipal" xlink:label="NumberOfBusinessDaysForPriorWrittenNoticeToPrepayOutstandingPrincipal" xlink:title="NumberOfBusinessDaysForPriorWrittenNoticeToPrepayOutstandingPrincipal" />
    <link:label xlink:type="resource" xlink:label="adma_NumberOfBusinessDaysForPriorWrittenNoticeToPrepayOutstandingPrincipal_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_NumberOfBusinessDaysForPriorWrittenNoticeToPrepayOutstandingPrincipal_lbl" xml:lang="en-US" id="adma_NumberOfBusinessDaysForPriorWrittenNoticeToPrepayOutstandingPrincipal_lbl">Number of business days for prior written notice to pay outstanding principal loans, Number of business days, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfBusinessDaysForPriorWrittenNoticeToPrepayOutstandingPrincipal" xlink:to="adma_NumberOfBusinessDaysForPriorWrittenNoticeToPrepayOutstandingPrincipal_lbl" xlink:title="label: NumberOfBusinessDaysForPriorWrittenNoticeToPrepayOutstandingPrincipal to adma_NumberOfBusinessDaysForPriorWrittenNoticeToPrepayOutstandingPrincipal_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_NumberOfBusinessDaysForPriorWrittenNoticeToPrepayOutstandingPrincipal_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_NumberOfBusinessDaysForPriorWrittenNoticeToPrepayOutstandingPrincipal_lbl1" xml:lang="en-US" id="adma_NumberOfBusinessDaysForPriorWrittenNoticeToPrepayOutstandingPrincipal_lbl1">Number of Business Days for Prior Written Notice to Prepay Outstanding Principal</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfBusinessDaysForPriorWrittenNoticeToPrepayOutstandingPrincipal" xlink:to="adma_NumberOfBusinessDaysForPriorWrittenNoticeToPrepayOutstandingPrincipal_lbl1" xlink:title="label: NumberOfBusinessDaysForPriorWrittenNoticeToPrepayOutstandingPrincipal to adma_NumberOfBusinessDaysForPriorWrittenNoticeToPrepayOutstandingPrincipal_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_NumberOfBusinessDaysForPriorWrittenNoticeToPrepayOutstandingPrincipal" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_NumberOfBusinessDaysForPriorWrittenNoticeToPrepayOutstandingPrincipal" xml:lang="en-US" id="adma_NumberOfBusinessDaysForPriorWrittenNoticeToPrepayOutstandingPrincipal">Number of business days for prior written notice</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfBusinessDaysForPriorWrittenNoticeToPrepayOutstandingPrincipal" xlink:to="adma_NumberOfBusinessDaysForPriorWrittenNoticeToPrepayOutstandingPrincipal" xlink:title="label: NumberOfBusinessDaysForPriorWrittenNoticeToPrepayOutstandingPrincipal to adma_NumberOfBusinessDaysForPriorWrittenNoticeToPrepayOutstandingPrincipal" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_MinimumLiquidityCovenantsCreditFacilities" xlink:label="MinimumLiquidityCovenantsCreditFacilities" xlink:title="MinimumLiquidityCovenantsCreditFacilities" />
    <link:label xlink:type="resource" xlink:label="adma_MinimumLiquidityCovenantsCreditFacilities_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_MinimumLiquidityCovenantsCreditFacilities_lbl" xml:lang="en-US" id="adma_MinimumLiquidityCovenantsCreditFacilities_lbl">The carrying amount of minimum liquidity requirements required to be maintained by the borrower per the Company's credit facilities covenants under the loan agreement that are not restricted as to withdrawal or usage.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MinimumLiquidityCovenantsCreditFacilities" xlink:to="adma_MinimumLiquidityCovenantsCreditFacilities_lbl" xlink:title="label: MinimumLiquidityCovenantsCreditFacilities to adma_MinimumLiquidityCovenantsCreditFacilities_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_MinimumLiquidityCovenantsCreditFacilities_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_MinimumLiquidityCovenantsCreditFacilities_lbl1" xml:lang="en-US" id="adma_MinimumLiquidityCovenantsCreditFacilities_lbl1">Minimum Liquidity Covenants, Credit Facilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MinimumLiquidityCovenantsCreditFacilities" xlink:to="adma_MinimumLiquidityCovenantsCreditFacilities_lbl1" xlink:title="label: MinimumLiquidityCovenantsCreditFacilities to adma_MinimumLiquidityCovenantsCreditFacilities_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_MinimumLiquidityCovenantsCreditFacilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_MinimumLiquidityCovenantsCreditFacilities" xml:lang="en-US" id="adma_MinimumLiquidityCovenantsCreditFacilities">Minimum liquidity covenant</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MinimumLiquidityCovenantsCreditFacilities" xlink:to="adma_MinimumLiquidityCovenantsCreditFacilities" xlink:title="label: MinimumLiquidityCovenantsCreditFacilities to adma_MinimumLiquidityCovenantsCreditFacilities" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_PercentageOfExitFeeOfOutstandingPrincipalAmountBeingPaid" xlink:label="PercentageOfExitFeeOfOutstandingPrincipalAmountBeingPaid" xlink:title="PercentageOfExitFeeOfOutstandingPrincipalAmountBeingPaid" />
    <link:label xlink:type="resource" xlink:label="adma_PercentageOfExitFeeOfOutstandingPrincipalAmountBeingPaid_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_PercentageOfExitFeeOfOutstandingPrincipalAmountBeingPaid_lbl" xml:lang="en-US" id="adma_PercentageOfExitFeeOfOutstandingPrincipalAmountBeingPaid_lbl">The percentage of exit fee on outstanding principal amount being paid.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PercentageOfExitFeeOfOutstandingPrincipalAmountBeingPaid" xlink:to="adma_PercentageOfExitFeeOfOutstandingPrincipalAmountBeingPaid_lbl" xlink:title="label: PercentageOfExitFeeOfOutstandingPrincipalAmountBeingPaid to adma_PercentageOfExitFeeOfOutstandingPrincipalAmountBeingPaid_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_PercentageOfExitFeeOfOutstandingPrincipalAmountBeingPaid_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_PercentageOfExitFeeOfOutstandingPrincipalAmountBeingPaid_lbl1" xml:lang="en-US" id="adma_PercentageOfExitFeeOfOutstandingPrincipalAmountBeingPaid_lbl1">Percentage of Exit Fee of Outstanding Principal Amount being Paid</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PercentageOfExitFeeOfOutstandingPrincipalAmountBeingPaid" xlink:to="adma_PercentageOfExitFeeOfOutstandingPrincipalAmountBeingPaid_lbl1" xlink:title="label: PercentageOfExitFeeOfOutstandingPrincipalAmountBeingPaid to adma_PercentageOfExitFeeOfOutstandingPrincipalAmountBeingPaid_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_PercentageOfExitFeeOfOutstandingPrincipalAmountBeingPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_PercentageOfExitFeeOfOutstandingPrincipalAmountBeingPaid" xml:lang="en-US" id="adma_PercentageOfExitFeeOfOutstandingPrincipalAmountBeingPaid">Percentage of exit fee on outstanding principal amount being paid</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PercentageOfExitFeeOfOutstandingPrincipalAmountBeingPaid" xlink:to="adma_PercentageOfExitFeeOfOutstandingPrincipalAmountBeingPaid" xlink:title="label: PercentageOfExitFeeOfOutstandingPrincipalAmountBeingPaid to adma_PercentageOfExitFeeOfOutstandingPrincipalAmountBeingPaid" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_SharesIssuedUponExerciseOfWarrants" xlink:label="SharesIssuedUponExerciseOfWarrants" xlink:title="SharesIssuedUponExerciseOfWarrants" />
    <link:label xlink:type="resource" xlink:label="adma_SharesIssuedUponExerciseOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_SharesIssuedUponExerciseOfWarrants_lbl" xml:lang="en-US" id="adma_SharesIssuedUponExerciseOfWarrants_lbl">Number of shares issued upon exercise of warrants.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharesIssuedUponExerciseOfWarrants" xlink:to="adma_SharesIssuedUponExerciseOfWarrants_lbl" xlink:title="label: SharesIssuedUponExerciseOfWarrants to adma_SharesIssuedUponExerciseOfWarrants_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_SharesIssuedUponExerciseOfWarrants_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_SharesIssuedUponExerciseOfWarrants_lbl1" xml:lang="en-US" id="adma_SharesIssuedUponExerciseOfWarrants_lbl1">Shares Issued Upon Exercise Of Warrants</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharesIssuedUponExerciseOfWarrants" xlink:to="adma_SharesIssuedUponExerciseOfWarrants_lbl1" xlink:title="label: SharesIssuedUponExerciseOfWarrants to adma_SharesIssuedUponExerciseOfWarrants_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_SharesIssuedUponExerciseOfWarrants" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_SharesIssuedUponExerciseOfWarrants" xml:lang="en-US" id="adma_SharesIssuedUponExerciseOfWarrants">Shares issued upon exercise of warrants (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SharesIssuedUponExerciseOfWarrants" xlink:to="adma_SharesIssuedUponExerciseOfWarrants" xlink:title="label: SharesIssuedUponExerciseOfWarrants to adma_SharesIssuedUponExerciseOfWarrants" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_PrepaymentsOfDebtPremium" xlink:label="PrepaymentsOfDebtPremium" xlink:title="PrepaymentsOfDebtPremium" />
    <link:label xlink:type="resource" xlink:label="adma_PrepaymentsOfDebtPremium_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_PrepaymentsOfDebtPremium_lbl" xml:lang="en-US" id="adma_PrepaymentsOfDebtPremium_lbl">Amount represents the payments of premium.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PrepaymentsOfDebtPremium" xlink:to="adma_PrepaymentsOfDebtPremium_lbl" xlink:title="label: PrepaymentsOfDebtPremium to adma_PrepaymentsOfDebtPremium_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_PrepaymentsOfDebtPremium_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_PrepaymentsOfDebtPremium_lbl1" xml:lang="en-US" id="adma_PrepaymentsOfDebtPremium_lbl1">Prepayments of Debt Premium</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PrepaymentsOfDebtPremium" xlink:to="adma_PrepaymentsOfDebtPremium_lbl1" xlink:title="label: PrepaymentsOfDebtPremium to adma_PrepaymentsOfDebtPremium_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_PrepaymentsOfDebtPremium" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_PrepaymentsOfDebtPremium" xml:lang="en-US" id="adma_PrepaymentsOfDebtPremium">Prepayments of premium</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PrepaymentsOfDebtPremium" xlink:to="adma_PrepaymentsOfDebtPremium" xlink:title="label: PrepaymentsOfDebtPremium to adma_PrepaymentsOfDebtPremium" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_DebtInstrumentApplicableMargin" xlink:label="DebtInstrumentApplicableMargin" xlink:title="DebtInstrumentApplicableMargin" />
    <link:label xlink:type="resource" xlink:label="adma_DebtInstrumentApplicableMargin_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_DebtInstrumentApplicableMargin_lbl" xml:lang="en-US" id="adma_DebtInstrumentApplicableMargin_lbl">Percentage points added to the reference rate to compute the margin rate on the debt instrument.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentApplicableMargin" xlink:to="adma_DebtInstrumentApplicableMargin_lbl" xlink:title="label: DebtInstrumentApplicableMargin to adma_DebtInstrumentApplicableMargin_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_DebtInstrumentApplicableMargin_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_DebtInstrumentApplicableMargin_lbl1" xml:lang="en-US" id="adma_DebtInstrumentApplicableMargin_lbl1">Debt Instrument Applicable Margin</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentApplicableMargin" xlink:to="adma_DebtInstrumentApplicableMargin_lbl1" xlink:title="label: DebtInstrumentApplicableMargin to adma_DebtInstrumentApplicableMargin_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_DebtInstrumentApplicableMargin" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_DebtInstrumentApplicableMargin" xml:lang="en-US" id="adma_DebtInstrumentApplicableMargin">Applicable margin</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentApplicableMargin" xlink:to="adma_DebtInstrumentApplicableMargin" xlink:title="label: DebtInstrumentApplicableMargin to adma_DebtInstrumentApplicableMargin" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_DebtInstrumentUpfrontFeePaidInKind" xlink:label="DebtInstrumentUpfrontFeePaidInKind" xlink:title="DebtInstrumentUpfrontFeePaidInKind" />
    <link:label xlink:type="resource" xlink:label="adma_DebtInstrumentUpfrontFeePaidInKind_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_DebtInstrumentUpfrontFeePaidInKind_lbl" xml:lang="en-US" id="adma_DebtInstrumentUpfrontFeePaidInKind_lbl">The cash outflow for payment of an upfront fee paid in kind to consortium of lenders under the debt instrument.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentUpfrontFeePaidInKind" xlink:to="adma_DebtInstrumentUpfrontFeePaidInKind_lbl" xlink:title="label: DebtInstrumentUpfrontFeePaidInKind to adma_DebtInstrumentUpfrontFeePaidInKind_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_DebtInstrumentUpfrontFeePaidInKind_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_DebtInstrumentUpfrontFeePaidInKind_lbl1" xml:lang="en-US" id="adma_DebtInstrumentUpfrontFeePaidInKind_lbl1">Debt Instrument, Upfront Fee, Paid in Kind</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentUpfrontFeePaidInKind" xlink:to="adma_DebtInstrumentUpfrontFeePaidInKind_lbl1" xlink:title="label: DebtInstrumentUpfrontFeePaidInKind to adma_DebtInstrumentUpfrontFeePaidInKind_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_DebtInstrumentUpfrontFeePaidInKind" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_DebtInstrumentUpfrontFeePaidInKind" xml:lang="en-US" id="adma_DebtInstrumentUpfrontFeePaidInKind">Upfront fee paid in kind</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentUpfrontFeePaidInKind" xlink:to="adma_DebtInstrumentUpfrontFeePaidInKind" xlink:title="label: DebtInstrumentUpfrontFeePaidInKind to adma_DebtInstrumentUpfrontFeePaidInKind" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_DebtInstrumentInterestAmountToBePayInKind" xlink:label="DebtInstrumentInterestAmountToBePayInKind" xlink:title="DebtInstrumentInterestAmountToBePayInKind" />
    <link:label xlink:type="resource" xlink:label="adma_DebtInstrumentInterestAmountToBePayInKind_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_DebtInstrumentInterestAmountToBePayInKind_lbl" xml:lang="en-US" id="adma_DebtInstrumentInterestAmountToBePayInKind_lbl">The interest amount to be pay in kind during the reporting period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentInterestAmountToBePayInKind" xlink:to="adma_DebtInstrumentInterestAmountToBePayInKind_lbl" xlink:title="label: DebtInstrumentInterestAmountToBePayInKind to adma_DebtInstrumentInterestAmountToBePayInKind_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_DebtInstrumentInterestAmountToBePayInKind_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_DebtInstrumentInterestAmountToBePayInKind_lbl1" xml:lang="en-US" id="adma_DebtInstrumentInterestAmountToBePayInKind_lbl1">Debt Instrument, Interest Amount to be Pay in Kind</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentInterestAmountToBePayInKind" xlink:to="adma_DebtInstrumentInterestAmountToBePayInKind_lbl1" xlink:title="label: DebtInstrumentInterestAmountToBePayInKind to adma_DebtInstrumentInterestAmountToBePayInKind_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_DebtInstrumentInterestAmountToBePayInKind" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_DebtInstrumentInterestAmountToBePayInKind" xml:lang="en-US" id="adma_DebtInstrumentInterestAmountToBePayInKind">Percentage of interest amount to pay in kind</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentInterestAmountToBePayInKind" xlink:to="adma_DebtInstrumentInterestAmountToBePayInKind" xlink:title="label: DebtInstrumentInterestAmountToBePayInKind to adma_DebtInstrumentInterestAmountToBePayInKind" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_OriginalDiscountPayableCreditFacility" xlink:label="OriginalDiscountPayableCreditFacility" xlink:title="OriginalDiscountPayableCreditFacility" />
    <link:label xlink:type="resource" xlink:label="adma_OriginalDiscountPayableCreditFacility_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_OriginalDiscountPayableCreditFacility_lbl" xml:lang="en-US" id="adma_OriginalDiscountPayableCreditFacility_lbl">Amount represent the original discount payable in related transaction in credit facility.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OriginalDiscountPayableCreditFacility" xlink:to="adma_OriginalDiscountPayableCreditFacility_lbl" xlink:title="label: OriginalDiscountPayableCreditFacility to adma_OriginalDiscountPayableCreditFacility_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_OriginalDiscountPayableCreditFacility_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_OriginalDiscountPayableCreditFacility_lbl1" xml:lang="en-US" id="adma_OriginalDiscountPayableCreditFacility_lbl1">Original Discount Payable, Credit Facility</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OriginalDiscountPayableCreditFacility" xlink:to="adma_OriginalDiscountPayableCreditFacility_lbl1" xlink:title="label: OriginalDiscountPayableCreditFacility to adma_OriginalDiscountPayableCreditFacility_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_OriginalDiscountPayableCreditFacility" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_OriginalDiscountPayableCreditFacility" xml:lang="en-US" id="adma_OriginalDiscountPayableCreditFacility">Original discount payable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OriginalDiscountPayableCreditFacility" xlink:to="adma_OriginalDiscountPayableCreditFacility" xlink:title="label: OriginalDiscountPayableCreditFacility to adma_OriginalDiscountPayableCreditFacility" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_DebtInstrumentExitFee" xlink:label="DebtInstrumentExitFee" xlink:title="DebtInstrumentExitFee" />
    <link:label xlink:type="resource" xlink:label="adma_DebtInstrumentExitFee_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_DebtInstrumentExitFee_lbl" xml:lang="en-US" id="adma_DebtInstrumentExitFee_lbl">Amount of expenses associated with exit fee of debt instrument.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentExitFee" xlink:to="adma_DebtInstrumentExitFee_lbl" xlink:title="label: DebtInstrumentExitFee to adma_DebtInstrumentExitFee_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_DebtInstrumentExitFee_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_DebtInstrumentExitFee_lbl1" xml:lang="en-US" id="adma_DebtInstrumentExitFee_lbl1">Debt Instrument, Exit Fee</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentExitFee" xlink:to="adma_DebtInstrumentExitFee_lbl1" xlink:title="label: DebtInstrumentExitFee to adma_DebtInstrumentExitFee_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_DebtInstrumentExitFee" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_DebtInstrumentExitFee" xml:lang="en-US" id="adma_DebtInstrumentExitFee">Exit fee</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentExitFee" xlink:to="adma_DebtInstrumentExitFee" xlink:title="label: DebtInstrumentExitFee to adma_DebtInstrumentExitFee" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_DebtInstrumentTermOfVariableRate" xlink:label="DebtInstrumentTermOfVariableRate" xlink:title="DebtInstrumentTermOfVariableRate" />
    <link:label xlink:type="resource" xlink:label="adma_DebtInstrumentTermOfVariableRate_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_DebtInstrumentTermOfVariableRate_lbl" xml:lang="en-US" id="adma_DebtInstrumentTermOfVariableRate_lbl">Term of the interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentTermOfVariableRate" xlink:to="adma_DebtInstrumentTermOfVariableRate_lbl" xlink:title="label: DebtInstrumentTermOfVariableRate to adma_DebtInstrumentTermOfVariableRate_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_DebtInstrumentTermOfVariableRate_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_DebtInstrumentTermOfVariableRate_lbl1" xml:lang="en-US" id="adma_DebtInstrumentTermOfVariableRate_lbl1">Debt Instrument, Term of Variable Rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentTermOfVariableRate" xlink:to="adma_DebtInstrumentTermOfVariableRate_lbl1" xlink:title="label: DebtInstrumentTermOfVariableRate to adma_DebtInstrumentTermOfVariableRate_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_DebtInstrumentTermOfVariableRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_DebtInstrumentTermOfVariableRate" xml:lang="en-US" id="adma_DebtInstrumentTermOfVariableRate">Term of variable rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DebtInstrumentTermOfVariableRate" xlink:to="adma_DebtInstrumentTermOfVariableRate" xlink:title="label: DebtInstrumentTermOfVariableRate to adma_DebtInstrumentTermOfVariableRate" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_PrepaidAfterTheFirstAnniversaryMember" xlink:label="PrepaidAfterTheFirstAnniversaryMember" xlink:title="PrepaidAfterTheFirstAnniversaryMember" />
    <link:label xlink:type="resource" xlink:label="adma_PrepaidAfterTheFirstAnniversaryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_PrepaidAfterTheFirstAnniversaryMember_lbl" xml:lang="en-US" id="adma_PrepaidAfterTheFirstAnniversaryMember_lbl">The first anniversary representing most prepaid of after period of debt redemption features under terms of the debt agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PrepaidAfterTheFirstAnniversaryMember" xlink:to="adma_PrepaidAfterTheFirstAnniversaryMember_lbl" xlink:title="label: PrepaidAfterTheFirstAnniversaryMember to adma_PrepaidAfterTheFirstAnniversaryMember_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_PrepaidAfterTheFirstAnniversaryMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_PrepaidAfterTheFirstAnniversaryMember_lbl1" xml:lang="en-US" id="adma_PrepaidAfterTheFirstAnniversaryMember_lbl1">Prepaid after the First Anniversary [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PrepaidAfterTheFirstAnniversaryMember" xlink:to="adma_PrepaidAfterTheFirstAnniversaryMember_lbl1" xlink:title="label: PrepaidAfterTheFirstAnniversaryMember to adma_PrepaidAfterTheFirstAnniversaryMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_PrepaidAfterTheFirstAnniversaryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_PrepaidAfterTheFirstAnniversaryMember" xml:lang="en-US" id="adma_PrepaidAfterTheFirstAnniversaryMember">Prepaid after the First Anniversary [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PrepaidAfterTheFirstAnniversaryMember" xlink:to="adma_PrepaidAfterTheFirstAnniversaryMember" xlink:title="label: PrepaidAfterTheFirstAnniversaryMember to adma_PrepaidAfterTheFirstAnniversaryMember" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_PrepaidOnOrPriorToThirdAnniversaryMember" xlink:label="PrepaidOnOrPriorToThirdAnniversaryMember" xlink:title="PrepaidOnOrPriorToThirdAnniversaryMember" />
    <link:label xlink:type="resource" xlink:label="adma_PrepaidOnOrPriorToThirdAnniversaryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_PrepaidOnOrPriorToThirdAnniversaryMember_lbl" xml:lang="en-US" id="adma_PrepaidOnOrPriorToThirdAnniversaryMember_lbl">The third anniversary representing most current period of debt redemption features under terms of the debt agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PrepaidOnOrPriorToThirdAnniversaryMember" xlink:to="adma_PrepaidOnOrPriorToThirdAnniversaryMember_lbl" xlink:title="label: PrepaidOnOrPriorToThirdAnniversaryMember to adma_PrepaidOnOrPriorToThirdAnniversaryMember_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_PrepaidOnOrPriorToThirdAnniversaryMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_PrepaidOnOrPriorToThirdAnniversaryMember_lbl1" xml:lang="en-US" id="adma_PrepaidOnOrPriorToThirdAnniversaryMember_lbl1">Prepaid on or Prior to Third Anniversary [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PrepaidOnOrPriorToThirdAnniversaryMember" xlink:to="adma_PrepaidOnOrPriorToThirdAnniversaryMember_lbl1" xlink:title="label: PrepaidOnOrPriorToThirdAnniversaryMember to adma_PrepaidOnOrPriorToThirdAnniversaryMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_PrepaidOnOrPriorToThirdAnniversaryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_PrepaidOnOrPriorToThirdAnniversaryMember" xml:lang="en-US" id="adma_PrepaidOnOrPriorToThirdAnniversaryMember">Prepaid on or Prior to Third Anniversary [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PrepaidOnOrPriorToThirdAnniversaryMember" xlink:to="adma_PrepaidOnOrPriorToThirdAnniversaryMember" xlink:title="label: PrepaidOnOrPriorToThirdAnniversaryMember to adma_PrepaidOnOrPriorToThirdAnniversaryMember" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_SeniorNotesPayableBeforeDebtDiscount" xlink:label="SeniorNotesPayableBeforeDebtDiscount" xlink:title="SeniorNotesPayableBeforeDebtDiscount" />
    <link:label xlink:type="resource" xlink:label="adma_SeniorNotesPayableBeforeDebtDiscount_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_SeniorNotesPayableBeforeDebtDiscount_lbl" xml:lang="en-US" id="adma_SeniorNotesPayableBeforeDebtDiscount_lbl">Carrying value as of the balance sheet date of Notes with the highest claim on the assets of the issuer in case of bankruptcy or liquidation (with maturities initially due after one year or beyond the operating cycle if longer), excluding debt discount and current portion.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SeniorNotesPayableBeforeDebtDiscount" xlink:to="adma_SeniorNotesPayableBeforeDebtDiscount_lbl" xlink:title="label: SeniorNotesPayableBeforeDebtDiscount to adma_SeniorNotesPayableBeforeDebtDiscount_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_SeniorNotesPayableBeforeDebtDiscount_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_SeniorNotesPayableBeforeDebtDiscount_lbl1" xml:lang="en-US" id="adma_SeniorNotesPayableBeforeDebtDiscount_lbl1">Senior Notes Payable Before Debt Discount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SeniorNotesPayableBeforeDebtDiscount" xlink:to="adma_SeniorNotesPayableBeforeDebtDiscount_lbl1" xlink:title="label: SeniorNotesPayableBeforeDebtDiscount to adma_SeniorNotesPayableBeforeDebtDiscount_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_SeniorNotesPayableBeforeDebtDiscount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_SeniorNotesPayableBeforeDebtDiscount" xml:lang="en-US" id="adma_SeniorNotesPayableBeforeDebtDiscount">Senior notes payable before debt discount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="SeniorNotesPayableBeforeDebtDiscount" xlink:to="adma_SeniorNotesPayableBeforeDebtDiscount" xlink:title="label: SeniorNotesPayableBeforeDebtDiscount to adma_SeniorNotesPayableBeforeDebtDiscount" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_ExitFeeLiability" xlink:label="ExitFeeLiability" xlink:title="ExitFeeLiability" />
    <link:label xlink:type="resource" xlink:label="adma_ExitFeeLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_ExitFeeLiability_lbl" xml:lang="en-US" id="adma_ExitFeeLiability_lbl">Amount of exit fee liability.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ExitFeeLiability" xlink:to="adma_ExitFeeLiability_lbl" xlink:title="label: ExitFeeLiability to adma_ExitFeeLiability_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_ExitFeeLiability_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_ExitFeeLiability_lbl1" xml:lang="en-US" id="adma_ExitFeeLiability_lbl1">Exit Fee Liability</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ExitFeeLiability" xlink:to="adma_ExitFeeLiability_lbl1" xlink:title="label: ExitFeeLiability to adma_ExitFeeLiability_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_ExitFeeLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_ExitFeeLiability" xml:lang="en-US" id="adma_ExitFeeLiability">Exit fee liability</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ExitFeeLiability" xlink:to="adma_ExitFeeLiability" xlink:title="label: ExitFeeLiability to adma_ExitFeeLiability" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_HayfinCreditFacilityMember" xlink:label="HayfinCreditFacilityMember" xlink:title="HayfinCreditFacilityMember" />
    <link:label xlink:type="resource" xlink:label="adma_HayfinCreditFacilityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_HayfinCreditFacilityMember_lbl" xml:lang="en-US" id="adma_HayfinCreditFacilityMember_lbl">Arrangement in which facility proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HayfinCreditFacilityMember" xlink:to="adma_HayfinCreditFacilityMember_lbl" xlink:title="label: HayfinCreditFacilityMember to adma_HayfinCreditFacilityMember_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_HayfinCreditFacilityMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_HayfinCreditFacilityMember_lbl1" xml:lang="en-US" id="adma_HayfinCreditFacilityMember_lbl1">Hayfin Credit Facility [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HayfinCreditFacilityMember" xlink:to="adma_HayfinCreditFacilityMember_lbl1" xlink:title="label: HayfinCreditFacilityMember to adma_HayfinCreditFacilityMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_HayfinCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_HayfinCreditFacilityMember" xml:lang="en-US" id="adma_HayfinCreditFacilityMember">Hayfin Credit Facility [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HayfinCreditFacilityMember" xlink:to="adma_HayfinCreditFacilityMember" xlink:title="label: HayfinCreditFacilityMember to adma_HayfinCreditFacilityMember" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_HayfinDelayedDrawLoanMember" xlink:label="HayfinDelayedDrawLoanMember" xlink:title="HayfinDelayedDrawLoanMember" />
    <link:label xlink:type="resource" xlink:label="adma_HayfinDelayedDrawLoanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_HayfinDelayedDrawLoanMember_lbl" xml:lang="en-US" id="adma_HayfinDelayedDrawLoanMember_lbl">Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HayfinDelayedDrawLoanMember" xlink:to="adma_HayfinDelayedDrawLoanMember_lbl" xlink:title="label: HayfinDelayedDrawLoanMember to adma_HayfinDelayedDrawLoanMember_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_HayfinDelayedDrawLoanMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_HayfinDelayedDrawLoanMember_lbl1" xml:lang="en-US" id="adma_HayfinDelayedDrawLoanMember_lbl1">Hayfin Delayed Draw Loan [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HayfinDelayedDrawLoanMember" xlink:to="adma_HayfinDelayedDrawLoanMember_lbl1" xlink:title="label: HayfinDelayedDrawLoanMember to adma_HayfinDelayedDrawLoanMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_HayfinDelayedDrawLoanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_HayfinDelayedDrawLoanMember" xml:lang="en-US" id="adma_HayfinDelayedDrawLoanMember">Hayfin Delayed Draw Loan [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HayfinDelayedDrawLoanMember" xlink:to="adma_HayfinDelayedDrawLoanMember" xlink:title="label: HayfinDelayedDrawLoanMember to adma_HayfinDelayedDrawLoanMember" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_HayfinClosingDateLoanMember" xlink:label="HayfinClosingDateLoanMember" xlink:title="HayfinClosingDateLoanMember" />
    <link:label xlink:type="resource" xlink:label="adma_HayfinClosingDateLoanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_HayfinClosingDateLoanMember_lbl" xml:lang="en-US" id="adma_HayfinClosingDateLoanMember_lbl">Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HayfinClosingDateLoanMember" xlink:to="adma_HayfinClosingDateLoanMember_lbl" xlink:title="label: HayfinClosingDateLoanMember to adma_HayfinClosingDateLoanMember_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_HayfinClosingDateLoanMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_HayfinClosingDateLoanMember_lbl1" xml:lang="en-US" id="adma_HayfinClosingDateLoanMember_lbl1">Hayfin Closing Date Loan [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HayfinClosingDateLoanMember" xlink:to="adma_HayfinClosingDateLoanMember_lbl1" xlink:title="label: HayfinClosingDateLoanMember to adma_HayfinClosingDateLoanMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_HayfinClosingDateLoanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_HayfinClosingDateLoanMember" xml:lang="en-US" id="adma_HayfinClosingDateLoanMember">Hayfin Closing Date Loan [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HayfinClosingDateLoanMember" xlink:to="adma_HayfinClosingDateLoanMember" xlink:title="label: HayfinClosingDateLoanMember to adma_HayfinClosingDateLoanMember" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_AresClosingDateLoanMember" xlink:label="AresClosingDateLoanMember" xlink:title="AresClosingDateLoanMember" />
    <link:label xlink:type="resource" xlink:label="adma_AresClosingDateLoanMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_AresClosingDateLoanMember_lbl1" xml:lang="en-US" id="adma_AresClosingDateLoanMember_lbl1">Ares Closing Date Loan [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AresClosingDateLoanMember" xlink:to="adma_AresClosingDateLoanMember_lbl1" xlink:title="label: AresClosingDateLoanMember to adma_AresClosingDateLoanMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_AresClosingDateLoanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_AresClosingDateLoanMember" xml:lang="en-US" id="adma_AresClosingDateLoanMember">Ares Closing Date Loan [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AresClosingDateLoanMember" xlink:to="adma_AresClosingDateLoanMember" xlink:title="label: AresClosingDateLoanMember to adma_AresClosingDateLoanMember" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_LongTermDebtPrepaymentPenalty" xlink:label="LongTermDebtPrepaymentPenalty" xlink:title="LongTermDebtPrepaymentPenalty" />
    <link:label xlink:type="resource" xlink:label="adma_LongTermDebtPrepaymentPenalty_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_LongTermDebtPrepaymentPenalty_lbl" xml:lang="en-US" id="adma_LongTermDebtPrepaymentPenalty_lbl">The amount of penalty on prepayment of long-term debt.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LongTermDebtPrepaymentPenalty" xlink:to="adma_LongTermDebtPrepaymentPenalty_lbl" xlink:title="label: LongTermDebtPrepaymentPenalty to adma_LongTermDebtPrepaymentPenalty_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_LongTermDebtPrepaymentPenalty_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_LongTermDebtPrepaymentPenalty_lbl1" xml:lang="en-US" id="adma_LongTermDebtPrepaymentPenalty_lbl1">Long Term Debt, Prepayment Penalty</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LongTermDebtPrepaymentPenalty" xlink:to="adma_LongTermDebtPrepaymentPenalty_lbl1" xlink:title="label: LongTermDebtPrepaymentPenalty to adma_LongTermDebtPrepaymentPenalty_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_LongTermDebtPrepaymentPenalty" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_LongTermDebtPrepaymentPenalty" xml:lang="en-US" id="adma_LongTermDebtPrepaymentPenalty">Prepayment penalty</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LongTermDebtPrepaymentPenalty" xlink:to="adma_LongTermDebtPrepaymentPenalty" xlink:title="label: LongTermDebtPrepaymentPenalty to adma_LongTermDebtPrepaymentPenalty" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_PrepaidOnOrPriorToSecondAnniversaryMember" xlink:label="PrepaidOnOrPriorToSecondAnniversaryMember" xlink:title="PrepaidOnOrPriorToSecondAnniversaryMember" />
    <link:label xlink:type="resource" xlink:label="adma_PrepaidOnOrPriorToSecondAnniversaryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_PrepaidOnOrPriorToSecondAnniversaryMember_lbl" xml:lang="en-US" id="adma_PrepaidOnOrPriorToSecondAnniversaryMember_lbl">The second anniversary representing most current period of debt redemption features under terms of the debt agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PrepaidOnOrPriorToSecondAnniversaryMember" xlink:to="adma_PrepaidOnOrPriorToSecondAnniversaryMember_lbl" xlink:title="label: PrepaidOnOrPriorToSecondAnniversaryMember to adma_PrepaidOnOrPriorToSecondAnniversaryMember_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_PrepaidOnOrPriorToSecondAnniversaryMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_PrepaidOnOrPriorToSecondAnniversaryMember_lbl1" xml:lang="en-US" id="adma_PrepaidOnOrPriorToSecondAnniversaryMember_lbl1">Prepaid on or Prior to Second Anniversary [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PrepaidOnOrPriorToSecondAnniversaryMember" xlink:to="adma_PrepaidOnOrPriorToSecondAnniversaryMember_lbl1" xlink:title="label: PrepaidOnOrPriorToSecondAnniversaryMember to adma_PrepaidOnOrPriorToSecondAnniversaryMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_PrepaidOnOrPriorToSecondAnniversaryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_PrepaidOnOrPriorToSecondAnniversaryMember" xml:lang="en-US" id="adma_PrepaidOnOrPriorToSecondAnniversaryMember">Prepaid on or Prior to Second Anniversary [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PrepaidOnOrPriorToSecondAnniversaryMember" xlink:to="adma_PrepaidOnOrPriorToSecondAnniversaryMember" xlink:title="label: PrepaidOnOrPriorToSecondAnniversaryMember to adma_PrepaidOnOrPriorToSecondAnniversaryMember" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_HayfinCreditAgreementMember" xlink:label="HayfinCreditAgreementMember" xlink:title="HayfinCreditAgreementMember" />
    <link:label xlink:type="resource" xlink:label="adma_HayfinCreditAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_HayfinCreditAgreementMember_lbl" xml:lang="en-US" id="adma_HayfinCreditAgreementMember_lbl">A Hayfin credit agreement is a legally-binding contract documenting the terms of a loan agreement; it is made between a person or party borrowing money and a lender.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HayfinCreditAgreementMember" xlink:to="adma_HayfinCreditAgreementMember_lbl" xlink:title="label: HayfinCreditAgreementMember to adma_HayfinCreditAgreementMember_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_HayfinCreditAgreementMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_HayfinCreditAgreementMember_lbl1" xml:lang="en-US" id="adma_HayfinCreditAgreementMember_lbl1">Hayfin Credit Agreement [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HayfinCreditAgreementMember" xlink:to="adma_HayfinCreditAgreementMember_lbl1" xlink:title="label: HayfinCreditAgreementMember to adma_HayfinCreditAgreementMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_HayfinCreditAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_HayfinCreditAgreementMember" xml:lang="en-US" id="adma_HayfinCreditAgreementMember">Hayfin Credit Agreement [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HayfinCreditAgreementMember" xlink:to="adma_HayfinCreditAgreementMember" xlink:title="label: HayfinCreditAgreementMember to adma_HayfinCreditAgreementMember" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_TrailingPeriodForVolumeWeightedAveragePrice" xlink:label="TrailingPeriodForVolumeWeightedAveragePrice" xlink:title="TrailingPeriodForVolumeWeightedAveragePrice" />
    <link:label xlink:type="resource" xlink:label="adma_TrailingPeriodForVolumeWeightedAveragePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_TrailingPeriodForVolumeWeightedAveragePrice_lbl" xml:lang="en-US" id="adma_TrailingPeriodForVolumeWeightedAveragePrice_lbl">The trailing period for volume-weighted average price, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TrailingPeriodForVolumeWeightedAveragePrice" xlink:to="adma_TrailingPeriodForVolumeWeightedAveragePrice_lbl" xlink:title="label: TrailingPeriodForVolumeWeightedAveragePrice to adma_TrailingPeriodForVolumeWeightedAveragePrice_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_TrailingPeriodForVolumeWeightedAveragePrice_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_TrailingPeriodForVolumeWeightedAveragePrice_lbl1" xml:lang="en-US" id="adma_TrailingPeriodForVolumeWeightedAveragePrice_lbl1">Trailing Period for Volume Weighted Average Price</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TrailingPeriodForVolumeWeightedAveragePrice" xlink:to="adma_TrailingPeriodForVolumeWeightedAveragePrice_lbl1" xlink:title="label: TrailingPeriodForVolumeWeightedAveragePrice to adma_TrailingPeriodForVolumeWeightedAveragePrice_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_TrailingPeriodForVolumeWeightedAveragePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_TrailingPeriodForVolumeWeightedAveragePrice" xml:lang="en-US" id="adma_TrailingPeriodForVolumeWeightedAveragePrice">Trailing period for VWAP</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TrailingPeriodForVolumeWeightedAveragePrice" xlink:to="adma_TrailingPeriodForVolumeWeightedAveragePrice" xlink:title="label: TrailingPeriodForVolumeWeightedAveragePrice to adma_TrailingPeriodForVolumeWeightedAveragePrice" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_AresCreditFacilityMember" xlink:label="AresCreditFacilityMember" xlink:title="AresCreditFacilityMember" />
    <link:label xlink:type="resource" xlink:label="adma_AresCreditFacilityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_AresCreditFacilityMember_lbl" xml:lang="en-US" id="adma_AresCreditFacilityMember_lbl">Arrangement in which facility proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AresCreditFacilityMember" xlink:to="adma_AresCreditFacilityMember_lbl" xlink:title="label: AresCreditFacilityMember to adma_AresCreditFacilityMember_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_AresCreditFacilityMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_AresCreditFacilityMember_lbl1" xml:lang="en-US" id="adma_AresCreditFacilityMember_lbl1">Ares Credit Facility [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AresCreditFacilityMember" xlink:to="adma_AresCreditFacilityMember_lbl1" xlink:title="label: AresCreditFacilityMember to adma_AresCreditFacilityMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_AresCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_AresCreditFacilityMember" xml:lang="en-US" id="adma_AresCreditFacilityMember">Ares Credit Facility [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AresCreditFacilityMember" xlink:to="adma_AresCreditFacilityMember" xlink:title="label: AresCreditFacilityMember to adma_AresCreditFacilityMember" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_NumberOfBusinessDays" xlink:label="NumberOfBusinessDays" xlink:title="NumberOfBusinessDays" />
    <link:label xlink:type="resource" xlink:label="adma_NumberOfBusinessDays_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_NumberOfBusinessDays_lbl" xml:lang="en-US" id="adma_NumberOfBusinessDays_lbl">Number of business days, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfBusinessDays" xlink:to="adma_NumberOfBusinessDays_lbl" xlink:title="label: NumberOfBusinessDays to adma_NumberOfBusinessDays_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_NumberOfBusinessDays_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_NumberOfBusinessDays_lbl1" xml:lang="en-US" id="adma_NumberOfBusinessDays_lbl1">Number of Business Days</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfBusinessDays" xlink:to="adma_NumberOfBusinessDays_lbl1" xlink:title="label: NumberOfBusinessDays to adma_NumberOfBusinessDays_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_NumberOfBusinessDays" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_NumberOfBusinessDays" xml:lang="en-US" id="adma_NumberOfBusinessDays">Number of business days</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfBusinessDays" xlink:to="adma_NumberOfBusinessDays" xlink:title="label: NumberOfBusinessDays to adma_NumberOfBusinessDays" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_TermLoanMember" xlink:label="TermLoanMember" xlink:title="TermLoanMember" />
    <link:label xlink:type="resource" xlink:label="adma_TermLoanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_TermLoanMember_lbl" xml:lang="en-US" id="adma_TermLoanMember_lbl">A contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time, and under which borrowings outstanding may be either short-term or long-term, depending upon the particulars.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TermLoanMember" xlink:to="adma_TermLoanMember_lbl" xlink:title="label: TermLoanMember to adma_TermLoanMember_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_TermLoanMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_TermLoanMember_lbl1" xml:lang="en-US" id="adma_TermLoanMember_lbl1">Term Loan [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TermLoanMember" xlink:to="adma_TermLoanMember_lbl1" xlink:title="label: TermLoanMember to adma_TermLoanMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_TermLoanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_TermLoanMember" xml:lang="en-US" id="adma_TermLoanMember">Term Loan [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TermLoanMember" xlink:to="adma_TermLoanMember" xlink:title="label: TermLoanMember to adma_TermLoanMember" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_DilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmountShares" xlink:label="DilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmountShares" xlink:title="DilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmountShares" />
    <link:label xlink:type="resource" xlink:label="adma_DilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmountShares_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_DilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmountShares_lbl" xml:lang="en-US" id="adma_DilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmountShares_lbl">Number of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would have been antidilutive for the period presented.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmountShares" xlink:to="adma_DilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmountShares_lbl" xlink:title="label: DilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmountShares to adma_DilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmountShares_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_DilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmountShares_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_DilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmountShares_lbl1" xml:lang="en-US" id="adma_DilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmountShares_lbl1">Potentially dilutive securities not included in computation of diluted net loss per share (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmountShares" xlink:to="adma_DilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmountShares_lbl1" xlink:title="label: DilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmountShares to adma_DilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmountShares_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_DilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmountShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_DilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmountShares" xml:lang="en-US" id="adma_DilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmountShares">Potentially dilutive securities not included in computation of diluted loss per share amount (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmountShares" xlink:to="adma_DilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmountShares" xlink:title="label: DilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmountShares to adma_DilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmountShares" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_TaxesPaidOnVestedRestrictedStockUnits" xlink:label="TaxesPaidOnVestedRestrictedStockUnits" xlink:title="TaxesPaidOnVestedRestrictedStockUnits" />
    <link:label xlink:type="resource" xlink:label="adma_TaxesPaidOnVestedRestrictedStockUnits_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_TaxesPaidOnVestedRestrictedStockUnits_lbl" xml:lang="en-US" id="adma_TaxesPaidOnVestedRestrictedStockUnits_lbl">Amount of cash outflow related to taxes on vested Restricted Stock Units.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TaxesPaidOnVestedRestrictedStockUnits" xlink:to="adma_TaxesPaidOnVestedRestrictedStockUnits_lbl" xlink:title="label: TaxesPaidOnVestedRestrictedStockUnits to adma_TaxesPaidOnVestedRestrictedStockUnits_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_TaxesPaidOnVestedRestrictedStockUnits_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_TaxesPaidOnVestedRestrictedStockUnits_lbl1" xml:lang="en-US" id="adma_TaxesPaidOnVestedRestrictedStockUnits_lbl1">Taxes Paid on Vested Restricted Stock Units</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TaxesPaidOnVestedRestrictedStockUnits" xlink:to="adma_TaxesPaidOnVestedRestrictedStockUnits_lbl1" xlink:title="label: TaxesPaidOnVestedRestrictedStockUnits to adma_TaxesPaidOnVestedRestrictedStockUnits_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_TaxesPaidOnVestedRestrictedStockUnits" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="adma_TaxesPaidOnVestedRestrictedStockUnits" xml:lang="en-US" id="adma_TaxesPaidOnVestedRestrictedStockUnits">Taxes paid on vested Restricted Stock Units</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TaxesPaidOnVestedRestrictedStockUnits" xlink:to="adma_TaxesPaidOnVestedRestrictedStockUnits" xlink:title="label: TaxesPaidOnVestedRestrictedStockUnits to adma_TaxesPaidOnVestedRestrictedStockUnits" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_PaymentOfDebtRefinancingFees" xlink:label="PaymentOfDebtRefinancingFees" xlink:title="PaymentOfDebtRefinancingFees" />
    <link:label xlink:type="resource" xlink:label="adma_PaymentOfDebtRefinancingFees_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_PaymentOfDebtRefinancingFees_lbl" xml:lang="en-US" id="adma_PaymentOfDebtRefinancingFees_lbl">The cash outflow for payment of debt refinancing fees.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PaymentOfDebtRefinancingFees" xlink:to="adma_PaymentOfDebtRefinancingFees_lbl" xlink:title="label: PaymentOfDebtRefinancingFees to adma_PaymentOfDebtRefinancingFees_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_PaymentOfDebtRefinancingFees_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_PaymentOfDebtRefinancingFees_lbl1" xml:lang="en-US" id="adma_PaymentOfDebtRefinancingFees_lbl1">Payment of debt refinancing fees</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PaymentOfDebtRefinancingFees" xlink:to="adma_PaymentOfDebtRefinancingFees_lbl1" xlink:title="label: PaymentOfDebtRefinancingFees to adma_PaymentOfDebtRefinancingFees_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_PaymentOfDebtRefinancingFees" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="adma_PaymentOfDebtRefinancingFees" xml:lang="en-US" id="adma_PaymentOfDebtRefinancingFees">Prepayment penalties on repayment of debt</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PaymentOfDebtRefinancingFees" xlink:to="adma_PaymentOfDebtRefinancingFees" xlink:title="label: PaymentOfDebtRefinancingFees to adma_PaymentOfDebtRefinancingFees" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_PaymentOfEndOfTermFee" xlink:label="PaymentOfEndOfTermFee" xlink:title="PaymentOfEndOfTermFee" />
    <link:label xlink:type="resource" xlink:label="adma_PaymentOfEndOfTermFee_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_PaymentOfEndOfTermFee_lbl" xml:lang="en-US" id="adma_PaymentOfEndOfTermFee_lbl">Amount of cash outflow for end of term fee.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PaymentOfEndOfTermFee" xlink:to="adma_PaymentOfEndOfTermFee_lbl" xlink:title="label: PaymentOfEndOfTermFee to adma_PaymentOfEndOfTermFee_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_PaymentOfEndOfTermFee_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_PaymentOfEndOfTermFee_lbl1" xml:lang="en-US" id="adma_PaymentOfEndOfTermFee_lbl1">Payment of End of Term Fee</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PaymentOfEndOfTermFee" xlink:to="adma_PaymentOfEndOfTermFee_lbl1" xlink:title="label: PaymentOfEndOfTermFee to adma_PaymentOfEndOfTermFee_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_PaymentOfEndOfTermFee" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="adma_PaymentOfEndOfTermFee" xml:lang="en-US" id="adma_PaymentOfEndOfTermFee">Payment of end of term fee</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PaymentOfEndOfTermFee" xlink:to="adma_PaymentOfEndOfTermFee" xlink:title="label: PaymentOfEndOfTermFee to adma_PaymentOfEndOfTermFee" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_IncreaseDecreaseInDepositsAndOtherAssets" xlink:label="IncreaseDecreaseInDepositsAndOtherAssets" xlink:title="IncreaseDecreaseInDepositsAndOtherAssets" />
    <link:label xlink:type="resource" xlink:label="adma_IncreaseDecreaseInDepositsAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_IncreaseDecreaseInDepositsAndOtherAssets_lbl" xml:lang="en-US" id="adma_IncreaseDecreaseInDepositsAndOtherAssets_lbl">Amount of increase (decrease) in deposits and operating assets classified as other.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInDepositsAndOtherAssets" xlink:to="adma_IncreaseDecreaseInDepositsAndOtherAssets_lbl" xlink:title="label: IncreaseDecreaseInDepositsAndOtherAssets to adma_IncreaseDecreaseInDepositsAndOtherAssets_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_IncreaseDecreaseInDepositsAndOtherAssets_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_IncreaseDecreaseInDepositsAndOtherAssets_lbl1" xml:lang="en-US" id="adma_IncreaseDecreaseInDepositsAndOtherAssets_lbl1">Increase (Decrease) in Deposits and Other Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInDepositsAndOtherAssets" xlink:to="adma_IncreaseDecreaseInDepositsAndOtherAssets_lbl1" xlink:title="label: IncreaseDecreaseInDepositsAndOtherAssets to adma_IncreaseDecreaseInDepositsAndOtherAssets_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_IncreaseDecreaseInDepositsAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="adma_IncreaseDecreaseInDepositsAndOtherAssets" xml:lang="en-US" id="adma_IncreaseDecreaseInDepositsAndOtherAssets">Deposits and other assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IncreaseDecreaseInDepositsAndOtherAssets" xlink:to="adma_IncreaseDecreaseInDepositsAndOtherAssets" xlink:title="label: IncreaseDecreaseInDepositsAndOtherAssets to adma_IncreaseDecreaseInDepositsAndOtherAssets" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_AmortizationOfLicenseRevenue" xlink:label="AmortizationOfLicenseRevenue" xlink:title="AmortizationOfLicenseRevenue" />
    <link:label xlink:type="resource" xlink:label="adma_AmortizationOfLicenseRevenue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_AmortizationOfLicenseRevenue_lbl" xml:lang="en-US" id="adma_AmortizationOfLicenseRevenue_lbl">Amount of noncash revenue related to amortization of license revenue.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AmortizationOfLicenseRevenue" xlink:to="adma_AmortizationOfLicenseRevenue_lbl" xlink:title="label: AmortizationOfLicenseRevenue to adma_AmortizationOfLicenseRevenue_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_AmortizationOfLicenseRevenue_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_AmortizationOfLicenseRevenue_lbl1" xml:lang="en-US" id="adma_AmortizationOfLicenseRevenue_lbl1">Amortization of License Revenue</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AmortizationOfLicenseRevenue" xlink:to="adma_AmortizationOfLicenseRevenue_lbl1" xlink:title="label: AmortizationOfLicenseRevenue to adma_AmortizationOfLicenseRevenue_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_AmortizationOfLicenseRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_AmortizationOfLicenseRevenue" xml:lang="en-US" id="adma_AmortizationOfLicenseRevenue">Amortization of license revenue</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AmortizationOfLicenseRevenue" xlink:to="adma_AmortizationOfLicenseRevenue" xlink:title="label: AmortizationOfLicenseRevenue to adma_AmortizationOfLicenseRevenue" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_OtherOperatingExpensesPolicyTextBlock" xlink:label="OtherOperatingExpensesPolicyTextBlock" xlink:title="OtherOperatingExpensesPolicyTextBlock" />
    <link:label xlink:type="resource" xlink:label="adma_OtherOperatingExpensesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_OtherOperatingExpensesPolicyTextBlock_lbl" xml:lang="en-US" id="adma_OtherOperatingExpensesPolicyTextBlock_lbl">Disclosure of accounting policy for other operating expenses related to plasma center.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherOperatingExpensesPolicyTextBlock" xlink:to="adma_OtherOperatingExpensesPolicyTextBlock_lbl" xlink:title="label: OtherOperatingExpensesPolicyTextBlock to adma_OtherOperatingExpensesPolicyTextBlock_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_OtherOperatingExpensesPolicyTextBlock_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_OtherOperatingExpensesPolicyTextBlock_lbl1" xml:lang="en-US" id="adma_OtherOperatingExpensesPolicyTextBlock_lbl1">Other Operating Expenses [Policy Text Block]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherOperatingExpensesPolicyTextBlock" xlink:to="adma_OtherOperatingExpensesPolicyTextBlock_lbl1" xlink:title="label: OtherOperatingExpensesPolicyTextBlock to adma_OtherOperatingExpensesPolicyTextBlock_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_OtherOperatingExpensesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_OtherOperatingExpensesPolicyTextBlock" xml:lang="en-US" id="adma_OtherOperatingExpensesPolicyTextBlock">Plasma Center Operating Expenses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OtherOperatingExpensesPolicyTextBlock" xlink:to="adma_OtherOperatingExpensesPolicyTextBlock" xlink:title="label: OtherOperatingExpensesPolicyTextBlock to adma_OtherOperatingExpensesPolicyTextBlock" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_EquipmentAcquiredReflectedInAccountsPayableAndAccruedLiabilities" xlink:label="EquipmentAcquiredReflectedInAccountsPayableAndAccruedLiabilities" xlink:title="EquipmentAcquiredReflectedInAccountsPayableAndAccruedLiabilities" />
    <link:label xlink:type="resource" xlink:label="adma_EquipmentAcquiredReflectedInAccountsPayableAndAccruedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_EquipmentAcquiredReflectedInAccountsPayableAndAccruedLiabilities_lbl" xml:lang="en-US" id="adma_EquipmentAcquiredReflectedInAccountsPayableAndAccruedLiabilities_lbl">Amount of equipment acquired in a noncash (or part noncash) acquisition and reflected in accounts payable and accrued liabilities.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EquipmentAcquiredReflectedInAccountsPayableAndAccruedLiabilities" xlink:to="adma_EquipmentAcquiredReflectedInAccountsPayableAndAccruedLiabilities_lbl" xlink:title="label: EquipmentAcquiredReflectedInAccountsPayableAndAccruedLiabilities to adma_EquipmentAcquiredReflectedInAccountsPayableAndAccruedLiabilities_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_EquipmentAcquiredReflectedInAccountsPayableAndAccruedLiabilities_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_EquipmentAcquiredReflectedInAccountsPayableAndAccruedLiabilities_lbl1" xml:lang="en-US" id="adma_EquipmentAcquiredReflectedInAccountsPayableAndAccruedLiabilities_lbl1">Equipment Acquired Reflected in Accounts Payable and Accrued Liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EquipmentAcquiredReflectedInAccountsPayableAndAccruedLiabilities" xlink:to="adma_EquipmentAcquiredReflectedInAccountsPayableAndAccruedLiabilities_lbl1" xlink:title="label: EquipmentAcquiredReflectedInAccountsPayableAndAccruedLiabilities to adma_EquipmentAcquiredReflectedInAccountsPayableAndAccruedLiabilities_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_EquipmentAcquiredReflectedInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_EquipmentAcquiredReflectedInAccountsPayableAndAccruedLiabilities" xml:lang="en-US" id="adma_EquipmentAcquiredReflectedInAccountsPayableAndAccruedLiabilities">Equipment acquired reflected in accounts payable and accrued liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EquipmentAcquiredReflectedInAccountsPayableAndAccruedLiabilities" xlink:to="adma_EquipmentAcquiredReflectedInAccountsPayableAndAccruedLiabilities" xlink:title="label: EquipmentAcquiredReflectedInAccountsPayableAndAccruedLiabilities to adma_EquipmentAcquiredReflectedInAccountsPayableAndAccruedLiabilities" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_WarrantsIssuedInConnectionWithNotesPayable" xlink:label="WarrantsIssuedInConnectionWithNotesPayable" xlink:title="WarrantsIssuedInConnectionWithNotesPayable" />
    <link:label xlink:type="resource" xlink:label="adma_WarrantsIssuedInConnectionWithNotesPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_WarrantsIssuedInConnectionWithNotesPayable_lbl" xml:lang="en-US" id="adma_WarrantsIssuedInConnectionWithNotesPayable_lbl">Amount of warrants issued in connection with the issuance of notes payable.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WarrantsIssuedInConnectionWithNotesPayable" xlink:to="adma_WarrantsIssuedInConnectionWithNotesPayable_lbl" xlink:title="label: WarrantsIssuedInConnectionWithNotesPayable to adma_WarrantsIssuedInConnectionWithNotesPayable_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_WarrantsIssuedInConnectionWithNotesPayable_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_WarrantsIssuedInConnectionWithNotesPayable_lbl1" xml:lang="en-US" id="adma_WarrantsIssuedInConnectionWithNotesPayable_lbl1">Warrants Issued in Connection with Notes Payable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WarrantsIssuedInConnectionWithNotesPayable" xlink:to="adma_WarrantsIssuedInConnectionWithNotesPayable_lbl1" xlink:title="label: WarrantsIssuedInConnectionWithNotesPayable to adma_WarrantsIssuedInConnectionWithNotesPayable_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_WarrantsIssuedInConnectionWithNotesPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_WarrantsIssuedInConnectionWithNotesPayable" xml:lang="en-US" id="adma_WarrantsIssuedInConnectionWithNotesPayable">Warrants issued in connection with notes payable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WarrantsIssuedInConnectionWithNotesPayable" xlink:to="adma_WarrantsIssuedInConnectionWithNotesPayable" xlink:title="label: WarrantsIssuedInConnectionWithNotesPayable to adma_WarrantsIssuedInConnectionWithNotesPayable" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_UseOfEstimatesAbstract" xlink:label="UseOfEstimatesAbstract" xlink:title="UseOfEstimatesAbstract" />
    <link:label xlink:type="resource" xlink:label="adma_UseOfEstimatesAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_UseOfEstimatesAbstract_lbl1" xml:lang="en-US" id="adma_UseOfEstimatesAbstract_lbl1">Use of Estimates [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="UseOfEstimatesAbstract" xlink:to="adma_UseOfEstimatesAbstract_lbl1" xlink:title="label: UseOfEstimatesAbstract to adma_UseOfEstimatesAbstract_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_UseOfEstimatesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_UseOfEstimatesAbstract" xml:lang="en-US" id="adma_UseOfEstimatesAbstract">Use of Estimates [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="UseOfEstimatesAbstract" xlink:to="adma_UseOfEstimatesAbstract" xlink:title="label: UseOfEstimatesAbstract to adma_UseOfEstimatesAbstract" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_AccrualForUSMedicaidRebatesMember" xlink:label="AccrualForUSMedicaidRebatesMember" xlink:title="AccrualForUSMedicaidRebatesMember" />
    <link:label xlink:type="resource" xlink:label="adma_AccrualForUSMedicaidRebatesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_AccrualForUSMedicaidRebatesMember_lbl" xml:lang="en-US" id="adma_AccrualForUSMedicaidRebatesMember_lbl">Accrual for U.S. Medicaid Rebates.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccrualForUSMedicaidRebatesMember" xlink:to="adma_AccrualForUSMedicaidRebatesMember_lbl" xlink:title="label: AccrualForUSMedicaidRebatesMember to adma_AccrualForUSMedicaidRebatesMember_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_AccrualForUSMedicaidRebatesMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_AccrualForUSMedicaidRebatesMember_lbl1" xml:lang="en-US" id="adma_AccrualForUSMedicaidRebatesMember_lbl1">Accrual for U.S. Medicaid Rebates [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccrualForUSMedicaidRebatesMember" xlink:to="adma_AccrualForUSMedicaidRebatesMember_lbl1" xlink:title="label: AccrualForUSMedicaidRebatesMember to adma_AccrualForUSMedicaidRebatesMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_AccrualForUSMedicaidRebatesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_AccrualForUSMedicaidRebatesMember" xml:lang="en-US" id="adma_AccrualForUSMedicaidRebatesMember">Accrual for U.S. Medicaid Rebates [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccrualForUSMedicaidRebatesMember" xlink:to="adma_AccrualForUSMedicaidRebatesMember" xlink:title="label: AccrualForUSMedicaidRebatesMember to adma_AccrualForUSMedicaidRebatesMember" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_NumberOfExecutiveOfficers" xlink:label="NumberOfExecutiveOfficers" xlink:title="NumberOfExecutiveOfficers" />
    <link:label xlink:type="resource" xlink:label="adma_NumberOfExecutiveOfficers_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_NumberOfExecutiveOfficers_lbl" xml:lang="en-US" id="adma_NumberOfExecutiveOfficers_lbl">The milestone-based equity awards which were awarded to number of executive officers.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfExecutiveOfficers" xlink:to="adma_NumberOfExecutiveOfficers_lbl" xlink:title="label: NumberOfExecutiveOfficers to adma_NumberOfExecutiveOfficers_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_NumberOfExecutiveOfficers_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_NumberOfExecutiveOfficers_lbl1" xml:lang="en-US" id="adma_NumberOfExecutiveOfficers_lbl1">Number of Executive Officers</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfExecutiveOfficers" xlink:to="adma_NumberOfExecutiveOfficers_lbl1" xlink:title="label: NumberOfExecutiveOfficers to adma_NumberOfExecutiveOfficers_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_NumberOfExecutiveOfficers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_NumberOfExecutiveOfficers" xml:lang="en-US" id="adma_NumberOfExecutiveOfficers">Number of executive officers</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfExecutiveOfficers" xlink:to="adma_NumberOfExecutiveOfficers" xlink:title="label: NumberOfExecutiveOfficers to adma_NumberOfExecutiveOfficers" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_PlasmaCollectionCentersSegmentMember" xlink:label="PlasmaCollectionCentersSegmentMember" xlink:title="PlasmaCollectionCentersSegmentMember" />
    <link:label xlink:type="resource" xlink:label="adma_PlasmaCollectionCentersSegmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_PlasmaCollectionCentersSegmentMember_lbl" xml:lang="en-US" id="adma_PlasmaCollectionCentersSegmentMember_lbl">Component of Plasma Collection Centers segment that usually provides financial, operational and administrative support and is considered an operating segment.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PlasmaCollectionCentersSegmentMember" xlink:to="adma_PlasmaCollectionCentersSegmentMember_lbl" xlink:title="label: PlasmaCollectionCentersSegmentMember to adma_PlasmaCollectionCentersSegmentMember_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_PlasmaCollectionCentersSegmentMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_PlasmaCollectionCentersSegmentMember_lbl1" xml:lang="en-US" id="adma_PlasmaCollectionCentersSegmentMember_lbl1">Plasma Collection Centers Segment [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PlasmaCollectionCentersSegmentMember" xlink:to="adma_PlasmaCollectionCentersSegmentMember_lbl1" xlink:title="label: PlasmaCollectionCentersSegmentMember to adma_PlasmaCollectionCentersSegmentMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_PlasmaCollectionCentersSegmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_PlasmaCollectionCentersSegmentMember" xml:lang="en-US" id="adma_PlasmaCollectionCentersSegmentMember">Plasma Collection Centers [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PlasmaCollectionCentersSegmentMember" xlink:to="adma_PlasmaCollectionCentersSegmentMember" xlink:title="label: PlasmaCollectionCentersSegmentMember to adma_PlasmaCollectionCentersSegmentMember" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_NumberOfCustomers" xlink:label="NumberOfCustomers" xlink:title="NumberOfCustomers" />
    <link:label xlink:type="resource" xlink:label="adma_NumberOfCustomers_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_NumberOfCustomers_lbl" xml:lang="en-US" id="adma_NumberOfCustomers_lbl">Number of major customers of the organization.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfCustomers" xlink:to="adma_NumberOfCustomers_lbl" xlink:title="label: NumberOfCustomers to adma_NumberOfCustomers_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_NumberOfCustomers_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_NumberOfCustomers_lbl1" xml:lang="en-US" id="adma_NumberOfCustomers_lbl1">Number of Customers</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfCustomers" xlink:to="adma_NumberOfCustomers_lbl1" xlink:title="label: NumberOfCustomers to adma_NumberOfCustomers_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_NumberOfCustomers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_NumberOfCustomers" xml:lang="en-US" id="adma_NumberOfCustomers">Number of customers</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfCustomers" xlink:to="adma_NumberOfCustomers" xlink:title="label: NumberOfCustomers to adma_NumberOfCustomers" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_ThreeCustomersMember" xlink:label="ThreeCustomersMember" xlink:title="ThreeCustomersMember" />
    <link:label xlink:type="resource" xlink:label="adma_ThreeCustomersMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_ThreeCustomersMember_lbl" xml:lang="en-US" id="adma_ThreeCustomersMember_lbl">Information about number of customers accounting for a percentage of consolidated revenues.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ThreeCustomersMember" xlink:to="adma_ThreeCustomersMember_lbl" xlink:title="label: ThreeCustomersMember to adma_ThreeCustomersMember_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_ThreeCustomersMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_ThreeCustomersMember_lbl1" xml:lang="en-US" id="adma_ThreeCustomersMember_lbl1">Three Customers [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ThreeCustomersMember" xlink:to="adma_ThreeCustomersMember_lbl1" xlink:title="label: ThreeCustomersMember to adma_ThreeCustomersMember_lbl1" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_TwoCustomersMember" xlink:label="TwoCustomersMember" xlink:title="TwoCustomersMember" />
    <link:label xlink:type="resource" xlink:label="adma_TwoCustomersMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_TwoCustomersMember_lbl" xml:lang="en-US" id="adma_TwoCustomersMember_lbl">Information about number of customers accounting for a percentage of consolidated revenues.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TwoCustomersMember" xlink:to="adma_TwoCustomersMember_lbl" xlink:title="label: TwoCustomersMember to adma_TwoCustomersMember_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_TwoCustomersMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_TwoCustomersMember_lbl1" xml:lang="en-US" id="adma_TwoCustomersMember_lbl1">Two Customers [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="TwoCustomersMember" xlink:to="adma_TwoCustomersMember_lbl1" xlink:title="label: TwoCustomersMember to adma_TwoCustomersMember_lbl1" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_FiveCustomersMember" xlink:label="FiveCustomersMember" xlink:title="FiveCustomersMember" />
    <link:label xlink:type="resource" xlink:label="adma_FiveCustomersMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_FiveCustomersMember_lbl" xml:lang="en-US" id="adma_FiveCustomersMember_lbl">Information about number of customers accounting for a percentage of consolidated revenues.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FiveCustomersMember" xlink:to="adma_FiveCustomersMember_lbl" xlink:title="label: FiveCustomersMember to adma_FiveCustomersMember_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_FiveCustomersMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_FiveCustomersMember_lbl1" xml:lang="en-US" id="adma_FiveCustomersMember_lbl1">Five Customers [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FiveCustomersMember" xlink:to="adma_FiveCustomersMember_lbl1" xlink:title="label: FiveCustomersMember to adma_FiveCustomersMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_FiveCustomersMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_FiveCustomersMember" xml:lang="en-US" id="adma_FiveCustomersMember">Five Customers [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="FiveCustomersMember" xlink:to="adma_FiveCustomersMember" xlink:title="label: FiveCustomersMember to adma_FiveCustomersMember" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesShares" xlink:label="VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesShares" xlink:title="VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesShares" />
    <link:label xlink:type="resource" xlink:label="adma_VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesShares_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesShares_lbl" xml:lang="en-US" id="adma_VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesShares_lbl">Number of shares issued during the period related to restricted stock awards, net of shares withheld to cover grantees' income tax liability.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesShares" xlink:to="adma_VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesShares_lbl" xlink:title="label: VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesShares to adma_VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesShares_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesShares_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesShares_lbl1" xml:lang="en-US" id="adma_VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesShares_lbl1">Vesting of Restricted Stock Units Net of Shares Withheld for Taxes, Shares</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesShares" xlink:to="adma_VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesShares_lbl1" xlink:title="label: VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesShares to adma_VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesShares_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesShares" xml:lang="en-US" id="adma_VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesShares">Vesting of Restricted Stock Units, net of shares withheld for taxes (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesShares" xlink:to="adma_VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesShares" xlink:title="label: VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesShares to adma_VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesShares" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_StockIssuedDuringPeriodSharesCashlessExerciseOfWarrants" xlink:label="StockIssuedDuringPeriodSharesCashlessExerciseOfWarrants" xlink:title="StockIssuedDuringPeriodSharesCashlessExerciseOfWarrants" />
    <link:label xlink:type="resource" xlink:label="adma_StockIssuedDuringPeriodSharesCashlessExerciseOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_StockIssuedDuringPeriodSharesCashlessExerciseOfWarrants_lbl" xml:lang="en-US" id="adma_StockIssuedDuringPeriodSharesCashlessExerciseOfWarrants_lbl">Number of shares issued during the period as a result of the cashless exercise of warrants.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesCashlessExerciseOfWarrants" xlink:to="adma_StockIssuedDuringPeriodSharesCashlessExerciseOfWarrants_lbl" xlink:title="label: StockIssuedDuringPeriodSharesCashlessExerciseOfWarrants to adma_StockIssuedDuringPeriodSharesCashlessExerciseOfWarrants_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_StockIssuedDuringPeriodSharesCashlessExerciseOfWarrants_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_StockIssuedDuringPeriodSharesCashlessExerciseOfWarrants_lbl1" xml:lang="en-US" id="adma_StockIssuedDuringPeriodSharesCashlessExerciseOfWarrants_lbl1">Stock Issued During Period Shares Cashless Exercise Of Warrants</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesCashlessExerciseOfWarrants" xlink:to="adma_StockIssuedDuringPeriodSharesCashlessExerciseOfWarrants_lbl1" xlink:title="label: StockIssuedDuringPeriodSharesCashlessExerciseOfWarrants to adma_StockIssuedDuringPeriodSharesCashlessExerciseOfWarrants_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_StockIssuedDuringPeriodSharesCashlessExerciseOfWarrants" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_StockIssuedDuringPeriodSharesCashlessExerciseOfWarrants" xml:lang="en-US" id="adma_StockIssuedDuringPeriodSharesCashlessExerciseOfWarrants">Cashless exercise of warrants (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodSharesCashlessExerciseOfWarrants" xlink:to="adma_StockIssuedDuringPeriodSharesCashlessExerciseOfWarrants" xlink:title="label: StockIssuedDuringPeriodSharesCashlessExerciseOfWarrants to adma_StockIssuedDuringPeriodSharesCashlessExerciseOfWarrants" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAmount" xlink:label="VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAmount" xlink:title="VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAmount" />
    <link:label xlink:type="resource" xlink:label="adma_VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAmount_lbl" xml:lang="en-US" id="adma_VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAmount_lbl">Value of stock related to restricted stock awards issued during the period, net of shares withheld to cover grantees' income tax liability.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAmount" xlink:to="adma_VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAmount_lbl" xlink:title="label: VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAmount to adma_VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAmount_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAmount_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAmount_lbl1" xml:lang="en-US" id="adma_VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAmount_lbl1">Vesting of Restricted Stock Units Net of Shares Withheld for Taxes, Amount</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAmount" xlink:to="adma_VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAmount_lbl1" xlink:title="label: VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAmount to adma_VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAmount_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAmount" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="adma_VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAmount" xml:lang="en-US" id="adma_VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAmount">Vesting of Restricted Stock Units, net of shares withheld for taxes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAmount" xlink:to="adma_VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAmount" xlink:title="label: VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAmount to adma_VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAmount" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_StockIssuedDuringPeriodValueCashlessExerciseOfWarrants" xlink:label="StockIssuedDuringPeriodValueCashlessExerciseOfWarrants" xlink:title="StockIssuedDuringPeriodValueCashlessExerciseOfWarrants" />
    <link:label xlink:type="resource" xlink:label="adma_StockIssuedDuringPeriodValueCashlessExerciseOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_StockIssuedDuringPeriodValueCashlessExerciseOfWarrants_lbl" xml:lang="en-US" id="adma_StockIssuedDuringPeriodValueCashlessExerciseOfWarrants_lbl">Aggregate change in value for stock issued during the period as a result of the cashless exercise of warrants.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodValueCashlessExerciseOfWarrants" xlink:to="adma_StockIssuedDuringPeriodValueCashlessExerciseOfWarrants_lbl" xlink:title="label: StockIssuedDuringPeriodValueCashlessExerciseOfWarrants to adma_StockIssuedDuringPeriodValueCashlessExerciseOfWarrants_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_StockIssuedDuringPeriodValueCashlessExerciseOfWarrants_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_StockIssuedDuringPeriodValueCashlessExerciseOfWarrants_lbl1" xml:lang="en-US" id="adma_StockIssuedDuringPeriodValueCashlessExerciseOfWarrants_lbl1">Stock Issued During Period Value Cashless Exercise Of Warrants</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodValueCashlessExerciseOfWarrants" xlink:to="adma_StockIssuedDuringPeriodValueCashlessExerciseOfWarrants_lbl1" xlink:title="label: StockIssuedDuringPeriodValueCashlessExerciseOfWarrants to adma_StockIssuedDuringPeriodValueCashlessExerciseOfWarrants_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_StockIssuedDuringPeriodValueCashlessExerciseOfWarrants" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_StockIssuedDuringPeriodValueCashlessExerciseOfWarrants" xml:lang="en-US" id="adma_StockIssuedDuringPeriodValueCashlessExerciseOfWarrants">Cashless exercise of warrants</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockIssuedDuringPeriodValueCashlessExerciseOfWarrants" xlink:to="adma_StockIssuedDuringPeriodValueCashlessExerciseOfWarrants" xlink:title="label: StockIssuedDuringPeriodValueCashlessExerciseOfWarrants to adma_StockIssuedDuringPeriodValueCashlessExerciseOfWarrants" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_DepositsAndOtherNoncurrentAssets" xlink:label="DepositsAndOtherNoncurrentAssets" xlink:title="DepositsAndOtherNoncurrentAssets" />
    <link:label xlink:type="resource" xlink:label="adma_DepositsAndOtherNoncurrentAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_DepositsAndOtherNoncurrentAssets_lbl" xml:lang="en-US" id="adma_DepositsAndOtherNoncurrentAssets_lbl">Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment after one year or beyond the operating cycle, if longer and amount of noncurrent assets classified as other.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DepositsAndOtherNoncurrentAssets" xlink:to="adma_DepositsAndOtherNoncurrentAssets_lbl" xlink:title="label: DepositsAndOtherNoncurrentAssets to adma_DepositsAndOtherNoncurrentAssets_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_DepositsAndOtherNoncurrentAssets_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_DepositsAndOtherNoncurrentAssets_lbl1" xml:lang="en-US" id="adma_DepositsAndOtherNoncurrentAssets_lbl1">Deposits and Other Noncurrent Assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DepositsAndOtherNoncurrentAssets" xlink:to="adma_DepositsAndOtherNoncurrentAssets_lbl1" xlink:title="label: DepositsAndOtherNoncurrentAssets to adma_DepositsAndOtherNoncurrentAssets_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_DepositsAndOtherNoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_DepositsAndOtherNoncurrentAssets" xml:lang="en-US" id="adma_DepositsAndOtherNoncurrentAssets">Deposits and other assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DepositsAndOtherNoncurrentAssets" xlink:to="adma_DepositsAndOtherNoncurrentAssets" xlink:title="label: DepositsAndOtherNoncurrentAssets to adma_DepositsAndOtherNoncurrentAssets" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_LongTermLiabilityEndOfTermFeePayable" xlink:label="LongTermLiabilityEndOfTermFeePayable" xlink:title="LongTermLiabilityEndOfTermFeePayable" />
    <link:label xlink:type="resource" xlink:label="adma_LongTermLiabilityEndOfTermFeePayable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_LongTermLiabilityEndOfTermFeePayable_lbl" xml:lang="en-US" id="adma_LongTermLiabilityEndOfTermFeePayable_lbl">Principal balance of the loans and any other obligations advanced or otherwise owed.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LongTermLiabilityEndOfTermFeePayable" xlink:to="adma_LongTermLiabilityEndOfTermFeePayable_lbl" xlink:title="label: LongTermLiabilityEndOfTermFeePayable to adma_LongTermLiabilityEndOfTermFeePayable_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_LongTermLiabilityEndOfTermFeePayable_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_LongTermLiabilityEndOfTermFeePayable_lbl1" xml:lang="en-US" id="adma_LongTermLiabilityEndOfTermFeePayable_lbl1">Long Term Liability, End of Term Fee Payable</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LongTermLiabilityEndOfTermFeePayable" xlink:to="adma_LongTermLiabilityEndOfTermFeePayable_lbl1" xlink:title="label: LongTermLiabilityEndOfTermFeePayable to adma_LongTermLiabilityEndOfTermFeePayable_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_LongTermLiabilityEndOfTermFeePayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_LongTermLiabilityEndOfTermFeePayable" xml:lang="en-US" id="adma_LongTermLiabilityEndOfTermFeePayable">End of term fee</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LongTermLiabilityEndOfTermFeePayable" xlink:to="adma_LongTermLiabilityEndOfTermFeePayable" xlink:title="label: LongTermLiabilityEndOfTermFeePayable to adma_LongTermLiabilityEndOfTermFeePayable" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_OperatingAndFinancingLeaseLiability" xlink:label="OperatingAndFinancingLeaseLiability" xlink:title="OperatingAndFinancingLeaseLiability" />
    <link:label xlink:type="resource" xlink:label="adma_OperatingAndFinancingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_OperatingAndFinancingLeaseLiability_lbl" xml:lang="en-US" id="adma_OperatingAndFinancingLeaseLiability_lbl">Present value of lessee's discounted obligation for lease payments from operating and finance leases.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingAndFinancingLeaseLiability" xlink:to="adma_OperatingAndFinancingLeaseLiability_lbl" xlink:title="label: OperatingAndFinancingLeaseLiability to adma_OperatingAndFinancingLeaseLiability_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_OperatingAndFinancingLeaseLiability_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_OperatingAndFinancingLeaseLiability_lbl1" xml:lang="en-US" id="adma_OperatingAndFinancingLeaseLiability_lbl1">Operating and Financing Lease, Liability</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingAndFinancingLeaseLiability" xlink:to="adma_OperatingAndFinancingLeaseLiability_lbl1" xlink:title="label: OperatingAndFinancingLeaseLiability to adma_OperatingAndFinancingLeaseLiability_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_OperatingAndFinancingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_OperatingAndFinancingLeaseLiability" xml:lang="en-US" id="adma_OperatingAndFinancingLeaseLiability">Operating and financing lease liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingAndFinancingLeaseLiability" xlink:to="adma_OperatingAndFinancingLeaseLiability" xlink:title="label: OperatingAndFinancingLeaseLiability to adma_OperatingAndFinancingLeaseLiability" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_LesseeOperatingLeaseRightOfUseAssetRelatedToPropertyLease" xlink:label="LesseeOperatingLeaseRightOfUseAssetRelatedToPropertyLease" xlink:title="LesseeOperatingLeaseRightOfUseAssetRelatedToPropertyLease" />
    <link:label xlink:type="resource" xlink:label="adma_LesseeOperatingLeaseRightOfUseAssetRelatedToPropertyLease_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_LesseeOperatingLeaseRightOfUseAssetRelatedToPropertyLease_lbl" xml:lang="en-US" id="adma_LesseeOperatingLeaseRightOfUseAssetRelatedToPropertyLease_lbl">Right to use assets recognized in connection with property lease.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeOperatingLeaseRightOfUseAssetRelatedToPropertyLease" xlink:to="adma_LesseeOperatingLeaseRightOfUseAssetRelatedToPropertyLease_lbl" xlink:title="label: LesseeOperatingLeaseRightOfUseAssetRelatedToPropertyLease to adma_LesseeOperatingLeaseRightOfUseAssetRelatedToPropertyLease_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_LesseeOperatingLeaseRightOfUseAssetRelatedToPropertyLease_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_LesseeOperatingLeaseRightOfUseAssetRelatedToPropertyLease_lbl1" xml:lang="en-US" id="adma_LesseeOperatingLeaseRightOfUseAssetRelatedToPropertyLease_lbl1">Lessee, Operating Lease, Right-of-Use Asset Related to Property Lease</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeOperatingLeaseRightOfUseAssetRelatedToPropertyLease" xlink:to="adma_LesseeOperatingLeaseRightOfUseAssetRelatedToPropertyLease_lbl1" xlink:title="label: LesseeOperatingLeaseRightOfUseAssetRelatedToPropertyLease to adma_LesseeOperatingLeaseRightOfUseAssetRelatedToPropertyLease_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_LesseeOperatingLeaseRightOfUseAssetRelatedToPropertyLease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_LesseeOperatingLeaseRightOfUseAssetRelatedToPropertyLease" xml:lang="en-US" id="adma_LesseeOperatingLeaseRightOfUseAssetRelatedToPropertyLease">Right-of-use assets</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeOperatingLeaseRightOfUseAssetRelatedToPropertyLease" xlink:to="adma_LesseeOperatingLeaseRightOfUseAssetRelatedToPropertyLease" xlink:title="label: LesseeOperatingLeaseRightOfUseAssetRelatedToPropertyLease to adma_LesseeOperatingLeaseRightOfUseAssetRelatedToPropertyLease" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_LesseeOperatingLeaseLiabilitiesRelatedToPropertyLease" xlink:label="LesseeOperatingLeaseLiabilitiesRelatedToPropertyLease" xlink:title="LesseeOperatingLeaseLiabilitiesRelatedToPropertyLease" />
    <link:label xlink:type="resource" xlink:label="adma_LesseeOperatingLeaseLiabilitiesRelatedToPropertyLease_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_LesseeOperatingLeaseLiabilitiesRelatedToPropertyLease_lbl" xml:lang="en-US" id="adma_LesseeOperatingLeaseLiabilitiesRelatedToPropertyLease_lbl">Lease liability recognized in connection with property lease.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeOperatingLeaseLiabilitiesRelatedToPropertyLease" xlink:to="adma_LesseeOperatingLeaseLiabilitiesRelatedToPropertyLease_lbl" xlink:title="label: LesseeOperatingLeaseLiabilitiesRelatedToPropertyLease to adma_LesseeOperatingLeaseLiabilitiesRelatedToPropertyLease_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_LesseeOperatingLeaseLiabilitiesRelatedToPropertyLease_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_LesseeOperatingLeaseLiabilitiesRelatedToPropertyLease_lbl1" xml:lang="en-US" id="adma_LesseeOperatingLeaseLiabilitiesRelatedToPropertyLease_lbl1">Lessee Operating Lease Liabilities Related to Property Lease</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeOperatingLeaseLiabilitiesRelatedToPropertyLease" xlink:to="adma_LesseeOperatingLeaseLiabilitiesRelatedToPropertyLease_lbl1" xlink:title="label: LesseeOperatingLeaseLiabilitiesRelatedToPropertyLease to adma_LesseeOperatingLeaseLiabilitiesRelatedToPropertyLease_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_LesseeOperatingLeaseLiabilitiesRelatedToPropertyLease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_LesseeOperatingLeaseLiabilitiesRelatedToPropertyLease" xml:lang="en-US" id="adma_LesseeOperatingLeaseLiabilitiesRelatedToPropertyLease">Lease liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LesseeOperatingLeaseLiabilitiesRelatedToPropertyLease" xlink:to="adma_LesseeOperatingLeaseLiabilitiesRelatedToPropertyLease" xlink:title="label: LesseeOperatingLeaseLiabilitiesRelatedToPropertyLease to adma_LesseeOperatingLeaseLiabilitiesRelatedToPropertyLease" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_OperatingLeaseIncrementalBorrowingRatePercent" xlink:label="OperatingLeaseIncrementalBorrowingRatePercent" xlink:title="OperatingLeaseIncrementalBorrowingRatePercent" />
    <link:label xlink:type="resource" xlink:label="adma_OperatingLeaseIncrementalBorrowingRatePercent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_OperatingLeaseIncrementalBorrowingRatePercent_lbl" xml:lang="en-US" id="adma_OperatingLeaseIncrementalBorrowingRatePercent_lbl">Weighted average incremental borrowing rate for operating lease calculated at point in time.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLeaseIncrementalBorrowingRatePercent" xlink:to="adma_OperatingLeaseIncrementalBorrowingRatePercent_lbl" xlink:title="label: OperatingLeaseIncrementalBorrowingRatePercent to adma_OperatingLeaseIncrementalBorrowingRatePercent_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_OperatingLeaseIncrementalBorrowingRatePercent_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_OperatingLeaseIncrementalBorrowingRatePercent_lbl1" xml:lang="en-US" id="adma_OperatingLeaseIncrementalBorrowingRatePercent_lbl1">Operating Lease Incremental Borrowing Rate Percent</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLeaseIncrementalBorrowingRatePercent" xlink:to="adma_OperatingLeaseIncrementalBorrowingRatePercent_lbl1" xlink:title="label: OperatingLeaseIncrementalBorrowingRatePercent to adma_OperatingLeaseIncrementalBorrowingRatePercent_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_OperatingLeaseIncrementalBorrowingRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_OperatingLeaseIncrementalBorrowingRatePercent" xml:lang="en-US" id="adma_OperatingLeaseIncrementalBorrowingRatePercent">Incremental borrowing rate</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="OperatingLeaseIncrementalBorrowingRatePercent" xlink:to="adma_OperatingLeaseIncrementalBorrowingRatePercent" xlink:title="label: OperatingLeaseIncrementalBorrowingRatePercent to adma_OperatingLeaseIncrementalBorrowingRatePercent" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_NumberOfNewPropertyLeases" xlink:label="NumberOfNewPropertyLeases" xlink:title="NumberOfNewPropertyLeases" />
    <link:label xlink:type="resource" xlink:label="adma_NumberOfNewPropertyLeases_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_NumberOfNewPropertyLeases_lbl" xml:lang="en-US" id="adma_NumberOfNewPropertyLeases_lbl">Number of new property leases related to additional plasma collection facilities.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfNewPropertyLeases" xlink:to="adma_NumberOfNewPropertyLeases_lbl" xlink:title="label: NumberOfNewPropertyLeases to adma_NumberOfNewPropertyLeases_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_NumberOfNewPropertyLeases_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_NumberOfNewPropertyLeases_lbl1" xml:lang="en-US" id="adma_NumberOfNewPropertyLeases_lbl1">Number of New Property Leases</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfNewPropertyLeases" xlink:to="adma_NumberOfNewPropertyLeases_lbl1" xlink:title="label: NumberOfNewPropertyLeases to adma_NumberOfNewPropertyLeases_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_NumberOfNewPropertyLeases" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_NumberOfNewPropertyLeases" xml:lang="en-US" id="adma_NumberOfNewPropertyLeases">Number of new property leases</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfNewPropertyLeases" xlink:to="adma_NumberOfNewPropertyLeases" xlink:title="label: NumberOfNewPropertyLeases to adma_NumberOfNewPropertyLeases" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_Two022CompensationPlanMember" xlink:label="Two022CompensationPlanMember" xlink:title="Two022CompensationPlanMember" />
    <link:label xlink:type="resource" xlink:label="adma_Two022CompensationPlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_Two022CompensationPlanMember_lbl" xml:lang="en-US" id="adma_Two022CompensationPlanMember_lbl">Represents 2022 compensation plan of equity based compensation arrangement plan.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Two022CompensationPlanMember" xlink:to="adma_Two022CompensationPlanMember_lbl" xlink:title="label: Two022CompensationPlanMember to adma_Two022CompensationPlanMember_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_Two022CompensationPlanMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_Two022CompensationPlanMember_lbl1" xml:lang="en-US" id="adma_Two022CompensationPlanMember_lbl1">Two022 Compensation Plan [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Two022CompensationPlanMember" xlink:to="adma_Two022CompensationPlanMember_lbl1" xlink:title="label: Two022CompensationPlanMember to adma_Two022CompensationPlanMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_Two022CompensationPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_Two022CompensationPlanMember" xml:lang="en-US" id="adma_Two022CompensationPlanMember">2022 Compensation Plan [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="Two022CompensationPlanMember" xlink:to="adma_Two022CompensationPlanMember" xlink:title="label: Two022CompensationPlanMember to adma_Two022CompensationPlanMember" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_ExercisePriceRange6Member" xlink:label="ExercisePriceRange6Member" xlink:title="ExercisePriceRange6Member" />
    <link:label xlink:type="resource" xlink:label="adma_ExercisePriceRange6Member_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_ExercisePriceRange6Member_lbl" xml:lang="en-US" id="adma_ExercisePriceRange6Member_lbl">Information by range of option prices pertaining to options granted.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ExercisePriceRange6Member" xlink:to="adma_ExercisePriceRange6Member_lbl" xlink:title="label: ExercisePriceRange6Member to adma_ExercisePriceRange6Member_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_ExercisePriceRange6Member_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_ExercisePriceRange6Member_lbl1" xml:lang="en-US" id="adma_ExercisePriceRange6Member_lbl1">Exercise Price Range 6 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ExercisePriceRange6Member" xlink:to="adma_ExercisePriceRange6Member_lbl1" xlink:title="label: ExercisePriceRange6Member to adma_ExercisePriceRange6Member_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_ExercisePriceRange6Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_ExercisePriceRange6Member" xml:lang="en-US" id="adma_ExercisePriceRange6Member">$10.80 - $17.49 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ExercisePriceRange6Member" xlink:to="adma_ExercisePriceRange6Member" xlink:title="label: ExercisePriceRange6Member to adma_ExercisePriceRange6Member" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_ExercisePriceRange5Member" xlink:label="ExercisePriceRange5Member" xlink:title="ExercisePriceRange5Member" />
    <link:label xlink:type="resource" xlink:label="adma_ExercisePriceRange5Member_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_ExercisePriceRange5Member_lbl" xml:lang="en-US" id="adma_ExercisePriceRange5Member_lbl">Information by range of option prices pertaining to options granted.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ExercisePriceRange5Member" xlink:to="adma_ExercisePriceRange5Member_lbl" xlink:title="label: ExercisePriceRange5Member to adma_ExercisePriceRange5Member_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_ExercisePriceRange5Member_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_ExercisePriceRange5Member_lbl1" xml:lang="en-US" id="adma_ExercisePriceRange5Member_lbl1">Exercise Price Range 5 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ExercisePriceRange5Member" xlink:to="adma_ExercisePriceRange5Member_lbl1" xlink:title="label: ExercisePriceRange5Member to adma_ExercisePriceRange5Member_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_ExercisePriceRange5Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_ExercisePriceRange5Member" xml:lang="en-US" id="adma_ExercisePriceRange5Member">$6.54 - $9.81 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ExercisePriceRange5Member" xlink:to="adma_ExercisePriceRange5Member" xlink:title="label: ExercisePriceRange5Member to adma_ExercisePriceRange5Member" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_ExercisePriceRange4Member" xlink:label="ExercisePriceRange4Member" xlink:title="ExercisePriceRange4Member" />
    <link:label xlink:type="resource" xlink:label="adma_ExercisePriceRange4Member_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_ExercisePriceRange4Member_lbl" xml:lang="en-US" id="adma_ExercisePriceRange4Member_lbl">Information by range of option prices pertaining to options granted.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ExercisePriceRange4Member" xlink:to="adma_ExercisePriceRange4Member_lbl" xlink:title="label: ExercisePriceRange4Member to adma_ExercisePriceRange4Member_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_ExercisePriceRange4Member_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_ExercisePriceRange4Member_lbl1" xml:lang="en-US" id="adma_ExercisePriceRange4Member_lbl1">Exercise Price Range 4 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ExercisePriceRange4Member" xlink:to="adma_ExercisePriceRange4Member_lbl1" xlink:title="label: ExercisePriceRange4Member to adma_ExercisePriceRange4Member_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_ExercisePriceRange4Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_ExercisePriceRange4Member" xml:lang="en-US" id="adma_ExercisePriceRange4Member">$4.09 - $6.14 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ExercisePriceRange4Member" xlink:to="adma_ExercisePriceRange4Member" xlink:title="label: ExercisePriceRange4Member to adma_ExercisePriceRange4Member" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_ExercisePriceRange3Member" xlink:label="ExercisePriceRange3Member" xlink:title="ExercisePriceRange3Member" />
    <link:label xlink:type="resource" xlink:label="adma_ExercisePriceRange3Member_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_ExercisePriceRange3Member_lbl" xml:lang="en-US" id="adma_ExercisePriceRange3Member_lbl">Information by range of option prices pertaining to options granted.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ExercisePriceRange3Member" xlink:to="adma_ExercisePriceRange3Member_lbl" xlink:title="label: ExercisePriceRange3Member to adma_ExercisePriceRange3Member_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_ExercisePriceRange3Member_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_ExercisePriceRange3Member_lbl1" xml:lang="en-US" id="adma_ExercisePriceRange3Member_lbl1">Exercise Price Range 3 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ExercisePriceRange3Member" xlink:to="adma_ExercisePriceRange3Member_lbl1" xlink:title="label: ExercisePriceRange3Member to adma_ExercisePriceRange3Member_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_ExercisePriceRange3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_ExercisePriceRange3Member" xml:lang="en-US" id="adma_ExercisePriceRange3Member">$2.67 - $4.01 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ExercisePriceRange3Member" xlink:to="adma_ExercisePriceRange3Member" xlink:title="label: ExercisePriceRange3Member to adma_ExercisePriceRange3Member" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_EmployeesMember" xlink:label="EmployeesMember" xlink:title="EmployeesMember" />
    <link:label xlink:type="resource" xlink:label="adma_EmployeesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_EmployeesMember_lbl" xml:lang="en-US" id="adma_EmployeesMember_lbl">A group of person working with the entity.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EmployeesMember" xlink:to="adma_EmployeesMember_lbl" xlink:title="label: EmployeesMember to adma_EmployeesMember_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_EmployeesMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_EmployeesMember_lbl1" xml:lang="en-US" id="adma_EmployeesMember_lbl1">Employees [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EmployeesMember" xlink:to="adma_EmployeesMember_lbl1" xlink:title="label: EmployeesMember to adma_EmployeesMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_EmployeesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_EmployeesMember" xml:lang="en-US" id="adma_EmployeesMember">Employees [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EmployeesMember" xlink:to="adma_EmployeesMember" xlink:title="label: EmployeesMember to adma_EmployeesMember" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_ExercisePriceRange2Member" xlink:label="ExercisePriceRange2Member" xlink:title="ExercisePriceRange2Member" />
    <link:label xlink:type="resource" xlink:label="adma_ExercisePriceRange2Member_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_ExercisePriceRange2Member_lbl" xml:lang="en-US" id="adma_ExercisePriceRange2Member_lbl">Information by range of option prices pertaining to options granted.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ExercisePriceRange2Member" xlink:to="adma_ExercisePriceRange2Member_lbl" xlink:title="label: ExercisePriceRange2Member to adma_ExercisePriceRange2Member_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_ExercisePriceRange2Member_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_ExercisePriceRange2Member_lbl1" xml:lang="en-US" id="adma_ExercisePriceRange2Member_lbl1">Exercise Price Range 2 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ExercisePriceRange2Member" xlink:to="adma_ExercisePriceRange2Member_lbl1" xlink:title="label: ExercisePriceRange2Member to adma_ExercisePriceRange2Member_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_ExercisePriceRange2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_ExercisePriceRange2Member" xml:lang="en-US" id="adma_ExercisePriceRange2Member">$1.73 - $2.60 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ExercisePriceRange2Member" xlink:to="adma_ExercisePriceRange2Member" xlink:title="label: ExercisePriceRange2Member to adma_ExercisePriceRange2Member" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_ExercisePriceRange1Member" xlink:label="ExercisePriceRange1Member" xlink:title="ExercisePriceRange1Member" />
    <link:label xlink:type="resource" xlink:label="adma_ExercisePriceRange1Member_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_ExercisePriceRange1Member_lbl" xml:lang="en-US" id="adma_ExercisePriceRange1Member_lbl">Information by range of option prices pertaining to options granted.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ExercisePriceRange1Member" xlink:to="adma_ExercisePriceRange1Member_lbl" xlink:title="label: ExercisePriceRange1Member to adma_ExercisePriceRange1Member_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_ExercisePriceRange1Member_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_ExercisePriceRange1Member_lbl1" xml:lang="en-US" id="adma_ExercisePriceRange1Member_lbl1">Exercise Price Range 1 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ExercisePriceRange1Member" xlink:to="adma_ExercisePriceRange1Member_lbl1" xlink:title="label: ExercisePriceRange1Member to adma_ExercisePriceRange1Member_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_ExercisePriceRange1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_ExercisePriceRange1Member" xml:lang="en-US" id="adma_ExercisePriceRange1Member">$1.10 - $1.67 [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ExercisePriceRange1Member" xlink:to="adma_ExercisePriceRange1Member" xlink:title="label: ExercisePriceRange1Member to adma_ExercisePriceRange1Member" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_RestrictedStockUnitsAbstract" xlink:label="RestrictedStockUnitsAbstract" xlink:title="RestrictedStockUnitsAbstract" />
    <link:label xlink:type="resource" xlink:label="adma_RestrictedStockUnitsAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_RestrictedStockUnitsAbstract_lbl1" xml:lang="en-US" id="adma_RestrictedStockUnitsAbstract_lbl1">Restricted Stock Units [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RestrictedStockUnitsAbstract" xlink:to="adma_RestrictedStockUnitsAbstract_lbl1" xlink:title="label: RestrictedStockUnitsAbstract to adma_RestrictedStockUnitsAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_NumberOfIndividualsThatReceivedModificationsToTheirOutstandingStockOptionAndRSUAwards" xlink:label="NumberOfIndividualsThatReceivedModificationsToTheirOutstandingStockOptionAndRSUAwards" xlink:title="NumberOfIndividualsThatReceivedModificationsToTheirOutstandingStockOptionAndRSUAwards" />
    <link:label xlink:type="resource" xlink:label="adma_NumberOfIndividualsThatReceivedModificationsToTheirOutstandingStockOptionAndRSUAwards_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_NumberOfIndividualsThatReceivedModificationsToTheirOutstandingStockOptionAndRSUAwards_lbl" xml:lang="en-US" id="adma_NumberOfIndividualsThatReceivedModificationsToTheirOutstandingStockOptionAndRSUAwards_lbl">The number of employees that received stock option and restricted stock units modifications during the year.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfIndividualsThatReceivedModificationsToTheirOutstandingStockOptionAndRSUAwards" xlink:to="adma_NumberOfIndividualsThatReceivedModificationsToTheirOutstandingStockOptionAndRSUAwards_lbl" xlink:title="label: NumberOfIndividualsThatReceivedModificationsToTheirOutstandingStockOptionAndRSUAwards to adma_NumberOfIndividualsThatReceivedModificationsToTheirOutstandingStockOptionAndRSUAwards_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_NumberOfIndividualsThatReceivedModificationsToTheirOutstandingStockOptionAndRSUAwards_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_NumberOfIndividualsThatReceivedModificationsToTheirOutstandingStockOptionAndRSUAwards_lbl1" xml:lang="en-US" id="adma_NumberOfIndividualsThatReceivedModificationsToTheirOutstandingStockOptionAndRSUAwards_lbl1">Number of Individuals That Received Modifications To Their Outstanding Stock Option and RSU Awards</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfIndividualsThatReceivedModificationsToTheirOutstandingStockOptionAndRSUAwards" xlink:to="adma_NumberOfIndividualsThatReceivedModificationsToTheirOutstandingStockOptionAndRSUAwards_lbl1" xlink:title="label: NumberOfIndividualsThatReceivedModificationsToTheirOutstandingStockOptionAndRSUAwards to adma_NumberOfIndividualsThatReceivedModificationsToTheirOutstandingStockOptionAndRSUAwards_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_NumberOfIndividualsThatReceivedModificationsToTheirOutstandingStockOptionAndRSUAwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_NumberOfIndividualsThatReceivedModificationsToTheirOutstandingStockOptionAndRSUAwards" xml:lang="en-US" id="adma_NumberOfIndividualsThatReceivedModificationsToTheirOutstandingStockOptionAndRSUAwards">Number of individuals that received modifications to stock option and RSU awards</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfIndividualsThatReceivedModificationsToTheirOutstandingStockOptionAndRSUAwards" xlink:to="adma_NumberOfIndividualsThatReceivedModificationsToTheirOutstandingStockOptionAndRSUAwards" xlink:title="label: NumberOfIndividualsThatReceivedModificationsToTheirOutstandingStockOptionAndRSUAwards to adma_NumberOfIndividualsThatReceivedModificationsToTheirOutstandingStockOptionAndRSUAwards" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesWithheldForEmployeesTaxLiabilities" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesWithheldForEmployeesTaxLiabilities" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesWithheldForEmployeesTaxLiabilities" />
    <link:label xlink:type="resource" xlink:label="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesWithheldForEmployeesTaxLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesWithheldForEmployeesTaxLiabilities_lbl" xml:lang="en-US" id="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesWithheldForEmployeesTaxLiabilities_lbl">The number of shares withheld by the Company to cover employees' tax liabilities under share-based payment arrangement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesWithheldForEmployeesTaxLiabilities" xlink:to="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesWithheldForEmployeesTaxLiabilities_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesWithheldForEmployeesTaxLiabilities to adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesWithheldForEmployeesTaxLiabilities_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesWithheldForEmployeesTaxLiabilities_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesWithheldForEmployeesTaxLiabilities_lbl1" xml:lang="en-US" id="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesWithheldForEmployeesTaxLiabilities_lbl1">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Shares Withheld for Employees Tax Liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesWithheldForEmployeesTaxLiabilities" xlink:to="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesWithheldForEmployeesTaxLiabilities_lbl1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesWithheldForEmployeesTaxLiabilities to adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesWithheldForEmployeesTaxLiabilities_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesWithheldForEmployeesTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesWithheldForEmployeesTaxLiabilities" xml:lang="en-US" id="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesWithheldForEmployeesTaxLiabilities">Shares withheld for tax withholding obligation (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesWithheldForEmployeesTaxLiabilities" xlink:to="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesWithheldForEmployeesTaxLiabilities" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesWithheldForEmployeesTaxLiabilities to adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesWithheldForEmployeesTaxLiabilities" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_StockOptionsAbstract" xlink:label="StockOptionsAbstract" xlink:title="StockOptionsAbstract" />
    <link:label xlink:type="resource" xlink:label="adma_StockOptionsAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_StockOptionsAbstract_lbl1" xml:lang="en-US" id="adma_StockOptionsAbstract_lbl1">Stock Options [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockOptionsAbstract" xlink:to="adma_StockOptionsAbstract_lbl1" xlink:title="label: StockOptionsAbstract to adma_StockOptionsAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_StockOptionsWeightedAverageExercisePriceAbstract" xlink:label="StockOptionsWeightedAverageExercisePriceAbstract" xlink:title="StockOptionsWeightedAverageExercisePriceAbstract" />
    <link:label xlink:type="resource" xlink:label="adma_StockOptionsWeightedAverageExercisePriceAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_StockOptionsWeightedAverageExercisePriceAbstract_lbl1" xml:lang="en-US" id="adma_StockOptionsWeightedAverageExercisePriceAbstract_lbl1">Stock Options, Weighted Average Exercise Price [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockOptionsWeightedAverageExercisePriceAbstract" xlink:to="adma_StockOptionsWeightedAverageExercisePriceAbstract_lbl1" xlink:title="label: StockOptionsWeightedAverageExercisePriceAbstract to adma_StockOptionsWeightedAverageExercisePriceAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSharesWithheldToCoverAggregateExercisePrices" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSharesWithheldToCoverAggregateExercisePrices" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSharesWithheldToCoverAggregateExercisePrices" />
    <link:label xlink:type="resource" xlink:label="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSharesWithheldToCoverAggregateExercisePrices_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSharesWithheldToCoverAggregateExercisePrices_lbl" xml:lang="en-US" id="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSharesWithheldToCoverAggregateExercisePrices_lbl">The number of shares withheld by the Company to cover aggregate exercise prices under share-based payment arrangement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSharesWithheldToCoverAggregateExercisePrices" xlink:to="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSharesWithheldToCoverAggregateExercisePrices_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSharesWithheldToCoverAggregateExercisePrices to adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSharesWithheldToCoverAggregateExercisePrices_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSharesWithheldToCoverAggregateExercisePrices_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSharesWithheldToCoverAggregateExercisePrices_lbl1" xml:lang="en-US" id="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSharesWithheldToCoverAggregateExercisePrices_lbl1">Share-based Compensation Arrangement by Share-based Payment Award, Options, Shares Withheld to Cover Aggregate Exercise Prices</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSharesWithheldToCoverAggregateExercisePrices" xlink:to="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSharesWithheldToCoverAggregateExercisePrices_lbl1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSharesWithheldToCoverAggregateExercisePrices to adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSharesWithheldToCoverAggregateExercisePrices_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSharesWithheldToCoverAggregateExercisePrices" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSharesWithheldToCoverAggregateExercisePrices" xml:lang="en-US" id="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSharesWithheldToCoverAggregateExercisePrices">Shares withheld to cover aggregate exercise prices (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSharesWithheldToCoverAggregateExercisePrices" xlink:to="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSharesWithheldToCoverAggregateExercisePrices" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSharesWithheldToCoverAggregateExercisePrices to adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSharesWithheldToCoverAggregateExercisePrices" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_StockOptionSharesAbstract" xlink:label="StockOptionSharesAbstract" xlink:title="StockOptionSharesAbstract" />
    <link:label xlink:type="resource" xlink:label="adma_StockOptionSharesAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_StockOptionSharesAbstract_lbl1" xml:lang="en-US" id="adma_StockOptionSharesAbstract_lbl1">Stock Option, Shares [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockOptionSharesAbstract" xlink:to="adma_StockOptionSharesAbstract_lbl1" xlink:title="label: StockOptionSharesAbstract to adma_StockOptionSharesAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedNumber" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedNumber" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedNumber" />
    <link:label xlink:type="resource" xlink:label="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedNumber_lbl" xml:lang="en-US" id="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedNumber_lbl">Number of shares under fully vested and expected to vest options that were granted during the current period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedNumber" xlink:to="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedNumber_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedNumber to adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedNumber_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedNumber_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedNumber_lbl1" xml:lang="en-US" id="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedNumber_lbl1">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Granted, Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedNumber" xlink:to="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedNumber_lbl1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedNumber to adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedNumber_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedNumber" xml:lang="en-US" id="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedNumber">Granted (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedNumber" xlink:to="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedNumber" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedNumber to adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedNumber" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedNumber" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedNumber" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedNumber" />
    <link:label xlink:type="resource" xlink:label="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedNumber_lbl" xml:lang="en-US" id="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedNumber_lbl">Number of shares under fully vested and expected to vest options that were exercised during the current period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedNumber" xlink:to="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedNumber_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedNumber to adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedNumber_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedNumber_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedNumber_lbl1" xml:lang="en-US" id="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedNumber_lbl1">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercised, Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedNumber" xlink:to="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedNumber_lbl1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedNumber to adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedNumber_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedNumber" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedNumber" xml:lang="en-US" id="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedNumber">Exercised (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedNumber" xlink:to="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedNumber" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedNumber to adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedNumber" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredNumber" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredNumber" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredNumber" />
    <link:label xlink:type="resource" xlink:label="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredNumber_lbl" xml:lang="en-US" id="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredNumber_lbl">Number of shares under fully vested and expected to vest options for which rights to exercise lapsed.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredNumber" xlink:to="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredNumber_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredNumber to adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredNumber_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredNumber_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredNumber_lbl1" xml:lang="en-US" id="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredNumber_lbl1">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Expired, Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredNumber" xlink:to="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredNumber_lbl1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredNumber to adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredNumber_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredNumber" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredNumber" xml:lang="en-US" id="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredNumber">Expired (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredNumber" xlink:to="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredNumber" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredNumber to adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredNumber" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedWeightedAverageExercisePrice" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedWeightedAverageExercisePrice" />
    <link:label xlink:type="resource" xlink:label="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedWeightedAverageExercisePrice_lbl" xml:lang="en-US" id="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedWeightedAverageExercisePrice_lbl">Weighted-average exercise price, for fully vested and expected to vest that were not exercised or put into effect as a result of the occurrence of a terminating event.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedWeightedAverageExercisePrice" xlink:to="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedWeightedAverageExercisePrice_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedWeightedAverageExercisePrice to adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedWeightedAverageExercisePrice_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedWeightedAverageExercisePrice_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedWeightedAverageExercisePrice_lbl1" xml:lang="en-US" id="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedWeightedAverageExercisePrice_lbl1">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Forfeited, Weighted Average Exercise Price</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedWeightedAverageExercisePrice" xlink:to="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedWeightedAverageExercisePrice_lbl1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedWeightedAverageExercisePrice to adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedWeightedAverageExercisePrice_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedWeightedAverageExercisePrice" xml:lang="en-US" id="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedWeightedAverageExercisePrice">Forfeited (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedWeightedAverageExercisePrice" xlink:to="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedWeightedAverageExercisePrice" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedWeightedAverageExercisePrice to adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedWeightedAverageExercisePrice" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedWeightedAverageExercisePrice" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedWeightedAverageExercisePrice" />
    <link:label xlink:type="resource" xlink:label="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedWeightedAverageExercisePrice_lbl" xml:lang="en-US" id="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedWeightedAverageExercisePrice_lbl">Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest granted.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedWeightedAverageExercisePrice" xlink:to="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedWeightedAverageExercisePrice_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedWeightedAverageExercisePrice to adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedWeightedAverageExercisePrice_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedWeightedAverageExercisePrice_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedWeightedAverageExercisePrice_lbl1" xml:lang="en-US" id="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedWeightedAverageExercisePrice_lbl1">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Granted, Weighted Average Exercise Price</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedWeightedAverageExercisePrice" xlink:to="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedWeightedAverageExercisePrice_lbl1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedWeightedAverageExercisePrice to adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedWeightedAverageExercisePrice_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedWeightedAverageExercisePrice" xml:lang="en-US" id="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedWeightedAverageExercisePrice">Granted (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedWeightedAverageExercisePrice" xlink:to="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedWeightedAverageExercisePrice" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedWeightedAverageExercisePrice to adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedWeightedAverageExercisePrice" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredWeightedAverageExercisePrice" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredWeightedAverageExercisePrice" />
    <link:label xlink:type="resource" xlink:label="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredWeightedAverageExercisePrice_lbl" xml:lang="en-US" id="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredWeightedAverageExercisePrice_lbl">Weighted-average exercise price, for fully vested and expected to vest that were expired.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredWeightedAverageExercisePrice" xlink:to="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredWeightedAverageExercisePrice_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredWeightedAverageExercisePrice to adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredWeightedAverageExercisePrice_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredWeightedAverageExercisePrice_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredWeightedAverageExercisePrice_lbl1" xml:lang="en-US" id="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredWeightedAverageExercisePrice_lbl1">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Expired, Weighted Average Exercise Price</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredWeightedAverageExercisePrice" xlink:to="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredWeightedAverageExercisePrice_lbl1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredWeightedAverageExercisePrice to adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredWeightedAverageExercisePrice_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredWeightedAverageExercisePrice" xml:lang="en-US" id="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredWeightedAverageExercisePrice">Expired (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredWeightedAverageExercisePrice" xlink:to="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredWeightedAverageExercisePrice" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredWeightedAverageExercisePrice to adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredWeightedAverageExercisePrice" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedWeightedAverageExercisePrice" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedWeightedAverageExercisePrice" />
    <link:label xlink:type="resource" xlink:label="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedWeightedAverageExercisePrice_lbl" xml:lang="en-US" id="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedWeightedAverageExercisePrice_lbl">Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercised.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedWeightedAverageExercisePrice" xlink:to="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedWeightedAverageExercisePrice_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedWeightedAverageExercisePrice to adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedWeightedAverageExercisePrice_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedWeightedAverageExercisePrice_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedWeightedAverageExercisePrice_lbl1" xml:lang="en-US" id="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedWeightedAverageExercisePrice_lbl1">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercised, Weighted Average Exercise Price</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedWeightedAverageExercisePrice" xlink:to="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedWeightedAverageExercisePrice_lbl1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedWeightedAverageExercisePrice to adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedWeightedAverageExercisePrice_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedWeightedAverageExercisePrice" xml:lang="en-US" id="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedWeightedAverageExercisePrice">Exercised (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedWeightedAverageExercisePrice" xlink:to="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedWeightedAverageExercisePrice" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedWeightedAverageExercisePrice to adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedWeightedAverageExercisePrice" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedNumber" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedNumber" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedNumber" />
    <link:label xlink:type="resource" xlink:label="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedNumber_lbl" xml:lang="en-US" id="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedNumber_lbl">Number of shares under fully vested and expected to vest options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedNumber" xlink:to="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedNumber_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedNumber to adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedNumber_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedNumber_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedNumber_lbl1" xml:lang="en-US" id="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedNumber_lbl1">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Forfeited, Number</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedNumber" xlink:to="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedNumber_lbl1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedNumber to adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedNumber_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedNumber" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedNumber" xml:lang="en-US" id="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedNumber">Forfeited (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedNumber" xlink:to="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedNumber" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedNumber to adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedNumber" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_StockOptionOutstandingAndExcercisableAbstract" xlink:label="StockOptionOutstandingAndExcercisableAbstract" xlink:title="StockOptionOutstandingAndExcercisableAbstract" />
    <link:label xlink:type="resource" xlink:label="adma_StockOptionOutstandingAndExcercisableAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_StockOptionOutstandingAndExcercisableAbstract_lbl1" xml:lang="en-US" id="adma_StockOptionOutstandingAndExcercisableAbstract_lbl1">Stock Option Outstanding and Exercisable [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="StockOptionOutstandingAndExcercisableAbstract" xlink:to="adma_StockOptionOutstandingAndExcercisableAbstract_lbl1" xlink:title="label: StockOptionOutstandingAndExcercisableAbstract to adma_StockOptionOutstandingAndExcercisableAbstract_lbl1" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_EquityIncentivePlanMember" xlink:label="EquityIncentivePlanMember" xlink:title="EquityIncentivePlanMember" />
    <link:label xlink:type="resource" xlink:label="adma_EquityIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_EquityIncentivePlanMember_lbl" xml:lang="en-US" id="adma_EquityIncentivePlanMember_lbl">Equity compensation is often a significant portion of the total compensation paid to employees and other service providers.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EquityIncentivePlanMember" xlink:to="adma_EquityIncentivePlanMember_lbl" xlink:title="label: EquityIncentivePlanMember to adma_EquityIncentivePlanMember_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_EquityIncentivePlanMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_EquityIncentivePlanMember_lbl1" xml:lang="en-US" id="adma_EquityIncentivePlanMember_lbl1">Equity Incentive Plans [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EquityIncentivePlanMember" xlink:to="adma_EquityIncentivePlanMember_lbl1" xlink:title="label: EquityIncentivePlanMember to adma_EquityIncentivePlanMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_EquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_EquityIncentivePlanMember" xml:lang="en-US" id="adma_EquityIncentivePlanMember">Equity Incentive Plans [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="EquityIncentivePlanMember" xlink:to="adma_EquityIncentivePlanMember" xlink:title="label: EquityIncentivePlanMember to adma_EquityIncentivePlanMember" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesValueWithheldForEmployeesTaxLiabilities" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesValueWithheldForEmployeesTaxLiabilities" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesValueWithheldForEmployeesTaxLiabilities" />
    <link:label xlink:type="resource" xlink:label="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesValueWithheldForEmployeesTaxLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesValueWithheldForEmployeesTaxLiabilities_lbl" xml:lang="en-US" id="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesValueWithheldForEmployeesTaxLiabilities_lbl">The shares value withheld by the Company to cover employees' tax liabilities under share-based payment arrangement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesValueWithheldForEmployeesTaxLiabilities" xlink:to="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesValueWithheldForEmployeesTaxLiabilities_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesValueWithheldForEmployeesTaxLiabilities to adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesValueWithheldForEmployeesTaxLiabilities_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesValueWithheldForEmployeesTaxLiabilities_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesValueWithheldForEmployeesTaxLiabilities_lbl1" xml:lang="en-US" id="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesValueWithheldForEmployeesTaxLiabilities_lbl1">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Shares Value Withheld for Employees Tax Liabilities</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesValueWithheldForEmployeesTaxLiabilities" xlink:to="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesValueWithheldForEmployeesTaxLiabilities_lbl1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesValueWithheldForEmployeesTaxLiabilities to adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesValueWithheldForEmployeesTaxLiabilities_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesValueWithheldForEmployeesTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesValueWithheldForEmployeesTaxLiabilities" xml:lang="en-US" id="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesValueWithheldForEmployeesTaxLiabilities">Amount of shares withheld for tax withholding obligation</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesValueWithheldForEmployeesTaxLiabilities" xlink:to="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesValueWithheldForEmployeesTaxLiabilities" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesValueWithheldForEmployeesTaxLiabilities to adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesValueWithheldForEmployeesTaxLiabilities" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSharesWithheldForPayrollTaxes" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSharesWithheldForPayrollTaxes" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSharesWithheldForPayrollTaxes" />
    <link:label xlink:type="resource" xlink:label="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSharesWithheldForPayrollTaxes_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSharesWithheldForPayrollTaxes_lbl" xml:lang="en-US" id="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSharesWithheldForPayrollTaxes_lbl">The number of shares withheld by the Company to cover payroll taxes under share-based payment arrangement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSharesWithheldForPayrollTaxes" xlink:to="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSharesWithheldForPayrollTaxes_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSharesWithheldForPayrollTaxes to adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSharesWithheldForPayrollTaxes_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSharesWithheldForPayrollTaxes_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSharesWithheldForPayrollTaxes_lbl1" xml:lang="en-US" id="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSharesWithheldForPayrollTaxes_lbl1">Share-based Compensation Arrangement by Share-based Payment Award, Options, Shares Withheld for Payroll Taxes</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSharesWithheldForPayrollTaxes" xlink:to="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSharesWithheldForPayrollTaxes_lbl1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSharesWithheldForPayrollTaxes to adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSharesWithheldForPayrollTaxes_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSharesWithheldForPayrollTaxes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSharesWithheldForPayrollTaxes" xml:lang="en-US" id="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSharesWithheldForPayrollTaxes">Shares withheld for payroll taxes (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSharesWithheldForPayrollTaxes" xlink:to="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSharesWithheldForPayrollTaxes" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSharesWithheldForPayrollTaxes to adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSharesWithheldForPayrollTaxes" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_CustomerPaymentTerms" xlink:label="CustomerPaymentTerms" xlink:title="CustomerPaymentTerms" />
    <link:label xlink:type="resource" xlink:label="adma_CustomerPaymentTerms_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_CustomerPaymentTerms_lbl" xml:lang="en-US" id="adma_CustomerPaymentTerms_lbl">The term within which customers are generally required to make payments, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CustomerPaymentTerms" xlink:to="adma_CustomerPaymentTerms_lbl" xlink:title="label: CustomerPaymentTerms to adma_CustomerPaymentTerms_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_CustomerPaymentTerms_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_CustomerPaymentTerms_lbl1" xml:lang="en-US" id="adma_CustomerPaymentTerms_lbl1">Customer Payment Terms</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CustomerPaymentTerms" xlink:to="adma_CustomerPaymentTerms_lbl1" xlink:title="label: CustomerPaymentTerms to adma_CustomerPaymentTerms_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_CustomerPaymentTerms" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_CustomerPaymentTerms" xml:lang="en-US" id="adma_CustomerPaymentTerms">Customer payment term</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CustomerPaymentTerms" xlink:to="adma_CustomerPaymentTerms" xlink:title="label: CustomerPaymentTerms to adma_CustomerPaymentTerms" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_DeferredRevenueRemainingAmortizationPeriod" xlink:label="DeferredRevenueRemainingAmortizationPeriod" xlink:title="DeferredRevenueRemainingAmortizationPeriod" />
    <link:label xlink:type="resource" xlink:label="adma_DeferredRevenueRemainingAmortizationPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_DeferredRevenueRemainingAmortizationPeriod_lbl" xml:lang="en-US" id="adma_DeferredRevenueRemainingAmortizationPeriod_lbl">Remaining amortization period of deferred revenue, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredRevenueRemainingAmortizationPeriod" xlink:to="adma_DeferredRevenueRemainingAmortizationPeriod_lbl" xlink:title="label: DeferredRevenueRemainingAmortizationPeriod to adma_DeferredRevenueRemainingAmortizationPeriod_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_DeferredRevenueRemainingAmortizationPeriod_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_DeferredRevenueRemainingAmortizationPeriod_lbl1" xml:lang="en-US" id="adma_DeferredRevenueRemainingAmortizationPeriod_lbl1">Amortization period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredRevenueRemainingAmortizationPeriod" xlink:to="adma_DeferredRevenueRemainingAmortizationPeriod_lbl1" xlink:title="label: DeferredRevenueRemainingAmortizationPeriod to adma_DeferredRevenueRemainingAmortizationPeriod_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_DeferredRevenueRemainingAmortizationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_DeferredRevenueRemainingAmortizationPeriod" xml:lang="en-US" id="adma_DeferredRevenueRemainingAmortizationPeriod">Amortization period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DeferredRevenueRemainingAmortizationPeriod" xlink:to="adma_DeferredRevenueRemainingAmortizationPeriod" xlink:title="label: DeferredRevenueRemainingAmortizationPeriod to adma_DeferredRevenueRemainingAmortizationPeriod" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_BiotestLicenseAgreementMember" xlink:label="BiotestLicenseAgreementMember" xlink:title="BiotestLicenseAgreementMember" />
    <link:label xlink:type="resource" xlink:label="adma_BiotestLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_BiotestLicenseAgreementMember_lbl" xml:lang="en-US" id="adma_BiotestLicenseAgreementMember_lbl">Name of license agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BiotestLicenseAgreementMember" xlink:to="adma_BiotestLicenseAgreementMember_lbl" xlink:title="label: BiotestLicenseAgreementMember to adma_BiotestLicenseAgreementMember_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_BiotestLicenseAgreementMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_BiotestLicenseAgreementMember_lbl1" xml:lang="en-US" id="adma_BiotestLicenseAgreementMember_lbl1">Biotest License Agreement [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BiotestLicenseAgreementMember" xlink:to="adma_BiotestLicenseAgreementMember_lbl1" xlink:title="label: BiotestLicenseAgreementMember to adma_BiotestLicenseAgreementMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_BiotestLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_BiotestLicenseAgreementMember" xml:lang="en-US" id="adma_BiotestLicenseAgreementMember">Biotest License Agreement [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BiotestLicenseAgreementMember" xlink:to="adma_BiotestLicenseAgreementMember" xlink:title="label: BiotestLicenseAgreementMember to adma_BiotestLicenseAgreementMember" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_AccountsReceivableAllowanceForContractualCreditsAndDoubtfulAccounts" xlink:label="AccountsReceivableAllowanceForContractualCreditsAndDoubtfulAccounts" xlink:title="AccountsReceivableAllowanceForContractualCreditsAndDoubtfulAccounts" />
    <link:label xlink:type="resource" xlink:label="adma_AccountsReceivableAllowanceForContractualCreditsAndDoubtfulAccounts_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_AccountsReceivableAllowanceForContractualCreditsAndDoubtfulAccounts_lbl" xml:lang="en-US" id="adma_AccountsReceivableAllowanceForContractualCreditsAndDoubtfulAccounts_lbl">Amount of allowance for contractual credits and doubtful accounts.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccountsReceivableAllowanceForContractualCreditsAndDoubtfulAccounts" xlink:to="adma_AccountsReceivableAllowanceForContractualCreditsAndDoubtfulAccounts_lbl" xlink:title="label: AccountsReceivableAllowanceForContractualCreditsAndDoubtfulAccounts to adma_AccountsReceivableAllowanceForContractualCreditsAndDoubtfulAccounts_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_AccountsReceivableAllowanceForContractualCreditsAndDoubtfulAccounts_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_AccountsReceivableAllowanceForContractualCreditsAndDoubtfulAccounts_lbl1" xml:lang="en-US" id="adma_AccountsReceivableAllowanceForContractualCreditsAndDoubtfulAccounts_lbl1">Accounts Receivable, Allowance for Contractual Credits and Doubtful Accounts</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccountsReceivableAllowanceForContractualCreditsAndDoubtfulAccounts" xlink:to="adma_AccountsReceivableAllowanceForContractualCreditsAndDoubtfulAccounts_lbl1" xlink:title="label: AccountsReceivableAllowanceForContractualCreditsAndDoubtfulAccounts to adma_AccountsReceivableAllowanceForContractualCreditsAndDoubtfulAccounts_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_AccountsReceivableAllowanceForContractualCreditsAndDoubtfulAccounts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_AccountsReceivableAllowanceForContractualCreditsAndDoubtfulAccounts" xml:lang="en-US" id="adma_AccountsReceivableAllowanceForContractualCreditsAndDoubtfulAccounts">Accounts receivable, allowances for contractual credits and credit losses</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccountsReceivableAllowanceForContractualCreditsAndDoubtfulAccounts" xlink:to="adma_AccountsReceivableAllowanceForContractualCreditsAndDoubtfulAccounts" xlink:title="label: AccountsReceivableAllowanceForContractualCreditsAndDoubtfulAccounts to adma_AccountsReceivableAllowanceForContractualCreditsAndDoubtfulAccounts" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_HayfinWarrantsMember" xlink:label="HayfinWarrantsMember" xlink:title="HayfinWarrantsMember" />
    <link:label xlink:type="resource" xlink:label="adma_HayfinWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_HayfinWarrantsMember_lbl" xml:lang="en-US" id="adma_HayfinWarrantsMember_lbl">On the hayfin closing date, the Company issued the hayfin warrant.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HayfinWarrantsMember" xlink:to="adma_HayfinWarrantsMember_lbl" xlink:title="label: HayfinWarrantsMember to adma_HayfinWarrantsMember_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_HayfinWarrantsMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_HayfinWarrantsMember_lbl1" xml:lang="en-US" id="adma_HayfinWarrantsMember_lbl1">Hayfin Warrants [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="HayfinWarrantsMember" xlink:to="adma_HayfinWarrantsMember_lbl1" xlink:title="label: HayfinWarrantsMember to adma_HayfinWarrantsMember_lbl1" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_WarrantsAbstract" xlink:label="WarrantsAbstract" xlink:title="WarrantsAbstract" />
    <link:label xlink:type="resource" xlink:label="adma_WarrantsAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_WarrantsAbstract_lbl1" xml:lang="en-US" id="adma_WarrantsAbstract_lbl1">Warrants [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WarrantsAbstract" xlink:to="adma_WarrantsAbstract_lbl1" xlink:title="label: WarrantsAbstract to adma_WarrantsAbstract_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_WarrantsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_WarrantsAbstract" xml:lang="en-US" id="adma_WarrantsAbstract">Warrants [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="WarrantsAbstract" xlink:to="adma_WarrantsAbstract" xlink:title="label: WarrantsAbstract to adma_WarrantsAbstract" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_ClassOfWarrantOrRightExercised" xlink:label="ClassOfWarrantOrRightExercised" xlink:title="ClassOfWarrantOrRightExercised" />
    <link:label xlink:type="resource" xlink:label="adma_ClassOfWarrantOrRightExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_ClassOfWarrantOrRightExercised_lbl" xml:lang="en-US" id="adma_ClassOfWarrantOrRightExercised_lbl">The number of warrants exercised during the period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClassOfWarrantOrRightExercised" xlink:to="adma_ClassOfWarrantOrRightExercised_lbl" xlink:title="label: ClassOfWarrantOrRightExercised to adma_ClassOfWarrantOrRightExercised_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_ClassOfWarrantOrRightExercised_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_ClassOfWarrantOrRightExercised_lbl1" xml:lang="en-US" id="adma_ClassOfWarrantOrRightExercised_lbl1">Class Of Warrant Or Right Exercised</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClassOfWarrantOrRightExercised" xlink:to="adma_ClassOfWarrantOrRightExercised_lbl1" xlink:title="label: ClassOfWarrantOrRightExercised to adma_ClassOfWarrantOrRightExercised_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_ClassOfWarrantOrRightExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_ClassOfWarrantOrRightExercised" xml:lang="en-US" id="adma_ClassOfWarrantOrRightExercised">Warrants exercised (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ClassOfWarrantOrRightExercised" xlink:to="adma_ClassOfWarrantOrRightExercised" xlink:title="label: ClassOfWarrantOrRightExercised to adma_ClassOfWarrantOrRightExercised" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod" />
    <link:label xlink:type="resource" xlink:label="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod_lbl" xml:lang="en-US" id="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod_lbl">The number of equity-based payment instruments, excluding stock (or unit) options, that expired during the reporting period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod" xlink:to="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod to adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod_lbl1" xml:lang="en-US" id="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod_lbl1">Share Based Compensation Arrangement by Share Based Payment Award Equity Instruments Other than Options Expired in Period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod" xlink:to="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod_lbl1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod to adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod" xml:lang="en-US" id="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod">Expired (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod" xlink:to="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod to adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageGrantDateFairValue" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageGrantDateFairValue" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageGrantDateFairValue" />
    <link:label xlink:type="resource" xlink:label="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" id="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageGrantDateFairValue_lbl">The weighted average fair value at exercised date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageGrantDateFairValue" xlink:to="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageGrantDateFairValue to adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageGrantDateFairValue_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageGrantDateFairValue_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageGrantDateFairValue_lbl1" xml:lang="en-US" id="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageGrantDateFairValue_lbl1">Share Based Compensation Arrangement by Share Based Payment Award Equity Instruments Other Than Options Exercised in Period Weighted Average Grant Date Fair Value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageGrantDateFairValue" xlink:to="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageGrantDateFairValue_lbl1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageGrantDateFairValue to adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageGrantDateFairValue_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageGrantDateFairValue" xml:lang="en-US" id="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageGrantDateFairValue">Exercised (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageGrantDateFairValue" xlink:to="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageGrantDateFairValue" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageGrantDateFairValue to adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageGrantDateFairValue" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod" />
    <link:label xlink:type="resource" xlink:label="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod_lbl" xml:lang="en-US" id="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod_lbl">The number of equity-based payment instruments, excluding stock (or unit) options, that exercised during the reporting period.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod" xlink:to="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod to adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod_lbl1" xml:lang="en-US" id="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod_lbl1">Share Based Compensation Arrangement by Share Based Payment Award Equity Instruments Other than Options Exercised in Period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod" xlink:to="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod_lbl1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod to adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:title="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod" xml:lang="en-US" id="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod">Exercised (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod" xlink:to="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod to adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriodWeightedAverageGrantDateFairValue" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriodWeightedAverageGrantDateFairValue" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriodWeightedAverageGrantDateFairValue" />
    <link:label xlink:type="resource" xlink:label="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" id="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriodWeightedAverageGrantDateFairValue_lbl">The weighted average fair value at expired date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriodWeightedAverageGrantDateFairValue" xlink:to="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriodWeightedAverageGrantDateFairValue to adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriodWeightedAverageGrantDateFairValue_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriodWeightedAverageGrantDateFairValue_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriodWeightedAverageGrantDateFairValue_lbl1" xml:lang="en-US" id="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriodWeightedAverageGrantDateFairValue_lbl1">Share Based Compensation Arrangement by Share Based Payment Award Equity Instruments Other Than Options Expired in Period Weighted Average Grant Date Fair Value</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriodWeightedAverageGrantDateFairValue" xlink:to="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriodWeightedAverageGrantDateFairValue_lbl1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriodWeightedAverageGrantDateFairValue to adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriodWeightedAverageGrantDateFairValue_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriodWeightedAverageGrantDateFairValue" xml:lang="en-US" id="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriodWeightedAverageGrantDateFairValue">Expired (in dollars per share)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriodWeightedAverageGrantDateFairValue" xlink:to="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriodWeightedAverageGrantDateFairValue" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriodWeightedAverageGrantDateFairValue to adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriodWeightedAverageGrantDateFairValue" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_AccruedTestingCurrent" xlink:label="AccruedTestingCurrent" xlink:title="AccruedTestingCurrent" />
    <link:label xlink:type="resource" xlink:label="adma_AccruedTestingCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_AccruedTestingCurrent_lbl" xml:lang="en-US" id="adma_AccruedTestingCurrent_lbl">Carrying value as of the balance sheet date of obligations incurred through that date and payable for testing. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccruedTestingCurrent" xlink:to="adma_AccruedTestingCurrent_lbl" xlink:title="label: AccruedTestingCurrent to adma_AccruedTestingCurrent_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_AccruedTestingCurrent_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_AccruedTestingCurrent_lbl1" xml:lang="en-US" id="adma_AccruedTestingCurrent_lbl1">Accrued Testing, Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccruedTestingCurrent" xlink:to="adma_AccruedTestingCurrent_lbl1" xlink:title="label: AccruedTestingCurrent to adma_AccruedTestingCurrent_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_AccruedTestingCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_AccruedTestingCurrent" xml:lang="en-US" id="adma_AccruedTestingCurrent">Accrued testing</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccruedTestingCurrent" xlink:to="adma_AccruedTestingCurrent" xlink:title="label: AccruedTestingCurrent to adma_AccruedTestingCurrent" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_AccruedRebatesCurrent" xlink:label="AccruedRebatesCurrent" xlink:title="AccruedRebatesCurrent" />
    <link:label xlink:type="resource" xlink:label="adma_AccruedRebatesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_AccruedRebatesCurrent_lbl" xml:lang="en-US" id="adma_AccruedRebatesCurrent_lbl">Carrying value as of the balance sheet date of rebates for Medicaid or other third parties related to sale of product.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccruedRebatesCurrent" xlink:to="adma_AccruedRebatesCurrent_lbl" xlink:title="label: AccruedRebatesCurrent to adma_AccruedRebatesCurrent_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_AccruedRebatesCurrent_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_AccruedRebatesCurrent_lbl1" xml:lang="en-US" id="adma_AccruedRebatesCurrent_lbl1">Accrued Rebates, Current</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccruedRebatesCurrent" xlink:to="adma_AccruedRebatesCurrent_lbl1" xlink:title="label: AccruedRebatesCurrent to adma_AccruedRebatesCurrent_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_AccruedRebatesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_AccruedRebatesCurrent" xml:lang="en-US" id="adma_AccruedRebatesCurrent">Accrued rebates</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AccruedRebatesCurrent" xlink:to="adma_AccruedRebatesCurrent" xlink:title="label: AccruedRebatesCurrent to adma_AccruedRebatesCurrent" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_DirectOwnershipMember" xlink:label="DirectOwnershipMember" xlink:title="DirectOwnershipMember" />
    <link:label xlink:type="resource" xlink:label="adma_DirectOwnershipMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_DirectOwnershipMember_lbl" xml:lang="en-US" id="adma_DirectOwnershipMember_lbl">Direct owner refers to individuals and entities who directly own shares or are partners in any legal entity.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DirectOwnershipMember" xlink:to="adma_DirectOwnershipMember_lbl" xlink:title="label: DirectOwnershipMember to adma_DirectOwnershipMember_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_DirectOwnershipMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_DirectOwnershipMember_lbl1" xml:lang="en-US" id="adma_DirectOwnershipMember_lbl1">Direct Ownership [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DirectOwnershipMember" xlink:to="adma_DirectOwnershipMember_lbl1" xlink:title="label: DirectOwnershipMember to adma_DirectOwnershipMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_DirectOwnershipMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_DirectOwnershipMember" xml:lang="en-US" id="adma_DirectOwnershipMember">Direct [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="DirectOwnershipMember" xlink:to="adma_DirectOwnershipMember" xlink:title="label: DirectOwnershipMember to adma_DirectOwnershipMember" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_BryantFongMember" xlink:label="BryantFongMember" xlink:title="BryantFongMember" />
    <link:label xlink:type="resource" xlink:label="adma_BryantFongMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_BryantFongMember_lbl" xml:lang="en-US" id="adma_BryantFongMember_lbl">Name of the entity associated with related party.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BryantFongMember" xlink:to="adma_BryantFongMember_lbl" xlink:title="label: BryantFongMember to adma_BryantFongMember_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_BryantFongMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_BryantFongMember_lbl1" xml:lang="en-US" id="adma_BryantFongMember_lbl1">Bryant Fong [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="BryantFongMember" xlink:to="adma_BryantFongMember_lbl1" xlink:title="label: BryantFongMember to adma_BryantFongMember_lbl1" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_GenesisBPSMember" xlink:label="GenesisBPSMember" xlink:title="GenesisBPSMember" />
    <link:label xlink:type="resource" xlink:label="adma_GenesisBPSMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_GenesisBPSMember_lbl" xml:lang="en-US" id="adma_GenesisBPSMember_lbl">Name of the entity associated with related party.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GenesisBPSMember" xlink:to="adma_GenesisBPSMember_lbl" xlink:title="label: GenesisBPSMember to adma_GenesisBPSMember_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_GenesisBPSMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_GenesisBPSMember_lbl1" xml:lang="en-US" id="adma_GenesisBPSMember_lbl1">GenesisBPS [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GenesisBPSMember" xlink:to="adma_GenesisBPSMember_lbl1" xlink:title="label: GenesisBPSMember to adma_GenesisBPSMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_GenesisBPSMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_GenesisBPSMember" xml:lang="en-US" id="adma_GenesisBPSMember">Genesis [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="GenesisBPSMember" xlink:to="adma_GenesisBPSMember" xlink:title="label: GenesisBPSMember to adma_GenesisBPSMember" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_ArethLLCMember" xlink:label="ArethLLCMember" xlink:title="ArethLLCMember" />
    <link:label xlink:type="resource" xlink:label="adma_ArethLLCMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_ArethLLCMember_lbl" xml:lang="en-US" id="adma_ArethLLCMember_lbl">Name of the entity associated with related party.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ArethLLCMember" xlink:to="adma_ArethLLCMember_lbl" xlink:title="label: ArethLLCMember to adma_ArethLLCMember_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_ArethLLCMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_ArethLLCMember_lbl1" xml:lang="en-US" id="adma_ArethLLCMember_lbl1">Areth, LLC [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ArethLLCMember" xlink:to="adma_ArethLLCMember_lbl1" xlink:title="label: ArethLLCMember to adma_ArethLLCMember_lbl1" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_PresidentAndChiefExecutiveOfficerMember" xlink:label="PresidentAndChiefExecutiveOfficerMember" xlink:title="PresidentAndChiefExecutiveOfficerMember" />
    <link:label xlink:type="resource" xlink:label="adma_PresidentAndChiefExecutiveOfficerMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_PresidentAndChiefExecutiveOfficerMember_lbl" xml:lang="en-US" id="adma_PresidentAndChiefExecutiveOfficerMember_lbl">Person with designation of president and chief executive officer.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PresidentAndChiefExecutiveOfficerMember" xlink:to="adma_PresidentAndChiefExecutiveOfficerMember_lbl" xlink:title="label: PresidentAndChiefExecutiveOfficerMember to adma_PresidentAndChiefExecutiveOfficerMember_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_PresidentAndChiefExecutiveOfficerMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_PresidentAndChiefExecutiveOfficerMember_lbl1" xml:lang="en-US" id="adma_PresidentAndChiefExecutiveOfficerMember_lbl1">President and Chief Executive Officer [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PresidentAndChiefExecutiveOfficerMember" xlink:to="adma_PresidentAndChiefExecutiveOfficerMember_lbl1" xlink:title="label: PresidentAndChiefExecutiveOfficerMember to adma_PresidentAndChiefExecutiveOfficerMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_PresidentAndChiefExecutiveOfficerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_PresidentAndChiefExecutiveOfficerMember" xml:lang="en-US" id="adma_PresidentAndChiefExecutiveOfficerMember">Mr. Grossman [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PresidentAndChiefExecutiveOfficerMember" xlink:to="adma_PresidentAndChiefExecutiveOfficerMember" xlink:title="label: PresidentAndChiefExecutiveOfficerMember to adma_PresidentAndChiefExecutiveOfficerMember" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_ExecutiveVicePresidentAndChiefFinancialOfficerMember" xlink:label="ExecutiveVicePresidentAndChiefFinancialOfficerMember" xlink:title="ExecutiveVicePresidentAndChiefFinancialOfficerMember" />
    <link:label xlink:type="resource" xlink:label="adma_ExecutiveVicePresidentAndChiefFinancialOfficerMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_ExecutiveVicePresidentAndChiefFinancialOfficerMember_lbl" xml:lang="en-US" id="adma_ExecutiveVicePresidentAndChiefFinancialOfficerMember_lbl">Person with designation of executive vice president and chief financial officer.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ExecutiveVicePresidentAndChiefFinancialOfficerMember" xlink:to="adma_ExecutiveVicePresidentAndChiefFinancialOfficerMember_lbl" xlink:title="label: ExecutiveVicePresidentAndChiefFinancialOfficerMember to adma_ExecutiveVicePresidentAndChiefFinancialOfficerMember_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_ExecutiveVicePresidentAndChiefFinancialOfficerMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_ExecutiveVicePresidentAndChiefFinancialOfficerMember_lbl1" xml:lang="en-US" id="adma_ExecutiveVicePresidentAndChiefFinancialOfficerMember_lbl1">Executive Vice President and Chief Financial Officer [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ExecutiveVicePresidentAndChiefFinancialOfficerMember" xlink:to="adma_ExecutiveVicePresidentAndChiefFinancialOfficerMember_lbl1" xlink:title="label: ExecutiveVicePresidentAndChiefFinancialOfficerMember to adma_ExecutiveVicePresidentAndChiefFinancialOfficerMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_ExecutiveVicePresidentAndChiefFinancialOfficerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_ExecutiveVicePresidentAndChiefFinancialOfficerMember" xml:lang="en-US" id="adma_ExecutiveVicePresidentAndChiefFinancialOfficerMember">Brian Lenz [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ExecutiveVicePresidentAndChiefFinancialOfficerMember" xlink:to="adma_ExecutiveVicePresidentAndChiefFinancialOfficerMember" xlink:title="label: ExecutiveVicePresidentAndChiefFinancialOfficerMember to adma_ExecutiveVicePresidentAndChiefFinancialOfficerMember" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_RelatedPartyTransactionAbstract" xlink:label="RelatedPartyTransactionAbstract" xlink:title="RelatedPartyTransactionAbstract" />
    <link:label xlink:type="resource" xlink:label="adma_RelatedPartyTransactionAbstract_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_RelatedPartyTransactionAbstract_lbl1" xml:lang="en-US" id="adma_RelatedPartyTransactionAbstract_lbl1">Related Party Transaction [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RelatedPartyTransactionAbstract" xlink:to="adma_RelatedPartyTransactionAbstract_lbl1" xlink:title="label: RelatedPartyTransactionAbstract to adma_RelatedPartyTransactionAbstract_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_RelatedPartyTransactionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_RelatedPartyTransactionAbstract" xml:lang="en-US" id="adma_RelatedPartyTransactionAbstract">Related Party Transactions [Abstract]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RelatedPartyTransactionAbstract" xlink:to="adma_RelatedPartyTransactionAbstract" xlink:title="label: RelatedPartyTransactionAbstract to adma_RelatedPartyTransactionAbstract" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_RelatedPartyTransactionLeaseRenewalPeriod" xlink:label="RelatedPartyTransactionLeaseRenewalPeriod" xlink:title="RelatedPartyTransactionLeaseRenewalPeriod" />
    <link:label xlink:type="resource" xlink:label="adma_RelatedPartyTransactionLeaseRenewalPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_RelatedPartyTransactionLeaseRenewalPeriod_lbl" xml:lang="en-US" id="adma_RelatedPartyTransactionLeaseRenewalPeriod_lbl">Term of lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days in related party transaction.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RelatedPartyTransactionLeaseRenewalPeriod" xlink:to="adma_RelatedPartyTransactionLeaseRenewalPeriod_lbl" xlink:title="label: RelatedPartyTransactionLeaseRenewalPeriod to adma_RelatedPartyTransactionLeaseRenewalPeriod_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_RelatedPartyTransactionLeaseRenewalPeriod_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_RelatedPartyTransactionLeaseRenewalPeriod_lbl1" xml:lang="en-US" id="adma_RelatedPartyTransactionLeaseRenewalPeriod_lbl1">Related Party Transaction, Lease Renewal Period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RelatedPartyTransactionLeaseRenewalPeriod" xlink:to="adma_RelatedPartyTransactionLeaseRenewalPeriod_lbl1" xlink:title="label: RelatedPartyTransactionLeaseRenewalPeriod to adma_RelatedPartyTransactionLeaseRenewalPeriod_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_RelatedPartyTransactionLeaseRenewalPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_RelatedPartyTransactionLeaseRenewalPeriod" xml:lang="en-US" id="adma_RelatedPartyTransactionLeaseRenewalPeriod">Lease automatic renewal period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RelatedPartyTransactionLeaseRenewalPeriod" xlink:to="adma_RelatedPartyTransactionLeaseRenewalPeriod" xlink:title="label: RelatedPartyTransactionLeaseRenewalPeriod to adma_RelatedPartyTransactionLeaseRenewalPeriod" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_NumberOfExecutiveOfficersThatExercisedOptions" xlink:label="NumberOfExecutiveOfficersThatExercisedOptions" xlink:title="NumberOfExecutiveOfficersThatExercisedOptions" />
    <link:label xlink:type="resource" xlink:label="adma_NumberOfExecutiveOfficersThatExercisedOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_NumberOfExecutiveOfficersThatExercisedOptions_lbl" xml:lang="en-US" id="adma_NumberOfExecutiveOfficersThatExercisedOptions_lbl">The number of executive officers who have exercised options to purchase shares.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfExecutiveOfficersThatExercisedOptions" xlink:to="adma_NumberOfExecutiveOfficersThatExercisedOptions_lbl" xlink:title="label: NumberOfExecutiveOfficersThatExercisedOptions to adma_NumberOfExecutiveOfficersThatExercisedOptions_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_NumberOfExecutiveOfficersThatExercisedOptions_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_NumberOfExecutiveOfficersThatExercisedOptions_lbl1" xml:lang="en-US" id="adma_NumberOfExecutiveOfficersThatExercisedOptions_lbl1">Number of Executive Officers that Exercised Options</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfExecutiveOfficersThatExercisedOptions" xlink:to="adma_NumberOfExecutiveOfficersThatExercisedOptions_lbl1" xlink:title="label: NumberOfExecutiveOfficersThatExercisedOptions to adma_NumberOfExecutiveOfficersThatExercisedOptions_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_NumberOfExecutiveOfficersThatExercisedOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_NumberOfExecutiveOfficersThatExercisedOptions" xml:lang="en-US" id="adma_NumberOfExecutiveOfficersThatExercisedOptions">Number of executive officers that exercised options</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfExecutiveOfficersThatExercisedOptions" xlink:to="adma_NumberOfExecutiveOfficersThatExercisedOptions" xlink:title="label: NumberOfExecutiveOfficersThatExercisedOptions to adma_NumberOfExecutiveOfficersThatExercisedOptions" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedInCashlessTransactionForAward" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedInCashlessTransactionForAward" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedInCashlessTransactionForAward" />
    <link:label xlink:type="resource" xlink:label="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedInCashlessTransactionForAward_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedInCashlessTransactionForAward_lbl" xml:lang="en-US" id="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedInCashlessTransactionForAward_lbl">Number of shares purchased in cashless exercise for issuance under share-based payment arrangement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedInCashlessTransactionForAward" xlink:to="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedInCashlessTransactionForAward_lbl" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedInCashlessTransactionForAward to adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedInCashlessTransactionForAward_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedInCashlessTransactionForAward_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedInCashlessTransactionForAward_lbl1" xml:lang="en-US" id="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedInCashlessTransactionForAward_lbl1">Share Based Compensation Arrangement By Share Based Payment Award, Shares Purchased in Cashless Transaction for Award</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedInCashlessTransactionForAward" xlink:to="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedInCashlessTransactionForAward_lbl1" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedInCashlessTransactionForAward to adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedInCashlessTransactionForAward_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedInCashlessTransactionForAward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedInCashlessTransactionForAward" xml:lang="en-US" id="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedInCashlessTransactionForAward">Shares purchased in cashless transaction (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedInCashlessTransactionForAward" xlink:to="adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedInCashlessTransactionForAward" xlink:title="label: ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedInCashlessTransactionForAward to adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedInCashlessTransactionForAward" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_RelatedPartyTransactionLeaseTerminationPeriod" xlink:label="RelatedPartyTransactionLeaseTerminationPeriod" xlink:title="RelatedPartyTransactionLeaseTerminationPeriod" />
    <link:label xlink:type="resource" xlink:label="adma_RelatedPartyTransactionLeaseTerminationPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_RelatedPartyTransactionLeaseTerminationPeriod_lbl" xml:lang="en-US" id="adma_RelatedPartyTransactionLeaseTerminationPeriod_lbl">Notice period for lease termination, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days in related party transaction.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RelatedPartyTransactionLeaseTerminationPeriod" xlink:to="adma_RelatedPartyTransactionLeaseTerminationPeriod_lbl" xlink:title="label: RelatedPartyTransactionLeaseTerminationPeriod to adma_RelatedPartyTransactionLeaseTerminationPeriod_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_RelatedPartyTransactionLeaseTerminationPeriod_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_RelatedPartyTransactionLeaseTerminationPeriod_lbl1" xml:lang="en-US" id="adma_RelatedPartyTransactionLeaseTerminationPeriod_lbl1">Related Party Transaction, Lease Termination Period</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RelatedPartyTransactionLeaseTerminationPeriod" xlink:to="adma_RelatedPartyTransactionLeaseTerminationPeriod_lbl1" xlink:title="label: RelatedPartyTransactionLeaseTerminationPeriod to adma_RelatedPartyTransactionLeaseTerminationPeriod_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_RelatedPartyTransactionLeaseTerminationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_RelatedPartyTransactionLeaseTerminationPeriod" xml:lang="en-US" id="adma_RelatedPartyTransactionLeaseTerminationPeriod">Notice period for termination</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="RelatedPartyTransactionLeaseTerminationPeriod" xlink:to="adma_RelatedPartyTransactionLeaseTerminationPeriod" xlink:title="label: RelatedPartyTransactionLeaseTerminationPeriod to adma_RelatedPartyTransactionLeaseTerminationPeriod" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_MinimumPercentageOfCommonStockHeldByLender" xlink:label="MinimumPercentageOfCommonStockHeldByLender" xlink:title="MinimumPercentageOfCommonStockHeldByLender" />
    <link:label xlink:type="resource" xlink:label="adma_MinimumPercentageOfCommonStockHeldByLender_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_MinimumPercentageOfCommonStockHeldByLender_lbl" xml:lang="en-US" id="adma_MinimumPercentageOfCommonStockHeldByLender_lbl">Minimum percentage of common stock held by lender and administrative agent of credit facility.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MinimumPercentageOfCommonStockHeldByLender" xlink:to="adma_MinimumPercentageOfCommonStockHeldByLender_lbl" xlink:title="label: MinimumPercentageOfCommonStockHeldByLender to adma_MinimumPercentageOfCommonStockHeldByLender_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_MinimumPercentageOfCommonStockHeldByLender_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_MinimumPercentageOfCommonStockHeldByLender_lbl1" xml:lang="en-US" id="adma_MinimumPercentageOfCommonStockHeldByLender_lbl1">Minimum Percentage of Common Stock held by Lender</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MinimumPercentageOfCommonStockHeldByLender" xlink:to="adma_MinimumPercentageOfCommonStockHeldByLender_lbl1" xlink:title="label: MinimumPercentageOfCommonStockHeldByLender to adma_MinimumPercentageOfCommonStockHeldByLender_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_MinimumPercentageOfCommonStockHeldByLender" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_MinimumPercentageOfCommonStockHeldByLender" xml:lang="en-US" id="adma_MinimumPercentageOfCommonStockHeldByLender">Minimum percentage of common stock held by lender</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="MinimumPercentageOfCommonStockHeldByLender" xlink:to="adma_MinimumPercentageOfCommonStockHeldByLender" xlink:title="label: MinimumPercentageOfCommonStockHeldByLender to adma_MinimumPercentageOfCommonStockHeldByLender" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_PerceptiveCreditHoldingsIILPMember" xlink:label="PerceptiveCreditHoldingsIILPMember" xlink:title="PerceptiveCreditHoldingsIILPMember" />
    <link:label xlink:type="resource" xlink:label="adma_PerceptiveCreditHoldingsIILPMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_PerceptiveCreditHoldingsIILPMember_lbl" xml:lang="en-US" id="adma_PerceptiveCreditHoldingsIILPMember_lbl">Name of the Lender in credit facility agreement.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PerceptiveCreditHoldingsIILPMember" xlink:to="adma_PerceptiveCreditHoldingsIILPMember_lbl" xlink:title="label: PerceptiveCreditHoldingsIILPMember to adma_PerceptiveCreditHoldingsIILPMember_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_PerceptiveCreditHoldingsIILPMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_PerceptiveCreditHoldingsIILPMember_lbl1" xml:lang="en-US" id="adma_PerceptiveCreditHoldingsIILPMember_lbl1">Perceptive Credit Holdings II, LP [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PerceptiveCreditHoldingsIILPMember" xlink:to="adma_PerceptiveCreditHoldingsIILPMember_lbl1" xlink:title="label: PerceptiveCreditHoldingsIILPMember to adma_PerceptiveCreditHoldingsIILPMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_PerceptiveCreditHoldingsIILPMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_PerceptiveCreditHoldingsIILPMember" xml:lang="en-US" id="adma_PerceptiveCreditHoldingsIILPMember">Perceptive [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="PerceptiveCreditHoldingsIILPMember" xlink:to="adma_PerceptiveCreditHoldingsIILPMember" xlink:title="label: PerceptiveCreditHoldingsIILPMember to adma_PerceptiveCreditHoldingsIILPMember" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_IndirectOwnershipMember" xlink:label="IndirectOwnershipMember" xlink:title="IndirectOwnershipMember" />
    <link:label xlink:type="resource" xlink:label="adma_IndirectOwnershipMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_IndirectOwnershipMember_lbl" xml:lang="en-US" id="adma_IndirectOwnershipMember_lbl">Indirect Ownership means an interest in an entity that has direct or indirect ownership interest in the Applicant. The amount of indirect ownership in the Applicant that is held by any other entity is determined by multiplying the percentage of ownership interest at each level.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IndirectOwnershipMember" xlink:to="adma_IndirectOwnershipMember_lbl" xlink:title="label: IndirectOwnershipMember to adma_IndirectOwnershipMember_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_IndirectOwnershipMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_IndirectOwnershipMember_lbl1" xml:lang="en-US" id="adma_IndirectOwnershipMember_lbl1">Indirect Ownership [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IndirectOwnershipMember" xlink:to="adma_IndirectOwnershipMember_lbl1" xlink:title="label: IndirectOwnershipMember to adma_IndirectOwnershipMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_IndirectOwnershipMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_IndirectOwnershipMember" xml:lang="en-US" id="adma_IndirectOwnershipMember">Indirect [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="IndirectOwnershipMember" xlink:to="adma_IndirectOwnershipMember" xlink:title="label: IndirectOwnershipMember to adma_IndirectOwnershipMember" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_NumberOfPlasmaCollectionFacilitiesUnderDevelopment" xlink:label="NumberOfPlasmaCollectionFacilitiesUnderDevelopment" xlink:title="NumberOfPlasmaCollectionFacilitiesUnderDevelopment" />
    <link:label xlink:type="resource" xlink:label="adma_NumberOfPlasmaCollectionFacilitiesUnderDevelopment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_NumberOfPlasmaCollectionFacilitiesUnderDevelopment_lbl" xml:lang="en-US" id="adma_NumberOfPlasmaCollectionFacilitiesUnderDevelopment_lbl">Number of plasma collection facilities under various stages of development.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfPlasmaCollectionFacilitiesUnderDevelopment" xlink:to="adma_NumberOfPlasmaCollectionFacilitiesUnderDevelopment_lbl" xlink:title="label: NumberOfPlasmaCollectionFacilitiesUnderDevelopment to adma_NumberOfPlasmaCollectionFacilitiesUnderDevelopment_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_NumberOfPlasmaCollectionFacilitiesUnderDevelopment_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_NumberOfPlasmaCollectionFacilitiesUnderDevelopment_lbl1" xml:lang="en-US" id="adma_NumberOfPlasmaCollectionFacilitiesUnderDevelopment_lbl1">Number of Plasma Collection Facilities Under Development</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfPlasmaCollectionFacilitiesUnderDevelopment" xlink:to="adma_NumberOfPlasmaCollectionFacilitiesUnderDevelopment_lbl1" xlink:title="label: NumberOfPlasmaCollectionFacilitiesUnderDevelopment to adma_NumberOfPlasmaCollectionFacilitiesUnderDevelopment_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_NumberOfPlasmaCollectionFacilitiesUnderDevelopment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_NumberOfPlasmaCollectionFacilitiesUnderDevelopment" xml:lang="en-US" id="adma_NumberOfPlasmaCollectionFacilitiesUnderDevelopment">Number of plasma collection facilities under development</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="NumberOfPlasmaCollectionFacilitiesUnderDevelopment" xlink:to="adma_NumberOfPlasmaCollectionFacilitiesUnderDevelopment" xlink:title="label: NumberOfPlasmaCollectionFacilitiesUnderDevelopment to adma_NumberOfPlasmaCollectionFacilitiesUnderDevelopment" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_ADMABioManufacturingSegmentMember" xlink:label="ADMABioManufacturingSegmentMember" xlink:title="ADMABioManufacturingSegmentMember" />
    <link:label xlink:type="resource" xlink:label="adma_ADMABioManufacturingSegmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_ADMABioManufacturingSegmentMember_lbl" xml:lang="en-US" id="adma_ADMABioManufacturingSegmentMember_lbl">Component of ADMA BioManufacturing that usually provides financial, operational and administrative support and is considered an operating segment.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ADMABioManufacturingSegmentMember" xlink:to="adma_ADMABioManufacturingSegmentMember_lbl" xlink:title="label: ADMABioManufacturingSegmentMember to adma_ADMABioManufacturingSegmentMember_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_ADMABioManufacturingSegmentMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_ADMABioManufacturingSegmentMember_lbl1" xml:lang="en-US" id="adma_ADMABioManufacturingSegmentMember_lbl1">ADMA BioManufacturing Segment [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ADMABioManufacturingSegmentMember" xlink:to="adma_ADMABioManufacturingSegmentMember_lbl1" xlink:title="label: ADMABioManufacturingSegmentMember to adma_ADMABioManufacturingSegmentMember_lbl1" />
    <link:label xlink:type="resource" xlink:label="adma_ADMABioManufacturingSegmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:title="adma_ADMABioManufacturingSegmentMember" xml:lang="en-US" id="adma_ADMABioManufacturingSegmentMember">ADMA BioManufacturing [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ADMABioManufacturingSegmentMember" xlink:to="adma_ADMABioManufacturingSegmentMember" xlink:title="label: ADMABioManufacturingSegmentMember to adma_ADMABioManufacturingSegmentMember" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_AdamGrossmanMember" xlink:label="AdamGrossmanMember" xlink:title="AdamGrossmanMember" />
    <link:label xlink:type="resource" xlink:label="adma_AdamGrossmanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_AdamGrossmanMember_lbl" xml:lang="en-US" id="adma_AdamGrossmanMember_lbl">The name of President and CEO.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AdamGrossmanMember" xlink:to="adma_AdamGrossmanMember_lbl" xlink:title="label: AdamGrossmanMember to adma_AdamGrossmanMember_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_AdamGrossmanMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_AdamGrossmanMember_lbl1" xml:lang="en-US" id="adma_AdamGrossmanMember_lbl1">Adam Grossman [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AdamGrossmanMember" xlink:to="adma_AdamGrossmanMember_lbl1" xlink:title="label: AdamGrossmanMember to adma_AdamGrossmanMember_lbl1" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_AdamGrossmanTradingPlanCommonStockMember" xlink:label="AdamGrossmanTradingPlanCommonStockMember" xlink:title="AdamGrossmanTradingPlanCommonStockMember" />
    <link:label xlink:type="resource" xlink:label="adma_AdamGrossmanTradingPlanCommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_AdamGrossmanTradingPlanCommonStockMember_lbl" xml:lang="en-US" id="adma_AdamGrossmanTradingPlanCommonStockMember_lbl">Common stock that to be issued under Insider trading plan.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AdamGrossmanTradingPlanCommonStockMember" xlink:to="adma_AdamGrossmanTradingPlanCommonStockMember_lbl" xlink:title="label: AdamGrossmanTradingPlanCommonStockMember to adma_AdamGrossmanTradingPlanCommonStockMember_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_AdamGrossmanTradingPlanCommonStockMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_AdamGrossmanTradingPlanCommonStockMember_lbl1" xml:lang="en-US" id="adma_AdamGrossmanTradingPlanCommonStockMember_lbl1">Adam Grossman Trading Plan, Common Stock [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AdamGrossmanTradingPlanCommonStockMember" xlink:to="adma_AdamGrossmanTradingPlanCommonStockMember_lbl1" xlink:title="label: AdamGrossmanTradingPlanCommonStockMember to adma_AdamGrossmanTradingPlanCommonStockMember_lbl1" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_AdamGrossmanTradingPlanStockOptionsMember" xlink:label="AdamGrossmanTradingPlanStockOptionsMember" xlink:title="AdamGrossmanTradingPlanStockOptionsMember" />
    <link:label xlink:type="resource" xlink:label="adma_AdamGrossmanTradingPlanStockOptionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:title="adma_AdamGrossmanTradingPlanStockOptionsMember_lbl" xml:lang="en-US" id="adma_AdamGrossmanTradingPlanStockOptionsMember_lbl">Stock option that to be issued under Insider trading plan.</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AdamGrossmanTradingPlanStockOptionsMember" xlink:to="adma_AdamGrossmanTradingPlanStockOptionsMember_lbl" xlink:title="label: AdamGrossmanTradingPlanStockOptionsMember to adma_AdamGrossmanTradingPlanStockOptionsMember_lbl" />
    <link:label xlink:type="resource" xlink:label="adma_AdamGrossmanTradingPlanStockOptionsMember_lbl1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:title="adma_AdamGrossmanTradingPlanStockOptionsMember_lbl1" xml:lang="en-US" id="adma_AdamGrossmanTradingPlanStockOptionsMember_lbl1">Adam Grossman Trading Plan, Stock Options [Member]</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="AdamGrossmanTradingPlanStockOptionsMember" xlink:to="adma_AdamGrossmanTradingPlanStockOptionsMember_lbl1" xlink:title="label: AdamGrossmanTradingPlanStockOptionsMember to adma_AdamGrossmanTradingPlanStockOptionsMember_lbl1" />
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>17
<FILENAME>adma-20241231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--Generated by Broadridge PROfile 25.2.1.5287 Broadridge-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" />
  <link:roleRef roleURI="http://admabiologics.com/role/ScheduleIiValuationAndQualifyingAccountsDetails" xlink:type="simple" xlink:href="adma-20241231.xsd#ScheduleIiValuationAndQualifyingAccountsDetails" />
  <link:roleRef roleURI="http://admabiologics.com/role/ConcentrationsDetails" xlink:type="simple" xlink:href="adma-20241231.xsd#ConcentrationsDetails" />
  <link:roleRef roleURI="http://admabiologics.com/role/SupplementalDisclosureOfCashFlowInformationDetails" xlink:type="simple" xlink:href="adma-20241231.xsd#SupplementalDisclosureOfCashFlowInformationDetails" />
  <link:roleRef roleURI="http://admabiologics.com/role/OtherEmployeeBenefitsDetails" xlink:type="simple" xlink:href="adma-20241231.xsd#OtherEmployeeBenefitsDetails" />
  <link:roleRef roleURI="http://admabiologics.com/role/SegmentsNetRevenuesAccordingToGeographicAreaDetails" xlink:type="simple" xlink:href="adma-20241231.xsd#SegmentsNetRevenuesAccordingToGeographicAreaDetails" />
  <link:roleRef roleURI="http://admabiologics.com/role/SegmentsSummarizedFinancialInformationBySegmentDetails" xlink:type="simple" xlink:href="adma-20241231.xsd#SegmentsSummarizedFinancialInformationBySegmentDetails" />
  <link:roleRef roleURI="http://admabiologics.com/role/LeaseObligationsDetailsCalc01" xlink:type="simple" xlink:href="adma-20241231.xsd#LeaseObligationsDetailsCalc01" />
  <link:roleRef roleURI="http://admabiologics.com/role/LeaseObligationsDetails" xlink:type="simple" xlink:href="adma-20241231.xsd#LeaseObligationsDetails" />
  <link:roleRef roleURI="http://admabiologics.com/role/IncomeTaxesNetOperatingLossCarryforwardsDetails" xlink:type="simple" xlink:href="adma-20241231.xsd#IncomeTaxesNetOperatingLossCarryforwardsDetails" />
  <link:roleRef roleURI="http://admabiologics.com/role/IncomeTaxesDeferredTaxAssetsDetails" xlink:type="simple" xlink:href="adma-20241231.xsd#IncomeTaxesDeferredTaxAssetsDetails" />
  <link:roleRef roleURI="http://admabiologics.com/role/IncomeTaxesReconciliationOfIncomeTaxesDetails" xlink:type="simple" xlink:href="adma-20241231.xsd#IncomeTaxesReconciliationOfIncomeTaxesDetails" />
  <link:roleRef roleURI="http://admabiologics.com/role/IncomeTaxesIncomeTaxExpenseBenefitDetails" xlink:type="simple" xlink:href="adma-20241231.xsd#IncomeTaxesIncomeTaxExpenseBenefitDetails" />
  <link:roleRef roleURI="http://admabiologics.com/role/CommitmentsAndContingenciesDetails" xlink:type="simple" xlink:href="adma-20241231.xsd#CommitmentsAndContingenciesDetails" />
  <link:roleRef roleURI="http://admabiologics.com/role/RelatedPartyTransactionsDetails" xlink:type="simple" xlink:href="adma-20241231.xsd#RelatedPartyTransactionsDetails" />
  <link:roleRef roleURI="http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails" xlink:type="simple" xlink:href="adma-20241231.xsd#StockholdersEquityEquityIncentivePlansDetails" />
  <link:roleRef roleURI="http://admabiologics.com/role/StockholdersEquityWarrantsDetails" xlink:type="simple" xlink:href="adma-20241231.xsd#StockholdersEquityWarrantsDetails" />
  <link:roleRef roleURI="http://admabiologics.com/role/StockholdersEquityCommonStockDetails" xlink:type="simple" xlink:href="adma-20241231.xsd#StockholdersEquityCommonStockDetails" />
  <link:roleRef roleURI="http://admabiologics.com/role/StockholdersEquityPreferredStockDetails" xlink:type="simple" xlink:href="adma-20241231.xsd#StockholdersEquityPreferredStockDetails" />
  <link:roleRef roleURI="http://admabiologics.com/role/NotesPayableDetails" xlink:type="simple" xlink:href="adma-20241231.xsd#NotesPayableDetails" />
  <link:roleRef roleURI="http://admabiologics.com/role/AccruedExpensesAndOtherLiabilitiesDetails" xlink:type="simple" xlink:href="adma-20241231.xsd#AccruedExpensesAndOtherLiabilitiesDetails" />
  <link:roleRef roleURI="http://admabiologics.com/role/IntangibleAssetsFutureAggregateAmortizationExpenseDetails" xlink:type="simple" xlink:href="adma-20241231.xsd#IntangibleAssetsFutureAggregateAmortizationExpenseDetails" />
  <link:roleRef roleURI="http://admabiologics.com/role/IntangibleAssetsSummaryDetails" xlink:type="simple" xlink:href="adma-20241231.xsd#IntangibleAssetsSummaryDetails" />
  <link:roleRef roleURI="http://admabiologics.com/role/PropertyAndEquipmentDetails" xlink:type="simple" xlink:href="adma-20241231.xsd#PropertyAndEquipmentDetails" />
  <link:roleRef roleURI="http://admabiologics.com/role/InventoriesDetails" xlink:type="simple" xlink:href="adma-20241231.xsd#InventoriesDetails" />
  <link:roleRef roleURI="http://admabiologics.com/role/SignificantAccountingPoliciesEarningsLossPerShareDetails" xlink:type="simple" xlink:href="adma-20241231.xsd#SignificantAccountingPoliciesEarningsLossPerShareDetails" />
  <link:roleRef roleURI="http://admabiologics.com/role/SignificantAccountingPoliciesStockbasedCompensationDetails" xlink:type="simple" xlink:href="adma-20241231.xsd#SignificantAccountingPoliciesStockbasedCompensationDetails" />
  <link:roleRef roleURI="http://admabiologics.com/role/SignificantAccountingPoliciesAdvertisingAndMarketingExpensesDetails" xlink:type="simple" xlink:href="adma-20241231.xsd#SignificantAccountingPoliciesAdvertisingAndMarketingExpensesDetails" />
  <link:roleRef roleURI="http://admabiologics.com/role/SignificantAccountingPoliciesRevenueRecognitionDetails" xlink:type="simple" xlink:href="adma-20241231.xsd#SignificantAccountingPoliciesRevenueRecognitionDetails" />
  <link:roleRef roleURI="http://admabiologics.com/role/SignificantAccountingPoliciesImpairmentOfLonglivedAssetsDetails" xlink:type="simple" xlink:href="adma-20241231.xsd#SignificantAccountingPoliciesImpairmentOfLonglivedAssetsDetails" />
  <link:roleRef roleURI="http://admabiologics.com/role/SignificantAccountingPoliciesGoodwillDetails" xlink:type="simple" xlink:href="adma-20241231.xsd#SignificantAccountingPoliciesGoodwillDetails" />
  <link:roleRef roleURI="http://admabiologics.com/role/SignificantAccountingPoliciesPropertyAndEquipmentDetails" xlink:type="simple" xlink:href="adma-20241231.xsd#SignificantAccountingPoliciesPropertyAndEquipmentDetails" />
  <link:roleRef roleURI="http://admabiologics.com/role/SignificantAccountingPoliciesAccountsReceivableDetails" xlink:type="simple" xlink:href="adma-20241231.xsd#SignificantAccountingPoliciesAccountsReceivableDetails" />
  <link:roleRef roleURI="http://admabiologics.com/role/SignificantAccountingPoliciesUseOfEstimatesDetails" xlink:type="simple" xlink:href="adma-20241231.xsd#SignificantAccountingPoliciesUseOfEstimatesDetails" />
  <link:roleRef roleURI="http://admabiologics.com/role/OrganizationAndBusinessDetails" xlink:type="simple" xlink:href="adma-20241231.xsd#OrganizationAndBusinessDetails" />
  <link:roleRef roleURI="http://admabiologics.com/role/SupplementalDisclosureOfCashFlowInformationTables" xlink:type="simple" xlink:href="adma-20241231.xsd#SupplementalDisclosureOfCashFlowInformationTables" />
  <link:roleRef roleURI="http://admabiologics.com/role/SegmentsTables" xlink:type="simple" xlink:href="adma-20241231.xsd#SegmentsTables" />
  <link:roleRef roleURI="http://admabiologics.com/role/LeaseObligationsTables" xlink:type="simple" xlink:href="adma-20241231.xsd#LeaseObligationsTables" />
  <link:roleRef roleURI="http://admabiologics.com/role/IncomeTaxesTables" xlink:type="simple" xlink:href="adma-20241231.xsd#IncomeTaxesTables" />
  <link:roleRef roleURI="http://admabiologics.com/role/StockholdersEquityTables" xlink:type="simple" xlink:href="adma-20241231.xsd#StockholdersEquityTables" />
  <link:roleRef roleURI="http://admabiologics.com/role/NotesPayableTables" xlink:type="simple" xlink:href="adma-20241231.xsd#NotesPayableTables" />
  <link:roleRef roleURI="http://admabiologics.com/role/AccruedExpensesAndOtherLiabilitiesTables" xlink:type="simple" xlink:href="adma-20241231.xsd#AccruedExpensesAndOtherLiabilitiesTables" />
  <link:roleRef roleURI="http://admabiologics.com/role/IntangibleAssetsTables" xlink:type="simple" xlink:href="adma-20241231.xsd#IntangibleAssetsTables" />
  <link:roleRef roleURI="http://admabiologics.com/role/PropertyAndEquipmentTables" xlink:type="simple" xlink:href="adma-20241231.xsd#PropertyAndEquipmentTables" />
  <link:roleRef roleURI="http://admabiologics.com/role/InventoriesTables" xlink:type="simple" xlink:href="adma-20241231.xsd#InventoriesTables" />
  <link:roleRef roleURI="http://admabiologics.com/role/SignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="adma-20241231.xsd#SignificantAccountingPoliciesTables" />
  <link:roleRef roleURI="http://admabiologics.com/role/SignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="adma-20241231.xsd#SignificantAccountingPoliciesPolicies" />
  <link:roleRef roleURI="http://admabiologics.com/role/InsiderTradingArrangements" xlink:type="simple" xlink:href="adma-20241231.xsd#InsiderTradingArrangements" />
  <link:roleRef roleURI="http://admabiologics.com/role/CybersecurityRiskManagementAndStrategyDisclosure" xlink:type="simple" xlink:href="adma-20241231.xsd#CybersecurityRiskManagementAndStrategyDisclosure" />
  <link:roleRef roleURI="http://admabiologics.com/role/ScheduleIiValuationAndQualifyingAccounts" xlink:type="simple" xlink:href="adma-20241231.xsd#ScheduleIiValuationAndQualifyingAccounts" />
  <link:roleRef roleURI="http://admabiologics.com/role/Concentrations" xlink:type="simple" xlink:href="adma-20241231.xsd#Concentrations" />
  <link:roleRef roleURI="http://admabiologics.com/role/SupplementalDisclosureOfCashFlowInformation" xlink:type="simple" xlink:href="adma-20241231.xsd#SupplementalDisclosureOfCashFlowInformation" />
  <link:roleRef roleURI="http://admabiologics.com/role/OtherEmployeeBenefits" xlink:type="simple" xlink:href="adma-20241231.xsd#OtherEmployeeBenefits" />
  <link:roleRef roleURI="http://admabiologics.com/role/Segments" xlink:type="simple" xlink:href="adma-20241231.xsd#Segments" />
  <link:roleRef roleURI="http://admabiologics.com/role/LeaseObligations" xlink:type="simple" xlink:href="adma-20241231.xsd#LeaseObligations" />
  <link:roleRef roleURI="http://admabiologics.com/role/IncomeTaxes" xlink:type="simple" xlink:href="adma-20241231.xsd#IncomeTaxes" />
  <link:roleRef roleURI="http://admabiologics.com/role/CommitmentsAndContingencies" xlink:type="simple" xlink:href="adma-20241231.xsd#CommitmentsAndContingencies" />
  <link:roleRef roleURI="http://admabiologics.com/role/RelatedPartyTransactions" xlink:type="simple" xlink:href="adma-20241231.xsd#RelatedPartyTransactions" />
  <link:roleRef roleURI="http://admabiologics.com/role/StockholdersEquity" xlink:type="simple" xlink:href="adma-20241231.xsd#StockholdersEquity" />
  <link:roleRef roleURI="http://admabiologics.com/role/NotesPayable" xlink:type="simple" xlink:href="adma-20241231.xsd#NotesPayable" />
  <link:roleRef roleURI="http://admabiologics.com/role/AccruedExpensesAndOtherLiabilities" xlink:type="simple" xlink:href="adma-20241231.xsd#AccruedExpensesAndOtherLiabilities" />
  <link:roleRef roleURI="http://admabiologics.com/role/IntangibleAssets" xlink:type="simple" xlink:href="adma-20241231.xsd#IntangibleAssets" />
  <link:roleRef roleURI="http://admabiologics.com/role/PropertyAndEquipment" xlink:type="simple" xlink:href="adma-20241231.xsd#PropertyAndEquipment" />
  <link:roleRef roleURI="http://admabiologics.com/role/Inventories" xlink:type="simple" xlink:href="adma-20241231.xsd#Inventories" />
  <link:roleRef roleURI="http://admabiologics.com/role/SignificantAccountingPolicies" xlink:type="simple" xlink:href="adma-20241231.xsd#SignificantAccountingPolicies" />
  <link:roleRef roleURI="http://admabiologics.com/role/OrganizationAndBusiness" xlink:type="simple" xlink:href="adma-20241231.xsd#OrganizationAndBusiness" />
  <link:roleRef roleURI="http://admabiologics.com/role/ConsolidatedStatementsOfCashFlows" xlink:type="simple" xlink:href="adma-20241231.xsd#ConsolidatedStatementsOfCashFlows" />
  <link:roleRef roleURI="http://admabiologics.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity" xlink:type="simple" xlink:href="adma-20241231.xsd#ConsolidatedStatementsOfChangesInStockholdersEquity" />
  <link:roleRef roleURI="http://admabiologics.com/role/ConsolidatedStatementsOfOperations" xlink:type="simple" xlink:href="adma-20241231.xsd#ConsolidatedStatementsOfOperations" />
  <link:roleRef roleURI="http://admabiologics.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="adma-20241231.xsd#ConsolidatedBalanceSheetsParenthetical" />
  <link:roleRef roleURI="http://admabiologics.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="adma-20241231.xsd#ConsolidatedBalanceSheets" />
  <link:roleRef roleURI="http://admabiologics.com/role/DocumentAndEntityInformation" xlink:type="simple" xlink:href="adma-20241231.xsd#DocumentAndEntityInformation" />
  <link:presentationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/DocumentAndEntityInformation">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="CoverAbstract" xlink:title="CoverAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentInformationTable" xlink:label="DocumentInformationTable" xlink:title="DocumentInformationTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis" xlink:label="CounterpartyNameAxis" xlink:title="CounterpartyNameAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="RepurchaseAgreementCounterpartyNameDomain" xlink:title="RepurchaseAgreementCounterpartyNameDomain" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_CohnReznickLLPMember" xlink:label="CohnReznickLLPMember" xlink:title="CohnReznickLLPMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RepurchaseAgreementCounterpartyNameDomain" xlink:to="CohnReznickLLPMember" xlink:title="presentation: RepurchaseAgreementCounterpartyNameDomain to CohnReznickLLPMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CounterpartyNameAxis" xlink:to="RepurchaseAgreementCounterpartyNameDomain" xlink:title="presentation: CounterpartyNameAxis to RepurchaseAgreementCounterpartyNameDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentInformationTable" xlink:to="CounterpartyNameAxis" xlink:title="presentation: DocumentInformationTable to CounterpartyNameAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentInformationLineItems" xlink:label="DocumentInformationLineItems" xlink:title="DocumentInformationLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="DocumentType" xlink:title="DocumentType" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentInformationLineItems" xlink:to="DocumentType" xlink:title="presentation: DocumentInformationLineItems to DocumentType" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="AmendmentFlag" xlink:title="AmendmentFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentInformationLineItems" xlink:to="AmendmentFlag" xlink:title="presentation: DocumentInformationLineItems to AmendmentFlag" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport" xlink:label="DocumentAnnualReport" xlink:title="DocumentAnnualReport" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentInformationLineItems" xlink:to="DocumentAnnualReport" xlink:title="presentation: DocumentInformationLineItems to DocumentAnnualReport" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="DocumentPeriodEndDate" xlink:title="DocumentPeriodEndDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentInformationLineItems" xlink:to="DocumentPeriodEndDate" xlink:title="presentation: DocumentInformationLineItems to DocumentPeriodEndDate" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate" xlink:label="CurrentFiscalYearEndDate" xlink:title="CurrentFiscalYearEndDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentInformationLineItems" xlink:to="CurrentFiscalYearEndDate" xlink:title="presentation: DocumentInformationLineItems to CurrentFiscalYearEndDate" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="DocumentFiscalYearFocus" xlink:title="DocumentFiscalYearFocus" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentInformationLineItems" xlink:to="DocumentFiscalYearFocus" xlink:title="presentation: DocumentInformationLineItems to DocumentFiscalYearFocus" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="DocumentFiscalPeriodFocus" xlink:title="DocumentFiscalPeriodFocus" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentInformationLineItems" xlink:to="DocumentFiscalPeriodFocus" xlink:title="presentation: DocumentInformationLineItems to DocumentFiscalPeriodFocus" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport" xlink:label="DocumentTransitionReport" xlink:title="DocumentTransitionReport" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentInformationLineItems" xlink:to="DocumentTransitionReport" xlink:title="presentation: DocumentInformationLineItems to DocumentTransitionReport" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="EntityFileNumber" xlink:title="EntityFileNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentInformationLineItems" xlink:to="EntityFileNumber" xlink:title="presentation: DocumentInformationLineItems to EntityFileNumber" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="EntityRegistrantName" xlink:title="EntityRegistrantName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentInformationLineItems" xlink:to="EntityRegistrantName" xlink:title="presentation: DocumentInformationLineItems to EntityRegistrantName" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="EntityCentralIndexKey" xlink:title="EntityCentralIndexKey" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentInformationLineItems" xlink:to="EntityCentralIndexKey" xlink:title="presentation: DocumentInformationLineItems to EntityCentralIndexKey" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="EntityIncorporationStateCountryCode" xlink:title="EntityIncorporationStateCountryCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentInformationLineItems" xlink:to="EntityIncorporationStateCountryCode" xlink:title="presentation: DocumentInformationLineItems to EntityIncorporationStateCountryCode" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="EntityTaxIdentificationNumber" xlink:title="EntityTaxIdentificationNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentInformationLineItems" xlink:to="EntityTaxIdentificationNumber" xlink:title="presentation: DocumentInformationLineItems to EntityTaxIdentificationNumber" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="EntityAddressAddressLine1" xlink:title="EntityAddressAddressLine1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentInformationLineItems" xlink:to="EntityAddressAddressLine1" xlink:title="presentation: DocumentInformationLineItems to EntityAddressAddressLine1" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="EntityAddressCityOrTown" xlink:title="EntityAddressCityOrTown" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentInformationLineItems" xlink:to="EntityAddressCityOrTown" xlink:title="presentation: DocumentInformationLineItems to EntityAddressCityOrTown" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="EntityAddressStateOrProvince" xlink:title="EntityAddressStateOrProvince" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentInformationLineItems" xlink:to="EntityAddressStateOrProvince" xlink:title="presentation: DocumentInformationLineItems to EntityAddressStateOrProvince" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="EntityAddressPostalZipCode" xlink:title="EntityAddressPostalZipCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentInformationLineItems" xlink:to="EntityAddressPostalZipCode" xlink:title="presentation: DocumentInformationLineItems to EntityAddressPostalZipCode" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="CityAreaCode" xlink:title="CityAreaCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentInformationLineItems" xlink:to="CityAreaCode" xlink:title="presentation: DocumentInformationLineItems to CityAreaCode" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="LocalPhoneNumber" xlink:title="LocalPhoneNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentInformationLineItems" xlink:to="LocalPhoneNumber" xlink:title="presentation: DocumentInformationLineItems to LocalPhoneNumber" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="Security12bTitle" xlink:title="Security12bTitle" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentInformationLineItems" xlink:to="Security12bTitle" xlink:title="presentation: DocumentInformationLineItems to Security12bTitle" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="TradingSymbol" xlink:title="TradingSymbol" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentInformationLineItems" xlink:to="TradingSymbol" xlink:title="presentation: DocumentInformationLineItems to TradingSymbol" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="SecurityExchangeName" xlink:title="SecurityExchangeName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentInformationLineItems" xlink:to="SecurityExchangeName" xlink:title="presentation: DocumentInformationLineItems to SecurityExchangeName" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="EntityWellKnownSeasonedIssuer" xlink:title="EntityWellKnownSeasonedIssuer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentInformationLineItems" xlink:to="EntityWellKnownSeasonedIssuer" xlink:title="presentation: DocumentInformationLineItems to EntityWellKnownSeasonedIssuer" order="22.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers" xlink:label="EntityVoluntaryFilers" xlink:title="EntityVoluntaryFilers" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentInformationLineItems" xlink:to="EntityVoluntaryFilers" xlink:title="presentation: DocumentInformationLineItems to EntityVoluntaryFilers" order="23.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus" xlink:label="EntityCurrentReportingStatus" xlink:title="EntityCurrentReportingStatus" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentInformationLineItems" xlink:to="EntityCurrentReportingStatus" xlink:title="presentation: DocumentInformationLineItems to EntityCurrentReportingStatus" order="24.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent" xlink:label="EntityInteractiveDataCurrent" xlink:title="EntityInteractiveDataCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentInformationLineItems" xlink:to="EntityInteractiveDataCurrent" xlink:title="presentation: DocumentInformationLineItems to EntityInteractiveDataCurrent" order="25.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="EntityFilerCategory" xlink:title="EntityFilerCategory" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentInformationLineItems" xlink:to="EntityFilerCategory" xlink:title="presentation: DocumentInformationLineItems to EntityFilerCategory" order="26.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="EntitySmallBusiness" xlink:title="EntitySmallBusiness" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentInformationLineItems" xlink:to="EntitySmallBusiness" xlink:title="presentation: DocumentInformationLineItems to EntitySmallBusiness" order="27.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="EntityEmergingGrowthCompany" xlink:title="EntityEmergingGrowthCompany" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentInformationLineItems" xlink:to="EntityEmergingGrowthCompany" xlink:title="presentation: DocumentInformationLineItems to EntityEmergingGrowthCompany" order="28.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="IcfrAuditorAttestationFlag" xlink:title="IcfrAuditorAttestationFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentInformationLineItems" xlink:to="IcfrAuditorAttestationFlag" xlink:title="presentation: DocumentInformationLineItems to IcfrAuditorAttestationFlag" order="29.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFinStmtErrorCorrectionFlag" xlink:label="DocumentFinStmtErrorCorrectionFlag" xlink:title="DocumentFinStmtErrorCorrectionFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentInformationLineItems" xlink:to="DocumentFinStmtErrorCorrectionFlag" xlink:title="presentation: DocumentInformationLineItems to DocumentFinStmtErrorCorrectionFlag" order="30.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany" xlink:label="EntityShellCompany" xlink:title="EntityShellCompany" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentInformationLineItems" xlink:to="EntityShellCompany" xlink:title="presentation: DocumentInformationLineItems to EntityShellCompany" order="31.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat" xlink:label="EntityPublicFloat" xlink:title="EntityPublicFloat" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentInformationLineItems" xlink:to="EntityPublicFloat" xlink:title="presentation: DocumentInformationLineItems to EntityPublicFloat" order="32.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="EntityCommonStockSharesOutstanding" xlink:title="EntityCommonStockSharesOutstanding" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentInformationLineItems" xlink:to="EntityCommonStockSharesOutstanding" xlink:title="presentation: DocumentInformationLineItems to EntityCommonStockSharesOutstanding" order="33.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorFirmId" xlink:label="AuditorFirmId" xlink:title="AuditorFirmId" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentInformationLineItems" xlink:to="AuditorFirmId" xlink:title="presentation: DocumentInformationLineItems to AuditorFirmId" order="34.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorName" xlink:label="AuditorName" xlink:title="AuditorName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentInformationLineItems" xlink:to="AuditorName" xlink:title="presentation: DocumentInformationLineItems to AuditorName" order="35.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorLocation" xlink:label="AuditorLocation" xlink:title="AuditorLocation" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentInformationLineItems" xlink:to="AuditorLocation" xlink:title="presentation: DocumentInformationLineItems to AuditorLocation" order="36.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentInformationTable" xlink:to="DocumentInformationLineItems" xlink:title="presentation: DocumentInformationTable to DocumentInformationLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="DocumentInformationTable" xlink:title="presentation: CoverAbstract to DocumentInformationTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/ConsolidatedBalanceSheets">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="StatementOfFinancialPositionAbstract" xlink:title="StatementOfFinancialPositionAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract" xlink:label="AssetsAbstract" xlink:title="AssetsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="AssetsCurrentAbstract" xlink:title="AssetsCurrentAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="CashAndCashEquivalentsAtCarryingValue" xlink:title="CashAndCashEquivalentsAtCarryingValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetsCurrentAbstract" xlink:to="CashAndCashEquivalentsAtCarryingValue" xlink:title="presentation: AssetsCurrentAbstract to CashAndCashEquivalentsAtCarryingValue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="AccountsReceivableNetCurrent" xlink:title="AccountsReceivableNetCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetsCurrentAbstract" xlink:to="AccountsReceivableNetCurrent" xlink:title="presentation: AssetsCurrentAbstract to AccountsReceivableNetCurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNet" xlink:label="InventoryNet" xlink:title="InventoryNet" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetsCurrentAbstract" xlink:to="InventoryNet" xlink:title="presentation: AssetsCurrentAbstract to InventoryNet" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="PrepaidExpenseAndOtherAssetsCurrent" xlink:title="PrepaidExpenseAndOtherAssetsCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetsCurrentAbstract" xlink:to="PrepaidExpenseAndOtherAssetsCurrent" xlink:title="presentation: AssetsCurrentAbstract to PrepaidExpenseAndOtherAssetsCurrent" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="AssetsCurrent" xlink:title="AssetsCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetsCurrentAbstract" xlink:to="AssetsCurrent" xlink:title="presentation: AssetsCurrentAbstract to AssetsCurrent" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetsAbstract" xlink:to="AssetsCurrentAbstract" xlink:title="presentation: AssetsAbstract to AssetsCurrentAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="PropertyPlantAndEquipmentNet" xlink:title="PropertyPlantAndEquipmentNet" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetsAbstract" xlink:to="PropertyPlantAndEquipmentNet" xlink:title="presentation: AssetsAbstract to PropertyPlantAndEquipmentNet" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="IntangibleAssetsNetExcludingGoodwill" xlink:title="IntangibleAssetsNetExcludingGoodwill" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetsAbstract" xlink:to="IntangibleAssetsNetExcludingGoodwill" xlink:title="presentation: AssetsAbstract to IntangibleAssetsNetExcludingGoodwill" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Goodwill" xlink:label="Goodwill" xlink:title="Goodwill" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetsAbstract" xlink:to="Goodwill" xlink:title="presentation: AssetsAbstract to Goodwill" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxAssetsNet" xlink:label="DeferredIncomeTaxAssetsNet" xlink:title="DeferredIncomeTaxAssetsNet" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetsAbstract" xlink:to="DeferredIncomeTaxAssetsNet" xlink:title="presentation: AssetsAbstract to DeferredIncomeTaxAssetsNet" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="OperatingLeaseRightOfUseAsset" xlink:title="OperatingLeaseRightOfUseAsset" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetsAbstract" xlink:to="OperatingLeaseRightOfUseAsset" xlink:title="presentation: AssetsAbstract to OperatingLeaseRightOfUseAsset" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_DepositsAndOtherNoncurrentAssets" xlink:label="DepositsAndOtherNoncurrentAssets" xlink:title="DepositsAndOtherNoncurrentAssets" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetsAbstract" xlink:to="DepositsAndOtherNoncurrentAssets" xlink:title="presentation: AssetsAbstract to DepositsAndOtherNoncurrentAssets" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="Assets" xlink:title="Assets" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetsAbstract" xlink:to="Assets" xlink:title="presentation: AssetsAbstract to Assets" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="AssetsAbstract" xlink:title="presentation: StatementOfFinancialPositionAbstract to AssetsAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="LiabilitiesAndStockholdersEquityAbstract" xlink:title="LiabilitiesAndStockholdersEquityAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="LiabilitiesCurrentAbstract" xlink:title="LiabilitiesCurrentAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="AccountsPayableCurrent" xlink:title="AccountsPayableCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesCurrentAbstract" xlink:to="AccountsPayableCurrent" xlink:title="presentation: LiabilitiesCurrentAbstract to AccountsPayableCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="AccruedLiabilitiesAndOtherLiabilities" xlink:title="AccruedLiabilitiesAndOtherLiabilities" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesCurrentAbstract" xlink:to="AccruedLiabilitiesAndOtherLiabilities" xlink:title="presentation: LiabilitiesCurrentAbstract to AccruedLiabilitiesAndOtherLiabilities" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="ContractWithCustomerLiabilityCurrent" xlink:title="ContractWithCustomerLiabilityCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesCurrentAbstract" xlink:to="ContractWithCustomerLiabilityCurrent" xlink:title="presentation: LiabilitiesCurrentAbstract to ContractWithCustomerLiabilityCurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="OperatingLeaseLiabilityCurrent" xlink:title="OperatingLeaseLiabilityCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesCurrentAbstract" xlink:to="OperatingLeaseLiabilityCurrent" xlink:title="presentation: LiabilitiesCurrentAbstract to OperatingLeaseLiabilityCurrent" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="LiabilitiesCurrent" xlink:title="LiabilitiesCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesCurrentAbstract" xlink:to="LiabilitiesCurrent" xlink:title="presentation: LiabilitiesCurrentAbstract to LiabilitiesCurrent" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesAndStockholdersEquityAbstract" xlink:to="LiabilitiesCurrentAbstract" xlink:title="presentation: LiabilitiesAndStockholdersEquityAbstract to LiabilitiesCurrentAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeniorLongTermNotes" xlink:label="SeniorLongTermNotes" xlink:title="SeniorLongTermNotes" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesAndStockholdersEquityAbstract" xlink:to="SeniorLongTermNotes" xlink:title="presentation: LiabilitiesAndStockholdersEquityAbstract to SeniorLongTermNotes" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="DeferredRevenueNoncurrent" xlink:title="DeferredRevenueNoncurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesAndStockholdersEquityAbstract" xlink:to="DeferredRevenueNoncurrent" xlink:title="presentation: LiabilitiesAndStockholdersEquityAbstract to DeferredRevenueNoncurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_LongTermLiabilityEndOfTermFeePayable" xlink:label="LongTermLiabilityEndOfTermFeePayable" xlink:title="LongTermLiabilityEndOfTermFeePayable" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesAndStockholdersEquityAbstract" xlink:to="LongTermLiabilityEndOfTermFeePayable" xlink:title="presentation: LiabilitiesAndStockholdersEquityAbstract to LongTermLiabilityEndOfTermFeePayable" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="OperatingLeaseLiabilityNoncurrent" xlink:title="OperatingLeaseLiabilityNoncurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesAndStockholdersEquityAbstract" xlink:to="OperatingLeaseLiabilityNoncurrent" xlink:title="presentation: LiabilitiesAndStockholdersEquityAbstract to OperatingLeaseLiabilityNoncurrent" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="OtherLiabilitiesNoncurrent" xlink:title="OtherLiabilitiesNoncurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesAndStockholdersEquityAbstract" xlink:to="OtherLiabilitiesNoncurrent" xlink:title="presentation: LiabilitiesAndStockholdersEquityAbstract to OtherLiabilitiesNoncurrent" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="Liabilities" xlink:title="Liabilities" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesAndStockholdersEquityAbstract" xlink:to="Liabilities" xlink:title="presentation: LiabilitiesAndStockholdersEquityAbstract to Liabilities" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="CommitmentsAndContingencies" xlink:title="CommitmentsAndContingencies" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesAndStockholdersEquityAbstract" xlink:to="CommitmentsAndContingencies" xlink:title="presentation: LiabilitiesAndStockholdersEquityAbstract to CommitmentsAndContingencies" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="StockholdersEquityAbstract" xlink:title="StockholdersEquityAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue" xlink:label="PreferredStockValue" xlink:title="PreferredStockValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityAbstract" xlink:to="PreferredStockValue" xlink:title="presentation: StockholdersEquityAbstract to PreferredStockValue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="CommonStockValue" xlink:title="CommonStockValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityAbstract" xlink:to="CommonStockValue" xlink:title="presentation: StockholdersEquityAbstract to CommonStockValue" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="AdditionalPaidInCapital" xlink:title="AdditionalPaidInCapital" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityAbstract" xlink:to="AdditionalPaidInCapital" xlink:title="presentation: StockholdersEquityAbstract to AdditionalPaidInCapital" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="RetainedEarningsAccumulatedDeficit" xlink:title="RetainedEarningsAccumulatedDeficit" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityAbstract" xlink:to="RetainedEarningsAccumulatedDeficit" xlink:title="presentation: StockholdersEquityAbstract to RetainedEarningsAccumulatedDeficit" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="StockholdersEquity" xlink:title="StockholdersEquity" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityAbstract" xlink:to="StockholdersEquity" xlink:title="presentation: StockholdersEquityAbstract to StockholdersEquity" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesAndStockholdersEquityAbstract" xlink:to="StockholdersEquityAbstract" xlink:title="presentation: LiabilitiesAndStockholdersEquityAbstract to StockholdersEquityAbstract" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="LiabilitiesAndStockholdersEquity" xlink:title="LiabilitiesAndStockholdersEquity" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiabilitiesAndStockholdersEquityAbstract" xlink:to="LiabilitiesAndStockholdersEquity" xlink:title="presentation: LiabilitiesAndStockholdersEquityAbstract to LiabilitiesAndStockholdersEquity" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="LiabilitiesAndStockholdersEquityAbstract" xlink:title="presentation: StatementOfFinancialPositionAbstract to LiabilitiesAndStockholdersEquityAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/ConsolidatedBalanceSheetsParenthetical">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="StatementOfFinancialPositionAbstract" xlink:title="StatementOfFinancialPositionAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="StockholdersEquityAbstract" xlink:title="StockholdersEquityAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="PreferredStockParOrStatedValuePerShare" xlink:title="PreferredStockParOrStatedValuePerShare" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityAbstract" xlink:to="PreferredStockParOrStatedValuePerShare" xlink:title="presentation: StockholdersEquityAbstract to PreferredStockParOrStatedValuePerShare" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="PreferredStockSharesAuthorized" xlink:title="PreferredStockSharesAuthorized" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityAbstract" xlink:to="PreferredStockSharesAuthorized" xlink:title="presentation: StockholdersEquityAbstract to PreferredStockSharesAuthorized" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="PreferredStockSharesIssued" xlink:title="PreferredStockSharesIssued" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityAbstract" xlink:to="PreferredStockSharesIssued" xlink:title="presentation: StockholdersEquityAbstract to PreferredStockSharesIssued" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="PreferredStockSharesOutstanding" xlink:title="PreferredStockSharesOutstanding" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityAbstract" xlink:to="PreferredStockSharesOutstanding" xlink:title="presentation: StockholdersEquityAbstract to PreferredStockSharesOutstanding" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="CommonStockParOrStatedValuePerShare" xlink:title="CommonStockParOrStatedValuePerShare" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityAbstract" xlink:to="CommonStockParOrStatedValuePerShare" xlink:title="presentation: StockholdersEquityAbstract to CommonStockParOrStatedValuePerShare" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="CommonStockSharesAuthorized" xlink:title="CommonStockSharesAuthorized" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityAbstract" xlink:to="CommonStockSharesAuthorized" xlink:title="presentation: StockholdersEquityAbstract to CommonStockSharesAuthorized" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="CommonStockSharesIssued" xlink:title="CommonStockSharesIssued" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityAbstract" xlink:to="CommonStockSharesIssued" xlink:title="presentation: StockholdersEquityAbstract to CommonStockSharesIssued" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="CommonStockSharesOutstanding" xlink:title="CommonStockSharesOutstanding" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityAbstract" xlink:to="CommonStockSharesOutstanding" xlink:title="presentation: StockholdersEquityAbstract to CommonStockSharesOutstanding" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="StockholdersEquityAbstract" xlink:title="presentation: StatementOfFinancialPositionAbstract to StockholdersEquityAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/ConsolidatedStatementsOfOperations">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract" xlink:label="IncomeStatementAbstract" xlink:title="IncomeStatementAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="RevenueFromContractWithCustomerExcludingAssessedTax" xlink:title="RevenueFromContractWithCustomerExcludingAssessedTax" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="RevenueFromContractWithCustomerExcludingAssessedTax" xlink:title="presentation: IncomeStatementAbstract to RevenueFromContractWithCustomerExcludingAssessedTax" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfRevenue" xlink:label="CostOfRevenue" xlink:title="CostOfRevenue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="CostOfRevenue" xlink:title="presentation: IncomeStatementAbstract to CostOfRevenue" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GrossProfit" xlink:label="GrossProfit" xlink:title="GrossProfit" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="GrossProfit" xlink:title="presentation: IncomeStatementAbstract to GrossProfit" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostsAndExpensesAbstract" xlink:label="CostsAndExpensesAbstract" xlink:title="CostsAndExpensesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="ResearchAndDevelopmentExpense" xlink:title="ResearchAndDevelopmentExpense" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CostsAndExpensesAbstract" xlink:to="ResearchAndDevelopmentExpense" xlink:title="presentation: CostsAndExpensesAbstract to ResearchAndDevelopmentExpense" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCostAndExpenseOperating" xlink:label="OtherCostAndExpenseOperating" xlink:title="OtherCostAndExpenseOperating" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CostsAndExpensesAbstract" xlink:to="OtherCostAndExpenseOperating" xlink:title="presentation: CostsAndExpensesAbstract to OtherCostAndExpenseOperating" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="AmortizationOfIntangibleAssets" xlink:title="AmortizationOfIntangibleAssets" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CostsAndExpensesAbstract" xlink:to="AmortizationOfIntangibleAssets" xlink:title="presentation: CostsAndExpensesAbstract to AmortizationOfIntangibleAssets" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="SellingGeneralAndAdministrativeExpense" xlink:title="SellingGeneralAndAdministrativeExpense" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CostsAndExpensesAbstract" xlink:to="SellingGeneralAndAdministrativeExpense" xlink:title="presentation: CostsAndExpensesAbstract to SellingGeneralAndAdministrativeExpense" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="OperatingExpenses" xlink:title="OperatingExpenses" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CostsAndExpensesAbstract" xlink:to="OperatingExpenses" xlink:title="presentation: CostsAndExpensesAbstract to OperatingExpenses" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="CostsAndExpensesAbstract" xlink:title="presentation: IncomeStatementAbstract to CostsAndExpensesAbstract" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="OperatingIncomeLoss" xlink:title="OperatingIncomeLoss" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="OperatingIncomeLoss" xlink:title="presentation: IncomeStatementAbstract to OperatingIncomeLoss" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="NonoperatingIncomeExpenseAbstract" xlink:title="NonoperatingIncomeExpenseAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="InvestmentIncomeInterest" xlink:title="InvestmentIncomeInterest" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NonoperatingIncomeExpenseAbstract" xlink:to="InvestmentIncomeInterest" xlink:title="presentation: NonoperatingIncomeExpenseAbstract to InvestmentIncomeInterest" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseNonoperating" xlink:label="InterestExpenseNonoperating" xlink:title="InterestExpenseNonoperating" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NonoperatingIncomeExpenseAbstract" xlink:to="InterestExpenseNonoperating" xlink:title="presentation: NonoperatingIncomeExpenseAbstract to InterestExpenseNonoperating" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="GainsLossesOnExtinguishmentOfDebt" xlink:title="GainsLossesOnExtinguishmentOfDebt" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NonoperatingIncomeExpenseAbstract" xlink:to="GainsLossesOnExtinguishmentOfDebt" xlink:title="presentation: NonoperatingIncomeExpenseAbstract to GainsLossesOnExtinguishmentOfDebt" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="OtherNonoperatingIncomeExpense" xlink:title="OtherNonoperatingIncomeExpense" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NonoperatingIncomeExpenseAbstract" xlink:to="OtherNonoperatingIncomeExpense" xlink:title="presentation: NonoperatingIncomeExpenseAbstract to OtherNonoperatingIncomeExpense" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="NonoperatingIncomeExpense" xlink:title="NonoperatingIncomeExpense" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NonoperatingIncomeExpenseAbstract" xlink:to="NonoperatingIncomeExpense" xlink:title="presentation: NonoperatingIncomeExpenseAbstract to NonoperatingIncomeExpense" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="NonoperatingIncomeExpenseAbstract" xlink:title="presentation: IncomeStatementAbstract to NonoperatingIncomeExpenseAbstract" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:title="IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:title="presentation: IncomeStatementAbstract to IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="IncomeTaxExpenseBenefit" xlink:title="IncomeTaxExpenseBenefit" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="IncomeTaxExpenseBenefit" xlink:title="presentation: IncomeStatementAbstract to IncomeTaxExpenseBenefit" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="NetIncomeLoss" xlink:title="NetIncomeLoss" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="NetIncomeLoss" xlink:title="presentation: IncomeStatementAbstract to NetIncomeLoss" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic" xlink:label="EarningsPerShareBasic" xlink:title="EarningsPerShareBasic" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="EarningsPerShareBasic" xlink:title="presentation: IncomeStatementAbstract to EarningsPerShareBasic" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="EarningsPerShareDiluted" xlink:title="EarningsPerShareDiluted" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="EarningsPerShareDiluted" xlink:title="presentation: IncomeStatementAbstract to EarningsPerShareDiluted" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="WeightedAverageNumberOfSharesOutstandingAbstract" xlink:title="WeightedAverageNumberOfSharesOutstandingAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="WeightedAverageNumberOfSharesOutstandingBasic" xlink:title="WeightedAverageNumberOfSharesOutstandingBasic" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="WeightedAverageNumberOfSharesOutstandingBasic" xlink:title="presentation: WeightedAverageNumberOfSharesOutstandingAbstract to WeightedAverageNumberOfSharesOutstandingBasic" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="WeightedAverageNumberOfDilutedSharesOutstanding" xlink:title="WeightedAverageNumberOfDilutedSharesOutstanding" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="WeightedAverageNumberOfDilutedSharesOutstanding" xlink:title="presentation: WeightedAverageNumberOfSharesOutstandingAbstract to WeightedAverageNumberOfDilutedSharesOutstanding" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="WeightedAverageNumberOfSharesOutstandingAbstract" xlink:title="presentation: IncomeStatementAbstract to WeightedAverageNumberOfSharesOutstandingAbstract" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="StatementOfStockholdersEquityAbstract" xlink:title="StatementOfStockholdersEquityAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="StatementTable" xlink:title="StatementTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="StatementEquityComponentsAxis" xlink:title="StatementEquityComponentsAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="CommonStockMember" xlink:title="CommonStockMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementEquityComponentsAxis" xlink:to="CommonStockMember" xlink:title="presentation: StatementEquityComponentsAxis to CommonStockMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="AdditionalPaidInCapitalMember" xlink:title="AdditionalPaidInCapitalMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementEquityComponentsAxis" xlink:to="AdditionalPaidInCapitalMember" xlink:title="presentation: StatementEquityComponentsAxis to AdditionalPaidInCapitalMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="RetainedEarningsMember" xlink:title="RetainedEarningsMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementEquityComponentsAxis" xlink:to="RetainedEarningsMember" xlink:title="presentation: StatementEquityComponentsAxis to RetainedEarningsMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="EquityComponentDomain" xlink:title="EquityComponentDomain" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementEquityComponentsAxis" xlink:to="EquityComponentDomain" xlink:title="presentation: StatementEquityComponentsAxis to EquityComponentDomain" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementTable" xlink:to="StatementEquityComponentsAxis" xlink:title="presentation: StatementTable to StatementEquityComponentsAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="StatementLineItems" xlink:title="StatementLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="IncreaseDecreaseInStockholdersEquityRollForward" xlink:title="IncreaseDecreaseInStockholdersEquityRollForward" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="StockholdersEquity" xlink:title="StockholdersEquity" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="StockholdersEquity" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to StockholdersEquity" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="SharesOutstanding" xlink:title="SharesOutstanding" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="SharesOutstanding" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to SharesOutstanding" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:label="AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:title="AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="StockIssuedDuringPeriodValueNewIssues" xlink:title="StockIssuedDuringPeriodValueNewIssues" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="StockIssuedDuringPeriodValueNewIssues" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to StockIssuedDuringPeriodValueNewIssues" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="StockIssuedDuringPeriodSharesNewIssues" xlink:title="StockIssuedDuringPeriodSharesNewIssues" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="StockIssuedDuringPeriodSharesNewIssues" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to StockIssuedDuringPeriodSharesNewIssues" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAmount" xlink:label="VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAmount" xlink:title="VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAmount" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAmount" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAmount" order="5.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesShares" xlink:label="VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesShares" xlink:title="VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesShares" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesShares" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesShares" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:title="AdjustmentsToAdditionalPaidInCapitalWarrantIssued" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to AdjustmentsToAdditionalPaidInCapitalWarrantIssued" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="StockIssuedDuringPeriodValueStockOptionsExercised" xlink:title="StockIssuedDuringPeriodValueStockOptionsExercised" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="StockIssuedDuringPeriodValueStockOptionsExercised" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to StockIssuedDuringPeriodValueStockOptionsExercised" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:title="StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to StockIssuedDuringPeriodSharesStockOptionsExercised" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_StockIssuedDuringPeriodValueCashlessExerciseOfWarrants" xlink:label="StockIssuedDuringPeriodValueCashlessExerciseOfWarrants" xlink:title="StockIssuedDuringPeriodValueCashlessExerciseOfWarrants" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="StockIssuedDuringPeriodValueCashlessExerciseOfWarrants" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to StockIssuedDuringPeriodValueCashlessExerciseOfWarrants" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_StockIssuedDuringPeriodSharesCashlessExerciseOfWarrants" xlink:label="StockIssuedDuringPeriodSharesCashlessExerciseOfWarrants" xlink:title="StockIssuedDuringPeriodSharesCashlessExerciseOfWarrants" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="StockIssuedDuringPeriodSharesCashlessExerciseOfWarrants" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to StockIssuedDuringPeriodSharesCashlessExerciseOfWarrants" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="NetIncomeLoss" xlink:title="NetIncomeLoss" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="NetIncomeLoss" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to NetIncomeLoss" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="StockholdersEquity_2" xlink:title="StockholdersEquity" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="StockholdersEquity_2" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to StockholdersEquity" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="SharesOutstanding_2" xlink:title="SharesOutstanding" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="SharesOutstanding_2" xlink:title="presentation: IncreaseDecreaseInStockholdersEquityRollForward to SharesOutstanding" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementLineItems" xlink:to="IncreaseDecreaseInStockholdersEquityRollForward" xlink:title="presentation: StatementLineItems to IncreaseDecreaseInStockholdersEquityRollForward" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementTable" xlink:to="StatementLineItems" xlink:title="presentation: StatementTable to StatementLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfStockholdersEquityAbstract" xlink:to="StatementTable" xlink:title="presentation: StatementOfStockholdersEquityAbstract to StatementTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/ConsolidatedStatementsOfCashFlows">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="StatementOfCashFlowsAbstract" xlink:title="StatementOfCashFlowsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:title="NetCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="NetIncomeLoss" xlink:title="NetIncomeLoss" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="NetIncomeLoss" xlink:title="presentation: NetCashProvidedByUsedInOperatingActivitiesAbstract to NetIncomeLoss" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:title="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationAndAmortization" xlink:label="DepreciationAndAmortization" xlink:title="DepreciationAndAmortization" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="DepreciationAndAmortization" xlink:title="presentation: AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to DepreciationAndAmortization" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnDispositionOfAssets" xlink:label="GainLossOnDispositionOfAssets" xlink:title="GainLossOnDispositionOfAssets" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="GainLossOnDispositionOfAssets" xlink:title="presentation: AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to GainLossOnDispositionOfAssets" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:label="IncreaseDecreaseInDeferredIncomeTaxes" xlink:title="IncreaseDecreaseInDeferredIncomeTaxes" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="IncreaseDecreaseInDeferredIncomeTaxes" xlink:title="presentation: AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to IncreaseDecreaseInDeferredIncomeTaxes" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaidInKindInterest" xlink:label="PaidInKindInterest" xlink:title="PaidInKindInterest" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="PaidInKindInterest" xlink:title="presentation: AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to PaidInKindInterest" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="ShareBasedCompensation" xlink:title="ShareBasedCompensation" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="ShareBasedCompensation" xlink:title="presentation: AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to ShareBasedCompensation" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="AmortizationOfDebtDiscountPremium" xlink:title="AmortizationOfDebtDiscountPremium" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="AmortizationOfDebtDiscountPremium" xlink:title="presentation: AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to AmortizationOfDebtDiscountPremium" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="GainsLossesOnExtinguishmentOfDebt" xlink:title="GainsLossesOnExtinguishmentOfDebt" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="GainsLossesOnExtinguishmentOfDebt" xlink:title="presentation: AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to GainsLossesOnExtinguishmentOfDebt" order="6.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_AmortizationOfLicenseRevenue" xlink:label="AmortizationOfLicenseRevenue" xlink:title="AmortizationOfLicenseRevenue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="AmortizationOfLicenseRevenue" xlink:title="presentation: AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract to AmortizationOfLicenseRevenue" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:title="presentation: NetCashProvidedByUsedInOperatingActivitiesAbstract to AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="IncreaseDecreaseInOperatingCapitalAbstract" xlink:title="IncreaseDecreaseInOperatingCapitalAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="IncreaseDecreaseInAccountsReceivable" xlink:title="IncreaseDecreaseInAccountsReceivable" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="IncreaseDecreaseInAccountsReceivable" xlink:title="presentation: IncreaseDecreaseInOperatingCapitalAbstract to IncreaseDecreaseInAccountsReceivable" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="IncreaseDecreaseInInventories" xlink:title="IncreaseDecreaseInInventories" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="IncreaseDecreaseInInventories" xlink:title="presentation: IncreaseDecreaseInOperatingCapitalAbstract to IncreaseDecreaseInInventories" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:title="IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:title="presentation: IncreaseDecreaseInOperatingCapitalAbstract to IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_IncreaseDecreaseInDepositsAndOtherAssets" xlink:label="IncreaseDecreaseInDepositsAndOtherAssets" xlink:title="IncreaseDecreaseInDepositsAndOtherAssets" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="IncreaseDecreaseInDepositsAndOtherAssets" xlink:title="presentation: IncreaseDecreaseInOperatingCapitalAbstract to IncreaseDecreaseInDepositsAndOtherAssets" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="IncreaseDecreaseInAccountsPayable" xlink:title="IncreaseDecreaseInAccountsPayable" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="IncreaseDecreaseInAccountsPayable" xlink:title="presentation: IncreaseDecreaseInOperatingCapitalAbstract to IncreaseDecreaseInAccountsPayable" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="IncreaseDecreaseInAccruedLiabilities" xlink:title="IncreaseDecreaseInAccruedLiabilities" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="IncreaseDecreaseInAccruedLiabilities" xlink:title="presentation: IncreaseDecreaseInOperatingCapitalAbstract to IncreaseDecreaseInAccruedLiabilities" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:label="IncreaseDecreaseInOtherOperatingLiabilities" xlink:title="IncreaseDecreaseInOtherOperatingLiabilities" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="IncreaseDecreaseInOtherOperatingLiabilities" xlink:title="presentation: IncreaseDecreaseInOperatingCapitalAbstract to IncreaseDecreaseInOtherOperatingLiabilities" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="IncreaseDecreaseInOperatingCapitalAbstract" xlink:title="presentation: NetCashProvidedByUsedInOperatingActivitiesAbstract to IncreaseDecreaseInOperatingCapitalAbstract" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="NetCashProvidedByUsedInOperatingActivities" xlink:title="NetCashProvidedByUsedInOperatingActivities" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="NetCashProvidedByUsedInOperatingActivities" xlink:title="presentation: NetCashProvidedByUsedInOperatingActivitiesAbstract to NetCashProvidedByUsedInOperatingActivities" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:title="presentation: StatementOfCashFlowsAbstract to NetCashProvidedByUsedInOperatingActivitiesAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:title="NetCashProvidedByUsedInInvestingActivitiesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="PaymentsToAcquirePropertyPlantAndEquipment" xlink:title="PaymentsToAcquirePropertyPlantAndEquipment" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="PaymentsToAcquirePropertyPlantAndEquipment" xlink:title="presentation: NetCashProvidedByUsedInInvestingActivitiesAbstract to PaymentsToAcquirePropertyPlantAndEquipment" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="PaymentsToAcquireIntangibleAssets" xlink:title="PaymentsToAcquireIntangibleAssets" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="PaymentsToAcquireIntangibleAssets" xlink:title="presentation: NetCashProvidedByUsedInInvestingActivitiesAbstract to PaymentsToAcquireIntangibleAssets" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="NetCashProvidedByUsedInInvestingActivities" xlink:title="NetCashProvidedByUsedInInvestingActivities" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="NetCashProvidedByUsedInInvestingActivities" xlink:title="presentation: NetCashProvidedByUsedInInvestingActivitiesAbstract to NetCashProvidedByUsedInInvestingActivities" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:title="presentation: StatementOfCashFlowsAbstract to NetCashProvidedByUsedInInvestingActivitiesAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:title="NetCashProvidedByUsedInFinancingActivitiesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="RepaymentsOfNotesPayable" xlink:title="RepaymentsOfNotesPayable" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="RepaymentsOfNotesPayable" xlink:title="presentation: NetCashProvidedByUsedInFinancingActivitiesAbstract to RepaymentsOfNotesPayable" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="ProceedsFromIssuanceOfCommonStock" xlink:title="ProceedsFromIssuanceOfCommonStock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="ProceedsFromIssuanceOfCommonStock" xlink:title="presentation: NetCashProvidedByUsedInFinancingActivitiesAbstract to ProceedsFromIssuanceOfCommonStock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_PaymentOfDebtRefinancingFees" xlink:label="PaymentOfDebtRefinancingFees" xlink:title="PaymentOfDebtRefinancingFees" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="PaymentOfDebtRefinancingFees" xlink:title="presentation: NetCashProvidedByUsedInFinancingActivitiesAbstract to PaymentOfDebtRefinancingFees" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="ProceedsFromNotesPayable" xlink:title="ProceedsFromNotesPayable" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="ProceedsFromNotesPayable" xlink:title="presentation: NetCashProvidedByUsedInFinancingActivitiesAbstract to ProceedsFromNotesPayable" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_TaxesPaidOnVestedRestrictedStockUnits" xlink:label="TaxesPaidOnVestedRestrictedStockUnits" xlink:title="TaxesPaidOnVestedRestrictedStockUnits" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="TaxesPaidOnVestedRestrictedStockUnits" xlink:title="presentation: NetCashProvidedByUsedInFinancingActivitiesAbstract to TaxesPaidOnVestedRestrictedStockUnits" order="4.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinanceLeasePrincipalPayments" xlink:label="FinanceLeasePrincipalPayments" xlink:title="FinanceLeasePrincipalPayments" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="FinanceLeasePrincipalPayments" xlink:title="presentation: NetCashProvidedByUsedInFinancingActivitiesAbstract to FinanceLeasePrincipalPayments" order="5.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="ProceedsFromStockOptionsExercised" xlink:title="ProceedsFromStockOptionsExercised" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="ProceedsFromStockOptionsExercised" xlink:title="presentation: NetCashProvidedByUsedInFinancingActivitiesAbstract to ProceedsFromStockOptionsExercised" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_PaymentOfEndOfTermFee" xlink:label="PaymentOfEndOfTermFee" xlink:title="PaymentOfEndOfTermFee" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="PaymentOfEndOfTermFee" xlink:title="presentation: NetCashProvidedByUsedInFinancingActivitiesAbstract to PaymentOfEndOfTermFee" order="7.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfFinancingCosts" xlink:label="PaymentsOfFinancingCosts" xlink:title="PaymentsOfFinancingCosts" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="PaymentsOfFinancingCosts" xlink:title="presentation: NetCashProvidedByUsedInFinancingActivitiesAbstract to PaymentsOfFinancingCosts" order="8.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="NetCashProvidedByUsedInFinancingActivities" xlink:title="NetCashProvidedByUsedInFinancingActivities" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="NetCashProvidedByUsedInFinancingActivities" xlink:title="presentation: NetCashProvidedByUsedInFinancingActivitiesAbstract to NetCashProvidedByUsedInFinancingActivities" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:title="presentation: StatementOfCashFlowsAbstract to NetCashProvidedByUsedInFinancingActivitiesAbstract" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:title="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:title="presentation: StatementOfCashFlowsAbstract to CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:title="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:title="presentation: StatementOfCashFlowsAbstract to CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2" xlink:title="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2" xlink:title="presentation: StatementOfCashFlowsAbstract to CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/OrganizationAndBusiness">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:title="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:title="OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:title="presentation: OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract to OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/SignificantAccountingPolicies">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="AccountingPoliciesAbstract" xlink:title="AccountingPoliciesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="SignificantAccountingPoliciesTextBlock" xlink:title="SignificantAccountingPoliciesTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="SignificantAccountingPoliciesTextBlock" xlink:title="presentation: AccountingPoliciesAbstract to SignificantAccountingPoliciesTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/Inventories">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="InventoryDisclosureAbstract" xlink:title="InventoryDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="InventoryDisclosureTextBlock" xlink:title="InventoryDisclosureTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InventoryDisclosureAbstract" xlink:to="InventoryDisclosureTextBlock" xlink:title="presentation: InventoryDisclosureAbstract to InventoryDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/PropertyAndEquipment">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="PropertyPlantAndEquipmentAbstract" xlink:title="PropertyPlantAndEquipmentAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="PropertyPlantAndEquipmentDisclosureTextBlock" xlink:title="PropertyPlantAndEquipmentDisclosureTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentAbstract" xlink:to="PropertyPlantAndEquipmentDisclosureTextBlock" xlink:title="presentation: PropertyPlantAndEquipmentAbstract to PropertyPlantAndEquipmentDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/IntangibleAssets">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:title="GoodwillAndIntangibleAssetsDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:label="IntangibleAssetsDisclosureTextBlock" xlink:title="IntangibleAssetsDisclosureTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="IntangibleAssetsDisclosureTextBlock" xlink:title="presentation: GoodwillAndIntangibleAssetsDisclosureAbstract to IntangibleAssetsDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/AccruedExpensesAndOtherLiabilities">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="PayablesAndAccrualsAbstract" xlink:title="PayablesAndAccrualsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:title="AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PayablesAndAccrualsAbstract" xlink:to="AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:title="presentation: PayablesAndAccrualsAbstract to AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/NotesPayable">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="DebtDisclosureAbstract" xlink:title="DebtDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtTextBlock" xlink:label="LongTermDebtTextBlock" xlink:title="LongTermDebtTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtDisclosureAbstract" xlink:to="LongTermDebtTextBlock" xlink:title="presentation: DebtDisclosureAbstract to LongTermDebtTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/StockholdersEquity">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="EquityAbstract" xlink:title="EquityAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="StockholdersEquityNoteDisclosureTextBlock" xlink:title="StockholdersEquityNoteDisclosureTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityAbstract" xlink:to="StockholdersEquityNoteDisclosureTextBlock" xlink:title="presentation: EquityAbstract to StockholdersEquityNoteDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/RelatedPartyTransactions">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="RelatedPartyTransactionsAbstract" xlink:title="RelatedPartyTransactionsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="RelatedPartyTransactionsDisclosureTextBlock" xlink:title="RelatedPartyTransactionsDisclosureTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsAbstract" xlink:to="RelatedPartyTransactionsDisclosureTextBlock" xlink:title="presentation: RelatedPartyTransactionsAbstract to RelatedPartyTransactionsDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/CommitmentsAndContingencies">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="CommitmentsAndContingenciesDisclosureAbstract" xlink:title="CommitmentsAndContingenciesDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="CommitmentsAndContingenciesDisclosureTextBlock" xlink:title="CommitmentsAndContingenciesDisclosureTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsAndContingenciesDisclosureAbstract" xlink:to="CommitmentsAndContingenciesDisclosureTextBlock" xlink:title="presentation: CommitmentsAndContingenciesDisclosureAbstract to CommitmentsAndContingenciesDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/IncomeTaxes">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="IncomeTaxDisclosureAbstract" xlink:title="IncomeTaxDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="IncomeTaxDisclosureTextBlock" xlink:title="IncomeTaxDisclosureTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="IncomeTaxDisclosureTextBlock" xlink:title="presentation: IncomeTaxDisclosureAbstract to IncomeTaxDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/LeaseObligations">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract" xlink:label="LeasesAbstract" xlink:title="LeasesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="LesseeOperatingLeasesTextBlock" xlink:title="LesseeOperatingLeasesTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesAbstract" xlink:to="LesseeOperatingLeasesTextBlock" xlink:title="presentation: LeasesAbstract to LesseeOperatingLeasesTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/Segments">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract" xlink:label="SegmentReportingAbstract" xlink:title="SegmentReportingAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="SegmentReportingDisclosureTextBlock" xlink:title="SegmentReportingDisclosureTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SegmentReportingAbstract" xlink:to="SegmentReportingDisclosureTextBlock" xlink:title="presentation: SegmentReportingAbstract to SegmentReportingDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/OtherEmployeeBenefits">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="CompensationAndRetirementDisclosureAbstract" xlink:title="CompensationAndRetirementDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:label="PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:title="PensionAndOtherPostretirementBenefitsDisclosureTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CompensationAndRetirementDisclosureAbstract" xlink:to="PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:title="presentation: CompensationAndRetirementDisclosureAbstract to PensionAndOtherPostretirementBenefitsDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/SupplementalDisclosureOfCashFlowInformation">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowElementsAbstract" xlink:label="SupplementalCashFlowElementsAbstract" xlink:title="SupplementalCashFlowElementsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashFlowSupplementalDisclosuresTextBlock" xlink:label="CashFlowSupplementalDisclosuresTextBlock" xlink:title="CashFlowSupplementalDisclosuresTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SupplementalCashFlowElementsAbstract" xlink:to="CashFlowSupplementalDisclosuresTextBlock" xlink:title="presentation: SupplementalCashFlowElementsAbstract to CashFlowSupplementalDisclosuresTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/Concentrations">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRisksTypesNoConcentrationPercentageAbstract" xlink:label="ConcentrationRisksTypesNoConcentrationPercentageAbstract" xlink:title="ConcentrationRisksTypesNoConcentrationPercentageAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskDisclosureTextBlock" xlink:label="ConcentrationRiskDisclosureTextBlock" xlink:title="ConcentrationRiskDisclosureTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConcentrationRisksTypesNoConcentrationPercentageAbstract" xlink:to="ConcentrationRiskDisclosureTextBlock" xlink:title="presentation: ConcentrationRisksTypesNoConcentrationPercentageAbstract to ConcentrationRiskDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/ScheduleIiValuationAndQualifyingAccounts">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ValuationAndQualifyingAccountsAbstract" xlink:label="ValuationAndQualifyingAccountsAbstract" xlink:title="ValuationAndQualifyingAccountsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock" xlink:label="ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock" xlink:title="ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ValuationAndQualifyingAccountsAbstract" xlink:to="ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock" xlink:title="presentation: ValuationAndQualifyingAccountsAbstract to ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/CybersecurityRiskManagementAndStrategyDisclosure">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:label="CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:title="CybersecurityRiskManagementStrategyAndGovernanceAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:label="CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:title="CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedFlag" xlink:label="CybersecurityRiskManagementProcessesIntegratedFlag" xlink:title="CybersecurityRiskManagementProcessesIntegratedFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="CybersecurityRiskManagementProcessesIntegratedFlag" xlink:title="presentation: CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock to CybersecurityRiskManagementProcessesIntegratedFlag" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock" xlink:label="CybersecurityRiskManagementProcessesIntegratedTextBlock" xlink:title="CybersecurityRiskManagementProcessesIntegratedTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="CybersecurityRiskManagementProcessesIntegratedTextBlock" xlink:title="presentation: CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock to CybersecurityRiskManagementProcessesIntegratedTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementThirdPartyEngagedFlag" xlink:label="CybersecurityRiskManagementThirdPartyEngagedFlag" xlink:title="CybersecurityRiskManagementThirdPartyEngagedFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="CybersecurityRiskManagementThirdPartyEngagedFlag" xlink:title="presentation: CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock to CybersecurityRiskManagementThirdPartyEngagedFlag" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" xlink:label="CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" xlink:title="CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" xlink:title="presentation: CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock to CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" xlink:label="CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" xlink:title="CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" xlink:title="presentation: CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock to CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" xlink:label="CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" xlink:title="CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:to="CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" xlink:title="presentation: CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock to CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:to="CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" xlink:title="presentation: CybersecurityRiskManagementStrategyAndGovernanceAbstract to CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:label="CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:title="CybersecurityRiskBoardOfDirectorsOversightTextBlock" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:label="CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:title="CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:title="presentation: CybersecurityRiskBoardOfDirectorsOversightTextBlock to CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:label="CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:title="CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" xlink:title="presentation: CybersecurityRiskBoardOfDirectorsOversightTextBlock to CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskRoleOfManagementTextBlock" xlink:label="CybersecurityRiskRoleOfManagementTextBlock" xlink:title="CybersecurityRiskRoleOfManagementTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="CybersecurityRiskRoleOfManagementTextBlock" xlink:title="presentation: CybersecurityRiskBoardOfDirectorsOversightTextBlock to CybersecurityRiskRoleOfManagementTextBlock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" xlink:label="CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" xlink:title="CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" xlink:title="presentation: CybersecurityRiskBoardOfDirectorsOversightTextBlock to CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" xlink:label="CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" xlink:title="CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" xlink:title="presentation: CybersecurityRiskBoardOfDirectorsOversightTextBlock to CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" xlink:label="CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" xlink:title="CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" xlink:title="presentation: CybersecurityRiskBoardOfDirectorsOversightTextBlock to CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" xlink:label="CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" xlink:title="CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" xlink:title="presentation: CybersecurityRiskBoardOfDirectorsOversightTextBlock to CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd#cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" xlink:label="CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" xlink:title="CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:to="CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" xlink:title="presentation: CybersecurityRiskBoardOfDirectorsOversightTextBlock to CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CybersecurityRiskManagementStrategyAndGovernanceAbstract" xlink:to="CybersecurityRiskBoardOfDirectorsOversightTextBlock" xlink:title="presentation: CybersecurityRiskManagementStrategyAndGovernanceAbstract to CybersecurityRiskBoardOfDirectorsOversightTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/InsiderTradingArrangements">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTradingArrLineItems" xlink:label="InsiderTradingArrLineItems" xlink:title="InsiderTradingArrLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TradingArrByIndTable" xlink:label="TradingArrByIndTable" xlink:title="TradingArrByIndTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TradingArrAxis" xlink:label="TradingArrAxis" xlink:title="TradingArrAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllTradingArrangementsMember" xlink:label="AllTradingArrangementsMember" xlink:title="AllTradingArrangementsMember" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_AdamGrossmanTradingPlanCommonStockMember" xlink:label="AdamGrossmanTradingPlanCommonStockMember" xlink:title="AdamGrossmanTradingPlanCommonStockMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AllTradingArrangementsMember" xlink:to="AdamGrossmanTradingPlanCommonStockMember" xlink:title="presentation: AllTradingArrangementsMember to AdamGrossmanTradingPlanCommonStockMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_AdamGrossmanTradingPlanStockOptionsMember" xlink:label="AdamGrossmanTradingPlanStockOptionsMember" xlink:title="AdamGrossmanTradingPlanStockOptionsMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AllTradingArrangementsMember" xlink:to="AdamGrossmanTradingPlanStockOptionsMember" xlink:title="presentation: AllTradingArrangementsMember to AdamGrossmanTradingPlanStockOptionsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TradingArrAxis" xlink:to="AllTradingArrangementsMember" xlink:title="presentation: TradingArrAxis to AllTradingArrangementsMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TradingArrByIndTable" xlink:to="TradingArrAxis" xlink:title="presentation: TradingArrByIndTable to TradingArrAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis" xlink:label="IndividualAxis" xlink:title="IndividualAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember" xlink:label="AllIndividualsMember" xlink:title="AllIndividualsMember" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_AdamGrossmanMember" xlink:label="AdamGrossmanMember" xlink:title="AdamGrossmanMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AllIndividualsMember" xlink:to="AdamGrossmanMember" xlink:title="presentation: AllIndividualsMember to AdamGrossmanMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IndividualAxis" xlink:to="AllIndividualsMember" xlink:title="presentation: IndividualAxis to AllIndividualsMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TradingArrByIndTable" xlink:to="IndividualAxis" xlink:title="presentation: TradingArrByIndTable to IndividualAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InsiderTradingArrLineItems" xlink:to="TradingArrByIndTable" xlink:title="presentation: InsiderTradingArrLineItems to TradingArrByIndTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrAdoptedFlag" xlink:label="Rule10b51ArrAdoptedFlag" xlink:title="Rule10b51ArrAdoptedFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InsiderTradingArrLineItems" xlink:to="Rule10b51ArrAdoptedFlag" xlink:title="presentation: InsiderTradingArrLineItems to Rule10b51ArrAdoptedFlag" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrTrmntdFlag" xlink:label="Rule10b51ArrTrmntdFlag" xlink:title="Rule10b51ArrTrmntdFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InsiderTradingArrLineItems" xlink:to="Rule10b51ArrTrmntdFlag" xlink:title="presentation: InsiderTradingArrLineItems to Rule10b51ArrTrmntdFlag" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrAdoptedFlag" xlink:label="NonRule10b51ArrAdoptedFlag" xlink:title="NonRule10b51ArrAdoptedFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InsiderTradingArrLineItems" xlink:to="NonRule10b51ArrAdoptedFlag" xlink:title="presentation: InsiderTradingArrLineItems to NonRule10b51ArrAdoptedFlag" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrTrmntdFlag" xlink:label="NonRule10b51ArrTrmntdFlag" xlink:title="NonRule10b51ArrTrmntdFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InsiderTradingArrLineItems" xlink:to="NonRule10b51ArrTrmntdFlag" xlink:title="presentation: InsiderTradingArrLineItems to NonRule10b51ArrTrmntdFlag" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MtrlTermsOfTrdArrTextBlock" xlink:label="MtrlTermsOfTrdArrTextBlock" xlink:title="MtrlTermsOfTrdArrTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InsiderTradingArrLineItems" xlink:to="MtrlTermsOfTrdArrTextBlock" xlink:title="presentation: InsiderTradingArrLineItems to MtrlTermsOfTrdArrTextBlock" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrIndName" xlink:label="TrdArrIndName" xlink:title="TrdArrIndName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InsiderTradingArrLineItems" xlink:to="TrdArrIndName" xlink:title="presentation: InsiderTradingArrLineItems to TrdArrIndName" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrIndTitle" xlink:label="TrdArrIndTitle" xlink:title="TrdArrIndTitle" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InsiderTradingArrLineItems" xlink:to="TrdArrIndTitle" xlink:title="presentation: InsiderTradingArrLineItems to TrdArrIndTitle" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrAdoptionDate" xlink:label="TrdArrAdoptionDate" xlink:title="TrdArrAdoptionDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InsiderTradingArrLineItems" xlink:to="TrdArrAdoptionDate" xlink:title="presentation: InsiderTradingArrLineItems to TrdArrAdoptionDate" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrExpirationDate" xlink:label="TrdArrExpirationDate" xlink:title="TrdArrExpirationDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InsiderTradingArrLineItems" xlink:to="TrdArrExpirationDate" xlink:title="presentation: InsiderTradingArrLineItems to TrdArrExpirationDate" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrDuration" xlink:label="TrdArrDuration" xlink:title="TrdArrDuration" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InsiderTradingArrLineItems" xlink:to="TrdArrDuration" xlink:title="presentation: InsiderTradingArrLineItems to TrdArrDuration" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrSecuritiesAggAvailAmt" xlink:label="TrdArrSecuritiesAggAvailAmt" xlink:title="TrdArrSecuritiesAggAvailAmt" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InsiderTradingArrLineItems" xlink:to="TrdArrSecuritiesAggAvailAmt" xlink:title="presentation: InsiderTradingArrLineItems to TrdArrSecuritiesAggAvailAmt" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/SignificantAccountingPoliciesPolicies">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="AccountingPoliciesAbstract" xlink:title="AccountingPoliciesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:label="OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:title="OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" xlink:title="presentation: AccountingPoliciesAbstract to OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates" xlink:label="UseOfEstimates" xlink:title="UseOfEstimates" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="UseOfEstimates" xlink:title="presentation: AccountingPoliciesAbstract to UseOfEstimates" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="CashAndCashEquivalentsPolicyTextBlock" xlink:title="CashAndCashEquivalentsPolicyTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="CashAndCashEquivalentsPolicyTextBlock" xlink:title="presentation: AccountingPoliciesAbstract to CashAndCashEquivalentsPolicyTextBlock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReceivablesPolicyTextBlock" xlink:label="ReceivablesPolicyTextBlock" xlink:title="ReceivablesPolicyTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="ReceivablesPolicyTextBlock" xlink:title="presentation: AccountingPoliciesAbstract to ReceivablesPolicyTextBlock" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="InventoryPolicyTextBlock" xlink:title="InventoryPolicyTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="InventoryPolicyTextBlock" xlink:title="presentation: AccountingPoliciesAbstract to InventoryPolicyTextBlock" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="PropertyPlantAndEquipmentPolicyTextBlock" xlink:title="PropertyPlantAndEquipmentPolicyTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="PropertyPlantAndEquipmentPolicyTextBlock" xlink:title="presentation: AccountingPoliciesAbstract to PropertyPlantAndEquipmentPolicyTextBlock" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:label="GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:title="GoodwillAndIntangibleAssetsGoodwillPolicy" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:title="presentation: AccountingPoliciesAbstract to GoodwillAndIntangibleAssetsGoodwillPolicy" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" xlink:label="ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" xlink:title="ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" xlink:title="presentation: AccountingPoliciesAbstract to ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="RevenueRecognitionPolicyTextBlock" xlink:title="RevenueRecognitionPolicyTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="RevenueRecognitionPolicyTextBlock" xlink:title="presentation: AccountingPoliciesAbstract to RevenueRecognitionPolicyTextBlock" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfSalesPolicyTextBlock" xlink:label="CostOfSalesPolicyTextBlock" xlink:title="CostOfSalesPolicyTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="CostOfSalesPolicyTextBlock" xlink:title="presentation: AccountingPoliciesAbstract to CostOfSalesPolicyTextBlock" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="ResearchAndDevelopmentExpensePolicy" xlink:title="ResearchAndDevelopmentExpensePolicy" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="ResearchAndDevelopmentExpensePolicy" xlink:title="presentation: AccountingPoliciesAbstract to ResearchAndDevelopmentExpensePolicy" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_OtherOperatingExpensesPolicyTextBlock" xlink:label="OtherOperatingExpensesPolicyTextBlock" xlink:title="OtherOperatingExpensesPolicyTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="OtherOperatingExpensesPolicyTextBlock" xlink:title="presentation: AccountingPoliciesAbstract to OtherOperatingExpensesPolicyTextBlock" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdvertisingCostsPolicyTextBlock" xlink:label="AdvertisingCostsPolicyTextBlock" xlink:title="AdvertisingCostsPolicyTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="AdvertisingCostsPolicyTextBlock" xlink:title="presentation: AccountingPoliciesAbstract to AdvertisingCostsPolicyTextBlock" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:title="ShareBasedCompensationOptionAndIncentivePlansPolicy" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:title="presentation: AccountingPoliciesAbstract to ShareBasedCompensationOptionAndIncentivePlansPolicy" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="IncomeTaxPolicyTextBlock" xlink:title="IncomeTaxPolicyTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="IncomeTaxPolicyTextBlock" xlink:title="presentation: AccountingPoliciesAbstract to IncomeTaxPolicyTextBlock" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="EarningsPerSharePolicyTextBlock" xlink:title="EarningsPerSharePolicyTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="EarningsPerSharePolicyTextBlock" xlink:title="presentation: AccountingPoliciesAbstract to EarningsPerSharePolicyTextBlock" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="FairValueOfFinancialInstrumentsPolicy" xlink:title="FairValueOfFinancialInstrumentsPolicy" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="FairValueOfFinancialInstrumentsPolicy" xlink:title="presentation: AccountingPoliciesAbstract to FairValueOfFinancialInstrumentsPolicy" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:title="NewAccountingPronouncementsPolicyPolicyTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:title="presentation: AccountingPoliciesAbstract to NewAccountingPronouncementsPolicyPolicyTextBlock" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/SignificantAccountingPoliciesTables">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="AccountingPoliciesAbstract" xlink:title="AccountingPoliciesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:title="ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:title="presentation: AccountingPoliciesAbstract to ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:title="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:title="presentation: AccountingPoliciesAbstract to ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/InventoriesTables">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="InventoryDisclosureAbstract" xlink:title="InventoryDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="ScheduleOfInventoryCurrentTableTextBlock" xlink:title="ScheduleOfInventoryCurrentTableTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InventoryDisclosureAbstract" xlink:to="ScheduleOfInventoryCurrentTableTextBlock" xlink:title="presentation: InventoryDisclosureAbstract to ScheduleOfInventoryCurrentTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/PropertyAndEquipmentTables">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="PropertyPlantAndEquipmentAbstract" xlink:title="PropertyPlantAndEquipmentAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="PropertyPlantAndEquipmentTextBlock" xlink:title="PropertyPlantAndEquipmentTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentAbstract" xlink:to="PropertyPlantAndEquipmentTextBlock" xlink:title="presentation: PropertyPlantAndEquipmentAbstract to PropertyPlantAndEquipmentTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/IntangibleAssetsTables">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:title="GoodwillAndIntangibleAssetsDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:label="ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:title="ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:title="presentation: GoodwillAndIntangibleAssetsDisclosureAbstract to ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:label="ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:title="ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:title="presentation: GoodwillAndIntangibleAssetsDisclosureAbstract to ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/AccruedExpensesAndOtherLiabilitiesTables">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="PayablesAndAccrualsAbstract" xlink:title="PayablesAndAccrualsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:title="ScheduleOfAccruedLiabilitiesTableTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PayablesAndAccrualsAbstract" xlink:to="ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:title="presentation: PayablesAndAccrualsAbstract to ScheduleOfAccruedLiabilitiesTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/NotesPayableTables">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="DebtDisclosureAbstract" xlink:title="DebtDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDebtTableTextBlock" xlink:label="ScheduleOfDebtTableTextBlock" xlink:title="ScheduleOfDebtTableTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtDisclosureAbstract" xlink:to="ScheduleOfDebtTableTextBlock" xlink:title="presentation: DebtDisclosureAbstract to ScheduleOfDebtTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/StockholdersEquityTables">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="EquityAbstract" xlink:title="EquityAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:title="ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityAbstract" xlink:to="ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:title="presentation: EquityAbstract to ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:title="ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityAbstract" xlink:to="ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:title="presentation: EquityAbstract to ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:title="ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityAbstract" xlink:to="ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:title="presentation: EquityAbstract to ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:label="ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:title="ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityAbstract" xlink:to="ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:title="presentation: EquityAbstract to ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock" xlink:label="ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock" xlink:title="ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityAbstract" xlink:to="ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock" xlink:title="presentation: EquityAbstract to ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:label="ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:title="ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityAbstract" xlink:to="ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:title="presentation: EquityAbstract to ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/IncomeTaxesTables">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="IncomeTaxDisclosureAbstract" xlink:title="IncomeTaxDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:title="ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:title="presentation: IncomeTaxDisclosureAbstract to ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:title="ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:title="presentation: IncomeTaxDisclosureAbstract to ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:title="ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:title="presentation: IncomeTaxDisclosureAbstract to ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock" xlink:label="SummaryOfOperatingLossCarryforwardsTextBlock" xlink:title="SummaryOfOperatingLossCarryforwardsTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="SummaryOfOperatingLossCarryforwardsTextBlock" xlink:title="presentation: IncomeTaxDisclosureAbstract to SummaryOfOperatingLossCarryforwardsTextBlock" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/LeaseObligationsTables">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract" xlink:label="LeasesAbstract" xlink:title="LeasesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:title="LesseeOperatingLeaseLiabilityMaturityTableTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesAbstract" xlink:to="LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:title="presentation: LeasesAbstract to LesseeOperatingLeaseLiabilityMaturityTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/SegmentsTables">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract" xlink:label="SegmentReportingAbstract" xlink:title="SegmentReportingAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:label="ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:title="ScheduleOfSegmentReportingInformationBySegmentTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SegmentReportingAbstract" xlink:to="ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:title="presentation: SegmentReportingAbstract to ScheduleOfSegmentReportingInformationBySegmentTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:label="RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:title="RevenueFromExternalCustomersByGeographicAreasTableTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SegmentReportingAbstract" xlink:to="RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:title="presentation: SegmentReportingAbstract to RevenueFromExternalCustomersByGeographicAreasTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/SupplementalDisclosureOfCashFlowInformationTables">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowElementsAbstract" xlink:label="SupplementalCashFlowElementsAbstract" xlink:title="SupplementalCashFlowElementsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:label="ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:title="ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SupplementalCashFlowElementsAbstract" xlink:to="ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:title="presentation: SupplementalCashFlowElementsAbstract to ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/OrganizationAndBusinessDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:title="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquityAbstract" xlink:label="ProceedsFromIssuanceOrSaleOfEquityAbstract" xlink:title="ProceedsFromIssuanceOrSaleOfEquityAbstract" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_NumberOfFDALicensedPlasmaCollectionFacilities" xlink:label="NumberOfFDALicensedPlasmaCollectionFacilities" xlink:title="NumberOfFDALicensedPlasmaCollectionFacilities" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ProceedsFromIssuanceOrSaleOfEquityAbstract" xlink:to="NumberOfFDALicensedPlasmaCollectionFacilities" xlink:title="presentation: ProceedsFromIssuanceOrSaleOfEquityAbstract to NumberOfFDALicensedPlasmaCollectionFacilities" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_NumberOfFDAApprovedProduct" xlink:label="NumberOfFDAApprovedProduct" xlink:title="NumberOfFDAApprovedProduct" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ProceedsFromIssuanceOrSaleOfEquityAbstract" xlink:to="NumberOfFDAApprovedProduct" xlink:title="presentation: ProceedsFromIssuanceOrSaleOfEquityAbstract to NumberOfFDAApprovedProduct" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="ProceedsFromIssuanceOrSaleOfEquityAbstract" xlink:title="presentation: OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract to ProceedsFromIssuanceOrSaleOfEquityAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/SignificantAccountingPoliciesUseOfEstimatesDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="AccountingPoliciesAbstract" xlink:title="AccountingPoliciesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfChangeInAccountingEstimateTable" xlink:label="ScheduleOfChangeInAccountingEstimateTable" xlink:title="ScheduleOfChangeInAccountingEstimateTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ChangeInAccountingEstimateByTypeAxis" xlink:label="ChangeInAccountingEstimateByTypeAxis" xlink:title="ChangeInAccountingEstimateByTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ChangeInAccountingEstimateTypeDomain" xlink:label="ChangeInAccountingEstimateTypeDomain" xlink:title="ChangeInAccountingEstimateTypeDomain" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_AccrualForUSMedicaidRebatesMember" xlink:label="AccrualForUSMedicaidRebatesMember" xlink:title="AccrualForUSMedicaidRebatesMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ChangeInAccountingEstimateTypeDomain" xlink:to="AccrualForUSMedicaidRebatesMember" xlink:title="presentation: ChangeInAccountingEstimateTypeDomain to AccrualForUSMedicaidRebatesMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ChangeInAccountingEstimateByTypeAxis" xlink:to="ChangeInAccountingEstimateTypeDomain" xlink:title="presentation: ChangeInAccountingEstimateByTypeAxis to ChangeInAccountingEstimateTypeDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfChangeInAccountingEstimateTable" xlink:to="ChangeInAccountingEstimateByTypeAxis" xlink:title="presentation: ScheduleOfChangeInAccountingEstimateTable to ChangeInAccountingEstimateByTypeAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ChangeInAccountingEstimateLineItems" xlink:label="ChangeInAccountingEstimateLineItems" xlink:title="ChangeInAccountingEstimateLineItems" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_UseOfEstimatesAbstract" xlink:label="UseOfEstimatesAbstract" xlink:title="UseOfEstimatesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="RevenueFromContractWithCustomerExcludingAssessedTax" xlink:title="RevenueFromContractWithCustomerExcludingAssessedTax" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="UseOfEstimatesAbstract" xlink:to="RevenueFromContractWithCustomerExcludingAssessedTax" xlink:title="presentation: UseOfEstimatesAbstract to RevenueFromContractWithCustomerExcludingAssessedTax" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="AccruedLiabilitiesAndOtherLiabilities" xlink:title="AccruedLiabilitiesAndOtherLiabilities" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="UseOfEstimatesAbstract" xlink:to="AccruedLiabilitiesAndOtherLiabilities" xlink:title="presentation: UseOfEstimatesAbstract to AccruedLiabilitiesAndOtherLiabilities" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ChangeInAccountingEstimateLineItems" xlink:to="UseOfEstimatesAbstract" xlink:title="presentation: ChangeInAccountingEstimateLineItems to UseOfEstimatesAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfChangeInAccountingEstimateTable" xlink:to="ChangeInAccountingEstimateLineItems" xlink:title="presentation: ScheduleOfChangeInAccountingEstimateTable to ChangeInAccountingEstimateLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="ScheduleOfChangeInAccountingEstimateTable" xlink:title="presentation: AccountingPoliciesAbstract to ScheduleOfChangeInAccountingEstimateTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/SignificantAccountingPoliciesAccountsReceivableDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="AccountingPoliciesAbstract" xlink:title="AccountingPoliciesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetAbstract" xlink:label="AccountsReceivableNetAbstract" xlink:title="AccountsReceivableNetAbstract" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_AccountsReceivableAllowanceForContractualCreditsAndDoubtfulAccounts" xlink:label="AccountsReceivableAllowanceForContractualCreditsAndDoubtfulAccounts" xlink:title="AccountsReceivableAllowanceForContractualCreditsAndDoubtfulAccounts" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountsReceivableNetAbstract" xlink:to="AccountsReceivableAllowanceForContractualCreditsAndDoubtfulAccounts" xlink:title="presentation: AccountsReceivableNetAbstract to AccountsReceivableAllowanceForContractualCreditsAndDoubtfulAccounts" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="AccountsReceivableNetAbstract" xlink:title="presentation: AccountingPoliciesAbstract to AccountsReceivableNetAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/SignificantAccountingPoliciesPropertyAndEquipmentDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="AccountingPoliciesAbstract" xlink:title="AccountingPoliciesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="ScheduleOfPropertyPlantAndEquipmentTable" xlink:title="ScheduleOfPropertyPlantAndEquipmentTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="PropertyPlantAndEquipmentByTypeAxis" xlink:title="PropertyPlantAndEquipmentByTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="PropertyPlantAndEquipmentTypeDomain" xlink:title="PropertyPlantAndEquipmentTypeDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BuildingMember" xlink:label="BuildingMember" xlink:title="BuildingMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentTypeDomain" xlink:to="BuildingMember" xlink:title="presentation: PropertyPlantAndEquipmentTypeDomain to BuildingMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentByTypeAxis" xlink:to="PropertyPlantAndEquipmentTypeDomain" xlink:title="presentation: PropertyPlantAndEquipmentByTypeAxis to PropertyPlantAndEquipmentTypeDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="PropertyPlantAndEquipmentByTypeAxis" xlink:title="presentation: ScheduleOfPropertyPlantAndEquipmentTable to PropertyPlantAndEquipmentByTypeAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="RangeAxis" xlink:title="RangeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="RangeMember" xlink:title="RangeMember" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="MinimumMember" xlink:title="MinimumMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangeMember" xlink:to="MinimumMember" xlink:title="presentation: RangeMember to MinimumMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="MaximumMember" xlink:title="MaximumMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangeMember" xlink:to="MaximumMember" xlink:title="presentation: RangeMember to MaximumMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangeAxis" xlink:to="RangeMember" xlink:title="presentation: RangeAxis to RangeMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="RangeAxis" xlink:title="presentation: ScheduleOfPropertyPlantAndEquipmentTable to RangeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="PropertyPlantAndEquipmentLineItems" xlink:title="PropertyPlantAndEquipmentLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="PropertyPlantAndEquipmentAbstract" xlink:title="PropertyPlantAndEquipmentAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="PropertyPlantAndEquipmentUsefulLife" xlink:title="PropertyPlantAndEquipmentUsefulLife" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentAbstract" xlink:to="PropertyPlantAndEquipmentUsefulLife" xlink:title="presentation: PropertyPlantAndEquipmentAbstract to PropertyPlantAndEquipmentUsefulLife" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentLineItems" xlink:to="PropertyPlantAndEquipmentAbstract" xlink:title="presentation: PropertyPlantAndEquipmentLineItems to PropertyPlantAndEquipmentAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="PropertyPlantAndEquipmentLineItems" xlink:title="presentation: ScheduleOfPropertyPlantAndEquipmentTable to PropertyPlantAndEquipmentLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="ScheduleOfPropertyPlantAndEquipmentTable" xlink:title="presentation: AccountingPoliciesAbstract to ScheduleOfPropertyPlantAndEquipmentTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/SignificantAccountingPoliciesGoodwillDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="AccountingPoliciesAbstract" xlink:title="AccountingPoliciesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillImpairedAccumulatedImpairmentLossAbstract" xlink:label="GoodwillImpairedAccumulatedImpairmentLossAbstract" xlink:title="GoodwillImpairedAccumulatedImpairmentLossAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Goodwill" xlink:label="Goodwill" xlink:title="Goodwill" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GoodwillImpairedAccumulatedImpairmentLossAbstract" xlink:to="Goodwill" xlink:title="presentation: GoodwillImpairedAccumulatedImpairmentLossAbstract to Goodwill" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="GoodwillImpairmentLoss" xlink:title="GoodwillImpairmentLoss" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GoodwillImpairedAccumulatedImpairmentLossAbstract" xlink:to="GoodwillImpairmentLoss" xlink:title="presentation: GoodwillImpairedAccumulatedImpairmentLossAbstract to GoodwillImpairmentLoss" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="GoodwillImpairedAccumulatedImpairmentLossAbstract" xlink:title="presentation: AccountingPoliciesAbstract to GoodwillImpairedAccumulatedImpairmentLossAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/SignificantAccountingPoliciesImpairmentOfLonglivedAssetsDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="AccountingPoliciesAbstract" xlink:title="AccountingPoliciesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetImpairmentChargesAbstract" xlink:label="AssetImpairmentChargesAbstract" xlink:title="AssetImpairmentChargesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:label="ImpairmentOfLongLivedAssetsHeldForUse" xlink:title="ImpairmentOfLongLivedAssetsHeldForUse" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AssetImpairmentChargesAbstract" xlink:to="ImpairmentOfLongLivedAssetsHeldForUse" xlink:title="presentation: AssetImpairmentChargesAbstract to ImpairmentOfLongLivedAssetsHeldForUse" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="AssetImpairmentChargesAbstract" xlink:title="presentation: AccountingPoliciesAbstract to AssetImpairmentChargesAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/SignificantAccountingPoliciesRevenueRecognitionDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="AccountingPoliciesAbstract" xlink:title="AccountingPoliciesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:label="RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:title="RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="TypeOfArrangementAxis" xlink:title="TypeOfArrangementAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="ArrangementsAndNonarrangementTransactionsMember" xlink:title="ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_BiotestLicenseAgreementMember" xlink:label="BiotestLicenseAgreementMember" xlink:title="BiotestLicenseAgreementMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ArrangementsAndNonarrangementTransactionsMember" xlink:to="BiotestLicenseAgreementMember" xlink:title="presentation: ArrangementsAndNonarrangementTransactionsMember to BiotestLicenseAgreementMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TypeOfArrangementAxis" xlink:to="ArrangementsAndNonarrangementTransactionsMember" xlink:title="presentation: TypeOfArrangementAxis to ArrangementsAndNonarrangementTransactionsMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:to="TypeOfArrangementAxis" xlink:title="presentation: RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable to TypeOfArrangementAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:label="RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:title="RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="RevenueFromContractWithCustomerAbstract" xlink:title="RevenueFromContractWithCustomerAbstract" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_DeferredRevenueRemainingAmortizationPeriod" xlink:label="DeferredRevenueRemainingAmortizationPeriod" xlink:title="DeferredRevenueRemainingAmortizationPeriod" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RevenueFromContractWithCustomerAbstract" xlink:to="DeferredRevenueRemainingAmortizationPeriod" xlink:title="presentation: RevenueFromContractWithCustomerAbstract to DeferredRevenueRemainingAmortizationPeriod" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_CustomerPaymentTerms" xlink:label="CustomerPaymentTerms" xlink:title="CustomerPaymentTerms" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RevenueFromContractWithCustomerAbstract" xlink:to="CustomerPaymentTerms" xlink:title="presentation: RevenueFromContractWithCustomerAbstract to CustomerPaymentTerms" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:to="RevenueFromContractWithCustomerAbstract" xlink:title="presentation: RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems to RevenueFromContractWithCustomerAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:to="RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:title="presentation: RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable to RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:title="presentation: AccountingPoliciesAbstract to RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/SignificantAccountingPoliciesAdvertisingAndMarketingExpensesDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="AccountingPoliciesAbstract" xlink:title="AccountingPoliciesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketingAndAdvertisingExpenseAbstract" xlink:label="MarketingAndAdvertisingExpenseAbstract" xlink:title="MarketingAndAdvertisingExpenseAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketingAndAdvertisingExpense" xlink:label="MarketingAndAdvertisingExpense" xlink:title="MarketingAndAdvertisingExpense" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="MarketingAndAdvertisingExpenseAbstract" xlink:to="MarketingAndAdvertisingExpense" xlink:title="presentation: MarketingAndAdvertisingExpenseAbstract to MarketingAndAdvertisingExpense" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="MarketingAndAdvertisingExpenseAbstract" xlink:title="presentation: AccountingPoliciesAbstract to MarketingAndAdvertisingExpenseAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/SignificantAccountingPoliciesStockbasedCompensationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="AccountingPoliciesAbstract" xlink:title="AccountingPoliciesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="AwardTypeAxis" xlink:title="AwardTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="EmployeeStockOptionMember" xlink:title="EmployeeStockOptionMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="EmployeeStockOptionMember" xlink:title="presentation: ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain to EmployeeStockOptionMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="RestrictedStockUnitsRSUMember" xlink:title="RestrictedStockUnitsRSUMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="RestrictedStockUnitsRSUMember" xlink:title="presentation: ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain to RestrictedStockUnitsRSUMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AwardTypeAxis" xlink:to="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="presentation: AwardTypeAxis to ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="AwardTypeAxis" xlink:title="presentation: ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to AwardTypeAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationAbstract" xlink:label="ShareBasedCompensationAbstract" xlink:title="ShareBasedCompensationAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:title="presentation: ShareBasedCompensationAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:title="presentation: ShareBasedCompensationAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_NumberOfExecutiveOfficers" xlink:label="NumberOfExecutiveOfficers" xlink:title="NumberOfExecutiveOfficers" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationAbstract" xlink:to="NumberOfExecutiveOfficers" xlink:title="presentation: ShareBasedCompensationAbstract to NumberOfExecutiveOfficers" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationAbstract" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:title="presentation: ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="presentation: AccountingPoliciesAbstract to ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/SignificantAccountingPoliciesEarningsLossPerShareDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="AccountingPoliciesAbstract" xlink:title="AccountingPoliciesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:title="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:title="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="AntidilutiveSecuritiesNameDomain" xlink:title="AntidilutiveSecuritiesNameDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="EmployeeStockOptionMember" xlink:title="EmployeeStockOptionMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AntidilutiveSecuritiesNameDomain" xlink:to="EmployeeStockOptionMember" xlink:title="presentation: AntidilutiveSecuritiesNameDomain to EmployeeStockOptionMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="WarrantMember" xlink:title="WarrantMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AntidilutiveSecuritiesNameDomain" xlink:to="WarrantMember" xlink:title="presentation: AntidilutiveSecuritiesNameDomain to WarrantMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="RestrictedStockUnitsRSUMember" xlink:title="RestrictedStockUnitsRSUMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AntidilutiveSecuritiesNameDomain" xlink:to="RestrictedStockUnitsRSUMember" xlink:title="presentation: AntidilutiveSecuritiesNameDomain to RestrictedStockUnitsRSUMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="AntidilutiveSecuritiesNameDomain" xlink:title="presentation: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis to AntidilutiveSecuritiesNameDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:title="presentation: ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable to AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:title="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="EarningsPerShareAbstract" xlink:title="EarningsPerShareAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="NetIncomeLoss" xlink:title="NetIncomeLoss" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EarningsPerShareAbstract" xlink:to="NetIncomeLoss" xlink:title="presentation: EarningsPerShareAbstract to NetIncomeLoss" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="WeightedAverageNumberOfSharesOutstandingBasic" xlink:title="WeightedAverageNumberOfSharesOutstandingBasic" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EarningsPerShareAbstract" xlink:to="WeightedAverageNumberOfSharesOutstandingBasic" xlink:title="presentation: EarningsPerShareAbstract to WeightedAverageNumberOfSharesOutstandingBasic" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic" xlink:label="EarningsPerShareBasic" xlink:title="EarningsPerShareBasic" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EarningsPerShareAbstract" xlink:to="EarningsPerShareBasic" xlink:title="presentation: EarningsPerShareAbstract to EarningsPerShareBasic" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:label="WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:title="WeightedAverageNumberDilutedSharesOutstandingAdjustment" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EarningsPerShareAbstract" xlink:to="WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:title="presentation: EarningsPerShareAbstract to WeightedAverageNumberDilutedSharesOutstandingAdjustment" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="WeightedAverageNumberOfDilutedSharesOutstanding" xlink:title="WeightedAverageNumberOfDilutedSharesOutstanding" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EarningsPerShareAbstract" xlink:to="WeightedAverageNumberOfDilutedSharesOutstanding" xlink:title="presentation: EarningsPerShareAbstract to WeightedAverageNumberOfDilutedSharesOutstanding" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="EarningsPerShareDiluted" xlink:title="EarningsPerShareDiluted" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EarningsPerShareAbstract" xlink:to="EarningsPerShareDiluted" xlink:title="presentation: EarningsPerShareAbstract to EarningsPerShareDiluted" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="EarningsPerShareAbstract" xlink:title="presentation: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems to EarningsPerShareAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract" xlink:label="EarningsPerShareDilutedOtherDisclosuresAbstract" xlink:title="EarningsPerShareDilutedOtherDisclosuresAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:title="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EarningsPerShareDilutedOtherDisclosuresAbstract" xlink:to="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:title="presentation: EarningsPerShareDilutedOtherDisclosuresAbstract to AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_DilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmountShares" xlink:label="DilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmountShares" xlink:title="DilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmountShares" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EarningsPerShareDilutedOtherDisclosuresAbstract" xlink:to="DilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmountShares" xlink:title="presentation: EarningsPerShareDilutedOtherDisclosuresAbstract to DilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmountShares" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="EarningsPerShareDilutedOtherDisclosuresAbstract" xlink:title="presentation: AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems to EarningsPerShareDilutedOtherDisclosuresAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:title="presentation: ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable to AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccountingPoliciesAbstract" xlink:to="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:title="presentation: AccountingPoliciesAbstract to ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/InventoriesDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="InventoryDisclosureAbstract" xlink:title="InventoryDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryRawMaterials" xlink:label="InventoryRawMaterials" xlink:title="InventoryRawMaterials" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InventoryDisclosureAbstract" xlink:to="InventoryRawMaterials" xlink:title="presentation: InventoryDisclosureAbstract to InventoryRawMaterials" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryWorkInProcess" xlink:label="InventoryWorkInProcess" xlink:title="InventoryWorkInProcess" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InventoryDisclosureAbstract" xlink:to="InventoryWorkInProcess" xlink:title="presentation: InventoryDisclosureAbstract to InventoryWorkInProcess" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryFinishedGoods" xlink:label="InventoryFinishedGoods" xlink:title="InventoryFinishedGoods" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InventoryDisclosureAbstract" xlink:to="InventoryFinishedGoods" xlink:title="presentation: InventoryDisclosureAbstract to InventoryFinishedGoods" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNet" xlink:label="InventoryNet" xlink:title="InventoryNet" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="InventoryDisclosureAbstract" xlink:to="InventoryNet" xlink:title="presentation: InventoryDisclosureAbstract to InventoryNet" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/PropertyAndEquipmentDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="PropertyPlantAndEquipmentAbstract" xlink:title="PropertyPlantAndEquipmentAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="ScheduleOfPropertyPlantAndEquipmentTable" xlink:title="ScheduleOfPropertyPlantAndEquipmentTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="PropertyPlantAndEquipmentByTypeAxis" xlink:title="PropertyPlantAndEquipmentByTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="PropertyPlantAndEquipmentTypeDomain" xlink:title="PropertyPlantAndEquipmentTypeDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ManufacturingFacilityMember" xlink:label="ManufacturingFacilityMember" xlink:title="ManufacturingFacilityMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentTypeDomain" xlink:to="ManufacturingFacilityMember" xlink:title="presentation: PropertyPlantAndEquipmentTypeDomain to ManufacturingFacilityMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OfficeEquipmentMember" xlink:label="OfficeEquipmentMember" xlink:title="OfficeEquipmentMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentTypeDomain" xlink:to="OfficeEquipmentMember" xlink:title="presentation: PropertyPlantAndEquipmentTypeDomain to OfficeEquipmentMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="FurnitureAndFixturesMember" xlink:title="FurnitureAndFixturesMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentTypeDomain" xlink:to="FurnitureAndFixturesMember" xlink:title="presentation: PropertyPlantAndEquipmentTypeDomain to FurnitureAndFixturesMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetUnderConstructionMember" xlink:label="AssetUnderConstructionMember" xlink:title="AssetUnderConstructionMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentTypeDomain" xlink:to="AssetUnderConstructionMember" xlink:title="presentation: PropertyPlantAndEquipmentTypeDomain to AssetUnderConstructionMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="LeaseholdImprovementsMember" xlink:title="LeaseholdImprovementsMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentTypeDomain" xlink:to="LeaseholdImprovementsMember" xlink:title="presentation: PropertyPlantAndEquipmentTypeDomain to LeaseholdImprovementsMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LandMember" xlink:label="LandMember" xlink:title="LandMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentTypeDomain" xlink:to="LandMember" xlink:title="presentation: PropertyPlantAndEquipmentTypeDomain to LandMember" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BuildingAndBuildingImprovementsMember" xlink:label="BuildingAndBuildingImprovementsMember" xlink:title="BuildingAndBuildingImprovementsMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentTypeDomain" xlink:to="BuildingAndBuildingImprovementsMember" xlink:title="presentation: PropertyPlantAndEquipmentTypeDomain to BuildingAndBuildingImprovementsMember" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentByTypeAxis" xlink:to="PropertyPlantAndEquipmentTypeDomain" xlink:title="presentation: PropertyPlantAndEquipmentByTypeAxis to PropertyPlantAndEquipmentTypeDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="PropertyPlantAndEquipmentByTypeAxis" xlink:title="presentation: ScheduleOfPropertyPlantAndEquipmentTable to PropertyPlantAndEquipmentByTypeAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="PropertyPlantAndEquipmentLineItems" xlink:title="PropertyPlantAndEquipmentLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:label="PropertyPlantAndEquipmentNetAbstract" xlink:title="PropertyPlantAndEquipmentNetAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="PropertyPlantAndEquipmentGross" xlink:title="PropertyPlantAndEquipmentGross" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentNetAbstract" xlink:to="PropertyPlantAndEquipmentGross" xlink:title="presentation: PropertyPlantAndEquipmentNetAbstract to PropertyPlantAndEquipmentGross" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:title="AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentNetAbstract" xlink:to="AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:title="presentation: PropertyPlantAndEquipmentNetAbstract to AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="PropertyPlantAndEquipmentNet" xlink:title="PropertyPlantAndEquipmentNet" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentNetAbstract" xlink:to="PropertyPlantAndEquipmentNet" xlink:title="presentation: PropertyPlantAndEquipmentNetAbstract to PropertyPlantAndEquipmentNet" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentLineItems" xlink:to="PropertyPlantAndEquipmentNetAbstract" xlink:title="presentation: PropertyPlantAndEquipmentLineItems to PropertyPlantAndEquipmentNetAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="DepreciationDepletionAndAmortization" xlink:title="DepreciationDepletionAndAmortization" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentLineItems" xlink:to="DepreciationDepletionAndAmortization" xlink:title="presentation: PropertyPlantAndEquipmentLineItems to DepreciationDepletionAndAmortization" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="PropertyPlantAndEquipmentLineItems" xlink:title="presentation: ScheduleOfPropertyPlantAndEquipmentTable to PropertyPlantAndEquipmentLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PropertyPlantAndEquipmentAbstract" xlink:to="ScheduleOfPropertyPlantAndEquipmentTable" xlink:title="presentation: PropertyPlantAndEquipmentAbstract to ScheduleOfPropertyPlantAndEquipmentTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/IntangibleAssetsSummaryDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:title="GoodwillAndIntangibleAssetsDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:title="ScheduleOfFiniteLivedIntangibleAssetsTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:title="FiniteLivedIntangibleAssetsByMajorClassAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:title="FiniteLivedIntangibleAssetsMajorClassNameDomain" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_TrademarkAndOtherIntangibleRightsRelatedToNabiHBMember" xlink:label="TrademarkAndOtherIntangibleRightsRelatedToNabiHBMember" xlink:title="TrademarkAndOtherIntangibleRightsRelatedToNabiHBMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="TrademarkAndOtherIntangibleRightsRelatedToNabiHBMember" xlink:title="presentation: FiniteLivedIntangibleAssetsMajorClassNameDomain to TrademarkAndOtherIntangibleRightsRelatedToNabiHBMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:label="ComputerSoftwareIntangibleAssetMember" xlink:title="ComputerSoftwareIntangibleAssetMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="ComputerSoftwareIntangibleAssetMember" xlink:title="presentation: FiniteLivedIntangibleAssetsMajorClassNameDomain to ComputerSoftwareIntangibleAssetMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_RightToIntermediatesMember" xlink:label="RightToIntermediatesMember" xlink:title="RightToIntermediatesMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="RightToIntermediatesMember" xlink:title="presentation: FiniteLivedIntangibleAssetsMajorClassNameDomain to RightToIntermediatesMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:title="presentation: FiniteLivedIntangibleAssetsByMajorClassAxis to FiniteLivedIntangibleAssetsMajorClassNameDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:title="presentation: ScheduleOfFiniteLivedIntangibleAssetsTable to FiniteLivedIntangibleAssetsByMajorClassAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="FiniteLivedIntangibleAssetsLineItems" xlink:title="FiniteLivedIntangibleAssetsLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:label="FiniteLivedIntangibleAssetsNetAbstract" xlink:title="FiniteLivedIntangibleAssetsNetAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="FiniteLivedIntangibleAssetsGross" xlink:title="FiniteLivedIntangibleAssetsGross" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FiniteLivedIntangibleAssetsNetAbstract" xlink:to="FiniteLivedIntangibleAssetsGross" xlink:title="presentation: FiniteLivedIntangibleAssetsNetAbstract to FiniteLivedIntangibleAssetsGross" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:title="FiniteLivedIntangibleAssetsAccumulatedAmortization" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FiniteLivedIntangibleAssetsNetAbstract" xlink:to="FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:title="presentation: FiniteLivedIntangibleAssetsNetAbstract to FiniteLivedIntangibleAssetsAccumulatedAmortization" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="FiniteLivedIntangibleAssetsNet" xlink:title="FiniteLivedIntangibleAssetsNet" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FiniteLivedIntangibleAssetsNetAbstract" xlink:to="FiniteLivedIntangibleAssetsNet" xlink:title="presentation: FiniteLivedIntangibleAssetsNetAbstract to FiniteLivedIntangibleAssetsNet" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FiniteLivedIntangibleAssetsLineItems" xlink:to="FiniteLivedIntangibleAssetsNetAbstract" xlink:title="presentation: FiniteLivedIntangibleAssetsLineItems to FiniteLivedIntangibleAssetsNetAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:label="FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:title="FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FiniteLivedIntangibleAssetsLineItems" xlink:to="FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:title="presentation: FiniteLivedIntangibleAssetsLineItems to FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="AmortizationOfIntangibleAssets" xlink:title="AmortizationOfIntangibleAssets" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FiniteLivedIntangibleAssetsLineItems" xlink:to="AmortizationOfIntangibleAssets" xlink:title="presentation: FiniteLivedIntangibleAssetsLineItems to AmortizationOfIntangibleAssets" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="FiniteLivedIntangibleAssetsLineItems" xlink:title="presentation: ScheduleOfFiniteLivedIntangibleAssetsTable to FiniteLivedIntangibleAssetsLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:title="presentation: GoodwillAndIntangibleAssetsDisclosureAbstract to ScheduleOfFiniteLivedIntangibleAssetsTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/IntangibleAssetsFutureAggregateAmortizationExpenseDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:title="GoodwillAndIntangibleAssetsDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:label="FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:title="FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths" xlink:label="FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths" xlink:title="FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:to="FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths" xlink:title="presentation: FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract to FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo" xlink:label="FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo" xlink:title="FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:to="FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo" xlink:title="presentation: FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract to FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree" xlink:label="FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree" xlink:title="FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:to="FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree" xlink:title="presentation: FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract to FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour" xlink:label="FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour" xlink:title="FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:to="FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour" xlink:title="presentation: FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract to FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" xlink:title="presentation: GoodwillAndIntangibleAssetsDisclosureAbstract to FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/AccruedExpensesAndOtherLiabilitiesDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="PayablesAndAccrualsAbstract" xlink:title="PayablesAndAccrualsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:label="AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:title="AccruedLiabilitiesAndOtherLiabilitiesAbstract" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_AccruedRebatesCurrent" xlink:label="AccruedRebatesCurrent" xlink:title="AccruedRebatesCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:to="AccruedRebatesCurrent" xlink:title="presentation: AccruedLiabilitiesAndOtherLiabilitiesAbstract to AccruedRebatesCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="AccruedProfessionalFeesCurrent" xlink:title="AccruedProfessionalFeesCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:to="AccruedProfessionalFeesCurrent" xlink:title="presentation: AccruedLiabilitiesAndOtherLiabilitiesAbstract to AccruedProfessionalFeesCurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedBonusesCurrent" xlink:label="AccruedBonusesCurrent" xlink:title="AccruedBonusesCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:to="AccruedBonusesCurrent" xlink:title="presentation: AccruedLiabilitiesAndOtherLiabilitiesAbstract to AccruedBonusesCurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPayableCurrent" xlink:label="InterestPayableCurrent" xlink:title="InterestPayableCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:to="InterestPayableCurrent" xlink:title="presentation: AccruedLiabilitiesAndOtherLiabilitiesAbstract to InterestPayableCurrent" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_AccruedTestingCurrent" xlink:label="AccruedTestingCurrent" xlink:title="AccruedTestingCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:to="AccruedTestingCurrent" xlink:title="presentation: AccruedLiabilitiesAndOtherLiabilitiesAbstract to AccruedTestingCurrent" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedSalariesCurrent" xlink:label="AccruedSalariesCurrent" xlink:title="AccruedSalariesCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:to="AccruedSalariesCurrent" xlink:title="presentation: AccruedLiabilitiesAndOtherLiabilitiesAbstract to AccruedSalariesCurrent" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxesPayableCurrent" xlink:label="TaxesPayableCurrent" xlink:title="TaxesPayableCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:to="TaxesPayableCurrent" xlink:title="presentation: AccruedLiabilitiesAndOtherLiabilitiesAbstract to TaxesPayableCurrent" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="OtherAccruedLiabilitiesCurrent" xlink:title="OtherAccruedLiabilitiesCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:to="OtherAccruedLiabilitiesCurrent" xlink:title="presentation: AccruedLiabilitiesAndOtherLiabilitiesAbstract to OtherAccruedLiabilitiesCurrent" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="AccruedLiabilitiesAndOtherLiabilities" xlink:title="AccruedLiabilitiesAndOtherLiabilities" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:to="AccruedLiabilitiesAndOtherLiabilities" xlink:title="presentation: AccruedLiabilitiesAndOtherLiabilitiesAbstract to AccruedLiabilitiesAndOtherLiabilities" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PayablesAndAccrualsAbstract" xlink:to="AccruedLiabilitiesAndOtherLiabilitiesAbstract" xlink:title="presentation: PayablesAndAccrualsAbstract to AccruedLiabilitiesAndOtherLiabilitiesAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/NotesPayableDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="DebtDisclosureAbstract" xlink:title="DebtDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTable" xlink:label="DebtInstrumentTable" xlink:title="DebtInstrumentTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis" xlink:label="DebtInstrumentAxis" xlink:title="DebtInstrumentAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="DebtInstrumentNameDomain" xlink:title="DebtInstrumentNameDomain" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_AresCreditFacilityMember" xlink:label="AresCreditFacilityMember" xlink:title="AresCreditFacilityMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentNameDomain" xlink:to="AresCreditFacilityMember" xlink:title="presentation: DebtInstrumentNameDomain to AresCreditFacilityMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_HayfinCreditFacilityMember" xlink:label="HayfinCreditFacilityMember" xlink:title="HayfinCreditFacilityMember" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_HayfinClosingDateLoanMember" xlink:label="HayfinClosingDateLoanMember" xlink:title="HayfinClosingDateLoanMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="HayfinCreditFacilityMember" xlink:to="HayfinClosingDateLoanMember" xlink:title="presentation: HayfinCreditFacilityMember to HayfinClosingDateLoanMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_HayfinDelayedDrawLoanMember" xlink:label="HayfinDelayedDrawLoanMember" xlink:title="HayfinDelayedDrawLoanMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="HayfinCreditFacilityMember" xlink:to="HayfinDelayedDrawLoanMember" xlink:title="presentation: HayfinCreditFacilityMember to HayfinDelayedDrawLoanMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_AresClosingDateLoanMember" xlink:label="AresClosingDateLoanMember" xlink:title="AresClosingDateLoanMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="HayfinCreditFacilityMember" xlink:to="AresClosingDateLoanMember" xlink:title="presentation: HayfinCreditFacilityMember to AresClosingDateLoanMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentNameDomain" xlink:to="HayfinCreditFacilityMember" xlink:title="presentation: DebtInstrumentNameDomain to HayfinCreditFacilityMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentAxis" xlink:to="DebtInstrumentNameDomain" xlink:title="presentation: DebtInstrumentAxis to DebtInstrumentNameDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentTable" xlink:to="DebtInstrumentAxis" xlink:title="presentation: DebtInstrumentTable to DebtInstrumentAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityAxis" xlink:label="CreditFacilityAxis" xlink:title="CreditFacilityAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityDomain" xlink:label="CreditFacilityDomain" xlink:title="CreditFacilityDomain" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_TermLoanMember" xlink:label="TermLoanMember" xlink:title="TermLoanMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CreditFacilityDomain" xlink:to="TermLoanMember" xlink:title="presentation: CreditFacilityDomain to TermLoanMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevolvingCreditFacilityMember" xlink:label="RevolvingCreditFacilityMember" xlink:title="RevolvingCreditFacilityMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CreditFacilityDomain" xlink:to="RevolvingCreditFacilityMember" xlink:title="presentation: CreditFacilityDomain to RevolvingCreditFacilityMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CreditFacilityAxis" xlink:to="CreditFacilityDomain" xlink:title="presentation: CreditFacilityAxis to CreditFacilityDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentTable" xlink:to="CreditFacilityAxis" xlink:title="presentation: DebtInstrumentTable to CreditFacilityAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis" xlink:label="CounterpartyNameAxis" xlink:title="CounterpartyNameAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="RepurchaseAgreementCounterpartyNameDomain" xlink:title="RepurchaseAgreementCounterpartyNameDomain" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_AresCreditAgreementMember" xlink:label="AresCreditAgreementMember" xlink:title="AresCreditAgreementMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RepurchaseAgreementCounterpartyNameDomain" xlink:to="AresCreditAgreementMember" xlink:title="presentation: RepurchaseAgreementCounterpartyNameDomain to AresCreditAgreementMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_HayfinCreditAgreementMember" xlink:label="HayfinCreditAgreementMember" xlink:title="HayfinCreditAgreementMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RepurchaseAgreementCounterpartyNameDomain" xlink:to="HayfinCreditAgreementMember" xlink:title="presentation: RepurchaseAgreementCounterpartyNameDomain to HayfinCreditAgreementMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_HayfinSecondAmendmentMember" xlink:label="HayfinSecondAmendmentMember" xlink:title="HayfinSecondAmendmentMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RepurchaseAgreementCounterpartyNameDomain" xlink:to="HayfinSecondAmendmentMember" xlink:title="presentation: RepurchaseAgreementCounterpartyNameDomain to HayfinSecondAmendmentMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CounterpartyNameAxis" xlink:to="RepurchaseAgreementCounterpartyNameDomain" xlink:title="presentation: CounterpartyNameAxis to RepurchaseAgreementCounterpartyNameDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentTable" xlink:to="CounterpartyNameAxis" xlink:title="presentation: DebtInstrumentTable to CounterpartyNameAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VariableRateAxis" xlink:label="VariableRateAxis" xlink:title="VariableRateAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VariableRateDomain" xlink:label="VariableRateDomain" xlink:title="VariableRateDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SecuredOvernightFinancingRateSofrMember" xlink:label="SecuredOvernightFinancingRateSofrMember" xlink:title="SecuredOvernightFinancingRateSofrMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="VariableRateDomain" xlink:to="SecuredOvernightFinancingRateSofrMember" xlink:title="presentation: VariableRateDomain to SecuredOvernightFinancingRateSofrMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BaseRateMember" xlink:label="BaseRateMember" xlink:title="BaseRateMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="VariableRateDomain" xlink:to="BaseRateMember" xlink:title="presentation: VariableRateDomain to BaseRateMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="VariableRateAxis" xlink:to="VariableRateDomain" xlink:title="presentation: VariableRateAxis to VariableRateDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentTable" xlink:to="VariableRateAxis" xlink:title="presentation: DebtInstrumentTable to VariableRateAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="RangeAxis" xlink:title="RangeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="RangeMember" xlink:title="RangeMember" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="MinimumMember" xlink:title="MinimumMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangeMember" xlink:to="MinimumMember" xlink:title="presentation: RangeMember to MinimumMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="MaximumMember" xlink:title="MaximumMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangeMember" xlink:to="MaximumMember" xlink:title="presentation: RangeMember to MaximumMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangeAxis" xlink:to="RangeMember" xlink:title="presentation: RangeAxis to RangeMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentTable" xlink:to="RangeAxis" xlink:title="presentation: DebtInstrumentTable to RangeAxis" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:label="DebtInstrumentRedemptionPeriodAxis" xlink:title="DebtInstrumentRedemptionPeriodAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:label="DebtInstrumentRedemptionPeriodDomain" xlink:title="DebtInstrumentRedemptionPeriodDomain" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_PrepaidOnOrPriorToFirstAnniversaryMember" xlink:label="PrepaidOnOrPriorToFirstAnniversaryMember" xlink:title="PrepaidOnOrPriorToFirstAnniversaryMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentRedemptionPeriodDomain" xlink:to="PrepaidOnOrPriorToFirstAnniversaryMember" xlink:title="presentation: DebtInstrumentRedemptionPeriodDomain to PrepaidOnOrPriorToFirstAnniversaryMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_PrepaidAfterTheFirstAnniversaryMember" xlink:label="PrepaidAfterTheFirstAnniversaryMember" xlink:title="PrepaidAfterTheFirstAnniversaryMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentRedemptionPeriodDomain" xlink:to="PrepaidAfterTheFirstAnniversaryMember" xlink:title="presentation: DebtInstrumentRedemptionPeriodDomain to PrepaidAfterTheFirstAnniversaryMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_PrepaidOnOrPriorToSecondAnniversaryMember" xlink:label="PrepaidOnOrPriorToSecondAnniversaryMember" xlink:title="PrepaidOnOrPriorToSecondAnniversaryMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentRedemptionPeriodDomain" xlink:to="PrepaidOnOrPriorToSecondAnniversaryMember" xlink:title="presentation: DebtInstrumentRedemptionPeriodDomain to PrepaidOnOrPriorToSecondAnniversaryMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_PrepaidOnOrPriorToThirdAnniversaryMember" xlink:label="PrepaidOnOrPriorToThirdAnniversaryMember" xlink:title="PrepaidOnOrPriorToThirdAnniversaryMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentRedemptionPeriodDomain" xlink:to="PrepaidOnOrPriorToThirdAnniversaryMember" xlink:title="presentation: DebtInstrumentRedemptionPeriodDomain to PrepaidOnOrPriorToThirdAnniversaryMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentRedemptionPeriodAxis" xlink:to="DebtInstrumentRedemptionPeriodDomain" xlink:title="presentation: DebtInstrumentRedemptionPeriodAxis to DebtInstrumentRedemptionPeriodDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentTable" xlink:to="DebtInstrumentRedemptionPeriodAxis" xlink:title="presentation: DebtInstrumentTable to DebtInstrumentRedemptionPeriodAxis" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="DebtInstrumentLineItems" xlink:title="DebtInstrumentLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentsAbstract" xlink:label="DebtInstrumentsAbstract" xlink:title="DebtInstrumentsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NotesPayableAbstract" xlink:label="NotesPayableAbstract" xlink:title="NotesPayableAbstract" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_SeniorNotesPayableBeforeDebtDiscount" xlink:label="SeniorNotesPayableBeforeDebtDiscount" xlink:title="SeniorNotesPayableBeforeDebtDiscount" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotesPayableAbstract" xlink:to="SeniorNotesPayableBeforeDebtDiscount" xlink:title="presentation: NotesPayableAbstract to SeniorNotesPayableBeforeDebtDiscount" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="DebtInstrumentUnamortizedDiscount" xlink:title="DebtInstrumentUnamortizedDiscount" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotesPayableAbstract" xlink:to="DebtInstrumentUnamortizedDiscount" xlink:title="presentation: NotesPayableAbstract to DebtInstrumentUnamortizedDiscount" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeniorLongTermNotes" xlink:label="SeniorLongTermNotes" xlink:title="SeniorLongTermNotes" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NotesPayableAbstract" xlink:to="SeniorLongTermNotes" xlink:title="presentation: NotesPayableAbstract to SeniorLongTermNotes" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentsAbstract" xlink:to="NotesPayableAbstract" xlink:title="presentation: DebtInstrumentsAbstract to NotesPayableAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="DebtInstrumentMaturityDate" xlink:title="DebtInstrumentMaturityDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentsAbstract" xlink:to="DebtInstrumentMaturityDate" xlink:title="presentation: DebtInstrumentsAbstract to DebtInstrumentMaturityDate" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="DebtInstrumentCarryingAmount" xlink:title="DebtInstrumentCarryingAmount" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentsAbstract" xlink:to="DebtInstrumentCarryingAmount" xlink:title="presentation: DebtInstrumentsAbstract to DebtInstrumentCarryingAmount" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_LongTermDebtPrepaymentPenalty" xlink:label="LongTermDebtPrepaymentPenalty" xlink:title="LongTermDebtPrepaymentPenalty" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentsAbstract" xlink:to="LongTermDebtPrepaymentPenalty" xlink:title="presentation: DebtInstrumentsAbstract to LongTermDebtPrepaymentPenalty" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="GainsLossesOnExtinguishmentOfDebt" xlink:title="GainsLossesOnExtinguishmentOfDebt" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentsAbstract" xlink:to="GainsLossesOnExtinguishmentOfDebt" xlink:title="presentation: DebtInstrumentsAbstract to GainsLossesOnExtinguishmentOfDebt" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfLongTermLinesOfCredit" xlink:label="RepaymentsOfLongTermLinesOfCredit" xlink:title="RepaymentsOfLongTermLinesOfCredit" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentsAbstract" xlink:to="RepaymentsOfLongTermLinesOfCredit" xlink:title="presentation: DebtInstrumentsAbstract to RepaymentsOfLongTermLinesOfCredit" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="LineOfCreditFacilityMaximumBorrowingCapacity" xlink:title="LineOfCreditFacilityMaximumBorrowingCapacity" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentsAbstract" xlink:to="LineOfCreditFacilityMaximumBorrowingCapacity" xlink:title="presentation: DebtInstrumentsAbstract to LineOfCreditFacilityMaximumBorrowingCapacity" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" xlink:label="LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" xlink:title="LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentsAbstract" xlink:to="LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" xlink:title="presentation: DebtInstrumentsAbstract to LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_DebtInstrumentTermOfVariableRate" xlink:label="DebtInstrumentTermOfVariableRate" xlink:title="DebtInstrumentTermOfVariableRate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentsAbstract" xlink:to="DebtInstrumentTermOfVariableRate" xlink:title="presentation: DebtInstrumentsAbstract to DebtInstrumentTermOfVariableRate" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_NumberOfBusinessDays" xlink:label="NumberOfBusinessDays" xlink:title="NumberOfBusinessDays" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentsAbstract" xlink:to="NumberOfBusinessDays" xlink:title="presentation: DebtInstrumentsAbstract to NumberOfBusinessDays" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_DebtInstrumentApplicableMargin" xlink:label="DebtInstrumentApplicableMargin" xlink:title="DebtInstrumentApplicableMargin" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentsAbstract" xlink:to="DebtInstrumentApplicableMargin" xlink:title="presentation: DebtInstrumentsAbstract to DebtInstrumentApplicableMargin" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="DebtInstrumentInterestRateStatedPercentage" xlink:title="DebtInstrumentInterestRateStatedPercentage" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentsAbstract" xlink:to="DebtInstrumentInterestRateStatedPercentage" xlink:title="presentation: DebtInstrumentsAbstract to DebtInstrumentInterestRateStatedPercentage" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_ExitFeeLiability" xlink:label="ExitFeeLiability" xlink:title="ExitFeeLiability" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentsAbstract" xlink:to="ExitFeeLiability" xlink:title="presentation: DebtInstrumentsAbstract to ExitFeeLiability" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentPeriodicPaymentPrincipal" xlink:label="DebtInstrumentPeriodicPaymentPrincipal" xlink:title="DebtInstrumentPeriodicPaymentPrincipal" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentsAbstract" xlink:to="DebtInstrumentPeriodicPaymentPrincipal" xlink:title="presentation: DebtInstrumentsAbstract to DebtInstrumentPeriodicPaymentPrincipal" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFrequencyOfPeriodicPayment" xlink:label="DebtInstrumentFrequencyOfPeriodicPayment" xlink:title="DebtInstrumentFrequencyOfPeriodicPayment" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentsAbstract" xlink:to="DebtInstrumentFrequencyOfPeriodicPayment" xlink:title="presentation: DebtInstrumentsAbstract to DebtInstrumentFrequencyOfPeriodicPayment" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentPeriodicPaymentInterest" xlink:label="DebtInstrumentPeriodicPaymentInterest" xlink:title="DebtInstrumentPeriodicPaymentInterest" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentsAbstract" xlink:to="DebtInstrumentPeriodicPaymentInterest" xlink:title="presentation: DebtInstrumentsAbstract to DebtInstrumentPeriodicPaymentInterest" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_NumberOfBusinessDaysForPriorWrittenNoticeToPrepayOutstandingPrincipal" xlink:label="NumberOfBusinessDaysForPriorWrittenNoticeToPrepayOutstandingPrincipal" xlink:title="NumberOfBusinessDaysForPriorWrittenNoticeToPrepayOutstandingPrincipal" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentsAbstract" xlink:to="NumberOfBusinessDaysForPriorWrittenNoticeToPrepayOutstandingPrincipal" xlink:title="presentation: DebtInstrumentsAbstract to NumberOfBusinessDaysForPriorWrittenNoticeToPrepayOutstandingPrincipal" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_PrepaymentsOfDebtPremium" xlink:label="PrepaymentsOfDebtPremium" xlink:title="PrepaymentsOfDebtPremium" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentsAbstract" xlink:to="PrepaymentsOfDebtPremium" xlink:title="presentation: DebtInstrumentsAbstract to PrepaymentsOfDebtPremium" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:label="LineOfCreditFacilityCommitmentFeePercentage" xlink:title="LineOfCreditFacilityCommitmentFeePercentage" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentsAbstract" xlink:to="LineOfCreditFacilityCommitmentFeePercentage" xlink:title="presentation: DebtInstrumentsAbstract to LineOfCreditFacilityCommitmentFeePercentage" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" xlink:label="DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" xlink:title="DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentsAbstract" xlink:to="DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" xlink:title="presentation: DebtInstrumentsAbstract to DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFeeAmount" xlink:label="DebtInstrumentFeeAmount" xlink:title="DebtInstrumentFeeAmount" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentsAbstract" xlink:to="DebtInstrumentFeeAmount" xlink:title="presentation: DebtInstrumentsAbstract to DebtInstrumentFeeAmount" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_OriginalDiscountPayableCreditFacility" xlink:label="OriginalDiscountPayableCreditFacility" xlink:title="OriginalDiscountPayableCreditFacility" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentsAbstract" xlink:to="OriginalDiscountPayableCreditFacility" xlink:title="presentation: DebtInstrumentsAbstract to OriginalDiscountPayableCreditFacility" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_DebtInstrumentExitFee" xlink:label="DebtInstrumentExitFee" xlink:title="DebtInstrumentExitFee" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentsAbstract" xlink:to="DebtInstrumentExitFee" xlink:title="presentation: DebtInstrumentsAbstract to DebtInstrumentExitFee" order="22.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="DebtInstrumentInterestRateEffectivePercentage" xlink:title="DebtInstrumentInterestRateEffectivePercentage" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentsAbstract" xlink:to="DebtInstrumentInterestRateEffectivePercentage" xlink:title="presentation: DebtInstrumentsAbstract to DebtInstrumentInterestRateEffectivePercentage" order="23.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_MinimumLiquidityCovenantsCreditFacilities" xlink:label="MinimumLiquidityCovenantsCreditFacilities" xlink:title="MinimumLiquidityCovenantsCreditFacilities" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentsAbstract" xlink:to="MinimumLiquidityCovenantsCreditFacilities" xlink:title="presentation: DebtInstrumentsAbstract to MinimumLiquidityCovenantsCreditFacilities" order="24.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateIncreaseDecrease" xlink:label="DebtInstrumentInterestRateIncreaseDecrease" xlink:title="DebtInstrumentInterestRateIncreaseDecrease" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentsAbstract" xlink:to="DebtInstrumentInterestRateIncreaseDecrease" xlink:title="presentation: DebtInstrumentsAbstract to DebtInstrumentInterestRateIncreaseDecrease" order="25.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="RepaymentsOfNotesPayable" xlink:title="RepaymentsOfNotesPayable" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentsAbstract" xlink:to="RepaymentsOfNotesPayable" xlink:title="presentation: DebtInstrumentsAbstract to RepaymentsOfNotesPayable" order="26.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentUnamortizedPremium" xlink:label="DebtInstrumentUnamortizedPremium" xlink:title="DebtInstrumentUnamortizedPremium" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentsAbstract" xlink:to="DebtInstrumentUnamortizedPremium" xlink:title="presentation: DebtInstrumentsAbstract to DebtInstrumentUnamortizedPremium" order="27.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:label="PaymentsOfDebtIssuanceCosts" xlink:title="PaymentsOfDebtIssuanceCosts" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentsAbstract" xlink:to="PaymentsOfDebtIssuanceCosts" xlink:title="presentation: DebtInstrumentsAbstract to PaymentsOfDebtIssuanceCosts" order="28.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_DebtInstrumentUpfrontFeePaidInKind" xlink:label="DebtInstrumentUpfrontFeePaidInKind" xlink:title="DebtInstrumentUpfrontFeePaidInKind" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentsAbstract" xlink:to="DebtInstrumentUpfrontFeePaidInKind" xlink:title="presentation: DebtInstrumentsAbstract to DebtInstrumentUpfrontFeePaidInKind" order="29.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_DebtInstrumentFloorInterestRate" xlink:label="DebtInstrumentFloorInterestRate" xlink:title="DebtInstrumentFloorInterestRate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentsAbstract" xlink:to="DebtInstrumentFloorInterestRate" xlink:title="presentation: DebtInstrumentsAbstract to DebtInstrumentFloorInterestRate" order="30.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_DebtInstrumentInterestAmountToBePayInKind" xlink:label="DebtInstrumentInterestAmountToBePayInKind" xlink:title="DebtInstrumentInterestAmountToBePayInKind" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentsAbstract" xlink:to="DebtInstrumentInterestAmountToBePayInKind" xlink:title="presentation: DebtInstrumentsAbstract to DebtInstrumentInterestAmountToBePayInKind" order="31.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaidInKindInterest" xlink:label="PaidInKindInterest" xlink:title="PaidInKindInterest" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentsAbstract" xlink:to="PaidInKindInterest" xlink:title="presentation: DebtInstrumentsAbstract to PaidInKindInterest" order="32.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_PercentageOfExitFeeOfOutstandingPrincipalAmountBeingPaid" xlink:label="PercentageOfExitFeeOfOutstandingPrincipalAmountBeingPaid" xlink:title="PercentageOfExitFeeOfOutstandingPrincipalAmountBeingPaid" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentsAbstract" xlink:to="PercentageOfExitFeeOfOutstandingPrincipalAmountBeingPaid" xlink:title="presentation: DebtInstrumentsAbstract to PercentageOfExitFeeOfOutstandingPrincipalAmountBeingPaid" order="33.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Cash" xlink:label="Cash" xlink:title="Cash" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentsAbstract" xlink:to="Cash" xlink:title="presentation: DebtInstrumentsAbstract to Cash" order="34.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="RevenueFromContractWithCustomerExcludingAssessedTax" xlink:title="RevenueFromContractWithCustomerExcludingAssessedTax" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentsAbstract" xlink:to="RevenueFromContractWithCustomerExcludingAssessedTax" xlink:title="presentation: DebtInstrumentsAbstract to RevenueFromContractWithCustomerExcludingAssessedTax" order="35.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_SharesIssuedUponExerciseOfWarrants" xlink:label="SharesIssuedUponExerciseOfWarrants" xlink:title="SharesIssuedUponExerciseOfWarrants" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentsAbstract" xlink:to="SharesIssuedUponExerciseOfWarrants" xlink:title="presentation: DebtInstrumentsAbstract to SharesIssuedUponExerciseOfWarrants" order="36.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:title="ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentsAbstract" xlink:to="ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:title="presentation: DebtInstrumentsAbstract to ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="37.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:title="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentsAbstract" xlink:to="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:title="presentation: DebtInstrumentsAbstract to ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="38.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_TrailingPeriodForVolumeWeightedAveragePrice" xlink:label="TrailingPeriodForVolumeWeightedAveragePrice" xlink:title="TrailingPeriodForVolumeWeightedAveragePrice" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentsAbstract" xlink:to="TrailingPeriodForVolumeWeightedAveragePrice" xlink:title="presentation: DebtInstrumentsAbstract to TrailingPeriodForVolumeWeightedAveragePrice" order="39.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="FairValueAdjustmentOfWarrants" xlink:title="FairValueAdjustmentOfWarrants" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentsAbstract" xlink:to="FairValueAdjustmentOfWarrants" xlink:title="presentation: DebtInstrumentsAbstract to FairValueAdjustmentOfWarrants" order="40.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="WarrantsAndRightsOutstanding" xlink:title="WarrantsAndRightsOutstanding" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentsAbstract" xlink:to="WarrantsAndRightsOutstanding" xlink:title="presentation: DebtInstrumentsAbstract to WarrantsAndRightsOutstanding" order="41.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentLineItems" xlink:to="DebtInstrumentsAbstract" xlink:title="presentation: DebtInstrumentLineItems to DebtInstrumentsAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtInstrumentTable" xlink:to="DebtInstrumentLineItems" xlink:title="presentation: DebtInstrumentTable to DebtInstrumentLineItems" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DebtDisclosureAbstract" xlink:to="DebtInstrumentTable" xlink:title="presentation: DebtDisclosureAbstract to DebtInstrumentTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/StockholdersEquityPreferredStockDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="EquityAbstract" xlink:title="EquityAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:label="PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:title="PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockCapitalSharesReservedForFutureIssuance" xlink:label="PreferredStockCapitalSharesReservedForFutureIssuance" xlink:title="PreferredStockCapitalSharesReservedForFutureIssuance" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="PreferredStockCapitalSharesReservedForFutureIssuance" xlink:title="presentation: PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract to PreferredStockCapitalSharesReservedForFutureIssuance" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="PreferredStockParOrStatedValuePerShare" xlink:title="PreferredStockParOrStatedValuePerShare" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="PreferredStockParOrStatedValuePerShare" xlink:title="presentation: PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract to PreferredStockParOrStatedValuePerShare" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="PreferredStockSharesOutstanding" xlink:title="PreferredStockSharesOutstanding" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="PreferredStockSharesOutstanding" xlink:title="presentation: PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract to PreferredStockSharesOutstanding" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityAbstract" xlink:to="PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:title="presentation: EquityAbstract to PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/StockholdersEquityCommonStockDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="EquityAbstract" xlink:title="EquityAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="ScheduleOfStockByClassTable" xlink:title="ScheduleOfStockByClassTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="StatementEquityComponentsAxis" xlink:title="StatementEquityComponentsAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="EquityComponentDomain" xlink:title="EquityComponentDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="CommonStockMember" xlink:title="CommonStockMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityComponentDomain" xlink:to="CommonStockMember" xlink:title="presentation: EquityComponentDomain to CommonStockMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementEquityComponentsAxis" xlink:to="EquityComponentDomain" xlink:title="presentation: StatementEquityComponentsAxis to EquityComponentDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockByClassTable" xlink:to="StatementEquityComponentsAxis" xlink:title="presentation: ScheduleOfStockByClassTable to StatementEquityComponentsAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="SubsidiarySaleOfStockAxis" xlink:title="SubsidiarySaleOfStockAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="SaleOfStockNameOfTransactionDomain" xlink:title="SaleOfStockNameOfTransactionDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OverAllotmentOptionMember" xlink:label="OverAllotmentOptionMember" xlink:title="OverAllotmentOptionMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SaleOfStockNameOfTransactionDomain" xlink:to="OverAllotmentOptionMember" xlink:title="presentation: SaleOfStockNameOfTransactionDomain to OverAllotmentOptionMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsidiarySaleOfStockAxis" xlink:to="SaleOfStockNameOfTransactionDomain" xlink:title="presentation: SubsidiarySaleOfStockAxis to SaleOfStockNameOfTransactionDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockByClassTable" xlink:to="SubsidiarySaleOfStockAxis" xlink:title="presentation: ScheduleOfStockByClassTable to SubsidiarySaleOfStockAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems" xlink:label="ClassOfStockLineItems" xlink:title="ClassOfStockLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:label="CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:title="CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="CommonStockSharesAuthorized" xlink:title="CommonStockSharesAuthorized" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="CommonStockSharesAuthorized" xlink:title="presentation: CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract to CommonStockSharesAuthorized" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="CommonStockParOrStatedValuePerShare" xlink:title="CommonStockParOrStatedValuePerShare" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="CommonStockParOrStatedValuePerShare" xlink:title="presentation: CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract to CommonStockParOrStatedValuePerShare" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="CommonStockSharesOutstanding" xlink:title="CommonStockSharesOutstanding" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="CommonStockSharesOutstanding" xlink:title="presentation: CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract to CommonStockSharesOutstanding" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="CommonStockCapitalSharesReservedForFutureIssuance" xlink:title="CommonStockCapitalSharesReservedForFutureIssuance" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="CommonStockCapitalSharesReservedForFutureIssuance" xlink:title="presentation: CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract to CommonStockCapitalSharesReservedForFutureIssuance" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:title="StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:title="presentation: CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract to StockIssuedDuringPeriodSharesStockOptionsExercised" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="ProceedsFromStockOptionsExercised" xlink:title="ProceedsFromStockOptionsExercised" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="ProceedsFromStockOptionsExercised" xlink:title="presentation: CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract to ProceedsFromStockOptionsExercised" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="StockIssuedDuringPeriodSharesNewIssues" xlink:title="StockIssuedDuringPeriodSharesNewIssues" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="StockIssuedDuringPeriodSharesNewIssues" xlink:title="presentation: CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract to StockIssuedDuringPeriodSharesNewIssues" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="ProceedsFromIssuanceOfCommonStock" xlink:title="ProceedsFromIssuanceOfCommonStock" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="ProceedsFromIssuanceOfCommonStock" xlink:title="presentation: CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract to ProceedsFromIssuanceOfCommonStock" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClassOfStockLineItems" xlink:to="CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:title="presentation: ClassOfStockLineItems to CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockByClassTable" xlink:to="ClassOfStockLineItems" xlink:title="presentation: ScheduleOfStockByClassTable to ClassOfStockLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityAbstract" xlink:to="ScheduleOfStockByClassTable" xlink:title="presentation: EquityAbstract to ScheduleOfStockByClassTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/StockholdersEquityWarrantsDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="EquityAbstract" xlink:title="EquityAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="ClassOfWarrantOrRightTable" xlink:title="ClassOfWarrantOrRightTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="ClassOfWarrantOrRightAxis" xlink:title="ClassOfWarrantOrRightAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="ClassOfWarrantOrRightDomain" xlink:title="ClassOfWarrantOrRightDomain" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_HayfinWarrantsMember" xlink:label="HayfinWarrantsMember" xlink:title="HayfinWarrantsMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClassOfWarrantOrRightDomain" xlink:to="HayfinWarrantsMember" xlink:title="presentation: ClassOfWarrantOrRightDomain to HayfinWarrantsMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantMember" xlink:label="WarrantMember" xlink:title="WarrantMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClassOfWarrantOrRightDomain" xlink:to="WarrantMember" xlink:title="presentation: ClassOfWarrantOrRightDomain to WarrantMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClassOfWarrantOrRightAxis" xlink:to="ClassOfWarrantOrRightDomain" xlink:title="presentation: ClassOfWarrantOrRightAxis to ClassOfWarrantOrRightDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClassOfWarrantOrRightTable" xlink:to="ClassOfWarrantOrRightAxis" xlink:title="presentation: ClassOfWarrantOrRightTable to ClassOfWarrantOrRightAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="StatementEquityComponentsAxis" xlink:title="StatementEquityComponentsAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="EquityComponentDomain" xlink:title="EquityComponentDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="CommonStockMember" xlink:title="CommonStockMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityComponentDomain" xlink:to="CommonStockMember" xlink:title="presentation: EquityComponentDomain to CommonStockMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementEquityComponentsAxis" xlink:to="EquityComponentDomain" xlink:title="presentation: StatementEquityComponentsAxis to EquityComponentDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClassOfWarrantOrRightTable" xlink:to="StatementEquityComponentsAxis" xlink:title="presentation: ClassOfWarrantOrRightTable to StatementEquityComponentsAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis" xlink:label="CounterpartyNameAxis" xlink:title="CounterpartyNameAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="RepurchaseAgreementCounterpartyNameDomain" xlink:title="RepurchaseAgreementCounterpartyNameDomain" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_HayfinSecondAmendmentMember" xlink:label="HayfinSecondAmendmentMember" xlink:title="HayfinSecondAmendmentMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RepurchaseAgreementCounterpartyNameDomain" xlink:to="HayfinSecondAmendmentMember" xlink:title="presentation: RepurchaseAgreementCounterpartyNameDomain to HayfinSecondAmendmentMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CounterpartyNameAxis" xlink:to="RepurchaseAgreementCounterpartyNameDomain" xlink:title="presentation: CounterpartyNameAxis to RepurchaseAgreementCounterpartyNameDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClassOfWarrantOrRightTable" xlink:to="CounterpartyNameAxis" xlink:title="presentation: ClassOfWarrantOrRightTable to CounterpartyNameAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="ClassOfWarrantOrRightLineItems" xlink:title="ClassOfWarrantOrRightLineItems" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_WarrantsAbstract" xlink:label="WarrantsAbstract" xlink:title="WarrantsAbstract" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_ClassOfWarrantOrRightExercised" xlink:label="ClassOfWarrantOrRightExercised" xlink:title="ClassOfWarrantOrRightExercised" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WarrantsAbstract" xlink:to="ClassOfWarrantOrRightExercised" xlink:title="presentation: WarrantsAbstract to ClassOfWarrantOrRightExercised" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="CommonStockSharesIssued" xlink:title="CommonStockSharesIssued" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WarrantsAbstract" xlink:to="CommonStockSharesIssued" xlink:title="presentation: WarrantsAbstract to CommonStockSharesIssued" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:title="ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WarrantsAbstract" xlink:to="ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:title="presentation: WarrantsAbstract to ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="WarrantsAndRightsOutstanding" xlink:title="WarrantsAndRightsOutstanding" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WarrantsAbstract" xlink:to="WarrantsAndRightsOutstanding" xlink:title="presentation: WarrantsAbstract to WarrantsAndRightsOutstanding" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WarrantsAbstract" xlink:to="SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:title="presentation: WarrantsAbstract to SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WarrantsAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:title="presentation: WarrantsAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WarrantsAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:title="presentation: WarrantsAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WarrantsAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:title="presentation: WarrantsAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:title="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WarrantsAbstract" xlink:to="ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:title="presentation: WarrantsAbstract to ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="ClassOfWarrantOrRightOutstanding" xlink:title="ClassOfWarrantOrRightOutstanding" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WarrantsAbstract" xlink:to="ClassOfWarrantOrRightOutstanding" xlink:title="presentation: WarrantsAbstract to ClassOfWarrantOrRightOutstanding" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClassOfWarrantOrRightLineItems" xlink:to="WarrantsAbstract" xlink:title="presentation: ClassOfWarrantOrRightLineItems to WarrantsAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward to ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward to ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward to ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward to ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward to ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClassOfWarrantOrRightLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:title="presentation: ClassOfWarrantOrRightLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward to ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriodWeightedAverageGrantDateFairValue" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriodWeightedAverageGrantDateFairValue" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriodWeightedAverageGrantDateFairValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriodWeightedAverageGrantDateFairValue" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward to ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriodWeightedAverageGrantDateFairValue" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward to ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageGrantDateFairValue" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageGrantDateFairValue" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageGrantDateFairValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageGrantDateFairValue" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward to ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageGrantDateFairValue" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward to ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClassOfWarrantOrRightLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:title="presentation: ClassOfWarrantOrRightLineItems to ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ClassOfWarrantOrRightTable" xlink:to="ClassOfWarrantOrRightLineItems" xlink:title="presentation: ClassOfWarrantOrRightTable to ClassOfWarrantOrRightLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityAbstract" xlink:to="ClassOfWarrantOrRightTable" xlink:title="presentation: EquityAbstract to ClassOfWarrantOrRightTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="EquityAbstract" xlink:title="EquityAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="AwardTypeAxis" xlink:title="AwardTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="EmployeeStockOptionMember" xlink:title="EmployeeStockOptionMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="EmployeeStockOptionMember" xlink:title="presentation: ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain to EmployeeStockOptionMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="RestrictedStockUnitsRSUMember" xlink:title="RestrictedStockUnitsRSUMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="RestrictedStockUnitsRSUMember" xlink:title="presentation: ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain to RestrictedStockUnitsRSUMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AwardTypeAxis" xlink:to="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="presentation: AwardTypeAxis to ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="AwardTypeAxis" xlink:title="presentation: ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to AwardTypeAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="PlanNameAxis" xlink:title="PlanNameAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="PlanNameDomain" xlink:title="PlanNameDomain" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_Two022CompensationPlanMember" xlink:label="Two022CompensationPlanMember" xlink:title="Two022CompensationPlanMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PlanNameDomain" xlink:to="Two022CompensationPlanMember" xlink:title="presentation: PlanNameDomain to Two022CompensationPlanMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_EquityIncentivePlanMember" xlink:label="EquityIncentivePlanMember" xlink:title="EquityIncentivePlanMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PlanNameDomain" xlink:to="EquityIncentivePlanMember" xlink:title="presentation: PlanNameDomain to EquityIncentivePlanMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PlanNameAxis" xlink:to="PlanNameDomain" xlink:title="presentation: PlanNameAxis to PlanNameDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="PlanNameAxis" xlink:title="presentation: ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to PlanNameAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="TitleOfIndividualAxis" xlink:title="TitleOfIndividualAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="TitleOfIndividualWithRelationshipToEntityDomain" xlink:title="TitleOfIndividualWithRelationshipToEntityDomain" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_EmployeesMember" xlink:label="EmployeesMember" xlink:title="EmployeesMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="EmployeesMember" xlink:title="presentation: TitleOfIndividualWithRelationshipToEntityDomain to EmployeesMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_DirectorMember" xlink:label="DirectorMember" xlink:title="DirectorMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="DirectorMember" xlink:title="presentation: TitleOfIndividualWithRelationshipToEntityDomain to DirectorMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TitleOfIndividualAxis" xlink:to="TitleOfIndividualWithRelationshipToEntityDomain" xlink:title="presentation: TitleOfIndividualAxis to TitleOfIndividualWithRelationshipToEntityDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="TitleOfIndividualAxis" xlink:title="presentation: ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to TitleOfIndividualAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="RangeAxis" xlink:title="RangeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="RangeMember" xlink:title="RangeMember" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="MinimumMember" xlink:title="MinimumMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangeMember" xlink:to="MinimumMember" xlink:title="presentation: RangeMember to MinimumMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="MaximumMember" xlink:title="MaximumMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangeMember" xlink:to="MaximumMember" xlink:title="presentation: RangeMember to MaximumMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangeAxis" xlink:to="RangeMember" xlink:title="presentation: RangeAxis to RangeMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="RangeAxis" xlink:title="presentation: ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to RangeAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:title="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:title="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_ExercisePriceRange1Member" xlink:label="ExercisePriceRange1Member" xlink:title="ExercisePriceRange1Member" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="ExercisePriceRange1Member" xlink:title="presentation: ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain to ExercisePriceRange1Member" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_ExercisePriceRange2Member" xlink:label="ExercisePriceRange2Member" xlink:title="ExercisePriceRange2Member" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="ExercisePriceRange2Member" xlink:title="presentation: ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain to ExercisePriceRange2Member" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_ExercisePriceRange3Member" xlink:label="ExercisePriceRange3Member" xlink:title="ExercisePriceRange3Member" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="ExercisePriceRange3Member" xlink:title="presentation: ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain to ExercisePriceRange3Member" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_ExercisePriceRange4Member" xlink:label="ExercisePriceRange4Member" xlink:title="ExercisePriceRange4Member" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="ExercisePriceRange4Member" xlink:title="presentation: ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain to ExercisePriceRange4Member" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_ExercisePriceRange5Member" xlink:label="ExercisePriceRange5Member" xlink:title="ExercisePriceRange5Member" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="ExercisePriceRange5Member" xlink:title="presentation: ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain to ExercisePriceRange5Member" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_ExercisePriceRange6Member" xlink:label="ExercisePriceRange6Member" xlink:title="ExercisePriceRange6Member" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="ExercisePriceRange6Member" xlink:title="presentation: ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain to ExercisePriceRange6Member" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:title="presentation: ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis to ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:title="presentation: ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="IncomeStatementLocationAxis" xlink:title="IncomeStatementLocationAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="IncomeStatementLocationDomain" xlink:title="IncomeStatementLocationDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="ResearchAndDevelopmentExpenseMember" xlink:title="ResearchAndDevelopmentExpenseMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementLocationDomain" xlink:to="ResearchAndDevelopmentExpenseMember" xlink:title="presentation: IncomeStatementLocationDomain to ResearchAndDevelopmentExpenseMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenseMember" xlink:label="OperatingExpenseMember" xlink:title="OperatingExpenseMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementLocationDomain" xlink:to="OperatingExpenseMember" xlink:title="presentation: IncomeStatementLocationDomain to OperatingExpenseMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="SellingGeneralAndAdministrativeExpensesMember" xlink:title="SellingGeneralAndAdministrativeExpensesMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementLocationDomain" xlink:to="SellingGeneralAndAdministrativeExpensesMember" xlink:title="presentation: IncomeStatementLocationDomain to SellingGeneralAndAdministrativeExpensesMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfSalesMember" xlink:label="CostOfSalesMember" xlink:title="CostOfSalesMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementLocationDomain" xlink:to="CostOfSalesMember" xlink:title="presentation: IncomeStatementLocationDomain to CostOfSalesMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementLocationAxis" xlink:to="IncomeStatementLocationDomain" xlink:title="presentation: IncomeStatementLocationAxis to IncomeStatementLocationDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="IncomeStatementLocationAxis" xlink:title="presentation: ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to IncomeStatementLocationAxis" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_StockOptionsAbstract" xlink:label="StockOptionsAbstract" xlink:title="StockOptionsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="CommonStockCapitalSharesReservedForFutureIssuance" xlink:title="CommonStockCapitalSharesReservedForFutureIssuance" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockOptionsAbstract" xlink:to="CommonStockCapitalSharesReservedForFutureIssuance" xlink:title="presentation: StockOptionsAbstract to CommonStockCapitalSharesReservedForFutureIssuance" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockOptionsAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:title="presentation: StockOptionsAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSharesWithheldToCoverAggregateExercisePrices" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSharesWithheldToCoverAggregateExercisePrices" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSharesWithheldToCoverAggregateExercisePrices" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockOptionsAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSharesWithheldToCoverAggregateExercisePrices" xlink:title="presentation: StockOptionsAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSharesWithheldToCoverAggregateExercisePrices" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="ProceedsFromStockOptionsExercised" xlink:title="ProceedsFromStockOptionsExercised" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockOptionsAbstract" xlink:to="ProceedsFromStockOptionsExercised" xlink:title="presentation: StockOptionsAbstract to ProceedsFromStockOptionsExercised" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSharesWithheldForPayrollTaxes" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSharesWithheldForPayrollTaxes" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSharesWithheldForPayrollTaxes" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockOptionsAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSharesWithheldForPayrollTaxes" xlink:title="presentation: StockOptionsAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSharesWithheldForPayrollTaxes" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:title="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockOptionsAbstract" xlink:to="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:title="presentation: StockOptionsAbstract to EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockOptionsAbstract" xlink:to="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:title="presentation: StockOptionsAbstract to SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockOptionsAbstract" xlink:to="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:title="presentation: StockOptionsAbstract to SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockOptionsAbstract" xlink:to="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:title="presentation: StockOptionsAbstract to SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract to SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockOptionsAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:title="presentation: StockOptionsAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_StockOptionSharesAbstract" xlink:label="StockOptionSharesAbstract" xlink:title="StockOptionSharesAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockOptionSharesAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:title="presentation: StockOptionSharesAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedNumber" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedNumber" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockOptionSharesAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedNumber" xlink:title="presentation: StockOptionSharesAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedNumber" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredNumber" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredNumber" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockOptionSharesAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredNumber" xlink:title="presentation: StockOptionSharesAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredNumber" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedNumber" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedNumber" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockOptionSharesAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedNumber" xlink:title="presentation: StockOptionSharesAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedNumber" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedNumber" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedNumber" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockOptionSharesAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedNumber" xlink:title="presentation: StockOptionSharesAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedNumber" order="4.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_2" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockOptionSharesAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_2" xlink:title="presentation: StockOptionSharesAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockOptionSharesAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:title="presentation: StockOptionSharesAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract" xlink:to="StockOptionSharesAbstract" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract to StockOptionSharesAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_StockOptionsWeightedAverageExercisePriceAbstract" xlink:label="StockOptionsWeightedAverageExercisePriceAbstract" xlink:title="StockOptionsWeightedAverageExercisePriceAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockOptionsWeightedAverageExercisePriceAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:title="presentation: StockOptionsWeightedAverageExercisePriceAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedWeightedAverageExercisePrice" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedWeightedAverageExercisePrice" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockOptionsWeightedAverageExercisePriceAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedWeightedAverageExercisePrice" xlink:title="presentation: StockOptionsWeightedAverageExercisePriceAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedWeightedAverageExercisePrice" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredWeightedAverageExercisePrice" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredWeightedAverageExercisePrice" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockOptionsWeightedAverageExercisePriceAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredWeightedAverageExercisePrice" xlink:title="presentation: StockOptionsWeightedAverageExercisePriceAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredWeightedAverageExercisePrice" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedWeightedAverageExercisePrice" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedWeightedAverageExercisePrice" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockOptionsWeightedAverageExercisePriceAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedWeightedAverageExercisePrice" xlink:title="presentation: StockOptionsWeightedAverageExercisePriceAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedWeightedAverageExercisePrice" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedWeightedAverageExercisePrice" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedWeightedAverageExercisePrice" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockOptionsWeightedAverageExercisePriceAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedWeightedAverageExercisePrice" xlink:title="presentation: StockOptionsWeightedAverageExercisePriceAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedWeightedAverageExercisePrice" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_2" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockOptionsWeightedAverageExercisePriceAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_2" xlink:title="presentation: StockOptionsWeightedAverageExercisePriceAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockOptionsWeightedAverageExercisePriceAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:title="presentation: StockOptionsWeightedAverageExercisePriceAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract" xlink:to="StockOptionsWeightedAverageExercisePriceAbstract" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract to StockOptionsWeightedAverageExercisePriceAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockOptionsAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract" xlink:title="presentation: StockOptionsAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="StockOptionsAbstract" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to StockOptionsAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_StockOptionOutstandingAndExcercisableAbstract" xlink:label="StockOptionOutstandingAndExcercisableAbstract" xlink:title="StockOptionOutstandingAndExcercisableAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:label="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:title="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockOptionOutstandingAndExcercisableAbstract" xlink:to="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:title="presentation: StockOptionOutstandingAndExcercisableAbstract to ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:label="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:title="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockOptionOutstandingAndExcercisableAbstract" xlink:to="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:title="presentation: StockOptionOutstandingAndExcercisableAbstract to ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:label="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:title="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockOptionOutstandingAndExcercisableAbstract" xlink:to="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:title="presentation: StockOptionOutstandingAndExcercisableAbstract to ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockOptionOutstandingAndExcercisableAbstract" xlink:to="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:title="presentation: StockOptionOutstandingAndExcercisableAbstract to SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:label="SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:title="SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockOptionOutstandingAndExcercisableAbstract" xlink:to="SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:title="presentation: StockOptionOutstandingAndExcercisableAbstract to SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockOptionOutstandingAndExcercisableAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:title="presentation: StockOptionOutstandingAndExcercisableAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:label="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:title="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockOptionOutstandingAndExcercisableAbstract" xlink:to="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:title="presentation: StockOptionOutstandingAndExcercisableAbstract to ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:label="SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:title="SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockOptionOutstandingAndExcercisableAbstract" xlink:to="SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" xlink:title="presentation: StockOptionOutstandingAndExcercisableAbstract to SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:label="SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:title="SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockOptionOutstandingAndExcercisableAbstract" xlink:to="SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:title="presentation: StockOptionOutstandingAndExcercisableAbstract to SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:title="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockOptionOutstandingAndExcercisableAbstract" xlink:to="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:title="presentation: StockOptionOutstandingAndExcercisableAbstract to SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="StockOptionOutstandingAndExcercisableAbstract" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to StockOptionOutstandingAndExcercisableAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:title="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:title="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_RestrictedStockUnitsAbstract" xlink:label="RestrictedStockUnitsAbstract" xlink:title="RestrictedStockUnitsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RestrictedStockUnitsAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:title="presentation: RestrictedStockUnitsAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RestrictedStockUnitsAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:title="presentation: RestrictedStockUnitsAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesWithheldForEmployeesTaxLiabilities" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesWithheldForEmployeesTaxLiabilities" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesWithheldForEmployeesTaxLiabilities" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RestrictedStockUnitsAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesWithheldForEmployeesTaxLiabilities" xlink:title="presentation: RestrictedStockUnitsAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesWithheldForEmployeesTaxLiabilities" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesValueWithheldForEmployeesTaxLiabilities" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesValueWithheldForEmployeesTaxLiabilities" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesValueWithheldForEmployeesTaxLiabilities" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RestrictedStockUnitsAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesValueWithheldForEmployeesTaxLiabilities" xlink:title="presentation: RestrictedStockUnitsAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesValueWithheldForEmployeesTaxLiabilities" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_NumberOfIndividualsThatReceivedModificationsToTheirOutstandingStockOptionAndRSUAwards" xlink:label="NumberOfIndividualsThatReceivedModificationsToTheirOutstandingStockOptionAndRSUAwards" xlink:title="NumberOfIndividualsThatReceivedModificationsToTheirOutstandingStockOptionAndRSUAwards" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RestrictedStockUnitsAbstract" xlink:to="NumberOfIndividualsThatReceivedModificationsToTheirOutstandingStockOptionAndRSUAwards" xlink:title="presentation: RestrictedStockUnitsAbstract to NumberOfIndividualsThatReceivedModificationsToTheirOutstandingStockOptionAndRSUAwards" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="AllocatedShareBasedCompensationExpense" xlink:title="AllocatedShareBasedCompensationExpense" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RestrictedStockUnitsAbstract" xlink:to="AllocatedShareBasedCompensationExpense" xlink:title="presentation: RestrictedStockUnitsAbstract to AllocatedShareBasedCompensationExpense" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward to ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward to ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward to ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward to ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_2" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward to ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RestrictedStockUnitsAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:title="presentation: RestrictedStockUnitsAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward to ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward to ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward to ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward to ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward to ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RestrictedStockUnitsAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:title="presentation: RestrictedStockUnitsAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="RestrictedStockUnitsAbstract" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to RestrictedStockUnitsAbstract" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract" xlink:label="ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract" xlink:title="ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="ShareBasedCompensation" xlink:title="ShareBasedCompensation" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract" xlink:to="ShareBasedCompensation" xlink:title="presentation: ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract to ShareBasedCompensation" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract" xlink:title="presentation: ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems to ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:title="presentation: ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable to ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EquityAbstract" xlink:to="ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:title="presentation: EquityAbstract to ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/RelatedPartyTransactionsDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="RelatedPartyTransactionsAbstract" xlink:title="RelatedPartyTransactionsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:title="ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="RelatedPartyTransactionsByRelatedPartyAxis" xlink:title="RelatedPartyTransactionsByRelatedPartyAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyDomain" xlink:label="RelatedPartyDomain" xlink:title="RelatedPartyDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyMember" xlink:label="RelatedPartyMember" xlink:title="RelatedPartyMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyDomain" xlink:to="RelatedPartyMember" xlink:title="presentation: RelatedPartyDomain to RelatedPartyMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="RelatedPartyDomain" xlink:title="presentation: RelatedPartyTransactionsByRelatedPartyAxis to RelatedPartyDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="RelatedPartyTransactionsByRelatedPartyAxis" xlink:title="presentation: ScheduleOfRelatedPartyTransactionsByRelatedPartyTable to RelatedPartyTransactionsByRelatedPartyAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_CounterpartyNameAxis" xlink:label="CounterpartyNameAxis" xlink:title="CounterpartyNameAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="RepurchaseAgreementCounterpartyNameDomain" xlink:title="RepurchaseAgreementCounterpartyNameDomain" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_ArethLLCMember" xlink:label="ArethLLCMember" xlink:title="ArethLLCMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RepurchaseAgreementCounterpartyNameDomain" xlink:to="ArethLLCMember" xlink:title="presentation: RepurchaseAgreementCounterpartyNameDomain to ArethLLCMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_GenesisBPSMember" xlink:label="GenesisBPSMember" xlink:title="GenesisBPSMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RepurchaseAgreementCounterpartyNameDomain" xlink:to="GenesisBPSMember" xlink:title="presentation: RepurchaseAgreementCounterpartyNameDomain to GenesisBPSMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_BryantFongMember" xlink:label="BryantFongMember" xlink:title="BryantFongMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RepurchaseAgreementCounterpartyNameDomain" xlink:to="BryantFongMember" xlink:title="presentation: RepurchaseAgreementCounterpartyNameDomain to BryantFongMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CounterpartyNameAxis" xlink:to="RepurchaseAgreementCounterpartyNameDomain" xlink:title="presentation: CounterpartyNameAxis to RepurchaseAgreementCounterpartyNameDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="CounterpartyNameAxis" xlink:title="presentation: ScheduleOfRelatedPartyTransactionsByRelatedPartyTable to CounterpartyNameAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="RangeAxis" xlink:title="RangeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="RangeMember" xlink:title="RangeMember" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="MinimumMember" xlink:title="MinimumMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangeMember" xlink:to="MinimumMember" xlink:title="presentation: RangeMember to MinimumMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="MaximumMember" xlink:title="MaximumMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangeMember" xlink:to="MaximumMember" xlink:title="presentation: RangeMember to MaximumMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangeAxis" xlink:to="RangeMember" xlink:title="presentation: RangeAxis to RangeMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="RangeAxis" xlink:title="presentation: ScheduleOfRelatedPartyTransactionsByRelatedPartyTable to RangeAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="AwardTypeAxis" xlink:title="AwardTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="RestrictedStockUnitsRSUMember" xlink:title="RestrictedStockUnitsRSUMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="RestrictedStockUnitsRSUMember" xlink:title="presentation: ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain to RestrictedStockUnitsRSUMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AwardTypeAxis" xlink:to="ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:title="presentation: AwardTypeAxis to ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="AwardTypeAxis" xlink:title="presentation: ScheduleOfRelatedPartyTransactionsByRelatedPartyTable to AwardTypeAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityAxis" xlink:label="LineOfCreditFacilityAxis" xlink:title="LineOfCreditFacilityAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="LineOfCreditFacilityLenderDomain" xlink:title="LineOfCreditFacilityLenderDomain" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_PerceptiveCreditHoldingsIILPMember" xlink:label="PerceptiveCreditHoldingsIILPMember" xlink:title="PerceptiveCreditHoldingsIILPMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LineOfCreditFacilityLenderDomain" xlink:to="PerceptiveCreditHoldingsIILPMember" xlink:title="presentation: LineOfCreditFacilityLenderDomain to PerceptiveCreditHoldingsIILPMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LineOfCreditFacilityAxis" xlink:to="LineOfCreditFacilityLenderDomain" xlink:title="presentation: LineOfCreditFacilityAxis to LineOfCreditFacilityLenderDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="LineOfCreditFacilityAxis" xlink:title="presentation: ScheduleOfRelatedPartyTransactionsByRelatedPartyTable to LineOfCreditFacilityAxis" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="TitleOfIndividualAxis" xlink:title="TitleOfIndividualAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="TitleOfIndividualWithRelationshipToEntityDomain" xlink:title="TitleOfIndividualWithRelationshipToEntityDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ExecutiveOfficerMember" xlink:label="ExecutiveOfficerMember" xlink:title="ExecutiveOfficerMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="ExecutiveOfficerMember" xlink:title="presentation: TitleOfIndividualWithRelationshipToEntityDomain to ExecutiveOfficerMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_PresidentAndChiefExecutiveOfficerMember" xlink:label="PresidentAndChiefExecutiveOfficerMember" xlink:title="PresidentAndChiefExecutiveOfficerMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="PresidentAndChiefExecutiveOfficerMember" xlink:title="presentation: TitleOfIndividualWithRelationshipToEntityDomain to PresidentAndChiefExecutiveOfficerMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_ExecutiveVicePresidentAndChiefFinancialOfficerMember" xlink:label="ExecutiveVicePresidentAndChiefFinancialOfficerMember" xlink:title="ExecutiveVicePresidentAndChiefFinancialOfficerMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="ExecutiveVicePresidentAndChiefFinancialOfficerMember" xlink:title="presentation: TitleOfIndividualWithRelationshipToEntityDomain to ExecutiveVicePresidentAndChiefFinancialOfficerMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TitleOfIndividualAxis" xlink:to="TitleOfIndividualWithRelationshipToEntityDomain" xlink:title="presentation: TitleOfIndividualAxis to TitleOfIndividualWithRelationshipToEntityDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="TitleOfIndividualAxis" xlink:title="presentation: ScheduleOfRelatedPartyTransactionsByRelatedPartyTable to TitleOfIndividualAxis" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OwnershipAxis" xlink:label="OwnershipAxis" xlink:title="OwnershipAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_OwnershipDomain" xlink:label="OwnershipDomain" xlink:title="OwnershipDomain" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_DirectOwnershipMember" xlink:label="DirectOwnershipMember" xlink:title="DirectOwnershipMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OwnershipDomain" xlink:to="DirectOwnershipMember" xlink:title="presentation: OwnershipDomain to DirectOwnershipMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_IndirectOwnershipMember" xlink:label="IndirectOwnershipMember" xlink:title="IndirectOwnershipMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OwnershipDomain" xlink:to="IndirectOwnershipMember" xlink:title="presentation: OwnershipDomain to IndirectOwnershipMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OwnershipAxis" xlink:to="OwnershipDomain" xlink:title="presentation: OwnershipAxis to OwnershipDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="OwnershipAxis" xlink:title="presentation: ScheduleOfRelatedPartyTransactionsByRelatedPartyTable to OwnershipAxis" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="RelatedPartyTransactionLineItems" xlink:title="RelatedPartyTransactionLineItems" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_RelatedPartyTransactionAbstract" xlink:label="RelatedPartyTransactionAbstract" xlink:title="RelatedPartyTransactionAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingCostsAndExpenses" xlink:label="OperatingCostsAndExpenses" xlink:title="OperatingCostsAndExpenses" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionAbstract" xlink:to="OperatingCostsAndExpenses" xlink:title="presentation: RelatedPartyTransactionAbstract to OperatingCostsAndExpenses" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseExpirationDate1" xlink:label="LeaseExpirationDate1" xlink:title="LeaseExpirationDate1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionAbstract" xlink:to="LeaseExpirationDate1" xlink:title="presentation: RelatedPartyTransactionAbstract to LeaseExpirationDate1" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_RelatedPartyTransactionLeaseRenewalPeriod" xlink:label="RelatedPartyTransactionLeaseRenewalPeriod" xlink:title="RelatedPartyTransactionLeaseRenewalPeriod" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionAbstract" xlink:to="RelatedPartyTransactionLeaseRenewalPeriod" xlink:title="presentation: RelatedPartyTransactionAbstract to RelatedPartyTransactionLeaseRenewalPeriod" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_RelatedPartyTransactionLeaseTerminationPeriod" xlink:label="RelatedPartyTransactionLeaseTerminationPeriod" xlink:title="RelatedPartyTransactionLeaseTerminationPeriod" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionAbstract" xlink:to="RelatedPartyTransactionLeaseTerminationPeriod" xlink:title="presentation: RelatedPartyTransactionAbstract to RelatedPartyTransactionLeaseTerminationPeriod" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty" xlink:label="RelatedPartyTransactionPurchasesFromRelatedParty" xlink:title="RelatedPartyTransactionPurchasesFromRelatedParty" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionAbstract" xlink:to="RelatedPartyTransactionPurchasesFromRelatedParty" xlink:title="presentation: RelatedPartyTransactionAbstract to RelatedPartyTransactionPurchasesFromRelatedParty" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:title="presentation: RelatedPartyTransactionAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:title="presentation: RelatedPartyTransactionAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:title="presentation: RelatedPartyTransactionAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" xlink:title="presentation: RelatedPartyTransactionAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="ShareBasedCompensation" xlink:title="ShareBasedCompensation" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionAbstract" xlink:to="ShareBasedCompensation" xlink:title="presentation: RelatedPartyTransactionAbstract to ShareBasedCompensation" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_NumberOfExecutiveOfficersThatExercisedOptions" xlink:label="NumberOfExecutiveOfficersThatExercisedOptions" xlink:title="NumberOfExecutiveOfficersThatExercisedOptions" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionAbstract" xlink:to="NumberOfExecutiveOfficersThatExercisedOptions" xlink:title="presentation: RelatedPartyTransactionAbstract to NumberOfExecutiveOfficersThatExercisedOptions" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedInCashlessTransactionForAward" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedInCashlessTransactionForAward" xlink:title="ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedInCashlessTransactionForAward" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedInCashlessTransactionForAward" xlink:title="presentation: RelatedPartyTransactionAbstract to ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedInCashlessTransactionForAward" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:title="StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionAbstract" xlink:to="StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:title="presentation: RelatedPartyTransactionAbstract to StockIssuedDuringPeriodSharesStockOptionsExercised" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:label="SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:title="SharesPaidForTaxWithholdingForShareBasedCompensation" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionAbstract" xlink:to="SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:title="presentation: RelatedPartyTransactionAbstract to SharesPaidForTaxWithholdingForShareBasedCompensation" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_MinimumPercentageOfCommonStockHeldByLender" xlink:label="MinimumPercentageOfCommonStockHeldByLender" xlink:title="MinimumPercentageOfCommonStockHeldByLender" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionAbstract" xlink:to="MinimumPercentageOfCommonStockHeldByLender" xlink:title="presentation: RelatedPartyTransactionAbstract to MinimumPercentageOfCommonStockHeldByLender" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="StockIssuedDuringPeriodSharesNewIssues" xlink:title="StockIssuedDuringPeriodSharesNewIssues" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionAbstract" xlink:to="StockIssuedDuringPeriodSharesNewIssues" xlink:title="presentation: RelatedPartyTransactionAbstract to StockIssuedDuringPeriodSharesNewIssues" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="SharesIssuedPricePerShare" xlink:title="SharesIssuedPricePerShare" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionAbstract" xlink:to="SharesIssuedPricePerShare" xlink:title="presentation: RelatedPartyTransactionAbstract to SharesIssuedPricePerShare" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionLineItems" xlink:to="RelatedPartyTransactionAbstract" xlink:title="presentation: RelatedPartyTransactionLineItems to RelatedPartyTransactionAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="RelatedPartyTransactionLineItems" xlink:title="presentation: ScheduleOfRelatedPartyTransactionsByRelatedPartyTable to RelatedPartyTransactionLineItems" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RelatedPartyTransactionsAbstract" xlink:to="ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:title="presentation: RelatedPartyTransactionsAbstract to ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/CommitmentsAndContingenciesDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="CommitmentsAndContingenciesDisclosureAbstract" xlink:title="CommitmentsAndContingenciesDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingenciesTable" xlink:label="LossContingenciesTable" xlink:title="LossContingenciesTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="TypeOfArrangementAxis" xlink:title="TypeOfArrangementAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="ArrangementsAndNonarrangementTransactionsMember" xlink:title="ArrangementsAndNonarrangementTransactionsMember" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_PlasmaPurchaseAgreementOneMember" xlink:label="PlasmaPurchaseAgreementOneMember" xlink:title="PlasmaPurchaseAgreementOneMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ArrangementsAndNonarrangementTransactionsMember" xlink:to="PlasmaPurchaseAgreementOneMember" xlink:title="presentation: ArrangementsAndNonarrangementTransactionsMember to PlasmaPurchaseAgreementOneMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_ARGrifolsAgreementMember" xlink:label="ARGrifolsAgreementMember" xlink:title="ARGrifolsAgreementMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ArrangementsAndNonarrangementTransactionsMember" xlink:to="ARGrifolsAgreementMember" xlink:title="presentation: ArrangementsAndNonarrangementTransactionsMember to ARGrifolsAgreementMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_KEDPlasmaAgreementMember" xlink:label="KEDPlasmaAgreementMember" xlink:title="KEDPlasmaAgreementMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ArrangementsAndNonarrangementTransactionsMember" xlink:to="KEDPlasmaAgreementMember" xlink:title="presentation: ArrangementsAndNonarrangementTransactionsMember to KEDPlasmaAgreementMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TypeOfArrangementAxis" xlink:to="ArrangementsAndNonarrangementTransactionsMember" xlink:title="presentation: TypeOfArrangementAxis to ArrangementsAndNonarrangementTransactionsMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LossContingenciesTable" xlink:to="TypeOfArrangementAxis" xlink:title="presentation: LossContingenciesTable to TypeOfArrangementAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="RangeAxis" xlink:title="RangeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="RangeMember" xlink:title="RangeMember" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="MinimumMember" xlink:title="MinimumMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangeMember" xlink:to="MinimumMember" xlink:title="presentation: RangeMember to MinimumMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="MaximumMember" xlink:title="MaximumMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangeMember" xlink:to="MaximumMember" xlink:title="presentation: RangeMember to MaximumMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangeAxis" xlink:to="RangeMember" xlink:title="presentation: RangeAxis to RangeMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LossContingenciesTable" xlink:to="RangeAxis" xlink:title="presentation: LossContingenciesTable to RangeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="SubsequentEventTypeAxis" xlink:title="SubsequentEventTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="SubsequentEventTypeDomain" xlink:title="SubsequentEventTypeDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="SubsequentEventMember" xlink:title="SubsequentEventMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventTypeDomain" xlink:to="SubsequentEventMember" xlink:title="presentation: SubsequentEventTypeDomain to SubsequentEventMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventTypeAxis" xlink:to="SubsequentEventTypeDomain" xlink:title="presentation: SubsequentEventTypeAxis to SubsequentEventTypeDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LossContingenciesTable" xlink:to="SubsequentEventTypeAxis" xlink:title="presentation: LossContingenciesTable to SubsequentEventTypeAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductOrServiceAxis" xlink:label="ProductOrServiceAxis" xlink:title="ProductOrServiceAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ProductsAndServicesDomain" xlink:label="ProductsAndServicesDomain" xlink:title="ProductsAndServicesDomain" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_ASCENIVMember" xlink:label="ASCENIVMember" xlink:title="ASCENIVMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ProductsAndServicesDomain" xlink:to="ASCENIVMember" xlink:title="presentation: ProductsAndServicesDomain to ASCENIVMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_BIVIGAMMember" xlink:label="BIVIGAMMember" xlink:title="BIVIGAMMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ProductsAndServicesDomain" xlink:to="BIVIGAMMember" xlink:title="presentation: ProductsAndServicesDomain to BIVIGAMMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ProductOrServiceAxis" xlink:to="ProductsAndServicesDomain" xlink:title="presentation: ProductOrServiceAxis to ProductsAndServicesDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LossContingenciesTable" xlink:to="ProductOrServiceAxis" xlink:title="presentation: LossContingenciesTable to ProductOrServiceAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingenciesLineItems" xlink:label="LossContingenciesLineItems" xlink:title="LossContingenciesLineItems" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_VendorAndLicensorCommitmentsAbstract" xlink:label="VendorAndLicensorCommitmentsAbstract" xlink:title="VendorAndLicensorCommitmentsAbstract" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_ITTechnologySystemsInaccessiblePeriod" xlink:label="ITTechnologySystemsInaccessiblePeriod" xlink:title="ITTechnologySystemsInaccessiblePeriod" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="VendorAndLicensorCommitmentsAbstract" xlink:to="ITTechnologySystemsInaccessiblePeriod" xlink:title="presentation: VendorAndLicensorCommitmentsAbstract to ITTechnologySystemsInaccessiblePeriod" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_NumberOfBatchesInProductionAtTheTimeOfDisruption" xlink:label="NumberOfBatchesInProductionAtTheTimeOfDisruption" xlink:title="NumberOfBatchesInProductionAtTheTimeOfDisruption" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="VendorAndLicensorCommitmentsAbstract" xlink:to="NumberOfBatchesInProductionAtTheTimeOfDisruption" xlink:title="presentation: VendorAndLicensorCommitmentsAbstract to NumberOfBatchesInProductionAtTheTimeOfDisruption" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryWriteDown" xlink:label="InventoryWriteDown" xlink:title="InventoryWriteDown" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="VendorAndLicensorCommitmentsAbstract" xlink:to="InventoryWriteDown" xlink:title="presentation: VendorAndLicensorCommitmentsAbstract to InventoryWriteDown" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCostAndExpenseOperating" xlink:label="OtherCostAndExpenseOperating" xlink:title="OtherCostAndExpenseOperating" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="VendorAndLicensorCommitmentsAbstract" xlink:to="OtherCostAndExpenseOperating" xlink:title="presentation: VendorAndLicensorCommitmentsAbstract to OtherCostAndExpenseOperating" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_RestorationCostsReceived" xlink:label="RestorationCostsReceived" xlink:title="RestorationCostsReceived" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="VendorAndLicensorCommitmentsAbstract" xlink:to="RestorationCostsReceived" xlink:title="presentation: VendorAndLicensorCommitmentsAbstract to RestorationCostsReceived" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromInsuranceSettlementOperatingActivities" xlink:label="ProceedsFromInsuranceSettlementOperatingActivities" xlink:title="ProceedsFromInsuranceSettlementOperatingActivities" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="VendorAndLicensorCommitmentsAbstract" xlink:to="ProceedsFromInsuranceSettlementOperatingActivities" xlink:title="presentation: VendorAndLicensorCommitmentsAbstract to ProceedsFromInsuranceSettlementOperatingActivities" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_NumberOfPlasmaCollectionFacilities" xlink:label="NumberOfPlasmaCollectionFacilities" xlink:title="NumberOfPlasmaCollectionFacilities" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="VendorAndLicensorCommitmentsAbstract" xlink:to="NumberOfPlasmaCollectionFacilities" xlink:title="presentation: VendorAndLicensorCommitmentsAbstract to NumberOfPlasmaCollectionFacilities" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_NumberOfRenewalTerms" xlink:label="NumberOfRenewalTerms" xlink:title="NumberOfRenewalTerms" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="VendorAndLicensorCommitmentsAbstract" xlink:to="NumberOfRenewalTerms" xlink:title="presentation: VendorAndLicensorCommitmentsAbstract to NumberOfRenewalTerms" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_PlasmaPurchaseAgreementRenewalPeriod" xlink:label="PlasmaPurchaseAgreementRenewalPeriod" xlink:title="PlasmaPurchaseAgreementRenewalPeriod" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="VendorAndLicensorCommitmentsAbstract" xlink:to="PlasmaPurchaseAgreementRenewalPeriod" xlink:title="presentation: VendorAndLicensorCommitmentsAbstract to PlasmaPurchaseAgreementRenewalPeriod" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_AgreementWithTermExpirationDate" xlink:label="AgreementWithTermExpirationDate" xlink:title="AgreementWithTermExpirationDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="VendorAndLicensorCommitmentsAbstract" xlink:to="AgreementWithTermExpirationDate" xlink:title="presentation: VendorAndLicensorCommitmentsAbstract to AgreementWithTermExpirationDate" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_QuantityOfRespiratorySyncytialVirusPlasmaUsed" xlink:label="QuantityOfRespiratorySyncytialVirusPlasmaUsed" xlink:title="QuantityOfRespiratorySyncytialVirusPlasmaUsed" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="VendorAndLicensorCommitmentsAbstract" xlink:to="QuantityOfRespiratorySyncytialVirusPlasmaUsed" xlink:title="presentation: VendorAndLicensorCommitmentsAbstract to QuantityOfRespiratorySyncytialVirusPlasmaUsed" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_RespiratorySyncytialVirusPlasmaVolumeSuppliedPeriod" xlink:label="RespiratorySyncytialVirusPlasmaVolumeSuppliedPeriod" xlink:title="RespiratorySyncytialVirusPlasmaVolumeSuppliedPeriod" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="VendorAndLicensorCommitmentsAbstract" xlink:to="RespiratorySyncytialVirusPlasmaVolumeSuppliedPeriod" xlink:title="presentation: VendorAndLicensorCommitmentsAbstract to RespiratorySyncytialVirusPlasmaVolumeSuppliedPeriod" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_IncreaseInMinimumAnnualPriceTerm" xlink:label="IncreaseInMinimumAnnualPriceTerm" xlink:title="IncreaseInMinimumAnnualPriceTerm" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="VendorAndLicensorCommitmentsAbstract" xlink:to="IncreaseInMinimumAnnualPriceTerm" xlink:title="presentation: VendorAndLicensorCommitmentsAbstract to IncreaseInMinimumAnnualPriceTerm" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_PlasmaSupplyAgreementTerm" xlink:label="PlasmaSupplyAgreementTerm" xlink:title="PlasmaSupplyAgreementTerm" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="VendorAndLicensorCommitmentsAbstract" xlink:to="PlasmaSupplyAgreementTerm" xlink:title="presentation: VendorAndLicensorCommitmentsAbstract to PlasmaSupplyAgreementTerm" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LossContingenciesLineItems" xlink:to="VendorAndLicensorCommitmentsAbstract" xlink:title="presentation: LossContingenciesLineItems to VendorAndLicensorCommitmentsAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_PostMarketingCommitmentsAbstract" xlink:label="PostMarketingCommitmentsAbstract" xlink:title="PostMarketingCommitmentsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="ResearchAndDevelopmentExpense" xlink:title="ResearchAndDevelopmentExpense" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="PostMarketingCommitmentsAbstract" xlink:to="ResearchAndDevelopmentExpense" xlink:title="presentation: PostMarketingCommitmentsAbstract to ResearchAndDevelopmentExpense" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LossContingenciesLineItems" xlink:to="PostMarketingCommitmentsAbstract" xlink:title="presentation: LossContingenciesLineItems to PostMarketingCommitmentsAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LossContingenciesTable" xlink:to="LossContingenciesLineItems" xlink:title="presentation: LossContingenciesTable to LossContingenciesLineItems" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CommitmentsAndContingenciesDisclosureAbstract" xlink:to="LossContingenciesTable" xlink:title="presentation: CommitmentsAndContingenciesDisclosureAbstract to LossContingenciesTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/IncomeTaxesIncomeTaxExpenseBenefitDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="IncomeTaxDisclosureAbstract" xlink:title="IncomeTaxDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:title="CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="CurrentFederalTaxExpenseBenefit" xlink:title="CurrentFederalTaxExpenseBenefit" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="CurrentFederalTaxExpenseBenefit" xlink:title="presentation: CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract to CurrentFederalTaxExpenseBenefit" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="CurrentStateAndLocalTaxExpenseBenefit" xlink:title="CurrentStateAndLocalTaxExpenseBenefit" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="CurrentStateAndLocalTaxExpenseBenefit" xlink:title="presentation: CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract to CurrentStateAndLocalTaxExpenseBenefit" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="CurrentIncomeTaxExpenseBenefit" xlink:title="CurrentIncomeTaxExpenseBenefit" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="CurrentIncomeTaxExpenseBenefit" xlink:title="presentation: CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract to CurrentIncomeTaxExpenseBenefit" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:title="presentation: IncomeTaxDisclosureAbstract to CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:title="DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="DeferredFederalIncomeTaxExpenseBenefit" xlink:title="DeferredFederalIncomeTaxExpenseBenefit" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="DeferredFederalIncomeTaxExpenseBenefit" xlink:title="presentation: DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract to DeferredFederalIncomeTaxExpenseBenefit" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:title="DeferredStateAndLocalIncomeTaxExpenseBenefit" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:title="presentation: DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract to DeferredStateAndLocalIncomeTaxExpenseBenefit" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="DeferredIncomeTaxExpenseBenefit" xlink:title="DeferredIncomeTaxExpenseBenefit" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="DeferredIncomeTaxExpenseBenefit" xlink:title="presentation: DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract to DeferredIncomeTaxExpenseBenefit" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:title="presentation: IncomeTaxDisclosureAbstract to DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="IncomeTaxExpenseBenefit" xlink:title="IncomeTaxExpenseBenefit" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="IncomeTaxExpenseBenefit" xlink:title="presentation: IncomeTaxDisclosureAbstract to IncomeTaxExpenseBenefit" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/IncomeTaxesReconciliationOfIncomeTaxesDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="IncomeTaxDisclosureAbstract" xlink:title="IncomeTaxDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:title="IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:title="presentation: IncomeTaxDisclosureAbstract to IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:title="IncomeTaxReconciliationStateAndLocalIncomeTaxes" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:title="presentation: IncomeTaxDisclosureAbstract to IncomeTaxReconciliationStateAndLocalIncomeTaxes" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:label="IncomeTaxReconciliationNondeductibleExpense" xlink:title="IncomeTaxReconciliationNondeductibleExpense" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="IncomeTaxReconciliationNondeductibleExpense" xlink:title="presentation: IncomeTaxDisclosureAbstract to IncomeTaxReconciliationNondeductibleExpense" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" xlink:label="EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" xlink:title="EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" xlink:title="presentation: IncomeTaxDisclosureAbstract to EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:title="IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:title="presentation: IncomeTaxDisclosureAbstract to IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:label="IncomeTaxReconciliationOtherAdjustments" xlink:title="IncomeTaxReconciliationOtherAdjustments" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="IncomeTaxReconciliationOtherAdjustments" xlink:title="presentation: IncomeTaxDisclosureAbstract to IncomeTaxReconciliationOtherAdjustments" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="IncomeTaxExpenseBenefit" xlink:title="IncomeTaxExpenseBenefit" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="IncomeTaxExpenseBenefit" xlink:title="presentation: IncomeTaxDisclosureAbstract to IncomeTaxExpenseBenefit" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/IncomeTaxesDeferredTaxAssetsDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="IncomeTaxDisclosureAbstract" xlink:title="IncomeTaxDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:label="ComponentsOfDeferredTaxAssetsAbstract" xlink:title="ComponentsOfDeferredTaxAssetsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:label="DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:title="DeferredTaxAssetsOperatingLossCarryforwardsDomestic" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ComponentsOfDeferredTaxAssetsAbstract" xlink:to="DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:title="presentation: ComponentsOfDeferredTaxAssetsAbstract to DeferredTaxAssetsOperatingLossCarryforwardsDomestic" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetInterestCarryforward" xlink:label="DeferredTaxAssetInterestCarryforward" xlink:title="DeferredTaxAssetInterestCarryforward" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ComponentsOfDeferredTaxAssetsAbstract" xlink:to="DeferredTaxAssetInterestCarryforward" xlink:title="presentation: ComponentsOfDeferredTaxAssetsAbstract to DeferredTaxAssetInterestCarryforward" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsInventory" xlink:label="DeferredTaxAssetsInventory" xlink:title="DeferredTaxAssetsInventory" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ComponentsOfDeferredTaxAssetsAbstract" xlink:to="DeferredTaxAssetsInventory" xlink:title="presentation: ComponentsOfDeferredTaxAssetsAbstract to DeferredTaxAssetsInventory" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:title="DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ComponentsOfDeferredTaxAssetsAbstract" xlink:to="DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:title="presentation: ComponentsOfDeferredTaxAssetsAbstract to DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_DeferredTaxAssetsLeaseObligations" xlink:label="DeferredTaxAssetsLeaseObligations" xlink:title="DeferredTaxAssetsLeaseObligations" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ComponentsOfDeferredTaxAssetsAbstract" xlink:to="DeferredTaxAssetsLeaseObligations" xlink:title="presentation: ComponentsOfDeferredTaxAssetsAbstract to DeferredTaxAssetsLeaseObligations" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:label="DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:title="DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ComponentsOfDeferredTaxAssetsAbstract" xlink:to="DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:title="presentation: ComponentsOfDeferredTaxAssetsAbstract to DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="DeferredTaxAssetsGross" xlink:title="DeferredTaxAssetsGross" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ComponentsOfDeferredTaxAssetsAbstract" xlink:to="DeferredTaxAssetsGross" xlink:title="presentation: ComponentsOfDeferredTaxAssetsAbstract to DeferredTaxAssetsGross" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="DeferredTaxAssetsValuationAllowance" xlink:title="DeferredTaxAssetsValuationAllowance" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ComponentsOfDeferredTaxAssetsAbstract" xlink:to="DeferredTaxAssetsValuationAllowance" xlink:title="presentation: ComponentsOfDeferredTaxAssetsAbstract to DeferredTaxAssetsValuationAllowance" order="7.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="DeferredTaxAssetsNet" xlink:title="DeferredTaxAssetsNet" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ComponentsOfDeferredTaxAssetsAbstract" xlink:to="DeferredTaxAssetsNet" xlink:title="presentation: ComponentsOfDeferredTaxAssetsAbstract to DeferredTaxAssetsNet" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="ComponentsOfDeferredTaxAssetsAbstract" xlink:title="presentation: IncomeTaxDisclosureAbstract to ComponentsOfDeferredTaxAssetsAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:label="ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:title="ComponentsOfDeferredTaxLiabilitiesAbstract" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_DeferredTaxLiabilitiesDepreciationOfPropertyAndEquipment" xlink:label="DeferredTaxLiabilitiesDepreciationOfPropertyAndEquipment" xlink:title="DeferredTaxLiabilitiesDepreciationOfPropertyAndEquipment" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:to="DeferredTaxLiabilitiesDepreciationOfPropertyAndEquipment" xlink:title="presentation: ComponentsOfDeferredTaxLiabilitiesAbstract to DeferredTaxLiabilitiesDepreciationOfPropertyAndEquipment" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_DeferredTaxLiabilitiesRightOfUseAsset" xlink:label="DeferredTaxLiabilitiesRightOfUseAsset" xlink:title="DeferredTaxLiabilitiesRightOfUseAsset" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:to="DeferredTaxLiabilitiesRightOfUseAsset" xlink:title="presentation: ComponentsOfDeferredTaxLiabilitiesAbstract to DeferredTaxLiabilitiesRightOfUseAsset" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesOther" xlink:label="DeferredTaxLiabilitiesOther" xlink:title="DeferredTaxLiabilitiesOther" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:to="DeferredTaxLiabilitiesOther" xlink:title="presentation: ComponentsOfDeferredTaxLiabilitiesAbstract to DeferredTaxLiabilitiesOther" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="DeferredIncomeTaxLiabilities" xlink:title="DeferredIncomeTaxLiabilities" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:to="DeferredIncomeTaxLiabilities" xlink:title="presentation: ComponentsOfDeferredTaxLiabilitiesAbstract to DeferredIncomeTaxLiabilities" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:title="presentation: IncomeTaxDisclosureAbstract to ComponentsOfDeferredTaxLiabilitiesAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="DeferredTaxAssetsLiabilitiesNet" xlink:title="DeferredTaxAssetsLiabilitiesNet" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="DeferredTaxAssetsLiabilitiesNet" xlink:title="presentation: IncomeTaxDisclosureAbstract to DeferredTaxAssetsLiabilitiesNet" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/IncomeTaxesNetOperatingLossCarryforwardsDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="IncomeTaxDisclosureAbstract" xlink:title="IncomeTaxDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="OperatingLossCarryforwardsTable" xlink:title="OperatingLossCarryforwardsTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="IncomeTaxAuthorityAxis" xlink:title="IncomeTaxAuthorityAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="IncomeTaxAuthorityDomain" xlink:title="IncomeTaxAuthorityDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InternalRevenueServiceIRSMember" xlink:label="InternalRevenueServiceIRSMember" xlink:title="InternalRevenueServiceIRSMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxAuthorityDomain" xlink:to="InternalRevenueServiceIRSMember" xlink:title="presentation: IncomeTaxAuthorityDomain to InternalRevenueServiceIRSMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="StateAndLocalJurisdictionMember" xlink:title="StateAndLocalJurisdictionMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxAuthorityDomain" xlink:to="StateAndLocalJurisdictionMember" xlink:title="presentation: IncomeTaxAuthorityDomain to StateAndLocalJurisdictionMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxAuthorityAxis" xlink:to="IncomeTaxAuthorityDomain" xlink:title="presentation: IncomeTaxAuthorityAxis to IncomeTaxAuthorityDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingLossCarryforwardsTable" xlink:to="IncomeTaxAuthorityAxis" xlink:title="presentation: OperatingLossCarryforwardsTable to IncomeTaxAuthorityAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="RangeAxis" xlink:title="RangeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="RangeMember" xlink:title="RangeMember" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="MinimumMember" xlink:title="MinimumMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangeMember" xlink:to="MinimumMember" xlink:title="presentation: RangeMember to MinimumMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="MaximumMember" xlink:title="MaximumMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangeMember" xlink:to="MaximumMember" xlink:title="presentation: RangeMember to MaximumMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RangeAxis" xlink:to="RangeMember" xlink:title="presentation: RangeAxis to RangeMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingLossCarryforwardsTable" xlink:to="RangeAxis" xlink:title="presentation: OperatingLossCarryforwardsTable to RangeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxPeriodAxis" xlink:label="TaxPeriodAxis" xlink:title="TaxPeriodAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxPeriodDomain" xlink:label="TaxPeriodDomain" xlink:title="TaxPeriodDomain" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_TaxYear2028Through2043Member" xlink:label="TaxYear2028Through2043Member" xlink:title="TaxYear2028Through2043Member" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TaxPeriodDomain" xlink:to="TaxYear2028Through2043Member" xlink:title="presentation: TaxPeriodDomain to TaxYear2028Through2043Member" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_TaxYear2031Member" xlink:label="TaxYear2031Member" xlink:title="TaxYear2031Member" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TaxPeriodDomain" xlink:to="TaxYear2031Member" xlink:title="presentation: TaxPeriodDomain to TaxYear2031Member" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_TaxYear2032Member" xlink:label="TaxYear2032Member" xlink:title="TaxYear2032Member" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TaxPeriodDomain" xlink:to="TaxYear2032Member" xlink:title="presentation: TaxPeriodDomain to TaxYear2032Member" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_TaxYear2033Member" xlink:label="TaxYear2033Member" xlink:title="TaxYear2033Member" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TaxPeriodDomain" xlink:to="TaxYear2033Member" xlink:title="presentation: TaxPeriodDomain to TaxYear2033Member" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_TaxYear2034Member" xlink:label="TaxYear2034Member" xlink:title="TaxYear2034Member" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TaxPeriodDomain" xlink:to="TaxYear2034Member" xlink:title="presentation: TaxPeriodDomain to TaxYear2034Member" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_TaxYear2035Member" xlink:label="TaxYear2035Member" xlink:title="TaxYear2035Member" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TaxPeriodDomain" xlink:to="TaxYear2035Member" xlink:title="presentation: TaxPeriodDomain to TaxYear2035Member" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_TaxYear2036Member" xlink:label="TaxYear2036Member" xlink:title="TaxYear2036Member" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TaxPeriodDomain" xlink:to="TaxYear2036Member" xlink:title="presentation: TaxPeriodDomain to TaxYear2036Member" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_TaxYear2037Member" xlink:label="TaxYear2037Member" xlink:title="TaxYear2037Member" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TaxPeriodDomain" xlink:to="TaxYear2037Member" xlink:title="presentation: TaxPeriodDomain to TaxYear2037Member" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_TaxYearAfter2037Member" xlink:label="TaxYearAfter2037Member" xlink:title="TaxYearAfter2037Member" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TaxPeriodDomain" xlink:to="TaxYearAfter2037Member" xlink:title="presentation: TaxPeriodDomain to TaxYearAfter2037Member" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="TaxPeriodAxis" xlink:to="TaxPeriodDomain" xlink:title="presentation: TaxPeriodAxis to TaxPeriodDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingLossCarryforwardsTable" xlink:to="TaxPeriodAxis" xlink:title="presentation: OperatingLossCarryforwardsTable to TaxPeriodAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="OperatingLossCarryforwardsLineItems" xlink:title="OperatingLossCarryforwardsLineItems" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_NetOperatingLossCarryforwardsAbstract" xlink:label="NetOperatingLossCarryforwardsAbstract" xlink:title="NetOperatingLossCarryforwardsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="OperatingLossCarryforwards" xlink:title="OperatingLossCarryforwards" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetOperatingLossCarryforwardsAbstract" xlink:to="OperatingLossCarryforwards" xlink:title="presentation: NetOperatingLossCarryforwardsAbstract to OperatingLossCarryforwards" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwardsExpirationDate" xlink:label="OperatingLossCarryforwardsExpirationDate" xlink:title="OperatingLossCarryforwardsExpirationDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetOperatingLossCarryforwardsAbstract" xlink:to="OperatingLossCarryforwardsExpirationDate" xlink:title="presentation: NetOperatingLossCarryforwardsAbstract to OperatingLossCarryforwardsExpirationDate" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardValuationAllowance" xlink:label="TaxCreditCarryforwardValuationAllowance" xlink:title="TaxCreditCarryforwardValuationAllowance" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetOperatingLossCarryforwardsAbstract" xlink:to="TaxCreditCarryforwardValuationAllowance" xlink:title="presentation: NetOperatingLossCarryforwardsAbstract to TaxCreditCarryforwardValuationAllowance" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="UnrecognizedTaxBenefits" xlink:title="UnrecognizedTaxBenefits" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NetOperatingLossCarryforwardsAbstract" xlink:to="UnrecognizedTaxBenefits" xlink:title="presentation: NetOperatingLossCarryforwardsAbstract to UnrecognizedTaxBenefits" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingLossCarryforwardsLineItems" xlink:to="NetOperatingLossCarryforwardsAbstract" xlink:title="presentation: OperatingLossCarryforwardsLineItems to NetOperatingLossCarryforwardsAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingLossCarryforwardsTable" xlink:to="OperatingLossCarryforwardsLineItems" xlink:title="presentation: OperatingLossCarryforwardsTable to OperatingLossCarryforwardsLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="OperatingLossCarryforwardsTable" xlink:title="presentation: IncomeTaxDisclosureAbstract to OperatingLossCarryforwardsTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/LeaseObligationsDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract" xlink:label="LeasesAbstract" xlink:title="LeasesAbstract" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_OperatingLeaseIncrementalBorrowingRatePercent" xlink:label="OperatingLeaseIncrementalBorrowingRatePercent" xlink:title="OperatingLeaseIncrementalBorrowingRatePercent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesAbstract" xlink:to="OperatingLeaseIncrementalBorrowingRatePercent" xlink:title="presentation: LeasesAbstract to OperatingLeaseIncrementalBorrowingRatePercent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="OperatingLeaseWeightedAverageDiscountRatePercent" xlink:title="OperatingLeaseWeightedAverageDiscountRatePercent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesAbstract" xlink:to="OperatingLeaseWeightedAverageDiscountRatePercent" xlink:title="presentation: LeasesAbstract to OperatingLeaseWeightedAverageDiscountRatePercent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseExpense" xlink:label="OperatingLeaseExpense" xlink:title="OperatingLeaseExpense" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesAbstract" xlink:to="OperatingLeaseExpense" xlink:title="presentation: LeasesAbstract to OperatingLeaseExpense" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeasePayments" xlink:label="OperatingLeasePayments" xlink:title="OperatingLeasePayments" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesAbstract" xlink:to="OperatingLeasePayments" xlink:title="presentation: LeasesAbstract to OperatingLeasePayments" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_NumberOfNewPropertyLeases" xlink:label="NumberOfNewPropertyLeases" xlink:title="NumberOfNewPropertyLeases" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesAbstract" xlink:to="NumberOfNewPropertyLeases" xlink:title="presentation: LeasesAbstract to NumberOfNewPropertyLeases" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_LesseeOperatingLeaseRightOfUseAssetRelatedToPropertyLease" xlink:label="LesseeOperatingLeaseRightOfUseAssetRelatedToPropertyLease" xlink:title="LesseeOperatingLeaseRightOfUseAssetRelatedToPropertyLease" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesAbstract" xlink:to="LesseeOperatingLeaseRightOfUseAssetRelatedToPropertyLease" xlink:title="presentation: LeasesAbstract to LesseeOperatingLeaseRightOfUseAssetRelatedToPropertyLease" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_LesseeOperatingLeaseLiabilitiesRelatedToPropertyLease" xlink:label="LesseeOperatingLeaseLiabilitiesRelatedToPropertyLease" xlink:title="LesseeOperatingLeaseLiabilitiesRelatedToPropertyLease" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesAbstract" xlink:to="LesseeOperatingLeaseLiabilitiesRelatedToPropertyLease" xlink:title="presentation: LeasesAbstract to LesseeOperatingLeaseLiabilitiesRelatedToPropertyLease" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_OperatingAndFinancingLeaseLiability" xlink:label="OperatingAndFinancingLeaseLiability" xlink:title="OperatingAndFinancingLeaseLiability" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesAbstract" xlink:to="OperatingAndFinancingLeaseLiability" xlink:title="presentation: LeasesAbstract to OperatingAndFinancingLeaseLiability" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:title="OperatingLeaseWeightedAverageRemainingLeaseTerm1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesAbstract" xlink:to="OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:title="presentation: LeasesAbstract to OperatingLeaseWeightedAverageRemainingLeaseTerm1" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:label="OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:title="OperatingLeaseLiabilitiesPaymentsDueAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:title="LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:title="presentation: OperatingLeaseLiabilitiesPaymentsDueAbstract to LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:title="LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:title="presentation: OperatingLeaseLiabilitiesPaymentsDueAbstract to LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:title="LesseeOperatingLeaseLiabilityPaymentsDueYearThree" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:title="presentation: OperatingLeaseLiabilitiesPaymentsDueAbstract to LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:title="LesseeOperatingLeaseLiabilityPaymentsDueYearFour" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:title="presentation: OperatingLeaseLiabilitiesPaymentsDueAbstract to LesseeOperatingLeaseLiabilityPaymentsDueYearFour" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:title="LesseeOperatingLeaseLiabilityPaymentsDueYearFive" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:title="presentation: OperatingLeaseLiabilitiesPaymentsDueAbstract to LesseeOperatingLeaseLiabilityPaymentsDueYearFive" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:title="LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:title="presentation: OperatingLeaseLiabilitiesPaymentsDueAbstract to LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="LesseeOperatingLeaseLiabilityPaymentsDue" xlink:title="LesseeOperatingLeaseLiabilityPaymentsDue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="LesseeOperatingLeaseLiabilityPaymentsDue" xlink:title="presentation: OperatingLeaseLiabilitiesPaymentsDueAbstract to LesseeOperatingLeaseLiabilityPaymentsDue" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:title="LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:title="presentation: OperatingLeaseLiabilitiesPaymentsDueAbstract to LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="7.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="OperatingLeaseLiabilityCurrent" xlink:title="OperatingLeaseLiabilityCurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="OperatingLeaseLiabilityCurrent" xlink:title="presentation: OperatingLeaseLiabilitiesPaymentsDueAbstract to OperatingLeaseLiabilityCurrent" order="8.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="OperatingLeaseLiabilityNoncurrent" xlink:title="OperatingLeaseLiabilityNoncurrent" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="OperatingLeaseLiabilityNoncurrent" xlink:title="presentation: OperatingLeaseLiabilitiesPaymentsDueAbstract to OperatingLeaseLiabilityNoncurrent" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LeasesAbstract" xlink:to="OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:title="presentation: LeasesAbstract to OperatingLeaseLiabilitiesPaymentsDueAbstract" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/LeaseObligationsDetailsCalc01" />
  <link:presentationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/SegmentsSummarizedFinancialInformationBySegmentDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract" xlink:label="SegmentReportingAbstract" xlink:title="SegmentReportingAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="ScheduleOfSegmentReportingInformationBySegmentTable" xlink:title="ScheduleOfSegmentReportingInformationBySegmentTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidationItemsAxis" xlink:label="ConsolidationItemsAxis" xlink:title="ConsolidationItemsAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidationItemsDomain" xlink:label="ConsolidationItemsDomain" xlink:title="ConsolidationItemsDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingSegmentsMember" xlink:label="OperatingSegmentsMember" xlink:title="OperatingSegmentsMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConsolidationItemsDomain" xlink:to="OperatingSegmentsMember" xlink:title="presentation: ConsolidationItemsDomain to OperatingSegmentsMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MaterialReconcilingItemsMember" xlink:label="MaterialReconcilingItemsMember" xlink:title="MaterialReconcilingItemsMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConsolidationItemsDomain" xlink:to="MaterialReconcilingItemsMember" xlink:title="presentation: ConsolidationItemsDomain to MaterialReconcilingItemsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CorporateNonSegmentMember" xlink:label="CorporateNonSegmentMember" xlink:title="CorporateNonSegmentMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConsolidationItemsDomain" xlink:to="CorporateNonSegmentMember" xlink:title="presentation: ConsolidationItemsDomain to CorporateNonSegmentMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConsolidationItemsAxis" xlink:to="ConsolidationItemsDomain" xlink:title="presentation: ConsolidationItemsAxis to ConsolidationItemsDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="ConsolidationItemsAxis" xlink:title="presentation: ScheduleOfSegmentReportingInformationBySegmentTable to ConsolidationItemsAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="StatementBusinessSegmentsAxis" xlink:title="StatementBusinessSegmentsAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain" xlink:label="SegmentDomain" xlink:title="SegmentDomain" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_ADMABioManufacturingSegmentMember" xlink:label="ADMABioManufacturingSegmentMember" xlink:title="ADMABioManufacturingSegmentMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SegmentDomain" xlink:to="ADMABioManufacturingSegmentMember" xlink:title="presentation: SegmentDomain to ADMABioManufacturingSegmentMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_PlasmaCollectionCentersSegmentMember" xlink:label="PlasmaCollectionCentersSegmentMember" xlink:title="PlasmaCollectionCentersSegmentMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SegmentDomain" xlink:to="PlasmaCollectionCentersSegmentMember" xlink:title="presentation: SegmentDomain to PlasmaCollectionCentersSegmentMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementBusinessSegmentsAxis" xlink:to="SegmentDomain" xlink:title="presentation: StatementBusinessSegmentsAxis to SegmentDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="StatementBusinessSegmentsAxis" xlink:title="presentation: ScheduleOfSegmentReportingInformationBySegmentTable to StatementBusinessSegmentsAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="SegmentReportingInformationLineItems" xlink:title="SegmentReportingInformationLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingInformationProfitLossAbstract" xlink:label="SegmentReportingInformationProfitLossAbstract" xlink:title="SegmentReportingInformationProfitLossAbstract" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_NumberOfPlasmaCollectionFacilitiesUnderDevelopment" xlink:label="NumberOfPlasmaCollectionFacilitiesUnderDevelopment" xlink:title="NumberOfPlasmaCollectionFacilitiesUnderDevelopment" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SegmentReportingInformationProfitLossAbstract" xlink:to="NumberOfPlasmaCollectionFacilitiesUnderDevelopment" xlink:title="presentation: SegmentReportingInformationProfitLossAbstract to NumberOfPlasmaCollectionFacilitiesUnderDevelopment" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="NumberOfOperatingSegments" xlink:title="NumberOfOperatingSegments" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SegmentReportingInformationProfitLossAbstract" xlink:to="NumberOfOperatingSegments" xlink:title="presentation: SegmentReportingInformationProfitLossAbstract to NumberOfOperatingSegments" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="RevenueFromContractWithCustomerExcludingAssessedTax" xlink:title="RevenueFromContractWithCustomerExcludingAssessedTax" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SegmentReportingInformationProfitLossAbstract" xlink:to="RevenueFromContractWithCustomerExcludingAssessedTax" xlink:title="presentation: SegmentReportingInformationProfitLossAbstract to RevenueFromContractWithCustomerExcludingAssessedTax" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfRevenue" xlink:label="CostOfRevenue" xlink:title="CostOfRevenue" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SegmentReportingInformationProfitLossAbstract" xlink:to="CostOfRevenue" xlink:title="presentation: SegmentReportingInformationProfitLossAbstract to CostOfRevenue" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="ResearchAndDevelopmentExpense" xlink:title="ResearchAndDevelopmentExpense" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SegmentReportingInformationProfitLossAbstract" xlink:to="ResearchAndDevelopmentExpense" xlink:title="presentation: SegmentReportingInformationProfitLossAbstract to ResearchAndDevelopmentExpense" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCostAndExpenseOperating" xlink:label="OtherCostAndExpenseOperating" xlink:title="OtherCostAndExpenseOperating" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SegmentReportingInformationProfitLossAbstract" xlink:to="OtherCostAndExpenseOperating" xlink:title="presentation: SegmentReportingInformationProfitLossAbstract to OtherCostAndExpenseOperating" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingAndMarketingExpense" xlink:label="SellingAndMarketingExpense" xlink:title="SellingAndMarketingExpense" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SegmentReportingInformationProfitLossAbstract" xlink:to="SellingAndMarketingExpense" xlink:title="presentation: SegmentReportingInformationProfitLossAbstract to SellingAndMarketingExpense" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationAndAmortization" xlink:label="DepreciationAndAmortization" xlink:title="DepreciationAndAmortization" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SegmentReportingInformationProfitLossAbstract" xlink:to="DepreciationAndAmortization" xlink:title="presentation: SegmentReportingInformationProfitLossAbstract to DepreciationAndAmortization" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="GeneralAndAdministrativeExpense" xlink:title="GeneralAndAdministrativeExpense" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SegmentReportingInformationProfitLossAbstract" xlink:to="GeneralAndAdministrativeExpense" xlink:title="presentation: SegmentReportingInformationProfitLossAbstract to GeneralAndAdministrativeExpense" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="NonoperatingIncomeExpense" xlink:title="NonoperatingIncomeExpense" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SegmentReportingInformationProfitLossAbstract" xlink:to="NonoperatingIncomeExpense" xlink:title="presentation: SegmentReportingInformationProfitLossAbstract to NonoperatingIncomeExpense" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:title="IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SegmentReportingInformationProfitLossAbstract" xlink:to="IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:title="presentation: SegmentReportingInformationProfitLossAbstract to IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentExpenditureAdditionToLongLivedAssets" xlink:label="SegmentExpenditureAdditionToLongLivedAssets" xlink:title="SegmentExpenditureAdditionToLongLivedAssets" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SegmentReportingInformationProfitLossAbstract" xlink:to="SegmentExpenditureAdditionToLongLivedAssets" xlink:title="presentation: SegmentReportingInformationProfitLossAbstract to SegmentExpenditureAdditionToLongLivedAssets" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="Assets" xlink:title="Assets" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SegmentReportingInformationProfitLossAbstract" xlink:to="Assets" xlink:title="presentation: SegmentReportingInformationProfitLossAbstract to Assets" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SegmentReportingInformationLineItems" xlink:to="SegmentReportingInformationProfitLossAbstract" xlink:title="presentation: SegmentReportingInformationLineItems to SegmentReportingInformationProfitLossAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract" xlink:label="ReconciliationFromSegmentTotalsToConsolidatedAbstract" xlink:title="ReconciliationFromSegmentTotalsToConsolidatedAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="SellingGeneralAndAdministrativeExpense" xlink:title="SellingGeneralAndAdministrativeExpense" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ReconciliationFromSegmentTotalsToConsolidatedAbstract" xlink:to="SellingGeneralAndAdministrativeExpense" xlink:title="presentation: ReconciliationFromSegmentTotalsToConsolidatedAbstract to SellingGeneralAndAdministrativeExpense" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseNonoperating" xlink:label="InterestExpenseNonoperating" xlink:title="InterestExpenseNonoperating" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ReconciliationFromSegmentTotalsToConsolidatedAbstract" xlink:to="InterestExpenseNonoperating" xlink:title="presentation: ReconciliationFromSegmentTotalsToConsolidatedAbstract to InterestExpenseNonoperating" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="GainsLossesOnExtinguishmentOfDebt" xlink:title="GainsLossesOnExtinguishmentOfDebt" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ReconciliationFromSegmentTotalsToConsolidatedAbstract" xlink:to="GainsLossesOnExtinguishmentOfDebt" xlink:title="presentation: ReconciliationFromSegmentTotalsToConsolidatedAbstract to GainsLossesOnExtinguishmentOfDebt" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="InvestmentIncomeInterest" xlink:title="InvestmentIncomeInterest" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ReconciliationFromSegmentTotalsToConsolidatedAbstract" xlink:to="InvestmentIncomeInterest" xlink:title="presentation: ReconciliationFromSegmentTotalsToConsolidatedAbstract to InvestmentIncomeInterest" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SegmentReportingInformationLineItems" xlink:to="ReconciliationFromSegmentTotalsToConsolidatedAbstract" xlink:title="presentation: SegmentReportingInformationLineItems to ReconciliationFromSegmentTotalsToConsolidatedAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="SegmentReportingInformationLineItems" xlink:title="presentation: ScheduleOfSegmentReportingInformationBySegmentTable to SegmentReportingInformationLineItems" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SegmentReportingAbstract" xlink:to="ScheduleOfSegmentReportingInformationBySegmentTable" xlink:title="presentation: SegmentReportingAbstract to ScheduleOfSegmentReportingInformationBySegmentTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/SegmentsNetRevenuesAccordingToGeographicAreaDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract" xlink:label="SegmentReportingAbstract" xlink:title="SegmentReportingAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:label="ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:title="ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidationItemsAxis" xlink:label="ConsolidationItemsAxis" xlink:title="ConsolidationItemsAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ConsolidationItemsDomain" xlink:label="ConsolidationItemsDomain" xlink:title="ConsolidationItemsDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingSegmentsMember" xlink:label="OperatingSegmentsMember" xlink:title="OperatingSegmentsMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConsolidationItemsDomain" xlink:to="OperatingSegmentsMember" xlink:title="presentation: ConsolidationItemsDomain to OperatingSegmentsMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MaterialReconcilingItemsMember" xlink:label="MaterialReconcilingItemsMember" xlink:title="MaterialReconcilingItemsMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConsolidationItemsDomain" xlink:to="MaterialReconcilingItemsMember" xlink:title="presentation: ConsolidationItemsDomain to MaterialReconcilingItemsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConsolidationItemsAxis" xlink:to="ConsolidationItemsDomain" xlink:title="presentation: ConsolidationItemsAxis to ConsolidationItemsDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:to="ConsolidationItemsAxis" xlink:title="presentation: ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable to ConsolidationItemsAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="StatementBusinessSegmentsAxis" xlink:title="StatementBusinessSegmentsAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain" xlink:label="SegmentDomain" xlink:title="SegmentDomain" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_ADMABioManufacturingSegmentMember" xlink:label="ADMABioManufacturingSegmentMember" xlink:title="ADMABioManufacturingSegmentMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SegmentDomain" xlink:to="ADMABioManufacturingSegmentMember" xlink:title="presentation: SegmentDomain to ADMABioManufacturingSegmentMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_PlasmaCollectionCentersSegmentMember" xlink:label="PlasmaCollectionCentersSegmentMember" xlink:title="PlasmaCollectionCentersSegmentMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SegmentDomain" xlink:to="PlasmaCollectionCentersSegmentMember" xlink:title="presentation: SegmentDomain to PlasmaCollectionCentersSegmentMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementBusinessSegmentsAxis" xlink:to="SegmentDomain" xlink:title="presentation: StatementBusinessSegmentsAxis to SegmentDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:to="StatementBusinessSegmentsAxis" xlink:title="presentation: ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable to StatementBusinessSegmentsAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis" xlink:label="StatementGeographicalAxis" xlink:title="StatementGeographicalAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain" xlink:label="SegmentGeographicalDomain" xlink:title="SegmentGeographicalDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_US" xlink:label="US" xlink:title="US" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SegmentGeographicalDomain" xlink:to="US" xlink:title="presentation: SegmentGeographicalDomain to US" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonUsMember" xlink:label="NonUsMember" xlink:title="NonUsMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SegmentGeographicalDomain" xlink:to="NonUsMember" xlink:title="presentation: SegmentGeographicalDomain to NonUsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementGeographicalAxis" xlink:to="SegmentGeographicalDomain" xlink:title="presentation: StatementGeographicalAxis to SegmentGeographicalDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:to="StatementGeographicalAxis" xlink:title="presentation: ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable to StatementGeographicalAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:label="RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:title="RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentsGeographicalAreasAbstract" xlink:label="SegmentsGeographicalAreasAbstract" xlink:title="SegmentsGeographicalAreasAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="RevenueFromContractWithCustomerExcludingAssessedTax" xlink:title="RevenueFromContractWithCustomerExcludingAssessedTax" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SegmentsGeographicalAreasAbstract" xlink:to="RevenueFromContractWithCustomerExcludingAssessedTax" xlink:title="presentation: SegmentsGeographicalAreasAbstract to RevenueFromContractWithCustomerExcludingAssessedTax" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:to="SegmentsGeographicalAreasAbstract" xlink:title="presentation: RevenuesFromExternalCustomersAndLongLivedAssetsLineItems to SegmentsGeographicalAreasAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:to="RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:title="presentation: ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable to RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SegmentReportingAbstract" xlink:to="ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:title="presentation: SegmentReportingAbstract to ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/OtherEmployeeBenefitsDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="CompensationAndRetirementDisclosureAbstract" xlink:title="CompensationAndRetirementDisclosureAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:label="DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:title="DefinedContributionPlanEmployerDiscretionaryContributionAmount" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CompensationAndRetirementDisclosureAbstract" xlink:to="DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:title="presentation: CompensationAndRetirementDisclosureAbstract to DefinedContributionPlanEmployerDiscretionaryContributionAmount" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/SupplementalDisclosureOfCashFlowInformationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowElementsAbstract" xlink:label="SupplementalCashFlowElementsAbstract" xlink:title="SupplementalCashFlowElementsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="SupplementalCashFlowInformationAbstract" xlink:title="SupplementalCashFlowInformationAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPaidNet" xlink:label="InterestPaidNet" xlink:title="InterestPaidNet" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SupplementalCashFlowInformationAbstract" xlink:to="InterestPaidNet" xlink:title="presentation: SupplementalCashFlowInformationAbstract to InterestPaidNet" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxesPaid" xlink:label="IncomeTaxesPaid" xlink:title="IncomeTaxesPaid" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SupplementalCashFlowInformationAbstract" xlink:to="IncomeTaxesPaid" xlink:title="presentation: SupplementalCashFlowInformationAbstract to IncomeTaxesPaid" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="NoncashInvestingAndFinancingItemsAbstract" xlink:title="NoncashInvestingAndFinancingItemsAbstract" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_EquipmentAcquiredReflectedInAccountsPayableAndAccruedLiabilities" xlink:label="EquipmentAcquiredReflectedInAccountsPayableAndAccruedLiabilities" xlink:title="EquipmentAcquiredReflectedInAccountsPayableAndAccruedLiabilities" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NoncashInvestingAndFinancingItemsAbstract" xlink:to="EquipmentAcquiredReflectedInAccountsPayableAndAccruedLiabilities" xlink:title="presentation: NoncashInvestingAndFinancingItemsAbstract to EquipmentAcquiredReflectedInAccountsPayableAndAccruedLiabilities" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:title="RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NoncashInvestingAndFinancingItemsAbstract" xlink:to="RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:title="presentation: NoncashInvestingAndFinancingItemsAbstract to RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_WarrantsIssuedInConnectionWithNotesPayable" xlink:label="WarrantsIssuedInConnectionWithNotesPayable" xlink:title="WarrantsIssuedInConnectionWithNotesPayable" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NoncashInvestingAndFinancingItemsAbstract" xlink:to="WarrantsIssuedInConnectionWithNotesPayable" xlink:title="presentation: NoncashInvestingAndFinancingItemsAbstract to WarrantsIssuedInConnectionWithNotesPayable" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SupplementalCashFlowInformationAbstract" xlink:to="NoncashInvestingAndFinancingItemsAbstract" xlink:title="presentation: SupplementalCashFlowInformationAbstract to NoncashInvestingAndFinancingItemsAbstract" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SupplementalCashFlowElementsAbstract" xlink:to="SupplementalCashFlowInformationAbstract" xlink:title="presentation: SupplementalCashFlowElementsAbstract to SupplementalCashFlowInformationAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/ConcentrationsDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRisksTypesNoConcentrationPercentageAbstract" xlink:label="ConcentrationRisksTypesNoConcentrationPercentageAbstract" xlink:title="ConcentrationRisksTypesNoConcentrationPercentageAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskTable" xlink:label="ConcentrationRiskTable" xlink:title="ConcentrationRiskTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="ConcentrationRiskByBenchmarkAxis" xlink:title="ConcentrationRiskByBenchmarkAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="ConcentrationRiskBenchmarkDomain" xlink:title="ConcentrationRiskBenchmarkDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableMember" xlink:label="AccountsReceivableMember" xlink:title="AccountsReceivableMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConcentrationRiskBenchmarkDomain" xlink:to="AccountsReceivableMember" xlink:title="presentation: ConcentrationRiskBenchmarkDomain to AccountsReceivableMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerProductAndServiceBenchmarkMember" xlink:label="RevenueFromContractWithCustomerProductAndServiceBenchmarkMember" xlink:title="RevenueFromContractWithCustomerProductAndServiceBenchmarkMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConcentrationRiskBenchmarkDomain" xlink:to="RevenueFromContractWithCustomerProductAndServiceBenchmarkMember" xlink:title="presentation: ConcentrationRiskBenchmarkDomain to RevenueFromContractWithCustomerProductAndServiceBenchmarkMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConcentrationRiskByBenchmarkAxis" xlink:to="ConcentrationRiskBenchmarkDomain" xlink:title="presentation: ConcentrationRiskByBenchmarkAxis to ConcentrationRiskBenchmarkDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConcentrationRiskTable" xlink:to="ConcentrationRiskByBenchmarkAxis" xlink:title="presentation: ConcentrationRiskTable to ConcentrationRiskByBenchmarkAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="ConcentrationRiskByTypeAxis" xlink:title="ConcentrationRiskByTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="ConcentrationRiskTypeDomain" xlink:title="ConcentrationRiskTypeDomain" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="CustomerConcentrationRiskMember" xlink:title="CustomerConcentrationRiskMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConcentrationRiskTypeDomain" xlink:to="CustomerConcentrationRiskMember" xlink:title="presentation: ConcentrationRiskTypeDomain to CustomerConcentrationRiskMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConcentrationRiskByTypeAxis" xlink:to="ConcentrationRiskTypeDomain" xlink:title="presentation: ConcentrationRiskByTypeAxis to ConcentrationRiskTypeDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConcentrationRiskTable" xlink:to="ConcentrationRiskByTypeAxis" xlink:title="presentation: ConcentrationRiskTable to ConcentrationRiskByTypeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MajorCustomersAxis" xlink:label="MajorCustomersAxis" xlink:title="MajorCustomersAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_NameOfMajorCustomerDomain" xlink:label="NameOfMajorCustomerDomain" xlink:title="NameOfMajorCustomerDomain" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_ThreeCustomersMember" xlink:label="ThreeCustomersMember" xlink:title="ThreeCustomersMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NameOfMajorCustomerDomain" xlink:to="ThreeCustomersMember" xlink:title="presentation: NameOfMajorCustomerDomain to ThreeCustomersMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_FiveCustomersMember" xlink:label="FiveCustomersMember" xlink:title="FiveCustomersMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NameOfMajorCustomerDomain" xlink:to="FiveCustomersMember" xlink:title="presentation: NameOfMajorCustomerDomain to FiveCustomersMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_TwoCustomersMember" xlink:label="TwoCustomersMember" xlink:title="TwoCustomersMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="NameOfMajorCustomerDomain" xlink:to="TwoCustomersMember" xlink:title="presentation: NameOfMajorCustomerDomain to TwoCustomersMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="MajorCustomersAxis" xlink:to="NameOfMajorCustomerDomain" xlink:title="presentation: MajorCustomersAxis to NameOfMajorCustomerDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConcentrationRiskTable" xlink:to="MajorCustomersAxis" xlink:title="presentation: ConcentrationRiskTable to MajorCustomersAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="StatementBusinessSegmentsAxis" xlink:title="StatementBusinessSegmentsAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain" xlink:label="SegmentDomain" xlink:title="SegmentDomain" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_PlasmaCollectionCentersSegmentMember" xlink:label="PlasmaCollectionCentersSegmentMember" xlink:title="PlasmaCollectionCentersSegmentMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SegmentDomain" xlink:to="PlasmaCollectionCentersSegmentMember" xlink:title="presentation: SegmentDomain to PlasmaCollectionCentersSegmentMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementBusinessSegmentsAxis" xlink:to="SegmentDomain" xlink:title="presentation: StatementBusinessSegmentsAxis to SegmentDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConcentrationRiskTable" xlink:to="StatementBusinessSegmentsAxis" xlink:title="presentation: ConcentrationRiskTable to StatementBusinessSegmentsAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskLineItems" xlink:label="ConcentrationRiskLineItems" xlink:title="ConcentrationRiskLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RisksAndUncertaintiesAbstract" xlink:label="RisksAndUncertaintiesAbstract" xlink:title="RisksAndUncertaintiesAbstract" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_NumberOfCustomers" xlink:label="NumberOfCustomers" xlink:title="NumberOfCustomers" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RisksAndUncertaintiesAbstract" xlink:to="NumberOfCustomers" xlink:title="presentation: RisksAndUncertaintiesAbstract to NumberOfCustomers" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="ConcentrationRiskPercentage1" xlink:title="ConcentrationRiskPercentage1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="RisksAndUncertaintiesAbstract" xlink:to="ConcentrationRiskPercentage1" xlink:title="presentation: RisksAndUncertaintiesAbstract to ConcentrationRiskPercentage1" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConcentrationRiskLineItems" xlink:to="RisksAndUncertaintiesAbstract" xlink:title="presentation: ConcentrationRiskLineItems to RisksAndUncertaintiesAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConcentrationRiskTable" xlink:to="ConcentrationRiskLineItems" xlink:title="presentation: ConcentrationRiskTable to ConcentrationRiskLineItems" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ConcentrationRisksTypesNoConcentrationPercentageAbstract" xlink:to="ConcentrationRiskTable" xlink:title="presentation: ConcentrationRisksTypesNoConcentrationPercentageAbstract to ConcentrationRiskTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
  <link:presentationLink xlink:type="extended" xlink:role="http://admabiologics.com/role/ScheduleIiValuationAndQualifyingAccountsDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ValuationAndQualifyingAccountsAbstract" xlink:label="ValuationAndQualifyingAccountsAbstract" xlink:title="ValuationAndQualifyingAccountsAbstract" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:label="ValuationAndQualifyingAccountsDisclosureTable" xlink:title="ValuationAndQualifyingAccountsDisclosureTable" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:label="ValuationAllowancesAndReservesTypeAxis" xlink:title="ValuationAllowancesAndReservesTypeAxis" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowancesAndReservesDomain" xlink:label="ValuationAllowancesAndReservesDomain" xlink:title="ValuationAllowancesAndReservesDomain" />
    <link:loc xlink:type="locator" xlink:href="adma-20241231.xsd#adma_SECSchedule1209ReserveAccruedRebatesMember" xlink:label="SECSchedule1209ReserveAccruedRebatesMember" xlink:title="SECSchedule1209ReserveAccruedRebatesMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ValuationAllowancesAndReservesDomain" xlink:to="SECSchedule1209ReserveAccruedRebatesMember" xlink:title="presentation: ValuationAllowancesAndReservesDomain to SECSchedule1209ReserveAccruedRebatesMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryValuationReserveMember" xlink:label="InventoryValuationReserveMember" xlink:title="InventoryValuationReserveMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ValuationAllowancesAndReservesDomain" xlink:to="InventoryValuationReserveMember" xlink:title="presentation: ValuationAllowancesAndReservesDomain to InventoryValuationReserveMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember" xlink:label="ValuationAllowanceOfDeferredTaxAssetsMember" xlink:title="ValuationAllowanceOfDeferredTaxAssetsMember" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ValuationAllowancesAndReservesDomain" xlink:to="ValuationAllowanceOfDeferredTaxAssetsMember" xlink:title="presentation: ValuationAllowancesAndReservesDomain to ValuationAllowanceOfDeferredTaxAssetsMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ValuationAllowancesAndReservesTypeAxis" xlink:to="ValuationAllowancesAndReservesDomain" xlink:title="presentation: ValuationAllowancesAndReservesTypeAxis to ValuationAllowancesAndReservesDomain" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ValuationAndQualifyingAccountsDisclosureTable" xlink:to="ValuationAllowancesAndReservesTypeAxis" xlink:title="presentation: ValuationAndQualifyingAccountsDisclosureTable to ValuationAllowancesAndReservesTypeAxis" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:label="ValuationAndQualifyingAccountsDisclosureLineItems" xlink:title="ValuationAndQualifyingAccountsDisclosureLineItems" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:label="MovementInValuationAllowancesAndReservesRollForward" xlink:title="MovementInValuationAllowancesAndReservesRollForward" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowancesAndReservesBalance" xlink:label="ValuationAllowancesAndReservesBalance" xlink:title="ValuationAllowancesAndReservesBalance" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="MovementInValuationAllowancesAndReservesRollForward" xlink:to="ValuationAllowancesAndReservesBalance" xlink:title="presentation: MovementInValuationAllowancesAndReservesRollForward to ValuationAllowancesAndReservesBalance" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense" xlink:label="ValuationAllowancesAndReservesChargedToCostAndExpense" xlink:title="ValuationAllowancesAndReservesChargedToCostAndExpense" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="MovementInValuationAllowancesAndReservesRollForward" xlink:to="ValuationAllowancesAndReservesChargedToCostAndExpense" xlink:title="presentation: MovementInValuationAllowancesAndReservesRollForward to ValuationAllowancesAndReservesChargedToCostAndExpense" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts" xlink:label="ValuationAllowancesAndReservesChargedToOtherAccounts" xlink:title="ValuationAllowancesAndReservesChargedToOtherAccounts" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="MovementInValuationAllowancesAndReservesRollForward" xlink:to="ValuationAllowancesAndReservesChargedToOtherAccounts" xlink:title="presentation: MovementInValuationAllowancesAndReservesRollForward to ValuationAllowancesAndReservesChargedToOtherAccounts" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowancesAndReservesDeductions" xlink:label="ValuationAllowancesAndReservesDeductions" xlink:title="ValuationAllowancesAndReservesDeductions" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="MovementInValuationAllowancesAndReservesRollForward" xlink:to="ValuationAllowancesAndReservesDeductions" xlink:title="presentation: MovementInValuationAllowancesAndReservesRollForward to ValuationAllowancesAndReservesDeductions" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowancesAndReservesBalance" xlink:label="ValuationAllowancesAndReservesBalance_2" xlink:title="ValuationAllowancesAndReservesBalance" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="MovementInValuationAllowancesAndReservesRollForward" xlink:to="ValuationAllowancesAndReservesBalance_2" xlink:title="presentation: MovementInValuationAllowancesAndReservesRollForward to ValuationAllowancesAndReservesBalance" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ValuationAndQualifyingAccountsDisclosureLineItems" xlink:to="MovementInValuationAllowancesAndReservesRollForward" xlink:title="presentation: ValuationAndQualifyingAccountsDisclosureLineItems to MovementInValuationAllowancesAndReservesRollForward" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ValuationAndQualifyingAccountsDisclosureTable" xlink:to="ValuationAndQualifyingAccountsDisclosureLineItems" xlink:title="presentation: ValuationAndQualifyingAccountsDisclosureTable to ValuationAndQualifyingAccountsDisclosureLineItems" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ValuationAndQualifyingAccountsAbstract" xlink:to="ValuationAndQualifyingAccountsDisclosureTable" xlink:title="presentation: ValuationAndQualifyingAccountsAbstract to ValuationAndQualifyingAccountsDisclosureTable" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>image00001.jpg
<TEXT>
begin 644 image00001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  8$!08%! 8&!08'!P8("A *"@D)
M"A0.#PP0%Q08&!<4%A8:'24?&ALC'!86("P@(R8G*2HI&1\M,"TH,"4H*2C_
MVP!# 0<'!PH("A,*"A,H&A8:*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H
M*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"C_P  1"  F %X# 2(  A$! Q$!_\0
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/RK.I4O-[&^'A&$/=/__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>image00002.jpg
<TEXT>
begin 644 image00002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  8$!08%! 8&!08'!P8("A *"@D)
M"A0.#PP0%Q08&!<4%A8:'24?&ALC'!86("P@(R8G*2HI&1\M,"TH,"4H*2C_
MVP!# 0<'!PH("A,*"A,H&A8:*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H
M*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"C_P  1" $S GL# 2(  A$! Q$!_\0
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M3PRL%KIGD/#>6[SR,SYR05SNSSMX)'W: -S5/$_]G>,]*T.>TQ#J,3M%=F3
M$BYRFW'ICG/\72N9NOBBD=E-<0:294;46T^T9KI8TG*]79F&$'(ZYZ]>#6W\
M2/#-YXBL+!]'N(K75;&Y6>":5B /49 )]#T[5E2>"M1M/ VE:)IW]CW#P9:Z
MBOXF:&9VY)# ;@02<$8./2@#L/#FI3ZKI,=U>6$MA.Q(:!W#XP>H8<,IZ@BO
M(=<UW7_#VKZMX/@OKBYN=1N(O[.O)K@E[>.0X(+$Y!' 'IR1UKTKX=^';GPO
MX933[NX2XF\QY#L)V)G^%<\X_P 37)W/PUO-4TG6KC6+FU/B2]N1<07$3,8X
M-OW$!*@XP2#QZ>E &7X\N1HOB[P_I6J>)M;L=*73_P!_<V]S())'!?#-@-DD
M@=C5>U\0:O-\&/$%[_:\\LL%VL=K=";%P(_-C'S$'()R>O.">V*Z?5?#/BV;
MQ!H>NVD^B-J=E9?9IQ</*8W<[@6&U0<$-GMS50_#K5)/"OB>WFN[ ZOK<T4K
M",,EO'LD#8'!//S=O3ZT >B:+,6T&QFN),DVT;O([?[()))KYTTB)==UTVMM
M*3K_ -N>Y.LO=LJ-;J>=B_Q'@G@9X],X^A7TGS_"QTBXDV^99?9'>/ME-I(K
MS";X9>(KS3M/TF[O=%6SL&(@OHHY/M2*3DC'"XYZ9_&@#U;1=5LM;TR'4-+F
M\^SFW>7)L9<X8J>& /4'M7A6MZ\$UWQ>M_XIUZRO;>Z==-M;6>0QN<M\I7&
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !15?4+VVTZSEN[^>.WMHAN>21MJK_GI5'_ (231!%:R-J^GHETN^ O<(OF
M#./E!///'UH UJ*J+J=@VHMIZWMJ;]%W-;"53*HP#DKG.,$?G1:ZG87EU/;6
ME[:SW%N=LT44JL\9SC# '(Y'>@"W151=3L&U%M/6]M3?HNYK82J95& <E<YQ
M@C\Z-.U.PU.-WTV]M;Q$;:S6\JR!3Z'!.#0!;J&T_P!4W_71_P#T(U-4-I_J
MF_ZZ/_Z$: "T_P!4W_71_P#T(U,>G'6H;3_5-_UT?_T(U-0!#MN/^>L7_?H_
M_%4;;C_GK%_WZ/\ \54U% $.VX_YZQ?]^C_\51MN/^>L7_?H_P#Q5344 0[;
MC_GK%_WZ/_Q5&VX_YZQ?]^C_ /%5-10!#MN/^>L7_?H__%4;;C_GK%_WZ/\
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M3?X5-10!#]IC])?^_3?X4?:8_27_ +]-_A4U% $/VF/TE_[]-_A1]IC])?\
MOTW^%344 0_:8_27_OTW^%'VF/TE_P"_3?X5-10!#]IC])?^_3?X4?:8_27_
M +]-_A4U% $/VF/TE_[]-_A1]IC])?\ OTW^%344 0_:8_27_OTW^%'VF/TE
M_P"_3?X5-10!#]IC])?^_3?X4?:8_27_ +]-_A4U% $/VF/TE_[]-_A1]IC]
M)?\ OTW^%344 0_:8_27_OTW^%'VF/TE_P"_3?X5-10!#]IC])?^_3?X4?:8
M_27_ +]-_A4U% $/VF/TE_[]-_A1]IC])?\ OTW^%344 0_:8_27_OTW^%'V
MF/TE_P"_3?X5-10!#]IC])?^_3?X4?:8_27_ +]-_A4U% $/VF/TE_[]-_A1
M]IC])?\ OTW^%344 0_:8_27_OTW^%'VF/TE_P"_3?X5-10!#]IC])?^_3?X
M4?:8_27_ +]-_A4U% $/VF/TE_[]-_A1]IC])?\ OTW^%344 0_:8_27_OTW
M^%'VF/TE_P"_3?X5-10!#]IC])?^_3?X4?:8_27_ +]-_A4U% $/VF/TE_[]
M-_A1]IC])?\ OTW^%344 0_:8_27_OTW^%'VF/TE_P"_3?X5-10!#]IC])?^
M_3?X4?:8_27_ +]-_A4U% $/VF/TE_[]-_A1]IC])?\ OTW^%344 0_:8_27
M_OTW^%'VF/TE_P"_3?X5-10!#]IC])?^_3?X4?:8_27_ +]-_A4U% $/VF/T
ME_[]-_A1]IC])?\ OTW^%35AZ9XHT[4_$%[I%DTDEQ:+NED"_N^H! ;/4$_S
M]*J,)23:6PG)+1FM]IC])?\ OTW^%'VF/TE_[]-_A4U%2,A^TQ^DO_?IO\*/
MM,?I+_WZ;_"IJ* (?M,?I+_WZ;_"I58,H(S@^HQ2T4 8WBS^T3I!&DK.96D4
M2FV*"819^8Q[_EW?7WQSBN.USQG!9:?86NFZWMFB*23SW^Q)G03>68RC*OS9
M#[CM! 0Y^\#7=ZSI<&K6@@GDN(BK;XY;>9HI(VP1E64Y'!(^A--71;!=)731
M!_H:L'V%V)+!]^XMG).[DDGD]: ,+3;_ %"/Q-Y>J3:C]ENYY%L2JVS6LB!"
MZC<H\P-M5CR0#BH?"NJZC<W>CS7EZUQ#J]I-<^1Y:!;9E9" A !(P^T[B3D#
MFNCBT6RCU3^T,3R77S;3-<R2+'NZ[$9BJ>GR@<9'0U7M?#.EVCSO:PS1-,"I
M*7,H\M2VXK'\W[L%N<)@=/2@#EM4\1:II\-UK NO-@6]N[1; HGEA8HY-K;@
M-^[=%D_-C#' &!6[X;N;^/5IK"_OWU &R@NUE>-$*,Q=67Y% V_*",\]>35\
M>'-*&HRWQM=TTI9F5I&:/<R[681D[ Q'!(&3DYZFI-%T2PT9)%T^*1?,"JS2
M3/*Q51A5W.2=HYP.@R?6@#2J&T_U3?\ 71__ $(U-4-I_JF_ZZ/_ .A&@ M/
M]4W_ %T?_P!"-35#:?ZIO^NC_P#H1J8\B@ HJ'[,G]Z7_OZW^-'V9/[TO_?U
MO\: )J*A^S)_>E_[^M_C1]F3^]+_ -_6_P : )J*A^S)_>E_[^M_C1]F3^]+
M_P!_6_QH FHJ'[,G]Z7_ +^M_C1]F3^]+_W];_&@":BH?LR?WI?^_K?XT?9D
M_O2_]_6_QH FHJ'[,G]Z7_OZW^-'V9/[TO\ W];_ !H FHJ'[,G]Z7_OZW^-
M'V9/[TO_ '];_&@":BH?LR?WI?\ OZW^-'V9/[TO_?UO\: )J*A^S)_>E_[^
MM_C1]F3^]+_W];_&@":BH?LR?WI?^_K?XT?9D_O2_P#?UO\ &@":BH?LR?WI
M?^_K?XT?9D_O2_\ ?UO\: )J*A^S)_>E_P"_K?XT?9D_O2_]_6_QH FHJ'[,
MG]Z7_OZW^-'V9/[TO_?UO\: )J*A^S)_>E_[^M_C1]F3^]+_ -_6_P : )J*
MA^S)_>E_[^M_C1]F3^]+_P!_6_QH FHJ'[,G]Z7_ +^M_C1]F3^]+_W];_&@
M":BH?LR?WI?^_K?XT?9D_O2_]_6_QH FHJ'[,G]Z7_OZW^-'V9/[TO\ W];_
M !H FHJ'[,G]Z7_OZW^-'V9/[TO_ '];_&@":BH?LR?WI?\ OZW^-'V9/[TO
M_?UO\: )J*A^S)_>E_[^M_C1]F3^]+_W];_&@":BH?LR?WI?^_K?XT?9D_O2
M_P#?UO\ &@":BH?LR?WI?^_K?XT?9D_O2_\ ?UO\: )J*A^S)_>E_P"_K?XT
M?9D_O2_]_6_QH FHJ'[,G]Z7_OZW^-'V9/[TO_?UO\: )J*A^S)_>E_[^M_C
M1]F3^]+_ -_6_P : )J*A^S)_>E_[^M_C1]F3^]+_P!_6_QH FHJ'[,G]Z7_
M +^M_C1]F3^]+_W];_&@":BH?LR?WI?^_K?XT?9D_O2_]_6_QH FHJ'[,G]Z
M7_OZW^-'V9/[TO\ W];_ !H FHJ'[,G]Z7_OZW^-87C+6K/PSHDM[.TC2GY8
M(O.8&1^PZ].Y/I50A*<E&.[%*2BKLROB1XGGTZ.'1M$S)KE]\B*G)B4\;O8G
MM^)[5K>!?#$/A?1EMU(DNY<27,W]]_3Z#M^?>N?^'/AB?=)XCU]I'U>^&]02
M084/Z@D8^@P/6N\^S)_>E_[^M_C737FJ<?84_F^[_P D8TXN3]I+Y>1-14/V
M9/[TO_?UO\:/LR?WI?\ OZW^-<AN345#]F3^]+_W];_&C[,G]Z7_ +^M_C0!
M-14/V9/[TO\ W];_ !J55VJ ,X'J<T 5-6U&WTJS:YNC(5R%5(D+O(QZ*JCD
MD^@_E5:?7["UTVTO;UYK6*ZD6*-9X'63>V<*4QD'@]1CC/2H?%\22Z4OFZ=>
M:@B2JY2RE\N>,@'#QG<IR#@<$<$]>AY74O#GB74=+AN)[R&2[0+&EM<P*\B+
M]H#ABZ2*F_8J;L#!V$#KD@'8QZ]ITFK'34G8W89DQY3["P7<5$F-A8#DJ#D<
M^E&FZ]IVI7DEK9SL\R!FYB=5=5;:61B ' /&5)'2N=L-)U1=2M[2XM-MO;ZK
M-J)OE= DBN'(55W%PV9,'(QA3R>*9X=T[5+%M*6ZTR55T:TEM@T<L1^ULS(
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MP_\ Q-&ZX_YY1?\ ?P__ !- $U%0[KC_ )Y1?]_#_P#$T;KC_GE%_P!_#_\
M$T 345#NN/\ GE%_W\/_ ,31NN/^>47_ '\/_P 30!-14.ZX_P">47_?P_\
MQ-&ZX_YY1?\ ?P__ !- $U%0[KC_ )Y1?]_#_P#$T;KC_GE%_P!_#_\ $T 3
M45#NN/\ GE%_W\/_ ,31NN/^>47_ '\/_P 30!-14.ZX_P">47_?P_\ Q-&Z
MX_YY1?\ ?P__ !- $U%0[KC_ )Y1?]_#_P#$T;KC_GE%_P!_#_\ $T 345#N
MN/\ GE%_W\/_ ,31NN/^>47_ '\/_P 30!-14.ZX_P">47_?P_\ Q-&ZX_YY
M1?\ ?P__ !- $U%0[KC_ )Y1?]_#_P#$T;KC_GE%_P!_#_\ $T 345#NN/\
MGE%_W\/_ ,31NN/^>47_ '\/_P 30!-14.ZX_P">47_?P_\ Q-&ZX_YY1?\
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M_OL4 345#]JM_P#GO%_WV*/M5O\ \]XO^^Q0!-14/VJW_P">\7_?8H^U6_\
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M^2_X5-17*;$/DR?\_$OY+_A1Y,G_ #\2_DO^%344 0^3)_S\2_DO^%'DR?\
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M\\HO^_A_^)K/URXU:"S#Z9:0RS;L,"^["X/(''?'^% &M39'6-2TC*JCJ6.
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M=<?\\HO^_A_^)H YC9XOD_Y:V47X _T-']F^*Y/]9J]LO^XO_P!B*Z?=<?\
M/*+_ +^'_P")HW7'_/*+_OX?_B: .0N/"6I7G_'[JROGK^ZW?X5#'\.X1]^^
M)_W80/ZUVNZX_P">47_?P_\ Q-&ZX_YY1?\ ?P__ !-0X1;NT6JDTK)G)Q^
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MH/RHVCT'Y5%]JM_^>\7_ 'V*/M5O_P ]XO\ OL4 2[1Z#\J-H]!^51?:K?\
MY[Q?]]BC[5;_ //>+_OL4 2[1Z#\J-H]!^51?:K?_GO%_P!]BC[5;_\ />+_
M +[% $NT>@_*C:/0?E47VJW_ .>\7_?8H^U6_P#SWB_[[% $NT>@_*E  Z"H
M?M5O_P ]XO\ OL4?:K?_ )[Q?]]B@":BH?M5O_SWB_[[%'VJW_Y[Q?\ ?8H
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M_0C3YRXAD,?W]IV_7'%,M/\ 5-_UT?\ ]"-34 0^2_\ S\R_DO\ \31Y+_\
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MU.YT^WN%DN[90TJ*#A<G'7&,\=,Y'>@"QY+_ //S+^2__$T>2_\ S\R_DO\
M\363?^*--L+RZM[HW*FV4-(T=N\H QN/W 2 H*DD@ ;UYYJ9O$6EC4H['[3N
MGD*A2L;M'E@64&0#8"0,@$Y/&.HH T/)?_GYE_)?_B:/)?\ Y^9?R7_XFL__
M (2/2Q>36SW#1R1+([-)"Z(PC^_M<C:Q7N%)(P?0U8TK5;35%F^R-+NA<))'
M-"\+H2 1E' 89!!!Q@T 6/)?_GYE_)?_ (FF/%,&CVSRD%L-PO P?;UQ5FB@
M"'R7_P"?F7\E_P#B:/)?_GYE_)?_ (FIJBNKB&TMY+BZE2&"-=SR.<!1ZDT
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MEBAMKBZBFN"^QE9VD:0_)R@ +DC:V ,XJRBS7<'AG1[JVDMW51<W4,CH2$@
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M9,XR0?;!H ]8HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ J&T_U3?]='_]"-35#:?ZIO\ KH__ *$: "T_U3?]='_]
M"-35#:?ZIO\ KH__ *$:FH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M[,G]Z7_OZW^-%% !]F3^]+_W];_&C[,G]Z7_ +^M_C110 ?9D_O2_P#?UO\
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M_6_QH^S)_>E_[^M_C110 ?9D_O2_]_6_QH^S)_>E_P"_K?XT44 'V9/[TO\
MW];_ !H^S)_>E_[^M_C110 ?9D_O2_\ ?UO\:/LR?WI?^_K?XT44 'V9/[TO
M_?UO\:/LR?WI?^_K?XT44 'V9/[TO_?UO\:/LR?WI?\ OZW^-%% !]F3^]+_
M -_6_P :/LR?WI?^_K?XT44 'V9/[TO_ '];_&C[,G]Z7_OZW^-%% !]F3^]
M+_W];_&C[,G]Z7_OZW^-%% !]F3^]+_W];_&C[,G]Z7_ +^M_C110 ?9D_O2
8_P#?UO\ &I(XUC3:F<9)Y.>O-%% '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>image00003.jpg
<TEXT>
begin 644 image00003.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  8$!08%! 8&!08'!P8("A *"@D)
M"A0.#PP0%Q08&!<4%A8:'24?&ALC'!86("P@(R8G*2HI&1\M,"TH,"4H*2C_
MVP!# 0<'!PH("A,*"A,H&A8:*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H
M*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"C_P  1"  R &0# 2(  A$! Q$!_\0
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MWV6*40Q]LLRDM(WIG'X"K?[2'C#4/#NI:'I^C7K)??9)?M$K1H[/&[)@$%<
MEHB> .G'%;T\%.->--M7?X:=3*>(C*FYI:'T!17S;XPU?XQ>#M$CUC6-=L7M
M#(B,B00%@6Z CRQZ=C6OXL^+6K)\&="URQ>.QUW4KAH2R1JZ@1E@[*K C!PO
M7INJ?[/J/E<9)INVC_X!7UJ*OS)JVIZ7)_R.P_Z_8O\ TDGKL*^7_@SXW\3>
M(?BG86VOWYGCE5[AD,$<>6$#A&^51_"Q_.NQ^/?Q1U#PYJ%GH/A.X$>K$B6Y
ME6-92@/W8PK C)SGIG&/6KJX&I[:-%6O;Y$PQ,/9NH]KGM]<7X)_Y#-]_P!<
MF_\ 2RZKR_X >//&'C#QC<6^MZL;G3K:T:9T^S0IEMRJHRJ ]R>O:N:UWXEZ
M[-XHGT3P"I%S-+):^>BK(\Q^T3.#'G("XDZGTSQ51P%12E1NKZ:]$)XF#2J'
MU365XM_Y%76?^O*;_P! -?.WB7PC\6=!T&77+GQ3>W#1E3):VVH3.Z@D#[N
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M 4^T6\L>V1"1PT<A!].,''KWI?6*==5H<R3;T;V:6@_93ING*S:1O?$_QO\
M%#PKJ-S>S1Q:=HDUTT5D'6VE8KR5R%+-G R<UV?PWU[Q/XL^%]_<ZQ:SW]U?
MK<16LD2P1)LV[ .64_?#<XKSGQ)X+^+GC[[''XDM[=(;<EHC)+!&JEL9)$9)
MSP.H_K7T-X(T3_A'/".D:02I>TMDCD9.C/C+D>Q8DURXJ5*G1C%*+G?H;45.
J51MWY?,VZ***\@[@HHHH **** "BBB@ HHHH **** "BBB@ HHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Mar. 10, 2025</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-36728<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">ADMA BIOLOGICS, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001368514<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">56-2590442<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">465 State Route 17<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Ramsey<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NJ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">07446<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">201<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">478-5552<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common stock, par value $0.0001 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ADMA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFinStmtErrorCorrectionFlag', window );">Document Financial Statement Error Correction [Flag]</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,535,856,298<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">237,615,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">185<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">KPMG LLP<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Stamford, Connecticut<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=adma_CohnReznickLLPMember', window );">CohnReznick LLP [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">596<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">CohnReznick LLP<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Parsippany, New Jersey<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFinStmtErrorCorrectionFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates whether any of the financial statement period in the filing include a restatement due to error correction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection w<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFinStmtErrorCorrectionFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=adma_CohnReznickLLPMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=adma_CohnReznickLLPMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 103,147<span></span>
</td>
<td class="nump">$ 51,352<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">49,999<span></span>
</td>
<td class="nump">27,421<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories</a></td>
<td class="nump">170,235<span></span>
</td>
<td class="nump">172,906<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">8,029<span></span>
</td>
<td class="nump">5,334<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">331,410<span></span>
</td>
<td class="nump">257,013<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">54,707<span></span>
</td>
<td class="nump">53,835<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="nump">460<span></span>
</td>
<td class="nump">499<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">3,530<span></span>
</td>
<td class="nump">3,530<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxAssetsNet', window );">Deferred tax assets, net</a></td>
<td class="nump">84,280<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use assets</a></td>
<td class="nump">8,634<span></span>
</td>
<td class="nump">9,635<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_DepositsAndOtherNoncurrentAssets', window );">Deposits and other assets</a></td>
<td class="nump">5,657<span></span>
</td>
<td class="nump">4,670<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">TOTAL ASSETS</a></td>
<td class="nump">488,678<span></span>
</td>
<td class="nump">329,182<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">20,219<span></span>
</td>
<td class="nump">15,660<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">33,962<span></span>
</td>
<td class="nump">32,919<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Current portion of deferred revenue</a></td>
<td class="nump">143<span></span>
</td>
<td class="nump">182<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current portion of lease obligations</a></td>
<td class="nump">1,218<span></span>
</td>
<td class="nump">1,045<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">55,542<span></span>
</td>
<td class="nump">49,806<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SeniorLongTermNotes', window );">Senior notes payable, net of discount</a></td>
<td class="nump">72,337<span></span>
</td>
<td class="nump">130,594<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredRevenueNoncurrent', window );">Deferred revenue, net of current portion</a></td>
<td class="nump">1,547<span></span>
</td>
<td class="nump">1,690<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_LongTermLiabilityEndOfTermFeePayable', window );">End of term fee</a></td>
<td class="nump">1,313<span></span>
</td>
<td class="nump">1,688<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Lease obligations, net of current portion</a></td>
<td class="nump">8,561<span></span>
</td>
<td class="nump">9,779<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other non-current liabilities</a></td>
<td class="nump">360<span></span>
</td>
<td class="nump">419<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">TOTAL LIABILITIES</a></td>
<td class="nump">139,660<span></span>
</td>
<td class="nump">193,976<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">COMMITMENTS AND CONTINGENCIES</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>STOCKHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred Stock, $0.0001 par value, 10,000,000 shares authorized, no shares issued and outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common Stock - voting, $0.0001 par value, 300,000,000 shares authorized, 236,620,545 and 226,063,032 shares issued and outstanding at December 31, 2024 and December 31, 2023</a></td>
<td class="nump">24<span></span>
</td>
<td class="nump">23<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">657,577<span></span>
</td>
<td class="nump">641,439<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(308,583)<span></span>
</td>
<td class="num">(506,256)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">TOTAL STOCKHOLDERS' EQUITY</a></td>
<td class="nump">349,018<span></span>
</td>
<td class="nump">135,206<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY</a></td>
<td class="nump">$ 488,678<span></span>
</td>
<td class="nump">$ 329,182<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_DepositsAndOtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment after one year or beyond the operating cycle, if longer and amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_DepositsAndOtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_LongTermLiabilityEndOfTermFeePayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Principal balance of the loans and any other obligations advanced or otherwise owed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_LongTermLiabilityEndOfTermFeePayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesAndOtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 30: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482598/350-20-45-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SeniorLongTermNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of Notes with the highest claim on the assets of the issuer in case of bankruptcy or liquidation (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion. Senior note holders are paid off in full before any payments are made to junior note holders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SeniorLongTermNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>STOCKHOLDERS' EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">300,000,000<span></span>
</td>
<td class="nump">300,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">236,620,545<span></span>
</td>
<td class="nump">226,063,032<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">236,620,545<span></span>
</td>
<td class="nump">226,063,032<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>CONSOLIDATED STATEMENTS OF OPERATIONS [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">REVENUES</a></td>
<td class="nump">$ 426,454<span></span>
</td>
<td class="nump">$ 258,215<span></span>
</td>
<td class="nump">$ 154,080<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">Cost of product revenue</a></td>
<td class="nump">206,901<span></span>
</td>
<td class="nump">169,273<span></span>
</td>
<td class="nump">118,815<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross profit</a></td>
<td class="nump">219,553<span></span>
</td>
<td class="nump">88,942<span></span>
</td>
<td class="nump">35,265<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpensesAbstract', window );"><strong>OPERATING EXPENSES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">1,813<span></span>
</td>
<td class="nump">3,300<span></span>
</td>
<td class="nump">3,614<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCostAndExpenseOperating', window );">Plasma center operating expenses</a></td>
<td class="nump">4,245<span></span>
</td>
<td class="nump">4,266<span></span>
</td>
<td class="nump">17,843<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangible assets</a></td>
<td class="nump">388<span></span>
</td>
<td class="nump">724<span></span>
</td>
<td class="nump">715<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">74,124<span></span>
</td>
<td class="nump">59,020<span></span>
</td>
<td class="nump">52,458<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">80,570<span></span>
</td>
<td class="nump">67,310<span></span>
</td>
<td class="nump">74,630<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">INCOME (LOSS) FROM OPERATIONS</a></td>
<td class="nump">138,983<span></span>
</td>
<td class="nump">21,632<span></span>
</td>
<td class="num">(39,365)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>OTHER INCOME (EXPENSE):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">2,097<span></span>
</td>
<td class="nump">1,617<span></span>
</td>
<td class="nump">45<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseNonoperating', window );">Interest expense</a></td>
<td class="num">(13,930)<span></span>
</td>
<td class="num">(25,027)<span></span>
</td>
<td class="num">(19,279)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of debt</a></td>
<td class="num">(1,243)<span></span>
</td>
<td class="num">(26,174)<span></span>
</td>
<td class="num">(6,670)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other expense</a></td>
<td class="num">(193)<span></span>
</td>
<td class="num">(287)<span></span>
</td>
<td class="num">(635)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Other expense, net</a></td>
<td class="num">(13,269)<span></span>
</td>
<td class="num">(49,871)<span></span>
</td>
<td class="num">(26,539)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">INCOME (LOSS) BEFORE INCOME TAXES</a></td>
<td class="nump">125,714<span></span>
</td>
<td class="num">(28,239)<span></span>
</td>
<td class="num">(65,904)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax benefit</a></td>
<td class="num">(71,959)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">NET INCOME (LOSS)</a></td>
<td class="nump">$ 197,673<span></span>
</td>
<td class="num">$ (28,239)<span></span>
</td>
<td class="num">$ (65,904)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">BASIC EARNINGS (LOSS) PER COMMON SHARE (in dollars per share)</a></td>
<td class="nump">$ 0.85<span></span>
</td>
<td class="num">$ (0.13)<span></span>
</td>
<td class="num">$ (0.33)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">DILUTED EARNINGS (LOSS) PER COMMON SHARE (in dollars per share)</a></td>
<td class="nump">$ 0.81<span></span>
</td>
<td class="num">$ (0.13)<span></span>
</td>
<td class="num">$ (0.33)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>WEIGHTED AVERAGE COMMON SHARES OUTSTANDING:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic (in shares)</a></td>
<td class="nump">233,084,236<span></span>
</td>
<td class="nump">223,977,315<span></span>
</td>
<td class="nump">197,874,895<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted (in shares)</a></td>
<td class="nump">243,342,466<span></span>
</td>
<td class="nump">223,977,315<span></span>
</td>
<td class="nump">197,874,895<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate cost of goods produced and sold and services rendered during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481303/470-50-40-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481303/470-50-40-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseNonoperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense classified as nonoperating.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseNonoperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCostAndExpenseOperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount of other operating cost and expense items that are associated with the entity's normal revenue producing operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(7)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCostAndExpenseOperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Common Stock [Member]</div></th>
<th class="th"><div>Additional Paid-in Capital [Member]</div></th>
<th class="th"><div>Accumulated Deficit [Member]</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2021</a></td>
<td class="nump">$ 20<span></span>
</td>
<td class="nump">$ 553,266<span></span>
</td>
<td class="num">$ (412,113)<span></span>
</td>
<td class="nump">$ 141,173<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2021</a></td>
<td class="nump">195,813,817<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Stock-based compensation</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">5,215<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">5,215<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock, net of offering expenses</a></td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">64,642<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">64,644<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, net of offering expenses (in shares)</a></td>
<td class="nump">24,125,873<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAmount', window );">Vesting of Restricted Stock Units, net of shares withheld for taxes</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">(2,899)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(2,899)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesShares', window );">Vesting of Restricted Stock Units, net of shares withheld for taxes (in shares)</a></td>
<td class="nump">1,808,561<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued', window );">Warrants issued in connection with notes payable</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">9,570<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">9,570<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">175<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">175<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="nump">68,679<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(65,904)<span></span>
</td>
<td class="num">(65,904)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2022</a></td>
<td class="nump">$ 22<span></span>
</td>
<td class="nump">629,969<span></span>
</td>
<td class="num">(478,017)<span></span>
</td>
<td class="nump">151,974<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2022</a></td>
<td class="nump">221,816,930<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Stock-based compensation</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">6,187<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">6,187<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAmount', window );">Vesting of Restricted Stock Units, net of shares withheld for taxes</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">(1,415)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(1,415)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesShares', window );">Vesting of Restricted Stock Units, net of shares withheld for taxes (in shares)</a></td>
<td class="nump">833,722<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued', window );">Warrants issued in connection with notes payable</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">5,595<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">5,595<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">1,103<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,104<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="nump">1,444,533<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_StockIssuedDuringPeriodValueCashlessExerciseOfWarrants', window );">Cashless exercise of warrants</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_StockIssuedDuringPeriodSharesCashlessExerciseOfWarrants', window );">Cashless exercise of warrants (in shares)</a></td>
<td class="nump">1,967,847<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(28,239)<span></span>
</td>
<td class="num">(28,239)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2023</a></td>
<td class="nump">$ 23<span></span>
</td>
<td class="nump">641,439<span></span>
</td>
<td class="num">(506,256)<span></span>
</td>
<td class="nump">135,206<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2023</a></td>
<td class="nump">226,063,032<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition', window );">Stock-based compensation</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">13,616<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">13,616<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAmount', window );">Vesting of Restricted Stock Units, net of shares withheld for taxes</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">(4,971)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(4,971)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesShares', window );">Vesting of Restricted Stock Units, net of shares withheld for taxes (in shares)</a></td>
<td class="nump">1,344,555<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">7,494<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,494<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="nump">1,988,066<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_StockIssuedDuringPeriodValueCashlessExerciseOfWarrants', window );">Cashless exercise of warrants</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_StockIssuedDuringPeriodSharesCashlessExerciseOfWarrants', window );">Cashless exercise of warrants (in shares)</a></td>
<td class="nump">7,224,892<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">197,673<span></span>
</td>
<td class="nump">197,673<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2024</a></td>
<td class="nump">$ 24<span></span>
</td>
<td class="nump">$ 657,577<span></span>
</td>
<td class="num">$ (308,583)<span></span>
</td>
<td class="nump">$ 349,018<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2024</a></td>
<td class="nump">236,620,545<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_StockIssuedDuringPeriodSharesCashlessExerciseOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the cashless exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_StockIssuedDuringPeriodSharesCashlessExerciseOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_StockIssuedDuringPeriodValueCashlessExerciseOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate change in value for stock issued during the period as a result of the cashless exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_StockIssuedDuringPeriodValueCashlessExerciseOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock related to restricted stock awards issued during the period, net of shares withheld to cover grantees' income tax liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period related to restricted stock awards, net of shares withheld to cover grantees' income tax liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481284/470-20-25-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>CASH FLOWS FROM OPERATING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="nump">$ 197,673<span></span>
</td>
<td class="num">$ (28,239)<span></span>
</td>
<td class="num">$ (65,904)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">8,045<span></span>
</td>
<td class="nump">8,332<span></span>
</td>
<td class="nump">7,113<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnDispositionOfAssets', window );">Loss on disposal of fixed assets</a></td>
<td class="nump">106<span></span>
</td>
<td class="nump">182<span></span>
</td>
<td class="nump">427<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes', window );">Deferred income tax benefit</a></td>
<td class="num">(84,280)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaidInKindInterest', window );">Interest paid in kind</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,836<span></span>
</td>
<td class="nump">2,998<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">13,616<span></span>
</td>
<td class="nump">6,187<span></span>
</td>
<td class="nump">5,215<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Amortization of debt discount</a></td>
<td class="nump">951<span></span>
</td>
<td class="nump">2,594<span></span>
</td>
<td class="nump">2,402<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of debt</a></td>
<td class="nump">1,243<span></span>
</td>
<td class="nump">26,174<span></span>
</td>
<td class="nump">6,670<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_AmortizationOfLicenseRevenue', window );">Amortization of license revenue</a></td>
<td class="num">(143)<span></span>
</td>
<td class="num">(143)<span></span>
</td>
<td class="num">(143)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="num">(22,578)<span></span>
</td>
<td class="num">(11,916)<span></span>
</td>
<td class="nump">13,072<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventories</a></td>
<td class="nump">2,671<span></span>
</td>
<td class="num">(9,626)<span></span>
</td>
<td class="num">(38,556)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="num">(2,695)<span></span>
</td>
<td class="num">(239)<span></span>
</td>
<td class="num">(756)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_IncreaseDecreaseInDepositsAndOtherAssets', window );">Deposits and other assets</a></td>
<td class="nump">15<span></span>
</td>
<td class="nump">1,080<span></span>
</td>
<td class="nump">122<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">4,150<span></span>
</td>
<td class="nump">3,839<span></span>
</td>
<td class="nump">800<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses</a></td>
<td class="nump">1,042<span></span>
</td>
<td class="nump">7,530<span></span>
</td>
<td class="nump">7,534<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities', window );">Other current and non-current liabilities</a></td>
<td class="num">(1,144)<span></span>
</td>
<td class="num">(791)<span></span>
</td>
<td class="num">(502)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash provided by (used in) operating activities</a></td>
<td class="nump">118,672<span></span>
</td>
<td class="nump">8,800<span></span>
</td>
<td class="num">(59,508)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>CASH FLOWS FROM INVESTING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property and equipment</a></td>
<td class="num">(8,226)<span></span>
</td>
<td class="num">(4,771)<span></span>
</td>
<td class="num">(13,911)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Acquisition of intangible assets</a></td>
<td class="num">(349)<span></span>
</td>
<td class="num">(210)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(8,575)<span></span>
</td>
<td class="num">(4,981)<span></span>
</td>
<td class="num">(13,911)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>CASH FLOWS FROM FINANCING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfNotesPayable', window );">Principal payments on notes payable</a></td>
<td class="num">(60,000)<span></span>
</td>
<td class="num">(158,584)<span></span>
</td>
<td class="num">(100,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock, net of offering expenses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">64,645<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_PaymentOfDebtRefinancingFees', window );">Prepayment penalties on repayment of debt</a></td>
<td class="num">(450)<span></span>
</td>
<td class="num">(11,140)<span></span>
</td>
<td class="num">(2,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromNotesPayable', window );">Proceeds from issuance of note payable</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">135,000<span></span>
</td>
<td class="nump">151,750<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_TaxesPaidOnVestedRestrictedStockUnits', window );">Taxes paid on vested Restricted Stock Units</a></td>
<td class="num">(4,971)<span></span>
</td>
<td class="num">(1,415)<span></span>
</td>
<td class="num">(2,899)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeasePrincipalPayments', window );">Payments on finance lease obligations</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(17)<span></span>
</td>
<td class="num">(36)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Net proceeds from the exercise of stock options</a></td>
<td class="nump">7,494<span></span>
</td>
<td class="nump">1,104<span></span>
</td>
<td class="nump">175<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_PaymentOfEndOfTermFee', window );">Payment of end of term fee</a></td>
<td class="num">(375)<span></span>
</td>
<td class="num">(1,586)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfFinancingCosts', window );">Payment of deferred financing fees</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(2,351)<span></span>
</td>
<td class="num">(2,783)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash (used in) provided by financing activities</a></td>
<td class="num">(58,302)<span></span>
</td>
<td class="num">(38,989)<span></span>
</td>
<td class="nump">108,852<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase (decrease) in cash and cash equivalents</a></td>
<td class="nump">51,795<span></span>
</td>
<td class="num">(35,170)<span></span>
</td>
<td class="nump">35,433<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents - beginning of year</a></td>
<td class="nump">51,352<span></span>
</td>
<td class="nump">86,522<span></span>
</td>
<td class="nump">51,089<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents - end of year</a></td>
<td class="nump">$ 103,147<span></span>
</td>
<td class="nump">$ 51,352<span></span>
</td>
<td class="nump">$ 86,522<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_AmortizationOfLicenseRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash revenue related to amortization of license revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_AmortizationOfLicenseRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_IncreaseDecreaseInDepositsAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in deposits and operating assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_IncreaseDecreaseInDepositsAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_PaymentOfDebtRefinancingFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for payment of debt refinancing fees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_PaymentOfDebtRefinancingFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_PaymentOfEndOfTermFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for end of term fee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_PaymentOfEndOfTermFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_TaxesPaidOnVestedRestrictedStockUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow related to taxes on vested Restricted Stock Units.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_TaxesPaidOnVestedRestrictedStockUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDebtDiscountPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfDebtDiscountPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeasePrincipalPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for principal payment on finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeasePrincipalPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDispositionOfAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, excluding oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482130/360-10-45-5<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDispositionOfAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481303/470-50-40-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481303/470-50-40-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the account that represents the temporary difference that results from Income or Loss that is recognized for accounting purposes but not for tax purposes and vice versa.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaidInKindInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Interest paid other than in cash for example by issuing additional debt securities. As a noncash item, it is added to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaidInKindInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for loan and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ORGANIZATION AND BUSINESS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>ORGANIZATION AND BUSINESS [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">ORGANIZATION AND BUSINESS</a></td>
<td class="text">
<div>
          <table cellpadding="0" cellspacing="0" class="DSPFListTable" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt; border-spacing: 0;">


  <tr style="vertical-align: top;">

    <td style="vertical-align: top; width: 27pt;">
                  <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: left;"><strong>1.</strong></p>
                </td>

    <td style="align: left; vertical-align: top; width: auto;">
                  <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: left;"><strong><span style="text-decoration: underline;">ORGANIZATION AND BUSINESS</span></strong></p>
                </td>

  </tr>


</table>
        </div>

<div><br/></div>
<p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-indent: 45px; text-align: left;">ADMA Biologics, Inc. (&#8220;ADMA&#8221; or the &#8220;Company&#8221;) is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing
          and developing specialty biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The Company&#8217;s targeted patient populations include immune-compromised individuals who
          suffer from an underlying immune deficiency disorder or who may be immune-suppressed for medical reasons.</p><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-indent: 45px; text-align: left;"><br/>
        </p><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-indent: 45px; text-align: left;">ADMA operates through its wholly-owned subsidiaries ADMA BioManufacturing, LLC (&#8220;ADMA BioManufacturing&#8221;) and ADMA BioCenters Georgia Inc.
          (&#8220;ADMA BioCenters&#8221;). ADMA BioManufacturing was formed in January 2017 to facilitate the acquisition of certain assets held by the Company&#8217;s former third-party contract manufacturer, which included the U.S. Food and Drug Administration
          (&#8220;FDA&#8221;)-licensed BIVIGAM and Nabi-HB immunoglobulin products, and an FDA-licensed plasma fractionation manufacturing facility located in Boca Raton, FL (the &#8220;Boca Facility&#8221;). ADMA BioCenters is the Company&#8217;s source plasma collection business with
          ten plasma collection facilities located throughout the U.S., all of which hold an approved license with the FDA.</p><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-indent: 45px; text-align: left;"><br/>
        </p><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-indent: 45px; text-align: left;">The Company has three
          FDA-approved products, all of which are currently marketed and commercially available: (i) <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: left; text-indent: 45px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">ASCENIV (Immune Globulin Intravenous, Human &#8211; slra 10% Liquid), an intravenous immune globulin (&#8220;IVIG&#8221;) product indicated for the treatment of Primary Humoral Immunodeficiency (&#8220;PI&#8221;), also known as Primary
            Immunodeficiency Disease (&#8220;PIDD&#8221;) or Inborn Errors of Immunity, for which the Company received FDA approval on April 1, 2019 and commenced first commercial sales in October 2019; (ii) BIVIGAM (Immune Globulin Intravenous, Human), an IVIG
            product indicated for the treatment of PI, and for which the Company received FDA approval on May 9, 2019 and commenced commercial sales in August 2019;&#160; and (iii) Nabi-HB (Hepatitis B Immune Globulin, Human), which is indicated for the
            treatment of acute exposure to blood containing Hepatitis B surface antigen (&#8220;HBsAg&#8221;) and other listed exposures to Hepatitis B. In addition to its commercially available immunoglobulin products, the Company generates revenues from the sale of
            intermediate by-products that result from the immunoglobulin production process and from time to time provides contract manufacturing and laboratory services for certain clients. The Company seeks to develop a pipeline of plasma-derived
            therapeutics, and its products and product candidates are intended to be used by physician specialists focused on caring for immune-compromised patients with or at risk for certain infectious diseases</span>.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480424/946-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480424/946-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/810/tableOfContent<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/205/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>SIGNIFICANT ACCOUNTING POLICIES [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text">
<div>
          <table cellpadding="0" cellspacing="0" class="DSPFListTable" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt; border-spacing: 0;">


  <tr style="vertical-align: top;">

    <td style="vertical-align: top; width: 27pt;">
                  <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;"><strong>2.</strong></p>
                </td>

    <td style="align: left; vertical-align: top; width: auto;">
                  <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;"><strong><span style="text-decoration: underline;">SIGNIFICANT ACCOUNTING POLICIES</span></strong></p>
                </td>

  </tr>


</table>
        </div>
<p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;"><span style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
          </span> </p><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;"><span style="text-decoration:underline">Principles of consolidation and basis of presentation</span></p><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;">&#160;</p><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-indent: 45px; text-align: left;">The accompanying consolidated financial statements include the accounts of ADMA and its wholly-owned subsidiaries and have been prepared
          in conformity with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;) and in accordance with Article 3 of Regulation S-X of the Securities and Exchange Commission (the &#8220;SEC&#8221;). All intercompany balances have
          been eliminated in consolidation. Any reference in these notes to applicable guidance is meant to refer to U.S. GAAP as found in the Accounting Standards Codification (&#8220;ASC&#8221;) and Accounting Standards Updates (&#8220;ASU&#8221;) of the Financial Accounting
          Standards Board (the &#8220;FASB&#8221;). </p><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-indent: 45px; text-align: left;"> <span style="font-size: 10pt; font-family: 'Times New Roman';"><br/>
          </span></p><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-indent: 45px; text-align: left;">During the years ended December 31, 2024, 2023 and 2022, <span style="font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">comprehensive income (loss) was equal to the net income (loss) amounts presented for the respective periods in the accompanying consolidated statements of operations.&#160;</span><span style="font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial;">In addition, certain prior year balances have been reclassified to conform to the current presentation. Specifically, the disaggregation of some of the Company&#8217;s accrued expenses and other current liabilities
            (see Note 6) and deferred tax assets and liabilities, as well as the rate reconciliation for U.S. federal income taxes (see Note 11), as of December 31, 2023 have been adjusted to conform to the presentation as of December 31, 2024</span>.</p><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-indent: 45px; text-align: left;"> </p><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;"><span style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
          </span> </p>
<div><span style="font-family: 'Times New Roman'; font-size: 10pt;"><span style="text-decoration: underline;"></span></span></div>
<p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 9pt; text-indent: -9pt; text-align: left;"><span style="text-decoration: underline;">Use of estimates</span></p><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 9pt; text-indent: -9pt; text-align: left;"> <span style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
          </span> </p><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-indent: 45px; text-align: left;">The preparation of financial statements requires management to make estimates and assumptions that affect the reported amounts of assets
          and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.
          Significant estimates include rebates and chargebacks deducted from gross revenues, assumptions used in the fair value of awards granted under the Company&#8217;s equity incentive plans and the valuation allowance for the Company&#8217;s deferred tax assets.</p><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-indent: 45px; text-align: left;"><span style="font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"> <br/>
          </span></p><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-indent: 45px; text-align: left; font-weight: normal; font-style: normal; font-variant: normal; text-transform: none;"><span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; text-align: left; text-indent: 48px; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">The
            Company engaged a third-party specialist to assist in the evaluation of the Company&#8217;s accrual for U.S. Medicaid rebates related to the sale of the Company&#8217;s immunoglobulin products. As a result of this evaluation, the Company recognized a
            reduction in this accrual and a corresponding increase to net revenues of $12.6 million for the year ended December 31, 2024. The
            Company considered several qualitative factors when evaluating its rebate accrual, such as the absence of a statutory limitation on the rebate amounts drug manufacturers pay to state Medicaid programs and general uncertainty that pharmaceutical
            manufacturers have historically seen with government payors often submitting lagged claims many periods after the initial dispensing of a product to an end patient. There was additional new information that arose during June 2024 that suggested
            the Company&#8217;s liabilities for certain payor claims were successfully resolved, which resulted in the $12.6 million adjustment to the
            accrual for U.S. Medicaid rebates in June 2024.</span></p><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;">&#160;</p><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;"><span style="text-decoration:underline">Cash and cash equivalents</span></p><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;">&#160;</p><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-indent: 45px; text-align: left;">The Company considers all highly liquid instruments purchased with a maturity of three months or less to be cash equivalents. </p>
<div><span style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
        </span></div>
<p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-indent: 45px; text-align: left;">The Company regularly maintains cash and cash equivalents at third-party financial institutions in excess of the Federal Deposit Insurance
          Corporation insurance limit. Although the Company monitors the daily cash balances in its operating accounts and adjusts the balances as appropriate, these balances could be impacted, and there could be a material adverse effect on the Company&#8217;s
          business, if one or more of the financial institutions with which the Company has deposits fails or is subject to other adverse conditions in the financial or credit markets. To date, the Company has not experienced a loss or lack of access to
          its deposited cash or cash equivalents; however, the Company cannot provide assurance that access to its cash and cash equivalents will not be impacted by adverse conditions in the financial and credit markets in the future.</p><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;"><span style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
          </span> </p><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;"><span style="text-decoration:underline">Accounts receivable</span></p><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;">&#160;</p><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-indent: 45px; text-align: left;"><span style="font-family: 'Times New Roman'; font-size: 10pt;">Accounts receivable is reported at realizable value, net of allowances for
            contractual credits and doubtful accounts in the amount of $0.2 million and $0.1 million at December 31, 2024 and 2023, respectively, which are recognized in the period the related revenue is recorded. The Company extends credit to its customers
            based upon an evaluation of each customer&#8217;s financial condition and credit history. Evaluations of the financial condition and associated credit risk of customers are performed on an ongoing basis.<br/>
          </span> </p><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;"><span style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
          </span> </p><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;"><span style="text-decoration:underline">Inventories</span></p><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;">&#160;</p><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-indent: 45px; text-align: left;">Raw materials inventory consists of <span style="font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"><span style="font-weight: normal; font-style: normal; font-variant: normal; text-transform: none;">normal source plasma (&#8220;NSP&#8221;) and Respiratory Syncytial Virus (&#8220;RSV&#8221;) high titer plasma collected at the Company&#8217;s plasma collection
              facilities or purchased from third parties, along with</span> </span>various materials purchased from suppliers, used in the production of the Company&#8217;s products. Work-in-process and finished goods inventories (see Note 3) reflect the cost
          of raw materials as well as costs for direct and indirect labor, primarily salaries, wages and benefits for applicable employees, as well as an allocation of overhead costs related to the Boca Facility including utilities, property taxes, general
          repairs and maintenance, consumable supplies and depreciation. The allocation of Boca Facility overhead to inventory is generally based upon the estimated square footage of the Boca Facility that is used in the production of the Company&#8217;s
          products relative to the total square footage of the facility. </p><p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-bottom: 0px; text-align: left;"> </p>
<div><br/></div>

<div style="display:none;"><br/></div>
<div style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-indent: 45px; text-align: left;">Inventories, including plasma intended for resale and plasma intended for internal use in the Company&#8217;s manufacturing, commercialization
          or research and development activities, are carried at the lower of cost or net realizable value determined by the first-in, first-out method. For both the Company&#8217;s immune globulin products and plasma intended for resale and internal use, net
          realizable value is generally determined based upon the consideration the Company expects to receive when the inventory is sold, less costs to deliver the inventory to the recipient. The estimates for net realizable value of inventory are based
          on contractual terms or upon historical experience and certain other assumptions, and the Company believes that such assumptions are reasonable. Inventory is periodically reviewed to ensure that its carrying value does not exceed its net
          realizable value, and adjustments are recorded to write down such inventory, with a corresponding charge to cost of product revenue, when the carrying value or historical cost exceeds its estimated net realizable value. In addition, costs
          associated with the production of engineering lots that would not qualify as immediately available for commercial sale are charged to cost of product revenue and not capitalized into inventory.</div>
<p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;"><span style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
          </span> </p><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;"><span style="text-decoration: underline; font-family: 'Times New Roman'; font-size: 10pt;">Property and equipment</span> </p><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;">&#160;</p><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-indent: 45px; text-align: left;"><span style="font-family: 'Times New Roman'; font-size: 10pt;">Assets comprising property and equipment (see Note 4) are stated at cost
            less accumulated depreciation. Depreciation is calculated using the straight-line method over the asset&#8217;s estimated useful life. Land is not depreciated. The buildings have been assigned a useful life of 30 years. Property and equipment other than land and buildings have useful lives ranging from 3 to 15 years. Leasehold improvements are amortized over the
            lesser of the lease term or their estimated useful lives.</span> </p><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;"><span style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
          </span> </p><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;"><span style="text-decoration:underline">Goodwill</span></p><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;">&#160;</p><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-indent: 45px; text-align: left;">Goodwill represents the excess of purchase price over the fair value of net assets acquired by the Company. Goodwill at December 31, 2024
          and 2023 was $3.5 million, all of which is attributable to the Company&#8217;s ADMA BioManufacturing business segment. There were no changes to the carrying amount of goodwill during the years ended December 31, 2024, 2023 and 2022.</p>
<div><span style="font-family: 'Times New Roman'; font-size: 10pt;"> &#160; </span></div>
<p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-indent: 45px; text-align: left;">Goodwill is not amortized but is assessed for impairment on an annual basis or more frequently if impairment indicators exist. The Company
          has the option to perform a qualitative assessment of goodwill to determine whether it is more likely than not that the fair value of its reporting unit is less than its carrying amount, including goodwill and other intangible assets. If the
          Company concludes that this is the case, then it must perform a goodwill impairment test by comparing the fair value of the reporting unit to its carrying value. An impairment charge is recorded to the extent the reporting unit&#8217;s carrying value
          exceeds its fair value, not to exceed the total amount of goodwill allocated to that reporting unit. The Company performs its annual goodwill impairment assessment as of October 1 of each year. The Company&#8217;s annual goodwill impairment assessments
          as of October 1, 2024, 2023 and 2022 did not result in any impairment charges related to goodwill for the years ended December 31, 2024, 2023 and 2022.</p><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;"><span style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
          </span> </p><p style="margin: 0px; font-family: 'Times New Roman'; font-size: 10pt; text-align: left;"><span style="text-decoration:underline">Impairment of long-lived assets</span></p><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;">&#160;</p><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-indent: 45px; text-align: left;">The Company assesses the recoverability of its long-lived assets, which include property and equipment and finite-lived intangible assets,
          whenever significant events or changes in circumstances indicate impairment may have occurred. If indicators of impairment exist, projected future undiscounted cash flows associated with the asset are compared to its carrying amount to determine
          whether the asset&#8217;s carrying value is recoverable. Any resulting impairment is recorded as a reduction in the carrying value of the related asset in excess of fair value and a charge to operating results. For the years ended December 31, 2024,
          2023 and 2022, the Company determined that there was no impairment of its long-lived assets. </p><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;"><span style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
          </span> </p><p style="margin: 0px; font-family: 'Times New Roman'; font-size: 10pt; text-align: left;"><span style="text-decoration:underline">Revenue recognition</span></p><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;">&#160;</p><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-indent: 45px; text-align: left;">Revenues for the years ended December 31, 2024, 2023 and 2022 are comprised of (i) revenues from the sale of the Company&#8217;s immunoglobulin
          products, ASCENIV, BIVIGAM and Nabi-HB, (ii) product revenues from the sale of human plasma collected by the Company&#8217;s Plasma Collection Centers business segment, (iii) contract manufacturing and laboratory services revenue, (iv) revenues from
          the sale of intermediate by-products and (v) license and other revenues primarily attributable to the out-licensing of ASCENIV to Biotest AG (&#8220;Biotest&#8221;) in 2012 to market and sell this product in Europe and selected countries in North Africa and
          the Middle East. Biotest has provided the Company with certain services and financial payments in accordance with the related Biotest license agreement and is obligated to pay the Company certain amounts in the future if certain milestones are
          achieved. Deferred revenue is amortized into income over the term of the Biotest license, representing a period of approximately 22 years.
        </p>
<div><br/></div>

<div style="display:none;"><br/></div>
<div style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-indent: 45px; text-align: left;">Product revenue is recognized when the customer is deemed to have control over the product and the performance obligation is satisfied.
          Control is determined based on when the product is shipped or delivered and title passes to the customer. Revenue is recorded in an amount that reflects the consideration the Company expects to receive in exchange. Revenue from the sale of the
          Company&#8217;s immunoglobulin products is recognized when the product reaches the customer&#8217;s destination, and is recorded net of estimated rebates, <span style="font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">wholesaler distribution and related
            fees, customer incentives, including prompt pay discounts, wholesaler chargebacks, group purchasing organization fees and reimbursements for patient assistance. These estimates are based on contractual arrangements, historical experience and
            certain other assumptions, and while the Company believes that such estimates are reasonable, they are subject to change based on future developments and other factors.</span></div>

<div style="display:none;"><br/></div>
<div style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-indent: 45px; text-align: left;"><span style="font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"> <br/>
          </span></div>

<div style="display:none;"><br/></div>
<div style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-indent: 45px; text-align: left;"><span style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">For revenues
            associated with contract manufacturing and the sale of intermediates, control transfers to the customer and the performance obligation is satisfied when the customer takes possession of the product from the Boca Facility</span><span style="font-family: 'Times New Roman'; font-size: 10pt;">.</span></div>
<p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-indent: 45px; text-align: left;">&#160;</p><p style="margin: 0px; font-family: 'Times New Roman'; font-size: 10pt; text-align: left; text-indent: 45px;">Product revenues from the sale of human plasma collected at the Company&#8217;s plasma collection centers are recognized at the time control of
          the product has been transferred to the customer<span style="font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"> and the performance obligation is satisfied, which generally occurs at the time of shipment from
            one of the Company&#8217;s plasma collection facilities or from a third-party warehouse that is utilized by the Company. Product revenues are recognized at the time of delivery if the Company retains control of the product during shipment</span>.</p><p style="margin: 0px; font-family: 'Times New Roman'; font-size: 10pt; text-align: left; text-indent: 45px;"> <br/>
        </p><p style="margin: 0px; font-family: 'Times New Roman'; font-size: 10pt; text-align: left; text-indent: 45px;"><span style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">For all of the Company&#8217;s product revenues, payment from the customer is typically due within 90 days of sale.</span><span style="font-size: 10pt; font-family: 'Times New Roman';"> </span></p>
<div><span style="font-size: 10pt; font-family: 'Times New Roman';">  </span></div>
<p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;">&#160;</p><p style="margin: 0px; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-align: left; text-indent: 0px; text-transform: none;"><span style="text-decoration: underline;">Cost of product revenue</span></p><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;">&#160;</p><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-indent: 45px; text-align: left;"><span style="font-family: 'Times New Roman'; font-size: 10pt;">Cost of product revenue includes costs associated with the manufacture of
            the Company&#8217;s FDA approved products and intermediates and for the collection of human source plasma, as well as expenses related to conformance batch production, process development and scientific and technical operations when these operations
            are attributable to marketed products. When the activities of these operations are attributable to new products in development, the expenses are classified as research and development expenses.</span> </p><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;"><span style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
          </span> </p><p style="margin: 0px; font-family: 'Times New Roman'; font-size: 10pt; text-align: left; text-indent: 0px;"><span style="text-decoration:underline">Research and development expenses</span></p><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;">&#160;</p><p style="margin: 0px; font-family: 'Times New Roman'; font-size: 10pt; text-align: left; text-indent: 45px;"><span style="font-family: 'Times New Roman'; font-size: 10pt;">Research and development expenses consist of clinical research organization
            costs, costs related to clinical trials, post-marketing commitment studies for BIVIGAM and ASCENIV and salaries, benefits and stock-based compensation for employees directly related to research and development activities. All research and
            development costs are expensed as incurred.</span> </p><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;"><span style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
          </span> </p><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;"> </p>
<div style="display:none;"><br/></div>
<div style="margin: 0px; font-family: 'Times New Roman'; font-size: 10pt; text-align: left; text-indent: 0px;"><span style="text-decoration: underline;">Plasma center operating expenses</span></div>

<div style="display:none;"><br/></div>
<div style="margin: 0px; font-family: 'Times New Roman'; font-size: 10pt; text-align: left; text-indent: 0px;"><span style="text-decoration: underline;"> <br/>
          </span></div>

<div style="display:none;"><br/></div>
<div style="margin: 0px; font-family: 'Times New Roman'; font-size: 10pt; text-align: left; text-indent: 45px;">Plasma center operating expenses consist of certain general and administrative plasma center costs, initial opening, marketing and
          start-up costs, rent expense, maintenance, utilities and compensation and benefits for administrative staff.</div>
<p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;"> <span style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
          </span> </p><p style="margin: 0px; font-family: 'Times New Roman'; font-size: 10pt; text-align: left; text-indent: 0px;"><span style="text-decoration:underline">Advertising and marketing expenses</span></p><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;">&#160;</p><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-indent: 45px; text-align: left;">Advertising and marketing expense includes cost for promotional materials and trade show expenses for the marketing of the Company&#8217;s
          products and expenses incurred for attracting donors to the Company&#8217;s plasma collection centers. All advertising and marketing expenses are expensed as incurred.&#160; Advertising and marketing expenses were $2.7 million, $3.3 million and $2.2 million for the years ended December 31, 2024, 2023 and 2022, respectively.</p><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;"><span style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
          </span> </p><p style="margin: 0px; font-family: 'Times New Roman'; font-size: 10pt; text-align: left; text-indent: 0px;"><span style="text-decoration:underline">Stock-based compensation</span></p><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;">&#160;</p><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-indent: 45px; text-align: left;">The Company follows recognized accounting guidance which requires all equity-based payments, including grants of stock options and
          restricted stock unit awards (&#8220;RSUs&#8221;), to be recognized in the statement of operations as compensation expense based on their fair values at the date of grant. Compensation expense related to awards to employees and directors with service-based
          vesting conditions is recognized on a straight-line basis over the associated vesting period of the award based on the grant date fair value of the award. Stock options granted to employees under the Company&#8217;s equity incentive plans generally
          have a four-year vesting period and a term of 10 years. RSUs granted to employees also have a four-year vesting period. For milestone-based equity
          awards, <span style="font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">which were awarded to two
            of the Company&#8217;s executive officers in September of 2021 and vested during fiscal 2022,</span> the Company would periodically assess the probability of vesting for each milestone-based award and adjust compensation expense based on its
          probability assessment. Pursuant to ASU No. 2016-09, <span style="font-style: italic;">Improvements to Employee Share-Based Payment Accounting (Topic 718)</span>, the Company has elected not to establish a forfeiture rate, as stock-based
          compensation expense related to forfeitures of unvested equity awards is fully reversed at the time of forfeiture.</p><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;">&#160;</p><p style="margin: 0px; font-family: 'Times New Roman'; font-size: 10pt; text-align: left; text-indent: 0px;"><span style="text-decoration:underline">Income taxes</span></p><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;">&#160;</p><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-indent: 45px; text-align: left;">The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of events that have been included in
          the consolidated financial statements or its tax returns. Under this method, deferred tax assets and liabilities are recognized for the temporary differences between the tax bases of assets and liabilities and their respective financial reporting
          amounts at enacted tax rates in effect for the years in which the temporary differences are expected to reverse. The Company records a valuation allowance on its deferred tax assets if it is more likely than not that the Company will not generate
          sufficient taxable income to utilize its deferred tax assets (see Note 11). The Company is subject to income tax examinations by major taxing authorities for all tax years since 2020 and for previous periods as it relates to the Company&#8217;s net
          operating loss carryforwards.</p><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-indent: 45px; text-align: left;"> </p>
<div><span style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
        </span></div>
<p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 9pt; text-align: left; text-indent: -9pt;"><span style="font-family: 'Times New Roman'; font-size: 10pt;"><span style="text-decoration: underline;">Earnings (Loss) Per Share</span></span> </p><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 9pt; text-align: left; text-indent: -9pt;"><span style="text-decoration: underline;"> <br/>
          </span></p><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-indent: 45px; text-align: left;">Basic earnings (loss) per share is computed by dividing net income or loss attributable to common stockholders by the weighted average
          number of shares of common stock outstanding during the period. Diluted loss per share is calculated by dividing net income or loss attributable to common stockholders as adjusted for the effect of dilutive securities, if any, by the weighted
          average number of shares of common stock and dilutive common stock outstanding during the period. Potentially dilutive common stock includes the shares of common stock issuable upon the exercise of outstanding stock options and warrants (using
          the treasury stock method) <span style="font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">and upon the vesting of restricted stock units (&#8220;RSUs&#8221;). Potentially dilutive common stock in the diluted net
            earnings (loss) per share computation is excluded to the extent that it would be anti-dilutive. <span style="font-style: normal; font-weight: 400; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; color: rgb(0, 0, 0);">For the year ended December 31, 2024, basic and diluted earnings per share are calculated as follows:</span></span></p>
<div style="display:none;"><br/></div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial;"><span style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
          </span> </div>

<table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="letter-spacing: normal; width: 100%; word-spacing: 0px; font-family: 'Times New Roman'; font-size: 10pt; text-align: left; text-transform: none; border-spacing: 0;">


  <tr>

    <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-align: center; text-transform: none;"><br/>
              </td>

    <td colspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">
                <div style="text-align: center; font-weight: bold;">Year Ended</div>
              </td>

    <td colspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; white-space: nowrap; padding: 0px 0px 0px; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none;">&#160;</td>

    <td colspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                <div style="text-align: center; font-weight: bold;">December 31, 2024</div>
              </td>

    <td colspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; width: 88%; background-color: #CCEEFF;" valign="bottom">
                <div>Net income available to common stockholders ($000&#8217;s) (numerator)</div>
              </td>

    <td colspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>$</div>
              </td>

    <td colspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>197,673</div>
              </td>

    <td colspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; width: 88%; padding-bottom: 2px;" valign="bottom">
                <div>Weighted-average number of common shares (denominator)</div>
              </td>

    <td colspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                <div>233,084,236</div>
              </td>

    <td colspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; white-space: nowrap; padding: 0px 0px 4px; color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; width: 88%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">
                <div>Basic earnings per common shares</div>
              </td>

    <td colspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>$</div>
              </td>

    <td colspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>0.85</div>
              </td>

    <td colspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; font-style: normal; font-variant: normal; text-transform: none; width: 88%;" valign="bottom"><br/>
              </td>

    <td colspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; width: 88%; background-color: #CCEEFF;" valign="bottom">
                <div>Weighted-average number of common shares</div>
              </td>

    <td colspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>233,084,236</div>
              </td>

    <td colspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; width: 88%;" valign="bottom">
                <div>Potential shares of common stock arising from outstanding stock options</div>
              </td>

    <td colspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                <div>4,150,584</div>
              </td>

    <td colspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; width: 88%; background-color: #CCEEFF;" valign="bottom">
                <div>Potential shares of common stock arising from outstanding warrants</div>
              </td>

    <td colspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>3,085,640</div>
              </td>

    <td colspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; width: 88%; padding-bottom: 2px;" valign="bottom">
                <div>Potential shares of common stock arising from unvested RSUs</div>
              </td>

    <td colspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                <div>3,022,006</div>
              </td>

    <td colspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; width: 88%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">
                <div>Total shares - diluted (denominator)</div>
              </td>

    <td colspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>243,342,466</div>
              </td>

    <td colspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; width: 88%; padding-bottom: 4px;" valign="bottom">
                <div>Diluted earnings per common share</div>
              </td>

    <td colspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom">
                <div>$</div>
              </td>

    <td colspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom">
                <div>0.81</div>
              </td>

    <td colspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>
<p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-indent: 45px; text-align: left;"> <span style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
          </span> </p><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-indent: 45px; text-align: left;"><span style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">For the year ended December 31, 2024, there were no shares with an anti-dilutive effect that needed to be excluded
            from the earnings per share computation. For the years ended December 31, 2023 and 2022, no potentially dilutive securities are
            included in the computation of diluted loss per share in the accompanying consolidated financial statements as the Company reported a net loss for these periods.</span><span style="font-family: 'Times New Roman'; font-size: 10pt;"> <span style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; color: rgb(0, 0, 0);">For
            the years ended December 31, 2023 and 2022, the following securities were excluded from the calculation of diluted loss per common share because of their anti-dilutive effects:</span></span></p><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px;"><span style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;&#160; <br/>
          </span> </p>
<table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="text-align: left; font: 10pt 'Times New Roman'; width: 100%; border-spacing: 0;">


  <tr style="height: 15px;">

    <td style="font-family: 'Times New Roman'; font-size: 10pt; padding-bottom: 2px;" valign="bottom">
                <p style="margin: 0px;">&#160;</p>
              </td>

    <td colspan="1" rowspan="1" style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="6" rowspan="1" style="vertical-align: bottom; text-align: center; font-family: 'Times New Roman'; font-size: 10pt; border-bottom: #000000 solid 2px;" valign="bottom">
                <p style="margin: 0px 0px 0px 0in; text-align: center;"><strong>For the Years Ended December 31,</strong></p>
              </td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td style="font-family: 'Times New Roman'; font-size: 10pt; padding-bottom: 2px;" valign="bottom">
                <p style="margin: 0px;">&#160;</p>
              </td>

    <td colspan="1" style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; text-align: center; font-family: 'Times New Roman'; font-size: 10pt; border-bottom: #000000 solid 2px;" valign="bottom">
                <p style="margin: 0px 0px 0px 0in; text-align: center;"><strong>2023<br/>
                  </strong></p>
              </td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: center; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="text-align: center; vertical-align: bottom; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">2022</td>

    <td colspan="1" style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td style="vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt; width: 76%; background-color: #CCEEFF;" valign="bottom">
                <p style="margin: 0px 0px 0px 0in;">Stock Options</p>
              </td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">5,906,184<br/>
              </td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">8,256,211<br/>
              </td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td style="vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt; width: 76%;" valign="bottom">
                <p style="margin: 0px 0px 0px 0in;">Restricted Stock Units</p>
              </td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">4,657,297<br/>
              </td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">2,866,987<br/>
              </td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td style="vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">
                <p style="margin: 0px 0px 0px 0in;">Warrants</p>
              </td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">12,502,906<br/>
              </td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">13,525,148<br/>
              </td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td style="font-family: 'Times New Roman'; font-size: 10pt; width: 76%; padding-bottom: 4px;" valign="bottom">
                <p style="margin-top: 0px; margin-bottom: 0px; margin-left: 9pt;">Total<br/>
                </p>
              </td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" valign="bottom">23,066,387</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom">24,648,346</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt;"> </span></div>
<p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;">&#160; </p><p style="margin: 0px; line-height: normal; font-family: 'Times New Roman'; font-size: 10pt; text-align: left; text-indent: 0px;"><span style="text-decoration:underline">Fair value of financial instruments</span></p><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;">&#160;</p><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-indent: 45px; text-align: left;"><span style="font-family: 'Times New Roman'; font-size: 10pt;">The carrying amounts of certain of the Company&#8217;s financial instruments,
            including cash and cash equivalents, accounts receivable and accounts payable are shown at cost, which approximates fair value due to the short-term nature of these instruments. The debt outstanding under the Company&#8217;s senior notes payable (see
            Note 7) also approximates fair value, based on a Level 3 classification under the fair value hierarchy, due to the variable interest rate on this debt.</span> </p><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;">&#160;</p><p style="margin: 0px; font-family: 'Times New Roman'; font-size: 10pt; text-align: left; text-indent: 0px;"><span style="text-decoration:underline">Recent Accounting Pronouncements</span></p><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;">&#160;</p>
<div style="display:none;"><br/></div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-transform: none; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; text-indent: 36pt;">In November of 2024 the FASB issued ASU No. 2024-03,&#160;<span style="font-style: italic;">Income Statement - Reporting Comprehensive Income &#8211;
              Expense Disaggregation Disclosures (Subtopic 220-40).&#160;</span>The amendments in this Update require disclosure, in the notes to the financial statements, of specified information about certain costs and expenses, including but not limited to,
            purchases of inventory, employee compensation and selling expense. This Update becomes effective for fiscal years beginning after December 15, 2026. The Company has yet to determine the impact this Update may have on the Company&#8217;s consolidated
            financial statements.</div>

<div style="display:none;"><br/></div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial;"><br/>
          </div>

<div style="display:none;"><br/></div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-transform: none; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; text-indent: 36pt;">In December of 2023 the FASB issued ASU 2023-09,&#160;<span style="font-style: italic;">Income Taxes (Topic 740):</span>&#160;<span style="font-style: italic;">Improvements to Income Tax Disclosures.&#160;</span>This Update requires disaggregated information about a reporting entity&#8217;s effective tax rate reconciliation as well as information on income taxes paid and becomes
            effective for public business entities for fiscal years beginning after December 15, 2024. The Company is currently evaluating the impact that this Update may have on the Company&#8217;s consolidated financial statements.</div>

<div style="display:none;"><br/></div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial;"><br/>
          </div>

<div style="display:none;"><br/></div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-transform: none; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; text-indent: 36pt;">In November of 2023 the FASB issued ASU No. 2023-07,&#160;<span style="font-style: italic;">Segment Reporting (Topic 280): Improvements to
              Reportable Segment Disclosures.&#160;</span>The amendments in this Update are intended to provide financial statement users with more disaggregated expense information about a public entity&#8217;s reportable segments, however the Update does not change
            the definition of a business segment or the method for determining reportable segments. This update became effective for fiscal years beginning after December 15, 2023 (see Note 13). Adoption of this Update did not have a material impact on the
            Company&#8217;s consolidated financial statements.</div>

<div style="display:none;"><br/></div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial;"><br/>
          </div>

<div style="display:none;"><br/></div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-transform: none; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; text-indent: 36pt;">There were no new accounting pronouncements adopted during the years ended December 31, 2023 and 2022 that had a significant impact on the
            Company&#8217;s consolidated financial statements.</div>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/235/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INVENTORIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>INVENTORIES [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">INVENTORIES</a></td>
<td class="text">
<div>
          <table cellpadding="0" cellspacing="0" class="DSPFListTable" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt; border-spacing: 0;">


  <tr style="vertical-align: top;">

    <td style="vertical-align: top; width: 27pt;">
                  <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;"><strong>3.</strong></p>
                </td>

    <td style="align: left; vertical-align: top; width: auto;">
                  <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;"><strong><span style="text-decoration: underline;">INVENTORIES</span></strong></p>
                </td>

  </tr>


</table>
        </div>
<p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;">&#160;</p><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-indent: 45px; text-align: left;">The following table provides the components of inventories:</p><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px;"><br/>
        </p>
<table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="text-align: left; font: 10pt 'Times New Roman'; width: 100%; border-spacing: 0;">


  <tr style="height: 15px;">

    <td style="padding-bottom: 2px;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px;">&#160;</p>
              </td>

    <td colspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: center;"><strong>December 31,<br/>
                    2024</strong></p>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: center;"><strong>December 31,<br/>
                    2023</strong></p>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td rowspan="1" style="vertical-align: top;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: center; vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="6" rowspan="1" style="text-align: center; vertical-align: bottom;" valign="bottom"><span style="font-style: italic;">(In thousands)</span><br/>
              </td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td style="vertical-align: top; width: 76%; background-color: #CCEEFF;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in;">Raw materials</p>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">$</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">60,473</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">$</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">52,999</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td style="vertical-align: top; width: 76%;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in;">Work-in-process</p>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">61,641</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">49,621</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td style="vertical-align: top; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in;">Finished goods</p>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">48,121</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">70,286</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td style="vertical-align: top; width: 76%; padding-bottom: 4px;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in;">Total inventories</p>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom">$</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom">170,235</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom">$</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom">172,906</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>
<p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-indent: 45px; text-align: left;"> <br/>
        </p><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-indent: 45px; text-align: left;">Raw materials includes plasma and other materials expected to be used in the production of ASCENIV, BIVIGAM and Nabi-HB. These materials
          will be consumed in the production of products expected to be available for sale or otherwise have alternative uses that provide a probable future benefit.<br/>
        </p>
<div><br/></div>
<p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-indent: 45px; text-align: left;">Work-in-process inventory primarily consists <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">of the Company&#8217;s IVIG products that are manufactured to the bulk drug substance and unlabeled filled vials stage of
            production</span>.</p><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-indent: 45px; text-align: left;"> <br/>
        </p><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-indent: 45px; text-align: left;"> Finished goods inventory is comprised <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">of the Company&#8217;s immunoglobulin products that have reached the filled, labeled and serialized vial stage of production and related
            intermediates that are available for commercial sale, as well as plasma collected at the Company&#8217;s plasma collection centers which is expected to be sold to third-party customers</span>. </p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/330/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROPERTY AND EQUIPMENT<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>PROPERTY AND EQUIPMENT [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">PROPERTY AND EQUIPMENT</a></td>
<td class="text">
<div>
          <table cellpadding="0" cellspacing="0" class="DSPFListTable" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt; border-spacing: 0;">


  <tr style="vertical-align: top;">

    <td style="vertical-align: top; width: 27pt;">
                  <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;"><strong>4.</strong></p>
                </td>

    <td style="align: left; vertical-align: top; width: auto;">
                  <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;"><strong><span style="text-decoration: underline;">PROPERTY AND EQUIPMENT</span></strong></p>
                </td>

  </tr>


</table>
        </div>
<p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;">&#160;</p><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-indent: 45px; text-align: left;">Property and equipment at December 31, 2024 and 2023 is summarized as follows:</p><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;">&#160; </p>
<table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="text-align: left; font: 10pt 'Times New Roman'; width: 100%; border-spacing: 0;">


  <tr style="height: 15px;">

    <td style="padding-bottom: 2px;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px;">&#160;</p>
              </td>

    <td colspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: center;"><strong>December 31, 2024</strong></p>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: center;"><strong>December 31, 2023</strong></p>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td rowspan="1" style="vertical-align: top;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: center; vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="6" rowspan="1" style="text-align: center; vertical-align: bottom;" valign="bottom"><span style="font-style: italic;">(In thousands)</span><br/>
              </td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td style="vertical-align: top; width: 76%; background-color: #CCEEFF;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px;">Manufacturing and laboratory equipment</p>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">$</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">21,305</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">$</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">21,093</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td style="vertical-align: top; width: 76%;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px;">Office equipment and computer software</p>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">5,772</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">6,062</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td style="vertical-align: top; width: 76%; background-color: #CCEEFF;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px;">Furniture and fixtures</p>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">5,840</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">5,776</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td style="vertical-align: top; width: 76%;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px;">Construction in process</p>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">8,149</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">2,273</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td style="vertical-align: top; width: 76%; background-color: #CCEEFF;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px;">Leasehold improvements</p>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">21,066</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">20,811</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td style="vertical-align: top; width: 76%;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px;">Land</p>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">4,339</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">4,339</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td style="vertical-align: top; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px;">Buildings and building improvements</p>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">21,788</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">20,218</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td style="width: 76%;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px;">&#160;</p>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">88,259</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">80,572</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td style="vertical-align: top; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px;">Less: Accumulated depreciation </p>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">(33,552</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">)</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">(26,737</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">)</td>

  </tr>

  <tr style="height: 15px;">

    <td style="vertical-align: top; width: 76%; padding-bottom: 4px;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px;">Total property and equipment, net</p>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom">$</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom">54,707</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom">$</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom">53,835</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>
<p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;">&#160; &#160;</p><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-indent: 45px; text-align: left;">The Company recorded depreciation expense on property and equipment of $7.7 million, $7.6 million and $6.4 million for the years ended December 31, 2024, 2023 and 2022, respectively.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/360/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INTANGIBLE ASSETS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>INTANGIBLE ASSETS [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsDisclosureTextBlock', window );">INTANGIBLE ASSETS</a></td>
<td class="text">
<div>
          <table cellpadding="0" cellspacing="0" class="DSPFListTable" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt; border-spacing: 0;">


  <tr style="vertical-align: top;">

    <td style="vertical-align: top; width: 27pt;">
                  <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;"><strong>5.</strong></p>
                </td>

    <td style="align: left; vertical-align: top; width: auto;">
                  <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;"><strong><span style="text-decoration: underline;">INTANGIBLE ASSETS</span></strong></p>
                </td>

  </tr>


</table>
        </div>
<p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;">&#160;</p><p style="margin: 0px 0px; font-family: 'Times New Roman'; font-size: 10pt; text-align: left; text-indent: 45px;">Intangible assets at December 31, 2024 and 2023 consist of the following:</p><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;">&#160; </p>
<table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="text-align: left; font: 10pt 'Times New Roman'; width: 100%; border-spacing: 0;">


  <tr style="height: 15px;">

    <td style="padding-bottom: 2px;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px;">&#160;</p>
              </td>

    <td colspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="10" style="vertical-align: bottom; text-align: center; border-bottom: #000000 solid 2px;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: center;"><span style="font-weight: bold;">December 31, 2024</span><br/>
                </p>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="10" style="vertical-align: bottom; text-align: center; border-bottom: #000000 solid 2px;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: center;"><span style="font-weight: bold;">December 31, 2023</span><br/>
                </p>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td rowspan="1" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: center; vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="22" rowspan="1" style="vertical-align: bottom; text-align: center;" valign="bottom"><span style="font-style: italic;">(In thousands) </span> <br/>
              </td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td style="padding-bottom: 2px;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px;">&#160;</p>
              </td>

    <td colspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: #000000 solid 2px;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: center;"><strong> Cost</strong></p>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: #000000 solid 2px;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in;"><strong>Accumulated</strong></p>
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in;"><strong>Amortization</strong></p>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: #000000 solid 2px;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: center;"><strong>Net</strong></p>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: #000000 solid 2px;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: center;"><strong>Cost</strong></p>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: #000000 solid 2px;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in;"><strong>Accumulated</strong></p>
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in;"><strong>Amortization</strong></p>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: #000000 solid 2px;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: center;"><strong>Net</strong></p>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td style="vertical-align: top; width: 28%; background-color: #CCEEFF;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-bottom: 0px; text-indent: -9pt; margin-left: 9pt;">Trademark and other intangible rights related to Nabi-HB</p>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">$</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">4,100</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">$</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">4,100</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">$</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">-</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">$</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">4,100</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">$</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">3,856</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">$</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">244</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td rowspan="1" style="vertical-align: top; font-size: 10pt; width: 28%;" valign="bottom"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: -9.6px; text-transform: none; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">Internally developed software</span></td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">559</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">99</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">460</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">210</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">9</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">201</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td style="vertical-align: top; width: 28%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-bottom: 0px; text-indent: -9pt; margin-left: 9pt;">Rights to intermediates</p>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">907</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">907</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">-</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">907</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">853</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">54</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td style="width: 28%; padding-bottom: 4px;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px;">&#160;</p>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom">$</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom">5,566</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom">$</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom">5,106</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom">$</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom">460</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom">$</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom">5,217</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom">$</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom">4,718</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom">$</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom">499</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>
<p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;">&#160; &#160;</p><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-indent: 45px; text-align: left;"> </p>
<div style="display:none;"><br/></div>
<div style="margin: 0px 0px 0px; font-family: 'Times New Roman'; font-size: 10pt; text-align: left; text-indent: 27pt;">Under the previous contract manufacturing agreement between ADMA and Biotest, intermediate by-products derived from the
          manufacture of ASCENIV were property of Biotest.&#160; As a result of the acquisition of certain assets from Biotest on June 6, 2017, ADMA obtained the right to these intermediate products as well as the intangible rights to Nabi-HB, which were
          amortized over a period of seven years. As of December 31, 2024, the Company&#8217;s intangible assets are comprised of several internally
          developed data intelligence and analytics programs at a cost of approximately $0.6 million which is being amortized over a period of four years.</div>

<div style="display:none;"><br/></div>
<div style="margin: 0px 0px 0px; font-family: 'Times New Roman'; font-size: 10pt; text-align: left; text-indent: 27pt;"> <br/>
        </div>
<p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-bottom: 0px; text-align: left; text-indent: 27pt;">Amortization expense related to the Company&#8217;s intangible assets for the years ended December 31, 2024, 2023 and
          2022 was $0.4 million, $0.7
          million and $0.7 million, respectively. Estimated aggregate future aggregate amortization expense is expected to be as follows (in
          thousands):</p><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="text-align: left; font: 10pt 'Times New Roman'; width: 100%; border-spacing: 0;">


  <tr style="height: 15px;">

    <td style="vertical-align: top; width: 88%; background-color: #CCEEFF;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in;">2025<br/>
                </p>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">$<br/>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">140</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td style="vertical-align: top; width: 88%;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in;">2026<br/>
                </p>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">$ <br/>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">140</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td rowspan="1" style="vertical-align: top; width: 88%; background-color: #CCEEFF;" valign="bottom">
                <div>2027<br/>
                </div>
              </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">$ <br/>
              </td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">130</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td rowspan="1" style="vertical-align: top; width: 88%;" valign="bottom">2028<br/>
              </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">$ <br/>
              </td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">50</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all or part of the information related to intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/350-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/985-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACCRUED EXPENSES AND OTHER LIABILITIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>ACCRUED EXPENSES AND OTHER LIABILITIES [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">ACCRUED EXPENSES AND OTHER LIABILITIES</a></td>
<td class="text">
<div>
          <table cellpadding="0" cellspacing="0" class="DSPFListTable" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt; border-spacing: 0;">


  <tr style="vertical-align: top;">

    <td style="vertical-align: top; width: 27pt;">
                  <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;"><strong>6.</strong></p>
                </td>

    <td style="align: left; vertical-align: top; width: auto;">
                  <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;"><strong><span style="text-decoration: underline;">ACCRUED EXPENSES AND OTHER LIABILITIES</span></strong></p>
                </td>

  </tr>


</table>
        </div>
<p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;">&#160;</p><p style="margin: 0px 0px; font-family: 'Times New Roman'; font-size: 10pt; text-align: left; text-indent: 45px;">Accrued expenses and other current liabilities at December 31, 2024 and 2023 are as follows:</p><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="text-align: left; font: 10pt 'Times New Roman'; width: 100%; border-spacing: 0;">


  <tr style="height: 15px;">

    <td style="padding-bottom: 2px; white-space: nowrap;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px;">&#160;</p>
              </td>

    <td colspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: center;"><strong>December 31, 2024
                  </strong></p>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"><strong>December 31, 2023</strong></td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td rowspan="1" style="white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: center; vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="6" rowspan="1" style="vertical-align: bottom; text-align: center;" valign="bottom"><span style="font-style: italic;">(In thousands)</span> <br/>
              </td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td style="vertical-align: top; width: 76%; background-color: #CCEEFF;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-bottom: 0px; text-indent: -9pt; margin-left: 9pt;">Accrued rebates</p>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">$ <br/>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">4,155</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">$</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">16,608</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td style="vertical-align: top; width: 76%;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-bottom: 0px; text-indent: -9pt; margin-left: 9pt;">Accrued distribution fees</p>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">11,565</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">5,954</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td style="vertical-align: top; width: 76%; background-color: #CCEEFF;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-bottom: 0px; text-indent: -9pt; margin-left: 9pt;">Accrued incentives</p>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">5,892</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">4,961</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td rowspan="1" style="vertical-align: top; width: 76%;" valign="bottom">Accrued interest<br/>
              </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">2,857</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">546</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td style="vertical-align: top; width: 76%; background-color: #CCEEFF;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-bottom: 0px; text-indent: -9pt; margin-left: 9pt;">Accrued testing</p>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">827</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">282</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td style="vertical-align: top; width: 76%;" valign="bottom">
                <div style="color: rgb(0, 0, 0); text-indent: -9pt; margin-left: 9pt;">Accrued payroll and other compensation</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">3,332</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">2,203</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td rowspan="1" style="vertical-align: top; width: 76%; background-color: #CCEEFF;" valign="bottom">Income taxes payable<br/>
              </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">3,481</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">-</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td style="vertical-align: top; width: 76%; padding-bottom: 2px;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-bottom: 0px; text-indent: -9pt; margin-left: 9pt;">Other</p>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom">1,853</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom">2,365</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td style="vertical-align: top; width: 76%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-bottom: 0px; text-indent: -9pt; margin-left: 18pt;">Total accrued expenses and other current liabilities</p>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 4px double rgb(0, 0, 0);" valign="bottom">$ <br/>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 4px double rgb(0, 0, 0);" valign="bottom">33,962</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 4px double rgb(0, 0, 0);" valign="bottom">$</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 4px double rgb(0, 0, 0);" valign="bottom">32,919</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 720<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483384/720-30-45-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NOTES PAYABLE<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>NOTES PAYABLE [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtTextBlock', window );">NOTES PAYABLE</a></td>
<td class="text">
<div>
          <table cellpadding="0" cellspacing="0" class="DSPFListTable" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt; border-spacing: 0;">


  <tr style="vertical-align: top;">

    <td style="vertical-align: top; width: 27pt;">
                  <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;"><strong>7.</strong></p>
                </td>

    <td style="vertical-align: top; width: auto;">
                  <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;"><strong><span style="text-decoration: underline;">NOTES PAYABLE<br/>
                      </span></strong></p>
                </td>

  </tr>


</table>
        </div>
<p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;">&#160;</p><p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-bottom: 0px; text-align: left;"><span style="text-decoration: underline;">Senior Notes Payable</span></p><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;">&#160;</p><p style="margin-top: 0px; margin-bottom: 0px; font-family: 'Times New Roman'; font-size: 10pt; text-align: left; text-indent: 27pt;">A summary of outstanding senior notes payable is as follows:</p><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px;">&#160;&#160; <br/>
        </p>
<table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="text-align: left; font: 10pt 'Times New Roman'; width: 100%; border-spacing: 0;">


  <tr style="height: 15px;">

    <td style="padding-bottom: 2px; white-space: nowrap;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px;">&#160;</p>
              </td>

    <td colspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: center;"><strong>December 31, 2024</strong></p>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: center;"><strong>December 31, 2023</strong></p>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td rowspan="1" style="vertical-align: top; width: 76%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="6" rowspan="1" style="text-align: center; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"><span style="font-style: italic;">(In thousands)</span><br/>
              </td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td style="vertical-align: top; width: 76%; background-color: rgb(204, 238, 255);" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 9pt; text-indent: -9pt;">Term loan<br/>
                </p>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom">$</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" valign="bottom">32,500</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom">$</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" valign="bottom">62,500</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td rowspan="1" style="vertical-align: top; width: 76%;" valign="bottom">
                <div style="margin-left: 9pt; text-indent: -9pt;">Revolving credit facility<br/>
                </div>
              </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">42,500</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">72,500</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td style="vertical-align: top; width: 76%; background-color: rgb(204, 238, 255);" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in;">Less:<br/>
                </p>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td style="vertical-align: top; width: 76%; padding-bottom: 2px;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 15px;">Debt discount</p>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom">(2,663</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">)</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom">(4,406</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">)</td>

  </tr>

  <tr style="height: 15px;">

    <td style="vertical-align: top; width: 76%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in;">Senior notes payable</p>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 4px double rgb(0, 0, 0);" valign="bottom">$</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 4px double rgb(0, 0, 0);" valign="bottom">72,337</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 4px double rgb(0, 0, 0);" valign="bottom">$</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 4px double rgb(0, 0, 0);" valign="bottom">130,594</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>
<p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px;">&#160;&#160; &#160;</p>
<div style="display:none;"><br/></div>
<div style="text-align: left; font-size: 10pt; text-indent: 27pt; font-weight: normal; font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none;">On December 18, 2023 (the &#8220;Ares Closing Date&#8221;), the Company
            and all of its subsidiaries entered into a new senior secured credit facility (the &#8220;Ares Credit Agreement&#8221;) with Ares Capital Corporation and certain credit funds affiliated with Ares Capital Corporation (collectively, &#8220;Ares&#8221;). The Ares Credit
            Agreement provided for a total of $135.0 million in senior secured credit facilities (the &#8220;Ares Credit Facility&#8221;) consisting of (i) a
            term loan in the aggregate principal amount of $62.5 million and (ii) a revolving credit facility in the aggregate principal amount
            of $72.5 million (collectively, the &#8220;Ares Loans&#8221;), both of which were fully drawn on the Ares Closing Date. The Ares Credit Facility
            has a maturity date of December 20, 2027 (the &#8220;Ares Maturity Date&#8221;). On the Ares Closing Date, the Company used the proceeds from
            the Ares Loans, along with a portion of its existing cash on hand, to terminate and pay in full all of the outstanding obligations under the Company&#8217;s previous senior credit facility (the &#8220;Hayfin Credit Facility&#8221;) with Hayfin Services LLP
            (&#8220;Hayfin&#8221;) including the outstanding principal in the amount of $158.6 million, a prepayment penalty in the amount $11.1 million, an exit fee of $1.6
            million, all accrued and unpaid interest outstanding on the Hayfin Credit Facility as of the Ares Closing date, as well as certain fees and expenses related thereto. In connection with the payoff and termination of the Hayfin Credit Facility,
            the Company also wrote off $15.0 million of unamortized debt discount related to the Hayfin Credit Facility. As a result of this
            transaction, the Company recorded a loss on the extinguishment of the Hayfin Credit Facility for the year ended December 31, 2023 in the amount of $26.2
            million, which is mainly comprised of the write-off of unamortized debt discount and the prepayment penalty.</div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt;"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-align: left; font-size: 10pt; text-indent: 27pt; font-weight: normal; font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none;"><span style="font-family: 'Times New Roman'; font-size: 10pt;">
              <br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt;"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-indent: 27pt;"><span style="font-family: 'Times New Roman'; font-size: 10pt;">On August 14, 2024, the Company repaid $30.0
                million against the revolving credit facility and the outstanding balance on the revolving credit facility as of December 31, 2024 was $42.5
                million, with an additional $30.0 million of availability through the Ares Maturity Date. The Company is required to pay an
                unused commitment fee of 0.5% per annum for this availability. </span> </div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
              </span></div>

<div style="display:none;"><br/></div>
<div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; text-indent: 27pt;">On December 19, 2024 the Company repaid $30.0
              million against the term loan and the outstanding balance on the term loan as of December 31, 2024 was $32.5 million. In connection
              with the repayment against the term loan, the Company recognized a loss on extinguishment of debt in the approximate amount of $1.2
              million, which is comprised of a prepayment penalty in the amount of $0.5 million and a partial write-off of unamortized discount
              attributable to the term loan in the amount of $0.8 million.</div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt;"> <span style="font-weight: normal; font-style: normal; font-variant: normal; text-transform: none;"> </span></span></div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt;"> <span style="font-weight: normal; font-style: normal; font-variant: normal; text-transform: none;"> </span> </span></div>

<div><span style="font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt;"> <span style="font-weight: normal; font-style: normal; font-variant: normal; text-transform: none;"> </span> </span></div>

<div style="display:none;"><br/></div>
<div style="text-align: left; font-size: 10pt; text-indent: 27pt; font-weight: normal; font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none;">Borrowings under the term loan bear interest at the adjusted
            Term SOFR for a three-month tenor in effect on the day that is <span style="-sec-ix-hidden:Fact_712874e87fcc4abab5ec40411ed75dc9">two</span> business days prior to the first day of the applicable calendar quarter plus 6.50%.
            Borrowings under the revolving facility initially bear interest at the adjusted Term SOFR for a three-month tenor in effect on the
            day that is <span style="-sec-ix-hidden:Fact_00f7b4da42784c0b85e89298c6447e23">two</span> business days prior to the first day of the applicable calendar quarter&#160;plus 3.75%. As of December 31, 2024 and December 31, 2023, the interest rate on the term loan was approximately 10.85% and 11.88%, respectively, and the interest rate on
            the revolving facility was&#160;approximately 8.34% and 9.13%, respectively.</div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt;"> <span style="font-weight: normal; font-style: normal; font-variant: normal; text-transform: none;"> </span> </span></div>

<div><span style="font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
            </span> </div>

<div style="display:none;"><br/></div>
<div style="text-indent: 27pt;"><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">On the
            Ares Maturity Date, the Company is required to pay Ares the entire outstanding principal amount underlying the Ares Loans and any accrued and unpaid interest thereon. Prior to the Ares Maturity Date, there are no scheduled principal payments on the Ares Credit Facilities. After giving effect to the principal payments made during the year ended December 31,
            2024, the Company is required to make quarterly interest payments to Ares of approximately $1.8 million. The Company may prepay the outstanding principal under the revolving facility, together with any accrued but unpaid interest on the prepaid principal amount,
            at any time and from time to time upon <span style="-sec-ix-hidden:Fact_d55916c1abbd41dd8edc1e45abe3c678">three</span> business days&#8217; prior written notice with no prepayment premium. However, in the event the Company pays down an aggregate amount under the Revolving Facility that is greater than 50% of the $72.5 million commitment
            amount, the Company will still be required to pay interest on 50% of this amount, or $36.3 million, through the term of Ares Credit Facility. The Company may prepay the outstanding principal on the term loan, together with any accrued but unpaid interest on
            the prepaid principal amount, at any time and from time to time upon <span style="-sec-ix-hidden:Fact_2496c3fd576a452da07200cbae1170f2">three</span> business days&#8217; prior written notice, subject to the
            payment to Ares of a prepayment premium equal to (i) the present value as of such date of all remaining required interest payments on the principal amount being repaid plus 1.5% of the prepaid principal amount, if prepaid on or prior to the first anniversary of the Ares Closing Date, (ii) 1.5% of the prepaid principal amount, if prepaid after the first anniversary of the Ares Closing Date and on or prior to the second anniversary of the Ares Closing Date, or (iii) 1.0% of the prepaid principal amount, if prepaid on or prior to the third anniversary of the Ares Closing Date. </span></div>

<div style="font-family: 'Times New Roman';"><span style="font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<div style="display:none;"><br/></div>
<div style="text-indent: 27pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">In connection with
            the closing of the Ares Credit Facility, the Company incurred fees and expenses related to the transaction of $2.8 million, including
            a $1.7 million original discount payable to Ares, all of which was deducted from the Ares loan proceeds. In addition, the Company is
            also required to pay Ares an exit fee of $1.7 million upon the earlier of any prepayment date or the Ares Maturity Date, and this
            obligation was accrued as a separate liability in the Company&#8217;s consolidated balance sheet as of December 31, 2023. As a result, the Company recognized an aggregate debt discount of $4.4 million as of the Ares Closing Date, and the weighted-average effective interest rate on the Ares Loans was 10.81% and 11.39% as of December 31, 2024 and 2023, respectively. This
            debt discount was recorded as a reduction to the face amount of the debt and is being amortized as interest expense over the term of the debt using the interest method. In connection with the prepayment of the term loan on December 19, 2024,
            the Company also paid a pro rata portion of the exit fee in the amount of $0.4 million, and the balance of the exit fee liability as
            of December 31, 2024 is $1.3 million. </div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt;"> </span></div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
          </span> </div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt;"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; text-indent: 27pt;">All of the Company&#8217;s obligations under the Ares Credit Agreement are secured by a first-priority lien and security interest in substantially all
              of the Company&#8217;s tangible and intangible assets, including intellectual property and all of the equity interests in the Company&#8217;s subsidiaries. The Ares Credit Agreement contains certain representations and warranties, affirmative covenants,
              negative covenants and conditions that are customarily required for similar debt financings. The negative covenants include certain financial covenants, including maximum total leverage ratios and a $15.0 million minimum liquidity covenant, and also restrict or limit the Company&#8217;s ability and the ability of the Company&#8217;s subsidiaries to, among other things and subject
              to certain exceptions contained in the Ares Credit Agreement, incur new indebtedness; create liens on assets; engage in certain fundamental corporate changes, such as mergers or acquisitions, or changes to the Company&#8217;s or the Company&#8217;s
              subsidiaries&#8217; business activities; make certain Investments or Restricted Payments (each as defined in the Ares Credit Agreement); engage in certain affiliate transactions; or enter into, amend or terminate any other agreements that have the
              impact of restricting the Company&#8217;s ability to make loan repayments under the Ares Credit Agreement. As of December 31, 2024 the Company was in compliance with all of the covenants contained in the Ares Credit Agreement.</div>

<div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"> <span style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
              </span></div>

<div style="display:none;"><br/></div>
<div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; text-indent: 27pt;">Events of Default on the Ares Loans include, among others, non-payment of principal, interest or fees, violation of covenants, inaccuracy of
            representations and warranties, bankruptcy and insolvency events, material judgments, cross-defaults to material contracts and events constituting a change of control. If there is an event of default, the Company will incur an increase in the
            rate of interest on the Ares Loans of 2% per annum.</div>

<div style="display:none;"><br/></div>
<div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; text-indent: 27pt;"> <span style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
            </span> </div>

<div><span style="font-family: 'Times New Roman'; font-size: 10pt;"> </span></div>
<p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px;"> </p>
<div><span style="font-family: 'Times New Roman'; font-size: 10pt;"> </span></div>
<p style="margin-top: 0px; margin-bottom: 0px; font-family: 'Times New Roman'; font-size: 10pt; text-align: left; text-indent: 27pt;"><span style="font-family: 'Times New Roman'; font-size: 10pt;">On <span style="color: rgb(0, 0, 0); background-color: rgb(255, 255, 255); font-weight: normal; font-style: normal; font-variant: normal; text-transform: none;">March 23,&#160;2022 (the &#8220;Hayfin Closing Date&#8221;), the Company and all of its subsidiaries entered into the Hayfin Credit
              Agreement with Hayfin. The Hayfin Credit Agreement provided for a senior secured term loan facility in a principal amount of up to</span> $175.0
            million, <span style="color: rgb(0, 0, 0); background-color: rgb(255, 255, 255); font-weight: normal; font-style: normal; font-variant: normal; text-transform: none;">composed of (i) a term loan made on the Hayfin Closing Date in the principal
              amount of</span> $150.0 million<span style="color: rgb(0, 0, 0); font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"> (<span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">the &#8220;Hayfin Closing Date
                Loan&#8221;), and (ii) a delayed draw term loan in the principal amount of </span></span>$25.0 million (the &#8220;<span style="color: rgb(0, 0, 0); background-color: rgb(255, 255, 255); font-weight: normal; font-style: normal; font-variant: normal; text-transform: none;">Hayfin </span><span style="color: rgb(0, 0, 0); font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">Delayed Draw Loan</span>&#8221; <span style="color: rgb(0, 0, 0); font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">and, together with the Hayfin Closing Date Loan, the &#8220;Hayfin Loans</span></span>&#8221;). <span style="color: rgb(0, 0, 0); font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: left; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">The Hayfin Delayed Draw Loan was not drawn prior to the Ares Closing Date. The Hayfin Credit Facility had a maturity date of March 23, 2027 (the &#8220;Hayfin Maturity Date&#8221;), subject to acceleration pursuant to the Hayfin Credit Agreement, including upon an Event of Default
              (as defined in the Hayfin Credit Agreement).</span></span><span style="font-size: 10pt;"> <br/>
          </span> </p>
<div><span style="font-size: 10pt;"> </span></div>

<div><span style="font-size: 10pt;"> <br/>
      </span></div>

<div style="display:none;"><br/></div>
<div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; text-indent: 27pt;">On the
        Hayfin Closing Date, the Company used $100.0 million of the Hayfin Closing Date Loan to terminate and pay in full all of the outstanding
        obligations under the Company&#8217;s previously existing credit facility (the &#8220;Perceptive Credit Facility&#8221;) with Perceptive Credit Holdings II, LP (&#8220;Perceptive&#8221;). The Company also used $2.0 million of the Hayfin Closing Date Loan proceeds to pay a redemption premium to Perceptive and used approximately $1.0 million of the Hayfin Closing Date Loan proceeds to pay certain fees and expenses incurred in connection with this transaction. In addition, a $1.8 million upfront fee payable to Hayfin was paid &#8220;in kind&#8221; and was added to the outstanding principal balance in accordance with the terms of the Hayfin Credit Agreement. In
        connection with the retirement of the Perceptive Credit Facility and all of the obligations thereunder, the Company recorded a loss on extinguishment of debt in the amount of $6.7 million, consisting of the write-off of unamortized discount related to the Perceptive indebtedness and the redemption premium paid to Perceptive.</div>

<div><span style="font-size: 10pt;"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"> <span style="font-size: 10pt;"><br/>
        </span> </div>

<div><span style="font-size: 10pt;"> </span></div>

<div style="display:none;"><br/></div>
<div style="text-align: left; text-indent: 27pt;"><span style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0); background-color: rgb(255, 255, 255); font-weight: normal; font-style: normal; font-variant: normal; text-transform: none;"><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none;">Borrowings under the Hayfin Credit Agreement bore
            interest, at the Company&#8217;s election, at the adjusted Term SOFR for a one-month tenor, subject to a floor of 1.25%, plus an applicable margin of 9.5%
            (the &#8220;Applicable Margin&#8221;); provided, however, that upon, and during the continuance of, an Event of Default, the Applicable Margin would increase by an additional 3% per annum. On May 1, 2023 the Hayfin Credit Agreement was amended to reduce the Applicable Margin from 9.5% to 8.5%. On the last day of each calendar month prior to the Ares
            Closing Date, the Company paid accrued interest to Hayfin. The rate of interest in effect as of the Hayfin Closing Date, December 31, 2022 and the Ares Closing Date was 10.75%, approximately 13.7% and approximately 13.9%, respectively. The Company was also permitted to pay &#8220;in kind&#8221; a portion of the interest on the Hayfin Loans for each monthly interest period
            in an amount equal to 2.5% per annum, which was added to the principal amount of the outstanding debt under the Hayfin Credit
            Facility. From the Hayfin Closing Date through December 31, 2022, $3.0 million of interest was paid in kind and added to the balance
            of the outstanding Hayfin Loans. For the year ended December 31, 2023, $3.8 million of interest was paid in kind and added to the
            balance of the outstanding Hayfin Loans.</span></span> </div>

<div><span style="font-size: 10pt;"> </span></div>
<p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-indent: 45px; text-align: left;"> </p>
<div><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>
<p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-bottom: 0px; text-align: left; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; text-indent: 27pt;">&#160; &#160;</p><p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-bottom: 0px; text-align: left; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; text-indent: 27pt;"> <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: left; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">On the Ares Closing Date, the Company
            paid Hayfin the entire outstanding principal amount underlying the Hayfin Loans and all accrued and unpaid interest thereon, as well as the exit fee of 1.0% of the outstanding principal amount paid. This exit fee had been recorded separately as a non-current liability on the accompanying consolidated balance sheet as of December 31,
            2022. In accordance with the terms of the Hayfin Credit Agreement, the Company also paid Hayfin the early prepayment fee in the amount equal to 7.0%
            of the prepaid principal amount of $158.6 million, or $11.1 million.</span></p><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-indent: 45px; text-align: left; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"> <span style="font-size: 10pt;"><br/>
          </span> </p>
<div><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>
<p style="background-color: rgb(255, 255, 255); margin-top: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-align: left; text-transform: none; text-indent: 27pt;">All of the Company&#8217;s obligations under the Hayfin Credit Agreement were secured by a first-priority lien and security interest in substantially all of the Company&#8217;s tangible and intangible assets,
          including intellectual property, and all of the equity interests in the Company&#8217;s subsidiaries. The Hayfin Credit Agreement contained certain representations and warranties, affirmative covenants, negative covenants and conditions that are
          customarily required for similar debt financings. The negative covenants restricted or limited the ability of the Company and its subsidiaries to, among other things and subject to certain exceptions contained in the Hayfin Credit Agreement,
          incur new indebtedness; create liens on assets; engage in certain fundamental corporate changes, such as mergers or acquisitions, or changes to the Company&#8217;s or its subsidiaries&#8217; business activities; make certain Investments or Restricted
          Payments (each as defined in the Hayfin Credit Agreement); change its fiscal year; pay dividends; repay certain other indebtedness; engage in certain affiliate transactions; or enter into, amend or terminate any other agreements that have the
          impact of restricting the Company&#8217;s ability to make loan repayments under the Hayfin Credit Agreement. In addition, the Company was required (i) at all times prior to the Hayfin Maturity Date to maintain a minimum cash balance of $6.0 million; and (ii) as of the last day of each fiscal quarter, report IVIG product and related revenues for the trailing 12-month period that exceed
          the amounts set forth in the <span style="font-family: 'Times New Roman'; color: rgb(0, 0, 0); background-color: rgb(255, 255, 255); font-weight: normal; font-style: normal; font-variant: normal; text-transform: none;"><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none;">Hayfin</span></span> Credit Agreement, which ranged from $75.0 million for the fiscal quarter ended June 30, 2022 to $110.0 million for the fiscal quarter ended September 30, 2023. As of the Ares Closing Date and December 31, 2022, the Company was in compliance with all of the covenants contained in the <span style="font-family: 'Times New Roman'; color: rgb(0, 0, 0); background-color: rgb(255, 255, 255); font-weight: normal; font-style: normal; font-variant: normal; text-transform: none;"><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none;">Hayfin</span></span> Credit Agreement. </p>
<div><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>
<p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-indent: 45px; text-align: left; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
<div><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>

<div style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; As consideration for the Hayfin
          Credit Agreement, on the Hayfin Closing Date the Company issued to various entities affiliated with Hayfin warrants to purchase an aggregate of 9,103,047
          shares of the Company&#8217;s common stock (the &#8220;Hayfin Warrants&#8221;). The Hayfin Warrants have an exercise price equal to $1.6478 per share,
          which is equal to the trailing 30-day Volume Weighted-average Price of the Company&#8217;s common stock on the business day immediately
          prior to the Hayfin Closing Date. The Hayfin Warrants were valued by the Company at approximately $9.6 million as of the Hayfin Closing
          Date and have an expiration date of March 23, 2029 (see Note 8). As consideration for the foregoing amendment to the Hayfin Credit
          Agreement on May 1, 2023, the Company issued additional warrants to the lenders to purchase 2,391,244 shares of the Company&#8217;s common
          stock at an exercise price of $3.2619 per share (the &#8220;Hayfin Second Amendment Warrants&#8221;). The Hayfin Second Amendment Warrants were
          valued at approximately $5.6 million and have an expiration date of May 1, 2030.</div>

<div><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>

<div><span style="font-size: 10pt;"> </span></div>

<div><br/></div>
<p style="margin-top: 0px; margin-bottom: 0px; font-family: 'Times New Roman'; font-size: 10pt; text-align: left; text-indent: 27pt;"><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">As a result of the upfront fee and exit fee paid or payable to Hayfin, the expenses incurred by the Company&#160; in connection with this transaction and
            the value of the Hayfin Warrants and Hayfin Second Amendment Warrants, the Company recognized a discount on the Hayfin Loans in the amount of $13.9
            million for the year ended December 31, 2022 and an additional debt discount in the year ended December 31, 2023 in the amount of $5.7
            million. The Company records debt discount as a reduction to the face amount of the debt, and the debt discount is amortized as interest expense over the life of the debt using the interest method. As of the Ares Closing Date, $15.0 million of the aggregate debt discount associated with the Hayfin Credit Facility was unamortized, and this amount is reflected in the loss on
            extinguishment of debt for the year ended December 31, 2023. Based on the fair value of the Hayfin Warrants and the aggregate amount of fees and expenses associated with obtaining the Hayfin Credit Facility, the effective interest rate on the
            Hayfin Loans as of the Hayfin Closing Date and as of December 31, 2022 was approximately 13.0% and 16.1%, respectively<span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: left; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">.</span> </span><span style="font-size: 10pt;"><br/>
          </span> </p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/470/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>STOCKHOLDERS' EQUITY [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">STOCKHOLDERS' EQUITY</a></td>
<td class="text">
<div>
          <table cellpadding="0" cellspacing="0" class="DSPFListTable" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt; border-spacing: 0;">


  <tr style="vertical-align: top;">

    <td style="vertical-align: top; width: 27pt;">
                  <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"><strong>8.</strong></p>
                </td>

    <td style="vertical-align: top; width: auto;">
                  <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"><span style="text-decoration: underline;"><strong>STOCKHOLDERS</strong></span><strong><span style="text-decoration: underline;">&#8217; EQUITY</span><br/>
                    </strong></p>
                </td>

  </tr>


</table>
        </div>
<p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"><span style="text-decoration: underline;">Preferred Stock</span></p><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p><p style="margin: 0px; font-family: 'Times New Roman'; font-size: 10pt; text-align: left; text-indent: 36pt; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">The Company is currently authorized to issue up to 10 million shares of preferred stock, $0.0001
          par value per share. There were no shares of preferred stock outstanding at December 31, 2024 and 2023.</p><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"><span style="text-decoration: underline;">Common Stock</span></p><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-indent: 45px; text-align: left;"> </p>
<div style="display:none;"><br/></div>
<div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">As of
          December 31, 2024 and 2023, the Company was authorized to issue 300,000,000 shares of its common stock, $0.0001 par value per share, and 236,620,545
          and 226,063,032 shares of common stock were outstanding as of December 31, 2024 and 2023, respectively.&#160; After giving effect to shares
          reserved for the issuance of warrants and for awards issued under the Company&#8217;s equity incentive plans, 36,093,118 shares of common
          stock were available for issuance as of December 31, 2024.</div>

<div style="display:none;"><br/></div>
<div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"><span style="background-color: rgb(255, 255, 255); display: inline; float: none; letter-spacing: normal; white-space: normal; word-spacing: 0px; font-weight: 400; text-align: left;"> <br/>
          </span></div>

<div style="display:none;"><br/></div>
<div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"><span style="background-color: rgb(255, 255, 255); display: inline; float: none; letter-spacing: normal; white-space: normal; word-spacing: 0px; font-weight: 400; text-align: left;"><span style="background-color: rgb(255, 255, 255); font-weight: normal;"> During the years ended December 31, 2024, 2023 and 2022, outstanding stock options aggregating to 1,988,066, 1,444,533 and 68,679 shares,
              respectively, of common stock were exercised, and the Company received net proceeds from the exercises of approximately $7.5
              million, $1.1 million and $0.2
              million, respectively.</span><br/>
          </span></div>

<div style="display:none;"><br/></div>
<div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"><span style="background-color: rgb(255, 255, 255); display: inline; float: none; letter-spacing: normal; white-space: normal; word-spacing: 0px; font-weight: 400; text-align: left;"> <br/>
          </span></div>

<div style="display:none;"><br/></div>
<div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"><span style="background-color: rgb(255, 255, 255); display: inline; float: none; letter-spacing: normal; white-space: normal; word-spacing: 0px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-weight: 400; text-align: left; text-transform: none; font-variant: normal;">On December 9, 2022, the Company completed an underwritten public offering whereby the Company issued 24,125,873 shares of its common stock. Net proceeds after underwriting discounts and expenses associated with the offering were approximately $64.6 million and were used to accelerate commercialization and production activities, complete plasma center buildouts and obtain FDA approvals, to conclude post&#8209;FDA
            marketing approval research and development projects, and for working capital, capital expenditures and general corporate purposes.</span><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
          </span> </div>

<div><span style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"> </span>
       <span style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"> </span> <span style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"> <span style="background-color: rgb(255, 255, 255); font-weight: normal;"> </span> </span></div>

<div><span style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">
          </span></div>

<div><br/></div>

<div><span style="text-decoration: underline;"><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Warrants</span></span><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
              </span> </div>
<p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"> <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
                </span> </p>
<div><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>

<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-indent: 36pt;"><span style="font-weight: normal; letter-spacing: normal; text-align: left; text-indent: 48px; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"><span style="background-color: rgb(255, 255, 255); font-weight: normal;">
                    During the year ended December 31, 2024, several of the Company&#8217;s former noteholders exercised an aggregate of 11,308,702
                    warrants in cashless exercise transactions resulting in the Company issuing 7,224,892 shares of its common stock. Also
                    during the year ended December 31, 2024, warrants to purchase 227,650 shares of common stock that had been issued to former
                    noteholders of the Company expired in accordance with their terms.</span><br/>
                </span></div>

<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-indent: 36pt;"><span style="font-weight: normal; letter-spacing: normal; text-align: left; text-indent: 48px; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"> <br/>
                </span></div>

<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-indent: 36pt;"> <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">On June 16, 2023, various entities affiliated with Hayfin exercised 3,388,686 Hayfin Warrants in a cashless exercise transaction resulting in the Company issuing 1,967,847 shares of its common stock to such entities. On May 1, 2023 the Company issued the Hayfin Second Amendment Warrants (see Note 7), which were valued at $5.6 million using the Black-Scholes option-pricing model assuming an expected term of seven years, a volatility of 67.8%, a dividend yield of 0% and a risk-free rate of interest of 3.62%.</span></div>

<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-indent: 36pt;"><span style="font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 48px; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"> <br/>
                </span></div>

<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-indent: 36pt;">On March 23, 2022, the Company issued the Hayfin Warrants, whereby affiliates of Hayfin may purchase an aggregate
                of 9,103,047 shares of common stock at an exercise price of $1.6478 per share (see Note 7). The Hayfin Warrants were valued at $9.6
                million, using the Black-Scholes option pricing model assuming an expected term of 7 years, a volatility of 68.1%, a dividend yield of 0%
                and a risk-free interest rate of 2.36%. During the year ended December 31, 2022, warrants to purchase 106,059 shares of common stock that had been issued to former noteholders of the Company expired. </div>

<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-indent: 36pt;"> <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
                </span> </div>

<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-indent: 36pt;">At December 31, 2024 and 2023, the Company had outstanding warrants to purchase an aggregate of 966,554 and 12,502,906 shares,
                  respectively, of common stock, with a weighted average exercise price of $1.98 and $2.32 per share, respectively, and expiration dates ranging between March 2029 and May 2030. <span style="background-color: rgb(255, 255, 255); font-weight: normal;">
                    <span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; text-align: left; text-indent: 48px; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"><span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal;">The






























                      following table summarizes information about warrants outstanding as of December 31, 2024, 2023 and 2022:</span></span> </span></div>

<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-indent: 36pt;"><span style="background-color: rgb(255, 255, 255); font-weight: normal;"><span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; text-align: left; text-indent: 48px; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"> <br/>
                    </span></span></div>

<table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; letter-spacing: normal; text-transform: none; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%; border-spacing: 0;">


  <tr>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"><br class="Apple-interchange-newline"/>
                          &#160;</td>

    <td colspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"><span style="font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Shares </span><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
                          </span> </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom">
                          <div style="text-align: center; font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Weighted</div>
                          <div style="text-align: center; font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Average</div>
                          <div style="text-align: center; font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Exercise Price</div>
                        </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                          <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Warrants outstanding at December 31, 2021</div>
                        </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                          <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">4,528,160</div>
                        </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                          <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">$</div>
                        </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                          <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">2.82</div>
                        </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; white-space: nowrap;" valign="bottom">
                          <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Expired</div>
                        </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                          <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">(106,059</div>
                        </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">
                          <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">)</div>
                        </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">
                          <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">$</div>
                        </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                          <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">8.23</div>
                        </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                          <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Granted</div>
                        </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                          <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">9,103,047</div>
                        </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                          <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">$</div>
                        </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                          <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">1.65</div>
                        </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">
                          <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Exercised</div>
                        </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                          <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">-</div>
                        </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">
                          <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">$</div>
                        </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">
                          <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">-</div>
                        </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                          <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Warrants outstanding at December 31, 2022</div>
                        </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                          <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">13,525,148</div>
                        </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                          <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">$</div>
                        </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                          <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">1.99</div>
                        </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; white-space: nowrap;" valign="bottom">
                          <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Expired</div>
                        </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                          <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">(24,800</div>
                        </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">
                          <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">)</div>
                        </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">
                          <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">$</div>
                        </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                          <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">6.37</div>
                        </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                          <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Granted</div>
                        </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                          <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">2,391,244</div>
                        </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                          <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">$</div>
                        </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                          <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">3.26</div>
                        </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">
                          <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Exercised</div>
                        </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                          <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">(3,388,686</div>
                        </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">
                          <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">)</div>
                        </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">
                          <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">$</div>
                        </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">
                          <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">1.65</div>
                        </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                          <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Warrants outstanding at December 31, 2023</div>
                        </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                          <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">12,502,906</div>
                        </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                          <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">$</div>
                        </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                          <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">2.32</div>
                        </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td rowspan="1" style="vertical-align: bottom; width: 76%; white-space: nowrap;" valign="bottom"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Expired<br/>
                          </span> </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">(227,650</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">)</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">$</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">4.21</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td rowspan="1" style="vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Granted<br/>
                          </span> </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">-</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">$</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">-</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td rowspan="1" style="vertical-align: bottom; width: 76%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Exercised<br/>
                          </span> </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">(11,308,702</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; padding-bottom: 2px; white-space: nowrap;" valign="bottom">)</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; padding-bottom: 2px; white-space: nowrap;" valign="bottom">$</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; padding-bottom: 2px; white-space: nowrap;" valign="bottom">2.31</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td rowspan="1" style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Warrants outstanding at December 31, 2024<br/>
                          </span> </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">966,554</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">$</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">1.98</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>

<div>
                   <span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; text-align: left; text-indent: 48px; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"> </span></span></div>

<div><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>

<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-indent: 36pt;"><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span><span style="font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
                  </span></div>

<div><span style="text-decoration: underline;"><span style="font-family: 'Times New Roman'; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Equity Incentive Plans</span></span>

                <span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>
<p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p><p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-bottom: 0px; text-align: left; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; text-indent: 36pt;"><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> On June 21, 2022, the Company&#8217;s stockholders approved the ADMA Biologics, Inc. 2022 Compensation Plan (the &#8220;2022 Equity Plan&#8221;), which replaced the Company&#8217;s Amended and Restated 2014 Omnibus Incentive Compensation
                  Plan (the &#8220;2014 Plan&#8221;). Approval of the 2022 Equity Plan resulted in approximately 18 million additional shares of the
                  Company&#8217;s common stock being reserved for future awards. The 2022 Equity Plan provides for the Company&#8217;s Board of Directors (the &#8220;Board&#8221;) or a Committee of the Board (the &#8220;Committee&#8221;) to grant awards to grantees and to determine the
                  exercise price, vesting term, expiration date and all other terms and conditions of the awards, including acceleration of the vesting of an award at any time. Any options granted under the 2022 Equity Plan are intended to be Incentive
                  Stock Options (&#8220;ISOs&#8221;), unless specified by the Committee to be Non-Qualified Options (&#8220;NQOs&#8221;) as defined by the Internal Revenue Code. ISOs and NQOs may be granted to employees, consultants or Board members at an option price not less
                  than the fair market value of the common stock subject to the stock option agreement. Shares issued in connection with the exercise of stock options or the vesting of RSUs are newly issued shares.</span> </p>
<div style="display:none;"><br/></div>
<div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"> <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
                  </span> </div>

<div style="display:none;"><br/></div>
<div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">For the years ended December 31,
                  2024, 2023 and 2022, the Company granted options to purchase an aggregate of 1,531,635, 1,826,380 and 1,194,032
                  shares, respectively, of common stock to employees and directors under the 2022 Equity Plan and 2014 Plan. During the year ended December 31, 2024, options to purchase 2,020,142 shares of common stock were exercised, for which 32,076
                  shares were withheld to cover the aggregate exercise prices and payroll taxes, and the Company received aggregate net exercise proceeds of $7.5
                  million. During the year ended December 31, 2023, options to purchase 3,814,122 shares of common stock were exercised, for
                  which 2,109,722 shares were withheld to cover the aggregate exercise prices and 259,867 shares were withheld to cover payroll taxes, and the Company received aggregate net exercise proceeds of $1.1 million.</div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
                </span> </div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">The fair value of
                stock options granted was determined on the date of grant using the Black-Scholes model. The Black-Scholes option pricing model was developed for use in estimating the fair value of publicly traded options, which have no vesting
                restrictions and are fully transferable. The Company&#8217;s employee stock options have characteristics significantly different from those of traded options, and changes in the underlying Black-Scholes assumptions can materially affect the fair
                value estimate. To determine the risk-free interest rate, the Company utilized the U.S. Treasury yield curve in effect at the time of the grant with a term consistent with the term of the awards granted by the Company. The expected term of
                all options granted is in accordance with Staff Accounting Bulletins 107 and 110, which is based on the average between vesting terms and contractual terms as the Company had a limited history of option exercises prior to the middle of
                fiscal 2023. The expected dividend yield reflects the Company&#8217;s current and expected future policy for dividends on the Company&#8217;s common stock. For the years ended December 31, 2024, 2023 and 2022, the expected stock price volatility for
                the Company&#8217;s stock options was calculated by examining the historical volatility of the Company&#8217;s common stock since the stock became publicly traded in the fourth quarter of 2013. </div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
                </span> </div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt;"><span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">The grant date fair values of stock options
              awarded during the years ended December 31, 2024, 2023 and 2022 were determined using the Black-Scholes option pricing model with the following assumptions:</span> <span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> </div>
<p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px;"><span style="font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><span style="font-weight: normal;">&#160; </span><br/>
          </span> </p>
<table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="text-align: left; font: 10pt 'Times New Roman'; margin-right: auto; width: 100%; border-spacing: 0;">


  <tr style="height: 15px;">

    <td style="padding-bottom: 2px;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td colspan="1" rowspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="10" rowspan="1" style="vertical-align: bottom; text-align: center; border-bottom: #000000 solid 2px;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; text-align: center; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"><strong>Years Ended
                  </strong></p>
              </td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td style="padding-bottom: 2px;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td colspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-bottom: 0px; text-align: center; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"><strong>December 31,</strong></p>
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-bottom: 0px; text-align: center; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"><strong>2024 </strong></p>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: center; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-bottom: 0px; text-align: center; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"><strong>December 31,</strong></p>
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-bottom: 0px; text-align: center; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"><strong>2023 </strong></p>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="text-align: left; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                <div style="text-align: center;"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><strong>December 31,</strong> <br/>
                  </span> </div>
                <div style="text-align: center;"><span style="font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">202<strong>2</strong></span><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><strong><br/>
                    </strong></span></div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">Expected term</p>
              </td>

    <td colspan="1" style="text-align: center; vertical-align: bottom; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; text-align: center; background-color: rgb(204, 238, 255);" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; text-align: right; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">5.5-6.3 years</p>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: center; vertical-align: bottom; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; text-align: center; background-color: rgb(204, 238, 255);" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; text-align: right; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">5.5-6.3 years</p>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; text-align: right; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div style="text-align: right; font-family: 'Times New Roman'; font-size: 10pt; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">5.5-6.3 years</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td style="vertical-align: bottom; width: 64%;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">Volatility</p>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">66</p>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">%</p>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">68</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">%</td>

    <td colspan="1" style="text-align: right; font-weight: normal; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-weight: normal; text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-weight: normal; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">68<br/>
                </span> </td>

    <td colspan="1" style="font-weight: normal; text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"><strong style="font-weight: normal;">%</strong></td>

  </tr>

  <tr style="height: 15px;">

    <td style="vertical-align: top; width: 64%; background-color: rgb(204, 238, 255);" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">Dividend yield</p>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">0.0<br/>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">0.0<br/>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">0.0</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td style="vertical-align: top; width: 64%;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">Risk-free interest rate</p>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">4.16-4.39</p>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">%</p>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">4.20-4.62</p>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">%</p>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">1.72-1.73</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">%</td>

  </tr>


</table>

<div style="display:none;"><br/></div>
<div style="text-indent: 9pt;"> <span style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"><br/>
        </span></div>

<div><span style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"> </span> </div>
<p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-bottom: 0px; text-align: left; text-indent: 36pt; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"><span style="font-size: 10pt;">The following table summarizes information about stock options outstanding as of December 31, <strong><span style="font-weight: normal;">2024,</span> </strong>2023 and 2022:</span> </p><p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px;"><span style="font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;&#160;&#160; <br/>
          </span> </p>
<table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="text-align: left; font: 10pt 'Times New Roman'; width: 100%; border-spacing: 0;">


  <tr style="height: 15px;">

    <td style="padding-bottom: 2px;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td colspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: #000000 solid 2px;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; text-align: center; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"><strong>Shares</strong></p>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: #000000 solid 2px;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; text-align: center; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"><strong>Weighted</strong></p>
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; text-align: center; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"><strong>Average</strong></p>
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; text-align: center; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"><strong>Exercise
                    Price</strong></p>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td style="vertical-align: top; width: 76%; background-color: #CCEEFF;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">Options outstanding, vested and
                  expected to vest at December 31, 2021</p>
              </td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">7,862,722</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">$</td>

    <td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">3.93</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td style="vertical-align: top; width: 76%;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">Forfeited</p>
              </td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">(31,540</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">)</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">$</td>

    <td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">2.37</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td style="vertical-align: top; width: 76%; background-color: #CCEEFF;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">Expired</p>
              </td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">(700,324</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">)</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">$</td>

    <td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">6.86</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td style="vertical-align: top; width: 76%;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">Granted</p>
              </td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">1,194,032</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">$</td>

    <td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">1.67</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td style="vertical-align: top; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">Exercised</p>
              </td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">(68,679</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">)</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">$</td>

    <td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">2.55</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td style="vertical-align: top; width: 76%;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">Options outstanding, vested and
                  expected to vest at December 31, 2022</p>
              </td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">8,256,211</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">$</td>

    <td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">3.37</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td style="vertical-align: top; width: 76%; background-color: #CCEEFF;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">Forfeited</p>
              </td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">(99,345</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">)</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">$</td>

    <td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">2.73</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td style="vertical-align: top; width: 76%;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">Expired</p>
              </td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">(262,940</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">)</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">$</td>

    <td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">6.42</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td style="vertical-align: top; width: 76%; background-color: #CCEEFF;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">Granted</p>
              </td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">1,826,380</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">$</td>

    <td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">3.36</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td style="vertical-align: top; width: 76%; padding-bottom: 2px;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">Exercised</p>
              </td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">(3,814,122</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">)</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">$</td>

    <td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">3.15</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td style="vertical-align: top; width: 76%; background-color: #CCEEFF;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">Options outstanding, vested and
                  expected to vest at December 31, 2023</p>
              </td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">5,906,184</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">$</td>

    <td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">3.38</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td rowspan="1" style="vertical-align: top; width: 76%;" valign="bottom"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Forfeited<br/>
                </span> </td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">(30,094</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">)</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">$</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">3.36</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td rowspan="1" style="vertical-align: top; width: 76%; background-color: #CCEEFF;" valign="bottom"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Expired<br/>
                </span> </td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">(246,067</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">)</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">$</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">7.01</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td rowspan="1" style="vertical-align: top; width: 76%;" valign="bottom"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Granted<br/>
                </span> </td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">1,531,635</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">$</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">6.40</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td rowspan="1" style="vertical-align: top; width: 76%; background-color: rgb(204, 238, 255); padding-bottom: 2px;" valign="bottom"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Exercised<br/>
                </span> </td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom">(2,020,142</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; padding-bottom: 2px; white-space: nowrap;" valign="bottom">)</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; padding-bottom: 2px;" valign="bottom">$</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; padding-bottom: 2px;" valign="bottom">3.90</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td rowspan="1" style="vertical-align: top; width: 76%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; padding-bottom: 4px;" valign="bottom">Options
                outstanding, vested and expected to vest at December 31, 2024</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom">5,141,516</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; padding-bottom: 4px;" valign="bottom">$</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; padding-bottom: 4px;" valign="bottom">3.90</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td style="width: 76%; background-color: #CCEEFF;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td style="vertical-align: top; width: 76%; padding-bottom: 4px;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">Options exercisable</p>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom">2,657,932<br/>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom">$</td>

    <td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom">3.03</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>

<div><span style="font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
          </span> </div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt;"> <span style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">As of December 31, 2024, the Company had $6.7 million of unrecognized compensation expense related to stock options granted under the Company&#8217;s equity incentive plans, which is expected to
            be recognized over a weighted-average period of 2.8 years. The weighted average remaining contractual term of stock options
            outstanding and expected to vest at December 31, 2024 is 7.1 years. The weighted average remaining contractual term of stock
            options exercisable at December 31, 2024 is 5.7 years. <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal;">The following table summarizes additional information regarding
            outstanding and exercisable options under the stock option plans at December 31, 2024: </span></span></div>
<p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px;"><span style="font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160; <br/>
          </span> </p>
<table border="0" cellpadding="0" cellspacing="0" style="text-align: left; font: 10pt 'Times New Roman'; width: 100%; border-spacing: 0;">


  <tr style="height: 15px;">

    <td style="width: 28%; padding-bottom: 2px;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td colspan="1" style="white-space: nowrap; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td style="white-space: nowrap; width: 1%; padding-bottom: 2px;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td class="hdcell" colspan="14" style="border-bottom: 2px solid rgb(0, 0, 0); vertical-align: bottom; text-align: center;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; text-align: center; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"><strong>Stock
                    Options Outstanding</strong></p>
              </td>

    <td style="white-space: nowrap; width: 1%; padding-bottom: 2px;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td style="white-space: nowrap; width: 1%; padding-bottom: 2px;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td class="hdcell" colspan="14" style="border-bottom: 2px solid rgb(0, 0, 0); vertical-align: bottom; text-align: center;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; text-align: center; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"><strong>Stock
                    Options Exercisable</strong></p>
              </td>

    <td style="white-space: nowrap; width: 1%; padding-bottom: 2px;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

  </tr>

  <tr style="height: 15px;">

    <td style="vertical-align: bottom; width: 28%; padding-bottom: 2px; white-space: nowrap;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; text-align: center; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">Range of</p>
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; text-align: center; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">Exercise Prices</p>
              </td>

    <td colspan="1" style="white-space: nowrap; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td style="white-space: nowrap; width: 1%; padding-bottom: 2px;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td class="hdcell" colspan="2" style="border-bottom: 2px solid rgb(0, 0, 0); vertical-align: bottom; text-align: center;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; text-align: center; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">Options Outstanding</p>
              </td>

    <td style="padding-bottom: 2px; white-space: nowrap; width: 1%;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td style="white-space: nowrap; width: 1%; padding-bottom: 2px;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td class="hdcell" colspan="2" style="border-bottom: 2px solid rgb(0, 0, 0); vertical-align: bottom; text-align: center;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; text-align: center; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">Weighted</p>
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; text-align: center; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">Average</p>
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; text-align: center; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">Remaining</p>
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; text-align: center; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">Contractual</p>
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; text-align: center; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">Life (Years)</p>
              </td>

    <td style="padding-bottom: 2px; white-space: nowrap; width: 1%;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td style="white-space: nowrap; width: 1%; padding-bottom: 2px;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td class="hdcell" colspan="2" style="border-bottom: 2px solid rgb(0, 0, 0); vertical-align: bottom; text-align: center;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; text-align: center; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">Weighted Average
                  Exercise Price</p>
              </td>

    <td style="padding-bottom: 2px; white-space: nowrap; width: 1%;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td style="white-space: nowrap; width: 1%; padding-bottom: 2px;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td class="hdcell" colspan="2" style="border-bottom: 2px solid rgb(0, 0, 0); vertical-align: bottom; text-align: center;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; text-align: center; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">Aggregate Intrinsic
                  Value</p>
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; text-align: center;"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> ($000&#8217;s)<br/>
                  </span> </p>
              </td>

    <td style="padding-bottom: 2px; white-space: nowrap; width: 1%;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td style="white-space: nowrap; width: 1%; padding-bottom: 2px;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td class="hdcell" colspan="2" style="border-bottom: 2px solid rgb(0, 0, 0); vertical-align: bottom; text-align: center;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; text-align: center; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">Options Outstanding</p>
              </td>

    <td style="padding-bottom: 2px; white-space: nowrap; width: 1%;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td style="white-space: nowrap; width: 1%; padding-bottom: 2px;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td class="hdcell" colspan="2" style="border-bottom: 2px solid rgb(0, 0, 0); vertical-align: bottom; text-align: center;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; text-align: center; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">Weighted</p>
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; text-align: center; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">Average</p>
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; text-align: center; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">Remaining</p>
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; text-align: center; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">Contractual</p>
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; text-align: center; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">Life (Years)</p>
              </td>

    <td style="padding-bottom: 2px; white-space: nowrap; width: 1%;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td style="white-space: nowrap; width: 1%; padding-bottom: 2px;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td class="hdcell" colspan="2" style="border-bottom: 2px solid rgb(0, 0, 0); vertical-align: bottom; text-align: center; white-space: nowrap;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; text-align: center; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">Weighted</p>
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; text-align: center; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"> Average</p>
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; text-align: center; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"> Exercise</p>
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; text-align: center; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"> Price</p>
              </td>

    <td style="padding-bottom: 2px; white-space: nowrap; width: 1%;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td style="white-space: nowrap; width: 1%; padding-bottom: 2px;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td class="hdcell" colspan="2" style="border-bottom: 2px solid rgb(0, 0, 0); vertical-align: bottom; text-align: center; white-space: nowrap;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; text-align: center; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">Aggregate</p>
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; text-align: center; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"> Intrinsic</p>
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; text-align: center; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"> Value</p>
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; text-align: center; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"> ($000&#8217;s)</p>
              </td>

    <td style="padding-bottom: 2px; white-space: nowrap; width: 1%;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

  </tr>

  <tr style="height: 15px;">

    <td style="vertical-align: top; width: 28%; background-color: rgb(204, 238, 255);">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">$1.10 - $1.67</p>
              </td>

    <td colspan="1" style="width: 1%; white-space: nowrap; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td style="width: 1%; white-space: nowrap; background-color: rgb(204, 238, 255);">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td style="width: 1%; white-space: nowrap; background-color: rgb(204, 238, 255);">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td class="ffcell" style="width: 6%; vertical-align: bottom; text-align: right; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">981,093</td>

    <td style="width: 1%; white-space: nowrap; background-color: rgb(204, 238, 255);">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td style="width: 1%; white-space: nowrap; background-color: rgb(204, 238, 255);">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td style="width: 1%; white-space: nowrap; background-color: rgb(204, 238, 255);">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td class="ffcell" style="width: 6%; vertical-align: bottom; text-align: right; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">6.8</td>

    <td style="width: 1%; white-space: nowrap; background-color: rgb(204, 238, 255);">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td style="width: 1%; white-space: nowrap; background-color: rgb(204, 238, 255);">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td style="width: 1%; vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">$</td>

    <td class="ffcell" style="width: 6%; vertical-align: bottom; text-align: right; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">1.60</td>

    <td style="width: 1%; white-space: nowrap; background-color: rgb(204, 238, 255);">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td style="width: 1%; white-space: nowrap; background-color: rgb(204, 238, 255);">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td style="width: 1%; vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">$</td>

    <td class="ffcell" style="width: 6%; vertical-align: bottom; text-align: right; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">15,252</td>

    <td style="width: 1%; white-space: nowrap; background-color: rgb(204, 238, 255);">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td style="width: 1%; white-space: nowrap; background-color: rgb(204, 238, 255);">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td style="width: 1%; white-space: nowrap; background-color: rgb(204, 238, 255);">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td class="ffcell" style="width: 6%; vertical-align: bottom; text-align: right; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">676,542</td>

    <td style="width: 1%; white-space: nowrap; background-color: rgb(204, 238, 255);">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td style="width: 1%; white-space: nowrap; background-color: rgb(204, 238, 255);">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td style="width: 1%; white-space: nowrap; background-color: rgb(204, 238, 255);">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td class="ffcell" style="width: 6%; vertical-align: bottom; text-align: right; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">6.6</td>

    <td style="width: 1%; white-space: nowrap; background-color: rgb(204, 238, 255);">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td style="width: 1%; white-space: nowrap; background-color: rgb(204, 238, 255);">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td style="width: 1%; vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">$</td>

    <td class="ffcell" style="width: 6%; vertical-align: bottom; text-align: right; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">1.58</td>

    <td style="width: 1%; white-space: nowrap; background-color: rgb(204, 238, 255);">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td style="width: 1%; white-space: nowrap; background-color: rgb(204, 238, 255);">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td style="width: 1%; vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">$</td>

    <td class="ffcell" style="width: 6%; vertical-align: bottom; text-align: right; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">10,532</td>

    <td style="width: 1%; white-space: nowrap; background-color: rgb(204, 238, 255);">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

  </tr>

  <tr style="height: 15px;">

    <td style="vertical-align: top; width: 28%;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">$1.73 - $2.60</p>
              </td>

    <td colspan="1" style="white-space: nowrap; width: 1%; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td style="white-space: nowrap; width: 1%;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td style="white-space: nowrap; width: 1%;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td class="ffcell" style="vertical-align: bottom; text-align: right; width: 6%; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">629,655</td>

    <td style="white-space: nowrap; width: 1%;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td style="white-space: nowrap; width: 1%;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td style="white-space: nowrap; width: 1%;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td class="ffcell" style="vertical-align: bottom; text-align: right; width: 6%; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">5.7</td>

    <td style="white-space: nowrap; width: 1%;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td style="white-space: nowrap; width: 1%;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td style="vertical-align: bottom; white-space: nowrap; width: 1%; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">$</td>

    <td class="ffcell" style="vertical-align: bottom; text-align: right; width: 6%; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">2.32</td>

    <td style="white-space: nowrap; width: 1%;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td style="white-space: nowrap; width: 1%;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td style="white-space: nowrap; width: 1%;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td class="ffcell" style="vertical-align: bottom; text-align: right; width: 6%; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">9,336</td>

    <td style="white-space: nowrap; width: 1%;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td style="white-space: nowrap; width: 1%;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td style="white-space: nowrap; width: 1%;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td class="ffcell" style="vertical-align: bottom; text-align: right; width: 6%; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">585,771</td>

    <td style="white-space: nowrap; width: 1%;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td style="white-space: nowrap; width: 1%;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td style="white-space: nowrap; width: 1%;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td class="ffcell" style="vertical-align: bottom; text-align: right; width: 6%; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">5.6</td>

    <td style="white-space: nowrap; width: 1%;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td style="white-space: nowrap; width: 1%;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td style="vertical-align: bottom; white-space: nowrap; width: 1%; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">$</td>

    <td class="ffcell" style="vertical-align: bottom; text-align: right; width: 6%; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">2.33</td>

    <td style="white-space: nowrap; width: 1%;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td style="white-space: nowrap; width: 1%;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td style="white-space: nowrap; width: 1%;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td class="ffcell" style="vertical-align: bottom; text-align: right; width: 6%; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">8,683</td>

    <td style="white-space: nowrap; width: 1%;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

  </tr>

  <tr style="height: 15px;">

    <td style="vertical-align: top; width: 28%; background-color: rgb(204, 238, 255);">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">$2.67 - $4.01</p>
              </td>

    <td colspan="1" style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255);">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255);">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td class="ffcell" style="vertical-align: bottom; text-align: right; width: 6%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">1,809,746</td>

    <td style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255);">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255);">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255);">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td class="ffcell" style="vertical-align: bottom; text-align: right; width: 6%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">6.6</td>

    <td style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255);">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255);">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td style="vertical-align: bottom; white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">$</td>

    <td class="ffcell" style="vertical-align: bottom; text-align: right; width: 6%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">3.41</td>

    <td style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255);">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255);">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255);">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td class="ffcell" style="vertical-align: bottom; text-align: right; width: 6%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">24,868</td>

    <td style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255);">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255);">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255);">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td class="ffcell" style="vertical-align: bottom; text-align: right; width: 6%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">1,012,271</td>

    <td style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255);">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255);">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255);">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td class="ffcell" style="vertical-align: bottom; text-align: right; width: 6%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">5.4</td>

    <td style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255);">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255);">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td style="vertical-align: bottom; white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">$</td>

    <td class="ffcell" style="vertical-align: bottom; text-align: right; width: 6%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">3.46</td>

    <td style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255);">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255);">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255);">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td class="ffcell" style="vertical-align: bottom; text-align: right; width: 6%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">13,863</td>

    <td style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255);">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

  </tr>

  <tr style="height: 15px;">

    <td rowspan="1" style="vertical-align: top; width: 28%; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">$4.09 - $6.14</td>

    <td colspan="1" rowspan="1" style="white-space: nowrap; width: 1%; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td rowspan="1" style="white-space: nowrap; width: 1%; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td rowspan="1" style="white-space: nowrap; width: 1%; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td class="ffcell" rowspan="1" style="vertical-align: bottom; text-align: right; width: 6%; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">1,264,083</td>

    <td rowspan="1" style="white-space: nowrap; width: 1%; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td rowspan="1" style="white-space: nowrap; width: 1%; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td rowspan="1" style="white-space: nowrap; width: 1%; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td class="ffcell" rowspan="1" style="vertical-align: bottom; text-align: right; width: 6%; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">8.1</td>

    <td rowspan="1" style="white-space: nowrap; width: 1%; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td rowspan="1" style="white-space: nowrap; width: 1%; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td rowspan="1" style="vertical-align: bottom; white-space: nowrap; width: 1%;"><span style="font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">$<br/>
                </span> </td>

    <td class="ffcell" rowspan="1" style="vertical-align: bottom; text-align: right; width: 6%; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">5.35</td>

    <td rowspan="1" style="white-space: nowrap; width: 1%; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td rowspan="1" style="white-space: nowrap; width: 1%; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td rowspan="1" style="white-space: nowrap; width: 1%; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td class="ffcell" rowspan="1" style="vertical-align: bottom; text-align: right; width: 6%; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">14,913</td>

    <td rowspan="1" style="white-space: nowrap; width: 1%; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td rowspan="1" style="white-space: nowrap; width: 1%; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td rowspan="1" style="white-space: nowrap; width: 1%; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td class="ffcell" rowspan="1" style="vertical-align: bottom; text-align: right; width: 6%; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">361,848</td>

    <td rowspan="1" style="white-space: nowrap; width: 1%; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td rowspan="1" style="white-space: nowrap; width: 1%; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td rowspan="1" style="white-space: nowrap; width: 1%; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td class="ffcell" rowspan="1" style="vertical-align: bottom; text-align: right; width: 6%; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">5.4</td>

    <td rowspan="1" style="white-space: nowrap; width: 1%; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td rowspan="1" style="white-space: nowrap; width: 1%; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td rowspan="1" style="vertical-align: bottom; white-space: nowrap; width: 1%;"><span style="font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">$<br/>
                </span> </td>

    <td class="ffcell" rowspan="1" style="vertical-align: bottom; text-align: right; width: 6%; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">5.23</td>

    <td rowspan="1" style="white-space: nowrap; width: 1%; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td rowspan="1" style="white-space: nowrap; width: 1%; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td rowspan="1" style="white-space: nowrap; width: 1%; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td class="ffcell" rowspan="1" style="vertical-align: bottom; text-align: right; width: 6%; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">4,312</td>

    <td rowspan="1" style="white-space: nowrap; width: 1%; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td rowspan="1" style="vertical-align: top; width: 28%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">$6.54 - $9.81</td>

    <td colspan="1" rowspan="1" style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td rowspan="1" style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td rowspan="1" style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td class="ffcell" rowspan="1" style="vertical-align: bottom; text-align: right; width: 6%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">307,828</td>

    <td rowspan="1" style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td rowspan="1" style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td rowspan="1" style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td class="ffcell" rowspan="1" style="vertical-align: bottom; text-align: right; width: 6%; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; background-color: rgb(204, 238, 255);">9.0</td>

    <td rowspan="1" style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td rowspan="1" style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td rowspan="1" style="vertical-align: bottom; white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255);"><span style="font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">$<br/>
                </span> </td>

    <td class="ffcell" rowspan="1" style="vertical-align: bottom; text-align: right; width: 6%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">6.60</td>

    <td rowspan="1" style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td rowspan="1" style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td rowspan="1" style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td class="ffcell" rowspan="1" style="vertical-align: bottom; text-align: right; width: 6%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">3,248</td>

    <td rowspan="1" style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td rowspan="1" style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td rowspan="1" style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td class="ffcell" rowspan="1" style="vertical-align: bottom; text-align: right; width: 6%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">7,500</td>

    <td rowspan="1" style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td rowspan="1" style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td rowspan="1" style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td class="ffcell" rowspan="1" style="vertical-align: bottom; text-align: right; width: 6%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">0.6</td>

    <td rowspan="1" style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td rowspan="1" style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td rowspan="1" style="vertical-align: bottom; white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255);"><span style="font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">$<br/>
                </span> </td>

    <td class="ffcell" rowspan="1" style="vertical-align: bottom; text-align: right; width: 6%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">8.98</td>

    <td rowspan="1" style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td rowspan="1" style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td rowspan="1" style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td class="ffcell" rowspan="1" style="vertical-align: bottom; text-align: right; width: 6%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">61</td>

    <td rowspan="1" style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td style="vertical-align: top; width: 28%; padding-bottom: 2px;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">$10.80 - $17.49</p>
              </td>

    <td colspan="1" style="white-space: nowrap; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td style="white-space: nowrap; width: 1%; padding-bottom: 2px;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td style="border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap; width: 1%;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td class="ffcell" style="border-bottom: 2px solid rgb(0, 0, 0); vertical-align: bottom; text-align: right; width: 6%;"><span style="font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">149,111<br/>
                </span> </td>

    <td style="padding-bottom: 2px; white-space: nowrap; width: 1%;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td style="white-space: nowrap; width: 1%; padding-bottom: 2px;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td style="white-space: nowrap; width: 1%; padding-bottom: 2px;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td class="ffcell" style="vertical-align: bottom; text-align: right; width: 6%; padding-bottom: 2px; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><span style="font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">8.7<br/>
                </span> </td>

    <td style="white-space: nowrap; width: 1%; padding-bottom: 2px;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td style="white-space: nowrap; width: 1%; padding-bottom: 2px;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td style="vertical-align: bottom; white-space: nowrap; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">$</td>

    <td class="ffcell" style="vertical-align: bottom; text-align: right; width: 6%; padding-bottom: 2px;"><span style="font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">8.74<br/>
                </span> </td>

    <td style="white-space: nowrap; width: 1%; padding-bottom: 2px;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td style="white-space: nowrap; width: 1%; padding-bottom: 2px;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td style="border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap; width: 1%;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td class="ffcell" style="border-bottom: 2px solid rgb(0, 0, 0); vertical-align: bottom; text-align: right; width: 6%;"><span style="font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">500<br/>
                </span> </td>

    <td style="padding-bottom: 2px; white-space: nowrap; width: 1%;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td style="white-space: nowrap; width: 1%; padding-bottom: 2px;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td style="border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap; width: 1%;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td class="ffcell" style="border-bottom: 2px solid rgb(0, 0, 0); vertical-align: bottom; text-align: right; width: 6%;"><span style="font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">14,000<br/>
                </span> </td>

    <td style="padding-bottom: 2px; white-space: nowrap; width: 1%;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td style="white-space: nowrap; width: 1%; padding-bottom: 2px;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td style="white-space: nowrap; width: 1%; padding-bottom: 2px;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td class="ffcell" style="vertical-align: bottom; text-align: right; width: 6%; padding-bottom: 2px;"><span style="font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">0.1<br/>
                </span> </td>

    <td style="white-space: nowrap; width: 1%; padding-bottom: 2px;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td style="white-space: nowrap; width: 1%; padding-bottom: 2px;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td style="vertical-align: bottom; white-space: nowrap; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">$</td>

    <td class="ffcell" style="vertical-align: bottom; text-align: right; width: 6%; padding-bottom: 2px;"><span style="font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">10.80<br/>
                </span> </td>

    <td style="white-space: nowrap; width: 1%; padding-bottom: 2px;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td style="white-space: nowrap; width: 1%; padding-bottom: 2px;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td style="border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap; width: 1%;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td class="ffcell" style="border-bottom: 2px solid rgb(0, 0, 0); vertical-align: bottom; text-align: right; width: 6%; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">89</td>

    <td style="padding-bottom: 2px; white-space: nowrap; width: 1%;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

  </tr>

  <tr style="height: 15px;">

    <td style="width: 28%; background-color: rgb(204, 238, 255); padding-bottom: 4px;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td colspan="1" style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; padding-bottom: 4px;">&#160;</td>

    <td style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 4px double rgb(0, 0, 0);">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td class="ffcell" style="vertical-align: bottom; text-align: right; width: 6%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; border-bottom: 4px double rgb(0, 0, 0);">5,141,516</td>

    <td style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td class="ffcell" style="vertical-align: bottom; text-align: right; width: 6%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; padding-bottom: 4px;">7.1</td>

    <td style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td style="vertical-align: bottom; white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; padding-bottom: 4px;">$</td>

    <td class="ffcell" style="vertical-align: bottom; text-align: right; width: 6%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; padding-bottom: 4px;">3.90</td>

    <td style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td style="vertical-align: bottom; white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; border-bottom: 4px double rgb(0, 0, 0);">$</td>

    <td class="ffcell" style="vertical-align: bottom; text-align: right; width: 6%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; border-bottom: 4px double rgb(0, 0, 0);">68,117</td>

    <td style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 4px double rgb(0, 0, 0);">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td class="ffcell" style="vertical-align: bottom; text-align: right; width: 6%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; border-bottom: 4px double rgb(0, 0, 0);">2,657,932</td>

    <td style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td class="ffcell" style="vertical-align: bottom; text-align: right; width: 6%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; padding-bottom: 4px;">5.7</td>

    <td style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td style="vertical-align: bottom; white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; padding-bottom: 4px;">$</td>

    <td class="ffcell" style="vertical-align: bottom; text-align: right; width: 6%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; padding-bottom: 4px;">3.03</td>

    <td style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td style="vertical-align: bottom; white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; border-bottom: 4px double rgb(0, 0, 0);">$</td>

    <td class="ffcell" style="vertical-align: bottom; text-align: right; width: 6%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; border-bottom: 4px double rgb(0, 0, 0);">37,540</td>

    <td style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

  </tr>


</table>
<p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; text-align: left; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;&#160; </p>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><span style="background-color: rgb(255, 255, 255); font-weight: normal;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; During the
            years ended December 31, 2024, 2023 and 2022, the Company granted RSUs representing an aggregate of 3,278,688, 3,389,760 and 1,174,266 shares,
            respectively, to certain employees and consultants of the Company and to members of the Board. The RSUs generally vest annually over a period of four years for employees and semi-annually over a period of one year for directors. </span></div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> <br/>
        </div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt;"><span style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">During the years ended December 31, 2024, 2023 and 2022, 1,886,463,&#160;1,199,445 and 2,727,412 shares, <span style="font-weight: normal; letter-spacing: normal; text-align: left; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">respectively, vested in connection with grants of RSUs. <span style="font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 48px; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">With respect to RSUs vested during the year ended December 31, 2024, 541,908
                shares valued at approximately $5.0 million were withheld were withheld to cover employees&#8217; tax liabilities. </span>With respect
              to RSUs vested during the year ended December 31, 2023, 365,722 shares valued at approximately $1.3 million were withheld by the Company to cover employees&#8217; tax liabilities</span><span style="background-color: rgb(255, 255, 255); font-weight: normal;">. <span style="font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">With respect to the RSUs vested during the year ended December 31, 2022</span>, 918,851 shares valued at approximately $2.9 million were
              withheld by the Company to cover employees&#8217; tax liabilities.<span style="letter-spacing: normal; text-align: left; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"> All of these shares have been retired by the Company or were otherwise no longer outstanding as of December 31, 2024</span></span>. <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal;">A summary of the Company&#8217;s unvested RSU activity and related information is as follows: </span><br/>
          </span> </div>

<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left;"> <span style="font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="text-align: left; font: 10pt 'Times New Roman'; width: 100%; border-spacing: 0;">


  <tr style="height: 15px;">

    <td style="padding-bottom: 2px;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td colspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; text-align: center; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"><strong>Shares</strong></p>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; text-align: center; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"><strong>Weighted</strong></p>
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; text-align: center; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"><strong>Average
                    Grant</strong></p>
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; text-align: center; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"><strong>Date Fair
                    Value</strong></p>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td style="vertical-align: top; width: 76%; background-color: #CCEEFF;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">Balance at December 31, 2021</p>
              </td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">4,485,133</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">$</td>

    <td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">1.34</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td style="vertical-align: top; width: 76%;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">Granted</p>
              </td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">1,174,266</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">$</td>

    <td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">1.74</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td style="vertical-align: top; width: 76%; background-color: #CCEEFF;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">Vested</p>
              </td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">(2,727,412</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">)</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">$</td>

    <td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">1.25</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td style="vertical-align: top; width: 76%; padding-bottom: 2px;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">Forfeited</p>
              </td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">(65,000</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">)</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">$</td>

    <td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">1.40</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td rowspan="1" style="vertical-align: top; font-family: 'Times New Roman'; width: 76%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">Balance at December 31, 2022</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">2,866,987</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">$</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">1.59</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td rowspan="1" style="vertical-align: top; width: 76%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">Granted<br/>
              </td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">3,389,760</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">$</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">3.42</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td rowspan="1" style="vertical-align: top; width: 76%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">Vested<br/>
              </td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">(1,199,445</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">)</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">$</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">1.63</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td rowspan="1" style="vertical-align: top; width: 76%; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">Forfeited<br/>
              </td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">(400,005</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">)</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">$</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">2.71</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td style="vertical-align: top; width: 76%; background-color: #CCEEFF;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">Balance at December 31, 2023</p>
              </td>

    <td colspan="1" style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom">&#160;</td>

    <td colspan="1" style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom">&#160;</td>

    <td colspan="1" style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" valign="bottom">4,657,297<br/>
              </td>

    <td colspan="1" style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">$</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">2.81</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td rowspan="1" style="vertical-align: top; width: 76%;" valign="bottom"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Granted<br/>
                </span> </td>

    <td colspan="1" rowspan="1" style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">3,278,688</td>

    <td colspan="1" rowspan="1" style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">$<br/>
                </span> </td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">7.44</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td rowspan="1" style="vertical-align: top; width: 76%; background-color: rgb(204, 238, 255);" valign="bottom"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Vested<br/>
                </span> </td>

    <td colspan="1" rowspan="1" style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" valign="bottom">(1,886,463</td>

    <td colspan="1" rowspan="1" style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">)</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">$<br/>
                </span> </td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">2.50</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td rowspan="1" style="vertical-align: top; width: 76%; padding-bottom: 2px;" valign="bottom"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Forfeited<br/>
                </span> </td>

    <td colspan="1" rowspan="1" style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom">(303,532</td>

    <td colspan="1" rowspan="1" style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">)</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">$<br/>
                </span> </td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">3.92</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td rowspan="1" style="vertical-align: top; width: 76%; padding-bottom: 4px; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">Balance at December 31, 2024</td>

    <td colspan="1" rowspan="1" style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom">5,745,990</td>

    <td colspan="1" rowspan="1" style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" valign="bottom"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">$<br/>
                </span> </td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">5.50</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>

<div> <span style="font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
          </span> </div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><span style="background-color: rgb(255, 255, 255); font-weight: normal;">As of
          December 31, 2024, the Company had $25.3 million of unrecognized compensation expense related to unvested RSUs granted under the
          Company&#8217;s equity incentive plans, which is expected to be recognized over a weighted-average period of 3.1 years.</span></div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt;"><span style="font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
        </span> <span style="font-family: 'Times New Roman'; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> <span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> </div>
<p style="background-color: rgb(255, 255, 255); margin: 0px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-align: left; text-indent: 36pt; text-transform: none;"><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span><span style="font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><span style="background-color: rgb(255, 255, 255); font-weight: normal;">During the year ended
              December 31, 2024, three of the Company&#8217;s employees and one of the Company&#8217;s non-employee directors received modifications to their outstanding stock option and RSU awards in connection with their departure from the Company or
              transition from an employee to a consulting role (see Note 9). The modifications allowed, among other things, the former employees to continue to participate in the Company&#8217;s equity incentive plans with respect to certain of their outstanding
              awards when they would otherwise not be eligible to do so. In connection with these modifications, the Company recognized an aggregate of $2.5
              million of additional compensation expense in the year ended December 31, 2024. <span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal;">Total stock-based compensation expense for all awards granted under the Company&#8217;s equity incentive plans for the years ended December 31, 2024, 2023 and 2022
              was as follows (in thousands):</span></span><br/>
          </span> </p>
<div><span style="font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
        </span>
         <span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>

<table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="text-align: left; font: 10pt 'Times New Roman'; margin-left: auto; margin-right: auto; width: 100%; border-spacing: 0;">


  <tr style="height: 15px;">

    <td rowspan="1" style="text-align: center; font-style: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: center; vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="10" rowspan="1" style="vertical-align: bottom; text-align: center;" valign="bottom"><span style="font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Year Ended December 31, </span><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
                </span> </td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td rowspan="1" style="padding-bottom: 2px; text-align: center; font-style: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;" valign="bottom">&#160;(in thousands)</td>

    <td colspan="1" rowspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="2" rowspan="1" style="vertical-align: bottom; text-align: center; border-top: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: center; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"><strong> 2024<br/>
                  </strong></p>
              </td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; border-top: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; border-top: 2px solid rgb(0, 0, 0);" valign="bottom">&#160;</td>

    <td colspan="2" rowspan="1" style="vertical-align: bottom; text-align: center; border-top: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;<strong>2023</strong></td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; border-top: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: center; font-family: 'Times New Roman'; vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; border-top: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" rowspan="1" style="text-align: center; vertical-align: bottom; font-family: 'Times New Roman'; border-top: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;<span style="font-weight: bold;">2022</span></td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td style="vertical-align: top; width: 64%; background-color: #CCEEFF;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">Research and development</p>
              </td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">$</td>

    <td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">98</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">$</td>

    <td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">40</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">$</td>

    <td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">19</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td style="vertical-align: top; width: 64%;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">Plasma center operating expenses</p>
              </td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">184</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">146</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">82</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td style="vertical-align: top; width: 64%; background-color: #CCEEFF;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">Selling, general and administrative</p>
              </td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">11,720</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">5,331</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">4,717</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td style="vertical-align: top; width: 64%; padding-bottom: 2px;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">Cost of product revenue</p>
              </td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">1,614</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">670</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">397</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td style="vertical-align: top; width: 64%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-indent: 9.5pt; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">Total stock-based compensation expense</p>
              </td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">$</td>

    <td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">13,616</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">$</td>

    <td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">6,187</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">$</td>

    <td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">5,215</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480237/815-40-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RELATED PARTY TRANSACTIONS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>RELATED PARTY TRANSACTIONS [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">RELATED PARTY TRANSACTIONS</a></td>
<td class="text">
<div>
          <table cellpadding="0" cellspacing="0" class="DSPFListTable" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt; border-spacing: 0;">


  <tr style="vertical-align: top;">

    <td style="vertical-align: top; width: 27pt;">
                  <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;"><strong>9.</strong></p>
                </td>

    <td style="align: left; vertical-align: top; width: auto;">
                  <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;"><span style="text-decoration: underline;"><span style="background-color: rgb(255, 255, 255); font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><strong>RELATED PARTY TRANSACTIONS</strong></span></span><strong><span style="text-decoration: underline;"><br/>
                      </span></strong></p>
                </td>

  </tr>


</table>
        </div>
<p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;">&#160;</p><p style="margin: 0px; font-family: 'Times New Roman'; font-size: 10pt; text-align: left; text-indent: 36pt;"><span style="font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none;">The Company leases an office building and equipment from Areth, LLC (&#8220;Areth&#8221;) pursuant to an agreement for services effective as of January 1, 2016, as amended from time
            to time<span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; text-align: left; text-indent: 48px; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">, and pays</span> monthly rent on this facility in the amount of $10,000. On <span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; text-align: left; text-indent: 48px; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">October 18, 2022</span>, the <span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; text-align: left; text-indent: 48px; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">Company</span> <span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; text-align: left; text-indent: 48px; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">amended the agreement to extend its term to December 31, 2026, with automatic successive one-year
              renewals thereafter. Either party may terminate the agreement by providing the other party with</span> one year<span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; text-align: left; text-indent: 48px; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">&#8217;s prior written notice</span>. Rent expense for the years ended December 31, 2024, 2023 and 2022 amounted to $0.1
            million. Areth is a company controlled by Dr. Jerrold B. Grossman, the Vice Chairman of the Board, and Adam S. Grossman, the Company&#8217;s President and Chief Executive Officer. The Company also reimburses Areth for office, warehousing and building
            related (common area) expenses, equipment and certain other operational expenses, which were not material to the consolidated financial statements for the years ended <span style="font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none;">December 31, 2024, 2023 and 2022</span>.</span> </p><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-indent: 45px; text-align: left;">&#160;</p><p style="margin: 0px; font-family: 'Times New Roman'; font-size: 10pt; text-align: left; text-indent: 36pt;">During the years ended December 31, 2024, 2023 and 2022, the Company purchased certain specialized equipment and repair services used for
          the collection and processing of source plasma from GenesisBPS and its affiliates (&#8220;Genesis&#8221;) in the amount of $0.2 million, $0.4 million and $0.2 million,
          respectively. Genesis is owned by Dr. Grossman and Adam Grossman.</p><p style="margin: 0px; font-family: 'Times New Roman'; font-size: 10pt; text-align: left; text-indent: 36pt;"> <br/>
        </p><p style="margin: 0px; font-family: 'Times New Roman'; font-size: 10pt; text-align: left; text-indent: 36pt;">On November 19, 2024, the Company entered into an agreement with Bryant Fong whereby the Company agreed, in conjunction with Mr. Fong&#8217;s
          resignation from the Board, to immediately vest all of Mr. Fong&#8217;s 12,020 unvested RSUs. The agreement also extended the
          post-termination exercise period for his vested stock options from 90 days to two years (or earlier, if such options&#8217; 10-year expiration date occurs
          sooner than November 19, 2026). All of Mr. Fong&#8217;s unvested stock options were forfeited in accordance with the terms of the 2022
          Equity Plan. In connection with this modification of Mr. Fong&#8217;s equity awards, the Company recorded additional compensation expense of $0.3
          million (see Note 8) in the year ended December 31, 2024.</p><p style="margin: 0px; font-family: 'Times New Roman'; font-size: 10pt; text-align: left; text-indent: 36pt;">&#160;</p><p style="margin: 0px; font-family: 'Times New Roman'; font-size: 10pt; text-align: left; text-indent: 36pt;">On April 1, 2024, the Company entered into a consulting agreement with Brian Lenz, the Company&#8217;s former Executive Vice President, Chief
          Financial Officer and General Manager, ADMA BioCenters, whereby Mr. Lenz&#8217;s outstanding equity awards were modified in connection with his transition to a consulting role. Under the terms of the consulting agreement, Mr. Lenz remained eligible to
          participate in the Company&#8217;s equity compensation plans with respect to continued vesting of the subject awards as set forth in the agreement. In addition, the post-termination exercise period for Mr. Lenz&#8217;s vested stock options was extended from
          90 days to two years
          from the date of the consulting agreement (or earlier, if such options&#8217; 10-year expiration date occurs sooner than March 31, 2026). In connection with this modification, the Company recorded $1.6 million of additional compensation expense for the year ended December 31, 2024.</p><p style="margin: 0px; font-family: 'Times New Roman'; font-size: 10pt; text-align: left; text-indent: 36pt;"> </p><p style="margin: 0px; font-family: 'Times New Roman'; font-size: 10pt; text-align: left; text-indent: 36pt;"> </p><p style="margin: 0px; font-family: 'Times New Roman'; font-size: 10pt; text-align: left; text-indent: 36pt;"> <br/>
        </p><p style="margin: 0px; font-family: 'Times New Roman'; font-size: 10pt; text-align: left; text-indent: 36pt;"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">On August 15, 2023, two of the Company&#8217;s executive
            officers exercised options to purchase 2,909,721 shares of the Company&#8217;s common stock on a cashless basis, and 688,657 shares of common stock were issued to these executive officers, net of 257,867 shares of common stock to cover a portion of their tax liabilities (see Note 8)</span><span style="font-size: 10pt;">.</span><br/>
        </p><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-indent: 45px; text-align: left;"><br/>
        </p>
<div style="display:none;"><br/></div>
<div style="margin: 0px 0px 0px; font-family: 'Times New Roman'; font-size: 10pt; text-align: left; text-indent: 36pt;">See Note 7 for a discussion of the Company&#8217;s prior credit facility and related transactions with Perceptive, a holder of more
          than 5% of the Company&#8217;s common stock during the year ended December 31, 2022.</div>

<div style="display:none;"><br/></div>
<div style="margin: 0px 0px 0px; font-family: 'Times New Roman'; font-size: 10pt; text-align: left; text-indent: 36pt;"> <br/>
        </div>

<div style="display:none;"><br/></div>
<div style="margin: 0px 0px 0px; font-family: 'Times New Roman'; font-size: 10pt; text-align: left; text-indent: 36pt;">In connection with the 2022 public offering of the Company&#8217;s common stock (see Note 8) on December 9, 2022: (i) Mr. Grossman
          purchased 14,983 shares of common stock directly and 14,982 shares of common stock indirectly through an entity he controls, and (ii) Mr. Lenz purchased 6,993
          shares of common stock, all at the public offering price of $2.86 per share. </div>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(g)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(e))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/850/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-6<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 850<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483326/850-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>COMMITMENTS AND CONTINGENCIES [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">COMMITMENTS AND CONTINGENCIES</a></td>
<td class="text">
<div>
          <table cellpadding="0" cellspacing="0" class="DSPFListTable" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt; border-spacing: 0;">


  <tr style="vertical-align: top;">

    <td style="vertical-align: top; width: 27pt;">
                  <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;"><strong>10.</strong></p>
                </td>

    <td style="align: left; vertical-align: top; width: auto;">
                  <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;"><span style="text-decoration: underline;"><span style="background-color: rgb(255, 255, 255); font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><strong>COMMITMENTS AND CONTINGENCIES</strong></span></span><strong><span style="text-decoration: underline;"><br/>
                      </span></strong></p>
                </td>

  </tr>


</table>
        </div>
<p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;">&#160;</p><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;"><span style="text-decoration:underline">General Legal Matters</span></p><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;">&#160;</p><p style="margin: 0px; font-family: 'Times New Roman'; font-size: 10pt; text-align: left; text-indent: 36pt;">From time to time the Company is or may become subject to certain legal proceedings and claims arising in connection with the normal
          course of its business. Management does not expect that the outcome of any such claims or actions will have a material effect on the Company&#8217;s liquidity, results of operations or financial condition.</p><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;">&#160;</p><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;"><span style="text-decoration:underline">IT Systems Disruption</span></p><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;">&#160;</p><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-indent: 45px; text-align: left;"> </p>
<div style="display:none;"><br/></div>
<div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; text-indent: 36pt;">On June 19, 2023, the Company experienced an IT systems disruption, which rendered certain of the Company&#8217;s IT technology
          systems inaccessible for less than <span style="-sec-ix-hidden:Fact_4754ce8ea55d44e195b5e28a95f3e9f0">one</span> week. The Company&#8217;s investigation of the disruption has essentially been completed with the
          assistance of third-party consultants, and no definitive root cause was identified. At the time of the disruption, the Company was in production of two
          batches of BIVIGAM, and after a prolonged hold time, it was deemed to be a prudent GMP quality decision to discard these two
          in-process production batches as these batches were no longer viable for further production or had any alternative use. As a result, the Company recorded a one-time, non-recurring charge of $2.1 million in the second quarter of 2023 for this inventory, which is reflected in Cost of product revenue in the accompanying consolidated statement of operations for the year ending
          December 31, 2023. In addition, the Company&#8217;s Plasma center operating expenses were adversely impacted by approximately $0.7 million
          due to the temporary closing of the Company&#8217;s plasma collection centers while their IT systems were restored.</div>

<div style="display:none;"><br/></div>
<div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; text-indent: 36pt;"> <br/>
        </div>

<div style="display:none;"><br/></div>
<div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; text-indent: 36pt;"> The Company carries appropriate insurance for these types of instances. During each of the years ended December 31, 2024 and
          2023, the Company&#8217;s cybersecurity insurer paid the Company an aggregate of $0.2 million for approved restoration-related costs.&#160;
          During the first quarter of 2025, the Company&#8217;s cybersecurity insurer paid the Company $0.4 million in business interruption loss
          coverage.</div>

<div><br/></div>
<p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left; font-style: normal;"><span style="text-decoration:underline">Vendor Commitments</span></p><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;">&#160;</p><p style="margin: 0px; font-family: 'Times New Roman'; font-size: 10pt; text-align: left; text-indent: 36pt;">Pursuant to the terms of a Plasma Purchase Agreement dated as of November 17, 2011 (the &#8220;2011 Plasma Purchase Agreement&#8221;), the Company
          agreed to purchase from its former contract manufacturer an annual minimum volume of source plasma containing antibodies to RSV to be used in the manufacture of ASCENIV. The Company must purchase a to-be-determined and agreed upon annual minimum
          volume from the counterparty, and under the original 2011 Plasma Purchase Agreement the Company was permitted to also collect high-titer plasma from up to five wholly-owned ADMA plasma collection facilities. During 2015, the Company amended the 2011 Plasma Purchase Agreement to (i) allow the Company to collect its raw material high-titer
          plasma from any number of wholly-owned ADMA plasma collection facilities and (ii) allow the Company to purchase its raw material high-titer plasma from other third-party collection organizations, in each case, provided that the annual minimum
          volumes from the Company&#8217;s former contract manufacturer were met, thus allowing the Company to expand its reach for raw material supply as it executes its commercialization plans for ASCENIV. On December 10, 2018, the Company&#8217;s former contract
          manufacturer assigned its rights and obligations under the 2011 Plasma Purchase Agreement to Grifols Worldwide Operations Limited (&#8220;Grifols&#8221;) as its successor-in-interest, effective January 1, 2019. Effective October 1, 2024, the Company entered
          into an Amended and Restated Plasma Purchase Agreement with Grifols (the &#8220;A&amp;R Grifols Agreement&#8221;) with a term expiring in <span style="-sec-ix-hidden:Fact_596502cac0e64068963eb61419709634">September 2039</span>,
          after which it may be renewed for two additional multi-year periods if agreed to by the parties. Pursuant to the A&amp;R Grifols
          Agreement, Grifols supplies, on a non-exclusive basis, to ADMA BioManufacturing a minimum of 35,000 liters of RSV plasma annually to
          be used in the manufacture of ASCENIV, with an escalating price per liter depending on the volume supplied in a given 12-month period,
          with a minimum annual price increase every 12 months.&#160; Additionally, Grifols will be entitled to receive a fixed bonus payment in the
          event that a specified liter amount of high-titer plasma is supplied to the Company in any 12-month period during the term of the
          A&amp;R Grifols Agreement.</p><p style="margin: 0px; font-family: 'Times New Roman'; font-size: 10pt; text-align: left; text-indent: 36pt;"> <br/>
        </p><p style="margin: 0px; font-family: 'Times New Roman'; font-size: 10pt; text-align: left; text-indent: 36pt;">Effective August 6, 2024, the Company entered into a Plasma Purchase Agreement with KEDPlasma LLC (&#8220;KEDPlasma&#8221;) with a term expiring in <span style="-sec-ix-hidden:Fact_08cb0657423a4fc9a23ab84cedf6874f">July 2031</span>, after which it may be renewed for an additional five-year period if agreed to by the parties (the &#8220;KEDPlasma Agreement&#8221;).&#160; Pursuant to the KEDPlasma Agreement, KEDPlasma supplies, on a non-exclusive basis, to ADMA BioManufacturing a minimum of 35,000 liters of RSV plasma annually commencing with the 12-month
          period ending July 31, 2026, with an escalating price per liter depending on the volume supplied in a given 12-month period. The price
          per liter of high-titer plasma supplied pursuant to the KEDPlasma Agreement is also scheduled to increase on an annual basis. Additionally, KEDPlasma will be entitled to receive a fixed bonus payment in the event that a specified liter amount of
          RSV plasma is supplied to the Company in any 12-month period during the term of the KEDPlasma Agreement. </p>
<div><br/></div>
<p style="margin: 0px; font-family: 'Times New Roman'; font-size: 10pt; text-align: left; text-indent: 36pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">On June 6, 2017, the Company entered into a Plasma Supply Agreement with its former contract manufacturer, pursuant to which the counterparty supplies, on an exclusive basis subject to certain exceptions, to ADMA BioManufacturing an annual
          minimum volume of hyperimmune plasma that contain antibodies to the Hepatitis B virus for the manufacture of Nabi-HB. The Plasma Supply Agreement has a 10-year
          term. On July 19, 2018, <span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; text-align: left; text-indent: 48px; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">the Plasma Supply Agreement was amended to provide, among other things, that in the event the counterparty elects not to supply in excess of ADMA BioManufacturing&#8217;s
            specified amount of Hepatitis B plasma and ADMA BioManufacturing is unable to secure Hepatitis B plasma from a third party at a price that is within a low double- digit percentage of the price that ADMA BioManufacturing pays to the
            counterparty, then the counterparty shall reimburse ADMA BioManufacturing for the difference in price ADMA BioManufacturing incurs. On December 10, 2018, the Company&#8217;s former contract manufacturer assigned its rights and obligations under the
            Plasma Supply Agreement to Grifols, effective January 1, 201</span>9.</p>
<div><br/></div>
<p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left; font-style: normal;"><span style="text-decoration:underline">Post-Marketing Commitments</span></p><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;">&#160;</p><p style="margin: 0px; font-family: 'Times New Roman'; font-size: 10pt; text-align: left; text-indent: 36pt;"> In connection with the FDA approval of ASCENIV on April 1, 2019, the Company is required to perform a pediatric study to evaluate the
          safety and efficacy of ASCENIV in children and adolescents, for which patient enrollment has been successfully completed. For the years ended December 31, 2024, 2023 and 2022, the Company incurred expenses related to this study in the amount of $1.2 million, $1.0 million and $0.5 million, respectively. The Company expects to incur expenses of approximately $1.0 million to complete this study, which is required to be completed by June of 2026.</p><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;"> <br/>
        </p><p style="margin: 0px; font-family: 'Times New Roman'; font-size: 10pt; text-align: left; text-indent: 36pt;"> In connection with the FDA approval of the BLA for BIVIGAM on December 19, 2012, Biotest committed to perform two additional
          post-marketing studies, a pediatric study to evaluate the efficacy and safety of BIVIGAM in children and adolescents, and a post-authorization safety study to further assess the potential risk of hypotension and hepatic and renal impairment in
          BIVIGAM-treated patients with primary humoral immunodeficiency. These studies were required to be completed by June 30, 2023. Both studies have been completed and the study reports have been submitted to the FDA. ADMA had assumed the remaining
          obligations, and the costs of the studies were expensed as incurred as research and development expenses. The Company did not incur
          any expenses related to this commitment for the year ended December 31, 2024. For the years ended December 31, 2023 and 2022, the Company incurred expenses related to these studies of $1.7 million and $2.2 million, respectively.</p>
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-size: 10pt;"><br/>
            </span> </div>

<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial;"><span style="text-decoration:underline">Other Commitments</span></div>

<div><span style="font-size: 10pt;"> </span></div>

<div style="display:none;"><br/></div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-indent: 36pt;"> <br/>
          </div>

<div style="display:none;"><br/></div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-indent: 36pt;">In the normal course of business, the Company enters into contracts that contain a variety of indemnifications with its employees, licensors, suppliers and service
            providers. Further, the Company indemnifies its directors and officers who are, or were, serving at the Company&#8217;s request in such capacities. The Company&#8217;s maximum exposure under these arrangements is unknown as of December 31, 2024. The
            Company does not anticipate recognizing any significant losses relating to these arrangements.</div>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 405<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/405-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/450/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>INCOME TAXES [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">INCOME TAXES</a></td>
<td class="text">
<table cellpadding="0" cellspacing="0" class="DSPFListTable" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt; border-spacing: 0;">


  <tr style="vertical-align: top;">

    <td style="vertical-align: top; width: 27pt;">
                  <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;"><strong>11.</strong></p>
                </td>

    <td style="vertical-align: top; width: auto;">
                  <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;"><span style="text-decoration: underline;"><span style="background-color: rgb(255, 255, 255); font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><strong>INCOME TAXES</strong></span></span><strong><span style="text-decoration: underline;"><br/>
                      </span></strong></p>
                </td>

  </tr>


</table>
<p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;">&#160;</p><p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-bottom: 0px; text-align: left;"> </p><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 36pt; text-align: left;">The components of the Company&#8217;s income tax expense (benefit) are as follows:<br/>
        </p><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 36pt; text-align: left;"> <br/>
        </p><p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-bottom: 0px; text-align: left;"> </p>
<table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="text-align: left; font: 10pt 'Times New Roman'; width: 100%; border-spacing: 0;">


  <tr style="height: 15px;">

    <td style="padding-bottom: 2px;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px;">&#160;</p>
              </td>

    <td colspan="1" rowspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="10" rowspan="1" style="vertical-align: bottom; text-align: center; border-bottom: #000000 solid 2px;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: center;"><strong>Year Ended December 31,</strong></p>
              </td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td rowspan="1" style="padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="10" rowspan="1" style="vertical-align: bottom; text-align: center; border-bottom: #000000 solid 2px;" valign="bottom"><span style="font-style: italic;">(In thousands) </span> <br/>
              </td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td style="vertical-align: bottom; padding: 0px 0px 2px; padding-bottom: 2px;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px;">&#160;</p>
              </td>

    <td colspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"><span style="font-weight: bold;">2024</span><br/>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"><span style="font-weight: bold;">2023</span><br/>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" rowspan="1" style="vertical-align: bottom; text-align: center; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"><span style="font-weight: bold;">2022</span><br/>
              </td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td style="vertical-align: top;" valign="bottom">Current:<br/>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; text-align: right;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; text-align: right;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; text-align: right;" valign="bottom"><br/>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td style="vertical-align: top; text-indent: 9pt; width: 64%; background-color: #CCEEFF;" valign="bottom">Federal<br/>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">$</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">10,434</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">$</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">-</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">$</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">-</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td style="vertical-align: top; text-indent: 9pt; width: 64%; padding-bottom: 2px;" valign="bottom">State<br/>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom">1,887</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom">-</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">-</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td style="vertical-align: top; text-indent: 18pt; width: 64%; background-color: #CCEEFF;" valign="bottom">Total current<br/>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">12,321</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">-</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">-</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td rowspan="1" style="vertical-align: top; width: 64%;" valign="bottom">Deferred:<br/>
              </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"><br/>
              </td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td rowspan="1" style="vertical-align: top; text-indent: 9pt; width: 64%; background-color: #CCEEFF;" valign="bottom">Federal<br/>
              </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">(72,858</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">)</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">-</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">-</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td style="vertical-align: top; text-indent: 9pt; width: 64%; padding-bottom: 2px;" valign="bottom">State<br/>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom">(11,422</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">)</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom">-</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">-</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td rowspan="1" style="vertical-align: top; text-indent: 18pt; width: 64%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">Total deferred<br/>
              </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">(84,280</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">)</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">-</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">-</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td style="vertical-align: top; width: 64%; padding-bottom: 4px;" valign="bottom">Total benefit from income taxes<br/>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" valign="bottom">$</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" valign="bottom">(71,959</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">)</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" valign="bottom">$</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" valign="bottom">-</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom">$</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom">-</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>
<p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;"> <br/>
        </p><p style="margin: 0px; font-family: 'Times New Roman'; font-size: 10pt; text-align: left; text-indent: 36pt;">A reconciliation of income taxes at the U.S. federal statutory rate to the benefit for income taxes is as follows:</p><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="text-align: left; font: 10pt 'Times New Roman'; width: 100%; border-spacing: 0;">


  <tr style="height: 15px;">

    <td style="padding-bottom: 2px;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px;">&#160;</p>
              </td>

    <td colspan="1" rowspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="10" rowspan="1" style="vertical-align: bottom; text-align: center; border-bottom: #000000 solid 2px;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: center;"><strong>Year Ended December 31,</strong></p>
              </td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td rowspan="1" style="padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="10" rowspan="1" style="vertical-align: bottom; text-align: center; border-bottom: #000000 solid 2px;" valign="bottom"><span style="font-style: italic;">(In thousands) </span> <br/>
              </td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td style="padding-bottom: 2px;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px;">&#160;</p>
              </td>

    <td colspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: #000000 solid 2px;" valign="bottom"><span style="font-weight: bold;">2024</span><br/>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: #000000 solid 2px;" valign="bottom"><span style="font-weight: bold;">2023</span><br/>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" rowspan="1" style="text-align: center; vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><span style="font-weight: bold;">2022</span><br/>
              </td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td style="vertical-align: top; width: 64%; background-color: rgb(204, 238, 255);" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-bottom: 0px; text-indent: -9pt; margin-left: 9pt;">Tax provision (benefit) at U.S. federal statutory rate</p>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">$</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">26,400</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">$</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">(5,930</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">)</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">$</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">(13,840</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">)</td>

  </tr>

  <tr style="height: 15px;">

    <td style="vertical-align: top; width: 64%;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-bottom: 0px; text-indent: -9pt; margin-left: 9pt;">State taxes<span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">,</span> net of federal benefit<br/>
                </p>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">(9,931</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">)</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">(763</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">)</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">(1,773</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">)</td>

  </tr>

  <tr style="height: 15px;">

    <td rowspan="1" style="vertical-align: top; width: 64%; background-color: rgb(204, 238, 255);" valign="bottom">
                <div style="text-indent: -9pt; margin-left: 9pt;">Non-deductible executive compensation<br/>
                </div>
              </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">
                <div>4,340</div>
              </td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">983</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">862<br/>
              </td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td rowspan="1" style="vertical-align: top; width: 64%;" valign="bottom">
                <div style="text-indent: -9pt; margin-left: 9pt;">Excess tax benefits related to stock-based compensation<br/>
                </div>
              </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">(5,661</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">)</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">-</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">-<br/>
              </td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td style="vertical-align: top; width: 64%; background-color: rgb(204, 238, 255);" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-bottom: 0px; text-indent: -9pt; margin-left: 9pt;">Change in valuation allowance</p>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">(87,969</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">)</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">4,696</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">15,117</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td style="vertical-align: top; width: 64%; padding-bottom: 2px;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-bottom: 0px; text-indent: -9pt; margin-left: 9pt;">Other</p>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom">862</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom">1,014</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">(366</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">)</td>

  </tr>

  <tr style="height: 15px;">

    <td style="vertical-align: top; width: 64%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-bottom: 0px; text-indent: -9pt; margin-left: 9pt;">Benefit for income taxes</p>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom">$</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom">(71,959</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">)</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom">$</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom">-</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">$</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">-</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>
<p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;">&#160; &#160;</p><p style="margin: 0px; font-family: 'Times New Roman'; font-size: 10pt; text-align: left; text-indent: 36pt;">The significant components of the Company&#8217;s deferred tax assets are as follows:</p><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="text-align: left; font: 10pt 'Times New Roman'; width: 100%; border-spacing: 0;">


  <tr style="height: 15px;">

    <td style="padding-bottom: 2px;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px;">&#160;</p>
              </td>

    <td colspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="6" style="vertical-align: bottom; text-align: center; border-bottom: #000000 solid 2px;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: center;"><strong>Year Ended December 31,</strong></p>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td style="padding-bottom: 2px;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px;">&#160;</p>
              </td>

    <td colspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: #000000 solid 2px;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: center;"><strong> 2024<br/>
                  </strong></p>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: #000000 solid 2px;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: center;"><strong>2023<br/>
                  </strong></p>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td rowspan="1" valign="bottom">Deferred tax assets: <br/>
              </td>

    <td colspan="1" rowspan="1" style="text-align: center; vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="6" rowspan="1" style="vertical-align: bottom; text-align: center;" valign="bottom"><span style="font-style: italic;">(in thousands)</span> <br/>
              </td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td style="vertical-align: top; width: 76%; background-color: #CCEEFF;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-indent: 9pt;">Federal and state net operating loss carryforwards</p>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">$</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">65,615</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">$</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">76,645</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td style="vertical-align: top; width: 76%;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-indent: 9pt;">Interest expense limitation carryforwards</p>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">13,604</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">21,165</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td style="vertical-align: top; width: 76%; background-color: #CCEEFF;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-indent: 9pt;">Inventory</p>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">3,911</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">2,937</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td style="vertical-align: top; width: 76%;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-indent: 9pt;">Stock-based compensation<br/>
                </p>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">2,523</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">1,795</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td rowspan="1" style="vertical-align: top; text-indent: 9pt; width: 76%; background-color: #CCEEFF;" valign="bottom">Lease obligations <br/>
              </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">2,549</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">2,330</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td style="vertical-align: top; width: 76%; padding-bottom: 2px;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-indent: 9pt;">Accrued expenses and other</p>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom">5,779</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom">5,831</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td style="vertical-align: top; width: 76%; background-color: #CCEEFF;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-bottom: 0px; text-indent: 9pt;">Total gross deferred tax assets</p>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">93,981</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">110,703</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td style="vertical-align: top; width: 76%; padding-bottom: 2px;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in;">Less: valuation allowance for deferred tax assets</p>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom">-</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom">(101,422</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">)</td>

  </tr>

  <tr style="height: 15px;">

    <td rowspan="1" style="vertical-align: top; text-indent: 18pt; width: 76%; background-color: #CCEEFF;" valign="bottom">Total deferred tax assets, net of valuation allowance<br/>
              </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">93,981<br/>
              </td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">9,281<br/>
              </td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td rowspan="1" style="vertical-align: top; width: 76%;" valign="bottom">Deferred tax liabilities:<br/>
              </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td rowspan="1" style="vertical-align: top; text-indent: 9pt; width: 76%; background-color: #CCEEFF;" valign="bottom">Depreciation of property and equipment <br/>
              </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">(6,166</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">)</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">(6,837</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">)</td>

  </tr>

  <tr style="height: 15px;">

    <td rowspan="1" style="vertical-align: top; text-indent: 9pt; width: 76%;" valign="bottom">Right-of-use assets<br/>
              </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">(2,247</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">)</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">(2,077</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">)</td>

  </tr>

  <tr style="height: 15px;">

    <td rowspan="1" style="vertical-align: top; text-indent: 9pt; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">Other deferred tax liabilities <br/>
              </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">(1,288</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">)</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">(367</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">)</td>

  </tr>

  <tr style="height: 15px;">

    <td rowspan="1" style="vertical-align: top; text-indent: 18pt; width: 76%; padding-bottom: 2px;" valign="bottom">Total deferred tax liabilities <br/>
              </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom">(9,701</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">)</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom">(9,281</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">)</td>

  </tr>

  <tr style="height: 15px;">

    <td style="vertical-align: top; width: 76%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in;">Net deferred tax assets</p>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom">$</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom">84,280</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom">$</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom">-</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>
<p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;">&#160;</p><p style="margin: 0px; font-family: 'Times New Roman'; font-size: 10pt; text-indent: 36pt;"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">As of December 31, 2024, the Company has federal and state (post-apportioned basis) net operating losses (&#8220;NOLs&#8221;) of $265.6 million and $204.0 million, respectively. Approximately
            $33.4 million and $62.0
            million of the foregoing Federal and state NOLs, respectively, will expire at various dates from <span style="-sec-ix-hidden:Fact_3caad71a9a1b440ba964fc32940d472a">2029</span> through <span style="-sec-ix-hidden:Fact_8b85b23ae8fb4a49b2e8cb82e0d4603d">2043</span>, if not limited by triggering events prior to such time. </span>Under the provisions of the Internal Revenue Code, changes in ownership of the
          Company, in certain circumstances, would limit the amount of federal NOLs that can be utilized annually in the future to offset taxable income. In particular, Section 382 of the Internal Revenue Code (&#8220;Section 382&#8221;) imposes limitations on an
          entity&#8217;s ability to use NOLs upon certain changes in ownership. If the Company is limited in its ability to use its NOLs in future years in which it has taxable income, then the Company will pay more taxes than if it were otherwise able to fully
          utilize its NOLs. The Company may experience ownership changes in the future as a result of subsequent shifts in ownership of the Company&#8217;s capital stock that the Company cannot predict or control that could result in further limitations being
          placed on the Company&#8217;s ability to utilize its Federal NOLs. <span style="font-family: 'Times New Roman'; font-size: 10pt; color: rgb(0, 0, 0);">The annual amount of Federal NOLs that expire each year is as follows (in thousands):<br/>
        </span></p><p style="margin: 0px; font-family: 'Times New Roman'; font-size: 10pt; text-indent: 36pt;"> <br/>
        </p><p style="margin: 0px; font-family: 'Times New Roman'; font-size: 10pt; text-indent: 36pt;"> </p>
<table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="text-align: left; font: 10pt 'Times New Roman'; width: 100%; border-spacing: 0;">


  <tr style="height: 15px;">

    <td colspan="1" rowspan="1" style="vertical-align: top; width: 12%; padding-top: 0px; padding-right: 0px; padding-left: 0px; text-align: center; border-bottom: 2px solid rgb(0, 0, 0);">Expiration Date</td>

    <td rowspan="1" style="vertical-align: top; width: 74%; padding: 0px 0px 2px;">&#160;<br/>
              </td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; white-space: nowrap; width: 1.18%; padding: 0px 0px 2px; text-align: right;">&#160;</td>

    <td colspan="2" rowspan="1" style="border-bottom: 2px solid; vertical-align: bottom; white-space: nowrap; text-align: center;">Remaining Available&#160; <br/>
              </td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; white-space: nowrap; width: 1.18%; padding: 0px 0px 2px; text-align: left;">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td colspan="1" rowspan="1" style="vertical-align: top; width: 12%; text-align: center; background-color: rgb(204, 238, 255);" valign="bottom">2031</td>

    <td rowspan="1" style="vertical-align: top; width: 74%; text-align: center; background-color: rgb(204, 238, 255);" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1.18%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">$ <br/>
              </td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 11%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">2,409</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1.18%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td colspan="1" style="vertical-align: top; width: 12%; text-align: center;" valign="bottom">2032 <br/>
              </td>

    <td style="vertical-align: top; width: 74%; text-align: center;" valign="bottom"><br/>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1.18%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;<br/>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 11%; white-space: nowrap;" valign="bottom">7,430</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1.18%; white-space: nowrap;" valign="bottom"><br/>
              </td>

  </tr>

  <tr style="height: 15px;">

    <td colspan="1" rowspan="1" style="vertical-align: top; width: 12%; text-align: center; background-color: rgb(204, 238, 255);" valign="bottom">&#160;2033</td>

    <td rowspan="1" style="vertical-align: top; width: 74%; text-align: center; background-color: rgb(204, 238, 255);" valign="bottom"><br/>
              </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1.18%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 11%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">11,295</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1.18%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td colspan="1" rowspan="1" style="vertical-align: top; width: 12%; text-align: center;" valign="bottom">&#160;2034</td>

    <td rowspan="1" style="vertical-align: top; width: 74%; text-align: center;" valign="bottom"><br/>
              </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1.18%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 11%; white-space: nowrap;" valign="bottom">1,025</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1.18%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td colspan="1" style="vertical-align: top; width: 12%; text-align: center; background-color: rgb(204, 238, 255);" valign="bottom">&#160;2035</td>

    <td style="vertical-align: top; width: 74%; text-align: center; background-color: rgb(204, 238, 255);" valign="bottom"><br/>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1.18%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 11%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">1,025</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1.18%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td colspan="1" rowspan="1" style="vertical-align: top; width: 12%; text-align: center;" valign="bottom">&#160;2036</td>

    <td rowspan="1" style="vertical-align: top; width: 74%; text-align: center;" valign="bottom"><br/>
              </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1.18%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 11%; white-space: nowrap;" valign="bottom">1,025</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1.18%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td colspan="1" rowspan="1" style="vertical-align: top; width: 12%; text-align: center; background-color: rgb(204, 238, 255);" valign="bottom">&#160;2037</td>

    <td rowspan="1" style="vertical-align: top; width: 74%; text-align: center; background-color: rgb(204, 238, 255);" valign="bottom"><br/>
              </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1.18%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 11%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">9,157</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1.18%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td colspan="1" style="vertical-align: top; width: 12%; padding-bottom: 2px; text-align: center;" valign="bottom">&#160;Indefinite</td>

    <td style="vertical-align: top; width: 74%; padding-bottom: 2px; text-align: center;" valign="bottom"><br/>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1.18%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 11%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">232,240</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1.18%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"><br/>
              </td>

  </tr>

  <tr style="height: 15px;">

    <td colspan="1" style="vertical-align: top; width: 12%; text-align: center; padding-bottom: 4px; background-color: rgb(204, 238, 255);" valign="bottom">&#160;Total</td>

    <td style="vertical-align: top; width: 74%; text-align: center; padding-bottom: 4px; background-color: rgb(204, 238, 255);" valign="bottom"><br/>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1.18%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">$</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 11%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">265,606<br/>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1.18%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>
<p style="margin: 0px; font-family: 'Times New Roman'; font-size: 10pt; text-indent: 36pt;"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"> <br/>
          </span></p><p style="margin: 0px; font-family: 'Times New Roman'; font-size: 10pt; text-align: left; text-indent: 36pt;">A valuation allowance, if needed, reduces deferred tax assets to the amount expected to be realized. When determining the amount of net
          deferred tax assets that are more likely than not to be realized, the Company assesses all available positive and negative evidence. This evidence includes, but is not limited to, prior earnings history, expected future earnings, carry-back and
          carry-forward periods and the feasibility of ongoing tax strategies that could potentially enhance the likelihood of the realization of a deferred tax asset. The weight given to the positive and negative evidence is commensurate with the extent
          the evidence may be objectively verified.<br/>
        </p>
<div><br/></div>
<p style="margin: 0px; font-family: 'Times New Roman'; font-size: 10pt; text-align: left; text-indent: 36pt;"> As of December 31, 2024, the Company believes it is more-likely-than-not that the Company&#8217;s federal and state deferred tax assets will be
          realized. The Company recorded a release of its valuation allowance associated with federal and state deferred tax assets which was due in part to achieving three years of cumulative taxable income and projected taxable income that is more than
          adequate to realize the Company&#8217;s federal and state deferred tax assets. As a result, the Company reversed the federal and state valuation allowance recorded as of December 31, 2023 of $88.0 million and $13.4 million, respectively, resulting in a
          tax benefit to the income tax provision for the year ended December 31, 2024.<br/>
        </p><p style="margin: 0px; font-family: 'Times New Roman'; font-size: 10pt; text-align: left; text-indent: 36pt;"> <br/>
        </p><p style="margin: 0px; font-family: 'Times New Roman'; font-size: 10pt; text-align: left; text-indent: 36pt;">In accordance with U.S. GAAP, the Company is required to determine whether a tax position of the Company is more likely than not to be
          sustained upon examination by the applicable taxing authority, including resolution of any related appeals or litigation processes, based on the technical merits of the position. The tax benefit to be recognized is measured as the largest amount
          of benefit that is greater than 50% likely of being realized upon ultimate settlement. Derecognition of a tax benefit previously recognized could result in the Company recording a tax liability that would reduce net assets. The amount of the
          liability for which an exposure exists is measured as the largest amount of benefit determined on a cumulative probability basis that the Company believes is more likely than not to be realized upon ultimate settlement of the position. Components
          of the liability are classified as either a current or a long-term liability in the accompanying consolidated balance sheets based on when the Company expects each of the items to be settled. The Company does not have any unrecognized tax benefits as of December 31, 2024 and 2023 and does not anticipate a significant change in unrecognized tax benefits
          during the next 12 months. </p><p style="margin: 0px; font-family: 'Times New Roman'; font-size: 10pt; text-align: left; text-indent: 36pt;"><br/>
        </p><p style="margin: 0px; font-family: 'Times New Roman'; font-size: 10pt; text-align: left; text-indent: 36pt;">The Company files income tax returns in the U.S. federal and various state jurisdictions. All net operating losses and tax credits
          generated to date are subject to adjustment for U.S. federal and state income tax purposes. The Company&#8217;s income tax returns are open to examination for tax years 2007 through 2023.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12C<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12B<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477891/740-270-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/740/tableOfContent<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-14<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-21<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASE OBLIGATIONS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>LEASE OBLIGATIONS [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">LEASE OBLIGATIONS</a></td>
<td class="text">
<div>
          <table cellpadding="0" cellspacing="0" class="DSPFListTable" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt; border-spacing: 0;">


  <tr style="vertical-align: top;">

    <td style="vertical-align: top; width: 27pt;">
                  <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;"><strong>12.</strong></p>
                </td>

    <td style="align: left; vertical-align: top; width: auto;">
                  <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;"><span style="text-decoration: underline;"><span style="background-color: rgb(255, 255, 255); font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><strong>LEASE OBLIGATIONS</strong></span></span><strong><span style="text-decoration: underline;"><br/>
                      </span></strong></p>
                </td>

  </tr>


</table>
        </div>
<p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;">&#160;</p><p style="margin: 0px; font-family: 'Times New Roman'; font-size: 10pt; text-align: left; text-indent: 36pt;">The Company leases certain properties and equipment for its ADMA BioCenters and ADMA BioManufacturing subsidiaries, which leases provide
          the right to use the underlying assets and require lease payments through the respective lease terms which expire at various dates through 2033. The Company&#8217;s lease agreements do not contain any material residual value guarantees or material
          restrictive covenants. Upon adoption of ASU No. 2016-02, <span style="font-style: italic;">Leases (Topic 842)</span> effective January 1, 2019, the Company elected the package of practical expedients, which permits the Company to not reassess
          under the new standard its prior conclusions about lease identification, lease classification and initial direct costs. In addition, the Company elected the short-term lease recognition exemption for all leases that qualify, </p>
<div><span style="font-size: 10pt;"> </span></div>
<p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-indent: 45px; text-align: left;">&#160;</p>
<div><span style="font-size: 10pt;"> </span></div>
<p style="margin: 0px; font-family: 'Times New Roman'; font-size: 10pt; text-align: left; text-indent: 36pt;"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">The Company determines if an arrangement is an operating lease or a financing lease at inception. Leases with an initial term of 12 months or less are not recorded on
            the balance sheet and lease expense for such leases are recognized on a straight-line basis over the lease term. All other leases are recorded on the balance sheet with assets representing the right to use the underlying asset for the lease
            term and lease liabilities representing the obligation to make lease payments arising from the lease. Right-of-use assets and lease liabilities are recognized at the lease commencement date based on the present value of lease payments over the
            lease term and include options to extend or terminate the lease when they are reasonably certain to be exercised. The present value of the lease payments is determined using the Company&#8217;s estimated incremental borrowing rate as of the lease
            commencement date. There were no new material leases entered into during the year ended December 31, 2024. For the lease liabilities recognized during the years ended December 31, 2023 and 2022, the Company used discount rates of 13% to 16%, representing a weighted
            average discount rate of 13.02%, to determine the present value of its lease obligations. The Company&#8217;s operating lease expense is
            recognized on a straight-line basis over the lease term and is reflected in Plasma center operating expenses and Selling, general and administrative expenses in the accompanying consolidated statements of operations. Aggregate lease expense for
            the Company&#8217;s operating leases for the years ended December 31, 2024, 2023 and 2022 was $2.4 million, $2.4 million and <span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">$2.1 million</span>, respectively. Aggregate
            cash paid on these leases for the years ended December 31, 2024, 2023 and 2022 was $2.4 million, $2.4 million and $1.8 million,
            respectively.</span> </p>
<div><span style="font-size: 10pt;"> </span></div>
<p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-indent: 45px; text-align: left;">&#160;</p>
<div><span style="font-size: 10pt;"> </span></div>
<p style="margin: 0px; font-family: 'Times New Roman'; font-size: 10pt; text-align: left; text-indent: 36pt;"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 48px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; display: inline !important; float: none;"><span style="font-size: 10pt;"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 48px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; display: inline !important; float: none;">During the year ended December 31, 2023, the Company recognized one additional right-of-use
                asset and corresponding lease liability in the amount of $0.1 million for office equipment leased for the Boca Facility.</span>
              During the year ended December 31, 2022, the Company recognized additional right-of-use assets and corresponding lease liabilities aggregating to approximately $4.0 million in connection with two new property leases where the Company
              has opened additional plasma collection facilities, a property lease for the storage of raw materials inventory and a property lease for the building that the Company utilizes as its corporate headquarters (see Note 9). The Company has
              aggregate lease liabilities of $9.8 million and $10.8 million as of December 31, 2024 and 2023, respectively, which are comprised primarily of the leases for the Company&#8217;s plasma collection centers.&#160; </span><span style="font-size: 10pt;"><span style="font-size: 10pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-weight: 400;">The Company&#8217;s operating leases
              have a weighted average remaining term of 6.8</span><span style="font-size: 10pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-weight: 400;"> years. Scheduled payments under the Company&#8217;s lease obligations</span><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal;"> are as follows</span></span></span></span><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal;"> (in thousands)</span></span><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 48px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; display: inline !important; float: none;"><span style="font-size: 10pt;"><span style="font-size: 10pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-weight: 400;">:</span></span></span></p><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-indent: 45px; text-align: left;"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 48px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; display: inline !important; float: none;"><br/>
          </span> </p>
<table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="text-align: left; font: 10pt 'Times New Roman'; width: 100%; border-spacing: 0;">


  <tr style="height: 15px;">

    <td style="vertical-align: top; width: 88%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: left;">Year ended December 31, 2025</p>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"><br/>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">2,421</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td style="vertical-align: top; width: 88%;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: left;">2026<br/>
                </p>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">2,157</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td style="vertical-align: top; width: 88%; background-color: #CCEEFF;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: left;">2027<br/>
                </p>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">2,041</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td style="vertical-align: top; width: 88%;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: left;">2028<br/>
                </p>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">2,088</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td style="vertical-align: top; width: 88%; background-color: #CCEEFF;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: left;">2029<br/>
                </p>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">2,109</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td style="vertical-align: top; width: 88%; padding-bottom: 2px;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: left;">Thereafter</p>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom">4,041</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td style="vertical-align: top; width: 88%; background-color: #CCEEFF;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: left;">Total payments</p>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">14,857</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td style="vertical-align: top; width: 88%;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: left;">Less: imputed interest</p>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">(5,078</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">)</td>

  </tr>

  <tr style="height: 15px;">

    <td style="vertical-align: top; width: 88%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: left;">Current portion</p>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">(1,218</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">)</td>

  </tr>

  <tr style="height: 15px;">

    <td style="vertical-align: top; width: 88%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: left;">Balance at December 31, 2024</p>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom">$</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom">8,561</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/842-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SEGMENTS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>SEGMENTS [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">SEGMENTS</a></td>
<td class="text">
<div>
          <table cellpadding="0" cellspacing="0" class="DSPFListTable" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt; border-spacing: 0;">


  <tr style="vertical-align: top;">

    <td style="vertical-align: top; width: 27pt;">
                  <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;"><strong>13.</strong></p>
                </td>

    <td style="align: left; vertical-align: top; width: auto;">
                  <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;"><span style="text-decoration: underline;"><span style="background-color: rgb(255, 255, 255); font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><strong>SEGMENTS</strong></span></span><strong><span style="text-decoration: underline;"><br/>
                      </span></strong></p>
                </td>

  </tr>


</table>
        </div>
<p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;">&#160;</p><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-indent: 45px; text-align: left;">The Company is engaged in the manufacture, marketing and development of specialty plasma-derived biologics.&#160; The Company&#8217;s ADMA
          BioManufacturing operating segment reflects the Company&#8217;s immunoglobulin manufacturing, commercial and development operations in Boca Raton, FL.&#160; The Plasma Collection Centers operating segment consists of ten plasma collection facilities located throughout the United States, all of which are operational, collecting plasma and currently holding FDA
          licenses. The Company defines its operating segments as those business units whose operating results are regularly reviewed by the chief operating decision maker (&#8220;CODM&#8221;) to analyze performance and allocate resources. The Corporate information
          included in the reconciliations below generally consists of certain unallocated general and administrative overhead expenses and interest expense on the Company&#8217;s senior debt (see Note 7). The Company&#8217;s CODM is its President and Chief Executive
          Officer. For the Company&#8217;s two operating segments, the CODM uses income/loss before taxes as the measure of segment profit to determine the allocation of resources for each segment. Transactions between the two operating segments consist solely of the transfer of raw material plasma inventory at cost from the Plasma Collection Centers segment to the ADMA
          BioManufacturing segment with no markup or intercompany profit. Income tax benefit/expense is recorded at the Corporate entity and is not allocated to the operating segments. <span style="font-family: 'Times New Roman'; font-size: 10pt; color: rgb(0, 0, 0);">Summarized financial information concerning reportable segments is
          shown in the following tables:</span></p><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;">&#160;&#160;&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="text-align: left; font: 10pt 'Times New Roman'; width: 100%; border-spacing: 0;">


  <tr style="height: 15px;">

    <td colspan="12" style="vertical-align: top; border-bottom: #000000 solid 2px;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: center;"><strong>Year Ended December 31, 2024</strong></p>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td style="padding-bottom: 2px;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: center;"><span style="font-style: italic;">(in thousands)</span><br/>
                </p>
              </td>

    <td colspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: center;"><strong>ADMA</strong></p>
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: center;"><strong> BioManufacturing</strong></p>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: center;"><strong>Plasma Collection<br/>
                  </strong></p>
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: center;"><span style="font-weight: bold;">Centers</span><strong><br/>
                  </strong></p>
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: center;"><strong> </strong></p>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: center;"><strong>Total</strong></p>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td style="vertical-align: top; width: 64%; background-color: #CCEEFF;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in;">Revenues</p>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">$</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">415,806</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">$</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">10,505</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">$</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">426,311</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td style="width: 64%;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px;">&#160;</p>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td style="vertical-align: top; width: 64%; background-color: #CCEEFF;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in;">Cost of product revenue</p>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">195,605</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">11,296</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">206,901</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td style="width: 64%;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px;">&#160;</p>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td style="vertical-align: top; width: 64%; background-color: #CCEEFF;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in;">Research and development<br/>
                </p>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">1,813</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">-</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">1,813</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td style="width: 64%;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px;">&#160;</p>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td style="vertical-align: top; width: 64%; background-color: #CCEEFF;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in;">Plasma center operating expenses<br/>
                </p>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">-</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">4,245</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">4,245</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td style="width: 64%;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px;">&#160;</p>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td rowspan="1" style="vertical-align: top; width: 64%; background-color: #CCEEFF;" valign="bottom">Selling, marketing and distribution<br/>
              </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">18,683</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">-</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">18,683</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td rowspan="1" style="vertical-align: top; width: 64%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td style="vertical-align: top; width: 64%; background-color: #CCEEFF;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in;">Depreciation and amortization expense<br/>
                </p>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">4,827</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">3,218</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">8,045</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td style="width: 64%;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px;">&#160;</p>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td rowspan="1" style="width: 64%; background-color: #CCEEFF;" valign="bottom">General and administrative expense<br/>
              </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">26,001</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">-</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">26,001</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td rowspan="1" style="width: 64%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td rowspan="1" style="width: 64%; background-color: #CCEEFF;" valign="bottom">Other expense, net<br/>
              </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">(178</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">)</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">(5</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">)</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">(183</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">)</td>

  </tr>

  <tr style="height: 15px;">

    <td rowspan="1" style="width: 64%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td rowspan="1" style="width: 64%; background-color: #CCEEFF;" valign="bottom">Income (loss) before taxes<br/>
              </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">173,138</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">(5,041</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">)</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">168,097</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td rowspan="1" style="width: 64%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td style="vertical-align: top; width: 64%; background-color: #CCEEFF;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in;">Expenditures for additions to long-lived assets<br/>
                </p>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">8,352</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">223</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">8,575</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td style="vertical-align: top; width: 64%;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in;">Total assets</p>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">289,297</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">30,477</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">319,774</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td rowspan="1" style="vertical-align: top; width: 64%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td rowspan="1" style="vertical-align: top; width: 64%;" valign="bottom"><span style="font-style: italic;">Reconciliation of revenues:</span><br/>
              </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td rowspan="1" style="vertical-align: top; text-indent: 9pt; width: 64%; background-color: #CCEEFF;" valign="bottom">Segment revenue<br/>
              </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">$</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">426,311</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td rowspan="1" style="vertical-align: top; text-indent: 9pt; width: 64%; padding-bottom: 2px;" valign="bottom">License revenue (see Note 2 - Revenue Recognition)<br/>
              </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom">143</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td rowspan="1" style="vertical-align: top; text-indent: 18pt; width: 64%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom">Consolidated revenues<br/>
              </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 4px double rgb(0, 0, 0);" valign="bottom">$<br/>
              </td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 4px double rgb(0, 0, 0);" valign="bottom">426,454</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td rowspan="1" style="vertical-align: top; width: 64%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td rowspan="1" style="vertical-align: top; width: 64%; background-color: rgb(204, 238, 255);" valign="bottom">
                <div style="margin-left: 9pt; text-indent: -9pt;"><span style="font-style: italic;">Reconciliation of selling, general and administrative expense:</span><br/>
                </div>
              </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td rowspan="1" style="vertical-align: top; text-indent: 9pt; width: 64%;" valign="bottom">Segment selling, marketing and distribution expense<br/>
              </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">$</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">18,683</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td rowspan="1" style="vertical-align: top; text-indent: 9pt; width: 64%; background-color: #CCEEFF;" valign="bottom">Segment general and administrative expense<br/>
              </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">26,001</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td rowspan="1" style="vertical-align: top; text-indent: 9pt; width: 64%; padding-bottom: 2px;" valign="bottom">Corporate general and administrative expense (a)<br/>
              </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom">29,440</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td rowspan="1" style="vertical-align: top; width: 64%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom">
                <div style="margin-left: 9pt">
                  <div style="margin-left: 9pt">
                    <div style="margin-left: 9pt; text-indent: -9pt;">Consolidated selling, general and administrative expense<br/>
                    </div>
                  </div>
                </div>
              </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 4px double rgb(0, 0, 0);" valign="bottom">$<br/>
              </td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 4px double rgb(0, 0, 0);" valign="bottom">74,124</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td rowspan="1" style="vertical-align: top; width: 64%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td rowspan="1" style="vertical-align: top; width: 64%; background-color: #CCEEFF;" valign="bottom"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: italic; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: nowrap; background-color: rgb(204, 238, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; display: inline !important; float: none;">Reconciliation of income (loss) before taxes:</span> </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td rowspan="1" style="vertical-align: top; text-indent: 9pt; width: 64%;" valign="bottom">Segment income before taxes<br/>
              </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">$</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">168,097</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td rowspan="1" style="vertical-align: top; text-indent: 9pt; width: 64%; background-color: #CCEEFF;" valign="bottom">License revenue<br/>
              </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">143</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td rowspan="1" style="vertical-align: top; width: 64%;" valign="bottom">
                <div style="margin-left: 9pt">
                  <div style="margin-left: 9pt; text-indent: -9pt;">Unallocated interest expense, primarily related to interest on senior debt (see Note 7)<br/>
                  </div>
                </div>
              </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">(13,930</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">)</td>

  </tr>

  <tr style="height: 15px;">

    <td rowspan="1" style="vertical-align: top; text-indent: 9pt; width: 64%; background-color: #CCEEFF;" valign="bottom">Loss on extinguishment of debt (see Note 7)<br/>
              </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">(1,243</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">)</td>

  </tr>

  <tr style="height: 15px;">

    <td rowspan="1" style="vertical-align: top; text-indent: 9pt; width: 64%;" valign="bottom">Unallocated interest income<br/>
              </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">2,087</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td rowspan="1" style="vertical-align: top; text-indent: 9pt; width: 64%; background-color: rgb(204, 238, 255); padding-bottom: 2px;" valign="bottom">Corporate general and administrative expense (a)<br/>
              </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom">(29,440</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; white-space: nowrap;" valign="bottom">)</td>

  </tr>

  <tr style="height: 15px;">

    <td rowspan="1" style="vertical-align: top; text-indent: 18pt; width: 64%; padding-bottom: 4px;" valign="bottom">Consolidated income before taxes<br/>
              </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom">$<br/>
              </td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom">125,714</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td rowspan="1" style="vertical-align: top; width: 64%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td rowspan="1" style="vertical-align: top; width: 64%;" valign="bottom"><span style="font-style: italic;">Reconciliation of total assets:</span><br/>
              </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td rowspan="1" style="vertical-align: top; text-indent: 9pt; width: 64%; background-color: #CCEEFF;" valign="bottom">Total segment assets<br/>
              </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">$</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">319,774</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td rowspan="1" style="vertical-align: top; text-indent: 9pt; width: 64%; padding-bottom: 2px;" valign="bottom">Corporate (b)<br/>
              </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom">168,904</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td rowspan="1" style="vertical-align: top; text-indent: 18pt; width: 64%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom">Consolidated total assets<br/>
              </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 4px double rgb(0, 0, 0);" valign="bottom">$<br/>
              </td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 4px double rgb(0, 0, 0);" valign="bottom">488,678</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>
<p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;"><br/>
        </p>
<div>
          <table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-spacing: 0;">


  <tr style="vertical-align: top;">

    <td style="text-align: right; vertical-align: top; width: 27pt;">
                  <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;">(a) - <br/>
                  </p>
                </td>

    <td style="text-align: left; vertical-align: top;">
                  <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: justify;">Primarily includes compensation expense,
                    including stock-based compensation expense, for certain executive officers and consultants, insurance, legal and investor relations expenses and accounting and tax fees that are not allocated to the Company&#8217;s operating segments.</p>
                </td>

  </tr>


</table>
        </div>
<p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;"><br/>
        </p>
<table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-spacing: 0;">


  <tr style="vertical-align: top;">

    <td style="text-align: right; vertical-align: top; width: 27pt;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;">(b) -<br/>
                </p>
              </td>

    <td style="text-align: left; vertical-align: top;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;">Primarily consists of cash and deferred tax
                  assets.</p>
              </td>

  </tr>


</table>
<p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;"><br/>
        </p><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;"> </p>
<table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="text-align: left; font: 10pt 'Times New Roman'; width: 100%; border-spacing: 0;">


  <tr style="height: 15px;">

    <td colspan="12" style="vertical-align: top; border-bottom: #000000 solid 2px;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: center;"><strong>Year Ended December 31, 2023</strong></p>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td style="padding-bottom: 2px;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: center;"><span style="font-style: italic;">(in thousands)</span><br/>
                </p>
              </td>

    <td colspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: center;"><strong>ADMA</strong></p>
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: center;"><strong> BioManufacturing</strong></p>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: center;"><strong>Plasma Collection<br/>
                  </strong></p>
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: center;"><span style="font-weight: bold;">Centers</span><strong><br/>
                  </strong></p>
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: center;"><strong> </strong></p>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: center;"><strong>Total</strong></p>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td style="vertical-align: top; width: 64%; background-color: #CCEEFF;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in;">Revenues</p>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">$</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">249,738</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">$</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">8,334</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">$</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">258,072</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td style="width: 64%;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px;">&#160;</p>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td style="vertical-align: top; width: 64%; background-color: #CCEEFF;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in;">Cost of product revenue</p>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">161,157</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">8,116</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">169,273</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td style="width: 64%;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px;">&#160;</p>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td style="vertical-align: top; width: 64%; background-color: #CCEEFF;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in;">Research and development<br/>
                </p>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">3,300</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">-</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">3,300</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td style="width: 64%;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px;">&#160;</p>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td style="vertical-align: top; width: 64%; background-color: #CCEEFF;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in;">Plasma center operating expenses<br/>
                </p>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">-</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">4,266</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">4,266</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td style="width: 64%;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px;">&#160;</p>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td rowspan="1" style="vertical-align: top; width: 64%; background-color: #CCEEFF;" valign="bottom">Selling, marketing and distribution<br/>
              </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">18,407</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">-</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">18,407</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td rowspan="1" style="vertical-align: top; width: 64%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td style="vertical-align: top; width: 64%; background-color: #CCEEFF;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in;">Depreciation and amortization expense<br/>
                </p>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">5,156</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">3,176</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">8,332</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td style="width: 64%;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px;">&#160;</p>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td rowspan="1" style="width: 64%; background-color: #CCEEFF;" valign="bottom">General and administrative expense<br/>
              </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">18,625</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">-</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">18,625</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td rowspan="1" style="width: 64%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td rowspan="1" style="width: 64%; background-color: #CCEEFF;" valign="bottom">Income (loss) before taxes<br/>
              </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">47,267</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">(4,049</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">)</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">43,218</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td rowspan="1" style="width: 64%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td style="vertical-align: top; width: 64%; background-color: #CCEEFF;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in;">Expenditures for additions to long-lived assets<br/>
                </p>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">2,952</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">1,819</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">4,771</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td style="vertical-align: top; width: 64%;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in;">Total assets</p>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">246,719</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">34,733</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">281,452</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td rowspan="1" style="vertical-align: top; width: 64%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td rowspan="1" style="vertical-align: top; width: 64%;" valign="bottom"><span style="font-style: italic;">Reconciliation of revenues:</span><br/>
              </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td rowspan="1" style="vertical-align: top; text-indent: 9pt; width: 64%; background-color: #CCEEFF;" valign="bottom">Segment revenue<br/>
              </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">$ <br/>
              </td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">258,072</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td rowspan="1" style="vertical-align: top; text-indent: 9pt; width: 64%; padding-bottom: 2px;" valign="bottom">License revenue (see Note 2 - Revenue Recognition)<br/>
              </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom">143</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td rowspan="1" style="vertical-align: top; text-indent: 18pt; width: 64%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom">Consolidated revenues<br/>
              </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 4px double rgb(0, 0, 0);" valign="bottom">$</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 4px double rgb(0, 0, 0);" valign="bottom">258,215</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td rowspan="1" style="vertical-align: top; width: 64%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td rowspan="1" style="vertical-align: top; width: 64%; background-color: rgb(204, 238, 255);" valign="bottom">
                <div style="margin-left: 9pt; text-indent: -9pt;"><span style="font-style: italic;">Reconciliation of selling, general and administrative expense:</span><br/>
                </div>
              </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td rowspan="1" style="vertical-align: top; text-indent: 9pt; width: 64%;" valign="bottom">Segment selling, marketing and distribution expense<br/>
              </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">$</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">18,407</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td rowspan="1" style="vertical-align: top; text-indent: 9pt; width: 64%; background-color: #CCEEFF;" valign="bottom">Segment general and administrative expense<br/>
              </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">18,625</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td rowspan="1" style="vertical-align: top; text-indent: 9pt; width: 64%; padding-bottom: 2px;" valign="bottom">Corporate general and administrative expense (a)<br/>
              </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom">21,988</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td rowspan="1" style="vertical-align: top; width: 64%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom">
                <div style="margin-left: 9pt">
                  <div style="margin-left: 9pt">
                    <div style="margin-left: 9pt; text-indent: -9pt;">Consolidated selling, general and administrative expense<br/>
                    </div>
                  </div>
                </div>
              </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 4px double rgb(0, 0, 0);" valign="bottom">$</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 4px double rgb(0, 0, 0);" valign="bottom">59,020</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td rowspan="1" style="vertical-align: top; width: 64%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td rowspan="1" style="vertical-align: top; width: 64%; background-color: #CCEEFF;" valign="bottom"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: italic; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: nowrap; background-color: rgb(204, 238, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; display: inline !important; float: none;">Reconciliation of income (loss) before taxes:</span></td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td rowspan="1" style="vertical-align: top; text-indent: 9pt; width: 64%;" valign="bottom">Segment income before taxes<br/>
              </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">$</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">43,218</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td rowspan="1" style="vertical-align: top; text-indent: 9pt; width: 64%; background-color: #CCEEFF;" valign="bottom">License revenue<br/>
              </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">143</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td rowspan="1" style="vertical-align: top; width: 64%;" valign="bottom">
                <div style="margin-left: 9pt">
                  <div style="margin-left: 9pt; text-indent: -9pt;">Unallocated interest expense, primaril related to interest on senior debt (see Note 7)<br/>
                  </div>
                </div>
              </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">(25,027</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">)</td>

  </tr>

  <tr style="height: 15px;">

    <td rowspan="1" style="vertical-align: top; text-indent: 9pt; width: 64%; background-color: #CCEEFF;" valign="bottom">Loss on extinguishment of debt (see Note 7)<br/>
              </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">(26,174</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">)</td>

  </tr>

  <tr style="height: 15px;">

    <td rowspan="1" style="vertical-align: top; text-indent: 9pt; width: 64%;" valign="bottom">Unallocated interest income<br/>
              </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">1,589</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td rowspan="1" style="vertical-align: top; text-indent: 9pt; width: 64%; background-color: rgb(204, 238, 255); padding-bottom: 2px;" valign="bottom">Corporate general and administrative expense (a)<br/>
              </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom">(21,988</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; white-space: nowrap;" valign="bottom">)</td>

  </tr>

  <tr style="height: 15px;">

    <td rowspan="1" style="vertical-align: top; text-indent: 18pt; width: 64%; padding-bottom: 4px;" valign="bottom">Consolidated income before taxes<br/>
              </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom">$</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom">(28,239</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">)</td>

  </tr>

  <tr style="height: 15px;">

    <td rowspan="1" style="vertical-align: top; width: 64%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td rowspan="1" style="vertical-align: top; width: 64%;" valign="bottom"><span style="font-style: italic;">Reconciliation of total assets:</span><br/>
              </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td rowspan="1" style="vertical-align: top; text-indent: 9pt; width: 64%; background-color: #CCEEFF;" valign="bottom">Total segment assets<br/>
              </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">$ <br/>
              </td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">281,452</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td rowspan="1" style="vertical-align: top; text-indent: 9pt; width: 64%; padding-bottom: 2px;" valign="bottom">Corporate (b)<br/>
              </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom">47,730</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td rowspan="1" style="vertical-align: top; text-indent: 18pt; width: 64%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom">Consolidated total assets<br/>
              </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 4px double rgb(0, 0, 0);" valign="bottom">$</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 4px double rgb(0, 0, 0);" valign="bottom">329,182</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>
<p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;"> <br/>
        </p>
<table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-spacing: 0;">


  <tr style="vertical-align: top;">

    <td style="text-align: right; vertical-align: top; width: 27pt;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;">(a) - <br/>
                </p>
              </td>

    <td style="text-align: left; vertical-align: top;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: justify;">Primarily includes compensation expense, including stock-based compensation expense, for certain executive officers and consultants, insurance,
                  legal and investor relations expenses and accounting and tax fees that are not allocated to the Company&#8217;s operating segments.</p>
              </td>

  </tr>


</table>
<p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;"> </p><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;"> </p><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;"> <br/>
        </p>
<table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-spacing: 0;">


  <tr style="vertical-align: top;">

    <td style="text-align: right; vertical-align: top; width: 27pt;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;">(b) -<br/>
                </p>
              </td>

    <td style="text-align: left; vertical-align: top;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;">Primarily consists of cash.</p>
              </td>

  </tr>


</table>
<p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;"> </p><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;"> </p><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;"> <br/>
        </p>
<table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="text-align: left; font: 10pt 'Times New Roman'; width: 100%; border-spacing: 0;">


  <tr style="height: 15px;">

    <td colspan="12" style="vertical-align: top; border-bottom: #000000 solid 2px;" valign="bottom">
                  <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: center;"><strong>Year Ended December 31, 2022</strong></p>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td style="padding-bottom: 2px;" valign="bottom">
                  <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: center;"><span style="font-style: italic;">(in thousands)</span><br/>
                  </p>
                </td>

    <td colspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                  <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: center;"><strong>ADMA</strong></p>
                  <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: center;"><strong> BioManufacturing</strong></p>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                  <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: center;"><strong>Plasma Collection<br/>
                    </strong></p>
                  <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: center;"><span style="font-weight: bold;">Centers</span><strong><br/>
                    </strong></p>
                  <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: center;"><strong> </strong></p>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                  <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: center;"><strong>Total</strong></p>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td style="vertical-align: top; width: 64%; background-color: #CCEEFF;" valign="bottom">
                  <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in;">Revenues</p>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">$</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">144,070</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">$</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">9,867</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">$</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">153,937</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td style="width: 64%;" valign="bottom">
                  <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px;">&#160;</p>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td style="vertical-align: top; width: 64%; background-color: #CCEEFF;" valign="bottom">
                  <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in;">Cost of product revenue</p>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">108,882</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">9,933</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">118,815</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td style="width: 64%;" valign="bottom">
                  <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px;">&#160;</p>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td style="vertical-align: top; width: 64%; background-color: #CCEEFF;" valign="bottom">
                  <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in;">Research and development<br/>
                  </p>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">3,614</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">-</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">3,614</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td style="width: 64%;" valign="bottom">
                  <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px;">&#160;</p>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td style="vertical-align: top; width: 64%; background-color: #CCEEFF;" valign="bottom">
                  <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in;">Plasma center operating expenses<br/>
                  </p>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">-</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">17,843</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">17,843</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td style="width: 64%;" valign="bottom">
                  <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px;">&#160;</p>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td rowspan="1" style="vertical-align: top; width: 64%; background-color: #CCEEFF;" valign="bottom">Selling, marketing and distribution<br/>
                </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">13,667</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">-</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">13,667</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td rowspan="1" style="vertical-align: top; width: 64%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td style="vertical-align: top; width: 64%; background-color: #CCEEFF;" valign="bottom">
                  <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in;">Depreciation and amortization expense<br/>
                  </p>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">4,709</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">2,404</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">7,113</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td style="width: 64%;" valign="bottom">
                  <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px;">&#160;</p>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td rowspan="1" style="width: 64%; background-color: #CCEEFF;" valign="bottom">General and administrative expense<br/>
                </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">16,312</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">-</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">16,312</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td rowspan="1" style="width: 64%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td rowspan="1" style="width: 64%; background-color: #CCEEFF;" valign="bottom">Income (loss) before taxes<br/>
                </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">374</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">(17,911</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">)</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">(17,537</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">)</td>

  </tr>

  <tr style="height: 15px;">

    <td rowspan="1" style="width: 64%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td style="vertical-align: top; width: 64%; background-color: #CCEEFF;" valign="bottom">
                  <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in;">Expenditures for additions to long-lived assets<br/>
                  </p>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">5,247</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">8,664</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">13,911</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td style="vertical-align: top; width: 64%;" valign="bottom">
                  <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in;">Total assets</p>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">238,159</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">37,071</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">275,230</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td rowspan="1" style="vertical-align: top; width: 64%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td rowspan="1" style="vertical-align: top; width: 64%;" valign="bottom"><span style="font-style: italic;">Reconciliation of revenues:</span><br/>
                </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td rowspan="1" style="vertical-align: top; text-indent: 9pt; width: 64%; background-color: #CCEEFF;" valign="bottom">Segment revenue<br/>
                </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">$</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">153,937</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td rowspan="1" style="vertical-align: top; text-indent: 9pt; width: 64%; padding-bottom: 2px;" valign="bottom">License revenue (see Note 2 - Revenue Recognition)<br/>
                </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom">143</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td rowspan="1" style="vertical-align: top; text-indent: 18pt; width: 64%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom">Consolidated revenues<br/>
                </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 4px double rgb(0, 0, 0);" valign="bottom">$</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 4px double rgb(0, 0, 0);" valign="bottom">154,080</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td rowspan="1" style="vertical-align: top; width: 64%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td rowspan="1" style="vertical-align: top; width: 64%; background-color: rgb(204, 238, 255); font-style: italic;" valign="bottom">
                  <div style="margin-left: 9pt; text-indent: -9pt;">Reconciliation of selling, general and administrative expense:<br/>
                  </div>
                </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td rowspan="1" style="vertical-align: top; text-indent: 9pt; width: 64%;" valign="bottom">Segment selling, marketing and distribution expense<br/>
                </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">$</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">13,667</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td rowspan="1" style="vertical-align: top; text-indent: 9pt; width: 64%; background-color: #CCEEFF;" valign="bottom">Segment general and administrative expense<br/>
                </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">16,312</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td rowspan="1" style="vertical-align: top; text-indent: 9pt; width: 64%; padding-bottom: 2px;" valign="bottom">Corporate general and administrative expense (a)<br/>
                </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom">22,479</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td rowspan="1" style="vertical-align: top; width: 64%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom">
                  <div style="margin-left: 27pt; text-indent: -9pt;">Consolidated selling, general and administrative expense<br/>
                  </div>
                </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 4px double rgb(0, 0, 0);" valign="bottom">$</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 4px double rgb(0, 0, 0);" valign="bottom">52,458</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td rowspan="1" style="vertical-align: top; width: 64%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td rowspan="1" style="vertical-align: top; width: 64%; background-color: #CCEEFF;" valign="bottom"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: italic; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: nowrap; background-color: rgb(204, 238, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; display: inline !important; float: none;">Reconciliation of income (loss) before taxes:</span> </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td rowspan="1" style="vertical-align: top; text-indent: 9pt; width: 64%;" valign="bottom">Segment income before taxes<br/>
                </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">$</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">(17,537</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">)</td>

  </tr>

  <tr style="height: 15px;">

    <td rowspan="1" style="vertical-align: top; text-indent: 9pt; width: 64%; background-color: #CCEEFF;" valign="bottom">License revenue<br/>
                </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">143</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td rowspan="1" style="vertical-align: top; width: 64%;" valign="bottom">
                  <div style="margin-left: 9pt">
                    <div style="margin-left: 9pt; text-indent: -9pt;">Unallocated interest expense, primaril related to interest on senior debt (see Note 7)<br/>
                    </div>
                  </div>
                </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">(19,276</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">)</td>

  </tr>

  <tr style="height: 15px;">

    <td rowspan="1" style="vertical-align: top; text-indent: 9pt; width: 64%; background-color: #CCEEFF;" valign="bottom">Loss on extinguishment of debt (see Note 7)<br/>
                </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">(6,670</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">)</td>

  </tr>

  <tr style="height: 15px;">

    <td rowspan="1" style="vertical-align: top; text-indent: 9pt; width: 64%;" valign="bottom">Other expense<br/>
                </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">(85</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">)</td>

  </tr>

  <tr style="height: 15px;">

    <td rowspan="1" style="vertical-align: top; text-indent: 9pt; width: 64%; background-color: rgb(204, 238, 255); padding-bottom: 2px;" valign="bottom">Corporate general and administrative expense (a)<br/>
                </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom">(22,479</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; white-space: nowrap;" valign="bottom">)</td>

  </tr>

  <tr style="height: 15px;">

    <td rowspan="1" style="vertical-align: top; text-indent: 18pt; width: 64%; padding-bottom: 4px;" valign="bottom">Consolidated income before taxes<br/>
                </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom">$</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom">(65,904</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">)</td>

  </tr>

  <tr style="height: 15px;">

    <td rowspan="1" style="vertical-align: top; width: 64%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td rowspan="1" style="vertical-align: top; width: 64%;" valign="bottom"><span style="font-style: italic;">Reconciliation of total assets:</span><br/>
                </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td rowspan="1" style="vertical-align: top; text-indent: 9pt; width: 64%; background-color: #CCEEFF;" valign="bottom">Total segment assets<br/>
                </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">$</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">275,230</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td rowspan="1" style="vertical-align: top; text-indent: 9pt; width: 64%; padding-bottom: 2px;" valign="bottom">Corporate (b)<br/>
                </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom">73,231</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td rowspan="1" style="vertical-align: top; text-indent: 18pt; width: 64%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom">Consolidated total assets<br/>
                </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 4px double rgb(0, 0, 0);" valign="bottom">$</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 4px double rgb(0, 0, 0);" valign="bottom">348,461</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>

<div><br/>
          </div>

<div>
            <table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-spacing: 0;">


  <tr style="vertical-align: top;">

    <td style="text-align: right; vertical-align: top; width: 27pt;">
                    <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;">(a) - <br/>
                    </p>
                  </td>

    <td style="text-align: left; vertical-align: top;">
                    <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: justify;">Primarily includes compensation expense, including stock-based compensation expense, for certain executive officers and consultants,
                      insurance, legal and investor relations expenses and accounting and tax fees that are not allocated to the Company&#8217;s operating segments.</p>
                  </td>

  </tr>


</table>
          </div>

<div><br/>
          </div>

<div>
            <table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-spacing: 0;">


  <tr style="vertical-align: top;">

    <td style="text-align: right; vertical-align: top; width: 27pt;">
                    <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;">(b) -<br/>
                    </p>
                  </td>

    <td style="text-align: left; vertical-align: top;">
                    <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;">Primarily consists of cash.</p>
                  </td>

  </tr>


</table>
             </div>

<div style="display:none;"><br/></div>
<div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;"> <br/>
            </div>

<div style="display:none;"><br/></div>
<div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">Net revenues according to geographic area, based on the location of where the product is shipped, are as follows:</div>

<div><br/>
            </div>

<table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%; border-spacing: 0;">


  <tr>

    <td style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="18" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom">
                    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Year Ended December 31, 2024</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">ADMA </div>
                    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">BioManufacturing</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Plasma Centers</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Total Segment </div>
                    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Revenue</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">License </div>
                    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Revenue</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Consolidated </div>
                    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Revenue</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 40%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">United States</div>
                  </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
                  </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;">400,336</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
                  </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;">9,669</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
                  </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;">410,005</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
                  </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;">143</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
                  </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;">410,148</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 40%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">
                    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">International</div>
                  </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;">15,470</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;">836</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;">16,306</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;">-</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;">16,306</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 40%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Total revenues</div>
                  </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
                  </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;">415,806</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
                  </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;">10,505</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
                  </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;">426,311</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
                  </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;">143</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
                  </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;">426,454</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>

<div><br/>
            </div>

<table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%; border-spacing: 0;">


  <tr>

    <td style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="18" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom">
                    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Year Ended December 31, 2023</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">ADMA </div>
                    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">BioManufacturing</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Plasma Centers</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Total Segment </div>
                    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Revenue</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">License </div>
                    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Revenue</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Consolidated </div>
                    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Revenue</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 40%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">United States</div>
                  </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
                  </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;">237,454</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
                  </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;">7,284</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
                  </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;">244,738</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
                  </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;">143</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
                  </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;">244,881</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 40%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">
                    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">International</div>
                  </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;">12,284</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;">1,050</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;">13,334</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;">-</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;">13,334</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 40%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Total revenues</div>
                  </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
                  </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;">249,738</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
                  </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;">8,334</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
                  </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;">258,072</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
                  </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;">143</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
                  </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;">258,215</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>

<div><br/>
            </div>

<table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%; border-spacing: 0;">


  <tr>

    <td style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="18" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom">
                    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Year Ended December 31, 2022</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">ADMA </div>
                    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">BioManufacturing</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Plasma Centers</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Total Segment </div>
                    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Revenue</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">License </div>
                    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Revenue</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Consolidated </div>
                    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Revenue</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 40%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">United States</div>
                  </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
                  </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;">136,827</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
                  </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;">9,457</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
                  </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;">146,284</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
                  </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;">143</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
                  </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;">146,427</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 40%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">
                    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">International</div>
                  </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;">7,243</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;">410</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;">7,653</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;">-</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;">7,653</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 40%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Total revenues</div>
                  </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
                  </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;">144,070</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
                  </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;">9,867</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
                  </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;">153,937</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
                  </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;">143</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
                  </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;">154,080</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 34<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-34<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-15<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/280/tableOfContent<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>OTHER EMPLOYEE BENEFITS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>OTHER EMPLOYEE BENEFITS [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock', window );">OTHER EMPLOYEE BENEFITS</a></td>
<td class="text">
<div>
          <table cellpadding="0" cellspacing="0" class="DSPFListTable" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt; border-spacing: 0;">


  <tr style="vertical-align: top;">

    <td style="vertical-align: top; width: 27pt;">
                  <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: justify;"><strong>14.</strong></p>
                </td>

    <td style="vertical-align: top; width: auto;">
                  <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: justify;"><span style="text-decoration: underline;"><span style="background-color: rgb(255, 255, 255); font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><strong>OTHER EMPLOYEE BENEFITS</strong></span></span><strong><span style="text-decoration: underline;"><br/>
                      </span></strong></p>
                </td>

  </tr>


</table>
        </div>
<p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: justify;">&#160;</p><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-indent: 45px; text-align: justify;">The Company sponsors a 401(k) savings plan. Under the plan, employees may make contributions which are eligible for a Company
          discretionary percentage contribution as defined in the plan and determined by the Board. The Company recognized $1.5 million, $1.3 million and $1.3 million of related
          compensation expense for the years ended December 31, 2024, 2023 and 2022, respectively.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for retirement benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 70<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480794/715-70-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480482/715-20-55-17<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (q)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/715/tableOfContent<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (o)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (p)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480506/715-20-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480126/715-20-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480266/715-60-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowElementsAbstract', window );"><strong>SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowSupplementalDisclosuresTextBlock', window );">SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION</a></td>
<td class="text">
<div>
          <table cellpadding="0" cellspacing="0" class="DSPFListTable" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt; border-spacing: 0;">


  <tr style="vertical-align: top;">

    <td style="vertical-align: top; width: 27pt;">
                  <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;"><strong>15.</strong></p>
                </td>

    <td style="align: left; vertical-align: top; width: auto;">
                  <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;"><span style="text-decoration: underline;"><span style="background-color: rgb(255, 255, 255); font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><strong>SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION</strong></span></span><strong><span style="text-decoration: underline;"><br/>
                      </span></strong></p>
                </td>

  </tr>


</table>
        </div>
<p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;">&#160;</p><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-indent: 45px; text-align: justify;">Supplemental cash flow information for the years ended December 31, 2024, 2023 and 2022 is as follows:</p><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px;">&#160; <br/>
        </p>
<table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="text-align: left; font: 10pt 'Times New Roman'; width: 100%; border-spacing: 0;">


  <tr style="height: 15px;">

    <td style="padding-bottom: 2px;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px;">&#160;</p>
              </td>

    <td colspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: #000000 solid 2px;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: center;"><strong>2024</strong></p>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: #000000 solid 2px;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: center;"><strong>2023</strong></p>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"><span style="font-weight: bold;">2022</span><br/>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td rowspan="1" style="vertical-align: top;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="10" rowspan="1" style="text-align: center;" valign="bottom"><span style="font-style: italic;">(In thousands)</span><br/>
              </td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td style="vertical-align: top;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in;"><strong>SUPPLEMENTAL CASH FLOW INFORMATION:</strong></p>
              </td>

    <td colspan="1" style="vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="2" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="2" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td style="vertical-align: top; width: 64%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 15px;">Cash paid for interest</p>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 4px double rgb(0, 0, 0);" valign="bottom">$</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 4px double rgb(0, 0, 0);" valign="bottom">10,668</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 4px double rgb(0, 0, 0);" valign="bottom">$</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 4px double rgb(0, 0, 0);" valign="bottom">18,051</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom">$</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom">13,880</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td rowspan="1" style="margin-top: 0px; margin-right: 0px; margin-bottom: 0px; vertical-align: top; width: 64%; padding: 0px 0px 4px; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">
                <div style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 15px;">Cash paid for income taxes<br/>
                </div>
              </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom">$</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom">9,392</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom">$<br/>
              </td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom">-</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom">$<br/>
              </td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom">-</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td style="vertical-align: top; width: 64%; background-color: rgb(204, 238, 255);" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in;"><strong>Noncash Financing and Investing Activities:</strong></p>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td style="vertical-align: top; width: 64%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 15px;">Equipment acquired reflected in accounts payable and accrued liabilities</p>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom">$</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom">725</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom">$</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom">86</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom">$</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom">1,495</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td style="vertical-align: top; width: 64%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 15px;">Right-to-use assets in exchange for lease obligations</p>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom">$</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom">-</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom">$</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom">130</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">$</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">4,048</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td style="vertical-align: top; width: 64%; padding-bottom: 4px;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 15px;">Warrants issued in connection with notes payable</p>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom">$</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom">-</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom">$</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom">5,595</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom">$</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom">9,570</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>
<p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;"> <br/>
        </p><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: justify;">See Note 8 and the Consolidated Statement of Stockholders&#8217; Equity for cashless exercise activity related to the Company&#8217;s outstanding warrants.<br/>
        </p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowSupplementalDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for supplemental cash flow activities, including cash, noncash, and part noncash transactions, for the period. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/230/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowSupplementalDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowElementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowElementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONCENTRATIONS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRisksTypesNoConcentrationPercentageAbstract', window );"><strong>CONCENTRATIONS [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskDisclosureTextBlock', window );">CONCENTRATIONS</a></td>
<td class="text">
<div>
          <table cellpadding="0" cellspacing="0" class="DSPFListTable" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt; border-spacing: 0;">


  <tr style="vertical-align: top;">

    <td style="vertical-align: top; width: 27pt;">
                  <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: justify;"><strong>16.</strong></p>
                </td>

    <td style="vertical-align: top; width: auto;">
                  <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: justify;"><span style="text-decoration: underline;"><span style="background-color: rgb(255, 255, 255); font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><strong>CONCENTRATIONS</strong></span></span><strong><span style="text-decoration: underline;"><br/>
                      </span></strong></p>
                </td>

  </tr>


</table>
        </div>
<p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: justify;">&#160;</p><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-indent: 45px; text-align: justify;">Financial instruments that potentially subject the Company to concentrations of credit risk consist of accounts receivable. At December
          31, 2024, three customers accounted for approximately 91% of the Company&#8217;s consolidated accounts receivable. At December 31, 2023, five
          customers accounted for approximately 98% of the Company&#8217;s consolidated accounts receivable. </p><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-indent: 45px; text-align: justify;">&#160;</p><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-indent: 45px; text-align: justify;"><span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">For the years ended December 31, 2024 and 2023, two
            customers accounted for approximately 72% of the Company&#8217;s consolidated revenues. For the year ended December 31, 2022, two customers accounted for approximately 74%
            of the Company&#8217;s consolidated revenues. </span>Revenues for both of these customers are attributable to the ADMA BioManufacturing business segment. There were no customers attributable to the Plasma Collections Center whose revenues exceeded 10%
          of the Company&#8217;s consolidated revenues.</p><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-indent: 45px;"> </p><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-indent: 45px;"> </p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for any concentrations existing at the date of the financial statements that make an entity vulnerable to a reasonably possible, near-term, severe impact. This disclosure informs financial statement users about the general nature of the risk associated with the concentration, and may indicate the percentage of concentration risk as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 275<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/275/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRisksTypesNoConcentrationPercentageAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRisksTypesNoConcentrationPercentageAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE II - VALUATION AND QUALIFYING ACCOUNTS<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ValuationAndQualifyingAccountsAbstract', window );"><strong>Schedule II - Valuation and Qualifying Accounts [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock', window );">Schedule II - Valuation and Qualifying Accounts</a></td>
<td class="text">
<div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Schedule II &#8211; Valuation and Qualifying Accounts</div>

<div><span style="font-size: 10pt; font-family: 'Times New Roman';"> </span></div>

<div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold; text-align: center;">Years ended December 31, 2024, 2023 and 2022</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold; text-align: center;"> <br/>
      </div>

<table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%; border-spacing: 0;">


  <tr>

    <td style="vertical-align: top; font-family: 'Times New Roman'; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: top; font-family: 'Times New Roman';" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="6" rowspan="1" style="vertical-align: top; border-bottom: #000000 solid 2px;" valign="bottom">
            <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Additions</div>
          </td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: top; font-family: 'Times New Roman';" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: top; font-family: 'Times New Roman';" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td colspan="1" style="vertical-align: bottom; text-align: right; padding-bottom: 2px;" valign="bottom"><span style="font-style: italic;">(in thousands)</span><br/>
          </td>

    <td colspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
            <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Balance at</div>
            <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">beginning of year</div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: top; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
            <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Charged to costs</div>
            <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">and expenses</div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: #000000 solid 2px;" valign="bottom">
            <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Other</div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: #000000 solid 2px;" valign="bottom">
            <div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Deductions</div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: top; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
            <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Balance at</div>
            <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">end of year</div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td colspan="1" style="vertical-align: top; border-bottom: #000000 solid 2px;" valign="bottom">
            <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Year ended December 31, 2024</div>
          </td>

    <td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: top; font-family: 'Times New Roman';" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: top; font-family: 'Times New Roman';" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: top; font-family: 'Times New Roman';" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: top; font-family: 'Times New Roman';" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: top; font-family: 'Times New Roman';" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td colspan="1" style="vertical-align: top; width: 40%; background-color: #CCEEFF;" valign="bottom">
            <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; text-indent: 18pt;">Accrued rebates</div>
          </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">
            <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
          </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">
            <div style="font-family: 'Times New Roman'; font-size: 10pt;">16,608</div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">
            <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
          </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">
            <div style="font-family: 'Times New Roman'; font-size: 10pt;">8,514</div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">
            <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
          </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">
            <div style="font-family: 'Times New Roman'; font-size: 10pt;">(12,618</div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
            <div style="font-family: 'Times New Roman'; font-size: 10pt;">)</div>
          </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">
            <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
          </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">
            <div style="font-family: 'Times New Roman'; font-size: 10pt;">8,349</div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">
            <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
          </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">
            <div style="font-family: 'Times New Roman'; font-size: 10pt;">4,155</div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td colspan="1" style="vertical-align: top; width: 40%;" valign="bottom">
            <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; text-indent: -18pt; margin-left: 36pt;">Inventory valuation allowance</div>
          </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">
            <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
          </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">
            <div style="font-family: 'Times New Roman'; font-size: 10pt;">2,992</div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">
            <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
          </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">
            <div style="font-family: 'Times New Roman'; font-size: 10pt;">9,338</div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">
            <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
          </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">
            <div style="font-family: 'Times New Roman'; font-size: 10pt;">118</div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">
            <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
          </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">
            <div style="font-family: 'Times New Roman'; font-size: 10pt;">7,287</div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">
            <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
          </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">
            <div style="font-family: 'Times New Roman'; font-size: 10pt;">5,161</div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td colspan="1" style="vertical-align: top; width: 40%; background-color: #CCEEFF;" valign="bottom">
            <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; text-indent: -9pt; margin-left: 27pt;">Deferred tax asset valuation allowance</div>
          </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">
            <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
          </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">
            <div style="font-family: 'Times New Roman'; font-size: 10pt;">101,421</div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">
            <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
          </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">
            <div style="font-family: 'Times New Roman'; font-size: 10pt;">(84,280</div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
            <div style="font-family: 'Times New Roman'; font-size: 10pt;">)</div>
          </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">
            <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
          </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">
            <div style="font-family: 'Times New Roman'; font-size: 10pt;">-</div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">
            <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
          </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">
            <div style="font-family: 'Times New Roman'; font-size: 10pt;">17,141</div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">
            <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
          </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">
            <div style="font-family: 'Times New Roman'; font-size: 10pt;">-</div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; font-family: 'Times New Roman'; width: 40%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; font-family: 'Times New Roman'; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; font-family: 'Times New Roman'; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; font-family: 'Times New Roman'; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; font-family: 'Times New Roman'; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; font-family: 'Times New Roman'; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; font-family: 'Times New Roman'; width: 40%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; font-family: 'Times New Roman'; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; font-family: 'Times New Roman'; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; font-family: 'Times New Roman'; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; font-family: 'Times New Roman'; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; font-family: 'Times New Roman'; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td colspan="1" style="vertical-align: top; width: 40%; border-bottom: #000000 solid 2px;" valign="bottom">
            <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Year ended December 31, 2023</div>
          </td>

    <td colspan="1" style="text-align: right; font-family: 'Times New Roman'; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; font-family: 'Times New Roman'; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; font-family: 'Times New Roman'; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; font-family: 'Times New Roman'; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; font-family: 'Times New Roman'; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td colspan="1" style="vertical-align: top; width: 40%; background-color: #CCEEFF;" valign="bottom">
            <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; text-indent: 18pt;">Accrued rebates</div>
          </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">
            <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
          </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">
            <div style="font-family: 'Times New Roman'; font-size: 10pt;">11,437</div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">
            <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
          </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">
            <div style="font-family: 'Times New Roman'; font-size: 10pt;">8,448</div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; font-family: 'Times New Roman'; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">$ <br/>
          </td>

    <td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">-</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">
            <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
          </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">
            <div style="font-family: 'Times New Roman'; font-size: 10pt;">3,277</div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">
            <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
          </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">
            <div style="font-family: 'Times New Roman'; font-size: 10pt;">16,608</div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td colspan="1" style="vertical-align: top; width: 40%;" valign="bottom">
            <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; text-indent: -9pt; margin-left: 27pt;">Inventory valuation allowance</div>
          </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">
            <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
          </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">
            <div style="font-family: 'Times New Roman'; font-size: 10pt;">5,400</div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">
            <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
          </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">
            <div style="font-family: 'Times New Roman'; font-size: 10pt;">6,963</div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">
            <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
          </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">
            <div style="font-family: 'Times New Roman'; font-size: 10pt;">6</div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">
            <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
          </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">
            <div style="font-family: 'Times New Roman'; font-size: 10pt;">9,377</div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">
            <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
          </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">
            <div style="font-family: 'Times New Roman'; font-size: 10pt;">2,992</div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td colspan="1" style="vertical-align: top; width: 40%; background-color: #CCEEFF;" valign="bottom">
            <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; text-indent: -9pt; margin-left: 27pt;">Deferred tax asset valuation allowance</div>
          </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">
            <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
          </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">
            <div style="font-family: 'Times New Roman'; font-size: 10pt;">96,725</div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">
            <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
          </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">
            <div style="font-family: 'Times New Roman'; font-size: 10pt;">4,696</div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">
            <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
          </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">
            <div style="font-family: 'Times New Roman'; font-size: 10pt;">-</div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">
            <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
          </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">
            <div style="font-family: 'Times New Roman'; font-size: 10pt;">-</div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">
            <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
          </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">
            <div style="font-family: 'Times New Roman'; font-size: 10pt;">101,421</div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; font-family: 'Times New Roman'; width: 40%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; font-family: 'Times New Roman'; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; font-family: 'Times New Roman'; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; font-family: 'Times New Roman'; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; font-family: 'Times New Roman'; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; font-family: 'Times New Roman'; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: top; font-family: 'Times New Roman'; width: 40%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; font-family: 'Times New Roman'; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; font-family: 'Times New Roman'; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; font-family: 'Times New Roman'; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; font-family: 'Times New Roman'; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; font-family: 'Times New Roman'; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td colspan="1" style="vertical-align: top; width: 40%; border-bottom: #000000 solid 2px;" valign="bottom">
            <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Year ended December 31, 2022</div>
          </td>

    <td colspan="1" style="text-align: right; font-family: 'Times New Roman'; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; font-family: 'Times New Roman'; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; font-family: 'Times New Roman'; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; font-family: 'Times New Roman'; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; font-family: 'Times New Roman'; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td colspan="1" style="vertical-align: top; width: 40%; background-color: #CCEEFF;" valign="bottom">
            <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; text-indent: 18pt;">Accrued rebates</div>
          </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">
            <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
          </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">
            <div style="font-family: 'Times New Roman'; font-size: 10pt;">5,040</div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">
            <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
          </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">
            <div style="font-family: 'Times New Roman'; font-size: 10pt;">8,227</div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"><br/>
          </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">
            <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
          </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">
            <div style="font-family: 'Times New Roman'; font-size: 10pt;">1,830</div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">
            <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
          </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">
            <div style="font-family: 'Times New Roman'; font-size: 10pt;">11,437</div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td colspan="1" style="vertical-align: top; width: 40%;" valign="bottom">
            <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; text-indent: -9pt; margin-left: 27pt;">Inventory valuation allowance</div>
          </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">
            <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
          </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">
            <div style="font-family: 'Times New Roman'; font-size: 10pt;">8,577</div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">
            <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
          </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">
            <div style="font-family: 'Times New Roman'; font-size: 10pt;">2,744</div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">
            <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
          </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">
            <div style="font-family: 'Times New Roman'; font-size: 10pt;">-</div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">
            <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
          </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">
            <div style="font-family: 'Times New Roman'; font-size: 10pt;">5,921</div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">
            <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
          </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">
            <div style="font-family: 'Times New Roman'; font-size: 10pt;">5,400</div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td colspan="1" style="vertical-align: top; width: 40%; background-color: #CCEEFF;" valign="bottom">
            <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; text-indent: -9pt; margin-left: 27pt;">Deferred tax asset valuation allowance</div>
          </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">
            <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
          </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">
            <div style="font-family: 'Times New Roman'; font-size: 10pt;">81,608</div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">
            <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
          </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">
            <div style="font-family: 'Times New Roman'; font-size: 10pt;">15,117</div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">
            <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
          </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">
            <div style="font-family: 'Times New Roman'; font-size: 10pt;">-</div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">
            <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
          </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">
            <div style="font-family: 'Times New Roman'; font-size: 10pt;">-</div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">
            <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
          </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">
            <div style="font-family: 'Times New Roman'; font-size: 10pt;">96,725</div>
          </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for valuation and qualifying accounts and reserves.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 12<br> -Subsection 09<br> -Publisher SEC<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ValuationAndQualifyingAccountsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ValuationAndQualifyingAccountsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CYBERSECURITY RISK MANAGEMENT AND STRATEGY DISCLOSURE<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract', window );"><strong>Cybersecurity Risk Management, Strategy, and Governance [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock', window );">Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]</a></td>
<td class="text">
<div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"><span style="text-decoration: underline;">Risk Management and Strategy</span></div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">We recognize the importance of managing the material risks of cybersecurity threats, and we have implemented processes for identifying and assessing cybersecurity
            risks and incidents. <span style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000;">We have also integrated these processes into our overall risk management system, including senior management&#8217;s periodic reviews of cybersecurity risks or threats. Senior management oversees and works closely with our IT department to continuously review and evaluate cybersecurity risks in alignment with
            our business goals and needs.</span></div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
          </div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">With respect to cybersecurity risks and threats, we utilize various third-party consultants and advisors to assist us with regular reviews, internal audits and best practices, including threat prevention and detection, security reviews and enhancements, penetration testing and full scope IT audits.
            ADMA also has strict processes in place for the review of third-party service providers engaged, including thorough security assessments before engagement and annual monitoring of their IT environments and controls.</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
          </div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">During the year ended December 31, 2023, as initially disclosed in our Quarterly Report on Form 10-Q for the period ending June 30, 2023 and updated elsewhere in our
            subsequent filings with the SEC, we experienced an IT systems disruption, which did result in a non-recurring charge to our results of operations.
            There was no original financial systems data loss or any evidence of data exfiltrated due to this disruption. Normal course operations quickly resumed across the Company&#8217;s business units.</div>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesIntegratedFlag', window );">Cybersecurity Risk Management Processes Integrated [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock', window );">Cybersecurity Risk Management Processes Integrated [Text Block]</a></td>
<td class="text"><span style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000;">We have also integrated these processes into our overall risk management system, including senior management&#8217;s periodic reviews of cybersecurity risks or threats. Senior management oversees and works closely with our IT department to continuously review and evaluate cybersecurity risks in alignment with
            our business goals and needs.</span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementThirdPartyEngagedFlag', window );">Cybersecurity Risk Management Third Party Engaged [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag', window );">Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag', window );">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock', window );">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block]</a></td>
<td class="text">
<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">During the year ended December 31, 2023, as initially disclosed in our Quarterly Report on Form 10-Q for the period ending June 30, 2023 and updated elsewhere in our
            subsequent filings with the SEC, we experienced an IT systems disruption, which did result in a non-recurring charge to our results of operations.
            There was no original financial systems data loss or any evidence of data exfiltrated due to this disruption. Normal course operations quickly resumed across the Company&#8217;s business units.</div>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock', window );">Cybersecurity Risk Board of Directors Oversight [Text Block]</a></td>
<td class="text">
<div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"><span style="text-decoration: underline;">Governance</span></div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">Our President and Chief Executive Officer and Chief Operating Officer are primarily responsible for timely updating the Board and Audit Committee about any material
            cybersecurity incidents or threats or any cybersecurity related issues worthy of their attention.</div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
          </div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000;">Our Board has designated the Audit Committee as the primary committee responsible for reviewing and managing cybersecurity risks and threats at ADMA.</span> <span style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000;">The Audit Committee is comprised of Board members with diverse experience in healthcare, finance and information
            technology, enabling them to effectively oversee cybersecurity risks and threats.</span> <span style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000;">Our management team, with
            assistance from third-party consultants or advisors as appropriate, provides quarterly updates regarding cybersecurity risks and threats to the Audit Committee and ad hoc updates or communications are provided to the entire Board as needed.</span></div>

<div style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
          </div>

<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000;">The Data Integrity and IT Operations team are primarily responsible for the timely identification, review, severity assessment and management of cybersecurity incidents.</span> In the event of a cybersecurity incident, the IT Department leadership follows the procedures outlined in our Cybersecurity Incident Response Policy and works closely with
            management to form a Security Incident Response Team comprised of members from the appropriate functional teams. In accordance with this policy, senior management will also communicate the occurrence of any significant cybersecurity incidents to our Board, Audit Committee and auditors on a timely basis and will keep them informed of the remediation plans and progress.</div>
<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock', window );">Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]</a></td>
<td class="text"><span style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000;">Our Board has designated the Audit Committee as the primary committee responsible for reviewing and managing cybersecurity risks and threats at ADMA.</span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock', window );">Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]</a></td>
<td class="text"><span style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000;">Our management team, with
            assistance from third-party consultants or advisors as appropriate, provides quarterly updates regarding cybersecurity risks and threats to the Audit Committee and ad hoc updates or communications are provided to the entire Board as needed.</span><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskRoleOfManagementTextBlock', window );">Cybersecurity Risk Role of Management [Text Block]</a></td>
<td class="text">
<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000;">The Data Integrity and IT Operations team are primarily responsible for the timely identification, review, severity assessment and management of cybersecurity incidents.</span> In the event of a cybersecurity incident, the IT Department leadership follows the procedures outlined in our Cybersecurity Incident Response Policy and works closely with
            management to form a Security Incident Response Team comprised of members from the appropriate functional teams. In accordance with this policy, senior management will also communicate the occurrence of any significant cybersecurity incidents to our Board, Audit Committee and auditors on a timely basis and will keep them informed of the remediation plans and progress.</div>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag', window );">Cybersecurity Risk Management Positions or Committees Responsible [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock', window );">Cybersecurity Risk Management Positions or Committees Responsible [Text Block]</a></td>
<td class="text"><span style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000;">The Data Integrity and IT Operations team are primarily responsible for the timely identification, review, severity assessment and management of cybersecurity incidents.</span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock', window );">Cybersecurity Risk Management Expertise of Management Responsible [Text Block]</a></td>
<td class="text"><span style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000;">The Audit Committee is comprised of Board members with diverse experience in healthcare, finance and information
            technology, enabling them to effectively oversee cybersecurity risks and threats.</span><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock', window );">Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]</a></td>
<td class="text">
<div style="display:none;"><br/></div>
<div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;"><span style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000;">The Data Integrity and IT Operations team are primarily responsible for the timely identification, review, severity assessment and management of cybersecurity incidents.</span> In the event of a cybersecurity incident, the IT Department leadership follows the procedures outlined in our Cybersecurity Incident Response Policy and works closely with
            management to form a Security Incident Response Team comprised of members from the appropriate functional teams. In accordance with this policy, senior management will also communicate the occurrence of any significant cybersecurity incidents to our Board, Audit Committee and auditors on a timely basis and will keep them informed of the remediation plans and progress.</div>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag', window );">Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph iii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph iii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesIntegratedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesIntegratedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementThirdPartyEngagedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph ii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph ii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementThirdPartyEngagedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 2<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 2<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph ii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph ii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskRoleOfManagementTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskRoleOfManagementTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph iii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph iii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INSIDER TRADING ARRANGEMENTS<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2024 </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual [Table]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrAdoptedFlag', window );">Non-Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrTrmntdFlag', window );">Non-Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_IndividualAxis=adma_AdamGrossmanMember', window );">Adam Grossman [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual [Table]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrTrmntdFlag', window );">Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_MtrlTermsOfTrdArrTextBlock', window );">Material Terms of Trading Arrangement</a></td>
<td class="text">
<div style="display:none;"><br/></div>
<div style="text-indent: 36pt;">During the quarter ended December 31, 2024, none of our directors or executive officers adopted or terminated any such contract, instruction or written plans except for Adam Grossman, our President and CEO, who entered into a Rule 105b-1 trading plan with Fidelity Brokerage Services LLC on December 5, 2024 (the &#8220;Grossman Plan&#8221;).&#160;The Grossman Plan provides that Mr. Grossman may sell up to an aggregate of (i) 60,000
        shares of our common stock and (ii) 150,000 shares of our common stock to be received upon the exercise of vested options granted to Mr.
        Grossman. The Grossman Plan is scheduled to terminate on December 31, 2025, subject to earlier <span style="-sec-ix-hidden:Fact_7095587f31264a6b95943ba8d0a4f402">termination</span> upon the sale of all shares subject to the plan, upon termination by Mr. Grossman or the broker, or as otherwise provided in the plan.</div>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrIndName', window );">Name</a></td>
<td class="text">Adam Grossman<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrIndTitle', window );">Title</a></td>
<td class="text">President and CEO<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrAdoptionDate', window );">Adoption Date</a></td>
<td class="text">December 5, 2024<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrExpirationDate', window );">Expiration Date</a></td>
<td class="text">December 31, 2025<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrDuration', window );">Arrangement Duration</a></td>
<td class="text">391 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrAxis=adma_AdamGrossmanTradingPlanCommonStockMember', window );">Adam Grossman Trading Plan, Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual [Table]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrSecuritiesAggAvailAmt', window );">Aggregate Available</a></td>
<td class="nump">60,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrAxis=adma_AdamGrossmanTradingPlanStockOptionsMember', window );">Adam Grossman Trading Plan, Stock Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual [Table]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrSecuritiesAggAvailAmt', window );">Aggregate Available</a></td>
<td class="nump">150,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_MtrlTermsOfTrdArrTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_MtrlTermsOfTrdArrTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TradingArrByIndTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TradingArrByIndTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrAdoptionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrAdoptionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrDuration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph C<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrDuration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrExpirationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph C<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrExpirationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrIndName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrIndName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrIndTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrIndTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrSecuritiesAggAvailAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph D<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrSecuritiesAggAvailAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_IndividualAxis=adma_AdamGrossmanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_IndividualAxis=adma_AdamGrossmanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TradingArrAxis=adma_AdamGrossmanTradingPlanCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TradingArrAxis=adma_AdamGrossmanTradingPlanCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TradingArrAxis=adma_AdamGrossmanTradingPlanStockOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TradingArrAxis=adma_AdamGrossmanTradingPlanStockOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>SIGNIFICANT ACCOUNTING POLICIES [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock', window );">Principles of Consolidation and Basis of Presentation</a></td>
<td class="text"><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;"><span style="text-decoration:underline">Principles of consolidation and basis of presentation</span></p><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;">&#160;</p><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-indent: 45px; text-align: left;">The accompanying consolidated financial statements include the accounts of ADMA and its wholly-owned subsidiaries and have been prepared
          in conformity with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;) and in accordance with Article 3 of Regulation S-X of the Securities and Exchange Commission (the &#8220;SEC&#8221;). All intercompany balances have
          been eliminated in consolidation. Any reference in these notes to applicable guidance is meant to refer to U.S. GAAP as found in the Accounting Standards Codification (&#8220;ASC&#8221;) and Accounting Standards Updates (&#8220;ASU&#8221;) of the Financial Accounting
          Standards Board (the &#8220;FASB&#8221;). </p><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-indent: 45px; text-align: left;"> <span style="font-size: 10pt; font-family: 'Times New Roman';"><br/>
          </span></p><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-indent: 45px; text-align: left;">During the years ended December 31, 2024, 2023 and 2022, <span style="font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">comprehensive income (loss) was equal to the net income (loss) amounts presented for the respective periods in the accompanying consolidated statements of operations.&#160;</span><span style="font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial;">In addition, certain prior year balances have been reclassified to conform to the current presentation. Specifically, the disaggregation of some of the Company&#8217;s accrued expenses and other current liabilities
            (see Note 6) and deferred tax assets and liabilities, as well as the rate reconciliation for U.S. federal income taxes (see Note 11), as of December 31, 2023 have been adjusted to conform to the presentation as of December 31, 2024</span>.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text">
<div><span style="font-family: 'Times New Roman'; font-size: 10pt;"><span style="text-decoration: underline;"></span></span></div>
<p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 9pt; text-indent: -9pt; text-align: left;"><span style="text-decoration: underline;">Use of estimates</span></p><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 9pt; text-indent: -9pt; text-align: left;"> <span style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
          </span> </p><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-indent: 45px; text-align: left;">The preparation of financial statements requires management to make estimates and assumptions that affect the reported amounts of assets
          and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.
          Significant estimates include rebates and chargebacks deducted from gross revenues, assumptions used in the fair value of awards granted under the Company&#8217;s equity incentive plans and the valuation allowance for the Company&#8217;s deferred tax assets.</p><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-indent: 45px; text-align: left;"><span style="font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"> <br/>
          </span></p><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-indent: 45px; text-align: left; font-weight: normal; font-style: normal; font-variant: normal; text-transform: none;"><span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; text-align: left; text-indent: 48px; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">The
            Company engaged a third-party specialist to assist in the evaluation of the Company&#8217;s accrual for U.S. Medicaid rebates related to the sale of the Company&#8217;s immunoglobulin products. As a result of this evaluation, the Company recognized a
            reduction in this accrual and a corresponding increase to net revenues of $12.6 million for the year ended December 31, 2024. The
            Company considered several qualitative factors when evaluating its rebate accrual, such as the absence of a statutory limitation on the rebate amounts drug manufacturers pay to state Medicaid programs and general uncertainty that pharmaceutical
            manufacturers have historically seen with government payors often submitting lagged claims many periods after the initial dispensing of a product to an end patient. There was additional new information that arose during June 2024 that suggested
            the Company&#8217;s liabilities for certain payor claims were successfully resolved, which resulted in the $12.6 million adjustment to the
            accrual for U.S. Medicaid rebates in June 2024.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;"><span style="text-decoration:underline">Cash and cash equivalents</span></p><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;">&#160;</p><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-indent: 45px; text-align: left;">The Company considers all highly liquid instruments purchased with a maturity of three months or less to be cash equivalents. </p>
<div><span style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
        </span></div>
<p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-indent: 45px; text-align: left;">The Company regularly maintains cash and cash equivalents at third-party financial institutions in excess of the Federal Deposit Insurance
          Corporation insurance limit. Although the Company monitors the daily cash balances in its operating accounts and adjusts the balances as appropriate, these balances could be impacted, and there could be a material adverse effect on the Company&#8217;s
          business, if one or more of the financial institutions with which the Company has deposits fails or is subject to other adverse conditions in the financial or credit markets. To date, the Company has not experienced a loss or lack of access to
          its deposited cash or cash equivalents; however, the Company cannot provide assurance that access to its cash and cash equivalents will not be impacted by adverse conditions in the financial and credit markets in the future.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivablesPolicyTextBlock', window );">Accounts Receivable</a></td>
<td class="text"><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;"><span style="text-decoration:underline">Accounts receivable</span></p><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;">&#160;</p><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-indent: 45px; text-align: left;"><span style="font-family: 'Times New Roman'; font-size: 10pt;">Accounts receivable is reported at realizable value, net of allowances for
            contractual credits and doubtful accounts in the amount of $0.2 million and $0.1 million at December 31, 2024 and 2023, respectively, which are recognized in the period the related revenue is recorded. The Company extends credit to its customers
            based upon an evaluation of each customer&#8217;s financial condition and credit history. Evaluations of the financial condition and associated credit risk of customers are performed on an ongoing basis.<br/>
          </span> </p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventories</a></td>
<td class="text"><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;"><span style="text-decoration:underline">Inventories</span></p><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;">&#160;</p><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-indent: 45px; text-align: left;">Raw materials inventory consists of <span style="font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"><span style="font-weight: normal; font-style: normal; font-variant: normal; text-transform: none;">normal source plasma (&#8220;NSP&#8221;) and Respiratory Syncytial Virus (&#8220;RSV&#8221;) high titer plasma collected at the Company&#8217;s plasma collection
              facilities or purchased from third parties, along with</span> </span>various materials purchased from suppliers, used in the production of the Company&#8217;s products. Work-in-process and finished goods inventories (see Note 3) reflect the cost
          of raw materials as well as costs for direct and indirect labor, primarily salaries, wages and benefits for applicable employees, as well as an allocation of overhead costs related to the Boca Facility including utilities, property taxes, general
          repairs and maintenance, consumable supplies and depreciation. The allocation of Boca Facility overhead to inventory is generally based upon the estimated square footage of the Boca Facility that is used in the production of the Company&#8217;s
          products relative to the total square footage of the facility. </p><p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-bottom: 0px; text-align: left;"> </p>
<div><br/></div>

<div style="display:none;"><br/></div>
<div style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-indent: 45px; text-align: left;">Inventories, including plasma intended for resale and plasma intended for internal use in the Company&#8217;s manufacturing, commercialization
          or research and development activities, are carried at the lower of cost or net realizable value determined by the first-in, first-out method. For both the Company&#8217;s immune globulin products and plasma intended for resale and internal use, net
          realizable value is generally determined based upon the consideration the Company expects to receive when the inventory is sold, less costs to deliver the inventory to the recipient. The estimates for net realizable value of inventory are based
          on contractual terms or upon historical experience and certain other assumptions, and the Company believes that such assumptions are reasonable. Inventory is periodically reviewed to ensure that its carrying value does not exceed its net
          realizable value, and adjustments are recorded to write down such inventory, with a corresponding charge to cost of product revenue, when the carrying value or historical cost exceeds its estimated net realizable value. In addition, costs
          associated with the production of engineering lots that would not qualify as immediately available for commercial sale are charged to cost of product revenue and not capitalized into inventory.</div>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text"><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;"><span style="text-decoration: underline; font-family: 'Times New Roman'; font-size: 10pt;">Property and equipment</span> </p><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;">&#160;</p><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-indent: 45px; text-align: left;"><span style="font-family: 'Times New Roman'; font-size: 10pt;">Assets comprising property and equipment (see Note 4) are stated at cost
            less accumulated depreciation. Depreciation is calculated using the straight-line method over the asset&#8217;s estimated useful life. Land is not depreciated. The buildings have been assigned a useful life of 30 years. Property and equipment other than land and buildings have useful lives ranging from 3 to 15 years. Leasehold improvements are amortized over the
            lesser of the lease term or their estimated useful lives.</span> </p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy', window );">Goodwill</a></td>
<td class="text"><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;"><span style="text-decoration:underline">Goodwill</span></p><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;">&#160;</p><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-indent: 45px; text-align: left;">Goodwill represents the excess of purchase price over the fair value of net assets acquired by the Company. Goodwill at December 31, 2024
          and 2023 was $3.5 million, all of which is attributable to the Company&#8217;s ADMA BioManufacturing business segment. There were no changes to the carrying amount of goodwill during the years ended December 31, 2024, 2023 and 2022.</p>
<div><span style="font-family: 'Times New Roman'; font-size: 10pt;"> &#160; </span></div>
<p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-indent: 45px; text-align: left;">Goodwill is not amortized but is assessed for impairment on an annual basis or more frequently if impairment indicators exist. The Company
          has the option to perform a qualitative assessment of goodwill to determine whether it is more likely than not that the fair value of its reporting unit is less than its carrying amount, including goodwill and other intangible assets. If the
          Company concludes that this is the case, then it must perform a goodwill impairment test by comparing the fair value of the reporting unit to its carrying value. An impairment charge is recorded to the extent the reporting unit&#8217;s carrying value
          exceeds its fair value, not to exceed the total amount of goodwill allocated to that reporting unit. The Company performs its annual goodwill impairment assessment as of October 1 of each year. The Company&#8217;s annual goodwill impairment assessments
          as of October 1, 2024, 2023 and 2022 did not result in any impairment charges related to goodwill for the years ended December 31, 2024, 2023 and 2022.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock', window );">Impairment of Long-Lived Assets</a></td>
<td class="text"><p style="margin: 0px; font-family: 'Times New Roman'; font-size: 10pt; text-align: left;"><span style="text-decoration:underline">Impairment of long-lived assets</span></p><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;">&#160;</p><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-indent: 45px; text-align: left;">The Company assesses the recoverability of its long-lived assets, which include property and equipment and finite-lived intangible assets,
          whenever significant events or changes in circumstances indicate impairment may have occurred. If indicators of impairment exist, projected future undiscounted cash flows associated with the asset are compared to its carrying amount to determine
          whether the asset&#8217;s carrying value is recoverable. Any resulting impairment is recorded as a reduction in the carrying value of the related asset in excess of fair value and a charge to operating results. For the years ended December 31, 2024,
          2023 and 2022, the Company determined that there was no impairment of its long-lived assets. </p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><p style="margin: 0px; font-family: 'Times New Roman'; font-size: 10pt; text-align: left;"><span style="text-decoration:underline">Revenue recognition</span></p><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;">&#160;</p><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-indent: 45px; text-align: left;">Revenues for the years ended December 31, 2024, 2023 and 2022 are comprised of (i) revenues from the sale of the Company&#8217;s immunoglobulin
          products, ASCENIV, BIVIGAM and Nabi-HB, (ii) product revenues from the sale of human plasma collected by the Company&#8217;s Plasma Collection Centers business segment, (iii) contract manufacturing and laboratory services revenue, (iv) revenues from
          the sale of intermediate by-products and (v) license and other revenues primarily attributable to the out-licensing of ASCENIV to Biotest AG (&#8220;Biotest&#8221;) in 2012 to market and sell this product in Europe and selected countries in North Africa and
          the Middle East. Biotest has provided the Company with certain services and financial payments in accordance with the related Biotest license agreement and is obligated to pay the Company certain amounts in the future if certain milestones are
          achieved. Deferred revenue is amortized into income over the term of the Biotest license, representing a period of approximately 22 years.
        </p>
<div><br/></div>

<div style="display:none;"><br/></div>
<div style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-indent: 45px; text-align: left;">Product revenue is recognized when the customer is deemed to have control over the product and the performance obligation is satisfied.
          Control is determined based on when the product is shipped or delivered and title passes to the customer. Revenue is recorded in an amount that reflects the consideration the Company expects to receive in exchange. Revenue from the sale of the
          Company&#8217;s immunoglobulin products is recognized when the product reaches the customer&#8217;s destination, and is recorded net of estimated rebates, <span style="font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">wholesaler distribution and related
            fees, customer incentives, including prompt pay discounts, wholesaler chargebacks, group purchasing organization fees and reimbursements for patient assistance. These estimates are based on contractual arrangements, historical experience and
            certain other assumptions, and while the Company believes that such estimates are reasonable, they are subject to change based on future developments and other factors.</span></div>

<div style="display:none;"><br/></div>
<div style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-indent: 45px; text-align: left;"><span style="font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"> <br/>
          </span></div>

<div style="display:none;"><br/></div>
<div style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-indent: 45px; text-align: left;"><span style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">For revenues
            associated with contract manufacturing and the sale of intermediates, control transfers to the customer and the performance obligation is satisfied when the customer takes possession of the product from the Boca Facility</span><span style="font-family: 'Times New Roman'; font-size: 10pt;">.</span></div>
<p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-indent: 45px; text-align: left;">&#160;</p><p style="margin: 0px; font-family: 'Times New Roman'; font-size: 10pt; text-align: left; text-indent: 45px;">Product revenues from the sale of human plasma collected at the Company&#8217;s plasma collection centers are recognized at the time control of
          the product has been transferred to the customer<span style="font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"> and the performance obligation is satisfied, which generally occurs at the time of shipment from
            one of the Company&#8217;s plasma collection facilities or from a third-party warehouse that is utilized by the Company. Product revenues are recognized at the time of delivery if the Company retains control of the product during shipment</span>.</p><p style="margin: 0px; font-family: 'Times New Roman'; font-size: 10pt; text-align: left; text-indent: 45px;"> <br/>
        </p><p style="margin: 0px; font-family: 'Times New Roman'; font-size: 10pt; text-align: left; text-indent: 45px;"><span style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">For all of the Company&#8217;s product revenues, payment from the customer is typically due within 90 days of sale.</span><span style="font-size: 10pt; font-family: 'Times New Roman';"> </span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfSalesPolicyTextBlock', window );">Cost of Product Revenue</a></td>
<td class="text"><p style="margin: 0px; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-align: left; text-indent: 0px; text-transform: none;"><span style="text-decoration: underline;">Cost of product revenue</span></p><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;">&#160;</p><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-indent: 45px; text-align: left;"><span style="font-family: 'Times New Roman'; font-size: 10pt;">Cost of product revenue includes costs associated with the manufacture of
            the Company&#8217;s FDA approved products and intermediates and for the collection of human source plasma, as well as expenses related to conformance batch production, process development and scientific and technical operations when these operations
            are attributable to marketed products. When the activities of these operations are attributable to new products in development, the expenses are classified as research and development expenses.</span> </p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expenses</a></td>
<td class="text"><p style="margin: 0px; font-family: 'Times New Roman'; font-size: 10pt; text-align: left; text-indent: 0px;"><span style="text-decoration:underline">Research and development expenses</span></p><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;">&#160;</p><p style="margin: 0px; font-family: 'Times New Roman'; font-size: 10pt; text-align: left; text-indent: 45px;"><span style="font-family: 'Times New Roman'; font-size: 10pt;">Research and development expenses consist of clinical research organization
            costs, costs related to clinical trials, post-marketing commitment studies for BIVIGAM and ASCENIV and salaries, benefits and stock-based compensation for employees directly related to research and development activities. All research and
            development costs are expensed as incurred.</span> </p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_OtherOperatingExpensesPolicyTextBlock', window );">Plasma Center Operating Expenses</a></td>
<td class="text">
<div style="display:none;"><br/></div>
<div style="margin: 0px; font-family: 'Times New Roman'; font-size: 10pt; text-align: left; text-indent: 0px;"><span style="text-decoration: underline;">Plasma center operating expenses</span></div>

<div style="display:none;"><br/></div>
<div style="margin: 0px; font-family: 'Times New Roman'; font-size: 10pt; text-align: left; text-indent: 0px;"><span style="text-decoration: underline;"> <br/>
          </span></div>

<div style="display:none;"><br/></div>
<div style="margin: 0px; font-family: 'Times New Roman'; font-size: 10pt; text-align: left; text-indent: 45px;">Plasma center operating expenses consist of certain general and administrative plasma center costs, initial opening, marketing and
          start-up costs, rent expense, maintenance, utilities and compensation and benefits for administrative staff.</div>
<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdvertisingCostsPolicyTextBlock', window );">Advertising and Marketing Expenses</a></td>
<td class="text"><p style="margin: 0px; font-family: 'Times New Roman'; font-size: 10pt; text-align: left; text-indent: 0px;"><span style="text-decoration:underline">Advertising and marketing expenses</span></p><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;">&#160;</p><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-indent: 45px; text-align: left;">Advertising and marketing expense includes cost for promotional materials and trade show expenses for the marketing of the Company&#8217;s
          products and expenses incurred for attracting donors to the Company&#8217;s plasma collection centers. All advertising and marketing expenses are expensed as incurred.&#160; Advertising and marketing expenses were $2.7 million, $3.3 million and $2.2 million for the years ended December 31, 2024, 2023 and 2022, respectively.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-Based Compensation</a></td>
<td class="text"><p style="margin: 0px; font-family: 'Times New Roman'; font-size: 10pt; text-align: left; text-indent: 0px;"><span style="text-decoration:underline">Stock-based compensation</span></p><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;">&#160;</p><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-indent: 45px; text-align: left;">The Company follows recognized accounting guidance which requires all equity-based payments, including grants of stock options and
          restricted stock unit awards (&#8220;RSUs&#8221;), to be recognized in the statement of operations as compensation expense based on their fair values at the date of grant. Compensation expense related to awards to employees and directors with service-based
          vesting conditions is recognized on a straight-line basis over the associated vesting period of the award based on the grant date fair value of the award. Stock options granted to employees under the Company&#8217;s equity incentive plans generally
          have a four-year vesting period and a term of 10 years. RSUs granted to employees also have a four-year vesting period. For milestone-based equity
          awards, <span style="font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">which were awarded to two
            of the Company&#8217;s executive officers in September of 2021 and vested during fiscal 2022,</span> the Company would periodically assess the probability of vesting for each milestone-based award and adjust compensation expense based on its
          probability assessment. Pursuant to ASU No. 2016-09, <span style="font-style: italic;">Improvements to Employee Share-Based Payment Accounting (Topic 718)</span>, the Company has elected not to establish a forfeiture rate, as stock-based
          compensation expense related to forfeitures of unvested equity awards is fully reversed at the time of forfeiture.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="margin: 0px; font-family: 'Times New Roman'; font-size: 10pt; text-align: left; text-indent: 0px;"><span style="text-decoration:underline">Income taxes</span></p><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;">&#160;</p><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-indent: 45px; text-align: left;">The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of events that have been included in
          the consolidated financial statements or its tax returns. Under this method, deferred tax assets and liabilities are recognized for the temporary differences between the tax bases of assets and liabilities and their respective financial reporting
          amounts at enacted tax rates in effect for the years in which the temporary differences are expected to reverse. The Company records a valuation allowance on its deferred tax assets if it is more likely than not that the Company will not generate
          sufficient taxable income to utilize its deferred tax assets (see Note 11). The Company is subject to income tax examinations by major taxing authorities for all tax years since 2020 and for previous periods as it relates to the Company&#8217;s net
          operating loss carryforwards.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Earnings (Loss) Per Share</a></td>
<td class="text"><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 9pt; text-align: left; text-indent: -9pt;"><span style="font-family: 'Times New Roman'; font-size: 10pt;"><span style="text-decoration: underline;">Earnings (Loss) Per Share</span></span> </p><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 9pt; text-align: left; text-indent: -9pt;"><span style="text-decoration: underline;"> <br/>
          </span></p><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-indent: 45px; text-align: left;">Basic earnings (loss) per share is computed by dividing net income or loss attributable to common stockholders by the weighted average
          number of shares of common stock outstanding during the period. Diluted loss per share is calculated by dividing net income or loss attributable to common stockholders as adjusted for the effect of dilutive securities, if any, by the weighted
          average number of shares of common stock and dilutive common stock outstanding during the period. Potentially dilutive common stock includes the shares of common stock issuable upon the exercise of outstanding stock options and warrants (using
          the treasury stock method) <span style="font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">and upon the vesting of restricted stock units (&#8220;RSUs&#8221;). Potentially dilutive common stock in the diluted net
            earnings (loss) per share computation is excluded to the extent that it would be anti-dilutive. <span style="font-style: normal; font-weight: 400; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; color: rgb(0, 0, 0);">For the year ended December 31, 2024, basic and diluted earnings per share are calculated as follows:</span></span></p>
<div style="display:none;"><br/></div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial;"><span style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
          </span> </div>

<table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="letter-spacing: normal; width: 100%; word-spacing: 0px; font-family: 'Times New Roman'; font-size: 10pt; text-align: left; text-transform: none; border-spacing: 0;">


  <tr>

    <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-align: center; text-transform: none;"><br/>
              </td>

    <td colspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">
                <div style="text-align: center; font-weight: bold;">Year Ended</div>
              </td>

    <td colspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; white-space: nowrap; padding: 0px 0px 0px; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none;">&#160;</td>

    <td colspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                <div style="text-align: center; font-weight: bold;">December 31, 2024</div>
              </td>

    <td colspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; width: 88%; background-color: #CCEEFF;" valign="bottom">
                <div>Net income available to common stockholders ($000&#8217;s) (numerator)</div>
              </td>

    <td colspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>$</div>
              </td>

    <td colspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>197,673</div>
              </td>

    <td colspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; width: 88%; padding-bottom: 2px;" valign="bottom">
                <div>Weighted-average number of common shares (denominator)</div>
              </td>

    <td colspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                <div>233,084,236</div>
              </td>

    <td colspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; white-space: nowrap; padding: 0px 0px 4px; color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; width: 88%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">
                <div>Basic earnings per common shares</div>
              </td>

    <td colspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>$</div>
              </td>

    <td colspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>0.85</div>
              </td>

    <td colspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; font-style: normal; font-variant: normal; text-transform: none; width: 88%;" valign="bottom"><br/>
              </td>

    <td colspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; width: 88%; background-color: #CCEEFF;" valign="bottom">
                <div>Weighted-average number of common shares</div>
              </td>

    <td colspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>233,084,236</div>
              </td>

    <td colspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; width: 88%;" valign="bottom">
                <div>Potential shares of common stock arising from outstanding stock options</div>
              </td>

    <td colspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                <div>4,150,584</div>
              </td>

    <td colspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; width: 88%; background-color: #CCEEFF;" valign="bottom">
                <div>Potential shares of common stock arising from outstanding warrants</div>
              </td>

    <td colspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>3,085,640</div>
              </td>

    <td colspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; width: 88%; padding-bottom: 2px;" valign="bottom">
                <div>Potential shares of common stock arising from unvested RSUs</div>
              </td>

    <td colspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                <div>3,022,006</div>
              </td>

    <td colspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; width: 88%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">
                <div>Total shares - diluted (denominator)</div>
              </td>

    <td colspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>243,342,466</div>
              </td>

    <td colspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; width: 88%; padding-bottom: 4px;" valign="bottom">
                <div>Diluted earnings per common share</div>
              </td>

    <td colspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom">
                <div>$</div>
              </td>

    <td colspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom">
                <div>0.81</div>
              </td>

    <td colspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>
<p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-indent: 45px; text-align: left;"> <span style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
          </span> </p><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-indent: 45px; text-align: left;"><span style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">For the year ended December 31, 2024, there were no shares with an anti-dilutive effect that needed to be excluded
            from the earnings per share computation. For the years ended December 31, 2023 and 2022, no potentially dilutive securities are
            included in the computation of diluted loss per share in the accompanying consolidated financial statements as the Company reported a net loss for these periods.</span><span style="font-family: 'Times New Roman'; font-size: 10pt;"> <span style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; color: rgb(0, 0, 0);">For
            the years ended December 31, 2023 and 2022, the following securities were excluded from the calculation of diluted loss per common share because of their anti-dilutive effects:</span></span></p><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px;"><span style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;&#160; <br/>
          </span> </p>
<table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="text-align: left; font: 10pt 'Times New Roman'; width: 100%; border-spacing: 0;">


  <tr style="height: 15px;">

    <td style="font-family: 'Times New Roman'; font-size: 10pt; padding-bottom: 2px;" valign="bottom">
                <p style="margin: 0px;">&#160;</p>
              </td>

    <td colspan="1" rowspan="1" style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="6" rowspan="1" style="vertical-align: bottom; text-align: center; font-family: 'Times New Roman'; font-size: 10pt; border-bottom: #000000 solid 2px;" valign="bottom">
                <p style="margin: 0px 0px 0px 0in; text-align: center;"><strong>For the Years Ended December 31,</strong></p>
              </td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td style="font-family: 'Times New Roman'; font-size: 10pt; padding-bottom: 2px;" valign="bottom">
                <p style="margin: 0px;">&#160;</p>
              </td>

    <td colspan="1" style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; text-align: center; font-family: 'Times New Roman'; font-size: 10pt; border-bottom: #000000 solid 2px;" valign="bottom">
                <p style="margin: 0px 0px 0px 0in; text-align: center;"><strong>2023<br/>
                  </strong></p>
              </td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: center; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="text-align: center; vertical-align: bottom; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">2022</td>

    <td colspan="1" style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td style="vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt; width: 76%; background-color: #CCEEFF;" valign="bottom">
                <p style="margin: 0px 0px 0px 0in;">Stock Options</p>
              </td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">5,906,184<br/>
              </td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">8,256,211<br/>
              </td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td style="vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt; width: 76%;" valign="bottom">
                <p style="margin: 0px 0px 0px 0in;">Restricted Stock Units</p>
              </td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">4,657,297<br/>
              </td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">2,866,987<br/>
              </td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td style="vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">
                <p style="margin: 0px 0px 0px 0in;">Warrants</p>
              </td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">12,502,906<br/>
              </td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">13,525,148<br/>
              </td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td style="font-family: 'Times New Roman'; font-size: 10pt; width: 76%; padding-bottom: 4px;" valign="bottom">
                <p style="margin-top: 0px; margin-bottom: 0px; margin-left: 9pt;">Total<br/>
                </p>
              </td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" valign="bottom">23,066,387</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom">24,648,346</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>
<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments</a></td>
<td class="text"><p style="margin: 0px; line-height: normal; font-family: 'Times New Roman'; font-size: 10pt; text-align: left; text-indent: 0px;"><span style="text-decoration:underline">Fair value of financial instruments</span></p><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;">&#160;</p><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-indent: 45px; text-align: left;"><span style="font-family: 'Times New Roman'; font-size: 10pt;">The carrying amounts of certain of the Company&#8217;s financial instruments,
            including cash and cash equivalents, accounts receivable and accounts payable are shown at cost, which approximates fair value due to the short-term nature of these instruments. The debt outstanding under the Company&#8217;s senior notes payable (see
            Note 7) also approximates fair value, based on a Level 3 classification under the fair value hierarchy, due to the variable interest rate on this debt.</span> </p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><p style="margin: 0px; font-family: 'Times New Roman'; font-size: 10pt; text-align: left; text-indent: 0px;"><span style="text-decoration:underline">Recent Accounting Pronouncements</span></p><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;">&#160;</p>
<div style="display:none;"><br/></div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-transform: none; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; text-indent: 36pt;">In November of 2024 the FASB issued ASU No. 2024-03,&#160;<span style="font-style: italic;">Income Statement - Reporting Comprehensive Income &#8211;
              Expense Disaggregation Disclosures (Subtopic 220-40).&#160;</span>The amendments in this Update require disclosure, in the notes to the financial statements, of specified information about certain costs and expenses, including but not limited to,
            purchases of inventory, employee compensation and selling expense. This Update becomes effective for fiscal years beginning after December 15, 2026. The Company has yet to determine the impact this Update may have on the Company&#8217;s consolidated
            financial statements.</div>

<div style="display:none;"><br/></div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial;"><br/>
          </div>

<div style="display:none;"><br/></div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-transform: none; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; text-indent: 36pt;">In December of 2023 the FASB issued ASU 2023-09,&#160;<span style="font-style: italic;">Income Taxes (Topic 740):</span>&#160;<span style="font-style: italic;">Improvements to Income Tax Disclosures.&#160;</span>This Update requires disaggregated information about a reporting entity&#8217;s effective tax rate reconciliation as well as information on income taxes paid and becomes
            effective for public business entities for fiscal years beginning after December 15, 2024. The Company is currently evaluating the impact that this Update may have on the Company&#8217;s consolidated financial statements.</div>

<div style="display:none;"><br/></div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial;"><br/>
          </div>

<div style="display:none;"><br/></div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-transform: none; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; text-indent: 36pt;">In November of 2023 the FASB issued ASU No. 2023-07,&#160;<span style="font-style: italic;">Segment Reporting (Topic 280): Improvements to
              Reportable Segment Disclosures.&#160;</span>The amendments in this Update are intended to provide financial statement users with more disaggregated expense information about a public entity&#8217;s reportable segments, however the Update does not change
            the definition of a business segment or the method for determining reportable segments. This update became effective for fiscal years beginning after December 15, 2023 (see Note 13). Adoption of this Update did not have a material impact on the
            Company&#8217;s consolidated financial statements.</div>

<div style="display:none;"><br/></div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial;"><br/>
          </div>

<div style="display:none;"><br/></div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-transform: none; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; text-indent: 36pt;">There were no new accounting pronouncements adopted during the years ended December 31, 2023 and 2022 that had a significant impact on the
            Company&#8217;s consolidated financial statements.</div>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_OtherOperatingExpensesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for other operating expenses related to plasma center.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_OtherOperatingExpensesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdvertisingCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for advertising cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -SubTopic 35<br> -Topic 720<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483406/720-35-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdvertisingCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfSalesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cost of product sold and service rendered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Topic 705<br> -Publisher FASB<br> -URI https://asc.fasb.org/705/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfSalesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 825<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/350-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the impairment and disposal of long-lived assets including goodwill and other intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-20<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-19<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483080/330-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483489/210-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 912<br> -SubTopic 330<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478411/912-330-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/330/tableOfContent<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483080/330-10-50-4<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 270<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482989/270-10-45-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the general note to the financial statements for the reporting entity which may include, descriptions of the basis of presentation, business description, significant accounting policies, consolidations, reclassifications, new pronouncements not yet adopted and changes in accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/235/tableOfContent<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 275<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/275/tableOfContent<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/810/tableOfContent<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 250<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/250/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for receivable. Includes, but is not limited to, accounts receivable and financing receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481569/310-20-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483044/730-10-05-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.C.Q3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.1.Q5)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.3.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>SIGNIFICANT ACCOUNTING POLICIES [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Calculation of Basic and Diluted Earnings Per Share</a></td>
<td class="text"><span style="font-style: normal; font-weight: 400; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; color: rgb(0, 0, 0);">For the year ended December 31, 2024, basic and diluted earnings per share are calculated as follows:</span>
<div style="display:none;"><br/></div>
<div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial;"><span style="font-family: 'Times New Roman'; font-size: 10pt;"><br/>
          </span> </div>

<table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="letter-spacing: normal; width: 100%; word-spacing: 0px; font-family: 'Times New Roman'; font-size: 10pt; text-align: left; text-transform: none; border-spacing: 0;">


  <tr>

    <td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-align: center; text-transform: none;"><br/>
              </td>

    <td colspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">
                <div style="text-align: center; font-weight: bold;">Year Ended</div>
              </td>

    <td colspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; white-space: nowrap; padding: 0px 0px 0px; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none;">&#160;</td>

    <td colspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                <div style="text-align: center; font-weight: bold;">December 31, 2024</div>
              </td>

    <td colspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; width: 88%; background-color: #CCEEFF;" valign="bottom">
                <div>Net income available to common stockholders ($000&#8217;s) (numerator)</div>
              </td>

    <td colspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>$</div>
              </td>

    <td colspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>197,673</div>
              </td>

    <td colspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; width: 88%; padding-bottom: 2px;" valign="bottom">
                <div>Weighted-average number of common shares (denominator)</div>
              </td>

    <td colspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                <div>233,084,236</div>
              </td>

    <td colspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; white-space: nowrap; padding: 0px 0px 4px; color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; width: 88%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">
                <div>Basic earnings per common shares</div>
              </td>

    <td colspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>$</div>
              </td>

    <td colspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>0.85</div>
              </td>

    <td colspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; font-style: normal; font-variant: normal; text-transform: none; width: 88%;" valign="bottom"><br/>
              </td>

    <td colspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; width: 88%; background-color: #CCEEFF;" valign="bottom">
                <div>Weighted-average number of common shares</div>
              </td>

    <td colspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>233,084,236</div>
              </td>

    <td colspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; width: 88%;" valign="bottom">
                <div>Potential shares of common stock arising from outstanding stock options</div>
              </td>

    <td colspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                <div>4,150,584</div>
              </td>

    <td colspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; width: 88%; background-color: #CCEEFF;" valign="bottom">
                <div>Potential shares of common stock arising from outstanding warrants</div>
              </td>

    <td colspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>3,085,640</div>
              </td>

    <td colspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; width: 88%; padding-bottom: 2px;" valign="bottom">
                <div>Potential shares of common stock arising from unvested RSUs</div>
              </td>

    <td colspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                <div>3,022,006</div>
              </td>

    <td colspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; width: 88%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">
                <div>Total shares - diluted (denominator)</div>
              </td>

    <td colspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <div>243,342,466</div>
              </td>

    <td colspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; width: 88%; padding-bottom: 4px;" valign="bottom">
                <div>Diluted earnings per common share</div>
              </td>

    <td colspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom">
                <div>$</div>
              </td>

    <td colspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom">
                <div>0.81</div>
              </td>

    <td colspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Calculation of Diluted Loss Per Common Share</a></td>
<td class="text"><span style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; color: rgb(0, 0, 0);">For
            the years ended December 31, 2023 and 2022, the following securities were excluded from the calculation of diluted loss per common share because of their anti-dilutive effects:</span><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px;"><span style="font-family: 'Times New Roman'; font-size: 10pt;">&#160;&#160; <br/>
          </span> </p>
<table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="text-align: left; font: 10pt 'Times New Roman'; width: 100%; border-spacing: 0;">


  <tr style="height: 15px;">

    <td style="font-family: 'Times New Roman'; font-size: 10pt; padding-bottom: 2px;" valign="bottom">
                <p style="margin: 0px;">&#160;</p>
              </td>

    <td colspan="1" rowspan="1" style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="6" rowspan="1" style="vertical-align: bottom; text-align: center; font-family: 'Times New Roman'; font-size: 10pt; border-bottom: #000000 solid 2px;" valign="bottom">
                <p style="margin: 0px 0px 0px 0in; text-align: center;"><strong>For the Years Ended December 31,</strong></p>
              </td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td style="font-family: 'Times New Roman'; font-size: 10pt; padding-bottom: 2px;" valign="bottom">
                <p style="margin: 0px;">&#160;</p>
              </td>

    <td colspan="1" style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; text-align: center; font-family: 'Times New Roman'; font-size: 10pt; border-bottom: #000000 solid 2px;" valign="bottom">
                <p style="margin: 0px 0px 0px 0in; text-align: center;"><strong>2023<br/>
                  </strong></p>
              </td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: center; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="text-align: center; vertical-align: bottom; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">2022</td>

    <td colspan="1" style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td style="vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt; width: 76%; background-color: #CCEEFF;" valign="bottom">
                <p style="margin: 0px 0px 0px 0in;">Stock Options</p>
              </td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">5,906,184<br/>
              </td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">8,256,211<br/>
              </td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td style="vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt; width: 76%;" valign="bottom">
                <p style="margin: 0px 0px 0px 0in;">Restricted Stock Units</p>
              </td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">4,657,297<br/>
              </td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">2,866,987<br/>
              </td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td style="vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">
                <p style="margin: 0px 0px 0px 0in;">Warrants</p>
              </td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">12,502,906<br/>
              </td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">13,525,148<br/>
              </td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td style="font-family: 'Times New Roman'; font-size: 10pt; width: 76%; padding-bottom: 4px;" valign="bottom">
                <p style="margin-top: 0px; margin-bottom: 0px; margin-left: 9pt;">Total<br/>
                </p>
              </td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" valign="bottom">23,066,387</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom">24,648,346</td>

    <td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INVENTORIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>INVENTORIES [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Components of Inventory</a></td>
<td class="text"><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-indent: 45px; text-align: left;">The following table provides the components of inventories:</p><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px;"><br/>
        </p>
<table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="text-align: left; font: 10pt 'Times New Roman'; width: 100%; border-spacing: 0;">


  <tr style="height: 15px;">

    <td style="padding-bottom: 2px;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px;">&#160;</p>
              </td>

    <td colspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: center;"><strong>December 31,<br/>
                    2024</strong></p>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: center;"><strong>December 31,<br/>
                    2023</strong></p>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td rowspan="1" style="vertical-align: top;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: center; vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="6" rowspan="1" style="text-align: center; vertical-align: bottom;" valign="bottom"><span style="font-style: italic;">(In thousands)</span><br/>
              </td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td style="vertical-align: top; width: 76%; background-color: #CCEEFF;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in;">Raw materials</p>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">$</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">60,473</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">$</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">52,999</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td style="vertical-align: top; width: 76%;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in;">Work-in-process</p>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">61,641</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">49,621</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td style="vertical-align: top; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in;">Finished goods</p>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">48,121</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">70,286</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td style="vertical-align: top; width: 76%; padding-bottom: 4px;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in;">Total inventories</p>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom">$</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom">170,235</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom">$</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom">172,906</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483489/210-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROPERTY AND EQUIPMENT (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>PROPERTY AND EQUIPMENT [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Property and Equipment</a></td>
<td class="text"><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-indent: 45px; text-align: left;">Property and equipment at December 31, 2024 and 2023 is summarized as follows:</p><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;">&#160; </p>
<table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="text-align: left; font: 10pt 'Times New Roman'; width: 100%; border-spacing: 0;">


  <tr style="height: 15px;">

    <td style="padding-bottom: 2px;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px;">&#160;</p>
              </td>

    <td colspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: center;"><strong>December 31, 2024</strong></p>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: center;"><strong>December 31, 2023</strong></p>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td rowspan="1" style="vertical-align: top;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: center; vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="6" rowspan="1" style="text-align: center; vertical-align: bottom;" valign="bottom"><span style="font-style: italic;">(In thousands)</span><br/>
              </td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td style="vertical-align: top; width: 76%; background-color: #CCEEFF;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px;">Manufacturing and laboratory equipment</p>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">$</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">21,305</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">$</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">21,093</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td style="vertical-align: top; width: 76%;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px;">Office equipment and computer software</p>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">5,772</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">6,062</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td style="vertical-align: top; width: 76%; background-color: #CCEEFF;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px;">Furniture and fixtures</p>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">5,840</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">5,776</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td style="vertical-align: top; width: 76%;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px;">Construction in process</p>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">8,149</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">2,273</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td style="vertical-align: top; width: 76%; background-color: #CCEEFF;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px;">Leasehold improvements</p>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">21,066</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">20,811</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td style="vertical-align: top; width: 76%;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px;">Land</p>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">4,339</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">4,339</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td style="vertical-align: top; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px;">Buildings and building improvements</p>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">21,788</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">20,218</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td style="width: 76%;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px;">&#160;</p>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">88,259</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">80,572</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td style="vertical-align: top; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px;">Less: Accumulated depreciation </p>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">(33,552</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">)</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">(26,737</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">)</td>

  </tr>

  <tr style="height: 15px;">

    <td style="vertical-align: top; width: 76%; padding-bottom: 4px;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px;">Total property and equipment, net</p>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom">$</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom">54,707</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom">$</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom">53,835</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INTANGIBLE ASSETS (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>INTANGIBLE ASSETS [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock', window );">Schedule of Intangible Assets</a></td>
<td class="text"><p style="margin: 0px 0px; font-family: 'Times New Roman'; font-size: 10pt; text-align: left; text-indent: 45px;">Intangible assets at December 31, 2024 and 2023 consist of the following:</p><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;">&#160; </p>
<table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="text-align: left; font: 10pt 'Times New Roman'; width: 100%; border-spacing: 0;">


  <tr style="height: 15px;">

    <td style="padding-bottom: 2px;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px;">&#160;</p>
              </td>

    <td colspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="10" style="vertical-align: bottom; text-align: center; border-bottom: #000000 solid 2px;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: center;"><span style="font-weight: bold;">December 31, 2024</span><br/>
                </p>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="10" style="vertical-align: bottom; text-align: center; border-bottom: #000000 solid 2px;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: center;"><span style="font-weight: bold;">December 31, 2023</span><br/>
                </p>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td rowspan="1" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: center; vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="22" rowspan="1" style="vertical-align: bottom; text-align: center;" valign="bottom"><span style="font-style: italic;">(In thousands) </span> <br/>
              </td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td style="padding-bottom: 2px;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px;">&#160;</p>
              </td>

    <td colspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: #000000 solid 2px;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: center;"><strong> Cost</strong></p>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: #000000 solid 2px;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in;"><strong>Accumulated</strong></p>
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in;"><strong>Amortization</strong></p>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: #000000 solid 2px;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: center;"><strong>Net</strong></p>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: #000000 solid 2px;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: center;"><strong>Cost</strong></p>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: #000000 solid 2px;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in;"><strong>Accumulated</strong></p>
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in;"><strong>Amortization</strong></p>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: #000000 solid 2px;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: center;"><strong>Net</strong></p>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td style="vertical-align: top; width: 28%; background-color: #CCEEFF;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-bottom: 0px; text-indent: -9pt; margin-left: 9pt;">Trademark and other intangible rights related to Nabi-HB</p>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">$</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">4,100</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">$</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">4,100</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">$</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">-</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">$</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">4,100</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">$</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">3,856</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">$</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">244</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td rowspan="1" style="vertical-align: top; font-size: 10pt; width: 28%;" valign="bottom"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: -9.6px; text-transform: none; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">Internally developed software</span></td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">559</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">99</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">460</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">210</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">9</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">201</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td style="vertical-align: top; width: 28%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-bottom: 0px; text-indent: -9pt; margin-left: 9pt;">Rights to intermediates</p>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">907</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">907</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">-</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">907</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">853</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">54</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td style="width: 28%; padding-bottom: 4px;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px;">&#160;</p>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom">$</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom">5,566</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom">$</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom">5,106</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom">$</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom">460</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom">$</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom">5,217</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom">$</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom">4,718</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom">$</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom">499</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock', window );">Intangible Asset Future Aggregate Amortization Expense</a></td>
<td class="text"><p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-bottom: 0px; text-align: left; text-indent: 27pt;">Amortization expense related to the Company&#8217;s intangible assets for the years ended December 31, 2024, 2023 and
          2022 was $0.4 million, $0.7
          million and $0.7 million, respectively. Estimated aggregate future aggregate amortization expense is expected to be as follows (in
          thousands):</p><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="text-align: left; font: 10pt 'Times New Roman'; width: 100%; border-spacing: 0;">


  <tr style="height: 15px;">

    <td style="vertical-align: top; width: 88%; background-color: #CCEEFF;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in;">2025<br/>
                </p>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">$<br/>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">140</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td style="vertical-align: top; width: 88%;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in;">2026<br/>
                </p>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">$ <br/>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">140</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td rowspan="1" style="vertical-align: top; width: 88%; background-color: #CCEEFF;" valign="bottom">
                <div>2027<br/>
                </div>
              </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">$ <br/>
              </td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">130</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td rowspan="1" style="vertical-align: top; width: 88%;" valign="bottom">2028<br/>
              </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">$ <br/>
              </td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">50</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance and exist in perpetuity, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ACCRUED EXPENSES AND OTHER LIABILITIES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>ACCRUED EXPENSES AND OTHER LIABILITIES [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Accrued Expenses and Other Current Liabilities</a></td>
<td class="text"><p style="margin: 0px 0px; font-family: 'Times New Roman'; font-size: 10pt; text-align: left; text-indent: 45px;">Accrued expenses and other current liabilities at December 31, 2024 and 2023 are as follows:</p><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="text-align: left; font: 10pt 'Times New Roman'; width: 100%; border-spacing: 0;">


  <tr style="height: 15px;">

    <td style="padding-bottom: 2px; white-space: nowrap;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px;">&#160;</p>
              </td>

    <td colspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: center;"><strong>December 31, 2024
                  </strong></p>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"><strong>December 31, 2023</strong></td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td rowspan="1" style="white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: center; vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="6" rowspan="1" style="vertical-align: bottom; text-align: center;" valign="bottom"><span style="font-style: italic;">(In thousands)</span> <br/>
              </td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td style="vertical-align: top; width: 76%; background-color: #CCEEFF;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-bottom: 0px; text-indent: -9pt; margin-left: 9pt;">Accrued rebates</p>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">$ <br/>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">4,155</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">$</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">16,608</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td style="vertical-align: top; width: 76%;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-bottom: 0px; text-indent: -9pt; margin-left: 9pt;">Accrued distribution fees</p>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">11,565</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">5,954</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td style="vertical-align: top; width: 76%; background-color: #CCEEFF;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-bottom: 0px; text-indent: -9pt; margin-left: 9pt;">Accrued incentives</p>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">5,892</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">4,961</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td rowspan="1" style="vertical-align: top; width: 76%;" valign="bottom">Accrued interest<br/>
              </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">2,857</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">546</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td style="vertical-align: top; width: 76%; background-color: #CCEEFF;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-bottom: 0px; text-indent: -9pt; margin-left: 9pt;">Accrued testing</p>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">827</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">282</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td style="vertical-align: top; width: 76%;" valign="bottom">
                <div style="color: rgb(0, 0, 0); text-indent: -9pt; margin-left: 9pt;">Accrued payroll and other compensation</div>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">3,332</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">2,203</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td rowspan="1" style="vertical-align: top; width: 76%; background-color: #CCEEFF;" valign="bottom">Income taxes payable<br/>
              </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">3,481</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">-</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td style="vertical-align: top; width: 76%; padding-bottom: 2px;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-bottom: 0px; text-indent: -9pt; margin-left: 9pt;">Other</p>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom">1,853</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom">2,365</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td style="vertical-align: top; width: 76%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-bottom: 0px; text-indent: -9pt; margin-left: 18pt;">Total accrued expenses and other current liabilities</p>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 4px double rgb(0, 0, 0);" valign="bottom">$ <br/>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 4px double rgb(0, 0, 0);" valign="bottom">33,962</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 4px double rgb(0, 0, 0);" valign="bottom">$</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 4px double rgb(0, 0, 0);" valign="bottom">32,919</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NOTES PAYABLE (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>NOTES PAYABLE [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtTableTextBlock', window );">Summary of Outstanding Senior Notes Payable</a></td>
<td class="text"><p style="margin-top: 0px; margin-bottom: 0px; font-family: 'Times New Roman'; font-size: 10pt; text-align: left; text-indent: 27pt;">A summary of outstanding senior notes payable is as follows:</p><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px;">&#160;&#160; <br/>
        </p>
<table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="text-align: left; font: 10pt 'Times New Roman'; width: 100%; border-spacing: 0;">


  <tr style="height: 15px;">

    <td style="padding-bottom: 2px; white-space: nowrap;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px;">&#160;</p>
              </td>

    <td colspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: center;"><strong>December 31, 2024</strong></p>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: center;"><strong>December 31, 2023</strong></p>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td rowspan="1" style="vertical-align: top; width: 76%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="6" rowspan="1" style="text-align: center; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"><span style="font-style: italic;">(In thousands)</span><br/>
              </td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td style="vertical-align: top; width: 76%; background-color: rgb(204, 238, 255);" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 9pt; text-indent: -9pt;">Term loan<br/>
                </p>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom">$</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" valign="bottom">32,500</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom">$</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" valign="bottom">62,500</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td rowspan="1" style="vertical-align: top; width: 76%;" valign="bottom">
                <div style="margin-left: 9pt; text-indent: -9pt;">Revolving credit facility<br/>
                </div>
              </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">42,500</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">72,500</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td style="vertical-align: top; width: 76%; background-color: rgb(204, 238, 255);" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in;">Less:<br/>
                </p>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td style="vertical-align: top; width: 76%; padding-bottom: 2px;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 15px;">Debt discount</p>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom">(2,663</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">)</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom">(4,406</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">)</td>

  </tr>

  <tr style="height: 15px;">

    <td style="vertical-align: top; width: 76%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in;">Senior notes payable</p>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 4px double rgb(0, 0, 0);" valign="bottom">$</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 4px double rgb(0, 0, 0);" valign="bottom">72,337</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 4px double rgb(0, 0, 0);" valign="bottom">$</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 4px double rgb(0, 0, 0);" valign="bottom">130,594</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS EQUITY (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>STOCKHOLDERS' EQUITY [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock', window );">Warrants Outstanding</a></td>
<td class="text"><span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal;">The






























                      following table summarizes information about warrants outstanding as of December 31, 2024, 2023 and 2022:</span>
<div style="display:none;"><br/></div>
<div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-indent: 36pt;"><span style="background-color: rgb(255, 255, 255); font-weight: normal;"><span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; text-align: left; text-indent: 48px; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"> <br/>
                    </span></span></div>

<table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; letter-spacing: normal; text-transform: none; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%; border-spacing: 0;">


  <tr>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"><br class="Apple-interchange-newline"/>
                          &#160;</td>

    <td colspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"><span style="font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Shares </span><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
                          </span> </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom">
                          <div style="text-align: center; font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Weighted</div>
                          <div style="text-align: center; font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Average</div>
                          <div style="text-align: center; font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Exercise Price</div>
                        </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                          <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Warrants outstanding at December 31, 2021</div>
                        </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                          <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">4,528,160</div>
                        </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                          <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">$</div>
                        </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                          <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">2.82</div>
                        </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; white-space: nowrap;" valign="bottom">
                          <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Expired</div>
                        </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                          <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">(106,059</div>
                        </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">
                          <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">)</div>
                        </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">
                          <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">$</div>
                        </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                          <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">8.23</div>
                        </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                          <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Granted</div>
                        </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                          <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">9,103,047</div>
                        </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                          <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">$</div>
                        </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                          <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">1.65</div>
                        </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">
                          <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Exercised</div>
                        </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                          <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">-</div>
                        </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">
                          <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">$</div>
                        </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">
                          <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">-</div>
                        </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                          <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Warrants outstanding at December 31, 2022</div>
                        </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                          <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">13,525,148</div>
                        </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                          <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">$</div>
                        </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                          <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">1.99</div>
                        </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; white-space: nowrap;" valign="bottom">
                          <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Expired</div>
                        </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                          <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">(24,800</div>
                        </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">
                          <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">)</div>
                        </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">
                          <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">$</div>
                        </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">
                          <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">6.37</div>
                        </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                          <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Granted</div>
                        </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                          <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">2,391,244</div>
                        </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                          <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">$</div>
                        </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                          <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">3.26</div>
                        </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">
                          <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Exercised</div>
                        </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                          <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">(3,388,686</div>
                        </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">
                          <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">)</div>
                        </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">
                          <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">$</div>
                        </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">
                          <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">1.65</div>
                        </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                          <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Warrants outstanding at December 31, 2023</div>
                        </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                          <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">12,502,906</div>
                        </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                          <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">$</div>
                        </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                          <div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">2.32</div>
                        </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td rowspan="1" style="vertical-align: bottom; width: 76%; white-space: nowrap;" valign="bottom"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Expired<br/>
                          </span> </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">(227,650</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">)</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">$</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">4.21</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td rowspan="1" style="vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Granted<br/>
                          </span> </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">-</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">$</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">-</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td rowspan="1" style="vertical-align: bottom; width: 76%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Exercised<br/>
                          </span> </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">(11,308,702</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; padding-bottom: 2px; white-space: nowrap;" valign="bottom">)</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; padding-bottom: 2px; white-space: nowrap;" valign="bottom">$</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; padding-bottom: 2px; white-space: nowrap;" valign="bottom">2.31</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td rowspan="1" style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Warrants outstanding at December 31, 2024<br/>
                          </span> </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">966,554</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">$</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">1.98</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Assumptions</a></td>
<td class="text">
<div style="display:none;"><br/></div>
<div style="text-indent: 36pt;"><span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">The grant date fair values of stock options
              awarded during the years ended December 31, 2024, 2023 and 2022 were determined using the Black-Scholes option pricing model with the following assumptions:</span> <span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span> </div>
<p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px;"><span style="font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><span style="font-weight: normal;">&#160; </span><br/>
          </span> </p>
<table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="text-align: left; font: 10pt 'Times New Roman'; margin-right: auto; width: 100%; border-spacing: 0;">


  <tr style="height: 15px;">

    <td style="padding-bottom: 2px;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td colspan="1" rowspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="10" rowspan="1" style="vertical-align: bottom; text-align: center; border-bottom: #000000 solid 2px;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; text-align: center; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"><strong>Years Ended
                  </strong></p>
              </td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td style="padding-bottom: 2px;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td colspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-bottom: 0px; text-align: center; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"><strong>December 31,</strong></p>
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-bottom: 0px; text-align: center; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"><strong>2024 </strong></p>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: center; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-bottom: 0px; text-align: center; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"><strong>December 31,</strong></p>
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-bottom: 0px; text-align: center; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"><strong>2023 </strong></p>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="text-align: left; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">
                <div style="text-align: center;"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><strong>December 31,</strong> <br/>
                  </span> </div>
                <div style="text-align: center;"><span style="font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">202<strong>2</strong></span><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><strong><br/>
                    </strong></span></div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td style="vertical-align: bottom; background-color: rgb(204, 238, 255);" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">Expected term</p>
              </td>

    <td colspan="1" style="text-align: center; vertical-align: bottom; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; text-align: center; background-color: rgb(204, 238, 255);" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; text-align: right; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">5.5-6.3 years</p>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: center; vertical-align: bottom; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; text-align: center; background-color: rgb(204, 238, 255);" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; text-align: right; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">5.5-6.3 years</p>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; text-align: right; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">
                <div style="text-align: right; font-family: 'Times New Roman'; font-size: 10pt; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">5.5-6.3 years</div>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td style="vertical-align: bottom; width: 64%;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">Volatility</p>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">66</p>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">%</p>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">68</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">%</td>

    <td colspan="1" style="text-align: right; font-weight: normal; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-weight: normal; text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-weight: normal; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">68<br/>
                </span> </td>

    <td colspan="1" style="font-weight: normal; text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"><strong style="font-weight: normal;">%</strong></td>

  </tr>

  <tr style="height: 15px;">

    <td style="vertical-align: top; width: 64%; background-color: rgb(204, 238, 255);" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">Dividend yield</p>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">0.0<br/>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">0.0<br/>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">0.0</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td style="vertical-align: top; width: 64%;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">Risk-free interest rate</p>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">4.16-4.39</p>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">%</p>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">4.20-4.62</p>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">%</p>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">1.72-1.73</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">%</td>

  </tr>


</table>
<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of Option Activity</a></td>
<td class="text">
<div><span style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"> </span> </div>
<p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-bottom: 0px; text-align: left; text-indent: 36pt; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"><span style="font-size: 10pt;">The following table summarizes information about stock options outstanding as of December 31, <strong><span style="font-weight: normal;">2024,</span> </strong>2023 and 2022:</span> </p><p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px;"><span style="font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;&#160;&#160; <br/>
          </span> </p>
<table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="text-align: left; font: 10pt 'Times New Roman'; width: 100%; border-spacing: 0;">


  <tr style="height: 15px;">

    <td style="padding-bottom: 2px;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td colspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: #000000 solid 2px;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; text-align: center; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"><strong>Shares</strong></p>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: #000000 solid 2px;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; text-align: center; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"><strong>Weighted</strong></p>
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; text-align: center; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"><strong>Average</strong></p>
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; text-align: center; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"><strong>Exercise
                    Price</strong></p>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td style="vertical-align: top; width: 76%; background-color: #CCEEFF;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">Options outstanding, vested and
                  expected to vest at December 31, 2021</p>
              </td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">7,862,722</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">$</td>

    <td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">3.93</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td style="vertical-align: top; width: 76%;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">Forfeited</p>
              </td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">(31,540</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">)</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">$</td>

    <td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">2.37</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td style="vertical-align: top; width: 76%; background-color: #CCEEFF;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">Expired</p>
              </td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">(700,324</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">)</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">$</td>

    <td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">6.86</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td style="vertical-align: top; width: 76%;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">Granted</p>
              </td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">1,194,032</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">$</td>

    <td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">1.67</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td style="vertical-align: top; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">Exercised</p>
              </td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">(68,679</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">)</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">$</td>

    <td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">2.55</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td style="vertical-align: top; width: 76%;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">Options outstanding, vested and
                  expected to vest at December 31, 2022</p>
              </td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">8,256,211</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">$</td>

    <td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">3.37</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td style="vertical-align: top; width: 76%; background-color: #CCEEFF;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">Forfeited</p>
              </td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">(99,345</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">)</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">$</td>

    <td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">2.73</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td style="vertical-align: top; width: 76%;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">Expired</p>
              </td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">(262,940</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">)</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">$</td>

    <td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">6.42</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td style="vertical-align: top; width: 76%; background-color: #CCEEFF;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">Granted</p>
              </td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">1,826,380</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">$</td>

    <td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">3.36</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td style="vertical-align: top; width: 76%; padding-bottom: 2px;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">Exercised</p>
              </td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">(3,814,122</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">)</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">$</td>

    <td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">3.15</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td style="vertical-align: top; width: 76%; background-color: #CCEEFF;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">Options outstanding, vested and
                  expected to vest at December 31, 2023</p>
              </td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">5,906,184</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">$</td>

    <td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">3.38</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td rowspan="1" style="vertical-align: top; width: 76%;" valign="bottom"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Forfeited<br/>
                </span> </td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">(30,094</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">)</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">$</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">3.36</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td rowspan="1" style="vertical-align: top; width: 76%; background-color: #CCEEFF;" valign="bottom"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Expired<br/>
                </span> </td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">(246,067</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">)</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">$</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">7.01</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td rowspan="1" style="vertical-align: top; width: 76%;" valign="bottom"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Granted<br/>
                </span> </td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">1,531,635</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">$</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">6.40</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td rowspan="1" style="vertical-align: top; width: 76%; background-color: rgb(204, 238, 255); padding-bottom: 2px;" valign="bottom"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Exercised<br/>
                </span> </td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom">(2,020,142</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; padding-bottom: 2px; white-space: nowrap;" valign="bottom">)</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; padding-bottom: 2px;" valign="bottom">$</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; padding-bottom: 2px;" valign="bottom">3.90</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td rowspan="1" style="vertical-align: top; width: 76%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; padding-bottom: 4px;" valign="bottom">Options
                outstanding, vested and expected to vest at December 31, 2024</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom">5,141,516</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; padding-bottom: 4px;" valign="bottom">$</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; padding-bottom: 4px;" valign="bottom">3.90</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td style="width: 76%; background-color: #CCEEFF;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td style="vertical-align: top; width: 76%; padding-bottom: 4px;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">Options exercisable</p>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom">2,657,932<br/>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom">$</td>

    <td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom">3.03</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock', window );">Summary of Outstanding and Exercisable Options by Price Range</a></td>
<td class="text"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal;">The following table summarizes additional information regarding
            outstanding and exercisable options under the stock option plans at December 31, 2024: </span><p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px;"><span style="font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160; <br/>
          </span> </p>
<table border="0" cellpadding="0" cellspacing="0" style="text-align: left; font: 10pt 'Times New Roman'; width: 100%; border-spacing: 0;">


  <tr style="height: 15px;">

    <td style="width: 28%; padding-bottom: 2px;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td colspan="1" style="white-space: nowrap; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td style="white-space: nowrap; width: 1%; padding-bottom: 2px;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td class="hdcell" colspan="14" style="border-bottom: 2px solid rgb(0, 0, 0); vertical-align: bottom; text-align: center;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; text-align: center; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"><strong>Stock
                    Options Outstanding</strong></p>
              </td>

    <td style="white-space: nowrap; width: 1%; padding-bottom: 2px;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td style="white-space: nowrap; width: 1%; padding-bottom: 2px;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td class="hdcell" colspan="14" style="border-bottom: 2px solid rgb(0, 0, 0); vertical-align: bottom; text-align: center;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; text-align: center; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"><strong>Stock
                    Options Exercisable</strong></p>
              </td>

    <td style="white-space: nowrap; width: 1%; padding-bottom: 2px;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

  </tr>

  <tr style="height: 15px;">

    <td style="vertical-align: bottom; width: 28%; padding-bottom: 2px; white-space: nowrap;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; text-align: center; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">Range of</p>
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; text-align: center; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">Exercise Prices</p>
              </td>

    <td colspan="1" style="white-space: nowrap; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td style="white-space: nowrap; width: 1%; padding-bottom: 2px;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td class="hdcell" colspan="2" style="border-bottom: 2px solid rgb(0, 0, 0); vertical-align: bottom; text-align: center;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; text-align: center; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">Options Outstanding</p>
              </td>

    <td style="padding-bottom: 2px; white-space: nowrap; width: 1%;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td style="white-space: nowrap; width: 1%; padding-bottom: 2px;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td class="hdcell" colspan="2" style="border-bottom: 2px solid rgb(0, 0, 0); vertical-align: bottom; text-align: center;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; text-align: center; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">Weighted</p>
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; text-align: center; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">Average</p>
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; text-align: center; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">Remaining</p>
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; text-align: center; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">Contractual</p>
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; text-align: center; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">Life (Years)</p>
              </td>

    <td style="padding-bottom: 2px; white-space: nowrap; width: 1%;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td style="white-space: nowrap; width: 1%; padding-bottom: 2px;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td class="hdcell" colspan="2" style="border-bottom: 2px solid rgb(0, 0, 0); vertical-align: bottom; text-align: center;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; text-align: center; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">Weighted Average
                  Exercise Price</p>
              </td>

    <td style="padding-bottom: 2px; white-space: nowrap; width: 1%;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td style="white-space: nowrap; width: 1%; padding-bottom: 2px;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td class="hdcell" colspan="2" style="border-bottom: 2px solid rgb(0, 0, 0); vertical-align: bottom; text-align: center;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; text-align: center; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">Aggregate Intrinsic
                  Value</p>
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; text-align: center;"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> ($000&#8217;s)<br/>
                  </span> </p>
              </td>

    <td style="padding-bottom: 2px; white-space: nowrap; width: 1%;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td style="white-space: nowrap; width: 1%; padding-bottom: 2px;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td class="hdcell" colspan="2" style="border-bottom: 2px solid rgb(0, 0, 0); vertical-align: bottom; text-align: center;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; text-align: center; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">Options Outstanding</p>
              </td>

    <td style="padding-bottom: 2px; white-space: nowrap; width: 1%;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td style="white-space: nowrap; width: 1%; padding-bottom: 2px;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td class="hdcell" colspan="2" style="border-bottom: 2px solid rgb(0, 0, 0); vertical-align: bottom; text-align: center;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; text-align: center; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">Weighted</p>
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; text-align: center; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">Average</p>
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; text-align: center; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">Remaining</p>
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; text-align: center; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">Contractual</p>
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; text-align: center; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">Life (Years)</p>
              </td>

    <td style="padding-bottom: 2px; white-space: nowrap; width: 1%;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td style="white-space: nowrap; width: 1%; padding-bottom: 2px;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td class="hdcell" colspan="2" style="border-bottom: 2px solid rgb(0, 0, 0); vertical-align: bottom; text-align: center; white-space: nowrap;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; text-align: center; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">Weighted</p>
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; text-align: center; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"> Average</p>
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; text-align: center; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"> Exercise</p>
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; text-align: center; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"> Price</p>
              </td>

    <td style="padding-bottom: 2px; white-space: nowrap; width: 1%;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td style="white-space: nowrap; width: 1%; padding-bottom: 2px;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td class="hdcell" colspan="2" style="border-bottom: 2px solid rgb(0, 0, 0); vertical-align: bottom; text-align: center; white-space: nowrap;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; text-align: center; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">Aggregate</p>
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; text-align: center; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"> Intrinsic</p>
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; text-align: center; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"> Value</p>
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; text-align: center; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"> ($000&#8217;s)</p>
              </td>

    <td style="padding-bottom: 2px; white-space: nowrap; width: 1%;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

  </tr>

  <tr style="height: 15px;">

    <td style="vertical-align: top; width: 28%; background-color: rgb(204, 238, 255);">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">$1.10 - $1.67</p>
              </td>

    <td colspan="1" style="width: 1%; white-space: nowrap; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td style="width: 1%; white-space: nowrap; background-color: rgb(204, 238, 255);">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td style="width: 1%; white-space: nowrap; background-color: rgb(204, 238, 255);">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td class="ffcell" style="width: 6%; vertical-align: bottom; text-align: right; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">981,093</td>

    <td style="width: 1%; white-space: nowrap; background-color: rgb(204, 238, 255);">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td style="width: 1%; white-space: nowrap; background-color: rgb(204, 238, 255);">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td style="width: 1%; white-space: nowrap; background-color: rgb(204, 238, 255);">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td class="ffcell" style="width: 6%; vertical-align: bottom; text-align: right; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">6.8</td>

    <td style="width: 1%; white-space: nowrap; background-color: rgb(204, 238, 255);">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td style="width: 1%; white-space: nowrap; background-color: rgb(204, 238, 255);">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td style="width: 1%; vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">$</td>

    <td class="ffcell" style="width: 6%; vertical-align: bottom; text-align: right; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">1.60</td>

    <td style="width: 1%; white-space: nowrap; background-color: rgb(204, 238, 255);">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td style="width: 1%; white-space: nowrap; background-color: rgb(204, 238, 255);">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td style="width: 1%; vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">$</td>

    <td class="ffcell" style="width: 6%; vertical-align: bottom; text-align: right; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">15,252</td>

    <td style="width: 1%; white-space: nowrap; background-color: rgb(204, 238, 255);">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td style="width: 1%; white-space: nowrap; background-color: rgb(204, 238, 255);">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td style="width: 1%; white-space: nowrap; background-color: rgb(204, 238, 255);">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td class="ffcell" style="width: 6%; vertical-align: bottom; text-align: right; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">676,542</td>

    <td style="width: 1%; white-space: nowrap; background-color: rgb(204, 238, 255);">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td style="width: 1%; white-space: nowrap; background-color: rgb(204, 238, 255);">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td style="width: 1%; white-space: nowrap; background-color: rgb(204, 238, 255);">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td class="ffcell" style="width: 6%; vertical-align: bottom; text-align: right; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">6.6</td>

    <td style="width: 1%; white-space: nowrap; background-color: rgb(204, 238, 255);">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td style="width: 1%; white-space: nowrap; background-color: rgb(204, 238, 255);">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td style="width: 1%; vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">$</td>

    <td class="ffcell" style="width: 6%; vertical-align: bottom; text-align: right; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">1.58</td>

    <td style="width: 1%; white-space: nowrap; background-color: rgb(204, 238, 255);">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td style="width: 1%; white-space: nowrap; background-color: rgb(204, 238, 255);">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td style="width: 1%; vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">$</td>

    <td class="ffcell" style="width: 6%; vertical-align: bottom; text-align: right; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">10,532</td>

    <td style="width: 1%; white-space: nowrap; background-color: rgb(204, 238, 255);">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

  </tr>

  <tr style="height: 15px;">

    <td style="vertical-align: top; width: 28%;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">$1.73 - $2.60</p>
              </td>

    <td colspan="1" style="white-space: nowrap; width: 1%; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td style="white-space: nowrap; width: 1%;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td style="white-space: nowrap; width: 1%;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td class="ffcell" style="vertical-align: bottom; text-align: right; width: 6%; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">629,655</td>

    <td style="white-space: nowrap; width: 1%;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td style="white-space: nowrap; width: 1%;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td style="white-space: nowrap; width: 1%;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td class="ffcell" style="vertical-align: bottom; text-align: right; width: 6%; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">5.7</td>

    <td style="white-space: nowrap; width: 1%;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td style="white-space: nowrap; width: 1%;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td style="vertical-align: bottom; white-space: nowrap; width: 1%; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">$</td>

    <td class="ffcell" style="vertical-align: bottom; text-align: right; width: 6%; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">2.32</td>

    <td style="white-space: nowrap; width: 1%;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td style="white-space: nowrap; width: 1%;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td style="white-space: nowrap; width: 1%;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td class="ffcell" style="vertical-align: bottom; text-align: right; width: 6%; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">9,336</td>

    <td style="white-space: nowrap; width: 1%;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td style="white-space: nowrap; width: 1%;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td style="white-space: nowrap; width: 1%;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td class="ffcell" style="vertical-align: bottom; text-align: right; width: 6%; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">585,771</td>

    <td style="white-space: nowrap; width: 1%;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td style="white-space: nowrap; width: 1%;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td style="white-space: nowrap; width: 1%;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td class="ffcell" style="vertical-align: bottom; text-align: right; width: 6%; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">5.6</td>

    <td style="white-space: nowrap; width: 1%;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td style="white-space: nowrap; width: 1%;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td style="vertical-align: bottom; white-space: nowrap; width: 1%; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">$</td>

    <td class="ffcell" style="vertical-align: bottom; text-align: right; width: 6%; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">2.33</td>

    <td style="white-space: nowrap; width: 1%;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td style="white-space: nowrap; width: 1%;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td style="white-space: nowrap; width: 1%;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td class="ffcell" style="vertical-align: bottom; text-align: right; width: 6%; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">8,683</td>

    <td style="white-space: nowrap; width: 1%;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

  </tr>

  <tr style="height: 15px;">

    <td style="vertical-align: top; width: 28%; background-color: rgb(204, 238, 255);">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">$2.67 - $4.01</p>
              </td>

    <td colspan="1" style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255);">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255);">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td class="ffcell" style="vertical-align: bottom; text-align: right; width: 6%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">1,809,746</td>

    <td style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255);">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255);">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255);">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td class="ffcell" style="vertical-align: bottom; text-align: right; width: 6%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">6.6</td>

    <td style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255);">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255);">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td style="vertical-align: bottom; white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">$</td>

    <td class="ffcell" style="vertical-align: bottom; text-align: right; width: 6%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">3.41</td>

    <td style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255);">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255);">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255);">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td class="ffcell" style="vertical-align: bottom; text-align: right; width: 6%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">24,868</td>

    <td style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255);">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255);">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255);">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td class="ffcell" style="vertical-align: bottom; text-align: right; width: 6%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">1,012,271</td>

    <td style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255);">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255);">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255);">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td class="ffcell" style="vertical-align: bottom; text-align: right; width: 6%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">5.4</td>

    <td style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255);">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255);">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td style="vertical-align: bottom; white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">$</td>

    <td class="ffcell" style="vertical-align: bottom; text-align: right; width: 6%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">3.46</td>

    <td style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255);">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255);">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255);">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td class="ffcell" style="vertical-align: bottom; text-align: right; width: 6%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">13,863</td>

    <td style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255);">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

  </tr>

  <tr style="height: 15px;">

    <td rowspan="1" style="vertical-align: top; width: 28%; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">$4.09 - $6.14</td>

    <td colspan="1" rowspan="1" style="white-space: nowrap; width: 1%; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td rowspan="1" style="white-space: nowrap; width: 1%; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td rowspan="1" style="white-space: nowrap; width: 1%; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td class="ffcell" rowspan="1" style="vertical-align: bottom; text-align: right; width: 6%; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">1,264,083</td>

    <td rowspan="1" style="white-space: nowrap; width: 1%; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td rowspan="1" style="white-space: nowrap; width: 1%; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td rowspan="1" style="white-space: nowrap; width: 1%; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td class="ffcell" rowspan="1" style="vertical-align: bottom; text-align: right; width: 6%; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">8.1</td>

    <td rowspan="1" style="white-space: nowrap; width: 1%; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td rowspan="1" style="white-space: nowrap; width: 1%; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td rowspan="1" style="vertical-align: bottom; white-space: nowrap; width: 1%;"><span style="font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">$<br/>
                </span> </td>

    <td class="ffcell" rowspan="1" style="vertical-align: bottom; text-align: right; width: 6%; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">5.35</td>

    <td rowspan="1" style="white-space: nowrap; width: 1%; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td rowspan="1" style="white-space: nowrap; width: 1%; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td rowspan="1" style="white-space: nowrap; width: 1%; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td class="ffcell" rowspan="1" style="vertical-align: bottom; text-align: right; width: 6%; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">14,913</td>

    <td rowspan="1" style="white-space: nowrap; width: 1%; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td rowspan="1" style="white-space: nowrap; width: 1%; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td rowspan="1" style="white-space: nowrap; width: 1%; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td class="ffcell" rowspan="1" style="vertical-align: bottom; text-align: right; width: 6%; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">361,848</td>

    <td rowspan="1" style="white-space: nowrap; width: 1%; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td rowspan="1" style="white-space: nowrap; width: 1%; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td rowspan="1" style="white-space: nowrap; width: 1%; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td class="ffcell" rowspan="1" style="vertical-align: bottom; text-align: right; width: 6%; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">5.4</td>

    <td rowspan="1" style="white-space: nowrap; width: 1%; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td rowspan="1" style="white-space: nowrap; width: 1%; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td rowspan="1" style="vertical-align: bottom; white-space: nowrap; width: 1%;"><span style="font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">$<br/>
                </span> </td>

    <td class="ffcell" rowspan="1" style="vertical-align: bottom; text-align: right; width: 6%; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">5.23</td>

    <td rowspan="1" style="white-space: nowrap; width: 1%; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td rowspan="1" style="white-space: nowrap; width: 1%; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td rowspan="1" style="white-space: nowrap; width: 1%; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td class="ffcell" rowspan="1" style="vertical-align: bottom; text-align: right; width: 6%; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">4,312</td>

    <td rowspan="1" style="white-space: nowrap; width: 1%; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td rowspan="1" style="vertical-align: top; width: 28%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">$6.54 - $9.81</td>

    <td colspan="1" rowspan="1" style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td rowspan="1" style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td rowspan="1" style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td class="ffcell" rowspan="1" style="vertical-align: bottom; text-align: right; width: 6%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">307,828</td>

    <td rowspan="1" style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td rowspan="1" style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td rowspan="1" style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td class="ffcell" rowspan="1" style="vertical-align: bottom; text-align: right; width: 6%; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; background-color: rgb(204, 238, 255);">9.0</td>

    <td rowspan="1" style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td rowspan="1" style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td rowspan="1" style="vertical-align: bottom; white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255);"><span style="font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">$<br/>
                </span> </td>

    <td class="ffcell" rowspan="1" style="vertical-align: bottom; text-align: right; width: 6%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">6.60</td>

    <td rowspan="1" style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td rowspan="1" style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td rowspan="1" style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td class="ffcell" rowspan="1" style="vertical-align: bottom; text-align: right; width: 6%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">3,248</td>

    <td rowspan="1" style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td rowspan="1" style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td rowspan="1" style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td class="ffcell" rowspan="1" style="vertical-align: bottom; text-align: right; width: 6%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">7,500</td>

    <td rowspan="1" style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td rowspan="1" style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td rowspan="1" style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td class="ffcell" rowspan="1" style="vertical-align: bottom; text-align: right; width: 6%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">0.6</td>

    <td rowspan="1" style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td rowspan="1" style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td rowspan="1" style="vertical-align: bottom; white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255);"><span style="font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">$<br/>
                </span> </td>

    <td class="ffcell" rowspan="1" style="vertical-align: bottom; text-align: right; width: 6%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">8.98</td>

    <td rowspan="1" style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td rowspan="1" style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td rowspan="1" style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td class="ffcell" rowspan="1" style="vertical-align: bottom; text-align: right; width: 6%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">61</td>

    <td rowspan="1" style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td style="vertical-align: top; width: 28%; padding-bottom: 2px;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">$10.80 - $17.49</p>
              </td>

    <td colspan="1" style="white-space: nowrap; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">&#160;</td>

    <td style="white-space: nowrap; width: 1%; padding-bottom: 2px;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td style="border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap; width: 1%;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td class="ffcell" style="border-bottom: 2px solid rgb(0, 0, 0); vertical-align: bottom; text-align: right; width: 6%;"><span style="font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">149,111<br/>
                </span> </td>

    <td style="padding-bottom: 2px; white-space: nowrap; width: 1%;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td style="white-space: nowrap; width: 1%; padding-bottom: 2px;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td style="white-space: nowrap; width: 1%; padding-bottom: 2px;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td class="ffcell" style="vertical-align: bottom; text-align: right; width: 6%; padding-bottom: 2px; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><span style="font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">8.7<br/>
                </span> </td>

    <td style="white-space: nowrap; width: 1%; padding-bottom: 2px;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td style="white-space: nowrap; width: 1%; padding-bottom: 2px;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td style="vertical-align: bottom; white-space: nowrap; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">$</td>

    <td class="ffcell" style="vertical-align: bottom; text-align: right; width: 6%; padding-bottom: 2px;"><span style="font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">8.74<br/>
                </span> </td>

    <td style="white-space: nowrap; width: 1%; padding-bottom: 2px;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td style="white-space: nowrap; width: 1%; padding-bottom: 2px;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td style="border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap; width: 1%;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td class="ffcell" style="border-bottom: 2px solid rgb(0, 0, 0); vertical-align: bottom; text-align: right; width: 6%;"><span style="font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">500<br/>
                </span> </td>

    <td style="padding-bottom: 2px; white-space: nowrap; width: 1%;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td style="white-space: nowrap; width: 1%; padding-bottom: 2px;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td style="border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap; width: 1%;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td class="ffcell" style="border-bottom: 2px solid rgb(0, 0, 0); vertical-align: bottom; text-align: right; width: 6%;"><span style="font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">14,000<br/>
                </span> </td>

    <td style="padding-bottom: 2px; white-space: nowrap; width: 1%;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td style="white-space: nowrap; width: 1%; padding-bottom: 2px;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td style="white-space: nowrap; width: 1%; padding-bottom: 2px;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td class="ffcell" style="vertical-align: bottom; text-align: right; width: 6%; padding-bottom: 2px;"><span style="font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">0.1<br/>
                </span> </td>

    <td style="white-space: nowrap; width: 1%; padding-bottom: 2px;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td style="white-space: nowrap; width: 1%; padding-bottom: 2px;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td style="vertical-align: bottom; white-space: nowrap; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">$</td>

    <td class="ffcell" style="vertical-align: bottom; text-align: right; width: 6%; padding-bottom: 2px;"><span style="font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">10.80<br/>
                </span> </td>

    <td style="white-space: nowrap; width: 1%; padding-bottom: 2px;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td style="white-space: nowrap; width: 1%; padding-bottom: 2px;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td style="border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap; width: 1%;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td class="ffcell" style="border-bottom: 2px solid rgb(0, 0, 0); vertical-align: bottom; text-align: right; width: 6%; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">89</td>

    <td style="padding-bottom: 2px; white-space: nowrap; width: 1%;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

  </tr>

  <tr style="height: 15px;">

    <td style="width: 28%; background-color: rgb(204, 238, 255); padding-bottom: 4px;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td colspan="1" style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; padding-bottom: 4px;">&#160;</td>

    <td style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 4px double rgb(0, 0, 0);">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td class="ffcell" style="vertical-align: bottom; text-align: right; width: 6%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; border-bottom: 4px double rgb(0, 0, 0);">5,141,516</td>

    <td style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td class="ffcell" style="vertical-align: bottom; text-align: right; width: 6%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; padding-bottom: 4px;">7.1</td>

    <td style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td style="vertical-align: bottom; white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; padding-bottom: 4px;">$</td>

    <td class="ffcell" style="vertical-align: bottom; text-align: right; width: 6%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; padding-bottom: 4px;">3.90</td>

    <td style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td style="vertical-align: bottom; white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; border-bottom: 4px double rgb(0, 0, 0);">$</td>

    <td class="ffcell" style="vertical-align: bottom; text-align: right; width: 6%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; border-bottom: 4px double rgb(0, 0, 0);">68,117</td>

    <td style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 4px double rgb(0, 0, 0);">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td class="ffcell" style="vertical-align: bottom; text-align: right; width: 6%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; border-bottom: 4px double rgb(0, 0, 0);">2,657,932</td>

    <td style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td class="ffcell" style="vertical-align: bottom; text-align: right; width: 6%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; padding-bottom: 4px;">5.7</td>

    <td style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td style="vertical-align: bottom; white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; padding-bottom: 4px;">$</td>

    <td class="ffcell" style="vertical-align: bottom; text-align: right; width: 6%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; padding-bottom: 4px;">3.03</td>

    <td style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td style="vertical-align: bottom; white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; border-bottom: 4px double rgb(0, 0, 0);">$</td>

    <td class="ffcell" style="vertical-align: bottom; text-align: right; width: 6%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; border-bottom: 4px double rgb(0, 0, 0);">37,540</td>

    <td style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

  </tr>


</table>
<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock', window );">Schedule of Unvested RSU Activity</a></td>
<td class="text"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal;">A summary of the Company&#8217;s unvested RSU activity and related information is as follows: </span>
<div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left;"> <span style="font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
            </span> </div>

<table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="text-align: left; font: 10pt 'Times New Roman'; width: 100%; border-spacing: 0;">


  <tr style="height: 15px;">

    <td style="padding-bottom: 2px;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">&#160;</p>
              </td>

    <td colspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; text-align: center; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"><strong>Shares</strong></p>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; text-align: center; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"><strong>Weighted</strong></p>
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; text-align: center; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"><strong>Average
                    Grant</strong></p>
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; text-align: center; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"><strong>Date Fair
                    Value</strong></p>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td style="vertical-align: top; width: 76%; background-color: #CCEEFF;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">Balance at December 31, 2021</p>
              </td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">4,485,133</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">$</td>

    <td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">1.34</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td style="vertical-align: top; width: 76%;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">Granted</p>
              </td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">1,174,266</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">$</td>

    <td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">1.74</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td style="vertical-align: top; width: 76%; background-color: #CCEEFF;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">Vested</p>
              </td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">(2,727,412</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">)</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">$</td>

    <td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">1.25</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td style="vertical-align: top; width: 76%; padding-bottom: 2px;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">Forfeited</p>
              </td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">(65,000</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">)</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">$</td>

    <td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">1.40</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td rowspan="1" style="vertical-align: top; font-family: 'Times New Roman'; width: 76%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">Balance at December 31, 2022</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">2,866,987</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">$</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">1.59</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td rowspan="1" style="vertical-align: top; width: 76%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">Granted<br/>
              </td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">3,389,760</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">$</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">3.42</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td rowspan="1" style="vertical-align: top; width: 76%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">Vested<br/>
              </td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">(1,199,445</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">)</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">$</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">1.63</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td rowspan="1" style="vertical-align: top; width: 76%; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">Forfeited<br/>
              </td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">(400,005</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">)</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">$</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">2.71</td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td style="vertical-align: top; width: 76%; background-color: #CCEEFF;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">Balance at December 31, 2023</p>
              </td>

    <td colspan="1" style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom">&#160;</td>

    <td colspan="1" style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom">&#160;</td>

    <td colspan="1" style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" valign="bottom">4,657,297<br/>
              </td>

    <td colspan="1" style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">$</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">2.81</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td rowspan="1" style="vertical-align: top; width: 76%;" valign="bottom"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Granted<br/>
                </span> </td>

    <td colspan="1" rowspan="1" style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">3,278,688</td>

    <td colspan="1" rowspan="1" style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">$<br/>
                </span> </td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">7.44</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td rowspan="1" style="vertical-align: top; width: 76%; background-color: rgb(204, 238, 255);" valign="bottom"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Vested<br/>
                </span> </td>

    <td colspan="1" rowspan="1" style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" valign="bottom">(1,886,463</td>

    <td colspan="1" rowspan="1" style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">)</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">$<br/>
                </span> </td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">2.50</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td rowspan="1" style="vertical-align: top; width: 76%; padding-bottom: 2px;" valign="bottom"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Forfeited<br/>
                </span> </td>

    <td colspan="1" rowspan="1" style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom">(303,532</td>

    <td colspan="1" rowspan="1" style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">)</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">$<br/>
                </span> </td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">3.92</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td rowspan="1" style="vertical-align: top; width: 76%; padding-bottom: 4px; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">Balance at December 31, 2024</td>

    <td colspan="1" rowspan="1" style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom">5,745,990</td>

    <td colspan="1" rowspan="1" style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" valign="bottom"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">$<br/>
                </span> </td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">5.50</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock', window );">Schedule of Stock-Based Compensation Expense</a></td>
<td class="text"><span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal;">Total stock-based compensation expense for all awards granted under the Company&#8217;s equity incentive plans for the years ended December 31, 2024, 2023 and 2022
              was as follows (in thousands):</span>
<div><span style="font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
        </span>
         <span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"> </span></div>

<table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="text-align: left; font: 10pt 'Times New Roman'; margin-left: auto; margin-right: auto; width: 100%; border-spacing: 0;">


  <tr style="height: 15px;">

    <td rowspan="1" style="text-align: center; font-style: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: center; vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="10" rowspan="1" style="vertical-align: bottom; text-align: center;" valign="bottom"><span style="font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">Year Ended December 31, </span><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"><br/>
                </span> </td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td rowspan="1" style="padding-bottom: 2px; text-align: center; font-style: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;" valign="bottom">&#160;(in thousands)</td>

    <td colspan="1" rowspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="2" rowspan="1" style="vertical-align: bottom; text-align: center; border-top: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: center; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"><strong> 2024<br/>
                  </strong></p>
              </td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; border-top: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; border-top: 2px solid rgb(0, 0, 0);" valign="bottom">&#160;</td>

    <td colspan="2" rowspan="1" style="vertical-align: bottom; text-align: center; border-top: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;<strong>2023</strong></td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; border-top: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: center; font-family: 'Times New Roman'; vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; border-top: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" rowspan="1" style="text-align: center; vertical-align: bottom; font-family: 'Times New Roman'; border-top: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;<span style="font-weight: bold;">2022</span></td>

    <td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td style="vertical-align: top; width: 64%; background-color: #CCEEFF;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">Research and development</p>
              </td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">$</td>

    <td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">98</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">$</td>

    <td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">40</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">$</td>

    <td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">19</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td style="vertical-align: top; width: 64%;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">Plasma center operating expenses</p>
              </td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">184</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">146</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">82</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td style="vertical-align: top; width: 64%; background-color: #CCEEFF;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">Selling, general and administrative</p>
              </td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">11,720</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">5,331</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">4,717</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td style="vertical-align: top; width: 64%; padding-bottom: 2px;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">Cost of product revenue</p>
              </td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">1,614</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">670</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">397</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td style="vertical-align: top; width: 64%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-indent: 9.5pt; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">Total stock-based compensation expense</p>
              </td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">$</td>

    <td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">13,616</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">$</td>

    <td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom">6,187</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">$</td>

    <td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">5,215</td>

    <td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of option exercise prices, by grouped ranges, including the upper and lower limits of the price range, the number of shares under option, weighted average exercise price and remaining contractual option terms.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (f)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in restricted stock units (RSUs).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>INCOME TAXES [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Income Tax Expense (Benefit)</a></td>
<td class="text"><p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-bottom: 0px; text-align: left;"> </p><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 36pt; text-align: left;">The components of the Company&#8217;s income tax expense (benefit) are as follows:<br/>
        </p><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 36pt; text-align: left;"> <br/>
        </p><p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-bottom: 0px; text-align: left;"> </p>
<table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="text-align: left; font: 10pt 'Times New Roman'; width: 100%; border-spacing: 0;">


  <tr style="height: 15px;">

    <td style="padding-bottom: 2px;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px;">&#160;</p>
              </td>

    <td colspan="1" rowspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="10" rowspan="1" style="vertical-align: bottom; text-align: center; border-bottom: #000000 solid 2px;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: center;"><strong>Year Ended December 31,</strong></p>
              </td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td rowspan="1" style="padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="10" rowspan="1" style="vertical-align: bottom; text-align: center; border-bottom: #000000 solid 2px;" valign="bottom"><span style="font-style: italic;">(In thousands) </span> <br/>
              </td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td style="vertical-align: bottom; padding: 0px 0px 2px; padding-bottom: 2px;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px;">&#160;</p>
              </td>

    <td colspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"><span style="font-weight: bold;">2024</span><br/>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"><span style="font-weight: bold;">2023</span><br/>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" rowspan="1" style="vertical-align: bottom; text-align: center; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"><span style="font-weight: bold;">2022</span><br/>
              </td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td style="vertical-align: top;" valign="bottom">Current:<br/>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; text-align: right;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; text-align: right;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; text-align: right;" valign="bottom"><br/>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td style="vertical-align: top; text-indent: 9pt; width: 64%; background-color: #CCEEFF;" valign="bottom">Federal<br/>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">$</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">10,434</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">$</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">-</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">$</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">-</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td style="vertical-align: top; text-indent: 9pt; width: 64%; padding-bottom: 2px;" valign="bottom">State<br/>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom">1,887</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom">-</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">-</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td style="vertical-align: top; text-indent: 18pt; width: 64%; background-color: #CCEEFF;" valign="bottom">Total current<br/>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">12,321</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">-</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">-</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td rowspan="1" style="vertical-align: top; width: 64%;" valign="bottom">Deferred:<br/>
              </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"><br/>
              </td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td rowspan="1" style="vertical-align: top; text-indent: 9pt; width: 64%; background-color: #CCEEFF;" valign="bottom">Federal<br/>
              </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">(72,858</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">)</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">-</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">-</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td style="vertical-align: top; text-indent: 9pt; width: 64%; padding-bottom: 2px;" valign="bottom">State<br/>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom">(11,422</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">)</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom">-</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">-</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td rowspan="1" style="vertical-align: top; text-indent: 18pt; width: 64%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">Total deferred<br/>
              </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">(84,280</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">)</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">-</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">-</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td style="vertical-align: top; width: 64%; padding-bottom: 4px;" valign="bottom">Total benefit from income taxes<br/>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" valign="bottom">$</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" valign="bottom">(71,959</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">)</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" valign="bottom">$</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" valign="bottom">-</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom">$</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom">-</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Reconciliation of Income Taxes</a></td>
<td class="text"><p style="margin: 0px; font-family: 'Times New Roman'; font-size: 10pt; text-align: left; text-indent: 36pt;">A reconciliation of income taxes at the U.S. federal statutory rate to the benefit for income taxes is as follows:</p><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="text-align: left; font: 10pt 'Times New Roman'; width: 100%; border-spacing: 0;">


  <tr style="height: 15px;">

    <td style="padding-bottom: 2px;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px;">&#160;</p>
              </td>

    <td colspan="1" rowspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="10" rowspan="1" style="vertical-align: bottom; text-align: center; border-bottom: #000000 solid 2px;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: center;"><strong>Year Ended December 31,</strong></p>
              </td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td rowspan="1" style="padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="10" rowspan="1" style="vertical-align: bottom; text-align: center; border-bottom: #000000 solid 2px;" valign="bottom"><span style="font-style: italic;">(In thousands) </span> <br/>
              </td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td style="padding-bottom: 2px;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px;">&#160;</p>
              </td>

    <td colspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: #000000 solid 2px;" valign="bottom"><span style="font-weight: bold;">2024</span><br/>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: #000000 solid 2px;" valign="bottom"><span style="font-weight: bold;">2023</span><br/>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" rowspan="1" style="text-align: center; vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"><span style="font-weight: bold;">2022</span><br/>
              </td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td style="vertical-align: top; width: 64%; background-color: rgb(204, 238, 255);" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-bottom: 0px; text-indent: -9pt; margin-left: 9pt;">Tax provision (benefit) at U.S. federal statutory rate</p>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">$</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">26,400</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">$</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">(5,930</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">)</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">$</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">(13,840</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">)</td>

  </tr>

  <tr style="height: 15px;">

    <td style="vertical-align: top; width: 64%;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-bottom: 0px; text-indent: -9pt; margin-left: 9pt;">State taxes<span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;">,</span> net of federal benefit<br/>
                </p>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">(9,931</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">)</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">(763</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">)</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">(1,773</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">)</td>

  </tr>

  <tr style="height: 15px;">

    <td rowspan="1" style="vertical-align: top; width: 64%; background-color: rgb(204, 238, 255);" valign="bottom">
                <div style="text-indent: -9pt; margin-left: 9pt;">Non-deductible executive compensation<br/>
                </div>
              </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">
                <div>4,340</div>
              </td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">983</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">862<br/>
              </td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td rowspan="1" style="vertical-align: top; width: 64%;" valign="bottom">
                <div style="text-indent: -9pt; margin-left: 9pt;">Excess tax benefits related to stock-based compensation<br/>
                </div>
              </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">(5,661</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">)</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">-</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom">-<br/>
              </td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td style="vertical-align: top; width: 64%; background-color: rgb(204, 238, 255);" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-bottom: 0px; text-indent: -9pt; margin-left: 9pt;">Change in valuation allowance</p>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">(87,969</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">)</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">4,696</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">15,117</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td style="vertical-align: top; width: 64%; padding-bottom: 2px;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-bottom: 0px; text-indent: -9pt; margin-left: 9pt;">Other</p>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom">862</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom">1,014</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">(366</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">)</td>

  </tr>

  <tr style="height: 15px;">

    <td style="vertical-align: top; width: 64%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-bottom: 0px; text-indent: -9pt; margin-left: 9pt;">Benefit for income taxes</p>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom">$</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom">(71,959</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">)</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom">$</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom">-</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">$</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">-</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>
<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Deferred Tax Assets</a></td>
<td class="text"><p style="margin: 0px; font-family: 'Times New Roman'; font-size: 10pt; text-align: left; text-indent: 36pt;">The significant components of the Company&#8217;s deferred tax assets are as follows:</p><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;">&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="text-align: left; font: 10pt 'Times New Roman'; width: 100%; border-spacing: 0;">


  <tr style="height: 15px;">

    <td style="padding-bottom: 2px;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px;">&#160;</p>
              </td>

    <td colspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="6" style="vertical-align: bottom; text-align: center; border-bottom: #000000 solid 2px;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: center;"><strong>Year Ended December 31,</strong></p>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td style="padding-bottom: 2px;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px;">&#160;</p>
              </td>

    <td colspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: #000000 solid 2px;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: center;"><strong> 2024<br/>
                  </strong></p>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: #000000 solid 2px;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: center;"><strong>2023<br/>
                  </strong></p>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td rowspan="1" valign="bottom">Deferred tax assets: <br/>
              </td>

    <td colspan="1" rowspan="1" style="text-align: center; vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="6" rowspan="1" style="vertical-align: bottom; text-align: center;" valign="bottom"><span style="font-style: italic;">(in thousands)</span> <br/>
              </td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td style="vertical-align: top; width: 76%; background-color: #CCEEFF;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-indent: 9pt;">Federal and state net operating loss carryforwards</p>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">$</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">65,615</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">$</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">76,645</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td style="vertical-align: top; width: 76%;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-indent: 9pt;">Interest expense limitation carryforwards</p>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">13,604</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">21,165</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td style="vertical-align: top; width: 76%; background-color: #CCEEFF;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-indent: 9pt;">Inventory</p>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">3,911</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">2,937</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td style="vertical-align: top; width: 76%;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-indent: 9pt;">Stock-based compensation<br/>
                </p>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">2,523</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">1,795</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td rowspan="1" style="vertical-align: top; text-indent: 9pt; width: 76%; background-color: #CCEEFF;" valign="bottom">Lease obligations <br/>
              </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">2,549</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">2,330</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td style="vertical-align: top; width: 76%; padding-bottom: 2px;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-indent: 9pt;">Accrued expenses and other</p>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom">5,779</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom">5,831</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td style="vertical-align: top; width: 76%; background-color: #CCEEFF;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-bottom: 0px; text-indent: 9pt;">Total gross deferred tax assets</p>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">93,981</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">110,703</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td style="vertical-align: top; width: 76%; padding-bottom: 2px;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in;">Less: valuation allowance for deferred tax assets</p>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom">-</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom">(101,422</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">)</td>

  </tr>

  <tr style="height: 15px;">

    <td rowspan="1" style="vertical-align: top; text-indent: 18pt; width: 76%; background-color: #CCEEFF;" valign="bottom">Total deferred tax assets, net of valuation allowance<br/>
              </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">93,981<br/>
              </td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">9,281<br/>
              </td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td rowspan="1" style="vertical-align: top; width: 76%;" valign="bottom">Deferred tax liabilities:<br/>
              </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td rowspan="1" style="vertical-align: top; text-indent: 9pt; width: 76%; background-color: #CCEEFF;" valign="bottom">Depreciation of property and equipment <br/>
              </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">(6,166</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">)</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">(6,837</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">)</td>

  </tr>

  <tr style="height: 15px;">

    <td rowspan="1" style="vertical-align: top; text-indent: 9pt; width: 76%;" valign="bottom">Right-of-use assets<br/>
              </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">(2,247</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">)</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">(2,077</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">)</td>

  </tr>

  <tr style="height: 15px;">

    <td rowspan="1" style="vertical-align: top; text-indent: 9pt; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">Other deferred tax liabilities <br/>
              </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">(1,288</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">)</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">(367</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">)</td>

  </tr>

  <tr style="height: 15px;">

    <td rowspan="1" style="vertical-align: top; text-indent: 18pt; width: 76%; padding-bottom: 2px;" valign="bottom">Total deferred tax liabilities <br/>
              </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom">(9,701</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">)</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom">(9,281</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">)</td>

  </tr>

  <tr style="height: 15px;">

    <td style="vertical-align: top; width: 76%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in;">Net deferred tax assets</p>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom">$</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom">84,280</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom">$</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom">-</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock', window );">Expiration of Federal Net Operating Loss</a></td>
<td class="text"><span style="font-family: 'Times New Roman'; font-size: 10pt; color: rgb(0, 0, 0);">The annual amount of Federal NOLs that expire each year is as follows (in thousands):<br/>
        </span><p style="margin: 0px; font-family: 'Times New Roman'; font-size: 10pt; text-indent: 36pt;"> <br/>
        </p><p style="margin: 0px; font-family: 'Times New Roman'; font-size: 10pt; text-indent: 36pt;"> </p>
<table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="text-align: left; font: 10pt 'Times New Roman'; width: 100%; border-spacing: 0;">


  <tr style="height: 15px;">

    <td colspan="1" rowspan="1" style="vertical-align: top; width: 12%; padding-top: 0px; padding-right: 0px; padding-left: 0px; text-align: center; border-bottom: 2px solid rgb(0, 0, 0);">Expiration Date</td>

    <td rowspan="1" style="vertical-align: top; width: 74%; padding: 0px 0px 2px;">&#160;<br/>
              </td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; white-space: nowrap; width: 1.18%; padding: 0px 0px 2px; text-align: right;">&#160;</td>

    <td colspan="2" rowspan="1" style="border-bottom: 2px solid; vertical-align: bottom; white-space: nowrap; text-align: center;">Remaining Available&#160; <br/>
              </td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; white-space: nowrap; width: 1.18%; padding: 0px 0px 2px; text-align: left;">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td colspan="1" rowspan="1" style="vertical-align: top; width: 12%; text-align: center; background-color: rgb(204, 238, 255);" valign="bottom">2031</td>

    <td rowspan="1" style="vertical-align: top; width: 74%; text-align: center; background-color: rgb(204, 238, 255);" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1.18%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">$ <br/>
              </td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 11%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">2,409</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1.18%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td colspan="1" style="vertical-align: top; width: 12%; text-align: center;" valign="bottom">2032 <br/>
              </td>

    <td style="vertical-align: top; width: 74%; text-align: center;" valign="bottom"><br/>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1.18%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;<br/>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 11%; white-space: nowrap;" valign="bottom">7,430</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1.18%; white-space: nowrap;" valign="bottom"><br/>
              </td>

  </tr>

  <tr style="height: 15px;">

    <td colspan="1" rowspan="1" style="vertical-align: top; width: 12%; text-align: center; background-color: rgb(204, 238, 255);" valign="bottom">&#160;2033</td>

    <td rowspan="1" style="vertical-align: top; width: 74%; text-align: center; background-color: rgb(204, 238, 255);" valign="bottom"><br/>
              </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1.18%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 11%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">11,295</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1.18%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td colspan="1" rowspan="1" style="vertical-align: top; width: 12%; text-align: center;" valign="bottom">&#160;2034</td>

    <td rowspan="1" style="vertical-align: top; width: 74%; text-align: center;" valign="bottom"><br/>
              </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1.18%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 11%; white-space: nowrap;" valign="bottom">1,025</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1.18%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td colspan="1" style="vertical-align: top; width: 12%; text-align: center; background-color: rgb(204, 238, 255);" valign="bottom">&#160;2035</td>

    <td style="vertical-align: top; width: 74%; text-align: center; background-color: rgb(204, 238, 255);" valign="bottom"><br/>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1.18%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 11%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">1,025</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1.18%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td colspan="1" rowspan="1" style="vertical-align: top; width: 12%; text-align: center;" valign="bottom">&#160;2036</td>

    <td rowspan="1" style="vertical-align: top; width: 74%; text-align: center;" valign="bottom"><br/>
              </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1.18%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 11%; white-space: nowrap;" valign="bottom">1,025</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1.18%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td colspan="1" rowspan="1" style="vertical-align: top; width: 12%; text-align: center; background-color: rgb(204, 238, 255);" valign="bottom">&#160;2037</td>

    <td rowspan="1" style="vertical-align: top; width: 74%; text-align: center; background-color: rgb(204, 238, 255);" valign="bottom"><br/>
              </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1.18%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 11%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">9,157</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1.18%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td colspan="1" style="vertical-align: top; width: 12%; padding-bottom: 2px; text-align: center;" valign="bottom">&#160;Indefinite</td>

    <td style="vertical-align: top; width: 74%; padding-bottom: 2px; text-align: center;" valign="bottom"><br/>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1.18%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 11%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom">232,240</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1.18%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"><br/>
              </td>

  </tr>

  <tr style="height: 15px;">

    <td colspan="1" style="vertical-align: top; width: 12%; text-align: center; padding-bottom: 4px; background-color: rgb(204, 238, 255);" valign="bottom">&#160;Total</td>

    <td style="vertical-align: top; width: 74%; text-align: center; padding-bottom: 4px; background-color: rgb(204, 238, 255);" valign="bottom"><br/>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1.18%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">$</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 11%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">265,606<br/>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1.18%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASE OBLIGATIONS (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>LEASE OBLIGATIONS [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Payments Under Lease Obligations</a></td>
<td class="text"><span style="font-size: 10pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-weight: 400;">The Company&#8217;s operating leases
              have a weighted average remaining term of 6.8</span><span style="font-size: 10pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-weight: 400;"> years. Scheduled payments under the Company&#8217;s lease obligations</span><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal;"> are as follows</span><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal;"> (in thousands)</span><span style="font-size: 10pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-weight: 400;">:</span><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-indent: 45px; text-align: left;"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 48px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; display: inline !important; float: none;"><br/>
          </span> </p>
<table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="text-align: left; font: 10pt 'Times New Roman'; width: 100%; border-spacing: 0;">


  <tr style="height: 15px;">

    <td style="vertical-align: top; width: 88%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: left;">Year ended December 31, 2025</p>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"><br/>
              </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">2,421</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td style="vertical-align: top; width: 88%;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: left;">2026<br/>
                </p>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">2,157</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td style="vertical-align: top; width: 88%; background-color: #CCEEFF;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: left;">2027<br/>
                </p>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">2,041</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td style="vertical-align: top; width: 88%;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: left;">2028<br/>
                </p>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">2,088</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td style="vertical-align: top; width: 88%; background-color: #CCEEFF;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: left;">2029<br/>
                </p>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">2,109</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td style="vertical-align: top; width: 88%; padding-bottom: 2px;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: left;">Thereafter</p>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom">4,041</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td style="vertical-align: top; width: 88%; background-color: #CCEEFF;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: left;">Total payments</p>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">14,857</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td style="vertical-align: top; width: 88%;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: left;">Less: imputed interest</p>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">(5,078</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">)</td>

  </tr>

  <tr style="height: 15px;">

    <td style="vertical-align: top; width: 88%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: left;">Current portion</p>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom">(1,218</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">)</td>

  </tr>

  <tr style="height: 15px;">

    <td style="vertical-align: top; width: 88%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: left;">Balance at December 31, 2024</p>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom">$</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom">8,561</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SEGMENTS (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>SEGMENTS [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock', window );">Summarized Financial Information Concerning Reportable Segments</a></td>
<td class="text"><span style="font-family: 'Times New Roman'; font-size: 10pt; color: rgb(0, 0, 0);">Summarized financial information concerning reportable segments is
          shown in the following tables:</span><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;">&#160;&#160;&#160;</p>
<table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="text-align: left; font: 10pt 'Times New Roman'; width: 100%; border-spacing: 0;">


  <tr style="height: 15px;">

    <td colspan="12" style="vertical-align: top; border-bottom: #000000 solid 2px;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: center;"><strong>Year Ended December 31, 2024</strong></p>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td style="padding-bottom: 2px;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: center;"><span style="font-style: italic;">(in thousands)</span><br/>
                </p>
              </td>

    <td colspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: center;"><strong>ADMA</strong></p>
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: center;"><strong> BioManufacturing</strong></p>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: center;"><strong>Plasma Collection<br/>
                  </strong></p>
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: center;"><span style="font-weight: bold;">Centers</span><strong><br/>
                  </strong></p>
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: center;"><strong> </strong></p>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: center;"><strong>Total</strong></p>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td style="vertical-align: top; width: 64%; background-color: #CCEEFF;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in;">Revenues</p>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">$</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">415,806</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">$</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">10,505</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">$</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">426,311</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td style="width: 64%;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px;">&#160;</p>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td style="vertical-align: top; width: 64%; background-color: #CCEEFF;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in;">Cost of product revenue</p>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">195,605</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">11,296</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">206,901</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td style="width: 64%;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px;">&#160;</p>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td style="vertical-align: top; width: 64%; background-color: #CCEEFF;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in;">Research and development<br/>
                </p>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">1,813</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">-</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">1,813</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td style="width: 64%;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px;">&#160;</p>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td style="vertical-align: top; width: 64%; background-color: #CCEEFF;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in;">Plasma center operating expenses<br/>
                </p>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">-</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">4,245</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">4,245</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td style="width: 64%;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px;">&#160;</p>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td rowspan="1" style="vertical-align: top; width: 64%; background-color: #CCEEFF;" valign="bottom">Selling, marketing and distribution<br/>
              </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">18,683</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">-</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">18,683</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td rowspan="1" style="vertical-align: top; width: 64%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td style="vertical-align: top; width: 64%; background-color: #CCEEFF;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in;">Depreciation and amortization expense<br/>
                </p>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">4,827</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">3,218</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">8,045</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td style="width: 64%;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px;">&#160;</p>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td rowspan="1" style="width: 64%; background-color: #CCEEFF;" valign="bottom">General and administrative expense<br/>
              </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">26,001</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">-</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">26,001</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td rowspan="1" style="width: 64%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td rowspan="1" style="width: 64%; background-color: #CCEEFF;" valign="bottom">Other expense, net<br/>
              </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">(178</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">)</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">(5</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">)</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">(183</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">)</td>

  </tr>

  <tr style="height: 15px;">

    <td rowspan="1" style="width: 64%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td rowspan="1" style="width: 64%; background-color: #CCEEFF;" valign="bottom">Income (loss) before taxes<br/>
              </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">173,138</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">(5,041</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">)</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">168,097</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td rowspan="1" style="width: 64%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td style="vertical-align: top; width: 64%; background-color: #CCEEFF;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in;">Expenditures for additions to long-lived assets<br/>
                </p>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">8,352</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">223</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">8,575</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td style="vertical-align: top; width: 64%;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in;">Total assets</p>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">289,297</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">30,477</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">319,774</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td rowspan="1" style="vertical-align: top; width: 64%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td rowspan="1" style="vertical-align: top; width: 64%;" valign="bottom"><span style="font-style: italic;">Reconciliation of revenues:</span><br/>
              </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td rowspan="1" style="vertical-align: top; text-indent: 9pt; width: 64%; background-color: #CCEEFF;" valign="bottom">Segment revenue<br/>
              </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">$</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">426,311</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td rowspan="1" style="vertical-align: top; text-indent: 9pt; width: 64%; padding-bottom: 2px;" valign="bottom">License revenue (see Note 2 - Revenue Recognition)<br/>
              </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom">143</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td rowspan="1" style="vertical-align: top; text-indent: 18pt; width: 64%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom">Consolidated revenues<br/>
              </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 4px double rgb(0, 0, 0);" valign="bottom">$<br/>
              </td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 4px double rgb(0, 0, 0);" valign="bottom">426,454</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td rowspan="1" style="vertical-align: top; width: 64%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td rowspan="1" style="vertical-align: top; width: 64%; background-color: rgb(204, 238, 255);" valign="bottom">
                <div style="margin-left: 9pt; text-indent: -9pt;"><span style="font-style: italic;">Reconciliation of selling, general and administrative expense:</span><br/>
                </div>
              </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td rowspan="1" style="vertical-align: top; text-indent: 9pt; width: 64%;" valign="bottom">Segment selling, marketing and distribution expense<br/>
              </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">$</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">18,683</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td rowspan="1" style="vertical-align: top; text-indent: 9pt; width: 64%; background-color: #CCEEFF;" valign="bottom">Segment general and administrative expense<br/>
              </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">26,001</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td rowspan="1" style="vertical-align: top; text-indent: 9pt; width: 64%; padding-bottom: 2px;" valign="bottom">Corporate general and administrative expense (a)<br/>
              </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom">29,440</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td rowspan="1" style="vertical-align: top; width: 64%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom">
                <div style="margin-left: 9pt">
                  <div style="margin-left: 9pt">
                    <div style="margin-left: 9pt; text-indent: -9pt;">Consolidated selling, general and administrative expense<br/>
                    </div>
                  </div>
                </div>
              </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 4px double rgb(0, 0, 0);" valign="bottom">$<br/>
              </td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 4px double rgb(0, 0, 0);" valign="bottom">74,124</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td rowspan="1" style="vertical-align: top; width: 64%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td rowspan="1" style="vertical-align: top; width: 64%; background-color: #CCEEFF;" valign="bottom"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: italic; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: nowrap; background-color: rgb(204, 238, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; display: inline !important; float: none;">Reconciliation of income (loss) before taxes:</span> </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td rowspan="1" style="vertical-align: top; text-indent: 9pt; width: 64%;" valign="bottom">Segment income before taxes<br/>
              </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">$</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">168,097</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td rowspan="1" style="vertical-align: top; text-indent: 9pt; width: 64%; background-color: #CCEEFF;" valign="bottom">License revenue<br/>
              </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">143</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td rowspan="1" style="vertical-align: top; width: 64%;" valign="bottom">
                <div style="margin-left: 9pt">
                  <div style="margin-left: 9pt; text-indent: -9pt;">Unallocated interest expense, primarily related to interest on senior debt (see Note 7)<br/>
                  </div>
                </div>
              </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">(13,930</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">)</td>

  </tr>

  <tr style="height: 15px;">

    <td rowspan="1" style="vertical-align: top; text-indent: 9pt; width: 64%; background-color: #CCEEFF;" valign="bottom">Loss on extinguishment of debt (see Note 7)<br/>
              </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">(1,243</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">)</td>

  </tr>

  <tr style="height: 15px;">

    <td rowspan="1" style="vertical-align: top; text-indent: 9pt; width: 64%;" valign="bottom">Unallocated interest income<br/>
              </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">2,087</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td rowspan="1" style="vertical-align: top; text-indent: 9pt; width: 64%; background-color: rgb(204, 238, 255); padding-bottom: 2px;" valign="bottom">Corporate general and administrative expense (a)<br/>
              </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom">(29,440</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; white-space: nowrap;" valign="bottom">)</td>

  </tr>

  <tr style="height: 15px;">

    <td rowspan="1" style="vertical-align: top; text-indent: 18pt; width: 64%; padding-bottom: 4px;" valign="bottom">Consolidated income before taxes<br/>
              </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom">$<br/>
              </td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom">125,714</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td rowspan="1" style="vertical-align: top; width: 64%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td rowspan="1" style="vertical-align: top; width: 64%;" valign="bottom"><span style="font-style: italic;">Reconciliation of total assets:</span><br/>
              </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td rowspan="1" style="vertical-align: top; text-indent: 9pt; width: 64%; background-color: #CCEEFF;" valign="bottom">Total segment assets<br/>
              </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">$</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">319,774</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td rowspan="1" style="vertical-align: top; text-indent: 9pt; width: 64%; padding-bottom: 2px;" valign="bottom">Corporate (b)<br/>
              </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom">168,904</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td rowspan="1" style="vertical-align: top; text-indent: 18pt; width: 64%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom">Consolidated total assets<br/>
              </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 4px double rgb(0, 0, 0);" valign="bottom">$<br/>
              </td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 4px double rgb(0, 0, 0);" valign="bottom">488,678</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>
<p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;"><br/>
        </p>
<div>
          <table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-spacing: 0;">


  <tr style="vertical-align: top;">

    <td style="text-align: right; vertical-align: top; width: 27pt;">
                  <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;">(a) - <br/>
                  </p>
                </td>

    <td style="text-align: left; vertical-align: top;">
                  <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: justify;">Primarily includes compensation expense,
                    including stock-based compensation expense, for certain executive officers and consultants, insurance, legal and investor relations expenses and accounting and tax fees that are not allocated to the Company&#8217;s operating segments.</p>
                </td>

  </tr>


</table>
        </div>
<p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;"><br/>
        </p>
<table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-spacing: 0;">


  <tr style="vertical-align: top;">

    <td style="text-align: right; vertical-align: top; width: 27pt;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;">(b) -<br/>
                </p>
              </td>

    <td style="text-align: left; vertical-align: top;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;">Primarily consists of cash and deferred tax
                  assets.</p>
              </td>

  </tr>


</table>
<p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;"><br/>
        </p><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;"> </p>
<table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="text-align: left; font: 10pt 'Times New Roman'; width: 100%; border-spacing: 0;">


  <tr style="height: 15px;">

    <td colspan="12" style="vertical-align: top; border-bottom: #000000 solid 2px;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: center;"><strong>Year Ended December 31, 2023</strong></p>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td style="padding-bottom: 2px;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: center;"><span style="font-style: italic;">(in thousands)</span><br/>
                </p>
              </td>

    <td colspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: center;"><strong>ADMA</strong></p>
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: center;"><strong> BioManufacturing</strong></p>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: center;"><strong>Plasma Collection<br/>
                  </strong></p>
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: center;"><span style="font-weight: bold;">Centers</span><strong><br/>
                  </strong></p>
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: center;"><strong> </strong></p>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: center;"><strong>Total</strong></p>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td style="vertical-align: top; width: 64%; background-color: #CCEEFF;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in;">Revenues</p>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">$</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">249,738</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">$</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">8,334</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">$</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">258,072</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td style="width: 64%;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px;">&#160;</p>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td style="vertical-align: top; width: 64%; background-color: #CCEEFF;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in;">Cost of product revenue</p>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">161,157</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">8,116</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">169,273</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td style="width: 64%;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px;">&#160;</p>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td style="vertical-align: top; width: 64%; background-color: #CCEEFF;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in;">Research and development<br/>
                </p>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">3,300</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">-</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">3,300</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td style="width: 64%;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px;">&#160;</p>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td style="vertical-align: top; width: 64%; background-color: #CCEEFF;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in;">Plasma center operating expenses<br/>
                </p>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">-</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">4,266</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">4,266</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td style="width: 64%;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px;">&#160;</p>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td rowspan="1" style="vertical-align: top; width: 64%; background-color: #CCEEFF;" valign="bottom">Selling, marketing and distribution<br/>
              </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">18,407</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">-</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">18,407</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td rowspan="1" style="vertical-align: top; width: 64%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td style="vertical-align: top; width: 64%; background-color: #CCEEFF;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in;">Depreciation and amortization expense<br/>
                </p>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">5,156</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">3,176</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">8,332</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td style="width: 64%;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px;">&#160;</p>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td rowspan="1" style="width: 64%; background-color: #CCEEFF;" valign="bottom">General and administrative expense<br/>
              </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">18,625</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">-</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">18,625</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td rowspan="1" style="width: 64%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td rowspan="1" style="width: 64%; background-color: #CCEEFF;" valign="bottom">Income (loss) before taxes<br/>
              </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">47,267</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">(4,049</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">)</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">43,218</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td rowspan="1" style="width: 64%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td style="vertical-align: top; width: 64%; background-color: #CCEEFF;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in;">Expenditures for additions to long-lived assets<br/>
                </p>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">2,952</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">1,819</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">4,771</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td style="vertical-align: top; width: 64%;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in;">Total assets</p>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">246,719</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">34,733</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">281,452</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td rowspan="1" style="vertical-align: top; width: 64%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td rowspan="1" style="vertical-align: top; width: 64%;" valign="bottom"><span style="font-style: italic;">Reconciliation of revenues:</span><br/>
              </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td rowspan="1" style="vertical-align: top; text-indent: 9pt; width: 64%; background-color: #CCEEFF;" valign="bottom">Segment revenue<br/>
              </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">$ <br/>
              </td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">258,072</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td rowspan="1" style="vertical-align: top; text-indent: 9pt; width: 64%; padding-bottom: 2px;" valign="bottom">License revenue (see Note 2 - Revenue Recognition)<br/>
              </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom">143</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td rowspan="1" style="vertical-align: top; text-indent: 18pt; width: 64%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom">Consolidated revenues<br/>
              </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 4px double rgb(0, 0, 0);" valign="bottom">$</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 4px double rgb(0, 0, 0);" valign="bottom">258,215</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td rowspan="1" style="vertical-align: top; width: 64%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td rowspan="1" style="vertical-align: top; width: 64%; background-color: rgb(204, 238, 255);" valign="bottom">
                <div style="margin-left: 9pt; text-indent: -9pt;"><span style="font-style: italic;">Reconciliation of selling, general and administrative expense:</span><br/>
                </div>
              </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td rowspan="1" style="vertical-align: top; text-indent: 9pt; width: 64%;" valign="bottom">Segment selling, marketing and distribution expense<br/>
              </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">$</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">18,407</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td rowspan="1" style="vertical-align: top; text-indent: 9pt; width: 64%; background-color: #CCEEFF;" valign="bottom">Segment general and administrative expense<br/>
              </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">18,625</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td rowspan="1" style="vertical-align: top; text-indent: 9pt; width: 64%; padding-bottom: 2px;" valign="bottom">Corporate general and administrative expense (a)<br/>
              </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom">21,988</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td rowspan="1" style="vertical-align: top; width: 64%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom">
                <div style="margin-left: 9pt">
                  <div style="margin-left: 9pt">
                    <div style="margin-left: 9pt; text-indent: -9pt;">Consolidated selling, general and administrative expense<br/>
                    </div>
                  </div>
                </div>
              </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 4px double rgb(0, 0, 0);" valign="bottom">$</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 4px double rgb(0, 0, 0);" valign="bottom">59,020</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td rowspan="1" style="vertical-align: top; width: 64%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td rowspan="1" style="vertical-align: top; width: 64%; background-color: #CCEEFF;" valign="bottom"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: italic; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: nowrap; background-color: rgb(204, 238, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; display: inline !important; float: none;">Reconciliation of income (loss) before taxes:</span></td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td rowspan="1" style="vertical-align: top; text-indent: 9pt; width: 64%;" valign="bottom">Segment income before taxes<br/>
              </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">$</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">43,218</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td rowspan="1" style="vertical-align: top; text-indent: 9pt; width: 64%; background-color: #CCEEFF;" valign="bottom">License revenue<br/>
              </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">143</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td rowspan="1" style="vertical-align: top; width: 64%;" valign="bottom">
                <div style="margin-left: 9pt">
                  <div style="margin-left: 9pt; text-indent: -9pt;">Unallocated interest expense, primaril related to interest on senior debt (see Note 7)<br/>
                  </div>
                </div>
              </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">(25,027</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">)</td>

  </tr>

  <tr style="height: 15px;">

    <td rowspan="1" style="vertical-align: top; text-indent: 9pt; width: 64%; background-color: #CCEEFF;" valign="bottom">Loss on extinguishment of debt (see Note 7)<br/>
              </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">(26,174</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">)</td>

  </tr>

  <tr style="height: 15px;">

    <td rowspan="1" style="vertical-align: top; text-indent: 9pt; width: 64%;" valign="bottom">Unallocated interest income<br/>
              </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">1,589</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td rowspan="1" style="vertical-align: top; text-indent: 9pt; width: 64%; background-color: rgb(204, 238, 255); padding-bottom: 2px;" valign="bottom">Corporate general and administrative expense (a)<br/>
              </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom">(21,988</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; white-space: nowrap;" valign="bottom">)</td>

  </tr>

  <tr style="height: 15px;">

    <td rowspan="1" style="vertical-align: top; text-indent: 18pt; width: 64%; padding-bottom: 4px;" valign="bottom">Consolidated income before taxes<br/>
              </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom">$</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom">(28,239</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">)</td>

  </tr>

  <tr style="height: 15px;">

    <td rowspan="1" style="vertical-align: top; width: 64%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td rowspan="1" style="vertical-align: top; width: 64%;" valign="bottom"><span style="font-style: italic;">Reconciliation of total assets:</span><br/>
              </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td rowspan="1" style="vertical-align: top; text-indent: 9pt; width: 64%; background-color: #CCEEFF;" valign="bottom">Total segment assets<br/>
              </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">$ <br/>
              </td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">281,452</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td rowspan="1" style="vertical-align: top; text-indent: 9pt; width: 64%; padding-bottom: 2px;" valign="bottom">Corporate (b)<br/>
              </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom">47,730</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td rowspan="1" style="vertical-align: top; text-indent: 18pt; width: 64%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom">Consolidated total assets<br/>
              </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 4px double rgb(0, 0, 0);" valign="bottom">$</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 4px double rgb(0, 0, 0);" valign="bottom">329,182</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>
<p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;"> <br/>
        </p>
<table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-spacing: 0;">


  <tr style="vertical-align: top;">

    <td style="text-align: right; vertical-align: top; width: 27pt;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;">(a) - <br/>
                </p>
              </td>

    <td style="text-align: left; vertical-align: top;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: justify;">Primarily includes compensation expense, including stock-based compensation expense, for certain executive officers and consultants, insurance,
                  legal and investor relations expenses and accounting and tax fees that are not allocated to the Company&#8217;s operating segments.</p>
              </td>

  </tr>


</table>
<p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;"> </p><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;"> </p><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;"> <br/>
        </p>
<table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-spacing: 0;">


  <tr style="vertical-align: top;">

    <td style="text-align: right; vertical-align: top; width: 27pt;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;">(b) -<br/>
                </p>
              </td>

    <td style="text-align: left; vertical-align: top;">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;">Primarily consists of cash.</p>
              </td>

  </tr>


</table>
<p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;"> </p><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;"> </p><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;"> <br/>
        </p>
<table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="text-align: left; font: 10pt 'Times New Roman'; width: 100%; border-spacing: 0;">


  <tr style="height: 15px;">

    <td colspan="12" style="vertical-align: top; border-bottom: #000000 solid 2px;" valign="bottom">
                  <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: center;"><strong>Year Ended December 31, 2022</strong></p>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td style="padding-bottom: 2px;" valign="bottom">
                  <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: center;"><span style="font-style: italic;">(in thousands)</span><br/>
                  </p>
                </td>

    <td colspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                  <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: center;"><strong>ADMA</strong></p>
                  <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: center;"><strong> BioManufacturing</strong></p>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                  <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: center;"><strong>Plasma Collection<br/>
                    </strong></p>
                  <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: center;"><span style="font-weight: bold;">Centers</span><strong><br/>
                    </strong></p>
                  <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: center;"><strong> </strong></p>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                  <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: center;"><strong>Total</strong></p>
                </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td style="vertical-align: top; width: 64%; background-color: #CCEEFF;" valign="bottom">
                  <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in;">Revenues</p>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">$</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">144,070</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">$</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">9,867</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">$</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">153,937</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td style="width: 64%;" valign="bottom">
                  <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px;">&#160;</p>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td style="vertical-align: top; width: 64%; background-color: #CCEEFF;" valign="bottom">
                  <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in;">Cost of product revenue</p>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">108,882</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">9,933</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">118,815</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td style="width: 64%;" valign="bottom">
                  <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px;">&#160;</p>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td style="vertical-align: top; width: 64%; background-color: #CCEEFF;" valign="bottom">
                  <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in;">Research and development<br/>
                  </p>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">3,614</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">-</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">3,614</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td style="width: 64%;" valign="bottom">
                  <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px;">&#160;</p>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td style="vertical-align: top; width: 64%; background-color: #CCEEFF;" valign="bottom">
                  <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in;">Plasma center operating expenses<br/>
                  </p>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">-</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">17,843</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">17,843</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td style="width: 64%;" valign="bottom">
                  <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px;">&#160;</p>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td rowspan="1" style="vertical-align: top; width: 64%; background-color: #CCEEFF;" valign="bottom">Selling, marketing and distribution<br/>
                </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">13,667</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">-</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">13,667</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td rowspan="1" style="vertical-align: top; width: 64%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td style="vertical-align: top; width: 64%; background-color: #CCEEFF;" valign="bottom">
                  <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in;">Depreciation and amortization expense<br/>
                  </p>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">4,709</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">2,404</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">7,113</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td style="width: 64%;" valign="bottom">
                  <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px;">&#160;</p>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td rowspan="1" style="width: 64%; background-color: #CCEEFF;" valign="bottom">General and administrative expense<br/>
                </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">16,312</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">-</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">16,312</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td rowspan="1" style="width: 64%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td rowspan="1" style="width: 64%; background-color: #CCEEFF;" valign="bottom">Income (loss) before taxes<br/>
                </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">374</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">(17,911</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">)</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">(17,537</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">)</td>

  </tr>

  <tr style="height: 15px;">

    <td rowspan="1" style="width: 64%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td style="vertical-align: top; width: 64%; background-color: #CCEEFF;" valign="bottom">
                  <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in;">Expenditures for additions to long-lived assets<br/>
                  </p>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">5,247</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">8,664</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">13,911</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td style="vertical-align: top; width: 64%;" valign="bottom">
                  <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in;">Total assets</p>
                </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">238,159</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">37,071</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">275,230</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td rowspan="1" style="vertical-align: top; width: 64%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td rowspan="1" style="vertical-align: top; width: 64%;" valign="bottom"><span style="font-style: italic;">Reconciliation of revenues:</span><br/>
                </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td rowspan="1" style="vertical-align: top; text-indent: 9pt; width: 64%; background-color: #CCEEFF;" valign="bottom">Segment revenue<br/>
                </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">$</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">153,937</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td rowspan="1" style="vertical-align: top; text-indent: 9pt; width: 64%; padding-bottom: 2px;" valign="bottom">License revenue (see Note 2 - Revenue Recognition)<br/>
                </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom">143</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td rowspan="1" style="vertical-align: top; text-indent: 18pt; width: 64%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom">Consolidated revenues<br/>
                </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 4px double rgb(0, 0, 0);" valign="bottom">$</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 4px double rgb(0, 0, 0);" valign="bottom">154,080</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td rowspan="1" style="vertical-align: top; width: 64%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td rowspan="1" style="vertical-align: top; width: 64%; background-color: rgb(204, 238, 255); font-style: italic;" valign="bottom">
                  <div style="margin-left: 9pt; text-indent: -9pt;">Reconciliation of selling, general and administrative expense:<br/>
                  </div>
                </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td rowspan="1" style="vertical-align: top; text-indent: 9pt; width: 64%;" valign="bottom">Segment selling, marketing and distribution expense<br/>
                </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">$</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">13,667</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td rowspan="1" style="vertical-align: top; text-indent: 9pt; width: 64%; background-color: #CCEEFF;" valign="bottom">Segment general and administrative expense<br/>
                </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">16,312</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td rowspan="1" style="vertical-align: top; text-indent: 9pt; width: 64%; padding-bottom: 2px;" valign="bottom">Corporate general and administrative expense (a)<br/>
                </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom">22,479</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td rowspan="1" style="vertical-align: top; width: 64%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom">
                  <div style="margin-left: 27pt; text-indent: -9pt;">Consolidated selling, general and administrative expense<br/>
                  </div>
                </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 4px double rgb(0, 0, 0);" valign="bottom">$</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 4px double rgb(0, 0, 0);" valign="bottom">52,458</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td rowspan="1" style="vertical-align: top; width: 64%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td rowspan="1" style="vertical-align: top; width: 64%; background-color: #CCEEFF;" valign="bottom"><span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: italic; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: nowrap; background-color: rgb(204, 238, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; display: inline !important; float: none;">Reconciliation of income (loss) before taxes:</span> </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td rowspan="1" style="vertical-align: top; text-indent: 9pt; width: 64%;" valign="bottom">Segment income before taxes<br/>
                </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">$</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">(17,537</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">)</td>

  </tr>

  <tr style="height: 15px;">

    <td rowspan="1" style="vertical-align: top; text-indent: 9pt; width: 64%; background-color: #CCEEFF;" valign="bottom">License revenue<br/>
                </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">143</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td rowspan="1" style="vertical-align: top; width: 64%;" valign="bottom">
                  <div style="margin-left: 9pt">
                    <div style="margin-left: 9pt; text-indent: -9pt;">Unallocated interest expense, primaril related to interest on senior debt (see Note 7)<br/>
                    </div>
                  </div>
                </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">(19,276</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">)</td>

  </tr>

  <tr style="height: 15px;">

    <td rowspan="1" style="vertical-align: top; text-indent: 9pt; width: 64%; background-color: #CCEEFF;" valign="bottom">Loss on extinguishment of debt (see Note 7)<br/>
                </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">(6,670</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">)</td>

  </tr>

  <tr style="height: 15px;">

    <td rowspan="1" style="vertical-align: top; text-indent: 9pt; width: 64%;" valign="bottom">Other expense<br/>
                </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">(85</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">)</td>

  </tr>

  <tr style="height: 15px;">

    <td rowspan="1" style="vertical-align: top; text-indent: 9pt; width: 64%; background-color: rgb(204, 238, 255); padding-bottom: 2px;" valign="bottom">Corporate general and administrative expense (a)<br/>
                </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom">(22,479</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; white-space: nowrap;" valign="bottom">)</td>

  </tr>

  <tr style="height: 15px;">

    <td rowspan="1" style="vertical-align: top; text-indent: 18pt; width: 64%; padding-bottom: 4px;" valign="bottom">Consolidated income before taxes<br/>
                </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom">$</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom">(65,904</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">)</td>

  </tr>

  <tr style="height: 15px;">

    <td rowspan="1" style="vertical-align: top; width: 64%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td rowspan="1" style="vertical-align: top; width: 64%;" valign="bottom"><span style="font-style: italic;">Reconciliation of total assets:</span><br/>
                </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td rowspan="1" style="vertical-align: top; text-indent: 9pt; width: 64%; background-color: #CCEEFF;" valign="bottom">Total segment assets<br/>
                </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom">$</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom">275,230</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td rowspan="1" style="vertical-align: top; text-indent: 9pt; width: 64%; padding-bottom: 2px;" valign="bottom">Corporate (b)<br/>
                </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom">73,231</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td rowspan="1" style="vertical-align: top; text-indent: 18pt; width: 64%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom">Consolidated total assets<br/>
                </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 4px double rgb(0, 0, 0);" valign="bottom">$</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 4px double rgb(0, 0, 0);" valign="bottom">348,461</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>

<div><br/>
          </div>

<div>
            <table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-spacing: 0;">


  <tr style="vertical-align: top;">

    <td style="text-align: right; vertical-align: top; width: 27pt;">
                    <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;">(a) - <br/>
                    </p>
                  </td>

    <td style="text-align: left; vertical-align: top;">
                    <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: justify;">Primarily includes compensation expense, including stock-based compensation expense, for certain executive officers and consultants,
                      insurance, legal and investor relations expenses and accounting and tax fees that are not allocated to the Company&#8217;s operating segments.</p>
                  </td>

  </tr>


</table>
          </div>

<div><br/>
          </div>

<div>
            <table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-spacing: 0;">


  <tr style="vertical-align: top;">

    <td style="text-align: right; vertical-align: top; width: 27pt;">
                    <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;">(b) -<br/>
                    </p>
                  </td>

    <td style="text-align: left; vertical-align: top;">
                    <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;">Primarily consists of cash.</p>
                  </td>

  </tr>


</table>
             </div>
<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock', window );">Net Revenues According to Geographic Area</a></td>
<td class="text">
<div style="display:none;"><br/></div>
<div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;">Net revenues according to geographic area, based on the location of where the product is shipped, are as follows:</div>

<div><br/>
            </div>

<table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%; border-spacing: 0;">


  <tr>

    <td style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="18" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom">
                    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Year Ended December 31, 2024</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">ADMA </div>
                    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">BioManufacturing</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Plasma Centers</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Total Segment </div>
                    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Revenue</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">License </div>
                    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Revenue</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Consolidated </div>
                    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Revenue</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 40%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">United States</div>
                  </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
                  </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;">400,336</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
                  </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;">9,669</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
                  </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;">410,005</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
                  </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;">143</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
                  </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;">410,148</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 40%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">
                    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">International</div>
                  </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;">15,470</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;">836</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;">16,306</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;">-</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;">16,306</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 40%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Total revenues</div>
                  </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
                  </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;">415,806</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
                  </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;">10,505</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
                  </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;">426,311</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
                  </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;">143</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
                  </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;">426,454</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>

<div><br/>
            </div>

<table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%; border-spacing: 0;">


  <tr>

    <td style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="18" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom">
                    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Year Ended December 31, 2023</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">ADMA </div>
                    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">BioManufacturing</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Plasma Centers</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Total Segment </div>
                    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Revenue</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">License </div>
                    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Revenue</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Consolidated </div>
                    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Revenue</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 40%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">United States</div>
                  </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
                  </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;">237,454</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
                  </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;">7,284</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
                  </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;">244,738</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
                  </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;">143</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
                  </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;">244,881</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 40%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">
                    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">International</div>
                  </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;">12,284</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;">1,050</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;">13,334</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;">-</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;">13,334</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 40%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Total revenues</div>
                  </td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
                  </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;">249,738</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
                  </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;">8,334</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
                  </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;">258,072</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
                  </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;">143</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
                  </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;">258,215</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>

<div><br/>
            </div>

<table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%; border-spacing: 0;">


  <tr>

    <td style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="18" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom">
                    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Year Ended December 31, 2022</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">ADMA </div>
                    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">BioManufacturing</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Plasma Centers</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Total Segment </div>
                    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Revenue</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">License </div>
                    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Revenue</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Consolidated </div>
                    <div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;">Revenue</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 40%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">United States</div>
                  </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
                  </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;">136,827</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
                  </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;">9,457</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
                  </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;">146,284</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
                  </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;">143</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
                  </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;">146,427</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 40%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">
                    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">International</div>
                  </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;">7,243</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;">410</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;">7,653</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;">-</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;">7,653</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr>

    <td style="vertical-align: bottom; width: 40%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;">Total revenues</div>
                  </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
                  </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;">144,070</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
                  </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;">9,867</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
                  </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;">153,937</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
                  </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;">143</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;">$</div>
                  </td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">
                    <div style="font-family: 'Times New Roman'; font-size: 10pt;">154,080</div>
                  </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-25<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowElementsAbstract', window );"><strong>SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock', window );">Supplemental Cash Flow Information</a></td>
<td class="text"><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-indent: 45px; text-align: justify;">Supplemental cash flow information for the years ended December 31, 2024, 2023 and 2022 is as follows:</p><p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px;">&#160; <br/>
        </p>
<table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="text-align: left; font: 10pt 'Times New Roman'; width: 100%; border-spacing: 0;">


  <tr style="height: 15px;">

    <td style="padding-bottom: 2px;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px;">&#160;</p>
              </td>

    <td colspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: #000000 solid 2px;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: center;"><strong>2024</strong></p>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px;" valign="bottom">&#160;</td>

    <td colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: #000000 solid 2px;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: center;"><strong>2023</strong></p>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"><span style="font-weight: bold;">2022</span><br/>
              </td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td rowspan="1" style="vertical-align: top;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="10" rowspan="1" style="text-align: center;" valign="bottom"><span style="font-style: italic;">(In thousands)</span><br/>
              </td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td style="vertical-align: top;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in;"><strong>SUPPLEMENTAL CASH FLOW INFORMATION:</strong></p>
              </td>

    <td colspan="1" style="vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="2" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom;" valign="bottom">&#160;</td>

    <td colspan="2" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="2" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td style="vertical-align: top; width: 64%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 15px;">Cash paid for interest</p>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 4px double rgb(0, 0, 0);" valign="bottom">$</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 4px double rgb(0, 0, 0);" valign="bottom">10,668</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 4px double rgb(0, 0, 0);" valign="bottom">$</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 4px double rgb(0, 0, 0);" valign="bottom">18,051</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom">$</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom">13,880</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td rowspan="1" style="margin-top: 0px; margin-right: 0px; margin-bottom: 0px; vertical-align: top; width: 64%; padding: 0px 0px 4px; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;">
                <div style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 15px;">Cash paid for income taxes<br/>
                </div>
              </td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom">$</td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom">9,392</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom">$<br/>
              </td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom">-</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom">$<br/>
              </td>

    <td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom">-</td>

    <td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td style="vertical-align: top; width: 64%; background-color: rgb(204, 238, 255);" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in;"><strong>Noncash Financing and Investing Activities:</strong></p>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td style="vertical-align: top; width: 64%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 15px;">Equipment acquired reflected in accounts payable and accrued liabilities</p>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom">$</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom">725</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom">$</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom">86</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom">$</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom">1,495</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td style="vertical-align: top; width: 64%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 15px;">Right-to-use assets in exchange for lease obligations</p>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom">$</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom">-</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom">$</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom">130</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">$</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">4,048</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>

  <tr style="height: 15px;">

    <td style="vertical-align: top; width: 64%; padding-bottom: 4px;" valign="bottom">
                <p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 15px;">Warrants issued in connection with notes payable</p>
              </td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom">$</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom">-</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom">$</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom">5,595</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom">$</td>

    <td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom">9,570</td>

    <td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom">&#160;</td>

  </tr>


</table>
<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of supplemental cash flow information for the periods presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowElementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowElementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ORGANIZATION AND BUSINESS (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2024 </div>
<div>Facility </div>
<div>Product</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquityAbstract', window );"><strong>Organization and Business [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_NumberOfFDALicensedPlasmaCollectionFacilities', window );">Number of FDA-licensed plasma collection facilities | Facility</a></td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_NumberOfFDAApprovedProduct', window );">Number of FDA approved product | Product</a></td>
<td class="nump">3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_NumberOfFDAApprovedProduct">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of products approved by FDA.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_NumberOfFDAApprovedProduct</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_NumberOfFDALicensedPlasmaCollectionFacilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of plasma collection facilities having FDA license.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_NumberOfFDALicensedPlasmaCollectionFacilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOrSaleOfEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES, Use of Estimates (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_UseOfEstimatesAbstract', window );"><strong>Use of Estimates [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 426,454<span></span>
</td>
<td class="nump">$ 258,215<span></span>
</td>
<td class="nump">$ 154,080<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities', window );">Accrual adjustments</a></td>
<td class="nump">33,962<span></span>
</td>
<td class="nump">$ 32,919<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ChangeInAccountingEstimateByTypeAxis=adma_AccrualForUSMedicaidRebatesMember', window );">Accrual for U.S. Medicaid Rebates [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_UseOfEstimatesAbstract', window );"><strong>Use of Estimates [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">12,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities', window );">Accrual adjustments</a></td>
<td class="nump">$ 12,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_UseOfEstimatesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_UseOfEstimatesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesAndOtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ChangeInAccountingEstimateByTypeAxis=adma_AccrualForUSMedicaidRebatesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ChangeInAccountingEstimateByTypeAxis=adma_AccrualForUSMedicaidRebatesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES, Accounts Receivable (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetAbstract', window );"><strong>Accounts Receivable [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_AccountsReceivableAllowanceForContractualCreditsAndDoubtfulAccounts', window );">Accounts receivable, allowances for contractual credits and credit losses</a></td>
<td class="nump">$ 0.2<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_AccountsReceivableAllowanceForContractualCreditsAndDoubtfulAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for contractual credits and doubtful accounts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_AccountsReceivableAllowanceForContractualCreditsAndDoubtfulAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES, Property and Equipment (Details)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful life</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful life</a></td>
<td class="text">15 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember', window );">Buildings [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful life</a></td>
<td class="text">30 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES, Goodwill (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairedAccumulatedImpairmentLossAbstract', window );"><strong>Goodwill [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">$ 3,530<span></span>
</td>
<td class="nump">$ 3,530<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Impairment charges related to goodwill</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482598/350-20-45-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairedAccumulatedImpairmentLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairedAccumulatedImpairmentLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of impairment loss from asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482598/350-20-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES, Impairment of Long-lived Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetImpairmentChargesAbstract', window );"><strong>Impairment of Long-lived Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse', window );">Impairment of long-lived assets</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentChargesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentChargesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-2<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482130/360-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLongLivedAssetsHeldForUse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES, Revenue Recognition (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue Recognition [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_CustomerPaymentTerms', window );">Customer payment term</a></td>
<td class="text">90 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=adma_BiotestLicenseAgreementMember', window );">Biotest License Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue Recognition [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_DeferredRevenueRemainingAmortizationPeriod', window );">Amortization period</a></td>
<td class="text">22 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_CustomerPaymentTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The term within which customers are generally required to make payments, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_CustomerPaymentTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_DeferredRevenueRemainingAmortizationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Remaining amortization period of deferred revenue, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_DeferredRevenueRemainingAmortizationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=adma_BiotestLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=adma_BiotestLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES, Advertising and Marketing Expenses (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketingAndAdvertisingExpenseAbstract', window );"><strong>Advertising and Marketing Expenses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketingAndAdvertisingExpense', window );">Advertising and marketing expenses</a></td>
<td class="nump">$ 2.7<span></span>
</td>
<td class="nump">$ 3.3<span></span>
</td>
<td class="nump">$ 2.2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketingAndAdvertisingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total expense recognized in the period for promotion, public relations, and brand or product advertising.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketingAndAdvertisingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketingAndAdvertisingExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketingAndAdvertisingExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES, Stock-based Compensation (Details) - Officer<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationAbstract', window );"><strong>Stock-based Compensation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_NumberOfExecutiveOfficers', window );">Number of executive officers</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationAbstract', window );"><strong>Stock-based Compensation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Equity incentive plans, vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1', window );">Equity incentive plans, term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationAbstract', window );"><strong>Stock-based Compensation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Equity incentive plans, vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_NumberOfExecutiveOfficers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The milestone-based equity awards which were awarded to number of executive officers.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_NumberOfExecutiveOfficers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Estimated period over which an employee is required to provide service in exchange for the equity-based payment award, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT ACCOUNTING POLICIES, Earnings (Loss) Per Share (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings (Loss) Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income available to common stockholders (numerator)</a></td>
<td class="nump">$ 197,673<span></span>
</td>
<td class="num">$ (28,239)<span></span>
</td>
<td class="num">$ (65,904)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average number of common shares (denominator) (in shares)</a></td>
<td class="nump">233,084,236<span></span>
</td>
<td class="nump">223,977,315<span></span>
</td>
<td class="nump">197,874,895<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic earnings per common shares (in dollars per share)</a></td>
<td class="nump">$ 0.85<span></span>
</td>
<td class="num">$ (0.13)<span></span>
</td>
<td class="num">$ (0.33)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Total shares - diluted (denominator) (in shares)</a></td>
<td class="nump">243,342,466<span></span>
</td>
<td class="nump">223,977,315<span></span>
</td>
<td class="nump">197,874,895<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted earnings per common share (in dollars per share)</a></td>
<td class="nump">$ 0.81<span></span>
</td>
<td class="num">$ (0.13)<span></span>
</td>
<td class="num">$ (0.33)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract', window );"><strong>Loss Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive securities (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">23,066,387<span></span>
</td>
<td class="nump">24,648,346<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_DilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmountShares', window );">Potentially dilutive securities not included in computation of diluted loss per share amount (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings (Loss) Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment', window );">Potential shares of common stock arising from outstanding stock options, warrants and unvested RSUs (in shares)</a></td>
<td class="nump">4,150,584<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract', window );"><strong>Loss Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive securities (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,906,184<span></span>
</td>
<td class="nump">8,256,211<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings (Loss) Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment', window );">Potential shares of common stock arising from outstanding stock options, warrants and unvested RSUs (in shares)</a></td>
<td class="nump">3,085,640<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract', window );"><strong>Loss Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive securities (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,502,906<span></span>
</td>
<td class="nump">13,525,148<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings (Loss) Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment', window );">Potential shares of common stock arising from outstanding stock options, warrants and unvested RSUs (in shares)</a></td>
<td class="nump">3,022,006<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract', window );"><strong>Loss Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive securities (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,657,297<span></span>
</td>
<td class="nump">2,866,987<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_DilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmountShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would have been antidilutive for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_DilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmountShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>INVENTORIES (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>INVENTORIES [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryRawMaterials', window );">Raw materials</a></td>
<td class="nump">$ 60,473<span></span>
</td>
<td class="nump">$ 52,999<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcess', window );">Work-in-process</a></td>
<td class="nump">61,641<span></span>
</td>
<td class="nump">49,621<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoods', window );">Finished goods</a></td>
<td class="nump">48,121<span></span>
</td>
<td class="nump">70,286<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Total inventories</a></td>
<td class="nump">$ 170,235<span></span>
</td>
<td class="nump">$ 172,906<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterials">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterials</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>PROPERTY AND EQUIPMENT (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 88,259<span></span>
</td>
<td class="nump">$ 80,572<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: accumulated depreciation</a></td>
<td class="num">(33,552)<span></span>
</td>
<td class="num">(26,737)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Total property and equipment, net</a></td>
<td class="nump">54,707<span></span>
</td>
<td class="nump">53,835<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation expense</a></td>
<td class="nump">7,700<span></span>
</td>
<td class="nump">7,600<span></span>
</td>
<td class="nump">$ 6,400<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ManufacturingFacilityMember', window );">Manufacturing and Laboratory Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">21,305<span></span>
</td>
<td class="nump">21,093<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember', window );">Office Equipment and Computer Software [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">5,772<span></span>
</td>
<td class="nump">6,062<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and Fixtures [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">5,840<span></span>
</td>
<td class="nump">5,776<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_AssetUnderConstructionMember', window );">Construction in Process [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">8,149<span></span>
</td>
<td class="nump">2,273<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">21,066<span></span>
</td>
<td class="nump">20,811<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandMember', window );">Land [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">4,339<span></span>
</td>
<td class="nump">4,339<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingAndBuildingImprovementsMember', window );">Buildings and Building Improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 21,788<span></span>
</td>
<td class="nump">$ 20,218<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ManufacturingFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ManufacturingFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_AssetUnderConstructionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_AssetUnderConstructionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingAndBuildingImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingAndBuildingImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INTANGIBLE ASSETS, Summary (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>Finite-Lived Intangible Assets, Net [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Cost</a></td>
<td class="nump">$ 5,566<span></span>
</td>
<td class="nump">$ 5,217<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated amortization</a></td>
<td class="nump">5,106<span></span>
</td>
<td class="nump">4,718<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net</a></td>
<td class="nump">460<span></span>
</td>
<td class="nump">499<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangible assets</a></td>
<td class="nump">388<span></span>
</td>
<td class="nump">724<span></span>
</td>
<td class="nump">$ 715<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=adma_TrademarkAndOtherIntangibleRightsRelatedToNabiHBMember', window );">Trademark and Other Intangible Rights Related to Nabi-HB [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>Finite-Lived Intangible Assets, Net [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Cost</a></td>
<td class="nump">4,100<span></span>
</td>
<td class="nump">4,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated amortization</a></td>
<td class="nump">4,100<span></span>
</td>
<td class="nump">3,856<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">244<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1', window );">Amortization period</a></td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ComputerSoftwareIntangibleAssetMember', window );">Internally Developed Software [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>Finite-Lived Intangible Assets, Net [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Cost</a></td>
<td class="nump">$ 559<span></span>
</td>
<td class="nump">210<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated amortization</a></td>
<td class="nump">99<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net</a></td>
<td class="nump">$ 460<span></span>
</td>
<td class="nump">201<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1', window );">Amortization period</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=adma_RightToIntermediatesMember', window );">Rights to Intermediates [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>Finite-Lived Intangible Assets, Net [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Cost</a></td>
<td class="nump">$ 907<span></span>
</td>
<td class="nump">907<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated amortization</a></td>
<td class="nump">907<span></span>
</td>
<td class="nump">853<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 54<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480265/350-10-S45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480265/350-10-S45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 928<br> -SubTopic 340<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478859/928-340-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Remaining amortization period of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=adma_TrademarkAndOtherIntangibleRightsRelatedToNabiHBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=adma_TrademarkAndOtherIntangibleRightsRelatedToNabiHBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ComputerSoftwareIntangibleAssetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ComputerSoftwareIntangibleAssetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=adma_RightToIntermediatesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=adma_RightToIntermediatesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>INTANGIBLE ASSETS, Future Aggregate Amortization Expense (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract', window );"><strong>Estimated Aggregate Amortization Expense [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths', window );">2025</a></td>
<td class="nump">$ 140<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo', window );">2026</a></td>
<td class="nump">140<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree', window );">2027</a></td>
<td class="nump">130<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour', window );">2028</a></td>
<td class="nump">$ 50<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized in the next rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized in the fourth rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized in the third rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized in the second rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>ACCRUED EXPENSES AND OTHER LIABILITIES (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract', window );"><strong>Accrued Expenses and Other Current Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_AccruedRebatesCurrent', window );">Accrued rebates</a></td>
<td class="nump">$ 4,155<span></span>
</td>
<td class="nump">$ 16,608<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Accrued distribution fees</a></td>
<td class="nump">11,565<span></span>
</td>
<td class="nump">5,954<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedBonusesCurrent', window );">Accrued incentives</a></td>
<td class="nump">5,892<span></span>
</td>
<td class="nump">4,961<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPayableCurrent', window );">Accrued interest</a></td>
<td class="nump">2,857<span></span>
</td>
<td class="nump">546<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_AccruedTestingCurrent', window );">Accrued testing</a></td>
<td class="nump">827<span></span>
</td>
<td class="nump">282<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedSalariesCurrent', window );">Accrued payroll and other compensation</a></td>
<td class="nump">3,332<span></span>
</td>
<td class="nump">2,203<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxesPayableCurrent', window );">Income taxes payable</a></td>
<td class="nump">3,481<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">1,853<span></span>
</td>
<td class="nump">2,365<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities', window );">Total accrued expenses and other current liabilities</a></td>
<td class="nump">$ 33,962<span></span>
</td>
<td class="nump">$ 32,919<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_AccruedRebatesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of rebates for Medicaid or other third parties related to sale of product.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_AccruedRebatesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_AccruedTestingCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for testing. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_AccruedTestingCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedBonusesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for incentive compensation awarded to employees and directors or earned by them based on the terms of one or more relevant arrangements. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedBonusesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesAndOtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedSalariesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of the obligations incurred through that date and payable for employees' services provided. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 8<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedSalariesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NOTES PAYABLE (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 19, 2024</div></th>
<th class="th"><div>Aug. 14, 2024</div></th>
<th class="th"><div>Dec. 18, 2023</div></th>
<th class="th"><div>May 01, 2023</div></th>
<th class="th"><div>Apr. 30, 2023</div></th>
<th class="th"><div>Mar. 23, 2022</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableAbstract', window );"><strong>Senior Notes Payable [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_SeniorNotesPayableBeforeDebtDiscount', window );">Senior notes payable before debt discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 135,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Less: Debt discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (2,663)<span></span>
</td>
<td class="num">$ (4,406)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SeniorLongTermNotes', window );">Senior notes payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">72,337<span></span>
</td>
<td class="nump">130,594<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,243)<span></span>
</td>
<td class="num">(26,174)<span></span>
</td>
<td class="num">$ (6,670)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfNotesPayable', window );">Payment for outstanding obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,000<span></span>
</td>
<td class="nump">158,584<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaidInKindInterest', window );">Interest paid-in-kind</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,836<span></span>
</td>
<td class="nump">2,998<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 426,454<span></span>
</td>
<td class="nump">258,215<span></span>
</td>
<td class="nump">$ 154,080<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrant to purchase shares of common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">227,650<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">106,059<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=adma_AresCreditAgreementMember', window );">Ares Credit Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableAbstract', window );"><strong>Senior Notes Payable [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_MinimumLiquidityCovenantsCreditFacilities', window );">Minimum liquidity covenant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateIncreaseDecrease', window );">Increase applicable margin</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=adma_AresCreditAgreementMember', window );">Ares Credit Agreement [Member] | Prepaid on or Prior to First Anniversary [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableAbstract', window );"><strong>Senior Notes Payable [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed', window );">Percentage of prepaid principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=adma_AresCreditAgreementMember', window );">Ares Credit Agreement [Member] | Prepaid after the First Anniversary [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableAbstract', window );"><strong>Senior Notes Payable [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed', window );">Percentage of prepaid principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=adma_AresCreditAgreementMember', window );">Ares Credit Agreement [Member] | Prepaid on or Prior to Second Anniversary [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableAbstract', window );"><strong>Senior Notes Payable [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed', window );">Percentage of prepaid principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=adma_AresCreditAgreementMember', window );">Ares Credit Agreement [Member] | Prepaid on or Prior to Third Anniversary [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableAbstract', window );"><strong>Senior Notes Payable [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed', window );">Percentage of prepaid principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=adma_AresCreditAgreementMember', window );">Ares Credit Agreement [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableAbstract', window );"><strong>Senior Notes Payable [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityCommitmentFeePercentage', window );">Revolving facility percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=adma_HayfinCreditAgreementMember', window );">Hayfin Credit Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableAbstract', window );"><strong>Senior Notes Payable [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Less: Debt discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (15,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Maturity date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Mar. 23,  2029<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (6,700)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_DebtInstrumentApplicableMargin', window );">Applicable margin</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed', window );">Percentage of prepaid principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16.10%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateIncreaseDecrease', window );">Increase applicable margin</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_DebtInstrumentUpfrontFeePaidInKind', window );">Upfront fee paid in kind</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_DebtInstrumentInterestAmountToBePayInKind', window );">Percentage of interest amount to pay in kind</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaidInKindInterest', window );">Interest paid-in-kind</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,800<span></span>
</td>
<td class="nump">3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_PercentageOfExitFeeOfOutstandingPrincipalAmountBeingPaid', window );">Percentage of exit fee on outstanding principal amount being paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_SharesIssuedUponExerciseOfWarrants', window );">Shares issued upon exercise of warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,103,047<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price per share (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.6478<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_TrailingPeriodForVolumeWeightedAveragePrice', window );">Trailing period for VWAP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Fair value of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=adma_HayfinCreditAgreementMember', window );">Hayfin Credit Agreement [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableAbstract', window );"><strong>Senior Notes Payable [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=adma_HayfinCreditAgreementMember', window );">Hayfin Credit Agreement [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableAbstract', window );"><strong>Senior Notes Payable [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 110,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=adma_HayfinCreditAgreementMember', window );">Hayfin Credit Agreement [Member] | SOFR [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableAbstract', window );"><strong>Senior Notes Payable [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_DebtInstrumentTermOfVariableRate', window );">Term of variable rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 month<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=adma_HayfinCreditAgreementMember', window );">Hayfin Credit Agreement [Member] | Base Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableAbstract', window );"><strong>Senior Notes Payable [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_DebtInstrumentFloorInterestRate', window );">Percentage of floor interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=adma_HayfinSecondAmendmentMember', window );">Hayfin Second Amendment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableAbstract', window );"><strong>Senior Notes Payable [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Less: Debt discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,700)<span></span>
</td>
<td class="num">$ (13,900)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Maturity date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">May  01,  2030<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrant to purchase shares of common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,391,244<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price per share (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.2619<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Fair value of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=adma_HayfinSecondAmendmentMember', window );">Hayfin Second Amendment [Member] | SOFR [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableAbstract', window );"><strong>Senior Notes Payable [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_DebtInstrumentApplicableMargin', window );">Applicable margin</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.50%<span></span>
</td>
<td class="nump">9.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=adma_TermLoanMember', window );">Term Loan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableAbstract', window );"><strong>Senior Notes Payable [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_SeniorNotesPayableBeforeDebtDiscount', window );">Senior notes payable before debt discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 32,500<span></span>
</td>
<td class="nump">$ 62,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Less: Debt discount</a></td>
<td class="num">$ (800)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_LongTermDebtPrepaymentPenalty', window );">Prepayment penalty</a></td>
<td class="nump">500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of debt</a></td>
<td class="num">(1,200)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermLinesOfCredit', window );">Repayment of revolving credit facility</a></td>
<td class="nump">30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_ExitFeeLiability', window );">Exit fee liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_DebtInstrumentExitFee', window );">Exit fee</a></td>
<td class="nump">$ 400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=adma_TermLoanMember', window );">Term Loan [Member] | SOFR [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableAbstract', window );"><strong>Senior Notes Payable [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_DebtInstrumentTermOfVariableRate', window );">Term of variable rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_NumberOfBusinessDays', window );">Number of business days</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_DebtInstrumentApplicableMargin', window );">Applicable margin</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.85%<span></span>
</td>
<td class="nump">11.88%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableAbstract', window );"><strong>Senior Notes Payable [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_SeniorNotesPayableBeforeDebtDiscount', window );">Senior notes payable before debt discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 42,500<span></span>
</td>
<td class="nump">$ 72,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermLinesOfCredit', window );">Repayment of revolving credit facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility [Member] | SOFR [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableAbstract', window );"><strong>Senior Notes Payable [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_DebtInstrumentTermOfVariableRate', window );">Term of variable rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_NumberOfBusinessDays', window );">Number of business days</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_DebtInstrumentApplicableMargin', window );">Applicable margin</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.34%<span></span>
</td>
<td class="nump">9.13%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=adma_AresCreditFacilityMember', window );">Ares Credit Facility [Member] | Ares Credit Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableAbstract', window );"><strong>Senior Notes Payable [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Less: Debt discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (4,400)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Maturity date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Dec. 20,  2027<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Aggregate principal amount revolving credit facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 36,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage', window );">Unused commitment fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPaymentPrincipal', window );">Scheduled principal payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFrequencyOfPeriodicPayment', window );">Frequency of periodic payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">quarterly<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPaymentInterest', window );">Interest payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_NumberOfBusinessDaysForPriorWrittenNoticeToPrepayOutstandingPrincipal', window );">Number of business days for prior written notice</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_PrepaymentsOfDebtPremium', window );">Prepayments of premium</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFeeAmount', window );">Incurred fees and expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_OriginalDiscountPayableCreditFacility', window );">Original discount payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_DebtInstrumentExitFee', window );">Exit fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.81%<span></span>
</td>
<td class="nump">11.39%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=adma_HayfinCreditFacilityMember', window );">Hayfin Credit Facility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableAbstract', window );"><strong>Senior Notes Payable [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Less: Debt discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(15,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Outstanding principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">158,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_LongTermDebtPrepaymentPenalty', window );">Prepayment penalty</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (26,200)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_DebtInstrumentExitFee', window );">Exit fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=adma_HayfinCreditFacilityMember', window );">Hayfin Credit Facility [Member] | Hayfin Credit Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableAbstract', window );"><strong>Senior Notes Payable [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Maturity date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Mar. 23,  2027<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=adma_HayfinCreditFacilityMember', window );">Hayfin Credit Facility [Member] | Hayfin Credit Agreement [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableAbstract', window );"><strong>Senior Notes Payable [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_SeniorNotesPayableBeforeDebtDiscount', window );">Senior notes payable before debt discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 175,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=adma_HayfinClosingDateLoanMember', window );">Hayfin Closing Date Loan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableAbstract', window );"><strong>Senior Notes Payable [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfNotesPayable', window );">Payment for outstanding obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=adma_HayfinClosingDateLoanMember', window );">Hayfin Closing Date Loan [Member] | Hayfin Credit Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableAbstract', window );"><strong>Senior Notes Payable [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_SeniorNotesPayableBeforeDebtDiscount', window );">Senior notes payable before debt discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13.70%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedPremium', window );">Redemption premium</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtIssuanceCosts', window );">Payment for certain fees and expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=adma_HayfinDelayedDrawLoanMember', window );">Hayfin Delayed Draw Loan [Member] | Hayfin Credit Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableAbstract', window );"><strong>Senior Notes Payable [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_SeniorNotesPayableBeforeDebtDiscount', window );">Senior notes payable before debt discount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=adma_AresClosingDateLoanMember', window );">Ares Closing Date Loan [Member] | Ares Credit Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableAbstract', window );"><strong>Senior Notes Payable [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_DebtInstrumentApplicableMargin">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the margin rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_DebtInstrumentApplicableMargin</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_DebtInstrumentExitFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit fee of debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_DebtInstrumentExitFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_DebtInstrumentFloorInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage floor rate on debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_DebtInstrumentFloorInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_DebtInstrumentInterestAmountToBePayInKind">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The interest amount to be pay in kind during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_DebtInstrumentInterestAmountToBePayInKind</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_DebtInstrumentTermOfVariableRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of the interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_DebtInstrumentTermOfVariableRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_DebtInstrumentUpfrontFeePaidInKind">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for payment of an upfront fee paid in kind to consortium of lenders under the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_DebtInstrumentUpfrontFeePaidInKind</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_ExitFeeLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of exit fee liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_ExitFeeLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_LongTermDebtPrepaymentPenalty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of penalty on prepayment of long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_LongTermDebtPrepaymentPenalty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_MinimumLiquidityCovenantsCreditFacilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The carrying amount of minimum liquidity requirements required to be maintained by the borrower per the Company's credit facilities covenants under the loan agreement that are not restricted as to withdrawal or usage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_MinimumLiquidityCovenantsCreditFacilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_NumberOfBusinessDays">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of business days, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_NumberOfBusinessDays</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_NumberOfBusinessDaysForPriorWrittenNoticeToPrepayOutstandingPrincipal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of business days for prior written notice to pay outstanding principal loans, Number of business days, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_NumberOfBusinessDaysForPriorWrittenNoticeToPrepayOutstandingPrincipal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_OriginalDiscountPayableCreditFacility">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount represent the original discount payable in related transaction in credit facility.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_OriginalDiscountPayableCreditFacility</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_PercentageOfExitFeeOfOutstandingPrincipalAmountBeingPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of exit fee on outstanding principal amount being paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_PercentageOfExitFeeOfOutstandingPrincipalAmountBeingPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_PrepaymentsOfDebtPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount represents the payments of premium.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_PrepaymentsOfDebtPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_SeniorNotesPayableBeforeDebtDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of Notes with the highest claim on the assets of the issuer in case of bankruptcy or liquidation (with maturities initially due after one year or beyond the operating cycle if longer), excluding debt discount and current portion.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_SeniorNotesPayableBeforeDebtDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_SharesIssuedUponExerciseOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued upon exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_SharesIssuedUponExerciseOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_TrailingPeriodForVolumeWeightedAveragePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The trailing period for volume-weighted average price, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_TrailingPeriodForVolumeWeightedAveragePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477796/946-210-45-21<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 210<br> -Topic 946<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477796/946-210-45-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFeeAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the fee that accompanies borrowing money under the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFeeAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFrequencyOfPeriodicPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of the frequency of periodic payments (monthly, quarterly, annual).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477734/942-470-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFrequencyOfPeriodicPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateEffectivePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Incremental percentage increase (decrease) in the stated rate on a debt instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentPeriodicPaymentInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the required periodic payments applied to interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentPeriodicPaymentInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentPeriodicPaymentPrincipal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the required periodic payments applied to principal.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentPeriodicPaymentPrincipal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of principal amount of debt redeemed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-1A<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt premium.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-1A<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 13<br> -SubTopic 10<br> -Topic 480<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481766/480-10-25-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481303/470-50-40-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481303/470-50-40-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityCommitmentFeePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fee, expressed as a percentage of the line of credit facility, for the line of credit facility regardless of whether the facility has been used.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityCommitmentFeePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The fee, expressed as a percentage of the line of credit facility, for available but unused credit capacity under the credit facility.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaidInKindInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Interest paid other than in cash for example by issuing additional debt securities. As a noncash item, it is added to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaidInKindInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDebtIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDebtIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermLinesOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for the settlement of obligation drawn from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with maturities due beyond one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermLinesOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SeniorLongTermNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of Notes with the highest claim on the assets of the issuer in case of bankruptcy or liquidation (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion. Senior note holders are paid off in full before any payments are made to junior note holders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SeniorLongTermNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=adma_AresCreditAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=adma_AresCreditAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=adma_PrepaidOnOrPriorToFirstAnniversaryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPeriodAxis=adma_PrepaidOnOrPriorToFirstAnniversaryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=adma_PrepaidAfterTheFirstAnniversaryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPeriodAxis=adma_PrepaidAfterTheFirstAnniversaryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=adma_PrepaidOnOrPriorToSecondAnniversaryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPeriodAxis=adma_PrepaidOnOrPriorToSecondAnniversaryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=adma_PrepaidOnOrPriorToThirdAnniversaryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPeriodAxis=adma_PrepaidOnOrPriorToThirdAnniversaryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=adma_HayfinCreditAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=adma_HayfinCreditAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_SecuredOvernightFinancingRateSofrMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_SecuredOvernightFinancingRateSofrMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_BaseRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_BaseRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=adma_HayfinSecondAmendmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=adma_HayfinSecondAmendmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=adma_TermLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=adma_TermLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=adma_AresCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=adma_AresCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=adma_HayfinCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=adma_HayfinCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=adma_HayfinClosingDateLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=adma_HayfinClosingDateLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=adma_HayfinDelayedDrawLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=adma_HayfinDelayedDrawLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=adma_AresClosingDateLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=adma_AresClosingDateLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY, Preferred Stock (Details) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract', window );"><strong>Preferred Stock [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockCapitalSharesReservedForFutureIssuance', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of nonredeemable preferred shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY, Common Stock (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 09, 2022</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract', window );"><strong>Common Stock [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000,000<span></span>
</td>
<td class="nump">300,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">236,620,545<span></span>
</td>
<td class="nump">226,063,032<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock, available for issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,093,118<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Net proceeds from stock options exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,494<span></span>
</td>
<td class="nump">$ 1,104<span></span>
</td>
<td class="nump">$ 175<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 64,645<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract', window );"><strong>Common Stock [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Stock options exercised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,988,066<span></span>
</td>
<td class="nump">1,444,533<span></span>
</td>
<td class="nump">68,679<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Net proceeds from stock options exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,500<span></span>
</td>
<td class="nump">$ 1,100<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock shares sold during the period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,125,873<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | Underwritten Public Offering [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract', window );"><strong>Common Stock [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock shares sold during the period (in shares)</a></td>
<td class="nump">24,125,873<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="nump">$ 64,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY, Warrants (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 16, 2023</div></th>
<th class="th"><div>May 01, 2023</div></th>
<th class="th"><div>Mar. 23, 2022</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_WarrantsAbstract', window );"><strong>Warrants [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_ClassOfWarrantOrRightExercised', window );">Warrants exercised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,308,702<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">236,620,545<span></span>
</td>
<td class="nump">226,063,032<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrant to purchase shares of common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">227,650<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">106,059<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=adma_HayfinSecondAmendmentMember', window );">Hayfin Second Amendment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_WarrantsAbstract', window );"><strong>Warrants [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrant to purchase shares of common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,391,244<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Fair value of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">67.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.62%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.2619<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_WarrantsAbstract', window );"><strong>Warrants [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.98<span></span>
</td>
<td class="nump">$ 2.32<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">966,554<span></span>
</td>
<td class="nump">12,502,906<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=adma_HayfinWarrantsMember', window );">Hayfin Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_WarrantsAbstract', window );"><strong>Warrants [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_ClassOfWarrantOrRightExercised', window );">Warrants exercised (in shares)</a></td>
<td class="nump">3,388,686<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">1,967,847<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrant to purchase shares of common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,103,047<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Fair value of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">68.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.36%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.6478<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_WarrantsAbstract', window );"><strong>Warrants [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,224,892<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Warrants Outstanding [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Beginning balance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,502,906<span></span>
</td>
<td class="nump">13,525,148<span></span>
</td>
<td class="nump">4,528,160<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod', window );">Expired (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(227,650)<span></span>
</td>
<td class="num">(24,800)<span></span>
</td>
<td class="num">(106,059)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,391,244<span></span>
</td>
<td class="nump">9,103,047<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod', window );">Exercised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(11,308,702)<span></span>
</td>
<td class="num">(3,388,686)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Ending balance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">966,554<span></span>
</td>
<td class="nump">12,502,906<span></span>
</td>
<td class="nump">13,525,148<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Warrants Outstanding, Weighted Average Exercise Price [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Beginning balance (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.32<span></span>
</td>
<td class="nump">$ 1.99<span></span>
</td>
<td class="nump">$ 2.82<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriodWeightedAverageGrantDateFairValue', window );">Expired (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.21<span></span>
</td>
<td class="nump">6.37<span></span>
</td>
<td class="nump">8.23<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">3.26<span></span>
</td>
<td class="nump">1.65<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageGrantDateFairValue', window );">Exercised (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.31<span></span>
</td>
<td class="nump">1.65<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Ending balance (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.98<span></span>
</td>
<td class="nump">$ 2.32<span></span>
</td>
<td class="nump">$ 1.99<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_ClassOfWarrantOrRightExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of warrants exercised during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_ClassOfWarrantOrRightExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that exercised during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at exercised date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that expired during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at expired date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_WarrantsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_WarrantsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=adma_HayfinSecondAmendmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=adma_HayfinSecondAmendmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=adma_HayfinWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=adma_HayfinWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCKHOLDERS' EQUITY, Equity Incentive Plans (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($) </div>
<div>Employee </div>
<div>Director </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 21, 2022 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_StockOptionsAbstract', window );"><strong>Stock Options [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares reserved for grant (in shares) | shares</a></td>
<td class="nump">36,093,118<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Aggregate exercise proceeds | $</a></td>
<td class="nump">$ 7,494<span></span>
</td>
<td class="nump">$ 1,104<span></span>
</td>
<td class="nump">$ 175<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life of stock options, outstanding</a></td>
<td class="text">7 years 1 month 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_StockOptionOutstandingAndExcercisableAbstract', window );"><strong>Stock Option Outstanding and Exercisable [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Outstanding at beginning of period (in shares) | shares</a></td>
<td class="nump">5,141,516<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life of stock options, outstanding</a></td>
<td class="text">7 years 1 month 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Options outstanding, weighted average exercise price (in dollars per share)</a></td>
<td class="nump">$ 3.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Options outstanding, aggregate intrinsic value | $</a></td>
<td class="nump">$ 68,117<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options exercisable (in shares) | shares</a></td>
<td class="nump">2,657,932<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life of stock options, exercisable</a></td>
<td class="text">5 years 8 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Options exercisable, weighted average exercise price (in dollars per share)</a></td>
<td class="nump">$ 3.03<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Options exercisable, aggregate intrinsic value | $</a></td>
<td class="nump">$ 37,540<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract', window );"><strong>Stock-based compensation expense [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense | $</a></td>
<td class="nump">13,616<span></span>
</td>
<td class="nump">6,187<span></span>
</td>
<td class="nump">5,215<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract', window );"><strong>Stock-based compensation expense [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense | $</a></td>
<td class="nump">98<span></span>
</td>
<td class="nump">40<span></span>
</td>
<td class="nump">19<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OperatingExpenseMember', window );">Plasma Center Operating Expenses [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract', window );"><strong>Stock-based compensation expense [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense | $</a></td>
<td class="nump">184<span></span>
</td>
<td class="nump">146<span></span>
</td>
<td class="nump">82<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, General and Administrative [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract', window );"><strong>Stock-based compensation expense [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense | $</a></td>
<td class="nump">11,720<span></span>
</td>
<td class="nump">5,331<span></span>
</td>
<td class="nump">4,717<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember', window );">Cost of Product Revenue [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract', window );"><strong>Stock-based compensation expense [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense | $</a></td>
<td class="nump">$ 1,614<span></span>
</td>
<td class="nump">$ 670<span></span>
</td>
<td class="nump">$ 397<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=adma_ExercisePriceRange1Member', window );">$1.10 - $1.67 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_StockOptionsAbstract', window );"><strong>Stock Options [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life of stock options, outstanding</a></td>
<td class="text">6 years 9 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_StockOptionOutstandingAndExcercisableAbstract', window );"><strong>Stock Option Outstanding and Exercisable [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Exercise price range, lower limit (in dollars per share)</a></td>
<td class="nump">$ 1.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Exercise price range, upper limit (in dollars per share)</a></td>
<td class="nump">$ 1.67<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Outstanding at beginning of period (in shares) | shares</a></td>
<td class="nump">981,093<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life of stock options, outstanding</a></td>
<td class="text">6 years 9 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Options outstanding, weighted average exercise price (in dollars per share)</a></td>
<td class="nump">$ 1.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Options outstanding, aggregate intrinsic value | $</a></td>
<td class="nump">$ 15,252<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options exercisable (in shares) | shares</a></td>
<td class="nump">676,542<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life of stock options, exercisable</a></td>
<td class="text">6 years 7 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Options exercisable, weighted average exercise price (in dollars per share)</a></td>
<td class="nump">$ 1.58<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Options exercisable, aggregate intrinsic value | $</a></td>
<td class="nump">$ 10,532<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=adma_ExercisePriceRange2Member', window );">$1.73 - $2.60 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_StockOptionsAbstract', window );"><strong>Stock Options [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life of stock options, outstanding</a></td>
<td class="text">5 years 8 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_StockOptionOutstandingAndExcercisableAbstract', window );"><strong>Stock Option Outstanding and Exercisable [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Exercise price range, lower limit (in dollars per share)</a></td>
<td class="nump">$ 1.73<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Exercise price range, upper limit (in dollars per share)</a></td>
<td class="nump">$ 2.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Outstanding at beginning of period (in shares) | shares</a></td>
<td class="nump">629,655<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life of stock options, outstanding</a></td>
<td class="text">5 years 8 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Options outstanding, weighted average exercise price (in dollars per share)</a></td>
<td class="nump">$ 2.32<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Options outstanding, aggregate intrinsic value | $</a></td>
<td class="nump">$ 9,336<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options exercisable (in shares) | shares</a></td>
<td class="nump">585,771<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life of stock options, exercisable</a></td>
<td class="text">5 years 7 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Options exercisable, weighted average exercise price (in dollars per share)</a></td>
<td class="nump">$ 2.33<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Options exercisable, aggregate intrinsic value | $</a></td>
<td class="nump">$ 8,683<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=adma_ExercisePriceRange3Member', window );">$2.67 - $4.01 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_StockOptionsAbstract', window );"><strong>Stock Options [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life of stock options, outstanding</a></td>
<td class="text">6 years 7 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_StockOptionOutstandingAndExcercisableAbstract', window );"><strong>Stock Option Outstanding and Exercisable [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Exercise price range, lower limit (in dollars per share)</a></td>
<td class="nump">$ 2.67<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Exercise price range, upper limit (in dollars per share)</a></td>
<td class="nump">$ 4.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Outstanding at beginning of period (in shares) | shares</a></td>
<td class="nump">1,809,746<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life of stock options, outstanding</a></td>
<td class="text">6 years 7 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Options outstanding, weighted average exercise price (in dollars per share)</a></td>
<td class="nump">$ 3.41<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Options outstanding, aggregate intrinsic value | $</a></td>
<td class="nump">$ 24,868<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options exercisable (in shares) | shares</a></td>
<td class="nump">1,012,271<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life of stock options, exercisable</a></td>
<td class="text">5 years 4 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Options exercisable, weighted average exercise price (in dollars per share)</a></td>
<td class="nump">$ 3.46<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Options exercisable, aggregate intrinsic value | $</a></td>
<td class="nump">$ 13,863<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=adma_ExercisePriceRange4Member', window );">$4.09 - $6.14 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_StockOptionsAbstract', window );"><strong>Stock Options [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life of stock options, outstanding</a></td>
<td class="text">8 years 1 month 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_StockOptionOutstandingAndExcercisableAbstract', window );"><strong>Stock Option Outstanding and Exercisable [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Exercise price range, lower limit (in dollars per share)</a></td>
<td class="nump">$ 4.09<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Exercise price range, upper limit (in dollars per share)</a></td>
<td class="nump">$ 6.14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Outstanding at beginning of period (in shares) | shares</a></td>
<td class="nump">1,264,083<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life of stock options, outstanding</a></td>
<td class="text">8 years 1 month 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Options outstanding, weighted average exercise price (in dollars per share)</a></td>
<td class="nump">$ 5.35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Options outstanding, aggregate intrinsic value | $</a></td>
<td class="nump">$ 14,913<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options exercisable (in shares) | shares</a></td>
<td class="nump">361,848<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life of stock options, exercisable</a></td>
<td class="text">5 years 4 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Options exercisable, weighted average exercise price (in dollars per share)</a></td>
<td class="nump">$ 5.23<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Options exercisable, aggregate intrinsic value | $</a></td>
<td class="nump">$ 4,312<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=adma_ExercisePriceRange5Member', window );">$6.54 - $9.81 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_StockOptionsAbstract', window );"><strong>Stock Options [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life of stock options, outstanding</a></td>
<td class="text">9 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_StockOptionOutstandingAndExcercisableAbstract', window );"><strong>Stock Option Outstanding and Exercisable [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Exercise price range, lower limit (in dollars per share)</a></td>
<td class="nump">$ 6.54<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Exercise price range, upper limit (in dollars per share)</a></td>
<td class="nump">$ 9.81<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Outstanding at beginning of period (in shares) | shares</a></td>
<td class="nump">307,828<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life of stock options, outstanding</a></td>
<td class="text">9 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Options outstanding, weighted average exercise price (in dollars per share)</a></td>
<td class="nump">$ 6.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Options outstanding, aggregate intrinsic value | $</a></td>
<td class="nump">$ 3,248<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options exercisable (in shares) | shares</a></td>
<td class="nump">7,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life of stock options, exercisable</a></td>
<td class="text">7 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Options exercisable, weighted average exercise price (in dollars per share)</a></td>
<td class="nump">$ 8.98<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Options exercisable, aggregate intrinsic value | $</a></td>
<td class="nump">$ 61<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=adma_ExercisePriceRange6Member', window );">$10.80 - $17.49 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_StockOptionsAbstract', window );"><strong>Stock Options [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life of stock options, outstanding</a></td>
<td class="text">8 years 8 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_StockOptionOutstandingAndExcercisableAbstract', window );"><strong>Stock Option Outstanding and Exercisable [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Exercise price range, lower limit (in dollars per share)</a></td>
<td class="nump">$ 10.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Exercise price range, upper limit (in dollars per share)</a></td>
<td class="nump">$ 17.49<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Outstanding at beginning of period (in shares) | shares</a></td>
<td class="nump">149,111<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life of stock options, outstanding</a></td>
<td class="text">8 years 8 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Options outstanding, weighted average exercise price (in dollars per share)</a></td>
<td class="nump">$ 8.74<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Options outstanding, aggregate intrinsic value | $</a></td>
<td class="nump">$ 500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options exercisable (in shares) | shares</a></td>
<td class="nump">14,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life of stock options, exercisable</a></td>
<td class="text">1 month 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Options exercisable, weighted average exercise price (in dollars per share)</a></td>
<td class="nump">$ 10.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Options exercisable, aggregate intrinsic value | $</a></td>
<td class="nump">$ 89<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=adma_EmployeesMember', window );">Employees [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_RestrictedStockUnitsAbstract', window );"><strong>Restricted Stock Units [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_NumberOfIndividualsThatReceivedModificationsToTheirOutstandingStockOptionAndRSUAwards', window );">Number of individuals that received modifications to stock option and RSU awards | Employee</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_DirectorMember', window );">Directors [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_RestrictedStockUnitsAbstract', window );"><strong>Restricted Stock Units [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_NumberOfIndividualsThatReceivedModificationsToTheirOutstandingStockOptionAndRSUAwards', window );">Number of individuals that received modifications to stock option and RSU awards | Director</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=adma_Two022CompensationPlanMember', window );">2022 Compensation Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_StockOptionsAbstract', window );"><strong>Stock Options [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares reserved for grant (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_StockOptionsAbstract', window );"><strong>Stock Options [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of stock options granted (in shares) | shares</a></td>
<td class="nump">1,531,635<span></span>
</td>
<td class="nump">1,826,380<span></span>
</td>
<td class="nump">1,194,032<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSharesWithheldForPayrollTaxes', window );">Shares withheld for payroll taxes (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">259,867<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life of stock options, outstanding</a></td>
<td class="text">7 years 1 month 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Weighted average remaining contractual life of stock options, expected to vest</a></td>
<td class="text">7 years 1 month 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted average remaining contractual life of stock options, exercisable</a></td>
<td class="text">5 years 8 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Fair Value Assumptions and Methodology [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Volatility</a></td>
<td class="nump">66.00%<span></span>
</td>
<td class="nump">68.00%<span></span>
</td>
<td class="nump">68.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_StockOptionSharesAbstract', window );"><strong>Stock Option, Shares [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Options outstanding, vested and expected to vest, beginning balance (in shares) | shares</a></td>
<td class="nump">5,906,184<span></span>
</td>
<td class="nump">8,256,211<span></span>
</td>
<td class="nump">7,862,722<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedNumber', window );">Forfeited (in shares) | shares</a></td>
<td class="num">(30,094)<span></span>
</td>
<td class="num">(99,345)<span></span>
</td>
<td class="num">(31,540)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredNumber', window );">Expired (in shares) | shares</a></td>
<td class="num">(246,067)<span></span>
</td>
<td class="num">(262,940)<span></span>
</td>
<td class="num">(700,324)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedNumber', window );">Granted (in shares) | shares</a></td>
<td class="nump">1,531,635<span></span>
</td>
<td class="nump">1,826,380<span></span>
</td>
<td class="nump">1,194,032<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedNumber', window );">Exercised (in shares) | shares</a></td>
<td class="num">(2,020,142)<span></span>
</td>
<td class="num">(3,814,122)<span></span>
</td>
<td class="num">(68,679)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Options outstanding, vested and expected to vest, ending balance (in shares) | shares</a></td>
<td class="nump">5,141,516<span></span>
</td>
<td class="nump">5,906,184<span></span>
</td>
<td class="nump">8,256,211<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Options exercisable (in shares) | shares</a></td>
<td class="nump">2,657,932<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_StockOptionsWeightedAverageExercisePriceAbstract', window );"><strong>Stock Options, Weighted Average Exercise Price [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Options outstanding, vested and expected to vest, beginning balance (in dollars per share)</a></td>
<td class="nump">$ 3.38<span></span>
</td>
<td class="nump">$ 3.37<span></span>
</td>
<td class="nump">$ 3.93<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedWeightedAverageExercisePrice', window );">Forfeited (in dollars per share)</a></td>
<td class="nump">3.36<span></span>
</td>
<td class="nump">2.73<span></span>
</td>
<td class="nump">2.37<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredWeightedAverageExercisePrice', window );">Expired (in dollars per share)</a></td>
<td class="nump">7.01<span></span>
</td>
<td class="nump">6.42<span></span>
</td>
<td class="nump">6.86<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedWeightedAverageExercisePrice', window );">Granted (in dollars per share)</a></td>
<td class="nump">6.4<span></span>
</td>
<td class="nump">3.36<span></span>
</td>
<td class="nump">1.67<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedWeightedAverageExercisePrice', window );">Exercised (in dollars per share)</a></td>
<td class="nump">3.9<span></span>
</td>
<td class="nump">3.15<span></span>
</td>
<td class="nump">2.55<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Options outstanding, vested and expected to vest, ending balance (in dollars per share)</a></td>
<td class="nump">3.9<span></span>
</td>
<td class="nump">$ 3.38<span></span>
</td>
<td class="nump">$ 3.37<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Options exercisable (in dollars per share)</a></td>
<td class="nump">$ 3.03<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_StockOptionOutstandingAndExcercisableAbstract', window );"><strong>Stock Option Outstanding and Exercisable [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contractual life of stock options, outstanding</a></td>
<td class="text">7 years 1 month 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_RestrictedStockUnitsAbstract', window );"><strong>Restricted Stock Units [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Restricted stock units vested over a period</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Fair Value Assumptions and Methodology [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
<td class="text">5 years 6 months<span></span>
</td>
<td class="text">5 years 6 months<span></span>
</td>
<td class="text">5 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">4.16%<span></span>
</td>
<td class="nump">4.20%<span></span>
</td>
<td class="nump">1.72%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Fair Value Assumptions and Methodology [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
<td class="text">6 years 3 months 18 days<span></span>
</td>
<td class="text">6 years 3 months 18 days<span></span>
</td>
<td class="text">6 years 3 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">4.39%<span></span>
</td>
<td class="nump">4.62%<span></span>
</td>
<td class="nump">1.73%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options [Member] | Equity Incentive Plans [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_StockOptionsAbstract', window );"><strong>Stock Options [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSharesWithheldToCoverAggregateExercisePrices', window );">Shares withheld to cover aggregate exercise prices (in shares) | shares</a></td>
<td class="nump">32,076<span></span>
</td>
<td class="nump">2,109,722<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Aggregate exercise proceeds | $</a></td>
<td class="nump">$ 7,500<span></span>
</td>
<td class="nump">$ 1,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized compensation expense, stock options | $</a></td>
<td class="nump">$ 6,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_StockOptionOutstandingAndExcercisableAbstract', window );"><strong>Stock Option Outstanding and Exercisable [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized compensation expense recognition period</a></td>
<td class="text">2 years 9 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">RSUs [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_RestrictedStockUnitsAbstract', window );"><strong>Restricted Stock Units [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted', window );">Number of restricted stock units granted (in shares) | shares</a></td>
<td class="nump">3,278,688<span></span>
</td>
<td class="nump">3,389,760<span></span>
</td>
<td class="nump">1,174,266<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Restricted stock units vested over a period</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesWithheldForEmployeesTaxLiabilities', window );">Shares withheld for tax withholding obligation (in shares) | shares</a></td>
<td class="nump">541,908<span></span>
</td>
<td class="nump">365,722<span></span>
</td>
<td class="nump">918,851<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesValueWithheldForEmployeesTaxLiabilities', window );">Amount of shares withheld for tax withholding obligation | $</a></td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="nump">$ 1,300<span></span>
</td>
<td class="nump">$ 2,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share based compensation expense | $</a></td>
<td class="nump">$ 2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Unvested RSU, Shares [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Beginning balance (in shares) | shares</a></td>
<td class="nump">4,657,297<span></span>
</td>
<td class="nump">2,866,987<span></span>
</td>
<td class="nump">4,485,133<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares) | shares</a></td>
<td class="nump">3,278,688<span></span>
</td>
<td class="nump">3,389,760<span></span>
</td>
<td class="nump">1,174,266<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (in shares) | shares</a></td>
<td class="num">(1,886,463)<span></span>
</td>
<td class="num">(1,199,445)<span></span>
</td>
<td class="num">(2,727,412)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited (in shares) | shares</a></td>
<td class="num">(303,532)<span></span>
</td>
<td class="num">(400,005)<span></span>
</td>
<td class="num">(65,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Ending balance (in shares) | shares</a></td>
<td class="nump">5,745,990<span></span>
</td>
<td class="nump">4,657,297<span></span>
</td>
<td class="nump">2,866,987<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Unvested RSU, Weighted Average Grant Date Fair Value [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Beginning balance (in dollars per share)</a></td>
<td class="nump">$ 2.81<span></span>
</td>
<td class="nump">$ 1.59<span></span>
</td>
<td class="nump">$ 1.34<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in dollars per share)</a></td>
<td class="nump">7.44<span></span>
</td>
<td class="nump">3.42<span></span>
</td>
<td class="nump">1.74<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested (in dollars per share)</a></td>
<td class="nump">2.5<span></span>
</td>
<td class="nump">1.63<span></span>
</td>
<td class="nump">1.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeited (in dollars per share)</a></td>
<td class="nump">3.92<span></span>
</td>
<td class="nump">2.71<span></span>
</td>
<td class="nump">1.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Ending balance (in dollars per share)</a></td>
<td class="nump">$ 5.5<span></span>
</td>
<td class="nump">$ 2.81<span></span>
</td>
<td class="nump">$ 1.59<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">RSUs [Member] | Employees [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_RestrictedStockUnitsAbstract', window );"><strong>Restricted Stock Units [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Restricted stock units vested over a period</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">RSUs [Member] | Directors [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_RestrictedStockUnitsAbstract', window );"><strong>Restricted Stock Units [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Restricted stock units vested over a period</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">RSUs [Member] | Equity Incentive Plans [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_StockOptionOutstandingAndExcercisableAbstract', window );"><strong>Stock Option Outstanding and Exercisable [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Unrecognized compensation expense, non option | $</a></td>
<td class="nump">$ 25,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized compensation expense recognition period</a></td>
<td class="text">3 years 1 month 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_NumberOfIndividualsThatReceivedModificationsToTheirOutstandingStockOptionAndRSUAwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of employees that received stock option and restricted stock units modifications during the year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_NumberOfIndividualsThatReceivedModificationsToTheirOutstandingStockOptionAndRSUAwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_RestrictedStockUnitsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_RestrictedStockUnitsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesValueWithheldForEmployeesTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The shares value withheld by the Company to cover employees' tax liabilities under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesValueWithheldForEmployeesTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesWithheldForEmployeesTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares withheld by the Company to cover employees' tax liabilities under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesWithheldForEmployeesTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSharesWithheldForPayrollTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares withheld by the Company to cover payroll taxes under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSharesWithheldForPayrollTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSharesWithheldToCoverAggregateExercisePrices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares withheld by the Company to cover aggregate exercise prices under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSharesWithheldToCoverAggregateExercisePrices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares under fully vested and expected to vest options that were exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares under fully vested and expected to vest options for which rights to exercise lapsed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, for fully vested and expected to vest that were expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares under fully vested and expected to vest options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, for fully vested and expected to vest that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares under fully vested and expected to vest options that were granted during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest granted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_StockOptionOutstandingAndExcercisableAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_StockOptionOutstandingAndExcercisableAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_StockOptionSharesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_StockOptionSharesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_StockOptionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_StockOptionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_StockOptionsWeightedAverageExercisePriceAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_StockOptionsWeightedAverageExercisePriceAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net number of non-option equity instruments granted to participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The floor of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares reserved for issuance pertaining to the outstanding exercisable stock options as of the balance sheet date in the customized range of exercise prices for which the market and performance vesting condition has been satisfied.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares reserved for issuance pertaining to the outstanding stock options as of the balance sheet date for all option plans in the customized range of exercise prices.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average exercise price as of the balance sheet date for those equity-based payment arrangements exercisable and outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term of exercisable stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average price as of the balance sheet date at which grantees could acquire the underlying shares with respect to all outstanding stock options which are in the customized range of exercise prices.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OperatingExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_OperatingExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=adma_ExercisePriceRange1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=adma_ExercisePriceRange1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=adma_ExercisePriceRange2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=adma_ExercisePriceRange2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=adma_ExercisePriceRange3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=adma_ExercisePriceRange3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=adma_ExercisePriceRange4Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=adma_ExercisePriceRange4Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=adma_ExercisePriceRange5Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=adma_ExercisePriceRange5Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=adma_ExercisePriceRange6Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=adma_ExercisePriceRange6Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=adma_EmployeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=adma_EmployeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_DirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_DirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=adma_Two022CompensationPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=adma_Two022CompensationPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=adma_EquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=adma_EquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>RELATED PARTY TRANSACTIONS (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Nov. 19, 2024 </div>
<div>shares</div>
</th>
<th class="th">
<div>Aug. 15, 2023 </div>
<div>Officer </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 09, 2022 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jan. 31, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_RelatedPartyTransactionAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Compensation expenses | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,616,000<span></span>
</td>
<td class="nump">$ 6,187,000<span></span>
</td>
<td class="nump">$ 5,215,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_RelatedPartyTransactionAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,886,463<span></span>
</td>
<td class="nump">1,199,445<span></span>
</td>
<td class="nump">2,727,412<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Exercise period for his vested stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party [Member] | Executive Officer [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_RelatedPartyTransactionAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_NumberOfExecutiveOfficersThatExercisedOptions', window );">Number of executive officers that exercised options | Officer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedInCashlessTransactionForAward', window );">Shares purchased in cashless transaction (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,909,721<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Common stock shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">688,657<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation', window );">Shares withheld to cover portion of tax liabilities (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">257,867<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party [Member] | Mr. Grossman [Member] | Direct [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_RelatedPartyTransactionAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock shares sold during the period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,983<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party [Member] | Mr. Grossman [Member] | Indirect [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_RelatedPartyTransactionAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock shares sold during the period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,982<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party [Member] | Brian Lenz [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_RelatedPartyTransactionAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1', window );">Exercise term for his vested stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate', window );">Award expiration date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Mar. 31,  2026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Compensation expenses | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock shares sold during the period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,993<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Public offering price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.86<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party [Member] | Perceptive [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_RelatedPartyTransactionAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_MinimumPercentageOfCommonStockHeldByLender', window );">Minimum percentage of common stock held by lender</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party [Member] | Minimum [Member] | Brian Lenz [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_RelatedPartyTransactionAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Exercise period for his vested stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">90 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party [Member] | Maximum [Member] | Brian Lenz [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_RelatedPartyTransactionAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Exercise period for his vested stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party [Member] | Areth, LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_RelatedPartyTransactionAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingCostsAndExpenses', window );">Rent expense | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseExpirationDate1', window );">Lease extended maturity date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Dec. 31,  2026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_RelatedPartyTransactionLeaseRenewalPeriod', window );">Lease automatic renewal period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_RelatedPartyTransactionLeaseTerminationPeriod', window );">Notice period for termination</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party [Member] | Genesis [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_RelatedPartyTransactionAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty', window );">Purchased materials amount | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party [Member] | Bryant Fong [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_RelatedPartyTransactionAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1', window );">Exercise term for his vested stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate', window );">Award expiration date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Nov. 19,  2026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Compensation expenses | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party [Member] | Bryant Fong [Member] | Restricted Stock Units (RSUs) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_RelatedPartyTransactionAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (in shares)</a></td>
<td class="nump">12,020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party [Member] | Bryant Fong [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_RelatedPartyTransactionAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Exercise period for his vested stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">90 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party [Member] | Bryant Fong [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_RelatedPartyTransactionAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Exercise period for his vested stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_MinimumPercentageOfCommonStockHeldByLender">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Minimum percentage of common stock held by lender and administrative agent of credit facility.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_MinimumPercentageOfCommonStockHeldByLender</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_NumberOfExecutiveOfficersThatExercisedOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of executive officers who have exercised options to purchase shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_NumberOfExecutiveOfficersThatExercisedOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_RelatedPartyTransactionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_RelatedPartyTransactionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_RelatedPartyTransactionLeaseRenewalPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days in related party transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_RelatedPartyTransactionLeaseRenewalPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_RelatedPartyTransactionLeaseTerminationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Notice period for lease termination, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days in related party transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_RelatedPartyTransactionLeaseTerminationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedInCashlessTransactionForAward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares purchased in cashless exercise for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedInCashlessTransactionForAward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseExpirationDate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date which lease or group of leases is set to expire, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseExpirationDate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingCostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Excludes Selling, General and Administrative Expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingCostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchases during the period (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Estimated period over which an employee is required to provide service in exchange for the equity-based payment award, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date the equity-based award expires, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares used to settle grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_ExecutiveOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_ExecutiveOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=adma_PresidentAndChiefExecutiveOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=adma_PresidentAndChiefExecutiveOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=adma_DirectOwnershipMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=adma_DirectOwnershipMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=adma_IndirectOwnershipMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=adma_IndirectOwnershipMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=adma_ExecutiveVicePresidentAndChiefFinancialOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=adma_ExecutiveVicePresidentAndChiefFinancialOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityAxis=adma_PerceptiveCreditHoldingsIILPMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityAxis=adma_PerceptiveCreditHoldingsIILPMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=adma_ArethLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=adma_ArethLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=adma_GenesisBPSMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=adma_GenesisBPSMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=adma_BryantFongMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=adma_BryantFongMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>COMMITMENTS AND CONTINGENCIES (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Oct. 01, 2024 </div>
<div>Term </div>
<div>l</div>
</th>
<th class="th">
<div>Aug. 06, 2024 </div>
<div>l</div>
</th>
<th class="th">
<div>Jun. 19, 2023 </div>
<div>Batch</div>
</th>
<th class="th">
<div>Apr. 01, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 18, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($) </div>
<div>Facility</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_VendorAndLicensorCommitmentsAbstract', window );"><strong>Vendor and Licensor Commitments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_NumberOfBatchesInProductionAtTheTimeOfDisruption', window );">Number of batches in production at the time of disruption | Batch</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryWriteDown', window );">Non recurring charge of inventory</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCostAndExpenseOperating', window );">Impact of operating expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700<span></span>
</td>
<td class="nump">$ 4,245<span></span>
</td>
<td class="nump">$ 4,266<span></span>
</td>
<td class="nump">$ 17,843<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_RestorationCostsReceived', window );">Restoration costs received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_PlasmaSupplyAgreementTerm', window );">Plasma supply agreement term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_PostMarketingCommitmentsAbstract', window );"><strong>Post-Marketing Commitments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Amount of expenses to complete studies</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,813<span></span>
</td>
<td class="nump">3,300<span></span>
</td>
<td class="nump">3,614<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=adma_ASCENIVMember', window );">ASCENIV [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_PostMarketingCommitmentsAbstract', window );"><strong>Post-Marketing Commitments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Amount of expenses to complete studies</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,200<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="nump">500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=adma_BIVIGAMMember', window );">BIVIGAM [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_PostMarketingCommitmentsAbstract', window );"><strong>Post-Marketing Commitments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Amount of expenses to complete studies</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1,700<span></span>
</td>
<td class="nump">$ 2,200<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_VendorAndLicensorCommitmentsAbstract', window );"><strong>Vendor and Licensor Commitments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromInsuranceSettlementOperatingActivities', window );">Proceeds on business interruption loss coverage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_VendorAndLicensorCommitmentsAbstract', window );"><strong>Vendor and Licensor Commitments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_ITTechnologySystemsInaccessiblePeriod', window );">IT technology systems inaccessible period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=adma_PlasmaPurchaseAgreementOneMember', window );">2011 Plasma Purchase Agreement [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_VendorAndLicensorCommitmentsAbstract', window );"><strong>Vendor and Licensor Commitments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_NumberOfPlasmaCollectionFacilities', window );">Number of plasma collection facilities | Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=adma_ARGrifolsAgreementMember', window );">A&amp;R Grifols Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_VendorAndLicensorCommitmentsAbstract', window );"><strong>Vendor and Licensor Commitments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_NumberOfRenewalTerms', window );">Number of renewal terms | Term</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_AgreementWithTermExpirationDate', window );">Agreement term expiring date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Sep. 30,  2039<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_RespiratorySyncytialVirusPlasmaVolumeSuppliedPeriod', window );">Volume supplied period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_IncreaseInMinimumAnnualPriceTerm', window );">Increase in minimum annual price, term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=adma_ARGrifolsAgreementMember', window );">A&amp;R Grifols Agreement [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_VendorAndLicensorCommitmentsAbstract', window );"><strong>Vendor and Licensor Commitments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_QuantityOfRespiratorySyncytialVirusPlasmaUsed', window );">Quantity of RSV plasma used | l</a></td>
<td class="nump">35,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=adma_KEDPlasmaAgreementMember', window );">KEDPlasma Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_VendorAndLicensorCommitmentsAbstract', window );"><strong>Vendor and Licensor Commitments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_PlasmaPurchaseAgreementRenewalPeriod', window );">Plasma purchase agreement renewal period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_AgreementWithTermExpirationDate', window );">Agreement term expiring date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jul. 31,  2031<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_RespiratorySyncytialVirusPlasmaVolumeSuppliedPeriod', window );">Volume supplied period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=adma_KEDPlasmaAgreementMember', window );">KEDPlasma Agreement [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_VendorAndLicensorCommitmentsAbstract', window );"><strong>Vendor and Licensor Commitments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_QuantityOfRespiratorySyncytialVirusPlasmaUsed', window );">Quantity of RSV plasma used | l</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_AgreementWithTermExpirationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date the agreement with term expired, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_AgreementWithTermExpirationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_ITTechnologySystemsInaccessiblePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>IT technology systems inaccessible period at the time disruption in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_ITTechnologySystemsInaccessiblePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_IncreaseInMinimumAnnualPriceTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase in annual price term period on usage of RSV Plasma, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_IncreaseInMinimumAnnualPriceTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_NumberOfBatchesInProductionAtTheTimeOfDisruption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of batches that were in production at the time of disruption.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_NumberOfBatchesInProductionAtTheTimeOfDisruption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_NumberOfPlasmaCollectionFacilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of wholly-owned plasma collection facilities of the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_NumberOfPlasmaCollectionFacilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_NumberOfRenewalTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of renewal terms to extend purchase agreement, if agreed to by the parties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_NumberOfRenewalTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_PlasmaPurchaseAgreementRenewalPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Plasma purchase agreement renewal period, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_PlasmaPurchaseAgreementRenewalPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_PlasmaSupplyAgreementTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Plasma supply agreement term period, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_PlasmaSupplyAgreementTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_PostMarketingCommitmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_PostMarketingCommitmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_QuantityOfRespiratorySyncytialVirusPlasmaUsed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Respiratory Syncytial Virus (RSV) Converted human plasma used by company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_QuantityOfRespiratorySyncytialVirusPlasmaUsed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_RespiratorySyncytialVirusPlasmaVolumeSuppliedPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Supplied period on usage of RSV plasma in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_RespiratorySyncytialVirusPlasmaVolumeSuppliedPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_RestorationCostsReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Restoration cost received from cybersecurity insurance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_RestorationCostsReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_VendorAndLicensorCommitmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_VendorAndLicensorCommitmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWriteDown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483080/330-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWriteDown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCostAndExpenseOperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount of other operating cost and expense items that are associated with the entity's normal revenue producing operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(7)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCostAndExpenseOperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromInsuranceSettlementOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow for proceeds from settlement of insurance claim, classified as operating activities. Excludes insurance settlement classified as investing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-16<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 21B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-21B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromInsuranceSettlementOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=adma_ASCENIVMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=adma_ASCENIVMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=adma_BIVIGAMMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=adma_BIVIGAMMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=adma_PlasmaPurchaseAgreementOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=adma_PlasmaPurchaseAgreementOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=adma_ARGrifolsAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=adma_ARGrifolsAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=adma_KEDPlasmaAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=adma_KEDPlasmaAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES, Income Tax Expense (Benefit) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Current:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentFederalTaxExpenseBenefit', window );">Federal</a></td>
<td class="nump">$ 10,434<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit', window );">State</a></td>
<td class="nump">1,887<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Total current</a></td>
<td class="nump">12,321<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Deferred:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit', window );">Federal</a></td>
<td class="num">(72,858)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit', window );">State</a></td>
<td class="num">(11,422)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Total deferred</a></td>
<td class="num">(84,280)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Total benefit from income taxes</a></td>
<td class="num">$ (71,959)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES, Reconciliation of Income Taxes (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>INCOME TAXES [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate', window );">Tax provision (benefit) at U.S. Federal statutory rate</a></td>
<td class="nump">$ 26,400<span></span>
</td>
<td class="num">$ (5,930)<span></span>
</td>
<td class="num">$ (13,840)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes', window );">State taxes, net of federal benefit</a></td>
<td class="num">(9,931)<span></span>
</td>
<td class="num">(763)<span></span>
</td>
<td class="num">(1,773)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpense', window );">Non-deductible executive compensation</a></td>
<td class="nump">4,340<span></span>
</td>
<td class="nump">983<span></span>
</td>
<td class="nump">862<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount', window );">Excess tax benefits related to stock-based compensation</a></td>
<td class="num">(5,661)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="num">(87,969)<span></span>
</td>
<td class="nump">4,696<span></span>
</td>
<td class="nump">15,117<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationOtherAdjustments', window );">Other</a></td>
<td class="nump">862<span></span>
</td>
<td class="nump">1,014<span></span>
</td>
<td class="num">(366)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Total benefit from income taxes</a></td>
<td class="num">$ (71,959)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to expense for award under share-based payment arrangement. Excludes expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -SubTopic 740<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479176/718-740-35-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationNondeductibleExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>INCOME TAXES, Deferred Tax Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComponentsOfDeferredTaxAssetsAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic', window );">Federal and state net operating loss carryforwards</a></td>
<td class="nump">$ 65,615<span></span>
</td>
<td class="nump">$ 76,645<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetInterestCarryforward', window );">Interest expense limitations carryforwards</a></td>
<td class="nump">13,604<span></span>
</td>
<td class="nump">21,165<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInventory', window );">Inventory</a></td>
<td class="nump">3,911<span></span>
</td>
<td class="nump">2,937<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock-based compensation</a></td>
<td class="nump">2,523<span></span>
</td>
<td class="nump">1,795<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_DeferredTaxAssetsLeaseObligations', window );">Lease obligations</a></td>
<td class="nump">2,549<span></span>
</td>
<td class="nump">2,330<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals', window );">Accrued expenses and other</a></td>
<td class="nump">5,779<span></span>
</td>
<td class="nump">5,831<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total gross deferred tax assets</a></td>
<td class="nump">93,981<span></span>
</td>
<td class="nump">110,703<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Less: valuation allowance for deferred tax assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(101,422)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Total deferred tax assets, net of valuation allowance</a></td>
<td class="nump">93,981<span></span>
</td>
<td class="nump">9,281<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract', window );"><strong>Deferred tax liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_DeferredTaxLiabilitiesDepreciationOfPropertyAndEquipment', window );">Depreciation of property and equipment</a></td>
<td class="num">(6,166)<span></span>
</td>
<td class="num">(6,837)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_DeferredTaxLiabilitiesRightOfUseAsset', window );">Right-of-use assets</a></td>
<td class="num">(2,247)<span></span>
</td>
<td class="num">(2,077)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesOther', window );">Other deferred tax liabilities</a></td>
<td class="num">(1,288)<span></span>
</td>
<td class="num">(367)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Total deferred tax liabilities</a></td>
<td class="num">(9,701)<span></span>
</td>
<td class="num">(9,281)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Net deferred tax assets</a></td>
<td class="nump">$ 84,280<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_DeferredTaxAssetsLeaseObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_DeferredTaxAssetsLeaseObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_DeferredTaxLiabilitiesDepreciationOfPropertyAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from depreciation of property and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_DeferredTaxLiabilitiesDepreciationOfPropertyAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_DeferredTaxLiabilitiesRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from right-of-use assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_DeferredTaxLiabilitiesRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComponentsOfDeferredTaxAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComponentsOfDeferredTaxAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetInterestCarryforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible interest carryforward.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetInterestCarryforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInventory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from inventory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInventory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible domestic operating loss carryforwards. Excludes state and local operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from reserves and accruals.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES, Net Operating Loss Carryforwards (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_NetOperatingLossCarryforwardsAbstract', window );"><strong>Net Operating Loss Carryforwards [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax benefits</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_NetOperatingLossCarryforwardsAbstract', window );"><strong>Net Operating Loss Carryforwards [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsExpirationDate', window );">Net operating loss carryforwards, expiration</a></td>
<td class="text">Dec. 31,  2029<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_NetOperatingLossCarryforwardsAbstract', window );"><strong>Net Operating Loss Carryforwards [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsExpirationDate', window );">Net operating loss carryforwards, expiration</a></td>
<td class="text">Dec. 31,  2043<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_InternalRevenueServiceIRSMember', window );">Federal [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_NetOperatingLossCarryforwardsAbstract', window );"><strong>Net Operating Loss Carryforwards [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 265,606,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardValuationAllowance', window );">Valuation allowance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">88,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_InternalRevenueServiceIRSMember', window );">Federal [Member] | 2028 through 2043 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_NetOperatingLossCarryforwardsAbstract', window );"><strong>Net Operating Loss Carryforwards [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">33,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_InternalRevenueServiceIRSMember', window );">Federal [Member] | 2031 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_NetOperatingLossCarryforwardsAbstract', window );"><strong>Net Operating Loss Carryforwards [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">2,409,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_InternalRevenueServiceIRSMember', window );">Federal [Member] | 2032 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_NetOperatingLossCarryforwardsAbstract', window );"><strong>Net Operating Loss Carryforwards [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">7,430,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_InternalRevenueServiceIRSMember', window );">Federal [Member] | 2033 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_NetOperatingLossCarryforwardsAbstract', window );"><strong>Net Operating Loss Carryforwards [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">11,295,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_InternalRevenueServiceIRSMember', window );">Federal [Member] | 2034 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_NetOperatingLossCarryforwardsAbstract', window );"><strong>Net Operating Loss Carryforwards [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">1,025,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_InternalRevenueServiceIRSMember', window );">Federal [Member] | 2035 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_NetOperatingLossCarryforwardsAbstract', window );"><strong>Net Operating Loss Carryforwards [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">1,025,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_InternalRevenueServiceIRSMember', window );">Federal [Member] | 2036 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_NetOperatingLossCarryforwardsAbstract', window );"><strong>Net Operating Loss Carryforwards [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">1,025,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_InternalRevenueServiceIRSMember', window );">Federal [Member] | 2037 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_NetOperatingLossCarryforwardsAbstract', window );"><strong>Net Operating Loss Carryforwards [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">9,157,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_InternalRevenueServiceIRSMember', window );">Federal [Member] | Indefinite [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_NetOperatingLossCarryforwardsAbstract', window );"><strong>Net Operating Loss Carryforwards [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">232,240,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_NetOperatingLossCarryforwardsAbstract', window );"><strong>Net Operating Loss Carryforwards [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">204,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardValuationAllowance', window );">Valuation allowance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,400,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State [Member] | 2028 through 2043 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_NetOperatingLossCarryforwardsAbstract', window );"><strong>Net Operating Loss Carryforwards [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 62,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_NetOperatingLossCarryforwardsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_NetOperatingLossCarryforwardsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsExpirationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expiration date of each operating loss carryforward included in operating loss carryforward, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsExpirationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of valuation allowance pertaining to the deferred tax asset representing potential future taxable deductions from tax credit carryforwards for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-10B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_InternalRevenueServiceIRSMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_InternalRevenueServiceIRSMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=adma_TaxYear2028Through2043Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=adma_TaxYear2028Through2043Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=adma_TaxYear2031Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=adma_TaxYear2031Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=adma_TaxYear2032Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=adma_TaxYear2032Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=adma_TaxYear2033Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=adma_TaxYear2033Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=adma_TaxYear2034Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=adma_TaxYear2034Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=adma_TaxYear2035Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=adma_TaxYear2035Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=adma_TaxYear2036Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=adma_TaxYear2036Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=adma_TaxYear2037Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=adma_TaxYear2037Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=adma_TaxYearAfter2037Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=adma_TaxYearAfter2037Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LEASE OBLIGATIONS (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>Lease</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>Lease</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>LEASE OBLIGATIONS [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_OperatingLeaseIncrementalBorrowingRatePercent', window );">Incremental borrowing rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13.00%<span></span>
</td>
<td class="nump">16.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted average discount rate</a></td>
<td class="nump">13.02%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Aggregate lease expense</a></td>
<td class="nump">$ 2,400<span></span>
</td>
<td class="nump">$ 2,400<span></span>
</td>
<td class="nump">$ 2,100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Cash payments for lease</a></td>
<td class="nump">2,400<span></span>
</td>
<td class="nump">$ 2,400<span></span>
</td>
<td class="nump">$ 1,800<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_NumberOfNewPropertyLeases', window );">Number of new property leases | Lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_LesseeOperatingLeaseRightOfUseAssetRelatedToPropertyLease', window );">Right-of-use assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="nump">$ 4,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_LesseeOperatingLeaseLiabilitiesRelatedToPropertyLease', window );">Lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="nump">$ 4,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_OperatingAndFinancingLeaseLiability', window );">Operating and financing lease liabilities</a></td>
<td class="nump">$ 9,800<span></span>
</td>
<td class="nump">10,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted average remaining term</a></td>
<td class="text">6 years 9 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Payments Under Lease Obligations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">Year ended December 31, 2025</a></td>
<td class="nump">$ 2,421<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2026</a></td>
<td class="nump">2,157<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2027</a></td>
<td class="nump">2,041<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2028</a></td>
<td class="nump">2,088<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2029</a></td>
<td class="nump">2,109<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">Thereafter</a></td>
<td class="nump">4,041<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total payments</a></td>
<td class="nump">14,857<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: imputed interest</a></td>
<td class="num">(5,078)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current portion</a></td>
<td class="num">(1,218)<span></span>
</td>
<td class="num">(1,045)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Balance at December 31, 2024</a></td>
<td class="nump">$ 8,561<span></span>
</td>
<td class="nump">$ 9,779<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_LesseeOperatingLeaseLiabilitiesRelatedToPropertyLease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lease liability recognized in connection with property lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_LesseeOperatingLeaseLiabilitiesRelatedToPropertyLease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_LesseeOperatingLeaseRightOfUseAssetRelatedToPropertyLease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Right to use assets recognized in connection with property lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_LesseeOperatingLeaseRightOfUseAssetRelatedToPropertyLease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_NumberOfNewPropertyLeases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new property leases related to additional plasma collection facilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_NumberOfNewPropertyLeases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_OperatingAndFinancingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating and finance leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_OperatingAndFinancingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_OperatingLeaseIncrementalBorrowingRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average incremental borrowing rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_OperatingLeaseIncrementalBorrowingRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>SEGMENTS, Summarized Financial Information by Segment (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="6">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Apr. 01, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th" colspan="2">
<div>Dec. 31, 2024 </div>
<div>USD ($) </div>
<div>Facility </div>
<div>Segment</div>
</th>
<th class="th" colspan="2">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th" colspan="2">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationProfitLossAbstract', window );"><strong>Segment Reporting Information [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_NumberOfPlasmaCollectionFacilitiesUnderDevelopment', window );">Number of plasma collection facilities under development | Facility</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments | Segment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 426,454<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 258,215<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 154,080<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">Cost of product revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">206,901<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">169,273<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">118,815<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,813<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">3,300<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">3,614<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCostAndExpenseOperating', window );">Plasma center operating expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700<span></span>
</td>
<td class="nump">4,245<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">4,266<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">17,843<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,045<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">8,332<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">7,113<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Other expense, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(13,269)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(49,871)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(26,539)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income (loss) before taxes</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">125,714<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(28,239)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(65,904)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">488,678<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">329,182<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">348,461<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract', window );"><strong>Segment Reconciliation [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Consolidated selling, general and administrative expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">74,124<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">59,020<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">52,458<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseNonoperating', window );">Unallocated interest expense, primarily related to interest on senior debt (see Note 7)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(13,930)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(25,027)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(19,279)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of debt (see Note 7)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,243)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(26,174)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(6,670)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Unallocated interest income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,097<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1,617<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">45<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationProfitLossAbstract', window );"><strong>Segment Reporting Information [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">426,311<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">258,072<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">153,937<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">Cost of product revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">206,901<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">169,273<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">118,815<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,813<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">3,300<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">3,614<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCostAndExpenseOperating', window );">Plasma center operating expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,245<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">4,266<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">17,843<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingAndMarketingExpense', window );">Selling, marketing and distribution</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,683<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">18,407<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">13,667<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,045<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">8,332<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">7,113<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,001<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">18,625<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">16,312<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Other expense, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(183)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(85)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income (loss) before taxes</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">168,097<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">43,218<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(17,537)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentExpenditureAdditionToLongLivedAssets', window );">Expenditures for additions to long-lived assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,575<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">4,771<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">13,911<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">319,774<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">281,452<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">275,230<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments [Member] | ADMA BioManufacturing [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationProfitLossAbstract', window );"><strong>Segment Reporting Information [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">415,806<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">249,738<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">144,070<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">Cost of product revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">195,605<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">161,157<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">108,882<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,813<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">3,300<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">3,614<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCostAndExpenseOperating', window );">Plasma center operating expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingAndMarketingExpense', window );">Selling, marketing and distribution</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,683<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">18,407<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">13,667<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,827<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">5,156<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">4,709<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,001<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">18,625<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">16,312<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Other expense, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(178)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income (loss) before taxes</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">173,138<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">47,267<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">374<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentExpenditureAdditionToLongLivedAssets', window );">Expenditures for additions to long-lived assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,352<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">2,952<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">5,247<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">289,297<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">246,719<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">238,159<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments [Member] | Plasma Collection Centers [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationProfitLossAbstract', window );"><strong>Segment Reporting Information [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,505<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">8,334<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">9,867<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">Cost of product revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,296<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">8,116<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">9,933<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCostAndExpenseOperating', window );">Plasma center operating expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,245<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">4,266<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">17,843<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingAndMarketingExpense', window );">Selling, marketing and distribution</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,218<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">3,176<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">2,404<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Other expense, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income (loss) before taxes</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,041)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(4,049)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(17,911)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentExpenditureAdditionToLongLivedAssets', window );">Expenditures for additions to long-lived assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">223<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1,819<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">8,664<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,477<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">34,733<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">37,071<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_MaterialReconcilingItemsMember', window );">Reconciling Item [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationProfitLossAbstract', window );"><strong>Segment Reporting Information [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">143<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">143<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">143<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income (loss) before taxes</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">143<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">143<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">143<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract', window );"><strong>Segment Reconciliation [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseNonoperating', window );">Unallocated interest expense, primarily related to interest on senior debt (see Note 7)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(13,930)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(25,027)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(19,276)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of debt (see Note 7)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,243)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(26,174)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(6,670)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Unallocated interest income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,087<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">1,589<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember', window );">Corporate [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationProfitLossAbstract', window );"><strong>Segment Reporting Information [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,440<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">21,988<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">22,479<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income (loss) before taxes</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(29,440)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(21,988)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(22,479)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 168,904<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">$ 47,730<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="nump">$ 73,231<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[3]</sup></td>
</tr>
<tr><td colspan="9"></td></tr>
<tr><td colspan="9"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Primarily includes compensation expense,
                    including stock-based compensation expense, for certain executive officers and consultants, insurance, legal and investor relations expenses and accounting and tax fees that are not allocated to the Company&#8217;s operating segments.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">Primarily consists of cash and deferred tax
                  assets.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[3]</td>
<td style="vertical-align: top;" valign="top">Primarily consists of cash.</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_NumberOfPlasmaCollectionFacilitiesUnderDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of plasma collection facilities under various stages of development.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_NumberOfPlasmaCollectionFacilitiesUnderDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 30: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate cost of goods produced and sold and services rendered during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481303/470-50-40-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481303/470-50-40-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseNonoperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense classified as nonoperating.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseNonoperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCostAndExpenseOperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount of other operating cost and expense items that are associated with the entity's normal revenue producing operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(7)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCostAndExpenseOperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentExpenditureAdditionToLongLivedAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenditure for addition to long-lived assets included in determination of segment assets by chief operating decision maker (CODM) or otherwise regularly provided to CODM. Excludes expenditure for addition to financial instrument, long-term customer relationship of financial institution, mortgage and other servicing rights, deferred policy acquisition cost, and deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentExpenditureAdditionToLongLivedAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationProfitLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationProfitLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingAndMarketingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total amount of expenses directly related to the marketing or selling of products or services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingAndMarketingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=adma_ADMABioManufacturingSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=adma_ADMABioManufacturingSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=adma_PlasmaCollectionCentersSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=adma_PlasmaCollectionCentersSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_MaterialReconcilingItemsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_MaterialReconcilingItemsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SEGMENTS, Net Revenues According to Geographic Area (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentsGeographicalAreasAbstract', window );"><strong>Revenues, Geographic Area [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 426,454<span></span>
</td>
<td class="nump">$ 258,215<span></span>
</td>
<td class="nump">$ 154,080<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentsGeographicalAreasAbstract', window );"><strong>Revenues, Geographic Area [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">410,148<span></span>
</td>
<td class="nump">244,881<span></span>
</td>
<td class="nump">146,427<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">International [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentsGeographicalAreasAbstract', window );"><strong>Revenues, Geographic Area [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">16,306<span></span>
</td>
<td class="nump">13,334<span></span>
</td>
<td class="nump">7,653<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentsGeographicalAreasAbstract', window );"><strong>Revenues, Geographic Area [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">426,311<span></span>
</td>
<td class="nump">258,072<span></span>
</td>
<td class="nump">153,937<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments [Member] | United States [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentsGeographicalAreasAbstract', window );"><strong>Revenues, Geographic Area [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">410,005<span></span>
</td>
<td class="nump">244,738<span></span>
</td>
<td class="nump">146,284<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments [Member] | International [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentsGeographicalAreasAbstract', window );"><strong>Revenues, Geographic Area [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">16,306<span></span>
</td>
<td class="nump">13,334<span></span>
</td>
<td class="nump">7,653<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments [Member] | ADMA BioManufacturing [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentsGeographicalAreasAbstract', window );"><strong>Revenues, Geographic Area [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">415,806<span></span>
</td>
<td class="nump">249,738<span></span>
</td>
<td class="nump">144,070<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments [Member] | ADMA BioManufacturing [Member] | United States [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentsGeographicalAreasAbstract', window );"><strong>Revenues, Geographic Area [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">400,336<span></span>
</td>
<td class="nump">237,454<span></span>
</td>
<td class="nump">136,827<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments [Member] | ADMA BioManufacturing [Member] | International [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentsGeographicalAreasAbstract', window );"><strong>Revenues, Geographic Area [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">15,470<span></span>
</td>
<td class="nump">12,284<span></span>
</td>
<td class="nump">7,243<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments [Member] | Plasma Collection Centers [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentsGeographicalAreasAbstract', window );"><strong>Revenues, Geographic Area [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">10,505<span></span>
</td>
<td class="nump">8,334<span></span>
</td>
<td class="nump">9,867<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments [Member] | Plasma Collection Centers [Member] | United States [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentsGeographicalAreasAbstract', window );"><strong>Revenues, Geographic Area [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">9,669<span></span>
</td>
<td class="nump">7,284<span></span>
</td>
<td class="nump">9,457<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments [Member] | Plasma Collection Centers [Member] | International [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentsGeographicalAreasAbstract', window );"><strong>Revenues, Geographic Area [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">836<span></span>
</td>
<td class="nump">1,050<span></span>
</td>
<td class="nump">410<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_MaterialReconcilingItemsMember', window );">Reconciling Item [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentsGeographicalAreasAbstract', window );"><strong>Revenues, Geographic Area [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">143<span></span>
</td>
<td class="nump">143<span></span>
</td>
<td class="nump">143<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_MaterialReconcilingItemsMember', window );">Reconciling Item [Member] | United States [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentsGeographicalAreasAbstract', window );"><strong>Revenues, Geographic Area [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">143<span></span>
</td>
<td class="nump">143<span></span>
</td>
<td class="nump">143<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_MaterialReconcilingItemsMember', window );">Reconciling Item [Member] | International [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentsGeographicalAreasAbstract', window );"><strong>Revenues, Geographic Area [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentsGeographicalAreasAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentsGeographicalAreasAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=us-gaap_NonUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=adma_ADMABioManufacturingSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=adma_ADMABioManufacturingSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=adma_PlasmaCollectionCentersSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=adma_PlasmaCollectionCentersSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_MaterialReconcilingItemsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_MaterialReconcilingItemsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>OTHER EMPLOYEE BENEFITS (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>OTHER EMPLOYEE BENEFITS [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount', window );">Compensation expense</a></td>
<td class="nump">$ 1.5<span></span>
</td>
<td class="nump">$ 1.3<span></span>
</td>
<td class="nump">$ 1.3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of discretionary contributions made by an employer to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>SUPPLEMENTAL CASH FLOW INFORMATION [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest</a></td>
<td class="nump">$ 10,668<span></span>
</td>
<td class="nump">$ 18,051<span></span>
</td>
<td class="nump">$ 13,880<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaid', window );">Cash paid for income taxes</a></td>
<td class="nump">9,392<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Noncash Financing and Investing Activities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_EquipmentAcquiredReflectedInAccountsPayableAndAccruedLiabilities', window );">Equipment acquired reflected in accounts payable and accrued liabilities</a></td>
<td class="nump">725<span></span>
</td>
<td class="nump">86<span></span>
</td>
<td class="nump">1,495<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right-to-use assets in exchange for lease obligations</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">130<span></span>
</td>
<td class="nump">4,048<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_WarrantsIssuedInConnectionWithNotesPayable', window );">Warrants issued in connection with notes payable</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 5,595<span></span>
</td>
<td class="nump">$ 9,570<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_EquipmentAcquiredReflectedInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equipment acquired in a noncash (or part noncash) acquisition and reflected in accounts payable and accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_EquipmentAcquiredReflectedInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_WarrantsIssuedInConnectionWithNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of warrants issued in connection with the issuance of notes payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_WarrantsIssuedInConnectionWithNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2A<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 23<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-23<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-22<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONCENTRATIONS (Details) - Customer Concentration Risk [Member] - Customer<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember', window );">Accounts Receivable [Member] | Three Customers [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RisksAndUncertaintiesAbstract', window );"><strong>Risks and Uncertainties [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_NumberOfCustomers', window );">Number of customers</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">91.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember', window );">Accounts Receivable [Member] | Five Customers [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RisksAndUncertaintiesAbstract', window );"><strong>Risks and Uncertainties [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_NumberOfCustomers', window );">Number of customers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">98.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerProductAndServiceBenchmarkMember', window );">Revenue [Member] | Plasma Collection Centers [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RisksAndUncertaintiesAbstract', window );"><strong>Risks and Uncertainties [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_NumberOfCustomers', window );">Number of customers</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerProductAndServiceBenchmarkMember', window );">Revenue [Member] | Two Customers [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RisksAndUncertaintiesAbstract', window );"><strong>Risks and Uncertainties [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_adma_NumberOfCustomers', window );">Number of customers</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">72.00%<span></span>
</td>
<td class="nump">72.00%<span></span>
</td>
<td class="nump">74.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_adma_NumberOfCustomers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of major customers of the organization.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">adma_NumberOfCustomers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>adma_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-21<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-20<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RisksAndUncertaintiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RisksAndUncertaintiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=adma_ThreeCustomersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=adma_ThreeCustomersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=adma_FiveCustomersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=adma_FiveCustomersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerProductAndServiceBenchmarkMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerProductAndServiceBenchmarkMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=adma_PlasmaCollectionCentersSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=adma_PlasmaCollectionCentersSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=adma_TwoCustomersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=adma_TwoCustomersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SCHEDULE II - VALUATION AND QUALIFYING ACCOUNTS (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=adma_SECSchedule1209ReserveAccruedRebatesMember', window );">Accrued Rebates [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MovementInValuationAllowancesAndReservesRollForward', window );"><strong>Valuation and Qualifying Accounts [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance at beginning of year</a></td>
<td class="nump">$ 16,608<span></span>
</td>
<td class="nump">$ 11,437<span></span>
</td>
<td class="nump">$ 5,040<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense', window );">Charged to costs and expenses</a></td>
<td class="nump">8,514<span></span>
</td>
<td class="nump">8,448<span></span>
</td>
<td class="nump">8,227<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts', window );">Other</a></td>
<td class="num">(12,618)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesDeductions', window );">Deductions</a></td>
<td class="nump">8,349<span></span>
</td>
<td class="nump">3,277<span></span>
</td>
<td class="nump">1,830<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance at end of year</a></td>
<td class="nump">4,155<span></span>
</td>
<td class="nump">16,608<span></span>
</td>
<td class="nump">11,437<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_InventoryValuationReserveMember', window );">Inventory Valuation Allowance [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MovementInValuationAllowancesAndReservesRollForward', window );"><strong>Valuation and Qualifying Accounts [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance at beginning of year</a></td>
<td class="nump">2,992<span></span>
</td>
<td class="nump">5,400<span></span>
</td>
<td class="nump">8,577<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense', window );">Charged to costs and expenses</a></td>
<td class="nump">9,338<span></span>
</td>
<td class="nump">6,963<span></span>
</td>
<td class="nump">2,744<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts', window );">Other</a></td>
<td class="nump">118<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesDeductions', window );">Deductions</a></td>
<td class="nump">7,287<span></span>
</td>
<td class="nump">9,377<span></span>
</td>
<td class="nump">5,921<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance at end of year</a></td>
<td class="nump">5,161<span></span>
</td>
<td class="nump">2,992<span></span>
</td>
<td class="nump">5,400<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember', window );">Deferred Tax Asset Valuation Allowance [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MovementInValuationAllowancesAndReservesRollForward', window );"><strong>Valuation and Qualifying Accounts [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance at beginning of year</a></td>
<td class="nump">101,421<span></span>
</td>
<td class="nump">96,725<span></span>
</td>
<td class="nump">81,608<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense', window );">Charged to costs and expenses</a></td>
<td class="num">(84,280)<span></span>
</td>
<td class="nump">4,696<span></span>
</td>
<td class="nump">15,117<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts', window );">Other</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesDeductions', window );">Deductions</a></td>
<td class="nump">17,141<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance at end of year</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 101,421<span></span>
</td>
<td class="nump">$ 96,725<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MovementInValuationAllowancesAndReservesRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MovementInValuationAllowancesAndReservesRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of valuation and qualifying accounts and reserves.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column E))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in valuation and qualifying accounts and reserves from charge to cost and expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column C)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in valuation and qualifying accounts and reserves from charge to accounts other than cost and expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column C)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesDeductions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in valuation and qualifying accounts and reserves.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column D))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesDeductions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=adma_SECSchedule1209ReserveAccruedRebatesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=adma_SECSchedule1209ReserveAccruedRebatesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_InventoryValuationReserveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_InventoryValuationReserveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>92
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    ( ("!<EI&QTU(E0   ,T    0    9&]C4')O<',O87!P+GAM
M;$W/30O", P&X+]2=K>9BAZD#D0]BIZ\SRYUA;8I;83Z[^T$/VYY><@;HBZ)
M(B:VF$7Q+N1M,S+'#4#6(_H^R\JABJ'D>ZXQW8&,L1H/I!\> \.B;=> A3$,
M.,SBM[#IU"Y&9W7/ED)WLCI1)L/B6#0ZL2<?J]P<"A#G>B4^BQ-+.9<K!?^+
M4\L54Y[FRF_\9 6_![H74$L#!!0    ( ("!<EJ"<\1F\P   "L"   1
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M0JQW%9="R-7Z;7+]X7<5=M[8O?U/QI7DXIOQ1;!MX-==M)]02P,$%     @
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M3@H\W/[O#;#"Q([A[8N_ 5!+ P04    " " @7):/LDHQ#@(   R.   &
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M4A#TBW4JDV&T)@SE*\RTGA76[LST&#;"43;"@7-_X>ZC.%NB^7OZ1!,M2EA
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MX$C.#H+G[8+GZ5<C>(R+V8) &X$^_0("9 5R DT%3TU C\J)H(),TS"D/$!
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MJ*HA0OIP3R8D26HD.H\O+>A@^YWUP-WGW]#?-,Y39V[#DDSRY&,\JQ;' W<
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M&R+7\[@T%:WX-.W#85CQMJQX3\U*7]YZXD;O&JYE0XXGY40/35N=8($F,"9
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MZ'N)F4!-'Q++3:<;X"\7#E!4#B[&CKCI:%4.6M$"76CLS]&==D!/KQU0OW9
M8LMO61Z?K1(K/EO[@%@:.NV -&H')&H'7JHB2<\/#<S[VR\>Y$![FANT<PSQ
M1.H!B>H!FJ9I8?XW)O4$#EUS6M$"76@L^9U^0&K], G+14+*$I"=**S;A2@E
MO5]+H'XMT6\2*$U8;SL%@=0*0NEM;[I)NGO/=ER3/P)23^+@=--ZIJ +C0U
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MG#LKL1<URDXU>"'W+,/VA_R>R?AM(VMPRSM,92Y9"(831[OV86N[^$4G"00
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M"Y9]EJ6W,N\4"<.N/;T86#N1RUB'[LX>#Q]Z@8G.6GHO->KI,2_J;=05>3S
MNJ8#P78\-RD/B-INU][(Q5>#PVCH15A/HS>8(1M;\7O:C PZR<O,_+?^57"7
M\@:T<+F\1^YMWJSH;+-42]PZ'CT[.TH;>3>;?( )\?O0YG7;UAO^<ZUR>!==
M@-^7-5S6?J %_ ORGO\O4$L#!!0    ( ("!<EJX!_*&] ,  *X(   8
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M?I]?@=*Q3\E58XHWW2+;57+L;%SEG*CL;%);6_L SH DXN&  69$:W_]=C>
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MN%FC!DLPOE[#2K";_)$93B&A4,:\%\5#&LOD19BPWT#82,JDD9+MM;J7D ?
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M(J=&M^[ 9#N>@WI!$+>_D22?]+-I1[$[_D6POVKP/U17T$"S$CQ#(J-[A\"
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M< Y<!1+12N!.0Y6#29K=N"AAZCZN4_$DM?'9KQFT@Z2A\O$V(?B9FR@4/S4
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ME0SY^"B]VFR8L,$]+VH+#5KEH^HR6=<!L(SV;<D[3S(&7>ZE\[5!VO::G1K
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M AZ4J-DV(>M"CG9HJ/;2>TWM0NOPW<W[9C3]KF1 3/DD7^4@,I;&>C,4U9\
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M;?CC6J:P'QJ ]ZL*P4)_H06&7SR^_#]02P,$%     @ @(%R6EHS0IMF!P
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M)I=\880(YAIM ]@0P3(QGPM?NHQ;A&7_YD6%]L&\*H;CB!YSF$%Q(:Y#T^C
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MEYGPVB/<.%WZ5PTS[?!SR%]F@D-EM #?SS525]]0@/;=T_G_ 5!+ P04
M" " @7):E&W<3ZD*  !7'   &0   'AL+W=O<FMS:&5E=',O<VAE970Q-BYX
M;6RE6=ERV[@2?==7H#13J4R5=CN[[2IY2YP;+Q5[,@]3]P$B(1$W),$ H!7-
MU]_3 +A(D>29S(LMD4#C]':Z&SI:*OW5)$)8]CU+<W/<3:PMW@Z')DI$QLU
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M5?7<C<B*&/061F4S5/S4JD@) V,=6LQ5.*^]P<N#BF3+ 8CA"B*GJ;"2>**
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MS^1LG\ 88@RRA+TL+\.C%%_)XHI%W&=A$,9'Z$6#;I&E%WU!-_:O%U/3: 3
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M@/PBF^SD#ID3D5.[3 >O1DPKN;5V:3RS5)NZ3ZTYK*0VM-HN-$^\?TJA70?
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M,F+:??WB;AJUME^<3%73J)4=TI^F4M,"/)\K@%1W0PR&3Y"N_PM02P,$%
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MD5I 9;M].-V#209BU;&SME/@O[^QD[)=71=II7V(,[9GOOEF;,\,]E(]ZQS
MD$/!A1YZN3'EM>_K-(>"ZHXL0>#.5JJ"&IRJG:]+!31S1@7WHR#H^P5EPAL-
MW-I*C0:R,IP)6"FBJZ*@ZG@#7.Z'7NB]+CRP76[L@C\:E'0':S"/Y4KAS#^A
M9*P H9D41,%VZ(W#ZYN>U7<*WQCL]1N9V$@V4C[;R3P;>H$E!!Q28Q$H_EY@
M IQ;(*3QO<'T3BZMX5OY%7WF8L=8-E3#1/(GEIE\Z"4>R6!+*VX>Y/X+-/'$
M%B^57+N1[&O=?N"1M-)&%HTQ,BB8J/_TT.3AC4'R*X.H,8@<[]J18WE+#1T-
ME-P39;41S0HN5&>-Y)BPA[(V"G<9VIG1^G&UNIO>3Q=?QW?D=KZ>W"W7CP]3
MLIR1R7C]A<SNED]DOI@M'^['7^?+Q< WZ-7:^FGCX:;V$/W"0QB1>RE,KLE4
M9)#]#. CW1/GZ)7S3706\1;2#NF&;1(%4>\,7O>4@Z[#Z_ZA')!_QAMM%%ZH
M?]]+1^VL][XS^\BN=4E3&'KXBC2H%_!&'S^$_>#SF5!ZIU!ZY]#_R'&>]Q#&
MG=9O)VQ=E24'?,N&<I)2G9,M5@/"1%U5[/-$B9@<R!&HT@3L52%XT%!L0)T.
MVXU=0D5FA8@P3:A&4XYH^KIE55I.P^ZV_IX+A)251GW]Z6?6[_*\;DTLMY*R
MS/%AP@">D2%_D3!H]_N)%9)V$(=6Z+:3)/B?12H+((8>0*/.5;M[%>'_PGZM
MA10N]AD35*1,[%P@<_&"+NQL;"L4,PPPE.GWBI4V85BW4%28#2Q7MI:AQ&PU
M2V4EC$;71[KAX*!P456XSQG=,.Z0T/%E%..8]"WG=N\J;KG*>V'D1:713FM
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MX0U8GVKMJ@=F4'^T<O ?4$L#!!0    ( ("!<EID-TWV[P0  !02   9
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M8.LO%M@?[:#);Z #&E0BG*D0 -*71/PZ_Z(B:'1*.+!NO6&1!6_R-LT7"^B
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MAMM,"]9;JWM)OU7%-1X&*<Z^:;@P:F6L5BXJF2LEW86A(\ZBB- 6>JPO(=]
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MH6GMC C7T4*USHL3#" %;#AG2-$[MHVB/!X#%R;-.EV2E,?] JJR+2L.^B-
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M[WK[N<3'%4AC@.MS@?+J!B; ]KDV_ =02P,$%     @ @(%R6O_9 Z29 @
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MD :'MS8+W):@; +&<RG-SK$%VOV;_ 502P,$%     @ @(%R6JO>%2XZ P
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M[#_L:MTX=B&IE!9%8TP,"E[6(WMISN'(H.__Q"!L#$++NW9D67YAFDU&4NQ
M&FU",X(-U5H3.5Z:2UEJ2;N<[/1D<?<XO?MM,?M]#M/E<OZXA,M'MLI1?1IY
MFO"-EI<T6+,:*_P)5A#"=U'JC8)YF6+Z%L C8BV[\)7=+#R+^ 63:^@&'0C]
M,#J#UVVC[5J\[B]'^_=TI;2DW/CG5+PU6G0:S=3+4&U9@F.7"D*A?$9W\O%#
MT/,_G^$:M5RC<^B3)=5?6N4(8@V+4K,RXW0O,%4*M3I%]BS<:;)'N,SB M-
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MZ'L@ZW51.UI4;D270IN!=V9A-BQ*FV#.<V$ZV#F6H-G9R6]02P,$%     @
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M!0I6IX1B0VE 'LJ"OQ/-DY 8-0K!(V"]5&JN+628!-^,'P%SF4!+&&)#=(&
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M*!+ ^:649MNA#?KWX^Q?4$L#!!0    ( ("!<EH?1]$O^@(  $<&   9
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MKM7<-6<R&TMM)^#[1 %6VXYET/]./_\O4$L#!!0    ( ("!<EJ=_4[54P,
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M1=_YZJ <9F11JGN^^@ZMGC/#E_%2VB=:M;6N@[*%5+QJP;J#BK+F39Y;'S8
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MDG"&!&QG3C28S,=&WRI\);"71WMD(MEP_F2$))LYGB$$):3*(&"]/$,,96F
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MY,6>B^)$LG6^"V'*I&1Q?KBB9$YY%J!^7S FWTZR!JJ=+Z/_ 5!+ P04
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MP&@ZO7F:7H!I^@B CRX1V _X)W )OD]=\/'#)_ !^!%X6M$-QY''^Z:0(<1
MYCP;;IP.APX,!Q&XHY%8<7 3><0K Y@R]IP >B4P1DI$E\RO0 M> &2A=D-
MD_>[MQK<W?>[(P6;5CX=K02O=0#OLQ_Y@EQ^E6O! [>1P-'2GP4$C#@G@E^
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MKCJ2'DLWE](30=?)=LN,"D'#Y'!%L$=8;"#O+R@5KR?Q /D6W_ W4$L#!!0
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M3X3IM^QYBKI;9&&S7JV3Q7376Z_?3_5NT_V'M[ELS"-:W$&U\*!=>HLG.JA
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M]=YO)\K3BWNIN<G6R40K4*@6H9I -8EJ"M4TJAE4BU'-4EHUOD53:H#OI39
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MV09+TS$<R[#,BKB*&E@2MU^(V^\@+MJ*/1?-(PS$:1"$C&U0XN/W!&ZMH:O
M_?ID=XRA!>&@HJ_*6CU%L%((!D4(!JTA^%6<S->4^!@'#"PHB;-H +*6IUH&
M\!NF?LBJ9Y-,^U9T5^TS6.](^[X]M"NZUXT@-"I&7H-1_S!!2C(-"YF&K3(]
MEB0JQB99 /]H##=IU,KMJM&PUK/J=O6NA5>W<&S'/J$/- ZG:N.<N9R?M>YQ
M/,>T\:35SNFJB%*:JY3FJ:*5(W*4YT!5I]^<I"HF*FFN4IJGBE:.B7F(B=DZ
M2V;-B^M[FUP[M7-\S-HV!X>#@>$XE<6DR="V[9YE5=:4!D-GX/2')Q:50_X&
M6Q.2;]N=VMF=1;/J^U.OEBTT6(D-JKH$-UB91T9EL0[I%3P_O]J?5!F) A!L
MJ#RI\A66.4!(WA]N2G,MI317*<V#]?3.M*'9&_2M$^$X9&3PK)2LO"&"?\%+
M$F"ZHR'G. &/FWD4^N!AL<!IC%HW3J4IFE*:JY3FJ:*5(W=(^:"C;.-4FM\I
MI;E*:9XJ6CDFATP1GI\J?N/B5D_R:E,^#X?*+,]52O-4T<KA.&2-L#UM_/_Y
M$*QG9R+_J&Z1T_;Z.VNODN:IHF7:ZT=7&3&FR_0.B0D=-PG/?O<O2K-[JJF\
MIY)7(97R6WASF][:Z =,=OEUC^@R%,>E""\$TKCN"_5I=I^4O7"R3B],YH1S
M$J>/*XS$/B4-Q/<+0OC^1590W.I-_@-02P,$%     @ @(%R6O?D]>)B"0
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MENE#=:QU1I;)-LYWIP7O/]T=G<WI>U&=,-WY_(J^OZH.DIXTF-UYW#=!6HR
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M_>FOY?!$48^WJM>[_?^]3T/9Y86WNM^U]6;X<->"3;4]_%E\'B(A?"!*3WR
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MVAA VM)#52(9_=Q#)0-[N1WV=KMSN /)Z XD7^V"N\1@%K X7&J9'723G.F
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MH:[;XU_Z"C[5S1_[9K_\?U!+ P04    " " @7):-#1Z-PH,  !"E   &0
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M=GNB:628IRIV3Q99E#RJN?!JX7I?I(9Z&% :=1H\ &\TW' *&+10#J4%4)I
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MP]X+7XOS192TG2%G4K+K:$=B.A*C2,Q 8FR%C;:+6AD,Q+HVD3U:2,P&8<*
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M5,ATIR^7,K$#4P!Y?TZI>!NH!<K_ ,%_4$L#!!0    ( ("!<EHPI/F<NP,
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MDNF8LP/BVEI%TQ?%W!3>2@W-]3+.)5=OJ?*3T[NOM]^^?$(/-_]^FE^A&:R
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M&;&*9K;4="\4FA'[:-9(=H,^8M1P1X?[[EN; C,"@YDYZ#"[P))'3ZXE-=T
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MESP4;&S% C@>Q'XT5E0 C@5ZW!'!+2<W3@''G0('WQMG<HXWJ4W ;5D/6M\
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MDHIT <AO%L1^.&Y:;1R7223&0P@ QZ26E5--JU'JXM#T^M'&'\[D'&]2=2X
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M ^CO;RLM>[<?NA/LWOYY\5]02P,$%     @ @(%R6D3:>PBK!@  -#<  !D
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M:5R^7(E@(;(B0'W^F*;RY:*XP>Z@W.1_4$L#!!0    ( ("!<EHN70%N;@(
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MR9JI&=]>0S//P/"EG$G[B[9U[D GIVNI>-& =0<%+>LG>6SVL =PSY\!> W
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M$J< _OV&4O9VD3Z@_&_#]%]02P,$%     @ @(%R6I@+R)A& P  S!0   T
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M2VZC0!2%X:U8+""X[HND%6?4DTRC;  YY8=B&T312K+[MIR!?5 />A)Q1JA
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MW'R]_&7YO1/O%\T%Y_JVHCS]!5!+ P04    " " @7):I,C#=_H!  "T*
M$P   %M#;VYT96YT7U1Y<&5S72YX;6S-VLM.PS 0!=!?J;)%C>LG#]%N@"VP
MX =,,J51D]BR72A_CY,"$@@J4)&XFT:M[;D3CW16/;][]A0GVZ[MX[Q8I>3/
M&(O5BCH;2^>ISRM+%SJ;\M?PP+RMUO:!F)C-#*M<GZA/TS34*!;GE[2TFS9-
MKK;YY]BX?EX$:F,QN=AM'++FA?6^;2J;\CI[[.M/*=/7A#*?'/?$5>/C4=Y0
ML"\3AI7O U[/W3Q2"$U-DUL;TK7M\BZV;5E,SRW%<G^)+WITRV534>VJ39>/
ME-$'LG5<$:6N+7=%C_8GIWS#M/OD!^>/9?8%YIVWP?F8)Q;H]W%O(QE.3WTN
M1"$U^U_Q/3&7/OC]:)AV3?4/L_/U/KFP'N<1V?@X_(X_SOB]_B_[$"!]2) ^
M%$@?&J0/ ]+',4@?)R!]G(+TP6<HC:"(RE%(Y2BF<A14.8JJ'(55CN(J1X&5
MH\@J4&05*+(*%%D%BJP"15:!(JM D56@R"I09!4HLDH4626*K!)%5HDBJT21
M5:+(*E%DE2BR2A19)8JL"D56A2*K0I%5H<BJ4&15*+(J%%D5BJP*15:%(JM&
MD56CR*I19-4HLFH4636*K!I%5HTBJT:15:/(:E!D-2BR&A19#8JL!D56@R*K
M09'5H,AJ4&0U*+(>_Z>L]\ZM_SA^?):=;?JW?#;^67'Q E!+ 0(4 Q0    (
M ("!<EI&QTU(E0   ,T    0              "  0    !D;V-0<F]P<R]A
M<' N>&UL4$L! A0#%     @ @(%R6H)SQ&;S    *P(  !$
M ( !PP   &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @ @(%R6IE<G",0
M!@  G"<  !,              ( !Y0$  'AL+W1H96UE+W1H96UE,2YX;6Q0
M2P$"% ,4    " " @7):/LDHQ#@(   R.   &               @($F"
M>&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%     @ @(%R6BVH],F?
M!@  <!L  !@              ("!E!   'AL+W=O<FMS:&5E=',O<VAE970R
M+GAM;%!+ 0(4 Q0    ( ("!<EK=.#R&]0(  $D*   8              "
M@6D7  !X;"]W;W)K<VAE971S+W-H965T,RYX;6Q02P$"% ,4    " " @7):
ME$RY!&T&   =&P  &               @(&4&@  >&PO=V]R:W-H965T<R]S
M:&5E=#0N>&UL4$L! A0#%     @ @(%R6CLHF)R\!P  ,S(  !@
M     ("!-R$  'AL+W=O<FMS:&5E=',O<VAE970U+GAM;%!+ 0(4 Q0    (
M ("!<EI"[QKHJ0@  %8G   8              " @2DI  !X;"]W;W)K<VAE
M971S+W-H965T-BYX;6Q02P$"% ,4    " " @7):$"9QB*4&  #8#P  &
M            @($(,@  >&PO=V]R:W-H965T<R]S:&5E=#<N>&UL4$L! A0#
M%     @ @(%R6B8"B<*B&@  +$\  !@              ("!XS@  'AL+W=O
M<FMS:&5E=',O<VAE970X+GAM;%!+ 0(4 Q0    ( ("!<EJX!_*&] ,  *X(
M   8              " @;M3  !X;"]W;W)K<VAE971S+W-H965T.2YX;6Q0
M2P$"% ,4    " " @7):])5P77X#  !^!P  &0              @('E5P
M>&PO=V]R:W-H965T<R]S:&5E=#$P+GAM;%!+ 0(4 Q0    ( ("!<EH0A0X"
MD 0  #8*   9              " @9I;  !X;"]W;W)K<VAE971S+W-H965T
M,3$N>&UL4$L! A0#%     @ @(%R6D(E:$4" P  W@8  !D
M ("!86   'AL+W=O<FMS:&5E=',O<VAE970Q,BYX;6Q02P$"% ,4    " "
M@7):;+/\V/P1  #M/@  &0              @(&:8P  >&PO=V]R:W-H965T
M<R]S:&5E=#$S+GAM;%!+ 0(4 Q0    ( ("!<EHXV_N< A,  /TX   9
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M970Q."YX;6Q02P$"% ,4    " " @7):*<'L 98*  ".)   &0
M    @(%6K   >&PO=V]R:W-H965T<R]S:&5E=#$Y+GAM;%!+ 0(4 Q0    (
M ("!<EK+D<UAUP(  #D&   9              " @2.W  !X;"]W;W)K<VAE
M971S+W-H965T,C N>&UL4$L! A0#%     @ @(%R6AO>#MV= P  U0<  !D
M             ("!,;H  'AL+W=O<FMS:&5E=',O<VAE970R,2YX;6Q02P$"
M% ,4    " " @7):6PFL_\P"   S!P  &0              @($%O@  >&PO
M=V]R:W-H965T<R]S:&5E=#(R+GAM;%!+ 0(4 Q0    ( ("!<EHS.G8FD ,
M ( (   9              " @0C!  !X;"]W;W)K<VAE971S+W-H965T,C,N
M>&UL4$L! A0#%     @ @(%R6NVBB M9"   P"(  !D              ("!
MS\0  'AL+W=O<FMS:&5E=',O<VAE970R-"YX;6Q02P$"% ,4    " " @7):
M9#=-]N\$   4$@  &0              @(%?S0  >&PO=V]R:W-H965T<R]S
M:&5E=#(U+GAM;%!+ 0(4 Q0    ( ("!<EJR7L0\)!P  -98   9
M      " @872  !X;"]W;W)K<VAE971S+W-H965T,C8N>&UL4$L! A0#%
M  @ @(%R6H#\1]H;!   N@D  !D              ("!X.X  'AL+W=O<FMS
M:&5E=',O<VAE970R-RYX;6Q02P$"% ,4    " " @7):_]D#I)D"  "+!0
M&0              @($R\P  >&PO=V]R:W-H965T<R]S:&5E=#(X+GAM;%!+
M 0(4 Q0    ( ("!<EJKWA4N.@,  ,P&   9              " @0+V  !X
M;"]W;W)K<VAE971S+W-H965T,CDN>&UL4$L! A0#%     @ @(%R6NS[ JZB
M P  <P@  !D              ("!<_D  'AL+W=O<FMS:&5E=',O<VAE970S
M,"YX;6Q02P$"% ,4    " " @7): DS7!A #  #%!@  &0
M@(%,_0  >&PO=V]R:W-H965T<R]S:&5E=#,Q+GAM;%!+ 0(4 Q0    ( ("!
M<EH@A3$0H (  +\%   9              " @9,  0!X;"]W;W)K<VAE971S
M+W-H965T,S(N>&UL4$L! A0#%     @ @(%R6GCL>:6O"   .!<  !D
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M=#,W+GAM;%!+ 0(4 Q0    ( ("!<EICM6R2;@(  &,%   9
M  " @<XA 0!X;"]W;W)K<VAE971S+W-H965T,S@N>&UL4$L! A0#%     @
M@(%R6L82,)(M P  1 P  !D              ("!<R0! 'AL+W=O<FMS:&5E
M=',O<VAE970S.2YX;6Q02P$"% ,4    " " @7):,IYE:U$"  !2!0  &0
M            @('7)P$ >&PO=V]R:W-H965T<R]S:&5E=#0P+GAM;%!+ 0(4
M Q0    ( ("!<EITZ.DR=0(  (X(   9              " @5\J 0!X;"]W
M;W)K<VAE971S+W-H965T-#$N>&UL4$L! A0#%     @ @(%R6A!1=OR= @
M? <  !D              ("!"RT! 'AL+W=O<FMS:&5E=',O<VAE970T,BYX
M;6Q02P$"% ,4    " " @7):C4]U;(4"  #!!@  &0              @('?
M+P$ >&PO=V]R:W-H965T<R]S:&5E=#0S+GAM;%!+ 0(4 Q0    ( ("!<EI@
MS"<_@0(  +<&   9              " @9LR 0!X;"]W;W)K<VAE971S+W-H
M965T-#0N>&UL4$L! A0#%     @ @(%R6M;W?^2/ @  SP8  !D
M     ("!4S4! 'AL+W=O<FMS:&5E=',O<VAE970T-2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( ("!<EJD]_-EY 0  .X;   9              "
M@>E) 0!X;"]W;W)K<VAE971S+W-H965T-3 N>&UL4$L! A0#%     @ @(%R
M6H- =M9% @  A 4  !D              ("!!$\! 'AL+W=O<FMS:&5E=',O
M<VAE970U,2YX;6Q02P$"% ,4    " " @7):4]V/;U<#  !4"@  &0
M        @(& 40$ >&PO=V]R:W-H965T<R]S:&5E=#4R+GAM;%!+ 0(4 Q0
M   ( ("!<EJEG>>&IQT  ,;X 0 9              " @0Y5 0!X;"]W;W)K
M<VAE971S+W-H965T-3,N>&UL4$L! A0#%     @ @(%R6G+Z;U9Q @  E 8
M !D              ("!['(! 'AL+W=O<FMS:&5E=',O<VAE970U-"YX;6Q0
M2P$"% ,4    " " @7):(]<E=NX$  #A&P  &0              @(&4=0$
M>&PO=V]R:W-H965T<R]S:&5E=#4U+GAM;%!+ 0(4 Q0    ( ("!<EKWY/7B
M8@D  '1<   9              " @;EZ 0!X;"]W;W)K<VAE971S+W-H965T
M-38N>&UL4$L! A0#%     @ @(%R6IF,W43F&@  2#$! !D
M ("!4H0! 'AL+W=O<FMS:&5E=',O<VAE970U-RYX;6Q02P$"% ,4    " "
M@7):-#1Z-PH,  !"E   &0              @(%OGP$ >&PO=V]R:W-H965T
M<R]S:&5E=#4X+GAM;%!+ 0(4 Q0    ( ("!<EI$>72=RPH  %6!   9
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M970V,RYX;6Q02P$"% ,4    " " @7):E4_?:T,%  "#&@  &0
M    @(%^R $ >&PO=V]R:W-H965T<R]S:&5E=#8T+GAM;%!+ 0(4 Q0    (
M ("!<EHB?+6-0 X   ET   9              " @?C- 0!X;"]W;W)K<VAE
M971S+W-H965T-C4N>&UL4$L! A0#%     @ @(%R6D3:>PBK!@  -#<  !D
M             ("!;]P! 'AL+W=O<FMS:&5E=',O<VAE970V-BYX;6Q02P$"
M% ,4    " " @7):+ET!;FX"  "*!@  &0              @(%1XP$ >&PO
M=V]R:W-H965T<R]S:&5E=#8W+GAM;%!+ 0(4 Q0    ( ("!<EKK@\ (J@,
M )4+   9              " @?;E 0!X;"]W;W)K<VAE971S+W-H965T-C@N
M>&UL4$L! A0#%     @ @(%R6@MF62<!!   A!<  !D              ("!
MU^D! 'AL+W=O<FMS:&5E=',O<VAE970V.2YX;6Q02P$"% ,4    " " @7):
MQ3=)2P,%  !Y&   &0              @($/[@$ >&PO=V]R:W-H965T<R]S
M:&5E=#<P+GAM;%!+ 0(4 Q0    ( ("!<EJ8"\B81@,  ,P4   -
M      "  4GS 0!X;"]S='EL97,N>&UL4$L! A0#%     @ @(%R6I>*NQS
M    $P(   L              ( !NO8! %]R96QS+RYR96QS4$L! A0#%
M  @ @(%R6IM-I)NZ!0  +"X   \              ( !H_<! 'AL+W=O<FMB
M;V]K+GAM;%!+ 0(4 Q0    ( ("!<EK;=K!Q,0(  (DI   :
M  "  8K] 0!X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<U!+ 0(4 Q0    (
M ("!<EJDR,-W^@$  +0H   3              "  ?/_ 0!;0V]N=&5N=%]4
?>7!E<UTN>&UL4$L%!@    !. $X 614  !X" @    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>333</ContextCount>
  <ElementCount>440</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>103</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>15</UnitCount>
  <MyReports>
    <Report instance="ef20038923_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>000100 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/DocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="ef20038923_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>010000 - Statement - CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/ConsolidatedBalanceSheets</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="ef20038923_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>010100 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/ConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="ef20038923_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>020000 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/ConsolidatedStatementsOfOperations</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF OPERATIONS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="ef20038923_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>030000 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="ef20038923_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>040000 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/ConsolidatedStatementsOfCashFlows</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="ef20038923_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>060100 - Disclosure - ORGANIZATION AND BUSINESS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/OrganizationAndBusiness</Role>
      <ShortName>ORGANIZATION AND BUSINESS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="ef20038923_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>060200 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/SignificantAccountingPolicies</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="ef20038923_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>060300 - Disclosure - INVENTORIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/Inventories</Role>
      <ShortName>INVENTORIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="ef20038923_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>060400 - Disclosure - PROPERTY AND EQUIPMENT</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/PropertyAndEquipment</Role>
      <ShortName>PROPERTY AND EQUIPMENT</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="ef20038923_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>060500 - Disclosure - INTANGIBLE ASSETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/IntangibleAssets</Role>
      <ShortName>INTANGIBLE ASSETS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="ef20038923_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>060600 - Disclosure - ACCRUED EXPENSES AND OTHER LIABILITIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/AccruedExpensesAndOtherLiabilities</Role>
      <ShortName>ACCRUED EXPENSES AND OTHER LIABILITIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="ef20038923_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>060700 - Disclosure - NOTES PAYABLE</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://admabiologics.com/role/NotesPayable</Role>
      <ShortName>NOTES PAYABLE</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="ef20038923_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>060800 - Disclosure - STOCKHOLDERS' EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/StockholdersEquity</Role>
      <ShortName>STOCKHOLDERS' EQUITY</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="ef20038923_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>060900 - Disclosure - RELATED PARTY TRANSACTIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/RelatedPartyTransactions</Role>
      <ShortName>RELATED PARTY TRANSACTIONS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="ef20038923_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>061000 - Disclosure - COMMITMENTS AND CONTINGENCIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/CommitmentsAndContingencies</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="ef20038923_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>061100 - Disclosure - INCOME TAXES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/IncomeTaxes</Role>
      <ShortName>INCOME TAXES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="ef20038923_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>061200 - Disclosure - LEASE OBLIGATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/LeaseObligations</Role>
      <ShortName>LEASE OBLIGATIONS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="ef20038923_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>061300 - Disclosure - SEGMENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/Segments</Role>
      <ShortName>SEGMENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="ef20038923_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>061400 - Disclosure - OTHER EMPLOYEE BENEFITS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/OtherEmployeeBenefits</Role>
      <ShortName>OTHER EMPLOYEE BENEFITS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="ef20038923_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>061500 - Disclosure - SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/SupplementalDisclosureOfCashFlowInformation</Role>
      <ShortName>SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="ef20038923_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>061600 - Disclosure - CONCENTRATIONS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/Concentrations</Role>
      <ShortName>CONCENTRATIONS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="ef20038923_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>061700 - Disclosure - SCHEDULE II - VALUATION AND QUALIFYING ACCOUNTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/ScheduleIiValuationAndQualifyingAccounts</Role>
      <ShortName>SCHEDULE II - VALUATION AND QUALIFYING ACCOUNTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="ef20038923_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>061800 - Disclosure - CYBERSECURITY RISK MANAGEMENT AND STRATEGY DISCLOSURE</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/CybersecurityRiskManagementAndStrategyDisclosure</Role>
      <ShortName>CYBERSECURITY RISK MANAGEMENT AND STRATEGY DISCLOSURE</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="ef20038923_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>061900 - Disclosure - INSIDER TRADING ARRANGEMENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/InsiderTradingArrangements</Role>
      <ShortName>INSIDER TRADING ARRANGEMENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="ef20038923_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>070200 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/SignificantAccountingPoliciesPolicies</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="ef20038923_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>080200 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/SignificantAccountingPoliciesTables</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://admabiologics.com/role/SignificantAccountingPolicies</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="ef20038923_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>080300 - Disclosure - INVENTORIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/InventoriesTables</Role>
      <ShortName>INVENTORIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://admabiologics.com/role/Inventories</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="ef20038923_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>080400 - Disclosure - PROPERTY AND EQUIPMENT (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/PropertyAndEquipmentTables</Role>
      <ShortName>PROPERTY AND EQUIPMENT (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://admabiologics.com/role/PropertyAndEquipment</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="ef20038923_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>080500 - Disclosure - INTANGIBLE ASSETS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/IntangibleAssetsTables</Role>
      <ShortName>INTANGIBLE ASSETS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://admabiologics.com/role/IntangibleAssets</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="ef20038923_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>080600 - Disclosure - ACCRUED EXPENSES AND OTHER LIABILITIES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/AccruedExpensesAndOtherLiabilitiesTables</Role>
      <ShortName>ACCRUED EXPENSES AND OTHER LIABILITIES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://admabiologics.com/role/AccruedExpensesAndOtherLiabilities</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="ef20038923_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>080700 - Disclosure - NOTES PAYABLE (Tables)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://admabiologics.com/role/NotesPayableTables</Role>
      <ShortName>NOTES PAYABLE (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://admabiologics.com/role/NotesPayable</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="ef20038923_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>080800 - Disclosure - STOCKHOLDERS EQUITY (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/StockholdersEquityTables</Role>
      <ShortName>STOCKHOLDERS EQUITY (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="ef20038923_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>081100 - Disclosure - INCOME TAXES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/IncomeTaxesTables</Role>
      <ShortName>INCOME TAXES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://admabiologics.com/role/IncomeTaxes</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="ef20038923_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>081200 - Disclosure - LEASE OBLIGATIONS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/LeaseObligationsTables</Role>
      <ShortName>LEASE OBLIGATIONS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://admabiologics.com/role/LeaseObligations</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="ef20038923_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>081300 - Disclosure - SEGMENTS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/SegmentsTables</Role>
      <ShortName>SEGMENTS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://admabiologics.com/role/Segments</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="ef20038923_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>081500 - Disclosure - SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/SupplementalDisclosureOfCashFlowInformationTables</Role>
      <ShortName>SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://admabiologics.com/role/SupplementalDisclosureOfCashFlowInformation</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="ef20038923_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>090100 - Disclosure - ORGANIZATION AND BUSINESS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/OrganizationAndBusinessDetails</Role>
      <ShortName>ORGANIZATION AND BUSINESS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://admabiologics.com/role/OrganizationAndBusiness</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="ef20038923_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>090200 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES, Use of Estimates (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/SignificantAccountingPoliciesUseOfEstimatesDetails</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES, Use of Estimates (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="ef20038923_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>090202 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES, Accounts Receivable (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/SignificantAccountingPoliciesAccountsReceivableDetails</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES, Accounts Receivable (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="ef20038923_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>090204 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES, Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/SignificantAccountingPoliciesPropertyAndEquipmentDetails</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES, Property and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="ef20038923_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>090206 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES, Goodwill (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/SignificantAccountingPoliciesGoodwillDetails</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES, Goodwill (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="ef20038923_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>090208 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES, Impairment of Long-lived Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/SignificantAccountingPoliciesImpairmentOfLonglivedAssetsDetails</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES, Impairment of Long-lived Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="ef20038923_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>090210 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES, Revenue Recognition (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/SignificantAccountingPoliciesRevenueRecognitionDetails</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES, Revenue Recognition (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="ef20038923_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>090212 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES, Advertising and Marketing Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/SignificantAccountingPoliciesAdvertisingAndMarketingExpensesDetails</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES, Advertising and Marketing Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="ef20038923_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>090214 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES, Stock-based Compensation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/SignificantAccountingPoliciesStockbasedCompensationDetails</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES, Stock-based Compensation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="ef20038923_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>090216 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES, Earnings (Loss) Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/SignificantAccountingPoliciesEarningsLossPerShareDetails</Role>
      <ShortName>SIGNIFICANT ACCOUNTING POLICIES, Earnings (Loss) Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="ef20038923_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>090300 - Disclosure - INVENTORIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/InventoriesDetails</Role>
      <ShortName>INVENTORIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://admabiologics.com/role/InventoriesTables</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="ef20038923_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>090400 - Disclosure - PROPERTY AND EQUIPMENT (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/PropertyAndEquipmentDetails</Role>
      <ShortName>PROPERTY AND EQUIPMENT (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://admabiologics.com/role/PropertyAndEquipmentTables</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="ef20038923_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>090500 - Disclosure - INTANGIBLE ASSETS, Summary (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/IntangibleAssetsSummaryDetails</Role>
      <ShortName>INTANGIBLE ASSETS, Summary (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="ef20038923_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>090502 - Disclosure - INTANGIBLE ASSETS, Future Aggregate Amortization Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/IntangibleAssetsFutureAggregateAmortizationExpenseDetails</Role>
      <ShortName>INTANGIBLE ASSETS, Future Aggregate Amortization Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="ef20038923_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>090600 - Disclosure - ACCRUED EXPENSES AND OTHER LIABILITIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/AccruedExpensesAndOtherLiabilitiesDetails</Role>
      <ShortName>ACCRUED EXPENSES AND OTHER LIABILITIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://admabiologics.com/role/AccruedExpensesAndOtherLiabilitiesTables</ParentRole>
      <Position>52</Position>
    </Report>
    <Report instance="ef20038923_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>090700 - Disclosure - NOTES PAYABLE (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://admabiologics.com/role/NotesPayableDetails</Role>
      <ShortName>NOTES PAYABLE (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://admabiologics.com/role/NotesPayableTables</ParentRole>
      <Position>53</Position>
    </Report>
    <Report instance="ef20038923_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>090800 - Disclosure - STOCKHOLDERS' EQUITY, Preferred Stock (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/StockholdersEquityPreferredStockDetails</Role>
      <ShortName>STOCKHOLDERS' EQUITY, Preferred Stock (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="ef20038923_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>090802 - Disclosure - STOCKHOLDERS' EQUITY, Common Stock (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/StockholdersEquityCommonStockDetails</Role>
      <ShortName>STOCKHOLDERS' EQUITY, Common Stock (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="ef20038923_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>090804 - Disclosure - STOCKHOLDERS' EQUITY, Warrants (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/StockholdersEquityWarrantsDetails</Role>
      <ShortName>STOCKHOLDERS' EQUITY, Warrants (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="ef20038923_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>090806 - Disclosure - STOCKHOLDERS' EQUITY, Equity Incentive Plans (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails</Role>
      <ShortName>STOCKHOLDERS' EQUITY, Equity Incentive Plans (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="ef20038923_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>090900 - Disclosure - RELATED PARTY TRANSACTIONS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/RelatedPartyTransactionsDetails</Role>
      <ShortName>RELATED PARTY TRANSACTIONS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://admabiologics.com/role/RelatedPartyTransactions</ParentRole>
      <Position>58</Position>
    </Report>
    <Report instance="ef20038923_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>091000 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/CommitmentsAndContingenciesDetails</Role>
      <ShortName>COMMITMENTS AND CONTINGENCIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://admabiologics.com/role/CommitmentsAndContingencies</ParentRole>
      <Position>59</Position>
    </Report>
    <Report instance="ef20038923_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>091100 - Disclosure - INCOME TAXES, Income Tax Expense (Benefit) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/IncomeTaxesIncomeTaxExpenseBenefitDetails</Role>
      <ShortName>INCOME TAXES, Income Tax Expense (Benefit) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="ef20038923_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>091102 - Disclosure - INCOME TAXES, Reconciliation of Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/IncomeTaxesReconciliationOfIncomeTaxesDetails</Role>
      <ShortName>INCOME TAXES, Reconciliation of Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="ef20038923_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>091104 - Disclosure - INCOME TAXES, Deferred Tax Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/IncomeTaxesDeferredTaxAssetsDetails</Role>
      <ShortName>INCOME TAXES, Deferred Tax Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="ef20038923_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>091106 - Disclosure - INCOME TAXES, Net Operating Loss Carryforwards (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/IncomeTaxesNetOperatingLossCarryforwardsDetails</Role>
      <ShortName>INCOME TAXES, Net Operating Loss Carryforwards (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="ef20038923_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>091200 - Disclosure - LEASE OBLIGATIONS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/LeaseObligationsDetails</Role>
      <ShortName>LEASE OBLIGATIONS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://admabiologics.com/role/LeaseObligationsTables</ParentRole>
      <Position>64</Position>
    </Report>
    <Report instance="ef20038923_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>091300 - Disclosure - SEGMENTS, Summarized Financial Information by Segment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/SegmentsSummarizedFinancialInformationBySegmentDetails</Role>
      <ShortName>SEGMENTS, Summarized Financial Information by Segment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="ef20038923_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>091302 - Disclosure - SEGMENTS, Net Revenues According to Geographic Area (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/SegmentsNetRevenuesAccordingToGeographicAreaDetails</Role>
      <ShortName>SEGMENTS, Net Revenues According to Geographic Area (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="ef20038923_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>091400 - Disclosure - OTHER EMPLOYEE BENEFITS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/OtherEmployeeBenefitsDetails</Role>
      <ShortName>OTHER EMPLOYEE BENEFITS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://admabiologics.com/role/OtherEmployeeBenefits</ParentRole>
      <Position>67</Position>
    </Report>
    <Report instance="ef20038923_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>091500 - Disclosure - SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/SupplementalDisclosureOfCashFlowInformationDetails</Role>
      <ShortName>SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://admabiologics.com/role/SupplementalDisclosureOfCashFlowInformationTables</ParentRole>
      <Position>68</Position>
    </Report>
    <Report instance="ef20038923_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>091600 - Disclosure - CONCENTRATIONS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/ConcentrationsDetails</Role>
      <ShortName>CONCENTRATIONS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://admabiologics.com/role/Concentrations</ParentRole>
      <Position>69</Position>
    </Report>
    <Report instance="ef20038923_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>091700 - Disclosure - SCHEDULE II - VALUATION AND QUALIFYING ACCOUNTS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://admabiologics.com/role/ScheduleIiValuationAndQualifyingAccountsDetails</Role>
      <ShortName>SCHEDULE II - VALUATION AND QUALIFYING ACCOUNTS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://admabiologics.com/role/ScheduleIiValuationAndQualifyingAccounts</ParentRole>
      <Position>70</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>adma-20241231.xsd</File>
    <File>adma-20241231_cal.xml</File>
    <File>adma-20241231_def.xml</File>
    <File>adma-20241231_lab.xml</File>
    <File>adma-20241231_pre.xml</File>
    <File doctype="10-K" isDefinitelyFs="true" isUsgaap="true" original="ef20038923_10k.htm">ef20038923_10k.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>image00001.jpg</File>
    <File>image00002.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="1">http://fasb.org/srt/2024</BaseTaxonomy>
    <BaseTaxonomy items="1124">http://fasb.org/us-gaap/2024</BaseTaxonomy>
    <BaseTaxonomy items="16">http://xbrl.sec.gov/cyd/2024</BaseTaxonomy>
    <BaseTaxonomy items="40">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
    <BaseTaxonomy items="12">http://xbrl.sec.gov/ecd/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>99
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "ef20038923_10k.htm": {
   "nsprefix": "adma",
   "nsuri": "http://admabiologics.com/20241231",
   "dts": {
    "schema": {
     "local": [
      "adma-20241231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2004/ref-2004-08-10.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/2023/calculation-1.1.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd",
      "https://xbrl.sec.gov/country/2024/country-2024.xsd",
      "https://xbrl.sec.gov/currency/2024/currency-2024.xsd",
      "https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd",
      "https://xbrl.sec.gov/exch/2024/exch-2024.xsd",
      "https://xbrl.sec.gov/naics/2024/naics-2024.xsd",
      "https://xbrl.sec.gov/sic/2024/sic-2024.xsd",
      "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "adma-20241231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "adma-20241231_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "adma-20241231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "adma-20241231_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "ef20038923_10k.htm"
     ]
    }
   },
   "keyStandard": 356,
   "keyCustom": 84,
   "axisStandard": 35,
   "axisCustom": 0,
   "memberStandard": 41,
   "memberCustom": 59,
   "hidden": {
    "total": 17,
    "http://admabiologics.com/20241231": 7,
    "http://xbrl.sec.gov/dei/2024": 7,
    "http://fasb.org/us-gaap/2024": 2,
    "http://xbrl.sec.gov/ecd/2024": 1
   },
   "contextCount": 333,
   "entityCount": 1,
   "segmentCount": 103,
   "elementCount": 730,
   "unitCount": 15,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2024": 1124,
    "http://xbrl.sec.gov/dei/2024": 40,
    "http://xbrl.sec.gov/cyd/2024": 16,
    "http://xbrl.sec.gov/ecd/2024": 12,
    "http://fasb.org/srt/2024": 1
   },
   "report": {
    "R1": {
     "role": "http://admabiologics.com/role/DocumentAndEntityInformation",
     "longName": "000100 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c20240101to20241231",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "strong",
       "p",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20038923_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c20240101to20241231",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "strong",
       "p",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20038923_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://admabiologics.com/role/ConsolidatedBalanceSheets",
     "longName": "010000 - Statement - CONSOLIDATED BALANCE SHEETS",
     "shortName": "CONSOLIDATED BALANCE SHEETS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "c20241231",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "U001",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20038923_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c20241231",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "U001",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20038923_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R3": {
     "role": "http://admabiologics.com/role/ConsolidatedBalanceSheetsParenthetical",
     "longName": "010100 - Statement - CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "shortName": "CONSOLIDATED BALANCE SHEETS (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "c20241231",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "unitRef": "U003",
      "xsiNil": "false",
      "lang": null,
      "decimals": "4",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20038923_10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c20241231",
      "name": "us-gaap:PreferredStockSharesAuthorized",
      "unitRef": "U002",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "us-gaap:PreferredStockSharesAuthorized",
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20038923_10k.htm",
      "unique": true
     }
    },
    "R4": {
     "role": "http://admabiologics.com/role/ConsolidatedStatementsOfOperations",
     "longName": "020000 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS",
     "shortName": "CONSOLIDATED STATEMENTS OF OPERATIONS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "c20240101to20241231",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "U001",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20038923_10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c20240101to20241231",
      "name": "us-gaap:GrossProfit",
      "unitRef": "U001",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20038923_10k.htm",
      "unique": true
     }
    },
    "R5": {
     "role": "http://admabiologics.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity",
     "longName": "030000 - Statement - CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY",
     "shortName": "CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "c20211231_StatementEquityComponentsAxis_CommonStockMember",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "U001",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20038923_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c20211231_StatementEquityComponentsAxis_CommonStockMember",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "U001",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20038923_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R6": {
     "role": "http://admabiologics.com/role/ConsolidatedStatementsOfCashFlows",
     "longName": "040000 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "shortName": "CONSOLIDATED STATEMENTS OF CASH FLOWS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "c20240101to20241231",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "U001",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20038923_10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c20240101to20241231",
      "name": "us-gaap:GainLossOnDispositionOfAssets",
      "unitRef": "U001",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20038923_10k.htm",
      "unique": true
     }
    },
    "R7": {
     "role": "http://admabiologics.com/role/OrganizationAndBusiness",
     "longName": "060100 - Disclosure - ORGANIZATION AND BUSINESS",
     "shortName": "ORGANIZATION AND BUSINESS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "7",
     "firstAnchor": {
      "contextRef": "c20240101to20241231",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20038923_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c20240101to20241231",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20038923_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R8": {
     "role": "http://admabiologics.com/role/SignificantAccountingPolicies",
     "longName": "060200 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES",
     "shortName": "SIGNIFICANT ACCOUNTING POLICIES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "c20240101to20241231",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20038923_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c20240101to20241231",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20038923_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://admabiologics.com/role/Inventories",
     "longName": "060300 - Disclosure - INVENTORIES",
     "shortName": "INVENTORIES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "c20240101to20241231",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20038923_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c20240101to20241231",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20038923_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://admabiologics.com/role/PropertyAndEquipment",
     "longName": "060400 - Disclosure - PROPERTY AND EQUIPMENT",
     "shortName": "PROPERTY AND EQUIPMENT",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "c20240101to20241231",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20038923_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c20240101to20241231",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20038923_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://admabiologics.com/role/IntangibleAssets",
     "longName": "060500 - Disclosure - INTANGIBLE ASSETS",
     "shortName": "INTANGIBLE ASSETS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "c20240101to20241231",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20038923_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c20240101to20241231",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20038923_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://admabiologics.com/role/AccruedExpensesAndOtherLiabilities",
     "longName": "060600 - Disclosure - ACCRUED EXPENSES AND OTHER LIABILITIES",
     "shortName": "ACCRUED EXPENSES AND OTHER LIABILITIES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "c20240101to20241231",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20038923_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c20240101to20241231",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20038923_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://admabiologics.com/role/NotesPayable",
     "longName": "060700 - Disclosure - NOTES PAYABLE",
     "shortName": "NOTES PAYABLE",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "c20240101to20241231",
      "name": "us-gaap:LongTermDebtTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20038923_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c20240101to20241231",
      "name": "us-gaap:LongTermDebtTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20038923_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://admabiologics.com/role/StockholdersEquity",
     "longName": "060800 - Disclosure - STOCKHOLDERS' EQUITY",
     "shortName": "STOCKHOLDERS' EQUITY",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "c20240101to20241231",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20038923_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c20240101to20241231",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20038923_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://admabiologics.com/role/RelatedPartyTransactions",
     "longName": "060900 - Disclosure - RELATED PARTY TRANSACTIONS",
     "shortName": "RELATED PARTY TRANSACTIONS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "c20240101to20241231",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20038923_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c20240101to20241231",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20038923_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://admabiologics.com/role/CommitmentsAndContingencies",
     "longName": "061000 - Disclosure - COMMITMENTS AND CONTINGENCIES",
     "shortName": "COMMITMENTS AND CONTINGENCIES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "c20240101to20241231",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20038923_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c20240101to20241231",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20038923_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://admabiologics.com/role/IncomeTaxes",
     "longName": "061100 - Disclosure - INCOME TAXES",
     "shortName": "INCOME TAXES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "c20240101to20241231",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20038923_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c20240101to20241231",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20038923_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://admabiologics.com/role/LeaseObligations",
     "longName": "061200 - Disclosure - LEASE OBLIGATIONS",
     "shortName": "LEASE OBLIGATIONS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "c20240101to20241231",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20038923_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c20240101to20241231",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20038923_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://admabiologics.com/role/Segments",
     "longName": "061300 - Disclosure - SEGMENTS",
     "shortName": "SEGMENTS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "c20240101to20241231",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20038923_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c20240101to20241231",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20038923_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://admabiologics.com/role/OtherEmployeeBenefits",
     "longName": "061400 - Disclosure - OTHER EMPLOYEE BENEFITS",
     "shortName": "OTHER EMPLOYEE BENEFITS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "c20240101to20241231",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20038923_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c20240101to20241231",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20038923_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://admabiologics.com/role/SupplementalDisclosureOfCashFlowInformation",
     "longName": "061500 - Disclosure - SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION",
     "shortName": "SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "21",
     "firstAnchor": {
      "contextRef": "c20240101to20241231",
      "name": "us-gaap:CashFlowSupplementalDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20038923_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c20240101to20241231",
      "name": "us-gaap:CashFlowSupplementalDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20038923_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://admabiologics.com/role/Concentrations",
     "longName": "061600 - Disclosure - CONCENTRATIONS",
     "shortName": "CONCENTRATIONS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "22",
     "firstAnchor": {
      "contextRef": "c20240101to20241231",
      "name": "us-gaap:ConcentrationRiskDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20038923_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c20240101to20241231",
      "name": "us-gaap:ConcentrationRiskDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20038923_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://admabiologics.com/role/ScheduleIiValuationAndQualifyingAccounts",
     "longName": "061700 - Disclosure - SCHEDULE II - VALUATION AND QUALIFYING ACCOUNTS",
     "shortName": "SCHEDULE II - VALUATION AND QUALIFYING ACCOUNTS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "23",
     "firstAnchor": {
      "contextRef": "c20240101to20241231",
      "name": "srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20038923_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c20240101to20241231",
      "name": "srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20038923_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://admabiologics.com/role/CybersecurityRiskManagementAndStrategyDisclosure",
     "longName": "061800 - Disclosure - CYBERSECURITY RISK MANAGEMENT AND STRATEGY DISCLOSURE",
     "shortName": "CYBERSECURITY RISK MANAGEMENT AND STRATEGY DISCLOSURE",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "24",
     "firstAnchor": {
      "contextRef": "c20240101to20241231",
      "name": "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20038923_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c20240101to20241231",
      "name": "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20038923_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://admabiologics.com/role/InsiderTradingArrangements",
     "longName": "061900 - Disclosure - INSIDER TRADING ARRANGEMENTS",
     "shortName": "INSIDER TRADING ARRANGEMENTS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "25",
     "firstAnchor": {
      "contextRef": "c20241001to20241231",
      "name": "ecd:NonRule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ecd:MtrlTermsOfTrdArrTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20038923_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c20241001to20241231",
      "name": "ecd:NonRule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ecd:MtrlTermsOfTrdArrTextBlock",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20038923_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://admabiologics.com/role/SignificantAccountingPoliciesPolicies",
     "longName": "070200 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "shortName": "SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "26",
     "firstAnchor": {
      "contextRef": "c20240101to20241231",
      "name": "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20038923_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c20240101to20241231",
      "name": "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20038923_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://admabiologics.com/role/SignificantAccountingPoliciesTables",
     "longName": "080200 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Tables)",
     "shortName": "SIGNIFICANT ACCOUNTING POLICIES (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "27",
     "firstAnchor": {
      "contextRef": "c20240101to20241231",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20038923_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c20240101to20241231",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20038923_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://admabiologics.com/role/InventoriesTables",
     "longName": "080300 - Disclosure - INVENTORIES (Tables)",
     "shortName": "INVENTORIES (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "28",
     "firstAnchor": {
      "contextRef": "c20240101to20241231",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20038923_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c20240101to20241231",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20038923_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://admabiologics.com/role/PropertyAndEquipmentTables",
     "longName": "080400 - Disclosure - PROPERTY AND EQUIPMENT (Tables)",
     "shortName": "PROPERTY AND EQUIPMENT (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "29",
     "firstAnchor": {
      "contextRef": "c20240101to20241231",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20038923_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c20240101to20241231",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20038923_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://admabiologics.com/role/IntangibleAssetsTables",
     "longName": "080500 - Disclosure - INTANGIBLE ASSETS (Tables)",
     "shortName": "INTANGIBLE ASSETS (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "30",
     "firstAnchor": {
      "contextRef": "c20240101to20241231",
      "name": "us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20038923_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c20240101to20241231",
      "name": "us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20038923_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://admabiologics.com/role/AccruedExpensesAndOtherLiabilitiesTables",
     "longName": "080600 - Disclosure - ACCRUED EXPENSES AND OTHER LIABILITIES (Tables)",
     "shortName": "ACCRUED EXPENSES AND OTHER LIABILITIES (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "31",
     "firstAnchor": {
      "contextRef": "c20240101to20241231",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20038923_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c20240101to20241231",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20038923_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://admabiologics.com/role/NotesPayableTables",
     "longName": "080700 - Disclosure - NOTES PAYABLE (Tables)",
     "shortName": "NOTES PAYABLE (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "32",
     "firstAnchor": {
      "contextRef": "c20240101to20241231",
      "name": "us-gaap:ScheduleOfDebtTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20038923_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c20240101to20241231",
      "name": "us-gaap:ScheduleOfDebtTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20038923_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://admabiologics.com/role/StockholdersEquityTables",
     "longName": "080800 - Disclosure - STOCKHOLDERS EQUITY (Tables)",
     "shortName": "STOCKHOLDERS EQUITY (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "33",
     "firstAnchor": {
      "contextRef": "c20240101to20241231",
      "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20038923_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c20240101to20241231",
      "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20038923_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://admabiologics.com/role/IncomeTaxesTables",
     "longName": "081100 - Disclosure - INCOME TAXES (Tables)",
     "shortName": "INCOME TAXES (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "34",
     "firstAnchor": {
      "contextRef": "c20240101to20241231",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20038923_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c20240101to20241231",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20038923_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://admabiologics.com/role/LeaseObligationsTables",
     "longName": "081200 - Disclosure - LEASE OBLIGATIONS (Tables)",
     "shortName": "LEASE OBLIGATIONS (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "35",
     "firstAnchor": {
      "contextRef": "c20240101to20241231",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "p",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20038923_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c20240101to20241231",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "span",
       "p",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20038923_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://admabiologics.com/role/SegmentsTables",
     "longName": "081300 - Disclosure - SEGMENTS (Tables)",
     "shortName": "SEGMENTS (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "36",
     "firstAnchor": {
      "contextRef": "c20240101to20241231",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20038923_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c20240101to20241231",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20038923_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://admabiologics.com/role/SupplementalDisclosureOfCashFlowInformationTables",
     "longName": "081500 - Disclosure - SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION (Tables)",
     "shortName": "SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "37",
     "firstAnchor": {
      "contextRef": "c20240101to20241231",
      "name": "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20038923_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c20240101to20241231",
      "name": "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20038923_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R38": {
     "role": "http://admabiologics.com/role/OrganizationAndBusinessDetails",
     "longName": "090100 - Disclosure - ORGANIZATION AND BUSINESS (Details)",
     "shortName": "ORGANIZATION AND BUSINESS (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "38",
     "firstAnchor": {
      "contextRef": "c20240101to20241231",
      "name": "adma:NumberOfFDALicensedPlasmaCollectionFacilities",
      "unitRef": "U004",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20038923_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c20240101to20241231",
      "name": "adma:NumberOfFDALicensedPlasmaCollectionFacilities",
      "unitRef": "U004",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20038923_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R39": {
     "role": "http://admabiologics.com/role/SignificantAccountingPoliciesUseOfEstimatesDetails",
     "longName": "090200 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES, Use of Estimates (Details)",
     "shortName": "SIGNIFICANT ACCOUNTING POLICIES, Use of Estimates (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "39",
     "firstAnchor": {
      "contextRef": "c20240101to20241231",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "U001",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20038923_10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c20240101to20241231_ChangeInAccountingEstimateByTypeAxis_AccrualForUSMedicaidRebatesMember",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "U001",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20038923_10k.htm",
      "unique": true
     }
    },
    "R40": {
     "role": "http://admabiologics.com/role/SignificantAccountingPoliciesAccountsReceivableDetails",
     "longName": "090202 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES, Accounts Receivable (Details)",
     "shortName": "SIGNIFICANT ACCOUNTING POLICIES, Accounts Receivable (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "40",
     "firstAnchor": {
      "contextRef": "c20241231",
      "name": "adma:AccountsReceivableAllowanceForContractualCreditsAndDoubtfulAccounts",
      "unitRef": "U001",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20038923_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c20241231",
      "name": "adma:AccountsReceivableAllowanceForContractualCreditsAndDoubtfulAccounts",
      "unitRef": "U001",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20038923_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R41": {
     "role": "http://admabiologics.com/role/SignificantAccountingPoliciesPropertyAndEquipmentDetails",
     "longName": "090204 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES, Property and Equipment (Details)",
     "shortName": "SIGNIFICANT ACCOUNTING POLICIES, Property and Equipment (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "41",
     "firstAnchor": {
      "contextRef": "c20241231_RangeAxis_MinimumMember",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20038923_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c20241231_RangeAxis_MinimumMember",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20038923_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R42": {
     "role": "http://admabiologics.com/role/SignificantAccountingPoliciesGoodwillDetails",
     "longName": "090206 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES, Goodwill (Details)",
     "shortName": "SIGNIFICANT ACCOUNTING POLICIES, Goodwill (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "42",
     "firstAnchor": {
      "contextRef": "c20241231",
      "name": "us-gaap:Goodwill",
      "unitRef": "U001",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20038923_10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c20240101to20241231",
      "name": "us-gaap:GoodwillImpairmentLoss",
      "unitRef": "U001",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "us-gaap:GoodwillImpairmentLoss",
       "p",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20038923_10k.htm",
      "unique": true
     }
    },
    "R43": {
     "role": "http://admabiologics.com/role/SignificantAccountingPoliciesImpairmentOfLonglivedAssetsDetails",
     "longName": "090208 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES, Impairment of Long-lived Assets (Details)",
     "shortName": "SIGNIFICANT ACCOUNTING POLICIES, Impairment of Long-lived Assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "c20240101to20241231",
      "name": "us-gaap:ImpairmentOfLongLivedAssetsHeldForUse",
      "unitRef": "U001",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "us-gaap:ImpairmentOfLongLivedAssetsHeldForUse",
       "p",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20038923_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c20240101to20241231",
      "name": "us-gaap:ImpairmentOfLongLivedAssetsHeldForUse",
      "unitRef": "U001",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "us-gaap:ImpairmentOfLongLivedAssetsHeldForUse",
       "p",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20038923_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R44": {
     "role": "http://admabiologics.com/role/SignificantAccountingPoliciesRevenueRecognitionDetails",
     "longName": "090210 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES, Revenue Recognition (Details)",
     "shortName": "SIGNIFICANT ACCOUNTING POLICIES, Revenue Recognition (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "c20240101to20241231",
      "name": "adma:CustomerPaymentTerms",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20038923_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c20240101to20241231",
      "name": "adma:CustomerPaymentTerms",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20038923_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R45": {
     "role": "http://admabiologics.com/role/SignificantAccountingPoliciesAdvertisingAndMarketingExpensesDetails",
     "longName": "090212 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES, Advertising and Marketing Expenses (Details)",
     "shortName": "SIGNIFICANT ACCOUNTING POLICIES, Advertising and Marketing Expenses (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "c20240101to20241231",
      "name": "us-gaap:MarketingAndAdvertisingExpense",
      "unitRef": "U001",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20038923_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c20240101to20241231",
      "name": "us-gaap:MarketingAndAdvertisingExpense",
      "unitRef": "U001",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20038923_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R46": {
     "role": "http://admabiologics.com/role/SignificantAccountingPoliciesStockbasedCompensationDetails",
     "longName": "090214 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES, Stock-based Compensation (Details)",
     "shortName": "SIGNIFICANT ACCOUNTING POLICIES, Stock-based Compensation (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "c20210901to20210930",
      "name": "adma:NumberOfExecutiveOfficers",
      "unitRef": "U006",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20038923_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c20210901to20210930",
      "name": "adma:NumberOfExecutiveOfficers",
      "unitRef": "U006",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20038923_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R47": {
     "role": "http://admabiologics.com/role/SignificantAccountingPoliciesEarningsLossPerShareDetails",
     "longName": "090216 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES, Earnings (Loss) Per Share (Details)",
     "shortName": "SIGNIFICANT ACCOUNTING POLICIES, Earnings (Loss) Per Share (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "c20240101to20241231",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "U001",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20038923_10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c20240101to20241231",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "U002",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20038923_10k.htm",
      "unique": true
     }
    },
    "R48": {
     "role": "http://admabiologics.com/role/InventoriesDetails",
     "longName": "090300 - Disclosure - INVENTORIES (Details)",
     "shortName": "INVENTORIES (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "c20241231",
      "name": "us-gaap:InventoryRawMaterials",
      "unitRef": "U001",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20038923_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c20241231",
      "name": "us-gaap:InventoryRawMaterials",
      "unitRef": "U001",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20038923_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R49": {
     "role": "http://admabiologics.com/role/PropertyAndEquipmentDetails",
     "longName": "090400 - Disclosure - PROPERTY AND EQUIPMENT (Details)",
     "shortName": "PROPERTY AND EQUIPMENT (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "49",
     "firstAnchor": {
      "contextRef": "c20241231",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "U001",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20038923_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c20241231",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "U001",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20038923_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R50": {
     "role": "http://admabiologics.com/role/IntangibleAssetsSummaryDetails",
     "longName": "090500 - Disclosure - INTANGIBLE ASSETS, Summary (Details)",
     "shortName": "INTANGIBLE ASSETS, Summary (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "50",
     "firstAnchor": {
      "contextRef": "c20241231",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "unitRef": "U001",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20038923_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c20241231",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "unitRef": "U001",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20038923_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R51": {
     "role": "http://admabiologics.com/role/IntangibleAssetsFutureAggregateAmortizationExpenseDetails",
     "longName": "090502 - Disclosure - INTANGIBLE ASSETS, Future Aggregate Amortization Expense (Details)",
     "shortName": "INTANGIBLE ASSETS, Future Aggregate Amortization Expense (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "51",
     "firstAnchor": {
      "contextRef": "c20241231",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths",
      "unitRef": "U001",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20038923_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c20241231",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths",
      "unitRef": "U001",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20038923_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R52": {
     "role": "http://admabiologics.com/role/AccruedExpensesAndOtherLiabilitiesDetails",
     "longName": "090600 - Disclosure - ACCRUED EXPENSES AND OTHER LIABILITIES (Details)",
     "shortName": "ACCRUED EXPENSES AND OTHER LIABILITIES (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "52",
     "firstAnchor": {
      "contextRef": "c20241231",
      "name": "adma:AccruedRebatesCurrent",
      "unitRef": "U001",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20038923_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c20241231",
      "name": "adma:AccruedRebatesCurrent",
      "unitRef": "U001",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20038923_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R53": {
     "role": "http://admabiologics.com/role/NotesPayableDetails",
     "longName": "090700 - Disclosure - NOTES PAYABLE (Details)",
     "shortName": "NOTES PAYABLE (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "53",
     "firstAnchor": {
      "contextRef": "c20231218",
      "name": "adma:SeniorNotesPayableBeforeDebtDiscount",
      "unitRef": "U001",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20038923_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c20231218",
      "name": "adma:SeniorNotesPayableBeforeDebtDiscount",
      "unitRef": "U001",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20038923_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R54": {
     "role": "http://admabiologics.com/role/StockholdersEquityPreferredStockDetails",
     "longName": "090800 - Disclosure - STOCKHOLDERS' EQUITY, Preferred Stock (Details)",
     "shortName": "STOCKHOLDERS' EQUITY, Preferred Stock (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "54",
     "firstAnchor": {
      "contextRef": "c20241231",
      "name": "us-gaap:PreferredStockCapitalSharesReservedForFutureIssuance",
      "unitRef": "U002",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-6",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20038923_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c20241231",
      "name": "us-gaap:PreferredStockCapitalSharesReservedForFutureIssuance",
      "unitRef": "U002",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-6",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20038923_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R55": {
     "role": "http://admabiologics.com/role/StockholdersEquityCommonStockDetails",
     "longName": "090802 - Disclosure - STOCKHOLDERS' EQUITY, Common Stock (Details)",
     "shortName": "STOCKHOLDERS' EQUITY, Common Stock (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "55",
     "firstAnchor": {
      "contextRef": "c20241231",
      "name": "us-gaap:CommonStockSharesAuthorized",
      "unitRef": "U002",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20038923_10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c20240101to20241231_StatementEquityComponentsAxis_CommonStockMember",
      "name": "us-gaap:ProceedsFromStockOptionsExercised",
      "unitRef": "U001",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20038923_10k.htm",
      "unique": true
     }
    },
    "R56": {
     "role": "http://admabiologics.com/role/StockholdersEquityWarrantsDetails",
     "longName": "090804 - Disclosure - STOCKHOLDERS' EQUITY, Warrants (Details)",
     "shortName": "STOCKHOLDERS' EQUITY, Warrants (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "56",
     "firstAnchor": {
      "contextRef": "c20240101to20241231",
      "name": "adma:ClassOfWarrantOrRightExercised",
      "unitRef": "U002",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20038923_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c20240101to20241231",
      "name": "adma:ClassOfWarrantOrRightExercised",
      "unitRef": "U002",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20038923_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R57": {
     "role": "http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails",
     "longName": "090806 - Disclosure - STOCKHOLDERS' EQUITY, Equity Incentive Plans (Details)",
     "shortName": "STOCKHOLDERS' EQUITY, Equity Incentive Plans (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "57",
     "firstAnchor": {
      "contextRef": "c20241231",
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "unitRef": "U002",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20038923_10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c20241231",
      "name": "us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions",
      "unitRef": "U002",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20038923_10k.htm",
      "unique": true
     }
    },
    "R58": {
     "role": "http://admabiologics.com/role/RelatedPartyTransactionsDetails",
     "longName": "090900 - Disclosure - RELATED PARTY TRANSACTIONS (Details)",
     "shortName": "RELATED PARTY TRANSACTIONS (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "58",
     "firstAnchor": {
      "contextRef": "c20240101to20241231",
      "name": "us-gaap:ShareBasedCompensation",
      "unitRef": "U001",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20038923_10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c20230815to20230815_RelatedPartyTransactionsByRelatedPartyAxis_RelatedPartyMember_TitleOfIndividualAxis_ExecutiveOfficerMember",
      "name": "adma:NumberOfExecutiveOfficersThatExercisedOptions",
      "unitRef": "U006",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20038923_10k.htm",
      "unique": true
     }
    },
    "R59": {
     "role": "http://admabiologics.com/role/CommitmentsAndContingenciesDetails",
     "longName": "091000 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)",
     "shortName": "COMMITMENTS AND CONTINGENCIES (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "59",
     "firstAnchor": {
      "contextRef": "c20230619to20230619",
      "name": "adma:NumberOfBatchesInProductionAtTheTimeOfDisruption",
      "unitRef": "U010",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20038923_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c20230619to20230619",
      "name": "adma:NumberOfBatchesInProductionAtTheTimeOfDisruption",
      "unitRef": "U010",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20038923_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R60": {
     "role": "http://admabiologics.com/role/IncomeTaxesIncomeTaxExpenseBenefitDetails",
     "longName": "091100 - Disclosure - INCOME TAXES, Income Tax Expense (Benefit) (Details)",
     "shortName": "INCOME TAXES, Income Tax Expense (Benefit) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "60",
     "firstAnchor": {
      "contextRef": "c20240101to20241231",
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "unitRef": "U001",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20038923_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c20240101to20241231",
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "unitRef": "U001",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20038923_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R61": {
     "role": "http://admabiologics.com/role/IncomeTaxesReconciliationOfIncomeTaxesDetails",
     "longName": "091102 - Disclosure - INCOME TAXES, Reconciliation of Income Taxes (Details)",
     "shortName": "INCOME TAXES, Reconciliation of Income Taxes (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "61",
     "firstAnchor": {
      "contextRef": "c20240101to20241231",
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "unitRef": "U001",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20038923_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c20240101to20241231",
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "unitRef": "U001",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20038923_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R62": {
     "role": "http://admabiologics.com/role/IncomeTaxesDeferredTaxAssetsDetails",
     "longName": "091104 - Disclosure - INCOME TAXES, Deferred Tax Assets (Details)",
     "shortName": "INCOME TAXES, Deferred Tax Assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "62",
     "firstAnchor": {
      "contextRef": "c20241231",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic",
      "unitRef": "U001",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20038923_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c20241231",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic",
      "unitRef": "U001",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20038923_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R63": {
     "role": "http://admabiologics.com/role/IncomeTaxesNetOperatingLossCarryforwardsDetails",
     "longName": "091106 - Disclosure - INCOME TAXES, Net Operating Loss Carryforwards (Details)",
     "shortName": "INCOME TAXES, Net Operating Loss Carryforwards (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "63",
     "firstAnchor": {
      "contextRef": "c20241231",
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "unitRef": "U001",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20038923_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c20241231",
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "unitRef": "U001",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20038923_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R64": {
     "role": "http://admabiologics.com/role/LeaseObligationsDetails",
     "longName": "091200 - Disclosure - LEASE OBLIGATIONS (Details)",
     "shortName": "LEASE OBLIGATIONS (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "64",
     "firstAnchor": {
      "contextRef": "c20230101to20231231",
      "name": "adma:OperatingLeaseIncrementalBorrowingRatePercent",
      "unitRef": "U007",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20038923_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c20230101to20231231",
      "name": "adma:OperatingLeaseIncrementalBorrowingRatePercent",
      "unitRef": "U007",
      "xsiNil": "false",
      "lang": null,
      "decimals": "2",
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20038923_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R65": {
     "role": "http://admabiologics.com/role/SegmentsSummarizedFinancialInformationBySegmentDetails",
     "longName": "091300 - Disclosure - SEGMENTS, Summarized Financial Information by Segment (Details)",
     "shortName": "SEGMENTS, Summarized Financial Information by Segment (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "65",
     "firstAnchor": {
      "contextRef": "c20240101to20241231",
      "name": "adma:NumberOfPlasmaCollectionFacilitiesUnderDevelopment",
      "unitRef": "U004",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20038923_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c20240101to20241231",
      "name": "adma:NumberOfPlasmaCollectionFacilitiesUnderDevelopment",
      "unitRef": "U004",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20038923_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R66": {
     "role": "http://admabiologics.com/role/SegmentsNetRevenuesAccordingToGeographicAreaDetails",
     "longName": "091302 - Disclosure - SEGMENTS, Net Revenues According to Geographic Area (Details)",
     "shortName": "SEGMENTS, Net Revenues According to Geographic Area (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "66",
     "firstAnchor": {
      "contextRef": "c20240101to20241231",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "U001",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20038923_10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c20240101to20241231_StatementGeographicalAxis_US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "U001",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20038923_10k.htm",
      "unique": true
     }
    },
    "R67": {
     "role": "http://admabiologics.com/role/OtherEmployeeBenefitsDetails",
     "longName": "091400 - Disclosure - OTHER EMPLOYEE BENEFITS (Details)",
     "shortName": "OTHER EMPLOYEE BENEFITS (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "67",
     "firstAnchor": {
      "contextRef": "c20240101to20241231",
      "name": "us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount",
      "unitRef": "U001",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20038923_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c20240101to20241231",
      "name": "us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount",
      "unitRef": "U001",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20038923_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R68": {
     "role": "http://admabiologics.com/role/SupplementalDisclosureOfCashFlowInformationDetails",
     "longName": "091500 - Disclosure - SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION (Details)",
     "shortName": "SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "68",
     "firstAnchor": {
      "contextRef": "c20240101to20241231",
      "name": "us-gaap:InterestPaidNet",
      "unitRef": "U001",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20038923_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c20240101to20241231",
      "name": "us-gaap:InterestPaidNet",
      "unitRef": "U001",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20038923_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R69": {
     "role": "http://admabiologics.com/role/ConcentrationsDetails",
     "longName": "091600 - Disclosure - CONCENTRATIONS (Details)",
     "shortName": "CONCENTRATIONS (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "69",
     "firstAnchor": {
      "contextRef": "c20240101to20241231_ConcentrationRiskByBenchmarkAxis_AccountsReceivableMember_ConcentrationRiskByTypeAxis_CustomerConcentrationRiskMember_MajorCustomersAxis_ThreeCustomersMember",
      "name": "adma:NumberOfCustomers",
      "unitRef": "U015",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20038923_10k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c20240101to20241231_ConcentrationRiskByBenchmarkAxis_AccountsReceivableMember_ConcentrationRiskByTypeAxis_CustomerConcentrationRiskMember_MajorCustomersAxis_ThreeCustomersMember",
      "name": "adma:NumberOfCustomers",
      "unitRef": "U015",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20038923_10k.htm",
      "first": true,
      "unique": true
     }
    },
    "R70": {
     "role": "http://admabiologics.com/role/ScheduleIiValuationAndQualifyingAccountsDetails",
     "longName": "091700 - Disclosure - SCHEDULE II - VALUATION AND QUALIFYING ACCOUNTS (Details)",
     "shortName": "SCHEDULE II - VALUATION AND QUALIFYING ACCOUNTS (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "70",
     "firstAnchor": {
      "contextRef": "c20231231_ValuationAllowancesAndReservesTypeAxis_SECSchedule1209ReserveAccruedRebatesMember",
      "name": "us-gaap:ValuationAllowancesAndReservesBalance",
      "unitRef": "U001",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20038923_10k.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c20211231_ValuationAllowancesAndReservesTypeAxis_SECSchedule1209ReserveAccruedRebatesMember",
      "name": "us-gaap:ValuationAllowancesAndReservesBalance",
      "unitRef": "U001",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ef20038923_10k.htm",
      "unique": true
     }
    }
   },
   "tag": {
    "adma_ADMABioManufacturingSegmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://admabiologics.com/20241231",
     "localname": "ADMABioManufacturingSegmentMember",
     "presentation": [
      "http://admabiologics.com/role/SegmentsNetRevenuesAccordingToGeographicAreaDetails",
      "http://admabiologics.com/role/SegmentsSummarizedFinancialInformationBySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Component of ADMA BioManufacturing that usually provides financial, operational and administrative support and is considered an operating segment.",
        "label": "ADMA BioManufacturing Segment [Member]",
        "terseLabel": "ADMA BioManufacturing [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "adma_ARGrifolsAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://admabiologics.com/20241231",
     "localname": "ARGrifolsAgreementMember",
     "presentation": [
      "http://admabiologics.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restated Plasma Purchase Agreement with Grifols used in the manufacture of ASCENIV.",
        "label": "A&amp;R Grifols Agreement [Member]",
        "terseLabel": "A&amp;R Grifols Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "adma_ASCENIVMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://admabiologics.com/20241231",
     "localname": "ASCENIVMember",
     "presentation": [
      "http://admabiologics.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ASCENIV an Intravenous Immune Globulin (\"IVIG\") product indicated for the treatment of Primary Humoral Immunodeficiency (\"PI\"), also known as Primary Immunodeficiency Disease (\"PIDD\").",
        "label": "ASCENIV [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "SIGNIFICANT ACCOUNTING POLICIES [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
     "presentation": [
      "http://admabiologics.com/role/AccruedExpensesAndOtherLiabilities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ACCRUED EXPENSES AND OTHER LIABILITIES",
        "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]",
        "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period."
       }
      }
     },
     "auth_ref": [
      "r62",
      "r65",
      "r70",
      "r994"
     ]
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://admabiologics.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://admabiologics.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts payable",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r62",
      "r817"
     ]
    },
    "adma_AccountsReceivableAllowanceForContractualCreditsAndDoubtfulAccounts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://admabiologics.com/20241231",
     "localname": "AccountsReceivableAllowanceForContractualCreditsAndDoubtfulAccounts",
     "crdr": "credit",
     "presentation": [
      "http://admabiologics.com/role/SignificantAccountingPoliciesAccountsReceivableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of allowance for contractual credits and doubtful accounts.",
        "label": "Accounts Receivable, Allowance for Contractual Credits and Doubtful Accounts",
        "terseLabel": "Accounts receivable, allowances for contractual credits and credit losses"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsReceivableMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsReceivableMember",
     "presentation": [
      "http://admabiologics.com/role/ConcentrationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Receivable [Member]",
        "documentation": "Due from customers or clients for goods or services that have been delivered or sold."
       }
      }
     },
     "auth_ref": [
      "r750"
     ]
    },
    "us-gaap_AccountsReceivableNetAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsReceivableNetAbstract",
     "presentation": [
      "http://admabiologics.com/role/SignificantAccountingPoliciesAccountsReceivableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Receivable [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsReceivableNetCurrent",
     "crdr": "debit",
     "calculation": {
      "http://admabiologics.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://admabiologics.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts receivable, net",
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current."
       }
      }
     },
     "auth_ref": [
      "r932"
     ]
    },
    "adma_AccrualForUSMedicaidRebatesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://admabiologics.com/20241231",
     "localname": "AccrualForUSMedicaidRebatesMember",
     "presentation": [
      "http://admabiologics.com/role/SignificantAccountingPoliciesUseOfEstimatesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrual for U.S. Medicaid Rebates.",
        "label": "Accrual for U.S. Medicaid Rebates [Member]",
        "terseLabel": "Accrual for U.S. Medicaid Rebates [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedBonusesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedBonusesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://admabiologics.com/role/AccruedExpensesAndOtherLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://admabiologics.com/role/AccruedExpensesAndOtherLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued incentives",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for incentive compensation awarded to employees and directors or earned by them based on the terms of one or more relevant arrangements. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r65"
     ]
    },
    "us-gaap_AccruedLiabilitiesAndOtherLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedLiabilitiesAndOtherLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://admabiologics.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      },
      "http://admabiologics.com/role/AccruedExpensesAndOtherLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://admabiologics.com/role/AccruedExpensesAndOtherLiabilitiesDetails",
      "http://admabiologics.com/role/ConsolidatedBalanceSheets",
      "http://admabiologics.com/role/SignificantAccountingPoliciesUseOfEstimatesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrual adjustments",
        "verboseLabel": "Accrued expenses and other current liabilities",
        "totalLabel": "Total accrued expenses and other current liabilities",
        "label": "Accrued Liabilities and Other Liabilities",
        "documentation": "Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedLiabilitiesAndOtherLiabilitiesAbstract",
     "presentation": [
      "http://admabiologics.com/role/AccruedExpensesAndOtherLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Expenses and Other Current Liabilities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedProfessionalFeesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://admabiologics.com/role/AccruedExpensesAndOtherLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://admabiologics.com/role/AccruedExpensesAndOtherLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued distribution fees",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r65"
     ]
    },
    "adma_AccruedRebatesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://admabiologics.com/20241231",
     "localname": "AccruedRebatesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://admabiologics.com/role/AccruedExpensesAndOtherLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://admabiologics.com/role/AccruedExpensesAndOtherLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of rebates for Medicaid or other third parties related to sale of product.",
        "label": "Accrued Rebates, Current",
        "terseLabel": "Accrued rebates"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedSalariesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedSalariesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://admabiologics.com/role/AccruedExpensesAndOtherLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://admabiologics.com/role/AccruedExpensesAndOtherLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued payroll and other compensation",
        "documentation": "Carrying value as of the balance sheet date of the obligations incurred through that date and payable for employees' services provided. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r65",
      "r772"
     ]
    },
    "adma_AccruedTestingCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://admabiologics.com/20241231",
     "localname": "AccruedTestingCurrent",
     "crdr": "credit",
     "calculation": {
      "http://admabiologics.com/role/AccruedExpensesAndOtherLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://admabiologics.com/role/AccruedExpensesAndOtherLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for testing. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Testing, Current",
        "terseLabel": "Accrued testing"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://admabiologics.com/role/PropertyAndEquipmentDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://admabiologics.com/role/PropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less: accumulated depreciation",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services."
       }
      }
     },
     "auth_ref": [
      "r38",
      "r205",
      "r621"
     ]
    },
    "adma_AdamGrossmanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://admabiologics.com/20241231",
     "localname": "AdamGrossmanMember",
     "presentation": [
      "http://admabiologics.com/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name of President and CEO.",
        "label": "Adam Grossman [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "adma_AdamGrossmanTradingPlanCommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://admabiologics.com/20241231",
     "localname": "AdamGrossmanTradingPlanCommonStockMember",
     "presentation": [
      "http://admabiologics.com/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common stock that to be issued under Insider trading plan.",
        "label": "Adam Grossman Trading Plan, Common Stock [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "adma_AdamGrossmanTradingPlanStockOptionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://admabiologics.com/20241231",
     "localname": "AdamGrossmanTradingPlanStockOptionsMember",
     "presentation": [
      "http://admabiologics.com/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock option that to be issued under Insider trading plan.",
        "label": "Adam Grossman Trading Plan, Stock Options [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdditionalPaidInCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapital",
     "crdr": "credit",
     "calculation": {
      "http://admabiologics.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://admabiologics.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional paid-in capital",
        "label": "Additional Paid in Capital",
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock."
       }
      }
     },
     "auth_ref": [
      "r77",
      "r817",
      "r1062"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://admabiologics.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Paid-in Capital [Member]",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r671",
      "r919",
      "r920",
      "r921",
      "r922",
      "r1008",
      "r1063"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition",
     "crdr": "credit",
     "presentation": [
      "http://admabiologics.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Stock-based compensation",
        "label": "APIC, Share-Based Payment Arrangement, Option, Increase for Cost Recognition",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToAdditionalPaidInCapitalWarrantIssued",
     "crdr": "credit",
     "presentation": [
      "http://admabiologics.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants issued in connection with notes payable",
        "label": "Adjustments to Additional Paid in Capital, Warrant Issued",
        "documentation": "Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r39",
      "r116"
     ]
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://admabiologics.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdvertisingCostsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdvertisingCostsPolicyTextBlock",
     "presentation": [
      "http://admabiologics.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Advertising and Marketing Expenses",
        "documentation": "Disclosure of accounting policy for advertising cost."
       }
      }
     },
     "auth_ref": [
      "r141"
     ]
    },
    "adma_AgreementWithTermExpirationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://admabiologics.com/20241231",
     "localname": "AgreementWithTermExpirationDate",
     "presentation": [
      "http://admabiologics.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date the agreement with term expired, in YYYY-MM-DD format.",
        "label": "Agreement with Term Expiration Date",
        "terseLabel": "Agreement term expiring date"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AllIndividualsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllIndividualsMember",
     "presentation": [
      "http://admabiologics.com/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Individuals [Member]"
       }
      }
     },
     "auth_ref": [
      "r862",
      "r864",
      "r865",
      "r867",
      "r869",
      "r870",
      "r873"
     ]
    },
    "ecd_AllTradingArrangementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllTradingArrangementsMember",
     "presentation": [
      "http://admabiologics.com/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Trading Arrangements [Member]"
       }
      }
     },
     "auth_ref": [
      "r871"
     ]
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share based compensation expense",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r462",
      "r468"
     ]
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://admabiologics.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AmortizationOfDebtDiscountPremium": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AmortizationOfDebtDiscountPremium",
     "crdr": "debit",
     "calculation": {
      "http://admabiologics.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://admabiologics.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amortization of debt discount",
        "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r92",
      "r388",
      "r1015"
     ]
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AmortizationOfIntangibleAssets",
     "crdr": "debit",
     "calculation": {
      "http://admabiologics.com/role/ConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://admabiologics.com/role/ConsolidatedStatementsOfOperations",
      "http://admabiologics.com/role/IntangibleAssetsSummaryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Amortization of intangible assets",
        "label": "Amortization of intangible assets",
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r334",
      "r340",
      "r792"
     ]
    },
    "adma_AmortizationOfLicenseRevenue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://admabiologics.com/20241231",
     "localname": "AmortizationOfLicenseRevenue",
     "crdr": "debit",
     "calculation": {
      "http://admabiologics.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://admabiologics.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash revenue related to amortization of license revenue.",
        "label": "Amortization of License Revenue",
        "terseLabel": "Amortization of license revenue"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://admabiologics.com/role/SignificantAccountingPoliciesEarningsLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Potentially dilutive securities (in shares)",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r266"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "presentation": [
      "http://admabiologics.com/role/SignificantAccountingPoliciesEarningsLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities [Axis]",
        "documentation": "Information by type of antidilutive security."
       }
      }
     },
     "auth_ref": [
      "r22"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "presentation": [
      "http://admabiologics.com/role/SignificantAccountingPoliciesEarningsLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesNameDomain",
     "presentation": [
      "http://admabiologics.com/role/SignificantAccountingPoliciesEarningsLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Securities, Name [Domain]",
        "label": "Antidilutive Securities, Name [Domain]",
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r22"
     ]
    },
    "adma_AresClosingDateLoanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://admabiologics.com/20241231",
     "localname": "AresClosingDateLoanMember",
     "presentation": [
      "http://admabiologics.com/role/NotesPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ares Closing Date Loan [Member]",
        "terseLabel": "Ares Closing Date Loan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "adma_AresCreditAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://admabiologics.com/20241231",
     "localname": "AresCreditAgreementMember",
     "presentation": [
      "http://admabiologics.com/role/NotesPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ares credit agreement is a legally-binding contract documenting the terms of a loan agreement; it is made between a person or party borrowing money and a lender.",
        "label": "Ares Credit Agreement [Member]",
        "terseLabel": "Ares Credit Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "adma_AresCreditFacilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://admabiologics.com/20241231",
     "localname": "AresCreditFacilityMember",
     "presentation": [
      "http://admabiologics.com/role/NotesPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Arrangement in which facility proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount.",
        "label": "Ares Credit Facility [Member]",
        "terseLabel": "Ares Credit Facility [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "adma_ArethLLCMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://admabiologics.com/20241231",
     "localname": "ArethLLCMember",
     "presentation": [
      "http://admabiologics.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the entity associated with related party.",
        "label": "Areth, LLC [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "presentation": [
      "http://admabiologics.com/role/CommitmentsAndContingenciesDetails",
      "http://admabiologics.com/role/SignificantAccountingPoliciesRevenueRecognitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r516"
     ]
    },
    "us-gaap_AssetImpairmentChargesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetImpairmentChargesAbstract",
     "presentation": [
      "http://admabiologics.com/role/SignificantAccountingPoliciesImpairmentOfLonglivedAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Impairment of Long-lived Assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetUnderConstructionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetUnderConstructionMember",
     "presentation": [
      "http://admabiologics.com/role/PropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Construction in Process [Member]",
        "documentation": "Asset in process of being built."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://admabiologics.com/role/ConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://admabiologics.com/role/ConsolidatedBalanceSheets",
      "http://admabiologics.com/role/SegmentsSummarizedFinancialInformationBySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "TOTAL ASSETS",
        "label": "Total assets",
        "documentation": "Amount of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r125",
      "r137",
      "r208",
      "r232",
      "r269",
      "r276",
      "r294",
      "r298",
      "r311",
      "r362",
      "r363",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r371",
      "r372",
      "r517",
      "r519",
      "r535",
      "r611",
      "r700",
      "r785",
      "r786",
      "r817",
      "r845",
      "r961",
      "r962",
      "r1021"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://admabiologics.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ASSETS",
        "label": "Assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://admabiologics.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://admabiologics.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current assets",
        "label": "Assets, Current",
        "documentation": "Amount of asset recognized for present right to economic benefit, classified as current."
       }
      }
     },
     "auth_ref": [
      "r200",
      "r215",
      "r232",
      "r311",
      "r362",
      "r363",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r371",
      "r372",
      "r517",
      "r519",
      "r535",
      "r817",
      "r961",
      "r962",
      "r1021"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://admabiologics.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current assets:"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AuditorFirmId": {
     "xbrltype": "nonemptySequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorFirmId",
     "presentation": [
      "http://admabiologics.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Firm ID",
        "documentation": "PCAOB issued Audit Firm Identifier"
       }
      }
     },
     "auth_ref": [
      "r849",
      "r850",
      "r863"
     ]
    },
    "dei_AuditorLocation": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorLocation",
     "presentation": [
      "http://admabiologics.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location"
       }
      }
     },
     "auth_ref": [
      "r849",
      "r850",
      "r863"
     ]
    },
    "dei_AuditorName": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorName",
     "presentation": [
      "http://admabiologics.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name"
       }
      }
     },
     "auth_ref": [
      "r849",
      "r850",
      "r863"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://admabiologics.com/role/RelatedPartyTransactionsDetails",
      "http://admabiologics.com/role/SignificantAccountingPoliciesStockbasedCompensationDetails",
      "http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Axis]",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r433",
      "r434",
      "r435",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461"
     ]
    },
    "adma_BIVIGAMMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://admabiologics.com/20241231",
     "localname": "BIVIGAMMember",
     "presentation": [
      "http://admabiologics.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "BIVIGAM an Intravenous Immune Globulin (\"IVIG\") product indicated for the treatment of Primary Humoral Immunodeficiency (\"PI\"), also known as Primary Immunodeficiency Disease (\"PIDD\").",
        "label": "BIVIGAM [Member]",
        "terseLabel": "BIVIGAM [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BaseRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BaseRateMember",
     "presentation": [
      "http://admabiologics.com/role/NotesPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Base Rate [Member]",
        "documentation": "Minimum rate investor will accept."
       }
      }
     },
     "auth_ref": []
    },
    "adma_BiotestLicenseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://admabiologics.com/20241231",
     "localname": "BiotestLicenseAgreementMember",
     "presentation": [
      "http://admabiologics.com/role/SignificantAccountingPoliciesRevenueRecognitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of license agreement.",
        "label": "Biotest License Agreement [Member]",
        "terseLabel": "Biotest License Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "adma_BryantFongMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://admabiologics.com/20241231",
     "localname": "BryantFongMember",
     "presentation": [
      "http://admabiologics.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the entity associated with related party.",
        "label": "Bryant Fong [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BuildingAndBuildingImprovementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BuildingAndBuildingImprovementsMember",
     "presentation": [
      "http://admabiologics.com/role/PropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Buildings and Building Improvements [Member]",
        "documentation": "Facility held for productive use including, but not limited to, office, production, storage and distribution facilities and any addition, improvement, or renovation to the structure, for example, but not limited to, interior masonry, interior flooring, electrical, and plumbing."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BuildingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BuildingMember",
     "presentation": [
      "http://admabiologics.com/role/SignificantAccountingPoliciesPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Buildings [Member]",
        "documentation": "Facility held for productive use including, but not limited to, office, production, storage and distribution facilities."
       }
      }
     },
     "auth_ref": [
      "r108"
     ]
    },
    "us-gaap_Cash": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Cash",
     "crdr": "debit",
     "presentation": [
      "http://admabiologics.com/role/NotesPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash balance",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r139",
      "r614",
      "r672",
      "r695",
      "r817",
      "r845",
      "r900"
     ]
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://admabiologics.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://admabiologics.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and cash equivalents",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r203",
      "r770"
     ]
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "presentation": [
      "http://admabiologics.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and Cash Equivalents",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value."
       }
      }
     },
     "auth_ref": [
      "r20"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://admabiologics.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Cash and cash equivalents - beginning of year",
        "periodEndLabel": "Cash and cash equivalents - end of year",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r97",
      "r229"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://admabiologics.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://admabiologics.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net increase (decrease) in cash and cash equivalents",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r97"
     ]
    },
    "us-gaap_CashFlowSupplementalDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashFlowSupplementalDisclosuresTextBlock",
     "presentation": [
      "http://admabiologics.com/role/SupplementalDisclosureOfCashFlowInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION",
        "documentation": "The entire disclosure for supplemental cash flow activities, including cash, noncash, and part noncash transactions, for the period. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period."
       }
      }
     },
     "auth_ref": [
      "r94"
     ]
    },
    "us-gaap_ChangeInAccountingEstimateByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ChangeInAccountingEstimateByTypeAxis",
     "presentation": [
      "http://admabiologics.com/role/SignificantAccountingPoliciesUseOfEstimatesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in Accounting Estimate by Type [Axis]",
        "documentation": "Information by type of change in accounting estimate."
       }
      }
     },
     "auth_ref": [
      "r24",
      "r253"
     ]
    },
    "us-gaap_ChangeInAccountingEstimateLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ChangeInAccountingEstimateLineItems",
     "presentation": [
      "http://admabiologics.com/role/SignificantAccountingPoliciesUseOfEstimatesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in Accounting Estimate [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r253"
     ]
    },
    "us-gaap_ChangeInAccountingEstimateTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ChangeInAccountingEstimateTypeDomain",
     "presentation": [
      "http://admabiologics.com/role/SignificantAccountingPoliciesUseOfEstimatesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in Accounting Estimate, Type [Domain]",
        "documentation": "Identification of the accounting estimate that was changed that had the effect of adjusting the carrying amount of an existing asset or liability, or that will alter the subsequent accounting for existing or future assets or liabilities."
       }
      }
     },
     "auth_ref": [
      "r24",
      "r253"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://admabiologics.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfStockLineItems",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r210",
      "r211",
      "r212",
      "r271",
      "r393",
      "r394",
      "r395",
      "r397",
      "r400",
      "r405",
      "r407",
      "r662",
      "r663",
      "r664",
      "r665",
      "r799",
      "r890",
      "r910"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightAxis",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Axis]",
        "documentation": "Information by type of warrant or right issued."
       }
      }
     },
     "auth_ref": [
      "r48"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightDomain",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Domain]",
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "presentation": [
      "http://admabiologics.com/role/NotesPayableDetails",
      "http://admabiologics.com/role/StockholdersEquityWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant exercise price per share (in dollars per share)",
        "verboseLabel": "Warrant exercise price (in dollars per share)",
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": [
      "r408"
     ]
    },
    "adma_ClassOfWarrantOrRightExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://admabiologics.com/20241231",
     "localname": "ClassOfWarrantOrRightExercised",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of warrants exercised during the period.",
        "label": "Class Of Warrant Or Right Exercised",
        "terseLabel": "Warrants exercised (in shares)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightLineItems",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "presentation": [
      "http://admabiologics.com/role/NotesPayableDetails",
      "http://admabiologics.com/role/StockholdersEquityWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrant to purchase shares of common stock (in shares)",
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares."
       }
      }
     },
     "auth_ref": [
      "r408"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightOutstanding",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants outstanding (in shares)",
        "label": "Class of Warrant or Right, Outstanding",
        "documentation": "Number of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfWarrantOrRightTable",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right [Table]",
        "documentation": "Disclosure of information about warrant or right issued that give holder right to purchase security from issuer at specific price within certain time frame."
       }
      }
     },
     "auth_ref": [
      "r48"
     ]
    },
    "adma_CohnReznickLLPMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://admabiologics.com/20241231",
     "localname": "CohnReznickLLPMember",
     "presentation": [
      "http://admabiologics.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Previous auditor.",
        "label": "CohnReznick LLP [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "presentation": [
      "http://admabiologics.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "COMMITMENTS AND CONTINGENCIES",
        "label": "Commitments and Contingencies",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r71",
      "r129",
      "r613",
      "r686"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "COMMITMENTS AND CONTINGENCIES [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://admabiologics.com/role/CommitmentsAndContingencies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "COMMITMENTS AND CONTINGENCIES",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r110",
      "r353",
      "r354",
      "r751",
      "r949",
      "r954"
     ]
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityCommonStockDetails",
      "http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares reserved for grant (in shares)",
        "label": "Common stock, available for issuance (in shares)",
        "documentation": "Aggregate number of common shares reserved for future issuance."
       }
      }
     },
     "auth_ref": [
      "r76"
     ]
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockMember",
     "presentation": [
      "http://admabiologics.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity",
      "http://admabiologics.com/role/StockholdersEquityCommonStockDetails",
      "http://admabiologics.com/role/StockholdersEquityWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r835",
      "r836",
      "r837",
      "r839",
      "r840",
      "r841",
      "r842",
      "r919",
      "r920",
      "r922",
      "r1008",
      "r1060",
      "r1063"
     ]
    },
    "us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://admabiologics.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://admabiologics.com/role/StockholdersEquityCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, par value (in dollars per share)",
        "label": "Common stock, par value (in dollars per share)",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r76"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://admabiologics.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://admabiologics.com/role/StockholdersEquityCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Common stock, shares authorized (in shares)",
        "label": "Common stock, shares authorized (in shares)",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r76",
      "r687"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://admabiologics.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://admabiologics.com/role/StockholdersEquityWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common stock, shares issued (in shares)",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r76"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://admabiologics.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://admabiologics.com/role/StockholdersEquityCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares outstanding (in shares)",
        "label": "Common stock, shares outstanding (in shares)",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r76",
      "r687",
      "r706",
      "r1063",
      "r1064"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://admabiologics.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://admabiologics.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock - voting, $0.0001 par value, 300,000,000 shares authorized, 236,620,545 and 226,063,032 shares issued and outstanding at December 31, 2024 and December 31, 2023",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r76",
      "r616",
      "r817"
     ]
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "OTHER EMPLOYEE BENEFITS [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComponentsOfDeferredTaxAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ComponentsOfDeferredTaxAssetsAbstract",
     "presentation": [
      "http://admabiologics.com/role/IncomeTaxesDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred tax assets:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ComponentsOfDeferredTaxLiabilitiesAbstract",
     "presentation": [
      "http://admabiologics.com/role/IncomeTaxesDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred tax liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComputerSoftwareIntangibleAssetMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ComputerSoftwareIntangibleAssetMember",
     "presentation": [
      "http://admabiologics.com/role/IntangibleAssetsSummaryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Internally Developed Software [Member]",
        "documentation": "Collection of computer programs and related data that provide instructions to a computer, for example, but not limited to, application program, control module or operating system, that perform one or more particular functions or tasks."
       }
      }
     },
     "auth_ref": [
      "r764",
      "r769",
      "r937",
      "r938",
      "r939",
      "r940",
      "r941",
      "r942",
      "r945",
      "r946"
     ]
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskBenchmarkDomain",
     "presentation": [
      "http://admabiologics.com/role/ConcentrationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk Benchmark [Domain]",
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage."
       }
      }
     },
     "auth_ref": [
      "r26",
      "r27",
      "r55",
      "r56",
      "r305",
      "r750"
     ]
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "presentation": [
      "http://admabiologics.com/role/ConcentrationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk Benchmark [Axis]",
        "documentation": "Information by benchmark of concentration risk."
       }
      }
     },
     "auth_ref": [
      "r26",
      "r27",
      "r55",
      "r56",
      "r305",
      "r657",
      "r750"
     ]
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskByTypeAxis",
     "presentation": [
      "http://admabiologics.com/role/ConcentrationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk Type [Axis]",
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender."
       }
      }
     },
     "auth_ref": [
      "r26",
      "r27",
      "r55",
      "r56",
      "r305",
      "r750",
      "r893"
     ]
    },
    "us-gaap_ConcentrationRiskDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskDisclosureTextBlock",
     "presentation": [
      "http://admabiologics.com/role/Concentrations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "CONCENTRATIONS",
        "documentation": "The entire disclosure for any concentrations existing at the date of the financial statements that make an entity vulnerable to a reasonably possible, near-term, severe impact. This disclosure informs financial statement users about the general nature of the risk associated with the concentration, and may indicate the percentage of concentration risk as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r103"
     ]
    },
    "us-gaap_ConcentrationRiskLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskLineItems",
     "presentation": [
      "http://admabiologics.com/role/ConcentrationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r750"
     ]
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskPercentage1",
     "presentation": [
      "http://admabiologics.com/role/ConcentrationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration risk, percentage",
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division."
       }
      }
     },
     "auth_ref": [
      "r26",
      "r27",
      "r55",
      "r56",
      "r305"
     ]
    },
    "us-gaap_ConcentrationRiskTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskTable",
     "presentation": [
      "http://admabiologics.com/role/ConcentrationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk [Table]",
        "documentation": "Disclosure of information about concentration risk. Includes, but is not limited to, percentage of concentration risk and benchmark serving as denominator in calculation of percentage of concentration risk."
       }
      }
     },
     "auth_ref": [
      "r25",
      "r26",
      "r27",
      "r28",
      "r55",
      "r124",
      "r750"
     ]
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskTypeDomain",
     "presentation": [
      "http://admabiologics.com/role/ConcentrationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk Type [Domain]",
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration."
       }
      }
     },
     "auth_ref": [
      "r26",
      "r27",
      "r55",
      "r56",
      "r305",
      "r750"
     ]
    },
    "us-gaap_ConcentrationRisksTypesNoConcentrationPercentageAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRisksTypesNoConcentrationPercentageAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "CONCENTRATIONS [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_ConsolidationItemsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ConsolidationItemsAxis",
     "presentation": [
      "http://admabiologics.com/role/SegmentsNetRevenuesAccordingToGeographicAreaDetails",
      "http://admabiologics.com/role/SegmentsSummarizedFinancialInformationBySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidation Items [Axis]",
        "documentation": "Information by components, eliminations, non-segment corporate-level activity and reconciling items used in consolidating a parent entity and its subsidiaries or its operating segments."
       }
      }
     },
     "auth_ref": [
      "r135",
      "r151",
      "r183",
      "r184",
      "r185",
      "r186",
      "r187",
      "r188",
      "r189",
      "r190",
      "r191",
      "r238",
      "r269",
      "r278",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r298",
      "r299",
      "r300",
      "r362",
      "r363",
      "r364",
      "r365",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r785",
      "r786",
      "r896",
      "r897",
      "r961",
      "r962"
     ]
    },
    "srt_ConsolidationItemsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ConsolidationItemsDomain",
     "presentation": [
      "http://admabiologics.com/role/SegmentsNetRevenuesAccordingToGeographicAreaDetails",
      "http://admabiologics.com/role/SegmentsSummarizedFinancialInformationBySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidation Items [Domain]",
        "documentation": "Components, elimination, non-segment corporate-level activity and reconciling items used in consolidating a parent entity and its subsidiaries or its operating segments."
       }
      }
     },
     "auth_ref": [
      "r135",
      "r151",
      "r183",
      "r184",
      "r185",
      "r186",
      "r187",
      "r188",
      "r189",
      "r190",
      "r191",
      "r238",
      "r269",
      "r278",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r298",
      "r299",
      "r300",
      "r362",
      "r363",
      "r364",
      "r365",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r785",
      "r786",
      "r896",
      "r897",
      "r961",
      "r962"
     ]
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ContractWithCustomerLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://admabiologics.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://admabiologics.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current portion of deferred revenue",
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current."
       }
      }
     },
     "auth_ref": [
      "r410",
      "r411",
      "r414"
     ]
    },
    "us-gaap_CorporateNonSegmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CorporateNonSegmentMember",
     "presentation": [
      "http://admabiologics.com/role/SegmentsSummarizedFinancialInformationBySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Corporate [Member]",
        "documentation": "Corporate headquarters or functional department that may not earn revenues or may earn revenues that are only incidental to the activities of the entity and is not considered an operating segment."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r293",
      "r294",
      "r295",
      "r296",
      "r299",
      "r927"
     ]
    },
    "us-gaap_CostOfRevenue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CostOfRevenue",
     "crdr": "debit",
     "calculation": {
      "http://admabiologics.com/role/ConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_GrossProfit",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://admabiologics.com/role/ConsolidatedStatementsOfOperations",
      "http://admabiologics.com/role/SegmentsSummarizedFinancialInformationBySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cost of product revenue",
        "verboseLabel": "Cost of product revenue",
        "label": "Cost of Revenue",
        "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r87",
      "r232",
      "r311",
      "r362",
      "r363",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r371",
      "r372",
      "r535",
      "r785",
      "r961"
     ]
    },
    "us-gaap_CostOfSalesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CostOfSalesMember",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cost of Product Revenue [Member]",
        "documentation": "Primary financial statement caption encompassing cost of sales."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CostOfSalesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CostOfSalesPolicyTextBlock",
     "presentation": [
      "http://admabiologics.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cost of Product Revenue",
        "documentation": "Disclosure of accounting policy for cost of product sold and service rendered."
       }
      }
     },
     "auth_ref": [
      "r895"
     ]
    },
    "us-gaap_CostsAndExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CostsAndExpensesAbstract",
     "presentation": [
      "http://admabiologics.com/role/ConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "OPERATING EXPENSES:"
       }
      }
     },
     "auth_ref": []
    },
    "srt_CounterpartyNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "CounterpartyNameAxis",
     "presentation": [
      "http://admabiologics.com/role/DocumentAndEntityInformation",
      "http://admabiologics.com/role/NotesPayableDetails",
      "http://admabiologics.com/role/RelatedPartyTransactionsDetails",
      "http://admabiologics.com/role/StockholdersEquityWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "documentation": "Information by name of counterparty. A counterparty is the other party that participates in a financial transaction. Examples include, but not limited to, the name of the financial institution."
       }
      }
     },
     "auth_ref": [
      "r192",
      "r193",
      "r236",
      "r237",
      "r376",
      "r395",
      "r565",
      "r570",
      "r610",
      "r773",
      "r775"
     ]
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CreditFacilityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CreditFacilityAxis",
     "presentation": [
      "http://admabiologics.com/role/NotesPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Credit Facility [Axis]",
        "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing."
       }
      }
     },
     "auth_ref": [
      "r361",
      "r959"
     ]
    },
    "us-gaap_CreditFacilityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CreditFacilityDomain",
     "presentation": [
      "http://admabiologics.com/role/NotesPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Credit Facility [Domain]",
        "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing."
       }
      }
     },
     "auth_ref": [
      "r361",
      "r959",
      "r960"
     ]
    },
    "us-gaap_CurrentFederalTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CurrentFederalTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://admabiologics.com/role/IncomeTaxesIncomeTaxExpenseBenefitDetails": {
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://admabiologics.com/role/IncomeTaxesIncomeTaxExpenseBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Federal",
        "documentation": "Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r894",
      "r913",
      "r1006"
     ]
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://admabiologics.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CurrentIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://admabiologics.com/role/IncomeTaxesIncomeTaxExpenseBenefitDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://admabiologics.com/role/IncomeTaxesIncomeTaxExpenseBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current",
        "label": "Current Income Tax Expense (Benefit)",
        "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r501",
      "r913"
     ]
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "presentation": [
      "http://admabiologics.com/role/IncomeTaxesIncomeTaxExpenseBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CurrentStateAndLocalTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://admabiologics.com/role/IncomeTaxesIncomeTaxExpenseBenefitDetails": {
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://admabiologics.com/role/IncomeTaxesIncomeTaxExpenseBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "State",
        "documentation": "Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r894",
      "r913",
      "r1006"
     ]
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CustomerConcentrationRiskMember",
     "presentation": [
      "http://admabiologics.com/role/ConcentrationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer Concentration Risk [Member]",
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer."
       }
      }
     },
     "auth_ref": [
      "r104",
      "r305"
     ]
    },
    "adma_CustomerPaymentTerms": {
     "xbrltype": "durationItemType",
     "nsuri": "http://admabiologics.com/20241231",
     "localname": "CustomerPaymentTerms",
     "presentation": [
      "http://admabiologics.com/role/SignificantAccountingPoliciesRevenueRecognitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The term within which customers are generally required to make payments, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Customer Payment Terms",
        "terseLabel": "Customer payment term"
       }
      }
     },
     "auth_ref": []
    },
    "cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock",
     "presentation": [
      "http://admabiologics.com/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r857",
      "r883"
     ]
    },
    "cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskBoardOfDirectorsOversightTextBlock",
     "presentation": [
      "http://admabiologics.com/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Board of Directors Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r857",
      "r883"
     ]
    },
    "cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock",
     "presentation": [
      "http://admabiologics.com/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Expertise of Management Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r859",
      "r885"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag",
     "presentation": [
      "http://admabiologics.com/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible [Flag]"
       }
      }
     },
     "auth_ref": [
      "r859",
      "r885"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag",
     "presentation": [
      "http://admabiologics.com/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]"
       }
      }
     },
     "auth_ref": [
      "r861",
      "r887"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock",
     "presentation": [
      "http://admabiologics.com/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r859",
      "r885"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
     "presentation": [
      "http://admabiologics.com/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r852",
      "r878"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesIntegratedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementProcessesIntegratedFlag",
     "presentation": [
      "http://admabiologics.com/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes Integrated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r853",
      "r879"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementProcessesIntegratedTextBlock",
     "presentation": [
      "http://admabiologics.com/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes Integrated [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r853",
      "r879"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Abstract]"
       }
      }
     },
     "auth_ref": [
      "r851",
      "r877"
     ]
    },
    "cyd_CybersecurityRiskManagementThirdPartyEngagedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementThirdPartyEngagedFlag",
     "presentation": [
      "http://admabiologics.com/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Third Party Engaged [Flag]"
       }
      }
     },
     "auth_ref": [
      "r854",
      "r880"
     ]
    },
    "cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag",
     "presentation": [
      "http://admabiologics.com/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]"
       }
      }
     },
     "auth_ref": [
      "r856",
      "r882"
     ]
    },
    "cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock",
     "presentation": [
      "http://admabiologics.com/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r856",
      "r882"
     ]
    },
    "cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock",
     "presentation": [
      "http://admabiologics.com/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r857",
      "r883"
     ]
    },
    "cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock",
     "presentation": [
      "http://admabiologics.com/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r860",
      "r886"
     ]
    },
    "cyd_CybersecurityRiskRoleOfManagementTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskRoleOfManagementTextBlock",
     "presentation": [
      "http://admabiologics.com/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Role of Management [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r858",
      "r884"
     ]
    },
    "cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag",
     "presentation": [
      "http://admabiologics.com/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]"
       }
      }
     },
     "auth_ref": [
      "r855",
      "r881"
     ]
    },
    "us-gaap_DebtDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "NOTES PAYABLE [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "adma_DebtInstrumentApplicableMargin": {
     "xbrltype": "percentItemType",
     "nsuri": "http://admabiologics.com/20241231",
     "localname": "DebtInstrumentApplicableMargin",
     "presentation": [
      "http://admabiologics.com/role/NotesPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage points added to the reference rate to compute the margin rate on the debt instrument.",
        "label": "Debt Instrument Applicable Margin",
        "terseLabel": "Applicable margin"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentAxis",
     "presentation": [
      "http://admabiologics.com/role/NotesPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument [Axis]",
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r64",
      "r65",
      "r126",
      "r128",
      "r238",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r794",
      "r795",
      "r796",
      "r797",
      "r798",
      "r815",
      "r911",
      "r950",
      "r951",
      "r952",
      "r1014",
      "r1016"
     ]
    },
    "us-gaap_DebtInstrumentCarryingAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentCarryingAmount",
     "crdr": "credit",
     "presentation": [
      "http://admabiologics.com/role/NotesPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding principal amount",
        "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r128",
      "r390"
     ]
    },
    "adma_DebtInstrumentExitFee": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://admabiologics.com/20241231",
     "localname": "DebtInstrumentExitFee",
     "crdr": "credit",
     "presentation": [
      "http://admabiologics.com/role/NotesPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses associated with exit fee of debt instrument.",
        "label": "Debt Instrument, Exit Fee",
        "terseLabel": "Exit fee"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentFeeAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentFeeAmount",
     "crdr": "debit",
     "presentation": [
      "http://admabiologics.com/role/NotesPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Incurred fees and expenses",
        "label": "Debt Instrument, Fee Amount",
        "documentation": "Amount of the fee that accompanies borrowing money under the debt instrument."
       }
      }
     },
     "auth_ref": [
      "r68"
     ]
    },
    "adma_DebtInstrumentFloorInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://admabiologics.com/20241231",
     "localname": "DebtInstrumentFloorInterestRate",
     "presentation": [
      "http://admabiologics.com/role/NotesPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage floor rate on debt instrument.",
        "label": "Debt Instrument, Floor Interest Rate",
        "terseLabel": "Percentage of floor interest rate"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentFrequencyOfPeriodicPayment": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentFrequencyOfPeriodicPayment",
     "presentation": [
      "http://admabiologics.com/role/NotesPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Frequency of periodic payment",
        "documentation": "Description of the frequency of periodic payments (monthly, quarterly, annual)."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r60"
     ]
    },
    "adma_DebtInstrumentInterestAmountToBePayInKind": {
     "xbrltype": "percentItemType",
     "nsuri": "http://admabiologics.com/20241231",
     "localname": "DebtInstrumentInterestAmountToBePayInKind",
     "presentation": [
      "http://admabiologics.com/role/NotesPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The interest amount to be pay in kind during the reporting period.",
        "label": "Debt Instrument, Interest Amount to be Pay in Kind",
        "terseLabel": "Percentage of interest amount to pay in kind"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentInterestRateEffectivePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentInterestRateEffectivePercentage",
     "presentation": [
      "http://admabiologics.com/role/NotesPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective interest rate",
        "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium."
       }
      }
     },
     "auth_ref": [
      "r67",
      "r391",
      "r543",
      "r544",
      "r815"
     ]
    },
    "us-gaap_DebtInstrumentInterestRateIncreaseDecrease": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentInterestRateIncreaseDecrease",
     "presentation": [
      "http://admabiologics.com/role/NotesPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase applicable margin",
        "documentation": "Incremental percentage increase (decrease) in the stated rate on a debt instrument."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "presentation": [
      "http://admabiologics.com/role/NotesPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest rate",
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement."
       }
      }
     },
     "auth_ref": [
      "r67",
      "r374"
     ]
    },
    "us-gaap_DebtInstrumentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentLineItems",
     "presentation": [
      "http://admabiologics.com/role/NotesPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument [Line Items]",
        "label": "Debt Instrument [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r238",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r794",
      "r795",
      "r796",
      "r797",
      "r798",
      "r815",
      "r911",
      "r1014",
      "r1016"
     ]
    },
    "us-gaap_DebtInstrumentMaturityDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentMaturityDate",
     "presentation": [
      "http://admabiologics.com/role/NotesPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maturity date",
        "documentation": "Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": [
      "r209",
      "r794",
      "r1010",
      "r1011"
     ]
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentNameDomain",
     "presentation": [
      "http://admabiologics.com/role/NotesPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Name [Domain]",
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r238",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r794",
      "r795",
      "r796",
      "r797",
      "r798",
      "r815",
      "r911",
      "r950",
      "r951",
      "r952",
      "r1014",
      "r1016"
     ]
    },
    "us-gaap_DebtInstrumentPeriodicPaymentInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentPeriodicPaymentInterest",
     "crdr": "debit",
     "presentation": [
      "http://admabiologics.com/role/NotesPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest payments",
        "documentation": "Amount of the required periodic payments applied to interest."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "us-gaap_DebtInstrumentPeriodicPaymentPrincipal": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentPeriodicPaymentPrincipal",
     "crdr": "debit",
     "presentation": [
      "http://admabiologics.com/role/NotesPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scheduled principal payments",
        "documentation": "Amount of the required periodic payments applied to principal."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "us-gaap_DebtInstrumentRedemptionPeriodAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentRedemptionPeriodAxis",
     "presentation": [
      "http://admabiologics.com/role/NotesPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Redemption, Period [Axis]",
        "documentation": "Information by period of debt redemption feature under terms of debt agreement."
       }
      }
     },
     "auth_ref": [
      "r133"
     ]
    },
    "us-gaap_DebtInstrumentRedemptionPeriodDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentRedemptionPeriodDomain",
     "presentation": [
      "http://admabiologics.com/role/NotesPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Redemption, Period [Domain]",
        "documentation": "Period as defined under terms of the debt agreement for debt redemption features."
       }
      }
     },
     "auth_ref": [
      "r133"
     ]
    },
    "us-gaap_DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed",
     "presentation": [
      "http://admabiologics.com/role/NotesPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Percentage of prepaid principal amount",
        "documentation": "Percentage of principal amount of debt redeemed."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentTable",
     "presentation": [
      "http://admabiologics.com/role/NotesPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Long-term Debt Instruments [Table]",
        "documentation": "Disclosure of information about long-term debt instrument or arrangement."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r44",
      "r47",
      "r59",
      "r114",
      "r115",
      "r238",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r794",
      "r795",
      "r796",
      "r797",
      "r798",
      "r815",
      "r911",
      "r1014",
      "r1016"
     ]
    },
    "adma_DebtInstrumentTermOfVariableRate": {
     "xbrltype": "durationItemType",
     "nsuri": "http://admabiologics.com/20241231",
     "localname": "DebtInstrumentTermOfVariableRate",
     "presentation": [
      "http://admabiologics.com/role/NotesPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of the interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Debt Instrument, Term of Variable Rate",
        "terseLabel": "Term of variable rate"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentUnamortizedDiscount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentUnamortizedDiscount",
     "crdr": "debit",
     "calculation": {
      "http://admabiologics.com/role/NotesPayableDetails": {
       "parentTag": "us-gaap_SeniorLongTermNotes",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://admabiologics.com/role/NotesPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less: Debt discount",
        "label": "Debt Instrument, Unamortized Discount",
        "documentation": "Amount, after accumulated amortization, of debt discount."
       }
      }
     },
     "auth_ref": [
      "r964",
      "r1013",
      "r1014",
      "r1016"
     ]
    },
    "us-gaap_DebtInstrumentUnamortizedPremium": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentUnamortizedPremium",
     "crdr": "credit",
     "presentation": [
      "http://admabiologics.com/role/NotesPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Redemption premium",
        "label": "Debt Instrument, Unamortized Premium",
        "documentation": "Amount, after accumulated amortization, of debt premium."
       }
      }
     },
     "auth_ref": [
      "r964",
      "r1013",
      "r1014",
      "r1016"
     ]
    },
    "adma_DebtInstrumentUpfrontFeePaidInKind": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://admabiologics.com/20241231",
     "localname": "DebtInstrumentUpfrontFeePaidInKind",
     "crdr": "credit",
     "presentation": [
      "http://admabiologics.com/role/NotesPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for payment of an upfront fee paid in kind to consortium of lenders under the debt instrument.",
        "label": "Debt Instrument, Upfront Fee, Paid in Kind",
        "terseLabel": "Upfront fee paid in kind"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentsAbstract",
     "presentation": [
      "http://admabiologics.com/role/NotesPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instruments [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredFederalIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://admabiologics.com/role/IncomeTaxesIncomeTaxExpenseBenefitDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://admabiologics.com/role/IncomeTaxesIncomeTaxExpenseBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Federal",
        "label": "Deferred Federal Income Tax Expense (Benefit)",
        "documentation": "Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r913",
      "r1005",
      "r1006"
     ]
    },
    "us-gaap_DeferredIncomeTaxAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredIncomeTaxAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://admabiologics.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://admabiologics.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred tax assets, net",
        "label": "Deferred Income Tax Assets, Net",
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r476",
      "r477"
     ]
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://admabiologics.com/role/IncomeTaxesIncomeTaxExpenseBenefitDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://admabiologics.com/role/IncomeTaxesIncomeTaxExpenseBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total deferred",
        "label": "Deferred Income Tax Expense (Benefit)",
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r149",
      "r913"
     ]
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "presentation": [
      "http://admabiologics.com/role/IncomeTaxesIncomeTaxExpenseBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredIncomeTaxLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredIncomeTaxLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://admabiologics.com/role/IncomeTaxesDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://admabiologics.com/role/IncomeTaxesDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTotalLabel": "Total deferred tax liabilities",
        "label": "Deferred Tax Liabilities, Gross",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences."
       }
      }
     },
     "auth_ref": [
      "r72",
      "r73",
      "r127",
      "r493"
     ]
    },
    "us-gaap_DeferredRevenueNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredRevenueNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://admabiologics.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://admabiologics.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred revenue, net of current portion",
        "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r901"
     ]
    },
    "adma_DeferredRevenueRemainingAmortizationPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://admabiologics.com/20241231",
     "localname": "DeferredRevenueRemainingAmortizationPeriod",
     "presentation": [
      "http://admabiologics.com/role/SignificantAccountingPoliciesRevenueRecognitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Remaining amortization period of deferred revenue, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Amortization period",
        "terseLabel": "Amortization period"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://admabiologics.com/role/IncomeTaxesIncomeTaxExpenseBenefitDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://admabiologics.com/role/IncomeTaxesIncomeTaxExpenseBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "State",
        "label": "Deferred State and Local Income Tax Expense (Benefit)",
        "documentation": "Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r913",
      "r1005",
      "r1006"
     ]
    },
    "us-gaap_DeferredTaxAssetInterestCarryforward": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetInterestCarryforward",
     "crdr": "debit",
     "calculation": {
      "http://admabiologics.com/role/IncomeTaxesDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://admabiologics.com/role/IncomeTaxesDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest expense limitations carryforwards",
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible interest carryforward."
       }
      }
     },
     "auth_ref": [
      "r1003"
     ]
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsGross",
     "crdr": "debit",
     "calculation": {
      "http://admabiologics.com/role/IncomeTaxesDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://admabiologics.com/role/IncomeTaxesDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total gross deferred tax assets",
        "label": "Deferred Tax Assets, Gross",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r494"
     ]
    },
    "us-gaap_DeferredTaxAssetsInventory": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsInventory",
     "crdr": "debit",
     "calculation": {
      "http://admabiologics.com/role/IncomeTaxesDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://admabiologics.com/role/IncomeTaxesDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from inventory."
       }
      }
     },
     "auth_ref": [
      "r1003"
     ]
    },
    "adma_DeferredTaxAssetsLeaseObligations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://admabiologics.com/20241231",
     "localname": "DeferredTaxAssetsLeaseObligations",
     "crdr": "debit",
     "calculation": {
      "http://admabiologics.com/role/IncomeTaxesDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://admabiologics.com/role/IncomeTaxesDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from lease obligation.",
        "label": "Deferred Tax Assets, Lease Obligations",
        "terseLabel": "Lease obligations"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "crdr": "debit",
     "calculation": {
      "http://admabiologics.com/role/IncomeTaxesDeferredTaxAssetsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://admabiologics.com/role/IncomeTaxesDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net deferred tax assets",
        "label": "Deferred Tax Assets, Net",
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r998"
     ]
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://admabiologics.com/role/IncomeTaxesDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://admabiologics.com/role/IncomeTaxesDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total deferred tax assets, net of valuation allowance",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r998"
     ]
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsDomestic",
     "crdr": "debit",
     "calculation": {
      "http://admabiologics.com/role/IncomeTaxesDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://admabiologics.com/role/IncomeTaxesDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Federal and state net operating loss carryforwards",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible domestic operating loss carryforwards. Excludes state and local operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r1003"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "crdr": "debit",
     "calculation": {
      "http://admabiologics.com/role/IncomeTaxesDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://admabiologics.com/role/IncomeTaxesDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation."
       }
      }
     },
     "auth_ref": [
      "r1003"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals",
     "crdr": "debit",
     "calculation": {
      "http://admabiologics.com/role/IncomeTaxesDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://admabiologics.com/role/IncomeTaxesDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued expenses and other",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from reserves and accruals."
       }
      }
     },
     "auth_ref": [
      "r1003"
     ]
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsValuationAllowance",
     "crdr": "credit",
     "calculation": {
      "http://admabiologics.com/role/IncomeTaxesDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://admabiologics.com/role/IncomeTaxesDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less: valuation allowance for deferred tax assets",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized."
       }
      }
     },
     "auth_ref": [
      "r495"
     ]
    },
    "adma_DeferredTaxLiabilitiesDepreciationOfPropertyAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://admabiologics.com/20241231",
     "localname": "DeferredTaxLiabilitiesDepreciationOfPropertyAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://admabiologics.com/role/IncomeTaxesDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://admabiologics.com/role/IncomeTaxesDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from depreciation of property and equipment.",
        "label": "Deferred Tax Liabilities, Depreciation of Property and Equipment",
        "negatedLabel": "Depreciation of property and equipment"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxLiabilitiesOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxLiabilitiesOther",
     "crdr": "credit",
     "calculation": {
      "http://admabiologics.com/role/IncomeTaxesDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://admabiologics.com/role/IncomeTaxesDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Other deferred tax liabilities",
        "label": "Deferred Tax Liabilities, Other",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences classified as other."
       }
      }
     },
     "auth_ref": [
      "r1003"
     ]
    },
    "adma_DeferredTaxLiabilitiesRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://admabiologics.com/20241231",
     "localname": "DeferredTaxLiabilitiesRightOfUseAsset",
     "crdr": "credit",
     "calculation": {
      "http://admabiologics.com/role/IncomeTaxesDeferredTaxAssetsDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://admabiologics.com/role/IncomeTaxesDeferredTaxAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from right-of-use assets.",
        "label": "Deferred Tax Liabilities, Right Of Use Asset",
        "negatedLabel": "Right-of-use assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DefinedContributionPlanEmployerDiscretionaryContributionAmount",
     "crdr": "debit",
     "presentation": [
      "http://admabiologics.com/role/OtherEmployeeBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation expense",
        "documentation": "Amount of discretionary contributions made by an employer to a defined contribution plan."
       }
      }
     },
     "auth_ref": []
    },
    "adma_DepositsAndOtherNoncurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://admabiologics.com/20241231",
     "localname": "DepositsAndOtherNoncurrentAssets",
     "crdr": "debit",
     "calculation": {
      "http://admabiologics.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://admabiologics.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment after one year or beyond the operating cycle, if longer and amount of noncurrent assets classified as other.",
        "label": "Deposits and Other Noncurrent Assets",
        "terseLabel": "Deposits and other assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DepreciationAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DepreciationAndAmortization",
     "crdr": "debit",
     "calculation": {
      "http://admabiologics.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://admabiologics.com/role/ConsolidatedStatementsOfCashFlows",
      "http://admabiologics.com/role/SegmentsSummarizedFinancialInformationBySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Depreciation and amortization expense",
        "label": "Depreciation and amortization",
        "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r37"
     ]
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DepreciationDepletionAndAmortization",
     "crdr": "debit",
     "presentation": [
      "http://admabiologics.com/role/PropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation expense",
        "label": "Depreciation, Depletion and Amortization",
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r269",
      "r281",
      "r298",
      "r785",
      "r786"
     ]
    },
    "adma_DilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmountShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://admabiologics.com/20241231",
     "localname": "DilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmountShares",
     "presentation": [
      "http://admabiologics.com/role/SignificantAccountingPoliciesEarningsLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would have been antidilutive for the period presented.",
        "label": "Potentially dilutive securities not included in computation of diluted net loss per share (in shares)",
        "terseLabel": "Potentially dilutive securities not included in computation of diluted loss per share amount (in shares)"
       }
      }
     },
     "auth_ref": []
    },
    "adma_DirectOwnershipMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://admabiologics.com/20241231",
     "localname": "DirectOwnershipMember",
     "presentation": [
      "http://admabiologics.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Direct owner refers to individuals and entities who directly own shares or are partners in any legal entity.",
        "label": "Direct Ownership [Member]",
        "terseLabel": "Direct [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_DirectorMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "DirectorMember",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Directors [Member]",
        "label": "Director [Member]",
        "documentation": "Person serving on board of directors."
       }
      }
     },
     "auth_ref": [
      "r898",
      "r931",
      "r1061"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://admabiologics.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r849",
      "r850",
      "r863"
     ]
    },
    "dei_DocumentFinStmtErrorCorrectionFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFinStmtErrorCorrectionFlag",
     "presentation": [
      "http://admabiologics.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Financial Statement Error Correction [Flag]",
        "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction."
       }
      }
     },
     "auth_ref": [
      "r849",
      "r850",
      "r863",
      "r868"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://admabiologics.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://admabiologics.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentInformationLineItems",
     "presentation": [
      "http://admabiologics.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentInformationTable",
     "presentation": [
      "http://admabiologics.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Information [Table]",
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://admabiologics.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://admabiologics.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r866"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://admabiologics.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareAbstract",
     "presentation": [
      "http://admabiologics.com/role/SignificantAccountingPoliciesEarningsLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings (Loss) Per Share [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://admabiologics.com/role/ConsolidatedStatementsOfOperations",
      "http://admabiologics.com/role/SignificantAccountingPoliciesEarningsLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "BASIC EARNINGS (LOSS) PER COMMON SHARE (in dollars per share)",
        "terseLabel": "Basic earnings per common shares (in dollars per share)",
        "label": "Earnings Per Share, Basic",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r222",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r259",
      "r261",
      "r263",
      "r264",
      "r265",
      "r268",
      "r512",
      "r515",
      "r529",
      "r530",
      "r607",
      "r626",
      "r778"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://admabiologics.com/role/ConsolidatedStatementsOfOperations",
      "http://admabiologics.com/role/SignificantAccountingPoliciesEarningsLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "DILUTED EARNINGS (LOSS) PER COMMON SHARE (in dollars per share)",
        "terseLabel": "Diluted earnings per common share (in dollars per share)",
        "label": "Earnings Per Share, Diluted",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r222",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r261",
      "r263",
      "r264",
      "r265",
      "r268",
      "r512",
      "r515",
      "r529",
      "r530",
      "r607",
      "r626",
      "r778"
     ]
    },
    "us-gaap_EarningsPerShareDilutedOtherDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareDilutedOtherDisclosuresAbstract",
     "presentation": [
      "http://admabiologics.com/role/SignificantAccountingPoliciesEarningsLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loss Per Share [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerSharePolicyTextBlock",
     "presentation": [
      "http://admabiologics.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings (Loss) Per Share",
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r22",
      "r23",
      "r267"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount",
     "crdr": "debit",
     "calculation": {
      "http://admabiologics.com/role/IncomeTaxesReconciliationOfIncomeTaxesDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://admabiologics.com/role/IncomeTaxesReconciliationOfIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Excess tax benefits related to stock-based compensation",
        "documentation": "Amount of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to expense for award under share-based payment arrangement. Excludes expense determined to be nondeductible upon grant or after for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r891",
      "r995",
      "r996"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrecognized compensation expense recognition period",
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r463"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions",
     "crdr": "debit",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrecognized compensation expense, non option",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount",
        "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r993"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "crdr": "debit",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrecognized compensation expense, stock options",
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r993"
     ]
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://admabiologics.com/role/SignificantAccountingPoliciesEarningsLossPerShareDetails",
      "http://admabiologics.com/role/SignificantAccountingPoliciesStockbasedCompensationDetails",
      "http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Options [Member]",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": []
    },
    "adma_EmployeesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://admabiologics.com/20241231",
     "localname": "EmployeesMember",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A group of person working with the entity.",
        "label": "Employees [Member]",
        "terseLabel": "Employees [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://admabiologics.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://admabiologics.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://admabiologics.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://admabiologics.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://admabiologics.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r847"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://admabiologics.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://admabiologics.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://admabiologics.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r847"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://admabiologics.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://admabiologics.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r847"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://admabiologics.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://admabiologics.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r888"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://admabiologics.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://admabiologics.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r847"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://admabiologics.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r847"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://admabiologics.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r847"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://admabiologics.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r847"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://admabiologics.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://admabiologics.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r889"
     ]
    },
    "adma_EquipmentAcquiredReflectedInAccountsPayableAndAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://admabiologics.com/20241231",
     "localname": "EquipmentAcquiredReflectedInAccountsPayableAndAccruedLiabilities",
     "crdr": "debit",
     "presentation": [
      "http://admabiologics.com/role/SupplementalDisclosureOfCashFlowInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of equipment acquired in a noncash (or part noncash) acquisition and reflected in accounts payable and accrued liabilities.",
        "label": "Equipment Acquired Reflected in Accounts Payable and Accrued Liabilities",
        "terseLabel": "Equipment acquired reflected in accounts payable and accrued liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "STOCKHOLDERS' EQUITY [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://admabiologics.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity",
      "http://admabiologics.com/role/StockholdersEquityCommonStockDetails",
      "http://admabiologics.com/role/StockholdersEquityWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Component [Domain]",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r197",
      "r219",
      "r220",
      "r221",
      "r245",
      "r246",
      "r247",
      "r249",
      "r254",
      "r256",
      "r258",
      "r270",
      "r312",
      "r313",
      "r346",
      "r409",
      "r502",
      "r503",
      "r509",
      "r510",
      "r511",
      "r513",
      "r514",
      "r515",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r528",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r545",
      "r547",
      "r558",
      "r625",
      "r651",
      "r652",
      "r653",
      "r671",
      "r730"
     ]
    },
    "adma_EquityIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://admabiologics.com/20241231",
     "localname": "EquityIncentivePlanMember",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity compensation is often a significant portion of the total compensation paid to employees and other service providers.",
        "label": "Equity Incentive Plans [Member]",
        "terseLabel": "Equity Incentive Plans [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_ExecutiveOfficerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ExecutiveOfficerMember",
     "presentation": [
      "http://admabiologics.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Executive Officer [Member]",
        "label": "Executive Officer [Member]",
        "documentation": "Person with designation of executive officer."
       }
      }
     },
     "auth_ref": [
      "r931"
     ]
    },
    "adma_ExecutiveVicePresidentAndChiefFinancialOfficerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://admabiologics.com/20241231",
     "localname": "ExecutiveVicePresidentAndChiefFinancialOfficerMember",
     "presentation": [
      "http://admabiologics.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Person with designation of executive vice president and chief financial officer.",
        "label": "Executive Vice President and Chief Financial Officer [Member]",
        "terseLabel": "Brian Lenz [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "adma_ExercisePriceRange1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://admabiologics.com/20241231",
     "localname": "ExercisePriceRange1Member",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by range of option prices pertaining to options granted.",
        "label": "Exercise Price Range 1 [Member]",
        "terseLabel": "$1.10 - $1.67 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "adma_ExercisePriceRange2Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://admabiologics.com/20241231",
     "localname": "ExercisePriceRange2Member",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by range of option prices pertaining to options granted.",
        "label": "Exercise Price Range 2 [Member]",
        "terseLabel": "$1.73 - $2.60 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "adma_ExercisePriceRange3Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://admabiologics.com/20241231",
     "localname": "ExercisePriceRange3Member",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by range of option prices pertaining to options granted.",
        "label": "Exercise Price Range 3 [Member]",
        "terseLabel": "$2.67 - $4.01 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "adma_ExercisePriceRange4Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://admabiologics.com/20241231",
     "localname": "ExercisePriceRange4Member",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by range of option prices pertaining to options granted.",
        "label": "Exercise Price Range 4 [Member]",
        "terseLabel": "$4.09 - $6.14 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "adma_ExercisePriceRange5Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://admabiologics.com/20241231",
     "localname": "ExercisePriceRange5Member",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by range of option prices pertaining to options granted.",
        "label": "Exercise Price Range 5 [Member]",
        "terseLabel": "$6.54 - $9.81 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "adma_ExercisePriceRange6Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://admabiologics.com/20241231",
     "localname": "ExercisePriceRange6Member",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by range of option prices pertaining to options granted.",
        "label": "Exercise Price Range 6 [Member]",
        "terseLabel": "$10.80 - $17.49 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "adma_ExitFeeLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://admabiologics.com/20241231",
     "localname": "ExitFeeLiability",
     "crdr": "credit",
     "presentation": [
      "http://admabiologics.com/role/NotesPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of exit fee liability.",
        "label": "Exit Fee Liability",
        "terseLabel": "Exit fee liability"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueAdjustmentOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAdjustmentOfWarrants",
     "crdr": "debit",
     "presentation": [
      "http://admabiologics.com/role/NotesPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair value of warrants",
        "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r4"
     ]
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "presentation": [
      "http://admabiologics.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Fair Value of Financial Instruments",
        "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_FinanceLeasePrincipalPayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinanceLeasePrincipalPayments",
     "crdr": "credit",
     "calculation": {
      "http://admabiologics.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://admabiologics.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Payments on finance lease obligations",
        "label": "Finance Lease, Principal Payments",
        "documentation": "Amount of cash outflow for principal payment on finance lease."
       }
      }
     },
     "auth_ref": [
      "r550",
      "r552"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "crdr": "credit",
     "presentation": [
      "http://admabiologics.com/role/IntangibleAssetsSummaryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated amortization",
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r207",
      "r318",
      "r339",
      "r792"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths",
     "crdr": "debit",
     "presentation": [
      "http://admabiologics.com/role/IntangibleAssetsFutureAggregateAmortizationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2025",
        "label": "Finite-Lived Intangible Assets, Amortization Expense, Next Rolling 12 Months",
        "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized in the next rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour",
     "crdr": "debit",
     "presentation": [
      "http://admabiologics.com/role/IntangibleAssetsFutureAggregateAmortizationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2028",
        "label": "Finite-Lived Intangible Assets, Amortization Expense, Rolling Year Four",
        "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized in the fourth rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree",
     "crdr": "debit",
     "presentation": [
      "http://admabiologics.com/role/IntangibleAssetsFutureAggregateAmortizationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2027",
        "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized in the third rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo",
     "crdr": "debit",
     "presentation": [
      "http://admabiologics.com/role/IntangibleAssetsFutureAggregateAmortizationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2026",
        "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized in the second rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "presentation": [
      "http://admabiologics.com/role/IntangibleAssetsSummaryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite Lived Intangible Assets By Major Class Axis",
        "documentation": "Information by major type or class of finite-lived intangible assets."
       }
      }
     },
     "auth_ref": [
      "r333",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r341",
      "r342",
      "r574",
      "r575",
      "r764"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract",
     "presentation": [
      "http://admabiologics.com/role/IntangibleAssetsFutureAggregateAmortizationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Estimated Aggregate Amortization Expense [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsGross",
     "crdr": "debit",
     "presentation": [
      "http://admabiologics.com/role/IntangibleAssetsSummaryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cost",
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r318",
      "r339",
      "r575",
      "r792"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsLineItems",
     "presentation": [
      "http://admabiologics.com/role/IntangibleAssetsSummaryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r333",
      "r339",
      "r341",
      "r342",
      "r344",
      "r574",
      "r764",
      "r792"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "presentation": [
      "http://admabiologics.com/role/IntangibleAssetsSummaryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company."
       }
      }
     },
     "auth_ref": [
      "r333",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r341",
      "r342",
      "r764"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsNet",
     "crdr": "debit",
     "presentation": [
      "http://admabiologics.com/role/IntangibleAssetsSummaryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net",
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r574",
      "r942"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsNetAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsNetAbstract",
     "presentation": [
      "http://admabiologics.com/role/IntangibleAssetsSummaryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets, Net [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1",
     "presentation": [
      "http://admabiologics.com/role/IntangibleAssetsSummaryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization period",
        "label": "Finite-Lived Intangible Assets, Remaining Amortization Period",
        "documentation": "Remaining amortization period of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r574"
     ]
    },
    "adma_FiveCustomersMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://admabiologics.com/20241231",
     "localname": "FiveCustomersMember",
     "presentation": [
      "http://admabiologics.com/role/ConcentrationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information about number of customers accounting for a percentage of consolidated revenues.",
        "label": "Five Customers [Member]",
        "terseLabel": "Five Customers [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FurnitureAndFixturesMember",
     "presentation": [
      "http://admabiologics.com/role/PropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Furniture and Fixtures [Member]",
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GainLossOnDispositionOfAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GainLossOnDispositionOfAssets",
     "crdr": "credit",
     "calculation": {
      "http://admabiologics.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://admabiologics.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Loss on disposal of fixed assets",
        "label": "Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber Property",
        "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, excluding oil and gas property and timber property."
       }
      }
     },
     "auth_ref": [
      "r908",
      "r947",
      "r948"
     ]
    },
    "us-gaap_GainsLossesOnExtinguishmentOfDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GainsLossesOnExtinguishmentOfDebt",
     "crdr": "credit",
     "calculation": {
      "http://admabiologics.com/role/ConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 2.0
      },
      "http://admabiologics.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://admabiologics.com/role/ConsolidatedStatementsOfCashFlows",
      "http://admabiologics.com/role/ConsolidatedStatementsOfOperations",
      "http://admabiologics.com/role/NotesPayableDetails",
      "http://admabiologics.com/role/SegmentsSummarizedFinancialInformationBySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loss on extinguishment of debt",
        "verboseLabel": "Loss on extinguishment of debt",
        "negatedLabel": "Loss on extinguishment of debt",
        "label": "Loss on extinguishment of debt (see Note 7)",
        "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r40",
      "r41"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "presentation": [
      "http://admabiologics.com/role/SegmentsSummarizedFinancialInformationBySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and administrative expense",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r90",
      "r710"
     ]
    },
    "adma_GenesisBPSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://admabiologics.com/20241231",
     "localname": "GenesisBPSMember",
     "presentation": [
      "http://admabiologics.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the entity associated with related party.",
        "label": "GenesisBPS [Member]",
        "terseLabel": "Genesis [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Goodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Goodwill",
     "crdr": "debit",
     "calculation": {
      "http://admabiologics.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://admabiologics.com/role/ConsolidatedBalanceSheets",
      "http://admabiologics.com/role/SignificantAccountingPoliciesGoodwillDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Goodwill",
        "label": "Goodwill",
        "documentation": "Amount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized."
       }
      }
     },
     "auth_ref": [
      "r206",
      "r320",
      "r606",
      "r786",
      "r791",
      "r809",
      "r817",
      "r935",
      "r936"
     ]
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "INTANGIBLE ASSETS [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GoodwillAndIntangibleAssetsGoodwillPolicy",
     "presentation": [
      "http://admabiologics.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Goodwill",
        "label": "Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined."
       }
      }
     },
     "auth_ref": [
      "r319",
      "r331",
      "r791"
     ]
    },
    "us-gaap_GoodwillImpairedAccumulatedImpairmentLossAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GoodwillImpairedAccumulatedImpairmentLossAbstract",
     "presentation": [
      "http://admabiologics.com/role/SignificantAccountingPoliciesGoodwillDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goodwill [Abstract]",
        "label": "Goodwill, Impaired, Accumulated Impairment Loss [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GoodwillImpairmentLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GoodwillImpairmentLoss",
     "crdr": "debit",
     "presentation": [
      "http://admabiologics.com/role/SignificantAccountingPoliciesGoodwillDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairment charges related to goodwill",
        "label": "Goodwill, Impairment Loss",
        "documentation": "Amount of impairment loss from asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r321",
      "r327",
      "r331",
      "r791",
      "r809"
     ]
    },
    "us-gaap_GrossProfit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GrossProfit",
     "crdr": "credit",
     "calculation": {
      "http://admabiologics.com/role/ConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://admabiologics.com/role/ConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Gross profit",
        "label": "Gross Profit",
        "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity."
       }
      }
     },
     "auth_ref": [
      "r85",
      "r87",
      "r136",
      "r232",
      "r311",
      "r362",
      "r363",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r371",
      "r372",
      "r535",
      "r780",
      "r785",
      "r924",
      "r926",
      "r928",
      "r929",
      "r930",
      "r961"
     ]
    },
    "adma_HayfinClosingDateLoanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://admabiologics.com/20241231",
     "localname": "HayfinClosingDateLoanMember",
     "presentation": [
      "http://admabiologics.com/role/NotesPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount.",
        "label": "Hayfin Closing Date Loan [Member]",
        "terseLabel": "Hayfin Closing Date Loan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "adma_HayfinCreditAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://admabiologics.com/20241231",
     "localname": "HayfinCreditAgreementMember",
     "presentation": [
      "http://admabiologics.com/role/NotesPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A Hayfin credit agreement is a legally-binding contract documenting the terms of a loan agreement; it is made between a person or party borrowing money and a lender.",
        "label": "Hayfin Credit Agreement [Member]",
        "terseLabel": "Hayfin Credit Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "adma_HayfinCreditFacilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://admabiologics.com/20241231",
     "localname": "HayfinCreditFacilityMember",
     "presentation": [
      "http://admabiologics.com/role/NotesPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Arrangement in which facility proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount.",
        "label": "Hayfin Credit Facility [Member]",
        "terseLabel": "Hayfin Credit Facility [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "adma_HayfinDelayedDrawLoanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://admabiologics.com/20241231",
     "localname": "HayfinDelayedDrawLoanMember",
     "presentation": [
      "http://admabiologics.com/role/NotesPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount.",
        "label": "Hayfin Delayed Draw Loan [Member]",
        "terseLabel": "Hayfin Delayed Draw Loan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "adma_HayfinSecondAmendmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://admabiologics.com/20241231",
     "localname": "HayfinSecondAmendmentMember",
     "presentation": [
      "http://admabiologics.com/role/NotesPayableDetails",
      "http://admabiologics.com/role/StockholdersEquityWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Entity entered into second amendment \"Hayfin Second Amendment\" in a debt arrangement.",
        "label": "Hayfin Second Amendment [Member]",
        "terseLabel": "Hayfin Second Amendment [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "adma_HayfinWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://admabiologics.com/20241231",
     "localname": "HayfinWarrantsMember",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "On the hayfin closing date, the Company issued the hayfin warrant.",
        "label": "Hayfin Warrants [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "adma_ITTechnologySystemsInaccessiblePeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://admabiologics.com/20241231",
     "localname": "ITTechnologySystemsInaccessiblePeriod",
     "presentation": [
      "http://admabiologics.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "IT technology systems inaccessible period at the time disruption in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "IT Technology Systems Inaccessible Period",
        "terseLabel": "IT technology systems inaccessible period"
       }
      }
     },
     "auth_ref": []
    },
    "dei_IcfrAuditorAttestationFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "IcfrAuditorAttestationFlag",
     "presentation": [
      "http://admabiologics.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "auth_ref": [
      "r849",
      "r850",
      "r863"
     ]
    },
    "us-gaap_ImpairmentOfLongLivedAssetsHeldForUse": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ImpairmentOfLongLivedAssetsHeldForUse",
     "crdr": "debit",
     "presentation": [
      "http://admabiologics.com/role/SignificantAccountingPoliciesImpairmentOfLonglivedAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairment of long-lived assets",
        "label": "Impairment, Long-Lived Asset, Held-for-Use",
        "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale)."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r36",
      "r109",
      "r808"
     ]
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock",
     "presentation": [
      "http://admabiologics.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Impairment of Long-Lived Assets",
        "documentation": "Disclosure of accounting policy for the impairment and disposal of long-lived assets including goodwill and other intangible assets."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://admabiologics.com/role/ConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://admabiologics.com/role/ConsolidatedStatementsOfOperations",
      "http://admabiologics.com/role/SegmentsSummarizedFinancialInformationBySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "INCOME (LOSS) BEFORE INCOME TAXES",
        "label": "Income (loss) before taxes",
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r86",
      "r131",
      "r136",
      "r608",
      "r623",
      "r780",
      "r785",
      "r924",
      "r926",
      "r928",
      "r929",
      "r930"
     ]
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "CONSOLIDATED STATEMENTS OF OPERATIONS [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Income Location, Balance [Axis]",
        "documentation": "Information by location in statement of income where disaggregated amount has been reported."
       }
      }
     },
     "auth_ref": [
      "r347",
      "r349",
      "r350",
      "r532",
      "r533",
      "r534",
      "r648",
      "r650",
      "r715",
      "r764",
      "r810",
      "r1031"
     ]
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Income Location, Balance [Domain]",
        "documentation": "Location in statement of income where disaggregated amount has been reported."
       }
      }
     },
     "auth_ref": [
      "r349",
      "r350",
      "r532",
      "r533",
      "r534",
      "r648",
      "r650",
      "r715",
      "r764",
      "r810",
      "r1031"
     ]
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxAuthorityAxis",
     "presentation": [
      "http://admabiologics.com/role/IncomeTaxesNetOperatingLossCarryforwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Jurisdiction [Axis]",
        "documentation": "Information by income tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r228",
      "r479",
      "r480",
      "r489",
      "r498",
      "r807",
      "r1002"
     ]
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxAuthorityDomain",
     "presentation": [
      "http://admabiologics.com/role/IncomeTaxesNetOperatingLossCarryforwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Jurisdiction [Domain]",
        "documentation": "Income tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r228",
      "r479",
      "r480",
      "r489",
      "r498",
      "r807",
      "r1002"
     ]
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "INCOME TAXES [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://admabiologics.com/role/IncomeTaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "INCOME TAXES",
        "documentation": "The entire disclosure for income tax."
       }
      }
     },
     "auth_ref": [
      "r233",
      "r472",
      "r479",
      "r486",
      "r487",
      "r488",
      "r491",
      "r497",
      "r504",
      "r506",
      "r507",
      "r508",
      "r667",
      "r807"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://admabiologics.com/role/ConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 1.0
      },
      "http://admabiologics.com/role/IncomeTaxesIncomeTaxExpenseBenefitDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://admabiologics.com/role/IncomeTaxesReconciliationOfIncomeTaxesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://admabiologics.com/role/ConsolidatedStatementsOfOperations",
      "http://admabiologics.com/role/IncomeTaxesIncomeTaxExpenseBenefitDetails",
      "http://admabiologics.com/role/IncomeTaxesReconciliationOfIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income tax benefit",
        "totalLabel": "Total benefit from income taxes",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r138",
      "r150",
      "r257",
      "r258",
      "r269",
      "r284",
      "r298",
      "r478",
      "r479",
      "r505",
      "r628",
      "r807"
     ]
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxPolicyTextBlock",
     "presentation": [
      "http://admabiologics.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Taxes",
        "label": "Income Tax, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements."
       }
      }
     },
     "auth_ref": [
      "r218",
      "r474",
      "r475",
      "r491",
      "r492",
      "r496",
      "r500",
      "r661"
     ]
    },
    "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "crdr": "debit",
     "calculation": {
      "http://admabiologics.com/role/IncomeTaxesReconciliationOfIncomeTaxesDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://admabiologics.com/role/IncomeTaxesReconciliationOfIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in valuation allowance",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r483",
      "r807",
      "r995"
     ]
    },
    "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
     "crdr": "debit",
     "calculation": {
      "http://admabiologics.com/role/IncomeTaxesReconciliationOfIncomeTaxesDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://admabiologics.com/role/IncomeTaxesReconciliationOfIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax provision (benefit) at U.S. Federal statutory rate",
        "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r479",
      "r807"
     ]
    },
    "us-gaap_IncomeTaxReconciliationNondeductibleExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxReconciliationNondeductibleExpense",
     "crdr": "debit",
     "calculation": {
      "http://admabiologics.com/role/IncomeTaxesReconciliationOfIncomeTaxesDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://admabiologics.com/role/IncomeTaxesReconciliationOfIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-deductible executive compensation",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses."
       }
      }
     },
     "auth_ref": [
      "r484",
      "r485",
      "r995"
     ]
    },
    "us-gaap_IncomeTaxReconciliationOtherAdjustments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxReconciliationOtherAdjustments",
     "crdr": "debit",
     "calculation": {
      "http://admabiologics.com/role/IncomeTaxesReconciliationOfIncomeTaxesDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://admabiologics.com/role/IncomeTaxesReconciliationOfIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Other",
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments."
       }
      }
     },
     "auth_ref": [
      "r807",
      "r995",
      "r996"
     ]
    },
    "us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxReconciliationStateAndLocalIncomeTaxes",
     "crdr": "debit",
     "calculation": {
      "http://admabiologics.com/role/IncomeTaxesReconciliationOfIncomeTaxesDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://admabiologics.com/role/IncomeTaxesReconciliationOfIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "State taxes, net of federal benefit",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit)."
       }
      }
     },
     "auth_ref": [
      "r482",
      "r807",
      "r995"
     ]
    },
    "us-gaap_IncomeTaxesPaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxesPaid",
     "crdr": "credit",
     "presentation": [
      "http://admabiologics.com/role/SupplementalDisclosureOfCashFlowInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash paid for income taxes",
        "documentation": "Amount, before refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r99",
      "r909",
      "r1000",
      "r1001"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccountsPayable",
     "crdr": "debit",
     "calculation": {
      "http://admabiologics.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://admabiologics.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accounts payable",
        "label": "Increase (Decrease) in Accounts Payable",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "crdr": "credit",
     "calculation": {
      "http://admabiologics.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://admabiologics.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Accounts receivable",
        "label": "Increase (Decrease) in Accounts Receivable",
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://admabiologics.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 14.0
      }
     },
     "presentation": [
      "http://admabiologics.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued expenses",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_IncreaseDecreaseInDeferredIncomeTaxes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInDeferredIncomeTaxes",
     "crdr": "credit",
     "calculation": {
      "http://admabiologics.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://admabiologics.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Deferred income tax benefit",
        "label": "Increase (Decrease) in Deferred Income Taxes",
        "documentation": "The increase (decrease) during the reporting period in the account that represents the temporary difference that results from Income or Loss that is recognized for accounting purposes but not for tax purposes and vice versa."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "adma_IncreaseDecreaseInDepositsAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://admabiologics.com/20241231",
     "localname": "IncreaseDecreaseInDepositsAndOtherAssets",
     "crdr": "credit",
     "calculation": {
      "http://admabiologics.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://admabiologics.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in deposits and operating assets classified as other.",
        "label": "Increase (Decrease) in Deposits and Other Assets",
        "negatedLabel": "Deposits and other assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInInventories",
     "crdr": "credit",
     "calculation": {
      "http://admabiologics.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://admabiologics.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Inventories",
        "label": "Increase (Decrease) in Inventories",
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://admabiologics.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changes in operating assets and liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOtherOperatingLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://admabiologics.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 15.0
      }
     },
     "presentation": [
      "http://admabiologics.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other current and non-current liabilities",
        "documentation": "Amount of increase (decrease) in operating liabilities classified as other."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "crdr": "credit",
     "calculation": {
      "http://admabiologics.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://admabiologics.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Prepaid expenses and other current assets",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "presentation": [
      "http://admabiologics.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "adma_IncreaseInMinimumAnnualPriceTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://admabiologics.com/20241231",
     "localname": "IncreaseInMinimumAnnualPriceTerm",
     "presentation": [
      "http://admabiologics.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase in annual price term period on usage of RSV Plasma, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Increase in Minimum Annual Price, Term",
        "terseLabel": "Increase in minimum annual price, term"
       }
      }
     },
     "auth_ref": []
    },
    "adma_IndirectOwnershipMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://admabiologics.com/20241231",
     "localname": "IndirectOwnershipMember",
     "presentation": [
      "http://admabiologics.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indirect Ownership means an interest in an entity that has direct or indirect ownership interest in the Applicant. The amount of indirect ownership in the Applicant that is held by any other entity is determined by multiplying the percentage of ownership interest at each level.",
        "label": "Indirect Ownership [Member]",
        "terseLabel": "Indirect [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_IndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "IndividualAxis",
     "presentation": [
      "http://admabiologics.com/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Individual [Axis]"
       }
      }
     },
     "auth_ref": [
      "r862",
      "r864",
      "r865",
      "r867",
      "r869",
      "r870",
      "r873"
     ]
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTradingArrLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Arrangements [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r871"
     ]
    },
    "us-gaap_IntangibleAssetsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IntangibleAssetsDisclosureTextBlock",
     "presentation": [
      "http://admabiologics.com/role/IntangibleAssets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "INTANGIBLE ASSETS",
        "documentation": "The entire disclosure for all or part of the information related to intangible assets."
       }
      }
     },
     "auth_ref": [
      "r332",
      "r343",
      "r345",
      "r763",
      "r764"
     ]
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "crdr": "debit",
     "calculation": {
      "http://admabiologics.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://admabiologics.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intangible assets, net",
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges."
       }
      }
     },
     "auth_ref": [
      "r333",
      "r942",
      "r944"
     ]
    },
    "us-gaap_InterestExpenseNonoperating": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestExpenseNonoperating",
     "crdr": "debit",
     "calculation": {
      "http://admabiologics.com/role/ConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://admabiologics.com/role/ConsolidatedStatementsOfOperations",
      "http://admabiologics.com/role/SegmentsSummarizedFinancialInformationBySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Interest expense",
        "negatedTerseLabel": "Unallocated interest expense, primarily related to interest on senior debt (see Note 7)",
        "label": "Interest Expense, Nonoperating",
        "documentation": "Amount of interest expense classified as nonoperating."
       }
      }
     },
     "auth_ref": [
      "r280",
      "r907"
     ]
    },
    "us-gaap_InterestPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://admabiologics.com/role/SupplementalDisclosureOfCashFlowInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Cash paid for interest",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount."
       }
      }
     },
     "auth_ref": [
      "r223",
      "r226",
      "r227"
     ]
    },
    "us-gaap_InterestPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://admabiologics.com/role/AccruedExpensesAndOtherLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://admabiologics.com/role/AccruedExpensesAndOtherLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued interest",
        "documentation": "Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r65"
     ]
    },
    "us-gaap_InternalRevenueServiceIRSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InternalRevenueServiceIRSMember",
     "presentation": [
      "http://admabiologics.com/role/IncomeTaxesNetOperatingLossCarryforwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Federal [Member]",
        "documentation": "Designated tax department of the United States of America government entitled to levy and collect income taxes from the entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InventoryDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "INVENTORIES [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InventoryDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryDisclosureTextBlock",
     "presentation": [
      "http://admabiologics.com/role/Inventories"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "INVENTORIES",
        "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory."
       }
      }
     },
     "auth_ref": [
      "r314"
     ]
    },
    "us-gaap_InventoryFinishedGoods": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryFinishedGoods",
     "crdr": "debit",
     "calculation": {
      "http://admabiologics.com/role/InventoriesDetails": {
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://admabiologics.com/role/InventoriesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finished goods",
        "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r902"
     ]
    },
    "us-gaap_InventoryNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryNet",
     "crdr": "debit",
     "calculation": {
      "http://admabiologics.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      },
      "http://admabiologics.com/role/InventoriesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://admabiologics.com/role/ConsolidatedBalanceSheets",
      "http://admabiologics.com/role/InventoriesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inventories",
        "totalLabel": "Total inventories",
        "label": "Inventory, Net",
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r214",
      "r771",
      "r817"
     ]
    },
    "us-gaap_InventoryPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryPolicyTextBlock",
     "presentation": [
      "http://admabiologics.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Inventories",
        "label": "Inventory, Policy [Policy Text Block]",
        "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost."
       }
      }
     },
     "auth_ref": [
      "r140",
      "r202",
      "r213",
      "r314",
      "r315",
      "r317",
      "r572",
      "r776"
     ]
    },
    "us-gaap_InventoryRawMaterials": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryRawMaterials",
     "crdr": "debit",
     "calculation": {
      "http://admabiologics.com/role/InventoriesDetails": {
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://admabiologics.com/role/InventoriesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Raw materials",
        "documentation": "Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r904"
     ]
    },
    "us-gaap_InventoryValuationReserveMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryValuationReserveMember",
     "presentation": [
      "http://admabiologics.com/role/ScheduleIiValuationAndQualifyingAccountsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory Valuation Allowance [Member]",
        "documentation": "Reserve to reduce inventory to lower of cost or net realizable value."
       }
      }
     },
     "auth_ref": [
      "r914",
      "r915",
      "r916",
      "r917",
      "r918"
     ]
    },
    "us-gaap_InventoryWorkInProcess": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryWorkInProcess",
     "crdr": "debit",
     "calculation": {
      "http://admabiologics.com/role/InventoriesDetails": {
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://admabiologics.com/role/InventoriesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Work-in-process",
        "documentation": "Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r903"
     ]
    },
    "us-gaap_InventoryWriteDown": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryWriteDown",
     "crdr": "debit",
     "presentation": [
      "http://admabiologics.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non recurring charge of inventory",
        "label": "Inventory Write-down",
        "documentation": "Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels."
       }
      }
     },
     "auth_ref": [
      "r316"
     ]
    },
    "us-gaap_InvestmentIncomeInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestmentIncomeInterest",
     "crdr": "credit",
     "calculation": {
      "http://admabiologics.com/role/ConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://admabiologics.com/role/ConsolidatedStatementsOfOperations",
      "http://admabiologics.com/role/SegmentsSummarizedFinancialInformationBySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest income",
        "terseLabel": "Unallocated interest income",
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities."
       }
      }
     },
     "auth_ref": [
      "r269",
      "r279",
      "r298",
      "r785",
      "r906"
     ]
    },
    "adma_KEDPlasmaAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://admabiologics.com/20241231",
     "localname": "KEDPlasmaAgreementMember",
     "presentation": [
      "http://admabiologics.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plasma Purchase Agreement with KEDPlasma LLC for usage of RSV Plasma.",
        "label": "KEDPlasma Agreement [Member]",
        "terseLabel": "KEDPlasma Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LandMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LandMember",
     "presentation": [
      "http://admabiologics.com/role/PropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Land [Member]",
        "documentation": "Part of earth's surface not covered by water."
       }
      }
     },
     "auth_ref": [
      "r966"
     ]
    },
    "us-gaap_LeaseExpirationDate1": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeaseExpirationDate1",
     "presentation": [
      "http://admabiologics.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease extended maturity date",
        "label": "Lease Expiration Date",
        "documentation": "Date which lease or group of leases is set to expire, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeaseholdImprovementsMember",
     "presentation": [
      "http://admabiologics.com/role/PropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leasehold Improvements [Member]",
        "documentation": "Additions or improvements to assets held under a lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r108",
      "r557"
     ]
    },
    "us-gaap_LeasesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeasesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "LEASE OBLIGATIONS [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "adma_LesseeOperatingLeaseLiabilitiesRelatedToPropertyLease": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://admabiologics.com/20241231",
     "localname": "LesseeOperatingLeaseLiabilitiesRelatedToPropertyLease",
     "crdr": "credit",
     "presentation": [
      "http://admabiologics.com/role/LeaseObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease liability recognized in connection with property lease.",
        "label": "Lessee Operating Lease Liabilities Related to Property Lease",
        "terseLabel": "Lease liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "presentation": [
      "http://admabiologics.com/role/LeaseObligationsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments Under Lease Obligations",
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r1018"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "calculation": {
      "http://admabiologics.com/role/LeaseObligationsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://admabiologics.com/role/LeaseObligationsDetailsCalc01": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://admabiologics.com/role/LeaseObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total payments",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease."
       }
      }
     },
     "auth_ref": [
      "r556"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive",
     "crdr": "credit",
     "calculation": {
      "http://admabiologics.com/role/LeaseObligationsDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://admabiologics.com/role/LeaseObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Thereafter",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r556"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "calculation": {
      "http://admabiologics.com/role/LeaseObligationsDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://admabiologics.com/role/LeaseObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Year ended December 31, 2025",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r556"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "crdr": "credit",
     "calculation": {
      "http://admabiologics.com/role/LeaseObligationsDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://admabiologics.com/role/LeaseObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "2029",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r556"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "crdr": "credit",
     "calculation": {
      "http://admabiologics.com/role/LeaseObligationsDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://admabiologics.com/role/LeaseObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2028",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r556"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "crdr": "credit",
     "calculation": {
      "http://admabiologics.com/role/LeaseObligationsDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://admabiologics.com/role/LeaseObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "2027",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r556"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "calculation": {
      "http://admabiologics.com/role/LeaseObligationsDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://admabiologics.com/role/LeaseObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "2026",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r556"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "calculation": {
      "http://admabiologics.com/role/LeaseObligationsDetailsCalc01": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://admabiologics.com/role/LeaseObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less: imputed interest",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease."
       }
      }
     },
     "auth_ref": [
      "r556"
     ]
    },
    "adma_LesseeOperatingLeaseRightOfUseAssetRelatedToPropertyLease": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://admabiologics.com/20241231",
     "localname": "LesseeOperatingLeaseRightOfUseAssetRelatedToPropertyLease",
     "crdr": "debit",
     "presentation": [
      "http://admabiologics.com/role/LeaseObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right to use assets recognized in connection with property lease.",
        "label": "Lessee, Operating Lease, Right-of-Use Asset Related to Property Lease",
        "terseLabel": "Right-of-use assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeasesTextBlock",
     "presentation": [
      "http://admabiologics.com/role/LeaseObligations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "LEASE OBLIGATIONS",
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r546"
     ]
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://admabiologics.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://admabiologics.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "TOTAL LIABILITIES",
        "label": "Liabilities",
        "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r64",
      "r65",
      "r66",
      "r69",
      "r70",
      "r71",
      "r74",
      "r232",
      "r311",
      "r362",
      "r363",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r371",
      "r372",
      "r518",
      "r519",
      "r520",
      "r535",
      "r685",
      "r779",
      "r845",
      "r961",
      "r1021",
      "r1022"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://admabiologics.com/role/ConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://admabiologics.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY",
        "label": "Liabilities and Equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r81",
      "r130",
      "r618",
      "r817",
      "r912",
      "r934",
      "r1012"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://admabiologics.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "LIABILITIES AND STOCKHOLDERS' EQUITY"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://admabiologics.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://admabiologics.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current liabilities",
        "label": "Liabilities, Current",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r66",
      "r201",
      "r232",
      "r311",
      "r362",
      "r363",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r371",
      "r372",
      "r518",
      "r519",
      "r520",
      "r535",
      "r817",
      "r961",
      "r1021",
      "r1022"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://admabiologics.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LineOfCreditFacilityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LineOfCreditFacilityAxis",
     "presentation": [
      "http://admabiologics.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lender Name [Axis]",
        "documentation": "Information by name of lender, which may be a single entity (for example, but not limited to, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit."
       }
      }
     },
     "auth_ref": [
      "r63",
      "r68",
      "r911",
      "r959",
      "r960"
     ]
    },
    "us-gaap_LineOfCreditFacilityCommitmentFeePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LineOfCreditFacilityCommitmentFeePercentage",
     "presentation": [
      "http://admabiologics.com/role/NotesPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revolving facility percentage",
        "documentation": "The fee, expressed as a percentage of the line of credit facility, for the line of credit facility regardless of whether the facility has been used."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LineOfCreditFacilityLenderDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LineOfCreditFacilityLenderDomain",
     "presentation": [
      "http://admabiologics.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Line of Credit Facility, Lender [Domain]",
        "documentation": "Identification of the lender, which may be a single entity (for example, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit, including a letter of credit facility."
       }
      }
     },
     "auth_ref": [
      "r63",
      "r68",
      "r911",
      "r959"
     ]
    },
    "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacity",
     "crdr": "credit",
     "presentation": [
      "http://admabiologics.com/role/NotesPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate principal amount revolving credit facility",
        "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility."
       }
      }
     },
     "auth_ref": [
      "r63",
      "r68"
     ]
    },
    "us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage",
     "presentation": [
      "http://admabiologics.com/role/NotesPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unused commitment fee",
        "label": "Line of Credit Facility, Unused Capacity, Commitment Fee Percentage",
        "documentation": "The fee, expressed as a percentage of the line of credit facility, for available but unused credit capacity under the credit facility."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://admabiologics.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "adma_LongTermDebtPrepaymentPenalty": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://admabiologics.com/20241231",
     "localname": "LongTermDebtPrepaymentPenalty",
     "crdr": "credit",
     "presentation": [
      "http://admabiologics.com/role/NotesPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of penalty on prepayment of long-term debt.",
        "label": "Long Term Debt, Prepayment Penalty",
        "terseLabel": "Prepayment penalty"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongTermDebtTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongTermDebtTextBlock",
     "presentation": [
      "http://admabiologics.com/role/NotesPayable"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "NOTES PAYABLE",
        "documentation": "The entire disclosure for long-term debt."
       }
      }
     },
     "auth_ref": [
      "r111"
     ]
    },
    "adma_LongTermLiabilityEndOfTermFeePayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://admabiologics.com/20241231",
     "localname": "LongTermLiabilityEndOfTermFeePayable",
     "crdr": "credit",
     "calculation": {
      "http://admabiologics.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://admabiologics.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Principal balance of the loans and any other obligations advanced or otherwise owed.",
        "label": "Long Term Liability, End of Term Fee Payable",
        "terseLabel": "End of term fee"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LossContingenciesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LossContingenciesLineItems",
     "presentation": [
      "http://admabiologics.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contingencies [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r355",
      "r356",
      "r357",
      "r360",
      "r469",
      "r793",
      "r955",
      "r956"
     ]
    },
    "us-gaap_LossContingenciesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LossContingenciesTable",
     "presentation": [
      "http://admabiologics.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loss Contingencies [Table]",
        "documentation": "Disclosure of information about loss contingency. Excludes environmental contingency, warranty, and unconditional purchase obligation."
       }
      }
     },
     "auth_ref": [
      "r355",
      "r356",
      "r357",
      "r360",
      "r469",
      "r793",
      "r955",
      "r956"
     ]
    },
    "srt_MajorCustomersAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MajorCustomersAxis",
     "presentation": [
      "http://admabiologics.com/role/ConcentrationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Customer [Axis]",
        "label": "Customer [Axis]",
        "documentation": "Information by name or description of a single external customer or a group of external customers."
       }
      }
     },
     "auth_ref": [
      "r305",
      "r802",
      "r827",
      "r832",
      "r965",
      "r1030",
      "r1032",
      "r1033",
      "r1035",
      "r1036",
      "r1037",
      "r1038",
      "r1039",
      "r1040",
      "r1041",
      "r1042",
      "r1043",
      "r1044",
      "r1045",
      "r1046",
      "r1047",
      "r1048",
      "r1049",
      "r1050",
      "r1051",
      "r1052",
      "r1053",
      "r1054",
      "r1055",
      "r1056",
      "r1057",
      "r1058",
      "r1059"
     ]
    },
    "us-gaap_ManufacturingFacilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ManufacturingFacilityMember",
     "presentation": [
      "http://admabiologics.com/role/PropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Manufacturing and Laboratory Equipment [Member]",
        "documentation": "Structure used in the manufacturing of goods."
       }
      }
     },
     "auth_ref": [
      "r108"
     ]
    },
    "us-gaap_MarketingAndAdvertisingExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MarketingAndAdvertisingExpense",
     "crdr": "debit",
     "presentation": [
      "http://admabiologics.com/role/SignificantAccountingPoliciesAdvertisingAndMarketingExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Advertising and marketing expenses",
        "label": "Marketing and Advertising Expense",
        "documentation": "The total expense recognized in the period for promotion, public relations, and brand or product advertising."
       }
      }
     },
     "auth_ref": [
      "r90"
     ]
    },
    "us-gaap_MarketingAndAdvertisingExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MarketingAndAdvertisingExpenseAbstract",
     "presentation": [
      "http://admabiologics.com/role/SignificantAccountingPoliciesAdvertisingAndMarketingExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Advertising and Marketing Expenses [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MaterialReconcilingItemsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MaterialReconcilingItemsMember",
     "presentation": [
      "http://admabiologics.com/role/SegmentsNetRevenuesAccordingToGeographicAreaDetails",
      "http://admabiologics.com/role/SegmentsSummarizedFinancialInformationBySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reconciling Item [Member]",
        "documentation": "Items used in reconciling reportable segments' amounts to consolidated amount. Excludes corporate-level activity."
       }
      }
     },
     "auth_ref": [
      "r293",
      "r296",
      "r299",
      "r785",
      "r786"
     ]
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MaximumMember",
     "presentation": [
      "http://admabiologics.com/role/CommitmentsAndContingenciesDetails",
      "http://admabiologics.com/role/IncomeTaxesNetOperatingLossCarryforwardsDetails",
      "http://admabiologics.com/role/NotesPayableDetails",
      "http://admabiologics.com/role/RelatedPartyTransactionsDetails",
      "http://admabiologics.com/role/SignificantAccountingPoliciesPropertyAndEquipmentDetails",
      "http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "documentation": "Upper limit of the provided range."
       }
      }
     },
     "auth_ref": [
      "r158",
      "r160",
      "r162",
      "r163",
      "r165",
      "r195",
      "r196",
      "r356",
      "r357",
      "r358",
      "r359",
      "r429",
      "r469",
      "r531",
      "r571",
      "r647",
      "r649",
      "r656",
      "r677",
      "r678",
      "r738",
      "r740",
      "r742",
      "r743",
      "r745",
      "r761",
      "r762",
      "r790",
      "r799",
      "r804",
      "r811",
      "r812",
      "r813",
      "r814",
      "r828",
      "r963",
      "r1023",
      "r1024",
      "r1025",
      "r1026",
      "r1027",
      "r1028"
     ]
    },
    "adma_MinimumLiquidityCovenantsCreditFacilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://admabiologics.com/20241231",
     "localname": "MinimumLiquidityCovenantsCreditFacilities",
     "crdr": "debit",
     "presentation": [
      "http://admabiologics.com/role/NotesPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The carrying amount of minimum liquidity requirements required to be maintained by the borrower per the Company's credit facilities covenants under the loan agreement that are not restricted as to withdrawal or usage.",
        "label": "Minimum Liquidity Covenants, Credit Facilities",
        "terseLabel": "Minimum liquidity covenant"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MinimumMember",
     "presentation": [
      "http://admabiologics.com/role/CommitmentsAndContingenciesDetails",
      "http://admabiologics.com/role/IncomeTaxesNetOperatingLossCarryforwardsDetails",
      "http://admabiologics.com/role/NotesPayableDetails",
      "http://admabiologics.com/role/RelatedPartyTransactionsDetails",
      "http://admabiologics.com/role/SignificantAccountingPoliciesPropertyAndEquipmentDetails",
      "http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "documentation": "Lower limit of the provided range."
       }
      }
     },
     "auth_ref": [
      "r158",
      "r160",
      "r162",
      "r163",
      "r165",
      "r195",
      "r196",
      "r356",
      "r357",
      "r358",
      "r359",
      "r429",
      "r469",
      "r531",
      "r571",
      "r647",
      "r649",
      "r656",
      "r677",
      "r678",
      "r738",
      "r740",
      "r742",
      "r743",
      "r745",
      "r761",
      "r762",
      "r790",
      "r799",
      "r804",
      "r811",
      "r812",
      "r813",
      "r828",
      "r963",
      "r1023",
      "r1024",
      "r1025",
      "r1026",
      "r1027",
      "r1028"
     ]
    },
    "adma_MinimumPercentageOfCommonStockHeldByLender": {
     "xbrltype": "percentItemType",
     "nsuri": "http://admabiologics.com/20241231",
     "localname": "MinimumPercentageOfCommonStockHeldByLender",
     "presentation": [
      "http://admabiologics.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum percentage of common stock held by lender and administrative agent of credit facility.",
        "label": "Minimum Percentage of Common Stock held by Lender",
        "terseLabel": "Minimum percentage of common stock held by lender"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MovementInValuationAllowancesAndReservesRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MovementInValuationAllowancesAndReservesRollForward",
     "presentation": [
      "http://admabiologics.com/role/ScheduleIiValuationAndQualifyingAccountsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Valuation and Qualifying Accounts [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_MtrlTermsOfTrdArrTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MtrlTermsOfTrdArrTextBlock",
     "presentation": [
      "http://admabiologics.com/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Material Terms of Trading Arrangement",
        "label": "Material Terms of Trading Arrangement [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r872"
     ]
    },
    "srt_NameOfMajorCustomerDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "NameOfMajorCustomerDomain",
     "presentation": [
      "http://admabiologics.com/role/ConcentrationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Domain]",
        "documentation": "Single external customer or group of external customers."
       }
      }
     },
     "auth_ref": [
      "r305",
      "r802",
      "r827",
      "r832",
      "r965",
      "r1030",
      "r1032",
      "r1033",
      "r1035",
      "r1036",
      "r1037",
      "r1038",
      "r1039",
      "r1040",
      "r1041",
      "r1042",
      "r1043",
      "r1044",
      "r1045",
      "r1046",
      "r1047",
      "r1048",
      "r1049",
      "r1050",
      "r1051",
      "r1052",
      "r1053",
      "r1054",
      "r1055",
      "r1056",
      "r1057",
      "r1058",
      "r1059"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://admabiologics.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://admabiologics.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash (used in) provided by financing activities",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r225"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://admabiologics.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "CASH FLOWS FROM FINANCING ACTIVITIES:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://admabiologics.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://admabiologics.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in investing activities",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r225"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://admabiologics.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "CASH FLOWS FROM INVESTING ACTIVITIES:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://admabiologics.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://admabiologics.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by (used in) operating activities",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r97",
      "r98",
      "r100"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://admabiologics.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "CASH FLOWS FROM OPERATING ACTIVITIES:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://admabiologics.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 0.0
      },
      "http://admabiologics.com/role/ConsolidatedStatementsOfOperations": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://admabiologics.com/role/ConsolidatedStatementsOfCashFlows",
      "http://admabiologics.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity",
      "http://admabiologics.com/role/ConsolidatedStatementsOfOperations",
      "http://admabiologics.com/role/SignificantAccountingPoliciesEarningsLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net income (loss)",
        "totalLabel": "NET INCOME (LOSS)",
        "verboseLabel": "Net income available to common stockholders (numerator)",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r88",
      "r100",
      "r132",
      "r199",
      "r216",
      "r217",
      "r221",
      "r232",
      "r248",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r257",
      "r258",
      "r262",
      "r311",
      "r362",
      "r363",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r371",
      "r372",
      "r512",
      "r515",
      "r530",
      "r535",
      "r624",
      "r708",
      "r728",
      "r729",
      "r843",
      "r961"
     ]
    },
    "adma_NetOperatingLossCarryforwardsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://admabiologics.com/20241231",
     "localname": "NetOperatingLossCarryforwardsAbstract",
     "presentation": [
      "http://admabiologics.com/role/IncomeTaxesNetOperatingLossCarryforwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Operating Loss Carryforwards [Abstract]",
        "terseLabel": "Net Operating Loss Carryforwards [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://admabiologics.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Recent Accounting Pronouncements",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://admabiologics.com/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted",
        "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r872"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://admabiologics.com/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated",
        "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r872"
     ]
    },
    "us-gaap_NonUsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NonUsMember",
     "presentation": [
      "http://admabiologics.com/role/SegmentsNetRevenuesAccordingToGeographicAreaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "International [Member]",
        "documentation": "Countries excluding the United States of America (US)."
       }
      }
     },
     "auth_ref": [
      "r1065",
      "r1066",
      "r1067",
      "r1068"
     ]
    },
    "us-gaap_NoncashInvestingAndFinancingItemsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NoncashInvestingAndFinancingItemsAbstract",
     "presentation": [
      "http://admabiologics.com/role/SupplementalDisclosureOfCashFlowInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Noncash Financing and Investing Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://admabiologics.com/role/ConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://admabiologics.com/role/ConsolidatedStatementsOfOperations",
      "http://admabiologics.com/role/SegmentsSummarizedFinancialInformationBySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Other expense, net",
        "label": "Other expense, net",
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)."
       }
      }
     },
     "auth_ref": [
      "r91"
     ]
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NonoperatingIncomeExpenseAbstract",
     "presentation": [
      "http://admabiologics.com/role/ConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "OTHER INCOME (EXPENSE):"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NotesPayableAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NotesPayableAbstract",
     "presentation": [
      "http://admabiologics.com/role/NotesPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Senior Notes Payable [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "adma_NumberOfBatchesInProductionAtTheTimeOfDisruption": {
     "xbrltype": "integerItemType",
     "nsuri": "http://admabiologics.com/20241231",
     "localname": "NumberOfBatchesInProductionAtTheTimeOfDisruption",
     "presentation": [
      "http://admabiologics.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of batches that were in production at the time of disruption.",
        "label": "Number of Batches in Production at the Time of Disruption",
        "terseLabel": "Number of batches in production at the time of disruption"
       }
      }
     },
     "auth_ref": []
    },
    "adma_NumberOfBusinessDays": {
     "xbrltype": "durationItemType",
     "nsuri": "http://admabiologics.com/20241231",
     "localname": "NumberOfBusinessDays",
     "presentation": [
      "http://admabiologics.com/role/NotesPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of business days, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Number of Business Days",
        "terseLabel": "Number of business days"
       }
      }
     },
     "auth_ref": []
    },
    "adma_NumberOfBusinessDaysForPriorWrittenNoticeToPrepayOutstandingPrincipal": {
     "xbrltype": "durationItemType",
     "nsuri": "http://admabiologics.com/20241231",
     "localname": "NumberOfBusinessDaysForPriorWrittenNoticeToPrepayOutstandingPrincipal",
     "presentation": [
      "http://admabiologics.com/role/NotesPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of business days for prior written notice to pay outstanding principal loans, Number of business days, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Number of Business Days for Prior Written Notice to Prepay Outstanding Principal",
        "terseLabel": "Number of business days for prior written notice"
       }
      }
     },
     "auth_ref": []
    },
    "adma_NumberOfCustomers": {
     "xbrltype": "integerItemType",
     "nsuri": "http://admabiologics.com/20241231",
     "localname": "NumberOfCustomers",
     "presentation": [
      "http://admabiologics.com/role/ConcentrationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of major customers of the organization.",
        "label": "Number of Customers",
        "terseLabel": "Number of customers"
       }
      }
     },
     "auth_ref": []
    },
    "adma_NumberOfExecutiveOfficers": {
     "xbrltype": "integerItemType",
     "nsuri": "http://admabiologics.com/20241231",
     "localname": "NumberOfExecutiveOfficers",
     "presentation": [
      "http://admabiologics.com/role/SignificantAccountingPoliciesStockbasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The milestone-based equity awards which were awarded to number of executive officers.",
        "label": "Number of Executive Officers",
        "terseLabel": "Number of executive officers"
       }
      }
     },
     "auth_ref": []
    },
    "adma_NumberOfExecutiveOfficersThatExercisedOptions": {
     "xbrltype": "integerItemType",
     "nsuri": "http://admabiologics.com/20241231",
     "localname": "NumberOfExecutiveOfficersThatExercisedOptions",
     "presentation": [
      "http://admabiologics.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of executive officers who have exercised options to purchase shares.",
        "label": "Number of Executive Officers that Exercised Options",
        "terseLabel": "Number of executive officers that exercised options"
       }
      }
     },
     "auth_ref": []
    },
    "adma_NumberOfFDAApprovedProduct": {
     "xbrltype": "integerItemType",
     "nsuri": "http://admabiologics.com/20241231",
     "localname": "NumberOfFDAApprovedProduct",
     "presentation": [
      "http://admabiologics.com/role/OrganizationAndBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of products approved by FDA.",
        "label": "Number of FDA Approved Product",
        "terseLabel": "Number of FDA approved product"
       }
      }
     },
     "auth_ref": []
    },
    "adma_NumberOfFDALicensedPlasmaCollectionFacilities": {
     "xbrltype": "integerItemType",
     "nsuri": "http://admabiologics.com/20241231",
     "localname": "NumberOfFDALicensedPlasmaCollectionFacilities",
     "presentation": [
      "http://admabiologics.com/role/OrganizationAndBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of plasma collection facilities having FDA license.",
        "label": "Number of FDA-Licensed Plasma Collection Facilities",
        "terseLabel": "Number of FDA-licensed plasma collection facilities"
       }
      }
     },
     "auth_ref": []
    },
    "adma_NumberOfIndividualsThatReceivedModificationsToTheirOutstandingStockOptionAndRSUAwards": {
     "xbrltype": "integerItemType",
     "nsuri": "http://admabiologics.com/20241231",
     "localname": "NumberOfIndividualsThatReceivedModificationsToTheirOutstandingStockOptionAndRSUAwards",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of employees that received stock option and restricted stock units modifications during the year.",
        "label": "Number of Individuals That Received Modifications To Their Outstanding Stock Option and RSU Awards",
        "terseLabel": "Number of individuals that received modifications to stock option and RSU awards"
       }
      }
     },
     "auth_ref": []
    },
    "adma_NumberOfNewPropertyLeases": {
     "xbrltype": "integerItemType",
     "nsuri": "http://admabiologics.com/20241231",
     "localname": "NumberOfNewPropertyLeases",
     "presentation": [
      "http://admabiologics.com/role/LeaseObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new property leases related to additional plasma collection facilities.",
        "label": "Number of New Property Leases",
        "terseLabel": "Number of new property leases"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NumberOfOperatingSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NumberOfOperatingSegments",
     "presentation": [
      "http://admabiologics.com/role/SegmentsSummarizedFinancialInformationBySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of operating segments",
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues."
       }
      }
     },
     "auth_ref": [
      "r786",
      "r925"
     ]
    },
    "adma_NumberOfPlasmaCollectionFacilities": {
     "xbrltype": "integerItemType",
     "nsuri": "http://admabiologics.com/20241231",
     "localname": "NumberOfPlasmaCollectionFacilities",
     "presentation": [
      "http://admabiologics.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of wholly-owned plasma collection facilities of the entity.",
        "label": "Number of Plasma Collection Facilities",
        "terseLabel": "Number of plasma collection facilities"
       }
      }
     },
     "auth_ref": []
    },
    "adma_NumberOfPlasmaCollectionFacilitiesUnderDevelopment": {
     "xbrltype": "integerItemType",
     "nsuri": "http://admabiologics.com/20241231",
     "localname": "NumberOfPlasmaCollectionFacilitiesUnderDevelopment",
     "presentation": [
      "http://admabiologics.com/role/SegmentsSummarizedFinancialInformationBySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of plasma collection facilities under various stages of development.",
        "label": "Number of Plasma Collection Facilities Under Development",
        "terseLabel": "Number of plasma collection facilities under development"
       }
      }
     },
     "auth_ref": []
    },
    "adma_NumberOfRenewalTerms": {
     "xbrltype": "integerItemType",
     "nsuri": "http://admabiologics.com/20241231",
     "localname": "NumberOfRenewalTerms",
     "presentation": [
      "http://admabiologics.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of renewal terms to extend purchase agreement, if agreed to by the parties.",
        "label": "Number of Renewal Terms",
        "terseLabel": "Number of renewal terms"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OfficeEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OfficeEquipmentMember",
     "presentation": [
      "http://admabiologics.com/role/PropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Office Equipment and Computer Software [Member]",
        "documentation": "Tangible personal property used in an office setting. Examples include, but are not limited to, computers, copiers and fax machine."
       }
      }
     },
     "auth_ref": []
    },
    "adma_OperatingAndFinancingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://admabiologics.com/20241231",
     "localname": "OperatingAndFinancingLeaseLiability",
     "crdr": "credit",
     "presentation": [
      "http://admabiologics.com/role/LeaseObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating and finance leases.",
        "label": "Operating and Financing Lease, Liability",
        "terseLabel": "Operating and financing lease liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingCostsAndExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingCostsAndExpenses",
     "crdr": "debit",
     "presentation": [
      "http://admabiologics.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Rent expense",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Excludes Selling, General and Administrative Expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingExpenseMember",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plasma Center Operating Expenses [Member]",
        "documentation": "Primary financial statement caption encompassing expenses associated with normal operations."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "calculation": {
      "http://admabiologics.com/role/ConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://admabiologics.com/role/ConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total operating expenses",
        "label": "Operating Expenses",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://admabiologics.com/role/ConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://admabiologics.com/role/ConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "INCOME (LOSS) FROM OPERATIONS",
        "label": "Operating Income (Loss)",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r136",
      "r780",
      "r924",
      "r926",
      "r928",
      "r929",
      "r930"
     ]
    },
    "us-gaap_OperatingLeaseExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseExpense",
     "crdr": "debit",
     "presentation": [
      "http://admabiologics.com/role/LeaseObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Aggregate lease expense",
        "label": "Operating Lease, Expense",
        "documentation": "Amount of operating lease expense. Excludes sublease income."
       }
      }
     },
     "auth_ref": [
      "r1017"
     ]
    },
    "adma_OperatingLeaseIncrementalBorrowingRatePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://admabiologics.com/20241231",
     "localname": "OperatingLeaseIncrementalBorrowingRatePercent",
     "presentation": [
      "http://admabiologics.com/role/LeaseObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average incremental borrowing rate for operating lease calculated at point in time.",
        "label": "Operating Lease Incremental Borrowing Rate Percent",
        "terseLabel": "Incremental borrowing rate"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract",
     "presentation": [
      "http://admabiologics.com/role/LeaseObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments Under Lease Obligations [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://admabiologics.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      },
      "http://admabiologics.com/role/LeaseObligationsDetailsCalc01": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://admabiologics.com/role/ConsolidatedBalanceSheets",
      "http://admabiologics.com/role/LeaseObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current portion of lease obligations",
        "negatedLabel": "Current portion",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r549"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://admabiologics.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 3.0
      },
      "http://admabiologics.com/role/LeaseObligationsDetailsCalc01": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://admabiologics.com/role/ConsolidatedBalanceSheets",
      "http://admabiologics.com/role/LeaseObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Balance at December 31, 2024",
        "label": "Lease obligations, net of current portion",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r549"
     ]
    },
    "us-gaap_OperatingLeasePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeasePayments",
     "crdr": "credit",
     "presentation": [
      "http://admabiologics.com/role/LeaseObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash payments for lease",
        "label": "Operating Lease, Payments",
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use."
       }
      }
     },
     "auth_ref": [
      "r551",
      "r552"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://admabiologics.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://admabiologics.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Right-of-use assets",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r548"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "presentation": [
      "http://admabiologics.com/role/LeaseObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average discount rate",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "documentation": "Weighted average discount rate for operating lease calculated at point in time."
       }
      }
     },
     "auth_ref": [
      "r555",
      "r816"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "presentation": [
      "http://admabiologics.com/role/LeaseObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average remaining term",
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r554",
      "r816"
     ]
    },
    "us-gaap_OperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLossCarryforwards",
     "crdr": "debit",
     "presentation": [
      "http://admabiologics.com/role/IncomeTaxesNetOperatingLossCarryforwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net operating loss carryforwards",
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r499"
     ]
    },
    "us-gaap_OperatingLossCarryforwardsExpirationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLossCarryforwardsExpirationDate",
     "presentation": [
      "http://admabiologics.com/role/IncomeTaxesNetOperatingLossCarryforwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net operating loss carryforwards, expiration",
        "documentation": "Expiration date of each operating loss carryforward included in operating loss carryforward, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": [
      "r499"
     ]
    },
    "us-gaap_OperatingLossCarryforwardsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLossCarryforwardsLineItems",
     "presentation": [
      "http://admabiologics.com/role/IncomeTaxesNetOperatingLossCarryforwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Loss Carryforwards [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r499"
     ]
    },
    "us-gaap_OperatingLossCarryforwardsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLossCarryforwardsTable",
     "presentation": [
      "http://admabiologics.com/role/IncomeTaxesNetOperatingLossCarryforwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Loss Carryforwards [Table]",
        "documentation": "Disclosure of information about operating loss carryforward. Includes, but is not limited to, tax authority, amount and expiration date of operating loss carryforward, and likelihood of utilization."
       }
      }
     },
     "auth_ref": [
      "r499"
     ]
    },
    "us-gaap_OperatingSegmentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingSegmentsMember",
     "presentation": [
      "http://admabiologics.com/role/SegmentsNetRevenuesAccordingToGeographicAreaDetails",
      "http://admabiologics.com/role/SegmentsSummarizedFinancialInformationBySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Segments [Member]",
        "documentation": "Identifies components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity."
       }
      }
     },
     "auth_ref": [
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r299",
      "r785",
      "r786"
     ]
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "ORGANIZATION AND BUSINESS [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "presentation": [
      "http://admabiologics.com/role/OrganizationAndBusiness"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ORGANIZATION AND BUSINESS",
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure."
       }
      }
     },
     "auth_ref": [
      "r61",
      "r123",
      "r658",
      "r659"
     ]
    },
    "us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock",
     "presentation": [
      "http://admabiologics.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Principles of Consolidation and Basis of Presentation",
        "documentation": "The entire disclosure for the general note to the financial statements for the reporting entity which may include, descriptions of the basis of presentation, business description, significant accounting policies, consolidations, reclassifications, new pronouncements not yet adopted and changes in accounting principles."
       }
      }
     },
     "auth_ref": [
      "r101",
      "r102",
      "r103",
      "r123"
     ]
    },
    "adma_OriginalDiscountPayableCreditFacility": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://admabiologics.com/20241231",
     "localname": "OriginalDiscountPayableCreditFacility",
     "crdr": "debit",
     "presentation": [
      "http://admabiologics.com/role/NotesPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount represent the original discount payable in related transaction in credit facility.",
        "label": "Original Discount Payable, Credit Facility",
        "terseLabel": "Original discount payable"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://admabiologics.com/role/AccruedExpensesAndOtherLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://admabiologics.com/role/AccruedExpensesAndOtherLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other",
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r65"
     ]
    },
    "us-gaap_OtherCostAndExpenseOperating": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherCostAndExpenseOperating",
     "crdr": "debit",
     "calculation": {
      "http://admabiologics.com/role/ConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://admabiologics.com/role/CommitmentsAndContingenciesDetails",
      "http://admabiologics.com/role/ConsolidatedStatementsOfOperations",
      "http://admabiologics.com/role/SegmentsSummarizedFinancialInformationBySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impact of operating expenses",
        "label": "Plasma center operating expenses",
        "documentation": "The total amount of other operating cost and expense items that are associated with the entity's normal revenue producing operation."
       }
      }
     },
     "auth_ref": [
      "r89",
      "r627",
      "r785"
     ]
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherLiabilitiesNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://admabiologics.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://admabiologics.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other non-current liabilities",
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r70"
     ]
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherNonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://admabiologics.com/role/ConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://admabiologics.com/role/ConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other expense",
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r93"
     ]
    },
    "adma_OtherOperatingExpensesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://admabiologics.com/20241231",
     "localname": "OtherOperatingExpensesPolicyTextBlock",
     "presentation": [
      "http://admabiologics.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for other operating expenses related to plasma center.",
        "label": "Other Operating Expenses [Policy Text Block]",
        "terseLabel": "Plasma Center Operating Expenses"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OverAllotmentOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OverAllotmentOptionMember",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Underwritten Public Offering [Member]",
        "documentation": "Right given to the underwriter to sell additional shares over the initial allotment."
       }
      }
     },
     "auth_ref": []
    },
    "srt_OwnershipAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "OwnershipAxis",
     "presentation": [
      "http://admabiologics.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ownership [Axis]",
        "documentation": "Information by name of entity in which ownership interest is disclosed. Excludes equity method investee and named security investment."
       }
      }
     },
     "auth_ref": []
    },
    "srt_OwnershipDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "OwnershipDomain",
     "presentation": [
      "http://admabiologics.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ownership [Domain]",
        "documentation": "Name of entity in which ownership interest is disclosed. Excludes equity method investee and named security investment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaidInKindInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaidInKindInterest",
     "crdr": "debit",
     "calculation": {
      "http://admabiologics.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://admabiologics.com/role/ConsolidatedStatementsOfCashFlows",
      "http://admabiologics.com/role/NotesPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest paid-in-kind",
        "label": "Interest paid in kind",
        "documentation": "Interest paid other than in cash for example by issuing additional debt securities. As a noncash item, it is added to net income when calculating cash provided by or used in operations using the indirect method."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PayablesAndAccrualsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "ACCRUED EXPENSES AND OTHER LIABILITIES [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "adma_PaymentOfDebtRefinancingFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://admabiologics.com/20241231",
     "localname": "PaymentOfDebtRefinancingFees",
     "crdr": "credit",
     "calculation": {
      "http://admabiologics.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://admabiologics.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for payment of debt refinancing fees.",
        "label": "Payment of debt refinancing fees",
        "negatedLabel": "Prepayment penalties on repayment of debt"
       }
      }
     },
     "auth_ref": []
    },
    "adma_PaymentOfEndOfTermFee": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://admabiologics.com/20241231",
     "localname": "PaymentOfEndOfTermFee",
     "crdr": "credit",
     "calculation": {
      "http://admabiologics.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://admabiologics.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for end of term fee.",
        "label": "Payment of End of Term Fee",
        "negatedLabel": "Payment of end of term fee"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsOfDebtIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsOfDebtIssuanceCosts",
     "crdr": "credit",
     "presentation": [
      "http://admabiologics.com/role/NotesPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Payment for certain fees and expenses",
        "label": "Payments of Debt Issuance Costs",
        "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    },
    "us-gaap_PaymentsOfFinancingCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsOfFinancingCosts",
     "crdr": "credit",
     "calculation": {
      "http://admabiologics.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://admabiologics.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Payment of deferred financing fees",
        "label": "Payments of Financing Costs",
        "documentation": "The cash outflow for loan and debt issuance costs."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "us-gaap_PaymentsToAcquireIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquireIntangibleAssets",
     "crdr": "credit",
     "calculation": {
      "http://admabiologics.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://admabiologics.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Acquisition of intangible assets",
        "label": "Payments to Acquire Intangible Assets",
        "documentation": "The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill."
       }
      }
     },
     "auth_ref": [
      "r95"
     ]
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://admabiologics.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://admabiologics.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchase of property and equipment",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r95"
     ]
    },
    "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
     "presentation": [
      "http://admabiologics.com/role/OtherEmployeeBenefits"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "OTHER EMPLOYEE BENEFITS",
        "label": "Retirement Benefits [Text Block]",
        "documentation": "The entire disclosure for retirement benefits."
       }
      }
     },
     "auth_ref": [
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r803"
     ]
    },
    "adma_PercentageOfExitFeeOfOutstandingPrincipalAmountBeingPaid": {
     "xbrltype": "percentItemType",
     "nsuri": "http://admabiologics.com/20241231",
     "localname": "PercentageOfExitFeeOfOutstandingPrincipalAmountBeingPaid",
     "presentation": [
      "http://admabiologics.com/role/NotesPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage of exit fee on outstanding principal amount being paid.",
        "label": "Percentage of Exit Fee of Outstanding Principal Amount being Paid",
        "terseLabel": "Percentage of exit fee on outstanding principal amount being paid"
       }
      }
     },
     "auth_ref": []
    },
    "adma_PerceptiveCreditHoldingsIILPMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://admabiologics.com/20241231",
     "localname": "PerceptiveCreditHoldingsIILPMember",
     "presentation": [
      "http://admabiologics.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Lender in credit facility agreement.",
        "label": "Perceptive Credit Holdings II, LP [Member]",
        "terseLabel": "Perceptive [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Axis]",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r967",
      "r968",
      "r969",
      "r970",
      "r971",
      "r972",
      "r973",
      "r974",
      "r975",
      "r976",
      "r977",
      "r978",
      "r979",
      "r980",
      "r981",
      "r982",
      "r983",
      "r984",
      "r985",
      "r986",
      "r987",
      "r988",
      "r989",
      "r990",
      "r991",
      "r992"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Domain]",
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r967",
      "r968",
      "r969",
      "r970",
      "r971",
      "r972",
      "r973",
      "r974",
      "r975",
      "r976",
      "r977",
      "r978",
      "r979",
      "r980",
      "r981",
      "r982",
      "r983",
      "r984",
      "r985",
      "r986",
      "r987",
      "r988",
      "r989",
      "r990",
      "r991",
      "r992"
     ]
    },
    "adma_PlasmaCollectionCentersSegmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://admabiologics.com/20241231",
     "localname": "PlasmaCollectionCentersSegmentMember",
     "presentation": [
      "http://admabiologics.com/role/ConcentrationsDetails",
      "http://admabiologics.com/role/SegmentsNetRevenuesAccordingToGeographicAreaDetails",
      "http://admabiologics.com/role/SegmentsSummarizedFinancialInformationBySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Component of Plasma Collection Centers segment that usually provides financial, operational and administrative support and is considered an operating segment.",
        "label": "Plasma Collection Centers Segment [Member]",
        "terseLabel": "Plasma Collection Centers [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "adma_PlasmaPurchaseAgreementOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://admabiologics.com/20241231",
     "localname": "PlasmaPurchaseAgreementOneMember",
     "presentation": [
      "http://admabiologics.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plasma purchase agreement to purchase plasma containing antibodies to RSV to be used in the manufacture of ASCENIV.",
        "label": "Plasma Purchase Agreement One [Member]",
        "terseLabel": "2011 Plasma Purchase Agreement [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "adma_PlasmaPurchaseAgreementRenewalPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://admabiologics.com/20241231",
     "localname": "PlasmaPurchaseAgreementRenewalPeriod",
     "presentation": [
      "http://admabiologics.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plasma purchase agreement renewal period, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Plasma Purchase Agreement Renewal Period",
        "terseLabel": "Plasma purchase agreement renewal period"
       }
      }
     },
     "auth_ref": []
    },
    "adma_PlasmaSupplyAgreementTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://admabiologics.com/20241231",
     "localname": "PlasmaSupplyAgreementTerm",
     "presentation": [
      "http://admabiologics.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plasma supply agreement term period, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Plasma supply agreement term",
        "terseLabel": "Plasma supply agreement term"
       }
      }
     },
     "auth_ref": []
    },
    "adma_PostMarketingCommitmentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://admabiologics.com/20241231",
     "localname": "PostMarketingCommitmentsAbstract",
     "presentation": [
      "http://admabiologics.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Post-Marketing Commitments [Abstract]",
        "terseLabel": "Post-Marketing Commitments [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PreferredStockCapitalSharesReservedForFutureIssuance": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockCapitalSharesReservedForFutureIssuance",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityPreferredStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Preferred stock, shares authorized (in shares)",
        "label": "Preferred Stock, Capital Shares Reserved for Future Issuance",
        "documentation": "Aggregate number of nonredeemable preferred shares reserved for future issuance."
       }
      }
     },
     "auth_ref": [
      "r75"
     ]
    },
    "us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityPreferredStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockParOrStatedValuePerShare",
     "presentation": [
      "http://admabiologics.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://admabiologics.com/role/StockholdersEquityPreferredStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Preferred stock, par value (in dollars per share)",
        "label": "Preferred stock, par value (in dollars per share)",
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer."
       }
      }
     },
     "auth_ref": [
      "r75",
      "r393"
     ]
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesAuthorized",
     "presentation": [
      "http://admabiologics.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, shares authorized (in shares)",
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r75",
      "r687"
     ]
    },
    "us-gaap_PreferredStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesIssued",
     "presentation": [
      "http://admabiologics.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred stock, shares issued (in shares)",
        "documentation": "Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt."
       }
      }
     },
     "auth_ref": [
      "r75",
      "r393"
     ]
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesOutstanding",
     "presentation": [
      "http://admabiologics.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://admabiologics.com/role/StockholdersEquityPreferredStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Preferred stock, outstanding (in shares)",
        "label": "Preferred stock, shares outstanding (in shares)",
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased."
       }
      }
     },
     "auth_ref": [
      "r75",
      "r687",
      "r706",
      "r1063",
      "r1064"
     ]
    },
    "us-gaap_PreferredStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockValue",
     "crdr": "credit",
     "calculation": {
      "http://admabiologics.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://admabiologics.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, $0.0001 par value, 10,000,000 shares authorized, no shares issued and outstanding",
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r75",
      "r615",
      "r817"
     ]
    },
    "adma_PrepaidAfterTheFirstAnniversaryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://admabiologics.com/20241231",
     "localname": "PrepaidAfterTheFirstAnniversaryMember",
     "presentation": [
      "http://admabiologics.com/role/NotesPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The first anniversary representing most prepaid of after period of debt redemption features under terms of the debt agreement.",
        "label": "Prepaid after the First Anniversary [Member]",
        "terseLabel": "Prepaid after the First Anniversary [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://admabiologics.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://admabiologics.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid expenses and other current assets",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r905"
     ]
    },
    "adma_PrepaidOnOrPriorToFirstAnniversaryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://admabiologics.com/20241231",
     "localname": "PrepaidOnOrPriorToFirstAnniversaryMember",
     "presentation": [
      "http://admabiologics.com/role/NotesPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The first anniversary representing most current period of debt redemption features under terms of the debt agreement.",
        "label": "Prepaid on or Prior to First Anniversary [Member]",
        "terseLabel": "Prepaid on or Prior to First Anniversary [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "adma_PrepaidOnOrPriorToSecondAnniversaryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://admabiologics.com/20241231",
     "localname": "PrepaidOnOrPriorToSecondAnniversaryMember",
     "presentation": [
      "http://admabiologics.com/role/NotesPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The second anniversary representing most current period of debt redemption features under terms of the debt agreement.",
        "label": "Prepaid on or Prior to Second Anniversary [Member]",
        "terseLabel": "Prepaid on or Prior to Second Anniversary [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "adma_PrepaidOnOrPriorToThirdAnniversaryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://admabiologics.com/20241231",
     "localname": "PrepaidOnOrPriorToThirdAnniversaryMember",
     "presentation": [
      "http://admabiologics.com/role/NotesPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The third anniversary representing most current period of debt redemption features under terms of the debt agreement.",
        "label": "Prepaid on or Prior to Third Anniversary [Member]",
        "terseLabel": "Prepaid on or Prior to Third Anniversary [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "adma_PrepaymentsOfDebtPremium": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://admabiologics.com/20241231",
     "localname": "PrepaymentsOfDebtPremium",
     "crdr": "credit",
     "presentation": [
      "http://admabiologics.com/role/NotesPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount represents the payments of premium.",
        "label": "Prepayments of Debt Premium",
        "terseLabel": "Prepayments of premium"
       }
      }
     },
     "auth_ref": []
    },
    "adma_PresidentAndChiefExecutiveOfficerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://admabiologics.com/20241231",
     "localname": "PresidentAndChiefExecutiveOfficerMember",
     "presentation": [
      "http://admabiologics.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Person with designation of president and chief executive officer.",
        "label": "President and Chief Executive Officer [Member]",
        "terseLabel": "Mr. Grossman [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromInsuranceSettlementOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromInsuranceSettlementOperatingActivities",
     "crdr": "debit",
     "presentation": [
      "http://admabiologics.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds on business interruption loss coverage",
        "documentation": "Amount of cash inflow for proceeds from settlement of insurance claim, classified as operating activities. Excludes insurance settlement classified as investing activities."
       }
      }
     },
     "auth_ref": [
      "r224",
      "r765"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "calculation": {
      "http://admabiologics.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://admabiologics.com/role/ConsolidatedStatementsOfCashFlows",
      "http://admabiologics.com/role/StockholdersEquityCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from issuance of common stock, net of offering expenses",
        "terseLabel": "Proceeds from issuance of common stock",
        "documentation": "The cash inflow from the additional capital contribution to the entity."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOrSaleOfEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOrSaleOfEquityAbstract",
     "presentation": [
      "http://admabiologics.com/role/OrganizationAndBusinessDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Organization and Business [Abstract]",
        "label": "Proceeds from Issuance or Sale of Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromNotesPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromNotesPayable",
     "crdr": "debit",
     "calculation": {
      "http://admabiologics.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://admabiologics.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from issuance of note payable",
        "documentation": "The cash inflow from a borrowing supported by a written promise to pay an obligation."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromStockOptionsExercised",
     "crdr": "debit",
     "calculation": {
      "http://admabiologics.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://admabiologics.com/role/ConsolidatedStatementsOfCashFlows",
      "http://admabiologics.com/role/StockholdersEquityCommonStockDetails",
      "http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net proceeds from the exercise of stock options",
        "terseLabel": "Aggregate exercise proceeds",
        "verboseLabel": "Net proceeds from stock options exercised",
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r11"
     ]
    },
    "srt_ProductOrServiceAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ProductOrServiceAxis",
     "presentation": [
      "http://admabiologics.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]",
        "documentation": "Information by product and service, or group of similar products and similar services."
       }
      }
     },
     "auth_ref": [
      "r167",
      "r168",
      "r169",
      "r170",
      "r171",
      "r172",
      "r194",
      "r301",
      "r573",
      "r640",
      "r641",
      "r642",
      "r643",
      "r644",
      "r645",
      "r646",
      "r767",
      "r800",
      "r826",
      "r828",
      "r829",
      "r833",
      "r834",
      "r899",
      "r957",
      "r958",
      "r965",
      "r1030",
      "r1032",
      "r1033",
      "r1034",
      "r1035",
      "r1036",
      "r1037",
      "r1038",
      "r1039",
      "r1040",
      "r1041",
      "r1042",
      "r1043",
      "r1044",
      "r1045",
      "r1046",
      "r1047",
      "r1048",
      "r1049",
      "r1050",
      "r1051",
      "r1052",
      "r1053",
      "r1054",
      "r1055",
      "r1056",
      "r1057",
      "r1058",
      "r1059"
     ]
    },
    "srt_ProductsAndServicesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ProductsAndServicesDomain",
     "presentation": [
      "http://admabiologics.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]",
        "documentation": "Product or service, or a group of similar products or similar services."
       }
      }
     },
     "auth_ref": [
      "r167",
      "r168",
      "r169",
      "r170",
      "r171",
      "r172",
      "r194",
      "r301",
      "r573",
      "r640",
      "r641",
      "r642",
      "r643",
      "r644",
      "r645",
      "r646",
      "r767",
      "r800",
      "r826",
      "r828",
      "r829",
      "r833",
      "r834",
      "r899",
      "r957",
      "r958",
      "r965",
      "r1030",
      "r1032",
      "r1033",
      "r1034",
      "r1035",
      "r1036",
      "r1037",
      "r1038",
      "r1039",
      "r1040",
      "r1041",
      "r1042",
      "r1043",
      "r1044",
      "r1045",
      "r1046",
      "r1047",
      "r1048",
      "r1049",
      "r1050",
      "r1051",
      "r1052",
      "r1053",
      "r1054",
      "r1055",
      "r1056",
      "r1057",
      "r1058",
      "r1059"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentAbstract",
     "presentation": [
      "http://admabiologics.com/role/SignificantAccountingPoliciesPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PROPERTY AND EQUIPMENT [Abstract]",
        "terseLabel": "Property and Equipment [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "presentation": [
      "http://admabiologics.com/role/PropertyAndEquipmentDetails",
      "http://admabiologics.com/role/SignificantAccountingPoliciesPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Lived Tangible Asset [Axis]",
        "terseLabel": "Long-Lived Tangible Asset [Axis]",
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r557"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "presentation": [
      "http://admabiologics.com/role/PropertyAndEquipment"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PROPERTY AND EQUIPMENT",
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r107",
      "r144",
      "r147",
      "r148"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentGross",
     "crdr": "debit",
     "calculation": {
      "http://admabiologics.com/role/PropertyAndEquipmentDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://admabiologics.com/role/PropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property and equipment, gross",
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r108",
      "r204",
      "r622"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentLineItems",
     "presentation": [
      "http://admabiologics.com/role/PropertyAndEquipmentDetails",
      "http://admabiologics.com/role/SignificantAccountingPoliciesPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r557"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://admabiologics.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 6.0
      },
      "http://admabiologics.com/role/PropertyAndEquipmentDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://admabiologics.com/role/ConsolidatedBalanceSheets",
      "http://admabiologics.com/role/PropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total property and equipment, net",
        "label": "Property and equipment, net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r557",
      "r609",
      "r622",
      "r817"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentNetAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentNetAbstract",
     "presentation": [
      "http://admabiologics.com/role/PropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Property, Plant and Equipment [Abstract]",
        "label": "Property, Plant and Equipment, Net [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "presentation": [
      "http://admabiologics.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and Equipment",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r144",
      "r147",
      "r620"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "presentation": [
      "http://admabiologics.com/role/PropertyAndEquipmentTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and Equipment",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "presentation": [
      "http://admabiologics.com/role/PropertyAndEquipmentDetails",
      "http://admabiologics.com/role/SignificantAccountingPoliciesPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Lived Tangible Asset [Domain]",
        "terseLabel": "Long-Lived Tangible Asset [Domain]",
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "auth_ref": [
      "r108",
      "r557"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "presentation": [
      "http://admabiologics.com/role/SignificantAccountingPoliciesPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Useful life",
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment."
       }
      }
     },
     "auth_ref": []
    },
    "adma_QuantityOfRespiratorySyncytialVirusPlasmaUsed": {
     "xbrltype": "integerItemType",
     "nsuri": "http://admabiologics.com/20241231",
     "localname": "QuantityOfRespiratorySyncytialVirusPlasmaUsed",
     "presentation": [
      "http://admabiologics.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Respiratory Syncytial Virus (RSV) Converted human plasma used by company.",
        "label": "Quantity of Respiratory Syncytial Virus Plasma Used",
        "terseLabel": "Quantity of RSV plasma used"
       }
      }
     },
     "auth_ref": []
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeAxis",
     "presentation": [
      "http://admabiologics.com/role/CommitmentsAndContingenciesDetails",
      "http://admabiologics.com/role/IncomeTaxesNetOperatingLossCarryforwardsDetails",
      "http://admabiologics.com/role/NotesPayableDetails",
      "http://admabiologics.com/role/RelatedPartyTransactionsDetails",
      "http://admabiologics.com/role/SignificantAccountingPoliciesPropertyAndEquipmentDetails",
      "http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]",
        "documentation": "Information by statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median."
       }
      }
     },
     "auth_ref": [
      "r158",
      "r160",
      "r162",
      "r163",
      "r165",
      "r195",
      "r196",
      "r356",
      "r357",
      "r358",
      "r359",
      "r416",
      "r429",
      "r458",
      "r459",
      "r460",
      "r469",
      "r531",
      "r568",
      "r569",
      "r571",
      "r647",
      "r649",
      "r656",
      "r677",
      "r678",
      "r738",
      "r740",
      "r742",
      "r743",
      "r745",
      "r761",
      "r762",
      "r790",
      "r799",
      "r804",
      "r811",
      "r812",
      "r813",
      "r814",
      "r828",
      "r837",
      "r953",
      "r963",
      "r1010",
      "r1024",
      "r1025",
      "r1026",
      "r1027",
      "r1028"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeMember",
     "presentation": [
      "http://admabiologics.com/role/CommitmentsAndContingenciesDetails",
      "http://admabiologics.com/role/IncomeTaxesNetOperatingLossCarryforwardsDetails",
      "http://admabiologics.com/role/NotesPayableDetails",
      "http://admabiologics.com/role/RelatedPartyTransactionsDetails",
      "http://admabiologics.com/role/SignificantAccountingPoliciesPropertyAndEquipmentDetails",
      "http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "documentation": "Statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median."
       }
      }
     },
     "auth_ref": [
      "r158",
      "r160",
      "r162",
      "r163",
      "r165",
      "r195",
      "r196",
      "r356",
      "r357",
      "r358",
      "r359",
      "r416",
      "r429",
      "r458",
      "r459",
      "r460",
      "r469",
      "r531",
      "r568",
      "r569",
      "r571",
      "r647",
      "r649",
      "r656",
      "r677",
      "r678",
      "r738",
      "r740",
      "r742",
      "r743",
      "r745",
      "r761",
      "r762",
      "r790",
      "r799",
      "r804",
      "r811",
      "r812",
      "r813",
      "r814",
      "r828",
      "r837",
      "r953",
      "r963",
      "r1010",
      "r1024",
      "r1025",
      "r1026",
      "r1027",
      "r1028"
     ]
    },
    "us-gaap_ReceivablesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ReceivablesPolicyTextBlock",
     "presentation": [
      "http://admabiologics.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts Receivable",
        "label": "Receivable [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for receivable. Includes, but is not limited to, accounts receivable and financing receivable."
       }
      }
     },
     "auth_ref": [
      "r307",
      "r308",
      "r309",
      "r310",
      "r933"
     ]
    },
    "us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ReconciliationFromSegmentTotalsToConsolidatedAbstract",
     "presentation": [
      "http://admabiologics.com/role/SegmentsSummarizedFinancialInformationBySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reconciliation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyDomain",
     "presentation": [
      "http://admabiologics.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related and Nonrelated Parties [Domain]",
        "documentation": "Related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."
       }
      }
     },
     "auth_ref": [
      "r306",
      "r420",
      "r562",
      "r563",
      "r612",
      "r619",
      "r680",
      "r681",
      "r682",
      "r683",
      "r684",
      "r705",
      "r707",
      "r737"
     ]
    },
    "us-gaap_RelatedPartyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyMember",
     "presentation": [
      "http://admabiologics.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party [Member]",
        "documentation": "Party related to reporting entity. Includes, but is not limited to, affiliate, entity for which investment is accounted for by equity method, trust for benefit of employees, and principal owner, management, and members of immediate family."
       }
      }
     },
     "auth_ref": [
      "r234",
      "r235",
      "r562",
      "r563",
      "r564",
      "r565",
      "r612",
      "r619",
      "r680",
      "r681",
      "r682",
      "r683",
      "r684",
      "r705",
      "r707",
      "r737"
     ]
    },
    "adma_RelatedPartyTransactionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://admabiologics.com/20241231",
     "localname": "RelatedPartyTransactionAbstract",
     "presentation": [
      "http://admabiologics.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction [Abstract]",
        "terseLabel": "Related Party Transactions [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "adma_RelatedPartyTransactionLeaseRenewalPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://admabiologics.com/20241231",
     "localname": "RelatedPartyTransactionLeaseRenewalPeriod",
     "presentation": [
      "http://admabiologics.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days in related party transaction.",
        "label": "Related Party Transaction, Lease Renewal Period",
        "terseLabel": "Lease automatic renewal period"
       }
      }
     },
     "auth_ref": []
    },
    "adma_RelatedPartyTransactionLeaseTerminationPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://admabiologics.com/20241231",
     "localname": "RelatedPartyTransactionLeaseTerminationPeriod",
     "presentation": [
      "http://admabiologics.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Notice period for lease termination, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days in related party transaction.",
        "label": "Related Party Transaction, Lease Termination Period",
        "terseLabel": "Notice period for termination"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionLineItems",
     "presentation": [
      "http://admabiologics.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transaction [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r306",
      "r711",
      "r712",
      "r715"
     ]
    },
    "us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionPurchasesFromRelatedParty",
     "crdr": "debit",
     "presentation": [
      "http://admabiologics.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Purchased materials amount",
        "label": "Related Party Transaction, Purchases from Related Party",
        "documentation": "Purchases during the period (excluding transactions that are eliminated in consolidated or combined financial statements) with related party."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "RELATED PARTY TRANSACTIONS [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "presentation": [
      "http://admabiologics.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related and Nonrelated Parties [Axis]",
        "documentation": "Information by related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."
       }
      }
     },
     "auth_ref": [
      "r306",
      "r420",
      "r562",
      "r563",
      "r612",
      "r619",
      "r680",
      "r681",
      "r682",
      "r683",
      "r684",
      "r705",
      "r707",
      "r737",
      "r1020"
     ]
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "presentation": [
      "http://admabiologics.com/role/RelatedPartyTransactions"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "RELATED PARTY TRANSACTIONS",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates."
       }
      }
     },
     "auth_ref": [
      "r559",
      "r560",
      "r561",
      "r563",
      "r566",
      "r668",
      "r669",
      "r670",
      "r713",
      "r714",
      "r715",
      "r734",
      "r736"
     ]
    },
    "us-gaap_RepaymentsOfLongTermLinesOfCredit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RepaymentsOfLongTermLinesOfCredit",
     "crdr": "credit",
     "presentation": [
      "http://admabiologics.com/role/NotesPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Repayment of revolving credit facility",
        "label": "Repayments of Long-Term Lines of Credit",
        "documentation": "The cash outflow for the settlement of obligation drawn from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with maturities due beyond one year or the operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r96"
     ]
    },
    "us-gaap_RepaymentsOfNotesPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RepaymentsOfNotesPayable",
     "crdr": "credit",
     "calculation": {
      "http://admabiologics.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://admabiologics.com/role/ConsolidatedStatementsOfCashFlows",
      "http://admabiologics.com/role/NotesPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Principal payments on notes payable",
        "terseLabel": "Payment for outstanding obligations",
        "label": "Repayments of Notes Payable",
        "documentation": "The cash outflow for a borrowing supported by a written promise to pay an obligation."
       }
      }
     },
     "auth_ref": [
      "r96"
     ]
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "presentation": [
      "http://admabiologics.com/role/DocumentAndEntityInformation",
      "http://admabiologics.com/role/NotesPayableDetails",
      "http://admabiologics.com/role/RelatedPartyTransactionsDetails",
      "http://admabiologics.com/role/StockholdersEquityWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]",
        "documentation": "Named other party that participates in a financial transaction. Examples include, but not limited to, the name of the financial institution."
       }
      }
     },
     "auth_ref": [
      "r192",
      "r193",
      "r236",
      "r237",
      "r376",
      "r395",
      "r565",
      "r570",
      "r610",
      "r774",
      "r775"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://admabiologics.com/role/ConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://admabiologics.com/role/CommitmentsAndContingenciesDetails",
      "http://admabiologics.com/role/ConsolidatedStatementsOfOperations",
      "http://admabiologics.com/role/SegmentsSummarizedFinancialInformationBySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amount of expenses to complete studies",
        "label": "Research and development",
        "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity."
       }
      }
     },
     "auth_ref": [
      "r471",
      "r764",
      "r785",
      "r1029"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpenseMember",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development [Member]",
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "presentation": [
      "http://admabiologics.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expenses",
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process."
       }
      }
     },
     "auth_ref": [
      "r470"
     ]
    },
    "adma_RespiratorySyncytialVirusPlasmaVolumeSuppliedPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://admabiologics.com/20241231",
     "localname": "RespiratorySyncytialVirusPlasmaVolumeSuppliedPeriod",
     "presentation": [
      "http://admabiologics.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Supplied period on usage of RSV plasma in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Respiratory Syncytial Virus Plasma Volume Supplied Period",
        "terseLabel": "Volume supplied period"
       }
      }
     },
     "auth_ref": []
    },
    "adma_RestorationCostsReceived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://admabiologics.com/20241231",
     "localname": "RestorationCostsReceived",
     "crdr": "debit",
     "presentation": [
      "http://admabiologics.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restoration cost received from cybersecurity insurance.",
        "label": "Restoration Costs Received",
        "terseLabel": "Restoration costs received"
       }
      }
     },
     "auth_ref": []
    },
    "adma_RestrictedStockUnitsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://admabiologics.com/20241231",
     "localname": "RestrictedStockUnitsAbstract",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Stock Units [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestrictedStockUnitsRSUMember",
     "presentation": [
      "http://admabiologics.com/role/RelatedPartyTransactionsDetails",
      "http://admabiologics.com/role/SignificantAccountingPoliciesEarningsLossPerShareDetails",
      "http://admabiologics.com/role/SignificantAccountingPoliciesStockbasedCompensationDetails",
      "http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Stock Units [Member]",
        "terseLabel": "Restricted Stock Units (RSUs) [Member]",
        "verboseLabel": "RSUs [Member]",
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://admabiologics.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://admabiologics.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated deficit",
        "label": "Retained Earnings (Accumulated Deficit)",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r78",
      "r116",
      "r617",
      "r654",
      "r655",
      "r666",
      "r688",
      "r817"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://admabiologics.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated Deficit [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r197",
      "r245",
      "r246",
      "r247",
      "r249",
      "r254",
      "r256",
      "r258",
      "r312",
      "r313",
      "r346",
      "r502",
      "r503",
      "r509",
      "r510",
      "r511",
      "r513",
      "r514",
      "r515",
      "r521",
      "r523",
      "r524",
      "r526",
      "r528",
      "r545",
      "r547",
      "r651",
      "r653",
      "r671",
      "r1063"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueFromContractWithCustomerAbstract",
     "presentation": [
      "http://admabiologics.com/role/SignificantAccountingPoliciesRevenueRecognitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue Recognition [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "crdr": "credit",
     "calculation": {
      "http://admabiologics.com/role/ConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_GrossProfit",
       "weight": 1.0,
       "order": 0.0
      }
     },
     "presentation": [
      "http://admabiologics.com/role/ConsolidatedStatementsOfOperations",
      "http://admabiologics.com/role/NotesPayableDetails",
      "http://admabiologics.com/role/SegmentsNetRevenuesAccordingToGeographicAreaDetails",
      "http://admabiologics.com/role/SegmentsSummarizedFinancialInformationBySegmentDetails",
      "http://admabiologics.com/role/SignificantAccountingPoliciesUseOfEstimatesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "REVENUES",
        "verboseLabel": "Revenues",
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise."
       }
      }
     },
     "auth_ref": [
      "r134",
      "r135",
      "r269",
      "r277",
      "r278",
      "r292",
      "r298",
      "r301",
      "r303",
      "r305",
      "r412",
      "r413",
      "r573"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerProductAndServiceBenchmarkMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueFromContractWithCustomerProductAndServiceBenchmarkMember",
     "presentation": [
      "http://admabiologics.com/role/ConcentrationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue [Member]",
        "documentation": "Revenue from satisfaction of performance obligation by transferring promised product and service to customer for specified product or service, when it serves as benchmark in concentration of risk calculation."
       }
      }
     },
     "auth_ref": [
      "r892"
     ]
    },
    "us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueFromExternalCustomersByGeographicAreasTableTextBlock",
     "presentation": [
      "http://admabiologics.com/role/SegmentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Revenues According to Geographic Area",
        "documentation": "Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue."
       }
      }
     },
     "auth_ref": [
      "r105"
     ]
    },
    "us-gaap_RevenueRecognitionPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueRecognitionPolicyTextBlock",
     "presentation": [
      "http://admabiologics.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue Recognition",
        "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources."
       }
      }
     },
     "auth_ref": [
      "r709",
      "r766",
      "r777"
     ]
    },
    "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems",
     "presentation": [
      "http://admabiologics.com/role/SignificantAccountingPoliciesRevenueRecognitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable",
     "presentation": [
      "http://admabiologics.com/role/SignificantAccountingPoliciesRevenueRecognitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table]",
        "documentation": "Disclosure of information about expected timing for satisfying remaining performance obligation."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenuesFromExternalCustomersAndLongLivedAssetsLineItems",
     "presentation": [
      "http://admabiologics.com/role/SegmentsNetRevenuesAccordingToGeographicAreaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues from External Customers and Long-Lived Assets [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RevolvingCreditFacilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevolvingCreditFacilityMember",
     "presentation": [
      "http://admabiologics.com/role/NotesPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revolving Credit Facility [Member]",
        "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "crdr": "debit",
     "presentation": [
      "http://admabiologics.com/role/SupplementalDisclosureOfCashFlowInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Right-to-use assets in exchange for lease obligations",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r553",
      "r816"
     ]
    },
    "adma_RightToIntermediatesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://admabiologics.com/20241231",
     "localname": "RightToIntermediatesMember",
     "presentation": [
      "http://admabiologics.com/role/IntangibleAssetsSummaryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Entity's established relationships with its customers through contracts.",
        "label": "Right to Intermediates [Member]",
        "terseLabel": "Rights to Intermediates [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RisksAndUncertaintiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RisksAndUncertaintiesAbstract",
     "presentation": [
      "http://admabiologics.com/role/ConcentrationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Risks and Uncertainties [Abstract]",
        "label": "Risks and Uncertainties [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://admabiologics.com/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rule 10b5-1 Arrangement Adopted",
        "label": "Rule 10b5-1 Arrangement Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r872"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://admabiologics.com/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rule 10b5-1 Arrangement Terminated",
        "label": "Rule 10b5-1 Arrangement Terminated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r872"
     ]
    },
    "adma_SECSchedule1209ReserveAccruedRebatesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://admabiologics.com/20241231",
     "localname": "SECSchedule1209ReserveAccruedRebatesMember",
     "presentation": [
      "http://admabiologics.com/role/ScheduleIiValuationAndQualifyingAccountsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reserve for accrued rebates for Medicaid or other third parties related to sale of product.",
        "label": "SEC Schedule, 12-09, Reserve, Accrued Rebates [Member]",
        "terseLabel": "Accrued Rebates [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Domain]",
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "presentation": [
      "http://admabiologics.com/role/AccruedExpensesAndOtherLiabilitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued Expenses and Other Current Liabilities",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "documentation": "Tabular disclosure of the components of accrued liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "presentation": [
      "http://admabiologics.com/role/SignificantAccountingPoliciesEarningsLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Security, Excluded EPS Calculation [Table]",
        "documentation": "Disclosure of information about security that could potentially dilute basic earnings per share (EPS) in future that was not included in calculation of diluted EPS."
       }
      }
     },
     "auth_ref": [
      "r22"
     ]
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "presentation": [
      "http://admabiologics.com/role/SignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Calculation of Diluted Loss Per Common Share",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities."
       }
      }
     },
     "auth_ref": [
      "r22"
     ]
    },
    "us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
     "presentation": [
      "http://admabiologics.com/role/SupplementalDisclosureOfCashFlowInformationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information",
        "documentation": "Tabular disclosure of supplemental cash flow information for the periods presented."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfChangeInAccountingEstimateTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfChangeInAccountingEstimateTable",
     "presentation": [
      "http://admabiologics.com/role/SignificantAccountingPoliciesUseOfEstimatesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in Accounting Estimate [Table]",
        "documentation": "Disclosure of information about change in accounting estimate."
       }
      }
     },
     "auth_ref": [
      "r24",
      "r253"
     ]
    },
    "us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Stock-Based Compensation Expense",
        "documentation": "Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit."
       }
      }
     },
     "auth_ref": [
      "r54"
     ]
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "presentation": [
      "http://admabiologics.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax Expense (Benefit)",
        "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]",
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years."
       }
      }
     },
     "auth_ref": [
      "r1004"
     ]
    },
    "us-gaap_ScheduleOfDebtTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfDebtTableTextBlock",
     "presentation": [
      "http://admabiologics.com/role/NotesPayableTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of Outstanding Senior Notes Payable",
        "documentation": "Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "presentation": [
      "http://admabiologics.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets",
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r998"
     ]
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "presentation": [
      "http://admabiologics.com/role/SignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Calculation of Basic and Diluted Earnings Per Share",
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r923"
     ]
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "presentation": [
      "http://admabiologics.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reconciliation of Income Taxes",
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r481",
      "r807",
      "r995"
     ]
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable",
     "presentation": [
      "http://admabiologics.com/role/IntangibleAssetsSummaryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intangible Asset, Finite-Lived [Table]",
        "documentation": "Disclosure of information about finite-lived intangible asset. Excludes indefinite-lived intangible asset."
       }
      }
     },
     "auth_ref": [
      "r333",
      "r339",
      "r341",
      "r342",
      "r344",
      "r574",
      "r764",
      "r792"
     ]
    },
    "us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock",
     "presentation": [
      "http://admabiologics.com/role/IntangibleAssetsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Intangible Assets",
        "label": "Schedule of Indefinite-Lived Intangible Assets [Table Text Block]",
        "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance and exist in perpetuity, by either major class or business segment."
       }
      }
     },
     "auth_ref": [
      "r792",
      "r944"
     ]
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "presentation": [
      "http://admabiologics.com/role/InventoriesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Components of Inventory",
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r82",
      "r83",
      "r84"
     ]
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "presentation": [
      "http://admabiologics.com/role/PropertyAndEquipmentDetails",
      "http://admabiologics.com/role/SignificantAccountingPoliciesPropertyAndEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Table]",
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r557"
     ]
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "presentation": [
      "http://admabiologics.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Related Party Transactions, by Related Party [Table]",
        "documentation": "Disclosure of information about related party transaction."
       }
      }
     },
     "auth_ref": [
      "r57",
      "r58",
      "r711",
      "r712",
      "r715"
     ]
    },
    "us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable",
     "presentation": [
      "http://admabiologics.com/role/SegmentsNetRevenuesAccordingToGeographicAreaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Revenues from External Customers and Long-Lived Assets [Table]",
        "documentation": "Disclosure of information about revenue from external customer and long-lived asset by geographical area. Long-lived asset excludes financial instrument, customer relationship with financial institution, mortgage and other servicing right, deferred policy acquisition cost, and deferred tax asset."
       }
      }
     },
     "auth_ref": [
      "r35",
      "r85"
     ]
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTable",
     "presentation": [
      "http://admabiologics.com/role/SegmentsSummarizedFinancialInformationBySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Segment Reporting Information, by Segment [Table]",
        "documentation": "Disclosure of information about profit (loss) and total assets by reportable segment."
       }
      }
     },
     "auth_ref": [
      "r32",
      "r33",
      "r34"
     ]
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock",
     "presentation": [
      "http://admabiologics.com/role/SegmentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Summarized Financial Information Concerning Reportable Segments",
        "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss."
       }
      }
     },
     "auth_ref": [
      "r32",
      "r33",
      "r34"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "presentation": [
      "http://admabiologics.com/role/SignificantAccountingPoliciesStockbasedCompensationDetails",
      "http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "terseLabel": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of Outstanding and Exercisable Options by Price Range",
        "documentation": "Tabular disclosure of option exercise prices, by grouped ranges, including the upper and lower limits of the price range, the number of shares under option, weighted average exercise price and remaining contractual option terms."
       }
      }
     },
     "auth_ref": [
      "r49"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Option Activity",
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r10",
      "r117"
     ]
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Assumptions",
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions."
       }
      }
     },
     "auth_ref": [
      "r122"
     ]
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfStockByClassTable",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Stock by Class [Table]",
        "documentation": "Disclosure of information about stock by class. Includes, but is not limited to, common, convertible, and preferred stocks."
       }
      }
     },
     "auth_ref": [
      "r42",
      "r43",
      "r44",
      "r45",
      "r46",
      "r47",
      "r112",
      "r114",
      "r115",
      "r116",
      "r210",
      "r211",
      "r212",
      "r271",
      "r393",
      "r394",
      "r395",
      "r397",
      "r400",
      "r405",
      "r407",
      "r662",
      "r663",
      "r664",
      "r665",
      "r799",
      "r890",
      "r910"
     ]
    },
    "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants Outstanding",
        "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable."
       }
      }
     },
     "auth_ref": [
      "r48"
     ]
    },
    "us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Unvested RSU Activity",
        "documentation": "Tabular disclosure of the change in restricted stock units (RSUs)."
       }
      }
     },
     "auth_ref": []
    },
    "srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock",
     "presentation": [
      "http://admabiologics.com/role/ScheduleIiValuationAndQualifyingAccounts"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule II - Valuation and Qualifying Accounts",
        "label": "SEC Schedule, 12-09, Schedule of Valuation and Qualifying Accounts Disclosure [Text Block]",
        "documentation": "The entire disclosure for valuation and qualifying accounts and reserves."
       }
      }
     },
     "auth_ref": [
      "r157",
      "r244"
     ]
    },
    "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
     "presentation": [
      "http://admabiologics.com/role/IntangibleAssetsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intangible Asset Future Aggregate Amortization Expense",
        "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets."
       }
      }
     },
     "auth_ref": [
      "r792",
      "r943"
     ]
    },
    "us-gaap_SecuredOvernightFinancingRateSofrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SecuredOvernightFinancingRateSofrMember",
     "presentation": [
      "http://admabiologics.com/role/NotesPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SOFR [Member]",
        "documentation": "Interest rate at which bank can borrow U.S. dollar overnight while posting U.S. Treasury bond as collateral."
       }
      }
     },
     "auth_ref": [
      "r1007"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://admabiologics.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r846"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://admabiologics.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r848"
     ]
    },
    "us-gaap_SegmentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentDomain",
     "presentation": [
      "http://admabiologics.com/role/ConcentrationsDetails",
      "http://admabiologics.com/role/SegmentsNetRevenuesAccordingToGeographicAreaDetails",
      "http://admabiologics.com/role/SegmentsSummarizedFinancialInformationBySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segments [Domain]",
        "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity."
       }
      }
     },
     "auth_ref": [
      "r134",
      "r135",
      "r136",
      "r137",
      "r269",
      "r273",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r298",
      "r299",
      "r300",
      "r305",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r344",
      "r351",
      "r352",
      "r629",
      "r630",
      "r631",
      "r632",
      "r633",
      "r634",
      "r635",
      "r636",
      "r637",
      "r638",
      "r639",
      "r782",
      "r785",
      "r786",
      "r791",
      "r831",
      "r1030",
      "r1032",
      "r1033",
      "r1034",
      "r1035",
      "r1036",
      "r1037",
      "r1038",
      "r1039",
      "r1040",
      "r1041",
      "r1042",
      "r1043",
      "r1044",
      "r1045",
      "r1046",
      "r1047",
      "r1048",
      "r1049",
      "r1050",
      "r1051",
      "r1052",
      "r1053",
      "r1054",
      "r1055",
      "r1056",
      "r1057",
      "r1058",
      "r1059"
     ]
    },
    "us-gaap_SegmentExpenditureAdditionToLongLivedAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentExpenditureAdditionToLongLivedAssets",
     "crdr": "debit",
     "presentation": [
      "http://admabiologics.com/role/SegmentsSummarizedFinancialInformationBySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expenditures for additions to long-lived assets",
        "label": "Segment, Expenditure, Addition to Long-Lived Assets",
        "documentation": "Amount of expenditure for addition to long-lived assets included in determination of segment assets by chief operating decision maker (CODM) or otherwise regularly provided to CODM. Excludes expenditure for addition to financial instrument, long-term customer relationship of financial institution, mortgage and other servicing rights, deferred policy acquisition cost, and deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r269",
      "r287",
      "r298",
      "r785",
      "r786"
     ]
    },
    "srt_SegmentGeographicalDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "SegmentGeographicalDomain",
     "presentation": [
      "http://admabiologics.com/role/SegmentsNetRevenuesAccordingToGeographicAreaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]",
        "documentation": "Geographical area."
       }
      }
     },
     "auth_ref": [
      "r159",
      "r161",
      "r164",
      "r166",
      "r173",
      "r174",
      "r175",
      "r176",
      "r177",
      "r178",
      "r179",
      "r180",
      "r181",
      "r182",
      "r303",
      "r304",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600",
      "r601",
      "r602",
      "r603",
      "r604",
      "r605",
      "r674",
      "r675",
      "r676",
      "r739",
      "r741",
      "r744",
      "r746",
      "r749",
      "r752",
      "r753",
      "r754",
      "r755",
      "r756",
      "r757",
      "r758",
      "r759",
      "r760",
      "r768",
      "r801",
      "r818",
      "r819",
      "r820",
      "r821",
      "r822",
      "r823",
      "r824",
      "r825",
      "r830",
      "r837",
      "r965",
      "r1030",
      "r1032",
      "r1033",
      "r1035",
      "r1036",
      "r1037",
      "r1038",
      "r1039",
      "r1040",
      "r1041",
      "r1042",
      "r1043",
      "r1044",
      "r1045",
      "r1046",
      "r1047",
      "r1048",
      "r1049",
      "r1050",
      "r1051",
      "r1052",
      "r1053",
      "r1054",
      "r1055",
      "r1056",
      "r1057",
      "r1058",
      "r1059"
     ]
    },
    "us-gaap_SegmentReportingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "SEGMENTS [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingDisclosureTextBlock",
     "presentation": [
      "http://admabiologics.com/role/Segments"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SEGMENTS",
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments."
       }
      }
     },
     "auth_ref": [
      "r137",
      "r269",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r288",
      "r290",
      "r291",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r305",
      "r781",
      "r783",
      "r784",
      "r785",
      "r787",
      "r788",
      "r789"
     ]
    },
    "us-gaap_SegmentReportingInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingInformationLineItems",
     "presentation": [
      "http://admabiologics.com/role/SegmentsSummarizedFinancialInformationBySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingInformationProfitLossAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingInformationProfitLossAbstract",
     "presentation": [
      "http://admabiologics.com/role/SegmentsSummarizedFinancialInformationBySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting Information [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentsGeographicalAreasAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentsGeographicalAreasAbstract",
     "presentation": [
      "http://admabiologics.com/role/SegmentsNetRevenuesAccordingToGeographicAreaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues, Geographic Area [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SellingAndMarketingExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SellingAndMarketingExpense",
     "crdr": "debit",
     "presentation": [
      "http://admabiologics.com/role/SegmentsSummarizedFinancialInformationBySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Selling, marketing and distribution",
        "documentation": "The aggregate total amount of expenses directly related to the marketing or selling of products or services."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SellingGeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://admabiologics.com/role/ConsolidatedStatementsOfOperations": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://admabiologics.com/role/ConsolidatedStatementsOfOperations",
      "http://admabiologics.com/role/SegmentsSummarizedFinancialInformationBySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Selling, general and administrative",
        "terseLabel": "Consolidated selling, general and administrative expense",
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc."
       }
      }
     },
     "auth_ref": [
      "r90"
     ]
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SellingGeneralAndAdministrativeExpensesMember",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Selling, General and Administrative [Member]",
        "documentation": "Primary financial statement caption encompassing selling, general and administrative expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SeniorLongTermNotes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SeniorLongTermNotes",
     "crdr": "credit",
     "calculation": {
      "http://admabiologics.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 6.0
      },
      "http://admabiologics.com/role/NotesPayableDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://admabiologics.com/role/ConsolidatedBalanceSheets",
      "http://admabiologics.com/role/NotesPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Senior notes payable",
        "label": "Senior notes payable, net of discount",
        "documentation": "Carrying value as of the balance sheet date of Notes with the highest claim on the assets of the issuer in case of bankruptcy or liquidation (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion. Senior note holders are paid off in full before any payments are made to junior note holders."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r817"
     ]
    },
    "adma_SeniorNotesPayableBeforeDebtDiscount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://admabiologics.com/20241231",
     "localname": "SeniorNotesPayableBeforeDebtDiscount",
     "crdr": "credit",
     "calculation": {
      "http://admabiologics.com/role/NotesPayableDetails": {
       "parentTag": "us-gaap_SeniorLongTermNotes",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://admabiologics.com/role/NotesPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of Notes with the highest claim on the assets of the issuer in case of bankruptcy or liquidation (with maturities initially due after one year or beyond the operating cycle if longer), excluding debt discount and current portion.",
        "label": "Senior Notes Payable Before Debt Discount",
        "terseLabel": "Senior notes payable before debt discount"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://admabiologics.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://admabiologics.com/role/ConsolidatedStatementsOfCashFlows",
      "http://admabiologics.com/role/RelatedPartyTransactionsDetails",
      "http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Stock-based compensation",
        "label": "Stock-based compensation expense",
        "terseLabel": "Compensation expenses",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_ShareBasedCompensationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationAbstract",
     "presentation": [
      "http://admabiologics.com/role/SignificantAccountingPoliciesStockbasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-based Compensation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-based compensation expense [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1",
     "presentation": [
      "http://admabiologics.com/role/RelatedPartyTransactionsDetails",
      "http://admabiologics.com/role/SignificantAccountingPoliciesStockbasedCompensationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity incentive plans, term",
        "verboseLabel": "Exercise term for his vested stock options",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Requisite Service Period",
        "documentation": "Estimated period over which an employee is required to provide service in exchange for the equity-based payment award, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r805"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "presentation": [
      "http://admabiologics.com/role/RelatedPartyTransactionsDetails",
      "http://admabiologics.com/role/SignificantAccountingPoliciesStockbasedCompensationDetails",
      "http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity incentive plans, vesting period",
        "label": "Restricted stock units vested over a period",
        "verboseLabel": "Exercise period for his vested stock options",
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition."
       }
      }
     },
     "auth_ref": [
      "r805"
     ]
    },
    "adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://admabiologics.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that exercised during the reporting period.",
        "label": "Share Based Compensation Arrangement by Share Based Payment Award Equity Instruments Other than Options Exercised in Period",
        "negatedLabel": "Exercised (in shares)"
       }
      }
     },
     "auth_ref": []
    },
    "adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://admabiologics.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at exercised date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share Based Compensation Arrangement by Share Based Payment Award Equity Instruments Other Than Options Exercised in Period Weighted Average Grant Date Fair Value",
        "terseLabel": "Exercised (in dollars per share)"
       }
      }
     },
     "auth_ref": []
    },
    "adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://admabiologics.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that expired during the reporting period.",
        "label": "Share Based Compensation Arrangement by Share Based Payment Award Equity Instruments Other than Options Expired in Period",
        "negatedLabel": "Expired (in shares)"
       }
      }
     },
     "auth_ref": []
    },
    "adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://admabiologics.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at expired date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share Based Compensation Arrangement by Share Based Payment Award Equity Instruments Other Than Options Expired in Period Weighted Average Grant Date Fair Value",
        "terseLabel": "Expired (in dollars per share)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Forfeited (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r450"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forfeited (in dollars per share)",
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event."
       }
      }
     },
     "auth_ref": [
      "r450"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails",
      "http://admabiologics.com/role/StockholdersEquityWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Granted (in shares)",
        "terseLabel": "Granted (in shares)",
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r448"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails",
      "http://admabiologics.com/role/StockholdersEquityWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Granted (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r448"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails",
      "http://admabiologics.com/role/StockholdersEquityWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r445",
      "r446"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails",
      "http://admabiologics.com/role/StockholdersEquityWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unvested RSU, Shares [Abstract]",
        "terseLabel": "Warrants Outstanding [Abstract]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails",
      "http://admabiologics.com/role/StockholdersEquityWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Ending balance (in dollars per share)",
        "periodStartLabel": "Beginning balance (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r445",
      "r446"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails",
      "http://admabiologics.com/role/StockholdersEquityWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unvested RSU, Weighted Average Grant Date Fair Value [Abstract]",
        "verboseLabel": "Warrants Outstanding, Weighted Average Exercise Price [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesValueWithheldForEmployeesTaxLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://admabiologics.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesValueWithheldForEmployeesTaxLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The shares value withheld by the Company to cover employees' tax liabilities under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Shares Value Withheld for Employees Tax Liabilities",
        "terseLabel": "Amount of shares withheld for tax withholding obligation"
       }
      }
     },
     "auth_ref": []
    },
    "adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesWithheldForEmployeesTaxLiabilities": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://admabiologics.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesWithheldForEmployeesTaxLiabilities",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares withheld by the Company to cover employees' tax liabilities under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Shares Withheld for Employees Tax Liabilities",
        "terseLabel": "Shares withheld for tax withholding obligation (in shares)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "presentation": [
      "http://admabiologics.com/role/RelatedPartyTransactionsDetails",
      "http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Vested (in shares)",
        "terseLabel": "Vested (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r449"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vested (in dollars per share)",
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement."
       }
      }
     },
     "auth_ref": [
      "r449"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate",
     "presentation": [
      "http://admabiologics.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award expiration date",
        "documentation": "Date the equity-based award expires, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": [
      "r968"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Assumptions and Methodology [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails",
      "http://admabiologics.com/role/StockholdersEquityWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dividend yield",
        "verboseLabel": "Dividend yield",
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term."
       }
      }
     },
     "auth_ref": [
      "r459"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails",
      "http://admabiologics.com/role/StockholdersEquityWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Volatility",
        "verboseLabel": "Volatility",
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": [
      "r458"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails",
      "http://admabiologics.com/role/StockholdersEquityWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Risk-free interest rate",
        "verboseLabel": "Risk-free interest rate",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": [
      "r460"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://admabiologics.com/role/SignificantAccountingPoliciesStockbasedCompensationDetails",
      "http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of restricted stock units granted (in shares)",
        "documentation": "Net number of non-option equity instruments granted to participants."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options exercisable (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan."
       }
      }
     },
     "auth_ref": [
      "r439"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options exercisable (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r439"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of stock options granted (in shares)",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r441"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Options outstanding, aggregate intrinsic value",
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding."
       }
      }
     },
     "auth_ref": [
      "r49"
     ]
    },
    "adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSharesWithheldForPayrollTaxes": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://admabiologics.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSharesWithheldForPayrollTaxes",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares withheld by the Company to cover payroll taxes under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Shares Withheld for Payroll Taxes",
        "terseLabel": "Shares withheld for payroll taxes (in shares)"
       }
      }
     },
     "auth_ref": []
    },
    "adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSharesWithheldToCoverAggregateExercisePrices": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://admabiologics.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSharesWithheldToCoverAggregateExercisePrices",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares withheld by the Company to cover aggregate exercise prices under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Shares Withheld to Cover Aggregate Exercise Prices",
        "terseLabel": "Shares withheld to cover aggregate exercise prices (in shares)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestAbstract",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Options, Vested and Expected to Vest [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://admabiologics.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedNumber",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares under fully vested and expected to vest options that were exercised during the current period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercised, Number",
        "negatedLabel": "Exercised (in shares)"
       }
      }
     },
     "auth_ref": []
    },
    "adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://admabiologics.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedWeightedAverageExercisePrice",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercised.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercised, Weighted Average Exercise Price",
        "terseLabel": "Exercised (in dollars per share)"
       }
      }
     },
     "auth_ref": []
    },
    "adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://admabiologics.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredNumber",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares under fully vested and expected to vest options for which rights to exercise lapsed.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Expired, Number",
        "negatedLabel": "Expired (in shares)"
       }
      }
     },
     "auth_ref": []
    },
    "adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://admabiologics.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredWeightedAverageExercisePrice",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average exercise price, for fully vested and expected to vest that were expired.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Expired, Weighted Average Exercise Price",
        "terseLabel": "Expired (in dollars per share)"
       }
      }
     },
     "auth_ref": []
    },
    "adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://admabiologics.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedNumber",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares under fully vested and expected to vest options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Forfeited, Number",
        "negatedLabel": "Forfeited (in shares)"
       }
      }
     },
     "auth_ref": []
    },
    "adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://admabiologics.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedWeightedAverageExercisePrice",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average exercise price, for fully vested and expected to vest that were not exercised or put into effect as a result of the occurrence of a terminating event.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Forfeited, Weighted Average Exercise Price",
        "terseLabel": "Forfeited (in dollars per share)"
       }
      }
     },
     "auth_ref": []
    },
    "adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://admabiologics.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedNumber",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares under fully vested and expected to vest options that were granted during the current period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Granted, Number",
        "terseLabel": "Granted (in shares)"
       }
      }
     },
     "auth_ref": []
    },
    "adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://admabiologics.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedWeightedAverageExercisePrice",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest granted.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Granted, Weighted Average Exercise Price",
        "terseLabel": "Granted (in dollars per share)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Options outstanding, vested and expected to vest, beginning balance (in shares)",
        "periodEndLabel": "Options outstanding, vested and expected to vest, ending balance (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r453"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Options outstanding, vested and expected to vest, ending balance (in dollars per share)",
        "periodStartLabel": "Options outstanding, vested and expected to vest, beginning balance (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r453"
     ]
    },
    "adma_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedInCashlessTransactionForAward": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://admabiologics.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedInCashlessTransactionForAward",
     "presentation": [
      "http://admabiologics.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares purchased in cashless exercise for issuance under share-based payment arrangement.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award, Shares Purchased in Cashless Transaction for Award",
        "terseLabel": "Shares purchased in cashless transaction (in shares)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://admabiologics.com/role/RelatedPartyTransactionsDetails",
      "http://admabiologics.com/role/SignificantAccountingPoliciesStockbasedCompensationDetails",
      "http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Domain]",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r433",
      "r434",
      "r435",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461"
     ]
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "presentation": [
      "http://admabiologics.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-Based Compensation",
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost."
       }
      }
     },
     "auth_ref": [
      "r430",
      "r436",
      "r455",
      "r456",
      "r457",
      "r458",
      "r461",
      "r464",
      "r465",
      "r466",
      "r467"
     ]
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise Price Range [Axis]",
        "documentation": "Information by range of option prices pertaining to options granted."
       }
      }
     },
     "auth_ref": [
      "r52"
     ]
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise Price Range [Domain]",
        "documentation": "Supplementary information on outstanding and exercisable share awards as of the balance sheet date which stratifies outstanding options by ranges of exercise prices."
       }
      }
     },
     "auth_ref": [
      "r53"
     ]
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise price range, lower limit (in dollars per share)",
        "documentation": "The floor of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range."
       }
      }
     },
     "auth_ref": [
      "r53"
     ]
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options exercisable (in shares)",
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Shares Exercisable",
        "documentation": "The number of shares reserved for issuance pertaining to the outstanding exercisable stock options as of the balance sheet date in the customized range of exercise prices for which the market and performance vesting condition has been satisfied."
       }
      }
     },
     "auth_ref": [
      "r51"
     ]
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding at beginning of period (in shares)",
        "documentation": "The number of shares reserved for issuance pertaining to the outstanding stock options as of the balance sheet date for all option plans in the customized range of exercise prices."
       }
      }
     },
     "auth_ref": [
      "r118",
      "r119"
     ]
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise price range, upper limit (in dollars per share)",
        "documentation": "The ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range."
       }
      }
     },
     "auth_ref": [
      "r53"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails",
      "http://admabiologics.com/role/StockholdersEquityWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expected term",
        "verboseLabel": "Expected term",
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r457"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "crdr": "debit",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Options exercisable, aggregate intrinsic value",
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable."
       }
      }
     },
     "auth_ref": [
      "r49"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average remaining contractual life of stock options, exercisable",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r49"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average remaining contractual life of stock options, outstanding",
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r120"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average remaining contractual life of stock options, expected to vest",
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r453"
     ]
    },
    "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options exercisable, weighted average exercise price (in dollars per share)",
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Exercisable, Weighted Average Exercise Price",
        "documentation": "Weighted average exercise price as of the balance sheet date for those equity-based payment arrangements exercisable and outstanding."
       }
      }
     },
     "auth_ref": [
      "r50"
     ]
    },
    "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average remaining contractual life of stock options, exercisable",
        "documentation": "Weighted average remaining contractual term of exercisable stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r121"
     ]
    },
    "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Options outstanding, weighted average exercise price (in dollars per share)",
        "documentation": "The weighted average price as of the balance sheet date at which grantees could acquire the underlying shares with respect to all outstanding stock options which are in the customized range of exercise prices."
       }
      }
     },
     "auth_ref": [
      "r118",
      "r119"
     ]
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharesIssuedPricePerShare",
     "presentation": [
      "http://admabiologics.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Public offering price (in dollars per share)",
        "documentation": "Per share or per unit amount of equity securities issued."
       }
      }
     },
     "auth_ref": []
    },
    "adma_SharesIssuedUponExerciseOfWarrants": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://admabiologics.com/20241231",
     "localname": "SharesIssuedUponExerciseOfWarrants",
     "presentation": [
      "http://admabiologics.com/role/NotesPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued upon exercise of warrants.",
        "label": "Shares Issued Upon Exercise Of Warrants",
        "terseLabel": "Shares issued upon exercise of warrants (in shares)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharesOutstanding",
     "presentation": [
      "http://admabiologics.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Balance (in shares)",
        "periodStartLabel": "Balance (in shares)",
        "label": "Shares, Outstanding",
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharesPaidForTaxWithholdingForShareBasedCompensation",
     "presentation": [
      "http://admabiologics.com/role/RelatedPartyTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares withheld to cover portion of tax liabilities (in shares)",
        "label": "Share-Based Payment Arrangement, Shares Withheld for Tax Withholding Obligation",
        "documentation": "Number of shares used to settle grantee's tax withholding obligation for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://admabiologics.com/role/SignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SIGNIFICANT ACCOUNTING POLICIES",
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r101",
      "r230"
     ]
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StateAndLocalJurisdictionMember",
     "presentation": [
      "http://admabiologics.com/role/IncomeTaxesNetOperatingLossCarryforwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "State [Member]",
        "documentation": "Designated state or local jurisdiction entitled to levy and collect income tax."
       }
      }
     },
     "auth_ref": [
      "r479"
     ]
    },
    "us-gaap_StatementBusinessSegmentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementBusinessSegmentsAxis",
     "presentation": [
      "http://admabiologics.com/role/ConcentrationsDetails",
      "http://admabiologics.com/role/SegmentsNetRevenuesAccordingToGeographicAreaDetails",
      "http://admabiologics.com/role/SegmentsSummarizedFinancialInformationBySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segments [Axis]",
        "documentation": "Information by business segments."
       }
      }
     },
     "auth_ref": [
      "r134",
      "r135",
      "r136",
      "r137",
      "r198",
      "r269",
      "r273",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r298",
      "r299",
      "r300",
      "r305",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r344",
      "r348",
      "r351",
      "r352",
      "r629",
      "r630",
      "r631",
      "r632",
      "r633",
      "r634",
      "r635",
      "r636",
      "r637",
      "r638",
      "r639",
      "r782",
      "r785",
      "r786",
      "r791",
      "r831",
      "r1030",
      "r1032",
      "r1033",
      "r1034",
      "r1035",
      "r1036",
      "r1037",
      "r1038",
      "r1039",
      "r1040",
      "r1041",
      "r1042",
      "r1043",
      "r1044",
      "r1045",
      "r1046",
      "r1047",
      "r1048",
      "r1049",
      "r1050",
      "r1051",
      "r1052",
      "r1053",
      "r1054",
      "r1055",
      "r1056",
      "r1057",
      "r1058",
      "r1059"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://admabiologics.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity",
      "http://admabiologics.com/role/StockholdersEquityCommonStockDetails",
      "http://admabiologics.com/role/StockholdersEquityWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r76",
      "r79",
      "r80",
      "r197",
      "r219",
      "r220",
      "r221",
      "r245",
      "r246",
      "r247",
      "r249",
      "r254",
      "r256",
      "r258",
      "r270",
      "r312",
      "r313",
      "r346",
      "r409",
      "r502",
      "r503",
      "r509",
      "r510",
      "r511",
      "r513",
      "r514",
      "r515",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r528",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r545",
      "r547",
      "r558",
      "r625",
      "r651",
      "r652",
      "r653",
      "r671",
      "r730"
     ]
    },
    "srt_StatementGeographicalAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "StatementGeographicalAxis",
     "presentation": [
      "http://admabiologics.com/role/SegmentsNetRevenuesAccordingToGeographicAreaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]",
        "documentation": "Information by geographical components."
       }
      }
     },
     "auth_ref": [
      "r159",
      "r161",
      "r164",
      "r166",
      "r173",
      "r174",
      "r175",
      "r176",
      "r177",
      "r178",
      "r179",
      "r180",
      "r181",
      "r182",
      "r303",
      "r304",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600",
      "r601",
      "r602",
      "r603",
      "r604",
      "r605",
      "r674",
      "r675",
      "r676",
      "r739",
      "r741",
      "r744",
      "r746",
      "r749",
      "r752",
      "r753",
      "r754",
      "r755",
      "r756",
      "r757",
      "r758",
      "r759",
      "r760",
      "r768",
      "r801",
      "r818",
      "r819",
      "r820",
      "r821",
      "r822",
      "r823",
      "r824",
      "r825",
      "r830",
      "r837",
      "r965",
      "r1030",
      "r1032",
      "r1033",
      "r1035",
      "r1036",
      "r1037",
      "r1038",
      "r1039",
      "r1040",
      "r1041",
      "r1042",
      "r1043",
      "r1044",
      "r1045",
      "r1046",
      "r1047",
      "r1048",
      "r1049",
      "r1050",
      "r1051",
      "r1052",
      "r1053",
      "r1054",
      "r1055",
      "r1056",
      "r1057",
      "r1058",
      "r1059"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementLineItems",
     "presentation": [
      "http://admabiologics.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r245",
      "r246",
      "r247",
      "r270",
      "r547",
      "r573",
      "r660",
      "r673",
      "r679",
      "r680",
      "r681",
      "r682",
      "r683",
      "r684",
      "r687",
      "r690",
      "r691",
      "r692",
      "r693",
      "r694",
      "r696",
      "r697",
      "r698",
      "r699",
      "r701",
      "r702",
      "r703",
      "r704",
      "r705",
      "r707",
      "r709",
      "r710",
      "r716",
      "r717",
      "r718",
      "r719",
      "r720",
      "r721",
      "r722",
      "r723",
      "r724",
      "r725",
      "r726",
      "r727",
      "r730",
      "r838"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "CONSOLIDATED STATEMENTS OF CASH FLOWS [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "CONSOLIDATED BALANCE SHEETS [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS EQUITY [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementTable",
     "presentation": [
      "http://admabiologics.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Table]",
        "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity."
       }
      }
     },
     "auth_ref": [
      "r245",
      "r246",
      "r247",
      "r270",
      "r306",
      "r547",
      "r573",
      "r660",
      "r673",
      "r679",
      "r680",
      "r681",
      "r682",
      "r683",
      "r684",
      "r687",
      "r690",
      "r691",
      "r692",
      "r693",
      "r694",
      "r696",
      "r697",
      "r698",
      "r699",
      "r701",
      "r702",
      "r703",
      "r704",
      "r705",
      "r707",
      "r709",
      "r710",
      "r716",
      "r717",
      "r718",
      "r719",
      "r720",
      "r721",
      "r722",
      "r723",
      "r724",
      "r725",
      "r726",
      "r727",
      "r730",
      "r838"
     ]
    },
    "adma_StockIssuedDuringPeriodSharesCashlessExerciseOfWarrants": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://admabiologics.com/20241231",
     "localname": "StockIssuedDuringPeriodSharesCashlessExerciseOfWarrants",
     "presentation": [
      "http://admabiologics.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of the cashless exercise of warrants.",
        "label": "Stock Issued During Period Shares Cashless Exercise Of Warrants",
        "terseLabel": "Cashless exercise of warrants (in shares)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://admabiologics.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity",
      "http://admabiologics.com/role/RelatedPartyTransactionsDetails",
      "http://admabiologics.com/role/StockholdersEquityCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock, net of offering expenses (in shares)",
        "label": "Common stock shares sold during the period (in shares)",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r75",
      "r76",
      "r116",
      "r662",
      "r730",
      "r747"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://admabiologics.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity",
      "http://admabiologics.com/role/RelatedPartyTransactionsDetails",
      "http://admabiologics.com/role/StockholdersEquityCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise of stock options (in shares)",
        "terseLabel": "Stock options exercised (in shares)",
        "verboseLabel": "Common stock shares issued (in shares)",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r75",
      "r76",
      "r116",
      "r442"
     ]
    },
    "adma_StockIssuedDuringPeriodValueCashlessExerciseOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://admabiologics.com/20241231",
     "localname": "StockIssuedDuringPeriodValueCashlessExerciseOfWarrants",
     "crdr": "credit",
     "presentation": [
      "http://admabiologics.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate change in value for stock issued during the period as a result of the cashless exercise of warrants.",
        "label": "Stock Issued During Period Value Cashless Exercise Of Warrants",
        "terseLabel": "Cashless exercise of warrants"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://admabiologics.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of common stock, net of offering expenses",
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r75",
      "r76",
      "r116",
      "r671",
      "r730",
      "r747",
      "r844"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "crdr": "credit",
     "presentation": [
      "http://admabiologics.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exercise of stock options",
        "documentation": "Value of stock issued as a result of the exercise of stock options."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r76",
      "r79",
      "r80",
      "r116"
     ]
    },
    "adma_StockOptionOutstandingAndExcercisableAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://admabiologics.com/20241231",
     "localname": "StockOptionOutstandingAndExcercisableAbstract",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Option Outstanding and Exercisable [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "adma_StockOptionSharesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://admabiologics.com/20241231",
     "localname": "StockOptionSharesAbstract",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Option, Shares [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "adma_StockOptionsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://admabiologics.com/20241231",
     "localname": "StockOptionsAbstract",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Options [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "adma_StockOptionsWeightedAverageExercisePriceAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://admabiologics.com/20241231",
     "localname": "StockOptionsWeightedAverageExercisePriceAbstract",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Options, Weighted Average Exercise Price [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://admabiologics.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://admabiologics.com/role/ConsolidatedBalanceSheets",
      "http://admabiologics.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Balance",
        "periodStartLabel": "Balance",
        "totalLabel": "TOTAL STOCKHOLDERS' EQUITY",
        "label": "Equity, Attributable to Parent",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r76",
      "r79",
      "r80",
      "r106",
      "r689",
      "r706",
      "r731",
      "r732",
      "r817",
      "r845",
      "r912",
      "r934",
      "r1012",
      "r1063"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://admabiologics.com/role/ConsolidatedBalanceSheets",
      "http://admabiologics.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "STOCKHOLDERS' EQUITY",
        "terseLabel": "STOCKHOLDERS' EQUITY",
        "label": "Equity, Attributable to Parent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "STOCKHOLDERS' EQUITY",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r113",
      "r231",
      "r392",
      "r394",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r406",
      "r409",
      "r527",
      "r733",
      "r735",
      "r748"
     ]
    },
    "us-gaap_SubsequentEventMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventMember",
     "presentation": [
      "http://admabiologics.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Member]",
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r542",
      "r567"
     ]
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventTypeAxis",
     "presentation": [
      "http://admabiologics.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Axis]",
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r542",
      "r567"
     ]
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventTypeDomain",
     "presentation": [
      "http://admabiologics.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Domain]",
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r542",
      "r567"
     ]
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityCommonStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Axis]",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SummaryOfOperatingLossCarryforwardsTextBlock",
     "presentation": [
      "http://admabiologics.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expiration of Federal Net Operating Loss",
        "documentation": "Tabular disclosure of pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization."
       }
      }
     },
     "auth_ref": [
      "r1002"
     ]
    },
    "us-gaap_SupplementalCashFlowElementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SupplementalCashFlowElementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SupplementalCashFlowInformationAbstract",
     "presentation": [
      "http://admabiologics.com/role/SupplementalDisclosureOfCashFlowInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SUPPLEMENTAL CASH FLOW INFORMATION [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TaxCreditCarryforwardValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TaxCreditCarryforwardValuationAllowance",
     "crdr": "credit",
     "presentation": [
      "http://admabiologics.com/role/IncomeTaxesNetOperatingLossCarryforwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Valuation allowance",
        "documentation": "Amount of valuation allowance pertaining to the deferred tax asset representing potential future taxable deductions from tax credit carryforwards for which it is more likely than not that a tax benefit will not be realized."
       }
      }
     },
     "auth_ref": [
      "r999"
     ]
    },
    "us-gaap_TaxPeriodAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TaxPeriodAxis",
     "presentation": [
      "http://admabiologics.com/role/IncomeTaxesNetOperatingLossCarryforwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Period [Axis]",
        "documentation": "Information by period subject to enacted tax law."
       }
      }
     },
     "auth_ref": [
      "r997"
     ]
    },
    "us-gaap_TaxPeriodDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TaxPeriodDomain",
     "presentation": [
      "http://admabiologics.com/role/IncomeTaxesNetOperatingLossCarryforwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Period [Domain]",
        "documentation": "Identified tax period."
       }
      }
     },
     "auth_ref": [
      "r997"
     ]
    },
    "adma_TaxYear2028Through2043Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://admabiologics.com/20241231",
     "localname": "TaxYear2028Through2043Member",
     "presentation": [
      "http://admabiologics.com/role/IncomeTaxesNetOperatingLossCarryforwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identified as tax years 2028 through 2043.",
        "label": "Tax Year 2028 through 2043 [Member]",
        "terseLabel": "2028 through 2043 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "adma_TaxYear2031Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://admabiologics.com/20241231",
     "localname": "TaxYear2031Member",
     "presentation": [
      "http://admabiologics.com/role/IncomeTaxesNetOperatingLossCarryforwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identified as tax year 2031.",
        "label": "Tax Year 2031 [Member]",
        "terseLabel": "2031 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "adma_TaxYear2032Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://admabiologics.com/20241231",
     "localname": "TaxYear2032Member",
     "presentation": [
      "http://admabiologics.com/role/IncomeTaxesNetOperatingLossCarryforwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identified as tax year 2032.",
        "label": "Tax Year 2032 [Member]",
        "terseLabel": "2032 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "adma_TaxYear2033Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://admabiologics.com/20241231",
     "localname": "TaxYear2033Member",
     "presentation": [
      "http://admabiologics.com/role/IncomeTaxesNetOperatingLossCarryforwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identified as tax year 2033.",
        "label": "Tax Year 2033 [Member]",
        "terseLabel": "2033 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "adma_TaxYear2034Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://admabiologics.com/20241231",
     "localname": "TaxYear2034Member",
     "presentation": [
      "http://admabiologics.com/role/IncomeTaxesNetOperatingLossCarryforwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identified as tax year 2034.",
        "label": "Tax Year 2034 [Member]",
        "terseLabel": "2034 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "adma_TaxYear2035Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://admabiologics.com/20241231",
     "localname": "TaxYear2035Member",
     "presentation": [
      "http://admabiologics.com/role/IncomeTaxesNetOperatingLossCarryforwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identified as tax year 2035.",
        "label": "Tax Year 2035 [Member]",
        "terseLabel": "2035 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "adma_TaxYear2036Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://admabiologics.com/20241231",
     "localname": "TaxYear2036Member",
     "presentation": [
      "http://admabiologics.com/role/IncomeTaxesNetOperatingLossCarryforwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identified as tax year 2036.",
        "label": "Tax Year 2036 [Member]",
        "terseLabel": "2036 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "adma_TaxYear2037Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://admabiologics.com/20241231",
     "localname": "TaxYear2037Member",
     "presentation": [
      "http://admabiologics.com/role/IncomeTaxesNetOperatingLossCarryforwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identified as tax year 2037.",
        "label": "Tax Year 2037 [Member]",
        "terseLabel": "2037 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "adma_TaxYearAfter2037Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://admabiologics.com/20241231",
     "localname": "TaxYearAfter2037Member",
     "presentation": [
      "http://admabiologics.com/role/IncomeTaxesNetOperatingLossCarryforwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identified as tax year after 2037.",
        "label": "Tax Year After 2037 [Member]",
        "terseLabel": "Indefinite [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "adma_TaxesPaidOnVestedRestrictedStockUnits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://admabiologics.com/20241231",
     "localname": "TaxesPaidOnVestedRestrictedStockUnits",
     "crdr": "credit",
     "calculation": {
      "http://admabiologics.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://admabiologics.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow related to taxes on vested Restricted Stock Units.",
        "label": "Taxes Paid on Vested Restricted Stock Units",
        "negatedLabel": "Taxes paid on vested Restricted Stock Units"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TaxesPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TaxesPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://admabiologics.com/role/AccruedExpensesAndOtherLiabilitiesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://admabiologics.com/role/AccruedExpensesAndOtherLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income taxes payable",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r64",
      "r65"
     ]
    },
    "adma_TermLoanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://admabiologics.com/20241231",
     "localname": "TermLoanMember",
     "presentation": [
      "http://admabiologics.com/role/NotesPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time, and under which borrowings outstanding may be either short-term or long-term, depending upon the particulars.",
        "label": "Term Loan [Member]",
        "terseLabel": "Term Loan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "adma_ThreeCustomersMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://admabiologics.com/20241231",
     "localname": "ThreeCustomersMember",
     "presentation": [
      "http://admabiologics.com/role/ConcentrationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information about number of customers accounting for a percentage of consolidated revenues.",
        "label": "Three Customers [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_TitleOfIndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "TitleOfIndividualAxis",
     "presentation": [
      "http://admabiologics.com/role/RelatedPartyTransactionsDetails",
      "http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title and Position [Axis]",
        "documentation": "Information by title and position of individual or group within organization."
       }
      }
     },
     "auth_ref": [
      "r931",
      "r1019"
     ]
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "presentation": [
      "http://admabiologics.com/role/RelatedPartyTransactionsDetails",
      "http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title and Position [Domain]",
        "documentation": "Title and position of individual or group within organization."
       }
      }
     },
     "auth_ref": []
    },
    "adma_TrademarkAndOtherIntangibleRightsRelatedToNabiHBMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://admabiologics.com/20241231",
     "localname": "TrademarkAndOtherIntangibleRightsRelatedToNabiHBMember",
     "presentation": [
      "http://admabiologics.com/role/IntangibleAssetsSummaryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Entity's established relationships with its customers through contracts.",
        "label": "Trademark and Other Intangible Rights Related to Nabi-HB [Member]",
        "terseLabel": "Trademark and Other Intangible Rights Related to Nabi-HB [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TradingArrAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TradingArrAxis",
     "presentation": [
      "http://admabiologics.com/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r871"
     ]
    },
    "ecd_TradingArrByIndTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TradingArrByIndTable",
     "presentation": [
      "http://admabiologics.com/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Arrangements, by Individual [Table]"
       }
      }
     },
     "auth_ref": [
      "r873"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://admabiologics.com/role/DocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "adma_TrailingPeriodForVolumeWeightedAveragePrice": {
     "xbrltype": "durationItemType",
     "nsuri": "http://admabiologics.com/20241231",
     "localname": "TrailingPeriodForVolumeWeightedAveragePrice",
     "presentation": [
      "http://admabiologics.com/role/NotesPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The trailing period for volume-weighted average price, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Trailing Period for Volume Weighted Average Price",
        "terseLabel": "Trailing period for VWAP"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TrdArrAdoptionDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrAdoptionDate",
     "presentation": [
      "http://admabiologics.com/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adoption Date",
        "label": "Trading Arrangement Adoption Date"
       }
      }
     },
     "auth_ref": [
      "r874"
     ]
    },
    "ecd_TrdArrDuration": {
     "xbrltype": "durationItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrDuration",
     "presentation": [
      "http://admabiologics.com/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Arrangement Duration",
        "label": "Trading Arrangement Duration"
       }
      }
     },
     "auth_ref": [
      "r875"
     ]
    },
    "ecd_TrdArrExpirationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrExpirationDate",
     "presentation": [
      "http://admabiologics.com/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expiration Date",
        "label": "Trading Arrangement Expiration Date"
       }
      }
     },
     "auth_ref": [
      "r875"
     ]
    },
    "ecd_TrdArrIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrIndName",
     "presentation": [
      "http://admabiologics.com/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Trading Arrangement, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r873"
     ]
    },
    "ecd_TrdArrIndTitle": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrIndTitle",
     "presentation": [
      "http://admabiologics.com/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title",
        "label": "Trading Arrangement, Individual Title"
       }
      }
     },
     "auth_ref": [
      "r873"
     ]
    },
    "ecd_TrdArrSecuritiesAggAvailAmt": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrSecuritiesAggAvailAmt",
     "presentation": [
      "http://admabiologics.com/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Available",
        "label": "Trading Arrangement, Securities Aggregate Available Amount"
       }
      }
     },
     "auth_ref": [
      "r876"
     ]
    },
    "adma_Two022CompensationPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://admabiologics.com/20241231",
     "localname": "Two022CompensationPlanMember",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityEquityIncentivePlansDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents 2022 compensation plan of equity based compensation arrangement plan.",
        "label": "Two022 Compensation Plan [Member]",
        "terseLabel": "2022 Compensation Plan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "adma_TwoCustomersMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://admabiologics.com/20241231",
     "localname": "TwoCustomersMember",
     "presentation": [
      "http://admabiologics.com/role/ConcentrationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information about number of customers accounting for a percentage of consolidated revenues.",
        "label": "Two Customers [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TypeOfArrangementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TypeOfArrangementAxis",
     "presentation": [
      "http://admabiologics.com/role/CommitmentsAndContingenciesDetails",
      "http://admabiologics.com/role/SignificantAccountingPoliciesRevenueRecognitionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r516"
     ]
    },
    "country_US": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2024",
     "localname": "US",
     "presentation": [
      "http://admabiologics.com/role/SegmentsNetRevenuesAccordingToGeographicAreaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "United States [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UnrecognizedTaxBenefits",
     "crdr": "credit",
     "presentation": [
      "http://admabiologics.com/role/IncomeTaxesNetOperatingLossCarryforwardsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrecognized tax benefits",
        "label": "Unrecognized Tax Benefits",
        "documentation": "Amount of unrecognized tax benefits."
       }
      }
     },
     "auth_ref": [
      "r473",
      "r490",
      "r806"
     ]
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://admabiologics.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Use of Estimates",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r29",
      "r30",
      "r31",
      "r142",
      "r143",
      "r145",
      "r146"
     ]
    },
    "adma_UseOfEstimatesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://admabiologics.com/20241231",
     "localname": "UseOfEstimatesAbstract",
     "presentation": [
      "http://admabiologics.com/role/SignificantAccountingPoliciesUseOfEstimatesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Use of Estimates [Abstract]",
        "terseLabel": "Use of Estimates [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ValuationAllowanceOfDeferredTaxAssetsMember",
     "presentation": [
      "http://admabiologics.com/role/ScheduleIiValuationAndQualifyingAccountsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Asset Valuation Allowance [Member]",
        "documentation": "Valuation allowance of deferred tax asset attributable to deductible temporary difference and carryforward."
       }
      }
     },
     "auth_ref": [
      "r914",
      "r915",
      "r916",
      "r917",
      "r918"
     ]
    },
    "us-gaap_ValuationAllowancesAndReservesBalance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ValuationAllowancesAndReservesBalance",
     "crdr": "credit",
     "presentation": [
      "http://admabiologics.com/role/ScheduleIiValuationAndQualifyingAccountsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Balance at end of year",
        "periodStartLabel": "Balance at beginning of year",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount",
        "documentation": "Amount of valuation and qualifying accounts and reserves."
       }
      }
     },
     "auth_ref": [
      "r239",
      "r243"
     ]
    },
    "us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ValuationAllowancesAndReservesChargedToCostAndExpense",
     "crdr": "credit",
     "presentation": [
      "http://admabiologics.com/role/ScheduleIiValuationAndQualifyingAccountsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Charged to costs and expenses",
        "documentation": "Amount of increase in valuation and qualifying accounts and reserves from charge to cost and expense."
       }
      }
     },
     "auth_ref": [
      "r240"
     ]
    },
    "us-gaap_ValuationAllowancesAndReservesChargedToOtherAccounts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ValuationAllowancesAndReservesChargedToOtherAccounts",
     "crdr": "credit",
     "presentation": [
      "http://admabiologics.com/role/ScheduleIiValuationAndQualifyingAccountsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Other Account",
        "documentation": "Amount of increase in valuation and qualifying accounts and reserves from charge to accounts other than cost and expense."
       }
      }
     },
     "auth_ref": [
      "r241"
     ]
    },
    "us-gaap_ValuationAllowancesAndReservesDeductions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ValuationAllowancesAndReservesDeductions",
     "crdr": "debit",
     "presentation": [
      "http://admabiologics.com/role/ScheduleIiValuationAndQualifyingAccountsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deductions",
        "documentation": "Amount of decrease in valuation and qualifying accounts and reserves."
       }
      }
     },
     "auth_ref": [
      "r242"
     ]
    },
    "us-gaap_ValuationAllowancesAndReservesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ValuationAllowancesAndReservesDomain",
     "presentation": [
      "http://admabiologics.com/role/ScheduleIiValuationAndQualifyingAccountsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Valuation Allowances and Reserves [Domain]",
        "documentation": "Valuation and qualifying accounts and reserves."
       }
      }
     },
     "auth_ref": [
      "r239",
      "r240",
      "r241",
      "r242",
      "r243"
     ]
    },
    "us-gaap_ValuationAllowancesAndReservesTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ValuationAllowancesAndReservesTypeAxis",
     "presentation": [
      "http://admabiologics.com/role/ScheduleIiValuationAndQualifyingAccountsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Valuation Allowances and Reserves Type [Axis]",
        "documentation": "Information by valuation and qualifying accounts and reserves."
       }
      }
     },
     "auth_ref": [
      "r239",
      "r240",
      "r241",
      "r242",
      "r243"
     ]
    },
    "srt_ValuationAndQualifyingAccountsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ValuationAndQualifyingAccountsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule II - Valuation and Qualifying Accounts [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_ValuationAndQualifyingAccountsDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ValuationAndQualifyingAccountsDisclosureLineItems",
     "presentation": [
      "http://admabiologics.com/role/ScheduleIiValuationAndQualifyingAccountsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Valuation and Qualifying Accounts Disclosure [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r152",
      "r153",
      "r154",
      "r155",
      "r156",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243"
     ]
    },
    "srt_ValuationAndQualifyingAccountsDisclosureTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ValuationAndQualifyingAccountsDisclosureTable",
     "presentation": [
      "http://admabiologics.com/role/ScheduleIiValuationAndQualifyingAccountsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Valuation and Qualifying Accounts Disclosure [Table]",
        "documentation": "Disclosure of information about valuation allowance and qualifying account and reserve."
       }
      }
     },
     "auth_ref": [
      "r152",
      "r153",
      "r154",
      "r155",
      "r156",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243"
     ]
    },
    "us-gaap_VariableRateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "VariableRateAxis",
     "presentation": [
      "http://admabiologics.com/role/NotesPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Variable Rate [Axis]",
        "documentation": "Information by type of variable rate."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_VariableRateDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "VariableRateDomain",
     "presentation": [
      "http://admabiologics.com/role/NotesPayableDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Variable Rate [Domain]",
        "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index."
       }
      }
     },
     "auth_ref": []
    },
    "adma_VendorAndLicensorCommitmentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://admabiologics.com/20241231",
     "localname": "VendorAndLicensorCommitmentsAbstract",
     "presentation": [
      "http://admabiologics.com/role/CommitmentsAndContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vendor and Licensor Commitments [Abstract]",
        "terseLabel": "Vendor and Licensor Commitments [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "adma_VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://admabiologics.com/20241231",
     "localname": "VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAmount",
     "crdr": "credit",
     "presentation": [
      "http://admabiologics.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock related to restricted stock awards issued during the period, net of shares withheld to cover grantees' income tax liability.",
        "label": "Vesting of Restricted Stock Units Net of Shares Withheld for Taxes, Amount",
        "negatedLabel": "Vesting of Restricted Stock Units, net of shares withheld for taxes"
       }
      }
     },
     "auth_ref": []
    },
    "adma_VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://admabiologics.com/20241231",
     "localname": "VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesShares",
     "presentation": [
      "http://admabiologics.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period related to restricted stock awards, net of shares withheld to cover grantees' income tax liability.",
        "label": "Vesting of Restricted Stock Units Net of Shares Withheld for Taxes, Shares",
        "terseLabel": "Vesting of Restricted Stock Units, net of shares withheld for taxes (in shares)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WarrantMember",
     "presentation": [
      "http://admabiologics.com/role/SignificantAccountingPoliciesEarningsLossPerShareDetails",
      "http://admabiologics.com/role/StockholdersEquityWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants [Member]",
        "terseLabel": "Warrant [Member]",
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount."
       }
      }
     },
     "auth_ref": [
      "r835",
      "r836",
      "r839",
      "r840",
      "r841",
      "r842"
     ]
    },
    "adma_WarrantsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://admabiologics.com/20241231",
     "localname": "WarrantsAbstract",
     "presentation": [
      "http://admabiologics.com/role/StockholdersEquityWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants [Abstract]",
        "terseLabel": "Warrants [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WarrantsAndRightsOutstanding": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WarrantsAndRightsOutstanding",
     "crdr": "credit",
     "presentation": [
      "http://admabiologics.com/role/NotesPayableDetails",
      "http://admabiologics.com/role/StockholdersEquityWarrantsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Fair value of warrants",
        "label": "Warrants and Rights Outstanding",
        "documentation": "Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price."
       }
      }
     },
     "auth_ref": [
      "r1009",
      "r1010",
      "r1011"
     ]
    },
    "adma_WarrantsIssuedInConnectionWithNotesPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://admabiologics.com/20241231",
     "localname": "WarrantsIssuedInConnectionWithNotesPayable",
     "crdr": "credit",
     "presentation": [
      "http://admabiologics.com/role/SupplementalDisclosureOfCashFlowInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of warrants issued in connection with the issuance of notes payable.",
        "label": "Warrants Issued in Connection with Notes Payable",
        "terseLabel": "Warrants issued in connection with notes payable"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustment",
     "presentation": [
      "http://admabiologics.com/role/SignificantAccountingPoliciesEarningsLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Potential shares of common stock arising from outstanding stock options, warrants and unvested RSUs (in shares)",
        "documentation": "The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation."
       }
      }
     },
     "auth_ref": [
      "r923"
     ]
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://admabiologics.com/role/ConsolidatedStatementsOfOperations",
      "http://admabiologics.com/role/SignificantAccountingPoliciesEarningsLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Diluted (in shares)",
        "terseLabel": "Total shares - diluted (denominator) (in shares)",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r260",
      "r265"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfSharesOutstandingAbstract",
     "presentation": [
      "http://admabiologics.com/role/ConsolidatedStatementsOfOperations"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "WEIGHTED AVERAGE COMMON SHARES OUTSTANDING:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://admabiologics.com/role/ConsolidatedStatementsOfOperations",
      "http://admabiologics.com/role/SignificantAccountingPoliciesEarningsLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basic (in shares)",
        "terseLabel": "Weighted-average number of common shares (denominator) (in shares)",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r259",
      "r265"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "13",
   "SubTopic": "10",
   "Topic": "480",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481766/480-10-25-13"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "825",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-1"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2A"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "SubTopic": "10",
   "Topic": "280",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-4"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "815",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483489/210-10-50-1"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-1"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "270",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482989/270-10-45-14"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-16"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-20"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-21"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-8"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "30",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482130/360-10-45-4"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "20",
   "Section": "25",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481284/470-20-25-2"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "50",
   "Section": "40",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481303/470-50-40-2"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "50",
   "Section": "40",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481303/470-50-40-4"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481142/505-10-45-2"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-10"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-4"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-5"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-8"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-1"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-20"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "850",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "850",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "470",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "470",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/205/tableOfContent"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r91": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r92": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r93": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r94": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/230/tableOfContent"
  },
  "r95": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r96": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r97": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r98": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r99": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r100": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r101": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/235/tableOfContent"
  },
  "r102": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "250",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/250/tableOfContent"
  },
  "r103": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "275",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/275/tableOfContent"
  },
  "r104": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18"
  },
  "r105": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r106": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2"
  },
  "r107": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/360/tableOfContent"
  },
  "r108": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r109": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-2"
  },
  "r110": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/440/tableOfContent"
  },
  "r111": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/470/tableOfContent"
  },
  "r112": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r113": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/505/tableOfContent"
  },
  "r114": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6"
  },
  "r115": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-7"
  },
  "r116": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r117": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r118": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r119": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r120": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r121": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r122": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r123": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/810/tableOfContent"
  },
  "r124": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21"
  },
  "r125": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r126": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r127": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r128": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r129": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r130": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r131": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r132": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r133": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "470",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3"
  },
  "r134": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r135": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r136": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r137": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "SubTopic": "210",
   "Topic": "946",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-20"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "270",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482989/270-10-45-6"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "SubTopic": "35",
   "Topic": "720",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483406/720-35-50-1"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-1"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-11"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-6"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-7"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "04",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "09",
   "Paragraph": "Column B",
   "Publisher": "SEC"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "09",
   "Paragraph": "Column C",
   "Subparagraph": "(1)",
   "Publisher": "SEC"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "09",
   "Paragraph": "Column C",
   "Subparagraph": "(2)",
   "Publisher": "SEC"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "09",
   "Paragraph": "Column D",
   "Publisher": "SEC"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "09",
   "Paragraph": "Column E",
   "Publisher": "SEC"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "09",
   "Publisher": "SEC"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12",
   "Paragraph": "Column A",
   "Footnote": "2",
   "Publisher": "SEC"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12",
   "Paragraph": "Column C",
   "Footnote": "5",
   "Publisher": "SEC"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12A",
   "Paragraph": "Column A",
   "Footnote": "2",
   "Publisher": "SEC"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12A",
   "Paragraph": "Column C",
   "Footnote": "4",
   "Publisher": "SEC"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12B",
   "Paragraph": "Column A",
   "Subparagraph": "(a)",
   "Footnote": "4",
   "Publisher": "SEC"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12B",
   "Paragraph": "Column A",
   "Subparagraph": "(b)",
   "Footnote": "4",
   "Publisher": "SEC"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12B",
   "Paragraph": "Column C",
   "Footnote": "2",
   "Publisher": "SEC"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "14",
   "Paragraph": "Column A",
   "Footnote": "2",
   "Publisher": "SEC"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "14",
   "Paragraph": "Column F",
   "Footnote": "7",
   "Publisher": "SEC"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "17",
   "Paragraph": "Column A",
   "Publisher": "SEC"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "17",
   "Paragraph": "Column B",
   "Publisher": "SEC"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "17",
   "Paragraph": "Column C",
   "Publisher": "SEC"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "17",
   "Paragraph": "Column D",
   "Publisher": "SEC"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "17",
   "Paragraph": "Column E",
   "Publisher": "SEC"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "17",
   "Paragraph": "Column F",
   "Publisher": "SEC"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column A",
   "Footnote": "2",
   "Publisher": "SEC"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column B",
   "Publisher": "SEC"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column C",
   "Publisher": "SEC"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column D",
   "Publisher": "SEC"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column E",
   "Publisher": "SEC"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column F",
   "Publisher": "SEC"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column G",
   "Publisher": "SEC"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column H",
   "Publisher": "SEC"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column I",
   "Publisher": "SEC"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "29",
   "Paragraph": "Column A",
   "Footnote": "4",
   "Publisher": "SEC"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "13",
   "Subsection": "01",
   "Paragraph": "a",
   "Subparagraph": "(4)(i)",
   "Publisher": "SEC"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "13",
   "Subsection": "01",
   "Paragraph": "a",
   "Subparagraph": "(4)(iii)(A)",
   "Publisher": "SEC"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "13",
   "Subsection": "01",
   "Paragraph": "a",
   "Subparagraph": "(4)(iii)(B)",
   "Publisher": "SEC"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "13",
   "Subsection": "01",
   "Paragraph": "a",
   "Subparagraph": "(4)(iv)",
   "Publisher": "SEC"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "13",
   "Subsection": "02",
   "Paragraph": "a",
   "Subparagraph": "(4)(i)",
   "Publisher": "SEC"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "13",
   "Subsection": "02",
   "Paragraph": "a",
   "Subparagraph": "(4)(iii)(A)",
   "Publisher": "SEC"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "13",
   "Subsection": "02",
   "Paragraph": "a",
   "Subparagraph": "(4)(iii)(B)",
   "Publisher": "SEC"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "13",
   "Subsection": "02",
   "Paragraph": "a",
   "Subparagraph": "(4)(iii)(C)",
   "Publisher": "SEC"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "13",
   "Subsection": "02",
   "Paragraph": "a",
   "Subparagraph": "(4)(iv)",
   "Publisher": "SEC"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "4",
   "Subsection": "08",
   "Paragraph": "m",
   "Subparagraph": "(1)(iii)",
   "Publisher": "SEC"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "4",
   "Subsection": "08",
   "Paragraph": "m",
   "Subparagraph": "(2)(ii)",
   "Publisher": "SEC"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Staff Accounting Bulletin (SAB)",
   "Number": "Topic 11",
   "Section": "L",
   "Publisher": "SEC"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Staff Accounting Bulletin (SAB)",
   "Number": "Topic 5",
   "Section": "Y",
   "Paragraph": "Question 2",
   "Publisher": "SEC"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Staff Accounting Bulletin (SAB)",
   "Number": "Topic 5",
   "Section": "Y",
   "Paragraph": "Question 4",
   "Publisher": "SEC"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-1"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483489/210-10-50-1"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-1"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-17"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "21B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-21B"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2A"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SX 210.12-09(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-4"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SX 210.12-09(Column C)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-4"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SX 210.12-09(Column C)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-4"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SX 210.12-09(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-4"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SX 210.12-09(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-4"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SX 210.12-09)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-4"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/280/tableOfContent"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-15"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(j)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26A"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26B"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26C"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "34",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-34"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-2"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-2"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-2"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481569/310-20-50-1"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/330/tableOfContent"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483080/330-10-50-1"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483080/330-10-50-2"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483080/330-10-50-4"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480265/350-10-S45-1"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/350-20/tableOfContent"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482598/350-20-45-1"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482598/350-20-45-2"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-2"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/350-30/tableOfContent"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-2"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-4"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-1"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-3"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-4"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-6"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-1"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-2"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-4"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-8"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/715/tableOfContent"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(o)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(p)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(q)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(r)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(r)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480126/715-20-S99-2"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480266/715-60-50-3"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "70",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480794/715-70-50-1"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/718/tableOfContent"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.C.Q3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.1.Q5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.3.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483044/730-10-05-1"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/740/tableOfContent"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-10B"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-25"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-28"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-4"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-6"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12B"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12C"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-14"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15A"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-19"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-20"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-21"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-23"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-2"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477891/740-270-50-1"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482603/740-30-50-2"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-2"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/842-20/tableOfContent"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "12A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/850/tableOfContent"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-6"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-9"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "912",
   "SubTopic": "330",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478411/912-330-50-1"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483154/926-20-50-5"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "928",
   "SubTopic": "340",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478859/928-340-50-1"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478934/932-220-50-1"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-19"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-6"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-7"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "280",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478657/932-280-50-1"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478988/932-323-50-1"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(7)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column J))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column K))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4E"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.W.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "825",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477351/944-825-50-1B"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-1"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-2"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-13"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-2"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-5"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-6"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-21"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-2"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r684": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r685": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r686": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r687": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r688": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r689": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r690": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r691": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r692": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r693": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r694": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r695": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r696": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r697": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r698": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r699": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r700": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r701": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r702": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r703": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r704": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r705": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r706": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r707": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r708": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7"
  },
  "r709": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r710": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r711": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r712": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r713": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r714": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r715": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r716": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r717": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r718": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r719": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r720": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r721": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r722": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r723": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r724": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r725": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r726": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r727": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r728": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r729": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r730": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r731": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r732": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r733": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r734": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r735": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r736": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r737": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r738": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r739": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r740": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r741": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r742": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r743": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r744": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r745": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r746": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r747": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r748": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6"
  },
  "r749": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column A)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r750": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478785/954-310-50-2"
  },
  "r751": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1"
  },
  "r752": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r753": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r754": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r755": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r756": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r757": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r758": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r759": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r760": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r761": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1"
  },
  "r762": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1"
  },
  "r763": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/985-20/tableOfContent"
  },
  "r764": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2"
  },
  "r765": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-16"
  },
  "r766": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r767": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(a)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r768": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(b)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r769": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "38",
   "Subparagraph": "(b)",
   "SubTopic": "20",
   "Topic": "805",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-38"
  },
  "r770": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r771": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r772": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "8",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-8"
  },
  "r773": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-16"
  },
  "r774": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-21"
  },
  "r775": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-22"
  },
  "r776": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r777": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r778": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52"
  },
  "r779": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r780": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r781": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r782": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r783": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r784": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r785": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "48",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48"
  },
  "r786": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "49",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49"
  },
  "r787": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r788": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r789": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r790": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A"
  },
  "r791": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482548/350-20-55-24"
  },
  "r792": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482640/350-30-55-40"
  },
  "r793": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482395/460-10-55-27"
  },
  "r794": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r795": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B"
  },
  "r796": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C"
  },
  "r797": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69E"
  },
  "r798": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69F"
  },
  "r799": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r800": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r801": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r802": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r803": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17"
  },
  "r804": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8"
  },
  "r805": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r806": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "217",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-217"
  },
  "r807": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "231",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231"
  },
  "r808": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r809": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r810": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "102",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102"
  },
  "r811": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "103",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103"
  },
  "r812": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r813": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r814": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r815": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482949/835-30-55-8"
  },
  "r816": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53"
  },
  "r817": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10"
  },
  "r818": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-17"
  },
  "r819": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-21"
  },
  "r820": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-29"
  },
  "r821": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-3"
  },
  "r822": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-2"
  },
  "r823": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-4"
  },
  "r824": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-5"
  },
  "r825": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-6"
  },
  "r826": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479401/944-30-55-2"
  },
  "r827": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r828": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F"
  },
  "r829": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r830": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r831": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r832": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r833": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9E"
  },
  "r834": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-18"
  },
  "r835": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r836": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r837": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1"
  },
  "r838": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r839": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r840": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r841": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r842": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r843": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10"
  },
  "r844": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11"
  },
  "r845": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12"
  },
  "r846": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r847": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r848": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r849": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r850": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r851": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K"
  },
  "r852": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r853": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r854": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r855": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r856": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "2"
  },
  "r857": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "1"
  },
  "r858": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2"
  },
  "r859": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "i"
  },
  "r860": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r861": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r862": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r863": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r864": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r865": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r866": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r867": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6",
   "Subparagraph": "i"
  },
  "r868": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w"
  },
  "r869": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r870": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2"
  },
  "r871": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r872": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r873": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "A"
  },
  "r874": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "B"
  },
  "r875": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "C"
  },
  "r876": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "D"
  },
  "r877": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106"
  },
  "r878": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r879": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r880": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r881": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r882": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "2"
  },
  "r883": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "1"
  },
  "r884": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2"
  },
  "r885": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "i"
  },
  "r886": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r887": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r888": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r889": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r890": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3"
  },
  "r891": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "SubTopic": "740",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479176/718-740-35-2"
  },
  "r892": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18"
  },
  "r893": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "SubTopic": "825",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477351/944-825-50-1B"
  },
  "r894": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r895": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Topic": "705",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/705/tableOfContent"
  },
  "r896": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "13",
   "Subsection": "01",
   "Paragraph": "a",
   "Subparagraph": "(4)(ii)",
   "Publisher": "SEC"
  },
  "r897": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "13",
   "Subsection": "01",
   "Paragraph": "a",
   "Subparagraph": "(4)(iii)",
   "Publisher": "SEC"
  },
  "r898": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "6",
   "Subsection": "04",
   "Paragraph": "12",
   "Subparagraph": "(b)(1)",
   "Publisher": "SEC"
  },
  "r899": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Staff Accounting Bulletin (SAB)",
   "Number": "Topic 5",
   "Section": "Y",
   "Paragraph": "Question 2",
   "Publisher": "SEC"
  },
  "r900": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r901": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r902": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r903": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r904": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r905": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r906": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r907": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r908": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r909": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2A"
  },
  "r910": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r911": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(f))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r912": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r913": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r914": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SX 210.12-09(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-4"
  },
  "r915": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SX 210.12-09(Column C)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-4"
  },
  "r916": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SX 210.12-09(Column C)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-4"
  },
  "r917": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SX 210.12-09(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-4"
  },
  "r918": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SX 210.12-09(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-4"
  },
  "r919": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r920": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r921": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r922": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r923": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r924": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r925": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-18"
  },
  "r926": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r927": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r928": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r929": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r930": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r931": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r932": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-2"
  },
  "r933": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-2"
  },
  "r934": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r935": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r936": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r937": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1"
  },
  "r938": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r939": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r940": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r941": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r942": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r943": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r944": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r945": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r946": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r947": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482130/360-10-45-5"
  },
  "r948": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r949": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/405-30/tableOfContent"
  },
  "r950": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r951": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r952": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r953": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10"
  },
  "r954": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/450/tableOfContent"
  },
  "r955": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r956": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r957": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r958": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r959": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r960": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r961": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r962": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r963": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r964": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r965": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r966": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r967": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r968": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r969": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r970": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r971": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r972": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r973": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r974": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r975": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r976": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r977": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r978": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r979": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r980": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r981": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r982": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r983": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r984": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r985": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r986": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r987": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r988": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r989": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r990": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r991": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r992": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r993": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r994": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "720",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483384/720-30-45-1"
  },
  "r995": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r996": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r997": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15"
  },
  "r998": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r999": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r1000": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-22"
  },
  "r1001": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-23"
  },
  "r1002": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3"
  },
  "r1003": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-6"
  },
  "r1004": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r1005": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r1006": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r1007": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480682/815-20-25-6A"
  },
  "r1008": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r1009": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1010": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1011": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1012": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r1013": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-1A"
  },
  "r1014": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2"
  },
  "r1015": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-3"
  },
  "r1016": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1"
  },
  "r1017": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-4"
  },
  "r1018": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r1019": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2"
  },
  "r1020": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r1021": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r1022": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r1023": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1024": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1025": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1026": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1027": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1028": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1029": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1"
  },
  "r1030": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B"
  },
  "r1031": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3"
  },
  "r1032": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r1033": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r1034": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C"
  },
  "r1035": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D"
  },
  "r1036": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4G",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G"
  },
  "r1037": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1038": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1039": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1040": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1041": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1042": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1043": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1044": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1045": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1046": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1047": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1048": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1049": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1050": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1051": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1052": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1053": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1054": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1055": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1056": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1057": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1058": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r1059": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r1060": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r1061": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1062": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1063": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r1064": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r1065": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r1066": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r1067": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r1068": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>100
<FILENAME>0001140361-25-009257-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001140361-25-009257-xbrl.zip
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M)GY_&A4FI XF63J&[9.Y_W *!4+"#6% CX/U"C,Y'U!\RHMYG8OCL\OC;;^
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MF5@W ZMGM<W!U##;[>'=8&H-;HP1C*BVU6U RH-D>0\@HT\WD*0?E !PF0?
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MU9<AOM84EHV%95V/"G:PFI@XBWI(]O_@?OOR0'OE>YAM,N]M9+;#?-+=S&-
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M+8T2*B U2[A;<]5!A Q 0OM!O=9!F!0[32%'B9W>TIY/Z.$MB=J'CW1UTQZ
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M?52:W+Q+(WJ;9#>%T)U9#>(!24"+>7B/<!MU8S%=+9;(CL^:+A".@T3)"PI
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M^RY!2Y5Q.P2@*J?NP*XW9],9 (UC78%GNX $1I&_HM2'CD!#D7&[ 9 BIT[
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M=X&@5B'(X-@H- ,H&=EO=1!L"&$0<KL>E%6:EN=HB:+E;]S134+7&L*X='/
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M^(O"&7^9@S/X1H"=\9>.,TQ?-),[8['*D=(C J*V6WI$WOI&;@[,03T>_5?
M)CYM=4,OJ+]]BJ-UN2=TDA-% IGG0;S\X?VHDA^J_6G90['=!BG="7D5)4&R
MC(+X.EGA=%LJ=+:KZ1P>::HUN$?/.*59OX9Z-X(S33I%V*(WJ(B3I7ZQ9G<I
M7D4Y38,*SD$9E577"*^LJ\LM=%R-A]5(Z_X+@-QRZX">/-?9S_8)3_J*8VW
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MDI<_0_E#E#Y-3> ]#I,4W%00,4GG25=9J@3Z_NO)6"1_3LQ@H'0 _+-;3FN
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MM*E:4L0JFP>9JJ.PSB'XL:423:_R$-&G SJ?%%"V,N(H3R,5*TAIXOSLT7I
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MVFR6JW):SYHHZXEH<9(VZ:/&FA;^#BN8](E<"FEC6H&B,2>4RHV<2G)MKQ!
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M.J@'<>6 I)B$4!9?,-"4$P/8W74"U3BF@KL$%%)<%$^MW2*@\-Y!<WH*O$1
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M:%UZ.K"49A/WLIQGGU^BI&C!DS1KOE4:=]O4MQA@WUR6=37HWZ<'N8,K5+;
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M4Z\QJC*VL,KS; VO->,@S%9TO/03VA<?!P);;F'Q\"LIU3J&RZ)<,$M+OU]
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MKJI#3ER6UM\!7;:J$,LFO$+J"C$Y1LN3Y&!N(=%"!J1>%"-*52^6-$$58]]
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M'W",HS2[WI/H_I@<(TP/"O3#!N1;ZS=[X%!]>STAO8AM]\[!WH$=): ]+Q-
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M5&1+E[-GW[C>),(M"*)X?[6-(&61RM8/:4GV L(/?EKY!/ZN6 9%ZR-:17W
MG&-V8<+YCU<)&^(6%HLID)5>9,A6*'NE[]G60/0I>^(8\L!2)KIE426%7*?,
M$DT@]3-W4:P$+-(5ER\*J6*V0B1E.DTA]VX\/R$T+YV8$&AYIP?H7 ,,@@ZJ
M0B3@-UZ;F> +5Z8D@,CHL[D2O\?D*?(/S\':3]\]]D6+^L'RU6:-3-Y.4T<=
MD:7FC]01H$DDT4_KCA<<'G%\A<Y"B,H,9D,BO/R;K2DP:*HM++$:I]6E ;2>
M-Z8794M'&,9?TLHO]'>WQS@A>QS1G4%3$CY-@Q>\R3HQ\KWK)L8:V]O;&;.V
M ][DM]C;)-\R"M@^^E;&*UOM"PN(TA 5-M#)"!M%H&;>,3LH,S2T+?E&L.7N
MVK= A"+;&-GD[_VWPJQ>\I1FI%/!$3*F9O(B:6_&,"N9QF^:CPS\RS)1:[->
MV[PS'<K).,:()/;044TX;:V54XTUHO249/*^/IM3H3'GK;85759 M^>1,":[
M8./3TQ7Y'1 C&Z?TTLJ&<6XQB-P\L;1S+L\J;6P68\&HJCZ8'HX9P(BE\JZG
MBA:FJGG"!N+[61V9VIYO2Z<OC[X$]6:&5*98(<F7,5TC*?-LO$I28%RZ3I*K
MX]W2:X8?"1UH>L&5"S38Z8ZESVSB#"7/?HBJ2I^H)<=DE!<T 99+;8DE3[2R
MR!*$G%[(\)Z0S>=@MYOL#WX0I=1<KX_[XXZR-/N*AD?7+0AJR];Z^2MKH6](
ML-816SGXMXUW&3OU[7F%RF JQ/88(A:*M<I=;3-E7E\ F*V> -7:NU5$YZ=%
M%7I7J-"\0B5==%9&5/LK1[_DV*E^*>#PB*KL//V%'VSN2;3RO_P>),_/9$=/
MUD^_X%_:41\P-S!1OF!(VX2-&X-:QFVE'FP9@/)B'UV3V9UP,?I,A?&.W>&V
M)B]I@_5 C]5.NXUD2Q?BHMUY;]? ;J9L"[_Z13QF,"X&N5M8:ER5<PELL%J1
MF@1@FQ)Y=<J] _'<8[G*2QK]7A!G2R*ZN0R5?*#YXRYX&L"I "YY(JEI79#%
M87T[CY[\,+^IX#P<E'Y(@PSB^7:1_I@46ME7QS@(<1S?X7@=!8?BKH/LF*GT
M]RU297K"Y0I_26[2</^HKZ'JPU>Q$JM;7Z;KN?IX$\:KPCH.4KJVK%/?WB(*
MPG5PV&%VKT/% 1LJ8U[HH[(?QVO7>B$/Z1FCM75T7;JLK,;K-3OTL_<GVQ\>
M9[%%1W\G&AX$2!9[?622IGM\U%$8[^V1NI#NZ9%H>J/;VX>/XSLT_NMB/%N.
ML^/4YZO?Q@]H.AG=3*:3U60\G-L$(,5-M,JEMH='K%#9NZ.!);<MGS3",O_G
MV_L@]-/JPM\MTV]P=J@WGUI6;:I:,GHVNVJQM/EEG;5,-(-IU0+1\N'-']Z/
M9I/_PVX888GBYN-R,ALOAY,?[&(6TH P((.JH:!C&M0@,")9CR.FI1M(N<.A
MG.>5L<[*<RM#-QR/$-X?<!20S3C<J$<JJQ[48RYE>>__9^_-FR/'L3S!KP++
M/[8RS12]K<C)ZJD=,S?ST)&E:86DD1295INVUD:YPR5VNA->)%T*KT^_  C2
M>> D'DCJ&.NI##G? 1*_=P!X +Y$E'J!IS9O*.NGSF2'NC,;DQ@ULNX,1= .
M=YJ$*WJ<FE.:._6YW41;@^&M]+IV[LJVV[LS3M[]SB:R/L-.P$JD.W5ZP226
M%(Y0[<EK[/C&!_;I?"%HW-TQIWB%TQ0O[Z/O1:DJ*UX]K.GPRGC59**GE,Y^
M&$<I8!MA>K4>;@>,JWJ[K2]N4F<E.5^KF$_@' Q?<$EWK?C@M+-=Q4F8?)^*
M'^('=A5LN80D+-N^7E4'\HB#0+[@!*_BW-)=]);4<1D])(&YC=YO 5,IX-4.
M.Q_B+KD\L8MY$4&(?A2D8Z=Y /"3.A5?-'<<B[- N7-Y5;8!6S?@WXY !E)6
M$=1VF!YDL+]T]B-VE2(F#7%QD]E@.K9)Z:H)1K>K,6OYJE:?K5:8W;-V.$OO
M-LIQ<W^*9?CN+ZH3O_N( G-2_=\#SD'U:H.=<^HA>M;:&]9P2&,?N@D"0*F[
M\09TQ]6X2Y3[&@#[&-C/=,_\M_0JMHP='V)F!/,8MFT$SO MU-JY!*.@ZF*7
ML_HIF<56M?(TR!KW5!R"-7:DYN^(O(ZQF_CEICTAV 9*OFW5PF!7DEJ78*[Q
M3#B'#@MBJPPY#)(GD?]>),_4>9%T+]R8952R8^O$)!,;F&G;M0_.IHWZ[(S9
M(&;6'A0+ZJF8JB4JI(;JA*B.A>JYY?;I",9!#)-V\"8N;@V?)\OBY/='G+ J
MSM,X6ZQ)MDNQHL2K%Z_XH(Z\GG;:JZ6^QNJJ5&>Q;K)F)]=?OU[<?SV[NB]*
M,D^NK^XOKGX]NSJ94CEF/_P0SVYM6K23B+I9^P%XP#NJZ%C5:,D6E(T[HA24
M(%>\:%L!<T.+2H7Y@A4YYZQ^$])DS,NF4SN7F]A@0)B.AJ%[MX@=8@8]4X2:
M[462T_Z.:1@NEGV-AM*+MW66B"4OT-$+3BV%.G'!5JG-00MVLJ@)WL^O?KWX
M<GF&YG=W9_?3L<-^F)&<GM '=,)6G43(#DSH!]JA*R.B[.E\35[N=MOMFA<D
M1^M#*VTG0'M)Z59$N$F!6_'MTWK A5Y']9;KNTY29W4RQ'@18Z8!:T72S00V
M,/IB3;Y6ZP';[A*MBS#%\JR7 0R4((L!N46";*2L$F0-I7>";&R%?X*L4Z%/
MD-6<-#K_1@>CU[=3&G[:]"EQ^OCM_%C)T,R/[0$SB%6<XH?<:!!Z(O$A5$2>
M9J#7[6L!2NDZ\"N89E?7]Q3Q-_-_S%EB.A7D&SJ/V'[J)M[EM'6H6^)AJ(G/
MZM 1FMS>XCQ.>92RF?9TY3Q,>MIS^D]YNK828,+30:5ANM-:TJS8;W[V]>;R
M^A]G9^C+V=79^<6$QG]]\$*\.K(SQ6DKH#7!V1NL(U3$ETT](5G>.%U(G Y5
M.QPJFZ]YB_@F5ODQ1$Q*]F5_0Q'J4$L_<!ND5?B#M0&T1GG@+P=;V#Q<X^VK
MH8=J4Z/.XRZG/XE#V1J'@HDJILF,ND>P565]]3A.0UJ4/5!3U.7<8SFO@>.5
MO+G<>J[YJ4K9G!6;QOG>,OCX"NQ$DOX"P<*"[SO!^7B/EM@Y[-X*&MZW($4E
MZ52<K3<VI9X3"/$=-]A7KMRG@9G1: ZJ=+PO4;JLM_NW:+TKA@99MML4OSD[
M*W_A&L?E(SR $_-_UQ .S:M5KL[-0UFSG/A -CTG!X!I@\,#LQJ-\^NOP^0(
M <UR$*<X7_[W+BOJO.[)?+F,6<NB-3O5^"(YB;9Q'JW-;OX6_W,79W&.[W#Z
M'"_P#3_HA^T?>DRXQ)8G&5BK ,1@6CW]Z\!?Q\;Q/N/T@>CW$0W7:IUC'JH5
MLV(RX(%/!BQJ8L9UV4,;%AD-M4TG/Y#RNO?_\":-=H)N[AJXS1-P*&);V?SF
MXD1<[J"[_:&0>L1J5%-,R?CU#VP^"-5$?GBB 1'_7MS1B)OLOF5LIWJ6QYLH
MQ^TK0^4/1:^T'WIZ5+DN7Y_7D:KS2BWB&?V;#1VK7\:U?45G$-,G;!I1DZ:.
M=4-_#H+&RSAAL_HIII9V'K%3$O+]MV3';"O:TK_S_6$+S3EFAK1@-8*/;5!Y
MRQ$?S4..ISEXOP'(,08^K=!96G^YLX*,C0[$<[3"(R\2^J.- '9\T]Y[BZN[
MAE=H!J"9LW<K@MB"R&X9/S^+C$M I8@C)"REE')4V[>(J"!TD/1A/BW 3,F&
M1DP.96WN'X#[A]PAO0M 6'5U)7 Q5!DU;_$S63^S4ZU7@A1M)VS^G@;O'2%[
MVK,M3@<_)_S!]L@4-:GDQ.\N*>"QWJIV0)[=+=%A>T!WAW5VM]MLHG3/JRIJ
MI\C?X20F*;HB;+@E;G&:R@JDIK<51W ;T-%9'>QRJ [3-H)I$*.YQ5F>QHL<
M%^N,WY(XSV[OOGW%FP><ME!K12L^C('6TVZL6N)K."8E.LO1\\X.CXMR4,0)
MT!_%\Y%+\>VZF3CV1M-@M"QUBQD11TZC*>/,@E%5;S@=*_'T(Z7)?GJ3L%*,
M7&!PY7_3C5:\TXTW%FOF1F6]H?690HM"Z$TB2'$M#@R"1KXJA[!KY^(<7\;/
MN',DQ?DN9]N2-B3-Q0UV8N>!5<H,*;J58L.(!DK)(=\3*H4':I--R@^B:G9@
M+*[I004GFC\^IO@QRNF_:D*FM0,&%.B2T44 0VJ-1B TR$8O0>QTJ-$.IA!X
MFB?+4_R,UV3+YBY$ U5C'EN.P\C'S.&?7MBV"F 49*'*D&$8)<Q*(GZ$=XUL
M.JF'-0Q(KW[J9"$FQE8NXHRY80J#.]?>*\X+,!.6Y;<:0M\:-V,;O"O2=!JT
M]6-JQMG=Q:]7%^<7)_.K>S0_.;G^QH\Q13?7EQ>3.LG4HHN)2V>TBJ64](WZ
M)GOT#).PXT=FJ;=XR^)E\JBP#A-9F4@KR7R38H-^[P17+5^;K*K89G=GOQ8'
M^TX%_,8>)/9?NY7M*:@;F9LM, ;*PM8T]5_>1&F^OT^C)*,MX=O\Y."W):_R
M+Q.Y=_)EUQ[_S,NH1Y]V&=AGMV>7\_NS4W0SO[W_![J_G5_=S4_N+ZZOIF,V
MUGU/W/NGG7'IN9KIEB/$AHDEM3,$RW,%S];B' !%7'%@*6.,%8MOO'%HEW?L
ML=.EC4,V(F9WWVYN+L]86)I?HM.+NY/+Z[MOMV?H^AR=S._^CLXOKW]'%U?G
MU[=?Y\P*)V.$3B@A_7JQ%=,L.!OQK0\HAQD U0_C2)97)(D.O]1]AW3VH2=W
M.51RY?8=/_5KK?>@REFM=J3E*&UV0M:T=22-V,UW]0TV?"JC_G=Q,UG^%"6H
MR?3'*=E$<3+V^*PGV(@W EHC.3<AC>&=)^*'O7%BOLN?2!KG^_GWN+T314_4
MOF>B101UQ814-]CM$FWI5A=+-)GJ-WC_[UT:9\N8]R\-G?3QZ$?G:KM0=JN$
MKK.%=<AII7=)Z%$Q3$XJW2M6,],O>_FI!V(GV:^4,,\NDF('V:\IR=J&$E!#
MF?&&T.";((=[:^]\.DC3M.EW (VSJQT/+F2%,EY10PI:],B(\1+]&"<H8U*S
MGT;.S@,: !D$<:W<'UY18Z@P@#4/XEII<K.@0QUV,GK&Y_22Y7F<1,F"_OLB
MQQO5F-^93W2/ Y^G<W-NH:_+<E&H<T3V<F:"%%7/^6BAXBP/J..7P$YD&L =
M.,2C3YM.P9J];NK]$3OP?H6S*$UHFS+J4TK?$R_86FZ\WM%88[F5H9>4SBX'
M1RE@&R!ZM1YN;X2K>KMM$VY29R?1>K%;%[50-/'@U$5!1$&/2GEL*V,1**=1
M*]47?-)-%SXX[NS'<!(FWZKA9Q'##;,>.D=R\/14C +_A9??DB5]A<,Y'>S,
MW^SL.TX7<89OTGB!;UD2)'YAKR5RGM]Q_/A$7W7^C-.H(BA8CMO^: )-J0_<
M1FL*Q AOY.\(LO%AY!<Q#AS':MI,4"%\8#Q"+X('1053^12C+6/CP\XEFSQ.
M,[:AM1B"3F$$.K;)MX>J8[>G.Z8=J46=P>^'1W1O/.CI&E-XD:FZ17'&A_79
M=24WXNR(JZQ^+5QJJ0\)A2V>#]\Y%=^I.9'DPX%6G^?5CR]JAP58O/87_!@G
M;/SU):+B H\W@)H68OSAW;0I15^@[SRI0.S_3H/%9-^F5D,7<A#T,70!\QZA
MPC&L=PL1F3U;&"Q20SO?$8-V=Z7S0;'264M/+I(\C9,L7K +*"Q#,*0B;4"%
M410D/$)^@S#!#JB%[J$+1+%\#BVJ=I?')3UZ9@Q3C#6@9F*,' &,4AL'(/29
MO7H0#S#0-?*K.&$OPQKSL"M#T-EFNR9[G+);A%/,?HW2?9UHOF';&%N^"$98
M=2V]GS#OZ^LAWL7_FGO/5NC\HJ?P6>/R6#R%HS.  $B@8=#T5'XRZ]X(V$;&
MW'QY0VWQB3K-[)SV9)VF99]]V?6;,S7L839K&ML+=.:;L_(>.SK5XF;EHR5B
M=QRD<;3.4,3!-\EMG684F;=YVB)1O^U3*<5B&^ATP RZ:M57.22BQ>J0^ D5
M/5)C/$(5*V)(0PW*]X=YS8K*D, ?<^6B*N.Z2)8L7*O.K;(LLNPEI5-DZ2@%
MK,BR5^MAJH!ZM\&NTM)-:N.FW/8A=9.Y+[<?UJ0UE3ZP[=14.@F3UU2^"@.
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MG,SI"I8=;KR[37\SJ9['?#_;0)BR<[3VIT.9M?4'UW$'76\+2%;NMS^2ICA
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M?8%7:T;U'C3,L1M0<79.4G:U3);%R>/%DCX1I;/)DA/3?]Y3W5'>O;W>[%L
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MU^E-2I[CI ,N&U(9KCND4.!6M $,X5WY5C!OLW6P7I5RE"03 KRJ7V6HUV-
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M6/Q!K]<0*-1;*358A86,TDBV@K1F)FE!_)$%. "3] 2.S(KUW"V#ME$UA"5
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MB3@!VC**^GX?1,UHET6/?'GS]NXWX=??;0&P-2Y)#^RTQ@<&SL/0P$I%: ,
MFBBQU.0%_>,F]@4A*B@1)SWB*SYO$&NJ&1%(L/G.@UB^-\ 4B%E3;Z U,;81
M&*O[V:,);#X"QUA@>(68X1!5P4R\:DY#1M*:Q6B20"3H=8G!9BHD2HSY>(>G
MEH67%>H,VCS7Q-]S3(-XMYB=YA"KXB\^R_6PYY,3VRAEJ>=$9B>D_=[.T57]
M),_,Z]2=7+PK*@208.<59-*=(=28.RCWV?"GKQ@(A@D!)R0 #?IE[P$WS&])
M=T*!THF\4@  ]3UDP+O%&27E(>&$9'EVBQ>8#K;:I0TF,O%&:C(?H*JD@@=
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MAQ*JK+$E.&A9MUR758VCC'4V%XL Y64Z54J"8G8$\!H_LAW,GQ[BA&]!9DO
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M2N;=6XDBP1W13#Q36L]OZI_+]F\ M(G\,#O1A8CIY*4CV\&D3& *4\#%X9!
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M_ L4;BL/4W_''\F_D3^6?R+_1UM0SO\?4$L#!!0    ( ("!<EJX'GFB!X<
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M,%#8HX.!(:L@5Z\6ZW5UW"A*;J-X?9V>1\\QZ=_977<Y5;O/+J+R'!4PZW3
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MS5()(>6&69;T9'&IX2$7P955:(H+&L%L0LRP^FUC+V,:-8/,HCA<%SC8V%Q
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M>;Z+TD8@?1N/]A4XK3+S\RW1+-9:!2[F[J5A2!UA8P_T.P>9L.HE(; 0%UO
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M6(1[P.\.O>#DA>[/JV>-(-HV<:Z<UEMPZ-@(PXJ"8[A)("21%X-BF<Q_[0B
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MXURNZ)/YC".@<497*?K\6HS,OY(^70H(_MH[E%R5 "*(M7A-8PW##X]O"Z@
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M=ZN,=-PN2$G7)N,2T[D+"/#*PG!+F9B@E%&EXA+S#CC>*ML\-F@PC'M%,JJ
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MM+L\TR3TMBH1N_R0$LM6F6I]U!T1UX?B!D>YZY,JXFDMCTITW+ZE\A,B()L
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MW?V5N94-]TF2&3SU.Z+U@]:+%Y1%6U3- "Y(?WLX5^%T>\=$N_FZ,#WMWBJ
M/$2-AU Y[8&043N>IU_3!<OL0R@=W\W4O0)\]L9WNOR)BJ:*S;U7]AXA/8N0
M(X'SAN.DON?>IRBJS0A_ JJA7C-O"+Z'4\_"Z3C8O.%HJNVX-[QKZ4^4-%=M
M_GW/]UCI6:P<#9XW'"Y-?&>>)>5TAY]!+W"ZV-!]CZ*>1=$1<'G#\=-@D?-]
MC]G]=I^'F]!ZUIC/6F0W?ETC"?8^RQ!OEAYIN1D\M&@PQG&=]5G\T"+X+3O5
M.XLR1J?TS&+;>%=$3OR";I,H?7]RT7CL?7R<4Q5,<U$TY;W0:)UO.P:VQ]>%
MNVOY1 #G<0WNM\9LYIN7LS2AOX_*IVO:6H6O<$PI CJ',A+AY%6LW7."]PA5
M ;(>MG#? %'2M=%(3.?OE&\,(##<-YI3*0.MJG>9Q-H$^43='1E!9S'-IE99
M]"6-B_SN_@L7I2#:PZ,[4MJ31:N.C^9!K$(C\QUQ3Z9#_"X9,H\>WU/U:["G
M"6CN:Z1!N,_JV!]P8OF0C&EAML33NF7$!AG\6V1Q!KJ\3XU3^Y]<ZLT=H$H;
MK(5!H6#S^>$K_NO'CUTX45G<?A1"VN@K)W76D,7]GX9M_<8Y[+CDK)RE"A/4
M/V?%@S_45]'U%AZX=!Y6.]0J59U+^ 3^3#DWH&)%N.*[JQU>O \,I ,#21<V
MX;B@+]6?=Z$4C[(^4,<L-]?IFB;5+J.$,R:0TK0=%I_&F1F_Q\73'4JJ>LR?
MXN<'?$DB2['G#AT,2XM,5Y6VV/DTJQ*Y='4IEZXIY<Z[%U/W8Y6)_>:N*::[
MZI,['WT8M8J+.$,KPHJ+#O['QG/LQQ"Q(35P-#18[H$/4^0Q'H^-D0IWMR,;
M;2'O0Q\DK:1YQT "\?X\)JAZH9Z:RAD #7YO%[N/O\^J(G^5?OBEJR8_DD^G
MZ*<XC7?ECJLJ]UNC+//-W?/V''=BN>K,D_5'!K1M, 7]63=4U6/T*JY'WK>V
M'OO?O*M'B>KR>NP7M#S1F]LQ;"\O#B(<I[2]=J_0>X^,!@Z=MQ?NB#RU>P?5
MK_FB+)YP%O\+K;^DQ+[.EGQUWNQLWWO^1=2I3RA!>IYEI(3 *F-HAL;I(BL2
MQE>&6(+%E9R!C _\-1T57;NZ(Z;S[ R&G4K&<-= CE^,4JI:.1(KX]T.UD#5
MCT#H?01"[^/;@Q[?-8Z@]W'*12J[T/L!"+T?@-#[X>U!C^\:1]#[@8&>-TD#
MAJK^"(3>CT#H_?CVH,=WC2/H_<A ;_Y9$!AZ/P&A]Q,0>C^]/>CQ7>,(>C\Q
MT#.XP#H7]'X&0N]G(/1^?GO0X[O&$?1^9J#W4Z ;DE,NSP@/B=M<<+!6_R)S
MQ"?-1YKQOH2++$$%N% XX6+P),J;]VH.#[U?IRN\0_?$RY7K;J@0ZLWARC"
MLJDX*:5'1G+77$&T<D-=WK&\(VV&1(2G1;J^0"\HP<]4L\M7"G+!#CF\Q/$V
MF[J$LV@'JT!L8G@_(DD%-7?-U +\V?+60-GR&67$V'0K Y:<J'&IB,A_^(#,
MTT2,B*<_!Z=U]L=00MAM?T4I,2HAC6"QWL5I3'-'T-L,C8G\0[I&9=L]+;VR
M_B-MC#,T :@IRI\S;!JX/,=Y04:142+ GO![XU+.=_\QI#)*$R<<=N%F.H*,
M;+'>R!#DSG:ZJF#\/O%$@&J8=P(I5<)\C<EE;VV:F>Z&S:(V-B'I@.'89*(=
MAA;3:Q_7!7)!*BT926L3E\1-K[C;X;32YSQZCHLHJ9=#Z"0F>T'K*YQ=E469
MH>L\+Z-TQ:;/,BY_Z%6UR[N+:[**Q>-]P00NCK2Z#]:6XME%K3G"$S>=_Z\9
MSJW%*[6$L0%,)L';1C"]/V'-9!(]7$S(;;_ST-A7!PUZI>P))>L'?(Y?4+;8
M;K/J >S>8K?M)F,BVE);TA-]LHUL1 W,T_KT%'1VG&I\$I\,KQ!:YU>DVKN^
M/+RKP#0],'V;ZD=-[RW(=6V%(1/ U;<C4G8;$QD?$AJB;O(0O4X<VP6R)@GF
M UG> GM.'[L(UP.-G!W\LI>[EDRM2%_#]],A!W_EDOP!DSE9]SM=-?V,B_]&
MQ1U:X6U*#QET:X(];C:G3#:G[K0RO6V2+GP.:YHS:1;NXN6C.FP]"L+6LBSR
M(DK7<;IEGL^X0W01GOQ^CM.J*LHH>4#9[B.ONW2C0;<3G5L#;]NQ^_K0Z'#G
MUK-IXS^_J3;^6QT7TS7=Q*8)H!\P_4G?@1\L-WW[BEF*"#85.]E ,5GMS1,_
M;*K?A)6_O:FPTBP7T(UA1_%CA :6 H61!B<;$<;7QSQ-WTC/IHW_/;P9O/'2
MQN'AO$6>E[NF'M+U)U0\X35]_4OTE-:,$L<NI.E(#"I*\PP[='4V@S%8T-B8
M"Q#DV?6T:1 _)E+K5I;FVS3CK1P5WP'6!7GKP*K?6X?\AFD>U20N]G=18>U1
M;7V)4T1PD<0W%1]FK3YW@6)J,\.\@C*%9RYH&E^4KN>*%SQY4T:+OKSW6#%-
MU9U.I.@;&>25(*M^N8OS/Z\RA*Y3,N5%>3%UG)#)FR).\.6]QXEIJB[\.,$W
M<HJS5;XM(LZZ]C/Q 1\=O9JZ_>5M] 'RG13;:X-ZTBP=L%-*F^1>57V83'VY
MBD\WO&'%TIT0RCK[=9]+WGWZF<5.BSN.6!\Z @$.+1ST-'2_L$OH:VKCX"=<
M0_.EQ^?J!LY]$66%=T>K!?9?X6R#8O+GG*U2('3:-CD0^B9;I-SU[MOC0#^#
M9;U?ZM:85C=PUJ&T1/)7G,W;#KDBIVV%C,@WV09E;G?? AGM#);+PFQ_U37:
M>=L?5^2T[8\1^2;;G\SM[ML?H]VI7?$31IWF4N.\_1]7Z-0]("/T3;9!N>O=
MM\*!?@8W VWU@^]K.G*Q?W!O&KVOZKBK /?M5[RN8W!QL%[7N4Q#;L.=P]23
M-%8A?TMMDL/_M!N?RJ$SMC&.*N8W]/S8'9UI=PO#]X$L[:/#%*Q0(5;,Q>E;
M0!I#YA9(+[D.(,6A3G%.^D-8\1#[!NT[=CW;9Q_U0929;20H5\:'+DH/][,,
M&S5J4'QJ!&+6/"-,N3EO<S_1?<304F6FO<?W:#%E[7D;*X#&^/;.[[0[3.XC
MA(8BL^R*OD>'Z6K.V]@ ,L6W9YBGW?MR'QDT%)EEO_8],DQ7<]Y&!I I;VU_
MV'ULT%)EIKWD]_@P9>UY&R& QH2;U=;UVHU'*YL.=KG?H\K4=>AM9-%=W7S?
M59\QD&A*M;\#_QX8+-6)^_8/UOM]Q]]@Q]]DS]GE00"@OI9S[9S"M7BC:\_S
MO'FAU*FMSA!?<#7US<W@$4^L0(?5UGD0SS9 WP_A= :&%:)6A^Y#?0('7G9X
M_ 92UI\19'.@JBR><$:?L/B2DKKL6'.;1,>'G*K@>D<1<X._HJS^5[R+82D9
M[(J2CA5MB?(A^FM@4=@M3.)Z89^@UEC<6=C2](32<AJZY,OS\UQ-5"!JBB8Z
M$/7&FZC<]3XUT8&F)Y0'T] E]1GUY:93&\W@:LK6JI8Z1<.527WC;1A<(3XU
M9YG2EC-7!@.(1_7\ZE$P]9WPE2P-<,QM@/F9 -==P,!3ALUHV'QD"UMG:!NG
MU)5G$6&W0K W%]RJ)GVEP95JIQ)@O*C:22*/*\O,CR"X#DDC%EX[7KLF,3I.
M\WA5I2BUO!^HE&-I!U B)]"6/X/3)QE=6E$SW)=T;8^V.YN@,\X4Q5*GG"GR
MI)Y*ZYVZ0GR<*?*4GF*O/L!9P- U5A_/=J;5%&/_,5H%&CY\<)VW(_XQ1IW0
M.[M3>:]79-+U!D-5G,085I7WP#*BZH**)JPE@3_C.V+%M^.J_H1MPF>Y!8+L
MO[X]$'0J+7P"MSO>>9#I:?G]G%,X+ZA]MFWB@X00?8(\*G"Y>T[P'J%[E+V0
MOH+ON,\X?:E/O5(?Y0^XB)+N]W.<%Y]Q\=^HN$,KO$UI5W;D5!=:%D\H>WB*
M4OZ2D',]&APYU.-$6K$O-3E%1'!HF[.<%?Z&F-OJRML5SIJ?*!T[K',C?.I@
M(A#^'D'&UUE084-@D(L3*X*[#G?$)#())695HZDO1$?1$W\0TJ:2Y*3^;*0!
M@$*JO8[QE_\LXV)_G1(K2OHU;Q*6V-K=!@L:N[T-$.0L4($P-F8[6]?+_7 C
M4V_4]C5 K1.ZC !P2/4_]-X>F='5492[(&29]=BFQ65]NHU)[<F9F@]7$1?S
M?=MIH@;A@)UXU"O4O\?%TQ-*Z$BC'<OD#]'K31P]Q@D9=2#8"0\7"HUM<A85
M.MV&.E6MS=2\+:I_,JDE@3ZIUK"]"P^:6LT4(\!:O?E 859_?D4+L V^Y9QL
MC\)=I^OX)5Z749(3X^BJ XI?T/H37L>;>%5Y*W_ #T\HSCK;(YU-DT6ZOKO_
M4B]G, %@4AD-'":2X7WCG,.W>DUM(HW"3<2X2"J^W77_;A"BF672G+W7H%>H
MJ2AH(>]1;62]'DRA(D[HI+^-[NZP<'V'DX1T=+30;.,]F?#)AW5\X2=:NW;?
M.325.U^=NG\7T4VCF71X+Z]52WMO1O9/.R48V.WX&2N/ TZU(9%?I_4ZZVSQ
MAB]V\G##BGV/-G/5Z>D&&];L( \F3N>>.H'G[ &&+W;R ,.*?0\P<]7IZ088
MUFR#38]?Z@"3HBV=<)_D0.;P3.'LH48H>?)HPY'\'G!FK-G3C3D<RPTV3MY
MV/%DP<;> SOO2S8^+=FH'MTYH9 C6K0QV'"2O\[CX7:+TQ5[7S;R^:J:IX,Y
MR>GTP4G,'?1J%>*"=+-749Q5AR&<[@^9:#=?SZ6GW5L%D(>H\1 JISW^,6K'
M\W1HNF"9?>2DX[N9>E: S]ZWRF +_?Z$3T.]9MYL>P^DG@72<;!YP]%4VW'F
M.X*N3T[.M:GA3S UU&OFC<7W8.I9,!T'FS<<3+4=9_DAF=#C:+-14](+<]X$
M41.EYMHL!2KU'CX=;+2: .8-QTX]KX7[L)+S-1'OUD%=;/>^!TW/@N8(N+SA
MH&FP%OJ^ ^UZ3]"[+6H]6RR_*1!"8+WAI1K4R#DW16) N?A3>N6MOEH;5U>X
MSY,HSP\WOJ_3JSB-TE4<)??$NY7S1"D"IV$N'[$8,_?'^R O@KSA7\,?6_?"
MGL:D^1LJ(^XBK*?E<U]AILGAIVSZDV2/MZRPY:P#<P)A]83698*6&Z5G<Y%K
M'VBN?2O#PR&ZN!BPI?.HX5]'5\NG#F>L_GH,RPV\UH'!J\J^_*H^[,FU%)[_
M_?M!K9"Z_[/^QOW4JS'T6J!T?4PNVZLSFM3I,<8)WL:K_+L5WM7R[U!"[T#<
M1EFQ?R#VYL0Y=$9Q@8HH3O)O'8Q>1"H)$T;#R ])HU7D3D9L!RR*]#O;][YT
M\=X.Z,;P:,=[9CQ<N RFX.(U9K..Z1=40(=7T+5'+C!]25!B>9^ 8V%+X-J2
M3XAS@4E,P+&D)7"XV"7T.P;8PJXRL<SJ-80ADW G#09-% /@+7:D7 CKX)9Y
MN X>UU?@$4%4-,#6T(.M#I5\?W+:YUG1"7_DKV/H(W_\<8[+M$#9,U7]<[1#
MG,Y+1M)XF$\REPUWZ+G,5D]DH+S89J@:/;,*"?HFS7*'0 \N9R\YZB)#Q=/-
MS3FW;^)_;#,Q,A\=AEA=?V.%:6QT!?*O<BXR?%VT6$%5_XI2E,?YV>T]M[)%
MGQN?##^'5>$*\T94^9"SL^/(@IH_R_916ESA=,NM>='GQC7#SV'5O,*\$34_
MY&SY[.2,KI5VQ]B\5^N[ER>E'@2!N;_AH2I@R&1I4,J7Y$_B-=70C2YW\A9,
MV-_;H=?Q]UE5Y*\(#+]TU>0'X>D4_12G\:[<<57E?FN49;ZYZS,X[L1RU9DN
MX<B -@VF8#!3LD_1J[@>>=_:>NQ_\ZX>):K+Z[%?T')LF]LQ@^Y:&$0X3CGT
MPMU";[B?%743ME9\CNR#O&M3[Q<2 9P>EONM73'H?_/G/!%D?_2H?+J^3:)4
MN/PSI0CH670C$6ZV1X8'!N_NOPAV2@"TD@=U.[3^GB$: P[!^4^1CS0/"1EH
M)CH2VM'(O)<1+Y7,6)_\< <YSC,^"O3KKZ<)Z)".D09O>%0@Z]HLC0P8$4%>
M*+N)4V+X.=$T+JZB%7T6CG=V0476.%9,YHMM-_2D4L8="D#));;VR>TM"=^B
M;(6>B_@%U?+^@1/Z-EE^?7USR^U]X04::R %G 4#<,U@ \O[P4 EBK9[B(C
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M?A%V>"0,6OHDP>%#8N$X1/09FU]FG.B];O[5"-G#+3I%Y-=8?'FN1;OCTO>
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M3E;?V)J_0%&1HPH3&C55,&C0MCI<+13?Q=NG8KGYDJ,J)($@*R@CQ>>@S$F
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MS+PZSKQLVN3#C64#1G4 1D<=*Z1'&S(DYPH8JK_0_[Q%!?K7WU!+ P04
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MC9O]KFD,YZ<,B],&-&7Z],>ISTT[A,%L!V!%T[[E_OBS%T_YC]^8;S/=X==
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M9KO</&.^"P9(L!?86+RHG4')%2 [-DT;+4+F7#';O'!/V<0.F;,7D%NZMET
MX*S>7H-RZZ"LA(H_HPO57'<;7+<2ZMUZD*XI?%_@/F,$U@K^EN!;$6NVAN^K
MIM^:;^\+7:^GD=>:V>[JX.M!NN;@NP;?]3AX3<F[R[.K$D_(>(E:F_02U3Z"
MY_#,;A1DM=+X_)[9C09Q:ZMNCRBM9HX[1ULU<ZPPS=7!JN<'X$93L&J+=T<
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M<^%K<N3JV'-O0L_X+NG])M(#V[29/[UA#K^TZ!K=B]47QX[CA3C:)>475!/
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M>R914_!9$A\&=QS8, .0_I<#]8"^3YAIQM_EC(5 45"BK)[MW/)T2M=MRO?
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M$N6S^8/=85\;FEW5ZNJ VVS8T0?,'#(VU+5NEY?AZ#6./Q7'20=T8'BN,,,
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M4,@'BUJN>#>N160HY#,2\!KM1VL@]N/PY?2XEWOS,6W_%SSD!D:GC>@V<,]
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MW4"LAL>-:4:'0VL%K!9A",84EA%5GD[9-7AEC-81(_V1CKOW?!AH J1TSYP
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M<ZK2YU)%)#M?N-\2$[%-48)6AP24,4)GB9GI:X=(^7=MV#_LIQ8XY=E2%(&
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MI< Q:IG.%'0JP[#=!=XH66N4FR3=SW/3?'*EI?*K'AS?8= 71"^J:<G-(A3
M4$.F.ENLK\1[FTF2R5@4O8,ZS']$V4?G;P4(!9292AY_T!8H.SQ^H,@OZR7/
MB*V@E<S!+.,MM]TDR->(JT,EW0!H<YG&0?;0+8"$8UL<78=8-$2;XL"<LS7_
M%*9*<@SF9I$I?<63?_[$EM>BW_9(2'% %&"-8R&5YQXORFEF\J6*,?(]%UA
M/L, 4 Q5 :E% JI3*)+B"  W$Q8R$KAHV+X/#,.6S)O696!.C9_B$7)Q1MG:
M3=,SHK$(@DHW*PR'&F\3I-P8Y 1E?,M3>$4,7N3=VQ@]LBF^89-O3V8EVV
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M:HCN!)W9RUE2BC(OZU .$;E'#A,(<:$=C3I*9[G.@NSC_\3%.6F1_F<)N.
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MGR+T(J:S)/>8^6JO"RU:$%5.QUW*J++]&KMV,U+DN0""^;YTF?L)B! ;-JR
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M7_5:B!K@0ACZT?Q:+=WN#F=="[V$<9#_!)3B/2 CSU1[<AMFH^![CV.$!"A
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MA0+25F'-& W4SGZIJA5^[GJFBRC2#/)ZM)*0V#E:2F[M2HTYD@A2DG_D%H
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M_^-C.[Q9UY3;::'VNRH),/M__]?1_\*_5U02T7^S#_/L_/6W+X,1QW7^OS[
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M2/<M]W7XKHI=QZ2!).),62IQL@(-?K#>42$5HKX;"%-+TZ?)2)%EGDDH+BO
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M5>W:CJG6$\/SX$.'I0S!-R#M7(_]%SWPVZIB)315-7OVKV\',FCA.^FY&XW
M]=LX#4JM0[RV(8X,,3==M>&K"W\;EB[Q7R[PP%SZTP!@U2S>UMP=ZY%H1>*X
M2(I!DR-6Y2RT5"EQJ<0ADMS50JQ&M#'!2 DLJ<]2,=GG)(WL_:J!!R6)<.Y.
MY'X?+T"'I;Q+1_%;ZQ&*M=R8'Z*)::T:W@TW5<[G/.X$:,SYO8WN-%UY'Q?'
M#DOVFQ& +? 2F;0Y*5^ST#&V#V"-0FP+W 5%*]6"UM,>CH[^W('A46,GBI?/
MV=W+9,JU*L1 M:QG CJN*".G(836JUFI40C9&3E0Z;A%7HY+ZUMB^KY)\XM(
M2X6M%\*8:W( ,40D&$U1 TO&F6<:FENUN\PI7D;+$=]AP@82!^;E%[E=4-?5
M[YR\_;RYKN3?531WEH-@  IHB2O/$,HMFWT7B[3K3OY@\$!Y3F:_<*[;V>B9
MY#Q&1**'$ZFITC?&,UVR,>O3K2Q?/5RI93!=F6"32P>68*5-OZ+R H$RE+?&
M<21P):&<O:T[H6_D=DV61..^4 GS:K7 N1IBE?*QI>V<4&%LDH7TLPD;E^A/
M+BJSR%I^]QL_O#K7J)ST,X>#0_L@RT1/$!9982V+VJ&S/X+UU#\C@XMO,[OU
MY.CO[!34#1(4L&&<V,^5ENIWE![MK^%)\(;&HLAC0-= [;&)6+J29X0)#C]<
MH,=$=P7=4<B_M=R522DCRB^@O#[C[+B,&R1'W,MA"Q8O,6*;.?"&Q+D;;;KT
M!EQHR/-NJ=:X!=9CV#N'<HK6,C5WE!$Q*^Q/@EW-8K$BL0@5NA7/'L:#5^4F
M>Z>)WJ=B7C%4-J\)6[J^VWB@(R %UX,P +'?(T(+@$%%@J)P9(3'PUDP;V&*
M(?R^).?KX$1K>&?&,I0X23Y%?UM+N:#3[=5A[*B2V$L:N\L":4*JQUE V-](
M%WN7K^O$"M0X19RRZL3F'\S"C73M3/'01B$-94_X+8356_ALXZX0%IRJAG%D
M%"&_O' P>L8\EB'(DX/R!E6/+I>F?,E_;\3U;UY&X=Z32?BG:V9KUOU<\ <5
M<LZDA#N5='Q_G;"2<)N^\T\(SI.#:QE,BXF38IG+[S=?Y! DW/9&KLES@AK4
MEQ$<AQ2NH(#:W"J824MO4FK*((8MI-BGG),3MXYLC.5HE>X!B4TI(([[1?#2
M" I8+6LNE<N#PM5NE%"Y;AD<'*1L4,:;KSL5PO:#-?%CGJCUT,]I7&&+W%!2
M^7!REN.M&]Z \6KNW#B+M&C/KWA4;)BQU/@R94MOR5Z];5IRC=-%EF49[6$:
M*J=,W6!T.>Q9]B@VC[+$8=]ZO@&!5V^!]+C:(L=>4@985"A (=GEV/BXQN 1
M#_8:SR[YN\EF82A4-Y#BW08!SGI%3SI^H!<V' ;!!S4<XL_:\B:N>$J8Q61!
MTHNT5'@<>TMQHQ.#AY9;DD%EX=4\3!D%#J]0(VJTG/@<++^N5S9VAV-KV*SD
M7;L(^&W9;I@#&$4;L9>#K1(O9/I3Q*^'DV]1E2T7Z(M:KQJ-9T=,3#ZP3\D"
M6VOIVNEZ%)/3I\_?\!Y"GE"A4<F7E69Q3^EO)L>3>^&47EU5#$N<]#?- =YK
MXA9JQ2.\OOLT(/[L@\%G@P=XVV>9D,4A/Q*@Q2%/@47636E%("29R7..(.9(
MQ@5)R)&K7HE[YW1\!8 07B,K,Q5)Y$5GCAQO@%$962<71(^(EM_OW4:2$I8)
MK+9'0,]-UK6&Q'1($'\#("2,:3Z!9?;1')+$5_,F:&3."M5I_U5)KX>,VL-*
M*[T;];Q=MX9Y59F72@MO-D2?$S4S"&=QU4AW2K9VI/:5;!_CJ 2N&!X1K&U8
MM&8:K*#S:_1; *D7WX"GM(-.U'#S2@<;KWV#5:<@[5%:-*]1W:W;MU5X#? <
M)9\'*^L9M+B-!+9CE,YCUC[;!/$]$<E1D5RZ9,^Q LT-7Q#A\GTKNO7,EZKM
MH<DKCJ[O1=DQMZQ:F@@BID;1E"9=)_.Y%. ^X6;+)_ORV[[\]M<NO^4N44:Y
M:G!E'BF;T"[:M0*TA0EIM-E9WW5(2<?86QBIHP<J$DF/%9,LNZ=0&:5=<AI7
M.*_+-3\0"M!PA(RE3"VOE;)R'K%#75\T[PB/R]]0#*\M<8;?X\:QJQC7IK]4
M)-U#=RT(5$>$V?YN3,B=E"Q;UY(_"'Q;L'#AB"&GMJB(0[/N%EKY*2<D;7&8
MV=',W?$@813!]G1Y>(X_9WC=]!Q@MB&:F8*\8E24MD#$]#I]^IO4=?()HE@4
M(6>SEZ\#Y%Y9X"A!@3$P%;:\:V'RQ!)=K8.+%U;0X*W9Z&^Q6"_U$^!01MB@
M 0ZWVE+@AS94I/B5_4I? 247_*L15)LAA=$,3+^OO,X7OZK@UBQD&X3O:N;H
M0]I$-P"'2$^,\RH3H45*\#HJ\)(=''9.1$XIZRW2Y[7(>UD;NFU ZO%;]LJH
M-N5?*HX=!P&RN.B632CNP:)A/1GCLR)I!YGYX>2U>FY2,N5?P:^2CKA\U)]H
MU@Y9C;;+U<;/8#(QQ6G)((3HZ+GNI/)&_5L-#8E&(XFVYO+R $^0=!MMK Z_
M/#[^1@J/U.;957Z5&JI%4IG\8F338J-D,D U4W@&1^J.43Z;"J+FUJIU1CL#
M9J.L7'3I8XH0N]6-@<??\+<):I)+7,.D'1L9^MJ66:H7S0P-80FY9T9;2-F%
MTRBID$-FBR!_5N2K$%G0+!?&8A:+B> '5)2QH_M2VJ.%HBI>CMH70S0 PCC
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M<D(WT.1IW9S",?K@=I2?*;2 ]JJV=57O0./+RLWT^N8J>,S_99%\,Y^[G.Y
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M48,V:D%'1[V4E"@]VBF89.>!>A5ZN[@#9ME(E8<D5)--Y)OM(].%-L!Q8_,
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M0;+5J=*DEOI25\AD<!\RK_ 2TM!<A:8"-*NT<;8G=!Z6[21NQE)LFY>=P$^
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M=[SKA <O"^9-2Q"%8EI#Z)*X@>JO5^0FKI$+>J?JOE<XW5>@2I;%/_GI#3.
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M[?95<W".7Y^?$*RA"1KUDB0\@@ 0 $7\HTEQJ1A:1<?B#,C;))9OOFW^RM6
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M=T\V/0#>_ @<L=B-SS[3&A43T<Y\43GU0]=__-M DS>)>V:#BSCLB;LMA=B
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M/)9IMZ<L"Z:;X#J+$M,H[]JTK]#W7[;7LKUN\_:R:SO.Q+BPTOV&P]0!RZ?
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M1&?1N[(!KT/\:,IZ%Z=;%4],4O)(ST[GR*%T51%\4;QNW:P*?X*B8QO<T6/
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M76' K_&9_4%Q[\Y? A]NEX,Z70]K"1*H].XOFFH VG%]YW"\M#0!]D7(2+I
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M7 LQ=54748/,]+"2P$ZD&"51BI]X&JI=+K %^5B:R7&&HTKL<FRMH[.+)8:
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MCB;7<K=0>+JGHD\+U"E]JY\D'[_BP&GTP 74H92W+WI3]LU$XQ\CX[/XX[B
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M_^)'5G# DUTYR7+4C6:Y[+VG@G_2LY//X"A38*+W'*02S\CGWC! 4Q.EY#O
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M##< B,F^]M?)D4RQ8^""-J:30!Z_BA\2XPT(VRF E=UN[Y162&PS^QRA**>
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MY 95$JW5 "XS7-FJT1C'/5[\JLTFD0?G)L\&:?;C]\\NLIDJ_,7B#3=^?Z-
ML L_HV_2;N07_H@?_=]R]9:")IC@?N>8^'?QBE%B/[N\\GO]1JH#+U8"ZXQ3
M"$%HE=P?O49UBV>L)7I?",'PK?-?\:/B[N0N2]T8IO(*3=.=5K@+(CMT\9Q6
MH'X_Y6,!;\P89:SZDKP;K"F#:@Y)9)50=OOJ$@#/V"XRQL4%ET H''2DR'J"
M;4N'P^K(?<++D*0"=$?^1M<R4:LZ9EI8D]8 0) YPX3+;5IO IQ"P%0Y=_ZK
MA5L22DM9*X;*Y0K[N\K9^390&Z( V+>AB?)EF],-CC94@I8?N0])S+]_^<=L
M\0)6!_%>\$]ED2U>/O\I@3V,:37O3C%IM789MCU7IQ56HHDH0[&OG.+W3:II
M+=W4[:K32W"TZ<\_5GX<19ZQ@I,R0G60^PF:Q,RZB_G^X5(RDZIZ3^D92HE9
MO(%(Z,8+(^$M'33@D$8//O T@<HR'J1PV_EE,P*)_B;IA6=J%R97P(BLD:/0
M88'W1>]=VQTB$"ZQB+D[2Q$VFF#9\<H=7+5:'0P^-'$KJ38XN8 78<9KJ$PQ
MK'#IWF=-OG[6Y/0^:W*?-;G/FLRN>\^B_A$73NZ=!)?95MMCAB9;(=+9(OH;
M?87+=@#GUTGWQA;NWFY#TV_ZF7MZ@/,+Q2=PW4$X13<=8X?]$UJ@5^"L$HYQ
MWS*XTILUJZL<9$O3L0C''^"0I@1'T=<=+'IK+MUH'5S?.M@6\FB_' C/<N0V
M/(%)P;Q_L6'0"%O9"H">ZA?.M&AZBPSO:S!8!EI N;SU"J>_4:6.](@G<IA=
MZ-A@R'IGL$%T_S5]7(J2X=#\_7\BC!-+I'D ]6$0:=_7@#DS1Y__]G53[3<T
M8[HJRFN)O49N+&XB(N!>@0WQ:AO*Z22!)IMO7KR].G3>_LD%9775=%LZOI%?
M=B:$'@T)LH&,*6<#C6BTP>Y-F9B:2;MZ_X?;##/:#[6C,3@UI:-9MK@PBZM&
M*XOY0OF<P\1%$.G5I.JW1NK3]J;39R#Q%NPW^LLJH9Z2L+*@,B* L19>:4N)
M?#:F8!W"X\6?W&79&:/0V(@!]H?45*N@:D"4Q."43BR6@TFTRU6Y%=SG-*WS
M@F'-!?)")BUZO$C4W<\_OP&.3;G?@@^9&W4FA+*=(:NBK;YI:,FZT!-S\6/9
M=EI!&;\,D2F<L,0QF2Z!=O0L!JMSLZ\E@AA9:38(8ZRH6*1!OQ/_A6_R;Q>O
MOGOAW[%4S/.\N8W:/C:$21FU)9?\Y:13J"5*0UU.1/,'X7U%.NM[Z,LHQ"^
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M?4@E#59S#344EZ7SG8FO$*J)OU.O;MO^L<W>7:4\KKBO43?#!:E)E41(^G-
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MTF=B(C,+DU>4#SE$<-]P*MF"*I1K)4U<"SE*^"N\:N2W [US!7 M.3#K?14
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M/U-)M56M7.E^;$,OW[\$NNBP9T6[O^Q]4,NL>3,Y+X(<*YT+\CAI8?"]Z/B
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MF<Y\)1UOIE1!QCQ6L*'0_T?<U<'![](<>>4=A/GYI]/82;AIH\T3*+_C0K=
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M7!6)M6;V183=_E+*YZ_:5:Y%KR7I3(4A+?.*NTIJ.T;)6$Q/DJJ3NX#%_U$
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MT5+\;!LDI,Y7SPQ1FR-+=# !VZ_%1J%6!<K!51)R$)'JIKXW2^Y/RS_):3%
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M&/;K?$6U^*%3$-H'4V-'8M\E#@@*DW&(+6< XX(!C&3WK$!=FTD@2[R2WN?
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M#_F>L2C)81 >!KNZY<;OL_BF# S<N+ F-[^-%H?EP9\.TF8CL9W<SXP.6%@
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MHG/5A/#[@\1:L7N3_BO$P_5-=QA]TO=\$-CKQXNKQ.OE+,P%D1J%1BZ!];:
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M\\MA>U#Y8D@^>";4JZ1AG7$7]DA.83-[G88H(#ASIM]+\W^/@S\*TC*?:&X
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MOIPR+5R-$UWFQQ7">N<81\%<7.;*.D?C?)-UEX S"'M(Z>(:.(2I+OD$Z)9
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MJU=ZD&AN4^TB*1,O'7FA/J8G!-=4DJ%'P20^#MUD3?V 6WN4N8X*1ZJY/XT
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M#('8>^,])O9'-/'J78D'L>-.$K[05;F$MHUSVA$_SJ:<6WK4#PG>-3Q\_S&
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MH2;Z2R" E]WVL#6^H^3I#,>MWHTD#[//&K;Q\CP-)P49?OC^BR0JYN(P2$.
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MU1![E=C;?;?3VV?)_H@F7KTK\2!VW)JF);O0^&Y+?MSUW1BO]:BWU]G[ 6(
MJZP\'+O=W9@#OGT2V3V(&J)=U]#S:#N>Q>Z1R.Y!U!!M'=$.VFY_L!.MTYN
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M=7RC)]N]5D<_B3][.6B;?G34_L[W@9C@]RG #@_#"0(H7HK=_**E/N1D.LW
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M:,JS702[VP;NH685V2+!Y!+Y$:QZ,M 9],X]T!I@2W$-0R0D5U.9A'3T*BG
M* 00 [:B^86N/ 22YUF>AAB'Q6*F>4@5D(X2F4J(5 KF2K4E>>(B9Z&R1!NV
MY!]1.)GO;6G34>U3_)"M73)UAF38K2=ME[4M73I WIF 5$/+];5#Q3V"2)LL
M02;*UWA[@@-T!KEX(P!?1NC595U4K9BY;'N"4)N+]!SKJ#"&[0/VLE"67F*Z
MG7^LZJZ2M%0YZ920H^QI;62C 7#!M[79O56 G<87<!)S55;X51X+H.2+,G$/
MA,?08=.<ZY#UJF[WNMK&MD8 $KRKK@O>\#2I>C0ME2XL9>V_IU:0#$'M?<KN
M0#A?>#[?<Y#;4#6/BHZ4<T_27BN":X7;%1%C] $Q%H&[3>8+V&6L?%Q+V!BN
MVXSDZBW0VOM<-RIU>W^A>C3!67J45U_1OE(NE)@+Y502'UJ*4UO?KN4@<H<5
MU[D(DTC7P96D"?9@2CU_R8=TM<"<>/%WG(+@+Z7P!_,)7@5_4E@ ;P?+JQX:
M37\4P;F\O>FG298=RFUF?/*JTQ"< 0 A)2V_C,RS/,P+&6V7A<0$/_PZX8)4
MCCN%;'E>Z*PIK6'B 2PN*/N($B+3AH *U%==:@O[\&WW)V>!!!_'Q?Q^*QT_
MQYCW 6;&.@6@WVYMS<Z="_U62RV,VK0J?U@SK?DAE;N00, *\TH=7:583AMP
MF@[L8C2OM@"M6"!)O.R,+(WE$@LG,GE=K9R;>X&HEN_8KF^X)A+ E4AVV< U
M2"=*,)BWBNX"<.V6F/S&>UPK26Z]LBFK-A!T!U<#\$Z^^AV^V@+ D>5D=J!H
M'08^<E!IY=VE^KW2J:^L2J8]%K%S+9]VX,D4+-4I745E-92E<6*5^@5UI7XE
M!AG5H:JVTJ\4I<)J_TC>F\!;@UGAQ7E]M5/9RI"V%OFN@(SW2L2\D]+Z8%4+
MKWG=JWN7'&M.W10RONRT*XT/KR*434L4[Z$PD8CVBTC)[@.KX2 #W^P3UJV-
M-%G(PSFQG?0/VB(^P_N=I%A>4;R53%C>=/<&6]9EGC*(@5YY(/B>A@Y6PG<6
MK)0QP856$@FW7]:N'C2RPHXAZ?!26.=$E\OP*D$;KY3D %*>IJ! R1VV@D02
M5N1V<JLEA\%'WX'R+-G#V?$@, &M^N"V"JB$U.<Q20-CARD?/[M.:C270F^>
M #]J-PGP)@&^_4NAM65DZXQ0(!4K"GEU+9D(V?T$TT\<<BD9A8SA78=691G9
MJW21C.-?A;P89%L%>!$MH4!TI]4=_.1R7@A#L*8NB\\2?S-N#4Q54>FZP;HJ
MKM?:3G:=F<JDDK.,!@7#8Z6NY94GKDN=NG4&!UMS*PLZEW0I3+LW&.^+[:MF
M/=N%<<CM6#JJ!_&5[H&Q^NE"'B8-RF[^*C"44$!LX1-'\%]=S09,J@OV*(BA
MB_/XY!8K%0<EY4DIYS#0 7Y3LI!H%^8JPZ@:+NCJN-::,CMJ(V&M8\7']?YM
MFUH%PD=(3)6BM%YKQ-'QE<]70^7_E$$,#G.C49;G)M6R1C=7H]Y5I[8$*'$2
MG@ AOE14 3YY0H8&DA [+#I?V\53U90DRXPU*E9,@SK?JVHR4))CG8@P2?4/
M*DM59U6I+/W* ;O.RU[9,-/[U*:.Q".?C0V]KA%?!=K&9<NX,M=?A.\11$</
M#-%#N!KU-Z;^/WM?VMTV<JS]/;\"5W?R'OL&TJ"!QN:9^!Q9EF:4V):NI4EN
M/N4T@(:$#$4P &E9^?5O57=C(0FNX@)*R#)#@2#02^U5_908KWKWFN5)8W2Y
M0H'2V &<B<QC/5/=.)9)EUR6!^![I/F\ILDZD9RJ+PS#TJ5:LFLZ'R6YS)U.
MLC>DUK%2!<]&S4I>/?,$[J*4TTQUP=N4=9K*-54'O%?-.<V:<!4^;D_::6:R
MJ8)U*-^15?F%(O&C .B?D?IY1L)G7C#F>2F?*A:YI=3/[A,^LT)-/Y71\E%6
M@"N@3OJI7 ,T(T &@&G:CV! LE)-[ETQKO%EWFT.:2.9H^9P8RTF.5G;(H17
MR5 BW#P40F@H_/,QX[0I]#B.10^2N2\2M.(@<$US_^!4%LE/M6ARJ5NFK&2U
MA:H"5AQ$ %-/N_S;Y2\E(A@^IZ@T*G%$5)N**JB6,5@]6$EB*E])67MB]9$O
MU?EGJ68P@#?$APSO%_*G+"P2T!>JI.B'>BB_[)@Q/A>TDG \?QGUN689RBH7
MB0!B+/WK&Q GRLJ2C["*!.&8H])8'-=@,BZ70FQ(SR\MSC9NH)6S\&N3$(/G
M0UE5)/BB*.0LX%$4& H"UF0<U#46LF%%6:295">FK7NNI>7W3-5R3D* G&A?
M!$*(BF;* L7R1<*X5\5+DY V>9Z&-;0'8::5@^$U%)*)**M#:YUA9+5X5AS;
MKX7Y>0,.\20B82F/]7*A)MI0!*.D%Z'U**LH \'7%Q]/Y:"^@9FG2\@^5;B!
MZ*+JB!O>5>&,%O>C,.,BG2&[L("SEPX*7 K4D@7V8UK5$4QT$=++=D)C*//X
M*XG%4]=I@U&&V;,.76^M0"KI JE=('6W@=2F!G!G:#Y<(,3:LCV6%J@+] CB
MM-<3T5E-GM-&FUDI>@9V[,.#*L<6$K_">"O4L+0:T%U"-'@0X^^> 6VL*"Z,
MA^+^];&.%\,;-[%5'>MX=53C%9MQMZ2G_&Z&82P<QXQ&E[([_)Q!C8UDMJB9
MUU?Q'QBC.Y^*T>VLYV7;V\:O,+X5=V/5'O'97? &S'K\W]L&KF\\C_]&V-_I
M* ?#:(?MXG?"5V:;V0J+,%_6<K=D&&W?=:O;]5>XZ^;A[/J6]:4R+1WZQ\WV
MJUY66QZ]QUB,L-7+XMS@27LC8B-)_VT-;+H*?>RCPW=KF\]O8-/:TT%^$Y,A
MQ-,==W<L_A*)I*WC>O'$Z^F>872D^P+']>))]XWMZ[;A'03Q-HU_&7][A];8
M+DPN966)+DIY"XRLO7+T[E\^GRE7X#Q/MUV[/1NV+G>]@"U]&?1$=1_SB&W9
ML(Z>#IR>B*7[Y 40U [5?V/@:,\1FBHJ4X_5E&6;>S8>-K-BNW(?%L8_6S7R
M!>[#YB?3[&!XNF7L);"S-6[<CQ[K6.6ELXKE@0GG'RYM=:S2L<IN6(48GN[9
M!ZQ5]IXWW+;I*0^%8%D[&J'B>-%$+]OV>!:=+[B W6RBNWZ+8E4O=L->!+6\
ML6R=N'M)B+7<+ND(:BV" GJBUNZ*OM9<LQTJ[U89A"\Q[[M' [I-0VWK$G;C
MZDBN&U>KQ_6J26[?*:<M.O=GL]QY[5@+.-S?5RU,$ 2B-?&9-@7X8$ J'C9^
MVJAU//J<8<^((E@MBMGME2;:-Z*.2E4QKZ/;.SQKTFJ::-^(.BHM9:G1HE3A
M@1A'='_U.//L)H%:U1Z+:;U5VF^V-$I'B/^PL0UN3Y7_CN9+#$LGU.WH[R4-
MMF.6[<RW/9Y,J\GOH ;;\<IVYML>?VJ3Y#=EQ*H/?X"KB"Q5?+$"_MU""#$%
MA8#E-<*:O*Z?O?^MJ/*^*L_>GTY6=C_CI=KZD)%GDS@!"AT@[5<@7W-0S*G
M*O^!$*_>Y);E DF1J:[ /W@UG/,E'FI)L.*J1ULNT%1[3UHT$MBJX^C0][ 6
M'!&!$3D:WLO%S\N]3QYP>A*DN:AX0A SB4U:FRY\*;H@3(Q^P6!-L0+CXU/
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M">T6#JFMYOQY-&)9E&I?>1_!O'IL*S',-AG$!SWXG:J$W=!&IQ?VI1?4AY6
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M>I%LE\C4"A2]>)7<*'H$-&W-26?X'+KA\X)V:MSD:??6-)AE1^]7M&24,;%
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MA<II%(?V)S=^N6EM%Y>TT^6=+M^V+N^.A17'PNSN6%AW+.QU'PL;6Y7._N[
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M4^I?2I=AA*4!,#*T;= >/-*R]!'YZ\]'I%J68;3TST&6%3^O/VJ.-:E]XYD
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MH,?OVC3B%@NIX3N.Z3B^8[$MGXNQ3%\G7DN !C? 25M7RQLO+FYHNZ5^T%5
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MG#120-!<:D>$MMBM3ZY=L#,7XGGP@.Q.W8;45R1U:@B/AYLW6%"0E!K%P5K
M5##+L85M>U6QS$3VS([4\Y,B\Q,5EY$'%T4*1\B'H()VQH+S6K$H$FIG05,6
M1;Z:JN&;]7\"6;'@UG,SGM;$7S^8N9H\ENWP;16KZE1F>$VJ_KWOU_WBCCN5
ME+]\YX/O]TMW:.DZ'>JOA?%=']K#AQ-F:FH0/'!Y4^'M69B=5@O!W]40MQYB
M==*U?:\'_IVO_CWICHFNBORXT%_]3+LA*3DA5'!$&7 A- M6I[=1$_;!UEBF
M-F/GA1:1:'U,;_/4LO;HJP:$^P/"-6/0,\JD!^6%!JJ5 B8"QQ0!5I+;FCJ
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MHVI CG(%A'-.(E4S0Q2F6DH0(#%B-=EZFQ$Z*<OGN,N.P/,3(O.3%%<UMCZ
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MR<4B!@F4L8*<X00F7$(,N1382* QW"TGAUK5&Z']UAMMBE^W-2WZ^1QY/#$
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M>?6_H.Q3K^T+:Z)1<<L<"CTH44?,DYF"FJG-B7OM.'NLHWC='_3S1WC,Z\'
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M$0>$$T$Y(T A+/<[T8S'/?(\.T#._G\MXYZFOT176D\?I@$LU%'#X]A=<@:
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M 6./SYX8D6@4ZR;<L'++:Z7;-EM>[# HMAQNO=M= R"A440R0 Q&,18VYM9
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M!U)U*$?&95@O=.>"=0:ILT2IN;)52ZHZQ;>#S3 [!>U^+>^Y,)XLG'JH$1!
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MR6->+1]7-'K,9NAD$91YY,%6!^24\;<<+.UQ;.YBDW=L$/H<OOSS(@YQ<N+
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M^DNE-U7SN)^VMTNT%3MO/:ST,[I!-)#OW30"G4>8\DD.:)WW*.>?S"RUO0!
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MD:G8 83TJ42*@*0<&F*MAP00(!&D4 !D)$60P,.P:TTBH=O47(_*P)9%SBR
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MT#'8]\02N>JE;Y*_E[CV&)0XC-+96]'LR*:7>K;KB;\K)UHG$#N!V+A Q)U
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M*"G=BA+ BSIVY^R:;$Q3M=%K*4$>SMQG:9%G?38Z],II=@%!Q!:A4!@EG,+
M:485@10HP 67@&$%G 4Z@4)Q2A\)$=8'30Z>O,(S>[ZN5(N(V"F+"W7+6D6O
MMJ-I*"XY<DY*Z1DQC"FCN:=&4L",53@!\WI*UXW?@@9G6USA 3YG!Z^=7EP)
ME7'F7ERG<J^"&EV@<R><"VU$T'\@*$/&B59<0 D-0AA#24BR&.^4+A7L4PS[
M##=8>7]1!^TPQ7>=:+Y<CCD+/^?2I?*.'@R!W!(AC19*$J.T=H(J@0T(HML
MG<"?.*4'PVZ;1&"]J$-WSK[)CCY>&I>BC6[-'%'BS!V;-CG?Z>T_$\7;)D+N
M!OYP/@[6.=*V59 7D NKK+,0<$D IPHJHIP#% H%C&B9PX;Z ($^;!(9^!JE
M0+*%NTN-=8JJ[80\ ^>R_41L/W2'4<1 29GA&!$LO9026J0@]IP+;0^EE&J7
M1<HS]$S;SJ=G[=2VPA==(2O)UET<U17/= U<QT[@'*3]5L)I.)F<D_X_B9L4
M*-2SHT<]=.?J@[:,;*?NTEX%Z#"&>BN81U01I*D0U =U'EXBGG*;P+X_OF-)
M@U,)^Q1V_0U["+8N/=AIA,.1Z Q\O5.2Y]1B?D=7#FM.!9<B3ADC5!@-'47,
M<^V\08R81H7_53EP9R/W#^>:%9_N(!=+TG<(B4<OW[F2&$V'D-@R0IT[0W7
M?AV770Z=.K%U)0S5-MMW[XE.Y,(G.I7HXRYW2)4>N@/8Q4U'G$Z?%FKF^#?L
MR1Z3+,?*2ZPYN$^-.+625(<-4KV>'_&5I(,C4EHG ># $,:L1)S&B4Z:4L5X
M$MOA!-5LC/*^Q(EJMD3M\!4?S>,E'[J$P_&MNY;E3UN*!-XR*AU-LN^89Z 1
MYQ012AQ71&"MD5,"$@<<]HZ:%)+>"?(, )\'Z/<YYQ9F/_XNO!,YZ/GO,J+'
M_1_</ZJ"ZLNO_&[E\W]>NB1CMD]A)?]MC;3((N8!I 1[))ERW 2SPGH@*'9$
MY.P6/AD8=[KKIV3PR_YL!U\7^YJV;?"QNAF73))Y(U-\X@2)YW0,%\R:M(9.
MC3.6NUMT'/.G7'(3LQ<#*8=J$@[:R]\^O/D01,#+L5/_?!'^6G!CJ]]2Y7D3
M1(L;K]XEMQCSV^Q%[PIIQ8RRWPHG?H&TB^1^]OS-#:(%V0JJK7G^A_!\-SHN
M\T;Y\/0_]=3PF_H^64.+)7?^SW>SV$(ASHN3G7O=JSN0R_GLW5(& !"D0!F9
MJ$YX^SW(_B03;<5;S_ZT97G5+UE9T;\[%1YY>4G9[1:%Y+H-SX7<PJ[HT= 6
MC#VXMRYR^XVL\%O\2-"RD=F>_UGU[L91SO_^Q2]_??'R[?M?W__E[:N/;]^]
MNGT6N'V%4XI-'DS#UYN-W#!CF6?//T6YU!OYWJNHE.ZGDQE;J#6V_S(]3T6!
MA@C02W='SL1*1HB]%EV<\R8]E@7B/7L>J=&;D:/?BP3IO7CW2^_CWUY^?/O+
MVQ>_O7W]L6T/_>[]I]<?>Y_>]UZ]?_?Q_:]O?WGQZ?4OO3=OW[UX]^KMBU][
M'S^%%_[Z^MVGY),GSO'2*RN_UU>:LH[2I*!0FB5Y[6#R,%3??ZJJK5)'+>]"
M>10P*YARE;GWB(,>)I[Y8A+EQ$K!=;\WO7.]:%VK^^^].V5[?]ALDL],6S?^
M&DSGM(7^;G2?5WYG9O'DTR@<ZNK[KT:3Z;O1]+]<,(7-Z/-]H(ZMV,J3BD$.
MI//4"F8=\80CJ:$4@%,CK*$*R*<:Y/_]8:CNWX45YI?]W\?!]/O;^WB>!E]=
M?"]EM\.JW7Y#9X8[VXH]L J[V0M\,(QD#KOS>#^>D2,L:TZOK'C^?A*\)S=4
M10W])"ZE-RK"U)]SR(9PBZ#UJGOZOWXO$.0_3WHN6UMO4"ZN%]C[?M*/AK*Y
MZPTFU0+]A<.KX]?.'FL4S/Z>ZGTKW*D;E?M3O0<W'HQL7$7!/\$P"B^98['/
MA^S[WXS&Q4OQ.E@-Y"E   76(BH)A$1"*QP'WC"&G ;-@;3NS%$55KF9./.3
M?1Q_#S;5L^?H=C;3J2#B\UY\9W+;^Q0VMB1]KR3]V'U1@_O@ 65+B(SUJ(9!
M#HR_Q.U8X).%C:UT:NS>H1$Y9>,.9UNJM_OLNJF2P=_*Y;^:K_Y36/S"[EM+
MI8/2>F,(DUI1R)'FV!/CO;.)65ZU.\'6;NM!J;8_>5!UU)E4"G@&O 6"0(84
M-MIR+C4FT0L]"GGX+5SF^J9/P2+WKR;X3L/PZX-4NW VPX!RR#&,@2L(@T$C
M$3+866Z5= 0?8^OH7*\M;]5FRID[9Q^'[KU/ZX'LU<F+Q^G=:!QE_-^B<JL\
M6)2FDY??%V)YOT6J1Y/OY3!<]ZQB-PH,(+3* V:)Y4H&&@$GM N$PQBJK81Z
MUG-!SS]$HV_\Z%)&)N&,8@0MT8 0)9BFX2 Q:)UEC#+JX8FA9E(^57 BPVGR
MH^%P]"T>GBS4U9L\?@D>7?B222\&UR*QPV$:W.<L$"V2L?L<V"9\8HM*F1^N
M\L#-392J:LK-D>0)_&GNS2W+AVH09%/HJ+8W$?R".MX$S,5]^CNWLTD-WD+A
M&X]>>[%GR.NH%4@KH8%YI/$A$;<]#/<DMW+KI]!3N =%1S8_Q<8-8YS?A-.8
M917B[T6P//L]#^OEJ>9-X9]\9U([NA#G*Z*$Q3<&#EDL$'IZ[=)BW ^)1%D2
MNO"RI'H5^HE\3RH_4DW=)'OI6W7 -Z[X":OLV&<]^Y!G2RF!+2A5.R6IEU,K
M=S8*JG9LPWY1UB<EQB;3\>C^\_./*YY*^:<L2:SX>D&GY9_:=TN[\]'@^>B(
MV0F;2Q4VKZOUSYVP.='Y:*[^?TO9\#;;>DU=31LVZ7BG)XLQ]48^L747OO(R
MU-;+8FV3S@_I_)!3F :HLPP.W?>TX&344O<[JX_*06@'M=O$\YT Z03(60F0
M,H=Y?<91D;6]OH7/\M37M_1*9O[Z%O_KP+O>C_\5,_U_[(R$SDBX#&)V1L+Q
MC(1>H3,3(<C%4$,G7CKQ<AG$[,3+$2SQSY]C?=K4]=X&\VQP/QF8A(3YNQH^
MMME:;^=@NMZ/?P  E&T%?]S2@-7K!'<GN"^#F)W@[J+/U\;SG0#I!,A9"9 N
M^GQU"^^BSUWTN3,2.B/A,HAY%",A7<7760[7:3GTKM9TF"49KG#I75KEU**^
MTYN=WCQ_03++M5RA#)UEEZYP[6W/GAUJW4OIKTZ!7EHK5'7T2=8'M=/8F$O>
MG2V0@$\ [UF%[OEU],V-\Y\&7P;3*H:7X=)#"!#WC #-=3A#"CN,#:)>:KD=
MZ:AAE*$<+VGE9=@@U#>\A:LC17LWVT :&]V1OST\K-D1A86@@&,./27:,L&-
MX 0:KI&SDHG+W!&V"N+81!_<W.!/ZH'=9E=MDROM:XQK8MF7+'N?YEIVU#T\
M=>-TM#UF<9S302X]6^]SS_:(6B?'U7_O*Y4@J^# WE').:<".TLT!LH%^R".
M[/!(*,[63@4_H=JI.>-)"M@'<L^Q'YT4Z&1L1]V.NMNH>WT:K(T@S(Y1A8F7
M%C!##%/*$V2$$80PAU%$0VJ9-[46#YBM IAW9[TE9[VC[J&INQ9:Z>S=^LTC
M#:]=IVSRBE:42DVO:-4;VC37\*4+1R=JG9<JW,ZX*FX\AD AIRGC2!!*A;)<
M&6^LQ5Q9R-<.MCW+B-UJ#+63F"V2F!UU.WW4Z:.31NEVGZE;44&S\H>L%J"B
M7"R@SCKF/;&","NT5]@C(9C&Q"F52M6=6KDLSO3",^V"MVD7VD<T,7F]DX#M
MD8 ==3OJGB-U.YUUR,Q2!=EZ-;-$F<6>*@,EL$0PH2073!INF/5Q+'P+-5C-
MS!+CK$])I\%:*P4ZZG;4/5?J7I\&VR>S5%.!K2JN&MDF";T(VLU(K@WQ @GO
MI#?2&,LQ4@*<4[:)==FFEI[_CKI==*^+[IUKMFFKHEGX2#6[!+$7@ OB&2&$
M$ZPA@T)XK TC0K@V%N;5SBY1T?E.;9:0'74[_=/IGY/JG]U+Z"HJ9S&[5-4N
MTDH%B(:22T:D1<)121PSA@J%/'$MU"ZUTTN@3W$7G#NU"#QZT^DET[T=[:2:
M"*H]@Y0R3)@%6EE%I:!2"48A3$7X3Q( 08T:JWRUA:0U[:3$0D6-=A8X3!SF
MFAD'(.104PVY@9>X(RA=G';PL8KML"V:FZ!XR?+RD.A"'=W6T&T/:[[B [3C
M6+4@N;ZQ;5-AC 12WAA)"=-<BB#)O0RO8DH /W%R/2G>ZR;7D>PS2NO9[]W)
M[21>1[?6T^T"-44;VR.)4<(!AE5PU8@W0'KI@J_ I6%*"I<*^IS6.UB;L*:W
MO%;"NCN?G5QK@5P[$]=RI_#]!<KN\VI#I,9"BJD!'BL"J9,$2:X\=! R;%OI
M"M2.]-2-XW?RJY/['=U:3[<KTR4';B'4G!@O/402"6*TTM(J) V@GBKB=0I;
M\M2*H6Z.5_8Q9IUJZ$1<1[<+I=NUJX9#=NI!A*CDC!$- /$**2N1P=9[21D0
MEK504=1,)E!!^YS#3E-T$J^CVX72[0(UQ;ETQ'%CG2*.42$]X=A+J1!E&$%A
M/#4XA8C5V@1#O8ZX[LQVLJX%LJY+,+1CA6?9>28LD<8SKY4#!&NN@R#'A!#K
M!;0,XQ:Z _43"C7QX#MYU<GYCFZMI]NUZXZFN\:(YA B8(1P),A]I3QP1&C(
M=##CN6JA9JB;41!])CK=<$'M8%VS7CN:QASA&&D'F64B5JIKAS%PA@L.A($,
MM25&@)MM45J=>->:IC%EC69*<JX9(Q()30$7%#A'- DROC4S")O<$7(+4EF
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M&<":::6AF>^T#.6X0#__[0@HE&H <D97XD-371J>N+9VI7XU^C%W.^1UH.R
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MYUF>N$:!XIF6*)YOD6(U!JXN79P:/;=T;.=5-TYINE6_+Q_2*6C0%Z$UQA!
M#-,2:6ZL\]1!'@RERHJG#8=T(L.@]PIXK!U!U&HEK6?:.B6\98RD-*_UAG(>
M:OQF];3/ESR4$^YE*&<SA[-><S@#;[W^[4-V>_G_/9^QFXOG;*[M"%W-H;9@
M:[6>N[EZ\5OL&$^ZL%>+I)NBQ.[:1\LR8&;0U.+\\$)0%>&EMZ[K?#MGP542
MBV(3!)##''I%#/6QP-HJJ@0B0@N_C['2@&L'#.4Z[)$ X[2Q$C'FK:?*0FGA
M'HXVM]'2\<Z8:(OS4\:G7<+V@YQ^93KKJIM(?OK5;UP-T2V.86\4-OE?7@Y6
M ?O;NSQ/(D?:1<--V@F5LZ'Z?1R7SG[6.3K_$AU!T?7B>[%/Z.#7=9*-#G*X
ME:E7JVZBNQQN)3-9==/>$L)7'^Y:B5\'.8O*3+!5-[%=SJ*2M%?=M(^V][OP
MN\,?1&4<>-5-?)>#(.M;/;G!4C: -O0Q3ONEEM@_Q@^'<Z;/K I6,GO&+BX8
M!W'.Z?(3:^![6FKTI\43+_GDTAXGB("J'K(W<Z"L,\W9XI4*Z-+%5WD;9LV=
M_)8_994;S?I!# 3Q\?^\2L*O,_Y]LLS-U[3H_55K+;!@O*2B$5J6IK M72 X
MV!$]_:_=K5STDR'SWS&S[,-<RM@R.V/70\[I;),CG@T2_^BKARW.?9$I=%@Z
M+"]S!Y1\R62RRK'[ZLW/*3#:&PU4UPY^>4KRJ6RGUZ#O9L=9[.F)M:1-O7"A
M<W(*"LLHJ&<ZUO6T,E1%.3/>]VC+CWU+=2:6_8"[.?:G8\?-L9^I[%R( I6K
M7!,=T#F@0^U%9AZN>A=+*H(9>0A8IFX6"X%Y3.S,5S*-:?NAT>7X<BQ.T4"Z
M'I ^Z#*V!?_QV>3V4#@)%YQ.Z$GY/(7SC)%_J^P@_^[=AP\?/\8<-1>DG>H<
MGWM.W'O+%W@ "EAQ])LOZX^')8;QDN0&2UI>*5?(S.+LYZ*84ZT#+#1(*<JI
M)(8A3:VET )J#+-"5C2HV&#$-)X4PN%5I8&@1?#\1.(:8$)M^'9#3?6G)BJ1
ML!!#9VB@#N45H<8'XF)6<X?<ZEK<K:@I-?%]_;^NWWOUYG5#0^>RV., MA;4
MML8Z]T6"3&B# 8,4&T60(8JS0(V6(NF-AJ9B[-E,\7=#@F>@\5;[RV_B--33
M:KJ'='1NAQ*K0T7'-OZF>,9FRUN+2R0TN.S:3SVSG%=H"N-,/>H4A,0YH""R
M"F&JL'%,\-4C$O>D_+:$F.^,<30,.:D'N:&L9TE90GO,#&,0"$@$\U)!(J7B
M1 ;EV!K\K!7A,R:H&BJ_J]"X)A[-C4AO7_KPVO1(I5(L3@.S"!$NE=;.$,T%
M@9Q;[ROH\1EIQ7M&]!KHPU!LX@*^[0UC?X,<91I'\$F650/_U8*2EG)O7B4<
MD\IP; CA#,D@QKU$!AM-C#"KAR?M21]&+8S@,[.B&XIZB12%M83*08Q0("DI
MD*:,82.L-M0 H^&SUH.?"1W54"<^S5KKZA5>@PP%$MYQ[+S6!%LA%&."8^6
MT"Y<?-;J[S-R"I<TWNE2@/?.N]AY]P198B50'R*U<9LC/U6*Y1SQUP4@>\J
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MMX-N8<IO^]_^Q\J!?RB_N/):X_+*DP9OD]08/U_L'[AU)K0,2.E$[OTI;ZF
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M"#H4T"332:9/3J9!R!G1VN9$$<*ED\KFPBFAL44*T-7'+^XITUNRLBCO8/C
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MWGH;9+(W5I=97QF&G0P!A+WRK[YT7S?NP5M-]\C8BB)+JS69<C_N:6-%5U5
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M%?W+LU[WJS69' [M*+6C2$=^ZD(]E],N<Q7WG-=\<U%\\$SS(?#,><DRS2-
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MH)=;9K5F_@^AA ,@&7."H)Q*BYPQ(%J@EZ.H$G-./TZUQDG(U\7@IO"K;M?
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MK=MX%2/?Q[5=6[6VTFXWT_S?\7#4=3_\ZWZOVZ?\"$>Q>V/CGZ"+ZU!HJ1*
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M8:/@[^=O?CM_]?[3AT^_OG_]Y?W'U\^#**PX[WP7-TQ9YLG+$HD&3!#J!H7
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MT))U.+3^C[F0WYOMD0C%RCB+.+<DYU!1S#ERH?6ZR36QD29+4=P1)W*,\OB
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MOPE4^B?@1 H&%/4,$&2<ADQ2;SP1@FFE)$+]<P^?=/:TM^BG<)_]ZI_I*.1
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M!L 2(8(^$5Y:()W46@7% A5GJ:49-I4PE@F7XJ4&40>XY(RJ&57WF;PUFAO
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MI%J/+E!9YP,I#)E4#"BA9.!Q+A372+O Z\PC:&M"#LO[0% #C9A3WFM"J5<
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M5C..)QUP*:MS/9EGPZ &@T=APVR0J7[)[E5&K]1-H\=4[)-NABS $X#0 T
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M6:QY PF>!3L+]HL2[$EOVU&)@HLM$**06,V#$4["D6M-%,<(ZC4#DCN19=J
M;')XV2')\@Y"C>F5X=;TSAR,U'WKO.MVX[5N]:-09>EZZ40C<P8H9X#6 5R"
M+?%:>(&1)(X!)0U57@K"D/>JSHQ:*KPY^6M7?BA.-^K':12FS5;L M@@*!7X
MS7GDC")IHLAFJNJF1E:-)E#'6P#4(R*!EIP;C3VCT&"*)=R8=[8-@%FLKDZ0
MX+--CDLX0*#)=749OPX-O[8:,G82"$0MIHA!8A13P1,-+VC*)!3&IXU>XZ#E
MFS^</?FWZW9>O3XY!JC*-E'&E"0QI39&#:7E GNG$*:$:2>@<D;JX&EA[*#;
M7.II]VX6;T"2O:R,*!E1=EB*%DP/+2A$4FOB%!/(:@^!TU18;7C=3,240.1%
M&"/;"IW/X[WQ*M[-8=JJ';@WF[_;8%>2G:YK XFZ= BV2U6:V2ZS76:[S':9
M[3+;9;;+;)?9+DFV2\#7F>74IR0J6P[];(4I]KOD[<9X#H+,AZ4-CHOVF<4S
MBZ?&+YG%#Y',F<4SBV<6SRR>6?R0R9R8B_S$!3Z,(3]X&Z6A.8B5@U@Y=IK9
M+K-=9KO,=IGM,MMEMLMLE]ENM-27U\<@CQ/+%>_'4O&.A)9&.B.ML(1Q+33T
MA"BDC&66HIIQ8BCE_M00-@A.I<U3&N'<C"$90W;;]%4JH"&UEE%(B3!$>VP!
MT@8#H0EEHJ;CR>A27M+#"D6#D%2:0Z8!+CE7-&O)?RW^T-W?UF&-_>:-MMH"
M0!.I&95*  B)!U)0(P#'VG$>3!+F#P4EYEVZ2YI?LR&2#9%#-41J&P((+R4U
M3$B-+2' "<&<%,@3!377H*[;6I*H,F%[X ;BV;')>)+Q9(>]<KF4Q@B'B=>$
M,Z.)1LQ+#U2P4\+K:[9NS+/6#ZP0*+F^N7EX5VXGON>.*8H+XXBS'$#"(=.&
M(NNM]MX[[G'-@)^EXL<[:B=.0"IM)I.RG[(L'[$LSX_C:N4M4\P80"7AQ&@'
MH#$6:ZDDUJBF2>.*OM1.I)PU),-9RK.4OTPIGQJ&]31H;JD)L91(:85TS"F
M <;$.%^CP),6\BS@6<!?E(#71D$EA4XSXC17AA IXK0)CYG"T$KJ\(%I;MG
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M2WE)3^T3#812:?"6P67[X++N5*P4DSJ9V9*A7=9D^]5DM3?*D26"6X:(E81
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MAUX7\M)EWKF$40"!MJNR1F5OF?<3HC!4".A(^KZ%(Z&C:54/AYD!751 #\2
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M@<Q%_V'S7S2&+4H8?>U%2N%B(Q[^AAO>5 -IZ)[@+)HU'JI5(?!BDBH-7^R
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M3%148'L2E<Y*6/W*58.DN.>8K:1+N% >'8R)>\%%1-$VK9W"C5IOF#=#FZV
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MY#KV;7"]D:4D%FE<WOCK=U=8\;&?O;:]^QU;$ZE--E/&C>'6>!QRMGMS8]2
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M;^(8TQK]9WUC#OOKS218@"'H\]&FW,11LK2\NE;?1)+03SXJP#/M35OWR(%
MRG)9E/#BVRPJX,8FO4!IQ99!JI<V0"<A>>OXDL[9ZQ$50&[@%'1:B)LT(R6&
M=(Z)@&WPE1U$L2_:DT1>I4 95G#1<5V@IHYV5 D#Z!T#"ZDB K/V->CI#@V\
M*6S!=:Y^]4#"PR2 *J&8Y^BX![*RG4PLRB[Y)J.3?4"#TE$@1XR8S6*X,4
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MSL>&E9MM4;)ZMI'\) /T?(M:O(WC: J3!]]S(14<P%U1*?KF?RMDH@KWX%Y
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MA_0\)-73:UUQB;<%M@!RFL9K: EL_"Y-,;_5_@K/<5NM<*6LJ>(/V8BG*P3
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MY#F!*9[@1T!D>,-K6-B;BS-@LY%/?.$-CX&PP(R:)6 ;!_!Q_^C7X0CH9_,
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MU1#>^1HEK]H5WJ4(8DR:0>E;R=5[ID1:8[M>N2#2[!# N2CK['37=&NLV$)
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M$_.G,O4[04B^U.]\#YYY@XS?^1#OF4/\11-69[_UV-)W05+2=\TI_MQCV<8
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MUQQ2U:5"*B\R6#RK;+E$AQSHEJC#5_ N17Y0U /FP4O0)[VU!C,@\V6A?@Q
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M(9<V=^CF1R\ADV\:PQ7K#]PAQ0N'QKO H069-"!<\Q*C>?_&]@6N"*2PA,=
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M0<O\SA=;$WSKE^J-VHA_^5^NXC'8V$0L@?N<+F_%S9*:1A&RXE@#XVI/.=-
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M ]E2PST^OU1A4Y+&.!V1Z)"AFH.>]B3+@5GYFG7$-,%5.LR'36[$E>2N90A
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MW?3]Y 4WC? B.;%PU8IJKC@LRIP#>-\1ON\[@@F;Z*:+!6I%^7W9 @B>B.N
M,#VTST]QOIO(*524C:Q5G7%>Y;;\Q&F5"&^89!&#GDYY8--6TVX$C:$2MW 6
MZ+0D5!&SSY10SS (]F3%!:-X,#R(*P\T[-?!1J]#C0U)I!IT5QK:T$PU6<#!
MV?5I%M_1:_0GKJXO'#*>MK%NI_:J1%Y0YJXS6T=#F<9YX0 KM-XT1HJI.;OR
M!?WE!&;2_FRG+6>VD/(+WIFN<Y)FR6[LFV65W86\I @P$W]1DJ@B1 W*Q=(
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MK6!$738.W,@=*1T*4HR,%2"K*O?!G:7)Z.<+./]?)%_ F-)6)^LM!',7U9!
M/*N&<<@U0@7I')2E9B5^^ZX!MZ=R&JM\DOIX&\'O=<61Q!FGM+EN'_^"=*2O
M:IALE,V J$JGBP0F=P)@G)66?LNL@A%=0Z['"CY0,9 O* ^M3N"( UOW*8BZ
M'P00/^C!0=GL;O8[Q@O52!1(HUJC,8?[1VFXT?$KBD!%Q[FJO5I43J1]#14E
MW?F^*4=<, MH9U!+1LQM8K$1E46' KS+U!AV/(9SNHB+5"0W!1'<6#D8U!>.
M?2]=)UN;.:\X>(6V_WU#>7NK4-X_0R[A,@&'L^$Q!^W?CSYB5/S\_3#X.#BK
MY;F[C3WX?H0#B:CM6L+5:N];"SCO3-\CG25+Z#8CC_74ZUZ"VG+.-5=Z/B=N
M'^4@+CA)A\P45=ZL#2_7$:J<J9W@SPRLL "+NY63#7TAJ05@=!WX.D%(^PRO
M889%)J]41GCJS832R%,/^Y)FGR7L)]<.%F<03$>*56&X^U[U6D]K:$M0K#T#
M5UZEGG0N2Y52W.:YF$BX1*9/-PWFJ33_'9T<#C^<C(Y&!W1N6@[)PMM>98)S
MGR#,7P.:S%*P>[RD1:QH3".-* ?_$?F,BI0Y[XD+&9A1XEQS >D@3K3 11GI
MP#V+-PM^@%OX@CYAJA=]T'$%S%?/;@C/-4/ 0UVPSHH<!188288R$CFCV\U&
M)&?B.CL3X8*(9_@2TL M( %-)A(S0:T)+&RNE[&GXQNZE)L;$EBX>.5J*8(U
MM_'>TD$EFEHCA$3:KC+."E!8C'($;_R9:C?A,>FLW/I1K^*\K$A/0OV;=R65
M%W#HR-BG3$'[<T9.*A4PHYH&\R?3G\&OOU"^7%6-J8V,HN9*X=!$?D6-<G/:
MW-9 I"HNT5AG+9%*A@:@ER0W7HXC-:!PI$F[C<P5(N3$CI-D6B68J*<1$UK>
MIY+3+9]YQ2>*%1W^)(FHF):L$%7?T2;43"JVSAKDO#_W.D"7HW9JT9[@U83"
MFEF@83&X5Z$YP-QIV'VSP>"PP FP(92$Z_LOC27&G!G D2TD%\? '#G*4B]'
MT>]%KYO_6HPW6')WG&Q)S6<6=/W<FX>?X,[PLE0?3/R@:X)E\%'5 *NJ:5U"
MC/0DZT<YHQW4$G5C%AJ7S$7 U&THM2!<+/T6*Q:=&L127?HY$LRR$W,0"Q0K
M^92$LU+-V10DB E7JNB0(H:^I$V2=RUW5UKR8  Z"UD/\  W7$SQH!")K9E0
M+_'.A6UPW-*%+^8>?.RP)O@&;N$)-O*D(MLZ%&H![)FW>#'4<"?+E9#>("Y7
M^@\NG8#JU6YQ=*3 B*"7A^TT2SS8V/)!NJC,*V%8,9(F<^T94?NN)YHE*I]C
M2J!U+(4]$ !9PD"Z$U7M$+UNH8]W5NLA>AZM-HQKF"ZV1^OGD8=>XQM%?\]+
M0:]2Q[N#[[B4":T\ GZXD9$!V7?29,P L("Z-'"%J8]M33%X6@I>%EFIG!G\
M*XR=9A2PQ+BXCBD+[-+K^)D6/DXJ+LJJU'%H.UV^&O<.Y\X;I'PP(>."\1,=
M?W7)??O:-E!?6;>+0W.'F:G O:W:NF*G1YJFKI>*I7+8MS '=I\R,MP7V0N>
M" 4"H\RP:B[GA'0N;Q*A I>YIHZ5\L\JBD.M7=SH7??ADKWKQ:Z+IN]7N-2Q
MB>BB4=<;OX1-(&R#6<A$)Q>$EQFU.7=!J:GCAJ-B/5UCX*GT!*?L<K(#T'8^
M'JE<\A:C0&78'YV>49K[V[/AX. ]/E3+^',W]Q.8&F<D3U7?\8.-'@Z-B>Z8
M=C_\C(W??A\='^N$>;3<_PC>#SX/Z2UF0N:]QZ=C2GX?G1R<?AAV@H]GIT>C
M<QSP?'@V')]CJOUX\'ET\FX<O/V#O &GSLCP5ST2V$&C,Y@79=W3 @;''5S-
M>/A?GW@Y,/RGD]'Y"&:#PWX<'L O@\/!A\&[X1BN[Z,C>.>A]QX/_@I?"4K#
MV6@,\PF.SDX_X#CDL:",?GAL- X&[\Z&0VR!Y^3_4Y7 Z2>5_D\;U*&7C ?'
M-)E/XZ&N.' +",Z&[P9GA\=#)A(^ ,O]0-\\X$$("N#]D&@"NP#K/3\;,!7(
M+L09JSH#(M?YZ=F=$QN?GXT.SMVEVXW#]YT,WQV/W@U/#FCJ.&?>DV.8[3'^
M"B@.@[V%I;T[.P6N&7>(-X+1$5 9V$RS!>SI$'X]./P\&@,%M;L'>&*D7G>J
MGD ^H6H-O5T;3&R'X8GOL,1B &K8'[@=39;3>WW^?G >?!C\@84;GX[/>2_Q
MW3#?\=A=N;]6?,?1I^, ,YI/3PX_'9S37O""5B@TC^(,WE\Y@_]_:28Z.AE_
M LEU,&RYP.Y"5T5=M=8Y62>YN%NM\ $YLT993U;/,MTJV8^K.K21*NNWUCS,
MDD3D1;#V;QK\K^9<5M ;IBNV\J)0D(_5+.!T!<2E'[1O;Y1>:HN&6HPL\C;8
M#,2_5[+P/ 4J!]VS8#R->3&4H8BNN/36[U?2@*^_9?:>2;9-)EE<N%Z>61:1
MFME!)1;KC.KI/*;O260<X:S+MRR22B]U$K%K3&O/GTN%5A<A:)\BX8^@+%_,
MV-EC33[\BKA1GYJ>P49R/3M2' .^Z:ITD^5EF[?1M3+Y(3>_PJCJ-N,VE_%L
M@B%4,E)=>#H7V]TOG=$&\]+]VHZ!?,U\>#:V4ZE"*)HOR#TA(UU*KLT2]DMQ
MZJ<Y;_@3#KZ!R/(997(E*J2BOL06+M)$F;PB7=H+.VI83_5%^+ 4]7[L*I7B
M(X=#C%>A92-L&OE7S*^4<A%QM3-/&7&M1"9((4S?<&F-V3#J;.()2U7@1=/<
MOME/XZK;O-IWQ'N$&:NI^ZQ*2D(OHCHI7[5^W-N;%G#H6VK3M0\M:.YQ+3$-
MZ8;35Y7@#C:CF7V3K,2":9T:SLH93E88F[UE&O9BH=[+UKH/J8V=OQ&&!+9H
M(;M2L$K^<6D^0>?L.JO(CVGA?Z1.;6WA&E!]^&OZ;10G20@HB(2*XA^7 A-)
M3-8^AVOJ#!@]J#'_0S'X1+2UWQ- G<U>MS_=[$YV^IO=J>Q.X8.8[$<K##XZ
MPH?/'(,/^]F/3NHQUA7@WB,7K8Y2TS3#3V!4N>PQY[2B>.L$7@[$(O!TVT*O
MGOW10-'W\B]$G!3<RX->C)?&#%&K"56.':E<E:3KJ_S@J)NA21CFL2F-LO5=
M"Z!'""Q%!"&ZGQ<E2&O0E)J:KAS:3]>5^AB)2+<WL%J..QJM'=OZ#K;81KZJ
MH&()B%.&VQKE"(Q(X4.GT&HP/AB>C#[#X/V]S=?-TEV=,VJM+QBV]E#L(OE4
MJ88LFM1:!Q>P*T^7-QXCYX:@]"]B6WWF5,WXVUJ3+RAV%G*+M=.Q\B276@C4
M8JBH<]EL?Q01$Y%^R:MY&=Z@XN5C7U*6P(4).D9R4I+E")L(?,#5+4IMRRD[
M#BN^8%K3.#$*OTX@:8;'&"93)?%BE@AK?$5)T:%6Q"8\ L2.PKR7JY:K@@P(
M8FO,<=-FNQ\\H@>=OC0!U0?HFA4*T4E;(.#-%H] ,T<.Y3$UY,7@WD7*YH#*
M<]%YX#K^!#IL7*H6I3KXJ$GYA!L7/4;DB8[$K35$'0?W:P%ZF4C ;HAN'+!/
M7<] $&V-!UJAX]@TP_Y$5:)XR "G6G39!=VG+$I9QP"[AJ)PH\M>GU=*5S>(
MO6T=?U<._\=P^/>Z*X__/X/'_R0K\=:P@,OI37GI=!OB?.H<:ZI(3)>7 6=4
MLIM/>7.UBG57XI]J_*<<FT7=LSG@P#5"W)A/A^;3D?GTSGP:F4]_,Y]^(^\H
M"B4,OCNY1<M77_JI'!9T&7Y_@2-P38_Z&B78FI05\FL_N"3ZH<Z42;>[)7:W
MMS=%=]*/MD(1;O>V=[=V>KV=?K@GQ,J90LZ4X3-WIAR=GAT,@P^#OPT_G0U7
M[I0?YTXY:7&14%LV.OA:*W,[4;,78ZG<:T[K9%3W,H^_U$)M4\3(I[I]A#!@
M.-Z0]?MW&?J9XXSB:6"+)6SC@B1E.0JVP;7(.\&THAQ@8%19S%&_Q)YC=-O3
M,'&2$" _5Y(+]$7'H7D)C)9G.=@V:.S  C"T1DIFE%UC!4ZJK6IA&V%S(?P\
MFVO(#!&A<47MEG1?:IV/I^H,,>9Q?9DEF-SFUU6$.0&DHQUXVQN\<1?U]$/-
M%=3;BUSP<N#"L;F"#,)22D3E%8@47M0@;KVBGB(&$2YRE90[D3>9*@-RKAY3
M/33UC> UIQ.DCDZ24Z((J(L6MQZL&7UN_!,GB4\G8H+M'[+\1E=#P/[R0&W.
MM%KD^T[.5$9@L^/E&IH%0,&E0U,M+<KKG4N?K/'X&+XV#,0S"_M9HT$\HW+;
M$L\.EP8W2S$6](#W&HX2=ZL>]W.E9-7C<;91A_62P0_>T,KE@;X 8GS*"%$8
M)IPXC>' D,\.,;;UY?B-&)7W2'M<6W*/M3Y[8TE#@=L%4W-K-JA?@8^!8O-5
M,H5;!4-[DE:7"=2.S7(%-!B'G%O'B>.>5M%ORJF@T&-!T41"S*'6]";:O1"9
MQZ#K& PT]F<;A.YZ31$1WIDS <80V6QU0\/16B=H/4M$Y5W@E-L(;[)V..&]
MC4];%'TK_)ZN!'@,C^KXDB+.SN8V^-L SR 7S#AXW-I/E</MSOEAK$HX1,8G
M3B.[FZ]?PF?K5C>M*Y,JYRC7@RB-(_U/8X")KH@FO4B(O9WM_EXD]\/IWO9V
MK[L[C:(>?%H98'SK/QD#;#%_+9-A>7B*V/BC$TPK;\2VGX.5=2M@$_%#R_8V
M*J+=CB;<M;0&=T6-(6*^88S3&J,4B'C'FC4G]14M7U6Y,*;I@\:],<BF]?E@
M+5.:F2"D)2=<1[D26G$-[="MRM=UK%6ARXE\6"VZ]Z]3M\*O0K XO*-1/K8]
M1WWC;.VM LX#_=Q';]+.?/T*1K\,OD@YKR,]85%1;2%N4^\&()4'0;,(-NR1
M(<'NRV&V#DRUR,8X_@P>OT1H(E%0][HZ,C/26X,!1=(!7/8 V2:H#@ZL(7F(
M3$SHKK?9C,H U*:CI39=NAMXF[(-?)7%D5;"HJR:+.PBCC>R7J1NFYQ2,('"
MAQD7E#(HSXW^B_8T,.RC*(4MN#,ZY IEYSO'67JK.,M#:&.D1^WM3#;W1+??
M!WVJW^ON3>36YOY^=V=G(O:Z^T(NT*,>1)4+FNI%C09WZ&NWJ2ZNJM6NM325
MMJ]4R>XR7MYM?)WVY:I5K4NXSWS-O;"L[_MP-#XX/AU_.AMR(]^/G]X>CPY,
ME>9CZ%QO@CO,/;<S PY 0N&N(.17790M#NB.5^A>1YSV_"B4<,=(!]QXE5M.
M&G!BA7HHTA0D0:B<TA9ZCHSVA8U26]J<L2O$4D84NK#'*\<6#HQ&S;->9$[+
M-P9A[EC4196.X'L7S+,$J:^2()R(J ,HSR%"+Z/+<=K**49520M1+JY@5JE"
M %)0Z%L.$3VZ4;:877I<%)6,7CLY%9?9-2)'=9P2>;#D+S)J)N"H!I+ #QVX
M2@T_8X&."S\0BHB^&O)=\AL59DTCG,H@[?5.>-@QL$I-9V(7R=Y%H[H5>=0N
M_0!FSJ@YRQ?&C(<']9H%I5EQ]SU=SE-B+U2I7FE@Q9J1<QLM;P.(:4)4WD:T
M.H0U[9]W+B/)+A-I&[VZ\!<-U <?I9Q/(?KX$ G5 &RWN!HQ_6LVHU5QGJK*
M)O,Z!YH_*2PDQ_5;6 P3KG;IM'%#'6Z6L;%U2T1_"SH![%P-)MR'4O, T V4
M6KV""T;I*.:4ZC2Z!,;& A.EX$^(BW&.I0&R3"\Z37'"+200' ?,3^=P&ZB)
M2PO*[50NMM?ON?5D;=#CKL_++KX5 GV.J'A,S8[N\0',P_-0;U=O792];'II
MH]// )GI'@P@]KT($R+M((5<X'95:^=TWFZ*3-6PI(9?IUJO6\3PVEERG,<^
M(=R!N=,JYHABFIF&EP&#V""SZW;"RTW><I."R77,WQ)D?#G3./? #!U,AK0L
MW7$0453C;>7FT UW'  8L_<QP<JDJDZSU)U4'L0*^[$Y)E&T'PJQO=_;G/1W
M-K?VQ*:4<C*%D[?;F^RO<DSXQGK_9%R<7Y=C,AB/1^].$(CCGS3!Y*'T;94=
MW:))*<AK%%VZ46WN:4QM39&D[L2P")W*T^!5<%$4@8N>J)5*4^SO7KA: -Z!
M9*5PC#JVN 9_4'#/"'&E!T?([]N"M1[%W'6VU=SK>:$;M9VN"AC=8@Q:J#@+
M8XZ*4(@:,%]X!!*5NR0P2?*HNR?&.M(I\D9_@"M')?^[./*4 *^O6'H4O="\
M0(9_1\?A%2:_&XUR6B4PS417&RP7.^926D9N5\M!OB+"2 EKG=[V9U5_H+([
M[/+YAGYIKC1BMX0(#A>:"SK6EBMBJ<6)XMP30/%(FTW!(4<JEE%CJ:2FQ3-'
M$#.D47 -4PU2,5..S#CEA" =-'SF5^GVWG1K)]R5DW!;]L.]WJ2[)X3L[G2W
M]Z+]2;B_NDJY?/V97Z4GI^>C@^%]6K=JE#$CW6WQF7'L-Z!,&9./)3'B9$I@
MQ(B >4FK51T&V6K+C6.H<+J+41LQEF,DCYI$P']JQYNJ5B:>V" G@2E4891K
M$K7MX-8D\;&>"BU!"MIALX(8<^D8 K=C3%XNHE*H+Q)+1N.DX_>WI-\M[UF0
MZ_C]FG,!^R]&*!79 D=)U4X+E854.$GW$YEDU\$:WSR<;T/+79M?WA3(=31=
M>NM+_9HU6;RD4:R-2F6XID<@HZPV6QU.;A9?O02Z0V@?)+NU!?+RU7/2TK1"
MMM[K[CGQ(SS',%"_WZZF8<%Y5@^PX?E[]>VO6QQGNMW[>Y^'5/SPSJR8Y:CQ
MV_!0Q2F/CP^^=3!@K2\8]OR'^-:1^MUN\)M,@(7'8()+D%^]WB]%-5]X@>$&
MD:@&BU^NZ_A5SQL;5IDD&"A\4U[^\C.,]B8X2K(L_];)'L'9#HXEB**3OP7=
MW>YF_UM'')((>*5WNJ&8/'",8;E)D3(?9G/JKI>UG)8?,ZT[:+4XJ:]V@+>V
MV\=7]^WWWHI5\'QA\'QS%3RO_72/:/GN=&>R&>YO[T>3;C_:[.^%_?[F5M3M
M3WM;8:^_"$/G!T3+O?UH1,H7Q,GO>>/6CV%3GVF\1MWVK7;!(NT",Y"42K'$
M&^X3+;]=;6H14GK%M7G4]#;+9S6=[=[B^)U"?3Q@$&J?_'XG-/]OVWMPYY,&
MD4TI#B@QC?EM5F$SOSR"R_7W;[TJWF:A",Y$B5[_H^-@:ZN_M_O,KNJO=T\.
M7 .PQ>ZSO>1KX6/KB33A\@CM.S)_+-@9YV""(8>UM2DU?HRG:(1@LY-.O;-W
M29#_"E] A1T;':QKP3 ]AC*,;-<$=K@:*XOZMG:H<2,ZP199D!W=(RD%\GEA
M,1@G2;C,@N8IE$-*8\X4/M0"!X5K5BFU)+=OO\-(57[ >(I&HC,32X$%4\+G
MJ>\A0[^QFS.RK[Z*A3(H.YQV[WB.I['.<*2FF4#T>8GM#!A04X/[H72:4>"W
M_HC9O\PTY:%"0364[E_JHHN^?/Z.N7!GM[<)]DEO?VN[O[>U)[:VNZ(WZ>]M
M3_9WMKJ3E6..?"=_>^:..83)?W=&B?NO@\&'X<DAQKM>!\.CHZ'")M>_7 7!
M[,CG-;>C4TV(X;"R%.&E!OE58#.%32H3^L'"[QT$HV3Y'*M6V1.9RZFDZD"^
MO\JXK$I.RL"X/:*P&A>D;EOHIBC4FNKYV38:ZA?D7*G[ S:;>E?HN921]%"/
M56:<US^&HA>8OF*6UF$'JDXYXIYA<+/XV5J5ZATF9IFN3VZ?_5*3MHD5OG]6
MW*@ GZ6!!H@F1S!W@-:M%O5+5621ZRH1XRJO-"Z(=O-2L(;V"NT9/??G+_VW
MHKW=W?Z^V)_T>OVMS=U)M#F1O=ZT*_;V>EO]Z4KZD_3_[9E+_X/WIZ,#ZAMR
M//A])=\7R7=K$7"J'IWXC@[[HER W[#MD"#\HDX#+;% 5&>FV:1DS@NCM-22
MXOW3)&8 :7H:!&L:QH2QH"#T'%AVD$D)*,Y@C?P)FG@1<8]PKV!=Z^F<FNA/
MXOE+IIU);WNRN]??G4SV^K*WN[>_WY.;8J^_L[\_W9JLP)(5C/XSETPGI\'O
M@]%G#EFMI)+R;3A(.KJ[GC:JL613I^"RIT#^A2G\A<YSG6?77$#'1:%U=P?J
M1RKE5"'.B%BAPG.N-%;AJ6POS)K%]@FFPS3FD*K7>7G EJ#\4L*EN2;E4>7P
MVYI3;+,)0@L_FJ&TQT2%?.NO4+C-_M!V85Z_#W$%A%.@9P1CRIBWG.2T*@S\
MSK&-K55LXXG=H]--L2M[W=V>Z._UMV57""EVQ=Y^M!W*7MCMK^Y1ND<_//][
M=/SIK6[J=WIVGQ2L?_K[M%Y^CIU(4J&C!+;B'N]&!G3":VW"A5/4@-GH]!ZT
M0&MK7:K7($%S&PK>P]:J_UA-?7];B+"_N;V]O]6/MGK[6Z'<W-S9G.[N[':C
M:)7:R1+FY)E+F(/33]AJ%1M8KH3+8A<"^B G4E=/&5^CQK5 '3<&%47U-08U
M!_5JQI)'I3\D3$6G,-G-]I0"H2^I3@S[=5#^_36FG)NW^>FHNN67C6]B;;#3
M@\K,Q;A\];"E^$*I[!<</:.1'-\T8[1)4V!<",JFUZY3[9\]36DEA-/E+[?A
MAE9TLY-?EARF6-. ''.1@@GGZ?Q[^K[3OJ/F)\<5* AE43C!0*KZ;-NTP#1(
M^3YLJ-3]%I;[GS.)'2HC9BC4F^WB*<"  B*8)"+]\II<UPQJ2%_DP&MQ2VK9
MRA)Z"$NHO[*$'E;:;MZ='M6"K/'BS0@;/I^?8&?LW]\/SX:G1\O=7'X9L"KU
MI?P0(VUK(HPQ)>,\B"HL,>("[W_X'>^RZ30.)2B4PKB/APS;"P,?BO+ANMTM
MIP<R(]C\NJWM_>YD9V]K?W][I[^]MRUZ<J^W&TU[,MSM1]O1 V72*?[#=AUB
M7L!W]*?OE637JD?BR$"<]-<7FTNDIMVE(W$VV.CTP^#DTQ$889_.1B?O.LU$
M='TX;DNE>X3I8JH\VT7+SK"AFMV;XLUIN&L*<KB8Z'//\O1]J?3MK[C?,K4=
M\=/#I#R^O7EU?VY1<^CO/M D0-O_N?@Y&$1B%KS+LZ* ([T(<VBIF3T4=7C'
MGA*-CB3(L3C,@F,LF8V7IM*#,ED+S]_W*-U%GH=[Q;-;Q+>+O7M*;K\,'^R2
M5_6C^ .NDY9)-7A_=8<\#9XYQZ;BKX*/N2P(^H7,](/AZ8]G'#6S9>>RXI9'
MV!.T.D#"5!=8W;S3"38;%7\_@E.^>E;W* 5Y.'3#E2-DH2-D>^4(^0I_WQ(.
M^>%_OQ^]'9US@[I'<4+>-:EQ5F&1DZK ]EM@TAW4Z*+S^+[3M3&"KE#BMHQ>
MKKR@W_?P[ZP.__<]_&^?S.'7IYZ;&N1:"G ?K^('!$EN+Z"_1W#]FY4$^]GY
M=/N@>ASZZGW7OK1 ^*X"(*B)&Q((NRT"X>%(<>O*U5ZTB@L:!NA!PQCI\;7B
MP"NUY7)H]:N<!^3?L?A!>J;2$QM+$^27G[&K"'VX+&<)?/A_4$L#!!0    (
M ("!<EK-<L'%URD  #7\   5    968R,# S.#DR,U]E>#$Y+3$N:'1M[7UK
M<]O&DO;WK=K_@-79[,I5E .   '8CJL47\ZZ*G&\ML]NO1]G@ &)(Q!@<)',
M\^NWNV<&&("@1/E(,9V7KL262%SFTO?I?OK%JEGG+__U7RSKQ4JPA'Z"GYNL
MR<7+%S_*?]6'_W9Q8?V2Q:*H16(UY3/K4[M>9XWU-BM8$6<LE]?1G]=EW*Y%
MT5AQ)5@#U[=U5BRMGZN2)566+(7UX>-O:98+R_6?ND^=I[X;!L;]K\K-MLJ6
MJ\9RHLBW+BS7=GWS]HL+.>H?U;!?\#+96GP9EWE9_73VEY3^G%EUL\W%3V=I
M6307*5MG^?:9]9^?L[6HK??BQOI8KEGQG\\M^K[._B&>68Z]:9Y;C?C27+ \
M6Q;/K%RD\ D]^9GU%YO^/#^C]],8DNQ:K]&JLHJR7K$$WJE^.+/H,3^=P<HU
MHNJ&M!(XOV>6M_FR\W"+L_AJ695MD5R,OS)')A_YW%JS:ID5%SC09Q9KF[+[
MJ)(OD9_QLDH$/*LH"Z$F((>OQV0^F^Z$JZP7N#B#A;Q10^=EGL 5;[ZL,I[A
M5CUU7OR(5[Q\P2O]^!^-Y<$?K?Z[_2__>ULW6;K%AZ>IB)OL6EB?Q*81:RXJ
M) ;/?*YZ\G_\Q5G8SR>^Z EKW_OT0M)G69' K\^L^0(I86K&[]Y_>O?ZS4?K
M\\?+U^_>_]7Z\-LO[U[]O^&;;QG4(?.^?/WKI;5BM<62<H,<U*R$M2GS+,Z
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M45.@&P:!$[/$C<'<XS&/8G?!N.<'?APZ(/!.%'A\%/A1GEP0O15;V"#0K/!
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M/<K6B!:2#!39SC [47 @',?T!!\,;&,[@9EQ.$3"HQ(&&2SCY1BA6" >"DX
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M%I9:J%Z-E%6'<VP+D@BDH&\!(U10.U:IH-Y3B;=##3\$X9_B^ ;2%&[8;=9
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M_:VW/\F=% _K'TB-L/LE]A=02P,$%     @ @(%R6JY+W6^F!   *A0  !4
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M]E\)X"6%O<)Y(2JDBY/*]?:O.,'X]G]7V\.I63Z^A?Y=4>_./3_H]H=CY^K
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M>C:>Q;OY]>SJ< ]_3V8OFE_(_0]02P,$%     @ @(%R6K4)-*@-!0  )!(
M !4   !E9C(P,#,X.3(S7V5X,S(M,2YH=&WM6.MOVS80_SY@_\--P=H$L&P]
M;,>O!' =9S.6QH'M#-U'2J0LHA*I4703]Z_?49(=IW$W)VVW89A@P'S<F[^[
MHS2(=9J<?_\=P"!FA!8C'&NN$W8^:)3_U>(/M@U7/&0B9Q2T[,%\E:9<PR47
M1(2<)"5=\5S(<)4RH2%4C&BD7^5<+.&-DH0J3I<,;F;3B"<,O%;=J[OUEM<Y
MW>$?R6RM^#+6X':[+;#!<[S6+KMMEU8W*K,'@:1K"):A3*0ZLXZBXK$@U^N$
MG5F1%-J.2,J3=0]>+WC*<KAF=S"3*1&O^U#LY_PCZX'K9+H/FMUKFR1\*7J0
ML A7"LD].'**IV^5^BG_L(E/K*!@.+,P1IHI"X3,8T)1?378FA,SXUL/FMG]
M$\$0D/#]4LF5H/:G6[M6E4KZD!*UY,(V1O: K+3<+JE22;D62$49RA)2L,KX
M1^:7DXV!NXH*,56([BK# YE0E#*^CWF $/#Q" >-PX59YZ^.W+;3/XRG\M0Z
M'XUGB\GE9#1<3*;7,+V$Q<]C!-+D>C2Y&5[!^-UX=+N8_#K&+:0:SYXI_N9V
M-K\=7B]@,87Y>%0HZ3KMC:+Y</9F>#V>V]-W5^/?8#A:F!W/<;QGZCG(=RXH
MTO? ;V<F7A.!.!&"A9I+ 7=<QZ!C!D2(%4E L4PJ#3*"X<7;(;SAB)LE#_,:
M3$18KP&!"Y:0.Z(82E%(2PHQQT;$JZ..YSG]D4PS(M;%S.V?U$HC :DNI4HQ
M*^Q?$ *JT+IF1 %# RG*#5D:, 6^6S-)VD1E.9C,I@]6SEFX4EQS3#HB*(SO
MPY@(3&+4F?(\-Z;@SU!2+!8/92!FBJ%/NV;."D^W5L*D!D-*4IC7X2<E\QS3
MN08WBN7<A*]0-XHYBU I&J'Y!P;3*,(JIDRTC.#*\5JA+5CC,2G-(YQG*Y6O
M" K1$MP.W-;G]5'=^%+$SO5;3N$KH3(S%6Z7?$-DT%.IF1,5$,%R>WJ?L#4,
MP^*X#'IJN$]TS?"E:W@OY!T&;\EZSP/(7E!I$F")#5F2Y!D)L0*?68Y5S#-"
MZ6;^TAIYQZF.S<3Y\9"""6%"\OS,NIC?7%[Q7"^,<19P>F9]['BAZS#2/FUV
M@F84T*#9:G<#ZG?]+G.HYUCG#ZC8:1/HH3K?G9L5NG&HLJ\*T"!X0MK0]#!N
M^&! $9)DXZ&6&8H\=D\.DE%6X/TR'O-6)7F!@"F1#M$J21"4"-+$Y,\VIQ3[
M?<45,TTV-TAZP.4Q.0%,5+=U3$^VZ'O(P&WV51!TNWZ9M"0M4KIODN8QCCX3
M+EQ0>\X%E\W)_C5R[3*VCQK8?P+-[5.GV_98X+>=L.G[8:?KN('KM!V*PU/_
MWXIF[QNBF0ML'FG9=K"1:<(%UDQ>5OT-U E7B/4,J[=!=<ULDR1!@&#?Y$6;
MRS.$>5XKN*+-O=,(I+P0;>H]4JV2,BEDQLI6EW]2[>M?&^!?@MCR:O;UP%O*
M,Y?'A&0YTFQ&!^&Z0+#G$#=HD<AWVJ39;?O$I^2T%85^X'1(ITF^!,$M8^,S
MX/.6J##&#ES<+UH''5RI%EW#L.-]W-L&=I_:3;P"J;5,>^!E]Y#+A".2EL$Q
M-GGS._F<=8V\\>0&\A)P?9O8[4/EG\;L$W7/TW:-+:3W8F7-9VK[/^I5>34O
MZ7]?V ^Z7.^SIN(_OE$<RW:&=?L)V\E7+\N[??+IA7I_U7[!B[SW#[_(O]3;
MA_%F-&B8+RG%H/HV] =02P,$%     @ @(%R6E:4N!H#!0  9A(  !4   !E
M9C(P,#,X.3(S7V5X,S(M,BYH=&WM6.MO(C<0_UZI_\-TH]XE$H]E64AX)!(A
MH*+F( ).:C]Z;2]8MVOO><TEW%_?\>[RR$N%ZZ6MJJZ0&-OC>?DW,Y:[2Q-'
M5S_^ -!=<L(R"FDC3,2ONM7\OYC\J5R&6T&Y3#D#H]HP6\6Q,# 4DD@J2)3S
M9=^-HJN82P-4<V*0?Y4*N8!KK0C3@BTXW$TGH8@X>(V*5ZE5&M[%^=[^ODK6
M6BR6!FJM5@/*X+E>8W][N9Q;72W,[@:*K2%84!4I?>F<A-GG0&K6$;]T0B5-
M.22QB-9M>#\7,4]AS.]AJF(BWW<@6T_%5]Z&FIN8#AC^8,HD$@O9AHB'.)-)
M;L.)FWT=)]?/Q)=-?':DC::&;/>E@P$S7#L@5;HD#&TIB*UM2VX=;8.?/#S3
M @&AGQ9:K20K/UW:-S%7TH&8Z(6096MQ&\C*J.V4SI7D<X'2C*,LJ20O/'GF
M0C[<&+FO+!-5Q.R^,#Y0$4-)@X>E"! 3=:_B=:O'B'.NWIW4FF[GT%V%Q\Y5
M?S"=CX:C?F\^FHQA,H3Y+P-$UVC<']WU;F$X&O>01&HR1*[!]&@%=Q^GLX^]
M\1SF$Y@-^IF:EMO<J)KUIM>]\6!6GOQV._@=>OVY7?%<]^  ;#4=& $A&>YH
M0[V9V+B-)*)&2DZ-4!+NA5F"67(@4JY(!)HG2AM0(?1N/O3@6B"*%H*F)1A)
M6BD!@1L>D7NB.4K1R$LR,:=6Q+N3"\]S.WT5)T2NLU&M<U8"7!\J'6.JE']%
M&.A,WYH3#1Q-8RB1\CC@&NJUDLU<']6D8-.=[>R;<;K2P@C,1"(9#![HDDC,
M;-06BS2U1N /.??* C L)K#DFJ,_^R9.,R]W%HY*6"P(@SDF6@GZ2\'#79V"
M21AB'=,V*%9&X5\I$QRL\3RT$2&.DY5.5P2KF%%0NX"/E5FE7[&&9R&JU1MN
MYAAA*K$U;I]]PV2!4JB9$1T0R=/RY"'B:^C1[%0L4$JX3DS)[HO7\$FJ>XS4
M@K>/1<(K^#$DP$)+>12E":%8AR\=U\G&"6%L,_[62GDOF%G:@?OS(643:$32
M]-*YF=T-;T5JYM8X!P2[=+XV"7.)[WNL05M^P'U"+UR?-OW0/^?G 6\Z5_M8
MV*>ME_KJ\8R=8QNW"BN+0'6#%YBKAATJ ;Y8B% 2;7PU*D&QI[6S Z7D9?AE
M*4]W%W5YCA#*80[A*HH0I@C;R*;/-J4T_[P2FMO&FUIL[9!Z2LX \[36.&5G
M6SSN$G";? 4H:ZUZGK,DSC*Z8U/T*:Y>#1M.Z5=."I?L>1^"Z7(>Z4<=[;^"
M<[<5-.N,>IY/?9_P@)RS1MT+W5J3NA>\_J_'N??&.!<2NTJ<=R+L;88(B?55
M9.U@FP1$:,R"1//4XKUDETD4(6"PF8JL\Z4))D!:RG:%V^J/ IG(1-N^@URK
M*$\7E?"\^Z5/.D/E[:#_U["<W^.^'ZQS>?:F&9$D19X-=1#B,VQ[M2:C]:;K
MLJ#NAX2V&F$8-(,Z96Z#M^AWJ.$-:^E1D/I -%UB!\\N(XV##S-7CF[B$>!%
MWML&^27EF]@%RA@5M\%+'B!5D4"$+8)3O"C8W]GK-E;3ZN[*\NUX>[L@O@S4
M/PG>$Z7'ZAQC_WEV"SI*I7^TSO\/X8G.N7T$^+M/X94K^\M6%'M.[[1 [@39
MGVT\>\,2_KC+OG1I+\YM7^JWO!!X_]@+P6.G]D<[>D-UJ_8M)B.*UZ4_ %!+
M P04    " " @7):GQ3E4_<(  "-"0  #@   &EM86=E,# P,#$N:G!GG=%Y
M.-3['@?PW\^,;7*LPX@R95>D+)4:,P<A.>58AT&+-119!\5D+768+)$YF.P9
M)!ECR))E2)V:C SI5#-&"ME"&,M<G><NSW.?^\>]]_W]\_-^/L_W]7P$(P(.
M('W*RL8* $$0.+_] ,$[P (0@0J+"$-%1(1%1$5%Q&#2,)BX. PN*24AC8 K
M*B+@"@I*NS602LIJNQ04]NCN4=/4TMFGLQ.I=U!/^Z"&MH[VCR6@J*@H3 PF
M!X/):2LI*&G_SQ$\!63$ $W@+ 14!81D0(@,*.@!D   "H-_!?A[0"'(]G]%
MQ<1A.[8+C=* $ B!"$$APL)0Z/8T;GL.0&6$9?<>,A.1L[\@JAH*-TC(+!93
M,Z_OE'<8F%<W] I+%(<I(!1W*FEH:FGK[#,R/GSDJ,DQBQ.65M8G;4XY.CF[
M8%W=<-X^OG[^%P,"PR,BH_#1,;%)R2FI-VZFW<K*SKF;FW<OGU126E9>4?F@
MBO*X@=I(:Z(WMW1U]S!Z^Y[U/V<-OAEB#X^\'>6.\<8_37S^,CFU\&UQ:?G[
MRNH:_X<+!"#@/_(?73+;+B$H% (5_>$"A? _"C)0X;V'1&3-[$4OA,JI&B2(
MP<TSB^L[Q=4,'>;EO<(&8 KJ1ER-A1^TOV3_'2SQ_Y+]$_8OUR@@ 0&WCP>1
M 3  7XM!HZT\_A*U<L<R-'B%%^%P/_*2A<ZXBI3QD0W5^-T"X+Y(M@"X'BH
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MX5>^[1D3P4ONV*1Q#-ACE5\./#NK3B^YM-5J3#DY?9$D2SA]3V\ML)LRI3T
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MCUA[0LY]ET.R@A//66Q:V[Y)[$8C?.LNL1BS[%:0_;;P[G7WQQLLE'E5V;!
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M+(4S!J8](W6)=(L#FFEFC;DU+7G3<L )!XQ8_Q>O845@6&JD'M\4L&Z6'-1
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MO*5X82?F@OV1$H1;<5=//V9Y"<="D)]?'7TULYJJ&XI1;K[>+NFROIVS05+
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M .0A.-IM!=Y5-AP)7"(+])G<5UP#NU5)7@WE#O/$U,2"B)D3C9SW,JD]PYY
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M>L@C;>V>%;<>S\N(]@<,U55C)7([<L=S.O+VA#$%O!1D:U%90A2^,/Y77'.
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M4$L! A0#%     @ @(%R6E2/'..)%   ZR@! !4              ( !JQD
M &%D;6$M,C R-#$R,S%?8V%L+GAM;%!+ 0(4 Q0    ( ("!<EK'*JU_35D
M &3-!0 5              "  6<N  !A9&UA+3(P,C0Q,C,Q7V1E9BYX;6Q0
M2P$"% ,4    " " @7):=FXRG\ . 0 QZP\ %0              @ 'GAP
M861M82TR,#(T,3(S,5]L86(N>&UL4$L! A0#%     @ @(%R6K@>>:('AP
MZ"@) !4              ( !VI8! &%D;6$M,C R-#$R,S%?<')E+GAM;%!+
M 0(4 Q0    ( ("!<EKOT]-Q5*L$ ,:O,  2              "  10> @!E
M9C(P,#,X.3(S7S$P:RYH=&U02P$"% ,4    " " @7):7A@"9U<Z   T:@$
M%@              @ &8R08 968R,# S.#DR,U]E>#$P+3$Q+FAT;5!+ 0(4
M Q0    ( ("!<EJ=4.ZP-$@  &6J 0 5              "  2,$!P!E9C(P
M,#,X.3(S7V5X,3 M-RYH=&U02P$"% ,4    " " @7):S^QX"[!$   3>0$
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M.#DR,U]E>#(S+3$N:'1M4$L! A0#%     @ @(%R6MA:*ZDU!   1@T  !4
M             ( !C<,' &5F,C P,S@Y,C-?97@R,RTR+FAT;5!+ 0(4 Q0
M   ( ("!<EJPH2"I'@H  *8W   5              "  ?7'!P!E9C(P,#,X
M.3(S7V5X,S$M,2YH=&U02P$"% ,4    " " @7):QS*W_/,)   J-P  %0
M            @ %&T@< 968R,# S.#DR,U]E>#,Q+3(N:'1M4$L! A0#%
M  @ @(%R6K4)-*@-!0  )!(  !4              ( !;-P' &5F,C P,S@Y
M,C-?97@S,BTQ+FAT;5!+ 0(4 Q0    ( ("!<EI6E+@: P4  &82   5
M          "  :SA!P!E9C(P,#,X.3(S7V5X,S(M,BYH=&U02P$"% ,4
M" " @7):GQ3E4_<(  "-"0  #@              @ 'BY@< :6UA9V4P,# P
M,2YJ<&=02P$"% ,4    " " @7):Q*.]F8!$   &;   #@
J@ $%\ < :6UA9V4P,# P,BYJ<&=02P4&     !, $P#E!   L30(

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>ef20038923_10k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:adma="http://admabiologics.com/20241231"
  xmlns:country="http://xbrl.sec.gov/country/2024"
  xmlns:cyd="http://xbrl.sec.gov/cyd/2024"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2024"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2024"
  xmlns:us-gaap="http://fasb.org/us-gaap/2024"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="adma-20241231.xsd" xlink:type="simple"/>
    <context id="c20240101to20241231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c20240630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c20250310">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
        </entity>
        <period>
            <instant>2025-03-10</instant>
        </period>
    </context>
    <context id="c20240101to20241231_CounterpartyNameAxis_CohnReznickLLPMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adma:CohnReznickLLPMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c20241231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c20231231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c20230101to20231231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c20220101to20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c20211231_StatementEquityComponentsAxis_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c20211231_StatementEquityComponentsAxis_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c20211231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c20240101to20241231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c20220101to20221231_StatementEquityComponentsAxis_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c20220101to20221231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c20230101to20231231_StatementEquityComponentsAxis_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c20220101to20221231_StatementEquityComponentsAxis_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c20230101to20231231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c20240101to20241231_StatementEquityComponentsAxis_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c20240101to20241231_StatementEquityComponentsAxis_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c20230101to20231231_StatementEquityComponentsAxis_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c20221231_StatementEquityComponentsAxis_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c20231231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c20221231_StatementEquityComponentsAxis_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c20231231_StatementEquityComponentsAxis_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c20221231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c20241231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c20241231_StatementEquityComponentsAxis_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c20231231_StatementEquityComponentsAxis_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c20241231_StatementEquityComponentsAxis_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c20241001to20241231_IndividualAxis_AdamGrossmanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">adma:AdamGrossmanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c20241001to20241231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c20241231_TradingArrAxis_AdamGrossmanTradingPlanStockOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:TradingArrAxis">adma:AdamGrossmanTradingPlanStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c20241231_TradingArrAxis_AdamGrossmanTradingPlanCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:TradingArrAxis">adma:AdamGrossmanTradingPlanCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c20240101to20241231_ChangeInAccountingEstimateByTypeAxis_AccrualForUSMedicaidRebatesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ChangeInAccountingEstimateByTypeAxis">adma:AccrualForUSMedicaidRebatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c20241231_ChangeInAccountingEstimateByTypeAxis_AccrualForUSMedicaidRebatesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ChangeInAccountingEstimateByTypeAxis">adma:AccrualForUSMedicaidRebatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c20241231_RangeAxis_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c20241231_PropertyPlantAndEquipmentByTypeAxis_BuildingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c20241231_RangeAxis_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c20240101to20241231_TypeOfArrangementAxis_BiotestLicenseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adma:BiotestLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c20210101to20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="c20240101to20241231_AwardTypeAxis_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c20240101to20241231_AwardTypeAxis_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c20210901to20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
        </entity>
        <period>
            <startDate>2021-09-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="c20240101to20241231_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c20240101to20241231_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c20240101to20241231_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c20220101to20221231_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c20230101to20231231_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c20230101to20231231_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c20220101to20221231_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c20220101to20221231_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c20230101to20231231_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c20241231_PropertyPlantAndEquipmentByTypeAxis_AssetUnderConstructionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:AssetUnderConstructionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c20231231_PropertyPlantAndEquipmentByTypeAxis_OfficeEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c20231231_PropertyPlantAndEquipmentByTypeAxis_LeaseholdImprovementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c20231231_PropertyPlantAndEquipmentByTypeAxis_ManufacturingFacilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ManufacturingFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c20231231_PropertyPlantAndEquipmentByTypeAxis_FurnitureAndFixturesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c20241231_PropertyPlantAndEquipmentByTypeAxis_LandMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c20241231_PropertyPlantAndEquipmentByTypeAxis_FurnitureAndFixturesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c20241231_PropertyPlantAndEquipmentByTypeAxis_BuildingAndBuildingImprovementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c20241231_PropertyPlantAndEquipmentByTypeAxis_OfficeEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c20231231_PropertyPlantAndEquipmentByTypeAxis_AssetUnderConstructionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:AssetUnderConstructionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c20231231_PropertyPlantAndEquipmentByTypeAxis_LandMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c20241231_PropertyPlantAndEquipmentByTypeAxis_ManufacturingFacilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ManufacturingFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c20231231_PropertyPlantAndEquipmentByTypeAxis_BuildingAndBuildingImprovementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c20241231_PropertyPlantAndEquipmentByTypeAxis_LeaseholdImprovementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c20241231_FiniteLivedIntangibleAssetsByMajorClassAxis_RightToIntermediatesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">adma:RightToIntermediatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c20241231_FiniteLivedIntangibleAssetsByMajorClassAxis_TrademarkAndOtherIntangibleRightsRelatedToNabiHBMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">adma:TrademarkAndOtherIntangibleRightsRelatedToNabiHBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c20231231_FiniteLivedIntangibleAssetsByMajorClassAxis_RightToIntermediatesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">adma:RightToIntermediatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c20231231_FiniteLivedIntangibleAssetsByMajorClassAxis_ComputerSoftwareIntangibleAssetMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c20231231_FiniteLivedIntangibleAssetsByMajorClassAxis_TrademarkAndOtherIntangibleRightsRelatedToNabiHBMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">adma:TrademarkAndOtherIntangibleRightsRelatedToNabiHBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c20241231_FiniteLivedIntangibleAssetsByMajorClassAxis_ComputerSoftwareIntangibleAssetMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c20220323_CounterpartyNameAxis_HayfinCreditAgreementMember_DebtInstrumentAxis_HayfinDelayedDrawLoanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adma:HayfinCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">adma:HayfinDelayedDrawLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-23</instant>
        </period>
    </context>
    <context id="c20220323_CounterpartyNameAxis_HayfinCreditAgreementMember_DebtInstrumentAxis_HayfinCreditFacilityMember_RangeAxis_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adma:HayfinCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">adma:HayfinCreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-23</instant>
        </period>
    </context>
    <context id="c20220323_CounterpartyNameAxis_HayfinCreditAgreementMember_DebtInstrumentAxis_HayfinClosingDateLoanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adma:HayfinCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">adma:HayfinClosingDateLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-23</instant>
        </period>
    </context>
    <context id="c20241231_CreditFacilityAxis_RevolvingCreditFacilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c20231231_CreditFacilityAxis_TermLoanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">adma:TermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c20231218">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
        </entity>
        <period>
            <instant>2023-12-18</instant>
        </period>
    </context>
    <context id="c20231231_CreditFacilityAxis_RevolvingCreditFacilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c20241231_CreditFacilityAxis_TermLoanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">adma:TermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c20231218_DebtInstrumentAxis_HayfinCreditFacilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">adma:HayfinCreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-18</instant>
        </period>
    </context>
    <context id="c20231218_CounterpartyNameAxis_AresCreditAgreementMember_DebtInstrumentAxis_AresCreditFacilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adma:AresCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">adma:AresCreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-18</instant>
        </period>
    </context>
    <context id="c20221231_CounterpartyNameAxis_HayfinSecondAmendmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adma:HayfinSecondAmendmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c20231231_CounterpartyNameAxis_HayfinSecondAmendmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adma:HayfinSecondAmendmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c20231218_CounterpartyNameAxis_HayfinCreditAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adma:HayfinCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-18</instant>
        </period>
    </context>
    <context id="c20241219_CreditFacilityAxis_TermLoanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">adma:TermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-19</instant>
        </period>
    </context>
    <context id="c20240101to20241231_CounterpartyNameAxis_HayfinSecondAmendmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adma:HayfinSecondAmendmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c20240101to20241231_CounterpartyNameAxis_HayfinCreditAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adma:HayfinCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c20240101to20241231_CounterpartyNameAxis_HayfinCreditAgreementMember_DebtInstrumentAxis_HayfinCreditFacilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adma:HayfinCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">adma:HayfinCreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c20240101to20241231_CounterpartyNameAxis_AresCreditAgreementMember_DebtInstrumentAxis_AresCreditFacilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adma:AresCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">adma:AresCreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c20230101to20231231_DebtInstrumentAxis_HayfinCreditFacilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">adma:HayfinCreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c20220323to20220323_CounterpartyNameAxis_HayfinCreditAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adma:HayfinCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-23</startDate>
            <endDate>2022-03-23</endDate>
        </period>
    </context>
    <context id="c20241219to20241219_CreditFacilityAxis_TermLoanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">adma:TermLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-12-19</startDate>
            <endDate>2024-12-19</endDate>
        </period>
    </context>
    <context id="c20240814to20240814_CreditFacilityAxis_RevolvingCreditFacilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-08-14</startDate>
            <endDate>2024-08-14</endDate>
        </period>
    </context>
    <context id="c20241231_CounterpartyNameAxis_AresCreditAgreementMember_DebtInstrumentAxis_AresCreditFacilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adma:AresCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">adma:AresCreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c20240814_CounterpartyNameAxis_AresCreditAgreementMember_DebtInstrumentAxis_AresCreditFacilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adma:AresCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">adma:AresCreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-08-14</instant>
        </period>
    </context>
    <context id="c20231218to20231218_CreditFacilityAxis_TermLoanMember_VariableRateAxis_SecuredOvernightFinancingRateSofrMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">adma:TermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:SecuredOvernightFinancingRateSofrMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-12-18</startDate>
            <endDate>2023-12-18</endDate>
        </period>
    </context>
    <context id="c20240101to20241231_CounterpartyNameAxis_HayfinCreditAgreementMember_VariableRateAxis_SecuredOvernightFinancingRateSofrMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adma:HayfinCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:SecuredOvernightFinancingRateSofrMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c20231218to20231218_CreditFacilityAxis_RevolvingCreditFacilityMember_VariableRateAxis_SecuredOvernightFinancingRateSofrMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:SecuredOvernightFinancingRateSofrMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-12-18</startDate>
            <endDate>2023-12-18</endDate>
        </period>
    </context>
    <context id="c20230430to20230430_CounterpartyNameAxis_HayfinSecondAmendmentMember_VariableRateAxis_SecuredOvernightFinancingRateSofrMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adma:HayfinSecondAmendmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:SecuredOvernightFinancingRateSofrMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-04-30</startDate>
            <endDate>2023-04-30</endDate>
        </period>
    </context>
    <context id="c20230501to20230501_CounterpartyNameAxis_HayfinSecondAmendmentMember_VariableRateAxis_SecuredOvernightFinancingRateSofrMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adma:HayfinSecondAmendmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:SecuredOvernightFinancingRateSofrMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-05-01</startDate>
            <endDate>2023-05-01</endDate>
        </period>
    </context>
    <context id="c20241231_CreditFacilityAxis_RevolvingCreditFacilityMember_VariableRateAxis_SecuredOvernightFinancingRateSofrMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:SecuredOvernightFinancingRateSofrMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c20231231_CreditFacilityAxis_TermLoanMember_VariableRateAxis_SecuredOvernightFinancingRateSofrMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">adma:TermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:SecuredOvernightFinancingRateSofrMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c20241231_CreditFacilityAxis_TermLoanMember_VariableRateAxis_SecuredOvernightFinancingRateSofrMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">adma:TermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:SecuredOvernightFinancingRateSofrMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c20231231_CreditFacilityAxis_RevolvingCreditFacilityMember_VariableRateAxis_SecuredOvernightFinancingRateSofrMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:SecuredOvernightFinancingRateSofrMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c20231218to20231218_CounterpartyNameAxis_AresCreditAgreementMember_DebtInstrumentAxis_AresCreditFacilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adma:AresCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">adma:AresCreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-12-18</startDate>
            <endDate>2023-12-18</endDate>
        </period>
    </context>
    <context id="c20231218to20231218_CounterpartyNameAxis_AresCreditAgreementMember_RangeAxis_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adma:AresCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-12-18</startDate>
            <endDate>2023-12-18</endDate>
        </period>
    </context>
    <context id="c20231218to20231218_CounterpartyNameAxis_AresCreditAgreementMember_DebtInstrumentRedemptionPeriodAxis_PrepaidOnOrPriorToThirdAnniversaryMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adma:AresCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">adma:PrepaidOnOrPriorToThirdAnniversaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-12-18</startDate>
            <endDate>2023-12-18</endDate>
        </period>
    </context>
    <context id="c20231218to20231218_CounterpartyNameAxis_HayfinCreditAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adma:HayfinCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-12-18</startDate>
            <endDate>2023-12-18</endDate>
        </period>
    </context>
    <context id="c20231218to20231218_CounterpartyNameAxis_AresCreditAgreementMember_DebtInstrumentRedemptionPeriodAxis_PrepaidAfterTheFirstAnniversaryMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adma:AresCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">adma:PrepaidAfterTheFirstAnniversaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-12-18</startDate>
            <endDate>2023-12-18</endDate>
        </period>
    </context>
    <context id="c20231218to20231218_CounterpartyNameAxis_AresCreditAgreementMember_DebtInstrumentRedemptionPeriodAxis_PrepaidOnOrPriorToSecondAnniversaryMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adma:AresCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">adma:PrepaidOnOrPriorToSecondAnniversaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-12-18</startDate>
            <endDate>2023-12-18</endDate>
        </period>
    </context>
    <context id="c20231218to20231218_CounterpartyNameAxis_AresCreditAgreementMember_DebtInstrumentRedemptionPeriodAxis_PrepaidOnOrPriorToFirstAnniversaryMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adma:AresCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">adma:PrepaidOnOrPriorToFirstAnniversaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-12-18</startDate>
            <endDate>2023-12-18</endDate>
        </period>
    </context>
    <context id="c20231231_CounterpartyNameAxis_AresCreditAgreementMember_DebtInstrumentAxis_AresCreditFacilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adma:AresCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">adma:AresCreditFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c20220323_CounterpartyNameAxis_HayfinCreditAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adma:HayfinCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-23</instant>
        </period>
    </context>
    <context id="c20221231_CounterpartyNameAxis_HayfinCreditAgreementMember_DebtInstrumentAxis_HayfinClosingDateLoanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adma:HayfinCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">adma:HayfinClosingDateLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c20221231_CounterpartyNameAxis_HayfinCreditAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adma:HayfinCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c20231218_CounterpartyNameAxis_AresCreditAgreementMember_DebtInstrumentAxis_AresClosingDateLoanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adma:AresCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">adma:AresClosingDateLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-18</instant>
        </period>
    </context>
    <context id="c20241231_CounterpartyNameAxis_AresCreditAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adma:AresCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c20240101to20241231_CounterpartyNameAxis_AresCreditAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adma:AresCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c20220323to20220323_DebtInstrumentAxis_HayfinClosingDateLoanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">adma:HayfinClosingDateLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-23</startDate>
            <endDate>2022-03-23</endDate>
        </period>
    </context>
    <context id="c20220323to20220323_CounterpartyNameAxis_HayfinCreditAgreementMember_DebtInstrumentAxis_HayfinClosingDateLoanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adma:HayfinCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">adma:HayfinClosingDateLoanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-23</startDate>
            <endDate>2022-03-23</endDate>
        </period>
    </context>
    <context id="c20220323to20220323_CounterpartyNameAxis_HayfinCreditAgreementMember_VariableRateAxis_BaseRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adma:HayfinCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-23</startDate>
            <endDate>2022-03-23</endDate>
        </period>
    </context>
    <context id="c20230101to20231231_CounterpartyNameAxis_HayfinCreditAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adma:HayfinCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c20220323_CounterpartyNameAxis_HayfinCreditAgreementMember_RangeAxis_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adma:HayfinCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-23</instant>
        </period>
    </context>
    <context id="c20220401to20220630_CounterpartyNameAxis_HayfinCreditAgreementMember_RangeAxis_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adma:HayfinCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c20230701to20230930_CounterpartyNameAxis_HayfinCreditAgreementMember_RangeAxis_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adma:HayfinCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c20230501_CounterpartyNameAxis_HayfinSecondAmendmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adma:HayfinSecondAmendmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-05-01</instant>
        </period>
    </context>
    <context id="c20221209to20221209_StatementEquityComponentsAxis_CommonStockMember_SubsidiarySaleOfStockAxis_OverAllotmentOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-09</startDate>
            <endDate>2022-12-09</endDate>
        </period>
    </context>
    <context id="c20230616to20230616_ClassOfWarrantOrRightAxis_HayfinWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">adma:HayfinWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-06-16</startDate>
            <endDate>2023-06-16</endDate>
        </period>
    </context>
    <context id="c20230616_ClassOfWarrantOrRightAxis_HayfinWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">adma:HayfinWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-16</instant>
        </period>
    </context>
    <context id="c20241231_ClassOfWarrantOrRightAxis_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c20220323_ClassOfWarrantOrRightAxis_HayfinWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">adma:HayfinWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-23</instant>
        </period>
    </context>
    <context id="c20240101to20241231_ClassOfWarrantOrRightAxis_HayfinWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">adma:HayfinWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c20220323to20220323_ClassOfWarrantOrRightAxis_HayfinWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">adma:HayfinWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-23</startDate>
            <endDate>2022-03-23</endDate>
        </period>
    </context>
    <context id="c20230501to20230501_CounterpartyNameAxis_HayfinSecondAmendmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adma:HayfinSecondAmendmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-05-01</startDate>
            <endDate>2023-05-01</endDate>
        </period>
    </context>
    <context id="c20211231_ClassOfWarrantOrRightAxis_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c20220101to20221231_ClassOfWarrantOrRightAxis_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c20230101to20231231_ClassOfWarrantOrRightAxis_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c20240101to20241231_ClassOfWarrantOrRightAxis_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c20221231_ClassOfWarrantOrRightAxis_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c20231231_ClassOfWarrantOrRightAxis_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c20220621_PlanNameAxis_Two022CompensationPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">adma:Two022CompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-21</instant>
        </period>
    </context>
    <context id="c20230101to20231231_AwardTypeAxis_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c20220101to20221231_AwardTypeAxis_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c20231231_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_EquityIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">adma:EquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c20241231_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_EquityIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">adma:EquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c20240101to20241231_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_EquityIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">adma:EquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c20230101to20231231_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_EquityIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">adma:EquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c20231231_AwardTypeAxis_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c20230101to20231231_AwardTypeAxis_EmployeeStockOptionMember_RangeAxis_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c20220101to20221231_AwardTypeAxis_EmployeeStockOptionMember_RangeAxis_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c20230101to20231231_AwardTypeAxis_EmployeeStockOptionMember_RangeAxis_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c20240101to20241231_AwardTypeAxis_EmployeeStockOptionMember_RangeAxis_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c20220101to20221231_AwardTypeAxis_EmployeeStockOptionMember_RangeAxis_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c20240101to20241231_AwardTypeAxis_EmployeeStockOptionMember_RangeAxis_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c20211231_AwardTypeAxis_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c20221231_AwardTypeAxis_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c20241231_AwardTypeAxis_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c20240101to20241231_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ExercisePriceRange3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">adma:ExercisePriceRange3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c20240101to20241231_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ExercisePriceRange4Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">adma:ExercisePriceRange4Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c20240101to20241231_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ExercisePriceRange5Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">adma:ExercisePriceRange5Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c20240101to20241231_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ExercisePriceRange6Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">adma:ExercisePriceRange6Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c20240101to20241231_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ExercisePriceRange1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">adma:ExercisePriceRange1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c20240101to20241231_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ExercisePriceRange2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">adma:ExercisePriceRange2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c20241231_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ExercisePriceRange1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">adma:ExercisePriceRange1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c20241231_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ExercisePriceRange5Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">adma:ExercisePriceRange5Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c20241231_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ExercisePriceRange4Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">adma:ExercisePriceRange4Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c20241231_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ExercisePriceRange3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">adma:ExercisePriceRange3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c20241231_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ExercisePriceRange6Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">adma:ExercisePriceRange6Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c20241231_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ExercisePriceRange2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">adma:ExercisePriceRange2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c20241231_AwardTypeAxis_RestrictedStockUnitsRSUMember_PlanNameAxis_EquityIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">adma:EquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c20240101to20241231_AwardTypeAxis_RestrictedStockUnitsRSUMember_PlanNameAxis_EquityIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">adma:EquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c20230101to20231231_AwardTypeAxis_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c20220101to20221231_AwardTypeAxis_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c20240101to20241231_AwardTypeAxis_RestrictedStockUnitsRSUMember_TitleOfIndividualAxis_DirectorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c20240101to20241231_AwardTypeAxis_RestrictedStockUnitsRSUMember_TitleOfIndividualAxis_EmployeesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">adma:EmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c20241231_AwardTypeAxis_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c20221231_AwardTypeAxis_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c20231231_AwardTypeAxis_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c20240101to20241231_TitleOfIndividualAxis_DirectorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c20240101to20241231_TitleOfIndividualAxis_EmployeesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">adma:EmployeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c20211231_AwardTypeAxis_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c20240101to20241231_IncomeStatementLocationAxis_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c20230101to20231231_IncomeStatementLocationAxis_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c20240101to20241231_IncomeStatementLocationAxis_OperatingExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c20230101to20231231_IncomeStatementLocationAxis_OperatingExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c20230101to20231231_IncomeStatementLocationAxis_CostOfSalesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c20220101to20221231_IncomeStatementLocationAxis_OperatingExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c20220101to20221231_IncomeStatementLocationAxis_CostOfSalesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c20220101to20221231_IncomeStatementLocationAxis_SellingGeneralAndAdministrativeExpensesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c20240101to20241231_IncomeStatementLocationAxis_SellingGeneralAndAdministrativeExpensesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c20230101to20231231_IncomeStatementLocationAxis_SellingGeneralAndAdministrativeExpensesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c20220101to20221231_IncomeStatementLocationAxis_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c20240101to20241231_IncomeStatementLocationAxis_CostOfSalesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c20220101to20221231_CounterpartyNameAxis_ArethLLCMember_RelatedPartyTransactionsByRelatedPartyAxis_RelatedPartyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adma:ArethLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c20230101to20231231_CounterpartyNameAxis_ArethLLCMember_RelatedPartyTransactionsByRelatedPartyAxis_RelatedPartyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adma:ArethLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c20160101to20160131_CounterpartyNameAxis_ArethLLCMember_RelatedPartyTransactionsByRelatedPartyAxis_RelatedPartyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adma:ArethLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-01-01</startDate>
            <endDate>2016-01-31</endDate>
        </period>
    </context>
    <context id="c20240101to20241231_CounterpartyNameAxis_ArethLLCMember_RelatedPartyTransactionsByRelatedPartyAxis_RelatedPartyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adma:ArethLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c20240101to20241231_CounterpartyNameAxis_GenesisBPSMember_RelatedPartyTransactionsByRelatedPartyAxis_RelatedPartyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adma:GenesisBPSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c20220101to20221231_CounterpartyNameAxis_GenesisBPSMember_RelatedPartyTransactionsByRelatedPartyAxis_RelatedPartyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adma:GenesisBPSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c20230101to20231231_CounterpartyNameAxis_GenesisBPSMember_RelatedPartyTransactionsByRelatedPartyAxis_RelatedPartyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adma:GenesisBPSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c20241119to20241119_AwardTypeAxis_RestrictedStockUnitsRSUMember_CounterpartyNameAxis_BryantFongMember_RelatedPartyTransactionsByRelatedPartyAxis_RelatedPartyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adma:BryantFongMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-11-19</startDate>
            <endDate>2024-11-19</endDate>
        </period>
    </context>
    <context id="c20240101to20241231_RangeAxis_MaximumMember_RelatedPartyTransactionsByRelatedPartyAxis_RelatedPartyMember_TitleOfIndividualAxis_ExecutiveVicePresidentAndChiefFinancialOfficerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">adma:ExecutiveVicePresidentAndChiefFinancialOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c20240101to20241231_RangeAxis_MinimumMember_RelatedPartyTransactionsByRelatedPartyAxis_RelatedPartyMember_TitleOfIndividualAxis_ExecutiveVicePresidentAndChiefFinancialOfficerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">adma:ExecutiveVicePresidentAndChiefFinancialOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c20240101to20241231_CounterpartyNameAxis_BryantFongMember_RangeAxis_MaximumMember_RelatedPartyTransactionsByRelatedPartyAxis_RelatedPartyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adma:BryantFongMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c20240101to20241231_CounterpartyNameAxis_BryantFongMember_RangeAxis_MinimumMember_RelatedPartyTransactionsByRelatedPartyAxis_RelatedPartyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adma:BryantFongMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c20240101to20241231_RelatedPartyTransactionsByRelatedPartyAxis_RelatedPartyMember_TitleOfIndividualAxis_ExecutiveVicePresidentAndChiefFinancialOfficerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">adma:ExecutiveVicePresidentAndChiefFinancialOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c20240101to20241231_CounterpartyNameAxis_BryantFongMember_RelatedPartyTransactionsByRelatedPartyAxis_RelatedPartyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">adma:BryantFongMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c20230815to20230815_RelatedPartyTransactionsByRelatedPartyAxis_RelatedPartyMember_TitleOfIndividualAxis_ExecutiveOfficerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-15</startDate>
            <endDate>2023-08-15</endDate>
        </period>
    </context>
    <context id="c20220101to20221231_LineOfCreditFacilityAxis_PerceptiveCreditHoldingsIILPMember_RelatedPartyTransactionsByRelatedPartyAxis_RelatedPartyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">adma:PerceptiveCreditHoldingsIILPMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c20221209to20221209_OwnershipAxis_DirectOwnershipMember_RelatedPartyTransactionsByRelatedPartyAxis_RelatedPartyMember_TitleOfIndividualAxis_PresidentAndChiefExecutiveOfficerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">adma:DirectOwnershipMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">adma:PresidentAndChiefExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-09</startDate>
            <endDate>2022-12-09</endDate>
        </period>
    </context>
    <context id="c20221209to20221209_OwnershipAxis_IndirectOwnershipMember_RelatedPartyTransactionsByRelatedPartyAxis_RelatedPartyMember_TitleOfIndividualAxis_PresidentAndChiefExecutiveOfficerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">adma:IndirectOwnershipMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">adma:PresidentAndChiefExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-09</startDate>
            <endDate>2022-12-09</endDate>
        </period>
    </context>
    <context id="c20221209to20221209_RelatedPartyTransactionsByRelatedPartyAxis_RelatedPartyMember_TitleOfIndividualAxis_ExecutiveVicePresidentAndChiefFinancialOfficerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">adma:ExecutiveVicePresidentAndChiefFinancialOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-09</startDate>
            <endDate>2022-12-09</endDate>
        </period>
    </context>
    <context id="c20221209_RelatedPartyTransactionsByRelatedPartyAxis_RelatedPartyMember_TitleOfIndividualAxis_ExecutiveVicePresidentAndChiefFinancialOfficerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">adma:ExecutiveVicePresidentAndChiefFinancialOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-09</instant>
        </period>
    </context>
    <context id="c20230619to20230619_RangeAxis_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-06-19</startDate>
            <endDate>2023-06-19</endDate>
        </period>
    </context>
    <context id="c20230619to20230619">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
        </entity>
        <period>
            <startDate>2023-06-19</startDate>
            <endDate>2023-06-19</endDate>
        </period>
    </context>
    <context id="c20230401to20230630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
        </entity>
        <period>
            <startDate>2023-04-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c20250101to20250318_SubsequentEventTypeAxis_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-18</endDate>
        </period>
    </context>
    <context id="c20240101to20241231_RangeAxis_MaximumMember_TypeOfArrangementAxis_PlasmaPurchaseAgreementOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adma:PlasmaPurchaseAgreementOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c20241001to20241001_TypeOfArrangementAxis_ARGrifolsAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adma:ARGrifolsAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2024-10-01</endDate>
        </period>
    </context>
    <context id="c20240101to20241231_TypeOfArrangementAxis_KEDPlasmaAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adma:KEDPlasmaAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c20240101to20241231_TypeOfArrangementAxis_ARGrifolsAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adma:ARGrifolsAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c20240806to20240806_RangeAxis_MinimumMember_TypeOfArrangementAxis_KEDPlasmaAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adma:KEDPlasmaAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-08-06</startDate>
            <endDate>2024-08-06</endDate>
        </period>
    </context>
    <context id="c20241001to20241001_RangeAxis_MinimumMember_TypeOfArrangementAxis_ARGrifolsAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">adma:ARGrifolsAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2024-10-01</endDate>
        </period>
    </context>
    <context id="c20220101to20221231_ProductOrServiceAxis_ASCENIVMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">adma:ASCENIVMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c20190401to20190401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-04-01</endDate>
        </period>
    </context>
    <context id="c20230101to20231231_ProductOrServiceAxis_BIVIGAMMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">adma:BIVIGAMMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c20240101to20241231_ProductOrServiceAxis_BIVIGAMMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">adma:BIVIGAMMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c20220101to20221231_ProductOrServiceAxis_BIVIGAMMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">adma:BIVIGAMMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c20230101to20231231_ProductOrServiceAxis_ASCENIVMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">adma:ASCENIVMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c20240101to20241231_ProductOrServiceAxis_ASCENIVMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">adma:ASCENIVMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c20241231_IncomeTaxAuthorityAxis_InternalRevenueServiceIRSMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c20241231_IncomeTaxAuthorityAxis_InternalRevenueServiceIRSMember_TaxPeriodAxis_TaxYear2031Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">adma:TaxYear2031Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c20241231_IncomeTaxAuthorityAxis_InternalRevenueServiceIRSMember_TaxPeriodAxis_TaxYear2035Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">adma:TaxYear2035Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c20241231_IncomeTaxAuthorityAxis_StateAndLocalJurisdictionMember_TaxPeriodAxis_TaxYear2028Through2043Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">adma:TaxYear2028Through2043Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c20241231_IncomeTaxAuthorityAxis_InternalRevenueServiceIRSMember_TaxPeriodAxis_TaxYear2036Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">adma:TaxYear2036Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c20241231_IncomeTaxAuthorityAxis_InternalRevenueServiceIRSMember_TaxPeriodAxis_TaxYear2034Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">adma:TaxYear2034Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c20241231_IncomeTaxAuthorityAxis_InternalRevenueServiceIRSMember_TaxPeriodAxis_TaxYear2032Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">adma:TaxYear2032Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c20241231_IncomeTaxAuthorityAxis_InternalRevenueServiceIRSMember_TaxPeriodAxis_TaxYear2037Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">adma:TaxYear2037Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c20241231_IncomeTaxAuthorityAxis_InternalRevenueServiceIRSMember_TaxPeriodAxis_TaxYearAfter2037Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">adma:TaxYearAfter2037Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c20241231_IncomeTaxAuthorityAxis_InternalRevenueServiceIRSMember_TaxPeriodAxis_TaxYear2033Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">adma:TaxYear2033Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c20241231_IncomeTaxAuthorityAxis_InternalRevenueServiceIRSMember_TaxPeriodAxis_TaxYear2028Through2043Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">adma:TaxYear2028Through2043Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c20241231_IncomeTaxAuthorityAxis_StateAndLocalJurisdictionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c20240101to20241231_RangeAxis_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c20240101to20241231_RangeAxis_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c20231231_IncomeTaxAuthorityAxis_InternalRevenueServiceIRSMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c20231231_IncomeTaxAuthorityAxis_StateAndLocalJurisdictionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c20240101to20241231_ConsolidationItemsAxis_OperatingSegmentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c20230101to20231231_ConsolidationItemsAxis_MaterialReconcilingItemsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c20220101to20221231_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_ADMABioManufacturingSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">adma:ADMABioManufacturingSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c20230101to20231231_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_ADMABioManufacturingSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">adma:ADMABioManufacturingSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c20240101to20241231_ConsolidationItemsAxis_MaterialReconcilingItemsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c20240101to20241231_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_ADMABioManufacturingSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">adma:ADMABioManufacturingSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c20230101to20231231_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PlasmaCollectionCentersSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">adma:PlasmaCollectionCentersSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c20220101to20221231_ConsolidationItemsAxis_MaterialReconcilingItemsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c20240101to20241231_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PlasmaCollectionCentersSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">adma:PlasmaCollectionCentersSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c20220101to20221231_ConsolidationItemsAxis_OperatingSegmentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c20220101to20221231_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PlasmaCollectionCentersSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">adma:PlasmaCollectionCentersSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c20230101to20231231_ConsolidationItemsAxis_OperatingSegmentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c20240101to20241231_ConsolidationItemsAxis_CorporateNonSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c20220101to20221231_ConsolidationItemsAxis_CorporateNonSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c20230101to20231231_ConsolidationItemsAxis_CorporateNonSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c20241231_ConsolidationItemsAxis_OperatingSegmentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c20241231_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_ADMABioManufacturingSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">adma:ADMABioManufacturingSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c20221231_ConsolidationItemsAxis_CorporateNonSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c20231231_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PlasmaCollectionCentersSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">adma:PlasmaCollectionCentersSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c20231231_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_ADMABioManufacturingSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">adma:ADMABioManufacturingSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c20241231_ConsolidationItemsAxis_CorporateNonSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c20241231_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PlasmaCollectionCentersSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">adma:PlasmaCollectionCentersSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c20231231_ConsolidationItemsAxis_CorporateNonSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c20221231_ConsolidationItemsAxis_OperatingSegmentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c20221231_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PlasmaCollectionCentersSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">adma:PlasmaCollectionCentersSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c20231231_ConsolidationItemsAxis_OperatingSegmentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c20221231_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_ADMABioManufacturingSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">adma:ADMABioManufacturingSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c20230101to20231231_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_ADMABioManufacturingSegmentMember_StatementGeographicalAxis_NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">adma:ADMABioManufacturingSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c20240101to20241231_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PlasmaCollectionCentersSegmentMember_StatementGeographicalAxis_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">adma:PlasmaCollectionCentersSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c20230101to20231231_ConsolidationItemsAxis_OperatingSegmentsMember_StatementGeographicalAxis_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c20230101to20231231_ConsolidationItemsAxis_OperatingSegmentsMember_StatementGeographicalAxis_NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c20220101to20221231_ConsolidationItemsAxis_OperatingSegmentsMember_StatementGeographicalAxis_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c20230101to20231231_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_ADMABioManufacturingSegmentMember_StatementGeographicalAxis_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">adma:ADMABioManufacturingSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c20240101to20241231_ConsolidationItemsAxis_MaterialReconcilingItemsMember_StatementGeographicalAxis_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c20230101to20231231_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PlasmaCollectionCentersSegmentMember_StatementGeographicalAxis_NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">adma:PlasmaCollectionCentersSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c20220101to20221231_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_ADMABioManufacturingSegmentMember_StatementGeographicalAxis_NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">adma:ADMABioManufacturingSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c20240101to20241231_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PlasmaCollectionCentersSegmentMember_StatementGeographicalAxis_NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">adma:PlasmaCollectionCentersSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c20240101to20241231_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_ADMABioManufacturingSegmentMember_StatementGeographicalAxis_NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">adma:ADMABioManufacturingSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c20220101to20221231_ConsolidationItemsAxis_OperatingSegmentsMember_StatementGeographicalAxis_NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c20240101to20241231_ConsolidationItemsAxis_MaterialReconcilingItemsMember_StatementGeographicalAxis_NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c20240101to20241231_ConsolidationItemsAxis_OperatingSegmentsMember_StatementGeographicalAxis_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c20230101to20231231_ConsolidationItemsAxis_MaterialReconcilingItemsMember_StatementGeographicalAxis_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c20240101to20241231_StatementGeographicalAxis_NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c20220101to20221231_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_ADMABioManufacturingSegmentMember_StatementGeographicalAxis_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">adma:ADMABioManufacturingSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c20220101to20221231_StatementGeographicalAxis_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c20230101to20231231_ConsolidationItemsAxis_MaterialReconcilingItemsMember_StatementGeographicalAxis_NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c20240101to20241231_StatementGeographicalAxis_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c20220101to20221231_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PlasmaCollectionCentersSegmentMember_StatementGeographicalAxis_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">adma:PlasmaCollectionCentersSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c20230101to20231231_StatementGeographicalAxis_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c20240101to20241231_ConsolidationItemsAxis_OperatingSegmentsMember_StatementGeographicalAxis_NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c20240101to20241231_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_ADMABioManufacturingSegmentMember_StatementGeographicalAxis_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">adma:ADMABioManufacturingSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c20230101to20231231_StatementGeographicalAxis_NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c20220101to20221231_StatementGeographicalAxis_NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c20220101to20221231_ConsolidationItemsAxis_MaterialReconcilingItemsMember_StatementGeographicalAxis_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c20220101to20221231_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PlasmaCollectionCentersSegmentMember_StatementGeographicalAxis_NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">adma:PlasmaCollectionCentersSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c20230101to20231231_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PlasmaCollectionCentersSegmentMember_StatementGeographicalAxis_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">adma:PlasmaCollectionCentersSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c20220101to20221231_ConsolidationItemsAxis_MaterialReconcilingItemsMember_StatementGeographicalAxis_NonUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c20230101to20231231_ConcentrationRiskByBenchmarkAxis_AccountsReceivableMember_ConcentrationRiskByTypeAxis_CustomerConcentrationRiskMember_MajorCustomersAxis_FiveCustomersMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">adma:FiveCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c20220101to20221231_ConcentrationRiskByBenchmarkAxis_RevenueFromContractWithCustomerProductAndServiceBenchmarkMember_ConcentrationRiskByTypeAxis_CustomerConcentrationRiskMember_MajorCustomersAxis_TwoCustomersMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">adma:TwoCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerProductAndServiceBenchmarkMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c20240101to20241231_ConcentrationRiskByBenchmarkAxis_RevenueFromContractWithCustomerProductAndServiceBenchmarkMember_ConcentrationRiskByTypeAxis_CustomerConcentrationRiskMember_StatementBusinessSegmentsAxis_PlasmaCollectionCentersSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerProductAndServiceBenchmarkMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">adma:PlasmaCollectionCentersSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c20230101to20231231_ConcentrationRiskByBenchmarkAxis_RevenueFromContractWithCustomerProductAndServiceBenchmarkMember_ConcentrationRiskByTypeAxis_CustomerConcentrationRiskMember_MajorCustomersAxis_TwoCustomersMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">adma:TwoCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerProductAndServiceBenchmarkMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c20240101to20241231_ConcentrationRiskByBenchmarkAxis_RevenueFromContractWithCustomerProductAndServiceBenchmarkMember_ConcentrationRiskByTypeAxis_CustomerConcentrationRiskMember_MajorCustomersAxis_TwoCustomersMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">adma:TwoCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerProductAndServiceBenchmarkMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c20240101to20241231_ConcentrationRiskByBenchmarkAxis_AccountsReceivableMember_ConcentrationRiskByTypeAxis_CustomerConcentrationRiskMember_MajorCustomersAxis_ThreeCustomersMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">adma:ThreeCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c20211231_ValuationAllowancesAndReservesTypeAxis_SECSchedule1209ReserveAccruedRebatesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">adma:SECSchedule1209ReserveAccruedRebatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c20231231_ValuationAllowancesAndReservesTypeAxis_ValuationAllowanceOfDeferredTaxAssetsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c20231231_ValuationAllowancesAndReservesTypeAxis_SECSchedule1209ReserveAccruedRebatesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">adma:SECSchedule1209ReserveAccruedRebatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c20221231_ValuationAllowancesAndReservesTypeAxis_InventoryValuationReserveMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:InventoryValuationReserveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c20211231_ValuationAllowancesAndReservesTypeAxis_InventoryValuationReserveMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:InventoryValuationReserveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c20221231_ValuationAllowancesAndReservesTypeAxis_SECSchedule1209ReserveAccruedRebatesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">adma:SECSchedule1209ReserveAccruedRebatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c20221231_ValuationAllowancesAndReservesTypeAxis_ValuationAllowanceOfDeferredTaxAssetsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c20231231_ValuationAllowancesAndReservesTypeAxis_InventoryValuationReserveMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:InventoryValuationReserveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c20211231_ValuationAllowancesAndReservesTypeAxis_ValuationAllowanceOfDeferredTaxAssetsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c20230101to20231231_ValuationAllowancesAndReservesTypeAxis_InventoryValuationReserveMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:InventoryValuationReserveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c20240101to20241231_ValuationAllowancesAndReservesTypeAxis_ValuationAllowanceOfDeferredTaxAssetsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c20240101to20241231_ValuationAllowancesAndReservesTypeAxis_SECSchedule1209ReserveAccruedRebatesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">adma:SECSchedule1209ReserveAccruedRebatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c20230101to20231231_ValuationAllowancesAndReservesTypeAxis_SECSchedule1209ReserveAccruedRebatesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">adma:SECSchedule1209ReserveAccruedRebatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c20240101to20241231_ValuationAllowancesAndReservesTypeAxis_InventoryValuationReserveMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:InventoryValuationReserveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c20220101to20221231_ValuationAllowancesAndReservesTypeAxis_ValuationAllowanceOfDeferredTaxAssetsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c20230101to20231231_ValuationAllowancesAndReservesTypeAxis_ValuationAllowanceOfDeferredTaxAssetsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c20220101to20221231_ValuationAllowancesAndReservesTypeAxis_SECSchedule1209ReserveAccruedRebatesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">adma:SECSchedule1209ReserveAccruedRebatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c20220101to20221231_ValuationAllowancesAndReservesTypeAxis_InventoryValuationReserveMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:InventoryValuationReserveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c20241231_ValuationAllowancesAndReservesTypeAxis_ValuationAllowanceOfDeferredTaxAssetsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c20241231_ValuationAllowancesAndReservesTypeAxis_InventoryValuationReserveMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:InventoryValuationReserveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c20241231_ValuationAllowancesAndReservesTypeAxis_SECSchedule1209ReserveAccruedRebatesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001368514</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">adma:SECSchedule1209ReserveAccruedRebatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <unit id="U001">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="U002">
        <measure>shares</measure>
    </unit>
    <unit id="U003">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="U004">
        <measure>adma:Facility</measure>
    </unit>
    <unit id="U005">
        <measure>adma:Product</measure>
    </unit>
    <unit id="U006">
        <measure>adma:Officer</measure>
    </unit>
    <unit id="U007">
        <measure>pure</measure>
    </unit>
    <unit id="U008">
        <measure>adma:Director</measure>
    </unit>
    <unit id="U009">
        <measure>adma:Employee</measure>
    </unit>
    <unit id="U010">
        <measure>adma:Batch</measure>
    </unit>
    <unit id="U011">
        <measure>adma:Term</measure>
    </unit>
    <unit id="U012">
        <measure>utr:l</measure>
    </unit>
    <unit id="U013">
        <measure>adma:Lease</measure>
    </unit>
    <unit id="U014">
        <measure>adma:Segment</measure>
    </unit>
    <unit id="U015">
        <measure>adma:Customer</measure>
    </unit>
    <dei:AmendmentFlag
      contextRef="c20240101to20241231"
      id="Fact_f913f05aeb804866b4528912837538bd">false</dei:AmendmentFlag>
    <dei:CurrentFiscalYearEndDate
      contextRef="c20240101to20241231"
      id="Fact_c4538a1742b046abbb2573809a77a124">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="c20240101to20241231"
      id="Fact_ddf2b11c0b2b4bdcbf61876eb49a0317">2024</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="c20240101to20241231"
      id="Fact_50033b203c194a99b7b57117ffdf281b">FY</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey
      contextRef="c20240101to20241231"
      id="Fact_f6d4536bbc1b495fb7cd5dae2f035e52">0001368514</dei:EntityCentralIndexKey>
    <ecd:TrdArrDuration
      contextRef="c20241001to20241231_IndividualAxis_AdamGrossmanMember"
      id="Fact_7095587f31264a6b95943ba8d0a4f402">P391D</ecd:TrdArrDuration>
    <adma:NumberOfBusinessDays
      contextRef="c20231218to20231218_CreditFacilityAxis_TermLoanMember_VariableRateAxis_SecuredOvernightFinancingRateSofrMember"
      id="Fact_712874e87fcc4abab5ec40411ed75dc9">P2D</adma:NumberOfBusinessDays>
    <adma:NumberOfBusinessDays
      contextRef="c20231218to20231218_CreditFacilityAxis_RevolvingCreditFacilityMember_VariableRateAxis_SecuredOvernightFinancingRateSofrMember"
      id="Fact_00f7b4da42784c0b85e89298c6447e23">P2D</adma:NumberOfBusinessDays>
    <adma:NumberOfBusinessDaysForPriorWrittenNoticeToPrepayOutstandingPrincipal
      contextRef="c20240101to20241231_CounterpartyNameAxis_AresCreditAgreementMember_DebtInstrumentAxis_AresCreditFacilityMember"
      id="Fact_2496c3fd576a452da07200cbae1170f2">P3D</adma:NumberOfBusinessDaysForPriorWrittenNoticeToPrepayOutstandingPrincipal>
    <adma:NumberOfBusinessDaysForPriorWrittenNoticeToPrepayOutstandingPrincipal
      contextRef="c20240101to20241231_CounterpartyNameAxis_AresCreditAgreementMember_DebtInstrumentAxis_AresCreditFacilityMember"
      id="Fact_d55916c1abbd41dd8edc1e45abe3c678">P3D</adma:NumberOfBusinessDaysForPriorWrittenNoticeToPrepayOutstandingPrincipal>
    <adma:ITTechnologySystemsInaccessiblePeriod
      contextRef="c20230619to20230619_RangeAxis_MaximumMember"
      id="Fact_4754ce8ea55d44e195b5e28a95f3e9f0">P7D</adma:ITTechnologySystemsInaccessiblePeriod>
    <dei:AuditorFirmId
      contextRef="c20240101to20241231"
      id="Fact_89c3f38fba7e479a9bb9abf5fd1f116f">185</dei:AuditorFirmId>
    <dei:AuditorFirmId
      contextRef="c20240101to20241231_CounterpartyNameAxis_CohnReznickLLPMember"
      id="Fact_8de9ba90e6904aadaccdf07a6e27430f">596</dei:AuditorFirmId>
    <adma:AgreementWithTermExpirationDate
      contextRef="c20240101to20241231_TypeOfArrangementAxis_ARGrifolsAgreementMember"
      id="Fact_596502cac0e64068963eb61419709634">2039-09-30</adma:AgreementWithTermExpirationDate>
    <adma:AgreementWithTermExpirationDate
      contextRef="c20240101to20241231_TypeOfArrangementAxis_KEDPlasmaAgreementMember"
      id="Fact_08cb0657423a4fc9a23ab84cedf6874f">2031-07-31</adma:AgreementWithTermExpirationDate>
    <us-gaap:OperatingLossCarryforwardsExpirationDate
      contextRef="c20240101to20241231_RangeAxis_MinimumMember"
      id="Fact_3caad71a9a1b440ba964fc32940d472a">2029-12-31</us-gaap:OperatingLossCarryforwardsExpirationDate>
    <us-gaap:OperatingLossCarryforwardsExpirationDate
      contextRef="c20240101to20241231_RangeAxis_MaximumMember"
      id="Fact_8b85b23ae8fb4a49b2e8cb82e0d4603d">2043-12-31</us-gaap:OperatingLossCarryforwardsExpirationDate>
    <dei:DocumentType
      contextRef="c20240101to20241231"
      id="Fact_4f28663ed1034d3bbe4d7a16732807a5">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport
      contextRef="c20240101to20241231"
      id="Fact_8cb682f76d8349aea88d002e9257fcb4">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate
      contextRef="c20240101to20241231"
      id="Fact_30a135f0fe584c1caff9f8be11aaec0d">2024-12-31</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="c20240101to20241231"
      id="Fact_4cc330f2682f418797872935f3700c11">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="c20240101to20241231"
      id="Fact_8969207dfb554932922cfd2f711c1f42">001-36728</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="c20240101to20241231"
      id="Fact_5b0256a1d461411f8d2572ab7acef8b9">ADMA BIOLOGICS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="c20240101to20241231"
      id="Fact_f086bbebe3c74f73a547adcf4adda6cc">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="c20240101to20241231"
      id="Fact_716d33906e774f45a14878e24f0dba51">56-2590442</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="c20240101to20241231"
      id="Fact_b0ecb973cb57414fbf911e8aa59772b7">465 State Route 17</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="c20240101to20241231"
      id="Fact_6947d7319bb849f681a362f4c16adf8d">Ramsey</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="c20240101to20241231"
      id="Fact_38a9760044ea4a23a7f08fb0956380ca">NJ</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="c20240101to20241231"
      id="Fact_92a43b4ca38a4d7989aefddffd358bfa">07446</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="c20240101to20241231"
      id="Fact_102e3e0d8f4c4a95aab192e254b49a60">201</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="c20240101to20241231"
      id="Fact_d2f9c96d063c43adac848a93380dda4d">478-5552</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="c20240101to20241231"
      id="Fact_67d6bfd0b57b438eb1cdb914f38187f9">Common stock, par value $0.0001 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="c20240101to20241231"
      id="Fact_0748a300a2ae4ac5ab139bc47fa848df">ADMA</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="c20240101to20241231"
      id="Fact_d35b82726b1b4376b5219ecd86615019">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="c20240101to20241231"
      id="Fact_15e81501d13d4799a8e9a5c53bec405c">Yes</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers
      contextRef="c20240101to20241231"
      id="Fact_9c76db4427294482b3c00882d5761216">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus
      contextRef="c20240101to20241231"
      id="Fact_4cec08d5f45043edb2c54208a242f7d7">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="c20240101to20241231"
      id="Fact_859719d50f5b420a94b8ad9aa9b155e6">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="c20240101to20241231"
      id="Fact_23f05c13253747748ce8dc1cc9fb0a2b">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="c20240101to20241231"
      id="Fact_11eead77ad3d4a6590b094844258ac94">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="c20240101to20241231"
      id="Fact_b306d48ec53e44b18bd0469a184db8b2">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag
      contextRef="c20240101to20241231"
      id="Fact_e3c1e3aa83b146c68befe24d32fc154a">true</dei:IcfrAuditorAttestationFlag>
    <dei:DocumentFinStmtErrorCorrectionFlag
      contextRef="c20240101to20241231"
      id="Fact_bc0c88570262449a8fee521ad36ae235">false</dei:DocumentFinStmtErrorCorrectionFlag>
    <dei:EntityShellCompany
      contextRef="c20240101to20241231"
      id="Fact_0bf64eade1f74315aac6fe1a683970d1">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="c20240630"
      decimals="0"
      id="Fact_02f9013899604461b9d0df3a5a42edad"
      unitRef="U001">2535856298</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="c20250310"
      decimals="INF"
      id="Fact_c7817761f6034283b88206091f43baf2"
      unitRef="U002">237615100</dei:EntityCommonStockSharesOutstanding>
    <cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock
      contextRef="c20240101to20241231"
      id="Text_95aac64285b64b8395916ca032524c20">
&lt;div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="text-decoration: underline;"&gt;Risk Management and Strategy&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt;We recognize the importance of managing the material risks of cybersecurity threats, and we have implemented processes for identifying and assessing cybersecurity
            risks and incidents. &lt;span style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000;"&gt;We have also integrated these processes into our overall risk management system, including senior management&#x2019;s periodic reviews of cybersecurity risks or threats. Senior management oversees and works closely with our IT department to continuously review and evaluate cybersecurity risks in alignment with
            our business goals and needs.&lt;/span&gt;&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
          &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt;With respect to cybersecurity risks and threats, we utilize various third-party consultants and advisors to assist us with regular reviews, internal audits and best practices, including threat prevention and detection, security reviews and enhancements, penetration testing and full scope IT audits.
            ADMA also has strict processes in place for the review of third-party service providers engaged, including thorough security assessments before engagement and annual monitoring of their IT environments and controls.&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
          &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt;During the year ended December 31, 2023, as initially disclosed in our Quarterly Report on Form 10-Q for the period ending June 30, 2023 and updated elsewhere in our
            subsequent filings with the SEC, we experienced an IT systems disruption, which did result in a non-recurring charge to our results of operations.
            There was no original financial systems data loss or any evidence of data exfiltrated due to this disruption. Normal course operations quickly resumed across the Company&#x2019;s business units.&lt;/div&gt;
</cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock>
    <cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock
      contextRef="c20240101to20241231"
      id="Text_cc2a0e3e85fd40fdb8df7d12166848ce">&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000;"&gt;We have also integrated these processes into our overall risk management system, including senior management&#x2019;s periodic reviews of cybersecurity risks or threats. Senior management oversees and works closely with our IT department to continuously review and evaluate cybersecurity risks in alignment with
            our business goals and needs.&lt;/span&gt;</cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock>
    <cyd:CybersecurityRiskManagementProcessesIntegratedFlag
      contextRef="c20240101to20241231"
      id="Fact_9961142de24947e7b88fedccb2e08cf9">true</cyd:CybersecurityRiskManagementProcessesIntegratedFlag>
    <cyd:CybersecurityRiskManagementThirdPartyEngagedFlag
      contextRef="c20240101to20241231"
      id="Fact_25fb28637942491e93d356e606175fb2">true</cyd:CybersecurityRiskManagementThirdPartyEngagedFlag>
    <cyd:CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag
      contextRef="c20240101to20241231"
      id="Fact_ce2dc3476554478281ceaef6e632f10e">true</cyd:CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag>
    <cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock
      contextRef="c20240101to20241231"
      id="Text_d544260485b84bc6903515637a3f275c">
&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt;During the year ended December 31, 2023, as initially disclosed in our Quarterly Report on Form 10-Q for the period ending June 30, 2023 and updated elsewhere in our
            subsequent filings with the SEC, we experienced an IT systems disruption, which did result in a non-recurring charge to our results of operations.
            There was no original financial systems data loss or any evidence of data exfiltrated due to this disruption. Normal course operations quickly resumed across the Company&#x2019;s business units.&lt;/div&gt;
</cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock>
    <cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag
      contextRef="c20240101to20241231"
      id="Fact_869c0f8300564044ae323bb0b0dc1772">true</cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag>
    <cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock
      contextRef="c20240101to20241231"
      id="Text_b1dba2831457485093db4c91c86dacb2">
&lt;div style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="text-decoration: underline;"&gt;Governance&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt;Our President and Chief Executive Officer and Chief Operating Officer are primarily responsible for timely updating the Board and Audit Committee about any material
            cybersecurity incidents or threats or any cybersecurity related issues worthy of their attention.&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
          &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000;"&gt;Our Board has designated the Audit Committee as the primary committee responsible for reviewing and managing cybersecurity risks and threats at ADMA.&lt;/span&gt; &lt;span style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000;"&gt;The Audit Committee is comprised of Board members with diverse experience in healthcare, finance and information
            technology, enabling them to effectively oversee cybersecurity risks and threats.&lt;/span&gt; &lt;span style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000;"&gt;Our management team, with
            assistance from third-party consultants or advisors as appropriate, provides quarterly updates regarding cybersecurity risks and threats to the Audit Committee and ad hoc updates or communications are provided to the entire Board as needed.&lt;/span&gt;&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
          &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000;"&gt;The Data Integrity and IT Operations team are primarily responsible for the timely identification, review, severity assessment and management of cybersecurity incidents.&lt;/span&gt; In the event of a cybersecurity incident, the IT Department leadership follows the procedures outlined in our Cybersecurity Incident Response Policy and works closely with
            management to form a Security Incident Response Team comprised of members from the appropriate functional teams. In accordance with this policy, senior management will also communicate the occurrence of any significant cybersecurity incidents to our Board, Audit Committee and auditors on a timely basis and will keep them informed of the remediation plans and progress.&lt;/div&gt;
</cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock>
    <cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock
      contextRef="c20240101to20241231"
      id="Text_5290ed66ee024fc5ad78e2f0af1dfc81">&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000;"&gt;Our Board has designated the Audit Committee as the primary committee responsible for reviewing and managing cybersecurity risks and threats at ADMA.&lt;/span&gt;</cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock>
    <cyd:CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock
      contextRef="c20240101to20241231"
      id="Text_0cc1f53ac16f4c398c22a1a6b27982cf">&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000;"&gt;The Audit Committee is comprised of Board members with diverse experience in healthcare, finance and information
            technology, enabling them to effectively oversee cybersecurity risks and threats.&lt;/span&gt;</cyd:CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock>
    <cyd:CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock
      contextRef="c20240101to20241231"
      id="Text_1ac1af67993e4c2d9c8e84028a293c35">&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000;"&gt;Our management team, with
            assistance from third-party consultants or advisors as appropriate, provides quarterly updates regarding cybersecurity risks and threats to the Audit Committee and ad hoc updates or communications are provided to the entire Board as needed.&lt;/span&gt;</cyd:CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock>
    <cyd:CybersecurityRiskRoleOfManagementTextBlock
      contextRef="c20240101to20241231"
      id="Text_04c39f02ab2140e4abb758ce149b52fe">
&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000;"&gt;The Data Integrity and IT Operations team are primarily responsible for the timely identification, review, severity assessment and management of cybersecurity incidents.&lt;/span&gt; In the event of a cybersecurity incident, the IT Department leadership follows the procedures outlined in our Cybersecurity Incident Response Policy and works closely with
            management to form a Security Incident Response Team comprised of members from the appropriate functional teams. In accordance with this policy, senior management will also communicate the occurrence of any significant cybersecurity incidents to our Board, Audit Committee and auditors on a timely basis and will keep them informed of the remediation plans and progress.&lt;/div&gt;
</cyd:CybersecurityRiskRoleOfManagementTextBlock>
    <cyd:CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock
      contextRef="c20240101to20241231"
      id="Text_1fcba4777d9044c59dfcce55b8dbd907">
&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000;"&gt;The Data Integrity and IT Operations team are primarily responsible for the timely identification, review, severity assessment and management of cybersecurity incidents.&lt;/span&gt; In the event of a cybersecurity incident, the IT Department leadership follows the procedures outlined in our Cybersecurity Incident Response Policy and works closely with
            management to form a Security Incident Response Team comprised of members from the appropriate functional teams. In accordance with this policy, senior management will also communicate the occurrence of any significant cybersecurity incidents to our Board, Audit Committee and auditors on a timely basis and will keep them informed of the remediation plans and progress.&lt;/div&gt;
</cyd:CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock>
    <cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock
      contextRef="c20240101to20241231"
      id="Text_9367888ccfce414485c2bc5a51d8ca4f">&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; color: #000000;"&gt;The Data Integrity and IT Operations team are primarily responsible for the timely identification, review, severity assessment and management of cybersecurity incidents.&lt;/span&gt;</cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock>
    <cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag
      contextRef="c20240101to20241231"
      id="Fact_f5d242371e3e4a1c8970022c7ff829e1">true</cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag>
    <cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag
      contextRef="c20240101to20241231"
      id="Fact_37f218e86cb14d2891be4c746016e1bd">true</cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag>
    <ecd:MtrlTermsOfTrdArrTextBlock
      contextRef="c20241001to20241231_IndividualAxis_AdamGrossmanMember"
      id="Text_7c487e6e04094111a51f1e383ea32939">
&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt;"&gt;During the quarter ended December 31, 2024, none of our directors or executive officers adopted or terminated any such contract, instruction or written plans except for Adam Grossman, our President and CEO, who entered into a Rule 105b-1 trading plan with Fidelity Brokerage Services LLC on December 5, 2024 (the &#x201c;Grossman Plan&#x201d;).&#160;The Grossman Plan provides that Mr. Grossman may sell up to an aggregate of (i) 60,000
        shares of our common stock and (ii) 150,000 shares of our common stock to be received upon the exercise of vested options granted to Mr.
        Grossman. The Grossman Plan is scheduled to terminate on December 31, 2025, subject to earlier &lt;span style="-sec-ix-hidden:Fact_7095587f31264a6b95943ba8d0a4f402"&gt;termination&lt;/span&gt; upon the sale of all shares subject to the plan, upon termination by Mr. Grossman or the broker, or as otherwise provided in the plan.&lt;/div&gt;
</ecd:MtrlTermsOfTrdArrTextBlock>
    <ecd:NonRule10b51ArrAdoptedFlag
      contextRef="c20241001to20241231"
      id="Fact_9cf971c178de474986334675d24b8e8f">false</ecd:NonRule10b51ArrAdoptedFlag>
    <ecd:NonRule10b51ArrTrmntdFlag
      contextRef="c20241001to20241231"
      id="Fact_354e25ef00234919a134028df3ab65d7">false</ecd:NonRule10b51ArrTrmntdFlag>
    <ecd:Rule10b51ArrTrmntdFlag
      contextRef="c20241001to20241231_IndividualAxis_AdamGrossmanMember"
      id="Fact_2e40f150ef574124963441af7ff18ed7">false</ecd:Rule10b51ArrTrmntdFlag>
    <ecd:TrdArrIndName
      contextRef="c20241001to20241231_IndividualAxis_AdamGrossmanMember"
      id="Fact_001e940f94f0432585fbebbbde0b0fc0">Adam Grossman</ecd:TrdArrIndName>
    <ecd:TrdArrIndTitle
      contextRef="c20241001to20241231_IndividualAxis_AdamGrossmanMember"
      id="Fact_fdff22a2ae1540bdaab34cf5163d0ec2">President and CEO</ecd:TrdArrIndTitle>
    <ecd:Rule10b51ArrAdoptedFlag
      contextRef="c20241001to20241231_IndividualAxis_AdamGrossmanMember"
      id="Fact_54d28122aa704b3fa1fb55066d80fb7e">true</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:TrdArrAdoptionDate
      contextRef="c20241001to20241231_IndividualAxis_AdamGrossmanMember"
      id="Fact_39fae28a74db4de9b19171e8e0d46df8">December 5, 2024</ecd:TrdArrAdoptionDate>
    <ecd:TrdArrSecuritiesAggAvailAmt
      contextRef="c20241231_TradingArrAxis_AdamGrossmanTradingPlanCommonStockMember"
      decimals="0"
      id="Fact_c0cfdcd889d94ca38955bbf9b7b1784a"
      unitRef="U002">60000</ecd:TrdArrSecuritiesAggAvailAmt>
    <ecd:TrdArrSecuritiesAggAvailAmt
      contextRef="c20241231_TradingArrAxis_AdamGrossmanTradingPlanStockOptionsMember"
      decimals="0"
      id="Fact_5eb3986a564642a68aa910150d247927"
      unitRef="U002">150000</ecd:TrdArrSecuritiesAggAvailAmt>
    <ecd:TrdArrExpirationDate
      contextRef="c20241001to20241231_IndividualAxis_AdamGrossmanMember"
      id="Fact_30c212d1f9fc41e4b04406b54f0df7da">December 31, 2025</ecd:TrdArrExpirationDate>
    <dei:AuditorName
      contextRef="c20240101to20241231"
      id="Fact_d5266f29c405489bbc9397454341ea01">KPMG LLP</dei:AuditorName>
    <dei:AuditorLocation
      contextRef="c20240101to20241231"
      id="Fact_d8617e76d72e452191cac73d2844ecd8">Stamford, Connecticut</dei:AuditorLocation>
    <dei:AuditorName
      contextRef="c20240101to20241231_CounterpartyNameAxis_CohnReznickLLPMember"
      id="Fact_dd1485d3a71c4bebb5607ae7503fd7ae">CohnReznick LLP</dei:AuditorName>
    <dei:AuditorLocation
      contextRef="c20240101to20241231_CounterpartyNameAxis_CohnReznickLLPMember"
      id="Fact_70fb6afd89164593a8eadb274a02335e">Parsippany, New Jersey</dei:AuditorLocation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="c20241231"
      decimals="-3"
      id="Fact_0dd990aea60f4236a8737a5fde657bc1"
      unitRef="U001">103147000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="c20231231"
      decimals="-3"
      id="Fact_068a3019356e497a8e44066729a663b5"
      unitRef="U001">51352000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="c20241231"
      decimals="-3"
      id="Fact_ed3bbc4e659848908fac8137ddf4e073"
      unitRef="U001">49999000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="c20231231"
      decimals="-3"
      id="Fact_e14390b1f9a147e9a59f82163f669e41"
      unitRef="U001">27421000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet
      contextRef="c20241231"
      decimals="-3"
      id="Fact_d4018025e54944918461856069cda7f4"
      unitRef="U001">170235000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="c20231231"
      decimals="-3"
      id="Fact_54e39784c23f40f0ac31321a8f8221f1"
      unitRef="U001">172906000</us-gaap:InventoryNet>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="c20241231"
      decimals="-3"
      id="Fact_1f822fe2eea4497d985026e22d2b6b04"
      unitRef="U001">8029000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="c20231231"
      decimals="-3"
      id="Fact_fcbcd37d63004138a4339866a7da1965"
      unitRef="U001">5334000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="c20241231"
      decimals="-3"
      id="Fact_a1833916b8754fb88f08e82ba4952f88"
      unitRef="U001">331410000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="c20231231"
      decimals="-3"
      id="Fact_98688a7ecdbc4d4683fd5124e37b1074"
      unitRef="U001">257013000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="c20241231"
      decimals="-3"
      id="Fact_bcffa5a7b2e44feb964946ff4a5529d4"
      unitRef="U001">54707000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="c20231231"
      decimals="-3"
      id="Fact_5ba34ddabe454913917ca75232b3c7fa"
      unitRef="U001">53835000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="c20241231"
      decimals="-3"
      id="Fact_4d15e111e7154fa19f80999f64f5f69e"
      unitRef="U001">460000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="c20231231"
      decimals="-3"
      id="Fact_1de4b6195ac841aeb817cdab57df468d"
      unitRef="U001">499000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:Goodwill
      contextRef="c20241231"
      decimals="-3"
      id="Fact_d8e2154aea9f444785261aa1bf34c8b8"
      unitRef="U001">3530000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="c20231231"
      decimals="-3"
      id="Fact_dc37b03726934a94b159a4bd3e3fa106"
      unitRef="U001">3530000</us-gaap:Goodwill>
    <us-gaap:DeferredIncomeTaxAssetsNet
      contextRef="c20241231"
      decimals="-3"
      id="Fact_18b8139a094748229a149678c55b7152"
      unitRef="U001">84280000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:DeferredIncomeTaxAssetsNet
      contextRef="c20231231"
      decimals="-3"
      id="Fact_cd79bfc17d00436486ffb6a6b63ec138"
      unitRef="U001">0</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="c20241231"
      decimals="-3"
      id="Fact_5f174980e6d54933b37976ebf5bc4ac6"
      unitRef="U001">8634000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="c20231231"
      decimals="-3"
      id="Fact_6017bca0542441fda9ebb31d6be4186c"
      unitRef="U001">9635000</us-gaap:OperatingLeaseRightOfUseAsset>
    <adma:DepositsAndOtherNoncurrentAssets
      contextRef="c20241231"
      decimals="-3"
      id="Fact_05ec2b3a0f784810a62bb76c61fdc257"
      unitRef="U001">5657000</adma:DepositsAndOtherNoncurrentAssets>
    <adma:DepositsAndOtherNoncurrentAssets
      contextRef="c20231231"
      decimals="-3"
      id="Fact_79232a7388144eb19fe14d4fb1b176ac"
      unitRef="U001">4670000</adma:DepositsAndOtherNoncurrentAssets>
    <us-gaap:Assets
      contextRef="c20241231"
      decimals="-3"
      id="Fact_9f34eeb3c3fd4808ad1d89e6dc020563"
      unitRef="U001">488678000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="c20231231"
      decimals="-3"
      id="Fact_15b46b1d6b754de3ac40966266963a74"
      unitRef="U001">329182000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="c20241231"
      decimals="-3"
      id="Fact_b6749577bd374ee6828a6ce0284b9734"
      unitRef="U001">20219000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="c20231231"
      decimals="-3"
      id="Fact_253d0afba69b428d879bc422e16e1cee"
      unitRef="U001">15660000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities
      contextRef="c20241231"
      decimals="-3"
      id="Fact_9eee52eb8f514db1882ba4325e82a4c2"
      unitRef="U001">33962000</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities
      contextRef="c20231231"
      decimals="-3"
      id="Fact_eeca5f2b173d4a41af769710ac5e1762"
      unitRef="U001">32919000</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="c20241231"
      decimals="-3"
      id="Fact_3e7166e1004e4ee28cafcad11e3fb4fc"
      unitRef="U001">143000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="c20231231"
      decimals="-3"
      id="Fact_9f53c187f29a443f96b2c372553b64dc"
      unitRef="U001">182000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="c20241231"
      decimals="-3"
      id="Fact_859602c0a67b47cdbf15b601feebdd9f"
      unitRef="U001">1218000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="c20231231"
      decimals="-3"
      id="Fact_38ad720aa9484e84870dff234708b77e"
      unitRef="U001">1045000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="c20241231"
      decimals="-3"
      id="Fact_d5817405c5ff4055950f615064f15169"
      unitRef="U001">55542000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="c20231231"
      decimals="-3"
      id="Fact_fb5c3c9a3d834498839dc5ac5c961add"
      unitRef="U001">49806000</us-gaap:LiabilitiesCurrent>
    <us-gaap:SeniorLongTermNotes
      contextRef="c20241231"
      decimals="-3"
      id="Fact_33a7acbbc8a643b4ab65e9ad4971676b"
      unitRef="U001">72337000</us-gaap:SeniorLongTermNotes>
    <us-gaap:SeniorLongTermNotes
      contextRef="c20231231"
      decimals="-3"
      id="Fact_4519bad714214f4ea45e1ad1bbaffd80"
      unitRef="U001">130594000</us-gaap:SeniorLongTermNotes>
    <us-gaap:DeferredRevenueNoncurrent
      contextRef="c20241231"
      decimals="-3"
      id="Fact_f4b76fb1b2df4de9bfe6df06e2b9b826"
      unitRef="U001">1547000</us-gaap:DeferredRevenueNoncurrent>
    <us-gaap:DeferredRevenueNoncurrent
      contextRef="c20231231"
      decimals="-3"
      id="Fact_85bac8ddf19e41899f7b4392d55f72ed"
      unitRef="U001">1690000</us-gaap:DeferredRevenueNoncurrent>
    <adma:LongTermLiabilityEndOfTermFeePayable
      contextRef="c20241231"
      decimals="-3"
      id="Fact_b3e4fb112805457fa441d3ae69243ffd"
      unitRef="U001">1313000</adma:LongTermLiabilityEndOfTermFeePayable>
    <adma:LongTermLiabilityEndOfTermFeePayable
      contextRef="c20231231"
      decimals="-3"
      id="Fact_4c7e9504c47e4029bbe79e17c76c634c"
      unitRef="U001">1688000</adma:LongTermLiabilityEndOfTermFeePayable>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="c20241231"
      decimals="-3"
      id="Fact_2641be08e11545a88275bee9a021a576"
      unitRef="U001">8561000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="c20231231"
      decimals="-3"
      id="Fact_97e5eb0a8dfa443a9271d4f1ec2b223f"
      unitRef="U001">9779000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="c20241231"
      decimals="-3"
      id="Fact_4fe31e7bdbc64e86bb6b5f510b142626"
      unitRef="U001">360000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="c20231231"
      decimals="-3"
      id="Fact_906a8f82f95445378f0936525b4b1282"
      unitRef="U001">419000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="c20241231"
      decimals="-3"
      id="Fact_34509b57d150448e9df0ad3c18ae54dd"
      unitRef="U001">139660000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="c20231231"
      decimals="-3"
      id="Fact_2aaafe323504468b928c2d3f6df0eb4b"
      unitRef="U001">193976000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="c20241231"
      id="Fact_2175e880d30e4057b795f147338c612e"
      unitRef="U001"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="c20231231"
      id="Fact_d6745333bacc42ff9b396000cd446ce1"
      unitRef="U001"
      xsi:nil="true"/>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c20241231"
      decimals="4"
      id="Fact_a99858e5d5ee4c36a79e79e2430c7ea2"
      unitRef="U003">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c20231231"
      decimals="4"
      id="Fact_6eb2d4dfa57e43f0ad65b1c524e4385a"
      unitRef="U003">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="c20231231"
      decimals="0"
      id="Fact_51222fc46b6b4a36ad9ad11cac554740"
      unitRef="U002">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="c20241231"
      decimals="0"
      id="Fact_03ae8cce83534553925a2c1ee6288837"
      unitRef="U002">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="c20241231"
      decimals="INF"
      id="Fact_fc95638b28284512977c274e49771ac7"
      unitRef="U002">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="c20231231"
      decimals="INF"
      id="Fact_fa58feaf160e47de9e51b5aeec819008"
      unitRef="U002">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="c20231231"
      decimals="INF"
      id="Fact_dedfc06f266044e3bf7e595c2c65d33c"
      unitRef="U002">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="c20241231"
      decimals="INF"
      id="Fact_03e2971dd5814c33a0b8b7618cbf616b"
      unitRef="U002">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockValue
      contextRef="c20241231"
      decimals="-3"
      id="Fact_f0df411966894d0c932cd9203c41d28e"
      unitRef="U001">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="c20231231"
      decimals="-3"
      id="Fact_a94025c3bbbd462191439d0777cfa65f"
      unitRef="U001">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c20241231"
      decimals="4"
      id="Fact_9f26d6e4ec8841089effb3ef1e1d2be2"
      unitRef="U003">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c20231231"
      decimals="4"
      id="Fact_17bda77f14504f87a118f150b7c981e5"
      unitRef="U003">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c20241231"
      decimals="0"
      id="Fact_ba922c30134e420d88739a7810a4a1a9"
      unitRef="U002">300000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c20231231"
      decimals="0"
      id="Fact_5375042f6e5f46fb95707eb658af72a7"
      unitRef="U002">300000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="c20241231"
      decimals="0"
      id="Fact_d97461d96dca4e56b9b6589d8fa32c1c"
      unitRef="U002">236620545</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c20241231"
      decimals="0"
      id="Fact_940057368b6744ac8542981b26c5540d"
      unitRef="U002">236620545</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c20231231"
      decimals="0"
      id="Fact_e55f5cf8a8c64c459e1856cf16f19e9f"
      unitRef="U002">226063032</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="c20231231"
      decimals="0"
      id="Fact_982c0a47c98c43f3b275cf3064166bab"
      unitRef="U002">226063032</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="c20241231"
      decimals="-3"
      id="Fact_64215ef58a8b492b91a0eb6e4c1d4c3b"
      unitRef="U001">24000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="c20231231"
      decimals="-3"
      id="Fact_ed4f929379334e0a85d77ce2d314d378"
      unitRef="U001">23000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="c20241231"
      decimals="-3"
      id="Fact_8d893cc91c1c446c8ff7903a7f6fe4fe"
      unitRef="U001">657577000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="c20231231"
      decimals="-3"
      id="Fact_6ace361aed7144a4b137c0045fa688db"
      unitRef="U001">641439000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="c20241231"
      decimals="-3"
      id="Fact_4bec83f2a7de421b96d640747ef82ba6"
      unitRef="U001">-308583000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="c20231231"
      decimals="-3"
      id="Fact_10067ad05ec54addae1ffb23d3107806"
      unitRef="U001">-506256000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="c20241231"
      decimals="-3"
      id="Fact_0c2c1d0885f44a7c8bca301e053bfe2a"
      unitRef="U001">349018000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="c20231231"
      decimals="-3"
      id="Fact_182da382183d40baaf1ed7081cf8ce56"
      unitRef="U001">135206000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="c20241231"
      decimals="-3"
      id="Fact_e9215b422f1e4c36b09e986822c8d22e"
      unitRef="U001">488678000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="c20231231"
      decimals="-3"
      id="Fact_db9c5e54cd5246859d41c64e635be1da"
      unitRef="U001">329182000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20240101to20241231"
      decimals="-3"
      id="Fact_8441c2eee5f64cbcbfd4af516b16fb44"
      unitRef="U001">426454000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20230101to20231231"
      decimals="-3"
      id="Fact_6e83eaf3da7c4ac6865bfdd903d49a09"
      unitRef="U001">258215000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20220101to20221231"
      decimals="-3"
      id="Fact_e213a96045854ef486dd409e855a3104"
      unitRef="U001">154080000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfRevenue
      contextRef="c20240101to20241231"
      decimals="-3"
      id="Fact_34d9efb510f04dd1946432195dc53356"
      unitRef="U001">206901000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="c20230101to20231231"
      decimals="-3"
      id="Fact_1f54b51c41c240c0be0151d2d198b81e"
      unitRef="U001">169273000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="c20220101to20221231"
      decimals="-3"
      id="Fact_fe2ed189ca244f7781e59579e680cc07"
      unitRef="U001">118815000</us-gaap:CostOfRevenue>
    <us-gaap:GrossProfit
      contextRef="c20240101to20241231"
      decimals="-3"
      id="Fact_6cf0ed75e4d042a4a957dcf7ea541e1e"
      unitRef="U001">219553000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="c20230101to20231231"
      decimals="-3"
      id="Fact_fa0ff4ed65ab4bfea5b4477d1fbc5176"
      unitRef="U001">88942000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="c20220101to20221231"
      decimals="-3"
      id="Fact_b069b41efaec4b078677c97514472525"
      unitRef="U001">35265000</us-gaap:GrossProfit>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="c20240101to20241231"
      decimals="-3"
      id="Fact_06cc04d2a9fa40d782af19fe7390a996"
      unitRef="U001">1813000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="c20230101to20231231"
      decimals="-3"
      id="Fact_741aeae524c644c9923937f9c16926af"
      unitRef="U001">3300000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="c20220101to20221231"
      decimals="-3"
      id="Fact_7921ec6d8f9048d9bc5e314b8c3c06b3"
      unitRef="U001">3614000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:OtherCostAndExpenseOperating
      contextRef="c20240101to20241231"
      decimals="-3"
      id="Fact_c3122830ecd64d218180cf982da922eb"
      unitRef="U001">4245000</us-gaap:OtherCostAndExpenseOperating>
    <us-gaap:OtherCostAndExpenseOperating
      contextRef="c20230101to20231231"
      decimals="-3"
      id="Fact_77ceeb9a17af44e3976dc1be23915d42"
      unitRef="U001">4266000</us-gaap:OtherCostAndExpenseOperating>
    <us-gaap:OtherCostAndExpenseOperating
      contextRef="c20220101to20221231"
      decimals="-3"
      id="Fact_bc33aa5f2821419b8f69581e4f98dab4"
      unitRef="U001">17843000</us-gaap:OtherCostAndExpenseOperating>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="c20240101to20241231"
      decimals="-3"
      id="Fact_41facc4c11384f3883bf2d6004558468"
      unitRef="U001">388000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="c20230101to20231231"
      decimals="-3"
      id="Fact_5e2c4933b6e34cffb64991bb6b2979ad"
      unitRef="U001">724000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="c20220101to20221231"
      decimals="-3"
      id="Fact_9b82deccea1d490e96077064752f5bf5"
      unitRef="U001">715000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="c20240101to20241231"
      decimals="-3"
      id="Fact_457ce99c4eb049c2876a1e008f1c2fb6"
      unitRef="U001">74124000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="c20230101to20231231"
      decimals="-3"
      id="Fact_e5426dd3e6ab46f3a287e173570eef14"
      unitRef="U001">59020000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="c20220101to20221231"
      decimals="-3"
      id="Fact_453d8acbed3040509da7136a0fb06ce7"
      unitRef="U001">52458000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="c20240101to20241231"
      decimals="-3"
      id="Fact_4c46c3dd004645fca629d306c3567250"
      unitRef="U001">80570000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="c20230101to20231231"
      decimals="-3"
      id="Fact_ae4f4d0f71b04814bed832cb69649875"
      unitRef="U001">67310000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="c20220101to20221231"
      decimals="-3"
      id="Fact_ec84f46ddd5a4da9aa8fa278ad90b2fe"
      unitRef="U001">74630000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="c20240101to20241231"
      decimals="-3"
      id="Fact_8589ad04f794443e96e06027238b649a"
      unitRef="U001">138983000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="c20230101to20231231"
      decimals="-3"
      id="Fact_c0a0fe25d07645a7883a605441fc0b1c"
      unitRef="U001">21632000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="c20220101to20221231"
      decimals="-3"
      id="Fact_8d571bbcb2f04ec284c4c7ef8e2bc523"
      unitRef="U001">-39365000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InvestmentIncomeInterest
      contextRef="c20240101to20241231"
      decimals="-3"
      id="Fact_36e811b341fb49feb9f43a08bc51f88b"
      unitRef="U001">2097000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="c20230101to20231231"
      decimals="-3"
      id="Fact_927da705790f4a4b9dfad8f1f1f73228"
      unitRef="U001">1617000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="c20220101to20221231"
      decimals="-3"
      id="Fact_28e95287cc9b443c8e7ec36406ae7447"
      unitRef="U001">45000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InterestExpenseNonoperating
      contextRef="c20240101to20241231"
      decimals="-3"
      id="Fact_a398c69a4f1a4c07ba7ec3e9d22e3cc9"
      unitRef="U001">13930000</us-gaap:InterestExpenseNonoperating>
    <us-gaap:InterestExpenseNonoperating
      contextRef="c20230101to20231231"
      decimals="-3"
      id="Fact_f907a7db3e7b4d9c91a135a73c71b97d"
      unitRef="U001">25027000</us-gaap:InterestExpenseNonoperating>
    <us-gaap:InterestExpenseNonoperating
      contextRef="c20220101to20221231"
      decimals="-3"
      id="Fact_d0ad4ad1c75e440086744e1923f25f5a"
      unitRef="U001">19279000</us-gaap:InterestExpenseNonoperating>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="c20240101to20241231"
      decimals="-3"
      id="Fact_ac4422d0fc2842f0833f95f0cffe4b93"
      unitRef="U001">-1243000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="c20230101to20231231"
      decimals="-3"
      id="Fact_0e96bb9b5eb745559d4267f65f722122"
      unitRef="U001">-26174000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="c20220101to20221231"
      decimals="-3"
      id="Fact_4b2c2e0cd8a04c48851b7531598e396a"
      unitRef="U001">-6670000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="c20240101to20241231"
      decimals="-3"
      id="Fact_0de861c1959c45d29d400b3da306dd04"
      unitRef="U001">-193000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="c20230101to20231231"
      decimals="-3"
      id="Fact_cf51f4ea7c93457d91bc853e3dee8837"
      unitRef="U001">-287000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="c20220101to20221231"
      decimals="-3"
      id="Fact_3d86f0fd2287471d9ae96ca4d4eb554a"
      unitRef="U001">-635000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="c20240101to20241231"
      decimals="-3"
      id="Fact_00f538777a414d988f030d64f37bc696"
      unitRef="U001">-13269000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="c20230101to20231231"
      decimals="-3"
      id="Fact_f308679fd57f41d1aae4c81742478c5d"
      unitRef="U001">-49871000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="c20220101to20221231"
      decimals="-3"
      id="Fact_bd2c53addbeb473c8c4d658d7d848a33"
      unitRef="U001">-26539000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="c20240101to20241231"
      decimals="-3"
      id="Fact_621c6258109a4361a7aa22f58f9f126c"
      unitRef="U001">125714000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="c20230101to20231231"
      decimals="-3"
      id="Fact_26137543ed1547499e9d14c76e8fc817"
      unitRef="U001">-28239000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="c20220101to20221231"
      decimals="-3"
      id="Fact_9f7d4eb2f0034edbb03977ce06922b80"
      unitRef="U001">-65904000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="c20240101to20241231"
      decimals="-3"
      id="Fact_039c3e26d0bf4410b4a4bbec6c7329cb"
      unitRef="U001">-71959000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="c20230101to20231231"
      decimals="-3"
      id="Fact_6c116cf8cee6489d938399abf0b3a281"
      unitRef="U001">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="c20220101to20221231"
      decimals="-3"
      id="Fact_00963fac0e24459493048b3971b7dbf0"
      unitRef="U001">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="c20240101to20241231"
      decimals="-3"
      id="Fact_46f886d7f28f43dfabe25ef0087b7596"
      unitRef="U001">197673000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="c20230101to20231231"
      decimals="-3"
      id="Fact_37d64baf4c76490a95b688902bdbd4f2"
      unitRef="U001">-28239000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="c20220101to20221231"
      decimals="-3"
      id="Fact_ad49603301a04cd78537f6fe115e1b19"
      unitRef="U001">-65904000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="c20240101to20241231"
      decimals="2"
      id="Fact_589c4b0450ce4d42bb8aa77a1a0b613c"
      unitRef="U003">0.85</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c20230101to20231231"
      decimals="2"
      id="Fact_03f09bc663074a54beff258a46e9c6ce"
      unitRef="U003">-0.13</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c20220101to20221231"
      decimals="2"
      id="Fact_911bb3cc40284474804bf1e9454a8be3"
      unitRef="U003">-0.33</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c20240101to20241231"
      decimals="2"
      id="Fact_a9281e2d94054363914f30e200817d56"
      unitRef="U003">0.81</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c20230101to20231231"
      decimals="2"
      id="Fact_c7b8dba182c84ea1b8b4be8c293cec49"
      unitRef="U003">-0.13</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c20220101to20221231"
      decimals="2"
      id="Fact_e4d86b5a1f97425b9f881ba143e0ba0a"
      unitRef="U003">-0.33</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c20240101to20241231"
      decimals="0"
      id="Fact_41c77f3f09ef4b6396de0107f9c16470"
      unitRef="U002">233084236</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c20230101to20231231"
      decimals="0"
      id="Fact_833e6c4bdcb04c1990329ee5970d2d72"
      unitRef="U002">223977315</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c20220101to20221231"
      decimals="0"
      id="Fact_b902d11a63b64f55b82a987db59aaedf"
      unitRef="U002">197874895</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="c20240101to20241231"
      decimals="0"
      id="Fact_f34133a90d214c0b81c019ae9be144be"
      unitRef="U002">243342466</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="c20230101to20231231"
      decimals="0"
      id="Fact_9dd045022277405b986093936727e926"
      unitRef="U002">223977315</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="c20220101to20221231"
      decimals="0"
      id="Fact_f9ab553e1ea248189a99b8455a132e6d"
      unitRef="U002">197874895</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="c20211231_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_341e56e1ad9c4bb5bc287c7a1fbb9041"
      unitRef="U002">195813817</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="c20211231_StatementEquityComponentsAxis_CommonStockMember"
      decimals="-3"
      id="Fact_0b87f6d277f44a809bbc6ff0c82ac41a"
      unitRef="U001">20000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="c20211231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact_bcd3dd368df24122b910cd51dff9b82d"
      unitRef="U001">553266000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="c20211231_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="-3"
      id="Fact_38a7538d45c4498c92b85f92cc482785"
      unitRef="U001">-412113000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="c20211231"
      decimals="-3"
      id="Fact_9572fcefa5424a728479ff110b319766"
      unitRef="U001">141173000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="c20220101to20221231_StatementEquityComponentsAxis_CommonStockMember"
      decimals="-3"
      id="Fact_51128c74f1124146b9b253a9e4a112ef"
      unitRef="U001">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="c20220101to20221231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact_d1a3dce8a6a0401886cc9030813dcedd"
      unitRef="U001">5215000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="c20220101to20221231_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="-3"
      id="Fact_8bf40810b65f42beb8a28bca611d9656"
      unitRef="U001">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="c20220101to20221231"
      decimals="-3"
      id="Fact_ea896c2d947f483881fcca0f6dcef402"
      unitRef="U001">5215000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c20220101to20221231_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_bd76ec52997d47ebbb445969fbe326fa"
      unitRef="U002">24125873</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="c20220101to20221231_StatementEquityComponentsAxis_CommonStockMember"
      decimals="-3"
      id="Fact_797e264061b54ca399bf4349e3c48fa9"
      unitRef="U001">2000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="c20220101to20221231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact_01d9e2c66eba4812bd4a3f040f060968"
      unitRef="U001">64642000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="c20220101to20221231_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="-3"
      id="Fact_14846006528c4338bf80307323765d02"
      unitRef="U001">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="c20220101to20221231"
      decimals="-3"
      id="Fact_66c5b9a9f96341ee82e6afcfa66f4994"
      unitRef="U001">64644000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <adma:VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesShares
      contextRef="c20220101to20221231_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_b75f0705b7164b4587242ec5317ab5f3"
      unitRef="U002">1808561</adma:VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesShares>
    <adma:VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAmount
      contextRef="c20220101to20221231_StatementEquityComponentsAxis_CommonStockMember"
      decimals="-3"
      id="Fact_782da4e3d95f484a98e4031873058176"
      unitRef="U001">0</adma:VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAmount>
    <adma:VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAmount
      contextRef="c20220101to20221231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact_b9e97117738849268ae8ba06a4f4f1cc"
      unitRef="U001">2899000</adma:VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAmount>
    <adma:VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAmount
      contextRef="c20220101to20221231_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="-3"
      id="Fact_a6334213280148f68d8097109bca7820"
      unitRef="U001">0</adma:VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAmount>
    <adma:VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAmount
      contextRef="c20220101to20221231"
      decimals="-3"
      id="Fact_7880d8599dbc4dadb676a8dce224dfdf"
      unitRef="U001">2899000</adma:VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAmount>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="c20220101to20221231_StatementEquityComponentsAxis_CommonStockMember"
      decimals="-3"
      id="Fact_54b5a2202cab4462a684bbfabdfcf524"
      unitRef="U001">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="c20220101to20221231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact_2c266dd20506485389bd82a7c8b402f9"
      unitRef="U001">9570000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="c20220101to20221231_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="-3"
      id="Fact_095a1a1efbc4472f8c5ae5322c9c2312"
      unitRef="U001">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="c20220101to20221231"
      decimals="-3"
      id="Fact_a8e5ba06d2ff454c96cb0e805134a0ee"
      unitRef="U001">9570000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="c20220101to20221231_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_4aa22eecd2ad462c8899a4cde067d32f"
      unitRef="U002">68679</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="c20220101to20221231_StatementEquityComponentsAxis_CommonStockMember"
      decimals="-3"
      id="Fact_42c7751c362b40ca98fe44c98cc78d33"
      unitRef="U001">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="c20220101to20221231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact_061622ca6bac41cea109222c7f59254d"
      unitRef="U001">175000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="c20220101to20221231_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="-3"
      id="Fact_0159da5e860f437390524420e977b2d3"
      unitRef="U001">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="c20220101to20221231"
      decimals="-3"
      id="Fact_dad4ac27fbb04ac29ab371551ac9ea52"
      unitRef="U001">175000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:NetIncomeLoss
      contextRef="c20220101to20221231_StatementEquityComponentsAxis_CommonStockMember"
      decimals="-3"
      id="Fact_ed34d4f8c4f1451ca9b0eee91ce741a7"
      unitRef="U001">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="c20220101to20221231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact_bbce859aa3a148db8cb9b15d152bf50e"
      unitRef="U001">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="c20220101to20221231_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="-3"
      id="Fact_2ca81145c7cf418b852e848c066aad7a"
      unitRef="U001">-65904000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="c20220101to20221231"
      decimals="-3"
      id="Fact_561d383061c749b996b3efb9e510e4f6"
      unitRef="U001">-65904000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="c20221231_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_ec0660d449bb4fd29a321bcb535b1b59"
      unitRef="U002">221816930</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="c20221231_StatementEquityComponentsAxis_CommonStockMember"
      decimals="-3"
      id="Fact_92db333566674749b5337fd2ff197fed"
      unitRef="U001">22000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="c20221231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact_6519cd2b2a4f4aee8de97e8d79e88cd2"
      unitRef="U001">629969000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="c20221231_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="-3"
      id="Fact_3a763d31fde7403caef02501eb321a28"
      unitRef="U001">-478017000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="c20221231"
      decimals="-3"
      id="Fact_864f2c932dd54fb0b486cc4ea8361125"
      unitRef="U001">151974000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="c20230101to20231231_StatementEquityComponentsAxis_CommonStockMember"
      decimals="-3"
      id="Fact_e4d26de2092c4352af5ca5fbee71cf32"
      unitRef="U001">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="c20230101to20231231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact_c47351a2a2a84f19a71664238a2821ac"
      unitRef="U001">6187000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="c20230101to20231231_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="-3"
      id="Fact_de7893fcafa44c3aa8e0e11df4153aaa"
      unitRef="U001">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="c20230101to20231231"
      decimals="-3"
      id="Fact_98d9b22c1ebe422eafb5241be203c81a"
      unitRef="U001">6187000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <adma:VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesShares
      contextRef="c20230101to20231231_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_64cd0442c54e4b9283b6330d6869d260"
      unitRef="U002">833722</adma:VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesShares>
    <adma:VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAmount
      contextRef="c20230101to20231231_StatementEquityComponentsAxis_CommonStockMember"
      decimals="-3"
      id="Fact_adca6f7468234f1ca00a795d3adfe434"
      unitRef="U001">0</adma:VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAmount>
    <adma:VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAmount
      contextRef="c20230101to20231231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact_1887487de75745c08c154c38c6705721"
      unitRef="U001">1415000</adma:VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAmount>
    <adma:VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAmount
      contextRef="c20230101to20231231_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="-3"
      id="Fact_9966989d5dc44ce7a6d96d519ddd7d14"
      unitRef="U001">0</adma:VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAmount>
    <adma:VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAmount
      contextRef="c20230101to20231231"
      decimals="-3"
      id="Fact_ecf0462edcf74bc5a93289fd782b3284"
      unitRef="U001">1415000</adma:VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAmount>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="c20230101to20231231_StatementEquityComponentsAxis_CommonStockMember"
      decimals="-3"
      id="Fact_f925ae0589064a0b8ab00ce2b494ac8d"
      unitRef="U001">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="c20230101to20231231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact_27735ccc3ad44011a90c14eb6ef95c5b"
      unitRef="U001">5595000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="c20230101to20231231_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="-3"
      id="Fact_f7395889fcc041de99ff96c09f259f33"
      unitRef="U001">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="c20230101to20231231"
      decimals="-3"
      id="Fact_1bfddcd0201c4fc0a3f3d635a9873b9e"
      unitRef="U001">5595000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="c20230101to20231231_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_d17414a6cdf1424994b4c1b8233093ac"
      unitRef="U002">1444533</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="c20230101to20231231_StatementEquityComponentsAxis_CommonStockMember"
      decimals="-3"
      id="Fact_fb2a84df4c604074898e0f75e4c88563"
      unitRef="U001">1000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="c20230101to20231231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact_4e692b54297c496e9a2b63744ccb2637"
      unitRef="U001">1103000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="c20230101to20231231_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="-3"
      id="Fact_a8f7612556de40798a70f02742e27b48"
      unitRef="U001">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="c20230101to20231231"
      decimals="-3"
      id="Fact_28fcb77983524cde8f70183d12cd61a7"
      unitRef="U001">1104000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <adma:StockIssuedDuringPeriodSharesCashlessExerciseOfWarrants
      contextRef="c20230101to20231231_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_0459c87db28a445f8d2cbb38f9cffa3f"
      unitRef="U002">1967847</adma:StockIssuedDuringPeriodSharesCashlessExerciseOfWarrants>
    <adma:StockIssuedDuringPeriodValueCashlessExerciseOfWarrants
      contextRef="c20230101to20231231_StatementEquityComponentsAxis_CommonStockMember"
      decimals="-3"
      id="Fact_aefc6574de174857af69e809db06d8af"
      unitRef="U001">0</adma:StockIssuedDuringPeriodValueCashlessExerciseOfWarrants>
    <adma:StockIssuedDuringPeriodValueCashlessExerciseOfWarrants
      contextRef="c20230101to20231231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact_5f55198aa5d24661b9b129dba4611ce5"
      unitRef="U001">0</adma:StockIssuedDuringPeriodValueCashlessExerciseOfWarrants>
    <adma:StockIssuedDuringPeriodValueCashlessExerciseOfWarrants
      contextRef="c20230101to20231231_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="-3"
      id="Fact_b5348b2e54b3489689f99511d9783141"
      unitRef="U001">0</adma:StockIssuedDuringPeriodValueCashlessExerciseOfWarrants>
    <adma:StockIssuedDuringPeriodValueCashlessExerciseOfWarrants
      contextRef="c20230101to20231231"
      decimals="-3"
      id="Fact_01c84a664db443328e25e1ffd801cea0"
      unitRef="U001">0</adma:StockIssuedDuringPeriodValueCashlessExerciseOfWarrants>
    <us-gaap:NetIncomeLoss
      contextRef="c20230101to20231231_StatementEquityComponentsAxis_CommonStockMember"
      decimals="-3"
      id="Fact_6f1bf817e5f949d5909106dfde579061"
      unitRef="U001">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="c20230101to20231231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact_cbbceeef04404058955f32041dcc12a3"
      unitRef="U001">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="c20230101to20231231_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="-3"
      id="Fact_6208c2b9df744597bf9a2a7ec00ceb9f"
      unitRef="U001">-28239000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="c20230101to20231231"
      decimals="-3"
      id="Fact_13cf9f64ba99421db4f4b6c46aa1465d"
      unitRef="U001">-28239000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="c20231231_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_c50cbb1c86b044a1a984cc8af0e8ad9e"
      unitRef="U002">226063032</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="c20231231_StatementEquityComponentsAxis_CommonStockMember"
      decimals="-3"
      id="Fact_be652c6f05174ee381a179c2ca94e472"
      unitRef="U001">23000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="c20231231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact_8612862bf7214c3d8aafc64adf6f499a"
      unitRef="U001">641439000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="c20231231_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="-3"
      id="Fact_b962a1851cbf442a9881d54916a37832"
      unitRef="U001">-506256000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="c20231231"
      decimals="-3"
      id="Fact_dbe1fd332b1b4d84b05cc863a2442f11"
      unitRef="U001">135206000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="c20240101to20241231_StatementEquityComponentsAxis_CommonStockMember"
      decimals="-3"
      id="Fact_abffced7c2a44828b6859688847abca6"
      unitRef="U001">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="c20240101to20241231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact_d9b7e4b9a9c145468de1b12d92859415"
      unitRef="U001">13616000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="c20240101to20241231_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="-3"
      id="Fact_a3023bf8c83446b4bd2e5532b64899f7"
      unitRef="U001">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="c20240101to20241231"
      decimals="-3"
      id="Fact_3134a85fb61e4610bf14af92f2e09dd1"
      unitRef="U001">13616000</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <adma:VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesShares
      contextRef="c20240101to20241231_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_c6e047b2ce1c445680e2c36e652724cf"
      unitRef="U002">1344555</adma:VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesShares>
    <adma:VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAmount
      contextRef="c20240101to20241231_StatementEquityComponentsAxis_CommonStockMember"
      decimals="-3"
      id="Fact_88252ace49064803ad5cebbfad6c87da"
      unitRef="U001">0</adma:VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAmount>
    <adma:VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAmount
      contextRef="c20240101to20241231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact_59e5094aac854376933b175bde228318"
      unitRef="U001">4971000</adma:VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAmount>
    <adma:VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAmount
      contextRef="c20240101to20241231_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="-3"
      id="Fact_cbd605074d0b4665be7b44583616b9b2"
      unitRef="U001">0</adma:VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAmount>
    <adma:VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAmount
      contextRef="c20240101to20241231"
      decimals="-3"
      id="Fact_7af6ddf84a9f44cd82ed37f112e52bfd"
      unitRef="U001">4971000</adma:VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAmount>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="c20240101to20241231_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_4bfb828c541f4ddd9fc1bb5ec55b32e0"
      unitRef="U002">1988066</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="c20240101to20241231_StatementEquityComponentsAxis_CommonStockMember"
      decimals="-3"
      id="Fact_15f632ff75c040c1b988ea2f1affbaec"
      unitRef="U001">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="c20240101to20241231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact_8997f7944ec5488384e08cffb5873cd9"
      unitRef="U001">7494000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="c20240101to20241231"
      decimals="-3"
      id="Fact_b5a2a622241d4ec9b151031cfd75506a"
      unitRef="U001">7494000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <adma:StockIssuedDuringPeriodSharesCashlessExerciseOfWarrants
      contextRef="c20240101to20241231_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_eaaefe130c804edba8db604e7f353995"
      unitRef="U002">7224892</adma:StockIssuedDuringPeriodSharesCashlessExerciseOfWarrants>
    <adma:StockIssuedDuringPeriodValueCashlessExerciseOfWarrants
      contextRef="c20240101to20241231_StatementEquityComponentsAxis_CommonStockMember"
      decimals="-3"
      id="Fact_63eff24008de4c1faaba83a1b07d56f9"
      unitRef="U001">1000</adma:StockIssuedDuringPeriodValueCashlessExerciseOfWarrants>
    <adma:StockIssuedDuringPeriodValueCashlessExerciseOfWarrants
      contextRef="c20240101to20241231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact_97177ce4d3f94af69d193b2512db9b2e"
      unitRef="U001">-1000</adma:StockIssuedDuringPeriodValueCashlessExerciseOfWarrants>
    <adma:StockIssuedDuringPeriodValueCashlessExerciseOfWarrants
      contextRef="c20240101to20241231_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="-3"
      id="Fact_244fa1eb3f68481a960f093c5485f28f"
      unitRef="U001">0</adma:StockIssuedDuringPeriodValueCashlessExerciseOfWarrants>
    <adma:StockIssuedDuringPeriodValueCashlessExerciseOfWarrants
      contextRef="c20240101to20241231"
      decimals="-3"
      id="Fact_a28cfe11b9114f2ea1eeebc38256c355"
      unitRef="U001">0</adma:StockIssuedDuringPeriodValueCashlessExerciseOfWarrants>
    <us-gaap:NetIncomeLoss
      contextRef="c20240101to20241231_StatementEquityComponentsAxis_CommonStockMember"
      decimals="-3"
      id="Fact_e2108b9c1a764cbca2eb7f6da506193a"
      unitRef="U001">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="c20240101to20241231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact_a08ee1f791b14cb6a0f06d0b3d2bf248"
      unitRef="U001">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="c20240101to20241231_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="-3"
      id="Fact_571869f9b4864a46b21adea2d67fe833"
      unitRef="U001">197673000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="c20240101to20241231"
      decimals="-3"
      id="Fact_4c79d811eebf453e8501cb13f7e8d445"
      unitRef="U001">197673000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="c20241231_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_cb279aec97b74557941910e742aefeee"
      unitRef="U002">236620545</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="c20241231_StatementEquityComponentsAxis_CommonStockMember"
      decimals="-3"
      id="Fact_50a83989754d4837864af02b9c61786e"
      unitRef="U001">24000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="c20241231_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="Fact_16416af1ae4a4f58b21626dac535b978"
      unitRef="U001">657577000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="c20241231_StatementEquityComponentsAxis_RetainedEarningsMember"
      decimals="-3"
      id="Fact_30ef5ca48da941638393a202eec8ab10"
      unitRef="U001">-308583000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="c20241231"
      decimals="-3"
      id="Fact_db999768439f48b28be28cb5f7ab92b8"
      unitRef="U001">349018000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="c20240101to20241231"
      decimals="-3"
      id="Fact_1e982170e59245dabe35456dd64ff7ce"
      unitRef="U001">197673000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="c20230101to20231231"
      decimals="-3"
      id="Fact_4dab74ee418a4a99b02f040f0b4d712e"
      unitRef="U001">-28239000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="c20220101to20221231"
      decimals="-3"
      id="Fact_bafd7c280cdc4f0b96f97caca73aa117"
      unitRef="U001">-65904000</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationAndAmortization
      contextRef="c20240101to20241231"
      decimals="-3"
      id="Fact_48aab7d322c34d20bd96d9802f13248a"
      unitRef="U001">8045000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="c20230101to20231231"
      decimals="-3"
      id="Fact_8851c9b949a146e99698c22918149f46"
      unitRef="U001">8332000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="c20220101to20221231"
      decimals="-3"
      id="Fact_50e0f60ba1ad40eb895452ff243c0758"
      unitRef="U001">7113000</us-gaap:DepreciationAndAmortization>
    <us-gaap:GainLossOnDispositionOfAssets
      contextRef="c20240101to20241231"
      decimals="-3"
      id="Fact_4da852e24d484dd8b874fa68ad27ac1d"
      unitRef="U001">-106000</us-gaap:GainLossOnDispositionOfAssets>
    <us-gaap:GainLossOnDispositionOfAssets
      contextRef="c20230101to20231231"
      decimals="-3"
      id="Fact_3b26b89eb1734833b964cc41375c61c4"
      unitRef="U001">-182000</us-gaap:GainLossOnDispositionOfAssets>
    <us-gaap:GainLossOnDispositionOfAssets
      contextRef="c20220101to20221231"
      decimals="-3"
      id="Fact_600eff9fadbc4dea95954adc4a352213"
      unitRef="U001">-427000</us-gaap:GainLossOnDispositionOfAssets>
    <us-gaap:IncreaseDecreaseInDeferredIncomeTaxes
      contextRef="c20240101to20241231"
      decimals="-3"
      id="Fact_e886223760354677a5fca3760075efc6"
      unitRef="U001">84280000</us-gaap:IncreaseDecreaseInDeferredIncomeTaxes>
    <us-gaap:IncreaseDecreaseInDeferredIncomeTaxes
      contextRef="c20230101to20231231"
      decimals="-3"
      id="Fact_ee5358e49e7a43a99457f613041986c0"
      unitRef="U001">0</us-gaap:IncreaseDecreaseInDeferredIncomeTaxes>
    <us-gaap:IncreaseDecreaseInDeferredIncomeTaxes
      contextRef="c20220101to20221231"
      decimals="-3"
      id="Fact_737fec08a55f499fbb30ee76e358db29"
      unitRef="U001">0</us-gaap:IncreaseDecreaseInDeferredIncomeTaxes>
    <us-gaap:PaidInKindInterest
      contextRef="c20240101to20241231"
      decimals="-3"
      id="Fact_1bafda83913741b9894c3d320dd56d4f"
      unitRef="U001">0</us-gaap:PaidInKindInterest>
    <us-gaap:PaidInKindInterest
      contextRef="c20230101to20231231"
      decimals="-3"
      id="Fact_30f420b58d4d4e3a840f7f745fede7e1"
      unitRef="U001">3836000</us-gaap:PaidInKindInterest>
    <us-gaap:PaidInKindInterest
      contextRef="c20220101to20221231"
      decimals="-3"
      id="Fact_c20a5f49341e48588f54dd2dbc6a8f00"
      unitRef="U001">2998000</us-gaap:PaidInKindInterest>
    <us-gaap:ShareBasedCompensation
      contextRef="c20240101to20241231"
      decimals="-3"
      id="Fact_c1456b495c884804b49bfe8092e9c0f8"
      unitRef="U001">13616000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="c20230101to20231231"
      decimals="-3"
      id="Fact_8320ddaff4cf4bbc8c1cf55b1e3eba5c"
      unitRef="U001">6187000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="c20220101to20221231"
      decimals="-3"
      id="Fact_1548d1e168814e1fb7a8eaf1d624f4b5"
      unitRef="U001">5215000</us-gaap:ShareBasedCompensation>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="c20240101to20241231"
      decimals="-3"
      id="Fact_83896ecd612a482a9e5e4ece331de76d"
      unitRef="U001">951000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="c20230101to20231231"
      decimals="-3"
      id="Fact_c86fc82f0d40469dad9a2888cb3eb759"
      unitRef="U001">2594000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="c20220101to20221231"
      decimals="-3"
      id="Fact_854de1c510b94cfbb44f58085045db49"
      unitRef="U001">2402000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="c20240101to20241231"
      decimals="-3"
      id="Fact_f67927914b48491e9aa063e57868178d"
      unitRef="U001">-1243000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="c20230101to20231231"
      decimals="-3"
      id="Fact_c20be1fc061d44e694222827e3493f06"
      unitRef="U001">-26174000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="c20220101to20221231"
      decimals="-3"
      id="Fact_bd928a1efb824f32b8c0867848ad8da8"
      unitRef="U001">-6670000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <adma:AmortizationOfLicenseRevenue
      contextRef="c20240101to20241231"
      decimals="-3"
      id="Fact_f0fe00b8757c46c08e0fa6083b117573"
      unitRef="U001">-143000</adma:AmortizationOfLicenseRevenue>
    <adma:AmortizationOfLicenseRevenue
      contextRef="c20230101to20231231"
      decimals="-3"
      id="Fact_60199c8cb254441d8d336796b3903ea3"
      unitRef="U001">-143000</adma:AmortizationOfLicenseRevenue>
    <adma:AmortizationOfLicenseRevenue
      contextRef="c20220101to20221231"
      decimals="-3"
      id="Fact_93ce053fc4064893af499841ee1b39f2"
      unitRef="U001">-143000</adma:AmortizationOfLicenseRevenue>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="c20240101to20241231"
      decimals="-3"
      id="Fact_04fb81e0e6274dce908dd36d3114ad12"
      unitRef="U001">22578000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="c20230101to20231231"
      decimals="-3"
      id="Fact_e4a0e1f108844c3087eb8e26bdfd94c0"
      unitRef="U001">11916000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="c20220101to20221231"
      decimals="-3"
      id="Fact_46c1ecae59c24d218296e1b9c4ec1fea"
      unitRef="U001">-13072000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="c20240101to20241231"
      decimals="-3"
      id="Fact_e7cf5e4641bc45af870c12fb278516d7"
      unitRef="U001">-2671000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="c20230101to20231231"
      decimals="-3"
      id="Fact_e53bbe123b194eb3aa18f5606807377d"
      unitRef="U001">9626000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="c20220101to20221231"
      decimals="-3"
      id="Fact_696c3813ea984938b7b4812165ebe8d4"
      unitRef="U001">38556000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="c20240101to20241231"
      decimals="-3"
      id="Fact_c662b0469907430e959c7b4b0f21c88d"
      unitRef="U001">2695000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="c20230101to20231231"
      decimals="-3"
      id="Fact_9eb1a95a32cb4140af0dc16f1b9b612a"
      unitRef="U001">239000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="c20220101to20221231"
      decimals="-3"
      id="Fact_82af8b5ff070491e8257c0d549710be4"
      unitRef="U001">756000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <adma:IncreaseDecreaseInDepositsAndOtherAssets
      contextRef="c20240101to20241231"
      decimals="-3"
      id="Fact_d8a8adabe5094e459f17ea01449c70d7"
      unitRef="U001">-15000</adma:IncreaseDecreaseInDepositsAndOtherAssets>
    <adma:IncreaseDecreaseInDepositsAndOtherAssets
      contextRef="c20230101to20231231"
      decimals="-3"
      id="Fact_02b855e13667495cb128769a18a834d7"
      unitRef="U001">-1080000</adma:IncreaseDecreaseInDepositsAndOtherAssets>
    <adma:IncreaseDecreaseInDepositsAndOtherAssets
      contextRef="c20220101to20221231"
      decimals="-3"
      id="Fact_e3cd7802bf4a48d997158eae7d4f067c"
      unitRef="U001">-122000</adma:IncreaseDecreaseInDepositsAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="c20240101to20241231"
      decimals="-3"
      id="Fact_d8ebd70a203845e896e21b7e332bb9e2"
      unitRef="U001">4150000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="c20230101to20231231"
      decimals="-3"
      id="Fact_1f545f8f2cdd4b38a7f3305d867169a8"
      unitRef="U001">3839000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="c20220101to20221231"
      decimals="-3"
      id="Fact_f0046a7804044f4c8e3021a6e6df4e0a"
      unitRef="U001">800000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="c20240101to20241231"
      decimals="-3"
      id="Fact_69847d4661a848fd88d5eb5878b1ca90"
      unitRef="U001">1042000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="c20230101to20231231"
      decimals="-3"
      id="Fact_9a569cc34bc04c90971ff3e84ee5c7a9"
      unitRef="U001">7530000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="c20220101to20221231"
      decimals="-3"
      id="Fact_354be84296884a869e515478e678e9fa"
      unitRef="U001">7534000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities
      contextRef="c20240101to20241231"
      decimals="-3"
      id="Fact_4f3b1e89ec5f400da9ca494def09052c"
      unitRef="U001">-1144000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities
      contextRef="c20230101to20231231"
      decimals="-3"
      id="Fact_eb2949933541432c8b63e21187b3409e"
      unitRef="U001">-791000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities
      contextRef="c20220101to20221231"
      decimals="-3"
      id="Fact_6c55065b50174b10bcd0c55be8a37bab"
      unitRef="U001">-502000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="c20240101to20241231"
      decimals="-3"
      id="Fact_6cad2392826444ce85e31b8c8896fcf9"
      unitRef="U001">118672000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="c20230101to20231231"
      decimals="-3"
      id="Fact_f704cb8ae12947a08d164df6022c107c"
      unitRef="U001">8800000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="c20220101to20221231"
      decimals="-3"
      id="Fact_cb962bcbf8094179b698e74d7aa764bc"
      unitRef="U001">-59508000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="c20240101to20241231"
      decimals="-3"
      id="Fact_6abf001b5532488299b7d3ccebce13be"
      unitRef="U001">8226000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="c20230101to20231231"
      decimals="-3"
      id="Fact_fe6b1d83c3fa43b7a821dbd468d22f0e"
      unitRef="U001">4771000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="c20220101to20221231"
      decimals="-3"
      id="Fact_2a7b8b67379340728b1100d95c7d06c6"
      unitRef="U001">13911000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="c20240101to20241231"
      decimals="-3"
      id="Fact_bf2276a47e8c4ebeafeb890ddf6a963d"
      unitRef="U001">349000</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="c20230101to20231231"
      decimals="-3"
      id="Fact_bdacd63424c4493884a956c4ef2b89b0"
      unitRef="U001">210000</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="c20220101to20221231"
      decimals="-3"
      id="Fact_bdfef01d52534d5ba716e3ea3f56a6f1"
      unitRef="U001">0</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="c20240101to20241231"
      decimals="-3"
      id="Fact_ac7f86b39caa44bd959cd8dc70acd72c"
      unitRef="U001">-8575000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="c20230101to20231231"
      decimals="-3"
      id="Fact_f7a51116283f49caa2038cda74415fec"
      unitRef="U001">-4981000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="c20220101to20221231"
      decimals="-3"
      id="Fact_56a0b20d5170410ca782b52082995c99"
      unitRef="U001">-13911000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:RepaymentsOfNotesPayable
      contextRef="c20240101to20241231"
      decimals="-3"
      id="Fact_364b022883ef46828e0534c35447a69a"
      unitRef="U001">60000000</us-gaap:RepaymentsOfNotesPayable>
    <us-gaap:RepaymentsOfNotesPayable
      contextRef="c20230101to20231231"
      decimals="-3"
      id="Fact_a6840b4dab694e7f8a989fee88640a50"
      unitRef="U001">158584000</us-gaap:RepaymentsOfNotesPayable>
    <us-gaap:RepaymentsOfNotesPayable
      contextRef="c20220101to20221231"
      decimals="-3"
      id="Fact_61376d9fb5ce4451ae5d209729c2356c"
      unitRef="U001">100000000</us-gaap:RepaymentsOfNotesPayable>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="c20240101to20241231"
      decimals="-3"
      id="Fact_38eb9b07eeae4ab784fb39b386c4703b"
      unitRef="U001">0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="c20230101to20231231"
      decimals="-3"
      id="Fact_414099d5f3b24dc4b410d81cb4822ec5"
      unitRef="U001">0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="c20220101to20221231"
      decimals="-3"
      id="Fact_a554f1b0e0444d42867329005248bd55"
      unitRef="U001">64645000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <adma:PaymentOfDebtRefinancingFees
      contextRef="c20240101to20241231"
      decimals="-3"
      id="Fact_aca301fa4fcb45208de42cbb0ae0a543"
      unitRef="U001">450000</adma:PaymentOfDebtRefinancingFees>
    <adma:PaymentOfDebtRefinancingFees
      contextRef="c20230101to20231231"
      decimals="-3"
      id="Fact_1282ee9fa6af4ac395c9211a7175e2e1"
      unitRef="U001">11140000</adma:PaymentOfDebtRefinancingFees>
    <adma:PaymentOfDebtRefinancingFees
      contextRef="c20220101to20221231"
      decimals="-3"
      id="Fact_bcd173c6f8d84d399c842a73abae4750"
      unitRef="U001">2000000</adma:PaymentOfDebtRefinancingFees>
    <us-gaap:ProceedsFromNotesPayable
      contextRef="c20240101to20241231"
      decimals="-3"
      id="Fact_b6b11e3e07894e3989a64c5cc40ae9d7"
      unitRef="U001">0</us-gaap:ProceedsFromNotesPayable>
    <us-gaap:ProceedsFromNotesPayable
      contextRef="c20230101to20231231"
      decimals="-3"
      id="Fact_40d3694266624e35b2913a8847481059"
      unitRef="U001">135000000</us-gaap:ProceedsFromNotesPayable>
    <us-gaap:ProceedsFromNotesPayable
      contextRef="c20220101to20221231"
      decimals="-3"
      id="Fact_ca04129c096b491b940347184e402de3"
      unitRef="U001">151750000</us-gaap:ProceedsFromNotesPayable>
    <adma:TaxesPaidOnVestedRestrictedStockUnits
      contextRef="c20240101to20241231"
      decimals="-3"
      id="Fact_565d503174ed4445900bf7a975e5f5a2"
      unitRef="U001">4971000</adma:TaxesPaidOnVestedRestrictedStockUnits>
    <adma:TaxesPaidOnVestedRestrictedStockUnits
      contextRef="c20230101to20231231"
      decimals="-3"
      id="Fact_1d8ee1ce932645c0a013907689f8004a"
      unitRef="U001">1415000</adma:TaxesPaidOnVestedRestrictedStockUnits>
    <adma:TaxesPaidOnVestedRestrictedStockUnits
      contextRef="c20220101to20221231"
      decimals="-3"
      id="Fact_dc8de57eff954f658914b4e23311901d"
      unitRef="U001">2899000</adma:TaxesPaidOnVestedRestrictedStockUnits>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="c20240101to20241231"
      decimals="-3"
      id="Fact_dba53f2ea537473d81f35a0ee9aba9fc"
      unitRef="U001">0</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="c20230101to20231231"
      decimals="-3"
      id="Fact_a99d6ae8351546fa99b5969ac5b329e9"
      unitRef="U001">17000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="c20220101to20221231"
      decimals="-3"
      id="Fact_190f85e762d84d4c97af77713957c3f7"
      unitRef="U001">36000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="c20240101to20241231"
      decimals="-3"
      id="Fact_462eb58d67364e309b90fd056393c990"
      unitRef="U001">7494000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="c20230101to20231231"
      decimals="-3"
      id="Fact_6492be3a19d54a1dbf35dcd4257411a8"
      unitRef="U001">1104000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="c20220101to20221231"
      decimals="-3"
      id="Fact_abe2c49bf26e466ab11110cd5dcf86c4"
      unitRef="U001">175000</us-gaap:ProceedsFromStockOptionsExercised>
    <adma:PaymentOfEndOfTermFee
      contextRef="c20240101to20241231"
      decimals="-3"
      id="Fact_785546c6344542f591f943f775446721"
      unitRef="U001">375000</adma:PaymentOfEndOfTermFee>
    <adma:PaymentOfEndOfTermFee
      contextRef="c20230101to20231231"
      decimals="-3"
      id="Fact_fc5cdbc5a4884427a562ddec49f06c27"
      unitRef="U001">1586000</adma:PaymentOfEndOfTermFee>
    <adma:PaymentOfEndOfTermFee
      contextRef="c20220101to20221231"
      decimals="-3"
      id="Fact_9be6f73500624ae8876a00999ef056dd"
      unitRef="U001">0</adma:PaymentOfEndOfTermFee>
    <us-gaap:PaymentsOfFinancingCosts
      contextRef="c20240101to20241231"
      decimals="-3"
      id="Fact_335b0edd2478421b9cf63abb40edeb9b"
      unitRef="U001">0</us-gaap:PaymentsOfFinancingCosts>
    <us-gaap:PaymentsOfFinancingCosts
      contextRef="c20230101to20231231"
      decimals="-3"
      id="Fact_34a9c1887fce4c609c0f7e130f1d98b9"
      unitRef="U001">2351000</us-gaap:PaymentsOfFinancingCosts>
    <us-gaap:PaymentsOfFinancingCosts
      contextRef="c20220101to20221231"
      decimals="-3"
      id="Fact_be16c95103b64f70961b109417f39f0e"
      unitRef="U001">2783000</us-gaap:PaymentsOfFinancingCosts>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="c20240101to20241231"
      decimals="-3"
      id="Fact_a00311f2fc384f59863011980c10251a"
      unitRef="U001">-58302000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="c20230101to20231231"
      decimals="-3"
      id="Fact_f04b16306a204fdb8a3e075dbe55d84b"
      unitRef="U001">-38989000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="c20220101to20221231"
      decimals="-3"
      id="Fact_8aa9bb01d3ee4f0eb0ce34a4957493c0"
      unitRef="U001">108852000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="c20240101to20241231"
      decimals="-3"
      id="Fact_b6eedd3f6bd740c1a4105460c0141845"
      unitRef="U001">51795000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="c20230101to20231231"
      decimals="-3"
      id="Fact_9aaf34310e8540c58f1ca4e78ef8b892"
      unitRef="U001">-35170000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="c20220101to20221231"
      decimals="-3"
      id="Fact_d1bed04c4196465e9feec2e77c31c347"
      unitRef="U001">35433000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="c20231231"
      decimals="-3"
      id="Fact_87e8086a42f74fe497fe93492567be5d"
      unitRef="U001">51352000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="c20221231"
      decimals="-3"
      id="Fact_18a04f61a60541a3bc4dcaf1d930dd30"
      unitRef="U001">86522000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="c20211231"
      decimals="-3"
      id="Fact_33f22b16561c4f16a6f004b2f03238ea"
      unitRef="U001">51089000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="c20241231"
      decimals="-3"
      id="Fact_a1dac8c7935a4c5fac7a44c0abb65547"
      unitRef="U001">103147000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="c20231231"
      decimals="-3"
      id="Fact_5ea6f406df8845689101d89ae70ecaea"
      unitRef="U001">51352000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="c20221231"
      decimals="-3"
      id="Fact_9e603a16150443abbb8de73eed3f81bd"
      unitRef="U001">86522000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock
      contextRef="c20240101to20241231"
      id="Text_bc8b2ab4f01b481a8021ac1c87a4e540">
&lt;div&gt;
          &lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt; border-spacing: 0;"&gt;


  &lt;tr style="vertical-align: top;"&gt;

    &lt;td style="vertical-align: top; width: 27pt;"&gt;
                  &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: left;"&gt;&lt;strong&gt;1.&lt;/strong&gt;&lt;/p&gt;
                &lt;/td&gt;

    &lt;td style="align: left; vertical-align: top; width: auto;"&gt;
                  &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: left;"&gt;&lt;strong&gt;&lt;span style="text-decoration: underline;"&gt;ORGANIZATION AND BUSINESS&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;
                &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
        &lt;/div&gt;

&lt;div&gt;&lt;br/&gt;&lt;/div&gt;
&lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-indent: 45px; text-align: left;"&gt;ADMA Biologics, Inc. (&#x201c;ADMA&#x201d; or the &#x201c;Company&#x201d;) is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing
          and developing specialty biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The Company&#x2019;s targeted patient populations include immune-compromised individuals who
          suffer from an underlying immune deficiency disorder or who may be immune-suppressed for medical reasons.&lt;/p&gt;&lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-indent: 45px; text-align: left;"&gt;&lt;br/&gt;
        &lt;/p&gt;&lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-indent: 45px; text-align: left;"&gt;ADMA operates through its wholly-owned subsidiaries ADMA BioManufacturing, LLC (&#x201c;ADMA BioManufacturing&#x201d;) and ADMA BioCenters Georgia Inc.
          (&#x201c;ADMA BioCenters&#x201d;). ADMA BioManufacturing was formed in January 2017 to facilitate the acquisition of certain assets held by the Company&#x2019;s former third-party contract manufacturer, which included the U.S. Food and Drug Administration
          (&#x201c;FDA&#x201d;)-licensed BIVIGAM and Nabi-HB immunoglobulin products, and an FDA-licensed plasma fractionation manufacturing facility located in Boca Raton, FL (the &#x201c;Boca Facility&#x201d;). ADMA BioCenters is the Company&#x2019;s source plasma collection business with
          ten plasma collection facilities located throughout the U.S., all of which hold an approved license with the FDA.&lt;/p&gt;&lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-indent: 45px; text-align: left;"&gt;&lt;br/&gt;
        &lt;/p&gt;&lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-indent: 45px; text-align: left;"&gt;The Company has three
          FDA-approved products, all of which are currently marketed and commercially available: (i) &lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: left; text-indent: 45px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;ASCENIV (Immune Globulin Intravenous, Human &#x2013; slra 10% Liquid), an intravenous immune globulin (&#x201c;IVIG&#x201d;) product indicated for the treatment of Primary Humoral Immunodeficiency (&#x201c;PI&#x201d;), also known as Primary
            Immunodeficiency Disease (&#x201c;PIDD&#x201d;) or Inborn Errors of Immunity, for which the Company received FDA approval on April 1, 2019 and commenced first commercial sales in October 2019; (ii) BIVIGAM (Immune Globulin Intravenous, Human), an IVIG
            product indicated for the treatment of PI, and for which the Company received FDA approval on May 9, 2019 and commenced commercial sales in August 2019;&#160; and (iii) Nabi-HB (Hepatitis B Immune Globulin, Human), which is indicated for the
            treatment of acute exposure to blood containing Hepatitis B surface antigen (&#x201c;HBsAg&#x201d;) and other listed exposures to Hepatitis B. In addition to its commercially available immunoglobulin products, the Company generates revenues from the sale of
            intermediate by-products that result from the immunoglobulin production process and from time to time provides contract manufacturing and laboratory services for certain clients. The Company seeks to develop a pipeline of plasma-derived
            therapeutics, and its products and product candidates are intended to be used by physician specialists focused on caring for immune-compromised patients with or at risk for certain infectious diseases&lt;/span&gt;.&lt;/p&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <adma:NumberOfFDALicensedPlasmaCollectionFacilities
      contextRef="c20240101to20241231"
      decimals="INF"
      id="Fact_47d59e153b5b4569b8bbc893e294a40f"
      unitRef="U004">10</adma:NumberOfFDALicensedPlasmaCollectionFacilities>
    <adma:NumberOfFDAApprovedProduct
      contextRef="c20240101to20241231"
      decimals="INF"
      id="Fact_92b435a310ae4071b48979b882fbf4b0"
      unitRef="U005">3</adma:NumberOfFDAApprovedProduct>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="c20240101to20241231"
      id="Text_f55c9b9ba1a3493492e762fba0f4466c">
&lt;div&gt;
          &lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt; border-spacing: 0;"&gt;


  &lt;tr style="vertical-align: top;"&gt;

    &lt;td style="vertical-align: top; width: 27pt;"&gt;
                  &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;"&gt;&lt;strong&gt;2.&lt;/strong&gt;&lt;/p&gt;
                &lt;/td&gt;

    &lt;td style="align: left; vertical-align: top; width: auto;"&gt;
                  &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;"&gt;&lt;strong&gt;&lt;span style="text-decoration: underline;"&gt;SIGNIFICANT ACCOUNTING POLICIES&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;
                &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
        &lt;/div&gt;
&lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;"&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
          &lt;/span&gt; &lt;/p&gt;&lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;"&gt;&lt;span style="text-decoration:underline"&gt;Principles of consolidation and basis of presentation&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;"&gt;&#160;&lt;/p&gt;&lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-indent: 45px; text-align: left;"&gt;The accompanying consolidated financial statements include the accounts of ADMA and its wholly-owned subsidiaries and have been prepared
          in conformity with accounting principles generally accepted in the United States of America (&#x201c;U.S. GAAP&#x201d;) and in accordance with Article 3 of Regulation S-X of the Securities and Exchange Commission (the &#x201c;SEC&#x201d;). All intercompany balances have
          been eliminated in consolidation. Any reference in these notes to applicable guidance is meant to refer to U.S. GAAP as found in the Accounting Standards Codification (&#x201c;ASC&#x201d;) and Accounting Standards Updates (&#x201c;ASU&#x201d;) of the Financial Accounting
          Standards Board (the &#x201c;FASB&#x201d;). &lt;/p&gt;&lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-indent: 45px; text-align: left;"&gt; &lt;span style="font-size: 10pt; font-family: 'Times New Roman';"&gt;&lt;br/&gt;
          &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-indent: 45px; text-align: left;"&gt;During the years ended December 31, 2024, 2023 and 2022, &lt;span style="font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;comprehensive income (loss) was equal to the net income (loss) amounts presented for the respective periods in the accompanying consolidated statements of operations.&#160;&lt;/span&gt;&lt;span style="font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial;"&gt;In addition, certain prior year balances have been reclassified to conform to the current presentation. Specifically, the disaggregation of some of the Company&#x2019;s accrued expenses and other current liabilities
            (see Note 6) and deferred tax assets and liabilities, as well as the rate reconciliation for U.S. federal income taxes (see Note 11), as of December 31, 2023 have been adjusted to conform to the presentation as of December 31, 2024&lt;/span&gt;.&lt;/p&gt;&lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-indent: 45px; text-align: left;"&gt; &lt;/p&gt;&lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;"&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
          &lt;/span&gt; &lt;/p&gt;
&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="text-decoration: underline;"&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
&lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 9pt; text-indent: -9pt; text-align: left;"&gt;&lt;span style="text-decoration: underline;"&gt;Use of estimates&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 9pt; text-indent: -9pt; text-align: left;"&gt; &lt;span style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
          &lt;/span&gt; &lt;/p&gt;&lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-indent: 45px; text-align: left;"&gt;The preparation of financial statements requires management to make estimates and assumptions that affect the reported amounts of assets
          and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.
          Significant estimates include rebates and chargebacks deducted from gross revenues, assumptions used in the fair value of awards granted under the Company&#x2019;s equity incentive plans and the valuation allowance for the Company&#x2019;s deferred tax assets.&lt;/p&gt;&lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-indent: 45px; text-align: left;"&gt;&lt;span style="font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt; &lt;br/&gt;
          &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-indent: 45px; text-align: left; font-weight: normal; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; text-align: left; text-indent: 48px; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;The
            Company engaged a third-party specialist to assist in the evaluation of the Company&#x2019;s accrual for U.S. Medicaid rebates related to the sale of the Company&#x2019;s immunoglobulin products. As a result of this evaluation, the Company recognized a
            reduction in this accrual and a corresponding increase to net revenues of $12.6 million for the year ended December 31, 2024. The
            Company considered several qualitative factors when evaluating its rebate accrual, such as the absence of a statutory limitation on the rebate amounts drug manufacturers pay to state Medicaid programs and general uncertainty that pharmaceutical
            manufacturers have historically seen with government payors often submitting lagged claims many periods after the initial dispensing of a product to an end patient. There was additional new information that arose during June 2024 that suggested
            the Company&#x2019;s liabilities for certain payor claims were successfully resolved, which resulted in the $12.6 million adjustment to the
            accrual for U.S. Medicaid rebates in June 2024.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;"&gt;&#160;&lt;/p&gt;&lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;"&gt;&lt;span style="text-decoration:underline"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;"&gt;&#160;&lt;/p&gt;&lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-indent: 45px; text-align: left;"&gt;The Company considers all highly liquid instruments purchased with a maturity of three months or less to be cash equivalents. &lt;/p&gt;
&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
        &lt;/span&gt;&lt;/div&gt;
&lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-indent: 45px; text-align: left;"&gt;The Company regularly maintains cash and cash equivalents at third-party financial institutions in excess of the Federal Deposit Insurance
          Corporation insurance limit. Although the Company monitors the daily cash balances in its operating accounts and adjusts the balances as appropriate, these balances could be impacted, and there could be a material adverse effect on the Company&#x2019;s
          business, if one or more of the financial institutions with which the Company has deposits fails or is subject to other adverse conditions in the financial or credit markets. To date, the Company has not experienced a loss or lack of access to
          its deposited cash or cash equivalents; however, the Company cannot provide assurance that access to its cash and cash equivalents will not be impacted by adverse conditions in the financial and credit markets in the future.&lt;/p&gt;&lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;"&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
          &lt;/span&gt; &lt;/p&gt;&lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;"&gt;&lt;span style="text-decoration:underline"&gt;Accounts receivable&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;"&gt;&#160;&lt;/p&gt;&lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-indent: 45px; text-align: left;"&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;Accounts receivable is reported at realizable value, net of allowances for
            contractual credits and doubtful accounts in the amount of $0.2 million and $0.1 million at December 31, 2024 and 2023, respectively, which are recognized in the period the related revenue is recorded. The Company extends credit to its customers
            based upon an evaluation of each customer&#x2019;s financial condition and credit history. Evaluations of the financial condition and associated credit risk of customers are performed on an ongoing basis.&lt;br/&gt;
          &lt;/span&gt; &lt;/p&gt;&lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;"&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
          &lt;/span&gt; &lt;/p&gt;&lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;"&gt;&lt;span style="text-decoration:underline"&gt;Inventories&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;"&gt;&#160;&lt;/p&gt;&lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-indent: 45px; text-align: left;"&gt;Raw materials inventory consists of &lt;span style="font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;&lt;span style="font-weight: normal; font-style: normal; font-variant: normal; text-transform: none;"&gt;normal source plasma (&#x201c;NSP&#x201d;) and Respiratory Syncytial Virus (&#x201c;RSV&#x201d;) high titer plasma collected at the Company&#x2019;s plasma collection
              facilities or purchased from third parties, along with&lt;/span&gt; &lt;/span&gt;various materials purchased from suppliers, used in the production of the Company&#x2019;s products. Work-in-process and finished goods inventories (see Note 3) reflect the cost
          of raw materials as well as costs for direct and indirect labor, primarily salaries, wages and benefits for applicable employees, as well as an allocation of overhead costs related to the Boca Facility including utilities, property taxes, general
          repairs and maintenance, consumable supplies and depreciation. The allocation of Boca Facility overhead to inventory is generally based upon the estimated square footage of the Boca Facility that is used in the production of the Company&#x2019;s
          products relative to the total square footage of the facility. &lt;/p&gt;&lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-bottom: 0px; text-align: left;"&gt; &lt;/p&gt;
&lt;div&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-indent: 45px; text-align: left;"&gt;Inventories, including plasma intended for resale and plasma intended for internal use in the Company&#x2019;s manufacturing, commercialization
          or research and development activities, are carried at the lower of cost or net realizable value determined by the first-in, first-out method. For both the Company&#x2019;s immune globulin products and plasma intended for resale and internal use, net
          realizable value is generally determined based upon the consideration the Company expects to receive when the inventory is sold, less costs to deliver the inventory to the recipient. The estimates for net realizable value of inventory are based
          on contractual terms or upon historical experience and certain other assumptions, and the Company believes that such assumptions are reasonable. Inventory is periodically reviewed to ensure that its carrying value does not exceed its net
          realizable value, and adjustments are recorded to write down such inventory, with a corresponding charge to cost of product revenue, when the carrying value or historical cost exceeds its estimated net realizable value. In addition, costs
          associated with the production of engineering lots that would not qualify as immediately available for commercial sale are charged to cost of product revenue and not capitalized into inventory.&lt;/div&gt;
&lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;"&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
          &lt;/span&gt; &lt;/p&gt;&lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;"&gt;&lt;span style="text-decoration: underline; font-family: 'Times New Roman'; font-size: 10pt;"&gt;Property and equipment&lt;/span&gt; &lt;/p&gt;&lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;"&gt;&#160;&lt;/p&gt;&lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-indent: 45px; text-align: left;"&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;Assets comprising property and equipment (see Note 4) are stated at cost
            less accumulated depreciation. Depreciation is calculated using the straight-line method over the asset&#x2019;s estimated useful life. Land is not depreciated. The buildings have been assigned a useful life of 30 years. Property and equipment other than land and buildings have useful lives ranging from 3 to 15 years. Leasehold improvements are amortized over the
            lesser of the lease term or their estimated useful lives.&lt;/span&gt; &lt;/p&gt;&lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;"&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
          &lt;/span&gt; &lt;/p&gt;&lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;"&gt;&lt;span style="text-decoration:underline"&gt;Goodwill&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;"&gt;&#160;&lt;/p&gt;&lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-indent: 45px; text-align: left;"&gt;Goodwill represents the excess of purchase price over the fair value of net assets acquired by the Company. Goodwill at December 31, 2024
          and 2023 was $3.5 million, all of which is attributable to the Company&#x2019;s ADMA BioManufacturing business segment. There were no changes to the carrying amount of goodwill during the years ended December 31, 2024, 2023 and 2022.&lt;/p&gt;
&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt;"&gt; &#160; &lt;/span&gt;&lt;/div&gt;
&lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-indent: 45px; text-align: left;"&gt;Goodwill is not amortized but is assessed for impairment on an annual basis or more frequently if impairment indicators exist. The Company
          has the option to perform a qualitative assessment of goodwill to determine whether it is more likely than not that the fair value of its reporting unit is less than its carrying amount, including goodwill and other intangible assets. If the
          Company concludes that this is the case, then it must perform a goodwill impairment test by comparing the fair value of the reporting unit to its carrying value. An impairment charge is recorded to the extent the reporting unit&#x2019;s carrying value
          exceeds its fair value, not to exceed the total amount of goodwill allocated to that reporting unit. The Company performs its annual goodwill impairment assessment as of October 1 of each year. The Company&#x2019;s annual goodwill impairment assessments
          as of October 1, 2024, 2023 and 2022 did not result in any impairment charges related to goodwill for the years ended December 31, 2024, 2023 and 2022.&lt;/p&gt;&lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;"&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
          &lt;/span&gt; &lt;/p&gt;&lt;p style="margin: 0px; font-family: 'Times New Roman'; font-size: 10pt; text-align: left;"&gt;&lt;span style="text-decoration:underline"&gt;Impairment of long-lived assets&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;"&gt;&#160;&lt;/p&gt;&lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-indent: 45px; text-align: left;"&gt;The Company assesses the recoverability of its long-lived assets, which include property and equipment and finite-lived intangible assets,
          whenever significant events or changes in circumstances indicate impairment may have occurred. If indicators of impairment exist, projected future undiscounted cash flows associated with the asset are compared to its carrying amount to determine
          whether the asset&#x2019;s carrying value is recoverable. Any resulting impairment is recorded as a reduction in the carrying value of the related asset in excess of fair value and a charge to operating results. For the years ended December 31, 2024,
          2023 and 2022, the Company determined that there was no impairment of its long-lived assets. &lt;/p&gt;&lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;"&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
          &lt;/span&gt; &lt;/p&gt;&lt;p style="margin: 0px; font-family: 'Times New Roman'; font-size: 10pt; text-align: left;"&gt;&lt;span style="text-decoration:underline"&gt;Revenue recognition&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;"&gt;&#160;&lt;/p&gt;&lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-indent: 45px; text-align: left;"&gt;Revenues for the years ended December 31, 2024, 2023 and 2022 are comprised of (i) revenues from the sale of the Company&#x2019;s immunoglobulin
          products, ASCENIV, BIVIGAM and Nabi-HB, (ii) product revenues from the sale of human plasma collected by the Company&#x2019;s Plasma Collection Centers business segment, (iii) contract manufacturing and laboratory services revenue, (iv) revenues from
          the sale of intermediate by-products and (v) license and other revenues primarily attributable to the out-licensing of ASCENIV to Biotest AG (&#x201c;Biotest&#x201d;) in 2012 to market and sell this product in Europe and selected countries in North Africa and
          the Middle East. Biotest has provided the Company with certain services and financial payments in accordance with the related Biotest license agreement and is obligated to pay the Company certain amounts in the future if certain milestones are
          achieved. Deferred revenue is amortized into income over the term of the Biotest license, representing a period of approximately 22 years.
        &lt;/p&gt;
&lt;div&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-indent: 45px; text-align: left;"&gt;Product revenue is recognized when the customer is deemed to have control over the product and the performance obligation is satisfied.
          Control is determined based on when the product is shipped or delivered and title passes to the customer. Revenue is recorded in an amount that reflects the consideration the Company expects to receive in exchange. Revenue from the sale of the
          Company&#x2019;s immunoglobulin products is recognized when the product reaches the customer&#x2019;s destination, and is recorded net of estimated rebates, &lt;span style="font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;wholesaler distribution and related
            fees, customer incentives, including prompt pay discounts, wholesaler chargebacks, group purchasing organization fees and reimbursements for patient assistance. These estimates are based on contractual arrangements, historical experience and
            certain other assumptions, and while the Company believes that such estimates are reasonable, they are subject to change based on future developments and other factors.&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-indent: 45px; text-align: left;"&gt;&lt;span style="font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt; &lt;br/&gt;
          &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-indent: 45px; text-align: left;"&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;For revenues
            associated with contract manufacturing and the sale of intermediates, control transfers to the customer and the performance obligation is satisfied when the customer takes possession of the product from the Boca Facility&lt;/span&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;.&lt;/span&gt;&lt;/div&gt;
&lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-indent: 45px; text-align: left;"&gt;&#160;&lt;/p&gt;&lt;p style="margin: 0px; font-family: 'Times New Roman'; font-size: 10pt; text-align: left; text-indent: 45px;"&gt;Product revenues from the sale of human plasma collected at the Company&#x2019;s plasma collection centers are recognized at the time control of
          the product has been transferred to the customer&lt;span style="font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt; and the performance obligation is satisfied, which generally occurs at the time of shipment from
            one of the Company&#x2019;s plasma collection facilities or from a third-party warehouse that is utilized by the Company. Product revenues are recognized at the time of delivery if the Company retains control of the product during shipment&lt;/span&gt;.&lt;/p&gt;&lt;p style="margin: 0px; font-family: 'Times New Roman'; font-size: 10pt; text-align: left; text-indent: 45px;"&gt; &lt;br/&gt;
        &lt;/p&gt;&lt;p style="margin: 0px; font-family: 'Times New Roman'; font-size: 10pt; text-align: left; text-indent: 45px;"&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;For all of the Company&#x2019;s product revenues, payment from the customer is typically due within 90 days of sale.&lt;/span&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/p&gt;
&lt;div&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman';"&gt;  &lt;/span&gt;&lt;/div&gt;
&lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;"&gt;&#160;&lt;/p&gt;&lt;p style="margin: 0px; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-align: left; text-indent: 0px; text-transform: none;"&gt;&lt;span style="text-decoration: underline;"&gt;Cost of product revenue&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;"&gt;&#160;&lt;/p&gt;&lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-indent: 45px; text-align: left;"&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;Cost of product revenue includes costs associated with the manufacture of
            the Company&#x2019;s FDA approved products and intermediates and for the collection of human source plasma, as well as expenses related to conformance batch production, process development and scientific and technical operations when these operations
            are attributable to marketed products. When the activities of these operations are attributable to new products in development, the expenses are classified as research and development expenses.&lt;/span&gt; &lt;/p&gt;&lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;"&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
          &lt;/span&gt; &lt;/p&gt;&lt;p style="margin: 0px; font-family: 'Times New Roman'; font-size: 10pt; text-align: left; text-indent: 0px;"&gt;&lt;span style="text-decoration:underline"&gt;Research and development expenses&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;"&gt;&#160;&lt;/p&gt;&lt;p style="margin: 0px; font-family: 'Times New Roman'; font-size: 10pt; text-align: left; text-indent: 45px;"&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;Research and development expenses consist of clinical research organization
            costs, costs related to clinical trials, post-marketing commitment studies for BIVIGAM and ASCENIV and salaries, benefits and stock-based compensation for employees directly related to research and development activities. All research and
            development costs are expensed as incurred.&lt;/span&gt; &lt;/p&gt;&lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;"&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
          &lt;/span&gt; &lt;/p&gt;&lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;"&gt; &lt;/p&gt;
&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="margin: 0px; font-family: 'Times New Roman'; font-size: 10pt; text-align: left; text-indent: 0px;"&gt;&lt;span style="text-decoration: underline;"&gt;Plasma center operating expenses&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="margin: 0px; font-family: 'Times New Roman'; font-size: 10pt; text-align: left; text-indent: 0px;"&gt;&lt;span style="text-decoration: underline;"&gt; &lt;br/&gt;
          &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="margin: 0px; font-family: 'Times New Roman'; font-size: 10pt; text-align: left; text-indent: 45px;"&gt;Plasma center operating expenses consist of certain general and administrative plasma center costs, initial opening, marketing and
          start-up costs, rent expense, maintenance, utilities and compensation and benefits for administrative staff.&lt;/div&gt;
&lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;"&gt; &lt;span style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
          &lt;/span&gt; &lt;/p&gt;&lt;p style="margin: 0px; font-family: 'Times New Roman'; font-size: 10pt; text-align: left; text-indent: 0px;"&gt;&lt;span style="text-decoration:underline"&gt;Advertising and marketing expenses&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;"&gt;&#160;&lt;/p&gt;&lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-indent: 45px; text-align: left;"&gt;Advertising and marketing expense includes cost for promotional materials and trade show expenses for the marketing of the Company&#x2019;s
          products and expenses incurred for attracting donors to the Company&#x2019;s plasma collection centers. All advertising and marketing expenses are expensed as incurred.&#160; Advertising and marketing expenses were $2.7 million, $3.3 million and $2.2 million for the years ended December 31, 2024, 2023 and 2022, respectively.&lt;/p&gt;&lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;"&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
          &lt;/span&gt; &lt;/p&gt;&lt;p style="margin: 0px; font-family: 'Times New Roman'; font-size: 10pt; text-align: left; text-indent: 0px;"&gt;&lt;span style="text-decoration:underline"&gt;Stock-based compensation&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;"&gt;&#160;&lt;/p&gt;&lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-indent: 45px; text-align: left;"&gt;The Company follows recognized accounting guidance which requires all equity-based payments, including grants of stock options and
          restricted stock unit awards (&#x201c;RSUs&#x201d;), to be recognized in the statement of operations as compensation expense based on their fair values at the date of grant. Compensation expense related to awards to employees and directors with service-based
          vesting conditions is recognized on a straight-line basis over the associated vesting period of the award based on the grant date fair value of the award. Stock options granted to employees under the Company&#x2019;s equity incentive plans generally
          have a four-year vesting period and a term of 10 years. RSUs granted to employees also have a four-year vesting period. For milestone-based equity
          awards, &lt;span style="font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;which were awarded to two
            of the Company&#x2019;s executive officers in September of 2021 and vested during fiscal 2022,&lt;/span&gt; the Company would periodically assess the probability of vesting for each milestone-based award and adjust compensation expense based on its
          probability assessment. Pursuant to ASU No. 2016-09, &lt;span style="font-style: italic;"&gt;Improvements to Employee Share-Based Payment Accounting (Topic 718)&lt;/span&gt;, the Company has elected not to establish a forfeiture rate, as stock-based
          compensation expense related to forfeitures of unvested equity awards is fully reversed at the time of forfeiture.&lt;/p&gt;&lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;"&gt;&#160;&lt;/p&gt;&lt;p style="margin: 0px; font-family: 'Times New Roman'; font-size: 10pt; text-align: left; text-indent: 0px;"&gt;&lt;span style="text-decoration:underline"&gt;Income taxes&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;"&gt;&#160;&lt;/p&gt;&lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-indent: 45px; text-align: left;"&gt;The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of events that have been included in
          the consolidated financial statements or its tax returns. Under this method, deferred tax assets and liabilities are recognized for the temporary differences between the tax bases of assets and liabilities and their respective financial reporting
          amounts at enacted tax rates in effect for the years in which the temporary differences are expected to reverse. The Company records a valuation allowance on its deferred tax assets if it is more likely than not that the Company will not generate
          sufficient taxable income to utilize its deferred tax assets (see Note 11). The Company is subject to income tax examinations by major taxing authorities for all tax years since 2020 and for previous periods as it relates to the Company&#x2019;s net
          operating loss carryforwards.&lt;/p&gt;&lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-indent: 45px; text-align: left;"&gt; &lt;/p&gt;
&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
        &lt;/span&gt;&lt;/div&gt;
&lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 9pt; text-align: left; text-indent: -9pt;"&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="text-decoration: underline;"&gt;Earnings (Loss) Per Share&lt;/span&gt;&lt;/span&gt; &lt;/p&gt;&lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 9pt; text-align: left; text-indent: -9pt;"&gt;&lt;span style="text-decoration: underline;"&gt; &lt;br/&gt;
          &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-indent: 45px; text-align: left;"&gt;Basic earnings (loss) per share is computed by dividing net income or loss attributable to common stockholders by the weighted average
          number of shares of common stock outstanding during the period. Diluted loss per share is calculated by dividing net income or loss attributable to common stockholders as adjusted for the effect of dilutive securities, if any, by the weighted
          average number of shares of common stock and dilutive common stock outstanding during the period. Potentially dilutive common stock includes the shares of common stock issuable upon the exercise of outstanding stock options and warrants (using
          the treasury stock method) &lt;span style="font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;and upon the vesting of restricted stock units (&#x201c;RSUs&#x201d;). Potentially dilutive common stock in the diluted net
            earnings (loss) per share computation is excluded to the extent that it would be anti-dilutive. &lt;span style="font-style: normal; font-weight: 400; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; color: rgb(0, 0, 0);"&gt;For the year ended December 31, 2024, basic and diluted earnings per share are calculated as follows:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
          &lt;/span&gt; &lt;/div&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="letter-spacing: normal; width: 100%; word-spacing: 0px; font-family: 'Times New Roman'; font-size: 10pt; text-align: left; text-transform: none; border-spacing: 0;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-align: center; text-transform: none;"&gt;&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="text-align: center; font-weight: bold;"&gt;Year Ended&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px 0px 0px; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none;"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="text-align: center; font-weight: bold;"&gt;December 31, 2024&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; width: 88%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div&gt;Net income available to common stockholders ($000&#x2019;s) (numerator)&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;197,673&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; width: 88%; padding-bottom: 2px;" valign="bottom"&gt;
                &lt;div&gt;Weighted-average number of common shares (denominator)&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;233,084,236&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px 0px 4px; color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; width: 88%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div&gt;Basic earnings per common shares&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;0.85&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; font-style: normal; font-variant: normal; text-transform: none; width: 88%;" valign="bottom"&gt;&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; width: 88%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div&gt;Weighted-average number of common shares&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;233,084,236&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; width: 88%;" valign="bottom"&gt;
                &lt;div&gt;Potential shares of common stock arising from outstanding stock options&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;4,150,584&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; width: 88%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div&gt;Potential shares of common stock arising from outstanding warrants&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;3,085,640&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; width: 88%; padding-bottom: 2px;" valign="bottom"&gt;
                &lt;div&gt;Potential shares of common stock arising from unvested RSUs&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;3,022,006&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; width: 88%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div&gt;Total shares - diluted (denominator)&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;243,342,466&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; width: 88%; padding-bottom: 4px;" valign="bottom"&gt;
                &lt;div&gt;Diluted earnings per common share&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;0.81&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
&lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-indent: 45px; text-align: left;"&gt; &lt;span style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
          &lt;/span&gt; &lt;/p&gt;&lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-indent: 45px; text-align: left;"&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;For the year ended December 31, 2024, there were no shares with an anti-dilutive effect that needed to be excluded
            from the earnings per share computation. For the years ended December 31, 2023 and 2022, no potentially dilutive securities are
            included in the computation of diluted loss per share in the accompanying consolidated financial statements as the Company reported a net loss for these periods.&lt;/span&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; color: rgb(0, 0, 0);"&gt;For
            the years ended December 31, 2023 and 2022, the following securities were excluded from the calculation of diluted loss per common share because of their anti-dilutive effects:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px;"&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#160;&#160; &lt;br/&gt;
          &lt;/span&gt; &lt;/p&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="text-align: left; font: 10pt 'Times New Roman'; width: 100%; border-spacing: 0;"&gt;


  &lt;tr style="height: 15px;"&gt;

    &lt;td style="font-family: 'Times New Roman'; font-size: 10pt; padding-bottom: 2px;" valign="bottom"&gt;
                &lt;p style="margin: 0px;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="6" rowspan="1" style="vertical-align: bottom; text-align: center; font-family: 'Times New Roman'; font-size: 10pt; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                &lt;p style="margin: 0px 0px 0px 0in; text-align: center;"&gt;&lt;strong&gt;For the Years Ended December 31,&lt;/strong&gt;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td style="font-family: 'Times New Roman'; font-size: 10pt; padding-bottom: 2px;" valign="bottom"&gt;
                &lt;p style="margin: 0px;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; text-align: center; font-family: 'Times New Roman'; font-size: 10pt; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                &lt;p style="margin: 0px 0px 0px 0in; text-align: center;"&gt;&lt;strong&gt;2023&lt;br/&gt;
                  &lt;/strong&gt;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: center; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="text-align: center; vertical-align: bottom; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;2022&lt;/td&gt;

    &lt;td colspan="1" style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td style="vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt; width: 76%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;p style="margin: 0px 0px 0px 0in;"&gt;Stock Options&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;5,906,184&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;8,256,211&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td style="vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt; width: 76%;" valign="bottom"&gt;
                &lt;p style="margin: 0px 0px 0px 0in;"&gt;Restricted Stock Units&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;4,657,297&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;2,866,987&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td style="vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;p style="margin: 0px 0px 0px 0in;"&gt;Warrants&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;12,502,906&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;13,525,148&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td style="font-family: 'Times New Roman'; font-size: 10pt; width: 76%; padding-bottom: 4px;" valign="bottom"&gt;
                &lt;p style="margin-top: 0px; margin-bottom: 0px; margin-left: 9pt;"&gt;Total&lt;br/&gt;
                &lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" valign="bottom"&gt;23,066,387&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"&gt;24,648,346&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;/span&gt;&lt;/div&gt;
&lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;"&gt;&#160; &lt;/p&gt;&lt;p style="margin: 0px; line-height: normal; font-family: 'Times New Roman'; font-size: 10pt; text-align: left; text-indent: 0px;"&gt;&lt;span style="text-decoration:underline"&gt;Fair value of financial instruments&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;"&gt;&#160;&lt;/p&gt;&lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-indent: 45px; text-align: left;"&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;The carrying amounts of certain of the Company&#x2019;s financial instruments,
            including cash and cash equivalents, accounts receivable and accounts payable are shown at cost, which approximates fair value due to the short-term nature of these instruments. The debt outstanding under the Company&#x2019;s senior notes payable (see
            Note 7) also approximates fair value, based on a Level 3 classification under the fair value hierarchy, due to the variable interest rate on this debt.&lt;/span&gt; &lt;/p&gt;&lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;"&gt;&#160;&lt;/p&gt;&lt;p style="margin: 0px; font-family: 'Times New Roman'; font-size: 10pt; text-align: left; text-indent: 0px;"&gt;&lt;span style="text-decoration:underline"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;"&gt;&#160;&lt;/p&gt;
&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-transform: none; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; text-indent: 36pt;"&gt;In November of 2024 the FASB issued ASU No. 2024-03,&#160;&lt;span style="font-style: italic;"&gt;Income Statement - Reporting Comprehensive Income &#x2013;
              Expense Disaggregation Disclosures (Subtopic 220-40).&#160;&lt;/span&gt;The amendments in this Update require disclosure, in the notes to the financial statements, of specified information about certain costs and expenses, including but not limited to,
            purchases of inventory, employee compensation and selling expense. This Update becomes effective for fiscal years beginning after December 15, 2026. The Company has yet to determine the impact this Update may have on the Company&#x2019;s consolidated
            financial statements.&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;br/&gt;
          &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-transform: none; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; text-indent: 36pt;"&gt;In December of 2023 the FASB issued ASU 2023-09,&#160;&lt;span style="font-style: italic;"&gt;Income Taxes (Topic 740):&lt;/span&gt;&#160;&lt;span style="font-style: italic;"&gt;Improvements to Income Tax Disclosures.&#160;&lt;/span&gt;This Update requires disaggregated information about a reporting entity&#x2019;s effective tax rate reconciliation as well as information on income taxes paid and becomes
            effective for public business entities for fiscal years beginning after December 15, 2024. The Company is currently evaluating the impact that this Update may have on the Company&#x2019;s consolidated financial statements.&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;br/&gt;
          &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-transform: none; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; text-indent: 36pt;"&gt;In November of 2023 the FASB issued ASU No. 2023-07,&#160;&lt;span style="font-style: italic;"&gt;Segment Reporting (Topic 280): Improvements to
              Reportable Segment Disclosures.&#160;&lt;/span&gt;The amendments in this Update are intended to provide financial statement users with more disaggregated expense information about a public entity&#x2019;s reportable segments, however the Update does not change
            the definition of a business segment or the method for determining reportable segments. This update became effective for fiscal years beginning after December 15, 2023 (see Note 13). Adoption of this Update did not have a material impact on the
            Company&#x2019;s consolidated financial statements.&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;br/&gt;
          &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-transform: none; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; text-indent: 36pt;"&gt;There were no new accounting pronouncements adopted during the years ended December 31, 2023 and 2022 that had a significant impact on the
            Company&#x2019;s consolidated financial statements.&lt;/div&gt;
</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock
      contextRef="c20240101to20241231"
      id="Text_3754daa7e856458586d1a364d9ab905f">&lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;"&gt;&lt;span style="text-decoration:underline"&gt;Principles of consolidation and basis of presentation&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;"&gt;&#160;&lt;/p&gt;&lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-indent: 45px; text-align: left;"&gt;The accompanying consolidated financial statements include the accounts of ADMA and its wholly-owned subsidiaries and have been prepared
          in conformity with accounting principles generally accepted in the United States of America (&#x201c;U.S. GAAP&#x201d;) and in accordance with Article 3 of Regulation S-X of the Securities and Exchange Commission (the &#x201c;SEC&#x201d;). All intercompany balances have
          been eliminated in consolidation. Any reference in these notes to applicable guidance is meant to refer to U.S. GAAP as found in the Accounting Standards Codification (&#x201c;ASC&#x201d;) and Accounting Standards Updates (&#x201c;ASU&#x201d;) of the Financial Accounting
          Standards Board (the &#x201c;FASB&#x201d;). &lt;/p&gt;&lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-indent: 45px; text-align: left;"&gt; &lt;span style="font-size: 10pt; font-family: 'Times New Roman';"&gt;&lt;br/&gt;
          &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-indent: 45px; text-align: left;"&gt;During the years ended December 31, 2024, 2023 and 2022, &lt;span style="font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;comprehensive income (loss) was equal to the net income (loss) amounts presented for the respective periods in the accompanying consolidated statements of operations.&#160;&lt;/span&gt;&lt;span style="font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial;"&gt;In addition, certain prior year balances have been reclassified to conform to the current presentation. Specifically, the disaggregation of some of the Company&#x2019;s accrued expenses and other current liabilities
            (see Note 6) and deferred tax assets and liabilities, as well as the rate reconciliation for U.S. federal income taxes (see Note 11), as of December 31, 2023 have been adjusted to conform to the presentation as of December 31, 2024&lt;/span&gt;.&lt;/p&gt;</us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="c20240101to20241231"
      id="Text_39934c12f03e4ae29b1b729042ad214d">
&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="text-decoration: underline;"&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
&lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 9pt; text-indent: -9pt; text-align: left;"&gt;&lt;span style="text-decoration: underline;"&gt;Use of estimates&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 9pt; text-indent: -9pt; text-align: left;"&gt; &lt;span style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
          &lt;/span&gt; &lt;/p&gt;&lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-indent: 45px; text-align: left;"&gt;The preparation of financial statements requires management to make estimates and assumptions that affect the reported amounts of assets
          and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.
          Significant estimates include rebates and chargebacks deducted from gross revenues, assumptions used in the fair value of awards granted under the Company&#x2019;s equity incentive plans and the valuation allowance for the Company&#x2019;s deferred tax assets.&lt;/p&gt;&lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-indent: 45px; text-align: left;"&gt;&lt;span style="font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt; &lt;br/&gt;
          &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-indent: 45px; text-align: left; font-weight: normal; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; text-align: left; text-indent: 48px; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;The
            Company engaged a third-party specialist to assist in the evaluation of the Company&#x2019;s accrual for U.S. Medicaid rebates related to the sale of the Company&#x2019;s immunoglobulin products. As a result of this evaluation, the Company recognized a
            reduction in this accrual and a corresponding increase to net revenues of $12.6 million for the year ended December 31, 2024. The
            Company considered several qualitative factors when evaluating its rebate accrual, such as the absence of a statutory limitation on the rebate amounts drug manufacturers pay to state Medicaid programs and general uncertainty that pharmaceutical
            manufacturers have historically seen with government payors often submitting lagged claims many periods after the initial dispensing of a product to an end patient. There was additional new information that arose during June 2024 that suggested
            the Company&#x2019;s liabilities for certain payor claims were successfully resolved, which resulted in the $12.6 million adjustment to the
            accrual for U.S. Medicaid rebates in June 2024.&lt;/span&gt;&lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20240101to20241231_ChangeInAccountingEstimateByTypeAxis_AccrualForUSMedicaidRebatesMember"
      decimals="-5"
      id="Fact_ce16ab952e4044458b0765a4689d3a37"
      unitRef="U001">12600000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities
      contextRef="c20241231_ChangeInAccountingEstimateByTypeAxis_AccrualForUSMedicaidRebatesMember"
      decimals="-5"
      id="Fact_c72074835f594a39b8d474724f6931d9"
      unitRef="U001">12600000</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="c20240101to20241231"
      id="Text_d17c6fece48a455da94ca52ef400c45d">&lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;"&gt;&lt;span style="text-decoration:underline"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;"&gt;&#160;&lt;/p&gt;&lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-indent: 45px; text-align: left;"&gt;The Company considers all highly liquid instruments purchased with a maturity of three months or less to be cash equivalents. &lt;/p&gt;
&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
        &lt;/span&gt;&lt;/div&gt;
&lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-indent: 45px; text-align: left;"&gt;The Company regularly maintains cash and cash equivalents at third-party financial institutions in excess of the Federal Deposit Insurance
          Corporation insurance limit. Although the Company monitors the daily cash balances in its operating accounts and adjusts the balances as appropriate, these balances could be impacted, and there could be a material adverse effect on the Company&#x2019;s
          business, if one or more of the financial institutions with which the Company has deposits fails or is subject to other adverse conditions in the financial or credit markets. To date, the Company has not experienced a loss or lack of access to
          its deposited cash or cash equivalents; however, the Company cannot provide assurance that access to its cash and cash equivalents will not be impacted by adverse conditions in the financial and credit markets in the future.&lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:ReceivablesPolicyTextBlock
      contextRef="c20240101to20241231"
      id="Text_e6c40437b8c84bd5882b6bfd34f4f709">&lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;"&gt;&lt;span style="text-decoration:underline"&gt;Accounts receivable&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;"&gt;&#160;&lt;/p&gt;&lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-indent: 45px; text-align: left;"&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;Accounts receivable is reported at realizable value, net of allowances for
            contractual credits and doubtful accounts in the amount of $0.2 million and $0.1 million at December 31, 2024 and 2023, respectively, which are recognized in the period the related revenue is recorded. The Company extends credit to its customers
            based upon an evaluation of each customer&#x2019;s financial condition and credit history. Evaluations of the financial condition and associated credit risk of customers are performed on an ongoing basis.&lt;br/&gt;
          &lt;/span&gt; &lt;/p&gt;</us-gaap:ReceivablesPolicyTextBlock>
    <adma:AccountsReceivableAllowanceForContractualCreditsAndDoubtfulAccounts
      contextRef="c20241231"
      decimals="-5"
      id="Fact_fc8700678ba34ca2a530323c463be289"
      unitRef="U001">200000</adma:AccountsReceivableAllowanceForContractualCreditsAndDoubtfulAccounts>
    <adma:AccountsReceivableAllowanceForContractualCreditsAndDoubtfulAccounts
      contextRef="c20231231"
      decimals="-5"
      id="Fact_cb99e23b4dbb428ea10b8aa366f8a86c"
      unitRef="U001">100000</adma:AccountsReceivableAllowanceForContractualCreditsAndDoubtfulAccounts>
    <us-gaap:InventoryPolicyTextBlock
      contextRef="c20240101to20241231"
      id="Text_f6f5e5fc1c6d4b319280cb596c3a4d2a">&lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;"&gt;&lt;span style="text-decoration:underline"&gt;Inventories&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;"&gt;&#160;&lt;/p&gt;&lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-indent: 45px; text-align: left;"&gt;Raw materials inventory consists of &lt;span style="font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;&lt;span style="font-weight: normal; font-style: normal; font-variant: normal; text-transform: none;"&gt;normal source plasma (&#x201c;NSP&#x201d;) and Respiratory Syncytial Virus (&#x201c;RSV&#x201d;) high titer plasma collected at the Company&#x2019;s plasma collection
              facilities or purchased from third parties, along with&lt;/span&gt; &lt;/span&gt;various materials purchased from suppliers, used in the production of the Company&#x2019;s products. Work-in-process and finished goods inventories (see Note 3) reflect the cost
          of raw materials as well as costs for direct and indirect labor, primarily salaries, wages and benefits for applicable employees, as well as an allocation of overhead costs related to the Boca Facility including utilities, property taxes, general
          repairs and maintenance, consumable supplies and depreciation. The allocation of Boca Facility overhead to inventory is generally based upon the estimated square footage of the Boca Facility that is used in the production of the Company&#x2019;s
          products relative to the total square footage of the facility. &lt;/p&gt;&lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-bottom: 0px; text-align: left;"&gt; &lt;/p&gt;
&lt;div&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-indent: 45px; text-align: left;"&gt;Inventories, including plasma intended for resale and plasma intended for internal use in the Company&#x2019;s manufacturing, commercialization
          or research and development activities, are carried at the lower of cost or net realizable value determined by the first-in, first-out method. For both the Company&#x2019;s immune globulin products and plasma intended for resale and internal use, net
          realizable value is generally determined based upon the consideration the Company expects to receive when the inventory is sold, less costs to deliver the inventory to the recipient. The estimates for net realizable value of inventory are based
          on contractual terms or upon historical experience and certain other assumptions, and the Company believes that such assumptions are reasonable. Inventory is periodically reviewed to ensure that its carrying value does not exceed its net
          realizable value, and adjustments are recorded to write down such inventory, with a corresponding charge to cost of product revenue, when the carrying value or historical cost exceeds its estimated net realizable value. In addition, costs
          associated with the production of engineering lots that would not qualify as immediately available for commercial sale are charged to cost of product revenue and not capitalized into inventory.&lt;/div&gt;
</us-gaap:InventoryPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="c20240101to20241231"
      id="Text_7868c3d564fa4c1e8147b54693ecfd11">&lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;"&gt;&lt;span style="text-decoration: underline; font-family: 'Times New Roman'; font-size: 10pt;"&gt;Property and equipment&lt;/span&gt; &lt;/p&gt;&lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;"&gt;&#160;&lt;/p&gt;&lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-indent: 45px; text-align: left;"&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;Assets comprising property and equipment (see Note 4) are stated at cost
            less accumulated depreciation. Depreciation is calculated using the straight-line method over the asset&#x2019;s estimated useful life. Land is not depreciated. The buildings have been assigned a useful life of 30 years. Property and equipment other than land and buildings have useful lives ranging from 3 to 15 years. Leasehold improvements are amortized over the
            lesser of the lease term or their estimated useful lives.&lt;/span&gt; &lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="c20241231_PropertyPlantAndEquipmentByTypeAxis_BuildingMember"
      id="Fact_8ea857edb33a42c7808a6a9b42eb12d0">P30Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="c20241231_RangeAxis_MinimumMember"
      id="Fact_ecf4032f3e104ec89d255a3f03600b14">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="c20241231_RangeAxis_MaximumMember"
      id="Fact_3b4b126ba1c941e78cd8f7354b299dd2">P15Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy
      contextRef="c20240101to20241231"
      id="Text_00e559e88d2845e689436e9102998e31">&lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;"&gt;&lt;span style="text-decoration:underline"&gt;Goodwill&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;"&gt;&#160;&lt;/p&gt;&lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-indent: 45px; text-align: left;"&gt;Goodwill represents the excess of purchase price over the fair value of net assets acquired by the Company. Goodwill at December 31, 2024
          and 2023 was $3.5 million, all of which is attributable to the Company&#x2019;s ADMA BioManufacturing business segment. There were no changes to the carrying amount of goodwill during the years ended December 31, 2024, 2023 and 2022.&lt;/p&gt;
&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt;"&gt; &#160; &lt;/span&gt;&lt;/div&gt;
&lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-indent: 45px; text-align: left;"&gt;Goodwill is not amortized but is assessed for impairment on an annual basis or more frequently if impairment indicators exist. The Company
          has the option to perform a qualitative assessment of goodwill to determine whether it is more likely than not that the fair value of its reporting unit is less than its carrying amount, including goodwill and other intangible assets. If the
          Company concludes that this is the case, then it must perform a goodwill impairment test by comparing the fair value of the reporting unit to its carrying value. An impairment charge is recorded to the extent the reporting unit&#x2019;s carrying value
          exceeds its fair value, not to exceed the total amount of goodwill allocated to that reporting unit. The Company performs its annual goodwill impairment assessment as of October 1 of each year. The Company&#x2019;s annual goodwill impairment assessments
          as of October 1, 2024, 2023 and 2022 did not result in any impairment charges related to goodwill for the years ended December 31, 2024, 2023 and 2022.&lt;/p&gt;</us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy>
    <us-gaap:Goodwill
      contextRef="c20241231"
      decimals="-5"
      id="Fact_f68aadafa9464ae0967f6c1fa756b42b"
      unitRef="U001">3500000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="c20231231"
      decimals="-5"
      id="Fact_7a4d9aa6c5874c1f965f3ecca6ebbd27"
      unitRef="U001">3500000</us-gaap:Goodwill>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="c20220101to20221231"
      decimals="-3"
      id="Fact_f78a05ec586e4bb8a30fe31383a7e47c"
      unitRef="U001">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="c20240101to20241231"
      decimals="-3"
      id="Fact_b232bc9588ea49e5aecaa5c99300b09d"
      unitRef="U001">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="c20230101to20231231"
      decimals="-3"
      id="Fact_0467a3bcb4104afe8db57a7682d7e259"
      unitRef="U001">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock
      contextRef="c20240101to20241231"
      id="Text_f38a8775e287430db5d7d3cd5a2a6792">&lt;p style="margin: 0px; font-family: 'Times New Roman'; font-size: 10pt; text-align: left;"&gt;&lt;span style="text-decoration:underline"&gt;Impairment of long-lived assets&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;"&gt;&#160;&lt;/p&gt;&lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-indent: 45px; text-align: left;"&gt;The Company assesses the recoverability of its long-lived assets, which include property and equipment and finite-lived intangible assets,
          whenever significant events or changes in circumstances indicate impairment may have occurred. If indicators of impairment exist, projected future undiscounted cash flows associated with the asset are compared to its carrying amount to determine
          whether the asset&#x2019;s carrying value is recoverable. Any resulting impairment is recorded as a reduction in the carrying value of the related asset in excess of fair value and a charge to operating results. For the years ended December 31, 2024,
          2023 and 2022, the Company determined that there was no impairment of its long-lived assets. &lt;/p&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="c20230101to20231231"
      decimals="-3"
      id="Fact_88e73a6bfdd84f1ab8d9c5baa2c2f5c3"
      unitRef="U001">0</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="c20240101to20241231"
      decimals="-3"
      id="Fact_7d47420384544482b425d24fa574a9c5"
      unitRef="U001">0</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="c20220101to20221231"
      decimals="-3"
      id="Fact_09a296926b2349139ab9c06dd4e21826"
      unitRef="U001">0</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:RevenueRecognitionPolicyTextBlock
      contextRef="c20240101to20241231"
      id="Text_1b42af333ebe4902a12f992e07550b40">&lt;p style="margin: 0px; font-family: 'Times New Roman'; font-size: 10pt; text-align: left;"&gt;&lt;span style="text-decoration:underline"&gt;Revenue recognition&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;"&gt;&#160;&lt;/p&gt;&lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-indent: 45px; text-align: left;"&gt;Revenues for the years ended December 31, 2024, 2023 and 2022 are comprised of (i) revenues from the sale of the Company&#x2019;s immunoglobulin
          products, ASCENIV, BIVIGAM and Nabi-HB, (ii) product revenues from the sale of human plasma collected by the Company&#x2019;s Plasma Collection Centers business segment, (iii) contract manufacturing and laboratory services revenue, (iv) revenues from
          the sale of intermediate by-products and (v) license and other revenues primarily attributable to the out-licensing of ASCENIV to Biotest AG (&#x201c;Biotest&#x201d;) in 2012 to market and sell this product in Europe and selected countries in North Africa and
          the Middle East. Biotest has provided the Company with certain services and financial payments in accordance with the related Biotest license agreement and is obligated to pay the Company certain amounts in the future if certain milestones are
          achieved. Deferred revenue is amortized into income over the term of the Biotest license, representing a period of approximately 22 years.
        &lt;/p&gt;
&lt;div&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-indent: 45px; text-align: left;"&gt;Product revenue is recognized when the customer is deemed to have control over the product and the performance obligation is satisfied.
          Control is determined based on when the product is shipped or delivered and title passes to the customer. Revenue is recorded in an amount that reflects the consideration the Company expects to receive in exchange. Revenue from the sale of the
          Company&#x2019;s immunoglobulin products is recognized when the product reaches the customer&#x2019;s destination, and is recorded net of estimated rebates, &lt;span style="font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;wholesaler distribution and related
            fees, customer incentives, including prompt pay discounts, wholesaler chargebacks, group purchasing organization fees and reimbursements for patient assistance. These estimates are based on contractual arrangements, historical experience and
            certain other assumptions, and while the Company believes that such estimates are reasonable, they are subject to change based on future developments and other factors.&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-indent: 45px; text-align: left;"&gt;&lt;span style="font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt; &lt;br/&gt;
          &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-indent: 45px; text-align: left;"&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;For revenues
            associated with contract manufacturing and the sale of intermediates, control transfers to the customer and the performance obligation is satisfied when the customer takes possession of the product from the Boca Facility&lt;/span&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;.&lt;/span&gt;&lt;/div&gt;
&lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-indent: 45px; text-align: left;"&gt;&#160;&lt;/p&gt;&lt;p style="margin: 0px; font-family: 'Times New Roman'; font-size: 10pt; text-align: left; text-indent: 45px;"&gt;Product revenues from the sale of human plasma collected at the Company&#x2019;s plasma collection centers are recognized at the time control of
          the product has been transferred to the customer&lt;span style="font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt; and the performance obligation is satisfied, which generally occurs at the time of shipment from
            one of the Company&#x2019;s plasma collection facilities or from a third-party warehouse that is utilized by the Company. Product revenues are recognized at the time of delivery if the Company retains control of the product during shipment&lt;/span&gt;.&lt;/p&gt;&lt;p style="margin: 0px; font-family: 'Times New Roman'; font-size: 10pt; text-align: left; text-indent: 45px;"&gt; &lt;br/&gt;
        &lt;/p&gt;&lt;p style="margin: 0px; font-family: 'Times New Roman'; font-size: 10pt; text-align: left; text-indent: 45px;"&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;For all of the Company&#x2019;s product revenues, payment from the customer is typically due within 90 days of sale.&lt;/span&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
    <adma:DeferredRevenueRemainingAmortizationPeriod
      contextRef="c20240101to20241231_TypeOfArrangementAxis_BiotestLicenseAgreementMember"
      id="Fact_96ebe731caac45deadba18287277afb1">P22Y</adma:DeferredRevenueRemainingAmortizationPeriod>
    <adma:CustomerPaymentTerms
      contextRef="c20240101to20241231"
      id="Fact_aaaf8b6498e84a1dafce6025d305a87c">P90D</adma:CustomerPaymentTerms>
    <us-gaap:CostOfSalesPolicyTextBlock
      contextRef="c20240101to20241231"
      id="Text_f12240e613db430ba73d76321a1921ee">&lt;p style="margin: 0px; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-align: left; text-indent: 0px; text-transform: none;"&gt;&lt;span style="text-decoration: underline;"&gt;Cost of product revenue&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;"&gt;&#160;&lt;/p&gt;&lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-indent: 45px; text-align: left;"&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;Cost of product revenue includes costs associated with the manufacture of
            the Company&#x2019;s FDA approved products and intermediates and for the collection of human source plasma, as well as expenses related to conformance batch production, process development and scientific and technical operations when these operations
            are attributable to marketed products. When the activities of these operations are attributable to new products in development, the expenses are classified as research and development expenses.&lt;/span&gt; &lt;/p&gt;</us-gaap:CostOfSalesPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="c20240101to20241231"
      id="Text_6284068be49f44f0b5ccb6e0e2e860ac">&lt;p style="margin: 0px; font-family: 'Times New Roman'; font-size: 10pt; text-align: left; text-indent: 0px;"&gt;&lt;span style="text-decoration:underline"&gt;Research and development expenses&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;"&gt;&#160;&lt;/p&gt;&lt;p style="margin: 0px; font-family: 'Times New Roman'; font-size: 10pt; text-align: left; text-indent: 45px;"&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;Research and development expenses consist of clinical research organization
            costs, costs related to clinical trials, post-marketing commitment studies for BIVIGAM and ASCENIV and salaries, benefits and stock-based compensation for employees directly related to research and development activities. All research and
            development costs are expensed as incurred.&lt;/span&gt; &lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <adma:OtherOperatingExpensesPolicyTextBlock
      contextRef="c20240101to20241231"
      id="Text_6c66c0d7d7a647c58e69ddba41f70301">
&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="margin: 0px; font-family: 'Times New Roman'; font-size: 10pt; text-align: left; text-indent: 0px;"&gt;&lt;span style="text-decoration: underline;"&gt;Plasma center operating expenses&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="margin: 0px; font-family: 'Times New Roman'; font-size: 10pt; text-align: left; text-indent: 0px;"&gt;&lt;span style="text-decoration: underline;"&gt; &lt;br/&gt;
          &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="margin: 0px; font-family: 'Times New Roman'; font-size: 10pt; text-align: left; text-indent: 45px;"&gt;Plasma center operating expenses consist of certain general and administrative plasma center costs, initial opening, marketing and
          start-up costs, rent expense, maintenance, utilities and compensation and benefits for administrative staff.&lt;/div&gt;
</adma:OtherOperatingExpensesPolicyTextBlock>
    <us-gaap:AdvertisingCostsPolicyTextBlock
      contextRef="c20240101to20241231"
      id="Text_1420b2c05dce42c5afef742834375b0d">&lt;p style="margin: 0px; font-family: 'Times New Roman'; font-size: 10pt; text-align: left; text-indent: 0px;"&gt;&lt;span style="text-decoration:underline"&gt;Advertising and marketing expenses&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;"&gt;&#160;&lt;/p&gt;&lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-indent: 45px; text-align: left;"&gt;Advertising and marketing expense includes cost for promotional materials and trade show expenses for the marketing of the Company&#x2019;s
          products and expenses incurred for attracting donors to the Company&#x2019;s plasma collection centers. All advertising and marketing expenses are expensed as incurred.&#160; Advertising and marketing expenses were $2.7 million, $3.3 million and $2.2 million for the years ended December 31, 2024, 2023 and 2022, respectively.&lt;/p&gt;</us-gaap:AdvertisingCostsPolicyTextBlock>
    <us-gaap:MarketingAndAdvertisingExpense
      contextRef="c20240101to20241231"
      decimals="-5"
      id="Fact_e84ec44532b0411f9b5907bdb1aed7c1"
      unitRef="U001">2700000</us-gaap:MarketingAndAdvertisingExpense>
    <us-gaap:MarketingAndAdvertisingExpense
      contextRef="c20230101to20231231"
      decimals="-5"
      id="Fact_3650d7390aed4368937ce9c7a285c709"
      unitRef="U001">3300000</us-gaap:MarketingAndAdvertisingExpense>
    <us-gaap:MarketingAndAdvertisingExpense
      contextRef="c20210101to20211231"
      decimals="-5"
      id="Fact_ca981ef63a1e4b15a11a893c5471f6b8"
      unitRef="U001">2200000</us-gaap:MarketingAndAdvertisingExpense>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="c20240101to20241231"
      id="Text_c06d7acd7a154c838cab1d55352a88f6">&lt;p style="margin: 0px; font-family: 'Times New Roman'; font-size: 10pt; text-align: left; text-indent: 0px;"&gt;&lt;span style="text-decoration:underline"&gt;Stock-based compensation&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;"&gt;&#160;&lt;/p&gt;&lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-indent: 45px; text-align: left;"&gt;The Company follows recognized accounting guidance which requires all equity-based payments, including grants of stock options and
          restricted stock unit awards (&#x201c;RSUs&#x201d;), to be recognized in the statement of operations as compensation expense based on their fair values at the date of grant. Compensation expense related to awards to employees and directors with service-based
          vesting conditions is recognized on a straight-line basis over the associated vesting period of the award based on the grant date fair value of the award. Stock options granted to employees under the Company&#x2019;s equity incentive plans generally
          have a four-year vesting period and a term of 10 years. RSUs granted to employees also have a four-year vesting period. For milestone-based equity
          awards, &lt;span style="font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;which were awarded to two
            of the Company&#x2019;s executive officers in September of 2021 and vested during fiscal 2022,&lt;/span&gt; the Company would periodically assess the probability of vesting for each milestone-based award and adjust compensation expense based on its
          probability assessment. Pursuant to ASU No. 2016-09, &lt;span style="font-style: italic;"&gt;Improvements to Employee Share-Based Payment Accounting (Topic 718)&lt;/span&gt;, the Company has elected not to establish a forfeiture rate, as stock-based
          compensation expense related to forfeitures of unvested equity awards is fully reversed at the time of forfeiture.&lt;/p&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="c20240101to20241231_AwardTypeAxis_EmployeeStockOptionMember"
      id="Fact_1422437a30924586ab3d39ca21e5a446">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1
      contextRef="c20240101to20241231_AwardTypeAxis_EmployeeStockOptionMember"
      id="Fact_7ffa535a9eb447dba3631f86108655e7">P10Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="c20240101to20241231_AwardTypeAxis_RestrictedStockUnitsRSUMember"
      id="Fact_17997dbb1c9f4b47bc4962c0135d341f">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <adma:NumberOfExecutiveOfficers
      contextRef="c20210901to20210930"
      decimals="INF"
      id="Fact_8672cd6c32e5438fbff9e8b1c63dc29a"
      unitRef="U006">2</adma:NumberOfExecutiveOfficers>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="c20240101to20241231"
      id="Text_eb96bceb2c0944d8bde71a50bde19653">&lt;p style="margin: 0px; font-family: 'Times New Roman'; font-size: 10pt; text-align: left; text-indent: 0px;"&gt;&lt;span style="text-decoration:underline"&gt;Income taxes&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;"&gt;&#160;&lt;/p&gt;&lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-indent: 45px; text-align: left;"&gt;The Company recognizes deferred tax assets and liabilities for the expected future tax consequences of events that have been included in
          the consolidated financial statements or its tax returns. Under this method, deferred tax assets and liabilities are recognized for the temporary differences between the tax bases of assets and liabilities and their respective financial reporting
          amounts at enacted tax rates in effect for the years in which the temporary differences are expected to reverse. The Company records a valuation allowance on its deferred tax assets if it is more likely than not that the Company will not generate
          sufficient taxable income to utilize its deferred tax assets (see Note 11). The Company is subject to income tax examinations by major taxing authorities for all tax years since 2020 and for previous periods as it relates to the Company&#x2019;s net
          operating loss carryforwards.&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="c20240101to20241231"
      id="Text_7014fa885d7644e980bf5bc564f13e37">&lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 9pt; text-align: left; text-indent: -9pt;"&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="text-decoration: underline;"&gt;Earnings (Loss) Per Share&lt;/span&gt;&lt;/span&gt; &lt;/p&gt;&lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 9pt; text-align: left; text-indent: -9pt;"&gt;&lt;span style="text-decoration: underline;"&gt; &lt;br/&gt;
          &lt;/span&gt;&lt;/p&gt;&lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-indent: 45px; text-align: left;"&gt;Basic earnings (loss) per share is computed by dividing net income or loss attributable to common stockholders by the weighted average
          number of shares of common stock outstanding during the period. Diluted loss per share is calculated by dividing net income or loss attributable to common stockholders as adjusted for the effect of dilutive securities, if any, by the weighted
          average number of shares of common stock and dilutive common stock outstanding during the period. Potentially dilutive common stock includes the shares of common stock issuable upon the exercise of outstanding stock options and warrants (using
          the treasury stock method) &lt;span style="font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;and upon the vesting of restricted stock units (&#x201c;RSUs&#x201d;). Potentially dilutive common stock in the diluted net
            earnings (loss) per share computation is excluded to the extent that it would be anti-dilutive. &lt;span style="font-style: normal; font-weight: 400; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; color: rgb(0, 0, 0);"&gt;For the year ended December 31, 2024, basic and diluted earnings per share are calculated as follows:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;
&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
          &lt;/span&gt; &lt;/div&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="letter-spacing: normal; width: 100%; word-spacing: 0px; font-family: 'Times New Roman'; font-size: 10pt; text-align: left; text-transform: none; border-spacing: 0;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-align: center; text-transform: none;"&gt;&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="text-align: center; font-weight: bold;"&gt;Year Ended&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px 0px 0px; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none;"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="text-align: center; font-weight: bold;"&gt;December 31, 2024&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; width: 88%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div&gt;Net income available to common stockholders ($000&#x2019;s) (numerator)&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;197,673&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; width: 88%; padding-bottom: 2px;" valign="bottom"&gt;
                &lt;div&gt;Weighted-average number of common shares (denominator)&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;233,084,236&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px 0px 4px; color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; width: 88%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div&gt;Basic earnings per common shares&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;0.85&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; font-style: normal; font-variant: normal; text-transform: none; width: 88%;" valign="bottom"&gt;&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; width: 88%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div&gt;Weighted-average number of common shares&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;233,084,236&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; width: 88%;" valign="bottom"&gt;
                &lt;div&gt;Potential shares of common stock arising from outstanding stock options&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;4,150,584&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; width: 88%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div&gt;Potential shares of common stock arising from outstanding warrants&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;3,085,640&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; width: 88%; padding-bottom: 2px;" valign="bottom"&gt;
                &lt;div&gt;Potential shares of common stock arising from unvested RSUs&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;3,022,006&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; width: 88%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div&gt;Total shares - diluted (denominator)&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;243,342,466&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; width: 88%; padding-bottom: 4px;" valign="bottom"&gt;
                &lt;div&gt;Diluted earnings per common share&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;0.81&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
&lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-indent: 45px; text-align: left;"&gt; &lt;span style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
          &lt;/span&gt; &lt;/p&gt;&lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-indent: 45px; text-align: left;"&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;For the year ended December 31, 2024, there were no shares with an anti-dilutive effect that needed to be excluded
            from the earnings per share computation. For the years ended December 31, 2023 and 2022, no potentially dilutive securities are
            included in the computation of diluted loss per share in the accompanying consolidated financial statements as the Company reported a net loss for these periods.&lt;/span&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; color: rgb(0, 0, 0);"&gt;For
            the years ended December 31, 2023 and 2022, the following securities were excluded from the calculation of diluted loss per common share because of their anti-dilutive effects:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px;"&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#160;&#160; &lt;br/&gt;
          &lt;/span&gt; &lt;/p&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="text-align: left; font: 10pt 'Times New Roman'; width: 100%; border-spacing: 0;"&gt;


  &lt;tr style="height: 15px;"&gt;

    &lt;td style="font-family: 'Times New Roman'; font-size: 10pt; padding-bottom: 2px;" valign="bottom"&gt;
                &lt;p style="margin: 0px;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="6" rowspan="1" style="vertical-align: bottom; text-align: center; font-family: 'Times New Roman'; font-size: 10pt; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                &lt;p style="margin: 0px 0px 0px 0in; text-align: center;"&gt;&lt;strong&gt;For the Years Ended December 31,&lt;/strong&gt;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td style="font-family: 'Times New Roman'; font-size: 10pt; padding-bottom: 2px;" valign="bottom"&gt;
                &lt;p style="margin: 0px;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; text-align: center; font-family: 'Times New Roman'; font-size: 10pt; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                &lt;p style="margin: 0px 0px 0px 0in; text-align: center;"&gt;&lt;strong&gt;2023&lt;br/&gt;
                  &lt;/strong&gt;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: center; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="text-align: center; vertical-align: bottom; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;2022&lt;/td&gt;

    &lt;td colspan="1" style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td style="vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt; width: 76%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;p style="margin: 0px 0px 0px 0in;"&gt;Stock Options&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;5,906,184&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;8,256,211&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td style="vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt; width: 76%;" valign="bottom"&gt;
                &lt;p style="margin: 0px 0px 0px 0in;"&gt;Restricted Stock Units&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;4,657,297&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;2,866,987&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td style="vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;p style="margin: 0px 0px 0px 0in;"&gt;Warrants&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;12,502,906&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;13,525,148&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td style="font-family: 'Times New Roman'; font-size: 10pt; width: 76%; padding-bottom: 4px;" valign="bottom"&gt;
                &lt;p style="margin-top: 0px; margin-bottom: 0px; margin-left: 9pt;"&gt;Total&lt;br/&gt;
                &lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" valign="bottom"&gt;23,066,387&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"&gt;24,648,346&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="c20240101to20241231"
      id="Text_ea5ca822722a40b78455d5aa0974104b">&lt;span style="font-style: normal; font-weight: 400; font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; color: rgb(0, 0, 0);"&gt;For the year ended December 31, 2024, basic and diluted earnings per share are calculated as follows:&lt;/span&gt;
&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
          &lt;/span&gt; &lt;/div&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="letter-spacing: normal; width: 100%; word-spacing: 0px; font-family: 'Times New Roman'; font-size: 10pt; text-align: left; text-transform: none; border-spacing: 0;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; white-space: nowrap; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-align: center; text-transform: none;"&gt;&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="text-align: center; font-weight: bold;"&gt;Year Ended&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px 0px 0px; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none;"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="text-align: center; font-weight: bold;"&gt;December 31, 2024&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; width: 88%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div&gt;Net income available to common stockholders ($000&#x2019;s) (numerator)&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;197,673&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; width: 88%; padding-bottom: 2px;" valign="bottom"&gt;
                &lt;div&gt;Weighted-average number of common shares (denominator)&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;233,084,236&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; white-space: nowrap; padding: 0px 0px 4px; color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-transform: none; width: 88%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div&gt;Basic earnings per common shares&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;0.85&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; font-style: normal; font-variant: normal; text-transform: none; width: 88%;" valign="bottom"&gt;&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; width: 88%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div&gt;Weighted-average number of common shares&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;233,084,236&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; width: 88%;" valign="bottom"&gt;
                &lt;div&gt;Potential shares of common stock arising from outstanding stock options&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;4,150,584&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; width: 88%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div&gt;Potential shares of common stock arising from outstanding warrants&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;3,085,640&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; width: 88%; padding-bottom: 2px;" valign="bottom"&gt;
                &lt;div&gt;Potential shares of common stock arising from unvested RSUs&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;3,022,006&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; width: 88%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div&gt;Total shares - diluted (denominator)&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;243,342,466&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; width: 88%; padding-bottom: 4px;" valign="bottom"&gt;
                &lt;div&gt;Diluted earnings per common share&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;$&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"&gt;
                &lt;div&gt;0.81&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-size: 10pt; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="c20240101to20241231"
      decimals="-3"
      id="Fact_ab6144541a99494eb74f182153f91816"
      unitRef="U001">197673000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c20240101to20241231"
      decimals="0"
      id="Fact_e3981f93a83e49b7883b51d5427fbecf"
      unitRef="U002">233084236</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c20240101to20241231"
      decimals="2"
      id="Fact_7ca0804959f74ea3bef1b028d6646e8c"
      unitRef="U003">0.85</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c20240101to20241231"
      decimals="0"
      id="Fact_2adf932e22644489996608076f9f4d0e"
      unitRef="U002">233084236</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="c20240101to20241231_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_EmployeeStockOptionMember"
      decimals="0"
      id="Fact_7279edcb069a47a6bd2bf5c2085932f7"
      unitRef="U002">4150584</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="c20240101to20241231_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_WarrantMember"
      decimals="0"
      id="Fact_eac4d6d114ef4972a1d227e100ce4fa6"
      unitRef="U002">3085640</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="c20240101to20241231_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_RestrictedStockUnitsRSUMember"
      decimals="0"
      id="Fact_e09215834b024bd89c254c06c6a21298"
      unitRef="U002">3022006</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="c20240101to20241231"
      decimals="0"
      id="Fact_0ff92aa3bca14d28baebb5d4663dace3"
      unitRef="U002">243342466</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c20240101to20241231"
      decimals="2"
      id="Fact_488932243faa48869143e8b4ecacb1bf"
      unitRef="U003">0.81</us-gaap:EarningsPerShareDiluted>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c20240101to20241231"
      decimals="INF"
      id="Fact_1e962461f4c94dfcaeee073eb17f2fbf"
      unitRef="U002">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <adma:DilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmountShares
      contextRef="c20230101to20231231"
      decimals="INF"
      id="Fact_ee09b96234c24a0489145b0eff1808fe"
      unitRef="U002">0</adma:DilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmountShares>
    <adma:DilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmountShares
      contextRef="c20220101to20221231"
      decimals="INF"
      id="Fact_aeb789a87da04e898c6aad3ab76c4211"
      unitRef="U002">0</adma:DilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmountShares>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="c20240101to20241231"
      id="Text_9fc1c73cd75141cca1b7d186ce684320">&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; color: rgb(0, 0, 0);"&gt;For
            the years ended December 31, 2023 and 2022, the following securities were excluded from the calculation of diluted loss per common share because of their anti-dilutive effects:&lt;/span&gt;&lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px;"&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&#160;&#160; &lt;br/&gt;
          &lt;/span&gt; &lt;/p&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="text-align: left; font: 10pt 'Times New Roman'; width: 100%; border-spacing: 0;"&gt;


  &lt;tr style="height: 15px;"&gt;

    &lt;td style="font-family: 'Times New Roman'; font-size: 10pt; padding-bottom: 2px;" valign="bottom"&gt;
                &lt;p style="margin: 0px;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="6" rowspan="1" style="vertical-align: bottom; text-align: center; font-family: 'Times New Roman'; font-size: 10pt; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                &lt;p style="margin: 0px 0px 0px 0in; text-align: center;"&gt;&lt;strong&gt;For the Years Ended December 31,&lt;/strong&gt;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td style="font-family: 'Times New Roman'; font-size: 10pt; padding-bottom: 2px;" valign="bottom"&gt;
                &lt;p style="margin: 0px;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; text-align: center; font-family: 'Times New Roman'; font-size: 10pt; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                &lt;p style="margin: 0px 0px 0px 0in; text-align: center;"&gt;&lt;strong&gt;2023&lt;br/&gt;
                  &lt;/strong&gt;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: center; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="text-align: center; vertical-align: bottom; font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;2022&lt;/td&gt;

    &lt;td colspan="1" style="font-weight: bold; font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td style="vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt; width: 76%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;p style="margin: 0px 0px 0px 0in;"&gt;Stock Options&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;5,906,184&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;8,256,211&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td style="vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt; width: 76%;" valign="bottom"&gt;
                &lt;p style="margin: 0px 0px 0px 0in;"&gt;Restricted Stock Units&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;4,657,297&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;2,866,987&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td style="vertical-align: top; font-family: 'Times New Roman'; font-size: 10pt; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;p style="margin: 0px 0px 0px 0in;"&gt;Warrants&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;12,502,906&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;13,525,148&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td style="font-family: 'Times New Roman'; font-size: 10pt; width: 76%; padding-bottom: 4px;" valign="bottom"&gt;
                &lt;p style="margin-top: 0px; margin-bottom: 0px; margin-left: 9pt;"&gt;Total&lt;br/&gt;
                &lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" valign="bottom"&gt;23,066,387&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"&gt;24,648,346&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c20230101to20231231_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_EmployeeStockOptionMember"
      decimals="0"
      id="Fact_0b4d2d542e8448b8b3836681f39a5c6f"
      unitRef="U002">5906184</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c20220101to20221231_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_EmployeeStockOptionMember"
      decimals="0"
      id="Fact_ee69a4e376f04a50810d658a46e464cf"
      unitRef="U002">8256211</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c20230101to20231231_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_RestrictedStockUnitsRSUMember"
      decimals="0"
      id="Fact_8ac68441ad9443b8b061f3564dc2064c"
      unitRef="U002">4657297</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c20220101to20221231_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_RestrictedStockUnitsRSUMember"
      decimals="0"
      id="Fact_42f665449a814fada762a880fbbb8194"
      unitRef="U002">2866987</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c20230101to20231231_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_WarrantMember"
      decimals="0"
      id="Fact_b618ba4a26b847ce9ee743483a5e8e17"
      unitRef="U002">12502906</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c20220101to20221231_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_WarrantMember"
      decimals="0"
      id="Fact_2517a71120ba4e369e616d228507b9ba"
      unitRef="U002">13525148</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c20230101to20231231"
      decimals="0"
      id="Fact_933058c0dd6049fcbe600389e9e96e54"
      unitRef="U002">23066387</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c20220101to20221231"
      decimals="0"
      id="Fact_f02539349b6a4ae0991e197b3c48b48b"
      unitRef="U002">24648346</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy
      contextRef="c20240101to20241231"
      id="Text_7cead0bd46204dea8748b918efdbd677">&lt;p style="margin: 0px; line-height: normal; font-family: 'Times New Roman'; font-size: 10pt; text-align: left; text-indent: 0px;"&gt;&lt;span style="text-decoration:underline"&gt;Fair value of financial instruments&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;"&gt;&#160;&lt;/p&gt;&lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-indent: 45px; text-align: left;"&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;The carrying amounts of certain of the Company&#x2019;s financial instruments,
            including cash and cash equivalents, accounts receivable and accounts payable are shown at cost, which approximates fair value due to the short-term nature of these instruments. The debt outstanding under the Company&#x2019;s senior notes payable (see
            Note 7) also approximates fair value, based on a Level 3 classification under the fair value hierarchy, due to the variable interest rate on this debt.&lt;/span&gt; &lt;/p&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="c20240101to20241231"
      id="Text_94063da814ab4996a6453d69ff1d5772">&lt;p style="margin: 0px; font-family: 'Times New Roman'; font-size: 10pt; text-align: left; text-indent: 0px;"&gt;&lt;span style="text-decoration:underline"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;"&gt;&#160;&lt;/p&gt;
&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-transform: none; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; text-indent: 36pt;"&gt;In November of 2024 the FASB issued ASU No. 2024-03,&#160;&lt;span style="font-style: italic;"&gt;Income Statement - Reporting Comprehensive Income &#x2013;
              Expense Disaggregation Disclosures (Subtopic 220-40).&#160;&lt;/span&gt;The amendments in this Update require disclosure, in the notes to the financial statements, of specified information about certain costs and expenses, including but not limited to,
            purchases of inventory, employee compensation and selling expense. This Update becomes effective for fiscal years beginning after December 15, 2026. The Company has yet to determine the impact this Update may have on the Company&#x2019;s consolidated
            financial statements.&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;br/&gt;
          &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-transform: none; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; text-indent: 36pt;"&gt;In December of 2023 the FASB issued ASU 2023-09,&#160;&lt;span style="font-style: italic;"&gt;Income Taxes (Topic 740):&lt;/span&gt;&#160;&lt;span style="font-style: italic;"&gt;Improvements to Income Tax Disclosures.&#160;&lt;/span&gt;This Update requires disaggregated information about a reporting entity&#x2019;s effective tax rate reconciliation as well as information on income taxes paid and becomes
            effective for public business entities for fiscal years beginning after December 15, 2024. The Company is currently evaluating the impact that this Update may have on the Company&#x2019;s consolidated financial statements.&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;br/&gt;
          &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-transform: none; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; text-indent: 36pt;"&gt;In November of 2023 the FASB issued ASU No. 2023-07,&#160;&lt;span style="font-style: italic;"&gt;Segment Reporting (Topic 280): Improvements to
              Reportable Segment Disclosures.&#160;&lt;/span&gt;The amendments in this Update are intended to provide financial statement users with more disaggregated expense information about a public entity&#x2019;s reportable segments, however the Update does not change
            the definition of a business segment or the method for determining reportable segments. This update became effective for fiscal years beginning after December 15, 2023 (see Note 13). Adoption of this Update did not have a material impact on the
            Company&#x2019;s consolidated financial statements.&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 0px; text-transform: none; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;br/&gt;
          &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-transform: none; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; text-indent: 36pt;"&gt;There were no new accounting pronouncements adopted during the years ended December 31, 2023 and 2022 that had a significant impact on the
            Company&#x2019;s consolidated financial statements.&lt;/div&gt;
</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:InventoryDisclosureTextBlock
      contextRef="c20240101to20241231"
      id="Text_5842db1e643b42c7a22429b6a5cc1610">
&lt;div&gt;
          &lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt; border-spacing: 0;"&gt;


  &lt;tr style="vertical-align: top;"&gt;

    &lt;td style="vertical-align: top; width: 27pt;"&gt;
                  &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;"&gt;&lt;strong&gt;3.&lt;/strong&gt;&lt;/p&gt;
                &lt;/td&gt;

    &lt;td style="align: left; vertical-align: top; width: auto;"&gt;
                  &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;"&gt;&lt;strong&gt;&lt;span style="text-decoration: underline;"&gt;INVENTORIES&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;
                &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
        &lt;/div&gt;
&lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;"&gt;&#160;&lt;/p&gt;&lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-indent: 45px; text-align: left;"&gt;The following table provides the components of inventories:&lt;/p&gt;&lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px;"&gt;&lt;br/&gt;
        &lt;/p&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="text-align: left; font: 10pt 'Times New Roman'; width: 100%; border-spacing: 0;"&gt;


  &lt;tr style="height: 15px;"&gt;

    &lt;td style="padding-bottom: 2px;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: center;"&gt;&lt;strong&gt;December 31,&lt;br/&gt;
                    2024&lt;/strong&gt;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: center;"&gt;&lt;strong&gt;December 31,&lt;br/&gt;
                    2023&lt;/strong&gt;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td rowspan="1" style="vertical-align: top;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: center; vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="6" rowspan="1" style="text-align: center; vertical-align: bottom;" valign="bottom"&gt;&lt;span style="font-style: italic;"&gt;(In thousands)&lt;/span&gt;&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td style="vertical-align: top; width: 76%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in;"&gt;Raw materials&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;60,473&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;52,999&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td style="vertical-align: top; width: 76%;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in;"&gt;Work-in-process&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;61,641&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;49,621&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td style="vertical-align: top; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in;"&gt;Finished goods&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;48,121&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;70,286&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td style="vertical-align: top; width: 76%; padding-bottom: 4px;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in;"&gt;Total inventories&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom"&gt;170,235&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom"&gt;172,906&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
&lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-indent: 45px; text-align: left;"&gt; &lt;br/&gt;
        &lt;/p&gt;&lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-indent: 45px; text-align: left;"&gt;Raw materials includes plasma and other materials expected to be used in the production of ASCENIV, BIVIGAM and Nabi-HB. These materials
          will be consumed in the production of products expected to be available for sale or otherwise have alternative uses that provide a probable future benefit.&lt;br/&gt;
        &lt;/p&gt;
&lt;div&gt;&lt;br/&gt;&lt;/div&gt;
&lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-indent: 45px; text-align: left;"&gt;Work-in-process inventory primarily consists &lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;of the Company&#x2019;s IVIG products that are manufactured to the bulk drug substance and unlabeled filled vials stage of
            production&lt;/span&gt;.&lt;/p&gt;&lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-indent: 45px; text-align: left;"&gt; &lt;br/&gt;
        &lt;/p&gt;&lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-indent: 45px; text-align: left;"&gt; Finished goods inventory is comprised &lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;of the Company&#x2019;s immunoglobulin products that have reached the filled, labeled and serialized vial stage of production and related
            intermediates that are available for commercial sale, as well as plasma collected at the Company&#x2019;s plasma collection centers which is expected to be sold to third-party customers&lt;/span&gt;. &lt;/p&gt;</us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock
      contextRef="c20240101to20241231"
      id="Text_3f978a7e17f74bb0a907c88e26b773cf">&lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-indent: 45px; text-align: left;"&gt;The following table provides the components of inventories:&lt;/p&gt;&lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px;"&gt;&lt;br/&gt;
        &lt;/p&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="text-align: left; font: 10pt 'Times New Roman'; width: 100%; border-spacing: 0;"&gt;


  &lt;tr style="height: 15px;"&gt;

    &lt;td style="padding-bottom: 2px;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: center;"&gt;&lt;strong&gt;December 31,&lt;br/&gt;
                    2024&lt;/strong&gt;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: center;"&gt;&lt;strong&gt;December 31,&lt;br/&gt;
                    2023&lt;/strong&gt;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td rowspan="1" style="vertical-align: top;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: center; vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="6" rowspan="1" style="text-align: center; vertical-align: bottom;" valign="bottom"&gt;&lt;span style="font-style: italic;"&gt;(In thousands)&lt;/span&gt;&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td style="vertical-align: top; width: 76%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in;"&gt;Raw materials&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;60,473&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;52,999&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td style="vertical-align: top; width: 76%;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in;"&gt;Work-in-process&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;61,641&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;49,621&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td style="vertical-align: top; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in;"&gt;Finished goods&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;48,121&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;70,286&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td style="vertical-align: top; width: 76%; padding-bottom: 4px;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in;"&gt;Total inventories&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom"&gt;170,235&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom"&gt;172,906&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryRawMaterials
      contextRef="c20241231"
      decimals="-3"
      id="Fact_ababcb9226644f059ecf7d71ff87c676"
      unitRef="U001">60473000</us-gaap:InventoryRawMaterials>
    <us-gaap:InventoryRawMaterials
      contextRef="c20231231"
      decimals="-3"
      id="Fact_543dd9811e0e42488ccf781175bd36f2"
      unitRef="U001">52999000</us-gaap:InventoryRawMaterials>
    <us-gaap:InventoryWorkInProcess
      contextRef="c20241231"
      decimals="-3"
      id="Fact_8052c96b93654a95a0958ce1da260183"
      unitRef="U001">61641000</us-gaap:InventoryWorkInProcess>
    <us-gaap:InventoryWorkInProcess
      contextRef="c20231231"
      decimals="-3"
      id="Fact_4bbe08fd2a414c528cbcefaf028e85f0"
      unitRef="U001">49621000</us-gaap:InventoryWorkInProcess>
    <us-gaap:InventoryFinishedGoods
      contextRef="c20241231"
      decimals="-3"
      id="Fact_622be231ac2c4c5485b50eed52d8bc88"
      unitRef="U001">48121000</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryFinishedGoods
      contextRef="c20231231"
      decimals="-3"
      id="Fact_6b17adaeee1a4be8a38d19f1d8f02f4c"
      unitRef="U001">70286000</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryNet
      contextRef="c20241231"
      decimals="-3"
      id="Fact_2ea7132a86e2498ca6049223a75a86c1"
      unitRef="U001">170235000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="c20231231"
      decimals="-3"
      id="Fact_bcc0b372000140a2a21b4e3523ae87c1"
      unitRef="U001">172906000</us-gaap:InventoryNet>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock
      contextRef="c20240101to20241231"
      id="Text_25e7f8717b9f42dca455b5e4b0aeeb1d">
&lt;div&gt;
          &lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt; border-spacing: 0;"&gt;


  &lt;tr style="vertical-align: top;"&gt;

    &lt;td style="vertical-align: top; width: 27pt;"&gt;
                  &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;"&gt;&lt;strong&gt;4.&lt;/strong&gt;&lt;/p&gt;
                &lt;/td&gt;

    &lt;td style="align: left; vertical-align: top; width: auto;"&gt;
                  &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;"&gt;&lt;strong&gt;&lt;span style="text-decoration: underline;"&gt;PROPERTY AND EQUIPMENT&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;
                &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
        &lt;/div&gt;
&lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;"&gt;&#160;&lt;/p&gt;&lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-indent: 45px; text-align: left;"&gt;Property and equipment at December 31, 2024 and 2023 is summarized as follows:&lt;/p&gt;&lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;"&gt;&#160; &lt;/p&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="text-align: left; font: 10pt 'Times New Roman'; width: 100%; border-spacing: 0;"&gt;


  &lt;tr style="height: 15px;"&gt;

    &lt;td style="padding-bottom: 2px;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: center;"&gt;&lt;strong&gt;December 31, 2024&lt;/strong&gt;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: center;"&gt;&lt;strong&gt;December 31, 2023&lt;/strong&gt;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td rowspan="1" style="vertical-align: top;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: center; vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="6" rowspan="1" style="text-align: center; vertical-align: bottom;" valign="bottom"&gt;&lt;span style="font-style: italic;"&gt;(In thousands)&lt;/span&gt;&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td style="vertical-align: top; width: 76%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px;"&gt;Manufacturing and laboratory equipment&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;21,305&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;21,093&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td style="vertical-align: top; width: 76%;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px;"&gt;Office equipment and computer software&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;5,772&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;6,062&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td style="vertical-align: top; width: 76%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px;"&gt;Furniture and fixtures&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;5,840&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;5,776&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td style="vertical-align: top; width: 76%;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px;"&gt;Construction in process&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;8,149&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;2,273&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td style="vertical-align: top; width: 76%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px;"&gt;Leasehold improvements&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;21,066&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;20,811&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td style="vertical-align: top; width: 76%;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px;"&gt;Land&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;4,339&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;4,339&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td style="vertical-align: top; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px;"&gt;Buildings and building improvements&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;21,788&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;20,218&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td style="width: 76%;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;88,259&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;80,572&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td style="vertical-align: top; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px;"&gt;Less: Accumulated depreciation &lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;(33,552&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;)&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;(26,737&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;)&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td style="vertical-align: top; width: 76%; padding-bottom: 4px;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px;"&gt;Total property and equipment, net&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom"&gt;54,707&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom"&gt;53,835&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
&lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;"&gt;&#160; &#160;&lt;/p&gt;&lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-indent: 45px; text-align: left;"&gt;The Company recorded depreciation expense on property and equipment of $7.7 million, $7.6 million and $6.4 million for the years ended December 31, 2024, 2023 and 2022, respectively.&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="c20240101to20241231"
      id="Text_e933337894f14c85baba60c14f8fd2a7">&lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-indent: 45px; text-align: left;"&gt;Property and equipment at December 31, 2024 and 2023 is summarized as follows:&lt;/p&gt;&lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;"&gt;&#160; &lt;/p&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="text-align: left; font: 10pt 'Times New Roman'; width: 100%; border-spacing: 0;"&gt;


  &lt;tr style="height: 15px;"&gt;

    &lt;td style="padding-bottom: 2px;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: center;"&gt;&lt;strong&gt;December 31, 2024&lt;/strong&gt;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: center;"&gt;&lt;strong&gt;December 31, 2023&lt;/strong&gt;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td rowspan="1" style="vertical-align: top;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: center; vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="6" rowspan="1" style="text-align: center; vertical-align: bottom;" valign="bottom"&gt;&lt;span style="font-style: italic;"&gt;(In thousands)&lt;/span&gt;&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td style="vertical-align: top; width: 76%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px;"&gt;Manufacturing and laboratory equipment&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;21,305&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;21,093&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td style="vertical-align: top; width: 76%;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px;"&gt;Office equipment and computer software&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;5,772&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;6,062&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td style="vertical-align: top; width: 76%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px;"&gt;Furniture and fixtures&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;5,840&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;5,776&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td style="vertical-align: top; width: 76%;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px;"&gt;Construction in process&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;8,149&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;2,273&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td style="vertical-align: top; width: 76%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px;"&gt;Leasehold improvements&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;21,066&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;20,811&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td style="vertical-align: top; width: 76%;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px;"&gt;Land&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;4,339&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;4,339&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td style="vertical-align: top; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px;"&gt;Buildings and building improvements&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;21,788&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;20,218&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td style="width: 76%;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;88,259&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;80,572&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td style="vertical-align: top; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px;"&gt;Less: Accumulated depreciation &lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;(33,552&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;)&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;(26,737&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;)&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td style="vertical-align: top; width: 76%; padding-bottom: 4px;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px;"&gt;Total property and equipment, net&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom"&gt;54,707&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom"&gt;53,835&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="c20241231_PropertyPlantAndEquipmentByTypeAxis_ManufacturingFacilityMember"
      decimals="-3"
      id="Fact_aa6dbf497b564214ab43ccfdd9535918"
      unitRef="U001">21305000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="c20231231_PropertyPlantAndEquipmentByTypeAxis_ManufacturingFacilityMember"
      decimals="-3"
      id="Fact_a47e53229d6240d5a048fd8a8b22bd85"
      unitRef="U001">21093000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="c20241231_PropertyPlantAndEquipmentByTypeAxis_OfficeEquipmentMember"
      decimals="-3"
      id="Fact_36abaf9bb11c484fb52773346d8edfab"
      unitRef="U001">5772000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="c20231231_PropertyPlantAndEquipmentByTypeAxis_OfficeEquipmentMember"
      decimals="-3"
      id="Fact_107912be80b64011bc60694ad8f94e49"
      unitRef="U001">6062000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="c20241231_PropertyPlantAndEquipmentByTypeAxis_FurnitureAndFixturesMember"
      decimals="-3"
      id="Fact_30119b6ed38d47b4b3d5135f83c7c329"
      unitRef="U001">5840000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="c20231231_PropertyPlantAndEquipmentByTypeAxis_FurnitureAndFixturesMember"
      decimals="-3"
      id="Fact_46fc38e5353247edb47a8907215e4a41"
      unitRef="U001">5776000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="c20241231_PropertyPlantAndEquipmentByTypeAxis_AssetUnderConstructionMember"
      decimals="-3"
      id="Fact_e0c83890b374412c917a59159bf875c0"
      unitRef="U001">8149000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="c20231231_PropertyPlantAndEquipmentByTypeAxis_AssetUnderConstructionMember"
      decimals="-3"
      id="Fact_06f4f3f9723d4b398fa9034db5633c02"
      unitRef="U001">2273000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="c20241231_PropertyPlantAndEquipmentByTypeAxis_LeaseholdImprovementsMember"
      decimals="-3"
      id="Fact_aff492e75f9c4986896e96393e223a76"
      unitRef="U001">21066000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="c20231231_PropertyPlantAndEquipmentByTypeAxis_LeaseholdImprovementsMember"
      decimals="-3"
      id="Fact_88d3b55ecd4a421f8fdf400edb659c74"
      unitRef="U001">20811000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="c20241231_PropertyPlantAndEquipmentByTypeAxis_LandMember"
      decimals="-3"
      id="Fact_0a3e74b485584eb7bea25b949a606c37"
      unitRef="U001">4339000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="c20231231_PropertyPlantAndEquipmentByTypeAxis_LandMember"
      decimals="-3"
      id="Fact_8a1351672878495386c5ec3a2e402a9b"
      unitRef="U001">4339000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="c20241231_PropertyPlantAndEquipmentByTypeAxis_BuildingAndBuildingImprovementsMember"
      decimals="-3"
      id="Fact_532b19e3f53344a68069f09928210551"
      unitRef="U001">21788000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="c20231231_PropertyPlantAndEquipmentByTypeAxis_BuildingAndBuildingImprovementsMember"
      decimals="-3"
      id="Fact_b891b7bfc6e84dd5bc7e8b579d68148e"
      unitRef="U001">20218000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="c20241231"
      decimals="-3"
      id="Fact_1e4d15e6d32b4c629ca8cf77df291d81"
      unitRef="U001">88259000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="c20231231"
      decimals="-3"
      id="Fact_847117890a41452381585968751b34ac"
      unitRef="U001">80572000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="c20241231"
      decimals="-3"
      id="Fact_43899c0decaf4f3db7ab64a9565a6017"
      unitRef="U001">33552000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="c20231231"
      decimals="-3"
      id="Fact_cfde5134cc644d89a297b6cf39c4c8a4"
      unitRef="U001">26737000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="c20241231"
      decimals="-3"
      id="Fact_0693a2b468234da6b2d3a5e7e53b7e1b"
      unitRef="U001">54707000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="c20231231"
      decimals="-3"
      id="Fact_3c3a5252c63d4f0abd2c9f376cbd828b"
      unitRef="U001">53835000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="c20240101to20241231"
      decimals="-5"
      id="Fact_42ffff15e85c41209d48374b23672321"
      unitRef="U001">7700000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="c20230101to20231231"
      decimals="-5"
      id="Fact_88c379b7469e4058920e1a1fd9fc30c5"
      unitRef="U001">7600000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="c20220101to20221231"
      decimals="-5"
      id="Fact_11a2db5a715d43049e08ed29fe7b0770"
      unitRef="U001">6400000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:IntangibleAssetsDisclosureTextBlock
      contextRef="c20240101to20241231"
      id="Text_9d38a8bafc864fcd8a731e561133b603">
&lt;div&gt;
          &lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt; border-spacing: 0;"&gt;


  &lt;tr style="vertical-align: top;"&gt;

    &lt;td style="vertical-align: top; width: 27pt;"&gt;
                  &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;"&gt;&lt;strong&gt;5.&lt;/strong&gt;&lt;/p&gt;
                &lt;/td&gt;

    &lt;td style="align: left; vertical-align: top; width: auto;"&gt;
                  &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;"&gt;&lt;strong&gt;&lt;span style="text-decoration: underline;"&gt;INTANGIBLE ASSETS&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;
                &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
        &lt;/div&gt;
&lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;"&gt;&#160;&lt;/p&gt;&lt;p style="margin: 0px 0px; font-family: 'Times New Roman'; font-size: 10pt; text-align: left; text-indent: 45px;"&gt;Intangible assets at December 31, 2024 and 2023 consist of the following:&lt;/p&gt;&lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;"&gt;&#160; &lt;/p&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="text-align: left; font: 10pt 'Times New Roman'; width: 100%; border-spacing: 0;"&gt;


  &lt;tr style="height: 15px;"&gt;

    &lt;td style="padding-bottom: 2px;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="10" style="vertical-align: bottom; text-align: center; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: center;"&gt;&lt;span style="font-weight: bold;"&gt;December 31, 2024&lt;/span&gt;&lt;br/&gt;
                &lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="10" style="vertical-align: bottom; text-align: center; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: center;"&gt;&lt;span style="font-weight: bold;"&gt;December 31, 2023&lt;/span&gt;&lt;br/&gt;
                &lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td rowspan="1" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: center; vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="22" rowspan="1" style="vertical-align: bottom; text-align: center;" valign="bottom"&gt;&lt;span style="font-style: italic;"&gt;(In thousands) &lt;/span&gt; &lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td style="padding-bottom: 2px;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: center;"&gt;&lt;strong&gt; Cost&lt;/strong&gt;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in;"&gt;&lt;strong&gt;Accumulated&lt;/strong&gt;&lt;/p&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in;"&gt;&lt;strong&gt;Amortization&lt;/strong&gt;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: center;"&gt;&lt;strong&gt;Net&lt;/strong&gt;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: center;"&gt;&lt;strong&gt;Cost&lt;/strong&gt;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in;"&gt;&lt;strong&gt;Accumulated&lt;/strong&gt;&lt;/p&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in;"&gt;&lt;strong&gt;Amortization&lt;/strong&gt;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: center;"&gt;&lt;strong&gt;Net&lt;/strong&gt;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td style="vertical-align: top; width: 28%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-bottom: 0px; text-indent: -9pt; margin-left: 9pt;"&gt;Trademark and other intangible rights related to Nabi-HB&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;4,100&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;4,100&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;-&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;4,100&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;3,856&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;244&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td rowspan="1" style="vertical-align: top; font-size: 10pt; width: 28%;" valign="bottom"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: -9.6px; text-transform: none; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;Internally developed software&lt;/span&gt;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;559&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;99&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;460&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;210&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;9&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;201&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td style="vertical-align: top; width: 28%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-bottom: 0px; text-indent: -9pt; margin-left: 9pt;"&gt;Rights to intermediates&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;907&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;907&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;-&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;907&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;853&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;54&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td style="width: 28%; padding-bottom: 4px;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom"&gt;5,566&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom"&gt;5,106&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom"&gt;460&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom"&gt;5,217&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom"&gt;4,718&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom"&gt;499&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
&lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;"&gt;&#160; &#160;&lt;/p&gt;&lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-indent: 45px; text-align: left;"&gt; &lt;/p&gt;
&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="margin: 0px 0px 0px; font-family: 'Times New Roman'; font-size: 10pt; text-align: left; text-indent: 27pt;"&gt;Under the previous contract manufacturing agreement between ADMA and Biotest, intermediate by-products derived from the
          manufacture of ASCENIV were property of Biotest.&#160; As a result of the acquisition of certain assets from Biotest on June 6, 2017, ADMA obtained the right to these intermediate products as well as the intangible rights to Nabi-HB, which were
          amortized over a period of seven years. As of December 31, 2024, the Company&#x2019;s intangible assets are comprised of several internally
          developed data intelligence and analytics programs at a cost of approximately $0.6 million which is being amortized over a period of four years.&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="margin: 0px 0px 0px; font-family: 'Times New Roman'; font-size: 10pt; text-align: left; text-indent: 27pt;"&gt; &lt;br/&gt;
        &lt;/div&gt;
&lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-bottom: 0px; text-align: left; text-indent: 27pt;"&gt;Amortization expense related to the Company&#x2019;s intangible assets for the years ended December 31, 2024, 2023 and
          2022 was $0.4 million, $0.7
          million and $0.7 million, respectively. Estimated aggregate future aggregate amortization expense is expected to be as follows (in
          thousands):&lt;/p&gt;&lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;"&gt;&#160;&lt;/p&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="text-align: left; font: 10pt 'Times New Roman'; width: 100%; border-spacing: 0;"&gt;


  &lt;tr style="height: 15px;"&gt;

    &lt;td style="vertical-align: top; width: 88%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in;"&gt;2025&lt;br/&gt;
                &lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;$&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;140&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td style="vertical-align: top; width: 88%;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in;"&gt;2026&lt;br/&gt;
                &lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;$ &lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;140&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td rowspan="1" style="vertical-align: top; width: 88%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div&gt;2027&lt;br/&gt;
                &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;$ &lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;130&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td rowspan="1" style="vertical-align: top; width: 88%;" valign="bottom"&gt;2028&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;$ &lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;50&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
</us-gaap:IntangibleAssetsDisclosureTextBlock>
    <us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock
      contextRef="c20240101to20241231"
      id="Text_c02597785ecc4e12b70404aeb5f94939">&lt;p style="margin: 0px 0px; font-family: 'Times New Roman'; font-size: 10pt; text-align: left; text-indent: 45px;"&gt;Intangible assets at December 31, 2024 and 2023 consist of the following:&lt;/p&gt;&lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;"&gt;&#160; &lt;/p&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="text-align: left; font: 10pt 'Times New Roman'; width: 100%; border-spacing: 0;"&gt;


  &lt;tr style="height: 15px;"&gt;

    &lt;td style="padding-bottom: 2px;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="10" style="vertical-align: bottom; text-align: center; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: center;"&gt;&lt;span style="font-weight: bold;"&gt;December 31, 2024&lt;/span&gt;&lt;br/&gt;
                &lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="10" style="vertical-align: bottom; text-align: center; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: center;"&gt;&lt;span style="font-weight: bold;"&gt;December 31, 2023&lt;/span&gt;&lt;br/&gt;
                &lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td rowspan="1" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: center; vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="22" rowspan="1" style="vertical-align: bottom; text-align: center;" valign="bottom"&gt;&lt;span style="font-style: italic;"&gt;(In thousands) &lt;/span&gt; &lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td style="padding-bottom: 2px;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: center;"&gt;&lt;strong&gt; Cost&lt;/strong&gt;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in;"&gt;&lt;strong&gt;Accumulated&lt;/strong&gt;&lt;/p&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in;"&gt;&lt;strong&gt;Amortization&lt;/strong&gt;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: center;"&gt;&lt;strong&gt;Net&lt;/strong&gt;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: center;"&gt;&lt;strong&gt;Cost&lt;/strong&gt;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in;"&gt;&lt;strong&gt;Accumulated&lt;/strong&gt;&lt;/p&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in;"&gt;&lt;strong&gt;Amortization&lt;/strong&gt;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: center;"&gt;&lt;strong&gt;Net&lt;/strong&gt;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td style="vertical-align: top; width: 28%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-bottom: 0px; text-indent: -9pt; margin-left: 9pt;"&gt;Trademark and other intangible rights related to Nabi-HB&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;4,100&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;4,100&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;-&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;4,100&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;3,856&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;244&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td rowspan="1" style="vertical-align: top; font-size: 10pt; width: 28%;" valign="bottom"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: -9.6px; text-transform: none; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;Internally developed software&lt;/span&gt;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;559&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;99&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;460&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;210&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;9&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;201&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td style="vertical-align: top; width: 28%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-bottom: 0px; text-indent: -9pt; margin-left: 9pt;"&gt;Rights to intermediates&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;907&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;907&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;-&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;907&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;853&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;54&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td style="width: 28%; padding-bottom: 4px;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom"&gt;5,566&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom"&gt;5,106&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom"&gt;460&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom"&gt;5,217&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom"&gt;4,718&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom"&gt;499&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
</us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="c20241231_FiniteLivedIntangibleAssetsByMajorClassAxis_TrademarkAndOtherIntangibleRightsRelatedToNabiHBMember"
      decimals="-3"
      id="Fact_534fc1de43f44be1b24f66ca7b877327"
      unitRef="U001">4100000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="c20241231_FiniteLivedIntangibleAssetsByMajorClassAxis_TrademarkAndOtherIntangibleRightsRelatedToNabiHBMember"
      decimals="-3"
      id="Fact_0479e2bce8f64fb9aa7bed020a2af6cf"
      unitRef="U001">4100000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="c20241231_FiniteLivedIntangibleAssetsByMajorClassAxis_TrademarkAndOtherIntangibleRightsRelatedToNabiHBMember"
      decimals="-3"
      id="Fact_2aa9cfad7a4d441d8993094838ebf649"
      unitRef="U001">0</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="c20231231_FiniteLivedIntangibleAssetsByMajorClassAxis_TrademarkAndOtherIntangibleRightsRelatedToNabiHBMember"
      decimals="-3"
      id="Fact_d76168a506fc45de82f46cca41c13a7c"
      unitRef="U001">4100000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="c20231231_FiniteLivedIntangibleAssetsByMajorClassAxis_TrademarkAndOtherIntangibleRightsRelatedToNabiHBMember"
      decimals="-3"
      id="Fact_5e6d01896e914b8c830d79cbfd996aa7"
      unitRef="U001">3856000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="c20231231_FiniteLivedIntangibleAssetsByMajorClassAxis_TrademarkAndOtherIntangibleRightsRelatedToNabiHBMember"
      decimals="-3"
      id="Fact_c1b3dee22278445ea13416936b914cdd"
      unitRef="U001">244000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="c20241231_FiniteLivedIntangibleAssetsByMajorClassAxis_ComputerSoftwareIntangibleAssetMember"
      decimals="-3"
      id="Fact_3352f25612b944b1b8ca2fbf5f8b0328"
      unitRef="U001">559000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="c20241231_FiniteLivedIntangibleAssetsByMajorClassAxis_ComputerSoftwareIntangibleAssetMember"
      decimals="-3"
      id="Fact_8126edd30a4b4d8a9f9ec2fde01e56f3"
      unitRef="U001">99000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="c20241231_FiniteLivedIntangibleAssetsByMajorClassAxis_ComputerSoftwareIntangibleAssetMember"
      decimals="-3"
      id="Fact_97298e60f3694fe1966380e12b466030"
      unitRef="U001">460000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="c20231231_FiniteLivedIntangibleAssetsByMajorClassAxis_ComputerSoftwareIntangibleAssetMember"
      decimals="-3"
      id="Fact_504f6fdde49a4bcf8ccd23455230bdc4"
      unitRef="U001">210000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="c20231231_FiniteLivedIntangibleAssetsByMajorClassAxis_ComputerSoftwareIntangibleAssetMember"
      decimals="-3"
      id="Fact_426c54bda1124e7fb774b857e2e4b4b1"
      unitRef="U001">9000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="c20231231_FiniteLivedIntangibleAssetsByMajorClassAxis_ComputerSoftwareIntangibleAssetMember"
      decimals="-3"
      id="Fact_7da85b5734694e39ac4610e300189cb0"
      unitRef="U001">201000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="c20241231_FiniteLivedIntangibleAssetsByMajorClassAxis_RightToIntermediatesMember"
      decimals="-3"
      id="Fact_cd2db5e1b50944469cf7cbc23fb182eb"
      unitRef="U001">907000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="c20241231_FiniteLivedIntangibleAssetsByMajorClassAxis_RightToIntermediatesMember"
      decimals="-3"
      id="Fact_7b1605ed35054eecb92e7189ce58d666"
      unitRef="U001">907000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="c20241231_FiniteLivedIntangibleAssetsByMajorClassAxis_RightToIntermediatesMember"
      decimals="-3"
      id="Fact_e6feb7f4495f43109e3e87c432870678"
      unitRef="U001">0</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="c20231231_FiniteLivedIntangibleAssetsByMajorClassAxis_RightToIntermediatesMember"
      decimals="-3"
      id="Fact_00d2ccdaffc248169b383103970c463f"
      unitRef="U001">907000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="c20231231_FiniteLivedIntangibleAssetsByMajorClassAxis_RightToIntermediatesMember"
      decimals="-3"
      id="Fact_ee0f724f67b849ff87345b9e0fa4de89"
      unitRef="U001">853000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="c20231231_FiniteLivedIntangibleAssetsByMajorClassAxis_RightToIntermediatesMember"
      decimals="-3"
      id="Fact_3e48ffb1becf4744ae890916360e9775"
      unitRef="U001">54000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="c20241231"
      decimals="-3"
      id="Fact_9559a344ab084f93ba7db85035e579bb"
      unitRef="U001">5566000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="c20241231"
      decimals="-3"
      id="Fact_ec50e08f01524352a984c94040cc44e6"
      unitRef="U001">5106000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="c20241231"
      decimals="-3"
      id="Fact_382a62bd170e4c8d891beed28dc413b2"
      unitRef="U001">460000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="c20231231"
      decimals="-3"
      id="Fact_8ec4bd2649f044c9ac74dea20865c49e"
      unitRef="U001">5217000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="c20231231"
      decimals="-3"
      id="Fact_ac0bae978421496dbb21c5bc12e92aaf"
      unitRef="U001">4718000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="c20231231"
      decimals="-3"
      id="Fact_8390571e75fa4c5d9b4184613d373abf"
      unitRef="U001">499000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1
      contextRef="c20241231_FiniteLivedIntangibleAssetsByMajorClassAxis_TrademarkAndOtherIntangibleRightsRelatedToNabiHBMember"
      id="Fact_fcd67a71fa3440f586a12eece43d3035">P7Y</us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="c20241231_FiniteLivedIntangibleAssetsByMajorClassAxis_ComputerSoftwareIntangibleAssetMember"
      decimals="-5"
      id="Fact_2ac313a3adda4c118f1f868eb7f4d822"
      unitRef="U001">600000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1
      contextRef="c20241231_FiniteLivedIntangibleAssetsByMajorClassAxis_ComputerSoftwareIntangibleAssetMember"
      id="Fact_a264a5e595b54ce4a17382d1a2f801a4">P4Y</us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1>
    <us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock
      contextRef="c20240101to20241231"
      id="Text_9bcc8822d32f4c3e9de7c27000ab8495">&lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-bottom: 0px; text-align: left; text-indent: 27pt;"&gt;Amortization expense related to the Company&#x2019;s intangible assets for the years ended December 31, 2024, 2023 and
          2022 was $0.4 million, $0.7
          million and $0.7 million, respectively. Estimated aggregate future aggregate amortization expense is expected to be as follows (in
          thousands):&lt;/p&gt;&lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;"&gt;&#160;&lt;/p&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="text-align: left; font: 10pt 'Times New Roman'; width: 100%; border-spacing: 0;"&gt;


  &lt;tr style="height: 15px;"&gt;

    &lt;td style="vertical-align: top; width: 88%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in;"&gt;2025&lt;br/&gt;
                &lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;$&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;140&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td style="vertical-align: top; width: 88%;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in;"&gt;2026&lt;br/&gt;
                &lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;$ &lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;140&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td rowspan="1" style="vertical-align: top; width: 88%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div&gt;2027&lt;br/&gt;
                &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;$ &lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;130&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td rowspan="1" style="vertical-align: top; width: 88%;" valign="bottom"&gt;2028&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;$ &lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;50&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
</us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="c20240101to20241231"
      decimals="-5"
      id="Fact_267044ebfc6b4560a757a9bc2b642e5d"
      unitRef="U001">400000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="c20230101to20231231"
      decimals="-5"
      id="Fact_c273c5446532412c817cb4d801c9e96f"
      unitRef="U001">700000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="c20220101to20221231"
      decimals="-5"
      id="Fact_1e8b7036359b462cabe0dc4ce4ea8771"
      unitRef="U001">700000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths
      contextRef="c20241231"
      decimals="-3"
      id="Fact_72efdd44d1364ed6b8e52365d2022111"
      unitRef="U001">140000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo
      contextRef="c20241231"
      decimals="-3"
      id="Fact_e92dc7cb12f84c13bdd57149c2b28638"
      unitRef="U001">140000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree
      contextRef="c20241231"
      decimals="-3"
      id="Fact_a7d614e9ded14bbe84c05fa4f8c4d342"
      unitRef="U001">130000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour
      contextRef="c20241231"
      decimals="-3"
      id="Fact_72beb712b8134178a3debcd79a032fe4"
      unitRef="U001">50000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock
      contextRef="c20240101to20241231"
      id="Text_ca422ff2de49406a93a9174f6351500f">
&lt;div&gt;
          &lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt; border-spacing: 0;"&gt;


  &lt;tr style="vertical-align: top;"&gt;

    &lt;td style="vertical-align: top; width: 27pt;"&gt;
                  &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;"&gt;&lt;strong&gt;6.&lt;/strong&gt;&lt;/p&gt;
                &lt;/td&gt;

    &lt;td style="align: left; vertical-align: top; width: auto;"&gt;
                  &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;"&gt;&lt;strong&gt;&lt;span style="text-decoration: underline;"&gt;ACCRUED EXPENSES AND OTHER LIABILITIES&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;
                &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
        &lt;/div&gt;
&lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;"&gt;&#160;&lt;/p&gt;&lt;p style="margin: 0px 0px; font-family: 'Times New Roman'; font-size: 10pt; text-align: left; text-indent: 45px;"&gt;Accrued expenses and other current liabilities at December 31, 2024 and 2023 are as follows:&lt;/p&gt;&lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;"&gt;&#160;&lt;/p&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="text-align: left; font: 10pt 'Times New Roman'; width: 100%; border-spacing: 0;"&gt;


  &lt;tr style="height: 15px;"&gt;

    &lt;td style="padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: center;"&gt;&lt;strong&gt;December 31, 2024
                  &lt;/strong&gt;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;&lt;strong&gt;December 31, 2023&lt;/strong&gt;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td rowspan="1" style="white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: center; vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="6" rowspan="1" style="vertical-align: bottom; text-align: center;" valign="bottom"&gt;&lt;span style="font-style: italic;"&gt;(In thousands)&lt;/span&gt; &lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td style="vertical-align: top; width: 76%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-bottom: 0px; text-indent: -9pt; margin-left: 9pt;"&gt;Accrued rebates&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;$ &lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;4,155&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;16,608&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td style="vertical-align: top; width: 76%;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-bottom: 0px; text-indent: -9pt; margin-left: 9pt;"&gt;Accrued distribution fees&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;11,565&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;5,954&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td style="vertical-align: top; width: 76%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-bottom: 0px; text-indent: -9pt; margin-left: 9pt;"&gt;Accrued incentives&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;5,892&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;4,961&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td rowspan="1" style="vertical-align: top; width: 76%;" valign="bottom"&gt;Accrued interest&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;2,857&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;546&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td style="vertical-align: top; width: 76%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-bottom: 0px; text-indent: -9pt; margin-left: 9pt;"&gt;Accrued testing&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;827&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;282&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td style="vertical-align: top; width: 76%;" valign="bottom"&gt;
                &lt;div style="color: rgb(0, 0, 0); text-indent: -9pt; margin-left: 9pt;"&gt;Accrued payroll and other compensation&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;3,332&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;2,203&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td rowspan="1" style="vertical-align: top; width: 76%; background-color: #CCEEFF;" valign="bottom"&gt;Income taxes payable&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;3,481&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;-&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td style="vertical-align: top; width: 76%; padding-bottom: 2px;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-bottom: 0px; text-indent: -9pt; margin-left: 9pt;"&gt;Other&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"&gt;1,853&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"&gt;2,365&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td style="vertical-align: top; width: 76%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-bottom: 0px; text-indent: -9pt; margin-left: 18pt;"&gt;Total accrued expenses and other current liabilities&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 4px double rgb(0, 0, 0);" valign="bottom"&gt;$ &lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 4px double rgb(0, 0, 0);" valign="bottom"&gt;33,962&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 4px double rgb(0, 0, 0);" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 4px double rgb(0, 0, 0);" valign="bottom"&gt;32,919&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="c20240101to20241231"
      id="Text_efc75356c82444eabb05c5bcc9aad4db">&lt;p style="margin: 0px 0px; font-family: 'Times New Roman'; font-size: 10pt; text-align: left; text-indent: 45px;"&gt;Accrued expenses and other current liabilities at December 31, 2024 and 2023 are as follows:&lt;/p&gt;&lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;"&gt;&#160;&lt;/p&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="text-align: left; font: 10pt 'Times New Roman'; width: 100%; border-spacing: 0;"&gt;


  &lt;tr style="height: 15px;"&gt;

    &lt;td style="padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: center;"&gt;&lt;strong&gt;December 31, 2024
                  &lt;/strong&gt;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;&lt;strong&gt;December 31, 2023&lt;/strong&gt;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td rowspan="1" style="white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: center; vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="6" rowspan="1" style="vertical-align: bottom; text-align: center;" valign="bottom"&gt;&lt;span style="font-style: italic;"&gt;(In thousands)&lt;/span&gt; &lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td style="vertical-align: top; width: 76%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-bottom: 0px; text-indent: -9pt; margin-left: 9pt;"&gt;Accrued rebates&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;$ &lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;4,155&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;16,608&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td style="vertical-align: top; width: 76%;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-bottom: 0px; text-indent: -9pt; margin-left: 9pt;"&gt;Accrued distribution fees&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;11,565&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;5,954&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td style="vertical-align: top; width: 76%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-bottom: 0px; text-indent: -9pt; margin-left: 9pt;"&gt;Accrued incentives&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;5,892&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;4,961&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td rowspan="1" style="vertical-align: top; width: 76%;" valign="bottom"&gt;Accrued interest&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;2,857&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;546&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td style="vertical-align: top; width: 76%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-bottom: 0px; text-indent: -9pt; margin-left: 9pt;"&gt;Accrued testing&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;827&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;282&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td style="vertical-align: top; width: 76%;" valign="bottom"&gt;
                &lt;div style="color: rgb(0, 0, 0); text-indent: -9pt; margin-left: 9pt;"&gt;Accrued payroll and other compensation&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;3,332&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;2,203&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td rowspan="1" style="vertical-align: top; width: 76%; background-color: #CCEEFF;" valign="bottom"&gt;Income taxes payable&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;3,481&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;-&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td style="vertical-align: top; width: 76%; padding-bottom: 2px;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-bottom: 0px; text-indent: -9pt; margin-left: 9pt;"&gt;Other&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"&gt;1,853&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"&gt;2,365&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td style="vertical-align: top; width: 76%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-bottom: 0px; text-indent: -9pt; margin-left: 18pt;"&gt;Total accrued expenses and other current liabilities&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 4px double rgb(0, 0, 0);" valign="bottom"&gt;$ &lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 4px double rgb(0, 0, 0);" valign="bottom"&gt;33,962&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 4px double rgb(0, 0, 0);" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 4px double rgb(0, 0, 0);" valign="bottom"&gt;32,919&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <adma:AccruedRebatesCurrent
      contextRef="c20241231"
      decimals="-3"
      id="Fact_2520dc9659e6456382d3b2598fd5800a"
      unitRef="U001">4155000</adma:AccruedRebatesCurrent>
    <adma:AccruedRebatesCurrent
      contextRef="c20231231"
      decimals="-3"
      id="Fact_d244dfd97ccb4da299238074a38a8d0f"
      unitRef="U001">16608000</adma:AccruedRebatesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="c20241231"
      decimals="-3"
      id="Fact_d055a4f1abb6441dbf84dd4adc217854"
      unitRef="U001">11565000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="c20231231"
      decimals="-3"
      id="Fact_4b9deac527db4a9893c6436d01cabb70"
      unitRef="U001">5954000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedBonusesCurrent
      contextRef="c20241231"
      decimals="-3"
      id="Fact_8b76dd60c6974e739dad88d11ec39233"
      unitRef="U001">5892000</us-gaap:AccruedBonusesCurrent>
    <us-gaap:AccruedBonusesCurrent
      contextRef="c20231231"
      decimals="-3"
      id="Fact_5d5b91778c7b41fb8ad8368becc5c251"
      unitRef="U001">4961000</us-gaap:AccruedBonusesCurrent>
    <us-gaap:InterestPayableCurrent
      contextRef="c20241231"
      decimals="-3"
      id="Fact_b161695ff8834e8eadcb90e9876dd36c"
      unitRef="U001">2857000</us-gaap:InterestPayableCurrent>
    <us-gaap:InterestPayableCurrent
      contextRef="c20231231"
      decimals="-3"
      id="Fact_eb6746edff8f42179244467604520382"
      unitRef="U001">546000</us-gaap:InterestPayableCurrent>
    <adma:AccruedTestingCurrent
      contextRef="c20241231"
      decimals="-3"
      id="Fact_c67935c3b02846f18b7b5b199a6f3844"
      unitRef="U001">827000</adma:AccruedTestingCurrent>
    <adma:AccruedTestingCurrent
      contextRef="c20231231"
      decimals="-3"
      id="Fact_ad81e063c08843449d4a1637d9d6f84a"
      unitRef="U001">282000</adma:AccruedTestingCurrent>
    <us-gaap:AccruedSalariesCurrent
      contextRef="c20241231"
      decimals="-3"
      id="Fact_c9bc5533fa18499a9d544a44b787d360"
      unitRef="U001">3332000</us-gaap:AccruedSalariesCurrent>
    <us-gaap:AccruedSalariesCurrent
      contextRef="c20231231"
      decimals="-3"
      id="Fact_c435e74add454f2993fb472cef56c0c8"
      unitRef="U001">2203000</us-gaap:AccruedSalariesCurrent>
    <us-gaap:TaxesPayableCurrent
      contextRef="c20241231"
      decimals="-3"
      id="Fact_5d65b6e6a59747bba0b8cfb2c7fcc6fa"
      unitRef="U001">3481000</us-gaap:TaxesPayableCurrent>
    <us-gaap:TaxesPayableCurrent
      contextRef="c20231231"
      decimals="-3"
      id="Fact_6a4ecf3a44a342d6af3c65bc691fce6b"
      unitRef="U001">0</us-gaap:TaxesPayableCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="c20241231"
      decimals="-3"
      id="Fact_15d72dec1c21407abc16c779291c02c4"
      unitRef="U001">1853000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="c20231231"
      decimals="-3"
      id="Fact_ed0341fc4057473f90de6fb1c1ca38b8"
      unitRef="U001">2365000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities
      contextRef="c20241231"
      decimals="-3"
      id="Fact_d91dcf9a3ce644a29b87e130926d727f"
      unitRef="U001">33962000</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities
      contextRef="c20231231"
      decimals="-3"
      id="Fact_15ac5c61a7e74ec28f279f8c090ecb5e"
      unitRef="U001">32919000</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:LongTermDebtTextBlock
      contextRef="c20240101to20241231"
      id="Text_a51f5e7cb0d14433ac93262403a99623">
&lt;div&gt;
          &lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt; border-spacing: 0;"&gt;


  &lt;tr style="vertical-align: top;"&gt;

    &lt;td style="vertical-align: top; width: 27pt;"&gt;
                  &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;"&gt;&lt;strong&gt;7.&lt;/strong&gt;&lt;/p&gt;
                &lt;/td&gt;

    &lt;td style="vertical-align: top; width: auto;"&gt;
                  &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;"&gt;&lt;strong&gt;&lt;span style="text-decoration: underline;"&gt;NOTES PAYABLE&lt;br/&gt;
                      &lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;
                &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
        &lt;/div&gt;
&lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;"&gt;&#160;&lt;/p&gt;&lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-bottom: 0px; text-align: left;"&gt;&lt;span style="text-decoration: underline;"&gt;Senior Notes Payable&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;"&gt;&#160;&lt;/p&gt;&lt;p style="margin-top: 0px; margin-bottom: 0px; font-family: 'Times New Roman'; font-size: 10pt; text-align: left; text-indent: 27pt;"&gt;A summary of outstanding senior notes payable is as follows:&lt;/p&gt;&lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px;"&gt;&#160;&#160; &lt;br/&gt;
        &lt;/p&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="text-align: left; font: 10pt 'Times New Roman'; width: 100%; border-spacing: 0;"&gt;


  &lt;tr style="height: 15px;"&gt;

    &lt;td style="padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: center;"&gt;&lt;strong&gt;December 31, 2024&lt;/strong&gt;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: center;"&gt;&lt;strong&gt;December 31, 2023&lt;/strong&gt;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td rowspan="1" style="vertical-align: top; width: 76%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="6" rowspan="1" style="text-align: center; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&lt;span style="font-style: italic;"&gt;(In thousands)&lt;/span&gt;&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td style="vertical-align: top; width: 76%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 9pt; text-indent: -9pt;"&gt;Term loan&lt;br/&gt;
                &lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;32,500&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;62,500&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td rowspan="1" style="vertical-align: top; width: 76%;" valign="bottom"&gt;
                &lt;div style="margin-left: 9pt; text-indent: -9pt;"&gt;Revolving credit facility&lt;br/&gt;
                &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;42,500&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;72,500&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td style="vertical-align: top; width: 76%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in;"&gt;Less:&lt;br/&gt;
                &lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td style="vertical-align: top; width: 76%; padding-bottom: 2px;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 15px;"&gt;Debt discount&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"&gt;(2,663&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;)&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"&gt;(4,406&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;)&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td style="vertical-align: top; width: 76%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in;"&gt;Senior notes payable&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 4px double rgb(0, 0, 0);" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 4px double rgb(0, 0, 0);" valign="bottom"&gt;72,337&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 4px double rgb(0, 0, 0);" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 4px double rgb(0, 0, 0);" valign="bottom"&gt;130,594&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
&lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px;"&gt;&#160;&#160; &#160;&lt;/p&gt;
&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: left; font-size: 10pt; text-indent: 27pt; font-weight: normal; font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none;"&gt;On December 18, 2023 (the &#x201c;Ares Closing Date&#x201d;), the Company
            and all of its subsidiaries entered into a new senior secured credit facility (the &#x201c;Ares Credit Agreement&#x201d;) with Ares Capital Corporation and certain credit funds affiliated with Ares Capital Corporation (collectively, &#x201c;Ares&#x201d;). The Ares Credit
            Agreement provided for a total of $135.0 million in senior secured credit facilities (the &#x201c;Ares Credit Facility&#x201d;) consisting of (i) a
            term loan in the aggregate principal amount of $62.5 million and (ii) a revolving credit facility in the aggregate principal amount
            of $72.5 million (collectively, the &#x201c;Ares Loans&#x201d;), both of which were fully drawn on the Ares Closing Date. The Ares Credit Facility
            has a maturity date of December 20, 2027 (the &#x201c;Ares Maturity Date&#x201d;). On the Ares Closing Date, the Company used the proceeds from
            the Ares Loans, along with a portion of its existing cash on hand, to terminate and pay in full all of the outstanding obligations under the Company&#x2019;s previous senior credit facility (the &#x201c;Hayfin Credit Facility&#x201d;) with Hayfin Services LLP
            (&#x201c;Hayfin&#x201d;) including the outstanding principal in the amount of $158.6 million, a prepayment penalty in the amount $11.1 million, an exit fee of $1.6
            million, all accrued and unpaid interest outstanding on the Hayfin Credit Facility as of the Ares Closing date, as well as certain fees and expenses related thereto. In connection with the payoff and termination of the Hayfin Credit Facility,
            the Company also wrote off $15.0 million of unamortized debt discount related to the Hayfin Credit Facility. As a result of this
            transaction, the Company recorded a loss on the extinguishment of the Hayfin Credit Facility for the year ended December 31, 2023 in the amount of $26.2
            million, which is mainly comprised of the write-off of unamortized debt discount and the prepayment penalty.&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: left; font-size: 10pt; text-indent: 27pt; font-weight: normal; font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;
              &lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 27pt;"&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;On August 14, 2024, the Company repaid $30.0
                million against the revolving credit facility and the outstanding balance on the revolving credit facility as of December 31, 2024 was $42.5
                million, with an additional $30.0 million of availability through the Ares Maturity Date. The Company is required to pay an
                unused commitment fee of 0.5% per annum for this availability. &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;br/&gt;
              &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; text-indent: 27pt;"&gt;On December 19, 2024 the Company repaid $30.0
              million against the term loan and the outstanding balance on the term loan as of December 31, 2024 was $32.5 million. In connection
              with the repayment against the term loan, the Company recognized a loss on extinguishment of debt in the approximate amount of $1.2
              million, which is comprised of a prepayment penalty in the amount of $0.5 million and a partial write-off of unamortized discount
              attributable to the term loan in the amount of $0.8 million.&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;span style="font-weight: normal; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;span style="font-weight: normal; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;span style="font-weight: normal; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: left; font-size: 10pt; text-indent: 27pt; font-weight: normal; font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none;"&gt;Borrowings under the term loan bear interest at the adjusted
            Term SOFR for a three-month tenor in effect on the day that is &lt;span style="-sec-ix-hidden:Fact_712874e87fcc4abab5ec40411ed75dc9"&gt;two&lt;/span&gt; business days prior to the first day of the applicable calendar quarter plus 6.50%.
            Borrowings under the revolving facility initially bear interest at the adjusted Term SOFR for a three-month tenor in effect on the
            day that is &lt;span style="-sec-ix-hidden:Fact_00f7b4da42784c0b85e89298c6447e23"&gt;two&lt;/span&gt; business days prior to the first day of the applicable calendar quarter&#160;plus 3.75%. As of December 31, 2024 and December 31, 2023, the interest rate on the term loan was approximately 10.85% and 11.88%, respectively, and the interest rate on
            the revolving facility was&#160;approximately 8.34% and 9.13%, respectively.&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;span style="font-weight: normal; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-weight: normal; font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 27pt;"&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;On the
            Ares Maturity Date, the Company is required to pay Ares the entire outstanding principal amount underlying the Ares Loans and any accrued and unpaid interest thereon. Prior to the Ares Maturity Date, there are no scheduled principal payments on the Ares Credit Facilities. After giving effect to the principal payments made during the year ended December 31,
            2024, the Company is required to make quarterly interest payments to Ares of approximately $1.8 million. The Company may prepay the outstanding principal under the revolving facility, together with any accrued but unpaid interest on the prepaid principal amount,
            at any time and from time to time upon &lt;span style="-sec-ix-hidden:Fact_d55916c1abbd41dd8edc1e45abe3c678"&gt;three&lt;/span&gt; business days&#x2019; prior written notice with no prepayment premium. However, in the event the Company pays down an aggregate amount under the Revolving Facility that is greater than 50% of the $72.5 million commitment
            amount, the Company will still be required to pay interest on 50% of this amount, or $36.3 million, through the term of Ares Credit Facility. The Company may prepay the outstanding principal on the term loan, together with any accrued but unpaid interest on
            the prepaid principal amount, at any time and from time to time upon &lt;span style="-sec-ix-hidden:Fact_2496c3fd576a452da07200cbae1170f2"&gt;three&lt;/span&gt; business days&#x2019; prior written notice, subject to the
            payment to Ares of a prepayment premium equal to (i) the present value as of such date of all remaining required interest payments on the principal amount being repaid plus 1.5% of the prepaid principal amount, if prepaid on or prior to the first anniversary of the Ares Closing Date, (ii) 1.5% of the prepaid principal amount, if prepaid after the first anniversary of the Ares Closing Date and on or prior to the second anniversary of the Ares Closing Date, or (iii) 1.0% of the prepaid principal amount, if prepaid on or prior to the third anniversary of the Ares Closing Date. &lt;/span&gt;&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman';"&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 27pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;In connection with
            the closing of the Ares Credit Facility, the Company incurred fees and expenses related to the transaction of $2.8 million, including
            a $1.7 million original discount payable to Ares, all of which was deducted from the Ares loan proceeds. In addition, the Company is
            also required to pay Ares an exit fee of $1.7 million upon the earlier of any prepayment date or the Ares Maturity Date, and this
            obligation was accrued as a separate liability in the Company&#x2019;s consolidated balance sheet as of December 31, 2023. As a result, the Company recognized an aggregate debt discount of $4.4 million as of the Ares Closing Date, and the weighted-average effective interest rate on the Ares Loans was 10.81% and 11.39% as of December 31, 2024 and 2023, respectively. This
            debt discount was recorded as a reduction to the face amount of the debt and is being amortized as interest expense over the term of the debt using the interest method. In connection with the prepayment of the term loan on December 19, 2024,
            the Company also paid a pro rata portion of the exit fee in the amount of $0.4 million, and the balance of the exit fee liability as
            of December 31, 2024 is $1.3 million. &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
          &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; text-indent: 27pt;"&gt;All of the Company&#x2019;s obligations under the Ares Credit Agreement are secured by a first-priority lien and security interest in substantially all
              of the Company&#x2019;s tangible and intangible assets, including intellectual property and all of the equity interests in the Company&#x2019;s subsidiaries. The Ares Credit Agreement contains certain representations and warranties, affirmative covenants,
              negative covenants and conditions that are customarily required for similar debt financings. The negative covenants include certain financial covenants, including maximum total leverage ratios and a $15.0 million minimum liquidity covenant, and also restrict or limit the Company&#x2019;s ability and the ability of the Company&#x2019;s subsidiaries to, among other things and subject
              to certain exceptions contained in the Ares Credit Agreement, incur new indebtedness; create liens on assets; engage in certain fundamental corporate changes, such as mergers or acquisitions, or changes to the Company&#x2019;s or the Company&#x2019;s
              subsidiaries&#x2019; business activities; make certain Investments or Restricted Payments (each as defined in the Ares Credit Agreement); engage in certain affiliate transactions; or enter into, amend or terminate any other agreements that have the
              impact of restricting the Company&#x2019;s ability to make loan repayments under the Ares Credit Agreement. As of December 31, 2024 the Company was in compliance with all of the covenants contained in the Ares Credit Agreement.&lt;/div&gt;

&lt;div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;span style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
              &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; text-indent: 27pt;"&gt;Events of Default on the Ares Loans include, among others, non-payment of principal, interest or fees, violation of covenants, inaccuracy of
            representations and warranties, bankruptcy and insolvency events, material judgments, cross-defaults to material contracts and events constituting a change of control. If there is an event of default, the Company will incur an increase in the
            rate of interest on the Ares Loans of 2% per annum.&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; text-indent: 27pt;"&gt; &lt;span style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;/span&gt;&lt;/div&gt;
&lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px;"&gt; &lt;/p&gt;
&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;/span&gt;&lt;/div&gt;
&lt;p style="margin-top: 0px; margin-bottom: 0px; font-family: 'Times New Roman'; font-size: 10pt; text-align: left; text-indent: 27pt;"&gt;&lt;span style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;On &lt;span style="color: rgb(0, 0, 0); background-color: rgb(255, 255, 255); font-weight: normal; font-style: normal; font-variant: normal; text-transform: none;"&gt;March 23,&#160;2022 (the &#x201c;Hayfin Closing Date&#x201d;), the Company and all of its subsidiaries entered into the Hayfin Credit
              Agreement with Hayfin. The Hayfin Credit Agreement provided for a senior secured term loan facility in a principal amount of up to&lt;/span&gt; $175.0
            million, &lt;span style="color: rgb(0, 0, 0); background-color: rgb(255, 255, 255); font-weight: normal; font-style: normal; font-variant: normal; text-transform: none;"&gt;composed of (i) a term loan made on the Hayfin Closing Date in the principal
              amount of&lt;/span&gt; $150.0 million&lt;span style="color: rgb(0, 0, 0); font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt; (&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;the &#x201c;Hayfin Closing Date
                Loan&#x201d;), and (ii) a delayed draw term loan in the principal amount of &lt;/span&gt;&lt;/span&gt;$25.0 million (the &#x201c;&lt;span style="color: rgb(0, 0, 0); background-color: rgb(255, 255, 255); font-weight: normal; font-style: normal; font-variant: normal; text-transform: none;"&gt;Hayfin &lt;/span&gt;&lt;span style="color: rgb(0, 0, 0); font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;Delayed Draw Loan&lt;/span&gt;&#x201d; &lt;span style="color: rgb(0, 0, 0); font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;and, together with the Hayfin Closing Date Loan, the &#x201c;Hayfin Loans&lt;/span&gt;&lt;/span&gt;&#x201d;). &lt;span style="color: rgb(0, 0, 0); font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: left; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;The Hayfin Delayed Draw Loan was not drawn prior to the Ares Closing Date. The Hayfin Credit Facility had a maturity date of March 23, 2027 (the &#x201c;Hayfin Maturity Date&#x201d;), subject to acceleration pursuant to the Hayfin Credit Agreement, including upon an Event of Default
              (as defined in the Hayfin Credit Agreement).&lt;/span&gt;&lt;/span&gt;&lt;span style="font-size: 10pt;"&gt; &lt;br/&gt;
          &lt;/span&gt; &lt;/p&gt;
&lt;div&gt;&lt;span style="font-size: 10pt;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-size: 10pt;"&gt; &lt;br/&gt;
      &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; text-indent: 27pt;"&gt;On the
        Hayfin Closing Date, the Company used $100.0 million of the Hayfin Closing Date Loan to terminate and pay in full all of the outstanding
        obligations under the Company&#x2019;s previously existing credit facility (the &#x201c;Perceptive Credit Facility&#x201d;) with Perceptive Credit Holdings II, LP (&#x201c;Perceptive&#x201d;). The Company also used $2.0 million of the Hayfin Closing Date Loan proceeds to pay a redemption premium to Perceptive and used approximately $1.0 million of the Hayfin Closing Date Loan proceeds to pay certain fees and expenses incurred in connection with this transaction. In addition, a $1.8 million upfront fee payable to Hayfin was paid &#x201c;in kind&#x201d; and was added to the outstanding principal balance in accordance with the terms of the Hayfin Credit Agreement. In
        connection with the retirement of the Perceptive Credit Facility and all of the obligations thereunder, the Company recorded a loss on extinguishment of debt in the amount of $6.7 million, consisting of the write-off of unamortized discount related to the Perceptive indebtedness and the redemption premium paid to Perceptive.&lt;/div&gt;

&lt;div&gt;&lt;span style="font-size: 10pt;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;span style="font-size: 10pt;"&gt;&lt;br/&gt;
        &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-size: 10pt;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: left; text-indent: 27pt;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0); background-color: rgb(255, 255, 255); font-weight: normal; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none;"&gt;Borrowings under the Hayfin Credit Agreement bore
            interest, at the Company&#x2019;s election, at the adjusted Term SOFR for a one-month tenor, subject to a floor of 1.25%, plus an applicable margin of 9.5%
            (the &#x201c;Applicable Margin&#x201d;); provided, however, that upon, and during the continuance of, an Event of Default, the Applicable Margin would increase by an additional 3% per annum. On May 1, 2023 the Hayfin Credit Agreement was amended to reduce the Applicable Margin from 9.5% to 8.5%. On the last day of each calendar month prior to the Ares
            Closing Date, the Company paid accrued interest to Hayfin. The rate of interest in effect as of the Hayfin Closing Date, December 31, 2022 and the Ares Closing Date was 10.75%, approximately 13.7% and approximately 13.9%, respectively. The Company was also permitted to pay &#x201c;in kind&#x201d; a portion of the interest on the Hayfin Loans for each monthly interest period
            in an amount equal to 2.5% per annum, which was added to the principal amount of the outstanding debt under the Hayfin Credit
            Facility. From the Hayfin Closing Date through December 31, 2022, $3.0 million of interest was paid in kind and added to the balance
            of the outstanding Hayfin Loans. For the year ended December 31, 2023, $3.8 million of interest was paid in kind and added to the
            balance of the outstanding Hayfin Loans.&lt;/span&gt;&lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-size: 10pt;"&gt; &lt;/span&gt;&lt;/div&gt;
&lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-indent: 45px; text-align: left;"&gt; &lt;/p&gt;
&lt;div&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;
&lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-bottom: 0px; text-align: left; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; text-indent: 27pt;"&gt;&#160; &#160;&lt;/p&gt;&lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-bottom: 0px; text-align: left; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; text-indent: 27pt;"&gt; &lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: left; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;On the Ares Closing Date, the Company
            paid Hayfin the entire outstanding principal amount underlying the Hayfin Loans and all accrued and unpaid interest thereon, as well as the exit fee of 1.0% of the outstanding principal amount paid. This exit fee had been recorded separately as a non-current liability on the accompanying consolidated balance sheet as of December 31,
            2022. In accordance with the terms of the Hayfin Credit Agreement, the Company also paid Hayfin the early prepayment fee in the amount equal to 7.0%
            of the prepaid principal amount of $158.6 million, or $11.1 million.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-indent: 45px; text-align: left; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;span style="font-size: 10pt;"&gt;&lt;br/&gt;
          &lt;/span&gt; &lt;/p&gt;
&lt;div&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;
&lt;p style="background-color: rgb(255, 255, 255); margin-top: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-align: left; text-transform: none; text-indent: 27pt;"&gt;All of the Company&#x2019;s obligations under the Hayfin Credit Agreement were secured by a first-priority lien and security interest in substantially all of the Company&#x2019;s tangible and intangible assets,
          including intellectual property, and all of the equity interests in the Company&#x2019;s subsidiaries. The Hayfin Credit Agreement contained certain representations and warranties, affirmative covenants, negative covenants and conditions that are
          customarily required for similar debt financings. The negative covenants restricted or limited the ability of the Company and its subsidiaries to, among other things and subject to certain exceptions contained in the Hayfin Credit Agreement,
          incur new indebtedness; create liens on assets; engage in certain fundamental corporate changes, such as mergers or acquisitions, or changes to the Company&#x2019;s or its subsidiaries&#x2019; business activities; make certain Investments or Restricted
          Payments (each as defined in the Hayfin Credit Agreement); change its fiscal year; pay dividends; repay certain other indebtedness; engage in certain affiliate transactions; or enter into, amend or terminate any other agreements that have the
          impact of restricting the Company&#x2019;s ability to make loan repayments under the Hayfin Credit Agreement. In addition, the Company was required (i) at all times prior to the Hayfin Maturity Date to maintain a minimum cash balance of $6.0 million; and (ii) as of the last day of each fiscal quarter, report IVIG product and related revenues for the trailing 12-month period that exceed
          the amounts set forth in the &lt;span style="font-family: 'Times New Roman'; color: rgb(0, 0, 0); background-color: rgb(255, 255, 255); font-weight: normal; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none;"&gt;Hayfin&lt;/span&gt;&lt;/span&gt; Credit Agreement, which ranged from $75.0 million for the fiscal quarter ended June 30, 2022 to $110.0 million for the fiscal quarter ended September 30, 2023. As of the Ares Closing Date and December 31, 2022, the Company was in compliance with all of the covenants contained in the &lt;span style="font-family: 'Times New Roman'; color: rgb(0, 0, 0); background-color: rgb(255, 255, 255); font-weight: normal; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none;"&gt;Hayfin&lt;/span&gt;&lt;/span&gt; Credit Agreement. &lt;/p&gt;
&lt;div&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;
&lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-indent: 45px; text-align: left; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; As consideration for the Hayfin
          Credit Agreement, on the Hayfin Closing Date the Company issued to various entities affiliated with Hayfin warrants to purchase an aggregate of 9,103,047
          shares of the Company&#x2019;s common stock (the &#x201c;Hayfin Warrants&#x201d;). The Hayfin Warrants have an exercise price equal to $1.6478 per share,
          which is equal to the trailing 30-day Volume Weighted-average Price of the Company&#x2019;s common stock on the business day immediately
          prior to the Hayfin Closing Date. The Hayfin Warrants were valued by the Company at approximately $9.6 million as of the Hayfin Closing
          Date and have an expiration date of March 23, 2029 (see Note 8). As consideration for the foregoing amendment to the Hayfin Credit
          Agreement on May 1, 2023, the Company issued additional warrants to the lenders to purchase 2,391,244 shares of the Company&#x2019;s common
          stock at an exercise price of $3.2619 per share (the &#x201c;Hayfin Second Amendment Warrants&#x201d;). The Hayfin Second Amendment Warrants were
          valued at approximately $5.6 million and have an expiration date of May 1, 2030.&lt;/div&gt;

&lt;div&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-size: 10pt;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;br/&gt;&lt;/div&gt;
&lt;p style="margin-top: 0px; margin-bottom: 0px; font-family: 'Times New Roman'; font-size: 10pt; text-align: left; text-indent: 27pt;"&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;As a result of the upfront fee and exit fee paid or payable to Hayfin, the expenses incurred by the Company&#160; in connection with this transaction and
            the value of the Hayfin Warrants and Hayfin Second Amendment Warrants, the Company recognized a discount on the Hayfin Loans in the amount of $13.9
            million for the year ended December 31, 2022 and an additional debt discount in the year ended December 31, 2023 in the amount of $5.7
            million. The Company records debt discount as a reduction to the face amount of the debt, and the debt discount is amortized as interest expense over the life of the debt using the interest method. As of the Ares Closing Date, $15.0 million of the aggregate debt discount associated with the Hayfin Credit Facility was unamortized, and this amount is reflected in the loss on
            extinguishment of debt for the year ended December 31, 2023. Based on the fair value of the Hayfin Warrants and the aggregate amount of fees and expenses associated with obtaining the Hayfin Credit Facility, the effective interest rate on the
            Hayfin Loans as of the Hayfin Closing Date and as of December 31, 2022 was approximately 13.0% and 16.1%, respectively&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: left; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;.&lt;/span&gt; &lt;/span&gt;&lt;span style="font-size: 10pt;"&gt;&lt;br/&gt;
          &lt;/span&gt; &lt;/p&gt;</us-gaap:LongTermDebtTextBlock>
    <us-gaap:ScheduleOfDebtTableTextBlock
      contextRef="c20240101to20241231"
      id="Text_fbdb6915daed4323a06f872dafe9a2af">&lt;p style="margin-top: 0px; margin-bottom: 0px; font-family: 'Times New Roman'; font-size: 10pt; text-align: left; text-indent: 27pt;"&gt;A summary of outstanding senior notes payable is as follows:&lt;/p&gt;&lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px;"&gt;&#160;&#160; &lt;br/&gt;
        &lt;/p&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="text-align: left; font: 10pt 'Times New Roman'; width: 100%; border-spacing: 0;"&gt;


  &lt;tr style="height: 15px;"&gt;

    &lt;td style="padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: center;"&gt;&lt;strong&gt;December 31, 2024&lt;/strong&gt;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: center;"&gt;&lt;strong&gt;December 31, 2023&lt;/strong&gt;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td rowspan="1" style="vertical-align: top; width: 76%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="6" rowspan="1" style="text-align: center; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&lt;span style="font-style: italic;"&gt;(In thousands)&lt;/span&gt;&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td style="vertical-align: top; width: 76%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 9pt; text-indent: -9pt;"&gt;Term loan&lt;br/&gt;
                &lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;32,500&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;62,500&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td rowspan="1" style="vertical-align: top; width: 76%;" valign="bottom"&gt;
                &lt;div style="margin-left: 9pt; text-indent: -9pt;"&gt;Revolving credit facility&lt;br/&gt;
                &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;42,500&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;72,500&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td style="vertical-align: top; width: 76%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in;"&gt;Less:&lt;br/&gt;
                &lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td style="vertical-align: top; width: 76%; padding-bottom: 2px;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 15px;"&gt;Debt discount&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"&gt;(2,663&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;)&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"&gt;(4,406&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;)&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td style="vertical-align: top; width: 76%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in;"&gt;Senior notes payable&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 4px double rgb(0, 0, 0);" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 4px double rgb(0, 0, 0);" valign="bottom"&gt;72,337&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 4px double rgb(0, 0, 0);" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 4px double rgb(0, 0, 0);" valign="bottom"&gt;130,594&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
</us-gaap:ScheduleOfDebtTableTextBlock>
    <adma:SeniorNotesPayableBeforeDebtDiscount
      contextRef="c20241231_CreditFacilityAxis_TermLoanMember"
      decimals="-3"
      id="Fact_9d0dd84a5e764974b5fe205672e8523b"
      unitRef="U001">32500000</adma:SeniorNotesPayableBeforeDebtDiscount>
    <adma:SeniorNotesPayableBeforeDebtDiscount
      contextRef="c20231231_CreditFacilityAxis_TermLoanMember"
      decimals="-3"
      id="Fact_b8cb21b7157e4f31849c0a5ee02bcd4d"
      unitRef="U001">62500000</adma:SeniorNotesPayableBeforeDebtDiscount>
    <adma:SeniorNotesPayableBeforeDebtDiscount
      contextRef="c20241231_CreditFacilityAxis_RevolvingCreditFacilityMember"
      decimals="-3"
      id="Fact_63d32cc0856f40e8bd166cc04cd4e84a"
      unitRef="U001">42500000</adma:SeniorNotesPayableBeforeDebtDiscount>
    <adma:SeniorNotesPayableBeforeDebtDiscount
      contextRef="c20231231_CreditFacilityAxis_RevolvingCreditFacilityMember"
      decimals="-3"
      id="Fact_4c4499632d58430abc9e9a32d333dc64"
      unitRef="U001">72500000</adma:SeniorNotesPayableBeforeDebtDiscount>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="c20241231"
      decimals="-3"
      id="Fact_11c432f666f34c7694c8af6fb0fe4743"
      unitRef="U001">2663000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="c20231231"
      decimals="-3"
      id="Fact_d9ef24ea668f46f1b2643b9b3a6dcba4"
      unitRef="U001">4406000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:SeniorLongTermNotes
      contextRef="c20241231"
      decimals="-3"
      id="Fact_f035b68443964af39d20af8975fedfa6"
      unitRef="U001">72337000</us-gaap:SeniorLongTermNotes>
    <us-gaap:SeniorLongTermNotes
      contextRef="c20231231"
      decimals="-3"
      id="Fact_f79c082a7ec94b49995d7ba0c531a119"
      unitRef="U001">130594000</us-gaap:SeniorLongTermNotes>
    <adma:SeniorNotesPayableBeforeDebtDiscount
      contextRef="c20231218"
      decimals="-5"
      id="Fact_3583fceccc6e4d038ec945011c367736"
      unitRef="U001">135000000</adma:SeniorNotesPayableBeforeDebtDiscount>
    <adma:SeniorNotesPayableBeforeDebtDiscount
      contextRef="c20231231_CreditFacilityAxis_TermLoanMember"
      decimals="-5"
      id="Fact_0b91c70b806e4c8cb3ec5aef33328c28"
      unitRef="U001">62500000</adma:SeniorNotesPayableBeforeDebtDiscount>
    <adma:SeniorNotesPayableBeforeDebtDiscount
      contextRef="c20231231_CreditFacilityAxis_RevolvingCreditFacilityMember"
      decimals="-5"
      id="Fact_f7896de8cb124b048313cb85323eee36"
      unitRef="U001">72500000</adma:SeniorNotesPayableBeforeDebtDiscount>
    <us-gaap:DebtInstrumentMaturityDate
      contextRef="c20240101to20241231_CounterpartyNameAxis_AresCreditAgreementMember_DebtInstrumentAxis_AresCreditFacilityMember"
      id="Fact_26c04a165e944612ba27afe84f85f788">2027-12-20</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="c20231218_DebtInstrumentAxis_HayfinCreditFacilityMember"
      decimals="-5"
      id="Fact_f48ff84a07b3435eb448923bffd4c1ab"
      unitRef="U001">158600000</us-gaap:DebtInstrumentCarryingAmount>
    <adma:LongTermDebtPrepaymentPenalty
      contextRef="c20231218_DebtInstrumentAxis_HayfinCreditFacilityMember"
      decimals="-5"
      id="Fact_8fc951edb9eb490699ce77510f9327a0"
      unitRef="U001">11100000</adma:LongTermDebtPrepaymentPenalty>
    <adma:DebtInstrumentExitFee
      contextRef="c20231218_DebtInstrumentAxis_HayfinCreditFacilityMember"
      decimals="-5"
      id="Fact_49793c36e5ad43fb8a6996ac887e02e1"
      unitRef="U001">1600000</adma:DebtInstrumentExitFee>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="c20231218_DebtInstrumentAxis_HayfinCreditFacilityMember"
      decimals="-5"
      id="Fact_7ca2cddd21aa43a4abbc0351a2e62ab4"
      unitRef="U001">15000000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="c20230101to20231231_DebtInstrumentAxis_HayfinCreditFacilityMember"
      decimals="-5"
      id="Fact_c4bebc1029794b76830602db0eef68b2"
      unitRef="U001">-26200000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:RepaymentsOfLongTermLinesOfCredit
      contextRef="c20240814to20240814_CreditFacilityAxis_RevolvingCreditFacilityMember"
      decimals="-5"
      id="Fact_fda7d7b72c604a92ab4aca800dec6845"
      unitRef="U001">30000000</us-gaap:RepaymentsOfLongTermLinesOfCredit>
    <adma:SeniorNotesPayableBeforeDebtDiscount
      contextRef="c20241231_CreditFacilityAxis_RevolvingCreditFacilityMember"
      decimals="-5"
      id="Fact_d2f0f38a7f3b46f8a6ab45b5d9dc1850"
      unitRef="U001">42500000</adma:SeniorNotesPayableBeforeDebtDiscount>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="c20240814_CounterpartyNameAxis_AresCreditAgreementMember_DebtInstrumentAxis_AresCreditFacilityMember"
      decimals="-5"
      id="Fact_00aede4314d244e1bcf593a859ce6283"
      unitRef="U001">30000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage
      contextRef="c20240101to20241231_CounterpartyNameAxis_AresCreditAgreementMember_DebtInstrumentAxis_AresCreditFacilityMember"
      decimals="3"
      id="Fact_c3ead516860a40e5a3f33c3e964ad3b6"
      unitRef="U007">0.005</us-gaap:LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage>
    <us-gaap:RepaymentsOfLongTermLinesOfCredit
      contextRef="c20241219to20241219_CreditFacilityAxis_TermLoanMember"
      decimals="-5"
      id="Fact_5801c883bada4f828ad6fd4a4613d5f4"
      unitRef="U001">30000000</us-gaap:RepaymentsOfLongTermLinesOfCredit>
    <adma:SeniorNotesPayableBeforeDebtDiscount
      contextRef="c20241231_CreditFacilityAxis_TermLoanMember"
      decimals="-5"
      id="Fact_1f375045f1904f00b8ed3e6d406fd503"
      unitRef="U001">32500000</adma:SeniorNotesPayableBeforeDebtDiscount>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="c20241219to20241219_CreditFacilityAxis_TermLoanMember"
      decimals="-5"
      id="Fact_4ca13ed17e9741f8af710bc2762bd1ca"
      unitRef="U001">-1200000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <adma:LongTermDebtPrepaymentPenalty
      contextRef="c20241219_CreditFacilityAxis_TermLoanMember"
      decimals="-5"
      id="Fact_adf245de51424d55beba4935aa79c663"
      unitRef="U001">500000</adma:LongTermDebtPrepaymentPenalty>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="c20241219_CreditFacilityAxis_TermLoanMember"
      decimals="-5"
      id="Fact_0e08ac39b5f94e73ab15da0a144ea2f7"
      unitRef="U001">800000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <adma:DebtInstrumentTermOfVariableRate
      contextRef="c20231218to20231218_CreditFacilityAxis_TermLoanMember_VariableRateAxis_SecuredOvernightFinancingRateSofrMember"
      id="Fact_dc7f109102454a9fb2db750fc47ae480">P3M</adma:DebtInstrumentTermOfVariableRate>
    <adma:DebtInstrumentApplicableMargin
      contextRef="c20231218to20231218_CreditFacilityAxis_TermLoanMember_VariableRateAxis_SecuredOvernightFinancingRateSofrMember"
      decimals="4"
      id="Fact_2f31cf9427214a4487f1c1c6fccf09c1"
      unitRef="U007">0.065</adma:DebtInstrumentApplicableMargin>
    <adma:DebtInstrumentTermOfVariableRate
      contextRef="c20231218to20231218_CreditFacilityAxis_RevolvingCreditFacilityMember_VariableRateAxis_SecuredOvernightFinancingRateSofrMember"
      id="Fact_103c36c429204ae1a37b07043655c4a5">P3M</adma:DebtInstrumentTermOfVariableRate>
    <adma:DebtInstrumentApplicableMargin
      contextRef="c20231218to20231218_CreditFacilityAxis_RevolvingCreditFacilityMember_VariableRateAxis_SecuredOvernightFinancingRateSofrMember"
      decimals="4"
      id="Fact_8b2a8740400c4a898c0486e4860563ce"
      unitRef="U007">0.0375</adma:DebtInstrumentApplicableMargin>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c20241231_CreditFacilityAxis_TermLoanMember_VariableRateAxis_SecuredOvernightFinancingRateSofrMember"
      decimals="4"
      id="Fact_5a46654e774145a78236d7ce8dc85e6d"
      unitRef="U007">0.1085</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c20231231_CreditFacilityAxis_TermLoanMember_VariableRateAxis_SecuredOvernightFinancingRateSofrMember"
      decimals="4"
      id="Fact_e4add2ccb9804900baafbbad8777177c"
      unitRef="U007">0.1188</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c20241231_CreditFacilityAxis_RevolvingCreditFacilityMember_VariableRateAxis_SecuredOvernightFinancingRateSofrMember"
      decimals="4"
      id="Fact_7df64436c4e041808959db59c8dfd2dc"
      unitRef="U007">0.0834</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c20231231_CreditFacilityAxis_RevolvingCreditFacilityMember_VariableRateAxis_SecuredOvernightFinancingRateSofrMember"
      decimals="4"
      id="Fact_e2ae150492704308a177844771dac32d"
      unitRef="U007">0.0913</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentPeriodicPaymentPrincipal
      contextRef="c20231218to20231218_CounterpartyNameAxis_AresCreditAgreementMember_DebtInstrumentAxis_AresCreditFacilityMember"
      decimals="-6"
      id="Fact_0f2b9740fdc94489b7a256b5c85b3a29"
      unitRef="U001">0</us-gaap:DebtInstrumentPeriodicPaymentPrincipal>
    <us-gaap:DebtInstrumentFrequencyOfPeriodicPayment
      contextRef="c20240101to20241231_CounterpartyNameAxis_AresCreditAgreementMember_DebtInstrumentAxis_AresCreditFacilityMember"
      id="Fact_6540f7076d374059bcdbe4dba734ad60">quarterly</us-gaap:DebtInstrumentFrequencyOfPeriodicPayment>
    <us-gaap:DebtInstrumentPeriodicPaymentInterest
      contextRef="c20231218to20231218_CounterpartyNameAxis_AresCreditAgreementMember_DebtInstrumentAxis_AresCreditFacilityMember"
      decimals="-5"
      id="Fact_9fad5f10948643da9e410e7c0d40e0f1"
      unitRef="U001">1800000</us-gaap:DebtInstrumentPeriodicPaymentInterest>
    <adma:PrepaymentsOfDebtPremium
      contextRef="c20231218to20231218_CounterpartyNameAxis_AresCreditAgreementMember_DebtInstrumentAxis_AresCreditFacilityMember"
      decimals="-6"
      id="Fact_3e8b8d3660e74d2785474da40f1b1904"
      unitRef="U001">0</adma:PrepaymentsOfDebtPremium>
    <us-gaap:LineOfCreditFacilityCommitmentFeePercentage
      contextRef="c20231218to20231218_CounterpartyNameAxis_AresCreditAgreementMember_RangeAxis_MinimumMember"
      decimals="2"
      id="Fact_d72e81843abe4a1ea2a868c8ad570750"
      unitRef="U007">0.50</us-gaap:LineOfCreditFacilityCommitmentFeePercentage>
    <adma:SeniorNotesPayableBeforeDebtDiscount
      contextRef="c20231231_CreditFacilityAxis_RevolvingCreditFacilityMember"
      decimals="-5"
      id="Fact_d1d479cc86bb4479bfeebce95d67da85"
      unitRef="U001">72500000</adma:SeniorNotesPayableBeforeDebtDiscount>
    <us-gaap:LineOfCreditFacilityCommitmentFeePercentage
      contextRef="c20231218to20231218_CounterpartyNameAxis_AresCreditAgreementMember_RangeAxis_MinimumMember"
      decimals="2"
      id="Fact_052923961b9847f08664191d0d968634"
      unitRef="U007">0.50</us-gaap:LineOfCreditFacilityCommitmentFeePercentage>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="c20241231_CounterpartyNameAxis_AresCreditAgreementMember_DebtInstrumentAxis_AresCreditFacilityMember"
      decimals="-5"
      id="Fact_dfbd8a9a76fd42729523a3c54bd1016d"
      unitRef="U001">36300000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed
      contextRef="c20231218to20231218_CounterpartyNameAxis_AresCreditAgreementMember_DebtInstrumentRedemptionPeriodAxis_PrepaidOnOrPriorToFirstAnniversaryMember"
      decimals="3"
      id="Fact_1363e9d8a1184cc48176a08c6444093e"
      unitRef="U007">0.015</us-gaap:DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed>
    <us-gaap:DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed
      contextRef="c20231218to20231218_CounterpartyNameAxis_AresCreditAgreementMember_DebtInstrumentRedemptionPeriodAxis_PrepaidOnOrPriorToSecondAnniversaryMember"
      decimals="3"
      id="Fact_e6d8befa4dc342d2882a272f25c55e60"
      unitRef="U007">0.015</us-gaap:DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed>
    <us-gaap:DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed
      contextRef="c20231218to20231218_CounterpartyNameAxis_AresCreditAgreementMember_DebtInstrumentRedemptionPeriodAxis_PrepaidAfterTheFirstAnniversaryMember"
      decimals="3"
      id="Fact_92268f303f2e4571b11b9248d01d34a9"
      unitRef="U007">0.015</us-gaap:DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed>
    <us-gaap:DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed
      contextRef="c20231218to20231218_CounterpartyNameAxis_AresCreditAgreementMember_DebtInstrumentRedemptionPeriodAxis_PrepaidOnOrPriorToThirdAnniversaryMember"
      decimals="3"
      id="Fact_bdd1ddc0c8444081ad46e6a328777d00"
      unitRef="U007">0.01</us-gaap:DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed>
    <us-gaap:DebtInstrumentFeeAmount
      contextRef="c20241231_CounterpartyNameAxis_AresCreditAgreementMember_DebtInstrumentAxis_AresCreditFacilityMember"
      decimals="-5"
      id="Fact_e3249724132e469e91939698cfbd967a"
      unitRef="U001">2800000</us-gaap:DebtInstrumentFeeAmount>
    <adma:OriginalDiscountPayableCreditFacility
      contextRef="c20241231_CounterpartyNameAxis_AresCreditAgreementMember_DebtInstrumentAxis_AresCreditFacilityMember"
      decimals="-5"
      id="Fact_aac4a50024a342d4ae24a6d49704d940"
      unitRef="U001">1700000</adma:OriginalDiscountPayableCreditFacility>
    <adma:DebtInstrumentExitFee
      contextRef="c20241231_CounterpartyNameAxis_AresCreditAgreementMember_DebtInstrumentAxis_AresCreditFacilityMember"
      decimals="-5"
      id="Fact_f5a4e57daa63465a8edb571a237bf00b"
      unitRef="U001">1700000</adma:DebtInstrumentExitFee>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="c20231218_CounterpartyNameAxis_AresCreditAgreementMember_DebtInstrumentAxis_AresCreditFacilityMember"
      decimals="-5"
      id="Fact_865c21a3cadd49d3827911bef7aa0a15"
      unitRef="U001">4400000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="c20241231_CounterpartyNameAxis_AresCreditAgreementMember_DebtInstrumentAxis_AresCreditFacilityMember"
      decimals="4"
      id="Fact_b133aee534bb4f5ca8b62b09f35fec56"
      unitRef="U007">0.1081</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="c20231231_CounterpartyNameAxis_AresCreditAgreementMember_DebtInstrumentAxis_AresCreditFacilityMember"
      decimals="4"
      id="Fact_cd344bc22dd140a8873ed3b379ab569b"
      unitRef="U007">0.1139</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <adma:DebtInstrumentExitFee
      contextRef="c20241219_CreditFacilityAxis_TermLoanMember"
      decimals="-5"
      id="Fact_63614b1ef06b4939a6562136e705a8f1"
      unitRef="U001">400000</adma:DebtInstrumentExitFee>
    <adma:ExitFeeLiability
      contextRef="c20241231_CreditFacilityAxis_TermLoanMember"
      decimals="-5"
      id="Fact_35c221b208094909874db44e9374ea4f"
      unitRef="U001">1300000</adma:ExitFeeLiability>
    <adma:MinimumLiquidityCovenantsCreditFacilities
      contextRef="c20241231_CounterpartyNameAxis_AresCreditAgreementMember"
      decimals="-5"
      id="Fact_7ee82f8111644a29b1d1d11e144affe6"
      unitRef="U001">15000000</adma:MinimumLiquidityCovenantsCreditFacilities>
    <us-gaap:DebtInstrumentInterestRateIncreaseDecrease
      contextRef="c20240101to20241231_CounterpartyNameAxis_AresCreditAgreementMember"
      decimals="2"
      id="Fact_4adb98e25a364fb7926896ec467627f2"
      unitRef="U007">0.02</us-gaap:DebtInstrumentInterestRateIncreaseDecrease>
    <adma:SeniorNotesPayableBeforeDebtDiscount
      contextRef="c20220323_CounterpartyNameAxis_HayfinCreditAgreementMember_DebtInstrumentAxis_HayfinCreditFacilityMember_RangeAxis_MaximumMember"
      decimals="-5"
      id="Fact_b96df6933a5c416482db6cf5b2a67b5d"
      unitRef="U001">175000000</adma:SeniorNotesPayableBeforeDebtDiscount>
    <adma:SeniorNotesPayableBeforeDebtDiscount
      contextRef="c20220323_CounterpartyNameAxis_HayfinCreditAgreementMember_DebtInstrumentAxis_HayfinClosingDateLoanMember"
      decimals="-5"
      id="Fact_acab3009ec7e4ba883c4f34a71105654"
      unitRef="U001">150000000</adma:SeniorNotesPayableBeforeDebtDiscount>
    <adma:SeniorNotesPayableBeforeDebtDiscount
      contextRef="c20220323_CounterpartyNameAxis_HayfinCreditAgreementMember_DebtInstrumentAxis_HayfinDelayedDrawLoanMember"
      decimals="-5"
      id="Fact_358df53a73ad45c19cde9406cdbdfe15"
      unitRef="U001">25000000</adma:SeniorNotesPayableBeforeDebtDiscount>
    <us-gaap:DebtInstrumentMaturityDate
      contextRef="c20240101to20241231_CounterpartyNameAxis_HayfinCreditAgreementMember_DebtInstrumentAxis_HayfinCreditFacilityMember"
      id="Fact_116027784ff64e9bbaf2464454b2e310">2027-03-23</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:RepaymentsOfNotesPayable
      contextRef="c20220323to20220323_DebtInstrumentAxis_HayfinClosingDateLoanMember"
      decimals="-5"
      id="Fact_f00128d2a70945e9b9d0093b589539c2"
      unitRef="U001">100000000</us-gaap:RepaymentsOfNotesPayable>
    <us-gaap:DebtInstrumentUnamortizedPremium
      contextRef="c20220323_CounterpartyNameAxis_HayfinCreditAgreementMember_DebtInstrumentAxis_HayfinClosingDateLoanMember"
      decimals="-5"
      id="Fact_f2d7dd0613ee48bdab6df240365e281d"
      unitRef="U001">2000000</us-gaap:DebtInstrumentUnamortizedPremium>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="c20220323to20220323_CounterpartyNameAxis_HayfinCreditAgreementMember_DebtInstrumentAxis_HayfinClosingDateLoanMember"
      decimals="-5"
      id="Fact_e7421535dc834d64bac715353c3e9992"
      unitRef="U001">1000000</us-gaap:PaymentsOfDebtIssuanceCosts>
    <adma:DebtInstrumentUpfrontFeePaidInKind
      contextRef="c20220323to20220323_CounterpartyNameAxis_HayfinCreditAgreementMember"
      decimals="-5"
      id="Fact_ac52a9f15a7f4a858b12a6952503dd22"
      unitRef="U001">1800000</adma:DebtInstrumentUpfrontFeePaidInKind>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="c20220323to20220323_CounterpartyNameAxis_HayfinCreditAgreementMember"
      decimals="-5"
      id="Fact_0a38348b0b1244d29e65a71d0012029e"
      unitRef="U001">-6700000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <adma:DebtInstrumentTermOfVariableRate
      contextRef="c20240101to20241231_CounterpartyNameAxis_HayfinCreditAgreementMember_VariableRateAxis_SecuredOvernightFinancingRateSofrMember"
      id="Fact_adc4caa915304208a671c809ea58f8cd">P1M</adma:DebtInstrumentTermOfVariableRate>
    <adma:DebtInstrumentFloorInterestRate
      contextRef="c20220323to20220323_CounterpartyNameAxis_HayfinCreditAgreementMember_VariableRateAxis_BaseRateMember"
      decimals="4"
      id="Fact_d26f491b872243fe8fd329d5f6ec10cf"
      unitRef="U007">0.0125</adma:DebtInstrumentFloorInterestRate>
    <adma:DebtInstrumentApplicableMargin
      contextRef="c20220323to20220323_CounterpartyNameAxis_HayfinCreditAgreementMember"
      decimals="3"
      id="Fact_da7a909ac9a7412eb7866ed01f97e59e"
      unitRef="U007">0.095</adma:DebtInstrumentApplicableMargin>
    <us-gaap:DebtInstrumentInterestRateIncreaseDecrease
      contextRef="c20220323to20220323_CounterpartyNameAxis_HayfinCreditAgreementMember"
      decimals="2"
      id="Fact_c28c13228f1647c081836bfd17481da5"
      unitRef="U007">0.03</us-gaap:DebtInstrumentInterestRateIncreaseDecrease>
    <adma:DebtInstrumentApplicableMargin
      contextRef="c20230430to20230430_CounterpartyNameAxis_HayfinSecondAmendmentMember_VariableRateAxis_SecuredOvernightFinancingRateSofrMember"
      decimals="3"
      id="Fact_8ba15853057c427f8d6e51b7574da0fd"
      unitRef="U007">0.095</adma:DebtInstrumentApplicableMargin>
    <adma:DebtInstrumentApplicableMargin
      contextRef="c20230501to20230501_CounterpartyNameAxis_HayfinSecondAmendmentMember_VariableRateAxis_SecuredOvernightFinancingRateSofrMember"
      decimals="3"
      id="Fact_191541fdfa70411aadc0d591f7da5ca9"
      unitRef="U007">0.085</adma:DebtInstrumentApplicableMargin>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="c20220323_CounterpartyNameAxis_HayfinCreditAgreementMember_DebtInstrumentAxis_HayfinClosingDateLoanMember"
      decimals="4"
      id="Fact_8d3a26a91c2a400eb4b28af7c4ce0091"
      unitRef="U007">0.1075</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="c20221231_CounterpartyNameAxis_HayfinCreditAgreementMember_DebtInstrumentAxis_HayfinClosingDateLoanMember"
      decimals="3"
      id="Fact_d23ba2d8de1c4fbd9250a5d53a29d13f"
      unitRef="U007">0.137</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="c20231218_CounterpartyNameAxis_AresCreditAgreementMember_DebtInstrumentAxis_AresClosingDateLoanMember"
      decimals="3"
      id="Fact_7bceb21e1dc949b5b192e3ea33feffd7"
      unitRef="U007">0.139</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <adma:DebtInstrumentInterestAmountToBePayInKind
      contextRef="c20220323to20220323_CounterpartyNameAxis_HayfinCreditAgreementMember"
      decimals="3"
      id="Fact_dd9eca0ac5044c76908132dbfa624504"
      unitRef="U007">0.025</adma:DebtInstrumentInterestAmountToBePayInKind>
    <us-gaap:PaidInKindInterest
      contextRef="c20230101to20231231_CounterpartyNameAxis_HayfinCreditAgreementMember"
      decimals="-5"
      id="Fact_af1f2239cd1749cc85249e527ab61bef"
      unitRef="U001">3000000</us-gaap:PaidInKindInterest>
    <us-gaap:PaidInKindInterest
      contextRef="c20240101to20241231_CounterpartyNameAxis_HayfinCreditAgreementMember"
      decimals="-5"
      id="Fact_672605cd67c641e999494dbdd77e7e5f"
      unitRef="U001">3800000</us-gaap:PaidInKindInterest>
    <adma:PercentageOfExitFeeOfOutstandingPrincipalAmountBeingPaid
      contextRef="c20231218to20231218_CounterpartyNameAxis_HayfinCreditAgreementMember"
      decimals="3"
      id="Fact_faf38bd428c24761bb1afdd19a98874d"
      unitRef="U007">0.01</adma:PercentageOfExitFeeOfOutstandingPrincipalAmountBeingPaid>
    <us-gaap:DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed
      contextRef="c20231218to20231218_CounterpartyNameAxis_HayfinCreditAgreementMember"
      decimals="3"
      id="Fact_b0d604280bc24c6c83a1af5f9f1cfc9a"
      unitRef="U007">0.07</us-gaap:DebtInstrumentRedemptionPricePercentageOfPrincipalAmountRedeemed>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="c20231218_DebtInstrumentAxis_HayfinCreditFacilityMember"
      decimals="-5"
      id="Fact_362decde0240484b96dee65c5e6b6cfc"
      unitRef="U001">158600000</us-gaap:DebtInstrumentCarryingAmount>
    <adma:LongTermDebtPrepaymentPenalty
      contextRef="c20231218_DebtInstrumentAxis_HayfinCreditFacilityMember"
      decimals="-5"
      id="Fact_e7715346fb694f7788953a775330ef42"
      unitRef="U001">11100000</adma:LongTermDebtPrepaymentPenalty>
    <us-gaap:Cash
      contextRef="c20220323_CounterpartyNameAxis_HayfinCreditAgreementMember_RangeAxis_MinimumMember"
      decimals="-5"
      id="Fact_c5228979a4ef451ab148becef8a3563c"
      unitRef="U001">6000000</us-gaap:Cash>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20220401to20220630_CounterpartyNameAxis_HayfinCreditAgreementMember_RangeAxis_MinimumMember"
      decimals="-5"
      id="Fact_74caae59e979443285ab4504193b6990"
      unitRef="U001">75000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20230701to20230930_CounterpartyNameAxis_HayfinCreditAgreementMember_RangeAxis_MaximumMember"
      decimals="-5"
      id="Fact_b158297267e7478eae492595eaecb9bf"
      unitRef="U001">110000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <adma:SharesIssuedUponExerciseOfWarrants
      contextRef="c20220323to20220323_CounterpartyNameAxis_HayfinCreditAgreementMember"
      decimals="0"
      id="Fact_3e59ab66e4524ddfb3a916ef7b0cf674"
      unitRef="U002">9103047</adma:SharesIssuedUponExerciseOfWarrants>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c20220323_CounterpartyNameAxis_HayfinCreditAgreementMember"
      decimals="4"
      id="Fact_8e51d53f35174c67b42f3564e71035e6"
      unitRef="U003">1.6478</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <adma:TrailingPeriodForVolumeWeightedAveragePrice
      contextRef="c20240101to20241231_CounterpartyNameAxis_HayfinCreditAgreementMember"
      id="Fact_fbf1e05eb11c473eab42586e459bf193">P30D</adma:TrailingPeriodForVolumeWeightedAveragePrice>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="c20220323to20220323_CounterpartyNameAxis_HayfinCreditAgreementMember"
      decimals="-5"
      id="Fact_78bf1724d03148fda424b209e117d85d"
      unitRef="U001">9600000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:DebtInstrumentMaturityDate
      contextRef="c20240101to20241231_CounterpartyNameAxis_HayfinCreditAgreementMember"
      id="Fact_7345e896d16c4ea38920d74a90723dd3">2029-03-23</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c20230501_CounterpartyNameAxis_HayfinSecondAmendmentMember"
      decimals="0"
      id="Fact_7f29acaeae1948e89399ec7b402fc51e"
      unitRef="U002">2391244</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c20230501_CounterpartyNameAxis_HayfinSecondAmendmentMember"
      decimals="4"
      id="Fact_49feb7ce2e8343ffad540bf0278791e1"
      unitRef="U003">3.2619</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="c20230501_CounterpartyNameAxis_HayfinSecondAmendmentMember"
      decimals="-5"
      id="Fact_67d13b07df784755839b86b1e56703aa"
      unitRef="U001">5600000</us-gaap:WarrantsAndRightsOutstanding>
    <us-gaap:DebtInstrumentMaturityDate
      contextRef="c20240101to20241231_CounterpartyNameAxis_HayfinSecondAmendmentMember"
      id="Fact_5e35bced93e34709b0b331a9666538c4">2030-05-01</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="c20221231_CounterpartyNameAxis_HayfinSecondAmendmentMember"
      decimals="-5"
      id="Fact_d6714d355e9d424db7009453b0c12abb"
      unitRef="U001">13900000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="c20231231_CounterpartyNameAxis_HayfinSecondAmendmentMember"
      decimals="-5"
      id="Fact_2253e1acc3834842917cbe85269250d0"
      unitRef="U001">5700000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="c20231218_CounterpartyNameAxis_HayfinCreditAgreementMember"
      decimals="-5"
      id="Fact_4a324304f65a43088371c17ce60de103"
      unitRef="U001">15000000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="c20220323_CounterpartyNameAxis_HayfinCreditAgreementMember"
      decimals="3"
      id="Fact_561bb3d249e74eceb4b44c3c404e3b83"
      unitRef="U007">0.13</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="c20221231_CounterpartyNameAxis_HayfinCreditAgreementMember"
      decimals="3"
      id="Fact_3b720d463c12485a89707a26281f6b5b"
      unitRef="U007">0.161</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="c20240101to20241231"
      id="Text_d2a744264d9845e4b504a91fa7aad051">
&lt;div&gt;
          &lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt; border-spacing: 0;"&gt;


  &lt;tr style="vertical-align: top;"&gt;

    &lt;td style="vertical-align: top; width: 27pt;"&gt;
                  &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;strong&gt;8.&lt;/strong&gt;&lt;/p&gt;
                &lt;/td&gt;

    &lt;td style="vertical-align: top; width: auto;"&gt;
                  &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;span style="text-decoration: underline;"&gt;&lt;strong&gt;STOCKHOLDERS&lt;/strong&gt;&lt;/span&gt;&lt;strong&gt;&lt;span style="text-decoration: underline;"&gt;&#x2019; EQUITY&lt;/span&gt;&lt;br/&gt;
                    &lt;/strong&gt;&lt;/p&gt;
                &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
        &lt;/div&gt;
&lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/p&gt;&lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;span style="text-decoration: underline;"&gt;Preferred Stock&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/p&gt;&lt;p style="margin: 0px; font-family: 'Times New Roman'; font-size: 10pt; text-align: left; text-indent: 36pt; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;The Company is currently authorized to issue up to 10 million shares of preferred stock, $0.0001
          par value per share. There were no shares of preferred stock outstanding at December 31, 2024 and 2023.&lt;/p&gt;&lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/p&gt;&lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;span style="text-decoration: underline;"&gt;Common Stock&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/p&gt;&lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-indent: 45px; text-align: left;"&gt; &lt;/p&gt;
&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;As of
          December 31, 2024 and 2023, the Company was authorized to issue 300,000,000 shares of its common stock, $0.0001 par value per share, and 236,620,545
          and 226,063,032 shares of common stock were outstanding as of December 31, 2024 and 2023, respectively.&#160; After giving effect to shares
          reserved for the issuance of warrants and for awards issued under the Company&#x2019;s equity incentive plans, 36,093,118 shares of common
          stock were available for issuance as of December 31, 2024.&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;span style="background-color: rgb(255, 255, 255); display: inline; float: none; letter-spacing: normal; white-space: normal; word-spacing: 0px; font-weight: 400; text-align: left;"&gt; &lt;br/&gt;
          &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;span style="background-color: rgb(255, 255, 255); display: inline; float: none; letter-spacing: normal; white-space: normal; word-spacing: 0px; font-weight: 400; text-align: left;"&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal;"&gt; During the years ended December 31, 2024, 2023 and 2022, outstanding stock options aggregating to 1,988,066, 1,444,533 and 68,679 shares,
              respectively, of common stock were exercised, and the Company received net proceeds from the exercises of approximately $7.5
              million, $1.1 million and $0.2
              million, respectively.&lt;/span&gt;&lt;br/&gt;
          &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;span style="background-color: rgb(255, 255, 255); display: inline; float: none; letter-spacing: normal; white-space: normal; word-spacing: 0px; font-weight: 400; text-align: left;"&gt; &lt;br/&gt;
          &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;span style="background-color: rgb(255, 255, 255); display: inline; float: none; letter-spacing: normal; white-space: normal; word-spacing: 0px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-weight: 400; text-align: left; text-transform: none; font-variant: normal;"&gt;On December 9, 2022, the Company completed an underwritten public offering whereby the Company issued 24,125,873 shares of its common stock. Net proceeds after underwriting discounts and expenses associated with the offering were approximately $64.6 million and were used to accelerate commercialization and production activities, complete plasma center buildouts and obtain FDA approvals, to conclude post&#x2011;FDA
            marketing approval research and development projects, and for working capital, capital expenditures and general corporate purposes.&lt;/span&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
          &lt;/span&gt; &lt;/div&gt;

&lt;div&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;
       &lt;span style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt; &lt;span style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;span style="background-color: rgb(255, 255, 255); font-weight: normal;"&gt; &lt;/span&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;
          &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;br/&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="text-decoration: underline;"&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;Warrants&lt;/span&gt;&lt;/span&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
              &lt;/span&gt; &lt;/div&gt;
&lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
                &lt;/span&gt; &lt;/p&gt;
&lt;div&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-indent: 36pt;"&gt;&lt;span style="font-weight: normal; letter-spacing: normal; text-align: left; text-indent: 48px; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal;"&gt;
                    During the year ended December 31, 2024, several of the Company&#x2019;s former noteholders exercised an aggregate of 11,308,702
                    warrants in cashless exercise transactions resulting in the Company issuing 7,224,892 shares of its common stock. Also
                    during the year ended December 31, 2024, warrants to purchase 227,650 shares of common stock that had been issued to former
                    noteholders of the Company expired in accordance with their terms.&lt;/span&gt;&lt;br/&gt;
                &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-indent: 36pt;"&gt;&lt;span style="font-weight: normal; letter-spacing: normal; text-align: left; text-indent: 48px; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt; &lt;br/&gt;
                &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-indent: 36pt;"&gt; &lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;On June 16, 2023, various entities affiliated with Hayfin exercised 3,388,686 Hayfin Warrants in a cashless exercise transaction resulting in the Company issuing 1,967,847 shares of its common stock to such entities. On May 1, 2023 the Company issued the Hayfin Second Amendment Warrants (see Note 7), which were valued at $5.6 million using the Black-Scholes option-pricing model assuming an expected term of seven years, a volatility of 67.8%, a dividend yield of 0% and a risk-free rate of interest of 3.62%.&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-indent: 36pt;"&gt;&lt;span style="font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 48px; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt; &lt;br/&gt;
                &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-indent: 36pt;"&gt;On March 23, 2022, the Company issued the Hayfin Warrants, whereby affiliates of Hayfin may purchase an aggregate
                of 9,103,047 shares of common stock at an exercise price of $1.6478 per share (see Note 7). The Hayfin Warrants were valued at $9.6
                million, using the Black-Scholes option pricing model assuming an expected term of 7 years, a volatility of 68.1%, a dividend yield of 0%
                and a risk-free interest rate of 2.36%. During the year ended December 31, 2022, warrants to purchase 106,059 shares of common stock that had been issued to former noteholders of the Company expired. &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-indent: 36pt;"&gt; &lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
                &lt;/span&gt; &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-indent: 36pt;"&gt;At December 31, 2024 and 2023, the Company had outstanding warrants to purchase an aggregate of 966,554 and 12,502,906 shares,
                  respectively, of common stock, with a weighted average exercise price of $1.98 and $2.32 per share, respectively, and expiration dates ranging between March 2029 and May 2030. &lt;span style="background-color: rgb(255, 255, 255); font-weight: normal;"&gt;
                    &lt;span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; text-align: left; text-indent: 48px; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;&lt;span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal;"&gt;The






























                      following table summarizes information about warrants outstanding as of December 31, 2024, 2023 and 2022:&lt;/span&gt;&lt;/span&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-indent: 36pt;"&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal;"&gt;&lt;span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; text-align: left; text-indent: 48px; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt; &lt;br/&gt;
                    &lt;/span&gt;&lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; letter-spacing: normal; text-transform: none; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%; border-spacing: 0;"&gt;


  &lt;tr&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&lt;br class="Apple-interchange-newline"/&gt;
                          &#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"&gt;&lt;span style="font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;Shares &lt;/span&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
                          &lt;/span&gt; &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"&gt;
                          &lt;div style="text-align: center; font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;Weighted&lt;/div&gt;
                          &lt;div style="text-align: center; font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;Average&lt;/div&gt;
                          &lt;div style="text-align: center; font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;Exercise Price&lt;/div&gt;
                        &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                          &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;Warrants outstanding at December 31, 2021&lt;/div&gt;
                        &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                          &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;4,528,160&lt;/div&gt;
                        &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                          &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                        &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                          &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;2.82&lt;/div&gt;
                        &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; white-space: nowrap;" valign="bottom"&gt;
                          &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;Expired&lt;/div&gt;
                        &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                          &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;(106,059&lt;/div&gt;
                        &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;
                          &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;)&lt;/div&gt;
                        &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;
                          &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                        &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                          &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;8.23&lt;/div&gt;
                        &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                          &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;Granted&lt;/div&gt;
                        &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                          &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;9,103,047&lt;/div&gt;
                        &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                          &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                        &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                          &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;1.65&lt;/div&gt;
                        &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;
                          &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;Exercised&lt;/div&gt;
                        &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                          &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;-&lt;/div&gt;
                        &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;
                          &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                        &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;
                          &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;-&lt;/div&gt;
                        &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                          &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;Warrants outstanding at December 31, 2022&lt;/div&gt;
                        &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                          &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;13,525,148&lt;/div&gt;
                        &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                          &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                        &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                          &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;1.99&lt;/div&gt;
                        &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; white-space: nowrap;" valign="bottom"&gt;
                          &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;Expired&lt;/div&gt;
                        &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                          &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;(24,800&lt;/div&gt;
                        &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;
                          &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;)&lt;/div&gt;
                        &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;
                          &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                        &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                          &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;6.37&lt;/div&gt;
                        &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                          &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;Granted&lt;/div&gt;
                        &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                          &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;2,391,244&lt;/div&gt;
                        &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                          &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                        &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                          &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;3.26&lt;/div&gt;
                        &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;
                          &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;Exercised&lt;/div&gt;
                        &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                          &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;(3,388,686&lt;/div&gt;
                        &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;
                          &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;)&lt;/div&gt;
                        &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;
                          &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                        &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;
                          &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;1.65&lt;/div&gt;
                        &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                          &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;Warrants outstanding at December 31, 2023&lt;/div&gt;
                        &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                          &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;12,502,906&lt;/div&gt;
                        &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                          &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                        &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                          &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;2.32&lt;/div&gt;
                        &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; width: 76%; white-space: nowrap;" valign="bottom"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;Expired&lt;br/&gt;
                          &lt;/span&gt; &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;(227,650&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;)&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;4.21&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;Granted&lt;br/&gt;
                          &lt;/span&gt; &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;-&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;-&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; width: 76%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;Exercised&lt;br/&gt;
                          &lt;/span&gt; &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;(11,308,702&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;)&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;2.31&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;Warrants outstanding at December 31, 2024&lt;br/&gt;
                          &lt;/span&gt; &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;966,554&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;1.98&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div&gt;
                   &lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; text-align: left; text-indent: 48px; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt; &lt;/span&gt;&lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-indent: 36pt;"&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;span style="font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
                  &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="text-decoration: underline;"&gt;&lt;span style="font-family: 'Times New Roman'; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;Equity Incentive Plans&lt;/span&gt;&lt;/span&gt;

                &lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;
&lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/p&gt;&lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-bottom: 0px; text-align: left; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none; text-indent: 36pt;"&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; On June 21, 2022, the Company&#x2019;s stockholders approved the ADMA Biologics, Inc. 2022 Compensation Plan (the &#x201c;2022 Equity Plan&#x201d;), which replaced the Company&#x2019;s Amended and Restated 2014 Omnibus Incentive Compensation
                  Plan (the &#x201c;2014 Plan&#x201d;). Approval of the 2022 Equity Plan resulted in approximately 18 million additional shares of the
                  Company&#x2019;s common stock being reserved for future awards. The 2022 Equity Plan provides for the Company&#x2019;s Board of Directors (the &#x201c;Board&#x201d;) or a Committee of the Board (the &#x201c;Committee&#x201d;) to grant awards to grantees and to determine the
                  exercise price, vesting term, expiration date and all other terms and conditions of the awards, including acceleration of the vesting of an award at any time. Any options granted under the 2022 Equity Plan are intended to be Incentive
                  Stock Options (&#x201c;ISOs&#x201d;), unless specified by the Committee to be Non-Qualified Options (&#x201c;NQOs&#x201d;) as defined by the Internal Revenue Code. ISOs and NQOs may be granted to employees, consultants or Board members at an option price not less
                  than the fair market value of the common stock subject to the stock option agreement. Shares issued in connection with the exercise of stock options or the vesting of RSUs are newly issued shares.&lt;/span&gt; &lt;/p&gt;
&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
                  &lt;/span&gt; &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt; font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;For the years ended December 31,
                  2024, 2023 and 2022, the Company granted options to purchase an aggregate of 1,531,635, 1,826,380 and 1,194,032
                  shares, respectively, of common stock to employees and directors under the 2022 Equity Plan and 2014 Plan. During the year ended December 31, 2024, options to purchase 2,020,142 shares of common stock were exercised, for which 32,076
                  shares were withheld to cover the aggregate exercise prices and payroll taxes, and the Company received aggregate net exercise proceeds of $7.5
                  million. During the year ended December 31, 2023, options to purchase 3,814,122 shares of common stock were exercised, for
                  which 2,109,722 shares were withheld to cover the aggregate exercise prices and 259,867 shares were withheld to cover payroll taxes, and the Company received aggregate net exercise proceeds of $1.1 million.&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
                &lt;/span&gt; &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;The fair value of
                stock options granted was determined on the date of grant using the Black-Scholes model. The Black-Scholes option pricing model was developed for use in estimating the fair value of publicly traded options, which have no vesting
                restrictions and are fully transferable. The Company&#x2019;s employee stock options have characteristics significantly different from those of traded options, and changes in the underlying Black-Scholes assumptions can materially affect the fair
                value estimate. To determine the risk-free interest rate, the Company utilized the U.S. Treasury yield curve in effect at the time of the grant with a term consistent with the term of the awards granted by the Company. The expected term of
                all options granted is in accordance with Staff Accounting Bulletins 107 and 110, which is based on the average between vesting terms and contractual terms as the Company had a limited history of option exercises prior to the middle of
                fiscal 2023. The expected dividend yield reflects the Company&#x2019;s current and expected future policy for dividends on the Company&#x2019;s common stock. For the years ended December 31, 2024, 2023 and 2022, the expected stock price volatility for
                the Company&#x2019;s stock options was calculated by examining the historical volatility of the Company&#x2019;s common stock since the stock became publicly traded in the fourth quarter of 2013. &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
                &lt;/span&gt; &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt;"&gt;&lt;span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;The grant date fair values of stock options
              awarded during the years ended December 31, 2024, 2023 and 2022 were determined using the Black-Scholes option pricing model with the following assumptions:&lt;/span&gt; &lt;span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt; &lt;/div&gt;
&lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px;"&gt;&lt;span style="font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;span style="font-weight: normal;"&gt;&#160; &lt;/span&gt;&lt;br/&gt;
          &lt;/span&gt; &lt;/p&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="text-align: left; font: 10pt 'Times New Roman'; margin-right: auto; width: 100%; border-spacing: 0;"&gt;


  &lt;tr style="height: 15px;"&gt;

    &lt;td style="padding-bottom: 2px;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="10" rowspan="1" style="vertical-align: bottom; text-align: center; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; text-align: center; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;strong&gt;Years Ended
                  &lt;/strong&gt;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td style="padding-bottom: 2px;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-bottom: 0px; text-align: center; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;strong&gt;December 31,&lt;/strong&gt;&lt;/p&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-bottom: 0px; text-align: center; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;strong&gt;2024 &lt;/strong&gt;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: center; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-bottom: 0px; text-align: center; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;strong&gt;December 31,&lt;/strong&gt;&lt;/p&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-bottom: 0px; text-align: center; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;strong&gt;2023 &lt;/strong&gt;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="text-align: left; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="text-align: center;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;strong&gt;December 31,&lt;/strong&gt; &lt;br/&gt;
                  &lt;/span&gt; &lt;/div&gt;
                &lt;div style="text-align: center;"&gt;&lt;span style="font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;202&lt;strong&gt;2&lt;/strong&gt;&lt;/span&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;strong&gt;&lt;br/&gt;
                    &lt;/strong&gt;&lt;/span&gt;&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;Expected term&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: center; vertical-align: bottom; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; text-align: center; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; text-align: right; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;5.5-6.3 years&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: center; vertical-align: bottom; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; text-align: center; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; text-align: right; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;5.5-6.3 years&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; text-align: right; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="text-align: right; font-family: 'Times New Roman'; font-size: 10pt; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;5.5-6.3 years&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td style="vertical-align: bottom; width: 64%;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;Volatility&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;66&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;%&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;68&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;%&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; font-weight: normal; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-weight: normal; text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-weight: normal; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;68&lt;br/&gt;
                &lt;/span&gt; &lt;/td&gt;

    &lt;td colspan="1" style="font-weight: normal; text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&lt;strong style="font-weight: normal;"&gt;%&lt;/strong&gt;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td style="vertical-align: top; width: 64%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;Dividend yield&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;0.0&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;0.0&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;0.0&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td style="vertical-align: top; width: 64%;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;Risk-free interest rate&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;4.16-4.39&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;%&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;4.20-4.62&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;%&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;1.72-1.73&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;%&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 9pt;"&gt; &lt;span style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
        &lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt; &lt;/div&gt;
&lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-bottom: 0px; text-align: left; text-indent: 36pt; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;span style="font-size: 10pt;"&gt;The following table summarizes information about stock options outstanding as of December 31, &lt;strong&gt;&lt;span style="font-weight: normal;"&gt;2024,&lt;/span&gt; &lt;/strong&gt;2023 and 2022:&lt;/span&gt; &lt;/p&gt;&lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px;"&gt;&lt;span style="font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&#160;&#160; &lt;br/&gt;
          &lt;/span&gt; &lt;/p&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="text-align: left; font: 10pt 'Times New Roman'; width: 100%; border-spacing: 0;"&gt;


  &lt;tr style="height: 15px;"&gt;

    &lt;td style="padding-bottom: 2px;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; text-align: center; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;strong&gt;Shares&lt;/strong&gt;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; text-align: center; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;strong&gt;Weighted&lt;/strong&gt;&lt;/p&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; text-align: center; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;strong&gt;Average&lt;/strong&gt;&lt;/p&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; text-align: center; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;strong&gt;Exercise
                    Price&lt;/strong&gt;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td style="vertical-align: top; width: 76%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;Options outstanding, vested and
                  expected to vest at December 31, 2021&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;7,862,722&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;3.93&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td style="vertical-align: top; width: 76%;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;Forfeited&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;(31,540&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;)&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;2.37&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td style="vertical-align: top; width: 76%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;Expired&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;(700,324&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;)&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;6.86&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td style="vertical-align: top; width: 76%;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;Granted&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;1,194,032&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;1.67&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td style="vertical-align: top; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;Exercised&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;(68,679&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;)&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;2.55&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td style="vertical-align: top; width: 76%;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;Options outstanding, vested and
                  expected to vest at December 31, 2022&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;8,256,211&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;3.37&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td style="vertical-align: top; width: 76%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;Forfeited&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;(99,345&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;)&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;2.73&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td style="vertical-align: top; width: 76%;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;Expired&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;(262,940&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;)&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;6.42&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td style="vertical-align: top; width: 76%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;Granted&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;1,826,380&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;3.36&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td style="vertical-align: top; width: 76%; padding-bottom: 2px;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;Exercised&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;(3,814,122&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;)&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;3.15&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td style="vertical-align: top; width: 76%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;Options outstanding, vested and
                  expected to vest at December 31, 2023&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;5,906,184&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;3.38&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td rowspan="1" style="vertical-align: top; width: 76%;" valign="bottom"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;Forfeited&lt;br/&gt;
                &lt;/span&gt; &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;(30,094&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;)&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;3.36&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td rowspan="1" style="vertical-align: top; width: 76%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;Expired&lt;br/&gt;
                &lt;/span&gt; &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;(246,067&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;)&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;7.01&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td rowspan="1" style="vertical-align: top; width: 76%;" valign="bottom"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;Granted&lt;br/&gt;
                &lt;/span&gt; &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;1,531,635&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;6.40&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td rowspan="1" style="vertical-align: top; width: 76%; background-color: rgb(204, 238, 255); padding-bottom: 2px;" valign="bottom"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;Exercised&lt;br/&gt;
                &lt;/span&gt; &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"&gt;(2,020,142&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;)&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; padding-bottom: 2px;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; padding-bottom: 2px;" valign="bottom"&gt;3.90&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td rowspan="1" style="vertical-align: top; width: 76%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; padding-bottom: 4px;" valign="bottom"&gt;Options
                outstanding, vested and expected to vest at December 31, 2024&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom"&gt;5,141,516&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; padding-bottom: 4px;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; padding-bottom: 4px;" valign="bottom"&gt;3.90&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td style="width: 76%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td style="vertical-align: top; width: 76%; padding-bottom: 4px;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;Options exercisable&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom"&gt;2,657,932&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom"&gt;3.03&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
          &lt;/span&gt; &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt;"&gt; &lt;span style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;As of December 31, 2024, the Company had $6.7 million of unrecognized compensation expense related to stock options granted under the Company&#x2019;s equity incentive plans, which is expected to
            be recognized over a weighted-average period of 2.8 years. The weighted average remaining contractual term of stock options
            outstanding and expected to vest at December 31, 2024 is 7.1 years. The weighted average remaining contractual term of stock
            options exercisable at December 31, 2024 is 5.7 years. &lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal;"&gt;The following table summarizes additional information regarding
            outstanding and exercisable options under the stock option plans at December 31, 2024: &lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
&lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px;"&gt;&lt;span style="font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160; &lt;br/&gt;
          &lt;/span&gt; &lt;/p&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="text-align: left; font: 10pt 'Times New Roman'; width: 100%; border-spacing: 0;"&gt;


  &lt;tr style="height: 15px;"&gt;

    &lt;td style="width: 28%; padding-bottom: 2px;"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="white-space: nowrap; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/td&gt;

    &lt;td style="white-space: nowrap; width: 1%; padding-bottom: 2px;"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td class="hdcell" colspan="14" style="border-bottom: 2px solid rgb(0, 0, 0); vertical-align: bottom; text-align: center;"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; text-align: center; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;strong&gt;Stock
                    Options Outstanding&lt;/strong&gt;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td style="white-space: nowrap; width: 1%; padding-bottom: 2px;"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td style="white-space: nowrap; width: 1%; padding-bottom: 2px;"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td class="hdcell" colspan="14" style="border-bottom: 2px solid rgb(0, 0, 0); vertical-align: bottom; text-align: center;"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; text-align: center; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;strong&gt;Stock
                    Options Exercisable&lt;/strong&gt;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td style="white-space: nowrap; width: 1%; padding-bottom: 2px;"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td style="vertical-align: bottom; width: 28%; padding-bottom: 2px; white-space: nowrap;"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; text-align: center; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;Range of&lt;/p&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; text-align: center; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;Exercise Prices&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="white-space: nowrap; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/td&gt;

    &lt;td style="white-space: nowrap; width: 1%; padding-bottom: 2px;"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td class="hdcell" colspan="2" style="border-bottom: 2px solid rgb(0, 0, 0); vertical-align: bottom; text-align: center;"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; text-align: center; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;Options Outstanding&lt;/p&gt;
              &lt;/td&gt;

    &lt;td style="padding-bottom: 2px; white-space: nowrap; width: 1%;"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td style="white-space: nowrap; width: 1%; padding-bottom: 2px;"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td class="hdcell" colspan="2" style="border-bottom: 2px solid rgb(0, 0, 0); vertical-align: bottom; text-align: center;"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; text-align: center; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;Weighted&lt;/p&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; text-align: center; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;Average&lt;/p&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; text-align: center; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;Remaining&lt;/p&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; text-align: center; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;Contractual&lt;/p&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; text-align: center; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;Life (Years)&lt;/p&gt;
              &lt;/td&gt;

    &lt;td style="padding-bottom: 2px; white-space: nowrap; width: 1%;"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td style="white-space: nowrap; width: 1%; padding-bottom: 2px;"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td class="hdcell" colspan="2" style="border-bottom: 2px solid rgb(0, 0, 0); vertical-align: bottom; text-align: center;"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; text-align: center; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;Weighted Average
                  Exercise Price&lt;/p&gt;
              &lt;/td&gt;

    &lt;td style="padding-bottom: 2px; white-space: nowrap; width: 1%;"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td style="white-space: nowrap; width: 1%; padding-bottom: 2px;"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td class="hdcell" colspan="2" style="border-bottom: 2px solid rgb(0, 0, 0); vertical-align: bottom; text-align: center;"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; text-align: center; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;Aggregate Intrinsic
                  Value&lt;/p&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; text-align: center;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; ($000&#x2019;s)&lt;br/&gt;
                  &lt;/span&gt; &lt;/p&gt;
              &lt;/td&gt;

    &lt;td style="padding-bottom: 2px; white-space: nowrap; width: 1%;"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td style="white-space: nowrap; width: 1%; padding-bottom: 2px;"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td class="hdcell" colspan="2" style="border-bottom: 2px solid rgb(0, 0, 0); vertical-align: bottom; text-align: center;"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; text-align: center; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;Options Outstanding&lt;/p&gt;
              &lt;/td&gt;

    &lt;td style="padding-bottom: 2px; white-space: nowrap; width: 1%;"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td style="white-space: nowrap; width: 1%; padding-bottom: 2px;"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td class="hdcell" colspan="2" style="border-bottom: 2px solid rgb(0, 0, 0); vertical-align: bottom; text-align: center;"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; text-align: center; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;Weighted&lt;/p&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; text-align: center; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;Average&lt;/p&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; text-align: center; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;Remaining&lt;/p&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; text-align: center; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;Contractual&lt;/p&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; text-align: center; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;Life (Years)&lt;/p&gt;
              &lt;/td&gt;

    &lt;td style="padding-bottom: 2px; white-space: nowrap; width: 1%;"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td style="white-space: nowrap; width: 1%; padding-bottom: 2px;"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td class="hdcell" colspan="2" style="border-bottom: 2px solid rgb(0, 0, 0); vertical-align: bottom; text-align: center; white-space: nowrap;"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; text-align: center; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;Weighted&lt;/p&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; text-align: center; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt; Average&lt;/p&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; text-align: center; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt; Exercise&lt;/p&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; text-align: center; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt; Price&lt;/p&gt;
              &lt;/td&gt;

    &lt;td style="padding-bottom: 2px; white-space: nowrap; width: 1%;"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td style="white-space: nowrap; width: 1%; padding-bottom: 2px;"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td class="hdcell" colspan="2" style="border-bottom: 2px solid rgb(0, 0, 0); vertical-align: bottom; text-align: center; white-space: nowrap;"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; text-align: center; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;Aggregate&lt;/p&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; text-align: center; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt; Intrinsic&lt;/p&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; text-align: center; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt; Value&lt;/p&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; text-align: center; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt; ($000&#x2019;s)&lt;/p&gt;
              &lt;/td&gt;

    &lt;td style="padding-bottom: 2px; white-space: nowrap; width: 1%;"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td style="vertical-align: top; width: 28%; background-color: rgb(204, 238, 255);"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;$1.10 - $1.67&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="width: 1%; white-space: nowrap; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/td&gt;

    &lt;td style="width: 1%; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td style="width: 1%; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td class="ffcell" style="width: 6%; vertical-align: bottom; text-align: right; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;981,093&lt;/td&gt;

    &lt;td style="width: 1%; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td style="width: 1%; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td style="width: 1%; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td class="ffcell" style="width: 6%; vertical-align: bottom; text-align: right; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;6.8&lt;/td&gt;

    &lt;td style="width: 1%; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td style="width: 1%; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td style="width: 1%; vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;$&lt;/td&gt;

    &lt;td class="ffcell" style="width: 6%; vertical-align: bottom; text-align: right; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;1.60&lt;/td&gt;

    &lt;td style="width: 1%; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td style="width: 1%; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td style="width: 1%; vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;$&lt;/td&gt;

    &lt;td class="ffcell" style="width: 6%; vertical-align: bottom; text-align: right; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;15,252&lt;/td&gt;

    &lt;td style="width: 1%; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td style="width: 1%; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td style="width: 1%; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td class="ffcell" style="width: 6%; vertical-align: bottom; text-align: right; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;676,542&lt;/td&gt;

    &lt;td style="width: 1%; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td style="width: 1%; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td style="width: 1%; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td class="ffcell" style="width: 6%; vertical-align: bottom; text-align: right; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;6.6&lt;/td&gt;

    &lt;td style="width: 1%; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td style="width: 1%; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td style="width: 1%; vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;$&lt;/td&gt;

    &lt;td class="ffcell" style="width: 6%; vertical-align: bottom; text-align: right; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;1.58&lt;/td&gt;

    &lt;td style="width: 1%; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td style="width: 1%; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td style="width: 1%; vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;$&lt;/td&gt;

    &lt;td class="ffcell" style="width: 6%; vertical-align: bottom; text-align: right; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;10,532&lt;/td&gt;

    &lt;td style="width: 1%; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td style="vertical-align: top; width: 28%;"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;$1.73 - $2.60&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="white-space: nowrap; width: 1%; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/td&gt;

    &lt;td style="white-space: nowrap; width: 1%;"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td style="white-space: nowrap; width: 1%;"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td class="ffcell" style="vertical-align: bottom; text-align: right; width: 6%; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;629,655&lt;/td&gt;

    &lt;td style="white-space: nowrap; width: 1%;"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td style="white-space: nowrap; width: 1%;"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td style="white-space: nowrap; width: 1%;"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td class="ffcell" style="vertical-align: bottom; text-align: right; width: 6%; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;5.7&lt;/td&gt;

    &lt;td style="white-space: nowrap; width: 1%;"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td style="white-space: nowrap; width: 1%;"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td style="vertical-align: bottom; white-space: nowrap; width: 1%; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;$&lt;/td&gt;

    &lt;td class="ffcell" style="vertical-align: bottom; text-align: right; width: 6%; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;2.32&lt;/td&gt;

    &lt;td style="white-space: nowrap; width: 1%;"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td style="white-space: nowrap; width: 1%;"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td style="white-space: nowrap; width: 1%;"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td class="ffcell" style="vertical-align: bottom; text-align: right; width: 6%; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;9,336&lt;/td&gt;

    &lt;td style="white-space: nowrap; width: 1%;"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td style="white-space: nowrap; width: 1%;"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td style="white-space: nowrap; width: 1%;"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td class="ffcell" style="vertical-align: bottom; text-align: right; width: 6%; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;585,771&lt;/td&gt;

    &lt;td style="white-space: nowrap; width: 1%;"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td style="white-space: nowrap; width: 1%;"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td style="white-space: nowrap; width: 1%;"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td class="ffcell" style="vertical-align: bottom; text-align: right; width: 6%; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;5.6&lt;/td&gt;

    &lt;td style="white-space: nowrap; width: 1%;"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td style="white-space: nowrap; width: 1%;"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td style="vertical-align: bottom; white-space: nowrap; width: 1%; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;$&lt;/td&gt;

    &lt;td class="ffcell" style="vertical-align: bottom; text-align: right; width: 6%; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;2.33&lt;/td&gt;

    &lt;td style="white-space: nowrap; width: 1%;"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td style="white-space: nowrap; width: 1%;"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td style="white-space: nowrap; width: 1%;"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td class="ffcell" style="vertical-align: bottom; text-align: right; width: 6%; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;8,683&lt;/td&gt;

    &lt;td style="white-space: nowrap; width: 1%;"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td style="vertical-align: top; width: 28%; background-color: rgb(204, 238, 255);"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;$2.67 - $4.01&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/td&gt;

    &lt;td style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255);"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255);"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td class="ffcell" style="vertical-align: bottom; text-align: right; width: 6%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;1,809,746&lt;/td&gt;

    &lt;td style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255);"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255);"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255);"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td class="ffcell" style="vertical-align: bottom; text-align: right; width: 6%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;6.6&lt;/td&gt;

    &lt;td style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255);"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255);"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td style="vertical-align: bottom; white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;$&lt;/td&gt;

    &lt;td class="ffcell" style="vertical-align: bottom; text-align: right; width: 6%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;3.41&lt;/td&gt;

    &lt;td style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255);"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255);"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255);"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td class="ffcell" style="vertical-align: bottom; text-align: right; width: 6%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;24,868&lt;/td&gt;

    &lt;td style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255);"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255);"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255);"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td class="ffcell" style="vertical-align: bottom; text-align: right; width: 6%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;1,012,271&lt;/td&gt;

    &lt;td style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255);"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255);"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255);"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td class="ffcell" style="vertical-align: bottom; text-align: right; width: 6%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;5.4&lt;/td&gt;

    &lt;td style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255);"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255);"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td style="vertical-align: bottom; white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;$&lt;/td&gt;

    &lt;td class="ffcell" style="vertical-align: bottom; text-align: right; width: 6%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;3.46&lt;/td&gt;

    &lt;td style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255);"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255);"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255);"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td class="ffcell" style="vertical-align: bottom; text-align: right; width: 6%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;13,863&lt;/td&gt;

    &lt;td style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255);"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td rowspan="1" style="vertical-align: top; width: 28%; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;$4.09 - $6.14&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="white-space: nowrap; width: 1%; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/td&gt;

    &lt;td rowspan="1" style="white-space: nowrap; width: 1%; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/td&gt;

    &lt;td rowspan="1" style="white-space: nowrap; width: 1%; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/td&gt;

    &lt;td class="ffcell" rowspan="1" style="vertical-align: bottom; text-align: right; width: 6%; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;1,264,083&lt;/td&gt;

    &lt;td rowspan="1" style="white-space: nowrap; width: 1%; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/td&gt;

    &lt;td rowspan="1" style="white-space: nowrap; width: 1%; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/td&gt;

    &lt;td rowspan="1" style="white-space: nowrap; width: 1%; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/td&gt;

    &lt;td class="ffcell" rowspan="1" style="vertical-align: bottom; text-align: right; width: 6%; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;8.1&lt;/td&gt;

    &lt;td rowspan="1" style="white-space: nowrap; width: 1%; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/td&gt;

    &lt;td rowspan="1" style="white-space: nowrap; width: 1%; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/td&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; white-space: nowrap; width: 1%;"&gt;&lt;span style="font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;$&lt;br/&gt;
                &lt;/span&gt; &lt;/td&gt;

    &lt;td class="ffcell" rowspan="1" style="vertical-align: bottom; text-align: right; width: 6%; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;5.35&lt;/td&gt;

    &lt;td rowspan="1" style="white-space: nowrap; width: 1%; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/td&gt;

    &lt;td rowspan="1" style="white-space: nowrap; width: 1%; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/td&gt;

    &lt;td rowspan="1" style="white-space: nowrap; width: 1%; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/td&gt;

    &lt;td class="ffcell" rowspan="1" style="vertical-align: bottom; text-align: right; width: 6%; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;14,913&lt;/td&gt;

    &lt;td rowspan="1" style="white-space: nowrap; width: 1%; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/td&gt;

    &lt;td rowspan="1" style="white-space: nowrap; width: 1%; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/td&gt;

    &lt;td rowspan="1" style="white-space: nowrap; width: 1%; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/td&gt;

    &lt;td class="ffcell" rowspan="1" style="vertical-align: bottom; text-align: right; width: 6%; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;361,848&lt;/td&gt;

    &lt;td rowspan="1" style="white-space: nowrap; width: 1%; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/td&gt;

    &lt;td rowspan="1" style="white-space: nowrap; width: 1%; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/td&gt;

    &lt;td rowspan="1" style="white-space: nowrap; width: 1%; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/td&gt;

    &lt;td class="ffcell" rowspan="1" style="vertical-align: bottom; text-align: right; width: 6%; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;5.4&lt;/td&gt;

    &lt;td rowspan="1" style="white-space: nowrap; width: 1%; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/td&gt;

    &lt;td rowspan="1" style="white-space: nowrap; width: 1%; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/td&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; white-space: nowrap; width: 1%;"&gt;&lt;span style="font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;$&lt;br/&gt;
                &lt;/span&gt; &lt;/td&gt;

    &lt;td class="ffcell" rowspan="1" style="vertical-align: bottom; text-align: right; width: 6%; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;5.23&lt;/td&gt;

    &lt;td rowspan="1" style="white-space: nowrap; width: 1%; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/td&gt;

    &lt;td rowspan="1" style="white-space: nowrap; width: 1%; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/td&gt;

    &lt;td rowspan="1" style="white-space: nowrap; width: 1%; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/td&gt;

    &lt;td class="ffcell" rowspan="1" style="vertical-align: bottom; text-align: right; width: 6%; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;4,312&lt;/td&gt;

    &lt;td rowspan="1" style="white-space: nowrap; width: 1%; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td rowspan="1" style="vertical-align: top; width: 28%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;$6.54 - $9.81&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/td&gt;

    &lt;td rowspan="1" style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/td&gt;

    &lt;td rowspan="1" style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/td&gt;

    &lt;td class="ffcell" rowspan="1" style="vertical-align: bottom; text-align: right; width: 6%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;307,828&lt;/td&gt;

    &lt;td rowspan="1" style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/td&gt;

    &lt;td rowspan="1" style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/td&gt;

    &lt;td rowspan="1" style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/td&gt;

    &lt;td class="ffcell" rowspan="1" style="vertical-align: bottom; text-align: right; width: 6%; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; background-color: rgb(204, 238, 255);"&gt;9.0&lt;/td&gt;

    &lt;td rowspan="1" style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/td&gt;

    &lt;td rowspan="1" style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/td&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255);"&gt;&lt;span style="font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;$&lt;br/&gt;
                &lt;/span&gt; &lt;/td&gt;

    &lt;td class="ffcell" rowspan="1" style="vertical-align: bottom; text-align: right; width: 6%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;6.60&lt;/td&gt;

    &lt;td rowspan="1" style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/td&gt;

    &lt;td rowspan="1" style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/td&gt;

    &lt;td rowspan="1" style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/td&gt;

    &lt;td class="ffcell" rowspan="1" style="vertical-align: bottom; text-align: right; width: 6%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;3,248&lt;/td&gt;

    &lt;td rowspan="1" style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/td&gt;

    &lt;td rowspan="1" style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/td&gt;

    &lt;td rowspan="1" style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/td&gt;

    &lt;td class="ffcell" rowspan="1" style="vertical-align: bottom; text-align: right; width: 6%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;7,500&lt;/td&gt;

    &lt;td rowspan="1" style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/td&gt;

    &lt;td rowspan="1" style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/td&gt;

    &lt;td rowspan="1" style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/td&gt;

    &lt;td class="ffcell" rowspan="1" style="vertical-align: bottom; text-align: right; width: 6%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;0.6&lt;/td&gt;

    &lt;td rowspan="1" style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/td&gt;

    &lt;td rowspan="1" style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/td&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255);"&gt;&lt;span style="font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;$&lt;br/&gt;
                &lt;/span&gt; &lt;/td&gt;

    &lt;td class="ffcell" rowspan="1" style="vertical-align: bottom; text-align: right; width: 6%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;8.98&lt;/td&gt;

    &lt;td rowspan="1" style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/td&gt;

    &lt;td rowspan="1" style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/td&gt;

    &lt;td rowspan="1" style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/td&gt;

    &lt;td class="ffcell" rowspan="1" style="vertical-align: bottom; text-align: right; width: 6%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;61&lt;/td&gt;

    &lt;td rowspan="1" style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td style="vertical-align: top; width: 28%; padding-bottom: 2px;"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;$10.80 - $17.49&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="white-space: nowrap; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/td&gt;

    &lt;td style="white-space: nowrap; width: 1%; padding-bottom: 2px;"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td style="border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap; width: 1%;"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td class="ffcell" style="border-bottom: 2px solid rgb(0, 0, 0); vertical-align: bottom; text-align: right; width: 6%;"&gt;&lt;span style="font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;149,111&lt;br/&gt;
                &lt;/span&gt; &lt;/td&gt;

    &lt;td style="padding-bottom: 2px; white-space: nowrap; width: 1%;"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td style="white-space: nowrap; width: 1%; padding-bottom: 2px;"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td style="white-space: nowrap; width: 1%; padding-bottom: 2px;"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td class="ffcell" style="vertical-align: bottom; text-align: right; width: 6%; padding-bottom: 2px; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;span style="font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;8.7&lt;br/&gt;
                &lt;/span&gt; &lt;/td&gt;

    &lt;td style="white-space: nowrap; width: 1%; padding-bottom: 2px;"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td style="white-space: nowrap; width: 1%; padding-bottom: 2px;"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td style="vertical-align: bottom; white-space: nowrap; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;$&lt;/td&gt;

    &lt;td class="ffcell" style="vertical-align: bottom; text-align: right; width: 6%; padding-bottom: 2px;"&gt;&lt;span style="font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;8.74&lt;br/&gt;
                &lt;/span&gt; &lt;/td&gt;

    &lt;td style="white-space: nowrap; width: 1%; padding-bottom: 2px;"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td style="white-space: nowrap; width: 1%; padding-bottom: 2px;"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td style="border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap; width: 1%;"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td class="ffcell" style="border-bottom: 2px solid rgb(0, 0, 0); vertical-align: bottom; text-align: right; width: 6%;"&gt;&lt;span style="font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;500&lt;br/&gt;
                &lt;/span&gt; &lt;/td&gt;

    &lt;td style="padding-bottom: 2px; white-space: nowrap; width: 1%;"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td style="white-space: nowrap; width: 1%; padding-bottom: 2px;"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td style="border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap; width: 1%;"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td class="ffcell" style="border-bottom: 2px solid rgb(0, 0, 0); vertical-align: bottom; text-align: right; width: 6%;"&gt;&lt;span style="font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;14,000&lt;br/&gt;
                &lt;/span&gt; &lt;/td&gt;

    &lt;td style="padding-bottom: 2px; white-space: nowrap; width: 1%;"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td style="white-space: nowrap; width: 1%; padding-bottom: 2px;"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td style="white-space: nowrap; width: 1%; padding-bottom: 2px;"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td class="ffcell" style="vertical-align: bottom; text-align: right; width: 6%; padding-bottom: 2px;"&gt;&lt;span style="font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;0.1&lt;br/&gt;
                &lt;/span&gt; &lt;/td&gt;

    &lt;td style="white-space: nowrap; width: 1%; padding-bottom: 2px;"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td style="white-space: nowrap; width: 1%; padding-bottom: 2px;"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td style="vertical-align: bottom; white-space: nowrap; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;$&lt;/td&gt;

    &lt;td class="ffcell" style="vertical-align: bottom; text-align: right; width: 6%; padding-bottom: 2px;"&gt;&lt;span style="font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;10.80&lt;br/&gt;
                &lt;/span&gt; &lt;/td&gt;

    &lt;td style="white-space: nowrap; width: 1%; padding-bottom: 2px;"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td style="white-space: nowrap; width: 1%; padding-bottom: 2px;"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td style="border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap; width: 1%;"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td class="ffcell" style="border-bottom: 2px solid rgb(0, 0, 0); vertical-align: bottom; text-align: right; width: 6%; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;89&lt;/td&gt;

    &lt;td style="padding-bottom: 2px; white-space: nowrap; width: 1%;"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td style="width: 28%; background-color: rgb(204, 238, 255); padding-bottom: 4px;"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; padding-bottom: 4px;"&gt;&#160;&lt;/td&gt;

    &lt;td style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 4px double rgb(0, 0, 0);"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td class="ffcell" style="vertical-align: bottom; text-align: right; width: 6%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; border-bottom: 4px double rgb(0, 0, 0);"&gt;5,141,516&lt;/td&gt;

    &lt;td style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td class="ffcell" style="vertical-align: bottom; text-align: right; width: 6%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; padding-bottom: 4px;"&gt;7.1&lt;/td&gt;

    &lt;td style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td style="vertical-align: bottom; white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; padding-bottom: 4px;"&gt;$&lt;/td&gt;

    &lt;td class="ffcell" style="vertical-align: bottom; text-align: right; width: 6%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; padding-bottom: 4px;"&gt;3.90&lt;/td&gt;

    &lt;td style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td style="vertical-align: bottom; white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; border-bottom: 4px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;

    &lt;td class="ffcell" style="vertical-align: bottom; text-align: right; width: 6%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; border-bottom: 4px double rgb(0, 0, 0);"&gt;68,117&lt;/td&gt;

    &lt;td style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 4px double rgb(0, 0, 0);"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td class="ffcell" style="vertical-align: bottom; text-align: right; width: 6%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; border-bottom: 4px double rgb(0, 0, 0);"&gt;2,657,932&lt;/td&gt;

    &lt;td style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td class="ffcell" style="vertical-align: bottom; text-align: right; width: 6%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; padding-bottom: 4px;"&gt;5.7&lt;/td&gt;

    &lt;td style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td style="vertical-align: bottom; white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; padding-bottom: 4px;"&gt;$&lt;/td&gt;

    &lt;td class="ffcell" style="vertical-align: bottom; text-align: right; width: 6%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; padding-bottom: 4px;"&gt;3.03&lt;/td&gt;

    &lt;td style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td style="vertical-align: bottom; white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; border-bottom: 4px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;

    &lt;td class="ffcell" style="vertical-align: bottom; text-align: right; width: 6%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; border-bottom: 4px double rgb(0, 0, 0);"&gt;37,540&lt;/td&gt;

    &lt;td style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
&lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; text-align: left; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&#160; &lt;/p&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal;"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; During the
            years ended December 31, 2024, 2023 and 2022, the Company granted RSUs representing an aggregate of 3,278,688, 3,389,760 and 1,174,266 shares,
            respectively, to certain employees and consultants of the Company and to members of the Board. The RSUs generally vest annually over a period of four years for employees and semi-annually over a period of one year for directors. &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;br/&gt;
        &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt;"&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;During the years ended December 31, 2024, 2023 and 2022, 1,886,463,&#160;1,199,445 and 2,727,412 shares, &lt;span style="font-weight: normal; letter-spacing: normal; text-align: left; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;respectively, vested in connection with grants of RSUs. &lt;span style="font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 48px; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;With respect to RSUs vested during the year ended December 31, 2024, 541,908
                shares valued at approximately $5.0 million were withheld were withheld to cover employees&#x2019; tax liabilities. &lt;/span&gt;With respect
              to RSUs vested during the year ended December 31, 2023, 365,722 shares valued at approximately $1.3 million were withheld by the Company to cover employees&#x2019; tax liabilities&lt;/span&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal;"&gt;. &lt;span style="font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;With respect to the RSUs vested during the year ended December 31, 2022&lt;/span&gt;, 918,851 shares valued at approximately $2.9 million were
              withheld by the Company to cover employees&#x2019; tax liabilities.&lt;span style="letter-spacing: normal; text-align: left; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt; All of these shares have been retired by the Company or were otherwise no longer outstanding as of December 31, 2024&lt;/span&gt;&lt;/span&gt;. &lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal;"&gt;A summary of the Company&#x2019;s unvested RSU activity and related information is as follows: &lt;/span&gt;&lt;br/&gt;
          &lt;/span&gt; &lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left;"&gt; &lt;span style="font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="text-align: left; font: 10pt 'Times New Roman'; width: 100%; border-spacing: 0;"&gt;


  &lt;tr style="height: 15px;"&gt;

    &lt;td style="padding-bottom: 2px;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; text-align: center; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;strong&gt;Shares&lt;/strong&gt;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; text-align: center; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;strong&gt;Weighted&lt;/strong&gt;&lt;/p&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; text-align: center; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;strong&gt;Average
                    Grant&lt;/strong&gt;&lt;/p&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; text-align: center; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;strong&gt;Date Fair
                    Value&lt;/strong&gt;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td style="vertical-align: top; width: 76%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;Balance at December 31, 2021&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;4,485,133&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;1.34&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td style="vertical-align: top; width: 76%;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;Granted&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;1,174,266&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;1.74&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td style="vertical-align: top; width: 76%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;Vested&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;(2,727,412&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;)&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;1.25&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td style="vertical-align: top; width: 76%; padding-bottom: 2px;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;Forfeited&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;(65,000&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;)&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;1.40&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td rowspan="1" style="vertical-align: top; font-family: 'Times New Roman'; width: 76%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;Balance at December 31, 2022&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;2,866,987&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;1.59&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td rowspan="1" style="vertical-align: top; width: 76%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;Granted&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;3,389,760&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;3.42&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td rowspan="1" style="vertical-align: top; width: 76%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;Vested&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;(1,199,445&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;)&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;1.63&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td rowspan="1" style="vertical-align: top; width: 76%; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;Forfeited&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;(400,005&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;)&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;2.71&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td style="vertical-align: top; width: 76%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;Balance at December 31, 2023&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;4,657,297&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;2.81&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td rowspan="1" style="vertical-align: top; width: 76%;" valign="bottom"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;Granted&lt;br/&gt;
                &lt;/span&gt; &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;3,278,688&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;$&lt;br/&gt;
                &lt;/span&gt; &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;7.44&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td rowspan="1" style="vertical-align: top; width: 76%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;Vested&lt;br/&gt;
                &lt;/span&gt; &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;(1,886,463&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;)&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;$&lt;br/&gt;
                &lt;/span&gt; &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;2.50&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td rowspan="1" style="vertical-align: top; width: 76%; padding-bottom: 2px;" valign="bottom"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;Forfeited&lt;br/&gt;
                &lt;/span&gt; &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"&gt;(303,532&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;)&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;$&lt;br/&gt;
                &lt;/span&gt; &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;3.92&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td rowspan="1" style="vertical-align: top; width: 76%; padding-bottom: 4px; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;Balance at December 31, 2024&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom"&gt;5,745,990&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;$&lt;br/&gt;
                &lt;/span&gt; &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;5.50&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div&gt; &lt;span style="font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
          &lt;/span&gt; &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal;"&gt;As of
          December 31, 2024, the Company had $25.3 million of unrecognized compensation expense related to unvested RSUs granted under the
          Company&#x2019;s equity incentive plans, which is expected to be recognized over a weighted-average period of 3.1 years.&lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt;"&gt;&lt;span style="font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
        &lt;/span&gt; &lt;span style="font-family: 'Times New Roman'; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt; &lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt; &lt;/div&gt;
&lt;p style="background-color: rgb(255, 255, 255); margin: 0px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; text-align: left; text-indent: 36pt; text-transform: none;"&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;span style="font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal;"&gt;During the year ended
              December 31, 2024, three of the Company&#x2019;s employees and one of the Company&#x2019;s non-employee directors received modifications to their outstanding stock option and RSU awards in connection with their departure from the Company or
              transition from an employee to a consulting role (see Note 9). The modifications allowed, among other things, the former employees to continue to participate in the Company&#x2019;s equity incentive plans with respect to certain of their outstanding
              awards when they would otherwise not be eligible to do so. In connection with these modifications, the Company recognized an aggregate of $2.5
              million of additional compensation expense in the year ended December 31, 2024. &lt;span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal;"&gt;Total stock-based compensation expense for all awards granted under the Company&#x2019;s equity incentive plans for the years ended December 31, 2024, 2023 and 2022
              was as follows (in thousands):&lt;/span&gt;&lt;/span&gt;&lt;br/&gt;
          &lt;/span&gt; &lt;/p&gt;
&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
        &lt;/span&gt;
         &lt;span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="text-align: left; font: 10pt 'Times New Roman'; margin-left: auto; margin-right: auto; width: 100%; border-spacing: 0;"&gt;


  &lt;tr style="height: 15px;"&gt;

    &lt;td rowspan="1" style="text-align: center; font-style: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: center; vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="10" rowspan="1" style="vertical-align: bottom; text-align: center;" valign="bottom"&gt;&lt;span style="font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;Year Ended December 31, &lt;/span&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
                &lt;/span&gt; &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td rowspan="1" style="padding-bottom: 2px; text-align: center; font-style: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;(in thousands)&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" rowspan="1" style="vertical-align: bottom; text-align: center; border-top: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: center; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;strong&gt; 2024&lt;br/&gt;
                  &lt;/strong&gt;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; border-top: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; border-top: 2px solid rgb(0, 0, 0);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" rowspan="1" style="vertical-align: bottom; text-align: center; border-top: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;strong&gt;2023&lt;/strong&gt;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; border-top: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: center; font-family: 'Times New Roman'; vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; border-top: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" rowspan="1" style="text-align: center; vertical-align: bottom; font-family: 'Times New Roman'; border-top: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;span style="font-weight: bold;"&gt;2022&lt;/span&gt;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td style="vertical-align: top; width: 64%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;Research and development&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;98&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;40&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;19&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td style="vertical-align: top; width: 64%;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;Plasma center operating expenses&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;184&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;146&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;82&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td style="vertical-align: top; width: 64%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;Selling, general and administrative&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;11,720&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;5,331&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;4,717&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td style="vertical-align: top; width: 64%; padding-bottom: 2px;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;Cost of product revenue&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;1,614&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;670&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;397&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td style="vertical-align: top; width: 64%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-indent: 9.5pt; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;Total stock-based compensation expense&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;13,616&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;6,187&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;5,215&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:PreferredStockCapitalSharesReservedForFutureIssuance
      contextRef="c20241231"
      decimals="-6"
      id="Fact_171a85c03c514919aec6117d955cf139"
      unitRef="U002">10000000</us-gaap:PreferredStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:PreferredStockCapitalSharesReservedForFutureIssuance
      contextRef="c20231231"
      decimals="-6"
      id="Fact_09ab236f400c4f87a98940893a91b3e7"
      unitRef="U002">10000000</us-gaap:PreferredStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c20241231"
      decimals="4"
      id="Fact_d89a6f2ab4de4dac91479eae5e729385"
      unitRef="U003">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c20231231"
      decimals="4"
      id="Fact_67c6359c525d474d86b16dbea70c8977"
      unitRef="U003">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="c20231231"
      decimals="INF"
      id="Fact_ae0a3f4fdb294bd4a5332de2db680cb7"
      unitRef="U002">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="c20241231"
      decimals="INF"
      id="Fact_16e4119a40e9496a8185bf0d3697eb23"
      unitRef="U002">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c20241231"
      decimals="0"
      id="Fact_a902b445fd914c2c83161cb608827c47"
      unitRef="U002">300000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c20231231"
      decimals="0"
      id="Fact_194a715a494f4ec693662aac78d4340e"
      unitRef="U002">300000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c20231231"
      decimals="4"
      id="Fact_865ee28bbbd94e03979bb50d751d4703"
      unitRef="U003">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c20241231"
      decimals="4"
      id="Fact_110a81c970df4047a9f25ac93fee6271"
      unitRef="U003">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c20241231"
      decimals="0"
      id="Fact_1047011eb9194116941456ebb8b4bc2c"
      unitRef="U002">236620545</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="c20231231"
      decimals="0"
      id="Fact_6088a0a43dee428bbaff950524d94b2a"
      unitRef="U002">226063032</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="c20241231"
      decimals="0"
      id="Fact_075f00de28744193a7b7105ad8515899"
      unitRef="U002">36093118</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="c20240101to20241231_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_0bda77157e944a818d906f8285760c06"
      unitRef="U002">1988066</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="c20230101to20231231_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_2405063e46d947bd9791e66cfa3d4c55"
      unitRef="U002">1444533</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="c20220101to20221231_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_5428a67635eb4790aec89f603a7bf721"
      unitRef="U002">68679</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="c20240101to20241231_StatementEquityComponentsAxis_CommonStockMember"
      decimals="-5"
      id="Fact_be293a9582bf4766af924ab70126f475"
      unitRef="U001">7500000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="c20230101to20231231_StatementEquityComponentsAxis_CommonStockMember"
      decimals="-5"
      id="Fact_57d6461bd593485787eed86f3aef627d"
      unitRef="U001">1100000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="c20220101to20221231_StatementEquityComponentsAxis_CommonStockMember"
      decimals="-5"
      id="Fact_ed6f2bc0b8354ca997aa898918ad5175"
      unitRef="U001">200000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c20221209to20221209_StatementEquityComponentsAxis_CommonStockMember_SubsidiarySaleOfStockAxis_OverAllotmentOptionMember"
      decimals="0"
      id="Fact_0b4676f2466840b4bcb0cfb4bc793f89"
      unitRef="U002">24125873</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="c20221209to20221209_StatementEquityComponentsAxis_CommonStockMember_SubsidiarySaleOfStockAxis_OverAllotmentOptionMember"
      decimals="-5"
      id="Fact_25f5460f04cc4563add02bd4595f503a"
      unitRef="U001">64600000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <adma:ClassOfWarrantOrRightExercised
      contextRef="c20240101to20241231"
      decimals="0"
      id="Fact_8eb3bc376c334b598bc9f2026f26363f"
      unitRef="U002">11308702</adma:ClassOfWarrantOrRightExercised>
    <us-gaap:CommonStockSharesIssued
      contextRef="c20241231_ClassOfWarrantOrRightAxis_WarrantMember"
      decimals="0"
      id="Fact_9303b9bca5d24f3a94ca7dd954c91fdb"
      unitRef="U002">7224892</us-gaap:CommonStockSharesIssued>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c20241231"
      decimals="0"
      id="Fact_e2bce4ba46ff48e08357a41e906a4be9"
      unitRef="U002">227650</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <adma:ClassOfWarrantOrRightExercised
      contextRef="c20230616to20230616_ClassOfWarrantOrRightAxis_HayfinWarrantsMember"
      decimals="0"
      id="Fact_098cb36b4ad9424ea4bdc1f5ba46cb9b"
      unitRef="U002">3388686</adma:ClassOfWarrantOrRightExercised>
    <us-gaap:CommonStockSharesIssued
      contextRef="c20230616_ClassOfWarrantOrRightAxis_HayfinWarrantsMember"
      decimals="0"
      id="Fact_b56eaec63b384f64aa28f64da6ef1f54"
      unitRef="U002">1967847</us-gaap:CommonStockSharesIssued>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="c20230501_CounterpartyNameAxis_HayfinSecondAmendmentMember"
      decimals="-5"
      id="Fact_13be2e8a097c45118092b3440b8ac8b8"
      unitRef="U001">5600000</us-gaap:WarrantsAndRightsOutstanding>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="c20240101to20241231_CounterpartyNameAxis_HayfinSecondAmendmentMember"
      id="Fact_aa575bc68b8946f0850a45d1a722d3d2">P7Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="c20230501to20230501_CounterpartyNameAxis_HayfinSecondAmendmentMember"
      decimals="3"
      id="Fact_bd57b751f72a4b85a4bd082b4683b243"
      unitRef="U007">0.678</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="c20230501to20230501_CounterpartyNameAxis_HayfinSecondAmendmentMember"
      decimals="2"
      id="Fact_ad696fcaec7441209d8021d8aa97d0e1"
      unitRef="U007">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="c20230501to20230501_CounterpartyNameAxis_HayfinSecondAmendmentMember"
      decimals="4"
      id="Fact_691e2ae9196542429767af3635a22867"
      unitRef="U007">0.0362</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c20220323_ClassOfWarrantOrRightAxis_HayfinWarrantsMember"
      decimals="0"
      id="Fact_a1f6fc29cc504542bed65320b267009d"
      unitRef="U002">9103047</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c20220323_ClassOfWarrantOrRightAxis_HayfinWarrantsMember"
      decimals="4"
      id="Fact_9b477fd1a2834049978ff805143134ec"
      unitRef="U003">1.6478</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="c20220323_ClassOfWarrantOrRightAxis_HayfinWarrantsMember"
      decimals="-5"
      id="Fact_e564d0ff72d240ad81e95a0e3b096dbd"
      unitRef="U001">9600000</us-gaap:WarrantsAndRightsOutstanding>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="c20240101to20241231_ClassOfWarrantOrRightAxis_HayfinWarrantsMember"
      id="Fact_504d540f2b164991b3ea743e1177a090">P7Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="c20220323to20220323_ClassOfWarrantOrRightAxis_HayfinWarrantsMember"
      decimals="3"
      id="Fact_ed877cf8c50b48988d83888ba1ba9e9b"
      unitRef="U007">0.681</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="c20220323to20220323_ClassOfWarrantOrRightAxis_HayfinWarrantsMember"
      decimals="2"
      id="Fact_81a8a7f6b4f64c1d9544a073f1b0c824"
      unitRef="U007">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="c20220323to20220323_ClassOfWarrantOrRightAxis_HayfinWarrantsMember"
      decimals="4"
      id="Fact_aee346211c9b4086a5b69fc884e50480"
      unitRef="U007">0.0236</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c20221231"
      decimals="0"
      id="Fact_8c81f2422cc84138a800ca6c4e920c78"
      unitRef="U002">106059</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c20241231_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_39fac70ee80f40e28840be95d2da2a51"
      unitRef="U002">966554</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="c20231231_StatementEquityComponentsAxis_CommonStockMember"
      decimals="0"
      id="Fact_06aec9d2b09445f8abcda19fbd633ca7"
      unitRef="U002">12502906</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c20241231_StatementEquityComponentsAxis_CommonStockMember"
      decimals="2"
      id="Fact_7cd9bba577c7470da63cd79b7f9d68d5"
      unitRef="U003">1.98</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c20231231_StatementEquityComponentsAxis_CommonStockMember"
      decimals="2"
      id="Fact_b83571c4ddf1404092151802c9521417"
      unitRef="U003">2.32</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock
      contextRef="c20240101to20241231"
      id="Text_818bae965ac04c37b65fbafa5c0999d9">&lt;span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal;"&gt;The






























                      following table summarizes information about warrants outstanding as of December 31, 2024, 2023 and 2022:&lt;/span&gt;
&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; text-indent: 36pt;"&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal;"&gt;&lt;span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; text-align: left; text-indent: 48px; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt; &lt;br/&gt;
                    &lt;/span&gt;&lt;/span&gt;&lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; letter-spacing: normal; text-transform: none; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%; border-spacing: 0;"&gt;


  &lt;tr&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&lt;br class="Apple-interchange-newline"/&gt;
                          &#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"&gt;&lt;span style="font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;Shares &lt;/span&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
                          &lt;/span&gt; &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"&gt;
                          &lt;div style="text-align: center; font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;Weighted&lt;/div&gt;
                          &lt;div style="text-align: center; font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;Average&lt;/div&gt;
                          &lt;div style="text-align: center; font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;Exercise Price&lt;/div&gt;
                        &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                          &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;Warrants outstanding at December 31, 2021&lt;/div&gt;
                        &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                          &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;4,528,160&lt;/div&gt;
                        &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                          &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                        &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                          &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;2.82&lt;/div&gt;
                        &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; white-space: nowrap;" valign="bottom"&gt;
                          &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;Expired&lt;/div&gt;
                        &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                          &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;(106,059&lt;/div&gt;
                        &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;
                          &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;)&lt;/div&gt;
                        &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;
                          &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                        &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                          &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;8.23&lt;/div&gt;
                        &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                          &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;Granted&lt;/div&gt;
                        &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                          &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;9,103,047&lt;/div&gt;
                        &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                          &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                        &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                          &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;1.65&lt;/div&gt;
                        &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;
                          &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;Exercised&lt;/div&gt;
                        &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                          &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;-&lt;/div&gt;
                        &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;
                          &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                        &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;
                          &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;-&lt;/div&gt;
                        &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                          &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;Warrants outstanding at December 31, 2022&lt;/div&gt;
                        &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                          &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;13,525,148&lt;/div&gt;
                        &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                          &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                        &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                          &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;1.99&lt;/div&gt;
                        &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; white-space: nowrap;" valign="bottom"&gt;
                          &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;Expired&lt;/div&gt;
                        &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                          &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;(24,800&lt;/div&gt;
                        &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;
                          &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;)&lt;/div&gt;
                        &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;
                          &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                        &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;
                          &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;6.37&lt;/div&gt;
                        &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                          &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;Granted&lt;/div&gt;
                        &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                          &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;2,391,244&lt;/div&gt;
                        &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                          &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                        &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                          &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;3.26&lt;/div&gt;
                        &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;
                          &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;Exercised&lt;/div&gt;
                        &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                          &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;(3,388,686&lt;/div&gt;
                        &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;
                          &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;)&lt;/div&gt;
                        &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;
                          &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                        &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;
                          &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;1.65&lt;/div&gt;
                        &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                          &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;Warrants outstanding at December 31, 2023&lt;/div&gt;
                        &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                          &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;12,502,906&lt;/div&gt;
                        &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                          &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;$&lt;/div&gt;
                        &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                          &lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;2.32&lt;/div&gt;
                        &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; width: 76%; white-space: nowrap;" valign="bottom"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;Expired&lt;br/&gt;
                          &lt;/span&gt; &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;(227,650&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;)&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;4.21&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; width: 76%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;Granted&lt;br/&gt;
                          &lt;/span&gt; &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;-&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;-&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; width: 76%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;Exercised&lt;br/&gt;
                          &lt;/span&gt; &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;(11,308,702&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;)&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;2.31&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; width: 76%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;Warrants outstanding at December 31, 2024&lt;br/&gt;
                          &lt;/span&gt; &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;966,554&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;1.98&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c20211231_ClassOfWarrantOrRightAxis_WarrantMember"
      decimals="0"
      id="Fact_ed1b27bcd04944b9ab9a0bdf8bfb3ccd"
      unitRef="U002">4528160</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c20211231_ClassOfWarrantOrRightAxis_WarrantMember"
      decimals="2"
      id="Fact_16ed96969de140ee96a4225010b61ea7"
      unitRef="U003">2.82</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <adma:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod
      contextRef="c20220101to20221231_ClassOfWarrantOrRightAxis_WarrantMember"
      decimals="0"
      id="Fact_561954a945054ee78437b56b9b788f44"
      unitRef="U002">106059</adma:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod>
    <adma:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriodWeightedAverageGrantDateFairValue
      contextRef="c20220101to20221231_ClassOfWarrantOrRightAxis_WarrantMember"
      decimals="2"
      id="Fact_dfd3c0b4ea72421095fe1aa3f6372215"
      unitRef="U003">8.23</adma:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="c20220101to20221231_ClassOfWarrantOrRightAxis_WarrantMember"
      decimals="0"
      id="Fact_b27bb0ddfba744b4b9ae3411d596261b"
      unitRef="U002">9103047</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c20220101to20221231_ClassOfWarrantOrRightAxis_WarrantMember"
      decimals="2"
      id="Fact_8e4f57f19c9149ea90d24ddb11540e7a"
      unitRef="U003">1.65</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <adma:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod
      contextRef="c20220101to20221231_ClassOfWarrantOrRightAxis_WarrantMember"
      decimals="INF"
      id="Fact_ea9c02ff810f4dc2b54381686665adde"
      unitRef="U002">0</adma:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod>
    <adma:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageGrantDateFairValue
      contextRef="c20220101to20221231_ClassOfWarrantOrRightAxis_WarrantMember"
      decimals="0"
      id="Fact_a108b7a1b84d4b4e8ff022ee2ce34c2d"
      unitRef="U003">0</adma:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c20221231_ClassOfWarrantOrRightAxis_WarrantMember"
      decimals="0"
      id="Fact_9884369018914b9da80f20e1ef4aec62"
      unitRef="U002">13525148</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c20221231_ClassOfWarrantOrRightAxis_WarrantMember"
      decimals="2"
      id="Fact_066ca890123c4399b984a24cd0c7766e"
      unitRef="U003">1.99</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <adma:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod
      contextRef="c20230101to20231231_ClassOfWarrantOrRightAxis_WarrantMember"
      decimals="0"
      id="Fact_31dfd4afd8ff49c387e91d15f9ab713d"
      unitRef="U002">24800</adma:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod>
    <adma:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriodWeightedAverageGrantDateFairValue
      contextRef="c20230101to20231231_ClassOfWarrantOrRightAxis_WarrantMember"
      decimals="2"
      id="Fact_0ecb61044a6b43158c4f105388ca43f0"
      unitRef="U003">6.37</adma:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="c20230101to20231231_ClassOfWarrantOrRightAxis_WarrantMember"
      decimals="0"
      id="Fact_ebdaac7ff3734f76b8e8219fe6f6015b"
      unitRef="U002">2391244</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c20230101to20231231_ClassOfWarrantOrRightAxis_WarrantMember"
      decimals="2"
      id="Fact_0559b1871447401d9ba548f5267f64bd"
      unitRef="U003">3.26</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <adma:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod
      contextRef="c20230101to20231231_ClassOfWarrantOrRightAxis_WarrantMember"
      decimals="0"
      id="Fact_d1a7338cade84766a53477f9746a993c"
      unitRef="U002">3388686</adma:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod>
    <adma:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageGrantDateFairValue
      contextRef="c20230101to20231231_ClassOfWarrantOrRightAxis_WarrantMember"
      decimals="2"
      id="Fact_890dc5da46aa406a89a5ea3f22f9e5b4"
      unitRef="U003">1.65</adma:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c20231231_ClassOfWarrantOrRightAxis_WarrantMember"
      decimals="0"
      id="Fact_242a177106d34b09ab34d021433866e9"
      unitRef="U002">12502906</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c20231231_ClassOfWarrantOrRightAxis_WarrantMember"
      decimals="2"
      id="Fact_2d5c0aecbee841959540726981f479b1"
      unitRef="U003">2.32</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <adma:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod
      contextRef="c20240101to20241231_ClassOfWarrantOrRightAxis_WarrantMember"
      decimals="0"
      id="Fact_7c71f2ce5fdd48fa94f73f8ba96497a8"
      unitRef="U002">227650</adma:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriod>
    <adma:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriodWeightedAverageGrantDateFairValue
      contextRef="c20240101to20241231_ClassOfWarrantOrRightAxis_WarrantMember"
      decimals="2"
      id="Fact_06044553a4ff4fc6be8d71ab75908e98"
      unitRef="U003">4.21</adma:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpiredInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="c20240101to20241231_ClassOfWarrantOrRightAxis_WarrantMember"
      decimals="INF"
      id="Fact_2fd19d92c6c04422bcc0f184de68ce13"
      unitRef="U002">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c20240101to20241231_ClassOfWarrantOrRightAxis_WarrantMember"
      decimals="0"
      id="Fact_a4604e36a54a4709bc7633972397d7b1"
      unitRef="U003">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <adma:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod
      contextRef="c20240101to20241231_ClassOfWarrantOrRightAxis_WarrantMember"
      decimals="0"
      id="Fact_c23b856b5b104f7f90825751360d7e65"
      unitRef="U002">11308702</adma:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriod>
    <adma:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageGrantDateFairValue
      contextRef="c20240101to20241231_ClassOfWarrantOrRightAxis_WarrantMember"
      decimals="2"
      id="Fact_556401170f964072b47209360a4e8bc4"
      unitRef="U003">2.31</adma:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExercisedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c20241231_ClassOfWarrantOrRightAxis_WarrantMember"
      decimals="0"
      id="Fact_1d153626d71d4bdebdf42697f0f63852"
      unitRef="U002">966554</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c20241231_ClassOfWarrantOrRightAxis_WarrantMember"
      decimals="2"
      id="Fact_79f8b0b4bb7c4ad9933115efec60de79"
      unitRef="U003">1.98</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="c20220621_PlanNameAxis_Two022CompensationPlanMember"
      decimals="-6"
      id="Fact_2ab185c599b048c5a0eb608443126078"
      unitRef="U002">18000000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="c20240101to20241231_AwardTypeAxis_EmployeeStockOptionMember"
      decimals="0"
      id="Fact_13e7ef50d673430980e97cdf9b0d3617"
      unitRef="U002">1531635</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="c20230101to20231231_AwardTypeAxis_EmployeeStockOptionMember"
      decimals="0"
      id="Fact_1d96e2c908ab4e6fb148c9e3acd23685"
      unitRef="U002">1826380</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="c20220101to20221231_AwardTypeAxis_EmployeeStockOptionMember"
      decimals="0"
      id="Fact_c5806177a2d44d26be31cd683eb4d987"
      unitRef="U002">1194032</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <adma:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedNumber
      contextRef="c20240101to20241231_AwardTypeAxis_EmployeeStockOptionMember"
      decimals="0"
      id="Fact_7f7f3b574cca4d5aa08927f0c2eab215"
      unitRef="U002">2020142</adma:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedNumber>
    <adma:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSharesWithheldToCoverAggregateExercisePrices
      contextRef="c20241231_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_EquityIncentivePlanMember"
      decimals="0"
      id="Fact_6b6eab4d715748be81c2bc7597a7ea47"
      unitRef="U002">32076</adma:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSharesWithheldToCoverAggregateExercisePrices>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="c20240101to20241231_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_EquityIncentivePlanMember"
      decimals="-5"
      id="Fact_897d3cedc58446ff8b89595961156362"
      unitRef="U001">7500000</us-gaap:ProceedsFromStockOptionsExercised>
    <adma:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedNumber
      contextRef="c20230101to20231231_AwardTypeAxis_EmployeeStockOptionMember"
      decimals="0"
      id="Fact_a9f08eba66274efcb9027fef86718520"
      unitRef="U002">3814122</adma:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedNumber>
    <adma:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSharesWithheldToCoverAggregateExercisePrices
      contextRef="c20231231_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_EquityIncentivePlanMember"
      decimals="0"
      id="Fact_ea5bbe6a28f641f2a15aa2a4892f7521"
      unitRef="U002">2109722</adma:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSharesWithheldToCoverAggregateExercisePrices>
    <adma:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSharesWithheldForPayrollTaxes
      contextRef="c20231231_AwardTypeAxis_EmployeeStockOptionMember"
      decimals="0"
      id="Fact_34b278ebf2b14a50927246cd97c2b4fa"
      unitRef="U002">259867</adma:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsSharesWithheldForPayrollTaxes>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="c20230101to20231231_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_EquityIncentivePlanMember"
      decimals="-5"
      id="Fact_c132b181bb4143749726b5419fb60bbf"
      unitRef="U001">1100000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="c20240101to20241231"
      id="Text_6a64f989a1b84e6582cf1f436059143b">
&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-indent: 36pt;"&gt;&lt;span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;The grant date fair values of stock options
              awarded during the years ended December 31, 2024, 2023 and 2022 were determined using the Black-Scholes option pricing model with the following assumptions:&lt;/span&gt; &lt;span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt; &lt;/div&gt;
&lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px;"&gt;&lt;span style="font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;span style="font-weight: normal;"&gt;&#160; &lt;/span&gt;&lt;br/&gt;
          &lt;/span&gt; &lt;/p&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="text-align: left; font: 10pt 'Times New Roman'; margin-right: auto; width: 100%; border-spacing: 0;"&gt;


  &lt;tr style="height: 15px;"&gt;

    &lt;td style="padding-bottom: 2px;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="10" rowspan="1" style="vertical-align: bottom; text-align: center; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; text-align: center; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;strong&gt;Years Ended
                  &lt;/strong&gt;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td style="padding-bottom: 2px;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-bottom: 0px; text-align: center; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;strong&gt;December 31,&lt;/strong&gt;&lt;/p&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-bottom: 0px; text-align: center; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;strong&gt;2024 &lt;/strong&gt;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: center; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-bottom: 0px; text-align: center; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;strong&gt;December 31,&lt;/strong&gt;&lt;/p&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-bottom: 0px; text-align: center; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;strong&gt;2023 &lt;/strong&gt;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="text-align: left; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="text-align: center;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;strong&gt;December 31,&lt;/strong&gt; &lt;br/&gt;
                  &lt;/span&gt; &lt;/div&gt;
                &lt;div style="text-align: center;"&gt;&lt;span style="font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;202&lt;strong&gt;2&lt;/strong&gt;&lt;/span&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;strong&gt;&lt;br/&gt;
                    &lt;/strong&gt;&lt;/span&gt;&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td style="vertical-align: bottom; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;Expected term&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: center; vertical-align: bottom; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; text-align: center; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; text-align: right; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;5.5-6.3 years&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: center; vertical-align: bottom; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; text-align: center; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; text-align: right; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;5.5-6.3 years&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; text-align: right; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;
                &lt;div style="text-align: right; font-family: 'Times New Roman'; font-size: 10pt; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;5.5-6.3 years&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td style="vertical-align: bottom; width: 64%;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;Volatility&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;66&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;%&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;68&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;%&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; font-weight: normal; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-weight: normal; text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-weight: normal; vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;68&lt;br/&gt;
                &lt;/span&gt; &lt;/td&gt;

    &lt;td colspan="1" style="font-weight: normal; text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&lt;strong style="font-weight: normal;"&gt;%&lt;/strong&gt;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td style="vertical-align: top; width: 64%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;Dividend yield&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;0.0&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;0.0&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;0.0&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td style="vertical-align: top; width: 64%;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;Risk-free interest rate&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;4.16-4.39&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;%&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;4.20-4.62&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;%&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;1.72-1.73&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;%&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="c20240101to20241231_AwardTypeAxis_EmployeeStockOptionMember_RangeAxis_MinimumMember"
      id="Fact_e790aaca6e244c03bba149a77cd0c528">P5Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="c20240101to20241231_AwardTypeAxis_EmployeeStockOptionMember_RangeAxis_MaximumMember"
      id="Fact_3b7b248c1dc0433a984a7c770f5e317e">P6Y3M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="c20230101to20231231_AwardTypeAxis_EmployeeStockOptionMember_RangeAxis_MinimumMember"
      id="Fact_21cfc9cbc2bd45188e0fab59cd65dd5a">P5Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="c20230101to20231231_AwardTypeAxis_EmployeeStockOptionMember_RangeAxis_MaximumMember"
      id="Fact_0a24ce0016904ea6873f31f930bcd524">P6Y3M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="c20220101to20221231_AwardTypeAxis_EmployeeStockOptionMember_RangeAxis_MinimumMember"
      id="Fact_30a391a8163541ce9d641d367cce5e71">P5Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="c20220101to20221231_AwardTypeAxis_EmployeeStockOptionMember_RangeAxis_MaximumMember"
      id="Fact_d5c97fa495ff48c3a75a0a0922dd2650">P6Y3M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="c20240101to20241231_AwardTypeAxis_EmployeeStockOptionMember"
      decimals="2"
      id="Fact_5485e1151c1b46509ff4cccf47313f58"
      unitRef="U007">0.66</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="c20230101to20231231_AwardTypeAxis_EmployeeStockOptionMember"
      decimals="2"
      id="Fact_07e759826ffb4b778e34187c34d82951"
      unitRef="U007">0.68</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="c20220101to20221231_AwardTypeAxis_EmployeeStockOptionMember"
      decimals="2"
      id="Fact_3f7431b5ba6644bda14b9c3c283f8435"
      unitRef="U007">0.68</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="c20240101to20241231_AwardTypeAxis_EmployeeStockOptionMember"
      decimals="1"
      id="Fact_f5c88f0e77434a09a2f9fff1b14d71ee"
      unitRef="U007">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="c20230101to20231231_AwardTypeAxis_EmployeeStockOptionMember"
      decimals="1"
      id="Fact_e41568a8f26c4215979c2d6a0949e7ae"
      unitRef="U007">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="c20220101to20221231_AwardTypeAxis_EmployeeStockOptionMember"
      decimals="1"
      id="Fact_78d870e3b46d401aa2a1501b02f14075"
      unitRef="U007">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="c20240101to20241231_AwardTypeAxis_EmployeeStockOptionMember_RangeAxis_MinimumMember"
      decimals="4"
      id="Fact_ba0ddcfea276406aa68ae0f0872f4336"
      unitRef="U007">0.0416</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="c20240101to20241231_AwardTypeAxis_EmployeeStockOptionMember_RangeAxis_MaximumMember"
      decimals="4"
      id="Fact_859d40684d5c4cd8a80becf3cbe125e4"
      unitRef="U007">0.0439</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="c20230101to20231231_AwardTypeAxis_EmployeeStockOptionMember_RangeAxis_MinimumMember"
      decimals="4"
      id="Fact_4a2526a1c1104da9817a823d84d20e85"
      unitRef="U007">0.042</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="c20230101to20231231_AwardTypeAxis_EmployeeStockOptionMember_RangeAxis_MaximumMember"
      decimals="4"
      id="Fact_0a0e4933aee143f29371b24799f083e5"
      unitRef="U007">0.0462</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="c20220101to20221231_AwardTypeAxis_EmployeeStockOptionMember_RangeAxis_MinimumMember"
      decimals="4"
      id="Fact_8815224f797a4fd89f4f7248ce02b298"
      unitRef="U007">0.0172</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="c20220101to20221231_AwardTypeAxis_EmployeeStockOptionMember_RangeAxis_MaximumMember"
      decimals="4"
      id="Fact_810c825b81794177a81dee0572aad2bf"
      unitRef="U007">0.0173</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="c20240101to20241231"
      id="Text_28fce9198907494bbd8538ebc489c8b6">
&lt;div&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt; &lt;/div&gt;
&lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-bottom: 0px; text-align: left; text-indent: 36pt; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;span style="font-size: 10pt;"&gt;The following table summarizes information about stock options outstanding as of December 31, &lt;strong&gt;&lt;span style="font-weight: normal;"&gt;2024,&lt;/span&gt; &lt;/strong&gt;2023 and 2022:&lt;/span&gt; &lt;/p&gt;&lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px;"&gt;&lt;span style="font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&#160;&#160; &lt;br/&gt;
          &lt;/span&gt; &lt;/p&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="text-align: left; font: 10pt 'Times New Roman'; width: 100%; border-spacing: 0;"&gt;


  &lt;tr style="height: 15px;"&gt;

    &lt;td style="padding-bottom: 2px;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; text-align: center; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;strong&gt;Shares&lt;/strong&gt;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; text-align: center; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;strong&gt;Weighted&lt;/strong&gt;&lt;/p&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; text-align: center; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;strong&gt;Average&lt;/strong&gt;&lt;/p&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; text-align: center; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;strong&gt;Exercise
                    Price&lt;/strong&gt;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td style="vertical-align: top; width: 76%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;Options outstanding, vested and
                  expected to vest at December 31, 2021&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;7,862,722&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;3.93&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td style="vertical-align: top; width: 76%;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;Forfeited&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;(31,540&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;)&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;2.37&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td style="vertical-align: top; width: 76%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;Expired&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;(700,324&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;)&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;6.86&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td style="vertical-align: top; width: 76%;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;Granted&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;1,194,032&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;1.67&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td style="vertical-align: top; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;Exercised&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;(68,679&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;)&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;2.55&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td style="vertical-align: top; width: 76%;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;Options outstanding, vested and
                  expected to vest at December 31, 2022&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;8,256,211&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;3.37&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td style="vertical-align: top; width: 76%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;Forfeited&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;(99,345&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;)&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;2.73&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td style="vertical-align: top; width: 76%;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;Expired&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;(262,940&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;)&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;6.42&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td style="vertical-align: top; width: 76%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;Granted&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;1,826,380&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;3.36&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td style="vertical-align: top; width: 76%; padding-bottom: 2px;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;Exercised&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;(3,814,122&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;)&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;3.15&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td style="vertical-align: top; width: 76%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;Options outstanding, vested and
                  expected to vest at December 31, 2023&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;5,906,184&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;3.38&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td rowspan="1" style="vertical-align: top; width: 76%;" valign="bottom"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;Forfeited&lt;br/&gt;
                &lt;/span&gt; &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;(30,094&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;)&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;3.36&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td rowspan="1" style="vertical-align: top; width: 76%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;Expired&lt;br/&gt;
                &lt;/span&gt; &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;(246,067&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;)&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;7.01&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td rowspan="1" style="vertical-align: top; width: 76%;" valign="bottom"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;Granted&lt;br/&gt;
                &lt;/span&gt; &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;1,531,635&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;6.40&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td rowspan="1" style="vertical-align: top; width: 76%; background-color: rgb(204, 238, 255); padding-bottom: 2px;" valign="bottom"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;Exercised&lt;br/&gt;
                &lt;/span&gt; &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"&gt;(2,020,142&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;)&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; padding-bottom: 2px;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; padding-bottom: 2px;" valign="bottom"&gt;3.90&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td rowspan="1" style="vertical-align: top; width: 76%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; padding-bottom: 4px;" valign="bottom"&gt;Options
                outstanding, vested and expected to vest at December 31, 2024&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom"&gt;5,141,516&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; padding-bottom: 4px;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; padding-bottom: 4px;" valign="bottom"&gt;3.90&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td style="width: 76%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td style="vertical-align: top; width: 76%; padding-bottom: 4px;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;Options exercisable&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom"&gt;2,657,932&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom"&gt;3.03&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="c20211231_AwardTypeAxis_EmployeeStockOptionMember"
      decimals="0"
      id="Fact_5ab09d8ab6cc49efa99e41f6f2aa6530"
      unitRef="U002">7862722</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="c20211231_AwardTypeAxis_EmployeeStockOptionMember"
      decimals="2"
      id="Fact_246a386c69da42c9a4d24de2285506d2"
      unitRef="U003">3.93</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <adma:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedNumber
      contextRef="c20220101to20221231_AwardTypeAxis_EmployeeStockOptionMember"
      decimals="0"
      id="Fact_f3ffd95473af4e91aa610dca3ecdfe8c"
      unitRef="U002">31540</adma:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedNumber>
    <adma:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedWeightedAverageExercisePrice
      contextRef="c20220101to20221231_AwardTypeAxis_EmployeeStockOptionMember"
      decimals="2"
      id="Fact_4f98ec69f2504af1a3e14f8b65ac83d9"
      unitRef="U003">2.37</adma:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedWeightedAverageExercisePrice>
    <adma:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredNumber
      contextRef="c20220101to20221231_AwardTypeAxis_EmployeeStockOptionMember"
      decimals="0"
      id="Fact_c50dbb2ba088431fa3de40d873385f09"
      unitRef="U002">700324</adma:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredNumber>
    <adma:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredWeightedAverageExercisePrice
      contextRef="c20220101to20221231_AwardTypeAxis_EmployeeStockOptionMember"
      decimals="2"
      id="Fact_616eb9f014e7404e9f8a0ae6c4bb3773"
      unitRef="U003">6.86</adma:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredWeightedAverageExercisePrice>
    <adma:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedNumber
      contextRef="c20220101to20221231_AwardTypeAxis_EmployeeStockOptionMember"
      decimals="0"
      id="Fact_af9c9831bfd449dcbd424882344d8dd2"
      unitRef="U002">1194032</adma:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedNumber>
    <adma:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedWeightedAverageExercisePrice
      contextRef="c20220101to20221231_AwardTypeAxis_EmployeeStockOptionMember"
      decimals="2"
      id="Fact_65bda1a44ab0452ba9d5c1b5835dfefb"
      unitRef="U003">1.67</adma:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedWeightedAverageExercisePrice>
    <adma:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedNumber
      contextRef="c20220101to20221231_AwardTypeAxis_EmployeeStockOptionMember"
      decimals="0"
      id="Fact_45bf2eeb1b5241d5a538f3f377a87aa1"
      unitRef="U002">68679</adma:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedNumber>
    <adma:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedWeightedAverageExercisePrice
      contextRef="c20220101to20221231_AwardTypeAxis_EmployeeStockOptionMember"
      decimals="2"
      id="Fact_302459abfe324e32a33769a0046a5366"
      unitRef="U003">2.55</adma:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="c20221231_AwardTypeAxis_EmployeeStockOptionMember"
      decimals="0"
      id="Fact_147791beeb874021bbd4cdea0dae260b"
      unitRef="U002">8256211</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="c20221231_AwardTypeAxis_EmployeeStockOptionMember"
      decimals="2"
      id="Fact_c03b3b4361bc4032a25396e0b48ca6d7"
      unitRef="U003">3.37</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <adma:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedNumber
      contextRef="c20230101to20231231_AwardTypeAxis_EmployeeStockOptionMember"
      decimals="0"
      id="Fact_f7421a33aa934816880badd539c9b4b1"
      unitRef="U002">99345</adma:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedNumber>
    <adma:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedWeightedAverageExercisePrice
      contextRef="c20230101to20231231_AwardTypeAxis_EmployeeStockOptionMember"
      decimals="2"
      id="Fact_63149b7d709e49e0bd3ae66870f9686a"
      unitRef="U003">2.73</adma:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedWeightedAverageExercisePrice>
    <adma:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredNumber
      contextRef="c20230101to20231231_AwardTypeAxis_EmployeeStockOptionMember"
      decimals="0"
      id="Fact_4ef0ce8359ea4e528ea4862a645b6d4f"
      unitRef="U002">262940</adma:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredNumber>
    <adma:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredWeightedAverageExercisePrice
      contextRef="c20230101to20231231_AwardTypeAxis_EmployeeStockOptionMember"
      decimals="2"
      id="Fact_722e06668aee48758d1efd0be9b8872d"
      unitRef="U003">6.42</adma:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredWeightedAverageExercisePrice>
    <adma:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedNumber
      contextRef="c20230101to20231231_AwardTypeAxis_EmployeeStockOptionMember"
      decimals="0"
      id="Fact_5140e2c2a2ca4e66b5dc366debe07ea7"
      unitRef="U002">1826380</adma:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedNumber>
    <adma:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedWeightedAverageExercisePrice
      contextRef="c20230101to20231231_AwardTypeAxis_EmployeeStockOptionMember"
      decimals="2"
      id="Fact_2677dd96e80c428987c25446b44c8746"
      unitRef="U003">3.36</adma:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedWeightedAverageExercisePrice>
    <adma:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedNumber
      contextRef="c20230101to20231231_AwardTypeAxis_EmployeeStockOptionMember"
      decimals="0"
      id="Fact_517532f962ac45049fefd613a6037703"
      unitRef="U002">3814122</adma:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedNumber>
    <adma:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedWeightedAverageExercisePrice
      contextRef="c20230101to20231231_AwardTypeAxis_EmployeeStockOptionMember"
      decimals="2"
      id="Fact_839b14bb59b9426a9be8617989cf5a25"
      unitRef="U003">3.15</adma:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="c20231231_AwardTypeAxis_EmployeeStockOptionMember"
      decimals="0"
      id="Fact_fbcf3be7b9a3475baac296d761b18cb9"
      unitRef="U002">5906184</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="c20231231_AwardTypeAxis_EmployeeStockOptionMember"
      decimals="2"
      id="Fact_87c5713fd74e4d7ead8ac7e5e021626e"
      unitRef="U003">3.38</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <adma:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedNumber
      contextRef="c20240101to20241231_AwardTypeAxis_EmployeeStockOptionMember"
      decimals="0"
      id="Fact_195ace18aedb44ee967d3a38759eb975"
      unitRef="U002">30094</adma:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedNumber>
    <adma:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedWeightedAverageExercisePrice
      contextRef="c20240101to20241231_AwardTypeAxis_EmployeeStockOptionMember"
      decimals="2"
      id="Fact_dcca7468c90b4bb39d3e9a0cbd0dd9e5"
      unitRef="U003">3.36</adma:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestForfeitedWeightedAverageExercisePrice>
    <adma:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredNumber
      contextRef="c20240101to20241231_AwardTypeAxis_EmployeeStockOptionMember"
      decimals="0"
      id="Fact_ca8ea30eb65a4150a07879063a0ed0bf"
      unitRef="U002">246067</adma:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredNumber>
    <adma:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredWeightedAverageExercisePrice
      contextRef="c20240101to20241231_AwardTypeAxis_EmployeeStockOptionMember"
      decimals="2"
      id="Fact_a7972ee999f64c66acb7f5c9506cda31"
      unitRef="U003">7.01</adma:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExpiredWeightedAverageExercisePrice>
    <adma:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedNumber
      contextRef="c20240101to20241231_AwardTypeAxis_EmployeeStockOptionMember"
      decimals="0"
      id="Fact_bc806c0acb674ba78191c22331944cb9"
      unitRef="U002">1531635</adma:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedNumber>
    <adma:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedWeightedAverageExercisePrice
      contextRef="c20240101to20241231_AwardTypeAxis_EmployeeStockOptionMember"
      decimals="2"
      id="Fact_417d489cb8a94cabbe85a83c0674c0b6"
      unitRef="U003">6.4</adma:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestGrantedWeightedAverageExercisePrice>
    <adma:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedNumber
      contextRef="c20240101to20241231_AwardTypeAxis_EmployeeStockOptionMember"
      decimals="0"
      id="Fact_178daded10794075a1a4aee0518a0c89"
      unitRef="U002">2020142</adma:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedNumber>
    <adma:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedWeightedAverageExercisePrice
      contextRef="c20240101to20241231_AwardTypeAxis_EmployeeStockOptionMember"
      decimals="2"
      id="Fact_ca4c1956c732439f9991d2a13f778bd9"
      unitRef="U003">3.9</adma:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisedWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="c20241231_AwardTypeAxis_EmployeeStockOptionMember"
      decimals="0"
      id="Fact_fcc5fd86f25a42b5885f1d2fd84f57d7"
      unitRef="U002">5141516</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="c20241231_AwardTypeAxis_EmployeeStockOptionMember"
      decimals="2"
      id="Fact_3b758798be9b458cb1e526f7befc264c"
      unitRef="U003">3.9</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="c20241231_AwardTypeAxis_EmployeeStockOptionMember"
      decimals="0"
      id="Fact_e499de90070c466d92755049b55a67bf"
      unitRef="U002">2657932</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="c20241231_AwardTypeAxis_EmployeeStockOptionMember"
      decimals="2"
      id="Fact_5edb42454e7a483bb2ea814e0e3fe5c5"
      unitRef="U003">3.03</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="c20241231_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_EquityIncentivePlanMember"
      decimals="-5"
      id="Fact_09ef5d86de4f4729b198075c8dc5a095"
      unitRef="U001">6700000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="c20240101to20241231_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_EquityIncentivePlanMember"
      id="Fact_ea04050dd259411491d8e70fc662eb0f">P2Y9M18D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
      contextRef="c20240101to20241231_AwardTypeAxis_EmployeeStockOptionMember"
      id="Fact_edd59e19dfcc469ba5172b73f4cffede">P7Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="c20240101to20241231_AwardTypeAxis_EmployeeStockOptionMember"
      id="Fact_89aa0f60fd084162a3cbd779b343e48e">P7Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="c20240101to20241231_AwardTypeAxis_EmployeeStockOptionMember"
      id="Fact_630571731edb4117bd922c3ed7da9e43">P5Y8M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock
      contextRef="c20240101to20241231"
      id="Text_d83011daf06d4d7a93ed0e8beedb331a">&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal;"&gt;The following table summarizes additional information regarding
            outstanding and exercisable options under the stock option plans at December 31, 2024: &lt;/span&gt;&lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px;"&gt;&lt;span style="font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160; &lt;br/&gt;
          &lt;/span&gt; &lt;/p&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" style="text-align: left; font: 10pt 'Times New Roman'; width: 100%; border-spacing: 0;"&gt;


  &lt;tr style="height: 15px;"&gt;

    &lt;td style="width: 28%; padding-bottom: 2px;"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="white-space: nowrap; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/td&gt;

    &lt;td style="white-space: nowrap; width: 1%; padding-bottom: 2px;"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td class="hdcell" colspan="14" style="border-bottom: 2px solid rgb(0, 0, 0); vertical-align: bottom; text-align: center;"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; text-align: center; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;strong&gt;Stock
                    Options Outstanding&lt;/strong&gt;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td style="white-space: nowrap; width: 1%; padding-bottom: 2px;"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td style="white-space: nowrap; width: 1%; padding-bottom: 2px;"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td class="hdcell" colspan="14" style="border-bottom: 2px solid rgb(0, 0, 0); vertical-align: bottom; text-align: center;"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; text-align: center; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;strong&gt;Stock
                    Options Exercisable&lt;/strong&gt;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td style="white-space: nowrap; width: 1%; padding-bottom: 2px;"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td style="vertical-align: bottom; width: 28%; padding-bottom: 2px; white-space: nowrap;"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; text-align: center; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;Range of&lt;/p&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; text-align: center; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;Exercise Prices&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="white-space: nowrap; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/td&gt;

    &lt;td style="white-space: nowrap; width: 1%; padding-bottom: 2px;"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td class="hdcell" colspan="2" style="border-bottom: 2px solid rgb(0, 0, 0); vertical-align: bottom; text-align: center;"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; text-align: center; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;Options Outstanding&lt;/p&gt;
              &lt;/td&gt;

    &lt;td style="padding-bottom: 2px; white-space: nowrap; width: 1%;"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td style="white-space: nowrap; width: 1%; padding-bottom: 2px;"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td class="hdcell" colspan="2" style="border-bottom: 2px solid rgb(0, 0, 0); vertical-align: bottom; text-align: center;"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; text-align: center; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;Weighted&lt;/p&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; text-align: center; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;Average&lt;/p&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; text-align: center; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;Remaining&lt;/p&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; text-align: center; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;Contractual&lt;/p&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; text-align: center; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;Life (Years)&lt;/p&gt;
              &lt;/td&gt;

    &lt;td style="padding-bottom: 2px; white-space: nowrap; width: 1%;"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td style="white-space: nowrap; width: 1%; padding-bottom: 2px;"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td class="hdcell" colspan="2" style="border-bottom: 2px solid rgb(0, 0, 0); vertical-align: bottom; text-align: center;"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; text-align: center; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;Weighted Average
                  Exercise Price&lt;/p&gt;
              &lt;/td&gt;

    &lt;td style="padding-bottom: 2px; white-space: nowrap; width: 1%;"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td style="white-space: nowrap; width: 1%; padding-bottom: 2px;"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td class="hdcell" colspan="2" style="border-bottom: 2px solid rgb(0, 0, 0); vertical-align: bottom; text-align: center;"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; text-align: center; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;Aggregate Intrinsic
                  Value&lt;/p&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; text-align: center;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; ($000&#x2019;s)&lt;br/&gt;
                  &lt;/span&gt; &lt;/p&gt;
              &lt;/td&gt;

    &lt;td style="padding-bottom: 2px; white-space: nowrap; width: 1%;"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td style="white-space: nowrap; width: 1%; padding-bottom: 2px;"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td class="hdcell" colspan="2" style="border-bottom: 2px solid rgb(0, 0, 0); vertical-align: bottom; text-align: center;"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; text-align: center; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;Options Outstanding&lt;/p&gt;
              &lt;/td&gt;

    &lt;td style="padding-bottom: 2px; white-space: nowrap; width: 1%;"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td style="white-space: nowrap; width: 1%; padding-bottom: 2px;"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td class="hdcell" colspan="2" style="border-bottom: 2px solid rgb(0, 0, 0); vertical-align: bottom; text-align: center;"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; text-align: center; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;Weighted&lt;/p&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; text-align: center; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;Average&lt;/p&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; text-align: center; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;Remaining&lt;/p&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; text-align: center; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;Contractual&lt;/p&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; text-align: center; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;Life (Years)&lt;/p&gt;
              &lt;/td&gt;

    &lt;td style="padding-bottom: 2px; white-space: nowrap; width: 1%;"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td style="white-space: nowrap; width: 1%; padding-bottom: 2px;"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td class="hdcell" colspan="2" style="border-bottom: 2px solid rgb(0, 0, 0); vertical-align: bottom; text-align: center; white-space: nowrap;"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; text-align: center; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;Weighted&lt;/p&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; text-align: center; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt; Average&lt;/p&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; text-align: center; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt; Exercise&lt;/p&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; text-align: center; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt; Price&lt;/p&gt;
              &lt;/td&gt;

    &lt;td style="padding-bottom: 2px; white-space: nowrap; width: 1%;"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td style="white-space: nowrap; width: 1%; padding-bottom: 2px;"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td class="hdcell" colspan="2" style="border-bottom: 2px solid rgb(0, 0, 0); vertical-align: bottom; text-align: center; white-space: nowrap;"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; text-align: center; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;Aggregate&lt;/p&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; text-align: center; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt; Intrinsic&lt;/p&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; text-align: center; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt; Value&lt;/p&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; text-align: center; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt; ($000&#x2019;s)&lt;/p&gt;
              &lt;/td&gt;

    &lt;td style="padding-bottom: 2px; white-space: nowrap; width: 1%;"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td style="vertical-align: top; width: 28%; background-color: rgb(204, 238, 255);"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;$1.10 - $1.67&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="width: 1%; white-space: nowrap; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/td&gt;

    &lt;td style="width: 1%; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td style="width: 1%; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td class="ffcell" style="width: 6%; vertical-align: bottom; text-align: right; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;981,093&lt;/td&gt;

    &lt;td style="width: 1%; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td style="width: 1%; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td style="width: 1%; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td class="ffcell" style="width: 6%; vertical-align: bottom; text-align: right; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;6.8&lt;/td&gt;

    &lt;td style="width: 1%; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td style="width: 1%; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td style="width: 1%; vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;$&lt;/td&gt;

    &lt;td class="ffcell" style="width: 6%; vertical-align: bottom; text-align: right; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;1.60&lt;/td&gt;

    &lt;td style="width: 1%; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td style="width: 1%; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td style="width: 1%; vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;$&lt;/td&gt;

    &lt;td class="ffcell" style="width: 6%; vertical-align: bottom; text-align: right; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;15,252&lt;/td&gt;

    &lt;td style="width: 1%; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td style="width: 1%; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td style="width: 1%; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td class="ffcell" style="width: 6%; vertical-align: bottom; text-align: right; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;676,542&lt;/td&gt;

    &lt;td style="width: 1%; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td style="width: 1%; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td style="width: 1%; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td class="ffcell" style="width: 6%; vertical-align: bottom; text-align: right; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;6.6&lt;/td&gt;

    &lt;td style="width: 1%; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td style="width: 1%; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td style="width: 1%; vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;$&lt;/td&gt;

    &lt;td class="ffcell" style="width: 6%; vertical-align: bottom; text-align: right; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;1.58&lt;/td&gt;

    &lt;td style="width: 1%; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td style="width: 1%; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td style="width: 1%; vertical-align: bottom; white-space: nowrap; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;$&lt;/td&gt;

    &lt;td class="ffcell" style="width: 6%; vertical-align: bottom; text-align: right; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;10,532&lt;/td&gt;

    &lt;td style="width: 1%; white-space: nowrap; background-color: rgb(204, 238, 255);"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td style="vertical-align: top; width: 28%;"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;$1.73 - $2.60&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="white-space: nowrap; width: 1%; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/td&gt;

    &lt;td style="white-space: nowrap; width: 1%;"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td style="white-space: nowrap; width: 1%;"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td class="ffcell" style="vertical-align: bottom; text-align: right; width: 6%; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;629,655&lt;/td&gt;

    &lt;td style="white-space: nowrap; width: 1%;"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td style="white-space: nowrap; width: 1%;"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td style="white-space: nowrap; width: 1%;"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td class="ffcell" style="vertical-align: bottom; text-align: right; width: 6%; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;5.7&lt;/td&gt;

    &lt;td style="white-space: nowrap; width: 1%;"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td style="white-space: nowrap; width: 1%;"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td style="vertical-align: bottom; white-space: nowrap; width: 1%; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;$&lt;/td&gt;

    &lt;td class="ffcell" style="vertical-align: bottom; text-align: right; width: 6%; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;2.32&lt;/td&gt;

    &lt;td style="white-space: nowrap; width: 1%;"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td style="white-space: nowrap; width: 1%;"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td style="white-space: nowrap; width: 1%;"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td class="ffcell" style="vertical-align: bottom; text-align: right; width: 6%; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;9,336&lt;/td&gt;

    &lt;td style="white-space: nowrap; width: 1%;"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td style="white-space: nowrap; width: 1%;"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td style="white-space: nowrap; width: 1%;"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td class="ffcell" style="vertical-align: bottom; text-align: right; width: 6%; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;585,771&lt;/td&gt;

    &lt;td style="white-space: nowrap; width: 1%;"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td style="white-space: nowrap; width: 1%;"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td style="white-space: nowrap; width: 1%;"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td class="ffcell" style="vertical-align: bottom; text-align: right; width: 6%; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;5.6&lt;/td&gt;

    &lt;td style="white-space: nowrap; width: 1%;"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td style="white-space: nowrap; width: 1%;"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td style="vertical-align: bottom; white-space: nowrap; width: 1%; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;$&lt;/td&gt;

    &lt;td class="ffcell" style="vertical-align: bottom; text-align: right; width: 6%; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;2.33&lt;/td&gt;

    &lt;td style="white-space: nowrap; width: 1%;"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td style="white-space: nowrap; width: 1%;"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td style="white-space: nowrap; width: 1%;"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td class="ffcell" style="vertical-align: bottom; text-align: right; width: 6%; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;8,683&lt;/td&gt;

    &lt;td style="white-space: nowrap; width: 1%;"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td style="vertical-align: top; width: 28%; background-color: rgb(204, 238, 255);"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;$2.67 - $4.01&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/td&gt;

    &lt;td style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255);"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255);"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td class="ffcell" style="vertical-align: bottom; text-align: right; width: 6%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;1,809,746&lt;/td&gt;

    &lt;td style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255);"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255);"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255);"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td class="ffcell" style="vertical-align: bottom; text-align: right; width: 6%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;6.6&lt;/td&gt;

    &lt;td style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255);"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255);"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td style="vertical-align: bottom; white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;$&lt;/td&gt;

    &lt;td class="ffcell" style="vertical-align: bottom; text-align: right; width: 6%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;3.41&lt;/td&gt;

    &lt;td style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255);"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255);"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255);"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td class="ffcell" style="vertical-align: bottom; text-align: right; width: 6%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;24,868&lt;/td&gt;

    &lt;td style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255);"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255);"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255);"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td class="ffcell" style="vertical-align: bottom; text-align: right; width: 6%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;1,012,271&lt;/td&gt;

    &lt;td style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255);"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255);"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255);"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td class="ffcell" style="vertical-align: bottom; text-align: right; width: 6%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;5.4&lt;/td&gt;

    &lt;td style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255);"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255);"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td style="vertical-align: bottom; white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;$&lt;/td&gt;

    &lt;td class="ffcell" style="vertical-align: bottom; text-align: right; width: 6%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;3.46&lt;/td&gt;

    &lt;td style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255);"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255);"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255);"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td class="ffcell" style="vertical-align: bottom; text-align: right; width: 6%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;13,863&lt;/td&gt;

    &lt;td style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255);"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td rowspan="1" style="vertical-align: top; width: 28%; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;$4.09 - $6.14&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="white-space: nowrap; width: 1%; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/td&gt;

    &lt;td rowspan="1" style="white-space: nowrap; width: 1%; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/td&gt;

    &lt;td rowspan="1" style="white-space: nowrap; width: 1%; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/td&gt;

    &lt;td class="ffcell" rowspan="1" style="vertical-align: bottom; text-align: right; width: 6%; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;1,264,083&lt;/td&gt;

    &lt;td rowspan="1" style="white-space: nowrap; width: 1%; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/td&gt;

    &lt;td rowspan="1" style="white-space: nowrap; width: 1%; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/td&gt;

    &lt;td rowspan="1" style="white-space: nowrap; width: 1%; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/td&gt;

    &lt;td class="ffcell" rowspan="1" style="vertical-align: bottom; text-align: right; width: 6%; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;8.1&lt;/td&gt;

    &lt;td rowspan="1" style="white-space: nowrap; width: 1%; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/td&gt;

    &lt;td rowspan="1" style="white-space: nowrap; width: 1%; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/td&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; white-space: nowrap; width: 1%;"&gt;&lt;span style="font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;$&lt;br/&gt;
                &lt;/span&gt; &lt;/td&gt;

    &lt;td class="ffcell" rowspan="1" style="vertical-align: bottom; text-align: right; width: 6%; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;5.35&lt;/td&gt;

    &lt;td rowspan="1" style="white-space: nowrap; width: 1%; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/td&gt;

    &lt;td rowspan="1" style="white-space: nowrap; width: 1%; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/td&gt;

    &lt;td rowspan="1" style="white-space: nowrap; width: 1%; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/td&gt;

    &lt;td class="ffcell" rowspan="1" style="vertical-align: bottom; text-align: right; width: 6%; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;14,913&lt;/td&gt;

    &lt;td rowspan="1" style="white-space: nowrap; width: 1%; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/td&gt;

    &lt;td rowspan="1" style="white-space: nowrap; width: 1%; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/td&gt;

    &lt;td rowspan="1" style="white-space: nowrap; width: 1%; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/td&gt;

    &lt;td class="ffcell" rowspan="1" style="vertical-align: bottom; text-align: right; width: 6%; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;361,848&lt;/td&gt;

    &lt;td rowspan="1" style="white-space: nowrap; width: 1%; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/td&gt;

    &lt;td rowspan="1" style="white-space: nowrap; width: 1%; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/td&gt;

    &lt;td rowspan="1" style="white-space: nowrap; width: 1%; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/td&gt;

    &lt;td class="ffcell" rowspan="1" style="vertical-align: bottom; text-align: right; width: 6%; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;5.4&lt;/td&gt;

    &lt;td rowspan="1" style="white-space: nowrap; width: 1%; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/td&gt;

    &lt;td rowspan="1" style="white-space: nowrap; width: 1%; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/td&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; white-space: nowrap; width: 1%;"&gt;&lt;span style="font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;$&lt;br/&gt;
                &lt;/span&gt; &lt;/td&gt;

    &lt;td class="ffcell" rowspan="1" style="vertical-align: bottom; text-align: right; width: 6%; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;5.23&lt;/td&gt;

    &lt;td rowspan="1" style="white-space: nowrap; width: 1%; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/td&gt;

    &lt;td rowspan="1" style="white-space: nowrap; width: 1%; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/td&gt;

    &lt;td rowspan="1" style="white-space: nowrap; width: 1%; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/td&gt;

    &lt;td class="ffcell" rowspan="1" style="vertical-align: bottom; text-align: right; width: 6%; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;4,312&lt;/td&gt;

    &lt;td rowspan="1" style="white-space: nowrap; width: 1%; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td rowspan="1" style="vertical-align: top; width: 28%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;$6.54 - $9.81&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/td&gt;

    &lt;td rowspan="1" style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/td&gt;

    &lt;td rowspan="1" style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/td&gt;

    &lt;td class="ffcell" rowspan="1" style="vertical-align: bottom; text-align: right; width: 6%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;307,828&lt;/td&gt;

    &lt;td rowspan="1" style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/td&gt;

    &lt;td rowspan="1" style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/td&gt;

    &lt;td rowspan="1" style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/td&gt;

    &lt;td class="ffcell" rowspan="1" style="vertical-align: bottom; text-align: right; width: 6%; font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; background-color: rgb(204, 238, 255);"&gt;9.0&lt;/td&gt;

    &lt;td rowspan="1" style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/td&gt;

    &lt;td rowspan="1" style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/td&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255);"&gt;&lt;span style="font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;$&lt;br/&gt;
                &lt;/span&gt; &lt;/td&gt;

    &lt;td class="ffcell" rowspan="1" style="vertical-align: bottom; text-align: right; width: 6%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;6.60&lt;/td&gt;

    &lt;td rowspan="1" style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/td&gt;

    &lt;td rowspan="1" style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/td&gt;

    &lt;td rowspan="1" style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/td&gt;

    &lt;td class="ffcell" rowspan="1" style="vertical-align: bottom; text-align: right; width: 6%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;3,248&lt;/td&gt;

    &lt;td rowspan="1" style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/td&gt;

    &lt;td rowspan="1" style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/td&gt;

    &lt;td rowspan="1" style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/td&gt;

    &lt;td class="ffcell" rowspan="1" style="vertical-align: bottom; text-align: right; width: 6%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;7,500&lt;/td&gt;

    &lt;td rowspan="1" style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/td&gt;

    &lt;td rowspan="1" style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/td&gt;

    &lt;td rowspan="1" style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/td&gt;

    &lt;td class="ffcell" rowspan="1" style="vertical-align: bottom; text-align: right; width: 6%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;0.6&lt;/td&gt;

    &lt;td rowspan="1" style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/td&gt;

    &lt;td rowspan="1" style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/td&gt;

    &lt;td rowspan="1" style="vertical-align: bottom; white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255);"&gt;&lt;span style="font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;$&lt;br/&gt;
                &lt;/span&gt; &lt;/td&gt;

    &lt;td class="ffcell" rowspan="1" style="vertical-align: bottom; text-align: right; width: 6%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;8.98&lt;/td&gt;

    &lt;td rowspan="1" style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/td&gt;

    &lt;td rowspan="1" style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/td&gt;

    &lt;td rowspan="1" style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/td&gt;

    &lt;td class="ffcell" rowspan="1" style="vertical-align: bottom; text-align: right; width: 6%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;61&lt;/td&gt;

    &lt;td rowspan="1" style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td style="vertical-align: top; width: 28%; padding-bottom: 2px;"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;$10.80 - $17.49&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="white-space: nowrap; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/td&gt;

    &lt;td style="white-space: nowrap; width: 1%; padding-bottom: 2px;"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td style="border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap; width: 1%;"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td class="ffcell" style="border-bottom: 2px solid rgb(0, 0, 0); vertical-align: bottom; text-align: right; width: 6%;"&gt;&lt;span style="font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;149,111&lt;br/&gt;
                &lt;/span&gt; &lt;/td&gt;

    &lt;td style="padding-bottom: 2px; white-space: nowrap; width: 1%;"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td style="white-space: nowrap; width: 1%; padding-bottom: 2px;"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td style="white-space: nowrap; width: 1%; padding-bottom: 2px;"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td class="ffcell" style="vertical-align: bottom; text-align: right; width: 6%; padding-bottom: 2px; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;span style="font-family: 'Times New Roman'; font-weight: normal; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;8.7&lt;br/&gt;
                &lt;/span&gt; &lt;/td&gt;

    &lt;td style="white-space: nowrap; width: 1%; padding-bottom: 2px;"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td style="white-space: nowrap; width: 1%; padding-bottom: 2px;"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td style="vertical-align: bottom; white-space: nowrap; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;$&lt;/td&gt;

    &lt;td class="ffcell" style="vertical-align: bottom; text-align: right; width: 6%; padding-bottom: 2px;"&gt;&lt;span style="font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;8.74&lt;br/&gt;
                &lt;/span&gt; &lt;/td&gt;

    &lt;td style="white-space: nowrap; width: 1%; padding-bottom: 2px;"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td style="white-space: nowrap; width: 1%; padding-bottom: 2px;"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td style="border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap; width: 1%;"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td class="ffcell" style="border-bottom: 2px solid rgb(0, 0, 0); vertical-align: bottom; text-align: right; width: 6%;"&gt;&lt;span style="font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;500&lt;br/&gt;
                &lt;/span&gt; &lt;/td&gt;

    &lt;td style="padding-bottom: 2px; white-space: nowrap; width: 1%;"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td style="white-space: nowrap; width: 1%; padding-bottom: 2px;"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td style="border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap; width: 1%;"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td class="ffcell" style="border-bottom: 2px solid rgb(0, 0, 0); vertical-align: bottom; text-align: right; width: 6%;"&gt;&lt;span style="font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;14,000&lt;br/&gt;
                &lt;/span&gt; &lt;/td&gt;

    &lt;td style="padding-bottom: 2px; white-space: nowrap; width: 1%;"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td style="white-space: nowrap; width: 1%; padding-bottom: 2px;"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td style="white-space: nowrap; width: 1%; padding-bottom: 2px;"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td class="ffcell" style="vertical-align: bottom; text-align: right; width: 6%; padding-bottom: 2px;"&gt;&lt;span style="font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;0.1&lt;br/&gt;
                &lt;/span&gt; &lt;/td&gt;

    &lt;td style="white-space: nowrap; width: 1%; padding-bottom: 2px;"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td style="white-space: nowrap; width: 1%; padding-bottom: 2px;"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td style="vertical-align: bottom; white-space: nowrap; width: 1%; padding-bottom: 2px; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;$&lt;/td&gt;

    &lt;td class="ffcell" style="vertical-align: bottom; text-align: right; width: 6%; padding-bottom: 2px;"&gt;&lt;span style="font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;10.80&lt;br/&gt;
                &lt;/span&gt; &lt;/td&gt;

    &lt;td style="white-space: nowrap; width: 1%; padding-bottom: 2px;"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td style="white-space: nowrap; width: 1%; padding-bottom: 2px;"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td style="border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap; width: 1%;"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td class="ffcell" style="border-bottom: 2px solid rgb(0, 0, 0); vertical-align: bottom; text-align: right; width: 6%; font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;89&lt;/td&gt;

    &lt;td style="padding-bottom: 2px; white-space: nowrap; width: 1%;"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td style="width: 28%; background-color: rgb(204, 238, 255); padding-bottom: 4px;"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; padding-bottom: 4px;"&gt;&#160;&lt;/td&gt;

    &lt;td style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 4px double rgb(0, 0, 0);"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td class="ffcell" style="vertical-align: bottom; text-align: right; width: 6%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; border-bottom: 4px double rgb(0, 0, 0);"&gt;5,141,516&lt;/td&gt;

    &lt;td style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td class="ffcell" style="vertical-align: bottom; text-align: right; width: 6%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; padding-bottom: 4px;"&gt;7.1&lt;/td&gt;

    &lt;td style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td style="vertical-align: bottom; white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; padding-bottom: 4px;"&gt;$&lt;/td&gt;

    &lt;td class="ffcell" style="vertical-align: bottom; text-align: right; width: 6%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; padding-bottom: 4px;"&gt;3.90&lt;/td&gt;

    &lt;td style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td style="vertical-align: bottom; white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; border-bottom: 4px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;

    &lt;td class="ffcell" style="vertical-align: bottom; text-align: right; width: 6%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; border-bottom: 4px double rgb(0, 0, 0);"&gt;68,117&lt;/td&gt;

    &lt;td style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 4px double rgb(0, 0, 0);"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td class="ffcell" style="vertical-align: bottom; text-align: right; width: 6%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; border-bottom: 4px double rgb(0, 0, 0);"&gt;2,657,932&lt;/td&gt;

    &lt;td style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td class="ffcell" style="vertical-align: bottom; text-align: right; width: 6%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; padding-bottom: 4px;"&gt;5.7&lt;/td&gt;

    &lt;td style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td style="vertical-align: bottom; white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; padding-bottom: 4px;"&gt;$&lt;/td&gt;

    &lt;td class="ffcell" style="vertical-align: bottom; text-align: right; width: 6%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; padding-bottom: 4px;"&gt;3.03&lt;/td&gt;

    &lt;td style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td style="vertical-align: bottom; white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; border-bottom: 4px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;

    &lt;td class="ffcell" style="vertical-align: bottom; text-align: right; width: 6%; background-color: rgb(204, 238, 255); font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; border-bottom: 4px double rgb(0, 0, 0);"&gt;37,540&lt;/td&gt;

    &lt;td style="white-space: nowrap; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
</us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="c20240101to20241231_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ExercisePriceRange1Member"
      decimals="2"
      id="Fact_ec79f11027f640b7badda3e33c25f9b9"
      unitRef="U003">1.1</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="c20240101to20241231_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ExercisePriceRange1Member"
      decimals="2"
      id="Fact_a388507371f54bd687c8741c7b2ed968"
      unitRef="U003">1.67</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="c20241231_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ExercisePriceRange1Member"
      decimals="0"
      id="Fact_fe59777583ed4b30ae110b2eaf28a76c"
      unitRef="U002">981093</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="c20240101to20241231_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ExercisePriceRange1Member"
      id="Fact_e65a34f9d06c4c6aaf42c8c8446e3214">P6Y9M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="c20241231_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ExercisePriceRange1Member"
      decimals="2"
      id="Fact_310a2eb567284558ad7acfcdd37ad17f"
      unitRef="U003">1.6</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="c20241231_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ExercisePriceRange1Member"
      decimals="-3"
      id="Fact_d05ede6ff4d846d8bfa3f2886b34eaa9"
      unitRef="U001">15252000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="c20241231_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ExercisePriceRange1Member"
      decimals="0"
      id="Fact_56d3f5ac190d4868a97869c7c6df83bb"
      unitRef="U002">676542</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2
      contextRef="c20240101to20241231_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ExercisePriceRange1Member"
      id="Fact_91f8c19c97bc4f828fe9fc9ccd732a80">P6Y7M6D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="c20241231_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ExercisePriceRange1Member"
      decimals="2"
      id="Fact_13f80784f6444743b16188f3bc6488ec"
      unitRef="U003">1.58</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="c20241231_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ExercisePriceRange1Member"
      decimals="-3"
      id="Fact_9d9a04b1979649d28e594e6cc58a2f4e"
      unitRef="U001">10532000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="c20240101to20241231_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ExercisePriceRange2Member"
      decimals="2"
      id="Fact_b485bf61556346d0bada59859a86511b"
      unitRef="U003">1.73</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="c20240101to20241231_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ExercisePriceRange2Member"
      decimals="2"
      id="Fact_4d1a5cbed0e34e37b6ce01171b5b17c1"
      unitRef="U003">2.6</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="c20241231_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ExercisePriceRange2Member"
      decimals="0"
      id="Fact_a33282afcc9546b798240f933235407b"
      unitRef="U002">629655</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="c20240101to20241231_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ExercisePriceRange2Member"
      id="Fact_4ca8e063ad0b4fc09f9ebed79c6a98ee">P5Y8M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="c20241231_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ExercisePriceRange2Member"
      decimals="2"
      id="Fact_5cd1535c0f3a415e94297af1e1163d7b"
      unitRef="U003">2.32</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="c20241231_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ExercisePriceRange2Member"
      decimals="-3"
      id="Fact_b74cf9f129284cbab9da29c05f5a4fb8"
      unitRef="U001">9336000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="c20241231_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ExercisePriceRange2Member"
      decimals="0"
      id="Fact_122597664b004fa2ad92c3dff95608d6"
      unitRef="U002">585771</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2
      contextRef="c20240101to20241231_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ExercisePriceRange2Member"
      id="Fact_7cdea4e6589f473f99a2563218cf5c3f">P5Y7M6D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="c20241231_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ExercisePriceRange2Member"
      decimals="2"
      id="Fact_8d49cf6fbae043b7b3f93444df81d633"
      unitRef="U003">2.33</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="c20241231_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ExercisePriceRange2Member"
      decimals="-3"
      id="Fact_94b71120c88e4202aaf0e48b16b1017a"
      unitRef="U001">8683000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="c20240101to20241231_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ExercisePriceRange3Member"
      decimals="2"
      id="Fact_e4732be16d68407bbe330ec78708c162"
      unitRef="U003">2.67</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="c20240101to20241231_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ExercisePriceRange3Member"
      decimals="2"
      id="Fact_adcb6a977b664928b507850ee4b402a8"
      unitRef="U003">4.01</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="c20241231_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ExercisePriceRange3Member"
      decimals="0"
      id="Fact_0f11c57203ba42489361d37b690b2baf"
      unitRef="U002">1809746</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="c20240101to20241231_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ExercisePriceRange3Member"
      id="Fact_d30d56bddd534d9fabea41384342fdac">P6Y7M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="c20241231_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ExercisePriceRange3Member"
      decimals="2"
      id="Fact_0c36a27f40214b4e9c9843c2de0d9fc2"
      unitRef="U003">3.41</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="c20241231_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ExercisePriceRange3Member"
      decimals="-3"
      id="Fact_6563ef367ae44f99a6c643b58745206a"
      unitRef="U001">24868000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="c20241231_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ExercisePriceRange3Member"
      decimals="0"
      id="Fact_a6a731deba7b4498ab4eba353cc814a3"
      unitRef="U002">1012271</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2
      contextRef="c20240101to20241231_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ExercisePriceRange3Member"
      id="Fact_aedcfa0de8844dc5b09af0b3a82ce3a8">P5Y4M24D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="c20241231_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ExercisePriceRange3Member"
      decimals="2"
      id="Fact_2f753a140a47472195dcf41b804d0f0e"
      unitRef="U003">3.46</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="c20241231_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ExercisePriceRange3Member"
      decimals="-3"
      id="Fact_1861fddadb714875b86f9878cac49dc8"
      unitRef="U001">13863000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="c20240101to20241231_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ExercisePriceRange4Member"
      decimals="2"
      id="Fact_c42575e4d4b5453b9b3b8279b2f5b177"
      unitRef="U003">4.09</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="c20240101to20241231_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ExercisePriceRange4Member"
      decimals="2"
      id="Fact_115ac93605bb4d248d16e373b38c7f19"
      unitRef="U003">6.14</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="c20241231_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ExercisePriceRange4Member"
      decimals="0"
      id="Fact_2e7fdfc242204862a39d315d347008ca"
      unitRef="U002">1264083</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="c20240101to20241231_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ExercisePriceRange4Member"
      id="Fact_97a2155c14aa4fff9e675d99bc353e68">P8Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="c20241231_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ExercisePriceRange4Member"
      decimals="2"
      id="Fact_7653ff81b81e408ab4cb6f6ec1cb5a1a"
      unitRef="U003">5.35</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="c20241231_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ExercisePriceRange4Member"
      decimals="-3"
      id="Fact_2297ecb28df340fab62c5e0c418d07d1"
      unitRef="U001">14913000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="c20241231_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ExercisePriceRange4Member"
      decimals="0"
      id="Fact_3a429b0197224a1bb7bd93970bfd601b"
      unitRef="U002">361848</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2
      contextRef="c20240101to20241231_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ExercisePriceRange4Member"
      id="Fact_005ff17387624f7b8d5ad087d95930b0">P5Y4M24D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="c20241231_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ExercisePriceRange4Member"
      decimals="2"
      id="Fact_745fe88d1b3d4ad998849212b50114b1"
      unitRef="U003">5.23</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="c20241231_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ExercisePriceRange4Member"
      decimals="-3"
      id="Fact_2669dcf87d8d4c20b44a1b8b0d7b8842"
      unitRef="U001">4312000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="c20240101to20241231_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ExercisePriceRange5Member"
      decimals="2"
      id="Fact_cd216e5d9a0e429e8598a65ded14b5a4"
      unitRef="U003">6.54</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="c20240101to20241231_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ExercisePriceRange5Member"
      decimals="2"
      id="Fact_25b15c1265884957b6d77a7e839da54f"
      unitRef="U003">9.81</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="c20241231_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ExercisePriceRange5Member"
      decimals="0"
      id="Fact_8631d2abeb85439b981a27604189a28c"
      unitRef="U002">307828</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="c20240101to20241231_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ExercisePriceRange5Member"
      id="Fact_b026a0252d474ae2a8530af1d2edf0a3">P9Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="c20241231_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ExercisePriceRange5Member"
      decimals="2"
      id="Fact_dd9a7a7111e34f26ad1ccb12e513467c"
      unitRef="U003">6.6</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="c20241231_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ExercisePriceRange5Member"
      decimals="-3"
      id="Fact_822d53b84e9a4914bfa2aeacbf1e187a"
      unitRef="U001">3248000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="c20241231_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ExercisePriceRange5Member"
      decimals="0"
      id="Fact_3f2d798b6315436d8267625516a68a1c"
      unitRef="U002">7500</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2
      contextRef="c20240101to20241231_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ExercisePriceRange5Member"
      id="Fact_9567d37e365e46abbcf063d71a716e90">P0Y7M6D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="c20241231_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ExercisePriceRange5Member"
      decimals="2"
      id="Fact_311155ba33e64b8faacf66469ab96306"
      unitRef="U003">8.98</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="c20241231_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ExercisePriceRange5Member"
      decimals="-3"
      id="Fact_27794cd5a6044d0d9af8db75d84c354c"
      unitRef="U001">61000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="c20240101to20241231_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ExercisePriceRange6Member"
      decimals="2"
      id="Fact_2d1b7155c22842b2b1fe675e4b1aa06d"
      unitRef="U003">10.8</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="c20240101to20241231_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ExercisePriceRange6Member"
      decimals="2"
      id="Fact_02ce9e15c4a7468faebeb3299307b861"
      unitRef="U003">17.49</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="c20241231_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ExercisePriceRange6Member"
      decimals="0"
      id="Fact_c18f33ffa9d145988ee78b0bae8c27b3"
      unitRef="U002">149111</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="c20240101to20241231_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ExercisePriceRange6Member"
      id="Fact_f82c4e7ebee14b47b30a3c2dc2508fa4">P8Y8M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="c20241231_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ExercisePriceRange6Member"
      decimals="2"
      id="Fact_f3726c327eaf48f1aa1692dde27daf31"
      unitRef="U003">8.74</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="c20241231_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ExercisePriceRange6Member"
      decimals="-3"
      id="Fact_0829fcd5c153466992ff355e37fdbd2d"
      unitRef="U001">500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="c20241231_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ExercisePriceRange6Member"
      decimals="0"
      id="Fact_731bb7cd609c49189c7e2acb17107fd5"
      unitRef="U002">14000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2
      contextRef="c20240101to20241231_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ExercisePriceRange6Member"
      id="Fact_fb961bb906cb45908b75599a37693df9">P0Y1M6D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="c20241231_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ExercisePriceRange6Member"
      decimals="2"
      id="Fact_de9ae107284640b8839a1cc465b45b79"
      unitRef="U003">10.8</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="c20241231_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_ExercisePriceRange6Member"
      decimals="-3"
      id="Fact_d58a8def70b64aa1a59416aba6d825dc"
      unitRef="U001">89000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="c20241231"
      decimals="0"
      id="Fact_8de4cd99452d47a2a212e0158ed8a778"
      unitRef="U002">5141516</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="c20240101to20241231"
      id="Fact_2b529d363b7a40c5a6f6a4f3e1b501c2">P7Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="c20241231"
      decimals="2"
      id="Fact_989106913a25416382da00b223d16762"
      unitRef="U003">3.9</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="c20241231"
      decimals="-3"
      id="Fact_ef5c31c198b74c56a6ee5e8ad51ddfa8"
      unitRef="U001">68117000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="c20241231"
      decimals="0"
      id="Fact_2ef5df55495c4064a975fb562bc6a716"
      unitRef="U002">2657932</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2
      contextRef="c20240101to20241231"
      id="Fact_d755b85bd693435680a8aab963658632">P5Y8M12D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="c20241231"
      decimals="2"
      id="Fact_03cde827eec44d319929b8e824b201ef"
      unitRef="U003">3.03</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="c20241231"
      decimals="-3"
      id="Fact_04d76419ddc3481bbcda8ac463317cbc"
      unitRef="U001">37540000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted
      contextRef="c20240101to20241231_AwardTypeAxis_RestrictedStockUnitsRSUMember"
      decimals="0"
      id="Fact_6edf1cdf0b7e40d7b3d12ad60cda11be"
      unitRef="U002">3278688</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted
      contextRef="c20230101to20231231_AwardTypeAxis_RestrictedStockUnitsRSUMember"
      decimals="0"
      id="Fact_fa157343ff924b03b215afa5ea24b08c"
      unitRef="U002">3389760</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted
      contextRef="c20220101to20221231_AwardTypeAxis_RestrictedStockUnitsRSUMember"
      decimals="0"
      id="Fact_ef0c45768ed045669ffd945027c66507"
      unitRef="U002">1174266</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="c20240101to20241231_AwardTypeAxis_RestrictedStockUnitsRSUMember_TitleOfIndividualAxis_EmployeesMember"
      id="Fact_44bf68822544466fb46b507888bb89e6">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="c20240101to20241231_AwardTypeAxis_RestrictedStockUnitsRSUMember_TitleOfIndividualAxis_DirectorMember"
      id="Fact_f1e89c147b154ad1a28f27d8022c94b0">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="c20240101to20241231_AwardTypeAxis_RestrictedStockUnitsRSUMember"
      decimals="0"
      id="Fact_22dfbce76aaa4656ac5120fa75a416d8"
      unitRef="U002">1886463</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="c20230101to20231231_AwardTypeAxis_RestrictedStockUnitsRSUMember"
      decimals="0"
      id="Fact_a2c3899226324d7690ea37bba2836996"
      unitRef="U002">1199445</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="c20220101to20221231_AwardTypeAxis_RestrictedStockUnitsRSUMember"
      decimals="0"
      id="Fact_5b8f5d9a5e1c4a4a98bbf911c4d7c0df"
      unitRef="U002">2727412</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <adma:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesWithheldForEmployeesTaxLiabilities
      contextRef="c20241231_AwardTypeAxis_RestrictedStockUnitsRSUMember"
      decimals="0"
      id="Fact_5ed75399d2da432697f35793caa440d3"
      unitRef="U002">541908</adma:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesWithheldForEmployeesTaxLiabilities>
    <adma:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesValueWithheldForEmployeesTaxLiabilities
      contextRef="c20241231_AwardTypeAxis_RestrictedStockUnitsRSUMember"
      decimals="-5"
      id="Fact_ab054ff077f54df4a263ab30ad77e991"
      unitRef="U001">5000000</adma:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesValueWithheldForEmployeesTaxLiabilities>
    <adma:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesWithheldForEmployeesTaxLiabilities
      contextRef="c20231231_AwardTypeAxis_RestrictedStockUnitsRSUMember"
      decimals="0"
      id="Fact_5d4fd31704e04ac581bebbccd4df6f22"
      unitRef="U002">365722</adma:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesWithheldForEmployeesTaxLiabilities>
    <adma:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesValueWithheldForEmployeesTaxLiabilities
      contextRef="c20231231_AwardTypeAxis_RestrictedStockUnitsRSUMember"
      decimals="-5"
      id="Fact_0791c2b163ac475098c968b4402bb59f"
      unitRef="U001">1300000</adma:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesValueWithheldForEmployeesTaxLiabilities>
    <adma:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesWithheldForEmployeesTaxLiabilities
      contextRef="c20221231_AwardTypeAxis_RestrictedStockUnitsRSUMember"
      decimals="0"
      id="Fact_abc97bfc8eda4c3995a67fd8e6e317ff"
      unitRef="U002">918851</adma:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesWithheldForEmployeesTaxLiabilities>
    <adma:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesValueWithheldForEmployeesTaxLiabilities
      contextRef="c20221231_AwardTypeAxis_RestrictedStockUnitsRSUMember"
      decimals="-5"
      id="Fact_e00a78ca6aa84987bf008c2fd9751a68"
      unitRef="U001">2900000</adma:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSharesValueWithheldForEmployeesTaxLiabilities>
    <us-gaap:ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock
      contextRef="c20240101to20241231"
      id="Text_87a2312734e04197a39a66f812b397f5">&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal;"&gt;A summary of the Company&#x2019;s unvested RSU activity and related information is as follows: &lt;/span&gt;
&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left;"&gt; &lt;span style="font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="text-align: left; font: 10pt 'Times New Roman'; width: 100%; border-spacing: 0;"&gt;


  &lt;tr style="height: 15px;"&gt;

    &lt;td style="padding-bottom: 2px;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; text-align: center; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;strong&gt;Shares&lt;/strong&gt;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; text-align: center; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;strong&gt;Weighted&lt;/strong&gt;&lt;/p&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; text-align: center; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;strong&gt;Average
                    Grant&lt;/strong&gt;&lt;/p&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; text-align: center; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;strong&gt;Date Fair
                    Value&lt;/strong&gt;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td style="vertical-align: top; width: 76%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;Balance at December 31, 2021&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;4,485,133&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;1.34&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td style="vertical-align: top; width: 76%;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;Granted&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;1,174,266&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;1.74&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td style="vertical-align: top; width: 76%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;Vested&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;(2,727,412&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;)&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;1.25&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td style="vertical-align: top; width: 76%; padding-bottom: 2px;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;Forfeited&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;(65,000&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;)&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;1.40&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td rowspan="1" style="vertical-align: top; font-family: 'Times New Roman'; width: 76%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;Balance at December 31, 2022&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;2,866,987&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;1.59&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td rowspan="1" style="vertical-align: top; width: 76%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;Granted&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;3,389,760&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;3.42&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td rowspan="1" style="vertical-align: top; width: 76%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;Vested&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;(1,199,445&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;)&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;1.63&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td rowspan="1" style="vertical-align: top; width: 76%; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;Forfeited&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;(400,005&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;)&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;2.71&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td style="vertical-align: top; width: 76%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-right: 0px; margin-bottom: 0px; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;Balance at December 31, 2023&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;4,657,297&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;2.81&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td rowspan="1" style="vertical-align: top; width: 76%;" valign="bottom"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;Granted&lt;br/&gt;
                &lt;/span&gt; &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;3,278,688&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;$&lt;br/&gt;
                &lt;/span&gt; &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;7.44&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td rowspan="1" style="vertical-align: top; width: 76%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;Vested&lt;br/&gt;
                &lt;/span&gt; &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;(1,886,463&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;)&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;$&lt;br/&gt;
                &lt;/span&gt; &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;2.50&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td rowspan="1" style="vertical-align: top; width: 76%; padding-bottom: 2px;" valign="bottom"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;Forfeited&lt;br/&gt;
                &lt;/span&gt; &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"&gt;(303,532&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;)&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;$&lt;br/&gt;
                &lt;/span&gt; &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;3.92&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td rowspan="1" style="vertical-align: top; width: 76%; padding-bottom: 4px; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;Balance at December 31, 2024&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom"&gt;5,745,990&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;$&lt;br/&gt;
                &lt;/span&gt; &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;5.50&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
</us-gaap:ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c20211231_AwardTypeAxis_RestrictedStockUnitsRSUMember"
      decimals="0"
      id="Fact_d418c7d137214bf9835b7abaf11aaaf7"
      unitRef="U002">4485133</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c20211231_AwardTypeAxis_RestrictedStockUnitsRSUMember"
      decimals="2"
      id="Fact_d9f188430bdb4be0a3061d62b417d8c8"
      unitRef="U003">1.34</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="c20220101to20221231_AwardTypeAxis_RestrictedStockUnitsRSUMember"
      decimals="0"
      id="Fact_fb432319d3c44a1b94a07a5ced0acd32"
      unitRef="U002">1174266</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c20220101to20221231_AwardTypeAxis_RestrictedStockUnitsRSUMember"
      decimals="2"
      id="Fact_e660f37e0d2a4d829ec64cdae64e362a"
      unitRef="U003">1.74</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="c20220101to20221231_AwardTypeAxis_RestrictedStockUnitsRSUMember"
      decimals="0"
      id="Fact_10f07536474c4bab80031d0bbf3f01ad"
      unitRef="U002">2727412</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="c20220101to20221231_AwardTypeAxis_RestrictedStockUnitsRSUMember"
      decimals="2"
      id="Fact_bef97b13d8f94a0a86a1380df2ead166"
      unitRef="U003">1.25</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="c20220101to20221231_AwardTypeAxis_RestrictedStockUnitsRSUMember"
      decimals="0"
      id="Fact_16bfab3e91b14a64b0179aa9c385e7c8"
      unitRef="U002">65000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="c20220101to20221231_AwardTypeAxis_RestrictedStockUnitsRSUMember"
      decimals="2"
      id="Fact_61b6665583114b0dad7757cf92f1855e"
      unitRef="U003">1.4</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c20221231_AwardTypeAxis_RestrictedStockUnitsRSUMember"
      decimals="0"
      id="Fact_7064c412a1934ed0859b37048262b7a4"
      unitRef="U002">2866987</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c20221231_AwardTypeAxis_RestrictedStockUnitsRSUMember"
      decimals="2"
      id="Fact_343984b1e4904f54b5f2e34dbb9b45bb"
      unitRef="U003">1.59</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="c20230101to20231231_AwardTypeAxis_RestrictedStockUnitsRSUMember"
      decimals="0"
      id="Fact_58ca734ad6e840758254282e3690263d"
      unitRef="U002">3389760</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c20230101to20231231_AwardTypeAxis_RestrictedStockUnitsRSUMember"
      decimals="2"
      id="Fact_55a7e60252d0468cb94b50ce4f4f80d4"
      unitRef="U003">3.42</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="c20230101to20231231_AwardTypeAxis_RestrictedStockUnitsRSUMember"
      decimals="0"
      id="Fact_c50920e413a14e08a274a7391f039150"
      unitRef="U002">1199445</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="c20230101to20231231_AwardTypeAxis_RestrictedStockUnitsRSUMember"
      decimals="2"
      id="Fact_550c78f825d946d78bf8c3a6cac719ef"
      unitRef="U003">1.63</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="c20230101to20231231_AwardTypeAxis_RestrictedStockUnitsRSUMember"
      decimals="0"
      id="Fact_3209f84920574cc08ff1671e4fd08b67"
      unitRef="U002">400005</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="c20230101to20231231_AwardTypeAxis_RestrictedStockUnitsRSUMember"
      decimals="2"
      id="Fact_b2943c3449b344a29ae8e01570c54d96"
      unitRef="U003">2.71</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c20231231_AwardTypeAxis_RestrictedStockUnitsRSUMember"
      decimals="0"
      id="Fact_992969368a2d4e4b94dc2cc433e66ece"
      unitRef="U002">4657297</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c20231231_AwardTypeAxis_RestrictedStockUnitsRSUMember"
      decimals="2"
      id="Fact_d97a46c259944d64932cdae632f4b0a5"
      unitRef="U003">2.81</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="c20240101to20241231_AwardTypeAxis_RestrictedStockUnitsRSUMember"
      decimals="0"
      id="Fact_6cfd4c95162f486f92a39a8f56cfb829"
      unitRef="U002">3278688</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c20240101to20241231_AwardTypeAxis_RestrictedStockUnitsRSUMember"
      decimals="2"
      id="Fact_d69ab82b6217460f9632435809b4f512"
      unitRef="U003">7.44</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="c20240101to20241231_AwardTypeAxis_RestrictedStockUnitsRSUMember"
      decimals="0"
      id="Fact_d0391685eb4948f2b9ead3797387bd0a"
      unitRef="U002">1886463</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="c20240101to20241231_AwardTypeAxis_RestrictedStockUnitsRSUMember"
      decimals="2"
      id="Fact_adafcc68553749849c70d461aeea6ca5"
      unitRef="U003">2.5</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="c20240101to20241231_AwardTypeAxis_RestrictedStockUnitsRSUMember"
      decimals="0"
      id="Fact_2f9fc91239f149c4ac6d69b44eaa4e89"
      unitRef="U002">303532</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="c20240101to20241231_AwardTypeAxis_RestrictedStockUnitsRSUMember"
      decimals="2"
      id="Fact_9d8ae6dedf884193ba65c887c6a1964c"
      unitRef="U003">3.92</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c20241231_AwardTypeAxis_RestrictedStockUnitsRSUMember"
      decimals="0"
      id="Fact_a44fa255c9b2460894668e578887b429"
      unitRef="U002">5745990</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c20241231_AwardTypeAxis_RestrictedStockUnitsRSUMember"
      decimals="2"
      id="Fact_4343c775daaa47eebc9bc2da75468576"
      unitRef="U003">5.5</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
      contextRef="c20241231_AwardTypeAxis_RestrictedStockUnitsRSUMember_PlanNameAxis_EquityIncentivePlanMember"
      decimals="-5"
      id="Fact_80536c021f4a4112b250696f261c44df"
      unitRef="U001">25300000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="c20240101to20241231_AwardTypeAxis_RestrictedStockUnitsRSUMember_PlanNameAxis_EquityIncentivePlanMember"
      id="Fact_96ef003358a04ef990e13b4759ab33c3">P3Y1M6D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <adma:NumberOfIndividualsThatReceivedModificationsToTheirOutstandingStockOptionAndRSUAwards
      contextRef="c20240101to20241231_TitleOfIndividualAxis_EmployeesMember"
      decimals="INF"
      id="Fact_97fadf7cdbd54bcc9d088d34483d4aef"
      unitRef="U009">3</adma:NumberOfIndividualsThatReceivedModificationsToTheirOutstandingStockOptionAndRSUAwards>
    <adma:NumberOfIndividualsThatReceivedModificationsToTheirOutstandingStockOptionAndRSUAwards
      contextRef="c20240101to20241231_TitleOfIndividualAxis_DirectorMember"
      decimals="INF"
      id="Fact_a67250288c214449bc57606ca1fde918"
      unitRef="U008">1</adma:NumberOfIndividualsThatReceivedModificationsToTheirOutstandingStockOptionAndRSUAwards>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="c20240101to20241231_AwardTypeAxis_RestrictedStockUnitsRSUMember"
      decimals="-5"
      id="Fact_254f1178dbf74204a2a7722ae9d974d5"
      unitRef="U001">2500000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock
      contextRef="c20240101to20241231"
      id="Text_bdb87adfaf7b4ef8b1ee6faafa1e7de4">&lt;span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal;"&gt;Total stock-based compensation expense for all awards granted under the Company&#x2019;s equity incentive plans for the years ended December 31, 2024, 2023 and 2022
              was as follows (in thousands):&lt;/span&gt;
&lt;div&gt;&lt;span style="font-family: 'Times New Roman'; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
        &lt;/span&gt;
         &lt;span style="font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="text-align: left; font: 10pt 'Times New Roman'; margin-left: auto; margin-right: auto; width: 100%; border-spacing: 0;"&gt;


  &lt;tr style="height: 15px;"&gt;

    &lt;td rowspan="1" style="text-align: center; font-style: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: center; vertical-align: bottom; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="10" rowspan="1" style="vertical-align: bottom; text-align: center;" valign="bottom"&gt;&lt;span style="font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;Year Ended December 31, &lt;/span&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;br/&gt;
                &lt;/span&gt; &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td rowspan="1" style="padding-bottom: 2px; text-align: center; font-style: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;(in thousands)&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" rowspan="1" style="vertical-align: bottom; text-align: center; border-top: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: center; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;strong&gt; 2024&lt;br/&gt;
                  &lt;/strong&gt;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; border-top: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; border-top: 2px solid rgb(0, 0, 0);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" rowspan="1" style="vertical-align: bottom; text-align: center; border-top: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;strong&gt;2023&lt;/strong&gt;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; border-top: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: center; font-family: 'Times New Roman'; vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; border-top: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" rowspan="1" style="text-align: center; vertical-align: bottom; font-family: 'Times New Roman'; border-top: 2px solid rgb(0, 0, 0); border-bottom: 2px solid rgb(0, 0, 0); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;span style="font-weight: bold;"&gt;2022&lt;/span&gt;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; padding-bottom: 2px; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td style="vertical-align: top; width: 64%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;Research and development&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;98&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;40&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;19&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td style="vertical-align: top; width: 64%;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;Plasma center operating expenses&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;184&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;146&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;82&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td style="vertical-align: top; width: 64%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;Selling, general and administrative&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;11,720&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;5,331&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;4,717&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td style="vertical-align: top; width: 64%; padding-bottom: 2px;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;Cost of product revenue&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;1,614&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;670&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;397&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td style="vertical-align: top; width: 64%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-indent: 9.5pt; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;Total stock-based compensation expense&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;13,616&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;" valign="bottom"&gt;6,187&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;5,215&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); color: rgb(0, 0, 0); font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
</us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock>
    <us-gaap:ShareBasedCompensation
      contextRef="c20240101to20241231_IncomeStatementLocationAxis_ResearchAndDevelopmentExpenseMember"
      decimals="-3"
      id="Fact_38bf5208486c478a84e61a0163ccd7af"
      unitRef="U001">98000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="c20230101to20231231_IncomeStatementLocationAxis_ResearchAndDevelopmentExpenseMember"
      decimals="-3"
      id="Fact_7c67f1626cde4d06aacb99c32aeee1e0"
      unitRef="U001">40000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="c20220101to20221231_IncomeStatementLocationAxis_ResearchAndDevelopmentExpenseMember"
      decimals="-3"
      id="Fact_187ed1ca24454d0fa89a6af2ab62e545"
      unitRef="U001">19000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="c20240101to20241231_IncomeStatementLocationAxis_OperatingExpenseMember"
      decimals="-3"
      id="Fact_fc1bf715ff5444ff83433909d2f6830e"
      unitRef="U001">184000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="c20230101to20231231_IncomeStatementLocationAxis_OperatingExpenseMember"
      decimals="-3"
      id="Fact_205751fd30894aaaaeb308085d6105a3"
      unitRef="U001">146000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="c20220101to20221231_IncomeStatementLocationAxis_OperatingExpenseMember"
      decimals="-3"
      id="Fact_31fde3b26bf34d57a4082b5a8932cc98"
      unitRef="U001">82000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="c20240101to20241231_IncomeStatementLocationAxis_SellingGeneralAndAdministrativeExpensesMember"
      decimals="-3"
      id="Fact_7550905e2d084922bd5ad85cf45f7855"
      unitRef="U001">11720000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="c20230101to20231231_IncomeStatementLocationAxis_SellingGeneralAndAdministrativeExpensesMember"
      decimals="-3"
      id="Fact_fa6a387ff3bc4c43b2fbc3ecbc289d93"
      unitRef="U001">5331000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="c20220101to20221231_IncomeStatementLocationAxis_SellingGeneralAndAdministrativeExpensesMember"
      decimals="-3"
      id="Fact_caadf250883347929357ae29d2c303dc"
      unitRef="U001">4717000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="c20240101to20241231_IncomeStatementLocationAxis_CostOfSalesMember"
      decimals="-3"
      id="Fact_61c5340becc24518b8f7e68a160c64ab"
      unitRef="U001">1614000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="c20230101to20231231_IncomeStatementLocationAxis_CostOfSalesMember"
      decimals="-3"
      id="Fact_06958c9a33024464a6d752ea08918cf6"
      unitRef="U001">670000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="c20220101to20221231_IncomeStatementLocationAxis_CostOfSalesMember"
      decimals="-3"
      id="Fact_b0ad4535327848e19a40b874f389bcf6"
      unitRef="U001">397000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="c20240101to20241231"
      decimals="-3"
      id="Fact_e301cd14405c4cc4a7b318e08c53f87a"
      unitRef="U001">13616000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="c20230101to20231231"
      decimals="-3"
      id="Fact_28b6a4bca5954e9ea03107e859a4e4db"
      unitRef="U001">6187000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="c20220101to20221231"
      decimals="-3"
      id="Fact_682a6601217a42b283d8d26f78aee1d5"
      unitRef="U001">5215000</us-gaap:ShareBasedCompensation>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock
      contextRef="c20240101to20241231"
      id="Text_674930182f70406e9c3674013f1474da">
&lt;div&gt;
          &lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt; border-spacing: 0;"&gt;


  &lt;tr style="vertical-align: top;"&gt;

    &lt;td style="vertical-align: top; width: 27pt;"&gt;
                  &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;"&gt;&lt;strong&gt;9.&lt;/strong&gt;&lt;/p&gt;
                &lt;/td&gt;

    &lt;td style="align: left; vertical-align: top; width: auto;"&gt;
                  &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;"&gt;&lt;span style="text-decoration: underline;"&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;strong&gt;RELATED PARTY TRANSACTIONS&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;strong&gt;&lt;span style="text-decoration: underline;"&gt;&lt;br/&gt;
                      &lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;
                &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
        &lt;/div&gt;
&lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;"&gt;&#160;&lt;/p&gt;&lt;p style="margin: 0px; font-family: 'Times New Roman'; font-size: 10pt; text-align: left; text-indent: 36pt;"&gt;&lt;span style="font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none;"&gt;The Company leases an office building and equipment from Areth, LLC (&#x201c;Areth&#x201d;) pursuant to an agreement for services effective as of January 1, 2016, as amended from time
            to time&lt;span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; text-align: left; text-indent: 48px; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;, and pays&lt;/span&gt; monthly rent on this facility in the amount of $10,000. On &lt;span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; text-align: left; text-indent: 48px; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;October 18, 2022&lt;/span&gt;, the &lt;span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; text-align: left; text-indent: 48px; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;Company&lt;/span&gt; &lt;span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; text-align: left; text-indent: 48px; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;amended the agreement to extend its term to December 31, 2026, with automatic successive one-year
              renewals thereafter. Either party may terminate the agreement by providing the other party with&lt;/span&gt; one year&lt;span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; text-align: left; text-indent: 48px; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;&#x2019;s prior written notice&lt;/span&gt;. Rent expense for the years ended December 31, 2024, 2023 and 2022 amounted to $0.1
            million. Areth is a company controlled by Dr. Jerrold B. Grossman, the Vice Chairman of the Board, and Adam S. Grossman, the Company&#x2019;s President and Chief Executive Officer. The Company also reimburses Areth for office, warehousing and building
            related (common area) expenses, equipment and certain other operational expenses, which were not material to the consolidated financial statements for the years ended &lt;span style="font-size: 10pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-variant: normal; text-transform: none;"&gt;December 31, 2024, 2023 and 2022&lt;/span&gt;.&lt;/span&gt; &lt;/p&gt;&lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-indent: 45px; text-align: left;"&gt;&#160;&lt;/p&gt;&lt;p style="margin: 0px; font-family: 'Times New Roman'; font-size: 10pt; text-align: left; text-indent: 36pt;"&gt;During the years ended December 31, 2024, 2023 and 2022, the Company purchased certain specialized equipment and repair services used for
          the collection and processing of source plasma from GenesisBPS and its affiliates (&#x201c;Genesis&#x201d;) in the amount of $0.2 million, $0.4 million and $0.2 million,
          respectively. Genesis is owned by Dr. Grossman and Adam Grossman.&lt;/p&gt;&lt;p style="margin: 0px; font-family: 'Times New Roman'; font-size: 10pt; text-align: left; text-indent: 36pt;"&gt; &lt;br/&gt;
        &lt;/p&gt;&lt;p style="margin: 0px; font-family: 'Times New Roman'; font-size: 10pt; text-align: left; text-indent: 36pt;"&gt;On November 19, 2024, the Company entered into an agreement with Bryant Fong whereby the Company agreed, in conjunction with Mr. Fong&#x2019;s
          resignation from the Board, to immediately vest all of Mr. Fong&#x2019;s 12,020 unvested RSUs. The agreement also extended the
          post-termination exercise period for his vested stock options from 90 days to two years (or earlier, if such options&#x2019; 10-year expiration date occurs
          sooner than November 19, 2026). All of Mr. Fong&#x2019;s unvested stock options were forfeited in accordance with the terms of the 2022
          Equity Plan. In connection with this modification of Mr. Fong&#x2019;s equity awards, the Company recorded additional compensation expense of $0.3
          million (see Note 8) in the year ended December 31, 2024.&lt;/p&gt;&lt;p style="margin: 0px; font-family: 'Times New Roman'; font-size: 10pt; text-align: left; text-indent: 36pt;"&gt;&#160;&lt;/p&gt;&lt;p style="margin: 0px; font-family: 'Times New Roman'; font-size: 10pt; text-align: left; text-indent: 36pt;"&gt;On April 1, 2024, the Company entered into a consulting agreement with Brian Lenz, the Company&#x2019;s former Executive Vice President, Chief
          Financial Officer and General Manager, ADMA BioCenters, whereby Mr. Lenz&#x2019;s outstanding equity awards were modified in connection with his transition to a consulting role. Under the terms of the consulting agreement, Mr. Lenz remained eligible to
          participate in the Company&#x2019;s equity compensation plans with respect to continued vesting of the subject awards as set forth in the agreement. In addition, the post-termination exercise period for Mr. Lenz&#x2019;s vested stock options was extended from
          90 days to two years
          from the date of the consulting agreement (or earlier, if such options&#x2019; 10-year expiration date occurs sooner than March 31, 2026). In connection with this modification, the Company recorded $1.6 million of additional compensation expense for the year ended December 31, 2024.&lt;/p&gt;&lt;p style="margin: 0px; font-family: 'Times New Roman'; font-size: 10pt; text-align: left; text-indent: 36pt;"&gt; &lt;/p&gt;&lt;p style="margin: 0px; font-family: 'Times New Roman'; font-size: 10pt; text-align: left; text-indent: 36pt;"&gt; &lt;/p&gt;&lt;p style="margin: 0px; font-family: 'Times New Roman'; font-size: 10pt; text-align: left; text-indent: 36pt;"&gt; &lt;br/&gt;
        &lt;/p&gt;&lt;p style="margin: 0px; font-family: 'Times New Roman'; font-size: 10pt; text-align: left; text-indent: 36pt;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; word-spacing: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;On August 15, 2023, two of the Company&#x2019;s executive
            officers exercised options to purchase 2,909,721 shares of the Company&#x2019;s common stock on a cashless basis, and 688,657 shares of common stock were issued to these executive officers, net of 257,867 shares of common stock to cover a portion of their tax liabilities (see Note 8)&lt;/span&gt;&lt;span style="font-size: 10pt;"&gt;.&lt;/span&gt;&lt;br/&gt;
        &lt;/p&gt;&lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-indent: 45px; text-align: left;"&gt;&lt;br/&gt;
        &lt;/p&gt;
&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="margin: 0px 0px 0px; font-family: 'Times New Roman'; font-size: 10pt; text-align: left; text-indent: 36pt;"&gt;See Note 7 for a discussion of the Company&#x2019;s prior credit facility and related transactions with Perceptive, a holder of more
          than 5% of the Company&#x2019;s common stock during the year ended December 31, 2022.&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="margin: 0px 0px 0px; font-family: 'Times New Roman'; font-size: 10pt; text-align: left; text-indent: 36pt;"&gt; &lt;br/&gt;
        &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="margin: 0px 0px 0px; font-family: 'Times New Roman'; font-size: 10pt; text-align: left; text-indent: 36pt;"&gt;In connection with the 2022 public offering of the Company&#x2019;s common stock (see Note 8) on December 9, 2022: (i) Mr. Grossman
          purchased 14,983 shares of common stock directly and 14,982 shares of common stock indirectly through an entity he controls, and (ii) Mr. Lenz purchased 6,993
          shares of common stock, all at the public offering price of $2.86 per share. &lt;/div&gt;
</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:OperatingCostsAndExpenses
      contextRef="c20160101to20160131_CounterpartyNameAxis_ArethLLCMember_RelatedPartyTransactionsByRelatedPartyAxis_RelatedPartyMember"
      decimals="0"
      id="Fact_a14a1e27b8eb4d7f87d82d0eb5bbb99f"
      unitRef="U001">10000</us-gaap:OperatingCostsAndExpenses>
    <us-gaap:LeaseExpirationDate1
      contextRef="c20240101to20241231_CounterpartyNameAxis_ArethLLCMember_RelatedPartyTransactionsByRelatedPartyAxis_RelatedPartyMember"
      id="Fact_c8b6d664cf77495d95799e8d28a38c8e">2026-12-31</us-gaap:LeaseExpirationDate1>
    <adma:RelatedPartyTransactionLeaseRenewalPeriod
      contextRef="c20240101to20241231_CounterpartyNameAxis_ArethLLCMember_RelatedPartyTransactionsByRelatedPartyAxis_RelatedPartyMember"
      id="Fact_424e89fd78a44e7392ce41eb8e4e095f">P1Y</adma:RelatedPartyTransactionLeaseRenewalPeriod>
    <adma:RelatedPartyTransactionLeaseTerminationPeriod
      contextRef="c20240101to20241231_CounterpartyNameAxis_ArethLLCMember_RelatedPartyTransactionsByRelatedPartyAxis_RelatedPartyMember"
      id="Fact_520d06d1ae1b4101959a606d379ecd01">P1Y</adma:RelatedPartyTransactionLeaseTerminationPeriod>
    <us-gaap:OperatingCostsAndExpenses
      contextRef="c20230101to20231231_CounterpartyNameAxis_ArethLLCMember_RelatedPartyTransactionsByRelatedPartyAxis_RelatedPartyMember"
      decimals="-5"
      id="Fact_ffd63497f53445aa9b3498359fd6e0eb"
      unitRef="U001">100000</us-gaap:OperatingCostsAndExpenses>
    <us-gaap:OperatingCostsAndExpenses
      contextRef="c20220101to20221231_CounterpartyNameAxis_ArethLLCMember_RelatedPartyTransactionsByRelatedPartyAxis_RelatedPartyMember"
      decimals="-5"
      id="Fact_ba199790a8af46f09979ccc6cbec9e42"
      unitRef="U001">100000</us-gaap:OperatingCostsAndExpenses>
    <us-gaap:OperatingCostsAndExpenses
      contextRef="c20240101to20241231_CounterpartyNameAxis_ArethLLCMember_RelatedPartyTransactionsByRelatedPartyAxis_RelatedPartyMember"
      decimals="-5"
      id="Fact_628b0e508d514c7eb4c521a89f845f2d"
      unitRef="U001">100000</us-gaap:OperatingCostsAndExpenses>
    <us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty
      contextRef="c20240101to20241231_CounterpartyNameAxis_GenesisBPSMember_RelatedPartyTransactionsByRelatedPartyAxis_RelatedPartyMember"
      decimals="-5"
      id="Fact_276ff91b5af5421ca068e8ee4e9aa5f8"
      unitRef="U001">200000</us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty>
    <us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty
      contextRef="c20230101to20231231_CounterpartyNameAxis_GenesisBPSMember_RelatedPartyTransactionsByRelatedPartyAxis_RelatedPartyMember"
      decimals="-5"
      id="Fact_d4da687522fc4aedaa8d53ef957322bc"
      unitRef="U001">400000</us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty>
    <us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty
      contextRef="c20220101to20221231_CounterpartyNameAxis_GenesisBPSMember_RelatedPartyTransactionsByRelatedPartyAxis_RelatedPartyMember"
      decimals="-5"
      id="Fact_a764d87779244aadadad1b00842f6cf3"
      unitRef="U001">200000</us-gaap:RelatedPartyTransactionPurchasesFromRelatedParty>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="c20241119to20241119_AwardTypeAxis_RestrictedStockUnitsRSUMember_CounterpartyNameAxis_BryantFongMember_RelatedPartyTransactionsByRelatedPartyAxis_RelatedPartyMember"
      decimals="0"
      id="Fact_13c2ef9759ee49aaaf3700ec4cd65f2a"
      unitRef="U002">12020</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="c20240101to20241231_CounterpartyNameAxis_BryantFongMember_RangeAxis_MinimumMember_RelatedPartyTransactionsByRelatedPartyAxis_RelatedPartyMember"
      id="Fact_03cdd40b2c744f69b18d41f2e56afaa4">P90D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="c20240101to20241231_CounterpartyNameAxis_BryantFongMember_RangeAxis_MaximumMember_RelatedPartyTransactionsByRelatedPartyAxis_RelatedPartyMember"
      id="Fact_07ddfe7e7af341eaa57c59b4d55003c2">P2Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1
      contextRef="c20240101to20241231_CounterpartyNameAxis_BryantFongMember_RelatedPartyTransactionsByRelatedPartyAxis_RelatedPartyMember"
      id="Fact_702c3f0d9d574d0ab0b291fbf19f1038">P10Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate
      contextRef="c20240101to20241231_CounterpartyNameAxis_BryantFongMember_RelatedPartyTransactionsByRelatedPartyAxis_RelatedPartyMember"
      id="Fact_0f64d308348b44dc9437e7a5d558700d">2026-11-19</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate>
    <us-gaap:ShareBasedCompensation
      contextRef="c20240101to20241231_CounterpartyNameAxis_BryantFongMember_RelatedPartyTransactionsByRelatedPartyAxis_RelatedPartyMember"
      decimals="-5"
      id="Fact_296c5595fd3c4f71ba9fabfb8a48c5a3"
      unitRef="U001">300000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="c20240101to20241231_RangeAxis_MinimumMember_RelatedPartyTransactionsByRelatedPartyAxis_RelatedPartyMember_TitleOfIndividualAxis_ExecutiveVicePresidentAndChiefFinancialOfficerMember"
      id="Fact_4bee219989df4b8cb7712d2508c85373">P90D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="c20240101to20241231_RangeAxis_MaximumMember_RelatedPartyTransactionsByRelatedPartyAxis_RelatedPartyMember_TitleOfIndividualAxis_ExecutiveVicePresidentAndChiefFinancialOfficerMember"
      id="Fact_9a89ccc086b2487f854230c9bc1db637">P2Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1
      contextRef="c20240101to20241231_RelatedPartyTransactionsByRelatedPartyAxis_RelatedPartyMember_TitleOfIndividualAxis_ExecutiveVicePresidentAndChiefFinancialOfficerMember"
      id="Fact_2d5e8aef71404604aaf0616e7f839e02">P10Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate
      contextRef="c20240101to20241231_RelatedPartyTransactionsByRelatedPartyAxis_RelatedPartyMember_TitleOfIndividualAxis_ExecutiveVicePresidentAndChiefFinancialOfficerMember"
      id="Fact_7f76d2feb14e4bef841565139378575f">2026-03-31</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationDate>
    <us-gaap:ShareBasedCompensation
      contextRef="c20240101to20241231_RelatedPartyTransactionsByRelatedPartyAxis_RelatedPartyMember_TitleOfIndividualAxis_ExecutiveVicePresidentAndChiefFinancialOfficerMember"
      decimals="-5"
      id="Fact_5f273c74892c41e28f00bbc298c308df"
      unitRef="U001">1600000</us-gaap:ShareBasedCompensation>
    <adma:NumberOfExecutiveOfficersThatExercisedOptions
      contextRef="c20230815to20230815_RelatedPartyTransactionsByRelatedPartyAxis_RelatedPartyMember_TitleOfIndividualAxis_ExecutiveOfficerMember"
      decimals="INF"
      id="Fact_cc34bb6fc29d44a8a5c997f8d3e4f6db"
      unitRef="U006">2</adma:NumberOfExecutiveOfficersThatExercisedOptions>
    <adma:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedInCashlessTransactionForAward
      contextRef="c20230815to20230815_RelatedPartyTransactionsByRelatedPartyAxis_RelatedPartyMember_TitleOfIndividualAxis_ExecutiveOfficerMember"
      decimals="0"
      id="Fact_20d53f5167a64aec81cab0bc8e617183"
      unitRef="U002">2909721</adma:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedInCashlessTransactionForAward>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="c20230815to20230815_RelatedPartyTransactionsByRelatedPartyAxis_RelatedPartyMember_TitleOfIndividualAxis_ExecutiveOfficerMember"
      decimals="0"
      id="Fact_70ab7f3cf5b74e0dbdb47f82467a3614"
      unitRef="U002">688657</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation
      contextRef="c20230815to20230815_RelatedPartyTransactionsByRelatedPartyAxis_RelatedPartyMember_TitleOfIndividualAxis_ExecutiveOfficerMember"
      decimals="0"
      id="Fact_e60522463dd04ab1a0734edc529cb8d2"
      unitRef="U002">257867</us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation>
    <adma:MinimumPercentageOfCommonStockHeldByLender
      contextRef="c20220101to20221231_LineOfCreditFacilityAxis_PerceptiveCreditHoldingsIILPMember_RelatedPartyTransactionsByRelatedPartyAxis_RelatedPartyMember"
      decimals="2"
      id="Fact_61ac4aba87504d9f93eec53583d84bee"
      unitRef="U007">0.05</adma:MinimumPercentageOfCommonStockHeldByLender>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c20221209to20221209_OwnershipAxis_DirectOwnershipMember_RelatedPartyTransactionsByRelatedPartyAxis_RelatedPartyMember_TitleOfIndividualAxis_PresidentAndChiefExecutiveOfficerMember"
      decimals="0"
      id="Fact_ac80364d5ee54bbd88f29bb173ec8a2f"
      unitRef="U002">14983</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c20221209to20221209_OwnershipAxis_IndirectOwnershipMember_RelatedPartyTransactionsByRelatedPartyAxis_RelatedPartyMember_TitleOfIndividualAxis_PresidentAndChiefExecutiveOfficerMember"
      decimals="0"
      id="Fact_5634fb52b0ef4f76ba5cafa5a8d6cf3e"
      unitRef="U002">14982</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c20221209to20221209_RelatedPartyTransactionsByRelatedPartyAxis_RelatedPartyMember_TitleOfIndividualAxis_ExecutiveVicePresidentAndChiefFinancialOfficerMember"
      decimals="0"
      id="Fact_d85cd60f028a409dada1eed69a529e37"
      unitRef="U002">6993</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="c20221209_RelatedPartyTransactionsByRelatedPartyAxis_RelatedPartyMember_TitleOfIndividualAxis_ExecutiveVicePresidentAndChiefFinancialOfficerMember"
      decimals="2"
      id="Fact_1a868ed132da4763b926db93443daea4"
      unitRef="U003">2.86</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="c20240101to20241231"
      id="Text_3764710572044ead9e6dfb83c5c95cdc">
&lt;div&gt;
          &lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt; border-spacing: 0;"&gt;


  &lt;tr style="vertical-align: top;"&gt;

    &lt;td style="vertical-align: top; width: 27pt;"&gt;
                  &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;"&gt;&lt;strong&gt;10.&lt;/strong&gt;&lt;/p&gt;
                &lt;/td&gt;

    &lt;td style="align: left; vertical-align: top; width: auto;"&gt;
                  &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;"&gt;&lt;span style="text-decoration: underline;"&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;strong&gt;COMMITMENTS AND CONTINGENCIES&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;strong&gt;&lt;span style="text-decoration: underline;"&gt;&lt;br/&gt;
                      &lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;
                &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
        &lt;/div&gt;
&lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;"&gt;&#160;&lt;/p&gt;&lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;"&gt;&lt;span style="text-decoration:underline"&gt;General Legal Matters&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;"&gt;&#160;&lt;/p&gt;&lt;p style="margin: 0px; font-family: 'Times New Roman'; font-size: 10pt; text-align: left; text-indent: 36pt;"&gt;From time to time the Company is or may become subject to certain legal proceedings and claims arising in connection with the normal
          course of its business. Management does not expect that the outcome of any such claims or actions will have a material effect on the Company&#x2019;s liquidity, results of operations or financial condition.&lt;/p&gt;&lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;"&gt;&#160;&lt;/p&gt;&lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;"&gt;&lt;span style="text-decoration:underline"&gt;IT Systems Disruption&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;"&gt;&#160;&lt;/p&gt;&lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-indent: 45px; text-align: left;"&gt; &lt;/p&gt;
&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; text-indent: 36pt;"&gt;On June 19, 2023, the Company experienced an IT systems disruption, which rendered certain of the Company&#x2019;s IT technology
          systems inaccessible for less than &lt;span style="-sec-ix-hidden:Fact_4754ce8ea55d44e195b5e28a95f3e9f0"&gt;one&lt;/span&gt; week. The Company&#x2019;s investigation of the disruption has essentially been completed with the
          assistance of third-party consultants, and no definitive root cause was identified. At the time of the disruption, the Company was in production of two
          batches of BIVIGAM, and after a prolonged hold time, it was deemed to be a prudent GMP quality decision to discard these two
          in-process production batches as these batches were no longer viable for further production or had any alternative use. As a result, the Company recorded a one-time, non-recurring charge of $2.1 million in the second quarter of 2023 for this inventory, which is reflected in Cost of product revenue in the accompanying consolidated statement of operations for the year ending
          December 31, 2023. In addition, the Company&#x2019;s Plasma center operating expenses were adversely impacted by approximately $0.7 million
          due to the temporary closing of the Company&#x2019;s plasma collection centers while their IT systems were restored.&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; text-indent: 36pt;"&gt; &lt;br/&gt;
        &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: left; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; text-indent: 36pt;"&gt; The Company carries appropriate insurance for these types of instances. During each of the years ended December 31, 2024 and
          2023, the Company&#x2019;s cybersecurity insurer paid the Company an aggregate of $0.2 million for approved restoration-related costs.&#160;
          During the first quarter of 2025, the Company&#x2019;s cybersecurity insurer paid the Company $0.4 million in business interruption loss
          coverage.&lt;/div&gt;

&lt;div&gt;&lt;br/&gt;&lt;/div&gt;
&lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left; font-style: normal;"&gt;&lt;span style="text-decoration:underline"&gt;Vendor Commitments&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;"&gt;&#160;&lt;/p&gt;&lt;p style="margin: 0px; font-family: 'Times New Roman'; font-size: 10pt; text-align: left; text-indent: 36pt;"&gt;Pursuant to the terms of a Plasma Purchase Agreement dated as of November 17, 2011 (the &#x201c;2011 Plasma Purchase Agreement&#x201d;), the Company
          agreed to purchase from its former contract manufacturer an annual minimum volume of source plasma containing antibodies to RSV to be used in the manufacture of ASCENIV. The Company must purchase a to-be-determined and agreed upon annual minimum
          volume from the counterparty, and under the original 2011 Plasma Purchase Agreement the Company was permitted to also collect high-titer plasma from up to five wholly-owned ADMA plasma collection facilities. During 2015, the Company amended the 2011 Plasma Purchase Agreement to (i) allow the Company to collect its raw material high-titer
          plasma from any number of wholly-owned ADMA plasma collection facilities and (ii) allow the Company to purchase its raw material high-titer plasma from other third-party collection organizations, in each case, provided that the annual minimum
          volumes from the Company&#x2019;s former contract manufacturer were met, thus allowing the Company to expand its reach for raw material supply as it executes its commercialization plans for ASCENIV. On December 10, 2018, the Company&#x2019;s former contract
          manufacturer assigned its rights and obligations under the 2011 Plasma Purchase Agreement to Grifols Worldwide Operations Limited (&#x201c;Grifols&#x201d;) as its successor-in-interest, effective January 1, 2019. Effective October 1, 2024, the Company entered
          into an Amended and Restated Plasma Purchase Agreement with Grifols (the &#x201c;A&amp;amp;R Grifols Agreement&#x201d;) with a term expiring in &lt;span style="-sec-ix-hidden:Fact_596502cac0e64068963eb61419709634"&gt;September 2039&lt;/span&gt;,
          after which it may be renewed for two additional multi-year periods if agreed to by the parties. Pursuant to the A&amp;amp;R Grifols
          Agreement, Grifols supplies, on a non-exclusive basis, to ADMA BioManufacturing a minimum of 35,000 liters of RSV plasma annually to
          be used in the manufacture of ASCENIV, with an escalating price per liter depending on the volume supplied in a given 12-month period,
          with a minimum annual price increase every 12 months.&#160; Additionally, Grifols will be entitled to receive a fixed bonus payment in the
          event that a specified liter amount of high-titer plasma is supplied to the Company in any 12-month period during the term of the
          A&amp;amp;R Grifols Agreement.&lt;/p&gt;&lt;p style="margin: 0px; font-family: 'Times New Roman'; font-size: 10pt; text-align: left; text-indent: 36pt;"&gt; &lt;br/&gt;
        &lt;/p&gt;&lt;p style="margin: 0px; font-family: 'Times New Roman'; font-size: 10pt; text-align: left; text-indent: 36pt;"&gt;Effective August 6, 2024, the Company entered into a Plasma Purchase Agreement with KEDPlasma LLC (&#x201c;KEDPlasma&#x201d;) with a term expiring in &lt;span style="-sec-ix-hidden:Fact_08cb0657423a4fc9a23ab84cedf6874f"&gt;July 2031&lt;/span&gt;, after which it may be renewed for an additional five-year period if agreed to by the parties (the &#x201c;KEDPlasma Agreement&#x201d;).&#160; Pursuant to the KEDPlasma Agreement, KEDPlasma supplies, on a non-exclusive basis, to ADMA BioManufacturing a minimum of 35,000 liters of RSV plasma annually commencing with the 12-month
          period ending July 31, 2026, with an escalating price per liter depending on the volume supplied in a given 12-month period. The price
          per liter of high-titer plasma supplied pursuant to the KEDPlasma Agreement is also scheduled to increase on an annual basis. Additionally, KEDPlasma will be entitled to receive a fixed bonus payment in the event that a specified liter amount of
          RSV plasma is supplied to the Company in any 12-month period during the term of the KEDPlasma Agreement. &lt;/p&gt;
&lt;div&gt;&lt;br/&gt;&lt;/div&gt;
&lt;p style="margin: 0px; font-family: 'Times New Roman'; font-size: 10pt; text-align: left; text-indent: 36pt; background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;"&gt;On June 6, 2017, the Company entered into a Plasma Supply Agreement with its former contract manufacturer, pursuant to which the counterparty supplies, on an exclusive basis subject to certain exceptions, to ADMA BioManufacturing an annual
          minimum volume of hyperimmune plasma that contain antibodies to the Hepatitis B virus for the manufacture of Nabi-HB. The Plasma Supply Agreement has a 10-year
          term. On July 19, 2018, &lt;span style="font-variant-ligatures: normal; font-variant-caps: normal; letter-spacing: normal; text-align: left; text-indent: 48px; word-spacing: 0px; white-space: normal; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;the Plasma Supply Agreement was amended to provide, among other things, that in the event the counterparty elects not to supply in excess of ADMA BioManufacturing&#x2019;s
            specified amount of Hepatitis B plasma and ADMA BioManufacturing is unable to secure Hepatitis B plasma from a third party at a price that is within a low double- digit percentage of the price that ADMA BioManufacturing pays to the
            counterparty, then the counterparty shall reimburse ADMA BioManufacturing for the difference in price ADMA BioManufacturing incurs. On December 10, 2018, the Company&#x2019;s former contract manufacturer assigned its rights and obligations under the
            Plasma Supply Agreement to Grifols, effective January 1, 201&lt;/span&gt;9.&lt;/p&gt;
&lt;div&gt;&lt;br/&gt;&lt;/div&gt;
&lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left; font-style: normal;"&gt;&lt;span style="text-decoration:underline"&gt;Post-Marketing Commitments&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;"&gt;&#160;&lt;/p&gt;&lt;p style="margin: 0px; font-family: 'Times New Roman'; font-size: 10pt; text-align: left; text-indent: 36pt;"&gt; In connection with the FDA approval of ASCENIV on April 1, 2019, the Company is required to perform a pediatric study to evaluate the
          safety and efficacy of ASCENIV in children and adolescents, for which patient enrollment has been successfully completed. For the years ended December 31, 2024, 2023 and 2022, the Company incurred expenses related to this study in the amount of $1.2 million, $1.0 million and $0.5 million, respectively. The Company expects to incur expenses of approximately $1.0 million to complete this study, which is required to be completed by June of 2026.&lt;/p&gt;&lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;"&gt; &lt;br/&gt;
        &lt;/p&gt;&lt;p style="margin: 0px; font-family: 'Times New Roman'; font-size: 10pt; text-align: left; text-indent: 36pt;"&gt; In connection with the FDA approval of the BLA for BIVIGAM on December 19, 2012, Biotest committed to perform two additional
          post-marketing studies, a pediatric study to evaluate the efficacy and safety of BIVIGAM in children and adolescents, and a post-authorization safety study to further assess the potential risk of hypotension and hepatic and renal impairment in
          BIVIGAM-treated patients with primary humoral immunodeficiency. These studies were required to be completed by June 30, 2023. Both studies have been completed and the study reports have been submitted to the FDA. ADMA had assumed the remaining
          obligations, and the costs of the studies were expensed as incurred as research and development expenses. The Company did not incur
          any expenses related to this commitment for the year ended December 31, 2024. For the years ended December 31, 2023 and 2022, the Company incurred expenses related to these studies of $1.7 million and $2.2 million, respectively.&lt;/p&gt;
&lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;br/&gt;
            &lt;/span&gt; &lt;/div&gt;

&lt;div style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;span style="text-decoration:underline"&gt;Other Commitments&lt;/span&gt;&lt;/div&gt;

&lt;div&gt;&lt;span style="font-size: 10pt;"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; text-indent: 36pt;"&gt; &lt;br/&gt;
          &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; text-indent: 36pt;"&gt;In the normal course of business, the Company enters into contracts that contain a variety of indemnifications with its employees, licensors, suppliers and service
            providers. Further, the Company indemnifies its directors and officers who are, or were, serving at the Company&#x2019;s request in such capacities. The Company&#x2019;s maximum exposure under these arrangements is unknown as of December 31, 2024. The
            Company does not anticipate recognizing any significant losses relating to these arrangements.&lt;/div&gt;
</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <adma:NumberOfBatchesInProductionAtTheTimeOfDisruption
      contextRef="c20230619to20230619"
      decimals="INF"
      id="Fact_34fa1d4cc4494acd8e3e801bea3409bf"
      unitRef="U010">2</adma:NumberOfBatchesInProductionAtTheTimeOfDisruption>
    <adma:NumberOfBatchesInProductionAtTheTimeOfDisruption
      contextRef="c20230619to20230619"
      decimals="INF"
      id="Fact_bb82d26ddc944240a0480d393b8390fb"
      unitRef="U010">2</adma:NumberOfBatchesInProductionAtTheTimeOfDisruption>
    <us-gaap:InventoryWriteDown
      contextRef="c20230401to20230630"
      decimals="-5"
      id="Fact_9a38b7f121254b83b7c6661f8a9442e1"
      unitRef="U001">2100000</us-gaap:InventoryWriteDown>
    <us-gaap:OtherCostAndExpenseOperating
      contextRef="c20230401to20230630"
      decimals="-5"
      id="Fact_ab59fb8b1a494363bc1953dfc4ac4a62"
      unitRef="U001">700000</us-gaap:OtherCostAndExpenseOperating>
    <adma:RestorationCostsReceived
      contextRef="c20230101to20231231"
      decimals="-5"
      id="Fact_251584b58f804f2493bf01047265d992"
      unitRef="U001">200000</adma:RestorationCostsReceived>
    <adma:RestorationCostsReceived
      contextRef="c20240101to20241231"
      decimals="-5"
      id="Fact_12ff9470323c47de98fd7cd55e674388"
      unitRef="U001">200000</adma:RestorationCostsReceived>
    <us-gaap:ProceedsFromInsuranceSettlementOperatingActivities
      contextRef="c20250101to20250318_SubsequentEventTypeAxis_SubsequentEventMember"
      decimals="-5"
      id="Fact_e8a4b46ab388413ab82c33c22d032ac5"
      unitRef="U001">400000</us-gaap:ProceedsFromInsuranceSettlementOperatingActivities>
    <adma:NumberOfPlasmaCollectionFacilities
      contextRef="c20240101to20241231_RangeAxis_MaximumMember_TypeOfArrangementAxis_PlasmaPurchaseAgreementOneMember"
      decimals="INF"
      id="Fact_b99e96ac92f34dd9b64dfcc8cc4d8aed"
      unitRef="U004">5</adma:NumberOfPlasmaCollectionFacilities>
    <adma:NumberOfRenewalTerms
      contextRef="c20241001to20241001_TypeOfArrangementAxis_ARGrifolsAgreementMember"
      decimals="INF"
      id="Fact_718fb7633ede4a02be83f48f3b0fda6a"
      unitRef="U011">2</adma:NumberOfRenewalTerms>
    <adma:QuantityOfRespiratorySyncytialVirusPlasmaUsed
      contextRef="c20241001to20241001_RangeAxis_MinimumMember_TypeOfArrangementAxis_ARGrifolsAgreementMember"
      decimals="0"
      id="Fact_442ef8ce2d5042579eb510f53c250d0a"
      unitRef="U012">35000</adma:QuantityOfRespiratorySyncytialVirusPlasmaUsed>
    <adma:RespiratorySyncytialVirusPlasmaVolumeSuppliedPeriod
      contextRef="c20240101to20241231_TypeOfArrangementAxis_ARGrifolsAgreementMember"
      id="Fact_8c0d6d6afb4c4b44889c290b95a36a1a">P12M</adma:RespiratorySyncytialVirusPlasmaVolumeSuppliedPeriod>
    <adma:IncreaseInMinimumAnnualPriceTerm
      contextRef="c20240101to20241231_TypeOfArrangementAxis_ARGrifolsAgreementMember"
      id="Fact_71326e76750749089b06bd3784ce77e9">P12M</adma:IncreaseInMinimumAnnualPriceTerm>
    <adma:RespiratorySyncytialVirusPlasmaVolumeSuppliedPeriod
      contextRef="c20240101to20241231_TypeOfArrangementAxis_ARGrifolsAgreementMember"
      id="Fact_4817b31887004ebb9152e60edb77d432">P12M</adma:RespiratorySyncytialVirusPlasmaVolumeSuppliedPeriod>
    <adma:PlasmaPurchaseAgreementRenewalPeriod
      contextRef="c20240101to20241231_TypeOfArrangementAxis_KEDPlasmaAgreementMember"
      id="Fact_d78ce8d2f8144bf5acdf5021981f2378">P5Y</adma:PlasmaPurchaseAgreementRenewalPeriod>
    <adma:QuantityOfRespiratorySyncytialVirusPlasmaUsed
      contextRef="c20240806to20240806_RangeAxis_MinimumMember_TypeOfArrangementAxis_KEDPlasmaAgreementMember"
      decimals="0"
      id="Fact_42ccf61e34c2403a8778ac785ef88e5e"
      unitRef="U012">35000</adma:QuantityOfRespiratorySyncytialVirusPlasmaUsed>
    <adma:RespiratorySyncytialVirusPlasmaVolumeSuppliedPeriod
      contextRef="c20240101to20241231_TypeOfArrangementAxis_KEDPlasmaAgreementMember"
      id="Fact_92daecc2b4b740a5b7a52a826f4a052c">P12M</adma:RespiratorySyncytialVirusPlasmaVolumeSuppliedPeriod>
    <adma:RespiratorySyncytialVirusPlasmaVolumeSuppliedPeriod
      contextRef="c20240101to20241231_TypeOfArrangementAxis_KEDPlasmaAgreementMember"
      id="Fact_84ec38ceca094e1bac9049a9cdb12350">P12M</adma:RespiratorySyncytialVirusPlasmaVolumeSuppliedPeriod>
    <adma:RespiratorySyncytialVirusPlasmaVolumeSuppliedPeriod
      contextRef="c20240101to20241231_TypeOfArrangementAxis_KEDPlasmaAgreementMember"
      id="Fact_4e45db2701b4442fafbe40dc1219b7a8">P12M</adma:RespiratorySyncytialVirusPlasmaVolumeSuppliedPeriod>
    <adma:PlasmaSupplyAgreementTerm
      contextRef="c20240101to20241231"
      id="Fact_566e61ac8bae440e8eb3546ca1cf2796">P10Y</adma:PlasmaSupplyAgreementTerm>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="c20240101to20241231_ProductOrServiceAxis_ASCENIVMember"
      decimals="-5"
      id="Fact_7f8c4dfa57a740cd8d3baf1e2d7623ed"
      unitRef="U001">1200000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="c20230101to20231231_ProductOrServiceAxis_ASCENIVMember"
      decimals="-5"
      id="Fact_334f15802b3f420e941d3e5127f05b17"
      unitRef="U001">1000000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="c20220101to20221231_ProductOrServiceAxis_ASCENIVMember"
      decimals="-5"
      id="Fact_e2915302d1ec485baf32dbbc3e82a5fd"
      unitRef="U001">500000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="c20190401to20190401"
      decimals="-5"
      id="Fact_294ac1199fe84e5491e99603b6bab1c4"
      unitRef="U001">1000000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="c20240101to20241231_ProductOrServiceAxis_BIVIGAMMember"
      decimals="-6"
      id="Fact_61cb6030c7dd4741b4432499b4e0bb4a"
      unitRef="U001">0</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="c20230101to20231231_ProductOrServiceAxis_BIVIGAMMember"
      decimals="-5"
      id="Fact_98e893f87fc9410c8d2d78b02d6b4955"
      unitRef="U001">1700000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="c20220101to20221231_ProductOrServiceAxis_BIVIGAMMember"
      decimals="-5"
      id="Fact_626a03f4e9d641d388821e912a0c20b2"
      unitRef="U001">2200000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="c20240101to20241231"
      id="Text_858651dccc404c6b92b7cdef5e17400e">
&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt; border-spacing: 0;"&gt;


  &lt;tr style="vertical-align: top;"&gt;

    &lt;td style="vertical-align: top; width: 27pt;"&gt;
                  &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;"&gt;&lt;strong&gt;11.&lt;/strong&gt;&lt;/p&gt;
                &lt;/td&gt;

    &lt;td style="vertical-align: top; width: auto;"&gt;
                  &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;"&gt;&lt;span style="text-decoration: underline;"&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;strong&gt;INCOME TAXES&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;strong&gt;&lt;span style="text-decoration: underline;"&gt;&lt;br/&gt;
                      &lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;
                &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
&lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;"&gt;&#160;&lt;/p&gt;&lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-bottom: 0px; text-align: left;"&gt; &lt;/p&gt;&lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 36pt; text-align: left;"&gt;The components of the Company&#x2019;s income tax expense (benefit) are as follows:&lt;br/&gt;
        &lt;/p&gt;&lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 36pt; text-align: left;"&gt; &lt;br/&gt;
        &lt;/p&gt;&lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-bottom: 0px; text-align: left;"&gt; &lt;/p&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="text-align: left; font: 10pt 'Times New Roman'; width: 100%; border-spacing: 0;"&gt;


  &lt;tr style="height: 15px;"&gt;

    &lt;td style="padding-bottom: 2px;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="10" rowspan="1" style="vertical-align: bottom; text-align: center; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: center;"&gt;&lt;strong&gt;Year Ended December 31,&lt;/strong&gt;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td rowspan="1" style="padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="10" rowspan="1" style="vertical-align: bottom; text-align: center; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;span style="font-style: italic;"&gt;(In thousands) &lt;/span&gt; &lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td style="vertical-align: bottom; padding: 0px 0px 2px; padding-bottom: 2px;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"&gt;&lt;span style="font-weight: bold;"&gt;2024&lt;/span&gt;&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"&gt;&lt;span style="font-weight: bold;"&gt;2023&lt;/span&gt;&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" rowspan="1" style="vertical-align: bottom; text-align: center; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"&gt;&lt;span style="font-weight: bold;"&gt;2022&lt;/span&gt;&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td style="vertical-align: top;" valign="bottom"&gt;Current:&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; text-align: right;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; text-align: right;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; text-align: right;" valign="bottom"&gt;&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td style="vertical-align: top; text-indent: 9pt; width: 64%; background-color: #CCEEFF;" valign="bottom"&gt;Federal&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;10,434&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;-&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;-&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td style="vertical-align: top; text-indent: 9pt; width: 64%; padding-bottom: 2px;" valign="bottom"&gt;State&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"&gt;1,887&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"&gt;-&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;-&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td style="vertical-align: top; text-indent: 18pt; width: 64%; background-color: #CCEEFF;" valign="bottom"&gt;Total current&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;12,321&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;-&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;-&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td rowspan="1" style="vertical-align: top; width: 64%;" valign="bottom"&gt;Deferred:&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td rowspan="1" style="vertical-align: top; text-indent: 9pt; width: 64%; background-color: #CCEEFF;" valign="bottom"&gt;Federal&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;(72,858&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;)&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;-&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;-&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td style="vertical-align: top; text-indent: 9pt; width: 64%; padding-bottom: 2px;" valign="bottom"&gt;State&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"&gt;(11,422&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;)&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"&gt;-&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;-&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td rowspan="1" style="vertical-align: top; text-indent: 18pt; width: 64%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;Total deferred&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;(84,280&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;)&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;-&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;-&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td style="vertical-align: top; width: 64%; padding-bottom: 4px;" valign="bottom"&gt;Total benefit from income taxes&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" valign="bottom"&gt;(71,959&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;)&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" valign="bottom"&gt;-&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"&gt;-&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
&lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;"&gt; &lt;br/&gt;
        &lt;/p&gt;&lt;p style="margin: 0px; font-family: 'Times New Roman'; font-size: 10pt; text-align: left; text-indent: 36pt;"&gt;A reconciliation of income taxes at the U.S. federal statutory rate to the benefit for income taxes is as follows:&lt;/p&gt;&lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;"&gt;&#160;&lt;/p&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="text-align: left; font: 10pt 'Times New Roman'; width: 100%; border-spacing: 0;"&gt;


  &lt;tr style="height: 15px;"&gt;

    &lt;td style="padding-bottom: 2px;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="10" rowspan="1" style="vertical-align: bottom; text-align: center; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: center;"&gt;&lt;strong&gt;Year Ended December 31,&lt;/strong&gt;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td rowspan="1" style="padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="10" rowspan="1" style="vertical-align: bottom; text-align: center; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;span style="font-style: italic;"&gt;(In thousands) &lt;/span&gt; &lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td style="padding-bottom: 2px;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;span style="font-weight: bold;"&gt;2024&lt;/span&gt;&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;span style="font-weight: bold;"&gt;2023&lt;/span&gt;&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" rowspan="1" style="text-align: center; vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;span style="font-weight: bold;"&gt;2022&lt;/span&gt;&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td style="vertical-align: top; width: 64%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-bottom: 0px; text-indent: -9pt; margin-left: 9pt;"&gt;Tax provision (benefit) at U.S. federal statutory rate&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;26,400&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;(5,930&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;)&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;(13,840&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;)&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td style="vertical-align: top; width: 64%;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-bottom: 0px; text-indent: -9pt; margin-left: 9pt;"&gt;State taxes&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;,&lt;/span&gt; net of federal benefit&lt;br/&gt;
                &lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;(9,931&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;)&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;(763&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;)&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;(1,773&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;)&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td rowspan="1" style="vertical-align: top; width: 64%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                &lt;div style="text-indent: -9pt; margin-left: 9pt;"&gt;Non-deductible executive compensation&lt;br/&gt;
                &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div&gt;4,340&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;983&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;862&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td rowspan="1" style="vertical-align: top; width: 64%;" valign="bottom"&gt;
                &lt;div style="text-indent: -9pt; margin-left: 9pt;"&gt;Excess tax benefits related to stock-based compensation&lt;br/&gt;
                &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;(5,661&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;)&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;-&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;-&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td style="vertical-align: top; width: 64%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-bottom: 0px; text-indent: -9pt; margin-left: 9pt;"&gt;Change in valuation allowance&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;(87,969&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;)&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;4,696&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;15,117&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td style="vertical-align: top; width: 64%; padding-bottom: 2px;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-bottom: 0px; text-indent: -9pt; margin-left: 9pt;"&gt;Other&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"&gt;862&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"&gt;1,014&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;(366&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;)&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td style="vertical-align: top; width: 64%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-bottom: 0px; text-indent: -9pt; margin-left: 9pt;"&gt;Benefit for income taxes&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;(71,959&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;)&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;-&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;-&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
&lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;"&gt;&#160; &#160;&lt;/p&gt;&lt;p style="margin: 0px; font-family: 'Times New Roman'; font-size: 10pt; text-align: left; text-indent: 36pt;"&gt;The significant components of the Company&#x2019;s deferred tax assets are as follows:&lt;/p&gt;&lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;"&gt;&#160;&lt;/p&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="text-align: left; font: 10pt 'Times New Roman'; width: 100%; border-spacing: 0;"&gt;


  &lt;tr style="height: 15px;"&gt;

    &lt;td style="padding-bottom: 2px;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="6" style="vertical-align: bottom; text-align: center; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: center;"&gt;&lt;strong&gt;Year Ended December 31,&lt;/strong&gt;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td style="padding-bottom: 2px;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: center;"&gt;&lt;strong&gt; 2024&lt;br/&gt;
                  &lt;/strong&gt;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: center;"&gt;&lt;strong&gt;2023&lt;br/&gt;
                  &lt;/strong&gt;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td rowspan="1" valign="bottom"&gt;Deferred tax assets: &lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: center; vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="6" rowspan="1" style="vertical-align: bottom; text-align: center;" valign="bottom"&gt;&lt;span style="font-style: italic;"&gt;(in thousands)&lt;/span&gt; &lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td style="vertical-align: top; width: 76%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-indent: 9pt;"&gt;Federal and state net operating loss carryforwards&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;65,615&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;76,645&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td style="vertical-align: top; width: 76%;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-indent: 9pt;"&gt;Interest expense limitation carryforwards&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;13,604&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;21,165&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td style="vertical-align: top; width: 76%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-indent: 9pt;"&gt;Inventory&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;3,911&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;2,937&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td style="vertical-align: top; width: 76%;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-indent: 9pt;"&gt;Stock-based compensation&lt;br/&gt;
                &lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;2,523&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;1,795&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td rowspan="1" style="vertical-align: top; text-indent: 9pt; width: 76%; background-color: #CCEEFF;" valign="bottom"&gt;Lease obligations &lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;2,549&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;2,330&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td style="vertical-align: top; width: 76%; padding-bottom: 2px;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-indent: 9pt;"&gt;Accrued expenses and other&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"&gt;5,779&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"&gt;5,831&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td style="vertical-align: top; width: 76%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-bottom: 0px; text-indent: 9pt;"&gt;Total gross deferred tax assets&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;93,981&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;110,703&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td style="vertical-align: top; width: 76%; padding-bottom: 2px;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in;"&gt;Less: valuation allowance for deferred tax assets&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"&gt;-&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"&gt;(101,422&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;)&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td rowspan="1" style="vertical-align: top; text-indent: 18pt; width: 76%; background-color: #CCEEFF;" valign="bottom"&gt;Total deferred tax assets, net of valuation allowance&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;93,981&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;9,281&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td rowspan="1" style="vertical-align: top; width: 76%;" valign="bottom"&gt;Deferred tax liabilities:&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td rowspan="1" style="vertical-align: top; text-indent: 9pt; width: 76%; background-color: #CCEEFF;" valign="bottom"&gt;Depreciation of property and equipment &lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;(6,166&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;)&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;(6,837&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;)&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td rowspan="1" style="vertical-align: top; text-indent: 9pt; width: 76%;" valign="bottom"&gt;Right-of-use assets&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;(2,247&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;)&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;(2,077&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;)&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td rowspan="1" style="vertical-align: top; text-indent: 9pt; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;Other deferred tax liabilities &lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;(1,288&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;)&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;(367&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;)&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td rowspan="1" style="vertical-align: top; text-indent: 18pt; width: 76%; padding-bottom: 2px;" valign="bottom"&gt;Total deferred tax liabilities &lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"&gt;(9,701&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;)&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"&gt;(9,281&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;)&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td style="vertical-align: top; width: 76%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in;"&gt;Net deferred tax assets&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;84,280&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;-&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
&lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;"&gt;&#160;&lt;/p&gt;&lt;p style="margin: 0px; font-family: 'Times New Roman'; font-size: 10pt; text-indent: 36pt;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;As of December 31, 2024, the Company has federal and state (post-apportioned basis) net operating losses (&#x201c;NOLs&#x201d;) of $265.6 million and $204.0 million, respectively. Approximately
            $33.4 million and $62.0
            million of the foregoing Federal and state NOLs, respectively, will expire at various dates from &lt;span style="-sec-ix-hidden:Fact_3caad71a9a1b440ba964fc32940d472a"&gt;2029&lt;/span&gt; through &lt;span style="-sec-ix-hidden:Fact_8b85b23ae8fb4a49b2e8cb82e0d4603d"&gt;2043&lt;/span&gt;, if not limited by triggering events prior to such time. &lt;/span&gt;Under the provisions of the Internal Revenue Code, changes in ownership of the
          Company, in certain circumstances, would limit the amount of federal NOLs that can be utilized annually in the future to offset taxable income. In particular, Section 382 of the Internal Revenue Code (&#x201c;Section 382&#x201d;) imposes limitations on an
          entity&#x2019;s ability to use NOLs upon certain changes in ownership. If the Company is limited in its ability to use its NOLs in future years in which it has taxable income, then the Company will pay more taxes than if it were otherwise able to fully
          utilize its NOLs. The Company may experience ownership changes in the future as a result of subsequent shifts in ownership of the Company&#x2019;s capital stock that the Company cannot predict or control that could result in further limitations being
          placed on the Company&#x2019;s ability to utilize its Federal NOLs. &lt;span style="font-family: 'Times New Roman'; font-size: 10pt; color: rgb(0, 0, 0);"&gt;The annual amount of Federal NOLs that expire each year is as follows (in thousands):&lt;br/&gt;
        &lt;/span&gt;&lt;/p&gt;&lt;p style="margin: 0px; font-family: 'Times New Roman'; font-size: 10pt; text-indent: 36pt;"&gt; &lt;br/&gt;
        &lt;/p&gt;&lt;p style="margin: 0px; font-family: 'Times New Roman'; font-size: 10pt; text-indent: 36pt;"&gt; &lt;/p&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="text-align: left; font: 10pt 'Times New Roman'; width: 100%; border-spacing: 0;"&gt;


  &lt;tr style="height: 15px;"&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: top; width: 12%; padding-top: 0px; padding-right: 0px; padding-left: 0px; text-align: center; border-bottom: 2px solid rgb(0, 0, 0);"&gt;Expiration Date&lt;/td&gt;

    &lt;td rowspan="1" style="vertical-align: top; width: 74%; padding: 0px 0px 2px;"&gt;&#160;&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; white-space: nowrap; width: 1.18%; padding: 0px 0px 2px; text-align: right;"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" rowspan="1" style="border-bottom: 2px solid; vertical-align: bottom; white-space: nowrap; text-align: center;"&gt;Remaining Available&#160; &lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; white-space: nowrap; width: 1.18%; padding: 0px 0px 2px; text-align: left;"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: top; width: 12%; text-align: center; background-color: rgb(204, 238, 255);" valign="bottom"&gt;2031&lt;/td&gt;

    &lt;td rowspan="1" style="vertical-align: top; width: 74%; text-align: center; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1.18%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;$ &lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 11%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;2,409&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1.18%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td colspan="1" style="vertical-align: top; width: 12%; text-align: center;" valign="bottom"&gt;2032 &lt;br/&gt;
              &lt;/td&gt;

    &lt;td style="vertical-align: top; width: 74%; text-align: center;" valign="bottom"&gt;&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1.18%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 11%; white-space: nowrap;" valign="bottom"&gt;7,430&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1.18%; white-space: nowrap;" valign="bottom"&gt;&lt;br/&gt;
              &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: top; width: 12%; text-align: center; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;2033&lt;/td&gt;

    &lt;td rowspan="1" style="vertical-align: top; width: 74%; text-align: center; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1.18%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 11%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;11,295&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1.18%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: top; width: 12%; text-align: center;" valign="bottom"&gt;&#160;2034&lt;/td&gt;

    &lt;td rowspan="1" style="vertical-align: top; width: 74%; text-align: center;" valign="bottom"&gt;&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1.18%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 11%; white-space: nowrap;" valign="bottom"&gt;1,025&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1.18%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td colspan="1" style="vertical-align: top; width: 12%; text-align: center; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;2035&lt;/td&gt;

    &lt;td style="vertical-align: top; width: 74%; text-align: center; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1.18%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 11%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;1,025&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1.18%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: top; width: 12%; text-align: center;" valign="bottom"&gt;&#160;2036&lt;/td&gt;

    &lt;td rowspan="1" style="vertical-align: top; width: 74%; text-align: center;" valign="bottom"&gt;&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1.18%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 11%; white-space: nowrap;" valign="bottom"&gt;1,025&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1.18%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: top; width: 12%; text-align: center; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;2037&lt;/td&gt;

    &lt;td rowspan="1" style="vertical-align: top; width: 74%; text-align: center; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1.18%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 11%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;9,157&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1.18%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td colspan="1" style="vertical-align: top; width: 12%; padding-bottom: 2px; text-align: center;" valign="bottom"&gt;&#160;Indefinite&lt;/td&gt;

    &lt;td style="vertical-align: top; width: 74%; padding-bottom: 2px; text-align: center;" valign="bottom"&gt;&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1.18%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 11%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;232,240&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1.18%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&lt;br/&gt;
              &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td colspan="1" style="vertical-align: top; width: 12%; text-align: center; padding-bottom: 4px; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;Total&lt;/td&gt;

    &lt;td style="vertical-align: top; width: 74%; text-align: center; padding-bottom: 4px; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1.18%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 11%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;265,606&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1.18%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
&lt;p style="margin: 0px; font-family: 'Times New Roman'; font-size: 10pt; text-indent: 36pt;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt; &lt;br/&gt;
          &lt;/span&gt;&lt;/p&gt;&lt;p style="margin: 0px; font-family: 'Times New Roman'; font-size: 10pt; text-align: left; text-indent: 36pt;"&gt;A valuation allowance, if needed, reduces deferred tax assets to the amount expected to be realized. When determining the amount of net
          deferred tax assets that are more likely than not to be realized, the Company assesses all available positive and negative evidence. This evidence includes, but is not limited to, prior earnings history, expected future earnings, carry-back and
          carry-forward periods and the feasibility of ongoing tax strategies that could potentially enhance the likelihood of the realization of a deferred tax asset. The weight given to the positive and negative evidence is commensurate with the extent
          the evidence may be objectively verified.&lt;br/&gt;
        &lt;/p&gt;
&lt;div&gt;&lt;br/&gt;&lt;/div&gt;
&lt;p style="margin: 0px; font-family: 'Times New Roman'; font-size: 10pt; text-align: left; text-indent: 36pt;"&gt; As of December 31, 2024, the Company believes it is more-likely-than-not that the Company&#x2019;s federal and state deferred tax assets will be
          realized. The Company recorded a release of its valuation allowance associated with federal and state deferred tax assets which was due in part to achieving three years of cumulative taxable income and projected taxable income that is more than
          adequate to realize the Company&#x2019;s federal and state deferred tax assets. As a result, the Company reversed the federal and state valuation allowance recorded as of December 31, 2023 of $88.0 million and $13.4 million, respectively, resulting in a
          tax benefit to the income tax provision for the year ended December 31, 2024.&lt;br/&gt;
        &lt;/p&gt;&lt;p style="margin: 0px; font-family: 'Times New Roman'; font-size: 10pt; text-align: left; text-indent: 36pt;"&gt; &lt;br/&gt;
        &lt;/p&gt;&lt;p style="margin: 0px; font-family: 'Times New Roman'; font-size: 10pt; text-align: left; text-indent: 36pt;"&gt;In accordance with U.S. GAAP, the Company is required to determine whether a tax position of the Company is more likely than not to be
          sustained upon examination by the applicable taxing authority, including resolution of any related appeals or litigation processes, based on the technical merits of the position. The tax benefit to be recognized is measured as the largest amount
          of benefit that is greater than 50% likely of being realized upon ultimate settlement. Derecognition of a tax benefit previously recognized could result in the Company recording a tax liability that would reduce net assets. The amount of the
          liability for which an exposure exists is measured as the largest amount of benefit determined on a cumulative probability basis that the Company believes is more likely than not to be realized upon ultimate settlement of the position. Components
          of the liability are classified as either a current or a long-term liability in the accompanying consolidated balance sheets based on when the Company expects each of the items to be settled. The Company does not have any unrecognized tax benefits as of December 31, 2024 and 2023 and does not anticipate a significant change in unrecognized tax benefits
          during the next 12 months. &lt;/p&gt;&lt;p style="margin: 0px; font-family: 'Times New Roman'; font-size: 10pt; text-align: left; text-indent: 36pt;"&gt;&lt;br/&gt;
        &lt;/p&gt;&lt;p style="margin: 0px; font-family: 'Times New Roman'; font-size: 10pt; text-align: left; text-indent: 36pt;"&gt;The Company files income tax returns in the U.S. federal and various state jurisdictions. All net operating losses and tax credits
          generated to date are subject to adjustment for U.S. federal and state income tax purposes. The Company&#x2019;s income tax returns are open to examination for tax years 2007 through 2023.&lt;/p&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock
      contextRef="c20240101to20241231"
      id="Text_53c101e371fa4c5f81f2da5a8248b8fc">&lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-bottom: 0px; text-align: left;"&gt; &lt;/p&gt;&lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 36pt; text-align: left;"&gt;The components of the Company&#x2019;s income tax expense (benefit) are as follows:&lt;br/&gt;
        &lt;/p&gt;&lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 36pt; text-align: left;"&gt; &lt;br/&gt;
        &lt;/p&gt;&lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-bottom: 0px; text-align: left;"&gt; &lt;/p&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="text-align: left; font: 10pt 'Times New Roman'; width: 100%; border-spacing: 0;"&gt;


  &lt;tr style="height: 15px;"&gt;

    &lt;td style="padding-bottom: 2px;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="10" rowspan="1" style="vertical-align: bottom; text-align: center; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: center;"&gt;&lt;strong&gt;Year Ended December 31,&lt;/strong&gt;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td rowspan="1" style="padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="10" rowspan="1" style="vertical-align: bottom; text-align: center; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;span style="font-style: italic;"&gt;(In thousands) &lt;/span&gt; &lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td style="vertical-align: bottom; padding: 0px 0px 2px; padding-bottom: 2px;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"&gt;&lt;span style="font-weight: bold;"&gt;2024&lt;/span&gt;&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"&gt;&lt;span style="font-weight: bold;"&gt;2023&lt;/span&gt;&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" rowspan="1" style="vertical-align: bottom; text-align: center; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"&gt;&lt;span style="font-weight: bold;"&gt;2022&lt;/span&gt;&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td style="vertical-align: top;" valign="bottom"&gt;Current:&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; text-align: right;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; text-align: right;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; text-align: right;" valign="bottom"&gt;&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td style="vertical-align: top; text-indent: 9pt; width: 64%; background-color: #CCEEFF;" valign="bottom"&gt;Federal&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;10,434&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;-&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;-&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td style="vertical-align: top; text-indent: 9pt; width: 64%; padding-bottom: 2px;" valign="bottom"&gt;State&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"&gt;1,887&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"&gt;-&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;-&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td style="vertical-align: top; text-indent: 18pt; width: 64%; background-color: #CCEEFF;" valign="bottom"&gt;Total current&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;12,321&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;-&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;-&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td rowspan="1" style="vertical-align: top; width: 64%;" valign="bottom"&gt;Deferred:&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td rowspan="1" style="vertical-align: top; text-indent: 9pt; width: 64%; background-color: #CCEEFF;" valign="bottom"&gt;Federal&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;(72,858&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;)&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;-&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;-&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td style="vertical-align: top; text-indent: 9pt; width: 64%; padding-bottom: 2px;" valign="bottom"&gt;State&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"&gt;(11,422&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;)&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"&gt;-&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;-&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td rowspan="1" style="vertical-align: top; text-indent: 18pt; width: 64%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;Total deferred&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;(84,280&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;)&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;-&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;-&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td style="vertical-align: top; width: 64%; padding-bottom: 4px;" valign="bottom"&gt;Total benefit from income taxes&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" valign="bottom"&gt;(71,959&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;)&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px;" valign="bottom"&gt;-&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; white-space: nowrap;" valign="bottom"&gt;-&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="c20240101to20241231"
      decimals="-3"
      id="Fact_29d1c2aa57594c62b5dd51d05cc6d897"
      unitRef="U001">10434000</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="c20230101to20231231"
      decimals="-3"
      id="Fact_5928d131ec5241afa45cfaa56db7e2e5"
      unitRef="U001">0</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="c20220101to20221231"
      decimals="-3"
      id="Fact_68bc306153ca42c4a76ec5d529fcb1c9"
      unitRef="U001">0</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="c20240101to20241231"
      decimals="-3"
      id="Fact_b51edb75ea114ee0a12da235a3ce6879"
      unitRef="U001">1887000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="c20230101to20231231"
      decimals="-3"
      id="Fact_8bf36c661081486f9a1499a74931edc3"
      unitRef="U001">0</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="c20220101to20221231"
      decimals="-3"
      id="Fact_59aa6d78cd22479abbec4b784177dff3"
      unitRef="U001">0</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="c20240101to20241231"
      decimals="-3"
      id="Fact_ea8e69ac73c4476298bff92c3cb4c8c8"
      unitRef="U001">12321000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="c20230101to20231231"
      decimals="-3"
      id="Fact_3b91ae13223c4982b5663c8dbc5c0cb1"
      unitRef="U001">0</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="c20220101to20221231"
      decimals="-3"
      id="Fact_3828fe73efbb43d88a66873ae08beefb"
      unitRef="U001">0</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="c20240101to20241231"
      decimals="-3"
      id="Fact_3434b7f5b7c64bc8a11ec4ef29fce9df"
      unitRef="U001">-72858000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="c20230101to20231231"
      decimals="-3"
      id="Fact_53a1fe926f974a30b74f493cc7d93095"
      unitRef="U001">0</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="c20220101to20221231"
      decimals="-3"
      id="Fact_dd19071a896e4d8e92f1435b43aa89b7"
      unitRef="U001">0</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="c20240101to20241231"
      decimals="-3"
      id="Fact_46d76394f880404dae9ef0e7e2bde0e8"
      unitRef="U001">-11422000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="c20230101to20231231"
      decimals="-3"
      id="Fact_da3e343c8cc94a7c9667a6359185f676"
      unitRef="U001">0</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="c20220101to20221231"
      decimals="-3"
      id="Fact_b757f0a08e8944d79dbd55784dc178e7"
      unitRef="U001">0</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="c20240101to20241231"
      decimals="-3"
      id="Fact_19364bf7dd4d4790b6560a1bf9d0359b"
      unitRef="U001">-84280000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="c20230101to20231231"
      decimals="-3"
      id="Fact_ea0bf190102e419a8ec4f7daa9a7ef1d"
      unitRef="U001">0</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="c20220101to20221231"
      decimals="-3"
      id="Fact_bde1a1c8ffe044548f5b60d7118b900f"
      unitRef="U001">0</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="c20240101to20241231"
      decimals="-3"
      id="Fact_35b7a3e2569b4875b2267896557edfdd"
      unitRef="U001">-71959000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="c20230101to20231231"
      decimals="-3"
      id="Fact_89cb54cf420d47e08e3e27a48300b387"
      unitRef="U001">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="c20220101to20221231"
      decimals="-3"
      id="Fact_22dd55e791484be2a4425e264a6f028f"
      unitRef="U001">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="c20240101to20241231"
      id="Text_f0d42a4f475c4fc68acb5e7fba470fa9">&lt;p style="margin: 0px; font-family: 'Times New Roman'; font-size: 10pt; text-align: left; text-indent: 36pt;"&gt;A reconciliation of income taxes at the U.S. federal statutory rate to the benefit for income taxes is as follows:&lt;/p&gt;&lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;"&gt;&#160;&lt;/p&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="text-align: left; font: 10pt 'Times New Roman'; width: 100%; border-spacing: 0;"&gt;


  &lt;tr style="height: 15px;"&gt;

    &lt;td style="padding-bottom: 2px;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="10" rowspan="1" style="vertical-align: bottom; text-align: center; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: center;"&gt;&lt;strong&gt;Year Ended December 31,&lt;/strong&gt;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td rowspan="1" style="padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="10" rowspan="1" style="vertical-align: bottom; text-align: center; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;span style="font-style: italic;"&gt;(In thousands) &lt;/span&gt; &lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td style="padding-bottom: 2px;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;span style="font-weight: bold;"&gt;2024&lt;/span&gt;&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;span style="font-weight: bold;"&gt;2023&lt;/span&gt;&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" rowspan="1" style="text-align: center; vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&lt;span style="font-weight: bold;"&gt;2022&lt;/span&gt;&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td style="vertical-align: top; width: 64%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-bottom: 0px; text-indent: -9pt; margin-left: 9pt;"&gt;Tax provision (benefit) at U.S. federal statutory rate&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;26,400&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;(5,930&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;)&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;(13,840&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;)&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td style="vertical-align: top; width: 64%;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-bottom: 0px; text-indent: -9pt; margin-left: 9pt;"&gt;State taxes&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-transform: none; white-space: normal; word-spacing: 0px; text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;,&lt;/span&gt; net of federal benefit&lt;br/&gt;
                &lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;(9,931&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;)&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;(763&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;)&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;(1,773&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;)&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td rowspan="1" style="vertical-align: top; width: 64%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                &lt;div style="text-indent: -9pt; margin-left: 9pt;"&gt;Non-deductible executive compensation&lt;br/&gt;
                &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;div&gt;4,340&lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;983&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;862&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td rowspan="1" style="vertical-align: top; width: 64%;" valign="bottom"&gt;
                &lt;div style="text-indent: -9pt; margin-left: 9pt;"&gt;Excess tax benefits related to stock-based compensation&lt;br/&gt;
                &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;(5,661&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;)&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;-&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; white-space: nowrap;" valign="bottom"&gt;-&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td style="vertical-align: top; width: 64%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-bottom: 0px; text-indent: -9pt; margin-left: 9pt;"&gt;Change in valuation allowance&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;(87,969&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;)&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;4,696&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;15,117&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td style="vertical-align: top; width: 64%; padding-bottom: 2px;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-bottom: 0px; text-indent: -9pt; margin-left: 9pt;"&gt;Other&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"&gt;862&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"&gt;1,014&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;(366&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;)&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td style="vertical-align: top; width: 64%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-bottom: 0px; text-indent: -9pt; margin-left: 9pt;"&gt;Benefit for income taxes&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;(71,959&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;)&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;-&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;-&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="c20240101to20241231"
      decimals="-3"
      id="Fact_e8916b8fa9624552a7d60c2c9d39ac77"
      unitRef="U001">26400000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="c20230101to20231231"
      decimals="-3"
      id="Fact_ee69eadd0f52485d9dfc2ab6e9b87ded"
      unitRef="U001">-5930000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="c20220101to20221231"
      decimals="-3"
      id="Fact_bd98861f7d754d6b9e52748e63924fab"
      unitRef="U001">-13840000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="c20240101to20241231"
      decimals="-3"
      id="Fact_e28e7806781f488ebab0219b57716114"
      unitRef="U001">-9931000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="c20230101to20231231"
      decimals="-3"
      id="Fact_5988ddd8d6374bbdab8b5ffb199d27e7"
      unitRef="U001">-763000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="c20220101to20221231"
      decimals="-3"
      id="Fact_fc79db6ada3444fabfc8b6926eb1a829"
      unitRef="U001">-1773000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpense
      contextRef="c20240101to20241231"
      decimals="-3"
      id="Fact_6d317bd7bceb41bbbabdc31766e2d733"
      unitRef="U001">4340000</us-gaap:IncomeTaxReconciliationNondeductibleExpense>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpense
      contextRef="c20230101to20231231"
      decimals="-3"
      id="Fact_04cd55ab1a1640038827dbe4598526f7"
      unitRef="U001">983000</us-gaap:IncomeTaxReconciliationNondeductibleExpense>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpense
      contextRef="c20220101to20221231"
      decimals="-3"
      id="Fact_e1858b2cc8df461b874af9acc2c5fcd9"
      unitRef="U001">862000</us-gaap:IncomeTaxReconciliationNondeductibleExpense>
    <us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount
      contextRef="c20240101to20241231"
      decimals="-3"
      id="Fact_d9983c0f86464eb5b77e83f33771ab05"
      unitRef="U001">-5661000</us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount>
    <us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount
      contextRef="c20230101to20231231"
      decimals="-3"
      id="Fact_c9c647cd48f84c9d9957d9ac82c16ffb"
      unitRef="U001">0</us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount>
    <us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount
      contextRef="c20220101to20221231"
      decimals="-3"
      id="Fact_bc76d864174144a8b7016255d3616b19"
      unitRef="U001">0</us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="c20240101to20241231"
      decimals="-3"
      id="Fact_e4292c6ddf8b42778a10e034d775e9f6"
      unitRef="U001">-87969000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="c20230101to20231231"
      decimals="-3"
      id="Fact_c46a0edea8484877a285da448a6f5759"
      unitRef="U001">4696000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="c20220101to20221231"
      decimals="-3"
      id="Fact_75182d53d6e64aed8c660677877ce2e9"
      unitRef="U001">15117000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments
      contextRef="c20240101to20241231"
      decimals="-3"
      id="Fact_1d47aa877046431d83042c1fafa7aad4"
      unitRef="U001">862000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments
      contextRef="c20230101to20231231"
      decimals="-3"
      id="Fact_782d6daec74e43d1ad5834862de65851"
      unitRef="U001">1014000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments
      contextRef="c20220101to20221231"
      decimals="-3"
      id="Fact_59969f468ca540f1b516cfcffa1f1ca7"
      unitRef="U001">-366000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="c20240101to20241231"
      decimals="-3"
      id="Fact_8e5e9ce76c684212b6c6b96face230bd"
      unitRef="U001">-71959000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="c20230101to20231231"
      decimals="-3"
      id="Fact_1afe101a8bd548d4975837d5ca60f7c0"
      unitRef="U001">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="c20220101to20221231"
      decimals="-3"
      id="Fact_cbf50e56dc814195981d4fb89f097889"
      unitRef="U001">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="c20240101to20241231"
      id="Text_86e07ad8ed5344718e0d6fda9bf0c818">&lt;p style="margin: 0px; font-family: 'Times New Roman'; font-size: 10pt; text-align: left; text-indent: 36pt;"&gt;The significant components of the Company&#x2019;s deferred tax assets are as follows:&lt;/p&gt;&lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;"&gt;&#160;&lt;/p&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="text-align: left; font: 10pt 'Times New Roman'; width: 100%; border-spacing: 0;"&gt;


  &lt;tr style="height: 15px;"&gt;

    &lt;td style="padding-bottom: 2px;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="6" style="vertical-align: bottom; text-align: center; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: center;"&gt;&lt;strong&gt;Year Ended December 31,&lt;/strong&gt;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td style="padding-bottom: 2px;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: center;"&gt;&lt;strong&gt; 2024&lt;br/&gt;
                  &lt;/strong&gt;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: center;"&gt;&lt;strong&gt;2023&lt;br/&gt;
                  &lt;/strong&gt;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td rowspan="1" valign="bottom"&gt;Deferred tax assets: &lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: center; vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="6" rowspan="1" style="vertical-align: bottom; text-align: center;" valign="bottom"&gt;&lt;span style="font-style: italic;"&gt;(in thousands)&lt;/span&gt; &lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td style="vertical-align: top; width: 76%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-indent: 9pt;"&gt;Federal and state net operating loss carryforwards&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;65,615&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;76,645&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td style="vertical-align: top; width: 76%;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-indent: 9pt;"&gt;Interest expense limitation carryforwards&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;13,604&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;21,165&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td style="vertical-align: top; width: 76%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-indent: 9pt;"&gt;Inventory&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;3,911&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;2,937&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td style="vertical-align: top; width: 76%;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-indent: 9pt;"&gt;Stock-based compensation&lt;br/&gt;
                &lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;2,523&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;1,795&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td rowspan="1" style="vertical-align: top; text-indent: 9pt; width: 76%; background-color: #CCEEFF;" valign="bottom"&gt;Lease obligations &lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;2,549&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;2,330&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td style="vertical-align: top; width: 76%; padding-bottom: 2px;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-indent: 9pt;"&gt;Accrued expenses and other&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"&gt;5,779&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"&gt;5,831&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td style="vertical-align: top; width: 76%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin-top: 0px; margin-bottom: 0px; text-indent: 9pt;"&gt;Total gross deferred tax assets&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;93,981&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;110,703&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td style="vertical-align: top; width: 76%; padding-bottom: 2px;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in;"&gt;Less: valuation allowance for deferred tax assets&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"&gt;-&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"&gt;(101,422&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;)&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td rowspan="1" style="vertical-align: top; text-indent: 18pt; width: 76%; background-color: #CCEEFF;" valign="bottom"&gt;Total deferred tax assets, net of valuation allowance&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;93,981&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;9,281&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td rowspan="1" style="vertical-align: top; width: 76%;" valign="bottom"&gt;Deferred tax liabilities:&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td rowspan="1" style="vertical-align: top; text-indent: 9pt; width: 76%; background-color: #CCEEFF;" valign="bottom"&gt;Depreciation of property and equipment &lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;(6,166&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;)&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;(6,837&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;)&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td rowspan="1" style="vertical-align: top; text-indent: 9pt; width: 76%;" valign="bottom"&gt;Right-of-use assets&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;(2,247&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;)&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;(2,077&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;)&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td rowspan="1" style="vertical-align: top; text-indent: 9pt; width: 76%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;Other deferred tax liabilities &lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;(1,288&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;)&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;(367&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;)&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td rowspan="1" style="vertical-align: top; text-indent: 18pt; width: 76%; padding-bottom: 2px;" valign="bottom"&gt;Total deferred tax liabilities &lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"&gt;(9,701&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;)&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"&gt;(9,281&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;)&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td style="vertical-align: top; width: 76%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in;"&gt;Net deferred tax assets&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;84,280&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF;" valign="bottom"&gt;-&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic
      contextRef="c20241231"
      decimals="-3"
      id="Fact_d1b7e8b1dfa447db896d923996adb1c3"
      unitRef="U001">65615000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic
      contextRef="c20231231"
      decimals="-3"
      id="Fact_d5fdb4d673a04bb1bcc4ffe88b344ab2"
      unitRef="U001">76645000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic>
    <us-gaap:DeferredTaxAssetInterestCarryforward
      contextRef="c20241231"
      decimals="-3"
      id="Fact_d3dcb1b0dc264f6c8e47cb70cf5ccf93"
      unitRef="U001">13604000</us-gaap:DeferredTaxAssetInterestCarryforward>
    <us-gaap:DeferredTaxAssetInterestCarryforward
      contextRef="c20231231"
      decimals="-3"
      id="Fact_bb76cf7b993140cebd7977fffb6e6f6b"
      unitRef="U001">21165000</us-gaap:DeferredTaxAssetInterestCarryforward>
    <us-gaap:DeferredTaxAssetsInventory
      contextRef="c20241231"
      decimals="-3"
      id="Fact_610645c789094f8f8e3aad671e0b2334"
      unitRef="U001">3911000</us-gaap:DeferredTaxAssetsInventory>
    <us-gaap:DeferredTaxAssetsInventory
      contextRef="c20231231"
      decimals="-3"
      id="Fact_3ec53b78284b449b94877a3e26bba4b3"
      unitRef="U001">2937000</us-gaap:DeferredTaxAssetsInventory>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="c20241231"
      decimals="-3"
      id="Fact_32fa22ff77794a9ab004753a38403e7a"
      unitRef="U001">2523000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="c20231231"
      decimals="-3"
      id="Fact_bb6e624e729346c8a3a24349230cd169"
      unitRef="U001">1795000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <adma:DeferredTaxAssetsLeaseObligations
      contextRef="c20241231"
      decimals="-3"
      id="Fact_a66784a84be54e07b004ea2d0d93ebe5"
      unitRef="U001">2549000</adma:DeferredTaxAssetsLeaseObligations>
    <adma:DeferredTaxAssetsLeaseObligations
      contextRef="c20231231"
      decimals="-3"
      id="Fact_b16ad11b2dd94728ad03585587b7b9c2"
      unitRef="U001">2330000</adma:DeferredTaxAssetsLeaseObligations>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
      contextRef="c20241231"
      decimals="-3"
      id="Fact_81f63bec5df94bc0a9e2cb15499959a5"
      unitRef="U001">5779000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
      contextRef="c20231231"
      decimals="-3"
      id="Fact_3d58947e399d464aa71cfa2348eaddd7"
      unitRef="U001">5831000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="c20241231"
      decimals="-3"
      id="Fact_9f80c16d582847deb77c37861c121edd"
      unitRef="U001">93981000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="c20231231"
      decimals="-3"
      id="Fact_d1f578a118a34ec0a4182eaa34b11947"
      unitRef="U001">110703000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="c20241231"
      decimals="-3"
      id="Fact_2682a714114d43179cbc8722291e2fc3"
      unitRef="U001">0</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="c20231231"
      decimals="-3"
      id="Fact_b67341e0bba8494dba75a59bf586dff4"
      unitRef="U001">101422000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="c20241231"
      decimals="-3"
      id="Fact_65deac69914f4bf6a7b445d7fd7afd2b"
      unitRef="U001">93981000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="c20231231"
      decimals="-3"
      id="Fact_77f9d4218a9c4c0cba82bc1208ade8bc"
      unitRef="U001">9281000</us-gaap:DeferredTaxAssetsNet>
    <adma:DeferredTaxLiabilitiesDepreciationOfPropertyAndEquipment
      contextRef="c20241231"
      decimals="-3"
      id="Fact_39cd3cfe97114b75846066bab11db026"
      unitRef="U001">6166000</adma:DeferredTaxLiabilitiesDepreciationOfPropertyAndEquipment>
    <adma:DeferredTaxLiabilitiesDepreciationOfPropertyAndEquipment
      contextRef="c20231231"
      decimals="-3"
      id="Fact_22580152a9344e52a504cdae64755bd3"
      unitRef="U001">6837000</adma:DeferredTaxLiabilitiesDepreciationOfPropertyAndEquipment>
    <adma:DeferredTaxLiabilitiesRightOfUseAsset
      contextRef="c20241231"
      decimals="-3"
      id="Fact_080cb502bc1b4209bfe4075864f5bb02"
      unitRef="U001">2247000</adma:DeferredTaxLiabilitiesRightOfUseAsset>
    <adma:DeferredTaxLiabilitiesRightOfUseAsset
      contextRef="c20231231"
      decimals="-3"
      id="Fact_dda8a4e0bcee43ffabbff198f2153868"
      unitRef="U001">2077000</adma:DeferredTaxLiabilitiesRightOfUseAsset>
    <us-gaap:DeferredTaxLiabilitiesOther
      contextRef="c20241231"
      decimals="-3"
      id="Fact_59394c2c73ea4a1da02a0f331bfedd35"
      unitRef="U001">1288000</us-gaap:DeferredTaxLiabilitiesOther>
    <us-gaap:DeferredTaxLiabilitiesOther
      contextRef="c20231231"
      decimals="-3"
      id="Fact_4ad1622566f047a78f3b3bf9a41132f4"
      unitRef="U001">367000</us-gaap:DeferredTaxLiabilitiesOther>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="c20241231"
      decimals="-3"
      id="Fact_c95031c4e99c4e4d933d005ecf5cee0d"
      unitRef="U001">9701000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="c20231231"
      decimals="-3"
      id="Fact_fb256aa0b9e340cda3c41403b57d9841"
      unitRef="U001">9281000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="c20241231"
      decimals="-3"
      id="Fact_be5b561db918419fa8920c1c9f97c7af"
      unitRef="U001">84280000</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="c20231231"
      decimals="-3"
      id="Fact_bc34f141a3d94ae8a0001323fbbdb592"
      unitRef="U001">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:OperatingLossCarryforwards
      contextRef="c20241231_IncomeTaxAuthorityAxis_InternalRevenueServiceIRSMember"
      decimals="-5"
      id="Fact_1b0cfd37782f4f28b9cdad0b14f6a48e"
      unitRef="U001">265600000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="c20241231_IncomeTaxAuthorityAxis_StateAndLocalJurisdictionMember"
      decimals="-5"
      id="Fact_5d177eb51b784a40b17cb28a3c9c7dfa"
      unitRef="U001">204000000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="c20241231_IncomeTaxAuthorityAxis_InternalRevenueServiceIRSMember_TaxPeriodAxis_TaxYear2028Through2043Member"
      decimals="-5"
      id="Fact_5202c6981fcb4cf89134d7f9d7e57ff2"
      unitRef="U001">33400000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="c20241231_IncomeTaxAuthorityAxis_StateAndLocalJurisdictionMember_TaxPeriodAxis_TaxYear2028Through2043Member"
      decimals="-5"
      id="Fact_e70aaf9620ce420d95676de6f2640595"
      unitRef="U001">62000000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:SummaryOfOperatingLossCarryforwardsTextBlock
      contextRef="c20240101to20241231"
      id="Text_3fc9760ca72b430d9a98caf5f67b16bb">&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; color: rgb(0, 0, 0);"&gt;The annual amount of Federal NOLs that expire each year is as follows (in thousands):&lt;br/&gt;
        &lt;/span&gt;&lt;p style="margin: 0px; font-family: 'Times New Roman'; font-size: 10pt; text-indent: 36pt;"&gt; &lt;br/&gt;
        &lt;/p&gt;&lt;p style="margin: 0px; font-family: 'Times New Roman'; font-size: 10pt; text-indent: 36pt;"&gt; &lt;/p&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="text-align: left; font: 10pt 'Times New Roman'; width: 100%; border-spacing: 0;"&gt;


  &lt;tr style="height: 15px;"&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: top; width: 12%; padding-top: 0px; padding-right: 0px; padding-left: 0px; text-align: center; border-bottom: 2px solid rgb(0, 0, 0);"&gt;Expiration Date&lt;/td&gt;

    &lt;td rowspan="1" style="vertical-align: top; width: 74%; padding: 0px 0px 2px;"&gt;&#160;&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; white-space: nowrap; width: 1.18%; padding: 0px 0px 2px; text-align: right;"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" rowspan="1" style="border-bottom: 2px solid; vertical-align: bottom; white-space: nowrap; text-align: center;"&gt;Remaining Available&#160; &lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; white-space: nowrap; width: 1.18%; padding: 0px 0px 2px; text-align: left;"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: top; width: 12%; text-align: center; background-color: rgb(204, 238, 255);" valign="bottom"&gt;2031&lt;/td&gt;

    &lt;td rowspan="1" style="vertical-align: top; width: 74%; text-align: center; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1.18%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;$ &lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 11%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;2,409&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1.18%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td colspan="1" style="vertical-align: top; width: 12%; text-align: center;" valign="bottom"&gt;2032 &lt;br/&gt;
              &lt;/td&gt;

    &lt;td style="vertical-align: top; width: 74%; text-align: center;" valign="bottom"&gt;&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1.18%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 11%; white-space: nowrap;" valign="bottom"&gt;7,430&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1.18%; white-space: nowrap;" valign="bottom"&gt;&lt;br/&gt;
              &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: top; width: 12%; text-align: center; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;2033&lt;/td&gt;

    &lt;td rowspan="1" style="vertical-align: top; width: 74%; text-align: center; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1.18%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 11%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;11,295&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1.18%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: top; width: 12%; text-align: center;" valign="bottom"&gt;&#160;2034&lt;/td&gt;

    &lt;td rowspan="1" style="vertical-align: top; width: 74%; text-align: center;" valign="bottom"&gt;&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1.18%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 11%; white-space: nowrap;" valign="bottom"&gt;1,025&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1.18%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td colspan="1" style="vertical-align: top; width: 12%; text-align: center; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;2035&lt;/td&gt;

    &lt;td style="vertical-align: top; width: 74%; text-align: center; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1.18%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 11%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;1,025&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1.18%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: top; width: 12%; text-align: center;" valign="bottom"&gt;&#160;2036&lt;/td&gt;

    &lt;td rowspan="1" style="vertical-align: top; width: 74%; text-align: center;" valign="bottom"&gt;&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1.18%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 11%; white-space: nowrap;" valign="bottom"&gt;1,025&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1.18%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: top; width: 12%; text-align: center; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;2037&lt;/td&gt;

    &lt;td rowspan="1" style="vertical-align: top; width: 74%; text-align: center; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1.18%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 11%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;9,157&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1.18%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td colspan="1" style="vertical-align: top; width: 12%; padding-bottom: 2px; text-align: center;" valign="bottom"&gt;&#160;Indefinite&lt;/td&gt;

    &lt;td style="vertical-align: top; width: 74%; padding-bottom: 2px; text-align: center;" valign="bottom"&gt;&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1.18%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 11%; border-bottom: 2px solid rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;232,240&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1.18%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&lt;br/&gt;
              &lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td colspan="1" style="vertical-align: top; width: 12%; text-align: center; padding-bottom: 4px; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;Total&lt;/td&gt;

    &lt;td style="vertical-align: top; width: 74%; text-align: center; padding-bottom: 4px; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1.18%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 11%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;265,606&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1.18%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
</us-gaap:SummaryOfOperatingLossCarryforwardsTextBlock>
    <us-gaap:OperatingLossCarryforwards
      contextRef="c20241231_IncomeTaxAuthorityAxis_InternalRevenueServiceIRSMember_TaxPeriodAxis_TaxYear2031Member"
      decimals="-3"
      id="Fact_d4cbc36017504bcdaaf06fe72669073b"
      unitRef="U001">2409000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="c20241231_IncomeTaxAuthorityAxis_InternalRevenueServiceIRSMember_TaxPeriodAxis_TaxYear2032Member"
      decimals="-3"
      id="Fact_e4f06bf32b004e3f878fd2a0d85a35ea"
      unitRef="U001">7430000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="c20241231_IncomeTaxAuthorityAxis_InternalRevenueServiceIRSMember_TaxPeriodAxis_TaxYear2033Member"
      decimals="-3"
      id="Fact_4fd1f29e0b6248b6859b256c7997e224"
      unitRef="U001">11295000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="c20241231_IncomeTaxAuthorityAxis_InternalRevenueServiceIRSMember_TaxPeriodAxis_TaxYear2034Member"
      decimals="-3"
      id="Fact_6d90c8df873d4acf95cade614cf1c29f"
      unitRef="U001">1025000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="c20241231_IncomeTaxAuthorityAxis_InternalRevenueServiceIRSMember_TaxPeriodAxis_TaxYear2035Member"
      decimals="-3"
      id="Fact_d5c9c0a238584e679b97e290e472dc15"
      unitRef="U001">1025000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="c20241231_IncomeTaxAuthorityAxis_InternalRevenueServiceIRSMember_TaxPeriodAxis_TaxYear2036Member"
      decimals="-3"
      id="Fact_066a189d525a4b74bb1e541da704c342"
      unitRef="U001">1025000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="c20241231_IncomeTaxAuthorityAxis_InternalRevenueServiceIRSMember_TaxPeriodAxis_TaxYear2037Member"
      decimals="-3"
      id="Fact_9a8dbb2ea67c456fbac805cbb8e9529e"
      unitRef="U001">9157000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="c20241231_IncomeTaxAuthorityAxis_InternalRevenueServiceIRSMember_TaxPeriodAxis_TaxYearAfter2037Member"
      decimals="-3"
      id="Fact_4ec67351c26b4f4893655146eb2e38da"
      unitRef="U001">232240000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="c20241231_IncomeTaxAuthorityAxis_InternalRevenueServiceIRSMember"
      decimals="-3"
      id="Fact_6b6ce1f608824faf99ba605a9424b9fa"
      unitRef="U001">265606000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:TaxCreditCarryforwardValuationAllowance
      contextRef="c20231231_IncomeTaxAuthorityAxis_InternalRevenueServiceIRSMember"
      decimals="-5"
      id="Fact_1fb63bc58cd54ef58e7b66ec459bd9a7"
      unitRef="U001">88000000</us-gaap:TaxCreditCarryforwardValuationAllowance>
    <us-gaap:TaxCreditCarryforwardValuationAllowance
      contextRef="c20231231_IncomeTaxAuthorityAxis_StateAndLocalJurisdictionMember"
      decimals="-5"
      id="Fact_961e4ef145474248a631cd304f21b905"
      unitRef="U001">13400000</us-gaap:TaxCreditCarryforwardValuationAllowance>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="c20241231"
      decimals="0"
      id="Fact_896cc76177d248b887669a96bb040b25"
      unitRef="U001">0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="c20231231"
      decimals="0"
      id="Fact_60d89ff97b004428854735d821b6641f"
      unitRef="U001">0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="c20240101to20241231"
      id="Text_a5ffab10c60b4ce997716f9eb2c61ef8">
&lt;div&gt;
          &lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt; border-spacing: 0;"&gt;


  &lt;tr style="vertical-align: top;"&gt;

    &lt;td style="vertical-align: top; width: 27pt;"&gt;
                  &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;"&gt;&lt;strong&gt;12.&lt;/strong&gt;&lt;/p&gt;
                &lt;/td&gt;

    &lt;td style="align: left; vertical-align: top; width: auto;"&gt;
                  &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;"&gt;&lt;span style="text-decoration: underline;"&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;strong&gt;LEASE OBLIGATIONS&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;strong&gt;&lt;span style="text-decoration: underline;"&gt;&lt;br/&gt;
                      &lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;
                &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
        &lt;/div&gt;
&lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;"&gt;&#160;&lt;/p&gt;&lt;p style="margin: 0px; font-family: 'Times New Roman'; font-size: 10pt; text-align: left; text-indent: 36pt;"&gt;The Company leases certain properties and equipment for its ADMA BioCenters and ADMA BioManufacturing subsidiaries, which leases provide
          the right to use the underlying assets and require lease payments through the respective lease terms which expire at various dates through 2033. The Company&#x2019;s lease agreements do not contain any material residual value guarantees or material
          restrictive covenants. Upon adoption of ASU No. 2016-02, &lt;span style="font-style: italic;"&gt;Leases (Topic 842)&lt;/span&gt; effective January 1, 2019, the Company elected the package of practical expedients, which permits the Company to not reassess
          under the new standard its prior conclusions about lease identification, lease classification and initial direct costs. In addition, the Company elected the short-term lease recognition exemption for all leases that qualify, &lt;/p&gt;
&lt;div&gt;&lt;span style="font-size: 10pt;"&gt; &lt;/span&gt;&lt;/div&gt;
&lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-indent: 45px; text-align: left;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;&lt;span style="font-size: 10pt;"&gt; &lt;/span&gt;&lt;/div&gt;
&lt;p style="margin: 0px; font-family: 'Times New Roman'; font-size: 10pt; text-align: left; text-indent: 36pt;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;The Company determines if an arrangement is an operating lease or a financing lease at inception. Leases with an initial term of 12 months or less are not recorded on
            the balance sheet and lease expense for such leases are recognized on a straight-line basis over the lease term. All other leases are recorded on the balance sheet with assets representing the right to use the underlying asset for the lease
            term and lease liabilities representing the obligation to make lease payments arising from the lease. Right-of-use assets and lease liabilities are recognized at the lease commencement date based on the present value of lease payments over the
            lease term and include options to extend or terminate the lease when they are reasonably certain to be exercised. The present value of the lease payments is determined using the Company&#x2019;s estimated incremental borrowing rate as of the lease
            commencement date. There were no new material leases entered into during the year ended December 31, 2024. For the lease liabilities recognized during the years ended December 31, 2023 and 2022, the Company used discount rates of 13% to 16%, representing a weighted
            average discount rate of 13.02%, to determine the present value of its lease obligations. The Company&#x2019;s operating lease expense is
            recognized on a straight-line basis over the lease term and is reflected in Plasma center operating expenses and Selling, general and administrative expenses in the accompanying consolidated statements of operations. Aggregate lease expense for
            the Company&#x2019;s operating leases for the years ended December 31, 2024, 2023 and 2022 was $2.4 million, $2.4 million and &lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; text-align: left; text-indent: 48px; text-transform: none; white-space: normal; word-spacing: 0px; background-color: rgb(255, 255, 255); text-decoration-style: initial; text-decoration-color: initial; display: inline ! important; float: none;"&gt;$2.1 million&lt;/span&gt;, respectively. Aggregate
            cash paid on these leases for the years ended December 31, 2024, 2023 and 2022 was $2.4 million, $2.4 million and $1.8 million,
            respectively.&lt;/span&gt; &lt;/p&gt;
&lt;div&gt;&lt;span style="font-size: 10pt;"&gt; &lt;/span&gt;&lt;/div&gt;
&lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-indent: 45px; text-align: left;"&gt;&#160;&lt;/p&gt;
&lt;div&gt;&lt;span style="font-size: 10pt;"&gt; &lt;/span&gt;&lt;/div&gt;
&lt;p style="margin: 0px; font-family: 'Times New Roman'; font-size: 10pt; text-align: left; text-indent: 36pt;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 48px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; display: inline !important; float: none;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 48px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: normal; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; display: inline !important; float: none;"&gt;During the year ended December 31, 2023, the Company recognized one additional right-of-use
                asset and corresponding lease liability in the amount of $0.1 million for office equipment leased for the Boca Facility.&lt;/span&gt;
              During the year ended December 31, 2022, the Company recognized additional right-of-use assets and corresponding lease liabilities aggregating to approximately $4.0 million in connection with two new property leases where the Company
              has opened additional plasma collection facilities, a property lease for the storage of raw materials inventory and a property lease for the building that the Company utilizes as its corporate headquarters (see Note 9). The Company has
              aggregate lease liabilities of $9.8 million and $10.8 million as of December 31, 2024 and 2023, respectively, which are comprised primarily of the leases for the Company&#x2019;s plasma collection centers.&#160; &lt;/span&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-size: 10pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-weight: 400;"&gt;The Company&#x2019;s operating leases
              have a weighted average remaining term of 6.8&lt;/span&gt;&lt;span style="font-size: 10pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-weight: 400;"&gt; years. Scheduled payments under the Company&#x2019;s lease obligations&lt;/span&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal;"&gt; are as follows&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal;"&gt; (in thousands)&lt;/span&gt;&lt;/span&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 48px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; display: inline !important; float: none;"&gt;&lt;span style="font-size: 10pt;"&gt;&lt;span style="font-size: 10pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-weight: 400;"&gt;:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-indent: 45px; text-align: left;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 48px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; display: inline !important; float: none;"&gt;&lt;br/&gt;
          &lt;/span&gt; &lt;/p&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="text-align: left; font: 10pt 'Times New Roman'; width: 100%; border-spacing: 0;"&gt;


  &lt;tr style="height: 15px;"&gt;

    &lt;td style="vertical-align: top; width: 88%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: left;"&gt;Year ended December 31, 2025&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;2,421&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td style="vertical-align: top; width: 88%;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: left;"&gt;2026&lt;br/&gt;
                &lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;2,157&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td style="vertical-align: top; width: 88%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: left;"&gt;2027&lt;br/&gt;
                &lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;2,041&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td style="vertical-align: top; width: 88%;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: left;"&gt;2028&lt;br/&gt;
                &lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;2,088&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td style="vertical-align: top; width: 88%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: left;"&gt;2029&lt;br/&gt;
                &lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;2,109&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td style="vertical-align: top; width: 88%; padding-bottom: 2px;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: left;"&gt;Thereafter&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"&gt;4,041&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td style="vertical-align: top; width: 88%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: left;"&gt;Total payments&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;14,857&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td style="vertical-align: top; width: 88%;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: left;"&gt;Less: imputed interest&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;(5,078&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;)&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td style="vertical-align: top; width: 88%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: left;"&gt;Current portion&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;(1,218&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;)&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td style="vertical-align: top; width: 88%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: left;"&gt;Balance at December 31, 2024&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom"&gt;8,561&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
</us-gaap:LesseeOperatingLeasesTextBlock>
    <adma:OperatingLeaseIncrementalBorrowingRatePercent
      contextRef="c20230101to20231231"
      decimals="2"
      id="Fact_171f99876b59493c97140ceb8bd9a164"
      unitRef="U007">0.13</adma:OperatingLeaseIncrementalBorrowingRatePercent>
    <adma:OperatingLeaseIncrementalBorrowingRatePercent
      contextRef="c20220101to20221231"
      decimals="2"
      id="Fact_5ae9c45c1e1f47cfab457cd89286fb84"
      unitRef="U007">0.16</adma:OperatingLeaseIncrementalBorrowingRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="c20241231"
      decimals="4"
      id="Fact_803e0c0e5feb4196abcbdc62c7f4a3c2"
      unitRef="U007">0.1302</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseExpense
      contextRef="c20240101to20241231"
      decimals="-5"
      id="Fact_01a1b5dbff9d4b29b204f75f8ab251ff"
      unitRef="U001">2400000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="c20230101to20231231"
      decimals="-5"
      id="Fact_86e368e678be4f14ac526ba2abcfa614"
      unitRef="U001">2400000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="c20220101to20221231"
      decimals="-5"
      id="Fact_0cf8aaf972d2408893aa86d05ac199d9"
      unitRef="U001">2100000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeasePayments
      contextRef="c20240101to20241231"
      decimals="-5"
      id="Fact_0751d0bb32474ce7ba29b84ac580e782"
      unitRef="U001">2400000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="c20230101to20231231"
      decimals="-5"
      id="Fact_fbddfcdd6e4b494382b18ace317dabbc"
      unitRef="U001">2400000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="c20220101to20221231"
      decimals="-5"
      id="Fact_f79d7e152edd480eb2f28f0277d2e806"
      unitRef="U001">1800000</us-gaap:OperatingLeasePayments>
    <adma:NumberOfNewPropertyLeases
      contextRef="c20230101to20231231"
      decimals="INF"
      id="Fact_f24a0065c9044eac8e4db49d66b00442"
      unitRef="U013">1</adma:NumberOfNewPropertyLeases>
    <adma:LesseeOperatingLeaseLiabilitiesRelatedToPropertyLease
      contextRef="c20231231"
      decimals="-5"
      id="Fact_f6436e8c2c7c4bd3a5baf0e7eac523bd"
      unitRef="U001">100000</adma:LesseeOperatingLeaseLiabilitiesRelatedToPropertyLease>
    <adma:LesseeOperatingLeaseRightOfUseAssetRelatedToPropertyLease
      contextRef="c20231231"
      decimals="-5"
      id="Fact_53ea3f5f6e414201a54f34bb2d1ebe98"
      unitRef="U001">100000</adma:LesseeOperatingLeaseRightOfUseAssetRelatedToPropertyLease>
    <adma:LesseeOperatingLeaseLiabilitiesRelatedToPropertyLease
      contextRef="c20221231"
      decimals="-5"
      id="Fact_c6254518a8c046dd9a316774dc9e7d02"
      unitRef="U001">4000000</adma:LesseeOperatingLeaseLiabilitiesRelatedToPropertyLease>
    <adma:LesseeOperatingLeaseRightOfUseAssetRelatedToPropertyLease
      contextRef="c20221231"
      decimals="-5"
      id="Fact_97609a061a9c4d0498919c1ffc7ce78d"
      unitRef="U001">4000000</adma:LesseeOperatingLeaseRightOfUseAssetRelatedToPropertyLease>
    <adma:NumberOfNewPropertyLeases
      contextRef="c20220101to20221231"
      decimals="INF"
      id="Fact_8fb7d32a3f6948bda95bd7e9d34788d7"
      unitRef="U013">2</adma:NumberOfNewPropertyLeases>
    <adma:OperatingAndFinancingLeaseLiability
      contextRef="c20241231"
      decimals="-5"
      id="Fact_34f79b1d29a540f2b600ebe08cde742e"
      unitRef="U001">9800000</adma:OperatingAndFinancingLeaseLiability>
    <adma:OperatingAndFinancingLeaseLiability
      contextRef="c20231231"
      decimals="-5"
      id="Fact_989217ae9380489ca2d3e23ec03d2242"
      unitRef="U001">10800000</adma:OperatingAndFinancingLeaseLiability>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="c20240101to20241231"
      id="Text_7ae4405ee9bd4ed9bd90c116671a3584">&lt;span style="font-size: 10pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-weight: 400;"&gt;The Company&#x2019;s operating leases
              have a weighted average remaining term of 6.8&lt;/span&gt;&lt;span style="font-size: 10pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-weight: 400;"&gt; years. Scheduled payments under the Company&#x2019;s lease obligations&lt;/span&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal;"&gt; are as follows&lt;/span&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal;"&gt; (in thousands)&lt;/span&gt;&lt;span style="font-size: 10pt; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-style: normal; font-weight: 400;"&gt;:&lt;/span&gt;&lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-indent: 45px; text-align: left;"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: normal; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 48px; text-transform: none; white-space: normal; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; display: inline !important; float: none;"&gt;&lt;br/&gt;
          &lt;/span&gt; &lt;/p&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="text-align: left; font: 10pt 'Times New Roman'; width: 100%; border-spacing: 0;"&gt;


  &lt;tr style="height: 15px;"&gt;

    &lt;td style="vertical-align: top; width: 88%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: left;"&gt;Year ended December 31, 2025&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;2,421&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td style="vertical-align: top; width: 88%;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: left;"&gt;2026&lt;br/&gt;
                &lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;2,157&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td style="vertical-align: top; width: 88%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: left;"&gt;2027&lt;br/&gt;
                &lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;2,041&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td style="vertical-align: top; width: 88%;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: left;"&gt;2028&lt;br/&gt;
                &lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;2,088&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td style="vertical-align: top; width: 88%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: left;"&gt;2029&lt;br/&gt;
                &lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;2,109&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td style="vertical-align: top; width: 88%; padding-bottom: 2px;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: left;"&gt;Thereafter&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px;" valign="bottom"&gt;4,041&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td style="vertical-align: top; width: 88%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: left;"&gt;Total payments&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;14,857&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td style="vertical-align: top; width: 88%;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: left;"&gt;Less: imputed interest&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;(5,078&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;)&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td style="vertical-align: top; width: 88%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: left;"&gt;Current portion&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; background-color: #CCEEFF;" valign="bottom"&gt;(1,218&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;)&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td style="vertical-align: top; width: 88%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: left;"&gt;Balance at December 31, 2024&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom"&gt;8,561&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="c20241231"
      id="Fact_092530dd0e5e4a8c9b34d21061c88fc4">P6Y9M18D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="c20241231"
      decimals="-3"
      id="Fact_d35fa105db0d4bd7860c9f15c9f68b56"
      unitRef="U001">2421000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="c20241231"
      decimals="-3"
      id="Fact_5aff44c50f3b41f68cbbed5cd9628d03"
      unitRef="U001">2157000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="c20241231"
      decimals="-3"
      id="Fact_f29ac4d9064742e6ad282ed46e2de203"
      unitRef="U001">2041000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="c20241231"
      decimals="-3"
      id="Fact_4be66520224d415bb0077bdfaddba8f6"
      unitRef="U001">2088000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive
      contextRef="c20241231"
      decimals="-3"
      id="Fact_90efb09170bb4a6084cccc0f1a69881d"
      unitRef="U001">2109000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
      contextRef="c20241231"
      decimals="-3"
      id="Fact_05f0e282fdaa48ce862fdd38bde3af45"
      unitRef="U001">4041000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="c20241231"
      decimals="-3"
      id="Fact_e4e35878beed4b7bb2a7aa9367262861"
      unitRef="U001">14857000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="c20241231"
      decimals="-3"
      id="Fact_dc22273d99ed452db58df6b2220f9a01"
      unitRef="U001">5078000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="c20241231"
      decimals="-3"
      id="Fact_eb519305d0174bd0a15206bd2b5445f3"
      unitRef="U001">1218000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="c20241231"
      decimals="-3"
      id="Fact_6b2a9f57bb994f7d953c6ccc4178381d"
      unitRef="U001">8561000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:SegmentReportingDisclosureTextBlock
      contextRef="c20240101to20241231"
      id="Text_97850d1a001748a1a11dbb0349e265c1">
&lt;div&gt;
          &lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt; border-spacing: 0;"&gt;


  &lt;tr style="vertical-align: top;"&gt;

    &lt;td style="vertical-align: top; width: 27pt;"&gt;
                  &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;"&gt;&lt;strong&gt;13.&lt;/strong&gt;&lt;/p&gt;
                &lt;/td&gt;

    &lt;td style="align: left; vertical-align: top; width: auto;"&gt;
                  &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;"&gt;&lt;span style="text-decoration: underline;"&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;strong&gt;SEGMENTS&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;strong&gt;&lt;span style="text-decoration: underline;"&gt;&lt;br/&gt;
                      &lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;
                &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
        &lt;/div&gt;
&lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;"&gt;&#160;&lt;/p&gt;&lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-indent: 45px; text-align: left;"&gt;The Company is engaged in the manufacture, marketing and development of specialty plasma-derived biologics.&#160; The Company&#x2019;s ADMA
          BioManufacturing operating segment reflects the Company&#x2019;s immunoglobulin manufacturing, commercial and development operations in Boca Raton, FL.&#160; The Plasma Collection Centers operating segment consists of ten plasma collection facilities located throughout the United States, all of which are operational, collecting plasma and currently holding FDA
          licenses. The Company defines its operating segments as those business units whose operating results are regularly reviewed by the chief operating decision maker (&#x201c;CODM&#x201d;) to analyze performance and allocate resources. The Corporate information
          included in the reconciliations below generally consists of certain unallocated general and administrative overhead expenses and interest expense on the Company&#x2019;s senior debt (see Note 7). The Company&#x2019;s CODM is its President and Chief Executive
          Officer. For the Company&#x2019;s two operating segments, the CODM uses income/loss before taxes as the measure of segment profit to determine the allocation of resources for each segment. Transactions between the two operating segments consist solely of the transfer of raw material plasma inventory at cost from the Plasma Collection Centers segment to the ADMA
          BioManufacturing segment with no markup or intercompany profit. Income tax benefit/expense is recorded at the Corporate entity and is not allocated to the operating segments. &lt;span style="font-family: 'Times New Roman'; font-size: 10pt; color: rgb(0, 0, 0);"&gt;Summarized financial information concerning reportable segments is
          shown in the following tables:&lt;/span&gt;&lt;/p&gt;&lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;"&gt;&#160;&#160;&#160;&lt;/p&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="text-align: left; font: 10pt 'Times New Roman'; width: 100%; border-spacing: 0;"&gt;


  &lt;tr style="height: 15px;"&gt;

    &lt;td colspan="12" style="vertical-align: top; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: center;"&gt;&lt;strong&gt;Year Ended December 31, 2024&lt;/strong&gt;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td style="padding-bottom: 2px;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: center;"&gt;&lt;span style="font-style: italic;"&gt;(in thousands)&lt;/span&gt;&lt;br/&gt;
                &lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: center;"&gt;&lt;strong&gt;ADMA&lt;/strong&gt;&lt;/p&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: center;"&gt;&lt;strong&gt; BioManufacturing&lt;/strong&gt;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: center;"&gt;&lt;strong&gt;Plasma Collection&lt;br/&gt;
                  &lt;/strong&gt;&lt;/p&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: center;"&gt;&lt;span style="font-weight: bold;"&gt;Centers&lt;/span&gt;&lt;strong&gt;&lt;br/&gt;
                  &lt;/strong&gt;&lt;/p&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: center;"&gt;&lt;strong&gt; &lt;/strong&gt;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: center;"&gt;&lt;strong&gt;Total&lt;/strong&gt;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td style="vertical-align: top; width: 64%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in;"&gt;Revenues&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;415,806&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;10,505&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;426,311&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td style="width: 64%;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td style="vertical-align: top; width: 64%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in;"&gt;Cost of product revenue&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;195,605&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;11,296&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;206,901&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td style="width: 64%;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td style="vertical-align: top; width: 64%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in;"&gt;Research and development&lt;br/&gt;
                &lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;1,813&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;-&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;1,813&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td style="width: 64%;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td style="vertical-align: top; width: 64%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in;"&gt;Plasma center operating expenses&lt;br/&gt;
                &lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;-&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;4,245&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;4,245&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td style="width: 64%;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td rowspan="1" style="vertical-align: top; width: 64%; background-color: #CCEEFF;" valign="bottom"&gt;Selling, marketing and distribution&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;18,683&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;-&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;18,683&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td rowspan="1" style="vertical-align: top; width: 64%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td style="vertical-align: top; width: 64%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in;"&gt;Depreciation and amortization expense&lt;br/&gt;
                &lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;4,827&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;3,218&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;8,045&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td style="width: 64%;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td rowspan="1" style="width: 64%; background-color: #CCEEFF;" valign="bottom"&gt;General and administrative expense&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;26,001&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;-&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;26,001&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td rowspan="1" style="width: 64%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td rowspan="1" style="width: 64%; background-color: #CCEEFF;" valign="bottom"&gt;Other expense, net&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;(178&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;)&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;(5&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;)&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;(183&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;)&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td rowspan="1" style="width: 64%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td rowspan="1" style="width: 64%; background-color: #CCEEFF;" valign="bottom"&gt;Income (loss) before taxes&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;173,138&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;(5,041&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;)&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;168,097&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td rowspan="1" style="width: 64%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td style="vertical-align: top; width: 64%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in;"&gt;Expenditures for additions to long-lived assets&lt;br/&gt;
                &lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;8,352&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;223&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;8,575&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td style="vertical-align: top; width: 64%;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in;"&gt;Total assets&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;289,297&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;30,477&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;319,774&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td rowspan="1" style="vertical-align: top; width: 64%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td rowspan="1" style="vertical-align: top; width: 64%;" valign="bottom"&gt;&lt;span style="font-style: italic;"&gt;Reconciliation of revenues:&lt;/span&gt;&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td rowspan="1" style="vertical-align: top; text-indent: 9pt; width: 64%; background-color: #CCEEFF;" valign="bottom"&gt;Segment revenue&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;426,311&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td rowspan="1" style="vertical-align: top; text-indent: 9pt; width: 64%; padding-bottom: 2px;" valign="bottom"&gt;License revenue (see Note 2 - Revenue Recognition)&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"&gt;143&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td rowspan="1" style="vertical-align: top; text-indent: 18pt; width: 64%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom"&gt;Consolidated revenues&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 4px double rgb(0, 0, 0);" valign="bottom"&gt;$&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 4px double rgb(0, 0, 0);" valign="bottom"&gt;426,454&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td rowspan="1" style="vertical-align: top; width: 64%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td rowspan="1" style="vertical-align: top; width: 64%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                &lt;div style="margin-left: 9pt; text-indent: -9pt;"&gt;&lt;span style="font-style: italic;"&gt;Reconciliation of selling, general and administrative expense:&lt;/span&gt;&lt;br/&gt;
                &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td rowspan="1" style="vertical-align: top; text-indent: 9pt; width: 64%;" valign="bottom"&gt;Segment selling, marketing and distribution expense&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;18,683&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td rowspan="1" style="vertical-align: top; text-indent: 9pt; width: 64%; background-color: #CCEEFF;" valign="bottom"&gt;Segment general and administrative expense&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;26,001&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td rowspan="1" style="vertical-align: top; text-indent: 9pt; width: 64%; padding-bottom: 2px;" valign="bottom"&gt;Corporate general and administrative expense (a)&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"&gt;29,440&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td rowspan="1" style="vertical-align: top; width: 64%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom"&gt;
                &lt;div style="margin-left: 9pt"&gt;
                  &lt;div style="margin-left: 9pt"&gt;
                    &lt;div style="margin-left: 9pt; text-indent: -9pt;"&gt;Consolidated selling, general and administrative expense&lt;br/&gt;
                    &lt;/div&gt;
                  &lt;/div&gt;
                &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 4px double rgb(0, 0, 0);" valign="bottom"&gt;$&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 4px double rgb(0, 0, 0);" valign="bottom"&gt;74,124&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td rowspan="1" style="vertical-align: top; width: 64%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td rowspan="1" style="vertical-align: top; width: 64%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: italic; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: nowrap; background-color: rgb(204, 238, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; display: inline !important; float: none;"&gt;Reconciliation of income (loss) before taxes:&lt;/span&gt; &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td rowspan="1" style="vertical-align: top; text-indent: 9pt; width: 64%;" valign="bottom"&gt;Segment income before taxes&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;168,097&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td rowspan="1" style="vertical-align: top; text-indent: 9pt; width: 64%; background-color: #CCEEFF;" valign="bottom"&gt;License revenue&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;143&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td rowspan="1" style="vertical-align: top; width: 64%;" valign="bottom"&gt;
                &lt;div style="margin-left: 9pt"&gt;
                  &lt;div style="margin-left: 9pt; text-indent: -9pt;"&gt;Unallocated interest expense, primarily related to interest on senior debt (see Note 7)&lt;br/&gt;
                  &lt;/div&gt;
                &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;(13,930&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;)&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td rowspan="1" style="vertical-align: top; text-indent: 9pt; width: 64%; background-color: #CCEEFF;" valign="bottom"&gt;Loss on extinguishment of debt (see Note 7)&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;(1,243&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;)&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td rowspan="1" style="vertical-align: top; text-indent: 9pt; width: 64%;" valign="bottom"&gt;Unallocated interest income&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;2,087&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td rowspan="1" style="vertical-align: top; text-indent: 9pt; width: 64%; background-color: rgb(204, 238, 255); padding-bottom: 2px;" valign="bottom"&gt;Corporate general and administrative expense (a)&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"&gt;(29,440&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;)&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td rowspan="1" style="vertical-align: top; text-indent: 18pt; width: 64%; padding-bottom: 4px;" valign="bottom"&gt;Consolidated income before taxes&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom"&gt;$&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom"&gt;125,714&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td rowspan="1" style="vertical-align: top; width: 64%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td rowspan="1" style="vertical-align: top; width: 64%;" valign="bottom"&gt;&lt;span style="font-style: italic;"&gt;Reconciliation of total assets:&lt;/span&gt;&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td rowspan="1" style="vertical-align: top; text-indent: 9pt; width: 64%; background-color: #CCEEFF;" valign="bottom"&gt;Total segment assets&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;319,774&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td rowspan="1" style="vertical-align: top; text-indent: 9pt; width: 64%; padding-bottom: 2px;" valign="bottom"&gt;Corporate (b)&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"&gt;168,904&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td rowspan="1" style="vertical-align: top; text-indent: 18pt; width: 64%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom"&gt;Consolidated total assets&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 4px double rgb(0, 0, 0);" valign="bottom"&gt;$&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 4px double rgb(0, 0, 0);" valign="bottom"&gt;488,678&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
&lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;"&gt;&lt;br/&gt;
        &lt;/p&gt;
&lt;div&gt;
          &lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-spacing: 0;"&gt;


  &lt;tr style="vertical-align: top;"&gt;

    &lt;td style="text-align: right; vertical-align: top; width: 27pt;"&gt;
                  &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;"&gt;(a) - &lt;br/&gt;
                  &lt;/p&gt;
                &lt;/td&gt;

    &lt;td style="text-align: left; vertical-align: top;"&gt;
                  &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: justify;"&gt;Primarily includes compensation expense,
                    including stock-based compensation expense, for certain executive officers and consultants, insurance, legal and investor relations expenses and accounting and tax fees that are not allocated to the Company&#x2019;s operating segments.&lt;/p&gt;
                &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
        &lt;/div&gt;
&lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;"&gt;&lt;br/&gt;
        &lt;/p&gt;
&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-spacing: 0;"&gt;


  &lt;tr style="vertical-align: top;"&gt;

    &lt;td style="text-align: right; vertical-align: top; width: 27pt;"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;"&gt;(b) -&lt;br/&gt;
                &lt;/p&gt;
              &lt;/td&gt;

    &lt;td style="text-align: left; vertical-align: top;"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;"&gt;Primarily consists of cash and deferred tax
                  assets.&lt;/p&gt;
              &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
&lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;"&gt;&lt;br/&gt;
        &lt;/p&gt;&lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;"&gt; &lt;/p&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="text-align: left; font: 10pt 'Times New Roman'; width: 100%; border-spacing: 0;"&gt;


  &lt;tr style="height: 15px;"&gt;

    &lt;td colspan="12" style="vertical-align: top; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: center;"&gt;&lt;strong&gt;Year Ended December 31, 2023&lt;/strong&gt;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td style="padding-bottom: 2px;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: center;"&gt;&lt;span style="font-style: italic;"&gt;(in thousands)&lt;/span&gt;&lt;br/&gt;
                &lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: center;"&gt;&lt;strong&gt;ADMA&lt;/strong&gt;&lt;/p&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: center;"&gt;&lt;strong&gt; BioManufacturing&lt;/strong&gt;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: center;"&gt;&lt;strong&gt;Plasma Collection&lt;br/&gt;
                  &lt;/strong&gt;&lt;/p&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: center;"&gt;&lt;span style="font-weight: bold;"&gt;Centers&lt;/span&gt;&lt;strong&gt;&lt;br/&gt;
                  &lt;/strong&gt;&lt;/p&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: center;"&gt;&lt;strong&gt; &lt;/strong&gt;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: center;"&gt;&lt;strong&gt;Total&lt;/strong&gt;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td style="vertical-align: top; width: 64%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in;"&gt;Revenues&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;249,738&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;8,334&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;258,072&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td style="width: 64%;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td style="vertical-align: top; width: 64%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in;"&gt;Cost of product revenue&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;161,157&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;8,116&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;169,273&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td style="width: 64%;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td style="vertical-align: top; width: 64%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in;"&gt;Research and development&lt;br/&gt;
                &lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;3,300&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;-&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;3,300&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td style="width: 64%;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td style="vertical-align: top; width: 64%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in;"&gt;Plasma center operating expenses&lt;br/&gt;
                &lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;-&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;4,266&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;4,266&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td style="width: 64%;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td rowspan="1" style="vertical-align: top; width: 64%; background-color: #CCEEFF;" valign="bottom"&gt;Selling, marketing and distribution&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;18,407&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;-&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;18,407&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td rowspan="1" style="vertical-align: top; width: 64%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td style="vertical-align: top; width: 64%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in;"&gt;Depreciation and amortization expense&lt;br/&gt;
                &lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;5,156&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;3,176&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;8,332&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td style="width: 64%;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td rowspan="1" style="width: 64%; background-color: #CCEEFF;" valign="bottom"&gt;General and administrative expense&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;18,625&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;-&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;18,625&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td rowspan="1" style="width: 64%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td rowspan="1" style="width: 64%; background-color: #CCEEFF;" valign="bottom"&gt;Income (loss) before taxes&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;47,267&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;(4,049&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;)&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;43,218&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td rowspan="1" style="width: 64%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td style="vertical-align: top; width: 64%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in;"&gt;Expenditures for additions to long-lived assets&lt;br/&gt;
                &lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;2,952&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;1,819&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;4,771&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td style="vertical-align: top; width: 64%;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in;"&gt;Total assets&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;246,719&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;34,733&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;281,452&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td rowspan="1" style="vertical-align: top; width: 64%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td rowspan="1" style="vertical-align: top; width: 64%;" valign="bottom"&gt;&lt;span style="font-style: italic;"&gt;Reconciliation of revenues:&lt;/span&gt;&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td rowspan="1" style="vertical-align: top; text-indent: 9pt; width: 64%; background-color: #CCEEFF;" valign="bottom"&gt;Segment revenue&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;$ &lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;258,072&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td rowspan="1" style="vertical-align: top; text-indent: 9pt; width: 64%; padding-bottom: 2px;" valign="bottom"&gt;License revenue (see Note 2 - Revenue Recognition)&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"&gt;143&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td rowspan="1" style="vertical-align: top; text-indent: 18pt; width: 64%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom"&gt;Consolidated revenues&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 4px double rgb(0, 0, 0);" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 4px double rgb(0, 0, 0);" valign="bottom"&gt;258,215&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td rowspan="1" style="vertical-align: top; width: 64%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td rowspan="1" style="vertical-align: top; width: 64%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                &lt;div style="margin-left: 9pt; text-indent: -9pt;"&gt;&lt;span style="font-style: italic;"&gt;Reconciliation of selling, general and administrative expense:&lt;/span&gt;&lt;br/&gt;
                &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td rowspan="1" style="vertical-align: top; text-indent: 9pt; width: 64%;" valign="bottom"&gt;Segment selling, marketing and distribution expense&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;18,407&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td rowspan="1" style="vertical-align: top; text-indent: 9pt; width: 64%; background-color: #CCEEFF;" valign="bottom"&gt;Segment general and administrative expense&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;18,625&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td rowspan="1" style="vertical-align: top; text-indent: 9pt; width: 64%; padding-bottom: 2px;" valign="bottom"&gt;Corporate general and administrative expense (a)&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"&gt;21,988&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td rowspan="1" style="vertical-align: top; width: 64%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom"&gt;
                &lt;div style="margin-left: 9pt"&gt;
                  &lt;div style="margin-left: 9pt"&gt;
                    &lt;div style="margin-left: 9pt; text-indent: -9pt;"&gt;Consolidated selling, general and administrative expense&lt;br/&gt;
                    &lt;/div&gt;
                  &lt;/div&gt;
                &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 4px double rgb(0, 0, 0);" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 4px double rgb(0, 0, 0);" valign="bottom"&gt;59,020&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td rowspan="1" style="vertical-align: top; width: 64%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td rowspan="1" style="vertical-align: top; width: 64%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: italic; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: nowrap; background-color: rgb(204, 238, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; display: inline !important; float: none;"&gt;Reconciliation of income (loss) before taxes:&lt;/span&gt;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td rowspan="1" style="vertical-align: top; text-indent: 9pt; width: 64%;" valign="bottom"&gt;Segment income before taxes&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;43,218&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td rowspan="1" style="vertical-align: top; text-indent: 9pt; width: 64%; background-color: #CCEEFF;" valign="bottom"&gt;License revenue&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;143&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td rowspan="1" style="vertical-align: top; width: 64%;" valign="bottom"&gt;
                &lt;div style="margin-left: 9pt"&gt;
                  &lt;div style="margin-left: 9pt; text-indent: -9pt;"&gt;Unallocated interest expense, primaril related to interest on senior debt (see Note 7)&lt;br/&gt;
                  &lt;/div&gt;
                &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;(25,027&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;)&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td rowspan="1" style="vertical-align: top; text-indent: 9pt; width: 64%; background-color: #CCEEFF;" valign="bottom"&gt;Loss on extinguishment of debt (see Note 7)&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;(26,174&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;)&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td rowspan="1" style="vertical-align: top; text-indent: 9pt; width: 64%;" valign="bottom"&gt;Unallocated interest income&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;1,589&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td rowspan="1" style="vertical-align: top; text-indent: 9pt; width: 64%; background-color: rgb(204, 238, 255); padding-bottom: 2px;" valign="bottom"&gt;Corporate general and administrative expense (a)&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"&gt;(21,988&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;)&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td rowspan="1" style="vertical-align: top; text-indent: 18pt; width: 64%; padding-bottom: 4px;" valign="bottom"&gt;Consolidated income before taxes&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom"&gt;(28,239&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;)&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td rowspan="1" style="vertical-align: top; width: 64%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td rowspan="1" style="vertical-align: top; width: 64%;" valign="bottom"&gt;&lt;span style="font-style: italic;"&gt;Reconciliation of total assets:&lt;/span&gt;&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td rowspan="1" style="vertical-align: top; text-indent: 9pt; width: 64%; background-color: #CCEEFF;" valign="bottom"&gt;Total segment assets&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;$ &lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;281,452&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td rowspan="1" style="vertical-align: top; text-indent: 9pt; width: 64%; padding-bottom: 2px;" valign="bottom"&gt;Corporate (b)&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"&gt;47,730&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td rowspan="1" style="vertical-align: top; text-indent: 18pt; width: 64%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom"&gt;Consolidated total assets&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 4px double rgb(0, 0, 0);" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 4px double rgb(0, 0, 0);" valign="bottom"&gt;329,182&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
&lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;"&gt; &lt;br/&gt;
        &lt;/p&gt;
&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-spacing: 0;"&gt;


  &lt;tr style="vertical-align: top;"&gt;

    &lt;td style="text-align: right; vertical-align: top; width: 27pt;"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;"&gt;(a) - &lt;br/&gt;
                &lt;/p&gt;
              &lt;/td&gt;

    &lt;td style="text-align: left; vertical-align: top;"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: justify;"&gt;Primarily includes compensation expense, including stock-based compensation expense, for certain executive officers and consultants, insurance,
                  legal and investor relations expenses and accounting and tax fees that are not allocated to the Company&#x2019;s operating segments.&lt;/p&gt;
              &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
&lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;"&gt; &lt;/p&gt;&lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;"&gt; &lt;/p&gt;&lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;"&gt; &lt;br/&gt;
        &lt;/p&gt;
&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-spacing: 0;"&gt;


  &lt;tr style="vertical-align: top;"&gt;

    &lt;td style="text-align: right; vertical-align: top; width: 27pt;"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;"&gt;(b) -&lt;br/&gt;
                &lt;/p&gt;
              &lt;/td&gt;

    &lt;td style="text-align: left; vertical-align: top;"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;"&gt;Primarily consists of cash.&lt;/p&gt;
              &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
&lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;"&gt; &lt;/p&gt;&lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;"&gt; &lt;/p&gt;&lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;"&gt; &lt;br/&gt;
        &lt;/p&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="text-align: left; font: 10pt 'Times New Roman'; width: 100%; border-spacing: 0;"&gt;


  &lt;tr style="height: 15px;"&gt;

    &lt;td colspan="12" style="vertical-align: top; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                  &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: center;"&gt;&lt;strong&gt;Year Ended December 31, 2022&lt;/strong&gt;&lt;/p&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td style="padding-bottom: 2px;" valign="bottom"&gt;
                  &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: center;"&gt;&lt;span style="font-style: italic;"&gt;(in thousands)&lt;/span&gt;&lt;br/&gt;
                  &lt;/p&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: center;"&gt;&lt;strong&gt;ADMA&lt;/strong&gt;&lt;/p&gt;
                  &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: center;"&gt;&lt;strong&gt; BioManufacturing&lt;/strong&gt;&lt;/p&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: center;"&gt;&lt;strong&gt;Plasma Collection&lt;br/&gt;
                    &lt;/strong&gt;&lt;/p&gt;
                  &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: center;"&gt;&lt;span style="font-weight: bold;"&gt;Centers&lt;/span&gt;&lt;strong&gt;&lt;br/&gt;
                    &lt;/strong&gt;&lt;/p&gt;
                  &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: center;"&gt;&lt;strong&gt; &lt;/strong&gt;&lt;/p&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: center;"&gt;&lt;strong&gt;Total&lt;/strong&gt;&lt;/p&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td style="vertical-align: top; width: 64%; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in;"&gt;Revenues&lt;/p&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;144,070&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;9,867&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;153,937&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td style="width: 64%;" valign="bottom"&gt;
                  &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px;"&gt;&#160;&lt;/p&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td style="vertical-align: top; width: 64%; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in;"&gt;Cost of product revenue&lt;/p&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;108,882&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;9,933&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;118,815&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td style="width: 64%;" valign="bottom"&gt;
                  &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px;"&gt;&#160;&lt;/p&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td style="vertical-align: top; width: 64%; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in;"&gt;Research and development&lt;br/&gt;
                  &lt;/p&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;3,614&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;-&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;3,614&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td style="width: 64%;" valign="bottom"&gt;
                  &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px;"&gt;&#160;&lt;/p&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td style="vertical-align: top; width: 64%; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in;"&gt;Plasma center operating expenses&lt;br/&gt;
                  &lt;/p&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;-&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;17,843&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;17,843&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td style="width: 64%;" valign="bottom"&gt;
                  &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px;"&gt;&#160;&lt;/p&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td rowspan="1" style="vertical-align: top; width: 64%; background-color: #CCEEFF;" valign="bottom"&gt;Selling, marketing and distribution&lt;br/&gt;
                &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;13,667&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;-&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;13,667&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td rowspan="1" style="vertical-align: top; width: 64%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td style="vertical-align: top; width: 64%; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in;"&gt;Depreciation and amortization expense&lt;br/&gt;
                  &lt;/p&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;4,709&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;2,404&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;7,113&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td style="width: 64%;" valign="bottom"&gt;
                  &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px;"&gt;&#160;&lt;/p&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td rowspan="1" style="width: 64%; background-color: #CCEEFF;" valign="bottom"&gt;General and administrative expense&lt;br/&gt;
                &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;16,312&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;-&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;16,312&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td rowspan="1" style="width: 64%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td rowspan="1" style="width: 64%; background-color: #CCEEFF;" valign="bottom"&gt;Income (loss) before taxes&lt;br/&gt;
                &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;374&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;(17,911&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;)&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;(17,537&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;)&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td rowspan="1" style="width: 64%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td style="vertical-align: top; width: 64%; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in;"&gt;Expenditures for additions to long-lived assets&lt;br/&gt;
                  &lt;/p&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;5,247&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;8,664&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;13,911&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td style="vertical-align: top; width: 64%;" valign="bottom"&gt;
                  &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in;"&gt;Total assets&lt;/p&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;238,159&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;37,071&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;275,230&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td rowspan="1" style="vertical-align: top; width: 64%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td rowspan="1" style="vertical-align: top; width: 64%;" valign="bottom"&gt;&lt;span style="font-style: italic;"&gt;Reconciliation of revenues:&lt;/span&gt;&lt;br/&gt;
                &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td rowspan="1" style="vertical-align: top; text-indent: 9pt; width: 64%; background-color: #CCEEFF;" valign="bottom"&gt;Segment revenue&lt;br/&gt;
                &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;153,937&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td rowspan="1" style="vertical-align: top; text-indent: 9pt; width: 64%; padding-bottom: 2px;" valign="bottom"&gt;License revenue (see Note 2 - Revenue Recognition)&lt;br/&gt;
                &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"&gt;143&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td rowspan="1" style="vertical-align: top; text-indent: 18pt; width: 64%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom"&gt;Consolidated revenues&lt;br/&gt;
                &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 4px double rgb(0, 0, 0);" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 4px double rgb(0, 0, 0);" valign="bottom"&gt;154,080&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td rowspan="1" style="vertical-align: top; width: 64%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td rowspan="1" style="vertical-align: top; width: 64%; background-color: rgb(204, 238, 255); font-style: italic;" valign="bottom"&gt;
                  &lt;div style="margin-left: 9pt; text-indent: -9pt;"&gt;Reconciliation of selling, general and administrative expense:&lt;br/&gt;
                  &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td rowspan="1" style="vertical-align: top; text-indent: 9pt; width: 64%;" valign="bottom"&gt;Segment selling, marketing and distribution expense&lt;br/&gt;
                &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;13,667&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td rowspan="1" style="vertical-align: top; text-indent: 9pt; width: 64%; background-color: #CCEEFF;" valign="bottom"&gt;Segment general and administrative expense&lt;br/&gt;
                &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;16,312&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td rowspan="1" style="vertical-align: top; text-indent: 9pt; width: 64%; padding-bottom: 2px;" valign="bottom"&gt;Corporate general and administrative expense (a)&lt;br/&gt;
                &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"&gt;22,479&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td rowspan="1" style="vertical-align: top; width: 64%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom"&gt;
                  &lt;div style="margin-left: 27pt; text-indent: -9pt;"&gt;Consolidated selling, general and administrative expense&lt;br/&gt;
                  &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 4px double rgb(0, 0, 0);" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 4px double rgb(0, 0, 0);" valign="bottom"&gt;52,458&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td rowspan="1" style="vertical-align: top; width: 64%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td rowspan="1" style="vertical-align: top; width: 64%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: italic; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: nowrap; background-color: rgb(204, 238, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; display: inline !important; float: none;"&gt;Reconciliation of income (loss) before taxes:&lt;/span&gt; &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td rowspan="1" style="vertical-align: top; text-indent: 9pt; width: 64%;" valign="bottom"&gt;Segment income before taxes&lt;br/&gt;
                &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;(17,537&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;)&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td rowspan="1" style="vertical-align: top; text-indent: 9pt; width: 64%; background-color: #CCEEFF;" valign="bottom"&gt;License revenue&lt;br/&gt;
                &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;143&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td rowspan="1" style="vertical-align: top; width: 64%;" valign="bottom"&gt;
                  &lt;div style="margin-left: 9pt"&gt;
                    &lt;div style="margin-left: 9pt; text-indent: -9pt;"&gt;Unallocated interest expense, primaril related to interest on senior debt (see Note 7)&lt;br/&gt;
                    &lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;(19,276&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;)&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td rowspan="1" style="vertical-align: top; text-indent: 9pt; width: 64%; background-color: #CCEEFF;" valign="bottom"&gt;Loss on extinguishment of debt (see Note 7)&lt;br/&gt;
                &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;(6,670&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;)&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td rowspan="1" style="vertical-align: top; text-indent: 9pt; width: 64%;" valign="bottom"&gt;Other expense&lt;br/&gt;
                &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;(85&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;)&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td rowspan="1" style="vertical-align: top; text-indent: 9pt; width: 64%; background-color: rgb(204, 238, 255); padding-bottom: 2px;" valign="bottom"&gt;Corporate general and administrative expense (a)&lt;br/&gt;
                &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"&gt;(22,479&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;)&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td rowspan="1" style="vertical-align: top; text-indent: 18pt; width: 64%; padding-bottom: 4px;" valign="bottom"&gt;Consolidated income before taxes&lt;br/&gt;
                &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom"&gt;(65,904&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;)&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td rowspan="1" style="vertical-align: top; width: 64%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td rowspan="1" style="vertical-align: top; width: 64%;" valign="bottom"&gt;&lt;span style="font-style: italic;"&gt;Reconciliation of total assets:&lt;/span&gt;&lt;br/&gt;
                &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td rowspan="1" style="vertical-align: top; text-indent: 9pt; width: 64%; background-color: #CCEEFF;" valign="bottom"&gt;Total segment assets&lt;br/&gt;
                &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;275,230&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td rowspan="1" style="vertical-align: top; text-indent: 9pt; width: 64%; padding-bottom: 2px;" valign="bottom"&gt;Corporate (b)&lt;br/&gt;
                &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"&gt;73,231&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td rowspan="1" style="vertical-align: top; text-indent: 18pt; width: 64%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom"&gt;Consolidated total assets&lt;br/&gt;
                &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 4px double rgb(0, 0, 0);" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 4px double rgb(0, 0, 0);" valign="bottom"&gt;348,461&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div&gt;&lt;br/&gt;
          &lt;/div&gt;

&lt;div&gt;
            &lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-spacing: 0;"&gt;


  &lt;tr style="vertical-align: top;"&gt;

    &lt;td style="text-align: right; vertical-align: top; width: 27pt;"&gt;
                    &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;"&gt;(a) - &lt;br/&gt;
                    &lt;/p&gt;
                  &lt;/td&gt;

    &lt;td style="text-align: left; vertical-align: top;"&gt;
                    &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: justify;"&gt;Primarily includes compensation expense, including stock-based compensation expense, for certain executive officers and consultants,
                      insurance, legal and investor relations expenses and accounting and tax fees that are not allocated to the Company&#x2019;s operating segments.&lt;/p&gt;
                  &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
          &lt;/div&gt;

&lt;div&gt;&lt;br/&gt;
          &lt;/div&gt;

&lt;div&gt;
            &lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-spacing: 0;"&gt;


  &lt;tr style="vertical-align: top;"&gt;

    &lt;td style="text-align: right; vertical-align: top; width: 27pt;"&gt;
                    &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;"&gt;(b) -&lt;br/&gt;
                    &lt;/p&gt;
                  &lt;/td&gt;

    &lt;td style="text-align: left; vertical-align: top;"&gt;
                    &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;"&gt;Primarily consists of cash.&lt;/p&gt;
                  &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
             &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt; &lt;br/&gt;
            &lt;/div&gt;

&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt;Net revenues according to geographic area, based on the location of where the product is shipped, are as follows:&lt;/div&gt;

&lt;div&gt;&lt;br/&gt;
            &lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%; border-spacing: 0;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="18" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                    &lt;div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"&gt;Year Ended December 31, 2024&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"&gt;ADMA &lt;/div&gt;
                    &lt;div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"&gt;BioManufacturing&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"&gt;Plasma Centers&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"&gt;Total Segment &lt;/div&gt;
                    &lt;div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"&gt;Revenue&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"&gt;License &lt;/div&gt;
                    &lt;div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"&gt;Revenue&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"&gt;Consolidated &lt;/div&gt;
                    &lt;div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"&gt;Revenue&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 40%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"&gt;United States&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;$&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;400,336&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;$&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;9,669&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;$&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;410,005&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;$&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;143&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;$&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;410,148&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 40%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"&gt;International&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;15,470&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;836&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;16,306&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;-&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;16,306&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 40%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"&gt;Total revenues&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;$&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;415,806&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;$&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;10,505&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;$&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;426,311&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;$&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;143&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;$&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;426,454&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div&gt;&lt;br/&gt;
            &lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%; border-spacing: 0;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="18" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                    &lt;div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"&gt;Year Ended December 31, 2023&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"&gt;ADMA &lt;/div&gt;
                    &lt;div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"&gt;BioManufacturing&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"&gt;Plasma Centers&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"&gt;Total Segment &lt;/div&gt;
                    &lt;div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"&gt;Revenue&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"&gt;License &lt;/div&gt;
                    &lt;div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"&gt;Revenue&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"&gt;Consolidated &lt;/div&gt;
                    &lt;div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"&gt;Revenue&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 40%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"&gt;United States&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;$&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;237,454&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;$&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;7,284&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;$&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;244,738&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;$&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;143&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;$&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;244,881&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 40%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"&gt;International&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;12,284&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;1,050&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;13,334&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;-&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;13,334&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 40%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"&gt;Total revenues&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;$&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;249,738&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;$&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;8,334&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;$&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;258,072&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;$&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;143&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;$&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;258,215&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div&gt;&lt;br/&gt;
            &lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%; border-spacing: 0;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="18" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                    &lt;div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"&gt;Year Ended December 31, 2022&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"&gt;ADMA &lt;/div&gt;
                    &lt;div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"&gt;BioManufacturing&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"&gt;Plasma Centers&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"&gt;Total Segment &lt;/div&gt;
                    &lt;div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"&gt;Revenue&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"&gt;License &lt;/div&gt;
                    &lt;div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"&gt;Revenue&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"&gt;Consolidated &lt;/div&gt;
                    &lt;div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"&gt;Revenue&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 40%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"&gt;United States&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;$&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;136,827&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;$&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;9,457&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;$&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;146,284&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;$&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;143&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;$&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;146,427&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 40%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"&gt;International&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;7,243&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;410&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;7,653&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;-&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;7,653&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 40%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"&gt;Total revenues&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;$&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;144,070&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;$&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;9,867&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;$&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;153,937&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;$&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;143&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;$&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;154,080&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
</us-gaap:SegmentReportingDisclosureTextBlock>
    <adma:NumberOfPlasmaCollectionFacilitiesUnderDevelopment
      contextRef="c20240101to20241231"
      decimals="INF"
      id="Fact_97173a504bcb44bfbd5b6d92a9da0d35"
      unitRef="U004">10</adma:NumberOfPlasmaCollectionFacilitiesUnderDevelopment>
    <us-gaap:NumberOfOperatingSegments
      contextRef="c20240101to20241231"
      decimals="INF"
      id="Fact_135c393eaf254fd3998993ab8df11c59"
      unitRef="U014">2</us-gaap:NumberOfOperatingSegments>
    <us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock
      contextRef="c20240101to20241231"
      id="Text_2e8a7ada35eb4cac85512185a7df2676">&lt;span style="font-family: 'Times New Roman'; font-size: 10pt; color: rgb(0, 0, 0);"&gt;Summarized financial information concerning reportable segments is
          shown in the following tables:&lt;/span&gt;&lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;"&gt;&#160;&#160;&#160;&lt;/p&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="text-align: left; font: 10pt 'Times New Roman'; width: 100%; border-spacing: 0;"&gt;


  &lt;tr style="height: 15px;"&gt;

    &lt;td colspan="12" style="vertical-align: top; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: center;"&gt;&lt;strong&gt;Year Ended December 31, 2024&lt;/strong&gt;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td style="padding-bottom: 2px;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: center;"&gt;&lt;span style="font-style: italic;"&gt;(in thousands)&lt;/span&gt;&lt;br/&gt;
                &lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: center;"&gt;&lt;strong&gt;ADMA&lt;/strong&gt;&lt;/p&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: center;"&gt;&lt;strong&gt; BioManufacturing&lt;/strong&gt;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: center;"&gt;&lt;strong&gt;Plasma Collection&lt;br/&gt;
                  &lt;/strong&gt;&lt;/p&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: center;"&gt;&lt;span style="font-weight: bold;"&gt;Centers&lt;/span&gt;&lt;strong&gt;&lt;br/&gt;
                  &lt;/strong&gt;&lt;/p&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: center;"&gt;&lt;strong&gt; &lt;/strong&gt;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: center;"&gt;&lt;strong&gt;Total&lt;/strong&gt;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td style="vertical-align: top; width: 64%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in;"&gt;Revenues&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;415,806&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;10,505&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;426,311&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td style="width: 64%;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td style="vertical-align: top; width: 64%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in;"&gt;Cost of product revenue&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;195,605&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;11,296&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;206,901&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td style="width: 64%;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td style="vertical-align: top; width: 64%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in;"&gt;Research and development&lt;br/&gt;
                &lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;1,813&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;-&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;1,813&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td style="width: 64%;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td style="vertical-align: top; width: 64%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in;"&gt;Plasma center operating expenses&lt;br/&gt;
                &lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;-&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;4,245&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;4,245&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td style="width: 64%;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td rowspan="1" style="vertical-align: top; width: 64%; background-color: #CCEEFF;" valign="bottom"&gt;Selling, marketing and distribution&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;18,683&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;-&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;18,683&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td rowspan="1" style="vertical-align: top; width: 64%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td style="vertical-align: top; width: 64%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in;"&gt;Depreciation and amortization expense&lt;br/&gt;
                &lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;4,827&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;3,218&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;8,045&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td style="width: 64%;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td rowspan="1" style="width: 64%; background-color: #CCEEFF;" valign="bottom"&gt;General and administrative expense&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;26,001&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;-&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;26,001&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td rowspan="1" style="width: 64%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td rowspan="1" style="width: 64%; background-color: #CCEEFF;" valign="bottom"&gt;Other expense, net&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;(178&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;)&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;(5&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;)&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;(183&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;)&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td rowspan="1" style="width: 64%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td rowspan="1" style="width: 64%; background-color: #CCEEFF;" valign="bottom"&gt;Income (loss) before taxes&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;173,138&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;(5,041&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;)&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;168,097&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td rowspan="1" style="width: 64%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td style="vertical-align: top; width: 64%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in;"&gt;Expenditures for additions to long-lived assets&lt;br/&gt;
                &lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;8,352&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;223&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;8,575&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td style="vertical-align: top; width: 64%;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in;"&gt;Total assets&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;289,297&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;30,477&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;319,774&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td rowspan="1" style="vertical-align: top; width: 64%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td rowspan="1" style="vertical-align: top; width: 64%;" valign="bottom"&gt;&lt;span style="font-style: italic;"&gt;Reconciliation of revenues:&lt;/span&gt;&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td rowspan="1" style="vertical-align: top; text-indent: 9pt; width: 64%; background-color: #CCEEFF;" valign="bottom"&gt;Segment revenue&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;426,311&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td rowspan="1" style="vertical-align: top; text-indent: 9pt; width: 64%; padding-bottom: 2px;" valign="bottom"&gt;License revenue (see Note 2 - Revenue Recognition)&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"&gt;143&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td rowspan="1" style="vertical-align: top; text-indent: 18pt; width: 64%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom"&gt;Consolidated revenues&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 4px double rgb(0, 0, 0);" valign="bottom"&gt;$&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 4px double rgb(0, 0, 0);" valign="bottom"&gt;426,454&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td rowspan="1" style="vertical-align: top; width: 64%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td rowspan="1" style="vertical-align: top; width: 64%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                &lt;div style="margin-left: 9pt; text-indent: -9pt;"&gt;&lt;span style="font-style: italic;"&gt;Reconciliation of selling, general and administrative expense:&lt;/span&gt;&lt;br/&gt;
                &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td rowspan="1" style="vertical-align: top; text-indent: 9pt; width: 64%;" valign="bottom"&gt;Segment selling, marketing and distribution expense&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;18,683&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td rowspan="1" style="vertical-align: top; text-indent: 9pt; width: 64%; background-color: #CCEEFF;" valign="bottom"&gt;Segment general and administrative expense&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;26,001&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td rowspan="1" style="vertical-align: top; text-indent: 9pt; width: 64%; padding-bottom: 2px;" valign="bottom"&gt;Corporate general and administrative expense (a)&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"&gt;29,440&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td rowspan="1" style="vertical-align: top; width: 64%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom"&gt;
                &lt;div style="margin-left: 9pt"&gt;
                  &lt;div style="margin-left: 9pt"&gt;
                    &lt;div style="margin-left: 9pt; text-indent: -9pt;"&gt;Consolidated selling, general and administrative expense&lt;br/&gt;
                    &lt;/div&gt;
                  &lt;/div&gt;
                &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 4px double rgb(0, 0, 0);" valign="bottom"&gt;$&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 4px double rgb(0, 0, 0);" valign="bottom"&gt;74,124&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td rowspan="1" style="vertical-align: top; width: 64%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td rowspan="1" style="vertical-align: top; width: 64%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: italic; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: nowrap; background-color: rgb(204, 238, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; display: inline !important; float: none;"&gt;Reconciliation of income (loss) before taxes:&lt;/span&gt; &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td rowspan="1" style="vertical-align: top; text-indent: 9pt; width: 64%;" valign="bottom"&gt;Segment income before taxes&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;168,097&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td rowspan="1" style="vertical-align: top; text-indent: 9pt; width: 64%; background-color: #CCEEFF;" valign="bottom"&gt;License revenue&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;143&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td rowspan="1" style="vertical-align: top; width: 64%;" valign="bottom"&gt;
                &lt;div style="margin-left: 9pt"&gt;
                  &lt;div style="margin-left: 9pt; text-indent: -9pt;"&gt;Unallocated interest expense, primarily related to interest on senior debt (see Note 7)&lt;br/&gt;
                  &lt;/div&gt;
                &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;(13,930&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;)&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td rowspan="1" style="vertical-align: top; text-indent: 9pt; width: 64%; background-color: #CCEEFF;" valign="bottom"&gt;Loss on extinguishment of debt (see Note 7)&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;(1,243&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;)&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td rowspan="1" style="vertical-align: top; text-indent: 9pt; width: 64%;" valign="bottom"&gt;Unallocated interest income&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;2,087&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td rowspan="1" style="vertical-align: top; text-indent: 9pt; width: 64%; background-color: rgb(204, 238, 255); padding-bottom: 2px;" valign="bottom"&gt;Corporate general and administrative expense (a)&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"&gt;(29,440&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;)&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td rowspan="1" style="vertical-align: top; text-indent: 18pt; width: 64%; padding-bottom: 4px;" valign="bottom"&gt;Consolidated income before taxes&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom"&gt;$&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom"&gt;125,714&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td rowspan="1" style="vertical-align: top; width: 64%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td rowspan="1" style="vertical-align: top; width: 64%;" valign="bottom"&gt;&lt;span style="font-style: italic;"&gt;Reconciliation of total assets:&lt;/span&gt;&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td rowspan="1" style="vertical-align: top; text-indent: 9pt; width: 64%; background-color: #CCEEFF;" valign="bottom"&gt;Total segment assets&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;319,774&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td rowspan="1" style="vertical-align: top; text-indent: 9pt; width: 64%; padding-bottom: 2px;" valign="bottom"&gt;Corporate (b)&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"&gt;168,904&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td rowspan="1" style="vertical-align: top; text-indent: 18pt; width: 64%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom"&gt;Consolidated total assets&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 4px double rgb(0, 0, 0);" valign="bottom"&gt;$&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 4px double rgb(0, 0, 0);" valign="bottom"&gt;488,678&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
&lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;"&gt;&lt;br/&gt;
        &lt;/p&gt;
&lt;div&gt;
          &lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-spacing: 0;"&gt;


  &lt;tr style="vertical-align: top;"&gt;

    &lt;td style="text-align: right; vertical-align: top; width: 27pt;"&gt;
                  &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;"&gt;(a) - &lt;br/&gt;
                  &lt;/p&gt;
                &lt;/td&gt;

    &lt;td style="text-align: left; vertical-align: top;"&gt;
                  &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: justify;"&gt;Primarily includes compensation expense,
                    including stock-based compensation expense, for certain executive officers and consultants, insurance, legal and investor relations expenses and accounting and tax fees that are not allocated to the Company&#x2019;s operating segments.&lt;/p&gt;
                &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
        &lt;/div&gt;
&lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;"&gt;&lt;br/&gt;
        &lt;/p&gt;
&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-spacing: 0;"&gt;


  &lt;tr style="vertical-align: top;"&gt;

    &lt;td style="text-align: right; vertical-align: top; width: 27pt;"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;"&gt;(b) -&lt;br/&gt;
                &lt;/p&gt;
              &lt;/td&gt;

    &lt;td style="text-align: left; vertical-align: top;"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;"&gt;Primarily consists of cash and deferred tax
                  assets.&lt;/p&gt;
              &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
&lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;"&gt;&lt;br/&gt;
        &lt;/p&gt;&lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;"&gt; &lt;/p&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="text-align: left; font: 10pt 'Times New Roman'; width: 100%; border-spacing: 0;"&gt;


  &lt;tr style="height: 15px;"&gt;

    &lt;td colspan="12" style="vertical-align: top; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: center;"&gt;&lt;strong&gt;Year Ended December 31, 2023&lt;/strong&gt;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td style="padding-bottom: 2px;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: center;"&gt;&lt;span style="font-style: italic;"&gt;(in thousands)&lt;/span&gt;&lt;br/&gt;
                &lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: center;"&gt;&lt;strong&gt;ADMA&lt;/strong&gt;&lt;/p&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: center;"&gt;&lt;strong&gt; BioManufacturing&lt;/strong&gt;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: center;"&gt;&lt;strong&gt;Plasma Collection&lt;br/&gt;
                  &lt;/strong&gt;&lt;/p&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: center;"&gt;&lt;span style="font-weight: bold;"&gt;Centers&lt;/span&gt;&lt;strong&gt;&lt;br/&gt;
                  &lt;/strong&gt;&lt;/p&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: center;"&gt;&lt;strong&gt; &lt;/strong&gt;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: center;"&gt;&lt;strong&gt;Total&lt;/strong&gt;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td style="vertical-align: top; width: 64%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in;"&gt;Revenues&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;249,738&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;8,334&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;258,072&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td style="width: 64%;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td style="vertical-align: top; width: 64%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in;"&gt;Cost of product revenue&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;161,157&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;8,116&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;169,273&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td style="width: 64%;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td style="vertical-align: top; width: 64%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in;"&gt;Research and development&lt;br/&gt;
                &lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;3,300&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;-&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;3,300&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td style="width: 64%;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td style="vertical-align: top; width: 64%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in;"&gt;Plasma center operating expenses&lt;br/&gt;
                &lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;-&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;4,266&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;4,266&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td style="width: 64%;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td rowspan="1" style="vertical-align: top; width: 64%; background-color: #CCEEFF;" valign="bottom"&gt;Selling, marketing and distribution&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;18,407&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;-&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;18,407&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td rowspan="1" style="vertical-align: top; width: 64%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td style="vertical-align: top; width: 64%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in;"&gt;Depreciation and amortization expense&lt;br/&gt;
                &lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;5,156&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;3,176&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;8,332&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td style="width: 64%;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td rowspan="1" style="width: 64%; background-color: #CCEEFF;" valign="bottom"&gt;General and administrative expense&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;18,625&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;-&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;18,625&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td rowspan="1" style="width: 64%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td rowspan="1" style="width: 64%; background-color: #CCEEFF;" valign="bottom"&gt;Income (loss) before taxes&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;47,267&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;(4,049&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;)&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;43,218&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td rowspan="1" style="width: 64%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td style="vertical-align: top; width: 64%; background-color: #CCEEFF;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in;"&gt;Expenditures for additions to long-lived assets&lt;br/&gt;
                &lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;2,952&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;1,819&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;4,771&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td style="vertical-align: top; width: 64%;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in;"&gt;Total assets&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;246,719&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;34,733&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;281,452&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td rowspan="1" style="vertical-align: top; width: 64%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td rowspan="1" style="vertical-align: top; width: 64%;" valign="bottom"&gt;&lt;span style="font-style: italic;"&gt;Reconciliation of revenues:&lt;/span&gt;&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td rowspan="1" style="vertical-align: top; text-indent: 9pt; width: 64%; background-color: #CCEEFF;" valign="bottom"&gt;Segment revenue&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;$ &lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;258,072&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td rowspan="1" style="vertical-align: top; text-indent: 9pt; width: 64%; padding-bottom: 2px;" valign="bottom"&gt;License revenue (see Note 2 - Revenue Recognition)&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"&gt;143&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td rowspan="1" style="vertical-align: top; text-indent: 18pt; width: 64%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom"&gt;Consolidated revenues&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 4px double rgb(0, 0, 0);" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 4px double rgb(0, 0, 0);" valign="bottom"&gt;258,215&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td rowspan="1" style="vertical-align: top; width: 64%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td rowspan="1" style="vertical-align: top; width: 64%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                &lt;div style="margin-left: 9pt; text-indent: -9pt;"&gt;&lt;span style="font-style: italic;"&gt;Reconciliation of selling, general and administrative expense:&lt;/span&gt;&lt;br/&gt;
                &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td rowspan="1" style="vertical-align: top; text-indent: 9pt; width: 64%;" valign="bottom"&gt;Segment selling, marketing and distribution expense&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;18,407&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td rowspan="1" style="vertical-align: top; text-indent: 9pt; width: 64%; background-color: #CCEEFF;" valign="bottom"&gt;Segment general and administrative expense&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;18,625&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td rowspan="1" style="vertical-align: top; text-indent: 9pt; width: 64%; padding-bottom: 2px;" valign="bottom"&gt;Corporate general and administrative expense (a)&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"&gt;21,988&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td rowspan="1" style="vertical-align: top; width: 64%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom"&gt;
                &lt;div style="margin-left: 9pt"&gt;
                  &lt;div style="margin-left: 9pt"&gt;
                    &lt;div style="margin-left: 9pt; text-indent: -9pt;"&gt;Consolidated selling, general and administrative expense&lt;br/&gt;
                    &lt;/div&gt;
                  &lt;/div&gt;
                &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 4px double rgb(0, 0, 0);" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 4px double rgb(0, 0, 0);" valign="bottom"&gt;59,020&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td rowspan="1" style="vertical-align: top; width: 64%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td rowspan="1" style="vertical-align: top; width: 64%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: italic; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: nowrap; background-color: rgb(204, 238, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; display: inline !important; float: none;"&gt;Reconciliation of income (loss) before taxes:&lt;/span&gt;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td rowspan="1" style="vertical-align: top; text-indent: 9pt; width: 64%;" valign="bottom"&gt;Segment income before taxes&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;43,218&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td rowspan="1" style="vertical-align: top; text-indent: 9pt; width: 64%; background-color: #CCEEFF;" valign="bottom"&gt;License revenue&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;143&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td rowspan="1" style="vertical-align: top; width: 64%;" valign="bottom"&gt;
                &lt;div style="margin-left: 9pt"&gt;
                  &lt;div style="margin-left: 9pt; text-indent: -9pt;"&gt;Unallocated interest expense, primaril related to interest on senior debt (see Note 7)&lt;br/&gt;
                  &lt;/div&gt;
                &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;(25,027&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;)&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td rowspan="1" style="vertical-align: top; text-indent: 9pt; width: 64%; background-color: #CCEEFF;" valign="bottom"&gt;Loss on extinguishment of debt (see Note 7)&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;(26,174&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;)&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td rowspan="1" style="vertical-align: top; text-indent: 9pt; width: 64%;" valign="bottom"&gt;Unallocated interest income&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;1,589&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td rowspan="1" style="vertical-align: top; text-indent: 9pt; width: 64%; background-color: rgb(204, 238, 255); padding-bottom: 2px;" valign="bottom"&gt;Corporate general and administrative expense (a)&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"&gt;(21,988&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;)&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td rowspan="1" style="vertical-align: top; text-indent: 18pt; width: 64%; padding-bottom: 4px;" valign="bottom"&gt;Consolidated income before taxes&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom"&gt;(28,239&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;)&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td rowspan="1" style="vertical-align: top; width: 64%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td rowspan="1" style="vertical-align: top; width: 64%;" valign="bottom"&gt;&lt;span style="font-style: italic;"&gt;Reconciliation of total assets:&lt;/span&gt;&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td rowspan="1" style="vertical-align: top; text-indent: 9pt; width: 64%; background-color: #CCEEFF;" valign="bottom"&gt;Total segment assets&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;$ &lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;281,452&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td rowspan="1" style="vertical-align: top; text-indent: 9pt; width: 64%; padding-bottom: 2px;" valign="bottom"&gt;Corporate (b)&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"&gt;47,730&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td rowspan="1" style="vertical-align: top; text-indent: 18pt; width: 64%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom"&gt;Consolidated total assets&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 4px double rgb(0, 0, 0);" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 4px double rgb(0, 0, 0);" valign="bottom"&gt;329,182&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
&lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;"&gt; &lt;br/&gt;
        &lt;/p&gt;
&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-spacing: 0;"&gt;


  &lt;tr style="vertical-align: top;"&gt;

    &lt;td style="text-align: right; vertical-align: top; width: 27pt;"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;"&gt;(a) - &lt;br/&gt;
                &lt;/p&gt;
              &lt;/td&gt;

    &lt;td style="text-align: left; vertical-align: top;"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: justify;"&gt;Primarily includes compensation expense, including stock-based compensation expense, for certain executive officers and consultants, insurance,
                  legal and investor relations expenses and accounting and tax fees that are not allocated to the Company&#x2019;s operating segments.&lt;/p&gt;
              &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
&lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;"&gt; &lt;/p&gt;&lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;"&gt; &lt;/p&gt;&lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;"&gt; &lt;br/&gt;
        &lt;/p&gt;
&lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-spacing: 0;"&gt;


  &lt;tr style="vertical-align: top;"&gt;

    &lt;td style="text-align: right; vertical-align: top; width: 27pt;"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;"&gt;(b) -&lt;br/&gt;
                &lt;/p&gt;
              &lt;/td&gt;

    &lt;td style="text-align: left; vertical-align: top;"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;"&gt;Primarily consists of cash.&lt;/p&gt;
              &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
&lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;"&gt; &lt;/p&gt;&lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;"&gt; &lt;/p&gt;&lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;"&gt; &lt;br/&gt;
        &lt;/p&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="text-align: left; font: 10pt 'Times New Roman'; width: 100%; border-spacing: 0;"&gt;


  &lt;tr style="height: 15px;"&gt;

    &lt;td colspan="12" style="vertical-align: top; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                  &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: center;"&gt;&lt;strong&gt;Year Ended December 31, 2022&lt;/strong&gt;&lt;/p&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td style="padding-bottom: 2px;" valign="bottom"&gt;
                  &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: center;"&gt;&lt;span style="font-style: italic;"&gt;(in thousands)&lt;/span&gt;&lt;br/&gt;
                  &lt;/p&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: center;"&gt;&lt;strong&gt;ADMA&lt;/strong&gt;&lt;/p&gt;
                  &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: center;"&gt;&lt;strong&gt; BioManufacturing&lt;/strong&gt;&lt;/p&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: center;"&gt;&lt;strong&gt;Plasma Collection&lt;br/&gt;
                    &lt;/strong&gt;&lt;/p&gt;
                  &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: center;"&gt;&lt;span style="font-weight: bold;"&gt;Centers&lt;/span&gt;&lt;strong&gt;&lt;br/&gt;
                    &lt;/strong&gt;&lt;/p&gt;
                  &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: center;"&gt;&lt;strong&gt; &lt;/strong&gt;&lt;/p&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                  &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: center;"&gt;&lt;strong&gt;Total&lt;/strong&gt;&lt;/p&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td style="vertical-align: top; width: 64%; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in;"&gt;Revenues&lt;/p&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;144,070&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;9,867&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;153,937&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td style="width: 64%;" valign="bottom"&gt;
                  &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px;"&gt;&#160;&lt;/p&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td style="vertical-align: top; width: 64%; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in;"&gt;Cost of product revenue&lt;/p&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;108,882&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;9,933&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;118,815&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td style="width: 64%;" valign="bottom"&gt;
                  &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px;"&gt;&#160;&lt;/p&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td style="vertical-align: top; width: 64%; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in;"&gt;Research and development&lt;br/&gt;
                  &lt;/p&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;3,614&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;-&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;3,614&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td style="width: 64%;" valign="bottom"&gt;
                  &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px;"&gt;&#160;&lt;/p&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td style="vertical-align: top; width: 64%; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in;"&gt;Plasma center operating expenses&lt;br/&gt;
                  &lt;/p&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;-&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;17,843&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;17,843&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td style="width: 64%;" valign="bottom"&gt;
                  &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px;"&gt;&#160;&lt;/p&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td rowspan="1" style="vertical-align: top; width: 64%; background-color: #CCEEFF;" valign="bottom"&gt;Selling, marketing and distribution&lt;br/&gt;
                &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;13,667&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;-&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;13,667&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td rowspan="1" style="vertical-align: top; width: 64%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td style="vertical-align: top; width: 64%; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in;"&gt;Depreciation and amortization expense&lt;br/&gt;
                  &lt;/p&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;4,709&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;2,404&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;7,113&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td style="width: 64%;" valign="bottom"&gt;
                  &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px;"&gt;&#160;&lt;/p&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td rowspan="1" style="width: 64%; background-color: #CCEEFF;" valign="bottom"&gt;General and administrative expense&lt;br/&gt;
                &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;16,312&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;-&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;16,312&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td rowspan="1" style="width: 64%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td rowspan="1" style="width: 64%; background-color: #CCEEFF;" valign="bottom"&gt;Income (loss) before taxes&lt;br/&gt;
                &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;374&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;(17,911&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;)&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;(17,537&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;)&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td rowspan="1" style="width: 64%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td style="vertical-align: top; width: 64%; background-color: #CCEEFF;" valign="bottom"&gt;
                  &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in;"&gt;Expenditures for additions to long-lived assets&lt;br/&gt;
                  &lt;/p&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;5,247&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;8,664&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;13,911&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td style="vertical-align: top; width: 64%;" valign="bottom"&gt;
                  &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in;"&gt;Total assets&lt;/p&gt;
                &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;238,159&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;37,071&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;275,230&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td rowspan="1" style="vertical-align: top; width: 64%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td rowspan="1" style="vertical-align: top; width: 64%;" valign="bottom"&gt;&lt;span style="font-style: italic;"&gt;Reconciliation of revenues:&lt;/span&gt;&lt;br/&gt;
                &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td rowspan="1" style="vertical-align: top; text-indent: 9pt; width: 64%; background-color: #CCEEFF;" valign="bottom"&gt;Segment revenue&lt;br/&gt;
                &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;153,937&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td rowspan="1" style="vertical-align: top; text-indent: 9pt; width: 64%; padding-bottom: 2px;" valign="bottom"&gt;License revenue (see Note 2 - Revenue Recognition)&lt;br/&gt;
                &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"&gt;143&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td rowspan="1" style="vertical-align: top; text-indent: 18pt; width: 64%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom"&gt;Consolidated revenues&lt;br/&gt;
                &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 4px double rgb(0, 0, 0);" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 4px double rgb(0, 0, 0);" valign="bottom"&gt;154,080&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td rowspan="1" style="vertical-align: top; width: 64%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td rowspan="1" style="vertical-align: top; width: 64%; background-color: rgb(204, 238, 255); font-style: italic;" valign="bottom"&gt;
                  &lt;div style="margin-left: 9pt; text-indent: -9pt;"&gt;Reconciliation of selling, general and administrative expense:&lt;br/&gt;
                  &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td rowspan="1" style="vertical-align: top; text-indent: 9pt; width: 64%;" valign="bottom"&gt;Segment selling, marketing and distribution expense&lt;br/&gt;
                &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;13,667&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td rowspan="1" style="vertical-align: top; text-indent: 9pt; width: 64%; background-color: #CCEEFF;" valign="bottom"&gt;Segment general and administrative expense&lt;br/&gt;
                &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;16,312&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td rowspan="1" style="vertical-align: top; text-indent: 9pt; width: 64%; padding-bottom: 2px;" valign="bottom"&gt;Corporate general and administrative expense (a)&lt;br/&gt;
                &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"&gt;22,479&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td rowspan="1" style="vertical-align: top; width: 64%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom"&gt;
                  &lt;div style="margin-left: 27pt; text-indent: -9pt;"&gt;Consolidated selling, general and administrative expense&lt;br/&gt;
                  &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 4px double rgb(0, 0, 0);" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 4px double rgb(0, 0, 0);" valign="bottom"&gt;52,458&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td rowspan="1" style="vertical-align: top; width: 64%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td rowspan="1" style="vertical-align: top; width: 64%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;span style="color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 13.3333px; font-style: italic; font-variant-ligatures: normal; font-variant-caps: normal; font-weight: 400; letter-spacing: normal; orphans: 2; text-align: left; text-indent: 0px; text-transform: none; widows: 2; word-spacing: 0px; -webkit-text-stroke-width: 0px; white-space: nowrap; background-color: rgb(204, 238, 255); text-decoration-thickness: initial; text-decoration-style: initial; text-decoration-color: initial; display: inline !important; float: none;"&gt;Reconciliation of income (loss) before taxes:&lt;/span&gt; &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td rowspan="1" style="vertical-align: top; text-indent: 9pt; width: 64%;" valign="bottom"&gt;Segment income before taxes&lt;br/&gt;
                &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;(17,537&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;)&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td rowspan="1" style="vertical-align: top; text-indent: 9pt; width: 64%; background-color: #CCEEFF;" valign="bottom"&gt;License revenue&lt;br/&gt;
                &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;143&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td rowspan="1" style="vertical-align: top; width: 64%;" valign="bottom"&gt;
                  &lt;div style="margin-left: 9pt"&gt;
                    &lt;div style="margin-left: 9pt; text-indent: -9pt;"&gt;Unallocated interest expense, primaril related to interest on senior debt (see Note 7)&lt;br/&gt;
                    &lt;/div&gt;
                  &lt;/div&gt;
                &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;(19,276&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;)&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td rowspan="1" style="vertical-align: top; text-indent: 9pt; width: 64%; background-color: #CCEEFF;" valign="bottom"&gt;Loss on extinguishment of debt (see Note 7)&lt;br/&gt;
                &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;(6,670&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;)&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td rowspan="1" style="vertical-align: top; text-indent: 9pt; width: 64%;" valign="bottom"&gt;Other expense&lt;br/&gt;
                &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;(85&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;)&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td rowspan="1" style="vertical-align: top; text-indent: 9pt; width: 64%; background-color: rgb(204, 238, 255); padding-bottom: 2px;" valign="bottom"&gt;Corporate general and administrative expense (a)&lt;br/&gt;
                &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"&gt;(22,479&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;)&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td rowspan="1" style="vertical-align: top; text-indent: 18pt; width: 64%; padding-bottom: 4px;" valign="bottom"&gt;Consolidated income before taxes&lt;br/&gt;
                &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom"&gt;(65,904&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;)&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td rowspan="1" style="vertical-align: top; width: 64%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td rowspan="1" style="vertical-align: top; width: 64%;" valign="bottom"&gt;&lt;span style="font-style: italic;"&gt;Reconciliation of total assets:&lt;/span&gt;&lt;br/&gt;
                &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td rowspan="1" style="vertical-align: top; text-indent: 9pt; width: 64%; background-color: #CCEEFF;" valign="bottom"&gt;Total segment assets&lt;br/&gt;
                &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;275,230&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td rowspan="1" style="vertical-align: top; text-indent: 9pt; width: 64%; padding-bottom: 2px;" valign="bottom"&gt;Corporate (b)&lt;br/&gt;
                &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 2px solid rgb(0, 0, 0);" valign="bottom"&gt;73,231&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td rowspan="1" style="vertical-align: top; text-indent: 18pt; width: 64%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom"&gt;Consolidated total assets&lt;br/&gt;
                &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 4px double rgb(0, 0, 0);" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 4px double rgb(0, 0, 0);" valign="bottom"&gt;348,461&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div&gt;&lt;br/&gt;
          &lt;/div&gt;

&lt;div&gt;
            &lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-spacing: 0;"&gt;


  &lt;tr style="vertical-align: top;"&gt;

    &lt;td style="text-align: right; vertical-align: top; width: 27pt;"&gt;
                    &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;"&gt;(a) - &lt;br/&gt;
                    &lt;/p&gt;
                  &lt;/td&gt;

    &lt;td style="text-align: left; vertical-align: top;"&gt;
                    &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: justify;"&gt;Primarily includes compensation expense, including stock-based compensation expense, for certain executive officers and consultants,
                      insurance, legal and investor relations expenses and accounting and tax fees that are not allocated to the Company&#x2019;s operating segments.&lt;/p&gt;
                  &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
          &lt;/div&gt;

&lt;div&gt;&lt;br/&gt;
          &lt;/div&gt;

&lt;div&gt;
            &lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="font-family: 'Times New Roman'; font-size: 10pt; width: 100%; border-spacing: 0;"&gt;


  &lt;tr style="vertical-align: top;"&gt;

    &lt;td style="text-align: right; vertical-align: top; width: 27pt;"&gt;
                    &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;"&gt;(b) -&lt;br/&gt;
                    &lt;/p&gt;
                  &lt;/td&gt;

    &lt;td style="text-align: left; vertical-align: top;"&gt;
                    &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;"&gt;Primarily consists of cash.&lt;/p&gt;
                  &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
             &lt;/div&gt;
</us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20240101to20241231_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_ADMABioManufacturingSegmentMember"
      decimals="-3"
      id="Fact_c3620621cb394dd783d0169bdd8075f3"
      unitRef="U001">415806000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20240101to20241231_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PlasmaCollectionCentersSegmentMember"
      decimals="-3"
      id="Fact_1c5297f4cca54f9198875c6ed4eb37f4"
      unitRef="U001">10505000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20240101to20241231_ConsolidationItemsAxis_OperatingSegmentsMember"
      decimals="-3"
      id="Fact_04caccce64b448afabe69fb9c3e2b051"
      unitRef="U001">426311000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfRevenue
      contextRef="c20240101to20241231_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_ADMABioManufacturingSegmentMember"
      decimals="-3"
      id="Fact_46a01c3649164cccb33893e524db6c19"
      unitRef="U001">195605000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="c20240101to20241231_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PlasmaCollectionCentersSegmentMember"
      decimals="-3"
      id="Fact_9ea8a72b8dae454b86551d456955de05"
      unitRef="U001">11296000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="c20240101to20241231_ConsolidationItemsAxis_OperatingSegmentsMember"
      decimals="-3"
      id="Fact_aba665100e114e759df5a3aa422fed35"
      unitRef="U001">206901000</us-gaap:CostOfRevenue>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="c20240101to20241231_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_ADMABioManufacturingSegmentMember"
      decimals="-3"
      id="Fact_91f2a2da3e464bc8a6f81fc70950f6a1"
      unitRef="U001">1813000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="c20240101to20241231_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PlasmaCollectionCentersSegmentMember"
      decimals="-3"
      id="Fact_17a8511b3d03464795695a397eacbd01"
      unitRef="U001">0</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="c20240101to20241231_ConsolidationItemsAxis_OperatingSegmentsMember"
      decimals="-3"
      id="Fact_fa4fe93c958241f9a2bf622cdf60dd09"
      unitRef="U001">1813000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:OtherCostAndExpenseOperating
      contextRef="c20240101to20241231_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_ADMABioManufacturingSegmentMember"
      decimals="-3"
      id="Fact_4b8ffbeb90fc4e64b8045ca1e5b234e8"
      unitRef="U001">0</us-gaap:OtherCostAndExpenseOperating>
    <us-gaap:OtherCostAndExpenseOperating
      contextRef="c20240101to20241231_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PlasmaCollectionCentersSegmentMember"
      decimals="-3"
      id="Fact_274946dad1154e9ca85d7645df5548ad"
      unitRef="U001">4245000</us-gaap:OtherCostAndExpenseOperating>
    <us-gaap:OtherCostAndExpenseOperating
      contextRef="c20240101to20241231_ConsolidationItemsAxis_OperatingSegmentsMember"
      decimals="-3"
      id="Fact_9f8f7f3ebb1f41a6a91d8f3f971bd785"
      unitRef="U001">4245000</us-gaap:OtherCostAndExpenseOperating>
    <us-gaap:SellingAndMarketingExpense
      contextRef="c20240101to20241231_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_ADMABioManufacturingSegmentMember"
      decimals="-3"
      id="Fact_d8672edcd57649fda7c976c73202895c"
      unitRef="U001">18683000</us-gaap:SellingAndMarketingExpense>
    <us-gaap:SellingAndMarketingExpense
      contextRef="c20240101to20241231_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PlasmaCollectionCentersSegmentMember"
      decimals="-3"
      id="Fact_97d394a0a1534e2a8071cd50fdbb1cb5"
      unitRef="U001">0</us-gaap:SellingAndMarketingExpense>
    <us-gaap:SellingAndMarketingExpense
      contextRef="c20240101to20241231_ConsolidationItemsAxis_OperatingSegmentsMember"
      decimals="-3"
      id="Fact_219f0327bbcb44e9a6d03e6b02455f2d"
      unitRef="U001">18683000</us-gaap:SellingAndMarketingExpense>
    <us-gaap:DepreciationAndAmortization
      contextRef="c20240101to20241231_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_ADMABioManufacturingSegmentMember"
      decimals="-3"
      id="Fact_255c50c739a54604ae8355a00c57e724"
      unitRef="U001">4827000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="c20240101to20241231_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PlasmaCollectionCentersSegmentMember"
      decimals="-3"
      id="Fact_a8e50c03a44645fc950f4723c806e69e"
      unitRef="U001">3218000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="c20240101to20241231_ConsolidationItemsAxis_OperatingSegmentsMember"
      decimals="-3"
      id="Fact_cbf7fadd7b1040938807b6e7ebb7e1de"
      unitRef="U001">8045000</us-gaap:DepreciationAndAmortization>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="c20240101to20241231_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_ADMABioManufacturingSegmentMember"
      decimals="-3"
      id="Fact_d1fb21ae472c4a2082c0bb5f7e63c255"
      unitRef="U001">26001000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="c20240101to20241231_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PlasmaCollectionCentersSegmentMember"
      decimals="-3"
      id="Fact_29ff77a6b9a640f48a705693a04bd957"
      unitRef="U001">0</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="c20240101to20241231_ConsolidationItemsAxis_OperatingSegmentsMember"
      decimals="-3"
      id="Fact_24da8a783c1a4a2e8ec2fc20446100de"
      unitRef="U001">26001000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="c20240101to20241231_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_ADMABioManufacturingSegmentMember"
      decimals="-3"
      id="Fact_c838cf5792744b5fb2d4a63960e5f5c9"
      unitRef="U001">-178000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="c20240101to20241231_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PlasmaCollectionCentersSegmentMember"
      decimals="-3"
      id="Fact_af1ec71281084fc1900f22cfd58e06f3"
      unitRef="U001">-5000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="c20240101to20241231_ConsolidationItemsAxis_OperatingSegmentsMember"
      decimals="-3"
      id="Fact_0028e46f41ad4e5789ec4602a9a1900b"
      unitRef="U001">-183000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="c20240101to20241231_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_ADMABioManufacturingSegmentMember"
      decimals="-3"
      id="Fact_30bd72760b01449999945f4487e06fd8"
      unitRef="U001">173138000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="c20240101to20241231_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PlasmaCollectionCentersSegmentMember"
      decimals="-3"
      id="Fact_2971ac15b5d24ac19c93c2c204e1073c"
      unitRef="U001">-5041000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="c20240101to20241231_ConsolidationItemsAxis_OperatingSegmentsMember"
      decimals="-3"
      id="Fact_ec41b21b79fc49e2a024493f9f0653fd"
      unitRef="U001">168097000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:SegmentExpenditureAdditionToLongLivedAssets
      contextRef="c20240101to20241231_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_ADMABioManufacturingSegmentMember"
      decimals="-3"
      id="Fact_8f81e80b244447bba3eee87b1ff6b2e4"
      unitRef="U001">8352000</us-gaap:SegmentExpenditureAdditionToLongLivedAssets>
    <us-gaap:SegmentExpenditureAdditionToLongLivedAssets
      contextRef="c20240101to20241231_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PlasmaCollectionCentersSegmentMember"
      decimals="-3"
      id="Fact_b5cd1945a9fb430caf06c760a931ac0e"
      unitRef="U001">223000</us-gaap:SegmentExpenditureAdditionToLongLivedAssets>
    <us-gaap:SegmentExpenditureAdditionToLongLivedAssets
      contextRef="c20240101to20241231_ConsolidationItemsAxis_OperatingSegmentsMember"
      decimals="-3"
      id="Fact_c0fcb914e7314235864809fd1a6c684d"
      unitRef="U001">8575000</us-gaap:SegmentExpenditureAdditionToLongLivedAssets>
    <us-gaap:Assets
      contextRef="c20241231_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_ADMABioManufacturingSegmentMember"
      decimals="-3"
      id="Fact_885de1c4cd434f11be03575ecc9a1557"
      unitRef="U001">289297000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="c20241231_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PlasmaCollectionCentersSegmentMember"
      decimals="-3"
      id="Fact_ea4cc76fe6ec40229cba601fcca5d8f1"
      unitRef="U001">30477000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="c20241231_ConsolidationItemsAxis_OperatingSegmentsMember"
      decimals="-3"
      id="Fact_09d85b6ddbee473083417eb7b6ebcff2"
      unitRef="U001">319774000</us-gaap:Assets>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20240101to20241231_ConsolidationItemsAxis_OperatingSegmentsMember"
      decimals="-3"
      id="Fact_a491b394cdf94b0ebd9706435d82beab"
      unitRef="U001">426311000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20240101to20241231_ConsolidationItemsAxis_MaterialReconcilingItemsMember"
      decimals="-3"
      id="Fact_e165a811a4614d9b9c593462302fee6d"
      unitRef="U001">143000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20240101to20241231"
      decimals="-3"
      id="Fact_9f8dc061e52140e88a54138e73088b0c"
      unitRef="U001">426454000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:SellingAndMarketingExpense
      contextRef="c20240101to20241231_ConsolidationItemsAxis_OperatingSegmentsMember"
      decimals="-3"
      id="Fact_68ea26b2cb214432aa686a3b9549ab01"
      unitRef="U001">18683000</us-gaap:SellingAndMarketingExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="c20240101to20241231_ConsolidationItemsAxis_OperatingSegmentsMember"
      decimals="-3"
      id="Fact_b7e205b88bea435e97b9b05d6a34fb32"
      unitRef="U001">26001000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="c20240101to20241231_ConsolidationItemsAxis_CorporateNonSegmentMember"
      decimals="-3"
      id="Fact_38cc8c1ba39345bb9c266112d2a58244"
      unitRef="U001">29440000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="c20240101to20241231"
      decimals="-3"
      id="Fact_038983a770644c7c807353c1782297e7"
      unitRef="U001">74124000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="c20240101to20241231_ConsolidationItemsAxis_OperatingSegmentsMember"
      decimals="-3"
      id="Fact_afa4436802544e3b8a92d8cc6c1fb874"
      unitRef="U001">168097000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="c20240101to20241231_ConsolidationItemsAxis_MaterialReconcilingItemsMember"
      decimals="-3"
      id="Fact_8f468320d8354b8b9dfe61bfa8bc87c0"
      unitRef="U001">143000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:InterestExpenseNonoperating
      contextRef="c20240101to20241231_ConsolidationItemsAxis_MaterialReconcilingItemsMember"
      decimals="-3"
      id="Fact_e69824c701094257952573ea2c6f96e4"
      unitRef="U001">13930000</us-gaap:InterestExpenseNonoperating>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="c20240101to20241231_ConsolidationItemsAxis_MaterialReconcilingItemsMember"
      decimals="-3"
      id="Fact_101b438a3a014300b9e4efd0fb8e66d4"
      unitRef="U001">-1243000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:InvestmentIncomeInterest
      contextRef="c20240101to20241231_ConsolidationItemsAxis_MaterialReconcilingItemsMember"
      decimals="-3"
      id="Fact_4fafbd5689374cf5928875e6d0ed8aae"
      unitRef="U001">2087000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="c20240101to20241231_ConsolidationItemsAxis_CorporateNonSegmentMember"
      decimals="-3"
      id="Fact_cde715de13354b49a38d7dda07a2e372"
      unitRef="U001">-29440000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="c20240101to20241231"
      decimals="-3"
      id="Fact_a04cc9906c7348e7b0a2eeab156d323c"
      unitRef="U001">125714000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:Assets
      contextRef="c20241231_ConsolidationItemsAxis_OperatingSegmentsMember"
      decimals="-3"
      id="Fact_044f824334c94aa3b7f04a9485500d74"
      unitRef="U001">319774000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="c20241231_ConsolidationItemsAxis_CorporateNonSegmentMember"
      decimals="-3"
      id="Fact_098496fadea04070a12725b9411291d8"
      unitRef="U001">168904000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="c20241231"
      decimals="-3"
      id="Fact_f67ce43a57e34a4c854548e5234dc3fa"
      unitRef="U001">488678000</us-gaap:Assets>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20230101to20231231_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_ADMABioManufacturingSegmentMember"
      decimals="-3"
      id="Fact_5f541712d1cf4c89863c736ad162978b"
      unitRef="U001">249738000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20230101to20231231_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PlasmaCollectionCentersSegmentMember"
      decimals="-3"
      id="Fact_aaf13fd70cbf4ff5ae34417fb8f88b3a"
      unitRef="U001">8334000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20230101to20231231_ConsolidationItemsAxis_OperatingSegmentsMember"
      decimals="-3"
      id="Fact_92ccdd883bbe48b6b9a3440706a2ee26"
      unitRef="U001">258072000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfRevenue
      contextRef="c20230101to20231231_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_ADMABioManufacturingSegmentMember"
      decimals="-3"
      id="Fact_28e73ffec29e416582b3e44ea730ad7a"
      unitRef="U001">161157000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="c20230101to20231231_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PlasmaCollectionCentersSegmentMember"
      decimals="-3"
      id="Fact_7ac9fc2044b04078a6a6fbaa5c713db8"
      unitRef="U001">8116000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="c20230101to20231231_ConsolidationItemsAxis_OperatingSegmentsMember"
      decimals="-3"
      id="Fact_2734e10fe9f748bdb5f7b5d9fd32941b"
      unitRef="U001">169273000</us-gaap:CostOfRevenue>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="c20230101to20231231_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_ADMABioManufacturingSegmentMember"
      decimals="-3"
      id="Fact_189c95ebe5d145cdb38a4e62a73582af"
      unitRef="U001">3300000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="c20230101to20231231_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PlasmaCollectionCentersSegmentMember"
      decimals="-3"
      id="Fact_77c0dc3d55d4488cb078bf765b4e3e68"
      unitRef="U001">0</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="c20230101to20231231_ConsolidationItemsAxis_OperatingSegmentsMember"
      decimals="-3"
      id="Fact_e44d2cd5bf9a4d3b9fbef95e80027983"
      unitRef="U001">3300000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:OtherCostAndExpenseOperating
      contextRef="c20230101to20231231_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_ADMABioManufacturingSegmentMember"
      decimals="-3"
      id="Fact_dd0c1c57c89843fbba6af02393ae682c"
      unitRef="U001">0</us-gaap:OtherCostAndExpenseOperating>
    <us-gaap:OtherCostAndExpenseOperating
      contextRef="c20230101to20231231_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PlasmaCollectionCentersSegmentMember"
      decimals="-3"
      id="Fact_13697e8831a045e684bff3f8845960d5"
      unitRef="U001">4266000</us-gaap:OtherCostAndExpenseOperating>
    <us-gaap:OtherCostAndExpenseOperating
      contextRef="c20230101to20231231_ConsolidationItemsAxis_OperatingSegmentsMember"
      decimals="-3"
      id="Fact_d856676e6c4c4e0ebf4cc07c4643efbd"
      unitRef="U001">4266000</us-gaap:OtherCostAndExpenseOperating>
    <us-gaap:SellingAndMarketingExpense
      contextRef="c20230101to20231231_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_ADMABioManufacturingSegmentMember"
      decimals="-3"
      id="Fact_e18eea701fc14e459e13e5511d7c386d"
      unitRef="U001">18407000</us-gaap:SellingAndMarketingExpense>
    <us-gaap:SellingAndMarketingExpense
      contextRef="c20230101to20231231_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PlasmaCollectionCentersSegmentMember"
      decimals="-3"
      id="Fact_50057d6e9d434cd79cd00d0e07f8d25e"
      unitRef="U001">0</us-gaap:SellingAndMarketingExpense>
    <us-gaap:SellingAndMarketingExpense
      contextRef="c20230101to20231231_ConsolidationItemsAxis_OperatingSegmentsMember"
      decimals="-3"
      id="Fact_414d0c803f3c4d41a0a5d05f745a6164"
      unitRef="U001">18407000</us-gaap:SellingAndMarketingExpense>
    <us-gaap:DepreciationAndAmortization
      contextRef="c20230101to20231231_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_ADMABioManufacturingSegmentMember"
      decimals="-3"
      id="Fact_ec797854ac3741e49b482220b27b91d8"
      unitRef="U001">5156000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="c20230101to20231231_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PlasmaCollectionCentersSegmentMember"
      decimals="-3"
      id="Fact_7b56c78b504e464882968bf21d99ff26"
      unitRef="U001">3176000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="c20230101to20231231_ConsolidationItemsAxis_OperatingSegmentsMember"
      decimals="-3"
      id="Fact_fcb614236487426ab7bbd0f6b01be4c0"
      unitRef="U001">8332000</us-gaap:DepreciationAndAmortization>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="c20230101to20231231_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_ADMABioManufacturingSegmentMember"
      decimals="-3"
      id="Fact_628ac3cbb7b04f459f0770a288b62092"
      unitRef="U001">18625000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="c20230101to20231231_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PlasmaCollectionCentersSegmentMember"
      decimals="-3"
      id="Fact_6a6e77cfb1464389890aada2fa65327e"
      unitRef="U001">0</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="c20230101to20231231_ConsolidationItemsAxis_OperatingSegmentsMember"
      decimals="-3"
      id="Fact_46462a3ba98e40fcb80bda530a705a98"
      unitRef="U001">18625000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="c20230101to20231231_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_ADMABioManufacturingSegmentMember"
      decimals="-3"
      id="Fact_2ee8518b832549e3b94020aad6b063bb"
      unitRef="U001">47267000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="c20230101to20231231_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PlasmaCollectionCentersSegmentMember"
      decimals="-3"
      id="Fact_63c03940be574ab0af7fdbb6631b9f2a"
      unitRef="U001">-4049000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="c20230101to20231231_ConsolidationItemsAxis_OperatingSegmentsMember"
      decimals="-3"
      id="Fact_0a5dd9007b0340ac9181f5ca5c512a51"
      unitRef="U001">43218000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:SegmentExpenditureAdditionToLongLivedAssets
      contextRef="c20230101to20231231_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_ADMABioManufacturingSegmentMember"
      decimals="-3"
      id="Fact_f8f78c1912d249afbe4bd053df7f5e9b"
      unitRef="U001">2952000</us-gaap:SegmentExpenditureAdditionToLongLivedAssets>
    <us-gaap:SegmentExpenditureAdditionToLongLivedAssets
      contextRef="c20230101to20231231_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PlasmaCollectionCentersSegmentMember"
      decimals="-3"
      id="Fact_6c0a9b0ac0894aba9ec291c5cb901b96"
      unitRef="U001">1819000</us-gaap:SegmentExpenditureAdditionToLongLivedAssets>
    <us-gaap:SegmentExpenditureAdditionToLongLivedAssets
      contextRef="c20230101to20231231_ConsolidationItemsAxis_OperatingSegmentsMember"
      decimals="-3"
      id="Fact_3416f57f15e042a4a1527af5f5735e02"
      unitRef="U001">4771000</us-gaap:SegmentExpenditureAdditionToLongLivedAssets>
    <us-gaap:Assets
      contextRef="c20231231_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_ADMABioManufacturingSegmentMember"
      decimals="-3"
      id="Fact_8d8d22a697d6490484d2574192cba8ca"
      unitRef="U001">246719000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="c20231231_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PlasmaCollectionCentersSegmentMember"
      decimals="-3"
      id="Fact_d797fcb2c4b74ed780a746116aa4149d"
      unitRef="U001">34733000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="c20231231_ConsolidationItemsAxis_OperatingSegmentsMember"
      decimals="-3"
      id="Fact_d9a64c183218446ab0c8b63acd16f238"
      unitRef="U001">281452000</us-gaap:Assets>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20230101to20231231_ConsolidationItemsAxis_OperatingSegmentsMember"
      decimals="-3"
      id="Fact_fedd377204174df0bb3a7dfa410c9501"
      unitRef="U001">258072000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20230101to20231231_ConsolidationItemsAxis_MaterialReconcilingItemsMember"
      decimals="-3"
      id="Fact_cfefda0de2f345df82ce3633a814b744"
      unitRef="U001">143000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20230101to20231231"
      decimals="-3"
      id="Fact_8c70def57fbc4414ac73f039de0476b4"
      unitRef="U001">258215000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:SellingAndMarketingExpense
      contextRef="c20230101to20231231_ConsolidationItemsAxis_OperatingSegmentsMember"
      decimals="-3"
      id="Fact_10bbaf3f1cb644b2ad9612fe946783de"
      unitRef="U001">18407000</us-gaap:SellingAndMarketingExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="c20230101to20231231_ConsolidationItemsAxis_OperatingSegmentsMember"
      decimals="-3"
      id="Fact_6e7ecc7cc7454800a77f94265ae2fdd0"
      unitRef="U001">18625000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="c20230101to20231231_ConsolidationItemsAxis_CorporateNonSegmentMember"
      decimals="-3"
      id="Fact_1ebee0d4064242ba89bb9e7237a76696"
      unitRef="U001">21988000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="c20230101to20231231"
      decimals="-3"
      id="Fact_ca4d6839999745f2a3ce25d30036a3fe"
      unitRef="U001">59020000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="c20230101to20231231_ConsolidationItemsAxis_OperatingSegmentsMember"
      decimals="-3"
      id="Fact_9e293c19334546728387bfc4030e02a6"
      unitRef="U001">43218000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="c20230101to20231231_ConsolidationItemsAxis_MaterialReconcilingItemsMember"
      decimals="-3"
      id="Fact_744bc2720acb40348cc4c2503eb8ac01"
      unitRef="U001">143000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:InterestExpenseNonoperating
      contextRef="c20230101to20231231_ConsolidationItemsAxis_MaterialReconcilingItemsMember"
      decimals="-3"
      id="Fact_5a4703098c3b4110bea4a7b670315895"
      unitRef="U001">25027000</us-gaap:InterestExpenseNonoperating>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="c20230101to20231231_ConsolidationItemsAxis_MaterialReconcilingItemsMember"
      decimals="-3"
      id="Fact_1eca47fbd2fb4aa0b039c90fd3e6b4ff"
      unitRef="U001">-26174000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:InvestmentIncomeInterest
      contextRef="c20230101to20231231_ConsolidationItemsAxis_MaterialReconcilingItemsMember"
      decimals="-3"
      id="Fact_1f2b517d71d14f6f8848374d9de6d3fd"
      unitRef="U001">1589000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="c20230101to20231231_ConsolidationItemsAxis_CorporateNonSegmentMember"
      decimals="-3"
      id="Fact_59d303f1d98c47bf8afbfb622cfe76d6"
      unitRef="U001">-21988000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="c20230101to20231231"
      decimals="-3"
      id="Fact_75bc1402d2b44c57af4f5a6040f47847"
      unitRef="U001">-28239000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:Assets
      contextRef="c20231231_ConsolidationItemsAxis_OperatingSegmentsMember"
      decimals="-3"
      id="Fact_ac41d72eaf96475dbf5d16581d82ad69"
      unitRef="U001">281452000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="c20231231_ConsolidationItemsAxis_CorporateNonSegmentMember"
      decimals="-3"
      id="Fact_c0dc9246cefd4ef981112d0b8e335383"
      unitRef="U001">47730000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="c20231231"
      decimals="-3"
      id="Fact_e413a6e1252545f2ac7d715724e468ac"
      unitRef="U001">329182000</us-gaap:Assets>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20220101to20221231_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_ADMABioManufacturingSegmentMember"
      decimals="-3"
      id="Fact_f96d1dbcd0134075955b04bbdca12cad"
      unitRef="U001">144070000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20220101to20221231_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PlasmaCollectionCentersSegmentMember"
      decimals="-3"
      id="Fact_d7a716999d1d4f6cb583eecb70b5d7ea"
      unitRef="U001">9867000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20220101to20221231_ConsolidationItemsAxis_OperatingSegmentsMember"
      decimals="-3"
      id="Fact_72336b532f954dcdb84d53ec77305175"
      unitRef="U001">153937000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfRevenue
      contextRef="c20220101to20221231_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_ADMABioManufacturingSegmentMember"
      decimals="-3"
      id="Fact_cf086a75ef524bf69b11a8012be7fc83"
      unitRef="U001">108882000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="c20220101to20221231_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PlasmaCollectionCentersSegmentMember"
      decimals="-3"
      id="Fact_d0fa356c45434ec4b8f546270f40701c"
      unitRef="U001">9933000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="c20220101to20221231_ConsolidationItemsAxis_OperatingSegmentsMember"
      decimals="-3"
      id="Fact_68c77333a7a54c8b860716e338e12c43"
      unitRef="U001">118815000</us-gaap:CostOfRevenue>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="c20220101to20221231_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_ADMABioManufacturingSegmentMember"
      decimals="-3"
      id="Fact_c011512cbed54d61aa377153553876b3"
      unitRef="U001">3614000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="c20220101to20221231_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PlasmaCollectionCentersSegmentMember"
      decimals="-3"
      id="Fact_a4b752a71f5547b5bd41d034637b1cb3"
      unitRef="U001">0</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="c20220101to20221231_ConsolidationItemsAxis_OperatingSegmentsMember"
      decimals="-3"
      id="Fact_fd7d859e097f4834b659fd8daf2625b7"
      unitRef="U001">3614000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:OtherCostAndExpenseOperating
      contextRef="c20220101to20221231_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_ADMABioManufacturingSegmentMember"
      decimals="-3"
      id="Fact_7dd536d22abc4f8eb78c45879b84b53c"
      unitRef="U001">0</us-gaap:OtherCostAndExpenseOperating>
    <us-gaap:OtherCostAndExpenseOperating
      contextRef="c20220101to20221231_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PlasmaCollectionCentersSegmentMember"
      decimals="-3"
      id="Fact_fa0e60b8c05541ef9b745e43e5b8ba2e"
      unitRef="U001">17843000</us-gaap:OtherCostAndExpenseOperating>
    <us-gaap:OtherCostAndExpenseOperating
      contextRef="c20220101to20221231_ConsolidationItemsAxis_OperatingSegmentsMember"
      decimals="-3"
      id="Fact_b662b88ed21645c3829c49430943f68a"
      unitRef="U001">17843000</us-gaap:OtherCostAndExpenseOperating>
    <us-gaap:SellingAndMarketingExpense
      contextRef="c20220101to20221231_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_ADMABioManufacturingSegmentMember"
      decimals="-3"
      id="Fact_cf26603248ed47448a1c16cda7d5e26d"
      unitRef="U001">13667000</us-gaap:SellingAndMarketingExpense>
    <us-gaap:SellingAndMarketingExpense
      contextRef="c20220101to20221231_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PlasmaCollectionCentersSegmentMember"
      decimals="-3"
      id="Fact_13596668ee4f4f79b0f7b653a3fa6088"
      unitRef="U001">0</us-gaap:SellingAndMarketingExpense>
    <us-gaap:SellingAndMarketingExpense
      contextRef="c20220101to20221231_ConsolidationItemsAxis_OperatingSegmentsMember"
      decimals="-3"
      id="Fact_ff99c9c2c0114411a69ab0e70645a877"
      unitRef="U001">13667000</us-gaap:SellingAndMarketingExpense>
    <us-gaap:DepreciationAndAmortization
      contextRef="c20220101to20221231_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_ADMABioManufacturingSegmentMember"
      decimals="-3"
      id="Fact_67fe4ffe95b8427db77c1de051d0fb49"
      unitRef="U001">4709000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="c20220101to20221231_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PlasmaCollectionCentersSegmentMember"
      decimals="-3"
      id="Fact_0a1859b34bb0496f8220534dc30e2a69"
      unitRef="U001">2404000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="c20220101to20221231_ConsolidationItemsAxis_OperatingSegmentsMember"
      decimals="-3"
      id="Fact_d1e6f8e02a7f489298750456aeec56c6"
      unitRef="U001">7113000</us-gaap:DepreciationAndAmortization>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="c20220101to20221231_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_ADMABioManufacturingSegmentMember"
      decimals="-3"
      id="Fact_336f0045a1c04933a1aca2e1e1d15a99"
      unitRef="U001">16312000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="c20220101to20221231_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PlasmaCollectionCentersSegmentMember"
      decimals="-3"
      id="Fact_9af1c560887c46c8a72763338b6274ed"
      unitRef="U001">0</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="c20220101to20221231_ConsolidationItemsAxis_OperatingSegmentsMember"
      decimals="-3"
      id="Fact_b8c7013cb32244ce80a91810a7e84747"
      unitRef="U001">16312000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="c20220101to20221231_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_ADMABioManufacturingSegmentMember"
      decimals="-3"
      id="Fact_eb4f5bf8650a40dda6d35a0f10d940e0"
      unitRef="U001">374000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="c20220101to20221231_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PlasmaCollectionCentersSegmentMember"
      decimals="-3"
      id="Fact_4b835b043227440b94ba4e14b5296fed"
      unitRef="U001">-17911000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="c20220101to20221231_ConsolidationItemsAxis_OperatingSegmentsMember"
      decimals="-3"
      id="Fact_91b3dc9ed1554bd88a7763bc97023bf8"
      unitRef="U001">-17537000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:SegmentExpenditureAdditionToLongLivedAssets
      contextRef="c20220101to20221231_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_ADMABioManufacturingSegmentMember"
      decimals="-3"
      id="Fact_3766fa168232400a9109a827f3b3407f"
      unitRef="U001">5247000</us-gaap:SegmentExpenditureAdditionToLongLivedAssets>
    <us-gaap:SegmentExpenditureAdditionToLongLivedAssets
      contextRef="c20220101to20221231_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PlasmaCollectionCentersSegmentMember"
      decimals="-3"
      id="Fact_56da8687941e4a32a8e20b1f27c49ab9"
      unitRef="U001">8664000</us-gaap:SegmentExpenditureAdditionToLongLivedAssets>
    <us-gaap:SegmentExpenditureAdditionToLongLivedAssets
      contextRef="c20220101to20221231_ConsolidationItemsAxis_OperatingSegmentsMember"
      decimals="-3"
      id="Fact_7f0afb0ea11a47008b50308f09c9e1a6"
      unitRef="U001">13911000</us-gaap:SegmentExpenditureAdditionToLongLivedAssets>
    <us-gaap:Assets
      contextRef="c20221231_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_ADMABioManufacturingSegmentMember"
      decimals="-3"
      id="Fact_ca255aabfbe54b9b98eb0bb30364b145"
      unitRef="U001">238159000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="c20221231_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PlasmaCollectionCentersSegmentMember"
      decimals="-3"
      id="Fact_1823cf8b14a84819a1a8a53c40bfe015"
      unitRef="U001">37071000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="c20221231_ConsolidationItemsAxis_OperatingSegmentsMember"
      decimals="-3"
      id="Fact_f6be072f53fb43638c4767d3ac86dfd6"
      unitRef="U001">275230000</us-gaap:Assets>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20220101to20221231_ConsolidationItemsAxis_OperatingSegmentsMember"
      decimals="-3"
      id="Fact_6453bdfe288e4681b53882fed47d6c4e"
      unitRef="U001">153937000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20220101to20221231_ConsolidationItemsAxis_MaterialReconcilingItemsMember"
      decimals="-3"
      id="Fact_0e65fb9e11d3400791d0cefa87e371e4"
      unitRef="U001">143000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20220101to20221231"
      decimals="-3"
      id="Fact_9ef9c00ce7724e4a96028448ccbf04ac"
      unitRef="U001">154080000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:SellingAndMarketingExpense
      contextRef="c20220101to20221231_ConsolidationItemsAxis_OperatingSegmentsMember"
      decimals="-3"
      id="Fact_4f3bb5e71b55455cbb14cc756fadfcab"
      unitRef="U001">13667000</us-gaap:SellingAndMarketingExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="c20220101to20221231_ConsolidationItemsAxis_OperatingSegmentsMember"
      decimals="-3"
      id="Fact_130fdb769184487eafd388e0df0668ad"
      unitRef="U001">16312000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="c20220101to20221231_ConsolidationItemsAxis_CorporateNonSegmentMember"
      decimals="-3"
      id="Fact_d50c136af3e64211860c504c901e8c64"
      unitRef="U001">22479000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="c20220101to20221231"
      decimals="-3"
      id="Fact_c2cf3e4b09b54d979b956374a9c5f0fd"
      unitRef="U001">52458000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="c20220101to20221231_ConsolidationItemsAxis_OperatingSegmentsMember"
      decimals="-3"
      id="Fact_7209d793b2994319b95fe9ef251f3e2d"
      unitRef="U001">-17537000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="c20220101to20221231_ConsolidationItemsAxis_MaterialReconcilingItemsMember"
      decimals="-3"
      id="Fact_6bb98e9f0a4844c1b5baac97ac44ad13"
      unitRef="U001">143000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:InterestExpenseNonoperating
      contextRef="c20220101to20221231_ConsolidationItemsAxis_MaterialReconcilingItemsMember"
      decimals="-3"
      id="Fact_09db89ae53b8440ab284f78e50c79e5b"
      unitRef="U001">19276000</us-gaap:InterestExpenseNonoperating>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="c20220101to20221231_ConsolidationItemsAxis_MaterialReconcilingItemsMember"
      decimals="-3"
      id="Fact_60450abc58df4411a8d9b2e7cf2fd1ca"
      unitRef="U001">-6670000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="c20220101to20221231_ConsolidationItemsAxis_OperatingSegmentsMember"
      decimals="-3"
      id="Fact_1702eb25c5774d3181942a7c1ee87126"
      unitRef="U001">-85000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="c20220101to20221231_ConsolidationItemsAxis_CorporateNonSegmentMember"
      decimals="-3"
      id="Fact_4dc192bb6874460db027219d6a8cbdc1"
      unitRef="U001">-22479000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="c20220101to20221231"
      decimals="-3"
      id="Fact_dc87a1ba197a49558c968cf461149ec5"
      unitRef="U001">-65904000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:Assets
      contextRef="c20221231_ConsolidationItemsAxis_OperatingSegmentsMember"
      decimals="-3"
      id="Fact_77ad8e25bc79486f937301c3ec7a7c1a"
      unitRef="U001">275230000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="c20221231_ConsolidationItemsAxis_CorporateNonSegmentMember"
      decimals="-3"
      id="Fact_92e4d85a8785438787156b3774d98556"
      unitRef="U001">73231000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="c20221231"
      decimals="-3"
      id="Fact_22b4ad4fed9242b39e838a90f901879f"
      unitRef="U001">348461000</us-gaap:Assets>
    <us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock
      contextRef="c20240101to20241231"
      id="Text_ecd64bba03eb424597eb6fcf5ab856c7">
&lt;div style="display:none;"&gt;&lt;br/&gt;&lt;/div&gt;
&lt;div style="text-align: left; text-indent: 36pt; font-family: 'Times New Roman'; font-size: 10pt;"&gt;Net revenues according to geographic area, based on the location of where the product is shipped, are as follows:&lt;/div&gt;

&lt;div&gt;&lt;br/&gt;
            &lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%; border-spacing: 0;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="18" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                    &lt;div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"&gt;Year Ended December 31, 2024&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"&gt;ADMA &lt;/div&gt;
                    &lt;div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"&gt;BioManufacturing&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"&gt;Plasma Centers&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"&gt;Total Segment &lt;/div&gt;
                    &lt;div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"&gt;Revenue&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"&gt;License &lt;/div&gt;
                    &lt;div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"&gt;Revenue&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"&gt;Consolidated &lt;/div&gt;
                    &lt;div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"&gt;Revenue&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 40%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"&gt;United States&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;$&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;400,336&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;$&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;9,669&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;$&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;410,005&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;$&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;143&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;$&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;410,148&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 40%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"&gt;International&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;15,470&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;836&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;16,306&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;-&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;16,306&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 40%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"&gt;Total revenues&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;$&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;415,806&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;$&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;10,505&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;$&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;426,311&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;$&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;143&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;$&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;426,454&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div&gt;&lt;br/&gt;
            &lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%; border-spacing: 0;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="18" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                    &lt;div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"&gt;Year Ended December 31, 2023&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"&gt;ADMA &lt;/div&gt;
                    &lt;div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"&gt;BioManufacturing&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"&gt;Plasma Centers&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"&gt;Total Segment &lt;/div&gt;
                    &lt;div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"&gt;Revenue&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"&gt;License &lt;/div&gt;
                    &lt;div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"&gt;Revenue&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"&gt;Consolidated &lt;/div&gt;
                    &lt;div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"&gt;Revenue&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 40%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"&gt;United States&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;$&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;237,454&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;$&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;7,284&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;$&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;244,738&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;$&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;143&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;$&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;244,881&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 40%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"&gt;International&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;12,284&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;1,050&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;13,334&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;-&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;13,334&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 40%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"&gt;Total revenues&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;$&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;249,738&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;$&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;8,334&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;$&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;258,072&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;$&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;143&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;$&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;258,215&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;

&lt;div&gt;&lt;br/&gt;
            &lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%; border-spacing: 0;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="18" style="vertical-align: bottom; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                    &lt;div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"&gt;Year Ended December 31, 2022&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"&gt;ADMA &lt;/div&gt;
                    &lt;div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"&gt;BioManufacturing&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"&gt;Plasma Centers&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"&gt;Total Segment &lt;/div&gt;
                    &lt;div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"&gt;Revenue&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"&gt;License &lt;/div&gt;
                    &lt;div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"&gt;Revenue&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"&gt;Consolidated &lt;/div&gt;
                    &lt;div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"&gt;Revenue&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 40%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"&gt;United States&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;$&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;136,827&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;$&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;9,457&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;$&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;146,284&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;$&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;143&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;$&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;146,427&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 40%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"&gt;International&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;7,243&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;410&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;7,653&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;-&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;7,653&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: bottom; width: 40%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"&gt;Total revenues&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;$&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;144,070&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;$&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;9,867&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;$&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;153,937&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;$&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;143&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;$&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: #000000 double 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
                    &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;154,080&lt;/div&gt;
                  &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
</us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20240101to20241231_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_ADMABioManufacturingSegmentMember_StatementGeographicalAxis_US"
      decimals="-3"
      id="Fact_1ee5c7750fee4a309a3c1072332325e7"
      unitRef="U001">400336000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20240101to20241231_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PlasmaCollectionCentersSegmentMember_StatementGeographicalAxis_US"
      decimals="-3"
      id="Fact_06bb92271c774c7db3be9bc65672b196"
      unitRef="U001">9669000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20240101to20241231_ConsolidationItemsAxis_OperatingSegmentsMember_StatementGeographicalAxis_US"
      decimals="-3"
      id="Fact_8634c730e39b423a82a243592aa311c7"
      unitRef="U001">410005000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20240101to20241231_ConsolidationItemsAxis_MaterialReconcilingItemsMember_StatementGeographicalAxis_US"
      decimals="-3"
      id="Fact_137825885e454d5ba7cbb255939c4a6c"
      unitRef="U001">143000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20240101to20241231_StatementGeographicalAxis_US"
      decimals="-3"
      id="Fact_de6a386d5581405dbce900eeece23f0e"
      unitRef="U001">410148000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20240101to20241231_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_ADMABioManufacturingSegmentMember_StatementGeographicalAxis_NonUsMember"
      decimals="-3"
      id="Fact_1f2de7f70a154db58e6281f1ee32956a"
      unitRef="U001">15470000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20240101to20241231_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PlasmaCollectionCentersSegmentMember_StatementGeographicalAxis_NonUsMember"
      decimals="-3"
      id="Fact_af6bb08259de4e8eb02751466f21ba52"
      unitRef="U001">836000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20240101to20241231_ConsolidationItemsAxis_OperatingSegmentsMember_StatementGeographicalAxis_NonUsMember"
      decimals="-3"
      id="Fact_e30b5a28a13c4e29ae7976594b5c1695"
      unitRef="U001">16306000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20240101to20241231_ConsolidationItemsAxis_MaterialReconcilingItemsMember_StatementGeographicalAxis_NonUsMember"
      decimals="-3"
      id="Fact_caf25de36915484a81c7bc2be4247f83"
      unitRef="U001">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20240101to20241231_StatementGeographicalAxis_NonUsMember"
      decimals="-3"
      id="Fact_b48ef3b4f5a34ef58fc99c316f76eb0b"
      unitRef="U001">16306000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20240101to20241231_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_ADMABioManufacturingSegmentMember"
      decimals="-3"
      id="Fact_96dce6ab5b7747ac92d3715d2282daa3"
      unitRef="U001">415806000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20240101to20241231_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PlasmaCollectionCentersSegmentMember"
      decimals="-3"
      id="Fact_b5cf992908704ac8959dc605894ecbf9"
      unitRef="U001">10505000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20240101to20241231_ConsolidationItemsAxis_OperatingSegmentsMember"
      decimals="-3"
      id="Fact_941188c6e74e4318bdc858ebdd9a1d4d"
      unitRef="U001">426311000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20240101to20241231_ConsolidationItemsAxis_MaterialReconcilingItemsMember"
      decimals="-3"
      id="Fact_354a9b038dfa4c6ead3b7c7217e41981"
      unitRef="U001">143000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20240101to20241231"
      decimals="-3"
      id="Fact_7dd1ac4efffb4f019e711dc76d0973b5"
      unitRef="U001">426454000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20230101to20231231_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_ADMABioManufacturingSegmentMember_StatementGeographicalAxis_US"
      decimals="-3"
      id="Fact_ae2744628c9444c7ad5745b01ff041fe"
      unitRef="U001">237454000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20230101to20231231_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PlasmaCollectionCentersSegmentMember_StatementGeographicalAxis_US"
      decimals="-3"
      id="Fact_1c1a22a3d5ab47d6af3f68d64a1b56be"
      unitRef="U001">7284000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20230101to20231231_ConsolidationItemsAxis_OperatingSegmentsMember_StatementGeographicalAxis_US"
      decimals="-3"
      id="Fact_aa444822605d42568890bf98641dfbdb"
      unitRef="U001">244738000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20230101to20231231_ConsolidationItemsAxis_MaterialReconcilingItemsMember_StatementGeographicalAxis_US"
      decimals="-3"
      id="Fact_00ccb6c323d0491485f7dd1b9b8e5bd9"
      unitRef="U001">143000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20230101to20231231_StatementGeographicalAxis_US"
      decimals="-3"
      id="Fact_6f0a386b81944a6088da937db876f6e9"
      unitRef="U001">244881000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20230101to20231231_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_ADMABioManufacturingSegmentMember_StatementGeographicalAxis_NonUsMember"
      decimals="-3"
      id="Fact_85370041d8ca4aa8966aeebf89c3c533"
      unitRef="U001">12284000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20230101to20231231_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PlasmaCollectionCentersSegmentMember_StatementGeographicalAxis_NonUsMember"
      decimals="-3"
      id="Fact_32ca595dee9844c9b9f951139c2f22ee"
      unitRef="U001">1050000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20230101to20231231_ConsolidationItemsAxis_OperatingSegmentsMember_StatementGeographicalAxis_NonUsMember"
      decimals="-3"
      id="Fact_a1bf8fdff1134f3f915c86dcca8483a3"
      unitRef="U001">13334000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20230101to20231231_ConsolidationItemsAxis_MaterialReconcilingItemsMember_StatementGeographicalAxis_NonUsMember"
      decimals="-3"
      id="Fact_a69eba547a7541dda2a3f10deaf215b8"
      unitRef="U001">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20230101to20231231_StatementGeographicalAxis_NonUsMember"
      decimals="-3"
      id="Fact_0f19cc0475b849f3983cd60e444df5f7"
      unitRef="U001">13334000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20230101to20231231_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_ADMABioManufacturingSegmentMember"
      decimals="-3"
      id="Fact_11adb00d4888498f9d09e9bba9831a76"
      unitRef="U001">249738000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20230101to20231231_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PlasmaCollectionCentersSegmentMember"
      decimals="-3"
      id="Fact_8cb7c0779a6c4f0e8225323591e0bd84"
      unitRef="U001">8334000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20230101to20231231_ConsolidationItemsAxis_OperatingSegmentsMember"
      decimals="-3"
      id="Fact_4ca9d6ab04644187b6e5a6cb960f5113"
      unitRef="U001">258072000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20230101to20231231_ConsolidationItemsAxis_MaterialReconcilingItemsMember"
      decimals="-3"
      id="Fact_02b6f09cc3104aa5bb8c4be8574eb355"
      unitRef="U001">143000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20230101to20231231"
      decimals="-3"
      id="Fact_21fc46a934434d858e98c9e75612f21b"
      unitRef="U001">258215000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20220101to20221231_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_ADMABioManufacturingSegmentMember_StatementGeographicalAxis_US"
      decimals="-3"
      id="Fact_843bdf3c4c584e3c97a2254308f05beb"
      unitRef="U001">136827000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20220101to20221231_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PlasmaCollectionCentersSegmentMember_StatementGeographicalAxis_US"
      decimals="-3"
      id="Fact_d3cb8c72d3b04decb7835a2b2678f866"
      unitRef="U001">9457000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20220101to20221231_ConsolidationItemsAxis_OperatingSegmentsMember_StatementGeographicalAxis_US"
      decimals="-3"
      id="Fact_d49112fdda4e436abb0a50413e287a4a"
      unitRef="U001">146284000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20220101to20221231_ConsolidationItemsAxis_MaterialReconcilingItemsMember_StatementGeographicalAxis_US"
      decimals="-3"
      id="Fact_b3616a6718854a9187fe4e5de5094ffb"
      unitRef="U001">143000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20220101to20221231_StatementGeographicalAxis_US"
      decimals="-3"
      id="Fact_fbc73f6ecc8640829af21068d586954d"
      unitRef="U001">146427000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20220101to20221231_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_ADMABioManufacturingSegmentMember_StatementGeographicalAxis_NonUsMember"
      decimals="-3"
      id="Fact_01d08f2030114af3941788677713adf6"
      unitRef="U001">7243000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20220101to20221231_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PlasmaCollectionCentersSegmentMember_StatementGeographicalAxis_NonUsMember"
      decimals="-3"
      id="Fact_a06d48a011284af4beaa946bcbb0bfce"
      unitRef="U001">410000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20220101to20221231_ConsolidationItemsAxis_OperatingSegmentsMember_StatementGeographicalAxis_NonUsMember"
      decimals="-3"
      id="Fact_58a4cd68080c4d11a67e35eae87f0d93"
      unitRef="U001">7653000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20220101to20221231_ConsolidationItemsAxis_MaterialReconcilingItemsMember_StatementGeographicalAxis_NonUsMember"
      decimals="-3"
      id="Fact_c9175b1ed2424b308053acc0a0bf5e3b"
      unitRef="U001">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20220101to20221231_StatementGeographicalAxis_NonUsMember"
      decimals="-3"
      id="Fact_54b05a920a134f9596367c8237b4cf46"
      unitRef="U001">7653000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20220101to20221231_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_ADMABioManufacturingSegmentMember"
      decimals="-3"
      id="Fact_906425153b154ba58d66b7683d51c743"
      unitRef="U001">144070000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20220101to20221231_ConsolidationItemsAxis_OperatingSegmentsMember_StatementBusinessSegmentsAxis_PlasmaCollectionCentersSegmentMember"
      decimals="-3"
      id="Fact_685fd1406a5c4d85855aac60e13b87b5"
      unitRef="U001">9867000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20220101to20221231_ConsolidationItemsAxis_OperatingSegmentsMember"
      decimals="-3"
      id="Fact_73ed5a0a23cc464db11e317f40a035c5"
      unitRef="U001">153937000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20220101to20221231_ConsolidationItemsAxis_MaterialReconcilingItemsMember"
      decimals="-3"
      id="Fact_34ccb488ca224416b690c3c5f9703f68"
      unitRef="U001">143000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="c20220101to20221231"
      decimals="-3"
      id="Fact_b1d18e6546e34c7f931c61daa9f70bed"
      unitRef="U001">154080000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock
      contextRef="c20240101to20241231"
      id="Text_3cd31721beed4c10b4a1000d193d1350">
&lt;div&gt;
          &lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt; border-spacing: 0;"&gt;


  &lt;tr style="vertical-align: top;"&gt;

    &lt;td style="vertical-align: top; width: 27pt;"&gt;
                  &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: justify;"&gt;&lt;strong&gt;14.&lt;/strong&gt;&lt;/p&gt;
                &lt;/td&gt;

    &lt;td style="vertical-align: top; width: auto;"&gt;
                  &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: justify;"&gt;&lt;span style="text-decoration: underline;"&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;strong&gt;OTHER EMPLOYEE BENEFITS&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;strong&gt;&lt;span style="text-decoration: underline;"&gt;&lt;br/&gt;
                      &lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;
                &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
        &lt;/div&gt;
&lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: justify;"&gt;&#160;&lt;/p&gt;&lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-indent: 45px; text-align: justify;"&gt;The Company sponsors a 401(k) savings plan. Under the plan, employees may make contributions which are eligible for a Company
          discretionary percentage contribution as defined in the plan and determined by the Board. The Company recognized $1.5 million, $1.3 million and $1.3 million of related
          compensation expense for the years ended December 31, 2024, 2023 and 2022, respectively.&lt;/p&gt;</us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount
      contextRef="c20240101to20241231"
      decimals="-5"
      id="Fact_908e4bf201b340c7bd552e08905a32f8"
      unitRef="U001">1500000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount
      contextRef="c20230101to20231231"
      decimals="-5"
      id="Fact_0bce84e1f695468c91641ccddb33de83"
      unitRef="U001">1300000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount
      contextRef="c20220101to20221231"
      decimals="-5"
      id="Fact_4cdc3d10cb3c462282162b7857f66dc9"
      unitRef="U001">1300000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <us-gaap:CashFlowSupplementalDisclosuresTextBlock
      contextRef="c20240101to20241231"
      id="Text_a3169a60a8a94cd78a7b2bec3d6f21dd">
&lt;div&gt;
          &lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt; border-spacing: 0;"&gt;


  &lt;tr style="vertical-align: top;"&gt;

    &lt;td style="vertical-align: top; width: 27pt;"&gt;
                  &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;"&gt;&lt;strong&gt;15.&lt;/strong&gt;&lt;/p&gt;
                &lt;/td&gt;

    &lt;td style="align: left; vertical-align: top; width: auto;"&gt;
                  &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;"&gt;&lt;span style="text-decoration: underline;"&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;strong&gt;SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;strong&gt;&lt;span style="text-decoration: underline;"&gt;&lt;br/&gt;
                      &lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;
                &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
        &lt;/div&gt;
&lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;"&gt;&#160;&lt;/p&gt;&lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-indent: 45px; text-align: justify;"&gt;Supplemental cash flow information for the years ended December 31, 2024, 2023 and 2022 is as follows:&lt;/p&gt;&lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px;"&gt;&#160; &lt;br/&gt;
        &lt;/p&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="text-align: left; font: 10pt 'Times New Roman'; width: 100%; border-spacing: 0;"&gt;


  &lt;tr style="height: 15px;"&gt;

    &lt;td style="padding-bottom: 2px;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: center;"&gt;&lt;strong&gt;2024&lt;/strong&gt;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: center;"&gt;&lt;strong&gt;2023&lt;/strong&gt;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;&lt;span style="font-weight: bold;"&gt;2022&lt;/span&gt;&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td rowspan="1" style="vertical-align: top;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="10" rowspan="1" style="text-align: center;" valign="bottom"&gt;&lt;span style="font-style: italic;"&gt;(In thousands)&lt;/span&gt;&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td style="vertical-align: top;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in;"&gt;&lt;strong&gt;SUPPLEMENTAL CASH FLOW INFORMATION:&lt;/strong&gt;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td style="vertical-align: top; width: 64%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 15px;"&gt;Cash paid for interest&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 4px double rgb(0, 0, 0);" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 4px double rgb(0, 0, 0);" valign="bottom"&gt;10,668&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 4px double rgb(0, 0, 0);" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 4px double rgb(0, 0, 0);" valign="bottom"&gt;18,051&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;13,880&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td rowspan="1" style="margin-top: 0px; margin-right: 0px; margin-bottom: 0px; vertical-align: top; width: 64%; padding: 0px 0px 4px; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;
                &lt;div style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 15px;"&gt;Cash paid for income taxes&lt;br/&gt;
                &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom"&gt;9,392&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom"&gt;$&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom"&gt;-&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;$&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;-&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td style="vertical-align: top; width: 64%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in;"&gt;&lt;strong&gt;Noncash Financing and Investing Activities:&lt;/strong&gt;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td style="vertical-align: top; width: 64%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 15px;"&gt;Equipment acquired reflected in accounts payable and accrued liabilities&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom"&gt;725&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom"&gt;86&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;1,495&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td style="vertical-align: top; width: 64%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 15px;"&gt;Right-to-use assets in exchange for lease obligations&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom"&gt;-&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom"&gt;130&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;4,048&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td style="vertical-align: top; width: 64%; padding-bottom: 4px;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 15px;"&gt;Warrants issued in connection with notes payable&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom"&gt;-&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom"&gt;5,595&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;9,570&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
&lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: left;"&gt; &lt;br/&gt;
        &lt;/p&gt;&lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: justify;"&gt;See Note 8 and the Consolidated Statement of Stockholders&#x2019; Equity for cashless exercise activity related to the Company&#x2019;s outstanding warrants.&lt;br/&gt;
        &lt;/p&gt;</us-gaap:CashFlowSupplementalDisclosuresTextBlock>
    <us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock
      contextRef="c20240101to20241231"
      id="Text_58f4837d87a74351b86e2556e60e2456">&lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-indent: 45px; text-align: justify;"&gt;Supplemental cash flow information for the years ended December 31, 2024, 2023 and 2022 is as follows:&lt;/p&gt;&lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px;"&gt;&#160; &lt;br/&gt;
        &lt;/p&gt;
&lt;table border="0" cellpadding="0" cellspacing="0" class="cfttable" style="text-align: left; font: 10pt 'Times New Roman'; width: 100%; border-spacing: 0;"&gt;


  &lt;tr style="height: 15px;"&gt;

    &lt;td style="padding-bottom: 2px;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px;"&gt;&#160;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: center;"&gt;&lt;strong&gt;2024&lt;/strong&gt;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in; text-align: center;"&gt;&lt;strong&gt;2023&lt;/strong&gt;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="text-align: center; vertical-align: bottom; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;&lt;span style="font-weight: bold;"&gt;2022&lt;/span&gt;&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td rowspan="1" style="vertical-align: top;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="10" rowspan="1" style="text-align: center;" valign="bottom"&gt;&lt;span style="font-style: italic;"&gt;(In thousands)&lt;/span&gt;&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td style="vertical-align: top;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in;"&gt;&lt;strong&gt;SUPPLEMENTAL CASH FLOW INFORMATION:&lt;/strong&gt;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td style="vertical-align: top; width: 64%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 15px;"&gt;Cash paid for interest&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 4px double rgb(0, 0, 0);" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 4px double rgb(0, 0, 0);" valign="bottom"&gt;10,668&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 4px double rgb(0, 0, 0);" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 4px double rgb(0, 0, 0);" valign="bottom"&gt;18,051&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;13,880&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td rowspan="1" style="margin-top: 0px; margin-right: 0px; margin-bottom: 0px; vertical-align: top; width: 64%; padding: 0px 0px 4px; font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;
                &lt;div style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 15px;"&gt;Cash paid for income taxes&lt;br/&gt;
                &lt;/div&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom"&gt;9,392&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom"&gt;$&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom"&gt;-&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;$&lt;br/&gt;
              &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;-&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td style="vertical-align: top; width: 64%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 0in;"&gt;&lt;strong&gt;Noncash Financing and Investing Activities:&lt;/strong&gt;&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td style="vertical-align: top; width: 64%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 15px;"&gt;Equipment acquired reflected in accounts payable and accrued liabilities&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom"&gt;725&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom"&gt;86&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;1,495&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td style="vertical-align: top; width: 64%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 15px;"&gt;Right-to-use assets in exchange for lease obligations&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom"&gt;-&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255);" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255);" valign="bottom"&gt;130&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;4,048&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; background-color: rgb(204, 238, 255); white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr style="height: 15px;"&gt;

    &lt;td style="vertical-align: top; width: 64%; padding-bottom: 4px;" valign="bottom"&gt;
                &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px 0px 0px 15px;"&gt;Warrants issued in connection with notes payable&lt;/p&gt;
              &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom"&gt;-&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0);" valign="bottom"&gt;5,595&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;$&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; border-bottom: 4px double rgb(0, 0, 0); white-space: nowrap;" valign="bottom"&gt;9,570&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; padding-bottom: 4px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
</us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock>
    <us-gaap:InterestPaidNet
      contextRef="c20240101to20241231"
      decimals="-3"
      id="Fact_4a525ff0c80e43f58988c822ab60e287"
      unitRef="U001">10668000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="c20230101to20231231"
      decimals="-3"
      id="Fact_99fd1ea3714e4d46a51fa745d7bac75f"
      unitRef="U001">18051000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="c20220101to20221231"
      decimals="-3"
      id="Fact_dd2758a535864f2c91d27c178b6adf42"
      unitRef="U001">13880000</us-gaap:InterestPaidNet>
    <us-gaap:IncomeTaxesPaid
      contextRef="c20240101to20241231"
      decimals="-3"
      id="Fact_2b8b19ea0d9345c3b8187482d30ad2ae"
      unitRef="U001">9392000</us-gaap:IncomeTaxesPaid>
    <us-gaap:IncomeTaxesPaid
      contextRef="c20230101to20231231"
      decimals="-3"
      id="Fact_58eb88de6ba54f75b6bc96f39fd71203"
      unitRef="U001">0</us-gaap:IncomeTaxesPaid>
    <us-gaap:IncomeTaxesPaid
      contextRef="c20220101to20221231"
      decimals="-3"
      id="Fact_90fb5cc803e84d158364024f61a2eff6"
      unitRef="U001">0</us-gaap:IncomeTaxesPaid>
    <adma:EquipmentAcquiredReflectedInAccountsPayableAndAccruedLiabilities
      contextRef="c20240101to20241231"
      decimals="-3"
      id="Fact_76924ad22184411794ed62eb9e340806"
      unitRef="U001">725000</adma:EquipmentAcquiredReflectedInAccountsPayableAndAccruedLiabilities>
    <adma:EquipmentAcquiredReflectedInAccountsPayableAndAccruedLiabilities
      contextRef="c20230101to20231231"
      decimals="-3"
      id="Fact_ffd9b6e8fc6a4782b7ee4985fdda9a5a"
      unitRef="U001">86000</adma:EquipmentAcquiredReflectedInAccountsPayableAndAccruedLiabilities>
    <adma:EquipmentAcquiredReflectedInAccountsPayableAndAccruedLiabilities
      contextRef="c20220101to20221231"
      decimals="-3"
      id="Fact_9704a17cdfd844a087b67d7bbb9be391"
      unitRef="U001">1495000</adma:EquipmentAcquiredReflectedInAccountsPayableAndAccruedLiabilities>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="c20240101to20241231"
      decimals="-3"
      id="Fact_9f857909992945ea8430ade00020ce34"
      unitRef="U001">0</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="c20230101to20231231"
      decimals="-3"
      id="Fact_89c1484f56134d769e2216939cf54236"
      unitRef="U001">130000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="c20220101to20221231"
      decimals="-3"
      id="Fact_dedbeb1b146d4693b1634571e1703694"
      unitRef="U001">4048000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <adma:WarrantsIssuedInConnectionWithNotesPayable
      contextRef="c20240101to20241231"
      decimals="-3"
      id="Fact_e994d22c6f4a491483c9560861474db1"
      unitRef="U001">0</adma:WarrantsIssuedInConnectionWithNotesPayable>
    <adma:WarrantsIssuedInConnectionWithNotesPayable
      contextRef="c20230101to20231231"
      decimals="-3"
      id="Fact_33cd574a6b1343b394fae8971ab893e3"
      unitRef="U001">5595000</adma:WarrantsIssuedInConnectionWithNotesPayable>
    <adma:WarrantsIssuedInConnectionWithNotesPayable
      contextRef="c20220101to20221231"
      decimals="-3"
      id="Fact_2161baabf73e4648a31d2e83f18ecbfa"
      unitRef="U001">9570000</adma:WarrantsIssuedInConnectionWithNotesPayable>
    <us-gaap:ConcentrationRiskDisclosureTextBlock
      contextRef="c20240101to20241231"
      id="Text_3e54a7496f0a43cdb3963175ff4e5c11">
&lt;div&gt;
          &lt;table cellpadding="0" cellspacing="0" class="DSPFListTable" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt; border-spacing: 0;"&gt;


  &lt;tr style="vertical-align: top;"&gt;

    &lt;td style="vertical-align: top; width: 27pt;"&gt;
                  &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: justify;"&gt;&lt;strong&gt;16.&lt;/strong&gt;&lt;/p&gt;
                &lt;/td&gt;

    &lt;td style="vertical-align: top; width: auto;"&gt;
                  &lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: justify;"&gt;&lt;span style="text-decoration: underline;"&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: bold; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;&lt;strong&gt;CONCENTRATIONS&lt;/strong&gt;&lt;/span&gt;&lt;/span&gt;&lt;strong&gt;&lt;span style="text-decoration: underline;"&gt;&lt;br/&gt;
                      &lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;
                &lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
        &lt;/div&gt;
&lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-align: justify;"&gt;&#160;&lt;/p&gt;&lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-indent: 45px; text-align: justify;"&gt;Financial instruments that potentially subject the Company to concentrations of credit risk consist of accounts receivable. At December
          31, 2024, three customers accounted for approximately 91% of the Company&#x2019;s consolidated accounts receivable. At December 31, 2023, five
          customers accounted for approximately 98% of the Company&#x2019;s consolidated accounts receivable. &lt;/p&gt;&lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-indent: 45px; text-align: justify;"&gt;&#160;&lt;/p&gt;&lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-indent: 45px; text-align: justify;"&gt;&lt;span style="background-color: rgb(255, 255, 255); font-weight: normal; color: rgb(0, 0, 0); font-family: 'Times New Roman'; font-size: 10pt; font-style: normal; font-variant: normal; text-transform: none;"&gt;For the years ended December 31, 2024 and 2023, two
            customers accounted for approximately 72% of the Company&#x2019;s consolidated revenues. For the year ended December 31, 2022, two customers accounted for approximately 74%
            of the Company&#x2019;s consolidated revenues. &lt;/span&gt;Revenues for both of these customers are attributable to the ADMA BioManufacturing business segment. There were no customers attributable to the Plasma Collections Center whose revenues exceeded 10%
          of the Company&#x2019;s consolidated revenues.&lt;/p&gt;&lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-indent: 45px;"&gt; &lt;/p&gt;&lt;p style="font-size: 10pt; font-family: 'Times New Roman'; margin: 0px; text-indent: 45px;"&gt; &lt;/p&gt;</us-gaap:ConcentrationRiskDisclosureTextBlock>
    <adma:NumberOfCustomers
      contextRef="c20240101to20241231_ConcentrationRiskByBenchmarkAxis_AccountsReceivableMember_ConcentrationRiskByTypeAxis_CustomerConcentrationRiskMember_MajorCustomersAxis_ThreeCustomersMember"
      decimals="INF"
      id="Fact_2bebdde6141c4f9c818adec260eee322"
      unitRef="U015">3</adma:NumberOfCustomers>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="c20240101to20241231_ConcentrationRiskByBenchmarkAxis_AccountsReceivableMember_ConcentrationRiskByTypeAxis_CustomerConcentrationRiskMember_MajorCustomersAxis_ThreeCustomersMember"
      decimals="2"
      id="Fact_18bf48e919824ece9bba44680810f61d"
      unitRef="U007">0.91</us-gaap:ConcentrationRiskPercentage1>
    <adma:NumberOfCustomers
      contextRef="c20230101to20231231_ConcentrationRiskByBenchmarkAxis_AccountsReceivableMember_ConcentrationRiskByTypeAxis_CustomerConcentrationRiskMember_MajorCustomersAxis_FiveCustomersMember"
      decimals="INF"
      id="Fact_bd8cfb783db6405daf51983e9a3f754f"
      unitRef="U015">5</adma:NumberOfCustomers>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="c20230101to20231231_ConcentrationRiskByBenchmarkAxis_AccountsReceivableMember_ConcentrationRiskByTypeAxis_CustomerConcentrationRiskMember_MajorCustomersAxis_FiveCustomersMember"
      decimals="2"
      id="Fact_c551604aa2e2480dbedacd3e37919985"
      unitRef="U007">0.98</us-gaap:ConcentrationRiskPercentage1>
    <adma:NumberOfCustomers
      contextRef="c20240101to20241231_ConcentrationRiskByBenchmarkAxis_RevenueFromContractWithCustomerProductAndServiceBenchmarkMember_ConcentrationRiskByTypeAxis_CustomerConcentrationRiskMember_MajorCustomersAxis_TwoCustomersMember"
      decimals="INF"
      id="Fact_8cb86e38e581476e9a432907773422fe"
      unitRef="U015">2</adma:NumberOfCustomers>
    <adma:NumberOfCustomers
      contextRef="c20230101to20231231_ConcentrationRiskByBenchmarkAxis_RevenueFromContractWithCustomerProductAndServiceBenchmarkMember_ConcentrationRiskByTypeAxis_CustomerConcentrationRiskMember_MajorCustomersAxis_TwoCustomersMember"
      decimals="INF"
      id="Fact_232e6e8dd2dd434ba4029c5f343226dd"
      unitRef="U015">2</adma:NumberOfCustomers>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="c20240101to20241231_ConcentrationRiskByBenchmarkAxis_RevenueFromContractWithCustomerProductAndServiceBenchmarkMember_ConcentrationRiskByTypeAxis_CustomerConcentrationRiskMember_MajorCustomersAxis_TwoCustomersMember"
      decimals="2"
      id="Fact_8d29ce6d85e644fabd9eaec4c3c694ef"
      unitRef="U007">0.72</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="c20230101to20231231_ConcentrationRiskByBenchmarkAxis_RevenueFromContractWithCustomerProductAndServiceBenchmarkMember_ConcentrationRiskByTypeAxis_CustomerConcentrationRiskMember_MajorCustomersAxis_TwoCustomersMember"
      decimals="2"
      id="Fact_59d310872f5448c59a70c578a52fe947"
      unitRef="U007">0.72</us-gaap:ConcentrationRiskPercentage1>
    <adma:NumberOfCustomers
      contextRef="c20220101to20221231_ConcentrationRiskByBenchmarkAxis_RevenueFromContractWithCustomerProductAndServiceBenchmarkMember_ConcentrationRiskByTypeAxis_CustomerConcentrationRiskMember_MajorCustomersAxis_TwoCustomersMember"
      decimals="INF"
      id="Fact_cfd8dc0f35c24632ab9a11bd4107aa29"
      unitRef="U015">2</adma:NumberOfCustomers>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="c20220101to20221231_ConcentrationRiskByBenchmarkAxis_RevenueFromContractWithCustomerProductAndServiceBenchmarkMember_ConcentrationRiskByTypeAxis_CustomerConcentrationRiskMember_MajorCustomersAxis_TwoCustomersMember"
      decimals="2"
      id="Fact_719e27d732a045c9aa60db1639cf2b9f"
      unitRef="U007">0.74</us-gaap:ConcentrationRiskPercentage1>
    <adma:NumberOfCustomers
      contextRef="c20240101to20241231_ConcentrationRiskByBenchmarkAxis_RevenueFromContractWithCustomerProductAndServiceBenchmarkMember_ConcentrationRiskByTypeAxis_CustomerConcentrationRiskMember_StatementBusinessSegmentsAxis_PlasmaCollectionCentersSegmentMember"
      decimals="INF"
      id="Fact_96a4f4ff21b94d958584bc5e2ce7453e"
      unitRef="U015">0</adma:NumberOfCustomers>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="c20240101to20241231_ConcentrationRiskByBenchmarkAxis_RevenueFromContractWithCustomerProductAndServiceBenchmarkMember_ConcentrationRiskByTypeAxis_CustomerConcentrationRiskMember_StatementBusinessSegmentsAxis_PlasmaCollectionCentersSegmentMember"
      decimals="2"
      id="Fact_398054758f8041b4bb26694c56f4e455"
      unitRef="U007">0.10</us-gaap:ConcentrationRiskPercentage1>
    <srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock
      contextRef="c20240101to20241231"
      id="Text_81057c8f0096429483805d774e33e559">
&lt;div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"&gt;Schedule II &#x2013; Valuation and Qualifying Accounts&lt;/div&gt;

&lt;div&gt;&lt;span style="font-size: 10pt; font-family: 'Times New Roman';"&gt; &lt;/span&gt;&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold; text-align: center;"&gt;Years ended December 31, 2024, 2023 and 2022&lt;/div&gt;

&lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold; text-align: center;"&gt; &lt;br/&gt;
      &lt;/div&gt;

&lt;table cellpadding="0" cellspacing="0" class="cfttable" style="font-family: 'Times New Roman'; font-size: 10pt; text-align: left; color: rgb(0, 0, 0); width: 100%; border-spacing: 0;"&gt;


  &lt;tr&gt;

    &lt;td style="vertical-align: top; font-family: 'Times New Roman'; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: top; font-family: 'Times New Roman';" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="6" rowspan="1" style="vertical-align: top; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
            &lt;div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"&gt;Additions&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" rowspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: top; font-family: 'Times New Roman';" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: top; font-family: 'Times New Roman';" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; padding-bottom: 2px;" valign="bottom"&gt;&lt;span style="font-style: italic;"&gt;(in thousands)&lt;/span&gt;&lt;br/&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
            &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"&gt;Balance at&lt;/div&gt;
            &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"&gt;beginning of year&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: top; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
            &lt;div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"&gt;Charged to costs&lt;/div&gt;
            &lt;div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"&gt;and expenses&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
            &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"&gt;Other&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: center; vertical-align: bottom; padding-bottom: 2px;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: bottom; text-align: center; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
            &lt;div style="font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"&gt;Deductions&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: top; border-bottom: #000000 solid 2px; white-space: nowrap;" valign="bottom"&gt;
            &lt;div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"&gt;Balance at&lt;/div&gt;
            &lt;div style="text-align: center; font-family: 'Times New Roman'; font-size: 10pt; font-weight: bold;"&gt;end of year&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; padding-bottom: 2px; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td colspan="1" style="vertical-align: top; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
            &lt;div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"&gt;Year ended December 31, 2024&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: top; font-family: 'Times New Roman';" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: top; font-family: 'Times New Roman';" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: top; font-family: 'Times New Roman';" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: top; font-family: 'Times New Roman';" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="2" style="vertical-align: top; font-family: 'Times New Roman';" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td colspan="1" style="vertical-align: top; width: 40%; background-color: #CCEEFF;" valign="bottom"&gt;
            &lt;div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; text-indent: 18pt;"&gt;Accrued rebates&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;
            &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;$&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
            &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;16,608&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;
            &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;$&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
            &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;8,514&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;
            &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;$&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
            &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;(12,618&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
            &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;)&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;
            &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;$&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
            &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;8,349&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;
            &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;$&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
            &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;4,155&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td colspan="1" style="vertical-align: top; width: 40%;" valign="bottom"&gt;
            &lt;div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; text-indent: -18pt; margin-left: 36pt;"&gt;Inventory valuation allowance&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;
            &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;$&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;
            &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;2,992&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;
            &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;$&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;
            &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;9,338&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;
            &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;$&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;
            &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;118&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;
            &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;$&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;
            &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;7,287&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;
            &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;$&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;
            &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;5,161&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td colspan="1" style="vertical-align: top; width: 40%; background-color: #CCEEFF;" valign="bottom"&gt;
            &lt;div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; text-indent: -9pt; margin-left: 27pt;"&gt;Deferred tax asset valuation allowance&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;
            &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;$&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
            &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;101,421&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;
            &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;$&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
            &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;(84,280&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;
            &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;)&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;
            &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;$&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
            &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;-&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;
            &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;$&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
            &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;17,141&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;
            &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;$&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
            &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;-&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; font-family: 'Times New Roman'; width: 40%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; font-family: 'Times New Roman'; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; font-family: 'Times New Roman'; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; font-family: 'Times New Roman'; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; font-family: 'Times New Roman'; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; font-family: 'Times New Roman'; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; font-family: 'Times New Roman'; width: 40%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; font-family: 'Times New Roman'; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; font-family: 'Times New Roman'; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; font-family: 'Times New Roman'; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; font-family: 'Times New Roman'; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; font-family: 'Times New Roman'; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td colspan="1" style="vertical-align: top; width: 40%; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
            &lt;div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"&gt;Year ended December 31, 2023&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; font-family: 'Times New Roman'; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; font-family: 'Times New Roman'; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; font-family: 'Times New Roman'; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; font-family: 'Times New Roman'; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; font-family: 'Times New Roman'; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td colspan="1" style="vertical-align: top; width: 40%; background-color: #CCEEFF;" valign="bottom"&gt;
            &lt;div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; text-indent: 18pt;"&gt;Accrued rebates&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;
            &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;$&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
            &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;11,437&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;
            &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;$&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
            &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;8,448&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; font-family: 'Times New Roman'; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;$ &lt;br/&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;-&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;
            &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;$&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
            &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;3,277&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;
            &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;$&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
            &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;16,608&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td colspan="1" style="vertical-align: top; width: 40%;" valign="bottom"&gt;
            &lt;div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; text-indent: -9pt; margin-left: 27pt;"&gt;Inventory valuation allowance&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;
            &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;$&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;
            &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;5,400&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;
            &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;$&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;
            &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;6,963&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;
            &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;$&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;
            &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;6&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;
            &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;$&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;
            &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;9,377&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;
            &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;$&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;
            &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;2,992&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td colspan="1" style="vertical-align: top; width: 40%; background-color: #CCEEFF;" valign="bottom"&gt;
            &lt;div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; text-indent: -9pt; margin-left: 27pt;"&gt;Deferred tax asset valuation allowance&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;
            &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;$&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
            &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;96,725&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;
            &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;$&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
            &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;4,696&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;
            &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;$&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
            &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;-&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;
            &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;$&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
            &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;-&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;
            &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;$&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
            &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;101,421&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; font-family: 'Times New Roman'; width: 40%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; font-family: 'Times New Roman'; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; font-family: 'Times New Roman'; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; font-family: 'Times New Roman'; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; font-family: 'Times New Roman'; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; font-family: 'Times New Roman'; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td style="vertical-align: top; font-family: 'Times New Roman'; width: 40%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; font-family: 'Times New Roman'; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; font-family: 'Times New Roman'; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; font-family: 'Times New Roman'; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; font-family: 'Times New Roman'; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; font-family: 'Times New Roman'; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td colspan="1" style="vertical-align: top; width: 40%; border-bottom: #000000 solid 2px;" valign="bottom"&gt;
            &lt;div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt;"&gt;Year ended December 31, 2022&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; font-family: 'Times New Roman'; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; font-family: 'Times New Roman'; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; font-family: 'Times New Roman'; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; font-family: 'Times New Roman'; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; font-family: 'Times New Roman'; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="font-family: 'Times New Roman'; text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td colspan="1" style="vertical-align: top; width: 40%; background-color: #CCEEFF;" valign="bottom"&gt;
            &lt;div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; text-indent: 18pt;"&gt;Accrued rebates&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;
            &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;$&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
            &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;5,040&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;
            &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;$&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
            &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;8,227&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&lt;br/&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;
            &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;$&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
            &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;1,830&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;
            &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;$&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
            &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;11,437&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td colspan="1" style="vertical-align: top; width: 40%;" valign="bottom"&gt;
            &lt;div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; text-indent: -9pt; margin-left: 27pt;"&gt;Inventory valuation allowance&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;
            &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;$&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;
            &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;8,577&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;
            &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;$&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;
            &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;2,744&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;
            &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;$&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;
            &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;-&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;
            &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;$&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;
            &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;5,921&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%;" valign="bottom"&gt;
            &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;$&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%;" valign="bottom"&gt;
            &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;5,400&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;

  &lt;tr&gt;

    &lt;td colspan="1" style="vertical-align: top; width: 40%; background-color: #CCEEFF;" valign="bottom"&gt;
            &lt;div style="text-align: left; font-family: 'Times New Roman'; font-size: 10pt; text-indent: -9pt; margin-left: 27pt;"&gt;Deferred tax asset valuation allowance&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;
            &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;$&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
            &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;81,608&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;
            &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;$&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
            &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;15,117&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;
            &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;$&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
            &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;-&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;
            &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;$&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
            &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;-&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: right; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;&#160;&lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF;" valign="bottom"&gt;
            &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;$&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="vertical-align: bottom; text-align: right; width: 9%; background-color: #CCEEFF;" valign="bottom"&gt;
            &lt;div style="font-family: 'Times New Roman'; font-size: 10pt;"&gt;96,725&lt;/div&gt;
          &lt;/td&gt;

    &lt;td colspan="1" style="text-align: left; vertical-align: bottom; width: 1%; background-color: #CCEEFF; white-space: nowrap;" valign="bottom"&gt;&#160;&lt;/td&gt;

  &lt;/tr&gt;


&lt;/table&gt;
</srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="c20231231_ValuationAllowancesAndReservesTypeAxis_SECSchedule1209ReserveAccruedRebatesMember"
      decimals="-3"
      id="Fact_b8465323bef642fca9c1006f98160609"
      unitRef="U001">16608000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense
      contextRef="c20240101to20241231_ValuationAllowancesAndReservesTypeAxis_SECSchedule1209ReserveAccruedRebatesMember"
      decimals="-3"
      id="Fact_458da5c7cd9b4278adca0d060a6f5a85"
      unitRef="U001">8514000</us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense>
    <us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts
      contextRef="c20240101to20241231_ValuationAllowancesAndReservesTypeAxis_SECSchedule1209ReserveAccruedRebatesMember"
      decimals="-3"
      id="Fact_27c3f5c861b04fd99820d33a92d40363"
      unitRef="U001">-12618000</us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="c20240101to20241231_ValuationAllowancesAndReservesTypeAxis_SECSchedule1209ReserveAccruedRebatesMember"
      decimals="-3"
      id="Fact_c5633a011f00404db4d85c9dfa4e4700"
      unitRef="U001">8349000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="c20241231_ValuationAllowancesAndReservesTypeAxis_SECSchedule1209ReserveAccruedRebatesMember"
      decimals="-3"
      id="Fact_33911fd248ad4024b62c90132f58b336"
      unitRef="U001">4155000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="c20231231_ValuationAllowancesAndReservesTypeAxis_InventoryValuationReserveMember"
      decimals="-3"
      id="Fact_deb2897448d347d8b6358f0936b81377"
      unitRef="U001">2992000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense
      contextRef="c20240101to20241231_ValuationAllowancesAndReservesTypeAxis_InventoryValuationReserveMember"
      decimals="-3"
      id="Fact_13c8f8cd3dcc42f5a47fabba70b869ea"
      unitRef="U001">9338000</us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense>
    <us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts
      contextRef="c20240101to20241231_ValuationAllowancesAndReservesTypeAxis_InventoryValuationReserveMember"
      decimals="-3"
      id="Fact_80627bb5bd444a6aaf69277d68537d43"
      unitRef="U001">118000</us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="c20240101to20241231_ValuationAllowancesAndReservesTypeAxis_InventoryValuationReserveMember"
      decimals="-3"
      id="Fact_40367eaba92746a5ad4bc12229158c57"
      unitRef="U001">7287000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="c20241231_ValuationAllowancesAndReservesTypeAxis_InventoryValuationReserveMember"
      decimals="-3"
      id="Fact_e5928b6822514db79ea4160bb4a7321b"
      unitRef="U001">5161000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="c20231231_ValuationAllowancesAndReservesTypeAxis_ValuationAllowanceOfDeferredTaxAssetsMember"
      decimals="-3"
      id="Fact_43d4fb8f83294e60a9c5af98462ffa57"
      unitRef="U001">101421000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense
      contextRef="c20240101to20241231_ValuationAllowancesAndReservesTypeAxis_ValuationAllowanceOfDeferredTaxAssetsMember"
      decimals="-3"
      id="Fact_cb41b3bef5f2490b977cb3f651c35391"
      unitRef="U001">-84280000</us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense>
    <us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts
      contextRef="c20240101to20241231_ValuationAllowancesAndReservesTypeAxis_ValuationAllowanceOfDeferredTaxAssetsMember"
      decimals="-3"
      id="Fact_e90825d352614ca6adb7825b56918cf1"
      unitRef="U001">0</us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="c20240101to20241231_ValuationAllowancesAndReservesTypeAxis_ValuationAllowanceOfDeferredTaxAssetsMember"
      decimals="-3"
      id="Fact_19d783fea23546be81aec9b29433e1e3"
      unitRef="U001">17141000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="c20241231_ValuationAllowancesAndReservesTypeAxis_ValuationAllowanceOfDeferredTaxAssetsMember"
      decimals="-3"
      id="Fact_dcf1b85129bb4ea682dbf10eb58dbc7e"
      unitRef="U001">0</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="c20221231_ValuationAllowancesAndReservesTypeAxis_SECSchedule1209ReserveAccruedRebatesMember"
      decimals="-3"
      id="Fact_28b9c9ec9d8d467b8b1f44a2acd6d529"
      unitRef="U001">11437000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense
      contextRef="c20230101to20231231_ValuationAllowancesAndReservesTypeAxis_SECSchedule1209ReserveAccruedRebatesMember"
      decimals="-3"
      id="Fact_9a0b15dd651548c4bf3d02bc308b4568"
      unitRef="U001">8448000</us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense>
    <us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts
      contextRef="c20230101to20231231_ValuationAllowancesAndReservesTypeAxis_SECSchedule1209ReserveAccruedRebatesMember"
      decimals="-3"
      id="Fact_b49b659a80114f0985c8073be77b9c6f"
      unitRef="U001">0</us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="c20230101to20231231_ValuationAllowancesAndReservesTypeAxis_SECSchedule1209ReserveAccruedRebatesMember"
      decimals="-3"
      id="Fact_8f995c689b3d440e886e982f4a1b7b07"
      unitRef="U001">3277000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="c20231231_ValuationAllowancesAndReservesTypeAxis_SECSchedule1209ReserveAccruedRebatesMember"
      decimals="-3"
      id="Fact_e799cc8e34fb476cb4b26f9f0a73bc8e"
      unitRef="U001">16608000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="c20221231_ValuationAllowancesAndReservesTypeAxis_InventoryValuationReserveMember"
      decimals="-3"
      id="Fact_da78ce4ed7014716bc52dfdbfffe7f3a"
      unitRef="U001">5400000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense
      contextRef="c20230101to20231231_ValuationAllowancesAndReservesTypeAxis_InventoryValuationReserveMember"
      decimals="-3"
      id="Fact_bafd6a6cc059474cbe01ccd3b9a93b21"
      unitRef="U001">6963000</us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense>
    <us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts
      contextRef="c20230101to20231231_ValuationAllowancesAndReservesTypeAxis_InventoryValuationReserveMember"
      decimals="-3"
      id="Fact_bf50149b44d5499d89e6ea030334cefa"
      unitRef="U001">6000</us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="c20230101to20231231_ValuationAllowancesAndReservesTypeAxis_InventoryValuationReserveMember"
      decimals="-3"
      id="Fact_951eb64eb7ac44989846f36a31d95e31"
      unitRef="U001">9377000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="c20231231_ValuationAllowancesAndReservesTypeAxis_InventoryValuationReserveMember"
      decimals="-3"
      id="Fact_e78d2b99ae4245e6853819befc288631"
      unitRef="U001">2992000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="c20221231_ValuationAllowancesAndReservesTypeAxis_ValuationAllowanceOfDeferredTaxAssetsMember"
      decimals="-3"
      id="Fact_1360fff8a4ed4a5a86aff1d3b52be419"
      unitRef="U001">96725000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense
      contextRef="c20230101to20231231_ValuationAllowancesAndReservesTypeAxis_ValuationAllowanceOfDeferredTaxAssetsMember"
      decimals="-3"
      id="Fact_606536fe97f949f9bf68fa95a4d5fb13"
      unitRef="U001">4696000</us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense>
    <us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts
      contextRef="c20230101to20231231_ValuationAllowancesAndReservesTypeAxis_ValuationAllowanceOfDeferredTaxAssetsMember"
      decimals="-3"
      id="Fact_b4ce525fdb4a46588c03ed125284cdc3"
      unitRef="U001">0</us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="c20230101to20231231_ValuationAllowancesAndReservesTypeAxis_ValuationAllowanceOfDeferredTaxAssetsMember"
      decimals="-3"
      id="Fact_09b5a83b5e0841b49f7f014822226a10"
      unitRef="U001">0</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="c20231231_ValuationAllowancesAndReservesTypeAxis_ValuationAllowanceOfDeferredTaxAssetsMember"
      decimals="-3"
      id="Fact_398321f563d54e79b563f1d3958b50ce"
      unitRef="U001">101421000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="c20211231_ValuationAllowancesAndReservesTypeAxis_SECSchedule1209ReserveAccruedRebatesMember"
      decimals="-3"
      id="Fact_0574ebaae2a1470baad5fb62afc55bab"
      unitRef="U001">5040000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense
      contextRef="c20220101to20221231_ValuationAllowancesAndReservesTypeAxis_SECSchedule1209ReserveAccruedRebatesMember"
      decimals="-3"
      id="Fact_156001a09b3240b1a11ab88570d852cc"
      unitRef="U001">8227000</us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="c20220101to20221231_ValuationAllowancesAndReservesTypeAxis_SECSchedule1209ReserveAccruedRebatesMember"
      decimals="-3"
      id="Fact_2d487d624d944151979a9543b1ac6cf8"
      unitRef="U001">1830000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="c20221231_ValuationAllowancesAndReservesTypeAxis_SECSchedule1209ReserveAccruedRebatesMember"
      decimals="-3"
      id="Fact_ecdc281211cf4b1886a4c04c68c66463"
      unitRef="U001">11437000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="c20211231_ValuationAllowancesAndReservesTypeAxis_InventoryValuationReserveMember"
      decimals="-3"
      id="Fact_564b32c73e1c4e6fb3d99b949da6fb30"
      unitRef="U001">8577000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense
      contextRef="c20220101to20221231_ValuationAllowancesAndReservesTypeAxis_InventoryValuationReserveMember"
      decimals="-3"
      id="Fact_3357706e24b6439089033a8130dedd30"
      unitRef="U001">2744000</us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense>
    <us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts
      contextRef="c20220101to20221231_ValuationAllowancesAndReservesTypeAxis_InventoryValuationReserveMember"
      decimals="-3"
      id="Fact_421992e9b44847dca93972e978c470c3"
      unitRef="U001">0</us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="c20220101to20221231_ValuationAllowancesAndReservesTypeAxis_InventoryValuationReserveMember"
      decimals="-3"
      id="Fact_ce6709c240d94b389ce06721028b13a9"
      unitRef="U001">5921000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="c20221231_ValuationAllowancesAndReservesTypeAxis_InventoryValuationReserveMember"
      decimals="-3"
      id="Fact_8dc8580be16d4f648459678945a685b3"
      unitRef="U001">5400000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="c20211231_ValuationAllowancesAndReservesTypeAxis_ValuationAllowanceOfDeferredTaxAssetsMember"
      decimals="-3"
      id="Fact_c7269ac33fb84ae5864358d57b53c089"
      unitRef="U001">81608000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense
      contextRef="c20220101to20221231_ValuationAllowancesAndReservesTypeAxis_ValuationAllowanceOfDeferredTaxAssetsMember"
      decimals="-3"
      id="Fact_c11f6b26eee34fe6962656fafa714e5c"
      unitRef="U001">15117000</us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense>
    <us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts
      contextRef="c20220101to20221231_ValuationAllowancesAndReservesTypeAxis_ValuationAllowanceOfDeferredTaxAssetsMember"
      decimals="-3"
      id="Fact_a20495d5757043098b7b09b7a04f172a"
      unitRef="U001">0</us-gaap:ValuationAllowancesAndReservesChargedToOtherAccounts>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="c20220101to20221231_ValuationAllowancesAndReservesTypeAxis_ValuationAllowanceOfDeferredTaxAssetsMember"
      decimals="-3"
      id="Fact_fe21b88e1d6a4d32a0deebcb295c2eec"
      unitRef="U001">0</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="c20221231_ValuationAllowancesAndReservesTypeAxis_ValuationAllowanceOfDeferredTaxAssetsMember"
      decimals="-3"
      id="Fact_56a6fdaec0a54f1ba7927b575242ab73"
      unitRef="U001">96725000</us-gaap:ValuationAllowancesAndReservesBalance>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#Fact_38cc8c1ba39345bb9c266112d2a58244"
          xlink:label="Fact_38cc8c1ba39345bb9c266112d2a58244"
          xlink:type="locator"/>
        <link:footnote id="Foot_09400bbe9814473cacf6009d441a9bbc" xlink:label="Foot_09400bbe9814473cacf6009d441a9bbc" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Primarily includes compensation expense,
                    including stock-based compensation expense, for certain executive officers and consultants, insurance, legal and investor relations expenses and accounting and tax fees that are not allocated to the Company&#x2019;s operating segments.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_38cc8c1ba39345bb9c266112d2a58244"
          xlink:to="Foot_09400bbe9814473cacf6009d441a9bbc"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_d50c136af3e64211860c504c901e8c64"
          xlink:label="Fact_d50c136af3e64211860c504c901e8c64"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_d50c136af3e64211860c504c901e8c64"
          xlink:to="Foot_09400bbe9814473cacf6009d441a9bbc"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_1ebee0d4064242ba89bb9e7237a76696"
          xlink:label="Fact_1ebee0d4064242ba89bb9e7237a76696"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_1ebee0d4064242ba89bb9e7237a76696"
          xlink:to="Foot_09400bbe9814473cacf6009d441a9bbc"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_cde715de13354b49a38d7dda07a2e372"
          xlink:label="Fact_cde715de13354b49a38d7dda07a2e372"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_cde715de13354b49a38d7dda07a2e372"
          xlink:to="Foot_09400bbe9814473cacf6009d441a9bbc"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_4dc192bb6874460db027219d6a8cbdc1"
          xlink:label="Fact_4dc192bb6874460db027219d6a8cbdc1"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_4dc192bb6874460db027219d6a8cbdc1"
          xlink:to="Foot_09400bbe9814473cacf6009d441a9bbc"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_59d303f1d98c47bf8afbfb622cfe76d6"
          xlink:label="Fact_59d303f1d98c47bf8afbfb622cfe76d6"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_59d303f1d98c47bf8afbfb622cfe76d6"
          xlink:to="Foot_09400bbe9814473cacf6009d441a9bbc"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_92e4d85a8785438787156b3774d98556"
          xlink:label="Fact_92e4d85a8785438787156b3774d98556"
          xlink:type="locator"/>
        <link:footnote id="Foot_0c35b5dd3cb44596b792fca041b80d28" xlink:label="Foot_0c35b5dd3cb44596b792fca041b80d28" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Primarily consists of cash.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_92e4d85a8785438787156b3774d98556"
          xlink:to="Foot_0c35b5dd3cb44596b792fca041b80d28"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_c0dc9246cefd4ef981112d0b8e335383"
          xlink:label="Fact_c0dc9246cefd4ef981112d0b8e335383"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_c0dc9246cefd4ef981112d0b8e335383"
          xlink:to="Foot_0c35b5dd3cb44596b792fca041b80d28"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact_098496fadea04070a12725b9411291d8"
          xlink:label="Fact_098496fadea04070a12725b9411291d8"
          xlink:type="locator"/>
        <link:footnote id="Foot_8c1cfdc8358b499c8ef892be7b50f8db" xlink:label="Foot_8c1cfdc8358b499c8ef892be7b50f8db" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Primarily consists of cash and deferred tax
                  assets.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact_098496fadea04070a12725b9411291d8"
          xlink:to="Foot_8c1cfdc8358b499c8ef892be7b50f8db"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
